PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Huang, CK; Yang, CY; Jeng, YM; Chen, CL; Wu, HH; Chang, YC; Ma, C; Kuo, WH; Chang, KJ; Shew, JY; Lee, WH				Huang, C-K; Yang, C-Y; Jeng, Y-M; Chen, C-L; Wu, H-H; Chang, Y-C; Ma, C.; Kuo, W-H; Chang, K-J; Shew, J-Y; Lee, W-H			Autocrine/paracrine mechanism of interleukin-17B receptor promotes breast tumorigenesis through NF-kappa B-mediated antiapoptotic pathway	ONCOGENE			English	Article						antiapoptosis; autocrine; IL-17RB; NF-kappa B; tumorigenesis	CYTOKINE RECEPTOR; TUMOR-DEVELOPMENT; PROSTATE-CANCER; IL-17; EXPRESSION; IDENTIFICATION; GROWTH; TRASTUZUMAB; METASTASIS; APOPTOSIS	Gain of function of membrane receptor was a good strategy exploited by cancer cells to benefit own growth and survival. Overexpression of HER2 has been found to serve as a target for developing trastuzumab to treat 20-25% of breast cancer. However, little or none of the other membrane receptor was found to be useful as a potential target for breast cancer treatment since then. Here, we showed that amplified signaling of interleukin-17 receptor B (IL-17RB) and its ligand IL-17B promoted tumorigenicity in breast cancer cells and impeded acinus formation in immortalized normal mammary epithelial cells. External signal transmitted through IL-17RB activated nuclear factor-kappa B to upregulate antiapoptotic factor Bcl-2 and induced etoposide resistance. Elevated expression of IL-17RB had a stronger correlation with poor prognosis than HER2 in breast cancer patients. Interestingly, breast cancer patients with high expression of IL-17RB and HER2 had the shortest survival rate. Depletion of IL-17RB in trastuzumab-resistant breast cancer cells significantly reduced their tumorigenic activity, suggesting that IL-17RB and HER2 have an independent role in breast carcinogenesis. Furthermore, treatment with antibodies specifically against IL-17RB or IL-17B effectively attenuated tumorigenicity of breast cancer cells. These results suggest that the amplified IL-17RB/IL-17B signaling pathways may serve as a therapeutic target for developing treatment to manage IL-17RB-associated breast cancer.	[Huang, C-K; Shew, J-Y; Lee, W-H] Natl Taiwan Univ, Coll Med, Inst Biochem & Mol Biol, Taipei 10764, Taiwan; [Huang, C-K; Yang, C-Y; Chen, C-L; Wu, H-H; Chang, Y-C; Ma, C.; Shew, J-Y; Lee, W-H] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan; [Jeng, Y-M] Natl Taiwan Univ Hosp, Dept Pathol, Taipei 100, Taiwan; [Kuo, W-H; Chang, K-J] Natl Taiwan Univ Hosp, Dept Surg, Taipei 100, Taiwan; [Chang, K-J] Cheng Chin Gen Hosp, Taichung, Taiwan; [Lee, W-H] Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA	National Taiwan University; Academia Sinica - Taiwan; National Taiwan University; National Taiwan University Hospital; National Taiwan University; National Taiwan University Hospital; University of California System; University of California Irvine	Lee, WH (corresponding author), Univ Calif Irvine, Dept Biol Chem, 124 Sprague Hall, Irvine, CA 92697 USA.	whlee@uci.edu	Chang, Yi-cheng/O-1334-2018; Alex, Che/AAF-3280-2019	Chang, Yi-cheng/0000-0002-8077-5011; Alex, Che/0000-0002-4741-2307; Chang, King jen/0000-0001-9811-3422; JENG, YUNG-MING/0000-0002-3878-4491; KUO, WEN-HUNG/0000-0002-9881-4605	Academia Sinica (Taiwan); NIH [CA94170]; NATIONAL CANCER INSTITUTE [R01CA094170] Funding Source: NIH RePORTER	Academia Sinica (Taiwan)(Academia Sinica - Taiwan); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Hung-Wen Lai for kindly providing a Herceptin (Trastuzumab)-resistant strain of SKBR3, and Dr Wendy W Hwang-Verslues and Dr Pei-Chi Wei for reading this manuscript. This work was supported by Academia Sinica (Taiwan) and by NIH (CA94170; to WHL).	Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Ammirante M, 2010, NATURE, V464, P302, DOI 10.1038/nature08782; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Furuta S, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3001374; He DG, 2010, J IMMUNOL, V184, P2281, DOI 10.4049/jimmunol.0902574; Kryczek I, 2009, BLOOD, V114, P357, DOI 10.1182/blood-2008-09-177360; Lee J, 2001, J BIOL CHEM, V276, P1660, DOI 10.1074/jbc.M008289200; Ma XJ, 2006, J CLIN ONCOL, V24, P4611, DOI 10.1200/JCO.2006.06.6944; Ma XJ, 2004, CANCER CELL, V5, P607, DOI 10.1016/j.ccr.2004.05.015; Maezawa Y, 2006, J IMMUNOL, V176, P1013, DOI 10.4049/jimmunol.176.2.1013; Martin-Orozco N, 2009, IMMUNITY, V31, P787, DOI 10.1016/j.immuni.2009.09.014; Moasser MM, 2007, ONCOGENE, V26, P6469, DOI 10.1038/sj.onc.1210477; Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306; Reeves PJ, 2002, P NATL ACAD SCI USA, V99, P13419, DOI 10.1073/pnas.212519299; Rickel EA, 2008, J IMMUNOL, V181, P4299, DOI 10.4049/jimmunol.181.6.4299; SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Shi YG, 2000, J BIOL CHEM, V275, P19167, DOI 10.1074/jbc.M910228199; Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477; Singer CF, 2003, CLIN CANCER RES, V9, P4877; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Taylor MA, 2013, J CLIN INVEST, V123, P150, DOI 10.1172/JCI64946; Tian EM, 2000, ONCOGENE, V19, P2098, DOI 10.1038/sj.onc.1203577; Vargo-Gogola T, 2007, NAT REV CANCER, V7, P659, DOI 10.1038/nrc2193; Wang L, 2010, CANCER RES, V70, P10112, DOI 10.1158/0008-5472.CAN-10-0775; Wang L, 2009, J EXP MED, V206, P1457, DOI 10.1084/jem.20090207; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Yao ZB, 1995, IMMUNITY, V3, P811, DOI 10.1016/1074-7613(95)90070-5; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888; Zhang SY, 2011, NAT MED, V17, P461, DOI 10.1038/nm.2309; Zhu XW, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2195	35	71	75	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2014	33	23					2968	2977		10.1038/onc.2013.268	http://dx.doi.org/10.1038/onc.2013.268			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EL	23851503				2022-12-28	WOS:000337232200003
J	Tang, W; Yu, F; Yao, H; Cui, X; Jiao, Y; Lin, L; Chen, J; Yin, D; Song, E; Liu, Q				Tang, W.; Yu, F.; Yao, H.; Cui, X.; Jiao, Y.; Lin, L.; Chen, J.; Yin, D.; Song, E.; Liu, Q.			miR-27a regulates endothelial differentiation of breast cancer stem like cells	ONCOGENE			English	Article						breast cancer; cancer stem cell; microRNA; miR-27a; angiogenesis; endothelial differentiation	TUMOR MICROVASCULATURE; MICROENVIRONMENT; ANGIOGENESIS; VASCULARIZATION; MICRORNAS; TARGETS	Recent studies suggested that cancer stem cells (CSCs) are capable of differentiating into endothelial cells and tumor endothelium may be derived from CSCs. But the mechanism remains unclear. We showed that vascular endothelial growth factor (VEGF) induced the expression of endothelial markers in breast cancer stem like cells (BCSLCs). In addition, the VEGF-treated BCSLCs formed capillary structure in matrigel and released vWF upon histamine treatment. The miR-27a expression was significantly increased in VEGF-treated BCSLCs. Antagonizing miR-27a by miR-27a anti-sense oligos (ASOs) in VEGF-treated BCSLCs led to decreased endothelial markers and function, while increasing miR-27a in BCSLCs resulted in enhanced endothelial properties. VEGF enhanced the transcription of miR-27a by increasing RUNX1 binding to miR-27a promoter. Increased miR-27a paralleled the reduced expression of ZBTB10, a known miR-27a target. Both expression of miR-27a and knockdown of ZBTB10 in BCSLCs promoted in vivo angiogenesis and tumor metastasis. Further, we demonstrated that VEGF-treated BCSLCs secreted more endogenous VEGF compared with undifferentiated BCSLCs. Thus, miR-27a promotes angiogenesis by mediating endothelial differentiation of BCSLCs and it may be a new target for anti-angiogenesis cancer therapy.	[Tang, W.; Yu, F.; Yao, H.; Lin, L.; Chen, J.; Song, E.; Liu, Q.] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Breast Tumor Ctr, Guangzhou 510120, Guangdong, Peoples R China; [Cui, X.; Yin, D.] Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Med Res Ctr, Key Lab Malignant Tumor Gene Regulat & Target The, Guangzhou 510120, Guangdong, Peoples R China; [Jiao, Y.] Sun Yat Sen Univ, Sch Life Sci, Guangzhou 510120, Guangdong, Peoples R China	Sun Yat Sen University; Sun Yat Sen University; Sun Yat Sen University	Liu, Q (corresponding author), Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Breast Tumor Ctr, 107 Yanjiang West Rd, Guangzhou 510120, Guangdong, Peoples R China.	songerwei02@yahoo.com.cn; victorlq@hotmail.com		Lin, Ling/0000-0001-5603-0688; Liu, Qiang/0000-0002-5451-4862; Yao, Herui/0000-0001-5520-6469	973 Projects from the Ministry of Science and Technology of China [2010CB912800, 2011CB504203]; Natural Science Foundation of China [81072178, 81272894, 81230060, 81261140373, 81071788]; Ministry of Education of China [20120171110075]; Ministry of Health of China [2011ZX09102-010-02]; Guangdong Natural Science Fundation for Distinguished Young Scholar [S20120011199]; Foundation for the Author of National Excellent Doctoral Dissertation of PR China (FANEDD) [81000-3149001]	973 Projects from the Ministry of Science and Technology of China; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Education of China(Ministry of Education, China); Ministry of Health of China; Guangdong Natural Science Fundation for Distinguished Young Scholar; Foundation for the Author of National Excellent Doctoral Dissertation of PR China (FANEDD)(Foundation for the Author of National Excellent Doctoral Dissertation of China)	This work was supported by the 973 Projects (2010CB912800, 2011CB504203) from the Ministry of Science and Technology of China, and grants from the Natural Science Foundation of China (81072178, 81272894, 81230060, 81261140373, 81071788), Ministry of Education of China (20120171110075), a grant for Development of Important New Drugs from the Ministry of Health of China (2011ZX09102-010-02), grants from Guangdong Natural Science Fundation for Distinguished Young Scholar (S20120011199) and Foundation for the Author of National Excellent Doctoral Dissertation of PR China (FANEDD, 81000-3149001).	Ben-Ami O, 2009, P NATL ACAD SCI USA, V106, P238, DOI 10.1073/pnas.0811466106; Bussolati B, 2009, J CELL MOL MED, V13, P309, DOI 10.1111/j.1582-4934.2008.00338.x; de Castro G, 2006, CRIT REV ONCOL HEMAT, V59, P40, DOI 10.1016/j.critrevonc.2006.02.007; Dome B, 2007, AM J PATHOL, V170, P1, DOI 10.2353/ajpath.2007.060302; Fang K, 2012, CURR MOL MED, V12, P536, DOI 10.2174/156652412800620002; Fukumura D, 2007, MICROVASC RES, V74, P72, DOI 10.1016/j.mvr.2007.05.003; Fukumura D, 2007, J CELL BIOCHEM, V101, P937, DOI 10.1002/jcb.21187; Fukumura D, 2010, MICROCIRCULATION, V17, P206, DOI 10.1111/j.1549-8719.2010.00029.x; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hendrix MJC, 2003, NAT REV CANCER, V3, P411, DOI 10.1038/nrc1092; JAIN RK, 1988, CANCER RES, V48, P2641; Lee S, 2007, CELL, V130, P691, DOI 10.1016/j.cell.2007.06.054; Leonardo TR, 2012, NAT CELL BIOL, V14, P1114, DOI 10.1038/ncb2613; Liu C, 2011, CANCER RES, V71, P5950, DOI 10.1158/0008-5472.CAN-11-1035; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Mertens-Talcott SU, 2007, CANCER RES, V67, P11001, DOI 10.1158/0008-5472.CAN-07-2416; Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557; Shcherbata HR, 2006, CELL CYCLE, V5, P172, DOI 10.4161/cc.5.2.2343; Stratman AN, 2011, BLOOD, V117, P3709, DOI 10.1182/blood-2010-11-316752; Tang W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051702; Wang H, 2005, CELL BIOL INT, V29, P654, DOI 10.1016/j.cellbi.2005.03.019; Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624; Weigand Melanie, 2005, Angiogenesis, V8, P197, DOI 10.1007/s10456-005-9010-0; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Zhou QB, 2011, P NATL ACAD SCI USA, V108, P8287, DOI 10.1073/pnas.1105254108	25	75	78	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2014	33	20					2629	2638		10.1038/onc.2013.214	http://dx.doi.org/10.1038/onc.2013.214			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH9YT	23752185				2022-12-28	WOS:000336502700009
J	Foley, CJ; Fanjul-Fernandez, M; Bohm, A; Nguyen, N; Agarwal, A; Austin, K; Koukos, G; Covic, L; Lopez-Otin, C; Kuliopulos, A				Foley, C. J.; Fanjul-Fernandez, M.; Bohm, A.; Nguyen, N.; Agarwal, A.; Austin, K.; Koukos, G.; Covic, L.; Lopez-Otin, C.; Kuliopulos, A.			Matrix metalloprotease 1a deficiency suppresses tumor growth and angiogenesis	ONCOGENE			English	Article						angiogenesis; lung cancer; Mmp1a; MMP1; PAR1	CELL-PENETRATING PEPDUCINS; BREAST-CANCER CELLS; ACTIVATED RECEPTOR-1; 13-DEFICIENT MICE; ENDOTHELIAL-CELLS; SIGNALING SYSTEM; POOR-PROGNOSIS; OVARIAN-CANCER; EXPRESSION; GENE	Matrix metalloprotease-1 (MMP1) is an important mediator of tumorigenesis, inflammation and tissue remodeling through its ability to degrade critical matrix components. Recent studies indicate that stromal-derived MMP1 may exert direct oncogenic activity by signaling through protease-activated receptor-1 (PAR1) in carcinoma cells; however, this has not been established in vivo. We generated an Mmp1a knockout mouse to ascertain whether stromal-derived Mmp1a affects tumor growth. Mmp1a-deficient mice are grossly normal and born in Mendelian ratios; however, deficiency of Mmp1a results in significantly decreased growth and angiogenesis of lung tumors. Coimplantation of lung cancer cells with wild-type Mmp1a(+/+) fibroblasts completely restored tumor growth in Mmp1a-deficient animals, highlighting the critical role of stromal-derived Mmp1a. Silencing of PAR1 expression in the lung carcinoma cells phenocopied stromal Mmp1a-deficiency, thus validating tumor-derived PAR1 as an Mmp1a target. Mmp1a secretion is controlled by the ability of its prodomain to facilitate autocleavage, whereas human MMP1 is efficiently secreted because of stable pro-and catalytic domain interactions. Taken together, these data demonstrate that stromal Mmp1a drives in vivo tumorigenesis and provide proof of concept that targeting the MMP1-PAR1 axis may afford effective treatments of lung cancer.	[Foley, C. J.; Nguyen, N.; Agarwal, A.; Austin, K.; Koukos, G.; Covic, L.; Kuliopulos, A.] Tufts Univ, Sch Med, Tufts Med Ctr, Div Hematol Oncol,Mol Oncol Res Inst, Boston, MA 02111 USA; [Foley, C. J.; Bohm, A.; Austin, K.; Koukos, G.; Covic, L.; Kuliopulos, A.] Tufts Univ, Sch Med, Dept Biochem, Sackler Sch Grad Biomed Sci,Program Genet, Boston, MA 02111 USA; [Foley, C. J.; Bohm, A.; Austin, K.; Koukos, G.; Covic, L.; Kuliopulos, A.] Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA; [Fanjul-Fernandez, M.; Lopez-Otin, C.] Univ Oviedo, Inst Univ Oncol, Fac Med, Dept Bioquim & Biol Mol, Oviedo, Spain	Tufts Medical Center; Tufts University; Tufts University; Tufts University; University of Oviedo; Instituto Universitario de Oncologia de Asturias	Kuliopulos, A (corresponding author), Tufts Univ, Sch Med, Tufts Med Ctr, Div Hematol Oncol,Mol Oncol Res Inst, 75 Kneeland St, Boston, MA 02111 USA.	athan.kuliopulos@tufts.edu	López-Otín, Carlos/AAB-2106-2020; Koukos, Georgios/B-1544-2009	López-Otín, Carlos/0000-0001-6964-1904; Koukos, Georgios/0000-0002-9470-0651; Miriam, Fanjul Fernandez/0000-0002-0074-2325	NIH [F30-HL104835, CA122992, HL64701, CA104406]; NATIONAL CANCER INSTITUTE [R01CA122992, R01CA104406] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F30HL104835, R01HL064701] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We are grateful to Sheida Sharifi for her expertise in quantifying tumor angiogenesis, and Rutika V Pradhan and Namrata Nammi for the analysis of endothelial tube formation. This work was supported, in part, by NIH grants F30-HL104835 (to CJF), CA122992, HL64701 (to AK) and CA104406 (to LC).	Agarwal A, 2008, MOL CANCER THER, V7, P2746, DOI 10.1158/1535-7163.MCT-08-0177; Agarwal A, 2010, CANCER RES, V70, P5880, DOI 10.1158/0008-5472.CAN-09-4341; Balbin M, 2003, NAT GENET, V35, P252, DOI 10.1038/ng1249; Balbin M, 2001, J BIOL CHEM, V276, P10253, DOI 10.1074/jbc.M009586200; BERTRAM JS, 1980, CANCER LETT, V11, P63, DOI 10.1016/0304-3835(80)90130-5; Blackburn JS, 2008, AM J PATHOL, V173, P1736, DOI 10.2353/ajpath.2008.080512; Boire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018; BOLON I, 1995, AM J PATHOL, V147, P1298; Bostrom P, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-348; Cisowski J, 2011, AM J PATHOL, V179, P513, DOI 10.1016/j.ajpath.2011.03.025; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Eck SM, 2009, J AUTOIMMUN, V33, P214, DOI 10.1016/j.jaut.2009.09.011; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Foley CJ, 2012, J BIOL CHEM, V287, P24330, DOI 10.1074/jbc.M112.356303; FOWLKES JL, 1994, J BIOL CHEM, V269, P25742; GEARING AJH, 1994, NATURE, V370, P555, DOI 10.1038/370555a0; Goerge T, 2006, CANCER RES, V66, P7766, DOI 10.1158/0008-5472.CAN-05-3897; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; Griffin CT, 2001, SCIENCE, V293, P1666, DOI 10.1126/science.1061259; Hartenstein B, 2006, J INVEST DERMATOL, V126, P486, DOI 10.1038/sj.jid.5700084; Heppner KJ, 1996, AM J PATHOL, V149, P273; Inada M, 2004, P NATL ACAD SCI USA, V101, P17192, DOI 10.1073/pnas.0407788101; Ito A, 1996, J BIOL CHEM, V271, P14657, DOI 10.1074/jbc.271.25.14657; Ito M, 2012, CHEST, V142, P151, DOI 10.1378/chest.11-2458; Jozic D, 2005, J BIOL CHEM, V280, P9578, DOI 10.1074/jbc.M411084200; Kanamori Y, 1999, CANCER RES, V59, P4225; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; Murray GI, 1996, NAT MED, V2, P461, DOI 10.1038/nm0496461; Murray GI, 1998, J PATHOL, V185, P256; Nguyen N, 2006, CANCER RES, V66, P2658, DOI 10.1158/0008-5472.CAN-05-2082; Nikkola J, 2002, INT J CANCER, V97, P432, DOI 10.1002/ijc.1636; Nuttall RK, 2004, FEBS LETT, V563, P129, DOI 10.1016/S0014-5793(04)00281-9; ODAKE S, 1994, BIOCHEM BIOPH RES CO, V199, P1442, DOI 10.1006/bbrc.1994.1392; Pfaffen S, 2010, EXP CELL RES, V316, P836, DOI 10.1016/j.yexcr.2009.11.004; Saarinen J, 1999, EUR J BIOCHEM, V259, P829, DOI 10.1046/j.1432-1327.1999.00105.x; Schonbeck U, 1998, J IMMUNOL, V161, P3340; Schwede T, 2003, NUCLEIC ACIDS RES, V31, P3381, DOI 10.1093/nar/gkg520; Smith Victoria, 2008, Cancer Genomics & Proteomics, V5, P263; Stickens D, 2004, DEVELOPMENT, V131, P5883, DOI 10.1242/dev.01461; Tressel SL, 2011, EMBO MOL MED, V3, P370, DOI 10.1002/emmm.201100145; Vanlaere I, 2009, CLIN MICROBIOL REV, V22, P224, DOI 10.1128/CMR.00047-08; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Vizoso FJ, 2007, BRIT J CANCER, V96, P903, DOI 10.1038/sj.bjc.6603666	43	30	30	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2014	33	17					2264	2272		10.1038/onc.2013.157	http://dx.doi.org/10.1038/onc.2013.157			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF8WJ	23708660	Green Accepted			2022-12-28	WOS:000334996000012
J	Barckhausen, C; Roos, WP; Naumann, SC; Kaina, B				Barckhausen, C.; Roos, W. P.; Naumann, S. C.; Kaina, B.			Malignant melanoma cells acquire resistance to DNA interstrand cross-linking chemotherapeutics by p53-triggered upregulation of DDB2/XPC-mediated DNA repair	ONCOGENE			English	Article						metastatic melanoma; interstrand cross-links; p53; drug resistance; DDB2; XPC	NUCLEOTIDE EXCISION-REPAIR; DOUBLE-STRAND BREAKS; GROUP-C GENE; ANTICANCER DRUGS; GLIOMA-CELLS; O6-ALKYLGUANINE-DNA ALKYLTRANSFERASE; ALKYLATING-AGENTS; INDUCED APOPTOSIS; P53; FOTEMUSTINE	Malignant melanoma is a cancer characterized by high chemoresistance although p53 is rarely mutated. Here, we show that p53 wild-type melanoma cells acquire resistance to cell death induced by fotemustine (FM), which is a representative of alkylating DNA interstrand cross-linking agents used in melanoma therapy. We show that drug-induced resistance is a result of p53-dependent upregulation of the nucleotide excision repair (NER) genes xeroderma pigmentosum complementation group C (XPC) and damaged DNA-binding protein 2 (DDB2), which stimulate the repair of DNA interstrand cross-links (ICLs) arising from O-6-chloroethylguanine. Consequently, TP53 mutated cells are unable to repair ICLs, leading to prolonged ATM, ATR and checkpoint kinase 1 (CHK1) activation, and finally apoptosis. The roles of p53 and NER in ICL-triggered cell death were confirmed by knockdown of p53 and XPC. Upregulation of XPC and DDB2 in p53wt cells following a single drug treatment is a robust and sustained response that lasts for up to 1 week. Pretreatment with an inducing dose followed by a high and toxic dose of FM provoked an adaptive response as the killing outcome of the challenge dose was reduced. Upregulation of XPC and DDB2 was also observed in a melanoma mouse xenograft model following systemic administration of FM. Additionally, XPC and DDB2 induction occurred upon treatment with other cross-linking anticancer drugs, such as cisplatin and mafosfamide, indicating it is a general response of cancer cells to this group of chemotherapeutics. Collectively, the data indicate that p53-dependent upregulation of XPC and DDB2 is a key mechanism upon genotoxic stress, whereby melanoma cells acquire resistance towards DNA cross-linking agents. To our knowledge, this is the first demonstration of upregulation of NER following a single dose of a DNA interstrand cross-linker, which is a robust and long-lasting effect that impacts the killing response of cancer cells to subsequent treatments.	[Barckhausen, C.; Roos, W. P.; Naumann, S. C.; Kaina, B.] Johannes Gutenberg Univ Mainz, Med Ctr, Inst Toxicol, D-55131 Mainz, Germany	Johannes Gutenberg University of Mainz	Kaina, B (corresponding author), Johannes Gutenberg Univ Mainz, Med Ctr, Inst Toxicol, Obere Zahlbacher Str 67, D-55131 Mainz, Germany.	kaina@uni-mainz.de	Roos, Wynand/B-4846-2008; Kaina, Bernd/AAE-4692-2020	Roos, Wynand/0000-0002-0474-7414; 	DFG [KA724, RO3617]	DFG(German Research Foundation (DFG))	We gratefully acknowledge a gift of DDB2 antibodies from Dr Vesna Rapic- Otrin, University of Pittsburgh and Dr Beate Koberle for her help. We thank Rebekka Kitzinger for technical assistance, Georg Nagel for his help with animal experiments and Christian Henninger for helpful advice concerning tumor sample processing. Work was supported by DFG KA724 and RO3617.	Adimoolam S, 2002, P NATL ACAD SCI USA, V99, P12985, DOI 10.1073/pnas.202485699; Akkari YMN, 2000, MOL CELL BIOL, V20, P8283, DOI 10.1128/MCB.20.21.8283-8289.2000; Batista LFZ, 2007, CANCER RES, V67, P11886, DOI 10.1158/0008-5472.CAN-07-2964; Batista LFZ, 2009, MOL CANCER RES, V7, P237, DOI 10.1158/1541-7786.MCR-08-0428; Berdelle N, 2011, MOL CANCER THER, V10, P2224, DOI 10.1158/1535-7163.MCT-11-0534; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRENT TP, 1987, CANCER RES, V47, P3384; Carson C, 2012, PIGM CELL MELANOMA R, V25, P514, DOI 10.1111/j.1755-148X.2012.01010.x; CASTRESANA JS, 1993, INT J CANCER, V55, P562, DOI 10.1002/ijc.2910550407; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; CHEN JM, 1992, CARCINOGENESIS, V13, P1503; Chen ZW, 2003, CARCINOGENESIS, V24, P1111, DOI 10.1093/carcin/bgg051; Christmann M, 2001, INT J CANCER, V92, P123, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1160>3.3.CO;2-M; De Silva IU, 2000, MOL CELL BIOL, V20, P7980, DOI 10.1128/MCB.20.21.7980-7990.2000; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DOLAN ME, 1989, CARCINOGENESIS, V10, P1613, DOI 10.1093/carcin/10.9.1613; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; FETY R, 1992, CANCER CHEMOTH PHARM, V31, P118, DOI 10.1007/BF00685097; Garbe C, 2010, EUR J CANCER, V46, P270, DOI 10.1016/j.ejca.2009.10.032; Grombacher T, 1998, ONCOGENE, V17, P845, DOI 10.1038/sj.onc.1202000; Haapajarvi T, 1999, CELL GROWTH DIFFER, V10, P163; Hayes MT, 1997, BIOCHEMISTRY-US, V36, P10646, DOI 10.1021/bi970791q; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Jaspers NGJ, 2007, AM J HUM GENET, V80, P457, DOI 10.1086/512486; Kaina B, 2007, DNA REPAIR, V6, P1079, DOI 10.1016/j.dnarep.2007.03.008; KLEEBERG UR, 1995, MELANOMA RES, V5, P195, DOI 10.1097/00008390-199506000-00009; LUBBE J, 1994, J INVEST DERMATOL, V102, P819, DOI 10.1111/1523-1747.ep12381544; Ludlum DB, 1986, IARC SCI PUBL, V70, P137; McHugh PJ, 2006, CELL CYCLE, V5, P1044, DOI 10.4161/cc.5.10.2763; Muller M, 1998, J EXP MED, V188, P2033, DOI 10.1084/jem.188.11.2033; Muniandy PA, 2009, J BIOL CHEM, V284, P27908, DOI 10.1074/jbc.M109.029025; Naumann SC, 2009, BRIT J CANCER, V100, P322, DOI 10.1038/sj.bjc.6604856; Padget K, 2000, BIOCHEM PHARMACOL, V59, P629, DOI 10.1016/S0006-2952(99)00372-X; Passagne I, 2003, J PHARMACOL EXP THER, V307, P816, DOI 10.1124/jpet.103.051938; Pavey S, 2004, ONCOGENE, V23, P4060, DOI 10.1038/sj.onc.1207563; PEGG AE, 1993, BIOCHEMISTRY-US, V32, P11998, DOI 10.1021/bi00096a009; Raschle M, 2008, CELL, V134, P969, DOI 10.1016/j.cell.2008.08.030; Rafferty JA, 1996, ONCOGENE, V12, P693; Roos W, 2004, ONCOGENE, V23, P359, DOI 10.1038/sj.onc.1207080; Roos WP, 2007, ONCOGENE, V26, P186, DOI 10.1038/sj.onc.1209785; Roos WP, 2011, CANCER RES, V71, P4150, DOI 10.1158/0008-5472.CAN-10-3498; Roos WP, 2009, DNA REPAIR, V8, P72, DOI 10.1016/j.dnarep.2008.09.003; Roos WP, 2009, MOL PHARMACOL, V76, P927, DOI 10.1124/mol.109.058131; Sasaki MS, 2004, CYTOGENET GENOME RES, V104, P28, DOI 10.1159/000077463; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Stark M, 2007, CANCER RES, V67, P2632, DOI 10.1158/0008-5472.CAN-06-4152; Tarhini AA, 2004, CURR OPIN ONCOL, V16, P161, DOI 10.1097/00001622-200403000-00014; Tellez CS, 2009, MELANOMA RES, V19, P146, DOI 10.1097/CMR.0b013e32832b274e; Thoma BS, 2005, NUCLEIC ACIDS RES, V33, P2993, DOI 10.1093/nar/gki610; Tian M, 2004, MOL CELL BIOL, V24, P1200, DOI 10.1128/MCB.24.3.1200-1205.2004; Tsaryk R, 2006, CANCER LETT, V239, P305, DOI 10.1016/j.canlet.2005.08.036; Usanova S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-248; Wang QE, 2004, CARCINOGENESIS, V25, P1033, DOI 10.1093/carcin/bgh085; Wu YH, 2007, ONCOGENE, V26, P4761, DOI 10.1038/sj.onc.1210284; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129	55	55	55	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2014	33	15					1964	1974		10.1038/onc.2013.141	http://dx.doi.org/10.1038/onc.2013.141			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RK	23604128				2022-12-28	WOS:000334346300009
J	Martineau, Y; Azar, R; Muller, D; Lasfargues, C; El Khawand, S; Anesia, R; Pelletier, J; Bousquet, C; Pyronnet, S				Martineau, Y.; Azar, R.; Mueller, D.; Lasfargues, C.; El Khawand, S.; Anesia, R.; Pelletier, J.; Bousquet, C.; Pyronnet, S.			Pancreatic tumours escape from translational control through 4E-BP1 loss	ONCOGENE			English	Article						4E-BP1; pancreatic cancer; translation initiation; eIF4E phosphorylation	4E-BINDING PROTEIN-1; INITIATION; CANCER; PHOSPHORYLATION; MNK1; INHIBITION; ACTIVATION; SURVIVAL; MICE	The mRNA cap-binding protein eIF4E (eukaryotic translation initiation factor 4E) permits ribosome recruitment to capped mRNAs, and its phosphorylated form has an important role in cell transformation. The oncogenic function of eIF4E is, however, antagonised by the hypophosphorylated forms of the inhibitory eIF4E-binding proteins 1 and 2. eIF4E-binding protein 1 and 2 (4E-BP1 and 2) are two major targets of the protein kinase mTOR, and are essential for the antiproliferative effects of mTOR inhibitors. Herein, we report that pancreas expresses specifically and massively 4E-BP1 (4E-BP2 is nearly undetectable). However, 4E-BP1 expression is extinguished in more than half of the human pancreatic ductal adenocarcinomas (PDAC). 4E-BP1 shutoff is recapitulated in a mouse genetic model of PDAC, which is based on a pancreas-specific mutation of Kras, the more frequently mutated oncogene in human pancreatic tumours. 4E-BP1 downregulation enhances eIF4E phosphorylation and facilitates pancreatic cancer cell proliferation in vitro and tumour development in vivo. Furthermore, 4E-BP1 loss combined with the absence of 4E-BP2 renders eIF4E phosphorylation, protein synthesis and cell proliferation resistant to mTOR inhibition. However, proliferation can be better limited by a recently developed compound that mimics the function of 4E-BP1 and 2 independently of mTOR inhibition.	[Martineau, Y.; Azar, R.; Mueller, D.; Lasfargues, C.; El Khawand, S.; Anesia, R.; Bousquet, C.; Pyronnet, S.] Univ Toulouse, CRCT, Equipe Labellise Ligue Contre Canc, F-31432 Toulouse, France; [Martineau, Y.; Azar, R.; Mueller, D.; Lasfargues, C.; El Khawand, S.; Anesia, R.; Bousquet, C.; Pyronnet, S.] Fac Med Toulouse, INSERM, UMR 1037, Lab Excellence Toulouse Canc, F-31073 Toulouse, France; [Azar, R.] Lebanese Univ, Fac Pharm, Dept Clin Pharm, Lebanon, NH USA; [Pelletier, J.] McGill Univ, Dept Biochem, Montreal, PQ, Canada; [Pelletier, J.] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ, Canada; [Pyronnet, S.] Univ Rangueil, Ctr Hospitalier, Pole Digestif, Toulouse, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; McGill University; McGill University; CHU de Toulouse	Pyronnet, S (corresponding author), Univ Toulouse, CRCT, Equipe Labellise Ligue Contre Canc, BP 84225, F-31432 Toulouse, France.	stephane.pyronnet@inserm.fr	Martineau, Yvan/G-2387-2017; Pyronnet, Stéphane/P-2419-2014; Müller, David/G-2517-2017; Bousquet, Corinne/P-2917-2014; Müller, David/P-4964-2017	Martineau, Yvan/0000-0002-0575-4085; Bousquet, Corinne/0000-0002-2501-0593; 	INSERM-Universite Paul Sabatier; La LIGUE; Fondation de France; FRM; ARC; La Ligue Nationale Contre le Cancer; CFP; RITC foundation	INSERM-Universite Paul Sabatier; La LIGUE; Fondation de France(Fondation de France); FRM(Fondation pour la Recherche Medicale); ARC(Australian Research Council); La Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); CFP; RITC foundation	This work was supported by grants from INSERM-Universite Paul Sabatier and from La LIGUE ('Comites de Hautes-Pyrenees et de Lot-et-Garonne' and 'Equipes Labellisees' programs) to SP. Yvan Martineau was a recipient of Fondation de France and FRM postdoctoral fellowships. Rania Azar, David Muller and Charline Lasfargues were recipients of doctoral fellowships from ARC, La Ligue Nationale Contre le Cancer and CFP, respectively. Rodica Anesia was supported by the RITC foundation. We thank Dr Marlene Dufresne, Dr Veronique Gigoux and Mr Pascal Clerc for their help in characterising Pdx1Cre-Kras<SUP>G12D</SUP> mice. We thank Professor Nahum Sonenberg for anti-eIF4GI antibody and Dr Philippe Pierre for the anti-puromycin antibody.	Adesso L, 2013, ONCOGENE, V32, P2848, DOI 10.1038/onc.2012.306; Alain T, 2012, CANCER RES, V72, P6468, DOI 10.1158/0008-5472.CAN-12-2395; Armengol G, 2007, CANCER RES, V67, P7551, DOI 10.1158/0008-5472.CAN-07-0881; Averous J, 2008, ONCOGENE, V27, P1106, DOI 10.1038/sj.onc.1210715; Azar R, 2009, EMBO J, V28, P3514, DOI 10.1038/emboj.2009.291; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Bidinosti M, 2010, MOL CELL, V37, P797, DOI 10.1016/j.molcel.2010.02.022; Blagden SP, 2011, NAT REV CLIN ONCOL, V8, P280, DOI 10.1038/nrclinonc.2011.16; Bragado MJ, 2000, GASTROENTEROLOGY, V119, P1731, DOI 10.1053/gast.2000.20242; Cencic R, 2011, J VIROL, V85, P6381, DOI 10.1128/JVI.00078-11; Cencic R, 2011, P NATL ACAD SCI USA, V108, P1046, DOI 10.1073/pnas.1011477108; Dowling RJO, 2010, SCIENCE, V328, P1172, DOI 10.1126/science.1187532; Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038; Furic L, 2010, P NATL ACAD SCI USA, V107, P14134, DOI 10.1073/pnas.1005320107; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Mamane Y, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000242; Martineau Y, 2013, ONCOGENE, V32, P671, DOI 10.1038/onc.2012.116; Morris JP, 2010, NAT REV CANCER, V10, P683, DOI 10.1038/nrc2899; O'Reilly KE, 2009, CLIN CANCER RES, V15, P2872, DOI 10.1158/1078-0432.CCR-08-2336; Pin CL, 2001, J CELL BIOL, V155, P519, DOI 10.1083/jcb.200105060; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Rojo F, 2007, CLIN CANCER RES, V13, P81, DOI 10.1158/1078-0432.CCR-06-1560; Sans MD, 2006, J NUTR, V136, P1792, DOI 10.1093/jn/136.7.1792; Schmidt EK, 2009, NAT METHODS, V6, P275, DOI [10.1038/NMETH.1314, 10.1038/nmeth.1314]; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Topisirovic I, 2004, CANCER RES, V64, P8639, DOI 10.1158/0008-5472.CAN-04-2677; Tsukiyama-Kohara K, 2001, NAT MED, V7, P1128, DOI 10.1038/nm1001-1128; TsukiyamaKohara K, 1996, GENOMICS, V38, P353, DOI 10.1006/geno.1996.0638; Ueda T, 2010, P NATL ACAD SCI USA, V107, P13984, DOI 10.1073/pnas.1008136107; Wander SA, 2011, J CLIN INVEST, V121, P1231, DOI 10.1172/JCI44145; Waskiewicz AJ, 1999, MOL CELL BIOL, V19, P1871; Wolpin BM, 2009, J CLIN ONCOL, V27, P193, DOI 10.1200/JCO.2008.18.9514	32	39	39	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2014	33	11					1367	1374		10.1038/onc.2013.100	http://dx.doi.org/10.1038/onc.2013.100			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD0SD	23563181				2022-12-28	WOS:000332943500004
J	Saito, K; Sakaguchi, M; Iioka, H; Matsui, M; Nakanishi, H; Huh, NH; Kondo, E				Saito, K.; Sakaguchi, M.; Iioka, H.; Matsui, M.; Nakanishi, H.; Huh, N. H.; Kondo, E.			Coxsackie and adenovirus receptor is a critical regulator for the survival and growth of oral squamous carcinoma cells	ONCOGENE			English	Article						CAR; ROCK; anoikis; SCC	RHO-KINASE; BLADDER-CANCER; TIGHT JUNCTION; E-CADHERIN; CAR; EXPRESSION; ANOIKIS; DOMAIN; KERATINOCYTES; ACTIVATION	Coxsackie and adenovirus receptor (CAR) is essential for adenovirus infection to target cells, and its constitutive expression in various cancerous and normal tissues has been reported. Recently, the biological role of CAR in human cancers of several different origins has been investigated with respect to tumor progression, metastasis and tumorigenesis. However, its biological function in tumor cells remains controversial. Here we report the critical role of CAR in growth regulation of oral squamous cell carcinomas (SCCs) in vitro and in vivo via the specific interaction with Rho-associated protein kinase (ROCK). Loss of endogenous CAR expression by knockdown using specific small interfering RNA (siRNA) against CAR facilitates growth suppression of SCC cells due to cell dissociation, followed by apoptosis. The consequent morphological reaction was reminiscent of anoikis, rather than epithelial-mesenchymal transition, and the dissociation of oral SCC cells was triggered not by lack of contact with extracellular matrix, but by loss of cell-to-cell contact caused by abnormal translocation of E-cadherin from surface membrane to cytoplasm. Immunoprecipitation assays of the CAR-transfected oral SCC cell line, HSC-2, with or without ROCK inhibitor (Y-27632) revealed that CAR directly associates with ROCK! and ROCKII, which results in inhibition of ROCK activity and contributes to maintenance of cell-to-cell adhesion for their growth and survival. Based on these findings, in vivo behavior of CAR-downregulated HSC-2 cells from siRNA knockdown was compared with that of normally CAR-expressing cells in intraperitoneally xenografted mouse models. The mice engrafted with CAR siRNA-pretreated HSC-2 cells showed poor formation of metastatic foci in contrast to those implanted with the control siRNA-pretreated cells. Thus, CAR substantially has an impact on growth and survival of oral SCC cells as a negative regulator of ROCK in vitro and in vivo.	[Saito, K.; Iioka, H.; Matsui, M.; Nakanishi, H.; Kondo, E.] Aichi Canc Ctr, Res Inst, Div Oncol Pathol, Nagoya, Aichi 4648681, Japan; [Sakaguchi, M.; Huh, N. H.] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Cell Biol, Okayama 7008530, Japan; [Iioka, H.] Aichi Med Univ, Adv Med Res Ctr, Div Translat Res, Nagakute, Aichi 48011, Japan; [Kondo, E.] Nagoya Univ, Grad Sch Med, Dept Epidemiol, Program Hlth & Community Med, Nagoya, Aichi 4648601, Japan	Aichi Cancer Center; Okayama University; Aichi Medical University; Nagoya University	Kondo, E (corresponding author), Aichi Canc Ctr, Res Inst, Div Oncol Pathol, Chikusa Ku, 1-1 Kanokoden, Nagoya, Aichi 4648681, Japan.	ekondo@aichi-cc.jp	Sakaguchi, Masakiyo/B-2280-2011; Iioka, Hidekazu/AAB-1424-2021	Iioka, Hidekazu/0000-0002-2639-8315	Grants-in-Aid for Scientific Research [23650625] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Anders M, 2009, CANCER GENE THER, V16, P508, DOI 10.1038/cgt.2008.103; Anders M, 2009, BRIT J CANCER, V100, P352, DOI 10.1038/sj.bjc.6604876; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Bruning A, 2005, CLIN CANCER RES, V11, P4316, DOI 10.1158/1078-0432.CCR-04-2370; Cheng HL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-126; Cohen CJ, 2001, P NATL ACAD SCI USA, V98, P15191, DOI 10.1073/pnas.261452898; Coyne CB, 2004, J BIOL CHEM, V279, P48079, DOI 10.1074/jbc.M409061200; Dorner AA, 2005, J CELL SCI, V118, P3509, DOI 10.1242/jcs.02476; Excoffon KJDA, 2004, J CELL SCI, V117, P4401, DOI 10.1242/jcs.01300; Fok PT, 2007, J BIOL CHEM, V282, P7512, DOI 10.1074/jbc.M607230200; Fouquet S, 2004, J BIOL CHEM, V279, P43061, DOI 10.1074/jbc.M405095200; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Giaginis C, 2010, APMIS, V118, P210, DOI 10.1111/j.1600-0463.2009.02582.x; HERMISTON ML, 1995, J CELL BIOL, V129, P489, DOI 10.1083/jcb.129.2.489; Huang KC, 2005, INT J CANCER, V113, P738, DOI 10.1002/ijc.20623; Lai JM, 2003, J CELL SCI, V116, P3491, DOI 10.1242/jcs.00660; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Marconi A, 2004, J CELL SCI, V117, P5815, DOI 10.1242/jcs.01490; Maseki S, 2012, BRIT J CANCER, V106, P1196, DOI 10.1038/bjc.2012.24; Matsumoto K, 2005, UROLOGY, V66, P441, DOI 10.1016/j.urology.2005.02.033; Mayr GA, 1997, J VIROL, V71, P412, DOI 10.1128/JVI.71.1.412-418.1997; Mege RM, 2006, CURR OPIN CELL BIOL, V18, P541, DOI 10.1016/j.ceb.2006.08.004; Okegawa T, 2000, CANCER RES, V60, P5031; Okegawa T, 2001, CANCER RES, V61, P6592; Qin M, 2004, CANCER RES, V64, P6377, DOI 10.1158/0008-5472.CAN-04-1490; Sakaguchi M, 2003, J CELL BIOL, V163, P825, DOI 10.1083/jcb.200304017; Sakaguchi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023132; Schackmann RCJ, 2011, J CLIN INVEST, V121, P3176, DOI 10.1172/JCI41695; Shewan AM, 2005, MOL BIOL CELL, V16, P4531, DOI 10.1091/mbc.E05-04-0330; Shi JJ, 2007, ARCH IMMUNOL THER EX, V55, P61, DOI 10.1007/s00005-007-0009-7; Sollerbrant K, 2003, J BIOL CHEM, V278, P7439, DOI 10.1074/jbc.M205927200; Stecker K, 2011, BRIT J CANCER, V104, P1426, DOI 10.1038/bjc.2011.116; Stoff A, 2006, WOUND REPAIR REGEN, V14, P608, DOI 10.1111/j.1743-6109.2006.00168.x; Street CA, 2011, ANTICANCER RES, V31, P3645; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; Valentijn AJ, 2004, J BIOL CHEM, V279, P32848, DOI 10.1074/jbc.M313375200; Verdino P, 2010, SCIENCE, V329, P1210, DOI 10.1126/science.1187996; Vigl B, 2009, EXP CELL RES, V315, P336, DOI 10.1016/j.yexcr.2008.10.020; Walters RW, 2002, CELL, V110, P789, DOI 10.1016/S0092-8674(02)00912-1; Xiao LQ, 2009, J BIOL CHEM, V284, P29365, DOI 10.1074/jbc.M109.007971; Yamashita M, 2007, INT J CANCER, V121, P1690, DOI 10.1002/ijc.22852; Yonemura S, 2011, CURR OPIN CELL BIOL, V23, P515, DOI 10.1016/j.ceb.2011.07.001	42	16	18	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2014	33	10					1274	1286		10.1038/onc.2013.66	http://dx.doi.org/10.1038/onc.2013.66			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AC6KI	23503462				2022-12-28	WOS:000332631100008
J	Nottingham, LK; Yan, CH; Yang, X; Si, H; Coupar, J; Bian, Y; Cheng, TF; Allen, C; Arun, P; Gius, D; Dang, L; Van Waes, C; Chen, Z				Nottingham, L. K.; Yan, C. H.; Yang, X.; Si, H.; Coupar, J.; Bian, Y.; Cheng, T-F; Allen, C.; Arun, P.; Gius, D.; Dang, L.; Van Waes, C.; Chen, Z.			Aberrant IKK alpha and IKK beta cooperatively activate NF-kappa B and induce EGFR/AP1 signaling to promote survival and migration of head and neck cancer	ONCOGENE			English	Article						IKK alpha; IKK beta; NF-kappa B; AP1; head and neck cancers	SQUAMOUS-CELL CARCINOMA; GROWTH-FACTOR RECEPTOR; INDUCED GENE-EXPRESSION; PROSTATE-CANCER; KINASE-ALPHA; TGF-BETA; CONSTITUTIVE ACTIVATION; TRANSCRIPTION FACTORS; TUMOR-GROWTH; IN-VIVO	The inhibitor-kappa B kinase-nuclear factor-kappa B (IKK-NF-kappa B) and epidermal growth factor receptor-activator protein-1 (EGFR-AP1) pathways are often co-activated and promote malignant behavior, but the underlying basis for this relationship is unclear. Resistance to inhibitors of IKK beta or EGFR is observed in head and neck squamous cell carcinomas (HNSCC). Here, we reveal that both IKK alpha and beta contribute to nuclear activation of canonical and alternate NF-kappa B/REL family transcription factors, and overexpression of signal components that enhance co-activation of the EGFR-AP1 pathway. We observed that IKK alpha and IKK beta exhibit increased protein expression, nuclear localization, and phosphorylation in HNSCC tissues and cell lines. Individually, IKK activity varied among different cell lines, but overexpression of both IKKs induced the strongest NF-kappa B activation. Conversely, siRNA knock down of both IKKs significantly decreased nuclear localization and phosphorylation of canonical RELA and I kappa B alpha and alternative p52 and RELB subunits. Knock down of both IKKs more effectively inhibited NF-kappa B activation, broadly modulated gene expression and suppressed cell proliferation and migration. Global expression profiling revealed that NF-kappa B, cytokine, inflammatory response and growth factor signaling are among the top pathways and networks regulated by IKKs. Importantly, IKK alpha and IKK beta together promoted the expression and activity of transforming growth factor a, EGFR and AP1 transcription factors cJun, JunB and Fra1. Knock down of AP1 subunits individually decreased 8/15 (53%) of IKK-targeted genes sampled and similarly inhibited cell proliferation and migration. Mutations of NF-kappa B and AP1-binding sites abolished or decreased IKK-induced interleukin-8 (IL-8) promoter activity. Compounds such as wedelactone with dual IKK inhibitory activity and geldanomycins that block IKK alpha/beta and EGFR pathways were more active than IKK beta-specific inhibitors in suppressing NF-kappa B activation and proliferation and inducing cell death. We conclude that IKK alpha and IKK beta cooperatively activate NF-kappa B and EGFR/AP1 networks of signaling pathways and contribute to the malignant phenotype and the intrinsic or acquired therapeutic resistance of HNSCC.	[Nottingham, L. K.; Yan, C. H.; Yang, X.; Si, H.; Coupar, J.; Bian, Y.; Cheng, T-F; Allen, C.; Arun, P.; Van Waes, C.; Chen, Z.] NIDCD, Tumor Biol Sect, Head & Neck Surg Branch, NIH, Bethesda, MD 20892 USA; [Yan, C. H.] NIH, Howard Hughes Med Inst, Res Scholars Program, Bethesda, MD 20892 USA; [Allen, C.] Clin Res Training Program, Bethesda, MD USA; [Allen, C.] Pfizer Inc, Bethesda, MD USA; [Gius, D.] Vanderbilt Univ, Med Ctr, Dept Radiat Oncol, Nashville, TN USA; [Dang, L.] Millennium Pharmaceut Inc, Cambridge, MA USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Howard Hughes Medical Institute; National Institutes of Health (NIH) - USA; Pfizer; Pfizer; Vanderbilt University; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Chen, Z (corresponding author), NIDCD, Tumor Biol Sect, Head & Neck Surg Branch, NIH, 10-5D55,MSC-1419, Bethesda, MD 20892 USA.	vanwaesc@nidcd.nih.gov; chenz@nidcd.nih.gov	Allen, Clint/AAD-7016-2021	Allen, Clint/0000-0001-6586-5804; Dang, Lenny/0000-0002-2073-6109; Yan, Carol/0000-0003-1934-4922	NIDCD [Z01-DC-00016, Z01-DC-00073, Z01-DC-00074]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [ZIADC000016, K08DC000073] Funding Source: NIH RePORTER	NIDCD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	This project is supported by NIDCD Intramural projects Z01-DC-00016, Z01-DC-00073 and Z01-DC-00074. We thank Dr Michael Karin (UC San Diego) and Dr Ulrich Siebenlist (NIH/NIAID) for kindly providing the IKK plasmids; Dr Neil Perkins (Newcastle University, UK) for kindly providing anti-p-p52 antibody; Dr Jialing Zhang for technical assistance; and Dr Michael Karin, Dr Christophe Cataisson (NCI/NIH) and Dr Claire Sauvageot (Millennium Pharmaceuticals, Inc) for critique of the manuscript.	Adams J, 2004, NAT REV CANCER, V4, P349, DOI 10.1038/nrc1361; Allen C, 2008, CLIN CANCER RES, V14, P4175, DOI 10.1158/1078-0432.CCR-07-4470; Ammirante M, 2010, NATURE, V464, P302, DOI 10.1038/nature08782; Anest V, 2003, NATURE, V423, P659, DOI 10.1038/nature01648; Anest V, 2004, J BIOL CHEM, V279, P31183, DOI 10.1074/jbc.M404380200; Argiris A, 2011, CLIN CANCER RES, V17, P5755, DOI 10.1158/1078-0432.CCR-11-0861; Barre B, 2010, CELL CYCLE, V9, P4774, DOI 10.4161/cc.9.24.14246; Barre B, 2010, MOL CELL, V38, P524, DOI 10.1016/j.molcel.2010.03.018; Basak S, 2008, CYTOKINE GROWTH F R, V19, P187, DOI 10.1016/j.cytogfr.2008.04.005; Basak S, 2008, MOL CELL BIOL, V28, P3139, DOI 10.1128/MCB.01469-07; Bednarski BK, 2008, MOL CANCER THER, V7, P1827, DOI 10.1158/1535-7163.MCT-08-0321; Bian Y, 2012, ONCOGENE, V31, P3322, DOI 10.1038/onc.2011.494; Bivona TG, 2011, NATURE, V471, P523, DOI 10.1038/nature09870; Carayol N, 2006, J BIOL CHEM, V281, P31142, DOI 10.1074/jbc.M603417200; Chen Z, 2008, MOL CANCER THER, V7, P1949, DOI 10.1158/1535-7163.MCT-07-2046; Cohen J, 2009, CANCER RES, V69, P3415, DOI 10.1158/0008-5472.CAN-08-3704; Debinski W, 2011, CANCER BIOL THER, V11, P254, DOI 10.4161/cbt.11.2.13953; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Duffey DC, 1999, CANCER RES, V59, P3468; Egorin MJ, 2002, CANCER CHEMOTH PHARM, V49, P7, DOI 10.1007/s00280-001-0380-8; Freudlsperger C, 2013, ONCOGENE, V32, P1549, DOI 10.1038/onc.2012.171; Fusco AJ, 2008, J BIOL CHEM, V283, P12324, DOI 10.1074/jbc.M707898200; Gomard T, 2010, PLOS ONE, V5, pA178, DOI 10.1371/journal.pone.0009585; GRANDIS JR, 1993, CANCER RES, V53, P3579; Hacker H., 2006, SCI STKE, V2006, P13, DOI [10.1126/stke.3572006re13, DOI 10.1126/STKE.3572006RE13]; Hertlein E, 2010, BLOOD, V116, P45, DOI 10.1182/blood-2010-01-263756; Hinz M, 2012, IMMUNOL REV, V246, P59, DOI 10.1111/j.1600-065X.2012.01102.x; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kobori M, 2004, CELL DEATH DIFFER, V11, P123, DOI 10.1038/sj.cdd.4401325; Krappmann D, 2004, MOL CELL BIOL, V24, P6488, DOI 10.1128/MCB.24.14.6488-6500.2004; Lam LT, 2008, P NATL ACAD SCI USA, V105, P20798, DOI 10.1073/pnas.0806491106; Lam LT, 2005, CLIN CANCER RES, V11, P28; Lee TL, 2006, MOL CANCER THER, V5, P8, DOI 10.1158/1535-7163.MCT-05-0069; Liu BG, 2008, CANCER CELL, V14, P212, DOI 10.1016/j.ccr.2008.07.017; Madge LA, 2008, J IMMUNOL, V180, P3467, DOI 10.4049/jimmunol.180.5.3467; Madge LA, 2010, J BIOL CHEM, V285, P38069, DOI 10.1074/jbc.M110.147207; Marinari B, 2008, P NATL ACAD SCI USA, V105, P17091, DOI 10.1073/pnas.0809288105; Mishra A, 2010, INT J CANCER, V126, P819, DOI 10.1002/ijc.24807; Nagashima K, 2006, BLOOD, V107, P4266, DOI 10.1182/blood-2005-09-3852; Ndlovu MN, 2009, MOL CELL BIOL, V29, P5488, DOI 10.1128/MCB.01657-08; Ondrey FG, 1999, MOL CARCINOGEN, V26, P119, DOI 10.1002/(SICI)1098-2744(199910)26:2<119::AID-MC6>3.0.CO;2-N; Park EM, 2011, FUTURE ONCOL, V7, P123, DOI [10.2217/fon.10.166, 10.2217/FON.10.166]; Pernas FG, 2009, CLIN CANCER RES, V15, P2361, DOI 10.1158/1078-0432.CCR-08-1011; Savinova OV, 2009, MOL CELL, V34, P591, DOI 10.1016/j.molcel.2009.04.033; Scheidereit C, 2012, KEYST S NF KAPPAB SI; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; Sharafinski ME, 2010, HEAD NECK-J SCI SPEC, V32, P1412, DOI 10.1002/hed.21365; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Sunwoo JB, 2001, CLIN CANCER RES, V7, P1419; Van Waes C, 2007, CLIN CANCER RES, V13, P1076, DOI 10.1158/1078-0432.CCR-06-2221; Wolf MJ, 2010, ONCOGENE, V29, P5006, DOI 10.1038/onc.2010.260; Yamamoto Y, 2000, MOL CELL BIOL, V20, P3655, DOI 10.1128/MCB.20.10.3655-3666.2000; Yang XP, 2011, CANCER RES, V71, P3688, DOI 10.1158/0008-5472.CAN-10-3445; Yemelyanov A, 2006, ONCOGENE, V25, P387, DOI 10.1038/sj.onc.1209066; Younes F, 1996, Oral Dis, V2, P25; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zerbini LF, 2003, CANCER RES, V63, P2206	58	63	67	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2014	33	9					1135	1147		10.1038/onc.2013.49	http://dx.doi.org/10.1038/onc.2013.49			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XT	23455325	Green Accepted			2022-12-28	WOS:000331933800007
J	Xie, X; Piao, L; Bullock, BN; Smith, A; Su, T; Zhang, M; Teknos, TN; Arora, PS; Pan, Q				Xie, X.; Piao, L.; Bullock, B. N.; Smith, A.; Su, T.; Zhang, M.; Teknos, T. N.; Arora, P. S.; Pan, Q.			Targeting HPV16 E6-p300 interaction reactivates p53 and inhibits the tumorigenicity of HPV-positive head and neck squamous cell carcinoma	ONCOGENE			English	Article						human papillomavirus; anticancer therapeutics; p53; p300; head and neck cancer	HUMAN-PAPILLOMAVIRUS TYPE-16; E6 ONCOPROTEIN; CERVICAL-CANCER; STRUCTURAL BASIS; STEM-CELLS; PROTEIN; ACETYLATION; ACTIVATION; UBIQUITINATION; IDENTIFICATION	The incidence of human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC) has rapidly increased over the past 30 years, prompting the suggestion that an epidemic maybe on the horizon. Therefore, there is a clinical need to develop alternate therapeutic strategies to manage the growing number of HPV-positive HNSCC patients. High-risk HPV E6 inactivates p53 through two distinct mechanisms; association with E6AP to degrade p53 and association with p300 to block p300-mediated p53 acetylation and activation. In this study, we determined if targeting the E6-p300 interaction is an effective approach to reactivate p53 in HPV-positive HNSCC. Ectopic expression of the CH1 domain of p300 in HPV-positive HNSCC blocks the association between E6 and p300, increases total and acetylated p53 levels and enhances p53 transcriptional activity. Moreover, expression of p21, miR-34a and miR-200c are increased, demonstrating functional p53 reactivation. CH1 overexpression in HPV-positive HNSCC has a global anticancer effect resulting in a decrease in cell proliferation and clonogenic survival and an increase in apoptosis. The in vivo tumor-initiating ability of HPV-positive HNSCC is severely compromised with CH1 overexpression, in part through a reduction in the cancer-initiating cell population. A novel small-molecule CH1 inhibitor, CH1iB, reactivates p53 and potentiates the anticancer activity of cis-platinum in HPV-positive HNSCC cells. Our work shows that CH1-domain inhibitors represent a novel class of p53-reactivation therapeutics for managing HPV-positive HNSCC patients.	[Xie, X.; Piao, L.; Smith, A.; Su, T.; Zhang, M.; Teknos, T. N.; Pan, Q.] Ohio State Univ, Med Ctr, Dept Otolaryngol Head & Neck Surg, Columbus, OH 43210 USA; [Xie, X.; Piao, L.; Smith, A.; Su, T.; Zhang, M.; Teknos, T. N.; Pan, Q.] Arthur G James Canc Hosp, Columbus, OH USA; [Xie, X.; Piao, L.; Smith, A.; Su, T.; Zhang, M.; Teknos, T. N.; Pan, Q.] Ohio State Univ, Ctr Comprehens Canc, Richard J Solove Res Inst, Columbus, OH 43210 USA; [Bullock, B. N.; Arora, P. S.] NYU, Dept Chem, New York, NY 10003 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; New York University	Pan, Q (corresponding author), Ohio State Univ, Med Ctr, Dept Otolaryngol Head & Neck Surg, 442 Tzagournis Med Res,420 West 12th Ave, Columbus, OH 43210 USA.	Quintin.Pan@osumc.edu	Pan, Quintin/E-3808-2011; Reever, Larson/H-9685-2019; Arora, Paramjit/AAR-3086-2020	Reever, Larson/0000-0002-5692-4793; 	National Institutes of Health [R01CA135096, R01GM073943]; Mary E. and John W. Alford Cancer Research Endowment Fund; Joan Bisesi Fund for Head and Neck Oncology Research; Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Ohio State University Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE [R01CA135096, P30CA016058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM073943] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mary E. and John W. Alford Cancer Research Endowment Fund; Joan Bisesi Fund for Head and Neck Oncology Research; Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Ohio State University Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported in part by National Institutes of Health grants R01CA135096 (to QP) and R01GM073943 (to PSA); Mary E. and John W. Alford Cancer Research Endowment Fund; The Michelle Theado Memorial Grant from the Joan Bisesi Fund for Head and Neck Oncology Research; and Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Ohio State University Comprehensive Cancer Center.	Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923; Balz V, 2003, CANCER RES, V63, P1188; Beerheide W, 2000, BIOORGAN MED CHEM, V8, P2549, DOI 10.1016/S0968-0896(00)00193-0; Beerheide W, 1999, J NATL CANCER I, V91, P1211, DOI 10.1093/jnci/91.14.1211; BeerRomero P, 1997, ONCOGENE, V14, P595, DOI 10.1038/sj.onc.1200872; Chang CJ, NAT CELL BIOL MAR, p[13, 317]; Chen YC, 2009, BIOCHEM BIOPH RES CO, V385, P307, DOI 10.1016/j.bbrc.2009.05.048; Choi YJ, NAT CELL BIOL, P1353; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Clay MR, 2010, HEAD NECK-J SCI SPEC, V32, P1195, DOI 10.1002/hed.21315; Courtete J, 2007, MOL CANCER THER, V6, P1728, DOI 10.1158/1535-7163.MCT-06-0808; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Gillison ML, 2000, JNCI-J NATL CANCER I, V92, P709, DOI 10.1093/jnci/92.9.709; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hammarstedt L, 2006, INT J CANCER, V119, P2620, DOI 10.1002/ijc.22177; Henchey LK, 2010, J AM CHEM SOC, V132, P941, DOI 10.1021/ja9082864; Hong H, 2009, NATURE, V460, P1132, DOI 10.1038/nature08235; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Ito A, 2002, EMBO J, V21, P6236, DOI 10.1093/emboj/cdf616; Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308; Kawamura T, 2009, NATURE, V460, P1140, DOI 10.1038/nature08311; Klussmann JP, 2003, AM J PATHOL, V162, P747, DOI 10.1016/S0002-9440(10)63871-0; Kobet E, 2000, P NATL ACAD SCI USA, V97, P12547, DOI 10.1073/pnas.97.23.12547; Koivusalo R, 2006, CANCER RES, V66, P11817, DOI 10.1158/0008-5472.CAN-06-2185; Laz TH, 2012, VACCINE, V30, P3534, DOI 10.1016/j.vaccine.2012.03.067; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Licitra Lisa, 2006, Curr Opin Otolaryngol Head Neck Surg, V14, P95, DOI 10.1097/01.moo.0000193170.23956.5f; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Munoz N, 2010, JNCI-J NATL CANCER I, V102, P325, DOI 10.1093/jnci/djp534; Pan Q, 2009, EXPERT OPIN PHARMACO, V10, P2291, DOI 10.1517/14656560903136754; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; Patgiri A, 2008, ACCOUNTS CHEM RES, V41, P1289, DOI 10.1021/ar700264k; Patgiri A, 2010, NAT PROTOC, V5, P1857, DOI 10.1038/nprot.2010.146; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Reiter PL, 2011, VACCINE, V29, P5595, DOI 10.1016/j.vaccine.2011.06.020; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Shiboski CH, 2005, CANCER-AM CANCER SOC, V103, P1843, DOI 10.1002/cncr.20998; Sigurdsson K, 2009, ACTA OBSTET GYN SCAN, V88, P27, DOI 10.1080/00016340802566770; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Sturgis EM, 2007, CANCER-AM CANCER SOC, V110, P1429, DOI 10.1002/cncr.22963; Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439; Thomas MC, 2005, MOL CELL, V17, P251, DOI 10.1016/j.molcel.2004.12.016; Utikal J, 2009, NATURE, V460, P1145, DOI 10.1038/nature08285; Villa LL, 2007, NEW ENGL J MED, V356, P1915, DOI 10.1056/NEJMoa061741; White JS, 2007, ORAL ONCOL, V43, P701, DOI 10.1016/j.oraloncology.2006.09.001; Zhao CY, 2010, CANCER RES, V70, P3372, DOI 10.1158/0008-5472.CAN-09-2787; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999	49	48	52	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2014	33	8					1037	1046		10.1038/onc.2013.25	http://dx.doi.org/10.1038/onc.2013.25			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XO	23474763	Green Accepted			2022-12-28	WOS:000331933200011
J	Zhai, C; Li, Y; Mascarenhas, C; Lin, Q; Li, K; Vyrides, I; Grant, CM; Panaretou, B				Zhai, C.; Li, Y.; Mascarenhas, C.; Lin, Q.; Li, K.; Vyrides, I.; Grant, C. M.; Panaretou, B.			The function of ORAOV1/LTO1, a gene that is overexpressed frequently in cancer: essential roles in the function and biogenesis of the ribosome	ONCOGENE			English	Article						ribosome biogenesis; translation; Fe - S cluster; squamous cell carcinoma	YEAST SACCHAROMYCES-CEREVISIAE; SQUAMOUS-CELL CARCINOMAS; NUCLEAR EXPORT; OXIDATIVE-STRESS; GLOBAL ANALYSIS; PROTEIN RLI1; ORAL-CANCER; TRANSLATION; 11Q13; ABCE1	ORAOV1 (oral cancer overexpressed) is overexpressed in many solid tumours, making a key contribution to the development of cancer, but the cellular role of ORAOV1 is unknown. The yeast orthologue of this protein is encoded by the hitherto uncharacterized essential gene, YNL260c. Expression of ORAOV1 restores viability to yeast cells lacking YNL260c. Under nonpermissive conditions, our conditional mutants of YNL260c are defective in the maturation of the 60S ribosomal subunit, whereas maturation of the 40S subunit is unaffected. Also, initiation of translation is abrogated when YNL260c function is lost. YNL260c is indispensible for life in oxygen, but is nonessential under anaerobic conditions. Consequently, the toxic affects of aerobic metabolism on biogenesis and function of the ribosome are alleviated by YNL260c, hence, we rename YNL260c as LTO1; required for biogenesis of the large ribosomal subunit and initiation of translation in oxygen. Lto1 is found in a complex with Rli1/ABCE1, an ATP-binding cassette (ABC)-ATPase bearing N-terminal [4Fe - 4S] clusters. Like Lto1, the Rli1/ABCE1 [4Fe - 4S] clusters are not required for viability under anaerobic conditions, but are essential in the presence of oxygen. Loss of Lto1 function renders cells susceptible to hydroperoxide pro-oxidants, though this type of sensitivity is specific to certain types of oxidative stress as the lto1 mutants are not sensitive to an agent that oxidizes thiols. These findings reflect a functional interaction between Lto1 and the Rli1/ABCE1 [4Fe - 4S] clusters, as part of a complex, which relieves the toxic effects of reactive oxygen species (ROS) on biogenesis and function of the ribosome. This complex also includes Yae1, which bridges the interaction between Lto1 and Rli1/ABCE1. Interactions between members of this complex were demonstrated both in vivo and in vitro. An increased generation of ROS is a feature shared by many cancers. The ORAOV1 complex could prevent ROS-induced ribosomal damage, explaining why overexpression of ORAOV1 is so common in solid tumours.	[Zhai, C.; Li, Y.; Lin, Q.; Li, K.; Vyrides, I.; Panaretou, B.] Kings Coll London, Inst Pharmaceut Sci, London SE1 9NH, England; [Mascarenhas, C.; Grant, C. M.] Univ Manchester, Fac Life Sci, Manchester, Lancs, England; [Li, K.] Chinese Acad Sci, Inst Hydrobiol, Wuhan, Peoples R China	University of London; King's College London; University of Manchester; Chinese Academy of Sciences; Institute of Hydrobiology, CAS	Panaretou, B (corresponding author), Kings Coll London, Inst Pharmaceut Sci, Franklin Wilkins Bldg,150 Stamford St, London SE1 9NH, England.	barry.panaretou@kcl.ac.uk	; Vyrides, Ioannis/D-1625-2016	Grant, Chris/0000-0002-0616-6576; Vyrides, Ioannis/0000-0001-8316-4577	National Natural Science Foundation of China [31100057]; Biotechnology and Biological Sciences Research Council [BB/E00623X/1] Funding Source: researchfish; BBSRC [BB/E00623X/1] Funding Source: UKRI	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	CZ was partly supported by the National Natural Science Foundation of China (grant No.31100057). We thank Ed Hurt (University of Heidelberg, Germany) for providing ribosomal subunit reporter plasmids.	AKERVALL JA, 1995, CANCER, V76, P853, DOI 10.1002/1097-0142(19950901)76:5<853::AID-CNCR2820760520>3.0.CO;2-6; Alhebshi A, 2012, MOL BIOL CELL, V23, P3582, DOI 10.1091/mbc.E12-05-0413; Ashe MP, 2000, MOL BIOL CELL, V11, P833, DOI 10.1091/mbc.11.3.833; Barthelme D, 2007, J BIOL CHEM, V282, P14598, DOI 10.1074/jbc.M700825200; Bassler J, 2001, MOL CELL, V8, P517, DOI 10.1016/S1097-2765(01)00342-2; Boal AK, 2005, BIOCHEMISTRY-US, V44, P8397, DOI 10.1021/bi047494n; Boal AK, 2009, P NATL ACAD SCI USA, V106, P15237, DOI 10.1073/pnas.0908059106; Chen ZQ, 2006, J BIOL CHEM, V281, P7452, DOI 10.1074/jbc.M510603200; Dong JS, 2004, J BIOL CHEM, V279, P42157, DOI 10.1074/jbc.M404502200; Gadal O, 2001, MOL CELL BIOL, V21, P3405, DOI 10.1128/MCB.21.10.3405-3415.2001; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Gollin SM, 2001, HEAD NECK-J SCI SPEC, V23, P238, DOI 10.1002/1097-0347(200103)23:3<238::AID-HED1025>3.0.CO;2-H; Hawle P, 2007, EUKARYOT CELL, V6, P521, DOI 10.1128/EC.00343-06; Hazbun TR, 2003, MOL CELL, V12, P1353, DOI 10.1016/S1097-2765(03)00476-3; Hu B, 2005, MOL MICROBIOL, V55, P1735, DOI 10.1111/j.1365-2958.2005.04531.x; Huang X, 2006, GENE CHROMOSOME CANC, V45, P1058, DOI 10.1002/gcc.20371; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; James P, 1996, GENETICS, V144, P1425; Janke C, 2004, YEAST, V21, P947, DOI 10.1002/yea.1142; Jiang L, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-20; Jin YS, 1998, GENE CHROMOSOME CANC, V22, P312, DOI 10.1002/(SICI)1098-2264(199808)22:4<312::AID-GCC7>3.0.CO;2-Y; Khoshnevis S, 2010, EMBO REP, V11, P214, DOI 10.1038/embor.2009.272; Kispal G, 2005, EMBO J, V24, P589, DOI 10.1038/sj.emboj.7600541; KOSOWER NS, 1995, METHOD ENZYMOL, V251, P123, DOI 10.1016/0076-6879(95)51116-4; Krogan NJ, 2006, NATURE, V440, P637, DOI 10.1038/nature04670; LESE CM, 1995, GENE CHROMOSOME CANC, V12, P288, DOI 10.1002/gcc.2870120409; Li ZH, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000213; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Mascarenhas C, 2008, MOL BIOL CELL, V19, P2995, DOI 10.1091/mbc.E07-11-1173; Mollapour M, 2007, MOL CELL BIOL, V27, P6446, DOI 10.1128/MCB.02205-06; Mroczek S, 2008, NUCLEIC ACIDS RES, V36, P2874, DOI 10.1093/nar/gkm1100; Pisarev AV, 2010, MOL CELL, V37, P196, DOI 10.1016/j.molcel.2009.12.034; Rose MD., 1990, METHODS YEAST GENETI; Shoemaker CJ, 2011, P NATL ACAD SCI USA, V108, pE1392, DOI 10.1073/pnas.1113956108; Snoek ISI, 2006, FEMS YEAST RES, V6, P393, DOI 10.1111/j.1567-1364.2005.00007.x; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Thorpe GW, 2004, P NATL ACAD SCI USA, V101, P6564, DOI 10.1073/pnas.0305888101; TOYOKUNI S, 1995, FEBS LETT, V358, P1, DOI 10.1016/0014-5793(94)01368-B; Trotter EW, 2008, BIOCHEM J, V412, P73, DOI 10.1042/BJ20071634; Tschochner H, 2003, TRENDS CELL BIOL, V13, P255, DOI 10.1016/S0962-8924(03)00054-0; Yao W, 2007, MOL CELL, V26, P51, DOI 10.1016/j.molcel.2007.02.018; Yarunin A, 2005, EMBO J, V24, P580, DOI 10.1038/sj.emboj.7600540; Zhai C, 2008, BIOCHEM J, V415, P455, DOI 10.1042/BJ20080209	44	29	31	2	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2014	33	4					484	494		10.1038/onc.2012.604	http://dx.doi.org/10.1038/onc.2012.604			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VX	23318452				2022-12-28	WOS:000330214600009
J	Meyer, DS; Aceto, N; Sausgruber, N; Brinkhaus, H; Muller, U; Pallen, CJ; Bentires-Alj, M				Meyer, D. S.; Aceto, N.; Sausgruber, N.; Brinkhaus, H.; Mueller, U.; Pallen, C. J.; Bentires-Alj, M.			Tyrosine phosphatase PTP alpha contributes to HER2-evoked breast tumor initiation and maintenance	ONCOGENE			English	Article						phosphatases; breast cancer; HER2	CANCER CELL-LINES; EPITHELIAL-CELLS; MAMMARY-TUMORS; IN-VITRO; SRC; 1B; ACTIVATION; IDENTIFICATION; TRANSFORMATION; KINASES	Protein tyrosine phosphatase alpha (PTP alpha/PTPRA) was shown previously to be overexpressed in human primary breast cancers, and to suppress apoptosis in estrogen receptor-negative breast cancer cells in vitro. However, it is not known whether PTP alpha is important for mammary tumor initiation, maintenance and/or progression. We have used a combination of three-dimensional cultures, a transgenic mouse model of breast cancer lacking PTP alpha as well as xenografts of human breast cancer cell lines to address these questions. We found that PTP alpha knockdown after overt tumor development reduced the growth of HER2-positive human breast cancer cell lines, and that this effect was accompanied by a reduction in AKT phosphorylation. However, PTP alpha knockdown did not affect invasiveness of HER2-positive human breast cancer cells grown in three-dimensional cultures. Moreover, in MMTV-NeuNT/PTP alpha(-/-) mice, PTP alpha ablation did not affect NeuNT-evoked tumor onset or metastasis but decreased the number of tumors per mouse. Thus, we demonstrate that PTP alpha contributes to both HER2/Neu-mediated mammary tumor initiation and maintenance. Our results suggest that inhibition of PTP alpha can have a beneficial effect on HER2-positive breast cancers, but that inhibition of additional targets is needed to block breast tumorigenesis.	[Meyer, D. S.; Aceto, N.; Sausgruber, N.; Brinkhaus, H.; Mueller, U.; Bentires-Alj, M.] Friedrich Miescher Inst Biomed Res FMI, Basel, Switzerland; [Pallen, C. J.] Univ British Columbia, Dept Pediat, Vancouver, BC V6T 1W5, Canada; [Pallen, C. J.] Univ British Columbia, Child & Family Res Inst, Vancouver, BC V5Z 1M9, Canada	Friedrich Miescher Institute for Biomedical Research; University of British Columbia; Child & Family Research Institute; University of British Columbia	Bentires-Alj, M (corresponding author), Friedrich Miescher Inst Biomed Res, Maulbeerstr 66, CH-4058 Basel, Switzerland.	bentires@fmi.ch	Mohamed, Bentires-Alj/F-4484-2015; Aceto, Nicola/O-2484-2014	Mohamed, Bentires-Alj/0000-0001-6344-1127; Pallen, Catherine/0000-0002-3576-5295; Aceto, Nicola/0000-0001-9579-6918	Novartis Research Foundation; European Research Council (ERC starting grant) [243211-PTPsBDC]; Swiss Cancer League; Krebsliga Beider Basel	Novartis Research Foundation; European Research Council (ERC starting grant)(European Research Council (ERC)); Swiss Cancer League; Krebsliga Beider Basel	We thank members of the Bentires-Alj laboratory for advice and discussions. Research in the laboratory of MBA is supported by the Novartis Research Foundation, the European Research Council (ERC starting grant 243211-PTPsBDC), the Swiss Cancer League and the Krebsliga Beider Basel.	Aceto N, 2012, NAT MED, V18, P529, DOI 10.1038/nm.2645; Ardini E, 2000, ONCOGENE, V19, P4979, DOI 10.1038/sj.onc.1203869; Arias-Romero LE, 2009, CANCER RES, V69, P4582, DOI 10.1158/0008-5472.CAN-08-4001; Balavenkatraman KK, 2011, MOL CANCER RES, V9, P1377, DOI 10.1158/1541-7786.MCR-11-0198; Bentires-Alj M, 2007, CANCER RES, V67, P2420, DOI 10.1158/0008-5472.CAN-06-4610; Bjorge JD, 2000, J BIOL CHEM, V275, P41439, DOI 10.1074/jbc.M004852200; Di Cosimo S, 2010, NAT REV CLIN ONCOL, V7, P139, DOI 10.1038/nrclinonc.2009.234; Elson A, 1999, ONCOGENE, V18, P7535, DOI 10.1038/sj.onc.1203098; Hunter T, 2009, CURR OPIN CELL BIOL, V21, P140, DOI 10.1016/j.ceb.2009.01.028; Julien SG, 2007, NAT GENET, V39, P338, DOI 10.1038/ng1963; Lin G, 2011, GENE DEV, V25, P1412, DOI 10.1101/gad.2018911; Meerbrey KL, 2011, P NATL ACAD SCI USA, V108, P3665, DOI 10.1073/pnas.1019736108; Ostman A, 2006, NAT REV CANCER, V6, P307, DOI 10.1038/nrc1837; Pallen CJ, 2003, CURR TOP MED CHEM, V3, P821, DOI 10.2174/1568026033452320; Perou CM, 2011, COLD SPRING HARB PER, V3; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; Sun TT, 2011, CELL, V144, P703, DOI 10.1016/j.cell.2011.02.003; Yip SC, 2010, TRENDS BIOCHEM SCI, V35, P442, DOI 10.1016/j.tibs.2010.03.004; Zheng X, 2008, INT J CANCER, V122, P1999, DOI 10.1002/ijc.23321; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0	20	13	14	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2014	33	3					398	402		10.1038/onc.2012.585	http://dx.doi.org/10.1038/onc.2012.585			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VR	23318421				2022-12-28	WOS:000330214000014
J	Casar, B; Rimann, I; Kato, H; Shattil, SJ; Quigley, JP; Deryugina, EI				Casar, B.; Rimann, I.; Kato, H.; Shattil, S. J.; Quigley, J. P.; Deryugina, E. I.			In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated beta 1 integrin and induction of FAK/PI3K/Akt motility signaling	ONCOGENE			English	Article						metastasis; intravasation; invasion; transendothelial migration; Src kinase; prostate cancer	DOMAIN-CONTAINING PROTEIN-1; FOCAL ADHESION KINASE; CUB-DOMAIN; TYROSINE PHOSPHORYLATION; CELL-MIGRATION; PKC-DELTA; SRC; SUBSTRATE; IDENTIFICATION; METASTASIS	Specific cleavage of the transmembrane molecule, CUB domain-containing protein-1 (CDCP1), by plasmin-like serine proteases induces outside-in signal transduction that facilitates early stages of spontaneous metastasis leading to tumor cell intravasation, namely cell escape from the primary tumor, stromal invasion and transendothelial migration. We identified active beta 1 integrin as a biochemical and functional partner of the membrane-retained 70-kDa CDCP1 fragment, newly generated from its full-length 135-kDa precursor though proteolytic cleavage by serine proteases. Both in cell cultures and in live animals, active beta 1 integrin complexed preferentially with functionally activated, phosphorylated 70-kDa CDCP1. Complexing of beta 1 integrin the 70-kDa with CDCP1 fragment induced intracellular phosphorylation signaling, involving focal adhesion kinase-1 (FAK) and PI3 kinase (PI3K)-dependent Akt activation. Thus, inhibition of FAK/PI3K activities by specific inhibitors as well as short-hairpin RNA downregulation of beta 1 integrin significantly reduced FAK/Akt phosphorylation under conditions where CDCP1 was processed by serine proteases, indicating that FAK/PI3K/Akt pathway operates downstream of cleaved CDCP1 complexed with beta 1 integrin. Furthermore, this complex-dependent signaling correlated positively with high levels of tumor cell intravasation and dissemination. Correspondingly, abrogation in vivo of CDCP1 cleavage either by unique cleavage-blocking monoclonal antibody 10-D7 or by inhibition of proteolytic activity of plasmin-like serine proteases with aprotinin prevented beta 1 integrin/CDCP1 complexing and downstream FAK/Akt signaling concomitant with significant reduction of stromal invasion and spontaneous metastasis. Therefore, beta 1 integrin appears to serve as a motility-regulating partner mediating cross-talk between proteolytically cleaved, membrane-retained CDCP1 and members of FAK/PI3K/Akt pathway. This CDCP1 cleavage-induced signaling cascade constitutes a unique mechanism, independent of extracellular matrix remodeling, whereby a proteolytically cleaved CDCP1 regulates in vivo locomotion and metastasis of tumor cells through beta 1 integrin partnering. Our findings indicate that CDCP1 cleavage, occurring at the apex of a beta 1 integrin/FAK/PI3K/Akt signaling cascade, may represent a therapeutic target for CDCP1-positive cancers.	[Casar, B.; Rimann, I.; Quigley, J. P.; Deryugina, E. I.] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; [Kato, H.; Shattil, S. J.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; [Shattil, S. J.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA	Scripps Research Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Quigley, JP (corresponding author), Scripps Res Inst, Dept Cell Biol, 10550 North Torrey Pines Rd,SP3030 3120, La Jolla, CA 92037 USA.	jquigley@scripps.edu; deryugin@scripps.edu	CASAR, BERTA/M-2291-2014	CASAR, BERTA/0000-0002-3058-5631	NIH [R01 CA 129484, R01 CA 105412, HL56595, HL57900]; NIH/NCRR/STSI [RR 025774]; Science and Innovation Ministry of Spain; Nachwuchsforderungskredit/Stiefel-Zangger Foundation, University of Zurich; NATIONAL CANCER INSTITUTE [R01CA129484, R01CA157792, R01CA105412] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR025774] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057900, R01HL056595] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH/NCRR/STSI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); Science and Innovation Ministry of Spain(Spanish Government); Nachwuchsforderungskredit/Stiefel-Zangger Foundation, University of Zurich; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This study was supported by NIH grants R01 CA 129484 and R01 CA 105412 (to JPQ), NIH/NCRR/STSI Grant RR 025774 (Pilot Award to EID), Postdoctoral Fellowship from the Science and Innovation Ministry of Spain (to BC), Research Fellowships from Nachwuchsforderungskredit/Stiefel-Zangger Foundation, University of Zurich (to IR), and NIH grants HL56595 and HL57900 (to SJS).	Alvares SM, 2008, BBA-GEN SUBJECTS, V1780, P486, DOI 10.1016/j.bbagen.2008.01.010; Awakura Y, 2008, J CANCER RES CLIN, V134, P1363, DOI 10.1007/s00432-008-0412-4; Bekes EM, 2011, NEOPLASIA, V13, P806, DOI 10.1593/neo.11704; Benes CH, 2012, ONCOGENE, V31, P653, DOI 10.1038/onc.2011.262; Benes CH, 2005, CELL, V121, P271, DOI 10.1016/j.cell.2005.02.019; Bhatt AS, 2005, ONCOGENE, V24, P5333, DOI 10.1038/sj.onc.1208582; Brown TA, 2004, J BIOL CHEM, V279, P14772, DOI 10.1074/jbc.M309678200; Casar B, 2012, ONCOGENE, V31, P3924, DOI 10.1038/onc.2011.555; Conn EM, 2009, AM J PATHOL, V175, P1638, DOI 10.2353/ajpath.2009.090384; Deryugina EI, 2005, CANCER RES, V65, P10959, DOI 10.1158/0008-5472.CAN-05-2228; Deryugina EI, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/564259; Deryugina EI, 2009, MOL CANCER RES, V7, P1197, DOI 10.1158/1541-7786.MCR-09-0100; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; He Y, 2010, J BIOL CHEM, V285, P26162, DOI 10.1074/jbc.M109.096453; Hooper JD, 2003, ONCOGENE, V22, P1783, DOI 10.1038/sj.onc.1206220; Ikeda JI, 2009, CANCER SCI, V100, P429, DOI 10.1111/j.1349-7006.2008.01066.x; Leroy C, 2009, CANCER RES, V69, P2279, DOI 10.1158/0008-5472.CAN-08-2354; Liu H, 2011, P NATL ACAD SCI USA, V108, P1379, DOI 10.1073/pnas.1017228108; Luque A, 1996, J BIOL CHEM, V271, P11067, DOI 10.1074/jbc.271.19.11067; Miyazawa Y, 2010, CANCER RES, V70, P5136, DOI 10.1158/0008-5472.CAN-10-0220; Perry SE, 2007, FEBS LETT, V581, P1137, DOI 10.1016/j.febslet.2007.02.025; Pylayeva Y, 2009, J CLIN INVEST, V119, P252, DOI 10.1172/JCI37160; Razorenova OV, 2011, P NATL ACAD SCI USA, V108, P1931, DOI 10.1073/pnas.1011777108; Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025; Scherl-Mostageer M, 2001, ONCOGENE, V20, P4402, DOI 10.1038/sj.onc.1204566; Shattil SJ, 2010, NAT REV MOL CELL BIO, V11, P288, DOI 10.1038/nrm2871; Siva AC, 2008, CANCER RES, V68, P3759, DOI 10.1158/0008-5472.CAN-07-1657; Spassov DS, 2011, MOL CELL BIOL, V31, P766, DOI 10.1128/MCB.00841-10; Uekita T, 2008, AM J PATHOL, V172, P1729, DOI 10.2353/ajpath.2008.070981; Uekita T, 2007, MOL CELL BIOL, V27, P7649, DOI 10.1128/MCB.01246-07; Wong CH, 2009, CLIN CANCER RES, V15, P2311, DOI 10.1158/1078-0432.CCR-08-2533; Wortmann A, 2011, J BIOL CHEM, V286, P42303, DOI 10.1074/jbc.M111.227462; Yang LF, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.007294; Zhao J, 2009, CANCER METAST REV, V28, P35, DOI 10.1007/s10555-008-9165-4; Zhao X, 2011, ADV DRUG DELIVER REV, V63, P610, DOI 10.1016/j.addr.2010.11.001	35	80	80	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2014	33	2					255	268		10.1038/onc.2012.547	http://dx.doi.org/10.1038/onc.2012.547			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286BY	23208492	Green Accepted			2022-12-28	WOS:000329440700013
J	Fang, YX; Gao, WQ				Fang, Y-X; Gao, W-Q			Roles of microRNAs during prostatic tumorigenesis and tumor progression	ONCOGENE			English	Review						microRNA; prostate cancer; tumorigenesis; progression; cancer stem cells; castration resistance	EPITHELIAL-MESENCHYMAL TRANSITION; RECEPTOR TRANSCRIPTIONAL ACTIVITY; ATTENUATES PACLITAXEL-RESISTANCE; CANCER STEM-CELLS; ANDROGEN RECEPTOR; CIRCULATING MICRORNAS; GENE-EXPRESSION; CLINICAL-SIGNIFICANCE; NEGATIVE FEEDBACK; SIGNAL TRANSDUCER	Prostate cancer (PCa) is considered to be a frequently diagnosed cancer in males with high mortality worldwide, but the molecular mechanism responsible for prostate tumorigenesis and progression remains unclear. Increasing evidence has shown that microRNAs (miRNAs) play an important role in PCa. In this review, we focus on the current advances about the role of miRNAs in regulating tumorigenesis and progression of PCa, mainly in suppressing or promoting PCa growth and metastasis, and maintaining the pluripotency of PCa stem cells (PCSC). More studies on miRNAs will provide a better understanding of their regulatory mechanisms in PCa.	[Fang, Y-X; Gao, W-Q] Shanghai Jiao Tong Univ, Sch Med, State Key Lab Oncogenes & Related Genes, Stem Cell Res Ctr,Renji Hosp, Shanghai 200127, Peoples R China; [Gao, W-Q] Shanghai Jiao Tong Univ, Med X Res Inst, Shanghai 200127, Peoples R China	Shanghai Jiao Tong University; Shanghai Jiao Tong University	Gao, WQ (corresponding author), Shanghai Jiao Tong Univ, Stem Cell Res Ctr, Sch Med, Renji Hosp, 1630 Dong Fang Rd, Shanghai 200127, Peoples R China.	gao.weiqiang@sjtu.edu.cn	Gao, Wei/GXH-0380-2022		Chinese Ministry of Science and Technology [2012CB966800, 2013CB945600]; National Natural Science Foundation of China [81130038]; Science and Technology Commission of Shanghai Municipality (Pujiang program); Shanghai Education Committee Key Disciplines and Specialties Foundation [J50208]; Shanghai Health Bureau Key Disciplines and Specialties Foundation; KC Wong foundation	Chinese Ministry of Science and Technology(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science and Technology Commission of Shanghai Municipality (Pujiang program); Shanghai Education Committee Key Disciplines and Specialties Foundation; Shanghai Health Bureau Key Disciplines and Specialties Foundation; KC Wong foundation	This study was supported by funds to W-Q Gao from the Chinese Ministry of Science and Technology (2012CB966800 and 2013CB945600), the National Natural Science Foundation of China (81130038), Science and Technology Commission of Shanghai Municipality (Pujiang program), Shanghai Education Committee Key Disciplines and Specialties Foundation (J50208), Shanghai Health Bureau Key Disciplines and Specialties Foundation and KC Wong foundation.	Acunzo M, 2012, ONCOGENE, V31, P634, DOI 10.1038/onc.2011.260; Agaoglu FY, 2011, TUMOR BIOL, V32, P583, DOI 10.1007/s13277-011-0154-9; Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Al-Alwan M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027339; Alshalalfa M, 2012, ADV BIOINFORMATICS, V2012, DOI DOI 10.1155/2012/839837; Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Andriole GL, 2009, NEW ENGL J MED, V360, P1310, DOI 10.1056/NEJMoa0810696; Bao JJ, 2002, CANCER RES, V62, P7264; Barron N, 2012, PROSTATE, V72, P1193, DOI 10.1002/pros.22469; Barton BE, 2004, MOL CANCER THER, V3, P11; Benassi B, 2012, CANCER DISCOV, V2, P236, DOI 10.1158/2159-8290.CD-11-0219; Bhatnagar N, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.85; Boll K, 2013, ONCOGENE, V32, P277, DOI 10.1038/onc.2012.55; Bonci D, 2008, NAT MED, V14, P1271, DOI 10.1038/nm.1880; Brase JC, 2011, INT J CANCER, V128, P608, DOI 10.1002/ijc.25376; Bryant RJ, 2012, BRIT J CANCER, V106, P768, DOI 10.1038/bjc.2011.595; Budd WT, 2012, CHEM BIODIVERS, V9, P857, DOI 10.1002/cbdv.201100386; Bussing I, 2008, TRENDS MOL MED, V14, P400, DOI 10.1016/j.molmed.2008.07.001; Cao P, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-108; Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333; Catz SD, 2003, APOPTOSIS, V8, P29, DOI 10.1023/A:1021692801278; Chan CH, 2010, NAT CELL BIOL, V12, P457, DOI 10.1038/ncb2047; Chang TC, 2009, P NATL ACAD SCI USA, V106, P3384, DOI 10.1073/pnas.0808300106; Chen Y, 2011, CANCER PREV RES, V4, P76, DOI 10.1158/1940-6207.CAPR-10-0167; Chiang YP, 2011, J GASTROINTEST SURG, V15, P63, DOI 10.1007/s11605-010-1367-8; Chiyomaru T, 2010, BRIT J CANCER, V102, P883, DOI 10.1038/sj.bjc.6605570; Chiyomaru T, 2011, PROSTATE, DOI [10.1002/pros.21372, DOI 10.1002/PR0S.21372)]; Chuang AY, 2007, AM J SURG PATHOL, V31, P1246, DOI 10.1097/PAS.0b013e31802f5d33; Clape C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007542; Clarke MF, 2006, CELL, V124, P1111, DOI 10.1016/j.cell.2006.03.011; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Coppola V, 2013, ONCOGENE, V32, P1843, DOI 10.1038/onc.2012.194; Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854; Dangi-Garimella S, 2009, EMBO J, V28, P347, DOI 10.1038/emboj.2008.294; Dehm SM, 2007, MOL ENDOCRINOL, V21, P2855, DOI 10.1210/me.2007-0223; Dong QC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010147; Farazi TA, 2011, CANCER RES, V71, P4443, DOI 10.1158/0008-5472.CAN-11-0608; Fletcher CE, 2012, HUM MOL GENET, V21, P3112, DOI 10.1093/hmg/dds139; Folini M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-12; Fujita S, 2008, J MOL BIOL, V378, P492, DOI 10.1016/j.jmb.2008.03.015; Fujita Y, 2010, J BIOL CHEM, V285, P19076, DOI 10.1074/jbc.M109.079525; Fuse M, 2012, J HUM GENET, V57, P691, DOI 10.1038/jhg.2012.95; Fuse M, 2011, INT J ONCOL, V38, P1093, DOI 10.3892/ijo.2011.919; Galardi S, 2007, J BIOL CHEM, V282, P23716, DOI 10.1074/jbc.M701805200; Galardi S, 2011, NUCLEIC ACIDS RES, V39, P3892, DOI 10.1093/nar/gkr006; Gandellini P, 2012, CELL DEATH DIFFER, V19, P1750, DOI 10.1038/cdd.2012.56; Gandellini P, 2009, CANCER RES, V69, P2287, DOI 10.1158/0008-5472.CAN-08-2894; Garofalo M, 2012, NAT MED, V18, P74, DOI 10.1038/nm.2577; Goldstein AS, 2010, SCIENCE, V329, P568, DOI 10.1126/science.1189992; Gong AY, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-492; Gonzales JC, 2011, CLIN GENITOURIN CANC, V9, P39, DOI 10.1016/j.clgc.2011.05.008; Green D, 2010, CELL CYCLE, V9, P656, DOI 10.4161/cc.9.4.10729; Hagman Z, 2010, INT J CANCER, V127, P2768, DOI 10.1002/ijc.25269; Hao YB, 2011, CANCER INVEST, V29, P318, DOI 10.3109/07357907.2011.554477; He X, 2008, CANCER RES, V68, P5591, DOI 10.1158/0008-5472.CAN-08-0025; Hobert O, 2008, SCIENCE, V319, P1785, DOI 10.1126/science.1151651; Hsieh IS, CARCINOGENESIS; Hu G, 2010, CANCER BIOL THER, V10, P190, DOI 10.4161/cbt.10.2.12186; Hu L, 2009, CANCER RES, V69, P3374, DOI 10.1158/0008-5472.CAN-08-4290; Huang S, 2012, ONCOL REP, V28, P1831, DOI 10.3892/or.2012.2015; Hudson RS, 2013, ONCOGENE, V32, P4139, DOI 10.1038/onc.2012.424; Hudson RS, 2012, NUCLEIC ACIDS RES, V40, P3689, DOI 10.1093/nar/gkr1222; Hulf T, 2013, ONCOGENE, V32, P2891, DOI 10.1038/onc.2012.300; Ichimi T, 2009, INT J CANCER, V125, P345, DOI 10.1002/ijc.24390; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Iorio MV, 2009, J CLIN ONCOL, V27, P5848, DOI 10.1200/JCO.2009.24.0317; Jalava SE, 2012, ONCOGENE, V31, P4460, DOI 10.1038/onc.2011.624; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jia YS, 2012, ONCOL REP, V27, P1865, DOI 10.3892/or.2012.1701; Jiang S, 2012, EMBO J, V31, P1985, DOI 10.1038/emboj.2012.45; Kano M, 2010, INT J CANCER, V127, P2804, DOI 10.1002/ijc.25284; Kasahara K, 2002, CANCER GENET CYTOGEN, V137, P59, DOI 10.1016/S0165-4608(02)00552-6; Kashat M, 2012, AM J TRANSL RES, V4, P432; Kent OA, 2010, GENE DEV, V24, P2754, DOI 10.1101/gad.1950610; Kim K, 2012, MOL CANCER THER, V11, P1852, DOI 10.1158/1535-7163.MCT-12-0181; Kogo R, 2011, CLIN CANCER RES, V17, P4277, DOI 10.1158/1078-0432.CCR-10-2866; Kojima K, 2010, PROSTATE, V70, P1501, DOI 10.1002/pros.21185; Kojima S, 2012, BRIT J CANCER, V106, P405, DOI 10.1038/bjc.2011.462; Kong DJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033729; Kong DJ, 2012, AM J TRANSL RES, V4, P14; Kong DJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012445; Kong DJ, 2009, STEM CELLS, V27, P1712, DOI 10.1002/stem.101; Kozaki KI, 2008, CANCER RES, V68, P2094, DOI 10.1158/0008-5472.CAN-07-5194; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Lawrie CH, 2008, BRIT J HAEMATOL, V141, P672, DOI 10.1111/j.1365-2141.2008.07077.x; Lawson DA, 2010, P NATL ACAD SCI USA, V107, P2610, DOI 10.1073/pnas.0913873107; Leite KRM, 2011, UROL ONCOL-SEMIN ORI, V29, P265, DOI 10.1016/j.urolonc.2009.02.002; Li BQ, 2011, PROSTATE, V71, P567, DOI 10.1002/pros.21272; Li T, 2012, J UROLOGY, V187, P1466, DOI 10.1016/j.juro.2011.11.082; Lin D, 2011, J INT MED RES, V39, P1870, DOI 10.1177/147323001103900530; Lin PC, 2013, CANCER RES, V73, P1232, DOI 10.1158/0008-5472.CAN-12-2968; Liu C, 2012, CANCER RES, V72, P3393, DOI 10.1158/0008-5472.CAN-11-3864; Liu C, 2011, CANCER RES, V71, P5950, DOI 10.1158/0008-5472.CAN-11-1035; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Liu LZ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019139; Liu T, 2012, EXP CELL RES, V318, P424, DOI 10.1016/j.yexcr.2011.12.004; Liu YN, 2013, ONCOGENE, V32, P296, DOI 10.1038/onc.2012.58; Liu YN, 2012, MOL CELL BIOL, V32, P941, DOI 10.1128/MCB.06306-11; Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lu Z, 2008, ONCOGENE, V27, P4373, DOI 10.1038/onc.2008.72; Majid S, 2013, CLIN CANCER RES, V19, P73, DOI 10.1158/1078-0432.CCR-12-2952; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mercatelli N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004029; Millikan RE, 2008, J CLIN ONCOL, V26, P5936, DOI 10.1200/JCO.2007.15.9830; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Mora LB, 2002, CANCER RES, V62, P6659; Murata T, 2010, PROSTATE CANCER P D, V13, P356, DOI 10.1038/pcan.2010.32; Musumeci M, 2011, ONCOGENE, V30, P4231, DOI 10.1038/onc.2011.140; Nadiminty N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032832; Nadiminty N, 2012, J BIOL CHEM, V287, P1527, DOI 10.1074/jbc.M111.278705; Nguyen HCN, 2013, PROSTATE, V73, P346, DOI 10.1002/pros.22572; Ostling P, 2011, CANCER RES, V71, P1956, DOI 10.1158/0008-5472.CAN-10-2421; Ouyang X, 2008, CANCER RES, V68, P2132, DOI 10.1158/0008-5472.CAN-07-6055; Ozen M, 2008, ONCOGENE, V27, P1788, DOI 10.1038/sj.onc.1210809; Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327; Patrawala L, 2007, CANCER RES, V67, P6796, DOI 10.1158/0008-5472.CAN-07-0490; Patron JP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035345; Peng XS, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020341; Pili R, 2011, J CLIN ONCOL, V29, P4022, DOI 10.1200/JCO.2011.35.6295; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Polytarchou C, 2012, P NATL ACAD SCI USA, V109, P14470, DOI 10.1073/pnas.1212811109; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Porkka KP, 2011, GENE CHROMOSOME CANC, V50, P499, DOI 10.1002/gcc.20873; Puhr M, 2012, AM J PATHOL, V181, P2188, DOI 10.1016/j.ajpath.2012.08.011; Reis ST, 2012, BMC UROL, V12, DOI 10.1186/1471-2490-12-14; Ribas J, 2009, CANCER RES, V69, P7165, DOI 10.1158/0008-5472.CAN-09-1448; Rokhlin OW, 2008, CANCER BIOL THER, V7, P1288, DOI 10.4161/cbt.7.8.6284; Rybak A, 2008, NAT CELL BIOL, V10, P987, DOI 10.1038/ncb1759; Saini S, 2012, CANCER RES, V72, P3618, DOI 10.1158/0008-5472.CAN-12-0540; Saini S, 2011, CLIN CANCER RES, V17, P5287, DOI 10.1158/1078-0432.CCR-10-2619; Sanders I, 2012, INT J UROL, V19, P1017, DOI 10.1111/j.1442-2042.2012.03082.x; Schneider TJ, 1999, J EXP MED, V189, P949, DOI 10.1084/jem.189.6.949; Selth LA, 2012, INT J CANCER, V131, P652, DOI 10.1002/ijc.26405; Shen J, 2012, PROSTATE, V72, P1469, DOI 10.1002/pros.22499; Shi GH, 2010, ACTA PHARMACOL SIN, V31, P867, DOI 10.1038/aps.2010.48; Shi XB, 2013, ONCOGENE, V32, P4130, DOI 10.1038/onc.2012.425; Shi XB, 2007, P NATL ACAD SCI USA, V104, P19983, DOI 10.1073/pnas.0706641104; Shi XB, 2011, PROSTATE, V71, P538, DOI 10.1002/pros.21270; Slabakova E, 2011, PROSTATE, V71, P1332, DOI 10.1002/pros.21350; Stark A, 2003, PLOS BIOL, V1, P397, DOI 10.1371/journal.pbio.0000060; Stewart CJR, 2012, J CLIN PATHOL, V65, P213, DOI 10.1136/jclinpath-2011-200425; Stinson S., 2011, SCI SIGNAL, V4; Suh SO, 2011, CARCINOGENESIS, V32, P772, DOI 10.1093/carcin/bgr036; Sun T, 2012, PROSTATE, V72, P1093, DOI 10.1002/pros.22456; Sun T, 2009, CANCER RES, V69, P3356, DOI 10.1158/0008-5472.CAN-08-4112; Takayama K, 2011, ONCOGENE, V30, P619, DOI 10.1038/onc.2010.436; Takeshita F, 2010, MOL THER, V18, P181, DOI 10.1038/mt.2009.207; Tao J, 2012, ONCOL REP, V27, P1967, DOI 10.3892/or.2012.1711; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tong AW, 2009, CANCER GENE THER, V16, P206, DOI 10.1038/cgt.2008.77; Tucci P, 2012, P NATL ACAD SCI USA, V109, P15312, DOI 10.1073/pnas.1110977109; Vandewalle C, 2007, NUCLEIC ACIDS RES, V33, P6566; Viswanathan SR, 2008, SCIENCE, V320, P97, DOI 10.1126/science.1154040; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Viticchie G, 2011, CELL CYCLE, V10, P1121, DOI 10.4161/cc.10.7.15180; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Waltering KK, 2011, PROSTATE, V71, P604, DOI 10.1002/pros.21276; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Watahiki A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024950; White NMA, 2012, BIOL CHEM, V393, P379, DOI 10.1515/hsz-2011-0246; White RWD, 2009, UROL ONCOL-SEMIN ORI, V27, P307, DOI 10.1016/j.urolonc.2009.01.004; Wu YJ, 2011, CANCER-AM CANCER SOC, V117, P3989, DOI 10.1002/cncr.25944; Wu Z, 2012, PROSTATE, DOI [10.1002/pros.22600, DOI 10.1002/PR0S.22600)]; Xiao J, 2012, PROSTATE, V72, P1514, DOI 10.1002/pros.22501; Xu B, 2011, MOL CELL BIOCHEM, V350, P207, DOI 10.1007/s11010-010-0700-6; Xu N, 2009, CELL, V137, P647, DOI 10.1016/j.cell.2009.02.038; Yamaguchi S, 2011, ATHEROSCLEROSIS, V219, P468, DOI 10.1016/j.atherosclerosis.2011.09.004; Yamamura S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029722; Yamasaki T, 2012, INT J ONCOL, V40, P1821, DOI 10.3892/ijo.2012.1391; Yang CH, 2010, CANCER RES, V70, P8108, DOI 10.1158/0008-5472.CAN-10-2579; Yu DC, 2011, INT J MOL SCI, V12, P2055, DOI 10.3390/ijms12032055; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Yuan X, 2009, UROL ONCOL-SEMIN ORI, V27, P36, DOI 10.1016/j.urolonc.2008.03.021; Zaman MS, 2010, BRIT J CANCER, V103, P256, DOI 10.1038/sj.bjc.6605742; Zhang HL, 2011, PROSTATE, V71, P326, DOI 10.1002/pros.21246; Zhang WS, 2009, CANCER RES, V69, P7466, DOI 10.1158/0008-5472.CAN-08-4385; Zhang XY, 2009, HEPATOLOGY, V50, P490, DOI 10.1002/hep.23008	179	91	95	0	26	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2014	33	2					135	147		10.1038/onc.2013.54	http://dx.doi.org/10.1038/onc.2013.54			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286BY	23455326				2022-12-28	WOS:000329440700001
J	Yeung, CL; Ngo, VN; Grohar, PJ; Arnaldez, FI; Asante, A; Wan, X; Khan, J; Hewitt, SM; Khanna, C; Staudt, LM; Helman, LJ				Yeung, C. L.; Ngo, V. N.; Grohar, P. J.; Arnaldez, F. I.; Asante, A.; Wan, X.; Khan, J.; Hewitt, S. M.; Khanna, C.; Staudt, L. M.; Helman, L. J.			Loss-of-function screen in rhabdomyosarcoma identifies CRKL-YES as a critical signal for tumor growth	ONCOGENE			English	Article						rhabdomyosarcoma; CRKL; SRC; YES; dasatinib	CHRONIC MYELOGENOUS LEUKEMIA; ALVEOLAR RHABDOMYOSARCOMA; CHROMOSOMAL LOCALIZATION; CELLS; CANCER; GENE; PATHWAY; PROTEIN; FUSION; FAMILY	To identify novel signaling pathways necessary for rhabdomyosarcoma (RMS) survival, we performed a loss-of-function screen using an inducible small hairpin RNA (shRNA) library in an alveolar and an embryonal RMS cell line. This screen identified CRKL expression as necessary for growth of alveolar RMS and embryonal RMS both in vitro and in vivo. We also found that CRKL was uniformly highly expressed in both RMS cell lines and tumor tissue. As CRKL is a member of the CRK adapter protein family that contains an SH2 and two SH3 domains and is involved in signal transduction from multiple tyrosine kinase receptors, we evaluated CRKL interaction with multiple tyrosine kinase receptor signaling pathways in RMS cells. While we saw no interaction of CRKL with IGFIR, MET or PI3KAKT/mTOR pathways, we determined that CRKL signaling was associated with SRC family kinase (SFK) signaling, specifically with YES kinase. Inhibition of SFK signaling with dasatinib or another SFK inhibitor, sarcatinib, suppressed RMS cell growth in vitro and in vivo. These data identify CRKL as a novel critical component of RMS growth. This study also demonstrates the use of functional screening to identify a potentially novel therapeutic target and treatment approach for these highly aggressive pediatric cancers.	[Yeung, C. L.; Grohar, P. J.; Arnaldez, F. I.; Asante, A.; Wan, X.; Khan, J.; Khanna, C.; Helman, L. J.] NCI, Pediat Oncol Branch, Ctr Canc Res, Bethesda, MD 20892 USA; [Ngo, V. N.] City Hope Natl Med Ctr, Beckman Res Inst, Div Hematopoiet Stem Cell & Leukemia Res, Duarte, CA 91010 USA; [Hewitt, S. M.] NCI, Ctr Canc Res, Pathol Lab, Bethesda, MD 20892 USA; [Staudt, L. M.] NCI, Metab Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); City of Hope; Beckman Research Institute of City of Hope; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Helman, LJ (corresponding author), NCI, Pediat Oncol Branch, Ctr Canc Res, Bldg 31,Room 3A11, Bethesda, MD 20892 USA.	helmanl@nih.gov	Staudt, Louis/AAC-5324-2019; Grohar, Patrick/V-2557-2018; Khan, Javed/P-9157-2014	Hewitt, Stephen/0000-0001-8283-1788; Ngo, Vu/0000-0002-9501-6990	National Cancer Institute; NATIONAL CANCER INSTITUTE [ZIABC011007, ZIABC010999, ZICBC010923, ZIABC010806, ZIASC006892] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported through funding to the Intramural Research Program of the National Cancer Institute. We would also like to thank the many patients and their families who continue to contribute to and inform our research. We thank Dr Su Young Kim experiments, Elena Kuznetsova, Dr Arnulfo Mendoza, and Dr Melinda G Hollings-head for advice and help with xenograft experiment. We also thank the Children's Oncology Group Soft-Tissue Sarcoma Committee for providing the tissue microarrays for analysis of CRKL expression. We thank Joan Massague for the sharing the Addgene plasmid 26 980.	Arai A, 2006, CELL SIGNAL, V18, P2162, DOI 10.1016/j.cellsig.2006.05.001; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Cheung HW, 2011, CANCER DISCOV, V1, P608, DOI 10.1158/2159-8290.CD-11-0046; DAVIS RJ, 1994, CANCER RES, V54, P2869; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; Guris DL, 2001, NAT GENET, V27, P293, DOI 10.1038/85855; Koval AP, 1998, J BIOL CHEM, V273, P14780, DOI 10.1074/jbc.273.24.14780; Luo B, 2008, P NATL ACAD SCI USA, V105, P20380, DOI 10.1073/pnas.0810485105; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; Ngo VN, 2006, NATURE, V441, P106, DOI 10.1038/nature04687; NICHOLS GL, 1994, BLOOD, V84, P2912; Oberlin O, 2008, J CLIN ONCOL, V26, P2384, DOI 10.1200/JCO.2007.14.7207; ODA T, 1994, J BIOL CHEM, V269, P22925; Sakkab D, 2000, J BIOL CHEM, V275, P10772, DOI 10.1074/jbc.275.15.10772; SCRABLE HJ, 1987, NATURE, V329, P645, DOI 10.1038/329645a0; SHAPIRO DN, 1993, CANCER RES, V53, P5108; Taulli R, 2006, CANCER RES, V66, P4742, DOI 10.1158/0008-5472.CAN-05-4292; TENHOEVE J, 1994, BLOOD, V84, P1731; TENHOEVE J, 1993, ONCOGENE, V8, P2469; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017	20	33	33	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2013	32	47					5429	5438		10.1038/onc.2012.590	http://dx.doi.org/10.1038/onc.2012.590			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	254PM	23318429	Green Published, hybrid			2022-12-28	WOS:000327177600006
J	Guo, L; Chen, C; Shi, M; Wang, F; Chen, X; Diao, D; Hu, M; Yu, M; Qian, L; Guo, N				Guo, L.; Chen, C.; Shi, M.; Wang, F.; Chen, X.; Diao, D.; Hu, M.; Yu, M.; Qian, L.; Guo, N.			Stat3-coordinated Lin-28-let-7-HMGA2 and miR-200-ZEB1 circuits initiate and maintain oncostatin M-driven epithelial-mesenchymal transition	ONCOGENE			English	Article						OSM; EMT; Stat3; let-7; miR-200	DOUBLE-EDGED-SWORD; NF-KAPPA-B; SELF-RENEWAL; FEEDBACK LOOP; CELL MOTILITY; TGF-BETA; CANCER; INFLAMMATION; EXPRESSION; EMT	Inflammation can act as a crucial mediator of epithelial-to-mesenchymal transition (EMT). In this study, we show that oncostatin M (OSM) is expressed in an autocrine/paracrine fashion in invasive breast carcinoma. OSM stimulation promotes spontaneous lung metastasis of MCF-7 xenografts in nude mice. A conspicuous epigenetic transition was induced by OSM stimulation not only in breast cancer cell lines but also in MCF-7 xenografts in nude mice. The expression of miR-200 and let-7 family members in response to OSM stimulation was downregulated in a signal transducer and activator of transcription factor 3 (Stat3)-dependent manner, resulting in comprehensive alterations of the transcription factors and oncoproteins targeted by these microRNAs. Inhibition of Stat3 activation or the ectopic expression of let-7 and miR-200 effectively reversed the mesenchymal phenotype of breast cancer cells. Stat3 promotes the transcription of Lin-28 by directly binding to the Lin-28 promoter, resulting in the repression of let-7 expression and concomitant upregulation of the let-7 target, high-mobility group A protein 2 (HMGA2). Knock down of HMGA2 significantly impairs OSM-driven EMT. Our data indicate that downregulation of let-7 and miR-200 levels initiates and maintains OSM-induced EMT phenotypes, and HMGA2 acts as a master switch of OSM-induced EMT. These findings highlight the importance of Stat3-coordinated Lin-28B-let-7-HMGA2 and miR-200-ZEB1 circuits in the cytokine-mediated phenotypic reprogramming of breast cancer cells.	[Guo, L.; Chen, C.; Shi, M.; Diao, D.; Hu, M.; Yu, M.; Qian, L.; Guo, N.] Beijing Inst Basic Med Sci, Dept Mol Immunol, Beijing, Peoples R China; [Wang, F.] Inst Basic Med Sci, Dept Brain Protect & Plast Res, Beijing 100850, Peoples R China; [Chen, X.] 307 Hosp, Beijing, Peoples R China; [Diao, D.] Henan Univ, Lab Cellular & Mol Immunol, Sch Med, Kaifeng, Peoples R China	Academy of Military Medical Sciences - China; Fifth Medical Center of Chinese PLA General Hospital; Henan University	Qian, L (corresponding author), Inst Basic Med Sci, Dept Mol Immunol, Beijing 100850, Peoples R China.	qianlubj@sohu.com; ningguo@nic.bmi.ac.cn		, Liang/0000-0002-8748-5770	National Basic Research Program of China (973 Program) [2010CB911904]; National Natural Science Foundation of China [30972690, 31271440, 81272232]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We are grateful to Dr Xuemin Zhang (National Center of Biomedical Analysis, Beijing) for kindly providing us the plasmids pRc/CMV-Stat3C-Flag and luciferase reporter vectors containing the binding sequences for Stat3, NF-kappa B, AP-1 and Smad. We also thank Dr Xiaofei Zheng (Beijing Institute of Radiation Medicine, Beijing) for the gift of the modified pGL3-control plasmid. This work is supported by National Basic Research Program of China (973 Program, No. 2010CB911904) and National Natural Science Foundation of China (Nos. 30972690, 31271440 and 81272232).	Azare J, 2007, MOL CELL BIOL, V27, P4444, DOI 10.1128/MCB.02404-06; Bhaumik D, 2009, CELL CYCLE, V8, P1822; Biddle A, 2012, CANCER METAST REV, V31, P285, DOI 10.1007/s10555-012-9345-0; Boyerinas B, 2008, CANCER RES, V68, P2587, DOI 10.1158/0008-5472.CAN-08-0264; Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Chen JJW, 2005, J CLIN ONCOL, V23, P953, DOI 10.1200/JCO.2005.12.172; Cheng GZ, 2008, J BIOL CHEM, V283, P14665, DOI 10.1074/jbc.M707429200; Chiappetta G, 1996, ONCOGENE, V13, P2439; Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127; Daheron L, 2004, STEM CELLS, V22, P770, DOI 10.1634/stemcells.22-5-770; Douglas AM, 1998, INT J CANCER, V75, P64, DOI 10.1002/(SICI)1097-0215(19980105)75:1<64::AID-IJC11>3.0.CO;2-D; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Fernando RI, 2011, CANCER RES, V71, P5296, DOI 10.1158/0008-5472.CAN-11-0156; Gomez-Lechon MJ, 1999, LIFE SCI, V65, P2019, DOI 10.1016/S0024-3205(99)00296-9; Grant SL, 1999, MOL MED TODAY, V5, P406, DOI 10.1016/S1357-4310(99)01540-3; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gregory PA, 2011, MOL BIOL CELL, V22, P1686, DOI 10.1091/mbc.E11-02-0103; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Jarnicki A, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-14; Jorcyk CL, 2006, CYTOKINE, V33, P323, DOI 10.1016/j.cyto.2006.03.004; Jun C, 2007, PROG BIOCHEM BIOPHYS, V34, P389; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675; Kong DJ, 2009, STEM CELLS, V27, P1712, DOI 10.1002/stem.101; Lee YS, 2007, GENE DEV, V21, P1025, DOI 10.1101/gad.1540407; Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537; Lopez-Novoa JM, 2009, EMBO MOL MED, V1, P303, DOI 10.1002/emmm.200900043; Newman MA, 2008, RNA, V14, P1539, DOI 10.1261/rna.1155108; Nightingale J, 2004, J AM SOC NEPHROL, V15, P21, DOI 10.1097/01.ASN.0000102479.92582.43; Peter ME, 2009, CELL CYCLE, V8, P843, DOI 10.4161/cc.8.6.7907; Pfannkuche K, 2009, STEM CELL REV REP, V5, P224, DOI 10.1007/s12015-009-9078-9; Pollack V, 2007, AM J PHYSIOL-RENAL, V293, pF1714, DOI 10.1152/ajprenal.00130.2007; Queen MM, 2005, CANCER RES, V65, P8896, DOI 10.1158/0008-5472.CAN-05-1734; Rokavec M, 2012, MOL CELL, V45, P777, DOI 10.1016/j.molcel.2012.01.015; Roush S, 2008, TRENDS CELL BIOL, V18, P505, DOI 10.1016/j.tcb.2008.07.007; Shi M, 2011, BREAST CANCER RES TR, V125, P351, DOI 10.1007/s10549-010-0822-2; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Sosic D, 2003, CELL, V112, P169, DOI 10.1016/S0092-8674(03)00002-3; Strippoli R, 2010, J CELL SCI, V123, P4321, DOI 10.1242/jcs.071647; Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180; Tan EJ, 2012, J BIOL CHEM, V287, P7134, DOI 10.1074/jbc.M111.291385; Thuault S, 2008, J BIOL CHEM, V283, P33437, DOI 10.1074/jbc.M802016200; Winder DM, 2011, J PATHOL, V225, P448, DOI 10.1002/path.2968; Wu Y, 2009, CANCER CELL, V15, P416, DOI 10.1016/j.ccr.2009.03.016; Xiong H, 2012, J BIOL CHEM, V287, P5819, DOI 10.1074/jbc.M111.295964; Yang L, 2010, CANCER METAST REV, V29, P263, DOI 10.1007/s10555-010-9226-3; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zentner MD, 2001, J BIOL CHEM, V276, P29805, DOI 10.1074/jbc.M103153200; Zhao SJ, 2008, CANCER RES, V68, P4221, DOI 10.1158/0008-5472.CAN-07-5123	53	152	158	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2013	32	45					5272	5282		10.1038/onc.2012.573	http://dx.doi.org/10.1038/onc.2012.573			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251IS	23318420	hybrid			2022-12-28	WOS:000326922100003
J	Okudaira, N; Okamura, T; Tamura, M; Iijma, K; Goto, M; Matsunaga, A; Ochiai, M; Nakagama, H; Kano, S; Fujii-Kuriyama, Y; Ishizaka, Y				Okudaira, N.; Okamura, T.; Tamura, M.; Iijma, K.; Goto, M.; Matsunaga, A.; Ochiai, M.; Nakagama, H.; Kano, S.; Fujii-Kuriyama, Y.; Ishizaka, Y.			Long interspersed element-1 is differentially regulated by food-borne carcinogens via the aryl hydrocarbon receptor	ONCOGENE			English	Article						PhIP; MeIQx; aryl hydrocarbon receptor; breast carcinomas; ER alpha	HUMAN L1 RETROTRANSPOSITION; NON-LTR RETROTRANSPOSONS; HUMAN LINE-1 PROTEIN; SOMATIC RETROTRANSPOSITION; NUCLEOTIDE ELEMENT-1; HETEROCYCLIC AMINES; DIOXIN RECEPTOR; MICE LACKING; COOKED FOOD; EXPRESSION	A single human cell contains more than 5.0 x 10(5) copies of long interspersed element-1 (L1), 80-100 of which are competent for retrotransposition (L1-RTP). Recent observations have revealed the presence of de novo L1 insertions in various tumors, but little is known about its mechanism. Here, we found that 2-amino-1-methyl-6-phenylimidazo[ 4,5-b] pyridine (PhIP) and 2-amino-3, 8-dimethyl-imidazo[ 4,5-f] quinoxaline (MeIQx), food-borne carcinogens that are present in broiled meats, induced L1-RTP. This induction was dependent on a cellular cascade comprising the aryl hydrocarbon receptor (AhR), a mitogen-activated protein kinase, and CCAAT/ enhancer-binding protein b. Notably, these compounds exhibited differential induction of L1-RTP. MeIQx-induced L1-RTP was dependent on AhR nuclear translocator 1 (ARNT1), a counterpart of AhR required for gene expression in response to environmental pollutants. By contrast, PhIP-induced L1-RTP did not require ARNT1 but was dependent on estrogen receptor a (ERa) and AhR repressor. In vivo studies using transgenic mice harboring the human L1 gene indicated that PhIP-induced L1-RTP was reproducibly detected in the mammary gland, which is a target organ of PhIP-induced carcinoma. Moreover, picomolar levels of each compound induced L1-RTP, which is comparable to the PhIP concentration detected in human breast milk. Data suggest that somatic cells possess machineries that induce L1-RTP in response to the carcinogenic compounds. Together with data showing that micromolar levels of heterocyclic amines (HCAs) were non-genotoxic, our observations indicate that L1-RTP by environmental compounds is a novel type of genomic instability, further suggesting that analysis of L1-RTP by HCAs is a novel approach to clarification of modes of carcinogenesis.	[Okudaira, N.; Tamura, M.; Iijma, K.; Matsunaga, A.; Ishizaka, Y.] Natl Ctr Global Hlth & Med NCGM, Dept Intractable Dis, Shinjuku Ku, Tokyo 1628655, Japan; [Okudaira, N.; Kano, S.] Univ Tsukuba, Grad Sch Comprehens Human Sci, Tsukuba, Ibaraki, Japan; [Okamura, T.; Goto, M.] Natl Ctr Global Hlth & Med NCGM, Dept Lab Anim Med, Shinjuku Ku, Tokyo 1628655, Japan; [Ochiai, M.; Nakagama, H.] Natl Canc Ctr, Div Canc Dev Syst, Chuo Ku, Tokyo, Japan; [Kano, S.] Natl Ctr Global Hlth & Med NCGM, Dept Trop Med & Malaria, Shinjuku Ku, Tokyo 1628655, Japan; [Fujii-Kuriyama, Y.] Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo, Japan; [Okamura, T.] Dept Infect Dis, Sect Anim Model, Tokyo, Japan	University of Tsukuba; National Cancer Center - Japan; University of Tokyo	Ishizaka, Y (corresponding author), Natl Ctr Global Hlth & Med NCGM, Dept Intractable Dis, Shinjuku Ku, 1-21-1 Toyama, Tokyo 1628655, Japan.	zakay@ri.ncgm.go.jp		yuan ren, hou teng/0000-0001-6288-4583	Ministry of Health, Labor and Welfare of Japan [09156296]; Log-range Research Initiative (LRI) from Japan; Chemical Industry Association (JCIA); Tokyo Biochemical Research Foundation; JointUse Research facility, Hyogo College of Medicine	Ministry of Health, Labor and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Log-range Research Initiative (LRI) from Japan; Chemical Industry Association (JCIA); Tokyo Biochemical Research Foundation; JointUse Research facility, Hyogo College of Medicine	We are grateful to Drs Elena. T Luning Prak (University of Pennsylvania Medical Center), Gilbert Nicolas (University of Michigan Medical School) and Gabriele Vielhaber (Symrise, Germany) for providing pEF06R, pCEP4/L1mneoI/ColE1 and MNF, respectively. An antibody to AhRR was a kind gift from Dr Mark E Hahn (Woods Hole Oceanographic Institution). This work was supported in parts by a Grant-in-Aid for Research from the Ministry of Health, Labor and Welfare of Japan (09156296), and a research grant for the Log-range Research Initiative (LRI) from Japan Chemical Industry Association (JCIA). NO was an applicant supported by Grant-in-Aid from the Tokyo Biochemical Research Foundation. This work was supported in part by a JointUse Research facility, Hyogo College of Medicine.	Babushok DV, 2007, HUM MUTAT, V28, P527, DOI 10.1002/humu.20486; Baillie JK, 2011, NATURE, V479, P534, DOI 10.1038/nature10531; Bannert N, 2004, P NATL ACAD SCI USA, V101, P14572, DOI 10.1073/pnas.0404838101; Beischlag TV, 2008, CRIT REV EUKAR GENE, V18, P207, DOI 10.1615/CritRevEukarGeneExpr.v18.i3.20; Belancio VP, 2008, GENOME RES, V18, P343, DOI 10.1101/gr.5558208; Belancio VP, 2010, SEMIN CANCER BIOL, V20, P200, DOI 10.1016/j.semcancer.2010.06.001; Beraldi R, 2006, MOL REPROD DEV, V73, P279, DOI 10.1002/mrd.20423; Brouha B, 2003, P NATL ACAD SCI USA, V100, P5280, DOI 10.1073/pnas.0831042100; Coufal NG, 2011, P NATL ACAD SCI USA, V108, P20382, DOI 10.1073/pnas.1100273108; Coufal NG, 2009, NATURE, V460, P1127, DOI 10.1038/nature08248; Dewannieux M, 2003, NAT GENET, V35, P41, DOI 10.1038/ng1223; Eguchi H, 1997, J BIOL CHEM, V272, P17640, DOI 10.1074/jbc.272.28.17640; Ema M, 1996, MOL CELL BIOL, V16, P5865; Farkash EA, 2006, NUCLEIC ACIDS RES, V34, P1196, DOI 10.1093/nar/gkj522; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; Fritsche E, 2007, P NATL ACAD SCI USA, V104, P8851, DOI 10.1073/pnas.0701764104; Gasior SL, 2006, J MOL BIOL, V357, P1383, DOI 10.1016/j.jmb.2006.01.089; Georgiou I, 2009, HUM MOL GENET, V18, P1221, DOI 10.1093/hmg/ddp022; Gilbert N, 2005, MOL CELL BIOL, V25, P7780, DOI 10.1128/MCB.25.17.7780-7795.2005; Gilbert N, 2002, CELL, V110, P315, DOI 10.1016/S0092-8674(02)00828-0; Goodier JL, 2008, CELL, V135, P23, DOI 10.1016/j.cell.2008.09.022; Goodier JL, 2007, MOL CELL BIOL, V27, P6469, DOI 10.1128/MCB.00332-07; Hahn ME, 2009, BIOCHEM PHARMACOL, V77, P485, DOI 10.1016/j.bcp.2008.09.016; Hahn ME, 2002, CHEM-BIOL INTERACT, V141, P131, DOI 10.1016/S0009-2797(02)00070-4; Hancks DC, 2012, CURR OPIN GENET DEV, V22, P191, DOI 10.1016/j.gde.2012.02.006; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Hohjoh H, 1996, EMBO J, V15, P630, DOI 10.1002/j.1460-2075.1996.tb00395.x; Ishizaka Y, PROTEIN KINASES, P187; Iskow RC, 2010, CELL, V141, P1253, DOI 10.1016/j.cell.2010.05.020; ITO N, 1991, CARCINOGENESIS, V12, P1503, DOI 10.1093/carcin/12.8.1503; Jurka J, 1997, P NATL ACAD SCI USA, V94, P1872, DOI 10.1073/pnas.94.5.1872; Kale Shubha P, 2005, Int J Environ Res Public Health, V2, P14, DOI 10.3390/ijerph2005010014; Kano H, 2009, GENE DEV, V23, P1303, DOI 10.1101/gad.1803909; Karchner SI, 2009, MOL CELL BIOL, V29, P3465, DOI 10.1128/MCB.00206-09; Kazazian HH, 2011, BMC BIOL, V9, DOI 10.1186/1741-7007-9-62; KLEMAN MI, 1992, CARCINOGENESIS, V13, P1619, DOI 10.1093/carcin/13.9.1619; Konkel MK, 2010, SEMIN CANCER BIOL, V20, P211, DOI 10.1016/j.semcancer.2010.03.001; Lauber SN, 2007, CANCER RES, V67, P9597, DOI 10.1158/0008-5472.CAN-07-1661; Lauber SN, 2004, CARCINOGENESIS, V25, P2509, DOI 10.1093/carcin/bgh268; LAYTON DW, 1995, CARCINOGENESIS, V16, P39, DOI 10.1093/carcin/16.1.39; Lee E, 2012, SCIENCE, V337, P967, DOI 10.1126/science.1222077; Macia A, 2011, MOL CELL BIOL, V31, P300, DOI 10.1128/MCB.00561-10; Martin SL, 2005, J MOL BIOL, V348, P549, DOI 10.1016/j.jmb.2005.03.003; MATHIAS SL, 1991, SCIENCE, V254, P1808, DOI 10.1126/science.1722352; McIntosh BE, 2010, ANNU REV PHYSIOL, V72, P625, DOI 10.1146/annurev-physiol-021909-135922; MIKI Y, 1992, CANCER RES, V52, P643; Mimura J, 1997, GENES CELLS, V2, P645, DOI 10.1046/j.1365-2443.1997.1490345.x; MORSE B, 1988, NATURE, V333, P87, DOI 10.1038/333087a0; Muotri AR, 2010, NATURE, V468, P443, DOI 10.1038/nature09544; Nakai Y, 2007, CANCER RES, V67, P1378, DOI 10.1158/0008-5472.CAN-06-1336; Nishikawa A, 2005, TOXICOL SCI, V84, P243, DOI 10.1093/toxsci/kfi079; OHGAKI H, 1987, CARCINOGENESIS, V8, P665, DOI 10.1093/carcin/8.5.665; Okudaira N, 2011, CANCER SCI, V102, P2000, DOI 10.1111/j.1349-7006.2011.02060.x; Okudaira N, 2010, P NATL ACAD SCI USA, V107, P18487, DOI 10.1073/pnas.1001252107; Oricchio E, 2007, ONCOGENE, V26, P4226, DOI 10.1038/sj.onc.1210214; Osborne CK, 2004, BRIT J CANCER, V90, pS2, DOI 10.1038/sj.bjc.6601629; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Quintana FJ, 2008, NATURE, V453, P65, DOI 10.1038/nature06880; Raiz J, 2012, NUCLEIC ACIDS RES, V40, P1666, DOI 10.1093/nar/gkr863; Schut HAJ, 1999, CARCINOGENESIS, V20, P353, DOI 10.1093/carcin/20.3.353; Scott KA, 2007, CHEM RES TOXICOL, V20, P88, DOI 10.1021/tx0601861; Shimizu Y, 2000, P NATL ACAD SCI USA, V97, P779, DOI 10.1073/pnas.97.2.779; Shirai T, 1997, CANCER RES, V57, P195; Stribinskis V, 2006, CANCER RES, V66, P2616, DOI 10.1158/0008-5472.CAN-05-3478; Sugimura T, 2004, CANCER SCI, V95, P290, DOI 10.1111/j.1349-7006.2004.tb03205.x; Symer DE, 2002, CELL, V110, P327, DOI 10.1016/S0092-8674(02)00839-5; Ting DT, 2011, SCIENCE, V331, P593, DOI 10.1126/science.1200801; Veldhoen M, 2008, NATURE, V453, P106, DOI 10.1038/nature06881; Vitullo P, 2012, MOL REPROD DEV, V79, P118, DOI 10.1002/mrd.22003; Wallace N, 2008, GENE, V419, P1, DOI 10.1016/j.gene.2008.04.007; Wei W, 2000, ANAL BIOCHEM, V284, P435, DOI 10.1006/abio.2000.4675; Wei W, 2001, MOL CELL BIOL, V21, P1429, DOI 10.1128/MCB.21.4.1429-1439.2001; Weiss C, 2005, ONCOGENE, V24, P4975, DOI 10.1038/sj.onc.1208679; Wincent E, 2012, P NATL ACAD SCI USA, V109, P4479, DOI 10.1073/pnas.1118467109; Wiseman M, 2008, P NUTR SOC, V67, P253, DOI 10.1017/S002966510800712X; Woodcock DM, 1997, J BIOL CHEM, V272, P7810, DOI 10.1074/jbc.272.12.7810	77	21	21	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2013	32	41					4903	4912		10.1038/onc.2012.516	http://dx.doi.org/10.1038/onc.2012.516			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235KQ	23208499	hybrid, Green Published			2022-12-28	WOS:000325717800006
J	Duijf, PHG; Benezra, R				Duijf, P. H. G.; Benezra, R.			The cancer biology of whole-chromosome instability	ONCOGENE			English	Review						whole-chromosome instability; aneuploidy; cancer biology; oncogene-induced mitotic stress; non-cell autonomous; tumor microenvironment	CELL-CYCLE PROGRESSION; AGING-ASSOCIATED PHENOTYPES; EARLY EMBRYONIC-DEVELOPMENT; TUMOR-SPECIFIC ANTIGENS; IN-SITU HYBRIDIZATION; DNA-DAMAGE; CENTROSOME AMPLIFICATION; GENOMIC INSTABILITY; SPINDLE ABNORMALITIES; MITOTIC CHECKPOINT	One form of chromosome instability (CIN), the recurrent missegregation of whole chromosomes during cell division (W-CIN), leads to aneuploidy. Although W-CIN is a hallmark of most cancers, mutations in genes involved in chromosome segregation are exceedingly rare. We discuss an oncogene-induced mitotic stress model that provides a mechanistic framework to explain this paradox. We also review the tumor-promoting and tumor-suppressing consequences of W-CIN. Importantly, we do this in the context of cancer as a complex systemic disease, rather than as a simple linearly progressing disorder that arises from a single abnormal cell population. Accordingly, we highlight the often neglected effects of W-CIN on key non-cell-autonomous entities, such as the immune system and the tumor microenvironment. Distinct tissue-specific susceptibilities to W-CIN-induced tumorigenesis and the clinical implications of W-CIN are also discussed.	[Duijf, P. H. G.; Benezra, R.] Mem Sloan Kettering Canc Ctr, Dept Canc Biol & Genet, New York, NY 10021 USA; [Duijf, P. H. G.] Univ Queensland, Diamantina Inst, Princess Alexandra Hosp, Brisbane, Qld 4102, Australia	Memorial Sloan Kettering Cancer Center; University of Queensland	Duijf, PHG (corresponding author), Univ Queensland, Diamantina Inst, Princess Alexandra Hosp, Ipswich Rd, Brisbane, Qld 4102, Australia.	p.duijf@uq.edu.au; r-benezra@ski.mskcc.org	Duijf, Pascal H.G./E-7110-2012	Duijf, Pascal H.G./0000-0001-8646-9843	Young Investigator Award from Alex's Lemonade Stand Foundation; Breast Cancer Research Foundation	Young Investigator Award from Alex's Lemonade Stand Foundation; Breast Cancer Research Foundation	We thank Peter J Cook, Zvi Granot, Rozario I Thomas, Daniel Marks and Rocio Sotillo for critical reading of the manuscript. PHGD is supported by a Young Investigator Award from Alex's Lemonade Stand Foundation and RB by the Breast Cancer Research Foundation.	Aivaliotis IL, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/536761; Guerrero AA, 2010, P NATL ACAD SCI USA, V107, P4159, DOI 10.1073/pnas.0912143106; Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Babu JR, 2003, J CELL BIOL, V160, P341, DOI 10.1083/jcb.200211048; Baker DJ, 2004, NAT GENET, V36, P744, DOI 10.1038/ng1382; Baker DJ, 2006, J CELL BIOL, V172, P529, DOI 10.1083/jcb.200507081; Barboza JA, 2006, P NATL ACAD SCI USA, V103, P19842, DOI 10.1073/pnas.0606343104; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bedard PL, 2010, NAT REV CLIN ONCOL, V7, P22, DOI 10.1038/nrclinonc.2009.186; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bhattacharya A, 2011, CLIN CANCER RES, V17, P7024, DOI 10.1158/1078-0432.CCR-11-1944; Bitomsky N, 2009, FEBS J, V276, P6074, DOI 10.1111/j.1742-4658.2009.07331.x; Burds AA, 2005, P NATL ACAD SCI USA, V102, P11296, DOI 10.1073/pnas.0505053102; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Celton-Morizur S, 2010, ADV EXP MED BIOL, V676, P123; Chang CC, 2006, J BIOL CHEM, V281, P18763, DOI 10.1074/jbc.M511525200; Chesnokova V, 2005, MOL ENDOCRINOL, V19, P2371, DOI 10.1210/me.2005-0137; Choi CM, 2009, LUNG CANCER, V64, P66, DOI 10.1016/j.lungcan.2008.07.016; Chulada PC, 2000, CANCER RES, V60, P4705; Colotta F, 2009, CARCINOGENESIS, V30, P1073, DOI 10.1093/carcin/bgp127; Coschi CH, 2010, GENE DEV, V24, P1351, DOI 10.1101/gad.1917610; Crasta K, 2012, NATURE, V482, P53, DOI 10.1038/nature10802; Cui YP, 2010, CANCER RES, V70, P675, DOI 10.1158/0008-5472.CAN-09-1491; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Deng YB, 2008, NAT REV CANCER, V8, P450, DOI 10.1038/nrc2393; Diaz-Rodriguez E, 2008, P NATL ACAD SCI USA, V105, P16719, DOI 10.1073/pnas.0803504105; Duensing A, 2010, ADV EXP MED BIOL, V676, P93; Duesberg P, 2000, P NATL ACAD SCI USA, V97, P14295, DOI 10.1073/pnas.97.26.14295; Duijf PH, INT J CANCER, DOI [10.1002/ijc.27924, DOI 10.1002/IJC.27924)]; Duncan AW, 2010, NATURE, V467, P707, DOI 10.1038/nature09414; Dunn GP, 2002, NAT IMMUNOL, V3, P991, DOI 10.1038/ni1102-991; DuPage M, 2012, NATURE, V482, P405, DOI 10.1038/nature10803; Ehlers JP, 2008, CLIN CANCER RES, V14, P115, DOI 10.1158/1078-0432.CCR-07-1825; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Galluzzi L, 2011, INT REV CEL MOL BIO, V289, P1, DOI 10.1016/B978-0-12-386039-2.00001-8; Garcia-Higuera I, 2008, NAT CELL BIOL, V10, P802, DOI 10.1038/ncb1742; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Gogvadze V, 2008, TRENDS CELL BIOL, V18, P165, DOI 10.1016/j.tcb.2008.01.006; Gordon DJ, 2012, NAT REV GENET, V13, P189, DOI 10.1038/nrg3123; Granot Z, 2011, CANCER CELL, V20, P300, DOI 10.1016/j.ccr.2011.08.012; Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Gutenberg A, 2010, CANCER GENET CYTOGEN, V198, P47, DOI 10.1016/j.cancergencyto.2009.12.006; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hasle H, 2000, LANCET, V355, P165, DOI 10.1016/S0140-6736(99)05264-2; HASLE H, 1995, BRIT J CANCER, V71, P416, DOI 10.1038/bjc.1995.85; Hayashi MT, 2012, NAT STRUCT MOL BIOL, V19, P387, DOI 10.1038/nsmb.2245; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Iwanaga Y, 2007, CANCER RES, V67, P160, DOI 10.1158/0008-5472.CAN-06-3326; Janisson-Dargaud D, 2008, J CUTAN PATHOL, V35, P916, DOI 10.1111/j.1600-0560.2007.00935.x; Janssen A, 2011, SCIENCE, V333, P1895, DOI 10.1126/science.1210214; Janssen A, 2009, P NATL ACAD SCI USA, V106, P19108, DOI 10.1073/pnas.0904343106; Jeganathan K, 2007, J CELL BIOL, V179, P255, DOI 10.1083/jcb.200706015; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kabeche L, 2012, CURR BIOL, V22, P638, DOI 10.1016/j.cub.2012.02.030; Kamata T, 2010, CANCER RES, V70, P8475, DOI 10.1158/0008-5472.CAN-10-0603; Karna P, 2011, CELL DEATH DIFFER, V18, P632, DOI 10.1038/cdd.2010.133; Khong HT, 2002, NAT IMMUNOL, V3, P999, DOI 10.1038/ni1102-999; Kimmelman AC, 2011, GENE DEV, V25, P1999, DOI 10.1101/gad.17558811; Ko MA, 2005, NAT GENET, V37, P883, DOI 10.1038/ng1605; Kreike B, 2009, CLIN CANCER RES, V15, P4181, DOI 10.1158/1078-0432.CCR-08-2644; Kwon M, 2008, GENE DEV, V22, P2189, DOI 10.1101/gad.1700908; Lagarde P, 2012, CLIN CANCER RES, V18, P826, DOI 10.1158/1078-0432.CCR-11-1610; Lakovschek IC, 2011, AM J MED GENET A, V155A, P2626, DOI 10.1002/ajmg.a.34284; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lewis CE, 2007, CANCER RES, V67, P8429, DOI 10.1158/0008-5472.CAN-07-1684; Li M, 2010, P NATL ACAD SCI USA, V107, P14188, DOI 10.1073/pnas.1005960107; Li M, 2009, J CELL BIOL, V185, P983, DOI 10.1083/jcb.200904020; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; Liu PF, 2011, CELL, V146, P888, DOI 10.1016/j.cell.2011.07.042; Loeb LA, 2001, CANCER RES, V61, P3230; Lonkar P, 2011, INT J CANCER, V128, P1999, DOI 10.1002/ijc.25815; Lu LY, 2008, J BIOL CHEM, V283, P31785, DOI 10.1074/jbc.M805880200; Lu LY, 2008, MOL CELL BIOL, V28, P6870, DOI 10.1128/MCB.00392-08; Malumbres M, 2011, CANCER CELL, V19, P691, DOI 10.1016/j.ccr.2011.05.023; Manchado E, 2012, CELL DEATH DIFFER, V19, P369, DOI 10.1038/cdd.2011.197; Manning AL, 2010, GENE DEV, V24, P1364, DOI 10.1101/gad.1917310; Mason SD, 2011, TRENDS CELL BIOL, V21, P228, DOI 10.1016/j.tcb.2010.12.002; McClelland SE, 2009, CELL CYCLE, V8, P3262, DOI 10.4161/cc.8.20.9690; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Mikule K, 2007, NAT CELL BIOL, V9, P160, DOI 10.1038/ncb1529; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Molenaar JJ, 2012, NATURE, V483, P589, DOI 10.1038/nature10910; Mukherjee M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022167; Nelsen CJ, 2005, J BIOL CHEM, V280, P768, DOI 10.1074/jbc.M407105200; Nguyen HG, 2009, FASEB J, V23, P2741, DOI 10.1096/fj.09-130963; Oikawa T, 2005, MOL CELL BIOL, V25, P4046, DOI 10.1128/MCB.25.10.4046-4061.2005; Oliveira RA, 2010, BIOCHEM SOC T, V38, P1639, DOI 10.1042/BST0381639; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Ostrand-Rosenberg S, 2008, CURR OPIN GENET DEV, V18, P11, DOI 10.1016/j.gde.2007.12.007; Pavelka N, 2010, NATURE, V468, P321, DOI 10.1038/nature09529; Pinto AE, 2012, CLIN ENDOCRINOL, V77, P302, DOI 10.1111/j.1365-2265.2012.04363.x; Png KJ, 2012, NATURE, V481, P190, DOI 10.1038/nature10661; Polager S, 2002, ONCOGENE, V21, P437, DOI 10.1038/sj.onc.1205102; Puente XS, 2011, NATURE, V475, P101, DOI 10.1038/nature10113; Rebacz B, 2007, CANCER RES, V67, P6342, DOI 10.1158/0008-5472.CAN-07-0663; Reinhardt HC, 2012, TRENDS GENET, V28, P128, DOI 10.1016/j.tig.2011.12.002; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Ricke RM, 2008, TRENDS GENET, V24, P457, DOI 10.1016/j.tig.2008.07.002; Ricke RM, 2011, J CELL BIOL, V193, P1049, DOI 10.1083/jcb.201012035; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Rodriguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305; Saavedra HI, 1999, J BIOL CHEM, V274, P38083, DOI 10.1074/jbc.274.53.38083; SANDA MG, 1995, J NATL CANCER I, V87, P280, DOI 10.1093/jnci/87.4.280; Satge D, 1998, CANCER RES, V58, P448; Sato H, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-182; Schardt JA, 2005, CANCER CELL, V8, P227, DOI 10.1016/j.ccr.2005.08.003; Schliekelman M, 2009, CANCER RES, V69, P45, DOI 10.1158/0008-5472.CAN-07-6330; Schmidt-Kittler O, 2003, P NATL ACAD SCI USA, V100, P7737, DOI 10.1073/pnas.1331931100; Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486; Schvartzman JM, 2011, CANCER CELL, V19, P701, DOI 10.1016/j.ccr.2011.04.017; Schvartzman JM, 2010, NAT REV CANCER, V10, P102, DOI 10.1038/nrc2781; Seremet T, 2011, CANCER J, V17, P325, DOI 10.1097/PPO.0b013e3182326004; Sheltzer JM, 2011, SCIENCE, V333, P1026, DOI 10.1126/science.1206412; Sherr CJ, 2002, CANCER CELL, V2, P103, DOI 10.1016/S1535-6108(02)00102-2; Skirnisdottir I, 2001, INT J ONCOL, V19, P1295; Smid M, 2011, BREAST CANCER RES TR, V128, P23, DOI 10.1007/s10549-010-1026-5; Solomon DA, 2011, SCIENCE, V333, P1039, DOI 10.1126/science.1203619; Sotillo R, 2007, CANCER CELL, V11, P9, DOI 10.1016/j.ccr.2006.10.019; Sotillo R, 2010, NATURE, V464, P436, DOI 10.1038/nature08803; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; Stoecklein NH, 2008, CANCER CELL, V13, P441, DOI 10.1016/j.ccr.2008.04.005; Susini T, 2011, INT J GYNECOL CANCER, V21, P678, DOI 10.1097/IGC.0b013e3182126f85; Swanton C, 2009, P NATL ACAD SCI USA, V106, P8671, DOI 10.1073/pnas.0811835106; Swerdlow AJ, 2005, J NATL CANCER I, V97, P1204, DOI 10.1093/jnci/dji240; Tang YC, 2011, CELL, V144, P499, DOI 10.1016/j.cell.2011.01.017; Terrano DT, 2010, MOL CELL BIOL, V30, P640, DOI 10.1128/MCB.00882-09; Thompson SL, 2010, CURR BIOL, V20, pR285, DOI 10.1016/j.cub.2010.01.034; Thompson SL, 2010, J CELL BIOL, V188, P369, DOI 10.1083/jcb.200905057; Torres EM, 2007, SCIENCE, V317, P916, DOI 10.1126/science.1142210; Torres EM, 2010, CELL, V143, P71, DOI 10.1016/j.cell.2010.08.038; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P1153, DOI 10.1038/cdd.2008.47; van Harn T, 2010, GENE DEV, V24, P1377, DOI 10.1101/gad.580710; van Ree JH, 2010, J CELL BIOL, V188, P83, DOI 10.1083/jcb.200906147; Visconti R, 2009, IDRUGS, V12, P240; Walther A, 2008, GUT, V57, P941, DOI 10.1136/gut.2007.135004; Wang ZY, 2001, MOL ENDOCRINOL, V15, P1870, DOI 10.1210/me.15.11.1870; Warth A, 2009, EXP MOL MED, V41, P349, DOI 10.3858/emm.2009.41.5.039; Weaver BAA, 2007, CANCER CELL, V11, P25, DOI 10.1016/j.ccr.2006.12.003; Weckermann D, 2009, J CLIN ONCOL, V27, P1549, DOI 10.1200/JCO.2008.17.0563; White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262; Williams BR, 2008, SCIENCE, V322, P703, DOI 10.1126/science.1160058; Wu GK, 2008, CANCER RES, V68, P8393, DOI 10.1158/0008-5472.CAN-08-1915; Yamada HY, 2012, CELL CYCLE, V11, P479, DOI 10.4161/cc.11.3.18994; Yang QH, 2002, LANCET, V359, P1019, DOI 10.1016/S0140-6736(02)08092-3; Zhang D, 2008, ONCOGENE, V27, P4305, DOI 10.1038/onc.2008.76; Zheng L, 2007, NAT MED, V13, P812, DOI 10.1038/nm1599; Zhou YL, 2003, J BIOL CHEM, V278, P462, DOI 10.1074/jbc.M203793200	155	81	82	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2013	32	40					4727	4736		10.1038/onc.2012.616	http://dx.doi.org/10.1038/onc.2012.616			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229NW	23318433				2022-12-28	WOS:000325274700001
J	Zhang, B; Chen, H; Zhang, L; Dakhova, O; Zhang, Y; Lewis, MT; Creighton, CJ; Ittmann, MM; Xin, L				Zhang, B.; Chen, H.; Zhang, L.; Dakhova, O.; Zhang, Y.; Lewis, M. T.; Creighton, C. J.; Ittmann, M. M.; Xin, L.			A dosage-dependent pleiotropic role of Dicer in prostate cancer growth and metastasis	ONCOGENE			English	Article						prostate cancer; Dicer; pten; senescence; apoptosis; invasiveness	MICRORNA EXPRESSION; ENZYME DICER; INTRAEPITHELIAL NEOPLASIA; CELL-PROLIFERATION; UP-REGULATION; DNA-DAMAGE; SENESCENCE; MOUSE; MORPHOGENESIS; DROSHA	Dicer is an RNase III enzyme essential for the maturation of the majority of microRNAs. Recent studies have revealed downregulation or hemizygous loss of Dicer in many tumor models and demonstrated that suppressing Dicer activity enhances tumorigenic activities of lung and breast cancer cells, which support Dicer as a haploinsufficient tumor suppressor in these cancer models. Surprisingly, we found that knocking down Dicer expression suppresses the growth and tumorigenic capacity of human prostate cancer cell lines, but enhances migratory capacities of some prostate cancer cell lines. Dicer is upregulated in human prostate cancer specimens, but lower Dicer expression portends a shorter time to recurrence. Complete ablation of Dicer activity in a Pten null mouse model for prostate cancer significantly halts tumor growth and progression, demonstrating that microRNAs have a critical role in maintaining cancer cell fitness. In comparison, hemizygous loss of Dicer in the same model also reduces primary tumor burden, but induces a more locally invasive phenotype and causes seminal vesicle obstruction at high penetrance. Disrupting Dicer activity leads to an increase in apoptosis and senescence in these models, presumably through upregulation of P16/INK4a and P27/Kip1. Collectively, these results highlight a pleotropic role of Dicer in tumorigenesis that is not only dosage-dependent but also tissue context-dependent.	[Zhang, B.; Chen, H.; Zhang, L.; Lewis, M. T.; Xin, L.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Dakhova, O.; Ittmann, M. M.; Xin, L.] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA; [Zhang, Y.; Lewis, M. T.; Creighton, C. J.; Ittmann, M. M.; Xin, L.] Dan L Duncan Canc Ctr, Houston, TX USA	Baylor College of Medicine; Baylor College of Medicine	Xin, L (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.	xin@bcm.edu	Lewis, Michael T/A-9572-2009		NIH [R00 CA125937, U01 CA141497, P30 CA125123]; Cancer Prevention Research Institute of Texas [RP110005]; National Cancer Institute, Cancer Prevention and Research Institute of Texas; NATIONAL CANCER INSTITUTE [P30CA125123] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention Research Institute of Texas; National Cancer Institute, Cancer Prevention and Research Institute of Texas; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Lawrence Donehower and Jeffrey Rosen for critical comments, Dr Xiongbin Lu for sharing reagents. This work is supported by NIH R00 CA125937 (LX), Cancer Prevention Research Institute of Texas RP110005 (LX), NIH U01 CA141497 (MMI), and NIH P30 CA125123 (PI: Kent Osborne). This study was supported by National Cancer Institute, Cancer Prevention and Research Institute of Texas.	Alimonti A, 2010, J CLIN INVEST, V120, P681, DOI 10.1172/JCI40535; Ambs S, 2008, CANCER RES, V68, P6162, DOI 10.1158/0008-5472.CAN-08-0144; Andl T, 2006, CURR BIOL, V16, P1041, DOI 10.1016/j.cub.2006.04.005; Arrate MP, 2010, CANCER RES, V70, P6083, DOI 10.1158/0008-5472.CAN-09-4736; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Chiosea S, 2007, CANCER RES, V67, P2345, DOI 10.1158/0008-5472.CAN-06-3533; Chiosea S, 2006, AM J PATHOL, V169, P1812, DOI 10.2353/ajpath.2006.060480; Faggad A, 2010, J PATHOL, V220, P382, DOI 10.1002/path.2658; Francia S, 2012, NATURE, V488, P231, DOI 10.1038/nature11179; Grelier G, 2009, BRIT J CANCER, V101, P673, DOI 10.1038/sj.bjc.6605193; Han L, 2010, INT J ONCOL, V37, P299, DOI 10.3892/ijo_00000678; Harfe BD, 2005, P NATL ACAD SCI USA, V102, P10898, DOI 10.1073/pnas.0504834102; Jafarnejad SM, 2013, ONCOGENE, V32, P2131, DOI 10.1038/onc.2012.239; Jin CL, 2003, PROSTATE, V57, P160, DOI 10.1002/pros.10283; Kanellopoulou C, 2005, GENE DEV, V19, P489, DOI 10.1101/gad.1248505; Karube Y, 2005, CANCER SCI, V96, P111, DOI 10.1111/j.1349-7006.2005.00015.x; Khoshnaw SM, 2012, BREAST CANCER RES TR, V135, P403, DOI 10.1007/s10549-012-2169-3; Kim J, 2012, P NATL ACAD SCI USA, V109, P3921, DOI 10.1073/pnas.1117135109; Koralov SB, 2008, CELL, V132, P860, DOI 10.1016/j.cell.2008.02.020; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Kumar MS, 2009, GENE DEV, V23, P2700, DOI 10.1101/gad.1848209; Lambertz I, 2010, CELL DEATH DIFFER, V17, P633, DOI 10.1038/cdd.2009.202; Lin RJ, 2010, CANCER RES, V70, P7841, DOI 10.1158/0008-5472.CAN-10-0970; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Ma ZH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020494; Majumder PK, 2008, CANCER CELL, V14, P146, DOI 10.1016/j.ccr.2008.06.002; Martello G, 2010, CELL, V141, P1195, DOI 10.1016/j.cell.2010.05.017; Merritt WM, 2008, NEW ENGL J MED, V359, P2641, DOI 10.1056/NEJMoa0803785; Mudhasani R, 2008, J CELL BIOL, V181, P1055, DOI 10.1083/jcb.200802105; Nakagawa A, 2010, SCIENCE, V328, P327, DOI 10.1126/science.1182374; Narayanan R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013637; Nittner D, 2012, NAT CELL BIOL, V14, P958, DOI 10.1038/ncb2556; Noh Hyangsoon, 2011, Genes Cancer, V2, P140, DOI 10.1177/1947601911408888; O'Rourke JR, 2007, DEV BIOL, V311, P359, DOI 10.1016/j.ydbio.2007.08.032; Ozen M, 2008, ONCOGENE, V27, P1788, DOI 10.1038/sj.onc.1210809; Park JH, 2002, AM J PATHOL, V161, P727, DOI 10.1016/S0002-9440(10)64228-9; Pastorelli LM, 2009, MAMM GENOME, V20, P140, DOI 10.1007/s00335-008-9169-y; Ravi A, 2012, CANCER CELL, V21, P848, DOI 10.1016/j.ccr.2012.04.037; Shlush LI, 2011, BMC CELL BIOL, V12, DOI 10.1186/1471-2121-12-16; Sun YT, 2012, CANCER RES, V72, P527, DOI 10.1158/0008-5472.CAN-11-3004; Tang KF, 2008, J CELL BIOL, V182, P233, DOI 10.1083/jcb.200801169; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Ting AH, 2008, CANCER RES, V68, P2570, DOI 10.1158/0008-5472.CAN-07-6405; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wei W, 2012, CELL, V149, P101, DOI 10.1016/j.cell.2012.03.002; Xin L, 2003, P NATL ACAD SCI USA, V100, P11896, DOI 10.1073/pnas.1734139100; Xu SL, 2012, BLOOD, V119, P767, DOI 10.1182/blood-2011-05-355412; Yi R, 2006, NAT GENET, V38, P356, DOI 10.1038/ng1744; Yu JY, 2009, DEVELOPMENT, V136, P1497, DOI 10.1242/dev.025999; Zhang L, 2010, STEM CELLS, V28, P1260, DOI 10.1002/stem.455	51	34	34	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2014	33	24					3099	3108		10.1038/onc.2013.281	http://dx.doi.org/10.1038/onc.2013.281			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK4QU	23851498	Green Accepted			2022-12-28	WOS:000338410000003
J	Yuan, X; Cai, C; Chen, S; Chen, S; Yu, Z; Balk, SP				Yuan, X.; Cai, C.; Chen, S.; Chen, S.; Yu, Z.; Balk, S. P. p			Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis	ONCOGENE			English	Review						androgen; androgen receptor; prostate cancer; castration-resistant prostate cancer	SERINE 81 PHOSPHORYLATION; LIGAND-BINDING DOMAIN; NUCLEAR RECEPTOR; SPLICE VARIANTS; GENE-EXPRESSION; BETA-CATENIN; STRUCTURAL BASIS; CELL-GROWTH; TYROSINE PHOSPHORYLATION; TRANSCRIPTIONAL ACTIVITY	The metabolic functions of androgen receptor (AR) in normal prostate are circumvented in prostate cancer (PCa) to drive tumor growth, and the AR also can acquire new growth-promoting functions during PCa development and progression through genetic and epigenetic mechanisms. Androgen deprivation therapy (ADT, surgical or medical castration) is the standard treatment for metastatic PCa, but patients invariably relapse despite castrate androgen levels (castration-resistant PCa, CRPC). Early studies from many groups had shown that AR was highly expressed and transcriptionally active in CRPC, and indicated that steroids from the adrenal glands were contributing to this AR activity. More recent studies showed that CRPC cells had increased expression of enzymes mediating androgen synthesis from adrenal steroids, and could synthesize androgens de novo from cholesterol. Phase III clinical trials showing a survival advantage in CRPC for treatment with abiraterone (inhibitor of the enzyme CYP17A1 required for androgen synthesis that markedly reduces androgens and precursor steroids) and for enzalutamide (new AR antagonist) have now confirmed that AR activity driven by residual androgens makes a major contribution to CRPC, and led to the recent Food and Drug Administration approval of both agents. Unfortunately, patients treated with these agents for advanced CRPC generally relapse within a year and AR appears to be active in the relapsed tumors, but the molecular mechanisms mediating intrinsic or acquired resistance to these AR-targeted therapies remain to be defined. This review outlines AR functions that contribute to PCa development and progression, the roles of intratumoral androgen synthesis and AR structural alterations in driving AR activity in CRPC, mechanisms of action for abiraterone and enzalutamide, and possible mechanisms of resistance to these agents.	[Yuan, X.; Cai, C.; Chen, S.; Chen, S.; Yu, Z.; Balk, S. P. p] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Hematol Oncol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Balk, SP (corresponding author), Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med,Div Hematol Oncol, 330 Brookline Ave, Boston, MA 02215 USA.	sbalk@bidmc.harvard.edu	CHEN, Shaoyong/ABF-3357-2021; Cai, Changmeng/AAE-6835-2020	Cai, Changmeng/0000-0002-8701-2586	National Institutes of Health; Department of Defense Prostate Cancer Research Program; Prostate Cancer Foundation; NATIONAL CANCER INSTITUTE [K99CA166507] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Prostate Cancer Research Program(United States Department of Defense); Prostate Cancer Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Work from the authors cited in this review has been supported by awards from the National Institutes of Health, Department of Defense Prostate Cancer Research Program and the Prostate Cancer Foundation. We apologize to the many colleagues whose work we were unable to discuss or cite.	Acevedo VD, 2007, CANCER CELL, V12, P559, DOI 10.1016/j.ccr.2007.11.004; Agoulnik IU, 2006, CANCER RES, V66, P10594, DOI 10.1158/0008-5472.CAN-06-1023; Agoulnik IU, 2005, CANCER RES, V65, P7959, DOI 10.1158/0008-5472.CAN-04-3541; Andersen RJ, 2010, CANCER CELL, V17, P535, DOI 10.1016/j.ccr.2010.04.027; Balk Steven P, 2008, Nucl Recept Signal, V6, pe001, DOI 10.1621/nrs.06001; Belandia B, 2005, MOL CELL BIOL, V25, P1425, DOI 10.1128/MCB.25.4.1425-1436.2005; BELANGER B, 1989, J STEROID BIOCHEM, V32, P695, DOI 10.1016/0022-4731(89)90514-1; Bhatt RS, 2011, OPEN PROSTATE CANC J, V4, P1; Bohl CE, 2007, J BIOL CHEM, V282, P13648, DOI 10.1074/jbc.M611711200; Bohl CE, 2005, P NATL ACAD SCI USA, V102, P6201, DOI 10.1073/pnas.0500381102; Cai CM, 2013, J CLIN INVEST, V123, P1109, DOI 10.1172/JCI66666; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Cai CM, 2011, CANCER RES, V71, P6503, DOI 10.1158/0008-5472.CAN-11-0532; Cai CM, 2011, ENDOCR-RELAT CANCER, V18, pR175, DOI 10.1530/ERC-10-0339; Cai CM, 2009, CANCER RES, V69, P6027, DOI 10.1158/0008-5472.CAN-09-0395; Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008; Chan SC, 2012, J BIOL CHEM, V287, P19736, DOI 10.1074/jbc.M112.352930; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chen SY, 2006, P NATL ACAD SCI USA, V103, P15969, DOI 10.1073/pnas.0604193103; Chen SY, 2012, J BIOL CHEM, V287, P8571, DOI 10.1074/jbc.M111.325290; Chen SY, 2009, J BIOL CHEM, V284, P25576, DOI 10.1074/jbc.M109.043133; Chen SY, 2006, MOL CELL BIOL, V26, P929, DOI 10.1128/MCB.26.3.929-939.2006; Cheng ST, 2002, MOL ENDOCRINOL, V16, P1492, DOI 10.1210/me.16.7.1492; Chesire DR, 2002, ONCOGENE, V21, P8453, DOI 10.1038/sj.onc.1206049; Chinnaiyan AM, 2008, NEOPLASIA, V10, P177, DOI 10.1593/neo.07822; Chng KR, 2012, EMBO J, V31, P2810, DOI 10.1038/emboj.2012.112; Clegg NJ, 2012, CANCER RES, V72, P1494, DOI 10.1158/0008-5472.CAN-11-3948; CULIG Z, 1993, MOL ENDOCRINOL, V7, P1541, DOI 10.1210/me.7.12.1541; Curtin D, 2001, MOL ENDOCRINOL, V15, P1906, DOI 10.1210/me.15.11.1906; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; Dehm SM, 2008, CANCER RES, V68, P5469, DOI 10.1158/0008-5472.CAN-08-0594; Dehm SM, 2011, ENDOCR-RELAT CANCER, V18, pR183, DOI 10.1530/ERC-11-0141; DEWINTER JAR, 1994, AM J PATHOL, V144, P735; Dillard PR, 2008, MOL CELL ENDOCRINOL, V295, P115, DOI 10.1016/j.mce.2008.08.013; Eisenberger MA, 1998, NEW ENGL J MED, V339, P1036, DOI 10.1056/NEJM199810083391504; Ettinger SL, 2004, CANCER RES, V64, P2212, DOI 10.1158/0008-5472.CAN-2148-2; Fang Z, 2012, J BIOL CHEM, V287, P2090, DOI 10.1074/jbc.M111.323303; Farla P, 2005, J CELL SCI, V118, P4187, DOI 10.1242/jcs.02546; Gamble SC, 2007, ONCOGENE, V26, P1757, DOI 10.1038/sj.onc.1209967; Garcia-Bassets I, 2007, CELL, V128, P505, DOI 10.1016/j.cell.2006.12.038; Gaughan L, 2005, NUCLEIC ACIDS RES, V33, P13, DOI 10.1093/nar/gki141; Gaughan L, 2011, NUCLEIC ACIDS RES, V39, P1266, DOI 10.1093/nar/gkq861; GELLER J, 1985, SEMIN ONCOL, V12, P28; GELLER J, 1987, UROL RES, V15, P151; GELLER J, 1984, J UROLOGY, V132, P693, DOI 10.1016/S0022-5347(17)49829-6; Gioeli D, 2006, MOL ENDOCRINOL, V20, P503, DOI 10.1210/me.2005-0351; Gioeli D, 2012, MOL CELL ENDOCRINOL, V352, P70, DOI 10.1016/j.mce.2011.07.004; Gordon V, 2010, MOL ENDOCRINOL, V24, P2267, DOI 10.1210/me.2010-0238; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Gregory CW, 2004, J BIOL CHEM, V279, P7119, DOI 10.1074/jbc.M307649200; Gregory CW, 1998, CANCER RES, V58, P5718; Gregory CW, 2001, CANCER RES, V61, P4315; Grosse A, 2012, MOL CELL ENDOCRINOL, V352, P46, DOI 10.1016/j.mce.2011.06.032; Guo ZY, 2006, CANCER CELL, V10, P309, DOI 10.1016/j.ccr.2006.08.021; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Ha S, 2013, ONCOGENE, V32, P3992, DOI 10.1038/onc.2012.412; Ha S, 2011, ENDOCR-RELAT CANCER, V18, P245, DOI 10.1530/ERC-10-0204; He B, 2004, MOL CELL, V16, P425, DOI 10.1016/j.molcel.2004.09.036; He HSHS, 2010, NAT GENET, V42, P343, DOI 10.1038/ng.545; Hodgson MC, 2005, J BIOL CHEM, V280, P6511, DOI 10.1074/jbc.M408972200; Hodgson MC, 2008, MOL CANCER THER, V7, P3187, DOI 10.1158/1535-7163.MCT-08-0461; Hodgson MC, 2007, CANCER RES, V67, P8388, DOI 10.1158/0008-5472.CAN-07-0617; Hofland J, 2010, CANCER RES, V70, P1256, DOI 10.1158/0008-5472.CAN-09-2092; Holzbeierlein J, 2004, AM J PATHOL, V164, P217, DOI 10.1016/S0002-9440(10)63112-4; Hu Q, 2008, P NATL ACAD SCI USA, V105, P19199, DOI 10.1073/pnas.0810634105; Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Huang ZH, 2012, ONCOTARGET, V3, P651, DOI 10.18632/oncotarget.531; Hur E, 2004, PLOS BIOL, V2, P1303, DOI 10.1371/journal.pbio.0020274; Jouravel N, 2007, ACTA CRYSTALLOGR D, V63, P1198, DOI 10.1107/S0907444907045702; Kang ZG, 2004, MOL ENDOCRINOL, V18, P2633, DOI 10.1210/me.2004-0245; Klokk TI, 2007, MOL CELL BIOL, V27, P1823, DOI 10.1128/MCB.01297-06; Knudsen KE, 1998, J BIOL CHEM, V273, P20213, DOI 10.1074/jbc.273.32.20213; Ko S, 2011, MOL ENDOCRINOL, V25, P433, DOI 10.1210/me.2010-0482; Kraus S, 2006, CANCER RES, V66, P11047, DOI 10.1158/0008-5472.CAN-06-0596; Kumar A, 2011, P NATL ACAD SCI USA, V108, P17087, DOI 10.1073/pnas.1108745108; Li Y, 2012, ONCOGENE, V31, P4759, DOI 10.1038/onc.2011.637; Li YM, 2013, CANCER RES, V73, P483, DOI 10.1158/0008-5472.CAN-12-3630; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lin HK, 2003, J BIOL CHEM, V278, P50902, DOI 10.1074/jbc.M300676200; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Locke JA, 2008, CANCER RES, V68, P6407, DOI 10.1158/0008-5472.CAN-07-5997; Locke JA, 2009, J STEROID BIOCHEM, V115, P126, DOI 10.1016/j.jsbmb.2009.03.011; Lu LF, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-22; Lu S, 1999, MOL ENDOCRINOL, V13, P376, DOI 10.1210/me.13.3.376; Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018; Mahajan NP, 2007, P NATL ACAD SCI USA, V104, P8438, DOI 10.1073/pnas.0700420104; MAHONEY EM, 1972, J UROLOGY, V108, P936, DOI 10.1016/S0022-5347(17)60911-X; Masiello D, 2002, J BIOL CHEM, V277, P26321, DOI 10.1074/jbc.M203310200; Massie CE, 2011, EMBO J, V30, P2719, DOI 10.1038/emboj.2011.158; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; Mendiratta P, 2009, J CLIN ONCOL, V27, P2022, DOI 10.1200/JCO.2008.17.2882; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Metzger E, 2008, NAT CELL BIOL, V10, P53, DOI 10.1038/ncb1668; Metzger E, 2010, NATURE, V464, P792, DOI 10.1038/nature08839; Mizokami A, 2004, CANCER RES, V64, P765, DOI 10.1158/0008-5472.CAN-03-0130; Moehren U, 2007, MOL ENDOCRINOL, V21, P1039, DOI 10.1210/me.2006-0468; Mohler JL, 2004, CLIN CANCER RES, V10, P440, DOI 10.1158/1078-0432.CCR-1146-03; Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008-5472.CAN-08-0249; Mostaghel EA, 2007, CANCER RES, V67, P5033, DOI 10.1158/0008-5472.CAN-06-3332; Mostaghel EA, 2011, CLIN CANCER RES, V17, P5913, DOI 10.1158/1078-0432.CCR-11-0728; Mulholland DJ, 2011, CANCER CELL, V19, P792, DOI 10.1016/j.ccr.2011.05.006; Mulholland DJ, 2003, ONCOGENE, V22, P5602, DOI 10.1038/sj.onc.1206802; Nishiyama T, 2004, CLIN CANCER RES, V10, P7121, DOI 10.1158/1078-0432.CCR-04-0913; Page ST, 2006, J CLIN ENDOCR METAB, V91, P3850, DOI 10.1210/jc.2006-0968; Perillo B, 2008, SCIENCE, V319, P202, DOI 10.1126/science.1147674; Ryan CJ, 2013, NEW ENGL J MED, V368, P138, DOI 10.1056/NEJMoa1209096; Sack JS, 2001, P NATL ACAD SCI USA, V98, P4904, DOI 10.1073/pnas.081565498; Samson DJ, 2002, CANCER, V95, P361, DOI 10.1002/cncr.10647; Schaeffer EM, 2008, ONCOGENE, V27, P7180, DOI 10.1038/onc.2008.327; Schaufele F, 2005, P NATL ACAD SCI USA, V102, P9802, DOI 10.1073/pnas.0408819102; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Shah S, 2003, J BIOL CHEM, V278, P48137, DOI 10.1074/jbc.M307154200; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Sharma A, 2010, J CLIN INVEST, V120, P4478, DOI 10.1172/JCI44239; Shen HC, 2012, MOL ENDOCRINOL, V26, P1836, DOI 10.1210/me.2012-1222; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Small EJ, 2004, J CLIN ONCOL, V22, P1025, DOI 10.1200/JCO.2004.06.037; Song LN, 2004, MOL ENDOCRINOL, V18, P70, DOI 10.1210/me.2003-0189; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; Taneja SS, 2005, J BIOL CHEM, V280, P40916, DOI 10.1074/jbc.M508442200; Taplin ME, 2009, CLIN CANCER RES, V15, P7099, DOI 10.1158/1078-0432.CCR-09-1722; Taplin ME, 1999, CANCER RES, V59, P2511; Taplin ME, 2003, J CLIN ONCOL, V21, P2673, DOI 10.1200/JCO.2003.11.102; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; THALMANN GN, 1994, CANCER RES, V54, P2577; Thomsen MK, 2008, DEV BIOL, V316, P302, DOI 10.1016/j.ydbio.2008.01.030; Thomsen MK, 2010, CANCER RES, V70, P979, DOI 10.1158/0008-5472.CAN-09-2370; Titus MA, 2005, CLIN CANCER RES, V11, P4653, DOI 10.1158/1078-0432.CCR-05-0525; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tomlins SA, 2007, NAT GENET, V39, P41, DOI 10.1038/ng1935; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; Truica CI, 2000, CANCER RES, V60, P4709; van Royen ME, 2007, J CELL BIOL, V177, P63, DOI 10.1083/jcb.200609178; van Royen ME, 2012, J CELL SCI, V125, P1970, DOI 10.1242/jcs.096792; VELDSCHOLTE J, 1990, BIOCHEM BIOPH RES CO, V173, P534, DOI 10.1016/S0006-291X(05)80067-1; Verras M, 2007, CANCER RES, V67, P967, DOI 10.1158/0008-5472.CAN-06-3552; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Wang H, 2008, CANCER RES, V68, P1625, DOI 10.1158/0008-5472.CAN-07-5915; Wang HY, 2007, CANCER RES, V67, P528, DOI 10.1158/0008-5472.CAN-06-1672; Wang HY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041330; Wang JX, 2007, NATURE, V446, P882, DOI 10.1038/nature05671; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Watson PA, 2010, P NATL ACAD SCI USA, V107, P16759, DOI 10.1073/pnas.1012443107; Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Xu KX, 2009, CANCER CELL, V15, P270, DOI 10.1016/j.ccr.2009.02.021; Xu YY, 2006, CANCER RES, V66, P7783, DOI 10.1158/0008-5472.CAN-05-4472; Yamane K, 2006, CELL, V125, P483, DOI 10.1016/j.cell.2006.03.027; YAN GC, 1992, MOL ENDOCRINOL, V6, P2123, DOI 10.1210/me.6.12.2123; Yang FJ, 2002, J BIOL CHEM, V277, P11336, DOI 10.1074/jbc.M111962200; Yap TA, 2008, CURR OPIN PHARMACOL, V8, P449, DOI 10.1016/j.coph.2008.06.004; Yoon HG, 2006, MOL ENDOCRINOL, V20, P1048, DOI 10.1210/me.2005-0324; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Yu X, 2001, MOL CELL BIOL, V21, P4614, DOI 10.1128/MCB.21.14.4614-4625.2001; Yuan X, 2001, J BIOL CHEM, V276, P46647, DOI 10.1074/jbc.M108404200; Yuan X, 2006, AM J PATHOL, V169, P682, DOI 10.2353/ajpath.2006.051047; Zegarra-Moro OL, 2002, CANCER RES, V62, P1008; Zhang XT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027970; Zhao JC, 2012, GENOME RES, V22, P322, DOI 10.1101/gr.131508.111; Zhao XY, 2000, NAT MED, V6, P703, DOI 10.1038/76287; Zhu P, 2006, CELL, V124, P615, DOI 10.1016/j.cell.2005.12.032	164	234	242	1	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2014	33	22					2815	2825		10.1038/onc.2013.235	http://dx.doi.org/10.1038/onc.2013.235			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EI	23752196	Green Accepted			2022-12-28	WOS:000337231800001
J	Chew, TW; Liu, XJ; Liu, L; Spitsbergen, J; Gong, Z; Low, BC				Chew, T. W.; Liu, X. J.; Liu, L.; Spitsbergen, J. M.; Gong, Z.; Low, B. C.			Crosstalk of Ras and Rho: activation of RhoA abates Kras-induced liver tumorigenesis in transgenic zebrafish models	ONCOGENE			English	Article						hepatocellular carcinoma; zebrafish; RhoA; Ras; signaling crosstalk; Akt	CELL-PROLIFERATION; SIGNALING PATHWAYS; IN-VIVO; DEPENDENT PHOSPHORYLATION; HEPATOCELLULAR-CARCINOMA; GENE-EXPRESSION; DOWN-REGULATION; KINASE PATHWAY; TET-ON; AKT	RAS and Rho small GTPases are key molecular switches that control cell dynamics, cell growth and tissue development through their distinct signaling pathways. Although much has been learnt about their individual functions in both cell and animal models, the physiological and pathophysiological consequences of their signaling crosstalk in multi-cellular context in vivo remain largely unknown, especially in liver development and liver tumorigenesis. Furthermore, the roles of RhoA in RAS-mediated transformation and their crosstalk in vitro remain highly controversial. When challenged with carcinogens, zebrafish developed liver cancer that resembles the human liver cancer both molecularly and histopathologically. Capitalizing on the growing importance and relevance of zebrafish ( Danio rerio) as an alternate cancer model, we have generated liver-specific, Tet-on-inducible transgenic lines expressing oncogenic Kras(G12V), RhoA, constitutively active RhoA(G14V) or dominant-negative Rho(AT19N). Double-transgenic lines expressing Kras(G12V) with one of the three RhoA genes were also generated. Based on quantitative bioimaging and molecular markers for genetic and signaling aberrations, we showed that the induced expression of oncogenic Kras during early development led to liver enlargement and hepatocyte proliferation, associated with elevated Erk phosphorylation, activation of Akt2 and modulation of its two downstream targets, p21Cip and S6 kinase. Such an increase in liver size and Akt2 expression was augmented by dominant-negative Rho(AT19N), but was abrogated by the constitutive-active Rho(AG14V). Consequently, induced expression of the oncogenic Kras in adult transgenic fish led to the development of hepatocellular carcinomas. Survival studies further revealed that the co-expression of dominant-negative Rho(AT19N) with oncogenic Kras increased the mortality rate compared with the other single or double-transgenic lines. This study provides evidence of the previously unappreciated signaling crosstalk between Kras and RhoA in regulating liver overgrowth and liver tumorigenesis. Our results also implicate that activating Rho could be beneficial to suppress the Kras-induced liver malignancies.	[Chew, T. W.; Liu, L.; Low, B. C.] Natl Univ Singapore, Dept Biol Sci, Cell Signaling & Dev Biol Lab, Singapore 117548, Singapore; [Chew, T. W.; Low, B. C.] Natl Univ Singapore, Mechanobiol Inst, T Lab Level 10,5A Engn Dr, Singapore 117411, Singapore; [Liu, X. J.; Gong, Z.] Natl Univ Singapore, Dept Biol Sci, Mol Biol Lab, Singapore 117548, Singapore; [Spitsbergen, J. M.] Oregon State Univ, Dept Microbiol & Marine, Corvallis, OR 97331 USA; [Spitsbergen, J. M.] Oregon State Univ, Freshwater Biomed Sci Ctr, Corvallis, OR 97331 USA	National University of Singapore; National University of Singapore; National University of Singapore; Oregon State University; Oregon State University	Low, BC (corresponding author), Natl Univ Singapore, Mechanobiol Inst, T Lab Level 10,5A Engn Dr, Singapore 117411, Singapore.	dbslowbc@nus.edu.sg	Gong, Zhiyuan/H-8794-2012; Low, Boon Chuan/AAU-7685-2021; Low, Boon Chuan/H-8049-2012	Gong, Zhiyuan/0000-0002-9660-5260; Low, Boon Chuan/0000-0003-0756-096X; Low, Boon Chuan/0000-0003-0756-096X	NUS graduate research scholarship; Biomedical Research Council of Singapore; National Medical Research Council; Mechanobiology Institute of Singapore; National Research Foundation; Ministry of Education, Singapore	NUS graduate research scholarship; Biomedical Research Council of Singapore(Agency for Science Technology & Research (A*STAR)); National Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Mechanobiology Institute of Singapore; National Research Foundation; Ministry of Education, Singapore(Ministry of Education, Singapore)	This work was supported by the NUS graduate research scholarship awarded to TWC and in part by grants from the Biomedical Research Council of Singapore (ZG and BCL), National Medical Research Council (ZG and BCL) and the Mechanobiology Institute of Singapore (BCL), which is co-funded through the National Research Foundation and the Ministry of Education, Singapore.	Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Amatruda JF, 2002, CANCER CELL, V1, P229, DOI 10.1016/S1535-6108(02)00052-1; Nguyen AT, 2012, DIS MODEL MECH, V5, P63, DOI 10.1242/dmm.008367; Nguyen AT, 2011, DIS MODEL MECH, V4, P801, DOI 10.1242/dmm.007831; Beis D, 2006, TRENDS CELL BIOL, V16, P105, DOI 10.1016/j.tcb.2005.12.001; Boorman GA, 1997, TOXICOL PATHOL, V25, P202, DOI 10.1177/019262339702500210; Chen JC, 2003, J BIOL CHEM, V278, P2807, DOI 10.1074/jbc.M207943200; Cox Adrienne D, 2010, Small GTPases, V1, P2; del Pulgar TG, 2005, BIOESSAYS, V27, P602, DOI 10.1002/bies.20238; Dreissigacker U, 2006, CELL SIGNAL, V18, P1156, DOI 10.1016/j.cellsig.2005.09.004; Emelyanov A, 2006, GENETICS, V174, P1095, DOI 10.1534/genetics.106.061184; Feitsma H, 2008, MOL CANCER RES, V6, P685, DOI 10.1158/1541-7786.MCR-07-2167; Fernandez-Medarde Alberto, 2011, Genes Cancer, V2, P344, DOI 10.1177/1947601911411084; Fleming YM, 2009, ONCOGENE, V28, P983, DOI 10.1038/onc.2008.449; Forti FL, 2007, ENDOCR-RELAT CANCER, V14, P1117, DOI 10.1677/ERC-07-0154; Frau M, 2010, MOL ASPECTS MED, V31, P179, DOI 10.1016/j.mam.2010.02.007; Fukui K, 2006, J CANCER RES CLIN, V132, P627, DOI 10.1007/s00432-006-0107-7; Gedaly R, 2012, J SURG RES, V176, P542, DOI 10.1016/j.jss.2011.10.045; Ghosh PM, 2002, CANCER RES, V62, P2630; Gomaa AI, 2008, WORLD J GASTROENTERO, V14, P4300, DOI 10.3748/wjg.14.4300; Gupta S, 2000, MOL CELL BIOL, V20, P9294, DOI 10.1128/MCB.20.24.9294-9306.2000; Hancock JF, 2003, NAT REV MOL CELL BIO, V4, P373, DOI 10.1038/nrm1105; Harada N, 2004, CANCER RES, V64, P48, DOI 10.1158/0008-5472.CAN-03-2123; Her GM, 2003, FEBS LETT, V538, P125, DOI 10.1016/S0014-5793(03)00157-1; Izawa I, 1998, ONCOGENE, V17, P2863, DOI 10.1038/sj.onc.1202213; Jackson LN, 2008, AM J PHYSIOL-GASTR L, V294, pG1401, DOI 10.1152/ajpgi.00062.2008; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Karaguni IM, 2002, CANCER RES, V62, P1718; Karreth FA, 2009, CURR OPIN GENET DEV, V19, P4, DOI 10.1016/j.gde.2008.12.006; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; KhosraviFar R, 1996, MOL CELL BIOL, V16, P3923; Kim JH, 2009, P NATL ACAD SCI USA, V106, P11149, DOI 10.1073/pnas.0812651106; Korzh S, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-84; Kumar MS, 2012, CELL, V149, P642, DOI 10.1016/j.cell.2012.02.059; Lam SH, 2006, NAT BIOTECHNOL, V24, P73, DOI 10.1038/nbt1169; Lam SH, 2006, CELL CYCLE, V5, P573, DOI 10.4161/cc.5.6.2550; Li XR, 2006, EJSO-EUR J SURG ONC, V32, P1130, DOI 10.1016/j.ejso.2006.05.012; Li Y, 2002, J BIOL CHEM, V277, P11352, DOI 10.1074/jbc.M109062200; Li Z, 2012, J HEPATOL, V56, P419, DOI 10.1016/j.jhep.2011.07.025; Liu LH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002850; Man JH, 2010, J CLIN INVEST, V120, P2829, DOI 10.1172/JCI42542; Mebratu Y, 2009, CELL CYCLE, V8, P1168, DOI 10.4161/cc.8.8.8147; Ming XF, 2002, MOL CELL BIOL, V22, P8467, DOI 10.1128/MCB.22.24.8467-8477.2002; Morin P, 2009, EUR J CELL BIOL, V88, P495, DOI 10.1016/j.ejcb.2009.04.005; Mullany LK, 2007, J BIOL CHEM, V282, P21244, DOI 10.1074/jbc.M702110200; Mure H, 2010, NEURO-ONCOLOGY, V12, P221, DOI 10.1093/neuonc/nop026; O'Shaughnessy RFL, 2007, CANCER RES, V67, P8207, DOI 10.1158/0008-5472.CAN-07-0755; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Pal I, 2012, ACTA PHARMACOL SIN, V33, P1441, DOI 10.1038/aps.2012.72; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Pawlak G, 2002, MOL BIOL CELL, V13, P336, DOI 10.1091/mbc.01-02-0302; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Ravichandran A, 2012, MOL BIOL CELL, V23; Reboredo M, 2008, HUM GENE THER, V19, P1233, DOI 10.1089/hum.2008.057; Rossig L, 2001, MOL CELL BIOL, V21, P5644, DOI 10.1128/MCB.21.16.5644-5657.2001; Roy HK, 2002, CARCINOGENESIS, V23, P201, DOI 10.1093/carcin/23.1.201; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Shah V, 2001, ONCOGENE, V20, P2112, DOI 10.1038/sj.onc.1204291; Skinner J, 2004, ONCOGENE, V23, P5994, DOI 10.1038/sj.onc.1207798; Spitsbergen JM, 2012, ILAR J, V53, P114, DOI 10.1093/ilar.53.2.114; Vial E, 2003, CANCER CELL, V4, P67, DOI 10.1016/S1535-6108(03)00162-4; Vidal A, 2002, J BIOL CHEM, V277, P16433, DOI 10.1074/jbc.M112090200; Wang DS, 2007, J GASTROEN HEPATOL, V22, P1916, DOI 10.1111/j.1440-1746.2006.04534.x; Westerfield M., 2000, ZEBRAFISH BOOK GUIDE; Whittaker S, 2010, ONCOGENE, V29, P4989, DOI 10.1038/onc.2010.236; Xia MX, 2007, NAT STRUCT MOL BIOL, V14, P215, DOI 10.1038/nsmb1208; Xu XD, 2004, ONCOL REP, V11, P25; Yang S, 2011, BIOMATERIALS, V32, P2851, DOI 10.1016/j.biomaterials.2011.01.015; Zhang YD, 2007, MOL CANCER RES, V5, P909, DOI 10.1158/1541-7786.MCR-06-0388; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou Q, 2011, FUTURE ONCOL, V7, P1149, DOI [10.2217/FON.11.95, 10.2217/fon.11.95]; Zhu S, 2008, ONCOGENE, V27, P1580, DOI 10.1038/sj.onc.1210790; Zhu SZ, 2012, METHODS MOL BIOL, V827, P321, DOI 10.1007/978-1-61779-442-1_21; Zhu SZ, 2006, CELL SIGNAL, V18, P359, DOI 10.1016/j.cellsig.2005.05.019; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	76	65	67	2	33	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2014	33	21					2717	2727		10.1038/onc.2013.240	http://dx.doi.org/10.1038/onc.2013.240			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EH	23812423				2022-12-28	WOS:000337231700005
J	Garcia-Murillas, I; Sharpe, R; Pearson, A; Campbell, J; Natrajan, R; Ashworth, A; Turner, NC				Garcia-Murillas, I.; Sharpe, R.; Pearson, A.; Campbell, J.; Natrajan, R.; Ashworth, A.; Turner, N. C.			An siRNA screen identifies the GNAS locus as a driver in 20q amplified breast cancer	ONCOGENE			English	Article						breast cancer; amplification; GNAS; siRNA	OVARIAN-CANCER; ALPHA-S; CELL-LINES; AMPLIFICATION; TUMORS; GROWTH; PHOSPHORYLATION; SENSITIVITY; ABERRATIONS; ACTIVATION	Poor-prognosis oestrogen receptor-positive breast cancer is characterised by the presence of high-level focal amplifications. We utilised a focused small interfering RNA screen in 14 breast cancer cell lines to define genes that were pathogenic in three genomic regions focally amplified in oestrogen receptor-positive breast cancer, 8p11-12, 11q13 and 20q. Silencing the GNAS locus, that encodes the G protein alpha stimulatory subunit Gas, specifically reduced the growth of 20q amplified breast cancer cell lines. Examination of a publically available small hairpin RNA data set confirmed GNAS silencing to be selective for 20q amplified cancer cell lines. Cell lines with 20q amplification were found to overexpress specifically the extra long Gas splice variant (XL alpha s). Overexpression of XL alpha s induced cAMP levels to a greater extent than Gas, suggesting that amplification of the GNAS locus, and overexpression of the XL alpha s variant in particular, enhanced cAMP signalling. GNAS silencing in amplified cell lines reduced extracellular-signal-regulated kinase 1/2 (ERK1/2) phosphorylation, and conversely overexpression of exogenous XL alpha s in a nonamplified cell line increased MEK-ERK1/2 phosphorylation, identifying one potential downstream consequence of enhanced cAMP signalling. Our data indicate that amplification of the GNAS locus may contribute to the pathogenesis of breast cancer, and highlight a previously unrecognised role for the GNAS XL alpha s variant in cancer.	[Garcia-Murillas, I.; Sharpe, R.; Pearson, A.; Campbell, J.; Natrajan, R.; Ashworth, A.; Turner, N. C.] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; [Turner, N. C.] Royal Marsden Hosp, Breast Unit, London SW3 6JJ, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust	Turner, NC (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, 237 Fulham Rd, London SW3 6JB, England.	nicholas.turner@icr.ac.uk		Natrajan, Rachael/0000-0002-9987-2946; Turner, Nicholas/0000-0001-8937-0873; garcia-murillas, isaac/0000-0001-8183-7969	Cancer Research UK; Breakthrough Breast Cancer; NIHR Biomedical Research Centre	Cancer Research UK(Cancer Research UK); Breakthrough Breast Cancer; NIHR Biomedical Research Centre(National Institute for Health Research (NIHR))	We thank Murat Bastepe for supplying cDNA contructs for G alpha s and XL alpha s. This work was supported by grants from Cancer Research UK and Breakthrough Breast Cancer. Dr Nicholas Turner is a CRUK Clinician Scientist. We acknowledge NHS funding to the NIHR Biomedical Research Centre.	Aydin C, 2009, ENDOCRINOLOGY, V150, P3567, DOI 10.1210/en.2009-0318; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Beroukhim R, 2007, P NATL ACAD SCI USA, V104, P20007, DOI 10.1073/pnas.0710052104; Bos JL, 2007, CELL, V129, P865, DOI 10.1016/j.cell.2007.05.018; Brough R, 2011, CANCER DISCOV, V1, P260, DOI 10.1158/2159-8290.CD-11-0107; Cheung HW, 2011, P NATL ACAD SCI USA, V108, P12372, DOI 10.1073/pnas.1109363108; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Collins C, 1998, P NATL ACAD SCI USA, V95, P8703, DOI 10.1073/pnas.95.15.8703; Consonni SV, 2012, P NATL ACAD SCI USA, V109, P3814, DOI 10.1073/pnas.1117599109; Courjal F, 1997, CANCER RES, V57, P4360; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Freda PU, 2007, PITUITARY, V10, P275, DOI 10.1007/s11102-007-0058-2; Gelsi-Boyer W, 2005, MOL CANCER RES, V3, P655, DOI 10.1158/1541-7786.MCR-05-0128; Goldsmith ZG, 2007, ONCOGENE, V26, P3122, DOI 10.1038/sj.onc.1210407; Hodgson JG, 2003, BREAST CANCER RES TR, V78, P337, DOI 10.1023/A:1023085825042; Holland DG, 2011, EMBO MOL MED, V3, P167, DOI 10.1002/emmm.201100122; Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208; Liu Z, 2011, J BIOL CHEM, V286, P38558, DOI 10.1074/jbc.M111.240150; Luttrell DK, 2004, ONCOGENE, V23, P7969, DOI 10.1038/sj.onc.1208162; Mackay A, 2009, BREAST CANCER RES TR, V118, P481, DOI 10.1007/s10549-008-0296-7; Mariot V, 2011, BONE, V48, P312, DOI 10.1016/j.bone.2010.09.032; Natrajan R, 2010, BREAST CANCER RES TR, V121, P575, DOI 10.1007/s10549-009-0501-3; Natrajan R, 2009, CLIN CANCER RES, V15, P2711, DOI 10.1158/1078-0432.CCR-08-1878; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nonet GH, 2001, CANCER RES, V61, P1250; Ormandy CJ, 2003, BREAST CANCER RES TR, V78, P323, DOI 10.1023/A:1023033708204; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Press MF, 2011, J CLIN ONCOL, V29, P859, DOI 10.1200/JCO.2009.27.5644; Schmitt JM, 2002, MOL CELL, V9, P85, DOI 10.1016/S1097-2765(01)00432-4; Sircoulomb F, 2011, EMBO MOL MED, V3, P153, DOI 10.1002/emmm.201100121; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Smith FD, 2010, NAT CELL BIOL, V12, P1242, DOI 10.1038/ncb2130; Stephens PJ, 2009, NATURE, V462, P1005, DOI 10.1038/nature08645; Turner N, 2010, CANCER RES, V70, P2085, DOI 10.1158/0008-5472.CAN-09-3746; Turner NC, 2008, EMBO J, V27, P1368, DOI 10.1038/emboj.2008.61; Wadhawan S, 2008, MOL BIOL EVOL, V25, P2745, DOI 10.1093/molbev/msn229; Weiss J, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001451; Wu J, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002543; Zhang L, 2005, CANCER RES, V65, P925	42	23	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2014	33	19					2478	2486		10.1038/onc.2013.202	http://dx.doi.org/10.1038/onc.2013.202			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH3OK	23752180	Green Accepted			2022-12-28	WOS:000336033600007
J	Masciarelli, S; Fontemaggi, G; Di Agostino, S; Donzelli, S; Carcarino, E; Strano, S; Blandino, G				Masciarelli, S.; Fontemaggi, G.; Di Agostino, S.; Donzelli, S.; Carcarino, E.; Strano, S.; Blandino, G.			Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells	ONCOGENE			English	Article						mutant p53; gain of function; chemoresistance; miR-223; stathmin-1	BREAST-CANCER PATIENTS; STATHMIN INTERACTION; EXPRESSION; PROTEIN; MICRORNA-223; RESISTANCE; CARCINOMA; KINASE; TARGET; SENSITIVITY	Mutant p53 proteins are expressed at high frequency in human tumors and are associated with poor clinical prognosis and resistance to chemotherapeutic treatments. Here we show that mutant p53 proteins downregulate micro-RNA (miR)-223 expression in breast and colon cancer cell lines. Mutant p53 binds the miR-223 promoter and reduces its transcriptional activity. This requires the transcriptional repressor ZEB-1. We found that miR-223 exogenous expression sensitizes breast and colon cancer cell lines expressing mutant p53 to treatment with DNA-damaging drugs. Among the putative miR-223 targets, we focused on stathmin-1 (STMN-1), an oncoprotein known to confer resistance to chemotherapeutic drugs associated with poor clinical prognosis. Mutant p53 silencing or miR-223 exogenous expression lowers the levels of STMN-1 and knockdown of STMN-1 by small interfering RNA increases cell death of mutant p53-expressing cell lines. On the basis of these findings, we propose that one of the pathways affected by mutant p53 to increase cellular resistance to chemotherapeutic agents involves miR-223 downregulation and the consequent upregulation of STMN-1.	[Masciarelli, S.; Fontemaggi, G.; Di Agostino, S.; Donzelli, S.; Carcarino, E.; Blandino, G.] Regina Elena Inst Canc Res, Translat Oncogen Unit, I-00144 Rome, Italy; [Strano, S.] Regina Elena Inst Canc Res, Chemoprevent Unit, I-00144 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Blandino, G (corresponding author), Regina Elena Inst Canc Res, Translat Oncogen Unit, Via Elio Chianesi 53, I-00144 Rome, Italy.	blandino@ifo.it	donzelli, sara/J-8182-2016; Donzelli, Sara/AAA-2557-2021; Di Agostino, Silvia/H-1121-2018; Strano, Sabrina/K-9654-2016; Di Agostino, Silvia/S-8566-2019; Fontemaggi, Giulia/K-9702-2016	donzelli, sara/0000-0002-8529-2895; Donzelli, Sara/0000-0002-8529-2895; Di Agostino, Silvia/0000-0003-3730-1125; Fontemaggi, Giulia/0000-0001-8332-8842; MASCIARELLI, SILVIA/0000-0002-6738-6281; strano, sabrina/0000-0002-6341-4230	AIRC [10454]	AIRC(Fondazione AIRC per la ricerca sul cancro)	We are grateful for the support given by AIRC (Grant Number: 10454) to GB. We thank Francesca Fausti for providing the SW480-sh53 cell line and Dr Taro Fukao for kindly providing the ppri-hmiR-223<SUP>-669</SUP>-Luc luciferase reporter.	Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Ahn J, 1999, ONCOGENE, V18, P5954, DOI 10.1038/sj.onc.1202986; Alli E, 2002, CANCER RES, V62, P6864; Alli E, 2007, ONCOGENE, V26, P1003, DOI 10.1038/sj.onc.1209864; Arumugam T, 2009, CANCER RES, V69, P5820, DOI 10.1158/0008-5472.CAN-08-2819; Baldassarre G, 2005, CANCER CELL, V7, P51, DOI 10.1016/j.ccr.2004.11.025; Bane AL, 2009, BREAST CANCER RES TR, V117, P183, DOI 10.1007/s10549-008-0087-1; Belletti B, 2011, EXPERT OPIN THER TAR, V15, P1249, DOI 10.1517/14728222.2011.620951; BERGH J, 1995, NAT MED, V1, P1029, DOI 10.1038/nm1095-1029; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Cheng AL, 2008, CLIN CANCER RES, V14, P435, DOI 10.1158/1078-0432.CCR-07-1215; Chicas A, 2000, BIOCHEM BIOPH RES CO, V279, P383, DOI 10.1006/bbrc.2000.3965; Di Agostino S, 2006, CANCER CELL, V10, P191, DOI 10.1016/j.ccr.2006.08.013; Donzelli S, 2012, CELL DEATH DIFFER, V19, P1038, DOI 10.1038/cdd.2011.190; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; Fontemaggi G, 2001, MOL CELL BIOL, V21, P8461, DOI 10.1128/MCB.21.24.8461-8470.2001; Fontemaggi G, 2009, NAT STRUCT MOL BIOL, V16, P1086, DOI 10.1038/nsmb.1669; Fukao T, 2007, CELL, V129, P617, DOI 10.1016/j.cell.2007.02.048; Gohler T, 2005, NUCLEIC ACIDS RES, V33, P1087, DOI 10.1093/nar/gki252; Golouh R, 2008, BREAST CANCER RES TR, V110, P317, DOI 10.1007/s10549-007-9724-3; Gottardo F, 2007, UROL ONCOL-SEMIN ORI, V25, P387, DOI 10.1016/j.urolonc.2007.01.019; Haddad Y, 2009, CLIN CANCER RES, V15, P532, DOI 10.1158/1078-0432.CCR-08-1733; Hainaut P, 2000, ADV CANCER RES, V77, P81; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Israel A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006045; Jia CY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027008; Jiang H, 2008, P NATL ACAD SCI USA, V105, P11299, DOI 10.1073/pnas.0801457105; Johnsen JI, 2000, INT J CANCER, V88, P685, DOI 10.1002/1097-0215(20001201)88:5<685::AID-IJC1>3.0.CO;2-Z; Kang W, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033919; Laios A, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-35; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; Lu C, 2009, APOPTOSIS, V14, P597, DOI 10.1007/s10495-009-0330-1; Manceau V, 1999, ELECTROPHORESIS, V20, P409, DOI 10.1002/(SICI)1522-2683(19990201)20:2<409::AID-ELPS409>3.3.CO;2-E; Matas D, 2001, EMBO J, V20, P4163, DOI 10.1093/emboj/20.15.4163; MAUCUER A, 1995, P NATL ACAD SCI USA, V92, P3100, DOI 10.1073/pnas.92.8.3100; MELHEM RF, 1991, BIOCHEM BIOPH RES CO, V179, P1649, DOI 10.1016/0006-291X(91)91764-4; Mistry SJ, 1998, BIOCHEM J, V334, P23, DOI 10.1042/bj3340023; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Ng DCH, 2006, J CELL BIOL, V172, P245, DOI 10.1083/jcb.200503021; Oren M, 2003, CELL DEATH DIFFER, V10, P431, DOI 10.1038/sj.cdd.4401183; Phadke AP, 2011, DNA CELL BIOL, V30, P715, DOI 10.1089/dna.2011.1240; Pulikkan JA, 2010, BLOOD, V115, P1768, DOI 10.1182/blood-2009-08-240101; Rana S, 2008, EXPERT REV ANTICANC, V8, P1461, DOI 10.1586/14737140.8.9.1461; Rubin CI, 2004, J CELL BIOCHEM, V93, P242, DOI 10.1002/jcb.20187; Salvesen HB, 2009, P NATL ACAD SCI USA, V106, P4834, DOI 10.1073/pnas.0806514106; Sampath J, 2001, J BIOL CHEM, V276, P39359, DOI 10.1074/jbc.M103429200; Shah AN, 2007, ANN SURG ONCOL, V14, P3629, DOI 10.1245/s10434-007-9583-5; Singer S, 2007, HEPATOLOGY, V46, P759, DOI 10.1002/hep.21736; Strano S, 2002, J BIOL CHEM, V277, P18817, DOI 10.1074/jbc.M201405200; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang L, 2012, ONCOGENE, V31, P2499, DOI 10.1038/onc.2011.444; Witta SE, 2006, CANCER RES, V66, P944, DOI 10.1158/0008-5472.CAN-05-1988; Wong QWL, 2008, GASTROENTEROLOGY, V135, P257, DOI 10.1053/j.gastro.2008.04.003; Zheng P, 2010, J PROTEOME RES, V9, P4897, DOI 10.1021/pr100712t	58	86	88	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2014	33	12					1601	1608		10.1038/onc.2013.106	http://dx.doi.org/10.1038/onc.2013.106			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD4TS	23584479				2022-12-28	WOS:000333244200013
J	Sarris, M; Nikolaou, K; Talianidis, I				Sarris, M.; Nikolaou, K.; Talianidis, I.			Context-specific regulation of cancer epigenomes by histone and transcription factor methylation	ONCOGENE			English	Review						cancer epigenetics; lysine methylation; histones; transcription factors	TUMOR-SUPPRESSOR GENE; NF-KAPPA-B; DEMETHYLASE JMJD3 CONTRIBUTES; PARTIAL TANDEM DUPLICATION; CHRONIC MYELOID-LEUKEMIA; POLYCOMB-GROUP PROTEINS; LYSINE METHYLATION; BREAST-CANCER; CELL-PROLIFERATION; ANDROGEN-RECEPTOR	Altered expression or activity of histone lysine methylases and demethylases in cancer lead to aberrant chromatin modification patterns, which contribute to uncontrolled cell proliferation via cancer-specific deregulation of gene expression programs or the induction of genome instability. Several transcription factors that regulate growth-associated genes undergo lysine methylation, expanding the repertoire of regulatory targets modulated by histone-methylating enzymes during tumorigenesis. In certain specific tumor types or specific physiological conditions, these enzymes may trigger chromatin structure and/or transcription factor activity changes that result in opposite effects on cancer initiation or progression. The mechanisms of such context-specific dual functions and those involved in the crosstalk between factor and histone modifications are subject to extensive research, which is beginning to shed light into this novel level of complexity of cancer-related epigenetic pathways.	[Sarris, M.; Nikolaou, K.; Talianidis, I.] Biomed Sci Res Ctr Alexander Fleming, Vari 16672, Athens, Greece	Alexander Fleming Biomedical Sciences Research Center	Talianidis, I (corresponding author), Biomed Sci Res Ctr Alexander Fleming, 34 Alexander Fleming St, Vari 16672, Athens, Greece.	talianidis@fleming.gr	Talianidis, Iannis/F-7556-2016; Nikolaou, Kostas/AAB-3428-2020	Talianidis, Iannis/0000-0002-1209-3609; Nikolaou, Kostas/0000-0003-2390-9156; Nikolaou, Konstantin/0000-0003-2668-7325	European Research Council Advanced Investigator Grant [ERC-2011-AdG294464]; Greek Operational Program 'Education and Lifelong Learning' of the National Strategic Reference Framework (NSRF)-Research Funding Program: Thales [Thales 656]	European Research Council Advanced Investigator Grant(European Research Council (ERC)); Greek Operational Program 'Education and Lifelong Learning' of the National Strategic Reference Framework (NSRF)-Research Funding Program: Thales	Work in the author's lab is supported by European Research Council Advanced Investigator Grant (ERC-2011-AdG294464) and the Greek Operational Program 'Education and Lifelong Learning' of the National Strategic Reference Framework (NSRF)-Research Funding Program: Thales (Thales 656).	Abu-Farha M, 2008, MOL CELL PROTEOMICS, V7, P560, DOI 10.1074/mcp.M700271-MCP200; Agger K, 2009, GENE DEV, V23, P1171, DOI 10.1101/gad.510809; Albert M, 2010, SEMIN CELL DEV BIOL, V21, P209, DOI 10.1016/j.semcdb.2009.10.007; Anderton JA, 2011, ONCOGENE, V30, P2037, DOI 10.1038/onc.2010.579; Angrand PO, 2001, GENOMICS, V74, P79, DOI 10.1006/geno.2001.6524; Asangani IA, 2013, MOL CELL, V49, P80, DOI 10.1016/j.molcel.2012.10.008; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Bachmann IM, 2006, J CLIN ONCOL, V24, P268, DOI 10.1200/JCO.2005.01.5180; Barradas M, 2009, GENE DEV, V23, P1177, DOI 10.1101/gad.511109; Beck DB, 2012, GENE DEV, V26, P2580, DOI 10.1101/gad.195636.112; Beke L, 2007, ONCOGENE, V26, P4590, DOI 10.1038/sj.onc.1210248; Berdasco M, 2009, P NATL ACAD SCI USA, V106, P21830, DOI 10.1073/pnas.0906831106; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Bhaumik SR, 2007, NAT STRUCT MOL BIOL, V14, P1008, DOI 10.1038/nsmb1337; Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Brown MA, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-26; Calnan DR, 2012, AGING-US, V4, P462, DOI 10.18632/aging.100471; Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333; Carr SM, 2011, EMBO J, V30, P317, DOI 10.1038/emboj.2010.311; Ceol CJ, 2011, NATURE, V471, P513, DOI 10.1038/nature09806; Cerveira N, 2003, LEUKEMIA, V17, P2244, DOI 10.1038/sj.leu.2403104; Chadwick RB, 2000, P NATL ACAD SCI USA, V97, P2662, DOI 10.1073/pnas.040579497; Chesi M, 1997, NAT GENET, V16, P260, DOI 10.1038/ng0797-260; Cho HS, 2012, INT J CANCER, V131, pE179, DOI 10.1002/ijc.26501; Chuikov S, 2004, NATURE, V432, P353, DOI 10.1038/nature03117; Cloos PAC, 2006, NATURE, V442, P307, DOI 10.1038/nature04837; Cock-Rada AM, 2012, CANCER RES, V72, P810, DOI 10.1158/0008-5472.CAN-11-1052; Collett K, 2006, CLIN CANCER RES, V12, P1168, DOI 10.1158/1078-0432.CCR-05-1533; Courts C, 2008, J NEUROPATH EXP NEUR, V67, P720, DOI 10.1097/NEN.0b013e31817dd02d; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; Deng QD, 2004, ONCOGENE, V23, P4903, DOI 10.1038/sj.onc.1207615; Dietrich N, 2007, EMBO J, V26, P1637, DOI 10.1038/sj.emboj.7601632; Dorrance AM, 2008, BLOOD, V112, P2508, DOI 10.1182/blood-2008-01-134338; Dorrance AM, 2006, J CLIN INVEST, V116, P2707, DOI 10.1172/JCI25546; Douglas J, 2003, AM J HUM GENET, V72, P132, DOI 10.1086/345647; Du Y, 2001, CANCER RES, V61, P8094; Duns G, 2010, CANCER RES, V70, P4287, DOI 10.1158/0008-5472.CAN-10-0120; Ea CK, 2009, P NATL ACAD SCI USA, V106, P18972, DOI 10.1073/pnas.0910439106; Ehrbrecht A, 2006, J PATHOL, V208, P554, DOI 10.1002/path.1925; Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Esteve PO, 2011, NAT STRUCT MOL BIOL, V18, P42, DOI 10.1038/nsmb.1939; Esteve PO, 2009, P NATL ACAD SCI USA, V106, P5076, DOI 10.1073/pnas.0810362106; Frescas D, 2008, CELL CYCLE, V7, P3539, DOI 10.4161/cc.7.22.7062; Frescas D, 2007, NATURE, V450, P309, DOI 10.1038/nature06255; Fujii S, 2008, CANCER SCI, V99, P738, DOI 10.1111/j.1349-7006.2008.00743.x; Gaughan L, 2011, NUCLEIC ACIDS RES, V39, P1266, DOI 10.1093/nar/gkq861; Gonzalez ME, 2011, CANCER RES, V71, P2360, DOI 10.1158/0008-5472.CAN-10-1933; Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151; Hamamoto R, 2006, CANCER SCI, V97, P113, DOI 10.1111/j.1349-7006.2006.00146.x; Hayami S, 2011, INT J CANCER, V128, P574, DOI 10.1002/ijc.25349; He J, 2008, NAT STRUCT MOL BIOL, V15, P1169, DOI 10.1038/nsmb.1499; He LS, 1998, CANCER RES, V58, P4238; Hu LP, 2009, CANCER RES, V69, P4067, DOI 10.1158/0008-5472.CAN-08-4097; Huang J, 2007, NATURE, V449, P105, DOI 10.1038/nature06092; Huang J, 2006, NATURE, V444, P629, DOI 10.1038/nature05287; Huang J, 2010, J BIOL CHEM, V285, P9636, DOI 10.1074/jbc.M109.062588; Hudlebusch HR, 2011, CLIN CANCER RES, V17, P2919, DOI 10.1158/1078-0432.CCR-10-1302; Italiano A, 2006, CANCER GENET CYTOGEN, V167, P122, DOI 10.1016/j.cancergencyto.2006.01.004; Ivanov GS, 2007, MOL CELL BIOL, V27, P6756, DOI 10.1128/MCB.00460-07; Jaju RJ, 2001, BLOOD, V98, P1264, DOI 10.1182/blood.V98.4.1264; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jiang GL, 1999, INT J CANCER, V83, P541, DOI 10.1002/(SICI)1097-0215(19991112)83:4<541::AID-IJC17>3.0.CO;2-F; Kachirskaia I, 2008, J BIOL CHEM, V283, P34660, DOI 10.1074/jbc.M806020200; Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570; Kassambara A, 2009, BIOCHEM BIOPH RES CO, V379, P840, DOI 10.1016/j.bbrc.2008.12.093; Kauffman EC, 2011, MOL CARCINOGEN, V50, P931, DOI 10.1002/mc.20758; Kim H, 2009, J BIOL CHEM, V284, P19867, DOI 10.1074/jbc.M109.021485; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Ko S, 2011, MOL ENDOCRINOL, V25, P433, DOI 10.1210/me.2010-0482; Kolomietz E, 2003, LEUKEMIA, V17, P1313, DOI 10.1038/sj.leu.2402969; Komatsu S, 2009, CARCINOGENESIS, V30, P1139, DOI 10.1093/carcin/bgp116; Kondo Y, 2007, HEPATOL RES, V37, P974, DOI 10.1111/j.1872-034X.2007.00141.x; Kontaki H, 2010, CELL CYCLE, V9, P3836, DOI 10.4161/cc.9.19.13384; Kontaki H, 2010, MOL CELL, V39, P152, DOI 10.1016/j.molcel.2010.06.006; Kouskouti A, 2004, MOL CELL, V14, P175, DOI 10.1016/S1097-2765(04)00182-0; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Krajewski WA, 2010, MOL CELL BIOL, V30, P552, DOI 10.1128/MCB.00775-09; Krivtsov AV, 2008, CANCER CELL, V14, P355, DOI 10.1016/j.ccr.2008.10.001; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; Kurotaki N, 2002, NAT GENET, V30, P365, DOI 10.1038/ng863; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lee J, 2008, CANCER CELL, V13, P69, DOI 10.1016/j.ccr.2007.12.005; Lee JM, 2012, MOL CELL, V48, P572, DOI 10.1016/j.molcel.2012.09.004; Lee ST, 2011, MOL CELL, V43, P798, DOI 10.1016/j.molcel.2011.08.011; Levy D, 2011, NAT IMMUNOL, V12, P29, DOI 10.1038/ni.1968; Li Q, 2011, CANCER RES, V71, P6899, DOI 10.1158/0008-5472.CAN-11-1523; Li WJ, 2011, BIOCHEM BIOPH RES CO, V416, P372, DOI 10.1016/j.bbrc.2011.11.045; Lim S, 2010, CARCINOGENESIS, V31, P512, DOI 10.1093/carcin/bgp324; Lin YH, 2009, BLOOD, V114, P651, DOI 10.1182/blood-2009-03-209395; Lin YW, 2010, EMBO J, V29, P1803, DOI 10.1038/emboj.2010.63; Ling BMT, 2012, P NATL ACAD SCI USA, V109, P841, DOI 10.1073/pnas.1111628109; Liu C, 2007, CANCER RES, V67, P2626, DOI 10.1158/0008-5472.CAN-06-4126; Liu XY, 2011, P NATL ACAD SCI USA, V108, P1925, DOI 10.1073/pnas.1019619108; Lu PJ, 1999, J BIOL CHEM, V274, P15633, DOI 10.1074/jbc.274.22.15633; Lu T, 2010, P NATL ACAD SCI USA, V107, P46, DOI 10.1073/pnas.0912493107; Magerl C, 2010, HUM PATHOL, V41, P181, DOI 10.1016/j.humpath.2009.08.007; Malgeri U, 2000, CANCER RES, V60, P4058; Martinez-Garcia E, 2011, BLOOD, V117, P211, DOI 10.1182/blood-2010-07-298349; McCabe MT, 2012, P NATL ACAD SCI USA, V109, P2989, DOI 10.1073/pnas.1116418109; McLaughlin-Drubin ME, 2011, P NATL ACAD SCI USA, V108, P2130, DOI 10.1073/pnas.1009933108; Metzger E, 2005, NATURE, V437, P436, DOI 10.1038/nature04020; Morin RD, 2011, NATURE, V476, P298, DOI 10.1038/nature10351; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Mueller D, 2007, BLOOD, V110, P4445, DOI 10.1182/blood-2007-05-090514; Munro S, 2010, ONCOGENE, V29, P2357, DOI 10.1038/onc.2009.511; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Nie K, 2008, AM J PATHOL, V173, P242, DOI 10.2353/ajpath.2008.080009; Nishikawa N, 2007, CANCER RES, V67, P9649, DOI 10.1158/0008-5472.CAN-06-4111; Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8; Niu X, 2012, ONCOGENE, V31, P776, DOI 10.1038/onc.2011.266; Northcott PA, 2009, NAT GENET, V41, P465, DOI 10.1038/ng.336; O'Carroll D, 2001, MOL CELL BIOL, V21, P4330, DOI 10.1128/MCB.21.13.4330-4336.2001; Oda H, 2010, MOL CELL, V40, P364, DOI 10.1016/j.molcel.2010.10.011; Oda H, 2009, MOL CELL BIOL, V29, P2278, DOI 10.1128/MCB.01768-08; Okada Y, 2005, CELL, V121, P167, DOI 10.1016/j.cell.2005.02.020; Okada Y, 2006, NAT CELL BIOL, V8, P1017, DOI 10.1038/ncb1464; Oshimo Y, 2004, INT J CANCER, V110, P212, DOI 10.1002/ijc.20090; Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056; Pasqualucci L, 2006, J EXP MED, V203, P311, DOI 10.1084/jem.20052204; Pedersen MT, 2010, TRENDS CELL BIOL, V20, P662, DOI 10.1016/j.tcb.2010.08.011; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Pfau R, 2008, P NATL ACAD SCI USA, V105, P1907, DOI 10.1073/pnas.0711865105; Piao GH, 2008, HISTOL HISTOPATHOL, V23, P1171, DOI 10.14670/HH-23.1171; Pless O, 2008, J BIOL CHEM, V283, P26357, DOI 10.1074/jbc.M802132200; Pollock JA, 2012, ACS CHEM BIOL, V7, P1221, DOI 10.1021/cb300108c; Reid AG, 2004, LEUKEMIA, V18, P178, DOI 10.1038/sj.leu.2403162; Rice JC, 2002, GENE DEV, V16, P2225, DOI 10.1101/gad.1014902; Rosati R, 2002, BLOOD, V99, P3857, DOI 10.1182/blood.V99.10.3857; Rui LX, 2010, CANCER CELL, V18, P590, DOI 10.1016/j.ccr.2010.11.013; Saddic LA, 2010, J BIOL CHEM, V285, P37733, DOI 10.1074/jbc.M110.137612; Sampath SC, 2007, MOL CELL, V27, P596, DOI 10.1016/j.molcel.2007.06.026; Sander S, 2008, BLOOD, V112, P4202, DOI 10.1182/blood-2008-03-147645; Saramaki OR, 2006, GENE CHROMOSOME CANC, V45, P639, DOI 10.1002/gcc.20327; Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735; Shi XB, 2007, MOL CELL, V27, P636, DOI 10.1016/j.molcel.2007.07.012; Shi YJ, 2004, CELL, V119, P941, DOI 10.1016/j.cell.2004.12.012; Skawran B, 2008, MODERN PATHOL, V21, P505, DOI 10.1038/modpathol.3800998; Steele-Perkins G, 2001, GENE DEV, V15, P2250, DOI 10.1101/gad.870101; Subramanian K, 2008, MOL CELL, V30, P336, DOI 10.1016/j.molcel.2008.03.022; Takawa M, 2012, CANCER RES, V72, P3217, DOI 10.1158/0008-5472.CAN-11-3701; Tam W, 2006, BLOOD, V107, P4090, DOI 10.1182/blood-2005-09-3778; Tatton-Brown K, 2005, AM J HUM GENET, V77, P193, DOI 10.1086/432082; Tokumaru Y, 2003, ONCOGENE, V22, P6954, DOI 10.1038/sj.onc.1206403; Towbin BD, 2012, CELL, V150, P934, DOI 10.1016/j.cell.2012.06.051; Trojer P, 2007, MOL CELL, V28, P1, DOI 10.1016/j.molcel.2007.09.011; Tzatsos A, 2009, P NATL ACAD SCI USA, V106, P2641, DOI 10.1073/pnas.0813139106; van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349; van Kemenade FJ, 2001, BLOOD, V97, P3896, DOI 10.1182/blood.V97.12.3896; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Varambally S, 2008, SCIENCE, V322, P1695, DOI 10.1126/science.1165395; Vermeulen M, 2007, CELL, V131, P58, DOI 10.1016/j.cell.2007.08.016; Wang J, 2009, NAT GENET, V41, P125, DOI 10.1038/ng.268; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050; Watanabe Y, 2007, CLIN CANCER RES, V13, P4786, DOI 10.1158/1078-0432.CCR-07-0305; Weikert S, 2005, INT J MOL MED, V16, P349; Whitman SP, 2008, BLOOD, V112, P2013, DOI 10.1182/blood-2008-01-128595; Wissmann M, 2007, NAT CELL BIOL, V9, P347, DOI 10.1038/ncb1546; Wu SM, 2010, GENE DEV, V24, P2531, DOI 10.1101/gad.1984210; Xiang Y, 2007, P NATL ACAD SCI USA, V104, P19226, DOI 10.1073/pnas.0700735104; Xiang Y, 2007, CELL RES, V17, P850, DOI 10.1038/cr.2007.83; Xie Q, 2012, EMBO REP, V13, P371, DOI 10.1038/embor.2012.25; Xu KX, 2012, SCIENCE, V338, P1465, DOI 10.1126/science.1227604; Yang F, 2012, EMBO J, V31, P110, DOI 10.1038/emboj.2011.364; Yang JB, 2010, P NATL ACAD SCI USA, V107, P21499, DOI 10.1073/pnas.1016147107; Yang LQ, 2011, CELL, V147, P773, DOI 10.1016/j.cell.2011.08.054; Yang XD, 2010, MOL CELL BIOL, V30, P2170, DOI 10.1128/MCB.01343-09; Yang XD, 2009, EMBO J, V28, P1055, DOI 10.1038/emboj.2009.55; Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016; Zeng JP, 2010, GASTROENTEROLOGY, V138, P981, DOI 10.1053/j.gastro.2009.10.004; Zuber J, 2011, GENE DEV, V25, P1628, DOI 10.1101/gad.17269211	172	26	27	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2014	33	10					1207	1217		10.1038/onc.2013.87	http://dx.doi.org/10.1038/onc.2013.87			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AC6KI	23503463				2022-12-28	WOS:000332631100001
J	Armacki, M; Joodi, G; Nimmagadda, SC; de Kimpe, L; Pusapati, GV; Vandoninck, S; Van Lint, J; Illing, A; Seufferlein, T				Armacki, M.; Joodi, G.; Nimmagadda, S. C.; de Kimpe, L.; Pusapati, G. V.; Vandoninck, S.; Van Lint, J.; Illing, A.; Seufferlein, T.			A novel splice variant of calcium and integrin-binding protein 1 mediates protein kinase D2-stimulated tumour growth by regulating angiogenesis	ONCOGENE			English	Article						PKD2; CIB1; angiogenesis; carcinogenesis	FOCAL ADHESION KINASE; ENDOTHELIAL-CELLS; CIB1; PHOSPHORYLATION; INVASION; D2; ACTIVATION; INHIBITION; EXPORT; IDENTIFICATION	Protein kinase D2 (PKD2) is a member of the PKD family of serine/threonine kinases, a subfamily of the CAMK super-family. PKDs have a critical role in cell motility, migration and invasion of cancer cells. Expression of PKD isoforms is deregulated in various tumours and PKDs, in particular PKD2, have been implicated in the regulation of tumour angiogenesis. In order to further elucidate the role of PKD2 in tumours, we investigated the signalling context of this kinase by performing an extensive substrate screen by in vitro expression cloning (IVEC). We identified a novel splice variant of calcium and integrin-binding protein 1, termed CIB1a, as a potential substrate of PKD2. CIB1 is a widely expressed protein that has been implicated in angiogenesis, cell migration and proliferation, all important hallmarks of cancer, and CIB1a was found to be highly expressed in various cancer cell lines. We identify Ser(118) as the major PKD2 phosphorylation site in CIB1a and show that PKD2 interacts with CIB1a via its alanine and proline-rich domain. Furthermore, we confirm that CIB1a is indeed a substrate of PKD2 also in intact cells using a phosphorylation-specific antibody against CIB1a-Ser(118). Functional analysis of PKD2-mediated CIB1a phosphorylation revealed that on phosphorylation, CIB1a mediates tumour cell invasion, tumour growth and angiogenesis by mediating PKD-induced vascular endothelial growth factor secretion by the tumour cells. Thus, CIB1a is a novel mediator of PKD2-driven carcinogenesis and a potentially interesting therapeutic target.	[Armacki, M.; Illing, A.; Seufferlein, T.] Univ Ulm, Dept Internal Med 1, D-89081 Baden Baden, Germany; [Armacki, M.; Joodi, G.; Nimmagadda, S. C.; Seufferlein, T.] Univ Halle Wittenberg, Dept Internal Med 1, D-06108 Halle, Saale, Germany; [de Kimpe, L.] Univ Amsterdam, AMC, Amsterdam, Netherlands; [de Kimpe, L.; Vandoninck, S.; Van Lint, J.] Katholieke Univ Leuven, Fac Med, Dept Cellular & Mol Med, Louvain, Belgium; [Pusapati, G. V.] Stanford Univ, Dept Biochem, Sch Med, Stanford, CA 94305 USA	Ulm University; Martin Luther University Halle Wittenberg; University of Amsterdam; Academic Medical Center Amsterdam; KU Leuven; Stanford University	Seufferlein, T (corresponding author), Univ Ulm, Dept Internal Med 1, Albert Einstein Allee 23, D-89081 Ulm, Germany.	Thomas.seufferlein@uniklinik-ulm.de	Van Lint, Johan/P-9073-2019; Seufferlein, Thomas TW/P-7147-2018	Pusapati, Ganesh/0000-0002-1406-2566; Van Lint, Johan/0000-0002-0275-571X; Joodi, Golsa/0000-0002-6371-433X	German Federal Ministry of Education and Research (BMBF) [PKB-01GS08209-4]; German Cancer Aid [109373]; Research Programme of the Research Foundation-Flanders (FWO);  [G.0612.07]	German Federal Ministry of Education and Research (BMBF)(Federal Ministry of Education & Research (BMBF)); German Cancer Aid(Deutsche Krebshilfe); Research Programme of the Research Foundation-Flanders (FWO)(FWO); 	This project was funded in part by the German Federal Ministry of Education and Research (BMBF) grant no. PKB-01GS08209-4 and the German Cancer Aid grant no. 109373 (both to TS) and in part by the Research Programme of the Research Foundation-Flanders (FWO) (PhD fellowship to LDK and grant G.0612.07 to JVL). We thank Holger Reim and Claudia Ruhland for expert technical assistance.	Albini A, 2004, INT J DEV BIOL, V48, P563, DOI 10.1387/ijdb.041822aa; ALBINI A, 1987, CANCER RES, V47, P3239; Albini A, 1998, Pathol Oncol Res, V4, P230; Auer A, 2005, MOL BIOL CELL, V16, P4375, DOI 10.1091/mbc.E05-03-0251; Azoitei N, 2011, NEURO-ONCOLOGY, V13, P710, DOI 10.1093/neuonc/nor084; Azoitei N, 2010, GUT, V59, P1316, DOI 10.1136/gut.2009.206813; Bagheri-Yarmand R, 2000, J BIOL CHEM, V275, P39451, DOI 10.1074/jbc.M006150200; Bard F, 2006, ANNU REV CELL DEV BI, V22, P439, DOI 10.1146/annurev.cellbio.21.012704.133126; Bartolome RA, 2004, CANCER RES, V64, P2534, DOI 10.1158/0008-5472.CAN-03-3398; Bowden ET, 1999, ONCOGENE, V18, P4440, DOI 10.1038/sj.onc.1202827; Cells J., 1998, CELL BIOL LAB HDB; Chen J, 2008, CANCER RES, V68, P3844, DOI 10.1158/0008-5472.CAN-07-5156; CONNOLLY CN, 1994, J CELL BIOL, V127, P641, DOI 10.1083/jcb.127.3.641; Dequiedt F, 2003, IMMUNITY, V18, P687, DOI 10.1016/S1074-7613(03)00109-2; Eiseler T, 2007, FEBS LETT, V581, P4279, DOI 10.1016/j.febslet.2007.07.079; Eiseler T, 2009, NAT CELL BIOL, V11, P545, DOI 10.1038/ncb1861; Engling A, 2002, J CELL SCI, V115, P3619, DOI 10.1242/jcs.00036; Evans IM, 2008, CELL SIGNAL, V20, P1375, DOI 10.1016/j.cellsig.2008.03.002; Evans IM, 2011, IUBMB LIFE, V63, P258, DOI 10.1002/iub.456; FLORKIEWICZ RZ, 1995, J CELL PHYSIOL, V162, P388, DOI 10.1002/jcp.1041620311; Florkiewicz RZ, 1998, J BIOL CHEM, V273, P544, DOI 10.1074/jbc.273.1.544; Gao ZH, 2000, BIOCHEM BIOPH RES CO, V268, P562, DOI 10.1006/bbrc.2000.2168; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Guha S, 2010, BIOCHEM PHARMACOL, V80, P1946, DOI 10.1016/j.bcp.2010.07.002; Ha CH, 2008, J BIOL CHEM, V283, P14590, DOI 10.1074/jbc.M800264200; Haataja L, 2002, J BIOL CHEM, V277, P8321, DOI 10.1074/jbc.M105363200; Hao Q, 2009, J BIOL CHEM, V284, P799, DOI 10.1074/jbc.M807546200; Hollenbach AD, 2002, BBA-GENE STRUCT EXPR, V1574, P321, DOI 10.1016/S0167-4781(02)00230-0; Hood JD, 2003, J CELL BIOL, V162, P933, DOI 10.1083/jcb.200304105; Jackson LN, 2006, BIOCHEM BIOPH RES CO, V348, P945, DOI 10.1016/j.bbrc.2006.07.142; Jamora C, 1999, CELL, V98, P59, DOI 10.1016/S0092-8674(00)80606-6; Kauselmann G, 1999, EMBO J, V18, P5528, DOI 10.1093/emboj/18.20.5528; Kiosses WB, 2002, CIRC RES, V90, P697, DOI 10.1161/01.RES.0000014227.76102.5D; Lacal PM, 2005, INT J ONCOL, V27, P1625; Leisner TM, 2005, J CELL BIOL, V170, P465, DOI 10.1083/jcb.200502090; Malhotra V, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005280; Mihailovic T, 2004, CANCER RES, V64, P8939, DOI 10.1158/0008-5472.CAN-04-0981; Naik MU, 2011, J CELL BIOCHEM, V112, P3289, DOI 10.1002/jcb.23255; Naik MU, 2011, INT J CANCER, V128, P587, DOI 10.1002/ijc.25388; Naik MU, 2003, BLOOD, V102, P3629, DOI 10.1182/blood-2003-05-1703; Naik UP, 1997, J BIOL CHEM, V272, P4651, DOI 10.1074/jbc.272.8.4651; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Norrby K, 2006, J CELL MOL MED, V10, P588, DOI 10.1111/j.1582-4934.2006.tb00423.x; Obenauer John C, 2004, Methods Mol Biol, V261, P445; Peterburs P, 2009, CANCER RES, V69, P5634, DOI 10.1158/0008-5472.CAN-09-0718; Prigozhina NL, 2004, CURR BIOL, V14, P88, DOI 10.1016/j.cub.2004.01.003; Pusapati GV, 2010, MOL BIOL CELL, V21, P1011, DOI 10.1091/mbc.E09-09-0814; Qazi H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020348; Qin LL, 2006, J BIOL CHEM, V281, P32550, DOI 10.1074/jbc.M604853200; Rozengurt E, 2011, PHYSIOLOGY, V26, P23, DOI 10.1152/physiol.00037.2010; Ruifrok AC, 1997, ANAL QUANT CYTOL, V19, P107; Rykx A, 2003, FEBS LETT, V546, P81, DOI 10.1016/S0014-5793(03)00487-3; Shen TL, 2005, J CELL BIOL, V169, P941, DOI 10.1083/jcb.200411155; Shock DD, 1999, BIOCHEM J, V342, P729, DOI 10.1042/0264-6021:3420729; Sturany S, 2001, J BIOL CHEM, V276, P3310, DOI 10.1074/jbc.M008719200; Vempati P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011860; Vogler M, 2005, ONCOGENE, V24, P7190, DOI 10.1038/sj.onc.1208876; von Blume J, 2007, EMBO J, V26, P4619, DOI 10.1038/sj.emboj.7601891; White C, 2006, J BIOL CHEM, V281, P20825, DOI 10.1074/jbc.M602175200; Wong C, 2005, J BIOL CHEM, V280, P33262, DOI 10.1074/jbc.M503198200; Wu HL, 2009, CELL RES, V19, P439, DOI 10.1038/cr.2009.18; Yuan W, 2006, MOL CELL BIOL, V26, P8507, DOI 10.1128/MCB.01488-06; Yuan WP, 2006, J CELL BIOL, V172, P169, DOI 10.1083/jcb.200505131; Zayed MA, 2007, CIRC RES, V101, P1185, DOI 10.1161/CIRCRESAHA.107.157586; Zayed MA, 2010, VASC CELL, V2, DOI 10.1186/2040-2384-2-17; Zhang C, 2004, METHODS, V33, P144, DOI 10.1016/j.ymeth.2003.11.004	66	13	19	2	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2014	33	9					1167	1180		10.1038/onc.2013.43	http://dx.doi.org/10.1038/onc.2013.43			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XT	23503467				2022-12-28	WOS:000331933800010
J	Shatnawi, A; Norris, JD; Chaveroux, C; Jasper, JS; Sherk, AB; McDonnell, DP; Giguere, V				Shatnawi, A.; Norris, J. D.; Chaveroux, C.; Jasper, J. S.; Sherk, A. B.; McDonnell, D. P.; Giguere, V.			ELF3 is a repressor of androgen receptor action in prostate cancer cells	ONCOGENE			English	Article						ETS factor; ChIP; nuclear receptor; LNCaP cells; xenograft	ETS TRANSCRIPTION FACTOR; EXPRESSION; GENE; EPITHELIUM; ESE-1; RECURRENCE; MECHANISM; BINDING; FAMILY; DIFFERENTIATION	The androgen receptor (AR) has a critical role in the development and progression of prostate cancer (PC) and is a major therapeutic target in this disease. The transcriptional activity of AR is modulated by the coregulators with which it interacts, and consequently deregulation of cofactor expression and/or activity impacts the expression of genes whose products can have a role in PC pathogenesis. Here we report that E74-like factor 3 (ELF3), a member of the ETS family of transcription factors, is a repressor of AR transcriptional activity. Exogenous expression of ELF3 represses AR transcriptional activity when assessed using reporter-based transfection assays or when evaluated on endogenous AR target genes. Conversely, ELF3 knock down increases the AR transcriptional activity. Biochemical dissection of this activity indicates that it results from the physical interaction between ELF3 and AR and that this interaction inhibits the recruitment of AR to specific androgen response elements within target gene promoters. Significantly, we observed that depletion of ELF3 expression in LNCaP cells promotes cell migration, whereas increased ELF3 expression severely inhibits tumor growth in vitro and in a mouse xenograft model. Taken together, these results suggest that modulation of ELF3 expression and/or AR/ELF3 interaction may have utility in the treatment of PC.	[Shatnawi, A.; Chaveroux, C.; Giguere, V.] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ H3A 1A3, Canada; [Norris, J. D.; Jasper, J. S.; Sherk, A. B.; McDonnell, D. P.] Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC USA; [Giguere, V.] McGill Univ, Dept Biochem, Montreal, PQ, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada; [Giguere, V.] McGill Univ, Dept Oncol, Montreal, PQ, Canada	McGill University; Duke University; McGill University; McGill University; McGill University	Giguere, V (corresponding author), McGill Univ, Goodman Canc Res Ctr, 1160 Pine Ave West, Montreal, PQ H3A 1A3, Canada.	vincent.giguere@mcgill.ca	shatnawi, Aymen/AAF-5661-2020	Chaveroux, Cedric/0000-0002-4116-3354; Norris, John/0000-0001-6553-8053; Giguere, Vincent/0000-0001-9567-3694; Jasper, Jeff/0000-0003-3941-0018	US Department of Defense [W81XWH-09-1-0605]; Canadian Institutes of Health Research [MOP-64275]; Terry Fox Foundation Program Project Grant; NIH [5RO1 CA139818]; NATIONAL CANCER INSTITUTE [R01CA139818] Funding Source: NIH RePORTER	US Department of Defense(United States Department of Defense); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Terry Fox Foundation Program Project Grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Angie Rizzino (University of Nebraska Medical Center) for providing the Flag-ELF3 construct and ELF3 mutants and Majid Ghahremani for technical help. This work was financially supported by a postdoctoral award (W81XWH-09-1-0605) from the US Department of Defense PC Research Program (to AS); the Canadian Institutes of Health Research (MOP-64275) and a Terry Fox Foundation Program Project Grant (to VG); and NIH Grant 5RO1 CA139818 (to DPMcD).	Agoulnik IU, 2006, CANCER RES, V66, P10594, DOI 10.1158/0008-5472.CAN-06-1023; Chang CH, 1999, ONCOGENE, V18, P3682, DOI 10.1038/sj.onc.1202674; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Chang CY, 2005, TRENDS PHARMACOL SCI, V26, P225, DOI 10.1016/j.tips.2005.03.002; Chang J, 2000, ONCOGENE, V19, P151, DOI 10.1038/sj.onc.1203252; Charest-Marcotte A, 2010, GENE DEV, V24, P537, DOI 10.1101/gad.1871610; Clegg NJ, 2012, CANCER RES, V72, P1494, DOI 10.1158/0008-5472.CAN-11-3948; Eckel KL, 2003, DNA CELL BIOL, V22, P79, DOI 10.1089/104454903321515896; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Frigo DE, 2009, MOL ENDOCRINOL, V23, P1385, DOI 10.1210/me.2009-0010; Gregory CW, 2001, CANCER RES, V61, P4315; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; Halkidou K, 2003, ONCOGENE, V22, P2466, DOI 10.1038/sj.onc.1206342; Heemers HV, 2007, ENDOCR REV, V28, P778, DOI 10.1210/er.2007-0019; Kahl P, 2006, CANCER RES, V66, P11341, DOI 10.1158/0008-5472.CAN-06-1570; Knudsen KE, 2011, EXPERT REV ENDOCRINO, V6, P483, DOI 10.1586/EEM.11.33; Knudsen KE, 2010, TRENDS ENDOCRIN MET, V21, P315, DOI 10.1016/j.tem.2010.01.002; Kopp JL, 2007, J BIOL CHEM, V282, P3027, DOI 10.1074/jbc.M609907200; Lessard L, 2012, CANCER RES, V72, P1529, DOI 10.1158/0008-5472.CAN-11-2602; Maniccia AW, 2009, J CELL PHYSIOL, V219, P634, DOI 10.1002/jcp.21708; Ng AYN, 2002, GASTROENTEROLOGY, V122, P1455, DOI 10.1053/gast.2002.32990; Norris JD, 2009, CHEM BIOL, V16, P452, DOI 10.1016/j.chembiol.2009.01.016; O'Malley BW, 2012, MOL ENDOCRINOL, V26, P1646, DOI 10.1210/me.2012-1114; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Oh S, 2012, BBA-REV CANCER, V1826, P1, DOI 10.1016/j.bbcan.2012.02.002; Oliver JR, 2012, LAB INVEST, V92, P320, DOI 10.1038/labinvest.2011.186; Pienta KJ, 2006, CLIN CANCER RES, V12, P1665, DOI 10.1158/1078-0432.CCR-06-0067; Prescott JD, 2004, MOL CELL BIOL, V24, P5548, DOI 10.1128/MCB.24.12.5548-5564.2004; Reddy SPM, 2003, J BIOL CHEM, V278, P21378, DOI 10.1074/jbc.M212258200; Rudders S, 2001, J BIOL CHEM, V276, P3302, DOI 10.1074/jbc.M006507200; Ryan CJ, 2011, J CLIN ONCOL, V29, P3651, DOI 10.1200/JCO.2011.35.2005; Shatnawi A, 2007, MOL ENDOCRINOL, V21, P635, DOI 10.1210/me.2006-0274; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; Yap TA, 2011, NAT REV CLIN ONCOL, V8, P597, DOI 10.1038/nrclinonc.2011.117; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Zhou HJ, 2005, CANCER RES, V65, P7976, DOI 10.1158/0008-5472.CAN-04-4076; Zong Y, 2009, P NATL ACAD SCI USA, V106, P12465, DOI 10.1073/pnas.0905931106	40	22	22	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2014	33	7					862	871		10.1038/onc.2013.15	http://dx.doi.org/10.1038/onc.2013.15			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB2MN	23435425	Green Accepted			2022-12-28	WOS:000331626900007
J	Stone, HR; Morris, JR				Stone, H. R.; Morris, J. R.			DNA damage emergency: cellular garbage disposal to the rescue?	ONCOGENE			English	Review						ubiquitin; DNA repair; proteasome; POH1; 53BP1	DOUBLE-STRAND BREAKS; UBIQUITIN E3 LIGASE; DEUBIQUITINATING ENZYME; AAA-ATPASE; 53BP1 RECRUITMENT; HOMOLOGOUS RECOMBINATION; PROTEIN-DEGRADATION; 26S PROTEASOME; RAP80 PROTEIN; KU80 REMOVAL	The proteasome is a cellular machine found in the cytosol, nucleus and on chromatin that performs much of the proteolysis in eukaryotic cells. Recent reports show it is enriched at sites of double-stranded DNA breaks (DSBs) in mammalian cells. What is it doing there? This review will address three possibilities suggested by recent reports: in degrading proteins after their ubiquitination at and eviction from chromatin; as a deubiquitinase, specific to the antagonism of ubiquitin conjugates generated as part of the signalling of a DSB; and as a functional component of DNA repair mechanism itself. These findings add complexity to the proteasome as a potential therapeutic target in cancer treatment.	[Stone, H. R.; Morris, J. R.] Univ Birmingham, Coll Med & Dent Sci, Sch Canc Sci, Birmingham B15 2TT, W Midlands, England	University of Birmingham	Morris, JR (corresponding author), Univ Birmingham, Coll Med & Dent Sci, Sch Canc Sci, Birmingham B15 2TT, W Midlands, England.	j.morris.3@bham.ac.uk	Morris, Joanna/AAK-3388-2021	Morris, Joanna/0000-0001-9762-8133	Breast Cancer Campaign [2010NovPhD02]	Breast Cancer Campaign	HRS is supported by the Breast Cancer Campaign Grant 2010NovPhD02.	Acs K, 2011, NAT STRUCT MOL BIOL, V18, P1345, DOI 10.1038/nsmb.2188; Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; Beaven AW, 2012, LEUKEMIA LYMPHOMA, V53, P254, DOI 10.3109/10428194.2011.608445; Ben-Aroya S, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000852; Ben-Saadon R, 2006, MOL CELL, V24, P701, DOI 10.1016/j.molcel.2006.10.022; Bin W, 2007, P NATL ACAD SCI USA, V104, P20759, DOI 10.1073/pnas.0710061104; Blickwedehl J, 2008, P NATL ACAD SCI USA, V105, P16165, DOI 10.1073/pnas.0803145105; Blickwedehl J, 2007, RADIAT RES, V167, P663, DOI 10.1667/RR0690.1; Bothmer A, 2011, MOL CELL, V42, P319, DOI 10.1016/j.molcel.2011.03.019; Bouwman P, 2010, NAT STRUCT MOL BIOL, V17, P688, DOI 10.1038/nsmb.1831; Brummelkamp TR, 2003, NATURE, V424, P797, DOI 10.1038/nature01811; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Burnett B, 2003, HUM MOL GENET, V12, P3195, DOI 10.1093/hmg/ddg344; Butler LR, 2012, EMBO J, V31, P3918, DOI 10.1038/emboj.2012.232; Cao L, 2009, MOL CELL, V35, P534, DOI 10.1016/j.molcel.2009.06.037; Chapman JR, 2012, J CELL SCI, V125, P3529, DOI 10.1242/jcs.105353; Chen Q, 2005, BLOOD, V106, P698, DOI 10.1182/blood-2004-11-4286; CIECHANOVER A, 1981, P NATL ACAD SCI-BIOL, V78, P761, DOI 10.1073/pnas.78.2.761; Cooper EM, 2009, EMBO J, V28, P621, DOI 10.1038/emboj.2009.27; Cvek B, 2011, CURR CANCER DRUG TAR, V11, P332, DOI 10.2174/156800911794519806; Cvek B, 2012, PROG MOL BIOL TRANSL, V109, P161, DOI 10.1016/B978-0-12-397863-9.00005-5; D'Arcy P, 2012, INT J BIOCHEM CELL B, V44, P1729, DOI 10.1016/j.biocel.2012.07.011; Dalla Via L, 2012, FUTURE MED CHEM, V4, P525, DOI [10.4155/FMC.11.187, 10.4155/fmc.11.187]; Dantuma NP, 2006, J CELL BIOL, V173, P19, DOI 10.1083/jcb.200510071; Dimitrova N, 2008, NATURE, V456, P524, DOI 10.1038/nature07433; Doil C, 2009, CELL, V136, P435, DOI 10.1016/j.cell.2008.12.041; Dou H, 2010, MOL CELL, V39, P333, DOI 10.1016/j.molcel.2010.07.021; Ernst R, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000605; Feng L, 2012, NAT STRUCT MOL BIOL, V19, P201, DOI 10.1038/nsmb.2211; Feng L, 2010, J BIOL CHEM, V285, P30982, DOI 10.1074/jbc.M110.135392; Franz A, 2011, MOL CELL, V44, P85, DOI 10.1016/j.molcel.2011.08.028; Fushman D, 2010, J MOL BIOL, V395, P803, DOI 10.1016/j.jmb.2009.10.039; Galanty Y, 2012, GENE DEV, V26, P1179, DOI 10.1101/gad.188284.112; Gallery M, 2007, MOL CANCER THER, V6, P262, DOI 10.1158/1535-7163.MCT-06-0542; GOLDKNOPF IL, 1977, P NATL ACAD SCI USA, V74, P864, DOI 10.1073/pnas.74.3.864; GOLDSTEIN G, 1975, P NATL ACAD SCI USA, V72, P11, DOI 10.1073/pnas.72.1.11; Gudjonsson T, 2012, CELL, V150, P697, DOI 10.1016/j.cell.2012.06.039; Gudmundsdottir K, 2007, ONCOGENE, V26, P7601, DOI 10.1038/sj.onc.1210579; Guzzo CM, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003485; Hanna J, 2003, MOL CELL BIOL, V23, P9251, DOI 10.1128/MCB.23.24.9251-9261.2003; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Hu X, 2012, J BIOL CHEM, V287, P25510, DOI 10.1074/jbc.M112.374116; Huang J, 2009, NAT CELL BIOL, V11, P592, DOI 10.1038/ncb1865; Huen MSY, 2007, CELL, V131, P901, DOI 10.1016/j.cell.2007.09.041; Indig FE, 2004, J STRUCT BIOL, V146, P251, DOI 10.1016/j.jsb.2003.11.009; Jacobson AD, 2009, J BIOL CHEM, V284, P35485, DOI 10.1074/jbc.M109.052928; Jacquemont C, 2007, CANCER RES, V67, P7395, DOI 10.1158/0008-5472.CAN-07-1015; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; Joo HY, 2007, NATURE, V449, P1068, DOI 10.1038/nature06256; Juang YC, 2012, MOL CELL, V45, P384, DOI 10.1016/j.molcel.2012.01.011; Kim HT, 2007, J BIOL CHEM, V282, P17375, DOI 10.1074/jbc.M609659200; Kim HT, 2012, METHODS MOL BIOL, V832, P653, DOI 10.1007/978-1-61779-474-2_46; Kim HT, 2009, EMBO J, V28, P1867, DOI 10.1038/emboj.2009.115; Kirisako T, 2006, EMBO J, V25, P4877, DOI 10.1038/sj.emboj.7601360; Kojic M, 2005, MOL CELL BIOL, V25, P2547, DOI 10.1128/MCB.25.7.2547-2557.2005; Kolas NK, 2007, SCIENCE, V318, P1637, DOI 10.1126/science.1150034; Komander D, 2009, NAT REV MOL CELL BIO, V10, P550, DOI 10.1038/nrm2731; Kovalenko A, 2003, NATURE, V424, P801, DOI 10.1038/nature01802; Kristensen CN, 2010, MUTAT RES-FUND MOL M, V694, P60, DOI 10.1016/j.mrfmmm.2010.08.007; Krogan NJ, 2004, MOL CELL, V16, P1027, DOI 10.1016/j.molcel.2004.11.033; Kuehn L, 1997, MOL BIOL REP, V24, P89, DOI 10.1023/A:1006897801858; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; Lander GC, 2012, NATURE, V482, P186, DOI 10.1038/nature10774; Lasker K, 2012, P NATL ACAD SCI USA, V109, P1380, DOI 10.1073/pnas.1120559109; Levy-Barda A, 2011, CELL CYCLE, V10, P4300, DOI 10.4161/cc.10.24.18642; Liu H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005544; Liu J, 2010, NAT STRUCT MOL BIOL, V17, P1260, DOI 10.1038/nsmb.1904; Liu YC, 2002, CELL, V111, P209, DOI 10.1016/S0092-8674(02)01012-7; Livingstone M, 2005, CANCER RES, V65, P7533, DOI 10.1158/0008-5472.CAN-04-3729; Lok GTM, 2012, NUCLEIC ACIDS RES, V40, P196, DOI 10.1093/nar/gkr655; Lou ZK, 2003, J BIOL CHEM, V278, P13599, DOI 10.1074/jbc.C300060200; Luo KT, 2012, EMBO J, V31, P3008, DOI 10.1038/emboj.2012.158; Mailand N, 2007, CELL, V131, P887, DOI 10.1016/j.cell.2007.09.040; Mallette FA, 2012, CELL RES, V22, P1221, DOI 10.1038/cr.2012.58; Mallette FA, 2012, EMBO J, V31, P1865, DOI 10.1038/emboj.2012.47; Marteijn JA, 2009, J CELL BIOL, V186, P835, DOI 10.1083/jcb.200902150; Matilla A, 2001, HUM MOL GENET, V10, P2821, DOI 10.1093/hmg/10.24.2821; Mattiroli F, 2012, CELL, V150, P1182, DOI 10.1016/j.cell.2012.08.005; Meerang M, 2011, NAT CELL BIOL, V13, P1376, DOI 10.1038/ncb2367; Meyer H, 2012, NAT CELL BIOL, V14, P117, DOI 10.1038/ncb2407; Min JR, 2007, NAT STRUCT MOL BIOL, V14, P1229, DOI 10.1038/nsmb1340; Mochan TA, 2003, CANCER RES, V63, P8586; Mok MTS, 2010, CELL SIGNAL, V22, P47, DOI 10.1016/j.cellsig.2009.09.007; Moreau P, 2012, BLOOD, V120, P947, DOI 10.1182/blood-2012-04-403733; Mott C, 2011, DNA REPAIR, V10, P408, DOI 10.1016/j.dnarep.2011.01.007; Murakawa Y, 2007, CANCER RES, V67, P8536, DOI 10.1158/0008-5472.CAN-07-1166; Nabhan JF, 2006, J BIOL CHEM, V281, P16099, DOI 10.1074/jbc.M512086200; Nakada S, 2012, CANCER RES, V72, P4974, DOI 10.1158/0008-5472.CAN-12-1057; Nakada S, 2010, NATURE, V466, P941, DOI 10.1038/nature09297; Neri P, 2011, BLOOD, V118, P6368, DOI 10.1182/blood-2011-06-363911; Nicassio F, 2007, CURR BIOL, V17, P1972, DOI 10.1016/j.cub.2007.10.034; Nijman SMB, 2005, MOL CELL, V17, P331, DOI 10.1016/j.molcel.2005.01.008; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Nishikawa H, 2004, J BIOL CHEM, V279, P3916, DOI 10.1074/jbc.M308540200; Nishio K, 2009, BIOCHEM BIOPH RES CO, V390, P855, DOI 10.1016/j.bbrc.2009.10.062; Patterson-Fortin J, 2010, J BIOL CHEM, V285, P30971, DOI 10.1074/jbc.M110.135319; Pegoraro G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031684; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Peth A, 2010, MOL CELL, V40, P671, DOI 10.1016/j.molcel.2010.11.002; Peth A, 2009, MOL CELL, V36, P794, DOI 10.1016/j.molcel.2009.11.015; Popov N, 2007, CELL CYCLE, V6, P2327, DOI 10.4161/cc.6.19.4804; Postow L, 2008, J CELL BIOL, V182, P467, DOI 10.1083/jcb.200802146; Raman M, 2011, MOL CELL, V44, P72, DOI 10.1016/j.molcel.2011.06.036; Ramchandren R, 2012, ONCOLOGIST, V17, P367, DOI 10.1634/theoncologist.2011-0258; Richly H, 2005, CELL, V120, P73, DOI 10.1016/j.cell.2004.11.013; Rumpf S, 2006, MOL CELL, V21, P261, DOI 10.1016/j.molcel.2005.12.014; Russell NS, 2004, BIOCHEMISTRY-US, V43, P4844, DOI 10.1021/bi035626r; San Miguel JF, 2008, NEW ENGL J MED, V359, P906, DOI 10.1056/NEJMoa0801479; Sato Y, 2012, J BIOL CHEM, V287, P25860, DOI 10.1074/jbc.M112.364752; Sauer RT, 2004, CELL, V119, P9, DOI 10.1016/j.cell.2004.09.020; Scheel H, 2003, HUM MOL GENET, V12, P2845, DOI 10.1093/hmg/ddg297; Schoenfeld AR, 2004, MOL CELL BIOL, V24, P7444, DOI 10.1128/MCB.24.17.7444-7455.2004; Shao G, 2009, P NATL ACAD SCI USA, V106, P3166, DOI 10.1073/pnas.0807485106; Shi W, 2008, J BIOL CHEM, V283, P31608, DOI 10.1074/jbc.M801082200; Sigurdsson S, 2001, GENE DEV, V15, P3308, DOI 10.1101/gad.935501; Sobhian B, 2007, SCIENCE, V316, P1198, DOI 10.1126/science.1139516; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Stewart GS, 2009, CELL, V136, P420, DOI 10.1016/j.cell.2008.12.042; Stewart GS, 2003, NATURE, V421, P961, DOI 10.1038/nature01446; Takeshita T, 2009, CANCER CHEMOTH PHARM, V64, P1039, DOI 10.1007/s00280-009-0961-5; Tan MKM, 2011, MOL CELL BIOL, V31, P3687, DOI 10.1128/MCB.05746-11; Trompouki E, 2003, NATURE, V424, P793, DOI 10.1038/nature01803; Ustrell V, 2002, EMBO J, V21, P3516, DOI 10.1093/emboj/cdf333; Varadan R, 2002, J MOL BIOL, V324, P637, DOI 10.1016/S0022-2836(02)01198-1; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; Verma R, 2011, MOL CELL, V41, P82, DOI 10.1016/j.molcel.2010.12.017; Virdee S, 2010, NAT CHEM BIOL, V6, P750, DOI [10.1038/NCHEMBIO.426, 10.1038/nchembio.426]; Vyas R, 2013, CELL DEATH DIFFER, V20, P490, DOI 10.1038/cdd.2012.145; Wang B, 2007, SCIENCE, V316, P1194, DOI 10.1126/science.1139476; Wang B, 2009, GENE DEV, V23, P729, DOI 10.1101/gad.1770309; Wang CY, 2001, NAT STRUCT BIOL, V8, P47; Wertz IE, 2004, NATURE, V430, P694, DOI 10.1038/nature02794; Wiener R, 2012, NATURE, V483, P618, DOI 10.1038/nature10911; Wilcox AJ, 2009, NAT CELL BIOL, V11, P1481, DOI 10.1038/ncb1997; Wu JX, 2012, J BIOL CHEM, V287, P22919, DOI 10.1074/jbc.M112.351007; Xu P, 2009, CELL, V137, P133, DOI 10.1016/j.cell.2009.01.041; Yamada T, 2000, FEBS LETT, V466, P287, DOI 10.1016/S0014-5793(99)01673-7; Yan J, 2008, CANCER LETT, V271, P179, DOI 10.1016/j.canlet.2008.04.046; Yao TT, 2002, NATURE, V419, P403, DOI 10.1038/nature01071; Yin YL, 2012, GENE DEV, V26, P1196, DOI 10.1101/gad.189274.112; Zhang D, 2006, CELL, V126, P529, DOI 10.1016/j.cell.2006.06.039; Zhang HT, 2000, DNA CELL BIOL, V19, P253, DOI 10.1089/10445490050021168; Zhou QW, 2007, MOL CELL BIOL, V27, P2512, DOI 10.1128/MCB.01907-06	145	14	14	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2014	33	7					805	813		10.1038/onc.2013.60	http://dx.doi.org/10.1038/onc.2013.60			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB2MN	23503465				2022-12-28	WOS:000331626900001
J	Thu, KL; Radulovich, N; Becker-Santos, DD; Pikor, LA; Pusic, A; Lockwood, WW; Lam, WL; Tsao, MS				Thu, K. L.; Radulovich, N.; Becker-Santos, D. D.; Pikor, L. A.; Pusic, A.; Lockwood, W. W.; Lam, W. L.; Tsao, M-S			SOX15 is a candidate tumor suppressor in pancreatic cancer with a potential role in Wnt/beta-catenin signaling	ONCOGENE			English	Article						SOX15; integrative genomics; tumor suppressor; pancreatic cancer; Wnt pathway	FREQUENT EPIGENETIC INACTIVATION; PROMOTER METHYLATION; WNT PATHWAY; GENE; MUTATIONS; ONCOGENE; BIOLOGY; PROLIFERATION; ANTAGONISTS; EVOLUTION	Pancreatic cancer is among the top five deadliest cancers in developed countries. Better knowledge of the molecular mechanisms contributing to its tumorigenesis is imperative to improve patient prognosis. Identification of novel tumor suppressor genes (TSGs) in pancreatic cancer will reveal new mechanisms of pathway deregulation and will ultimately help improve our understanding of this aggressive disease. According to Knudson's two-hit model, TSGs are classically disrupted by two concerted genetic events. In this study, we combined DNA methylation profiling with copy number and mRNA expression profiling to identify novel TSGs in a set of 20 pancreatic cancer cell lines. These data sets were integrated for each of similar to 12000 genes in each cell line enabling the elucidation of those genes that undergo DNA hypermethylation, copy-number loss and mRNA downregulation simultaneously in multiple cell lines. Using this integrative genomics strategy, we identified SOX15 (sex determining region Y-box 15) as a candidate TSG in pancreatic cancer. Expression of SOX15 in pancreatic cancer cell lines with undetectable expression resulted in reduced viability of cancer cells both in vitro and in vivo demonstrating its tumor suppressive capability. We also found reduced expression, homozygous deletion and aberrant DNA methylation of SOX15 in clinical pancreatic tumor data sets. Furthermore, we deduced a novel role for SOX15 in suppressing the Wnt/b-catenin signaling pathway, which we hypothesize is a pathway through which SOX15 may exert its tumor suppressive effects in pancreatic cancer.	[Thu, K. L.; Becker-Santos, D. D.; Pikor, L. A.; Pusic, A.; Lockwood, W. W.; Lam, W. L.] BC Canc Res Ctr, Vancouver, BC, Canada; [Radulovich, N.; Tsao, M-S] Univ Toronto, Ontario Canc Inst, Princess Margaret Hosp, Univ Hlth Network, Toronto, ON M5S 1A1, Canada; [Radulovich, N.; Tsao, M-S] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	British Columbia Cancer Agency; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto	Lam, WL (corresponding author), BC Canc Res Ctr, Vancouver, BC, Canada.	wanlam@bccrc.ca; Ming.Tsao@uhn.ca	Tsao, Ming-Sound/M-3503-2017; Tsao, Ming Sound/AFQ-7332-2022	Tsao, Ming Sound/0000-0002-9160-5405; Thu, Kelsie/0000-0001-9262-7238	Vanier Canada Graduate Scholarships; University of British Columbia 4YF scholarship; CIHR Jean-Francois Saint Denis Fellowship in Cancer Research; Canadian Cancer Society Research Institute [700809]; Canadian Institutes for Health Research; PMH Foundation; Ontario Ministry of Health and Long Term Care; M Qasim Choksi Chair in Lung Cancer Translational Research	Vanier Canada Graduate Scholarships; University of British Columbia 4YF scholarship; CIHR Jean-Francois Saint Denis Fellowship in Cancer Research(Canadian Institutes of Health Research (CIHR)); Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); PMH Foundation; Ontario Ministry of Health and Long Term Care(Ministry of Health and Long-Term Care, Ontario); M Qasim Choksi Chair in Lung Cancer Translational Research	KLT, NR and LAP are supported by Vanier Canada Graduate Scholarships, DDBS by University of British Columbia 4YF scholarship and WWL by a CIHR Jean-Francois Saint Denis Fellowship in Cancer Research. This work was supported by grants from the Canadian Cancer Society Research Institute (#700809), the Canadian Institutes for Health Research, PMH Foundation and Ontario Ministry of Health and Long Term Care. MST is the M Qasim Choksi Chair in Lung Cancer Translational Research.	Andreeva AV, 2010, GENE CHROMOSOME CANC, V49, P775, DOI 10.1002/gcc.20787; Bachman KE, 1999, CANCER RES, V59, P798; Bardeesy N, 2002, NAT REV CANCER, V2, P897, DOI 10.1038/nrc949; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Beranger F, 2000, J BIOL CHEM, V275, P16103, DOI 10.1074/jbc.275.21.16103; Berger AH, 2011, NATURE, V476, P163, DOI 10.1038/nature10275; Bernard P, 2010, INT J BIOCHEM CELL B, V42, P400, DOI 10.1016/j.biocel.2009.10.017; Bibikova M, 2006, GENOME RES, V16, P383, DOI 10.1101/gr.4410706; Birnbaum DJ, 2011, GENE CHROMOSOME CANC, V50, P456, DOI 10.1002/gcc.20870; Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095; Coe BP, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq548; di Magliano MP, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001155; Dihlmann S, 2005, INT J CANCER, V113, P515, DOI 10.1002/ijc.20609; Drew BA, 2012, BBA-REV CANCER, V1825, P37, DOI 10.1016/j.bbcan.2011.10.002; Du YC, 2009, GASTROENTEROLOGY, V137, P1346, DOI 10.1053/j.gastro.2009.06.041; Dull T, 1998, J VIROL, V72, P8463, DOI 10.1128/JVI.72.11.8463-8471.1998; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Gumz ML, 2007, CLIN CANCER RES, V13, P4740, DOI 10.1158/1078-0432.CCR-07-0143; Gustavsson E, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-187; Harada T, 2008, ONCOGENE, V27, P1951, DOI 10.1038/sj.onc.1210832; Hezel AF, 2006, GENE DEV, V20, P1218, DOI 10.1101/gad.1415606; Hong SM, 2012, CLIN CANCER RES, V18, P700, DOI 10.1158/1078-0432.CCR-11-1718; Ishkanian AS, 2004, NAT GENET, V36, P299, DOI 10.1038/ng1307; Ito M, 2010, INT J BIOCHEM CELL B, V42, P449, DOI 10.1016/j.biocel.2009.10.023; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jia Y, 2010, EPIGENETICS-US, V5, P743, DOI 10.4161/epi.5.8.13104; Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609; Joergensen MT, 2011, PANCREAS, V40, P540, DOI 10.1097/MPA.0b013e3182152fdf; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Khojasteh M, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-274; Klarmann GJ, 2008, EPIGENETICS-US, V3, P59, DOI 10.4161/epi.3.2.5899; Kongkham PN, 2010, ONCOGENE, V29, P3017, DOI 10.1038/onc.2010.32; Kormish JD, 2010, DEV DYNAM, V239, P56, DOI 10.1002/dvdy.22046; Lee HJ, 2004, MOL CELL BIOL, V24, P8428, DOI 10.1128/MCB.24.19.8428-8436.2004; Licchesi JDF, 2008, CARCINOGENESIS, V29, P895, DOI 10.1093/carcin/bgn017; Liu PB, 2006, CANCER RES, V66, P4011, DOI 10.1158/0008-5472.CAN-05-3055; Lochhead PA, 2012, BIOCHEM SOC T, V40, P251, DOI 10.1042/BST20110663; Lockwood WW, 2012, CLIN CANCER RES, V18, P1936, DOI 10.1158/1078-0432.CCR-11-1431; MacGrogan D, 1996, GENOMICS, V35, P55, DOI 10.1006/geno.1996.0322; Mak AB, 2010, MOL CELL PROTEOMICS, V9, P811, DOI 10.1074/mcp.M000002-MCP201; Mann KM, 2012, P NATL ACAD SCI USA, V109, P5934, DOI 10.1073/pnas.1202490109; McCleary-Wheeler AL, 2012, MOL CARCINOGEN, V51, P25, DOI 10.1002/mc.20827; Medina PP, 2009, HUM MOL GENET, V18, P1343, DOI 10.1093/hmg/ddp034; Meeson AP, 2007, EMBO J, V26, P1902, DOI 10.1038/sj.emboj.7601635; Moon Randall T, 2004, Nat Rev Genet, V5, P691, DOI 10.1038/nrg1427; Morris JP, 2010, NAT REV CANCER, V10, P683, DOI 10.1038/nrc2899; Polakis P, 2012, EMBO J, V31, P2737, DOI 10.1038/emboj.2012.126; Qin YR, 2011, CLIN CANCER RES, V17, P46, DOI 10.1158/1078-0432.CCR-10-1155; Radutovich N, 2008, METHOD ENZYMOL, V439, P1, DOI 10.1016/S0076-6879(07)00401-6; Rajan N, 2011, J PATHOL, V224, P309, DOI 10.1002/path.2896; Rubin JS, 2006, FRONT BIOSCI, V11, P2093, DOI 10.2741/1952; Sakai M, 2004, CANCER SCI, V95, P588, DOI 10.1111/j.1349-7006.2004.tb02491.x; Samuel N, 2012, NAT REV GASTRO HEPAT, V9, P77, DOI 10.1038/nrgastro.2011.215; Sato H, 2007, CARCINOGENESIS, V28, P2459, DOI 10.1093/carcin/bgm178; Savage J, 2009, STEM CELLS, V27, P1231, DOI 10.1002/stem.57; Simon R, 2007, CANCER INFORM, V3, P11; Singh P, 2011, PANCREAS, V40, P644, DOI 10.1097/MPA.0b013e31821ff741; Suzuki H, 2008, BRIT J CANCER, V98, P1147, DOI 10.1038/sj.bjc.6604259; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Tan AC, 2009, MOL ONCOL, V3, P425, DOI 10.1016/j.molonc.2009.03.004; Tennis MA, 2012, P AM THORAC SOC, V9, P83; Tennis MA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032921; Thu KL, 2011, J THORAC ONCOL, V6, P1521, DOI 10.1097/JTO.0b013e3182289479; van Noort M, 2002, J BIOL CHEM, V277, P17901, DOI 10.1074/jbc.M111635200; Vincent A, 2011, CLIN CANCER RES, V17, P4341, DOI 10.1158/1078-0432.CCR-10-3431; White BD, 2012, GASTROENTEROLOGY, V142, P219, DOI 10.1053/j.gastro.2011.12.001; Wu J, 2011, P NATL ACAD SCI USA, V108, P21188, DOI 10.1073/pnas.1118046108; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yan HT, 2007, MOL CELLS, V24, P323; Yao H, 2011, EXPERT OPIN THER TAR, V15, P873, DOI 10.1517/14728222.2011.577418; Ye YW, 2011, CANCER LETT, V307, P124, DOI 10.1016/j.canlet.2011.03.024; Zhang W, 2008, CANCER RES, V68, P2764, DOI 10.1158/0008-5472.CAN-07-6349	72	47	48	0	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2014	33	3					279	288		10.1038/onc.2012.595	http://dx.doi.org/10.1038/onc.2012.595			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VR	23318427				2022-12-28	WOS:000330214000002
J	Lu, H; Wang, X; Urvalek, AM; Li, T; Xie, H; Yu, L; Zhao, J				Lu, H.; Wang, X.; Urvalek, A. M.; Li, T.; Xie, H.; Yu, L.; Zhao, J.			Transformation of human ovarian surface epithelial cells by Kruppel-like factor 8	ONCOGENE			English	Article						KLF8; transformation; human ovarian epithelial cells; human ovarian cancer	FOCAL ADHESION KINASE; CANCER-CELLS; MESENCHYMAL TRANSITION; IONIZING-RADIATION; KLF8 TRANSCRIPTION; GENE-EXPRESSION; UP-REGULATION; HUMAN BREAST; ACTIVATION; PROTEIN	We have previously demonstrated that Kruppel-like factor 8 (KLF8) participates in oncogenic transformation of mouse fibroblasts and is highly overexpressed in human ovarian cancer. In this work, we first correlated KLF8 overexpression with the aggressiveness of ovarian patient tumors and then tested if KLF8 could transform human ovarian epithelial cells. Using the immortalized non-tumorigenic human ovarian surface epithelial cell line T80 and retroviral infection, we generated cell lines that constitutively overexpress KLF8 alone or its combination with the known ovarian oncogenes c-Myc, Stat3c and/or Akt and examined the cell lines for anchorage-independent growth and tumorigenesis. The soft agar clonogenic assay showed that T80/KLF8 cells formed significantly more colonies than the mock cells. Interestingly, the cells expressing both KLF8 and c-Myc formed the largest amounts of colonies, greater than the sum of colonies formed by the cells expressing KLF8 and c-Myc alone. These results suggested that KLF8 might be a weak oncogene that works cooperatively with c-Myc to transform ovarian cells. Surprisingly, overexpression of KLF8 alone was sufficient to induce tumorigenesis in nude mice resulting in short lifespan irrespective of whether the T80/KLF8 cells were injected subcutaneously, intraperitoneally or orthotopically into the ovarian bursa. Histopathological studies confirmed that the T80/KLF8 tumors were characteristic of human serous ovarian carcinomas. Comparative expression profiling and functional studies identified the cell cycle regulators cyclin D1 and USP44 as primary KLF8 targets and effectors for the T80 transformation. Overall, we identified KLF8 overexpression as an important factor in human ovarian carcinoma pathogenesis.	[Lu, H.; Wang, X.; Urvalek, A. M.; Li, T.; Yu, L.; Zhao, J.] Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, Orlando, FL 32827 USA; [Xie, H.] Florida Hosp, Translat Res Inst Metab & Diabet, Orlando, FL USA	State University System of Florida; University of Central Florida; Adventist Health Services; AdventHealth	Zhao, J (corresponding author), Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, 6900 Lake Nona Blvd, Orlando, FL 32827 USA.	Jihe.Zhao@ucf.edu	Li, Tianshu/L-6426-2014	Li, Tianshu/0000-0002-9972-4644	NCI [CA132977]; Susan G. Komen for Cure Breast Cancer Foundation [KG090444, KG080616]; American Cancer Society [RSG CCG-111381]; NATIONAL CANCER INSTITUTE [R01CA132977] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan G. Komen for Cure Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Alexander Yu Nikitin of Cornell University for helping with the intrabursal implantation techniques. We also thank all the members of Zhao lab for critical discussions and helpful comments. This work was supported by grants from NCI (CA132977), Susan G. Komen for Cure Breast Cancer Foundation (KG090444 and KG080616) and American Cancer Society (RSG CCG-111381) to JZ.	Cheng JQ, 2002, DRUG RESIST UPDATE, V5, P131, DOI 10.1016/S1368-7646(02)00003-1; CHENG JQ, 1992, P NATL ACAD SCI USA, V89, P9267, DOI 10.1073/pnas.89.19.9267; Connolly DC, 2003, CANCER RES, V63, P1389; Cox BD, 2006, J CELL BIOCHEM, V99, P36, DOI 10.1002/jcb.20956; Eaton SA, 2008, J BIOL CHEM, V283, P26937, DOI 10.1074/jbc.M804831200; Evans PM, 2008, ACTA BIOCH BIOPH SIN, V40, P554, DOI 10.1111/j.1745-7270.2008.00439.x; Flesken-Nikitin A, 2003, CANCER RES, V63, P3459; Fu WJ, 2010, J CANCER RES CLIN, V136, P1255, DOI 10.1007/s00432-010-0776-0; Gumireddy K, 2009, NAT CELL BIOL, V11, P1297, DOI 10.1038/ncb1974; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Johnson NC, 2004, EXP CELL RES, V298, P9, DOI 10.1016/j.yexcr.2004.04.003; Kang XN, 2010, J CANCER RES CLIN, V136, P1151, DOI 10.1007/s00432-010-0762-6; Lahiri SK, 2012, AM J TRANSL RES, V4, P357; Li JC, 2010, GASTROENTEROLOGY, V139, P2146, DOI 10.1053/j.gastro.2010.08.004; Liu AX, 1998, CANCER RES, V58, P2973; Liu JS, 2004, CANCER RES, V64, P1655, DOI 10.1158/0008-5472.CAN-03-3380; Liu LL, 2012, TUMOR BIOL, V33, P53, DOI 10.1007/s13277-011-0245-7; Lu H, 2011, J BIOL CHEM, V286, P20335, DOI 10.1074/jbc.M110.215632; McConnell BB, 2010, PHYSIOL REV, V90, P1337, DOI 10.1152/physrev.00058.2009; Mehta TS, 2009, CELL RES, V19, P1098, DOI 10.1038/cr.2009.64; Orsulic S, 2002, CANCER CELL, V1, P53, DOI 10.1016/S1535-6108(01)00002-2; Rosen DG, 2006, METHOD ENZYMOL, V407, P660, DOI 10.1016/S0076-6879(05)07052-7; Schnell O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030429; Shan WW, 2009, CELL CYCLE, V8, P731, DOI 10.4161/cc.8.5.7848; Siegel PM, 2003, J BIOL CHEM, V278, P35444, DOI 10.1074/jbc.M301413200; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Stegmeier F, 2007, NATURE, V446, P876, DOI 10.1038/nature05694; Suresh B, 2010, CELL BIOL INT, V34, P799, DOI 10.1042/CBI20090144; Urvalek AM, 2011, AM J TRANSL RES, V3, P121; Urvalek AM, 2010, CELL CYCLE, V9, P601, DOI 10.4161/cc.9.3.10606; van Vliet J, 2000, NUCLEIC ACIDS RES, V28, P1955; Wan WF, 2012, MOL MED REP, V5, P347, DOI 10.3892/mmr.2011.669; Wang X, 2007, ONCOGENE, V26, P456, DOI 10.1038/sj.onc.1209796; Wang X, 2011, ONCOGENE, V30, P1901, DOI 10.1038/onc.2010.563; Wang XH, 2008, J BIOL CHEM, V283, P13934, DOI 10.1074/jbc.M709300200; Wang XH, 2007, CANCER RES, V67, P7184, DOI 10.1158/0008-5472.CAN-06-4729; Wei HJ, 2006, J BIOL CHEM, V281, P16664, DOI 10.1074/jbc.M513135200; Yang F, 2011, MODERN PATHOL, V24, P836, DOI 10.1038/modpathol.2011.44; Yang G, 2003, ONCOGENE, V22, P5694, DOI 10.1038/sj.onc.1206858; Yang G, 2010, CLIN CANCER RES, V16, P3171, DOI 10.1158/1078-0432.CCR-09-3171; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488; Yang H, 2006, INT J CANCER, V119, P2304, DOI 10.1002/ijc.22154; Yang T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039668; Yuan ZQ, 2003, J BIOL CHEM, V278, P23432, DOI 10.1074/jbc.M302674200; Yuan ZQ, 2000, ONCOGENE, V19, P2324, DOI 10.1038/sj.onc.1203598; Zhang P, 2005, BLOOD CELL MOL DIS, V35, P227, DOI 10.1016/j.bcmd.2005.04.009; Zhang XL, 2012, P NATL ACAD SCI USA, V109, P9623, DOI 10.1073/pnas.1121606109; Zhao JH, 2003, MOL CELL, V11, P1503, DOI 10.1016/S1097-2765(03)00179-5; Zhao J, 2009, CANCER METAST REV, V28, P35, DOI 10.1007/s10555-008-9165-4; Zheng JF, 2010, CELL CYCLE, V9, P140, DOI 10.4161/cc.9.1.10264; Zhou CY, 2005, BIOCHEM BIOPH RES CO, V336, P952, DOI 10.1016/j.bbrc.2005.08.197; Zhou CY, 2003, ONCOGENE, V22, P2396, DOI 10.1038/sj.onc.1206319; Zhou CY, 2003, BIOCHEM BIOPH RES CO, V303, P130, DOI 10.1016/S0006-291X(03)00318-8	53	27	28	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2014	33	1					10	18		10.1038/onc.2012.545	http://dx.doi.org/10.1038/onc.2012.545			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	282YU	23222713	Green Accepted			2022-12-28	WOS:000329212000002
J	Chow, JPH; Poon, RYC				Chow, J. P. H.; Poon, R. Y. C.			The CDK1 inhibitory kinase MYT1 in DNA damage checkpoint recovery	ONCOGENE			English	Article						cell cycle; checkpoint; ionizing radiation	CELL-CYCLE; SOMATIC WEE1; PHOSPHORYLATION; CDC2; INACTIVATION; CHK1; ACTIVATION; ABROGATION; COMPLEXES; CLEAVAGE	Inhibition of cyclin-dependent kinase 1 (CDK1) by phosphorylation is a key regulatory mechanism for both the unperturbed cell cycle and the DNA damage checkpoint. Although both WEE1 and MYT1 can phosphorylate CDK1, little is known about the contribution of MYT1. We found that in contrast to WEE1, MYT1 was not important for the normal cell cycle or checkpoint activation. Time-lapse microscopy indicated that MYT1 did, however, have a rate-determining role during checkpoint recovery. Depletion of MYT1 induced precocious mitotic entry when the checkpoint was abrogated with inhibitors of either CHK1 or WEE1, indicating that MYT1 contributes to checkpoint recovery independently of WEE1. The acceleration of checkpoint recovery in MYT1-depleted cells was due to a lowering of threshold for CDK1 activation. The kinase activity of MYT1 was high during checkpoint activation and reduced during checkpoint recovery. Importantly, although depletion of MYT1 alone did not affect long-term cell growth, it potentiated with DNA damage to inhibit cell growth in clonogenic survival and tumor xenograft models. These results reveal the functions of MYT1 in checkpoint recovery and highlight the potential of MYT1 as a target for anti-cancer therapies.	[Poon, R. Y. C.] Hong Kong Univ Sci & Technol, Div Life Sci, Kowloon, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Ctr Canc Res, Kowloon, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology	Poon, RYC (corresponding author), Hong Kong Univ Sci & Technol, Div Life Sci, Kowloon, Hong Kong, Peoples R China.	rycpoon@ust.hk		Poon, Randy/0000-0001-5571-6231	 [AOE-MG/M-08/06];  [HKU7/CRG/09]	; 	We thank Helen Piwnica-Worms and Katsumi Yamashita for generous gifts of reagents. This work was supported in part by grants AOE-MG/M-08/06 and HKU7/CRG/09 to RYCP.	Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300; Chan YW, 2009, ONCOGENE, V28, P170, DOI 10.1038/onc.2008.369; Chan YW, 2008, J BIOL CHEM, V283, P15716, DOI 10.1074/jbc.M800629200; Chan YW, 2008, CELL CYCLE, V7, P1449, DOI 10.4161/cc.7.10.5880; Chen Y, 2008, FRONT BIOSCI-LANDMRK, V13, P5016; Chen Y, 2012, MOL CANCER RES, V10, P626, DOI 10.1158/1541-7786.MCR-11-0491; Chow JPH, 2011, MOL CELL BIOL, V31, P1478, DOI 10.1128/MCB.00891-10; Chow JPH, 2003, J BIOL CHEM, V278, P40815, DOI 10.1074/jbc.M306683200; Fung TK, 2005, SEMIN CELL DEV BIOL, V16, P335, DOI 10.1016/j.semcdb.2005.02.014; Jin P, 1996, J CELL BIOL, V134, P963, DOI 10.1083/jcb.134.4.963; Karisson-Rosenthal C, 2006, TRENDS CELL BIOL, V16, P285, DOI 10.1016/j.tcb.2006.04.002; Katayama K, 2005, MOL CELL BIOL, V25, P5725, DOI 10.1128/MCB.25.13.5725-5737.2005; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; Liu F, 1997, MOL CELL BIOL, V17, P571, DOI 10.1128/MCB.17.2.571; Ma HT, 2009, MOL CELL BIOL, V29, P6500, DOI 10.1128/MCB.00669-09; Mizuarai S, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-34; Nakajima H, 2003, J BIOL CHEM, V278, P25277, DOI 10.1074/jbc.C300126200; Nakajima H, 2008, J CELL BIOL, V181, P89, DOI 10.1083/jcb.200708176; Nakajo N, 2000, GENE DEV, V14, P328; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; Okumura E, 2002, NAT CELL BIOL, V4, P111, DOI 10.1038/ncb741; On KF, 2011, MOL CANCER THER, V10, P784, DOI 10.1158/1535-7163.MCT-10-0809; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Ruiz EJ, 2008, MOL CELL, V32, P210, DOI 10.1016/j.molcel.2008.08.029; Siu WY, 1999, EXP CELL RES, V250, P131, DOI 10.1006/excr.1999.4551; Stumpff J, 2004, CURR BIOL, V14, P2143, DOI 10.1016/j.cub.2004.11.050; TOMAYKO MM, 1989, CANCER CHEMOTH PHARM, V24, P148, DOI 10.1007/BF00300234; van Vugt MATM, 2005, ONCOGENE, V24, P2844, DOI 10.1038/sj.onc.1208617; van Vugt MATM, 2004, MOL CELL, V15, P799, DOI 10.1016/j.molcel.2004.07.015; Wang YL, 2004, CANCER BIOL THER, V3, P305, DOI 10.4161/cbt.3.3.697; Watanabe N, 2004, P NATL ACAD SCI USA, V101, P4419, DOI 10.1073/pnas.0307700101; Watanabe N, 2005, P NATL ACAD SCI USA, V102, P11663, DOI 10.1073/pnas.0500410102; Wells NJ, 1999, J CELL SCI, V112, P3361; Yam CH, 2000, J BIOL CHEM, V275, P3158, DOI 10.1074/jbc.275.5.3158; Yam CH, 2001, P NATL ACAD SCI USA, V98, P497, DOI 10.1073/pnas.240461397	36	41	41	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2013	32	40					4778	4788		10.1038/onc.2012.504	http://dx.doi.org/10.1038/onc.2012.504			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229NW	23146904				2022-12-28	WOS:000325274700006
J	Monteiro, LJ; Khongkow, P; Kongsema, M; Morris, JR; Man, C; Weekes, D; Koo, CY; Gomes, AR; Pinto, PH; Varghese, V; Kenny, LM; Coombes, RC; Freire, R; Medema, RH; Lam, EWF				Monteiro, L. J.; Khongkow, P.; Kongsema, M.; Morris, J. R.; Man, C.; Weekes, D.; Koo, C-Y; Gomes, A. R.; Pinto, P. H.; Varghese, V.; Kenny, L. M.; Coombes, R. Charles; Freire, R.; Medema, R. H.; Lam, E. W-F			The Forkhead Box M1 protein regulates BRIP1 expression and DNA damage repair in epirubicin treatment	ONCOGENE			English	Article						FOXM1; BRIP1; DNA damage; epirubicin; resistance; breast cancer	BREAST-CANCER CELLS; TRANSCRIPTION FACTOR FOXM1; DOUBLE-STRAND BREAKS; HOMOLOGOUS RECOMBINATION; MAMMALIAN-CELLS; BINDING DOMAIN; RESISTANCE; BACH1; PROGRESSION; GENE	FOXM1 is implicated in genotoxic drug resistance but its role and mechanism of action remain unclear. Here, we establish that gamma H2AX foci, indicative of DNA double-strand breaks (DSBs), accumulate in a time-dependent manner in the drug-sensitive MCF-7 cells but not in the resistant counterparts in response to epirubicin. We find that FOXM1 expression is associated with epirubicin sensitivity and DSB repair. Ectopic expression of FOXM1 can increase cell viability and abrogate DSBs sustained by MCF-7 cells following epirubicin, owing to an enhancement in repair efficiency. Conversely, alkaline comet and gamma H2AX foci formation assays show that Foxm1-null cells are hypersensitive to DNA damage, epirubicin and gamma-irradiation. Furthermore, we find that FOXM1 is required for DNA repair by homologous recombination (HR) but not non-homologous end joining (NHEJ), using HeLa cell lines harbouring an integrated direct repeat green fluorescent protein reporter for DSB repair. We also identify BRIP1 as a direct transcription target of FOXM1 by promoter analysis and chromatin-immunoprecipitation assay. In agreement, depletion of FOXM1 expression by small interfering RNA downregulates BRIP1 expression at the protein and mRNA levels in MCF-7 and the epirubicin-resistant MCF-7 Epi(R) cells. Remarkably, the requirement for FOXM1 for DSB repair can be circumvented by reintroduction of BRIP1, suggesting that BRIP1 is an important target of FOXM1 in DSB repair. Indeed, like FOXM1, BRIP1 is needed for HR. These data suggest that FOXM1 regulates BRIP1 expression to modulate epirubicin-induced DNA damage repair and drug resistance.	[Monteiro, L. J.; Khongkow, P.; Kongsema, M.; Koo, C-Y; Gomes, A. R.; Pinto, P. H.; Varghese, V.; Kenny, L. M.; Coombes, R. Charles; Lam, E. W-F] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, London W12 0NN, England; [Morris, J. R.] Univ Birmingham, Coll Med & Dent Sci, Sch Canc Sci, Birmingham, W Midlands, England; [Man, C.] Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, Kowloon, Hong Kong, Peoples R China; [Weekes, D.] Kings Coll London, Guys Hosp, Dept Med & Mol Genet, London SE1 9RT, England; [Freire, R.] Hosp Univ Canarias, Unidad Invest, Inst Tecnol Biomed, Tenerife, Spain; [Medema, R. H.] Netherlands Canc Inst, Div Cell Biol, Amsterdam, CX, Netherlands	Imperial College London; University of Birmingham; Hong Kong Polytechnic University; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Universidad de la Laguna; Netherlands Cancer Institute	Lam, EWF (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Room 134,1st Floor,Hammersmith Hosp Campus,Du Can, London W12 0NN, England.	eric.lam@imperial.ac.uk	Monteiro, Lara J/AAU-8518-2020; Morris, Joanna/AAK-3388-2021; Kongsema, Mesayamas/H-3063-2017; Lam, Eric W-F/AAW-8566-2020; Medema, Rene H/E-2981-2013; Freire, Raimundo/Q-7660-2019	Lam, Eric W-F/0000-0003-1274-3576; Freire, Raimundo/0000-0003-4473-8894; Weekes, Daniel/0000-0001-8083-7617; Morris, Joanna/0000-0001-9762-8133; Medema, Rene/0000-0002-6754-0381; Khongkow, Pasarat/0000-0003-3068-2412; Kongsema, Mesayamas/0000-0001-7146-9349; Coombes, Raoul Charles/0000-0002-4811-1100; Koo, Chuay Yeng/0000-0002-9495-0554	Cancer Research UK; Breast Cancer Campaign; Fundacao para a Ciencia e a Tecnologia; Royal Thai Government Scholarships; Imperial College NHS Trust; Cancer Research UK [12011] Funding Source: researchfish; National Institute for Health Research [NIHR/CS/009/009] Funding Source: researchfish; Breast Cancer Campaign [2012MayPR070, 2012NovPhD016] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Breast Cancer Campaign; Fundacao para a Ciencia e a Tecnologia(Portuguese Foundation for Science and TechnologyEuropean Commission); Royal Thai Government Scholarships; Imperial College NHS Trust; Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR)); Breast Cancer Campaign	EW-FL, ARG and RCC were supported by grants from Cancer Research UK, EW-FL and C-YK by grants from Breast Cancer Campaign and Imperial College NHS Trust, LJM grants from Fundacao para a Ciencia e a Tecnologia, and PK and MK from the Royal Thai Government Scholarships. We also thank Dr Keng Heng for help with the microscopy and flow cytometry work.	Ahmad A, 2010, BREAST CANCER RES TR, V122, P337, DOI 10.1007/s10549-009-0572-1; Alvarez RH, 2010, J CLIN ONCOL, V28, P3366, DOI 10.1200/JCO.2009.25.4011; Bennardo N, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000110; Cantor S, 2004, P NATL ACAD SCI USA, V101, P2357, DOI 10.1073/pnas.0308717101; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Carr JR, 2010, CANCER RES, V70, P5054, DOI 10.1158/0008-5472.CAN-10-0545; Dai B, 2007, ONCOGENE, V26, P6212, DOI 10.1038/sj.onc.1210443; de Olano N, 2012, MOL CANCER RES, V10, P1189, DOI 10.1158/1541-7786.MCR-11-0559; Delacote F, 2002, NUCLEIC ACIDS RES, V30, P3454, DOI 10.1093/nar/gkf452; Dohrn L, 2012, BIOCHEM J, V441, P919, DOI 10.1042/BJ20110314; Fu Z, 2008, NAT CELL BIOL, V10, P1076, DOI 10.1038/ncb1767; Garinis GA, 2005, EMBO J, V24, P3952, DOI 10.1038/sj.emboj.7600849; Gong ZH, 2010, MOL CELL, V37, P438, DOI 10.1016/j.molcel.2010.01.002; Hegde NS, 2011, NAT CHEM, V3, P725, DOI [10.1038/NCHEM.1114, 10.1038/nchem.1114]; Karadedou CT, 2012, ONCOGENE, V31, P1845, DOI 10.1038/onc.2011.368; Koo CY, 2012, BBA-GENE REGUL MECH, V1819, P28, DOI 10.1016/j.bbagrm.2011.09.004; Korver W, 1997, GENOMICS, V46, P435, DOI 10.1006/geno.1997.5065; Kruse V, 2011, ACTA CLIN BELG, V66, P2, DOI 10.1179/ACB.66.1.2062507; Kwok JMM, 2010, MOL CANCER RES, V8, P24, DOI 10.1158/1541-7786.MCR-09-0432; Kwok JMM, 2008, MOL CANCER THER, V7, P2022, DOI 10.1158/1535-7163.MCT-08-0188; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Li Q, 2009, CANCER RES, V69, P3501, DOI 10.1158/0008-5472.CAN-08-3045; Lin SX, 2010, NAT REV ENDOCRINOL, V6, P485, DOI 10.1038/nrendo.2010.92; Litman R, 2005, CANCER CELL, V8, P255, DOI 10.1016/j.ccr.2005.08.004; Madureira PA, 2006, J BIOL CHEM, V281, P25167, DOI 10.1074/jbc.M603906200; McGovern UB, 2009, MOL CANCER THER, V8, P582, DOI 10.1158/1535-7163.MCT-08-0805; Millour J, 2010, ONCOGENE, V29, P2983, DOI 10.1038/onc.2010.47; Millour J, 2011, MOL CANCER THER, V10, P1046, DOI 10.1158/1535-7163.MCT-11-0024; Minotti G, 2004, PHARMACOL REV, V56, P185, DOI 10.1124/pr.56.2.6; Myatt SS, 2008, NAT REV CANCER, V8, P244, DOI 10.1038/nrc2223-c2; Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223; Nowak DE, 2005, BIOTECHNIQUES, V39, P715, DOI 10.2144/000112014; Palmieri C, 2010, NAT REV CLIN ONCOL, V7, P561, DOI 10.1038/nrclinonc.2010.122; Park HJ, 2008, MOL CELL BIOL, V28, P5162, DOI 10.1128/MCB.00387-08; Park YY, 2012, CARCINOGENESIS, V33, P1843, DOI 10.1093/carcin/bgs167; Peck B, 2010, MOL CANCER THER, V9, P844, DOI 10.1158/1535-7163.MCT-09-0971; Raguz S, 2008, BRIT J CANCER, V99, P387, DOI 10.1038/sj.bjc.6604510; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Stearns V, 2004, PHARMACOGENOMICS J, V4, P143, DOI 10.1038/sj.tpj.6500242; Tan YJ, 2007, MOL CELL BIOL, V27, P1007, DOI 10.1128/MCB.01068-06; TEWEY KM, 1984, SCIENCE, V226, P466, DOI 10.1126/science.6093249; Turnbull C, 2008, ANNU REV GENOM HUM G, V9, P321, DOI 10.1146/annurev.genom.9.081307.164339; Weinstock David M, 2007, Nat Cell Biol, V9, P978; Weinstock DM, 2006, METHOD ENZYMOL, V409, P524, DOI 10.1016/S0076-6879(05)09031-2; Xie J, 2010, ONCOGENE, V29, P2499, DOI 10.1038/onc.2010.18; Yao KM, 1997, J BIOL CHEM, V272, P19827, DOI 10.1074/jbc.272.32.19827; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Zelnak A, 2010, BREAST J, V16, P309, DOI 10.1111/j.1524-4741.2010.00911.x; Zhang HJ, 2006, MOL ENDOCRINOL, V20, P1853, DOI 10.1210/me.2006-0056	50	65	68	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2013	32	39					4634	4645		10.1038/onc.2012.491	http://dx.doi.org/10.1038/onc.2012.491			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226YD	23108394	Green Accepted			2022-12-28	WOS:000325072200005
J	Peng, H; Liu, J; Sun, Q; Chen, R; Wang, Y; Duan, J; Li, C; Li, B; Jing, Y; Chen, X; Mao, Q; Xu, KF; Walker, CL; Li, J; Wang, J; Zhang, H				Peng, H.; Liu, J.; Sun, Q.; Chen, R.; Wang, Y.; Duan, J.; Li, C.; Li, B.; Jing, Y.; Chen, X.; Mao, Q.; Xu, K-F; Walker, C. L.; Li, J.; Wang, J.; Zhang, H.			mTORC1 enhancement of STIM1-mediated store-operated Ca2+ entry constrains tuberous sclerosis complex-related tumor development	ONCOGENE			English	Article						TSC; mTORC1; STIM1; calcium; tumorigenesis	MAMMALIAN TARGET; TRANSCRIPTIONAL CONTROL; CELL PROLIFERATION; MOUSE MODELS; IFN-GAMMA; CANCER; RAPAMYCIN; CALCIUM; GROWTH; ACTIVATION	The protein complex of tuberous sclerosis complex (TSC) 1 and TSC2 tumor suppressors is a key negative regulator of mammalian target of rapamycin (mTOR). Hyperactive mTOR signaling due to the loss-of-function of mutations in either TSC1 or TSC2 gene causes TSC, an autosomal dominant disorder featured with benign tumors in multiple organs. As the ubiquitous second messenger calcium (Ca2+) regulates various cellular processes involved in tumorigenesis, we explored the potential role of mTOR in modulation of cellular Ca2+ homeostasis, and in turn the effect of Ca2+ signaling in TSC-related tumor development. We found that loss of Tsc2 potentiated store-operated Ca2+ entry (SOCE) in an mTOR complex 1 (mTORC1)-dependent way. The endoplasmic reticulum Ca2+ sensor, stromal interaction molecule 1 (STIM1), was upregulated in Tsc2-deficient cells, and was suppressed by mTORC1 inhibitor rapamycin. In addition, SOCE repressed AKT1 phosphorylation. Blocking SOCE either by depleting STIM1 or ectopically expressing dominant-negative Orai1 accelerated TSC-related tumor development, likely because of restored AKT1 activity and enhanced tumor angiogenesis. Our data, therefore, suggest that mTORC1 enhancement of store-operated Ca2+ signaling hinders TSC-related tumor growth through suppression of AKT1 signaling. The augmented SOCE by hyperactive mTORC1-STIM1 cascade may contribute to the benign nature of TSC-related tumors. Application of SOCE agonists could thus be a contraindication for TSC patients. In contrast, SOCE agonists should attenuate mTOR inhibitors-mediated AKT reactivation and consequently potentiate their efficacy in the treatment of the patients with TSC.	[Peng, H.; Chen, R.; Wang, Y.; Duan, J.; Li, C.; Li, B.; Jing, Y.; Chen, X.; Zhang, H.] Chinese Acad Med Sci, Inst Basic Med Sci, State Key Lab Med Mol Biol, Dept Physiol & Pathophysiol, Beijing 100005, Peoples R China; [Peng, H.; Chen, R.; Wang, Y.; Duan, J.; Li, C.; Li, B.; Jing, Y.; Chen, X.; Zhang, H.] Chinese Acad Med Sci, Sch Basic Med, Beijing 100005, Peoples R China; [Peng, H.; Chen, R.; Wang, Y.; Duan, J.; Li, C.; Li, B.; Jing, Y.; Chen, X.; Zhang, H.] Peking Union Med Coll, Beijing 100005, Peoples R China; [Liu, J.; Wang, J.] Capital Med Univ, Dept Physiol, Beijing 100069, Peoples R China; [Sun, Q.] Tianjin Med Univ, Tianjin Canc Inst & Hosp, Dept Immunol, Tianjin, Peoples R China; [Mao, Q.] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Urol, Beijing 100005, Peoples R China; [Xu, K-F] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Resp Med, Beijing 100005, Peoples R China; [Walker, C. L.] Texas A&M Hlth Sci Ctr, Ctr Translat Canc Res, Inst Biosci & Technol, Houston, TX USA; [Li, J.] Huazhong Univ Sci & Technol, Inst Cardiovasc Dis, Union Hosp, Tongji Med Coll,Dept Cardiol, Wuhan 430074, Peoples R China; [Zhang, H.] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Beijing 100005, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Capital Medical University; Tianjin Medical University; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center; Huazhong University of Science & Technology; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College Hospital	Wang, J (corresponding author), Capital Med Univ, Sch Basic Med Sci, Dept Physiol, 10 Xitoutiao, Beijing 100069, Peoples R China.	wang_jun@ccmu.edu.cn; hbzhang@ibms.pumc.edu.cn	Peng, Haiyong/S-8045-2016; Xu, Kai-Feng/AAO-2445-2020		National Basic Research Program of China 973 Program [2009CB522107, 2009CB522203]; National Natural Science Foundation of China [30971503, 81130085]; Ministry of Education of China 111 Project [B08007]; NATIONAL CANCER INSTITUTE [R01CA143811] Funding Source: NIH RePORTER	National Basic Research Program of China 973 Program(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Education of China 111 Project; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The mouse kidney tumor tissues were kindly provided by David J Kwiatkowski, Brigham and Women's Hospital. This work was supported by the National Basic Research Program of China 973 Program Grant (2009CB522107 and 2009CB522203), the National Natural Science Foundation of China Grants (30971503 and 81130085), and the Ministry of Education of China 111 Project (B08007).	Alessi DR, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.267pe27; Bissler JJ, 2008, NEW ENGL J MED, V358, P140, DOI 10.1056/NEJMoa063564; Chen YF, 2011, P NATL ACAD SCI USA, V108, P15225, DOI 10.1073/pnas.1103315108; Choo AY, 2009, CELL CYCLE, V8, P567, DOI 10.4161/cc.8.4.7659; Clapham DE, 2007, CELL, V131, P1047, DOI 10.1016/j.cell.2007.11.028; Crino PB, 2006, NEW ENGL J MED, V355, P1345, DOI 10.1056/NEJMra055323; Davies DM, 2011, CLIN CANCER RES, V17, P4071, DOI 10.1158/1078-0432.CCR-11-0445; Derler I, 2012, ADV EXP MED BIOL, V740, P383, DOI 10.1007/978-94-007-2888-2_16; El Boustany C, 2008, HEPATOLOGY, V47, P2068, DOI 10.1002/hep.22263; El-Hashemite N, 2004, CANCER RES, V64, P3436, DOI 10.1158/0008-5472.CAN-03-3609; El-Hashemite N, 2003, CANCER RES, V63, P5173; Engh A, 2012, FRONT BIOSCI-LANDMRK, V17, P1613, DOI 10.2741/4007; Feng MY, 2010, CELL, V143, P84, DOI 10.1016/j.cell.2010.08.040; Feske S, 2010, CLIN IMMUNOL, V135, P169, DOI 10.1016/j.clim.2010.01.011; Feske S, 2010, PFLUG ARCH EUR J PHY, V460, P417, DOI 10.1007/s00424-009-0777-5; Flourakis M, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.52; Gilio K, 2010, J BIOL CHEM, V285, P23629, DOI 10.1074/jbc.M110.108696; Gough NR, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003044; Grosse J, 2007, J CLIN INVEST, V117, P3540, DOI 10.1172/JCI32312; Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008; Harrington LS, 2005, TRENDS BIOCHEM SCI, V30, P35, DOI 10.1016/j.tibs.2004.11.003; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; HOWE SR, 1995, AM J PATHOL, V146, P1568; Hsu PP, 2011, SCIENCE, V332, P1317, DOI 10.1126/science.1199498; Huang GN, 2006, NAT CELL BIOL, V8, P1003, DOI 10.1038/ncb1454; Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152; KOBAYASHI T, 1995, NAT GENET, V9, P70, DOI 10.1038/ng0195-70; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lee L, 2005, GENE CHROMOSOME CANC, V42, P213, DOI 10.1002/gcc.20118; Lewis RS, 2007, NATURE, V446, P284, DOI 10.1038/nature05637; Ma JH, 2010, J CLIN INVEST, V120, P103, DOI 10.1172/JCI37964; Monteith GR, 2007, NAT REV CANCER, V7, P519, DOI 10.1038/nrc2171; Ogawa A, 2012, AM J PHYSIOL-CELL PH, V302, pC405, DOI 10.1152/ajpcell.00337.2011; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Pollizzi K, 2009, HUM MOL GENET, V18, P2378, DOI 10.1093/hmg/ddp176; Roczniak-Ferguson A, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002790; Roderick HL, 2008, NAT REV CANCER, V8, P361, DOI 10.1038/nrc2374; Roskoski R, 2007, CRIT REV ONCOL HEMAT, V62, P179, DOI 10.1016/j.critrevonc.2007.01.006; Sabbioni S, 1997, CANCER RES, V57, P4493; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; Sun QA, 2011, P NATL ACAD SCI USA, V108, P4129, DOI 10.1073/pnas.1014769108; Suyama E, 2004, J BIOL CHEM, V279, P38083, DOI 10.1074/jbc.C400313200; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Vig M, 2006, CURR BIOL, V16, P2073, DOI 10.1016/j.cub.2006.08.085; Yang Q, 2007, CELL RES, V17, P666, DOI 10.1038/cr.2007.64; Yang SY, 2009, CANCER CELL, V15, P124, DOI 10.1016/j.ccr.2008.12.019; Yecies JL, 2011, CANCER RES, V71, P2815, DOI 10.1158/0008-5472.CAN-10-4158; Yu YH, 2011, SCIENCE, V332, P1322, DOI 10.1126/science.1199484; Zhang HB, 2003, J CLIN INVEST, V112, P1223, DOI 10.1172/JCI200317222; Zhang HB, 2007, J CLIN INVEST, V117, P730, DOI 10.1172/JCI28984	50	30	30	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2013	32	39					4702	4711		10.1038/onc.2012.481	http://dx.doi.org/10.1038/onc.2012.481			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226YD	23108404	Green Accepted			2022-12-28	WOS:000325072200012
J	Amato, R; Scumaci, D; D'Antona, L; Iuliano, R; Menniti, M; Di Sanzo, M; Faniello, MC; Colao, E; Malatesta, P; Zingone, A; Agosti, V; Costanzo, FS; Mileo, AM; Paggi, MG; Lang, F; Cuda, G; Lavia, P; Perrotti, N				Amato, R.; Scumaci, D.; D'Antona, L.; Iuliano, R.; Menniti, M.; Di Sanzo, M.; Faniello, M. C.; Colao, E.; Malatesta, P.; Zingone, A.; Agosti, V.; Costanzo, F. S.; Mileo, A. M.; Paggi, M. G.; Lang, F.; Cuda, G.; Lavia, P.; Perrotti, N.			Sgk1 enhances RANBP1 transcript levels and decreases taxol sensitivity in RKO colon carcinoma cells	ONCOGENE			English	Article						Sgk1; RANBP1; taxol sensitivity; mitotic microtubule stabilization	INDUCIBLE PROTEIN-KINASE; BINDING PROTEIN-1; DOWN-REGULATION; CANCER-CELLS; SERUM; ACTIVATION; PHOSPHORYLATION; IDENTIFICATION; COORDINATION; EXPRESSION	The serum- and glucocorticoid-regulated kinase (Sgk1) is essential for hormonal regulation of epithelial sodium channel-mediated sodium transport and is involved in the transduction of growth factor-dependent cell survival and proliferation signals. Growing evidence now points to Sgk1 as a key element in the development and/or progression of human cancer. To gain insight into the mechanisms through which Sgk1 regulates cell proliferation, we adopted a proteomic approach to identify up- or downregulated proteins after Sgk1-specific RNA silencing. Among several proteins, the abundance of which was found to be up- or downregulated upon Sgk1 silencing, we focused our attention of RAN-binding protein 1 (RANBP1), a major effector of the GTPase RAN. We report that Sgk1-dependent regulation of RANBP1 has functional consequences on both mitotic microtubule activity and taxol sensitivity of cancer cells.	[Amato, R.; D'Antona, L.; Menniti, M.; Perrotti, N.] Magna Graecia Univ Catanzaro, Dept Human Hlth, Catanzaro, Italy; [Scumaci, D.; Iuliano, R.; Di Sanzo, M.; Faniello, M. C.; Agosti, V.; Costanzo, F. S.; Cuda, G.] Magna Graecia Univ Catanzaro, Dept Expt & Clin Med, Catanzaro, Italy; [Iuliano, R.; Colao, E.; Malatesta, P.; Perrotti, N.] Univ Hosp, Unit Med Genet & Pathol, Policlin Mater Domini, Catanzaro, Italy; [Zingone, A.] NCI, Multiple Myeloma Sect, Metab Branch, Ctr Canc Res,NIH, Bethesda, MD 20892 USA; [Mileo, A. M.; Paggi, M. G.] Natl Canc Inst Regina Elena, Dept Dev Therapeut Programs, Rome, Italy; [Lang, F.] Univ Tubingen, Dept Physiol, Tubingen, Germany; [Lavia, P.] Univ Roma La Sapienza, CNR, IBPM Inst Mol Biol & Pathol, I-00185 Rome, Italy	Magna Graecia University of Catanzaro; Magna Graecia University of Catanzaro; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Eberhard Karls University of Tubingen; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR); Sapienza University Rome	Lavia, P (corresponding author), Univ Roma La Sapienza, CNR, IBPM Inst Mol Biol & Pathol, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	patrizia.lavia@uniroma1.it; perrotti@unicz.it	Scumaci, Domenica/AAH-1493-2019; Cuda, Giovanni/AAC-2821-2019; Paggi, Marco G./K-3494-2018; Mileo, Anna Maria/J-3667-2016; Lavia, Patrizia/AAL-3982-2021; Costanzo, Francesco Saverio/K-3168-2018; Cuda, Giovanni/F-5359-2012; Lavia, Patrizia/J-5793-2019	Cuda, Giovanni/0000-0001-6313-1866; Mileo, Anna Maria/0000-0002-1970-3297; Costanzo, Francesco Saverio/0000-0002-3096-9416; Cuda, Giovanni/0000-0001-6313-1866; Lavia, Patrizia/0000-0003-3310-6701; Scumaci, Domenica/0000-0002-8117-834X; AGOSTI, Valter/0000-0001-6785-093X; Amato, Rosario/0000-0001-7162-1099; FANIELLO, Concetta Maria/0000-0001-6938-2754	Italian Association for Cancer Research (AIRC) [IG10164]; INAIL, CZ	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); INAIL, CZ	This work was supported in part by the Italian Association for Cancer Research (AIRC grant IG10164 to PL). RA was supported in part by INAIL, CZ.	Amato R, 2007, J MOL MED, V85, P707, DOI 10.1007/s00109-007-0205-2; Amato R, 2009, J MOL MED, V87, P1221, DOI 10.1007/s00109-009-0525-5; Archer MC, 2011, CELL METABOL GENES C, V2, P712; BISCHOFF FR, 1995, EMBO J, V14, P705, DOI 10.1002/j.1460-2075.1995.tb07049.x; Chen SY, 1999, P NATL ACAD SCI USA, V96, P2514, DOI 10.1073/pnas.96.5.2514; Ciciarello M, 2007, CELL MOL LIFE SCI, V64, P1891, DOI 10.1007/s00018-007-6568-2; Clarke PR, 2008, NAT REV MOL CELL BIO, V9, P464, DOI 10.1038/nrm2410; de la Rosa DA, 1999, J BIOL CHEM, V274, P37834, DOI 10.1074/jbc.274.53.37834; Di Fiore B, 1999, J BIOL CHEM, V274, P10339, DOI 10.1074/jbc.274.15.10339; Di Fiore B, 2003, J CELL SCI, V116, P3399, DOI 10.1242/jcs.00624; Faletti CJ, 2001, AM J PHYSIOL, V283, pC494; Faniello MC, 2008, INT J BIOCHEM CELL B, V40, P2110, DOI 10.1016/j.biocel.2008.02.010; Feng Z, P NATL ACAD SCI US, V109, P7013; Firestone GL, 2003, CELL PHYSIOL BIOCHEM, V13, P1, DOI 10.1159/000070244; Gaspari M, 2007, J SEP SCI, V30, P2210, DOI 10.1002/jssc.200700192; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Guarguaglini G, 2000, CELL GROWTH DIFFER, V11, P455; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hong F, 2008, MOL CELL, V30, P701, DOI 10.1016/j.molcel.2008.04.027; Hu R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019490; Kalab P, 2008, J CELL SCI, V121, P1577, DOI 10.1242/jcs.005959; Kim HS, 2009, J BIOL CHEM, V284, P15475, DOI 10.1074/jbc.M808734200; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Lang F, 2006, PHYSIOL REV, V86, P1151, DOI 10.1152/physrev.00050.2005; Lang F, 2010, INT J BIOCHEM CELL B, V42, P1571, DOI 10.1016/j.biocel.2010.05.016; Leong MLL, 2003, J BIOL CHEM, V278, P5871, DOI 10.1074/jbc.M211649200; Li HY, 2007, CELL CYCLE, V6, P1886, DOI 10.4161/cc.6.15.4487; Liu D, 2000, CURR BIOL, V10, P1233, DOI 10.1016/S0960-9822(00)00733-8; McCaig C, 2011, BIOCHEM BIOPH RES CO, V411, P227, DOI 10.1016/j.bbrc.2011.06.092; Menniti M, 2005, AM J PHYSIOL-CELL PH, V288, pC148, DOI 10.1152/ajpcell.00284.2004; Menniti M, 2010, CELL PHYSIOL BIOCHEM, V26, P587, DOI 10.1159/000322326; Nasir O, 2009, IUBMB LIFE, V61, P768, DOI 10.1002/iub.209; Peloponese JM, 2005, P NATL ACAD SCI USA, V102, P18974, DOI 10.1073/pnas.0506659103; Perrotti N, 2001, J BIOL CHEM, V276, P9406, DOI 10.1074/jbc.M007052200; Plafker K, 2002, J BIOL CHEM, V277, P30121, DOI 10.1074/jbc.M203006200; Rensen WM, 2009, ONCOGENE, V28, P1748, DOI 10.1038/onc.2009.24; Tan NY, 2009, MOL CELL BIOL, V29, P2483, DOI 10.1128/MCB.01828-08; Tedeschi A, 2007, J CELL SCI, V120, P3748, DOI 10.1242/jcs.009308; Wang K, 2010, CELL PHYSIOL BIOCHEM, V25, P271, DOI 10.1159/000276561; Yamada HY, 2010, CURR CANCER DRUG TAR, V10, P623, DOI 10.2174/156800910791859434; Yuen HF, 2012, CLIN CANCER RES, V18, P380, DOI 10.1158/1078-0432.CCR-11-2035; Zhang Y, 2010, INT J BIOCHEM CELL B, V42, P1964, DOI 10.1016/j.biocel.2010.08.007	42	46	47	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2013	32	38					4572	4578		10.1038/onc.2012.470	http://dx.doi.org/10.1038/onc.2012.470			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223SW	23108393				2022-12-28	WOS:000324831300013
J	Alfonso-Perez, T; Dominguez-Sanchez, MS; Garcia-Dominguez, M; Reyes, JC				Alfonso-Perez, T.; Dominguez-Sanchez, M. S.; Garcia-Dominguez, M.; Reyes, J. C.			Cytoplasmic interaction of the tumour suppressor protein hSNF5 with dynamin-2 controls endocytosis	ONCOGENE			English	Article						rhabdoid tumours; nucleocytoplasmic shuttling; chromatin remodelling; endocytosis	CLATHRIN-MEDIATED ENDOCYTOSIS; CRYSTAL-STRUCTURE; TRANSCRIPTION FACTOR; SH3 DOMAIN; CELLS; CANCER; GTPASE; INI1/HSNF5; COMPLEX; TUMORIGENESIS	Human SNF5 (hSNF5; INI1, SMARCB1 or BAF47) is a component of the human SWI/SNF chromatin remodelling complex and a tumour suppressor mutated in rhabdoid tumours. It also associates with the integrase of the human immunodeficiency virus (HIV)-1. We show by fluorescence loss in photobleaching that hSNF5 is constantly shuttling between the nucleus and the cytoplasm, raising the question of what the role of hSNF5 is in the cytoplasm. Here, we demonstrate that hSNF5 directly interacts with the GTPase dynamin-2 (DNM2) in the cytoplasm. DNM2 is a large GTPase involved in endocytosis and vesicle dynamics, which has been related to HIV-1 internalization. We show that hSNF5 colocalizes with DNM2 in endocytic vesicles. Depletion of hSNF5, but not of other components of the SWI/SNF complex, destabilizes DNM2 and impairs DNM2-dependent endocytosis. Furthermore, we show that hSNF5 inhibits assembly-stimulated DNM2 GTPase activity but not basal GTPase activity in vitro. Altogether, these results indicate that hSNF5 affects both the stability and the activity of DNM2, uncovering an unexpected role of hSNF5 in modulating endocytosis, and open new perspectives in understanding the role of hSNF5 in tumour genesis.	[Alfonso-Perez, T.; Dominguez-Sanchez, M. S.; Reyes, J. C.] CSIC, Ctr Andaluz Biol Mol & Med Regenerat CABIMER, Dept Mol Biol, Seville 41092, Spain; [Garcia-Dominguez, M.] CSIC, Ctr Andaluz Biol Mol & Med Regenerat CABIMER, Stem Cells Dept, Seville 41092, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; University of Sevilla; CSIC - Centro Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER); Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; University of Sevilla; CSIC - Centro Andaluz de Biologia Molecular y Medicina Regenerativa (CABIMER)	Reyes, JC (corresponding author), CSIC, Ctr Andaluz Biol Mol & Med Regenerat CABIMER, Dept Mol Biol, Av Amer Vespucio, Seville 41092, Spain.	mario.garcia@cabimer.es; jose.reyes@cabimer.es	Reyes, Jose C/K-3699-2014; Alfonso-Perez, Tatiana/Q-9269-2016; Garcia-Dominguez, Mario/K-3674-2014	Reyes, Jose C/0000-0002-8042-5142; Garcia-Dominguez, Mario/0000-0003-2211-8731	Spanish Ministerio de Economia y Competitividad [BFU2011-23442, CSD2006-00049]; Junta de Andalucia and Fundacion Ramon Areces [P06-CVI-4844]	Spanish Ministerio de Economia y Competitividad(Spanish Government); Junta de Andalucia and Fundacion Ramon Areces(Junta de Andalucia)	We thank C Muchardt, M Yaniv, SL Schmid and MA McNiven for providing plasmids, and P Dominguez for microscopy technical support. This work was supported by Grants BFU2011-23442 and CSD2006-00049 from the Spanish Ministerio de Economia y Competitividad, P06-CVI-4844 from Junta de Andalucia and Fundacion Ramon Areces.	Bukrinsky M, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-49; Cao H, 2007, J CELL SCI, V120, P4167, DOI 10.1242/jcs.010686; Ceballos-Chavez M, 2012, P NATL ACAD SCI USA, V109, P8085, DOI 10.1073/pnas.1121522109; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; Craig E, 2002, EMBO J, V21, P31, DOI 10.1093/emboj/21.1.31; Das S, 2009, J BIOL CHEM, V284, P19903, DOI 10.1074/jbc.M808141200; Deitcher D, 2001, TRENDS NEUROSCI, V24, P625, DOI 10.1016/S0166-2236(00)01927-5; Dundr M, 2003, CURR PROTOC CELL BIO; Faelber K, 2011, NATURE, V477, P556, DOI 10.1038/nature10369; Ferguson SM, 2012, NAT REV MOL CELL BIO, V13, P75, DOI 10.1038/nrm3266; Ford MGJ, 2011, NATURE, V477, P561, DOI 10.1038/nature10441; Formstecher E, 2005, GENOME RES, V15, P376, DOI 10.1101/gr.2659105; Giebel B, 2006, CURR BIOL, V16, pR91, DOI 10.1016/j.cub.2006.01.022; Giudicelli F, 2003, DEV BIOL, V253, P150, DOI 10.1006/dbio.2002.0864; Goodwin JS, 2005, METHODS, V37, P154, DOI 10.1016/j.ymeth.2005.05.013; Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001; Hargreaves DC, 2011, CELL RES, V21, P396, DOI 10.1038/cr.2011.32; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Joshi S, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-78; KALPANA GV, 1994, SCIENCE, V266, P2002, DOI 10.1126/science.7801128; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Koster M, 2005, CURR OPIN BIOTECH, V16, P28, DOI 10.1016/j.copbio.2004.11.002; Lanzetti L, 2008, TRAFFIC, V9, P2011, DOI 10.1111/j.1600-0854.2008.00816.x; Leonard M, 2005, METHOD ENZYMOL, V404, P490, DOI 10.1016/S0076-6879(05)04043-7; Liu YW, 2008, MOL BIOL CELL, V19, P5347, DOI 10.1091/mbc.E08-08-0890; McKenna ES, 2012, CELL CYCLE, V11, P1956, DOI 10.4161/cc.20280; McMahon HT, 2011, NAT REV MOL CELL BIO, V12, P517, DOI 10.1038/nrm3151; Miyauchi K, 2009, CELL, V137, P433, DOI 10.1016/j.cell.2009.02.046; Muhlberg AB, 1997, EMBO J, V16, P6676, DOI 10.1093/emboj/16.22.6676; Narayanan R, 2005, J CELL BIOL, V169, P117, DOI 10.1083/jcb.200502042; Newmyer SL, 2003, DEV CELL, V4, P929, DOI 10.1016/S1534-5807(03)00157-6; Owen DJ, 1998, EMBO J, V17, P5273, DOI 10.1093/emboj/17.18.5273; Pant S, 2009, NAT CELL BIOL, V11, P1399, DOI 10.1038/ncb1986; PEARSE BMF, 1982, P NATL ACAD SCI-BIOL, V79, P451, DOI 10.1073/pnas.79.2.451; Roberts CWM, 2009, CANCER BIOL THER, V8, P412, DOI 10.4161/cbt.8.5.8019; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Snapp Erik L, 2003, Curr Protoc Cell Biol, VChapter 21, DOI 10.1002/0471143030.cb2101s19; Soulet F, 2005, MOL BIOL CELL, V16, P2058, DOI 10.1091/mbc.E04-11-1016; Stojanova A, 2009, BIOCHEM CELL BIOL, V87, P163, DOI 10.1139/O08-113; Thompson HM, 2002, CURR BIOL, V12, P2111, DOI 10.1016/S0960-9822(02)01390-8; Treich I, 1997, MOL CELL BIOL, V17, P1768, DOI 10.1128/MCB.17.4.1768; TUMA PL, 1995, J BIOL CHEM, V270, P26707, DOI 10.1074/jbc.270.44.26707; Turelli P, 2001, MOL CELL, V7, P1245, DOI 10.1016/S1097-2765(01)00255-6; Vachtenheim J, 2010, BIOCHEM BIOPH RES CO, V392, P454, DOI 10.1016/j.bbrc.2010.01.048; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Vries RGJ, 2005, GENE DEV, V19, P665, DOI 10.1101/gad.335805; Warnock DE, 1996, J BIOL CHEM, V271, P22310, DOI 10.1074/jbc.271.37.22310; Wigge P, 1997, CURR BIOL, V7, P554, DOI 10.1016/S0960-9822(06)00254-5; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068	51	5	5	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2014	33	23					3064	3074		10.1038/onc.2013.276	http://dx.doi.org/10.1038/onc.2013.276			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EL	23851497				2022-12-28	WOS:000337232200013
J	He, W; Wang, Q; Srinivasan, B; Xu, J; Padilla, MT; Li, Z; Wang, X; Liu, Y; Gou, X; Shen, HM; Xing, C; Lin, Y				He, W.; Wang, Q.; Srinivasan, B.; Xu, J.; Padilla, M. T.; Li, Z.; Wang, X.; Liu, Y.; Gou, X.; Shen, H-M; Xing, C.; Lin, Y.			A JNK-mediated autophagy pathway that triggers c-IAP degradation and necroptosis for anticancer chemotherapy	ONCOGENE			English	Article						autophagy; necroptosis; RIP1; RIP3; c-IAP; apoptosis	MIXED LINEAGE KINASE; INDUCED CELL-DEATH; PROGRAMMED NECROSIS; CANCER CELLS; DOMAIN-LIKE; APOPTOSIS; RIPOPTOSOME; MECHANISMS; CYTOTOXICITY; DOWNSTREAM	Killing cancer cells through the induction of apoptosis is one of the main mechanisms of chemotherapy. However, numerous cancer cells have primary or acquired apoptosis resistance, resulting in chemoresistance. In this study, using a novel chalcone derivative chalcone-24 (Chal-24), we identified a novel anticancer mechanism through autophagy-mediated necroptosis (RIP1- and RIP3-dependent necrosis). Chal-24 potently killed different cancer cells with induction of necrotic cellular morphology while causing no detectable caspase activation. Blocking the necroptosis pathway with either necrostatin-1 or by knockdown of RIP1 and RIP3 effectively blocked the cytotoxicity of Chal-24, suggesting that Chal-24-induced cell death is associated with necroptosis. Chal-24 robustly activated JNK and ERK and blockage of which effectively suppressed Chal-24-induced cytotoxicity. In addition, Chal-24 strongly induced autophagy that is dependent on JNK-mediated phosphorylation of Bcl-2 and Bcl-xL and dissociation of Bcl-2 or Bcl-xL from Beclin-1. Importantly, suppression of autophagy, with either pharmacological inhibitors or small interfering RNAs targeting the essential autophagy components ATG7 and Beclin-1, effectively attenuated Chal-24-induced cell death. Furthermore, we found that autophagy activation resulted in c-IAP1 and c-IAP2 degradation and formation of the Ripoptosome that contributes to necroptosis. These results thus establish a novel mechanism for killing cancer cells that involves autophagy-mediated necroptosis, which may be employed for overcoming chemoresistance.	[He, W.; Wang, Q.; Xu, J.; Padilla, M. T.; Li, Z.; Liu, Y.; Lin, Y.] Lovelace Resp Res Inst, Mol Biol & Lung Canc Program, Albuquerque, NM USA; [He, W.; Gou, X.] Chongqing Med Univ, Affiliated Hosp 1, Dept Urol, Chongqing, Peoples R China; [Wang, Q.; Wang, X.] Sichuan Univ, West China Univ Hosp 2, Lab Mol & Translat Med, Chengdu 610064, Peoples R China; [Srinivasan, B.; Xing, C.] Univ Minnesota, Dept Med Chem, Minneapolis, MN 55455 USA; [Shen, H-M] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 117595, Singapore	Lovelace Respiratory Research Institute; Chongqing Medical University; Sichuan University; University of Minnesota System; University of Minnesota Twin Cities; National University of Singapore	Xing, C (corresponding author), Univ Minnesota, Dept Med Chem, Minneapolis, MN 55455 USA.	xingx009@umn.edu; ylin@lrri.org	SHEN, Han-Ming/B-5942-2011; Liu, Yushi/A-1533-2014	SHEN, Han-Ming/0000-0001-7369-5227; Liu, Yushi/0000-0003-4185-4187; Xu, Jennings/0000-0002-3068-0559	NIEHS/NIH [R01ES017328]; NCI/NIH [R03CA156301]; Chongqing Health Bureau [2012-2-001]; NATIONAL CANCER INSTITUTE [R03CA156301] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES017328] Funding Source: NIH RePORTER	NIEHS/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Chongqing Health Bureau; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	This study was partly supported by grants from NIEHS/NIH (R01ES017328), NCI/NIH (R03CA156301), Chongqing Health Bureau (2012-2-001).	Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014; Bonapace L, 2010, J CLIN INVEST, V120, P1310, DOI 10.1172/JCI39987; Cagnol S, 2010, FEBS J, V277, P2, DOI 10.1111/j.1742-4658.2009.07366.x; Christofferson DE, 2010, CELL DEATH DIFFER, V17, P1942, DOI 10.1038/cdd.2010.123; Darding M, 2012, CELL DEATH DIFFER, V19, P58, DOI 10.1038/cdd.2011.163; Feoktistova M, 2011, MOL CELL, V43, P449, DOI 10.1016/j.molcel.2011.06.011; Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96; Galluzzi L, 2011, INT REV CEL MOL BIO, V289, P1, DOI 10.1016/B978-0-12-386039-2.00001-8; Ghavami S, 2009, J MED GENET, V46, P497, DOI 10.1136/jmg.2009.066944; Han JH, 2011, NAT IMMUNOL, V12, P1143, DOI 10.1038/ni.2159; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; He WY, 2012, AUTOPHAGY, V8, P1811, DOI 10.4161/auto.22145; Hitomi JI, 2008, CELL, V135, P1311, DOI 10.1016/j.cell.2008.10.044; Imre G, 2011, J MOL CELL BIOL, V3, P324, DOI 10.1093/jmcb/mjr034; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Kreuzaler P, 2012, NAT REV CANCER, V12, P411, DOI 10.1038/nrc3264; Lin Y, 1999, GENE DEV, V13, P2514, DOI 10.1101/gad.13.19.2514; Long JS, 2012, ONCOGENE, V31, P5045, DOI 10.1038/onc.2012.7; Lonning PE, 2010, MOL ONCOL, V4, P284, DOI 10.1016/j.molonc.2010.04.005; Marquez RT, 2012, AM J CANCER RES, V2, P214; Matsuzawa T, 2012, J IMMUNOL, V189, P813, DOI 10.4049/jimmunol.1102041; Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026; Mor Gil, 2008, V414, P1; Notte A, 2011, BIOCHEM PHARMACOL, V82, P427, DOI 10.1016/j.bcp.2011.06.015; Ocker M, 2012, EUR SURG RES, V48, P111, DOI 10.1159/000336875; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Salazar M, 2009, J CLIN INVEST, V119, P1359, DOI 10.1172/JCI37948; Seve Pascal, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P73, DOI 10.2174/1568011053352604; Shen HM, 2011, AUTOPHAGY, V7, P457, DOI 10.4161/auto.7.5.14226; Shen S, 2011, ONCOGENE, V30, P4544, DOI 10.1038/onc.2011.168; Shiao SL, 2011, GENE DEV, V25, P2559, DOI 10.1101/gad.169029.111; Srinivasan B, 2009, J MED CHEM, V52, P7228, DOI 10.1021/jm901278z; Sun LM, 2012, CELL, V148, P213, DOI 10.1016/j.cell.2011.11.031; Tenev T, 2011, MOL CELL, V43, P432, DOI 10.1016/j.molcel.2011.06.006; Todde V, 2009, BBA-MOL BASIS DIS, V1792, P3, DOI 10.1016/j.bbadis.2008.10.016; Vandenabeele P, 2010, NAT REV MOL CELL BIO, V11, P700, DOI 10.1038/nrm2970; Vanlangenakker N, 2011, CELL DEATH DIFFER, V18, P656, DOI 10.1038/cdd.2010.138; Wang X, 2006, CANCER RES, V66, P1089, DOI 10.1158/0008-5472.CAN-05-2698; Wang X, 2008, MOL CANCER THER, V7, P1156, DOI 10.1158/1535-7163.MCT-07-2183; Wang ZG, 2012, CELL, V148, P228, DOI 10.1016/j.cell.2011.11.030; Warmka JK, 2012, BIOCHEM BIOPH RES CO, V424, P488, DOI 10.1016/j.bbrc.2012.06.140; Wei YJ, 2008, MOL CELL, V30, P678, DOI 10.1016/j.molcel.2008.06.001; Wu WKK, 2012, ONCOGENE, V31, P939, DOI 10.1038/onc.2011.295; Xie CM, 2011, FREE RADICAL BIO MED, V51, P1365, DOI 10.1016/j.freeradbiomed.2011.06.016; Young A, 2009, ADV CANCER RES, V102, P1, DOI 10.1016/S0065-230X(09)02001-6; Zhao J, 2012, P NATL ACAD SCI USA, V109, P5322, DOI 10.1073/pnas.1200012109	46	78	85	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2014	33	23					3004	3013		10.1038/onc.2013.256	http://dx.doi.org/10.1038/onc.2013.256			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EL	23831571	Green Accepted			2022-12-28	WOS:000337232200007
J	Luo, J; Lee, SO; Liang, L; Huang, CK; Li, L; Wen, S; Chang, C				Luo, J.; Lee, S. Ok; Liang, L.; Huang, C-K; Li, L.; Wen, S.; Chang, C.			Infiltrating bone marrow mesenchymal stem cells increase prostate cancer stem cell population and metastatic ability via secreting cytokines to suppress androgen receptor signaling	ONCOGENE			English	Article						bone marrow mesenchymal stem cells; CCL5; androgen receptor; prostate cancer stem cells	STROMAL CELLS; GROWTH-FACTOR; DIFFERENTIATION; TUMORIGENESIS; MAINTENANCE; EXPRESSION; TUMORS; ROLES; CD133; MSCS	Although the contribution of the bone marrow mesenchymal stem cells (BM-MSCs) in cancer progression is emerging, their potential roles in prostate cancer (PCa) remain unclear. Here, we showed that PCa cells could recruit BM-MSCs and consequently the metastatic ability of PCa cells was increased. We also found that the increased metastatic ability of PCa cells could be due to the increased PCa stem cell population. Mechanism dissection studies found that the upregulation of Chemokine ligand 5 (CCL5) expression in BM-MSCs and PCa cells, after MSCs infiltrated into the PCa cells, subsequently downregulated androgen receptor (AR) signaling, which was due to inhibition of AR nuclear translocation. Interruption of such signaling led to suppression of the BM-MSCs-induced PCa stem cell population increase and thereby inhibited the metastatic ability of PCa cells. The PCa stem cell increase then led to the upregulation of matrix metalloproteinase 9, ZEB-1, CD133 and CXCR4 molecules, and enhanced the metastatic ability of PCa cells. Therefore, we conclude that the BM-MSCs-mediated increased metastatic ability of PCa cells can be due to the PCa stem cell increase via alteration of the CCL5-AR signaling pathway. Together, these results uncover the important roles of BM-MSCs as key components in the prostate tumor microenvironment to promote PCa metastasis and may provide a new potential target to suppress PCa metastasis by blocking BM-MSCs infiltration into PCa.	[Luo, J.; Lee, S. Ok; Liang, L.; Huang, C-K; Li, L.; Wen, S.; Chang, C.] Univ Rochester, Med Ctr, Dept Pathol, Dept Urol,Dept Radio Oncol,George Whipple Lab Can, Rochester, NY 14642 USA; [Luo, J.; Lee, S. Ok; Liang, L.; Huang, C-K; Li, L.; Wen, S.; Chang, C.] Univ Rochester, Med Ctr, Wilmot Canc Ctr, Rochester, NY 14642 USA; [Chang, C.] China Med Univ & Hosp, Sex Hormone Res Ctr, Taichung, Taiwan	University of Rochester; University of Rochester; China Medical University Taiwan; China Medical University Hospital - Taiwan	Chang, C (corresponding author), Univ Rochester, Med Ctr, Dept Pathol, Dept Urol,Dept Radio Oncol,George Whipple Lab Can, 601 Elmwood Ave, Rochester, NY 14642 USA.	chang@urmc.rochester.edu	Luo, Jie/AAG-3091-2019	Wen, Simeng/0000-0001-7989-7700	NIH [CA122840, CA256700]; Taiwan Department of Health Clinical Trial and Research Center of Excellence [DOH102-TD-B-111-004]; NATIONAL CANCER INSTITUTE [R01CA122840] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Taiwan Department of Health Clinical Trial and Research Center of Excellence; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Karen Wolf for help with the manuscript preparation. This work was supported by NIH Grants (CA122840 and CA256700), and Taiwan Department of Health Clinical Trial and Research Center of Excellence (DOH102-TD-B-111-004) to China Medical University, Taiwan.	Altuwaijri S, 2007, ASIAN J ANDROL, V9, P181, DOI 10.1111/j.1745-7262.2007.00258.x; Augsten M, 2009, P NATL ACAD SCI USA, V106, P3414, DOI 10.1073/pnas.0813144106; Auletta JJ, 2012, BLOOD, V119, P1801, DOI 10.1182/blood-2011-10-384354; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Charoenfuprasert S, 2011, ONCOGENE, V30, P3570, DOI 10.1038/onc.2011.77; Chong JJH, 2011, CELL STEM CELL, V9, P527, DOI 10.1016/j.stem.2011.10.002; Dayyani F, 2011, JNCI-J NATL CANCER I, V103, P1665, DOI 10.1093/jnci/djr362; Delude C, 2011, NATURE, V480, pS43, DOI 10.1038/480S43a; Dubrovska A, 2009, P NATL ACAD SCI USA, V106, P268, DOI 10.1073/pnas.0810956106; Gao Y, 2010, ONCOGENE, V29, P2784, DOI 10.1038/onc.2010.38; Goldstein RH, 2010, CANCER RES, V70, P10044, DOI 10.1158/0008-5472.CAN-10-1254; Huang XP, 2010, CIRCULATION, V122, P2419, DOI 10.1161/CIRCULATIONAHA.110.955971; Jodele S, 2005, CANCER RES, V65, P3200, DOI 10.1158/0008-5472.CAN-04-3770; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Kleeberger W, 2007, CANCER RES, V67, P9199, DOI 10.1158/0008-5472.CAN-07-0806; Kobayashi A, 2011, J EXP MED, V208, P2641, DOI 10.1084/jem.20110840; Kumar SM, 2012, ONCOGENE, V31, P4898, DOI 10.1038/onc.2011.656; Lee CH, 2010, J CLIN INVEST, V120, P3340, DOI 10.1172/JCI43230; Lee SO, 2013, J MOL CELL BIOL, V5, P14, DOI 10.1093/jmcb/mjs042; Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338; Li YM, 2004, CANCER CELL, V6, P459, DOI 10.1016/j.ccr.2004.09.027; Liu SL, 2011, CANCER RES, V71, P614, DOI 10.1158/0008-5472.CAN-10-0538; Loebinger MR, 2009, CANCER RES, V69, P4134, DOI 10.1158/0008-5472.CAN-08-4698; Mak P, 2010, CANCER CELL, V17, P319, DOI 10.1016/j.ccr.2010.02.030; Malanchi I, 2012, NATURE, V481, P85, DOI 10.1038/nature10694; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12188, DOI 10.1073/pnas.0804701105; Niu YJ, 2008, P NATL ACAD SCI USA, V105, P12182, DOI 10.1073/pnas.0804700105; Park D, 2012, CELL STEM CELL, V10, P259, DOI 10.1016/j.stem.2012.02.003; Quante M, 2011, CANCER CELL, V19, P257, DOI 10.1016/j.ccr.2011.01.020; Raaijmakers MHGP, 2010, NATURE, V464, P852, DOI 10.1038/nature08851; Richardson GD, 2004, J CELL SCI, V117, P3539, DOI 10.1242/jcs.01222; Rossi DJ, 2008, CELL, V132, P681, DOI 10.1016/j.cell.2008.01.036; Rybak AP, 2011, BBA-MOL CELL RES, V1813, P683, DOI 10.1016/j.bbamcr.2011.01.018; Shi XD, 2007, DEV BIOL, V312, P396, DOI 10.1016/j.ydbio.2007.09.042; Sun YT, 2012, CANCER RES, V72, P527, DOI 10.1158/0008-5472.CAN-11-3004; Trerotola M, 2010, AM J TRANSL RES, V2, P135; Wegiel B, 2008, JNCI-J NATL CANCER I, V100, P1022, DOI 10.1093/jnci/djn214; Xu S, 2012, STEM CELLS, V30, P266, DOI 10.1002/stem.787; Ye HM, 2012, CANCER INVEST, V30, P513, DOI 10.3109/07357907.2012.692171; Yong RL, 2009, CANCER RES, V69, P8932, DOI 10.1158/0008-5472.CAN-08-3873; Yu XZ, 2011, CURR COLORECT CANC R, V7, P253, DOI 10.1007/s11888-011-0106-1; Zeng YP, 2006, CANCER RES, V66, P9566, DOI 10.1158/0008-5472.CAN-06-1488; Zhu P, 2006, CELL, V124, P615, DOI 10.1016/j.cell.2005.12.032	43	109	112	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2014	33	21					2768	2778		10.1038/onc.2013.233	http://dx.doi.org/10.1038/onc.2013.233			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EH	23792449				2022-12-28	WOS:000337231700010
J	Taulli, R; Foglizzo, V; Morena, D; Coda, DM; Ala, U; Bersani, F; Maestro, N; Ponzetto, C				Taulli, R.; Foglizzo, V.; Morena, D.; Coda, D. M.; Ala, U.; Bersani, F.; Maestro, N.; Ponzetto, C.			Failure to downregulate the BAF53a subunit of the SWI/SNF chromatin remodeling complex contributes to the differentiation block in rhabdomyosarcoma	ONCOGENE			English	Article						BAF53a; chromatin remodeling; miR-206; rhabdomyosarcoma; differentiation therapy	TERMINAL DIFFERENTIATION; EXPRESSION; MIR-206; GENE; MYOD; PROLIFERATION; GROWTH; TRANSCRIPTION; INHIBITION; INDUCTION	Rhabdomyosarcoma (RMS), the most common soft tissue sarcoma in children and young adults, is characterized by a partially differentiated myogenic phenotype. We have previously shown that the blocking of tumor growth and resumption of differentiation can be achieved by re-expression of miR-206, a muscle-enriched microRNA missing in RMS. In this work, we focused on BAF53a, one of the genes downregulated in miR-206-expressing RMS cells, which codes for a subunit of the SWI/SNF chromatin remodeling complex. Here we show that the BAF53a transcript is significantly higher in primary RMS tumors than in normal muscle, and is a direct target of miR-206. Sustained expression of BAF53a interferes with differentiation in myogenic cells, whereas its silencing in RMS cells increases expression of myogenic markers and inhibits proliferation and anchorage-independent growth. Accordingly, BAF53a silencing also impairs embryonal RMS and alveolar RMS tumor growth, inducing their morphological and biochemical differentiation. These results indicate that failure to downregulate the BAF53a subunit may contribute to the pathogenesis of RMS, and suggest that BAF53a may represent a novel therapeutic target for this tumor.	[Taulli, R.; Foglizzo, V.; Morena, D.; Coda, D. M.; Bersani, F.; Maestro, N.; Ponzetto, C.] Univ Turin, Sch Med, Dept Oncol, I-10126 Turin, Italy; [Taulli, R.; Foglizzo, V.; Morena, D.; Coda, D. M.; Bersani, F.; Maestro, N.; Ponzetto, C.] Ctr Expt Res & Med Studies, CERMS, Turin, Italy; [Ala, U.] Univ Turin, Dept Mol Biotechnol & Hlth Sci, I-10126 Turin, Italy	University of Turin; University of Turin	Ponzetto, C (corresponding author), Univ Turin, Dept Oncol, Corso Massimo dAzeglio 52, I-10126 Turin, Italy.	carola.ponzetto@unito.it	Maestro, Nicola/AAA-6097-2020; Ala, Ugo/K-2029-2016; TAULLI, Riccardo/J-7347-2018	Maestro, Nicola/0000-0001-7909-3737; Ala, Ugo/0000-0001-5408-6397; TAULLI, Riccardo/0000-0003-1277-6263; Bersani, Francesca/0000-0002-0343-7078; Foglizzo, Valentina/0000-0001-5059-3279	Regione Piemonte (IMMONC Project); Italian Association for Cancer Research (AIRC); International Foundation of Research in Experimental Medicine (FIRMS)	Regione Piemonte (IMMONC Project)(Regione Piemonte); Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); International Foundation of Research in Experimental Medicine (FIRMS)	We are grateful to Janet Shipley and Zoe Walters of the Molecular Cytogenetics Team (The Institute of Cancer Research, Sutton, Surrey, UK), for indicating the appropriate RMS databanks, to PL Puri (Sanford-Burnham, San Diego) for providing reagents and feedback, to Elisa DeLuca for technical help with the confocal microscope and to Rosella Rota and Giorgia Bracaglia for providing the human myoblasts samples and for helpful suggestions. This work was supported by funding from the Regione Piemonte (IMMONC Project) and the Italian Association for Cancer Research (AIRC). The support of the International Foundation of Research in Experimental Medicine (FIRMS) is gratefully acknowledged.	Bao XM, 2013, CELL STEM CELL, V12, P193, DOI 10.1016/j.stem.2012.12.014; Belyea Brian, 2012, Sarcoma, V2012, P406239, DOI 10.1155/2012/406239; BOUCHE M, 1993, EXP CELL RES, V208, P209, DOI 10.1006/excr.1993.1239; Boutet SC, 2012, CELL STEM CELL, V10, P327, DOI 10.1016/j.stem.2012.01.017; Chen JF, 2010, J CELL BIOL, V190, P867, DOI 10.1083/jcb.200911036; Coutinho P, 2012, SOC MUSCLE BIOL FRON; de la Serna IL, 2001, J BIOL CHEM, V276, P41486, DOI 10.1074/jbc.M107281200; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; DeCristofaro MF, 1999, ONCOGENE, V18, P7559, DOI 10.1038/sj.onc.1203168; Follenzi A, 2000, NAT GENET, V25, P217, DOI 10.1038/76095; Forcales SV, 2012, EMBO J, V31, P301, DOI 10.1038/emboj.2011.391; Goljanek-Whysall K, 2012, J CELL SCI, V125, P3590, DOI 10.1242/jcs.101758; Ho L, 2010, NATURE, V463, P474, DOI 10.1038/nature08911; Kim HK, 2006, J CELL BIOL, V174, P677, DOI 10.1083/jcb.200603008; Krasteva V, 2012, BLOOD, V120, P4720, DOI 10.1182/blood-2012-04-427047; MacQuarrie KL, 2012, SKELET MUSCLE, V2, DOI 10.1186/2044-5040-2-7; Mallappa C, 2010, MOL CELL BIOL, V30, P3176, DOI 10.1128/MCB.00214-10; McDowell HP, 2003, ARCH DIS CHILD, V88, P354, DOI 10.1136/adc.88.4.354; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; Meyer WH, 2004, CANCER TREAT REV, V30, P269, DOI 10.1016/j.ctrv.2003.11.001; Missiaglia E, 2010, BRIT J CANCER, V102, P1769, DOI 10.1038/sj.bjc.6605684; Ohfuchi E, 2002, BIOSCI BIOTECH BIOCH, V66, P1740, DOI 10.1271/bbb.66.1740; Ohkawa Y, 2007, J BIOL CHEM, V282, P6564, DOI 10.1074/jbc.M608898200; Olave I, 2002, GENE DEV, V16, P2509, DOI 10.1101/gad.992102; Puri PL, 2000, GENE DEV, V14, P574; Raimondi L, 2012, CELL DEATH DIFFER, V19, P871, DOI 10.1038/cdd.2011.171; Raney R B, 2001, Sarcoma, V5, P9, DOI 10.1080/13577140120048890; Rao PK, 2010, FASEB J, V24, P3427, DOI 10.1096/fj.09-150698; Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; Ricaud S, 2003, ONCOGENE, V22, P8221, DOI 10.1038/sj.onc.1207177; Roberts CWM, 2002, CANCER CELL, V2, P415, DOI 10.1016/S1535-6108(02)00185-X; Roma J, 2011, CLIN CANCER RES, V17, P505, DOI 10.1158/1078-0432.CCR-10-0166; Rosenberg MI, 2006, J CELL BIOL, V175, P77, DOI 10.1083/jcb.200603039; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; Taulli R, 2006, CANCER RES, V66, P4742, DOI 10.1158/0008-5472.CAN-05-4292; Taulli R, 2010, CELL CYCLE, V9, P918, DOI 10.4161/cc.9.5.10864; Taulli R, 2009, J CLIN INVEST, V119, P2366, DOI 10.1172/JCI38075; Walters ZS, 2013, ONCOGENE, V1, P10; Wang H, 2008, CANCER CELL, V14, P369, DOI 10.1016/j.ccr.2008.10.006; Williamson D, 2010, J CLIN ONCOL, V28, P2151, DOI 10.1200/JCO.2009.26.3814; Wu JI, 2007, NEURON, V56, P94, DOI 10.1016/j.neuron.2007.08.021; Wu JI, 2012, ACTA BIOCH BIOPH SIN, V44, P54, DOI 10.1093/abbs/gmr099; Xia SJ, 2005, EUR J CANCER, V41, P2513, DOI 10.1016/j.ejca.2005.08.003; Yan D, 2009, J BIOL CHEM, V284, P29596, DOI 10.1074/jbc.M109.020511; Yang ZH, 2009, GENE DEV, V23, P694, DOI 10.1101/gad.1765109; Yoo AS, 2009, NATURE, V460, P642, DOI 10.1038/nature08139; Zhang L, 2013, CANCER LETT, V332, P94, DOI 10.1016/j.canlet.2013.01.023; Zhou J, 2013, BIOCHEM BIOPH RES CO, V13, P364	49	37	38	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2014	33	18					2354	2362		10.1038/onc.2013.188	http://dx.doi.org/10.1038/onc.2013.188			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AG5ID	23728344				2022-12-28	WOS:000335451800008
J	Zhou, W; Srinivasan, S; Nawaz, Z; Slingerland, JM				Zhou, W.; Srinivasan, S.; Nawaz, Z.; Slingerland, J. M.			ER alpha, SKP2 and E2F-1 form a feed forward loop driving late ER alpha targets and G1 cell cycle progression	ONCOGENE			English	Article						cyclin E-CDK2; ER alpha; E2F-1; SCFSKP2; ubiquitylation; coactivator	ESTROGEN-RECEPTOR-ALPHA; BREAST-CANCER-CELLS; UBIQUITIN LIGASE COMPLEX; CDK INHIBITOR P27; BOX PROTEIN SKP2; TRANSCRIPTIONAL ACTIVATION; HORMONE-RECEPTORS; DOWN-REGULATION; BINDING-SITES; DEPENDENT PHOSPHORYLATION	Estrogen triggers transactivation coupled estrogen receptor a (ER alpha) proteolysis, but mechanisms thereof remain obscure. Present data link estrogen: ER alpha-driven transcription with cell cycle progression. Although liganded ER alpha induces many genes within 1-4 h, gene activation after 6 h is thought to be indirect. Here, we identify SKP2 as a late-acting coactivator that drives ERa targets to promote G1-to-S progression. Data support a model in which estrogen-activated cyclin E-CDK2 binds and phosphorylates ER alpha S341, to prime ER alpha-SCFSKP2 binding via SKP2-L(248)QTLL(252) in late G1. SKP2 activates ERa ubiquitylation and proteolysis. Putative late ER alpha targets were identified by expression profiling. SKP2 knockdown attenuated E2F-1 and BLM induction. SKP2 overexpression, but not coactivator motif mutant SKP2-L(248)QTAA(252), enhanced estrogen-induced E2F-1 and BLM expression. SKP2 knockdown impaired estrogen-stimulated ER alpha, SKP2, SRC3 and RNA polymerase II recruitment to E2F-1 and BLM promoters. This work not only identifies these late-activated genes as bona fide ERa targets but describes a novel mechanism for their periodic activation. SKP2 serves as dual ER alpha E3 ligase/coactivator for late-activated target genes, revealing a novel mechanism whereby ER alpha/SCFSKP2 transactivation of E2F-1 feeds forward to drive G1-to-S.	[Zhou, W.; Srinivasan, S.; Nawaz, Z.; Slingerland, J. M.] Univ Miami, Sylvester Comprehens Canc Ctr, Braman Family Breast Canc Inst, Miami, FL 33136 USA; [Zhou, W.; Srinivasan, S.; Nawaz, Z.; Slingerland, J. M.] Univ Miami, Miller Sch Med, Dept Biochem & Mol Biol, Miami, FL 33136 USA; [Slingerland, J. M.] Univ Miami, Miller Sch Med, Dept Med, Miami, FL 33136 USA	University of Miami; University of Miami; University of Miami	Slingerland, JM (corresponding author), Univ Miami, Sylvester Comprehens Canc Ctr, Braman Family Breast Canc Inst, 1501 NW 10th Ave,BRB708, Miami, FL 33136 USA.	jslingerland@med.miami.edu	Zhou, Wen/A-5763-2010	Zhou, Wen/0000-0002-5496-5815	NIH [R01CA123415]; US DOD Pre-doctoral grant [W81XWH-11-1-0097]; NATIONAL CANCER INSTITUTE [R01CA123415] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US DOD Pre-doctoral grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank M Pagano for bacculovirus stocks (CUL1, SKP1, RBX1, SKP2), WL Kraus for pPK-FLAG-ER alpha plasmid, H-K Lin for pcDNA4-His-Max-Xpress SKP2, and J Sun for technical intellectual input. This work was supported by NIH R01CA123415 (JMS and ZN), and a US DOD Pre-doctoral grant W81XWH-11-1-0097 (WZ).	Alarid ET, 1999, MOL ENDOCRINOL, V13, P1522, DOI 10.1210/me.13.9.1522; Alarid ET, 2003, ENDOCRINOLOGY, V144, P3469, DOI 10.1210/en.2002-0092; Atsriku C, 2009, MOL CELL PROTEOMICS, V8, P467, DOI 10.1074/mcp.M800282-MCP200; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Bhatt S, 2012, MOL CELL BIOL, V32, P1928, DOI 10.1128/MCB.06561-11; Cariou S, 2000, P NATL ACAD SCI USA, V97, P9042, DOI 10.1073/pnas.160016897; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Cenciarelli C, 1999, CURR BIOL, V9, P1177, DOI 10.1016/S0960-9822(00)80020-2; Chi Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-10-r149; Chu I, 2007, CELL, V128, P281, DOI 10.1016/j.cell.2006.11.049; Chu I, 2007, J CLIN INVEST, V117, P2205, DOI 10.1172/JCI21739; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Dace A, 2000, P NATL ACAD SCI USA, V97, P8985, DOI 10.1073/pnas.160257997; DALY RJ, 1990, CANCER RES, V50, P5868; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; DUBIK D, 1987, CANCER RES, V47, P6517; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Fan MY, 2004, MOL ENDOCRINOL, V18, P2603, DOI 10.1210/me.2004-0164; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Hao B, 2005, MOL CELL, V20, P9, DOI 10.1016/j.molcel.2005.09.003; Harper JW, 2001, CHEM REV, V101, P2511, DOI 10.1021/cr0001030; Held JM, 2012, MOL CANCER RES, V10, P1120, DOI 10.1158/1541-7786.MCR-12-0099; Iso T, 2007, BIOL PHARM BULL, V30, P266, DOI 10.1248/bpb.30.266; Johnson AE, 2007, MOL CELL BIOCHEM, V301, P13, DOI 10.1007/s11010-006-9392-3; Kennedy BA, 2010, NUCLEIC ACIDS RES, V38, pD676, DOI 10.1093/nar/gkp734; Klinge CM, 2001, NUCLEIC ACIDS RES, V29, P2905, DOI 10.1093/nar/29.14.2905; Klinge CM, 2000, STEROIDS, V65, P227, DOI 10.1016/S0039-128X(99)00107-5; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Li XH, 2003, J BIOL CHEM, V278, P30854, DOI 10.1074/jbc.C300251200; Lin CY, 2007, PLOS GENET, V3, P867, DOI 10.1371/journal.pgen.0030087; Lin ZH, 2007, CANCER RES, V67, P5017, DOI 10.1158/0008-5472.CAN-06-3696; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Marti A, 1999, NAT CELL BIOL, V1, P14, DOI 10.1038/8984; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Moro L, 2006, J BIOL CHEM, V281, P22100, DOI 10.1074/jbc.M604636200; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nawaz Z, 1999, P NATL ACAD SCI USA, V96, P1858, DOI 10.1073/pnas.96.5.1858; Nawaz Z, 2004, MOL ENDOCRINOL, V18, P493, DOI 10.1210/me.2003-0388; Nawaz Z, 1999, MOL CELL BIOL, V19, P1182; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Nilsson S, 2000, BREAST CANCER RES, V2, P360, DOI 10.1186/bcr81; Ohtake F, 2003, NATURE, V423, P545, DOI 10.1038/nature01606; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Saji S, 2001, BIOCHEM BIOPH RES CO, V281, P259, DOI 10.1006/bbrc.2001.4339; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Shen TJ, 2001, MOL CELL BIOL, V21, P6122, DOI 10.1128/MCB.21.18.6122-6131.2001; Sherr CJ, 2000, CANCER RES, V60, P3689; Sun J, 2007, MOL ENDOCRINOL, V21, P2651, DOI 10.1210/me.2007-0082; Sun J, 2012, MOL ENDOCRINOL, V26, P1567, DOI 10.1210/me.2012-1140; Tansey WP, 2001, GENE DEV, V15, P1045, DOI 10.1101/gad.896501; TSAI LH, 1993, ONCOGENE, V8, P1593; Wang WL, 1999, MOL ENDOCRINOL, V13, P1373, DOI 10.1210/me.13.8.1373; Wirbelauer C, 2000, EMBO J, V19, P5362, DOI 10.1093/emboj/19.20.5362; Won KA, 1996, EMBO J, V15, P4182, DOI 10.1002/j.1460-2075.1996.tb00793.x; Woo RA, 2003, CELL CYCLE, V2, P316, DOI 10.4161/cc.2.4.468; Wu J, 2012, MOL CELL, V46, P351, DOI 10.1016/j.molcel.2012.02.018; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; Zhang L, 2006, ONCOGENE, V25, P2615, DOI 10.1038/sj.onc.1209286	62	15	18	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2014	33	18					2341	2353		10.1038/onc.2013.197	http://dx.doi.org/10.1038/onc.2013.197			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AG5ID	23770852				2022-12-28	WOS:000335451800007
J	Viotti, J; Duplan, E; Caillava, C; Condat, J; Goiran, T; Giordano, C; Marie, Y; Idbaih, A; Delattre, JY; Honnorat, J; Checler, F; Alves Da Costa, C				Viotti, J.; Duplan, E.; Caillava, C.; Condat, J.; Goiran, T.; Giordano, C.; Marie, Y.; Idbaih, A.; Delattre, J-Y; Honnorat, J.; Checler, F.; Alves Da Costa, C.			Glioma tumor grade correlates with parkin depletion in mutant p53-linked tumors and results from loss of function of p53 transcriptional activity	ONCOGENE			English	Article						human brain glioma; glioblastoma cells; tumor grade; parkin; p53; transcription	SUPPRESSOR GENE; HEPATOCELLULAR-CARCINOMA; CELL-PROLIFERATION; BRAIN-TUMORS; BAX GENE; IN-VITRO; MUTATIONS; PROTEIN; CANCER; EXPRESSION	Gliomas represent the most frequent form of primary brain tumors in adults, the prognosis of which remains extremely poor. Inactivating mutations on the tumor suppressor TP53 were proposed as a key etiological trigger of glioma development. p53 has been recently identified as a transcriptional target of parkin. Interestingly, somatic mutations on parkin have also been linked to glioma genesis. We examined the possibility that a disruption of a functional interaction between p53 and parkin could contribute to glioma development in samples devoid of somatic parkin mutations or genetic allele deletion. We show here that parkin levels inversely correlate to brain tumor grade and p53 levels in oligodendrogliomas, mixed gliomas and glioblastomas. We demonstrate that p53 levels negatively and positively correlate to bax and Bcl2 respectively, underlying a loss of p53 transcriptional activity in all types of glial tumors. Using various cell models lacking p53 or harboring either transcriptionally inactive or dominant negative p53, as well as in p53 knockout mice brain, we establish that p53 controls parkin promoter transactivation, mRNA and protein levels. Furthermore, we document an increase of parkin expression in mice brain after p53-bearing viral infection. Finally, both cancer-related p53 inactivating mutations and deletion of a consensus p53 binding sequence located on parkin promoter abolish p53-mediated control of parkin transcription, demonstrating that p53 regulates parkin transcription via its DNA binding properties. In conclusion, our work delineates a functional interplay between mutated p53 and parkin in glioma genesis that is disrupted by cancer-linked pathogenic mutations. It also allows envisioning parkin as a novel biomarker of glioma biopsies enabling to follow the progression of this type of cancers.	[Viotti, J.; Duplan, E.; Caillava, C.; Condat, J.; Goiran, T.; Giordano, C.; Checler, F.; Alves Da Costa, C.] CNRS, Inst Pharmacol Mol & Cellulaire, UNSA, Team Labeled Fdn,Rech Med & Lab Excellemce LABEX, F-06560 Valbonne, France; [Marie, Y.; Idbaih, A.; Delattre, J-Y] Univ Paris 06, AP HP, Grp Hosp Pitie Salpetriere,UMR 975, Ctr Rech,Inst Cerveau & Moelle Epiniere,Serv Neur, Paris, France; [Honnorat, J.] Hop Neurol, Hosp Civils Lyon, Ctr Reference Maladies Rares Syndromes Neurol Par, Lyon, France; [Honnorat, J.] Ctr Rech Neurosci Lyon, Inserm U1028, CNRS UMR 5292, Lyon, France; [Honnorat, J.] Univ Lyon 1, Univ Lyon, F-69365 Lyon, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU Lyon; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Jean Monnet; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Checler, F (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UNSA, Team Labeled Fdn,Rech Med & Lab Excellemce LABEX, Valbonne,PACA, F-06560 Valbonne, France.	checler@ipmc.cnrs.fr; acosta@ipmc.cnrs.fr	Honnorat, jerome/G-6394-2017; Duplan, Eric/AAK-8224-2020; Checler, Frederic/C-1241-2009; da Costa, Cristine Alves/G-8075-2011; Idbaih, Ahmed/N-8746-2017	Honnorat, jerome/0000-0002-4721-5952; Duplan, Eric/0000-0002-1348-1507; Checler, Frederic/0000-0003-2098-1750; da Costa, Cristine Alves/0000-0002-7777-005X; Giordano, Cecile/0000-0003-3641-8647; Idbaih, Ahmed/0000-0001-5290-1204; goiran, thomas/0000-0001-5838-8798	Fondation pour la Recherche Medicale; Conseil General des Alpes Maritimes; LABEX (excellence laboratory, program investment for the future) DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to Alzheimer's disease); AMPA (Association Monegasque Pour la recherche sur la Maladie d'Alzheimer); ARC ("Association pour la recherche contre le cancer")	Fondation pour la Recherche Medicale(Fondation pour la Recherche Medicale); Conseil General des Alpes Maritimes(Region Provence-Alpes-Cote d'Azur); LABEX (excellence laboratory, program investment for the future) DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to Alzheimer's disease); AMPA (Association Monegasque Pour la recherche sur la Maladie d'Alzheimer); ARC ("Association pour la recherche contre le cancer")(Fondation ARC pour la Recherche sur le Cancer)	Drs Roussel, Bourdon and Serrano are thanked for providing us with p53 knockout cells, MCF-7 cells and mice brains. Drs West and Oren are acknowledged for providing us with parkin-luciferase and PG13 constructs. JV was supported by AMPA (Association Monegasque Pour la recherche sur la Maladie d'Alzheimer) and ARC ("Association pour la recherche contre le cancer"). This work was supported by the 'Fondation pour la Recherche Medicale' and by the 'Conseil General des Alpes Maritimes'. This work has been developed and supported through the LABEX (excellence laboratory, program investment for the future) DISTALZ (Development of Innovative Strategies for a Transdisciplinary approach to Alzheimer's disease). Cristine Alves da Costa is recipient of a Hospital Contract for Translational Research (CHRT) between INSERM and the Hospices Civils de Lyon.	Agirre X, 2006, INT J CANCER, V118, P1945, DOI 10.1002/ijc.21584; Asker C, 1999, BIOCHEM BIOPH RES CO, V265, P1, DOI 10.1006/bbrc.1999.1446; Basu A, 1998, MOL HUM REPROD, V4, P1099, DOI 10.1093/molehr/4.12.1099; Bourdon JC, 2003, CELL DEATH DIFFER, V10, P397, DOI 10.1038/sj.cdd.4401243; Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693; Brown CJ, 2009, NAT REV CANCER, V9, P862, DOI 10.1038/nrc2763; Cesari R, 2003, P NATL ACAD SCI USA, V100, P5956, DOI 10.1073/pnas.0931262100; Costa SL, 2001, EUR J CANCER, V37, P520, DOI 10.1016/S0959-8049(00)00430-5; da Costa CA, 2006, J NEUROSCI, V26, P6377, DOI 10.1523/JNEUROSCI.0651-06.2006; da Costa CA, 2009, NAT CELL BIOL, V11, P1370, DOI 10.1038/ncb1981; Deguin-Chambon V, 2000, ONCOGENE, V19, P5831, DOI 10.1038/sj.onc.1203960; Edlund K, 2012, P NATL ACAD SCI USA, V109, P9551, DOI 10.1073/pnas.1200019109; Fujiwara M, 2008, ONCOGENE, V27, P6002, DOI 10.1038/onc.2008.199; Fulci G, 1998, BRAIN PATHOL, V8, P599, DOI 10.1111/j.1750-3639.1998.tb00187.x; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; GINSBERG D, 1990, ONCOGENE, V5, P1285; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hemann MT, 2006, CELL DEATH DIFFER, V13, P1256, DOI 10.1038/sj.cdd.4401962; Henn IH, 2005, J NEUROCHEM, V92, P114, DOI 10.1111/j.1471-4159.2004.02854.x; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Idbaih A, 2005, ANN NEUROL, V58, P483, DOI 10.1002/ana.20607; Idbaih A, 2008, INT J CANCER, V122, P1778, DOI 10.1002/ijc.23270; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Letessier A, 2007, ONCOGENE, V26, P298, DOI 10.1038/sj.onc.1209772; Lim YP, 2007, ONCOGENE, V26, P1517, DOI 10.1038/sj.onc.1209952; Maintz D, 1997, J NEUROPATH EXP NEUR, V56, P1098, DOI 10.1097/00005072-199710000-00003; Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, ONCOGENE, V9, P1799; MIYASHITA T, 1994, CANCER RES, V54, P3131; Nayak A, 2004, NEUROL INDIA, V52, P228; Nozaki M, 1999, Neuro Oncol, V1, P124, DOI 10.1093/neuonc/1.2.124; OHGAKI H, 1991, CANCER RES, V51, P6202; Ohgaki H, 2007, AM J PATHOL, V170, P1445, DOI 10.2353/ajpath.2007.070011; Pardossi-Piquard R, 2005, NEURON, V46, P541, DOI 10.1016/j.neuron.2005.04.008; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; Picchio MC, 2004, CLIN CANCER RES, V10, P2720, DOI 10.1158/1078-0432.CCR-03-0086; Poulogiannis G, 2010, P NATL ACAD SCI USA, V107, P15145, DOI 10.1073/pnas.1009941107; ROTTER V, 1983, P NATL ACAD SCI-BIOL, V80, P2613, DOI 10.1073/pnas.80.9.2613; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Sigal A, 2000, CANCER RES, V60, P6788; Soussi T, 2010, HUM MUTAT, V31, P1020, DOI 10.1002/humu.21313; Veeriah S, 2010, NAT GENET, V42, P77, DOI 10.1038/ng.491; Wang F, 2004, GENE CHROMOSOME CANC, V40, P85, DOI 10.1002/gcc.20020; Watanabe K, 1997, CLIN CANCER RES, V3, P523; Watanabe K, 1996, BRAIN PATHOL, V6, P217, DOI 10.1111/j.1750-3639.1996.tb00848.x; Weller M, 2009, J CLIN ONCOL, V27, P5743, DOI 10.1200/JCO.2009.23.0805; West AB, 2003, J MOL BIOL, V326, P11, DOI 10.1016/S0022-2836(02)01376-1; Yeo CWS, 2012, CANCER RES, V72, P2543, DOI 10.1158/0008-5472.CAN-11-3060; Zhang C, 2011, P NATL ACAD SCI USA, V108, P16259, DOI 10.1073/pnas.1113884108; Zinkel S, 2006, CELL DEATH DIFFER, V13, P1351, DOI 10.1038/sj.cdd.4401987	53	45	46	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2014	33	14					1764	1775		10.1038/onc.2013.124	http://dx.doi.org/10.1038/onc.2013.124			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RE	23644658				2022-12-28	WOS:000334345500003
J	Wasylishen, AR; Kalkat, M; Kim, SS; Pandyra, A; Chan, PK; Oliveri, S; Sedivy, E; Konforte, D; Bros, C; Raught, B; Penn, LZ				Wasylishen, A. R.; Kalkat, M.; Kim, S. S.; Pandyra, A.; Chan, P-K; Oliveri, S.; Sedivy, E.; Konforte, D.; Bros, C.; Raught, B.; Penn, L. Z.			MYC activity is negatively regulated by a C-terminal lysine cluster	ONCOGENE			English	Article						Myc; cellular transformation; apoptosis; lysine; transcription	TRANSACTIVATION DOMAIN; TRANSFORMATION; CELLS; ACETYLATION; FIBROBLASTS; ONCOPROTEIN; REPRESSES; PHENOTYPE; APOPTOSIS; LYMPHOMA	The MYC oncogene is not only deregulated in cancer through abnormally high levels of expression, but also through oncogenic lesions in upstream signalling cascades. Modelling MYC deregulation using signalling mutants is a productive research strategy. For example, the MYC threonine-58 to alanine substitution mutant (T58A) within MYC-homology box 1 is more transforming than wildtype (WT) MYC, because of decreased apoptosis and increased protein stability. Understanding the regulatory mechanisms controlling T58 phosphorylation has led to new approaches for the development of MYC inhibitors. In this manuscript, we have extensively characterized a MYC signalling mutant in which six lysine residues near the highly conserved MYC homology box IV and basic region have been substituted to arginines (6KR). Previous literature suggests these lysines can undergo both ubiquitylation and acetylation. We show MYC 6KR is able to fully rescue the slow growth phenotype of HO15.19 MYC-null fibroblasts, and promote cell cycle entry of serum-starved MCF10A cells. Remarkably, 6KR increased anchorage-independent colony growth compared with WT MYC in both SH-EP and MCF10A cells. Moreover, it was also more potent in promoting xenograft tumour growth of Rat1A and SH-EP cells. Combined, our data identify this region and these six lysines as important residues for the negative regulation of MYC-induced transformation. Mechanistically, we demonstrate that, unlike T58A, the increased transformation is not a result of increased protein stability or a reduced capacity for 6KR to induce apoptosis. Through expression analysis and luciferase reporter assays, we show that 6KR has increased transcriptional activity compared with WT MYC. Combined, through a comprehensive evaluation across multiple cell types, we identify an important regulatory region within MYC. A better understanding of the full scope of signalling through these residues will provide further insights into the mechanisms contributing to MYC-induced tumorigenesis and may unveil novel therapeutic strategies to target Myc in cancer.	[Wasylishen, A. R.; Kalkat, M.; Kim, S. S.; Pandyra, A.; Oliveri, S.; Sedivy, E.; Raught, B.; Penn, L. Z.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Wasylishen, A. R.; Kalkat, M.; Kim, S. S.; Pandyra, A.; Chan, P-K; Oliveri, S.; Sedivy, E.; Konforte, D.; Bros, C.; Raught, B.; Penn, L. Z.] Princess Margaret Hosp, Campbell Family Inst Canc Res, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Penn, LZ (corresponding author), Princess Margaret Hosp, Campbell Family Inst Canc Res, Ontario Canc Inst, Room 9-628,610 Univ Ave, Toronto, ON M5G 2M9, Canada.	lpenn@uhnres.utoronto.ca		Penn, Linda/0000-0001-8133-5459; Kalkat, Manpreet/0000-0002-4843-9755; Wasylishen, Amanda/0000-0002-1940-5169	Canadian Cancer Society Research Institute; Canadian Institute for Health Research; Canadian Breast Cancer Foundation Ontario Region Doctoral Fellowships; Ontario Graduate Student Fellowship; Ontario Ministry of Health; Ontario Long Term Care	Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Canadian Institute for Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Breast Cancer Foundation Ontario Region Doctoral Fellowships; Ontario Graduate Student Fellowship; Ontario Ministry of Health(Ministry of Health and Long-Term Care, Ontario); Ontario Long Term Care	We thank Dr Martin Eilers for kindly providing the Myc 6KR construct, Dr Garry Nolan for providing retroviral reagents and packaging cell lines. SH-EP Tet21/N-Myc, MCF10A, Rat-1A and HO15.19 cells were kindly provided by Dr Manfred Schwab, Dr Senthil Muthuswamy, Dr Edward Prochownick and Dr John Sedivy, respectively. Additionally we thank Drs Bruno Amati, Chi Dang and Stephen Hann for kindly providing luciferase reporter constructs. We also thank Andrew Rust and Drs Angelina Stojanova and Peter Mullen for technical assistance, and the members of the Penn Lab for helpful discussions and critical review of this manuscript. This research was funded by grants from the Canadian Cancer Society Research Institute and Canadian Institute for Health Research (LZP), Canadian Breast Cancer Foundation Ontario Region Doctoral Fellowships (ARW and AP) and an Ontario Graduate Student Fellowship (MK). BR and LZP hold the Canada Research Chairs in Proteomics & Molecular Medicine and Molecular Oncology, respectively. Additional support was provided by the Ontario Ministry of Health and Long Term Care. The views expressed do not necessarily reflect those of the OMOHLTC.	Adhikary S, 2005, CELL, V123, P409, DOI 10.1016/j.cell.2005.08.016; Berns K, 2000, ONCOGENE, V19, P3330, DOI 10.1038/sj.onc.1203639; BHATIA K, 1993, NAT GENET, V5, P56, DOI 10.1038/ng0993-56; Callus BA, 2008, CELL DEATH DIFFER, V15, P213, DOI 10.1038/sj.cdd.4402245; Chang DW, 2000, MOL CELL BIOL, V20, P4309, DOI 10.1128/MCB.20.12.4309-4319.2000; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Faiola F, 2005, MOL CELL BIOL, V25, P10220, DOI 10.1128/MCB.25.23.10220-10234.2005; Gartel AL, 2001, P NATL ACAD SCI USA, V98, P4510, DOI 10.1073/pnas.081074898; Graves JA, PLOS ONE, V5; Hann SR, 2006, SEMIN CANCER BIOL, V16, P288, DOI 10.1016/j.semcancer.2006.08.004; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; Kim W, 2011, MOL CELL, V44, P325, DOI 10.1016/j.molcel.2011.08.025; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; Marhin WW, 1997, ONCOGENE, V14, P2825, DOI 10.1038/sj.onc.1201138; Mateyak MK, 1997, CELL GROWTH DIFFER, V8, P1039; Ngo CV, 2000, CELL GROWTH DIFFER, V11, P201; Nie ZQ, 2012, CELL, V151, P68, DOI 10.1016/j.cell.2012.08.033; Oster SK, 2003, ONCOGENE, V22, P1998, DOI 10.1038/sj.onc.1206228; Patel JH, 2004, MOL CELL BIOL, V24, P10826, DOI 10.1128/MCB.24.24.10826-10834.2004; Popov N, 2007, NAT CELL BIOL, V9, P765, DOI 10.1038/ncb1601; RABBITTS TH, 1983, NATURE, V306, P760, DOI 10.1038/306760a0; Sears RC, 2004, CELL CYCLE, V3, P1133, DOI 10.4161/cc.3.9.1145; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; Thibodeaux CA, 2009, BREAST CANCER RES TR, V116, P281, DOI 10.1007/s10549-008-0127-x; Wang XY, 2011, CANCER RES, V71, P925, DOI 10.1158/0008-5472.CAN-10-1032; Wasylishen AR, 2011, ONCOGENE, V30, P3727, DOI 10.1038/onc.2011.88; Zhang KL, 2005, BIOCHEM BIOPH RES CO, V336, P274, DOI 10.1016/j.bbrc.2005.08.075	28	12	12	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2014	33	8					1066	1072		10.1038/onc.2013.36	http://dx.doi.org/10.1038/onc.2013.36			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XO	23435422				2022-12-28	WOS:000331933200014
J	Patel, RA; Liu, Y; Wang, B; Li, R; Sebti, SM				Patel, R. A.; Liu, Y.; Wang, B.; Li, R.; Sebti, S. M.			Identification of novel ROCK inhibitors with anti-migratory and anti-invasive activities	ONCOGENE			English	Article						RKI-18; ROCK1; ROCK2; invasion; migration; MLC-2	RHO-ASSOCIATED KINASE; BREAST-CANCER CELLS; TUMOR-CELLS; GTPASES; PROTEINS; OVEREXPRESSION; INVOLVEMENT; PROGRESSION; EXPRESSION; DISEASE	ROCK1 and ROCK2 mediate important processes such as cell migration, invasion and metastasis, making them good targets for the development of antitumor agents. Recently, using a fragment-based approach and X-ray crystallography, we reported on the design and synthesis of novel Rho-kinase inhibitors (RKIs). Here, we selected a pair of RKIs, the closely related structural analogs RKI-18 (potent; IC50 values of 397 nM (ROCK1) and 349 nM (ROCK2)) and RKI-11 (weak/inactive; IC50 values of 38 mu M (ROCK1) and 45 mu M (ROCK2)), as chemical probes and determined their effects on cytoskeleton organization, signaling, apoptosis, anchorage-dependent and independent growth, migration and invasion. RKI-18 but not RKI-11 suppresses potently the phosphorylation of the ROCK substrate myosin light chain 2 (MLC2) in intact human breast, lung, colon and prostate cancer cells. Furthermore, RKI-18 is highly selective at decreasing the levels of P-MLC2 over those of P-Akt, P-S6 and P-Erk 1/2. RKI-18 suppresses ROCK-mediated actin fiber formation, following stimulation with LPA as well as p21-activated kinase (PAK)-mediated lamellipodia and filopodia formation following bradykinin or PDGF stimulation. Furthermore, RKI-18 but not RKI-11 inhibits migration, invasion and anchorage-independent growth of human breast cancer cells. The fact that the active ROCK inhibitor RKI-18, but not the inactive closely related structural analog RKI-11 is effective at suppressing malignant transformation suggests that inhibition of ROCK with RKI-18 results in preventing migration, invasion and anchorage-independent growth. The potential of this class of RKIs as anti-tumor agents warrants further advanced preclinical studies.	[Patel, R. A.; Liu, Y.; Wang, B.; Li, R.; Sebti, S. M.] H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Dept, Tampa, FL 33612 USA; [Sebti, S. M.] Univ S Florida, Dept Oncol Sci, Tampa, FL USA; [Sebti, S. M.] Univ S Florida, Dept Mol Med, Tampa, FL USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Sebti, SM (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Drug Discovery Dept, SRB3-DRDIS,12902 Magnolia Dr, Tampa, FL 33612 USA.	said.sebti@moffitt.org			NCI [U19 CA 067771]; NATIONAL CANCER INSTITUTE [P30CA076292, R01CA098473, U19CA067771] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Nan Sun (Moffitt Cancer Center) and the following Moffitt Cancer Center core facilities: the Chemical Biology Core, the Analytical Microscopy Core and Comparative Medicine Core facility. This work was supported by NCI grant U19 CA 067771.	Amano M, 2000, EXP CELL RES, V261, P44, DOI 10.1006/excr.2000.5046; Balasis ME, 2011, CLIN CANCER RES, V17, P2852, DOI 10.1158/1078-0432.CCR-10-2544; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bourguignon LYW, 1999, CELL MOTIL CYTOSKEL, V43, P269, DOI 10.1002/(SICI)1097-0169(1999)43:4<269::AID-CM1>3.0.CO;2-5; Burbelo P, 2004, BREAST CANCER RES TR, V84, P43, DOI 10.1023/B:BREA.0000018422.02237.f9; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Imamura F, 2000, JPN J CANCER RES, V91, P811, DOI 10.1111/j.1349-7006.2000.tb01018.x; Itoh K, 1999, NAT MED, V5, P221, DOI 10.1038/5587; Kleer CG, 2002, AM J PATHOL, V160, P579, DOI 10.1016/S0002-9440(10)64877-8; Lane J, 2008, INT J ONCOL, V33, P585, DOI 10.3892/ijo_00000044; Li B, 2006, FEBS LETT, V580, P4252, DOI 10.1016/j.febslet.2006.06.056; Li RS, 2012, J MED CHEM, V55, P2474, DOI 10.1021/jm201289r; Liu SJ, 2009, CANCER RES, V69, P8742, DOI 10.1158/0008-5472.CAN-09-1541; Olson MF, 2009, CLIN EXP METASTAS, V26, P273, DOI 10.1007/s10585-008-9174-2; Olson MF, 2008, CURR OPIN CELL BIOL, V20, P242, DOI 10.1016/j.ceb.2008.01.002; Patel RA, 2012, CANCER RES, V72, P5025, DOI 10.1158/0008-5472.CAN-12-0954; Redowicz MJ, 1999, ARCH BIOCHEM BIOPHYS, V364, P122, DOI 10.1006/abbi.1999.1112; Ridley AJ, 2004, BREAST CANCER RES TR, V84, P13, DOI 10.1023/B:BREA.0000018423.47497.c6; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Routhier A, 2010, ONCOL REP, V23, P861, DOI 10.3892/or_00000708; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Scott RW, 2007, J MOL MED, V85, P555, DOI 10.1007/s00109-007-0165-6; Slack-Davis JK, 2003, J CELL BIOL, V162, P281, DOI 10.1083/jcb.200212141; Somlyo AP, 2003, PHYSIOL REV, V83, P1325, DOI 10.1152/physrev.00023.2003; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Tang Y, 2008, FRONT BIOSCI-LANDMRK, V13, P759, DOI 10.2741/2718; Vigil D, 2012, CANCER RES, V72, P5338, DOI 10.1158/0008-5472.CAN-11-2373; Wyckoff JB, 2006, CURR BIOL, V16, P1515, DOI 10.1016/j.cub.2006.05.065; Ying H, 2006, MOL CANCER THER, V5, P2158, DOI 10.1158/1535-7163.MCT-05-0440; Yoshioka K, 1999, CANCER RES, V59, P2004; Yoshioka K, 2003, P NATL ACAD SCI USA, V100, P7247, DOI 10.1073/pnas.1232344100; Zicha D, 2003, SCIENCE, V300, P142, DOI 10.1126/science.1082026	33	47	50	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2014	33	5					550	555		10.1038/onc.2012.634	http://dx.doi.org/10.1038/onc.2012.634			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5GW	23396364	Green Accepted			2022-12-28	WOS:000331125100003
J	Kuchenreuther, MJ; Weber, JD				Kuchenreuther, M. J.; Weber, J. D.			The ARF tumor-suppressor controls Drosha translation to prevent Ras-driven transformation	ONCOGENE			English	Article						ARF; Drosha; translation; tumor suppression; rRNA	RIBOSOMAL-RNA; PROTEIN; P53; EXPRESSION; P19(ARF); COMPLEX; DICER; MDM2; BIOGENESIS; MICRORNAS	ARF is a multifunctional tumor suppressor that acts as both a sensor of oncogenic stimuli and as a key regulator of ribosome biogenesis. Recently, our group established the DEAD-box RNA helicase and microRNA (miRNA) microprocessor accessory subunit, DDX5, as a critical target of basal ARF function. To identify other molecular targets of ARF, we focused on known interacting proteins of DDX5 in the microprocessor complex. Drosha, the catalytic core of the microprocessor complex, has a critical role in the maturation of specific non-coding RNAs, including miRNAs and ribosomal RNAs (rRNAs). Here, we report that chronic or acute loss of Arf enhanced Drosha protein expression. This induction did not involve Drosha mRNA transcription or protein stability but rather relied on the increased translation of existing Drosha mRNAs. Enhanced Drosha expression did not alter global miRNA production but rather modified expression of a subset of miRNAs in the absence of Arf. Elevated Drosha protein levels were required to maintain the increased rRNA synthesis and cellular proliferation observed in the absence of Arf. Arf-deficient cells transformed by oncogenic RasV12 were dependent on increased Drosha expression as Drosha knockdown was sufficient to inhibit Ras-dependent cellular transformation. Thus, we propose that ARF regulates Drosha mRNA translation to prevent aberrant cell proliferation and Ras-dependent transformation.	[Kuchenreuther, M. J.; Weber, J. D.] Washington Univ, Sch Med, BRIGHT Inst, St Louis, MO 63110 USA; [Kuchenreuther, M. J.; Weber, J. D.] Washington Univ, Sch Med, Dept Internal Med, Div Mol Oncol, St Louis, MO 63110 USA; [Weber, J. D.] Washington Univ, Sch Med, Dept Cell Biol, Siteman Canc Ctr, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Siteman Cancer Center; Washington University (WUSTL)	Weber, JD (corresponding author), Washington Univ, Sch Med, Dept Internal Med, BRIGHT Inst,Div Mol Oncol, 660 South Euclid Ave,Campus 8069, St Louis, MO 63110 USA.	jweber@dom.wustl.edu		Weber, Jason/0000-0002-1069-6983	Siteman Cancer Center, Cancer Biology Pathway Training Grant [T32 CA113275]; National Institutes of Health [R01 CA120436]; Department of Defense Era of Hope Scholar Award [BC075004]; NATIONAL CANCER INSTITUTE [R01CA120436, T32CA113275] Funding Source: NIH RePORTER	Siteman Cancer Center, Cancer Biology Pathway Training Grant; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense Era of Hope Scholar Award(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the members of the Weber lab for their technical input and suggestions. The Children's Discovery Institute and the Genome Institute at Washington University provided lentiviral knockdown constructs. MJK was supported by the Siteman Cancer Center, Cancer Biology Pathway Training Grant (T32 CA113275). Grants from the National Institutes of Health (R01 CA120436) and Department of Defense Era of Hope Scholar Award (BC075004) to JDW supported this work.	Apicelli AJ, 2008, MOL CELL BIOL, V28, P1068, DOI 10.1128/MCB.00484-07; Ayrault O, 2004, ONCOGENE, V23, P8097, DOI 10.1038/sj.onc.1207968; Bertwistle D, 2004, MOL CELL BIOL, V24, P985, DOI 10.1128/MCB.24.3.985-996.2004; Brady SN, 2004, MOL CELL BIOL, V24, P9327, DOI 10.1128/MCB.24.21.9327-9338.2004; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Denli AM, 2004, NATURE, V432, P231, DOI 10.1038/nature03049; Diederichs S, 2007, CELL, V131, P1097, DOI 10.1016/j.cell.2007.10.032; Fukuda T, 2007, NAT CELL BIOL, V9, P604, DOI 10.1038/ncb1577; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Han J, 2009, CELL, V136, P75, DOI 10.1016/j.cell.2008.10.053; Han JJ, 2004, GENE DEV, V18, P3016, DOI 10.1101/gad.1262504; Itahana K, 2003, MOL CELL, V12, P1151, DOI 10.1016/S1097-2765(03)00431-3; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kawagishi H, 2010, CANCER RES, V70, P4749, DOI 10.1158/0008-5472.CAN-10-0368; Kloosterman WP, 2006, DEV CELL, V11, P441, DOI 10.1016/j.devcel.2006.09.009; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385; Lessard F, 2010, MOL CELL, V38, P539, DOI 10.1016/j.molcel.2010.03.015; Lin RJ, 2010, CANCER RES, V70, P7841, DOI 10.1158/0008-5472.CAN-10-0970; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Maggi LB, 2008, MOL CELL BIOL, V28, P7050, DOI 10.1128/MCB.01548-07; Merritt WM, 2008, NEW ENGL J MED, V359, P2641, DOI 10.1056/NEJMoa0803785; Miceli AP, 2012, MOL CELL BIOL, V32, P348, DOI 10.1128/MCB.06030-11; Muralidhar B, 2011, J PATHOL, V224, P496, DOI 10.1002/path.2898; Olanich ME, 2011, ONCOGENE, V30, P77, DOI 10.1038/onc.2010.404; Oskowitz AZ, 2011, INT J BIOCHEM CELL B, V43, P1563, DOI 10.1016/j.biocel.2011.07.005; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; QUELLE DE, 1995, CELL, V83, P993; ROUSSEL MF, 1995, P NATL ACAD SCI USA, V92, P6837, DOI 10.1073/pnas.92.15.6837; Sand M, 2010, CANCER INVEST, V28, P649, DOI 10.3109/07357901003630918; Saporita AJ, 2011, CANCER RES, V71, P6708, DOI 10.1158/0008-5472.CAN-11-1472; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Shiohama A, 2007, EXP CELL RES, V313, P4196, DOI 10.1016/j.yexcr.2007.07.020; Strezoska Z, 2000, MOL CELL BIOL, V20, P5516, DOI 10.1128/MCB.20.15.5516-5528.2000; Sugimoto M, 2003, MOL CELL, V11, P415, DOI 10.1016/S1097-2765(03)00057-1; Sugito N, 2006, CLIN CANCER RES, V12, P7322, DOI 10.1158/1078-0432.CCR-06-0515; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wu HJ, 2000, J BIOL CHEM, V275, P36957, DOI 10.1074/jbc.M005494200; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4	41	11	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2014	33	3					300	307		10.1038/onc.2012.601	http://dx.doi.org/10.1038/onc.2012.601			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VR	23318441	Green Accepted			2022-12-28	WOS:000330214000004
J	Xiang, Y; Ma, N; Wang, D; Zhang, Y; Zhou, J; Wu, G; Zhao, R; Huang, H; Wang, X; Qiao, Y; Li, F; Han, D; Wang, L; Zhang, G; Gao, X				Xiang, Y.; Ma, N.; Wang, D.; Zhang, Y.; Zhou, J.; Wu, G.; Zhao, R.; Huang, H.; Wang, X.; Qiao, Y.; Li, F.; Han, D.; Wang, L.; Zhang, G.; Gao, X.			MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine	ONCOGENE			English	Article						cisplatin resistance; microRNA; DNMT1; decitabine; ovarian cancer	DNA METHYLTRANSFERASE 1; GENE-EXPRESSION; IN-VITRO; HEPATOCELLULAR-CARCINOMA; ENDOMETRIAL CANCER; PLATINUM-RESISTANT; DRUG-RESISTANCE; BREAST-CANCER; LINES; METHYLATION	Epithelial ovarian cancer (EOC) is a highly lethal gynaecological malignancy. Cisplatin is the basal chemotherapeutic agent used to treat EOC, but resistance to cisplatin leads to chemotherapy failure. MicroRNAs are a novel class of regulators that function by controlling gene expression at the post-transcriptional level. Several recent reports have identified some microRNAs that are related to chemotherapy sensitivity. In this study, we found two microRNAs miR-152 and miR-185 that were significantly downregulated in the cisplatin-resistant ovarian cell lines SKOV3/DDP and A2780/DDP, compared with their sensitive parent line SKOV3 and A2780, respectively. Subsequently, the roles of miR-152 and miR-185 were evaluated in vitro and in vivo. The overexpression of miR-152 or miR-185 increased cisplatin sensitivity of SKOV3/DDP and A2780/DDP cells by inhibiting proliferation and promoting apoptosis, then we further confirmed that these miRNAs functioned through suppressing DNA methyltransferase 1 (DNMT1) directly. Concordantly, CD-1/CD-1 nude mice that were injected intraperitoneally with SKOV3/DDP cells transfected with miR-152 mimics exhibited upregulated cisplatin sensitivity in vivo. Interestingly, we found that there were no significant changes in the expression of these two microRNAs after treatment with decitabine (DAC), a traditional epigenetic therapeutic agent, suggesting these miRNAs represented two new regulators independent of DAC. Finally, the survival assay in A549 and HepG2 cells revealed that the two microRNAs involved in cisplatin sensitivity were related to cell types. Our results indicated that miR-152 and miR-185 were involved in ovarian cancer cisplatin resistance in vitro and in vivo by targeting DNMT1 directly. These molecules may serve as potential epigenetic therapeutic targets in other cancers.	[Xiang, Y.; Ma, N.; Wang, D.; Zhou, J.; Wu, G.; Zhao, R.; Huang, H.; Wang, X.; Qiao, Y.; Li, F.; Han, D.; Wang, L.; Gao, X.] Harbin Med Univ, Dept Biochem & Mol Biol, Harbin 150086, Peoples R China; [Zhang, Y.] Harbin Med Univ, Dept Lab Diag, Affiliated Hosp 1, Harbin 150086, Peoples R China; [Zhang, G.] Harbin Med Univ, Dept Obstet & Gynecol, Affiliated Hosp 1, Harbin 150086, Peoples R China; [Gao, X.] Minist Educ, Key Lab Cardiovasc Med Res, Harbin, Peoples R China; [Gao, X.] Harbin Med Univ, State Prov Key Labs Biomed Pharmaceut China, Harbin 150086, Peoples R China	Harbin Medical University; Harbin Medical University; Harbin Medical University; Harbin Medical University	Zhang, G (corresponding author), Harbin Med Univ, Dept Obstet & Gynecol, Affiliated Hosp 1, Harbin 150086, Peoples R China.	zhangguangmei@126.com; gaoxu_671227@yahoo.com.cn	gao, xu/U-4765-2019	Xiang, Ying/0000-0002-4879-2751	Natural Science Foundation of Heilongjiang Province for youth and for outstanding youth [QC2010002, JC201110]; Natural Science Foundation of China [81101373, 81270511, 81001033]; Science Foundation of Health Department of Heilongjiang Province [2012-525]; Science Foundation of the First Affiliated Hospital of Harbin Medical University [2009Y24]	Natural Science Foundation of Heilongjiang Province for youth and for outstanding youth; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Science Foundation of Health Department of Heilongjiang Province; Science Foundation of the First Affiliated Hospital of Harbin Medical University	This work was supported by the Natural Science Foundation of Heilongjiang Province for youth (QC2010002) and for outstanding youth (JC201110), the Natural Science Foundation of China (81101373/81270511/81001033), the Science Foundation of Health Department of Heilongjiang Province(2012-525) and the Science Foundation of the First Affiliated Hospital of Harbin Medical University (2009Y24).	Akcakaya P, 2011, INT J ONCOL, V39, P311, DOI 10.3892/ijo.2011.1043; Barabas K, 2008, VET COMP ONCOL, V6, P1, DOI 10.1111/j.1476-5829.2007.00142.x; Basu A., 2010, J NUCL ACIDS, V2010; Blum KA, 2010, BRIT J HAEMATOL, V150, P189, DOI 10.1111/j.1365-2141.2010.08213.x; Blum W, 2012, BLOOD, V119, P6025, DOI 10.1182/blood-2012-03-413898; Chan TA, 2008, PLOS MED, V5, P823, DOI 10.1371/journal.pmed.0050114; Chen Huaping, 2011, Frontiers in Genetics, V2, P67, DOI 10.3389/fgene.2011.00067; Chen Y, 2010, J GASTROINTEST SURG, V14, P1170, DOI 10.1007/s11605-010-1202-2; Cho KR, 2009, ANNU REV PATHOL-MECH, V4, P287, DOI 10.1146/annurev.pathol.4.110807.092246; Fan H, 2009, WORLD J GASTROENTERO, V15, P2020, DOI 10.3748/wjg.15.2020; Fang F, 2010, CANCER-AM CANCER SOC, V116, P4043, DOI 10.1002/cncr.25204; Fu X, 2012, FEBS LETT, V586, P1279, DOI 10.1016/j.febslet.2012.03.006; Fung-Kee-Fung M, 2007, Curr Oncol, V14, P195; Glasspool RM, 2006, BRIT J CANCER, V94, P1087, DOI 10.1038/sj.bjc.6603024; Helleday T, 2008, NAT REV CANCER, V8, P193, DOI 10.1038/nrc2342; Hendrickson DG, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000238; Holleman A, 2011, ONCOGENE, V30, P4386, DOI 10.1038/onc.2011.148; Huang JF, 2010, HEPATOLOGY, V52, P60, DOI 10.1002/hep.23660; Imam JS, 2010, ONCOGENE, V29, P4971, DOI 10.1038/onc.2010.233; Ishida S, 2002, P NATL ACAD SCI USA, V99, P14298, DOI 10.1073/pnas.162491399; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kantarjian HM, 2005, SEMIN HEMATOL, V42, pS17, DOI 10.1053/j.seminhematol.2005.05.006; Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167; Kovalchuk O, 2008, MOL CANCER THER, V7, P2152, DOI 10.1158/1535-7163.MCT-08-0021; Kwon MJ, 2011, INT J MOL SCI, V12, P983, DOI 10.3390/ijms12020983; LENZI R, 1994, ANTICANCER RES, V14, P247; Li M, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-34; Liao JM, 2011, J BIOL CHEM, V286, P33901, DOI 10.1074/jbc.M111.262030; Lu JA, 2011, CANCER RES, V71, P225, DOI 10.1158/0008-5472.CAN-10-1850; Luszczek W, 2010, MOL CANCER THER, V9, P2309, DOI 10.1158/1535-7163.MCT-10-0309; Malizia AP, 2011, WIRES SYST BIOL MED, V3, P183, DOI 10.1002/wsbm.111; Matei D, 2012, CANCER RES, V72, P2197, DOI 10.1158/0008-5472.CAN-11-3909; Matei DE, 2010, GYNECOL ONCOL, V116, P195, DOI 10.1016/j.ygyno.2009.09.043; Myatt SS, 2010, CANCER RES, V70, P367, DOI 10.1158/0008-5472.CAN-09-1891; OZOLS RF, 1991, SEMIN ONCOL, V18, P222; Plumb JA, 2000, CANCER RES, V60, P6039; Qin TC, 2009, BLOOD, V113, P659, DOI 10.1182/blood-2008-02-140038; Saito Y, 2009, BIOCHEM BIOPH RES CO, V379, P726, DOI 10.1016/j.bbrc.2008.12.098; Sangodkar J, 2012, J CLIN INVEST, V122, P2637, DOI 10.1172/JCI62058; Selvakumaran M, 2003, CANCER RES, V63, P1311; Selvakumaran M, 2001, CANCER RES, V61, P1291; Singh RK, 2008, GYNECOL ONCOL, V109, P240, DOI 10.1016/j.ygyno.2008.01.042; Takahashi Y, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006677; Tang MQ, 2009, CURR GENOMICS, V10, P336, DOI 10.2174/138920209788920994; Tohyama K, 2012, CURR PHARM DESIGN, V18, P3190, DOI 10.2174/1381612811209023190; Tsai KW, 2011, INT J CANCER, V129, P2600, DOI 10.1002/ijc.25919; Tsuruta T, 2011, CANCER RES, V71, P6450, DOI 10.1158/0008-5472.CAN-11-0364; Yang DF, 2012, J IMMUNOL, V188, P4441, DOI 10.4049/jimmunol.1103035; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488; Yang N, 2008, CANCER RES, V68, P10307, DOI 10.1158/0008-5472.CAN-08-1954; Yi TZ, 2012, CHEMOTHERAPY, V58, P19, DOI 10.1159/000333077; Zhang JQ, 2012, GASTROENTEROLOGY, V143, P246, DOI 10.1053/j.gastro.2012.03.045; Zhang ZP, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-124; Zhao JJ, 2008, J BIOL CHEM, V283, P31079, DOI 10.1074/jbc.M806041200; Zhao ZW, 2012, BIOCHEM J, V444, P291, DOI 10.1042/BJ20111855; Zhou X, 2012, ONCOL REP, V27, P447, DOI 10.3892/or.2011.1482	56	165	177	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2014	33	3					378	386		10.1038/onc.2012.575	http://dx.doi.org/10.1038/onc.2012.575			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VR	23318422				2022-12-28	WOS:000330214000012
J	Portela, A; Liz, J; Nogales, V; Setien, F; Villanueva, A; Esteller, M				Portela, A.; Liz, J.; Nogales, V.; Setien, F.; Villanueva, A.; Esteller, M.			DNA methylation determines nucleosome occupancy in the 5 '-CpG islands of tumor suppressor genes	ONCOGENE			English	Article						DNA methylation; tumor suppressor gene; nucleosome; CpG island; DNA methyltransferase	CHROMATIN; PROMOTERS; TISSUES; DNMT3B	Promoter CpG island hypermethylation of tumor suppressor genes is an epigenetic hallmark of human cancer commonly associated with nucleosome occupancy and the transcriptional silencing of the neighboring gene. Nucleosomes can determine the underlying DNA methylation status. Herein, we show that the opposite is also true: DNA methylation can determine nucleosome positioning. Using a cancer model and digital nucleosome positioning techniques, we demonstrate that the induction of DNA hypomethylation events by genetic (DNMT1/DNMT3B deficient cells) or drug (a DNA demethylating agent) approaches is associated with the eviction of nucleosomes from previously hypermethylated CpG islands of tumor suppressor genes. Most importantly, the establishment of a stable cell line that restores DNMT1/DNMT3B deficiency shows that nucleosomes reoccupy their positions in de novo methylated CpG islands. Finally, we extend these results to the genomic level, combining a DNA methylation microarray and the nucleosome positioning technique. Using this global approach, we observe the dependency of nucleosome occupancy upon the DNA methylation status. Thus, our results suggest that there is a close association between hypermethylated CpG islands and the presence of nucleosomes, such that each of these epigenetic mechanisms can determine the recruitment of the other.	[Portela, A.; Liz, J.; Nogales, V.; Setien, F.; Esteller, M.] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, Barcelona, Catalonia, Spain; [Villanueva, A.] Bellvitge Biomed Res Inst IDIBELL, Translat Res Lab, Catalan Inst Oncol, Barcelona, Catalonia, Spain; [Esteller, M.] Univ Barcelona, Sch Med, Dept Physiol Sci 2, Barcelona, Catalonia, Spain; [Esteller, M.] ICREA, Barcelona, Catalonia, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; ICREA	Esteller, M (corresponding author), Hosp Duran & Reynals, Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Program PEBC, 3rd Floor,Avda Gran Via Km 2-7, Barcelona 08908, Catalonia, Spain.	mesteller@idibell.cat	Esteller, Manel/L-5956-2014	Esteller, Manel/0000-0003-4490-6093; Portela, Anna/0000-0003-2184-2584; Nogales, Vanesa/0000-0002-4905-5278	Ministerio de Ciencia e Innovacion (MICINN) [SAF2011-22803]; European Research Council (ERC) Advanced Grant EPINORC; Cellex Foundation; Health and Science Departments of the Catalan Government (Generalitat de Catalunya); Fondo de Investigaciones Sanitarias Grant [PI08-1345]; ICREA Funding Source: Custom	Ministerio de Ciencia e Innovacion (MICINN)(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); European Research Council (ERC) Advanced Grant EPINORC(European Research Council (ERC)); Cellex Foundation(Foundation CELLEX); Health and Science Departments of the Catalan Government (Generalitat de Catalunya); Fondo de Investigaciones Sanitarias Grant; ICREA(ICREA)	This work was supported by the Ministerio de Ciencia e Innovacion (MICINN), grant number SAF2011-22803 (ME), the European Research Council (ERC) Advanced Grant EPINORC (ME), Cellex Foundation, the Health and Science Departments of the Catalan Government (Generalitat de Catalunya) and a Fondo de Investigaciones Sanitarias Grant PI08-1345 (ME). AP is a Sara Borrell Postdoctoral Fellow. ME is an ICREA Research Professor.	Bartke T, 2010, CELL, V143, P470, DOI 10.1016/j.cell.2010.10.012; Bibikova M, 2006, GENOME RES, V16, P383, DOI 10.1101/gr.4410706; Byun HM, 2009, HUM MOL GENET, V18, P4808, DOI 10.1093/hmg/ddp445; Cairns BR, 2009, NATURE, V461, P193, DOI 10.1038/nature08450; Chodavarapu RK, 2010, NATURE, V466, P388, DOI 10.1038/nature09147; Christensen BC, 2009, CANCER RES, V69, P6315, DOI 10.1158/0008-5472.CAN-09-1073; Davey CS, 2004, NUCLEIC ACIDS RES, V32, P4322, DOI 10.1093/nar/gkh749; De Carvalho DD, 2012, CANCER CELL, V21, P655, DOI 10.1016/j.ccr.2012.03.045; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Fatemi M, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni180; Felle M, 2011, NUCLEIC ACIDS RES, V39, P6956, DOI 10.1093/nar/gkr263; Fernandez AF, 2012, GENOME RES, V22, P407, DOI 10.1101/gr.119867.110; Gowher H, 2005, BIOCHEMISTRY-US, V44, P9899, DOI 10.1021/bi047634t; Han H, 2011, HUM MOL GENET, V20, P4299, DOI 10.1093/hmg/ddr356; Hodges C, 2009, SCIENCE, V325, P626, DOI 10.1126/science.1172926; Jacinto FV, 2007, CANCER RES, V67, P11481, DOI 10.1158/0008-5472.CAN-07-2687; Carmona FJ, 2012, J PATHOL, V228, P230, DOI 10.1002/path.4011; Jeong S, 2009, MOL CELL BIOL, V29, P5366, DOI 10.1128/MCB.00484-09; Jiang CZ, 2009, NAT REV GENET, V10, P161, DOI 10.1038/nrg2522; Kelly TK, 2012, GENOME RES, V22, P2497, DOI 10.1101/gr.143008.112; Lee JY, 2012, J AM CHEM SOC, V134, P173, DOI 10.1021/ja210273w; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Lin JC, 2007, CANCER CELL, V12, P432, DOI 10.1016/j.ccr.2007.10.014; Pandiyan K, 2013, NUCLEIC ACIDS RES, V41, P3973, DOI 10.1093/nar/gkt077; Pennings Sari, 2005, Briefings in Functional Genomics & Proteomics, V3, P351, DOI 10.1093/bfgp/3.4.351; Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Sandoval J, 2011, EPIGENETICS-US, V6, P692, DOI 10.4161/epi.6.6.16196; Schones DE, 2008, CELL, V132, P887, DOI 10.1016/j.cell.2008.02.022; Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157; Sharma S, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001286; Shen L, 2007, PLOS GENET, V3, P2023, DOI 10.1371/journal.pgen.0030181; Shen L, 2010, NUCLEIC ACIDS RES, V38, P6054, DOI 10.1093/nar/gkq456; Youssef EM, 2004, CANCER BIOL THER, V3, P82, DOI 10.4161/cbt.3.1.591	34	27	29	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2013	32	47					5421	5428		10.1038/onc.2013.162	http://dx.doi.org/10.1038/onc.2013.162			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	254PM	23686312	hybrid, Green Published			2022-12-28	WOS:000327177600005
J	Conforti, F; Yang, AL; Piro, MC; Mellone, M; Terrinoni, A; Candi, E; Tucci, P; Thomas, GJ; Knight, RA; Melino, G; Sayan, BS				Conforti, F.; Yang, Ai Li; Piro, M. Cristina; Mellone, M.; Terrinoni, A.; Candi, E.; Tucci, P.; Thomas, G. J.; Knight, R. A.; Melino, G.; Sayan, B. S.			PIR2/Rnf144B regulates epithelial homeostasis by mediating degradation of p21WAF1 and p63	ONCOGENE			English	Article						PIR2; Rnf144B; p63; p21(WAF1); squamous cell carcinoma (SCC); skin	SQUAMOUS-CELL CARCINOMA; E3 UBIQUITIN LIGASE; STEM-CELLS; DIFFERENTIATION; PROTEASOME; APOPTOSIS; PROTEIN; CANCER; CYCLE; EXPRESSION	Delta Np63 is a transcription factor that is critical for the development of stratified epithelia and is overexpressed or amplified in >80% of squamous cell carcinomas (SCCs). We identified the RING finger E3 ubiquitin ligase PIR2/Rnf144b as a direct transcriptional target of Delta Np63 alpha and showed that its expression parallels that of Delta Np63 alpha in keratinocytes, SCC cell lines and SCCs. We used primary keratinocytes as a model system to investigate the function of PIR2/Rnf144b in stratified epithelia. Depletion of PIR2/Rnf144b severely impaired keratinocyte proliferation and differentiation, associated with accumulation of p21(WAF1/CIP1); a known target of PIR2/Rnf144b. More importantly, we found that PIR2/Rnf144b binds and mediates proteasomal degradation of Delta Np63 alpha, generating a hitherto unknown auto-regulatory feedback loop. These findings substantiate PIR2/Rnf144b as a potentially critical component of epithelial homeostasis, acting downstream of Delta Np63 alpha to regulate cellular levels of p21(WAF1/CIP1) and Delta Np63 alpha.	[Conforti, F.; Mellone, M.; Thomas, G. J.; Sayan, B. S.] Univ Southampton, Fac Med, Canc Sci Unit, Southampton SO16 6YD, Hants, England; [Yang, Ai Li; Tucci, P.; Knight, R. A.; Melino, G.] Univ Leicester, MRC, Toxicol Unit, Leicester, Leics, England; [Piro, M. Cristina; Terrinoni, A.; Candi, E.; Tucci, P.; Melino, G.] Univ Roma Tor Vergata, Dept Expt Med & Surg, IDI IRCCS, Biochem Lab, Rome, Italy	University of Southampton; University of Leicester; IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Rome Tor Vergata	Sayan, BS (corresponding author), Univ Southampton, Fac Med, Canc Sci Unit, Somers Canc Res Bldg,Tremona Rd,MP824, Southampton SO16 6YD, Hants, England.	b.s.sayan@soton.ac.uk	PIRO, MARIA CRISTINA/GVT-4380-2022; TERRINONI, Alessandro/J-1533-2012	PIRO, MARIA CRISTINA/0000-0003-3004-367X; TERRINONI, Alessandro/0000-0002-7442-2252; mellone, massimiliano/0000-0002-4964-9340; TUCCI, PAOLA/0000-0002-9349-5203	University of Southampton; Medical Research Council, UK; 'Alleanza contro il Cancro' [ACC12]; MIUR/PRIN [RBIP06LCA9_0023]; AIRC [2008-2010_33-08]; Italian Human ProteomeNet RBRN07BMCT; MRC [MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_U132670600] Funding Source: researchfish	University of Southampton; Medical Research Council, UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); 'Alleanza contro il Cancro'; MIUR/PRIN(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); AIRC(Fondazione AIRC per la ricerca sul cancro); Italian Human ProteomeNet RBRN07BMCT; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	This work has been supported by funding from the University of Southampton to BSS and by the Medical Research Council, UK; 'Alleanza contro il Cancro' (ACC12), MIUR/PRIN (RBIP06LCA9_0023), AIRC (2008-2010_33-08), Italian Human ProteomeNet RBRN07BMCT to GM.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Benard G, 2010, EMBO J, V29, P1458, DOI 10.1038/emboj.2010.39; Blagosklonny MV, 1996, BIOCHEM BIOPH RES CO, V227, P564, DOI 10.1006/bbrc.1996.1546; Blanpain C, 2009, NAT REV MOL CELL BIO, V10, P207, DOI 10.1038/nrm2636; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Candi E, 2008, CELL MOL LIFE SCI, V65, P3126, DOI 10.1007/s00018-008-8119-x; Candi E, 2006, CELL DEATH DIFFER, V13, P1037, DOI 10.1038/sj.cdd.4401926; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Cheok CF, 2011, NAT REV CLIN ONCOL, V8, P25, DOI 10.1038/nrclinonc.2010.174; Ciechanover A, 2005, NAT REV MOL CELL BIO, V6, P79, DOI 10.1038/nrm1552; Ciechanover A, 2005, CELL DEATH DIFFER, V12, P1178, DOI 10.1038/sj.cdd.4401692; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; DeYoung MP, 2007, ONCOGENE, V26, P5169, DOI 10.1038/sj.onc.1210337; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Graziano V, 2011, BBA-REV CANCER, V1816, P57, DOI 10.1016/j.bbcan.2011.04.002; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Huang J, 2006, FEBS LETT, V580, P940, DOI 10.1016/j.febslet.2005.09.105; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Lena AM, 2008, CELL DEATH DIFFER, V15, P1187, DOI 10.1038/cdd.2008.69; Li YC, 2009, MOL CELL BIOL, V29, P3953, DOI 10.1128/MCB.00449-09; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Ng CC, 2003, ONCOGENE, V22, P4449, DOI 10.1038/sj.onc.1206586; Nguyen BC, 2006, GENE DEV, V20, P1028, DOI 10.1101/gad.1406006; Okuyama R, 2004, J INVEST DERM SYMP P, V9, P248, DOI 10.1111/j.1087-0024.2004.09308.x; Ponassi R, 2006, BIOCHEM PHARMACOL, V72, P1417, DOI 10.1016/j.bcp.2006.07.031; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Sayan AE, 2012, ONCOGENE, V31, P1493, DOI 10.1038/onc.2011.336; Sayan AE, 2007, ANN NY ACAD SCI, V1095, P315, DOI 10.1196/annals.1397.035; Sayan AE, 2010, BIOCHEM BIOPH RES CO, V394, P824, DOI 10.1016/j.bbrc.2010.03.084; Sayan BS, 2010, P NATL ACAD SCI USA, V107, P12877, DOI 10.1073/pnas.0911828107; Schavolt KL, 2007, ONCOGENE, V26, P6125, DOI 10.1038/sj.onc.1210441; Sniezek JC, 2004, LARYNGOSCOPE, V114, P2063, DOI 10.1097/01.mlg.0000149437.35855.4b; Suh EK, 2006, NATURE, V444, P624, DOI 10.1038/nature05337; Taebunpakul P, 2012, APOPTOSIS, V17, P762, DOI 10.1007/s10495-012-0720-7; Truong AB, 2006, GENE DEV, V20, P3185, DOI 10.1101/gad.1463206; Vanbokhoven H, 2011, J INVEST DERMATOL, V131, P1196, DOI 10.1038/jid.2011.84; Watt FM, 2006, CURR OPIN GENET DEV, V16, P518, DOI 10.1016/j.gde.2006.08.006; Weinberg WC, 2002, CRIT REV ORAL BIOL M, V13, P453, DOI 10.1177/154411130201300603; Westra WH, 2009, HEAD NECK PATHOL, V3, P78, DOI 10.1007/s12105-009-0100-y; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539	42	18	19	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	2013	32	40					4758	4765		10.1038/onc.2012.497	http://dx.doi.org/10.1038/onc.2012.497			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229NW	23128396				2022-12-28	WOS:000325274700004
J	Sun, Y; Liu, PY; Scarlett, CJ; Malyukova, A; Liu, B; Marshall, GM; MacKenzie, KL; Biankin, AV; Liu, T				Sun, Y.; Liu, P. Y.; Scarlett, C. J.; Malyukova, A.; Liu, B.; Marshall, G. M.; MacKenzie, K. L.; Biankin, A. V.; Liu, T.			Histone deacetylase 5 blocks neuroblastoma cell differentiation by interacting with N-Myc	ONCOGENE			English	Article						N-Myc; neuroblastoma; histone deacetylase 5	EMBRYONIC STEM-CELLS; C-MYC; MUSCLE DIFFERENTIATION; GENOMIC TARGETS; PROTEIN; REPRESSION; HDAC5; TRANSCRIPTION; EXPRESSION; INHIBITORS	The N-Myc oncoprotein induces neuroblastoma, which arises from undifferentiated neuroblasts in the sympathetic nervous system, by modulating gene and protein expression and consequently causing cell differentiation block and cell proliferation. The class Ila histone deacetylase 5 (HDAC5) represses gene transcription, and blocks myoblast, osteoblast and leukemia cell differentiation. Here we showed that N-Myc upregulated HDAC5 expression in neuroblastoma cells. Conversely, HDAC5 repressed the ubiquitin-protein ligase NEDD4 gene expression, increased Aurora A gene expression and consequently upregulated N-Myc protein expression. Genome-wide gene expression analysis and protein co-immunoprecipitation assays revealed that HDAC5 and N-Myc repressed the expression of a common subset of genes by forming a protein complex, whereas HDAC5 and the class III HDAC SIRT2 independently repressed the expression of another common subset of genes without forming a protein complex. Moreover, HDAC5 blocked differentiation and induced proliferation in neuroblastoma cells. Taken together, our data identify HDAC5 as a novel co-factor in N-Myc oncogenesis, and provide the evidence for the potential application of HDAC5 inhibitors in the therapy of N-Myc-induced neuroblastoma and potentially other c-Myc-induced malignancies.	[Sun, Y.; Liu, P. Y.; Malyukova, A.; Liu, B.; Marshall, G. M.; MacKenzie, K. L.; Liu, T.] Childrens Canc Inst Australia Med Res, Randwick, NSW, Australia; [Scarlett, C. J.] Univ Newcastle, Sch Environm & Life Sci, Ourimbah, NSW, Australia; [Scarlett, C. J.; Biankin, A. V.] Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW, Australia; [Liu, B.] Kids Canc Alliance, Randwick, NSW, Australia; [Marshall, G. M.] Sydney Childrens Hosp, Kids Canc Ctr, Randwick, NSW, Australia; [Biankin, A. V.] Bankstown Hosp, Dept Surg, Bankstown, NSW, Australia; [Biankin, A. V.] Univ New S Wales, Fac Med, South Western Sydney Clin Sch, Liverpool, NSW, Australia; [Liu, T.] Univ New S Wales, UNSW Med, Sch Womens & Childrens Hlth, Randwick, NSW, Australia	Children's Cancer Institute; University of Newcastle; Garvan Institute of Medical Research; University of New South Wales Sydney; University of New South Wales Sydney	Liu, T (corresponding author), Univ New S Wales, Lowy Canc Res Ctr, Childrens Canc Inst Australia, Sydney, NSW 2052, Australia.	tliu@unsw.edu.au	Mackenzie, Karen/F-1310-2011; Liu, Tao/A-3922-2015; MacKenzie, Karen/N-5849-2019	Scarlett, Christopher/0000-0002-4140-7785; Biankin, Andrew/0000-0002-0362-5597; MacKenzie, Karen/0000-0003-2996-1617; Liu, Tao/0000-0001-6244-7316	National Health and Medical Research Council [1006002]; Cancer Council NSW project grant; ARC Future Fellowship; Cancer Institute New South Wales Fellowships; Cancer Research UK [17263] Funding Source: researchfish	National Health and Medical Research Council(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council NSW project grant(Cancer Council New South Wales); ARC Future Fellowship(Australian Research Council); Cancer Institute New South Wales Fellowships; Cancer Research UK(Cancer Research UK)	We thank Dr Eric Olsen for the HDAC5 expression constructs. This work was supported by a National Health and Medical Research Council project grant 1006002 (T Liu and CJ Scarlett) and a Cancer Council NSW project grant. T Liu is a recipient of an ARC Future Fellowship, AV Biankin and CJ Scarlett are recipients of Cancer Institute New South Wales Fellowships. Children's Cancer Institute Australia is affiliated with University of New South Wales and Sydney Children's Hospital.	Bibel M, 2004, NAT NEUROSCI, V7, P1003, DOI 10.1038/nn1301; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Cole MD, 2008, NAT REV MOL CELL BIO, V9, P810, DOI 10.1038/nrm2467; Eilers M, 2008, GENE DEV, V22, P2755, DOI 10.1101/gad.1712408; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Gustafson WC, 2010, ONCOGENE, V29, P1249, DOI 10.1038/onc.2009.512; Huang EY, 2000, GENE DEV, V14, P45; Kang JS, 2005, EMBO J, V24, P2543, DOI 10.1038/sj.emboj.7600729; Kao HY, 2000, GENE DEV, V14, P55; Lemercier C, 2000, J BIOL CHEM, V275, P15594, DOI 10.1074/jbc.M908437199; Lin CY, 2012, CELL, V151, P56, DOI 10.1016/j.cell.2012.08.026; Liu PY, 2013, CELL DEATH DIFFER, V20, P503, DOI 10.1038/cdd.2012.147; Liu T, 2007, P NATL ACAD SCI USA, V104, P18682, DOI 10.1073/pnas.0705524104; Liu T, 2009, EUR J CANCER, V45, P1846, DOI 10.1016/j.ejca.2009.03.002; Long XC, 2007, P NATL ACAD SCI USA, V104, P16570, DOI 10.1073/pnas.0708253104; Manji SSM, 2006, J NEUROSCI RES, V83, P181, DOI 10.1002/jnr.20721; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; Marshall GM, 2010, ONCOGENE, V29, P5957, DOI 10.1038/onc.2010.332; Marshall GM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002135; Martin M, 2007, ONCOGENE, V26, P5450, DOI 10.1038/sj.onc.1210613; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Milde T, 2010, CLIN CANCER RES, V16, P3240, DOI 10.1158/1078-0432.CCR-10-0395; Nie ZQ, 2012, CELL, V151, P68, DOI 10.1016/j.cell.2012.08.033; Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005; Patel JH, 2004, NAT REV CANCER, V4, P562, DOI 10.1038/nrc1393; Peixoto P, 2012, CELL DEATH DIFFER, V19, P1239, DOI 10.1038/cdd.2012.3; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Renthal W, 2007, NEURON, V56, P517, DOI 10.1016/j.neuron.2007.09.032; Silvagno F, 2002, FEBS LETT, V532, P153, DOI 10.1016/S0014-5793(02)03667-0; SUMMERHILL EM, 1987, MOL BRAIN RES, V2, P99, DOI 10.1016/0169-328X(87)90002-7; Tee AEL, 2010, J BIOL CHEM, V285, P3561, DOI 10.1074/jbc.M109.053041; van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819; Watamoto K, 2003, ONCOGENE, V22, P9176, DOI 10.1038/sj.onc.1206902; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Zhao XD, 2008, NAT CELL BIOL, V10, P643, DOI 10.1038/ncb1727; Zhou XB, 2000, P NATL ACAD SCI USA, V97, P1056, DOI 10.1073/pnas.97.3.1056	38	27	29	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2014	33	23					2987	2994		10.1038/onc.2013.253	http://dx.doi.org/10.1038/onc.2013.253			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EL	23812427				2022-12-28	WOS:000337232200005
J	Vargas, TR; Boudoukha, S; Simon, A; Souidi, M; Cuvellier, S; Pinna, G; Polesskaya, A				Vargas, T. Rivera; Boudoukha, S.; Simon, A.; Souidi, M.; Cuvellier, S.; Pinna, G.; Polesskaya, A.			Post-transcriptional regulation of cyclins D1, D3 and G1 and proliferation of human cancer cells depend on IMP-3 nuclear localization	ONCOGENE			English	Article						IMP-3; IGF2BP3; cyclins D1,D3 and G1; HNRNPM; post-transcriptional regulation	RNA-BINDING-PROTEIN; ACTIN MESSENGER-RNA; UNFAVORABLE PROGNOSIS; 3 IGF2BP3; TRANSLATION; EXPRESSION; ZBP1; TRANSCRIPTION; RADIATION; SURVIVAL	RNA-binding proteins of the IMP family (insulin-like growth factor 2 (IGF2) mRNA-binding proteins 1-3) are important post-transcriptional regulators of gene expression. Multiple studies have linked high expression of IMP proteins, and especially of IMP-3, to an unfavorable prognosis in numerous types of cancer. The specific importance of IMP-3 for cancer transformation remains poorly understood. We here show that all three IMPs can directly bind the mRNAs of cyclins D1, D3 and G1 (CCND1, D3 and G1) in vivo and in vitro, and yet only IMP-3 regulates the expression of these cyclins in a significant manner in six human cancer cell lines of different origins. In the absence of IMP-3, the levels of CCND1, D3 and G1 proteins fall dramatically, and the cells accumulate in the G1 phase of the cell cycle, leading to almost complete proliferation arrest. Our results show that, compared with IMP-1 and IMP2, IMP-3 is enriched in the nucleus, where it binds the transcripts of CCND1, D3 and G1. The nuclear localization of IMP-3 depends on its protein partner HNRNPM and is indispensable for the post-transcriptional regulation of expression of the cyclins. Cytoplasmic retention of IMP-3 and HNRNPM in human cancer cells leads to significant drop in proliferation. In conclusion, a nuclear IMP-3-HNRNPM complex is important for the efficient synthesis of CCND1, D3 and G1 and for the proliferation of human cancer cells.	[Vargas, T. Rivera; Boudoukha, S.; Simon, A.; Cuvellier, S.; Pinna, G.; Polesskaya, A.] CNR, FRE 3377, Gif Sur Yvette, France; [Vargas, T. Rivera; Boudoukha, S.; Simon, A.; Souidi, M.; Pinna, G.; Polesskaya, A.] Univ Paris 11, FRE 3377, Gif Sur Yvette, France; [Vargas, T. Rivera; Boudoukha, S.; Simon, A.; Souidi, M.; Pinna, G.; Polesskaya, A.] CEA, FRE 3377, Gif Sur Yvette, France; [Boudoukha, S.] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; [Cuvellier, S.] Inserm, Inst Cochin, Dept Genet & Dev, U1016, Paris, France	UDICE-French Research Universities; Universite Paris Saclay; CEA; UDICE-French Research Universities; Universite Paris Saclay; University of California System; University of California San Francisco; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Polesskaya, A (corresponding author), CEA Saclay, CNRS, IBiTeC S, SBIGeM,FRE 3377, Bat 144,P 65, F-91191 Gif Sur Yvette, France.	anna.polesskaya@cea.fr	SOUIDI, Mouloud/ABI-1444-2020	PINNA, Guillaume/0000-0001-7841-7250	Association Francais contre les Myopathies; Fondation ARC pour la Recherche sur le Cancer	Association Francais contre les Myopathies(Association Francaise contre les Myopathies); Fondation ARC pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le Cancer)	We thank Drs Annick Harel-Bellan and Linda L Pritchard for critical reading of the manuscript, Drs Jan Christianssen and Finn C Nielsen for the kind gifts of antibodies and for helpful discussions, Dr Yuh Min Chook for the kind gift of the M9M plasmid, and Dr Antoinette Lemoine for the HCC cell lines. This work was supported by a grant from the Association Francais contre les Myopathies to AP and from Fondation ARC pour la Recherche sur le Cancer to TRV.	Bell JL, 2012, CELL MOL LIFE SCI; Boudoukha S, 2010, MOL CELL BIOL, V30, P5710, DOI 10.1128/MCB.00665-10; Cansizoglu AE, 2007, NAT STRUCT MOL BIOL, V14, P452, DOI 10.1038/nsmb1229; Chao JA, 2010, GENE DEV, V24, P148, DOI 10.1101/gad.1862910; Dai N, 2011, GENE DEV, V25, P1159, DOI 10.1101/gad.2042311; Fornari F, 2009, CANCER RES, V69, P5761, DOI 10.1158/0008-5472.CAN-08-4797; Gu W, 2012, J CELL SCI, V125, P81, DOI 10.1242/jcs.086132; Hafner M, 2010, CELL, V141, P129, DOI 10.1016/j.cell.2010.03.009; Hammer NA, 2005, REPRODUCTION, V130, P203, DOI 10.1530/rep.1.00664; Jonson L, 2007, MOL CELL PROTEOMICS, V6, P798, DOI 10.1074/mcp.M600346-MCP200; Kobel M, 2009, MODERN PATHOL, V22, P469, DOI 10.1038/modpathol.2008.206; Lal A, 2004, EMBO J, V23, P3092, DOI 10.1038/sj.emboj.7600305; Liao BS, 2011, J BIOL CHEM, V286, P31145, DOI 10.1074/jbc.M111.263913; Liao BS, 2005, J BIOL CHEM, V280, P18517, DOI 10.1074/jbc.M500270200; Lochhead P, 2012, EUR J CANCER, V48, P3405, DOI 10.1016/j.ejca.2012.06.021; Mongroo PS, 2011, CANCER RES, V71, P2172, DOI 10.1158/0008-5472.CAN-10-3295; Munro TP, 2006, J CELL BIOL, V172, P577, DOI 10.1083/jcb.200510044; Nielsen J, 1999, MOL CELL BIOL, V19, P1262; Nielsen J, 2003, BIOCHEM J, V376, P383, DOI 10.1042/BJ20030943; Oleynikov Y, 2003, CURR BIOL, V13, P199, DOI 10.1016/S0960-9822(03)00044-7; Pan F, 2007, MOL CELL BIOL, V27, P8340, DOI 10.1128/MCB.00972-07; Runge S, 2000, J BIOL CHEM, V275, P29562, DOI 10.1074/jbc.M001156200; Schaeffer DF, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-59; Seo HR, 2006, CELL DEATH DIFFER, V13, P1475, DOI 10.1038/sj.cdd.4401822; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Stohr N, 2012, GENE DEV, V26, P176, DOI 10.1101/gad.177642.111; Vikesaa J, 2006, EMBO J, V25, P1456, DOI 10.1038/sj.emboj.7601039; Yisraeli JK, 2005, BIOL CELL, V97, P87	28	33	33	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2014	33	22					2866	2875		10.1038/onc.2013.252	http://dx.doi.org/10.1038/onc.2013.252			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EI	23812426				2022-12-28	WOS:000337231800006
J	Bae, HJ; Noh, JH; Kim, JK; Eun, JW; Jung, KH; Kim, MG; Chang, YG; Shen, Q; Kim, SJ; Park, WS; Lee, JY; Nam, SW				Bae, H. J.; Noh, J. H.; Kim, J. K.; Eun, J. W.; Jung, K. H.; Kim, M. G.; Chang, Y. G.; Shen, Q.; Kim, S-J; Park, W. S.; Lee, J. Y.; Nam, S. W.			MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma	ONCOGENE			English	Article						SIRT1; miR-29c; hepatocellular carcinoma; cell cycle; tumor suppressor	EXPRESSION; DEACETYLASE; CANCER; FAMILY; TUMORIGENESIS; INHIBITOR; PROGNOSIS; GENOMICS; MOUSE	Mammalian sirtuin 1 (SIRT1) has connected to an ever widening circle of activities that encompass cellular stress resistance, energy metabolism and tumorigenesis. However, underlying mechanisms leading to oncogenic SIRT1 overexpression are less understood. In this study, we identified SIRT1 regulatory microRNA (miRNA) and its function in hepatocellular carcinoma (HCC). Aberrant SIRT1 overexpression was demonstrated in a subset of human HCCs. SIRT1 knockdown suppressed HCC cell growth by transcriptional deregulation of cell cycle proteins. This led to hypophosphorylation of pRb, which inactivated E2F/DP1 target gene transcription, and thereby caused significant increase of HCC cells to remain in the G1/S phase. A comprehensive miRNA profiling analysis indentified five putative endogenous miRNAs that are significantly downregulated in HCC. Ectopic expression of miRNA mimics evidenced miR-29c to suppress SIRT1 in HCC cells. Notably, ectopic miR-29c expression repressed cancer cell growth and proliferation, and it recapitulated SIRT1 knockdown effects in HCC cells. In addition, miR-29c expression was downregulated in a large cohort of HCC patients, and low expression of miR-29c was significantly associated with poor prognosis of HCC patients. Taken together, we demonstrated that miR-29c suppresses oncogenic SIRT1 by way of binding to 30-untranslated region of SIRT1 mRNA causing translational inhibition in liver cancer cells. The loss or suppression of miR-29c may cause aberrant SIRT1 overexpression and promotes liver tumorigenesis. Overall, we suggest that miR-29c functions as a tumor suppressor by regulating abnormal SIRT1 activity in liver.	[Bae, H. J.; Noh, J. H.; Kim, J. K.; Eun, J. W.; Jung, K. H.; Kim, M. G.; Chang, Y. G.; Shen, Q.; Kim, S-J; Park, W. S.; Lee, J. Y.; Nam, S. W.] Catholic Univ Korea, Coll Med, Dept Pathol, Lab Oncogen, Seoul 137701, South Korea; [Bae, H. J.; Noh, J. H.; Kim, J. K.; Eun, J. W.; Jung, K. H.; Kim, M. G.; Chang, Y. G.; Shen, Q.; Kim, S-J; Park, W. S.; Lee, J. Y.; Nam, S. W.] Catholic Univ Korea, Funct RNom Res Ctr, Seoul 137701, South Korea; [Nam, S. W.] Catholic Univ Korea, Canc Evolut Res Ctr, Seoul 137701, South Korea	Catholic University of Korea; Catholic University of Korea; Catholic University of Korea	Nam, SW (corresponding author), Catholic Univ Korea, Funct RNom Res Ctr, Coll Med, Dept Pathol, Seoul 137701, South Korea.	swnam@catholic.ac.kr	Eun, Jung Woo/ABB-5127-2020	Eun, Jung Woo/0000-0002-2461-6702	National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology (MEST) [2011-0010705, 2012M3A9D1054476]; Korean Science and Engineering Foundation via the 'Cancer Evolution Research Center' at the Catholic University of Korea	National Research Foundation of Korea (NRF) - Ministry of Education, Science and Technology (MEST)(Ministry of Education, Science & Technology (MEST), Republic of KoreaNational Research Foundation of Korea); Korean Science and Engineering Foundation via the 'Cancer Evolution Research Center' at the Catholic University of Korea(Korea Science and Engineering Foundation)	This work was supported by the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (MEST; Grant No. 2011-0010705 and No. 2012M3A9D1054476), and by the Korean Science and Engineering Foundation via the 'Cancer Evolution Research Center' at the Catholic University of Korea.	Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Cao Q, 2011, CANCER CELL, V20, P187, DOI 10.1016/j.ccr.2011.06.016; Cha EJ, 2009, CLIN CANCER RES, V15, P4453, DOI 10.1158/1078-0432.CCR-08-3329; Chen J, 2011, CANCER RES, V71, P4138, DOI 10.1158/0008-5472.CAN-10-4274; Fabbri M, 2007, P NATL ACAD SCI USA, V104, P15805, DOI 10.1073/pnas.0707628104; Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020; Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085; Jang KY, 2009, PATHOLOGY, V41, P366, DOI 10.1080/00313020902884451; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jung KH, 2012, HEPATOLOGY, V56, P644, DOI 10.1002/hep.25699; Kabra N, 2009, J BIOL CHEM, V284, P18210, DOI 10.1074/jbc.M109.000034; Kim JK, 2013, HEPATOLOGY, V57, P1055, DOI 10.1002/hep.26101; Kriegel AJ, 2012, PHYSIOL GENOMICS, V44, P237, DOI 10.1152/physiolgenomics.00141.2011; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Niyazi M, 2007, RADIAT ONCOL, V2, DOI 10.1186/1748-717X-2-4; Noh JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028103; Ota H, 2006, ONCOGENE, V25, P176, DOI 10.1038/sj.onc.1209049; Pineau P, 2010, P NATL ACAD SCI USA, V107, P264, DOI 10.1073/pnas.0907904107; Saunders LR, 2010, AGING-US, V2, P415, DOI 10.18632/aging.100176; Stuenkel Walter, 2007, Biotechnology Journal, V2, P1360, DOI 10.1002/biot.200700087; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Whittaker S, 2010, ONCOGENE, V29, P4989, DOI 10.1038/onc.2010.236; Xie HJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034265; Xiong YJ, 2010, HEPATOLOGY, V51, P836, DOI 10.1002/hep.23380	25	122	129	2	25	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2014	33	20					2557	2567		10.1038/onc.2013.216	http://dx.doi.org/10.1038/onc.2013.216			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH9YT	23728341				2022-12-28	WOS:000336502700002
J	Busch, SE; Moser, RD; Gurley, KE; Kelly-Spratt, KS; Liggitt, HD; Kemp, CJ				Busch, S. E.; Moser, R. D.; Gurley, K. E.; Kelly-Spratt, K. S.; Liggitt, H. D.; Kemp, C. J.			ARF inhibits the growth and malignant progression of non-small-cell lung carcinoma	ONCOGENE			English	Article						p19(Arf); p14(ARF); ethyl carbamate; metastasis	P53-MEDIATED TUMOR SUPPRESSION; DNA-DAMAGE; MOUSE MODEL; CYCLE ARREST; WILD-TYPE; CANCER; P53; MICE; PATHWAY; LOCUS	Non-small-cell lung carcinoma (NSCLC) is among the deadliest of human cancers. The CDKN2A locus, which houses the INK4a and ARF tumor suppressor genes, is frequently altered in NSCLC. However, the specific role of ARF in pulmonary tumorigenesis remains unclear. KRAS and other oncogenes induce the expression of ARF, thus stabilizing p53 activity and arresting cell proliferation. To address the role of ARF in Kras-driven NSCLC, we compared the susceptibility of NIH/Ola strain wild-type and Arf-knockout mice to urethane-induced lung carcinogenesis. Lung tumor size, malignancy and associated morbidity were significantly increased in Arf(-/-) compared with Arf(+/+) animals at 25 weeks after induction. Pulmonary tumors from Arf-knockout mice exhibited increased cell proliferation and DNA damage compared with wild-type mice. A subgroup of tumors in Arf(-/-) animals presented as dedifferentiated and metastatic, with many characteristics of pulmonary sarcomatoid carcinoma, a neoplasm previously undocumented in mouse models. Our finding of a role for ARF in NSCLC is consistent with the observation that benign adenomas from Arf(+/+) mice robustly expressed ARF, while ARF expression was markedly reduced in malignant adenocarcinomas. ARF expression also frequently colocalized with the expression of p21(CIP1), a transcriptional target of p53, arguing that ARF induces the p53 checkpoint to arrest cell proliferation in vivo. Taken together, these findings demonstrate that induction of ARF is an early response in lung tumorigenesis that mounts a strong barrier against tumor growth and malignant progression.	[Busch, S. E.; Moser, R. D.; Gurley, K. E.; Kelly-Spratt, K. S.; Kemp, C. J.] Fred Hutchinson Canc Res Ctr, Div Human Biol, Seattle, WA 98109 USA; [Busch, S. E.] Univ Washington, Mol & Cellular Biol Grad Program, Seattle, WA 98195 USA; [Liggitt, H. D.] Univ Washington, Dept Comparat Med, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Kemp, CJ (corresponding author), Fred Hutchinson Canc Res Ctr, Div Human Biol, 1100 Fairview Ave North,Mail Stop C1-015, Seattle, WA 98109 USA.	cjkemp@fhcrc.org		Busch, Stephanie E/0000-0003-4073-5311	NCI MMHCC [U01 CA141550]; NIEHS [5 R01 ES020116]; PHS NRSA from NIGMS [T32 GM007270]; NATIONAL CANCER INSTITUTE [U01CA141550] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056465] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES020116] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER	NCI MMHCC; NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); PHS NRSA from NIGMS; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are grateful to Sue Knoblaugh for her assistance in analyzing tumor histopathology, and to numerous colleagues for their helpful commentary. This work was supported by NCI MMHCC U01 CA141550, and by NIEHS 5 R01 ES020116. SEB was supported by PHS NRSA T32 GM007270 from NIGMS.	Aggarwal P, 2007, GENE DEV, V21, P2908, DOI 10.1101/gad.1586007; Alt JR, 2005, J BIOL CHEM, V280, P18771, DOI 10.1074/jbc.M413387200; Andrique L, 2012, CELL SIGNAL, V24, P1074, DOI 10.1016/j.cellsig.2012.01.002; [Anonymous], 1975, SEER CANC STAT REV 1; Brunet A, 1999, EMBO J, V18, P664, DOI 10.1093/emboj/18.3.664; Busch SE, 2012, J PATHOL, V227, P298, DOI 10.1002/path.4024; Cardiff RD, 2005, CLIN CANCER RES, V11, P8534, DOI 10.1158/1078-0432.CCR-05-2250; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; D'Amico M, 2004, CANCER RES, V64, P4122, DOI 10.1158/0008-5472.CAN-03-2519; Dacic S, 2002, AM J SURG PATHOL, V26, P510, DOI 10.1097/00000478-200204000-00015; Debies MT, 2008, J CLIN INVEST, V118, P51, DOI 10.1172/JCI33320; di Tommaso A, 2009, EXP CELL RES, V315, P1326, DOI 10.1016/j.yexcr.2009.01.010; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Efeyan A, 2006, NATURE, V443, P159, DOI 10.1038/443159a; Eymin B, 2006, MOL CELL BIOL, V26, P4339, DOI 10.1128/MCB.02240-05; Feldser DM, 2010, NATURE, V468, P572, DOI 10.1038/nature09535; Gao N, 2001, J CANCER RES CLIN, V127, P359, DOI 10.1007/s004320000184; Gautschi O, 2007, LUNG CANCER, V55, P1, DOI 10.1016/j.lungcan.2006.09.024; Jackson EL, 2005, CANCER RES, V65, P10280, DOI 10.1158/0008-5472.CAN-05-2193; Junttila MR, 2010, NATURE, V468, P567, DOI 10.1038/nature09526; Kamijo T, 1999, CANCER RES, V59, P2217; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; Kelly-Spratt KS, 2009, ONCOGENE, V28, P3652, DOI 10.1038/onc.2009.226; Kelly-Spratt KS, 2004, PLOS BIOL, V2, P1138, DOI 10.1371/journal.pbio.0020242; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Lavoie J N, 1996, Prog Cell Cycle Res, V2, P49; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Manenti G, 1997, CANCER RES, V57, P4164; Nicholson SA, 2001, CANCER RES, V61, P5636; Nikitin AY, 2004, CANCER RES, V64, P2307, DOI 10.1158/0008-5472.CAN-03-3376; Normand G, 2005, J BIOL CHEM, V280, P7118, DOI 10.1074/jbc.M412330200; Pelosi G, 2010, INT J SURG PATHOL, V18, P103, DOI 10.1177/1066896908330049; Philipp-Staheli J, 2002, CANCER CELL, V1, P355, DOI 10.1016/S1535-6108(02)00054-5; Pontano LL, 2008, CELL DIV, V3, DOI 10.1186/1747-1028-3-12; QUELLE DE, 1995, CELL, V83, P993; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; ROGERS S, 1951, J EXP MED, V93, P427, DOI 10.1084/jem.93.5.427; Sanchez-Cespedes M, 1999, ONCOGENE, V18, P5843, DOI 10.1038/sj.onc.1203003; Saporita AJ, 2007, CURR MED CHEM, V14, P1815; Sharpless NE, 2005, MUTAT RES-FUND MOL M, V576, P22, DOI 10.1016/j.mrfmmm.2004.08.021; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Tam AS, 2003, CARCINOGENESIS, V24, P121, DOI 10.1093/carcin/24.1.121; TANNENBAUM A, 1962, CANCER RES, V22, P1105; Thompson L, 1996, AM J SURG PATHOL, V20, P277, DOI 10.1097/00000478-199603000-00003; Tompkins VS, 2007, J BIOL CHEM, V282, P1322, DOI 10.1074/jbc.M609612200; Vonlanthen S, 1998, ONCOGENE, V17, P2779, DOI 10.1038/sj.onc.1202501; Wang Y, 2006, ONCOGENE, V25, P1277, DOI 10.1038/sj.onc.1209182; Wang Y, 2003, CANCER RES, V63, P4389; Wang YYV, 2009, CANCER CELL, V16, P33, DOI 10.1016/j.ccr.2009.05.008; YOU M, 1989, P NATL ACAD SCI USA, V86, P3070, DOI 10.1073/pnas.86.9.3070; Young NP, 2010, P NATL ACAD SCI USA, V107, P10184, DOI 10.1073/pnas.1004796107; Zeng YX, 2011, CANCER RES, V71, P2781, DOI 10.1158/0008-5472.CAN-10-3483; Zhang W, 2010, J EXP CLIN CANC RES, V29, DOI 10.1186/1756-9966-29-74; Zhang ZQ, 2002, ONCOGENE, V21, P5960, DOI 10.1038/sj.onc.1205725; Zheng S, 2007, ONCOGENE, V26, P6896, DOI 10.1038/sj.onc.1210493	60	7	7	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2014	33	20					2665	2673		10.1038/onc.2013.208	http://dx.doi.org/10.1038/onc.2013.208			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH9YT	23752194	Green Accepted			2022-12-28	WOS:000336502700012
J	Feng, H; Hu, B; Vuori, K; Sarkaria, JN; Furnari, FB; Cavenee, WK; Cheng, SY				Feng, H.; Hu, B.; Vuori, K.; Sarkaria, J. N.; Furnari, F. B.; Cavenee, W. K.; Cheng, S-Y			EGFRvIII stimulates glioma growth and invasion through PKA-dependent serine phosphorylation of Dock180	ONCOGENE			English	Article						glioblastomas; EGFRvIII; Dock180; phosphorylation; PKA	PROTEIN-KINASE-A; CELL-MIGRATION; LIVING CELLS; RAC; GLIOBLASTOMA; ACTIVATION; GEF; TUMORIGENESIS; PATHWAY; COMPLEX	Glioblastomas (GBMs), the most common and malignant brain tumors, are highly resistant to current therapies. The failure of targeted therapies against aberrantly activated oncogenic signaling, such as that of the EGFR-PI3K/Akt pathway, underscores the urgent need to understand alternative downstream pathways and to identify new molecular targets for the development of more effective treatments for gliomas. Here, we report that EGFRvIII (Delta EGFR/de2-7EGFR), a constitutively active EGFR mutant that is frequently co-overexpressed with EGFR in clinical GBM tumors, promotes glioma growth and invasion through protein kinase A (PKA)-dependent phosphorylation of Dock180, a bipartite guanine nucleotide exchange factor (GEF) for Rac1. We demonstrate that EGFRvIII induces serine phosphorylation of Dock180, stimulates Rac1 activation and glioma cell migration. Treatments of glioma cells using the PKA inhibitors H-89 and KT5720, overexpression of a PKA inhibitor (PKI), and in vitro PKA kinase assays show that EGFRvIII induction of serine phosphorylation of Dock180 is PKA-dependent. Significantly, PKA induces phosphorylation of Dock180 at amino acid residue S1250 that resides within its Rac1-activating DHR-2 domain. Expression of the Dock180(S1250L) mutant, but not wild type Dock180(WT), protein in EGFRvIII-expressing glioma cells inhibited receptor-stimulated cell proliferation, survival, migration in vitro and glioma tumor growth and invasion in vivo. Together, our findings describe a novel mechanism by which EGFRvIII drives glioma tumorigenesis and invasion through PKA-dependent phosphorylation of Dock180, thereby suggesting that targeting EGFRvIII-PKA-Dock180-Rac1 signaling axis could provide a novel pathway to develop potential therapeutic strategies for malignant gliomas.	[Feng, H.; Hu, B.; Cheng, S-Y] Northwestern Univ, Feinberg Sch Med, Northwestern Brain Tumor Inst, Dept Neurol, Chicago, IL 60611 USA; [Feng, H.; Hu, B.; Cheng, S-Y] Northwestern Univ, Ctr Genet Med, Feinberg Sch Med, Chicago, IL 60611 USA; [Feng, H.; Hu, B.; Cheng, S-Y] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Feinberg Sch Med, Chicago, IL 60611 USA; [Feng, H.] Shanghai Jiao Tong Univ, Renji Hosp, Stem Cell Res Ctr, Sch Med, Shanghai 200030, Peoples R China; [Vuori, K.] Sanford Burnham Med Res Inst, La Jolla, CA USA; [Sarkaria, J. N.; Cavenee, W. K.] Mayo Clin, Dept Radiat Oncol, Rochester, MN USA; [Furnari, F. B.] Univ Calif San Diego, Sch Med, Ludwig Inst Canc Res, La Jolla, CA 92093 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Shanghai Jiao Tong University; Sanford Burnham Prebys Medical Discovery Institute; Mayo Clinic; Ludwig Institute for Cancer Research; University of California System; University of California San Diego	Hu, B (corresponding author), Northwestern Univ, Feinberg Sch Med, Northwestern Brain Tumor Inst, Dept Neurol, Chicago, IL 60611 USA.	bo.hu@northwestern.edu; shiyuan.cheng@northwestern.edu	Feng, Haizhong/E-5795-2017	Feng, Haizhong/0000-0003-3552-6865; Furnari, Frank/0000-0003-1909-4361	University of Pittsburgh Cancer Institute; NIH [CA130966, CA158911]; Northwestern Brain Tumor Institute; Department of Neurology at Northwestern University Feinberg School of Medicine; Zell Scholar Award from the Zell Family Foundation; Brain Cancer Research; Pennsylvania Department of Health; Innovative Research Scholar Awards of the Hillman Foundation; NATIONAL CANCER INSTITUTE [R01CA159811, R01CA130966, P30CA030199] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS080939] Funding Source: NIH RePORTER	University of Pittsburgh Cancer Institute; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Northwestern Brain Tumor Institute; Department of Neurology at Northwestern University Feinberg School of Medicine; Zell Scholar Award from the Zell Family Foundation; Brain Cancer Research; Pennsylvania Department of Health; Innovative Research Scholar Awards of the Hillman Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	Most of the studies (and all the animal studies) were performed at the University of Pittsburgh in accordance with a protocol approved by the IACUC of the University of Pittsburgh. We acknowledge the support of University of Pittsburgh Cancer Institute and various core facilities. We also thank M Matsuda, R Tsien, E van Meir and Y Zhou for providing reagents, and Angel Alvarez for proofreading of this manuscript. WK Cavenee is a Fellow of the National Foundation for Cancer Research. This work was supported in part by a NIH grant CA130966, CA158911 to S-Y Cheng, a Zell Scholar Award from the Zell Family Foundation and funds from Northwestern Brain Tumor Institute and Department of Neurology at Northwestern University Feinberg School of Medicine to S-Y Cheng; Brain Cancer Research Awards from the James S McDonnell Foundation to B Hu and F Furnari; a grant with the Pennsylvania Department of Health, and Innovative Research Scholar Awards of the Hillman Foundation to S-Y Cheng and B Hu.	Brugnera E, 2002, NAT CELL BIOL, V4, P574, DOI 10.1038/ncb824; Cai XM, 2005, INT J CANCER, V117, P905, DOI 10.1002/ijc.21251; Chahdi A, 2005, J BIOL CHEM, V280, P578, DOI 10.1074/jbc.M411130200; Chahdi A, 2008, MOL CELL BIOL, V28, P1679, DOI 10.1128/MCB.00898-07; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Cote JF, 2007, TRENDS CELL BIOL, V17, P383, DOI 10.1016/j.tcb.2007.05.001; de Farias CB, 2008, ONCOLOGY-BASEL, V75, P27, DOI 10.1159/000151616; Duchek P, 2001, SCIENCE, V291, P131, DOI 10.1126/science.291.5501.131; Dunn GP, 2012, GENE DEV, V26, P756, DOI 10.1101/gad.187922.112; Feng HZ, 2012, P NATL ACAD SCI USA, V109, P3018, DOI 10.1073/pnas.1121457109; Feng HZ, 2011, J CLIN INVEST, V121, P4670, DOI 10.1172/JCI58559; Giannini C, 2005, NEURO-ONCOLOGY, V7, P164, DOI 10.1215/S1152851704000821; Grimsley CM, 2004, J BIOL CHEM, V279, P6087, DOI 10.1074/jbc.M307087200; Ishii N, 1999, BRAIN PATHOL, V9, P469, DOI 10.1111/j.1750-3639.1999.tb00536.x; Jarzynka NJ, 2007, CANCER RES, V67, P7203, DOI 10.1158/0008-5472.CAN-07-0473; Kiyokawa E, 1998, J BIOL CHEM, V273, P24479, DOI 10.1074/jbc.273.38.24479; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Ku BM, 2011, MOL CELLS, V31, P275, DOI 10.1007/s10059-011-0027-5; Liu KW, 2011, J CLIN INVEST, V121, P905, DOI 10.1172/JCI43690; Martin BR, 2007, CHEM BIOL, V14, P1031, DOI 10.1016/j.chembiol.2007.07.017; Meiri D, 2009, MOL CELL BIOL, V29, P5963, DOI 10.1128/MCB.01268-08; NISHIKAWA R, 1994, P NATL ACAD SCI USA, V91, P7727, DOI 10.1073/pnas.91.16.7727; O'Connor KL, 2001, J BIOL CHEM, V276, P47895, DOI 10.1074/jbc.M107235200; Paulucci-Holthauzen AA, 2009, J BIOL CHEM, V284, P5956, DOI 10.1074/jbc.M805606200; Payner T, 2006, MOL CANCER THER, V5, P1817, DOI 10.1158/1535-7163.MCT-05-0548; Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822; Raymond E, 2000, DRUGS, V60, P15, DOI 10.2165/00003495-200060001-00002; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Van Meir EG, 2010, CA-CANCER J CLIN, V60, P166, DOI 10.3322/caac.20069; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Wykosky Jill, 2011, Chin J Cancer, V30, P5; Yang BC, 2003, J IMMUNOL, V171, P3947, DOI 10.4049/jimmunol.171.8.3947; Yiin JJ, 2010, MOL CANCER THER, V9, P929, DOI 10.1158/1535-7163.MCT-09-0953	33	54	56	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2014	33	19					2504	2512		10.1038/onc.2013.198	http://dx.doi.org/10.1038/onc.2013.198			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH3OK	23728337	Green Accepted			2022-12-28	WOS:000336033600010
J	Rimessi, A; Marchi, S; Patergnani, S; Pinton, P				Rimessi, A.; Marchi, S.; Patergnani, S.; Pinton, P.			H-Ras-driven tumoral maintenance is sustained through caveolin-1-dependent alterations in calcium signaling	ONCOGENE			English	Article						calcium signaling; caveolin-1; mitochondria; apoptosis; oncogenic H-Ras	MITOCHONDRIA-ASSOCIATED MEMBRANES; OXIDATIVE STRESS; CANCER-CELLS; ONCOGENIC TRANSFORMATION; MURINE FIBROBLASTS; PLASMA-MEMBRANE; GENE-EXPRESSION; DOWN-REGULATION; CAVEOLAE; METABOLISM	A growing body of research has highlighted the complex range of tumoral traits acquired during H-Ras-driven transformation and maintenance, which include proliferative signaling, growth suppressor evasion and resistance to cell death. Clear molecular information about these processes is not yet available, but recent evidence has provided solid support for the importance of mitochondria. Here, we show that the induction of oncogenic H-Ras leads to changes in intracellular calcium (Ca2+), evaluate the temporal relationship between oncogene expression and mitochondrial physiology, and demonstrate that Ca2+ homeostasis is altered by caveolin-1, a protein that has a key role in tumor maintenance. Our results indicate that tumor-suppressor caveolin-1 is a core component of the Ca2+-dependent apoptotic pathway and participates in the regulation of critical mitochondrial functions during tumor development. The compromised caveolin-1/Ca2+ axis contributes to failure in both mitochondrial metabolism and apoptosis, thereby sustaining the neoplastic phenotype. These results illustrate a direct link between Ca2+ regulation and mitochondrial biology in cancer.	[Rimessi, A.; Marchi, S.; Patergnani, S.; Pinton, P.] Univ Ferrar, Lab Technol Adv Therapies LTTA, Dept Morphol Surg & Expt Med, Sect Gen Pathol,Interdisciplinary Ctr Study Infla, I-44121 Ferrara, Italy		Pinton, P (corresponding author), Univ Ferrar, Lab Technol Adv Therapies LTTA, Dept Morphol Surg & Expt Med, Sect Gen Pathol,Interdisciplinary Ctr Study Infla, Via Borsari 46, I-44121 Ferrara, Italy.	pnp@unife.it	Marchi, Saverio/AAK-3308-2021; Rimessi, Alessandro/K-5420-2016; rimessi, alessandro/O-3335-2019; Marchi, Saverio/K-5997-2016; Pinton, Paolo/J-8025-2012; Patergnani, Simone/AAK-2929-2021; Patergnani, Simone/AAC-3969-2021	Marchi, Saverio/0000-0003-2708-1843; Rimessi, Alessandro/0000-0001-7091-5765; rimessi, alessandro/0000-0001-7091-5765; Marchi, Saverio/0000-0003-2708-1843; Pinton, Paolo/0000-0001-7108-6508; Patergnani, Simone/0000-0001-7951-9267; 	Italian Ministry of Health; FISM (Fondazione Italiana Sclerosi Multipla) research fellowship [2012/B/11]; FIRC (Fondazione Italiana Ricerca sul Cancro) fellowship; Italian Association for Cancer Research (AIRC), Telethon [GGP09128, GGP11139B]; local funds from the University of Ferrara; Italian Ministry of Education, University and Research (COFIN, FIRB and Futuro in Ricerca); Italian Cystic Fibrosis Research Foundation	Italian Ministry of Health(Ministry of Health, Italy); FISM (Fondazione Italiana Sclerosi Multipla) research fellowship; FIRC (Fondazione Italiana Ricerca sul Cancro) fellowship(Fondazione AIRC per la ricerca sul cancro); Italian Association for Cancer Research (AIRC), Telethon(Fondazione AIRC per la ricerca sul cancroFondazione Telethon); local funds from the University of Ferrara; Italian Ministry of Education, University and Research (COFIN, FIRB and Futuro in Ricerca)(Ministry of Education, Universities and Research (MIUR)); Italian Cystic Fibrosis Research Foundation(Ministry of Health, ItalyItalian Cystic Fibrosis Research Foundation)	This research was supported by: the Italian Ministry of Health to AR. SP is supported by a FISM (Fondazione Italiana Sclerosi Multipla) research fellowship (2012/B/11), whereas SM by FIRC (Fondazione Italiana Ricerca sul Cancro) fellowship. PP is financed by Italian Association for Cancer Research (AIRC), Telethon (GGP09128 and GGP11139B), local funds from the University of Ferrara, the Italian Ministry of Education, University and Research (COFIN, FIRB and Futuro in Ricerca), the Italian Cystic Fibrosis Research Foundation and Italian Ministry of Health.	Adebiyi A, 2011, J BIOL CHEM, V286, P4341, DOI 10.1074/jbc.M110.179747; Bender F, 2002, BIOL RES, V35, P151, DOI 10.4067/S0716-97602002000200006; Berridge MV, 2010, REJUV RES, V13, P139, DOI 10.1089/rej.2009.0948; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Clapham DE, 2007, CELL, V131, P1047, DOI 10.1016/j.cell.2007.11.028; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Ferdek PE, 2012, CURR BIOL, V22, P1241, DOI 10.1016/j.cub.2012.05.002; FUJIMOTO T, 1992, J CELL BIOL, V119, P1507, DOI 10.1083/jcb.119.6.1507; FUJIMOTO T, 1993, J CELL BIOL, V120, P1147, DOI 10.1083/jcb.120.5.1147; Galbiati F, 2001, MOL BIOL CELL, V12, P2229, DOI 10.1091/mbc.12.8.2229; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; GALLIMORE PH, 1986, ANTICANCER RES, V6, P499; Giorgi C, 2012, CELL CALCIUM, V52, P36, DOI 10.1016/j.ceca.2012.02.008; Giorgi C, 2012, MITOCHONDRION, V12, P77, DOI 10.1016/j.mito.2011.07.004; Giorgi C, 2009, INT J BIOCHEM CELL B, V41, P1817, DOI 10.1016/j.biocel.2009.04.010; Gogvadze V, 2008, TRENDS CELL BIOL, V18, P165, DOI 10.1016/j.tcb.2008.01.006; Gough DJ, 2009, SCIENCE, V324, P1713, DOI 10.1126/science.1171721; Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311; Hayer A, 2010, J CELL BIOL, V191, P615, DOI 10.1083/jcb.201003086; Hu YM, 2012, CELL RES, V22, P399, DOI 10.1038/cr.2011.145; Hulit J, 2000, J BIOL CHEM, V275, P21203, DOI 10.1074/jbc.M000321200; Isshiki M, 2002, J CELL SCI, V115, P475; Isshiki M, 2003, TRAFFIC, V4, P717, DOI 10.1034/j.1600-0854.2003.00130.x; JORGENSEN AO, 1989, J CELL BIOL, V109, P135, DOI 10.1083/jcb.109.1.135; Kai WC, 2001, AM J PATHOL, V159, P1635, DOI 10.1016/S0002-9440(10)63010-6; Kifor O, 1998, J BIOL CHEM, V273, P21708, DOI 10.1074/jbc.273.34.21708; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Krejci P, 2010, BONE, V47, P102, DOI 10.1016/j.bone.2010.03.021; Kroemer G, 2008, CANCER CELL, V13, P472, DOI 10.1016/j.ccr.2008.05.005; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Liu PS, 2002, J BIOL CHEM, V277, P41295, DOI 10.1074/jbc.R200020200; Liu XG, 2009, INT J BIOCHEM CELL B, V41, P1972, DOI 10.1016/j.biocel.2009.05.013; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P3256, DOI 10.4161/cc.9.16.12553; Murata T, 2007, J BIOL CHEM, V282, P16631, DOI 10.1074/jbc.M607948200; Pantoja C, 1999, ONCOGENE, V18, P4974, DOI 10.1038/sj.onc.1202880; Park DS, 2001, BIOCHEMISTRY-US, V40, P3354, DOI 10.1021/bi002787b; Patel HH, 2008, ANNU REV PHARMACOL, V48, P359, DOI 10.1146/annurev.pharmtox.48.121506.124841; Patergnani S, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-19; Pavlides S, 2010, AGING-US, V2, P185, DOI 10.18632/aging.100134; Peng TI, 2010, ANN NY ACAD SCI, V1201, P183, DOI 10.1111/j.1749-6632.2010.05634.x; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Pinton P, 2007, METHOD CELL BIOL, V80, P297, DOI 10.1016/S0091-679X(06)80015-4; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; Racine C, 1999, BIOCHEM BIOPH RES CO, V255, P580, DOI 10.1006/bbrc.1999.0236; Rajjayabun PH, 2001, UROLOGY, V58, P811, DOI 10.1016/S0090-4295(01)01337-1; Ralph SJ, 2010, MOL ASPECTS MED, V31, P145, DOI 10.1016/j.mam.2010.02.008; Razani B, 2000, J CELL SCI, V113, P2103; Rimessi A, 2008, BBA-BIOENERGETICS, V1777, P808, DOI 10.1016/j.bbabio.2008.05.449; Sano R, 2009, MOL CELL, V36, P500, DOI 10.1016/j.molcel.2009.10.021; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Thomas CM, 2008, J CELL MOL MED, V12, P796, DOI 10.1111/j.1582-4934.2008.00295.x; Volonte D, 2002, MOL BIOL CELL, V13, P2502, DOI 10.1091/mbc.01-11-0529; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293; Wiechen K, 2001, AM J PATHOL, V158, P833, DOI 10.1016/S0002-9440(10)64031-X; Wieckowski MR, 2009, NAT PROTOC, V4, P1582, DOI 10.1038/nprot.2009.151; Williams TM, 2004, ANN MED, V36, P584, DOI 10.1080/07853890410018899	60	53	54	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2014	33	18					2329	2340		10.1038/onc.2013.192	http://dx.doi.org/10.1038/onc.2013.192			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AG5ID	23728347				2022-12-28	WOS:000335451800006
J	Wu, CF; Liu, S; Lee, YC; Wang, R; Sun, S; Yin, F; Bornmann, WG; Yu-Lee, LY; Gallick, GE; Zhang, W; Lin, SH; Kuang, J				Wu, C. F.; Liu, S.; Lee, Y-C; Wang, R.; Sun, S.; Yin, F.; Bornmann, W. G.; Yu-Lee, L-Y; Gallick, G. E.; Zhang, W.; Lin, S-H; Kuang, J.			RSK promotes G2/M transition through activating phosphorylation of Cdc25A and Cdc25B	ONCOGENE			English	Article						RSK; Cdc25; activating phosphorylation; mitosis; G2/M transition; cell cycle	SIGNAL-REGULATED KINASE; XENOPUS OOCYTE MATURATION; ELEMENT-BINDING PROTEIN; CELL-CYCLE PROGRESSION; MAP KINASE; G(2)/M TRANSITION; DNA-DAMAGE; INHIBITORY KINASE; CANCER-CELLS; AURORA-A	Activation of the mitogen-activated protein kinase ( MAPK) cascade in mammalian cell lines positively regulates the G2/M transition. The molecular mechanism underlying this biological phenomenon remains poorly understood. Ribosomal S6 kinase (RSK) is a key downstream element of the MAPK cascade. Our previous studies established roles of RSK2 in Cdc25C activation during progesterone-induced meiotic maturation of Xenopus oocytes. In this study we demonstrate that both recombinant RSK and endogenous RSK in Xenopus egg extracts phosphorylate all three isoforms of human Cdc25 at a conserved motif near the catalytic domain. In human HEK293 and PC-3mm2 cell lines, RSK preferentially phosphorylates Cdc25A and Cdc25B in mitotic cells. Phosphorylation of the RSK sites in these Cdc25 isoforms increases their M-phase-inducing activities. Inhibition of RSK-mediated phosphorylation of Cdc25 inhibits G2/M transition. Moreover, RSK is likely to be more active in mitotic cells than in interphase cells, as evidenced by the phosphorylation status of T359/S363 in RSK. Together, these findings indicate that RSK promotes G2/M transition in mammalian cells through activating phosphorylation of Cdc25A and Cdc25B.	[Wu, C. F.; Wang, R.; Sun, S.; Bornmann, W. G.; Kuang, J.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; [Liu, S.; Yin, F.; Zhang, W.] Beijing Normal Univ, Coll Life Sci, Minist Educ, Key Lab Cell Proliferat & Regulat Biol, Beijing 100875, Peoples R China; [Lee, Y-C; Lin, S-H] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA; [Sun, S.; Gallick, G. E.; Lin, S-H; Kuang, J.] Univ Texas Houston, Grad Sch Biomed Sci, Houston, TX USA; [Yu-Lee, L-Y] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Gallick, G. E.] Univ Texas MD Anderson Canc Ctr, David H Koch Ctr Appl Res Genitourinary Canc, Dept Genitourinary Med Oncol Res, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Beijing Normal University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center	Lin, SH (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	slin@mdanderson.org; jkuang@mdanderson.org	Liu, Shuaishuai/AAB-3256-2020; Wang, Ruoning/C-1683-2014		Department of Defense (DOD) Prostate Cancer Research Program (PCRP) [W81XWH-09-1-0274, W81XWH-09-1-0272]; National Natural Science Foundation of China [30300173]; Beijing Talents Foundation [20071D0503100293]; PCF Challenge grant; NCI [CA140388, CA 16672]; Cancer Center [CA016672]; NATIONAL CANCER INSTITUTE [P50CA140388, P30CA016672] Funding Source: NIH RePORTER	Department of Defense (DOD) Prostate Cancer Research Program (PCRP); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Beijing Talents Foundation; PCF Challenge grant; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the Department of Defense (DOD) Prostate Cancer Research Program (PCRP) grants W81XWH-09-1-0274 (JK) and W81XWH-09-1-0272 (S-HL), by grant 30300173 from the National Natural Science Foundation of China and grant 20071D0503100293 from the Beijing Talents Foundation (WZ), and a PCF Challenge grant and NCI CA140388 (GEG). DNA sequencing was performed by the DNA Analysis Facility of UT MD Anderson Cancer Center supported by NCI grant CA 16672. The Translational Chemistry Core Facility at the MD Anderson Cancer Center was supported by the Cancer Center support grant CA016672.	Abbott DW, 1999, J BIOL CHEM, V274, P2732, DOI 10.1074/jbc.274.5.2732; ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; Anjum R, 2008, NAT REV MOL CELL BIO, V9, P747, DOI 10.1038/nrm2509; Aressy B, 2008, CELL CYCLE, V7, P2234, DOI 10.4161/cc.7.14.6305; Aressy B, 2008, ANTI-CANCER AGENT ME, V8, P818, DOI 10.2174/187152008786847756; Bhatt RR, 2000, J BIOL CHEM, V275, P32983, DOI 10.1074/jbc.M006386200; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Boutros R, 2006, CURR OPIN CELL BIOL, V18, P185, DOI 10.1016/j.ceb.2006.02.003; Boutros R, 2007, NAT REV CANCER, V7, P495, DOI 10.1038/nrc2169; Brown JR, 1998, MOL CELL BIOL, V18, P5609, DOI 10.1128/MCB.18.9.5609; Cangi MG, 2008, INT J CANCER, V123, P1466, DOI 10.1002/ijc.23659; Carriere A, 2008, FRONT BIOSCI-LANDMRK, V13, P4258, DOI 10.2741/3003; Castro A, 2001, BIOL CELL, V93, P15, DOI 10.1016/S0248-4900(01)01128-5; Cazales M, 2005, CELL CYCLE, V4, P1233, DOI 10.4161/cc.4.9.1964; Chen Y, 2008, FRONT BIOSCI-LANDMRK, V13, P5016; Clark DE, 2005, CANCER RES, V65, P3108; DAKSIS JI, 1994, ONCOGENE, V9, P3635; Dalby KN, 1998, J BIOL CHEM, V273, P1496, DOI 10.1074/jbc.273.3.1496; DAVIS FM, 1983, P NATL ACAD SCI-BIOL, V80, P2926, DOI 10.1073/pnas.80.10.2926; DENKO NC, 1994, P NATL ACAD SCI USA, V91, P5124, DOI 10.1073/pnas.91.11.5124; Donzelli M, 2003, EMBO REP, V4, P671, DOI 10.1038/sj.embor.embor887; Dumont J, 2005, J CELL BIOL, V169, P227, DOI 10.1083/jcb.200501027; Dutertre S, 2004, J CELL SCI, V117, P2523, DOI 10.1242/jcs.01108; Eisenmann KM, 2003, CANCER RES, V63, P8330; Foijer F, 2008, ONCOGENE, V27, P1142, DOI 10.1038/sj.onc.1210724; Fox KE, 2008, J BIOL CHEM, V283, P35096, DOI 10.1074/jbc.M806423200; GABRIELLI BG, 1992, J BIOL CHEM, V267, P18040; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; Gebauer F, 1997, BIOESSAYS, V19, P23, DOI 10.1002/bies.950190106; GOTOH Y, 1995, MOL REPROD DEV, V42, P486, DOI 10.1002/mrd.1080420417; Harding A, 2003, J BIOL CHEM, V278, P16747, DOI 10.1074/jbc.M301015200; Hauge C, 2006, J CELL SCI, V119, P3021, DOI 10.1242/jcs.02950; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; Kang SM, 2010, J CLIN INVEST, V120, P1165, DOI 10.1172/JCI40582; Karlsson C, 1999, J CELL BIOL, V146, P573, DOI 10.1083/jcb.146.3.573; Knauf JA, 2006, J BIOL CHEM, V281, P3800, DOI 10.1074/jbc.M511690200; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LEE MS, 1992, MOL BIOL CELL, V3, P73, DOI 10.1091/mbc.3.1.73; Lee RJ, 1999, J BIOL CHEM, V274, P7341, DOI 10.1074/jbc.274.11.7341; Liu X, 2004, ONCOGENE, V23, P763, DOI 10.1038/sj.onc.1207188; LoPiccolo J, 2008, DRUG RESIST UPDATE, V11, P32, DOI 10.1016/j.drup.2007.11.003; Maller J L, 1985, Dev Biol (N Y 1985), V1, P289; McCubrey JA, 2007, BBA-MOL CELL RES, V1773, P1263, DOI 10.1016/j.bbamcr.2006.10.001; Moritz A., 2010, SCI SIGNAL, V24, P3; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; Nam HJ, 2008, CELL SIGNAL, V20, P1349, DOI 10.1016/j.cellsig.2008.03.008; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Palmer A, 2000, Prog Cell Cycle Res, V4, P131; Palmer A, 1998, EMBO J, V17, P5037, DOI 10.1093/emboj/17.17.5037; Pearce LR, 2010, NAT REV MOL CELL BIO, V11, P9, DOI 10.1038/nrm2822; Reinhardt HC, 2009, CURR OPIN CELL BIOL, V21, P245, DOI 10.1016/j.ceb.2009.01.018; RIME H, 1994, BIOL CELL, V82, P11, DOI 10.1016/0248-4900(94)90061-2; Roberts EC, 2002, MOL CELL BIOL, V22, P7226, DOI 10.1128/MCB.22.20.7226-7241.2002; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Romeo Y, 2012, BIOCHEM J, V441, P553, DOI 10.1042/BJ20110289; SETH A, 1992, J BIOL CHEM, V267, P24796; Shapiro PS, 1998, J CELL BIOL, V142, P1533, DOI 10.1083/jcb.142.6.1533; Shaul YD, 2007, BBA-MOL CELL RES, V1773, P1213, DOI 10.1016/j.bbamcr.2006.10.005; TAMEMOTO H, 1992, J BIOL CHEM, V267, P20293; Varmeh S, 2008, MOL CANCER THER, V7, P3789, DOI 10.1158/1535-7163.MCT-08-0838; Wang RN, 2007, CELL, V128, P1119, DOI 10.1016/j.cell.2006.11.053; Wang RN, 2010, P NATL ACAD SCI USA, V107, P19885, DOI 10.1073/pnas.1003528107; Wright JH, 1999, P NATL ACAD SCI USA, V96, P11335, DOI 10.1073/pnas.96.20.11335; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218	64	18	20	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2014	33	18					2385	2394		10.1038/onc.2013.182	http://dx.doi.org/10.1038/onc.2013.182			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AG5ID	23708659	Green Accepted			2022-12-28	WOS:000335451800011
J	Sun, MM; Li, JF; Guo, LL; Xiao, HT; Dong, L; Wang, F; Huang, FB; Cao, D; Qin, T; Yin, XH; Li, JM; Wang, SL				Sun, M. M.; Li, J. F.; Guo, L. L.; Xiao, H. T.; Dong, L.; Wang, F.; Huang, F. B.; Cao, D.; Qin, T.; Yin, X. H.; Li, J. M.; Wang, S. L.			TGF-beta 1 suppression of microRNA-450b-5p expression: a novel mechanism for blocking myogenic differentiation of rhabdomyosarcoma	ONCOGENE			English	Article						rhabdomyosarcoma; TGF-beta 1; miR-450b-5p; differentiation	TGF-BETA; MUSCLE DIFFERENTIATION; CELL-PROLIFERATION; SKELETAL-MUSCLE; GROWTH; CANCER; SMAD3; TRANSFORMING-GROWTH-FACTOR-BETA-1; QUANTIFICATION; TRANSCRIPTION	Transforming growth factor beta 1 (TGF-beta 1) is the most potent inhibitor of myogenic differentiation (MyoD) of rhabdomyosarcoma (RMS); however, the underlying mechanisms of this inhibition remain unclear. In this study, we identified novel TGF-beta 1-related microRNAs (miRNAs); among these, miR-450b-5p is significantly regulated by TGF-beta 1. We provide evidence that TGF-beta 1 exerts it function by suppressing miR-450b-5p. Both in cultured cells and tumor implants, miR-450b-5p significantly arrested the growth of RMS and promoted its MyoD. Utilizing a bioinformatics approach, we identified miR-450b-5p target mRNAs. Among these candidates, only the expression of ecto-NOX disulfide-thiol exchanger 2 (ENOX2) and paired box 9 (PAX9) was augmented by miR-450b-5p knockdown examined by western blot; the engineered inhibition antagonized TGF-beta 1-mediated differentiation inhibition. Furthermore, we found that the Smad3 and Smad4 pathways, but not Smad2, are the principal mediator of TGF-beta 1 suppression of miR-450b-5p. Taken together, these results suggest that disrupting the TGF-beta 1 suppression of miR-450b-5p, or knockdown of ENOX2 and PAX9, are effective approaches in inducing RMS MyoD.	[Sun, M. M.; Qin, T.; Yin, X. H.] Soochow Univ, Sch Med, Dept Anat, Suzhou 215123, Peoples R China; [Li, J. F.] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Pathol, Hangzhou 310003, Zhejiang, Peoples R China; [Guo, L. L.; Dong, L.; Wang, F.; Huang, F. B.; Cao, D.; Li, J. M.; Wang, S. L.] Soochow Univ, Sch Med, Dept Pathol, Suzhou 215123, Peoples R China; [Xiao, H. T.] Sichuan Univ, West China Hosp, Dept Burn & Plast Surg, Chengdu 610064, Peoples R China	Soochow University - China; Zhejiang University; Soochow University - China; Sichuan University	Wang, SL (corresponding author), Soochow Univ, Sch Med, Dept Pathol, Suzhou 215123, Peoples R China.	jianmingli@suda.edu.cn; wangsoly112@hotmail.com			Chinese Nature Science Foundation [81072186, 81272738]; Jiangsu Provincial Nature Science Foundation [SBK20110743]; Jiangsu Provincial Higher Institution Nature Science Foundation [10KJB320018]; Suzhou Applied Basic Research Programs [SYS201207]; Jiangsu Overseas Research and Training Program for University Prominent Young and Middle-aged Teachers and Presidents	Chinese Nature Science Foundation; Jiangsu Provincial Nature Science Foundation; Jiangsu Provincial Higher Institution Nature Science Foundation; Suzhou Applied Basic Research Programs; Jiangsu Overseas Research and Training Program for University Prominent Young and Middle-aged Teachers and Presidents	We would like to thank the West China Hospital of Sichuan University for providing us with the tumor specimens. This work was supported partially by the Chinese Nature Science Foundation (81072186, 81272738), Jiangsu Provincial Nature Science Foundation (SBK20110743), Jiangsu Provincial Higher Institution Nature Science Foundation (10KJB320018), Suzhou Applied Basic Research Programs (SYS201207), and Sponsorship of Jiangsu Overseas Research and Training Program for University Prominent Young and Middle-aged Teachers and Presidents.	Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bouche M, 2000, FASEB J, V14, P1147, DOI 10.1096/fasebj.14.9.1147; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; Ge XJ, 2011, CELL RES, V21, P1591, DOI 10.1038/cr.2011.72; Guo H, 2007, CHINESE MED J-PEKING, V120, P515, DOI 10.1097/00029330-200703020-00016; Hatley ME, 2012, CANCER CELL, V22, P536, DOI 10.1016/j.ccr.2012.09.004; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Li Y, 2004, AM J PATHOL, V164, P1007, DOI 10.1016/S0002-9440(10)63188-4; Liu D, 2004, EMBO J, V23, P1557, DOI 10.1038/sj.emboj.7600179; Liu D, 2001, GENE DEV, V15, P2950, DOI 10.1101/gad.925901; Liu NC, 2012, J AGR FOOD CHEM, V60, P2758, DOI 10.1021/jf204869w; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Mishra PJ, 2009, J CLIN INVEST, V119, P2119, DOI 10.1172/JCI40107; Rodrigo I, 2003, DEVELOPMENT, V130, P473, DOI 10.1242/dev.00240; Schmittgen TD, 2008, METHODS, V44, P31, DOI 10.1016/j.ymeth.2007.09.006; Sebire NJ, 2003, J CLIN PATHOL, V56, P412, DOI 10.1136/jcp.56.6.412; Segev H, 2004, STEM CELLS, V22, P265, DOI 10.1634/stemcells.22-3-265; Shoji Y, 1996, J CLIN PATHOL, V49, P134, DOI 10.1136/jcp.49.2.134; Sun Q, 2008, NUCLEIC ACIDS RES, V36, P2690, DOI 10.1093/nar/gkn032; Suzuki HI, 2011, J BIOCHEM, V149, P15, DOI 10.1093/jb/mvq113; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; TAPSCOTT SJ, 1993, SCIENCE, V259, P1450, DOI 10.1126/science.8383879; Wang B, 2010, ONCOGENE, V29, P1787, DOI 10.1038/onc.2009.468; Wang SL, 2010, CANCER SCI, V101, P1108, DOI 10.1111/j.1349-7006.2010.01512.x; Wang SL, 2009, CANCER GENET CYTOGEN, V190, P8, DOI 10.1016/j.cancergencyto.2008.10.013; Wang V, 2009, BIODRUGS, V23, P15, DOI 10.2165/00063030-200923010-00002; Wurdinger T, 2007, PHARMACOGENOMICS J, V7, P297, DOI 10.1038/sj.tpj.6500429; Yamagata K, 2009, MOL CELL, V36, P340, DOI 10.1016/j.molcel.2009.08.017; Yang ZH, 2009, GENE DEV, V23, P694, DOI 10.1101/gad.1765109; Ye L, 2005, CHINESE MED J-PEKING, V118, P678; Zeng ZM, 2012, EXP CELL RES, V318, P1759, DOI 10.1016/j.yexcr.2012.04.021	35	37	40	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2014	33	16					2075	2086		10.1038/onc.2013.165	http://dx.doi.org/10.1038/onc.2013.165			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF3GH	23665678				2022-12-28	WOS:000334599100007
J	Ducker, GS; Atreya, CE; Simko, JP; Hom, YK; Matli, MR; Benes, CH; Hann, B; Nakakura, EK; Bergsland, EK; Donner, DB; Settleman, J; Shokat, KM; Warren, RS				Ducker, G. S.; Atreya, C. E.; Simko, J. P.; Hom, Y. K.; Matli, M. R.; Benes, C. H.; Hann, B.; Nakakura, E. K.; Bergsland, E. K.; Donner, D. B.; Settleman, J.; Shokat, K. M.; Warren, R. S.			Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors	ONCOGENE			English	Article						mTOR; colon cancer; PIK3CA; KRAS; xenograft; PP242	RENAL-CELL CARCINOMA; COLORECTAL-CANCER; KINASE INHIBITORS; BINDING PARTNER; PIK3CA MUTATION; GROWTH-CONTROL; COLON-CANCER; LUNG-CANCER; IN-VITRO; RAPAMYCIN	The mammalian target of rapamycin (mTOR) regulates cell growth by integrating nutrient and growth factor signaling and is strongly implicated in cancer. But mTOR is not an oncogene, and which tumors will be resistant or sensitive to new adenosine triphosphate (ATP) competitive mTOR inhibitors now in clinical trials remains unknown. We screened a panel of over 600 human cancer cell lines to identify markers of resistance and sensitivity to the mTOR inhibitor PP242. RAS and phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) mutations were the most significant genetic markers for resistance and sensitivity to PP242, respectively; colon origin was the most significant marker for resistance based on tissue type. Among colon cancer cell lines, those with KRAS mutations were most resistant to PP242, whereas those without KRAS mutations most sensitive. Surprisingly, cell lines with co-mutation of PIK3CA and KRAS had intermediate sensitivity. Immunoblot analysis of the signaling targets downstream of mTOR revealed that the degree of cellular growth inhibition induced by PP242 was correlated with inhibition of phosphorylation of the translational repressor eIF4E-binding protein 1 (4E-BP1), but not ribosomal protein S6 (rpS6). In a tumor growth inhibition trial of PP242 in patient-derived colon cancer xenografts, resistance to PP242-induced inhibition of 4E-BP1 phosphorylation and xenograft growth was again observed in KRAS mutant tumors without PIK3CA co-mutation, compared with KRAS wild-type controls. We show that, in the absence of PIK3CA co-mutation, KRAS mutations are associated with resistance to PP242 and that this is specifically linked to changes in the level of phosphorylation of 4E-BP1.	[Ducker, G. S.; Shokat, K. M.] Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; [Atreya, C. E.; Bergsland, E. K.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA; [Simko, J. P.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA; [Hom, Y. K.; Hann, B.] Univ Calif San Francisco, Preclin Therapeut Core, San Francisco, CA 94143 USA; [Hom, Y. K.; Matli, M. R.; Hann, B.; Nakakura, E. K.; Donner, D. B.; Shokat, K. M.; Warren, R. S.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA; [Matli, M. R.; Nakakura, E. K.; Donner, D. B.; Warren, R. S.] Univ Calif San Francisco, Dept Surg, Sect Surg Oncol, San Francisco, CA 94115 USA; [Benes, C. H.; Settleman, J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA USA; [Shokat, K. M.] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA USA; [Shokat, K. M.] Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA	University of California System; University of California Berkeley; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco; Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Shokat, KM (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, 600 E 16th St,MC 2280, San Francisco, CA 94158 USA.	shokat@cmp.ucsf.edu; robert.warren@ucsfmedctr.org		Ducker, Gregory/0000-0002-8651-6846	American Cancer Society Postdoctoral Fellowship [11-183-TBG]; Millennium Pharmaceuticals provided through the Alliance for Clinical Trials in Oncology Foundation; Littlefield Trust; Howard Hughes Medical Institute; Waxman Foundation; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB001987] Funding Source: NIH RePORTER	American Cancer Society Postdoctoral Fellowship(American Cancer Society); Millennium Pharmaceuticals provided through the Alliance for Clinical Trials in Oncology Foundation; Littlefield Trust; Howard Hughes Medical Institute(Howard Hughes Medical Institute); Waxman Foundation; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	We thank Dan Moore for his critical assistance in the statistical analysis, Sandy Devries for FISH analysis, Katherine Pogue-Guile for permission to use the ColoCarta oligonucleotide primer design files and Morris Feldman, Jon Ostrem and Iana Serafimova for reagents. CEA is supported in part by American Cancer Society Postdoctoral Fellowship 11-183-TBG; she also acknowledges support Millennium Pharmaceuticals provided through the Alliance for Clinical Trials in Oncology Foundation. RSW is supported in part by a charitable donation from the Littlefield 2000 Trust. KMS is supported by the Howard Hughes Medical Institute and the Waxman Foundation.	Alain T, 2012, CANCER RES, V72, P6468, DOI 10.1158/0008-5472.CAN-12-2395; Apsel B, 2008, NAT CHEM BIOL, V4, P691, DOI 10.1038/nchembio.117; Atreya CE, 2012, INVEST NEW DRUG, V30, P2219, DOI 10.1007/s10637-012-9793-y; Barrett SD, 2008, BIOORG MED CHEM LETT, V18, P6501, DOI 10.1016/j.bmcl.2008.10.054; Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109; Blaser B, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-86; Bohanes P, 2011, SEMIN ONCOL, V38, P576, DOI 10.1053/j.seminoncol.2011.05.012; Brough R, 2011, CURR OPIN GENET DEV, V21, P34, DOI 10.1016/j.gde.2010.10.009; Carriere A, 2008, CURR BIOL, V18, P1269, DOI 10.1016/j.cub.2008.07.078; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Cloughesy TF, 2008, PLOS MED, V5, P139, DOI 10.1371/journal.pmed.0050008; Cohen MS, 2005, SCIENCE, V308, P1318, DOI 10.1126/science1108367; Daniel VC, 2009, CANCER RES, V69, P3364, DOI 10.1158/0008-5472.CAN-08-4210; Dowling RJO, 2010, SCIENCE, V328, P1172, DOI 10.1126/science.1187532; Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038; Fumagalli D, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-101; Garcia-Martinez JM, 2009, BIOCHEM J, V421, P29, DOI 10.1042/BJ20090489; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; House MG, 2010, J AM COLL SURGEONS, V210, P744, DOI 10.1016/j.jamcollsurg.2009.12.040; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Hsieh AC, 2010, CANCER CELL, V17, P249, DOI 10.1016/j.ccr.2010.01.021; Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838; Ilic N, 2011, P NATL ACAD SCI USA, V108, pE699, DOI 10.1073/pnas.1108237108; Iyer G, 2012, SCIENCE, V338, P221, DOI 10.1126/science.1226344; Janne PA, 2009, NAT REV DRUG DISCOV, V8, P709, DOI 10.1038/nrd2871; Janku F, 2013, CANCER RES, V73, P276, DOI 10.1158/0008-5472.CAN-12-1726; Joseph EW, 2010, P NATL ACAD SCI USA, V107, P14903, DOI 10.1073/pnas.1008990107; Kantarjian H, 2002, NEW ENGL J MED, V346, P645, DOI 10.1056/NEJMoa011573; Knight ZA, 2010, NAT REV CANCER, V10, P130, DOI 10.1038/nrc2787; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Liao XY, 2012, NEW ENGL J MED, V367, P1596, DOI 10.1056/NEJMoa1207756; Lievre A, 2008, J CLIN ONCOL, V26, P374, DOI 10.1200/JCO.2007.12.5906; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; McDermott U, 2007, P NATL ACAD SCI USA, V104, P19936, DOI 10.1073/pnas.0707498104; Menon S, 2008, Oncogene, V27 Suppl 2, pS43, DOI 10.1038/onc.2009.352; Motzer RJ, 2008, LANCET, V372, P449, DOI 10.1016/S0140-6736(08)61039-9; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Le NT, 2012, CIRC RES, V110, P536, DOI 10.1161/CIRCRESAHA.111.254730; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Pinheiro J, 2001, MIXED EFFECTS MODELS; Rong L, 2008, RNA, V14, P1318, DOI 10.1261/rna.950608; Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Sato T, 2010, ONCOGENE, V29, P2746, DOI 10.1038/onc.2010.28; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023; Talmadge JE, 2007, AM J PATHOL, V170, P793, DOI 10.2353/ajpath.2007.060929; Taylor SJ, 2001, METHOD ENZYMOL, V333, P333; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Voskoglou-Nomikos T, 2003, CLIN CANCER RES, V9, P4227; Weigelt B, 2011, ONCOGENE, V30, P3222, DOI 10.1038/onc.2011.42; Zhang YJ, 2011, DRUG DISCOV TODAY, V16, P325, DOI 10.1016/j.drudis.2011.02.008; Zhao L, 2008, P NATL ACAD SCI USA, V105, P2652, DOI 10.1073/pnas.0712169105; Zunder ER, 2008, CANCER CELL, V14, P180, DOI 10.1016/j.ccr.2008.06.014	56	60	61	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2014	33	12					1590	1600		10.1038/onc.2013.92	http://dx.doi.org/10.1038/onc.2013.92			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD4TS	23542178	Green Submitted, Green Accepted			2022-12-28	WOS:000333244200012
J	Nguyen-Lefebvre, AT; Leprun, G; Morin, V; Vinuelas, J; Coute, Y; Madjar, JJ; Gandrillon, O; Gonin-Giraud, S				Nguyen-Lefebvre, A. T.; Leprun, G.; Morin, V.; Vinuelas, J.; Coute, Y.; Madjar, J-J; Gandrillon, O.; Gonin-Giraud, S.			V-erbA generates ribosomes devoid of RPL11 and regulates translational activity in avian erythroid progenitors	ONCOGENE			English	Article						v-erbA oncogene; ribosomal proteins; translational activity regulation; 2D-DIGE; proteomic	THYROID-HORMONE RECEPTOR; PROTEIN L11; TGF-BETA; EXPRESSION; CELLS; ONCOGENE; CANCER; DIFFERENTIATION; PROLIFERATION; GATA-1	The v-erbA oncogene transforms chicken erythrocytic progenitors (T2EC) by blocking their differentiation and freezing them in a state of self-renewal. Transcriptomes of T2EC, expressing either v-erbA or a non-transforming form of v-erbA (S61G), were compared using serial analysis of gene expression and some, but not all, mRNA-encoding ribosomal proteins were seen to be affected by v-erbA. These results suggest that this oncogene could modulate the composition of ribosomes. In the present study, we demonstrate, using two-dimensional difference in gel electrophoresis, that v-erbA-expressing cells have a lower amount of RPL11 associated with the ribosomes. The presence of ribosomes devoid of RPL11 in v-erbA-expressing cells was further confirmed by immunoprecipitation. In order to assess the possible impact of these specialized ribosomes on the translational activity, we analyzed proteomes of either v-erbA or S61G-expressing cells using 2D/mass spectrometry, and identified nine proteins present in differing amounts within these cells. Among these proteins, we focused on HSP70 because of its involvement in erythroid differentiation. Our results indicate that, in v-erbA-expressing cells, hsp70 is not only transcribed but also translated more efficiently, as shown by polyribosome fractionation experiments. We demonstrate here, for the first time, the existence of ribosomes with different protein components, notably ribosomes devoid of RPL11, and a regulation of mRNA translation depending on v-erbA oncogene expression.	[Nguyen-Lefebvre, A. T.; Leprun, G.; Morin, V.; Vinuelas, J.; Madjar, J-J; Gandrillon, O.; Gonin-Giraud, S.] Univ Lyon 1, Ctr Genet & Physiol Mol & Cellulaire, CNRS, UMR 5534, F-69622 Villeurbanne, France; [Coute, Y.] CEA, IRTSV, Lab Biol Grande Echelle, Grenoble, France; [Coute, Y.] INSERM, U1038, Grenoble, France; [Coute, Y.] Univ Grenoble 1, Grenoble, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CEA; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Gonin-Giraud, S (corresponding author), Univ Lyon 1, Ctr Genet & Physiol Mol & Cellulaire, Team Bases Mol Autorenouvellement & Alterat, CNRS,UMR 5534, Batiment Gregor Mendel,16 Rue Raphael Dubois, F-69622 Villeurbanne, France.	sandrine.giraud@univ-lyon1.fr	Couté, Yohann/G-2695-2015	Couté, Yohann/0000-0003-3896-6196	Association pour la Recherche contre le Cancer; Ligue contre le Cancer (Comite Departemental du Rhone); Societe Francaise d'Hematologie (SFH); Region Rhone-Alpes; Universite Claude Bernard Lyon 1 (UCBL1); Centre National de la Recherche Scientifique (CNRS)	Association pour la Recherche contre le Cancer(Fondation ARC pour la Recherche sur le Cancer); Ligue contre le Cancer (Comite Departemental du Rhone); Societe Francaise d'Hematologie (SFH); Region Rhone-Alpes(Region Auvergne-Rhone-Alpes); Universite Claude Bernard Lyon 1 (UCBL1); Centre National de la Recherche Scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS))	We thank Dr Stephanie Gobert-Gosse (Universite Claude Bernard Lyon 1, Villeurbanne, France) for her expert advice on the two-dimensional electrophoresis experiments and Clement Soleilhavoup for his technical help in the analysis of total mRNA levels by RT-qPCR. This work received support from grants from Association pour la Recherche contre le Cancer, Ligue contre le Cancer (Comite Departemental du Rhone), Societe Francaise d'Hematologie (SFH), Region Rhone-Alpes, Universite Claude Bernard Lyon 1 (UCBL1) and Centre National de la Recherche Scientifique (CNRS).	Anh TNL, 2011, J PROTEOMICS, V74, P167, DOI 10.1016/j.jprot.2010.10.007; BENCHAIBI M, 1989, VIROLOGY, V169, P15, DOI 10.1016/0042-6822(89)90036-6; BISTER K, 1979, P NATL ACAD SCI USA, V76, P5023, DOI 10.1073/pnas.76.10.5023; Bonamy GMC, 2005, MOL ENDOCRINOL, V19, P1213, DOI 10.1210/me.2004-0204; BONDE BG, 1991, J VIROL, V65, P2037, DOI 10.1128/JVI.65.4.2037-2046.1991; Bresson C, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-390; Cardenas D, 2012, NUCLEIC ACIDS RES, V40, P1; Casabona MG, 2013, ENVIRON MICROBIOL, V15, P471, DOI 10.1111/j.1462-2920.2012.02816.x; Challagundla KB, 2011, MOL CELL BIOL, V31, P4007, DOI 10.1128/MCB.05810-11; Dai MS, 2007, EMBO J, V26, P3332, DOI 10.1038/sj.emboj.7601776; DAMM K, 1989, NATURE, V339, P593, DOI 10.1038/339593a0; Gandrillon O, 1999, EMBO J, V18, P2764, DOI 10.1093/emboj/18.10.2764; GANDRILLON O, 1994, ONCOGENE, V9, P749; GANDRILLON O, 1989, CELL, V58, P115, DOI 10.1016/0092-8674(89)90408-X; GANDRILLON O, 1987, CELL, V49, P687, DOI 10.1016/0092-8674(87)90545-9; GANDRILLON O, 1995, INT J ONCOL, V6, P215; Gandrillon O, 2012, PROG BIOPHYS MOL BIO, V110, P1, DOI 10.1016/j.pbiomolbio.2012.05.006; Gonin-Giraud S, 2008, LEUKEMIA RES, V32, P1878, DOI 10.1016/j.leukres.2008.05.010; GRAF T, 1978, BIOCHIM BIOPHYS ACTA, V516, P269, DOI 10.1016/0304-419X(78)90011-2; Greco A, 1997, MOL GEN GENET, V256, P320, DOI 10.1007/s004380050575; Gregory T, 1999, BLOOD, V94, P87, DOI 10.1182/blood.V94.1.87.413k41_87_96; Habif G, 2013, J PROTEOMICS, V78, P231, DOI 10.1016/j.jprot.2012.09.009; Hill WE, 1990, AM SOC MICROBIOLOGY, Vxxiii, P678; Jaattela M, 1999, EXP CELL RES, V248, P30, DOI 10.1006/excr.1999.4455; Kaberdina AC, 2009, MOL CELL, V33, P227, DOI 10.1016/j.molcel.2008.12.014; Kiparisov S, 2005, MOL GENET GENOMICS, V274, P235, DOI 10.1007/s00438-005-0020-9; Komili S, 2007, CELL, V131, P557, DOI 10.1016/j.cell.2007.08.037; Madjar JJ, 1994, CELL BIOL LABORATORY, V1, P657; Marygold SJ, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-10-r216; Meyuhas O, 2009, PROG MOL BIOL TRANSL, V90, P109, DOI 10.1016/S1877-1173(09)90003-5; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Rabilloud T, 1999, METH MOL B, V112, P297; Rascle A, 1997, BASEL, V1, P119; Reed John C., 1999, Current Opinion in Oncology, V11, P68, DOI 10.1097/00001622-199901000-00014; Ribeil JA, 2007, NATURE, V445, P102, DOI 10.1038/nature05378; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; SHARIF M, 1991, CELL, V66, P885, DOI 10.1016/0092-8674(91)90435-2; Sugihara Y, 2010, J PROTEOME RES, V9, P1351, DOI 10.1021/pr9008964; TILL JE, 1963, RADIAT RES, V18, P96, DOI 10.2307/3571429; Vandelkerckhove J, 2008, M S-MED SCI, V24, P37, DOI 10.1051/medsci/200824137; Vargas-Roig LM, 1998, INT J CANCER, V79, P468, DOI 10.1002/(SICI)1097-0215(19981023)79:5<468::AID-IJC4>3.0.CO;2-Z; VargasRoig LM, 1997, CANCER DETECT PREV, V21, P441; WALLER JP, 1961, P NATL ACAD SCI USA, V47, P18, DOI 10.1073/pnas.47.1.18; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; WOOL IG, 1979, ANNU REV BIOCHEM, V48, P719, DOI 10.1146/annurev.bi.48.070179.003443; Xue SF, 2012, NAT REV MOL CELL BIO, V13, P355, DOI 10.1038/nrm3359; YEN PM, 1994, J BIOL CHEM, V269, P903; Zhang JY, 2007, GENE DEV, V21, P2580, DOI 10.1101/gad.1569307; Zhang Q, 2011, J BIOL CHEM, V286, P38264, DOI 10.1074/jbc.M111.277012	49	4	4	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2014	33	12					1581	1589		10.1038/onc.2013.93	http://dx.doi.org/10.1038/onc.2013.93			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD4TS	23563180				2022-12-28	WOS:000333244200011
J	Zhou, W; Bao, S				Zhou, W.; Bao, S.			PML-mediated signaling and its role in cancer stem cells	ONCOGENE			English	Review						PML; cancer stem cells; cell signaling; oncogenesis	PROMYELOCYTIC LEUKEMIA PROTEIN; ALPHA-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR PML; UBIQUITIN-LIKE PROTEIN; FAS-INDUCED APOPTOSIS; NUCLEAR-BODIES; RAR-ALPHA; DNA-DAMAGE; TRANSCRIPTIONAL REPRESSION; SUBNUCLEAR LOCALIZATION	The promyelocytic leukemia (PML) protein, initially discovered as a part of the PML/retinoic acid receptor alpha fusion protein, has been found to be a critical player in oncogenesis and tumor progression. Multiple cellular activities, including DNA repair, alternative lengthening of telomeres, transcriptional control, apoptosis and senescence, are regulated by PML and its featured subcellular structure, the PML nuclear body. In correspondence with its role in many important life processes, PML mediates several complex downstream signaling pathways. The determinant function of PML in tumorigenesis and cancer progression raises the interest in its involvement in cancer stem cells (CSCs), a subpopulation of cancer cells that share properties with stem cells and are critical for tumor propagation. Recently, there are exciting discoveries concerning the requirement of PML in CSC maintenance. Growing evidences strongly suggest a positive role of PML in regulating CSCs in both hematopoietic cancers and solid tumors, whereas the underlying mechanisms may be different and remain elusive. Here we summarize and discuss the PML-mediated signaling pathways in cancers and their potential roles in regulating CSCs.	[Zhou, W.; Bao, S.] Cleveland Clin, Lerner Res Inst, Dept Stem Cell Biol & Regenerat Med, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Bao, S (corresponding author), Cleveland Clin, Lerner Res Inst, Dept Stem Cell Biol & Regenerat Med, 9500 Euclid Ave,NE30, Cleveland, OH 44195 USA.	baos@ccf.org			Cleveland Clinic Foundation; NIH R01 Grant [NS070315]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS070315] Funding Source: NIH RePORTER	Cleveland Clinic Foundation; NIH R01 Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by the Cleveland Clinic Foundation and a NIH R01 Grant (NS070315) to SB. We thank other members in the Bao's lab for helpful discussion. We apologize for not including all PML references in this review due to space limit.	Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Aoto T, 2006, DEV BIOL, V298, P354, DOI 10.1016/j.ydbio.2006.04.450; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Bao-Lei T, 2006, J CELL BIOCHEM, V97, P561, DOI 10.1002/jcb.20584; Barr SM, 2003, CURR BIOL, V13, P1047, DOI 10.1016/S0960-9822(03)00376-2; Bernardi R, 2004, NAT CELL BIOL, V6, P665, DOI 10.1038/ncb1147; Bernardi R, 2007, NAT REV MOL CELL BIO, V8, P1006, DOI 10.1038/nrm2277; Best JL, 2002, MOL CELL, V10, P843, DOI 10.1016/S1097-2765(02)00699-8; Bischof O, 2001, J CELL BIOL, V153, P367, DOI 10.1083/jcb.153.2.367; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Boddy MN, 1996, ONCOGENE, V13, P971; Boddy MN, 1997, J CELL SCI, V110, P2197; Boe SO, 2006, J CELL SCI, V119, P3284, DOI 10.1242/jcs.03068; Boisvert FM, 2000, J CELL BIOL, V148, P283, DOI 10.1083/jcb.148.2.283; Brouwer AK, 2009, MOL BIOL CELL, V20, P4804, DOI 10.1091/mbc.E09-04-0309; Butler JT, 2009, J CELL BIOCHEM, V107, P609, DOI 10.1002/jcb.22183; Carbone R, 2002, ONCOGENE, V21, P1633, DOI 10.1038/sj.onc.1205227; Carracedo A, 2012, J CLIN INVEST, V122, P3088, DOI 10.1172/JCI62129; ChelbiAlix MK, 1995, LEUKEMIA, V9, P2027; Cho S, 2011, J BIOL CHEM, V286, P41115, DOI 10.1074/jbc.M111.248534; Chuang YS, 2011, STEM CELLS, V29, P660, DOI 10.1002/stem.623; Chung I, 2011, J CELL SCI, V124, P3603, DOI 10.1242/jcs.084681; Condemine W, 2007, J CELL SCI, V120, P3219, DOI 10.1242/jcs.007492; Condemine W, 2006, CANCER RES, V66, P6192, DOI 10.1158/0008-5472.CAN-05-3792; Crowder C, 2005, BLOOD, V105, P1280, DOI 10.1182/blood-2004-04-1614; Croxton R, 2006, CANCER RES, V66, P9026, DOI 10.1158/0008-5472.CAN-06-1047; Culjkovic B, 2008, J CELL BIOL, V181, P51, DOI 10.1083/jcb.200707018; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; de Stanchina E, 2004, MOL CELL, V13, P523, DOI 10.1016/S1097-2765(04)00062-0; de The H, 2010, NAT REV CANCER, V10, P775, DOI 10.1038/nrc2943; Dellaire G, 2006, J CELL BIOL, V175, P55, DOI 10.1083/jcb.200604009; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; Draskovic I, 2009, P NATL ACAD SCI USA, V106, P15726, DOI 10.1073/pnas.0907689106; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; Eskiw CH, 2003, J CELL SCI, V116, P4455, DOI 10.1242/jcs.00758; Fagioli M, 1998, ONCOGENE, V16, P2905, DOI 10.1038/sj.onc.1201811; FAGIOLI M, 1992, ONCOGENE, V7, P1083; Fang WZ, 2002, ONCOGENE, V21, P5557, DOI 10.1038/sj.onc.1205666; Fasching CL, 2007, CANCER RES, V67, P7072, DOI 10.1158/0008-5472.CAN-07-1556; Ferbeyre G, 2000, GENE DEV, V14, P2015; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Fu CH, 2005, ONCOGENE, V24, P5401, DOI 10.1038/sj.onc.1208714; Geng YY, 2012, J BIOL CHEM, V287, P30729, DOI 10.1074/jbc.M112.374769; Geoffroy MC, 2010, MOL BIOL CELL, V21, P4227, DOI 10.1091/mbc.E10-05-0449; Giorgi C, 2010, SCIENCE, V330, P1247, DOI 10.1126/science.1189157; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; Gong L, 2006, J BIOL CHEM, V281, P15869, DOI 10.1074/jbc.M511658200; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Grobelny JV, 2000, J CELL SCI, V113, P4577; Guan D, 2013, ONCOGENE, V32, P3819, DOI 10.1038/onc.2012.406; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Gupta P, 2008, P NATL ACAD SCI USA, V105, P11424, DOI 10.1073/pnas.0710561105; Hatakeyama S, 2011, NAT REV CANCER, V11, P792, DOI 10.1038/nrc3139; Haupt S, 2009, CANCER RES, V69, P4818, DOI 10.1158/0008-5472.CAN-08-4010; Hayakawa F, 2004, CANCER CELL, V5, P389, DOI 10.1016/S1535-6108(04)00082-0; Hayakawa F, 2008, J BIOL CHEM, V283, P24420, DOI 10.1074/jbc.M802217200; Herzer K, 2009, CANCER RES, V69, P855, DOI 10.1158/0008-5472.CAN-08-2831; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Hsu JK, 2012, J CELL BIOL, V197, P613, DOI 10.1083/jcb.201109038; Hubackova S, 2012, J BIOL CHEM, V287, P26702, DOI 10.1074/jbc.M111.316869; ISHOV AM, 1999, J CELL BIOL, V147, P221, DOI [10.1083/jcb.147.2.221, DOI 10.1083/JCB.147.2.221]; Ito K, 2008, NATURE, V453, P1072, DOI 10.1038/nature07016; Ito K, 2012, NAT MED, V18, P1350, DOI 10.1038/nm.2882; Jensen K, 2001, ONCOGENE, V20, P7223, DOI 10.1038/sj.onc.1204765; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kamitani T, 1998, J BIOL CHEM, V273, P3117, DOI 10.1074/jbc.273.6.3117; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kawai T, 2003, MOL CELL BIOL, V23, P6174, DOI 10.1128/MCB.23.17.6174-6186.2003; Kawasaki A, 2003, BLOOD, V101, P3668, DOI 10.1182/blood-2002-08-2474; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; Kim TK, 2007, CANCER RES, V67, P11133, DOI 10.1158/0008-5472.CAN-07-1342; Lallemand-Breitenbach V, 2008, NAT CELL BIOL, V10, P547, DOI 10.1038/ncb1717; Lallemand-Breitenbach V, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000661; LaMorte VJ, 1998, P NATL ACAD SCI USA, V95, P4991, DOI 10.1073/pnas.95.9.4991; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lapi E, 2008, MOL CELL, V32, P803, DOI 10.1016/j.molcel.2008.11.019; LAVAU C, 1995, ONCOGENE, V11, P871; Lehembre F, 2001, ONCOGENE, V20, P1, DOI 10.1038/sj.onc.1204063; Li H, 2000, MOL CELL BIOL, V20, P1784, DOI 10.1128/MCB.20.5.1784-1796.2000; Li Q, 2011, ONCOGENE, V30, P1194, DOI 10.1038/onc.2010.499; Li W, 2009, P NATL ACAD SCI USA, V106, P4725, DOI 10.1073/pnas.0807640106; Liang J, 2008, NAT CELL BIOL, V10, P731, DOI 10.1038/ncb1736; Lim JH, 2011, J BIOL CHEM, V286, P44403, DOI 10.1074/jbc.M111.289512; Lin DY, 2006, MOL CELL, V24, P341, DOI 10.1016/j.molcel.2006.10.019; Lin DY, 2003, J BIOL CHEM, V278, P15958, DOI 10.1074/jbc.M300387200; Lin HK, 2004, NATURE, V431, P205, DOI 10.1038/nature02783; Louria-Hayon I, 2003, J BIOL CHEM, V278, P33134, DOI 10.1074/jbc.M301264200; Louria-Hayon I, 2009, CELL DEATH DIFFER, V16, P1156, DOI 10.1038/cdd.2009.31; Mallette FA, 2004, ONCOGENE, V23, P91, DOI 10.1038/sj.onc.1206886; Martin N, 2012, EMBO J, V31, P95, DOI 10.1038/emboj.2011.370; Matic I, 2008, MOL CELL PROTEOMICS, V7, P132, DOI 10.1074/mcp.M700173-MCP200; Maul GG, 1995, J CELL BIOCHEM, V59, P498, DOI 10.1002/jcb.240590410; Meinecke I, 2007, P NATL ACAD SCI USA, V104, P5073, DOI 10.1073/pnas.0608773104; Moller A, 2003, CANCER RES, V63, P4310; Morgan M, 2002, J CELL BIOL, V157, P975, DOI 10.1083/jcb.200204039; Mukhopadhyay D, 2006, J CELL BIOL, V174, P939, DOI 10.1083/jcb.200510103; Nabetani A, 2004, J BIOL CHEM, V279, P25849, DOI 10.1074/jbc.M312652200; Nasr R, 2008, NAT MED, V14, P1333, DOI 10.1038/nm.1891; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Park J, 2005, MOL CELL BIOL, V25, P8202, DOI 10.1128/MCB.25.18.8202-8214.2005; Park SW, 2007, NAT STRUCT MOL BIOL, V14, P68, DOI 10.1038/nsmb1185; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pearson M, 2001, ONCOGENE, V20, P7250, DOI 10.1038/sj.onc.1204856; Peche LY, 2012, CELL DEATH DIFFER, V19, P926, DOI 10.1038/cdd.2011.173; Percherancier Y, 2009, J BIOL CHEM, V284, P16595, DOI 10.1074/jbc.M109.006387; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Rabellino A, 2012, CANCER RES, V72, P2275, DOI 10.1158/0008-5472.CAN-11-3159; Regad T, 2009, NAT NEUROSCI, V12, P132, DOI 10.1038/nn.2251; Reineke EL, 2008, MOL CELL BIOL, V28, P997, DOI 10.1128/MCB.01848-07; Renner F, 2010, MOL CELL, V37, P503, DOI 10.1016/j.molcel.2010.01.018; Salomoni P, 2005, BLOOD, V105, P3686, DOI 10.1182/blood-2004-09-3782; Scaglioni PP, 2006, CELL, V126, P269, DOI 10.1016/j.cell.2006.05.041; Scaglioni PP, 2012, EMBO MOL MED, V4, P594, DOI 10.1002/emmm.201200233; Shen TH, 2006, MOL CELL, V24, P331, DOI 10.1016/j.molcel.2006.09.013; Shima Y, 2008, MOL CELL BIOL, V28, P7126, DOI 10.1128/MCB.00897-08; Shin J, 2004, J BIOL CHEM, V279, P40994, DOI 10.1074/jbc.M407369200; Shtutman Michael, 2002, Cancer Research, V62, P5947; Silvestre DC, 2011, STEM CELLS, V29, P440, DOI 10.1002/stem.600; Slatter TL, 2012, J PATHOL, V226, P509, DOI 10.1002/path.2981; Smith KP, 2004, J CELL BIOCHEM, V93, P1282, DOI 10.1002/jcb.20273; Song MS, 2008, NATURE, V455, P813, DOI 10.1038/nature07290; Stadler M, 1995, ONCOGENE, V11, P2565; Sternsdorf T, 1997, J CELL BIOL, V139, P1621, DOI 10.1083/jcb.139.7.1621; Takahashi K, 2007, MOL BIOL CELL, V18, P1701, DOI 10.1091/mbc.E06-08-0747; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Tatham MH, 2008, NAT CELL BIOL, V10, P538, DOI 10.1038/ncb1716; Torii S, 1999, EMBO J, V18, P6037, DOI 10.1093/emboj/18.21.6037; Trotman LC, 2006, NATURE, V441, P523, DOI 10.1038/nature04809; Ulbricht T, 2012, J CELL BIOL, V199, P49, DOI 10.1083/jcb.201112015; Valent P, 2012, NAT REV CANCER, V12, P767, DOI 10.1038/nrc3368; Vallian S, 1998, ONCOGENE, V16, P2843, DOI 10.1038/sj.onc.1201837; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; Vernier M, 2011, GENE DEV, V25, P41, DOI 10.1101/gad.1975111; Vlasakova J, 2007, BLOOD, V109, P1373, DOI 10.1182/blood-2006-02-003418; Wang J, 2004, J CELL BIOL, V164, P515, DOI 10.1083/jcb.200305142; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wang ZG, 1998, SCIENCE, V279, P1547; Wei XL, 2003, J BIOL CHEM, V278, P29288, DOI 10.1074/jbc.M212215200; Welch JS, 2011, J CLIN INVEST, V121, P1636, DOI 10.1172/JCI42953; Wolyniec K, 2012, BLOOD, V120, P822, DOI 10.1182/blood-2011-10-387647; Wu GK, 2000, J BIOL CHEM, V275, P30618, DOI 10.1074/jbc.C000390200; Wu WS, 2003, J BIOL CHEM, V278, P12294, DOI 10.1074/jbc.M211849200; Wu WS, 2002, J BIOL CHEM, V277, P31734, DOI 10.1074/jbc.M201648200; Wu WS, 2002, ONCOGENE, V21, P3925, DOI 10.1038/sj.onc.1205491; Wu WS, 2001, MOL CELL BIOL, V21, P2259, DOI 10.1128/MCB.21.7.2259-2268.2001; Xu ZX, 2003, MOL CELL BIOL, V23, P4247, DOI 10.1128/MCB.23.12.4247-4256.2003; Yang Q, 2013, ONCOGENE, V32, P3156, DOI 10.1038/onc.2012.332; Yang ST, 2006, J BIOL CHEM, V281, P26645, DOI 10.1074/jbc.M604391200; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Ye XF, 2007, MOL CELL BIOL, V27, P2452, DOI 10.1128/MCB.01592-06; Ye XF, 2007, MOL CELL, V27, P183, DOI 10.1016/j.molcel.2007.05.034; Yeager TR, 1999, CANCER RES, V59, P4175; Yeung PL, 2012, J CELL BIOCHEM, V113, P1787, DOI 10.1002/jcb.24050; Yuan WC, 2011, CANCER CELL, V20, P214, DOI 10.1016/j.ccr.2011.07.008; Zhang P, 2008, CURR BIOL, V18, P1489, DOI 10.1016/j.cub.2008.08.048; Zhang RG, 2005, DEV CELL, V8, P19, DOI 10.1016/j.devcel.2004.10.019; Zhang XW, 2010, SCIENCE, V328, P240, DOI 10.1126/science.1183424; Zhong S, 2000, J EXP MED, V191, P631, DOI 10.1084/jem.191.4.631; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752; Zhu HY, 2003, J BIOL CHEM, V278, P49286, DOI 10.1074/jbc.M308302200; Zong S, 1999, ONCOGENE, V18, P7941, DOI 10.1038/sj.onc.1203367	164	19	19	0	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2014	33	12					1475	1484		10.1038/onc.2013.111	http://dx.doi.org/10.1038/onc.2013.111			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD4TS	23563177				2022-12-28	WOS:000333244200001
J	Sun, D; Layer, R; Mueller, AC; Cichewicz, MA; Negishi, M; Paschal, BM; Dutta, A				Sun, D.; Layer, R.; Mueller, A. C.; Cichewicz, M. A.; Negishi, M.; Paschal, B. M.; Dutta, A.			Regulation of several androgen-induced genes through the repression of the miR-99a/let-7c/miR-125b-2 miRNA cluster in prostate cancer cells	ONCOGENE			English	Article						miRNA cluster; androgen regulation; prostate cancer proliferation	GROWTH-FACTOR-I; CHROMATIN IMMUNOPRECIPITATION; RECEPTOR EXPRESSION; BREAST-CANCER; UP-REGULATION; POLYCOMB; NETWORK; PROTEIN; FAMILY; JMJD3	The androgen receptor (AR) stimulates and represses gene expression to promote the initiation and progression of prostate cancer. Here, we report that androgen represses the miR-99a/let7c/125b-2 cluster through AR and anti-androgen drugs block the androgen-repression of the miRNA cluster. AR directly binds to the host gene of the miR-99a/let7c/125b-2 cluster, LINC00478. Expression of the cluster is repressed or activated by chromatin remodelers EZH2 or JMJD3 in the presence or absence of androgen, respectively. Bioinformatics analysis reveals a significant enrichment of targets of miR-99a, let-7c and miR-125b in androgen-induced gene sets, suggesting that downregulation of the miR-99a/let7c/125b-2 cluster by androgen protects many of their target mRNAs from degradation and indirectly assists in the gene induction. We validated the hypothesis with 12 potential targets of the miR-99a/let7c/125b-2 cluster induced by androgen: 9 out of the 12 mRNAs are downregulated by the microRNA cluster. To ascertain the biological significance of this hypothesis, we focused on IGF1R, a known prostate cancer growth factor that is induced by androgen and directly targeted by the miR-99a/let7c/125b-2 cluster. The androgen-induced cell proliferation is ameliorated to a similar extent as anti-androgen drugs by preventing the repression of the microRNAs or induction of IGF1R in androgen-dependent prostate cancer cells. Expression of a microRNA-resistant form of IGF1R protects these cells from inhibition by the miR-99a/let7c/125b-2 cluster. These results indicate that a thorough understanding of how androgen stimulates prostate cancer growth requires not only an understanding of genes directly induced/repressed by AR, but also of genes indirectly induced by AR through the repression of key microRNAs.	[Sun, D.; Layer, R.; Mueller, A. C.; Cichewicz, M. A.; Negishi, M.; Paschal, B. M.; Dutta, A.] Univ Virginia, Hlth Sci Ctr, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; [Layer, R.] Univ Virginia, Dept Comp Sci, Charlottesville, VA 22908 USA; [Paschal, B. M.] Univ Virginia, Ctr Cell Signaling, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Dutta, A (corresponding author), Univ Virginia, Hlth Sci Ctr, Jordan Hall 1240,Box 800733, Charlottesville, VA 22908 USA.	ad8q@virginia.edu	Dutta, Anindya/P-3203-2016	Dutta, Anindya/0000-0002-4319-0073; Mueller, Adam/0000-0003-2678-0159	NIH [P01CA104106]; DOD from the US Army DOD [PC094499]; NATIONAL CANCER INSTITUTE [T32CA009109, P01CA104106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007267] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD from the US Army DOD; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by P01CA104106 from NIH to AD and BMP and DOD PC094499 from the US Army DOD to DS. We thank members of the Prostate Cancer Research Working group at UVA for helpful discussions.	Agger K, 2007, NATURE, V449, P731, DOI 10.1038/nature06145; Antonarakis ES, 2010, CANCER LETT, V291, P1, DOI 10.1016/j.canlet.2009.08.012; Baniwal SK, 2009, MOL ENDOCRINOL, V23, P1203, DOI 10.1210/me.2008-0470; Bolton EC, 2007, GENE DEV, V21, P2005, DOI 10.1101/gad.1564207; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Cardillo MR, 2003, ANTICANCER RES, V23, P3825; Chen ZJ, 2012, ORAL ONCOL, V48, P686, DOI 10.1016/j.oraloncology.2012.02.020; Chlenski A, 2001, PROSTATE, V47, P66; Curtin D, 2001, MOL ENDOCRINOL, V15, P1906, DOI 10.1210/me.15.11.1906; Dahle O, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000841; Denayer S, 2010, MOL ENDOCRINOL, V24, P898, DOI 10.1210/me.2009-0310; Ene CI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051407; Fletcher CE, 2012, HUM MOL GENET, V21, P3112, DOI 10.1093/hmg/dds139; Gennigens C, 2006, CRIT REV ONCOL HEMAT, V58, P124, DOI 10.1016/j.critrevonc.2005.10.003; Gommans Willemijn M, 2012, Methods Mol Biol, V822, P1, DOI 10.1007/978-1-61779-427-8_1; Gonit M, 2011, MOL ENDOCRINOL, V25, P621, DOI 10.1210/me.2010-0409; Grad JM, 1999, MOL ENDOCRINOL, V13, P1896, DOI 10.1210/me.13.11.1896; Guan Y, 2011, INT J CANCER, V128, P2274, DOI 10.1002/ijc.25575; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Huang L, 2011, INT J CANCER, V128, P1758, DOI 10.1002/ijc.25509; Jalava SE, 2012, ONCOGENE, V31, P4460, DOI 10.1038/onc.2011.624; Jiang JT, 2012, PROSTATE, V72, P225, DOI 10.1002/pros.21430; Jung JW, 2010, CELL MOL LIFE SCI, V67, P1165, DOI 10.1007/s00018-009-0242-9; Kim HK, 2006, J CELL BIOL, V174, P677, DOI 10.1083/jcb.200603008; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kojima S, 2009, INT J UROL, V16, P161, DOI 10.1111/j.1442-2042.2008.02224.x; Lanzino M, 2010, NUCLEIC ACIDS RES, V38, P5351, DOI 10.1093/nar/gkq278; Lee JG, 2009, MOL CARCINOGEN, V48, P141, DOI 10.1002/mc.20462; Liao YD, 2005, HUM PATHOL, V36, P1186, DOI 10.1016/j.humpath.2005.07.023; Liu YN, 2008, MOL CELL BIOL, V28, P7096, DOI 10.1128/MCB.00449-08; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018; Magee JA, 2006, ENDOCRINOLOGY, V147, P590, DOI 10.1210/en.2005-1001; Massie CE, 2007, EMBO REP, V8, P871, DOI 10.1038/sj.embor.7401046; Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105; Mueller AC, 2013, ONCOGENE, V32, P1164, DOI 10.1038/onc.2012.131; Nadiminty N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032832; Nadiminty N, 2012, J BIOL CHEM, V287, P1527, DOI 10.1074/jbc.M111.278705; Nelius T, 2007, INT J CANCER, V121, P999, DOI 10.1002/ijc.22802; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; Ngan S, 2009, ONCOGENE, V28, P2051, DOI 10.1038/onc.2009.68; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677; Ozkan EE, 2011, MOL CELL ENDOCRINOL, V344, P1, DOI 10.1016/j.mce.2011.07.002; Pandini G, 2005, CANCER RES, V65, P1849, DOI 10.1158/0008-5472.CAN-04-1837; Pandini G, 2009, ANN NY ACAD SCI, V1155, P263, DOI 10.1111/j.1749-6632.2009.04361.x; Papatsoris AG, 2005, TRENDS MOL MED, V11, P52, DOI 10.1016/j.molmed.2004.12.005; Piovan C, 2012, MOL ONCOL, V6, P458, DOI 10.1016/j.molonc.2012.03.003; Qin ZHS, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-369; Rae JM, 2006, PROSTATE, V66, P886, DOI 10.1002/pros.20403; Ramadoss S, 2012, J BIOL CHEM, V287, P44508, DOI 10.1074/jbc.M112.424903; Ribas J, 2009, CANCER RES, V69, P7165, DOI 10.1158/0008-5472.CAN-09-1448; Richter E, 2007, PROSTATE CANCER P D, V10, P114, DOI 10.1038/sj.pcan.4500936; Rubinstein M, 2004, ENDOCRINOLOGY, V145, P3769, DOI 10.1210/en.2004-0173; Sen GL, 2008, GENE DEV, V22, P1865, DOI 10.1101/gad.1673508; Sun DD, 2011, CANCER RES, V71, P1313, DOI 10.1158/0008-5472.CAN-10-1031; Sun JC, 2012, PLOS COMPUT BIOL, V8, DOI 10.1371/journal.pcbi.1002488; Takayama K, 2007, ONCOGENE, V26, P4453, DOI 10.1038/sj.onc.1210229; Takayama K, 2011, ONCOGENE, V30, P619, DOI 10.1038/onc.2010.436; Tong AW, 2009, CANCER GENE THER, V16, P206, DOI 10.1038/cgt.2008.77; van Royen ME, 2012, J CELL SCI, V125, P1970, DOI 10.1242/jcs.096792; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Waltering KK, 2011, PROSTATE, V71, P604, DOI 10.1002/pros.21276; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Wang WLW, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-58; Wang Y, 2011, GENOMICS, V98, P445, DOI 10.1016/j.ygeno.2011.09.004; Wu JD, 2006, J CELL BIOCHEM, V99, P392, DOI 10.1002/jcb.20929; Xiang Y, 2007, CELL RES, V17, P850, DOI 10.1038/cr.2007.83; Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Zhao JC, 2012, GENOME RES, V22, P322, DOI 10.1101/gr.131508.111; Zheng C, 2012, MED ONCOL, V29, P815, DOI 10.1007/s12032-011-9934-8; Zhu H, 2011, CELL, V147, P81, DOI 10.1016/j.cell.2011.08.033	72	77	82	2	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2014	33	11					1448	1457		10.1038/onc.2013.77	http://dx.doi.org/10.1038/onc.2013.77			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD0SD	23503464	Green Accepted			2022-12-28	WOS:000332943500012
J	Marques, N; Sese, M; Canovas, V; Valente, F; Bermudo, R; de Torres, I; Fernandez, Y; Abasolo, I; Fernandez, PL; Contreras, H; Castellon, E; Celia-Terrassa, T; Mendez, R; Cajal, SRY; Thomson, TM; Paciucci, R				Marques, N.; Sese, M.; Canovas, V.; Valente, F.; Bermudo, R.; de Torres, I.; Fernandez, Y.; Abasolo, I.; Fernandez, P. L.; Contreras, H.; Castellon, E.; Celia-Terrassa, T.; Mendez, R.; Ramon y Cajal, S.; Thomson, T. M.; Paciucci, R.			Regulation of protein translation and c-Jun expression by prostate tumor overexpressed 1	ONCOGENE			English	Article						PTOV1; c-Jun; translation; prostate cancer; invasion	RECEPTOR-INTERACTING PROTEIN; TRANSCRIPTION FACTOR SNAIL; GENE-EXPRESSION; KINASE-C; RACK1; ACTIVATION; CANCER; INVASION; GROWTH; VP16	Prostate tumor overexpressed-1 (PTOV1), a modulator of the Mediator transcriptional regulatory complex, is expressed at high levels in prostate cancer and other neoplasias in association with a more aggressive disease. Here we show that PTOV1 interacts directly with receptor of activated protein C kinase 1 (RACK1), a regulator of protein kinase C and Jun signaling and also a component of the 40S ribosome. Consistent with this interaction, PTOV1 was associated with ribosomes and its overexpression promoted global protein synthesis in prostate cancer cells and COS-7 fibroblasts in a mTORC1-dependent manner. Transfection of ectopic PTOV1 enhanced the expression of c-Jun protein without affecting the levels of c-Jun or RACK1 mRNA. Conversely, knockdown of PTOV1 caused significant declines in global protein synthesis and c-Jun protein levels. High levels of PTOV1 stimulated the motility and invasiveness of prostate cancer cells, which required c-Jun, whereas knockdown of PTOV1 strongly inhibited the tumorigenic and metastatic potentials of PC-3 prostate cancer cells. In human prostate cancer samples, the expression of high levels of PTOV1 in primary and metastatic tumors was significantly associated with increased nuclear localization of active c-Jun. These results unveil new functions of PTOV1 in the regulation of protein translation and in the progression of prostate cancer to an invasive and metastatic disease.	[Marques, N.; Sese, M.; Canovas, V.; Valente, F.; Paciucci, R.] Univ Autonoma Barcelona, Vall dHebron Inst Res, Res Unit Biomed Translat & Pediat Onco, E-08193 Barcelona, Spain; [Bermudo, R.; Celia-Terrassa, T.; Thomson, T. M.] CSIC, Inst Mol Biol, Dept Cell Biol, Barcelona, Spain; [Bermudo, R.; Fernandez, P. L.] Univ Barcelona, Inst Invest Biomed August Pi i Sunyer, Dept Pathol & Tumour Bank, Hosp Clin, Barcelona, Spain; [de Torres, I.; Ramon y Cajal, S.] Univ Autonoma Barcelona, Vall dHebron Hosp, Dept Pathol, E-08193 Barcelona, Spain; [Fernandez, Y.; Abasolo, I.] Vall dHebron Inst Recerca, Mol Imaging Platform CIBBIM Nanomed, Barcelona, Spain; [Contreras, H.; Castellon, E.] Univ Chile, Dept Physiol & Biophys, Lab Mol & Cellular Androl, Fac Med, Santiago, Chile; [Mendez, R.] Univ Barcelona, Inst Res Biomed, Barcelona, Spain	Autonomous University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB); University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR); Universidad de Chile; Barcelona Institute of Science & Technology; Institute for Research in Biomedicine - IRB Barcelona; University of Barcelona	Paciucci, R (corresponding author), Translat & Pediat Oncol Vall dHebron Inst Res, Res Unit Biomed, Collserola Bldg,Pg Vall dHebron 119-129, Barcelona 08035, Spain.		Paciucci, Rosanna/AGP-3844-2022; Thomson, Timothy/Z-6271-2019; Ramon y Cajal, Santiago/H-4955-2016; Abasolo, Ibane/H-7741-2012; Contreras, Hector/CAE-9087-2022; Fernandez, Pedro L/H-2594-2017; Sese, Marta/AAH-9749-2021; Castellon, Enrique A/D-3436-2014; Celia-Terrassa, Toni/M-4808-2014	Paciucci, Rosanna/0000-0001-5651-5933; Thomson, Timothy/0000-0002-4670-9440; Ramon y Cajal, Santiago/0000-0002-3867-1390; Abasolo, Ibane/0000-0001-5970-6276; Sese, Marta/0000-0003-1473-4833; Castellon, Enrique/0000-0002-3770-8550; Mendez, Raul/0000-0002-1952-6905; Celia-Terrassa, Toni/0000-0002-0615-8744; Valente, Filippo/0000-0001-5760-5949; Canovas, Veronica/0000-0002-1994-5763; Contreras, Hector/0000-0003-4012-2662	Ministry of Science and Innovation; MINECO [SAF2008-03936, SAF2011-30496]; TV3 Telemarathon; Instituto Carlos III [RD06/0020/0058 RETICS]; AGAUR [2009SGR1482]; Red Nacional de Biobancos, Instituto Carlos III; Fondo de Investigaciones de la Seguridad Social [PI20231];  [SAF2008-04136-C02-01];  [SAF2011-24686]	Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); MINECO(Spanish Government); TV3 Telemarathon; Instituto Carlos III(Instituto de Salud Carlos III); AGAUR(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)); Red Nacional de Biobancos, Instituto Carlos III; Fondo de Investigaciones de la Seguridad Social; ; 	We thank A. Esquerra, T. Moline and P. Guijarro for excellent technical help, J.J. Lozano for help with statistical analysis and J. Reventos for advice and support. This study was supported by Ministry of Science and Innovation and MINECO SAF2008-03936, SAF2011-30496, TV3 Telemarathon, and Instituto Carlos III RD06/0020/0058 RETICS (to RP); SAF2008-04136-C02-01 and SAF2011-24686 (to TMT); AGAUR 2009SGR1482 (to RP and TMT); Red Nacional de Biobancos, Instituto Carlos III (to RB); and Fondo de Investigaciones de la Seguridad Social PI20231 (to PLF).	Adams DR, 2011, CELL COMMUN SIGNAL, V9, DOI 10.1186/1478-811X-9-22; Antonyak MA, 2002, ONCOGENE, V21, P5038, DOI 10.1038/sj.onc.1205593; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Benedit P, 2001, ONCOGENE, V20, P1455, DOI 10.1038/sj.onc.1204233; Benzinger A, 2005, CELL RES, V15, P219, DOI 10.1038/sj.cr.7290290; Bilanges B, 2007, MOL CELL BIOL, V27, P5746, DOI 10.1128/MCB.02136-06; Bontems F, 2011, J STRUCT BIOL, V174, P245, DOI 10.1016/j.jsb.2010.10.011; Buensuceso CS, 2001, J CELL SCI, V114, P1691; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chantrel Y, 1998, GENETICS, V148, P559; Coleman LJ, 2009, BRIT J CANCER, V100, P1393, DOI 10.1038/sj.bjc.6605044; Coyle SM, 2009, MOL CELL BIOL, V29, P1626, DOI 10.1128/MCB.01718-08; Diaz VM, 2002, GASTROENTEROLOGY, V122, P806, DOI 10.1053/gast.2002.31885; Dresios J, 2006, MOL MICROBIOL, V59, P1651, DOI 10.1111/j.1365-2958.2006.05054.x; Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038; Fernandez S, 2011, VIRCHOWS ARCH, V458, P323, DOI 10.1007/s00428-010-1018-1; Graff JR, 2009, CANCER RES, V69, P3866, DOI 10.1158/0008-5472.CAN-08-3472; Grosso S, 2008, BIOCHEM J, V415, P77, DOI 10.1042/BJ20080463; Hermanto U, 2002, MOL CELL BIOL, V22, P2345, DOI 10.1128/MCB.22.7.2345-2365.2002; Hong IK, 2006, J BIOL CHEM, V281, P24279, DOI 10.1074/jbc.M601209200; Hovland R, 1996, INT J BIOCHEM CELL B, V28, P1089, DOI 10.1016/1357-2725(96)00059-3; Ikenoue T, 2008, EMBO J, V27, P1919, DOI 10.1038/emboj.2008.119; Janulis M, 1999, J BIOL CHEM, V274, P801, DOI 10.1074/jbc.274.2.801; Jiao XM, 2010, J BIOL CHEM, V285, P8218, DOI 10.1074/jbc.M110.100792; Kiely PA, 2002, J BIOL CHEM, V277, P22581, DOI 10.1074/jbc.M201758200; Knirsh R, 2009, MOL BIOL CELL, V20, P2121, DOI 10.1091/mbc.E08-12-1196; Kozak M, 2005, GENE, V361, P13, DOI 10.1016/j.gene.2005.06.037; Lee HK, 2007, EMBO J, V26, P3545, DOI 10.1038/sj.emboj.7601797; Li Y, 2010, J DERMATOL SCI, V60, P105, DOI 10.1016/j.jdermsci.2010.08.003; Lopez T, 2002, CANCER CELL, V1, P339, DOI 10.1016/S1535-6108(02)00055-7; Lopez-Bergami P, 2005, MOL CELL, V19, P309, DOI 10.1016/j.molcel.2005.06.025; Lynch M, 2004, J BIOL CHEM, V279, P3327, DOI 10.1074/jbc.M310872200; Malliri A, 1998, J CELL BIOL, V143, P1087, DOI 10.1083/jcb.143.4.1087; Merrick WC, 2004, GENE, V332, P1, DOI 10.1016/j.gene.2004.02.051; Milbradt AG, 2011, NAT STRUCT MOL BIOL, V18, P410, DOI 10.1038/nsmb.1999; Mittler G, 2003, EMBO J, V22, P6494, DOI 10.1093/emboj/cdg619; Nateri AS, 2005, NATURE, V437, P281, DOI 10.1038/nature03914; Nilsson J, 2004, EMBO REP, V5, P1137, DOI 10.1038/sj.embor.7400291; Ozanne BW, 2007, ONCOGENE, V26, P1, DOI 10.1038/sj.onc.1209759; PETRAK D, 1994, J IMMUNOL, V153, P2046; Regmi S, 2008, MOL MICROBIOL, V70, P724, DOI 10.1111/j.1365-2958.2008.06443.x; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Ruan YY, 2012, J CLIN INVEST, V122, P2554, DOI 10.1172/JCI58488; Santamaria A, 2005, MOL CELL BIOL, V25, P1900, DOI 10.1128/MCB.25.5.1900-1911.2005; Santamaria A, 2003, AM J PATHOL, V162, P897, DOI 10.1016/S0002-9440(10)63885-0; Sengupta J, 2004, NAT STRUCT MOL BIOL, V11, P957, DOI 10.1038/nsmb822; Stemmer V, 2008, ONCOGENE, V27, P5075, DOI 10.1038/onc.2008.140; Vesely PW, 2009, MUTAT RES-REV MUTAT, V682, P7, DOI 10.1016/j.mrrev.2009.01.001; Vojnic E, 2011, NAT STRUCT MOL BIOL, V18, P404, DOI 10.1038/nsmb.1997; Wang JH, 2010, MOL CANCER RES, V8, P266, DOI 10.1158/1541-7786.MCR-09-0221; Yan LQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016515; Yang FJ, 2004, P NATL ACAD SCI USA, V101, P2339, DOI 10.1073/pnas.0308676100; Yang YM, 2003, CLIN CANCER RES, V9, P391; Zhang J, 2012, ONCOGENE, V31, P1835, DOI 10.1038/onc.2011.369; Zhang WZ, 2006, MOL CELL BIOL, V26, P413, DOI 10.1128/MCB.26.2.413-424.2006; Zolotukhin AS, 2009, NUCLEIC ACIDS RES, V37, P7151, DOI 10.1093/nar/gkp782	56	25	25	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2014	33	9					1124	1134		10.1038/onc.2013.51	http://dx.doi.org/10.1038/onc.2013.51			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XT	23455324				2022-12-28	WOS:000331933800006
J	Metcalf, JL; Bradshaw, PS; Komosa, M; Greer, SN; Meyn, MS; Ohh, M				Metcalf, J. L.; Bradshaw, P. S.; Komosa, M.; Greer, S. N.; Meyn, M. Stephen; Ohh, M.			K63-Ubiquitylation of VHL by SOCS1 mediates DNA double-strand break repair	ONCOGENE			English	Article						DNA repair; K63-ubiquitylation; RCC; SOCS1; VHL	TUMOR-SUPPRESSOR PROTEIN; HOMOLOGOUS RECOMBINATION; CYTOPLASMIC LOCALIZATION; ATM ACTIVATION; HIF-ALPHA; NUCLEAR; FIBRONECTIN; PATHWAY; COMPLEX; PHOSPHORYLATION	DNA repair is essential for maintaining genomic stability, and defects in this process significantly increase the risk of cancer. Clear-cell renal cell carcinoma (CCRCC) caused by inactivation of the von Hippel-Lindau (VHL) tumor suppressor gene is characterized by high genomic instability. However, the molecular mechanism underlying the association between the loss of VHL and genomic instability remains unclear. Here, we show that suppressor of cytokine signaling 1 (SOCS1) promotes nuclear redistribution and K63-ubiquitylation of VHL in response to DNA double-strand breaks (DSBs). Loss of VHL or VHL mutations that compromise its K63-ubiquitylation attenuates the DNA-damage response (DDR), resulting in decreased homologous recombination repair and persistence of DSBs. These results identify VHL as a component of the DDR network, inactivation of which contributes to the genomic instability associated with CCRCC.	[Metcalf, J. L.; Greer, S. N.; Ohh, M.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON M5S 1A8, Canada; [Bradshaw, P. S.; Meyn, M. Stephen] Univ Toronto, Dept Mol Genet, Toronto, ON M5S 1A8, Canada; [Komosa, M.; Meyn, M. Stephen] Hosp Sick Children, Res Inst, Program Genet & Genome Biol, Toronto, ON M5G 1X8, Canada; [Meyn, M. Stephen] Hosp Sick Children, Dept Paediat, Toronto, ON M5G 1X8, Canada	University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Ohh, M (corresponding author), Univ Toronto, Dept Lab Med & Pathobiol, Med Sci Bldg,Room 6306,1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada.	michael.ohh@utoronto.ca			Canadian Institutes of Health Research [MOP77718]	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	This work was supported by funds from the Canadian Institutes of Health Research (MOP77718).	Allen C, 2003, MOL CANCER RES, V1, P913; Arai E, 2011, INT J CLIN EXP PATHO, V4, P58; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Ben-Zvi T, 2006, J CELL SCI, V119, P380, DOI 10.1242/jcs.02740; Bluyssen HAR, 2004, FEBS LETT, V556, P137, DOI 10.1016/S0014-5793(03)01392-9; Cai QL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009720; Calabrese V, 2009, MOL CELL, V36, P754, DOI 10.1016/j.molcel.2009.09.044; Celeste A, 2002, SCIENCE, V296, P922, DOI 10.1126/science.1069398; Christensen DE, 2007, NAT STRUCT MOL BIOL, V14, P941, DOI 10.1038/nsmb1295; Couedel C, 2004, GENE DEV, V18, P1293, DOI 10.1101/gad.1209204; Delacote F, 2002, NUCLEIC ACIDS RES, V30, P3454, DOI 10.1093/nar/gkf452; Evans AJ, 2007, MOL CELL BIOL, V27, P157, DOI 10.1128/MCB.00892-06; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Fukushima T, 2001, J BIOL CHEM, V276, P44413, DOI 10.1074/jbc.M106295200; Hoffman MA, 2001, HUM MOL GENET, V10, P1019, DOI 10.1093/hmg/10.10.1019; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Kim JS, 2005, J CELL BIOL, V170, P341, DOI 10.1083/jcb.200411083; Koshiji M, 2005, MOL CELL, V17, P793, DOI 10.1016/j.molcel.2005.02.015; Lavin MF, 2007, CELL CYCLE, V6, P931, DOI 10.4161/cc.6.8.4180; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Lee S, 1996, P NATL ACAD SCI USA, V93, P1770, DOI 10.1073/pnas.93.5.1770; Lee S, 1999, MOL CELL BIOL, V19, P1486; Lewis MD, 2003, ONCOGENE, V22, P3992, DOI 10.1038/sj.onc.1206683; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; O'Donovan PJ, 2010, CARCINOGENESIS, V31, P961, DOI 10.1093/carcin/bgq069; Ohh M, 1998, MOL CELL, V1, P959, DOI 10.1016/S1097-2765(00)80096-9; Panier S, 2009, DNA REPAIR, V8, P436, DOI 10.1016/j.dnarep.2009.01.013; Peng JM, 2003, NAT BIOTECHNOL, V21, P921, DOI 10.1038/nbt849; Pierce AJ, 2001, GENE DEV, V15, P3237, DOI 10.1101/gad.946401; Plans V, 2006, J CELL BIOCHEM, V97, P572, DOI 10.1002/jcb.20587; Qi H, 2003, CANCER RES, V63, P7076; Rezvani HR, 2010, NUCLEIC ACIDS RES, V38, P797, DOI 10.1093/nar/gkp1072; Riballo E, 2004, MOL CELL, V16, P715, DOI 10.1016/j.molcel.2004.10.029; Roberts AM, 2009, CANCER RES, V69, P9056, DOI 10.1158/0008-5472.CAN-09-1770; Russell RC, 2011, NAT MED, V17, P845, DOI 10.1038/nm.2370; Schermer B, 2006, J CELL BIOL, V175, P547, DOI 10.1083/jcb.200605092; Shiloh Y, 2001, ADV CANCER RES, V83, P209, DOI 10.1016/S0065-230X(01)83007-4; Stewart GS, 2009, CELL, V136, P420, DOI 10.1016/j.cell.2008.12.042; Stewart GS, 1999, CELL, V99, P577, DOI 10.1016/S0092-8674(00)81547-0; Stickle NH, 2004, MOL CELL BIOL, V24, P3251, DOI 10.1128/MCB.24.8.3251-3261.2004; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Wang Y, 2009, NAT MED, V15, P319, DOI 10.1038/nm.1922; Weinstock DM, 2006, METHOD ENZYMOL, V409, P524, DOI 10.1016/S0076-6879(05)09031-2; Yang H, 2007, MOL CELL, V28, P15, DOI 10.1016/j.molcel.2007.09.010; Young AP, 2008, NAT CELL BIOL, V10, P361, DOI 10.1038/ncb1699; Zhao GY, 2007, MOL CELL, V25, P663, DOI 10.1016/j.molcel.2007.01.029	53	34	34	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2014	33	8					1055	1065		10.1038/onc.2013.22	http://dx.doi.org/10.1038/onc.2013.22			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XO	23455319				2022-12-28	WOS:000331933200013
J	Tempe, D; Vives, E; Brockly, F; Brooks, H; De Rossi, S; Piechaczyk, M; Bossis, G				Tempe, D.; Vives, E.; Brockly, F.; Brooks, H.; De Rossi, S.; Piechaczyk, M.; Bossis, G.			SUMOylation of the inducible (c-Fos:c-Jun)/AP-1 transcription complex occurs on target promoters to limit transcriptional activation	ONCOGENE			English	Article						AP-1; SUMO; transcription; c-Fos	JUN PROTEINS; SUMO; AP-1; SPECIFICITY; PATHWAY; GENES	The inducible proto-oncogenic (c-Fos:c-Jun)/AP-1 transcription complex binds 12-O-tetradecanoylphorbol 13-acetate (TPA)-responsive elements (TRE) in its target genes. It is tightly controlled at multiple levels to avoid the deleterious effects of its inappropriate activation. In particular, SUMOylation represses its transactivation capacity in transient reporter assays using constitutively expressed proteins. This led to the presumption that (c-Fos:c-Jun)/AP-1 SUMOylation would be required to turn-off transcription of its target genes, as proposed for various transcription factors. Instead, thanks to the generation of an antibody specific for SUMO-modified c-Fos, we provide here direct evidence that SUMOylated c-Fos is present on a stably integrated reporter TPA-inducible promoter at the onset of transcriptional activation and colocalizes with RNA polymerase II within chromatin. Interestingly, (c-Fos:c-Jun)/AP-1 SUMOylation limits reporter gene induction, as well as the appearance of active transcription-specific histone marks on its promoter. Moreover, non-SUMOylatable mutant (c-Fos:c-Jun)/AP-1 dimers accumulate to higher levels on their target promoter, suggesting that SUMOylation might facilitate the release of (c-Fos:c-Jun)/AP-1 from promoters. Finally, activation of GADD153, an AP-1 target gene, is also associated with a rapid increase in SUMOylation at the level of its TRE and c-Fos SUMOylation dampens its induction by TPA. Taken together, our data suggest that SUMOylation could serve to buffer transcriptional activation of AP-1 target genes.	[Tempe, D.; Brockly, F.; Brooks, H.; Piechaczyk, M.; Bossis, G.] CNRS, UMR 5535, Inst Genet Mol Montpellier, Equipe Labellisee Ligue Canc, Montpellier 5, France; [Tempe, D.; Brockly, F.; Brooks, H.; Piechaczyk, M.; Bossis, G.] Univ Montpellier 2, Montpellier, France; [Tempe, D.; Brockly, F.; Brooks, H.; Piechaczyk, M.; Bossis, G.] Univ Montpellier I, Montpellier, France; [Vives, E.] IRCM, Montpellier, France; [Vives, E.] Univ Montpellier I, INSERM, U896, Montpellier, France; [Vives, E.] CRLC Val dAurelle Paul Lamarque, Montpellier, France; [De Rossi, S.] BIOCAMPUS Montpellier, Montpellier RIO Imaging, Montpellier, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Universite de Montpellier; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Universite de Montpellier	Piechaczyk, M (corresponding author), CNRS, UMR 5535, Inst Genet Mol Montpellier, Equipe Labellisee Ligue Canc, 1919 Route Mende, Montpellier 5, France.	marc.piechaczyk@igmm.cnrs.fr; guillaume.bossis@igmm.cnrs.fr	PIECHACZYK, Marc/E-7896-2013; Bossis, Guillaume/C-7172-2012; VIVES, Eric/AAG-6569-2020	PIECHACZYK, Marc/0000-0003-1367-2597; VIVES, Eric/0000-0001-5391-9641; bossis, guillaume/0000-0002-3349-8250	CNRS; Association pour la Recherche sur le Cancer (ARC); Agence Nationale de la Recherche [BLAN08-3_310119]	CNRS(Centre National de la Recherche Scientifique (CNRS)); Association pour la Recherche sur le Cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); Agence Nationale de la Recherche(French National Research Agency (ANR))	We are grateful to Drs R Hipskind, I Jariel-Encontre, T Salem and G Moquet-Torcy for fruitful discussions and critical reading of the manuscript. MP's laboratory is an 'Equipe Labellisee of the French Ligue Nationale contre le Cancer. This work was also supported by the CNRS, the Association pour la Recherche sur le Cancer (ARC), and the Agence Nationale de la Recherche (BLAN08-3_310119).	Bakiri L, 2002, MOL CELL BIOL, V22, P4952, DOI 10.1128/MCB.22.13.4952-4964.2002; Barry J, 2011, INT J BIOCHEM CELL B, V43, P37, DOI 10.1016/j.biocel.2010.09.022; Bettermann K, 2012, CANCER LETT, V316, P113, DOI 10.1016/j.canlet.2011.10.036; Bossis G, 2005, MOL CELL BIOL, V25, P6964, DOI 10.1128/MCB.25.16.6964-6979.2005; Bossis G, 2006, MOL CELL, V21, P349, DOI 10.1016/j.molcel.2005.12.019; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Fluhmann B, 1998, MOL CELL ENDOCRINOL, V139, P89, DOI 10.1016/S0303-7207(98)00070-7; Garcia-Dominguez M, 2009, BBA-GENE REGUL MECH, V1789, P451, DOI 10.1016/j.bbagrm.2009.07.001; Gareau JR, 2010, NAT REV MOL CELL BIO, V11, P861, DOI 10.1038/nrm3011; Geiss-Friedlander R, 2007, NAT REV MOL CELL BIO, V8, P947, DOI 10.1038/nrm2293; Glatter T, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2008.75; Golebiowski F, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000282; Gomard T, 2010, PLOS ONE, V5, pA178, DOI 10.1371/journal.pone.0009585; Guo BQ, 2011, NUCLEIC ACIDS RES, V39, P6403, DOI 10.1093/nar/gkr267; Guyton KZ, 1996, BIOCH J 2, V314; Harper CV, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1000607; Jakobs A, 2007, NAT METHODS, V4, P245, DOI 10.1038/NMETH1006; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Kubota Y, 2011, NAT CELL BIOL, V13, P282, DOI 10.1038/ncb2169; Liu HW, 2012, NUCLEIC ACIDS RES, V40, P10172, DOI 10.1093/nar/gks819; Lyst MJ, 2007, BIOCHEM SOC T, V35, P1389, DOI 10.1042/BST0351389; Maison C, 2011, NAT GENET, V43, P220, DOI 10.1038/ng.765; Malnou CE, 2010, J BIOL CHEM, V285, P6552, DOI 10.1074/jbc.M109.032680; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Milde-Langosch K, 2005, EUR J CANCER, V41, P2449, DOI 10.1016/j.ejca.2005.08.008; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Rosonina E, 2012, GENE DEV, V26, P350, DOI 10.1101/gad.184689.111; Rosonina E, 2010, GENE DEV, V24, P1242, DOI 10.1101/gad.1917910; Shaulian E, 2002, NAT CELL BIOL, V4, pE131, DOI 10.1038/ncb0502-e131; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Tempe D, 2008, BIOCHEM SOC T, V36, P874, DOI 10.1042/BST0360874; Ubeda M, 1999, MOL CELL BIOL, V19, P7589	33	37	39	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2014	33	7					921	927		10.1038/onc.2013.4	http://dx.doi.org/10.1038/onc.2013.4			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB2MN	23396363				2022-12-28	WOS:000331626900013
J	Chauvin, C; Koka, V; Nouschi, A; Mieulet, V; Hoareau-Aveilla, C; Dreazen, A; Cagnard, N; Carpentier, W; Kiss, T; Meyuhas, O; Pende, M				Chauvin, C.; Koka, V.; Nouschi, A.; Mieulet, V.; Hoareau-Aveilla, C.; Dreazen, A.; Cagnard, N.; Carpentier, W.; Kiss, T.; Meyuhas, O.; Pende, M.			Ribosomal protein S6 kinase activity controls the ribosome biogenesis transcriptional program	ONCOGENE			English	Article						signal transduction; ribosome biogenesis; mTOR	MESSENGER-RNA TRANSLATION; CELL-SIZE; PHOSPHORYLATION; MTOR; REVEALS; TARGET; GROWTH; GENES; YEAST; IDENTIFICATION	S6 kinases (S6Ks) are mechanistic target of rapamycin substrates that participate in cell growth control. S6Ks phosphorylate ribosomal protein S6 (rpS6) and additional proteins involved in the translational machinery, although the functional roles of these modifications remain elusive. Here we analyze the S6K-dependent transcriptional and translational regulation of gene expression by comparing whole-genome microarray of total and polysomal mouse liver RNA after feeding. We show that tissue lacking S6Ks 1 and 2 (S6K1 and S6K2), displays a defect in the ribosome biogenesis (RiBi) transcriptional program after feeding. Over 75% of RiBi factors are controlled by S6K, including Nop56, Nop14, Gar1, Rrp9, Rrp15, Rrp12 and Pwp2 nucleolar proteins. Importantly, the reduced activity of RiBi transcriptional promoters in S6K1;S6K2(-/-) cells is also observed in rpS6 knock-in mutants that cannot be phosphorylated. As ribosomal protein synthesis is not affected by these mutations, our data reveal a distinct and specific aspect of RiBi under the control of rpS6 kinase activity, that is, the RiBi transcriptional program.	[Chauvin, C.; Koka, V.; Nouschi, A.; Mieulet, V.; Pende, M.] INSERM, U845, F-75015 Paris, France; [Chauvin, C.; Koka, V.; Nouschi, A.; Mieulet, V.; Cagnard, N.; Pende, M.] Univ Paris 05, Sorbonne Paris Cite, Fac Med, UMRS 845, Paris, France; [Hoareau-Aveilla, C.; Kiss, T.] Univ Toulouse UPS, Lab Biol Mol Eucaryote, Toulouse, France; [Hoareau-Aveilla, C.; Kiss, T.] CNRS, Toulouse, France; [Dreazen, A.; Meyuhas, O.] Hebrew Univ Jerusalem, Hadassah Med Sch, IMRIC, Dept Biochem & Mol Biol, IL-91010 Jerusalem, Israel; [Carpentier, W.] Univ Paris 06, Grp Hosp Pitie Salpetriere, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Universite Federale Toulouse Midi-Pyrenees (ComUE); Centre National de la Recherche Scientifique (CNRS); Hebrew University of Jerusalem; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite	Pende, M (corresponding author), INSERM, U845, 156 Rue Vaugirard, F-75015 Paris, France.	mario.pende@inserm.fr	Pende, Mario/AFR-1348-2022; MIEULET, Virginie/F-1195-2017; Hoareau-Aveilla, Coralie/G-3787-2017; Cagnard, Nicolas/K-2754-2014	Pende, Mario/0000-0002-7864-8937; MIEULET, Virginie/0000-0001-5104-639X; Hoareau-Aveilla, Coralie/0000-0001-5506-4552; Cagnard, Nicolas/0000-0002-9051-1896; Kiss, Tamas/0000-0003-0293-3093	European Research Council; Fondation de la Recherche Medicale; Fondation Schlumberger pour l'Education et la Recherche; ANR; US-Israel Binational Science Foundation [2009054]; Israel Cancer Research Fund; Ministry of Health; Coddim Ile de France	European Research Council(European Research Council (ERC)European Commission); Fondation de la Recherche Medicale(Fondation pour la Recherche Medicale); Fondation Schlumberger pour l'Education et la Recherche; ANR(French National Research Agency (ANR)); US-Israel Binational Science Foundation(US-Israel Binational Science Foundation); Israel Cancer Research Fund; Ministry of Health; Coddim Ile de France	We thank the Novartis Foundation and George Thomas laboratory for the use of S6K mutant mice. We are grateful to the members of INSERM-U845 for support, and to Stefano Fumagalli and Olivier Jean-Jean for helpful discussions and sharing reagents. We thank Sophie Berissi, Ana Diaz and Sylvie Fabrega for excellent technical support. We thank Pfizer for the generous gift of Temsirolimus. This work was supported by grants to MP from the European Research Council, from Fondation de la Recherche Medicale, from Fondation Schlumberger pour l'Education et la Recherche and from ANR and by grants to OM from the US-Israel Binational Science Foundation (2009054), Israel Cancer Research Fund and Ministry of Health. CC received a fellowship from the Coddim Ile de France.	Bernstein KA, 2006, MOL CELL BIOL, V26, P1195, DOI 10.1128/MCB.26.4.1195-1208.2006; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Choo AY, 2008, P NATL ACAD SCI USA, V105, P17414, DOI 10.1073/pnas.0809136105; Dai MS, 2010, J BIOL CHEM, V285, P12587, DOI 10.1074/jbc.M109.056259; De Marchis ML, 2005, RNA, V11, P495, DOI 10.1261/rna.7200205; De S, 2010, BIOCHEM SOC T, V38, P1543, DOI 10.1042/BST0381543; De S, 2011, RNA, V17, P1713, DOI 10.1261/rna.2808411; Dibble CC, 2009, MOL CELL BIOL, V29, P5657, DOI 10.1128/MCB.00735-09; Dosil M, 2004, J BIOL CHEM, V279, P37385, DOI 10.1074/jbc.M404909200; Espeillac C, 2011, J CLIN INVEST, V121, P2821, DOI 10.1172/JCI44203; Gautier T, 1997, MOL CELL BIOL, V17, P7088, DOI 10.1128/MCB.17.12.7088; Ge JP, 2010, MOL CELL BIOL, V30, P413, DOI 10.1128/MCB.01128-09; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; GROVE JR, 1991, MOL CELL BIOL, V11, P5541, DOI 10.1128/MCB.11.11.5541; Guertin DA, 2006, CURR BIOL, V16, P958, DOI 10.1016/j.cub.2006.03.084; Hannan KM, 2003, MOL CELL BIOL, V23, P8862, DOI 10.1128/MCB.23.23.8862-8877.2003; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Huber A, 2011, EMBO J, V30, P3052, DOI 10.1038/emboj.2011.221; Iadevaia V, 2012, NUCLEIC ACIDS RES, V40, P2527, DOI 10.1093/nar/gkr1040; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; Jorgensen P, 2004, GENE DEV, V18, P2491, DOI 10.1101/gad.1228804; Jorgensen P, 2002, SCIENCE, V297, P395, DOI 10.1126/science.1070850; Kiss T, 2010, MOL CELL, V37, P597, DOI 10.1016/j.molcel.2010.01.032; KOZMA SC, 1990, P NATL ACAD SCI USA, V87, P7365, DOI 10.1073/pnas.87.19.7365; KRIEG J, 1988, J BIOL CHEM, V263, P11473; Laplante M, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011593; Lempiainen H, 2009, MOL CELL, V33, P704, DOI 10.1016/j.molcel.2009.01.034; Lempiainen H, 2009, CURR OPIN CELL BIOL, V21, P855, DOI 10.1016/j.ceb.2009.09.002; Liu PCC, 2001, MOL BIOL CELL, V12, P3644, DOI 10.1091/mbc.12.11.3644; Malygin AA, 2007, NUCLEIC ACIDS RES, V35, P6414, DOI 10.1093/nar/gkm701; Mariappan MM, 2011, AM J PHYSIOL-RENAL, V300, pF219, DOI 10.1152/ajprenal.00207.2010; Max X, 2008, CELL, V133, P303, DOI 10.1016/j.cell.2008.02.031; Mayer C, 2004, GENE DEV, V18, P423, DOI 10.1101/gad.285504; Mieulet V, 2007, AM J PHYSIOL-CELL PH, V293, pC712, DOI 10.1152/ajpcell.00499.2006; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Ohanna M, 2005, NAT CELL BIOL, V7, P286, DOI 10.1038/ncb1231; Patursky-Polischuk I, 2009, MOL CELL BIOL, V29, P640, DOI 10.1128/MCB.00980-08; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Pende M, 2000, NATURE, V408, P994, DOI 10.1038/35050135; Powley IR, 2009, GENE DEV, V23, P1207, DOI 10.1101/gad.516509; Ruvinsky I, 2005, GENE DEV, V19, P2199, DOI 10.1101/gad.351605; Shahbazian D, 2006, EMBO J, V25, P2781, DOI 10.1038/sj.emboj.7601166; Shima H, 1998, EMBO J, V17, P6649, DOI 10.1093/emboj/17.22.6649; THOMAS G, 1980, CELL, V19, P1015, DOI 10.1016/0092-8674(80)90092-6; Thoreen CC, 2012, NATURE, V485, P109, DOI 10.1038/nature11083; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Tremblay F, 2007, P NATL ACAD SCI USA, V104, P14056, DOI 10.1073/pnas.0706517104; Urban J, 2007, MOL CELL, V26, P663, DOI 10.1016/j.molcel.2007.04.020; Venema J, 2000, RNA, V6, P1660, DOI 10.1017/S1355838200001369; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Yoon A, 2006, SCIENCE, V312, P902, DOI 10.1126/science.1123835	52	173	180	4	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2014	33	4					474	483		10.1038/onc.2012.606	http://dx.doi.org/10.1038/onc.2012.606			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VX	23318442				2022-12-28	WOS:000330214600008
J	Romero, OA; Sanchez-Cespedes, M				Romero, O. A.; Sanchez-Cespedes, M.			The SWI/SNF genetic blockade: effects in cell differentiation, cancer and developmental diseases	ONCOGENE			English	Review						SWI/SNF; chromatin remodeling; BRG1; MYC; cancer; cell differentiation	CHROMATIN-REMODELING COMPLEX; IDENTIFIES FREQUENT MUTATION; TUMOR-SUPPRESSOR; ESTROGEN-RECEPTOR; CRITICAL REGULATOR; SOMATIC MUTATIONS; BAF COMPLEX; BRG1; LUNG; ARID1A	Our rapidly growing knowledge about cancer genetics attests to the widespread occurrence of alterations at genes encoding different components of the SWI/SNF complex. This reveals an important new feature that sustains cancer development: the blockade of chromatin remodeling. Here, we provide an overview of our current knowledge on the gene alterations of chromatin-remodeling factors, and how they relate to cancer and human developmental diseases. We also consider the functional repercussions, particularly how the inactivation of the SWI/SNF complex impairs the appropriate cell response to nuclear receptor signaling, which, in turn, prevents cell differentiation and sustains cell growth independently of the environment.	[Romero, O. A.; Sanchez-Cespedes, M.] Hosp Llobregat, IDIBELL, Bellvitge Biomed Res Inst, PEBC,Canc Epigenet & Biol Program,Genes & Canc Gr, Barcelona 08908, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona	Sanchez-Cespedes, M (corresponding author), Hosp Llobregat, IDIBELL, Bellvitge Biomed Res Inst, PEBC,Canc Epigenet & Biol Program,Genes & Canc Gr, Barcelona 08908, Spain.	mscespedes@idibell.cat	Sanchez-Cespedes, Montse/H-8485-2012; Romero, Octavio A./AAA-8078-2020	Sanchez-Cespedes, Montse/0000-0002-6045-5627; Romero, Octavio A./0000-0003-0229-6530				Albanese P, 2006, EUR J CANCER, V42, P2326, DOI 10.1016/j.ejca.2006.03.028; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Biddie SC, 2012, RHEUMATOLOGY, V51, P403, DOI 10.1093/rheumatology/ker215; Biegel JA, 1999, CANCER RES, V59, P74; Blanco R, 2009, HUM MUTAT, V30, P1199, DOI 10.1002/humu.21028; Bultman SJ, 2008, ONCOGENE, V27, P460, DOI 10.1038/sj.onc.1210664; Bultman SJ, 2005, GENE DEV, V19, P2849, DOI 10.1101/gad.1364105; Caramel J, 2008, ONCOGENE, V27, P2035, DOI 10.1038/sj.onc.1210847; Chai B, 2005, GENE DEV, V19, P1656, DOI 10.1101/gad.1273105; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; de la Serna IL, 2001, NAT GENET, V27, P187, DOI 10.1038/84826; Debril MB, 2004, J BIOL CHEM, V279, P16677, DOI 10.1074/jbc.M312288200; DelBove J, 2011, EPIGENETICS-US, V6, P1444, DOI 10.4161/epi.6.12.18492; Euskirchen GM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002008; Flajollet S, 2007, MOL CELL ENDOCRINOL, V270, P23, DOI 10.1016/j.mce.2007.02.004; Forcales SV, 2012, EMBO J, V31, P301, DOI 10.1038/emboj.2011.391; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Fujimoto A, 2012, NAT GENET, V44, P760, DOI 10.1038/ng.2291; Garcia-Pedrero JM, 2006, J BIOL CHEM, V281, P22656, DOI 10.1074/jbc.M602561200; Gayther SA, 2000, NAT GENET, V24, P300, DOI 10.1038/73536; Gebuhr TC, 2003, J EXP MED, V198, P1937, DOI 10.1084/jem.20030714; GERADTS J, 1993, CELL GROWTH DIFFER, V4, P799; GIBBONS RJ, 1995, CELL, V80, P837, DOI 10.1016/0092-8674(95)90287-2; Giulino-Roth L, 2012, BLOOD, V120, P5181, DOI 10.1182/blood-2012-06-437624; Glaros S, 2008, CANCER RES, V68, P3689, DOI 10.1158/0008-5472.CAN-07-6652; Gresh L, 2005, EMBO J, V24, P3313, DOI 10.1038/sj.emboj.7600802; Griffin CT, 2008, DEVELOPMENT, V135, P493, DOI 10.1242/dev.010090; Guan B, 2011, CANCER RES, V71, P6718, DOI 10.1158/0008-5472.CAN-11-1562; Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907; Guichard C, 2012, NAT GENET, V44, P694, DOI 10.1038/ng.2256; Halgren C, 2012, CLIN GENET, V82, P248, DOI 10.1111/j.1399-0004.2011.01755.x; Hargreaves DC, 2011, CELL RES, V21, P396, DOI 10.1038/cr.2011.32; Hasselblatt M, 2011, AM J SURG PATHOL, V35, P933, DOI 10.1097/PAS.0b013e3182196a39; Hendricks KB, 2004, MOL CELL BIOL, V24, P362, DOI 10.1128/MCB.24.1.362-376.2004; Hood RL, 2012, AM J HUM GENET, V90, P308, DOI 10.1016/j.ajhg.2011.12.001; Hoyer J, 2012, AM J HUM GENET, V90, P565, DOI 10.1016/j.ajhg.2012.02.007; Huang J, 2012, NAT GENET, V44, P1117, DOI 10.1038/ng.2391; Huang JM, 2007, GENE CHROMOSOME CANC, V46, P745, DOI 10.1002/gcc.20459; Hulsebos TJM, 2007, AM J HUM GENET, V80, P805, DOI 10.1086/513207; Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029; Johnson TA, 2008, MOL BIOL CELL, V19, P3308, DOI 10.1091/mbc.E08-02-0123; Jones DTW, 2012, NATURE, V488, P100, DOI 10.1038/nature11284; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Jung DJ, 2001, J BIOL CHEM, V276, P37280, DOI 10.1074/jbc.M106860200; Kim JK, 2001, MOL CELL BIOL, V21, P7787, DOI 10.1128/MCB.21.22.7787-7795.2001; Kiskinis E, 2006, BREAST CANCER RES TR, V98, P191, DOI 10.1007/s10549-005-9149-9; Ko M, 2008, MUTAT RES-FUND MOL M, V647, P59, DOI 10.1016/j.mrfmmm.2008.08.004; Kwon CS, 2007, TRENDS GENET, V23, P403, DOI 10.1016/j.tig.2007.05.010; Lai AY, 2011, NAT REV CANCER, V11, P588, DOI 10.1038/nrc3091; Lamba DA, 2008, DEV DYNAM, V237, P3016, DOI 10.1002/dvdy.21697; Le Gallo M, 2012, NAT GENET, V44, P1310, DOI 10.1038/ng.2455; Li S, 2008, CELL METAB, V8, P105, DOI 10.1016/j.cmet.2008.06.013; Lickert H, 2004, NATURE, V432, P107, DOI 10.1038/nature03071; Love C, 2012, NAT GENET, V44, P1321, DOI 10.1038/ng.2468; Mamo A, 2012, ONCOGENE, V31, P2090, DOI 10.1038/onc.2011.386; Manceau G, 2013, INT J CANCER, V132, P2217, DOI 10.1002/ijc.27900; Marshall TW, 2003, J BIOL CHEM, V278, P30605, DOI 10.1074/jbc.M304582200; Masetti R, 2012, ADV THER, V29, P747, DOI 10.1007/s12325-012-0047-3; Matsumoto S, 2006, DEV BIOL, V289, P372, DOI 10.1016/j.ydbio.2005.10.044; Medina PP, 2008, HUM MUTAT, V29, P617, DOI 10.1002/humu.20730; Medina PP, 2005, HUM MOL GENET, V14, P973, DOI 10.1093/hmg/ddi091; Medina PP, 2004, GENE CHROMOSOME CANC, V41, P170, DOI 10.1002/gcc.20068; Pal S, 2003, MOL CELL BIOL, V23, P7475, DOI 10.1128/MCB.23.21.7475-7487.2003; Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056; Pedersen TA, 2001, GENE DEV, V15, P3208, DOI 10.1101/gad.209901; Pottier N, 2008, JNCI-J NATL CANCER I, V100, P1792, DOI 10.1093/jnci/djn416; Pugh TJ, 2012, NATURE, V488, P106, DOI 10.1038/nature11329; Ramirez-Carrozzi VR, 2009, CELL, V138, P114, DOI 10.1016/j.cell.2009.04.020; Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4; Reyes JC, 1998, EMBO J, V17, P6979, DOI 10.1093/emboj/17.23.6979; Rhinn M, 2012, DEVELOPMENT, V139, P843, DOI 10.1242/dev.065938; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Rodriguez-Nieto S, 2011, HUM MUTAT, V32, pE1999, DOI 10.1002/humu.21415; Romero OA, 2012, EMBO MOL MED, V4, P603, DOI 10.1002/emmm.201200236; SAFFIOTTI U, 1967, CANCER-AM CANCER SOC, V20, P857, DOI 10.1002/1097-0142(1967)20:5&lt;857::AID-CNCR2820200545&gt;3.0.CO;2-3; Salma N, 2004, MOL CELL BIOL, V24, P4651, DOI 10.1128/MCB.24.11.4651-4663.2004; Santen GWE, 2012, NAT GENET, V44, P379, DOI 10.1038/ng.2217; Sausen M, 2013, NAT GENET, V45, P12, DOI 10.1038/ng.2493; Schmitz U, 2001, BRIT J CANCER, V84, P199, DOI 10.1054/bjoc.2000.1583; Schneppenheim R, 2010, AM J HUM GENET, V86, P279, DOI 10.1016/j.ajhg.2010.01.013; Schwartzentruber J, 2012, NATURE, V482, P226, DOI [10.1038/nature10833, 10.1007/s13311-012-0137-6]; Sevenet N, 1999, AM J HUM GENET, V65, P1342, DOI 10.1086/302639; Shain AH, 2012, P NATL ACAD SCI USA, V109, pE252, DOI 10.1073/pnas.1114817109; Shi Wei, 2009, Proc Am Thorac Soc, V6, P558, DOI 10.1513/pats.200905-031RM; Siersbaek R, 2012, TRENDS ENDOCRIN MET, V23, P56, DOI 10.1016/j.tem.2011.10.001; Singhal N, 2010, CELL, V141, P943, DOI 10.1016/j.cell.2010.04.037; Smith CL, 2005, MOL CELL BIOL, V25, P5880, DOI 10.1128/MCB.25.14.5880-5892.2005; Smith MJ, 2013, NAT GENET, V45, P295, DOI 10.1038/ng.2552; Stephens PJ, 2012, NATURE, V486, P400, DOI 10.1038/nature11017; Tsurusaki Y, 2012, NAT GENET, V44, P376, DOI 10.1038/ng.2219; Van Houdt JKJ, 2012, NAT GENET, V44, P445, DOI 10.1038/ng.1105; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Wang K, 2011, NAT GENET, V43, P1219, DOI 10.1038/ng.982; Wang Y, 2012, MOL CELL S, VS1097-2765; Wang Z, 2004, GENE DEV, V18, P3106, DOI 10.1101/gad.1238104; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Wilson BG, 2010, CANCER CELL, V18, P316, DOI 10.1016/j.ccr.2010.09.006; Wilson GB., 2011, NAT REV CANCER, V11, P281; Wolff D, 2011, MOL SYNDROMOL, V2, P237, DOI 10.1159/000337323; Wong AKC, 2000, CANCER RES, V60, P6171; Wu JI, 2007, NEURON, V56, P94, DOI 10.1016/j.neuron.2007.08.021; Xia W, 2008, CANCER RES, V68, P1667, DOI 10.1158/0008-5472.CAN-07-5276; Xu FH, 2012, J BIOL CHEM, V287, P5033, DOI 10.1074/jbc.M111.279968; Xu X, 2012, CELL, V148, P886, DOI 10.1016/j.cell.2012.02.025; Zhang YJ, 2007, J CELL BIOCHEM, V102, P1256, DOI 10.1002/jcb.21356	106	42	43	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2014	33	21					2681	2689		10.1038/onc.2013.227	http://dx.doi.org/10.1038/onc.2013.227			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EH	23752187				2022-12-28	WOS:000337231700001
J	Ai, J; Pascal, LE; O'Malley, KJ; Dar, JA; Isharwal, S; Qiao, Z; Ren, B; Rigatti, LH; Dhir, R; Xiao, W; Nelson, JB; Wang, Z				Ai, J.; Pascal, L. E.; O'Malley, K. J.; Dar, J. A.; Isharwal, S.; Qiao, Z.; Ren, B.; Rigatti, L. H.; Dhir, R.; Xiao, W.; Nelson, J. B.; Wang, Z.			Concomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model	ONCOGENE			English	Article						prostate cancer; EAF2/U19; Pten; knockout	INTRAEPITHELIAL NEOPLASIA; TUMOR ANGIOGENESIS; SUPPRESSOR GENE; CELL-SURVIVAL; CANCER; MICE; AKT; CARCINOMA; PATHWAY; ADENOCARCINOMA	Multiple genetic alterations are associated with prostate carcinogenesis. Tumor-suppressor genes phosphatase and tensin homolog deleted on chromosome 10 (Pten) and androgen upregulated gene 19 (U19), which encodes ELL-associated factor 2 (EAF2), are frequently inactivated or downregulated in advanced prostate cancers. Previous studies showed that EAF2 knockout caused tumors in multiple organs and prostatic intraepithelial neoplasia (PIN) in mice. However, EAF2-knockout mice did not develop prostate cancer even at 2 years of age. To further define the roles of EAF2 in prostate carcinogenesis, we crossed the Pten +/- and EAF2 +/- mice in the C57/BL6 background to generate EAF2 -/- Pten +/-, Pten +/-, EAF2 -/- and wild-type mice. The prostates from virgin male mice with the above four genotypes were analyzed at 7 weeks, 19 weeks and 12 months of age. Concomitant loss of EAF2 function and inactivation of one Pten allele induced spontaneous prostate cancer in 33% of the mice. Prostatic tissues from intact EAF2 -/- Pten +/- mice exhibited higher levels of phospho-Akt, -p44/42 and microvessel density. Moreover, phospho-Akt remained high after castration. Consistently, there was a synergistic increase in prostate epithelial proliferation in both intact and castrated EAF2 -/- Pten +/- mice. Using laser-capture microdissection coupled with real-time reverse transcription-PCR, we confirmed that co-downregulation of EAF2 and Pten occurred in > 50% clinical prostate cancer specimens with Gleason scores of 8-9 (n = 11), which is associated with poor prognosis. The above findings together demonstrated synergistic functional interactions and clinical relevance of concurrent EAF2 and Pten downregulation in prostate carcinogenesis.	[Ai, J.; Pascal, L. E.; O'Malley, K. J.; Dar, J. A.; Isharwal, S.; Ren, B.; Nelson, J. B.; Wang, Z.] Univ Pittsburgh, Sch Med, Dept Urol, Pittsburgh, PA 15232 USA; [Qiao, Z.] Harbin Med Univ, Affiliated Hosp 3, Dept Urol, Harbin, Peoples R China; [Rigatti, L. H.] Univ Pittsburgh, Sch Med, Div Lab Anim Resources, Pittsburgh, PA 15232 USA; [Dhir, R.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15232 USA; [Xiao, W.] Chinese Acad Sci, Inst Hydrobiol, Wuhan, Peoples R China; [Wang, Z.] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15232 USA; [Wang, Z.] Univ Pittsburgh, Sch Med, Inst Canc, Pittsburgh, PA 15232 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harbin Medical University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Chinese Academy of Sciences; Institute of Hydrobiology, CAS; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wang, Z (corresponding author), Univ Pittsburgh, Sch Med, Dept Urol, Suite G40,5200 Ctr Ave, Pittsburgh, PA 15232 USA.	wangz2@upmc.edu	Isharwal, Sudhir/I-4347-2019; Dar, Javid/D-6276-2015; Pascal, Laura E./AAH-5743-2019; Xiao, Wuhan/GLU-7352-2022	Dar, Javid/0000-0002-4102-6202; Pascal, Laura E./0000-0003-3840-1662; 	National Institutes of Health Grants [R01 CA 120386, 5 R37 DK51193, 1 P50 CA90386, T32 DK007774];  [P30CA047904]; NATIONAL CANCER INSTITUTE [R01CA120386, P50CA090386, P30CA047904] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007774, R37DK051193] Funding Source: NIH RePORTER	National Institutes of Health Grants(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This investigation was supported in part by the National Institutes of Health Grants R01 CA 120386, 5 R37 DK51193, 1 P50 CA90386 and T32 DK007774. This project used the UPCI Animal Facility and Tissue and Research Pathology Services (TARPS), and was supported in part by award P30CA047904. We thank Marie Acquafondata, Aiyuan Zhang, Katie Leschak and Dawn Everard (University of Pittsburgh, Pittsburgh, PA) for excellent technical assistance. We also thank all members of the Wang laboratory for insightful discussion and critical reading of the manuscript. LEP is a Tippins Foundation Scholar.	Abate-Shen C, 2003, CANCER RES, V63, P3886; Ahmad Imran, 2008, Expert Reviews in Molecular Medicine, V10, P1, DOI 10.1017/S1462399408000689; Backman SA, 2004, P NATL ACAD SCI USA, V101, P1725, DOI 10.1073/pnas.0308217100; Bedolla R, 2007, CLIN CANCER RES, V13, P3860, DOI 10.1158/1078-0432.CCR-07-0091; Bostwick DG, 1996, CANCER, V78, P330, DOI 10.1002/(SICI)1097-0142(19960715)78:2<330::AID-CNCR22>3.0.CO;2-W; BOSTWICK DG, 1987, CANCER, V59, P788, DOI 10.1002/1097-0142(19870215)59:4<788::AID-CNCR2820590421>3.0.CO;2-I; Chung JH, 2005, CANCER RES, V65, P8096, DOI 10.1158/0008-5472.CAN-05-1888; Coffer PJ, 1998, BIOCHEM J, V335, P1; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Eng C, 2003, HUM MUTAT, V22, P183, DOI 10.1002/humu.10257; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; Hamada K, 2005, GENE DEV, V19, P2054, DOI 10.1101/gad.1308805; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Kim MJ, 2002, P NATL ACAD SCI USA, V99, P2884, DOI 10.1073/pnas.042688999; Kinkade CW, 2008, J CLIN INVEST, V118, P3051, DOI 10.1172/JCI34764; Knobbe CB, 2008, ONCOGENE, V27, P5398, DOI 10.1038/onc.2008.238; Koul HK, 2004, ANN NY ACAD SCI, V1030, P243, DOI 10.1196/annals.1329.030; Leslie NR, 2004, BIOCHEM J, V382, P1, DOI 10.1042/BJ20040825; Liu JX, 2009, J BIOL CHEM, V284, P16679, DOI 10.1074/jbc.M109.009654; Ma XQ, 2005, CANCER RES, V65, P5730, DOI 10.1158/0008-5472.CAN-04-4519; Majumder PK, 2005, ONCOGENE, V24, P7465, DOI 10.1038/sj.onc.1209096; Maurus D, 2005, EMBO J, V24, P1181, DOI 10.1038/sj.emboj.7600603; Mulholland DJ, 2011, CANCER CELL, V19, P792, DOI 10.1016/j.ccr.2011.05.006; Pascal LE, 2011, ANGIOGENESIS, V14, P331, DOI 10.1007/s10456-011-9217-1; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; Salmena L, 2008, CELL, V133, P403, DOI 10.1016/j.cell.2008.04.013; Shappell SB, 2004, CANCER RES, V64, P2270, DOI 10.1158/0008-5472.CAN-03-0946; Shen MM, 2010, GENE DEV, V24, P1967, DOI 10.1101/gad.1965810; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stiles B, 2004, DEV BIOL, V273, P175, DOI 10.1016/j.ydbio.2004.06.008; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Vivanco I, 2007, CANCER CELL, V11, P555, DOI 10.1016/j.ccr.2007.04.021; Wan XY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009118; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; WEIDNER N, 1995, BREAST CANCER RES TR, V36, P169, DOI 10.1007/BF00666038; WEIDNER N, 1993, AM J PATHOL, V143, P401; Xiao W, 2008, ONCOGENE, V27, P1536, DOI 10.1038/sj.onc.1210786; Xiao WH, 2003, CANCER RES, V63, P4698	41	23	24	1	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2014	33	18					2286	2294		10.1038/onc.2013.190	http://dx.doi.org/10.1038/onc.2013.190			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AG5ID	23708662	Green Accepted			2022-12-28	WOS:000335451800002
J	Mukai, R; Ohshima, T				Mukai, R.; Ohshima, T.			HTLV-1 HBZ positively regulates the mTOR signaling pathway via inhibition of GADD34 activity in the cytoplasm	ONCOGENE			English	Article						HTLV-1; ATL; HBZ; GADD34; nuclear export	CELL LEUKEMIA-VIRUS; BZIP FACTOR HBZ; LEUCINE-ZIPPER-FACTOR; MOLECULAR-MECHANISMS; BINDING-PROTEIN; TYPE-1 TAX; C-JUN; AUTOPHAGY; GENE; TRANSCRIPTION	Human T-cell leukemia virus type-1 (HTLV-1) infection causes adult T-cell leukemia (ATL). Modulation of the transcriptional control of cellular genes by HTLV-1 is thought to be associated with the development of ATL. The viral protein HTLV-1 basic leucine-zipper factor (HBZ) has been shown to dysregulate the activity of cellular transcription factors. Here, we demonstrate that HBZ is exported from the nucleus to the cytoplasm, where it activates the mammalian target of rapamycin (mTOR) signaling pathway through an association with growth arrest and DNA damage gene 34 (GADD34). The N-terminal region of HBZ interacts with the C-terminal region of GADD34. HBZ contains a functional nuclear export signal (NES) sequence within its N-terminal region and it is exported from the nucleus via the CRM1-dependent pathway. Nuclear export of HBZ is essential for its interaction with GADD34 and increased phosphorylation of S6 kinase, which is an established downstream target of the mTOR pathway. Starvation-induced autophagy is significantly suppressed by the overexpression of HBZ. These findings indicate that HBZ is actively exported to the cytoplasm, where it dysregulates the function of cellular factors.	[Mukai, R.; Ohshima, T.] Tokushima Bunri Univ, Fac Engn, Sanuki, Kagawa 7692193, Japan; [Ohshima, T.] Tokushima Bunri Univ, Fac Pharmaceut Sci, Sanuki, Kagawa 7692193, Japan	Tokushima Bunri University; Tokushima Bunri University	Ohshima, T (corresponding author), Tokushima Bunri Univ, Fac Pharmaceut Sci, Kagawa Campus,1314-1 Shido, Sanuki, Kagawa 7692193, Japan.	ohshimat@kph.bunri-u.ac.jp		Mukai, Risa/0000-0003-4669-4100; OHSHIMA, Takayuki/0000-0002-1501-6430	Ministry of Education, Culture, Sports, Science and Technology of Japan; research funds from the Takeda Science Foundation; Suzuken Memorial Foundation; Japanese Leukemia Research Foundation; JSPS	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); research funds from the Takeda Science Foundation; Suzuken Memorial Foundation; Japanese Leukemia Research Foundation; JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	We thank Dr H. Miyoshi for providing the lentivirus-based transfection system. This work was supported by a Grant-in-Aid for Scientific Research on Priority Areas 'Integrative Research Toward the Conquest of Cancer' from the Ministry of Education, Culture, Sports, Science and Technology of Japan. In addition, this work was supported, in part, by research funds from the Takeda Science Foundation, the Suzuken Memorial Foundation and the Japanese Leukemia Research Foundation. R. Mukai was supported by a Research Fellowship from JSPS for Young Scientists.	Alavian SM, 2011, J VIRAL HEPATITIS, V18, P821, DOI 10.1111/j.1365-2893.2011.01530.x; Albrecht B, 2002, MICROBIOL MOL BIOL R, V66, P396, DOI 10.1128/MMBR.66.3.396-406.2002; Basbous J, 2003, J BIOL CHEM, V278, P43620, DOI 10.1074/jbc.M307275200; Bender C, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-74; Benjamin D, 2011, NAT REV DRUG DISCOV, V10, P868, DOI 10.1038/nrd3531; Bex F, 1998, MOL CELL BIOL, V18, P2392, DOI 10.1128/MCB.18.4.2392; Boxus M, 2008, RETROVIROLOGY, V5, DOI 10.1186/1742-4690-5-76; Cavanagh MH, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-15; Chaumorcel M, 2008, AUTOPHAGY, V4, P46, DOI 10.4161/auto.5184; CHOU J, 1994, P NATL ACAD SCI USA, V91, P5247, DOI 10.1073/pnas.91.12.5247; Chuluunbaatar U, 2010, GENE DEV, V24, P2627, DOI 10.1101/gad.1978310; Furukawa Y, 2001, BLOOD, V97, P987, DOI 10.1182/blood.V97.4.987; Gaudray G, 2002, J VIROL, V76, P12813, DOI 10.1128/JVI.76.24.12813-12822.2002; Grassmann R, 2005, ONCOGENE, V24, P5976, DOI 10.1038/sj.onc.1208978; Hagiya K, 2011, RETROVIROLOGY, V8, DOI 10.1186/1742-4690-8-19; Hardt M, 2011, GENES CELLS, V16, P141, DOI 10.1111/j.1365-2443.2010.01482.x; Harhaj EW, 1999, J BIOL CHEM, V274, P22911, DOI 10.1074/jbc.274.33.22911; Hasegawa H, 2006, NAT MED, V12, P466, DOI 10.1038/nm1389; Hivin P, 2005, J CELL SCI, V118, P1355, DOI 10.1242/jcs.01727; Isono O, 2008, J BIOL CHEM, V283, P34273, DOI 10.1074/jbc.M802527200; Jiang BH, 2008, DRUG RESIST UPDATE, V11, P63, DOI 10.1016/j.drup.2008.03.001; Jung CH, 2010, FEBS LETT, V584, P1287, DOI 10.1016/j.febslet.2010.01.017; Kapahi P, 2010, CELL METAB, V11, P453, DOI 10.1016/j.cmet.2010.05.001; Kirkegaard K, 2009, CURR TOP MICROBIOL, V335, P323, DOI 10.1007/978-3-642-00302-8_16; Koiwa T, 2002, J VIROL, V76, P9389, DOI 10.1128/JVI.76.18.9389-9397.2002; Kudchodkar SB, 2009, REV MED VIROL, V19, P359, DOI 10.1002/rmv.630; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Lee HK, 2008, CURR OPIN IMMUNOL, V20, P23, DOI 10.1016/j.coi.2008.01.001; Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018; Li J, 2011, AM J PHYSIOL-CELL PH, V301, pC213, DOI 10.1152/ajpcell.00067.2011; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Matsumoto J, 2005, ONCOGENE, V24, P1001, DOI 10.1038/sj.onc.1208297; Matsuoka M, 2009, RETROVIROLOGY, V6, DOI 10.1186/1742-4690-6-71; Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639; Murata K, 2006, J VIROL, V80, P2495, DOI 10.1128/JVI.80.5.2495-2505.2006; Ohshima T, 2010, J CELL BIOCHEM, V111, P187, DOI 10.1002/jcb.22687; Orvedahl A, 2010, CELL HOST MICROBE, V7, P115, DOI 10.1016/j.chom.2010.01.007; Orvedahl A, 2009, CURR TOP MICROBIOL, V335, P267, DOI 10.1007/978-3-642-00302-8_13; Rende F, 2011, BLOOD, V117, P4855, DOI 10.1182/blood-2010-11-316463; Satou Y, 2006, P NATL ACAD SCI USA, V103, P720, DOI 10.1073/pnas.0507631103; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; Shintani T, 2004, SCIENCE, V306, P990, DOI 10.1126/science.1099993; Simonis N, 2012, RETROVIROLOGY, V9, DOI 10.1186/1742-4690-9-26; Takeda S, 2004, INT J CANCER, V109, P559, DOI 10.1002/ijc.20007; Talloczy Z, 2002, P NATL ACAD SCI USA, V99, P190, DOI 10.1073/pnas.012485299; Tamiya S, 1996, BLOOD, V88, P3065, DOI 10.1182/blood.V88.8.3065.bloodjournal8883065; Taniguchi Y, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-64; Taylor MP, 2009, AUTOPHAGY, V5, P870, DOI 10.4161/auto.9046; Thebault S, 2004, FEBS LETT, V562, P165, DOI 10.1016/S0014-5793(04)00225-X; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; Uddin MN, 2011, BIOCHEM BIOPH RES CO, V407, P692, DOI 10.1016/j.bbrc.2011.03.077; Watanabe R, 2007, INT J MOL MED, V19, P475; Yasunaga J, 2011, INT J HEMATOL, V94, P435, DOI 10.1007/s12185-011-0937-1; Yoshida M, 2005, ONCOGENE, V24, P5931, DOI 10.1038/sj.onc.1208981; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Yoshida M, 2008, J VIROL, V82, P9359, DOI 10.1128/JVI.00242-08; Yoshita M, 2012, CANCER SCI, V103, P369, DOI 10.1111/j.1349-7006.2011.02123.x; Zhou W, 2011, J BIOL CHEM, V286, P21687, DOI 10.1074/jbc.M110.212787	58	27	29	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2014	33	18					2317	2328		10.1038/onc.2013.181	http://dx.doi.org/10.1038/onc.2013.181			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AG5ID	23708656				2022-12-28	WOS:000335451800005
J	Zou, Z; Huang, B; Wu, X; Zhang, H; Qi, J; Bradner, J; Nair, S; Chen, LF				Zou, Z.; Huang, B.; Wu, X.; Zhang, H.; Qi, J.; Bradner, J.; Nair, S.; Chen, L-F			Brd4 maintains constitutively active NF-kappa B in cancer cells by binding to acetylated RelA	ONCOGENE			English	Article						Brd4; cancer; degradation; JQ; NF-kappa B; ubiquitination	POSTTRANSLATIONAL MODIFICATIONS; DOWN-REGULATION; PROTEINS; TARGET; INFLAMMATION; INHIBITOR	Acetylation of the RelA subunit of NF-kappa B at lysine-310 regulates the transcriptional activation of NF-kappa B target genes and contributes to maintaining constitutively active NF-kappa B in tumors. Bromodomain-containing factor Brd4 has been shown to bind to acetylated lysine-310 (AcLys310) and to regulate the transcriptional activity of NF-kappa B, but the role of this binding in maintaining constitutively active NF-kappa B in tumors remains elusive. In this study, we demonstrate the structural basis for the binding of bromodomains (BDs) of bromodomain-containing protein 4 ( Brd4) to AcLys310 and identify the BD inhibitor JQ1 as an effective small molecule to block this interaction. JQ1 suppresses TNF-alpha-mediated NF-kappa B activation and NF-kappa B-dependent target gene expression. In addition, JQ1 inhibits the proliferation and transformation potential of A549 lung cancer cells and suppresses the tumorigenicity of A549 cells in severe combined immunodeficiency mice. Furthermore, we demonstrate that depletion of Brd4 or treatment of cells with JQ1 induces the ubiquitination and degradation of the constitutively active nuclear form of RelA. Our results identify a novel function of Brd4 in maintaining the persistently active form of NF-kappa B found in tumors, and they suggest that interference with the interaction between acetylated RelA and Brd4 could be a potential therapeutic approach for the treatment of NF-kappa B-driven cancer.	[Zou, Z.; Huang, B.; Wu, X.; Zhang, H.; Nair, S.; Chen, L-F] Univ Illinois, Coll Med, Dept Biochem, Urbana, IL 61801 USA; [Qi, J.; Bradner, J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Chen, L-F] Univ Illinois, Coll Med, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; Harvard University; Dana-Farber Cancer Institute; University of Illinois System; University of Illinois Urbana-Champaign	Chen, LF (corresponding author), Univ Illinois, Coll Med, Dept Biochem, MC-714, Urbana, IL 61801 USA.	lfchen@life.illinois.edu	Nair, Satish/AAY-2510-2021; 高, 雨莉/HGU-8187-2022	Zou, Zhenhua/0000-0003-0296-6231	UIUC; NIH [DK-085158]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK093865, R01DK085158] Funding Source: NIH RePORTER	UIUC; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank members in the Chen lab for discussion and A Lamb for assistance in the preparation of the manuscript. This work is supported in part by funds provided by UIUC (to LFC) and NIH grants DK-085158 (to LFC).	Adcock IM, 2007, CURR OPIN IMMUNOL, V19, P694, DOI 10.1016/j.coi.2007.07.016; Aggarwal BB, 2004, CANCER CELL, V6, P203, DOI 10.1016/j.ccr.2004.09.003; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Baud V, 2009, NAT REV DRUG DISCOV, V8, P33, DOI 10.1038/nrd2781; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Belkina AC, 2012, NAT REV CANCER, V12, P465, DOI 10.1038/nrc3256; Chaturvedi MM, 2011, ONCOGENE, V30, P1615, DOI 10.1038/onc.2010.566; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Chen LF, 2005, MOL CELL BIOL, V25, P7966, DOI 10.1128/MCB.25.18.7966-7975.2005; Chiarella C, 2009, ROUTL INT STUD MONEY, P1; Choi KC, 2009, MOL CANCER RES, V7, P2011, DOI 10.1158/1541-7786.MCR-09-0239; Chung CW, 2012, PROGR MED CHEM, V51, P1, DOI 10.1016/B978-0-12-396493-9.00001-7; Dai Y, 2005, MOL CELL BIOL, V25, P5429, DOI 10.1128/MCB.25.13.5429-5444.2005; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; French CA, 2012, ANNU REV PATHOL-MECH, V7, P247, DOI 10.1146/annurev-pathol-011811-132438; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gupta SC, 2010, BBA-GENE REGUL MECH, V1799, P775, DOI 10.1016/j.bbagrm.2010.05.004; Huang B, 2012, ONCOGENE, V31, P527, DOI 10.1038/onc.2011.252; Huang B, 2010, CELL SIGNAL, V22, P1282, DOI 10.1016/j.cellsig.2010.03.017; Huang B, 2009, MOL CELL BIOL, V29, P1375, DOI 10.1128/MCB.01365-08; Ishinaga H, 2007, EMBO J, V26, P1150, DOI 10.1038/sj.emboj.7601546; Jang MK, 2009, J VIROL, V83, P2592, DOI 10.1128/JVI.02275-08; Jeanmougin F, 1997, TRENDS BIOCHEM SCI, V22, P151, DOI 10.1016/S0968-0004(97)01042-6; Jiang YW, 1998, P NATL ACAD SCI USA, V95, P8538, DOI 10.1073/pnas.95.15.8538; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Lee AY, 2009, J BIOL CHEM, V284, P2778, DOI 10.1074/jbc.M805835200; Lee H, 2009, CANCER CELL, V15, P283, DOI 10.1016/j.ccr.2009.02.015; Maruyama T, 2002, MOL CELL BIOL, V22, P6509, DOI 10.1128/MCB.22.18.6509-6520.2002; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; Nicodeme E, 2010, NATURE, V468, P1119, DOI 10.1038/nature09589; Oliver SS, 2011, ANGEW CHEM INT EDIT, V50, P5801, DOI 10.1002/anie.201101414; Perkins ND, 2006, ONCOGENE, V25, P6717, DOI 10.1038/sj.onc.1209937; Perkins ND, 2012, NAT REV CANCER, V12, P121, DOI 10.1038/nrc3204; Saccani S, 2004, J EXP MED, V200, P107, DOI 10.1084/jem.20040196; Sen R, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000257; Sims RJ, 2008, NAT REV MOL CELL BIO, V9, P815, DOI 10.1038/nrm2502; Wu SY, 2007, J BIOL CHEM, V282, P13141, DOI 10.1074/jbc.R700001200; Yang XD, 2010, MOL CELL BIOL, V30, P2170, DOI 10.1128/MCB.01343-09; Yang XD, 2009, EMBO J, V28, P1055, DOI 10.1038/emboj.2009.55; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; You J, 2004, CELL, V117, P349, DOI 10.1016/S0092-8674(04)00402-7; Zhang GT, 2012, J BIOL CHEM, V287, P28840, DOI 10.1074/jbc.M112.359505; Zheng G, 2009, J VIROL, V83, P8683, DOI 10.1128/JVI.00674-09; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	51	169	177	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2014	33	18					2395	2404		10.1038/onc.2013.179	http://dx.doi.org/10.1038/onc.2013.179			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AG5ID	23686307	Green Accepted			2022-12-28	WOS:000335451800012
J	Bosco-Clement, G; Zhang, F; Chen, Z; Zhou, HM; Li, H; Mikami, I; Hirata, T; Yagui-Beltran, A; Lui, N; Do, HT; Cheng, T; Tseng, HH; Choi, H; Fang, LT; Kim, IJ; Yue, D; Wang, C; Zheng, Q; Fujii, N; Mann, M; Jablons, DM; He, B				Bosco-Clement, G.; Zhang, F.; Chen, Z.; Zhou, H-M; Li, H.; Mikami, I.; Hirata, T.; Yagui-Beltran, A.; Lui, N.; Do, H. T.; Cheng, T.; Tseng, H-H; Choi, H.; Fang, L-T; Kim, I-J; Yue, D.; Wang, C.; Zheng, Q.; Fujii, N.; Mann, M.; Jablons, D. M.; He, B.			Targeting Gli transcription activation by small molecule suppresses tumor growth	ONCOGENE			English	Article						cancer; targeted therapy; Gli; TAF9; Hedgehog pathway	HEDGEHOG PATHWAY INHIBITOR; SIGNALING PATHWAY; CANCER; MEDULLOBLASTOMA; MEDIATORS; PROMOTER; EMX2; P53	Targeted inhibition of Hedgehog signaling at the cell membrane has been associated with anticancer activity in preclinical and early clinical studies. Hedgehog signaling involves activation of Gli transcription factors that can also be induced by alternative pathways. In this study, we identified an interaction between Gli proteins and a transcription coactivator TBP-associated factor 9 (TAF9), and validated its functional relevance in regulating Gli transactivation. We also describe a novel, synthetic small molecule, FN1-8, that efficiently interferes with Gli/TAF9 interaction and downregulate Gli/TAF9-dependent transcriptional activity. More importantly, FN1-8 suppresses cancer cell proliferation in vitro and inhibits tumor growth in vivo. Our results suggest that blocking Gli transactivation, an important control point of multiple oncogenic pathways, may be an effective anticancer strategy.	[Bosco-Clement, G.; Zhang, F.; Chen, Z.; Li, H.; Mikami, I.; Hirata, T.; Yagui-Beltran, A.; Lui, N.; Do, H. T.; Cheng, T.; Tseng, H-H; Choi, H.; Fang, L-T; Kim, I-J; Yue, D.; Zheng, Q.; Jablons, D. M.; He, B.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Dept Surg, Thorac Oncol Program, San Francisco, CA 94115 USA; [Zhang, F.] Tsinghua Univ, Grad Sch Shenzhen, Div Life & Hlth Sci, Shenzhen 518057, Peoples R China; [Chen, Z.; Zhou, H-M] Tsinghua Univ, Sch Life Sci, Beijing 100084, Peoples R China; [Mikami, I.; Hirata, T.] Nippon Med Sch, Dept Surg, Div Thorac Surg, Tokyo 113, Japan; [Yue, D.; Wang, C.] Tianjin Med Univ, Canc Inst & Hosp, Dept Lung Canc, Tianjin, Peoples R China; [Zheng, Q.] Peking Univ, Canc Hosp & Inst, Minist Educ, Key Lab Carcinogenesis & Translat Res, Beijing 100871, Peoples R China; [Fujii, N.] St Jude Childrens Res Hosp, Dept Chem Biol & Therapeut, Memphis, TN 38105 USA; [Mann, M.] Univ Calif San Francisco, Dept Surg, Div Cardiothorac Surg, San Francisco, CA 94115 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Tsinghua University; University Town of Shenzhen; Tsinghua Shenzhen International Graduate School; Tsinghua University; Nippon Medical School; Tianjin Medical University; Peking University; St Jude Children's Research Hospital; University of California System; University of California San Francisco	He, B (corresponding author), Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Dept Surg, Thorac Oncol Program, San Francisco, CA 94115 USA.	david.jablons@ucsfmedctr.org; biao.he@ucsfmedctr.org	Fujii, Naoaki/I-6423-2013; Fang, Li Tai/ABA-6638-2021; Tseng, Hsin-Hui Katty/AAG-1941-2019	Fang, Li Tai/0000-0003-3201-5162; 	Joan's Legacy: Uniting Against Lung Cancer Research Grant; NIH/NCI [R01CA125030, R01CA132566]; Eileen D Ludwig Endowed for Thoracic Oncology Research; Bonnie J Addario Lung Cancer Foundation; Kazan, McClain, Abrams, Fernandez, Lyons, Greenwood, Harley and Oberman Foundation; Honeywell Foundation; Barbara Isackson Lung Cancer Research Fund; NATIONAL CANCER INSTITUTE [R01CA132566, R01CA125030] Funding Source: NIH RePORTER	Joan's Legacy: Uniting Against Lung Cancer Research Grant; NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Eileen D Ludwig Endowed for Thoracic Oncology Research; Bonnie J Addario Lung Cancer Foundation; Kazan, McClain, Abrams, Fernandez, Lyons, Greenwood, Harley and Oberman Foundation; Honeywell Foundation; Barbara Isackson Lung Cancer Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Joan's Legacy: Uniting Against Lung Cancer Research Grant, NIH/NCI Grant R01CA125030, and the Eileen D Ludwig Endowed for Thoracic Oncology Research (to BH); NIH/NCI Grant R01CA132566, the Bonnie J Addario Lung Cancer Foundation, the Kazan, McClain, Abrams, Fernandez, Lyons, Greenwood, Harley and Oberman Foundation, Honeywell Foundation and the Barbara Isackson Lung Cancer Research Fund (to DMJ).	Arai MA, 2011, ORG BIOMOL CHEM, V9, P1133, DOI 10.1039/c0ob00677g; Berman DM, 2002, SCIENCE, V297, P1559, DOI 10.1126/science.1073733; Choi Y, 2000, J BIOL CHEM, V275, P15912, DOI 10.1074/jbc.275.21.15912; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; Dennler S, 2007, CANCER RES, V67, P6981, DOI 10.1158/0008-5472.CAN-07-0491; Dennler S, 2009, J BIOL CHEM, V284, P31523, DOI 10.1074/jbc.M109.059964; di Magliano MP, 2006, GENE DEV, V20, P3161, DOI 10.1101/gad.1470806; Dijkgraaf GJP, 2011, CANCER RES, V71, P435, DOI 10.1158/0008-5472.CAN-10-2876; FALGOUT B, 1988, J VIROL, V62, P622, DOI 10.1128/JVI.62.2.622-625.1988; Feldmann G, 2007, CANCER RES, V67, P2187, DOI 10.1158/0008-5472.CAN-06-3281; Guo X, 2009, CELL RES, V19, P71, DOI 10.1038/cr.2008.302; He B, 2010, US Patent No, Patent No. 7714014; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; Hooper JE, 2005, NAT REV MOL CELL BIO, V6, P306, DOI 10.1038/nrm1622; Hosoya T, 2008, CHEMBIOCHEM, V9, P1082, DOI 10.1002/cbic.200700511; Huangfu D, 2006, DEVELOPMENT, V133, P3, DOI 10.1242/dev.02169; Hyman JM, 2009, P NATL ACAD SCI USA, V106, P14132, DOI 10.1073/pnas.0907134106; Ji ZY, 2007, J BIOL CHEM, V282, P14048, DOI 10.1074/jbc.M611089200; Jung DJ, 2006, DRUG DISCOV TODAY, V11, P452, DOI 10.1016/j.drudis.2006.03.011; Kalderon D, 2000, CELL, V103, P371, DOI 10.1016/S0092-8674(00)00129-X; Karhadkar SS, 2004, NATURE, V431, P707, DOI 10.1038/nature02962; Lauth M, 2007, CELL CYCLE, V6, P2458, DOI 10.4161/cc.6.20.4808; Lauth M, 2007, P NATL ACAD SCI USA, V104, P8455, DOI 10.1073/pnas.0609699104; LoRusso PM, 2011, CLIN CANCER RES, V17, P2502, DOI 10.1158/1078-0432.CCR-10-2745; Low JA, 2010, J CLIN ONCOL, V28, P5321, DOI 10.1200/JCO.2010.27.9943; Merchant AA, 2010, CLIN CANCER RES, V16, P3130, DOI 10.1158/1078-0432.CCR-09-2846; Mullor JL, 2001, CURR BIOL, V11, P769, DOI 10.1016/S0960-9822(01)00229-9; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Okamoto J, 2010, ONCOGENE, V29, P5969, DOI 10.1038/onc.2010.330; Okamoto J, 2011, CLIN LUNG CANCER, V12, P237, DOI 10.1016/j.cllc.2011.03.025; Raz DJ, 2008, CLIN CANCER RES, V14, P5565, DOI 10.1158/1078-0432.CCR-08-0544; Reguart N, 2004, BIOCHEM BIOPH RES CO, V323, P229, DOI 10.1016/j.bbrc.2004.08.075; Rifai Y, 2011, BIOORG MED CHEM LETT, V21, P718, DOI 10.1016/j.bmcl.2010.11.126; Riobo NA, 2006, P NATL ACAD SCI USA, V103, P4505, DOI 10.1073/pnas.0504337103; Riobo NA, 2006, CANCER RES, V66, P839, DOI 10.1158/0008-5472.CAN-05-2539; Rovnak J, 2006, J VIROL, V80, P12041, DOI 10.1128/JVI.01425-06; Rudin CM, 2009, NEW ENGL J MED, V361, P1173, DOI 10.1056/NEJMoa0902903; Ruiz i Altaba A, 2007, TRENDS CELL BIOL, V17, P438, DOI 10.1016/j.tcb.2007.06.007; Scales SJ, 2009, TRENDS PHARMACOL SCI, V30, P303, DOI 10.1016/j.tips.2009.03.007; Schnidar H, 2009, CANCER RES, V69, P1284, DOI 10.1158/0008-5472.CAN-08-2331; Shao HS, 2005, MOL CELL BIOL, V25, P206, DOI 10.1128/MCB.25.1.206-219.2005; Shimogawa H, 2004, J AM CHEM SOC, V126, P3461, DOI 10.1021/ja038855+; Stecca B, 2007, P NATL ACAD SCI USA, V104, P5895, DOI 10.1073/pnas.0700776104; Uesugi M, 1999, P NATL ACAD SCI USA, V96, P14801, DOI 10.1073/pnas.96.26.14801; Varjosalo M, 2008, GENE DEV, V22, P2454, DOI 10.1101/gad.1693608; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Watkins DN, 2003, NATURE, V422, P313, DOI 10.1038/nature01493; Yang L, 2010, ONCOGENE, V29, P469, DOI 10.1038/onc.2009.392; Yauch RL, 2008, NATURE, V455, P406, DOI 10.1038/nature07275; Yauch RL, 2009, SCIENCE, V326, P572, DOI 10.1126/science.1179386; Yoon JW, 1998, J BIOL CHEM, V273, P3496, DOI 10.1074/jbc.273.6.3496	51	37	38	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2014	33	16					2087	2097		10.1038/onc.2013.164	http://dx.doi.org/10.1038/onc.2013.164			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF3GH	23686308	Green Accepted, Green Submitted			2022-12-28	WOS:000334599100008
J	Choi, YJ; Anders, L				Choi, Y. J.; Anders, L.			Signaling through cyclin D-dependent kinases	ONCOGENE			English	Review						CDK4; CDK6; cyclin; cell cycle; senescence; apoptosis	MANTLE CELL LYMPHOMA; DNA-DAMAGE RESPONSE; E2F TARGET GENES; RETINOBLASTOMA PROTEIN; TUMOR-SUPPRESSOR; TRANSCRIPTION FACTOR; CRYSTAL-STRUCTURE; BREAST-CANCER; CDK4/6 INHIBITION; STRUCTURAL BASIS	Research over the past quarter century has identified cyclin D-dependent kinases, CDK4 and CDK6, as the major oncogenic drivers among members of the CDK superfamily. CDK4/6 are rendered hyperactive in the majority of human cancers through a multitude of genomic alterations. Sustained activation of these protein kinases provides cancer cells with the power to enter the cell cycle continuously by triggering G1-S-phase transitions and dramatically shortening the duration of the G1 phase. It has also become clear, however, that CDK4/6 effectively counter cancer cell-intrinsic tumor suppression mechanisms, senescence and apoptosis, which must be overcome during cell transformation and kept at bay throughout all stages of tumorigenesis. As a central 'node' in cellular signaling networks, cyclin D-dependent kinases sense a plethora of mitogenic signals to orchestrate specific transcriptional programs. As the complexity of the cellular signaling network regulated by these oncogenic kinases unfolds, much remains to be learned about its architecture, its dynamics and the consequences of its perturbation.	[Choi, Y. J.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; [Choi, Y. J.] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA; [Anders, L.] MIT, Whitehead Inst Biomed Res, Dept Biol, Cambridge, MA 02142 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Whitehead Institute	Anders, L (corresponding author), MIT, Whitehead Inst Biomed Res, Cambridge Ctr, Dept Biol, Cambridge, MA 02142 USA.	lars.anders.hms@gmail.com						Aggarwal P, 2010, CANCER CELL, V18, P329, DOI 10.1016/j.ccr.2010.08.012; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Anders L, 2011, CANCER CELL, V20, P620, DOI 10.1016/j.ccr.2011.10.001; [Anonymous], 2014, ONCOGENE, P1890; Antonysamy S, 2012, P NATL ACAD SCI USA, V109, P17960, DOI 10.1073/pnas.1209814109; ARNOLD A, 1989, J CLIN INVEST, V83, P2034, DOI 10.1172/JCI114114; Barbash O, 2008, CANCER CELL, V14, P68, DOI 10.1016/j.ccr.2008.05.017; Barnes DM, 1998, BREAST CANCER RES TR, V52, P1, DOI 10.1023/A:1006103831990; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; BATES S, 1994, ONCOGENE, V9, P71; Baughn LB, 2006, CANCER RES, V66, P7661, DOI 10.1158/0008-5472.CAN-06-1098; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; BETTICHER DC, 1995, ONCOGENE, V11, P1005; Bienvenu F, 2010, NATURE, V463, P374, DOI 10.1038/nature08684; Bignell GR, 2010, NATURE, V463, P893, DOI 10.1038/nature08768; Blain SW, 2008, CELL CYCLE, V7, P892, DOI 10.4161/cc.7.7.5637; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; Blanchet E, 2011, NAT CELL BIOL, V13, P1146, DOI 10.1038/ncb2309; Bockstaele L, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-25; Bockstaele L, 2006, MOL CELL BIOL, V26, P5070, DOI 10.1128/MCB.02006-05; Bockstaele L, 2009, MOL CELL BIOL, V29, P4188, DOI 10.1128/MCB.01823-08; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; Bracken AP, 2004, TRENDS BIOCHEM SCI, V29, P409, DOI 10.1016/j.tibs.2004.06.006; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; Burke JR, 2010, J BIOL CHEM, V285, P16286, DOI 10.1074/jbc.M110.108167; Campaner S, 2010, NAT CELL BIOL, V12, P54, DOI 10.1038/ncb2004; Campisi J, 2013, ANNU REV PHYSIOL, V75, P685, DOI 10.1146/annurev-physiol-030212-183653; Carr JR, 2012, CELL REP, V1, P715, DOI 10.1016/j.celrep.2012.05.005; Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Cato MH, 2011, MOL CELL BIOL, V31, P127, DOI 10.1128/MCB.00650-10; Chen CR, 2002, CELL, V110, P19, DOI 10.1016/S0092-8674(02)00801-2; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023; Cho EC, 2012, EMBO J, V31, P1785, DOI 10.1038/emboj.2012.17; Choi YJ, 2012, CANCER CELL, V22, P438, DOI 10.1016/j.ccr.2012.09.015; Chu I, 2007, CELL, V128, P281, DOI 10.1016/j.cell.2006.11.049; Cole AM, 2010, CANCER RES, V70, P8149, DOI 10.1158/0008-5472.CAN-10-0315; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; Costanzo V, 2011, DNA REPAIR, V10, P1060, DOI 10.1016/j.dnarep.2011.07.009; Costello JF, 1997, CANCER RES, V57, P1250; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Day PJ, 2009, P NATL ACAD SCI USA, V106, P4166, DOI 10.1073/pnas.0809645106; Dean JL, 2010, ONCOGENE, V29, P4018, DOI 10.1038/onc.2010.154; Dean JL, 2012, J BIOL CHEM, V287, P29075, DOI 10.1074/jbc.M112.365494; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; ERIKSON J, 1984, P NATL ACAD SCI-BIOL, V81, P4144, DOI 10.1073/pnas.81.13.4144; Farkas T, 2002, J BIOL CHEM, V277, P26741, DOI 10.1074/jbc.M200381200; Ferreira R, 1998, P NATL ACAD SCI USA, V95, P10493, DOI 10.1073/pnas.95.18.10493; Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419; Flaherty KT, 2012, CLIN CANCER RES, V18, P568, DOI 10.1158/1078-0432.CCR-11-0509; Friesen WJ, 2002, J BIOL CHEM, V277, P8243, DOI 10.1074/jbc.M109984200; Fry DW, 2004, MOL CANCER THER, V3, P1427; Ge XQ, 2007, GENE DEV, V21, P3331, DOI 10.1101/gad.457807; Gordon GM, 2011, PROTEIN CELL, V2, P864, DOI 10.1007/s13238-011-1117-z; Grimmler M, 2007, CELL, V128, P269, DOI 10.1016/j.cell.2006.11.047; Guan KL, 1996, MOL BIOL CELL, V7, P57, DOI 10.1091/mbc.7.1.57; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; Hansen K, 2001, EMBO J, V20, P422, DOI 10.1093/emboj/20.3.422; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HE J, 1994, CANCER RES, V54, P5804; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Huang XG, 2012, BLOOD, V120, P1095, DOI 10.1182/blood-2012-03-415984; Hukkelhoven E, 2012, J BIOL CHEM, V287, P38523, DOI 10.1074/jbc.M112.366542; Hulit J, 2004, MOL CELL BIOL, V24, P7598, DOI 10.1128/MCB.24.17.7598-7611.2004; Ibarra A, 2008, P NATL ACAD SCI USA, V105, P8956, DOI 10.1073/pnas.0803978105; James MK, 2008, MOL CELL BIOL, V28, P498, DOI 10.1128/MCB.02171-06; Jares P, 2007, NAT REV CANCER, V7, P750, DOI 10.1038/nrc2230; Jeffrey PD, 2000, GENE DEV, V14, P3115, DOI 10.1101/gad.851100; Ji P, 2004, MOL CELL, V16, P47, DOI 10.1016/j.molcel.2004.09.029; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Joshi I, 2009, BLOOD, V113, P1689, DOI 10.1182/blood-2008-03-147967; Kaldis P, 2001, MOL BIOL CELL, V12, P3987, DOI 10.1091/mbc.12.12.3987; Karkhanis V, 2011, TRENDS BIOCHEM SCI, V36, P633, DOI 10.1016/j.tibs.2011.09.001; KATO J, 1993, GENE DEV, V7, P331; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; Kawabata T, 2011, MOL CELL, V41, P543, DOI 10.1016/j.molcel.2011.02.006; Kerr JFR, 2002, TOXICOLOGY, V181, P471, DOI 10.1016/S0300-483X(02)00457-2; Kim JK, 2009, J CELL PHYSIOL, V220, P292, DOI 10.1002/jcp.21791; Klein EA, 2008, J CELL SCI, V121, P3853, DOI 10.1242/jcs.039131; Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Konecny GE, 2011, CLIN CANCER RES, V17, P1591, DOI 10.1158/1078-0432.CCR-10-2307; Koo CY, 2012, BBA-GENE REGUL MECH, V1819, P28, DOI 10.1016/j.bbagrm.2011.09.004; Kotake Y, 2007, GENE DEV, V21, P49, DOI 10.1101/gad.1499407; Kozar K, 2004, CELL, V118, P477, DOI 10.1016/j.cell.2004.07.025; Koziczak M, 2004, J BIOL CHEM, V279, P50004, DOI 10.1074/jbc.M404252200; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Landis MW, 2006, CANCER CELL, V9, P13, DOI 10.1016/j.ccr.2005.12.019; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Lenferink AEG, 2001, CANCER RES, V61, P6583; Leng XH, 2002, MOL CELL BIOL, V22, P2242, DOI 10.1128/MCB.22.7.2242-2254.2002; Leonard JP, 2012, BLOOD, V119, P4597, DOI 10.1182/blood-2011-10-388298; Lesage D, 2005, INT J CANCER, V115, P171, DOI 10.1002/ijc.20907; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Lin DI, 2008, ONCOGENE, V27, P1231, DOI 10.1038/sj.onc.1210738; Lu FM, 2003, CANCER RES, V63, P7056; Lu H, 2006, J MED CHEM, V49, P3826, DOI 10.1021/jm0600388; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Malumbres M, 2004, CELL, V118, P493, DOI 10.1016/j.cell.2004.08.002; Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602; Marzec M, 2006, BLOOD, V108, P1744, DOI 10.1182/blood-2006-04-016634; Massague J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; Matsuura I, 2004, NATURE, V430, P226, DOI 10.1038/nature02650; Matsuzaki K, 2009, CANCER RES, V69, P5321, DOI 10.1158/0008-5472.CAN-08-4203; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Michaud K, 2010, CANCER RES, V70, P3228, DOI 10.1158/0008-5472.CAN-09-4559; Millar EKA, 2009, ONCOGENE, V28, P1812, DOI 10.1038/onc.2009.13; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Muraoka RS, 2002, MOL CELL BIOL, V22, P2204, DOI 10.1128/MCB.22.7.2204-2219.2002; MUSGROVE EA, 1994, P NATL ACAD SCI USA, V91, P8022, DOI 10.1073/pnas.91.17.8022; Musgrove EA, 2011, NAT REV CANCER, V11, P558, DOI 10.1038/nrc3090; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; Ohtani K, 1995, P NATL ACAD SCI USA, V92, P12146, DOI 10.1073/pnas.92.26.12146; Okabe H, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000128; Ortega S, 2002, BBA-REV CANCER, V1602, P73, DOI 10.1016/S0304-419X(02)00037-9; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Parry D, 1999, MOL CELL BIOL, V19, P1775; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pear WS, 1996, J EXP MED, V183, P2283, DOI 10.1084/jem.183.5.2283; Peled JU, 2010, CELL RES, V20, P631, DOI 10.1038/cr.2010.55; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Puyol M, 2010, CANCER CELL, V18, P63, DOI 10.1016/j.ccr.2010.05.025; Qin HX, 2009, BMC SYST BIOL, V3, DOI 10.1186/1752-0509-3-73; QUELLE DE, 1995, CELL, V83, P993; Rane SG, 2002, MOL CELL BIOL, V22, P644, DOI 10.1128/MCB.22.2.644-656.2002; Ray A, 2009, MOL CELL BIOL, V29, P986, DOI 10.1128/MCB.00898-08; Ren B, 2002, GENE DEV, V16, P245, DOI 10.1101/gad.949802; Ressler S, 2006, AGING CELL, V5, P379, DOI 10.1111/j.1474-9726.2006.00231.x; Reynisdottir I, 1997, GENE DEV, V11, P492, DOI 10.1101/gad.11.4.492; Ronchini C, 2001, MOL CELL BIOL, V21, P5925, DOI 10.1128/MCB.21.17.5925-5934.2001; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; Ruas M, 1998, BBA-REV CANCER, V1378, pF115, DOI 10.1016/S0304-419X(98)00017-1; Ruas M, 2007, MOL CELL BIOL, V27, P4273, DOI 10.1128/MCB.02286-06; Rubin SM, 2005, CELL, V123, P1093, DOI 10.1016/j.cell.2005.09.044; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; Santra MK, 2009, NATURE, V459, P722, DOI 10.1038/nature08011; Sawai CM, 2012, CANCER CELL, V22, P452, DOI 10.1016/j.ccr.2012.09.016; SCHMIDT EE, 1994, CANCER RES, V54, P6321; Schmitz R, 2012, NATURE, V490, P116, DOI 10.1038/nature11378; Schwartz GK, 2011, BRIT J CANCER, V104, P1862, DOI 10.1038/bjc.2011.177; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; SHERR CJ, 1995, TRENDS BIOCHEM SCI, V20, P187, DOI 10.1016/S0968-0004(00)89005-2; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shin I, 2002, NAT MED, V8, P1145, DOI 10.1038/nm759; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sicinska E, 2003, CANCER CELL, V4, P451, DOI 10.1016/S1535-6108(03)00301-5; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Sotillo R, 2001, EMBO J, V20, P6637, DOI 10.1093/emboj/20.23.6637; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Sulli G, 2012, NAT REV CANCER, V12, DOI 10.1038/nrc3344; Takaki T, 2009, P NATL ACAD SCI USA, V106, P4171, DOI 10.1073/pnas.0809674106; Talluri S, 2012, CELL CYCLE, V11, P3189, DOI 10.4161/cc.21263; Tapon N, 2001, CURR OPIN CELL BIOL, V13, P731, DOI 10.1016/S0955-0674(00)00284-2; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9; Toogood PL, 2005, J MED CHEM, V48, P2388, DOI 10.1021/jm049354h; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; TSUJIMOTO Y, 1984, SCIENCE, V224, P1403, DOI 10.1126/science.6610211; TSUJIMOTO Y, 1985, NATURE, V315, P340, DOI 10.1038/315340a0; van der Velden PA, 2001, CANCER RES, V61, P5303; Vandel L, 2001, MOL CELL BIOL, V21, P6484, DOI 10.1128/MCB.21.19.6484-6494.2001; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Wang XH, 2002, P NATL ACAD SCI USA, V99, P16881, DOI 10.1073/pnas.252570299; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wiedemeyer WR, 2010, P NATL ACAD SCI USA, V107, P11501, DOI 10.1073/pnas.1001613107; Wierstra I, 2006, BIOL CHEM, V387, P949, DOI 10.1515/BC.2006.119; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; Witkiewicz AK, 2011, CELL CYCLE, V10, P2497, DOI 10.4161/cc.10.15.16776; Witzel II, 2010, BIOCHEM SOC T, V38, P217, DOI 10.1042/BST0380217; WOLFEL T, 1995, SCIENCE, V269, P1281, DOI 10.1126/science.7652577; Wong JV, 2011, CELL CYCLE, V10; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Yu QY, 2006, CANCER CELL, V9, P23, DOI 10.1016/j.ccr.2005.12.012; Yu ZK, 1998, P NATL ACAD SCI USA, V95, P11324, DOI 10.1073/pnas.95.19.11324; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; Zarkowska T, 1997, J BIOL CHEM, V272, P12738, DOI 10.1074/jbc.272.19.12738; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhao Fung, 2012, Front Med, V6, P376, DOI 10.1007/s11684-012-0228-0; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; ZHOU SY, 1994, CURR BIOL, V4, P973, DOI 10.1016/S0960-9822(00)00221-9; Zou XH, 2002, GENE DEV, V16, P2923, DOI 10.1101/gad.1033002; Zuo L, 1996, NAT GENET, V12, P97, DOI 10.1038/ng0196-97	204	187	203	4	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2014	33	15					1890	1903		10.1038/onc.2013.137	http://dx.doi.org/10.1038/onc.2013.137			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RK	23644662				2022-12-28	WOS:000334346300002
J	Casazza, A; Di Conza, G; Wenes, M; Finisguerra, V; Deschoemaeker, S; Mazzone, M				Casazza, A.; Di Conza, G.; Wenes, M.; Finisguerra, V.; Deschoemaeker, S.; Mazzone, M.			Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment	ONCOGENE			English	Review						tumor stroma; hypoxia; cancer progression; TAM; CAF; angiogenesis	CANCER-ASSOCIATED FIBROBLASTS; LYMPHATIC ENDOTHELIAL-CELLS; CHEMOKINE RECEPTOR CXCR4; HUMAN BREAST-CANCER; B-CELLS; MESENCHYMAL TRANSITION; GROWTH-FACTOR; NEUTROPHIL SURVIVAL; OXYGEN-TENSION; C EXPRESSION	A lot of effort has been done to study how cancer cells react to low-oxygen tension, a condition known as hypoxia. Indeed, abnormal and dysfunctional blood vessels in the tumor are incapable to restore oxygenation, therefore perpetuating hypoxia, which, in turn, will fuel tumor progression, metastasis and resistance to antitumor therapies. Nevertheless, how stromal components including blood and lymphatic endothelial cells, pericytes and fibroblasts, as well as hematopoietic cells, respond to low-oxygen tension in comparison with their normoxic counterparts has been a matter of investigation in the last few years only and, to date, this field of research remains poorly understood. In general, opposing phenotypes can arise from the same stromal component when embedded in different tumor microenvironments, and, vice versa, different stromal components can have opposite reaction to the same tumor microenvironment. In this article, we will discuss the emerging link between tumor stroma and hypoxia, and how this complexity is translated at the molecular level.	[Casazza, A.; Di Conza, G.; Wenes, M.; Finisguerra, V.; Deschoemaeker, S.; Mazzone, M.] VIB, Vesalius Res Ctr, Lab Mol Oncol & Angiogenesis, Louvain, Belgium; [Casazza, A.; Di Conza, G.; Wenes, M.; Finisguerra, V.; Deschoemaeker, S.; Mazzone, M.] Katholieke Univ Leuven, Vesalius Res Ctr, Lab Mol Oncol & Angiogenesis, B-3000 Louvain, Belgium	Flanders Institute for Biotechnology (VIB); KU Leuven	Mazzone, M (corresponding author), Katholieke Univ Leuven, VIB, Vesalius Res Ctr, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	massimiliano.mazzone@vib-kuleuven.be	Di Conza, Giusy/GPP-1438-2022; Finisguerra, Veronica/AGS-6956-2022; Deschoemaeker, Sofie/AAF-8321-2020; Deschoemaeker, Sofie/AAE-1359-2022	Deschoemaeker, Sofie/0000-0001-5449-282X; Deschoemaeker, Sofie/0000-0001-5449-282X; Mazzone, Massimiliano/0000-0001-8824-4015; Wenes, Mathias/0000-0001-8478-8592; Di Conza, Giusy/0000-0003-1353-5867	EMBO; FWO; ERC starting-Grant; FWO [G083613N, G068612N, G071810N]	EMBO(European Molecular Biology Organization (EMBO)); FWO(FWO); ERC starting-Grant; FWO(FWO)	We thank Sandy Smets for technical assistance. AC is granted by EMBO; GDC and VF are granted by FWO. MM was supported by an ERC starting-Grant and FWO (G083613N; G068612N; G071810N).	Acosta-Iborra B, 2009, J IMMUNOL, V182, P3155, DOI 10.4049/jimmunol.0801710; Andreu P, 2010, CANCER CELL, V17, P121, DOI 10.1016/j.ccr.2009.12.019; ARNOLD F, 1987, BRIT J EXP PATHOL, V68, P569; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Ben-Shoshan J, 2008, EUR J IMMUNOL, V38, P2412, DOI 10.1002/eji.200838318; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; Boes M, 1998, J EXP MED, V188, P2381, DOI 10.1084/jem.188.12.2381; Branco-Price C, 2012, CANCER CELL, V21, P52, DOI 10.1016/j.ccr.2011.11.017; Carmeliet P, 2011, NAT REV DRUG DISCOV, V10, P417, DOI 10.1038/nrd3455; Carraro F, 2007, J CELL PHYSIOL, V211, P439, DOI 10.1002/jcp.20951; Cascone T, 2012, J CLIN ONCOL, V30, P441, DOI 10.1200/JCO.2011.38.7621; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Chappell JC, 2009, DEV CELL, V17, P377, DOI 10.1016/j.devcel.2009.07.011; Chiavarina B, 2010, CELL CYCLE, V9, P3534, DOI 10.4161/cc.9.17.12908; Cooke VG, 2012, CANCER CELL, V21, P66, DOI 10.1016/j.ccr.2011.11.024; Cramer T, 2003, CELL, V112, P645, DOI 10.1016/S0092-8674(03)00154-5; Dang EV, 2011, CELL, V146, P772, DOI 10.1016/j.cell.2011.07.033; De Bock K, 2011, NAT REV CLIN ONCOL, V8, P393, DOI 10.1038/nrclinonc.2011.83; De Falco E, 2004, BLOOD, V104, P3472, DOI 10.1182/blood-2003-12-4423; de Oliveira RL, 2012, CANCER CELL, V22, P263, DOI 10.1016/j.ccr.2012.06.028; de Oliveira RL, 2011, MOL ASPECTS MED, V32, P71, DOI 10.1016/j.mam.2011.04.001; De Palma M, 2011, NATURE, V472, P303, DOI 10.1038/472303a; Denko NC, 2001, CANCER RES, V61, P795; Di Carlo E, 2001, J HEMATOTH STEM CELL, V10, P739, DOI 10.1089/152581601317210836; Doedens AL, 2010, CANCER RES, V70, P7465, DOI 10.1158/0008-5472.CAN-10-1439; Donohue PJ, 2003, ARTERIOSCL THROM VAS, V23, P594, DOI 10.1161/01.ATV.0000062883.93715.37; Dore-Duffy P, 2007, ANTIOXID REDOX SIGN, V9, P1363, DOI 10.1089/ars.2007.1713; Du R, 2008, CANCER CELL, V13, P206, DOI 10.1016/j.ccr.2008.01.034; Dutta D, 2008, J BIOL CHEM, V283, P25404, DOI 10.1074/jbc.M804349200; Elfiky AA, 2012, DISCOV MED, V13, P461; Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283; Elwood PC, 2009, LANCET, V373, P1301, DOI 10.1016/S0140-6736(09)60243-9; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Facciabene A, 2011, NATURE, V475, P226, DOI 10.1038/nature10169; Fainaru O, 2010, FASEB J, V24, P1411, DOI 10.1096/fj.09-147025; Fang HY, 2009, BLOOD, V114, P844, DOI 10.1182/blood-2008-12-195941; Feng WY, 2011, BLOOD, V117, P3893, DOI 10.1182/blood-2010-08-304808; Fink T, 2003, SCAND J IMMUNOL, V58, P607, DOI 10.1111/j.1365-3083.2003.01347.x; Finlay DK, 2012, J EXP MED, V209, P2441, DOI 10.1084/jem.20112607; Fox CJ, 2005, NAT REV IMMUNOL, V5, P844, DOI 10.1038/nri1710; Fraisl P, 2009, NAT REV DRUG DISCOV, V8, P139, DOI 10.1038/nrd2761; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Gay LJ, 2011, NAT REV CANCER, V11, P123, DOI 10.1038/nrc3004; Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047; GERRARD TL, 1981, J NATL CANCER I, V66, P483; Geudens I, 2010, ARTERIOSCL THROM VAS, V30, P1695, DOI 10.1161/ATVBAHA.110.203034; GODA F, 1995, CANCER RES, V55, P2249; Goda N, 2003, MOL CELL BIOL, V23, P359, DOI 10.1128/MCB.23.1.359-369.2003; Goetz JG, 2011, CELL, V146, P148, DOI 10.1016/j.cell.2011.05.040; Granot Z, 2011, CANCER CELL, V20, P300, DOI 10.1016/j.ccr.2011.08.012; Graven KK, 1997, KIDNEY INT, V51, P426, DOI 10.1038/ki.1997.57; Griffiths L, 2000, GENE THER, V7, P255, DOI 10.1038/sj.gt.3301058; Grunewald M, 2006, CELL, V124, P175, DOI 10.1016/j.cell.2005.10.036; Hagemann T, 2008, J EXP MED, V205, P1261, DOI 10.1084/jem.20080108; Hangai-Hoger N, 2004, AM J PHYSIOL-HEART C, V286, pH878, DOI 10.1152/ajpheart.00913.2003; HANNAH S, 1995, FEBS LETT, V372, P233, DOI 10.1016/0014-5793(95)00986-J; Harris DP, 2000, NAT IMMUNOL, V1, P475, DOI 10.1038/82717; HARRIS JW, 1976, CANCER RES, V36, P2733; Hellstrom M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571; Helmlinger G, 1997, NAT MED, V3, P177, DOI 10.1038/nm0297-177; Houghton AM, 2010, NAT MED, V16, P219, DOI 10.1038/nm.2084; Imahayashi S, 2000, CANCER INVEST, V18, P530, DOI 10.3109/07357900009012192; Imtiyaz HZ, 2010, J CLIN INVEST, V120, P2699, DOI 10.1172/JCI39506; Irigoyen M, 2007, BBA-MOL CELL RES, V1773, P880, DOI 10.1016/j.bbamcr.2007.03.001; Italiano JE, 2008, BLOOD, V111, P1227, DOI 10.1182/blood-2007-09-113837; Jakobsson L, 2010, NAT CELL BIOL, V12, P943, DOI 10.1038/ncb2103; Jantsch J, 2008, J IMMUNOL, V180, P4697, DOI 10.4049/jimmunol.180.7.4697; Kaiser J, 2012, SCIENCE, V337, P1471, DOI 10.1126/science.337.6101.1471; Kempner W, 1939, J CLIN INVEST, V18, P291, DOI 10.1172/JCI101045; Kim JW, 2012, CANCER RES, V72, P3187, DOI 10.1158/0008-5472.CAN-12-0534; Klement GL, 2009, BLOOD, V113, P2835, DOI 10.1182/blood-2008-06-159541; Koivunen P, 2004, J BIOL CHEM, V279, P9899, DOI 10.1074/jbc.M312254200; Kojima H, 2002, P NATL ACAD SCI USA, V99, P2170, DOI 10.1073/pnas.052706699; Kojima H, 2010, J IMMUNOL, V184, P154, DOI 10.4049/jimmunol.0800167; Kojima Y, 2010, P NATL ACAD SCI USA, V107, P20009, DOI 10.1073/pnas.1013805107; Kunz M, 1999, AM J PATHOL, V155, P753, DOI 10.1016/S0002-9440(10)65174-7; Le Bras A, 2007, ONCOGENE, V26, P7480, DOI 10.1038/sj.onc.1210566; Li Q, 2009, J IMMUNOL, V183, P3195, DOI 10.4049/jimmunol.0803773; Liang XH, 2008, ANTICANCER RES, V28, P1659; Lim Kok Haw Jonathan, 2010, Cancer Immun, V10, P3; Liu DF, 2012, J CLIN INVEST, V122, P2221, DOI 10.1172/JCI59535; LOEFFLER DA, 1991, INT J CANCER, V48, P895, DOI 10.1002/ijc.2910480617; LOEFFLER DA, 1992, BRIT J CANCER, V66, P619, DOI 10.1038/bjc.1992.326; Lynch CN, 1999, J BIOL CHEM, V274, P8455, DOI 10.1074/jbc.274.13.8455; Maftei CA, 2011, RADIOTHER ONCOL, V101, P209, DOI 10.1016/j.radonc.2011.05.023; Maftei CA, 2011, STRAHLENTHER ONKOL, V187, P260, DOI 10.1007/s00066-010-2216-0; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Martinez-Outschoorn UE, 2010, CELL CYCLE, V9, P3515, DOI 10.4161/cc.9.17.12928; Mazzone M, 2009, CELL, V136, P839, DOI 10.1016/j.cell.2009.01.020; McGovern NN, 2011, J IMMUNOL, V186, P453, DOI 10.4049/jimmunol.1002213; Mercier I, 2008, CANCER BIOL THER, V7, P1212, DOI 10.4161/cbt.7.8.6220; Milne K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006412; Mishra PJ, 2008, CANCER RES, V68, P4331, DOI 10.1158/0008-5472.CAN-08-0943; Morote-Garcia JC, 2012, P NATL ACAD SCI USA, V109, P14146, DOI 10.1073/pnas.1202165109; Movahedi K, 2012, CANCER RES, V72, P4165, DOI 10.1158/0008-5472.CAN-11-2994; Movahedi K, 2010, CANCER RES, V70, P5728, DOI 10.1158/0008-5472.CAN-09-4672; Mueller L, 2007, AM J PATHOL, V171, P1608, DOI 10.2353/ajpath.2007.060661; Munder M, 2009, BRIT J PHARMACOL, V158, P638, DOI 10.1111/j.1476-5381.2009.00291.x; Murdoch C, 2005, J IMMUNOL, V175, P6257, DOI 10.4049/jimmunol.175.10.6257; Naldini A, 2012, J CELL PHYSIOL, V227, P587, DOI 10.1002/jcp.22761; Naldini A, 2010, J LEUKOCYTE BIOL, V87, P365, DOI 10.1189/jlb.0709460; NATHAN CF, 1982, J IMMUNOL, V129, P2164; Nelson BH, 2010, J IMMUNOL, V185, P4977, DOI 10.4049/jimmunol.1001323; NIBBERING PH, 1987, IMMUNOLOGY, V62, P171; Ohta Y, 1999, BRIT J CANCER, V81, P54, DOI 10.1038/sj.bjc.6690650; Orimo A, 2006, CELL CYCLE, V5, P1597, DOI 10.4161/cc.5.15.3112; Ota H, 2007, FEBS LETT, V581, P5220, DOI 10.1016/j.febslet.2007.10.009; Ozerdem U, 2006, PROSTATE, V66, P294, DOI 10.1002/pros.20346; Palazon A, 2012, CLIN CANCER RES, V18, P1207, DOI 10.1158/1078-0432.CCR-11-1591; Pearce EL, 2010, CURR OPIN IMMUNOL, V22, P314, DOI 10.1016/j.coi.2010.01.018; Petersen OW, 2003, AM J PATHOL, V162, P391, DOI 10.1016/S0002-9440(10)63834-5; Piccard H, 2012, CRIT REV ONCOL HEMAT, V82, P296, DOI 10.1016/j.critrevonc.2011.06.004; Polet F, 2013, J INTERN MED, V273, P156, DOI 10.1111/joim.12016; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Quintero M, 2006, P NATL ACAD SCI USA, V103, P5379, DOI 10.1073/pnas.0601026103; Rama I, 2008, KIDNEY INT, V73, P816, DOI 10.1038/sj.ki.5002792; Ran S, 2010, PATHOPHYSIOLOGY, V17, P229, DOI DOI 10.1016/J.PATH0PHYS.2009.11.003; Rauch PJ, 2012, SCIENCE, V335, P597, DOI 10.1126/science.1215173; Saccani A, 2006, CANCER RES, V66, P11432, DOI 10.1158/0008-5472.CAN-06-1867; Schioppa T, 2003, J EXP MED, V198, P1391, DOI 10.1084/jem.20030267; Schito L, 2012, P NATL ACAD SCI USA, V109, pE2707, DOI 10.1073/pnas.1214019109; Schoppmann SF, 2006, BREAST CANCER RES TR, V99, P135, DOI 10.1007/s10549-006-9190-3; Schoppmann SF, 2001, ANTICANCER RES, V21, P2351; Scott AM, 2003, CLIN CANCER RES, V9, P1639; Shi LZ, 2011, J EXP MED, V208, P1367, DOI 10.1084/jem.20110278; Shi Q, 1999, CLIN CANCER RES, V5, P3711; Sierko E, 2007, SEMIN THROMB HEMOST, V33, P712, DOI 10.1055/s-2007-991540; Sitia G, 2012, P NATL ACAD SCI USA, V109, pE2165, DOI 10.1073/pnas.1209182109; Skuli N, 2012, J CLIN INVEST, V122, P1427, DOI 10.1172/JCI57322; Skuli N, 2009, BLOOD, V114, P469, DOI 10.1182/blood-2008-12-193581; Sotgia F, 2012, ANNU REV PATHOL-MECH, V7, P423, DOI 10.1146/annurev-pathol-011811-120856; Spinella F, 2009, CANCER RES, V69, P2669, DOI 10.1158/0008-5472.CAN-08-1879; Staller P, 2003, NATURE, V425, P307, DOI 10.1038/nature01874; Stockmann C, 2008, NATURE, V456, P814, DOI 10.1038/nature07445; Suzuki A, 2005, J BIOL CHEM, V280, P31557, DOI 10.1074/jbc.M503714200; Takeda N, 2010, GENE DEV, V24, P491, DOI 10.1101/gad.1881410; Takeda Y, 2011, NATURE, V479, P122, DOI 10.1038/nature10507; Tang N, 2004, CANCER CELL, V6, P485, DOI 10.1016/j.ccr.2004.09.026; Toullec A, 2010, EMBO MOL MED, V2, P211, DOI 10.1002/emmm.201000073; Verheul HMW, 1997, CLIN CANCER RES, V3, P2187; Vivier E, 2012, NAT REV IMMUNOL, V12, P239, DOI 10.1038/nri3174; Walmsley SR, 2006, BLOOD, V108, P3176, DOI 10.1182/blood-2006-04-018796; Walmsley SR, 2011, J CLIN INVEST, V121, P1053, DOI 10.1172/JCI43273; Walmsley SR, 2005, J EXP MED, V201, P105, DOI 10.1084/jem.20040624; Werno C, 2010, CARCINOGENESIS, V31, P1863, DOI 10.1093/carcin/bgq088; Wong BW, 2013, TRENDS BIOCHEM SCI, V38, P3, DOI 10.1016/j.tibs.2012.10.004; Xian XJ, 2006, J CLIN INVEST, V116, P642, DOI 10.1172/JCI25705; Yu JL, 2002, SCIENCE, V295, P1526, DOI 10.1126/science.1068327; Zaslavsky A, 2010, BLOOD, V115, P4605, DOI 10.1182/blood-2009-09-242065; Zeisberg EM, 2007, CANCER RES, V67, P10123, DOI 10.1158/0008-5472.CAN-07-3127; ZHANG H, 1995, CANCER RES, V55, P3584; Zhong XM, 2007, EUR J IMMUNOL, V37, P2400, DOI 10.1002/eji.200737296	153	155	163	1	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2014	33	14					1743	1754		10.1038/onc.2013.121	http://dx.doi.org/10.1038/onc.2013.121			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RE	23604130				2022-12-28	WOS:000334345500001
J	Ui, A; Ogiwara, H; Nakajima, S; Kanno, S; Watanabe, R; Harata, M; Okayama, H; Harris, CC; Yokota, J; Yasui, A; Kohno, T				Ui, A.; Ogiwara, H.; Nakajima, S.; Kanno, S.; Watanabe, R.; Harata, M.; Okayama, H.; Harris, C. C.; Yokota, J.; Yasui, A.; Kohno, T.			Possible involvement of LKB1-AMPK signaling in non-homologous end joining	ONCOGENE			English	Article						LKB1-AMPK signaling; non-homologous end joining; chromatin remodeling; tumor suppressor gene; genome instability	DOUBLE-STRAND BREAKS; ACTIVATED PROTEIN-KINASE; DNA-DAMAGE RESPONSE; CANCER CELL-LINES; HISTONE ACETYLATION; REPAIR PROTEINS; LKB1; LUNG; PHOSPHORYLATION; COMPLEX	LKB1/STK11 is a tumor suppressor gene responsible for Peutz-Jeghers syndrome, an inherited cancer disorder associated with genome instability. The LKB1 protein functions in the regulation of cell proliferation, polarization and differentiation. Here, we suggest a role of LKB1 in non-homologous end joining (NHEJ), a major DNA double-strand break (DSB) repair pathway. LKB1 localized to DNA ends upon the generation of micro-irradiation and I-SceI endonuclease-induced DSBs. LKB1 inactivation either by RNA interference or by kinase-dead mutation compromised NHEJ-mediated DNA repair by suppressing the accumulation of BRM, a catalytic subunit of the SWI/SNF complex, at DSB sites, which promotes the recruitment of an essential NHEJ factor, KU70. AMPK2, a major substrate of LKB1 and a histone H2B kinase, was recruited to DSBs in an LKB1-dependent manner. AMPK2 depletion and a mutation of H2B that disrupted the AMPK2 phoshorylation site impaired KU70 and BRM recruitment to DSB sites. LKB1 depletion induced the formation of chromosome breaks and radials. These results suggest that LKB1-AMPK signaling controls NHEJ and contributes to genome stability.	[Ui, A.; Ogiwara, H.; Kohno, T.] Natl Canc Ctr, Res Inst, Div Genome Biol, Chuo Ku, Tokyo 1040045, Japan; [Ui, A.; Kanno, S.; Watanabe, R.; Yasui, A.] Tohoku Univ, Inst Dev Aging & Canc, Div Dynam Proteome, Sendai, Miyagi 980, Japan; [Nakajima, S.; Yasui, A.] Tohoku Univ, Inst Dev Aging & Canc, Dept Mol Genet, Sendai, Miyagi 980, Japan; [Harata, M.] Tohoku Univ, Grad Sch Agr Sci, Dept Mol & Cell Biol, Div Life Sci,Lab Mol Biol, Sendai, Miyagi 980, Japan; [Okayama, H.; Harris, C. C.] NCI, Ctr Canc Res, Human Carcinogenesis Lab, NIH, Bethesda, MD USA; [Yokota, J.] Natl Canc Ctr, Res Inst, Div Multistage Carcinogenesis, Tokyo 104, Japan	National Cancer Center - Japan; Tohoku University; Tohoku University; Tohoku University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Cancer Center - Japan	Kohno, T (corresponding author), Natl Canc Ctr, Res Inst, Div Genome Biol, Chuo Ku, Tsukiji 5-1-1, Tokyo 1040045, Japan.	tkkohno@ncc.go.jp	Kanno, Shin-ichiro/AAE-4549-2019; Ui, Ayako/GON-4666-2022; Harata, Masahiko/T-5281-2019	Ui, Ayako/0000-0001-6698-7168; Okayama, Hirokazu/0000-0003-0966-4746; Ogiwara, Hideaki/0000-0003-0860-1807	Ministry of Education, Culture, Sports, Science and Technology of Japan for Scientific Research on Innovative Areas [22131006, 22131005]; Japan Society for the Promotion of Science for Young Scientists (B) KAKENHI [23701110, 24710057]; Government to the National Cancer Center; NATIONAL CANCER INSTITUTE [ZIABC011492, Z01BC005480] Funding Source: NIH RePORTER; Grants-in-Aid for Scientific Research [24710057] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan for Scientific Research on Innovative Areas; Japan Society for the Promotion of Science for Young Scientists (B) KAKENHI(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Government to the National Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by Grants-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan for Scientific Research on Innovative Areas (22131006 to TK and HO; and 22131005 to AY), from the Japan Society for the Promotion of Science for Young Scientists (B) KAKENHI (23701110 to HO and 24710057 to AU) and Management Expenses Grants from the Government to the National Cancer Center. A part of this work was carried out under the Cooperative Research Project Program of the Institute of Development, Aging and Cancer, Tohoku University.	Blanco R, 2009, HUM MUTAT, V30, P1199, DOI 10.1002/humu.21028; Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Bungard D, 2010, SCIENCE, V329, P1201, DOI 10.1126/science.1191241; Burma S, 2006, DNA REPAIR, V5, P1042, DOI 10.1016/j.dnarep.2006.05.026; Dover J, 2002, J BIOL CHEM, V277, P28368, DOI 10.1074/jbc.C200348200; Downs JA, 2004, MOL CELL, V16, P979, DOI 10.1016/j.molcel.2004.12.003; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hong SP, 2003, P NATL ACAD SCI USA, V100, P8839, DOI 10.1073/pnas.1533136100; Kim J, 2009, CELL, V137, P459, DOI 10.1016/j.cell.2009.02.027; Lan L, 2005, J CELL SCI, V118, P4153, DOI 10.1242/jcs.02544; Lan L, 2010, MOL CELL, V40, P976, DOI 10.1016/j.molcel.2010.12.003; Lieber MR, 2008, J BIOL CHEM, V283, P1, DOI 10.1074/jbc.R700039200; Marignani PA, 2001, J BIOL CHEM, V276, P32415, DOI 10.1074/jbc.C100207200; Matsumoto S, 2007, ONCOGENE, V26, P5911, DOI 10.1038/sj.onc.1210418; Medina PP, 2008, HUM MUTAT, V29, P617, DOI 10.1002/humu.20730; Mehenni H, 1998, AM J HUM GENET, V63, P1641, DOI 10.1086/302159; Miller KM, 2010, NAT STRUCT MOL BIOL, V17, P1144, DOI 10.1038/nsmb.1899; Mladenov E, 2011, MUTAT RES-FUND MOL M, V711, P61, DOI 10.1016/j.mrfmmm.2011.02.005; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; Nakajima S, 2006, J BIOL CHEM, V281, P34687, DOI 10.1074/jbc.M605545200; Ogiwara H, 2011, ONCOGENE, V30, P2135, DOI [10.1038/onc.2010.592, 10.1038/onc.2010.592;]; Ogiwara H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028756; Osley MA, 2006, TRENDS GENET, V22, P671, DOI 10.1016/j.tig.2006.09.007; Park JH, 2006, EMBO J, V25, P3986, DOI 10.1038/sj.emboj.7601291; Peng G, 2009, NAT CELL BIOL, V11, P865, DOI 10.1038/ncb1895; Perez-Cadahia B, 2010, CURR OPIN DRUG DISC, V13, P613; Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4; RICHARD F, 1994, CANCER GENET CYTOGEN, V73, P23, DOI 10.1016/0165-4608(94)90178-3; Rodrigue A, 2006, EMBO J, V25, P222, DOI 10.1038/sj.emboj.7600914; Roy BC, 2010, LUNG CANCER, V70, P136, DOI 10.1016/j.lungcan.2010.02.004; Sanchez-Cespedes M, 2002, CANCER RES, V62, P3659; Sapkota GP, 2002, BIOCHEM J, V368, P507, DOI 10.1042/BJ20021284; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shim EY, 2005, MOL CELL BIOL, V25, P3934, DOI 10.1128/MCB.25.10.3934-3944.2005; van Attikum H, 2007, EMBO J, V26, P4113, DOI 10.1038/sj.emboj.7601835; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Wingo SN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005137; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031	38	23	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2014	33	13					1640	1648		10.1038/onc.2013.125	http://dx.doi.org/10.1038/onc.2013.125			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9QY	23584481	Green Accepted			2022-12-28	WOS:000334344700004
J	Xia, L; Huang, W; Tian, D; Chen, Z; Zhang, L; Li, Y; Hu, H; Liu, J; Chen, Z; Tang, G; Dou, J; Sha, S; Xu, B; Liu, C; Ma, J; Zhang, S; Li, M; Fan, D; Nie, Y; Wu, K				Xia, L.; Huang, W.; Tian, D.; Chen, Z.; Zhang, L.; Li, Y.; Hu, H.; Liu, J.; Chen, Z.; Tang, G.; Dou, J.; Sha, S.; Xu, B.; Liu, C.; Ma, J.; Zhang, S.; Li, M.; Fan, D.; Nie, Y.; Wu, K.			ACP5, a direct transcriptional target of FoxM1, promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma	ONCOGENE			English	Article						Forkhead box M1; tartrate-resistant acid phosphatase 5; hepatocellular carcinoma; metastasis; transcriptional regulation	RESISTANT ACID-PHOSPHATASE; FORKHEAD BOX M1B; FOCAL-ADHESION KINASE; HUMAN BREAST-CANCER; BONE METASTASES; UP-REGULATION; SERUM MARKER; HEPATITIS-B; EXPRESSION; 5B	Tartrate-resistant acid phosphatase 5 (ACP5), which is essential for bone resorption and osteoclast differentiation, promotes cell motility through the modulation of focal adhesion kinase phosphorylation. However, whether ACP5 contributes to the metastasis and progression of hepatocellular carcinoma (HCC) remains unknown. In this paper, a complementary DNA microarray, serial deletion, site-directed mutagenesis and a chromatin immunoprecipitation assays confirmed that ACP5 is a direct transcriptional target of Forkhead box M1 (FoxM1). ACP5 expression was markedly higher in HCC tissues compared with adjacent noncancerous tissues. ACP5 overexpression was correlated with microvascular invasion, poor differentiation and higher tumor-node-metastasis stage. HCC patients with positive ACP5 expression had poorer prognoses than those with negative ACP5 expression. A multivariate analysis revealed that ACP5 expression was an independent and significant risk factor for disease recurrence and reduced-patient survival following curative resection. Transwell assays and an orthotopic metastatic model showed that the upregulation of ACP5 promoted HCC invasion and lung metastasis, whereas ACP5 knockdown inhibited these processes. The knockdown of ACP5 significantly attenuated FoxM1-enhanced invasion and lung metastasis. Immunohistochemistry revealed that ACP5 expression was positively correlated with FoxM1 expression in human HCC tissues, and their coexpression was associated with poor prognoses. In summary, ACP5 is a direct transcriptional and functional target of FoxM1. This novel FoxM1/ACP5 signaling pathway promotes HCC metastasis and may be a candidate biomarker for prognosis and a target for new therapies.	[Xia, L.; Huang, W.; Chen, Z.; Zhang, L.; Hu, H.; Liu, J.; Chen, Z.; Tang, G.; Dou, J.; Sha, S.; Xu, B.; Liu, C.; Ma, J.; Zhang, S.; Li, M.; Fan, D.; Nie, Y.; Wu, K.] Fourth Mil Med Univ, State Key Lab Canc Biol, Xian 710032, Shaanxi Provinc, Peoples R China; [Tian, D.] Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian 710032, Shaanxi Provinc, Peoples R China; [Li, Y.] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Gastroenterol, Wuhan 430074, Hubei Province, Peoples R China; [Xia, L.; Huang, W.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada	Air Force Military Medical University; Air Force Military Medical University; Huazhong University of Science & Technology; University of British Columbia	Nie, Y (corresponding author), Fourth Mil Med Univ, State Key Lab Canc Biol, Xian 710032, Shaanxi Provinc, Peoples R China.	yongznie@fmmu.edu.cn; wu_kaichun@yahoo.cn	Huang, Wenjie/G-1778-2017; meng, li/GVT-2063-2022		National Natural Science Foundation of China [81272652, 81172290, 91129723, 81090270, 81090273, 81120108005]; National Key and Basic Research Development Program of China [2010CB529302, 2010CB529306]; National Municipal Science and Technology Project [2009ZX09103-667, 2009ZX09301-009-RC06]; Chinese Postdoctoral Science Foundation [20100471776, 201104757]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Key and Basic Research Development Program of China(National Basic Research Program of China); National Municipal Science and Technology Project; Chinese Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This study was supported by combined grants from the National Natural Science Foundation of China (No. 81272652, No. 81172290, No. 91129723, No.81090270, No.81090273 and No.81120108005), the National Key and Basic Research Development Program of China (No. 2010CB529302 and 2010CB529306), the National Municipal Science and Technology Project (2009ZX09103-667 and 2009ZX09301-009-RC06) and the Chinese Postdoctoral Science Foundation (No. 20100471776 and No.201104757).	Adams LM, 2007, CELL BIOL INT, V31, P191, DOI 10.1016/j.cellbi.2006.09.022; Bao B, 2011, J CELL BIOCHEM, V112, P2296, DOI 10.1002/jcb.23150; Calvisi DF, 2009, GUT, V58, P679, DOI 10.1136/gut.2008.152652; Capeller B, 2003, ANTICANCER RES, V23, P1011; Chao TY, 2005, CLIN CANCER RES, V11, P544; Dai B, 2007, ONCOGENE, V26, P6212, DOI 10.1038/sj.onc.1210443; EDMONDSON HA, 1954, CANCER-AM CANCER SOC, V7, P462, DOI 10.1002/1097-0142(195405)7:3<462::AID-CNCR2820070308>3.0.CO;2-E; El-Serag HB, 2008, GASTROENTEROLOGY, V134, P1752, DOI 10.1053/j.gastro.2008.02.090; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; Gusarova GA, 2007, J CLIN INVEST, V117, P99, DOI 10.1172/JCI27527; Halleen JM, 2001, CLIN CHEM, V47, P597; Honig A, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-199; Huang C, 2012, CANCER RES, V72, P655, DOI 10.1158/0008-5472.CAN-11-3102; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; Laoukili J, 2007, BBA-REV CANCER, V1775, P92, DOI 10.1016/j.bbcan.2006.08.006; Li Y, 2012, NAT REV GASTRO HEPAT, V9, P32, DOI 10.1038/nrgastro.2011.196; Lyubimova NV, 2004, B EXP BIOL MED+, V138, P77, DOI 10.1007/BF02694481; McLean GW, 2005, NAT REV CANCER, V5, P505, DOI 10.1038/nrc1647; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; Park HJ, 2011, EMBO MOL MED, V3, P21, DOI 10.1002/emmm.201000107; Raychaudhuri P, 2011, CANCER RES, V71, P4329, DOI 10.1158/0008-5472.CAN-11-0640; Scott KL, 2011, CANCER CELL, V20, P92, DOI 10.1016/j.ccr.2011.05.025; Sun HC, 2011, CANCER LETT, V306, P214, DOI 10.1016/j.canlet.2011.03.009; Wang IC, 2008, J BIOL CHEM, V283, P20770, DOI 10.1074/jbc.M709892200; Wang XH, 2002, P NATL ACAD SCI USA, V99, P16881, DOI 10.1073/pnas.252570299; Wang XH, 2001, P NATL ACAD SCI USA, V98, P11468, DOI 10.1073/pnas.201360898; Wang ZW, 2007, CANCER RES, V67, P8293, DOI 10.1158/0008-5472.CAN-07-1265; Wu YY, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-158; Xia LM, 2012, CARCINOGENESIS, V33, P2250, DOI 10.1093/carcin/bgs249; Xia LM, 2012, J HEPATOL, V57, P600, DOI 10.1016/j.jhep.2012.04.020; Xia LM, 2012, J IMMUNOL, V188, P753, DOI 10.4049/jimmunol.1101652; Yang JD, 2010, NAT REV GASTRO HEPAT, V7, P448, DOI 10.1038/nrgastro.2010.100; Zenger S, 2011, CLIN EXP METASTAS, V28, P65, DOI 10.1007/s10585-010-9358-4	33	30	31	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2014	33	11					1395	1406		10.1038/onc.2013.90	http://dx.doi.org/10.1038/onc.2013.90			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD0SD	23604121				2022-12-28	WOS:000332943500007
J	Zhao, H; Chen, MS; Lo, YH; Waltz, SE; Wang, J; Ho, PC; Vasiliauskas, J; Plattner, R; Wang, YL; Wang, SC				Zhao, H.; Chen, M-S; Lo, Y-H; Waltz, S. E.; Wang, J.; Ho, P-C; Vasiliauskas, J.; Plattner, R.; Wang, Y-L; Wang, S-C			The Ron receptor tyrosine kinase activates c-Abl to promote cell proliferation through tyrosine phosphorylation of PCNA in breast cancer	ONCOGENE			English	Article						PCNA; Ron; receptor tyrosine kinase; tyrosine phosphorylation; Y211; c-Abl	GROWTH-FACTOR RECEPTOR; TERMINAL REPEATED DOMAIN; DAMAGE-INDUCED APOPTOSIS; NUCLEAR ANTIGEN PCNA; DNA MISMATCH REPAIR; RNA-POLYMERASE-II; TUMOR-FORMATION; PROTEIN; REPLICATION; FAMILY	Multiple growth pathways lead to enhanced proliferation in malignant cells. However, how the core machinery of DNA replication is regulated by growth signaling remains largely unclear. The sliding clamp proliferating cell nuclear antigen (PCNA) is an indispensable component of the DNA machinery responsible for replicating the genome and maintaining genomic integrity. We previously reported that epidermal growth factor receptor (EGFR) triggered tyrosine 211 (Y211) phosphorylation of PCNA, which in turn stabilized PCNA on chromatin to promote cell proliferation. Here we show that the phosphorylation can also be catalyzed by the non-receptor tyrosine kinase c-Abl. We further demonstrate that, in the absence of EGFR, signaling to PCNA can be attained through the activation of the Ron receptor tyrosine kinase and the downstream non-receptor tyrosine kinase c-Abl. We show that Ron and c-Abl form a complex, and that activation of Ron by its ligand, hepatocyte growth factor-like protein (HGFL), stimulates c-Abl kinase activity, which in turn directly phosphorylates PCNA at Y211 and leads to an increased level of chromatin-associated PCNA. Correspondingly, HGFL-induced Ron activation resulted in Y211 phosphorylation of PCNA while silencing of c-Abl blocked this effect. We show that c-Abl and Y211 phosphorylation of PCNA is an important axis downstream of Ron, which is required for cell proliferation. Treatment with a specific peptide that inhibits Y211 phosphorylation of PCNA or with the c-Abl pharmacological inhibitor imatinib suppressed HGFL-induced cell proliferation. Our findings identify the pathway of Ron-c-Abl-PCNA as a mechanism of oncogene-induced cell proliferation, with potentially important implications for development of combination therapy of breast cancer.	[Zhao, H.; Chen, M-S; Lo, Y-H; Waltz, S. E.; Ho, P-C; Vasiliauskas, J.; Wang, Y-L; Wang, S-C] Univ Cincinnati, Coll Med, Dept Canc Biol, Cincinnati, OH 45267 USA; [Waltz, S. E.] Cincinnati Vet Affairs Med Ctr, Cincinnati, OH USA; [Wang, J.] Univ Cincinnati Med Ctr, Dept Pathol & Lab Med, Cincinnati, OH USA; [Plattner, R.] Univ Kentucky, Sch Med, Dept Mol & Biomed Pharmacol, Lexington, KY USA	University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center; University System of Ohio; University of Cincinnati; University of Kentucky	Wang, SC (corresponding author), Univ Cincinnati, Coll Med, Vontz Ctr, Dept Canc Biol, 3125 Eden Ave,PO 670521, Cincinnati, OH 45267 USA.	wangsc@ucmail.uc.edu	Wang, Shao-Chun/P-9904-2019	Wang, Shao-Chun/0000-0002-5477-1682; Waltz, Susan/0000-0003-3572-4642	Susan G Komen Breast Cancer Research Award [KG080540]; Department of Defense Prostate Cancer Research Program New Investigator Award [PC073951]; Center for Clinical and Translational Science and Training (CCTST) of University of Cincinnati and Cincinnati Children's Hospital; Elsa Pardee Foundation; VA Merit Award [1001BX000803, R01 CA125379, R01 CA116784]; PHS [P30 DK078392]; NATIONAL CANCER INSTITUTE [R01CA125379, R01CA116784, R01CA100002, T32CA117846] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000077] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK078392] Funding Source: NIH RePORTER; Veterans Affairs [I01BX000803] Funding Source: NIH RePORTER	Susan G Komen Breast Cancer Research Award(Susan G. Komen Breast Cancer Foundation); Department of Defense Prostate Cancer Research Program New Investigator Award(United States Department of Defense); Center for Clinical and Translational Science and Training (CCTST) of University of Cincinnati and Cincinnati Children's Hospital; Elsa Pardee Foundation; VA Merit Award(US Department of Veterans Affairs); PHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Veterans Affairs(US Department of Veterans Affairs)	We thank Drs David Plas and Daniel Starczynowski for the help in discussion and reagents. We also like to thank Dr Belinda Peace and Glenn Doerman for assistance in editing the manuscript and preparing the graphics, and Jerylin Gray for technical assistance. This work was supported in part by the Susan G Komen Breast Cancer Research Award KG080540, the Department of Defense Prostate Cancer Research Program New Investigator Award PC073951, the Center for Clinical and Translational Science and Training (CCTST) of University of Cincinnati and Cincinnati Children's Hospital, and the Elsa Pardee Foundation (S-CW), the VA Merit Award 1001BX000803 and R01 CA125379 (SEW), and R01 CA116784 (RP). This project was also supported in part by PHS Grant P30 DK078392.	Agami R, 1999, NATURE, V399, P809; Andoniou CE, 1996, ONCOGENE, V12, P1981; AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; Baker MA, 2009, DEV BIOL, V333, P57, DOI 10.1016/j.ydbio.2009.06.022; Barila D, 2000, EMBO J, V19, P273, DOI 10.1093/emboj/19.2.273; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Baskaran R, 1999, CELL GROWTH DIFFER, V10, P387; DUYSTER J, 1995, P NATL ACAD SCI USA, V92, P1555, DOI 10.1073/pnas.92.5.1555; Essers J, 2005, MOL CELL BIOL, V25, P9350, DOI 10.1128/MCB.25.21.9350-9359.2005; Follenzi A, 2000, ONCOGENE, V19, P3041, DOI 10.1038/sj.onc.1203620; FURUKAWA T, 1991, J SURG ONCOL, V48, P188, DOI 10.1002/jso.2930480310; Gong JG, 1999, NATURE, V399, P806; Iwama A, 1996, EMBO J, V15, P5866, DOI 10.1002/j.1460-2075.1996.tb00973.x; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; Kharbanda S, 1998, ONCOGENE, V17, P3309, DOI 10.1038/sj.onc.1202571; Kim WJ, 2007, J BIOL CHEM, V282, P32021, DOI 10.1074/jbc.M701451200; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; Komatsu K, 2000, ONCOGENE, V19, P5291, DOI 10.1038/sj.onc.1203901; Lee WY, 2005, CLIN CANCER RES, V11, P2222, DOI 10.1158/1078-0432.CCR-04-1761; Lehmann AR, 2006, EXP CELL RES, V312, P2673, DOI 10.1016/j.yexcr.2006.06.010; Leong CO, 2007, J CLIN INVEST, V117, P1370, DOI 10.1172/JCI30866; Leonis Mike A, 2007, Future Oncol, V3, P441, DOI 10.2217/14796694.3.4.441; Levav-Cohen Y, 2005, BIOCHEM BIOPH RES CO, V331, P737, DOI 10.1016/j.bbrc.2005.03.152; Lin J, 2008, ONCOGENE, V27, P4385, DOI 10.1038/onc.2008.86; Lin J, 2007, ONCOGENE, V26, P6989, DOI 10.1038/sj.onc.1210500; Lo YH, 2011, ANTICANCER RES, V31, P789; Maga G, 2003, J CELL SCI, V116, P3051, DOI 10.1242/jcs.00653; Maggiora P, 1998, ONCOGENE, V16, P2927, DOI 10.1038/sj.onc.1201812; Mantovani F, 2004, MOL CELL, V14, P625, DOI 10.1016/j.molcel.2004.05.007; Marti TM, 2002, J CELL PHYSIOL, V191, P28, DOI 10.1002/jcp.10077; Matunis MJ, 2002, MOL CELL, V10, P441, DOI 10.1016/S1097-2765(02)00653-6; McClaine RJ, 2010, NEOPLASIA, V12, P650, DOI 10.1593/neo.10476; Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504; Moldovan GL, 2007, CELL, V129, P665, DOI 10.1016/j.cell.2007.05.003; Nehme A, 1997, CANCER RES, V57, P3253; O'Toole JM, 2006, CANCER RES, V66, P9162, DOI 10.1158/0008-5472.CAN-06-0283; Paunesku T, 2001, INT J RADIAT BIOL, V77, P1007, DOI 10.1080/09553000110069335; Peace BE, 2005, CANCER RES, V65, P1285, DOI 10.1158/0008-5472.CAN-03-3580; Peace BE, 2001, ONCOGENE, V20, P6142, DOI 10.1038/sj.onc.1204836; Plattner R, 2004, MOL CELL BIOL, V24, P2573, DOI 10.1128/mcb.24.6.2573-2583.2004; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Plattner R, 2003, NAT CELL BIOL, V5, P309, DOI 10.1038/ncb949; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shaul Y, 2005, CELL RES, V15, P33, DOI 10.1038/sj.cr.7290261; Sirvent A, 2007, ONCOGENE, V26, P7313, DOI 10.1038/sj.onc.1210543; Srinivasan D, 2008, ONCOGENE, V27, P1095, DOI 10.1038/sj.onc.1210714; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; Srinivasan D, 2009, CELL SIGNAL, V21, P1143, DOI 10.1016/j.cellsig.2009.03.003; Stuart JR, 2006, J BIOL CHEM, V281, P31290, DOI 10.1074/jbc.M602389200; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Tanos B, 2006, J BIOL CHEM, V281, P32714, DOI 10.1074/jbc.M603126200; Thobe MN, 2010, ONCOGENE, V29, P214, DOI 10.1038/onc.2009.331; Truong T, 2003, P NATL ACAD SCI USA, V100, P10281, DOI 10.1073/pnas.1635435100; Tsai KKC, 2003, CANCER RES, V63, P3418; Ulrich HD, 2004, CELL CYCLE, V3, P15; Wagh PK, 2008, ADV CANCER RES, V100, P1, DOI 10.1016/S0065-230X(08)00001-8; Wang JYJ, 2001, BIOCHEM SOC T, V29, P666, DOI 10.1042/0300-5127:0290666; Wang SC, 2006, NAT CELL BIOL, V8, P1359, DOI 10.1038/ncb1501; Welm AL, 2007, P NATL ACAD SCI USA, V104, P7570, DOI 10.1073/pnas.0702095104; Woodring PJ, 2003, J CELL SCI, V116, P2613, DOI 10.1242/jcs.00622; Yi W, 2006, CANCER RES, V66, P151, DOI 10.1158/0008-5472.CAN-05-3019; Yogalingam G, 2008, J BIOL CHEM, V283, P35941, DOI 10.1074/jbc.M804543200; Yoshida K, 2005, NAT CELL BIOL, V7, P278, DOI 10.1038/ncb1228; Yuan ZM, 1997, P NATL ACAD SCI USA, V94, P1437, DOI 10.1073/pnas.94.4.1437; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zhao HJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029416; Zhao HJ, 2011, MOL CANCER THER, V10, P29, DOI 10.1158/1535-7163.MCT-10-0778; Zhao HJ, 2011, MOL CARCINOGEN, V50, P383, DOI 10.1002/mc.20721; Zhao HJ, 2010, NEOPLASIA, V12, P214, DOI 10.1593/neo.91576; Zinser GM, 2006, CANCER RES, V66, P11967, DOI 10.1158/0008-5472.CAN-06-2473	72	36	41	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2014	33	11					1429	1437		10.1038/onc.2013.84	http://dx.doi.org/10.1038/onc.2013.84			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD0SD	23542172	Green Accepted			2022-12-28	WOS:000332943500010
J	Wang, J; Tian, X; Han, R; Zhang, X; Wang, X; Shen, H; Xue, L; Liu, Y; Yan, X; Shen, J; Mannoor, K; Deepak, J; Donahue, JM; Stass, SA; Xing, L; Jiang, F				Wang, J.; Tian, X.; Han, R.; Zhang, X.; Wang, X.; Shen, H.; Xue, L.; Liu, Y.; Yan, X.; Shen, J.; Mannoor, K.; Deepak, J.; Donahue, J. M.; Stass, S. A.; Xing, L.; Jiang, F.			Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer	ONCOGENE			English	Article						miR-486-5p; tumor-suppressor gene; lung cancer; ARHGAP5; therapy	MICRORNA MARKERS; P190B RHOGAP; CELL; SUPPRESSOR; CARCINOMA; IDENTIFICATION; TUMORIGENESIS; ACTIVATION; BIOMARKERS; DIAGNOSIS	We have previously shown that miR-486-5p is one of the most downregulated micro RNAs in lung cancer. The objective of the study was to investigate the role of miR-486-5p in the progression and metastasis of non-small-cell lung cancer (NSCLC). We evaluated miR-486-5p expression status on 76 frozen and 33 formalin-fixed paraffin-embedded tissues of NSCLC by quantitative reverse transcriptase PCR to determine its clinicopathologic significance. We then performed function analysis of miR-486-5p to determine its potential roles on cancer cell migration and invasion in vitro and metastasis in vivo. We also investigated the target genes of miR-486-5p in lung tumorigenesis. miR-486-5p expression level was significantly lower in lung tumors compared with their corresponding normal tissues (P<0.0001), and associated with stage (P = 0.0001) and lymph node metastasis of NSCLC (P = 0.0019). Forced expression of miR-486-5p inhibited NSCLC cell migration and invasion in vitro and metastasis in mice by inhibiting cell proliferation. Furthermore, ectopic expression of miR-486-5p in cancer cells reduced ARHGAP5 expression level, whereas miR-486-5p silencing increased its expression. Luciferase assay demonstrated that miR-486-5p could directly bind to the 30-untranslated region of ARHGAP5. The expression level of miR-486-5p was inversely correlated with that of ARHGAP5 in lung tumor tissues (P = 0.0156). Reduced expression of ARHGAP5 considerably inhibited lung cancer cell migration and invasion, resembling that of miR-486-5p overexpression. miR-486-5p may act as a tumor-suppressor contributing to the progression and metastasis of NSCLC by targeting ARHGAP5. miR-486-5p would provide potential diagnostic and therapeutic targets for the disease.	[Wang, J.; Tian, X.; Han, R.; Shen, H.; Xue, L.; Yan, X.; Xing, L.] Hebei Med Univ, Dept Pathol, Shijiazhuang 050017, Peoples R China; [Zhang, X.] Hebei Med Univ, Hosp 2, Dept Pathol, Shijiazhuang 050017, Peoples R China; [Wang, X.; Liu, Y.] Hebei Med Univ, Tumor Hosp, Dept Pathol, Shijiazhuang 050017, Peoples R China; [Shen, J.; Mannoor, K.; Stass, S. A.; Jiang, F.] Univ Maryland, Sch Med, Dept Pathol, Baltimore, MD 21201 USA; [Deepak, J.] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA; [Donahue, J. M.] Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA	Hebei Medical University; Hebei Medical University; Hebei Medical University; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Xing, L (corresponding author), Hebei Med Univ, Dept Pathol, 361 East Zhongshan Rd, Shijiazhuang 050017, Peoples R China.	xinglingxiao@hotmail.com; fjiang@som.umaryland.edu			National Natural Science Foundation of China [81101482]; Natural Science Foundation of Hebei province, China [C2011206001]; American Cancer Society-Research Scholar Grant in Basic, Preclinical, Clinical and Epidemiology Research [115154AF109040]; National Cancer Institute (NCI) [R01CA161837-01]; Maryland Stem Cell Research Fund; VA-Merit grant [I01 CX000512-01]; NATIONAL CANCER INSTITUTE [R01CA161837] Funding Source: NIH RePORTER; Veterans Affairs [I01CX000512] Funding Source: NIH RePORTER	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Hebei province, China(Natural Science Foundation of Hebei Province); American Cancer Society-Research Scholar Grant in Basic, Preclinical, Clinical and Epidemiology Research; National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Maryland Stem Cell Research Fund; VA-Merit grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Veterans Affairs(US Department of Veterans Affairs)	This work was supported by Grants 81101482 from the National Natural Science Foundation of China and Grants C2011206001 from the Natural Science Foundation of Hebei province, China (to LX) and American Cancer Society-Research Scholar Grant in Basic, Preclinical, Clinical and Epidemiology Research-115154AF109040, National Cancer Institute (NCI)-R01CA161837-01, an exploratory research grant from the Maryland Stem Cell Research Fund, and VA-Merit grant-I01 CX000512-01 (to FJ).	Ambros V, 2003, CELL, V113, P673, DOI 10.1016/S0092-8674(03)00428-8; Bansal A, 2011, AM J GASTROENTEROL, V106, P1055, DOI 10.1038/ajg.2011.37; Chakravarty G, 2003, MOL ENDOCRINOL, V17, P1054, DOI 10.1210/me.2002-0428; Fan T, CANC RES; Feng J, 2004, NEOPLASIA, V6, P623, DOI 10.1593/neo.04142; Gao SM, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-110; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gen Y, 2009, CANCER LETT, V275, P27, DOI 10.1016/j.canlet.2008.09.036; Heckman-Stoddard BM, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2352; Jenkins DE, 2003, CLIN EXP METASTAS, V20, P733, DOI 10.1023/B:CLIN.0000006815.49932.98; Kent OA, 2006, ONCOGENE, V25, P6188, DOI 10.1038/sj.onc.1209913; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; McHenry PR, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2643; Mei YP, 2012, ONCOGENE, V31, P2794, DOI 10.1038/onc.2011.449; Midorikawa Y, 2009, HEPATOLOGY, V49, P513, DOI 10.1002/hep.22698; Nakahara H, 1998, J BIOL CHEM, V273, P9, DOI 10.1074/jbc.273.1.9; Oh HK, 2011, CLIN CANCER RES, V17, P2657, DOI 10.1158/1078-0432.CCR-10-3152; Ragusa M, 2010, MOL CANCER THER, V9, P3396, DOI 10.1158/1535-7163.MCT-10-0137; Saito Y, 2006, CELL CYCLE, V5, P2220, DOI 10.4161/cc.5.19.3340; Shen J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-374; Small EM, 2010, P NATL ACAD SCI USA, V107, P4218, DOI 10.1073/pnas.1000300107; Sordella R, 2002, DEV CELL, V2, P553, DOI 10.1016/S1534-5807(02)00162-4; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Tan XG, 2011, CLIN CANCER RES, V17, P6802, DOI 10.1158/1078-0432.CCR-11-0419; Tarver T, 2012, J CONS HLTH INTERNET, V16, P366, DOI 10.1080/15398285.2012.701177; Teng DHF, 1997, CANCER RES, V57, P5221; Wang HJ, 2005, INT J CANCER, V116, P285, DOI 10.1002/ijc.21035; Xiao CC, 2009, CELL, V136, P26, DOI 10.1016/j.cell.2008.12.027; Xing LX, 2010, MODERN PATHOL, V23, P1157, DOI 10.1038/modpathol.2010.111; Yu L, 2010, INT J CANCER, V127, P2870, DOI 10.1002/ijc.25289	32	188	198	4	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2014	33	9					1181	1189		10.1038/onc.2013.42	http://dx.doi.org/10.1038/onc.2013.42			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XT	23474761	Green Accepted			2022-12-28	WOS:000331933800011
J	Marcos-Villar, L; Gallego, P; Munoz-Fontela, C; de la Cruz-Herrera, CF; Campagna, M; Gonzalez, D; Lopitz-Otsoa, F; Rodriguez, MS; Rivas, C				Marcos-Villar, L.; Gallego, P.; Munoz-Fontela, C.; de la Cruz-Herrera, C. F.; Campagna, M.; Gonzalez, D.; Lopitz-Otsoa, F.; Rodriguez, M. S.; Rivas, C.			Kaposi's sarcoma-associated herpesvirus lana2 protein interacts with the pocket proteins and inhibits their sumoylation	ONCOGENE			English	Article						pocket proteins; KSHV; LANA2; pocket proteins; sumoylation; LXCXE domain	RETINOBLASTOMA TUMOR-SUPPRESSOR; LARGE T-ANTIGEN; INTERFERON-REGULATORY FACTOR-3; PRIMARY EFFUSION LYMPHOMA; C-MYC; CELL-CYCLE; TRANSCRIPTIONAL REPRESSION; DISTINCT MECHANISMS; FAMILY-MEMBERS; GENE RB2/P130	The pocket proteins retinoblastoma protein (pRb), p107 and p130 are the key targets of oncoproteins expressed by DNA tumor viruses. Some of these viral proteins contain an LXCXE motif that mediates the interaction with the three pocket proteins and the inhibition of the pRb SUMOylation. Kaposi's sarcoma herpesvirus (KSHV) contains at least two proteins that can regulate pRb function but, so far, a KSHV-encoded protein targeting p107 and p130 has not been identified. Here, we show that the KSHV latent protein LANA2 binds to pRb, p107 and p130. LANA2 contains an LXCXE motif that is required for bypassing pRb-mediated cell-cycle arrest and for inhibiting pRb SUMOylation. Finally, we demonstrate that, in addition to pRb, both p107 and p130 can be SUMOylated, and this modification is also inhibited by LANA2 in an LXCXE-dependent manner. These results demonstrate, for the first time, the SUMOylation of p107 or p130 and, so far, they represent the first example of a KSHV protein able to interact with the three pocket proteins and to inhibit their conjugation to SUMO.	[Marcos-Villar, L.; Gallego, P.; de la Cruz-Herrera, C. F.; Campagna, M.; Gonzalez, D.; Rivas, C.] CSIC, Ctr Nacl Biotecnol, Madrid 28049, Spain; [Munoz-Fontela, C.] Heinrich Pette Inst, Leibniz Inst Expt Virol, Hamburg, Germany; [Lopitz-Otsoa, F.; Rodriguez, M. S.] CIBERehd, CIC BioGUNE, Prote Unit, Buildin Derio, Spain; [Rodriguez, M. S.] Inbiomed, Ubiquitylat & Canc Mol Biol Lab, San Sebastian, Gipuzkoa, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Heinrich Pette Institute; CIBER - Centro de Investigacion Biomedica en Red; CIBEREHD; CIC bioGUNE	Rivas, C (corresponding author), CSIC, Ctr Nacl Biotecnol, Campus Univ Autonoma Madrid, Madrid 28049, Spain.	crivas@cnb.csic.es	Rivas, Carmen/AAB-6278-2019; MARCOS-VILLAR, LAURA/L-8444-2014; de Llano, Dolores González/F-2219-2013; Lopitz-Otsoa, Fernando/A-1966-2017; Rivas, Carmen/L-3162-2017	Rivas, Carmen/0000-0002-0518-7199; MARCOS-VILLAR, LAURA/0000-0002-8635-6432; de Llano, Dolores González/0000-0001-8140-7045; Lopitz-Otsoa, Fernando/0000-0001-8452-6939; Rivas, Carmen/0000-0002-0518-7199; de la Cruz-Herrera, Carlos/0000-0002-7493-5154; Munoz-Fontela, Cesar/0000-0002-7725-2586	Juan de la Cierva Program; JAE predoctoral fellowship from CSIC; La Caixa fellowship;  [BFU-2008-03784];  [BFU-2011-27064]	Juan de la Cierva Program; JAE predoctoral fellowship from CSIC; La Caixa fellowship(La Caixa Foundation); ; 	This project has been possible thanks to the generous support from Patrick Moore and Yuan Chang (Pittsburg University, USA) in the initial experiments and to the reagents they provided. This work was supported by BFU-2008-03784 and BFU-2011-27064. MC and LM-V are supported by Juan de la Cierva Program. PG is supported by JAE predoctoral fellowship from CSIC. CFC-H is supported by La Caixa fellowship.	Araki K, 2008, CLIN CANCER RES, V14, P3514, DOI 10.1158/1078-0432.CCR-07-4538; BARBEAU D, 1994, ONCOGENE, V9, P359; Baresova P, 2012, J BIOL CHEM, V287, P16199, DOI 10.1074/jbc.M111.335216; BEIJERSBERGEN RL, 1994, EMBO J, V13, P4080, DOI 10.1002/j.1460-2075.1994.tb06725.x; BEIJERSBERGEN RL, 1995, GENE DEV, V9, P1340, DOI 10.1101/gad.9.11.1340; Benetti R, 2008, NAT STRUCT MOL BIOL, V15, P268, DOI 10.1038/nsmb.1399; Bowen C, 1998, CANCER RES, V58, P3275; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Campagna M, 2011, CELL DEATH DIFFER, V18, P72, DOI 10.1038/cdd.2010.77; Chan HM, 2001, NAT CELL BIOL, V3, P667, DOI 10.1038/35083062; Chang Y, 1996, NATURE, V382, P410, DOI 10.1038/382410a0; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHRISTENSEN JB, 1995, J VIROL, V69, P3945, DOI 10.1128/JVI.69.6.3945-3948.1995; Claudio PP, 2000, CANCER RES, V60, P372; Claudio PP, 2000, CANCER RES, V60, P8; Claudio PP, 1996, CANCER RES, V56, P2003; CLAUDIO PP, 1994, CANCER RES, V54, P5556; DeGregori J, 2006, CURR MOL MED, V6, P739; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; DYSON N, 1992, J VIROL, V66, P4606, DOI 10.1128/JVI.66.7.4606-4611.1992; DYSON N, 1992, CANCER SURV, V12, P161; Esteban M, 2003, J GEN VIROL, V84, P1463, DOI 10.1099/vir.0.19014-0; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; Fan SJ, 2001, ONCOGENE, V20, P4827, DOI 10.1038/sj.onc.1204666; GoddenKent D, 1997, J VIROL, V71, P4193, DOI 10.1128/JVI.71.6.4193-4198.1997; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GU W, 1994, SCIENCE, V264, P251, DOI 10.1126/science.8146655; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; Howard CM, 2000, CANCER RES, V60, P2737; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Joo CH, 2007, J VIROL, V81, P8282, DOI 10.1128/JVI.00235-07; JUNG JU, 1994, MOL CELL BIOL, V14, P7235, DOI 10.1128/MCB.14.11.7235; Kim HY, 2001, EMBO J, V20, P295, DOI 10.1093/emboj/20.1.295; Knudsen KE, 1999, ONCOGENE, V18, P5239, DOI 10.1038/sj.onc.1202910; Ledl A, 2005, ONCOGENE, V24, P3810, DOI 10.1038/sj.onc.1208539; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; Lemaire C, 2005, ONCOGENE, V24, P3297, DOI 10.1038/sj.onc.1208493; Li MT, 1997, J VIROL, V71, P1984, DOI 10.1128/JVI.71.3.1984-1991.1997; Li TW, 2006, J BIOL CHEM, V281, P36221, DOI 10.1074/jbc.M608236200; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; Lu F, 2010, J VIROL, V84, P2697, DOI 10.1128/JVI.01997-09; Lubyova B, 2004, J BIOL CHEM, V279, P7643, DOI 10.1074/jbc.M309485200; Lubyova B, 2007, J BIOL CHEM, V282, P31944, DOI 10.1074/jbc.M706430200; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Marcos-Villar L, J GEN VIROL 1, V92, P188; Marcos-Villar L, 2009, J VIROL, V83, P8849, DOI 10.1128/JVI.00339-09; MAYOL X, 1993, ONCOGENE, V8, P2561; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Miller G, 2007, ADV CANCER RES, V97, P81, DOI 10.1016/S0065-230X(06)97004-3; MORAN E, 1986, MOL CELL BIOL, V6, P3470, DOI 10.1128/MCB.6.10.3470; Pantry SN, 2009, SEMIN CANCER BIOL, V19, P153, DOI 10.1016/j.semcancer.2009.02.010; Platt G, 2002, ONCOGENE, V21, P1823, DOI 10.1038/sj.onc.1205360; Radkov SA, 2000, NAT MED, V6, P1121, DOI 10.1038/80459; Rivas C, 2001, J VIROL, V75, P429, DOI 10.1128/JVI.75.1.429-438.2001; Scambia G, 2006, ONCOGENE, V25, P5302, DOI 10.1038/sj.onc.1209620; Schwarze F, 2010, ONCOGENE, V29, P5755, DOI 10.1038/onc.2010.311; Seo T, 2004, ONCOGENE, V23, P6146, DOI 10.1038/sj.onc.1207807; Shin YC, 2008, CANCER RES, V68, P1751, DOI 10.1158/0008-5472.CAN-07-2766; Smith EJ, 1998, CELL GROWTH DIFFER, V9, P297; Starostik P, 1996, MOL CELL BIOL, V16, P3606; Sullivan CS, 2000, MOL CELL BIOL, V20, P6233, DOI 10.1128/MCB.20.17.6233-6243.2000; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Vertegaal ACO, 2006, MOL CELL PROTEOMICS, V5, P2298, DOI 10.1074/mcp.M600212-MCP200; WEINBERG RA, 1995, ANN NY ACAD SCI, V758, P331, DOI 10.1111/j.1749-6632.1995.tb24838.x; Wies E, 2008, BLOOD, V111, P320, DOI 10.1182/blood-2007-05-092288; Wies E, 2009, J BIOL CHEM, V284, P8525, DOI 10.1074/jbc.M809252200; Wirt SE, 2010, CELL DIV, V5, DOI 10.1186/1747-1028-5-9; Xiao ZX, 1996, P NATL ACAD SCI USA, V93, P4633, DOI 10.1073/pnas.93.10.4633; YEUNG RS, 1993, ONCOGENE, V8, P3465; Zalvide J, 1998, MOL CELL BIOL, V18, P1408, DOI 10.1128/MCB.18.3.1408; Zhang BY, 2006, P NATL ACAD SCI USA, V103, P437, DOI 10.1073/pnas.0510012103; Zhao X, 2001, UROLOGY, V57, P860, DOI 10.1016/S0090-4295(01)00946-3; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	73	17	17	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2014	33	4					495	503		10.1038/onc.2012.603	http://dx.doi.org/10.1038/onc.2012.603			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VX	23318443				2022-12-28	WOS:000330214600010
J	Solga, AC; Gianino, SM; Gutmann, DH				Solga, A. C.; Gianino, S. M.; Gutmann, D. H.			NG2-cells are not the cell of origin for murine neurofibromatosis-1 (Nf1) optic glioma	ONCOGENE			English	Article						genetically-engineered mice; NG2+; optic glioma; neurofibromatosis type 1	CENTRAL-NERVOUS-SYSTEM; GLIAL PROGENITORS; NG2 PROTEOGLYCAN; GROWTH-FACTOR; OLIGODENDROCYTE PRECURSORS; MALIGNANT GLIOMAS; PATHWAY GLIOMAS; CLONAL ANALYSIS; WHITE-MATTER; CHILDREN	Low-grade glial neoplasms (astrocytomas) represent one of the most common brain tumors in the pediatric population. These tumors frequently form in the optic pathway (optic pathway gliomas, OPGs), especially in children with the neurofibromatosis type 1 (NF1)-inherited tumor predisposition syndrome. To model these tumors in mice, we have previously developed several Nf1 genetically-engineered mouse strains that form optic gliomas. However, there are three distinct macroglial cell populations in the optic nerve (astrocytes, NG2 + (nerve/glial antigen 2) cells and oligodendrocytes). The presence of NG2 + cells in the optic nerve raises the intriguing possibility that these cells could be the tumor-initiating cells, as has been suggested for adult glioma. In this report, we used a combination of complementary in vitro and novel genetically-engineered mouse strains in vivo to determine whether NG2 + cells could give rise to Nf1 optic glioma. First, we show that Nf1 inactivation results in a cell-autonomous increase in glial fibrillary acidic protein + (GFAP + ), but not in NG2 + , cell proliferation in vitro. Second, similar to the GFAP-Cre transgenic strain that drives Nf1 optic gliomagenesis, NG2-expressing cells also give rise to all three macroglial lineages in vivo. Third, in contrast to the GFAP-Cre strain, Nf1 gene inactivation in NG2 + cells is not sufficient for optic gliomagenesis in vivo. Collectively, these data demonstrate that NG2 + cells are not the cell of origin for mouse optic glioma, and support a model in which gliomagenesis requires Nf1 loss in specific neuroglial progenitors during embryogenesis.	[Solga, A. C.; Gianino, S. M.; Gutmann, D. H.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Washington University (WUSTL)	Gutmann, DH (corresponding author), Washington Univ, Sch Med, Dept Neurol, Box 8111,660 South Euclid Ave, St Louis, MO 63110 USA.	gutmannd@neuro.wustl.edu		Gutmann, David/0000-0002-3127-5045	National Cancer Institute [U01-CA141549]; National Eye Institute [EY02687]; NATIONAL CANCER INSTITUTE [U01CA141549] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [P30EY002687] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Eye Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	We appreciate the excellent technical assistance of Angela Petti and Belinda McMahan in the Ophthalmology Core Facility for preparing the optic nerve sections. This work was funded by a grant from the National Cancer Institute (U01-CA141549 to DHG), whereas the Ophthalmology Core Facility is funded by a grant from the National Eye Institute EY02687).	Abel TW, 2009, MOL CANCER RES, V7, P645, DOI 10.1158/1541-7786.MCR-08-0477; Al-Mayhani MTF, 2011, NEURO-ONCOLOGY, V13, P830, DOI 10.1093/neuonc/nor088; Assanah M, 2006, J NEUROSCI, V26, P6781, DOI 10.1523/JNEUROSCI.0514-06.2006; Bajenaru ML, 2002, MOL CELL BIOL, V22, P5100, DOI 10.1128/MCB.22.14.5100-5113.2002; Bajenaru ML, 2003, CANCER RES, V63, P8573; Baracskay KL, 2007, GLIA, V55, P1001, DOI 10.1002/glia.20519; Blazo MA, 2004, AM J MED GENET A, V127A, P224, DOI 10.1002/ajmg.a.20650; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; Czyzyk E, 2003, J CHILD NEUROL, V18, P471, DOI 10.1177/08830738030180070401; Dahiya S, 2011, J NEUROPATH EXP NEUR, V70, P622, DOI 10.1097/NEN.0b013e31822200aa; Dawson MRL, 2003, MOL CELL NEUROSCI, V24, P476, DOI 10.1016/S1044-7431(03)00210-0; Doetsch F, 1999, P NATL ACAD SCI USA, V96, P11619, DOI 10.1073/pnas.96.20.11619; Ellis JA, 2012, NEUROSURGERY, V70, P198, DOI 10.1227/NEU.0b013e31822ce963; Gao LM, 2006, J NEUROSCI, V26, P7619, DOI 10.1523/JNEUROSCI.0855-06.2006; Hegedus B, 2008, CANCER RES, V68, P1520, DOI 10.1158/0008-5472.CAN-07-5916; Ju PJ, 2012, CYTOTHERAPY, V14, P608, DOI 10.3109/14653249.2011.651528; Kwon CH, 2008, CANCER RES, V68, P3286, DOI 10.1158/0008-5472.CAN-07-6867; Lee DY, 2012, CANCER CELL, V22, P131, DOI 10.1016/j.ccr.2012.05.036; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; Listernick R, 1997, ANN NEUROL, V41, P143, DOI 10.1002/ana.410410204; LISTERNICK R, 1995, J PEDIATR-US, V127, P718, DOI 10.1016/S0022-3476(95)70159-1; Liu C, 2011, CELL, V146, P209, DOI 10.1016/j.cell.2011.06.014; Llaguno SA, 2009, CANCER CELL, V15, P45, DOI 10.1016/j.ccr.2008.12.006; LUND AM, 1991, EUR J PEDIATR, V150, P835, DOI 10.1007/BF01955002; Madisen L, 2010, NAT NEUROSCI, V13, P133, DOI 10.1038/nn.2467; Masui K, 2010, GLIA, V58, P1050, DOI 10.1002/glia.20986; MILLER RH, 1985, DEV BIOL, V111, P35, DOI 10.1016/0012-1606(85)90432-4; Mokry J, 2008, STEM CELLS DEV, V17, P333, DOI 10.1089/scd.2007.0091; Neymeyer V, 1997, BRAIN RES, V766, P195, DOI 10.1016/S0006-8993(97)00528-3; Ogden AT, 2008, NEUROSURGERY, V62, P505, DOI 10.1227/01.neu.0000316019.28421.95; Ono K, 1997, NEURON, V19, P283, DOI 10.1016/S0896-6273(00)80939-3; Ozerdem U, 2001, DEV DYNAM, V222, P218, DOI 10.1002/dvdy.1200; RAFF MC, 1984, DEV BIOL, V106, P53, DOI 10.1016/0012-1606(84)90060-5; RAFF MC, 1983, J NEUROSCI, V3, P1289; SCHRAPPE M, 1991, CANCER RES, V51, P4986; Silber J, 2008, BMC MED, V6, DOI 10.1186/1741-7015-6-14; STALLCUP WB, 1987, J NEUROSCI, V7, P2737; Tchoghandjian A, 2010, BRAIN PATHOL, V20, P211, DOI 10.1111/j.1750-3639.2009.00269.x; Tchoghandjian A, 2009, BRAIN, V132, P1523, DOI 10.1093/brain/awp048; Wang J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023062; Winkler EA, 2011, NAT NEUROSCI, V14, P1398, DOI 10.1038/nn.2946; Wiranowska M, 2006, BRAIN CELL BIOL, V35, P159, DOI 10.1007/s11068-007-9009-0; Yeh TH, 2009, GLIA, V57, P1239, DOI 10.1002/glia.20845; Yoo S, 2007, DEV NEUROBIOL, V67, P860, DOI 10.1002/dneu.20369; Zhu XQ, 2008, DEVELOPMENT, V135, P145, DOI 10.1242/dev.004895; Zhu Y, 2005, DEVELOPMENT, V132, P5577, DOI 10.1242/dev.02162; Zhu Y, 2001, GENE DEV, V15, P859, DOI 10.1101/gad.862101	47	16	16	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2014	33	3					289	299		10.1038/onc.2012.580	http://dx.doi.org/10.1038/onc.2012.580			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VR	23318450	Green Accepted			2022-12-28	WOS:000330214000003
J	Gravells, P; Hoh, L; Solovieva, S; Patil, A; Dudziec, E; Rennie, IG; Sisley, K; Bryant, HE				Gravells, P.; Hoh, L.; Solovieva, S.; Patil, A.; Dudziec, E.; Rennie, I. G.; Sisley, K.; Bryant, H. E.			Reduced FANCD2 influences spontaneous SCE and RAD51 foci formation in uveal melanoma and Fanconi anaemia	ONCOGENE			English	Article						FANCD2; homologous recombination; non-homologous end-joining; uveal melanoma; sister chromatid exchange; RAD51	SISTER-CHROMATID EXCHANGE; DNA-DAMAGING AGENTS; BREAST-CANCER; HOMOLOGOUS RECOMBINATION; CHROMOSOME-DAMAGE; REPLICATION FORKS; ALKYLATING-AGENTS; GENE CONVERSION; MCL-1 PROMOTER; STRAND BREAKS	Uveal melanoma (UM) is unique among cancers in displaying reduced endogenous levels of sister chromatid exchange (SCE). Here we demonstrate that FANCD2 expression is reduced in UM and that ectopic expression of FANCD2 increased SCE. Similarly, FANCD2-deficient fibroblasts (PD20) derived from Fanconi anaemia patients displayed reduced spontaneous SCE formation relative to their FANCD2-complemented counterparts, suggesting that this observation is not specific to UM. In addition, spontaneous RAD51 foci were reduced in UM and PD20 cells compared with FANCD2-proficient cells. This is consistent with a model where spontaneous SCEs are the end product of endogenous recombination events and implicates FANCD2 in the promotion of recombination-mediated repair of endogenous DNA damage and in SCE formation during normal DNA replication. In both UM and PD20 cells, low SCE was reversed by inhibiting DNA-PKcs (DNA-dependent protein kinase, catalytic subunit). Finally, we demonstrate that both PD20 and UM are sensitive to acetaldehyde, supporting a role for FANCD2 in repair of lesions induced by such endogenous metabolites. Together, these data suggest FANCD2 may promote spontaneous SCE by influencing which double-strand break repair pathway predominates during normal S-phase progression.	[Gravells, P.; Hoh, L.; Solovieva, S.; Patil, A.; Dudziec, E.; Bryant, H. E.] Univ Sheffield, Fac Med Dent & Hlth Sci, Dept Oncol, Inst Canc Studies, Sheffield S10 2RX, Yorks, England; [Hoh, L.; Rennie, I. G.; Sisley, K.] Univ Sheffield, Acad Unit Ophthalmol & Orthopt, Dept Oncol, Fac Med Dent & Hlth Sci,Royal Hallamshire Hosp, Sheffield S10 2RX, Yorks, England	University of Sheffield; University of Sheffield	Bryant, HE (corresponding author), Univ Sheffield, Sch Med, Inst Canc studies, Beech Hill Rd, Sheffield S10 2RX, Yorks, England.	h.bryant@sheffield.ac.uk	bryant, helen/AHB-1139-2022; Sisley, Karen/B-7296-2019	bryant, helen/0000-0003-2720-7020; Sisley, Karen/0000-0002-5565-2618	RCUK fellowship; MRC studentship; Weston Park Hospital Cancer Appeal [CA95]; Sarcoma Trust; Yorkshire Eye Research and Yorkshire Cancer Research [S305PA]	RCUK fellowship(UK Research & Innovation (UKRI)); MRC studentship(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Weston Park Hospital Cancer Appeal; Sarcoma Trust; Yorkshire Eye Research and Yorkshire Cancer Research	We thank Professors Toshiyasu Taniguchi and Alan D'Andrea for providing cells, the FANCD2-expressing retroviral vectors and for their technical advice. They also thank Professors Tomas Lindahl and Mark Meuth and Dr Spencer Collis for critical reading of the manuscript and discussion. We are grateful for funding from an RCUK fellowship to HB and MRC studentship to PG and for general funding from Weston Park Hospital Cancer Appeal (CA95), The Sarcoma Trust, Yorkshire Eye Research and Yorkshire Cancer Research (S305PA).	Abraham J, 2011, ALCOHOL CLIN EXP RES, V35, P2113, DOI 10.1111/j.1530-0277.2011.01563.x; Adamo A, 2010, MOL CELL, V39, P25, DOI 10.1016/j.molcel.2010.06.026; AUERBACH AD, 1976, NATURE, V261, P494, DOI 10.1038/261494a0; Barroso E, 2006, CARCINOGENESIS, V27, P1930, DOI 10.1093/carcin/bgl062; BUERSTEDDE JM, 1990, EMBO J, V9, P921, DOI 10.1002/j.1460-2075.1990.tb08190.x; Campanero MR, 2000, P NATL ACAD SCI USA, V97, P6481, DOI 10.1073/pnas.100340697; Chen HZ, 2009, NAT REV CANCER, V9, P785, DOI 10.1038/nrc2696; Croxton R, 2002, ONCOGENE, V21, P1359, DOI 10.1038/sj.onc.1205157; Croxton R, 2002, ONCOGENE, V21, P1563, DOI 10.1038/sj.onc.1205232; Damato B, 2009, INVEST OPHTH VIS SCI, V50, P3048, DOI 10.1167/iovs.08-3165; Dronkert MLG, 2000, MOL CELL BIOL, V20, P3147, DOI 10.1128/MCB.20.9.3147-3156.2000; Eischen CM, 2001, ONCOGENE, V20, P6983, DOI 10.1038/sj.onc.1204892; Garcia CL, 2009, MUTAT RES-FUND MOL M, V662, P3, DOI 10.1016/j.mrfmmm.2008.11.008; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; GEBHART E, 1985, HUM GENET, V69, P309, DOI 10.1007/BF00291647; Godthelp BC, 2002, NUCLEIC ACIDS RES, V30, P2172, DOI 10.1093/nar/30.10.2172; Goyanes V., 1994, Cytobios, V77, P67; Gravells P, 2011, BRIT J CANCER, V104, P1098, DOI 10.1038/bjc.2011.56; Harbour JW, 2009, AM J OPHTHALMOL, V148, P823, DOI 10.1016/j.ajo.2009.07.004; HAYASHI K, 1975, HUMANGENETIK, V29, P201, DOI 10.1007/BF00297624; Hoh L, 2011, GENE CHROMOSOME CANC, V50, P34, DOI 10.1002/gcc.20829; Houghtaling S, 2003, GENE DEV, V17, P2021, DOI 10.1101/gad.1103403; HOWELL RT, 1991, J MED GENET, V28, P468, DOI 10.1136/jmg.28.7.468; KATO H, 1976, NATURE, V260, P447, DOI 10.1038/260447a0; Kim MK, 2004, CANCER LETT, V210, P85, DOI 10.1016/j.canlet.2004.01.014; Langevin F, 2011, NATURE, V475, P53, DOI 10.1038/nature10192; LATT SA, 1975, P NATL ACAD SCI USA, V72, P4066, DOI 10.1073/pnas.72.10.4066; Lyakhovich A, 2006, CANCER LETT, V232, P99, DOI 10.1016/j.canlet.2005.07.038; Miranda M, 1997, MUTAGENESIS, V12, P233, DOI 10.1093/mutage/12.4.233; NAGASAWA H, 1983, MUTAT RES, V107, P315, DOI 10.1016/0027-5107(83)90173-2; Nakanishi K, 2005, P NATL ACAD SCI USA, V102, P1110, DOI 10.1073/pnas.0407796102; Neveling K, 2007, CYTOGENET GENOME RES, V118, P166, DOI 10.1159/000108297; Niedzwiedz W, 2004, MOL CELL, V15, P607, DOI 10.1016/j.molcel.2004.08.009; NOVOTNA B, 1979, HUM GENET, V49, P41; Pace P, 2010, SCIENCE, V329, P219, DOI 10.1126/science.1192277; Pang QS, 2009, MUTAT RES-FUND MOL M, V668, P42, DOI 10.1016/j.mrfmmm.2009.03.013; Patel KA, 2001, BRIT J OPHTHALMOL, V85, P1440, DOI 10.1136/bjo.85.12.1440; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; PORFIRIO B, 1983, HUM GENET, V63, P117, DOI 10.1007/BF00291529; Rosado IV, 2011, NAT STRUCT MOL BIOL, V18, P1432, DOI 10.1038/nsmb.2173; Rudland PS, 2010, AM J PATHOL, V176, P2935, DOI 10.2353/ajpath.2010.090779; Saleh-Gohari N, 2005, MOL CELL BIOL, V25, P7158, DOI 10.1128/MCB.25.16.7158-7169.2005; Sisley K, 1997, GENE CHROMOSOME CANC, V19, P22, DOI 10.1002/(SICI)1098-2264(199705)19:1<22::AID-GCC4>3.0.CO;2-2; Smiraldo PG, 2005, CANCER RES, V65, P2089, DOI 10.1158/0008-5472.CAN-04-2079; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; SPERLING K, 1975, HUMANGENETIK, V27, P227, DOI 10.1007/BF00278349; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Taniguchi T, 2002, BLOOD, V100, P2414, DOI 10.1182/blood-2002-01-0278; Taniguchi T, 2003, NAT MED, V9, P568, DOI 10.1038/nm852; Tian X, 2011, CELL SIGNAL, V23, P193, DOI 10.1016/j.cellsig.2010.09.003; Timmers C, 2001, MOL CELL, V7, P241, DOI 10.1016/S1097-2765(01)00172-1; Tutt A, 2001, EMBO J, V20, P4704, DOI 10.1093/emboj/20.17.4704; van der Groep P, 2008, BREAST CANCER RES TR, V107, P41, DOI 10.1007/s10549-007-9534-7; Wang LC, 2008, DNA REPAIR, V7, P1973, DOI 10.1016/j.dnarep.2008.08.005; Wilson JB, 2001, CARCINOGENESIS, V22, P1939, DOI 10.1093/carcin/22.12.1939; Wojcik A, 2004, CYTOGENET GENOME RES, V104, P304, DOI 10.1159/000077507; Yamamoto K, 2005, MOL CELL BIOL, V25, P34, DOI 10.1128/MCB.25.1.34-43.2005	58	7	9	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2013	32	46					5338	5346		10.1038/onc.2012.627	http://dx.doi.org/10.1038/onc.2012.627			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251IU	23318456	Green Published, Green Accepted, hybrid			2022-12-28	WOS:000326922400004
J	Kostaras, E; Sflomos, G; Pedersen, NM; Stenmark, H; Fotsis, T; Murphy, C				Kostaras, E.; Sflomos, G.; Pedersen, N. M.; Stenmark, H.; Fotsis, T.; Murphy, C.			SARA and RNF11 interact with each other and ESCRT-0 core proteins and regulate degradative EGFR trafficking	ONCOGENE			English	Article							EPIDERMAL-GROWTH-FACTOR; FYVE DOMAIN PROTEIN; FACTOR RECEPTOR; ENDOCYTIC TRAFFICKING; ENDOTHELIAL-CELLS; EARLY ENDOSOMES; A431 CELLS; E3 LIGASE; HRS; BINDING	Smad anchor for receptor activation (SARA) is highly enriched on endocytic membranes via binding to phosphatidylinositol 3-phosphates through its FYVE (Fab1p-YOTB-Vps27p-EEA1) domain. SARA was originally identified as a protein that recruits non-phosphorylated SMAD2/3 to the activated TGF beta receptors for phosphorylation, but later reports suggested a regulatory role in endocytic trafficking. Here we demonstrate that the ubiquitin ligase RNF11 is a SARA-interacting protein residing on early and late endosomes, as well as the fast recycling compartment. RNF11 and SARA interact with the ESCRT-0 subunits STAM2 and Eps15b, but only RNF11 associates with the core subunit Hrs. Both gain- and loss-of-function perturbation of RNF11 and SARA levels result in delayed degradation of epidermal growth factor (EGF)-activated EGF receptor (EGFR), while loss-of-function sustained/enhanced EGF-induced ERK1/2 phosphorylation. These findings suggest that RNF11 and SARA are functional components of the ESCRT-0 complexes. Moreover, SARA interacts with clathrin, the ESCRT-I subunit Tsg101 and ubiquitinated cargo exhibiting all the properties of Hrs concerning ESCRT-0 function, indicating that it could substitute Hrs in some ESCRT-0 complexes. These results suggest that RNF11 and SARA participate structurally and functionally in the ESCRT-dependent lysosomal degradation of receptors. As a consequence, the negative influence that perturbation of RNF11 and SARA levels exerts on the lysosomal degradation of EGFRs could underscore the reported overexpression of RNF11 in several cancers. In these cancers, deficient termination of the oncogenic signaling of mutated receptors, such as the EGFRs, through suboptimal lysosomal degradation could contribute to the process of malignant transformation.	[Kostaras, E.; Sflomos, G.; Fotsis, T.] Univ Ioannina, Sch Med, Lab Biol Chem, GR-45110 Ioannina, Greece; [Kostaras, E.; Sflomos, G.; Fotsis, T.; Murphy, C.] Fdn Res & Technol Hellas, Dept Biomed Res, Inst Mol Biol & Biotechnol, Ioannina 45110, Greece; [Pedersen, N. M.; Stenmark, H.] Univ Oslo, Ctr Canc Biomed, Fac Med, Oslo, Norway	University of Ioannina; Foundation for Research & Technology - Hellas (FORTH); University of Oslo	Murphy, C (corresponding author), Fdn Res & Technol Hellas, Dept Biomed Res, Inst Mol Biol & Biotechnol, Univ Campus Ioannina, Ioannina 45110, Greece.	cmurphy@cc.uoi.gr	Stenmark, Harald/B-8868-2008; Sflomos, George/Q-2826-2019; Sflomos, George/D-9275-2016; Murphy, Carol/ABE-4282-2021	Sflomos, George/0000-0003-2972-0549; Murphy, Carol/0000-0003-1353-8558	European Union [LSH-2004-1.1.5-2]	European Union(European Commission)	We thank the confocal laser microscope facility of the University of Ioannina for the use of the Leica TCS-SP scanning confocal microscope. This work was supported by the European Union integrated project ENDOTRACK (EU FP6, LSH-2004-1.1.5-2).	Amano Y, 2011, J BIOL CHEM, V286, P15458, DOI 10.1074/jbc.M110.191924; Anderson LR, 2007, J NEUROPATH EXP NEUR, V66, P955, DOI 10.1097/nen.0b013e3181567f17; Azmi P, 2005, EUR J CANCER, V41, P2549, DOI 10.1016/j.ejca.2005.08.020; Bache KG, 2003, J CELL BIOL, V162, P435, DOI 10.1083/jcb.200302131; Bache KG, 2003, J BIOL CHEM, V278, P12513, DOI 10.1074/jbc.M210843200; Bache KG, 2006, MOL BIOL CELL, V17, P2513, DOI 10.1091/mbc.E05-10-0915; Bagli E, 2004, CANCER RES, V64, P7936, DOI 10.1158/0008-5472.CAN-03-3104; Bellou S, 2009, AM J PHYSIOL-CELL PH, V297, pC1477, DOI 10.1152/ajpcell.00058.2009; Bennett D, 2002, NAT GENET, V31, P419, DOI 10.1038/ng938; Bilodeau PS, 2003, J CELL BIOL, V163, P237, DOI 10.1083/jcb.200305007; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; Chen C, 2008, ONCOGENE, V27, P6845, DOI 10.1038/onc.2008.288; Chuang JZ, 2007, CELL, V130, P535, DOI 10.1016/j.cell.2007.06.030; Colland F, 2004, GENOME RES, V14, P1324, DOI 10.1101/gr.2334104; Collinet C, 2010, NATURE, V464, P243, DOI 10.1038/nature08779; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Grandal MV, 2008, J CELL MOL MED, V12, P1527, DOI 10.1111/j.1582-4934.2008.00298.x; Gullapalli A, 2006, MOL BIOL CELL, V17, P1228, DOI 10.1091/mbc.E05-09-0899; Hislop JN, 2004, J BIOL CHEM, V279, P22522, DOI 10.1074/jbc.M311062200; Hu Y, 2002, J CELL SCI, V115, P4755, DOI 10.1242/jcs.00177; Johannessen LE, 2006, MOL CELL BIOL, V26, P389, DOI 10.1128/MCB.26.2.389-401.2006; Katzmann DJ, 2003, J CELL BIOL, V162, P413, DOI 10.1083/jcb.200302136; Kitching R, 2003, BBA-MOL BASIS DIS, V1639, P104, DOI 10.1016/j.bbadis.2003.07.001; Li HX, 2004, ONCOGENE, V23, P1801, DOI 10.1038/sj.onc.1207319; Locasale JW, 2007, P NATL ACAD SCI USA, V104, P13307, DOI 10.1073/pnas.0706311104; Malerod L, 2007, TRAFFIC, V8, P1617, DOI 10.1111/j.1600-0854.2007.00630.x; Mimeault M, 2011, BRAIN PATHOL, V21, P479, DOI 10.1111/j.1750-3639.2011.00505.x; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Nielsen E, 2000, J CELL BIOL, V151, P601, DOI 10.1083/jcb.151.3.601; Panopoulou E, 2002, J BIOL CHEM, V277, P18046, DOI 10.1074/jbc.M107983200; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Petiot A, 2003, J CELL BIOL, V162, P971, DOI 10.1083/jcb.200303018; Raiborg C, 2001, EMBO J, V20, P5008, DOI 10.1093/emboj/20.17.5008; Raiborg C, 2001, BIOCHEM SOC T, V29, P472, DOI 10.1042/BST0290472; Raiborg C, 2008, EXP CELL RES, V314, P801, DOI 10.1016/j.yexcr.2007.10.014; Raiborg C, 2009, NATURE, V458, P445, DOI 10.1038/nature07961; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Roxrud I, 2008, J CELL BIOL, V180, P1205, DOI 10.1083/jcb.200708115; Santonico E, 2010, ONCOGENE, V29, P5604, DOI 10.1038/onc.2010.294; Sflomos G, 2011, J CELL SCI, V124, P3209, DOI 10.1242/jcs.062307; Shembade N, 2009, EMBO J, V28, P513, DOI 10.1038/emboj.2008.285; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Skarpen E, 1998, EXP CELL RES, V243, P161, DOI 10.1006/excr.1998.4127; Sonnichsen B, 2000, J CELL BIOL, V149, P901, DOI 10.1083/jcb.149.4.901; SORKIN AD, 1988, EXP CELL RES, V175, P192, DOI 10.1016/0014-4827(88)90266-2; STENMARK H, 1995, METHOD ENZYMOL, V257, P155; Stuffers S, 2009, TRAFFIC, V10, P925, DOI 10.1111/j.1600-0854.2009.00920.x; Subramaniam V, 2003, BRIT J CANCER, V89, P1538, DOI 10.1038/sj.bjc.6601301; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Wollert T, 2010, NATURE, V464, P864, DOI 10.1038/nature08849; Yamashita Y, 2008, J CELL SCI, V121, P1727, DOI 10.1242/jcs.024455	53	25	26	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2013	32	44					5220	5232		10.1038/onc.2012.554	http://dx.doi.org/10.1038/onc.2012.554			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245XH	23222715	Bronze			2022-12-28	WOS:000326497100005
J	Wang, Y; Balan, V; Kho, D; Hogan, V; Nangia-Makker, P; Raz, A				Wang, Y.; Balan, V.; Kho, D.; Hogan, V.; Nangia-Makker, P.; Raz, A.			Galectin-3 regulates p21 stability in human prostate cancer cells	ONCOGENE			English	Article						galectin-3; p21; stability; CRD	BREAST-CARCINOMA; UBIQUITIN LIGASE; CYCLE ARREST; S-PHASE; EXPRESSION; APOPTOSIS; INHIBITION; PROTEIN; P53; DEGRADATION	Galectin-3 (Gal-3) is a multifunctional protein involved in cancer through regulation of cell adhesion, cell growth, apoptosis and metastasis, while p21 (Cip1/WAF1) is a negative regulator of the cell cycle, involved in apoptosis, transcription, DNA repair and metastasis. The results presented here demonstrate for the first time that the level of Gal-3 protein is associated with the level of p21 protein expression in human prostate cancer cells and the effects of Gal-3 on cell growth and apoptosis were reversed by modulating p21 expression level. Furthermore, Gal-3 regulates p21 expression at the post-translational level by stabilizing p21 protein via the carbohydrate-recognition domain. This is the first report suggesting a molecular function not yet described for Gal-3 as the regulator of p21 protein stability. This study provides a unique insight into the relationship of these two molecules during prostate cancer progression, and may provide a novel therapeutic target.	[Wang, Y.; Balan, V.; Kho, D.; Hogan, V.; Nangia-Makker, P.; Raz, A.] Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Oncol Tumor Progress & Metastasis, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University	Nangia-Makker, P (corresponding author), Wayne State Univ, Sch Med, Karmanos Canc Inst, Dept Oncol Tumor Progress & Metastasis, 110 E Warren Ave, Detroit, MI 48201 USA.	makkerp@karmanos.org; raza@karmanos.org		Nangia-Makker, Pratima/0000-0002-1917-169X	National Institutes of Health [R37CA46120-19]; American Cancer Society [11-053-01-IRG]; NATIONAL CANCER INSTITUTE [R37CA046120] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Reuben Lotan for providing Gal-3-transfected LNCaP clones. This study was supported by the National Institutes of Health grant R37CA46120-19 (A Raz) and the American Cancer Society grant 11-053-01-IRG (V Balan).	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Amador V, 2007, MOL CELL, V27, P462, DOI 10.1016/j.molcel.2007.06.013; Anttila MA, 1999, BRIT J CANCER, V79, P1870, DOI 10.1038/sj.bjc.6690298; Balan V, 2012, J BIOL CHEM, V287, P5192, DOI 10.1074/jbc.C111.331686; Baretton GB, 1999, BRIT J CANCER, V80, P546, DOI 10.1038/sj.bjc.6690390; BARONDES SH, 1994, J BIOL CHEM, V269, P20807; Bartolazzi A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003768; Beck SE, 2007, CELL SIGNAL, V19, P1465, DOI 10.1016/j.cellsig.2007.01.017; Blagosklonny MV, 2002, CELL CYCLE, V1, P391, DOI 10.4161/cc.1.6.262; Bornstein G, 2003, J BIOL CHEM, V278, P25752, DOI 10.1074/jbc.M301774200; Brugarolas J, 1999, P NATL ACAD SCI USA, V96, P1002, DOI 10.1073/pnas.96.3.1002; Brustmann H, 2008, INT J GYNECOL PATHOL, V27, P380, DOI 10.1097/PGP.0b013e31815d060d; Caffo O, 1996, CLIN CANCER RES, V2, P1591; Califice S, 2004, INT J ONCOL, V25, P983; Coqueret O, 2003, TRENDS CELL BIOL, V13, P65, DOI 10.1016/S0962-8924(02)00043-0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Ellerhorst JA, 2002, PROSTATE, V50, P64, DOI 10.1002/pros.10033; Feilchenfeldt J, 2003, MODERN PATHOL, V16, P1117, DOI 10.1097/01.MP.0000096047.99202.31; Gan L, 2011, PROSTATE, V71, P1158, DOI 10.1002/pros.21331; Garner E, 2008, CELL CYCLE, V7, P277, DOI 10.4161/cc.7.3.5328; Gong JG, 2003, CANCER RES, V63, P3340; HARPER JW, 1993, CELL, V75, P805; Iacovazzi PA, 2010, IMMUNOPHARM IMMUNOT, V32, P160, DOI [10.3109/08923970902936880, 10.1080/08923970902936880]; Idikio H, 1998, INT J ONCOL, V12, P1287; Kim HRC, 1999, CANCER RES, V59, P4148; Kim Y, 2008, GENE DEV, V22, P2507, DOI 10.1101/gad.1703708; Lee EW, 2009, EMBO J, V28, P2100, DOI 10.1038/emboj.2009.164; Lin HM, 2000, CARCINOGENESIS, V21, P1941, DOI 10.1093/carcin/21.11.1941; Mashiach E, 2008, NUCLEIC ACIDS RES, V36, pW229, DOI 10.1093/nar/gkn186; Merseburger AS, 2008, PROSTATE, V68, P72, DOI 10.1002/pros.20688; Nangia-Makker P, 1998, BREAST CANCER RES TR, V49, P171, DOI 10.1023/A:1005913810250; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Ogawa M, 2001, INT J MOL MED, V7, P479; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Pavelic SK, 2008, CANCER GENE THER, V15, P576, DOI 10.1038/cgt.2008.28; PODUST VN, 1995, BIOCHEMISTRY-US, V34, P8869, DOI 10.1021/bi00027a039; Puglisi F, 2004, CANCER LETT, V212, P233, DOI 10.1016/j.canlet.2004.03.006; Roy A, 2010, NAT PROTOC, V5, P725, DOI 10.1038/nprot.2010.5; Schneidman-Duhovny D, 2005, NUCLEIC ACIDS RES, V33, pW363, DOI 10.1093/nar/gki481; Seetharaman J, 1998, J BIOL CHEM, V273, P13047, DOI 10.1074/jbc.273.21.13047; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Stivala LA, 2012, CURR CANCER DRUG TAR, V12, P85; Streetly MJ, 2010, BLOOD, V115, P3939, DOI 10.1182/blood-2009-10-251660; Suzuki A, 1999, ONCOGENE, V18, P1239, DOI 10.1038/sj.onc.1202409; Touitou R, 2001, EMBO J, V20, P2367, DOI 10.1093/emboj/20.10.2367; Van Le H, 2005, J BIOL CHEM, V280, P32018, DOI 10.1074/jbc.M504689200; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang Y, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.79; Wang Y, 2009, AM J PATHOL, V174, P1515, DOI 10.2353/ajpath.2009.080816; Yang LP, HEPATO-GASTROENTEROL, DOI DOI 10.5754/HGE12129)	50	16	18	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2013	32	42					5058	5065		10.1038/onc.2012.528	http://dx.doi.org/10.1038/onc.2012.528			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238IB	23160381	Green Accepted			2022-12-28	WOS:000325937900007
J	Li, S; Wang, M; Ao, X; Chang, AK; Yang, C; Zhao, F; Bi, H; Liu, Y; Xiao, L; Wu, H				Li, S.; Wang, M.; Ao, X.; Chang, A. K.; Yang, C.; Zhao, F.; Bi, H.; Liu, Y.; Xiao, L.; Wu, H.			CLOCK is a substrate of SUMO and sumoylation of CLOCK upregulates the transcriptional activity of estrogen receptor-alpha	ONCOGENE			English	Article						CLOCK; ERa; estrogen; sumoylation	CIRCADIAN CLOCK; DIFFERENTIAL REGULATION; BREAST; NUCLEAR; ACTIVATION; MECHANISMS; EXPRESSION; GENES; BETA; PHOSPHORYLATION	Disruption of the circadian rhythm is now believed to associate with a number of hormone-related cancers, such as breast cancer, in which aberrant estrogen receptor-a (ERa) signaling is a major contributor. However, the molecular mechanisms underlying the function of core clock proteins in cancer are still largely undefined. In this study, we showed that circadian locomotor output cycles kaput (CLOCK), a key circadian protein, can interact with ERa. Furthermore, this interaction was enhanced by estrogen. We also showed that CLOCK can be sumoylated and sumoylation of CLOCK, which is also stimulated by estrogen, had two consequences: (1) it increased the transcriptional activity of CLOCK; and (2) it increased the CLOCK-modulated transcriptional activity of ERa, as shown by increased transcription of cyclin D1. Sumoylation of CLOCK occurred at two lysine residues, K67 and K851. The enhancement of ERa transcriptional activity exerted by wild-type but not mutant (2K/2R) CLOCK in response to estrogen indicated that sumoylation of CLOCK may have an important role in estrogen-dependent signaling. 3-(4,5-dimethylthiazol-2-yl)-2,5diphenyltetrazolium bromide (MTT) assay conducted with breast cancer cell lines (MCF-7 and T47D) demonstrated that sumoylation of CLOCK stimulated cell growth and increased the proportion of S phase cells in the cell cycle. The results of this study uncovered new insight into the connection between a major circadian protein and a major estrogen-dependent transcription factor, providing the basis for further research into the involvement of circadian proteins in breast cancer.	[Li, S.; Wang, M.; Ao, X.; Chang, A. K.; Yang, C.; Zhao, F.; Bi, H.; Liu, Y.; Xiao, L.; Wu, H.] Dalian Univ Technol, Sch Life Sci & Biotechnol, Dalian 116024, Peoples R China	Dalian University of Technology	Wu, H (corresponding author), Dalian Univ Technol, Sch Life Sci & Biotechnol, 2 Ling Gong Rd, Dalian 116024, Peoples R China.	wuhj@dlut.edu.cn	Liu, Ying/ABF-6380-2021	Liu, Ying/0000-0003-1699-9309	National Natural Science Foundation of China [31271500, 31171353]; Ministry of Science and Technology of China [2011CB504201]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China)	We are grateful to Dr Miche le Teboul (Universitede Nice-Sophia Antipolis) and Dr Urs Albrecht (University of Fribourg) for their present of mouse CLOCK and GAL4- DBDCLOCK constructs. This work was supported by grants (31171353, 31271500 to HW) from National Natural Science Foundation of China and grants (973 program: 2011CB504201 to HW) from the Ministry of Science and Technology of China.	Al-Dhaheri M, 2011, CANCER RES, V71, P2118, DOI 10.1158/0008-5472.CAN-10-2426; Antoch MP, 2008, CELL CYCLE, V7, P1197, DOI 10.4161/cc.7.9.5886; Bailey D, 2002, J GEN VIROL, V83, P2951, DOI 10.1099/0022-1317-83-12-2951; Budanov AV, 2004, SCIENCE, V304, P596, DOI 10.1126/science.1095569; Cai W, 2008, MOL CELL BIOL, V28, P784, DOI 10.1128/MCB.00233-07; Cardone L, 2005, SCIENCE, V309, P1390, DOI 10.1126/science.1110689; Cascone I, 2005, J CELL BIOL, V170, P993, DOI 10.1083/jcb.200507082; Chauchereau A, 2003, J BIOL CHEM, V278, P12335, DOI 10.1074/jbc.M207148200; Doi M, 2006, CELL, V125, P497, DOI 10.1016/j.cell.2006.03.033; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Dutertre M, 2003, MOL ENDOCRINOL, V17, P1296, DOI 10.1210/me.2001-0316; Gery S, 2007, ONCOGENE, V26, P7916, DOI 10.1038/sj.onc.1210585; Gill G, 2005, CURR OPIN GENET DEV, V15, P536, DOI 10.1016/j.gde.2005.07.004; Gong L, 2006, J BIOL CHEM, V281, P15869, DOI 10.1074/jbc.M511658200; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Hang J, 2002, J BIOL CHEM, V277, P19961, DOI 10.1074/jbc.M201799200; Hoffman AE, 2010, CANCER RES, V70, P1459, DOI 10.1158/0008-5472.CAN-09-3798; Hong YD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023046; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Kobayashi Y, 2000, J BIOL CHEM, V275, P15645, DOI 10.1074/jbc.M000042200; Kotaja N, 2002, J BIOL CHEM, V277, P30283, DOI 10.1074/jbc.M204768200; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Kuo SJ, 2009, VIRCHOWS ARCH, V454, P467, DOI 10.1007/s00428-009-0761-7; Lee CC, 2006, CANCER CAUSE CONTROL, V17, P525, DOI 10.1007/s10552-005-9003-8; Li SJ, 2012, BIOL CELL, V104, P287, DOI 10.1111/boc.201100116; Lowrey PL, 2000, ANNU REV GENET, V34, P533, DOI 10.1146/annurev.genet.34.1.533; Mill P, 2003, GENE DEV, V17, P282, DOI 10.1101/gad.1038103; Osborne CK, 1998, BREAST CANCER RES TR, V51, P227, DOI 10.1023/A:1006132427948; Pearce ST, 2004, CRIT REV ONCOL HEMAT, V50, P3, DOI 10.1016/j.critrevonc.2003.09.003; Seeler JS, 2003, NAT REV MOL CELL BIO, V4, P690, DOI 10.1038/nrm1200; SHEIKH MS, 1994, INVAS METAST, V14, P329; Shim HS, 2007, EMBO REP, V8, P366, DOI 10.1038/sj.embor.7400920; Spengler ML, 2009, CELL CYCLE, V8, P4138, DOI 10.4161/cc.8.24.10273; Stade K, 2002, J BIOL CHEM, V277, P49554, DOI 10.1074/jbc.M207991200; Sternlicht MD, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1368; Tanimura N, 2011, TOXICOLOGY, V290, P203, DOI 10.1016/j.tox.2011.09.007; van der Horst GTJ, 1999, NATURE, V398, P627, DOI 10.1038/19323; Viswanathan AN, 2009, CANCER LETT, V281, P1, DOI 10.1016/j.canlet.2008.11.002; Vitaterna MH, 1999, P NATL ACAD SCI USA, V96, P12114, DOI 10.1073/pnas.96.21.12114; WALTER P, 1985, P NATL ACAD SCI USA, V82, P7889, DOI 10.1073/pnas.82.23.7889; Webb P, 1999, MOL ENDOCRINOL, V13, P1672, DOI 10.1210/me.13.10.1672; Winter SL, 2007, NEOPLASIA, V9, P797, DOI 10.1593/neo.07595; Wu HJ, 2005, NATURE, V438, P981, DOI 10.1038/nature04225; Wu HJ, 2006, J BIOL CHEM, V281, P21848, DOI 10.1074/jbc.M603772200; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776; Yang CW, 2006, CANCER RES, V66, P11649, DOI 10.1158/0008-5472.CAN-06-1645; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576	48	41	49	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2013	32	41					4883	4891		10.1038/onc.2012.518	http://dx.doi.org/10.1038/onc.2012.518			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235KQ	23160374				2022-12-28	WOS:000325717800004
J	Su, SF; Chang, YW; Andreu-Vieyra, C; Fang, JY; Yang, Z; Han, B; Lee, AS; Liang, G				Su, S-F; Chang, Y-W; Andreu-Vieyra, C.; Fang, J. Y.; Yang, Z.; Han, B.; Lee, A. S.; Liang, G.			miR-30d, miR-181a and miR-199a-5p cooperatively suppress the endoplasmic reticulum chaperone and signaling regulator GRP78 in cancer	ONCOGENE			English	Article						microRNA; GRP78; apoptosis; drug resistance; anti-cancer therapy	UNFOLDED PROTEIN RESPONSE; NEGATIVE REGULATION; PROSTATE-CANCER; DOWN-REGULATION; TUMOR-GROWTH; MICRORNAS; STRESS; TARGET; GENES; EXPRESSION	GRP78, a major endoplasmic reticulum chaperone and signaling regulator, is commonly overexpressed in cancer. Moreover, induction of GRP78 by a variety of anti-cancer drugs, including histone deacetylase inhibitors, confers chemoresistance to cancer, thereby contributing to tumorigenesis. Thus, therapies aimed at decreasing GRP78 levels, which results in the inhibition of tumor cell proliferation and resensitization of tumor cells to chemotherapeutic drugs may hold promise for cancer treatment. Despite advances in our understanding of GRP78 actions, little is known about endogenous inhibitors controlling its expression. As endogenous regulators, microRNAs (miRNAs) play important roles in modulating gene expression; therefore, we sought to identify miRNA(s) that target GRP78, under the hypothesis that these miRNAs may serve as therapeutic agents. Here, we report that three miRNAs (miR-30d, miR-181a, miR-199a-5p) predicted to target GRP78 are down-regulated in prostate, colon and bladder tumors, and human cancer cell lines. We show that in C42B prostate cancer cells, these miRNAs down-regulate GRP78 and induce apoptosis by directly targeting its 3' untranslated region. Importantly, we demonstrate that the three miRNAs act cooperatively to decrease GRP78 levels, suggesting that multiple miRNAs may be required to efficiently control the expression of some genes. In addition, delivery of multiple miRNAs by either transient transfection or lentivirus transduction increased the sensitivity of cancer cells to the histone deacetylase inhibitor, trichostatin A, in C42B, HCT116 and HL-60 cells. Together, our results indicate that the delivery of co-transcribed miRNAs can efficiently suppress GRP78 levels and GRP78-mediated chemoresistance, and suggest that this strategy holds therapeutic potential.	[Su, S-F; Chang, Y-W; Andreu-Vieyra, C.; Liang, G.] Univ So Calif, Sch Med, Dept Urol, Los Angeles, CA 90033 USA; [Su, S-F] Program Genet Mol & Cellular Biol, Los Angeles, CA USA; [Chang, Y-W; Lee, A. S.] Dept Biochem & Mol Biol, Los Angeles, CA USA; [Fang, J. Y.; Yang, Z.; Han, B.] Univ So Calif, Keck Sch Med, USC Norris Comprehens Canc Ctr, Dept Surg, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Liang, G (corresponding author), Univ So Calif, Keck Sch Med, USC Norris Comprehens Canc Ctr, Dept Urol, NOR7338,1441 Eastlake Ave, Los Angeles, CA 90089 USA.	gliang@usc.edu	Su, Sheng-Fang/AAT-3642-2021; Fang, Josephine/AAS-5996-2020	Su, Sheng-Fang/0000-0002-1624-5745; Liang, Gangning/0000-0001-8664-922X; Lee, Amy/0000-0002-0378-5443	NCI [RO1 CA138794, RO1 CA027607]; NATIONAL CANCER INSTITUTE [R01CA138794, R01CA027607] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr PA Jones for supporting this work; Dr KT Pfaffenbach for the experimental suggestions; Drs J Zhou and Q Li for data analysis; Drs TK Kelly for careful reading of the manuscript; Ms K Pandiyan and Mr C Duymich for the overview. This work was supported by NCI Grants (RO1 CA138794, GL, RO1 CA027607, ASL).	Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Backer MV, 2011, METHOD ENZYMOL, V491, P37, DOI 10.1016/B978-0-12-385928-0.00003-1; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Baumeister P, 2009, MOL CANCER THER, V8, P1086, DOI 10.1158/1535-7163.MCT-08-1166; Booth L, 2012, CANCER BIOL THER, V13, P224, DOI 10.4161/cbt.13.4.18877; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Cook KL, 2012, CANCER RES, V72, P3337, DOI 10.1158/0008-5472.CAN-12-0269; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Daneshmand S, 2007, HUM PATHOL, V38, P1547, DOI 10.1016/j.humpath.2007.03.014; Dong DZ, 2011, CANCER RES, V71, P2848, DOI 10.1158/0008-5472.CAN-10-3151; Duan QL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031518; Friedman JM, 2009, CANCER RES, V69, P2623, DOI 10.1158/0008-5472.CAN-08-3114; Fu Y, 2008, P NATL ACAD SCI USA, V105, P19444, DOI 10.1073/pnas.0807691105; Garzon R, 2010, NAT REV DRUG DISCOV, V9, P775, DOI 10.1038/nrd3179; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Grkovic S, 2013, ONCOGENE, V32, P2412, DOI 10.1038/onc.2012.264; Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267; Hetz C, 2006, SCIENCE, V312, P572, DOI 10.1126/science.1123480; Hu WW, 2010, MOL CELL, V38, P689, DOI 10.1016/j.molcel.2010.05.027; Kahali S, 2012, FASEB J, V26, P2437, DOI 10.1096/fj.11-193706; Kappelmann M, 2013, ONCOGENE, V32, P2984, DOI 10.1038/onc.2012.307; Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843; Kumar M, 2011, ONCOGENE, V30, P843, DOI 10.1038/onc.2010.457; Kuwahara K, 2010, TISSUE ENG PART C-ME, V16, P609, DOI 10.1089/ten.TEC.2009.0406; Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Leung AKL, 2010, MOL CELL, V40, P205, DOI 10.1016/j.molcel.2010.09.027; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li N, 2013, ONCOGENE, V32, P1933, DOI 10.1038/onc.2012.212; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lopez-Serra P, 2012, ONCOGENE, V31, P1609, DOI 10.1038/onc.2011.354; Luo B, 2013, ONCOGENE, V32, P805, DOI 10.1038/onc.2012.130; Marasa BS, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000442; Mavrakis KJ, 2011, CELL CYCLE, V10, P2845, DOI 10.4161/cc.10.17.16959; Mavrakis KJ, 2011, NAT GENET, V43, P673, DOI 10.1038/ng.858; Ni M, 2011, BIOCHEM J, V434, P181, DOI 10.1042/BJ20101569; Pfaffenbach KT, 2011, CURR OPIN CELL BIOL, V23, P150, DOI 10.1016/j.ceb.2010.09.007; Pootrakul L, 2006, CLIN CANCER RES, V12, P5987, DOI 10.1158/1078-0432.CCR-06-0133; Pyrko P, 2007, CANCER RES, V67, P9809, DOI 10.1158/0008-5472.CAN-07-0625; Qiu XN, 2011, BIOCHEM BIOPH RES CO, V411, P276, DOI 10.1016/j.bbrc.2011.06.123; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Roue G, 2011, BLOOD, V117, P1270, DOI 10.1182/blood-2010-04-278853; Saito Y, 2006, CANCER CELL, V9, P435, DOI 10.1016/j.ccr.2006.04.020; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Shen QL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-227; Virrey JJ, 2008, MOL CANCER RES, V6, P1268, DOI 10.1158/1541-7786.MCR-08-0060; Wey S, 2012, BLOOD, V119, P817, DOI 10.1182/blood-2011-06-357384; Wolff EM, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000917; Yeung BHY, 2008, ONCOGENE, V27, P6782, DOI 10.1038/onc.2008.290; Zhang J, 2001, J CLIN INVEST, V107, P1235, DOI 10.1172/JCI11685; Zhang Y, 2012, BLOOD, V120, P1678, DOI 10.1182/blood-2012-02-410647	53	93	103	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2013	32	39					4694	4701		10.1038/onc.2012.483	http://dx.doi.org/10.1038/onc.2012.483			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226YD	23085757	Green Published, hybrid			2022-12-28	WOS:000325072200011
J	Schroeder, MC; Chen, CL; Gajewski, K; Halder, G				Schroeder, M. C.; Chen, C-L; Gajewski, K.; Halder, G.			A non-cell-autonomous tumor suppressor role for Stat in eliminating oncogenic scribble cells	ONCOGENE			English	Article						cell competition; JAK/STAT; scribble	TISSUE OVERGROWTH; GENETIC MOSAICS; DROSOPHILA; GROWTH; POLARITY; PATHWAY; COMPETITION; ACTIVATION; EXPRESSION; MUTANTS	Elucidating signaling events between tumor cells and their microenvironment is a major challenge in understanding cancer development. Drosophila melanogaster has emerged as an important tool for dissecting the genetic circuits tumors depend on because their imaginal discs, simple epithelia present in the larva, can be genetically manipulated to serve as models to study cancer mechanisms. Imaginal disc cells mutant for the tumor-suppressor gene scribble (scrib) lose apical-basal polarity and have the potential to form large neoplastic tumors. Interestingly, when scrib mutant (scrib(-)) cells are surrounded by normal cells the scrib(-) population is eliminated. However, the signals and mechanisms that cause the elimination of clones of scrib(-) cells are poorly understood. Here, we analyzed the role of Stat, a component of the JAK/STAT signaling pathway, in tissues with clones of scrib(-) cells. We found that Stat activity is required in normal cells for the elimination of neighboring scrib(-) cells. Importantly, these competitive defects of stat mutant cells are not simply due to defects in cell proliferation because even stat(-) cells manipulated to hyperproliferate are unable to eliminate scrib(-) cells. These data identify Stat activity as a critical determinant of whether or not a tissue can eliminate abnormal cells and provide an important step forward in understanding the complex network of signals operating in and around tumorigenic cells.	[Schroeder, M. C.; Halder, G.] Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA; [Schroeder, M. C.; Chen, C-L; Halder, G.] Univ Texas MD Anderson Canc Ctr, Dept Biochem & Mol Biol, Houston, TX 77030 USA; [Chen, C-L; Halder, G.] Univ Texas MD Anderson Canc Ctr, Program Genes & Dev, Houston, TX 77030 USA; [Gajewski, K.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Halder, G.] Univ Louvain, KU Leuven Ctr Human Genet, VIB Ctr Biol Dis, B-3000 Louvain, Belgium; [Chen, C-L] Harvard Univ, Sch Med, Dept Genet, Boston, MA USA	Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Flanders Institute for Biotechnology (VIB); KU Leuven; Harvard University; Harvard Medical School	Halder, G (corresponding author), Univ Louvain, KU Leuven Ctr Human Genet, VIB Ctr Biol Dis, B-3000 Louvain, Belgium.	georg.halder@med.kuleuven.be	Halder, Georg/F-2966-2015	Halder, Georg/0000-0001-7580-3236	NIH; Baylor Research Advocates for Student Scientists scholarship	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Baylor Research Advocates for Student Scientists scholarship	We thank Erika Bach, Hugo Bellen, Andreas Bergmann, David Bilder, Michael Galko, Robert Holmgren, Kenneth Irvine, Jin Jiang, Ed Laufer, Graeme Mardon, Sang-Chul Nam, Duojia Pan, Hong Wen and the Developmental Studies Hybridoma Bank (University of Iowa) for fly stocks and antibodies. We thank Leisa McCord for artwork and the Halder lab for discussions. This work was supported by an NIH grant to GH and a Baylor Research Advocates for Student Scientists scholarship to MCS.	Bach EA, 2007, GENE EXPR PATTERNS, V7, P323, DOI 10.1016/j.modgep.2006.08.003; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Blair SS, 2003, DEVELOPMENT, V130, P5065, DOI 10.1242/dev.00774; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Chen CL, 2012, P NATL ACAD SCI USA, V109, P484, DOI 10.1073/pnas.1113882109; Cordero JB, 2010, DEV CELL, V18, P999, DOI 10.1016/j.devcel.2010.05.014; de la Cova C, 2004, CELL, V117, P107, DOI 10.1016/S0092-8674(04)00214-4; Doggett K, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-57; Ekas LA, 2006, DEVELOPMENT, V133, P4721, DOI 10.1242/dev.02675; Flaherty MS, 2009, DEV DYNAM, V238, P2235, DOI 10.1002/dvdy.21989; Grusche FA, 2011, DEV BIOL, V350, P255, DOI 10.1016/j.ydbio.2010.11.020; Halder G, 2011, DEVELOPMENT, V138, P9, DOI 10.1242/dev.045500; Hamaratoglu F, 2006, NAT CELL BIOL, V8, P27, DOI 10.1038/ncb1339; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Humbert PO, 2008, ONCOGENE, V27, P6888, DOI 10.1038/onc.2008.341; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; Igaki T, 2009, APOPTOSIS, V14, P1021, DOI 10.1007/s10495-009-0361-7; Igaki T, 2009, DEV CELL, V16, P458, DOI 10.1016/j.devcel.2009.01.002; Johnston LA, 2009, SCIENCE, V324, P1679, DOI 10.1126/science.1163862; Lee TM, 2001, TRENDS NEUROSCI, V24, P251, DOI 10.1016/S0166-2236(00)01791-4; Leong GR, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-62; MORATA G, 1975, DEV BIOL, V42, P211, DOI 10.1016/0012-1606(75)90330-9; Moreno E, 2008, NAT REV CANCER, V8, P141, DOI 10.1038/nrc2252; Narisawa A, 2012, HUM MOL GENET, V21, P1496, DOI 10.1093/hmg/ddr585; Neto-Silva RM, 2010, DEV CELL, V19, P507, DOI 10.1016/j.devcel.2010.09.009; Newsome TP, 2000, DEVELOPMENT, V127, P851; Ohsawa S, 2011, DEV CELL, V20, P315, DOI 10.1016/j.devcel.2011.02.007; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Rogulja D, 2008, DEV CELL, V15, P309, DOI 10.1016/j.devcel.2008.06.003; Silver DL, 2001, CELL, V107, P831, DOI 10.1016/S0092-8674(01)00607-9; Tyler DM, 2007, GENETICS, V175, P643, DOI 10.1534/genetics.106.061929; Uhlirova M, 2005, P NATL ACAD SCI USA, V102, P13123, DOI 10.1073/pnas.0504170102; Willecke M, 2008, P NATL ACAD SCI USA, V105, P14897, DOI 10.1073/pnas.0805201105; Wu M, 2010, NATURE, V463, P545, DOI 10.1038/nature08702; XU T, 1993, DEVELOPMENT, V117, P1223; XU TA, 1995, DEVELOPMENT, V121, P1053; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yuan M, 2008, CELL DEATH DIFFER, V15, P1752, DOI 10.1038/cdd.2008.108; Zeidler MP, 2000, ONCOGENE, V19, P2598, DOI 10.1038/sj.onc.1203482; Ziosi M, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001140	42	23	22	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2013	32	38					4471	4479		10.1038/onc.2012.476	http://dx.doi.org/10.1038/onc.2012.476			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223SW	23108407				2022-12-28	WOS:000324831300002
J	Deblois, G; St-Pierre, J; Giguere, V				Deblois, G.; St-Pierre, J.; Giguere, V.			The PGC-1/ERR signaling axis in cancer	ONCOGENE			English	Review						nuclear receptors; metabolism; mitochondrion; Warburg effect	ESTROGEN-RELATED-RECEPTOR; ALPHA ERR-ALPHA; PPAR-GAMMA COACTIVATOR; HUMAN BREAST-CANCER; ORPHAN NUCLEAR RECEPTORS; TRANSCRIPTIONAL CONTROL; MITOCHONDRIAL BIOGENESIS; GENE-EXPRESSION; CLINICAL-SIGNIFICANCE; METABOLIC REGULATOR	Proliferating cells need to produce a large amount of energy and, at the same time, need to maintain a constant supply of biosynthetic precursors of macromolecules that are used as building blocks for generating new cells. Indeed, many cancer cells undergo a switch from mitochondrial to glycolytic metabolism and display a truncated tricarboxylic acid cycle to match these specific metabolic requirements of proliferation. Understanding the mechanisms by which cancer cells reprogram various metabolic pathways to satisfy their unique bioenergetic requirements has become an active field of research. Concomitantly, it has emerged that members of a family of orphan nuclear receptors known as the estrogen-related receptors (ERRs), working in concert with members of the PPAR gamma coactivator (PGC)-1 family, act as central transcriptional regulators of metabolic gene networks involved in maintaining energy homeostasis in normal cells. Recent studies have suggested that the PGC-1/ERR transcriptional axis is also important in the metabolic reprogramming of cancer cells. This review focuses on the functional integration of the PGC-1/ERR axis with known oncogenes and the observation that modulation of the activity of this axis can have both pro- and anti-proliferative properties.	[Deblois, G.; St-Pierre, J.; Giguere, V.] McGill Univ, Dept Biochem, Montreal, PQ, Canada; [Deblois, G.; St-Pierre, J.; Giguere, V.] McGill Univ, Goodman Canc Res Ctr, Montreal, PQ, Canada; [Giguere, V.] McGill Univ, Dept Med, Montreal, PQ, Canada; [Giguere, V.] McGill Univ, Dept Oncol, Montreal, PQ, Canada	McGill University; McGill University; McGill University; McGill University	Deblois, G (corresponding author), McGill Univ, Goodman Canc Ctr, Montreal, PQ, Canada.	vincent.giguere@mcgill.ca	St-Pierre, Julie/AGB-3651-2022	St-Pierre, Julie/0000-0002-2815-7099; Giguere, Vincent/0000-0001-9567-3694	Canadian Institutes for Health Research [MOP-64275, MOP-106603]; Program Project Grant from the Terry Fox Foundation [TFF-116128]; predoctoral traineeship award from the US Department of Defense Breast Cancer Research Program [W81XWH-10-1-0489]	Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Program Project Grant from the Terry Fox Foundation; predoctoral traineeship award from the US Department of Defense Breast Cancer Research Program	This work was supported by grants from the Canadian Institutes for Health Research to VG (MOP-64275) and JSt-P (MOP-106603) and a Program Project Grant from the Terry Fox Foundation to VG and JSt-P (TFF-116128). GD was supported by a predoctoral traineeship award (W81XWH-10-1-0489) from the US Department of Defense Breast Cancer Research Program. JSt-P is an FRSQ research scholar.	Alaynick WA, 2007, CELL METAB, V6, P13, DOI 10.1016/j.cmet.2007.06.007; [Anonymous], 2013, ONCOGENE, P3483; Ao A, 2008, P NATL ACAD SCI USA, V105, P7821, DOI 10.1073/pnas.0711677105; Arany Z, 2008, NATURE, V451, P1008, DOI 10.1038/nature06613; Ariazi EA, 2002, CANCER RES, V62, P6510; Ariazi EA, 2007, MOL CANCER RES, V5, P71, DOI 10.1158/1541-7786.MCR-06-0227; Ba Yi, 2008, Zhonghua Zhongliu Zazhi, V30, P593; Bardet PL, 2005, EVOL DEV, V7, P223, DOI 10.1111/j.1525-142X.2005.05025.x; Barry JB, 2005, CANCER RES, V65, P6120, DOI 10.1158/0008-5472.CAN-05-0922; Bianco S, 2012, J STEROID BIOCHEM, V130, P180, DOI 10.1016/j.jsbmb.2011.03.014; Bookout AL, 2006, CELL, V126, P789, DOI 10.1016/j.cell.2006.06.049; Cavallini A, 2005, EUR J CANCER, V41, P1487, DOI 10.1016/j.ejca.2005.04.008; Cervera AM, 2008, CANCER RES, V68, P4058, DOI 10.1158/0008-5472.CAN-07-5580; Chang CY, 2011, CANCER CELL, V20, P500, DOI 10.1016/j.ccr.2011.08.023; Charest-Marcotte A, 2010, GENE DEV, V24, P537, DOI 10.1101/gad.1871610; Chen EI, 2007, CANCER RES, V67, P1472, DOI 10.1158/0008-5472.CAN-06-3137; Chen J, 2007, DEV CELL, V13, P325, DOI 10.1016/j.devcel.2007.07.011; Cheong H, 2012, NAT BIOTECHNOL, V30, P671, DOI 10.1038/nbt.2285; Chisarnore MJ, 2009, MOL CANCER THER, V8, P672, DOI 10.1158/1535-7163.MCT-08-1028; Cormio A, 2009, BIOCHEM BIOPH RES CO, V390, P1182, DOI 10.1016/j.bbrc.2009.10.114; Dang CV, 2012, GENE DEV, V26, P877, DOI 10.1101/gad.189365.112; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Deblois G, 2011, BBA-MOL BASIS DIS, V1812, P1032, DOI 10.1016/j.bbadis.2010.12.009; Deblois G, 2010, CANCER RES, V70, P10277, DOI 10.1158/0008-5472.CAN-10-2840; Deblois G, 2009, CANCER RES, V69, P6149, DOI 10.1158/0008-5472.CAN-09-1251; Dufour CR, 2007, CELL METAB, V5, P345, DOI 10.1016/j.cmet.2007.03.007; Dufour CR, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002143; Dwyer MA, 2010, CANCER RES, V70, P9298, DOI 10.1158/0008-5472.CAN-10-0226; Eichner LJ, 2011, MITOCHONDRION, V11, P544, DOI 10.1016/j.mito.2011.03.121; Eichner LJ, 2010, CELL METAB, V12, P352, DOI 10.1016/j.cmet.2010.09.002; Fantin VR, 2006, CANCER CELL, V9, P425, DOI 10.1016/j.ccr.2006.04.023; Feilchenfeldt J, 2004, CANCER LETT, V203, P25, DOI 10.1016/j.canlet.2003.08.024; Feng B, 2009, NAT CELL BIOL, V11, P197, DOI 10.1038/ncb1827; Fisher KW, 2011, MOL CELL BIOL, V31, P2453, DOI 10.1128/MCB.05255-11; Fradet A, 2011, CANCER RES, V71, P5728, DOI 10.1158/0008-5472.CAN-11-1431; Fujimoto J, 2007, J STEROID BIOCHEM, V104, P301, DOI 10.1016/j.jsbmb.2007.03.016; Fujimura T, 2010, CANCER SCI, V101, P646, DOI 10.1111/j.1349-7006.2009.01451.x; Gaillard S, 2007, MOL ENDOCRINOL, V21, P62, DOI 10.1210/me.2006-0179; Gaillard S, 2006, MOL CELL, V24, P797, DOI 10.1016/j.molcel.2006.10.012; Galmozzi E, 2004, J CELL PHYSIOL, V200, P82, DOI 10.1002/jcp.20012; Gao M, 2006, INT J GYNECOL CANCER, V16, P827, DOI 10.1111/j.1525-1438.2006.00527.x; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; Giguere V, 2008, ENDOCR REV, V29, P677, DOI 10.1210/er.2008-0017; Girnun GD, 2012, SEMIN CELL DEV BIOL, V23, P381, DOI 10.1016/j.semcdb.2012.01.007; Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037; Heck S, 2009, CANCER RES, V69, P5184, DOI 10.1158/0008-5472.CAN-08-3062; Hervouet E, 2007, BIOCHIMIE, V89, P1080, DOI 10.1016/j.biochi.2007.03.010; Hock MB, 2009, ANNU REV PHYSIOL, V71, P177, DOI 10.1146/annurev.physiol.010908.163119; Horard B, 2004, J MOL ENDOCRINOL, V33, P87, DOI 10.1677/jme.0.0330087; Huss JM, 2007, CELL METAB, V6, P25, DOI 10.1016/j.cmet.2007.06.005; Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200; Hynes NE, 2001, J MAMMARY GLAND BIOL, V6, P141, DOI 10.1023/A:1009528918064; Ijichi N, 2011, J STEROID BIOCHEM, V123, P1, DOI 10.1016/j.jsbmb.2010.09.002; Jarzabek K, 2009, J STEROID BIOCHEM, V113, P127, DOI 10.1016/j.jsbmb.2008.12.005; Jiang WG, 2003, INT J CANCER, V106, P752, DOI 10.1002/ijc.11302; Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509; Kamei Y, 2003, P NATL ACAD SCI USA, V100, P12378, DOI 10.1073/pnas.2135217100; Klimcakova E, 2012, CANCER RES, V72, P1538, DOI 10.1158/0008-5472.CAN-11-2967; Klomp JA, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-59; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Laganiere J, 2004, J BIOL CHEM, V279, P18504, DOI 10.1074/jbc.M313543200; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Luo JM, 1997, NATURE, V388, P778, DOI 10.1038/42022; Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261; Michalek RD, 2011, P NATL ACAD SCI USA, V108, P18348, DOI 10.1073/pnas.1108856108; Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Schreiber SN, 2004, P NATL ACAD SCI USA, V101, P6472, DOI 10.1073/pnas.0308686101; Schreiber SN, 2003, J BIOL CHEM, V278, P9013, DOI 10.1074/jbc.M212923200; Sladek R, 1997, MOL CELL BIOL, V17, P5400, DOI 10.1128/MCB.17.9.5400; Sonoda J, 2007, GENE DEV, V21, P1909, DOI 10.1101/gad.1553007; St-Pierre J, 2006, CELL, V127, P397, DOI 10.1016/j.cell.2006.09.024; Stein RA, 2006, ENDOCR-RELAT CANCER, V13, pS25, DOI 10.1677/erc.1.01292; Stein RA, 2008, CANCER RES, V68, P8805, DOI 10.1158/0008-5472.CAN-08-1594; Stein RA, 2009, J STEROID BIOCHEM, V114, P106, DOI 10.1016/j.jsbmb.2009.02.010; Sun PM, 2005, J MOL MED, V83, P457, DOI 10.1007/s00109-005-0639-3; Suzuki T, 2004, CANCER RES, V64, P4670, DOI 10.1158/0008-5472.CAN-04-0250; Tcherepanova I, 2000, J BIOL CHEM, V275, P16302, DOI 10.1074/jbc.M001364200; Tennessen JM, 2011, CELL METAB, V13, P139, DOI 10.1016/j.cmet.2011.01.005; Tiraby C, 2011, CANCER RES, V71, P2518, DOI 10.1158/0008-5472.CAN-10-1315; Tremblay AM, 2010, MOL ENDOCRINOL, V24, P22, DOI 10.1210/me.2009-0254; Tremblay Annie M, 2007, Nucl Recept Signal, V5, pe009, DOI 10.1621/nrs.05009; Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504; Vega RB, 1997, J BIOL CHEM, V272, P31693, DOI 10.1074/jbc.272.50.31693; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Villena JA, 2008, TRENDS ENDOCRIN MET, V19, P269, DOI 10.1016/j.tem.2008.07.005; WARBURG O, 1956, SCIENCE, V124, P269; Watkins G, 2004, ONCOL REP, V12, P483; Wirtenberger M, 2006, CARCINOGENESIS, V27, P2201, DOI 10.1093/carcin/bgl067; Yang XY, 2006, CELL, V126, P801, DOI 10.1016/j.cell.2006.06.050; Zhang HF, 2007, CANCER CELL, V11, P407, DOI 10.1016/j.ccr.2007.04.001; Zhang Y, 2007, CELL RES, V17, P363, DOI 10.1038/cr.2007.11	94	122	125	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 25	2013	32	30					3483	3490		10.1038/onc.2012.529	http://dx.doi.org/10.1038/onc.2012.529			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	188UQ	23208510				2022-12-28	WOS:000322220800001
J	Qiu, X; Dong, S; Qiao, F; Lu, S; Song, Y; Lao, Y; Li, Y; Zeng, T; Hu, J; Zhang, L; Zhang, L; Fan, H				Qiu, X.; Dong, S.; Qiao, F.; Lu, S.; Song, Y.; Lao, Y.; Li, Y.; Zeng, T.; Hu, J.; Zhang, L.; Zhang, L.; Fan, H.			HBx-mediated miR-21 upregulation represses tumor-suppressor function of PDCD4 in hepatocellular carcinoma	ONCOGENE			English	Article						hepatocellular carcinoma; hepatitis B virus X protein; PDCD4; miR-21	VIRUS-X-PROTEIN; HEPATITIS-B; GENE-EXPRESSION; CDNA MICROARRAY; DOWN-REGULATION; KAPPA-B; ACTIVATION; TRANSLATION; HEPATOCARCINOGENESIS; DEGRADATION	The hepatitis B virus (HBV) X protein (HBx) has a key role in the molecular pathogenesis of HBV-related hepatocellular carcinoma (HCC). However, the mechanism of HBx-mediated hepatocarcinogenesis remains to be elucidated. In this study, we aimed to better understand the effects of HBx on gene-expression profiles that participate in hepatocarcinogenesis and the mechanism by which HBx regulates these genes. Differentially expressed genes between L02-HBx and L02-Vector control cells were identified by microarray and validated using quantitative real-time PCR. HBx upregulates 456 genes and downregulates 843 genes, including programmed cell death 4 (PDCD4). PDCD4 was downregulated in clinical HCC specimens and the downregulation of PDCD4 in HCC is correlated with HBx. Furthermore, overexpression experiments in HCC cells proved that PDCD4 has strong tumor-suppressive effects both in vitro and in vivo, and may induce cell apoptosis to suppress the development of HCC. HBx induces expression of DNA methyltransferases (DNMTs), but failed to change the methylation status of the PDCD4 promoter. HBx downregulates PDCD4 expression at least partially through miR-21. Taken together, this study reported for the first time that HBx downregulates PDCD4 and upregulates miR-21 expression. The overexpression of PDCD4 could suppress tumorigenicity. The deregulation of PDCD4 by HBx through miR-21 represents a potential novel mechanism of the downregulation of PDCD4 in HBV-related HCC and provides new insights into HCC development.	[Qiu, X.; Qiao, F.; Song, Y.; Lao, Y.; Hu, J.; Fan, H.] Southeast Univ, Dept Med Genet & Dev Biol, Sch Med, Key Lab Dev Genes & Human Dis,Minist Educ, Nanjing 210009, Jiangsu, Peoples R China; [Dong, S.] Univ Hong Kong, Dept Clin Oncol, Hong Kong, Hong Kong, Peoples R China; [Lu, S.] Nanjing Med Univ, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China; [Li, Y.; Zeng, T.] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol Southern China, Guangzhou 510275, Guangdong, Peoples R China; [Zhang, L.] Shandong Univ, Sch Med, Dept Immunol, Jinan 250100, Peoples R China; [Zhang, L.] Southeast Univ, Affiliated Zhongda Hosp, Nanjing 210009, Jiangsu, Peoples R China	Southeast University - China; University of Hong Kong; Nanjing Medical University; State Key Lab Oncology South China; Sun Yat Sen University; Shandong University; Southeast University - China	Fan, H (corresponding author), Southeast Univ, Dept Med Genet & Dev Biol, Sch Med, Key Lab Dev Genes & Human Dis,Minist Educ, 87 Dingjiaqiao Rd, Nanjing 210009, Jiangsu, Peoples R China.	fanh@seu.edu.cn			National Natural Science Foundation of China [30470950, 91229107]; National 973 Basic Research Program of China [2013CB911302]; Innovative Scientific Research Projects for College Graduates of Jiangsu Province [CXZZ_0137]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National 973 Basic Research Program of China(National Basic Research Program of China); Innovative Scientific Research Projects for College Graduates of Jiangsu Province	This work was supported by The National Natural Science Foundation of China, no. 30470950, National 973 Basic Research Program of China 2013CB911302, National Natural Science Foundation of China, no. 91229107 and in part by Innovative Scientific Research Projects for College Graduates of Jiangsu Province, no. CXZZ_0137. We thank Professor Guan Xinyuan in the Univrsity of Hong Kong for providing the HBx construct, Dr Olubunmi Afonja in New York University for providing the PDCD4 construct and Dr Heike Allgayer in the University of Heidelberg for providing the PDCD4 promoter constructs.	Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Buendia MA, 2000, SEMIN CANCER BIOL, V10, P185; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Dorrello NV, 2006, SCIENCE, V314, P467, DOI 10.1126/science.1130276; Fan H, 2007, EUR J GASTROEN HEPAT, V19, P952, DOI 10.1097/MEG.0b013e3282c3a89e; Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200; Gao F, 2009, J CELL MOL MED, V13, P4257, DOI 10.1111/j.1582-4934.2008.00497.x; Hajjou M, 2005, J MED VIROL, V77, P57, DOI 10.1002/jmv.20427; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hilliard A, 2006, J IMMUNOL, V177, P8095, DOI 10.4049/jimmunol.177.11.8095; Huang JZ, 2003, WORLD J GASTROENTERO, V9, P84, DOI 10.3748/wjg.v9.i1.84; Jansen AP, 2005, CANCER RES, V65, P6034, DOI 10.1158/0008-5472.CAN-04-2119; Kong GY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019518; Kusano N, 1999, HEPATOLOGY, V29, P1858, DOI 10.1002/hep.510290636; Ladeiro Y, 2008, HEPATOLOGY, V47, P1955, DOI 10.1002/hep.22256; Lankat-Buttgereit B, 2003, BIOL CELL, V95, P515, DOI 10.1016/j.biolcel.2003.09.003; Lee JO, 2005, ONCOGENE, V24, P6617, DOI 10.1038/sj.onc.1208827; Leupold JH, 2012, BIOSCIENCE REP, V32, P281, DOI 10.1042/BSR20110045; Li J, 2010, BMC EVOL BIOL, V10, DOI [10.1186/1471-2148-10-68, 10.1186/1471-2407-10-354]; Lok AS, 2001, GASTROENTEROLOGY, V120, P1828, DOI 10.1053/gast.2001.24839; LUBER B, 1993, RES VIROLOGY, V144, P311, DOI 10.1016/S0923-2516(06)80047-6; Lupberger J, 2007, WORLD J GASTROENTERO, V13, P74, DOI 10.3748/wjg.v13.i1.74; Matsuhashi Sachiko, 1997, Research Communications in Biochemistry and Cell and Molecular Biology, V1, P109; Murakami Y, 2006, ONCOGENE, V25, P2537, DOI 10.1038/sj.onc.1209283; Okabe H, 2001, CANCER RES, V61, P2129; Ozaki I, 2000, CANCER RES, V60, P6519; Ozturk M, 1999, SEMIN LIVER DIS, V19, P235, DOI 10.1055/s-2007-1007113; Park IY, 2007, GASTROENTEROLOGY, V132, P1476, DOI 10.1053/j.gastro.2007.01.034; Schmid T, 2008, CANCER RES, V68, P1254, DOI 10.1158/0008-5472.CAN-07-1719; Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083; Soejima K, 2003, ONCOGENE, V22, P4723, DOI 10.1038/sj.onc.1206510; Talotta F, 2009, ONCOGENE, V28, P73, DOI 10.1038/onc.2008.370; Tan A, 2008, LIVER INT, V28, P175, DOI 10.1111/j.1478-3231.2007.01652.x; Tanaka Y, 2006, ONCOGENE, V25, P633, DOI 10.1038/sj.onc.1209093; Tsai CN, 2002, P NATL ACAD SCI USA, V99, P10084, DOI 10.1073/pnas.152059399; Wang Q, 2008, ONCOGENE, V27, P1527, DOI 10.1038/sj.onc.1210793; Wang YL, 2004, HEPATOLOGY, V39, P318, DOI 10.1002/hep.20076; Wang Y, 2010, J HEPATOL, V53, P57, DOI 10.1016/j.jhep.2009.12.043; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Yoshinaga H, 1999, PATHOL INT, V49, P1067, DOI 10.1046/j.1440-1827.1999.00995.x; YU MW, 1994, CRIT REV ONCOL HEMAT, V17, P71, DOI 10.1016/1040-8428(94)90020-5; Zhang H, 2006, ONCOGENE, V25, P6101, DOI 10.1038/sj.onc.1209634; Zhang S, 2009, J EXP CLIN CANC RES, V28, P1; Zhang X, 2010, CANCER SCI, V101, P2163, DOI 10.1111/j.1349-7006.2010.01664.x; Zhang XY, 2009, HEPATOLOGY, V50, P490, DOI 10.1002/hep.23008; Zheng DL, 2009, J HEPATOL, V50, P377, DOI 10.1016/j.jhep.2008.10.019	47	95	105	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 4	2013	32	27					3296	3305		10.1038/onc.2013.150	http://dx.doi.org/10.1038/onc.2013.150			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	176JZ	23604124				2022-12-28	WOS:000321301600009
J	Yang, J; Zhang, Z; Chen, C; Liu, Y; Si, Q; Chuang, TH; Li, N; Gomez-Cabrero, A; Reisfeld, RA; Xiang, R; Luo, Y				Yang, J.; Zhang, Z.; Chen, C.; Liu, Y.; Si, Q.; Chuang, T-H; Li, N.; Gomez-Cabrero, A.; Reisfeld, R. A.; Xiang, R.; Luo, Y.			MicroRNA-19a-3p inhibits breast cancer progression and metastasis by inducing macrophage polarization through downregulated expression of Fra-1 proto-oncogene	ONCOGENE			English	Article						tumor-associated macrophages; tumor microenvironment; Fra-1; miR-19a-3p	TUMOR; INVASION; MIGRATION; CELLS; INVASIVENESS; DIAGNOSTICS; PROGNOSIS; PROMOTES; IL-6; FOS	One of the hallmarks of malignancy is the polarization of tumor-associated macrophages (TAMs) from a pro-immune (M1-like) phenotype to an immune-suppressive (M2-like) phenotype. However, the molecular basis of the process is still unclear. MicroRNA (miRNA) comprises a group of small, non-coding RNAs that are broadly expressed by a variety of organisms and are involved in cell behaviors such as suppression or promotion of tumorigenesis. Here, we demonstrate that miR-19a-3p, broadly conserved among vertebrates, was downregulated in RAW264.7 macrophage cells of the M2 phenotype in conditoned medium of 4T1 mouse breast tumor cells. This downregulation correlated with an increased expression of the Fra-1 gene, which was reported to act as a pro-oncogene by supporting the invasion and progression of breast tumors. We found significant upregulation of miR-19a-3p in RAW264.7 macrophages after transfection with a miR-19a-3p mimic that resulted in a significant suppression of the expression of this gene. In addition, we could measure the activity of binding between miR-19a-3p and Fra-1 with a psiCHECK luciferase reporter system. Further, transfection of RAW264.7 macrophage cells with the miR-19a-3p mimic decreased the expression of the Fra-1 downstream genes VEGF, STAT3 and pSTAT3. Most importantly, the capacity of 4T1 breast tumor cells to migrate and invade was impaired in vivo by the intratumoral injection of miR-19a-3p. Taken together, these findings indicate that miR-19a-3p is capable of downregulating the M2 phenotype in M2 macrophages and that the low expression of this miRNA has an important role in the upregulation of Fra-1 expression and induction of M2 macrophage polarization.	[Yang, J.; Chen, C.; Liu, Y.; Si, Q.; Luo, Y.] Chinese Acad Med Sci, Inst Basic Med Sci, Dept Immunol, Beijing 100730, Peoples R China; [Yang, J.; Chen, C.; Liu, Y.; Si, Q.; Luo, Y.] Peking Union Med Coll, Beijing 100021, Peoples R China; [Yang, J.; Zhang, Z.; Li, N.; Xiang, R.] Nankai Univ, Dept Immunol, Tianjin 300071, Peoples R China; [Chuang, T-H] Natl Hlth Res Inst, Immunol Res Ctr, Miaoli, Taiwan; [Gomez-Cabrero, A.; Reisfeld, R. A.] Scripps Res Inst, Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA	Chinese Academy of Medical Sciences - Peking Union Medical College; Institute of Basic Medical Sciences - CAMS; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College; Nankai University; National Health Research Institutes - Taiwan; Scripps Research Institute	Xiang, R (corresponding author), Nankai Univ, Dept Immunol, Tianjin 300071, Peoples R China.	rxiang@nankai.edu.cn; yunpingluo@hotmail.com	Chuang, Tsung-Hsien/F-9679-2010; Yang, Jian/E-1051-2015		Major State Basic Research Development Program of China (973 program) [2013CB967202]; National Science Foundation of China (NSFC) [91029734, 81071711]; Department of Defense grant [BC097723];  [30830096];  [09ZCZDSF04000]	Major State Basic Research Development Program of China (973 program)(National Basic Research Program of China); National Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC)); Department of Defense grant(United States Department of Defense); ; 	This work was supported by grants from the Major State Basic Research Development Program of China (973 program): grant no. 2013CB967202 (to YL); the National Science Foundation of China (NSFC): grant no. 91029734 and 81071711 (to YL); grant nos 30830096 and 09ZCZDSF04000 (to RX); and Department of Defense grant, grant no. BC097723 (to RAR).	Babykutty S, 2012, CLIN EXP METASTAS, V29, P471, DOI 10.1007/s10585-012-9464-6; Bluml S, 2011, ARTHRITIS RHEUM-US, V63, P1281, DOI 10.1002/art.30281; Chandrasekar B, 2006, J BIOL CHEM, V281, P15099, DOI 10.1074/jbc.M600200200; Cubillos-Ruiz JR, 2012, ONCOIMMUNOLOGY, V1, P968, DOI 10.4161/onci.20020; De Vito C, 2012, CANCER CELL, V21, P807, DOI 10.1016/j.ccr.2012.04.023; Diehl S, 2002, MOL IMMUNOL, V39, P531, DOI 10.1016/S0161-5890(02)00210-9; Eulalio A, 2012, RNA BIOL, V9, P742, DOI 10.4161/rna.20018; Garzon R, 2012, CURR OPIN ONCOL, V24, P655, DOI 10.1097/CCO.0b013e328358522c; Giordano S, 2013, HEPATOLOGY, V57, P840, DOI 10.1002/hep.26095; Hermeking H, 2012, NAT REV CANCER, V12, P613, DOI 10.1038/nrc3318; Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209; Kesari S, 2011, CANCER BIOL THER, V11, P307, DOI 10.4161/cbt.11.3.14718; Kincaid RP, 2012, P NATL ACAD SCI USA, V109, P3077, DOI 10.1073/pnas.1116107109; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Liu DF, 2012, J CLIN INVEST, V122, P2221, DOI 10.1172/JCI59535; Luo YP, 2010, ONCOGENE, V29, P662, DOI 10.1038/onc.2009.308; Mikhaylova O, 2012, CANCER CELL, V21, P532, DOI 10.1016/j.ccr.2012.02.019; Milde-Langosch K, 2004, BREAST CANCER RES TR, V86, P139, DOI 10.1023/B:BREA.0000032982.49024.71; Mizoguchi F, 2010, J CELL BIOCHEM, V109, P866, DOI 10.1002/jcb.22228; Murdoch C, 2005, INT J CANCER, V117, P701, DOI 10.1002/ijc.21422; Rolny C, 2011, CANCER CELL, V19, P31, DOI 10.1016/j.ccr.2010.11.009; Ruffell B, 2012, TRENDS IMMUNOL, V33, P119, DOI 10.1016/j.it.2011.12.001; Setoyama Tetsuro, 2011, Keio Journal of Medicine, V60, P106; Sica A, 2008, SEMIN CANCER BIOL, V18, P349, DOI 10.1016/j.semcancer.2008.03.004; Singh PK, 2012, NAT REV GASTRO HEPAT, V9, P334, DOI 10.1038/nrgastro.2012.63; Song JH, 2012, GASTROENTEROLOGY, V143, P35, DOI 10.1053/j.gastro.2012.05.003; Sugatani T, 2011, BLOOD, V117, P3648, DOI 10.1182/blood-2010-10-311415; Tai SK, 2012, J IMMUNOL, V188, P2464, DOI 10.4049/jimmunol.1101101; Thomas RM, 2012, CLIN CANCER RES, V18, P4482, DOI 10.1158/1078-0432.CCR-12-2089; Usui A, 2012, CANCER-AM CANCER SOC, V118, P3387, DOI 10.1002/cncr.26652; Valleron W, 2012, BLOOD, V120, P3997, DOI 10.1182/blood-2012-06-438135; Volinia S, 2012, P NATL ACAD SCI USA, V109, P3024, DOI 10.1073/pnas.1200010109; Wang QS, 2010, CELL RES, V20, P701, DOI 10.1038/cr.2010.52; Wu JM, 2012, CARCINOGENESIS, V33, P519, DOI 10.1093/carcin/bgr304; Yang M, 2012, ARTERIOSCL THROM VAS, V32, P1675, DOI 10.1161/ATVBAHA.112.248732; Yang PY, 2012, CANCER CELL, V22, P291, DOI 10.1016/j.ccr.2012.07.023; Yang S, 2013, ONCOGENE, V32, P4294, DOI 10.1038/onc.2012.432; Yang WW, 2012, J BIOL CHEM, V287, P40140, DOI 10.1074/jbc.M112.348763	39	110	119	1	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2014	33	23					3014	3023		10.1038/onc.2013.258	http://dx.doi.org/10.1038/onc.2013.258			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EL	23831570				2022-12-28	WOS:000337232200008
J	Fernandez, BG; Jezowska, B; Janody, F				Fernandez, B. G.; Jezowska, B.; Janody, F.			Drosophila actin-Capping Protein limits JNK activation by the Src proto-oncogene	ONCOGENE			English	Article						capping protein; Src family kinases; JNK signaling; F-actin; Drosophila wing discs epithelium	REGULATE CELL-PROLIFERATION; RING CANAL MORPHOGENESIS; TUMOR-SUPPRESSOR GENES; FAMILY TYROSINE KINASE; N-TERMINAL KINASE; SMALL GTPASES; F-ACTIN; SIGNALING PATHWAY; DUAL FUNCTION; ORGAN GROWTH	The Src family kinases c-Src, and its downstream effectors, the Rho family of small GTPases RhoA and Jun N-terminal kinase (JNK) have a significant role in tumorigenesis. In this report, using the Drosophila wing disc epithelium as a model system, we demonstrate that the actin-Capping Protein (CP) alpha beta heterodimer, which regulates actin filament (F-actin) polymerization, limits Src-induced apoptosis or tissue overgrowth by restricting JNK activation. We show that overexpressing Src64B drives JNK-independent loss of epithelial integrity and JNK-dependent apoptosis via Btk29A, p120ctn and Rho1. However, when cells are kept alive with the Caspase inhibitor P35, JNK acts as a potent inducer of proliferation via activation of the Yorkie oncogene. Reducing CP levels direct apoptosis of overgrowing Src64B-overexpressing tissues. Conversely, overexpressing capping protein inhibits Src64B and Rho1, but not Rac1-induced JNK signaling. CP requires the actin-binding domain of the alpha-subunit to limit Src64B-induced apoptosis, arguing that the control of F-actin mediates this effect. In turn, JNK directs F-actin accumulation. Moreover, overexpressing capping protein also prevents apoptosis induced by ectopic JNK expression. Our data are consistent with a model in which the control of F-actin by CP limits Src-induced apoptosis or tissue overgrowth by acting downstream of Btk29A, p120ctn and Rho1, but upstream of JNK. In turn, JNK may counteract the effect of CP on F-actin, providing a positive feedback, which amplifies JNK activation. We propose that cytoskeletal changes triggered by misregulation of F-actin modulators may have a significant role in Src-mediated malignant phenotypes during the early stages of cellular transformation.	[Fernandez, B. G.; Jezowska, B.; Janody, F.] Inst Gulbenkian Ciencias, Oeiras, Portugal	Instituto Gulbenkian de Ciencia	Janody, F (corresponding author), Inst Gulbenkian Ciencias, Rua Quinta Grande 6,Apartado 14, P-2780156 Lisbon, Portugal.	fjanody@igc.gulbenkian.pt	Janody, Florence/AAT-1367-2020; Janody, Florence/A-4378-2017	Janody, Florence/0000-0003-4326-0163; Garcia Fernandez, Beatriz/0000-0001-9215-2447	Fundacao para a Ciencia e Tecnologia (FCT) [PTDC/SAU-OBD/73191/2006, PTDC/BIA-BCM/121455/2010]; FCT [SFRH/BPD/35915/2007, SFRH/BD/33215/2007]	Fundacao para a Ciencia e Tecnologia (FCT)(Portuguese Foundation for Science and TechnologyEuropean Commission); FCT(Portuguese Foundation for Science and TechnologyEuropean Commission)	We thank T Xu, B Hay, R Mann, A Laughon, G Morata, J Whited, the Bloomington Drosophila Stock Center, the National Institute of Genetics, The Vienna Drosophila Research Center and the Developmental Studies Hybridoma Bank for fly stocks and reagents. The manuscript was improved by the critical comments of Miguel G. Ferreira, Joana Vaz, Monica Bettencourt Dias and Christen Mirth. This work was supported by grants from Fundacao para a Ciencia e Tecnologia (FCT) (Grants PTDC/SAU-OBD/73191/2006 and PTDC/BIA-BCM/121455/2010). BGF and BJ were the recipients of fellowships from FCT SFRH/BPD/35915/2007 and SFRH/BD/33215/2007, respectively).	Adachi-Yamada T, 1999, NATURE, V400, P166, DOI 10.1038/22112; AMATRUDA JF, 1992, J CELL BIOL, V119, P1151, DOI 10.1083/jcb.119.5.1151; Bischof J, 2007, P NATL ACAD SCI USA, V104, P3312, DOI 10.1073/pnas.0611511104; Bresnick AR, 1999, CURR OPIN CELL BIOL, V11, P26, DOI 10.1016/S0955-0674(99)80004-0; Brumby AM, 2005, NAT REV CANCER, V5, P626, DOI 10.1038/nrc1671; Brumby AM, 2003, EMBO J, V22, P5769, DOI 10.1093/emboj/cdg548; Brumby AM, 2011, GENETICS, V188, P105, DOI 10.1534/genetics.111.127910; Brunton VG, 2004, BBA-MOL CELL RES, V1692, P121, DOI 10.1016/j.bbamcr.2004.04.010; Calleja M, 1996, SCIENCE, V274, P252, DOI 10.1126/science.274.5285.252; Casares F, 1998, NATURE, V392, P723, DOI 10.1038/33706; Castano J, 2007, MOL CELL BIOL, V27, P1745, DOI 10.1128/MCB.01974-06; Chan HL, 2010, J BIOL CHEM, V285, P4307, DOI 10.1074/jbc.M109.047027; Chang YWE, 2009, RECENT PAT ANTI-CANC, V4, P110, DOI 10.2174/157489209788452830; Chen F, 2012, CANCER RES, V72, P379, DOI 10.1158/0008-5472.CAN-11-1982; Cooper JA, 2008, INT REV CEL MOL BIO, V267, P183, DOI 10.1016/S1937-6448(08)00604-7; Cozzolino M, 2003, MOL BIOL CELL, V14, P1964, DOI 10.1091/mbc.E02-08-0469; del Pulgar TG, 2005, BIOESSAYS, V27, P602, DOI 10.1002/bies.20238; Delalle I, 2005, GENETICS, V171, P1757, DOI 10.1534/genetics.105.049213; Desprat N, 2008, DEV CELL, V15, P470, DOI 10.1016/j.devcel.2008.07.009; Dodson GS, 1998, DEVELOPMENT, V125, P2883; Doggett K, 2011, BMC DEV BIOL, V11, DOI 10.1186/1471-213X-11-57; Duffy JB, 2002, GENESIS, V34, P1, DOI 10.1002/gene.10150; Enomoto M, 2013, EMBO REP, V14, P65, DOI 10.1038/embor.2012.185; Fan Y, 2010, CELL DEATH DIFFER, V17, P534, DOI 10.1038/cdd.2009.185; Fanning PJ, 2003, J BIOL CHEM, V278, P50940, DOI 10.1074/jbc.M305107200; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Fernandez BG, 2011, DEVELOPMENT, V138, P2337, DOI 10.1242/dev.063545; Forster D, 2012, NAT CELL BIOL, V14, P526, DOI 10.1038/ncb2456; Gates J, 2009, DEV BIOL, V333, P90, DOI 10.1016/j.ydbio.2009.06.030; Giannone G, 2006, TRENDS CELL BIOL, V16, P213, DOI 10.1016/j.tcb.2006.02.005; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; Hamaratoglu F, 2006, NAT CELL BIOL, V8, P27, DOI 10.1038/ncb1339; Harden N, 1999, J CELL SCI, V112, P273; Hariharan IK, 2006, ANNU REV GENET, V40, P335, DOI 10.1146/annurev.genet.39.073003.100738; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HAY BA, 1994, DEVELOPMENT, V120, P2121; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; Janody F, 2006, DEVELOPMENT, V133, P3349, DOI 10.1242/dev.02511; Jezowska B, 2011, DEV BIOL, V360, P143, DOI 10.1016/j.ydbio.2011.09.016; Khoo P, DIS MODEL MECH; Kim JY, 2009, BIOCHEM PHARMACOL, V79, P431; Kim K, 2004, J CELL BIOL, V164, P567, DOI 10.1083/jcb.200308061; Klein T, 1998, DEV BIOL, V194, P196, DOI 10.1006/dbio.1997.8829; Kulshammer E, 2013, J CELL SCI, V126, P927, DOI 10.1242/jcs.114462; Kurant E, 1998, DEVELOPMENT, V125, P1037; Lee JD, 2001, CURR BIOL, V11, P1147, DOI 10.1016/S0960-9822(01)00323-2; Leong GR, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-62; Lu N, 2004, EMBO J, V23, P1089, DOI 10.1038/sj.emboj.7600127; LUO LQ, 1994, GENE DEV, V8, P1787, DOI 10.1101/gad.8.15.1787; Magie Craig R., 2002, Development (Cambridge), V129, P3771; Mahadev K, 2002, EXP CELL RES, V279, P40, DOI 10.1006/excr.2002.5583; Mammoto A, 2009, CURR OPIN CELL BIOL, V21, P864, DOI 10.1016/j.ceb.2009.08.001; Myster SH, 2003, J CELL BIOL, V160, P433, DOI 10.1083/jcb.200211083; Nagao M, 1999, ONCOGENE, V18, P4425, DOI 10.1038/sj.onc.1202832; Neisch AL, 2010, J CELL BIOL, V189, P311, DOI 10.1083/jcb.200912010; Nelson KS, 2012, NAT CELL BIOL, V14, P518, DOI 10.1038/ncb2467; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Oh H, 2008, DEVELOPMENT, V135, P1081, DOI 10.1242/dev.015255; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Pagliarini RA, 2003, SCIENCE, V302, P1227, DOI 10.1126/science.1088474; Pedraza LG, 2004, ONCOGENE, V23, P4754, DOI 10.1038/sj.onc.1207635; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; Read RD, 2004, MOL CELL BIOL, V24, P6676, DOI 10.1128/mcb.24.15.6676-6689.2004; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; Ridley AJ, 2004, BREAST CANCER RES TR, V84, P13, DOI 10.1023/B:BREA.0000018423.47497.c6; Roulier EM, 1998, MOL CELL, V1, P819, DOI 10.1016/S1097-2765(00)80081-7; Rudrapatna VA, DEV DYN, V241, P107; Saito K, 2001, J BIOL CHEM, V276, P16201, DOI 10.1074/jbc.M100873200; Sansores-Garcia L, 2011, EMBO J, V30, P2325, DOI 10.1038/emboj.2011.157; SCHAFER DA, 1992, J CELL BIOL, V118, P335, DOI 10.1083/jcb.118.2.335; Shah V, 1998, SOMAT CELL MOLEC GEN, V24, P273, DOI 10.1023/B:SCAM.0000007130.08611.fc; Shindo M, 2008, DEVELOPMENT, V135, P1355, DOI 10.1242/dev.015982; SIMON MA, 1985, CELL, V42, P831, DOI 10.1016/0092-8674(85)90279-X; Smadja-Lamere N, 2008, J BIOL CHEM, V283, P34352, DOI 10.1074/jbc.M803364200; Somogyi K, 2004, MECH DEVELOP, V121, P57, DOI 10.1016/j.mod.2003.10.003; Spiering D, 2011, CELL ADHES MIGR, V5, P170, DOI 10.4161/cam.5.2.14403; Spradling AC, 1999, GENETICS, V153, P135; Stewart RA, 2003, ONCOGENE, V22, P6436, DOI 10.1038/sj.onc.1206820; Takahashi F, 1996, GENE DEV, V10, P1645, DOI 10.1101/gad.10.13.1645; Tateno M, 2000, SCIENCE, V287, P324, DOI 10.1126/science.287.5451.324; Thomas JH, 2004, DEVELOPMENT, V131, P863, DOI 10.1242/dev.00989; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; Uemura T, 1996, GENE DEV, V10, P659, DOI 10.1101/gad.10.6.659; Uhlirova M, 2006, EMBO J, V25, P5294, DOI 10.1038/sj.emboj.7601401; Vidal M, 2006, DEV CELL, V10, P33, DOI 10.1016/j.devcel.2005.11.007; Vidal M, 2007, CANCER RES, V67, P10278, DOI 10.1158/0008-5472.CAN-07-1376; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Warner SJ, 2010, CURR BIOL, V20, P677, DOI 10.1016/j.cub.2010.03.025; Wear MA, 2003, CURR BIOL, V13, P1531, DOI 10.1016/S0960-9822(03)00559-1; Wear MA, 2004, TRENDS BIOCHEM SCI, V29, P418, DOI 10.1016/j.tibs.2004.06.003; Wear MA, 2004, J BIOL CHEM, V279, P14382, DOI 10.1074/jbc.M313412200; Whited JL, 2004, DEVELOPMENT, V131, P4677, DOI 10.1242/dev.01366; Yamamoto N, 2009, DEVELOPMENT, V136, P1977, DOI 10.1242/dev.030718; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366	96	27	27	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2014	33	16					2027	2039		10.1038/onc.2013.155	http://dx.doi.org/10.1038/onc.2013.155			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF3GH	23644660				2022-12-28	WOS:000334599100003
J	Medjkane, S; Perichon, M; Marsolier, J; Dairou, J; Weitzman, JB				Medjkane, S.; Perichon, M.; Marsolier, J.; Dairou, J.; Weitzman, J. B.			Theileria induces oxidative stress and HIF1 alpha activation that are essential for host leukocyte transformation	ONCOGENE			English	Article						leukocyte transformation; Warburg effect; metabolism; Theileria; host-parasite interactions	GLUCOSE-METABOLISM; CANCER; CELLS; ANNULATA; PARVA; HIF-1; TUMOR; SURVIVAL; HYPOXIA; GROWTH	Complex links between infection and cancer suggest that we still can learn much about tumorigenesis by studying how infectious agents hijack the host cell machinery. We studied the effects of an intracellular parasite called Theileria that infects bovine leukocytes and turns them into invasive cancer-like cells. We investigated the host cells pathways that are deregulated in infected leukocytes and might link infection and lymphoproliferative disease. We show that intracellular Theileria parasites drive a Warburg-like phenotype in infected host leukocytes, characterized by increased expression of metabolic regulators, increased glucose uptake and elevated lactate production, which were lost when the parasite was eliminated. The cohabitation of the parasites within the host cells leads to disruption of the redox balance (as measured by reduced/oxidized glutathione ratio) and elevated ROS (reactive oxygen species) levels, associated with chronic stabilization of the hypoxia-inducible factor 1 alpha (HIF1 alpha). Inhibition of HIF1 alpha (pharmacologically or genetically), or treatment with antioxidants, led to a marked reduction in expression of aerobic glycolytic genes and inhibited the transformed phenotype. These data show that stabilization of HIF1a, following increased ROS production, modulates host glucose metabolism and is critical for parasite-induced transformation. Our study expands knowledge about the molecular strategy used by the parasite Theileria to induce the transformed phenotypes of infected cells via reprogramming of glucose metabolism and redox signaling.	[Medjkane, S.; Perichon, M.; Marsolier, J.; Weitzman, J. B.] Univ Paris Diderot, Sorbonne Paris Cite, UMR 7216 CNRS, F-75013 Paris, France; [Dairou, J.] Univ Paris Diderot, Sorbonne Paris Cite, Lab Biol Fonctionnelle & Adaptat, Equipe RMCX, F-75013 Paris, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite	Weitzman, JB (corresponding author), Univ Paris Diderot, Sorbonne Paris Cite, UMR 7216 CNRS, Batiment Lamarck,35 Rue Helene Brion, F-75013 Paris, France.	jonathan.weitzman@univ-paris-diderot.fr		Marsolier, Justine/0000-0001-8464-9306; Medjkane, Souhila/0000-0001-7973-7707	Association pour la Recherche contre le Cancer (ARC) [4975, 7990]; Association for International Cancer Research (AICR) [08-0111]; appel d'offre 'Actions Specifiques Universite Paris Diderot	Association pour la Recherche contre le Cancer (ARC)(Fondation ARC pour la Recherche sur le CancerFrench National Research Agency (ANR)); Association for International Cancer Research (AICR); appel d'offre 'Actions Specifiques Universite Paris Diderot	We thank Slimane Ait-Si-Ali and Pierre-Antoine Defossez for critical reading of the manuscript and members of the UMR 7216 for helpful discussions. We thank Gordon Langsley for the generous gift of reagents, the Theileria-infected cell lines, the AP1-Luciferase reporter and for helpful discussions about our work. We thank Peter Staller (Biotech Research & Innovation Center, Denmark) for kindly providing the 5xHRE-luciferase constructs and Sebastien Jauliac for providing the NF-kappa B-Luciferase reporter. We also thank the Bioprofiler facility (Universite Paris Diderot) for HPLC analysis. We thank Ayad Eddaoudi (Institute of Child Health, London, UK) for expert technical support in flow cytometry analysis. This work was supported by grants from the Association pour la Recherche contre le Cancer (ARC no. 4975 and 7990) (JBW), the Association for International Cancer Research (AICR, no. 08-0111) (JBW) and appel d'offre 'Actions Specifiques 2012' Universite Paris Diderot. All infected bovine cell lines used in this study have been previously characterized and published.	Ballatori N, 2009, BIOL CHEM, V390, P191, DOI 10.1515/BC.2009.033; Baumgartner M, 2000, CELL MICROBIOL, V2, P329, DOI 10.1046/j.1462-5822.2000.00062.x; Chaussepied M, 1996, RES IMMUNOL, V147, P127, DOI 10.1016/0923-2494(96)83165-8; Chaussepied M, 1998, MOL BIOCHEM PARASIT, V94, P215, DOI 10.1016/S0166-6851(98)00070-X; Chaussepied M, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001197; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468; Dessauge G, 2005, ONCOGENE, V24, P1075, DOI 10.1038/sj.onc.1208314; Dobbelaere D, 1999, ANNU REV MICROBIOL, V53, P1, DOI 10.1146/annurev.micro.53.1.1; DOBBELAERE DAE, 1988, P NATL ACAD SCI USA, V85, P4730, DOI 10.1073/pnas.85.13.4730; Dobbelaere DAE, 2003, CURR OPIN MICROBIOL, V6, P377, DOI 10.1016/S1369-5274(03)00085-7; Favier J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007094; Fruehauf JP, 2007, CLIN CANCER RES, V13, P789, DOI 10.1158/1078-0432.CCR-06-2082; Galley Y, 1997, P NATL ACAD SCI USA, V94, P5119, DOI 10.1073/pnas.94.10.5119; Gao P, 2007, CANCER CELL, V12, P230, DOI 10.1016/j.ccr.2007.08.004; Gatenby RA, 2006, CANCER RES, V66, P5216, DOI 10.1158/0008-5472.CAN-05-4193; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; Gillies RJ, 2008, J NUCL MED, V49, p24S, DOI 10.2967/jnumed.107.047258; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; HUDSON AT, 1985, PARASITOLOGY, V90, P45, DOI 10.1017/S0031182000049003; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494; Lizundia R, 2006, CANCER RES, V66, P6105, DOI 10.1158/0008-5472.CAN-05-3861; Lopez-Lazaro M, 2007, CANCER LETT, V252, P1, DOI 10.1016/j.canlet.2006.10.029; Lopez-Lazaro M, 2007, INT J CANCER, V120, P1378, DOI 10.1002/ijc.22493; Masella R, 2005, J NUTR BIOCHEM, V16, P577, DOI 10.1016/j.jnutbio.2005.05.013; Mentis AFA, 2010, ASIAN PAC J CANCER P, V11, P1437; Moreau MF, 1999, INFECT IMMUN, V67, P6678; Muraguri GR, 1999, VET PARASITOL, V87, P25, DOI 10.1016/S0304-4017(99)00154-5; Narayanan BA, 2006, CURR CANCER DRUG TAR, V6, P711, DOI 10.2174/156800906779010218; OLOBO JO, 1989, VET IMMUNOL IMMUNOP, V20, P165, DOI 10.1016/0165-2427(89)90096-2; Poyton RO, 2009, TRENDS ENDOCRIN MET, V20, P332, DOI 10.1016/j.tem.2009.04.001; Ralph SJ, 2010, MOL ASPECTS MED, V31, P145, DOI 10.1016/j.mam.2010.02.008; Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2007, J BIOENERG BIOMEMBR, V39, P231, DOI 10.1007/s10863-007-9081-2; Seyfried TN, 2010, NUTR METAB, V7, DOI 10.1186/1743-7075-7-7; Shaw RJ, 2006, CURR OPIN CELL BIOL, V18, P598, DOI 10.1016/j.ceb.2006.10.005; Shiels B, 2006, INT J PARASITOL, V36, P9, DOI 10.1016/j.ijpara.2005.09.002; SHIELS BR, 1986, PARASITE IMMUNOL, V8, P69, DOI 10.1111/j.1365-3024.1986.tb00834.x; Somerville RPT, 1998, PARASITOLOGY, V116, P223, DOI 10.1017/S0031182097002151; Spear W, 2006, CELL MICROBIOL, V8, P339, DOI 10.1111/j.1462-5822.2005.00628.x; THEILEN GH, 1968, JNCI-J NATL CANCER I, V40, P737; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wellen KE, 2010, MOL CELL, V40, P323, DOI 10.1016/j.molcel.2010.10.004; Wenger Roland H, 2005, Sci STKE, V2005, pre12, DOI 10.1126/stke.3062005re12; Wiley M, 2010, J BIOL CHEM, V285, P26852, DOI 10.1074/jbc.M110.147041; Yeung SJ, 2008, CELL MOL LIFE SCI, V65, P3981, DOI 10.1007/s00018-008-8224-x; Zhang HF, 2008, P NATL ACAD SCI USA, V105, P19579, DOI 10.1073/pnas.0809763105	50	23	24	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2014	33	14					1809	1817		10.1038/onc.2013.134	http://dx.doi.org/10.1038/onc.2013.134			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RE	23665677				2022-12-28	WOS:000334345500007
J	Zhang, Y; Yan, W; Chen, X				Zhang, Y.; Yan, W.; Chen, X.			P63 regulates tubular formation via epithelial-to-mesenchymal transition	ONCOGENE			English	Article						p63; the p53 family; tubular formation; epithelial-to-mesenchymal transition; cell proliferation; migration and invasion	P53 HOMOLOG; MIR-200 FAMILY; CELL CARCINOMA; GENE-MUTATIONS; EEC-SYNDROME; E-CADHERIN; IN-VIVO; TARGET; KIDNEY; GROWTH	P63, a p53 family member, is expressed as Delta A and DN isoforms. Interestingly, both TAp63 and Delta Np63 are transcription factors, and regulate both common and distinct sets of target genes. p63 is required for survival of some epithelial cell lineages, and lack of p63 leads to loss of epidermis and other epithelia in humans and mice. Here, we explored the role of p63 isoforms in cell proliferation, migration and tubulogenesis by using Madin-Darby Canine Kidney (MDCK) tubular epithelial cells in two-or three-dimensional (2-D or 3-D) culture. We found that like downregulation of p53, downregulation of p63 and TAp63 decreases expression of growth-suppressing genes, including p21, PUMA and MIC-1, and consequently promotes cell proliferation and migration in 2-D culture. However, in 3-D culture, downregulation of p63, especially TAp63, but not p53, decapacitates MDCK cells to form a cyst structure through enhanced epithelial-to-mesenchymal transition (EMT). In contrast, downregulation of DNp63 inhibits MDCK cell proliferation and migration in 2-D culture, and delays but does not block MDCK cell cyst formation and tubulogenesis in 3-D culture. Consistent with this, downregulation of DNp63 markedly upregulates growth-suppressing genes, including p21, PUMA and MIC-1. Taken together, these data suggest that TAp63 is the major isoform required for tubulogenesis by maintaining an appropriate level of EMT, whereas DNp63 fine-tunes the rate of cyst formation and tubulogenesis by maintaining an appropriate expression level of genes involved in cell cycle arrest and apoptosis.	[Chen, X.] Univ Calif Davis, Ctr Comparat Oncol, Sch Med, Davis, CA 95616 USA; [Chen, X.] Univ Calif Davis, Ctr Comparat Oncol, Sch Vet Med, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Chen, X (corresponding author), Univ Calif Davis, Ctr Comparat Oncol, Sch Med, 2128 Tupper Hall, Davis, CA 95616 USA.	xbchen@ucdavis.edu			National Institutes of Health [CA102188, CA108122, CA076069]; NATIONAL CANCER INSTITUTE [R01CA102188, R01CA076069, R29CA076069, R01CA123227, R01CA081237] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by the National Institutes of Health grants CA102188, CA108122 and CA076069. We thank Jin Zhang for helpful comments on this manuscript.	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Allen LM, 2008, J ULTRAS MED, V27, P149, DOI 10.7863/jum.2008.27.1.149; Bakkers J, 2002, DEV CELL, V2, P617, DOI 10.1016/S1534-5807(02)00163-6; Brunner HG, 2002, AM J MED GENET, V112, P284, DOI 10.1002/ajmg.10778; Cao Y, 2008, CANCER RES, V68, P8667, DOI 10.1158/0008-5472.CAN-08-2614; Carroll DK, 2006, NAT CELL BIOL, V8, P551, DOI 10.1038/ncb1420; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; Cook HT, 2010, AM J PATHOL, V176, P22, DOI 10.2353/ajpath.2010.090898; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; Dressler GR, 2002, TRENDS CELL BIOL, V12, P390, DOI 10.1016/S0962-8924(02)02334-6; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Guo XC, 2009, NAT CELL BIOL, V11, P1451, DOI 10.1038/ncb1988; Herfs M, 2010, AM J PATHOL, V176, P1941, DOI 10.2353/ajpath.2010.090804; Ihrie RA, 2005, CELL, V120, P843, DOI 10.1016/j.cell.2005.01.008; Jia LW, 2011, MOL BIOL CELL, V22, P2031, DOI 10.1091/mbc.E11-01-0038; Keyes WM, 2005, GENE DEV, V19, P1986, DOI 10.1101/gad.342305; Kim D, 2005, J AM SOC NEPHROL, V16, P3527, DOI 10.1681/ASN.2005050544; Lee H, 2002, DEV CELL, V2, P607, DOI 10.1016/S1534-5807(02)00166-1; LEIGHTON J, 1970, CANCER-AM CANCER SOC, V26, P1022, DOI 10.1002/1097-0142(197011)26:5<1022::AID-CNCR2820260509>3.0.CO;2-M; Lindsay J, 2011, J BIOL CHEM, V286, P3915, DOI 10.1074/jbc.M110.162511; Lipschutz JH, 2000, MOL BIOL CELL, V11, P4259, DOI 10.1091/mbc.11.12.4259; Liu G, 2006, MOL CELL BIOL, V26, P1398, DOI 10.1128/MCB.26.4.1398-1413.2006; Lo Iacono M, 2006, CELL CYCLE, V5, P78; Massion PP, 2003, CANCER RES, V63, P7113; MCATEER JA, 1987, ANAT REC, V217, P229, DOI 10.1002/ar.1092170303; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; MONTESANO R, 1991, CELL, V66, P697, DOI 10.1016/0092-8674(91)90115-F; O'Brien LE, 2006, METHOD ENZYMOL, V406, P676, DOI 10.1016/S0076-6879(06)06053-8; O'Brien LE, 2004, DEV CELL, V7, P21, DOI 10.1016/j.devcel.2004.06.001; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Park BJ, 2000, CANCER RES, V60, P3370; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pollack AL, 1998, DEV BIOL, V204, P64, DOI 10.1006/dbio.1998.9091; Prindull G, 2004, BLOOD, V103, P2892, DOI 10.1182/blood-2003-08-2807; Rinne T, 2006, AM J MED GENET A, V140A, P1396, DOI 10.1002/ajmg.a.31271; Sasaki Y, 2002, J BIOL CHEM, V277, P719, DOI 10.1074/jbc.M108080200; Saxen L., 1987, Developmental and Cell Biology Series, V19, P1; Sensen CW, 1998, EXTREMOPHILES, V2, P305, DOI 10.1007/s007920050073; SIMONS K, 1985, ANNU REV CELL BIOL, V1, P243, DOI 10.1146/annurev.cb.01.110185.001331; Sniezek JC, 2004, LARYNGOSCOPE, V114, P2063, DOI 10.1097/01.mlg.0000149437.35855.4b; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; Su XH, 2009, CELL STEM CELL, V5, P64, DOI 10.1016/j.stem.2009.04.003; Tan MJ, 2000, P NATL ACAD SCI USA, V97, P109, DOI 10.1073/pnas.97.1.109; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tucci P, 2012, P NATL ACAD SCI USA, V109, P15312, DOI 10.1073/pnas.1110977109; van Bokhoven H, 2001, AM J HUM GENET, V69, P481, DOI 10.1086/323123; Vanbokhoven H, 2011, J INVEST DERMATOL, V131, P1196, DOI 10.1038/jid.2011.84; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Zeisberg M, 2005, J BIOL CHEM, V280, P8094, DOI 10.1074/jbc.M413102200; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhang J, 2009, MOL CANCER RES, V7, P67, DOI 10.1158/1541-7786.MCR-08-0347; Zhang YH, 2008, J BIOL CHEM, V283, P30689, DOI 10.1074/jbc.M801711200; Zhang YH, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.214585; Zheng Z, 2010, J CELL BIOL, V189, P275, DOI 10.1083/jcb.200910021; Zimmers TA, 2005, SHOCK, V23, P543, DOI 10.1097/01.shk.0000163393.55350.70	58	23	23	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2014	33	12					1548	1557		10.1038/onc.2013.101	http://dx.doi.org/10.1038/onc.2013.101			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD4TS	23542170	Green Accepted			2022-12-28	WOS:000333244200008
J	Kumar, SM; Dai, J; Li, S; Yang, R; Yu, H; Nathanson, KL; Liu, S; Zhou, H; Guo, J; Xu, X				Kumar, S. M.; Dai, J.; Li, S.; Yang, R.; Yu, H.; Nathanson, K. L.; Liu, S.; Zhou, H.; Guo, J.; Xu, X.			Human skin neural crest progenitor cells are susceptible to BRAF(V600E)-induced transformation	ONCOGENE			English	Article						melanoma; neural crest; transformation; melanocytes; BRAF(V600E)	ONCOGENE-INDUCED SENESCENCE; STEM-CELLS; SELF-RENEWAL; EXPRESSION; CANCER; CYCLE; GENE; MAINTENANCE; MUTATIONS; PATHWAYS	Adult stem cells are multipotent and persist in small numbers in adult tissues throughout the lifespan of an organism. Unlike differentiated cells, adult stem cells are intrinsically resistant to senescence. It is unclear how adult stem cells in solid organs respond to oncogenic stimulation and whether these cells have a role in tumor initiation. We report here that expression of BRAF(V600E) in human neural crest progenitor cells (hNCPCs) did not induce growth arrest as seen in human melanocytes, but instead, increased their cell proliferation capacity. These cells (hNCPCs(V600E)) acquired anchorage-independent growth ability and were weakly tumorigenic in vivo. Unlike in human melanocytes, BRAF(V600E) expression in hNCPCs did not induce p16(INK4a) expression. BRAF(V600E) induced elevated expression of CDK2, CDK4, MITF and EST1/2 protein in hNCPCs, and also induced melanocytic differentiation of these cells. Furthermore, overexpression of MITF in hNCPCs(V600E) dramatically increased their tumorigenicity and resulted in fully transformed tumor cells. These findings indicate that hNCPCs are susceptible to BRAF(V600E)-induced transformation, and MITF potentiates the oncogenic effect of BRAF(V600E) in these progenitor cells. These results suggest that the hNCPCs are potential targets for BRAF(V600E)-induced melanocytic tumor formation.	[Kumar, S. M.; Dai, J.; Yang, R.; Yu, H.; Liu, S.; Xu, X.] Univ Penn, Perelman Sch Med, Dept Pathol, Philadelphia, PA 19104 USA; [Kumar, S. M.; Dai, J.; Yang, R.; Yu, H.; Liu, S.; Xu, X.] Univ Penn, Perelman Sch Med, Dept Lab Med, Philadelphia, PA 19104 USA; [Dai, J.; Li, S.; Guo, J.] Peking Univ, Canc Hosp & Inst, Dept Renal Canc & Melanoma, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China; [Nathanson, K. L.] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA 19104 USA; [Zhou, H.] Univ Penn, Perelman Sch Med, Dept Emergency Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine; Peking University; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine	Guo, J (corresponding author), Peking Univ, Canc Hosp & Inst, Dept Renal Canc & Melanoma, Key Lab Carcinogenesis & Translat Res,Minist Educ, Beijing 100142, Peoples R China.	guoj307@126.com; xug@mail.med.upenn.edu		Liu, Shujing/0000-0002-2958-093X; Yu, Hong/0000-0002-1272-4511; Nathanson, Katherine/0000-0002-6740-0901	US National Institutes of Health [AR-054593, CA-116103]; NATIONAL CANCER INSTITUTE [R21CA116103, P01CA025874, P30CA016520, P50CA174523, P01CA114046] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR054593] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	We thank Drs M Herlyn from the Wistar Institute, Philadelphia, PA for melanoma cell lines, R Marais from the Institute of Cancer Research, London, UK for BRAF<SUP>V600E</SUP> plasmids, S Carreira from Marie Curie Research Institute, UK for MITF promoter-luciferase plasmids, F Liu from university of California for QCXIP-MiTF and QCXIP vectors, K Huang for editing the manuscript. CHTN for providing tissues and the immunohistochemical lab at the Department of Pathology and Laboratory medicine, University of Pennsylvania for immunohistochemical stains. This work is supported by US National Institutes of Health grants AR-054593, CA-116103 to XX.	Amoh Y, 2005, P NATL ACAD SCI USA, V102, P5530, DOI 10.1073/pnas.0501263102; Baird DM, 2008, BIOCHIMIE, V90, P116, DOI 10.1016/j.biochi.2007.08.003; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Bernardo ME, 2007, CANCER RES, V67, P9142, DOI 10.1158/0008-5472.CAN-06-4690; Bloethner S, 2007, GENE CHROMOSOME CANC, V46, P1019, DOI 10.1002/gcc.20488; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Carreira S, 2005, NATURE, V433, P764, DOI 10.1038/nature03269; Clarke MF, 2006, CELL, V124, P1111, DOI 10.1016/j.cell.2006.03.011; COTSARELIS G, 1990, CELL, V61, P1329, DOI 10.1016/0092-8674(90)90696-C; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Du JY, 2004, CANCER CELL, V6, P565, DOI 10.1016/j.ccr.2004.10.014; Duband JL, 2006, ADV EXP MED BIOL, V589, P45; Elder DE, 2009, TUMORIGENIC MELANOCY; Fernandes KJL, 2004, NAT CELL BIOL, V6, P1082, DOI 10.1038/ncb1181; Foroni C, 2007, CANCER RES, V67, P3725, DOI 10.1158/0008-5472.CAN-06-4577; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Greshock J, 2004, GENOME RES, V14, P179; Hilton MJ, 2008, NAT MED, V14, P306, DOI 10.1038/nm1716; Hu YF, 2006, STEM CELLS, V24, P2692, DOI 10.1634/stemcells.2006-0233; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Kruger GM, 2002, NEURON, V35, P657, DOI 10.1016/S0896-6273(02)00827-9; Kumar SM, 2005, AM J PATHOL, V166, P823, DOI 10.1016/S0002-9440(10)62303-6; Kumar SM, 2007, CANCER RES, V67, P3177, DOI 10.1158/0008-5472.CAN-06-3312; Li LN, 2003, P NATL ACAD SCI USA, V100, P9958, DOI 10.1073/pnas.1733025100; Matsuoka S, 2008, GENE DEV, V22, P986, DOI 10.1101/gad.1621808; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Milagre C, 2010, CANCER RES, V70, P5549, DOI 10.1158/0008-5472.CAN-09-4254; Mooi WJ, 2006, NEW ENGL J MED, V355, P1037, DOI 10.1056/NEJMra062285; Moran-Crusio K, 2011, CANCER CELL, V20, P11, DOI 10.1016/j.ccr.2011.06.001; Morrison SJ, 2008, CELL, V132, P598, DOI 10.1016/j.cell.2008.01.038; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Patton EE, 2005, CURR BIOL, V15, P249, DOI 10.1016/j.cub.2005.01.031; Polyak K, 2006, NAT MED, V12, P296, DOI 10.1038/nm1379; Rossi DJ, 2008, CELL, V132, P681, DOI 10.1016/j.cell.2008.01.036; Rubio D, 2005, CANCER RES, V65, P3035, DOI 10.1158/0008-5472.CAN-04-4194; Shiras A, 2007, STEM CELLS, V25, P1478, DOI 10.1634/stemcells.2006-0585; Sieber-Blum M, 2004, DEV DYNAM, V231, P258, DOI 10.1002/dvdy.20129; Sieber-Blum M, 2004, ANAT REC PART A, V276A, P34, DOI 10.1002/ar.a.10132; Sieber-Blum Maya, 2004, Birth Defects Res C Embryo Today, V72, P162, DOI 10.1002/bdrc.20008; Squarzoni P, 2011, DEVELOPMENT, V138, P1421, DOI 10.1242/dev.057323; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Vaquerizas JM, 2004, BIOINFORMATICS, V20, P3656, DOI 10.1093/bioinformatics/bth401; Wajapeyee N, 2010, CELL, V141, P746, DOI 10.1016/j.cell.2010.05.014; Wellbrock C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002734; Witkiewicz AK, 2011, CELL CYCLE, V10, P2497, DOI 10.4161/cc.10.15.16776; Wong CE, 2006, J CELL BIOL, V175, P1005, DOI 10.1083/jcb.200606062; Xu CH, 2001, NAT BIOTECHNOL, V19, P971, DOI 10.1038/nbt1001-971; Yaswen P, 2007, CELL, V128, P233, DOI 10.1016/j.cell.2007.01.005; Yu H, 2006, AM J PATHOL, V168, P1879, DOI 10.2353/ajpath.2006.051170; Yu H, 2010, J INVEST DERMATOL, V130, P1227, DOI 10.1038/jid.2009.322; Yu H, 2009, AM J PATHOL, V174, P2367, DOI 10.2353/ajpath.2009.081057	53	10	10	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2014	33	7					832	841		10.1038/onc.2012.642	http://dx.doi.org/10.1038/onc.2012.642			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB2MN	23334329	Green Accepted			2022-12-28	WOS:000331626900004
J	Tang, J; Li, Y; Lyon, K; Camps, J; Dalton, S; Ried, T; Zhao, S				Tang, J.; Li, Y.; Lyon, K.; Camps, J.; Dalton, S.; Ried, T.; Zhao, S.			Cancer driver-passenger distinction via sporadic human and dog cancer comparison: a proof-of-principle study with colorectal cancer	ONCOGENE			English	Article						CRC driver-passenger distinction; sporadic canine CRCs; human-dog comparison; epithelial cell apicobasal polarity; genomic amplifications/deletions	CELL POLARITY; TUMOR-SUPPRESSOR; DOMESTIC DOG; GENOME; SEQUENCE; PROTEIN; COLON; TRANSITION; NETWORK; BREAST	Herein we report a proof-of-principle study illustrating a novel dog-human comparison strategy that addresses a central aim of cancer research, namely cancer driver-passenger distinction. We previously demonstrated that sporadic canine colorectal cancers (CRCs) share similar molecular pathogenesis mechanisms as their human counterparts. In this study, we compared the genome-wide copy number abnormalities between 29 human and 10 canine sporadic CRCs. This led to the identification of 73 driver candidate genes (DCGs), altered in both species, and with 27 from the whole genome and 46 from dog-human genomic rearrangement breakpoint (GRB) regions, as well as 38 passenger candidate genes (PCGs), altered in humans only and located in GRB regions. We noted that DCGs significantly differ from PCGs in every analysis conducted to assess their cancer relevance and biological functions. Importantly, although PCGs are not enriched in any specific functions, DCGs possess significantly enhanced functionality closely associated with cell proliferation and death regulation, as well as with epithelial cell apicobasal polarity establishment/maintenance. These observations support the notion that, in sporadic CRCs of both species, cell polarity genes not only contribute in preventing cancer cell invasion and spreading, but also likely serve as tumor suppressors by modulating cell growth. This pilot study validates our novel strategy and has uncovered four new potential cell polarity and colorectal tumor suppressor genes (RASA3, NUPL1, DENND5A and AVL9). Expansion of this study would make more driver-passenger distinctions for cancers with large genomic amplifications or deletions, and address key questions regarding the relationship between cancer pathogenesis and epithelial cell polarity control in mammals.	[Tang, J.; Li, Y.; Lyon, K.; Dalton, S.; Zhao, S.] Univ Georgia, Inst Bioinformat, Dept Biochem & Mol Biol, Athens, GA 30602 USA; [Camps, J.; Ried, T.] NCI, Genet Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	University System of Georgia; University of Georgia; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Zhao, S (corresponding author), Univ Georgia, Inst Bioinformat, Dept Biochem & Mol Biol, B304B Life Sci Bldg,120 Green St, Athens, GA 30602 USA.	szhao@bmb.uga.edu	Tang, Jie/D-3764-2015; Camps, Jordi/AAG-3080-2020	Tang, Jie/0000-0002-3991-2539; Camps, Jordi/0000-0002-3165-3640; Dalton, Stephen/0000-0002-3450-1263	American Cancer Society; Georgia Cancer Coalition; NCI [P50 CA128613]; NATIONAL CANCER INSTITUTE [ZIABC010833, P50CA128613, ZIABC010835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM085354] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); Georgia Cancer Coalition; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Ms Huan Xiong for her work; Dr Bert Vogelstein for providing various CRC lines and Dr Timothy A Chan of Memorial Sloan-Kettering Cancer Center for providing the IHA cells; and Drs Dong M Shin, J David Puett, Claiborne Glover, Georgia Chen, and Lisa J Stubb for their help and advice on this study. This work was funded by the American Cancer Society and the Georgia Cancer Coalition (principal investigator (PI): S Zhao), as well as NCI P50 CA128613 (PI: Dr Dong M Shin) and GM085354 (PI: Dr Stephen Dalton).	Amann T, 2009, EXPERT OPIN THER TAR, V13, P1411, DOI 10.1517/14728220903307509; Bachmann O, 2011, ACTA PHYSIOL, V201, P33, DOI 10.1111/j.1748-1716.2010.02153.x; Barrios A, 2003, CURR BIOL, V13, P1571, DOI 10.1016/j.cub.2003.08.030; Beck CR, 2010, CELL, V141, P1159, DOI 10.1016/j.cell.2010.05.021; Belleannee C, 2010, AM J PHYSIOL-CELL PH, V298, pC817, DOI 10.1152/ajpcell.00460.2009; Beroukhim R, 2007, P NATL ACAD SCI USA, V104, P20007, DOI 10.1073/pnas.0710052104; Bouanene H, 2010, DIS MARKERS, V28, P385, DOI [10.3233/DMA-2010-0719, 10.1155/2010/918457]; Boyko AR, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-2-216; Bryant DM, 2008, NAT REV MOL CELL BIO, V9, P887, DOI 10.1038/nrm2523; Camps J, 2008, CANCER RES, V68, P1284, DOI 10.1158/0008-5472.CAN-07-2864; Dehal P, 2001, SCIENCE, V293, P104, DOI 10.1126/science.1060310; Farabaugh SM, ONCOGENE, V31, P552; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Haber DA, 2007, NATURE, V446, P145, DOI 10.1038/446145a; Harsay E, 2007, MOL BIOL CELL, V18, P1203, DOI 10.1091/mbc.E06-11-1035; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Hudson TJ, 2010, NATURE, V464, P993, DOI 10.1038/nature08987; Iden S, 2008, NAT REV MOL CELL BIO, V9, P846, DOI 10.1038/nrm2521; Igaki T, 2006, CURR BIOL, V16, P1139, DOI 10.1016/j.cub.2006.04.042; Jacobson Kenneth A, 2009, Handb Exp Pharmacol, P123, DOI 10.1007/978-3-540-89615-9_5; Ji XL, 2008, GENOMICS, V91, P249, DOI 10.1016/j.ygeno.2007.10.014; Ji XL, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-426; Jin BL, 2009, CANCER RES, V69, P7412, DOI 10.1158/0008-5472.CAN-09-0116; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Krais AM, 2011, CARCINOGENESIS, V32, P1388, DOI 10.1093/carcin/bgr090; Lee MH, 2008, J CELL SCI, V121, P1141, DOI 10.1242/jcs.016634; Levy F, 2005, MOL BIOL CELL, V16, P1777, DOI 10.1091/mbc.E04-09-0803; Li R, 2008, NAT REV MOL CELL BIO, V9, P860, DOI 10.1038/nrm2522; Lin J, 2007, GENOME RES, V17, P1304, DOI 10.1101/gr.6431107; Lindblad-Toh K, 2005, NATURE, V438, P803, DOI 10.1038/nature04338; Llovera L, 2012, CANCER LETT, V326, P114, DOI 10.1016/j.canlet.2012.08.001; Lott ST, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000068; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nafisi H, 2008, J BIOL CHEM, V283, P35908, DOI 10.1074/jbc.M803622200; Neff MW, 2006, CELL, V124, P229, DOI 10.1016/j.cell.2006.01.008; Nelson WJ, 2003, NATURE, V422, P766, DOI 10.1038/nature01602; Pontius JU, 2007, GENOME RES, V17, P1675, DOI 10.1101/gr.6380007; Reinhardt HC, 2010, MOL CELL, V40, P34, DOI 10.1016/j.molcel.2010.09.018; Rowell JL, 2011, TRENDS MOL MED, V17, P380, DOI 10.1016/j.molmed.2011.02.004; Royer C, 2011, CELL DEATH DIFFER, V18, P1470, DOI 10.1038/cdd.2011.60; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Skaletsky H, 2003, NATURE, V423, P825, DOI 10.1038/nature01722; Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943; Tang J, 2010, GENOME RES, V20, P341, DOI 10.1101/gr.092726.109; Veeriah S, 2009, P NATL ACAD SCI USA, V106, P9435, DOI 10.1073/pnas.0900571106; Youmans L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050813	50	21	23	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2014	33	7					814	822		10.1038/onc.2013.17	http://dx.doi.org/10.1038/onc.2013.17			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB2MN	23416983	Green Accepted			2022-12-28	WOS:000331626900002
J	Kong, W; He, L; Richards, EJ; Challa, S; Xu, CX; Permuth-Wey, J; Lancaster, JM; Coppola, D; Sellers, TA; Djeu, JY; Cheng, JQ				Kong, W.; He, L.; Richards, E. J.; Challa, S.; Xu, C-X; Permuth-Wey, J.; Lancaster, J. M.; Coppola, D.; Sellers, T. A.; Djeu, J. Y.; Cheng, J. Q.			Upregulation of miRNA-155 promotes tumour angiogenesis by targeting VHL and is associated with poor prognosis and triple-negative breast cancer	ONCOGENE			English	Article						miR-155; angiogenesis; VHL; breast cancer; inflammation	B-CELL LYMPHOMAS; TNF-ALPHA; MICRORNA-155; GROWTH; MIR-155; GENE; INFLAMMATION; EXPRESSION; TUMORIGENESIS; MACROPHAGES	MicroRNA-155 (miR-155) is frequently upregulated in various types of human cancer; however, its role in cancer angiogenesis remains unknown. Here, we demonstrate the role of miR-155 in angiogenesis through targeting von Hippel-Lindau (VHL) tumour suppressor in breast cancer. Ectopic expression of miR-155 induced whereas knockdown of miR-155 inhibited human umbilical vein endothelial cell network formation, proliferation, invasion and migration. Furthermore, mammary fat pad xenotransplantation of ectopically expressed miR-155 resulted in extensive angiogenesis, proliferation, tumour necrosis and recruitment of pro-inflammatory cells such as tumour-associated macrophages. Expression of VHL abrogated these miR-155 effects. Moreover, miR-155 expression inversely correlates with VHL expression level and is associated with late-stage, lymph node metastasis and poor prognosis, as well as triple-negative tumour in breast cancer. These findings indicate that miR-155 has a pivotal role in tumour angiogenesis by downregulation of VHL, and provide a basis for miR-155-expressing tumours to embody an aggressive malignant phenotype, and therefore miR-155 is an important therapeutic target in breast cancer.	[Kong, W.; He, L.; Richards, E. J.; Challa, S.; Xu, C-X; Cheng, J. Q.] H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL 33612 USA; [Permuth-Wey, J.; Sellers, T. A.] H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Epidemiol, Tampa, FL 33612 USA; [Lancaster, J. M.] H Lee Moffitt Canc Ctr & Res Inst, Dept Womens Oncol, Tampa, FL 33612 USA; [Coppola, D.] H Lee Moffitt Canc Ctr & Res Inst, Dept Pathol, Tampa, FL 33612 USA; [Djeu, J. Y.] H Lee Moffitt Canc Ctr & Res Inst, Dept Immunol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer Center & Research Institute	Cheng, JQ (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, 12909 Magnolia Dr,SRB3, Tampa, FL 33612 USA.	Jin.Cheng@moffitt.org	Xu, Cheng-Xiong/ACD-3271-2022; Xu, Cheng-Xiong/AAV-7733-2021	Xu, Cheng-Xiong/0000-0001-5714-8207; CHALLA, SRIDEVI/0000-0002-5308-9243	National Institute of Health [CA114343, CA115308, CA137041]; Florida Bankhead-Coley Cancer Research Program [2BB01]; NATIONAL CANCER INSTITUTE [T32CA115308, R01CA137041, P30CA076292, R01CA160455, R01CA114343] Funding Source: NIH RePORTER	National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Florida Bankhead-Coley Cancer Research Program; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the National Institute of Health (CA114343 to TAS, CA115308 to JYD, and CA137041 to JQC) and Florida Bankhead-Coley Cancer Research Program (2BB01 to JQC).	Albini A, 2005, CANCER RES, V65, P10637, DOI 10.1158/0008-5472.CAN-05-3473; Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Andorfer CA, 2011, TRENDS MOL MED, V17, P313, DOI 10.1016/j.molmed.2011.01.006; Babar IA, 2011, CANCER BIOL THER, V12, P908, DOI 10.4161/cbt.12.10.17681; Baeriswyl V, 2009, SEMIN CANCER BIOL, V19, P329, DOI 10.1016/j.semcancer.2009.05.003; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bergers G, 1998, INT J DEV BIOL, V42, P995; Bouck N, 1996, ADV CANCER RES, V69, P135, DOI 10.1016/S0065-230X(08)60862-3; Cha ST, 2010, CANCER RES, V70, P2675, DOI 10.1158/0008-5472.CAN-09-2448; Chang SH, 2011, NAT MED, V17, P1275, DOI 10.1038/nm.2459; Coultas L, 2005, NATURE, V438, P937, DOI 10.1038/nature04479; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Eis PS, 2005, P NATL ACAD SCI USA, V102, P3627, DOI 10.1073/pnas.0500613102; Fang L, 2011, ONCOGENE, V30, P806, DOI 10.1038/onc.2010.465; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Foulkes WD, 2003, J NATL CANCER I, V95, P1482, DOI 10.1093/jnci/djg050; Greer SN, 2012, EMBO J, V31, P2448, DOI 10.1038/emboj.2012.125; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Jiang SA, 2010, CANCER RES, V70, P3119, DOI 10.1158/0008-5472.CAN-09-4250; Kaelin WG, 2008, NAT REV CANCER, V8, P865, DOI 10.1038/nrc2502; Karginov FV, 2007, P NATL ACAD SCI USA, V104, P19291, DOI 10.1073/pnas.0709971104; Keene JD, 2006, NAT PROTOC, V1, P302, DOI 10.1038/nprot.2006.47; Kim WY, 2004, J CLIN ONCOL, V22, P4991, DOI 10.1200/JCO.2004.05.061; Kluiver J, 2005, J PATHOL, V207, P243, DOI 10.1002/path.1825; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Kong W, 2010, J BIOL CHEM, V285, P17869, DOI 10.1074/jbc.M110.101055; Krishnamachary B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044078; Lakhani SR, 2005, CLIN CANCER RES, V11, P5175, DOI 10.1158/1078-0432.CCR-04-2424; Li MQ, 2011, J CELL MOL MED, V15, P187, DOI 10.1111/j.1582-4934.2010.01238.x; Luo JL, 2004, CANCER CELL, V6, P297, DOI 10.1016/j.ccr.2004.08.012; Montagner M, 2012, NATURE, V487, P380, DOI 10.1038/nature11207; O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104; Ono M, 2008, CANCER SCI, V99, P1501, DOI 10.1111/j.1349-7006.2008.00853.x; Pedersen IM, 2009, EMBO MOL MED, V1, P288, DOI 10.1002/emmm.200900028; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; Solinas G, 2009, J LEUKOCYTE BIOL, V86, P1065, DOI 10.1189/jlb.0609385; Suarez Y, 2008, P NATL ACAD SCI USA, V105, P14082, DOI 10.1073/pnas.0804597105; Suarez Y, 2009, CIRC RES, V104, P442, DOI 10.1161/CIRCRESAHA.108.191270; Thai TH, 2007, SCIENCE, V316, P604, DOI 10.1126/science.1141229; Tili E, 2007, J IMMUNOL, V179, P5082, DOI 10.4049/jimmunol.179.8.5082; Tili E, 2011, P NATL ACAD SCI USA, V108, P4908, DOI 10.1073/pnas.1101795108; Vigorito E, 2007, IMMUNITY, V27, P847, DOI 10.1016/j.immuni.2007.10.009; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Yamakuchi M, 2010, P NATL ACAD SCI USA, V107, P6334, DOI 10.1073/pnas.0911082107; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; Zia MK, 2007, INT J MOL MED, V20, P605	53	288	300	5	86	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2014	33	6					679	689		10.1038/onc.2012.636	http://dx.doi.org/10.1038/onc.2012.636			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5IL	23353819	Green Accepted			2022-12-28	WOS:000331129200003
J	Zeilstra, J; Joosten, SPJ; van Andel, H; Tolg, C; Berns, A; Snoek, M; van de Wetering, MV; Spaargaren, M; Clevers, H; Pals, ST				Zeilstra, J.; Joosten, S. P. J.; van Andel, H.; Tolg, C.; Berns, A.; Snoek, M.; van de Wetering, M.; Spaargaren, M.; Clevers, H.; Pals, S. T.			Stem cell CD44v isoforms promote intestinal cancer formation in Apc(min) mice downstream of Wnt signaling	ONCOGENE			English	Article						CD44; colorectal cancer; stem cell; Wnt signaling	HUMAN COLORECTAL-CANCER; PROTEOGLYCAN FORMS; BETA-CATENIN; COLON-CANCER; C-MET; EXPRESSION; APC; DIFFERENTIATION; PROGRESSION; METASTASIS	A gene signature specific for intestinal stem cells (ISCs) has recently been shown to predict relapse in colorectal cancer (CRC) but the tumorigenic role of individual signature genes remains poorly defined. A prominent ISC-signature gene is the cancer stem cell marker CD44, which encodes various splice variants comprising a diverse repertoire of adhesion and signaling molecules. Using Lgr5 as ISC marker, we have fluorescence-activated cell sorting-purified ISCs to define their CD44 repertoire. ISCs display a specific set of CD44 variant isoforms (CD44v), but remarkably lack the CD44 standard (CD44s) isoform. These CD44v also stand-out in transformed human ISCs isolated from microadenomas of familial adenomatous polyposis patients. By employing knock-in mice expressing either CD44v4-10 or CD44s, we demonstrate that the CD44v isoform, but not CD44s, promotes adenoma initiation in Apc(Min/+) mice. Our data identify CD44v as component of the ISCs program critical for tumor initiation, and as potential treatment target in CRC.	[Zeilstra, J.; Joosten, S. P. J.; van Andel, H.; Spaargaren, M.; Pals, S. T.] Univ Amsterdam, Acad Med Ctr, Dept Pathol, NL-1105 AZ Amsterdam, Netherlands; [Tolg, C.; Berns, A.; Snoek, M.] Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; [van de Wetering, M.; Clevers, H.] Hubrecht Inst, Utrecht, Netherlands; [van de Wetering, M.; Clevers, H.] Univ Med Ctr Utrecht, Utrecht, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Vrije Universiteit Amsterdam; Netherlands Cancer Institute; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW); Utrecht University; Utrecht University Medical Center	Pals, ST (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Pathol, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.	s.t.pals@amc.uva.nl	Spaargaren, Marcel/AAU-1298-2021	Spaargaren, Marcel/0000-0002-3135-5109; Joosten, Sander/0000-0002-6699-3717; Pals, Steven/0000-0002-1419-0939	Dutch Cancer Society	Dutch Cancer Society(KWF Kankerbestrijding)	This work was supported by a grant from the Dutch Cancer Society. The authors declare no competing financial interests.	Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; BENNETT KL, 1995, J CELL BIOL, V131, P1623, DOI 10.1083/jcb.131.6.1623; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Boivin GP, 2003, GASTROENTEROLOGY, V124, P762, DOI 10.1053/gast.2003.50094; Boon EMJ, 2002, CANCER RES, V62, P5126; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; DIRENZO MF, 1995, CLIN CANCER RES, V1, P147; HEIDER KH, 1993, J CELL BIOL, V120, P227, DOI 10.1083/jcb.120.1.227; JACKSON DG, 1995, J CELL BIOL, V128, P673, DOI 10.1083/jcb.128.4.673; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Kuhnert F, 2004, P NATL ACAD SCI USA, V101, P266, DOI 10.1073/pnas.2536800100; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; McCart AE, 2008, PATHOL RES PRACT, V204, P479, DOI 10.1016/j.prp.2008.03.004; Merlos-Suarez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MULDER JWR, 1994, LANCET, V344, P1470, DOI 10.1016/S0140-6736(94)90290-9; Noah TK, 2011, EXP CELL RES, V317, P2702, DOI 10.1016/j.yexcr.2011.09.006; Nusse R, 2008, CELL RES, V18, P523, DOI 10.1038/cr.2008.47; Orian-Rousseau V, 2002, GENE DEV, V16, P3074, DOI 10.1101/gad.242602; Ramakers C, 2003, NEUROSCI LETT, V339, P62, DOI 10.1016/S0304-3940(02)01423-4; Sansom OJ, 2004, GENE DEV, V18, P1385, DOI 10.1101/gad.287404; Schmits R, 1997, BLOOD, V90, P2217, DOI 10.1182/blood.V90.6.2217.2217_2217_2233; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Van Der Flier LG, 2007, GASTROENTEROLOGY, V132, P628, DOI 10.1053/j.gastro.2006.08.039; van der Flier LG, 2009, CELL, V136, P903, DOI 10.1016/j.cell.2009.01.031; van der Voort R, 1999, J BIOL CHEM, V274, P6499, DOI 10.1074/jbc.274.10.6499; vanderNeut R, 1996, NAT GENET, V13, P366, DOI 10.1038/ng0796-366; VANDERVOORT R, 1995, BIOCHEM BIOPH RES CO, V214, P137, DOI 10.1006/bbrc.1995.2267; VANWEERING DHJ, 1993, PCR METH APPL, V3, P100; Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048; Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2; WIELENGA VJM, 1993, CANCER RES, V53, P4754; Wielenga VJM, 2000, ADV CANCER RES, V77, P169; Wielenga VJM, 2000, AM J PATHOL, V157, P1563, DOI 10.1016/S0002-9440(10)64793-1; Zeilstra J, 2008, CANCER RES, V68, P3655, DOI 10.1158/0008-5472.CAN-07-2940; Zoller M, 2011, NAT REV CANCER, V11, P254, DOI 10.1038/nrc3023	39	95	95	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2014	33	5					665	670		10.1038/onc.2012.611	http://dx.doi.org/10.1038/onc.2012.611			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5GW	23318432				2022-12-28	WOS:000331125100014
J	Streppel, MM; Lata, S; DelaBastide, M; Montgomery, EA; Wang, JS; Canto, MI; Macgregor-Das, AM; Pai, S; Morsink, FHM; Offerhaus, GJ; Antoniou, E; Maitra, A; McCombie, WR				Streppel, M. M.; Lata, S.; DelaBastide, M.; Montgomery, E. A.; Wang, J. S.; Canto, M. I.; Macgregor-Das, A. M.; Pai, S.; Morsink, F. H. M.; Offerhaus, G. J.; Antoniou, E.; Maitra, A.; McCombie, W. R.			Next-generation sequencing of endoscopic biopsies identifies ARID1A as a tumor-suppressor gene in Barrett's esophagus	ONCOGENE			English	Article						next-generation sequencing; endoscopic mucosal biopsies; Barrett's esophagus; esophageal adenocarcinoma; ARID1A	CALCIUM-BINDING PROTEIN; CARCINOEMBRYONIC ANTIGEN; FREQUENT MUTATIONS; SOMATIC MUTATIONS; CANCER; ADENOCARCINOMA; PROGRESSION; BREAST; TARGET; EXPRESSION	The incidence of Barrett's esophagus (BE)-associated esophageal adenocarcinoma (EAC) is increasing. Next-generation sequencing (NGS) provides an unprecedented opportunity to uncover genomic alterations during BE pathogenesis and progression to EAC, but treatment-naive surgical specimens are scarce. The objective of this study was to establish the feasibility of using widely available endoscopic mucosal biopsies for successful NGS, using samples obtained from a BE 'progressor'. Paired-end whole-genome NGS was performed on the Illumina platform using libraries generated from mucosal biopsies of normal squamous epithelium (NSE), BE and EAC obtained from a patient who progressed to adenocarcinoma during endoscopic surveillance. Selective validation studies, including Sanger sequencing, immunohistochemistry and functional assays, were performed to confirm the NGS findings. NGS identified somatic nonsense mutations of AT-rich interactive domain 1A (SWI like) (ARID1A) and PPIE and an additional 37 missense mutations in BE and/or EAC, which were confirmed by Sanger sequencing. ARID1A mutations were detected in 15% (3/20) high-grade dysplasia (HGD)/EAC patients. Immunohistochemistry performed on an independent archival cohort demonstrated ARID1A protein loss in 0% (0/76), 4.9% (2/40), 14.3% (4/28), 16.0% (8/50) and 12.2% (12/98) of NSE, BE, low-grade dysplasia, HGD and EAC tissues, respectively, and was inversely associated with nuclear p53 accumulation (P - 0.028). Enhanced cell growth, proliferation and invasion were observed on ARID1A knockdown in EAC cells. In addition, genes downstream of ARID1A that potentially contribute to the ARID1A knockdown phenotype were identified. Our studies establish the feasibility of using mucosal biopsies for NGS, which should enable the comparative analysis of larger 'progressor' versus 'non-progressor' cohorts. Further, we identify ARID1A as a novel tumor-suppressor gene in BE pathogenesis, reiterating the importance of aberrant chromatin in the metaplasiadysplasia sequence.	[Streppel, M. M.; Montgomery, E. A.; Macgregor-Das, A. M.; Pai, S.; Maitra, A.] Johns Hopkins Med Inst, Dept Pathol, Baltimore, MD USA; [Streppel, M. M.] Univ Med Ctr Utrecht, Dept Gastroenterol & Hepatol, Utrecht, Netherlands; [Streppel, M. M.; Morsink, F. H. M.; Offerhaus, G. J.] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands; [Lata, S.; DelaBastide, M.; Antoniou, E.; McCombie, W. R.] Cold Spring Harbor Lab, Stanley Inst Cognit Genom, Woodbury, NY USA; [Wang, J. S.] Washington Univ, Sch Med, Dept Med, Div Gastroenterol, St Louis, MO 63110 USA; [Canto, M. I.] Johns Hopkins Med Inst, Dept Med, Div Gastroenterol & Hepatol, Baltimore, MD USA; [Macgregor-Das, A. M.] Johns Hopkins Med Inst, Pathobiol Program, Baltimore, MD USA; [Maitra, A.] Johns Hopkins Med Inst, Dept Oncol, Baltimore, MD USA; [Maitra, A.] Johns Hopkins Med Inst, Dept Med Genet, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins Medicine; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Cold Spring Harbor Laboratory; Washington University (WUSTL); Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Maitra, A (corresponding author), Johns Hopkins Med Inst, Dept Pathol, CRBII Bldg,Room 341,1550 Orleans St, Baltimore, MD 21231 USA.	amaitra1@jhmi.edu; mccombie@cshl.edu		McCombie, W. Richard/0000-0003-1899-0682	Jerry D'Amato foundation; NIH [1K23DK068149, S10 RR023702-01]; NCI [CA045508]; Fulbright/the Netherland America Foundation; Rene Vogels Foundation; NATIONAL CANCER INSTITUTE [P30CA045508, R01CA113669] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR023702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K23DK068149] Funding Source: NIH RePORTER	Jerry D'Amato foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Fulbright/the Netherland America Foundation; Rene Vogels Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	The work at Johns Hopkins Medical Institutions was funded by the Jerry D'Amato foundation and the NIH (1K23DK068149) and the work at WRM's laboratory was supported by a Cancer Center Support Grant (CA045508) from the NCI and NIH Shared Instrument grant S10 RR023702-01. MMS has been sponsored by Fulbright/the Netherland America Foundation and the Rene Vogels Foundation.	Agrawal N, 2012, CANCER DISCOV, V2, P899, DOI 10.1158/2159-8290.CD-12-0189; Alvarez H, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001356; Alvarez H, 2010, CANCER BIOL THER, V10, P1009, DOI 10.4161/cbt.10.10.13248; Alvarez H, 2008, CANCER BIOL THER, V7, P1753; Ashworth A, 2011, CELL, V145, P30, DOI 10.1016/j.cell.2011.03.020; Berinstein NL, 2002, J CLIN ONCOL, V20, P2197, DOI 10.1200/JCO.2002.08.017; Birnbaum DJ, 2011, GENE CHROMOSOME CANC, V50, P456, DOI 10.1002/gcc.20870; Camacho-Leal P, 2008, ONCOGENE, V27, P1545, DOI 10.1038/sj.onc.1210789; Clark MJ, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000832; Cornen S, 2012, ONCOGENE, V31, P4255, DOI 10.1038/onc.2011.598; DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806; di Pietro M, 2012, P NATL ACAD SCI USA, V109, P9077, DOI 10.1073/pnas.1116933109; Fair K, 2001, MOL CELL BIOL, V21, P3589, DOI 10.1128/MCB.21.10.3589-3597.2001; Fujimoto A, 2012, NAT GENET, V44, P760, DOI 10.1038/ng.2291; Galipeau PC, 2007, PLOS MED, V4, P342, DOI 10.1371/jourmal.pmed.0040067; Gilbert EW, 2011, J GASTROINTEST SURG, V15, P708, DOI 10.1007/s11605-011-1485-y; Goh XY, 2011, GUT, V60, P1317, DOI 10.1136/gut.2010.234179; GRIFFIN M, 1987, HISTOPATHOLOGY, V11, P53; Gui YT, 2011, NAT GENET, V43, P875, DOI 10.1038/ng.907; Gupta S, 2012, CLIN CANCER RES, V18, P280, DOI 10.1158/1078-0432.CCR-11-2165; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang JM, 2007, GENE CHROMOSOME CANC, V46, P745, DOI 10.1002/gcc.20459; Hvid-Jensen F, 2011, NEW ENGL J MED, V365, P1375, DOI 10.1056/NEJMoa1103042; Jin Z, 2009, CANCER RES, V69, P4112, DOI 10.1158/0008-5472.CAN-09-0028; Jones S, 2012, HUM MUTAT, V33, P100, DOI 10.1002/humu.21633; Jones S, 2010, SCIENCE, V330, P228, DOI 10.1126/science.1196333; Kaz AM, CANC LETT; Kumar A, 2011, P NATL ACAD SCI USA, V108, P17087, DOI 10.1073/pnas.1108745108; Lee OJ, 2006, GASTROENTEROLOGY, V130, pA273; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Li M, 2011, NAT GENET, V43, P828, DOI 10.1038/ng.903; Li XH, 2008, CANCER PREV RES, V1, P413, DOI 10.1158/1940-6207.CAPR-08-0121; Link DC, 2011, JAMA-J AM MED ASSOC, V305, P1568, DOI 10.1001/jama.2011.473; Luby TM, 2008, EXPERT REV VACCINES, V7, P995, DOI 10.1586/14760584.7.7.995; Mamo A, 2012, ONCOGENE, V31, P2090, DOI 10.1038/onc.2011.386; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Martinez VG, 2008, BRIT J CANCER, V98, P564, DOI 10.1038/sj.bjc.6604195; McFadyen MCE, 2004, MOL CANCER THER, V3, P363; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Mishra SK, 2012, CANCER METAST REV, V31, P163, DOI 10.1007/s10555-011-9338-4; Nik-Zainal S, 2012, CELL, V149, P5; Nik-Zainal S, 2012, CELL, V149, P979, DOI 10.1016/j.cell.2012.04.024; Ordonez C, 2000, CANCER RES, V60, P3419; Park S, 2010, BIOCHEMISTRY-US, V49, P6576, DOI 10.1021/bi1009387; Paulson TG, 2009, CLIN CANCER RES, V15, P3305, DOI 10.1158/1078-0432.CCR-08-2494; Paulson TG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003809; Reid BJ, 2001, AM J GASTROENTEROL, V96, P1321; Reid BJ, 2010, NAT REV CANCER, V10, P87, DOI 10.1038/nrc2773; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rozen S, 2000, Methods Mol Biol, V132, P365; Sato F, 2006, CANCER-AM CANCER SOC, V106, P483, DOI 10.1002/cncr.21657; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Sherbet GV, 1998, ANTICANCER RES, V18, P2415; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Streppel MM, 2012, HUM PATHOL, V43, P1755, DOI 10.1016/j.humpath.2012.01.005; van Hagen P, 2012, NEW ENGL J MED, V366, P2074, DOI 10.1056/NEJMoa1112088; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang K, 2011, NAT GENET, V43, P1219, DOI 10.1038/ng.982; Wang Kenneth K, 2005, Gastroenterology, V128, P1468, DOI 10.1053/j.gastro.2005.03.076; Wang S, 2006, ONCOGENE, V25, P3346, DOI 10.1038/sj.onc.1209357; Wang ZX, 2010, CELL, V141, P1183, DOI 10.1016/j.cell.2010.05.016; Wiegand KC, 2010, NEW ENGL J MED, V363, P1532, DOI 10.1056/NEJMoa1008433; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Wu J, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002543; Yates LR, 2012, NAT REV GENET, V13, P795, DOI 10.1038/nrg3317; Yousef F, 2008, AM J EPIDEMIOL, V168, P237, DOI 10.1093/aje/kwn121; Zang ZJ, 2012, NAT GENET, V44, P570, DOI 10.1038/ng.2246	67	62	69	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2014	33	3					347	357		10.1038/onc.2012.586	http://dx.doi.org/10.1038/onc.2012.586			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VR	23318448	Green Accepted			2022-12-28	WOS:000330214000009
J	Henkels, KM; Boivin, GP; Dudley, ES; Berberich, SJ; Gomez-Cambronero, J				Henkels, K. M.; Boivin, G. P.; Dudley, E. S.; Berberich, S. J.; Gomez-Cambronero, J.			Phospholipase D (PLD) drives cell invasion, tumor growth and metastasis in a human breast cancer xenograph model	ONCOGENE			English	Article						cell signaling; human breast cancer; PLD; cell invasion and metastasis; SCID mice; xenotransplant	PHOSPHATIDIC-ACID; OVEREXPRESSION; EXPRESSION; KINASE; TRANSFORMATION; INHIBITORS; MIGRATION; INSIGHTS; SURVIVAL; PROTEIN	Breast cancer is one of the most common malignancies in human females in the world. One protein that has elevated enzymatic lipase activity in breast cancers in vitro is phospholipase D (PLD), which is also involved in cell migration. We demonstrate that the PLD2 isoform, which was analyzed directly in the tumors, is crucial for cell invasion that contributes critically to the growth and development of breast tumors and lung metastases in vivo. We used three complementary strategies in a SCID mouse model and also addressed the underlying molecular mechanism. First, the PLD2 gene was silenced in highly metastatic, aggressive breast cancer cells (MDA-MB-231) with lentivirus-based short hairpin RNA, which were xenotransplanted in SCID mice. The resulting mouse primary mammary tumors were reduced in size (65%, P<0.05) and their onset delayed when compared with control tumors. Second, we stably overexpressed PLD2 in low-invasive breast cancer cells (MCF-7) with a biscistronic MIEG retroviral vector and observed that these cells were converted into a highly aggressive phenotype, as primary tumors that formed following xenotransplantation were larger, grew faster and developed lung metastases more readily. Third, we implanted osmotic pumps into SCID xenotransplanted mice that delivered two different small-molecule inhibitors of PLD activity (5-fluoro-2-indolyl deschlorohalopemide and N-[2-(4-oxo-1-phenyl-1,3,8-triazaspiro[4,5]dec-8-yl)ethyl]-2-naphthalenecarboxamide). These inhibitors led to significant (>70%, P<0.05) inhibition of primary tumor growth, metastatic axillary tumors and lung metastases. In order to define the underlying mechanism, we determined that the machinery of PLD-induced cell invasion is mediated by phosphatidic acid, Wiscott-Aldrich Syndrome protein, growth receptor-bound protein 2 and Rac2 signaling events that ultimately affect actin polymerization and cell invasion. In summary, this study shows for the first time that PLD2 has a central role in the development, metastasis and level of aggressiveness of breast cancer, raising the possibility that PLD2 could be used as a new therapeutic target.	[Henkels, K. M.; Berberich, S. J.; Gomez-Cambronero, J.] Wright State Univ, Sch Med, Dept Biochem & Mol Biol, Boonshoft Sch Med, Dayton, OH 45435 USA; [Boivin, G. P.; Dudley, E. S.] Wright State Univ, Sch Med, Lab Anim Resources, Dayton, OH 45435 USA; [Boivin, G. P.] Vet Affairs Med Ctr, Cincinnati, OH 45267 USA	University System of Ohio; Wright State University Dayton; University System of Ohio; Wright State University Dayton; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Cincinnati VA Medical Center	Gomez-Cambronero, J (corresponding author), Wright State Univ, Sch Med, Dept Biochem & Mol Biol, 3640 Colonel Glenn Highway, Dayton, OH 45435 USA.	julian.cambronero@wright.edu		Gomez-Cambronero, Julian/0000-0002-7581-9227	National Institutes of Health (NIH/NHBLI) [HL056653]; Wright State University Boonshoft School of Medicine [229102]; State of Ohio Research Incentive [668372]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056653, R29HL056653] Funding Source: NIH RePORTER	National Institutes of Health (NIH/NHBLI); Wright State University Boonshoft School of Medicine; State of Ohio Research Incentive; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work has been supported by grant HL056653 from the National Institutes of Health (NIH/NHBLI) to JGC and from grants 229102 from Wright State University Boonshoft School of Medicine, and 668372 from the State of Ohio Research Incentive, also to JGC. We thank Dr Mary C Dinauer and Christophe Marchal for their help generating the pMIEG-PLD vectors and Dr Michael Frohman for providing the PA sensor and to Dr Frohman and to Dr H Alex Brown for guidance in the use of inhibitors. We also thank Dr Cambronero's lab members Qing Ye, Sam Kantonen, Madhu Mahankali, Nate Hatton and Ramya Ganesan, for their excellent help and care with the mice studies.	Benson JR, 2012, FUTURE ONCOL, V8, P697, DOI [10.2217/fon.12.61, 10.2217/FON.12.61]; Bray F, 2013, INT J CANCER, V132, P1133, DOI 10.1002/ijc.27711; Buchanan FG, 2005, P NATL ACAD SCI USA, V102, P1638, DOI 10.1073/pnas.0406698102; Chen Q, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003257; Chen YH, 2003, ONCOGENE, V22, P3937, DOI 10.1038/sj.onc.1206565; Cho JH, 2008, BBA-MOL CELL RES, V1783, P912, DOI 10.1016/j.bbamcr.2007.11.019; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Foster DA, 2003, MOL CANCER RES, V1, P789; Frondorf K, 2010, J BIOL CHEM, V285, P15837, DOI 10.1074/jbc.M109.070524; Gomez-Cambronero J, 2004, LEUKEMIA RES, V28, P755, DOI 10.1016/j.leukres.2003.11.012; Gomez-Cambronero J, 2012, J LEUKOCYTE BIOL, V92, P461, DOI 10.1189/jlb.0212073; Gomez-Cambronero J, 2010, THESCIENTIFICWORLDJO, V10, P1356, DOI 10.1100/tsw.2010.116; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Henkels KM, 2013, CELL SIGNAL, V25, P198, DOI 10.1016/j.cellsig.2012.08.010; Henkels KM, 2011, J MOL BIOL, V408, P850, DOI 10.1016/j.jmb.2011.03.017; Henkels KM, 2010, MOL CELL BIOL, V30, P2251, DOI 10.1128/MCB.01239-09; Itoh T, 2009, SCI SIGNAL; Jang JH, 2012, PROG LIPID RES, V51, P71, DOI 10.1016/j.plipres.2011.12.003; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; Joseph T, 2001, BIOCHEM BIOPH RES CO, V289, P1019, DOI 10.1006/bbrc.2001.6118; Kang DW, 2010, CANCER LETT, V294, P125, DOI 10.1016/j.canlet.2010.01.031; Kantonen S, 2011, MOL CELL BIOL, V31, P4524, DOI 10.1128/MCB.05684-11; Knapek K, 2010, MOL CELL BIOL, V30, P4492, DOI 10.1128/MCB.00229-10; Knoepp SM, 2008, MOL PHARMACOL, V74, P574, DOI 10.1124/mol.107.040105; Lorusso G, 2012, SEMIN CANCER BIOL, V22, P226, DOI 10.1016/j.semcancer.2012.03.007; Mahankali M, 2011, CELL SIGNAL, V23, P1291, DOI 10.1016/j.cellsig.2011.03.010; Min DS, 2001, CARCINOGENESIS, V22, P1641, DOI 10.1093/carcin/22.10.1641; Monovich L, 2007, BIOORG MED CHEM LETT, V17, P2310, DOI 10.1016/j.bmcl.2007.01.059; Nakanishi H, 2004, MOL BIOL CELL, V15, P1802, DOI 10.1091/mbc.e03-11-0798; Neiman AM, 2000, GENETICS, V155, P1643; Neiman AM, 1998, J CELL BIOL, V140, P29, DOI 10.1083/jcb.140.1.29; Nielsen SE, 1999, BRIT J NUTR, V81, P447, DOI 10.1017/S000711459900080X; Nishikimi A, 2009, SCIENCE, V324, P384, DOI 10.1126/science.1170179; Noh DY, 2000, CANCER LETT, V161, P207, DOI 10.1016/S0304-3835(00)00612-1; Park MH, 2009, CARCINOGENESIS, V30, P356, DOI 10.1093/carcin/bgn287; Peng HJ, 2011, MOL CELL BIOL, V31, P2227, DOI 10.1128/MCB.01348-10; Peng HJ, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.206672; Price JE, 1996, BREAST CANCER RES TR, V39, P93, DOI 10.1007/BF01806081; REICH R, 1995, CLIN EXP METASTAS, V13, P134, DOI 10.1007/BF00133618; Riebeling C, 2003, MELANOMA RES, V13, P555, DOI 10.1097/00008390-200312000-00003; Sanematsu F, 2013, J BIOL CHEM, V288, P8092, DOI 10.1074/jbc.M112.410423; Scott SA, 2009, NAT CHEM BIOL, V5, P108, DOI 10.1038/nchembio.140; Scully OJ, 2012, CANCER GENOM PROTEOM, V9, P311; Shen YJ, 2002, BIOCHEM BIOPH RES CO, V293, P201, DOI 10.1016/S0006-291X(02)00204-8; Shi M, 2007, CANCER LETT, V258, P268, DOI 10.1016/j.canlet.2007.09.003; Sossey-Alaoui K, 2007, AM J PATHOL, V170, P2112, DOI 10.2353/ajpath.2007.060975; Stasinopoulos I, 2007, MOL CANCER RES, V5, P435, DOI 10.1158/1541-7786.MCR-07-0010; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Su WJ, 2009, FUTURE ONCOL, V5, P1477, DOI [10.2217/fon.09.110, 10.2217/FON.09.110]; Su W, 2009, MOL PHARMACOL, V75, P437, DOI 10.1124/mol.108.053298; Taves J, 2008, ARCH BIOCHEM BIOPHYS, V477, P60, DOI 10.1016/j.abb.2008.05.007; Tsukahara T, 2010, MOL CELL, V39, P421, DOI 10.1016/j.molcel.2010.07.022; Weimbs T, 1997, P NATL ACAD SCI USA, V94, P3046, DOI 10.1073/pnas.94.7.3046; Williger BT, 1999, J BIOL CHEM, V274, P735, DOI 10.1074/jbc.274.2.735; Yamada Y, 2003, J MOL MED, V81, P126, DOI 10.1007/s00109-002-0411-x; You JC, 2009, ENDOCRINOLOGY, V150, P1607, DOI 10.1210/en.2008-0616; Zeniou-Meyer M, 2007, J BIOL CHEM, V282, P21746, DOI 10.1074/jbc.M702968200; Zhao YT, 2000, BIOCHEM BIOPH RES CO, V278, P140, DOI 10.1006/bbrc.2000.3719; Zheng Y, 2006, J BIOL CHEM, V281, P15862, DOI 10.1074/jbc.M600660200; Zhong MG, 2003, BIOCHEM BIOPH RES CO, V302, P615, DOI 10.1016/S0006-291X(03)00229-8; Zouwail S, 2005, BIOCHEM J, V389, P207, DOI 10.1042/BJ20050085	61	93	97	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2013	32	49					5551	5562		10.1038/onc.2013.207	http://dx.doi.org/10.1038/onc.2013.207			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	269XF	23752189	Green Accepted, hybrid			2022-12-28	WOS:000328276400006
J	Zhang, L; Wu, H; Lu, D; Li, G; Sun, C; Song, H; Li, J; Zhai, T; Huang, L; Hou, C; Wang, W; Zhou, B; Chen, S; Lu, B; Zhang, X				Zhang, L.; Wu, H.; Lu, D.; Li, G.; Sun, C.; Song, H.; Li, J.; Zhai, T.; Huang, Lv; Hou, C.; Wang, W.; Zhou, B.; Chen, S.; Lu, B.; Zhang, X.			The costimulatory molecule B7-H4 promote tumor progression and cell proliferation through translocating into nucleus	ONCOGENE			English	Article						B7-H4; nuclear localization sequence (NLS); tumor infiltrated lymphocyte (TIL); renal cell carcinoma (RCC); cell cycle; cell proliferation	B7 FAMILY-MEMBER; BREAST-CANCER; PROTEIN EXPRESSION; PANCREATIC-CANCER; OVARIAN-CANCER; CARCINOMA; LOCALIZATION; SURVIVAL; IMMUNORESISTANCE; ACTIVATION	B7-H4, a member of B7 family, is a transmembrane protein and inhibits T-cells immunity. However, in a variety of tumor cells, B7-H4 was detected predominantly in intracellular compartments with unknown mechanism and functions. In this study, we analyzed B7-H4 expression and subcellular distribution by immunohistochemistry in renal cell carcinoma (RCC) tissues. B7-H4 protein was detected on the membrane, in the cytosol and/or in the nucleus in tumor tissues. The membrane and nuclear expression of B7-H4 was significantly correlated with the tumor stages of RCC. Moreover, the membrane localization of B7-H4 was inversely correlated with the intensity of tumor infiltrates lymphocyte (TILs), whereas no association was observed between nuclear expression of B7-H4 and the density of TILs status. We further identified that B7-H4 is a cytoplasmic-nuclear shuttling protein containing a functional nuclear localization sequence (NLS) motif. A point mutation of B7-H4 NLS motif blocked the leptomycin B -induced nuclear accumulation of B7-H4. HEK293 cells stably expressing B7-H4 NLS mutant exhibited more potent inhibition in T-cell proliferation and cytokine production through increasing its surface expression compared with wild-type B7-H4 transfected cells owing to their increased surface expression. Most importantly, overexpression of wild-type B7-H4 in HEK293 cells enhanced tumor cell proliferation in vitro and tumorigenicity in vivo, promoted G1/S phase transition. The regulation of cell cycle by wild-type B7-H4 was partialy due to upregulation of Cyclin D 1 and Cyclin E. A mutation of B7-H4 NLS motif abolished the B7-H4-mediated cell proliferation and cell cycle regulation. Furthermore, B7-H4 wild-type confers chemoresistance activity to RCC cell lines including Caki-1 and ACHN. Our study provides a new insight into the functional implication of B7-H4 in its subcellular localization.	[Zhang, L.; Lu, D.; Zhang, X.] Soochow Univ, Coll Med, Inst Med Biotechnol, Jiangsu Stem Cell Res Lab, Suzhou 215006, Peoples R China; [Zhang, L.; Song, H.; Li, J.; Zhai, T.; Huang, Lv; Wang, W.; Chen, S.] Soochow Univ, Dept Pharm, Coll Pharmaceut Sci, Suzhou 215006, Peoples R China; [Wu, H.; Zhou, B.] Soochow Univ, Affiliated Hosp 1, Jiangsu Inst Clin Immunol, Suzhou 215006, Peoples R China; [Li, G.; Lu, B.] Univ Pittsburgh, Dept Immunol, Pittsburgh, PA USA; [Sun, C.; Hou, C.] Soochow Univ, Affiliated Hosp 2, Dept Urol, Suzhou 215006, Peoples R China	Soochow University - China; Soochow University - China; Soochow University - China; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Soochow University - China	Zhang, X (corresponding author), Soochow Univ, Coll Med, Inst Med Biotechnol, Jiangsu Stem Cell Res Lab, Renmin Rd 178, Suzhou 215006, Peoples R China.	xueguangzh@yahoo.com.cn	Zhai, Tianhang/HGD-2935-2022	Lu, Desheng/0000-0002-0314-5649; Zhang, Liang/0000-0002-5041-8005	National Nature Science Foundation of China [30901361]; Natural Science Fund for Colleges and Universities in Jiangsu Province [09KJB310013]; National Program on Key Basic Research Project (973 Program) [2013CB530501]; Program for Changjiang Scholars and Innovative Research Team [IRT0849]; National Natural Science Foundation of China [30930085]; Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Jiangsu Planned Projects for Postdoctoral Research Funds [0702053]; National University Student Innovation of Soochow University	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Fund for Colleges and Universities in Jiangsu Province; National Program on Key Basic Research Project (973 Program)(National Basic Research Program of China); Program for Changjiang Scholars and Innovative Research Team(Program for Changjiang Scholars & Innovative Research Team in University (PCSIRT)); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Jiangsu Planned Projects for Postdoctoral Research Funds; National University Student Innovation of Soochow University	We are grateful to Yu-ming Hu for his assistant in animal experiment; Wei Sun for collecting the clinical specimens; Ying Chen for her help in immunohistochemical analysis; and Kehua Yu as well as Yu Shen for their technical assistance in flow cytometry. This work was supported by National Nature Science Foundation of China (Grant No. 30901361); Natural Science Fund for Colleges and Universities in Jiangsu Province (Grant No. 09KJB310013); National Program on Key Basic Research Project (973 Program, Grant No. 2013CB530501); Program for Changjiang Scholars and Innovative Research Team (Grant No. IRT0849); National Natural Science Foundation of China (Grants No. 30930085); A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD); Jiangsu Planned Projects for Postdoctoral Research Funds (No. 0702053); National University Student Innovation of Soochow University.	ALLRED DC, 1993, J NATL CANCER I, V85, P200, DOI 10.1093/jnci/85.3.200; Arigami T, 2011, WORLD J SURG, V35, P2051, DOI 10.1007/s00268-011-1186-4; Arnoys EJ, 2007, ACTA HISTOCHEM, V109, P89, DOI 10.1016/j.acthis.2006.10.002; Awadallah NS, 2008, PANCREAS, V36, P200, DOI 10.1097/MPA.0b013e318150e4e0; Azuma T, 2009, PLOS MED, V6, DOI 10.1371/journal.pmed.1000166; Boucher MJ, 2000, J CELL BIOCHEM, V79, P355, DOI 10.1002/1097-4644(20001201)79:3<355::AID-JCB20>3.0.CO;2-0; Chen LJ, 2011, CANCER IMMUNOL IMMUN, V60, P1047, DOI 10.1007/s00262-011-1017-3; Chen YW, 2011, INFLAMMATION, V34, P688, DOI 10.1007/s10753-010-9280-6; Cheng L, 2009, INT J GYNECOL CANCER, V19, P1481, DOI 10.1111/IGC.0b013e3181ad0fa2; Crane CA, 2009, ONCOGENE, V28, P306, DOI 10.1038/onc.2008.384; Fei F, 2008, EXP HEMATOL, V36, P1297, DOI 10.1016/j.exphem.2008.05.002; Flies DB, 2007, J IMMUNOTHER, V30, P251, DOI 10.1097/CJI.0b013e31802e085a; Ghebeh H, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2605; Guida M, 2007, ANN ONCOL, V18, P149, DOI 10.1093/annonc/mdm245; Huang WC, 2011, J BIOL CHEM, V286, P20558, DOI 10.1074/jbc.M111.240796; Jiang JT, 2010, CANCER IMMUNOL IMMUN, V59, P1707, DOI 10.1007/s00262-010-0900-7; Kamimura Y, 2009, BIOCHEM BIOPH RES CO, V389, P349, DOI 10.1016/j.bbrc.2009.08.144; KIEFER P, 1994, EMBO J, V13, P4126, DOI 10.1002/j.1460-2075.1994.tb06730.x; Krambeck AE, 2006, P NATL ACAD SCI USA, V103, P10391, DOI 10.1073/pnas.0600937103; Kryczek I, 2006, J EXP MED, V203, P871, DOI 10.1084/jem.20050930; Kurebayashi Y, 2012, CELL REP, V1, P360, DOI 10.1016/j.celrep.2012.02.007; MICKISCH GH, 1994, WORLD J UROL, V12, P214; Miyatake T, 2007, GYNECOL ONCOL, V106, P119, DOI 10.1016/j.ygyno.2007.03.039; Parsa AT, 2007, NAT MED, V13, P84, DOI 10.1038/nm1517; Prasad DVR, 2003, IMMUNITY, V18, P863, DOI 10.1016/S1074-7613(03)00147-X; Quandt D, 2011, CLIN CANCER RES, V17, P3100, DOI 10.1158/1078-0432.CCR-10-2268; Salceda S, 2005, EXP CELL RES, V306, P128, DOI 10.1016/j.yexcr.2005.01.018; Sica GL, 2003, IMMUNITY, V18, P849, DOI 10.1016/S1074-7613(03)00152-3; Simon I, 2006, CANCER RES, V66, P1570, DOI 10.1158/0008-5472.CAN-04-3550; Tan DSW, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-17; Thompson RH, 2008, CANCER RES, V68, P6054, DOI 10.1158/0008-5472.CAN-08-0869; Tringler B, 2006, GYNECOL ONCOL, V100, P44, DOI 10.1016/j.ygyno.2005.08.060; Tringler B, 2005, CLIN CANCER RES, V11, P1842, DOI 10.1158/1078-0432.CCR-04-1658; Vasko R, 2011, EUR J PHARMACOL, V670, P50, DOI 10.1016/j.ejphar.2011.08.030; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang XJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028232; Zang XX, 2003, P NATL ACAD SCI USA, V100, P10388, DOI 10.1073/pnas.1434299100	37	67	82	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2013	32	46					5347	5358		10.1038/onc.2012.600	http://dx.doi.org/10.1038/onc.2012.600			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251IU	23318460	hybrid, Green Published			2022-12-28	WOS:000326922400005
J	Tait, S				Tait, S.			DNA: leukemia's secret weapon of bone mass destruction	ONCOGENE			English	Editorial Material							MYB	Interaction of tumour cells with their microenvironment impacts on all aspects of cancer, ranging from development through to treatment response. In this issue, Dvorak and colleagues(1) reveal a novel tumour/microevironment relationship that may drive leukemia pathogenesis. Specifically, they find that leukemic cells secrete chromatin-complexed DNA that, in turn, triggers a variety of harmful effects, including cell death, in neighbouring stromal cells. Through this toxicity, DNA-mediated bone marrow destruction could promote disease progression by allowing leukemic cells to exit the bone marrow into the circulation.	Univ Glasgow, Beatson Inst Canc Res, Inst Canc Sci, Glasgow G61 1BD, Lanark, Scotland	Beatson Institute; University of Glasgow	Tait, S (corresponding author), Univ Glasgow, Beatson Inst Canc Res, Inst Canc Sci, Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	stephen.tait@glasgow.ac.uk		Tait, Stephen/0000-0001-7697-132X				Dvorakova M, 2013, ONCOGENE, V32, P5201, DOI 10.1038/onc.2012.553; Dvorakova M, 2001, BLOOD CELL MOL DIS, V27, P437, DOI 10.1006/bcmd.2001.0402; Gahan PB, 2010, CELL BIOCHEM FUNCT, V28, P529, DOI 10.1002/cbf.1690; Karafiat V, 2001, BLOOD, V98, P3668, DOI 10.1182/blood.V98.13.3668; Nickel W, 2010, CURR OPIN BIOTECH, V21, P621, DOI 10.1016/j.copbio.2010.06.004; Pattabiraman DR, 2013, LEUKEMIA, V27, P269, DOI 10.1038/leu.2012.225	6	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2013	32	44					5199	5200		10.1038/onc.2012.639	http://dx.doi.org/10.1038/onc.2012.639			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245XH	23353820				2022-12-28	WOS:000326497100002
J	Felten, A; Brinckmann, D; Landsberg, G; Scheidtmann, KH				Felten, A.; Brinckmann, D.; Landsberg, G.; Scheidtmann, K. H.			Zipper-interacting protein kinase is involved in regulation of ubiquitination of the androgen receptor, thereby contributing to dynamic transcription complex assembly	ONCOGENE			English	Article						AR; ZIPK; AATF/Che-1; TSG101; Mdm2; ubiquitination	RESPONSIVE PROMOTERS; RECRUITMENT; MDM2; PROTEASOME; ALPHA; COREGULATORS; DEGRADATION; HOMOLOG; HDAC1	We have recently identified apoptosis-antagonizing transcription factor (AATF), tumor-susceptibility gene 101 (TSG101) and zipperinteracting protein kinase (ZIPK) as novel coactivators of the androgen receptor (AR). The mechanisms of coactivation remained obscure, however. Here we investigated the interplay and interdependence between these coactivators and the AR using the endogenous prostate specific antigen (PSA) gene as model for AR-target genes. Chromatin immunoprecipitation in combination with siRNA-mediated knockdown revealed that recruitment of AATF and ZIPK to the PSA enhancer was dependent on AR, whereas recruitment of TSG101 was dependent on AATF. Association of AR and its coactivators with the PSA enhancer or promoter occurred in cycles. Dissociation of AR-transcription complexes was due to degradation because inhibition of the proteasome system by MG132 caused accumulation of AR at enhancer/promoter elements. Moreover, inhibition of degradation strongly reduced transcription, indicating that continued and efficient transcription is based on initiation, degradation and reinitiation cycles. Interestingly, knockdown of ZIPK by siRNA had a similar effect as MG132, leading to reduced transcription but enhanced accumulation of AR at androgen-response elements. In addition, knockdown of ZIPK, as well as overexpression of a dominant-negative ZIPK mutant, diminished polyubiquitination of AR. Furthermore, ZIPK cooperated with the E3 ligase Mdm2 in AR-dependent transactivation, assembled into a single complex on chromatin and phosphorylated Mdm2 in vitro. These results suggest that ZIPK has a crucial role in regulation of ubiquitination and degradation of the AR, and hence promoter clearance and efficient transcription.	[Felten, A.; Brinckmann, D.; Landsberg, G.; Scheidtmann, K. H.] Univ Bonn, Inst Genet, D-53111 Bonn, Germany	University of Bonn	Felten, A (corresponding author), Univ Bonn, Dept Psychol, Kaiser Karl Ring 9, D-53111 Bonn, Germany.	andrea.felten@uni-bonn-diff.de			German Research Association [Sche246/20-1]	German Research Association(German Research Foundation (DFG))	We thank Dr Klemens Rottner and Dr Walter Witke from the Institute of Genetics (Bonn, Germany) for their hospitality during revision and Dr Maurizio Fanciulli (Regina Elena Cancer Institute, Rome, Italy) for antibodies against AATF/Che-1. This work was supported by the German Research Association to KHS (Sche246/20-1).	Bi J, 2009, INT J CANCER, V124, P1587, DOI 10.1002/ijc.24164; Brognard J, 2011, CANCER RES, V71, P3152, DOI 10.1158/0008-5472.CAN-10-3543; Bruno T, 2002, CANCER CELL, V2, P387, DOI 10.1016/S1535-6108(02)00182-4; Burch LR, 2004, J MOL BIOL, V337, P115, DOI 10.1016/j.jmb.2003.10.081; Burgdorf S, 2004, J BIOL CHEM, V279, P17524, DOI 10.1074/jbc.M313703200; Chymkowitch P, 2011, EMBO J, V30, P468, DOI 10.1038/emboj.2010.337; De Nicola F, 2007, J BIOL CHEM, V282, P19685, DOI 10.1074/jbc.M610282200; Di Padova M, 2003, J BIOL CHEM, V278, P36496, DOI 10.1074/jbc.M306694200; Engemann H, 2002, NUCLEIC ACIDS RES, V30, P1408, DOI 10.1093/nar/30.6.1408; Faus H, 2006, BIOMED PHARMACOTHER, V60, P520, DOI 10.1016/j.biopha.2006.07.082; Felten A, 2007, BIOL CHEM, V388, P569, DOI 10.1515/BC.2007.073; Gaughan L, 2005, NUCLEIC ACIDS RES, V33, P13, DOI 10.1093/nar/gki141; Gioeli D, 2012, MOL CELL ENDOCRINOL, V352, P70, DOI 10.1016/j.mce.2011.07.004; Graves PR, 2005, J BIOL CHEM, V280, P9363, DOI 10.1074/jbc.M412538200; Heemers HV, 2007, ENDOCR REV, V28, P778, DOI 10.1210/er.2007-0019; Hinojos CAD, 2005, TRENDS ENDOCRIN MET, V16, P12, DOI 10.1016/j.tem.2004.11.006; Johnsen S A, 2006, Ernst Schering Found Symp Proc, P1; Kang ZG, 2004, MOL ENDOCRINOL, V18, P2633, DOI 10.1210/me.2004-0245; Kang ZG, 2002, J BIOL CHEM, V277, P48366, DOI 10.1074/jbc.M209074200; Kawai T, 1998, MOL CELL BIOL, V18, P1642, DOI 10.1128/MCB.18.3.1642; Keppler BR, 2011, BBA-GENE REGUL MECH, V1809, P109, DOI 10.1016/j.bbagrm.2010.08.005; Leister P, 2008, ONCOGENE, V27, P3292, DOI 10.1038/sj.onc.1210995; Leister P., 2003, SIGNAL TRANSDUCTION, V3, P17, DOI [10.1002/sita.200300020, DOI 10.1002/SITA.200300020]; Li LM, 2001, P NATL ACAD SCI USA, V98, P1619, DOI 10.1073/pnas.98.4.1619; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lin HK, 2002, J BIOL CHEM, V277, P36570, DOI 10.1074/jbc.M204751200; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Natrajan R, 2012, J PATHOL, V227, P29, DOI 10.1002/path.4003; Page G, 1999, FEBS LETT, V462, P187, DOI 10.1016/S0014-5793(99)01529-X; Passananti C, 2007, BIOCHEM CELL BIOL, V85, P477, DOI 10.1139/O07-062; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Saji S, 2001, BIOCHEM BIOPH RES CO, V281, P259, DOI 10.1006/bbrc.2001.4339; Sato N, 2005, INT IMMUNOL, V17, P1543, DOI 10.1093/intimm/dxh331; Scheidtmann KH, 2007, SIGNAL TRANSDUCTION, V7, P248, DOI 10.1002/sita.200600112; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Sharma D, 2002, P NATL ACAD SCI USA, V99, P7934, DOI 10.1073/pnas.122004799; Vaisanen S, 2005, J MOL BIOL, V350, P65, DOI 10.1016/j.jmb.2005.04.057; Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018; Welsbie DS, 2009, CANCER RES, V69, P958, DOI 10.1158/0008-5472.CAN-08-2216; Xu KX, 2009, CANCER CELL, V15, P270, DOI 10.1016/j.ccr.2009.02.021	40	12	12	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2013	32	41					4981	4988		10.1038/onc.2012.503	http://dx.doi.org/10.1038/onc.2012.503			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235KQ	23146908				2022-12-28	WOS:000325717800014
J	Li, D; Takao, T; Tsunematsu, R; Morokuma, S; Fukushima, K; Kobayashi, H; Saito, T; Furue, M; Wake, N; Asanoma, K				Li, D.; Takao, T.; Tsunematsu, R.; Morokuma, S.; Fukushima, K.; Kobayashi, H.; Saito, T.; Furue, M.; Wake, N.; Asanoma, K.			Inhibition of AHR transcription by NF1C is affected by a single-nucleotide polymorphism, and is involved in suppression of human uterine endometrial cancer	ONCOGENE			English	Article						NF1C; AHR; single-nucleotide polymorphism; uterine endometrial cancer	ARYL-HYDROCARBON-RECEPTOR; ADENOVIRUS DNA-REPLICATION; MAMMARY-GLAND; CYP1A1 LEVELS; LUNG-CANCER; FACTOR 1-C2; IN-VIVO; EXPRESSION; GENE; OVEREXPRESSION	Involvement of the aryl hydrocarbon receptor (AHR) in carcinogenesis has been suggested in many studies. Upregulation of AHR has been reported in some cancer species, and an association between single-nucleotide polymorphisms (SNPs) of AHR and cancer risk or cancer development has also been reported. This evidence suggests the involvement of some specific SNPs in AHR transcriptional regulation in the process of carcinogenesis or cancer development, but there have been no studies to elucidate the mechanism involved. In this study, we identified the transcription factor Nuclear Factor 1-C (NF1C) as a candidate to regulate AHR transcription in a polymorphism-dependent manner. SNP rs10249788 was included in a consensus binding site for NF1C. Our results suggested that NF1C preferred the C allele to the T allele at rs10249788 for binding. Forced expression of NF1C suppressed the activity of the AHR promoter with C at rs10249788 stronger than that with T. Moreover, expression analysis of human uterine endometrial cancer (HEC) specimens showed greater upregulation of AHR and downregulation of NF1C than those of normal endometrium specimens. Sequence analysis showed HEC patients at advanced stages tended to possess T/T alleles more frequently than healthy women. We also demonstrated that NF1C suppressed proliferation, motility and invasion of HEC cells. This function was at least partially mediated by AHR. This study is the first to report that a polymorphism on the AHR regulatory region affected transcriptional regulation of the AHR gene in vitro. Because NF1C is a tumor suppressor, our new insights into AHR deregulation and its polymorphisms could reveal novel mechanisms of genetic susceptibility to cancer.	[Li, D.; Tsunematsu, R.; Fukushima, K.; Kobayashi, H.; Wake, N.; Asanoma, K.] Kyushu Univ, Grad Sch Med Sci, Dept Obstet & Gynecol, Fukuoka 8128582, Japan; [Takao, T.; Morokuma, S.; Wake, N.] Kyushu Univ, Grad Sch Med Sci, Res Ctr Environm & Dev Med Sci, Dept Genom Epidemiol, Fukuoka 8128582, Japan; [Saito, T.] Kyushu Natl Canc Ctr, Dept Gynecol, Fukuoka, Japan; [Furue, M.] Kyushu Univ, Grad Sch Med Sci, Dept Dermatol, Fukuoka 8128582, Japan	Kyushu University; Kyushu University; Kyushu University	Asanoma, K (corresponding author), Kyushu Univ, Grad Sch Med Sci, Dept Obstet & Gynecol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	asanoma@med.kyushu-u.ac.jp	Takao, Tomoka/K-1568-2015	Takao, Tomoka/0000-0002-6519-2301	Ministry of Education, Culture, Sports, Science and Technology, Japan [23249075, 23591596, 23791847, 23592405]; Ministry of Health, Labor and Welfare; Environment Technology Development Fund of the Ministry of the Environment, Japan; Grants-in-Aid for Scientific Research [23592405] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labor and Welfare(Ministry of Health, Labour and Welfare, Japan); Environment Technology Development Fund of the Ministry of the Environment, Japan; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank Dr Suminori Kono at the Division of Environmental and Social Medicine, Kyushu University for kindly providing us with DNA from blood samples. We appreciate the technical support from Kanako Okamoto, Dr Tomoko Yoneda and the Research Support Center, Graduate School of Medical Sciences, Kyushu University. We also thank Drs Kiyoko Kato and Kiyomi Tsukimori for their valuable discussions. This work was supported by a Grant-in-Aid (23249075, 23591596, 23791847 and 23592405) from the Ministry of Education, Culture, Sports, Science and Technology, Japan. This work was also partly supported by grants from The Ministry of Health, Labor and Welfare, and the Environment Technology Development Fund of the Ministry of the Environment, Japan.	ABBOTT BD, 1995, DEV DYNAM, V204, P133, DOI 10.1002/aja.1002040204; Andersson P, 2002, P NATL ACAD SCI USA, V99, P9990, DOI 10.1073/pnas.152706299; Anttila S, 2001, PHARMACOGENETICS, V11, P501, DOI 10.1097/00008571-200108000-00005; Asanoma K, 2012, J BIOL CHEM, V287, P2257, DOI 10.1074/jbc.M111.287128; Belguise K, 2007, CANCER RES, V67, P11742, DOI 10.1158/0008-5472.CAN-07-2730; Bradshaw TD, 2002, CURR PHARM DESIGN, V8, P2475, DOI 10.2174/1381612023392784; Cauchi S, 2001, CARCINOGENESIS, V22, P1819, DOI 10.1093/carcin/22.11.1819; Chaudhry AZ, 1997, DEV DYNAM, V208, P313; Crews ST, 1999, CURR OPIN GENET DEV, V9, P580, DOI 10.1016/S0959-437X(99)00003-9; EGUCHI H, 1994, BIOCHEM BIOPH RES CO, V203, P615, DOI 10.1006/bbrc.1994.2227; Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; HAY RT, 1985, EMBO J, V4, P421, DOI 10.1002/j.1460-2075.1985.tb03645.x; Higasa K, 2007, NUCLEIC ACIDS RES, V35, pD685, DOI 10.1093/nar/gkl848; Ikuta T, 2006, EXP CELL RES, V312, P3585, DOI 10.1016/j.yexcr.2006.08.002; Innocentin YLS, 2011, CELL, V147, P629, DOI 10.1016/j.cell.2011.09.025; Johansson EM, 2003, ONCOGENE, V22, P6061, DOI 10.1038/sj.onc.1206884; Khorram O, 2002, MOL HUM REPROD, V8, P75, DOI 10.1093/molehr/8.1.75; Kim JH, 2007, LUNG CANCER, V56, P9, DOI 10.1016/j.lungcan.2006.11.010; Kiss EA, 2011, SCIENCE, V334, P1561, DOI 10.1126/science.1214914; Koliopanos A, 2002, ONCOGENE, V21, P6059, DOI 10.1038/sj.onc.1205633; Kondo H, 2004, INVEST OPHTH VIS SCI, V45, P4433, DOI 10.1167/iovs.04-0544; Kuchenhoff A, 1999, FERTIL STERIL, V71, P354, DOI 10.1016/S0015-0282(98)00437-3; Kukita Y, 2005, GENOME RES, V15, P1511, DOI 10.1101/gr.4371105; Kyo S, 2003, AM J PATHOL, V163, P2259, DOI 10.1016/S0002-9440(10)63583-3; Lin PP, 2003, TOXICOL PATHOL, V31, P22, DOI 10.1080/01926230309746; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Long JR, 2006, PHARMACOGENET GENOM, V16, P237, DOI 10.1097/01.fpc.0000189803.34339.ed; Marconett CN, 2010, MOL BIOL CELL, V21, P1166, DOI 10.1091/mbc.E09-08-0689; Marlowe JL, 2005, J CELL BIOCHEM, V96, P1174, DOI 10.1002/jcb.20656; Moennikes O, 2004, CANCER RES, V64, P4707, DOI 10.1158/0008-5472.CAN-03-0875; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P6177, DOI 10.1073/pnas.80.20.6177; NAGATA K, 1983, P NATL ACAD SCI-BIOL, V80, P4266, DOI 10.1073/pnas.80.14.4266; NEBL G, 1994, J BIOL CHEM, V269, P7371; Nilsson J, 2010, CANCER RES, V70, P2020, DOI 10.1158/0008-5472.CAN-09-1677; Ohtake F, 2003, NATURE, V423, P545, DOI 10.1038/nature01606; Opitz CA, 2011, NATURE, V478, P197, DOI 10.1038/nature10491; Rafty LA, 2002, EMBO J, V21, P334, DOI 10.1093/emboj/21.3.334; Rozen S, 2000, Methods Mol Biol, V132, P365; Schlezinger JJ, 2006, BIOL CHEM, V387, P1175, DOI 10.1515/BC.2006.145; Shehu A, 2011, MOL ENDOCRINOL, V25, P754, DOI 10.1210/me.2010-0261; Smart J, 2000, PHARMACOGENETICS, V10, P11, DOI 10.1097/00008571-200002000-00003; Tang TA, 2010, FREE RADICAL BIO MED, V49, P487, DOI 10.1016/j.freeradbiomed.2010.05.007; Ueoka Y, 2003, MOL CELL ENDOCRINOL, V202, P81, DOI 10.1016/S0303-7207(03)00067-4; Wong JMY, 2001, BIOCHEM BIOPH RES CO, V288, P990, DOI 10.1006/bbrc.2001.5861; Wormke M, 2000, J STEROID BIOCHEM, V72, P197, DOI 10.1016/S0960-0760(00)00030-3; YANG BS, 1993, MOL CELL BIOL, V13, P3093, DOI 10.1128/MCB.13.5.3093	47	23	26	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2013	32	41					4950	4959		10.1038/onc.2012.509	http://dx.doi.org/10.1038/onc.2012.509			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235KQ	23208493				2022-12-28	WOS:000325717800011
J	Landman, AS; Danielian, PS; Lees, JA				Landman, A. S.; Danielian, P. S.; Lees, J. A.			Loss of pRB and p107 disrupts cartilage development and promotes enchondroma formation	ONCOGENE			English	Article						pRB; p107; Prx1-Cre; cartilage; chondrocytes; enchondroma	RETINOBLASTOMA PROTEIN; CELL-CYCLE; TUMOR-SUPPRESSOR; BONE-DEVELOPMENT; RB-LOSS; EXPRESSION; DEFICIENT; MUTATION; GENE; DIFFERENTIATION	The pocket proteins pRB, p107 and p130 have established roles in regulating the cell cycle through the control of E2F activity. The pocket proteins regulate differentiation of a number of tissues in both cell cycle-dependent and -independent manners. Prior studies showed that mutation of p107 and p130 in the mouse leads to defects in cartilage development during endochondral ossification, the process by which long bones form. Despite evidence of a role for pRB in osteoblast differentiation, it is unknown whether it functions during cartilage development. Here, we show that mutation of Rb in the early mesenchyme of p107-mutant mice results in severe cartilage defects in the growth plates of long bones. This is attributable to inappropriate chondrocyte proliferation that persists after birth and leads to the formation of enchondromas in the growth plates as early as 8 weeks of age. Genetic crosses show that development of these tumorigenic lesions is E2f3 dependent. These results reveal an overlapping role for pRB and p107 in cartilage development, endochondral ossification and enchondroma formation that reflects their coordination of cell-cycle exit at appropriate developmental stages.	[Landman, A. S.; Danielian, P. S.; Lees, J. A.] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Lees, JA (corresponding author), MIT, David H Koch Inst Integrat Canc Res, 77 Massachusetts Ave,Bldg 76-461B, Cambridge, MA 02139 USA.	jalees@mit.edu		Danielian, Paul/0000-0003-2651-0386	National Cancer Institute [CA121921]; Ludwig Graduate Fellowship; NATIONAL CANCER INSTITUTE [R01CA121921] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Ludwig Graduate Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Rbc/c, p107<SUP>-/-</SUP> and Rosa26-LSL-LacZ transgenic mice were kindly provided by Tyler Jacks (MIT). We are grateful to Seth Berman for initial mouse colony generation, and Julie West for immuno-histochemistry assistance, as well as all members of the Lees laboratory for helpful discussions throughout this work. We thank MIT Swanson Biotechnology Center members Eliza Vasile for assistance with mCT data collection and analysis and Alicia Caron for histological sectioning and H&E staining. We also thank Roderick Bronson for histopathological analyses and advice. This work was supported by a grant to JAL from the National Cancer Institute (CA121921), and a Ludwig Graduate Fellowship to ASL. JAL is a Ludwig Scholar.	Asp J, 2001, J ORTHOPAED RES, V19, P149, DOI 10.1016/S0736-0266(00)00022-X; Asp J, 2000, INT J CANCER, V85, P782, DOI 10.1002/(SICI)1097-0215(20000315)85:6<782::AID-IJC7>3.0.CO;2-O; Berman SD, 2008, MOL CANCER RES, V6, P1440, DOI 10.1158/1541-7786.MCR-08-0176; Berman SD, 2008, P NATL ACAD SCI USA, V105, P11851, DOI 10.1073/pnas.0805462105; Berman SD, 2009, P NATL ACAD SCI USA, V106, P14932, DOI 10.1073/pnas.0902408106; Boeuf S, 2008, J PATHOL, V216, P158, DOI 10.1002/path.2389; Bovee JVMG, 2010, NAT REV CANCER, V10, P481, DOI 10.1038/nrc2869; Calo E, 2010, NATURE, V466, P1110, DOI 10.1038/nature09264; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Danielian PS, 2008, ONCOGENE, V27, P6561, DOI 10.1038/onc.2008.253; de Bruin A, 2003, P NATL ACAD SCI USA, V100, P6546, DOI 10.1073/pnas.1031853100; Dirlam A, 2007, MOL CELL BIOL, V27, P8713, DOI 10.1128/MCB.01118-07; Ferguson KL, 2002, EMBO J, V21, P3337, DOI 10.1093/emboj/cdf338; Glatt V, 2007, J BONE MINER RES, V22, P1197, DOI 10.1359/JBMR.070507; GURNEY JG, 1995, CANCER, V75, P2186, DOI 10.1002/1097-0142(19950415)75:8<2186::AID-CNCR2820750825>3.0.CO;2-F; Gutierrez GM, 2008, P NATL ACAD SCI USA, V105, P18402, DOI 10.1073/pnas.0805925105; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEFEBVRE V, 1994, MATRIX BIOL, V14, P329, DOI 10.1016/0945-053X(94)90199-6; Lipinski MM, 2001, EMBO J, V20, P3402, DOI 10.1093/emboj/20.13.3402; Logan M, 2002, GENESIS, V33, P77, DOI 10.1002/gene.10092; MacPherson D, 2003, MOL CELL BIOL, V23, P1044, DOI 10.1128/MCB.23.3.1044-1053.2003; Miller MD, 2004, REV ORTHOPAEDICS, Vxv; Parisi T, 2007, MOL CELL BIOL, V27, P2283, DOI 10.1128/MCB.01854-06; Politi K, 2004, AM J PATHOL, V164, P325, DOI 10.1016/S0002-9440(10)63122-7; Robanus-Maandag E, 1998, GENE DEV, V12, P1599, DOI 10.1101/gad.12.11.1599; Ropke M, 2006, ONCOL REP, V15, P89; Rossi F, 2002, DEV BIOL, V247, P271, DOI 10.1006/dbio.2002.0691; Ruiz S, 2004, DEVELOPMENT, V131, P2737, DOI 10.1242/dev.01148; Saavedra HI, 2002, CELL GROWTH DIFFER, V13, P215; Sage C, 2006, P NATL ACAD SCI USA, V103, P7345, DOI 10.1073/pnas.0510631103; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; Scheijen B, 2003, MOL CELL BIOL, V23, P3656, DOI 10.1128/MCB.23.10.3656-3668.2003; Schrage YM, 2009, AM J PATHOL, V174, P979, DOI 10.2353/ajpath.2009.080623; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Tiet TD, 2006, AM J PATHOL, V168, P321, DOI 10.2353/ajpath.2006.050001; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Tsai KY, 1998, MOL CELL, V2, P293, DOI 10.1016/S1097-2765(00)80274-9; Tsai SY, 2008, NATURE, V454, P1137, DOI 10.1038/nature07066; Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wenzel PL, 2007, GENE DEV, V21, P85, DOI 10.1101/gad.1485307; Wu LZ, 2003, NATURE, V421, P942, DOI 10.1038/nature01417; Yamaguchi T, 1996, ANTICANCER RES, V16, P2009; Yamasaki L, 1998, NAT GENET, V18, P360, DOI 10.1038/ng0498-360; Zacksenhaus E, 1996, GENE DEV, V10, P3051, DOI 10.1101/gad.10.23.3051; Zheng QP, 2009, J BONE MINER RES, V24, P1022, DOI [10.1359/JBMR.081249, 10.1359/jbmr.081249]; Ziebold U, 2001, GENE DEV, V15, P386, DOI 10.1101/gad.858801	51	6	6	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2013	32	40					4798	4805		10.1038/onc.2012.496	http://dx.doi.org/10.1038/onc.2012.496			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229NW	23146901	Green Accepted, Green Submitted			2022-12-28	WOS:000325274700008
J	Christie, M; Jorissen, RN; Mouradov, D; Sakthianandeswaren, A; Li, S; Day, F; Tsui, C; Lipton, L; Desai, J; Jones, IT; McLaughlin, S; Ward, RL; Hawkins, NJ; Ruszkiewicz, AR; Moore, J; Burgess, AW; Busam, D; Zhao, Q; Strausberg, RL; Simpson, AJ; Tomlinson, IPM; Gibbs, P; Sieber, OM				Christie, M.; Jorissen, R. N.; Mouradov, D.; Sakthianandeswaren, A.; Li, S.; Day, F.; Tsui, C.; Lipton, L.; Desai, J.; Jones, I. T.; McLaughlin, S.; Ward, R. L.; Hawkins, N. J.; Ruszkiewicz, A. R.; Moore, J.; Burgess, A. W.; Busam, D.; Zhao, Q.; Strausberg, R. L.; Simpson, A. J.; Tomlinson, I. P. M.; Gibbs, P.; Sieber, O. M.			Different APC genotypes in proximal and distal sporadic colorectal cancers suggest distinct WNT/beta-catenin signalling thresholds for tumourigenesis	ONCOGENE			English	Article						APC; colorectal cancer; mutation; just-right signalling	FAMILIAL ADENOMATOUS POLYPOSIS; SOMATIC MUTATIONS; PROMOTER HYPERMETHYLATION; GERMLINE MUTATION; COLI GENE; TUMORS; PROTEIN; SITE; INSTABILITY; LOCATION	Biallelic protein-truncating mutations in the adenomatous polyposis coli (APC) gene are prevalent in sporadic colorectal cancer (CRC). Mutations may not be fully inactivating, instead producing WNT/beta-catenin signalling levels 'just-right' for tumourigenesis. However, the spectrum of optimal APC genotypes accounting for both hits, and the influence of clinicopathological features on genotype selection remain undefined. We analysed 630 sporadic CRCs for APC mutations and loss of heterozygosity (LOH) using sequencing and single-nucleotide polymorphism microarrays, respectively. Truncating APC mutations and/or LOH were detected in 75% of CRCs. Most truncating mutations occurred within a mutation cluster region (MCR; codons 1282-1581) leaving 1-3 intact 20 amino-acid repeats (20AARs) and abolishing all Ser-Ala-Met-Pro (SAMP) repeats. Cancers commonly had one MCR mutation plus either LOH or another mutation 5' to the MCR. LOH was associated with mutations leaving 1 intact 20AAR. MCR mutations leaving 1 vs 2-3 intact 20AARs were associated with 5' mutations disrupting or leaving intact the armadillo-repeat domain, respectively. Cancers with three hits had an over-representation of mutations upstream of codon 184, in the alternatively spliced region of exon 9, and 3' to the MCR. Microsatellite unstable cancers showed hyper-mutation at MCR mono- and di-nucleotide repeats, leaving 2-3 intact 20AARs. Proximal and distal cancers exhibited different preferred APC genotypes, leaving a total of 2 or 3 and 0 to 2 intact 20AARs, respectively. In conclusion, APC genotypes in sporadic CRCs demonstrate 'fine-tuned' interdependence of hits by type and location, consistent with selection for particular residual levels of WNT/beta-catenin signalling, with different 'optimal' thresholds for proximal and distal cancers.	[Christie, M.; Jorissen, R. N.; Mouradov, D.; Sakthianandeswaren, A.; Li, S.; Day, F.; Tsui, C.; Lipton, L.; Desai, J.; Gibbs, P.; Sieber, O. M.] Royal Melbourne Hosp, Ludwig Inst Canc Res, Ludwig Colon Canc Initiat Lab, Parkville, Vic 3050, Australia; [Christie, M.; Day, F.; Lipton, L.; Gibbs, P.; Sieber, O. M.] Univ Melbourne, Dept Surg, Royal Melbourne Hosp, Fac Med Dent & Hlth Sci, Parkville, Vic 3052, Australia; [Lipton, L.; Desai, J.; Gibbs, P.] Royal Melbourne Hosp, Dept Med Oncol, Parkville, Vic 3050, Australia; [Jones, I. T.] Royal Melbourne Hosp, Dept Colorectal Surg, Parkville, Vic 3050, Australia; [McLaughlin, S.] Western Hosp, Dept Colorectal Surg, Footscray, Vic, Australia; [Ward, R. L.] Univ New S Wales, Prince Wales Clin Sch, Lowy Canc Res Ctr, Sydney, NSW, Australia; [Hawkins, N. J.] Univ New S Wales, Sch Med Sci, Dept Pathol, Sydney, NSW, Australia; [Ruszkiewicz, A. R.] Inst Med & Vet Sci, Dept Pathol, Adelaide, SA 5000, Australia; [Moore, J.] Royal Adelaide Hosp, Dept Colorectal Surg, Adelaide, SA 5000, Australia; [Burgess, A. W.] Royal Melbourne Hosp, Ludwig Inst Canc Res, Epithelial Biol Lab, Parkville, Vic 3050, Australia; [Busam, D.; Zhao, Q.] J Craig Venter Inst, Rockville, MD USA; [Strausberg, R. L.; Simpson, A. J.] Johns Hopkins Univ, Sch Med, Dept Neurosurg, Ludwig Collaborat Lab Canc Biol & Therapy, Baltimore, MD 21205 USA; [Strausberg, R. L.; Simpson, A. J.] Ludwig Inst Canc Res Ltd, New York, NY USA; [Tomlinson, I. P. M.] Wellcome Trust Ctr Human Genet, Mol & Populat Genet Lab, Oxford, England	Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Royal Melbourne Hospital; University of Melbourne; Royal Melbourne Hospital; Royal Melbourne Hospital; Western Hospital; University of New South Wales Sydney; University of New South Wales Sydney; Institute Medical & Veterinary Science Australia; Royal Adelaide Hospital; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; J. Craig Venter Institute; Johns Hopkins University; Ludwig Institute for Cancer Research; University of Oxford; Wellcome Centre for Human Genetics	Sieber, OM (corresponding author), Royal Melbourne Hosp, Ludwig Inst Canc Res, Ludwig Colon Canc Initiat Lab, POB 2008, Parkville, Vic 3050, Australia.	oliver.sieber@ludwig.edu.au	Ward, Robyn L/I-2313-2013; Hawkins, Nicholas J/A-8461-2008; Sieber, Oliver/ABA-9211-2021; Desai, Jayesh/AAV-1237-2021; Sieber, Oliver/M-9473-2015	Ward, Robyn L/0000-0002-6877-8906; Hawkins, Nicholas J/0000-0002-2204-3189; Sieber, Oliver/0000-0001-9480-0786; Sieber, Oliver/0000-0001-9480-0786; Mouradov, Dmitri/0000-0001-8149-816X; Day, Fiona/0000-0002-5905-9408; Gibbs, Peter/0000-0003-1423-4484; Desai, Jayesh/0000-0003-4246-9344; Jorissen, Robert/0000-0001-9634-2803	CSIRO Preventative Health Flagship through an Australian Cancer Grid Project Grant; NHMRC [489418, 487922]; Hilton Ludwig Cancer Metastasis Initiative; Victorian Government through a Victorian Cancer Agency Translation Cancer Research Grant; Victorian Government, Australia; Cancer Council Victoria through Postgraduate Cancer Research Scholarships; CSIRO Preventative Health Flagship through a Clinical Researcher Fellowship; Cancer Research UK [16459] Funding Source: researchfish	CSIRO Preventative Health Flagship through an Australian Cancer Grid Project Grant; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Hilton Ludwig Cancer Metastasis Initiative; Victorian Government through a Victorian Cancer Agency Translation Cancer Research Grant; Victorian Government, Australia; Cancer Council Victoria through Postgraduate Cancer Research Scholarships(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); CSIRO Preventative Health Flagship through a Clinical Researcher Fellowship; Cancer Research UK(Cancer Research UK)	This work was supported by the CSIRO Preventative Health Flagship through an Australian Cancer Grid Project Grant (to LL, PG and OMS), the NHMRC through a Project Grant (Application ID 489418; to LL, OMS, PG and RLW) and a Program Grant (Application ID 487922; to AWB), the Hilton Ludwig Cancer Metastasis Initiative (to LL, PG and OMS) and the Victorian Government through a Victorian Cancer Agency Translation Cancer Research Grant (to LL, PG and OMS). This work was supported by funds from the Operational Infrastructure Support Program provided by the Victorian Government, Australia. MC and FD are supported by the Cancer Council Victoria through Postgraduate Cancer Research Scholarships and LL by the CSIRO Preventative Health Flagship through a Clinical Researcher Fellowship. We thank the Victorian Cancer Biobank for the provision of patient specimens, BioGrid Australia for providing de-identified clinical data.	Albuquerque C, 2002, HUM MOL GENET, V11, P1549, DOI 10.1093/hmg/11.13.1549; Albuquerque C, 2010, BIOCHIM BIOPHYS ACTA, V1816, P219; Albuquerque C, 2010, GENE CHROMOSOME CANC, V49, P746, DOI 10.1002/gcc.20786; Beroud C, 1996, NUCLEIC ACIDS RES, V24, P121, DOI 10.1093/nar/24.1.121; Boland CR, 1998, CANCER RES, V58, P5248; BUFILL JA, 1990, ANN INTERN MED, V113, P779, DOI 10.7326/0003-4819-113-10-779; Cheadle JP, 2002, CANCER RES, V62, P363; Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137; Crabtree M, 2003, ONCOGENE, V22, P4257, DOI 10.1038/sj.onc.1206471; Esteller M, 2000, CANCER RES, V60, P4366; Ewan K, 2010, CANCER RES, V70, P5963, DOI 10.1158/0008-5472.CAN-10-1028; Goss KH, 2002, P NATL ACAD SCI USA, V99, P8161, DOI 10.1073/pnas.112072199; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; JOSLYN G, 1993, P NATL ACAD SCI USA, V90, P11109, DOI 10.1073/pnas.90.23.11109; Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Lamlum H, 1999, NAT MED, V5, P1071, DOI 10.1038/12511; Leedham SJ, 2012, GUT, DOI [10.1136/gutjnl-2011-301601, DOI 10.1136/GUTJNL-2011-301601)]; MIYAKI M, 1994, CANCER RES, V54, P3011; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; Nathke IS, 2004, ANNU REV CELL DEV BI, V20, P337, DOI 10.1146/annurev.cellbio.20.012103.094541; Nieuwenhuis MH, 2007, CRIT REV ONCOL HEMAT, V61, P153, DOI 10.1016/j.critrevonc.2006.07.004; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; Ratcliffe MJ, 2000, J BIOL CHEM, V275, P35680, DOI 10.1074/jbc.C000639200; Roberts DM, 2011, MOL BIOL CELL, V22, P1845, DOI 10.1091/mbc.E10-11-0871; Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352; Sack U, 2011, MOL BIOL CELL, V22, P3344, DOI 10.1091/mbc.E10-09-0739; Samowitz WS, 2007, MOL CANCER RES, V5, P165, DOI 10.1158/1541-7786.MCR-06-0398; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Segditsas S, 2008, EXP MOL PATHOL, V85, P201, DOI 10.1016/j.yexmp.2008.09.006; Sieber OM, 2006, GUT, V55, P1440, DOI 10.1136/gut.2005.087106; TORNALETTI S, 1995, ONCOGENE, V10, P1493; Yau C, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-9-r92	33	89	93	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2013	32	39					4675	4682		10.1038/onc.2012.486	http://dx.doi.org/10.1038/onc.2012.486			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226YD	23085758	Green Published			2022-12-28	WOS:000325072200009
J	Xu, Z; Pei, L; Wang, L; Zhang, F; Hu, X; Gui, Y				Xu, Z.; Pei, L.; Wang, L.; Zhang, F.; Hu, X.; Gui, Y.			Snail1-dependent transcriptional repression of Cezanne2 in hepatocellular carcinoma	ONCOGENE			English	Article						Snail1; Cezanne2; HCC; metastasis	NF-KAPPA-B; EPITHELIAL-MESENCHYMAL TRANSITIONS; GENE-EXPRESSION; SNAIL; MICROENVIRONMENT; HEPATOCYTES; COOPERATION; MECHANISMS; ICAM-1; CELLS	High malignancy and early metastasis are the hallmarks of hepatocellular carcinoma (HCC). Here, we report that Cezanne2 expression is downregulated in HCC cells and in HCC patients' tumorous tissues and that Cezanne2 is inversely associated with Snail1 expression in HCC patients' tumorous tissues. Chromatin immunoprecipitation assays and the reporter gene assay showed that Snail1 binds to the promoter of the Cezanne2 gene and mediates the direct consequence of Cezanne2 repression. Enhanced expression of Cezanne2 could suppress proliferation, migration and invasion in HCC cells. Further, Cezanne2 could regulate MMP (matrix metalloproteinase) 2, MMP9 and ICAM1 (intercellular adhesion molecule) levels through modulation of the NF-kappa B (nuclear factor kappa-light-chain-enhancer of activated B cell) signaling cascade. Co-immunoprecipitation and in vivo deubiquitination assay indicated that Cezanne2 interacts with TNF receptor-associated factor (TRAF) 6 and cleaves the polyubiquitin from TRAF6 substrates. Our data reveal that Snail1-mediated suppression of Cezanne2 may have a key role in HCC malignancy.	[Xu, Z.; Pei, L.; Zhang, F.] ZhongCheng Translat Med Inc, Dept Mol Diag, Shanghai 2, Peoples R China; [Wang, L.] Shanghai Jiao Tong Univ, Sch Med, Shanghai 200030, Peoples R China; [Hu, X.; Gui, Y.] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Hangzhou 310027, Zhejiang, Peoples R China	Shanghai Jiao Tong University; Zhejiang University	Xu, Z (corresponding author), Univ Chicago, Dept Med, JFK R322, BSLC, 57th St, Chicago, IL 60637 USA.	Xuzhonping@gmail.com		GUI, YAXING/0000-0002-0466-3608	Institute of Health Science, Shanghai Institutes for Biological Sciences; Chinese Academy of Sciences; Department of Medicine, University of Chicago; Startup Package of Zhongcheng Translational- Medicine Incorporation, Shanghai, China; SLRC laboratory animal company, Shanghai, China	Institute of Health Science, Shanghai Institutes for Biological Sciences; Chinese Academy of Sciences(Chinese Academy of Sciences); Department of Medicine, University of Chicago(University of Chicago); Startup Package of Zhongcheng Translational- Medicine Incorporation, Shanghai, China; SLRC laboratory animal company, Shanghai, China	Dr Zhongping Xu obtained his PhD in January 2011 from the Institute of Health Science, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, and at present he works as a postdoctoral fellow at the Department of Medicine, University of Chicago. Dr Zhongping Xu started to found Zhongcheng Translational-medicine Incorporation in June 2011. This study was sponsored by the Startup Package of Zhongcheng Translational-Medicine Incorporation, Shanghai, China. The nude mice were supplied by SLRC laboratory animal company, Shanghai, China.	Astarci E, 2012, FEBS J, V279, P2966, DOI 10.1111/j.1742-4658.2012.08677.x; Bu W, 1997, Zhonghua Yi Xue Za Zhi, V77, P661; Budhu A, 2006, CANCER CELL, V10, P99, DOI 10.1016/j.ccr.2006.06.016; Chaffer CL, SCIENCE, V331, P1559; Doreau A, 2009, NAT IMMUNOL, V10, P778, DOI 10.1038/ni.1741; Enesa K, 2008, J BIOL CHEM, V283, P7036, DOI 10.1074/jbc.M708690200; Evans PC, 2001, BIOCHEM J, V357, P617, DOI 10.1042/0264-6021:3570617; Evans PC, 2003, J BIOL CHEM, V278, P23180, DOI 10.1074/jbc.M301863200; Gao JM, 2008, J BIOL CHEM, V283, P8802, DOI 10.1074/jbc.M708470200; de Herreros AG, 2010, J MAMMARY GLAND BIOL, V15, P135, DOI 10.1007/s10911-010-9179-8; Gotzmann J, 2002, J CELL SCI, V115, P1189; Katzenellenbogen M, 2006, CANCER RES, V66, P4001, DOI 10.1158/0008-5472.CAN-05-2937; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Khetchoumian K, 2007, NAT GENET, V39, P1500, DOI 10.1038/ng.2007.15; La Starza R, 2007, CANCER GENET CYTOGEN, V175, P73, DOI 10.1016/j.cancergencyto.2007.01.011; Massoumi R, 2009, J EXP MED, V206, P221, DOI 10.1084/jem.20082044; Nguyen H, 2006, VIROLOGY, V354, P58, DOI 10.1016/j.virol.2006.04.028; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Shalom-Barak T, 1998, J BIOL CHEM, V273, P27467, DOI 10.1074/jbc.273.42.27467; Sun HC, 2004, J CANCER RES CLIN, V130, P307, DOI 10.1007/s00432-003-0530-y; Tan C, 2001, ONCOGENE, V20, P133, DOI 10.1038/sj.onc.1204052; Xu ZP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014514; Xue JP, 2009, PHYSIOL GENOMICS, V38, P42, DOI 10.1152/physiolgenomics.00012.2009; Yang P, 2009, HEPATOL RES, V39, P1169, DOI 10.1111/j.1872-034X.2009.00563.x	24	20	22	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2014	33	22					2836	2845		10.1038/onc.2013.243	http://dx.doi.org/10.1038/onc.2013.243			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EI	23792447				2022-12-28	WOS:000337231800003
J	Comito, G; Giannoni, E; Segura, CP; Barcellos-de-Souza, P; Raspollini, MR; Baroni, G; Lanciotti, M; Serni, S; Chiarugi, P				Comito, G.; Giannoni, E.; Segura, C. P.; Barcellos-de-Souza, P.; Raspollini, M. R.; Baroni, G.; Lanciotti, M.; Serni, S.; Chiarugi, P.			Cancer-associated fibroblasts and M2-polarized macrophages synergize during prostate carcinoma progression	ONCOGENE			English	Article						prostate carcinoma progression; cancer-associated fibroblasts; cancer-associated macrophages; M1/M2 macrophage polarization; IL-6; SDF-1	ENDOTHELIAL PROGENITOR CELLS; TUMOR PROGRESSION; OXIDATIVE STRESS; GROWTH; MICROENVIRONMENT; DIFFERENTIATION; ANGIOGENESIS; ACTIVATION; TRANSITION; MONOCYTES	Inflammation is now acknowledged as an hallmark of cancer. Cancer-associated fibroblasts (CAFs) force a malignant cross talk with cancer cells, culminating in their epithelial-mesenchymal transition and achievement of stemness traits. Herein, we demonstrate that stromal tumor-associated cells cooperate to favor malignancy of prostate carcinoma (PCa). Indeed, prostate CAFs are active factors of monocyte recruitment toward tumor cells, mainly acting through stromal-derived growth factor-1 delivery and promote their trans-differentiation toward the M2 macrophage phenotype. The relationship between M2 macrophages and CAFs is reciprocal, as M2 macrophages are able to affect mesenchymal-mesenchymal transition of fibroblasts, leading to their enhanced reactivity. On the other side, PCa cells themselves participate in this cross talk through secretion of monocyte chemotactic protein-1, facilitating monocyte recruitment and again macrophage differentiation and M2 polarization. Finally, this complex interplay among cancer cells, CAFs and M2 macrophages, cooperates in increasing tumor cell motility, ultimately fostering cancer cells escaping from primary tumor and metastatic spread, as well as in activation of endothelial cells and their bone marrow-derived precursors to drive de novo angiogenesis. In keeping with our data obtained in vitro, the analysis of patients affected by prostate cancers at different clinical stages revealed a clear increase in the M2/M1 ratio in correlation with clinical values. These data, coupled with the role of CAFs in carcinoma malignancy to elicit expression of stem-like traits, should focus great interest for innovative strategies aimed at the co-targeting of inflammatory cells and fibroblasts to improve therapeutic efficacy.	[Comito, G.; Giannoni, E.; Segura, C. P.; Barcellos-de-Souza, P.; Chiarugi, P.] Univ Florence, Dept Expt & Clin Biomed Sci, Viale Morgagni 50, I-50134 Florence, Italy; [Raspollini, M. R.; Baroni, G.] Univ Florence, Histol & Mol Diagnost Univ, Careggi Hosp, I-50134 Florence, Italy; [Lanciotti, M.; Serni, S.] Univ Florence, Careggi Hosp, Dept Urol, I-50134 Florence, Italy; [Chiarugi, P.] Ctr Res Transfer & High Educ DenoTHE, Florence, Italy	University of Florence; University of Florence; Azienda Ospedaliero Universitaria Careggi; University of Florence; Azienda Ospedaliero Universitaria Careggi	Chiarugi, P (corresponding author), Univ Florence, Dept Expt & Clin Biomed Sci, Viale Morgagni 50, I-50134 Florence, Italy.	paola.chiarugi@unifi.it	Giannoni, Elisa/AAE-2092-2020; de Souza, Pedro Barcellos/E-4957-2017; Chiarugi, Paola/CDD-7988-2022	de Souza, Pedro Barcellos/0000-0003-1903-5089; Lanciotti, Michele/0000-0002-3368-8652; Comito, Giuseppina/0000-0002-4614-067X; Chiarugi, Paola/0000-0001-7655-2969; Giannoni, Elisa/0000-0001-7136-1098	Associazione Italiana Ricerca sul Cancro (AIRC); Istituto Toscano Tumori; MIUR (PRIN); Capes (Ministerio da Educacao, Brazil)	Associazione Italiana Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Istituto Toscano Tumori; MIUR (PRIN)(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); Capes (Ministerio da Educacao, Brazil)(Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES))	This work was supported by the Associazione Italiana Ricerca sul Cancro (AIRC), by Istituto Toscano Tumori, and by MIUR (PRIN 2008). Pedro Barcellos-de-Souza was supported by postdoctoral fellowship from Capes (Ministerio da Educacao, Brazil).	Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Balkwill FR, 2012, SEMIN CANCER BIOL, V22, P33, DOI 10.1016/j.semcancer.2011.12.005; Cat B, 2006, J CELL SCI, V119, P2727, DOI 10.1242/jcs.03011; Cirri P, 2012, CANCER METAST REV, V31, P195, DOI 10.1007/s10555-011-9340-x; Comito G, 2012, CANCER LETT, V324, P31, DOI 10.1016/j.canlet.2012.04.025; De Wever O, 2003, J PATHOL, V200, P429, DOI 10.1002/path.1398; Duda DG, 2010, P NATL ACAD SCI USA, V107, P21677, DOI 10.1073/pnas.1016234107; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Fiaschi T, 2012, CANCER RES, V72, P5130, DOI 10.1158/0008-5472.CAN-12-1949; Friedl P, 2004, INT J DEV BIOL, V48, P441, DOI 10.1387/ijdb.041821pf; Geldhof Anja B, 2003, Clin Dev Immunol, V10, P71, DOI 10.1080/10446670310001626580; Giannoni E, 2013, J MOL MED, V91, P103, DOI 10.1007/s00109-012-0941-9; Giannoni E, 2012, ANTIOXID REDOX SIGN, V16, P1248, DOI 10.1089/ars.2011.4280; Giannoni E, 2011, ANTIOXID REDOX SIGN, V14, P2361, DOI 10.1089/ars.2010.3727; Giannoni E, 2010, CANCER RES, V70, P6945, DOI 10.1158/0008-5472.CAN-10-0785; Guido C, 2012, CELL CYCLE, V11, P3019, DOI 10.4161/cc.21384; Hao NB, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/948098; Hembruff SL, 2010, NEOPLASIA, V12, P425, DOI 10.1593/neo.10200; Inoue H, 2005, CANCER LETT, V223, P121, DOI 10.1016/j.canlet.2004.09.053; Jinushi M, 2012, AM J CANCER RES, V2, P529; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675; Ksiazkiewicz M, 2010, IMMUNOBIOLOGY, V215, P737, DOI 10.1016/j.imbio.2010.05.019; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Mantovani A, 2007, EUR J IMMUNOL, V37, P14, DOI 10.1002/eji.200636910; Mantovani A, 2010, CURR OPIN IMMUNOL, V22, P231, DOI 10.1016/j.coi.2010.01.009; Margheri F, 2011, BLOOD, V118, P3743, DOI 10.1182/blood-2011-02-338681; Martinez FO, 2009, ANNU REV IMMUNOL, V27, P451, DOI 10.1146/annurev.immunol.021908.132532; Muerkoster SS, 2008, INT J CANCER, V123, P1751, DOI 10.1002/ijc.23703; Nolan DJ, 2007, GENE DEV, V21, P1546, DOI 10.1101/gad.436307; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Roodhart JML, 2011, CANCER CELL, V20, P370, DOI 10.1016/j.ccr.2011.08.010; Servais C, 2013, J PATHOL, V229, P198, DOI 10.1002/path.4103; Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003; Sica A, 2012, CANCER MICROENVIRON, V5, P133, DOI 10.1007/s12307-011-0091-6; Silzle T, 2003, EUR J IMMUNOL, V33, P1311, DOI 10.1002/eji.200323057; Solinas G, 2009, J LEUKOCYTE BIOL, V86, P1065, DOI 10.1189/jlb.0609385; Talmadge JE, 2007, CANCER METAST REV, V26, P373, DOI 10.1007/s10555-007-9072-0; Teicher BA, 2010, CLIN CANCER RES, V16, P2927, DOI 10.1158/1078-0432.CCR-09-2329; Toullec A, 2010, EMBO MOL MED, V2, P211, DOI 10.1002/emmm.201000073; Whiteside TL, 2008, ONCOGENE, V27, P5904, DOI 10.1038/onc.2008.271; Wu Y, 2009, CANCER CELL, V15, P416, DOI 10.1016/j.ccr.2009.03.016; Yoder MC, 2007, CELL STEM CELL, V1, P603, DOI 10.1016/j.stem.2007.11.005; Zumsteg A, 2009, CURR OPIN ONCOL, V21, P60, DOI 10.1097/CCO.0b013e32831bed7e	45	282	294	3	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2014	33	19					2423	2431		10.1038/onc.2013.191	http://dx.doi.org/10.1038/onc.2013.191			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH3OK	23728338				2022-12-28	WOS:000336033600002
J	Hunter, KE; Palermo, C; Kester, JC; Simpson, K; Li, JP; Tang, LH; Klimstra, DS; Vlodavsky, I; Joyce, JA				Hunter, K. E.; Palermo, C.; Kester, J. C.; Simpson, K.; Li, J-P; Tang, L. H.; Klimstra, D. S.; Vlodavsky, I.; Joyce, J. A.			Heparanase promotes lymphangiogenesis and tumor invasion in pancreatic neuroendocrine tumors	ONCOGENE			English	Article						tumor microenvironment; tumor-associated macrophages; matrix-degrading enzyme; heparan sulfate proteoglycans	MOUSE MODEL; SULFATE; MICE; METASTASIS; GROWTH; CANCER; ANGIOGENESIS; MACROPHAGES; CELLS	Heparan sulfate proteoglycans are an important and abundant component of the extracellular matrix, which undergo substantial remodeling throughout tumorigenesis via the enzymatic activity of heparanase. Heparanase has been shown to be upregulated in many human cancers; however, its specific functions in human pancreatic neuroendocrine tumors (PanNETs) and spontaneous mouse models of cancer have not been evaluated. Here, we investigated the role of heparanase in PanNETs using patient samples and the RIP1-Tag2 (RT2) PanNET-transgenic mouse model. High heparanase expression significantly correlated with more advanced tumor stage, higher tumor grade and the presence of distant metastasis in PanNET patients. We genetically manipulated heparanase levels in the RT2 model using heparanase-transgenic mice, which constitutively overexpress heparanase, and heparanase-knockout mice. Heparanase was found to have a critical role in promoting tumor invasion, through both macrophage and cancer cell sources in the tumor microenvironment. In addition, elevated heparanase levels significantly increased peritumoral lymphangiogenesis in vivo and promoted the trans-differentiation of macrophages into lymphatic endothelial cell-like structures in culture. Conversely, we found that heparanase deletion led to increased angiogenesis and pericyte coverage. Together, these data identify important roles for heparanase in regulating several critical aspects of tumorigenesis, demonstrating that heparanase represents a potential therapeutic target for PanNET patients.	[Hunter, K. E.; Palermo, C.; Kester, J. C.; Simpson, K.; Joyce, J. A.] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10065 USA; [Hunter, K. E.] Mem Sloan Kettering Canc Ctr, Louis V Gerstner Jr Grad Sch Biomed Sci, New York, NY 10021 USA; [Li, J-P] Uppsala Univ, Dept Med Biochem & Microbiol, Uppsala, Sweden; [Tang, L. H.; Klimstra, D. S.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; [Vlodavsky, I.] Technion Israel Inst Technol, Rappaport Fac Med, Canc & Vasc Res Ctr, IL-32000 Haifa, Israel	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Uppsala University; Memorial Sloan Kettering Cancer Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Joyce, JA (corresponding author), Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, 1275 York Ave,Box 372, New York, NY 10065 USA.	joycej@mskcc.org			National Cancer Institute [R01 CA125162]; Grayer Fellowship; NATIONAL CANCER INSTITUTE [R01CA125162] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Grayer Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of the Joyce Lab; Drs Jacqueline Bromberg and Andrew Koff for discussion on this topic; and Robert Bowman, Daniela Quail, Alberto Schuhmacher and Hao- Wei Wang for reading the manuscript. We gratefully acknowledge Xiaoping Chen and Lin Song for excellent technical assistance; Marsha Quick and Karoline Dubin for project assistance; Elyn Reidel, MSKCC Epidemiology and Biostatistics Department for statistical analysis of RT2 tumor grades; Sho Fujisawa and the Molecular Cytology Core Facility for assistance with the MetaMorph lymphangiogenesis analysis; the MSKCC Flow Cytometry Core for technical assistance and advice; and Aisha Khan of the cGMP Cell Processing Facility, Cell Transplant Center, Diabetes Research Institute, University of Miami School of Medicine for providing normal islets. This research was funded by the National Cancer Institute R01 CA125162 and Cycle for Survival (JAJ). KEH was supported in part by a Grayer Fellowship.	Arvatz G, 2011, CANCER METAST REV, V30, P253, DOI 10.1007/s10555-011-9288-x; Cohen-Kaplan V, 2008, INT J CANCER, V123, P2566, DOI 10.1002/ijc.23898; Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4; Ferrone CR, 2007, J CLIN ONCOL, V25, P5609, DOI 10.1200/JCO.2007.12.9809; Gocheva V, 2010, GENE DEV, V24, P241, DOI 10.1101/gad.1874010; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Hu Wenwei, 2010, Genes Cancer, V1, P360; Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609; Joyce JA, 2005, ONCOGENE, V24, P4037, DOI 10.1038/sj.onc.1208602; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Lindahl U, 2009, INT REV CEL MOL BIO, V276, P105, DOI 10.1016/S1937-6448(09)76003-4; Lopez T, 2002, CANCER CELL, V1, P339, DOI 10.1016/S1535-6108(02)00055-7; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Maruyama K, 2005, J CLIN INVEST, V115, P2363, DOI 10.1172/JCI23874; MCCULLAGH P, 1980, J ROY STAT SOC B MET, V42, P109; Nolan-Stevaux Olivier, 2010, Genes Cancer, V1, P125, DOI 10.1177/1947601909358722; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Ori A, 2011, J BIOL CHEM, V286, P19892, DOI 10.1074/jbc.M111.228114; Parish CR, 1999, CANCER RES, V59, P3433; Pyonteck SM, 2012, ONCOGENE, V31, P1459, DOI 10.1038/onc.2011.337; Stenzel D, 2009, BLOOD, V114, P915, DOI 10.1182/blood-2008-10-186239; Tammela T, 2010, CELL, V140, P460, DOI 10.1016/j.cell.2010.01.045; Tuveson D, 2011, NATURE, V471, P316, DOI 10.1038/471316a; Vlodavsky I, 2012, CANCER MICROENVIRON, V5, P115, DOI 10.1007/s12307-011-0082-7; Yao JC, 2008, J CLIN ONCOL, V26, P3063, DOI 10.1200/JCO.2007.15.4377; Yao JC, 2007, ANN SURG ONCOL, V14, P3492, DOI 10.1245/s10434-007-9566-6; Zcharia E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005181; Zumsteg A, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006494; Zumsteg A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007067	30	30	31	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2014	33	14					1799	1808		10.1038/onc.2013.142	http://dx.doi.org/10.1038/onc.2013.142			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RE	23644656				2022-12-28	WOS:000334345500006
J	Zhu, Y; Das, K; Wu, J; Lee, MH; Tan, P				Zhu, Y.; Das, K.; Wu, J.; Lee, M. H.; Tan, P.			RNH1 regulation of reactive oxygen species contributes to histone deacetylase inhibitor resistance in gastric cancer cells	ONCOGENE			English	Article						HDAC inhibitor; gastric cancer; RNH1; ROS	SUBEROYLANILIDE HYDROXAMIC ACID; RIBONUCLEASE INHIBITOR; HDAC INHIBITORS; ANTICANCER DRUGS; LEUKEMIA-CELLS; SP1 SITES; EXPRESSION; VORINOSTAT; APOPTOSIS; PROTEIN	Histone deacetylase inhibitors (HDACis) are a promising class of anticancer epigenetic drugs, however, molecular factors influencing the responses of individual tumors to HDACi therapies remain obscure. Here, we sought to identify genes associated with HDACi resistance in gastric cancer. Treating a panel of 17 gastric cancer cell lines with multiple HDACi compounds (trichostatin A, SAHA and MS275), we identified two distinct classes of lines exhibiting either HDACi sensitivity or resistance. Genomic comparisons between the sensitive and resistant classes using two independent microarray platforms identified RNH1, encoding a ribonuclease inhibitor, as a gene highly expressed in HDACi-resistant lines. Using genetic knockdown and overexpression assays, we show that RNH1 is both necessary and sufficient to induce HDACi resistance, and that RNH1 is likely to mediate this resistance through the dampening of HDACi-induced reactive oxygen species (ROS) in cancer cells. The discovery of RNH1 as a regulator of HDACi resistance in gastric cancer highlights a functional role for ROS induction in the cellular effects of this important drug class.	[Zhu, Y.; Das, K.; Tan, P.] Duke NUS Grad Med Sch, Singapore 169857, Singapore; [Zhu, Y.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 117595, Singapore; [Wu, J.; Lee, M. H.; Tan, P.] Natl Canc Ctr, Singapore, Singapore; [Tan, P.] Natl Univ Singapore, Yong Loo Lin Sch Med, Canc Sci Inst Singapore, Singapore 117595, Singapore; [Tan, P.] Genome Inst Singapore, Singapore, Singapore	National University of Singapore; National University of Singapore; National Cancer Centre Singapore (NCCS); National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS)	Tan, P (corresponding author), Duke NUS Grad Med Sch, 8 Coll Rd, Singapore 169857, Singapore.	gmstanp@duke-nus.edu.sg		Das, Kakoli/0000-0002-0990-276X	NMRC TCR grant [TCR/001/2007]; Duke-NUS core grant	NMRC TCR grant; Duke-NUS core grant	We thank that Dr Shang Li's lab for the gift of Hela, MCF7, HEPG2 and HCT116 cell lines. This work was funded by NMRC TCR grant TCR/001/2007 and a Duke-NUS core grant.	Alberts SR, 2003, ANN ONCOL, V14, P31, DOI 10.1093/annonc/mdg726; Aresvik DM, 2010, ANTICANCER RES, V30, P3879; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Borbone E, 2010, ONCOGENE, V29, P105, DOI 10.1038/onc.2009.306; Botella-Estrada R, 2001, CANCER GENE THER, V8, P278, DOI 10.1038/sj.cgt.7700302; Bragado P, 2007, APOPTOSIS, V12, P1733, DOI 10.1007/s10495-007-0082-8; Butler LM, 2002, P NATL ACAD SCI USA, V99, P11700, DOI 10.1073/pnas.182372299; Carew JS, 2008, CANCER LETT, V269, P7, DOI 10.1016/j.canlet.2008.03.037; Chen GA, 2002, MOL CELL PROTEOMICS, V1, P304, DOI 10.1074/mcp.M200008-MCP200; Chen JX, 2011, MOL CELL BIOCHEM, V349, P83, DOI 10.1007/s11010-010-0663-7; Claerhout S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024662; Cui XY, 2003, FREE RADICAL RES, V37, P1079, DOI 10.1080/10715760310001600408; Dickinson M, 2010, INVEST NEW DRUG, V28, pS3, DOI 10.1007/s10637-010-9596-y; Dickson KA, 2005, PROG NUCLEIC ACID RE, V80, P349, DOI 10.1016/S0079-6603(05)80009-1; Dokmanovic M, 2007, MOL CANCER RES, V5, P981, DOI 10.1158/1541-7786.MCR-07-0324; Duvic M, 2007, BLOOD, V109, P31, DOI 10.1182/blood-2006-06-025999; Futami J, 1997, DNA CELL BIOL, V16, P413, DOI 10.1089/dna.1997.16.413; Glaser KB, 2007, BIOCHEM PHARMACOL, V74, P659, DOI 10.1016/j.bcp.2007.04.007; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Hu YM, 2010, BLOOD, V116, P2732, DOI 10.1182/blood-2009-11-256354; Huang CH, 2007, BIOCHEM PHARMACOL, V73, P990, DOI 10.1016/j.bcp.2006.12.013; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Johnson RJ, 2007, BIOCHEMISTRY-US, V46, P13131, DOI 10.1021/bi701521q; Khan O, 2010, P NATL ACAD SCI USA, V107, P6532, DOI 10.1073/pnas.0913912107; Kim JH, 2004, J GASTROEN HEPATOL, V19, P218, DOI 10.1111/j.1440-1746.2004.03336.x; Kim TY, 2008, EXP MOL MED, V40, P639, DOI 10.3858/emm.2008.40.6.639; Klampfer L, 2007, CANCER RES, V67, P8477, DOI 10.1158/0008-5472.CAN-07-0210; Klose RJ, 2006, TRENDS BIOCHEM SCI, V31, P89, DOI 10.1016/j.tibs.2005.12.008; Kobayashi Takanori, 2004, Gastric Cancer, V7, P233, DOI 10.1007/s10120-004-0297-0; Lee JY, 2003, GENOMICS, V82, P78, DOI 10.1016/S0888-7543(03)00098-3; Ma XJ, 2009, DRUGS, V69, P1911, DOI 10.2165/11315680-000000000-00000; Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247; Marks PA, 2010, EXPERT OPIN INV DRUG, V19, P1049, DOI 10.1517/13543784.2010.510514; Minucci S, 2006, NAT REV CANCER, V6, P38, DOI 10.1038/nrc1779; Moenner M, 1998, BLOOD CELL MOL DIS, V24, P149, DOI 10.1006/bcmd.1998.0182; Monti DM, 2007, FEBS LETT, V581, P930, DOI 10.1016/j.febslet.2007.01.072; Mutze K, 2010, ANN SURG ONCOL, V17, P3336, DOI 10.1245/s10434-010-1182-1; NADANO D, 1994, ARCH BIOCHEM BIOPHYS, V312, P421, DOI 10.1006/abbi.1994.1328; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; Nebbioso A, 2010, J MOL ENDOCRINOL, V45, P219, DOI 10.1677/JME-10-0043; Olsen EA, 2007, J CLIN ONCOL, V25, P3109, DOI 10.1200/JCO.2006.10.2434; Ono S, 2002, J EXP CLIN CANC RES, V21, P377; Ree AH, 2010, LANCET ONCOL, V11, P459, DOI 10.1016/S1470-2045(10)70058-9; Rikiishi H, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/830260; Rosato RR, 2003, MOL CANCER THER, V2, P1273; Ruefli AA, 2001, P NATL ACAD SCI USA, V98, P10833, DOI 10.1073/pnas.191208598; Sade H, 2004, CELL DEATH DIFFER, V11, P416, DOI 10.1038/sj.cdd.4401347; Shapiro R, 2001, METHOD ENZYMOL, V341, P611, DOI 10.1016/S0076-6879(01)41180-3; Song SH, 2011, DRUGS, V71, P2391, DOI 10.2165/11596690-000000000-00000; Sowa Y, 1999, ANN NY ACAD SCI, V886, P195, DOI 10.1111/j.1749-6632.1999.tb09415.x; Stevens FE, 2008, ONCOGENE, V27, P1345, DOI 10.1038/sj.onc.1210779; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; SUZUKI Y, 1970, J NEUROCHEM, V17, P1521, DOI 10.1111/j.1471-4159.1970.tb00520.x; Trachootham D, 2008, BLOOD, V112, P1912, DOI 10.1182/blood-2008-04-149815; Ungerstedt JS, 2005, P NATL ACAD SCI USA, V102, P673, DOI 10.1073/pnas.0408732102; VANZANDWIJK N, 1995, J CELL BIOCHEM, P24; Weichert W, 2008, LANCET ONCOL, V9, P139, DOI 10.1016/S1470-2045(08)70004-4; WOJNAR RJ, 1965, CANCER RES, V25, P1913; Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620; Yoo CB, 2006, NAT REV DRUG DISCOV, V5, P37, DOI 10.1038/nrd1930; Zaina S, 2010, CURR GENOMICS, V11, P359, DOI 10.2174/138920210791616662; Zhang XT, 2006, ONCOL REP, V16, P563; Zhu P, 2004, CANCER CELL, V5, P455, DOI 10.1016/S1535-6108(04)00114-X	64	24	25	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2014	33	12					1527	1537		10.1038/onc.2013.104	http://dx.doi.org/10.1038/onc.2013.104			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD4TS	23584480				2022-12-28	WOS:000333244200006
J	Sheu, JJC; Lee, CC; Hua, CH; Li, CI; Lai, MT; Lee, SC; Cheng, J; Chen, CM; Chan, C; Chao, SCC; Chen, JY; Chang, JY; Lee, CH				Sheu, J. J-C; Lee, C-C; Hua, C-H; Li, C-I; Lai, M-T; Lee, S-C; Cheng, J.; Chen, C-M; Chan, C.; Chao, S. C-C; Chen, J-Y; Chang, J-Y; Lee, C-H			LRIG1 modulates aggressiveness of head and neck cancers by regulating EGFR-MAPK-SPHK1 signaling and extracellular matrix remodeling	ONCOGENE			English	Article						LRIG1; head and neck cancers; EGFR; MAPK; SPHK1; ECM remodeling	GROWTH-FACTOR RECEPTOR; SQUAMOUS-CELL CARCINOMA; NASOPHARYNGEAL CARCINOMA; NEGATIVE REGULATOR; BREAST-CANCER; SPHINGOSINE 1-PHOSPHATE; MESENCHYMAL TRANSITION; TUMOR PROGRESSION; GENE-EXPRESSION; ACTIVATION	EGFR overexpression and chromosome 3p deletion are two frequent events in head and neck cancers. We previously mapped the smallest region of recurrent copy-number loss at 3p12.2-p14.1. LRIG1, a negative regulator of EGFR, was found at 3p14, and its copy-number loss correlated with poor clinical outcome. Inducible expression of LRIG1 in head and neck cancer TW01 cells, a line with low LRIG1 levels, suppressed cell proliferation in vitro and tumor growth in vivo. Gene expression profiling, quantitative RT-PCR, chromatin immunoprecipitation, and western blot analysis demonstrated that LRIG1 modulated extracellular matrix (ECM) remodeling and EGFR-MAPK-SPHK1 transduction pathway by suppressing expression of EGFR ligands/activators, MMPs and SPHK1. In addition, LRIG1 induction triggered cell morphology changes and integrin inactivation, which coupled with reduced SNAI2 expression. By contrast, knockdown of endogenous LRIG1 in TW06 cells, a line with normal LRIG1 levels, significantly enhanced cell proliferation, migration and invasiveness. Such tumor-promoting effects could be abolished by specific MAPK or SPHK1 inhibitors. Our data suggest LRIG1 as a tumor suppressor for head and neck cancers; LRIG1 downregulation in cancer cells enhances EGFR-MAPK-SPHK1 signaling and ECM remodeling activity, leading to malignant phenotypes of head and neck cancers.	[Sheu, J. J-C; Cheng, J.; Chen, C-M; Chan, C.; Chao, S. C-C] China Med Univ Hosp, Ctr Human Genet, Taichung, Taiwan; [Sheu, J. J-C] China Med Univ, Sch Chinese Med, Taichung, Taiwan; [Sheu, J. J-C] Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung, Taiwan; [Lee, C-C; Li, C-I; Chen, J-Y; Chang, J-Y; Lee, C-H] Natl Inst Canc Res, Natl Hlth Res Inst, Zhunan Town 35053, Taiwan; [Hua, C-H] China Med Univ Hosp, Dept Otolaryngol, Taichung, Taiwan; [Lai, M-T] Chung Shan Med Univ Hosp, Dept Pathol, Taichung, Taiwan; [Lai, M-T] Chung Shan Med Univ, Sch Med, Taichung, Taiwan; [Lee, S-C] Chung Shan Med Univ, Coll Med Sci & Technol, Taichung, Taiwan	China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; Asia University Taiwan; National Health Research Institutes - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; Chung Shan Medical University; Chung Shan Medical University Hospital; Chung Shan Medical University; Chung Shan Medical University	Lee, CH (corresponding author), Natl Inst Canc Res, Natl Hlth Res Inst, R2,R1211,Keyan Rd, Zhunan Town 35053, Taiwan.	jimsheu@mail.cmu.edu.tw; chlee124@nhri.org.tw	Lee, Chia-Huei/B-1063-2010; Chen, Jen-Yang/D-2085-2010; Chang, Jang-Yang/D-2099-2010	Lee, Chia-Huei/0000-0002-8847-3288; Lee, Shan-Chih/0000-0001-6583-1575; Cheng, Jack/0000-0002-9305-0781	National Science Council, Taiwan [NSC99-2320-B-400-009, NSC100-2325-B-400-014, NSC101-2320-B-039-006]; National Health Research Institutes, Taiwan [CA-101-PP-01]; China Medical University Hospital, Taiwan [DMR99-047]; Department of Health, Taiwan [DOH101-TD-C-111-004, DOH101-TD-C-111-005]	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); National Health Research Institutes, Taiwan(National Health Research Institutes - Taiwan); China Medical University Hospital, Taiwan; Department of Health, Taiwan	We thank Dr Mien-Chie Hung (MD Anderson Cancer Center, TX, USA) and Dr Yosef Yarden (Weizmann Institute, Israel) for their critical comments on this study, which was supported by grants from the National Science Council, Taiwan (NSC99-2320-B-400-009, NSC100-2325-B-400-014, NSC101-2320-B-039-006 and NSC101-2320-B-039-006), the National Health Research Institutes, Taiwan (CA-101-PP-01), China Medical University Hospital, Taiwan (DMR99-047), and the Department of Health, Taiwan (DOH101-TD-C-111-004 and DOH101-TD-C-111-005).	Abhold EL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032459; Burtness B, 2005, EXPERT OPIN BIOL TH, V5, P1085, DOI 10.1517/14712598.5.8.1085; Chang H, 2002, CELL COMMUN ADHES, V9, P239, DOI 10.1080/15419060216303; Chang SJ, 2007, J ENDOCRINOL, V193, P393, DOI 10.1677/JOE-06-0168; Chevronnay HPG, 2012, BBA-PROTEINS PROTEOM, V1824, P146, DOI 10.1016/j.bbapap.2011.09.003; Fang CY, 2009, INT J CANCER, V124, P2016, DOI 10.1002/ijc.24179; Goldoni S, 2007, ONCOGENE, V26, P368, DOI 10.1038/sj.onc.1209803; Gur G, 2004, EMBO J, V23, P3270, DOI 10.1038/sj.emboj.7600342; Hedman H, 2002, ACTA ONCOL, V41, P352, DOI 10.1080/028418602760169398; Hedman H, 2007, EUR J CANCER, V43, P676, DOI 10.1016/j.ejca.2006.10.021; Huang ZX, 2004, GENE CHROMOSOME CANC, V40, P307, DOI 10.1002/gcc.20036; Jensen KB, 2008, CANCER LETT, V272, P23, DOI 10.1016/j.canlet.2008.06.014; Jensen KB, 2009, CELL STEM CELL, V4, P427, DOI 10.1016/j.stem.2009.04.014; Jin YS, 2005, CANCER GENET CYTOGEN, V156, P1, DOI 10.1016/j.cancergencyto.2004.04.023; Koy S, 2008, HEAD NECK-J SCI SPEC, V30, P1105, DOI 10.1002/hed.20857; Krig SR, 2011, MOL CANCER RES, V9, P1406, DOI 10.1158/1541-7786.MCR-11-0227; Laederich MB, 2004, J BIOL CHEM, V279, P47050, DOI 10.1074/jbc.M409703200; Ledda F, 2008, J NEUROSCI, V28, P39, DOI 10.1523/JNEUROSCI.2196-07.2008; LIN CT, 1990, LAB INVEST, V62, P713; Lindstrom AK, 2008, INT J GYNECOL CANCER, V18, P312, DOI 10.1111/j.1525-1438.2007.01021.x; Ljuslinder I, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2248; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; Ma BBT, 2003, HEAD NECK-J SCI SPEC, V25, P864, DOI 10.1002/hed.10307; Maseki S, 2012, BRIT J CANCER, V106, P1196, DOI 10.1038/bjc.2012.24; Milara J, 2012, THORAX, V67, P147, DOI 10.1136/thoraxjnl-2011-200026; Miller JK, 2008, CANCER RES, V68, P8286, DOI 10.1158/0008-5472.CAN-07-6316; Munger JS, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005017; Ordonez-Moran P, 2012, EMBO J, V31, P2064, DOI 10.1038/emboj.2012.73; Pai SI, 2009, ANNU REV PATHOL-MECH, V4, P49, DOI 10.1146/annurev.pathol.4.110807.092158; Pitson SM, 2003, EMBO J, V22, P5491, DOI 10.1093/emboj/cdg540; Powell AE, 2012, CELL, V149, P146, DOI 10.1016/j.cell.2012.02.042; Pyne NJ, 2012, BIOCHEM SOC T, V40, P94, DOI 10.1042/BST20110602; Pyne NJ, 2010, NAT REV CANCER, V10, P489, DOI 10.1038/nrc2875; Pyne S, 2011, CANCER RES, V71, P6576, DOI 10.1158/0008-5472.CAN-11-2364; Radisky ES, 2010, J MAMMARY GLAND BIOL, V15, P201, DOI 10.1007/s10911-010-9177-x; Ruan L, 2011, PROTEOME SCI, V9, DOI 10.1186/1477-5956-9-35; Shattuck DL, 2007, MOL CELL BIOL, V27, P1934, DOI 10.1128/MCB.00757-06; Sheu JJC, 2009, CANCER EPIDEM BIOMAR, V18, P2709, DOI 10.1158/1055-9965.EPI-09-0349; Sheu JJC, 2009, CANCER RES, V69, P2568, DOI 10.1158/0008-5472.CAN-08-3199; Shida D, 2004, FEBS LETT, V577, P333, DOI 10.1016/j.febslet.2004.10.024; Shida D, 2008, CURR DRUG TARGETS, V9, P662, DOI 10.2174/138945008785132402; Song WM, 2000, DEV BIOL, V227, P606, DOI 10.1006/dbio.2000.9919; Stutz MA, 2008, ONCOGENE, V27, P5741, DOI 10.1038/onc.2008.185; Thomasson M, 2003, BRIT J CANCER, V89, P1285, DOI 10.1038/sj.bjc.6601208; Watt FM, 2009, EMBO MOL MED, V1, P260, DOI 10.1002/emmm.200900033; Wong VWY, 2012, NAT CELL BIOL, V14, P401, DOI 10.1038/ncb2464; Ye F, 2009, J NEURO-ONCOL, V94, P183, DOI 10.1007/s11060-009-9836-1; Yi W, 2011, EXP CELL RES, V317, P504, DOI 10.1016/j.yexcr.2010.11.005	48	43	43	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2014	33	11					1375	1384		10.1038/onc.2013.98	http://dx.doi.org/10.1038/onc.2013.98			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD0SD	23624915				2022-12-28	WOS:000332943500005
J	Lei, R; Tang, J; Zhuang, X; Deng, R; Li, G; Yu, J; Liang, Y; Xiao, J; Wang, HY; Yang, Q; Hu, G				Lei, R.; Tang, J.; Zhuang, X.; Deng, R.; Li, G.; Yu, J.; Liang, Y.; Xiao, J.; Wang, H-Y; Yang, Q.; Hu, G.			Suppression of MIM by microRNA-182 activates RhoA and promotes breast cancer metastasis	ONCOGENE			English	Article						microRNA-182; MIM; breast cancer; metastasis; RhoA; cytoskeleton	HEDGEHOG-RESPONSIVE GENE; DOWN-REGULATION; 1 MTSS1; ACTIN; MIR-182; EXPRESSION; PROGRESSION; CYTOSKELETON; VARIANTS; PROTEIN	Breast cancer is the most common type of cancer among women worldwide, and metastasis represents the most devastating stage of the disease. Recent studies have revealed that microRNAs (miRNA) have critical roles to regulate cancer cell invasion and metastasis. Here we present evidence to show the role of miR-182 in breast cancer metastasis. miR-182 is upregulated in the malignant cell line variants of both human MCF10 and mouse 4T1 series. Ectopic expression of miR-182 enhanced breast cancer cell motility and invasiveness, whereas miR-182 inhibition resulted in opposite changes. In nude mice, miR-182 led to increased pulmonary colonization of cancer cells. We further demonstrated that miR-182 directly targets MIM (Missing in Metastasis), which suppresses metastasis by inhibiting ras homolog family member A (RhoA) activity and stress fiber formation in breast cancer cells. Restoring MIM expression completely blocked the pro-metastasis function of miR-182, while RhoA inhibition reversed the phenotypes of both miR-182 overexpression and MIM knockdown. In breast tumor samples, miR-182 induction is linked to downregulation of MIM, RhoA activation and poor prognosis. Hence, our data delineates the molecular pathway by which miR-182 promotes breast cancer invasion and metastasis, and may have important implication for the treatment of metastatic cancers.	[Lei, R.; Zhuang, X.; Li, G.; Yu, J.; Liang, Y.; Hu, G.] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Key Lab Stem Cell Biol, Shanghai, Peoples R China; [Lei, R.; Zhuang, X.; Li, G.; Yu, J.; Liang, Y.; Hu, G.] Shanghai Jiao Tong Univ, Sch Med, Shanghai 200025, Peoples R China; [Tang, J.] Sun Yat Sen Univ, Ctr Canc, Dept Breast Oncol, Guangzhou 510275, Guangdong, Peoples R China; [Tang, J.; Deng, R.; Wang, H-Y] Sun Yat Sen Univ, State Key Lab Oncol South China, Guangzhou 510275, Guangdong, Peoples R China; [Xiao, J.] Second Mil Med Univ, Changzheng Hosp, Dept Orthopaed Oncol, Shanghai, Peoples R China; [Yang, Q.] Shandong Univ, Qilu Hosp, Dept Breast Surg, Jinan 250100, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen University; Naval Medical University; Shandong University	Hu, G (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Inst Biol Sci,Chinese Acad Sci, Key Lab Stem Cell Biol,Inst Hlth Sci, 225 South Chongqing Rd, Shanghai 200025, Peoples R China.	ghhu@sibs.ac.cn	Xiao, Jian/GYU-4351-2022; yang, qiang/GYJ-0971-2022	Li, Gang/0000-0001-9761-1323; Yang, Qifeng/0000-0003-0576-8513; Hu, Guohong/0000-0002-2980-5166	Ministry of Science and Technology of China [2011CB510105, 2012ZX09506-001-005]; National Natural Science Foundation of China [81071754, 81222032]; Chinese Academy of Sciences [2009OHTP08, KSCX2-YW-R-192]; Shanghai Pujiang Talent Program [10PJ1411600]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Chinese Academy of Sciences(Chinese Academy of Sciences); Shanghai Pujiang Talent Program	We thank Dr Eva Hernando for providing the miR-182 overexpression plasmid. The study was funded by the grants from the Ministry of Science and Technology of China (2011CB510105, 2012ZX09506-001-005), National Natural Science Foundation of China (81071754, 81222032), Chinese Academy of Sciences (2009OHTP08, KSCX2-YW-R-192) and the Shanghai Pujiang Talent Program (10PJ1411600).	Acharya PS, 2008, J CELL SCI, V121, P1393, DOI 10.1242/jcs.021683; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bompard G, 2005, J CELL SCI, V118, P5393, DOI 10.1242/jcs.02640; Callahan CA, 2004, GENE DEV, V18, P2724, DOI 10.1101/gad.1221804; Dawson JC, 2012, ONCOGENE, V31, P1781, DOI 10.1038/onc.2011.376; Du P, 2011, ANTICANCER RES, V31, P3205; Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Gokhale A, 2010, J CANCER RES THER, V6, P521, DOI 10.4103/0973-1482.77072; Gonzalez-Quevedo R, 2005, J CELL BIOL, V168, P453, DOI 10.1083/jcb.200409078; Guttilla IK, 2009, J BIOL CHEM, V284, P23204, DOI 10.1074/jbc.M109.031427; Hall A, 2009, CANCER METAST REV, V28, P5, DOI 10.1007/s10555-008-9166-3; Hicks DG, 2006, CLIN CANCER RES, V12, P6702, DOI 10.1158/1078-0432.CCR-06-0635; Hu GH, 2009, CANCER CELL, V15, P9, DOI 10.1016/j.ccr.2008.11.013; Huynh C, 2011, ONCOGENE, V30, P1481, DOI 10.1038/onc.2010.523; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jiang LL, 2010, AM J PATHOL, V177, P29, DOI 10.2353/ajpath.2010.090812; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lee YG, 2002, NEOPLASIA, V4, P291, DOI 10.1038/sj.neo.7900231; Li HQ, 2010, J NEUROSCI, V30, P3254, DOI 10.1523/JNEUROSCI.4948-09.2010; Lin JX, 2005, ONCOGENE, V24, P2059, DOI 10.1038/sj.onc.1208412; Liu K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-428; Liu ZJ, 2012, J PATHOL, V228, P204, DOI 10.1002/path.4000; Lu X, 2010, J BIOL CHEM, V285, P9317, DOI 10.1074/jbc.C110.104448; Ma S, 2007, HUM PATHOL, V38, P1201, DOI 10.1016/j.humpath.2007.01.004; Mattila PK, 2003, J BIOL CHEM, V278, P8452, DOI 10.1074/jbc.M212113200; Moskwa P, 2011, MOL CELL, V41, P210, DOI 10.1016/j.molcel.2010.12.005; Nixdorf S, 2004, CANCER LETT, V215, P209, DOI 10.1016/j.canlet.2004.05.002; Parr C, 2009, EUR J CANCER, V45, P1673, DOI 10.1016/j.ejca.2009.02.019; Rajnicek AM, 2006, J CELL SCI, V119, P1723, DOI 10.1242/jcs.02896; Saarikangas J, 2011, J CELL SCI, V124, P1245, DOI 10.1242/jcs.082610; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273; Saus E, 2010, HUM MOL GENET, V19, P4017, DOI 10.1093/hmg/ddq316; Segura MF, 2009, P NATL ACAD SCI USA, V106, P1814, DOI 10.1073/pnas.0808263106; Sethi N, 2011, CANCER CELL, V19, P192, DOI 10.1016/j.ccr.2010.12.022; Stittrich AB, 2010, NAT IMMUNOL, V11, P1057, DOI 10.1038/ni.1945; Strickland LB, 2000, BREAST CANCER RES TR, V64, P235, DOI 10.1023/A:1026562720218; Sun YH, 2010, BIOCHEM BIOPH RES CO, V396, P501, DOI 10.1016/j.bbrc.2010.04.127; Wang D, 2011, J GASTROINTEST SURG, V15, P1205, DOI 10.1007/s11605-011-1546-2; Wang Y, 2007, CANCER INVEST, V25, P79, DOI 10.1080/07357900701205457; Woodings JA, 2003, BIOCHEM J, V371, P463, DOI 10.1042/BJ20021962; Xie F, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-95; Xie Fei, 2011, Front Biosci (Schol Ed), V3, P621, DOI 10.2741/s175; Xu SB, 2007, J BIOL CHEM, V282, P25053, DOI 10.1074/jbc.M700501200; Yamagishi A, 2004, J BIOL CHEM, V279, P14929, DOI 10.1074/jbc.M309408200	47	99	107	1	27	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2014	33	10					1287	1296		10.1038/onc.2013.65	http://dx.doi.org/10.1038/onc.2013.65			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AC6KI	23474751				2022-12-28	WOS:000332631100009
J	Castoldi, R; Ecker, V; Wiehle, L; Majety, M; Busl-Schuller, R; Asmussen, M; Nopora, A; Jucknischke, U; Osl, F; Kobold, S; Scheuer, W; Venturi, M; Klein, C; Niederfellner, G; Sustmann, C				Castoldi, R.; Ecker, V.; Wiehle, L.; Majety, M.; Busl-Schuller, R.; Asmussen, M.; Nopora, A.; Jucknischke, U.; Osl, F.; Kobold, S.; Scheuer, W.; Venturi, M.; Klein, C.; Niederfellner, G.; Sustmann, C.			A novel bispecific EGFR/Met antibody blocks tumor-promoting phenotypic effects induced by resistance to EGFR inhibition and has potent antitumor activity	ONCOGENE			English	Article						EGFR; Met; HGF; EGF; bispecific antibody	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITORS; HEPATOCYTE GROWTH; LUNG-CANCER; C-MET; GEFITINIB RESISTANCE; ACQUIRED-RESISTANCE; SIGNALING NETWORKS; CARCINOMA CELLS; TARGETING MET	Simultaneous targeting of epidermal growth factor receptor (EGFR) and Met in cancer therapy is under pre-clinical and clinical evaluation. Here, we report the finding that treatment with EGFR inhibitors of various tumor cells, when stimulated with hepatocyte growth factor (HGF) and EGF, results in transient upregulation of phosphorylated AKT. Furthermore, EGFR inhibition in this setting stimulates a pro-invasive phenotype as assessed in Matrigel-based assays. Simultaneous treatment with AKT and EGFR inhibitors abrogates this invasive growth, hence functionally linking signaling and phenotype. This observation implies that during treatment of tumors a balanced ratio of EGFR and Met inhibition is required. To address this, we designed a bispecific antibody targeting EGFR and Met, which has the advantage of a fixed 2:1 stoichiometry. This bispecific antibody inhibits proliferation in tumor cell cultures and co-cultures with fibroblasts in an additive manner compared with treatment with both single agents. In addition, cell migration assays reveal a higher potency of the bispecific antibody in comparison with the antibodies' combination at low doses. We demonstrate that the bispecific antibody inhibits invasive growth, which is specifically observed with cetuximab. Finally, the bispecific antibody potently inhibits tumor growth in a non-small cell lung cancer xenograft model bearing a strong autocrine HGF-loop. Together, our findings strongly support a combination treatment of EGFR and Met inhibitors and further evaluation of resistance mechanisms to EGFR inhibition in the context of active Met signaling.	[Castoldi, R.; Ecker, V.; Wiehle, L.; Majety, M.; Busl-Schuller, R.; Asmussen, M.; Nopora, A.; Jucknischke, U.; Osl, F.; Scheuer, W.; Venturi, M.; Niederfellner, G.; Sustmann, C.] Roche Diagnost GmbH, Pharma Res & Early Dev pRED, D-82377 Penzberg, Germany; [Kobold, S.] Univ Munich, Dept Internal Med 4, Div Clin Pharmacol, Munich, Germany; [Klein, C.] Glycart AG, pRED, Schlieren, Switzerland	Roche Holding; University of Munich	Sustmann, C (corresponding author), Roche Diagnost GmbH, Pharma Res & Early Dev pRED, Nonnenwald 2, D-82377 Penzberg, Germany.	claudio.sustmann@roche.com	Klein, Christian/G-1336-2010	Klein, Christian/0000-0001-7594-7280; Wiehle, Laura/0000-0001-6081-3925; Kobold, Sebastian/0000-0002-5612-4673	Bayerisches Immuntherapie-Netzwerk (BayImmuNet)	Bayerisches Immuntherapie-Netzwerk (BayImmuNet)	S.K. is supported by the Bayerisches Immuntherapie-Netzwerk (BayImmuNet).	Alexander S, 2012, TRENDS MOL MED, V18, P13, DOI 10.1016/j.molmed.2011.11.003; Amit I, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100195; Bachleitner-Hofmann T, 2008, MOL CANCER THER, V7, P3499, DOI 10.1158/1535-7163.MCT-08-0374; Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104; Bonine-Summers AR, 2007, CANCER BIOL THER, V6, P561, DOI 10.4161/cbt.6.4.3851; Brehmer D, 2005, CANCER RES, V65, P379; Chhatwani Laveena, 2009, Proc Am Thorac Soc, V6, P194, DOI 10.1513/pats.200807-068LC; Corso S, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-121; Croasdale R, 2012, ARCH BIOCHEM BIOPHYS, V526, P206, DOI 10.1016/j.abb.2012.03.016; Dikmen E, 2006, EUR RESPIR J, V27, P73, DOI 10.1183/09031936.06.00148704; Dong JY, 2011, MABS-AUSTIN, V3, P273, DOI 10.4161/mabs.3.3.15188; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Guo A, 2008, P NATL ACAD SCI USA, V105, P692, DOI 10.1073/pnas.0707270105; Gusenbauer S, 2013, ONCOGENE, V32, P3846, DOI 10.1038/onc.2012.396; Hammond DE, 2010, J PROTEOME RES, V9, P2734, DOI 10.1021/pr100145w; Jo MJ, 2000, J BIOL CHEM, V275, P8806, DOI 10.1074/jbc.275.12.8806; Karamouzis MV, 2009, LANCET ONCOL, V10, P709, DOI 10.1016/S1470-2045(09)70137-8; Kawaguchi K, 2009, CARCINOGENESIS, V30, P1097, DOI 10.1093/carcin/bgp097; Liska D, 2011, CLIN CANCER RES, V17, P472, DOI 10.1158/1078-0432.CCR-10-0568; Lu D, 2005, J BIOL CHEM, V280, P19665, DOI 10.1074/jbc.M500815200; Lu D, 2004, J BIOL CHEM, V279, P2856, DOI 10.1074/jbc.M310132200; Maseki S, 2012, BRIT J CANCER, V106, P1196, DOI 10.1038/bjc.2012.24; Merchant AM, 1998, NAT BIOTECHNOL, V16, P677, DOI 10.1038/nbt0798-677; Metz S, 2011, P NATL ACAD SCI USA, V108, P8194, DOI 10.1073/pnas.1018565108; Naito Y, 2012, CELL CYCLE, V11, P604, DOI 10.4161/cc.11.3.19114; Nedergaard MK, 2012, BIODRUGS, V26, P83, DOI 10.2165/11599760-000000000-00000; Nguyen KSH, 2009, CLIN LUNG CANCER, V10, P281, DOI 10.3816/CLC.2009.n.039; Puri Neelu, 2008, J Carcinog, V7, P9; Reusch U, 2006, CLIN CANCER RES, V12, P183, DOI 10.1158/1078-0432.CCR-05-1855; Ridgway JBB, 1996, PROTEIN ENG, V9, P617, DOI 10.1093/protein/9.7.617; Serrels A, 2011, CELL ADHES MIGR, V5, P360, DOI 10.4161/cam.5.4.17290; Sugahara K, 1998, INTENS CARE MED, V24, P434, DOI 10.1007/s001340050592; Surati M, 2011, EXPERT OPIN BIOL TH, V11, P1655, DOI 10.1517/14712598.2011.626762; Takata M, 2012, CANCER BIOL THER, V13, P6; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; Uchiyama A, 1999, BRIT J CANCER, V81, P721, DOI 10.1038/sj.bjc.6690754; Ungewickell EJ, 2007, CURR OPIN CELL BIOL, V19, P417, DOI 10.1016/j.ceb.2007.05.003; Wang SY, 2011, ANTI-CANCER AGENT ME, V11, P993, DOI 10.2174/187152011797927661; Xu H, 2011, CLIN CANCER RES, V17, P4425, DOI 10.1158/1078-0432.CCR-10-3339; Yamada T, 2012, J THORAC ONCOL, V7, P272, DOI 10.1097/JTO.0b013e3182398e69; Yang SY, 2011, FRONT BIOSCI-LANDMRK, V16, P531, DOI 10.2741/3703; Yano S, 2008, CANCER RES, V68, P9479, DOI 10.1158/0008-5472.CAN-08-1643; Yap TA, 2011, CURR DRUG TARGETS, V12, P2045; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang YW, 2010, CANCER RES, V70, P6880, DOI 10.1158/0008-5472.CAN-10-0898	47	43	53	2	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 12	2013	32	50					5593	5601		10.1038/onc.2013.245	http://dx.doi.org/10.1038/onc.2013.245			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	272LF	23812422	hybrid, Green Published			2022-12-28	WOS:000328461400004
J	Agrelo, R; Kishimoto, H; Novatchkova, M; Peraza, V; Paolino, M; Souabni, A; Wutz, A				Agrelo, R.; Kishimoto, H.; Novatchkova, M.; Peraza, V.; Paolino, M.; Souabni, A.; Wutz, A.			SATB1 collaborates with loss of p16 in cellular transformation	ONCOGENE			English	Article						senescence; SATB1; p16; tumor; cell cycle; RB; E2F	BINDING PROTEIN-1 SATB1; RETINOBLASTOMA PROTEIN; GASTRIC-CANCER; T-CELLS; EXPRESSION; GENE; CHROMATIN; SENESCENCE; GROWTH; DIFFERENTIATION	Tumor progression is associated with invasiveness and metastatic potential. The special AT-rich binding protein 1 (SATB1) has been identified as a key factor in the progression of breast cancer cells to a malignant phenotype and is associated with progression of human tumors. In normal development, SATB1 coordinates gene expression of progenitor cells by functioning as a genome organizer. In contrast to progenitor and tumor cells, SATB1 expression in nontransformed cells is not compatible with proliferation. Here we show that SATB1 expression in mouse embryonic fibroblasts induces cell cycle arrest and senescence that is associated with elevated p16 protein levels. Deletion of p16 overcomes the SATB1-induced senescence. We further provide evidence for an interaction of SATB1 with the retinoblastoma (RB)/E2F pathway downstream of p16. A combined deletion of the RB proteins, RB, p107 and p130 (triple-mutant; TM), prevents SATB1-induced G1 arrest, which is restored upon the reintroduction of RB into SATB1-expressing TM fibroblasts. SATB1 interacts with the E2F/RB complex and regulates the cyclin E promoter in an E2F-dependent manner. These findings demonstrate that p16 and the RB/E2F pathway are critical for SATB1-induced cell cycle arrest. In the absence of p16, SATB1 causes anchorage-independent growth and invasive phenotype in fibroblasts. Our data illustrate that p16 mutations collaborate with the oncogenic activity of SATB1. Consistent with our finding, a literature survey shows that deletion of p16 is generally associated with SATB1 expressing human cell lines and tumors.	[Agrelo, R.; Peraza, V.] Inst Pasteur Montevideo, Epigenet Canc & Aging Lab, Montevideo 11400, Uruguay; [Agrelo, R.; Kishimoto, H.; Novatchkova, M.; Paolino, M.; Souabni, A.; Wutz, A.] Res Inst Mol Pathol, A-1030 Vienna, Austria; [Kishimoto, H.] Univ Tsukuba, Life Sci Ctr, Tsukuba Adv Res Alliance, Tsukuba, Ibaraki, Japan; [Kishimoto, H.; Wutz, A.] Univ Cambridge, Dept Biochem, Wellcome Trust, Cambridge CB2 1QW, England; [Kishimoto, H.; Wutz, A.] Univ Cambridge, Med Res Council Stem Cell Inst, Cambridge CB2 1QW, England; [Wutz, A.] Swiss Fed Inst Technol, Inst Mol Hlth Sci, Zurich, Switzerland	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur de Montevideo; Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP); University of Tsukuba; University of Cambridge; Wellcome Trust Sanger Institute; University of Cambridge; Swiss Federal Institutes of Technology Domain; ETH Zurich	Agrelo, R (corresponding author), Inst Pasteur Montevideo, Epigenet Canc & Aging Lab, Mataojo 2020, Montevideo 11400, Uruguay.	agrelo@pasteur.edu.uy		Paolino, Magdalena/0000-0001-9724-9029	IMP; Vienna Science and Technology Fund (WWTF); Austrian Science Fund (FWF); ANII (Program ) INNOVA URU-European Union; Wellcome Trust [087530/Z/08/A]	IMP; Vienna Science and Technology Fund (WWTF); Austrian Science Fund (FWF)(Austrian Science Fund (FWF)); ANII (Program ) INNOVA URU-European Union; Wellcome Trust(Wellcome TrustEuropean Commission)	We thank M Saltik, MH Idarraga, G Stengl and P Pasierbek for technical assistance, V Bhaskara for helpful discussions, S Galande, JM Peters, H Beug and R Foisner for reagents and advice. This research was supported by the IMP, the Vienna Science and Technology Fund (WWTF), and the Austrian Science Fund (FWF). RA is supported by ANII (Program INNOVA URUGUAY-DCI-ALA/2007/19.040 URU-European Union). AW is supported by a Wellcome Trust Senior Research Fellowship (Grant reference 087530/Z/08/A).	Agrelo R, 2009, DEV CELL, V16, P507, DOI 10.1016/j.devcel.2009.03.006; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Alvarez JD, 2000, GENE DEV, V14, P521; Asanoma K, 2012, J BIOL CHEM, V287, P2257, DOI 10.1074/jbc.M111.287128; Beyer M, 2011, NAT IMMUNOL, V12, P898, DOI 10.1038/ni.2084; Cai ST, 2006, NAT GENET, V38, P1278, DOI 10.1038/ng1913; Cai ST, 2003, NAT GENET, V34, P42, DOI 10.1038/ng1146; Chen HX, 2011, J DERMATOL SCI, V64, P39, DOI 10.1016/j.jdermsci.2011.06.007; Cheng C, 2010, APMIS, V118, P855, DOI 10.1111/j.1600-0463.2010.02673.x; Conklin JF, 2009, J CELL BIOCHEM, V108, P1023, DOI 10.1002/jcb.22342; de Belle I, 1998, J CELL BIOL, V141, P335, DOI 10.1083/jcb.141.2.335; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; Fessing MY, 2011, J CELL BIOL, V194, P825, DOI 10.1083/jcb.201101148; Fiorentino FP, 2009, CELL RES, V19, P1044, DOI 10.1038/cr.2009.96; Geng Y, 1996, ONCOGENE, V12, P1173; Han HJ, 2008, NATURE, V452, P187, DOI 10.1038/nature06781; Hanker LC, 2011, BREAST, V20, P309, DOI 10.1016/j.breast.2010.10.002; Harb G, 2009, DIABETES, V58, P1852, DOI 10.2337/db08-0759; Iorns E, 2010, JNCI-J NATL CANCER I, V102, P1284, DOI 10.1093/jnci/djq243; Khan MZ, 2008, CELL DEATH DIFFER, V15, P1663, DOI 10.1038/cdd.2008.95; Kim H, 2001, ONCOGENE, V20, P3306, DOI 10.1038/sj.onc.1204423; Kim M, 2000, CELL DEATH DIFFER, V7, P706, DOI 10.1038/sj.cdd.4400703; Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003; Kohwi-Shigematsu T, 2010, J NATL CANCER I, V102, P1879, DOI 10.1093/jnci/djq440; Leeb M, 2007, J CELL BIOL, V178, P219, DOI 10.1083/jcb.200612127; Lu XM, 2010, ONCOL REP, V24, P981, DOI 10.3892/or_00000945; McInnes N, 2012, ONCOGENE, V31, P1045, DOI 10.1038/onc.2011.293; Meng WJ, 2012, INT J COLORECTAL DIS, V27, P143, DOI 10.1007/s00384-011-1302-9; Meyyappan M, 1998, MOL CELL BIOL, V18, P3163, DOI 10.1128/MCB.18.6.3163; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Notani D, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000296; Odell A, 2010, AGING-US, V2, P160, DOI 10.18632/aging.100129; Ordinario E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051786; Pavan KP, 2006, MOL CELL, V22, P231, DOI 10.1016/j.molcel.2006.03.010; Purbey PK, 2009, MOL CELL BIOL, V29, P1321, DOI 10.1128/MCB.00822-08; Quesnel B, 1996, BRIT J HAEMATOL, V95, P291, DOI 10.1046/j.1365-2141.1996.d01-1913.x; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Savarese F, 2009, GENE DEV, V23, P2625, DOI 10.1101/gad.1815709; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Takahashi A, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-10; Tan JAT, 2008, J BIOL CHEM, V283, P18124, DOI 10.1074/jbc.M800512200; White J, 2005, STEM CELL REV, V1, P131, DOI 10.1385/SCR:1:2:131; Yamayoshi A, 2011, OLIGONUCLEOTIDES, V21, P115, DOI 10.1089/oli.2010.0277; Yasui D, 2002, NATURE, V419, P641, DOI 10.1038/nature01084; Zhao XD, 2010, ORL-J OTO-RHIN-LARYN, V72, P1, DOI 10.1159/000264777	45	15	16	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2013	32	48					5492	5500		10.1038/onc.2013.158	http://dx.doi.org/10.1038/onc.2013.158			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263BE	23686316	Green Published, hybrid			2022-12-28	WOS:000327780800006
J	Adhikary, T; Brandt, DT; Kaddatz, K; Stockert, J; Naruhn, S; Meissner, W; Finkernagel, F; Obert, J; Lieber, S; Scharfe, M; Jarek, M; Toth, PM; Scheer, F; Diederich, WE; Reinartz, S; Grosse, R; Muller-Brusselbach, S; Muller, R				Adhikary, T.; Brandt, D. T.; Kaddatz, K.; Stockert, J.; Naruhn, S.; Meissner, W.; Finkernagel, F.; Obert, J.; Lieber, S.; Scharfe, M.; Jarek, M.; Toth, P. M.; Scheer, F.; Diederich, W. E.; Reinartz, S.; Grosse, R.; Mueller-Bruesselbach, S.; Mueller, R.			Inverse PPAR beta/delta agonists suppress oncogenic signaling to the ANGPTL4 gene and inhibit cancer cell invasion	ONCOGENE			English	Article						peroxisome proliferator-activated receptor beta/delta (PPAR beta/delta) angiopoietin-like 4 (ANGPTL4); transforming growth factor beta (TGF beta); transcriptional repression; invasion; ChIP-Seq	ANGIOPOIETIN-LIKE 4; ACTIVATED RECEPTOR-DELTA; PROMOTES VENOUS INVASION; TGF-BETA; ANOIKIS RESISTANCE; GAMMA LIGANDS; EXPRESSION; PROTEIN; MIGRATION; METASTASIS	Besides its established functions in intermediary metabolism and developmental processes, the nuclear receptor peroxisome proliferator-activated receptor beta/delta (PPAR beta/delta) has a less defined role in tumorigenesis. In the present study, we have identified a function for PPAR beta/delta in cancer cell invasion. We show that two structurally divergent inhibitory ligands for PPAR beta/delta, the inverse agonists ST247 and DG172, strongly inhibit the serum- and transforming growth factor beta (TGF beta)-induced invasion of MDA-MB-231 human breast cancer cells into a three-dimensional matrigel matrix. To elucidate the molecular basis of this finding, we performed chromatin immunoprecipitation sequencing (ChIP-Seq) and microarray analyses, which identified the gene encoding angiopoietin-like 4 (ANGPTL4) as the major transcriptional PPAR beta/delta target in MDA-MB-231 cells, previously implicated in TGF beta-mediated tumor progression and metastatic dissemination. We show that the induction of ANGPTL4 by TGF beta and other oncogenic signals is strongly repressed by ST247 and DG172 in a PPAR beta/delta-dependent fashion, resulting in the inhibition of ANGPTL4 secretion. This effect is attributable to these ligands' ability to induce a dominant transcriptional repressor complex at the site of transcription initiation that blocks preinitiation complex formation through an histone deacetylase-independent, non-canonical mechanism. Repression of ANGPTL4 transcription by inverse PPAR beta/delta agonists is functionally linked to the inhibition of cancer cell invasion into a three-dimensional matrix, as (i) invasion of MDA-MB-231 cells is critically dependent on ANGPTL4 expression, (ii) recombinant ANGPTL4 stimulates invasion, and (iii) reverses the inhibitory effect of ST247 and DG172. These findings indicate that a PPAR beta/delta-ANGPTL4 pathway is involved in the regulation of tumor cell invasion and that its pharmacological manipulation by inverse PPAR beta/delta agonists is feasible.	[Adhikary, T.; Kaddatz, K.; Stockert, J.; Naruhn, S.; Meissner, W.; Finkernagel, F.; Obert, J.; Lieber, S.; Mueller-Bruesselbach, S.; Mueller, R.] Univ Marburg, Inst Mol Biol & Tumor Res IMT, D-35032 Marburg, Germany; [Brandt, D. T.; Grosse, R.] Univ Marburg, Pharmacol Inst, D-35032 Marburg, Germany; [Scharfe, M.; Jarek, M.] Helmholtz Ctr Infect Res HZI, Braunschweig, Germany; [Toth, P. M.; Scheer, F.; Diederich, W. E.] Univ Marburg, Inst Pharmaceut Chem, D-35032 Marburg, Germany; [Reinartz, S.] Univ Marburg, Dept Gynecol Gynecol Endocrinol & Oncol, D-35032 Marburg, Germany	Philipps University Marburg; Philipps University Marburg; Helmholtz Association; Helmholtz-Center for Infection Research; Philipps University Marburg; Philipps University Marburg	Muller, R (corresponding author), Univ Marburg, Inst Mol Biol & Tumor Res IMT, Emil Mannkopff Str 2, D-35032 Marburg, Germany.	rmueller@imt.uni-marburg.de	Müller, Rolf/L-4997-2016; Adhikary, Till/O-5678-2018	Müller, Rolf/0000-0003-3339-4248; Adhikary, Till/0000-0003-1951-5605; Grosse, Robert/0000-0002-3380-5273	Deutsche Forschungsgemeinschaft [SFB/TRR17-A3, MU601/13]; LOEWE research cluster 'Tumor and Inflammation'	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); LOEWE research cluster 'Tumor and Inflammation'	This work was supported by research grants from the Deutsche Forschungsgemeinschaft to RM (SFB/TRR17-A3 and MU601/13) and by the LOEWE research cluster 'Tumor and Inflammation'.	Adhikary T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016344; Bailey T L, 1994, Proc Int Conf Intell Syst Mol Biol, V2, P28; Belanger AJ, 2002, J MOL CELL CARDIOL, V34, P765, DOI 10.1006/jmcc.2002.2021; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Borland MG, 2011, CELL SIGNAL, V23, P2039, DOI 10.1016/j.cellsig.2011.07.020; Cazes A, 2006, CIRC RES, V99, P1207, DOI 10.1161/01.RES.0000250758.63358.91; Desvergne B, 2006, PHYSIOL REV, V86, P465, DOI 10.1152/physrev.00025.2005; Dowell P, 1999, J BIOL CHEM, V274, P15901, DOI 10.1074/jbc.274.22.15901; Du J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015940; Farrow B, 2003, SURGERY, V134, P206, DOI 10.1067/msy.2003.221; Galaup A, 2006, P NATL ACAD SCI USA, V103, P18721, DOI 10.1073/pnas.0609025103; Ge HF, 2004, J LIPID RES, V45, P2071, DOI 10.1194/jlr.M400138-JLR200; Gealekman O, 2008, AM J PHYSIOL-ENDOC M, V295, pE1056, DOI 10.1152/ajpendo.90345.2008; Goh YY, 2010, AM J PATHOL, V177, P2791, DOI 10.2353/ajpath.2010.100129; Goh YY, 2010, J BIOL CHEM, V285, P32999, DOI 10.1074/jbc.M110.108175; Hu ZY, 2009, BMC MED, V7, DOI 10.1186/1741-7015-7-9; Huang RL, 2011, BLOOD, V118, P3990, DOI 10.1182/blood-2011-01-328716; Huang XF, 2012, ONCOL REP, V27, P1541, DOI 10.3892/or.2012.1672; Kaddatz K, 2010, J BIOL CHEM, V285, P29469, DOI 10.1074/jbc.M110.142018; Kitzing TM, 2007, GENE DEV, V21, P1478, DOI 10.1101/gad.424807; Koliwad SK, 2009, J BIOL CHEM, V284, P25593, DOI 10.1074/jbc.M109.025452; Kramer DK, 2007, J BIOL CHEM, V282, P19313, DOI 10.1074/jbc.M702329200; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Le Jan S, 2003, AM J PATHOL, V162, P1521, DOI 10.1016/S0002-9440(10)64285-X; Lei X, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.217638; Li H, 2011, HEPATOLOGY, V54, P910, DOI 10.1002/hep.24479; Lieber S, 2012, J MED CHEM, V55, P2858, DOI 10.1021/jm2017122; Lim HJ, 2009, ATHEROSCLEROSIS, V202, P446, DOI 10.1016/j.atherosclerosis.2008.05.023; Liu H, 2003, BREAST CANCER RES TR, V79, P63, DOI 10.1023/A:1023366117157; Mandard S, 2006, J BIOL CHEM, V281, P934, DOI 10.1074/jbc.M506519200; Mandard S, 2004, J BIOL CHEM, V279, P34411, DOI 10.1074/jbc.M403058200; Mannelqvist M, 2011, AM J PATHOL, V178, P861, DOI 10.1016/j.ajpath.2010.10.040; McLean CY, 2010, NAT BIOTECHNOL, V28, P495, DOI 10.1038/nbt.1630; Michalik L, 2011, PROSTAG LEUKOTR ESS, V85, P235, DOI 10.1016/j.plefa.2011.04.016; Muller R, 2008, PPAR RES, V2008; Nakayama T, 2011, ONCOL REP, V25, P929, DOI 10.3892/or.2011.1176; Nakayama T, 2010, ONCOL REP, V24, P599, DOI 10.3892/or_00000897; Naruhn S, 2011, MOL PHARMACOL, V80, P828, DOI 10.1124/mol.111.074039; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; Papi A, 2009, ONCOL REP, V21, P1083, DOI 10.3892/or_00000327; Peters JM, 2012, NAT REV CANCER, V12, P181, DOI 10.1038/nrc3214; Peters JM, 2009, BBA-REV CANCER, V1796, P230, DOI 10.1016/j.bbcan.2009.06.002; Ricote M, 2007, BBA-MOL CELL BIOL L, V1771, P926, DOI 10.1016/j.bbalip.2007.02.013; Rieck M, 2008, MOL PHARMACOL, V74, P1269, DOI 10.1124/mol.108.050625; Shearer BG, 2010, J MED CHEM, V53, P1857, DOI 10.1021/jm900464j; Shi YH, 2002, P NATL ACAD SCI USA, V99, P2613, DOI 10.1073/pnas.052707099; Stockert J, 2011, NUCLEIC ACIDS RES, V39, P119, DOI 10.1093/nar/gkq773; Tan MJ, 2012, MOL CANCER RES, V10, P677, DOI 10.1158/1541-7786.MCR-11-0519; Tan NS, 2007, MOL CELL BIOL, V27, P7161, DOI 10.1128/MCB.00436-07; Tian LF, 2009, CANCER RES, V69, P9236, DOI 10.1158/0008-5472.CAN-09-2067; Toth PM, 2012, CHEMMEDCHEM, V7, P159, DOI 10.1002/cmdc.201100408; Van Ginderachter JA, 2008, PPAR RES, V2008, DOI 10.1155/2008/169414; Verine J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010421; Yang YH, 2008, ARTERIOSCL THROM VAS, V28, P835, DOI 10.1161/ATVBAHA.107.157776; Yoon JC, 2000, MOL CELL BIOL, V20, P5343, DOI 10.1128/MCB.20.14.5343-5349.2000; Zaytseva YY, 2011, ANTICANCER RES, V31, P813; Zhang ZY, 2008, CANCER LETT, V267, P106, DOI 10.1016/j.canlet.2008.03.010; Zhu PC, 2012, BIOSCIENCE REP, V32, P211, DOI 10.1042/BSR20110102; Zhu PC, 2011, CANCER CELL, V19, P401, DOI 10.1016/j.ccr.2011.01.018	59	55	57	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2013	32	44					5241	5252		10.1038/onc.2012.549	http://dx.doi.org/10.1038/onc.2012.549			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245XH	23208498	Green Published, hybrid, Green Submitted			2022-12-28	WOS:000326497100007
J	Dvorakova, M; Karafiat, V; Pajer, P; Kluzakova, E; Jarkovska, K; Pekova, S; Krutilkova, L; Dvorak, M				Dvorakova, M.; Karafiat, V.; Pajer, P.; Kluzakova, E.; Jarkovska, K.; Pekova, S.; Krutilkova, L.; Dvorak, M.			DNA released by leukemic cells contributes to the disruption of the bone marrow microenvironment	ONCOGENE			English	Article						acute leukemia; tumor microenvironment; extracellular nucleosomes; extracellular DNA; DNA damage response; cell death	LEUCINE-ZIPPER; MYB; ONCOGENE; DAMAGE; PHOSPHORYLATION; TRANSFORMATION; PROLIFERATION	Reciprocal interactions between a tumor and its microenvironment control expansion of tumor cells. Here we show a specific type of interaction in which blasts of experimental leukemia destroy the bone marrow ( BM) structures and kill stromal cells. The in vitro experiments showed that the cytotoxic agent released by leukemic cells is the fragmented DNA derived from their genome and occurring in nucleosome-like complexes. This DNA entered nuclei of BM or other cells and induced H2A.X phosphorylation at serine 139, similar to double-strand break-inducing agents. There was a correlation between large amounts of acquired DNA and death of recipient cells. Moreover, the DNA integrated into chromosomal DNA of recipient cells. Primary human acute myeloid leukemia cells also released fragmented DNA that penetrated the nuclei of other cells both in vitro and in vivo. We suggest that DNA fragments released from leukemic and also perhaps other types of tumor cells can activate DNA repair mechanisms or death in recipient cells of a tumor microenvironment, depending on the amount of the acquired DNA. This can impair DNA stability and viability of tumor stromal cells, undermine homeostatic capacity of tumor microenvironment and facilitate tumor progression.	[Dvorakova, M.; Karafiat, V.; Pajer, P.; Dvorak, M.] AS CR, Inst Mol Genet, Prague 14220, Czech Republic; [Kluzakova, E.] Charles Univ Prague, Fac Med 1, Inst Anat, Prague, Czech Republic; [Jarkovska, K.] AS CR, Inst Anim Physiol & Genet, Libechov, Czech Republic; [Pekova, S.; Krutilkova, L.] Chambon Lab Mol Diagnost, Prague, Czech Republic	Czech Academy of Sciences; Institute of Molecular Genetics of the Czech Academy of Sciences; Charles University Prague; Czech Academy of Sciences; Institute of Animal Physiology & Genetics of the Czech Academy of Sciences	Dvorak, M (corresponding author), AS CR, Inst Mol Genet, Vvi, Videnska 1083, Prague 14220, Czech Republic.	mdvorak@img.cas.cz	Dvořák, Michal/I-9939-2014; Jarkovska, Karla/G-7137-2014; Pajer, Petr/G-5869-2014; Dvorak, Michal/G-5861-2014	Kluzakova, Eva/0000-0001-8714-2519	Academy of Sciences of the Czech Republic [AV0Z50520514, KAN200520801]; Ministry of Education, Youth and Sports [LC06061]; Grant Agency of the Czech Republic [204/06/1728, 301/09/1727]; Internal Grant Agency of the Ministry of Health of the Czech Republic [NR 9651-4]	Academy of Sciences of the Czech Republic(Czech Academy of Sciences); Ministry of Education, Youth and Sports(Ministry of Education, Youth & Sports - Czech Republic); Grant Agency of the Czech Republic(Grant Agency of the Czech Republic); Internal Grant Agency of the Ministry of Health of the Czech Republic	We thank Professor Milos Grim and Drs Vladimir Pecenka, Vladimir Cermak and Jan Kosla for critical comments on manuscript. We are indebted to Drs Petr Novak, Vladimir Havlicek and Petr Pompach for identification of proteins by mass spectrometry, to Drs A Ekefjard and D Enetoft from Ludesi for providing Viper software, and to Dr David W Hardekopf for his help in manuscript preparation. This work was supported by Grants AV0Z50520514 and KAN200520801 from the Academy of Sciences of the Czech Republic and LC06061 from the Ministry of Education, Youth and Sports and 204/06/1728 and 301/09/1727 from the Grant Agency of the Czech Republic to MD and from the Internal Grant Agency of the Ministry of Health of the Czech Republic, Grant no. NR 9651-4 to SP. We are also indebted to Tomas Hlavnicka, Roman Minarik, Miroslav Navratil, Leos Navratil, Vladimir Pecenka, Karel Rybacek, Miroslav Sobotka, Josef Soukal and Petr Streitberg for financial support.	Alcalay M, 2003, J CLIN INVEST, V112, P1751, DOI 10.1172/JCI17595; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bartunek P, 1997, ONCOGENE, V15, P2939, DOI 10.1038/sj.onc.1201457; Basso K, 2010, ADV IMMUNOL, V105, P193, DOI 10.1016/S0065-2776(10)05007-8; Braakhuis BJM, 2003, CANCER RES, V63, P1727; Burger-Kentischer A, 2010, J IMMUNOL METHODS, V358, P93, DOI 10.1016/j.jim.2010.03.020; Cramer K, 2008, CANCER RES, V68, P6884, DOI 10.1158/0008-5472.CAN-08-1101; Dvorakova M, 2001, BLOOD CELL MOL DIS, V27, P437, DOI 10.1006/bcmd.2001.0402; ECKERT EA, 1951, J NATL CANCER I, V12, P447; Estey E, 2006, LANCET, V368, P1894, DOI 10.1016/S0140-6736(06)69780-8; Fernandez-Capetillo O, 2004, DNA REPAIR, V3, P959, DOI 10.1016/j.dnarep.2004.03.024; Fleischhacker M, 2010, CANCER BIOMARK, V6, P211, DOI 10.3233/CBM-2009-0131; Gahan PB, 2010, CELL BIOCHEM FUNCT, V28, P529, DOI 10.1002/cbf.1690; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; HLOZANEK I, 1968, Veterinarni Medicina (Prague), V13, P561; INTRONA M, 1994, SEMIN CANCER BIOL, V5, P113; Jarkovska K, 2010, J PROTEOME RES, V9, P1289, DOI 10.1021/pr900802u; Jin CY, 2007, GENE DEV, V21, P1519, DOI 10.1101/gad.1547707; Karafiat V, 2005, CELL MOL LIFE SCI, V62, P2516, DOI 10.1007/s00018-005-5297-7; Karafiat V, 2001, BLOOD, V98, P3668, DOI 10.1182/blood.V98.13.3668; Labit H, 2008, BIOTECHNIQUES, V45, P649, DOI 10.2144/000113002; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; MacCallum DE, 1996, ONCOGENE, V13, P2575; Mani RS, 2010, NAT REV GENET, V11, P819, DOI 10.1038/nrg2883; Michalet X, 1997, SCIENCE, V277, P1518, DOI 10.1126/science.277.5331.1518; Ness SA, 1996, BBA-REV CANCER, V1288, pF123, DOI 10.1016/S0304-419X(96)00027-3; Pereg Y, 2010, NAT CELL BIOL, V12, P400, DOI 10.1038/ncb2041; Peters DL, 2011, CLIN CHIM ACTA, V412, P806, DOI 10.1016/j.cca.2011.01.026; Pickering MT, 2006, ONCOGENE, V25, P746, DOI 10.1038/sj.onc.1209103; Sallmyr A, 2008, CANCER LETT, V270, P1, DOI 10.1016/j.canlet.2008.03.036; Savic V, 2009, CELL CYCLE, V8, P3285, DOI 10.4161/cc.8.20.9719; Shimura T, 2010, ONCOGENE, V29, P4826, DOI 10.1038/onc.2010.238; Thiriet C, 2005, MOL CELL, V18, P617, DOI 10.1016/j.molcel.2005.05.008; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Vichalkovski A, 2010, ONCOGENE, V29, P3554, DOI 10.1038/onc.2010.115; Zuber J, 2011, GENE DEV, V25, P1628, DOI 10.1101/gad.17269211	37	29	29	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2013	32	44					5201	5209		10.1038/onc.2012.553	http://dx.doi.org/10.1038/onc.2012.553			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245XH	23222712				2022-12-28	WOS:000326497100003
J	Hayashi, MT; Karlseder, J				Hayashi, M. T.; Karlseder, J.			DNA damage associated with mitosis and cytokinesis failure	ONCOGENE			English	Review						mitosis; DNA damage; telomeres; checkpoints; cytokinesis	KINETOCHORE-MICROTUBULE ATTACHMENT; ANAPHASE-PROMOTING COMPLEX; DOUBLE-STRAND BREAKS; POLO-LIKE KINASE-1; HUMAN-CELLS; AURORA-B; MITOTIC CHECKPOINT; CHROMOSOME MISSEGREGATION; EXTRA CENTROSOMES; MAMMALIAN-CELLS	Mitosis is a highly dynamic process, aimed at separating identical copies of genomic material into two daughter cells. A failure of the mitotic process generates cells that carry abnormal chromosome numbers. Such cells are predisposed to become tumorigenic upon continuous cell division and thus need to be removed from the population to avoid cancer formation. Cells that fail in mitotic progression indeed activate cell death or cell cycle arrest pathways; however, these mechanisms are not well understood. Growing evidence suggests that the formation of de novo DNA damage during and after mitotic failure is one of the causal factors that initiate those pathways. Here, we analyze several distinct malfunctions during mitosis and cytokinesis that lead to de novo DNA damage generation.	[Hayashi, M. T.; Karlseder, J.] Salk Inst Biol Studies, Dept Mol & Cellular Biol, La Jolla, CA 92037 USA	Salk Institute	Karlseder, J (corresponding author), Salk Inst Biol Studies, Dept Mol & Cellular Biol, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	Karlseder@salk.edu	Hayashi, Makoto/K-7155-2019	Hayashi, Makoto/0000-0001-6360-7131	Human Frontier Science Program Long Term Fellowship; Japan Society for the Promotion of Science; NIH [P30 CA014195-38, GM087476]; NATIONAL CANCER INSTITUTE [P30CA014195] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM087476] Funding Source: NIH RePORTER	Human Frontier Science Program Long Term Fellowship(Human Frontier Science Program); Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	MTH is supported by a Human Frontier Science Program Long Term Fellowship and a Japan Society for the Promotion of Science Postdoctoral Fellowships for Research Abroad. This work was supported by the Cancer Center Core Grant P30 CA014195-38 and a grant from the NIH to JK (GM087476).	Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Baker DJ, 2005, CURR OPIN CELL BIOL, V17, P583, DOI 10.1016/j.ceb.2005.09.011; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Brito DA, 2006, CURR BIOL, V16, P1194, DOI 10.1016/j.cub.2006.04.043; Brito DA, 2009, CELL MOTIL CYTOSKEL, V66, P437, DOI 10.1002/cm.20316; Carvalho A, 2003, J CELL SCI, V116, P2987, DOI 10.1242/jcs.00612; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Cesare AJ, 2009, NAT STRUCT MOL BIOL, V16, P1244, DOI 10.1038/nsmb.1725; Chan KL, 2011, SEMIN CELL DEV BIOL, V22, P906, DOI 10.1016/j.semcdb.2011.07.001; Cheeseman IM, 2008, NAT REV MOL CELL BIO, V9, P33, DOI 10.1038/nrm2310; Cimini D, 2001, J CELL BIOL, V153, P517, DOI 10.1083/jcb.153.3.517; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; Compton DA, 2011, CURR OPIN CELL BIOL, V23, P109, DOI 10.1016/j.ceb.2010.08.007; Cowley DO, 2009, MOL CELL BIOL, V29, P1059, DOI 10.1128/MCB.01062-08; Crasta K, 2012, NATURE, V482, P53, DOI 10.1038/nature10802; Dalton WB, 2010, ONCOGENE, V29, P1929, DOI 10.1038/onc.2009.477; Dalton WB, 2007, CANCER RES, V67, P11487, DOI 10.1158/0008-5472.CAN-07-5162; Dalton WB, 2009, FUTURE ONCOL, V5, P1363, DOI 10.2217/FON.09.118; Davoli T, 2012, CANCER CELL, V21, P765, DOI 10.1016/j.ccr.2012.03.044; Davoli T, 2011, ANNU REV CELL DEV BI, V27, P585, DOI 10.1146/annurev-cellbio-092910-154234; de Lange T, 2010, COLD SH Q B, V75, P167, DOI 10.1101/sqb.2010.75.017; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Fuller BG, 2008, NATURE, V453, P1132, DOI 10.1038/nature06923; Fumagalli M, 2012, NAT CELL BIOL, V14, P355, DOI 10.1038/ncb2466; Ganem NJ, 2007, CELL, V131, P437, DOI 10.1016/j.cell.2007.10.024; Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Gassmann R, 2004, J CELL BIOL, V166, P179, DOI 10.1083/jcb.200404001; Giunta S, 2011, CELL CYCLE, V10, P1215, DOI 10.4161/cc.10.8.15334; Giunta S, 2010, J CELL BIOL, V190, P197, DOI 10.1083/jcb.200911156; Hauf S, 2003, J CELL BIOL, V161, P281, DOI 10.1083/jcb.200208092; Hayashi MT, 2012, NAT STRUCT MOL BIOL, V19, P387, DOI 10.1038/nsmb.2245; Hoffelder DR, 2004, CHROMOSOMA, V112, P389, DOI 10.1007/s00412-004-0284-6; Holland AJ, 2012, EMBO REP, V13, P501, DOI 10.1038/embor.2012.55; Huang YF, 2009, MOL CELL BIOL, V29, P2935, DOI 10.1128/MCB.01837-08; Janssen A, 2011, SCIENCE, V333, P1895, DOI 10.1126/science.1210214; Jeyaprakash AA, 2007, CELL, V131, P271, DOI 10.1016/j.cell.2007.07.045; Kalitsis P, 2000, GENE DEV, V14, P2277, DOI 10.1101/gad.827500; Kapoor TM, 2000, J CELL BIOL, V150, P975, DOI 10.1083/jcb.150.5.975; Li M, 2010, P NATL ACAD SCI USA, V107, P14188, DOI 10.1073/pnas.1005960107; Liu D, 2009, SCIENCE, V323, P1350, DOI 10.1126/science.1167000; McGuinness BE, 2005, PLOS BIOL, V3, P433, DOI 10.1371/journal.pbio.0030086; Meraldi P, 2004, DEV CELL, V7, P45, DOI 10.1016/j.devcel.2004.06.006; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Mikhailov A, 2002, CURR BIOL, V12, P1797, DOI 10.1016/S0960-9822(02)01226-5; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Nezi LG, 2009, CURR OPIN CELL BIOL, V21, P785, DOI 10.1016/j.ceb.2009.09.007; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Norden C, 2006, CELL, V125, P85, DOI 10.1016/j.cell.2006.01.045; Orth JD, 2012, MOL BIOL CELL, V23, P567, DOI 10.1091/mbc.E11-09-0781; Pampalona J, 2012, PLOS GENET, V8, P601, DOI 10.1371/journal.pgen.1002679; Petronczki M, 2007, DEV CELL, V12, P713, DOI 10.1016/j.devcel.2007.03.013; Pfau SJ, 2012, EMBO REP, V13, P515, DOI 10.1038/embor.2012.65; Pines J, 2001, NAT CELL BIOL, V3, pE3, DOI 10.1038/35050676; Polo SE, 2011, GENE DEV, V25, P409, DOI 10.1101/gad.2021311; Putkey FR, 2002, DEV CELL, V3, P351, DOI 10.1016/S1534-5807(02)00255-1; Quignon F, 2007, ONCOGENE, V26, P165, DOI 10.1038/sj.onc.1209787; RIEDER CL, 1995, J CELL BIOL, V130, P941, DOI 10.1083/jcb.130.4.941; Rieder CL, 2004, DEV CELL, V7, P637, DOI 10.1016/j.devcel.2004.09.002; Rieder CL, 1998, J CELL BIOL, V142, P1013, DOI 10.1083/jcb.142.4.1013; Rieder CL, 2011, CHROMOSOME RES, V19, P291, DOI 10.1007/s10577-010-9178-z; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Sanchez Y, 1999, SCIENCE, V286, P1166, DOI 10.1126/science.286.5442.1166; Sheltzer JM, 2012, P NATL ACAD SCI USA, V109, P12644, DOI 10.1073/pnas.1209227109; Shen K, 2006, J CELL BIOCHEM, V99, P1267, DOI 10.1002/jcb.20848; Shi J, 2008, CANCER RES, V68, P3269, DOI 10.1158/0008-5472.CAN-07-6699; Silkworth WT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006564; Skoufias DA, 2004, MOL CELL, V15, P977, DOI 10.1016/j.molcel.2004.08.018; Slonim DK, 2009, P NATL ACAD SCI USA, V106, P9425, DOI 10.1073/pnas.0903909106; Sotillo R, 2007, CANCER CELL, V11, P9, DOI 10.1016/j.ccr.2006.10.019; Steigemann P, 2009, CELL, V136, P473, DOI 10.1016/j.cell.2008.12.020; Stucki M, 2005, CELL, V123, P1213, DOI 10.1016/j.cell.2005.09.038; Sumara I, 2004, CURR BIOL, V14, P1712, DOI 10.1016/j.cub.2004.09.049; Thompson SL, 2011, P NATL ACAD SCI USA, V108, P17974, DOI 10.1073/pnas.1109720108; Thompson SL, 2010, J CELL BIOL, V188, P369, DOI 10.1083/jcb.200905057; Toyoda Y, 2006, MOL BIOL CELL, V17, P2287, DOI 10.1091/mbc.E05-11-1089; Uetake Y, 2004, J CELL BIOL, V165, P609, DOI 10.1083/jcb.200403014; Uetake Y, 2010, CURR BIOL, V20, P1666, DOI 10.1016/j.cub.2010.08.018; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P1153, DOI 10.1038/cdd.2008.47; van der Waal MS, 2012, EXP CELL RES, V318, P1407, DOI 10.1016/j.yexcr.2012.03.015; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; van Vugt MATM, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000287; Vitale I, 2011, NAT REV MOL CELL BIO, V12, P384, DOI 10.1038/nrm3115; Wang EX, 2011, J CELL BIOL, V194, P538, DOI 10.1083/jcb.201103044; Westhorpe FG, 2011, J CELL SCI, V124, P3905, DOI 10.1242/jcs.093286; Wong C, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-6; Yanagida M, 2009, NAT REV MOL CELL BIO, V10, P489, DOI 10.1038/nrm2712; Yang CY, 2011, MOL CELL, V44, P597, DOI 10.1016/j.molcel.2011.09.016; Yang Z, 2008, NAT CELL BIOL, V10, P748, DOI 10.1038/ncb1738; Zeng X, 2010, CANCER CELL, V18, P382, DOI 10.1016/j.ccr.2010.08.010; Zhang T, 2009, DEV CELL, V17, P541, DOI 10.1016/j.devcel.2009.09.006; Zhang W, 2011, J BIOL CHEM, V286, P35899, DOI 10.1074/jbc.M111.267690	96	91	94	3	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2013	32	39					4593	4601		10.1038/onc.2012.615	http://dx.doi.org/10.1038/onc.2012.615			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226YD	23318447	Green Accepted			2022-12-28	WOS:000325072200001
J	Zhang, J; Espinoza, LA; Kinders, RJ; Lawrence, SM; Pfister, TD; Zhou, M; Veenstra, TD; Thorgeirsson, SS; Jessup, JM				Zhang, J.; Espinoza, L. A.; Kinders, R. J.; Lawrence, S. M.; Pfister, T. D.; Zhou, M.; Veenstra, T. D.; Thorgeirsson, S. S.; Jessup, J. M.			NANOG modulates stemness in human colorectal cancer	ONCOGENE			English	Article						NANOG; NANOGP8; stemness; colorectal cancer; cancer stem cell	TRANSCRIPTIONAL NETWORK; GENE-EXPRESSION; CELLS; PLURIPOTENCY; SOX2; INHIBITOR; PROGNOSIS; SIGNATURE; PATHWAYS; LUNG	NANOG is a stem cell transcription factor that is essential for embryonic development, reprogramming normal adult cells and malignant transformation and progression. The nearly identical retrogene NANOGP8 is expressed in multiple cancers, but generally not in normal tissues and its function is not well defined. Our postulate is that NANOGP8 directly modulates the stemness of individual human colorectal carcinoma (CRC) cells. Stemness was measured in vitro as the spherogenicity of single CRC cells in serum-free medium and the size of the side population (SP) and in vivo as tumorigenicity and experimental metastatic potential in NOD/SCID mice. We found that 80% of clinical liver metastases express a NANOG with 75% of the positive metastases containing NANOGP8 transcripts. In all, 3-62% of single cells within six CRC lines form spheroids in serum-free medium in suspension. NANOGP8 is translated into protein. The relative expression of a NANOG gene increased 8- to 122-fold during spheroid formation, more than the increase in OCT4 or SOX2 transcripts with NANOGP8 the more prevalent family member. Short hairpin RNA (shRNA) to NANOG not only inhibits spherogenicity but also reduces expression of OCT4 and SOX2, the size of the SP and tumor growth in vivo. Inhibition of NANOG gene expression is associated with inhibition of proliferation and decreased phosphorylation of G2-related cell-cycle proteins. Overexpression of NANOGP8 rescues single-cell spherogenicity when NANOG gene expression is inhibited and increases the SP in CRC. Thus, NANOGP8 can substitute for NANOG in directly promoting stemness in CRC.	[Zhang, J.; Espinoza, L. A.; Thorgeirsson, S. S.; Jessup, J. M.] NCI, Expt Carcinogenesis Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; [Kinders, R. J.; Lawrence, S. M.; Pfister, T. D.] SAIC Frederick Inc, Lab Human Toxicol & Pharmacol, Appl Dev Res Support Directorate, Frederick Natl Lab Canc Res, Frederick, MD USA; [Zhou, M.; Veenstra, T. D.] SAIC Frederick, Lab Prote & Analyt Technol, Frederick Natl Lab Canc Res, Frederick, MD USA; [Jessup, J. M.] Div Canc Treatment & Diag, Canc Diag Program, Rockville, MD USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Jessup, JM (corresponding author), Canc Diag Program, Diagnost Evaluat Branch, Bethesda, MD 20892 USA.	jessupj@mail.nih.gov			Center for Cancer Research of the NCI [ZIA BC 011199]; Department of Defense [W81XWH-11-1-0327]; NATIONAL CANCER INSTITUTE [ZIABC011199] Funding Source: NIH RePORTER	Center for Cancer Research of the NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We acknowledge the valuable advice and support of Drs Elizabeth Conner and Valentina Factor. Also, we gratefully acknowledge the support provided by the Center for Cancer Research of the NCI for Project ZIA BC 011199 and by the Department of Defense for Grant Number W81XWH-11-1-0327. The opinions expressed in this manuscript are those of the authors and do not necessarily represent those of the National Cancer Institute, the National Institutes of Health, the Department of Health and Human Services or the Department of the Army.	Ambady S, 2010, INT J DEV BIOL, V54, P1743, DOI 10.1387/ijdb.103192sa; Bass AJ, 2009, NAT GENET, V41, P1238, DOI 10.1038/ng.465; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Booth HAF, 2004, GENOMICS, V84, P229, DOI 10.1016/j.ygeno.2004.02.014; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chambers I, 2007, NATURE, V450, P1230, DOI 10.1038/nature06403; Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043; Ding JJ, 2012, CELL RES, V22, P155, DOI 10.1038/cr.2011.179; Dykxhoorn DM, 2006, P NATL ACAD SCI USA, V103, P5953, DOI 10.1073/pnas.0601309103; Eberle I, 2010, NUCLEIC ACIDS RES, V38, P5384, DOI 10.1093/nar/gkq307; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Huang HJ, 2006, SCIENCE, V314, P294, DOI 10.1126/science.1130512; Huang H, 2009, NUCLEIC ACIDS RES, V37, P7560, DOI 10.1093/nar/gkp835; Ishiguro T, 2012, BIOCHEM BIOPH RES CO, V418, P199, DOI 10.1016/j.bbrc.2011.10.123; JESSUP JM, 1989, CANCER RES, V49, P6906; Jeter CR, 2011, ONCOGENE, V30, P3833, DOI 10.1038/onc.2011.114; Jeter CR, 2009, STEM CELLS, V27, P993, DOI 10.1002/stem.29; Ji J, 2010, HUM PATHOL, V41, P1438, DOI 10.1016/j.humpath.2009.11.021; Katoh M, 2011, CURR PHARM BIOTECHNO, V12, P160, DOI 10.2174/138920111794295710; Kim JW, 2008, CELL, V132, P1049, DOI 10.1016/j.cell.2008.02.039; Kinders RJ, 2010, CLIN CANCER RES, V16, P5447, DOI 10.1158/1078-0432.CCR-09-3076; Kong DJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012445; Kumar SM, 2012, ONCOGENE, V31, P4898, DOI 10.1038/onc.2011.656; Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338; Lengner CJ, 2007, CELL STEM CELL, V1, P403, DOI 10.1016/j.stem.2007.07.020; Lin KK, 2006, METHOD ENZYMOL, V420, P255, DOI 10.1016/S0076-6879(06)20011-9; Lu KP, 1996, NATURE, V380, P544; Macfarlan TS, 2012, NATURE, V487, P57, DOI 10.1038/nature11244; Meng HM, 2010, CANCER BIOL THER, V9, P295, DOI 10.4161/cbt.9.4.10666; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Miyanari Y, 2012, NATURE, V483, P470, DOI 10.1038/nature10807; Miyoshi N, 2010, P NATL ACAD SCI USA, V107, P40, DOI 10.1073/pnas.0912407107; MULDER JWR, 1994, LANCET, V344, P1470, DOI 10.1016/S0140-6736(94)90290-9; Nishi M, 2011, J BIOL CHEM, V286, P11593, DOI 10.1074/jbc.M110.187989; Park IH, 2008, CELL, V134, P877, DOI 10.1016/j.cell.2008.07.041; Po A, 2010, EMBO J, V29, P2646, DOI 10.1038/emboj.2010.131; Saiki Y, 2009, ANN SURG ONCOL, V16, P2638, DOI 10.1245/s10434-009-0567-5; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Santagata S, 2007, AM J SURG PATHOL, V31, P836, DOI 10.1097/PAS.0b013e31802e708a; Sholl LM, 2010, AM J SURG PATHOL, V34, P1193, DOI 10.1097/PAS.0b013e3181e5e024; Silva J, 2009, CELL, V138, P722, DOI 10.1016/j.cell.2009.07.039; Simkus C, 2009, IMMUNOLOGY, V128, P206, DOI 10.1111/j.1365-2567.2009.03101.x; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Utikal J, 2009, J CELL SCI, V122, P3502, DOI 10.1242/jcs.054783; Wang Q, 2009, ANTICANCER RES, V29, P1233; Xu F, 2012, DIGEST DIS SCI, V57, P2340, DOI 10.1007/s10620-012-2182-8; You JS, 2009, CANCER RES, V69, P5716, DOI 10.1158/0008-5472.CAN-08-4953; Yu JY, 2009, SCIENCE, V324, P797, DOI 10.1126/science.1172482; Zappone MV, 2000, DEVELOPMENT, V127, P2367; Zbinden M, 2010, EMBO J, V29, P2659, DOI 10.1038/emboj.2010.137; Zhang J, 2011, P 102 ANN M AM ASS C; Zhang J, 2010, J CLIN PATHOL, V63, P879, DOI 10.1136/jcp.2009.073593; Zhang JY, 2006, FEBS J, V273, P1723, DOI 10.1111/j.1742-4658.2006.05186.x; Zhang X, 2010, J GASTROINTEST SURG, V14, P1220, DOI 10.1007/s11605-010-1246-3	56	83	89	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2013	32	37					4397	4405		10.1038/onc.2012.461	http://dx.doi.org/10.1038/onc.2012.461			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218AF	23085761	Green Accepted			2022-12-28	WOS:000324404200008
J	Gang, EJ; Hsieh, YT; Pham, J; Zhao, Y; Nguyen, C; Huantes, S; Park, E; Naing, K; Klemm, L; Swaminathan, S; Conway, EM; Pelus, LM; Crispino, J; Mullighan, CG; McMillan, M; Muschen, M; Kahn, M; Kim, YM				Gang, E. J.; Hsieh, Y-T; Pham, J.; Zhao, Y.; Nguyen, C.; Huantes, S.; Park, E.; Naing, K.; Klemm, L.; Swaminathan, S.; Conway, E. M.; Pelus, L. M.; Crispino, J.; Mullighan, C. G.; McMillan, M.; Mueschen, M.; Kahn, M.; Kim, Y-M			Small-molecule inhibition of CBP/catenin interactions eliminates drug-resistant clones in acute lymphoblastic leukemia	ONCOGENE			English	Article						acute lymphoblastic leukemia; drug resistance; small-molecule inhibitor; CBP; p300; ICG-001	TRANSCRIPTIONAL COACTIVATOR CBP; CREB-BINDING PROTEIN; RUBINSTEIN-TAYBI-SYNDROME; WNT/BETA-CATENIN PATHWAY; HEMATOPOIETIC STEM-CELLS; BETA-CATENIN; SELF-RENEWAL; PRE-B; HISTONE ACETYLATION; DIFFERENTIAL ROLES	Drug resistance in acute lymphoblastic leukemia (ALL) remains a major problem warranting new treatment strategies. Wnt/catenin signaling is critical for the self-renewal of normal hematopoietic progenitor cells. Deregulated Wnt signaling is evident in chronic and acute myeloid leukemia; however, little is known about ALL. Differential interaction of catenin with either the Kat3 coactivator CREBBP (CREB-binding protein (CBP)) or the highly homologous EP300 (p300) is critical to determine divergent cellular responses and provides a rationale for the regulation of both proliferation and differentiation by the Wnt signaling pathway. Usage of the coactivator CBP by catenin leads to transcriptional activation of cassettes of genes that are involved in maintenance of progenitor cell self-renewal. However, the use of the coactivator p300 leads to activation of genes involved in the initiation of differentiation. ICG-001 is a novel small-molecule modulator of Wnt/catenin signaling, which specifically binds to the N-terminus of CBP and not p300, within amino acids 1-110, thereby disrupting the interaction between CBP and catenin. Here, we report that selective disruption of the CBP/beta-and gamma-catenin interactions using ICG-001 leads to differentiation of pre-B ALL cells and loss of self-renewal capacity. Survivin, an inhibitor-of-apoptosis protein, was also downregulated in primary ALL after treatment with ICG-001. Using chromatin immunoprecipitation assay, we demonstrate occupancy of the survivin promoter by CBP that is decreased by ICG-001 in primary ALL. CBP mutations have been recently identified in a significant percentage of ALL patients, however, almost all of the identified mutations reported occur C-terminal to the binding site for ICG-001. Importantly, ICG-001, regardless of CBP mutational status and chromosomal aberration, leads to eradication of drug-resistant primary leukemia in combination with conventional therapy in vitro and significantly prolongs the survival of NOD/SCID mice engrafted with primary ALL. Therefore, specifically inhibiting CBP/catenin transcription represents a novel approach to overcome relapse in ALL.	[Gang, E. J.; Hsieh, Y-T; Pham, J.; Huantes, S.; Park, E.; Naing, K.; Kim, Y-M] Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Div Hematol & Oncol,Dept Pediat, Los Angeles, CA 90033 USA; [Zhao, Y.; Nguyen, C.; McMillan, M.; Kahn, M.] Univ So Calif, Ctr Mol Pathways & Drug Discovery, Dept Mol Pharmacol & Toxicol, Norris Comprehens Canc Ctr,Dept Biochem & Mol Bio, Los Angeles, CA 90033 USA; [Klemm, L.; Swaminathan, S.; Mueschen, M.] Univ Calif San Francisco, Dept Lab Med, Ctr Comprehens Canc, San Francisco, CA 94143 USA; [Conway, E. M.] Univ British Columbia, Fac Med, Div Hematol, Ctr Blood Res, Vancouver, BC, Canada; [Pelus, L. M.] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA; [Crispino, J.] Northwestern Univ, Div Hematol Oncol, Chicago, IL 60611 USA; [Mullighan, C. G.] St Jude Childrens Res Hosp, Dept Pathol, Memphis, TN 38105 USA	Children's Hospital Los Angeles; University of Southern California; University of Southern California; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of British Columbia; Indiana University System; Indiana University Bloomington; Northwestern University; St Jude Children's Research Hospital	Kahn, M (corresponding author), Univ So Calif, Ctr Mol Pathways & Drug Discovery, Dept Mol Pharmacol & Toxicol, Norris Comprehens Canc Ctr,Dept Biochem & Mol Bio, 1450 Biggy St,NRT 4501, Los Angeles, CA 90033 USA.	kahnm@usc.edu	Mullighan, Charles/H-3253-2011; kim, y/AAR-6095-2020	Mullighan, Charles/0000-0002-1871-1850; Kim, Yong-Mi/0000-0003-3793-6438; Crispino, John/0000-0002-8182-8306; Conway, Edward/0000-0003-0081-0305	William Lawrence and Blanche Hughes Foundation; Concern Foundation; American Cancer Society [R01CA172896]; USC Norris Comprehensive Cancer Center [P30 CA014089, R01CA137060, R01CA139032, R01CA157644]; Canadian Institutes for Health Research (CIHR); Nautica Triathlon; NATIONAL CANCER INSTITUTE [R01CA169458, P30CA021765, R01CA166161, R01CA172558, R01CA139032, R01CA157644, P30CA014089, R01CA172896, R01CA137060] Funding Source: NIH RePORTER; Cancer Research UK [18131] Funding Source: researchfish	William Lawrence and Blanche Hughes Foundation; Concern Foundation; American Cancer Society(American Cancer Society); USC Norris Comprehensive Cancer Center; Canadian Institutes for Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Nautica Triathlon; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Research UK(Cancer Research UK)	This work was supported by Grants from: William Lawrence and Blanche Hughes Foundation, Concern Foundation, Nautica Triathlon and the American Cancer Society and R01CA172896 (YMK); and USC Norris Comprehensive Cancer Center Support Grant P30 CA014089 (MK); R01CA137060, R01CA139032, R01CA157644 (MM). EMC is supported by a CSL Behring Research Chair and a Canada Research Chair in Endothelial Cell Biology and by grants from the Canadian Institutes for Health Research (CIHR).	Altieri DC, 2008, NAT REV CANCER, V8, P61, DOI 10.1038/nrc2293; Blough RI, 2000, AM J MED GENET, V90, P29, DOI 10.1002/(SICI)1096-8628(20000103)90:1<29::AID-AJMG6>3.0.CO;2-Z; Chan WI, 2011, MOL CELL BIOL, V31, P5046, DOI 10.1128/MCB.05830-11; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101; Gastaldi T, 2006, CARCINOGENESIS, V27, P1758, DOI 10.1093/carcin/bgl008; Hardy RR, 2001, ANNU REV IMMUNOL, V19, P595, DOI 10.1146/annurev.immunol.19.1.595; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Herzog S, 2009, NAT REV IMMUNOL, V9, P195, DOI 10.1038/nri2491; Hu Y, 2009, LEUKEMIA, V23, P109, DOI 10.1038/leu.2008.262; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; Kahn M, 2011, FUTURE MED CHEM, V3, P1745, DOI [10.4155/FMC.11.126, 10.4155/fmc.11.126]; Kawasaki H., 1999, NUCL ACIDS S SER, V42, P263; Khan NI, 2007, BRIT J HAEMATOL, V138, P338, DOI 10.1111/j.1365-2141.2007.06667.x; Kim YM, 2011, CURR CANCER DRUG TAR, V11, P213, DOI 10.2174/156800911794328420; Klein F, 2005, J IMMUNOL, V174, P367, DOI 10.4049/jimmunol.174.1.367; Koch U, 2008, BLOOD, V111, P160, DOI 10.1182/blood-2007-07-099754; Kumar SR, 2009, CANCER RES, V69, P3736, DOI 10.1158/0008-5472.CAN-08-3232; Leung CG, 2007, J EXP MED, V204, P1603, DOI 10.1084/jem.20062395; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Luis TC, 2011, CELL STEM CELL, V9, P345, DOI 10.1016/j.stem.2011.07.017; Ma H, 2005, ONCOGENE, V24, P3619, DOI 10.1038/sj.onc.1208433; Marmorstein R, 2001, CELL MOL LIFE SCI, V58, P693, DOI 10.1007/PL00000893; Mazieres J, 2005, ONCOGENE, V24, P5396, DOI 10.1038/sj.onc.1208568; Morrison DJ, 2012, LEUKEMIA, V26, P271, DOI 10.1038/leu.2011.199; Muljo SA, 2003, NAT IMMUNOL, V4, P31, DOI 10.1038/ni870; Mullighan CG, 2011, NATURE, V471, P235, DOI 10.1038/nature09727; Park E, 2011, BLOOD, V118, P2191, DOI 10.1182/blood-2011-04-351239; Pasqualucci L, 2011, NAT GENET, V43, P830, DOI 10.1038/ng.892; Pear WS, 1998, BLOOD, V92, P3780, DOI 10.1182/blood.V92.10.3780.422k15_3780_3792; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Pui CH, 2008, LANCET, V371, P1030, DOI 10.1016/S0140-6736(08)60457-2; Ramos YFM, 2010, NUCLEIC ACIDS RES, V38, P5396, DOI 10.1093/nar/gkq184; Rebel VI, 2002, P NATL ACAD SCI USA, V99, P14789, DOI 10.1073/pnas.232568499; Reya T, 2003, NATURE, V423, P409, DOI 10.1038/nature01593; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Spencer VA, 2003, METHODS, V31, P67, DOI 10.1016/S1046-2023(03)00089-6; Takahashi-Yanaga F, 2010, CLIN CANCER RES, V16, P3153, DOI 10.1158/1078-0432.CCR-09-2943; Takebe N, 2011, NAT REV CLIN ONCOL, V8, P97, DOI 10.1038/nrclinonc.2010.196; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tanaka Y, 2000, MECH DEVELOP, V95, P133, DOI 10.1016/S0925-4773(00)00360-9; Teo JL, 2005, P NATL ACAD SCI USA, V102, P12171, DOI 10.1073/pnas.0504600102; Tyner JW, 2012, LEUKEMIA, V26, P623, DOI 10.1038/leu.2011.249; Verkaar F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019185; Wang YZ, 2010, SCIENCE, V327, P1650, DOI 10.1126/science.1186624; Xu W, 2006, BLOOD, V107, P4407, DOI 10.1182/blood-2005-08-3263; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Zhang JH, 2011, BLOOD, V118, P3080, DOI 10.1182/blood-2011-03-341412; Zhao C, 2007, CANCER CELL, V12, P528, DOI 10.1016/j.ccr.2007.11.003; Zheng XM, 2004, BLOOD, V103, P3535, DOI 10.1182/blood-2003-09-3335	50	120	127	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2014	33	17					2169	2178		10.1038/onc.2013.169	http://dx.doi.org/10.1038/onc.2013.169			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF8WJ	23728349	Green Submitted, Green Accepted			2022-12-28	WOS:000334996000003
J	Ye, Q; Cai, W; Zheng, Y; Evers, BM; She, QB				Ye, Q.; Cai, W.; Zheng, Y.; Evers, B. M.; She, Q-B			ERK and AKT signaling cooperate to translationally regulate survivin expression for metastatic progression of colorectal cancer	ONCOGENE			English	Article						translational regulation; metastasis; ERK; AKT; survivin; colorectal cancer	INITIATION-FACTOR 4E; INTRINSIC RESISTANCE; TUBEROUS SCLEROSIS; PROTEIN-SYNTHESIS; MAMMALIAN TARGET; ACTIVATION; MTOR; EIF4E; PHOSPHORYLATION; INHIBITION	The mitogen-activated extracellular signal-regulated kinase/extracellular signal-regulated kinase (MEK/ERK) and phosphatidylinositol 3-kinase (PI3K)/AKT pathways are often concurrently activated by separate genetic alterations in colorectal cancer (CRC), which is associated with CRC progression and poor survival. However, how activating both pathways is required for CRC metastatic progression remains unclear. Our recent study showed that both ERK and AKT signaling are required to activate eukaryotic translation initiation factor 4E (eIF4E)-initiated cap-dependent translation via convergent regulation of the translational repressor 4E-binding protein 1 (4E-BP1) for maintaining CRC transformation. Here, we identified that the activation of cap-dependent translation by cooperative ERK and AKT signaling is critical for promotion of CRC motility and metastasis. In CRC cells with coexistent mutational activation of ERK and AKT pathways, inhibition of either MEK or AKT alone showed limited activity in inhibiting cell migration and invasion, but combined inhibition resulted in profound effects. Genetic blockade of the translation initiation complex by eIF4E knockdown or expression of a dominant active 4E-BP1 mutant effectively inhibited migration, invasion and metastasis of CRC cells, whereas overexpression of eIF4E or knockdown of 4E-BP1 had the opposite effect and markedly reduced their dependence on ERK and AKT signaling for cell motility. Mechanistically, we found that these effects were largely dependent on the increase in mammalian target of rapamycin complex 1 (mTORC1)-mediated survivin translation by ERK and AKT signaling. Despite the modest effect of survivin knockdown on tumor growth, reduction of the translationally regulated survivin profoundly inhibited motility and metastasis of CRC. These findings reveal a critical mechanism underlying the translational regulation of CRC metastatic progression, and suggest that targeting cap-dependent translation may provide a promising treatment strategy for advanced CRC.	[Ye, Q.; Cai, W.; Zheng, Y.; Evers, B. M.; She, Q-B] Univ Kentucky, Coll Med, Markey Canc Ctr, Lexington, KY 40506 USA; [Ye, Q.; Cai, W.; Zheng, Y.; She, Q-B] Univ Kentucky, Coll Med, Dept Mol & Biomed Pharmacol, Lexington, KY 40506 USA; [Evers, B. M.] Univ Kentucky, Coll Med, Dept Surg, Lexington, KY 40506 USA	University of Kentucky; University of Kentucky; University of Kentucky	She, QB (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Biomed Pharmacol, 741 South Limestone,B365 BBSRB, Lexington, KY 40506 USA.	qing-bai.she@uky.edu		She, Qing-Bai/0000-0002-7207-0599	NCI [R01CA175105, P30CA147886]; Gastrointestinal Cancer [SPORE P20CA150343]; ACS [IRG85-001-22]; NIH/NCATS [UL1RR033173, KL2RR0033171]; Markey Cancer Center Start-up fund; NATIONAL CANCER INSTITUTE [R01CA175105, P30CA177558, P30CA147886, P20CA150343] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [KL2TR000116, UL1TR000117] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [KL2RR033171, UL1RR033173] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Gastrointestinal Cancer; ACS(American Cancer Society); NIH/NCATS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); Markey Cancer Center Start-up fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	We thank Drs Rina Plattner and Kathleen O'Connor and Ms Donna Gilbreath for critical reading and editing of this manuscript, Dr Ronald Blasberg for providing the SFG-FLuc-IRES2-GFP construct. Dr Piotr Rychahou for the assistance in the animal experiments, and Ms Dana Napier for the histologic tissue processing. This work was supported by grants from NCI (R01CA175105 to Q-B She, P30CA147886 and Gastrointestinal Cancer SPORE P20CA150343 to BM Evers), ACS (IRG85-001-22 to Q-B She), NIH/NCATS UL1RR033173 (KL2RR0033171 to Q-B She), and the Markey Cancer Center Start-up fund (to Q-B She).	Altieri DC, 2008, NAT REV CANCER, V8, P61, DOI 10.1038/nrc2293; Armengol G, 2007, CANCER RES, V67, P7551, DOI 10.1158/0008-5472.CAN-07-0881; Balmanno K, 2009, INT J CANCER, V125, P2332, DOI 10.1002/ijc.24604; Berkel HJ, 2001, CANCER EPIDEM BIOMAR, V10, P663; Cancer Genome Atlas N., 2012, NATURE, V487, P330, DOI [10.1038/nature11252, DOI 10.1038/NATURE11252]; Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751; Chu E, 2012, CLIN COLORECTAL CANC, V11, P1, DOI 10.1016/j.clcc.2011.05.005; Chu XY, 2012, J SURG ONCOL, V105, P520, DOI 10.1002/jso.22134; Dilling MB, 2002, J BIOL CHEM, V277, P13907, DOI 10.1074/jbc.M110782200; Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038; Floc'h N, 2012, CANCER RES, V72, P4483, DOI 10.1158/0008-5472.CAN-12-0283; Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058; Halilovic E, 2010, CANCER RES, V70, P6804, DOI 10.1158/0008-5472.CAN-10-0409; Hanrahan AJ, 2012, CANCER DISCOV, V2, P56, DOI 10.1158/2159-8290.CD-11-0170; Hernandez JM, 2011, CLIN COLORECTAL CANC, V10, P188, DOI 10.1016/j.clcc.2011.03.014; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Ilic N, 2011, P NATL ACAD SCI USA, V108, pE699, DOI 10.1073/pnas.1108237108; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Livingstone M, 2010, PHYS BIOL, V7, DOI 10.1088/1478-3975/7/2/021001; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Mamane Y, 2006, ONCOGENE, V25, P6416, DOI 10.1038/sj.onc.1209888; Mamane Y, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000242; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Martin ME, 2000, INT J BIOCHEM CELL B, V32, P633, DOI 10.1016/S1357-2725(00)00007-8; Mazzoletti M, 2011, CANCER RES, V71, P4573, DOI 10.1158/0008-5472.CAN-10-4322; McKenzie JA, 2010, CANCER RES, V70, P7927, DOI 10.1158/0008-5472.CAN-10-0194; Mehrotra S, 2010, CANCER CELL, V17, P53, DOI 10.1016/j.ccr.2009.11.021; Moroz E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005077; Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Parsons DW, 2005, NATURE, V436, P792, DOI 10.1038/436792a; PAUSE A, 1994, NATURE, V371, P762, DOI 10.1038/371762a0; Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868; Rosenwald IB, 1999, ONCOGENE, V18, P2507, DOI 10.1038/sj.onc.1202563; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Schwanhausser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023; She QB, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003065; Silvera D, 2010, NAT REV CANCER, V10, P254, DOI 10.1038/nrc2824; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Sun SY, 2005, CANCER RES, V65, P7052, DOI 10.1158/0008-5472.CAN-05-0917; Thomas H.E., 2012, SCI TRANSL MED, V4, pra184; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Wee S, 2009, CANCER RES, V69, P4286, DOI 10.1158/0008-5472.CAN-08-4765; Yap TA, 2011, J CLIN ONCOL, V29, P4688, DOI 10.1200/JCO.2011.35.5263; Zaytseva YY, 2012, CANCER RES, V72, P1504, DOI 10.1158/0008-5472.CAN-11-4057; Zhang M, 2010, INT J RADIAT ONCOL, V78, P1095, DOI 10.1016/j.ijrobp.2009.09.007; Zindy P, 2011, CANCER RES, V71, P4068, DOI 10.1158/0008-5472.CAN-11-0420; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	51	120	122	0	24	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2014	33	14					1828	1839		10.1038/onc.2013.122	http://dx.doi.org/10.1038/onc.2013.122			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RE	23624914	Green Accepted			2022-12-28	WOS:000334345500009
J	Wu, MH; Huang, CY; Lin, JA; Wang, SW; Peng, CY; Cheng, HC; Tang, CH				Wu, M-H; Huang, C-Y; Lin, J-A; Wang, S-W; Peng, C-Y; Cheng, H-C; Tang, C-H			Endothelin-1 promotes vascular endothelial growth factor-dependent angiogenesis in human chondrosarcoma cells	ONCOGENE			English	Article						ET-1; VEGF; angiogenesis; chondrosarcoma	INTEGRIN-LINKED KINASE; FACTOR-I ACTIVATION; ANTIANGIOGENIC AGENTS; TUMOR ANGIOGENESIS; OVARIAN-CARCINOMA; B-RECEPTOR; EXPRESSION; PATHWAYS; CANCER; OSTEOBLASTS	Chondrosarcoma is the second most common sarcoma in bone malignancy and is characterized by a high metastatic potential. Angiogenesis is essential for the cancer metastasis. Endothelin-1 (ET-1) has been implicated in tumor angiogenesis and metastasis. However, the relationship of ET-1 with vascular endothelial growth factor (VEGF) expression and angiogenesis in human chondrosarcoma cells is mostly unknown. Here, we found that the expression of ET-1 and VEGF were correlated with tumor stage and were significantly higher than that in the normal cartilage. Exogenous ET-1 with chondrosarcoma cells promoted VEGF expression and subsequently increased migration and tube formation in endothelial progenitor cells. ET-1 increased VEGF expression and angiogenesis through ETAR, integrin-linked kinase (ILK), Akt and hypoxia-inducible factor-1 alpha (HIF-1 alpha) signaling cascades. Knockdown of ET-1 decreased VEGF expression and also abolished chondrosarcoma conditional medium-mediated angiogenesis in vitro as well as angiogenesis effects in the chick chorioallantoic membrane and Matrigel plug nude mice model in vivo. In addition, in the xenograft tumor angiogenesis model, knockdown of ET-1 significantly reduced tumor growth and tumor-associated angiogenesis. Taken together, these results indicate that ET-1 occurs through ETAR, ILK and Akt, which in turn activates HIF-1 alpha, resulting in the activation of VEGF expression and contributing to the angiogenesis and tumor growth of human chondrosarcoma cells.	[Wu, M-H; Huang, C-Y; Lin, J-A; Tang, C-H] China Med Univ, Sch Med, Grad Inst Basic Med Sci, Taichung 404, Taiwan; [Huang, C-Y; Peng, C-Y] China Med Univ, Dept Chinese Med, Taichung 404, Taiwan; [Huang, C-Y] Asia Univ, Dept Hlth & Nutr Biotechnol, Taichung, Taiwan; [Wang, S-W] Mackay Med Coll, Dept Med, New Taipei City, Taiwan; [Peng, C-Y] China Med Univ Hosp, Nat Med Prod Res Ctr, Taichung, Taiwan; [Cheng, H-C] Natl Chung Hsing Univ, Dept Life Sci, Taichung 40227, Taiwan; [Tang, C-H] China Med Univ, Sch Med, Dept Pharmacol, Taichung 404, Taiwan; [Tang, C-H] Asia Univ, Coll Hlth Sci, Dept Biotechnol, Taichung, Taiwan	China Medical University Taiwan; China Medical University Taiwan; Asia University Taiwan; Mackay Medical College; China Medical University Taiwan; China Medical University Hospital - Taiwan; National Chung Hsing University; China Medical University Taiwan; Asia University Taiwan	Tang, CH (corresponding author), China Med Univ, Sch Med, Dept Pharmacol, 91 Hsueh Shih Rd, Taichung 404, Taiwan.	chtang@mail.cmu.edu.tw	Wang, Shih-Wei/AAH-1967-2020; 吳, 旻寰/ABG-2574-2020	Wang, Shih-Wei/0000-0001-7522-6352; 吳, 旻寰/0000-0002-6579-1515; Cheng, Hsu-Chen/0000-0002-6586-6425	National Science Council of Taiwan [NSC99-2320-B-039-003-MY3, NSC100-2320-B-039-028-MY3]	National Science Council of Taiwan(Ministry of Science and Technology, Taiwan)	We thank Dr WM Fu for providing Akt mutant and HRE promoter construct. This work was supported by grants from the National Science Council of Taiwan (NSC99-2320-B-039-003-MY3 and NSC100-2320-B-039-028-MY3).	Albini A, 2012, NAT REV CLIN ONCOL, V9, P498, DOI 10.1038/nrclinonc.2012.120; Bagnato A, 2003, TRENDS ENDOCRIN MET, V14, P44, DOI 10.1016/S1043-2760(02)00010-3; Bagnato A, 2008, CAN J PHYSIOL PHARM, V86, P473, DOI 10.1139/Y08-058; Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093; Bishayee A, 2012, CURR CANCER DRUG TAR, V12, P1095; Boldrini L, 2006, VIRCHOWS ARCH, V449, P546, DOI 10.1007/s00428-006-0273-7; Camenisch G, 2001, PFLUG ARCH EUR J PHY, V443, P240, DOI 10.1007/s004240100679; Cianfrocca R, 2010, CAN J PHYSIOL PHARM, V88, P796, DOI 10.1139/Y10-052; Demunter A, 2001, VIRCHOWS ARCH, V438, P485, DOI 10.1007/s004280000362; Herrmann E, 2006, EXPERT REV ANTICANC, V6, P73, DOI 10.1586/14737140.6.1.73; Hsieh MT, 2003, LIFE SCI, V73, P1007, DOI 10.1016/S0024-3205(03)00372-2; Huang HC, 2003, J BIOL CHEM, V278, P46750, DOI 10.1074/jbc.M305216200; Kaneko Y, 2004, J CELL SCI, V117, P407, DOI 10.1242/jcs.00871; Keating AM, 2011, OCUL SURF, V9, P227, DOI 10.1016/S1542-0124(11)70035-0; Lahav R, 2004, CANCER RES, V64, P8945, DOI 10.1158/0008-5472.CAN-04-1510; Lahav R, 1999, P NATL ACAD SCI USA, V96, P11496, DOI 10.1073/pnas.96.20.11496; Lamagna C, 2006, J LEUKOCYTE BIOL, V80, P705, DOI 10.1189/jlb.1105656; Merino M, 2011, EUR J CANCER, V47, P1846, DOI 10.1016/j.ejca.2011.04.020; Nagy JA, 2007, ANNU REV PATHOL-MECH, V2, P251, DOI 10.1146/annurev.pathol.2.010506.134925; Nickols NG, 2007, ACS CHEM BIOL, V2, P561, DOI 10.1021/cb700110z; PASSANITI A, 1992, LAB INVEST, V67, P519; Rosano L, 2006, MOL CANCER THER, V5, P833, DOI 10.1158/1535-7163.MCT-05-0523; Spinella F, 2004, J BIOL CHEM, V279, P46700, DOI 10.1074/jbc.M408584200; Spinella F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011241; Storgard C, 2005, METHODS MOL BIOL, V294, P123; Tang CH, 2007, J BIOL CHEM, V282, P25406, DOI 10.1074/jbc.M701001200; Terek RM, 1998, J ORTHOPAED RES, V16, P585, DOI 10.1002/jor.1100160510; Tseng CP, 2003, FEBS LETT, V541, P21, DOI 10.1016/S0014-5793(03)00281-3; Tseng WP, 2010, J CELL PHYSIOL, V223, P810, DOI 10.1002/jcp.22104; Venuti A, 2002, CLIN SCI, V103, p310S, DOI 10.1042/CS103S310S; Villers A, 2010, PROG UROL, V20, pS77, DOI 10.1016/S1166-7087(10)70033-6; Wang HH, 2011, ACS NANO, V5, P4337, DOI 10.1021/nn102752a; Wang YC, 2003, ANAL BIOCHEM, V319, P206, DOI 10.1016/S0003-2697(03)00330-0; Weis SM, 2011, NAT MED, V17, P1359, DOI 10.1038/nm.2537; Whitman EM, 2008, AM J PHYSIOL-LUNG C, V294, pL309, DOI 10.1152/ajplung.00091.2007; Wu MH, 2012, J CELL PHYSIOL, V227, P3016, DOI 10.1002/jcp.23043; Wulfing P, 2004, CLIN CANCER RES, V10, P2393, DOI 10.1158/1078-0432.CCR-03-0115; Xia XB, 2009, P NATL ACAD SCI USA, V106, P4260, DOI 10.1073/pnas.0810067106; Yen ML, 2005, MOL PHARMACOL, V68, P1061, DOI 10.1124/mol.104.010082; Zhang HM, 2011, EXP CELL RES, V317, P2904, DOI 10.1016/j.yexcr.2011.08.012; Zhou WQ, 2008, NATL J ANDROL, V14, P987	41	84	86	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2014	33	13					1725	1735		10.1038/onc.2013.109	http://dx.doi.org/10.1038/onc.2013.109			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9QY	23584483	Bronze			2022-12-28	WOS:000334344700012
J	Daenen, LGM; Houthuijzen, JM; Cirkel, GA; Roodhart, JML; Shaked, Y; Voest, EE				Daenen, L. G. M.; Houthuijzen, J. M.; Cirkel, G. A.; Roodhart, J. M. L.; Shaked, Y.; Voest, E. E.			Treatment-induced host-mediated mechanisms reducing the efficacy of antitumor therapies	ONCOGENE			English	Review						host response; antitumor therapy; therapy resistance; microenvironment; host-tumor interactions	MESENCHYMAL STEM-CELLS; METRONOMIC ORAL CYCLOPHOSPHAMIDE; ENDOTHELIAL PROGENITOR CELLS; GROWTH-FACTOR RECEPTOR; TUMOR ANGIOGENESIS; BONE-MARROW; DRUG-RESISTANCE; SUPPRESSOR-CELLS; MULTIPLE-MYELOMA; CANCER PATIENTS	In addition to its direct effects on tumor cells, chemotherapy can rapidly activate various host processes that contribute to therapy resistance and tumor regrowth. The host response to chemotherapy consists of changes in numerous cell types and cytokines. Examples include the acute mobilization and tumor homing of pro-angiogenic bone marrow-derived cells, activation of cells in the tumor microenvironment to produce systemic or paracrine factors, and tissue-specific responses that provide a protective niche for tumor cells. All of these factors reduce chemotherapy efficacy, and blocking the host response at various levels may therefore significantly improve treatment outcome. However, before the combination of conventional chemotherapy with agents blocking specific aspects of the host response can be implemented into clinical practice, a better understanding of the molecular mechanisms behind the host response is required.	[Daenen, L. G. M.; Houthuijzen, J. M.; Cirkel, G. A.; Roodhart, J. M. L.; Voest, E. E.] Univ Med Ctr Utrecht, Dept Med Oncol, NL-3508 GA Utrecht, Netherlands; [Shaked, Y.] Technion Israel Inst Technol, Rappaport Fac Med, Dept Mol Pharmacol, Haifa, Israel	Utrecht University; Utrecht University Medical Center; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Voest, EE (corresponding author), Univ Med Ctr Utrecht, Dept Med Oncol, POB 85500,F02-126, NL-3508 GA Utrecht, Netherlands.	e.e.voest@umcutrecht.nl		Houthuijzen, Julia/0000-0003-0404-1961				Abdullah SE, 2012, CANCER-AM CANCER SOC, V118, P3455, DOI 10.1002/cncr.26540; Ahn GO, 2010, P NATL ACAD SCI USA, V107, P8363, DOI 10.1073/pnas.0911378107; Apetoh L, 2011, CURR MOL MED, V11, P365, DOI 10.2174/156652411795976574; Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622; Bertolini F, 2003, CANCER RES, V63, P4342; Bian ZY, 2009, ARCH MED RES, V40, P163, DOI 10.1016/j.arcmed.2009.01.002; Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059; Bono A, 2010, CANCER BIOL THER, V10, P682, DOI 10.4161/cbt.10.7.12898; Bottini A, 2006, J CLIN ONCOL, V24, P3623, DOI 10.1200/JCO.2005.04.5773; Browder T, 2000, CANCER RES, V60, P1878; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Bruchard M, 2013, NAT MED, V19, P57, DOI 10.1038/nm.2999; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; CARMEL RJ, 1977, CANCER RES, V37, P145; Cerniglia GJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006539; Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Daenen LG, 2009, MOL CANCER THER, V8, P2872, DOI 10.1158/1535-7163.MCT-09-0583; Daenen LGM, 2011, CANCER RES, V71, P6976, DOI 10.1158/0008-5472.CAN-11-0627; Davis A J, 2000, Lancet Oncol, V1, P86, DOI 10.1016/S1470-2045(00)00019-X; De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002; Dellapasqua S, 2008, J CLIN ONCOL; DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028; DePrimo SE, 2007, J TRANSL MED, V5, DOI 10.1186/1479-5876-5-32; Ebos JML, 2007, P NATL ACAD SCI USA, V104, P17069, DOI 10.1073/pnas.0708148104; Ebos JML, 2009, CLIN CANCER RES, V15, P5020, DOI 10.1158/1078-0432.CCR-09-0095; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; Egeblad M, 2010, DEV CELL, V18, P884, DOI 10.1016/j.devcel.2010.05.012; Emmenegger U, 2011, NEOPLASIA, V13, P40, DOI 10.1593/neo.101174; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Farace F, 2007, ANN ONCOL, V18, P1421, DOI 10.1093/annonc/mdm367; Farmer P, 2009, NAT MED, V15, P68, DOI 10.1038/nm.1908; Frassanito MA, 2001, BLOOD, V97, P483, DOI 10.1182/blood.V97.2.483; Garcia AA, 2008, J CLIN ONCOL, V26, P76, DOI 10.1200/JCO.2007.12.1939; Giannoni E, 2010, CANCER RES, V70, P6945, DOI 10.1158/0008-5472.CAN-10-0785; Gilbert LA, 2010, CELL, V143, P355, DOI 10.1016/j.cell.2010.09.043; Gingis-Velitski S, 2011, CANCER RES, V71, P6986, DOI 10.1158/0008-5472.CAN-11-0629; Green SK, 1999, ANTI-CANCER DRUG DES, V14, P153; Hanahan D, 2000, J CLIN INVEST, V105, P1045, DOI 10.1172/JCI9872; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; HANNA N, 1981, J IMMUNOL, V127, P1754; Hartmann TN, 2005, ONCOGENE, V24, P4462, DOI 10.1038/sj.onc.1208621; Hazlehurst LA, 2001, BLOOD, V98, P1897, DOI 10.1182/blood.V98.6.1897; Hideshima T, 2007, NAT REV CANCER, V7, P585, DOI 10.1038/nrc2189; Jain RK, 2003, CANCER CELL, V3, P515, DOI 10.1016/S1535-6108(03)00138-7; Jin DK, 2006, NAT MED, V12, P557, DOI 10.1038/nm1400; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kato H, 2004, NEW ENGL J MED, V350, P1713, DOI 10.1056/NEJMoa032792; Kerbel RS, 2010, NAT MED, V16, P1084, DOI 10.1038/nm1010-1084; Kerbel RS, 2006, SCIENCE, V312, P1171, DOI 10.1126/science.1125950; Kerbel RS, 2004, NAT REV CANCER, V4, P423, DOI 10.1038/nrc1369; Kim JJ, 2005, NAT REV CANCER, V5, P516, DOI 10.1038/nrc1650; Kinzler KW, 1998, SCIENCE, V280, P1036, DOI 10.1126/science.280.5366.1036; Kitadai Y, 2006, AM J PATHOL, V169, P2054, DOI 10.2353/ajpath.2006.060653; Klement G, 2000, J CLIN INVEST, V105, pR15, DOI 10.1172/JCI8829; Klopp AH, 2007, CANCER RES, V67, P11687, DOI 10.1158/0008-5472.CAN-07-1406; Klopp AH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012180; KOBAYASHI H, 1993, P NATL ACAD SCI USA, V90, P3294, DOI 10.1073/pnas.90.8.3294; Kuilman T, 2009, NAT REV CANCER, V9, P81, DOI 10.1038/nrc2560; Langenberg MHG, 2010, CANCER BIOL THER, V9, P743, DOI 10.4161/cbt.9.9.11551; Le DT, 2012, CANCER RES, V72, P3439, DOI 10.1158/0008-5472.CAN-11-3912; Lewis CE, 2007, CANCER RES, V67, P8429, DOI 10.1158/0008-5472.CAN-07-1684; Li HJ, 2012, CANCER DISCOV, V2, P840, DOI 10.1158/2159-8290.CD-12-0101; Lindauer A, 2010, CLIN PHARMACOL THER, V87, P601, DOI 10.1038/clpt.2010.20; Loven D, 2013, DRUG DISCOV TODAY, V18, P193, DOI 10.1016/j.drudis.2012.07.015; Low JA, 2010, J CLIN ONCOL, V28, P5321, DOI 10.1200/JCO.2010.27.9943; Lyden D, 2001, NAT MED, V7, P1194, DOI 10.1038/nm1101-1194; Madden JI, 2012, INFINITY REPORTS UPD; Martin FT, 2010, BREAST CANCER RES TR, V124, P317, DOI 10.1007/s10549-010-0734-1; Meads MB, 2008, CLIN CANCER RES, V14, P2519, DOI 10.1158/1078-0432.CCR-07-2223; Meads MB, 2009, NAT REV CANCER, V9, P665, DOI 10.1038/nrc2714; Neesse A, 2011, GUT, V60, P861, DOI 10.1136/gut.2010.226092; Nguyen DH, 2011, CANCER CELL, V19, P640, DOI 10.1016/j.ccr.2011.03.011; Norden-Zfoni A, 2007, CLIN CANCER RES, V13, P2643, DOI 10.1158/1078-0432.CCR-06-0919; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Penel N, 2012, CRIT REV ONCOL HEMAT, V82, P40, DOI 10.1016/j.critrevonc.2011.04.009; Pietras K, 2005, J CLIN ONCOL, V23, P939, DOI 10.1200/JCO.2005.07.093; Pietras K, 2008, PLOS MED, V5, P123, DOI 10.1371/journal.pmed.0050019; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Roodhart JM, 2010, NEOPLASIA, V12, P87, DOI 10.1593/neo.91460; Roodhart JML, 2011, CANCER CELL, V20, P370, DOI 10.1016/j.ccr.2011.08.010; Roodhart JM, 2012, AACR ANN M; Samson DJ, 2004, J CLIN ONCOL, V22, P3618, DOI 10.1200/JCO.2004.04.077; Shaked Y, 2008, CANCER CELL, V14, P263, DOI 10.1016/j.ccr.2008.08.001; Shaked Y, 2006, SCIENCE, V313, P1785, DOI 10.1126/science.1127592; Shaked Y, 2009, CANCER RES, V69, P7524, DOI 10.1158/0008-5472.CAN-09-0381; Shojaei F, 2007, NAT BIOTECHNOL, V25, P911, DOI 10.1038/nbt1323; Shojaei F, 2009, P NATL ACAD SCI USA, V106, P6742, DOI 10.1073/pnas.0902280106; Shree T, 2011, GENE DEV, V25, P2465, DOI 10.1101/gad.180331.111; Sotgia F, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2892; Stupp R, 2007, J CLIN ONCOL, V25, P1637, DOI 10.1200/JCO.2006.09.8376; Sumida T, 2011, INT J CANCER, V128, P2050, DOI 10.1002/ijc.25812; Sun Y, 2012, NAT MED, V18, P1359, DOI 10.1038/nm.2890; Taylor M, 2012, CANCER DISCOV, V2, P434, DOI 10.1158/2159-8290.CD-11-0171; Tredan O, 2007, J NATL CANCER I, V99, P1441, DOI 10.1093/jnci/djm135; Vala IS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011222; Voloshin T, 2010, CANCER BIOL THER, V10, P686, DOI 10.4161/cbt.10.7.13240; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; Watanabe T, 2009, J CLIN ONCOL, V27, P1368, DOI 10.1200/JCO.2008.18.3939; Welford AF, 2011, J CLIN INVEST, V121, P1969, DOI 10.1172/JCI44562; Yamauchi K, 2008, CANCER RES, V68, P516, DOI 10.1158/0008-5472.CAN-07-3063; Yan XL, 2012, BREAST CANCER RES TR, V132, P153, DOI 10.1007/s10549-011-1577-0	103	26	27	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2014	33	11					1341	1347		10.1038/onc.2013.94	http://dx.doi.org/10.1038/onc.2013.94			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD0SD	23524584				2022-12-28	WOS:000332943500001
J	Dann, SG; Golas, J; Miranda, M; Shi, C; Wu, J; Jin, G; Rosfjord, E; Upeslacis, E; Klippel, A				Dann, S. G.; Golas, J.; Miranda, M.; Shi, C.; Wu, J.; Jin, G.; Rosfjord, E.; Upeslacis, E.; Klippel, A.			p120 catenin is a key effector of a Ras-PKC epsilon oncogenic signaling axis	ONCOGENE			English	Article						protein kinase C; epithelial to mesenchymal transition; triple negative breast cancer; p120 catenin; drug discovery	PROTEIN-KINASE-C; BREAST-CANCER; CELL-GROWTH; E-CADHERIN; MESENCHYMAL TRANSITION; COMPLEX CONTROLS; GENE-EXPRESSION; PHOSPHORYLATION; P120-CATENIN; PROSTATE	Within the family of protein kinase C (PKC) molecules, the novel isoform PRKCE (PKC epsilon) acts as a bona fide oncogene in in vitro and in vivo models of tumorigenesis. Previous studies have reported expression of PKC epsilon in breast, prostate and lung tumors above that of normal adjacent tissue. Data from the cancer genome atlas suggest increased copy number of PRKCE in triple negative breast cancer (TNBC). We find that overexpression of PKC epsilon in a non-tumorigenic breast epithelial cell line is sufficient to overcome contact inhibition and results in the formation of cellular foci. Correspondingly, inhibition of PKC epsilon in a TNBC cell model results in growth defects in two-dimensional (2D) and three-dimensional (3D) culture conditions and orthotopic xenografts. Using stable isotope labeling of amino acids in a cell culture phosphoproteomic approach, we find that CTNND1/p120ctn phosphorylation at serine 268 (P-S268) occurs in a strictly PKC epsilon-dependent manner, and that loss of PKC epsilon signaling in TNBC cells leads to reversal of mesenchymal morphology and signaling. In a model of Ras activation, inhibition of PKC epsilon is sufficient to block mesenchymal cell morphology. Finally, treatment with a PKC epsilon ATP mimetic inhibitor, PF-5263555, recapitulates genetic loss of function experiments impairing p120ctn phosphorylation as well as compromising TNBC cell growth in vitro and in vivo. We demonstrate PKC epsilon as a tractable therapeutic target for TNBC, where p120ctn phosphorylation may serve as a readout for monitoring patient response.	[Dann, S. G.; Golas, J.; Miranda, M.; Shi, C.; Jin, G.; Rosfjord, E.; Upeslacis, E.; Klippel, A.] Pfizer Oncol Res Unit, Pearl River, NY 10965 USA; [Wu, J.] Pfizer Struct Biol & Biophys, Groton, CT USA	Pfizer; Pfizer	Dann, SG (corresponding author), Pfizer Oncol Res Unit, 401 N Middletown Rd, Pearl River, NY 10965 USA.	stephen.dann@pfizer.com		Rosfjord, Edward/0000-0002-3449-7444				Bellovin DI, 2005, CANCER RES, V65, P10938, DOI 10.1158/0008-5472.CAN-05-1947; Benavides F, 2011, CELL CYCLE, V10, P268, DOI 10.4161/cc.10.2.14469; Bin Hafeez B, 2011, CANCER RES, V71, P2318, DOI 10.1158/0008-5472.CAN-10-4170; Brown MV, 2009, EXP CELL RES, V315, P39, DOI 10.1016/j.yexcr.2008.09.025; CACACE AM, 1993, ONCOGENE, V8, P2095; Cameron AJM, 2009, NAT STRUCT MOL BIOL, V16, P624, DOI 10.1038/nsmb.1606; Craig DW, 2013, MOL CANCER THER, V12, P104, DOI 10.1158/1535-7163.MCT-12-0781; Czauderna F, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng127; Doehn U, 2009, MOL CELL, V35, P511, DOI 10.1016/j.molcel.2009.08.002; Dohn MR, 2009, J CELL BIOL, V184, P437, DOI 10.1083/jcb.200807096; Gandellini P, 2009, CANCER RES, V69, P2287, DOI 10.1158/0008-5472.CAN-08-2894; Garofalo M, 2012, NAT MED, V18, P74, DOI 10.1038/nm.2577; Gorin MA, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-9; Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110; Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441; Ivaska J, 2005, EMBO J, V24, P3834, DOI 10.1038/sj.emboj.7600847; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Leask A, 2008, J CELL SCI, V121, P3459, DOI 10.1242/jcs.029215; Leenders F, 2004, EMBO J, V23, P3303, DOI 10.1038/sj.emboj.7600345; Mackay HJ, 2007, NAT REV CANCER, V7, P554, DOI 10.1038/nrc2168; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Okuzumi T, 2009, NAT CHEM BIOL, V5, P484, DOI 10.1038/nchembio.183; Ozawa M, 2001, J CELL SCI, V114, P503; Paredes J, 2008, J CLIN PATHOL, V61, P856, DOI 10.1136/jcp.2007.052704; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Prashad AS, 2009, BIOORG MED CHEM LETT, V19, P5799, DOI 10.1016/j.bmcl.2009.07.113; Pylayeva Y, 2009, J CLIN INVEST, V119, P252, DOI 10.1172/JCI37160; Reynolds AB, 2004, ONCOGENE, V23, P7947, DOI 10.1038/sj.onc.1208161; Saurin AT, 2008, NAT CELL BIOL, V10, P891, DOI 10.1038/ncb1749; Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029; Shibata T, 2004, AM J PATHOL, V164, P2269, DOI 10.1016/S0002-9440(10)63783-2; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Soto E, 2008, J CELL BIOL, V183, P737, DOI 10.1083/jcb.200805113; Sternberger M, 2002, ANTISENSE NUCLEIC A, V12, P131, DOI 10.1089/108729002760220734; Tuomi S, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000135; WEINSTEIN IB, 1988, CANCER RES, V48, P4135; Wu J, 2007, J PROTEOME RES, V6, P4684, DOI 10.1021/pr070481m; Xia XB, 2006, EXP CELL RES, V312, P3336, DOI 10.1016/j.yexcr.2006.07.007; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183	40	24	25	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2014	33	11					1385	1394		10.1038/onc.2013.91	http://dx.doi.org/10.1038/onc.2013.91			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD0SD	23542175				2022-12-28	WOS:000332943500006
J	Becker, TM; Boyd, SC; Mijatov, B; Gowrishankar, K; Snoyman, S; Pupo, GM; Scolyer, RA; Mann, GJ; Kefford, RF; Zhang, XD; Rizos, H				Becker, T. M.; Boyd, S. C.; Mijatov, B.; Gowrishankar, K.; Snoyman, S.; Pupo, G. M.; Scolyer, R. A.; Mann, G. J.; Kefford, R. F.; Zhang, X. D.; Rizos, H.			Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor	ONCOGENE			English	Article						MAPK; B-RAF; STAT3; Mcl-1; anoikis	HUMAN-MELANOMA CELLS; DNA-BINDING ACTIVITY; SERINE PHOSPHORYLATION; MCL-1 EXPRESSION; FAMILY KINASES; INHIBITION; CANCER; APOPTOSIS; SRC; ACTIVATION	Approximately 50% of melanomas depend on mutant B-RAF for proliferation, metastasis and survival. The inhibition of oncogenic B-RAF with highly targeted compounds has produced remarkable albeit short-lived clinical responses in B-RAF mutant melanoma patients. Reactivation of signaling downstream of B-RAF is frequently associated with acquired resistance to B-RAF inhibitors, and the identification of B-RAF targets may provide new strategies for managing melanoma. Oncogenic B-RAF(V600E) is known to promote the stabilizing phosphorylation of the anti-apoptotic protein Mcl-1, implicated in melanoma survival and chemoresistance. We now show that B-RAFV600E signaling also induces the transcription of Mcl-1 in melanocytes and melanoma. We demonstrate that activation of STAT3 serine-727 and tyrosine-705 phosphorylations is promoted by B-RAF(V600E) activity and that the Mcl-1 promoter is dependent on a STAT consensus-site for B-RAF-mediated activation. Consequently, suppression of STAT3 activity disrupted B-RAF(V600E)-mediated induction of Mcl-1 and reduced melanoma cell survival. We propose that STAT3 has a central role in the survival and contributes to chemoresistance of B-RAF(V600E) melanoma.	[Becker, T. M.; Boyd, S. C.; Mijatov, B.; Gowrishankar, K.; Snoyman, S.; Pupo, G. M.; Mann, G. J.; Kefford, R. F.; Rizos, H.] Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Westmead Inst Canc Res, Sydney, NSW 2145, Australia; [Scolyer, R. A.; Mann, G. J.; Kefford, R. F.] Melanoma Inst Australia, Sydney, NSW, Australia; [Zhang, X. D.] Univ Newcastle, Immunol & Oncol Unit, Newcastle, NSW 2300, Australia	University of Sydney; Westmead Institute for Medical Research; Melanoma Institute Australia; University of Newcastle	Becker, TM (corresponding author), Univ Sydney, Westmead Hosp, Westmead Millennium Inst, Westmead Inst Canc Res, Sydney, NSW 2145, Australia.	therese.becker@sydney.edu.au	Rizos, Helen/AAE-5010-2020; zhang, xu/GYE-3558-2022; Scolyer, Richard/AAE-8511-2019; Mann, Graham J/G-4758-2014; zhang, xu/GRX-9733-2022; zhang, xian/GYA-0290-2022; Zhang, xiaoyu/GXA-3206-2022	Rizos, Helen/0000-0002-2094-9198; Scolyer, Richard/0000-0002-8991-0013; Mann, Graham J/0000-0003-1301-405X; Kefford, Richard/0000-0001-9251-9229; Becker, Therese/0000-0002-5636-9902; Powter, Branka/0000-0003-2814-456X; Zhang, Xu Dong/0000-0001-9457-8003	National Health and Medical Research Council of Australia (NHMRC) [633004]; Cancer Institute New South Wales [10/TPG/1-02]; Health Department of NSW through Sydney West Area Health Service; Australian Cancer Research Foundation; Cancer Institute New South Wales, Research Fellowship; NHMRC Senior Research Fellowship	National Health and Medical Research Council of Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Cancer Institute New South Wales; Health Department of NSW through Sydney West Area Health Service; Australian Cancer Research Foundation; Cancer Institute New South Wales, Research Fellowship; NHMRC Senior Research Fellowship(National Health and Medical Research Council (NHMRC) of Australia)	This work is supported by the Program Grant 633004 and project grants of the National Health and Medical Research Council of Australia (NHMRC), Translational Research Program Grant 10/TPG/1-02 of the Cancer Institute New South Wales and an infrastructure grant to Westmead Millennium Institute by the Health Department of NSW through Sydney West Area Health Service. Westmead Institute for Cancer Research is the recipient of capital grant funding from the Australian Cancer Research Foundation. HR is a recipient of a Cancer Institute New South Wales, Research Fellowship and a NHMRC Senior Research Fellowship. RAS is a recipient of a Cancer Institute New South Wales, Research Fellowship.	Aggarwal BB, 2009, ANN NY ACAD SCI, V1171, P59, DOI 10.1111/j.1749-6632.2009.04911.x; Akgul C, 2009, CELL MOL LIFE SCI, V66, P1326, DOI 10.1007/s00018-008-8637-6; Alshamsan A, 2011, TRANSL ONCOL, V4, P178, DOI 10.1593/tlo.11100; Balch CM, 2001, J CLIN ONCOL, V19, P3622, DOI 10.1200/JCO.2001.19.16.3622; Becker TM, 2010, J INVEST DERMATOL, V130, P2144, DOI 10.1038/jid.2010.117; Bill MA, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-165; Boisvert-Adamo K, 2009, MOL CANCER RES, V7, P549, DOI 10.1158/1541-7786.MCR-08-0358; Buettner R, 2008, MOL CANCER RES, V6, P1766, DOI 10.1158/1541-7786.MCR-08-0169; Burdelya L, 2005, J IMMUNOL, V174, P3925, DOI 10.4049/jimmunol.174.7.3925; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Cirri P, 1997, BIOCHEM BIOPH RES CO, V239, P493, DOI 10.1006/bbrc.1997.7493; Cummins DL, 2006, MAYO CLIN PROC, V81, P500, DOI 10.4065/81.4.500; Curtis LM, 2009, MOL CANCER THER, V8, DOI 10.1158/1535-7163.TARG-09-B89; Dhomen N, 2009, HEMATOL ONCOL CLIN N, V23, P529, DOI 10.1016/j.hoc.2009.04.001; Ding YL, 2006, CANCER-AM CANCER SOC, V106, P1123, DOI 10.1002/cncr.21727; Falchook GS, 2012, LANCET, V379, P1893, DOI 10.1016/S0140-6736(12)60398-5; Fuh B, 2009, BRIT J CANCER, V100, P106, DOI 10.1038/sj.bjc.6604793; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Haferkamp S, 2009, J INVEST DERMATOL, V129, P1983, DOI 10.1038/jid.2009.5; Hong DS, 2008, J CLIN ONCOL, V26; Horiguchi A, 2010, BRIT J CANCER, V102, P1592, DOI 10.1038/sj.bjc.6605691; Jensen TO, 2011, CANCER, V118, P2476; Jiang CC, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.48; Kong LY, 2010, CLIN CANCER RES, V16, P2550, DOI 10.1158/1078-0432.CCR-10-0279; Kortylewski M, 2005, CANCER METAST REV, V24, P315, DOI 10.1007/s10555-005-1580-1; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; Lin L, 2009, ONCOGENE, V28, P961, DOI 10.1038/onc.2008.448; Lin L, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-217; Liu HT, 2003, BLOOD, V102, P344, DOI 10.1182/blood-2002-11-3396; Long GV, 2010, 35 EUR SOC MED ONC E; McMurray JS, 2006, CHEM BIOL, V13, P1123, DOI 10.1016/j.chembiol.2006.11.001; Messina Jane L, 2008, Cancer Control, V15, P196; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Niu G, 2002, ONCOGENE, V21, P7001, DOI 10.1038/sj.onc.1205859; OCONNOR TJ, 1995, CELL GROWTH DIFFER, V6, P123; Paraiso K, 2012, PIGM CELL MELANOMA R, P878; Platz A, 2008, MOL ONCOL, V1, P395, DOI 10.1016/j.molonc.2007.12.003; Scurr LL, 2010, CELL, V141, P717, DOI 10.1016/j.cell.2010.04.021; Shao YP, 2010, CANCER RES, V70, P6670, DOI 10.1158/0008-5472.CAN-09-4471; Shepherd C, 2010, CURR ONCOL REP, V12, P146, DOI 10.1007/s11912-010-0095-2; Siddiquee K, 2007, P NATL ACAD SCI USA, V104, P7391, DOI 10.1073/pnas.0609757104; Sumimoto H, 2006, J EXP MED, V203, P1651, DOI 10.1084/jem.20051848; Tang LR, 1998, CLIN CANCER RES, V4, P1865; Venkatasubbarao K, 2005, CANCER RES, V65, P2861, DOI 10.1158/0008-5472.CAN-04-2396; Vignais ML, 1996, MOL CELL BIOL, V16, P1759; Wang YF, 2007, CLIN CANCER RES, V13, P4934, DOI 10.1158/1078-0432.CCR-07-0665; Wellbrock C, 2010, BIOCHEM PHARMACOL, V80, P561, DOI 10.1016/j.bcp.2010.03.019; Wilmott JS, 2012, CLIN CANCER RES, V18, P1386, DOI 10.1158/1078-0432.CCR-11-2479; Wong RPC, 2008, ONCOL REP, V19, P933; Xie TX, 2006, CANCER RES, V66, P3188, DOI 10.1158/0008-5472.CAN-05-2674; Yeh HH, 2006, ONCOGENE, V25, P4300, DOI 10.1038/sj.onc.1209464; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Zhuang LQ, 2007, MODERN PATHOL, V20, P416, DOI 10.1038/modpathol.3800750	54	51	51	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2014	33	9					1158	1166		10.1038/onc.2013.45	http://dx.doi.org/10.1038/onc.2013.45			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XT	23455323				2022-12-28	WOS:000331933800009
J	Zhou, C; Tong, Y; Wawrowsky, K; Melmed, S				Zhou, C.; Tong, Y.; Wawrowsky, K.; Melmed, S.			PTTG acts as a STAT3 target gene for colorectal cancer cell growth and motility	ONCOGENE			English	Article						STAT3; PTTG; transformation	TUMOR-TRANSFORMING GENE; SIGNAL TRANSDUCER; MATRIX METALLOPROTEINASE-2; CONSTITUTIVE ACTIVATION; EXPRESSION; SECURIN; TRANSCRIPTION-3; OVEREXPRESSION; INHIBITOR; IDENTIFICATION	Pituitary tumor-transforming gene (PTTG), the index mammalian securin, is abundantly expressed in several tumors and regulates tumor growth and progression. Molecular mechanisms elucidating PTTG regulation and actions remain elusive. Here, we provide evidence that PTTG acts as a signal transducer and activator of transcription factor 3 (STAT3) target gene. Total STAT3 and Tyr705 phosphorylated STAT3 were concordantly expressed with PTTG in human colorectal tumors (n = 97 and n = 95, respectively, P<0.001). STAT3 specifically bound the human PTTG promoter and induced PTTG transcriptional activity (twofold) as assessed by chromatin immunoprecipitation and luciferase reporter assays. STAT3 transfection increased PTTG mRNA and protein abundance twofold in HCT116 human colon cancer cells, and induction was further enhanced (threefold) by constitutively active STAT3 (STAT3-C), whereas strongly abrogated by dominant-negative STAT3 (STAT3-DN). Attenuating PTTG expression by siRNA in STAT3 HCT116 stable transfectants suppressed cell growth and colony formation in vitro, and PTTG cell knockout also constrained activated STAT3-induced explanted murine tumor growth in vivo. STAT3 increased HCT116 cell migration and invasion up to fivefold, whereas cell mobility was abolished by STAT3-DN (>85%). Impairing PTTG expression by siRNA also strongly suppressed STAT3-faciliated cell migration and invasion by up to 90%. Knocking out PTTG in STAT3-C HCT116 stable transfectants strongly decreased tumor metastases in nude mice, indicating the requirement of PTTG for STAT3-promoted metastasis. These results elucidate a mechanism for tumor cell PTTG regulation, whereby STAT3 induces PTTG expression to facilitate tumor growth and metastasis, and further support the rationale for targeting PTTG to abrogate colorectal cancer growth.	[Zhou, C.; Tong, Y.; Wawrowsky, K.; Melmed, S.] Cedars Sinai Med Ctr, Dept Med, Los Angeles, CA 90048 USA	Cedars Sinai Medical Center	Melmed, S (corresponding author), Cedars Sinai Med Ctr, 8700 Beverly Blvd,Room 2015, Los Angeles, CA 90048 USA.	melmed@csmc.edu			National Institutes of Health [CA75979]; Doris Factor Molecular Endocrinology Laboratory; NATIONAL CANCER INSTITUTE [R01CA075979, R00CA138914] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Doris Factor Molecular Endocrinology Laboratory; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Dr Bert Vogelstein at Johns Hopkins University (Baltimore, MD, USA) for kindly providing HCT116 PTTG<SUP>+/+</SUP> and HCT116 PTTG<SUP>-/-</SUP> cells; and thank Patricia Lin at the Cedars-Sinai Flow Cytometry Core. This work was supported by National Institutes of Health Grant CA75979 (to SM) and the Doris Factor Molecular Endocrinology Laboratory.	Aggarwal BB, 2009, ANN NY ACAD SCI, V1171, P59, DOI 10.1111/j.1749-6632.2009.04911.x; Boelaert K, 2003, J CLIN ENDOCR METAB, V88, P2341, DOI 10.1210/jc.2002-021113; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Buettner R, 2002, CLIN CANCER RES, V8, P945; Filippella M, 2006, CLIN ENDOCRINOL, V65, P536, DOI 10.1111/j.1365-2265.2006.02630.x; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; Hamid T, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-3; Heaney AP, 2000, LANCET, V355, P716, DOI 10.1016/S0140-6736(99)10238-1; Horsch M, 2009, BRIT J CANCER, V100, P656, DOI 10.1038/sj.bjc.6604882; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; Kim CS, 2007, CARCINOGENESIS, V28, P932, DOI 10.1093/carcin/bgl231; Lin L, 2009, ONCOGENE, V28, P961, DOI 10.1038/onc.2008.448; Malik MT, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-61; Masuda M, 2002, CANCER RES, V62, P3351; Morikawa T, 2011, CLIN CANCER RES, V17, P1452, DOI 10.1158/1078-0432.CCR-10-2694; Ng DCH, 2006, J CELL BIOL, V172, P245, DOI 10.1083/jcb.200503021; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Ogbagabriel S, 2005, MODERN PATHOL, V18, P985, DOI 10.1038/modpathol.3800382; Panguluri SK, 2008, J OVARIAN RES, V1, DOI 10.1186/1757-2215-1-6; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Pei L, 2001, J BIOL CHEM, V276, P8484, DOI 10.1074/jbc.M009654200; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Romero F, 2004, MOL CELL BIOL, V24, P2720, DOI 10.1128/MCB.24.7.2720-2733.2004; Romero F, 2001, NUCLEIC ACIDS RES, V29, P1300, DOI 10.1093/nar/29.6.1300; Salehi F, 2008, ENDOCR-RELAT CANCER, V15, P721, DOI 10.1677/ERC-08-0012; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; Sasse J, 1997, MOL CELL BIOL, V17, P4677, DOI 10.1128/MCB.17.8.4677; Siddiquee K, 2007, P NATL ACAD SCI USA, V104, P7391, DOI 10.1073/pnas.0609757104; Silver DL, 2004, CANCER RES, V64, P3550, DOI 10.1158/0008-5472.CAN-03-3959; Song YH, 2008, MOL IMMUNOL, V45, P137, DOI 10.1016/j.molimm.2007.04.031; Tong Y, 2007, ONCOGENE, V26, P5596, DOI 10.1038/sj.onc.1210339; Tsareva SA, 2007, NEOPLASIA, V9, P279, DOI 10.1593/neo.06820; Vlotides G, 2007, ENDOCR REV, V28, P165, DOI 10.1210/er.2006-0042; Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781; Wicki A, 2010, SWISS MED WKLY, V140, P14, DOI 10.4414/smw.2010.13112; Xie TX, 2004, ONCOGENE, V23, P3550, DOI 10.1038/sj.onc.1207383; Yan S, 2009, CANCER RES, V69, P3283, DOI 10.1158/0008-5472.CAN-08-0367; Yu R, 2003, ENDOCRINOLOGY, V144, P4991, DOI 10.1210/en.2003-0305; Zhang X, 1999, MOL ENDOCRINOL, V13, P156, DOI 10.1210/me.13.1.156; Zhang X, 1999, J CLIN ENDOCR METAB, V84, P761, DOI 10.1210/jc.84.2.761; Zhou CQ, 2005, INT J CANCER, V113, P891, DOI 10.1002/ijc.20642; Zhou CQ, 2008, ENDOCR-RELAT CANCER, V15, P817, DOI 10.1677/ERC-08-0060; Zhou CQ, 2009, MOL ENDOCRINOL, V23, P2000, DOI 10.1210/me.2009-0161; Zou H, 1999, SCIENCE, V285, P418, DOI 10.1126/science.285.5426.418	46	39	39	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2014	33	7					851	861		10.1038/onc.2013.16	http://dx.doi.org/10.1038/onc.2013.16			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB2MN	23416975	Green Accepted			2022-12-28	WOS:000331626900006
J	Leikam, C; Hufnagel, A; Walz, S; Kneitz, S; Fekete, A; Muller, MJ; Eilers, M; Schartl, M; Meierjohann, S				Leikam, C.; Hufnagel, A.; Walz, S.; Kneitz, S.; Fekete, A.; Mueller, M. J.; Eilers, M.; Schartl, M.; Meierjohann, S.			Cystathionase mediates senescence evasion in melanocytes and melanoma cells	ONCOGENE			English	Article						ROS; melanoma; melanocyte; transsulfuration	MYC DOWN-REGULATION; EPIDERMAL-GROWTH-FACTOR; C-MYC; REACTIVE OXYGEN; GAMMA-LYASE; TRANSSULFURATION PATHWAY; UVEAL MELANOMA; BETA-SYNTHASE; EXPRESSION; PHOSPHORYLATION	The development of malignant melanoma is a highly complex process, which is still poorly understood. A majority of human melanomas are found to express a few oncogenic proteins, such as mutant RAS and BRAF variants. However, these oncogenes are also found in nevi, and it is now a well-accepted fact that their expression alone leads to senescence. This renders the understanding of senescence escape mechanisms an important point to understand tumor development. Here, we approached the question of senescence evasion by expressing the transcription factor v-myc myelocytomatosis viral oncogene homolog (c-MYC), which is known to act synergistically with many oncogenes, in melanocytes. We observed that MYC drives the evasion of reactive-oxygen stress-induced melanocyte senescence, caused by activated receptor tyrosine kinase signaling. Conversely, MIZ1, the growth suppressing interaction partner of MYC, is involved in mediating melanocyte senescence. Both, MYC overexpression and Miz1 knockdown led to a strong reduction of endogenous reactive-oxygen species (ROS), DNA damage and senescence. We identified the cystathionase (CTH) gene product as mediator of the ROS-related MYC and MIZ1 effects. Blocking CTH enzymatic activity in MYC-overexpressing and Miz1 knockdown cells increased intracellular stress and senescence. Importantly, pharmacological inhibition of CTH in human melanoma cells also reconstituted senescence in the majority of cell lines, and CTH knockdown reduced tumorigenic effects such as proliferation, H2O2 resistance and soft agar growth. Thus, we identified CTH as new MYC target gene with an important function in senescence evasion.	[Leikam, C.; Hufnagel, A.; Kneitz, S.; Schartl, M.; Meierjohann, S.] Univ Wurzburg, Dept Physiol Chem 1, Bioctr, D-97074 Wurzburg, Germany; [Walz, S.; Eilers, M.] Univ Wurzburg, Dept Biochem & Mol Biol, Bioctr, D-97074 Wurzburg, Germany; [Fekete, A.; Mueller, M. J.] Univ Wurzburg, Dept Pharmaceut Biol, Julius von Sachs Inst Biol Sci, D-97074 Wurzburg, Germany	University of Wurzburg; University of Wurzburg; University of Wurzburg	Meierjohann, S (corresponding author), Univ Wurzburg, Dept Physiol Chem 1, Bioctr, D-97074 Wurzburg, Germany.	svenja.meierjohann@biozentrum.uni-wuerzburg.de	Fekete, Agnes/C-8048-2019; mueller, martin j/C-7616-2019	Fekete, Agnes/0000-0003-3058-7570; Eilers, Martin/0000-0002-0376-6533; Schartl, Manfred/0000-0001-9882-5948	Deutsche Forschungsgesellschaft, Transregio 17 ('RAS-dependent pathways in human cancer'); German Excellence Initiative	Deutsche Forschungsgesellschaft, Transregio 17 ('RAS-dependent pathways in human cancer'); German Excellence Initiative	We thank Dorothy Bennett, St George's, University of London (Wellcome Trust Functional Genomics Cell Bank) for providing the cell lines Hermes 3a and melan-a sut. This work was supported by the Deutsche Forschungsgesellschaft, Transregio 17 ('RAS-dependent pathways in human cancer'). CL was supported by a grant of the German Excellence Initiative to the Graduate School of Life Sciences, University of Wurzburg.	Aziz N, 1999, MOL CELL BIOL, V19, P1101; Benassi B, 2006, MOL CELL, V21, P509, DOI 10.1016/j.molcel.2006.01.009; Benassi B, 2007, MOL PHARMACOL, V72, P1015, DOI 10.1124/mol.107.038687; Biroccio A, 2001, MOL PHARMACOL, V60, P174, DOI 10.1124/mol.60.1.174; Biroccio A, 2003, J BIOL CHEM, V278, P35693, DOI 10.1074/jbc.M304597200; Bischof O, 2002, EMBO J, V21, P3358, DOI 10.1093/emboj/cdf341; Blanco-Bose WE, 2008, HEPATOLOGY, V48, P1302, DOI 10.1002/hep.22475; Bucci B, 2005, CLIN CANCER RES, V11, P2756, DOI 10.1158/1078-0432.CCR-04-1582; Campaner S, 2010, NAT CELL BIOL, V12, P54, DOI 10.1038/ncb2004; Cao QH, 2010, ANTIOXID REDOX SIGN, V12, P1101, DOI 10.1089/ars.2009.2915; Chintala S, 2005, P NATL ACAD SCI USA, V102, P10964, DOI 10.1073/pnas.0502856102; Conrad M, 2012, AMINO ACIDS, V42, P231, DOI 10.1007/s00726-011-0867-5; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Denoyelle C, 2006, NAT CELL BIOL, V8, P1053, DOI 10.1038/ncb1471; Dickhout JG, 2012, J BIOL CHEM, V287, P7603, DOI 10.1074/jbc.M111.304576; Fried L, 2008, PIGM CELL MELANOMA R, V21, P117, DOI 10.1111/j.1755-148X.2008.00451.x; Grandori C, 2003, GENE DEV, V17, P1569, DOI 10.1101/gad.1100303; Gray-Schopfer VC, 2006, BRIT J CANCER, V95, P496, DOI 10.1038/sj.bjc.6603283; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Herold S, 2008, EMBO J, V27, P2851, DOI 10.1038/emboj.2008.200; Huang SF, 2010, J MOL BIOL, V396, P708, DOI 10.1016/j.jmb.2009.11.058; Hydbring P, 2010, P NATL ACAD SCI USA, V107, P58, DOI 10.1073/pnas.0900121106; Jamerson MH, 2000, ONCOGENE, V19, P1065, DOI 10.1038/sj.onc.1203268; Jhee KH, 2005, ANTIOXID REDOX SIGN, V7, P813, DOI 10.1089/ars.2005.7.813; Kandil S, 2010, NEUROCHEM INT, V56, P611, DOI 10.1016/j.neuint.2010.01.004; KOST DP, 1990, J CELL PHYSIOL, V144, P122, DOI 10.1002/jcp.1041440116; Kress TR, 2011, MOL CELL, V41, P445, DOI 10.1016/j.molcel.2011.01.023; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Leikam C, 2008, ONCOGENE, V27, P7070, DOI 10.1038/onc.2008.323; Li SKM, 2008, J BIOL CHEM, V283, P16545, DOI 10.1074/jbc.M709604200; Mallette FA, 2007, J BIOL CHEM, V282, P34938, DOI 10.1074/jbc.M707074200; Meierjohann S, 2006, CANCER RES, V66, P3145, DOI 10.1158/0008-5472.CAN-05-2667; Meierjohann S, 2006, TRENDS GENET, V22, P654, DOI 10.1016/j.tig.2006.09.013; Nogueira V, 2008, CANCER CELL, V14, P458, DOI 10.1016/j.ccr.2008.11.003; Onken MD, 2008, INVEST OPHTH VIS SCI, V49, P5230, DOI 10.1167/iovs.08-2145; Park J, 2007, BIOCHEM BIOPH RES CO, V360, P447, DOI 10.1016/j.bbrc.2007.06.077; Parrella P, 2001, INVEST OPHTH VIS SCI, V42, P1679; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Popov N, 2007, CELL CYCLE, V6, P2327, DOI 10.4161/cc.6.19.4804; Popov N, 2010, NAT CELL BIOL, V12, P973, DOI 10.1038/ncb2104; Rai P, 2011, ONCOGENE, V30, P1489, DOI 10.1038/onc.2010.520; RAO AM, 1990, J NUTR, V120, P837, DOI 10.1093/jn/120.8.837; Robinson K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005951; Rosado JO, 2007, MOL CELL BIOCHEM, V301, P1, DOI 10.1007/s11010-006-9389-y; Rzymski T, 2009, CELL CYCLE, V8, P3838, DOI 10.4161/cc.8.23.10086; Sankar N, 2009, J BIOL CHEM, V284, P15193, DOI 10.1074/jbc.M900776200; Schlagbauer-Wadl H, 1999, J INVEST DERMATOL, V112, P332, DOI 10.1046/j.1523-1747.1999.00506.x; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Sun QX, 2009, J BIOL CHEM, V284, P3076, DOI 10.1074/jbc.M805459200; Szabo C, 2007, NAT REV DRUG DISCOV, V6, P917, DOI 10.1038/nrd2425; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; Tulley PN, 2004, BRIT J OPHTHALMOL, V88, P1563, DOI 10.1136/bjo.2003.033498; Van Raamsdonk CD, 2009, NATURE, V457, P599, DOI 10.1038/nature07586; van Riggelen J, 2010, GENE DEV, V24, P1281, DOI 10.1101/gad.585710; Vene R, 2011, ANTIOXID REDOX SIGN, V15, P2439, DOI 10.1089/ars.2010.3830; Wanzel M, 2003, TRENDS CELL BIOL, V13, P146, DOI 10.1016/S0962-8924(03)00003-5; Wanzel M, 2005, NAT CELL BIOL, V7, P30, DOI 10.1038/ncb1202; Whitwam T, 2007, ONCOGENE, V26, P4563, DOI 10.1038/sj.onc.1210239; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; YAMAMOTO N, 1995, J NUTR SCI VITAMINOL, V41, P197, DOI 10.3177/jnsv.41.197; Yang GD, 2004, J BIOL CHEM, V279, P49199, DOI 10.1074/jbc.M408997200; Yang GD, 2008, SCIENCE, V322, P587, DOI 10.1126/science.1162667; Zhuang D, 2008, ONCOGENE, V27, P6623, DOI 10.1038/onc.2008.258	64	25	25	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2014	33	6					771	782		10.1038/onc.2012.641	http://dx.doi.org/10.1038/onc.2012.641			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5IL	23353821				2022-12-28	WOS:000331129200011
J	D'Assoro, AB; Liu, T; Quatraro, C; Amato, A; Opyrchal, M; Leontovich, A; Ikeda, Y; Ohmine, S; Lingle, W; Suman, V; Ecsedy, J; Iankov, I; Di Leonardo, A; Ayers-Ringler, J; Degnim, A; Billadeau, D; McCubrey, J; Ingle, J; Salisbury, JL; Galanis, E				D'Assoro, A. B.; Liu, T.; Quatraro, C.; Amato, A.; Opyrchal, M.; Leontovich, A.; Ikeda, Y.; Ohmine, S.; Lingle, W.; Suman, V.; Ecsedy, J.; Iankov, I.; Di Leonardo, A.; Ayers-Ringler, J.; Degnim, A.; Billadeau, D.; McCubrey, J.; Ingle, J.; Salisbury, J. L.; Galanis, E.			The mitotic kinase Aurora-A promotes distant metastases by inducing epithelial-to-mesenchymal transition in ER alpha(+) breast cancer cells	ONCOGENE			English	Article						breast cancer; stemness; metastases	P53 FUNCTION LEADS; CENTROSOME AMPLIFICATION; STEM-CELLS; ERBB2; PROGRESSION; OVEREXPRESSION; PROLIFERATION; TUMORIGENESIS; EXPRESSION; RESISTANCE	In this study, we demonstrate that constitutive activation of Raf-1 oncogenic signaling induces stabilization and accumulation of Aurora-A mitotic kinase that ultimately drives the transition from an epithelial to a highly invasive mesenchymal phenotype in estrogen receptor alpha-positive (ER alpha(+)) breast cancer cells. The transition from an epithelial- to a mesenchymal-like phenotype was characterized by reduced expression of ER alpha, HER-2/Neu overexpression and loss of CD24 surface receptor (CD24(-/low)). Importantly, expression of key epithelial-to-mesenchymal transition (EMT) markers and upregulation of the stemness gene SOX2 was linked to acquisition of stem cell-like properties such as the ability to form mammospheres in vitro and tumor self-renewal in vivo. Moreover, aberrant Aurora-A kinase activity induced phosphorylation and nuclear translocation of SMAD5, indicating a novel interplay between Aurora-A and SMAD5 signaling pathways in the development of EMT, stemness and ultimately tumor progression. Importantly, pharmacological and molecular inhibition of Aurora-A kinase activity restored a CD24(+) epithelial phenotype that was coupled to ER alpha expression, downregulation of HER-2/Neu, inhibition of EMT and impaired self-renewal ability, resulting in the suppression of distant metastases. Taken together, our findings show for the first time the causal role of Aurora-A kinase in the activation of EMT pathway responsible for the development of distant metastases in ER alpha(+) breast cancer cells. Moreover, this study has important translational implications because it highlights the mitotic kinase Aurora-A as a novel promising therapeutic target to selectively eliminate highly invasive cancer cells and improve the disease-free and overall survival of ER alpha(+) breast cancer patients resistant to conventional endocrine therapy.	[D'Assoro, A. B.; Liu, T.; Quatraro, C.; Amato, A.; Ayers-Ringler, J.; Salisbury, J. L.] Mayo Clin, Coll Med, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; [D'Assoro, A. B.; Opyrchal, M.; Suman, V.; Billadeau, D.; Ingle, J.; Galanis, E.] Mayo Clin, Coll Med, Dept Med Oncol, Rochester, MN 55905 USA; [Amato, A.; Di Leonardo, A.] Dept Cellular & Dev Biol, Palermo, Italy; [Opyrchal, M.; Ikeda, Y.; Ohmine, S.; Iankov, I.; Galanis, E.] Mayo Clin, Coll Med, Dept Mol Med, Rochester, MN 55905 USA; [Leontovich, A.] Mayo Clin, Coll Med, Dept Biomed Stat & Informat, Rochester, MN 55905 USA; [Lingle, W.] Mayo Clin, Coll Med, Dept Expt Pathol, Rochester, MN 55905 USA; [Ecsedy, J.] Millennium Pharmaceut Inc, Dept Oncol, Cambridge, MA USA; [Degnim, A.] Mayo Clin, Coll Med, Dept Gen Surg, Rochester, MN 55905 USA; [McCubrey, J.] E Carolina Univ, Brody Sch Med, Dept Microbiol & Immunol, Greenville, NC USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Mayo Clinic; University of North Carolina; East Carolina University	D'Assoro, AB (corresponding author), Mayo Clin, Coll Med, Dept Biochem & Mol Biol, 200 First St SW, Rochester, MN 55905 USA.	Dassoro.antonio@mayo.edu	Di Leonardo, Aldo/F-9833-2012; Amato, Angela/T-1221-2019; Di Leonardo, Aldo/AAQ-4009-2021	Di Leonardo, Aldo/0000-0003-4760-7179; Di Leonardo, Aldo/0000-0003-4760-7179; Salisbury, Jeffrey/0000-0001-9257-4578; McCubrey, James/0000-0001-6027-3156	NCI [CA72836]; USAMRMC [BC022276]; Intramural RECDA Award; Italian Association for Cancer Research (AIRC); Mayo Clinic Breast Cancer Specialized Program of Research Excellence NIH [CA116201]; Mayo Clinic School of Medicine; Atwater Foundation; NATIONAL CANCER INSTITUTE [R01CA072836, P50CA116201, P30CA015083] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); USAMRMC(United States Department of DefenseUnited States ArmyU.S. Army Medical Research & Materiel Command (USAMRMC)); Intramural RECDA Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Mayo Clinic Breast Cancer Specialized Program of Research Excellence NIH; Mayo Clinic School of Medicine; Atwater Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by NCI CA72836 to JLS, USAMRMC BC022276 and Intramural RECDA Award to ABD, the Italian Association for Cancer Research (AIRC) to AA, the Mayo Clinic Breast Cancer Specialized Program of Research Excellence NIH CA116201 to JI and the Mayo Clinic School of Medicine. This study was also supported by the Atwater Foundation. We also wish to acknowledge the Cytogenetic Shared Resource and TACMA core facilities of the Mayo Clinic Comprehensive Cancer Center for performing SKY, routine cytogenetic and immunohistochemistry analysis and assisting us with the interpretation of the results.	Abraham BK, 2005, CLIN CANCER RES, V11, P1154; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Aranda V, 2006, NAT CELL BIOL, V8, P1235, DOI 10.1038/ncb1485; Basaran G, 2011, MED ONCOL, V28, P726, DOI 10.1007/s12032-010-9516-1; Basto R, 2008, CELL, V133, P1032, DOI 10.1016/j.cell.2008.05.039; Beavon IRG, 2000, EUR J CANCER, V36, P1607, DOI 10.1016/S0959-8049(00)00158-1; Chang CJ, 2011, CANCER CELL, V19, P86, DOI 10.1016/j.ccr.2010.10.035; Chang H, 2009, ANN ONCOL, V20, P272, DOI 10.1093/annonc/mdn624; D'Assoro AB, 2008, ONCOGENE, V27, P3901, DOI 10.1038/onc.2008.18; D'Assoro AB, 2004, ONCOGENE, V23, P4068, DOI 10.1038/sj.onc.1207568; D'Assoro AB, 2002, BREAST CANCER RES TR, V75, P25, DOI 10.1023/A:1016550619925; D'Assoro AB, 2010, INT J ONCOL, V37, P1167, DOI 10.3892/ijo_00000768; Davis JM, 2003, CLIN CANCER RES, V9, P1161; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Eralp Y, 2008, ANN ONCOL, V19, P669, DOI 10.1093/annonc/mdm522; Ghayad SE, 2010, INT J CANCER, V126, P545, DOI 10.1002/ijc.24750; Giatromanolaki A, 2011, MED ONCOL, V28, P745, DOI 10.1007/s12032-010-9530-3; Guarino M, 2007, PATHOLOGY, V39, P305, DOI 10.1080/00313020701329914; Honeth G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2108; Hwang-Verslues WW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008377; Jin W, 2003, BRIT J CANCER, V89, P185, DOI 10.1038/sj.bjc.6601048; Kerkhoff E, 2000, CELL GROWTH DIFFER, V11, P185; Kim ES, 2005, CYTOKINE, V29, P84, DOI 10.1016/j.cyto.2004.10.001; Kim IY, 2009, CANCER LETT, V275, P227, DOI 10.1016/j.canlet.2008.10.013; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Korkaya H, 2010, NAT CELL BIOL, V12, P419, DOI 10.1038/ncb0510-419; Lu J, 2009, CANCER CELL, V16, P195, DOI 10.1016/j.ccr.2009.08.010; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marampon F, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-31; Murohashi M, 2010, BRIT J CANCER, V102, P206, DOI 10.1038/sj.bjc.6605468; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Roesler R, 2010, LANCET ONCOL, V11, P225, DOI 10.1016/S1470-2045(09)70404-8; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Strathdee G, 2002, SEMIN CANCER BIOL, V12, P373, DOI 10.1016/S1044-579X(02)00057-3; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Turley EA, 2008, NAT CLIN PRACT ONCOL, V5, P280, DOI 10.1038/ncponc1089; Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821; Wendt MK, 2010, ONCOGENE, V29, P6485, DOI 10.1038/onc.2010.377; Whyte J, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2361; Wicha MS, 2006, CANCER RES, V66, P1883, DOI 10.1158/0008-5472.CAN-05-3153; Yu DH, 2000, ONCOGENE, V19, P6115, DOI 10.1038/sj.onc.1203972; Yu DH, 2000, BIOESSAYS, V22, P673, DOI 10.1002/1521-1878(200007)22:7<673::AID-BIES10>3.0.CO;2-A; Yu XC, 2005, NAT GENET, V37, P401, DOI 10.1038/ng1538	44	87	88	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2014	33	5					599	610		10.1038/onc.2012.628	http://dx.doi.org/10.1038/onc.2012.628			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5GW	23334326	Green Accepted			2022-12-28	WOS:000331125100008
J	Do, TV; Xiao, F; Bickel, LE; Klein-Szanto, AJ; Pathak, HB; Hua, X; Howe, C; O'Brien, SW; Maglaty, M; Ecsedy, JA; Litwin, S; Golemis, EA; Schilder, RJ; Godwin, AK; Connolly, DC				Do, T-V; Xiao, F.; Bickel, L. E.; Klein-Szanto, A. J.; Pathak, H. B.; Hua, X.; Howe, C.; O'Brien, S. W.; Maglaty, M.; Ecsedy, J. A.; Litwin, S.; Golemis, E. A.; Schilder, R. J.; Godwin, A. K.; Connolly, D. C.			Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion	ONCOGENE			English	Article						Aurora kinase A; SRC; ovarian cancer; migration; alisertib; adhesion	SMALL-MOLECULE INHIBITOR; SUPPRESSES TUMOR-GROWTH; A KINASE; ANTITUMOR-ACTIVITY; IN-VIVO; OVEREXPRESSION; CARCINOMA; METASTASIS; ACTIVATION; EXPRESSION	Aurora kinase A (AURKA) localizes to centrosomes and mitotic spindles where it mediates mitotic progression and chromosomal stability. Overexpression of AURKA is common in cancer, resulting in acquisition of alternate non-mitotic functions. In the current study, we identified a novel role for AURKA in regulating ovarian cancer cell dissemination and evaluated the efficacy of an AURKA-selective small molecule inhibitor, alisertib (MLN8237), as a single agent and combined with paclitaxel using an orthotopic xenograft model of epithelial ovarian cancer (EOC). Ovarian carcinoma cell lines were used to evaluate the effects of AURKA inhibition and overexpression on migration and adhesion. Pharmacological or RNA interference-mediated inhibition of AURKA significantly reduced ovarian carcinoma cell migration and adhesion and the activation-associated phosphorylation of the cytoskeletal regulatory protein SRC at tyrosine 416 (pSRC(Y416)). Conversely, enforced expression of AURKA resulted in increased migration, adhesion and activation of SRC in cultured cells. In vivo tumor growth and dissemination were inhibited by alisertib treatment as a single agent. Moreover, combination of alisertib with paclitaxel, an agent commonly used in treatment of EOC, resulted in more potent inhibition of tumor growth and dissemination compared with either drug alone. Taken together, these findings support a role for AURKA in EOC dissemination by regulating migration and adhesion. They also point to the potential utility of combining AURKA inhibitors with taxanes as a therapeutic strategy for the treatment of EOC patients.	[Do, T-V; Xiao, F.; Bickel, L. E.; Pathak, H. B.; Howe, C.; Schilder, R. J.; Godwin, A. K.; Connolly, D. C.] Fox Chase Canc Ctr, Womens Canc Program, Philadelphia, PA 19111 USA; [Do, T-V; Pathak, H. B.; Godwin, A. K.] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, Kansas City, KS 66103 USA; [Xiao, F.; O'Brien, S. W.; Maglaty, M.; Golemis, E. A.; Connolly, D. C.] Fox Chase Canc Ctr, Dev Therapeut Program, Philadelphia, PA 19111 USA; [Klein-Szanto, A. J.] Fox Chase Canc Ctr, Dept Pathol, Philadelphia, PA 19111 USA; [Hua, X.] Fox Chase Canc Ctr, Transgen Facil, Philadelphia, PA 19111 USA; [Ecsedy, J. A.] Millennium Pharmaceut Inc, Dept Translat Med, Cambridge, MA USA; [Litwin, S.] Fox Chase Canc Ctr, Biostat Facil, Philadelphia, PA 19111 USA; [Schilder, R. J.] Fox Chase Canc Ctr, Dept Med Oncol, Philadelphia, PA 19111 USA; [Schilder, R. J.] Thomas Jefferson Univ, Dept Gynecol Med Oncol, Philadelphia, PA 19107 USA	Fox Chase Cancer Center; University of Kansas; University of Kansas Medical Center; Fox Chase Cancer Center; Fox Chase Cancer Center; Fox Chase Cancer Center; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Fox Chase Cancer Center; Fox Chase Cancer Center; Jefferson University	Connolly, DC (corresponding author), Fox Chase Canc Ctr, Dev Therapeut Program, 333 Cottman Ave,W310, Philadelphia, PA 19111 USA.	Denise.Connolly@fccc.edu		Golemis, Erica/0000-0003-3618-3673	State of Pennsylvania; Fox Chase Cancer Center; Ovarian Cancer Research Fund Program of Excellence Award; Ovarian SPORE [P50 CA083638]; Fox Chase Cancer Center Core Grant [NCI P30 CA006927];  [R01 CA136596];  [R01 CA63366];  [R01 CA140323]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD052027] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA006927, P30CA056036, P50CA083638, R01CA140323, R01CA063366, R01CA136596] Funding Source: NIH RePORTER	State of Pennsylvania; Fox Chase Cancer Center; Ovarian Cancer Research Fund Program of Excellence Award; Ovarian SPORE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Fox Chase Cancer Center Core Grant; ; ; ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We gratefully acknowledge Dr Maureen Murphy and Dr Timothy Yen for helpful discussions and critical review of this manuscript. We also thank Dr Maureen Murphy for providing access to the Guava EasyCyte system, and Dr Greg Enders for providing access to the Nikon Eclipse microscope. This work was supported by R01 CA136596, Tobacco Settlement funding from the State of Pennsylvania and Fox Chase Cancer Center via institutional support of the Keystone Program in Personalized Risk and Prevention (to DCC); Ovarian Cancer Research Fund Program of Excellence Award (to TVD); Ovarian SPORE P50 CA083638 (Project 4 to DCC, AKG and EAG and Pilot Award to TVD); R01 CA63366 (to EAG); R01 CA140323 (to AKG); and the Fox Chase Cancer Center Core Grant NCI P30 CA006927. The following Fox Chase Cancer Facilities were used: Laboratory Animal, Transgenic, Cell Culture, Biological Imaging, Histopathology, Biosample Repository and Biostatistics and Bioinformatics.	Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10; Chung CM, 2005, MOL CARCINOGEN, V43, P165, DOI 10.1002/mc.20098; Connolly DC, 2003, CANCER RES, V63, P1389; Connolly DC, 2009, CURR PROTOC PHARM, V45; Do TV, 2007, MOL CANCER RES, V5, P121, DOI 10.1158/1541-7786.MCR-06-0319; Feki A, 2009, CRIT REV ONCOL HEMAT, V72, P1, DOI 10.1016/j.critrevonc.2008.12.003; Gautschi O, 2008, CLIN CANCER RES, V14, P1639, DOI 10.1158/1078-0432.CCR-07-2179; Gritsko TM, 2003, CLIN CANCER RES, V9, P1420; Guan Z, 2007, CANCER RES, V67, P10436, DOI 10.1158/0008-5472.CAN-07-1379; Guarino M, 2010, J CELL PHYSIOL, V223, P14, DOI 10.1002/jcp.22011; Harrington EA, 2004, NAT MED, V10, P262, DOI 10.1038/nm1003; Hata T, 2005, CANCER RES, V65, P2899, DOI 10.1158/0008-5472.CAN-04-3981; Hsu LC, 2005, INT J CANCER, V113, P746, DOI 10.1002/ijc.20633; Hu W, 2005, ONCOL RES, V15, P49, DOI 10.3727/096504005775082101; Huck JJ, 2010, MOL CANCER RES, V8, P373, DOI 10.1158/1541-7786.MCR-09-0300; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Ji HB, 2007, NATURE, V448, P807, DOI 10.1038/nature06030; Keen N, 2004, NAT REV CANCER, V4, P927, DOI 10.1038/nrc1502; Kim M, 2006, CELL, V125, P1269, DOI 10.1016/j.cell.2006.06.008; Komlodi-Pasztor E, 2012, CLIN CANCER RES, V18, P51, DOI 10.1158/1078-0432.CCR-11-0999; Landen CN, 2007, CLIN CANCER RES, V13, P4098, DOI 10.1158/1078-0432.CCR-07-0431; Lassmann S, 2007, CLIN CANCER RES, V13, P4083, DOI 10.1158/1078-0432.CCR-06-2775; Lassus H, 2011, GYNECOL ONCOL, V120, P11, DOI 10.1016/j.ygyno.2010.09.003; Lin YG, 2008, CLIN CANCER RES, V14, P5437, DOI 10.1158/1078-0432.CCR-07-4922; Luker KE, 2008, ANTIVIR RES, V78, P179, DOI 10.1016/j.antiviral.2008.01.158; Manfredi MG, 2007, P NATL ACAD SCI USA, V104, P4106, DOI 10.1073/pnas.0608798104; Manfredi MG, 2011, CLIN CANCER RES, V17, P7614, DOI 10.1158/1078-0432.CCR-11-1536; Marumoto T, 2003, J BIOL CHEM, V278, P51786, DOI 10.1074/jbc.M306275200; Matsuo K, 2010, ARCH GYNECOL OBSTET, V281, P325, DOI 10.1007/s00404-009-1121-1; Mazumdar A, 2009, HEAD NECK-J SCI SPEC, V31, P625, DOI 10.1002/hed.21007; Mortlock A, 2005, CURR TOP MED CHEM, V5, P199, DOI 10.2174/1568026053507651; O'Neill GM, 2007, CANCER RES, V67, P8975, DOI 10.1158/0008-5472.CAN-07-1328; Payton M, 2010, CANCER RES, V70, P9846, DOI 10.1158/0008-5472.CAN-10-3001; Pugacheva EN, 2006, CELL CYCLE, V5, P384, DOI 10.4161/cc.5.4.2439; Pugacheva EN, 2005, NAT CELL BIOL, V7, P937, DOI 10.1038/ncb1309; Ratushny V, 2012, ONCOGENE, V31, P1217, DOI 10.1038/onc.2011.314; Reiter R, 2006, CLIN CANCER RES, V12, P5136, DOI 10.1158/1078-0432.CCR-05-1650; Shimomura T, 2010, MOL CANCER THER, V9, P157, DOI 10.1158/1535-7163.MCT-09-0609; Swift S., 2001, CURRENT PROTOCOLS IM; Tan DSP, 2006, LANCET ONCOL, V7, P925, DOI 10.1016/S1470-2045(06)70939-1; Tanaka E, 2007, CLIN CANCER RES, V13, P1331, DOI 10.1158/1078-0432.CCR-06-1192; Tanner MM, 2000, CLIN CANCER RES, V6, P1833; Tatsuka M, 2005, ONCOGENE, V24, P1122, DOI 10.1038/sj.onc.1208293; Tikhmyanova N, 2010, CELL MOL LIFE SCI, V67, P1025, DOI 10.1007/s00018-009-0213-1; Tong T, 2004, CLIN CANCER RES, V10, P7304, DOI 10.1158/1078-0432.CCR-04-0806; Wan XB, 2008, CARCINOGENESIS, V29, P1930, DOI 10.1093/carcin/bgn176; Wu JC, 2005, J BIOL CHEM, V280, P9013, DOI 10.1074/jbc.M411068200; Wysong DR, 2009, CELL CYCLE, V8, P876, DOI 10.4161/cc.8.6.7897; Yang H, 2006, INT J CANCER, V119, P2304, DOI 10.1002/ijc.22154; Yeatman TJ, 2004, NAT REV CANCER, V4, P470, DOI 10.1038/nrc1366; Zhang H, 2012, EUR ARCH OTO-RHINO-L, V269, P607, DOI 10.1007/s00405-011-1629-4	52	76	77	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2014	33	5					539	549		10.1038/onc.2012.632	http://dx.doi.org/10.1038/onc.2012.632			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5GW	23334327	Green Accepted			2022-12-28	WOS:000331125100002
J	Brouxhon, SM; Kyrkanides, S; Teng, X; Athar, M; Ghazizadeh, S; Simon, M; O'Banion, MK; Ma, L				Brouxhon, S. M.; Kyrkanides, S.; Teng, X.; Athar, M.; Ghazizadeh, S.; Simon, M.; O'Banion, M. K.; Ma, L.			Soluble E-cadherin: a critical oncogene modulating receptor tyrosine kinases, MAPK and PI3K/Akt/mTOR signaling	ONCOGENE			English	Article						squamous cell carcinomas; UV-irradiation; soluble E-cadherin; HER/ErbB receptors; IGF-1R; oncogenecity	GROWTH-FACTOR RECEPTOR; CELL CARCINOMA PROGRESSION; BREAST-CANCER CELLS; TRANSGENIC MICE; FACTOR-I; ULTRAVIOLET-IRRADIATION; PROSTATE-CANCER; TUMOR PROMOTION; DOWN-REGULATION; GASTRIC-CANCER	E-cadherin, a cell-cell adhesion glycoprotein, is frequently downregulated with tumorigenic progression. The extracellular domain of E-cadherin is cleaved by proteases to generate a soluble ectodomain fragment, termed sEcad, which is elevated in the urine or serum of cancer patients. In this study, we explored the functional role of sEcad in the progression of skin squamous cell carcinomas (SCCs). We found that full-length E-cadherin expression was decreased and sEcad increased in human clinical tumor samples as well as in ultraviolet (UV)-induced SCCs in mice. Interestingly, sEcad associated with members of the human epidermal growth factor receptor (HER) and insulin-like growth factor-1 (IGF-1R) family of receptors in human and UV-induced mouse tumors. Moreover, in both E-cadherin-positive (E-cadherin(+)) and -negative (E-cadherin(-)) cells in vitro, sEcad activated downstream mitogen-activated protein (MAP) kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) signaling and enhanced tumor growth, motility and invasion, the latter via activation of matrix metalloproteinase-2 (MMP-2) and MMP-9. To this end, HER, PI3K or MEK inhibitors suppressed sEcad's tumorigenic effects, including proliferation, migration and invasion. Taken together, our data suggest that sEcad contributes to skin carcinogenesis via association with the HER/IGF-1R-family of receptors and subsequent activation of the MAPK and PI3K/Akt/mTOR pathways, thereby implicating sEcad as a putative therapeutic target in cutaneous SCCs.	[Brouxhon, S. M.; Kyrkanides, S.; Teng, X.; Ghazizadeh, S.; Simon, M.; Ma, L.] SUNY Stony Brook, Hlth Sci Ctr, Dept Emergency Med, Stony Brook, NY 11794 USA; [Athar, M.] Univ Alabama Birmingham, Dept Dermatol, Birmingham, AL 35294 USA; [O'Banion, M. K.] Univ Rochester, Sch Med & Dent, Dept Neurobiol, Rochester, NY USA; [O'Banion, M. K.] Univ Rochester, Sch Med & Dent, Dept Anat, Rochester, NY USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Alabama System; University of Alabama Birmingham; University of Rochester; University of Rochester	Brouxhon, SM (corresponding author), SUNY Stony Brook, Hlth Sci Ctr, Sch Med, Westchester Hall,Room 154, Stony Brook, NY 11794 USA.	Sabine.Brouxhon@stonybrook.edu	Ma, Li/AAG-4109-2020	Ma, Li/0000-0001-8470-0378; O'Banion, M. Kerry/0000-0003-1246-3363	NIH [K08CA133910, R21ES015832, R01CA138998]; NATIONAL CANCER INSTITUTE [R01CA138998, K08CA133910] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR050948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES015832] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Dr Yuspa (NCI) and Dr Klein-Szanto (Fox Chase Cancer Center) for the PAM212 and CC4A cells, respectively. This work was supported by NIH grants K08CA133910 (NCI) and R21ES015832 (NIEHS) to SMB as well as NIH grant R01CA138998 (NCI) to MA.	Batistatou A, 2006, VIRCHOWS ARCH, V448, P763, DOI 10.1007/s00428-006-0183-8; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Bol D, 1998, MOL CARCINOGEN, V21, P2, DOI 10.1002/(SICI)1098-2744(199801)21:1<2::AID-MC2>3.3.CO;2-7; Bol DK, 1997, ONCOGENE, V14, P1725, DOI 10.1038/sj.onc.1201011; BONGIORNO PF, 1995, BRIT J CANCER, V71, P166, DOI 10.1038/bjc.1995.34; Brouxhon S, 2007, CANCER RES, V67, P7654, DOI 10.1158/0008-5472.CAN-06-4415; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Chan ACO, 2003, J CLIN ONCOL, V21, P2288, DOI 10.1200/JCO.2003.08.078; Davies G, 2001, CLIN CANCER RES, V7, P3289; DiGiovanni J, 2000, CANCER RES, V60, P1561; Dlugosz AA, 1997, CANCER RES, V57, P3180; El-Abaseri TB, 2006, CARCINOGENESIS, V27, P225, DOI 10.1093/carcin/bgi220; El-Abaseri TB, 2005, CANCER RES, V65, P3958, DOI 10.1158/0008-5472.CAN-04-2204; Esch TR, 2000, J AUTOIMMUN, V15, P387, DOI 10.1006/jaut.2000.0451; Fong KP, 2011, BLOOD, V117, pE15, DOI 10.1182/blood-2010-05-283838; Fujii K, 1996, EXP CELL RES, V223, P50, DOI 10.1006/excr.1996.0057; Galer CE, 2011, HEAD NECK-J SCI SPEC, V33, P189, DOI 10.1002/hed.21419; GAMALLO C, 1993, AM J PATHOL, V142, P987; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078; Higgins MJ, 2011, J CLIN INVEST, V121, P3797, DOI 10.1172/JCI57152; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Inge LJ, 2011, EXP CELL RES, V317, P838, DOI 10.1016/j.yexcr.2010.12.025; KATAYAMA M, 1994, BRIT J CANCER, V69, P580, DOI 10.1038/bjc.1994.106; Kim AL, 2002, PHOTOCHEM PHOTOBIOL, V75, P58, DOI 10.1562/0031-8655(2002)075<0058:SSAOCE>2.0.CO;2; Kuefer R, 2003, CLIN CANCER RES, V9, P6447; Kyrkanides S, 2007, J NEUROIMMUNOL, V188, P39, DOI 10.1016/j.jneuroim.2007.05.010; Madson JG, 2007, MOL CARCINOGEN, V46, P624, DOI 10.1002/mc.20335; Maretzky T, 2005, P NATL ACAD SCI USA, V102, P9182, DOI 10.1073/pnas.0500918102; Maretzky T, 2008, J INVEST DERMATOL, V128, P1737, DOI 10.1038/sj.jid.5701242; Margulis A, 2005, CANCER RES, V65, P1783, DOI 10.1158/0008-5472.CAN-04-3399; MAYER B, 1993, CANCER RES, V53, P1690; MOLL R, 1993, AM J PATHOL, V143, P1731; Nahta R, 2005, CANCER RES, V65, P11118, DOI 10.1158/0008-5472.CAN-04-3841; Najy AJ, 2008, J BIOL CHEM, V283, P18393, DOI 10.1074/jbc.M801329200; Nawrocki-Raby B, 2003, INT J CANCER, V105, P790, DOI 10.1002/ijc.11168; RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8; Saha B, 2007, ANTICANCER RES, V27, P3903; Symowicz J, 2007, CANCER RES, V67, P2030, DOI 10.1158/0008-5472.CAN-06-2808; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; Uchida Y, 2011, J IMMUNOL, V186, P6945, DOI 10.4049/jimmunol.1003853; Van den Bossche J, 2012, BLOOD, V119, P1623, DOI 10.1182/blood-2011-10-384289; VASSAR R, 1991, GENE DEV, V5, P714, DOI 10.1101/gad.5.5.714; Wan YS, 2001, INT J ONCOL, V18, P461; Wilding J, 1996, CANCER RES, V56, P5285; Wilker E, 2005, MOL CARCINOGEN, V44, P137, DOI 10.1002/mc.20132; Yang Jun, 2005, Zhonghua Zhong Liu Za Zhi, V27, P25	47	70	74	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2014	33	2					225	235		10.1038/onc.2012.563	http://dx.doi.org/10.1038/onc.2012.563			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286BY	23318419	Green Accepted			2022-12-28	WOS:000329440700010
J	Orre, LM; Panizza, E; Kaminskyy, VO; Vernet, E; Graslund, T; Zhivotovsky, B; Lehtio, J				Orre, L. M.; Panizza, E.; Kaminskyy, V. O.; Vernet, E.; Graslund, T.; Zhivotovsky, B.; Lehtio, J.			S100A4 interacts with p53 in the nucleus and promotes p53 degradation	ONCOGENE			English	Article						S100A4; p53; interaction study; proximity ligation assay; immunoprecipitation	METASTASIS-INDUCING PROTEIN; HUMAN BREAST-CANCER; CALCIUM-BINDING PROTEIN; TUMOR-SUPPRESSOR P53; N-TERMINAL DOMAIN; CELL LUNG-CANCER; COLORECTAL-CANCER; E-CADHERIN; DIFFERENTIAL EXPRESSION; PROGNOSTIC-SIGNIFICANCE	S100A4 is a small calcium-binding protein that is commonly overexpressed in a range of different tumor types, and it is widely accepted that S100A4 has an important role in the process of cancer metastasis. In vitro binding assays has shown that S100A4 interacts with the tumor suppressor protein p53, indicating that S100A4 may have additional roles in tumor development. In the present study, we show that endogenous S100A4 and p53 interact in complex samples, and that the interaction increases after inhibition of MDM2-dependent p53 degradation using Nutlin-3A. Further, using proximity ligation assay, we show that the interaction takes place in the cell nucleus. S100A4 knockdown experiments in two p53 wild-type cell lines, A549 and HeLa, resulted in stabilization of p53 protein, indicating that S100A4 is promoting p53 degradation. Finally, we demonstrate that S100A4 knockdown leads to p53-dependent cell cycle arrest and increased cisplatin-induced apoptosis. Thus, our data add a new layer to the oncogenic properties of S100A4 through its inhibition of p53-dependent processes.	[Orre, L. M.; Panizza, E.; Lehtio, J.] Karolinska Inst, Sci Life Lab, Dept Pathol & Oncol, S-17121 Stockholm, Sweden; [Kaminskyy, V. O.; Zhivotovsky, B.] Karolinska Inst, Inst Environm Med, Div Toxicol, S-17121 Stockholm, Sweden; [Vernet, E.; Graslund, T.] AlbaNova Univ Ctr, Royal Inst Technol, KTH, Div Mol Biotechnol,Sch Biotechnol, Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Royal Institute of Technology	Orre, LM (corresponding author), Karolinska Inst, Sci Life Lab, Dept Pathol & Oncol, POB 1031, S-17121 Stockholm, Sweden.	lukas.orre@ki.se	Vernet, Erik/O-1880-2019; Zhivotovsky, Boris/A-4346-2014; Vernet, Erik/G-8520-2011	Vernet, Erik/0000-0002-4175-1244; Zhivotovsky, Boris/0000-0002-2238-3482; Vernet, Erik/0000-0002-4175-1244; Kaminskyy, Vitaliy/0000-0002-8151-5270; Lehtio, Janne/0000-0002-8100-9562; Orre, Lukas/0000-0002-0384-1003; Panizza, Elena/0000-0003-3490-4107	Swedish Cancer Society; Swedish Research Foundation; Swedish Research council; Swedish Childhood Cancer Society; European Union; Swedish Institute; Karolinska Institutet; Karolinska Institutet KID funding; Stockholm Cancer Society	Swedish Cancer Society(Swedish Cancer Society); Swedish Research Foundation; Swedish Research council(Swedish Research CouncilEuropean Commission); Swedish Childhood Cancer Society; European Union(European Commission); Swedish Institute; Karolinska Institutet(Karolinska Institutet); Karolinska Institutet KID funding(Karolinska Institutet); Stockholm Cancer Society	We thank Professor Didier Trono at the School of Life Sciences, EPFL, Lausanne, Switzerland for providing the helper plasmids for viral vector production, pG32231 and pMD2.G. We also thank the group of Professor Hjalmar Brismar for assistance in the use of confocal microscopy. This study was supported by grants from the Swedish and Stockholm Cancer Societies, the Swedish Research Foundation, the Swedish Research council, the Swedish Childhood Cancer Society, the European Union (Chemores and Apo-Sys). VOK was supported by a fellowship from the Swedish Institute and Karolinska Institutet. EP was supported by Karolinska Institutet KID funding.	Ambartsumian NS, 1996, ONCOGENE, V13, P1621; Berge G, 2011, AMINO ACIDS, V41, P875, DOI 10.1007/s00726-010-0514-6; Berge G, 2011, AMINO ACIDS, V41, P863, DOI 10.1007/s00726-010-0497-3; Brooks CL, 2006, MOL CELL, V21, P307, DOI 10.1016/j.molcel.2006.01.020; Chen HL, 2001, BIOCHEM BIOPH RES CO, V286, P1212, DOI 10.1006/bbrc.2001.5517; Cho YG, 2003, APMIS, V111, P539, DOI 10.1034/j.1600-0463.2003.1110502.x; Cho YG, 2005, WORLD J GASTROENTERO, V11, P4852, DOI 10.3748/wjg.v11.i31.4852; DAVIES BR, 1993, ONCOGENE, V8, P999; Davies BR, 2002, J PATHOL, V196, P292, DOI 10.1002/path.1051; De Petris L, 2009, LUNG CANCER, V63, P410, DOI 10.1016/j.lungcan.2008.06.003; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; Fernandez-Fernandez MR, 2005, P NATL ACAD SCI USA, V102, P4735, DOI 10.1073/pnas.0501459102; Flatmark K, 2003, J PATHOL, V200, P589, DOI 10.1002/path.1381; Gongoll S, 2002, GASTROENTEROLOGY, V123, P1478, DOI 10.1053/gast.2002.36606; Grigorian M, 1996, INT J CANCER, V67, P831, DOI 10.1002/(SICI)1097-0215(19960917)67:6<831::AID-IJC13>3.0.CO;2-4; Grigorian M, 2001, J BIOL CHEM, V276, P22699, DOI 10.1074/jbc.M010231200; Gupta S, 2003, J CLIN ONCOL, V21, P106, DOI 10.1200/JCO.2003.03.024; Heizmann Claus W, 2002, Methods Mol Biol, V172, P69; Hemandas AK, 2006, J SURG ONCOL, V93, P498, DOI 10.1002/jso.20460; Hjerpe R, 2010, INT J BIOCHEM CELL B, V42, P725, DOI 10.1016/j.biocel.2010.01.010; Ismail TM, 2010, J BIOL CHEM, V285, P914, DOI 10.1074/jbc.M109.010892; Itahana Y, 2009, J BIOL CHEM, V284, P5158, DOI 10.1074/jbc.M805696200; Kaminskyy VO, 2012, AUTOPHAGY, V8, P1032, DOI 10.4161/auto.20123; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Kim JH, 2009, ONCOL REP, V22, P41, DOI 10.3892/or_00000404; Kimura K, 2000, INT J ONCOL, V16, P1125; Kriajevska M, 2000, BBA-MOL CELL RES, V1498, P252, DOI 10.1016/S0167-4889(00)00100-2; Lee WY, 2004, ONCOLOGY-BASEL, V66, P429, DOI 10.1159/000079496; Li ZH, 2006, CANCER RES, V66, P5173, DOI 10.1158/0008-5472.CAN-05-3087; Matsubara D, 2005, CANCER SCI, V96, P844, DOI 10.1111/j.1349-7006.2005.00121.x; Matsumoto K, 2007, UROLOGY, V70, P602, DOI 10.1016/j.urology.2007.04.007; Oida Y, 2006, ONCOL REP, V16, P457; Orre LM, 2007, MOL CELL PROTEOMICS, V6, P2122, DOI 10.1074/mcp.M700202-MCP200; Pedersen KB, 2002, BRIT J CANCER, V87, P1281, DOI 10.1038/sj.bjc.6600624; Platt-Higgins AM, 2000, INT J CANCER, V89, P198, DOI 10.1002/(SICI)1097-0215(20000320)89:2<198::AID-IJC16>3.0.CO;2-L; Poyurovsky MV, 2010, NAT STRUCT MOL BIOL, V17, P982, DOI 10.1038/nsmb.1872; Rosty C, 2002, AM J PATHOL, V160, P45, DOI 10.1016/S0002-9440(10)64347-7; Rudland PS, 2000, CANCER RES, V60, P1595; Sali A, 2003, NATURE, V422, P216, DOI 10.1038/nature01513; Santamaria-Kisiel L, 2006, BIOCHEM J, V396, P201, DOI 10.1042/BJ20060195; Sherr CJ, 2006, NAT REV CANCER, V6, P663, DOI 10.1038/nrc1954; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Soderberg O, 2008, METHODS, V45, P227, DOI 10.1016/j.ymeth.2008.06.014; Tang Y, 2008, CELL, V133, P612, DOI 10.1016/j.cell.2008.03.025; van Dieck J, 2010, ONCOGENE, V29, P2024, DOI 10.1038/onc.2009.490; van Dieck J, 2010, FEBS LETT, V584, P3269, DOI 10.1016/j.febslet.2010.06.024; van Dieck J, 2009, J MOL BIOL, V394, P922, DOI 10.1016/j.jmb.2009.10.002; van Dieck J, 2009, J BIOL CHEM, V284, P13804, DOI 10.1074/jbc.M901351200; Vasilescu J, 2004, PROTEOMICS, V4, P3845, DOI 10.1002/pmic.200400856; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Xie R, 2007, MODERN PATHOL, V20, P1045, DOI 10.1038/modpathol.3800940; Zou M, 2005, BRIT J CANCER, V93, P1277, DOI 10.1038/sj.bjc.6602856	52	69	71	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2013	32	49					5531	5540		10.1038/onc.2013.213	http://dx.doi.org/10.1038/onc.2013.213			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	269XF	23752197	hybrid			2022-12-28	WOS:000328276400004
J	Beauchamp, EM; Platanias, LC				Beauchamp, E. M.; Platanias, L. C.			The evolution of the TOR pathway and its role in cancer	ONCOGENE			English	Review						mTOR; cancer; leukemia	MESSENGER-RNA TRANSLATION; PHOSPHATIDYLINOSITOL KINASE HOMOLOG; SMALL-MOLECULE INHIBITORS; TUBEROUS SCLEROSIS GENE; RAPAMYCIN COMPLEX 2; RICH AKT SUBSTRATE; EXTENDS LIFE-SPAN; MAMMALIAN TARGET; MYELOID-LEUKEMIA; CELL-GROWTH	The target of rapamycin (TOR) pathway is highly conserved among eukaryotes and has evolved to couple nutrient sensing to cellular growth. TOR is found in two distinct signaling complexes in cells, TOR complex 1 (TORC1) and TOR complex 2 (TORC2). These complexes are differentially regulated and act as effectors for the generation of signals that drive diverse cellular processes such as growth, proliferation, protein synthesis, rearrangement of the cytoskeleton, autophagy, metabolism and survival. Mammalian TOR (mTOR) is very important for development in embryos, while in adult organisms it is linked to aging and lifespan effects. In humans, the mTOR pathway is implicated in the tumorigenesis of multiple cancer types and its deregulation is associated with familial cancer syndromes. Because of its high biological relevance, different therapeutic strategies have been developed to target this signaling cascade, resulting in the emergence of unique pharmacological inhibitors that are either already approved for use in clinical oncology or currently under preclinical or clinical development. Multimodal treatment strategies that simultaneously target multiple nodes of the pathway and/or negative feedback regulatory loops may ultimately provide the best therapeutic advantage in targeting this pathway for the treatment of malignancies.	[Beauchamp, E. M.; Platanias, L. C.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol, Chicago, IL 60611 USA; [Platanias, L. C.] Jesse Brown VA Med Ctr, Dept Med, Chicago, IL USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Jesse Brown VA Medical Center	Platanias, LC (corresponding author), Robert H Lurie Comprehens Canc Ctr, 303 East Super St,Lurie 3-107, Chicago, IL 60611 USA.	l-platanias@northwestern.edu						Agarwal NK, 2012, ONCOGENE, DOI [10.1038/onc.2012.287, DOI 10.1038/0NC.2012.287)]; Aimbetov R, 2012, ONCOGENE, V31, P2115, DOI 10.1038/onc.2011.404; Altman JK, 2011, CLIN CANCER RES, V17, P4378, DOI 10.1158/1078-0432.CCR-10-2285; Altman JK, 2010, MOL PHARMACOL, V78, P778, DOI 10.1124/mol.110.064642; Avruch J, 2009, AM J PHYSIOL-ENDOC M, V296, pE592, DOI 10.1152/ajpendo.90645.2008; Barbet NC, 1996, MOL BIOL CELL, V7, P25, DOI 10.1091/mbc.7.1.25; Baryawno N, 2010, CANCER RES, V70, P266, DOI 10.1158/0008-5472.CAN-09-0578; Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653; Beausoleil SA, 2004, P NATL ACAD SCI USA, V101, P12130, DOI 10.1073/pnas.0404720101; Bhaskar PT, 2007, DEV CELL, V12, P487, DOI 10.1016/j.devcel.2007.03.020; Bjornsti MA, 2004, NAT REV CANCER, V4, P335, DOI 10.1038/nrc1362; Brachmann SM, 2009, P NATL ACAD SCI USA, V106, P22299, DOI 10.1073/pnas.0905152106; Bray K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041831; Broderick DK, 2004, CANCER RES, V64, P5048, DOI 10.1158/0008-5472.CAN-04-1170; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; Buck E, 2008, CANCER RES, V68, P8322, DOI 10.1158/0008-5472.CAN-07-6720; Budanov AV, 2008, CELL, V134, P451, DOI 10.1016/j.cell.2008.06.028; Buonamici S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001599; Byfield MP, 2005, J BIOL CHEM, V280, P33076, DOI 10.1074/jbc.M507201200; Camposano SE, 2009, ANN HUM GENET, V73, P141, DOI 10.1111/j.1469-1809.2008.00496.x; Carayol N, 2010, P NATL ACAD SCI USA, V107, P12469, DOI 10.1073/pnas.1005114107; Carracedo A, 2008, J CLIN INVEST, V118, P3065, DOI [10.1172/jCI34739, 10.1172/JCI34739]; Chen B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042598; Chen CC, 2010, DEV CELL, V18, P592, DOI 10.1016/j.devcel.2010.03.008; Chen CH, 2011, J BIOL CHEM, V286, P40386, DOI 10.1074/jbc.M111.282590; Chen CH, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001731; CHEN YQ, 1994, BIOCHEM BIOPH RES CO, V203, P1, DOI 10.1006/bbrc.1994.2140; Chiarini F, 2009, CANCER RES, V69, P3520, DOI 10.1158/0008-5472.CAN-08-4884; CHIU MI, 1994, P NATL ACAD SCI USA, V91, P12574, DOI 10.1073/pnas.91.26.12574; Cho YJ, 2011, J CLIN ONCOL, V29, P1424, DOI 10.1200/JCO.2010.28.5148; Choo AY, 2008, P NATL ACAD SCI USA, V105, P17414, DOI 10.1073/pnas.0809136105; Dibble CC, 2012, MOL CELL, V47, P535, DOI 10.1016/j.molcel.2012.06.009; Dibble CC, 2009, MOL CELL BIOL, V29, P5657, DOI 10.1128/MCB.00735-09; Egan DF, 2011, AUTOPHAGY, V7, P645, DOI 10.4161/auto.7.6.15123; Egan DF, 2011, SCIENCE, V331, P456, DOI 10.1126/science.1196371; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Facchinetti V, 2008, EMBO J, V27, P1932, DOI 10.1038/emboj.2008.120; Fan QW, 2006, CANCER CELL, V9, P341, DOI 10.1016/j.ccr.2006.03.029; Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038; Feng ZH, 2007, CANCER RES, V67, P3043, DOI 10.1158/0008-5472.CAN-06-4149; Fonseca BD, 2007, J BIOL CHEM, V282, P24514, DOI 10.1074/jbc.M704406200; Frias MA, 2006, CURR BIOL, V16, P1865, DOI 10.1016/j.cub.2006.08.001; Galanis E, 2005, J CLIN ONCOL, V23, P5294, DOI 10.1200/JCO.2005.23.622; Gangloff YG, 2004, MOL CELL BIOL, V24, P9508, DOI 10.1128/MCB.24.21.9508-9516.2004; Garcia-Martinez JM, 2008, BIOCHEM J, V416, P375, DOI 10.1042/BJ20081668; Gentzler RD, 2012, EXPERT OPIN THER TAR, V16, P481, DOI 10.1517/14728222.2012.677439; Glidden EJ, 2012, J BIOL CHEM, V287, P581, DOI 10.1074/jbc.M111.304337; GREEN AJ, 1994, HUM MOL GENET, V3, P1833, DOI 10.1093/hmg/3.10.1833; GREEN AJ, 1994, NAT GENET, V6, P193, DOI 10.1038/ng0294-193; Guertin DA, 2006, DEV CELL, V11, P859, DOI 10.1016/j.devcel.2006.10.007; Guertin DA, 2009, CANCER CELL, V15, P148, DOI 10.1016/j.ccr.2008.12.017; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hambardzumyan D, 2008, GENE DEV, V22, P436, DOI 10.1101/gad.1627008; Hansen M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.0040024; Hansen M, 2007, WESTERN HUM REV, V61, P6; Hara K, 1997, J BIOL CHEM, V272, P26457, DOI 10.1074/jbc.272.42.26457; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; HEITMAN J, 1991, SCIENCE, V253, P905, DOI 10.1126/science.1715094; Helliwell SB, 1998, GENETICS, V148, P99; HELLIWELL SB, 1994, MOL BIOL CELL, V5, P105, DOI 10.1091/mbc.5.1.105; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hentges KE, 2001, P NATL ACAD SCI USA, V98, P13796, DOI 10.1073/pnas.241184198; Hess G, 2009, J CLIN ONCOL, V27, P3822, DOI 10.1200/JCO.2008.20.7977; Hietakangas V, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-282; Hong-Brown LQ, 2010, J CELL BIOCHEM, V109, P1172, DOI 10.1002/jcb.22496; Hsu PP, 2011, SCIENCE, V332, P1317, DOI 10.1126/science.1199498; Huang JX, 2009, CANCER RES, V69, P6107, DOI 10.1158/0008-5472.CAN-09-0975; Hudes G, 2007, NEW ENGL J MED, V356, P2271, DOI 10.1056/NEJMoa066838; Ikenoue T, 2008, EMBO J, V27, P1919, DOI 10.1038/emboj.2008.119; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Inoki K, 2006, CELL, V126, P955, DOI 10.1016/j.cell.2006.06.055; Inoki K, 2012, ANNU REV PHARMACOL, V52, P381, DOI 10.1146/annurev-pharmtox-010611-134537; Jacinto E, 2004, NAT CELL BIOL, V6, P1122, DOI 10.1038/ncb1183; Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033; Janes MR, 2010, NAT MED, V16, P205, DOI 10.1038/nm.2091; Jenne DE, 1998, NAT GENET, V18, P38, DOI 10.1038/ng0198-38; Jia K, 2004, DEVELOPMENT, V131, P3897, DOI 10.1242/dev.01255; Johnstone CN, 2005, GENOMICS, V85, P338, DOI 10.1016/j.ygeno.2004.11.002; Jones DTW, 2012, NATURE, V488, P100, DOI 10.1038/nature11284; Jones KT, 2009, PLOS BIOL, V7, P604, DOI 10.1371/journal.pbio.1000060; Juhasz G, 2008, J CELL BIOL, V181, P655, DOI 10.1083/jcb.200712051; Kapahi P, 2004, CURR BIOL, V14, P885, DOI 10.1016/j.cub.2004.03.059; Kapahi P, 2010, CELL METAB, V11, P453, DOI 10.1016/j.cmet.2010.05.001; Kaur S, 2008, P NATL ACAD SCI USA, V105, P4808, DOI 10.1073/pnas.0710907105; Kaur S, 2012, P NATL ACAD SCI USA, V109, P7723, DOI 10.1073/pnas.1118122109; Khokhar NZ, 2011, CURR OPIN ONCOL, V23, P578, DOI 10.1097/CCO.0b013e32834b892d; Kim E, 2008, NAT CELL BIOL, V10, P935, DOI 10.1038/ncb1753; Kobayashi T, 1999, CANCER RES, V59, P1206; Kobayashi T, 2001, P NATL ACAD SCI USA, V98, P8762, DOI 10.1073/pnas.151033798; Kovacina KS, 2003, J BIOL CHEM, V278, P10189, DOI 10.1074/jbc.M210837200; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; Laplante M, 2012, CELL METAB, V16, P202, DOI 10.1016/j.cmet.2012.07.008; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Laplante M, 2009, CURR BIOL, V19, pR1046, DOI 10.1016/j.cub.2009.09.058; Lee JH, 2010, SCIENCE, V327, P1223, DOI 10.1126/science.1182228; Lekmine F, 2003, J BIOL CHEM, V278, P27772, DOI 10.1074/jbc.M301364200; Liang C, 2006, NAT CELL BIOL, V8, P688, DOI 10.1038/ncb1426; Lindmo K, 2006, J CELL SCI, V119, P605, DOI 10.1242/jcs.02855; Liu TJ, 2009, MOL CANCER THER, V8, P2204, DOI 10.1158/1535-7163.MCT-09-0160; Loewith R, 2002, MOL CELL, V10, P457, DOI 10.1016/S1097-2765(02)00636-6; Long XM, 2002, CURR BIOL, V12, P1448, DOI 10.1016/S0960-9822(02)01091-6; Ly C, 2003, CANCER RES, V63, P5716; Lynch M, 2004, J BIOL CHEM, V279, P3327, DOI 10.1074/jbc.M310872200; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Mahalingam M, 2001, PROG MOLEC, V27, P131; Masri J, 2007, CANCER RES, V67, P11712, DOI 10.1158/0008-5472.CAN-07-2223; Mavrakis KJ, 2008, GENE DEV, V22, P2178, DOI 10.1101/gad.1690808; Max X, 2008, CELL, V133, P303, DOI 10.1016/j.cell.2008.02.031; Mayerhofer M, 2005, FASEB J, V19, P960, DOI 10.1096/fj.04-1973fje; Menon S, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002739; Mirzoeva OK, 2009, CANCER RES, V69, P565, DOI 10.1158/0008-5472.CAN-08-3389; Mohi MG, 2004, P NATL ACAD SCI USA, V101, P3130, DOI 10.1073/pnas.0400063101; Montagne J, 1999, SCIENCE, V285, P2126, DOI 10.1126/science.285.5436.2126; Motzer RJ, 2008, LANCET, V372, P449, DOI 10.1016/S0140-6736(08)61039-9; Murakami M, 2004, MOL CELL BIOL, V24, P6710, DOI 10.1128/mcb.24.15.6710-6718.2004; NELLIST M, 1993, CELL, V75, P1305; Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102; Nobukuni T, 2007, CURR OPIN CELL BIOL, V19, P135, DOI 10.1016/j.ceb.2007.02.019; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; Northcott PA, 2012, NATURE, V488, P49, DOI 10.1038/nature11327; Northcott PA, 2011, J CLIN ONCOL, V29, P1408, DOI 10.1200/JCO.2009.27.4324; Oldham S, 2000, GENE DEV, V14, P2689, DOI 10.1101/gad.845700; Oshiro N, 2007, J BIOL CHEM, V282, P20329, DOI 10.1074/jbc.M702636200; Pan KZ, 2007, AGING CELL, V6, P111, DOI 10.1111/j.1474-9726.2006.00266.x; Pattingre S, 2005, CELL, V122, P927, DOI 10.1016/j.cell.2005.07.002; Pearce LR, 2011, BIOCHEM J, V436, P169, DOI 10.1042/BJ20102103; Pei L, 2011, MOL MED REP, V4, P817, DOI 10.3892/mmr.2011.503; Pei YX, 2012, CANCER CELL, V21, P155, DOI 10.1016/j.ccr.2011.12.021; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Petroulakis E, 2009, CANCER CELL, V16, P439, DOI 10.1016/j.ccr.2009.09.025; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Pugh TJ, 2012, NATURE, V488, P106, DOI 10.1038/nature11329; Pyronnet S, 2000, BIOCHEM PHARMACOL, V60, P1237, DOI 10.1016/S0006-2952(00)00429-9; Raught B, 2004, EMBO J, V23, P1761, DOI 10.1038/sj.emboj.7600193; Reinke A, 2004, J BIOL CHEM, V279, P14752, DOI 10.1074/jbc.M313062200; Robinson G, 2012, NATURE, V488, P43, DOI 10.1038/nature11213; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; SABATINI DM, 1995, J BIOL CHEM, V270, P20875, DOI 10.1074/jbc.270.36.20875; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Saci A, 2011, MOL CELL, V42, P50, DOI 10.1016/j.molcel.2011.03.017; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Sanchez-Cespedes M, 2011, FAM CANCER, V10, P447, DOI 10.1007/s10689-011-9443-0; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sarbassov DD, 2004, CURR BIOL, V14, P1296, DOI 10.1016/j.cub.2004.06.054; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Schmidt A, 1996, P NATL ACAD SCI USA, V93, P13780, DOI 10.1073/pnas.93.24.13780; Schroder W, 2004, GENE, V339, P17, DOI 10.1016/j.gene.2004.07.001; Sehgal SN, 2003, TRANSPLANT P, V35, p7S, DOI 10.1016/S0041-1345(03)00211-2; Shah OJ, 2004, CURR BIOL, V14, P1650, DOI 10.1016/j.cub.2004.08.026; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023; Shiota C, 2006, DEV CELL, V11, P583, DOI 10.1016/j.devcel.2006.08.013; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Soukas AA, 2009, GENE DEV, V23, P496, DOI 10.1101/gad.1775409; Taylor MD, 2012, ACTA NEUROPATHOL, V123, P465, DOI 10.1007/s00401-011-0922-z; Thedieck K, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001217; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Urban J, 2007, MOL CELL, V26, P663, DOI 10.1016/j.molcel.2007.04.020; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; vanSlegtenhorst M, 1997, SCIENCE, V277, P805, DOI 10.1126/science.277.5327.805; Vellai T, 2003, NATURE, V426, P620, DOI 10.1038/426620a; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wang LF, 2007, J BIOL CHEM, V282, P20036, DOI 10.1074/jbc.M702376200; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370; Wang XR, 2007, MOL CELL BIOL, V27, P7405, DOI 10.1128/MCB.00760-07; Wang Y, 2012, CANCER CELL, V21, P374, DOI 10.1016/j.ccr.2011.12.028; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262; Woo SY, 2007, J BIOL CHEM, V282, P25604, DOI 10.1074/jbc.M704343200; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Wu X, 2012, NATURE, V482, P529, DOI 10.1038/nature10825; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Xu Q, 2003, BLOOD, V102, P972, DOI 10.1182/blood-2002-11-3429; Yang L, 2008, CLIN CANCER RES, V14, P3993, DOI 10.1158/1078-0432.CCR-07-4152; Yang Q, 2006, P NATL ACAD SCI USA, V103, P6811, DOI 10.1073/pnas.0602282103; Yang Q, 2006, GENE DEV, V20, P2820, DOI 10.1101/gad.1461206; Yao JC, 2011, NEW ENGL J MED, V364, P514, DOI 10.1056/NEJMoa1009290; Yen CH, 2012, MOL MED, V18, P286, DOI 10.2119/molmed.2011.00331; Yu YH, 2011, SCIENCE, V332, P1322, DOI 10.1126/science.1199484; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000; Zhao JH, 2008, AUTOPHAGY, V4, P378, DOI 10.4161/auto.5633; Zhao YC, 2011, MOL CELL, V44, P304, DOI 10.1016/j.molcel.2011.08.029; Zid BM, 2009, CELL, V139, P149, DOI 10.1016/j.cell.2009.07.034; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	195	106	108	1	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 22	2013	32	34					3923	3932		10.1038/onc.2012.567	http://dx.doi.org/10.1038/onc.2012.567			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IC	23246968				2022-12-28	WOS:000323748100001
J	Adam, J; Yang, M; Soga, T; Pollard, PJ				Adam, J.; Yang, M.; Soga, T.; Pollard, P. J.			Rare insights into cancer biology	ONCOGENE			English	Review						fumarate hydratase; HLRCC; dysregulated metabolism; succinate dehydrogenase; isocitrate dehydrogenase; clinical biomarkers	FUMARATE-HYDRATASE DEFICIENCY; RENAL-CELL CANCER; ISOCITRATE DEHYDROGENASE MUTATIONS; ACUTE MYELOID-LEUKEMIA; TUMOR-SUPPRESSOR; SUCCINATE-DEHYDROGENASE; GENE-MUTATIONS; IDH2 MUTATIONS; COMPLEX-II; HEREDITARY LEIOMYOMATOSIS	Cancer-associated mutations have been identified in the metabolic genes succinate dehydrogenase (SDH), fumarate hydratase (FH) and isocitrate dehydrogenase (IDH), advancing and challenging our understanding of cellular function and disease mechanisms and providing direct links between dysregulated metabolism and cancer. Some striking parallels exist in the cellular consequences of the genetic mutations within this triad of cancer syndromes, including accumulation of oncometabolites and competitive inhibition of 2-oxoglutarate-dependent dioxygenases, particularly, hypoxia-inducible factor (HIF) prolyl hydroxylases, JmjC domain-containing histone demethylases (part of the JMJD family) and the ten-eleven translocation (TET) family of 5methyl cytosine (5mC) DNA hydroxylases. These lead to activation of HIF-dependent oncogenic pathways and inhibition of histone and DNA demethylation. Mutations in FH, resulting in loss of enzyme activity, predispose affected individuals to a rare cancer, hereditary leiomyomatosis and renal cell cancer (HLRCC), characterised by benign smooth muscle cutaneous and uterine tumours (leiomyomata) and an aggressive form of collecting duct and type 2 papillary renal cancer. Interestingly, loss of FH activity results in the accumulation of high levels of fumarate that can lead to the non-enzymatic modification of cysteine residues in multiple proteins (succination) and in some cases to their disrupted function. Here we consider that the study of rare diseases such as HLRCC, combining analyses of human tumours and cell lines with in vitro and in vivo murine models has provided novel insights into cancer biology associated with dysregulated metabolism and represents a useful paradigm for cancer research.	[Adam, J.; Yang, M.; Pollard, P. J.] Univ Oxford, Nuffield Dept Med, Canc Biol & Metab Grp, Oxford OX3 7BN, England; [Soga, T.] Keio Univ, Inst Adv Biosci, Yamagata, Japan; [Soga, T.] Keio Univ, Oxford Keio Metabol Consortium, Yamagata, Japan; [Pollard, P. J.] Oxford Keio Metabol Consortium, Oxford, England	University of Oxford; Keio University; Keio University	Pollard, PJ (corresponding author), Univ Oxford, Nuffield Dept Med, Canc Biol & Metab Grp, Henry Wellcome Bldg Mol Physiol,Roosevelt Dr, Oxford OX3 7BN, England.	patrick.pollard@well.ox.ac.uk	Soga, Tomoyoshi/B-8105-2014	Soga, Tomoyoshi/0000-0001-9502-2509; Adam, Julie/0000-0002-7980-7151	European Research Council under the European Community's Seventh Framework Programme/ERC [310837]; Cancer Research UK; Yamagata Prefectural Government and City of Tsuruoka;  [22134007]	European Research Council under the European Community's Seventh Framework Programme/ERC; Cancer Research UK(Cancer Research UK); Yamagata Prefectural Government and City of Tsuruoka; 	The Cancer Biology and Metabolism Group, led by Dr Pollard, is funded by the European Research Council under the European Community's Seventh Framework Programme (FP7/2007-2013)/ERC grant agreement no. 310837 and Cancer Research UK. Professor Soga is funded from a Grant-in-Aid for scientific research on Innovative Areas, Japan No. 22134007 and the Yamagata Prefectural Government and City of Tsuruoka.	Adam J, 2013, CELL REP, VS2211-1247, P00173; Adam J, 2011, ONCOTARGET, V2, P820; Adam J, 2011, CANCER CELL, V20, P524, DOI 10.1016/j.ccr.2011.09.006; Alderson NL, 2006, ARCH BIOCHEM BIOPHYS, V450, P1, DOI 10.1016/j.abb.2006.03.005; Amar L, 2007, J CLIN ENDOCR METAB, V92, P3822, DOI 10.1210/jc.2007-0709; Amary MF, 2011, NAT GENET, V43, P1262, DOI 10.1038/ng.994; Amary MF, 2011, J PATHOL, V224, P334, DOI 10.1002/path.2913; Ashcroft FM, 2012, CELL, V148, P1160, DOI 10.1016/j.cell.2012.02.010; Ashrafian H, 2010, CANCER RES, V70, P9153, DOI 10.1158/0008-5472.CAN-10-1949; Astuti D, 2001, AM J HUM GENET, V69, P49, DOI 10.1086/321282; Bardella C, 2011, BBA-BIOENERGETICS, V1807, P1432, DOI 10.1016/j.bbabio.2011.07.003; Bardella C, 2011, J PATHOL, V225, P4, DOI 10.1002/path.2932; Bayley JP, 2010, CURR OPIN GENET DEV, V20, P324, DOI 10.1016/j.gde.2010.02.008; Bayley JP, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007987; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Biatnik M, 2008, ANN NY ACAD SCI, V1126, P272, DOI 10.1196/annals.1433.047; Blatnik M, 2008, DIABETES, V57, P41, DOI 10.2337/db07-0838; Borger DR, 2012, ONCOLOGIST, V17, P72, DOI 10.1634/theoncologist.2011-0386; Briere JJ, 2005, HUM MOL GENET, V14, P3263, DOI 10.1093/hmg/ddi359; Brosnan ME, 2004, J NUTR, V134, p2791S, DOI 10.1093/jn/134.10.2791S; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Burnichon N, 2010, HUM MOL GENET, V19, P3011, DOI 10.1093/hmg/ddq206; Cairns RA, 2012, BLOOD, V119, P1901, DOI 10.1182/blood-2011-11-391748; Choi C, 2012, NAT MED, V18, P624, DOI 10.1038/nm.2682; Choi C, 2011, MAGN RESON MED, V66, P609, DOI 10.1002/mrm.22857; Chowdhury R, 2011, EMBO REP, V12, P463, DOI 10.1038/embor.2011.43; Copeland NG, 2010, NAT REV CANCER, V10, P696, DOI 10.1038/nrc2916; Dahia PLM, 2006, ANN NY ACAD SCI, V1073, P208, DOI 10.1196/annals.1353.023; Dahia PLM, 2005, PLOS GENET, V1, P72, DOI 10.1371/journal.pgen.0010008; Dalgliesh GL, 2010, NATURE, V463, P360, DOI 10.1038/nature08672; Dang L, 2010, NATURE, V465, P966, DOI 10.1038/nature09132; De Bels D, 2011, NEW ENGL J MED, V365, P1845, DOI 10.1056/NEJMc1110602; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; DeBerardinis RJ, 2012, CELL, V148, P1132, DOI 10.1016/j.cell.2012.02.032; Dupuy AJ, 2005, NATURE, V436, P221, DOI 10.1038/nature03691; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; Frezza C, 2011, NATURE, V477, P225, DOI 10.1038/nature10363; Frezza C, 2011, J MOL MED, V89, P213, DOI 10.1007/s00109-011-0728-4; Frizzell N, 2011, FREE RADICAL RES, V45, P101, DOI 10.3109/10715762.2010.524643; Frizzell N, 2009, J BIOL CHEM, V284, P25772, DOI 10.1074/jbc.M109.019257; Gaal J, 2010, J CLIN ENDOCR METAB, V95, P1274, DOI 10.1210/jc.2009-2170; Gimenez-Roqueplo AP, 2003, CANCER RES, V63, P5615; Gimenez-Roqueplo AP, 2001, AM J HUM GENET, V69, P1186, DOI 10.1086/324413; Glunde K, 2011, NAT REV CANCER, V11, P835, DOI 10.1038/nrc3162; Gottlieb E, 2005, NAT REV CANCER, V5, P857, DOI 10.1038/nrc1737; Guzy RD, 2008, MOL CELL BIOL, V28, P718, DOI 10.1128/MCB.01338-07; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hanan EJ, 2012, J MED CHEM, V55, P10090, DOI 10.1021/jm3012239; Hao HX, 2009, SCIENCE, V325, P1139, DOI 10.1126/science.1175689; Hayes JD, 2010, ANTIOXID REDOX SIGN, V13, P1713, DOI 10.1089/ars.2010.3221; Hayes JD, 2009, TRENDS BIOCHEM SCI, V34, P176, DOI 10.1016/j.tibs.2008.12.008; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hemerly JP, 2010, EUR J ENDOCRINOL, V163, P747, DOI 10.1530/EJE-10-0473; Hewitson KS, 2007, J BIOL CHEM, V282, P3293, DOI 10.1074/jbc.M608337200; Isaacs JS, 2005, CANCER CELL, V8, P143, DOI 10.1016/j.ccr.2005.06.017; Ishii T, 2005, CANCER RES, V65, P203; Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597; Ito S, 2010, NATURE, V466, P1129, DOI 10.1038/nature09303; Itoh Ken, 2009, Seikagaku, V81, P447; Janeway KA, 2011, P NATL ACAD SCI USA, V108, P314, DOI 10.1073/pnas.1009199108; Kaelin WG, 2008, NAT REV CANCER, V8, P865, DOI 10.1038/nrc2502; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kaelin WG, 2009, GENOME MED, V1, DOI 10.1186/gm99; Kaelin WG, 2009, CANCER CELL, V16, P180, DOI 10.1016/j.ccr.2009.08.013; Kang MR, 2009, INT J CANCER, V125, P353, DOI 10.1002/ijc.24379; Kiuru M, 2001, AM J PATHOL, V159, P825, DOI 10.1016/S0002-9440(10)61757-9; KNUDSON AG, 1971, P NATL ACAD SCI USA, V68, P820, DOI 10.1073/pnas.68.4.820; Ko M, 2010, NATURE, V468, P839, DOI 10.1038/nature09586; Koglin N, 2011, CLIN CANCER RES, V17, P6000, DOI 10.1158/1078-0432.CCR-11-0687; Koivunen P, 2007, J BIOL CHEM, V282, P4524, DOI 10.1074/jbc.M610415200; Koivunen P, 2012, NATURE, V483, P485, DOI 10.1038/nature10898; Korpershoek E, 2011, J CLIN ENDOCR METAB, V96, pE1472, DOI 10.1210/jc.2011-1043; Launonen V, 2001, P NATL ACAD SCI USA, V98, P3387, DOI 10.1073/pnas.051633798; Lehtonen HJ, 2006, J MED GENET, V43, P523, DOI 10.1136/jmg.2005.036400; Lenders JWM, 2005, LANCET, V366, P665, DOI 10.1016/S0140-6736(05)67139-5; Leonardi R, 2012, J BIOL CHEM, V287, P14615, DOI 10.1074/jbc.C112.353946; Linehan WM, 2007, CLIN CANCER RES, V13, p671S, DOI 10.1158/1078-0432.CCR-06-1870; Lorsbach RB, 2003, LEUKEMIA, V17, P637, DOI 10.1038/sj.leu.2402834; Losman JA, 2013, SCIENCE, V339, P1621, DOI 10.1126/science.1231677; Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860; MacKenzie ED, 2007, MOL CELL BIOL, V27, P3282, DOI 10.1128/MCB.01927-06; Maher EA, 2012, NMR BIOMED, V25, P1234, DOI 10.1002/nbm.2794; Marcucci G, 2010, J CLIN ONCOL, V28, P2348, DOI 10.1200/JCO.2009.27.3730; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Maxwell PH, 2011, J PATHOL, V225, P1, DOI 10.1002/path.2950; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602; Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016; Mullen AR, 2012, NATURE, V481, P385, DOI 10.1038/nature10642; Murugan AK, 2010, BIOCHEM BIOPH RES CO, V393, P555, DOI 10.1016/j.bbrc.2010.02.095; Nagai R, 2007, J BIOL CHEM, V282, P34219, DOI 10.1074/jbc.M703551200; Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200; Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551; Noushmehr H, 2010, CANCER CELL, V17, P510, DOI 10.1016/j.ccr.2010.03.017; O'Flaherty L, 2010, HUM MOL GENET, V19, P3844, DOI 10.1093/hmg/ddq305; Ooi A, 2013, CANCER RES, V73, P2044, DOI 10.1158/0008-5472.CAN-12-3227; Ooi A, 2011, CANCER CELL, V20, P511, DOI 10.1016/j.ccr.2011.08.024; Pansuriya TC, 2011, NAT GENET, V43, P1256, DOI 10.1038/ng.1004; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pasini B, 2009, J INTERN MED, V266, P19, DOI 10.1111/j.1365-2796.2009.02111.x; Piruat JI, 2004, MOL CELL BIOL, V24, P10933, DOI 10.1128/MCB.24.24.10933-10940.2004; Pollard P, 2005, J PATHOL, V205, P41, DOI 10.1002/path.1686; Pollard PJ, 2007, CANCER CELL, V11, P311, DOI 10.1016/j.ccr.2007.02.005; Pollard PJ, 2009, SCIENCE, V324, P192, DOI 10.1126/science.1173362; Pollard PJ, 2005, HUM MOL GENET, V14, P2231, DOI 10.1093/hmg/ddi227; Qu WC, 2011, J AM CHEM SOC, V133, P1122, DOI 10.1021/ja109203d; Rankin EB, 2006, CANCER RES, V66, P2576, DOI 10.1158/0008-5472.CAN-05-3241; Ratcliffe PJ, 2007, CANCER CELL, V11, P303, DOI 10.1016/j.ccr.2007.03.015; Rawson JB, 2012, NUTR CANCER, V64, P919, DOI 10.1080/01635581.2012.711418; Ricketts C, 2008, J NATL CANCER I, V100, P1260, DOI 10.1093/jnci/djn254; Salway J.G., 2017, METABOLISM GLANCE; Sasaki M, 2012, GENE DEV, V26, P2038, DOI 10.1101/gad.198200.112; Sasaki M, 2012, NATURE, V488, P656, DOI 10.1038/nature11323; Scatena R, 2007, AM J PHYSIOL-CELL PH, V293, pC12, DOI 10.1152/ajpcell.00314.2006; Schulze A, 2012, NATURE, V491, P364, DOI 10.1038/nature11706; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; SHAMBAUGH GE, 1977, AM J CLIN NUTR, V30, P2083, DOI 10.1093/ajcn/30.12.2083; Shi Y, 2007, NAT REV GENET, V8, P829, DOI 10.1038/nrg2218; Shibata T, 2011, AM J PATHOL, V178, P1395, DOI 10.1016/j.ajpath.2010.12.011; Soga T, 2003, J PROTEOME RES, V2, P488, DOI 10.1021/pr034020m; Soga T, 2006, J BIOL CHEM, V281, P16768, DOI 10.1074/jbc.M601876200; Soga T, 2009, ANAL CHEM, V81, P6165, DOI 10.1021/ac900675k; STEPINSKI J, 1989, AM J KIDNEY DIS, V14, P307, DOI 10.1016/S0272-6386(89)80209-4; Stratton MR, 2013, EMBO MOL MED, V5, P169, DOI 10.1002/emmm.201202388; Sudarshan S, 2009, MOL CELL BIOL, V29, P4080, DOI 10.1128/MCB.00483-09; Taguchi K, 2011, GENES CELLS, V16, P123, DOI 10.1111/j.1365-2443.2010.01473.x; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Tan AY, 2009, J MOL CELL BIOL, V1, P82, DOI 10.1093/jmcb/mjp025; Ternette N, 2013, CELL REP, V3, P689, DOI 10.1016/j.celrep.2013.02.013; Thomas SA, 2012, OBESITY, V20, P263, DOI 10.1038/oby.2011.340; Thompson CB, 2009, NEW ENGL J MED, V360, P813, DOI 10.1056/NEJMe0810213; Tomita M, 2012, SCIENCE, V336, P990, DOI 10.1126/science.1223066; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; Toro JR, 2003, AM J HUM GENET, V73, P95, DOI 10.1086/376435; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Traykova-Brauch M, 2008, NAT MED, V14, P979, DOI 10.1038/nm.1865; Turcan S, 2012, NATURE, V483, P479, DOI 10.1038/nature10866; van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349; van Nederveen FH, 2009, LANCET ONCOL, V10, P764, DOI 10.1016/S1470-2045(09)70164-0; Vanharanta S, 2004, AM J HUM GENET, V74, P153, DOI 10.1086/381054; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Varier RA, 2011, BBA-REV CANCER, V1815, P75, DOI 10.1016/j.bbcan.2010.10.002; WARBURG O, 1956, SCIENCE, V124, P269; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Ward PS, 2012, ONCOGENE, V31, P2491, DOI 10.1038/onc.2011.416; Ward PS, 2012, CANCER CELL, V21, P297, DOI 10.1016/j.ccr.2012.02.014; Wise DR, 2011, P NATL ACAD SCI USA, V108, P19611, DOI 10.1073/pnas.1117773108; Xiao MT, 2012, GENE DEV, V26, P1326, DOI 10.1101/gad.191056.112; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yang M, 2012, FRONT ONCOL, V2, P1, DOI 10.3389/fonc.2012.00085; Yang YF, 2012, CANCER GENET-NY, V205, P377, DOI 10.1016/j.cancergen.2012.05.001; Yang Y, 2010, CANCER GENET CYTOGEN, V196, P45, DOI 10.1016/j.cancergencyto.2009.08.018; Yogev O, 2011, FEBS J, V278, P4230, DOI 10.1111/j.1742-4658.2011.08359.x; Yogev O, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000328; Young RM, 2012, NAT MED, V18, P1024, DOI 10.1038/nm.2865; Zhang DD, 2006, DRUG METAB REV, V38, P769, DOI 10.1080/03602530600971974	158	62	65	0	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2014	33	20					2547	2556		10.1038/onc.2013.222	http://dx.doi.org/10.1038/onc.2013.222			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH9YT	23812428				2022-12-28	WOS:000336502700001
J	Francescone, R; Ngernyuang, N; Yan, W; Bentley, B; Shao, R				Francescone, R.; Ngernyuang, N.; Yan, W.; Bentley, B.; Shao, R.			Tumor-derived mural-like cells coordinate with endothelial cells: role of YKL-40 in mural cell-mediated angiogenesis	ONCOGENE			English	Article						YKL-40; cadherins; vessel permeability; mural cells; tumor angiogenesis; VEGF	CHITINASE PROTEIN FAMILY; VE-CADHERIN; GROWTH-FACTOR; VESSEL MATURATION; BREAST-CANCER; N-CADHERIN; VASCULAR MORPHOGENESIS; COLORECTAL-CANCER; ADHERENS JUNCTION; ANDES VIRUS	Tumor neo-vasculature is characterized by spatial coordination of endothelial cells with mural cells, which delivers oxygen and nutrients. Here, we explored a key role of the secreted glycoprotein YKL-40, a mesenchymal marker, in the interaction between endothelial cells and mesenchymal mural-like cells for tumor angiogenesis. Xenotransplantation of tumor-derived mural-like cells (GSDCs) expressing YKL-40 in mice developed extensive and stable blood vessels covered with more GSDCs than those in YKL-40 gene knockdown tumors. YKL-40 expressed by GSDCs was associated with increased interaction of neural cadherin/beta-catenin/smooth muscle alpha actin; thus, mediating cell-cell adhesion and permeability. YKL-40 also induced the interaction of vascular endothelial cadherin/beta-catenin/actin in endothelial cells (HMVECs). In cell co-culture systems, YKL-40 enhanced both GSDC and HMVEC contacts, restricted vascular leakage, and stabilized vascular networks. Collectively, the data inform new mechanistic insights into the cooperation of mural cells with endothelial cells induced by YKL-40 during tumor angiogenesis, and also enhance our understanding of YKL-40 in both mural and endothelial cell biology.	[Francescone, R.; Shao, R.] Univ Massachusetts, Morrill Sci Ctr, Mol & Cellular Biol Program, Amherst, MA 01003 USA; [Ngernyuang, N.] Khon Khaen Univ, Grad Sch, Khon Khaen, Thailand; [Yan, W.; Bentley, B.; Shao, R.] Pioneer Valley Life Sci Inst, Springfield, MA USA; [Shao, R.] Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst; Khon Kaen University; University of Massachusetts System; University of Massachusetts Amherst	Shao, R (corresponding author), Univ Massachusetts Amherst, Pioneer Valley Life Sci Inst, Springfield, MA 01107 USA.	rong.shao@bhs.org		Francescone, Ralph/0000-0002-3149-6825; Ngernyuang, Nipaporn/0000-0002-8586-6115	NCI [R01 CA120659]; CEAR grant, John Adams Innovation Institute, Massachusetts; NATIONAL CANCER INSTITUTE [R01CA120659] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); CEAR grant, John Adams Innovation Institute, Massachusetts; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NCI R01 CA120659 and CEAR grant, John Adams Innovation Institute, Massachusetts (RS).	Abramsson A, 2003, J CLIN INVEST, V112, P1142, DOI 10.1172/JCI200318549; Armulik A, 2011, DEV CELL, V21, P193, DOI 10.1016/j.devcel.2011.07.001; Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929; Bergmann OJ, 2005, CLIN CANCER RES, V11, P8644, DOI 10.1158/1078-0432.CCR-05-1317; Bloch W, 2000, FASEB J, V14, P2373; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Carmeliet P, 2011, NAT REV DRUG DISCOV, V10, P417, DOI 10.1038/nrd3455; Chambers RC, 2003, AM J PATHOL, V162, P533, DOI 10.1016/S0002-9440(10)63847-3; Chen XL, 2012, DEV CELL, V22, P146, DOI 10.1016/j.devcel.2011.11.002; Cintin C, 1999, BRIT J CANCER, V79, P1494, DOI 10.1038/sj.bjc.6690238; Dejana E, 2008, J CELL SCI, V121, P2115, DOI 10.1242/jcs.017897; Dejana E, 2009, DEV CELL, V16, P209, DOI 10.1016/j.devcel.2009.01.004; Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133; Erber R, 2003, FASEB J, V17, P338, DOI 10.1096/fj.03-0271fje; Faibish M, 2011, MOL CANCER THER, V10, P742, DOI 10.1158/1535-7163.MCT-10-0868; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; Francescone R, 2012, J BIOL CHEM, V287, P24821, DOI 10.1074/jbc.M111.334540; Francescone RA, 2011, J BIOL CHEM, V286, P15332, DOI 10.1074/jbc.M110.212514; Fusetti F, 2003, J BIOL CHEM, V278, P37753, DOI 10.1074/jbc.M303137200; Gavard J, 2006, NAT CELL BIOL, V8, P1223, DOI 10.1038/ncb1486; Gerhardt H, 2000, DEV DYNAM, V218, P472, DOI 10.1002/1097-0177(200007)218:3<472::AID-DVDY1008>3.0.CO;2-#; Gerhardt H, 2008, J MOL MED, V86, P135, DOI 10.1007/s00109-007-0258-2; Gorbunova E, 2010, J VIROL, V84, P7405, DOI 10.1128/JVI.00576-10; Greenberg JI, 2008, NATURE, V456, P809, DOI 10.1038/nature07424; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Helfrich I, 2010, J EXP MED, V207, P491, DOI 10.1084/jem.20091846; Hellberg C, 2010, RECENT RESULTS CANC, V180, P103, DOI 10.1007/978-3-540-78281-0_7; Hellstrom M, 2001, J CELL BIOL, V153, P543, DOI 10.1083/jcb.153.3.543; Hogdall EVS, 2003, ONCOL REP, V10, P1535; Hottinger AF, 2011, ANN NEUROL, V70, P163, DOI 10.1002/ana.22360; Hu B, 1996, J BIOL CHEM, V271, P19415, DOI 10.1074/jbc.271.32.19415; Huang FJ, 2010, DEV BIOL, V344, P1035, DOI 10.1016/j.ydbio.2010.06.023; Jain RK, 2003, NAT MED, V9, P685, DOI 10.1038/nm0603-685; Jayson GC, 2005, J CLIN ONCOL, V23, P973, DOI 10.1200/JCO.2005.01.032; Jensen BV, 2003, CLIN CANCER RES, V9, P4423; JOHANSEN JS, 1992, J BONE MINER RES, V7, P501; Kzhyshkowska J, 2007, BIOMARK INSIGHTS, V2, P128; Lambeng N, 2005, CIRC RES, V96, P384, DOI 10.1161/01.RES.0000156652.99586.9f; Lin MI, 2007, CANCER RES, V67, P2849, DOI 10.1158/0008-5472.CAN-06-4082; Liu JQ, 2011, CLIN CANCER RES, V17, P3638, DOI 10.1158/1078-0432.CCR-10-2456; Luo Y, 2006, DEV BIOL, V299, P517, DOI 10.1016/j.ydbio.2006.09.003; Nakamura Y, 2008, CIRC RES, V102, P1182, DOI 10.1161/CIRCRESAHA.107.167080; NYIRKOS P, 1990, BIOCHEM J, V269, P265, DOI 10.1042/bj2690265; Orlova VV, 2006, J EXP MED, V203, P2703, DOI 10.1084/jem.20051730; Paik JH, 2004, GENE DEV, V18, P2392, DOI 10.1101/gad.1227804; Pelloski CE, 2005, CLIN CANCER RES, V11, P3326, DOI 10.1158/1078-0432.CCR-04-1765; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Rehli M, 1997, GENOMICS, V43, P221, DOI 10.1006/geno.1997.4778; Renkema GH, 1998, EUR J BIOCHEM, V251, P504, DOI 10.1046/j.1432-1327.1998.2510504.x; SHACKELTON LM, 1995, J BIOL CHEM, V270, P13076, DOI 10.1074/jbc.270.22.13076; Shao R, 2009, ONCOGENE, V28, P4456, DOI 10.1038/onc.2009.292; Shay-Salit A, 2002, P NATL ACAD SCI USA, V99, P9462, DOI 10.1073/pnas.142224299; Shrivastava-Ranjan P, 2010, J VIROL, V84, P11227, DOI 10.1128/JVI.01405-10; Stockmann C, 2008, NATURE, V456, P814, DOI 10.1038/nature07445; Tomasek JJ, 2002, NAT REV MOL CELL BIO, V3, P349, DOI 10.1038/nrm809; Vestweber D, 2008, ARTERIOSCL THROM VAS, V28, P223, DOI 10.1161/ATVBAHA.107.158014; Weis S, 2004, J CELL BIOL, V167, P223, DOI 10.1083/jcb.200408130; Yan W, 2008, MOL BIOL CELL, V19, P2278, DOI 10.1091/mbc.E07-10-1068; Yan W, 2010, J BIOL CHEM, V285, P14042, DOI 10.1074/jbc.M110.105262; Yonenaga Y, 2005, ONCOLOGY-BASEL, V69, P159, DOI 10.1159/000087840	61	25	26	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2014	33	16					2110	2122		10.1038/onc.2013.160	http://dx.doi.org/10.1038/onc.2013.160			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF3GH	23665676	Green Accepted			2022-12-28	WOS:000334599100010
J	Pedersen, K; Canals, F; Prat, A; Tabernero, J; Arribas, J				Pedersen, K.; Canals, F.; Prat, A.; Tabernero, J.; Arribas, J.			PELO negatively regulates HER receptor signalling and metastasis	ONCOGENE			English	Article						breast cancer; EGFR; metastasis; p95HER2; PELO; PI3K	GROWTH-FACTOR RECEPTOR; BREAST-CANCER METASTASIS; MOLECULAR CHARACTERIZATION; KINASE INHIBITOR; PROTEIN; NETWORK; PHOSPHORYLATION; PROTEOMICS; CARCINOMA; MIGRATION	The HER family is composed of four receptor tyrosine kinases, which are frequently deregulated in several types of cancer. Activated HER receptors initiate intracellular signalling pathways by attracting to the plasma membrane a plethora of adaptor and signalling molecules. Although there are more than a dozen HER-interacting proteins that regulate signal transduction and have been extensively studied, recent proteomic studies have shown the existence of many novel but largely uncharacterized factors that may bind HER receptors. In this report, we describe a cell-based identification of several new HER2-binding proteins, including HAX1, YWHAZ, PELO and ACP1. Analysis of these factors showed that one of them, PELO, binds to active HER2 and epidermal growth factor receptor and thereby attenuates phosphatidylinositol 3-kinase (PI3K)/AKT signalling, likely through regulation of the recruitment of p85-PI3K to activated receptor. Functional characterization of PELO showed that it negatively regulates cell migration and metastasis in vivo. These results reveal that PELO is a novel regulator of HER-signalling and therefore is likely to have a role in inhibiting tumour progression and invasion.	[Pedersen, K.; Canals, F.; Arribas, J.] Vall Hebron Inst Oncol, Preclin Res Program, Barcelona 08035, Spain; [Prat, A.] VHIO, Translat Genom Res Program, Barcelona 08035, Spain; [Tabernero, J.] VHIO, Clin Res Program, Barcelona 08035, Spain; [Arribas, J.] Univ Autonoma Barcelona, Dept Biochem & Mol Biol, Bellaterra, Spain; [Arribas, J.] ICREA, Barcelona, Spain	Vall d'Hebron Institut d'Oncologia (VHIO); Vall d'Hebron Institut d'Oncologia (VHIO); Autonomous University of Barcelona; ICREA	Pedersen, K (corresponding author), Vall Hebron Inst Oncol, Preclin Res Program, Psg Vall Hebron 119-129, Barcelona 08035, Spain.	kp@kim-pedersen.com; jarribas@vhio.net	Tabernero, Josep/AAG-5026-2019; Prat, Aleix/P-8561-2014; Arribas, Jose R/A-1595-2015; Arribas, Joaquin/M-4482-2014	Tabernero, Josep/0000-0002-2495-8139; Prat, Aleix/0000-0003-2377-540X; Arribas, Joaquin/0000-0002-0504-0664	Instituto de Salud Carlos III [PI081154]; Instituto de Salud Carlos III (network of cooperative cancer research) [RTICC-RD06/0020/0022]; Breast Cancer Research Foundation; Asociacion Espanola Contra el Cancer (AECC); AVON Foundation; AECC; ICREA Funding Source: Custom	Instituto de Salud Carlos III(Instituto de Salud Carlos IIIEuropean Commission); Instituto de Salud Carlos III (network of cooperative cancer research); Breast Cancer Research Foundation; Asociacion Espanola Contra el Cancer (AECC); AVON Foundation; AECC; ICREA(ICREA)	This work was supported by the Instituto de Salud Carlos III (Intrasalud PI081154 and the network of cooperative cancer research (RTICC-RD06/0020/0022)), the Breast Cancer Research Foundation, the Asociacion Espanola Contra el Cancer (AECC) and AVON Foundation. KP was supported by the postdoctoral program from the AECC.	Adham IM, 2003, MOL CELL BIOL, V23, P1470, DOI 10.1128/MCB.23.4.1470-1476.2003; Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Blagoev B, 2003, NAT BIOTECHNOL, V21, P315, DOI 10.1038/nbt790; Burnicka-Turek O, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-28; Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962; Davis L, 1998, GENETICS, V149, P45; EBERHART CG, 1995, DEVELOPMENT, V121, P3477; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Garcia-Castillo J, 2009, J BIOL CHEM, V284, P25302, DOI 10.1074/jbc.M109.001982; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Kang YB, 2003, CANCER CELL, V3, P537, DOI 10.1016/S1535-6108(03)00132-6; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Moasser MM, 2001, CANCER RES, V61, P7184; Morandell S, 2008, PROTEOMICS, V8, P4383, DOI 10.1002/pmic.200800204; Mukherjee M, 2012, EMBO J, V31, P1308, DOI 10.1038/emboj.2011.496; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220; Oppel F, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-137; Pedersen K, 2009, MOL CELL BIOL, V29, P3319, DOI 10.1128/MCB.01803-08; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Rhodes N, 2008, CANCER RES, V68, P2366, DOI 10.1158/0008-5472.CAN-07-5783; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Schulze WX, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100012; Segatto O, 2011, J CELL SCI, V124, P1785, DOI 10.1242/jcs.083303; STOVER DR, 1995, J BIOL CHEM, V270, P15591, DOI 10.1074/jbc.270.26.15591; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Yaffe MB, 2002, NAT REV MOL CELL BIO, V3, P177, DOI 10.1038/nrm759; Yarden Y, 2012, NAT REV CANCER, V12, P553, DOI 10.1038/nrc3309; Zhout PC, 2003, J BIOL CHEM, V278, P13829, DOI 10.1074/jbc.M209640200	33	10	10	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2014	33	9					1190	1197		10.1038/onc.2013.35	http://dx.doi.org/10.1038/onc.2013.35			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XT	23435426				2022-12-28	WOS:000331933800012
J	Weingarten-Gabbay, S; Khan, D; Liberman, N; Yoffe, Y; Bialik, S; Das, S; Oren, M; Kimchi, A				Weingarten-Gabbay, S.; Khan, D.; Liberman, N.; Yoffe, Y.; Bialik, S.; Das, S.; Oren, M.; Kimchi, A.			The translation initiation factor DAP5 promotes IRES-driven translation of p53 mRNA	ONCOGENE			English	Article						p53; Delta 40p53; DAP5; IRES; translational control	RIBOSOME ENTRY SITE; ENDOPLASMIC-RETICULUM STRESS; PROGRAMMED CELL-DEATH; MEDIATED TRANSLATION; EXPRESSION ANALYSIS; CASPASE CLEAVAGE; FACTOR 4G; ISOFORMS; IDENTIFICATION; INDUCTION	Translational regulation of the p53 mRNA can determine the ratio between p53 and its N-terminal truncated isoforms and therefore has a significant role in determining p53-regulated signaling pathways. Although its importance in cell fate decisions has been demonstrated repeatedly, little is known about the regulatory mechanisms that determine this ratio. Two internal ribosome entry sites (IRESs) residing within the 5'UTR and the coding sequence of p53 mRNA drive the translation of full-length p53 and Delta 40p53 isoform, respectively. Here, we report that DAP5, a translation initiation factor shown to positively regulate the translation of various IRES containing mRNAs, promotes IRES-driven translation of p53 mRNA. Upon DAP5 depletion, p53 and Delta 40p53 protein levels were decreased, with a greater effect on the N-terminal truncated isoform. Functional analysis using bicistronic vectors driving the expression of a reporter gene from each of these two IRESs indicated that DAP5 preferentially promotes translation from the second IRES residing in the coding sequence. Furthermore, p53 mRNA expressed from a plasmid carrying this second IRES was selectively shifted to lighter polysomes upon DAP5 knockdown. Consequently, Delta 40p53 protein levels and the subsequent transcriptional activation of the 14-3-3 sigma gene, a known target of Delta 40p53, were strongly reduced. In addition, we show here that DAP5 interacts with p53 IRES elements in in vitro and in vivo binding studies, proving for the first time that DAP5 directly binds a target mRNA. Thus, through its ability to regulate IRES-dependent translation of the p53 mRNA, DAP5 may control the ratio between different p53 isoforms encoded by a single mRNA.	[Weingarten-Gabbay, S.; Liberman, N.; Yoffe, Y.; Bialik, S.; Kimchi, A.] Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; [Khan, D.; Das, S.] Indian Inst Sci, Dept Microbiol & Cell Biol, Bangalore 560012, Karnataka, India; [Oren, M.] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Indian Institute of Science (IISC) - Bangalore; Weizmann Institute of Science	Kimchi, A (corresponding author), Weizmann Inst Sci, Dept Mol Genet, 234 Herzl St, IL-76100 Rehovot, Israel.	adi.kimchi@weizmann.ac.il		Khan, Debjit/0000-0001-5568-3361; Oren, Moshe/0000-0003-4311-7172	Flight Attendant Medical Research Institute; European Union FP7 APO-SYS; Indo French Centre for the Promotion of Advanced Research; Department of Biotechnology, India; Council of Scientific and Industrial Research, India	Flight Attendant Medical Research Institute; European Union FP7 APO-SYS; Indo French Centre for the Promotion of Advanced Research; Department of Biotechnology, India(Department of Biotechnology (DBT) India); Council of Scientific and Industrial Research, India(Council of Scientific & Industrial Research (CSIR) - India)	We gratefully acknowledge Dr Robin Fahraeus and Dr Jean-Christophe Bourdon for the p53 cDNA constructs, the Israel Structure Proteomic Center (ISPC) at the Weizmann Institute for supplying recombinant DAP5 protein and Sylvia Wilder for technical help. This work was supported by grants from the Flight Attendant Medical Research Institute (to AK and MO), the European Union FP7 APO-SYS (to AK), the Indo French Centre for the Promotion of Advanced Research (to SD), the Department of Biotechnology, India (to SD), and a pre-doctoral fellowship from the Council of Scientific and Industrial Research, India (to DK). AK and MO are incumbents of the Helena Rubinstein Chair of Cancer Research and the Andre Lwoff Chair in Molecular Biology, respectively.	Bourougaa K, 2010, MOL CELL, V38, P78, DOI 10.1016/j.molcel.2010.01.041; Candeias MM, 2006, ONCOGENE, V25, P6936, DOI 10.1038/sj.onc.1209996; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Courtois S, 2002, ONCOGENE, V21, P6722, DOI 10.1038/sj.onc.1205874; Grover R, 2008, CELL CYCLE, V7, P2189, DOI 10.4161/cc.7.14.6271; Grover R, 2011, RNA BIOL, V8, P132, DOI 10.4161/rna.8.1.14260; Henis-Korenblit S, 2002, P NATL ACAD SCI USA, V99, P5400, DOI 10.1073/pnas.082102499; Henis-Korenblit S, 2000, MOL CELL BIOL, V20, P496, DOI 10.1128/MCB.20.2.496-506.2000; Herbreteau CH, 2005, NAT STRUCT MOL BIOL, V12, P1001, DOI 10.1038/nsmb1011; Imataka H, 1997, EMBO J, V16, P817, DOI 10.1093/emboj/16.4.817; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; LevyStrumpf N, 1997, MOL CELL BIOL, V17, P1615, DOI 10.1128/MCB.17.3.1615; Lewis SM, 2008, NUCLEIC ACIDS RES, V36, P168, DOI 10.1093/nar/gkm1007; Liberman N, 2008, J MOL BIOL, V383, P539, DOI 10.1016/j.jmb.2008.08.013; Maier B, 2004, GENE DEV, V18, P306, DOI 10.1101/gad.1162404; Marash L, 2005, CELL DEATH DIFFER, V12, P554, DOI 10.1038/sj.cdd.4401609; Marash L, 2008, MOL CELL, V30, P447, DOI 10.1016/j.molcel.2008.03.018; Marcel V, 2011, CELL DEATH DIFFER, V18, P1815, DOI 10.1038/cdd.2011.120; Murray-Zmijewski F, 2006, CELL DEATH DIFFER, V13, P962, DOI 10.1038/sj.cdd.4401914; Nevins TA, 2003, J BIOL CHEM, V278, P3572, DOI 10.1074/jbc.M206781200; Ohki R, 2007, CANCER SCI, V98, P189, DOI 10.1111/j.1349-7006.2006.00375.x; Powell DJ, 2008, CELL CYCLE, V7, P950, DOI 10.4161/cc.7.7.5626; Pudi R, 2003, J BIOL CHEM, V278, P12231, DOI 10.1074/jbc.M210287200; Ray PS, 2006, EMBO REP, V7, P404, DOI 10.1038/sj.embor.7400623; Shaughnessy JD, 1997, GENOMICS, V39, P192, DOI 10.1006/geno.1996.4502; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Warnakulasuriyarachchi D, 2004, J BIOL CHEM, V279, P17148, DOI 10.1074/jbc.M308737200; Yamanaka S, 1997, GENE DEV, V11, P321, DOI 10.1101/gad.11.3.321; Yang DQ, 2006, ONCOGENE, V25, P4613, DOI 10.1038/sj.onc.1209483; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801	30	47	48	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2014	33	5					611	618		10.1038/onc.2012.626	http://dx.doi.org/10.1038/onc.2012.626			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5GW	23318444				2022-12-28	WOS:000331125100009
J	Yachida, S; Iacobuzio-Donahue, CA				Yachida, S.; Iacobuzio-Donahue, C. A.			Evolution and dynamics of pancreatic cancer progression	ONCOGENE			English	Review						pancreatic cancer; metastasis; clonal evolution; genetics	TUMOR-SUPPRESSOR GENE; GROWTH-FACTOR-BETA; TGF-BETA; MESENCHYMAL TRANSITION; ACQUIRED-RESISTANCE; COLORECTAL-CANCER; CLONAL EVOLUTION; STROMAL CELLS; METASTASIS; MUTATIONS	Efficient metastasis is believed as the result of multiple genetic, epigenetic and/or post-translational events in the lifetime of a carcinoma. At the genetic level, these events may be categorized into those that occur during carcinogenesis, and those that occur during subclonal evolution. This review summarizes current knowledge of the genetics of pancreatic cancer from its initiation within a normal cell until the time that is has disseminated to distant organs, many features of which can be extrapolated to other solid tumor types. The implications of these findings to personalize genome analyses of an individual patient's tumor are also discussed.	[Yachida, S.; Iacobuzio-Donahue, C. A.] Johns Hopkins Med Inst, Dept Pathol, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD 21231 USA; [Yachida, S.] Natl Canc Ctr, Res Inst, Div Refractory Canc Res, Tokyo 104, Japan; [Iacobuzio-Donahue, C. A.] Johns Hopkins Med Inst, Dept Oncol, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD 21231 USA; [Iacobuzio-Donahue, C. A.] Johns Hopkins Med Inst, Dept Surg, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD 21231 USA	Johns Hopkins University; Johns Hopkins Medicine; National Cancer Center - Japan; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Iacobuzio-Donahue, CA (corresponding author), Johns Hopkins Med Inst, Dept Pathol, 1550 Orleans St,CRBII 343, Baltimore, MD 21231 USA.	CIACOBU@jhmi.edu	Iacobuzio-Donahue, Christine/ABF-1295-2020	Iacobuzio-Donahue, Christine/0000-0002-4672-3023	NCI [CA140599]; Grants-in-Aid for Scientific Research [23390326] Funding Source: KAKEN; NATIONAL CANCER INSTITUTE [R01CA140599] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This study was supported by NCI CA140599 (CID).	Attwooll C, 2005, J BIOL CHEM, V280, P1199, DOI 10.1074/jbc.M412509200; Balakrishnan A, 2007, CANCER RES, V67, P3545, DOI 10.1158/0008-5472.CAN-07-0065; Ballard MS, 2012, ADV CANCER RES, V114, P187, DOI 10.1016/B978-0-12-386503-8.00005-3; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Blackford A, 2009, CLIN CANCER RES, V15, P4674, DOI 10.1158/1078-0432.CCR-09-0227; Bozic I, 2010, P NATL ACAD SCI USA, V107, P18545, DOI 10.1073/pnas.1010978107; Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013; Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Canto MI, 2012, GASTROENTEROLOGY, V142, P796, DOI 10.1053/j.gastro.2012.01.005; Comen E, 2011, NAT REV CLIN ONCOL, V8, P369, DOI 10.1038/nrclinonc.2011.64; Crane CH, 2012, J CLIN ONCOL, V30, P4049, DOI 10.1200/JCO.2012.45.1799; Crane CH, 2011, J CLIN ONCOL, V29, P3037, DOI 10.1200/JCO.2010.33.8038; Dai JL, 1999, P NATL ACAD SCI USA, V96, P1427, DOI 10.1073/pnas.96.4.1427; Dai JL, 1998, CANCER RES, V58, P4592; Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219; Egan JB, 2012, BLOOD, V120, P1060, DOI 10.1182/blood-2012-01-405977; Egawa S, 2004, PANCREAS, V28, P235, DOI 10.1097/00006676-200404000-00004; Fidler IJ, 2011, SEMIN CANCER BIOL, V21, P71, DOI 10.1016/j.semcancer.2010.12.004; Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Gisselsson D, 2011, ADV CANCER RES, V112, P1, DOI 10.1016/B978-0-12-387688-1.00001-6; Goedegebuure P, 2011, CURR CANCER DRUG TAR, V11, P734, DOI 10.2174/156800911796191024; Grau AM, 1997, CANCER RES, V57, P3929; Grubor V, 2009, BLOOD, V113, P1294, DOI 10.1182/blood-2008-05-158865; Guo Z, 2010, SCIENCE, V330, P517, DOI 10.1126/science.1192912; Haeno H, 2012, CELL, V148, P362, DOI 10.1016/j.cell.2011.11.060; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Hiraoka N, 2006, CLIN CANCER RES, V12, P5423, DOI 10.1158/1078-0432.CCR-06-0369; Hruban RH, 2001, AM J SURG PATHOL, V25, P579, DOI 10.1097/00000478-200105000-00003; Hruban RH, 2000, CLIN CANCER RES, V6, P2969; Iacobuzio-Donahue CA, 2012, GUT, V61, P1085, DOI 10.1136/gut.2010.236026; Iacobuzio-Donahue CA, 2009, J CLIN ONCOL, V27, P1806, DOI 10.1200/JCO.2008.17.7188; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Jones S, 2008, P NATL ACAD SCI USA, V105, P4283, DOI 10.1073/pnas.0712345105; Kanda M, 2012, GASTROENTEROLOGY, V142, P730, DOI 10.1053/j.gastro.2011.12.042; Langley RR, 2011, INT J CANCER, V128, P2527, DOI 10.1002/ijc.26031; Larsson LG, 2011, SEMIN CANCER BIOL, V21, P367, DOI 10.1016/j.semcancer.2011.10.005; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Liu WN, 2009, NAT MED, V15, P559, DOI 10.1038/nm.1944; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Macgregor-Das AM, 2013, J SURG ONCOL, V107, P8, DOI 10.1002/jso.23213; Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Matthaei H, 2011, NAT REV GASTRO HEPAT, V8, P141, DOI 10.1038/nrgastro.2011.2; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107; Murakami M, 2010, MOL BIOL REP, V37, P1279, DOI 10.1007/s11033-009-9502-x; Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807; Navin N, 2010, GENOME RES, V20, P68, DOI 10.1101/gr.099622.109; Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Nik-Zainal S, 2012, CELL, V149, DOI 10.1016/j.cell.2012.04.023; Nishimori H, 2012, J BIOL CHEM, V287, P20037, DOI 10.1074/jbc.M112.353094; Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362; Oshima M, 2013, ANN SURG IN PRESS; Oskarsson T, 2011, NAT MED, V17, P867, DOI 10.1038/nm.2379; Park CY, 2011, CANCER SCI, V102, P1889, DOI 10.1111/j.1349-7006.2011.02014.x; Peng BL, 2002, CLIN CANCER RES, V8, P3628; Porembka MR, 2012, CANCER IMMUNOL IMMUN, V61, P1373, DOI 10.1007/s00262-011-1178-0; Provenzano PP, 2012, CANCER CELL, V21, P418, DOI 10.1016/j.ccr.2012.01.007; Rabinovich GA, 2007, ANNU REV IMMUNOL, V25, P267, DOI 10.1146/annurev.immunol.25.022106.141609; Salnikov AV, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046391; Semenza GL, 2013, ONCOGENE, V32, P4057, DOI 10.1038/onc.2012.578; Shain AH, 2012, P NATL ACAD SCI USA, V109, pE252, DOI 10.1073/pnas.1114817109; Shin EJ, 2012, GASTROENTEROL CLIN N, V41, P143, DOI 10.1016/j.gtc.2011.12.001; Shoushtari AN, 2011, NAT REV CLIN ONCOL, V8, P333, DOI 10.1038/nrclinonc.2011.65; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Sohn TA, 2000, J GASTROINTEST SURG, V4, P567, DOI 10.1016/S1091-255X(00)80105-5; Stathis A, 2010, NAT REV CLIN ONCOL, V7, P163, DOI 10.1038/nrclinonc.2009.236; Stratton MR, 2011, SCIENCE, V331, P1553, DOI 10.1126/science.1204040; Talmadge JE, 2010, CANCER RES, V70, P5649, DOI 10.1158/0008-5472.CAN-10-1040; Tascilar M, 2001, CLIN CANCER RES, V7, P4115; Turajlic S, 2012, GENOME RES, V22, P196, DOI 10.1101/gr.125591.111; Warshaw AL, 2012, CURR OPIN GASTROEN, V28, P488, DOI 10.1097/MOG.0b013e3283567f2c; Wilentz RE, 2000, AM J PATHOL, V156, P37, DOI 10.1016/S0002-9440(10)64703-7; Wilentz RE, 1998, CANCER RES, V58, P4740; Wu J, 2011, P NATL ACAD SCI USA, V108, P21188, DOI 10.1073/pnas.1118046108; Yachida S, 2012, CLIN CANCER RES, V18, P6339, DOI 10.1158/1078-0432.CCR-12-1215; Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515; Yachida S, 2009, ARCH PATHOL LAB MED, V133, P413, DOI 10.1043/1543-2165-133.3.413; Yang L, 2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhou SB, 1998, P NATL ACAD SCI USA, V95, P2412, DOI 10.1073/pnas.95.5.2412	88	135	138	1	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2013	32	45					5253	5260		10.1038/onc.2013.29	http://dx.doi.org/10.1038/onc.2013.29			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251IS	23416985	Green Accepted			2022-12-28	WOS:000326922100001
J	Zhang, N; Li, X; Wu, CW; Dong, Y; Cai, M; Mok, MTS; Wang, H; Chen, J; Ng, SSM; Chen, M; Sung, JJY; Yu, J				Zhang, N.; Li, X.; Wu, C. W.; Dong, Y.; Cai, M.; Mok, M. T. S.; Wang, H.; Chen, J.; Ng, S. S. M.; Chen, M.; Sung, J. J. Y.; Yu, J.			microRNA-7 is a novel inhibitor of YY1 contributing to colorectal tumorigenesis	ONCOGENE			English	Article						miR-7; YY1; p53; Wnt; colorectal cancer	COLON-CANCER CELLS; NEGATIVE REGULATOR; CERVICAL CANCERS; P53; APOPTOSIS; EXPRESSION; GENE; ACTIVATION; YIN-YANG-1; PROGRESSION	Using microRNA (miRNA) expression array, we identified that miR-7 was deregulated in colorectal cancer (CRC). We studied the biological role and molecular target of miR-7 in CRC. miR-7 was downregulated in six out of seven colon cancer cell lines. Ectopic expression of miR-7 suppressed colon cancer cell proliferation (P<0.05), induced apoptosis (P<0.05) and caused cell-cycle arrest in G1 phase (P<0.05). The tumor suppressive function of miR-7 was further confirmed in nude mice (P<0.05). The 3'-untranslated region (3'UTR) of Yin Yang 1 (YY1) mRNA contains an evolutionarily conserved miR-7 binding site using in silico searches, luciferase reporter assay and western blot analysis confirmed that miR-7 directly bound to YY1 3'UTR to negatively regulate the protein expression of YY1 in colon cancer cell lines HCT116 and LOVO. Intriguingly, knock-down of YY1 in three colon cancer cell lines (HCT116, LOVO and DLD1) consistently suppressed cell proliferation (P<0.01) and induced apoptosis (P<0.01), indicating the opposite functions of miR-7 and YY1 in CRC. Consistent with these data, ectopic expression of YY1 promoted cell growth by increasing proliferation (P<0.01) and suppressing apoptosis (P<0.001). The tumorigenic ability of YY1 was further confirmed in vivo in xenograft-nude mouse model (P<0.01). In addition, pathway analyses revealed that the oncogenic effect by YY1 was associated with inhibiting p53 and modulating its downstream effectors p15, caspase cascades and C-Jun, and activating Wnt signaling pathway through activating beta-catenin, anti-apoptotic survivin and fibroblast growth factor 4. Furthermore, multivariate analysis revealed that patients with YY1 protein high expression had a significant decrease in overall survival, and Kaplan-Meier survival curves showed that these patients had significantly shorter survival than others (P<0.0001). In conclusion, MiR-7 is a novel miRNA with tumor suppressive function in colon cancer by targeting oncogenic YY1. YY1 promotes colon cancer growth through inhibiting p53 and promoting Wnt signaling pathways and serves as an independent prognostic biomarker for CRC patients.	[Zhang, N.; Li, X.; Wu, C. W.; Dong, Y.; Mok, M. T. S.; Sung, J. J. Y.; Yu, J.] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Inst Digest Dis, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China; [Zhang, N.; Chen, J.; Chen, M.] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Gastroenterol, Guangzhou 510275, Guangdong, Peoples R China; [Dong, Y.; Ng, S. S. M.] Chinese Univ Hong Kong, Li Ka Shing Inst Hlth Sci, Dept Surg, Shatin, Hong Kong, Peoples R China; [Cai, M.] Sun Yat Sen Univ, Ctr Canc, Dept Pathol, Guangzhou 510275, Guangdong, Peoples R China; [Wang, H.] Chinese Univ Hong Kong, Sch Publ Hlth & Primary Care, Stanley Ho Ctr Emerging Infect Dis, Shatin, Hong Kong, Peoples R China	Chinese University of Hong Kong; Sun Yat Sen University; Chinese University of Hong Kong; Sun Yat Sen University; Chinese University of Hong Kong	Yu, J (corresponding author), Chinese Univ Hong Kong, Prince Wales Hosp, Inst Digest Dis, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China.	chenminhu@vip.163.com; junyu@cuhk.edu.hk	Yu, Jun/D-8569-2015; Sung, Joseph J. Y./R-3203-2018; Li, Xiao-xing/B-9114-2008; Mok, Myth/M-2958-2013; Ng, Simon S. M./M-1219-2018; Wang, Huating/C-6719-2014	Yu, Jun/0000-0001-5008-2153; Sung, Joseph J. Y./0000-0003-3125-5199; Li, Xiao-xing/0000-0001-8791-7505; Mok, Myth/0000-0003-3156-4944; Ng, Simon S. M./0000-0002-5389-9297; Wang, Huating/0000-0001-5474-2905	National High-tech R&D Program of China (863 program) [2012AA02A203, 2012AA02A506]; Innovation and Technology Fund Hong Kong [ITS/276/11]; CUHK [2010.1.085]; National Natural Science Foundation of China [81072048]	National High-tech R&D Program of China (863 program)(National High Technology Research and Development Program of China); Innovation and Technology Fund Hong Kong; CUHK(Chinese University of Hong Kong); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	This project was supported by National High-tech R&D Program of China (863 program, 2012AA02A203; 863 program, 2012AA02A506), Innovation and Technology Fund Hong Kong (ITS/276/11), CUHK direct grant (2010.1.085) and National Natural Science Foundation of China (81072048).	Akao Y, 2006, BIOL PHARM BULL, V29, P903, DOI 10.1248/bpb.29.903; Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; Balaguer F, 2010, CANCER RES, V70, P6609, DOI 10.1158/0008-5472.CAN-10-0622; Balciunaite G, 2002, NAT IMMUNOL, V3, P1102, DOI 10.1038/ni850; Baritaki S, 2007, INT J ONCOL, V31, P69; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Begon DY, 2005, J BIOL CHEM, V280, P24428, DOI 10.1074/jbc.M503790200; Bodine PVN, 2004, MOL ENDOCRINOL, V18, P1222, DOI 10.1210/me.2003-0498; Buckland RA, 1998, MECH DEVELOP, V71, P143, DOI 10.1016/S0925-4773(98)00008-2; Chen X, 2009, ONCOGENE, V28, P1385, DOI 10.1038/onc.2008.474; Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4; Dale TC, 1998, BIOCHEM J, V329, P209; DONG XP, 1994, INT J CANCER, V58, P803, DOI 10.1002/ijc.2910580609; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Gronroos E, 2004, P NATL ACAD SCI USA, V101, P12165, DOI 10.1073/pnas.0402283101; Jiang L, 2010, BIOCHEM J, V432, P199, DOI 10.1042/BJ20100859; Kefas B, 2008, CANCER RES, V68, P3566, DOI 10.1158/0008-5472.CAN-07-6639; Kimura Y, 1997, GENOMICS, V41, P477, DOI 10.1006/geno.1997.4680; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; MAY M, 1994, EMBO J, V13, P1460, DOI 10.1002/j.1460-2075.1994.tb06400.x; Ng EKO, 2009, GUT, V58, P1375, DOI 10.1136/gut.2008.167817; Nugent M, 2011, EJSO-EUR J SURG ONC, V37, P649, DOI 10.1016/j.ejso.2011.05.005; Pan HC, 1998, MOL CELL, V2, P283, DOI 10.1016/S1097-2765(00)80273-7; Pritchard CC, 2011, GUT, V60, P116, DOI 10.1136/gut.2009.206250; Reddy SDN, 2008, CANCER RES, V68, P8195, DOI 10.1158/0008-5472.CAN-08-2103; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; Schuler M, 2000, J BIOL CHEM, V275, P7337, DOI 10.1074/jbc.275.10.7337; Seligson D, 2005, INT J ONCOL, V27, P131; Su DM, 2003, NAT IMMUNOL, V4, P1128, DOI 10.1038/ni983; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Tago K, 2000, GENE DEV, V14, P1741; Tazawa H, 2007, P NATL ACAD SCI USA, V104, P15472, DOI 10.1073/pnas.0707351104; Thorne CA, 2010, NAT CHEM BIOL, V6, P829, DOI 10.1038/NCHEMBIO.453; Walther A, 2009, NAT REV CANCER, V9, P489, DOI 10.1038/nrc2645; Wang P, 2009, CANCER RES, V69, P8157, DOI 10.1158/0008-5472.CAN-09-1996; Wieler S, 2003, J BIOL CHEM, V278, P18914, DOI 10.1074/jbc.M211641200; Wu CW, 2012, GUT, V61, P739, DOI 10.1136/gut.2011.239236; Wu WKK, 2011, CARCINOGENESIS, V32, P247, DOI 10.1093/carcin/bgq243; Yokoyama NN, 2010, NUCLEIC ACIDS RES, V38, P6375, DOI 10.1093/nar/gkq492	40	159	180	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2013	32	42					5078	5088		10.1038/onc.2012.526	http://dx.doi.org/10.1038/onc.2012.526			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238IB	23208495				2022-12-28	WOS:000325937900009
J	Lang, UE; Kocabayoglu, P; Cheng, GZ; Ghiassi-Nejad, Z; Munoz, U; Vetter, D; Eckstein, DA; Hannivoort, RA; Walsh, MJ; Friedman, SL				Lang, U. E.; Kocabayoglu, P.; Cheng, G. Z.; Ghiassi-Nejad, Z.; Munoz, U.; Vetter, D.; Eckstein, D. A.; Hannivoort, R. A.; Walsh, M. J.; Friedman, S. L.			GSK3 beta phosphorylation of the KLF6 tumor suppressor promotes its transactivation of p21	ONCOGENE			English	Article						KLF6; GSK3 beta; p21; phosphorylation	BETA-CATENIN; TRANSCRIPTIONAL ACTIVATION; DOWN-REGULATION; GENE; DEGRADATION; FREQUENT; PROTEIN; TARGET; MOUSE	KLF6, a ubiquitously expressed Kruppel-like transcription factor, is frequently inactivated in human cancer and has significant roles in cellular proliferation, apoptosis, differentiation and development. A key mechanism of KLF6-mediated growth suppression is through p53-independent transactivation of p21. Several cancer-derived KLF6 mutants lead to the loss of p21-mediated growth suppression through an unknown mechanism. Because several colorectal cancer and hepatocellular carcinoma-derived KLF6 mutations affect a glycogen synthase kinase 3 beta (GSK3 beta) phosphorylation consensus site, we investigated the role of GSK3 beta in the regulation of KLF6 function. Based on transient transfection, GSK3 beta augments the transactivation of a p21 promoter luciferase by KLF6. Reciprocal co-immunoprecipitation of hemagglutinin (HA)-GSK3 beta and Flag-KLF6 validated the interaction between these two proteins. KLF6 phosphorylation is augmented in the presence of GSK3 beta based on in vitro and in vivo P-32 incorporation assays. Site-directed mutagenesis of the candidate phosphorylation sites to alanines ('KLF6-4A' phosphomutant) eliminated a higher molecular weight phosphorylated isoform of KLF6 based on western blot. GSK3 beta augmented the transactivation by wild-type KLF6, but not KLF6-4A, towards the p21 promoter, and increased p21 protein. Functionally, GSK3 beta enhanced KLF6-mediated growth suppression, which was abrogated by the KLF6-4A phosphomutant. These data establish that GSK3 beta directly phosphorylates KLF6, which augments its induction of p21 and resultant growth suppression. This interaction may account for the growth-promoting effects of cancer-derived KLF6 mutants that lack tumor suppressor activity.	[Lang, U. E.; Kocabayoglu, P.; Cheng, G. Z.; Ghiassi-Nejad, Z.; Munoz, U.; Vetter, D.; Eckstein, D. A.; Hannivoort, R. A.; Friedman, S. L.] Mt Sinai Sch Med, Div Liver Dis, New York, NY 10029 USA; [Walsh, M. J.] Mt Sinai Sch Med, Dept Struct & Chem Biol, New York, NY 10029 USA; [Walsh, M. J.] Mt Sinai Sch Med, Dept Pediat, New York, NY 10029 USA; [Walsh, M. J.] Mt Sinai Sch Med, Dept Genet & Genom Sci, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai	Friedman, SL (corresponding author), Mt Sinai Sch Med, Dept Med, Div Liver Dis, 1425 Madison Ave,Room 11-70C,Box 1123, New York, NY 10029 USA.	scott.friedman@mssm.edu	De Cock, Martine/B-8567-2009; MUÑOZ MORON, URSULA/L-4561-2017	De Cock, Martine/0000-0001-7917-0771; MUÑOZ MORON, URSULA/0000-0001-6024-4697	NIH [RO1DK37340, RO1DK 56621, 1K05 AA018408, 1P20 AA017067, 1RO1CA154809-01, T32GM00728]; Deutsche Forschungsgemeinschaft (DFG); Graduate School for Drug Exploration (GUIDE) [KO 4086/11]; Stichting Nicholaas Muleriusfonds, Groningen; Netherlands; Ellison Medical Foundation Senior Scholar Award in Aging [SS-AG2482-1]; Swiss National Fund (SNF); Alonso Martin Escudero foundation; NATIONAL CANCER INSTITUTE [R01CA154809] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL103967] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG004508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037340, R01DK056621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P20AA017067, K05AA018408] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Graduate School for Drug Exploration (GUIDE); Stichting Nicholaas Muleriusfonds, Groningen; Netherlands(Netherlands Government); Ellison Medical Foundation Senior Scholar Award in Aging(Lawrence Ellison Foundation); Swiss National Fund (SNF)(Swiss National Science Foundation (SNSF)); Alonso Martin Escudero foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	We thank Dr Ming-Ming Zhou at the Mount Sinai School of Medicine for his expert advice in protein purification of GST-KLF6. Dr Jin Q Cheng at H Lee Moffitt Cancer Center shared all GSK3b plasmids and contributed technical support for the in vivo kinase assays. We acknowledge funding support from the NIH (to SLF: RO1DK37340, RO1DK 56621, 1K05 AA018408, 1P20 AA017067; to MJW: 1RO1CA154809-01; to UEL and ZGN: T32GM00728), Deutsche Forschungsgemeinschaft (DFG) (to PK) KO 4086/11, Graduate School for Drug Exploration (GUIDE) and the Stichting Nicholaas Muleriusfonds, Groningen, the Netherlands (to RAH), the Ellison Medical Foundation Senior Scholar Award in Aging (SS-AG2482-1) (to MJW), the Swiss National Fund (SNF) (to DV) and the Alonso Martin Escudero foundation (to UM).	Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Banck MS, 2006, FEBS LETT, V580, P6981, DOI 10.1016/j.febslet.2006.10.077; Benzeno S, 2004, CANCER RES, V64, P3885, DOI 10.1158/0008-5472.CAN-03-2818; Botella LM, 2002, BLOOD, V100, P4001, DOI 10.1182/blood.V100.12.4001; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; Difeo A, 2006, ONCOGENE, V25, P6026, DOI 10.1038/sj.onc.1209611; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Huang HD, 2005, NUCLEIC ACIDS RES, V33, pW226, DOI 10.1093/nar/gki471; Kremer-Tal S, 2004, HEPATOLOGY, V40, P1047, DOI 10.1002/hep.20460; Kremer-Tal S, 2007, J HEPATOL, V46, P645, DOI 10.1016/j.jhep.2006.10.012; Lee UE, 2010, FEBS LETT, V584, P1006, DOI 10.1016/j.febslet.2010.01.049; Li D, 2005, J BIOL CHEM, V280, P26941, DOI 10.1074/jbc.M500463200; Li D, 2005, CANCER RES, V65, P9216, DOI 10.1158/0008-5472.CAN-05-1040; Li D, 2000, HEPATOLOGY, V32, p209A; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu N, 2010, J BIOL CHEM, V285, P18858, DOI 10.1074/jbc.M109.099440; Narla G, 2007, ONCOGENE, V26, P4428, DOI 10.1038/sj.onc.1210223; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Nejak-Bowen KN, 2011, SEMIN CANCER BIOL, V21, P44, DOI 10.1016/j.semcancer.2010.12.010; Pan Xiu-cheng, 2006, J Zhejiang Univ Sci B, V7, P830, DOI 10.1631/jzus.2006.B0830; Reeves HL, 2004, GASTROENTEROLOGY, V126, P1090, DOI 10.1053/j.gastro.2004.01.005; Reeves HL, 2003, HEPATOLOGY, V2002; Rodriguez E, 2010, PLOS ONE, V5, P9; Slavin DA, 2004, ONCOGENE, V23, P8196, DOI 10.1038/sj.onc.1208020; Warke VG, 2003, J BIOL CHEM, V278, P14812, DOI 10.1074/jbc.M300787200; Whittaker S, 2010, ONCOGENE, V29, P4989, DOI 10.1038/onc.2010.236; Yang JD, 2010, NAT REV GASTRO HEPAT, V7, P448, DOI 10.1038/nrgastro.2010.100; Zeng CX, 2010, HEPATOLOGY, V52, P1702, DOI 10.1002/hep.23875	28	34	36	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2013	32	38					4557	4564		10.1038/onc.2012.457	http://dx.doi.org/10.1038/onc.2012.457			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223SW	23085750	Green Accepted			2022-12-28	WOS:000324831300011
J	Goard, CA; Schimmer, AD				Goard, C. A.; Schimmer, A. D.			Mitochondrial matrix proteases as novel therapeutic targets in malignancy	ONCOGENE			English	Review						mitochondrial protease; m-AAA; ClpP; Lon; AAA; protein quality control	M-AAA PROTEASE; DEPENDENT LON PROTEASE; HEREDITARY SPASTIC PARAPLEGIA; ESCHERICHIA-COLI CLPP; RESPIRATORY-CHAIN COMPLEXES; ELECTRON-TRANSPORT CHAIN; SACCHAROMYCES-CEREVISIAE; OXIDATIVE STRESS; CRYSTAL-STRUCTURE; SERINE-PROTEASE	Although mitochondrial function is often altered in cancer, it remains essential for tumor viability. Tight control of protein homeostasis is required for the maintenance of mitochondrial function, and the mitochondrial matrix houses several coordinated protein quality control systems. These include three evolutionarily conserved proteases of the AAA + superfamily-the Lon, ClpXP and m-AAA proteases. In humans, these proteases are proposed to degrade, process and chaperone the assembly of mitochondrial proteins in the matrix and inner membrane involved in oxidative phosphorylation, mitochondrial protein synthesis, mitochondrial network dynamics and nucleoid function. In addition, these proteases are upregulated by a variety of mitochondrial stressors, including oxidative stress, unfolded protein stress and imbalances in respiratory complex assembly. Given that tumor cells must survive and proliferate under dynamic cellular stress conditions, dysregulation of mitochondrial protein quality control systems may provide a selective advantage. The association of mitochondrial matrix AAA + proteases with cancer and their potential for therapeutic modulation therefore warrant further consideration. Although our current knowledge of the endogenous human substrates of these proteases is limited, we highlight functional insights gained from cultured human cells, protease-deficient mouse models and other eukaryotic model organisms. We also review the consequences of disrupting mitochondrial matrix AAA + proteases through genetic and pharmacological approaches, along with implications of these studies on the potential of these proteases as anticancer therapeutic targets.	[Goard, C. A.; Schimmer, A. D.] Ontario Canc Inst, Princess Margaret Canc Ctr, Univ Hlth Network, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Schimmer, AD (corresponding author), Ontario Canc Inst, Princess Margaret Canc Ctr, Univ Hlth Network, 610 Univ Ave,Room 9-516, Toronto, ON M5G 2M9, Canada.	aaron.schimmer@utoronto.ca		Schimmer, Aaron/0000-0003-4023-3899				Almajan ER, 2012, J CLIN INVEST, V122, P4048, DOI 10.1172/JCI64604; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; Apweiler R, 2012, NUCLEIC ACIDS RES, V40, pD71, DOI 10.1093/nar/gkr981; Arlt H, 1998, EMBO J, V17, P4837, DOI 10.1093/emboj/17.16.4837; Arlt H, 1996, CELL, V85, P875, DOI 10.1016/S0092-8674(00)81271-4; Atorino L, 2003, J CELL BIOL, V163, P777, DOI 10.1083/jcb.200304112; Augustin S, 2009, MOL CELL, V35, P574, DOI 10.1016/j.molcel.2009.07.018; Bakala H, 2003, EUR J BIOCHEM, V270, P2295, DOI 10.1046/j.1432-1033.2003.03598.x; Baker TA, 2012, BBA-MOL CELL RES, V1823, P15, DOI 10.1016/j.bbamcr.2011.06.007; Balsa E, 2012, CELL METAB, V16, P378, DOI 10.1016/j.cmet.2012.07.015; Banfi S, 1999, GENOMICS, V59, P51, DOI 10.1006/geno.1999.5818; Bayot A, 2008, BIOCHIMIE, V90, P260, DOI 10.1016/j.biochi.2007.10.010; Bayot A, 2010, J BIOL CHEM, V285, P11445, DOI 10.1074/jbc.M109.065425; Bender T, 2011, MOL BIOL CELL, V22, P541, DOI 10.1091/mbc.E10-08-0718; Bender T, 2010, PROTEOMICS, V10, P1426, DOI 10.1002/pmic.200800619; Benedetti C, 2006, GENETICS, V174, P229, DOI 10.1534/genetics.106.061580; Bernstein SH, 2012, BLOOD, V119, P3321, DOI 10.1182/blood-2011-02-340075; Bottcher T, 2008, J AM CHEM SOC, V130, P14400, DOI 10.1021/ja8051365; Bogenhagen DF, 2008, J BIOL CHEM, V283, P3665, DOI 10.1074/jbc.M708444200; Bonn F, 2011, EMBO J, V30, P2545, DOI 10.1038/emboj.2011.169; Bonn F, 2010, HUM MUTAT, V31, P617, DOI 10.1002/humu.21226; Bota DA, 2002, NAT CELL BIOL, V4, P674, DOI 10.1038/ncb836; Bota DA, 2005, FREE RADICAL BIO MED, V38, P665, DOI 10.1016/j.freeradbiomed.2004.11.017; Bota DA, 2002, FEBS LETT, V532, P103, DOI 10.1016/S0014-5793(02)03638-4; Bross P, 1995, FEBS LETT, V377, P249, DOI 10.1016/0014-5793(95)01353-9; Brotz-Oesterhelt H, 2005, NAT MED, V11, P1082, DOI 10.1038/nm1306; Carroll J, 2006, J BIOL CHEM, V281, P32724, DOI 10.1074/jbc.M607135200; Casari G, 1998, CELL, V93, P973, DOI 10.1016/S0092-8674(00)81203-9; Cha SS, 2010, EMBO J, V29, P3520, DOI 10.1038/emboj.2010.226; Chen B, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004374; Cheng XL, 2005, J BIOCHEM, V138, P673, DOI 10.1093/jb/mvi169; Chondrogianni N, 2012, PROG MOL BIOL TRANSL, V109, P41, DOI 10.1016/B978-0-12-397863-9.00002-X; Cole A, 2012, BLOOD, V120, DOI 10.1182/blood.V120.21.3603.3603; Corydon TJ, 2000, MAMM GENOME, V11, P899, DOI 10.1007/s003350010173; Corydon TJ, 1998, BIOCHEM J, V331, P309, DOI 10.1042/bj3310309; da Fonseca PCA, 2012, MOL CELL, V46, P54, DOI 10.1016/j.molcel.2012.03.026; De Luca A, 2012, EXPERT OPIN THER TAR, V16, pS17, DOI 10.1517/14728222.2011.639361; de Sagarra MR, 1999, J MOL BIOL, V292, P819, DOI 10.1006/jmbi.1999.3121; Delaval E, 2004, EUR J BIOCHEM, V271, P4559, DOI 10.1111/j.1432-1033.2004.04422.x; Di Bella D, 2010, NAT GENET, V42, P313, DOI 10.1038/ng.544; Duvezin-Caubet S, 2007, MOL BIOL CELL, V18, P3582, DOI 10.1091/mbc.E07-02-0164; Ehses S, 2009, J CELL BIOL, V187, P1023, DOI 10.1083/jcb.200906084; Ferreirinha F, 2004, J CLIN INVEST, V113, P231, DOI 10.1172/JCI200420138; Fishovitz J, 2011, ACS CHEM BIOL, V6, P781, DOI 10.1021/cb100408w; Flynn JM, 2003, MOL CELL, V11, P671, DOI 10.1016/S1097-2765(03)00060-1; Fu GK, 1998, BIOCHEMISTRY-US, V37, P1905, DOI 10.1021/bi970928c; Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047; Garcia-Nafria J, 2010, PROTEIN SCI, V19, P987, DOI 10.1002/pro.376; Gerdes F, 2012, BBA-MOL CELL RES, V1823, P49, DOI 10.1016/j.bbamcr.2011.09.015; Gersch M, 2013, ANGEW CHEM INT EDIT, V52, P3009, DOI 10.1002/anie.201204690; Granot Z, 2007, MOL ENDOCRINOL, V21, P2164, DOI 10.1210/me.2005-0458; Greene AW, 2012, EMBO REP, V13, P378, DOI 10.1038/embor.2012.14; Guelin E, 1996, FEBS LETT, V381, P42, DOI 10.1016/0014-5793(96)00074-9; Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003; Hartkamp J, 2010, MOL CELL, V37, P159, DOI 10.1016/j.molcel.2009.12.023; Haynes CM, 2013, TRENDS CELL BIOL, VS0962-8924; Haynes CM, 2007, DEV CELL, V13, P467, DOI 10.1016/j.devcel.2007.07.016; Haynes CM, 2010, MOL CELL, V37, P529, DOI 10.1016/j.molcel.2010.01.015; Hirst J, 2003, BBA-BIOENERGETICS, V1604, P135, DOI 10.1016/S0005-2728(03)00059-8; Hori O, 2002, J CELL BIOL, V157, P1151, DOI 10.1083/jcb.200108103; Hornig-Do HT, 2012, EMBO J, V31, P1293, DOI 10.1038/emboj.2011.477; Ishihara N, 2006, EMBO J, V25, P2966, DOI 10.1038/sj.emboj.7601184; Jhaveri K, 2012, ADV PHARMACOL, V65, P471, DOI 10.1016/B978-0-12-397927-8.00015-4; Johnson F, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007100; Kang SG, 2005, J BIOL CHEM, V280, P35424, DOI 10.1074/jbc.M507240200; Kang SG, 2004, J STRUCT BIOL, V148, P338, DOI 10.1016/j.jsb.2004.07.004; Kang SG, 2002, J BIOL CHEM, V277, P21095, DOI 10.1074/jbc.M201642200; Karlberg T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006975; Kehrein K, 2013, ANTIOXID REDOX SIGN, V19, P1928, DOI 10.1089/ars.2012.4896; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; Kita K, 2012, J BIOL CHEM, V287, P18163, DOI 10.1074/jbc.M112.362699; Koppen M, 2007, MOL CELL BIOL, V27, P758, DOI 10.1128/MCB.01470-06; Koppen M, 2009, MOL BIOL CELL, V20, P4216, DOI 10.1091/mbc.E09-03-0218; Lagadinou ED, 2013, CELL STEM CELL, V12, P329, DOI 10.1016/j.stem.2012.12.013; Lee BG, 2010, NAT STRUCT MOL BIOL, V17, P471, DOI 10.1038/nsmb.1787; Lee CK, 1999, SCIENCE, V285, P1390, DOI 10.1126/science.285.5432.1390; Lee HJ, 2011, DIABETOLOGIA, V54, P1437, DOI 10.1007/s00125-011-2074-z; Lee S, 2011, J BIOL CHEM, V286, P4404, DOI 10.1074/jbc.M110.158741; Leonhard K, 2000, MOL CELL, V5, P629, DOI 10.1016/S1097-2765(00)80242-7; Leu JIJ, 2009, MOL CELL, V36, P15, DOI 10.1016/j.molcel.2009.09.023; Li DHS, 2010, CHEM BIOL, V17, P959, DOI 10.1016/j.chembiol.2010.07.008; Liu T, 2004, J BIOL CHEM, V279, P13902, DOI 10.1074/jbc.M309642200; Lowth BR, 2012, J STRUCT BIOL, V179, P193, DOI 10.1016/j.jsb.2012.06.001; Lu B, 2003, GENE, V306, P45, DOI 10.1016/S0378-1119(03)00403-7; Lu B, 2007, J BIOL CHEM, V282, P17363, DOI 10.1074/jbc.M611540200; Lu B, 2013, MOL CELL, V49, P121, DOI 10.1016/j.molcel.2012.10.023; Luciakova K, 1999, FEBS LETT, V444, P186, DOI 10.1016/S0014-5793(99)00058-7; Luo B, 2013, ONCOGENE, V32, P805, DOI 10.1038/onc.2012.130; Major T, 2006, MOL CELL BIOL, V26, P762, DOI 10.1128/MCB.26.3.762-776.2006; Maltecca F, 2008, J NEUROSCI, V28, P2827, DOI 10.1523/JNEUROSCI.4677-07.2008; Maltecca F, 2012, HUM MOL GENET, V21, P3858, DOI 10.1093/hmg/dds214; Maltecca F, 2009, J NEUROSCI, V29, P9244, DOI 10.1523/JNEUROSCI.1532-09.2009; Martinelli P, 2009, HUM MOL GENET, V18, P2001, DOI 10.1093/hmg/ddp124; Martinus RD, 1996, EUR J BIOCHEM, V240, P98, DOI 10.1111/j.1432-1033.1996.0098h.x; Micel LN, 2013, J CLIN ONCOL, V31, P1231, DOI 10.1200/JCO.2012.44.0958; Ngo JK, 2011, J GERONTOL A-BIOL, V66, P1178, DOI 10.1093/gerona/glr145; Ngo JK, 2009, FREE RADICAL BIO MED, V46, P1042, DOI 10.1016/j.freeradbiomed.2008.12.024; Nishigaki R, 2005, PROTEOMICS, V5, P3205, DOI 10.1002/pmic.200401307; Nolden M, 2005, CELL, V123, P277, DOI 10.1016/j.cell.2005.08.003; Ondrovicova G, 2005, J BIOL CHEM, V280, P25103, DOI 10.1074/jbc.M502796200; PAJIC A, 1994, FEBS LETT, V353, P201, DOI 10.1016/0014-5793(94)01046-3; Park YE, 2009, AUTOPHAGY, V5, P795, DOI 10.4161/auto.8901; PAUL MF, 1995, FEBS LETT, V373, P66, DOI 10.1016/0014-5793(95)00979-J; Pellegrino MW, 2013, BBA-MOL CELL RES, V1833, P410, DOI 10.1016/j.bbamcr.2012.02.019; Pickart CM, 2004, NAT REV MOL CELL BIO, V5, P177, DOI 10.1038/nrm1336; Pierson TM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002325; Pinti M, 2011, MITOCHONDRION, V11, P200, DOI 10.1016/j.mito.2010.09.010; Rath E, 2012, GUT, V61, P1269, DOI 10.1136/gutjnl-2011-300767; Rendon OZ, 2012, HUM MOL GENET, V21, P3815, DOI 10.1093/hmg/dds209; Rep M, 1996, SCIENCE, V274, P103, DOI 10.1126/science.274.5284.103; Rep M, 1996, CURR GENET, V30, P206, DOI 10.1007/s002940050122; Rubinsztein DC, 2012, NAT REV DRUG DISCOV, V11, P709, DOI 10.1038/nrd3802; Skrtic M, 2011, CANCER CELL, V20, P674, DOI 10.1016/j.ccr.2011.10.015; Srinivasula SM, 2003, J BIOL CHEM, V278, P31469, DOI 10.1074/jbc.C300240200; Stahlberg H, 1999, P NATL ACAD SCI USA, V96, P6787, DOI 10.1073/pnas.96.12.6787; Stanyer L, 2008, NEUROCHEM INT, V53, P95, DOI 10.1016/j.neuint.2008.06.004; SUZUKI CK, 1994, SCIENCE, V264, P273, DOI 10.1126/science.8146662; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Szyk A, 2006, J STRUCT BIOL, V156, P165, DOI 10.1016/j.jsb.2006.03.013; Tatsuta T, 2007, EMBO J, V26, P325, DOI 10.1038/sj.emboj.7601514; TAUER R, 1994, FEBS LETT, V353, P197, DOI 10.1016/0014-5793(94)01045-5; Tian Q, 2011, J BIOL CHEM, V286, P26424, DOI 10.1074/jbc.M110.215772; Truscott KN, 2010, BIOCHEM CELL BIOL, V88, P97, DOI [10.1139/O09-167, 10.1139/o09-167]; TZAGOLOFF A, 1994, J BIOL CHEM, V269, P26144; UniProt Consortium, 2013, UNIPROT KOWL; Vande Walle L, 2007, J PROTEOME RES, V6, P1006, DOI 10.1021/pr060510d; VANDYCK L, 1994, J BIOL CHEM, V269, P238; Vazquez F, 2013, CANCER CELL, V23, P287, DOI 10.1016/j.ccr.2012.11.020; Venditti P, 2013, MITOCHONDRION, V13, P71, DOI 10.1016/j.mito.2013.01.008; Venkatesh S, 2012, BBA-MOL CELL RES, V1823, P56, DOI 10.1016/j.bbamcr.2011.11.003; Wang HM, 2010, CANCER SCI, V101, P2612, DOI 10.1111/j.1349-7006.2010.01701.x; WANG N, 1993, P NATL ACAD SCI USA, V90, P11247, DOI 10.1073/pnas.90.23.11247; WANG N, 1994, J BIOL CHEM, V269, P29308; Yang JS, 2013, SCI REP-UK, V3, DOI 10.1038/srep01403; Yoneda T, 2004, J CELL SCI, V117, P4055, DOI 10.1242/jcs.01275; Yu AYH, 2007, FEBS LETT, V581, P3749, DOI 10.1016/j.febslet.2007.04.076; Zhang X, 2011, FREE RADICAL BIO MED, V50, P811, DOI 10.1016/j.freeradbiomed.2010.12.036; Zhao Q, 2002, EMBO J, V21, P4411, DOI 10.1093/emboj/cdf445; Zhu YF, 2002, EXP CELL RES, V280, P97, DOI 10.1006/excr.2002.5621; Zurawa-Janicka D, 2010, EXPERT OPIN THER TAR, V14, P665, DOI 10.1517/14728222.2010.487867	141	57	57	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2014	33	21					2690	2699		10.1038/onc.2013.228	http://dx.doi.org/10.1038/onc.2013.228			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EH	23770858	Bronze			2022-12-28	WOS:000337231700002
J	Xu, W; Li, Y; Liu, C; Zhao, S				Xu, W.; Li, Y.; Liu, C.; Zhao, S.			Protein lysine acetylation guards metabolic homeostasis to fight against cancer	ONCOGENE			English	Review						acetylation; metabolic coordination; cancer metabolism	PYRUVATE-DEHYDROGENASE COMPLEX; LINKING HISTONE ACETYLATION; FATTY-ACID OXIDATION; GLYCOGEN-PHOSPHORYLASE; DEACETYLASE INHIBITORS; CALORIE RESTRICTION; FUMARATE HYDRATASE; RENAL-CANCER; DNA-BINDING; P53	Properly coordinated metabolism and maintained metabolite homeostasis are important because altered metabolite homeostasis has a causal role in many human diseases, including cancer. Metabolite homeostasis is maintained by fine-tuned coordination of metabolite generation and utilization. Metabolite deregulation has recently been shown to alter the signaling pathways and reprogram epigenetic factors associated with tumorigenesis. Protein lysine acetylation is emerging as a metabolism-coordinating mechanism. Mechanistic studies have shown that acetylation may have roles in nutrient adaptation and in maintaining metabolite homeostasis by exerting regulatory effects on metabolic enzymes, metabolic pathways and metabolic networks. Here we review recent progress in the determination of the role of acetylation regulation in metabolism coordination. In particular, we review links between deregulated acetylation in metabolic enzymes and tumorigenesis. We further hypothesize on applications of the mediation of acetylation to restore deregulated metabolism coordination and thus develop novel means of cancer treatment.	[Xu, W.; Li, Y.; Liu, C.; Zhao, S.] Fudan Univ, Sch Life Sci, Sate Key Lab Genet Engn, Shanghai 200032, Peoples R China; [Xu, W.; Zhao, S.] Fudan Univ, Inst Biomed Sci, Shanghai 200032, Peoples R China	Fudan University; Fudan University	Zhao, S (corresponding author), Fudan Univ, Sch Life Sci, Sate Key Lab Genet Engn, 713 Mingdao Bldg,131 Dongan Rd, Shanghai 200032, Peoples R China.	zhaosm@fudan.edu.cn			National 973 Programs of China [2012CB910300, 2012CB721102, 2013CB911204, 2013CB945400]; NSFC Foundation of China [31030042]; Shanghai Basic Research Fund [11JC1401100]	National 973 Programs of China(National Basic Research Program of China); NSFC Foundation of China(National Natural Science Foundation of China (NSFC)); Shanghai Basic Research Fund	The work was supported by the National 973 Programs of China (Nos. 2012CB910300, 2012CB721102, 2013CB911204 and 2013CB945400), NSFC Foundation of China (31030042) and the Shanghai Basic Research Fund (11JC1401100).	Aksoy P, 2006, BIOCHEM BIOPH RES CO, V345, P1386, DOI 10.1016/j.bbrc.2006.05.042; Alam NA, 2003, HUM MOL GENET, V12, P1241, DOI 10.1093/hmg/ddg148; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Anderson KA, 2012, ESSAYS BIOCHEM, V52, P23, DOI [10.1042/BSE0520023, 10.1042/bse0520023]; Andreyev AI, 2005, BIOCHEMISTRY-MOSCOW+, V70, P200, DOI 10.1007/s10541-005-0102-7; Astuti D, 2001, AM J HUM GENET, V69, P49, DOI 10.1086/321282; Balakin KV, 2007, ANTI-CANCER AGENT ME, V7, P576, DOI 10.2174/187152007781668698; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Brooks CL, 2011, PROTEIN CELL, V2, P456, DOI 10.1007/s13238-011-1063-9; Brownell JE, 1996, CURR OPIN GENET DEV, V6, P176, DOI 10.1016/S0959-437X(96)80048-7; Capello M, 2011, FEBS J, V278, P1064, DOI 10.1111/j.1742-4658.2011.08025.x; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; Christofk HR, 2008, NATURE, V452, P230, DOI 10.1038/nature06734; Christofk HR, 2008, NATURE, V452, P181, DOI 10.1038/nature06667; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Desvergne B, 2006, PHYSIOL REV, V86, P465, DOI 10.1152/physrev.00025.2005; DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642; Esteban MA, 2005, NAT MED, V11, P1047, DOI 10.1038/nm1005-1047; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Giles RH, 1998, TRENDS GENET, V14, P178, DOI 10.1016/S0168-9525(98)01438-3; Gorke B, 2008, NAT REV MICROBIOL, V6, P613, DOI 10.1038/nrmicro1932; Gray MW, 2001, GENOME BIOL, V2; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Gu W, 2004, NOVART FDN SYMP, V259, P23; Gu W, 2004, NOVART FDN SYMP, p[259, 53]; Gu Wei, 2004, Novartis Found Symp, V259, P197; Guarente L, 2011, CELL METAB, V14, P151, DOI 10.1016/j.cmet.2011.07.007; Hallows WC, 2006, P NATL ACAD SCI USA, V103, P10230, DOI 10.1073/pnas.0604392103; Hallows WC, 2011, MOL CELL, V41, P139, DOI 10.1016/j.molcel.2011.01.002; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hebert AS, 2013, MOL CELL, V49, P186, DOI 10.1016/j.molcel.2012.10.024; Heltweg B, 2006, CANCER RES, V66, P4368, DOI 10.1158/0008-5472.CAN-05-3617; Hirschey MD, 2010, NATURE, V464, P121, DOI 10.1038/nature08778; Hirschey MD, 2009, METHOD ENZYMOL, V457, P137, DOI 10.1016/S0076-6879(09)05008-3; Hodawadekar SC, 2007, ONCOGENE, V26, P5528, DOI 10.1038/sj.onc.1210619; Isaacs JS, 2005, CANCER CELL, V8, P143, DOI 10.1016/j.ccr.2005.06.017; Jiang WQ, 2011, MOL CELL, V43, P33, DOI 10.1016/j.molcel.2011.04.028; JOHNSON LN, 1992, FASEB J, V6, P2274, DOI 10.1096/fasebj.6.6.1544539; Kim J, 2009, MICROBIOL-SGM, V155, P2420, DOI 10.1099/mic.0.027060-0; Kim SC, 2006, MOL CELL, V23, P607, DOI 10.1016/j.molcel.2006.06.026; Koivunen P, 2012, NATURE, V483, P485, DOI 10.1038/nature10898; Kondoh H, 2005, CANCER RES, V65, P177; Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Lain S, 2008, CANCER CELL, V13, P454, DOI 10.1016/j.ccr.2008.03.004; Lara E, 2009, ONCOGENE, V28, P781, DOI 10.1038/onc.2008.436; Launonen V, 2001, P NATL ACAD SCI USA, V98, P3387, DOI 10.1073/pnas.051633798; LINN TC, 1969, P NATL ACAD SCI USA, V62, P234, DOI 10.1073/pnas.62.1.234; Liu J, 2012, ACTA BIOCH BIOPH SIN, V44, P629, DOI 10.1093/abbs/gms048; Liwer Stein JM, 1969, METHODS ENZYMOLOGY, V13; Lombard DB, 2007, MOL CELL BIOL, V27, P8807, DOI 10.1128/MCB.01636-07; Lombard David B, 2011, Handb Exp Pharmacol, V206, P163, DOI 10.1007/978-3-642-21631-2_8; Lu JY, 2011, CELL, V146, P968, DOI 10.1016/j.cell.2011.07.044; LUETHY MH, 1995, GENE, V164, P251, DOI 10.1016/0378-1119(95)00465-I; Lundby A, 2012, CELL REP, V2, P419, DOI 10.1016/j.celrep.2012.07.006; Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101; Lv L, 2011, MOL CELL, V42, P719, DOI 10.1016/j.molcel.2011.04.025; MCKEEHAN WL, 1982, CELL BIOL INT REP, V6, P635, DOI 10.1016/0309-1651(82)90125-4; Melino Gerry, 2010, Nature, V466, P905, DOI 10.1038/466905d; Mizzen CA, 1998, CELL MOL LIFE SCI, V54, P6, DOI 10.1007/s000180050121; Mullighan CG, 2011, NATURE, V471, P235, DOI 10.1038/nature09727; Muraoka M, 1996, ONCOGENE, V12, P1565; Nakagawa T, 2009, CELL, V137, P560, DOI 10.1016/j.cell.2009.02.026; Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551; Niinaka Y, 1998, CANCER RES, V58, P2667; Ota H, 2006, ONCOGENE, V25, P176, DOI 10.1038/sj.onc.1209049; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; POGO BGT, 1966, P NATL ACAD SCI USA, V55, P805, DOI 10.1073/pnas.55.4.805; Portnoy T, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-269; Schwer B, 2009, AGING CELL, V8, P604, DOI 10.1111/j.1474-9726.2009.00503.x; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; Sen N, 2012, TRANSCR-AUSTIN, V3, P119, DOI 10.4161/trns.20094; Someya S, 2010, CELL, V143, P802, DOI 10.1016/j.cell.2010.10.002; Starai VJ, 2002, SCIENCE, V298, P2390, DOI 10.1126/science.1077650; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Tan JH, 2010, J HEMATOL ONCOL, V3, DOI 10.1186/1756-8722-3-5; Tan MJ, 2011, CELL, V146, P1015, DOI 10.1016/j.cell.2011.08.008; Tang Y, 2008, CELL, V133, P612, DOI 10.1016/j.cell.2008.03.025; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; Tanner KG, 1999, J BIOL CHEM, V274, P18157, DOI 10.1074/jbc.274.26.18157; Timmermann S, 2001, CELL MOL LIFE SCI, V58, P728, DOI 10.1007/PL00000896; Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849; Wang QJ, 2010, SCIENCE, V327, P1004, DOI 10.1126/science.1179687; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Warburg O, 1924, BIOCHEM Z, V152, P319; Ward PS, 2010, CANCER CELL, V17, P225, DOI 10.1016/j.ccr.2010.01.020; Won KY, 2012, HUM PATHOL, V43, P221, DOI 10.1016/j.humpath.2011.04.021; Xekouki P, 2012, J CLIN ENDOCR METAB, V97, pE357, DOI 10.1210/jc.2011-1179; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yan H, 2009, NEW ENGL J MED, V360, P765, DOI 10.1056/NEJMoa0808710; Yang HY, 2007, CELL, V130, P1095, DOI 10.1016/j.cell.2007.07.035; Yang MH, 2012, P NATL ACAD SCI USA, V109, P10843, DOI 10.1073/pnas.1201487109; Yu W, 2009, J BIOL CHEM, V284, P13669, DOI 10.1074/jbc.M901921200; Zhang JM, 2009, MOL CELL PROTEOMICS, V8, P215, DOI 10.1074/mcp.M800187-MCP200; Zhang TF, 2012, CELL METAB, V15, P75, DOI 10.1016/j.cmet.2011.12.005; Zhao SM, 2010, CELL RES, V20, P1279, DOI 10.1038/cr.2010.160; Zhao SM, 2010, SCIENCE, V327, P1000, DOI 10.1126/science.1179689; Zhao SM, 2009, SCIENCE, V324, P261, DOI 10.1126/science.1170944; ZIELKE HR, 1984, FED PROC, V43, P121	102	26	29	1	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2014	33	18					2279	2285		10.1038/onc.2013.163	http://dx.doi.org/10.1038/onc.2013.163			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AG5ID	23665675				2022-12-28	WOS:000335451800001
J	Cardoso, AP; Pinto, ML; Pinto, AT; Oliveira, MI; Pinto, MT; Goncalves, R; Relvas, JB; Figueiredo, C; Seruca, R; Mantovani, A; Mareel, M; Barbosa, MA; Oliveira, MJ				Cardoso, A. P.; Pinto, M. L.; Pinto, A. T.; Oliveira, M. I.; Pinto, M. T.; Goncalves, R.; Relvas, J. B.; Figueiredo, C.; Seruca, R.; Mantovani, A.; Mareel, M.; Barbosa, M. A.; Oliveira, M. J.			Macrophages stimulate gastric and colorectal cancer invasion through EGFR Y-1086, c-Src, Erk1/2 and Akt phosphorylation and smallGTPase activity	ONCOGENE			English	Article						tumor microenvironment; cancer cell invasion; macrophages; invasion-related signaling pathways; colon cancer; gastric cancer	TUMOR-CELL MIGRATION; PHOSPHOLIPASE C-GAMMA-1; GROWTH; INFILTRATION; METASTASIS; INFLAMMATION; INVASIVENESS; ANGIOGENESIS; PROGRESSION; CARCINOMA	The interactions between cancer cells and their microenvironment are crucial for malignant progression, as they modulate invasion-related activities. Tumor-associated macrophages are generally considered allies in the process of tumor progression in several types of cancer, although their role on gastric and colorectal carcinomas is still poorly understood. In this report, we studied the influence of primary human macrophages on gastric and colorectal cancer cells, considering invasion, motility/migration, proteolysis and activated intracellular signaling pathways. We demonstrated that macrophages stimulate cancer cell invasion, motility and migration, and that these effects depend on matrix metalloproteinase (MMP) activity and on the activation of epidermal growth factor receptor (EGFR) (at the residue Y-1086), PLC-gamma (phospholipase C-gamma) and Gab1 (GRB2-associated binding protein-1), as evidenced by siRNA (small interference RNA) experiments. Epidermal growth factor (EGF)-immunodepletion impaired macrophage-mediated cancer cell invasion and motility, suggesting that EGF is the pro-invasive and pro-motile factor produced by macrophages. Macrophages also induced gastric and colorectal cancer cell phosphorylation of Akt, c-Src and ERK1/2, and led to an increase of RhoA and Cdc42 activity. Interestingly, whereas macrophage-mediated cancer cell c-Src and ERK1/2 phosphorylation occurred downstream EGFR activation, Akt phosphorylation seems to be a parallel event, taking place in an EGFR-independent manner. The involvement of EGF, EGFR-downstream signaling partners and MMPs in macrophage-mediated invasion provides novel insights into the molecular crosstalk established between cancer cells and macrophages, opening new perspectives for the design of new and more efficient therapeutic strategies to counteract cancer cell invasion.	[Cardoso, A. P.; Pinto, M. L.; Pinto, A. T.; Oliveira, M. I.; Goncalves, R.; Barbosa, M. A.; Oliveira, M. J.] Univ Porto, Inst Biomed Engn, P-4150180 Oporto, Portugal; [Cardoso, A. P.; Pinto, A. T.] Univ Porto, Fac Engn, P-4150180 Oporto, Portugal; [Pinto, M. L.; Barbosa, M. A.] Univ Porto, Inst Ciencias Biomed Abel Salazar, P-4150180 Oporto, Portugal; [Pinto, M. T.; Figueiredo, C.; Seruca, R.] Univ Porto, Inst Patol & Imunol Mol, P-4150180 Oporto, Portugal; [Relvas, J. B.] Univ Porto, Inst Biol Celular & Mol, P-4150180 Oporto, Portugal; [Relvas, J. B.] Univ Porto, Fac Med, Dept Biol Expt, P-4150180 Oporto, Portugal; [Figueiredo, C.; Seruca, R.; Oliveira, M. J.] Univ Porto, Fac Med, Dept Patol & Oncol, P-4150180 Oporto, Portugal; [Mantovani, A.] Humanitas Clin & Res Ctr, Rozzano, Italy; [Mantovani, A.] Univ Milan, BIOMETRA Dept, Milan, Italy; [Mareel, M.] Ghent Univ Hosp, Expt Cancerol Lab, Ghent, Belgium	Universidade do Porto; Universidade do Porto; Universidade do Porto; Universidade do Porto; Universidade do Porto; Universidade do Porto; Universidade do Porto; IRCCS Humanitas Research Hospital; University of Milan; Ghent University; Ghent University Hospital	Oliveira, MJ (corresponding author), Univ Porto, INEB Inst Engn Biomed, Rua Campo Alegre 823, P-4150180 Oporto, Portugal.	mariajo@ineb.up.pt	Pinto, Marta T/J-2519-2013; Figueiredo, Ceu/B-8776-2008; Barbosa, Mário A/F-5964-2011; Cardoso, Ana P/G-2150-2017; Oliveira, Marta I A/M-9386-2013; Mantovani, Alberto/HCI-7449-2022; Pinto, Marta/AAE-4575-2020; Relvas, Joao B/A-1142-2008; Pinto, Ana/AAZ-8360-2020; Gonçalves, Raquel M/C-5940-2012; Oliveira, Maria Jose/K-3275-2013	Pinto, Marta T/0000-0002-8521-2904; Figueiredo, Ceu/0000-0001-5247-840X; Barbosa, Mário A/0000-0003-3568-7482; Cardoso, Ana P/0000-0003-1987-0316; Oliveira, Marta I A/0000-0002-0578-9202; Mantovani, Alberto/0000-0001-5578-236X; Pinto, Marta/0000-0002-5783-3965; Relvas, Joao B/0000-0001-7636-0924; Pinto, Ana/0000-0003-0974-2206; Gonçalves, Raquel M/0000-0003-2841-0485; Seruca, Raquel/0000-0002-8851-4166; Oliveira, Maria Jose/0000-0002-0724-0272	FCT [PTDC-SAU-ONC/112511/2009, SFRH/BD/74144/2010, SFRH/BD/81103/2011, SFRH/BPD/37090/2007]; COMPETE [FCOMP-01-0124-FEDER-010915]; Prize L'Oreal for Women Science (Foundation L'Oreal/FCT/UNESCO); European project DISC Regeneration [NMP3-LA-2008-213904]; AIRC; ERC; Italian Ministry of Health [RF2010]	FCT(Portuguese Foundation for Science and TechnologyEuropean Commission); COMPETE; Prize L'Oreal for Women Science (Foundation L'Oreal/FCT/UNESCO)(L'Oreal Group); European project DISC Regeneration; AIRC(Fondazione AIRC per la ricerca sul cancro); ERC(European Research Council (ERC)European Commission); Italian Ministry of Health(Ministry of Health, Italy)	This work was financially supported by FCT (PTDC-SAU-ONC/112511/2009), COMPETE FCOMP-01-0124-FEDER-010915 and Prize L'Oreal for Women Science (Foundation L'Oreal/FCT/UNESCO). AP Cardoso is a PhD Fellow from the International Iberian Nanotechnology Laboratory (INL). AT Pinto and ML Pinto are PhD Fellows (SFRH/BD/74144/2010, SFRH/BD/81103/2011) and MI Oliveira a Postdoc Fellow (SFRH/BPD/37090/2007) from FCT. MJ Oliveira and MT Pinto are granted by Programa Ciencia2007-FCT. RGoncalves was funded by the European project DISC Regeneration, NMP3-LA-2008-213904 (FP7). A Mantovani is supported by AIRC, ERC and RF2010 Italian Ministry of Health.	Abella JV, 2010, J CELL SCI, V123, P1306, DOI 10.1242/jcs.062570; Allen M, 2011, J PATHOL, V223, P162, DOI 10.1002/path.2803; Avraham R, 2011, NAT REV MOL CELL BIO, V12, P104, DOI 10.1038/nrm3048; Chang C, 2001, TRENDS CELL BIOL, V11, pS37, DOI 10.1016/S0962-8924(01)82222-4; Chou J, 2003, EXP CELL RES, V287, P47, DOI 10.1016/S0014-4827(03)00119-8; Coffelt SB, 2009, BBA-REV CANCER, V1796, P11, DOI 10.1016/j.bbcan.2009.02.004; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Coniglio SJ, 2012, MOL MED, V18, P519, DOI 10.2119/molmed.2011.00217; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Foda HD, 2001, DRUG DISCOV TODAY, V6, P478, DOI 10.1016/S1359-6446(01)01752-4; Forssell J, 2007, CLIN CANCER RES, V13, P1472, DOI 10.1158/1078-0432.CCR-06-2073; Goswami S, 2005, CANCER RES, V65, P5278, DOI 10.1158/0008-5472.CAN-04-1853; Green CE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006713; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Hagemann T, 2004, CARCINOGENESIS, V25, P1543, DOI 10.1093/carcin/bgh146; Hagemann T, 2005, J IMMUNOL, V175, P1197, DOI 10.4049/jimmunol.175.2.1197; Hagemann T, 2007, CANCER CELL, V12, P300, DOI 10.1016/j.ccr.2007.10.005; Hakansson L, 1997, BRIT J CANCER, V75, P374, DOI 10.1038/bjc.1997.61; Humtsoe JO, 2010, ONCOGENE, V29, P1214, DOI 10.1038/onc.2009.419; Ishigami S, 2003, ANTICANCER RES, V23, P4079; Jones NP, 2005, J CELL SCI, V118, P2695, DOI 10.1242/jcs.02374; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Kang JC, 2010, J SURG ONCOL, V102, P242, DOI 10.1002/jso.21617; Karlsson R, 2009, BBA-REV CANCER, V1796, P91, DOI 10.1016/j.bbcan.2009.03.003; Kuroda T, 2005, CLIN CANCER RES, V11, P7629, DOI 10.1158/1078-0432.CCR-05-0798; Leek RD, 1996, CANCER RES, V56, P4625; Liguori Manuela, 2011, Cancers (Basel), V3, P3740, DOI 10.3390/cancers3043740; Lin EY, 2001, J EXP MED, V193, P727, DOI 10.1084/jem.193.6.727; Lin EY, 2002, J MAMMARY GLAND BIOL, V7, P147, DOI 10.1023/A:1020399802795; Liotta LA, 2001, NATURE, V411, P375, DOI 10.1038/35077241; Lombardo CR, 1995, BIOCHEMISTRY-US, V34, P16456, DOI 10.1021/bi00050a029; Machesky LM, 2008, FEBS LETT, V582, P2102, DOI 10.1016/j.febslet.2008.03.039; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Mateus AR, 2007, HUM MOL GENET, V16, P1639, DOI 10.1093/hmg/ddm113; Oguma K, 2008, EMBO J, V27, P1671, DOI 10.1038/emboj.2008.105; Ohno S, 2003, ANTICANCER RES, V23, P5015; Ohta M, 2003, INT J ONCOL, V22, P773; Oliveira MJ, 2006, J BIOL CHEM, V281, P34888, DOI 10.1074/jbc.M607067200; Oliveira MI, 2012, EUR CELLS MATER, V24, P136, DOI 10.22203/eCM.v024a10; Oliveira MJ, 2005, J CANCER RES CLIN, V131, P49, DOI 10.1007/s00432-004-0601-8; Oliveira MJ, 2003, EMBO J, V22, P6161, DOI 10.1093/emboj/cdg586; Patsialou A, 2009, CANCER RES, V69, P9498, DOI 10.1158/0008-5472.CAN-09-1868; Piccolo E, 2002, ONCOGENE, V21, P6520, DOI 10.1038/sj.onc.1205821; Pukrop T, 2006, P NATL ACAD SCI USA, V103, P5454, DOI 10.1073/pnas.0509703103; Rodrigues GA, 2000, MOL CELL BIOL, V20, P1448, DOI 10.1128/MCB.20.4.1448-1459.2000; Sala G, 2008, CANCER RES, V68, P10187, DOI 10.1158/0008-5472.CAN-08-1181; Solinas G, 2010, J IMMUNOL, V185, P642, DOI 10.4049/jimmunol.1000413; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Wang WG, 2005, TRENDS CELL BIOL, V15, P138, DOI 10.1016/j.tcb.2005.01.003; Wyckoff J, 2004, CANCER RES, V64, P7022, DOI 10.1158/0008-5472.CAN-04-1449	50	81	87	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2014	33	16					2123	2133		10.1038/onc.2013.154	http://dx.doi.org/10.1038/onc.2013.154			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF3GH	23644655				2022-12-28	WOS:000334599100011
J	Xie, X; Piao, L; Cavey, GS; Old, M; Teknos, TN; Mapp, AK; Pan, Q				Xie, X.; Piao, L.; Cavey, G. S.; Old, M.; Teknos, T. N.; Mapp, A. K.; Pan, Q.			Phosphorylation of Nanog is essential to regulate Bmi1 and promote tumorigenesis	ONCOGENE			English	Article						Head and neck cancer; protein kinase C; p300; cancer stem cells; cancer-initiating cells	SQUAMOUS-CELL CARCINOMA; STEM-LIKE CELLS; SELF-RENEWAL; KAPPA-B; PLURIPOTENCY; EXPRESSION; HEAD; PROGRESSION; ACTIVATION; PREDICTS	Emerging evidence indicates that Nanog is intimately involved in tumorigenesis, in part, through regulation of the cancer-initiating cell (CIC) population. However, the regulation and role of Nanog in tumorigenesis are still poorly understood. In this study, human Nanog was identified to be phosphorylated by human protein kinase C epsilon at multiple residues, including T200 and T280. Our work indicated that phosphorylation at T200 and T280 modulates Nanog function through several regulatory mechanisms. Results with phosphorylation-insensitive and phosphorylation-mimetic mutant Nanog revealed that phosphorylation at T200 and T280 enhance Nanog protein stability. Moreover, phosphorylation-insensitive T200A and T280A mutant Nanog had a dominant-negative function to inhibit endogenous Nanog transcriptional activity. Inactivation of Nanog was due to impaired homodimerization, DNA binding, promoter occupancy and p300, a transcriptional co-activator, recruitment resulting in a defect in target gene-promoter activation. Ectopic expression of phosphorylation-insensitive T200A or T280A mutant Nanog reduced cell proliferation, colony formation, invasion, migration and the CIC population in head and neck squamous cell carcinoma (HNSCC) cells. The in vivo cancer-initiating ability was severely compromised in HNSCC cells expressing phosphorylation-insensitive T200A or T280A mutant Nanog; 87.5% (14/16), 12.5% (1/8), and 0% (0/8) for control, T200A, and T280A, respectively. Nanog occupied the Bmi1 promoter to directly transactivate and regulate Bmi1. Genetic ablation and rescue experiments demonstrated that Bmi1 is a critical downstream signaling node for the pleiotropic, pro-oncogenic effects of Nanog. Taken together, our study revealed, for the first time, that post-translational phosphorylation of Nanog is essential to regulate Bmi1 and promote tumorigenesis.	[Xie, X.; Piao, L.; Old, M.; Teknos, T. N.; Pan, Q.] Ohio State Univ, Wexner Med Ctr, Dept Otolaryngol Head & Neck Surg, Columbus, OH 43210 USA; [Xie, X.; Piao, L.; Old, M.; Teknos, T. N.; Pan, Q.] Ohio State Univ, Ctr Comprehens Canc, Arthur G James Canc Hosp, Columbus, OH 43210 USA; [Xie, X.; Piao, L.; Old, M.; Teknos, T. N.; Pan, Q.] Ohio State Univ, Ctr Comprehens Canc, Richard J Solove Res Inst, Columbus, OH 43210 USA; [Cavey, G. S.] Van Andel Res Inst, Grand Rapids, MI USA; [Cavey, G. S.] Southwest Michigan Innovat Ctr, Kalamazoo, MI USA; [Mapp, A. K.] Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Van Andel Institute; University of Michigan System; University of Michigan	Pan, Q (corresponding author), Ohio State Univ, Wexner Med Ctr, Dept Otolaryngol Head & Neck Surg, 442 Tzagournis Med Res,420 West 12th Ave, Columbus, OH 43210 USA.	Quintin.Pan@osumc.edu	, Dr Anna Mapp/GPX-8261-2022; Old, Matthew/J-2315-2017; Pan, Quintin/E-3808-2011	Old, Matthew/0000-0003-1795-5877; 	National Cancer Institute at the National Institutes of Health [R01CA135096]; American Cancer Society [RSG0821901]; Michelle Theado Memorial Grant from The Joan Bisesi Fund for Head and Neck Oncology Research; Sloman Foundation; Arthur G. James Cancer Hospital, The Ohio State University Comprehensive Cancer Center; Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE [P30CA016058, R01CA135096] Funding Source: NIH RePORTER	National Cancer Institute at the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); American Cancer Society(American Cancer Society); Michelle Theado Memorial Grant from The Joan Bisesi Fund for Head and Neck Oncology Research; Sloman Foundation; Arthur G. James Cancer Hospital, The Ohio State University Comprehensive Cancer Center; Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported, in part, by the National Cancer Institute at the National Institutes of Health (R01CA135096); American Cancer Society (RSG0821901); The Michelle Theado Memorial Grant from The Joan Bisesi Fund for Head and Neck Oncology Research; The Sloman Foundation; and Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University Comprehensive Cancer Center.	Bourguignon LYW, 2012, ONCOGENE, V31, P149, DOI 10.1038/onc.2011.222; Bourguignon LYW, 2009, J BIOL CHEM, V284, P26533, DOI 10.1074/jbc.M109.027466; Chang DF, 2009, STEM CELLS, V27, P812, DOI 10.1634/stemcells.2008-0657; Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043; Chiba T, 2008, CANCER RES, V68, P7742, DOI 10.1158/0008-5472.CAN-07-5882; Chiou SH, 2008, CLIN CANCER RES, V14, P4085, DOI 10.1158/1078-0432.CCR-07-4404; Chiou SH, 2010, CANCER RES, V70, P10433, DOI 10.1158/0008-5472.CAN-10-2638; Choijamts B, 2011, STEM CELLS, V29, P1485, DOI 10.1002/stem.711; Das S, 2011, J BIOL CHEM, V286, P42690, DOI 10.1074/jbc.M111.290189; Do HJ, 2009, J CELL BIOCHEM, V106, P1079, DOI 10.1002/jcb.22089; Germann M, 2012, STEM CELLS, V30, P1076, DOI 10.1002/stem.1087; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Han JH, 2012, CANCER LETT, V321, P80, DOI 10.1016/j.canlet.2012.02.021; Hayry V, 2010, BRIT J CANCER, V102, P892, DOI 10.1038/sj.bjc.6605544; Ho BT, 2012, J BIOL CHEM, V287, P18656, DOI 10.1074/jbc.M111.322883; Jeter CR, 2009, STEM CELLS, V27, P993, DOI 10.1002/stem.29; Lavial F, 2012, GENE DEV, V26, P1445, DOI 10.1101/gad.188193.112; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; Li J, 2010, AM J PATHOL, V176, P699, DOI 10.2353/ajpath.2010.090502; Liu AG, 2013, INT J ONCOL, V42, P1399, DOI 10.3892/ijo.2013.1826; Lukacs RU, 2010, CELL STEM CELL, V7, P682, DOI 10.1016/j.stem.2010.11.013; Masui S, 2007, NAT CELL BIOL, V9, P625, DOI 10.1038/ncb1589; Meng HM, 2010, CANCER BIOL THER, V9, P295, DOI 10.4161/cbt.9.4.10666; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Moretto-Zita M, 2010, P NATL ACAD SCI USA, V107, P13312, DOI 10.1073/pnas.1005847107; Mullin NP, 2008, BIOCHEM J, V411, P227, DOI 10.1042/BJ20080134; Niggeweg R, 2006, PROTEOMICS, V6, P41, DOI 10.1002/pmic.200501332; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Pan GJ, 2005, J BIOL CHEM, V280, P1401, DOI 10.1074/jbc.M407847200; Pan Q, 2006, CANCER RES, V66, P9379, DOI 10.1158/0008-5472.CAN-06-2646; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Ramakrishna S, 2011, STEM CELLS DEV, V20, P1512, DOI 10.1089/scd.2010.0410; Song LB, 2006, CANCER RES, V66, P6225, DOI 10.1158/0008-5472.CAN-06-0094; Steen H, 2001, ANAL CHEM, V73, P1440, DOI 10.1021/ac001318c; Torres J, 2008, NAT CELL BIOL, V10, P194, DOI 10.1038/ncb1680; Tsai LL, 2011, J ORAL PATHOL MED, V40, P621, DOI 10.1111/j.1600-0714.2011.01015.x; Vormittag L, 2009, INT J RADIAT ONCOL, V73, P913, DOI 10.1016/j.ijrobp.2008.10.040; Vrzalikova K, 2008, J CANCER RES CLIN, V134, P1037, DOI 10.1007/s00432-008-0361-y; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yang WH, 2012, NAT CELL BIOL, V14, P366, DOI 10.1038/ncb2455; Yu CC, 2011, ORAL ONCOL, V47, P202, DOI 10.1016/j.oraloncology.2010.12.001; Zbinden M, 2010, EMBO J, V29, P2659, DOI 10.1038/emboj.2010.137; Zhang PL, 2010, J BIOL CHEM, V285, P9180, DOI 10.1074/jbc.M109.077958; Zhang Y, 2012, CANCER LETT, V322, P70, DOI 10.1016/j.canlet.2012.02.010	44	35	39	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2014	33	16					2040	2052		10.1038/onc.2013.173	http://dx.doi.org/10.1038/onc.2013.173			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF3GH	23708658	Green Accepted			2022-12-28	WOS:000334599100004
J	Zheng, H; Kang, Y				Zheng, H.; Kang, Y.			Multilayer control of the EMT master regulators	ONCOGENE			English	Review						cancer metastasis; EMT; Snail; Twist; Zeb; E3-ubiquitin ligase	EPITHELIAL-MESENCHYMAL TRANSITION; SMAD-INTERACTING PROTEIN-1; F-BOX PROTEIN; GLYCOGEN-SYNTHASE KINASE-3; TRANSCRIPTION FACTOR SNAIL; HYPOXIA-INDUCIBLE FACTOR; NEGATIVE FEEDBACK LOOP; E-CADHERIN EXPRESSION; CANCER METASTASIS; MIR-200 FAMILY	Metastasis is the leading cause of cancer-associated death in most tumor types. Metastatic dissemination of cancer cells from the primary tumor is believed to be initiated by the reactivation of an embryonic development program referred to as epithelial-mesenchymal transition (EMT), whereby epithelial cells lose apicobasal polarity and cell-cell contacts, and gain mesenchymal phenotypes with increased migratory and invasive capabilities. EMT has also been implicated in the regulation of cancer stem cell property, immune suppression and cancer regression. Several transcription factors have been identified as master regulators of EMT, including the Snail, Zeb and Twist families, and their expression is tightly regulated at different steps of transcription, translation and protein stability control by a variety of cell-intrinsic pathways as well as extracellular cues. Here, we review the recent literature on the signaling pathways and mechanisms that control the expression of these master transcription factors during EMT and cancer progression.	[Zheng, H.; Kang, Y.] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Kang, Y (corresponding author), Princeton Univ, Dept Mol Biol, LTL255,Washington Rd, Princeton, NJ 08544 USA.	ykang@princeton.edu		Zheng, Hanqiu/0000-0002-8062-1215; Kang, Yibin/0000-0002-1626-6730	National Institutes of Health [R01CA134519, R01CA141062]; Komen for the Cure; Brewster Foundation; Champalimaud Foundation; Komen for the Cure Postdoctoral Fellowship [KG111164]; NATIONAL CANCER INSTITUTE [R01CA134519, R01CA141062] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Komen for the Cure(Susan G. Komen Breast Cancer Foundation); Brewster Foundation; Champalimaud Foundation; Komen for the Cure Postdoctoral Fellowship(Susan G. Komen Breast Cancer Foundation); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We apologize to researchers whose studies we were unable to cite due to the space limitation of this review. We thank W Li and HA Smith for reading the manuscript and providing insightful advises. Research in our laboratory is supported by grants from the National Institutes of Health R01CA134519 and R01CA141062, Komen for the Cure, the Brewster Foundation and the Champalimaud Foundation. H Zheng is a recipient of a Komen for the Cure Postdoctoral Fellowship (KG111164).	Acloque H, 2011, DEV CELL, V21, P546, DOI 10.1016/j.devcel.2011.07.005; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036; Ansieau S, 2008, CANCER CELL, V14, P79, DOI 10.1016/j.ccr.2008.06.005; Arima Y, 2012, J BIOL CHEM, V287, P7896, DOI 10.1074/jbc.M111.313759; Bachelder RE, 2005, J CELL BIOL, V168, P29, DOI 10.1083/jcb.200409067; Barr S, 2008, CLIN EXP METASTAS, V25, P685, DOI 10.1007/s10585-007-9121-7; Bastea LI, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030459; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Bialek P, 2004, DEV CELL, V6, P423, DOI 10.1016/S1534-5807(04)00058-9; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Brabletz T, 2012, CANCER CELL, V22, P699, DOI 10.1016/j.ccr.2012.11.009; Brabletz T, 2012, NAT REV CANCER, V12, P425, DOI 10.1038/nrc3265; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Casas E, 2011, CANCER RES, V71, P245, DOI 10.1158/0008-5472.CAN-10-2330; Celia-Terrassa T, 2012, J CLIN INVEST, V122, P1849, DOI 10.1172/JCI59218; Chaffer CL, 2006, CANCER RES, V66, P11271, DOI 10.1158/0008-5472.CAN-06-2044; Chakrabarti R, 2012, NAT CELL BIOL, V14, P1212, DOI 10.1038/ncb2607; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chang CJ, 2011, ONCOL REP, V26, P1003, DOI 10.3892/or.2011.1360; Chao YL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-179; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; Cieply B, 2012, CANCER RES, V72, P2440, DOI 10.1158/0008-5472.CAN-11-4038; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Copple BL, 2010, LIVER INT, V30, P669, DOI 10.1111/j.1478-3231.2010.02205.x; Dontu G, 2003, CELL PROLIFERAT, V36, P59, DOI 10.1046/j.1365-2184.36.s.1.6.x; Du C, 2010, CANCER RES, V70, P7810, DOI 10.1158/0008-5472.CAN-09-4481; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Eiseler T, 2012, J BIOL CHEM, V287, P32367, DOI 10.1074/jbc.M112.370999; El-Haibi CP, 2012, P NATL ACAD SCI USA, V109, P17460, DOI 10.1073/pnas.1206653109; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Franci C, 2006, ONCOGENE, V25, P5134, DOI 10.1038/sj.onc.1209519; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; Graff JR, 2000, J BIOL CHEM, V275, P2727, DOI 10.1074/jbc.275.4.2727; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Hajra KM, 2002, CANCER RES, V62, P1613; Hartwell KA, 2006, P NATL ACAD SCI USA, V103, P18969, DOI 10.1073/pnas.0608636103; HEBROK M, 1994, DEV BIOL, V165, P537, DOI 10.1006/dbio.1994.1273; Hong J, 2011, CANCER RES, V71, P3980, DOI 10.1158/0008-5472.CAN-10-2914; Hu JJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045965; Huang D, 2008, WORLD J GASTROENTERO, V14, P1823, DOI 10.3748/wjg.14.1823; Hubbard EJA, 1997, GENE DEV, V11, P3182, DOI 10.1101/gad.11.23.3182; Imai T, 2003, AM J PATHOL, V163, P1437, DOI 10.1016/S0002-9440(10)63501-8; Imamichi Y, 2007, ONCOGENE, V26, P2381, DOI 10.1038/sj.onc.1210012; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jenkins RH, 2012, BIOCHEM SOC T, V40, P762, DOI 10.1042/BST20120085; Jeschke U, 2007, ANTICANCER RES, V27, P1969; Jung A, 2001, AM J PATHOL, V159, P1613, DOI 10.1016/S0002-9440(10)63007-6; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Karreth FA, 2011, CELL, V147, P382, DOI 10.1016/j.cell.2011.09.032; Kim NH, 2011, J CELL BIOL, V195, P417, DOI 10.1083/jcb.201103097; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401; Krishnamachary B, 2006, CANCER RES, V66, P2725, DOI 10.1158/0008-5472.CAN-05-3719; Krupa A, 2010, J AM SOC NEPHROL, V21, P438, DOI 10.1681/ASN.2009050530; Kudo-Saito C, 2009, CANCER CELL, V15, P195, DOI 10.1016/j.ccr.2009.01.023; Kumarswamy R, 2012, INT J CANCER, V130, P2044, DOI 10.1002/ijc.26218; Laffin B, 2008, MOL CELL BIOL, V28, P1936, DOI 10.1128/MCB.01701-07; Lander R, 2011, J CELL BIOL, V194, P17, DOI 10.1083/jcb.201012085; Lee MR, 2010, STEM CELLS, V28, P1550, DOI 10.1002/stem.490; Lester RD, 2007, J CELL BIOL, V178, P425, DOI 10.1083/jcb.200701092; Li B, 2012, FEBS J, V279, P2393, DOI 10.1111/j.1742-4658.2012.08618.x; Liskova P, 2007, HUM MUTAT, V28, DOI 10.1002/humu.9495; Liu N, 2010, J BIOL CHEM, V285, P18858, DOI 10.1074/jbc.M109.099440; Liu SJ, 2012, J PATHOL, V226, P61, DOI 10.1002/path.2964; Liu XQ, 2011, BIOCHEM J, V440, P23, DOI 10.1042/BJ20111006; Liu YN, 2013, ONCOGENE, V32, P296, DOI 10.1038/onc.2012.58; Liu YN, 2012, MOL CELL BIOL, V32, P941, DOI 10.1128/MCB.06306-11; Long JY, 2005, J BIOL CHEM, V280, P35477, DOI 10.1074/jbc.M504477200; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Maeda G, 2005, INT J ONCOL, V27, P1535; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mani SA, 2007, P NATL ACAD SCI USA, V104, P10069, DOI 10.1073/pnas.0703900104; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mejlvang J, 2007, MOL BIOL CELL, V18, P4615, DOI 10.1091/mbc.E07-05-0406; Lopez-Novoa JM, 2009, EMBO MOL MED, V1, P303, DOI 10.1002/emmm.200900043; Miyoshi A, 2004, BRIT J CANCER, V90, P1265, DOI 10.1038/sj.bjc.6601685; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Nairismagi ML, 2012, ONCOGENE, V31, P4960, DOI 10.1038/onc.2011.650; Nalls D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024099; Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Park D, 2007, APMIS, V115, P52, DOI 10.1111/j.1600-0463.2007.apm_524.x; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Peinado H, 2003, J BIOL CHEM, V278, P21113, DOI 10.1074/jbc.M211304200; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Polyak Kornelia, 2012, Cancer Cell, V22, P562, DOI 10.1016/j.ccr.2012.06.021; Pon YL, 2008, CANCER RES, V68, P6524, DOI 10.1158/0008-5472.CAN-07-6302; Radisky DC, 2005, NATURE, V436, P123, DOI 10.1038/nature03688; Remacle JE, 1999, EMBO J, V18, P5073, DOI 10.1093/emboj/18.18.5073; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Romano LA, 2000, DEV BIOL, V223, P91, DOI 10.1006/dbio.2000.9750; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Sahlgren C, 2008, P NATL ACAD SCI USA, V105, P6392, DOI 10.1073/pnas.0802047105; Saini S, 2011, CANCER RES, V71, P6208, DOI 10.1158/0008-5472.CAN-11-0073; Saini S, 2011, CLIN CANCER RES, V17, P5287, DOI 10.1158/1078-0432.CCR-10-2619; Sethi N, 2011, NAT REV CANCER, V11, P735, DOI 10.1038/nrc3125; Siemens H, 2011, CELL CYCLE, V10, P4256, DOI 10.4161/cc.10.24.18552; Spaderna S, 2008, CANCER RES, V68, P537, DOI 10.1158/0008-5472.CAN-07-5682; Spaderna S, 2006, GASTROENTEROLOGY, V131, P830, DOI 10.1053/j.gastro.2006.06.016; Spoelstra NS, 2006, CANCER RES, V66, P3893, DOI 10.1158/0008-5472.CAN-05-2881; Taki M, 2006, INT J ONCOL, V28, P487; Tarin D, 2005, CANCER RES, V65, P5996, DOI 10.1158/0008-5472.CAN-05-0699; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thompson EW, 2011, NAT MED, V17, P1048, DOI 10.1038/nm.2437; Thompson EW, 2008, CLIN EXP METASTAS, V25, P591, DOI 10.1007/s10585-008-9189-8; Thompson EW, 2005, CANCER RES, V65, P5991, DOI 10.1158/0008-5472.CAN-05-0616; Thuault S, 2008, J BIOL CHEM, V283, P33437, DOI 10.1074/jbc.M802016200; Timmerman LA, 2004, GENE DEV, V18, P99, DOI 10.1101/gad.276304; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Tsuji T, 2008, CANCER RES, V68, P10377, DOI 10.1158/0008-5472.CAN-08-1444; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Van de Putte T, 2003, AM J HUM GENET, V72, P465, DOI 10.1086/346092; Vandewalle C, 2005, NUCLEIC ACIDS RES, V33, P6566, DOI 10.1093/nar/gki965; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Vernon AE, 2006, DEVELOPMENT, V133, P3359, DOI 10.1242/dev.02504; Vinas-Castells R, 2010, J BIOL CHEM, V285, P3794, DOI 10.1074/jbc.M109.065995; Voulgari A, 2009, BBA-REV CANCER, V1796, P75, DOI 10.1016/j.bbcan.2009.03.002; Wakamatsu N, 2001, NAT GENET, V27, P369, DOI 10.1038/86860; Wang FE, 2010, FASEB J, V24, P1552, DOI 10.1096/fj.08-125856; Wang XH, 2007, CANCER RES, V67, P7184, DOI 10.1158/0008-5472.CAN-06-4729; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Welcker M, 2004, CURR BIOL, V14, P1852, DOI 10.1016/j.cub.2004.09.083; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; White NMA, 2011, BRIT J CANCER, V105, P1741, DOI 10.1038/bjc.2011.401; Wu ZQ, 2012, P NATL ACAD SCI USA, V109, P16654, DOI 10.1073/pnas.1205822109; Xia HP, 2012, J BIOL CHEM, V287, P9962, DOI 10.1074/jbc.M111.332627; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yang WH, 2012, NAT CELL BIOL, V14, P366, DOI 10.1038/ncb2455; Yang ZB, 2005, CANCER RES, V65, P3179, DOI 10.1158/0008-5472.CAN-04-3480; Yin G, 2013, ONCOGENE, V32, P39, DOI 10.1038/onc.2012.33; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Zhang HJ, 2011, CANCER RES, V71, P1292, DOI 10.1158/0008-5472.CAN-10-2825; Zhang K, 2012, EMBO J, V31, P29, DOI 10.1038/emboj.2011.357; Zhang Zhiqian, 2011, Genes Cancer, V2, P782, DOI 10.1177/1947601911429743; Zhao D, 2010, CANCER RES, V70, P4728, DOI 10.1158/0008-5472.CAN-10-0040; Zhou BHP, 2005, CELL CYCLE, V4, P772, DOI 10.4161/cc.4.6.1744; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	152	226	236	2	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2014	33	14					1755	1763		10.1038/onc.2013.128	http://dx.doi.org/10.1038/onc.2013.128			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RE	23604123				2022-12-28	WOS:000334345500002
J	Grayson, AR; Walsh, EM; Cameron, MJ; Godec, J; Ashworth, T; Ambrose, JM; Aserlind, AB; Wang, H; Evan, GI; Kluk, MJ; Bradner, JE; Aster, JC; French, CA				Grayson, A. R.; Walsh, E. M.; Cameron, M. J.; Godec, J.; Ashworth, T.; Ambrose, J. M.; Aserlind, A. B.; Wang, H.; Evan, G. I.; Kluk, M. J.; Bradner, J. E.; Aster, J. C.; French, C. A.			MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma	ONCOGENE			English	Article						BRD4; NUT; MYC; epigenetic; differentiation; fusion oncogene	SQUAMOUS-CELL CARCINOMA; SET ENRICHMENT ANALYSIS; C-MYC; POOR-PROGNOSIS; IN-VIVO; INDUCED APOPTOSIS; BET BROMODOMAINS; STEM-CELLS; GENE; REARRANGEMENT	NUT midline carcinoma (NMC) is an aggressive type of squamous cell carcinoma that is defined by the presence of BRD-NUT fusion oncogenes, which encode chimeric proteins that block differentiation and maintain tumor growth. BRD-NUT oncoproteins contain two bromodomains whose binding to acetylated histones is required for the blockade of differentiation in NMC, but the mechanisms by which BRD-NUT act remain uncertain. Here, we provide evidence that MYC is a key downstream target of BRD4-NUT. Expression profiling of NMCs shows that the set of genes whose expression is maintained by BRD4-NUT is highly enriched for MYC upregulated genes, and MYC and BRD4-NUT protein expression is strongly correlated in primary NMCs. More directly, we find that BRD4-NUT associates with the MYC promoter and is required to maintain MYC expression in NMC cell lines. Moreover, both siRNA knockdown of MYC and a dominant-negative form of MYC, omomyc, induce differentiation of NMC cells. Conversely, differentiation of NMC cells induced by knockdown of BRD4-NUT is abrogated by enforced expression of MYC. Together, these findings suggest that MYC is a downstream target of BRD4-NUT that is required for maintenance of NMC cells in an undifferentiated, proliferative state. Our findings support a model in which dysregulation of MYC by BRD-NUT fusion proteins has a central role in the pathogenesis of NMC.	[Grayson, A. R.; Walsh, E. M.; Cameron, M. J.; Ashworth, T.; Ambrose, J. M.; Aserlind, A. B.; Wang, H.; Kluk, M. J.; Aster, J. C.; French, C. A.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Grayson, A. R.; Walsh, E. M.; Cameron, M. J.; Ashworth, T.; Ambrose, J. M.; Aserlind, A. B.; Wang, H.; Kluk, M. J.; Bradner, J. E.; Aster, J. C.; French, C. A.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Godec, J.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA 02115 USA; [Godec, J.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [Evan, G. I.] Univ Cambridge, Dept Biochem, Cambridge CB2 1QW, England; [Bradner, J. E.] Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; University of Cambridge; Harvard University; Dana-Farber Cancer Institute	French, CA (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	cfrench@partners.org			Samuel Waxman Cancer Research Foundation; US National Institutes of Health [1R01CA124633]; Adolescent and Young Adult Gap Fund; American Association for Cancer Research [10-20-03-FREN]; NATIONAL CANCER INSTITUTE [R01CA124633] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007627] Funding Source: NIH RePORTER	Samuel Waxman Cancer Research Foundation; US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Adolescent and Young Adult Gap Fund; American Association for Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was supported by the Samuel Waxman Cancer Research Foundation (CAF and JEB), the US National Institutes of Health grant 1R01CA124633 (CAF), the Adolescent and Young Adult Gap Fund (CAF and JEB), and the American Association for Cancer Research grant 10-20-03-FREN. We would like to thank Dr Nicholas Haining for assistance with GSEA. Many thanks to Dr Paola Dal Cin for providing fluorescent in situ hybridization probes, and to Mr Dan Shea for his assistance with fluorescent in situ hybridization photomicrographs. High-throughput siRNA assays were performed at the Institute of Chemistry and Cell Biology, Longwood Campus (ICCB-L, http://iccb.med.harvard.edu/).	AbouElella A, 1996, MODERN PATHOL, V9, P95; Acosta JC, 2008, MOL CELL BIOL, V28, P7286, DOI 10.1128/MCB.00752-08; Akervall J, 2003, CLIN CANCER RES, V9, P1750; Arnold I, 2001, CURR BIOL, V11, P558, DOI 10.1016/S0960-9822(01)00154-3; Barrans S, 2010, J CLIN ONCOL, V28, P3360, DOI 10.1200/JCO.2009.26.3947; Bauer DE, 2012, CLIN CANCER RES, V18, P5773, DOI 10.1158/1078-0432.CCR-12-1153; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; FIELD JK, 1989, ONCOGENE, V4, P1463; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Flores I, 2004, ONCOGENE, V23, P5923, DOI 10.1038/sj.onc.1207796; French CA, 2008, ONCOGENE, V27, P2237, DOI 10.1038/sj.onc.1210852; French CA, 2003, CANCER RES, V63, P304; Gandarillas A, 1997, GENE DEV, V11, P2869, DOI 10.1101/gad.11.21.2869; Gomez-Casares MT, 2013, ONCOGENE, V32, P2239, DOI 10.1038/onc.2012.246; Haack H, 2009, AM J SURG PATHOL, V33, P984, DOI 10.1097/PAS.0b013e318198d666; Ince TA, 2007, CANCER CELL, V12, P160, DOI 10.1016/j.ccr.2007.06.013; Kluk MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033813; Knoepfler PS, 2006, EMBO J, V25, P2723, DOI 10.1038/sj.emboj.7601152; Lin CH, 2009, EMBO J, V28, P3157, DOI 10.1038/emboj.2009.254; Lin YJ, 2008, PROTEIN SCI, V17, P2174, DOI 10.1110/ps.037580.108; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; Mossafa H, 2006, LEUKEMIA LYMPHOMA, V47, P1885, DOI 10.1080/10428190600687547; Murphy DJ, 2008, CANCER CELL, V14, P447, DOI 10.1016/j.ccr.2008.10.018; Pelengaris S, 1999, MOL CELL, V3, P565, DOI 10.1016/S1097-2765(00)80350-0; Pelengaris S, 2002, CELL, V109, P321, DOI 10.1016/S0092-8674(02)00738-9; Pellakuru LG, 2012, AM J PATHOL, V181, P560, DOI 10.1016/j.ajpath.2012.04.021; Reynoird N, 2010, EMBO J, V29, P2943, DOI 10.1038/emboj.2010.176; Savage KJ, 2009, BLOOD, V114, P3533, DOI 10.1182/blood-2009-05-220095; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Schwartz BE, 2011, CANCER RES, V71, P2686, DOI 10.1158/0008-5472.CAN-10-3513; Senapedis WT, 2011, MOL BIOL CELL, V22, P1791, DOI 10.1091/mbc.E10-10-0854; Soucek L, 2004, CELL DEATH DIFFER, V11, P1038, DOI 10.1038/sj.cdd.4401443; Soucek L, 2002, CANCER RES, V62, P3507; Soucek L, 2008, NATURE, V455, P679, DOI 10.1038/nature07260; Stelow EB, 2008, AM J SURG PATHOL, V32A, P828, DOI 10.1097/PAS.0b013e31815a3900; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Subramanian A, 2007, BIOINFORMATICS, V23, P3251, DOI 10.1093/bioinformatics/btm369; Toretsky JA, 2003, AM J CLIN ONCOL-CANC, V26, P300, DOI 10.1097/00000421-200306000-00019; Varlakhanova NV, 2010, DIFFERENTIATION, V80, P9, DOI 10.1016/j.diff.2010.05.001; Varlakhanova NV, 2009, CANCER RES, V69, P7487, DOI 10.1158/0008-5472.CAN-08-4832; Watt FM, 2008, NAT REV CANCER, V8, P234, DOI 10.1038/nrc2328; Yan JP, 2011, J BIOL CHEM, V286, P27663, DOI 10.1074/jbc.M111.246975; YOUNG J, 1994, ONCOGENE, V9, P1053; Yu DN, 2005, ANN NY ACAD SCI, V1059, P145, DOI 10.1196/annals.1339.047; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	45	113	116	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2014	33	13					1736	1742		10.1038/onc.2013.126	http://dx.doi.org/10.1038/onc.2013.126			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9QY	23604113	Green Accepted			2022-12-28	WOS:000334344700013
J	Li, Y; Teo, WL; Low, MJ; Meijer, L; Sanderson, I; Pettersson, S; Greicius, G				Li, Y.; Teo, W. L.; Low, M. J.; Meijer, L.; Sanderson, I.; Pettersson, S.; Greicius, G.			Constitutive TLR4 signalling in intestinal epithelium reduces tumor load by increasing apoptosis in APC(Min/+) mice	ONCOGENE			English	Article						TLR4; APC(Min/+); Cox-2; apoptosis; Paneth cells; tumorigenesis	HUMAN COLON-CANCER; FAMILIAL ADENOMATOUS POLYPOSIS; CELLS IN-VITRO; CYCLOOXYGENASE-2 INHIBITOR; TRANSGENIC MICE; GROWTH; EXPRESSION; PROTEIN; VIVO; LIPOPOLYSACCHARIDE	The microbial pattern-recognizing Toll-like receptors (TLRs) are major signal transducers known to shape and influence the postnatal maturation of host intestinal epithelium. Perturbations in this intricate host-microbe cross-talk have been reported to be associated with uncontrolled epithelial cell growth and thus potential cancer development by mechanisms which are largely unknown. We therefore generated transgenic mice carrying a constitutively active TLR4 (CD4-TLR4) linked to an intestinal epithelial cell-specific promoter. Ex vivo analysis of transgenic crypt-villus organoid cultures revealed an increased proliferative capacity and a lowered cyclooxygenase 2 (Cox-2) expression in these organoids compared with wild-type control cultures. Introducing the CD4-TLR4 transgene into APC(Min/+) mice (CD4-TLR4-APC(Min/+)), a model of colorectal carcinoma, resulted in a dramatic drop in tumor load as compared with control APC(Min/+) mice. Intestinal tumors from CD4-TLR4-APC(Min/+) mice displayed reduced Cox-2 protein, elevated interferon beta expression and increased caspase-3 activity, which correlated with increased apoptosis in vivo. Thus, our data reveal that host microbiota-mediated signal transduction via TLR4 in intestinal epithelial cells is far more complex than what is previously reported.	[Li, Y.; Meijer, L.; Pettersson, S.] Karolinska Inst, Dept Microbiol Tumor & Cell Biol MTC, S-17177 Stockholm, Sweden; [Li, Y.] ASTAR, Singapore Immunol Network SIgN, Singapore, Singapore; [Teo, W. L.; Low, M. J.; Pettersson, S.; Greicius, G.] Natl Canc Ctr, Singapore, Singapore; [Sanderson, I.] Barts & London Queen Marys Sch Med & Dent, Digest Dis Clin Acad Unit, London, England; [Pettersson, S.] Nanyang Technol Univ, Sch Biol Sci, Singapore 639798, Singapore	Karolinska Institutet; Agency for Science Technology & Research (A*STAR); A*STAR - Singapore Immunology Network (SIgN); National Cancer Centre Singapore (NCCS); University of London; Queen Mary University London; Nanyang Technological University & National Institute of Education (NIE) Singapore; Nanyang Technological University	Pettersson, S (corresponding author), Karolinska Inst, Dept Microbiol Tumor & Cell Biol MTC, Theorells Vag 3, S-17177 Stockholm, Sweden.	Sven.Pettersson@ki.se	Pettersson, Sven/F-9511-2015; Li, Yinghui/K-8253-2018	Li, Yinghui/0000-0002-9023-9466; Greicius, Gediminas/0000-0001-8333-787X; Sanderson, Ian/0000-0002-9814-0161	Singapore Immunology Network [(SIgN)-SIgN 10-038]	Singapore Immunology Network(Agency for Science Technology & Research (A*STAR))	Our research work was funded by a grant from Singapore Immunology Network (SIgN)-SIgN 10-038. We would like to thank Dr Robert Wallin for his great expertise and assistance in using the deconvolution microscope for anti-CD4 fluorescence imaging. We thank Velmurugesan Arulampalam for valuable discussions regarding our study. We also thank Arlaine Anne Bautista Amoyo, Jieshun Wong and Annika Samuelsson for their technical support with animal care and handling.	Andreani V, 2007, CANCER RES, V67, P10519, DOI 10.1158/0008-5472.CAN-07-0079; ARULAMPALAM V, 1994, EUR J IMMUNOL, V24, P1671, DOI 10.1002/eji.1830240732; Bohnhorst J, 2006, LEUKEMIA, V20, P1138, DOI 10.1038/sj.leu.2404225; Brown SL, 2007, J CLIN INVEST, V117, P258, DOI 10.1172/JCI29159; Chicoine MR, 2007, NEUROSURGERY, V60, P372, DOI 10.1227/01.NEU.0000249280.61761.2E; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; Cursio R, 2008, TRANSPL P, V40, P2038, DOI 10.1016/j.transproceed.2008.05.039; Fukata M, 2006, GASTROENTEROLOGY, V131, P862, DOI 10.1053/j.gastro.2006.06.017; Fukata M, 2011, INFLAMM BOWEL DIS, V17, P1464, DOI 10.1002/ibd.21527; Garay RP, 2007, EUR J PHARMACOL, V563, P1, DOI 10.1016/j.ejphar.2007.02.018; Nunez NG, 2012, CANCER RES, V72, P592, DOI 10.1158/0008-5472.CAN-11-0534; Gregorieff A, 2005, GASTROENTEROLOGY, V129, P626, DOI 10.1053/j.gastro.2005.06.007; Harmey JH, 2002, INT J CANCER, V101, P415, DOI 10.1002/ijc.10632; KARGMAN SL, 1995, CANCER RES, V55, P2556; Klampfer L, 2007, ONCOGENE, V26, P2071, DOI 10.1038/sj.onc.1210015; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Li YH, 2012, CARCINOGENESIS, V33, P1231, DOI 10.1093/carcin/bgs137; Luo JL, 2004, CANCER CELL, V6, P297, DOI 10.1016/j.ccr.2004.08.012; MAEHARA Y, 1994, AM J SURG, V168, P36, DOI 10.1016/S0002-9610(05)80068-6; Matsushita K, 2009, NATURE, V458, P1185, DOI 10.1038/nature07924; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; Muller-Decker K, 2002, P NATL ACAD SCI USA, V99, P12483, DOI 10.1073/pnas.192323799; Nakamoto N, 2006, INT J ONCOL, V29, P625; Ohtsuka Y, 2001, GUT, V49, P526, DOI 10.1136/gut.49.4.526; Otto F, 1996, EUR J CANCER, V32A, P1712, DOI 10.1016/0959-8049(96)00186-4; Pidgeon GP, 1999, BRIT J CANCER, V81, P1311, DOI 10.1038/sj.bjc.6694369; Rakoff-Nahoum S, 2007, SCIENCE, V317, P124, DOI 10.1126/science.1140488; Razack AHA, 2007, ASIAN J SURG, V30, P302, DOI 10.1016/S1015-9584(08)60045-7; Sato M, 1997, APOPTOSIS, V2, P227, DOI 10.1023/A:1026428918301; Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637; Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935; Sheng HM, 1997, J CLIN INVEST, V99, P2254, DOI 10.1172/JCI119400; Singh B, 2005, INT J ONCOL, V26, P1393; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Swamy MV, 2006, CANCER RES, V66, P7370, DOI 10.1158/0008-5472.CAN-05-4619; SWEETSER DA, 1988, P NATL ACAD SCI USA, V85, P9611, DOI 10.1073/pnas.85.24.9611; Trifan OC, 2003, J CELL MOL MED, V7, P207, DOI 10.1111/j.1582-4934.2003.tb00222.x; Wang D, 2006, GUT, V55, P115, DOI 10.1136/gut.2004.047100; Yokota S, 2010, INFECT IMMUN, V78, P468, DOI 10.1128/IAI.00903-09	41	15	16	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2014	33	3					369	377		10.1038/onc.2012.581	http://dx.doi.org/10.1038/onc.2012.581			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VR	23318418	Green Submitted			2022-12-28	WOS:000330214000011
J	Kumari, U; Jun, WY; Bay, BH; Lyakhovich, A				Kumari, U.; Jun, W. Ya; Bay, B. Huat; Lyakhovich, A.			Evidence of mitochondrial dysfunction and impaired ROS detoxifying machinery in Fanconi Anemia cells	ONCOGENE			English	Article						Fanconi Anemia; reactive oxygen species; mitochondria	INTERSTRAND CROSS-LINK; OXIDATIVE STRESS; REACTIVE OXYGEN; SUPEROXIDE-DISMUTASE; SKELETAL-MUSCLE; DNA-REPAIR; PATHWAY; MUTATION; DAMAGE; FANCD2	Fanconi Anemia (FA) is a rare genetic disorder associated with a bone-marrow failure, cancer predisposition and hypersensitivity to DNA crosslinking agents. Majority of the 15 FA genes and encoded proteins characterized so far are integrated into DNA repair pathways, however, other important functions cannot be excluded. FA cells are sensitive to oxidants, and accumulation of oxidized proteins has been characterized for several FA subgroups. Clinical phenotypes of both FA and other closely related diseases suggest altered functions of mitochondria, organelles responsible for cellular energetic metabolism, and also serving as an important producer and the most susceptible target from reactive oxidative species (ROS). In this study, we have shown that elevated level of mitochondrial ROS in FA cells is in parallel with the decrease of mitochondrial membrane potential, the decrease of ATP production, impaired oxygen uptake and pathological changes in the morphology of mitochondria. This is accompanied by inactivation of enzymes that are essential for the energy production (F1F0ATPase and cytochrome C oxidase) and detoxification of ROS (superoxide dismutase, SOD1). In turn, overexpression of SOD1 could rescue oxygen consumption rate in FA-deficient cells. Importantly, the depletion of mitochondria improved survival rate of mitomycin C treated FA cells suggesting that hypersensitivity of FA cells to chemotherapeutic drugs could be in part due to the mitochondria-mediated oxidative stress. On the basis of our results, we propose that deficiency in FA genes lead to disabling mitochondrial ROS-scavenging machinery further affecting mitochondrial functions and suppressing cell respiration.	[Kumari, U.; Lyakhovich, A.] Duke NUS Grad Med Sch, Canc & Stem Cell Biol Program, Singapore 169857, Singapore; [Jun, W. Ya; Bay, B. Huat] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Singapore 117595, Singapore	National University of Singapore; National University of Singapore	Lyakhovich, A (corresponding author), Duke NUS Grad Med Sch, Canc & Stem Cell Biol Program, Coll Rd,Level 6, Singapore 169857, Singapore.	lyakhovich@gmail.com	Lyakhovich, Alex/B-4410-2008	Lyakhovich, Alex/0000-0002-8279-4697				Ali SS, 2010, J BIOL CHEM, V285, P32522, DOI 10.1074/jbc.M110.155432; Allan AC, 1997, PLANT CELL, V9, P1559, DOI 10.1105/tpc.9.9.1559; AMANO F, 1995, FEBS LETT, V368, P425, DOI 10.1016/0014-5793(95)00700-J; Bogliolo M, 2002, MUTAGENESIS, V17, P25, DOI 10.1093/mutage/17.1.25; Bogliolo M, 2007, EMBO J, V26, P1340, DOI 10.1038/sj.emboj.7601574; Chacinska A, 2009, CELL, V138, P628, DOI 10.1016/j.cell.2009.08.005; Cossarizza A., 2001, CURR PROTOC CYTOM, DOI [10.1002/0471142956.cy0914s13, DOI 10.1002/0471142956.CY0914S13]; Cuccarolo P, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-63; DALLAPICCOLA B, 1985, HUM GENET, V69, P62, DOI 10.1007/BF00295530; Deans AJ, 2011, NAT REV CANCER, V11, P467, DOI 10.1038/nrc3088; DEGAN P, 1995, CARCINOGENESIS, V16, P735, DOI 10.1093/carcin/16.4.735; Dirmeier R, 2002, J BIOL CHEM, V277, P34773, DOI 10.1074/jbc.M203902200; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Du W, 2012, BLOOD, V119, P4142, DOI 10.1182/blood-2011-09-381970; Frezza C, 2007, NAT PROTOC, V2, P287, DOI 10.1038/nprot.2006.478; Fridlyand LE, 2005, ANN NY ACAD SCI, V1066, P136, DOI 10.1196/annals.1363.019; Hadjur S, 2001, BLOOD, V98, P1003, DOI 10.1182/blood.V98.4.1003; Hutter E, 2007, AGING CELL, V6, P245, DOI 10.1111/j.1474-9726.2007.00282.x; JOENJE H, 1981, NATURE, V290, P142, DOI 10.1038/290142a0; Kennedy RD, 2005, GENE DEV, V19, P2925, DOI 10.1101/gad.1370505; Kim Y, 2011, NAT GENET, V43, P142, DOI 10.1038/ng.750; Kumar B, 2008, CANCER RES, V68, P1777, DOI 10.1158/0008-5472.CAN-07-5259; Li RC, 2008, BRAIN RES, V1190, P159, DOI 10.1016/j.brainres.2007.11.022; Lyakhovich A, 2010, MOL CANCER RES, V8, P46, DOI 10.1158/1541-7786.MCR-09-0373; Meetei AR, 2003, NAT GENET, V35, P165, DOI 10.1038/ng1241; Miller SW, 1996, J NEUROCHEM, V67, P1897; Moldovan GL, 2009, CELL, V139, P1222, DOI 10.1016/j.cell.2009.12.006; Mukhopadhyay SS, 2006, J CELL BIOL, V175, P225, DOI 10.1083/jcb.200607061; NORDENSON I, 1977, HEREDITAS, V86, P147; O'Neill HC, 2011, AM J RESP CELL MOL, V45, P323, DOI 10.1165/rcmb.2010-0214OC; Pagano G, 2004, CARCINOGENESIS, V25, P1899, DOI 10.1093/carcin/bgh194; Pagano G, 1997, BLOOD, V89, P1111, DOI 10.1182/blood.V89.3.1111; Pagano G, 2012, BIOL CHEM, V393, P11, DOI 10.1515/BC-2011-227; Pallardo FV, 2010, BIOGERONTOLOGY, V11, P401, DOI 10.1007/s10522-010-9269-4; Petrovic S, 2011, BIOL CHEM, V392, P625, DOI 10.1515/BC.2011.064; Ponte F, 2011, TOXICOLOGY, V289, P52, DOI 10.1016/j.tox.2011.07.009; Rachek LI, 2007, ENDOCRINOLOGY, V148, P293, DOI 10.1210/en.2006-0998; Rani R, 2008, CANCER RES, V68, P9693, DOI 10.1158/0008-5472.CAN-08-1790; RICHTER C, 1991, CHEM-BIOL INTERACT, V77, P1, DOI 10.1016/0009-2797(91)90002-O; Rousset S, 2002, PHOTOCHEM PHOTOBIOL, V75, P159, DOI 10.1562/0031-8655(2002)075<0159:MAIFAF>2.0.CO;2; ROUSSET S, 1990, CANCER RES, V50, P2443; Ruppitsch W, 1997, HUM GENET, V99, P710, DOI 10.1007/s004390050437; Saadatzadeh MR, 2004, J BIOL CHEM, V279, P16805, DOI 10.1074/jbc.M313721200; SCHINDLER D, 1988, AM J HUM GENET, V43, P429; TAKEUCHI T, 1993, CARCINOGENESIS, V14, P1115, DOI 10.1093/carcin/14.6.1115; Talbot DA, 2004, FEBS LETT, V556, P111, DOI 10.1016/S0014-5793(03)01386-3; Tobaben S, 2011, CELL DEATH DIFFER, V18, P282, DOI 10.1038/cdd.2010.92; Uchida K, 2003, PROG LIPID RES, V42, P318, DOI 10.1016/S0163-7827(03)00014-6; Vandenberg CJ, 2003, MOL CELL, V12, P247, DOI 10.1016/S1097-2765(03)00281-8; Vaz F, 2010, NAT GENET, V42, P406, DOI 10.1038/ng.570; Wu YL, 2010, BLOOD, V116, P3780, DOI 10.1182/blood-2009-11-256016; Xue YT, 2008, HUM MOL GENET, V17, P1641, DOI 10.1093/hmg/ddn054; Yu TZ, 2006, P NATL ACAD SCI USA, V103, P2653, DOI 10.1073/pnas.0511154103	53	74	75	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2014	33	2					165	172		10.1038/onc.2012.583	http://dx.doi.org/10.1038/onc.2012.583			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286BY	23318445				2022-12-28	WOS:000329440700004
J	Zhang, J; Bai, D; Ma, X; Guan, J; Zheng, X				Zhang, J.; Bai, D.; Ma, X.; Guan, J.; Zheng, X.			hCINAP is a novel regulator of ribosomal protein-HDM2-p53 pathway by controlling NEDDylation of ribosomal protein S14	ONCOGENE			English	Article						hCINAP; RPS14; NEDDylation; HDM2; p53	ADENYLATE KINASE; P53; HDM2; MDM2; IDENTIFICATION; DEGRADATION; ACTIVATION; FAP7	The tumor-suppressor p53 provides a critical brake on tumor development. HDM2 (human double-minute 2), a p53 E3 ubiquitin ligase, is the principal cellular antagonist of p53. Mounting evidence has suggested that ribosomal proteins (RPs) modulate HDM2-p53 as a novel pathway for regulating p53 signaling. However, the upstream regulators that mediate RP-HDM2-p53 circuits remain poorly understood. Here we identify human coilin-interacting nuclear ATPase protein (hCINAP) as an interacting partner of ribosomal protein S14 (RPS14). RPS14 stabilized and activated p53 by inhibiting HDM2-mediated p53 polyubiquitination and degradation. More importantly, RPS14 was specifically modified with NEDD8 and hCINAP inhibited RPS14 NEDDylation by recruiting NEDD8-specific protease 1. The decrease in RPS14 NEDDylation led to reduced stability and incorrect localization of RPS14, thereby attenuating the interaction between RPS14 and HDM2. Free HDM2 stimulated p53 polyubiquitination and degradation. In conclusion, we demonstrate that hCINAP acts as a novel regulator of RPS14-HDM2-p53 by regulating the interaction between RPS14 and HDM2 through the control of RPS14 NEDDylation. These findings suggest that hCINAP is an important regulator of RP-HDM2-p53 pathway and a potential anticancer drug target.	[Zhang, J.; Bai, D.; Guan, J.; Zheng, X.] State Key Lab Prot & Plant Gene Res, Beijing, Peoples R China; [Zhang, J.; Bai, D.; Ma, X.; Guan, J.; Zheng, X.] Peking Univ, Dept Biochem & Mol Biol, Sch Life Sci, Beijing 100871, Peoples R China	Peking University	Zheng, X (corresponding author), Peking Univ, Dept Biochem & Mol Biol, Sch Life Sci, Beijing 100871, Peoples R China.	xiaofengz@pku.edu.cn	关, 俊宏/AAG-1046-2021	关, 俊宏/0000-0003-4900-0610	National Science Foundation of China [31170709, 30930020]; National High Technology and Development Program of China (973 Program) [2010CB911804]; International Center for Genetic Engineering and Biotechnology [CRP/CHN09-01]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); National High Technology and Development Program of China (973 Program)(National Basic Research Program of ChinaNational High Technology Research and Development Program of China); International Center for Genetic Engineering and Biotechnology	We sincerely thank Dr Jian Wang from the State Key Laboratory of Proteomics, Beijing Proteome Research Center for providing plasmids for HDM2 and its truncation constructs. We thank Dr Jun Gu at Peking University for providing the HCT116 cells and reporter plasmids. This work was supported by Grants from the National Science Foundation of China (31170709, 30930020), the National High Technology and Development Program of China (973 Program, 2010CB911804) and the International Center for Genetic Engineering and Biotechnology (project no. CRP/CHN09-01). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.	Barlow JL, 2010, NAT MED, V16, P59, DOI 10.1038/nm.2063; Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Chen D, 2007, ONCOGENE, V26, P5029, DOI 10.1038/sj.onc.1210327; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; de Marval PLM, 2011, ONCOTARGET, V2, P234; Deisenroth C, 2010, ONCOGENE, V29, P4253, DOI 10.1038/onc.2010.189; Deisenroth Chad, 2011, Genes Cancer, V2, P392, DOI 10.1177/1947601911409737; Dey A, 2010, SEMIN CANCER BIOL, V20, P3, DOI 10.1016/j.semcancer.2010.02.004; Dutt S, 2011, BLOOD, V117, P2567, DOI 10.1182/blood-2010-07-295238; Ebert BL, 2008, NATURE, V451, P335, DOI 10.1038/nature06494; Fumagalli S, 2012, GENE DEV, V26, P1028, DOI 10.1101/gad.189951.112; Granneman S, 2005, MOL CELL BIOL, V25, P10352, DOI 10.1128/MCB.25.23.10352-10364.2005; Ha BH, 2008, BMB REP, V41, P435, DOI 10.5483/BMBRep.2008.41.6.435; Juhnke H, 2000, MOL MICROBIOL, V35, P936, DOI 10.1046/j.1365-2958.2000.01768.x; Lane D, 2010, COLD SPRING HARB PER, V2; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Malekkou A, 2010, FEBS LETT, V584, P4559, DOI 10.1016/j.febslet.2010.10.044; Meng G, 2008, BIOCHEMISTRY-MOSCOW+, V73, P38, DOI 10.1134/S0006297908010057; Moll UM, 2003, MOL CANCER RES, V1, P1001; Narla A, 2010, BLOOD, V115, P3196, DOI 10.1182/blood-2009-10-178129; Pan WQ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021625; Santama N, 2005, J BIOL CHEM, V280, P36429, DOI 10.1074/jbc.M501982200; Sasaki M, 2011, NAT MED, V17, P944, DOI 10.1038/nm.2392; Sundqvist A, 2009, EMBO REP, V10, P1132, DOI 10.1038/embor.2009.178; Takahashi T, 2010, J TOXICOL SCI, V35, P945, DOI 10.2131/jts.35.945; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Warner JR, 2009, MOL CELL, V34, P3, DOI 10.1016/j.molcel.2009.03.006; Xiong X, 2011, ONCOGENE, V30, P1798, DOI 10.1038/onc.2010.569; Xirodimas DP, 2008, EMBO REP, V9, P280, DOI 10.1038/embor.2008.10; Xirodimas DP, 2004, CELL, V118, P83, DOI 10.1016/j.cell.2004.06.016; Yadavilli S, 2009, DNA REPAIR, V8, P1215, DOI 10.1016/j.dnarep.2009.07.003; Zhai RT, 2006, FEBS LETT, V580, P3811, DOI 10.1016/j.febslet.2006.05.074; Zhang JF, 2010, CELL MOL LIFE SCI, V67, P1907, DOI 10.1007/s00018-010-0301-2; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhang Y, 2010, NUCLEIC ACIDS RES, V38, P6544, DOI 10.1093/nar/gkq536; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhou X, 2012, ONCOGENE, V63, P1; Zhu Y, 2009, MOL CELL, V35, P316, DOI 10.1016/j.molcel.2009.07.014	39	43	45	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2014	33	2					246	254		10.1038/onc.2012.560	http://dx.doi.org/10.1038/onc.2012.560			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286BY	23246961				2022-12-28	WOS:000329440700012
J	Choi, HH; Choi, HK; Jung, SY; Hyle, J; Kim, BJ; Yoon, K; Cho, EJ; Youn, HD; Lahti, JM; Qin, J; Kim, ST				Choi, H-H; Choi, H-K; Jung, S. Y.; Hyle, J.; Kim, B-J; Yoon, K.; Cho, E-J; Youn, H-D; Lahti, J. M.; Qin, J.; Kim, S-T			CHK2 kinase promotes pre-mRNA splicing via phosphorylating CDK11p110	ONCOGENE			English	Article						CHK2; pre-mRNA splicing; CDK11; DNA damage response pathway	DNA-DAMAGE CHECKPOINT; ACTIVATION; CANCER; P53; SUSCEPTIBILITY; COMPLEXES; BRCA1; CELLS; CHEK2; ATM	Checkpoint kinase 2 (CHK2) kinase is a key mediator in many cellular responses to genotoxic stresses, including ionizing radiation (IR) and topoisomerase inhibitors. Upon IR, CHK2 is activated by ataxia telangiectasia mutated kinase and regulates the S-phase and G1-S checkpoints, apoptosis and DNA repair by phosphorylating downstream target proteins, such as p53 and Brca1. In addition, CHK2 is thought to be a multi-organ cancer susceptibility gene. In this study, we used a tandem affinity purification strategy to identify proteins that interact with CHK2 kinase. Cyclin-dependent kinase 11 (CDK11)(p110) kinase, implicated in pre-mRNA splicing and transcription, was identified as a CHK2-interacting protein. CHK2 kinase phosphorylated CDK11(p110) on serine 737 in vitro. Unexpectedly, CHK2 kinase constitutively phosphorylated CDK11(p110) in a DNA damage-independent manner. At a molecular level, CDK11(p110) phosphorylation was required for homodimerization without affecting its kinase activity. Overexpression of CHK2 promoted pre-mRNA splicing. Conversely, CHK2 depletion decreased endogenous splicing activity. Mutation of the phosphorylation site in CDK11(p110) to alanine abrogated its splicing-activating activity. These results provide the first evidence that CHK2 kinase promotes pre-mRNA splicing via phosphorylating CDK11(p110).	[Choi, H-H; Choi, H-K; Kim, S-T] Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Dept Mol Cell Biol, 300 Chunchung Dong, Suwon 440746, South Korea; [Jung, S. Y.; Kim, B-J; Qin, J.] Baylor Coll Med, Verna & Marrs McLean Dept Biochem & Mol Biol, Ctr Mol Discovery, Houston, TX 77030 USA; [Hyle, J.; Lahti, J. M.] St Jude Childrens Res Hosp, Dept Genet & Tumor Cell Biol, Memphis, TN 38105 USA; [Yoon, K.] Sungkyunkwan Univ, Sch Life Sci & Biotechnol, Suwon 440746, South Korea; [Cho, E-J] Sungkyunkwan Univ, Sch Pharm, Suwon 440746, South Korea; [Youn, H-D] Seoul Natl Univ, Coll Med, Canc Res Inst, Natl Res Lab Metab Checkpoint,Dept Biomed Sci, Seoul, South Korea; [Youn, H-D] Seoul Natl Univ, Coll Med, Canc Res Inst, Natl Res Lab Metab Checkpoint,Dept Biochem & Mol, Seoul, South Korea	Sungkyunkwan University (SKKU); Baylor College of Medicine; St Jude Children's Research Hospital; Sungkyunkwan University (SKKU); Sungkyunkwan University (SKKU); Seoul National University (SNU); Seoul National University (SNU)	Kim, ST (corresponding author), Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Dept Mol Cell Biol, 300 Chunchung Dong, Suwon 440746, South Korea.	stkim@skku.edu	Lahti, Jari/P-7987-2018; Cho, Eun-Jung/AAR-1785-2020	Lahti, Jari/0000-0002-4310-5297; Cho, Eun-Jung/0000-0002-6610-5329; Yoon, Keejung/0000-0002-2361-9039; Jung, Sung Yun/0000-0003-1521-7977	NRF [20110008174]; Ministry of Science and Technology, Republic of Korea.; NATIONAL CANCER INSTITUTE [P30CA021765, R01CA067938] Funding Source: NIH RePORTER	NRF; Ministry of Science and Technology, Republic of Korea.(Ministry of Science & Technology (MOST), Republic of Korea); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Richard R Vaillancourt for providing HA-CDK11<SUP>p110</SUP> expression vector; Dr Anglus I Lamond for pBSAL4 plasmid; Dr Gideon Dreyfuss for pCMV-Luc 2CP/ARE and pCMV-Luc 2CP/Intron/ARE plasmids; Dr Eperon for the pTN24 plasmids; Dr Jin-Hyun Ahn for pDEST-SG5-HA, pDEST-SG5-flag destination vectors and early passage human diploid fibroblast cell lines. This work was supported by NRF Grants 20110008174, funded by the Ministry of Science and Technology, Republic of Korea.	Ahn J, 2002, J BIOL CHEM, V277, P48418, DOI 10.1074/jbc.M208321200; Bartek J, 2001, NAT REV MOL CELL BIO, V2, P877, DOI 10.1038/35103059; Blencowe BJ, 2003, CURR BIOL, V13, pR149, DOI 10.1016/S0960-9822(03)00079-4; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; Chi YY, 2011, J BIOL CHEM, V286, P1748, DOI 10.1074/jbc.M110.107367; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Cybulski C, 2004, AM J HUM GENET, V75, P1131, DOI 10.1086/426403; Darbon JM, 2000, J BIOL CHEM, V275, P15363, DOI 10.1074/jbc.275.20.15363; Dong XY, 2003, AM J HUM GENET, V72, P270, DOI 10.1086/346094; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Franck N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014600; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hu DL, 2003, J BIOL CHEM, V278, P8623, DOI 10.1074/jbc.M210057200; Hu DL, 2007, J CELL SCI, V120, P2424, DOI 10.1242/jcs.007963; LAMOND AI, 1987, GENE DEV, V1, P532, DOI 10.1101/gad.1.6.532; Lee JS, 2000, NATURE, V404, P201, DOI 10.1038/35004614; Lee SB, 2001, CANCER RES, V61, P8062; Loyer P, 2008, J BIOL CHEM, V283, P7721, DOI 10.1074/jbc.M708188200; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Nasim MT, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf108; Nybakken K, 2005, NAT GENET, V37, P1323, DOI 10.1038/ng1682; O'Neill T, 2002, J BIOL CHEM, V277, P16102, DOI 10.1074/jbc.M111705200; Pabla N, 2008, J BIOL CHEM, V283, P6572, DOI 10.1074/jbc.M707568200; Petretti C, 2006, EMBO REP, V7, P418, DOI 10.1038/sj.embor.7400639; Pommier Y, 2006, CLIN CANCER RES, V12, P2657, DOI 10.1158/1078-0432.CCR-06-0743; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Sachs NA, 2003, BBA-GEN SUBJECTS, V1624, P98, DOI 10.1016/j.bbagen.2003.10.001; Seo GJ, 2003, BIOCHEM BIOPH RES CO, V304, P339, DOI 10.1016/S0006-291X(03)00589-8; Shieh SY, 2000, GENE DEV, V14, P289; Solier S, 2009, MOL CELL BIOL, V29, P68, DOI 10.1128/MCB.00581-08; Stolz A, 2010, NAT CELL BIOL, V12, P492, DOI 10.1038/ncb2051; Trembley JH, 2002, J BIOL CHEM, V277, P2589, DOI 10.1074/jbc.M109755200; Valente ST, 2009, MOL CELL, V36, P279, DOI 10.1016/j.molcel.2009.10.004; Ward AJ, 2010, J PATHOL, V220, P152, DOI 10.1002/path.2649; Wilker EW, 2007, NATURE, V446, P329, DOI 10.1038/nature05584; Yang ST, 2002, NAT CELL BIOL, V4, P865, DOI 10.1038/ncb869; Younis I, 2010, MOL CELL BIOL, V30, P1718, DOI 10.1128/MCB.01301-09; Zong HL, 2007, MOL CELL BIOL, V27, P7125, DOI 10.1128/MCB.01753-06	41	21	29	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2014	33	1					108	115		10.1038/onc.2012.535	http://dx.doi.org/10.1038/onc.2012.535			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	282YU	23178491	Green Accepted			2022-12-28	WOS:000329212000012
J	Berger, T; Ueda, T; Arpaia, E; Chio, IIC; Shirdel, EA; Jurisica, I; Hamada, K; You-Ten, A; Haight, J; Wakeham, A; Cheung, CC; Mak, TW				Berger, T.; Ueda, T.; Arpaia, E.; Chio, I. I. C.; Shirdel, E. A.; Jurisica, I.; Hamada, K.; You-Ten, A.; Haight, J.; Wakeham, A.; Cheung, C. C.; Mak, T. W.			Flotillin-2 deficiency leads to reduced lung metastases in a mouse breast cancer model	ONCOGENE			English	Article						breast cancer; metastasis; MMTV-PyMT; flotillin-1; reggie1/2	SIGNAL-TRANSDUCTION; UP-REGULATION; LIPID RAFTS; CELL-LINES; MICROARRAY; EXPRESSION; PROTEINS; DISEASE; GENOME; CYTOSKELETON	Flotillin microdomains, specialized lipid raft domains in cell membranes, serve as physical platforms for many different molecules important in crucial intracellular signaling pathways. Flotillin-2 (Flot2), together with flotillin-1, is a marker for lipid raft microdomains distinct from caveolar lipid rafts, and has been implicated in the progression of cancer and metastasis formation. Based largely on studies in xenograft models, flotillin-2 has been implicated in the progression of multiple types of human tumors, including breast cancer. In our studies, we identified flotillin-2 as highly amplified in a high-throughput comparative genomic hybridization screen of human breast cancer cell lines and breast tumor samples. Short hairpin RNA-mediated reduction of flotillin-2 protein levels significantly reduced the tumorigenicity and metastatic capability of a human breast cancer cell line in vivo. We generated mice deficient for flotillin-2 and also found a reduction of flotillin-1 protein levels and complete absence of flotillin-specific membrane microdomains in these mice. To examine the role of Flot2 in mammary tumorigenesis and lung metastasis, we used an in vivo molecular genetics approach, crossing a well-characterized transgenic mouse model of breast cancer, the MMTV-PyMT (mouse mammary tumor virus-polyoma middle T antigen) mouse, with gene-targeted Flot2(-/-) mice. Flotillin-2 deficiency lead to a striking reduction in the number of lung metastasis observed, but had no influence on primary tumor formation in this model. Our results indicate, using a novel in vivo animal model approach, that Flot2 is an important regulator of mammary tumor-derived lung metastasis.	[Berger, T.; Ueda, T.; Arpaia, E.; Chio, I. I. C.; Shirdel, E. A.; You-Ten, A.; Haight, J.; Wakeham, A.; Mak, T. W.] Univ Hlth Network, Campbell Family Inst Breast Canc Res, Toronto, ON M5G 2M9, Canada; [Ueda, T.] Hiroshima Univ, Res Inst Radiat Biol & Med, Dept Dis Model, Hiroshima, Japan; [Shirdel, E. A.; Jurisica, I.] Univ Hlth Network, Techna Inst, Toronto, ON, Canada; [Shirdel, E. A.; Jurisica, I.] IBM Life Sci Discovery Ctr, Toronto, ON, Canada; [Jurisica, I.; Mak, T. W.] Univ Toronto, Dept Med Phys, Toronto, ON, Canada; [Jurisica, I.; Mak, T. W.] Univ Toronto, Dept Immunol, Toronto, ON, Canada; [Jurisica, I.] Univ Toronto, Dept Comp Sci, Toronto, ON, Canada; [Hamada, K.] Kumamoto Univ, Ctr AIDS Res, Okada Projects, Kumamoto, Japan; [Cheung, C. C.] Univ Hlth Network, Dept Pathol, Toronto, ON, Canada; [Mak, T. W.] Univ Hlth Network, Ontario Canc Inst, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Hiroshima University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto; University of Toronto; Kumamoto University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Mak, TW (corresponding author), Univ Hlth Network, Campbell Family Inst Breast Canc Res, 620 Univ Ave,Suite 706, Toronto, ON M5G 2M9, Canada.	tmak@uhnresearch.ca	Berger, Thorsten/J-7632-2012	Ueda, Takeshi/0000-0001-9823-6764	Ontario Research Fund [GL2-01-030]; Canada Research Chair Program; Canadian Institutes of Health Research [179815]	Ontario Research Fund; Canada Research Chair Program(Canada Research Chairs); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR))	We thank Lily Zhou for expert technical assistance, and Dr Mary Saunders for insightful scientific editing. This work was supported by grant no. 179815 from the Canadian Institutes of Health Research to TWM. This research was funded in part by the Ontario Ministry of Health and Long Term Care. The views expressed do not necessarily reflect those of the OMOHLTC. ES is in part supported by Ontario Research Fund (GL2-01-030) to IJ, and IJ was in part supported by Canada Research Chair Program.	Arpaia E, 2012, ONCOGENE, V31, P884, DOI 10.1038/onc.2011.288; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Boyle P, 2008, WORLD CANC REPORT 20; Buccione R, 2009, CANCER METAST REV, V28, P137, DOI 10.1007/s10555-008-9176-1; de Laurentiis Angela, 2007, Open Biochem J, V1, P12, DOI 10.2174/1874091X00701010012; de Leeuw RJ, 2004, HUM MOL GENET, V13, P1827, DOI 10.1093/hmg/ddh195; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hazarika P, 2004, CANCER RES, V64, P7361, DOI 10.1158/0008-5472.CAN-04-0823; Ishkanian AS, 2004, NAT GENET, V36, P299, DOI 10.1038/ng1307; LEMOYEC L, 1992, BRIT J CANCER, V66, P623, DOI 10.1038/bjc.1992.327; Lin CY, 2011, CLIN CANCER RES, V17, P3089, DOI 10.1158/1078-0432.CCR-10-3068; Lin EY, 2003, AM J PATHOL, V163, P2113, DOI 10.1016/S0002-9440(10)63568-7; Ludwig A, 2010, J CELL BIOL, V191, P771, DOI 10.1083/jcb.201005140; Maglione JE, 2001, CANCER RES, V61, P8298; Neumann-Giesen C, 2007, J CELL SCI, V120, P395, DOI 10.1242/jcs.03336; Nohara K, 1998, BREAST CANCER RES TR, V48, P149, DOI 10.1023/A:1005986606010; Pike LJ, 2003, J LIPID RES, V44, P655, DOI 10.1194/jlr.R200021-JLR200; Qiu TH, 2004, CANCER RES, V64, P5973, DOI 10.1158/0008-5472.CAN-04-0242; Rickman DS, 2008, ONCOGENE, V27, P6607, DOI 10.1038/onc.2008.251; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01; Saeed AI, 2006, METHOD ENZYMOL, V411, P134, DOI 10.1016/S0076-6879(06)11009-5; Schulte T, 1997, DEVELOPMENT, V124, P577; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Stuermer CAO, 2004, FASEB J, V18, P1731, DOI 10.1096/fj.04-2150fje; Watson SK, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-6; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P551, DOI 10.1083/jcb.1.6.551; Yamaguchi H, 2009, CANCER RES, V69, P8594, DOI 10.1158/0008-5472.CAN-09-2305	28	40	44	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2013	32	41					4989	4994		10.1038/onc.2012.499	http://dx.doi.org/10.1038/onc.2012.499			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235KQ	23146906				2022-12-28	WOS:000325717800015
J	Fallone, F; Britton, S; Nieto, L; Salles, B; Muller, C				Fallone, F.; Britton, S.; Nieto, L.; Salles, B.; Muller, C.			ATR controls cellular adaptation to hypoxia through positive regulation of hypoxia-inducible factor 1 (HIF-1) expression	ONCOGENE			English	Article						ATR; PIKK; hypoxia; HIF-1 alpha regulation; translation; replicative stress	DEPENDENT PROTEIN-KINASE; DNA-DAMAGE; MESSENGER-RNA; REQUIRES ATM; CANCER-CELLS; TUMOR-CELLS; PHOSPHORYLATION; HIF-1-ALPHA; INHIBITION; TRANSLATION	Tumor cells adaptation to severe oxygen deprivation (hypoxia) plays a major role in tumor progression. The transcription factor HIF-1 (hypoxia-inducible factor 1), whose alpha-subunit is stabilized under hypoxic conditions is a key component of this process. Recent studies showed that two members of the phosphoinositide 3-kinase-related kinases (PIKKs) family, ATM (ataxia telangiectasia mutated) and DNA-PK (DNA-dependent protein kinase), regulate the hypoxic-dependent accumulation of HIF-1. These proteins initiate cellular stress responses when DNA damage occurs. In addition, it has been demonstrated that extreme hypoxia induces a replicative stress resulting in regions of single-stranded DNA at stalled replication forks and the activation of ATR (ataxia telangiectasia and Rad3 related protein), another member of the PIKKs family. Here, we show that even less severe hypoxia (0.1% O-2) also induces activation of ATR through replicative stress. Importantly, in using either transiently silenced ATR cells, cells expressing an inactive form of ATR or cells exposed to an ATR inhibitor (CGK733), we demonstrate that hypoxic ATR activation positively regulates the key transcription factor HIF-1 independently of the checkpoint kinase Chk1. We show that ATR kinase activity regulates HIF-1 alpha at the translational level and we find that the elements necessary for the regulation of HIF-1 alpha translation are located within the coding region of HIF-1 alpha mRNA. Finally, by using three independent cellular models, we clearly show that the loss of ATR expression and/or kinase activity results in the decrease of HIF-1 DNA binding under hypoxia and consequently affects protein expression levels of two HIF-1 target genes, GLUT-1 and CAIX. Taken together, our data show a new function for ATR in cellular adaptation to hypoxia through regulation of HIF-1 alpha translation. Our work offers new prospect for cancer therapy using ATR inhibitors with the potential to decrease cellular adaptation in hypoxic tumors.	[Fallone, F.; Britton, S.; Nieto, L.; Salles, B.; Muller, C.] CNRS, IPBS, Toulouse, France; [Fallone, F.; Britton, S.; Nieto, L.; Salles, B.; Muller, C.] Univ Toulouse, UPS, IPBS, Toulouse, France	Centre National de la Recherche Scientifique (CNRS); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Muller, C (corresponding author), CNRS, UMR5089, IPBS, 205 Route Narbonne,BP 6418231077, Toulouse, France.	muller@ipbs.fr	Nieto, Laurence/AAJ-5703-2021; Britton, Sébastien/AAL-1862-2020; MULLER, Catherine/E-2060-2011; MULLER, Catherine/M-2185-2018	Nieto, Laurence/0000-0002-1006-0168; Britton, Sébastien/0000-0002-7008-5316; 	'Ligue Nationale Contre le Cancer' (Equipe Labelisee); Canceropole GSO; Association contre le Cancer, ARC; Radioprotection Committee of EDF	'Ligue Nationale Contre le Cancer' (Equipe Labelisee)(Ligue nationale contre le cancer); Canceropole GSO; Association contre le Cancer, ARC; Radioprotection Committee of EDF	We thank Catherine Botanch, Emilie Mirey and Christine Bordier for their help, Dr Nathalie Mazure and Dr Delphine Larrieu for critical comments on the manuscript and Aymeric Poizot for English rereading. We acknowledge Dr P Calsou, Dr Y Martineau and Dr S Pyronnet for technical advices and reagents. This work was supported by the 'Ligue Nationale Contre le Cancer' (Equipe Labelisee, BS), the Canceropole GSO (BS and CM), the Association contre le Cancer, ARC (2008-1102, CM) and the Radioprotection Committee of EDF (CM).	Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Abraham RT, 2003, CURR TOP MICROBIOL, V279, P299; Adams KE, 2006, ONCOGENE, V25, P3894, DOI 10.1038/sj.onc.1209426; Airley RE, 2003, INT J CANCER, V104, P85, DOI 10.1002/ijc.10904; Bencokova Z, 2009, MOL CELL BIOL, V29, P526, DOI 10.1128/MCB.01301-08; Bouquet F, 2011, J CELL SCI, V124, P1943, DOI 10.1242/jcs.078030; Brahimi-Horn MC, 2007, BIOCHEM PHARMACOL, V73, P450, DOI 10.1016/j.bcp.2006.10.013; Brahimi-Horn MC, 2009, J CELL SCI, V122, P1055, DOI 10.1242/jcs.035022; Cam H, 2010, MOL CELL, V40, P509, DOI 10.1016/j.molcel.2010.10.030; Chen CH, 2001, J BIOL CHEM, V276, P9519, DOI 10.1074/jbc.M010144200; Crescenzi E, 2008, CLIN CANCER RES, V14, P1877, DOI 10.1158/1078-0432.CCR-07-4298; Cuadrado M, 2006, J EXP MED, V203, P297, DOI 10.1084/jem.20051923; Dolt KS, 2007, GENE, V386, P73, DOI 10.1016/j.gene.2006.08.004; Economopoulou M, 2009, NAT MED, V15, P553, DOI 10.1038/nm.1947; Galban S, 2008, MOL CELL BIOL, V28, P93, DOI 10.1128/MCB.00973-07; Gibson SL, 2005, CANCER RES, V65, P10734, DOI 10.1158/0008-5472.CAN-05-1160; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Hammond EM, 2004, CANCER RES, V64, P6556, DOI 10.1158/0008-5472.CAN-04-1520; Hammond EM, 2003, MUTAT RES-FUND MOL M, V532, P205, DOI 10.1016/j.mrfmmm.2003.08.017; Hammond EM, 2003, J BIOL CHEM, V278, P12207, DOI 10.1074/jbc.M212360200; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Jazayeri A, 2006, NAT CELL BIOL, V8, P37, DOI 10.1038/ncb1337; Kang MJ, 2008, FEBS J, V275, P5969, DOI 10.1111/j.1742-4658.2008.06725.x; Koh MY, 2008, TRENDS BIOCHEM SCI, V33, P526, DOI 10.1016/j.tibs.2008.08.002; Lang KJD, 2002, MOL BIOL CELL, V13, P1792, DOI 10.1091/mbc.02-02-0017; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Lei Z, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007629; Lopez-Contreras AJ, 2010, DNA REPAIR, V9, P1249, DOI 10.1016/j.dnarep.2010.09.012; Lou JJW, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010522; Lovejoy CA, 2009, DNA REPAIR, V8, P1004, DOI 10.1016/j.dnarep.2009.04.006; Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022; Martin L, 2012, ONCOGENE, V31, P4076, DOI 10.1038/onc.2011.585; Masuda K, 2009, J CELL MOL MED, V13, P2759, DOI 10.1111/j.1582-4934.2009.00842.x; Monferran S, 2004, EMBO J, V23, P3758, DOI 10.1038/sj.emboj.7600403; Monti Elena, 2011, Curr Mol Pharmacol, V4, P62; Moretti F, 2010, RNA, V16, P2493, DOI 10.1261/rna.2384610; Myers JS, 2006, J BIOL CHEM, V281, P9346, DOI 10.1074/jbc.M513265200; Nghiem P, 2001, P NATL ACAD SCI USA, V98, P9092, DOI 10.1073/pnas.161281798; Onnis B, 2009, J CELL MOL MED, V13, P2780, DOI 10.1111/j.1582-4934.2009.00876.x; Ousset M, 2010, CELL CYCLE, V9, P2814, DOI 10.4161/cc.9.14.12253; Paulsen RD, 2007, DNA REPAIR, V6, P953, DOI 10.1016/j.dnarep.2007.02.015; Pereg Y, 2005, P NATL ACAD SCI USA, V102, P5056, DOI 10.1073/pnas.0408595102; Rapisarda A, 2007, ONCOGENE, V26, P6875, DOI 10.1038/sj.onc.1210489; Reaper PM, 2011, NAT CHEM BIOL, V7, P428, DOI [10.1038/NCHEMBIO.573, 10.1038/nchembio.573]; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Semenza GL, 2007, DRUG DISCOV TODAY, V12, P853, DOI 10.1016/j.drudis.2007.08.006; Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021; van Uden P, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001285; Veuger SJ, 2003, CANCER RES, V63, P6008; Wan C, 2010, MUTAT RES-FUND MOL M, V686, P39, DOI 10.1016/j.mrfmmm.2009.12.012; Wang CX, 2011, J GASTROEN HEPATOL, V26, P1630, DOI 10.1111/j.1440-1746.2011.06758.x; Willmore E, 2004, BLOOD, V103, P4659, DOI 10.1182/blood-2003-07-2527; Zhong H, 2000, CANCER RES, V60, P1541; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430; Zundel W, 2000, GENE DEV, V14, P391	56	22	23	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2013	32	37					4387	4396		10.1038/onc.2012.462	http://dx.doi.org/10.1038/onc.2012.462			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218AF	23085754	Green Published			2022-12-28	WOS:000324404200007
J	Martino, JJ; Wall, BA; Mastrantoni, E; Wilimczyk, BJ; La Cava, SN; Degenhardt, K; White, E; Chen, S				Martino, J. J.; Wall, B. A.; Mastrantoni, E.; Wilimczyk, B. J.; La Cava, S. N.; Degenhardt, K.; White, E.; Chen, S.			Metabotropic glutamate receptor 1 (Grm1) is an oncogene in epithelial cells	ONCOGENE			English	Article						Grm1; glutamatergic signaling; oncogene; cell transformation; kidney epithelial cells; carcinoma	PROTEIN-COUPLED RECEPTORS; SIGNALING PATHWAYS; MALIGNANT-MELANOMA; HUMAN MELANOCYTES; TRANSGENIC MICE; CANCER; GROWTH; GLUTAMATE-RECEPTOR-1; EXPRESSION; TARGETS	Non-neuronal expression of components of the glutamatergic system has been increasingly observed, and our laboratory previously had demonstrated the etiological role of ectopically expressed metabotropic glutamate receptor 1 (Grm1/mGluR1) in mouse models of melanoma. We hypothesize that inappropriate glutamatergic signaling in other cell types can dysregulate growth leading to transformation and tumorigenesis. As most cancers are carcinomas, we selected an immortalized primary baby mouse kidney (iBMK) cell model to assess whether Grm1 can transform epithelial cells. These iBMK cells, engineered to be immortal yet nontumorigenic and retaining normal epithelial characteristics, were used as recipients for exogenous Grm1 cDNA. Several stable Grm1-expressing clones were isolated and the Grm1-receptors were shown to be functional, as evidenced by the accumulation of second messengers in response to Grm1 agonist. Additionally activated by agonist were mitogen-activated protein kinase (MAPK) and AKT/protein kinase B signaling cascades, the major intracellular pathways shown by many investigators to be critical in melanomagenesis and other neoplasms. These Grm1-iBMK cells exhibited enhanced cell proliferation in in vitro methylthiazolyldiphenyl-tetrazolium bromide (MTT) assays and significant tumorigenicity in in vivo allografts. Persistent Grm1 expression was required for the maintenance of the in vivo tumorigenic phenotype as demonstrated by an inducible Grm1-silencing RNA. These are the first results that indicate that Grm1 can be an oncogene in epithelial cells. In addition, relevance to human disease in the corresponding tumor type of renal cell carcinoma (RCC) may be suggested by observed expression of GRM1/mGluR1 in a number of RCC tumor biopsy samples and cell lines, and the effects of GRM1 modulation on tumorigenicity therein. Moreover, RCC cell lines exhibited elevated levels of extracellular glutamate, and some lines responded to drugs, which modulate the glutamatergic system. These findings imply a possible role for glutamate signaling apparatus in RCC cell growth, and that the glutamatergic system may be a therapeutic target in RCC.	[Martino, J. J.; Wall, B. A.; Mastrantoni, E.; Wilimczyk, B. J.; La Cava, S. N.; Chen, S.] Rutgers State Univ, Ernest Mario Sch Pharm, Susan Lehman Cullman Lab Canc Res, Dept Biol Chem, Piscataway, NJ 08854 USA; [Mastrantoni, E.] Univ Rome Sapienze, Dept Physiol & Pharmacol, Rome, Italy; [Degenhardt, K.] Touro Coll Osteopath Med, Dept Basic Biomed Sci, New York, NY USA; [White, E.; Chen, S.] Canc Inst New Jersey, New Brunswick, NJ USA; [White, E.] Rutgers State Univ, Dept Mol & Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; Rutgers State University New Brunswick	Chen, S (corresponding author), Rutgers State Univ, Ernest Mario Sch Pharm, Susan Lehman Cullman Lab Canc Res, Dept Biol Chem, 164 Frelinghuysen Rd, Piscataway, NJ 08854 USA.	suziec@rci.rutgers.edu	White, Eileen/ABD-6745-2021	White, Eileen/0000-0003-2961-3065	Department of Physiology and Pharmacology, University of Rome "Sapienza", Rome, Itally;  [R01CA108720];  [09-1143-CCR-EO]; NATIONAL CANCER INSTITUTE [R01CA108720, R01CA130893, P30CA072720, R01CA074077] Funding Source: NIH RePORTER	Department of Physiology and Pharmacology, University of Rome "Sapienza", Rome, Itally; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants R01CA108720 and 09-1143-CCR-EO (SC) and PhD fellowship from the Department of Physiology and Pharmacology, University of Rome "Sapienza", Rome, Itally (EM). We would like to acknowledge the generosity of Dr WM Linehan (Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA) for RCC lines, Dr Daiya Takai (The University of Tokyo Hospital, Tokyo, Japan) for TetR plasmid components, Dr Tony Kong (Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ, USA) for Aperio digital slide scanning/quantification system access and Dr Hao Wu (The Cancer Institute of New Jersey, New Brunswick, NJ, USA) for keen pathological insights.	American Cancer Society, 2012, CANC FACTS FIG; ANGLARD P, 1992, CANCER RES, V52, P348; Bracarda S, 2009, EUR UROL SUPPL, V8, P787, DOI 10.1016/j.eursup.2009.07.007; Carroll FY, 2001, MOL PHARMACOL, V59, P965, DOI 10.1124/mol.59.5.965; Choi KY, 2011, P NATL ACAD SCI USA, V108, P15219, DOI 10.1073/pnas.1107304108; Cicenas J, 2008, INT J BIOL MARKER, V23, P1, DOI 10.1177/172460080802300101; Cohen-Solal KA, 2002, PIGM CELL RES, V15, P282, DOI 10.1034/j.1600-0749.2002.02024.x; D'Onofrio M, 2003, J NEUROCHEM, V84, P1288, DOI 10.1046/j.1471-4159.2003.01633.x; Degenhardt K, 2002, CANCER CELL, V2, P193, DOI 10.1016/S1535-6108(02)00126-5; Degenhardt K, 2002, J BIOL CHEM, V277, P14127, DOI 10.1074/jbc.M109939200; Degenhardt K, 2006, CLIN CANCER RES, V12, P5298, DOI 10.1158/1078-0432.CCR-06-0439; Ferraguti F, 2008, PHARMACOL REV, V60, P536, DOI 10.1124/pr.108.000166; Frati C, 2000, J CELL PHYSIOL, V183, P364, DOI 10.1002/(SICI)1097-4652(200006)183:3<364::AID-JCP9>3.3.CO;2-O; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Genever PG, 1999, J INVEST DERMATOL, V112, P337, DOI 10.1046/j.1523-1747.1999.00509.x; Gill SS, 1999, BRAIN RES BULL, V48, P143, DOI 10.1016/S0361-9230(98)00154-3; GUTKIND JS, 1991, P NATL ACAD SCI USA, V88, P4703, DOI 10.1073/pnas.88.11.4703; Hers I, 2011, CELL SIGNAL, V23, P1515, DOI 10.1016/j.cellsig.2011.05.004; Hoogduijn MJ, 2006, PIGM CELL RES, V19, P58, DOI 10.1111/j.1600-0749.2005.00284.x; Hoshino R, 1999, ONCOGENE, V18, P813, DOI 10.1038/sj.onc.1202367; Iacovelli L, 2006, J NEUROSCI, V26, P8388, DOI 10.1523/JNEUROSCI.2285-06.2006; Jong YJI, 2007, J NEUROCHEM, V101, P458, DOI 10.1111/j.1471-4159.2006.04382.x; JULIUS D, 1989, SCIENCE, V244, P1057, DOI 10.1126/science.2727693; Kim EK, 2010, BBA-MOL BASIS DIS, V1802, P396, DOI 10.1016/j.bbadis.2009.12.009; Kohler BA, 2011, JNCI-J NATL CANCER I, V103, P714, DOI 10.1093/jnci/djr077; Lappano R, 2011, NAT REV DRUG DISCOV, V10, P47, DOI 10.1038/nrd3320; Le MN, 2010, J INVEST DERMATOL, V130, P2240, DOI 10.1038/jid.2010.126; Lee HJ, 2011, CLIN CANCER RES, V17, P7080, DOI 10.1158/1078-0432.CCR-11-0098; Levine AJ, 2010, SCIENCE, V330, P1340, DOI 10.1126/science.1193494; Machado-Vieira R, 2009, CURR PHARM DESIGN, V15, P1595, DOI 10.2174/138161209788168010; Marin YE, 2006, CELL SIGNAL, V18, P1279, DOI 10.1016/j.cellsig.2005.10.012; Marin YE, 2004, J MOL MED, V82, P735, DOI 10.1007/s00109-004-0566-8; Mathew A, 2002, EUR J CANCER PREV, V11, P171, DOI 10.1097/00008469-200204000-00010; Matsukura S, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng077; Melchiorri D, 2007, NEUROPHARMACOLOGY, V53, P473, DOI 10.1016/j.neuropharm.2007.05.031; Meldrum BS, 2000, J NUTR, V130, p1007S, DOI 10.1093/jn/130.4.1007S; Miller RG, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001447.pub2; Milligan G, 2000, SCIENCE, V288, P65, DOI 10.1126/science.288.5463.65; Morimoto R, 2006, EMBO J, V25, P4175, DOI 10.1038/sj.emboj.7601317; Namkoong J, 2007, CANCER RES, V67, P2298, DOI 10.1158/0008-5472.CAN-06-3665; Nicoletti F, 2007, TRENDS PHARMACOL SCI, V28, P206, DOI 10.1016/j.tips.2007.03.008; Pollock PM, 2003, NAT GENET, V34, P108, DOI 10.1038/ng1148; Prezeau L, 1996, MOL PHARMACOL, V49, P422; Prickett TD, 2011, NAT GENET, V43, P1119, DOI 10.1038/ng.950; Recasens M, 2007, CURR DRUG TARGETS, V8, P651, DOI 10.2174/138945007780618544; Schmid-Wendtner MH, 2001, BRIT J DERMATOL, V145, P981, DOI 10.1046/j.1365-2133.2001.04507.x; Seidlitz EP, 2009, CLIN EXP METASTAS, V26, P781, DOI 10.1007/s10585-009-9277-4; Sharma MK, 2010, BIOCHEM BIOPH RES CO, V391, P91, DOI 10.1016/j.bbrc.2009.10.168; Sharon D, 1997, J GEN PHYSIOL, V109, P477, DOI 10.1085/jgp.109.4.477; Shin SS, 2008, NEUROPHARMACOLOGY, V55, P396, DOI 10.1016/j.neuropharm.2008.04.021; Shin SS, 2010, PIGM CELL MELANOMA R, V23, P103, DOI 10.1111/j.1755-148X.2009.00648.x; Speyer CL, 2012, BREAST CANCER RES TR, V132, P565, DOI 10.1007/s10549-011-1624-x; Steelman LS, 2011, AGING-US, V3, P192, DOI 10.18632/aging.100296; Stepulak A, 2005, P NATL ACAD SCI USA, V102, P15605, DOI 10.1073/pnas.0507679102; Storto M, 2000, HEPATOLOGY, V31, P649, DOI 10.1002/hep.510310315; Storto M, 2006, MOL PHARMACOL, V69, P1234, DOI 10.1124/mol.105.018390; Takano T, 2001, NAT MED, V7, P1010, DOI 10.1038/nm0901-1010; Teh Jessica, 2012, Wiley Interdiscip Rev Membr Transp Signal, V1, P211; Thandi S, 2002, J NEUROCHEM, V83, P1139, DOI 10.1046/j.1471-4159.2002.01217.x; Tihan T, 1996, CANCER-AM CANCER SOC, V77, P2325, DOI 10.1002/(SICI)1097-0142(19960601)77:11<2325::AID-CNCR22>3.0.CO;2-Y; Tong QC, 2002, AM J PHYSIOL-ENDOC M, V282, pE1324, DOI 10.1152/ajpendo.00460.2001; Tripathi VB, 2008, CNS NEUROL DISORD-DR, V7, P11; Wangari-Talbot J, MOL CANCER RES, DOI [10.1158/1541-7786.MCR-12-0158, DOI 10.1158/1541-7786.MCR-12-0158)]; WELCH DR, 1991, INT J CANCER, V47, P227, DOI 10.1002/ijc.2910470211; Wieronska JM, 2009, NEUROCHEM INT, V55, P85, DOI 10.1016/j.neuint.2009.02.019; Wu TY, 2012, MOL CARCINOGEN, V51, P761, DOI 10.1002/mc.20841; Yip D, 2009, CLIN CANCER RES, V15, P3896, DOI 10.1158/1078-0432.CCR-08-3303; Young VR, 2000, J NUTR, V130, p892S, DOI 10.1093/jn/130.4.892S; Zhu H, 1999, MOL BRAIN RES, V73, P93, DOI 10.1016/S0169-328X(99)00239-9; Zhu H, 1998, J INVEST DERMATOL, V110, P247, DOI 10.1046/j.1523-1747.1998.00133.x	70	41	42	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2013	32	37					4366	4376		10.1038/onc.2012.471	http://dx.doi.org/10.1038/onc.2012.471			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218AF	23085756	Green Accepted			2022-12-28	WOS:000324404200005
J	Kim, YJ; Greer, CB; Cecchini, KR; Harris, LN; Tuck, DP; Kim, TH				Kim, Y. J.; Greer, C. B.; Cecchini, K. R.; Harris, L. N.; Tuck, D. P.; Kim, T. H.			HDAC inhibitors induce transcriptional repression of high copy number genes in breast cancer through elongation blockade	ONCOGENE			English	Article						GRO-seq; transcription elongation; HDAC inhibition; oncogenes; amplicons	HISTONE DEACETYLASE INHIBITORS; RNA-POLYMERASE-II; P-TEFB; 7SK SNRNA; C-MYC; MECHANISMS; EXPRESSION; COMPLEXES; CHROMATIN; PROTEIN	Treatment with histone deacetylase inhibitors (HDACI) results in potent cytotoxicity of a variety of cancer cell types, and these drugs are used clinically to treat hematological tumors. They are known to repress the transcription of ERBB2 and many other oncogenes, but little is known about this mechanism. Using global run-on sequencing (GRO-seq) to measure nascent transcription, we find that HDACI cause transcriptional repression by blocking RNA polymerase II elongation. Our data show that HDACI preferentially repress the transcription of highly expressed genes as well as high copy number genes in HER2 + breast cancer genomes. In contrast, genes that are activated by HDACI are moderately expressed. We analyzed gene copy number in combination with microarray and GRO-seq analysis of expression level, in normal and breast cancer cells to show that high copy number genes are more likely to be repressed by HDACI than non-amplified genes. The inhibition of transcription of amplified oncogenes, which promote survival and proliferation of cancer cells, might explain the cancer-specific lethality of HDACI, and may represent a general therapeutic strategy for cancer.	[Kim, Y. J.; Cecchini, K. R.; Kim, T. H.] Yale Univ, Dept Genet, Sch Med, New Haven, CT 06520 USA; [Greer, C. B.] Yale Univ, Dept Pharmacol, Sch Med, New Haven, CT 06520 USA; [Harris, L. N.] Yale Univ, Dept Med, Sch Med, New Haven, CT 06520 USA; [Harris, L. N.; Tuck, D. P.; Kim, T. H.] Yale Univ, Yale Comprehens Canc Ctr, Sch Med, New Haven, CT 06520 USA; [Tuck, D. P.] Yale Univ, Dept Pathol, Sch Med, New Haven, CT 06520 USA	Yale University; Yale University; Yale University; Yale University; Yale University	Kim, TH (corresponding author), Yale Univ, Dept Genet, Sch Med, 333 Cedar St, New Haven, CT 06520 USA.	taehoon.kim@yale.edu		Kim, Tae Hoon/0000-0003-3950-7557; Greer, Celeste/0000-0001-6876-1189	Rita Allen Foundation; Sidney Kimmel Foundation for Cancer Research; Yale Comprehensive Cancer Center [CA-16359]; Alexander and Margaret Stewart Trust; National Cancer Institute [R01CA140485]; NATIONAL CANCER INSTITUTE [P30CA016359, R01CA140485] Funding Source: NIH RePORTER	Rita Allen Foundation; Sidney Kimmel Foundation for Cancer Research; Yale Comprehensive Cancer Center; Alexander and Margaret Stewart Trust; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the members of the laboratory for their comments on the manuscript. Yale Center for Genomic Analysis provided services for microarray labeling, hybridization and scanning. Bing Ren (Ludwig Institute for Cancer Research, La Jolla, CA, USA) provided critical help with sequencing the GRO-seq libraries. CBG is a PhRMA Foundation predoctoral fellow. Grants to THK from the Rita Allen Foundation, Sidney Kimmel Foundation for Cancer Research, Yale Comprehensive Cancer Center (CA-16359), Alexander and Margaret Stewart Trust supported this work. A portion of this work was also made possible by a grant from the National Cancer Institute (R01CA140485 to THK).	Albertson DG, 2006, TRENDS GENET, V22, P447, DOI 10.1016/j.tig.2006.06.007; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Chao SH, 2000, J BIOL CHEM, V275, P28345, DOI 10.1074/jbc.C000446200; Cheng B, 2007, J BIOL CHEM, V282, P21901, DOI 10.1074/jbc.M702936200; Chou CW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018087; Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371; Core LJ, 2008, SCIENCE, V319, P1791, DOI 10.1126/science.1150843; Core LJ, 2008, SCIENCE, V322, P1845, DOI 10.1126/science.1162228; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Federico M, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/475641; Gilmour DS, 2009, METHODS, V48, P368, DOI 10.1016/j.ymeth.2009.02.020; Govind CK, 2010, MOL CELL, V39, P234, DOI 10.1016/j.molcel.2010.07.003; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923; Huang XP, 2009, CANCER RES, V69, P8403, DOI 10.1158/0008-5472.CAN-09-2146; Khan N, 2008, BIOCHEM J, V409, P581, DOI 10.1042/BJ20070779; Khan O, 2012, IMMUNOL CELL BIOL, V90, P85, DOI 10.1038/icb.2011.100; Kim YJ, 2011, P NATL ACAD SCI USA, V108, P7391, DOI 10.1073/pnas.1018279108; Kozikowski AP, 2008, J MED CHEM, V51, P4370, DOI 10.1021/jm8002894; LaBonte MJ, 2011, CANCER RES, V71, P3635, DOI 10.1158/0008-5472.CAN-10-2430; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Li B, 2007, SCIENCE, V316, P1050, DOI 10.1126/science.1139004; Liu ZZ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010909; Marchion D, 2007, EXPERT REV ANTICANC, V7, P583, DOI 10.1586/14737140.7.4.583; Michels AA, 2004, EMBO J, V23, P2608, DOI 10.1038/sj.emboj.7600275; Mortazavi A, 2008, NAT METHODS, V5, P621, DOI 10.1038/nmeth.1226; Petrella A, 2011, MINI-REV MED CHEM, V11, P519, DOI 10.2174/138955711795843347; Rahl PB, 2010, CELL, V141, P432, DOI 10.1016/j.cell.2010.03.030; Reid G, 2005, ONCOGENE, V24, P4894, DOI 10.1038/sj.onc.1208662; Rikiishi H, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/830260; Sawarkar R, 2012, CELL, V149, P807, DOI 10.1016/j.cell.2012.02.061; Scott GK, 2008, MOL CANCER RES, V6, P1250, DOI 10.1158/1541-7786.MCR-07-2110; Sollars V, 2003, NAT GENET, V33, P70, DOI 10.1038/ng1067; Wang ZB, 2009, CELL, V138, P1019, DOI 10.1016/j.cell.2009.06.049; Xu WS, 2007, ONCOGENE, V26, P5541, DOI 10.1038/sj.onc.1210620; Yik JHN, 2003, MOL CELL, V12, P971, DOI 10.1016/S1097-2765(03)00388-5; Yokoyama S, 2008, PIGM CELL MELANOMA R, V21, P457, DOI 10.1111/j.1755-148X.2008.00480.x; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	38	66	67	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 6	2013	32	23					2828	2835		10.1038/onc.2013.32	http://dx.doi.org/10.1038/onc.2013.32			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	163WR	23435418	Green Accepted			2022-12-28	WOS:000320369100003
J	Ogino, S; Lochhead, P; Giovannucci, E; Meyerhardt, JA; Fuchs, CS; Chan, AT				Ogino, S.; Lochhead, P.; Giovannucci, E.; Meyerhardt, J. A.; Fuchs, C. S.; Chan, A. T.			Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology	ONCOGENE			English	Review						molecular pathologic epidemiology; systems biology; systems pathology; network medicine; unique tumor principle; translational epidemiology	ISLAND METHYLATOR PHENOTYPE; III COLON-CANCER; BODY-MASS INDEX; KRAS-MUTATION; PHYSICAL-ACTIVITY; MICROSATELLITE INSTABILITY; POOR SURVIVAL; LIFE-STYLE; PROVOCATIVE QUESTIONS; ADJUVANT THERAPY	Regular use of aspirin reduces incidence and mortality of various cancers, including colorectal cancer. Anticancer effect of aspirin represents one of the 'Provocative Questions' in cancer research. Experimental and clinical studies support a carcinogenic role for PTGS2 (cyclooxygenase-2), which is an important enzymatic mediator of inflammation, and a target of aspirin. Recent 'molecular pathological epidemiology' (MPE) research has shown that aspirin use is associated with better prognosis and clinical outcome in PIK3CA-mutated colorectal carcinoma, suggesting somatic PIK3CA mutation as a molecular biomarker that predicts response to aspirin therapy. The PI3K (phosphatidylinositol-4,5-bisphosphonate 3-kinase) enzyme has a pivotal role in the PI3K-AKT signaling pathway. Activating PIK3CA oncogene mutations are observed in various malignancies including breast cancer, ovarian cancer, brain tumor, hepatocellular carcinoma, lung cancer and colon cancer. The prevalence of PIK3CA mutations increases continuously from rectal to cecal cancers, supporting the 'colorectal continuum' paradigm, and an important interplay of gut microbiota and host immune/inflammatory reaction. MPE represents an interdisciplinary integrative science, conceptually defined as 'epidemiology of molecular heterogeneity of disease'. As exposome and interactome vary from person to person and influence disease process, each disease process is unique (the unique disease principle). Therefore, MPE concept and paradigm can extend to non-neoplastic diseases including diabetes mellitus, cardiovascular diseases, metabolic diseases, and so on. MPE research opportunities are currently limited by paucity of tumor molecular data in the existing large-scale population-based studies. However, genomic, epigenomic and molecular pathology testings (for example, analyses for microsatellite instability, MLH1 promoter CpG island methylation, and KRAS and BRAF mutations in colorectal tumors) are becoming routine clinical practices. In order for integrative molecular and population science to be routine practice, we must first reform education curricula by integrating both population and molecular biological sciences. As consequences, next-generation hybrid molecular biological and population scientists can advance science, moving closer to personalized precision medicine and health care.	[Ogino, S.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Ogino, S.; Meyerhardt, J. A.; Fuchs, C. S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA; [Ogino, S.; Giovannucci, E.] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; [Lochhead, P.] Univ Aberdeen, Inst Med Sci, Aberdeen, Scotland; [Giovannucci, E.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; [Giovannucci, E.; Fuchs, C. S.; Chan, A. T.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Div Network Med,Dept Med, Boston, MA 02115 USA; [Chan, A. T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard T.H. Chan School of Public Health; University of Aberdeen; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Massachusetts General Hospital	Ogino, S (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave,Room M422, Boston, MA 02215 USA.	shuji_ogino@dfci.harvard.edu			USA National Institute of Health (NIH) [R01 CA151993, R01 CA137178, P50 CA127003, R01 CA124908, P01 CA87969, UM1 CA167552]; NATIONAL CANCER INSTITUTE [UM1CA167552, R01CA137178, P50CA127003, R01CA151993, R01CA169141, P01CA087969, R01CA124908] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK098311] Funding Source: NIH RePORTER; Chief Scientist Office [CAF/10/15] Funding Source: researchfish	USA National Institute of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Chief Scientist Office	This work was supported by grants from the USA National Institute of Health (NIH) (R01 CA151993 (to SO), R01 CA137178 (to ATC), P50 CA127003 (to CSF), R01 CA124908 (to CSF), P01 CA87969 (to SEH) and UM1 CA167552 to WCW). ATC is a Damon Runyon Clinical Investigator.	Abubaker J, 2008, ONCOGENE, V27, P3539, DOI 10.1038/sj.onc.1211013; Algra AM, 2012, LANCET ONCOL, V13, P518, DOI 10.1016/S1470-2045(12)70112-2; Asada K, 2013, ONCOGENE, V32, P2140, DOI 10.1038/onc.2012.228; Baba Y, 2011, CANCER-AM CANCER SOC, V117, P1399, DOI 10.1002/cncr.25630; Baba Y, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-125; Bae JM, 2013, HISTOL HISTOPATHOL, V28, P585, DOI 10.14670/HH-28.585; Ballard-Barbash R, 2012, JNCI-J NATL CANCER I, V104, P815, DOI 10.1093/jnci/djs207; Barault L, 2008, INT J CANCER, V122, P2255, DOI 10.1002/ijc.23388; Baron JA, 2003, NEW ENGL J MED, V348, P891, DOI 10.1056/NEJMoa021735; Barry ER, 2013, NATURE, V493, P106, DOI 10.1038/nature11693; Bass AJ, 2011, NAT GENET, V43, P964, DOI 10.1038/ng.936; Bastiaannet E, 2012, BRIT J CANCER, V106, P1564, DOI 10.1038/bjc.2012.101; Begg CB, 2012, AM J EPIDEMIOL, V176, P512, DOI 10.1093/aje/kws128; Begg CB, 2011, INT J CANCER, V129, P931, DOI 10.1002/ijc.25714; Beggs AD, 2013, J PATHOL, V229, P697, DOI 10.1002/path.4132; Benamouzig R, 2012, GUT, V61, P255, DOI 10.1136/gutjnl-2011-300113; Benvenuti S, 2008, HUM MUTAT, V29, P284, DOI 10.1002/humu.20648; Berger AH, 2011, NATURE, V476, P163, DOI 10.1038/nature10275; Boyle T, 2011, AM J EPIDEMIOL, V173, P1183, DOI 10.1093/aje/kwq513; Brennan K, 2012, CANCER PREV RES, V5, P1345, DOI 10.1158/1940-6207.CAPR-12-0316; Buchanan DD, 2013, CANCER EPIDEM BIOMAR, V22, P917, DOI 10.1158/1055-9965.EPI-12-1211; Burn J, 2011, LANCET, V378, P2081, DOI 10.1016/S0140-6736(11)61049-0; Burnett-Hartman AN, 2013, CANCER RES, V73, P2863, DOI 10.1158/0008-5472.CAN-12-3462; Burnett-Hartman AN, 2013, AM J EPIDEMIOL, V177, P625, DOI 10.1093/aje/kws282; Campbell PT, 2013, J CLIN ONCOL, V31, P876, DOI 10.1200/JCO.2012.45.9735; Castellarin M, 2012, GENOME RES, V22, P299, DOI 10.1101/gr.126516.111; Chan AT, 2007, NEW ENGL J MED, V356, P2131, DOI 10.1056/NEJMoa067208; Chan AT, 2009, JAMA-J AM MED ASSOC, V302, P649, DOI 10.1001/jama.2009.1112; Chen CC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055793; Chia WK, 2012, NAT REV CLIN ONCOL, V9, P561, DOI 10.1038/nrclinonc.2012.137; Cho I, 2012, NAT REV GENET, V13, P260, DOI 10.1038/nrg3182; Christie M, 2013, ONCOGENE, V32, P4675, DOI 10.1038/onc.2012.486; Coghill AE, 2011, GUT, V60, P491, DOI 10.1136/gut.2010.221143; Colditz GA, 2005, NAT REV CANCER, V5, P388, DOI 10.1038/nrc1608; Colditz GA, 2010, CANCER CAUSE CONTROL, V21, P649, DOI 10.1007/s10552-009-9498-5; Curtin Karen, 2011, Patholog Res Int, V2011, P902674, DOI 10.4061/2011/902674; Dahlin AM, 2011, MODERN PATHOL, V24, P671, DOI 10.1038/modpathol.2010.234; Dahlin AM, 2010, CLIN CANCER RES, V16, P1845, DOI 10.1158/1078-0432.CCR-09-2594; Damania D, 2012, CANCER RES, V72, P2720, DOI 10.1158/0008-5472.CAN-11-3807; Day FL, CLIN CANCER RES, DOI [10.1158/1078-0432.CCR-1112-3614, DOI 10.1158/1078-0432.CCR-1112-3614]; De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3; Deming DA, 2014, ONCOGENE, V33, P2245, DOI 10.1038/onc.2013.167; Dogan S, 2012, CLIN CANCER RES, V18, P6169, DOI 10.1158/1078-0432.CCR-11-3265; Dube C, 2007, ANN INTERN MED, V146, P365, DOI 10.7326/0003-4819-146-5-200703060-00009; Edin S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047045; Eklof V, 2013, BRIT J CANCER, V108, P2153, DOI 10.1038/bjc.2013.212; Estecio MRH, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000399; Farina-Sarasqueta A, 2010, ANN ONCOL, V21, P2396, DOI 10.1093/annonc/mdq258; Febbo PG, 2011, J NATL COMPR CANC NE, V9, pS1, DOI 10.6004/jnccn.2011.0137; Fernandez AF, 2010, ONCOGENE, V29, P1405, DOI 10.1038/onc.2009.517; Flossmann E, 2007, LANCET, V369, P1603, DOI 10.1016/S0140-6736(07)60747-8; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; Funkhouser WK, 2012, J MOL DIAGN, V14, P91, DOI 10.1016/j.jmoldx.2011.11.001; Galon J, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-205; Garcia-Solano J, 2012, INT J CANCER, V131, P1790, DOI 10.1002/ijc.27454; Garrido-Laguna I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038033; Gavin PG, 2012, CLIN CANCER RES, V18, P6531, DOI 10.1158/1078-0432.CCR-12-0605; Gay LJ, 2012, J PATHOL, V228, P405, DOI 10.1002/path.4085; Ghosh S, 2011, NAT REV GENET, V12, P821, DOI 10.1038/nrg3096; Goel A, 2012, GASTROENTEROLOGY, V143, P1442, DOI 10.1053/j.gastro.2012.09.032; Greystoke A, 2012, GASTROENT RES PRACT, V2012; He YJ, 2009, CLIN CANCER RES, V15, P6956, DOI 10.1158/1078-0432.CCR-09-1165; Hinoue T, 2012, GENOME RES, V22, P271, DOI 10.1101/gr.117523.110; Hsieh LL, 2012, CLIN CHIM ACTA, V413, P1605, DOI 10.1016/j.cca.2012.04.029; Hughes LAE, 2012, INT J EPIDEMIOL, V41, P1060, DOI 10.1093/ije/dys055; Hughes LAE, 2012, BBA-REV CANCER, V1825, P77, DOI 10.1016/j.bbcan.2011.10.005; Hughes LAE, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018571; Iida S, 2012, ONCOL LETT, V3, P565, DOI 10.3892/ol.2011.544; Imamura Y, 2012, CLIN CANCER RES, V18, P4753, DOI 10.1158/1078-0432.CCR-11-3210; Janku F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022769; Jehan Z, 2009, J PATHOL, V219, P337, DOI 10.1002/path.2601; Jhawer M, 2008, CANCER RES, V68, P1953, DOI 10.1158/0008-5472.CAN-07-5659; Kamiyama H, 2012, ONCOGENE, V31, P5029, DOI 10.1038/onc.2011.652; Kato S, 2007, INT J CANCER, V121, P1771, DOI 10.1002/ijc.22890; Kaur J, 2010, TUMOR BIOL, V31, P623, DOI 10.1007/s13277-010-0078-9; Kelley RK, 2011, J NATL COMPR CANC NE, V9, P1293, DOI 10.6004/jnccn.2011.0105; Khoury MJ, 2013, CANCER EPIDEM BIOMAR, V22, P508, DOI 10.1158/1055-9965.EPI-13-0146; Kitkumthorn N, 2011, CLIN EPIGENETICS, V2, P315, DOI 10.1007/s13148-011-0032-8; Koshiol J, 2012, ANN EPIDEMIOL, V22, P520, DOI 10.1016/j.annepidem.2012.03.001; Kostic AD, 2012, GENOME RES, V22, P292, DOI 10.1101/gr.126573.111; Ku CS, 2012, MODERN PATHOL, V25, P1055, DOI 10.1038/modpathol.2012.62; Kuller LH, 2012, AM J EPIDEMIOL, V176, P668, DOI 10.1093/aje/kws227; Kure S, 2009, CANCER EPIDEM BIOMAR, V18, P2765, DOI 10.1158/1055-9965.EPI-09-0490; Lam TK, 2013, CANCER EPIDEM BIOMAR, V22, P496, DOI 10.1158/1055-9965.EPI-13-0101; Lam TK, 2013, CANCER EPIDEM BIOMAR, V22, P181, DOI 10.1158/1055-9965.EPI-12-1262; Langley RE, 2013, NAT REV CLIN ONCOL, V10, P8, DOI 10.1038/nrclinonc.2012.216; Lao VV, 2011, NAT REV GASTRO HEPAT, V8, P686, DOI 10.1038/nrgastro.2011.173; Liao XY, 2012, NEW ENGL J MED, V367, P1596, DOI 10.1056/NEJMoa1207756; Liao XY, 2012, CLIN CANCER RES, V18, P2257, DOI 10.1158/1078-0432.CCR-11-2410; Lievre A, 2010, ONCOGENE, V29, P3033, DOI 10.1038/onc.2010.89; Limburg PJ, 2012, CANCER EPIDEM BIOMAR, V21, P681, DOI 10.1158/1055-9965.EPI-11-1168; Markowitz SD, 2007, NEW ENGL J MED, V356, P2195, DOI 10.1056/NEJMe078044; Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261; McCowan C, 2013, EUR J CANCER, V49, P1049, DOI 10.1016/j.ejca.2012.10.024; McFarland CD, 2013, P NATL ACAD SCI USA, V110, P2910, DOI 10.1073/pnas.1213968110; Miyaki M, 2007, INT J CANCER, V121, P1627, DOI 10.1002/ijc.22829; Monzon FA, 2009, ARCH PATHOL LAB MED, V133, P1600, DOI 10.1043/1543-2165-133.10.1600; Morikawa T, 2011, JAMA-J AM MED ASSOC, V305, P1685, DOI 10.1001/jama.2011.513; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Myung SJ, 2006, P NATL ACAD SCI USA, V103, P12098, DOI 10.1073/pnas.0603235103; Naguib A, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-123; Neugut AI, 2009, JAMA-J AM MED ASSOC, V302, P688, DOI 10.1001/jama.2009.1145; Nosho K, 2008, NEOPLASIA, V10, P534, DOI 10.1593/neo.08336; Nosho K, 2010, J PATHOL, V222, P350, DOI 10.1002/path.2774; Nosho K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003698; Ogino S, 2005, J MOL DIAGN, V7, P413, DOI 10.1016/S1525-1578(10)60571-5; Ogino S, 2008, J MOL DIAGN, V10, P13, DOI 10.2353/jmoldx.2008.070082; Ogino S, 2013, MODERN PATHOL, V26, P465, DOI 10.1038/modpathol.2012.214; Ogino S, 2012, AM J EPIDEMIOL, V176, P659, DOI 10.1093/aje/kws226; Ogino S, 2012, AM J EPIDEMIOL, V176, P672, DOI 10.1093/aje/kws229; Ogino S, 2012, EXPERT REV MOL DIAGN, V12, P621, DOI [10.1586/ERM.12.46, 10.1586/erm.12.46]; Ogino S, 2011, NAT REV CLIN ONCOL, V8, P711, DOI 10.1038/nrclinonc.2011.122; Ogino S, 2011, GUT, V60, P397, DOI 10.1136/gut.2010.217182; Ogino S, 2010, J NATL CANCER I, V102, P365, DOI 10.1093/jnci/djq031; Ogino S, 2008, J CLIN ONCOL, V26, P5713, DOI [10.1200/JCO.2008.18.2675, 10.1200/JCO.2009.22.8858]; Ollikainen M, 2007, INT J CANCER, V121, P915, DOI 10.1002/ijc.22768; Pasche B, 2012, NEW ENGL J MED, V367, P1650, DOI 10.1056/NEJMe1210322; Pelucchi C, 2011, ANN ONCOL, V22, P1487, DOI 10.1093/annonc/mdq610; Phipps AI, 2013, BRIT J CANCER, V108, P1757, DOI 10.1038/bjc.2013.118; Phipps AI, 2013, INT J COLORECTAL DIS, DOI [10.1007/s00384-00013-01715-00388, DOI 10.1007/S00384-00013-01715-00388]; Phipps AI, 2013, J CLIN ONCOL, V31, P2016, DOI 10.1200/JCO.2012.46.2457; Phipps AI, 2012, CANCER EPIDEM BIOMAR, V21, P1792, DOI 10.1158/1055-9965.EPI-12-0674; Prenen H, 2009, CLIN CANCER RES, V15, P3184, DOI 10.1158/1078-0432.CCR-08-2961; Rex DK, 2012, AM J GASTROENTEROL, V107, P1315, DOI 10.1038/ajg.2012.161; Rosty C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065479; Rosty C, 2013, MODERN PATHOL, V26, P825, DOI 10.1038/modpathol.2012.240; Rothwell PM, 2012, LANCET, V379, P1591, DOI 10.1016/S0140-6736(12)60209-8; Rothwell PM, 2010, LANCET, V376, P1741, DOI 10.1016/S0140-6736(10)61543-7; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Sanchez JA, 2009, BRIT J SURG, V96, P1196, DOI 10.1002/bjs.6683; Sandler RS, 2003, NEW ENGL J MED, V348, P883, DOI 10.1056/NEJMoa021633; Sartore-Bianchi A, 2007, J CLIN ONCOL, V25, P3238, DOI 10.1200/JCO.2007.11.5956; Sartore-Bianchi A, 2009, CANCER RES, V69, P1851, DOI 10.1158/0008-5472.CAN-08-2466; Sepulveda Antonia R, 2009, J Mol Diagn, V11, P266, DOI 10.2353/jmoldx.2009.080125; Shanmuganathan R, 2013, J MOL DIAGN, V15, P17, DOI 10.1016/j.jmoldx.2012.06.007; Sharp PA, 2011, SCIENCE, V333, P527, DOI 10.1126/science.1205008; Sidler D, 2011, ONCOGENE, V30, P2411, DOI 10.1038/onc.2010.629; Souglakos J, 2009, BRIT J CANCER, V101, P465, DOI 10.1038/sj.bjc.6605164; Spitz MR, 2012, CANCER DISCOV, V2, P1087, DOI 10.1158/2159-8290.CD-12-0424; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Teodoridis JM, 2008, CANCER LETT, V268, P177, DOI 10.1016/j.canlet.2008.03.022; Tian S, 2013, GUT, V62, P540, DOI 10.1136/gutjnl-2012-302423; Tjalsma H, 2012, NAT REV MICROBIOL, V10, P575, DOI 10.1038/nrmicro2819; Tol J, 2010, EUR J CANCER, V46, P1997, DOI 10.1016/j.ejca.2010.03.036; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; Uddin S, 2010, INT J CANCER, V126, P382, DOI 10.1002/ijc.24757; Varmus H, 2012, NATURE, V481, P436, DOI 10.1038/481436a; Velho S, 2005, EUR J CANCER, V41, P1649, DOI 10.1016/j.ejca.2005.04.022; Voutsina A, 2013, MODERN PATHOL, V26, P302, DOI 10.1038/modpathol.2012.150; Vrieling A, 2010, AM J CLIN NUTR, V92, P471, DOI [10.3945/ajcn.2010.29005, 10.3945/ajcn.2009.29005]; Waldron L, 2012, CLIN CANCER RES, V18, P6136, DOI 10.1158/1078-0432.CCR-12-1915; Wang D, 2010, ONCOGENE, V29, P781, DOI 10.1038/onc.2009.421; Wang Dingzhi, 2011, Cancers (Basel), V3, P3894, DOI 10.3390/cancers3043894; Weijenberg Matty P, 2013, Curr Nutr Rep, V2, P19; Whitehall VLJ, 2012, INT J CANCER, V131, P813, DOI 10.1002/ijc.26440; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Worthley DL, 2010, ONCOGENE, V29, P1653, DOI 10.1038/onc.2009.449; Wu SJ, 2013, J CANCER RES CLIN, V139, P891, DOI 10.1007/s00432-013-1400-x; Wuchty S, 2007, SCIENCE, V316, P1036, DOI 10.1126/science.1136099; Xia DR, 2012, NAT MED, V18, P224, DOI 10.1038/nm.2608; Xu YM, 2012, GENOME RES, V22, P283, DOI 10.1101/gr.122788.111; Yamamoto E, 2012, AM J PATHOL, V181, P1847, DOI 10.1016/j.ajpath.2012.08.007; Yamauchi M, 2012, GUT, V61, P794, DOI 10.1136/gutjnl-2012-302014; Yamauchi M, 2012, GUT, V61, P847, DOI 10.1136/gutjnl-2011-300865; Yang Q, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2209; Zell JA, 2009, CANCER-AM CANCER SOC, V115, P5662, DOI 10.1002/cncr.24705; Zhao L, 2008, P NATL ACAD SCI USA, V105, P2652, DOI 10.1073/pnas.0712169105; Zlobec I, 2011, J PATHOL, V225, P336, DOI 10.1002/path.2879; Zlobec I, 2010, INT J CANCER, V127, P367, DOI 10.1002/ijc.25042	169	90	95	1	55	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2014	33	23					2949	2955		10.1038/onc.2013.244	http://dx.doi.org/10.1038/onc.2013.244			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EL	23792451	Green Accepted			2022-12-28	WOS:000337232200001
J	Novitskaya, V; Romanska, H; Kordek, R; Potemski, P; Kusinska, R; Parsons, M; Odintsova, E; Berditchevski, F				Novitskaya, V.; Romanska, H.; Kordek, R.; Potemski, P.; Kusinska, R.; Parsons, M.; Odintsova, E.; Berditchevski, F.			Integrin alpha 3 beta 1-CD151 complex regulates dimerization of ErbB2 via RhoA	ONCOGENE			English	Article						tetraspanin; integrin; CD151; breast cancer; ErbB2	BREAST-CANCER CELLS; SELF-ASSOCIATION; LIPID RAFTS; ADHESION; GROWTH; ACTIVATION; PROTEINS; BETA-1-INTEGRIN; PROLIFERATION; TRASTUZUMAB	Integrin alpha 3 beta 1 regulates adhesive interactions of cells with laminins and have a critical role in adhesion-dependent cellular responses. Here, we examined the role of alpha 3 beta 1-integrin in ErbB2-dependent proliferation of breast cancer cells in three-dimensional laminin-rich extracellular matrix (3D lr-ECM). Depletion of alpha 3 beta 1 in ErbB2-overexpressing breast cancer cells suppressed growth and restore cell polarity in 3D lr-ECM. The phenotype of alpha 3 beta 1-depleted cells was reproduced upon depletion of tetraspanin CD151 and mirrored that of the cells treated with Herceptin, an established ErbB2 antagonist. Breast cancer cells expressing the alpha 3 beta 1-CD151 complex have higher steady-state phosphorylation of ErbB2 and show enhanced dimerization of the protein when compared with alpha 3 beta 1-/CD151-depleted cells. Furthermore, Herceptin-dependent dephosphorylation of ErbB2 was only observed in alpha 3 beta 1-CD151-expressing cells. Importantly, the inhibitory activity of Herceptin was more pronounced when cells expressed both alpha 3 beta 1 and CD151. We also found that the level of active RhoA was increased in alpha 3 beta 1- and CD151-depleted cells and that Rho controls dimerization of ErbB2. Expression of alpha 3 beta 1 alone did not have significant prognostic value in patients with invasive ductal carcinoma of the breast. However, expression of alpha 3 beta 1 in combination with CD151 represented a more stringent indicator of poor survival than CD151 alone. Taken together, these results demonstrate that the alpha 3 beta 1-CD151 complex has a critical regulatory role in ErbB2-dependent signalling and thereby may be involved in breast cancer progression.	[Novitskaya, V.; Odintsova, E.; Berditchevski, F.] Univ Birmingham, Sch Canc Sci, Birmingham B15 2TT, W Midlands, England; [Romanska, H.; Kordek, R.; Potemski, P.; Kusinska, R.] Med Univ Lodz, Dept Pathol & Chemotherapy, Lodz, Poland; [Parsons, M.] Kings Coll London, Randall Div Cell & Mol Biophys, London, England	University of Birmingham; Medical University Lodz; University of London; King's College London	Odintsova, E (corresponding author), Univ Birmingham, Sch Canc Sci, Birmingham B15 2TT, W Midlands, England.	e.odintsova@bham.ac.uk; f.berditchevski@bham.ac.uk	Kordek, Radzislaw/S-9616-2016; Parsons, Maddy/B-2203-2013; Mieszkowska, Magdalena/O-6753-2017	Parsons, Maddy/0000-0002-2021-8379; Romanska-Knight, Hanna/0000-0002-2328-710X	WE Dunn Trust, CR UK [C1322/A5705]; Royal Society University Research Fellowship; NCN [2011/01/B/NZ4/04910]	WE Dunn Trust, CR UK; Royal Society University Research Fellowship(Royal Society of London); NCN	We are very grateful to all our colleagues for their generous gifts of the reagents that were used in this study. This work was supported by the WE Dunn Trust, CR UK Grant C1322/A5705 (to FB), Royal Society University Research Fellowship (to MP) and NCN Grant No. 2011/01/B/NZ4/04910 (to RK).	Alexi X, 2011, BIOCHEM SOC T, V39, P568, DOI 10.1042/BST0390568; Arteaga CL, 2012, NAT REV CLIN ONCOL, V9, P16, DOI 10.1038/nrclinonc.2011.177; Bailey Tameka A, 2011, J Carcinog, V10, P28, DOI 10.4103/1477-3163.90442; Baldwin G, 2008, J BIOL CHEM, V283, P35445, DOI 10.1074/jbc.M806394200; Banyard J, 2000, ONCOGENE, V19, P580, DOI 10.1038/sj.onc.1203338; Berditchevski F, 1997, J BIOL CHEM, V272, P29174, DOI 10.1074/jbc.272.46.29174; Berry MG, 2004, EJSO, V30, P484, DOI 10.1016/j.ejso.2004.01.016; Chen LL, 2008, CELL COMMUN ADHES, V15, P317, DOI 10.1080/15419060802428356; Dave B, 2011, J CLIN ONCOL, V29, P166, DOI 10.1200/JCO.2009.27.7814; Deng XY, 2012, NEOPLASIA, V14, P678, DOI 10.1593/neo.12922; Duan L, 2010, J BIOL CHEM, V285, P1555, DOI 10.1074/jbc.M109.057976; Falcioni R, 1997, EXP CELL RES, V236, P76, DOI 10.1006/excr.1997.3695; Ghosh R, 2011, CANCER RES, V71, P1871, DOI 10.1158/0008-5472.CAN-10-1872; Giancotti FG, 2007, TRENDS PHARMACOL SCI, V28, P506, DOI 10.1016/j.tips.2007.08.004; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; Haenssen KK, 2010, J CELL SCI, V123, P1373, DOI 10.1242/jcs.050906; HEMLER ME, 1983, J IMMUNOL, V131, P334; Hong IK, 2012, J BIOL CHEM, V287, P32027, DOI 10.1074/jbc.M111.314443; Hopkins AM, 2003, J CELL SCI, V116, P725, DOI 10.1242/jcs.00300; Huang C, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2936; Huck L, 2010, P NATL ACAD SCI USA, V107, P15559, DOI 10.1073/pnas.1003034107; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Itoh RE, 2002, MOL CELL BIOL, V22, P6582, DOI 10.1128/MCB.22.18.6582-6591.2002; Kazarov AR, 2002, J CELL BIOL, V158, P1299, DOI 10.1083/jcb.200204056; Kwon MJ, 2012, BRIT J CANCER, V106, P923, DOI 10.1038/bjc.2012.11; Lemmon MA, 2009, EXP CELL RES, V315, P638, DOI 10.1016/j.yexcr.2008.10.024; Lesniak D, 2009, CANCER RES, V69, P8620, DOI 10.1158/0008-5472.CAN-09-1591; Malaval C, 2009, CELL SIGNAL, V21, P120, DOI 10.1016/j.cellsig.2008.09.016; Morini M, 2000, INT J CANCER, V87, P336, DOI 10.1002/1097-0215(20000801)87:3<336::AID-IJC5>3.0.CO;2-3; Morton PE, 2011, METHODS MOL BIOL, V769, P403, DOI 10.1007/978-1-61779-207-6_27; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Nagy P, 2002, J CELL SCI, V115, P4251, DOI 10.1242/jcs.00118; Novitskaya V, 2010, CANCER RES, V70, P4698, DOI 10.1158/0008-5472.CAN-09-4330; Orr G, 2005, BIOPHYS J, V89, P1362, DOI 10.1529/biophysj.104.056192; Park CC, 2006, CANCER RES, V66, P1526, DOI 10.1158/0008-5472.CAN-05-3071; Parsons M, 2008, J CELL SCI, V121, P265, DOI 10.1242/jcs.018440; Penuel E, 2002, J BIOL CHEM, V277, P28468, DOI 10.1074/jbc.M202510200; Prakash A, 2011, BIOPHYS J, V101, P1949, DOI 10.1016/j.bpj.2011.09.017; Ramirez NE, 2011, J CLIN INVEST, V121, P226, DOI 10.1172/JCI42328; Reim F, 2009, CANCER RES, V69, P8058, DOI 10.1158/0008-5472.CAN-09-0834; Sadej R, 2009, MOL CANCER RES, V7, P787, DOI 10.1158/1541-7786.MCR-08-0574; Sahai E, 2001, EMBO J, V20, P755, DOI 10.1093/emboj/20.4.755; Scales TME, 2013, ONCOGENE, V32, P3965, DOI 10.1038/onc.2012.415; Scaltriti M, 2011, P NATL ACAD SCI USA, V108, P3761, DOI 10.1073/pnas.1014835108; Sharpe S, 2002, BIOCHEMISTRY-US, V41, P2341, DOI 10.1021/bi011340f; Sottocornola E, 2006, FEBS J, V273, P1821, DOI 10.1111/j.1742-4658.2006.05203.x; Stipp CS, 2010, EXPERT REV MOL MED, V12, DOI 10.1017/S1462399409001355; Tachibana I, 1997, J BIOL CHEM, V272, P29181, DOI 10.1074/jbc.272.46.29181; Wang SE, 2009, CANCER RES, V69, P475, DOI 10.1158/0008-5472.CAN-08-2649; Weigelt B, 2010, BREAST CANCER RES TR, V122, P35, DOI 10.1007/s10549-009-0502-2; WEITZMAN JB, 1993, J BIOL CHEM, V268, P8651; Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775; Yang XWH, 2010, CANCER RES, V70, P2256, DOI 10.1158/0008-5472.CAN-09-4032; Zhang F, 2011, BLOOD, V118, P4274, DOI 10.1182/blood-2011-03-339531	54	32	32	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2014	33	21					2779	2789		10.1038/onc.2013.231	http://dx.doi.org/10.1038/onc.2013.231			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EH	23792450				2022-12-28	WOS:000337231700011
J	Rudrapatna, VA; Bangi, E; Cagan, RL				Rudrapatna, V. A.; Bangi, E.; Cagan, R. L.			A Jnk-Rho-Actin remodeling positive feedback network directs Src-driven invasion	ONCOGENE			English	Article						Drosophila; Cofilin; Actin; Jnk; invasion; enabled	NUCLEAR ACTIN; CELL BIOLOGY; DROSOPHILA; CANCER; MICROENVIRONMENT; TRANSCRIPTION; LOCALIZATION; EXPRESSION; APOPTOSIS; MIGRATION	Current models of tumor cell invasion propose that oncogenic signaling converges upon key orchestrators of cytoskeletal dynamics, including c-Jun N-terminal kinase (Jnk) and RhoGTPase family members; these signals dynamically direct Actin remodeling proteins (ARPs) to catalyze the cytoskeletal changes required for migration. Src is a key driver of tumor aggression, metastasis and patient mortality. To clarify how Src regulates Actin dynamics to promote invasive migration, we performed a genetic modifier screen in a Drosophila model of invasion. Nine genes linked to Actin dynamics were identified that mediate invasion in situ. We found that ARPs were required for many oncogenic effects of Src including Mmp1 expression and initiation of apoptosis. Surprisingly, they were also regulators of Jnk pathway activity: both Src and the small GTPase Rho1 activated Jnk in a manner dependent on ARPs during invasion. Our results suggest that ARPs are not simply downstream executors of signal transduction pathways. Rather, they participate in a positive feedback network involving canonical oncogenic signaling pathways that promote tumor invasion.	[Rudrapatna, V. A.; Bangi, E.; Cagan, R. L.] Mt Sinai Sch Med, Dept Dev & Regenerat Biol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Cagan, RL (corresponding author), Mt Sinai Sch Med, Dept Dev & Regenerat Biol, One Gustave L Levy Pl,Annenberg 25-40, New York, NY 10029 USA.	ross.cagan@mssm.edu	Cagan, Ross Leigh/AAV-9528-2021; Tsai, Yu-Chen/B-5852-2008	Rudrapatna, Vivek/0000-0003-1789-3004; Cagan, Ross/0000-0001-5297-450X	National Institutes of Health [NCI R01 CA109730, 5R01EY011495];  [5T32CA078207];  [5T32GM007280]; NATIONAL CANCER INSTITUTE [R01CA109730, T32CA078207] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY011495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007280] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank members of the Cagan laboratory for important discussions and especially Jay Pendse for statistical assistance and Ruth Johnson for discussions and support regarding actin remodeling. Stocks were obtained from the Bloomington Drosophila Stock Center, Vienna Drosophila RNAi Center and the National Institute of Genetics Fly Stock Center. VAR was supported by 5T32CA078207 and 5T32GM007280. This work was also supported by the National Institutes of Health grants NCI R01 CA109730 and 5R01EY011495.	Bernstein BW, 2010, TRENDS CELL BIOL, V20, P187, DOI 10.1016/j.tcb.2010.01.001; Cagan RL, 2012, DEV CELL, V22, P472, DOI 10.1016/j.devcel.2012.02.014; Fan Y, 2010, CELL DEATH DIFFER, V17, P534, DOI 10.1038/cdd.2009.185; Fox DT, 2005, DEVELOPMENT, V132, P4819, DOI 10.1242/dev.02056; Godt D, 1998, NATURE, V395, P387, DOI 10.1038/26493; Goetz JG, 2011, CELL, V146, P148, DOI 10.1016/j.cell.2011.05.040; Guarino M, 2010, J CELL PHYSIOL, V223, P14, DOI 10.1002/jcp.22011; Kustermans G, 2008, BIOCHEM PHARMACOL, V76, P1310, DOI 10.1016/j.bcp.2008.05.028; Le Clainche C, 2008, PHYSIOL REV, V88, P489, DOI 10.1152/physrev.00021.2007; Leung CT, 2012, NATURE, V482, P410, DOI 10.1038/nature10826; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; Olson EN, 2010, NAT REV MOL CELL BIO, V11, P353, DOI 10.1038/nrm2890; Olson MF, 2009, CLIN EXP METASTAS, V26, P273, DOI 10.1007/s10585-008-9174-2; Rottner K, 2011, CURR OPIN CELL BIOL, V23, P569, DOI 10.1016/j.ceb.2011.07.003; Rudrapatna VA, 2013, EMBO REP, V14, P172, DOI 10.1038/embor.2012.217; Schwartz MA, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a005066; Speck O, 2003, NATURE, V421, P83, DOI 10.1038/nature01295; Szerlong H, 2008, NAT STRUCT MOL BIOL, V15, P469, DOI 10.1038/nsmb.1403; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Uhlirova M, 2006, EMBO J, V25, P5294, DOI 10.1038/sj.emboj.7601401; Vartiainen MK, 2007, SCIENCE, V316, P1749, DOI 10.1126/science.1141084; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Vidal M, 2006, DEV CELL, V10, P33, DOI 10.1016/j.devcel.2005.11.007; Vidal M, 2010, AM J PATHOL, V176, P3007, DOI 10.2353/ajpath.2010.090253; Zheng B, 2009, FEBS J, V276, P2669, DOI 10.1111/j.1742-4658.2009.06986.x	25	25	25	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2014	33	21					2801	2806		10.1038/onc.2013.232	http://dx.doi.org/10.1038/onc.2013.232			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EH	23831567				2022-12-28	WOS:000337231700013
J	Cui, D; Li, L; Lou, H; Sun, H; Ngai, SM; Shao, G; Tang, J				Cui, D.; Li, L.; Lou, H.; Sun, H.; Ngai, S-M; Shao, G.; Tang, J.			The ribosomal protein S26 regulates p53 activity in response to DNA damage	ONCOGENE			English	Article						ribosomal proteins; RPS26; p53; DNA damage response; p53 acetylation	INDUCED PHOSPHORYLATION; MEDIATES STABILIZATION; ACTIVATES P53; MDM2; L11; INHIBITION; L5; DEGRADATION; UBIQUITINATION; ACETYLATION	Ribosomal proteins have emerged as novel regulators of the Mdm2-p53 feedback loop, especially in the context of ribosomal stress. RPS26 is a recently identified Diamond-Blackfan Anemia-related ribosomal protein and its role in p53 activation has not been previously explored. In this study we found knockdown of RPS26 induced p53 stabilization and activation via a RPL11-dependent mechanism, resulting in p53-dependent cell growth inhibition. Moreover, RPS26 has the ability to interact with Mdm2 and inhibits Mdm2-mediated p53 ubiquitination that leads to p53 stabilization upon overexpression. Importantly, we discovered that RPS26 knockdown impaired p53' s ability to transcriptionally activate its target genes in response to DNA damage, without affecting its stability. Accordingly, the cells lost the ability to induce G2/M cell cycle arrest. We further found that upon RPS26 knockdown, the DNA damage induced recruitment of p53 to the promoters of its target genes and p53 acetylation were both greatly reduced. In addition, RPS26 can interact with p53 independent of Mdm2 and coexist in a complex with p53 and p300. These data establish a role of RPS26 in DNA damage response by directly influencing p53 transcriptional activity, and suggest that RPS26 acts distinctively in different scenarios of p53 activation. Our finding also implicates p53 transcriptional activity control as an important mechanism of p53 regulation by ribosomal proteins.	[Cui, D.; Li, L.; Lou, H.; Sun, H.; Tang, J.] China Agr Univ, State Key Lab Agrobiotechnol, Beijing 100193, Peoples R China; [Cui, D.; Li, L.; Sun, H.; Tang, J.] China Agr Univ, Coll Vet Med, Dept Basic Vet Med, Beijing 100193, Peoples R China; [Lou, H.] China Agr Univ, Coll Biol Sci, Beijing 100193, Peoples R China; [Ngai, S-M] Chinese Univ Hong Kong, Dept Biol, Hong Kong, Hong Kong, Peoples R China; [Ngai, S-M] Chinese Univ Hong Kong, State China Key Lab Agrobiotechnol, Hong Kong, Hong Kong, Peoples R China; [Shao, G.] Peking Univ, Hlth Sci Ctr, Sch Basic Med Sci, Dept Cell Biol, Beijing 100871, Peoples R China	China Agricultural University; China Agricultural University; China Agricultural University; Chinese University of Hong Kong; Chinese University of Hong Kong; Peking University	Tang, J (corresponding author), China Agr Univ, Coll Vet Med, 2 Yuanmingyuan West Rd, Beijing 100193, Peoples R China.	jtang@cau.edu.cn	Lou, Huiqiang/B-6287-2012; Ngai, Sai Ming/S-4898-2018	Lou, Huiqiang/0000-0003-4465-6186; Ngai, Sai Ming/0000-0002-4484-2483	National Natural Science Foundation of China [31171331]; Program for New Century Excellent Talents in University of China [NCET-09-0737]; State Key Laboratory of Agrobiotechnology of China [2010SKLAB06-5]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for New Century Excellent Talents in University of China(Program for New Century Excellent Talents in University (NCET)); State Key Laboratory of Agrobiotechnology of China	We thank Dr Xiaolu Yang for generously providing constructs and reagents; Dr Weiguo Zhu for providing the Ha-p300 expression plasmid; Yongqiang Wang for technical assistance; Dr Julia Hill for critically reading the manuscript and Caroline Kitzmiller for proofreading the manuscript. This work was supported by the National Natural Science Foundation of China (31171331); the Program for New Century Excellent Talents in University of China (NCET-09-0737) and the research fund from the State Key Laboratory of Agrobiotechnology of China (2010SKLAB06-5).	Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bhat KP, 2004, EMBO J, V23, P2402, DOI 10.1038/sj.emboj.7600247; Boulon S, 2010, MOL CELL, V40, P216, DOI 10.1016/j.molcel.2010.09.024; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chen D, 2007, ONCOGENE, V26, P5029, DOI 10.1038/sj.onc.1210327; Chen J, 2012, J BIOL CHEM, V287, P16467, DOI 10.1074/jbc.M112.349274; Cmejla R, 2009, HUM MUTAT, V30, P321, DOI 10.1002/humu.20874; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Dai MS, 2007, EMBO J, V26, P3332, DOI 10.1038/sj.emboj.7601776; Dai MS, 2006, J BIOL CHEM, V281, P24304, DOI 10.1074/jbc.M602596200; Deisenroth C, 2010, ONCOGENE, V29, P4253, DOI 10.1038/onc.2010.189; Doherty L, 2010, AM J HUM GENET, V86, P222, DOI 10.1016/j.ajhg.2009.12.015; Fumagalli S, 2012, GENE DEV, V26, P1028, DOI 10.1101/gad.189951.112; Fumagalli S, 2009, NAT CELL BIOL, V11, P501, DOI 10.1038/ncb1858; Gazda HT, 2012, HUM MUTAT, V33, P1037, DOI 10.1002/humu.22081; Gazda HT, 2008, AM J HUM GENET, V83, P769, DOI 10.1016/j.ajhg.2008.11.004; Gu B, 2012, INT J BIOL SCI, V8, P672, DOI 10.7150/ijbs.4283; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Horn HF, 2008, ONCOGENE, V27, P5774, DOI 10.1038/onc.2008.189; Ivanov AV, 2005, BBA-GENE STRUCT EXPR, V1727, P134, DOI 10.1016/j.bbaexp.2004.12.011; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; Kruse JP, 2009, CELL, V137, P609, DOI 10.1016/j.cell.2009.04.050; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kuroda T, 2011, EMBO J, V30, P1054, DOI 10.1038/emboj.2011.23; Lam YW, 2007, CURR BIOL, V17, P749, DOI 10.1016/j.cub.2007.03.064; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Li LJ, 2012, DNA REPAIR, V11, P112, DOI 10.1016/j.dnarep.2011.10.010; Llanos S, 2010, CELL CYCLE, V9, P4005, DOI 10.4161/cc.9.19.13299; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Mahata B, 2012, ONCOGENE, V31, P3060, DOI 10.1038/onc.2011.482; MARECHAL V, 1994, MOL CELL BIOL, V14, P7414, DOI 10.1128/MCB.14.11.7414; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Ofir-Rosenfeld Y, 2008, MOL CELL, V32, P180, DOI 10.1016/j.molcel.2008.08.031; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Scacheri PC, 2004, P NATL ACAD SCI USA, V101, P1892, DOI 10.1073/pnas.0308698100; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Sun XX, 2008, J BIOL CHEM, V283, P12387, DOI 10.1074/jbc.M801387200; Sun XX, 2007, J BIOL CHEM, V282, P8052, DOI 10.1074/jbc.M610621200; Sun XX, 2011, J BIOL CHEM, V286, P22730, DOI 10.1074/jbc.M111.223651; Sun XX, 2010, J BIOL CHEM, V285, P25812, DOI 10.1074/jbc.M109.098442; Sundqvist A, 2009, EMBO REP, V10, P1132, DOI 10.1038/embor.2009.178; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Tang J, 2006, NAT CELL BIOL, V8, P855, DOI 10.1038/ncb1442; Tang Y, 2008, CELL, V133, P612, DOI 10.1016/j.cell.2008.03.025; Teufel DP, 2009, ONCOGENE, V28, P2112, DOI 10.1038/onc.2009.71; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Wan FY, 2007, CELL, V131, P927, DOI 10.1016/j.cell.2007.10.009; Wanzel M, 2008, NAT CELL BIOL, V10, P1051, DOI 10.1038/ncb1764; Xiong X, 2011, ONCOGENE, V30, P1798, DOI 10.1038/onc.2010.569; Zhang X, 2013, ONCOGENE, V32, P2782, DOI 10.1038/onc.2012.289; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhang Y, 2010, NUCLEIC ACIDS RES, V38, P6544, DOI 10.1093/nar/gkq536; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003; Zhou X, 2013, ONCOGENE, V32, P388, DOI 10.1038/onc.2012.63; Zhu Y, 2009, MOL CELL, V35, P316, DOI 10.1016/j.molcel.2009.07.014	60	66	69	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2014	33	17					2225	2235		10.1038/onc.2013.170	http://dx.doi.org/10.1038/onc.2013.170			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF8WJ	23728348				2022-12-28	WOS:000334996000008
J	Guenther, GG; Liu, G; Ramirez, MU; McMonigle, RJ; Kim, SM; McCracken, AN; Joo, Y; Ushach, I; Nguyen, NL; Edinger, AL				Guenther, G. G.; Liu, G.; Ramirez, M. U.; McMonigle, R. J.; Kim, S. M.; McCracken, A. N.; Joo, Y.; Ushach, I.; Nguyen, N. L.; Edinger, A. L.			Loss of TSC2 confers resistance to ceramide and nutrient deprivation	ONCOGENE			English	Article						TSC2; mTOR; nutrient transporters; 4F2hc; GLUT1; ceramide	ACTIVATED PROTEIN-KINASE; TUBEROUS SCLEROSIS COMPLEX; TSC1-TSC2 COMPLEX; AMINO-ACIDS; INDUCED APOPTOSIS; CELL-GROWTH; TRANSLATIONAL CONTROL; TRANSPORTER PROTEINS; TSC2-NULL CELLS; MESSENGER-RNA	Nutrient stress that produces quiescence and catabolism in normal cells is lethal to cancer cells, because oncogenic mutations constitutively drive anabolism. One driver of biosynthesis in cancer cells is the mammalian target of rapamycin complex 1 (mTORC1) signaling complex. Activating mTORC1 by deleting its negative regulator tuberous sclerosis complex 2 (TSC2) leads to hypersensitivity to glucose deprivation. We have previously shown that ceramide kills cells in part by triggering nutrient transporter loss and restricting access to extracellular amino acids and glucose, suggesting that TSC2-deficient cells would be hypersensitive to ceramide. However, murine embryonic fibroblasts (MEFs) lacking TSC2 were highly resistant to ceramide-induced death. Consistent with the observation that ceramide limits access to both amino acids and glucose, TSC2(-/-) MEFs also had a survival advantage when extracellular amino acids and glucose were both reduced. As TSC2(-/-) MEFs were resistant to nutrient stress despite sustained mTORC1 activity, we assessed whether mTORC1 signaling might be beneficial under these conditions. In low amino acid and glucose medium, and following ceramide-induced nutrient transporter loss, elevated mTORC1 activity significantly enhanced the adaptive upregulation of new transporter proteins for amino acids and glucose. Strikingly, the introduction of oncogenic Ras abrogated the survival advantage of TSC2(-/-) MEFs upon ceramide treatment most likely by increasing nutrient demand. These results suggest that, in the absence of oncogene-driven biosynthetic demand, mTORC1-dependent translation facilitates the adaptive cellular response to nutrient stress.	[Guenther, G. G.; Liu, G.; Ramirez, M. U.; McMonigle, R. J.; Kim, S. M.; McCracken, A. N.; Joo, Y.; Ushach, I.; Nguyen, N. L.; Edinger, A. L.] Univ Calif Irvine, Dept Dev & Cell Biol, Irvine, CA 92697 USA	University of California System; University of California Irvine	Edinger, AL (corresponding author), Univ Calif Irvine, Dept Dev & Cell Biol, 2128 Nat Sci 1, Irvine, CA 92697 USA.	aedinger@uci.edu	Liu, Gang/B-7635-2012	Ushach, Irina/0000-0002-3223-4202; Kim, Seong Min/0000-0001-8328-8211	NIH [R01-GM089919]; American Cancer Society grant from the Army Medical Research & Materiel Command [120976-RSG-11-111-01-CDD, W81XWH-11-1-0535]; UCI CORCL [SIIG-1-2007-2008]; National Cancer Institute [T32CA009054]; NATIONAL CANCER INSTITUTE [T32CA009054] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM089919] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society grant from the Army Medical Research & Materiel Command; UCI CORCL; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported in part by NIH R01-GM089919, American Cancer Society grant 120976-RSG-11-111-01-CDD, W81XWH-11-1-0535 from the Army Medical Research & Materiel Command, and SIIG-1-2007-2008 from the UCI CORCL to ALE. GGG and ANM were supported by grant number T32CA009054 from the National Cancer Institute.	Aronova S, 2008, CELL METAB, V7, P148, DOI 10.1016/j.cmet.2007.11.015; Avruch J, 2009, AM J PHYSIOL-ENDOC M, V296, pE592, DOI 10.1152/ajpendo.90645.2008; Bain PJ, 2002, J NUTR, V132, P3023, DOI 10.1093/jn/131.10.3023; Bhaskar PT, 2009, MOL CELL BIOL, V29, P5136, DOI 10.1128/MCB.01946-08; Bhattacharyya SN, 2006, CELL, V125, P1111, DOI 10.1016/j.cell.2006.04.031; Brugarolas JB, 2003, CANCER CELL, V4, P147, DOI 10.1016/S1535-6108(03)00187-9; Choo AY, 2010, MOL CELL, V38, P487, DOI 10.1016/j.molcel.2010.05.007; Curatolo P, 2008, LANCET, V372, P657, DOI 10.1016/S0140-6736(08)61279-9; Dazert E, 2011, CURR OPIN CELL BIOL, V23, P744, DOI 10.1016/j.ceb.2011.09.003; Dibble CC, 2012, MOL CELL, V47, P535, DOI 10.1016/j.molcel.2012.06.009; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; Duran RV, 2012, EMBO REP, V13, P121, DOI 10.1038/embor.2011.257; Edinger AL, 2004, ONCOGENE, V23, P5654, DOI 10.1038/sj.onc.1207738; Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584; Fernandez J, 2001, J BIOL CHEM, V276, P12285, DOI 10.1074/jbc.M009714200; Gaccioli F, 2006, J BIOL CHEM, V281, P17929, DOI 10.1074/jbc.M600341200; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gazzola RF, 2001, FEBS LETT, V490, P11; Guenther GG, 2008, P NATL ACAD SCI USA, V105, P17402, DOI 10.1073/pnas.0802781105; Guertin DA, 2006, DEV CELL, V11, P859, DOI 10.1016/j.devcel.2006.10.007; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Harrington LS, 2004, J CELL BIOL, V166, P213, DOI 10.1083/jcb.200403069; Huang JX, 2008, MOL CELL BIOL, V28, P4104, DOI 10.1128/MCB.00289-08; Huang J, 2008, BIOCHEM J, V412, P179, DOI 10.1042/BJ20080281; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Jewell JL, 2013, NAT REV MOL CELL BIO, V14, P133, DOI 10.1038/nrm3522; Kanai Y, 1998, J BIOL CHEM, V273, P23629, DOI 10.1074/jbc.273.37.23629; Kang YJ, 2011, CELL DEATH DIFFER, V18, P133, DOI 10.1038/cdd.2010.82; Kaper F, 2006, CANCER RES, V66, P1561, DOI 10.1158/0008-5472.CAN-05-3375; Kim E, 2008, NAT CELL BIOL, V10, P935, DOI 10.1038/ncb1753; Kim J, 2011, ANNU REV BIOCHEM, V80, P1001, DOI 10.1146/annurev-biochem-062209-094414; Kim SG, 2013, MOL CELL, V49, P172, DOI 10.1016/j.molcel.2012.10.003; Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496; Lacher MD, 2010, ONCOGENE, V29, P6543, DOI 10.1038/onc.2010.393; Le Stunff H, 2007, J BIOL CHEM, V282, P34372, DOI 10.1074/jbc.M703329200; Li BH, 2010, CANCER CELL, V17, P469, DOI 10.1016/j.ccr.2010.03.019; Manel N, 2003, CELL, V115, P449, DOI 10.1016/S0092-8674(03)00881-X; Matsumoto S, 2002, GENETICS, V161, P1053; Menon S, 2008, Oncogene, V27 Suppl 2, pS43, DOI 10.1038/onc.2009.352; Ng S, 2011, AUTOPHAGY, V7, P1173, DOI 10.4161/auto.7.10.16681; Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; Ogretmen B, 2002, J BIOL CHEM, V277, P12960, DOI 10.1074/jbc.M110699200; Park NS, 2008, ANTICANCER RES, V28, P2649; Parkhitko A, 2011, P NATL ACAD SCI USA, V108, P12455, DOI 10.1073/pnas.1104361108; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Roccio M, 2006, ONCOGENE, V25, P657, DOI 10.1038/sj.onc.1209106; Rosales KR, 2011, BIOCHEM J, V439, P299, DOI 10.1042/BJ20110853; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Sancak Y, 2010, CELL, V141, P290, DOI 10.1016/j.cell.2010.02.024; Schubert KM, 2000, J BIOL CHEM, V275, P13330, DOI 10.1074/jbc.275.18.13330; Shah OJ, 2006, MOL CELL BIOL, V26, P6425, DOI 10.1128/MCB.01254-05; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; Short JD, 2008, CANCER RES, V68, P6496, DOI 10.1158/0008-5472.CAN-07-5756; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Teske BF, 2011, METHOD ENZYMOL, V490, P333, DOI 10.1016/B978-0-12-385114-7.00019-2; Tremblay F, 2007, P NATL ACAD SCI USA, V104, P14056, DOI 10.1073/pnas.0706517104; Wek RC, 2006, BIOCHEM SOC T, V34, P7, DOI 10.1042/BST0340007; Yecies JL, 2011, J MOL MED, V89, P221, DOI 10.1007/s00109-011-0726-6; Yuan HX, 2013, MOL CELL, V49, P379, DOI 10.1016/j.molcel.2013.01.019; Zhang HH, 2009, PLOS ONE, V4, DOI [10.1371/journal.pone.0006189, 10.1371/journal.pone.0007826]; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568	64	15	15	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2014	33	14					1776	1787		10.1038/onc.2013.139	http://dx.doi.org/10.1038/onc.2013.139			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RE	23604129	Green Accepted			2022-12-28	WOS:000334345500004
J	Kurokawa, K; Akaike, Y; Masuda, K; Kuwano, Y; Nishida, K; Yamagishi, N; Kajita, K; Tanahashi, T; Rokutan, K				Kurokawa, K.; Akaike, Y.; Masuda, K.; Kuwano, Y.; Nishida, K.; Yamagishi, N.; Kajita, K.; Tanahashi, T.; Rokutan, K.			Downregulation of serine/arginine-rich splicing factor 3 induces G1 cell cycle arrest and apoptosis in colon cancer cells	ONCOGENE			English	Article						SRSF3 (SRp20); G1 arrest; apoptosis; alternative splicing; HIPK2	INTERACTING PROTEIN KINASE-2; SR PROTEINS; OVARIAN-CANCER; FACTOR SRP20; P53 ACTIVITY; DNA-DAMAGE; HIPK2; TRANSCRIPTION; EXPRESSION; PHOSPHORYLATION	Serine/arginine-rich splicing factor 3 (SRSF3) likely has wide-ranging roles in gene expression and facilitation of tumor cell growth. SRSF3 knockdown induced G1 arrest and apoptosis in colon cancer cells (HCT116) in association with altered expression of 833 genes. Pathway analysis revealed 'G1/S Checkpoint Regulation' as the most highly enriched category in the affected genes. SRSF3 knockdown did not induce p53 or stimulate phosphorylation of p53 or histone H2A. X in wild-type HCT116 cells. Furthermore, the knockdown induced G1 arrest in p53-null HCT116 cells, suggesting that p53-dependent DNA damage responses did not mediate the G1 arrest. Real-time reverse transcription-polymerase chain reaction and western blotting confirmed that SRSF3 knockdown reduced mRNA and protein levels of cyclins (D1, D3 and E1), E2F1 and E2F7. The decreased expression of cyclin D and E2F1 likely impaired the G1-to-S-phase progression. Consequently, retinoblastoma protein remained hypophosphorylated in SRSF3 knockdown cells. The knockdown also induced apoptosis in association with reduction of BCL2 protein levels. We also found that SRSF3 knockdown facilitated skipping of 81 5'-nucleotides (27 amino acids) from exon 8 of homeodomain-interacting protein kinase-2 (HIPK2) and produced a HIPK2 Delta e8 isoform. Full-length HIPK2 (HIPK2 FL) is constantly degraded through association with an E3 ubiquitin ligase (Siah-1), whereas HIPK2 Delta e8, lacking the 27 amino acids, lost Siah-1-binding ability and became resistant to proteasome digestion. Interestingly, selective knockdown of HIPK2 FL induced apoptosis in various colon cancer cells expressing wild-type or mutated p53. Thus, these findings disclose an important role of SRSF3 in the regulation of the G1-to-S-phase progression and alternative splicing of HIPK2 in tumor growth.	[Kurokawa, K.; Akaike, Y.; Masuda, K.; Kuwano, Y.; Nishida, K.; Yamagishi, N.; Kajita, K.; Tanahashi, T.; Rokutan, K.] Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Stress Sci, Tokushima 7708503, Japan	Tokushima University	Kurokawa, K (corresponding author), Univ Tokushima, Grad Sch, Inst Hlth Biosci, Dept Stress Sci, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.	kurokawa178@basic.med.tokushima-u.ac.jp	Nishida, Kensei/AAF-2829-2020	Nishida, Kensei/0000-0003-2314-785X	Japan Society for the Promotion of Science	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work was funded by the Grants-in-Aid for Scientific Research from Japan Society for the Promotion of Science (to KR).	Anko ML, 2010, NAT STRUCT MOL BIOL, V17, P962, DOI 10.1038/nsmb.1862; Ahn EY, 2011, MOL CELL, V42, P185, DOI 10.1016/j.molcel.2011.03.014; Aikawa Y, 2006, EMBO J, V25, P3955, DOI 10.1038/sj.emboj.7601273; Anczukow O, 2012, NAT STRUCT MOL BIOL, V19, P220, DOI 10.1038/nsmb.2207; Calzado MA, 2009, NAT CELL BIOL, V11, P85, DOI 10.1038/ncb1816; Chen M, 2009, NAT REV MOL CELL BIO, V10, P741, DOI 10.1038/nrm2777; Choi DW, 2008, J BIOL CHEM, V283, P4682, DOI 10.1074/jbc.M708873200; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; D'Orazi G, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-63; Ghigna C, 1998, CANCER RES, V58, P5818; Giraud S, 2004, J VIROL, V78, P2984, DOI 10.1128/JVI.78.6.2984-2993.2004; Hailemariam K, 2010, J CELL SCI, V123, P3863, DOI 10.1242/jcs.073627; He X, 2011, ONCOGENE, V30, P356, DOI 10.1038/onc.2010.426; He XL, 2004, CLIN CANCER RES, V10, P4652, DOI 10.1158/1078-0432.CCR-03-0439; Hikasa H, 2010, DEV CELL, V19, P521, DOI 10.1016/j.devcel.2010.09.005; Hofmann TG, 2003, CANCER RES, V63, P8271; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Jumaa H, 1999, CURR BIOL, V9, P899, DOI 10.1016/S0960-9822(99)80394-7; Kim SY, 2009, CANCER LETT, V279, P177, DOI 10.1016/j.canlet.2009.01.036; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Kurokawa K, 2010, NEUROSCI LETT, V484, P128, DOI 10.1016/j.neulet.2010.08.031; Kuwano Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024723; Lazzari C, 2011, ONCOGENE, V30, P4802, DOI 10.1038/onc.2011.182; Li XL, 2005, GENE DEV, V19, P2705, DOI 10.1101/gad.1359305; Li XL, 2005, CELL, V122, P365, DOI 10.1016/j.cell.2005.06.008; Lin SR, 2008, NAT STRUCT MOL BIOL, V15, P819, DOI 10.1038/nsmb.1461; Loomis RJ, 2009, MOL CELL, V33, P450, DOI 10.1016/j.molcel.2009.02.003; Lou H, 1998, MOL CELL BIOL, V18, P4977, DOI 10.1128/MCB.18.9.4977; Manley JL, 2010, GENE DEV, V24, P1073, DOI 10.1101/gad.1934910; Moore MJ, 2010, CELL, V142, P625, DOI 10.1016/j.cell.2010.07.019; Puca R, 2010, ONCOGENE, V29, P4378, DOI 10.1038/onc.2010.183; Rinaldo C, 2007, MOL CELL, V25, P739, DOI 10.1016/j.molcel.2007.02.008; Sanford JR, 2004, GENE DEV, V18, P755, DOI 10.1101/gad.286404; Sapra AK, 2009, MOL CELL, V34, P179, DOI 10.1016/j.molcel.2009.02.031; Schwerk C, 2005, MOL CELL, V19, P1, DOI 10.1016/j.molcel.2005.05.026; Sombroek D, 2009, CELL DEATH DIFFER, V16, P187, DOI 10.1038/cdd.2008.154; Srebrow A, 2006, J CELL SCI, V119, P2635, DOI 10.1242/jcs.03053; Stickeler E, 1999, ONCOGENE, V18, P3574, DOI 10.1038/sj.onc.1202671; Wei GW, 2007, P NATL ACAD SCI USA, V104, P13040, DOI 10.1073/pnas.0703213104; Winter M, 2008, NAT CELL BIOL, V10, P812, DOI 10.1038/ncb1743; Xiao R, 2007, MOL CELL BIOL, V27, P5393, DOI 10.1128/MCB.00288-07; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X; Zhang Z, 2004, MOL CELL, V16, P597, DOI 10.1016/j.molcel.2004.10.031; Zhong XY, 2009, MOL CELL, V35, P1, DOI 10.1016/j.molcel.2009.06.016	44	65	68	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2014	33	11					1407	1417		10.1038/onc.2013.86	http://dx.doi.org/10.1038/onc.2013.86			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD0SD	23503458				2022-12-28	WOS:000332943500008
J	Rajbhandari, P; Schalper, KA; Solodin, NM; Ellison-Zelski, SJ; Lu, KP; Rimm, DL; Alarid, ET				Rajbhandari, P.; Schalper, K. A.; Solodin, N. M.; Ellison-Zelski, S. J.; Lu, K. Ping; Rimm, D. L.; Alarid, E. T.			Pin1 modulates ER alpha levels in breast cancer through inhibition of phosphorylation-dependent ubiquitination and degradation	ONCOGENE			English	Article						breast cancer; E3 ligase; proteasome; survival	ESTROGEN-RECEPTOR-ALPHA; PROLYL ISOMERASE PIN1; GENE-EXPRESSION; POSTTRANSLATIONAL MODIFICATIONS; TRANSCRIPTIONAL ACTIVATION; SUBCELLULAR-LOCALIZATION; DIFFERENTIAL REGULATION; E6-ASSOCIATED PROTEIN; TAMOXIFEN RESISTANCE; DOWN-REGULATION	Estrogen receptor-alpha (ER alpha) is an important biomarker used to classify and direct therapy decisions in breast cancer (BC). Both ER alpha protein and its transcript, ESR1, are used to predict response to tamoxifen therapy, yet certain tumors have discordant levels of ER alpha protein and ESR1, which is currently unexplained. Cellular ER alpha protein levels can be controlled post-translationally by the ubiquitin-proteasome pathway through a mechanism that depends on phosphorylation at residue S118. Phospho-S118 (pS118-ER alpha) is a substrate for the peptidyl prolyl isomerase, Pin1, which mediates cis-trans isomerization of the pS118-P119 bond to enhance ER alpha transcriptional function. Here, we demonstrate that Pin1 can increase ER alpha protein without affecting ESR1 transcript levels by inhibiting proteasome-dependent receptor degradation. Pin1 disrupts ER alpha ubiquitination by interfering with receptor interactions with the E3 ligase, E6AP, which also is shown to bind pS118-ER alpha. Quantitative in situ assessments of ER alpha protein, ESR1, and Pin1 in human tumors from a retrospective cohort show that Pin1 levels correlate with ER alpha protein but not to ESR1 levels. These data show that ER alpha protein is post-translationally regulated by Pin1 in a proportion of breast carcinomas. As Pin1 impacts both ER alpha protein levels and transactivation function, these data implicate Pin1 as a potential surrogate marker for predicting outcome of ER alpha-positive BC.	[Rajbhandari, P.; Solodin, N. M.; Ellison-Zelski, S. J.; Alarid, E. T.] Univ Wisconsin, UW Carbone Comprehens Canc Ctr, Dept Oncol, Madison, WI 53705 USA; [Schalper, K. A.; Rimm, D. L.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; [Lu, K. Ping] Harvard Univ, Sch Med, Dept Med, Canc Biol Program,Beth Isreal Deaconess Med Ctr, Boston, MA USA	University of Wisconsin System; University of Wisconsin Madison; Yale University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Rajbhandari, P (corresponding author), Univ Wisconsin, UW Carbone Comprehens Canc Ctr, Dept Oncol, Wisconsin Inst Med Res 6151, Madison, WI 53705 USA.	alarid@oncology.wisc.edu		Rajbhandari, Prashant/0000-0002-8146-3861; Rimm, David/0000-0001-5820-4397	NIH [CA159578, T32 CA009135]; Genoptix/Novartis; NATIONAL CANCER INSTITUTE [R01CA159578, T32CA009135] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Genoptix/Novartis; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank McArdle Laboratories for Cancer Research for support of this project. We also thank the UW Carbone Comprehensive Cancer Center (UWCCC) for use of its shared services to complete this research. We thank Drs Pierre Chambon, Vladimir Spiegelman, Robert Kalejta and Greg Finn for providing us appropriate expression plasmids and reagents. We also thank Dr Wei Xu for insightful comments. This work was supported by NIH grants CA159578 (to E.T.A.) and T32 CA009135 (to P.R.) and a sponsored research award from Genoptix/Novartis (to D.R.).	Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; Alarid ET, 2006, MOL ENDOCRINOL, V20, P1972, DOI 10.1210/me.2005-0481; Atsriku C, 2009, MOL CELL PROTEOMICS, V8, P467, DOI 10.1074/mcp.M800282-MCP200; Bhatt S, 2012, MOL CELL BIOL, V32, P1928, DOI 10.1128/MCB.06561-11; Bordeaux JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036559; BORRAS M, 1994, J STEROID BIOCHEM, V48, P325, DOI 10.1016/0960-0760(94)90072-8; Camp RL, 2002, NAT MED, V8, P1323, DOI 10.1038/nm791; Chen HZ, 2012, ONCOGENE, V31, P2876, DOI 10.1038/onc.2011.463; Cheng JW, 2007, ENDOCRINOLOGY, V148, P4634, DOI 10.1210/en.2007-0148; Dowsett M, 2010, J CLIN ONCOL, V28, P509, DOI 10.1200/JCO.2009.23.1274; Duong V, 2007, CANCER RES, V67, P5513, DOI 10.1158/0008-5472.CAN-07-0967; Duplessis TT, 2011, ENDOCRINOLOGY, V152, P2517, DOI 10.1210/en.2010-1281; Eakin CM, 2007, P NATL ACAD SCI USA, V104, P5794, DOI 10.1073/pnas.0610887104; Ellison-Zelski SJ, 2009, MOL CELL BIOL, V29, P4949, DOI 10.1128/MCB.00383-09; Faus H, 2006, BIOMED PHARMACOTHER, V60, P520, DOI 10.1016/j.biopha.2006.07.082; Fowler AM, 2006, MOL ENDOCRINOL, V20, P291, DOI 10.1210/me.2005-0288; Fowler AM, 2004, FASEB J, V18, P81, DOI 10.1096/fj.03-0038com; Frech MS, 2005, CANCER RES, V65, P681; Fujimoto Y, 2010, J BIOL CHEM, V285, P3126, DOI 10.1074/jbc.M109.055095; Gao XH, 2005, ENDOCRINOLOGY, V146, P1707, DOI 10.1210/en.2004-1198; Gong Y, 2007, LANCET ONCOL, V8, P203, DOI 10.1016/S1470-2045(07)70042-6; Harrell JC, 2007, CANCER RES, V67, P10582, DOI 10.1158/0008-5472.CAN-07-1655; Harrell JC, 2006, CANCER RES, V66, P9308, DOI 10.1158/0008-5472.CAN-06-1769; Hennig L, 1998, BIOCHEMISTRY-US, V37, P5953, DOI 10.1021/bi973162p; Kato K, 1997, ONCOGENE, V15, P3037, DOI 10.1038/sj.onc.1201497; Khan SA, 1998, J NATL CANCER I, V90, P37, DOI 10.1093/jnci/90.1.37; Khanal P, 2012, ONCOGENE, V31, P3845, DOI 10.1038/onc.2011.548; Kim C, 2011, J CLIN ONCOL, V29, P4160, DOI 10.1200/JCO.2010.32.9615; KUMAR V, 1987, CELL, V51, P941, DOI 10.1016/0092-8674(87)90581-2; Lannigan DA, 2003, STEROIDS, V68, P1, DOI 10.1016/S0039-128X(02)00110-1; Li L, 2006, J BIOL CHEM, V281, P1978, DOI 10.1074/jbc.M508545200; Liou YC, 2002, P NATL ACAD SCI USA, V99, P1335, DOI 10.1073/pnas.032404099; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lonard DM, 2000, MOL CELL, V5, P939, DOI 10.1016/S1097-2765(00)80259-2; Lu KP, 2002, TRENDS CELL BIOL, V12, P164, DOI 10.1016/S0962-8924(02)02253-5; Lu KP, 2007, NAT REV MOL CELL BIO, V8, P904, DOI 10.1038/nrm2261; Lu KP, 2007, NAT CHEM BIOL, V3, P619, DOI 10.1038/nchembio.2007.35; Lu PJ, 1999, NATURE, V399, P784; Lu Q, 2003, J BIOL CHEM, V278, P4639, DOI 10.1074/jbc.M210949200; Mantovani F, 2004, MOL CELL, V14, P625, DOI 10.1016/j.molcel.2004.05.007; Marsaud V, 2003, MOL ENDOCRINOL, V17, P2013, DOI 10.1210/me.2002-0269; Min SH, 2012, MOL CELL, V46, P771, DOI 10.1016/j.molcel.2012.04.012; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Nakajima A, 2007, BIOCHEM BIOPH RES CO, V357, P245, DOI 10.1016/j.bbrc.2007.03.134; Namgoong GM, 2010, J BIOL CHEM, V285, P23829, DOI 10.1074/jbc.M109.092874; Picard N, 2008, MOL ENDOCRINOL, V22, P317, DOI 10.1210/me.2007-0281; Pulikkan JA, 2010, LEUKEMIA, V24, P914, DOI 10.1038/leu.2010.37; Rajbhandari P, 2012, MOL CELL BIOL, V32, P445, DOI 10.1128/MCB.06073-11; Ramamoorthy S, 2008, NUCL RECEPT SIGNAL, V6, pe006; Ramamoorthy S, 2012, BREAST CANCER RES TR, V132, P97, DOI 10.1007/s10549-011-1567-2; Ranganathan R, 1997, CELL, V89, P875, DOI 10.1016/S0092-8674(00)80273-1; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Rochette-Egly C, 2003, CELL SIGNAL, V15, P355, DOI 10.1016/S0898-6568(02)00115-8; Ryo A, 2003, MOL CELL, V12, P1413, DOI 10.1016/S1097-2765(03)00490-8; Ryo A, 2001, NAT CELL BIOL, V3, P793, DOI 10.1038/ncb0901-793; Stanya KJ, 2008, J CELL BIOL, V183, P49, DOI 10.1083/jcb.200806172; Sun J, 2012, MOL ENDOCRINOL, V26, P1567, DOI 10.1210/me.2012-1140; Tateishi Y, 2004, EMBO J, V23, P4813, DOI 10.1038/sj.emboj.7600472; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; Valley CC, 2005, MOL CELL BIOL, V25, P5417, DOI 10.1128/MCB.25.13.5417-5428.2005; Wang YL, 2009, J BIOCHEM, V145, P331, DOI 10.1093/jb/mvn177; Wei XL, 2006, MOL CELL, V21, P295, DOI 10.1016/j.molcel.2005.11.030; Welsh AW, 2011, J CLIN ONCOL, V29, P2978, DOI 10.1200/JCO.2010.32.9706; Wulf G, 2004, EMBO J, V23, P3397, DOI 10.1038/sj.emboj.7600323; Wulf G, 2003, BREAST CANCER RES, V5, P76, DOI 10.1186/bcr572; Wulf G, 2005, NAT CELL BIOL, V7, P435, DOI 10.1038/ncb0505-435; Wulf GM, 2002, J BIOL CHEM, V277, P47976, DOI 10.1074/jbc.C200538200; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Yaffe MB, 1997, SCIENCE, V278, P1957, DOI 10.1126/science.278.5345.1957; Yang QY, 2009, J BIOL CHEM, V284, P23980, DOI 10.1074/jbc.M109.022814; Zheng HW, 2002, NATURE, V419, P849, DOI 10.1038/nature01116; Zhou XZ, 2000, MOL CELL, V6, P873, DOI 10.1016/S1097-2765(00)00085-X	72	56	58	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2014	33	11					1438	1447		10.1038/onc.2013.78	http://dx.doi.org/10.1038/onc.2013.78			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD0SD	23542176	Green Accepted			2022-12-28	WOS:000332943500011
J	Goicoechea, SM; Garcia-Mata, R; Staub, J; Valdivia, A; Sharek, L; McCulloch, CG; Hwang, RF; Urrutia, R; Yeh, JJ; Kim, HJ; Otey, CA				Goicoechea, S. M.; Garcia-Mata, R.; Staub, J.; Valdivia, A.; Sharek, L.; McCulloch, C. G.; Hwang, R. F.; Urrutia, R.; Yeh, J. J.; Kim, H. J.; Otey, C. A.			Palladin promotes invasion of pancreatic cancer cells by enhancing invadopodia formation in cancer-associated fibroblasts	ONCOGENE			English	Article						invasion; GTPases; Cdc42; actin; invadopodia; myofibroblasts	SMOOTH-MUSCLE-CELLS; EXTRACELLULAR-MATRIX DEGRADATION; STROMAL FIBROBLASTS; PODOSOME FORMATION; PROTEIN PALLADIN; BINDING PARTNER; RHO; SRC; CYTOSKELETON; PROGRESSION	The stromal compartment surrounding epithelial-derived pancreatic tumors is thought to have a key role in the aggressive phenotype of this malignancy. Emerging evidence suggests that cancer-associated fibroblasts (CAFs), the most abundant cells in the stroma of pancreatic tumors, contribute to the tumor's invasion, metastasis and resistance to therapy, but the precise molecular mechanisms that regulate CAFs behavior are poorly understood. In this study, we utilized immortalized human pancreatic CAFs to investigate molecular pathways that control the matrix-remodeling and invasion-promoting activity of CAFs. We showed previously that palladin, an actin-associated protein, is expressed at high levels in CAFs of pancreatic tumors and other solid tumors, and also in an immortalized line of human CAFs. In this study, we found that short-term exposure of CAFs to phorbol esters reduced the number of stress fibers and triggered the appearance of individual invadopodia and invadopodial rosettes in CAFs. Molecular analysis of invadopodia revealed that their composition resembled that of similar structures (that is, invadopodia and podosomes) described in other cell types. Pharmacological inhibition and small interfering RNA knockdown experiments demonstrated that protein kinase C, the small GTPase Cdc42 and palladin were necessary for the efficient assembly of invadopodia by CAFs. In addition, GTPase activity assays showed that palladin contributes to the activation of Cdc42. In mouse xenograft experiments using a mixture of CAFs and tumor cells, palladin expression in CAFs promoted the rapid growth and metastasis of human pancreatic tumor cells. Overall, these results indicate that high levels of palladin expression in CAFs enhance their ability to remodel the extracellular matrix by regulating the activity of Cdc42, which in turn promotes the assembly of matrix-degrading invadopodia in CAFs and tumor cell invasion. Together, these results identify a novel molecular signaling pathway that may provide new molecular targets for the inhibition of pancreatic cancer metastasis.	[Goicoechea, S. M.; Garcia-Mata, R.; Staub, J.; Valdivia, A.; Sharek, L.; Otey, C. A.] Univ N Carolina, Dept Cell Biol & Physiol, Chapel Hill, NC USA; [Hwang, R. F.] Univ Toronto, Fac Dent, CIHR Grp Matrix Dynam, Toronto, ON, Canada; [Hwang, R. F.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA; [Urrutia, R.] Mayo Clin, Dept Biochem & Mol Biol, Epigenet & Chromatin Dynam Lab,CIM, Div Gastroenterol & Hepatol,Translat Epigen Progr, Rochester, MN USA; [Yeh, J. J.] Univ N Carolina, Dept Pharmacol, Chapel Hill, NC USA; [Yeh, J. J.; Kim, H. J.; Otey, C. A.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Yeh, J. J.; Kim, H. J.] Univ N Carolina, Dept Surg, UNC Sch Med, Chapel Hill, NC USA	University of North Carolina; University of North Carolina Chapel Hill; University of Toronto; University of Texas System; UTMD Anderson Cancer Center; Mayo Clinic; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Goicoechea, SM (corresponding author), Univ Toledo, Dept Biol Sci, 2801 W Bancroft St, Toledo, OH 43606 USA.	Silvia.Goicoechea@utoledo.edu	, Animal Studies Core/ADK-4234-2022; , Animal Studies Core/AAF-4432-2022	Valdivia, Alejandra/0000-0003-1492-5066; Garcia-Mata, Rafael/0000-0002-7116-4411	NIH [GM081505, CA161136, DK52913]; NSF [MCB-1121365]; Elsa U Pardee Foundation; UNC University Cancer Research Fund; CIHR [MOP-36332]; Mayo Clinic Center for Cell Signaling in Gastroenterology [P30DK084567]; Div Of Molecular and Cellular Bioscience [1121365] Funding Source: National Science Foundation; NATIONAL CANCER INSTITUTE [R03CA161136, R01CA140424] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052913, R56DK052913, P30DK084567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM081505] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NSF(National Science Foundation (NSF)); Elsa U Pardee Foundation; UNC University Cancer Research Fund; CIHR(Canadian Institutes of Health Research (CIHR)); Mayo Clinic Center for Cell Signaling in Gastroenterology; Div Of Molecular and Cellular Bioscience(National Science Foundation (NSF)NSF - Directorate for Biological Sciences (BIO)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Angela Mathison (Mayo Clinic College of Medicine) for assistance in generating the imPSCs (imPSC-C2 and imPSC-C3) and Gabriela Herrera for assistance with the AsPC-1 pancreatic tumor cells labeled with firefly luciferase. We also thank Dr Teresa Brentnall (University of Washington) for helpful discussions, and the Lineberger Comprehensive Cancer Center Animal Studies Core for assistance with xenograft experiments. This study was supported by grants from the NIH (GM081505 to CAO; CA161136 to SMG; DK52913 to RU), the NSF (MCB-1121365 to CAO), the Elsa U Pardee Foundation (CAO), the UNC University Cancer Research Fund (SMG), the CIHR (MOP-36332 to CAGM) and the Mayo Clinic Center for Cell Signaling in Gastroenterology (P30DK084567 to RU).	Albiges-Rizo C, 2009, J CELL SCI, V122, P3037, DOI 10.1242/jcs.052704; Alves F, 2001, PANCREAS, V23, P227, DOI 10.1097/00006676-200110000-00002; Arumugam T, 2005, CLIN CANCER RES, V11, P5356, DOI 10.1158/1078-0432.CCR-05-0092; Ayala I, 2009, CANCER RES, V69, P747, DOI 10.1158/0008-5472.CAN-08-1980; Benard V, 2002, METHOD ENZYMOL, V345, P349; Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096; Boukhelifa M, 2006, FEBS J, V273, P26, DOI 10.1111/j.1742-4658.2005.05036.x; Boukhelifa M, 2004, CELL MOTIL CYTOSKEL, V58, P17, DOI 10.1002/cm.10173; Boukhelifa M, 2001, MOL BIOL CELL, V12, P2721, DOI 10.1091/mbc.12.9.2721; Bowden ET, 2001, METHOD CELL BIOL, V63, P613; Brentnall TA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030219; Buccione R, 2009, CANCER METAST REV, V28, P137, DOI 10.1007/s10555-008-9176-1; CHEN WT, 1989, J EXP ZOOL, V251, P167, DOI 10.1002/jez.1402510206; De Wever O, 2003, J PATHOL, V200, P429, DOI 10.1002/path.1398; Egeblad M, 2005, COLD SH Q B, V70, P383, DOI 10.1101/sqb.2005.70.007; Furmaniak-Kazmierczak E, 2007, CIRC RES, V100, P1328, DOI 10.1161/CIRCRESAHA.106.147744; Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658; Gimona M, 2003, MOL BIOL CELL, V14, P2482, DOI 10.1091/mbc.E02-11-0743; Gimona M, 2008, CURR OPIN CELL BIOL, V20, P235, DOI 10.1016/j.ceb.2008.01.005; Goicoechea S, 2006, J CELL SCI, V119, P3316, DOI 10.1242/jcs.03076; Goicoechea SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010347; Gupta V, PLOS ONE, V6; Hai CM, 2002, EXP CELL RES, V280, P64, DOI 10.1006/excr.2002.5592; Hwang RF, 2008, CANCER RES, V68, P918, DOI 10.1158/0008-5472.CAN-07-5714; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Karnoub AE, 2004, BREAST CANCER RES TR, V84, P61, DOI 10.1023/B:BREA.0000018427.84929.5c; Katz MH, 2003, J SURG RES, V113, P151, DOI 10.1016/S0022-4804(03)00234-8; Kuroiwa M, 2011, J CELL SCI, V124, P1726, DOI 10.1242/jcs.080291; Lazer G, 2011, CELL SIGNAL, V23, P969, DOI 10.1016/j.cellsig.2010.10.022; Luo HJ, 2005, MOL CELL NEUROSCI, V29, P507, DOI 10.1016/j.mcn.2004.12.002; Mathison A, 2010, PANCREATOLOGY, V10, P505, DOI [10.1016/S1424-3903(10)80035-3, 10.1159/000320540]; Micke P, 2005, EXPERT OPIN THER TAR, V9, P1217, DOI 10.1517/14728222.9.6.1217; Mishra PJ, 2009, CANCER RES, V69, P1255, DOI 10.1158/0008-5472.CAN-08-3562; Mizutani K, 2002, CANCER RES, V62, P669; MONSKY WL, 1994, CANCER RES, V54, P5702; Murphy DA, NAT REV MOL CELL BIO, V12, P413; Nakahara H, 2003, GENES CELLS, V8, P1019, DOI 10.1111/j.1365-2443.2003.00695.x; Ohuchida K, 2004, CANCER RES, V64, P3215, DOI 10.1158/0008-5472.CAN-03-2464; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Orimo A, 2006, CELL CYCLE, V5, P1597, DOI 10.4161/cc.5.15.3112; Parast MM, 2000, J CELL BIOL, V150, P643, DOI 10.1083/jcb.150.3.643; Radisky DC, 2007, J CELL BIOCHEM, V101, P830, DOI 10.1002/jcb.21186; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Ridley AJ, 2004, BREAST CANCER RES TR, V84, P13, DOI 10.1023/B:BREA.0000018423.47497.c6; Ronty M, 2005, EXP CELL RES, V310, P88, DOI 10.1016/j.yexcr.2005.06.026; Ronty M, 2007, EXP CELL RES, V313, P2575, DOI 10.1016/j.yexcr.2007.04.030; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Salaria SN, 2007, CANCER BIOL THER, V6, P324, DOI 10.4161/cbt.6.3.3904; Tatin F, 2006, J CELL SCI, V119, P769, DOI 10.1242/jcs.02787; TETI A, 1992, AM J PHYSIOL, V263, pC130, DOI 10.1152/ajpcell.1992.263.1.C130; Xiao HL, 2010, MOL CELL BIOL, V30, P5545, DOI 10.1128/MCB.00382-10; Yamaguchi H, 2006, EUR J CELL BIOL, V85, P213, DOI 10.1016/j.ejcb.2005.10.004	52	77	79	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2014	33	10					1265	1273		10.1038/onc.2013.68	http://dx.doi.org/10.1038/onc.2013.68			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AC6KI	23524582	Green Accepted, Green Published			2022-12-28	WOS:000332631100007
J	Kong, F; Zhang, J; Li, Y; Hao, X; Ren, X; Li, H; Zhou, P				Kong, F.; Zhang, J.; Li, Y.; Hao, X.; Ren, X.; Li, H.; Zhou, P.			Engineering a single ubiquitin ligase for the selective degradation of all activated ErbB receptor tyrosine kinases	ONCOGENE			English	Article						ubiquitin; ErbB; breast cancer; protein knockout; proteolysis; receptor tyrosine kinase	PHASE-II TRIAL; BREAST-CANCER; BETA-CATENIN; GROWTH; TRASTUZUMAB; TARGET; HER-2; GENE; PROLIFERATION; DESTRUCTION	Interrogating specific cellular activities often entails the dissection of posttranslational modifications or functional redundancy conferred by protein families, which demands more sophisticated research tools than simply eliminating a specific gene product by gene targeting or RNA interference. We have developed a novel methodology that involves engineering a single SCF beta TrCP-based ubiquitin ligase that is capable of not only simultaneously targeting the entire family of ErbB receptor tyrosine kinases for ubiquitination and degradation, but also selectively recruiting only activated ErbBs. The engineered SCF beta TrCP ubiquitin ligase effectively blocked ErbB signaling and attenuated oncogenicity in breast cancer cells, yet had little effect on the survival and growth of non-cancerous breast epithelial cells. Therefore, engineering ubiquitin ligases offers a simple research tool to dissect the specific traits of tumorigenic protein families, and provides a rapid and feasible means to expand the dimensionality of drug discovery by assessing protein families or posttranslational modifications as potential drug targets.	[Kong, F.; Zhang, J.; Li, Y.; Zhou, P.] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY USA; [Kong, F.; Hao, X.; Ren, X.; Li, H.] Tianjin Med Univ, Canc Inst & Hosp, Dept Biotherapy, Key Lab Canc Prevent & Therapy, Tianjin 300060, Peoples R China	Cornell University; Tianjin Medical University	Li, H (corresponding author), Tianjin Med Univ, Canc Inst & Hosp, Dept Biotherapy, Key Lab Canc Prevent & Therapy, Tianjin 300060, Peoples R China.	lihui_0105@yahoo.com; pez2001@med.cornell.edu			National Institutes of Health [CA92792]; Irma T. Hirschl Career Scientist Award; New York Academy of Medicine; Natural Science Foundation of China [30901754]; Innovation Funding for Graduates of Tianjin Medical University; 211 Project for Higher Education [2010GSI01]; NATIONAL CANCER INSTITUTE [R01CA159925, R21CA092792, R33CA092792, R01CA098210] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Irma T. Hirschl Career Scientist Award; New York Academy of Medicine; Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Innovation Funding for Graduates of Tianjin Medical University; 211 Project for Higher Education; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Bruce Mayer (University of Connecticut) for Shc plasmids, Alexandra Grassian for helpful discussions, and Jeffrey Hannah and Jennifer Lee for critical reading of the manuscript. This work is supported by National Institutes of Health Grant CA92792, the Irma T. Hirschl Career Scientist Award and the Speakers Fund from the New York Academy of Medicine to P.Z., and the Natural Science Foundation of China (No. 30901754) and Innovation Funding for Graduates of Tianjin Medical University, third Phase of the 211 Project for Higher Education (No. 2010GSI01).	Burstein HJ, 2001, J CLIN ONCOL, V19, P2722, DOI 10.1200/JCO.2001.19.10.2722; Carraway KL, 2010, SEMIN CELL DEV BIOL, V21, P936, DOI 10.1016/j.semcdb.2010.09.006; Castaneda CA, 2010, CANCER METAST REV, V29, P751, DOI 10.1007/s10555-010-9261-0; Chen W, 2004, CANCER RES, V64, P3949, DOI 10.1158/0008-5472.CAN-03-3906; Chen XA, 2001, J BIOL CHEM, V276, P48175, DOI 10.1074/jbc.M106808200; Chen XA, 2006, MOL CELL, V22, P489, DOI 10.1016/j.molcel.2006.04.021; Cohen J Craig, 2004, BMC Dev Biol, V4, P4; Colomer R, 2000, CLIN CANCER RES, V6, P2356; Cong F, 2003, BMC MOL BIOL, V4, DOI 10.1186/1471-2199-4-10; Faltus T, 2004, NEOPLASIA, V6, P786, DOI 10.1593/neo.04313; Garrett JT, 2011, P NATL ACAD SCI USA, V108, P5021, DOI 10.1073/pnas.1016140108; Gasparini G, 2007, BREAST CANCER RES TR, V101, P355, DOI 10.1007/s10549-006-9306-9; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hannah J, 2011, CELL RES, V21, P1152, DOI 10.1038/cr.2011.89; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Jones RB, 2006, NATURE, V439, P168, DOI 10.1038/nature04177; Klapper LN, 2000, CANCER RES, V60, P3384; Krause DS, 2005, NEW ENGL J MED, V353, P172, DOI 10.1056/NEJMra044389; Liu J, 2004, BIOCHEM BIOPH RES CO, V313, P1023, DOI 10.1016/j.bbrc.2003.12.035; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Marty M, 2005, J CLIN ONCOL, V23, P4265, DOI 10.1200/JCO.2005.04.173; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Palmieri D, 2006, BREAST CANCER RES TR, V100, P127, DOI 10.1007/s10549-006-9244-6; Panigada M, 2002, J EXP MED, V195, P1585, DOI 10.1084/jem.20020047; Persons DA, 1998, BLOOD CELL MOL DIS, V24, P167, DOI 10.1006/bcmd.1998.0184; Rabindran SK, 2005, CANCER LETT, V227, P9, DOI 10.1016/j.canlet.2004.11.015; Ross JS, 1998, STEM CELLS, V16, P413, DOI 10.1002/stem.160413; Sarikas A, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-4-220; Schulze WX, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100012; Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474; Sithanandam G, 2008, CANCER GENE THER, V15, P413, DOI 10.1038/cgt.2008.15; Sorkin A, 2009, EXP CELL RES, V315, P683, DOI [10.1016/j.yexcr.2008.07.029, 10.1016/j.yexcr.2008.08.013]; Su YY, 2003, P NATL ACAD SCI USA, V100, P12729, DOI 10.1073/pnas.2133261100; Suenaga A, 2009, BIOPHYS J, V96, P2278, DOI 10.1016/j.bpj.2008.11.018; Worster DT, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2001986; Yajnik V, 1996, J BIOL CHEM, V271, P1813, DOI 10.1074/jbc.271.4.1813; Yang G, 2004, J BIOL CHEM, V279, P4339, DOI 10.1074/jbc.M311153200; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang JX, 2003, P NATL ACAD SCI USA, V100, P14127, DOI 10.1073/pnas.2233012100; Zhou PB, 2000, MOL CELL, V6, P751, DOI 10.1016/S1097-2765(00)00074-5; Zhou PB, 2005, CURR OPIN CHEM BIOL, V9, P51, DOI 10.1016/j.cbpa.2004.10.012; Zhout PC, 2003, J BIOL CHEM, V278, P13829, DOI 10.1074/jbc.M209640200	46	11	11	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2014	33	8					986	995		10.1038/onc.2013.33	http://dx.doi.org/10.1038/onc.2013.33			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XO	23416973	Green Accepted			2022-12-28	WOS:000331933200006
J	Shiu, KK; Wetterskog, D; Mackay, A; Natrajan, R; Lambros, M; Sims, D; Bajrami, I; Brough, R; Frankum, J; Sharpe, R; Marchio, C; Horlings, H; Reyal, F; van der Vijver, M; Turner, N; Reis-Filho, JS; Lord, CJ; Ashworth, A				Shiu, K-K; Wetterskog, D.; Mackay, A.; Natrajan, R.; Lambros, M.; Sims, D.; Bajrami, I.; Brough, R.; Frankum, J.; Sharpe, R.; Marchio, C.; Horlings, H.; Reyal, F.; van der Vijver, M.; Turner, N.; Reis-Filho, J. S.; Lord, C. J.; Ashworth, A.			Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies	ONCOGENE			English	Article						HER2-positive breast cancer; microarrays; gene expression; comparative genomic hybridization; siRNA screens; TFAP2C	COMPARATIVE GENOMIC HYBRIDIZATION; PLUS ADJUVANT CHEMOTHERAPY; COPY-NUMBER ALTERATIONS; TRANSCRIPTION FACTOR; EXPRESSION LEVELS; FOLLOW-UP; TRASTUZUMAB; RESISTANCE; RECEPTOR; LAPATINIB	Overexpression of the receptor tyrosine kinase ERBB2 (also known as HER2) occurs in around 15% of breast cancers and is driven by amplification of the ERBB2 gene. ERBB2 amplification is a marker of poor prognosis, and although anti-ERBB2-targeted therapies have shown significant clinical benefit, de novo and acquired resistance remains an important problem. Genomic profiling has demonstrated that ERBB2+ve breast cancers are distinguished from ER+ve and 'triple-negative' breast cancers by harbouring not only the ERBB2 amplification on 17q12, but also a number of co-amplified genes on 17q12 and amplification events on other chromosomes. Some of these genes may have important roles in influencing clinical outcome, and could represent genetic dependencies in ERBB2+ve cancers and therefore potential therapeutic targets. Here, we describe an integrated genomic, gene expression and functional analysis to determine whether the genes present within amplicons are critical for the survival of ERBB2+ve breast tumour cells. We show that only a fraction of the ERBB2-amplified breast tumour lines are truly addicted to the ERBB2 oncogene at the mRNA level and display a heterogeneous set of additional genetic dependencies. These include an addiction to the transcription factor gene TFAP2C when it is amplified and overexpressed, suggesting that TFAP2C represents a genetic dependency in some ERBB2+ve breast cancer cells.	[Shiu, K-K; Wetterskog, D.; Mackay, A.; Natrajan, R.; Lambros, M.; Sims, D.; Bajrami, I.; Brough, R.; Frankum, J.; Turner, N.; Reis-Filho, J. S.; Lord, C. J.; Ashworth, A.] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; [Marchio, C.] Univ Turin, Dept Biomed Sci & Human Oncol, I-10124 Turin, Italy; [Horlings, H.; Reyal, F.; van der Vijver, M.] Acad Med Ctr, Dept Pathol, Amsterdam, Netherlands	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Turin; University of Amsterdam; Academic Medical Center Amsterdam	Reis-Filho, JS (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, 237 Fulham Rd, London SW3 6JB, England.	Jorge.Reis-Filho@icr.ac.uk; Chris.Lord@icr.ac.uk; Alan.Ashworth@icr.ac.uk	Lord, Christopher/AAX-7130-2021; Marchio, Caterina/J-9152-2016; Lord, Christopher J/B-3295-2012	Marchio, Caterina/0000-0003-2024-6131; Lord, Christopher J/0000-0002-3226-0515; Natrajan, Rachael/0000-0002-9987-2946; Turner, Nicholas/0000-0001-8937-0873	Cancer Research UK; AACR as part of the Stand Up To Cancer Breast Cancer Dream Team Initiative; Breakthrough Breast Cancer	Cancer Research UK(Cancer Research UK); AACR as part of the Stand Up To Cancer Breast Cancer Dream Team Initiative; Breakthrough Breast Cancer	This work was supported by grants from Cancer Research UK, AACR as part of the Stand Up To Cancer Breast Cancer Dream Team Initiative, and Breakthrough Breast Cancer. Dr Kai-Keen Shiu is an Avon Clinical Fellow.	Arriola E, 2008, LAB INVEST, V88, P491, DOI 10.1038/labinvest.2008.19; Baselga J, 2010, J CLIN ONCOL, V28, P1138, DOI 10.1200/JCO.2009.24.2024; BOSHER JM, 1995, P NATL ACAD SCI USA, V92, P744, DOI 10.1073/pnas.92.3.744; Boutros M, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-7-r66; Brough R, 2011, CANCER DISCOV, V1, P260, DOI 10.1158/2159-8290.CD-11-0107; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Chin SF, 2007, ONCOGENE, V26, P1959, DOI 10.1038/sj.onc.1209985; Cleator SJ, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1506; Dave B, 2011, J CLIN ONCOL, V29, P166, DOI 10.1200/JCO.2009.27.7814; Delacroix L, 2005, DNA CELL BIOL, V24, P582, DOI 10.1089/dna.2005.24.582; Eichhorn PJA, 2008, CANCER RES, V68, P9221, DOI 10.1158/0008-5472.CAN-08-1740; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Gee JMW, 2009, J PATHOL, V217, P32, DOI 10.1002/path.2430; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; Gianni L, 2011, LANCET ONCOL, V12, P236, DOI 10.1016/S1470-2045(11)70033-X; Guler G, 2007, CLIN CANCER RES, V13, P6115, DOI 10.1158/1078-0432.CCR-07-1282; Gunnarsson R, 2008, GENE CHROMOSOME CANC, V47, P697, DOI 10.1002/gcc.20575; Harris LN, 2007, CLIN CANCER RES, V13, P1198, DOI 10.1158/1078-0432.CCR-06-1304; He AL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-279; Hicks J, 2006, GENOME RES, V16, P1465, DOI 10.1101/gr.5460106; Hollestelle A, 2010, BREAST CANCER RES TR, V121, P53, DOI 10.1007/s10549-009-0460-8; Kao J, 2006, GENE CHROMOSOME CANC, V45, P761, DOI 10.1002/gcc.20339; Kreike B, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1771; Lambros MBK, 2006, LAB INVEST, V86, P398, DOI 10.1038/labinvest.3700390; Lee-Hoeflich ST, 2008, CANCER RES, V68, P5878, DOI 10.1158/0008-5472.CAN-08-0380; Mackay A, 2009, BREAST CANCER RES TR, V118, P481, DOI 10.1007/s10549-008-0296-7; Marchio C, 2008, J PATHOL, V216, P399, DOI 10.1002/path.2423; Natrajan R, 2010, BREAST CANCER RES TR, V121, P575, DOI 10.1007/s10549-009-0501-3; Natrajan R, 2009, CLIN CANCER RES, V15, P2711, DOI 10.1158/1078-0432.CCR-08-1878; O'Brien NA, 2010, MOL CANCER THER, V9, P1489, DOI 10.1158/1535-7163.MCT-09-1171; Perez EA, 2011, J CLIN ONCOL, V29, P3366, DOI 10.1200/JCO.2011.35.0868; Pietersen AM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2214; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; Santarius T, 2009, NAT REV, V10, P59; Santarius T, 2010, NAT REV CANCER, V10, P59, DOI 10.1038/nrc2771; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Scaltriti M, 2011, P NATL ACAD SCI USA, V108, P3761, DOI 10.1073/pnas.1014835108; Schoeberl B, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000352; Shiu KK, 2010, FUTURE ONCOL, V6, P967, DOI [10.2217/fon.10.56, 10.2217/FON.10.56]; Sims D, 2010, BREAST CANCER RES TR, V124, P567, DOI 10.1007/s10549-010-0945-5; Sircoulomb F, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-539; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Smith I, 2007, LANCET, V369, P29, DOI 10.1016/S0140-6736(07)60028-2; Staaf J, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2568; Tan DSR, 2008, PATHOBIOLOGY, V75, P63, DOI 10.1159/000123844; Turner BC, 1998, CANCER RES, V58, P5466; Turner N, 2010, ONCOGENE, V29, P2013, DOI 10.1038/onc.2009.489; Vernimmen D, 2003, BIOCHEM J, V370, P323, DOI 10.1042/BJ20021238; Vogel C, 2001, EUR J CANCER, V37, pS25, DOI 10.1016/S0959-8049(00)00405-6; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Williams CMJ, 2009, EMBO J, V28, P3591, DOI 10.1038/emboj.2009.290; Woodfield GW, 2010, GENE CHROMOSOME CANC, V49, P948, DOI 10.1002/gcc.20807; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206; Zhao C, 2003, CANCER, V98, P18, DOI 10.1002/cncr.11482	54	22	22	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2014	33	5					619	631		10.1038/onc.2012.625	http://dx.doi.org/10.1038/onc.2012.625			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5GW	23334330	Green Submitted			2022-12-28	WOS:000331125100010
J	Quail, DF; Zhang, G; Findlay, SD; Hess, DA; Postovit, LM				Quail, D. F.; Zhang, G.; Findlay, S. D.; Hess, D. A.; Postovit, L-M			Nodal promotes invasive phenotypes via a mitogen-activated protein kinase-dependent pathway	ONCOGENE			English	Article						Nodal; invasion; EMT; cancer; metastasis	EPITHELIAL-MESENCHYMAL TRANSITION; GROWTH-FACTOR-BETA; BREAST-CANCER; MAP KINASE; TROPHOBLAST MIGRATION; STEM-CELLS; EXPRESSION; ALK7; PHOSPHORYLATION; PLASTICITY	The progression of cancer from localized to invasive disease is requisite for metastasis, and is often characterized by epithelial-to-mesenchymal transition (EMT) and alterations in cellular adhesion and migration. Studies have shown that this transition is associated with an upregulation of embryonic stem cell-associated genes, resulting in a dedifferentiated phenotype and poor patient prognosis. Nodal is an embryonic factor that plays a critical role in promoting early invasive events during development. Nodal is silenced as stem cells differentiate; however, it re-emerges in adult life during placentation and mammary gland development, and is aberrantly expressed in many cancers. Here, we show that Nodal overexpression, in poorly invasive breast cancer and choriocarcinoma cells, causes increased invasion and migration in vitro. Furthermore, we show that Nodal overexpression in these epithelial cancer types induces an EMT-like event concomitant with the internalization of E-Cadherin. This ability of Nodal to promote cellular invasion and EMT-like phenomena is dependent upon the phosphorylation of ERK1/2. As Nodal normally signals through SMADs, these findings lend insight into an alternative pathway that is hijacked by this protein in cancer. To evaluate the clinical implications of our results, we show that Nodal inhibition reduces liver tumor burden in a model of spontaneous breast cancer metastasis in vivo, and that Nodal loss-of-function in aggressive breast cancer lines results in a decrease in invasive phenotypes. Our results demonstrate that Nodal is involved in promoting invasion in multiple cellular contexts, and that Nodal inhibition may be useful as a therapeutic target for patients with progressive disease.	[Quail, D. F.; Zhang, G.; Findlay, S. D.; Postovit, L-M] Univ Western Ontario, Schulich Sch Med & Dent, Dept Anat & Cell Biol, London, ON N6A 5C1, Canada; [Hess, D. A.] Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 5C1, Canada; [Zhang, G.; Findlay, S. D.; Hess, D. A.; Postovit, L-M] Univ Western Ontario, Robarts Res Inst, London, ON N6A 5C1, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Postovit, LM (corresponding author), Univ Western Ontario, Schulich Sch Med & Dent, Dept Anat & Cell Biol, Med Sci Bldg,Room 438, London, ON N6A 5C1, Canada.	Lynne.Postovit@schulich.uwo.ca	Hess, David A/M-2828-2013; zhang, guihua/GVU-4494-2022; Findlay, Scott D/AAP-9554-2021	Findlay, Scott D/0000-0002-0393-1623; Postovit, Lynne-Marie/0000-0002-8088-4197	Canadian Institutes for Health Research [MOP 89714, MOP 119589, PLS 95381]; Cancer Research Society; Canadian Breast Cancer Foundation; CIHR; Premier New Investigator Award from the CIHR; new investigator award; MacDonald Scholarship; Alberta Innovates [201300495] Funding Source: researchfish	Canadian Institutes for Health Research(Canadian Institutes of Health Research (CIHR)); Cancer Research Society; Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); CIHR(Canadian Institutes of Health Research (CIHR)); Premier New Investigator Award from the CIHR(Canadian Institutes of Health Research (CIHR)); new investigator award; MacDonald Scholarship; Alberta Innovates	We thank LA Walsh and SD Findlay for making the Nodal expression construct, and M Jewer and A Cloutier-Bosworth for assisting with tissue scoring. This work was supported by the Canadian Institutes for Health Research (MOP 89714, MOP 119589 and PLS 95381) and the Cancer Research Society to LMP. DQ is supported by fellowships from the Canadian Breast Cancer Foundation, and a CIHR training grant. LMP is the recipient of the Premier New Investigator Award from the CIHR. DAH is the recipient of a new investigator award and MacDonald Scholarship for the Canadian Heart and Stroke Foundation.	Beck S, 2002, NAT CELL BIOL, V4, P981, DOI 10.1038/ncb890; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bokobza SM, 2011, MOL CELL BIOCHEM, V349, P33, DOI 10.1007/s11010-010-0657-5; Cavallari C, 2013, ONCOGENE, V32, P819, DOI 10.1038/onc.2012.114; Chakraborty C, 2002, CAN J PHYSIOL PHARM, V80, P116, DOI 10.1139/Y02-016; CLEMENTS M, 2011, TLS TIMES LIT S 0325, P21; Davies M, 2005, J CELL BIOCHEM, V95, P918, DOI 10.1002/jcb.20458; Dhasarathy A, 2007, MOL ENDOCRINOL, V21, P2907, DOI 10.1210/me.2007-0293; Drasin DJ, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3037; Hendrix MJC, 2007, NAT REV CANCER, V7, P246, DOI 10.1038/nrc2108; Inman GJ, 2002, MOL PHARMACOL, V62, P65, DOI 10.1124/mol.62.1.65; Kannan S, 1997, J BIOL CHEM, V272, P3330, DOI 10.1074/jbc.272.6.3330; Kelber JA, 2009, ONCOGENE, V28, P2324, DOI 10.1038/onc.2009.97; Kolosova I, 2011, J CELL PHYSIOL, V226, P1248, DOI 10.1002/jcp.22448; Lawrence MG, 2011, PROSTATE, V71, P1198, DOI 10.1002/pros.21335; Lee CC, 2010, ONCOGENE, V29, P3110, DOI 10.1038/onc.2010.55; Lee MK, 2007, EMBO J, V26, P3957, DOI 10.1038/sj.emboj.7601818; Li QW, 2008, NEOPLASIA, V10, P1444, DOI 10.1593/neo.08968; Lonardo E, 2011, CELL STEM CELL, V9, P433, DOI 10.1016/j.stem.2011.10.001; Lu X, 2004, NEOPLASIA, V6, P603, DOI 10.1593/neo.04241; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; Munir S, 2004, J BIOL CHEM, V279, P31277, DOI 10.1074/jbc.M400641200; Nadeem L, 2011, AM J PATHOL, V178, P1177, DOI 10.1016/j.ajpath.2010.11.066; Papageorgiou I, 2009, REPROD BIOL ENDOCRIN, V7, DOI 10.1186/1477-7827-7-122; Postovit LM, 2008, PIGM CELL MELANOMA R, V21, P348, DOI 10.1111/j.1755-148X.2008.00463.x; Postovit LM, 2008, P NATL ACAD SCI USA, V105, P4329, DOI 10.1073/pnas.0800467105; Postovit LM, 2007, EXPERT OPIN THER TAR, V11, P497, DOI 10.1517/14728222.11.4.497; Quail DF, 2012, CANCER RES, V72, P3851, DOI 10.1158/0008-5472.CAN-11-3951; Quail DF, 2012, J BIOMOL SCREEN, V17, P1088, DOI 10.1177/1087057112449863; Quail DF, 2011, MOL BIOL CELL, V22, P4809, DOI 10.1091/mbc.E11-03-0263; Rangel MC, 2012, AM J PATHOL, V180, P2188, DOI 10.1016/j.ajpath.2012.02.031; Roberts HJ, 2003, BIOL REPROD, V68, P1719, DOI 10.1095/biolreprod.102.013045; Scherbakov AM, 2012, J CELL BIOCHEM, V113, P2147, DOI 10.1002/jcb.24087; Schier AF, 2003, ANNU REV CELL DEV BI, V19, P589, DOI 10.1146/annurev.cellbio.19.041603.094522; Schier AF, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a003459; Strizzi L, 2004, J CELL PHYSIOL, V201, P266, DOI 10.1002/jcp.20062; Strizzi L, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3185; Strizzi L, 2011, LAB INVEST, V91, P819, DOI 10.1038/labinvest.2011.63; Strizzi Luigi, 2008, Breast Dis, V29, P91; Strizzi Luigi, 2009, Expert Rev Dermatol, V4, P67, DOI 10.1586/17469872.4.1.67; Tabaries S, 2011, ONCOGENE, V30, P1318, DOI 10.1038/onc.2010.518; Taylor MA, 2010, J MAMMARY GLAND BIOL, V15, P169, DOI 10.1007/s10911-010-9181-1; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Topczewska JM, 2006, NAT MED, V12, P925, DOI 10.1038/nm1448; Vicovac L, 1996, ACTA ANAT, V156, P202; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006	47	34	36	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2014	33	4					461	473		10.1038/onc.2012.608	http://dx.doi.org/10.1038/onc.2012.608			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VX	23334323	Green Accepted, Green Submitted			2022-12-28	WOS:000330214600007
J	Wang, P; Chen, L; Zhang, J; Chen, H; Fan, J; Wang, K; Luo, J; Chen, Z; Meng, Z; Liu, L				Wang, P.; Chen, L.; Zhang, J.; Chen, H.; Fan, J.; Wang, K.; Luo, J.; Chen, Z.; Meng, Z.; Liu, L.			Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1	ONCOGENE			English	Article						miR-124; pancreatic cancer; methylation; prognosis; Rac1	HEPATOCELLULAR-CARCINOMA; TUMOR-SUPPRESSOR; DNA METHYLATION; MICRORNA; EXPRESSION; ADENOCARCINOMA; PATTERNS; SURVIVAL; GTPASES	Previous studies have demonstrated that microRNA (miRNA) expression is altered in human cancer. However, the molecular mechanism underlying these changes in miRNA expression remains unclear. In this study, we investigated the epigenetic modification of miR-124 genes and the potential function of miR-124 in pancreatic cancer. Using pyrosequencing analysis, we found that miR-124 genes (including miR-124-1, miR-124-2 and miR-124-3) are highly methylated in pancreatic cancer tissues compared with in non-cancerous tissues. Hypermethylation mediated the silencing of miR-124, which was a frequent event in pancreatic duct adenocarcinoma (PDAC). Furthermore, miR-124 downregulation was significantly associated with worse survival of PDAC patients. Functional studies showed that miR-124 inhibited cell proliferation, invasion and metastasis. Furthermore, we characterized Rac1 as a direct target of miR-124, and miR-124 interacted with the 3'-untranslated region of Rac1, which we showed to be a putative tumor promoter in pancreatic cancer. Thus, the miR-124-mediated downregulation of Rac1 led to the inactivation of the MKK4-JNK-c-Jun pathway. Therefore, our study demonstrates that miR-124 is a tumor suppressor miRNA that is epigenetically silenced in pancreatic cancer. Our findings suggest a previously unidentified molecular mechanism involved in the progression and metastasis of pancreatic cancer.	[Wang, P.; Chen, L.; Zhang, J.; Chen, H.; Wang, K.; Chen, Z.; Meng, Z.; Liu, L.] Fudan Univ, Shanghai Canc Ctr, Dept Integrat Oncol, Shanghai 200032, Peoples R China; [Wang, P.; Chen, L.; Zhang, J.; Chen, H.; Wang, K.; Chen, Z.; Meng, Z.; Liu, L.] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China; [Fan, J.] Fudan Univ, Huashan Hosp, Dept Pathol, Shanghai 200032, Peoples R China; [Luo, J.] Fudan Univ, Shanghai Canc Ctr, Cent Lab, Shanghai 200032, Peoples R China	Fudan University; Fudan University; Fudan University; Fudan University	Chen, Z (corresponding author), Fudan Univ, Shanghai Canc Ctr, Dept Integrat Oncol, 270 Dong An Rd, Shanghai 200032, Peoples R China.	cz.chenzhen@gmail.com; mengzhq@sh163.net; llm1010@yahoo.com.cn	Meng, Zhiqiang/ABE-7747-2021	Chen, Zhen/0000-0002-4502-0801	Science Fundation of China [81001061]; Shanghai Nature Science Fund, Shanghai, China [09ZR1406800]; Doctoral Programs Foundation of Ministry of Education of China [20090071120076]; Shanghai Science and Technology Committee Rising-Star Program [11QA1401300]; Medical Talents Training Program of Health Bureau of Shanghai [XYQ2011008]; 985 research grants	Science Fundation of China; Shanghai Nature Science Fund, Shanghai, China; Doctoral Programs Foundation of Ministry of Education of China(Ministry of Education, China); Shanghai Science and Technology Committee Rising-Star Program; Medical Talents Training Program of Health Bureau of Shanghai; 985 research grants	The authors would like to thank Professor Zude Xu from Department of Pathology, Huashan Hospital, Fudan University, Shanghai for providing human pancreatic cancer samples. This study was supported by National Science Fundation of China (81001061); Shanghai Nature Science Fund, Shanghai, China (09ZR1406800); Doctoral Programs Foundation of Ministry of Education of China (20090071120076); Shanghai Science and Technology Committee Rising-Star Program (11QA1401300); and Medical Talents Training Program of Health Bureau of Shanghai (XYQ2011008) and 985 research grants.	Ando T, 2009, INT J CANCER, V124, P2367, DOI 10.1002/ijc.24219; Azuma H, 2005, JNCI-J NATL CANCER I, V97, P1734, DOI 10.1093/jnci/dji399; Bloomston M, 2007, JAMA-J AM MED ASSOC, V297, P1901, DOI 10.1001/jama.297.17.1901; Chan AY, 2005, ONCOGENE, V24, P7821, DOI 10.1038/sj.onc.1208909; Chen LL, 2010, J CLIN INVEST, V120, P1178, DOI 10.1172/JCI40665; Deprez RHL, 2002, ANAL BIOCHEM, V307, P63, DOI 10.1016/S0003-2697(02)00021-0; Eckhardt F, 2006, NAT GENET, V38, P1378, DOI 10.1038/ng1909; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Furuta M, 2010, CARCINOGENESIS, V31, P766, DOI 10.1093/carcin/bgp250; Greither T, 2010, INT J CANCER, V126, P73, DOI 10.1002/ijc.24687; GRIFFIN JF, 1990, CANCER, V66, P56, DOI 10.1002/1097-0142(19900701)66:1<56::AID-CNCR2820660112>3.0.CO;2-6; Grijelmo C, 2007, CELL SIGNAL, V19, P1722, DOI 10.1016/j.cellsig.2007.03.008; Hanoun N, 2010, CLIN CHEM, V56, P1107, DOI 10.1373/clinchem.2010.144709; Heid I, 2011, GASTROENTEROLOGY, V141, P719, DOI 10.1053/j.gastro.2011.04.043; Hummel R, 2010, EUR J CANCER, V46, P298, DOI 10.1016/j.ejca.2009.10.027; Iorio MV, 2009, J CLIN ONCOL, V27, P5848, DOI 10.1200/JCO.2009.24.0317; Jamieson NB, 2012, CLIN CANCER RES, V18, P534, DOI 10.1158/1078-0432.CCR-11-0679; Kanwal R, 2012, J APPL PHYSIOL, V109, P598; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kim VN, 2009, NAT REV MOL CELL BIO, V10, P126, DOI 10.1038/nrm2632; Kong KL, 2012, GUT, V61, P33, DOI 10.1136/gutjnl-2011-300178; Kubo T, 2011, CLIN CANCER RES, V17, P4965, DOI 10.1158/1078-0432.CCR-10-3040; Lee KH, 2009, PANCREATOLOGY, V9, P293, DOI 10.1159/000186051; Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8; Li XH, 2010, GUT, V59, P579, DOI 10.1136/gut.2008.175497; Lodygin D, 2008, CELL CYCLE, V7, P2591, DOI 10.4161/cc.7.16.6533; Lujambio A, 2007, CANCER RES, V67, P1424, DOI 10.1158/0008-5472.CAN-06-4218; Mardin W, 2009, ANN SURG ONCOL, V16, P3183, DOI 10.1245/s10434-009-0623-1; Medina PP, 2009, NAT METHODS, V6, P37, DOI 10.1038/nmeth0109-37; Moore MJ, 2007, J CLIN ONCOL, V25, P1960, DOI 10.1200/JCO.2006.07.9525; Murphy JD, 2007, INT J RADIAT ONCOL, V68, P801, DOI 10.1016/j.ijrobp.2006.12.053; Nuovo GJ, 2009, NAT PROTOC, V4, P107, DOI 10.1038/nprot.2008.215; Ouyang HQ, 2011, PANCREAS, V40, P120, DOI 10.1097/MPA.0b013e3181e6e398; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Rathinam R, 2011, FRONT BIOSCI-LANDMRK, V16, P2561, DOI 10.2741/3872; Shi WD, 2009, CANCER LETT, V283, P84, DOI 10.1016/j.canlet.2009.03.030; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Su H, 2009, CANCER RES, V69, P1135, DOI 10.1158/0008-5472.CAN-08-2886; Szafranska AE, 2007, ONCOGENE, V26, P4442, DOI 10.1038/sj.onc.1210228; Takai Daiya, 2003, In Silico Biology, V3, P235; Wang P, 2009, CARCINOGENESIS, V30, P1497, DOI 10.1093/carcin/bgp154; Wilting SM, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-167; Yu SL, 2008, CANCER CELL, V13, P48, DOI 10.1016/j.ccr.2007.12.008; Zhang SY, 2011, CARCINOGENESIS, V32, P1183, DOI 10.1093/carcin/bgr105; Zhang Y, 2011, CANCER RES, V71, P3552, DOI 10.1158/0008-5472.CAN-10-2435; Zhao WG, 2010, CARCINOGENESIS, V31, P1726, DOI 10.1093/carcin/bgq160; Zheng F, 2012, GUT, V61, P278, DOI 10.1136/gut.2011.239145	47	165	182	3	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2014	33	4					514	524		10.1038/onc.2012.598	http://dx.doi.org/10.1038/onc.2012.598			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VX	23334332				2022-12-28	WOS:000330214600012
J	Lee, TH; Park, JM; Leem, SH; Kang, TH				Lee, T-H; Park, J-M; Leem, S-H; Kang, T-H			Coordinated regulation of XPA stability by ATR and HERC2 during nucleotide excision repair	ONCOGENE			English	Article						XPA; ATR; HERC2; protein stability; posttranslational modification	PIGMENTOSUM GROUP-A; INDUCED DNA-DAMAGE; XERODERMA-PIGMENTOSUM; E3 LIGASE; PROTEIN; KINASE; PHOTOPRODUCTS; RECOGNITION; ACTIVATION; CELLS	ATR (ATM and Rad3-related) is an essential regulator of the nucleotide excision repair (NER) mechanism. For NER activation, ATR phosphorylates XPA, the rate-limiting factor in the NER pathway. However, the role of XPA phosphorylation at serine 196 by ATR has been elusive. Here we show that ATR-mediated XPA phosphorylation enhances XPA stability by inhibiting HERC2-mediated ubiquitination and subsequent degradation. We analyzed stabilization of XPA with substitutions of Ser 196 either to aspartate (S196D), a phosphomimetic mutation, or to alanine (S196A), a phosphodeficient mutation. Upon ultraviolet damage, ATR facilitated HERC2 dissociation from the XPA complex to induce XPA stabilization. However, this regulation was abrogated in S196A-complemented XPA-deficient cells due to persistent association of HERC2 with this XPA complex, resulting in enhanced ubiquitination of S196A. Conversely, the S196D substitution showed delayed degradation kinetics compared with the wild-type and less binding with HERC2, resulting in reduced ubiquitination of S196D. We also found that XPA phosphorylation enhanced the chromatin retention of XPA, the interaction with its binding partners following DNA damage. Taken together, our study presents a novel control mechanism in the NER pathway by regulating the steady-state level of XPA through posttranslational modifications by which ATR-mediated phosphorylation induces XPA stabilization by antagonizing HERC2-catalyzed XPA ubiquitination.	[Lee, T-H; Park, J-M; Leem, S-H; Kang, T-H] Dong A Univ, Dept Biol Sci, Pusan 604714, South Korea	Dong A University	Kang, TH (corresponding author), Dong A Univ, Dept Biol Sci, 840 Hadan 2 Dong, Pusan 604714, South Korea.	thkang@dau.ac.kr	Kang, Tae-Hong/Y-8294-2019	Kang, Tae-Hong/0000-0002-6013-900X; Lee, Tae-Hee/0000-0002-6263-6499	Basic Science Research Program through the National Research Foundation of Korea; Ministry of Education, Science and Technology (MEST) [2011-0013804, 2012-0003981]; Collaborative research Program of Nuclear Medical Sciences through the Dongnam Institute of Radiological & Medical Sciences; MEST and Busan Metropolitan city [2011-0593]	Basic Science Research Program through the National Research Foundation of Korea(National Research Foundation of Korea); Ministry of Education, Science and Technology (MEST)(Ministry of Education, Science & Technology (MEST), Republic of Korea); Collaborative research Program of Nuclear Medical Sciences through the Dongnam Institute of Radiological & Medical Sciences; MEST and Busan Metropolitan city(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This research was supported by the Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (MEST) (2011-0013804 and 2012-0003981). This study was also supported by 2011 Collaborative research Program of Nuclear Medical Sciences through the Dongnam Institute of Radiological & Medical Sciences funded by the MEST and Busan Metropolitan city (2011-0593).	Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Aravind L, 1999, NUCLEIC ACIDS RES, V27, P1223, DOI 10.1093/nar/27.5.1223; Auclair Y, 2008, P NATL ACAD SCI USA, V105, P17896, DOI 10.1073/pnas.0801585105; Bekker-Jensen S, 2010, NAT CELL BIOL, V12, P80, DOI 10.1038/ncb2008; Cimprich KA, 2008, NAT REV MOL CELL BIO, V9, P616, DOI 10.1038/nrm2450; Cleaver JE, 2005, NAT REV CANCER, V5, P564, DOI 10.1038/nrc1652; D Bomgarden R, 2006, EMBO J, V25, P2605, DOI 10.1038/sj.emboj.7601123; Dzagnidze A, 2007, J NEUROSCI, V27, P9451, DOI 10.1523/JNEUROSCI.0523-07.2007; Gossage L, 2007, CANCER TREAT REV, V33, P565, DOI 10.1016/j.ctrv.2007.07.001; Huang TT, 2006, NAT REV MOL CELL BIO, V7, P323, DOI 10.1038/nrm1908; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; Izawa N, 2011, CANCER RES, V71, P5621, DOI 10.1158/0008-5472.CAN-11-0385; Kang TH, 2008, J CELL SCI, V121, P3035, DOI 10.1242/jcs.026757; Kang TH, 2008, BBA-MOL CELL RES, V1783, P49, DOI 10.1016/j.bbamcr.2007.10.011; Kang TH, 2006, NAT CELL BIOL, V8, P863, DOI 10.1038/ncb1447; Kang TH, 2011, NUCLEIC ACIDS RES, V39, P3176, DOI 10.1093/nar/gkq1318; Kang TH, 2010, P NATL ACAD SCI USA, V107, P4890, DOI 10.1073/pnas.0915085107; Kang TH, 2009, CELL CYCLE, V8, P1665, DOI 10.4161/cc.8.11.8707; Kang TH, 2009, P NATL ACAD SCI USA, V106, P2864, DOI 10.1073/pnas.0812638106; Koberle B, 2006, DNA REPAIR, V5, P641, DOI 10.1016/j.dnarep.2005.12.001; Kurz EU, 2004, DNA REPAIR, V3, P889, DOI 10.1016/j.dnarep.2004.03.029; Lehmann AR, 2003, BIOCHIMIE, V85, P1101, DOI 10.1016/j.biochi.2003.09.010; Leung-Pineda V, 2009, CANCER RES, V69, P2630, DOI 10.1158/0008-5472.CAN-08-3382; Li ZK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028326; Liu LR, 2010, J CELL PHYSIOL, V224, P585, DOI 10.1002/jcp.22205; Liu QH, 2000, GENE DEV, V14, P1448; Martin LP, 2008, CLIN CANCER RES, V14, P1291, DOI 10.1158/1078-0432.CCR-07-2238; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Medema RH, 2012, ONCOGENE, V31, P2601, DOI 10.1038/onc.2011.451; MITCHELL DL, 1988, PHOTOCHEM PHOTOBIOL, V48, P51; Nguyen TA, 2010, DNA REPAIR, V9, P813, DOI 10.1016/j.dnarep.2010.04.005; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Perdiz D, 2000, J BIOL CHEM, V275, P26732; Rotin D, 2009, NAT REV MOL CELL BIO, V10, P398, DOI 10.1038/nrm2690; Saijo M, 2011, J BIOL CHEM, V286, P5476, DOI 10.1074/jbc.M110.172916; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Shell SM, 2009, J BIOL CHEM, V284, P24213, DOI 10.1074/jbc.M109.000745; Sinha RP, 2002, PHOTOCH PHOTOBIO SCI, V1, P225, DOI 10.1039/b201230h; Smith J, 2010, ADV CANCER RES, V108, P73, DOI [10.1016/B978-0-12-380888-2.00003-0, 10.1016/S0065.230X(10)08002.4]; States JC, 1998, HUM MUTAT, V12, P103, DOI 10.1002/(SICI)1098-1004(1998)12:2<103::AID-HUMU5>3.0.CO;2-6; Volker M, 2001, MOL CELL, V8, P213, DOI 10.1016/S1097-2765(01)00281-7; Wang D, 2005, NAT REV DRUG DISCOV, V4, P307, DOI 10.1038/nrd1691; Wu WW, 2010, CANCER RES, V70, P6384, DOI 10.1158/0008-5472.CAN-10-1304; Wu X, 2007, ONCOGENE, V26, P757, DOI 10.1038/sj.onc.1209828; Wu XM, 2006, CANCER RES, V66, P2997, DOI 10.1158/0008-5472.CAN-05-3403; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	46	50	51	1	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2014	33	1					19	25		10.1038/onc.2012.539	http://dx.doi.org/10.1038/onc.2012.539			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	282YU	23178497				2022-12-28	WOS:000329212000003
J	Zhang, S; Mercado-Uribe, I; Xing, Z; Sun, B; Kuang, J; Liu, J				Zhang, S.; Mercado-Uribe, I.; Xing, Z.; Sun, B.; Kuang, J.; Liu, J.			Generation of cancer stem-like cells through the formation of polyploid giant cancer cells	ONCOGENE			English	Article						polyploid giant cancer cells; cancer stem cells; endocycle; cell fusion; asymmetric cell division	TUMOR-CELLS; NEOSIS; OXYGEN; DEATH; GENE	Polyploid giant cancer cells (PGCCs) have been observed by pathologists for over a century. PGCCs contribute to solid tumor heterogeneity, but their functions are largely undefined. Little attention has been given to these cells, largely because PGCCs have been generally thought to originate from repeated failure of mitosis/cytokinesis and have no capacity for long-term survival or proliferation. Here we report our successful purification and culture of PGCCs from human ovarian cancer cell lines and primary ovarian cancer. These cells are highly resistant to oxygen deprivation and could form through endoreduplication or cell fusion, generating regular-sized cancer cells quickly through budding or bursting similar to simple organisms like fungi. They express normal and cancer stem cell markers, they divide asymmetrically and they cycle slowly. They can differentiate into adipose, cartilage and bone. A single PGCC formed cancer spheroids in vitro and generated tumors in immunodeficient mice. These PGCC-derived tumors gained a mesenchymal phenotype with increased expression of cancer stem cell markers CD44 and CD133 and become more resistant to treatment with cisplatin. Taken together, our results reveal that PGCCs represent a resistant form of human cancer using an ancient, evolutionarily conserved mechanism in response to hypoxia stress; they can contribute to the generation of cancer stem-like cells, and also play a fundamental role in regulating tumor heterogeneity, tumor growth and chemoresistance in human cancer.	[Zhang, S.; Mercado-Uribe, I.; Xing, Z.; Liu, J.] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA; [Zhang, S.] Nankai Univ, Affiliated Hosp, Dept Pathol, Tianjin 300071, Peoples R China; [Sun, B.] Tianjin Med Univ, Dept Pathol, Tianjin, Peoples R China; [Sun, B.] Tianjin Canc Inst, Tianjin, Peoples R China; [Kuang, J.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Nankai University; Tianjin Medical University; Tianjin Medical University; University of Texas System; UTMD Anderson Cancer Center	Liu, J (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Pathol, Unit 85, 1515 Holcombe Blvd,Box 0085, Houston, TX 77030 USA.	jliu@mdanderson.org			National Institutes of Health [R01CA131183-01A2, P50CA83638]; Cancer Prevention and Research Institute of Texas (CPRIT) [RP1105995]; Cancer Center Support Grant [CA016672]; NATIONAL CANCER INSTITUTE [P50CA083638, P50CA083639, P30CA016672, R01CA131183] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Prevention and Research Institute of Texas (CPRIT); Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the Department of Scientific Publications and Ms Christine Wogan for their excellent editorial assistance on the manuscript and Ms Kim Vu for help in figure preparation. Jinsong Liu was supported by an R01 Grant (R01CA131183-01A2) and an ovarian cancer Specialized Programs of Research Excellence (SPORE) grant (P50CA83638) from the National Institutes of Health and a multi-investigator grant from Cancer Prevention and Research Institute of Texas (CPRIT) (RP1105995). Short tandem repeat DNA fingerprinting was carried out by the Cancer Center Support Grant-funded Characterized Cell Line core, NCI No. CA016672.	Alberts B., 2008, MOL BIOL CEL, V5th ed.; Brodbeck WG, 2009, CURR OPIN HEMATOL, V16, P53, DOI 10.1097/MOH.0b013e32831ac52e; Comai L, 2005, NAT REV GENET, V6, P836, DOI 10.1038/nrg1711; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Erenpreisa J, 2005, CELL BIOL INT, V29, P1012, DOI 10.1016/j.cellbi.2005.10.005; Erenpreisa J, 2005, CELL BIOL INT, V29, P1005, DOI 10.1016/j.cellbi.2005.10.008; Erenpreisa J, 2007, CELL BIOL INT, V31, P1507, DOI 10.1016/j.cellbi.2007.08.013; Erenpreisa J, 2011, CELL BIOL INT, V35, P687, DOI 10.1042/CBI20100762; Erenpreisa Jekaterina, 2001, Cancer Cell Int, V1, P1, DOI 10.1186/1475-2867-1-1; Geigl JB, 2008, TRENDS GENET, V24, P64, DOI 10.1016/j.tig.2007.11.006; Glotzer M, 2005, SCIENCE, V307, P1735, DOI 10.1126/science.1096896; Gurdon JB, 2008, SCIENCE, V322, P1811, DOI 10.1126/science.1160810; Heddleston JM, 2009, CELL CYCLE, V8, P3274, DOI 10.4161/cc.8.20.9701; HEPPNER GH, 1984, CANCER RES, V44, P2259; Ho VT, 1996, BIOCHEM BIOPH RES CO, V223, P175, DOI 10.1006/bbrc.1996.0865; Holland AJ, 2009, NAT REV MOL CELL BIO, V10, P478, DOI 10.1038/nrm2718; Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019; Knop M, 2011, CR BIOL, V334, P599, DOI 10.1016/j.crvi.2011.05.007; Konopleva MY, 2011, J CLIN ONCOL, V29, P591, DOI 10.1200/JCO.2010.31.0904; Kumar V.A., 2010, ROBBINS CONTRAN PATH, P262; Kusumbe AP, 2009, CANCER RES, V69, P9245, DOI 10.1158/0008-5472.CAN-09-2802; Lee HO, 2009, GENE DEV, V23, P2461, DOI 10.1101/gad.1829209; Liu GZ, 2010, JNCI-J NATL CANCER I, V102, P812, DOI 10.1093/jnci/djq127; Liu JS, 2004, CANCER RES, V64, P1655, DOI 10.1158/0008-5472.CAN-03-3380; Lu X, 2009, CANCER RES, V69, P8536, DOI 10.1158/0008-5472.CAN-09-2159; Malpica A, 2004, AM J SURG PATHOL, V28, P496, DOI 10.1097/00000478-200404000-00009; Mohyeldin A, 2010, CELL STEM CELL, V7, P150, DOI 10.1016/j.stem.2010.07.007; Piret JP, 2002, ANN NY ACAD SCI, V973, P443, DOI 10.1111/j.1749-6632.2002.tb04680.x; Rajaraman R, 2005, CELL BIOL INT, V29, P1084, DOI 10.1016/j.cellbi.2005.10.003; Siller KH, 2009, NAT CELL BIOL, V11, P365, DOI 10.1038/ncb0409-365; Sundaram M, 2004, CANCER BIOL THER, V3, P207, DOI 10.4161/cbt.3.2.663; Trail F, 2007, FEMS MICROBIOL LETT, V276, P12, DOI 10.1111/j.1574-6968.2007.00900.x; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P1153, DOI 10.1038/cdd.2008.47; Walen KH, 2006, IN VITRO CELL DEV-AN, V42, P216; Wang X, 2003, NATURE, V422, P897, DOI 10.1038/nature01531; Yang G, 2004, J BIOL CHEM, V279, P4339, DOI 10.1074/jbc.M311153200; Zhang WH, 2011, CANCER-AM CANCER SOC, V117, P4092, DOI 10.1002/cncr.26021	37	250	264	0	41	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2014	33	1					116	128		10.1038/onc.2013.96	http://dx.doi.org/10.1038/onc.2013.96			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	282YU	23524583	Green Accepted			2022-12-28	WOS:000329212000013
J	Di, K; Linskey, ME; Bota, DA				Di, K.; Linskey, M. E.; Bota, D. A.			TRIM11 is overexpressed in high-grade gliomas and promotes proliferation, invasion, migration and glial tumor growth	ONCOGENE			English	Article						TRIM11; oncogene; EGFR; malignant glioma; tumor formation	GLIOBLASTOMA STEM-CELLS; MALIGNANT GLIOMAS; PROGENITOR CELLS; EXPRESSION; CANCER; IDENTIFICATION; RECEPTOR; SYSTEM; NESTIN; GENE	TRIM11 (tripartite motif-containing protein 11), an E3 ubiquitin ligase, is known to be involved in the development of the central nervous system. However, very little is known regarding the role of TRIM11 in cancer biology. Here, we examined the expression profile of TRIM11, along with two stem cell markers CD133 and nestin, in multiple glioma patient specimens, glioma primary cultures derived from tumors taken at surgery and normal neural stem/progenitor cells (NSCs). The oncogenic function of TRIM11 in glioma biology was investigated by knockdown and/or overexpression in vitro and in vivo experiments. Our results showed that TRIM11 expression levels were upregulated in malignant glioma specimens and in high-grade glioma-derived primary cultures, whereas remaining low in glioblastoma multiforme (GBM) stable cell lines, low-grade glioma-derived primary cultures and NSCs. The expression pattern of TRIM11 strongly correlated with that of CD133 and nestin and differentiation status of malignant glioma cells. Knock down of TRIM11 inhibited proliferation, migration and invasion of GBM cells, significantly decreased epidermal growth factor receptor (EGFR) levels and mitogen-activated protein kinase activity, and downregulated HB-EGF (heparin-binding EGF-like growth factor) mRNA levels. Meanwhile, TRIM11 overexpression promoted a stem-like phenotype in vitro (tumorsphere formation) and enhanced glial tumor growth in immunocompromised mice. These findings suggest that TRIM11 might be an indicator of glioma malignancy and has an oncogenic function mediated through the EGFR signaling pathway. TRIM11 overexpression potentially leads to a more aggressive glioma phenotype, along with increased malignant tumor growth and poor survival. Taken together, clarification of the biological function of TRIM11 and pathways it affects may provide novel therapeutic strategies for treating malignant glioma patients.	[Di, K.; Linskey, M. E.; Bota, D. A.] UC Irvine Sch Med, Dept Neurol Surg, Orange, CA 92868 USA; [Linskey, M. E.; Bota, D. A.] UC Irvine Chao Family Comprehens Canc Ctr, Orange, CA USA; [Bota, D. A.] UC Irvine Sch Med, Dept Neurol, Orange, CA 92868 USA		Bota, DA (corresponding author), UC Irvine Sch Med, UC Irvine Med Ctr, 101 City Dr South,Shanbrom Hall,Suite 121, Orange, CA 92868 USA.	dbota@uci.edu		Bota, Daniela/0000-0002-9680-9060	Community Foundation of Jewish Federation; University of California, Irvine; UCI Cancer Center from the National Cancer Institute [P30CA062203]; NATIONAL CANCER INSTITUTE [P30CA062203] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS072234] Funding Source: NIH RePORTER	Community Foundation of Jewish Federation; University of California, Irvine(University of California System); UCI Cancer Center from the National Cancer Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Xing Gong for the preparation of glioma primary cultures, Dr Ronald C Kim for the neuropathological diagnosis of tumor samples and Dr Abhishek Chaturbedi for the organization of the tumor list used in the study. This work was supported by research funds donated by Ralph and Suzanne Stern and the Community Foundation of Jewish Federation. This study was also supported, in part, by start-up funds to DAB from the University of California, Irvine and the UCI Cancer Center Award Number P30CA062203 from the National Cancer Institute.	Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; BIGNER SH, 1990, CANCER RES, V50, P8017; Borden KLB, 1998, BIOCHEM CELL BIOL, V76, P351, DOI 10.1139/bcb-76-2-3-351; Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287; Corn BW, 2009, J NEURO-ONCOL, V95, P247, DOI 10.1007/s11060-009-9923-3; Dey M, 2011, STEM CELL REV REP, V7, P119, DOI 10.1007/s12015-010-9132-7; Eramo A, 2006, CELL DEATH DIFFER, V13, P1238, DOI 10.1038/sj.cdd.4401872; FREDENS K, 1986, HISTOCHEMISTRY, V84, P247, DOI 10.1007/BF00495790; Gladson CL, 2010, ANNU REV PATHOL-MECH, V5, P33, DOI 10.1146/annurev-pathol-121808-102109; Gong X, 2011, NEUROLOGY, V76, P1126, DOI 10.1212/WNL.0b013e318212a89f; Griguer CE, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003655; Hatakeyama S, 2011, NAT REV CANCER, V11, P792, DOI 10.1038/nrc3139; Hong SJ, 2008, BIOCHEM BIOPH RES CO, V368, P650, DOI 10.1016/j.bbrc.2008.01.165; Ishikawa H, 2006, FEBS LETT, V580, P4784, DOI 10.1016/j.febslet.2006.07.066; Kordes C, 2007, BIOCHEM BIOPH RES CO, V352, P410, DOI 10.1016/j.bbrc.2006.11.029; Kurihara H, 2000, GENE THER, V7, P686, DOI 10.1038/sj.gt.3301129; Li ZZ, 2009, J BIOL CHEM, V284, P16705, DOI 10.1074/jbc.R900013200; Lim DA, 2007, NEURO-ONCOLOGY, V9, P424, DOI 10.1215/15228517-2007-023; Ma YH, 2008, J NEURO-ONCOL, V86, P31, DOI 10.1007/s11060-007-9439-7; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; Mishima K, 1998, ACTA NEUROPATHOL, V96, P322, DOI 10.1007/s004010050901; Niikura T, 2003, EUR J NEUROSCI, V17, P1150, DOI 10.1046/j.1460-9568.2003.02553.x; Ongusaha PP, 2004, CANCER RES, V64, P5283, DOI 10.1158/0008-5472.CAN-04-0925; Pistollato F, 2009, STEM CELLS, V27, P7, DOI 10.1634/stemcells.2008-0402; Raab G, 1997, BBA-REV CANCER, V1333, pF179, DOI 10.1016/S0304-419X(97)00024-3; Rao RD, 2003, FRONT BIOSCI-LANDMRK, V8, pE270, DOI 10.2741/897; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422; Sanai N, 2005, NEW ENGL J MED, V353, P811, DOI 10.1056/NEJMra043666; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schmidinger M, 2003, J NEURO-ONCOL, V63, P55, DOI 10.1023/A:1023740303162; Schwartz PH, 2003, J NEUROSCI RES, V74, P838, DOI 10.1002/jnr.10854; Sherman JH, 2011, J NEUROSCI METH, V198, P99, DOI 10.1016/j.jneumeth.2011.03.003; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Suo ZH, 2002, INT J SURG PATHOL, V10, P91, DOI 10.1177/106689690201000202; Tarbe N, 2002, ANTICANCER RES, V22, P2015; Tuoc TC, 2008, GENE DEV, V22, P1972, DOI 10.1101/gad.471708; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; von Deimling A, 2011, BRAIN PATHOL, V21, P74, DOI 10.1111/j.1750-3639.2010.00454.x; Wen PY, 2008, NEW ENGL J MED, V359, P492, DOI 10.1056/NEJMra0708126; Zhang MY, 2008, J EXP CLIN CANC RES, V27, DOI 10.1186/1756-9966-27-85; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033; Zhou XD, 2009, J INT MED RES, V37, P503, DOI 10.1177/147323000903700226; ZIMMERMAN L, 1994, NEURON, V12, P11, DOI 10.1016/0896-6273(94)90148-1	46	53	56	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2013	32	42					5038	5047		10.1038/onc.2012.531	http://dx.doi.org/10.1038/onc.2012.531			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238IB	23178488	Green Accepted, Green Submitted			2022-12-28	WOS:000325937900005
J	Rubio, R; Gutierrez-Aranda, I; Saez-Castillo, AI; Labarga, A; Rosu-Myles, M; Gonzalez-Garcia, S; Toribio, ML; Menendez, P; Rodriguez, R				Rubio, R.; Gutierrez-Aranda, I.; Saez-Castillo, A. I.; Labarga, A.; Rosu-Myles, M.; Gonzalez-Garcia, S.; Toribio, M. L.; Menendez, P.; Rodriguez, R.			The differentiation stage of p53-Rb-deficient bone marrow mesenchymal stem cells imposes the phenotype of in vivo sarcoma development	ONCOGENE			English	Article						mesenchymal stem cells; leiomyosarcoma; osteosarcoma; osteogenic differentiation; p53; Rb	HUMAN OSTEOSARCOMA; P53; RB; MICE; RETINOBLASTOMA; INACTIVATION; LEIOMYOSARCOMAS; TRANSPLANTATION; TRANSFORMATION; TUMORIGENESIS	Increasing evidence suggests that mesenchymal stem/stromal cells (MSCs) carrying specific mutations are at the origin of some sarcomas. We have reported that the deficiency of p53 alone or in combination with Rb (Rb-/- p53 (-/-)) in adipose-derived MSCs (ASCs) promotes leiomyosarcoma-like tumors in vivo. Here, we hypothesized that the source of MSCs and/or the cell differentiation stage could determine the phenotype of sarcoma development. To investigate whether there is a link between the source of MSCs and sarcoma phenotype, we generated p53(-/-) and Rb-/- p53(-/-) MSCs from bone marrow (BM-MSCs). Both genotypes of BM-MSCs initiated leiomyosarcoma formation similar to p53(-/-) and Rb-/- p53(-/-) ASCs. In addition, gene expression profiling revealed transcriptome similarities between p53-or Rb-p53-deficient BM-MSCs/ASCs and muscle-associated sarcomagenesis. These data suggest that the tissue source of MSC does not seem to determine the development of a particular sarcoma phenotype. To analyze whether the differentiation stage defines the sarcoma phenotype, BM-MSCs and ASCs were induced to differentiate toward the osteogenic lineage, and both p53 and Rb were excised using Cre-expressing adenovectors at different stages along osteogenic differentiation. Regardless the level of osteogenic commitment, the inactivation of Rb and p53 in BM-MSC-derived, but not in ASC-derived, osteogenic progenitors gave rise to osteosarcoma-like tumors, which could be serially transplanted. This indicates that the osteogenic differentiation stage of BM-MSCs imposes the phenotype of in vivo sarcoma development, and that BM-MSC-derived osteogenic progenitors rather than undifferentiated BM-MSCs, undifferentiated ASCs or ASC-derived osteogenic progenitors, represent the cell of origin for osteosarcoma development.	[Rubio, R.; Labarga, A.; Menendez, P.; Rodriguez, R.] Univ Granada, Andalusian Reg Govt, GENYO Ctr Genom & Oncol Res Pfizer, Granada 18007, Spain; [Gutierrez-Aranda, I.; Saez-Castillo, A. I.] Andalusian Publ Hlth Syst Biobank, Granada, Spain; [Rosu-Myles, M.] Hlth Canada, Biol & Genet Therapies Directorate, Ctr Vaccine Evaluat, Ottawa, ON K1A 0L2, Canada; [Gonzalez-Garcia, S.; Toribio, M. L.] UAM, Ctr Biol Mol Severo Ochoa CSIC, Madrid, Spain; [Rodriguez, R.] Hosp Univ Cent Asturias, Oviedo 33006, Spain; [Rodriguez, R.] Inst Univ Oncol Principado Asturias, Oviedo 33006, Spain	Pfizer; University of Granada; Health Canada; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM); Central University Hospital Asturias; University of Oviedo; Instituto Universitario de Oncologia de Asturias	Menendez, P (corresponding author), Univ Granada, Andalusian Reg Govt, GENYO Ctr Genom & Oncol Res Pfizer, Avda Ilustrac 114, Granada 18007, Spain.	pablo.menendez@genyo.es; renerg@ficyt.es	Bujan, Pablo Menendez/W-3736-2017; González-García, Sara/Y-9913-2019; Rodriguez, Rene/P-2168-2018; Labarga, Alberto/AAA-9341-2019; Labarga, Alberto/J-9077-2014; Toribio, Maria L/C-2039-2017	Bujan, Pablo Menendez/0000-0001-9372-1007; González-García, Sara/0000-0002-0315-2136; Rodriguez, Rene/0000-0002-0768-7306; Labarga, Alberto/0000-0001-6781-893X; Labarga, Alberto/0000-0001-6781-893X; Toribio, Maria L/0000-0002-8637-0373; Rubio Amador, Ruth/0000-0003-3263-0819	Instituto de Salud Carlos III/FEDER [PI10/00449, CP11/00024, RD12/0036/0015]; Junta de Andalucia/FEDER [P08-CTS-3678]; MINECO; Spanish Association Against Cancer (Junta Provincial de Albacete) [CI110023]; Health Canada [H4084-112281]; ISCIII/FEDER;  [PLE-2009-0111]	Instituto de Salud Carlos III/FEDER(Instituto de Salud Carlos IIIEuropean Commission); Junta de Andalucia/FEDER(Junta de AndaluciaEuropean Commission); MINECO(Spanish Government); Spanish Association Against Cancer (Junta Provincial de Albacete); Health Canada; ISCIII/FEDER(Spanish Government); 	We thank the Andalusian Platform of Bioinformatics (PAB; University of Malaga) for providing access to IPA software. This work was supported by the Instituto de Salud Carlos III/FEDER (PI10/00449 to PM, CP11/00024-Miguet Servet Program-to RRo and RTICC RD12/0036/0015); the Junta de Andalucia/FEDER (P08-CTS-3678 to PM), the MINECO (Fondo Especial del Estado para Dinamizacion de la Economia y Empleo PLE-2009-0111 to PM and SAF2010-15106 to MLT), The Spanish Association Against Cancer (Junta Provincial de Albacete-CI110023 to PM and Junta Provincial de Granada to RRo), Health Canada (H4084-112281 to PM, RRo and MR-M) and Obra Social Cajastur-IUOPA. RRu was supported by a fellowship of the ISCIII/FEDER. Author contributions: RRu: conception and design, collection and/or of assembly data, data analysis, interpretation and manuscript writing. SG-G: collection of data, data analysis and interpretation IG-A, AIS-C, AL, MR-M and MLT: data analysis and interpretation. PM and RRo: conception and design, financial support, data analysis and interpretation and manuscript writing. The manuscript has been seen and approved by all authors.	Armesilla-Diaz A, 2009, EXP CELL RES, V315, P3598, DOI 10.1016/j.yexcr.2009.08.004; Barroso-delJesus A, 2011, FASEB J, V25, P1497, DOI 10.1096/fj.10-172221; Benassi MS, 2001, CANCER-AM CANCER SOC, V92, P3062, DOI 10.1002/1097-0142(20011215)92:12<3062::AID-CNCR10161>3.0.CO;2-X; Berman SD, 2008, P NATL ACAD SCI USA, V105, P11851, DOI 10.1073/pnas.0805462105; Bianco P, 2008, CELL STEM CELL, V2, P313, DOI 10.1016/j.stem.2008.03.002; Bueno C, 2010, CYTOTHERAPY, V12, P45, DOI 10.3109/14653240903377052; Calo E, 2010, NATURE, V466, P1110, DOI 10.1038/nature09264; Chillon MC, 2012, LEUKEMIA, V26, P2360, DOI 10.1038/leu.2012.161; Choi J, 2010, AM J PATHOL, V177, P2645, DOI 10.2353/ajpath.2010.100306; Clark-Knowles KV, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008534; Danielson LS, 2010, AM J PATHOL, V177, P908, DOI 10.2353/ajpath.2010.091150; De Falco G, 2006, ONCOGENE, V25, P5244, DOI 10.1038/sj.onc.1209623; Garcia-Castro J, 2008, J CELL MOL MED, V12, P2552, DOI 10.1111/j.1582-4934.2008.00516.x; Gutierrez GM, 2008, P NATL ACAD SCI USA, V105, P18402, DOI 10.1073/pnas.0805925105; Gutierrez-Aranda I, 2010, STEM CELLS, V28, P1568, DOI 10.1002/stem.471; Helman LJ, 2003, NAT REV CANCER, V3, P685, DOI 10.1038/nrc1168; Hernando E, 2007, NAT MED, V13, P748, DOI 10.1038/nm1560; Kirsch DG, 2007, NAT MED, V13, P992, DOI 10.1038/nm1602; Lengner CJ, 2006, J CELL BIOL, V172, P909, DOI 10.1083/jcb.200508130; Li H, 2007, CANCER RES, V67, P10889, DOI 10.1158/0008-5472.CAN-07-2665; Lin PP, 2009, CARCINOGENESIS, V30, P1789, DOI 10.1093/carcin/bgp180; Lopez-Guerrero JA, 2004, DIAGN MOL PATHOL, V13, P81; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Martinez-Cruz AB, 2008, CANCER RES, V68, P683, DOI 10.1158/0008-5472.CAN-07-3049; Menendez P, 2002, BRIT J HAEMATOL, V119, P135, DOI 10.1046/j.1365-2141.2002.03794.x; Menendez P, 2009, J EXP MED, V206, P3131, DOI 10.1084/jem.20091050; Miura M, 2006, STEM CELLS, V24, P1095, DOI 10.1634/stemcells.2005-0403; Mohseny AB, 2009, J PATHOL, V219, P294, DOI 10.1002/path.2603; Molchadsky A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003707; Rodriguez R, 2012, ADV EXP MED BIOL, V741, P187, DOI 10.1007/978-1-4614-2098-9_13; Rodriguez R, 2012, CELL RES, V22, P62, DOI 10.1038/cr.2011.157; Rodriguez R, 2011, STEM CELLS, V29, P179, DOI 10.1002/stem.571; Rodriguez R, 2009, NEOPLASIA, V11, P397, DOI 10.1593/neo.81620; Rubio R, 2010, CANCER RES, V70, P4185, DOI 10.1158/0008-5472.CAN-09-4640; Sanchez L, 2011, STEM CELLS, V29, P251, DOI 10.1002/stem.569; Shimizu T, 2010, ONCOGENE, V29, P5687, DOI 10.1038/onc.2010.312; Shojaei F, 2008, EXP HEMATOL, V36, P1436, DOI 10.1016/j.exphem.2008.06.001; Tang N, 2008, CLIN ORTHOP RELAT R, V466, P2114, DOI 10.1007/s11999-008-0335-z; Tataria M, 2006, J PEDIATR SURG, V41, P624, DOI 10.1016/j.jpedsurg.2005.12.001; Thomas DM, 2001, MOL CELL, V8, P303, DOI 10.1016/S1097-2765(01)00327-6; Tolar J, 2007, STEM CELLS, V25, P371, DOI 10.1634/stemcells.2005-0620; Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808	42	55	55	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2013	32	41					4970	4980		10.1038/onc.2012.507	http://dx.doi.org/10.1038/onc.2012.507			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235KQ	23222711				2022-12-28	WOS:000325717800013
J	Monaghan-Benson, E; Burridge, K				Monaghan-Benson, E.; Burridge, K.			Mutant B-RAF regulates a Rac-dependent cadherin switch in melanoma	ONCOGENE			English	Article						B-RAF; melanoma; Rac; cadherin; Tiam1	CELL-CELL ADHESION; SMALL-MOLECULE INHIBITOR; MALIGNANT-MELANOMA; EPITHELIAL-CELLS; SMALL GTPASES; RATIONAL DESIGN; MDCK CELLS; RHO; MIGRATION; INVASION	The ability of cells to invade into the dermis is a critical event in the development of cutaneous melanoma and ultimately an indicator of poor prognosis. However, the molecular events surrounding the acquisition of this invasive phenotype remain incompletely understood. Mutations in B-RAF are frequent in melanoma and are known to regulate the invasive phenotype. In this study, we sought to determine the molecular mechanisms controlling melanoma invasion. We found that mutant B-RAF signaling regulates a cadherin switch. In melanoma cells expressing mutant B-RAF we observed high levels of N-cadherin and low levels of E-cadherin. Depletion of mutant B-RAF, by small interfering RNA, caused a decrease in the levels of N-cadherin and an increase in the levels of E-cadherin. Mechanistically, we found that this cadherin switch required the activity of Rac1 and its GEF, Tiam1, both of which show suppressed activity in the presence of mutant B-RAF. Consistent with the work of others, we found that depletion of mutant B-RAF decreased the invasive capacity of the melanoma cells. However, simultaneous depletion of B-RAF and Rac or Tiam1 resulted in invasive capacity similar to that of control cells. Taken together, our results suggest that mutant B-RAF signaling downregulates Tiam1/Rac activity resulting in an increase in N-cadherin levels and a decrease in E-cadherin levels and ultimately enhanced invasion.	[Monaghan-Benson, E.; Burridge, K.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; [Monaghan-Benson, E.; Burridge, K.] Univ N Carolina, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Monaghan-Benson, E (corresponding author), Univ N Carolina, Dept Cell & Dev Biol, 12-026 Lineberger,CB 7295, Chapel Hill, NC 27599 USA.	ebenson@med.unc.edu			NIH [GM029860, HL080166]; American Cancer Society [PF-09_119-01-CSM]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL080166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029860] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by NIH grants GM029860 and HL080166 to KB. E M-B is supported by American Cancer Society PF-09_119-01-CSM.	Akbar H, 2006, METHOD ENZYMOL, V406, P554, DOI 10.1016/S0076-6879(06)06043-5; ALBINO AP, 1989, ONCOGENE, V4, P1363; Alsina J, 2003, CLIN CANCER RES, V9, P6419; Arozarena I, 2011, CANCER CELL, V19, P45, DOI 10.1016/j.ccr.2010.10.029; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Calipel A, 2003, J BIOL CHEM, V278, P42409, DOI 10.1074/jbc.M308709200; Chin L, 2003, NAT REV CANCER, V3, P559, DOI 10.1038/nrc1145; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dong JL, 2003, CANCER RES, V63, P3883; Dumaz N, 2006, CANCER RES, V66, P9483, DOI 10.1158/0008-5472.CAN-05-4227; Engers R, 2001, J BIOL CHEM, V276, P41889, DOI 10.1074/jbc.M105049200; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Garcia-Mata R, 2006, METHOD ENZYMOL, V406, P425, DOI 10.1016/S0076-6879(06)06031-9; Goodall J, 2008, CANCER RES, V68, P7788, DOI 10.1158/0008-5472.CAN-08-1053; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; Hirohashi S, 1998, AM J PATHOL, V153, P333, DOI 10.1016/S0002-9440(10)65575-7; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Hsu MY, 2000, J CELL SCI, V113, P1535; Hsu MY, 1996, JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, VOL 1, NO 2, APRIL 1996, P188; Jou TS, 1998, J CELL BIOL, V142, P101, DOI 10.1083/jcb.142.1.101; Klein RM, 2008, MOL BIOL CELL, V19, P498, DOI 10.1091/mbc.E07-09-0895; Klein RM, 2009, CANCER RES, V69, P2224, DOI 10.1158/0008-5472.CAN-08-3201; Kuroda S, 1997, BIOCHEM BIOPH RES CO, V240, P430, DOI 10.1006/bbrc.1997.7675; Li G, 2002, CRIT REV ORAL BIOL M, V13, P62, DOI 10.1177/154411130201300107; Li G, 2001, CANCER RES, V61, P3819; Massoumi R, 2009, J EXP MED, V206, P221, DOI 10.1084/jem.20082044; Michiels Frits, 1999, P125; Pollock PM, 2003, NAT GENET, V34, P108, DOI 10.1038/ng1148; Poser I, 2001, J BIOL CHEM, V276, P24661, DOI 10.1074/jbc.M011224200; Ray RM, 2007, CELL MOTIL CYTOSKEL, V64, P143, DOI 10.1002/cm.20172; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Sandig M, 1997, CELL MOTIL CYTOSKEL, V38, P351, DOI 10.1002/(SICI)1097-0169(1997)38:4<351::AID-CM5>3.3.CO;2-Z; Sauter ER, 1998, MOL CARCINOGEN, V23, P132, DOI 10.1002/(SICI)1098-2744(199811)23:3<132::AID-MC2>3.0.CO;2-1; Silye R, 1998, J PATHOL, V186, P350, DOI 10.1002/(SICI)1096-9896(199812)186:4<350::AID-PATH181>3.0.CO;2-K; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; Stam JC, 1997, J BIOL CHEM, V272, P28447, DOI 10.1074/jbc.272.45.28447; Stam JC, 1998, EMBO J, V17, P4066, DOI 10.1093/emboj/17.14.4066; Sumimoto H, 2004, ONCOGENE, V23, P6031, DOI 10.1038/sj.onc.1207812; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; TANG A, 1994, J CELL SCI, V107, P983; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; Uhlenbrock K, 2004, J CELL SCI, V117, P4863, DOI 10.1242/jcs.01367; Vleminckx K, 1999, BIOESSAYS, V21, P211, DOI 10.1002/(SICI)1521-1878(199903)21:3<211::AID-BIES5>3.3.CO;2-G; Zhang JD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022176; Zhong CL, 1997, MOL BIOL CELL, V8, P2329, DOI 10.1091/mbc.8.11.2329; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	47	18	19	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2013	32	40					4836	4844		10.1038/onc.2012.492	http://dx.doi.org/10.1038/onc.2012.492			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229NW	23208503	Green Accepted, Green Submitted			2022-12-28	WOS:000325274700012
J	Ruggieri, V; Pin, E; Russo, MT; Barone, F; Degan, P; Sanchez, M; Quaia, M; Minoprio, A; Turco, E; Mazzei, F; Viel, A; Bignami, M				Ruggieri, V.; Pin, E.; Russo, M. T.; Barone, F.; Degan, P.; Sanchez, M.; Quaia, M.; Minoprio, A.; Turco, E.; Mazzei, F.; Viel, A.; Bignami, M.			Loss of MUTYH function in human cells leads to accumulation of oxidative damage and genetic instability	ONCOGENE			English	Article						MUTYH variants; 8-oxodG; PIG-A; MUTYH-associated polyposis; DNA glycosylase activity	BASE-EXCISION-REPAIR; ADENOMATOUS POLYPOSIS; COLORECTAL-CANCER; DNA-DAMAGE; GLYCOSYLASE ACTIVITY; GERMLINE MUTATIONS; HUMAN HOMOLOG; MYH; HMYH; DEFICIENT	The DNA glycosylase MUTYH (mutY homolog (Escherichia coli)) counteracts the mutagenic effects of 8-oxo-7,8-dihydroguanine (8-oxodG) by removing adenine (A) misincorporated opposite the oxidized purine. Biallelic germline mutations in MUTYH cause the autosomal recessive MUTYH-associated adenomatous polyposis (MAP). Here we designed new tools to investigate the biochemical defects and biological consequences associated with different MUTYH mutations in human cells. To identify phenotype(s) associated with MUTYH mutations, lymphoblastoid cell lines (LCLs) were derived from seven MAP patients harboring missense as well as truncating mutations in MUTYH. These included homozygous p. Arg245His, p. Gly264TrpfsX7 or compound heterozygous variants (p. Gly396Asp/Arg245Cys, p. Gly396Asp/Tyr179Cys, p. Gly396Asp/Glu410GlyfsX43, p. Gly264TrpfsX7/Ala385ProfsX23 and p. Gly264TrpfsX7/ Glu480del). DNA glycosylase assays of MAP LCL extracts confirmed that all these variants were defective in removing A from an 8-oxoG: A DNA substrate, but retained wild-type OGG1 activity. As a consequence of this defect, MAP LCLs accumulated DNA 8-oxodG in their genome and exhibited a fourfold increase in spontaneous mutagenesis at the PIG-A gene compared with LCLs from healthy donors. They were also hypermutable by KBrO3-a source of DNA 8-oxodG-indicating that the relatively modest spontaneous mutator phenotype associated with MUTYH loss can be significantly enhanced by conditions of oxidative stress. These observations identify accumulation of DNA 8-oxodG and a mutator phenotype as likely contributors to the pathogenesis of MUTYH variants.	[Ruggieri, V.; Russo, M. T.; Barone, F.; Minoprio, A.; Turco, E.; Mazzei, F.; Bignami, M.] Ist Super Sanita, Dept Environm & Primary Prevent, I-00161 Rome, Italy; [Pin, E.; Quaia, M.; Viel, A.] IRCCS, Ctr Riferimento Oncol, Div Expt Oncol 1, Aviano, Italy; [Degan, P.] Ist Nazl Ric Cancro IST CBA, Dept Translat Oncol, Genoa, Italy; [Sanchez, M.] Ist Super Sanita, Dept Cell Biol & Neurosci, I-00161 Rome, Italy	Istituto Superiore di Sanita (ISS); IRCCS Aviano (CRO); University of Genoa; IRCCS AOU San Martino IST; Istituto Superiore di Sanita (ISS)	Bignami, M (corresponding author), Ist Super Sanita, Dept Environm & Primary Prevent, Viale Regina Elena 299, I-00161 Rome, Italy.	bignami@iss.it	Ruggieri, Vitalba/J-7847-2016; degan, paolo/AAB-6713-2019; Barone, Flavia/N-6983-2017; QUAIA, MICHELE/AAZ-2990-2020; degan, paolo/AAB-4093-2019; Sanchez, Massimo/AAD-1746-2021; Viel, Alessandra/J-7116-2018	Ruggieri, Vitalba/0000-0003-0860-3415; degan, paolo/0000-0003-0855-8896; Barone, Flavia/0000-0002-8929-7749; QUAIA, MICHELE/0000-0002-6656-2597; Sanchez, Massimo/0000-0003-3696-7582; Viel, Alessandra/0000-0003-2804-0840; Turco, Eleonora/0000-0002-5266-4592; PIN, ELISA/0000-0002-2158-2674	NIH/ISS, AIRC; Ministero della Salute Alleanza contro il Cancro	NIH/ISS, AIRC; Ministero della Salute Alleanza contro il Cancro	The authors are grateful to Drs M Fornasarig and D Barana for patient recruitment. This work has been supported by grants to MB from NIH/ISS, AIRC and by Ministero della Salute Alleanza contro il Cancro to AV and MB.	Al-Tassan N, 2002, NAT GENET, V30, P227, DOI 10.1038/ng828; Alhopuro Pia, 2005, Hum Mutat, V26, P393, DOI 10.1002/humu.9368; Ali M, 2008, GASTROENTEROLOGY, V135, P499, DOI 10.1053/j.gastro.2008.04.035; Araten DJ, 2005, CANCER RES, V65, P8111, DOI 10.1158/0008-5472.CAN-04-1198; Bai HB, 2007, CANCER LETT, V250, P74, DOI 10.1016/j.canlet.2006.09.016; Bignami M, 2000, MUTAT RES-REV MUTAT, V462, P71, DOI 10.1016/S1383-5742(00)00016-8; Cardoso J, 2006, CANCER RES, V66, P2514, DOI 10.1158/0008-5472.CAN-05-2407; Cheadle JP, 2007, DNA REPAIR, V6, P274, DOI 10.1016/j.dnarep.2006.11.001; Chiera F, 2008, FREE RADICAL BIO MED, V44, P332, DOI 10.1016/j.freeradbiomed.2007.09.018; Cleary SP, 2009, GASTROENTEROLOGY, V136, P1251, DOI 10.1053/j.gastro.2008.12.050; D'Agostino VG, 2010, DNA REPAIR, V9, P700, DOI 10.1016/j.dnarep.2010.03.008; David SS, 2007, NATURE, V447, P941, DOI 10.1038/nature05978; Farrington SM, 2005, AM J HUM GENET, V77, P112, DOI 10.1086/431213; Gismondi V, 2004, INT J CANCER, V109, P680, DOI 10.1002/ijc.20054; Glaab WE, 1998, CARCINOGENESIS, V19, P1931, DOI 10.1093/carcin/19.11.1931; Goto M, 2010, HUM MUTAT, V31, pE1861, DOI 10.1002/humu.21363; Gu YS, 2001, NUCLEIC ACIDS RES, V29, P2666, DOI 10.1093/nar/29.12.2666; Hirano S, 2003, J BIOL CHEM, V278, P38121, DOI 10.1074/jbc.C300316200; Isidro Gloria, 2004, Hum Mutat, V24, P353, DOI 10.1002/humu.9282; Jasperson KW, 2010, GASTROENTEROLOGY, V138, P2044, DOI 10.1053/j.gastro.2010.01.054; Jones S, 2002, HUM MOL GENET, V11, P2961, DOI 10.1093/hmg/11.23.2961; Kundu S, 2009, DNA REPAIR, V8, P1400, DOI 10.1016/j.dnarep.2009.09.009; Lipton L, 2003, CANCER RES, V63, P7595; Molatore S, 2010, HUM MUTAT, V31, P159, DOI 10.1002/humu.21158; Oka S, 2011, CANCER SCI, V102, P677, DOI 10.1111/j.1349-7006.2011.01869.x; Out AA, 2010, HUM MUTAT, V31, P1205, DOI 10.1002/humu.21343; Parker AR, 2005, CARCINOGENESIS, V26, P2010, DOI 10.1093/carcin/bgi166; Peruzzi B, 2010, MUTAT RES-REV MUTAT, V705, P3, DOI 10.1016/j.mrrev.2009.12.004; Pin E, INT J CANCER, DOI [10.1002/ijc.27761, DOI 10.1002/IJC.27761)]; Poulsen MLM, 2008, CURR GENOMICS, V9, P420, DOI 10.2174/138920208785699562; Russo MT, 2009, CANCER RES, V69, P4372, DOI 10.1158/0008-5472.CAN-08-3292; Sansom OJ, 2003, DNA REPAIR, V2, P1029, DOI 10.1016/S1568-7864(03)00111-3; Shi GL, 2006, BIOCHEM J, V400, P53, DOI 10.1042/BJ20060774; Sieber OM, 2003, NEW ENGL J MED, V348, P791, DOI 10.1056/NEJMoa025283; Slupska MM, 1999, J BACTERIOL, V181, P6210, DOI 10.1128/JB.181.19.6210-6213.1999; van Loon B, 2010, DNA REPAIR, V9, P604, DOI 10.1016/j.dnarep.2010.03.004; van Puijenbroek M, 2008, CLIN CANCER RES, V14, P139, DOI 10.1158/1078-0432.CCR-07-1705; Wang L, 2004, GASTROENTEROLOGY, V127, P9, DOI 10.1053/j.gastro.2004.03.070; Xu XXS, 2001, CANCER RES, V61, P3775; Yanaru-Fujisawa R, 2008, CLIN GENET, V73, P545, DOI 10.1111/j.1399-0004.2008.00998.x; Yi FM, 2009, VIROLOGY, V388, P236, DOI 10.1016/j.virol.2009.03.027	41	27	28	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2013	32	38					4500	4508		10.1038/onc.2012.479	http://dx.doi.org/10.1038/onc.2012.479			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223SW	23108399				2022-12-28	WOS:000324831300005
J	Xin, L				Xin, L.			Cells of origin for cancer: an updated view from prostate cancer	ONCOGENE			English	Review						cells of origin; prostate cancer; prostate stem cells; lineage hierarchy; lineage tracing; tumor initiation	UROGENITAL SINUS MESENCHYME; EPITHELIAL STEM-CELLS; MURINE PROSTATE; MAMMARY-GLAND; INTERMEDIATE CELLS; TUMOR INITIATION; MIR-200 FAMILY; BASAL-CELLS; EXPRESSION; DIFFERENTIATION	The cells of origin for cancer are the cells within tissues that serve as the target for transformation. Understanding the nature of these cells will benefit disease prevention, diagnosis and prognosis. During the past decade, much progress has been made in understanding the cellular origin for prostate cancer. This review aims to summarize the previous findings, describe the most recent results and discuss some controversies and unresolved issues in this field.	[Xin, L.] Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Xin, L.] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA; [Xin, L.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Xin, L (corresponding author), Baylor Coll Med, M533 DeBakey Bldg BCM MS130,1 Baylor Plaza, Houston, TX 77030 USA.	xin@bcm.edu			NIH [R00CA125937, R01DK092202, U01CA141497]; NATIONAL CANCER INSTITUTE [R00CA125937, U01CA141497] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK092202] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	I apologize to those authors whose work could not be cited because of space limitation, and thank Drs Michael Ittmann and Jeffrey Rosen for critical reading of the manuscript. This work is supported by NIH R00CA125937 (LX), R01DK092202 (LX) and U01CA141497 (MMI).	Abate-Shen C, 2000, GENE DEV, V14, P2410, DOI 10.1101/gad.819500; Baker CM, 2010, DEV BIOL, V343, P40, DOI 10.1016/j.ydbio.2010.04.005; Barabe F, 2007, SCIENCE, V316, P600, DOI 10.1126/science.1139851; Bethel CR, 2006, CANCER RES, V66, P10683, DOI 10.1158/0008-5472.CAN-06-0963; Bhatia-Gaur R, 1999, GENE DEV, V13, P966, DOI 10.1101/gad.13.8.966; BONKHOFF H, 1994, PROSTATE, V24, P114, DOI 10.1002/pros.2990240303; Burger PE, 2005, P NATL ACAD SCI USA, V102, P7180, DOI 10.1073/pnas.0502761102; Carver BS, 2009, NAT GENET, V41, P619, DOI 10.1038/ng.370; Choi N, 2012, CANCER CELL, V21, P253, DOI 10.1016/j.ccr.2012.01.005; CHUNG LWK, 1983, PROSTATE, V4, P503, DOI 10.1002/pros.2990040509; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; De Marzo AM, 1998, AM J PATHOL, V153, P911, DOI 10.1016/S0002-9440(10)65632-5; de Visser KE, 2012, J PATHOL, V228, P300, DOI 10.1002/path.4096; Doupe DP, 2012, SCIENCE, V337, P1091, DOI 10.1126/science.1218835; Du ZJ, 2007, CELL CYCLE, V6, P823, DOI 10.4161/cc.6.7.4074; El-Alfy M, 2000, MICROSC RES TECHNIQ, V51, P436, DOI 10.1002/1097-0029(20001201)51:5<436::AID-JEMT6>3.0.CO;2-T; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Gibson P, 2010, NATURE, V468, P1095, DOI 10.1038/nature09587; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; Goldstein AS, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002169; Goldstein AS, 2010, SCIENCE, V329, P568, DOI 10.1126/science.1189992; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hudson DL, 2001, J HISTOCHEM CYTOCHEM, V49, P271, DOI 10.1177/002215540104900214; Humphrey PA, 2007, J CLIN PATHOL, V60, P35, DOI 10.1136/jcp.2005.036442; Huntly BJP, 2004, CANCER CELL, V6, P587, DOI 10.1016/j.ccr.2004.10.015; Ince TA, 2007, CANCER CELL, V12, P160, DOI 10.1016/j.ccr.2007.06.013; Isaacs J.T., 1987, NIH PUBLICATION, P85; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; King JC, 2009, NAT GENET, V41, P524, DOI 10.1038/ng.371; Klezovitch O, 2008, P NATL ACAD SCI USA, V105, P2105, DOI 10.1073/pnas.0711711105; Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980; Kuhbandner S, 2000, GENESIS, V28, P15, DOI 10.1002/1526-968X(200009)28:1<15::AID-GENE20>3.0.CO;2-C; Lapouge G, 2011, P NATL ACAD SCI USA, V108, P7431, DOI 10.1073/pnas.1012720108; Lawson DA, 2007, P NATL ACAD SCI USA, V104, P181, DOI 10.1073/pnas.0609684104; Lawson DA, 2010, P NATL ACAD SCI USA, V107, P2610, DOI 10.1073/pnas.0913873107; Leong KG, 2008, NATURE, V456, P804, DOI 10.1038/nature07427; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Litvinov IV, 2006, CANCER RES, V66, P8598, DOI 10.1158/0008-5472.CAN-06-1228; Liu AY, 2002, AM J PATHOL, V160, P37, DOI 10.1016/S0002-9440(10)64346-5; Liu J, 2011, MOL ENDOCRINOL, V25, P1849, DOI 10.1210/me.2011-1081; Magee JA, 2003, CANCER CELL, V3, P273, DOI 10.1016/S1535-6108(03)00047-3; Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100; MOELLER H, 1988, RES EXP MED, V188, P451, DOI 10.1007/BF01852003; NEUBAUER BL, 1983, J CELL BIOL, V96, P1671, DOI 10.1083/jcb.96.6.1671; Ousset M, 2012, NAT CELL BIOL, V14, P1130, DOI 10.1038/ncb2600; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Pascal Laura E, 2007, BMC Urol, V7, P6, DOI 10.1186/1471-2490-7-6; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Peehl DM, 2005, ENDOCR-RELAT CANCER, V12, P19, DOI 10.1677/erc.1.00795; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Podsypanina K, 2008, SCIENCE, V321, P1841, DOI 10.1126/science.1161621; Sharma MK, 2007, CANCER RES, V67, P890, DOI 10.1158/0008-5472.CAN-06-0973; Shizuru JA, 2005, ANNU REV MED, V56, P509, DOI 10.1146/annurev.med.54.101601.152334; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Signoretti S, 2000, AM J PATHOL, V157, P1769, DOI 10.1016/S0002-9440(10)64814-6; SUTHERLAND K, 2011, TLS TIMES LIT S 0422, P19; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Taylor RA, 2006, NAT METHODS, V3, P179, DOI 10.1038/nmeth855; Taylor RA, 2009, STEM CELLS, V27, P3032, DOI 10.1002/stem.244; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Tran CP, 2002, MOL CANCER RES, V1, P113; Tuxhorn JA, 2001, J UROLOGY, V166, P2472, DOI 10.1016/S0022-5347(05)65620-0; Valdez JM, 2012, CELL STEM CELL, V11, P676, DOI 10.1016/j.stem.2012.07.003; van Amerongen R, 2012, CELL STEM CELL, V11, P387, DOI 10.1016/j.stem.2012.05.023; Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573; van Leenders G, 2000, LAB INVEST, V80, P1251, DOI 10.1038/labinvest.3780133; van Leenders GJLH, 2003, AM J PATHOL, V162, P1529, DOI 10.1016/S0002-9440(10)64286-1; Vashchenko N, 2005, EUR UROL, V47, P147, DOI 10.1016/j.eururo.2004.09.007; VERHAGEN APM, 1992, CANCER RES, V52, P6182; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; von Werder A, 2012, NAT PROTOC, V7, P1167, DOI 10.1038/nprot.2012.060; Wang SY, 2006, P NATL ACAD SCI USA, V103, P1480, DOI 10.1073/pnas.0510652103; Wang X, 2009, NATURE, V461, P495, DOI 10.1038/nature08361; Wang YZ, 2001, DIFFERENTIATION, V68, P270, DOI 10.1046/j.1432-0436.2001.680414.x; Welm AL, 2005, P NATL ACAD SCI USA, V102, P4324, DOI 10.1073/pnas.0500470102; Xin L, 2005, P NATL ACAD SCI USA, V102, P6942, DOI 10.1073/pnas.0502320102; Xin L, 2003, P NATL ACAD SCI USA, V100, P11896, DOI 10.1073/pnas.1734139100; Yang ZJ, 2008, CANCER CELL, V14, P135, DOI 10.1016/j.ccr.2008.07.003; Zhang L, 2010, PROSTATE, V70, P297, DOI 10.1002/pros.21064; Zong Y, 2009, P NATL ACAD SCI USA, V106, P12465, DOI 10.1073/pnas.0905931106	80	46	51	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 8	2013	32	32					3655	3663		10.1038/onc.2012.541	http://dx.doi.org/10.1038/onc.2012.541			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	198EH	23178496	Green Accepted			2022-12-28	WOS:000322904400001
J	Lu, H; Hu, L; Yu, L; Wang, X; Urvalek, AM; Li, T; Shen, C; Mukherjee, D; Lahiri, SK; Wason, MS; Zhao, J				Lu, H.; Hu, L.; Yu, L.; Wang, X.; Urvalek, A. M.; Li, T.; Shen, C.; Mukherjee, D.; Lahiri, S. K.; Wason, M. S.; Zhao, J.			KLF8 and FAK cooperatively enrich the active MMP14 on the cell surface required for the metastatic progression of breast cancer	ONCOGENE			English	Article						KLF8; FAK; MMP14; beta-catenin/TCF1; metastasis; breast cancer	FOCAL ADHESION KINASE; KRUPPEL-LIKE FACTOR-8; E-CADHERIN; 1-MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE-1; BETA-CATENIN/TCF4 COMPLEX; MESENCHYMAL TRANSITION; TUMOR-CELLS; TRANSCRIPTION; MT1-MMP	Kruppel-like factor 8 (KLF8) regulates critical gene transcription associated with cancer. The underlying mechanisms, however, remain largely unidentified. We have recently demonstrated that KLF8 expression enhances the activity but not expression of matrix metalloproteinase-2 (MMP2), the target substrate of MMP14. Here, we report a novel KLF8 to MMP14 signaling that promotes human breast cancer invasion and metastasis. Using cell lines for inducible expression and knockdown of KLF8, we demonstrate that KLF8 promotes MMP14 expression at the transcriptional level. Knocking down KLF8 expression inhibited the breast cancer cell invasion both in vitro and in vivo as well as the lung metastasis in mice, which could be rescued by ectopic expression of MMP14. Promoter reporter assays and oligonucleotide and chromatin immunoprecipitations determined that KLF8 activates the human MMP14 gene promoter by both directly acting on the promoter and indirectly via promoting the nuclear translocation of beta-catenin, the expression of T-cell factor-1 (TCF1) and subsequent activation of the promoter by the beta-catenin/TCF1 complex. Inhibition of focal adhesion kinase (FAK) using pharmacological inhibitor, RNA interference or knockout showed that the cell surface presentation of active MMP14 downstream of KLF8 depends on FAK expression and activity. Taken together, this work identified novel signaling mechanisms by which KLF8 and FAK work together to promote the extracellular activity of MMP14 critical for breast cancer metastasis.	[Lu, H.; Hu, L.; Yu, L.; Wang, X.; Urvalek, A. M.; Li, T.; Shen, C.; Mukherjee, D.; Lahiri, S. K.; Wason, M. S.; Zhao, J.] Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, Orlando, FL 32827 USA	State University System of Florida; University of Central Florida	Zhao, J (corresponding author), Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, 6900 Lake Nona Blvd, Orlando, FL 32827 USA.	Jihe.Zhao@ucf.edu	Lahiri, Satadru/J-3483-2019; Li, Tianshu/L-6426-2014	Li, Tianshu/0000-0002-9972-4644	NCI [CA132977]; Susan G Komen for Cure breast cancer foundation [KG090444, KG080616]; NATIONAL CANCER INSTITUTE [R01CA132977] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan G Komen for Cure breast cancer foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We appreciate Dr Jouko Lohi of University of Helsinki for kindly providing the human MMP14 gene promoter reporter vectors. This work was supported by grants from NCI (CA132977) and Susan G Komen for Cure breast cancer foundation (KG090444 and KG080616) to JZ.	Afsar NA, 2012, EUR J CLIN PHARMACOL, V68, P389, DOI 10.1007/s00228-011-1134-0; Ara T, 2000, CANCER LETT, V157, P115, DOI 10.1016/S0304-3835(00)00494-8; Barbolina MV, 2008, SEMIN CELL DEV BIOL, V19, P24, DOI 10.1016/j.semcdb.2007.06.008; Covington MD, 2006, AM J PHYSIOL-RENAL, V290, pF43, DOI 10.1152/ajprenal.00179.2005; Cristofanilli M, 2006, SEMIN ONCOL, V33, pS9, DOI 10.1053/j.seminoncol.2006.03.016; Dwivedi DJ, 2006, AM J PATHOL, V168, P69, DOI 10.2353/ajpath.2006.041089; Lahiri SK, 2012, AM J TRANSL RES, V4, P357; Liu P, 2010, J CELL PHYSIOL, V225, P810, DOI 10.1002/jcp.22292; Lohi J, 2000, GENE, V242, P75, DOI 10.1016/S0378-1119(99)00549-1; Lu H, 2014, ONCOGENE, V33, P10, DOI 10.1038/onc.2012.545; Lu H, 2012, J BIOL CHEM, V287, P43720, DOI 10.1074/jbc.M112.418053; Lu H, 2011, J BIOL CHEM, V286, P20335, DOI 10.1074/jbc.M110.215632; Mehta TS, 2009, CELL RES, V19, P1098, DOI 10.1038/cr.2009.64; Nawrocki-Raby B, 2003, INT J CANCER, V105, P790, DOI 10.1002/ijc.11168; Sanchez-Tillo E, 2011, P NATL ACAD SCI USA, V108, P19204, DOI 10.1073/pnas.1108977108; Schnell O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030429; Symowicz J, 2007, CANCER RES, V67, P2030, DOI 10.1158/0008-5472.CAN-06-2808; Takahashi M, 2002, ONCOGENE, V21, P5861, DOI 10.1038/sj.onc.1205755; Urvalek AM, 2011, AM J TRANSL RES, V3, P121; Urvalek AM, 2010, CELL CYCLE, V9, P601, DOI 10.4161/cc.9.3.10606; van Vliet J, 2000, NUCLEIC ACIDS RES, V28, P1955; Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960-9822(03)00240-9; Wang X, 2007, ONCOGENE, V26, P456, DOI 10.1038/sj.onc.1209796; Wang X, 2011, ONCOGENE, V30, P1901, DOI 10.1038/onc.2010.563; Wang XH, 2008, J BIOL CHEM, V283, P13934, DOI 10.1074/jbc.M709300200; Wang XH, 2007, CANCER RES, V67, P7184, DOI 10.1158/0008-5472.CAN-06-4729; Wei HJ, 2006, J BIOL CHEM, V281, P16664, DOI 10.1074/jbc.M513135200; Wu XY, 2005, DEV CELL, V9, P185, DOI 10.1016/j.devcel.2005.06.006; Zhang XL, 2012, P NATL ACAD SCI USA, V109, P9623, DOI 10.1073/pnas.1121606109; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997; Zhao JH, 2003, MOL CELL, V11, P1503, DOI 10.1016/S1097-2765(03)00179-5; Zhao J, 2009, CANCER METAST REV, V28, P35, DOI 10.1007/s10555-008-9165-4	32	43	47	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2014	33	22					2909	2917		10.1038/onc.2013.247	http://dx.doi.org/10.1038/onc.2013.247			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EI	23812425	Green Accepted			2022-12-28	WOS:000337231800010
J	Deming, DA; Leystra, AA; Nettekoven, L; Sievers, C; Miller, D; Middlebrooks, M; Clipson, L; Albrecht, D; Bacher, J; Washington, MK; Weichert, J; Halberg, RB				Deming, D. A.; Leystra, A. A.; Nettekoven, L.; Sievers, C.; Miller, D.; Middlebrooks, M.; Clipson, L.; Albrecht, D.; Bacher, J.; Washington, M. K.; Weichert, J.; Halberg, R. B.			PIK3CA and APC mutations are synergistic in the development of intestinal cancers	ONCOGENE			English	Article						colon cancer; APC; PI3K; PIK3CA; mouse models	COLORECTAL-CANCER; MICROSATELLITE INSTABILITY; BETA-CATENIN; TUMOR-SUPPRESSOR; KINASE; GENE; PHOSPHORYLATION; PATHWAY; INSULIN; COLON	Human colorectal cancers are known to possess multiple mutations, though how these mutations interact in tumor development and progression has not been fully investigated. We have previously described the FCPIK3ca* murine colon cancer model, which expresses a constitutively activated phosphoinositide-3 kinase (PI3K) in the intestinal epithelium. The expression of this dominantly active form of PI3K results in hyperplasia and invasive mucinous adenocarcinomas. These cancers form via a non-canonical mechanism of tumor initiation that is mediated through activation of PI3K and not through aberrations in WNT signaling. Since the Adenomatous Polyposis Coli (APC) gene is mutated in the majority of human colon cancers and often occurs simultaneously with PIK3CA mutations, we sought to better understand the interaction between APC and PIK3CA mutations in the mammalian intestine. In this study, we have generated mice in which the expression of a constitutively active PI3K and the loss of APC occur simultaneously in the distal small intestine and colon. Here, we demonstrate that expression of a dominant active PI3K synergizes with loss of APC activity resulting in a dramatic change in tumor multiplicity, size, morphology and invasiveness. Activation of the PI3K pathway is not able to directly activate WNT signaling through the nuclear localization of CTNNB1 (beta-catenin) in the absence of aberrant WNT signaling. Alterations at the transcriptional level, including increased CCND1, may be the etiology of synergy between these activated pathways.	[Deming, D. A.] Univ Wisconsin, Dept Med, Div Hematol & Oncol, Madison, WI 53792 USA; [Leystra, A. A.; Clipson, L.] Univ Wisconsin, Dept Oncol, Madison, WI 53792 USA; [Nettekoven, L.; Miller, D.; Middlebrooks, M.; Albrecht, D.; Halberg, R. B.] Univ Wisconsin, Dept Med, Div Gastroenterol & Hepatol, Madison, WI 53792 USA; [Sievers, C.] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI 53792 USA; [Bacher, J.] Promega Corp, Madison, WI USA; [Washington, M. K.] Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37212 USA; [Washington, M. K.] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA; [Weichert, J.] Univ Wisconsin, Dept Radiol, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Promega Corporation; Vanderbilt University; Vanderbilt University; University of Wisconsin System; University of Wisconsin Madison	Halberg, RB (corresponding author), Univ Wisconsin, Dept Med, Ctr Clin Sci, 600 Highland Ave,K4-532, Madison, WI 53792 USA.	rbhalberg@medicine.wisc.edu		Sievers, Chelsie/0000-0003-0088-753X	Conquer Cancer Foundation of the American Society of Clinical Oncology through A Young Investigator Award; National Cancer Institute of the US National Institutes of Health [T32 CA009614, P50 CA095103, R01 CA123438, P30 CA014520]; UW Division of Gastroenterology and Hepatology; UW Department of Medicine; UW School of Medicine and Public Health; NATIONAL CANCER INSTITUTE [T32CA009135, R01CA123438, P30CA014520, T32CA009614, P50CA095103] Funding Source: NIH RePORTER	Conquer Cancer Foundation of the American Society of Clinical Oncology through A Young Investigator Award; National Cancer Institute of the US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); UW Division of Gastroenterology and Hepatology; UW Department of Medicine; UW School of Medicine and Public Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Ella Ward and Jane Weeks in Experimental Pathology at the UW Carbone Cancer Center for their technical assistance. This project was supported by the Conquer Cancer Foundation of the American Society of Clinical Oncology through A Young Investigator Award (DAD); the National Cancer Institute of the US National Institutes of Health through T32 CA009614 (DAD), P50 CA095103 (Gastrointestinal Specialized Program of Research Excellence Grant, Vanderbilt Ingram Cancer Center), R01 CA123438 (RBH), P30 CA014520 (Core Grant, University of Wisconsin Carbone Cancer Center); and start-up funds (RBH) from the UW Division of Gastroenterology and Hepatology, the UW Department of Medicine, and the UW School of Medicine and Public Health.	American Cancer Society, 2012, CANC FACTS FIG 2012; Armaghany Tannaz, 2012, Gastrointest Cancer Res, V5, P19; Bacher JW, 2005, MOL CARCINOGEN, V44, P285, DOI 10.1002/mc.20146; Boland CR, 1998, CANCER RES, V58, P5248; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Des Guetz G, 2009, EUR J CANCER, V45, P1890, DOI 10.1016/j.ejca.2009.04.018; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Fang DX, 2007, J BIOL CHEM, V282, P11221, DOI 10.1074/jbc.M611871200; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Fukumoto S, 2001, J BIOL CHEM, V276, P17479, DOI 10.1074/jbc.C000880200; Goss KH, 2000, J CLIN ONCOL, V18, P1967, DOI 10.1200/JCO.2000.18.9.1967; Hinoi T, 2000, J BIOL CHEM, V275, P34399, DOI 10.1074/jbc.M003997200; Hung KE, 2010, P NATL ACAD SCI USA, V107, P1565, DOI 10.1073/pnas.0908682107; Kinzler K.W., 2002, GENETIC BASIS HUMAN, V2, P583; Leystra AA, 2012, CANCER RES, V72, P2931, DOI 10.1158/0008-5472.CAN-11-4097; Liao XY, 2012, NEW ENGL J MED, V367, P1596, DOI 10.1056/NEJMoa1207756; Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Naito AT, 2005, CIRC RES, V97, P144, DOI 10.1161/01.RES.0000175241.92285.f8; Ng SS, 2009, J BIOL CHEM, V284, P35308, DOI 10.1074/jbc.M109.078261; Nosho K, 2008, NEOPLASIA, V10, P534, DOI 10.1593/neo.08336; Saam JR, 1999, J BIOL CHEM, V274, P38071, DOI 10.1074/jbc.274.53.38071; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Srinivasan L, 2009, CELL, V139, P573, DOI 10.1016/j.cell.2009.08.041; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Tanwar PS, 2011, CANCER RES, V71, P1584, DOI 10.1158/0008-5472.CAN-10-3166; Velho S, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-255; Whitehall VLJ, 2012, INT J CANCER, V131, P813, DOI 10.1002/ijc.26440; Zhao L, 2010, CELL CYCLE, V9, P596, DOI 10.4161/cc.9.3.10599	32	44	46	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2014	33	17					2245	2254		10.1038/onc.2013.167	http://dx.doi.org/10.1038/onc.2013.167			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF8WJ	23708654	Green Accepted			2022-12-28	WOS:000334996000010
J	Raja, R; Kale, S; Thorat, D; Soundararajan, G; Lohite, K; Mane, A; Karnik, S; Kundu, GC				Raja, R.; Kale, S.; Thorat, D.; Soundararajan, G.; Lohite, K.; Mane, A.; Karnik, S.; Kundu, G. C.			Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1 alpha-mediated VEGF-dependent angiogenesis	ONCOGENE			English	Article						osteopontin; hypoxia; HIF1 alpha; angiogenesis	LINKED KINASE ILK; NF-KAPPA-B; INDUCIBLE FACTOR 1-ALPHA; CANCER-CELLS; PROSTATE-CANCER; GENE-EXPRESSION; MALIGNANT PROGRESSION; UP-REGULATION; ACTIVATION; HIF-1-ALPHA	Hypoxia is a salient feature of most solid tumors, and hypoxic adaptation of cancer cells has crucial implications in propagation of malignant clonal cell population. Osteopontin (OPN) has been identified as a hypoxia-responsive gene, but the mechanistic and regulatory role of OPN under hypoxia is less characterized. The present study identifies the existence of a positive inter-regulatory loop between hypoxia and OPN. We have shown that hypoxia induces OPN expression in breast cancer cells; however, the expression was found to be HIF1 alpha independent. OPN enabled transcriptional upregulation of HIF1 alpha expression both under normoxia and hypoxia, whereas stability of HIF1 alpha protein in breast cancer cells remained unaffected. Moreover, we have shown that OPN induces integrin-linked kinase (ILK)/Akt-mediated nuclear factor (NF)-kappa B p65 activation leading to HIF1 alpha-dependent vascular endothelial growth factor (VEGF) expression and angiogenesis in response to hypoxia. These in vitro data are biologically important as OPN expressing cells induce greater tumor growth and angiogenesis through enhanced expressions of proangiogenic molecules as compared with control. Immunohistochemical analysis of human breast cancer specimens revealed significant correlation between OPN and HIF1 alpha but not HIF2 alpha. Elevated expression of HIF1 alpha and OPN was observed in pre-neoplastic and early stage infiltrating ductal carcinoma implicating the role of these proteins in neoplastic progression of breast cancer. Together, our results substantiate the prime role of OPN in cellular adaptation through ILK and NF-kappa B-mediated HIF1 alpha-dependent VEGF expression in response to hypoxia that ultimately controls breast cancer progression and angiogenesis. Our study reinforces the fact that targeting OPN and its regulated signaling network hold important therapeutic implications.	[Raja, R.; Kale, S.; Thorat, D.; Soundararajan, G.; Kundu, G. C.] Natl Ctr Cell Sci, Lab Tumor Biol Angiogenesis & Nanomed Res, Pune 411007, Maharashtra, India; [Lohite, K.; Mane, A.; Karnik, S.] Ruby Hall Clin, Grant Med Fdn, Pune, Maharashtra, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Kundu, GC (corresponding author), Natl Ctr Cell Sci, Lab Tumor Biol Angiogenesis & Nanomed Res, NCCS Complex, Pune 411007, Maharashtra, India.	kundu@nccs.res.in	Kundu, Gopal C./ABA-9897-2020; Raja, Remya/GXM-8598-2022	Raja, Remya/0000-0002-7576-6778	Council of Scientific and Industrial Research (CSIR); Indian Council of Medical Research (ICMR); CSIR; ICMR; NCCS, Government of India	Council of Scientific and Industrial Research (CSIR)(Council of Scientific & Industrial Research (CSIR) - India); Indian Council of Medical Research (ICMR)(Indian Council of Medical Research (ICMR)); CSIR(Council of Scientific & Industrial Research (CSIR) - India); ICMR(Indian Council of Medical Research (ICMR)); NCCS, Government of India	We thank Dr B. Ramanamurthy, In-charge, Experimental Animal Facility (EAF), NCCS, India for breeding and maintaining NOD-SCID and OPN KO mice. We also thank Dr S. Ghaskabdi, Department of Zoology, University of Pune, India for providing the facility for CAM assay. This work was supported by grants from Council of Scientific and Industrial Research (CSIR) (to GCK, SK and GS) and Indian Council of Medical Research (ICMR) (to RR). This project was funded by CSIR, ICMR and NCCS, Government of India.	Ahmed M, 2011, EXPERT OPIN THER TAR, V15, P1113, DOI 10.1517/14728222.2011.594438; Ahmed M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-101; Behera R, 2010, CARCINOGENESIS, V31, P192, DOI 10.1093/carcin/bgp289; Bendinelli P, 2009, MOL CANCER RES, V7, P1328, DOI 10.1158/1541-7786.MCR-08-0548; Bos R, 2003, CANCER, V97, P1573, DOI 10.1002/cncr.11246; Brahimi Horn C, 2005, CELL SIGNAL, V17, P1; Chakraborty G, 2008, CANCER RES, V68, P152, DOI 10.1158/0008-5472.CAN-07-2126; Chakraborty G, 2006, CURR MOL MED, V6, P819, DOI 10.2174/156652406779010803; Chan DA, 2010, BRIT J CANCER, V103, P1, DOI 10.1038/sj.bjc.6605682; Chen R, 2011, ONCOGENE, V30, P2570, DOI 10.1038/onc.2010.623; Cook AC, 2005, MOL CARCINOGEN, V43, P225, DOI 10.1002/mc.20105; Dahl KDC, 2005, MOL BIOL CELL, V16, P1901; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; Denko NC, 2003, ONCOGENE, V22, P5907, DOI 10.1038/sj.onc.1206703; Doe MR, 2012, CANCER RES, V72, P949, DOI 10.1158/0008-5472.CAN-11-2371; Fedarko NS, 2001, CLIN CANCER RES, V7, P4060; Gu T, 2009, LUNG CANCER, V66, P176, DOI 10.1016/j.lungcan.2009.02.004; Hammond EM, 2006, CLIN CANCER RES, V12, P5007, DOI 10.1158/1078-0432.CCR-06-0613; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hockel M, 2001, SEMIN ONCOL, V28, P36, DOI 10.1016/S0093-7754(01)90211-8; Hockel M, 1996, CANCER RES, V56, P4509; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jain A, 2009, CLIN CANCER RES, V15, P5199, DOI 10.1158/1078-0432.CCR-09-0783; Jain S, 2008, CANCER RES, V68, P7750, DOI 10.1158/0008-5472.CAN-07-6689; Janji B, 2000, ONCOGENE, V19, P3069, DOI 10.1038/sj.onc.1203640; Kaidi A, 2006, CANCER RES, V66, P6683, DOI 10.1158/0008-5472.CAN-06-0425; Kim HK, 2009, J AM COLL CARDIOL, V53, P2009, DOI 10.1016/j.jacc.2009.01.066; Kumar V, 2010, CANCER RES, V70, P10381, DOI 10.1158/0008-5472.CAN-10-1470; Kuo HP, 2009, BIOCHEM BIOPH RES CO, V389, P640, DOI 10.1016/j.bbrc.2009.09.042; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Le QT, 2003, CLIN CANCER RES, V9, P59; Lech M, 2009, J IMMUNOL, V183, P4109, DOI 10.4049/jimmunol.0900118; Liao D, 2007, CANCER RES, V67, P563, DOI 10.1158/0008-5472.CAN-06-2701; Loboda A, 2010, MOL CELLS, V29, P435, DOI 10.1007/s10059-010-0067-2; Lu ZH, 2005, MOL CELL BIOL, V25, P4625, DOI 10.1128/MCB.25.11.4625-4637.2005; Machado-Linde F, 2012, REPROD SCI, V19, P1018, DOI 10.1177/1933719112446080; McAllister SS, 2008, CELL, V133, P994, DOI 10.1016/j.cell.2008.04.045; Mihai LG, 2012, FARMACIA, V60, P49; Miller RL, 1998, J LAB CLIN MED, V131, P45, DOI 10.1016/S0022-2143(98)90076-2; Mukundan H, 2004, J CARDIOVASC PHARM, V44, P93, DOI 10.1097/00005344-200407000-00013; Persad S, 2000, P NATL ACAD SCI USA, V97, P3207, DOI 10.1073/pnas.060579697; Pore N, 2006, MOL CANCER RES, V4, P471, DOI 10.1158/1541-7786.MCR-05-0234; Rangaswami H, 2006, TRENDS CELL BIOL, V16, P79, DOI 10.1016/j.tcb.2005.12.005; Rittling SR, 2004, BRIT J CANCER, V90, P1877, DOI 10.1038/sj.bjc.6601839; Rohwer N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012038; Said HM, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-55; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Semenza GL, 2000, CRIT REV BIOCHEM MOL, V35, P71, DOI 10.1080/10409230091169186; Sharma P, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-178; Singhal H, 1997, CLIN CANCER RES, V3, P605; Skuli N, 2009, CANCER RES, V69, P3308, DOI 10.1158/0008-5472.CAN-08-2158; Sliwa M, 2007, BRAIN, V130, P476, DOI 10.1093/brain/awl263; Song G, 2009, J CELL MOL MED, V13, P1706, DOI 10.1111/j.1582-4934.2008.00540.x; Stasinopoulos I, 2009, CANCER BIOL THER, V8, P31, DOI 10.4161/cbt.8.1.7079; Subarsky P, 2003, CLIN EXP METASTAS, V20, P237, DOI 10.1023/A:1022939318102; Tan C, 2004, CANCER CELL, V5, P79, DOI 10.1016/S1535-6108(03)00281-2; van Uden P, 2008, BIOCHEM J, V412, P477, DOI 10.1042/BJ20080476; Vaupel P, 2004, ONCOLOGIST, V9, P4, DOI 10.1634/theoncologist.9-90005-4; Vaupel P, 2003, CANCER RES, V63, P7634; Vaupel P., 2010, Experimental Oncology, V32, P125; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wai PY, 2004, J SURG RES, V121, P228, DOI 10.1016/j.jss.2004.03.028; Wong CCL, 2011, P NATL ACAD SCI USA, V108, P16369, DOI 10.1073/pnas.1113483108; Yang L, 2012, CHINESE MED J-PEKING, V125, P293, DOI 10.3760/cma.j.issn.0366-6999.2012.02.024; Zhong H, 1999, CANCER RES, V59, P5830; Zhu YH, 2005, ONCOGENE, V24, P6555, DOI 10.1038/sj.onc.1208800	66	83	90	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2014	33	16					2053	2064		10.1038/onc.2013.171	http://dx.doi.org/10.1038/onc.2013.171			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF3GH	23728336				2022-12-28	WOS:000334599100005
J	Lonning, PE; Knappskog, S				Lonning, P. E.; Knappskog, S.			Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers	ONCOGENE			English	Review						chemoresistance; TP53; DNA repair; mutations; germline; chemotherapy	NEGATIVE BREAST-CANCER; NUCLEOTIDE EXCISION-REPAIR; TOPOISOMERASE-II-ALPHA; PATIENTS RECEIVING COMBINATION; PLATINUM-BASED CHEMOTHERAPY; TUMOR-SUPPRESSOR STATUS; DNA-DAMAGE RESPONSE; CELL-CYCLE ARREST; P53 TARGET GENES; OVARIAN-CANCER	Although new agents are implemented to cancer therapy, we lack fundamental understandings of the mechanisms of chemoresistance, the main obstacle to cure in cancer. Here we review clinical evidence linking molecular defects to drug resistance across different tumour forms and discuss contemporary experimental evidence exploring these mechanisms. Although evidence, in general, is sparse and fragmentary, merging knowledge links drug resistance, and also sensitivity, to defects in functional pathways having a key role in cell growth arrest or death and DNA repair. As these pathways may act in concert, there is a need to explore multiple mechanisms in parallel. Taking advantage of massive parallel sequencing and other novel high-throughput technologies and base research on biological hypotheses, we now have the possibility to characterize functional defects related to these key pathways and to design a new generation of studies identifying the mechanisms controlling resistance to different treatment regimens in different tumour forms.	[Lonning, P. E.; Knappskog, S.] Univ Bergen, Inst Med, Sect Oncol, Bergen, Norway; [Lonning, P. E.; Knappskog, S.] Haukeland Hosp, Dept Oncol, N-5021 Bergen, Hordaland, Norway	University of Bergen; University of Bergen; Haukeland University Hospital	Lonning, PE (corresponding author), Haukeland Hosp, Dept Oncol, Jonas Lies Vei 65, N-5021 Bergen, Hordaland, Norway.	per.lonning@helse-bergen.no		Knappskog, Stian/0000-0002-4153-1655; Lonning, Per Eystein/0000-0002-8890-6303				Akakura S, 2010, CELL CYCLE, V9, P4656, DOI 10.4161/cc.9.23.13974; Al-Bahlani S, 2011, ONCOGENE, V30, P4219, DOI 10.1038/onc.2011.134; Aleskandarany MA, 2011, BREAST CANCER RES TR, V127, P407, DOI 10.1007/s10549-010-1012-y; Ali IU, 1999, JNCI-J NATL CANCER I, V91, P1922, DOI 10.1093/jnci/91.22.1922; Allocati N, 2012, EXP CELL RES, V318, P1285, DOI 10.1016/j.yexcr.2012.01.023; ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; Alsop K, 2012, J CLIN ONCOL, V30, P2654, DOI 10.1200/JCO.2011.39.8545; Arun B, 2011, J CLIN ONCOL, V29, P3739, DOI 10.1200/JCO.2011.35.2682; Ashcroft M, 2002, ONCOGENE, V21, P1955, DOI 10.1038/sj.onc.1205276; Atwal GS, 2009, P NATL ACAD SCI USA, V106, P10236, DOI 10.1073/pnas.0901298106; Audeh MW, 2010, LANCET, V376, P245, DOI 10.1016/S0140-6736(10)60893-8; Bachelot T, 2012, J CLIN ONCOL, V30, P2718, DOI 10.1200/JCO.2011.39.0708; Balana C, 2003, CLIN CANCER RES, V9, P1461; Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653; Baselga J, 2012, NEW ENGL J MED, V366, P109, DOI 10.1056/NEJMoa1113216; Baselga J, 2011, ONCOLOGIST, V16, P12, DOI 10.1634/theoncologist.2011-S1-12; Baumbusch LO, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-47; Bayraktar S, 2011, BREAST CANCER RES TR, V130, P145, DOI 10.1007/s10549-011-1711-z; Beeram M, 2007, ANN ONCOL, V18, P1323, DOI 10.1093/annonc/mdm170; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Bergamaschi D, 2003, CANCER CELL, V3, P387, DOI 10.1016/S1535-6108(03)00079-5; Berge EO, 2011, CLIN EXP METASTAS, V28, P319, DOI 10.1007/s10585-011-9375-y; Berge EO, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-173; Bhana S, 2008, MUTAGENESIS, V23, P131, DOI 10.1093/mutage/gen001; Blackwell KL, 2012, J CLIN ONCOL, V30, P2585, DOI 10.1200/JCO.2011.35.6725; Bleeker FE, 2008, ONCOGENE, V27, P5648, DOI 10.1038/onc.2008.170; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Bonnefoi H, 2011, LANCET ONCOL, V12, P527, DOI 10.1016/S1470-2045(11)70094-8; Bosco EE, 2007, J CLIN INVEST, V117, P218, DOI 10.1172/JCI28803; Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905; Bourdon JC, 2011, BREAST CANCER RES, V13, P1; Bowen C, 1998, CANCER RES, V58, P3275; Brady CA, 2011, CELL, V145, P571, DOI 10.1016/j.cell.2011.03.035; Brunner HG, 2002, AM J MED GENET, V112, P284, DOI 10.1002/ajmg.10778; Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443; Bukowski RM, 2012, EXPERT OPIN DRUG SAF, V11, P861, DOI 10.1517/14740338.2012.713344; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Byrski T, 2010, J CLIN ONCOL, V28, P375, DOI 10.1200/JCO.2008.20.7019; Carey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078-0432.CCR-06-1109; Castillo P, 2011, DNA REPAIR, V10, P518, DOI 10.1016/j.dnarep.2011.02.007; Chabalier C, 2006, CELL CYCLE, V5, P1001, DOI 10.4161/cc.5.9.2726; Chang CJ, 2004, J BIOL CHEM, V279, P29841, DOI 10.1074/jbc.M401488200; Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658; Chen JG, 2005, P NATL ACAD SCI USA, V102, P4813, DOI 10.1073/pnas.0407069102; Chipuk JE, 2004, SCIENCE, V303, P1010, DOI 10.1126/science.1092734; Chipuk JE, 2003, J CLIN IMMUNOL, V23, P355, DOI 10.1023/A:1025365432325; Chrisanthar R, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019249; Chrisanthar R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003062; Concin N, 2005, CLIN CANCER RES, V11, P8372, DOI 10.1158/1078-0432.CCR-05-0899; Cybulski C, 2004, AM J HUM GENET, V75, P1131, DOI 10.1086/426403; DABHOLKAR M, 1992, J NATL CANCER I, V84, P1512, DOI 10.1093/jnci/84.19.1512; Dal Bo M, 2010, BRIT J HAEMATOL, V150, P237, DOI 10.1111/j.1365-2141.2010.08185.x; Danks MK, 1998, CELL DEATH DIFFER, V5, P678, DOI 10.1038/sj.cdd.4400408; Dann RB, 2012, GYNECOL ONCOL, V125, P677, DOI 10.1016/j.ygyno.2012.03.006; Danovi D, 2004, MOL CELL BIOL, V24, P5835, DOI 10.1128/MCB.24.13.5835-5843.2004; Dedes KJ, 2011, CELL CYCLE, V10, P1192, DOI 10.4161/cc.10.8.15273; DeGraffenried LA, 2004, CLIN CANCER RES, V10, P8059, DOI 10.1158/1078-0432.CCR-04-0035; Deissler H, 2004, ONCOL REP, V11, P1281; Depowski PL, 2001, MODERN PATHOL, V14, P672, DOI 10.1038/modpathol.3880371; Derenzini M, 2009, J PATHOL, V219, P373, DOI 10.1002/path.2612; Diaz-Padilla I, 2012, CANCER TREAT REV, V38, P767, DOI 10.1016/j.ctrv.2012.02.001; DICCIANNI MB, 1994, BLOOD, V84, P3105; Ding H, 2011, BREAST CANCER RES TR, V125, P473, DOI 10.1007/s10549-010-0977-x; Diouf B, 2011, NAT MED, V17, P1298, DOI 10.1038/nm.2430; DOHNER H, 1995, BLOOD, V85, P1580, DOI 10.1182/blood.V85.6.1580.bloodjournal8561580; Domagala P, 2011, BREAST CANCER RES TR, V127, P861, DOI 10.1007/s10549-011-1441-2; Dommering CJ, 2012, FAM CANCER, V11, P225, DOI 10.1007/s10689-011-9505-3; Dowsett M, 2008, J CLIN ONCOL, V26, P1059, DOI 10.1200/JCO.2007.12.9437; Dumont P, 2003, NAT GENET, V33, P357, DOI 10.1038/ng1093; Dworkin AM, 2009, FAM CANCER, V8, P339, DOI 10.1007/s10689-009-9240-1; Easton D, 2004, AM J HUM GENET, V74, P1175, DOI 10.1086/421251; Edwards SL, 2008, NATURE, V451, P1111, DOI 10.1038/nature06548; Eisenhauer EA, 1997, ANN ONCOL, V8, P963, DOI 10.1023/A:1008240421028; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Evans DG, 2008, J MED GENET, V45, P62, DOI 10.1136/jmg.2007.054494; Evans DG, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-155; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Feng LJ, 2006, CELL CYCLE, V5, P2812, DOI 10.4161/cc.5.23.3526; Fernandez-Cuesta L, 2012, BREAST CANCER RES, V14, P3; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Fong PC, 2010, J CLIN ONCOL, V28, P2512, DOI 10.1200/JCO.2009.26.9589; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; Foray N, 2003, EMBO J, V22, P2860, DOI 10.1093/emboj/cdg274; Forslund A, 2008, MOL CANCER RES, V6, P205, DOI 10.1158/1541-7786.MCR-07-0239; Freed-Pastor WA, 2012, GENE DEV, V26, P1268, DOI 10.1101/gad.190678.112; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Friedberg EC, 2001, NAT REV CANCER, V1, P22, DOI 10.1038/35094000; Fu YP, 2003, CANCER RES, V63, P2440; Gajjar M, 2012, CANCER CELL, V21, P25, DOI 10.1016/j.ccr.2011.11.016; Garcia AI, 2011, EMBO MOL MED, V3, P279, DOI 10.1002/emmm.201100136; Garcia JM, 2004, GENE CHROMOSOME CANC, V41, P117, DOI 10.1002/gcc.20062; Garcia MJ, 2008, CLIN TRANSL ONCOL, V10, P78, DOI 10.1007/s12094-008-0160-6; Geisler S, 2003, CLIN CANCER RES, V9, P5582; Geisler S, 2001, CANCER RES, V61, P2505; Gelmon KA, 2011, LANCET ONCOL, V12, P852, DOI 10.1016/S1470-2045(11)70214-5; Gottlieb TM, 2002, ONCOGENE, V21, P1299, DOI 10.1038/sj.onc.1205181; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Gronwald J, 2009, J CLIN ONCOL S155, V27, P7; Grunwald V, 2002, CANCER RES, V62, P6141; Gurley KE, 2007, MOL CANCER RES, V5, P1312, DOI 10.1158/1541-7786.MCR-07-0223; Hartwell LH, 1997, SCIENCE, V278, P1064, DOI 10.1126/science.278.5340.1064; Hastak K, 2010, CANCER RES, V70, P7970, DOI 10.1158/0008-5472.CAN-09-4521; Hegi ME, 2005, NEW ENGL J MED, V352, P997, DOI 10.1056/NEJMoa043331; Hennessy BTJ, 2010, J CLIN ONCOL, V28, P3570, DOI 10.1200/JCO.2009.27.2997; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Honecker F, 2009, J CLIN ONCOL, V27, P2129, DOI 10.1200/JCO.2008.18.8623; Hsu DSS, 2010, CLIN CANCER RES, V16, P4561, DOI 10.1158/1078-0432.CCR-10-0593; Hugh J, 2009, J CLIN ONCOL, V27, P1168, DOI 10.1200/JCO.2008.18.1024; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Ianari A, 2009, CANCER CELL, V15, P184, DOI 10.1016/j.ccr.2009.01.026; Ibrahim YH, 2012, CANCER DISCOV, V2, P1036, DOI 10.1158/2159-8290.CD-11-0348; Ichikawa A, 1997, NEW ENGL J MED, V337, P529, DOI 10.1056/NEJM199708213370804; Irwin MS, 2003, CANCER CELL, V3, P403, DOI 10.1016/S1535-6108(03)00078-3; Jackson JG, 2012, CANCER CELL, V21, P793, DOI 10.1016/j.ccr.2012.04.027; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Jemaa M, 2012, CELL CYCLE, V11, P2149, DOI 10.4161/cc.20621; Johnston S, 2009, J CLIN ONCOL, V27, P5538, DOI 10.1200/JCO.2009.23.3734; Juvekar A, 2012, CANCER DISCOV, V2, P1048, DOI 10.1158/2159-8290.CD-11-0336; Kaina B, 2007, DNA REPAIR, V6, P1079, DOI 10.1016/j.dnarep.2007.03.008; Kandioler D, 2008, J THORAC CARDIOV SUR, V135, P1036, DOI 10.1016/j.jtcvs.2007.10.072; Kandioler-Eckersberger D, 1999, J THORAC CARDIOV SUR, V117, P744, DOI 10.1016/S0022-5223(99)70295-3; Kandioler-Eckersberger D, 2000, CLIN CANCER RES, V6, P50; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; Karakas B, 2006, BRIT J CANCER, V94, P455, DOI 10.1038/sj.bjc.6602970; Kaufman B, 2009, J CLIN ONCOL, V27, P5529, DOI 10.1200/JCO.2008.20.6847; Kerzendorfer C, 2009, DNA REPAIR, V8, P1139, DOI 10.1016/j.dnarep.2009.04.018; Kirkegaard T, 2005, J PATHOL, V207, P139, DOI 10.1002/path.1829; Knappskog S, 2007, INT J CANCER, V121, P908, DOI 10.1002/ijc.22777; Knappskog S, 2012, EUR J CANCER, V48, P1988, DOI 10.1016/j.ejca.2011.10.024; Knappskog S, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3147; Knappskog S, 2011, CANCER CELL, V19, P273, DOI 10.1016/j.ccr.2010.12.019; Knoop AS, 2005, J CLIN ONCOL, V23, P7483, DOI 10.1200/JCO.2005.11.007; Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Kriege M, 2012, CANCER-AM CANCER SOC, V118, P899, DOI 10.1002/cncr.26351; Kriege M, 2009, J CLIN ONCOL, V27, P3764, DOI 10.1200/JCO.2008.19.9067; Lachlan KL, 2007, J MED GENET, V44, DOI 10.1136/jmg.2007.049981; Lambert JMR, 2009, CANCER CELL, V15, P376, DOI 10.1016/j.ccr.2009.03.003; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Lavarino C, 2000, J CLIN ONCOL, V18, P3936, DOI 10.1200/JCO.2000.18.23.3936; Ledermann J, 2012, NEW ENGL J MED, V366, P1382, DOI 10.1056/NEJMoa1105535; Lehmann S, 2012, J CLIN ONCOL, V30, P3633, DOI 10.1200/JCO.2011.40.7783; Lehmann-Che J, 2010, ONCOLOGIST, V15, P246, DOI 10.1634/theoncologist.2009-0243; Leong CO, 2007, J CLIN INVEST, V117, P1370, DOI 10.1172/JCI30866; Leontieva OV, 2010, CELL CYCLE, V9, P4323, DOI 10.4161/cc.9.21.13584; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; Liedtke C, 2008, J CLIN ONCOL, V26, P1275, DOI 10.1200/JCO.2007.14.4147; Lin WC, 2001, GENE DEV, V15, P1833; Liu XS, 2009, MOL CANCER RES, V7, P1686, DOI 10.1158/1541-7786.MCR-09-0299; Lonning PE, 2007, ANN ONCOL, V18, P1293, DOI 10.1093/annonc/mdm013; Lonning PE, 2004, TRENDS MOL MED, V10, P113, DOI 10.1016/j.molmed.2004.01.005; Lonning PE, 2003, LANCET ONCOL, V4, P177; Lonning PE, 2010, MOL ONCOL, V4, P284, DOI 10.1016/j.molonc.2010.04.005; Lord CJ, 2012, NATURE, V481, P287, DOI 10.1038/nature10760; Loveday C, 2011, NAT GENET, V43, P879, DOI 10.1038/ng.893; Lynch HT, 2009, CLIN GENET, V76, P1, DOI 10.1111/j.1399-0004.2009.01230.x; Ma YL, 2011, BREAST CANCER RES TR, V125, P201, DOI 10.1007/s10549-010-0920-1; Marine JC, 2004, CELL CYCLE, V3, P900; MARTIN K, 1995, NATURE, V375, P691, DOI 10.1038/375691a0; Martin SA, 2008, CURR OPIN GENET DEV, V18, P80, DOI 10.1016/j.gde.2008.01.016; Martin SA, 2009, EMBO MOL MED, V1, P323, DOI 10.1002/emmm.200900040; Mayo LD, 2005, J BIOL CHEM, V280, P25953, DOI 10.1074/jbc.M503026200; Mayo LD, 2001, P NATL ACAD SCI USA, V98, P11598, DOI 10.1073/pnas.181181198; McGrogan BT, 2008, BBA-REV CANCER, V1785, P96, DOI 10.1016/j.bbcan.2007.10.004; Meindl A, 2010, NAT GENET, V42, P410, DOI 10.1038/ng.569; Merel P, 2002, ONCOGENE, V21, P5654, DOI 10.1038/sj.onc.1205742; Metzger R, 1998, J CLIN ONCOL, V16, P309, DOI 10.1200/JCO.1998.16.1.309; Micol R, 2011, J ALLERGY CLIN IMMUN, V128, P382, DOI 10.1016/j.jaci.2011.03.052; Morachis JM, 2010, GENE DEV, V24, P135, DOI 10.1101/gad.1856710; MORRELL D, 1986, J NATL CANCER I, V77, P89; Morselli E, 2008, CELL CYCLE, V7, P3056, DOI 10.4161/cc.7.19.6751; Moskwa P, 2011, MOL CELL, V41, P210, DOI 10.1016/j.molcel.2010.12.005; MUSS HB, 1994, NEW ENGL J MED, V330, P1260, DOI 10.1056/NEJM199405053301802; Muthusamy V, 2006, GENE CHROMOSOME CANC, V45, P447, DOI 10.1002/gcc.20310; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Norgauer J, 2003, EUR J DERMATOL, V13, P4; Norquist B, 2011, J CLIN ONCOL, V29, P3008, DOI 10.1200/JCO.2010.34.2980; O'Malley FP, 2009, JNCI-J NATL CANCER I, V101, P644, DOI 10.1093/jnci/djp067; O'Shaughnessy J, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.1007; O'Shaughnessy J, 2011, NEW ENGL J MED, V364, P205, DOI 10.1056/NEJMoa1011418; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Orloff MS, 2013, AM J HUM GENET, V92, P76, DOI 10.1016/j.ajhg.2012.10.021; Oshima K, 2011, CANCER LETT, V307, P149, DOI 10.1016/j.canlet.2011.03.027; Paik SM, 1998, JNCI-J NATL CANCER I, V90, P1361, DOI 10.1093/jnci/90.18.1361; Park DJ, 2001, CANCER RES, V61, P8654; Park JS, 2011, GYNECOL ONCOL, V120, P275, DOI 10.1016/j.ygyno.2010.10.034; Patel AG, 2012, CLIN CANCER RES, V18, P1655, DOI 10.1158/1078-0432.CCR-11-2890; Paz MF, 2004, CLIN CANCER RES, V10, P4933, DOI 10.1158/1078-0432.CCR-04-0392; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Pegram MD, 1997, ONCOGENE, V15, P537, DOI 10.1038/sj.onc.1201222; Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3; Petit T, 2001, CLIN CANCER RES, V7, P1577; Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144; Powers JT, 2004, MOL CANCER RES, V2, P203; Press MF, 2005, BREAST CANCER RES TR, V94, pS54; PREUDHOMME C, 1995, J CLIN ONCOL, V13, P812, DOI 10.1200/JCO.1995.13.4.812; Pritchard KI, 2006, NEW ENGL J MED, V354, P2103, DOI 10.1056/NEJMoa054504; Qian H, 2002, ONCOGENE, V21, P7901, DOI 10.1038/sj.onc.1205974; Rafnar T, 2011, NAT GENET, V43, P1104, DOI 10.1038/ng.955; Rahman N, 2007, NAT GENET, V39, P165, DOI 10.1038/ng1959; Rakha EA, 2009, CLIN CANCER RES, V15, P2302, DOI 10.1158/1078-0432.CCR-08-2132; Ray RM, 2011, APOPTOSIS, V16, P35, DOI 10.1007/s10495-010-0538-0; Ray-Coquard I, 2012, LANCET ONCOL, V13, P1133, DOI 10.1016/S1470-2045(12)70474-6; Reardon JT, 1999, CANCER RES, V59, P3968; Rehman FL, 2010, NAT REV CLIN ONCOL, V7, P718, DOI 10.1038/nrclinonc.2010.172; Ribic CM, 2003, NEW ENGL J MED, V349, P247, DOI 10.1056/NEJMoa022289; Riemenschneider MJ, 1999, CANCER RES, V59, P6091; Righetti SC, 1996, CANCER RES, V56, P689; Riviere JB, 2012, NAT GENET, V44, P934, DOI 10.1038/ng.2331; Romeo F, 2011, INT J BIOCHEM CELL B, V43, P1754, DOI 10.1016/j.biocel.2011.08.011; Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122; ROSE C, 1985, LANCET, V1, P16; Roth JA, 1996, NAT MED, V2, P985, DOI 10.1038/nm0996-985; Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421; Russnes HG, 2011, J CLIN INVEST, V121, P3810, DOI 10.1172/JCI57088; Sakai W, 2008, NATURE, V451, P1116, DOI 10.1038/nature06633; Salmena L, 2011, CELL, V146, P353, DOI 10.1016/j.cell.2011.07.014; Santonocito C, 2012, CLIN CHIM ACTA, V413, P1519, DOI 10.1016/j.cca.2012.06.013; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Schmitz KJ, 2004, MODERN PATHOL, V17, P15, DOI 10.1038/modpathol.3800002; Schrohl AS, 2006, CLIN CANCER RES, V12, P7054, DOI 10.1158/1078-0432.CCR-06-0950; Sharma A, 2007, CANCER RES, V67, P6192, DOI 10.1158/0008-5472.CAN-06-4424; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Silver DP, 2010, J CLIN ONCOL, V28, P1145, DOI 10.1200/JCO.2009.22.4725; Sirohi B, 2008, ANN ONCOL, V19, P1847, DOI 10.1093/annonc/mdn395; Sirvent N, 2007, AM J SURG PATHOL, V31, P1476, DOI 10.1097/PAS.0b013e3180581fff; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Sjogren S, 1996, J NATL CANCER I, V88, P173, DOI 10.1093/jnci/88.3-4.173; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Smeenk L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017574; Smiraldo PG, 2005, CANCER RES, V65, P2089, DOI 10.1158/0008-5472.CAN-04-2079; Somyajit K, 2012, J BIOL CHEM, V287, P3366, DOI 10.1074/jbc.M111.311241; Song H, 2007, CELL CYCLE, V6, P1570, DOI 10.4161/cc.6.13.4456; Song SS, 2012, CELL RES, V22, P1285, DOI 10.1038/cr.2012.107; Sorensen NM, 2007, CLIN CANCER RES, V13, P4117, DOI 10.1158/1078-0432.CCR-07-0186; Staalesen V, 2004, ONCOGENE, V23, P8535, DOI 10.1038/sj.onc.1207928; Staalesen V, 2004, CLIN CANCER RES, V10, P3438, DOI 10.1158/1078-0432.CCR-03-0796; Stevens C, 2003, NAT CELL BIOL, V5, P401, DOI 10.1038/ncb974; Stiewe T, 2007, NAT REV CANCER, V7, P165, DOI 10.1038/nrc2072; Swisher EM, 2008, CANCER RES, V68, P2581, DOI 10.1158/0008-5472.CAN-08-0088; Tan DSP, 2008, J CLIN ONCOL, V26, P5530, DOI 10.1200/JCO.2008.16.1703; Tanner M, 2006, J CLIN ONCOL, V24, P2428, DOI 10.1200/JCO.2005.02.9264; Tavtigian SV, 2009, AM J HUM GENET, V85, P427, DOI 10.1016/j.ajhg.2009.08.018; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Tomasini R, 2008, GENE DEV, V22, P2677, DOI 10.1101/gad.1695308; Trotman LC, 2003, CANCER CELL, V3, P97, DOI 10.1016/S1535-6108(03)00022-9; Tsai CM, 2000, JPN J CANCER RES, V91, P213, DOI 10.1111/j.1349-7006.2000.tb00934.x; Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6; Valeri A, 2011, CLIN TRANSL ONCOL, V13, P215, DOI 10.1007/s12094-011-0645-6; van der Kolk DM, 2010, BREAST CANCER RES TR, V124, P643, DOI 10.1007/s10549-010-0805-3; Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X; Vaseva AV, 2012, CELL, V149, P1536, DOI 10.1016/j.cell.2012.05.014; Vencken PMLH, 2011, ANN ONCOL, V22, P1346, DOI 10.1093/annonc/mdq628; Viktorsson K, 2005, BIOCHEM BIOPH RES CO, V331, P868, DOI 10.1016/j.bbrc.2005.03.192; Villarroel MC, 2011, MOL CANCER THER, V10, P3, DOI 10.1158/1535-7163.MCT-10-0893; von Minckwitz G, 2011, J CLIN ONCOL, V29, P2150, DOI 10.1200/JCO.2010.31.9079; Walsh T, 2011, P NATL ACAD SCI USA, V108, P18032, DOI 10.1073/pnas.1115052108; Wang QE, 2011, MOL CANCER, V10; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219; WATTEL E, 1994, BLOOD, V84, P3148, DOI 10.1182/blood.V84.9.3148.3148; Wendel HG, 2004, NATURE, V428, P332, DOI 10.1038/nature02369; Williams SA, 2011, HUM MOL GENET, V20, P4395, DOI 10.1093/hmg/ddr366; Witkiewicz AK, 2012, CLIN CANCER RES, V18, P5110, DOI 10.1158/1078-0432.CCR-12-0903; XIAO ZX, 1995, NATURE, V375, P694, DOI 10.1038/375694a0; Xue YW, 2012, CELL CYCLE, V11, P4181, DOI 10.4161/cc.22413; Yang D, 2011, JAMA-J AM MED ASSOC, V306, P1557, DOI 10.1001/jama.2011.1456; Yang J, 2010, ONCOGENE, V29, P463, DOI 10.1038/onc.2009.327; Yoon H, 2002, P NATL ACAD SCI USA, V99, P15632, DOI 10.1073/pnas.242597299; Young SR, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-86; Yunokawa M, 2012, CANCER SCI, V103, P1665, DOI 10.1111/j.1349-7006.2012.02359.x; Zagorski WA, 2007, CANCER RES, V67, P8264, DOI 10.1158/0008-5472.CAN-06-4753; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zenz T, 2010, J CLIN ONCOL, V28, P4473, DOI 10.1200/JCO.2009.27.8762; Zenz T, 2009, BLOOD, V113, P3801, DOI 10.1182/blood-2008-08-172254; Zhang HB, 1998, ONCOGENE, V16, P1713, DOI 10.1038/sj.onc.1201932; Zhang XP, 2011, P NATL ACAD SCI USA, V108, P8990, DOI 10.1073/pnas.1100600108; Zhang XB, 2012, EUR J CANCER, V48, P1581, DOI 10.1016/j.ejca.2012.02.053; Zhou W, 2004, CLIN CANCER RES, V10, P4939, DOI 10.1158/1078-0432.CCR-04-0247; Zurer I, 2004, CARCINOGENESIS, V25, P11, DOI 10.1093/carcin/bgg186; Zysman MA, 2002, AM J PATHOL, V160, P795, DOI 10.1016/S0002-9440(10)64902-4	283	41	41	0	29	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2013	32	46					5315	5330		10.1038/onc.2013.48	http://dx.doi.org/10.1038/onc.2013.48			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251IU	23474753	hybrid			2022-12-28	WOS:000326922400001
J	Bisikirska, BC; Adam, SJ; Alvarez, MJ; Rajbhandari, P; Cox, R; Lefebvre, C; Wang, K; Rieckhof, GE; Felsher, DW; Califano, A				Bisikirska, B. C.; Adam, S. J.; Alvarez, M. J.; Rajbhandari, P.; Cox, R.; Lefebvre, C.; Wang, K.; Rieckhof, G. E.; Felsher, D. W.; Califano, A.			STK38 is a critical upstream regulator of MYC's oncogenic activity in human B-cell lymphoma	ONCOGENE			English	Article						STK38; MYC post-translational modifications; protein turnover; transcriptional activity; protein-protein interaction	NDR PROTEIN-KINASE; C-MYC; TRANSCRIPTION FACTOR; TUMOR-REGRESSION; ACTIVATION; COMPLEX; BINDING; DNA; PHOSPHORYLATION; IDENTIFICATION	The MYC protooncogene is associated with the pathogenesis of most human neoplasia. Conversely, its experimental inactivation elicits oncogene addiction. Besides constituting a formidable therapeutic target, MYC also has an essential function in normal physiology, thus creating the need for context-specific targeting strategies. The analysis of post-translational MYC activity modulation yields novel targets for MYC inactivation. Specifically, following regulatory network analysis in human B-cells, we identify a novel role of the STK38 kinase as a regulator of MYC activity and a candidate target for abrogating tumorigenesis in MYC-addicted lymphoma. We found that STK38 regulates MYC protein stability and turnover in a kinase activity-dependent manner. STK38 kinase inactivation abrogates apoptosis following B-cell receptor activation, whereas its silencing significantly decreases MYC levels and increases apoptosis. Moreover, STK38 knockdown suppresses growth of MYC-addicted tumors in vivo, thus providing a novel viable target for treating these malignancies.	[Bisikirska, B. C.; Alvarez, M. J.; Rajbhandari, P.; Cox, R.; Lefebvre, C.; Rieckhof, G. E.; Califano, A.] Columbia Univ, Joint Ctr Syst Biol, New York, NY USA; [Adam, S. J.; Felsher, D. W.] Stanford Univ, Div Oncol, Dept Med, Stanford, CA 94305 USA; [Adam, S. J.; Felsher, D. W.] Stanford Univ, Div Oncol, Dept Pathol, Stanford, CA 94305 USA; [Cox, R.] Riverdale Country Sch, Bronx, NY USA; [Wang, K.; Califano, A.] Columbia Univ, Dept Biomed Informat, New York, NY USA; [Wang, K.] Pfizer Inc, San Diego, CA USA; [Califano, A.] Columbia Univ, Dept Pathol & Genet & Dev, New York, NY USA	Columbia University; Stanford University; Stanford University; Columbia University; Pfizer; Columbia University	Felsher, DW (corresponding author), Stanford Univ, Div Oncol, Dept Med, 1120 CCSR 269 Campus Dr, Stanford, CA 94305 USA.	dfelsher@stanford.edu; califano@c2b2.columbia.edu	Lefebvre, Celine/E-6290-2013	Wang, Kai/0000-0003-0567-3004; Califano, Andrea/0000-0003-4742-3679	NCI [R01CA109755]; NIAID [R01AI066116]; NCBC NIH Roadmap Initiative [U54CA121852]; Burroughs Welcome Fund Career Award; Damon Runyon Foundation; NIH [R01CA089305, R01CA105102]; National Cancer Institute's in-vivo Cellular and Molecular Imaging Center [P50CA114747]; Integrative Cancer Biology Program [1P20CA112973]; NIH/NCI [P01CA034233]; Leukemia and Lymphoma Society [R6223-07]; American Cancer Society [PF-10-237-01-TBG]; NATIONAL CANCER INSTITUTE [R01CA109755, R01CA105102, P50CA114747, R01CA170378, R01CA089305, P01CA034233, U54CA121852] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI066116] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008798] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCBC NIH Roadmap Initiative; Burroughs Welcome Fund Career Award(Burroughs Wellcome Fund); Damon Runyon Foundation; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Cancer Institute's in-vivo Cellular and Molecular Imaging Center; Integrative Cancer Biology Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Leukemia and Lymphoma Society(Leukemia and Lymphoma Society); American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Riccardo Dalla-Favera for critical review of this manuscript and Masumichi Saito for supplying MYC deletion mutant expression vectors (both from Columbia University). This work was supported by the NCI (R01CA109755), the NIAID (R01AI066116) and the NCBC NIH Roadmap Initiative (U54CA121852) (AC), Burroughs Welcome Fund Career Award, the Damon Runyon Foundation Lilly Clinical Investigator Award, NIH (R01CA089305, R01CA105102), National Cancer Institute's in-vivo Cellular and Molecular Imaging Center (P50CA114747), Integrative Cancer Biology Program (1P20CA112973), NIH/NCI (P01CA034233), the Leukemia and Lymphoma Society Translational Research grant number R6223-07 (DWF), and the American Cancer Society Fellowship PF-10-237-01-TBG (SJA).	Adeyinka A, 2002, CLIN CANCER RES, V8, P3788; Arnold HK, 2009, EMBO J, V28, P500, DOI 10.1038/emboj.2008.279; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Babu MM, 2011, CURR OPIN STRUC BIOL, V21, P432, DOI 10.1016/j.sbi.2011.03.011; Bansal M, 2012, METHODS MOL BIOL, V786, P131, DOI 10.1007/978-1-61779-292-2_8; Basso K, 2005, NAT GENET, V37, P382, DOI 10.1038/ng1532; Bhattacharya S, 2003, BIOCHEMISTRY-US, V42, P14416, DOI 10.1021/bi035089a; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; BONNEFOYBERARD N, 1994, BLOOD, V83, P1051; Bouchard C, 1998, TRENDS CELL BIOL, V8, P202, DOI 10.1016/S0962-8924(98)01251-3; Cornils H, 2011, CELL CYCLE, V10, P1897, DOI 10.4161/cc.10.12.15826; Cornils H, 2011, MOL CELL BIOL, V31, P1382, DOI 10.1128/MCB.01216-10; Cui DX, 2005, WORLD J GASTROENTERO, V11, P1273, DOI 10.3748/wjg.v11.i9.1273; Devroe E, 2004, J BIOL CHEM, V279, P24444, DOI 10.1074/jbc.M401999200; Dominguez-Sola D, 2007, NATURE, V448, P445, DOI 10.1038/nature05953; Engelberg D, 2004, SEMIN CANCER BIOL, V14, P271, DOI 10.1016/j.semcancer.2004.04.006; Enomoto A, 2008, ONCOGENE, V27, P1930, DOI 10.1038/sj.onc.1210828; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Felsher DW, 2004, SEMIN CANCER BIOL, V14, P1, DOI 10.1016/j.semcancer.2003.11.001; Felsher DW, 2004, CURR OPIN GENET DEV, V14, P37, DOI 10.1016/j.gde.2003.12.008; Follis AV, 2008, CHEM BIOL, V15, P1149, DOI 10.1016/j.chembiol.2008.09.011; Hann SR, 2006, SEMIN CANCER BIOL, V16, P288, DOI 10.1016/j.semcancer.2006.08.004; Herbst A, 2005, EMBO REP, V6, P177, DOI 10.1038/sj.embor.7400333; Herbst A, 2004, ONCOGENE, V23, P3863, DOI 10.1038/sj.onc.1207492; Hergovich A, 2007, MOL CELL, V25, P625, DOI 10.1016/j.molcel.2007.01.020; Hergovich A, 2006, BIOCHEM BIOPH RES CO, V345, P50, DOI 10.1016/j.bbrc.2006.03.244; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Kaptein JS, 1996, J BIOL CHEM, V271, P18875, DOI 10.1074/jbc.271.31.18875; Karlsson A, 2003, BLOOD, V101, P2797, DOI 10.1182/blood-2002-10-3091; KATO GJ, 1990, MOL CELL BIOL, V10, P5914, DOI 10.1128/MCB.10.11.5914; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; MILLWARD T, 1995, P NATL ACAD SCI USA, V92, P5022, DOI 10.1073/pnas.92.11.5022; Millward TA, 1999, J BIOL CHEM, V274, P33847, DOI 10.1074/jbc.274.48.33847; Millward TA, 1998, EMBO J, V17, P5913, DOI 10.1093/emboj/17.20.5913; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; Mooney LM, 2004, J BIOL CHEM, V279, P11843, DOI 10.1074/jbc.M311841200; Nair SK, 2003, CELL, V112, P193, DOI 10.1016/S0092-8674(02)01284-9; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tamaskovic R, 2003, J BIOL CHEM, V278, P6710, DOI 10.1074/jbc.M210590200; Tran PT, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002018; Tsvetkov P, 2009, NAT CHEM BIOL, V5, P778, DOI 10.1038/nchembio.233; Tsvetkov P, 2009, J BIOL CHEM, V284, P26234, DOI 10.1074/jbc.M109.040493; Vichalkovski A, 2008, CURR BIOL, V18, P1889, DOI 10.1016/j.cub.2008.10.060; Wang K, 2009, NAT BIOTECHNOL, V27, P829, DOI 10.1038/nbt.1563; Wang K, 2009, PACIFIC SYMPOSIUM ON BIOCOMPUTING 2009, P264; Ward JJ, 2004, J MOL BIOL, V337, P635, DOI 10.1016/j.jmb.2004.02.002; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Wu CH, 2007, P NATL ACAD SCI USA, V104, P13028, DOI 10.1073/pnas.0701953104; Wu KJ, 1999, NAT GENET, V21, P220, DOI 10.1038/6010; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69	52	30	33	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2013	32	45					5283	5291		10.1038/onc.2012.543	http://dx.doi.org/10.1038/onc.2012.543			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251IS	23178486	Green Accepted, hybrid			2022-12-28	WOS:000326922100004
J	Galluzzi, L; Vacchelli, E; Michels, J; Garcia, P; Kepp, O; Senovilla, L; Vitale, I; Kroemer, G				Galluzzi, L.; Vacchelli, E.; Michels, J.; Garcia, P.; Kepp, O.; Senovilla, L.; Vitale, I.; Kroemer, G.			Effects of vitamin B6 metabolism on oncogenesis, tumor progression and therapeutic responses	ONCOGENE			English	Review						ALDH7A1; homocysteine; NSCLC; pyridoxal phosphatase; pyridoxine; stress response	ONE-CARBON METABOLISM; COLORECTAL-CANCER RISK; NON-HODGKIN-LYMPHOMA; BREAST-CANCER; PYRIDOXINE-DEFICIENCY; DIETARY-FOLATE; ALCOHOL-CONSUMPTION; NUTRIENT INTAKE; PLASMA FOLATE; FOLIC-ACID	Pyridoxal-5'-phosphate (PLP), the bioactive form of vitamin B6, reportedly functions as a prosthetic group for >4% of classified enzymatic activities of the cell. It is therefore not surprising that alterations of vitamin B6 metabolism have been associated with multiple human diseases. As a striking example, mutations in the gene coding for antiquitin, an evolutionary old aldehyde dehydrogenase, result in pyridoxine-dependent seizures, owing to the accumulation of a metabolic intermediate that inactivates PLP. In addition, PLP is required for the catabolism of homocysteine by transsulfuration. Hence, reduced circulating levels of B6 vitamers (including PLP as well as its major precursor pyridoxine) are frequently paralleled by hyperhomocysteinemia, a condition that has been associated with an increased risk for multiple cardiovascular diseases. During the past 30 years, an intense wave of clinical investigation has attempted to dissect the putative links between vitamin B6 and cancer. Thus, high circulating levels of vitamin B6, as such or as they reflected reduced amounts of circulating homocysteine, have been associated with improved disease outcome in patients bearing a wide range of hematological and solid neoplasms. More recently, the proficiency of vitamin B6 metabolism has been shown to modulate the adaptive response of tumor cells to a plethora of physical and chemical stress conditions. Moreover, elevated levels of pyridoxal kinase (PDXK), the enzyme that converts pyridoxine and other vitamin B6 precursors into PLP, have been shown to constitute a good, therapy-independent prognostic marker in patients affected by non-small cell lung carcinoma (NSCLC). Here, we will discuss the clinical relevance of vitamin B6 metabolism as a prognostic factor in cancer patients.	[Galluzzi, L.; Kroemer, G.] Univ Paris 05, Sorbonne Paris Cite, Paris, France; [Galluzzi, L.; Vacchelli, E.; Michels, J.; Garcia, P.; Kepp, O.; Senovilla, L.; Vitale, I.; Kroemer, G.] Inst Gustave Roussy, F-94805 Villejuif, Val De Marne, France; [Vacchelli, E.; Michels, J.; Garcia, P.; Kepp, O.; Senovilla, L.; Vitale, I.] Univ Paris 11, Paris, France; [Vacchelli, E.; Michels, J.; Garcia, P.; Kepp, O.; Senovilla, L.; Vitale, I.; Kroemer, G.] INSERM, U848, Villejuif, France; [Kroemer, G.] Ctr Rech Cordeliers, Equipe Labellisee Ligue Canc 11, Paris, France; [Kroemer, G.] Hop Europeen Georges Pompidou, Pole Biol, Paris, France	UDICE-French Research Universities; Universite Paris Cite; UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Galluzzi, L (corresponding author), Inst Gustave Roussy, INSERM, U848, Pavillon Rech 1,39,Rue Camille Desmoulins, F-94805 Villejuif, Val De Marne, France.	deadoc@vodafone.it; kroemer@orange.fr	Michels, Judith/Q-5693-2018; Vitale, Ilio/M-3960-2017; Kepp, Oliver/GPX-8627-2022; Galluzzi, Lorenzo/AAG-6432-2019; Galluzzi, Lorenzo/AAH-3286-2021; Senovilla, Laura/AAX-5599-2021; Galluzzi, Lorenzo/AAG-6294-2019; Vacchelli, Erika/E-5212-2018; Kepp, Oliver/N-2763-2017; Kroemer, Guido/AAY-9859-2020; KROEMER, Guido/B-4263-2013	Michels, Judith/0000-0002-9640-0222; Vitale, Ilio/0000-0002-5918-1841; Vacchelli, Erika/0000-0001-8010-0594; Kepp, Oliver/0000-0002-6081-9558; KROEMER, Guido/0000-0002-9334-4405; Senovilla, Laura/0000-0001-6887-2436	European Commission (ArtForce); Agence National de la Recherche (ANR); Ligue contre le Cancer (Equipe labellisee); Fondation pour la Recherche Medicale (FRM); Institut National du Cancer (INCa); LabEx Immuno-Oncologie; Fondation de France; Fondation Bettencourt-Schueller; AXA Chair for Longevity Research; Canceropole Ile-de-France; Paris Alliance of Cancer Research Institutes (PACRI)	European Commission (ArtForce)(European CommissionEuropean Commission Joint Research Centre); Agence National de la Recherche (ANR)(French National Research Agency (ANR)); Ligue contre le Cancer (Equipe labellisee); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); LabEx Immuno-Oncologie; Fondation de France(Fondation de France); Fondation Bettencourt-Schueller; AXA Chair for Longevity Research(AXA Research Fund); Canceropole Ile-de-France(Region Ile-de-France); Paris Alliance of Cancer Research Institutes (PACRI)	We acknowledge the valuable help of Federico Pietrocola for the compilation of Table 1. The authors are supported by the European Commission (ArtForce); Agence National de la Recherche (ANR); Ligue contre le Cancer (Equipe labellisee); Fondation pour la Recherche Medicale (FRM); Institut National du Cancer (INCa); LabEx Immuno-Oncologie; Fondation de France; Fondation Bettencourt-Schueller; AXA Chair for Longevity Research; Canceropole Ile-de-France and Paris Alliance of Cancer Research Institutes (PACRI).	Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; Ames BN, 2001, MUTAT RES-FUND MOL M, V475, P7, DOI 10.1016/S0027-5107(01)00070-7; Ames BN, 1999, ANN NY ACAD SCI, V889, P87, DOI 10.1111/j.1749-6632.1999.tb08727.x; ATUKORALA TMS, 1983, CLIN ONCOL, V9, P3; BAIROCH A, 1994, NUCLEIC ACIDS RES, V22, P3626, DOI 10.1093/nar/22.17.3626; BAKER H, 1992, J AM COLL NUTR, V11, P482; BAKER H, 1981, CANCER, V47, P2883, DOI 10.1002/1097-0142(19810615)47:12<2883::AID-CNCR2820471222>3.0.CO;2-I; Banque M, 2012, NUTR CANCER, V64, P386, DOI 10.1080/01635581.2012.657334; Bosetti C, 2007, INT J CANCER, V120, P892, DOI 10.1002/ijc.22374; Bourquin F, 2011, PROTEIN SCI, V20, P1492, DOI 10.1002/pro.679; Boyapati SM, 2004, CANCER CAUSE CONTROL, V15, P493, DOI 10.1023/B:CACO.0000036447.45446.2c; BYAR D, 1977, Urology, V10, P556, DOI 10.1016/0090-4295(77)90101-7; CHANG YC, 1987, BIOCHEMISTRY-US, V26, P360, DOI 10.1021/bi00376a005; Chou YC, 2011, J EPIDEMIOL, V21, P329, DOI 10.2188/jea.JE20100188; CHRISTENSEN HN, 1954, J BIOL CHEM, V209, P413; Clayton PT, 2006, J INHERIT METAB DIS, V29, P317, DOI 10.1007/s10545-005-0243-2; D'Agostini F, 2013, ARCH DERMATOL RES, V305, P25, DOI 10.1007/s00403-012-1253-1; DALTON K, 1987, ACTA NEUROL SCAND, V76, P8, DOI 10.1111/j.1600-0404.1987.tb03536.x; de Vogel S, 2008, J NUTR, V138, P2372, DOI 10.3945/jn.108.091157; de Vogel S, 2011, CANCER EPIDEM BIOMAR, V20, P1726, DOI 10.1158/1055-9965.EPI-11-0359; DISORBO D M, 1983, Nutrition and Cancer, V5, P10, DOI 10.1080/01635588309513773; DISORBO D M, 1985, Nutrition and Cancer, V7, P43, DOI 10.1080/01635588509513838; DISORBO D M, 1982, Nutrition and Cancer, V3, P216, DOI 10.1080/01635588109513725; Dong LF, 2008, ONCOGENE, V27, P4324, DOI 10.1038/onc.2008.69; DRAUDINKRYLENKO VA, 1989, VOP ONKOL+, V35, P34; Eussen SJPM, 2010, CANCER EPIDEM BIOMAR, V19, P2549, DOI 10.1158/1055-9965.EPI-10-0407; Eussen SJPM, 2010, CANCER EPIDEM BIOMAR, V19, P28, DOI 10.1158/1055-9965.EPI-08-1096; FEDDE KN, 1990, AM J HUM GENET, V47, P767; Figueiredo JC, 2008, CANCER EPIDEM BIOMAR, V17, P2136, DOI 10.1158/1055-9965.EPI-07-2895; FOLKERS K, 1993, BIOCHEM BIOPH RES CO, V193, P88, DOI 10.1006/bbrc.1993.1593; FRIEDMAN MA, 1986, J AM ACAD DERMATOL, V14, P915, DOI 10.1016/S0190-9622(86)70112-6; Fritz V, 2010, ONCOGENE, V29, P4369, DOI 10.1038/onc.2010.182; Frohlich DA, 2008, ONCOGENE, V27, P4353, DOI 10.1038/onc.2008.79; GAILANI S, 1966, ANN INTERN MED, V65, P1044, DOI 10.7326/0003-4819-65-5-1044; GAILANI SD, 1968, CANCER-AM CANCER SOC, V21, P975, DOI 10.1002/1097-0142(196805)21:5&lt;975::AID-CNCR2820210522&gt;3.0.CO;2-3; Galeone C, 2006, ANN ONCOL, V17, P521, DOI 10.1093/annonc/mdj107; Galluzzi L, 2006, ONCOGENE, V25, P4812, DOI 10.1038/sj.onc.1209598; Galluzzi L, 2011, FRONT ONCOL, V1, P1; Galluzzi L, 2013, CELL CYCLE IN PRESS; Galluzzi L, 2012, CELL REP, V2, P257, DOI 10.1016/j.celrep.2012.06.017; Galluzzi L, 2012, NAT REV DRUG DISCOV, V11, P215, DOI 10.1038/nrd3626; Garcia-Closas R, 2007, EUR J CANCER, V43, P1731, DOI 10.1016/j.ejca.2007.05.007; Garg MB, 2011, CANCER CHEMOTH PHARM, V67, P963, DOI 10.1007/s00280-010-1476-9; Gdynia HJ, 2008, NEUROMUSCULAR DISORD, V18, P156, DOI 10.1016/j.nmd.2007.09.009; GEBHARD KJ, 1990, NUTR CANCER, V14, P15, DOI 10.1080/01635589009514074; Gong ZH, 2009, CANCER CAUSE CONTROL, V20, P1317, DOI 10.1007/s10552-009-9352-9; GRIDLEY DS, 1987, J NATL CANCER I, V78, P951; GRIMALDI T, 1971, Pathologica (Genoa), V63, P89; Gyorgy P, 1940, BIOCHEM J, V34, P1143; HA C, 1984, J NUTR, V114, P938, DOI 10.1093/jn/114.5.938; HA C, 1984, CELL IMMUNOL, V85, P318, DOI 10.1016/0008-8749(84)90246-6; Haberkorn U, 2011, ONCOGENE, V30, P4141, DOI 10.1038/onc.2011.169; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Harnack L, 2002, NUTR CANCER, V43, P152, DOI 10.1207/S15327914NC432_5; Harris HR, 2012, INT J CANCER, V131, pE518, DOI 10.1002/ijc.26455; Harrison LE, 1997, CANCER-AM CANCER SOC, V80, P1021; HOFSLI E, 1992, BIOTHERAPY, V5, P285, DOI 10.1007/BF02179046; Hong SW, 2013, ONCOGENE, V32, P1508, DOI 10.1038/onc.2012.176; Hotaling JM, 2011, J UROLOGY, V185, P1210, DOI 10.1016/j.juro.2010.11.081; Hubner RA, 2007, BRIT J CANCER, V97, P1449, DOI 10.1038/sj.bjc.6604056; INCULET RI, 1987, JPEN-PARENTER ENTER, V11, P243, DOI 10.1177/0148607187011003243; Ishihara J, 2007, J NUTR, V137, P1808, DOI 10.1093/jn/137.7.1808; Johansson M, 2010, JAMA-J AM MED ASSOC, V303, P2377, DOI 10.1001/jama.2010.808; Kaaks R, 1998, INT J CANCER, V78, P415, DOI 10.1002/(SICI)1097-0215(19981109)78:4&lt;415::AID-IJC4&gt;3.0.CO;2-X; Kanellis P, 2007, PLOS GENET, V3, P1438, DOI 10.1371/journal.pgen.0030134; Kayashima T, 2011, ONCOL LETT, V2, P1243, DOI 10.3892/ol.2011.370; Key TJA, 1997, BRIT J CANCER, V76, P678, DOI 10.1038/bjc.1997.445; King WD, 2012, MOL BIOL REP, V39, P7805, DOI 10.1007/s11033-012-1623-y; Komatsu S, 2003, BBA-PROTEINS PROTEOM, V1647, P127, DOI 10.1016/S1570-9639(03)00076-1; Komatsu S, 2002, J NUTR SCI VITAMINOL, V48, P65, DOI 10.3177/jnsv.48.65; Komatsu S, 2001, J NUTR, V131, P2204, DOI 10.1093/jn/131.8.2204; Komatsu SI, 2005, ONCOL REP, V14, P265; KORYTNYK W, 1977, J MED CHEM, V20, P745, DOI 10.1021/jm00216a002; KORYTNYK W, 1973, J MED CHEM, V16, P638, DOI 10.1021/jm00264a013; KORYTNYK W, 1976, J MED CHEM, V19, P999, DOI 10.1021/jm00230a003; KOSS LG, 1971, J NATL CANCER I, V46, P585; Kotsopoulos J, 2010, INT J CANCER, V126, P2191, DOI 10.1002/ijc.24723; KULCSAR G, 1995, CANCER BIOTHERAPY, V10, P157, DOI 10.1089/cbr.1995.10.157; Kulcsar G, 2013, INT J CANCER, V132, P1213, DOI 10.1002/ijc.27756; Kune G, 2006, NUTR CANCER, V56, P11, DOI 10.1207/s15327914nc5601_3; KURASHIGE S, 1988, JPN J EXP MED, V58, P197; Lajous M, 2006, CANCER EPIDEM BIOMAR, V15, P443, DOI 10.1158/1055-9965.EPI-05-0532; LAMM DL, 1994, J UROLOGY, V151, P21, DOI 10.1016/S0022-5347(17)34863-2; Larsson SC, 2005, GASTROENTEROLOGY, V128, P1830, DOI 10.1053/j.gastro.2005.03.005; Le Marchand L, 2011, CANCER CAUSE CONTROL, V22, P929, DOI 10.1007/s10552-011-9759-y; Le Marchand L, 2009, CANCER EPIDEM BIOMAR, V18, P2195, DOI 10.1158/1055-9965.EPI-09-0141; Lee JE, 2009, CANCER EPIDEM BIOMAR, V18, P1197, DOI 10.1158/1055-9965.EPI-08-1001; Lim U, 2005, AM J EPIDEMIOL, V162, P953, DOI 10.1093/aje/kwi310; Lim U, 2007, BLOOD, V109, P3050, DOI 10.1182/blood-2006-07-034330; Lim U, 2006, CANCER EPIDEM BIOMAR, V15, P1109, DOI 10.1158/1055-9965.EPI-05-0918; Lin J, 2008, AM J CLIN NUTR, V87, P734, DOI 10.1093/ajcn/87.3.734; LITTMAN ML, 1964, P SOC EXP BIOL MED, V116, P95, DOI 10.3181/00379727-116-29170; LUMENG L, 1974, J CLIN INVEST, V53, P693, DOI 10.1172/JCI107607; Lurie G, 2012, CANCER EPIDEM BIOMAR, V21, P1942, DOI 10.1158/1055-9965.EPI-12-0717-T; Ma E, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-122; Ma E, 2009, NUTR CANCER, V61, P447, DOI 10.1080/01635580802610123; Manegold C, 2009, J INHERIT METAB DIS, V32, P371, DOI 10.1007/s10545-009-1076-1; Marchand LL, 2002, CANCER CAUSE CONTROL, V13, P239, DOI 10.1023/A:1015057614870; Mayne ST, 2001, CANCER EPIDEM BIOMAR, V10, P1055; McCullough ML, 2004, ONCOGENE, V23, P6349, DOI 10.1038/sj.onc.1207716; Mehta R, 2011, TOXICOL IN VITRO, V25, P1114, DOI 10.1016/j.tiv.2011.03.015; MEISLER NT, 1982, CANCER RES, V42, P3538; MIHICH E, 1965, CANCER RES, V25, P794; MIHICH E, 1962, CANCER RES, V22, P218; Mills PB, 2006, NAT MED, V12, P307, DOI 10.1038/nm1366; Molina A, 1997, NUTR CANCER, V28, P206, DOI 10.1080/01635589709514576; NANDI DL, 1978, ARCH BIOCHEM BIOPHYS, V188, P266, DOI 10.1016/S0003-9861(78)80008-3; Negri E, 2000, INT J CANCER, V86, P122, DOI 10.1002/(SICI)1097-0215(20000401)86:1&lt;122::AID-IJC19&gt;3.0.CO;2-2; NEWLING DWW, 1995, EUR UROL, V27, P110, DOI 10.1159/000475139; NIKONOVA TV, 1988, EKSP ONKOL, V10, P17; Otani T, 2005, NUTR CANCER, V53, P42, DOI 10.1207/s15327914nc5301_5; PAIS RC, 1990, CANCER, V66, P2421, DOI 10.1002/1097-0142(19901201)66:11&lt;2421::AID-CNCR2820661130&gt;3.0.CO;2-M; Pelucchi C, 2009, ANN ONCOL, V20, P160, DOI 10.1093/annonc/mdn536; Pierotti MA, 2013, ONCOGENE, V32, P1475, DOI 10.1038/onc.2012.181; Polesel J, 2007, NUTR CANCER, V57, P146, DOI 10.1080/01635580701274202; POTERA C, 1977, AM J CLIN NUTR, V30, P1677, DOI 10.1093/ajcn/30.10.1677; RAMASWAMY P G, 1984, Nutrition and Cancer, V6, P176, DOI 10.1080/01635588509513821; Rauf Mariam, 2011, J Med Case Rep, V5, P372, DOI 10.1186/1752-1947-5-372; Ravasco P., 2005, Nutr. Hosp., V20, P165; RIGGS TR, 1953, BIOCHIM BIOPHYS ACTA, V11, P303, DOI 10.1016/0006-3002(53)90041-9; Rosenthal GA, 1997, LIFE SCI, V60, P1635, DOI 10.1016/S0024-3205(96)00595-4; Roth-Maier DA, 2002, INT J FOOD SCI NUTR, V53, P171, DOI 10.1080/09637480220132184; SCHAUMBURG H, 1983, NEW ENGL J MED, V309, P445, DOI 10.1056/NEJM198308253090801; Schemhammer ES, 2008, CANCER EPIDEM BIOMAR, V17, P2895, DOI 10.1158/1055-9965.EPI-08-0638; Schernhammer E, 2007, CANCER RES, V67, P5553, DOI 10.1158/0008-5472.CAN-06-4463; Schernhammer ES, 2008, GASTROENTEROLOGY, V135, P770, DOI 10.1053/j.gastro.2008.06.033; Schernhammer ES, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021102; SCHNACKERZ KD, 1983, J BIOL CHEM, V258, P872; SCHWAN TJ, 1965, J MED CHEM, V8, P750, DOI 10.1021/jm00330a004; Selhub J, 1999, ANNU REV NUTR, V19, P217, DOI 10.1146/annurev.nutr.19.1.217; Semeraro N, 1970, Pathologica, V62, P133; Sharp L, 2008, BRIT J NUTR, V99, P379, DOI 10.1017/S0007114507801073; Shi QL, 2005, CANCER EPIDEM BIOMAR, V14, P1477, DOI 10.1158/1055-9965.EPI-04-0905; Shimada D, 2006, BIOSCI BIOTECH BIOCH, V70, P1038, DOI 10.1271/bbb.70.1038; Shimada D, 2005, NUTR CANCER, V53, P202, DOI 10.1207/s15327914nc5302_9; SHULTZ TD, 1988, ANTICANCER RES, V8, P1313; Slattery ML, 1999, CANCER EPIDEM BIOMAR, V8, P513; STOERK HC, 1950, P SOC EXP BIOL MED, V74, P798, DOI 10.3181/00379727-74-18053; Swaffar DS, 1999, ANTI-CANCER DRUG, V10, P113, DOI 10.1097/00001813-199901000-00014; Takeuchi PL, 2007, TOXICOL IN VITRO, V21, P665, DOI 10.1016/j.tiv.2007.01.004; Theodoratou E, 2008, CANCER EPIDEM BIOMAR, V17, P171, DOI 10.1158/1055-9965.EPI-07-0621; Toney MD, 2005, ARCH BIOCHEM BIOPHYS, V433, P279, DOI 10.1016/j.abb.2004.09.037; TREBUKHINA R V, 1982, Voprosy Pitaniya, P40; Tryfiates G P, 1981, Cancer Detect Prev, V4, P159; TRYFIATES GP, 1974, JNCI-J NATL CANCER I, V52, P1259, DOI 10.1093/jnci/52.4.1259; TRYFIATES GP, 1981, ANTICANCER RES, V1, P263; TRYFIATES GP, 1974, EUR J CANCER, V10, P147, DOI 10.1016/0014-2964(74)90147-9; TRYFIATES GP, 1976, ONCOLOGY, V33, P209, DOI 10.1159/000225146; TRYFIATES GP, 1975, J NATL CANCER I, V54, P171, DOI 10.1093/jnci/54.1.171; Tryfiates GP, 1996, CANCER RES, V56, P3670; TRYFIATES GP, 1991, ANTICANCER RES, V11, P1281; TRYFIATES GP, 1995, ANTICANCER RES, V15, P379; TRYFIATES GP, 1983, ANTICANCER RES, V3, P53; Tucker KL, 2004, AM J CLIN NUTR, V79, P805; Venkateswaran V, 2004, CANCER RES, V64, P5891, DOI 10.1158/0008-5472.CAN-04-0690; Vidal AC, 2012, J CANCER EPIDEMIOL, V2012, DOI 10.1155/2012/957467; Vitale I, 2011, NAT REV MOL CELL BIO, V12, P384, DOI 10.1038/nrm3115; Wei EK, 2005, J NATL CANCER I, V97, P684, DOI 10.1093/jnci/dji116; Weinstein SJ, 2003, CANCER EPIDEM BIOMAR, V12, P1271; Weinstein SJ, 2008, CANCER EPIDEM BIOMAR, V17, P3233, DOI 10.1158/1055-9965.EPI-08-0459; WILLIAMS RD, 1984, CANCER RES, V44, P1918; WOLF H, 1979, SCAND J UROL NEPHROL, V13, P143, DOI 10.3109/00365597909181169; YUSPA SH, 1966, P SOC EXP BIOL MED, V123, P398, DOI 10.3181/00379727-123-31498; Zhang CX, 2011, BRIT J NUTR, V106, P936, DOI 10.1017/S0007114511001140; Zhang SMM, 2008, JAMA-J AM MED ASSOC, V300, P2012, DOI 10.1001/jama.2008.555; Zhang SM, 2006, AM J EPIDEMIOL, V163, P108, DOI 10.1093/aje/kwj016; Zhang SM, 2003, J NATL CANCER I, V95, P373, DOI 10.1093/jnci/95.5.373; Zhang XH, 2012, AM J CLIN NUTR, V96, P874, DOI 10.3945/ajcn.112.037267; Zhang ZF, 1997, NUTR CANCER, V27, P298, DOI 10.1080/01635589709514541; Zitvogel L, 2006, NAT REV IMMUNOL, V6, P715, DOI 10.1038/nri1936	170	87	91	2	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2013	32	42					4995	5004		10.1038/onc.2012.623	http://dx.doi.org/10.1038/onc.2012.623			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238IB	23334322				2022-12-28	WOS:000325937900001
J	Lahoz, A; Hall, A				Lahoz, A.; Hall, A.			A tumor suppressor role for srGAP3 in mammary epithelial cells	ONCOGENE			English	Article						srGAP; Rac; tumor suppressor; breast cancer; anchorage-independent growth	F-BAR DOMAIN; BREAST-CANCER; GENE-EXPRESSION; RHO-GTPASES; NEURONAL MIGRATION; RAC; MEMBRANE; PROTEINS; WAVE-1; KINASE	srGAP3, a member of the Slit-Robo sub-family of Rho GTPase-activating proteins (Rho GAPs), controls actin and microtubule dynamics through negative regulation of Rac. Here, we describe a potential role for srGAP3 as a tumor suppressor in mammary epithelial cells. We show that RNAi-mediated depletion of srGAP3 promotes Rac dependent, anchorage-independent growth of partially transformed human mammary epithelial cells (HMECs). Furthermore, srGAP3 expression is absent, or significantly reduced in 7/10 breast cancer cell lines compared with normal HMECs. Re-expression of srGAP3 in a subset of these cell lines inhibits both anchorage-independent growth and cell invasion in a GAP-dependent manner, and this is accompanied by an increase in phosphorylation of the ezrin/radixin/moesin (ERM) family proteins and myosin light chain 2 (MLC2). Inhibition of the Rho regulated kinase, ROCK, reduces ERM and MLC2 phosphorylation and restores invasion. We conclude that srGAP3 has tumor suppressor-like activity in HMECs, likely through its activity as a negative regulator of Rac1.	[Lahoz, A.; Hall, A.] Mem Sloan Kettering Canc Ctr, Cell Biol Program, New York, NY 10065 USA	Memorial Sloan Kettering Cancer Center	Hall, A (corresponding author), Mem Sloan Kettering Canc Ctr, Cell Biol Programn, 1275 York Ave, New York, NY 10065 USA.	halla@mskcc.org			Fundacion Caja Madrid, Spain; MSKCC Geoffrey Beene Cancer Research Center Grant	Fundacion Caja Madrid, Spain; MSKCC Geoffrey Beene Cancer Research Center Grant	We thank William C Hahn, Dana-Farber Cancer Institute, for providing the cell line HMEC/hTERT/LT/c-myc and John D Scott, University of Washington, for the gift of pCDNA3.1-WRP-V5His and pCDNA3.1-WRP Delta GAP-V5His plasmids. We also thank Memorial Sloan-Kettering Cancer Center Molecular Cytogenetics Core facility for performing the FISH assays, the Bioinformatic Core facility for the analysis of the microarray data and Overholtzer laboratories for critical reading of the manuscript and helpful discussions. This work was supported by Fundacion Caja Madrid, Spain (AL) and by an MSKCC Geoffrey Beene Cancer Research Center Grant (AH).	Aspenstrom P, 2009, INT REV CEL MOL BIO, V272, P1, DOI 10.1016/S1937-6448(08)01601-8; Carlson BR, 2011, J NEUROSCI, V31, P2447, DOI 10.1523/JNEUROSCI.4433-10.2011; Chen K, 2011, CELL MOL NEUROBIOL, V31, P675, DOI 10.1007/s10571-011-9664-7; Counter CM, 1998, ONCOGENE, V16, P1217, DOI 10.1038/sj.onc.1201882; Ellenbroek SIJ, 2007, CLIN EXP METASTAS, V24, P657, DOI 10.1007/s10585-007-9119-1; Endris V, 2002, P NATL ACAD SCI USA, V99, P11754, DOI 10.1073/pnas.162241099; Endris V, 2011, J CELL SCI, V124, P3941, DOI 10.1242/jcs.077081; Guerrier S, 2009, CELL, V138, P990, DOI 10.1016/j.cell.2009.06.047; Guo YJ, 2002, J BIOL CHEM, V277, P41571, DOI 10.1074/jbc.M201864200; Han J, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000684; IKEBE M, 1985, J BIOL CHEM, V260, P27; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kristensen LS, 2009, EUR J PHARMACOL, V625, P131, DOI 10.1016/j.ejphar.2009.10.011; Lazer G, 2011, CELL SIGNAL, V23, P969, DOI 10.1016/j.cellsig.2010.10.022; Lorentzen A, 2011, J CELL SCI, V124, P1256, DOI 10.1242/jcs.074849; Madura T, 2004, MOL BRAIN RES, V123, P76, DOI 10.1016/j.molbrainres.2004.01.002; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Radvanyi L, 2005, P NATL ACAD SCI USA, V102, P11005, DOI 10.1073/pnas.0500904102; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043; Shuib S, 2009, AM J MED GENET A, V149A, P2099, DOI 10.1002/ajmg.a.32824; Soderling SH, 2007, J NEUROSCI, V27, P355, DOI 10.1523/JNEUROSCI.3209-06.2006; Soderling SH, 2003, P NATL ACAD SCI USA, V100, P1723, DOI 10.1073/pnas.0438033100; Soderling SH, 2002, NAT CELL BIOL, V4, P970, DOI 10.1038/ncb886; Sosa MS, 2010, MOL CELL, V40, P877, DOI 10.1016/j.molcel.2010.11.029; Tang YA, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012417; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Westbrook TF, 2005, CELL, V121, P837, DOI 10.1016/j.cell.2005.03.033; Wong K, 2001, CELL, V107, P209, DOI 10.1016/S0092-8674(01)00530-X; Xue W, 2008, GENE DEV, V22, P1439, DOI 10.1101/gad.1672608; Yang CF, 2007, BIOCHEM J, V403, P1, DOI 10.1042/bj20061750; Yang Y, 2006, EXP CELL RES, V312, P2379, DOI 10.1016/j.yexcr.2006.04.001; Zajchowski DA, 2001, CANCER RES, V61, P5168; Zhao HJ, 2004, MOL BIOL CELL, V15, P2523, DOI 10.1091/mbc.E03-11-0786; Zhao JJ, 2003, CANCER CELL, V3, P483, DOI 10.1016/S1535-6108(03)00088-6; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	38	24	25	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	2013	32	40					4854	4860		10.1038/onc.2012.489	http://dx.doi.org/10.1038/onc.2012.489			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229NW	23108406				2022-12-28	WOS:000325274700014
J	Pandolfi, S; Montagnani, V; Penachioni, JY; Vinci, MC; Olivito, B; Borgognoni, L; Stecca, B				Pandolfi, S.; Montagnani, V.; Penachioni, J. Y.; Vinci, M. C.; Olivito, B.; Borgognoni, L.; Stecca, B.			WIP1 phosphatase modulates the Hedgehog signaling by enhancing GLI1 function	ONCOGENE			English	Article						Hedgehog; GLI1; WIP1; melanoma; xenograft; self-renewal; cancer stem cells	BASAL-CELL CARCINOMA; STEM-CELL; WILD-TYPE; PROTEIN PHOSPHATASE; SELF-RENEWAL; IN-VITRO; WIP1-DEPENDENT REGULATION; TUMOR-SUPPRESSOR; POOR-PROGNOSIS; HUMAN HOMOLOG	The Hedgehog-GLI (HH-GLI) signaling plays a critical role in controlling growth and tissue patterning during embryogenesis and is implicated in a variety of human malignancies, including those of the skin. Phosphorylation events have been shown to regulate the activity of the GLI transcription factors, the final effectors of the HH-GLI signaling pathway. Here, we show that WIP1 (or PPM1D), an oncogenic phosphatase amplified/overexpressed in several types of human cancer, is a positive modulator of the HH signaling. Mechanistically, WIP1 enhances the function of GLI1 by increasing its transcriptional activity, nuclear localization and protein stability, but not of GLI2 nor GLI3. We also find that WIP1 and GLI1 are in a complex. Modulation of the transcriptional activity of GLI1 by WIP1 depends on the latter's phosphatase activity and, remarkably, does not require p53, a known WIP1 target. Functionally, we find that WIP1 is required for melanoma and breast cancer cell proliferation and self-renewal in vitro and melanoma xenograft growth induced by activation of the HH signaling. Pharmacological blockade of the HH pathway with the SMOOTHENED antagonist cyclopamine acts synergistically with inhibition of WIP1 in reducing growth of melanoma and breast cancer cells in vitro. Overall, our data uncover a role for WIP1 in modulating the activity of GLI1 and in sustaining cancer cell growth and cancer stem cell self-renewal induced by activation of the HH pathway. These findings open a novel therapeutic approach for human melanomas and, possibly, other cancer types expressing WIP1 and with activated HH pathway.	[Pandolfi, S.; Montagnani, V.; Penachioni, J. Y.; Vinci, M. C.; Stecca, B.] Ist Toscani Tumori CRL ITT, Core Res Lab, Tumor Cell Biol Lab, I-50134 Florence, Italy; [Olivito, B.] Anna Meyer Childrens Hosp, Dept Pediat, Immunol Unit, Florence, Italy; [Borgognoni, L.] Ist Toscani Tumori, SM Annunziata Hosp, Reg Melanoma Referral Ctr, Plast Surg Unit, Florence, Italy	ISPRO Istituto per lo studio, la prevenzione e la rete oncologica; University of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; ISPRO Istituto per lo studio, la prevenzione e la rete oncologica	Stecca, B (corresponding author), Ist Toscani Tumori CRL ITT, Core Res Lab, Tumor Cell Biol Lab, Vle Morgagni 50, I-50134 Florence, Italy.	barbara.stecca@ittumori.it	Vinci, Maria Cristina/E-7401-2016; Borgognoni, Lorenzo/X-1981-2019; Stecca, Barbara/J-7209-2016	Vinci, Maria Cristina/0000-0001-6323-147X; Borgognoni, Lorenzo/0000-0002-3571-0366; Stecca, Barbara/0000-0003-1197-1622; OLIVITO, BIAGIO/0000-0002-4479-0708	Associazione Italiana per la Ricerca sul Cancro (AIRC) [9566]; Regional Health Research Program; Fondazione Cassa di Risparmio di Firenze; AIRC fellowship	Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro); Regional Health Research Program; Fondazione Cassa di Risparmio di Firenze(Fondazione Cassa Risparmio Firenze); AIRC fellowship(Fondazione AIRC per la ricerca sul cancro)	We thank G Del Sal, A Ruiz i Altaba, L Luzzatto for helpful comments on the paper and discussion. We are grateful to G Del Sal (Laboratorio Nazionale CIB, Padriciano, Italy) for HCT116 p53wt and p53ko cells, A Ruiz i Altaba (University of Geneva, Geneva, Switzerland), H Sasaki (NCCRI, Tokyo, Japan), RH Medema (University of Utrecht, Utrecht, The Netherlands) for plasmids, G Gerlini (S Maria Annunziata Hospital, Florence, Italy) for help in obtaining samples, E Rovida (University of Florence, Florence, Italy) for assistance with confocal microscopy. This work was supported by grants from Associazione Italiana per la Ricerca sul Cancro (AIRC, 9566), Regional Health Research Program 2009 and Fondazione Cassa di Risparmio di Firenze to BS. SP was supported by AIRC fellowship.	Abe Y, 2008, P NATL ACAD SCI USA, V105, P4838, DOI 10.1073/pnas.0712216105; Beachy PA, 2004, NATURE, V432, P324, DOI 10.1038/nature03100; Bulavin DV, 2004, NAT GENET, V36, P343, DOI 10.1038/ng1317; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Castellino RC, 2008, J NEURO-ONCOL, V86, P245, DOI 10.1007/s11060-007-9470-8; CASTRESANA JS, 1993, INT J CANCER, V55, P562, DOI 10.1002/ijc.2910550407; Cha H, 2010, CANCER RES, V70, P4112, DOI 10.1158/0008-5472.CAN-09-4244; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; Chin L, 2006, GENE DEV, V20, P2149, DOI 10.1101/gad.1437206; Choi J, 2002, MOL CELL BIOL, V22, P1094, DOI 10.1128/MCB.22.4.1094-1105.2002; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; Corbit KC, 2005, NATURE, V437, P1018, DOI 10.1038/nature04117; Das S, 2009, J BIOL CHEM, V284, P22888, DOI 10.1074/jbc.M109.021949; Demidov ON, 2007, ONCOGENE, V26, P2502, DOI 10.1038/sj.onc.1210032; Demidov ON, 2007, CELL STEM CELL, V1, P180, DOI 10.1016/j.stem.2007.05.020; Dennler S, 2007, CANCER RES, V67, P6981, DOI 10.1158/0008-5472.CAN-07-0491; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Doucette TA, 2012, NEUROSURGERY, V70, P1003, DOI 10.1227/NEU.0b013e31823e5332; Eberl M, 2012, EMBO MOL MED, V4, P218, DOI 10.1002/emmm.201100201; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fiscella M, 1997, P NATL ACAD SCI USA, V94, P6048, DOI 10.1073/pnas.94.12.6048; Fujimoto H, 2006, CELL DEATH DIFFER, V13, P1170, DOI 10.1038/sj.cdd.4401801; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hayashi R, 2011, BIOCHEMISTRY-US, V50, P4537, DOI 10.1021/bi101949t; Hershko T, 2006, J BIOL CHEM, V281, P31309, DOI 10.1074/jbc.M601758200; Hirasawa A, 2003, CLIN CANCER RES, V9, P1995; Huntzicker EG, 2006, GENE DEV, V20, P276, DOI 10.1101/gad.1380906; Ingham PW, 2001, GENE DEV, V15, P3059, DOI 10.1101/gad.938601; Jia H, 2009, DEVELOPMENT, V136, P307, DOI 10.1242/dev.030015; Jiang J, 2008, DEV CELL, V15, P801, DOI 10.1016/j.devcel.2008.11.010; Jin ZG, 2011, J BIOL CHEM, V286, P36171, DOI 10.1074/jbc.M111.274761; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kasper M, 2006, MOL CELL BIOL, V26, P6283, DOI 10.1128/MCB.02317-05; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Krauss S, 2008, CANCER RES, V68, P4658, DOI 10.1158/0008-5472.CAN-07-6174; Krauss S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007471; Lai K, 2004, BIOPHYS J, V86, P2748, DOI 10.1016/S0006-3495(04)74328-3; Lai K, 2003, NAT NEUROSCI, V6, P21, DOI 10.1038/nn983; Le Guezennec X, 2012, CELL METAB, V16, P68, DOI 10.1016/j.cmet.2012.06.003; Li J, 2002, NAT GENET, V31, P133, DOI 10.1038/ng888; Liang CH, 2012, BRAIN RES, V1444, P65, DOI 10.1016/j.brainres.2011.12.052; Lindqvist A, 2009, EMBO J, V28, P3196, DOI 10.1038/emboj.2009.246; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; Low JA, 2010, J CLIN ONCOL, V28, P5321, DOI 10.1200/JCO.2010.27.9943; Lu XB, 2005, GENE DEV, V19, P1162, DOI 10.1101/gad.1291305; Lu XB, 2008, CANCER METAST REV, V27, P123, DOI 10.1007/s10555-008-9127-x; Lu XB, 2007, CANCER CELL, V12, P342, DOI 10.1016/j.ccr.2007.08.033; Nannenga B, 2006, MOL CARCINOGEN, V45, P594, DOI 10.1002/mc.20195; Ng JMY, 2011, NAT REV CANCER, V11, P493, DOI 10.1038/nrc3079; Nolan-Stevaux O, 2009, GENE DEV, V23, P24, DOI 10.1101/gad.1753809; Pan Y, 2007, J BIOL CHEM, V282, P10846, DOI 10.1074/jbc.M608599200; Parssinen J, 2008, CANCER GENET CYTOGEN, V182, P33, DOI 10.1016/j.cancergencyto.2007.12.013; Peacock CD, 2007, P NATL ACAD SCI USA, V104, P4048, DOI 10.1073/pnas.0611682104; Rayter S, 2008, ONCOGENE, V27, P1036, DOI 10.1038/sj.onc.1210729; Roessler E, 2005, HUM MOL GENET, V14, P2181, DOI 10.1093/hmg/ddi222; Rohatgi R, 2007, NAT CELL BIOL, V9, P1005, DOI 10.1038/ncb435; Rohatgi R, 2007, SCIENCE, V317, P372, DOI 10.1126/science.1139740; Rorick AM, 2007, DEV BIOL, V302, P477, DOI 10.1016/j.ydbio.2006.10.011; Santini R, 2012, STEM CELLS, V30, P1808, DOI 10.1002/stem.1160; Sasaki H, 1997, DEVELOPMENT, V124, P1313; Shreeram S, 2006, MOL CELL, V23, P757, DOI 10.1016/j.molcel.2006.07.010; Stecca B, 2007, P NATL ACAD SCI USA, V104, P5895, DOI 10.1073/pnas.0700776104; Stecca B, 2010, J MOL CELL BIOL, V2, P84, DOI 10.1093/jmcb/mjp052; Stecca B, 2009, EMBO J, V28, P663, DOI 10.1038/emboj.2009.16; Taipale J, 2000, NATURE, V406, P1005, DOI 10.1038/35023008; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Teglund S, 2010, BBA-REV CANCER, V1805, P181, DOI 10.1016/j.bbcan.2010.01.003; Varjosalo M, 2008, GENE DEV, V22, P2454, DOI 10.1101/gad.1693608; Varnat F, 2009, EMBO MOL MED, V1, P338, DOI 10.1002/emmm.200900039; Wang Y, 2012, CANCER CELL, V21, P374, DOI 10.1016/j.ccr.2011.12.028; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Yamaguchi H, 2006, BIOCHEMISTRY-US, V45, P13193, DOI 10.1021/bi061356b; Zhang XN, 2010, CANCER RES, V70, P7176, DOI 10.1158/0008-5472.CAN-10-0697; Zhu YH, 2009, STEM CELLS, V27, P1433, DOI 10.1002/stem.65	75	38	39	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2013	32	40					4737	4747		10.1038/onc.2012.502	http://dx.doi.org/10.1038/onc.2012.502			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229NW	23146903				2022-12-28	WOS:000325274700002
J	Kliese, N; Gobrecht, P; Pachow, D; Andrae, N; Wilisch-Neumann, A; Kirches, E; Riek-Burchardt, M; Angenstein, F; Reifenberger, G; Riemenschneider, MJ; Meese, E; Panayotova-Dimitrova, D; Gutmann, DH; Mawrin, C				Kliese, N.; Gobrecht, P.; Pachow, D.; Andrae, N.; Wilisch-Neumann, A.; Kirches, E.; Riek-Burchardt, M.; Angenstein, F.; Reifenberger, G.; Riemenschneider, M. J.; Meese, E.; Panayotova-Dimitrova, D.; Gutmann, D. H.; Mawrin, C.			miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells	ONCOGENE			English	Article						miRNA; meningioma; invasion; collagen type 5	EXPRESSION; GENE; GROWTH; BRAIN; LINE; ESTABLISHMENT; MICRORNA-145; INVASIVENESS; MUTATIONS; TARGET	Meningiomas are frequent, mostly benign intracranial or spinal tumors. A small subset of meningiomas is characterized by histological features of atypia or anaplasia that are associated with more aggressive biological behavior resulting in increased morbidity and mortality. Infiltration into the adjacent brain tissue is a major factor linked to higher recurrence rates. The molecular mechanisms of progression, including brain invasion are still poorly understood. We have studied the role of micro-RNA 145 (miR-145) in meningiomas and detected significantly reduced miR-145 expression in atypical and anaplastic tumors as compared with benign meningiomas. Overexpression of miR-145 in IOMM-Lee meningioma cells resulted in reduced proliferation, increased sensitivity to apoptosis, reduced anchorage-independent growth and reduction of orthotopic tumor growth in nude mice as compared with control cells. Moreover, meningioma cells with high miR-145 levels had impaired migratory and invasive potential in vitro and in vivo. PCR-array studies of miR145-overexpressing cells suggested that collagen type V alpha (COL5A1) expression is downregulated by miR-145 overexpression. Accordingly, COL5A1 expression was significantly upregulated in atypical and anaplastic meningiomas. Collectively, our data indicate an important anti-migratory and anti-proliferative function of miR-145 in meningiomas.	[Kliese, N.; Gobrecht, P.; Pachow, D.; Andrae, N.; Wilisch-Neumann, A.; Kirches, E.; Mawrin, C.] Otto Von Guericke Univ, Inst Neuropathol, D-39120 Magdeburg, Germany; [Riek-Burchardt, M.] Leibniz Inst Neurobiol, Project Grp Neuropharmacol, Magdeburg, Germany; [Angenstein, F.] Leibniz Inst Neurobiol, Lab Noninvas Anim Imaging, Magdeburg, Germany; [Reifenberger, G.] Univ Dusseldorf, Dept Neuropathol, D-40225 Dusseldorf, Germany; [Riemenschneider, M. J.] Regensburg Univ Hosp, Dept Neuropathol, Regensburg, Germany; [Meese, E.] Univ Saarland, Dept Human Genet, Homburg, Germany; [Panayotova-Dimitrova, D.] Heidelberg Univ, Dept Dermatol, Heidelberg, Germany; [Gutmann, D. H.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Otto von Guericke University; Leibniz Institut fur Neurobiologie (LIN); Leibniz Institut fur Neurobiologie (LIN); Heinrich Heine University Dusseldorf; University of Regensburg; Saarland University; Ruprecht Karls University Heidelberg; Washington University (WUSTL)	Mawrin, C (corresponding author), Otto Von Guericke Univ, Inst Neuropathol, Leipziger St 44, D-39120 Magdeburg, Germany.	christian.mawrin@med.ovgu.de	Meese, Eckart Ulrich/ABD-1983-2021; Reifenberger, Guido/AAE-3599-2019	Gutmann, David/0000-0002-3127-5045	Wilhelm Sander-Stiftung [2010.017.1]	Wilhelm Sander-Stiftung	The skillful technical work of Ines Schellhase, Ines Meyer and Sandra Hartmann is highly appreciated. We thank Professor Till Acker (University of Giessen) for help with the morphometric quantification of tumor infiltration in mice and Grit Werner for her help with MR imaging. The work was supported by the Wilhelm Sander-Stiftung (grant #2010.017.1).	BLACK PM, 1993, NEUROSURGERY, V32, P643, DOI 10.1227/00006123-199304000-00023; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; DePaepe A, 1997, AM J HUM GENET, V60, P547; Gao P, 2013, ONCOGENE, V32, P491, DOI 10.1038/onc.2012.61; Gotte M, 2010, ONCOGENE, V29, P6569, DOI 10.1038/onc.2010.386; Haase D, 2010, NEURO-ONCOLOGY, V12, P844, DOI 10.1093/neuonc/noq004; Kilic T, 2002, NEUROSURGERY, V51, P183, DOI 10.1227/01.NEU.0000017466.25827.18; Kirches E, 2011, LAB INVEST, V91, P1766, DOI 10.1038/labinvest.2011.130; Koo S, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-143; La Rocca G, 2009, CELL CYCLE, V8, P2255, DOI 10.4161/cc.8.14.9026; LEE WH, 1990, NEUROSURGERY, V27, P389, DOI 10.1227/00006123-199009000-00008; Liang SL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018409; Mawrin C, 2010, J NEURO-ONCOL, V99, P379, DOI 10.1007/s11060-010-0342-2; Mawrin C, 2010, BRAIN PATHOL, V20, P200, DOI 10.1111/j.1750-3639.2009.00267.x; NITTA H, 1990, HISTOL HISTOPATHOL, V5, P267; Nordqvist ACS, 2001, J NEUROSURG, V95, P839, DOI 10.3171/jns.2001.95.5.0839; Perry A, 1999, CANCER, V85, P2046, DOI 10.1002/(SICI)1097-0142(19990501)85:9<2046::AID-CNCR23>3.0.CO;2-M; Puttmann S, 2005, LAB INVEST, V85, P1163, DOI 10.1038/labinvest.3700307; Ragel BT, 2008, SURG NEUROL, V70, P295, DOI 10.1016/j.surneu.2007.06.031; Saydam O, 2009, MOL CELL BIOL, V29, P5923, DOI 10.1128/MCB.00332-09; Schittenhelm J, 2006, NEUROPATH APPL NEURO, V32, P525, DOI 10.1111/j.1365-2990.2006.00761.x; Shi B, 2007, J BIOL CHEM, V282, P32582, DOI 10.1074/jbc.M702806200; Stuart JE, 2011, J NEUROPATH EXP NEUR, V70, P1, DOI 10.1097/NEN.0b013e3182018f1c; Suh SO, 2011, CARCINOGENESIS, V32, P772, DOI 10.1093/carcin/bgr036; Symoens S, 2009, HUM MUTAT, V30, pE395, DOI 10.1002/humu.20887; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637; TANAKA K, 1989, CANCER, V64, P2243, DOI 10.1002/1097-0142(19891201)64:11<2243::AID-CNCR2820641110>3.0.CO;2-S; Watson MA, 2002, AM J PATHOL, V161, P665, DOI 10.1016/S0002-9440(10)64222-8; Wenstrup RJ, 2006, J BIOL CHEM, V281, P12888, DOI 10.1074/jbc.M511528200; Zaman MS, 2010, BRIT J CANCER, V103, P256, DOI 10.1038/sj.bjc.6605742	30	50	52	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2013	32	39					4712	4720		10.1038/onc.2012.468	http://dx.doi.org/10.1038/onc.2012.468			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226YD	23108408	hybrid			2022-12-28	WOS:000325072200013
J	Berglund, FM; Weerasinghe, NR; Davidson, L; Lim, JC; Eickholt, BJ; Leslie, NR				Berglund, F. M.; Weerasinghe, N. R.; Davidson, L.; Lim, J. C.; Eickholt, B. J.; Leslie, N. R.			Disruption of epithelial architecture caused by loss of PTEN or by oncogenic mutant p110 alpha/PIK3CA but not by HER2 or mutant AKT1	ONCOGENE			English	Article						phosphoinositides; phosphoinositide 3-kinase; epithelia; breast cancer; AKT; cell polarity	LIPID PHOSPHATASE PTEN; CELL-POLARITY; PIK3CA MUTATIONS; BREAST-CANCER; MAMMARY-GLAND; PROLIFERATION; MORPHOGENESIS; TUMORIGENESIS; PATHWAY; EXPRESSION	Genetic changes in HER2, PTEN, PIK3CA and AKT1 are all common in breast cancer and lead to the elevated phosphorylation of downstream targets of the PI3K/AKT signalling pathway. Changes in HER2, PTEN, PIK3CA and AKT have all been reported to lead to both enhanced proliferation and failures in hollow lumen formation in three dimensional epithelial culture models, but it is not clear whether these failures in lumen formation are caused by any failure in the spatial coordination of lumen formation (hollowing) or purely a failure in the apoptosis and clearance of luminal cells (cavitation). Here, we use normal murine mammary gland (NMuMG) epithelial cells, which form a hollow lumen without significant apoptosis, to compare the transformation by these four genetic changes. We find that either mutant PIK3CA expression or PTEN loss, but not mutant AKT1 E17K, cause disrupted epithelial architecture, whereas HER2 overexpression drives strong proliferation without affecting lumen formation in these cells. We also show that PTEN requires both lipid and protein phosphatase activity, its extreme C-terminal PDZ binding sequence and probably Myosin 5A to control lumen formation through a mechanism that does not correlate with its ability to control AKT, but which is selectively lost through mutation in some tumours. These findings correlate AKT-independent signalling activated by mutant PIK3CA or PTEN loss, but not strongly by HER2, with disrupted epithelial architecture and tumour formation.	[Berglund, F. M.; Weerasinghe, N. R.; Davidson, L.; Lim, J. C.; Leslie, N. R.] Univ Dundee, Coll Life Sci, Div Cell Signalling & Immunol, Dundee DD1 5EH, Scotland; [Eickholt, B. J.] Charite, Cluster Excellence NeuroCure, D-13353 Berlin, Germany; [Eickholt, B. J.] Inst Biochem, Berlin, Germany	University of Dundee; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Leslie, NR (corresponding author), Univ Dundee, Coll Life Sci, Div Cell Signalling & Immunol, Dow St, Dundee DD1 5EH, Scotland.	n.r.leslie@dundee.ac.uk	Eickholt, Britta/C-5337-2009	LESLIE, Nicholas/0000-0001-5131-0541; Eickholt, Britta/0000-0001-7873-8687	Association for International Cancer Research; Wellcome Trust; Medical Research Council; DSTT consortium (Astra Zeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck Serono and Pfizer); Medical Research Council [G9403619, G0801865, G0802289] Funding Source: researchfish; MRC [G0802289, G0801865, G9403619] Funding Source: UKRI	Association for International Cancer Research; Wellcome Trust(Wellcome Trust); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); DSTT consortium (Astra Zeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck Serono and Pfizer); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank Jon Backer (Albert Einstein College of Medicine) and Dario Alessi, David Meek, Francis Fuller-Pace, Virginia Appleyard, Alastair Thompson, Emily Davis, John Rouse, Inke Nathke and Paul Crocker (all University of Dundee) for reagents and Peter Downes (University of Dundee) for helpful discussions. We thank Sam Swift, Paul Appleton, Martin Kierans and John James (University of Dundee, CHIPS microscopy facility) for assistance with light and electron microscopy. FB and JCL have been funded by a project grant from the Association for International Cancer Research and NRW is a Wellcome Trust Prize Student. Work in the Inositol Lipid Signalling laboratory is funded by the Medical Research Council, the Association for International Cancer Research and the pharmaceutical companies of the DSTT consortium (Astra Zeneca, Boehringer Ingelheim, GlaxoSmithKline, Merck Serono and Pfizer). We wish to dedicate this work to the memory of Joseph Lim, a valued colleague and friend.	Carpten JD, 2007, NATURE, V448, P439, DOI 10.1038/nature05933; Datta A, 2011, CURR BIOL, V21, pR126, DOI 10.1016/j.cub.2010.12.003; Davidson L, 2010, ONCOGENE, V29, P687, DOI 10.1038/onc.2009.384; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Debnath J, 2003, J CELL BIOL, V163, P315, DOI 10.1083/jcb.200304159; Debnath J, 2002, CELL, V111, P29, DOI 10.1016/S0092-8674(02)01001-2; Dillon RL, 2009, CANCER RES, V69, P5057, DOI 10.1158/0008-5472.CAN-08-4287; Dunlap J, 2010, BREAST CANCER RES TR, V120, P409, DOI 10.1007/s10549-009-0406-1; Duronio V, 2008, BIOCHEM J, V415, P333, DOI 10.1042/BJ20081056; Feng W, 2008, J BIOL CHEM, V283, P23440, DOI 10.1074/jbc.M802482200; Gonzalez-Angulo AM, 2009, CLIN CANCER RES, V15, P2472, DOI 10.1158/1078-0432.CCR-08-1763; Han SY, 2000, CANCER RES, V60, P3147; Hogan C, 2009, NAT CELL BIOL, V11, P460, DOI 10.1038/ncb1853; Isakoff SJ, 2005, CANCER RES, V65, P10992, DOI 10.1158/0008-5472.CAN-05-2612; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kim JW, 2008, GENE DEV, V22, P3147, DOI 10.1101/gad.1700108; Knobbe CB, 2008, ONCOGENE, V27, P5398, DOI 10.1038/onc.2008.238; Lauring J, 2010, ONCOGENE, V29, P2337, DOI 10.1038/onc.2009.516; Leslie NR, 2008, ONCOGENE, V27, P5464, DOI 10.1038/onc.2008.243; Leslie NR, 2007, CURR BIOL, V17, P115, DOI 10.1016/j.cub.2006.12.026; Leslie NR, 2001, BIOCHEM J, V357, P427, DOI 10.1042/0264-6021:3570427; Leung CT, 2012, NATURE, V482, P410, DOI 10.1038/nature10826; Li G, 2002, DEVELOPMENT, V129, P4159; Lin HH, 1999, KIDNEY INT, V55, P168, DOI 10.1046/j.1523-1755.1999.00249.x; Liu H, 2004, J CELL BIOL, V164, P603, DOI 10.1083/jcb.200306090; Liu PX, 2011, NAT MED, V17, P1116, DOI 10.1038/nm.2402; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Maroulakou IG, 2007, CANCER RES, V67, P167, DOI 10.1158/0008-5472.CAN-06-3782; Marsh V, 2008, NAT GENET, V40, P1436, DOI 10.1038/ng.256; Martin-Belmonte F, 2008, CURR BIOL, V18, P507, DOI 10.1016/j.cub.2008.02.076; Martin-Belmonte F, 2007, CELL, V128, P383, DOI 10.1016/j.cell.2006.11.051; McCaffrey LM, 2011, TRENDS CELL BIOL, V21, P727, DOI 10.1016/j.tcb.2011.06.005; Meyer DS, 2011, CANCER RES, V71, P4344, DOI 10.1158/0008-5472.CAN-10-3827; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Pang H, 2009, CANCER RES, V69, P8868, DOI 10.1158/0008-5472.CAN-09-1968; Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3; Pinal N, 2006, CURR BIOL, V16, P140, DOI 10.1016/j.cub.2005.11.068; Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502; Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854; Stiles B, 2002, MOL CELL BIOL, V22, P3842, DOI 10.1128/MCB.22.11.3842-3851.2002; STOKER M, 1985, J CELL SCI, V77, P209; Takahashi Y, 2006, EMBO J, V25, P910, DOI 10.1038/sj.emboj.7600979; Tibarewal P, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002138; van Diepen MT, 2009, NAT CELL BIOL, V11, P1191, DOI 10.1038/ncb1961; Vanhaesebroeck B, 2012, NAT REV MOL CELL BIO, V13, P195, DOI 10.1038/nrm3290; von Stein W, 2005, DEVELOPMENT, V132, P1675, DOI 10.1242/dev.01720; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Welch HCE, 2003, FEBS LETT, V546, P93, DOI 10.1016/S0014-5793(03)00454-X; Wodarz A, 2007, NAT CELL BIOL, V9, P1016, DOI 10.1038/ncb433; Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245; Zhan LX, 2008, CELL, V135, P865, DOI 10.1016/j.cell.2008.09.045	53	20	21	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2013	32	37					4417	4426		10.1038/onc.2012.459	http://dx.doi.org/10.1038/onc.2012.459			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218AF	23085752	Green Accepted			2022-12-28	WOS:000324404200010
J	Doci, CL; Zhou, G; Lingen, MW				Doci, C. L.; Zhou, G.; Lingen, M. W.			The novel tumor suppressor NOL7 post-transcriptionally regulates thrombospondin-1 expression	ONCOGENE			English	Article						NOL7; TSP-1; angiogenesis; post-transcriptional	ENDOTHELIAL GROWTH-FACTOR; PROMOTES TRANSCRIPTION TERMINATION; NUCLEAR-RNA SURVEILLANCE; ANTI-ANGIOGENIC ISOFORMS; PRE-MESSENGER-RNA; FACTOR-BETA; CCR4-NOT COMPLEX; 3'-UNTRANSLATED REGION; QUALITY-CONTROL; POLYMERASE-I	Thrombospondin-1 (TSP-1) is an endogenous inhibitor of angiogenesis whose expression suppresses tumor growth in vivo. Like many angiogenesis-related genes, TSP-1 expression is tightly controlled by various mechanisms, but there is little data regarding the contribution of post-transcriptional processing to this regulation. NOL7 is a novel tumor suppressor that induces an antiangiogenic phenotype and suppresses tumor growth, in part through upregulation of TSP-1. Here we demonstrate that NOL7 is an mRNA-binding protein that must localize to the nucleoplasm to exert its antiangiogenic and tumor suppressive effects. There, it associates with the RNA-processing machinery and specifically interacts with TSP-1 mRNA through its 3'UTR. Reintroduction of NOL7 into SiHa cells increases luciferase expression through interaction with the TSP-1 3'UTR at both the mRNA and protein levels. NOL7 also increases endogenous TSP-1 mRNA half-life. Further, NOL7 post-transcriptional stabilization is observed in a subset of angiogenesis-related mRNAs, suggesting that the stabilization of TSP-1 may be part of a larger novel mechanism. These data demonstrate that NOL7 significantly alters TSP-1 expression and may be a master regulator that coordinates the post-transcriptional expression of key signaling factors critical for the regulation of the angiogenic phenotype.	Univ Chicago, Dept Pathol Med & Radiat, Chicago, IL 60637 USA; Univ Chicago, Dept Cellular Oncol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Lingen, MW (corresponding author), Univ Chicago, Dept Pathol Med & Radiat, 5841S Maryland Ave MC6101, Chicago, IL 60637 USA.	mark.lingen@uchospitals.edu	Doci, Colleen L/M-4389-2015		Illinois Department of Public Health Penny Severns Cancer Research Fund	Illinois Department of Public Health Penny Severns Cancer Research Fund	We wish to thank Drs Ira Wool and Yuen-Ling Chan for their assistance in sucrose gradient ultracentrifugation. This work was supported in part by Illinois Department of Public Health Penny Severns Cancer Research Fund (MWL).	Anderson JT, 2009, CRIT REV BIOCHEM MOL, V44, P16, DOI [10.1080/10409230802640218 , 10.1080/10409230802640218]; Azzouz N, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006760; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Bleuel K, 1999, P NATL ACAD SCI USA, V96, P2065, DOI 10.1073/pnas.96.5.2065; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Carmeliet P, 2003, NAT MED, V9, P653, DOI 10.1038/nm0603-653; Chung JH, 2011, LUNG CANCER, V73, P176, DOI 10.1016/j.lungcan.2010.11.011; Claffey KP, 1998, MOL BIOL CELL, V9, P469, DOI 10.1091/mbc.9.2.469; Collart MA, 2004, PROG NUCLEIC ACID RE, V77, P289, DOI 10.1016/S0079-6603(04)77008-7; de Almeida SF, 2010, NUCLEIC ACIDS RES, V38, P8015, DOI 10.1093/nar/gkq703; Denis CL, 2003, PROG NUCLEIC ACID RE, V73, P221, DOI 10.1016/S0079-6603(03)01007-9; Dibrov A, 2006, GROWTH FACTORS, V24, P1, DOI 10.1080/08977190500365995; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; Doci CL, 2012, INT J GYNECOL PATHOL, V31, P15, DOI 10.1097/PGP.0b013e318220ba16; El Hage A, 2008, GENE DEV, V22, P1069, DOI 10.1101/gad.463708; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Gallouzi IE, 2000, P NATL ACAD SCI USA, V97, P3073, DOI 10.1073/pnas.97.7.3073; Garneau NL, 2007, NAT REV MOL CELL BIO, V8, P113, DOI 10.1038/nrm2104; Glaunsinger BA, 2010, RNA BIOL, V7, P13, DOI 10.4161/rna.7.1.10255; GOOD DJ, 1990, P NATL ACAD SCI USA, V87, P6624, DOI 10.1073/pnas.87.17.6624; Hall-Pogar T, 2005, NUCLEIC ACIDS RES, V33, P2565, DOI 10.1093/nar/gki544; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; HARGROVE JL, 1989, FASEB J, V3, P2360, DOI 10.1096/fasebj.3.12.2676679; Harper SJ, 2008, NAT REV CANCER, V8, P880, DOI 10.1038/nrc2505; HashimotoUoshima M, 1997, J CELL SCI, V110, P2271; Hasina R, 2006, ONCOGENE, V25, P588, DOI 10.1038/sj.onc.1209070; He YL, 1999, MOL ENDOCRINOL, V13, P537, DOI 10.1210/me.13.4.537; Heath VL, 2009, NAT REV CLIN ONCOL, V6, P395, DOI 10.1038/nrclinonc.2009.52; Hilleren P, 2001, NATURE, V413, P538, DOI 10.1038/35097110; Houseley J, 2006, NAT REV MOL CELL BIO, V7, P529, DOI 10.1038/nrm1964; Janz A, 2000, NUCLEIC ACIDS RES, V28, P2268, DOI 10.1093/nar/28.11.2268; Kang JH, 2006, FEBS LETT, V580, P510, DOI 10.1016/j.febslet.2005.12.065; Kanies CL, 2008, MOL CANCER RES, V6, P1124, DOI 10.1158/1541-7786.MCR-07-2095; Kawauchi J, 2008, GENE DEV, V22, P1082, DOI 10.1101/gad.463408; Kim M, 2004, NATURE, V432, P517, DOI 10.1038/nature03041; Laderoute KR, 2000, CLIN CANCER RES, V6, P2941; Ladomery MR, 2007, CANCER LETT, V249, P133, DOI 10.1016/j.canlet.2006.08.015; Lau NC, 2009, BIOCHEM J, V422, P443, DOI 10.1042/BJ20090500; Lawler J, 2004, INT J BIOCHEM CELL B, V36, P1038, DOI 10.1016/j.biocel.2004.01.008; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Levy AP, 1996, J BIOL CHEM, V271, P2746, DOI 10.1074/jbc.271.5.2746; Levy NS, 1997, BBA-GENE STRUCT EXPR, V1352, P167, DOI 10.1016/S0167-4781(97)00052-3; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Lingen MW, 2003, METH MOLEC MED, V78, P337; Lukiw WJ, 1997, J NEUROSCI RES, V50, P937, DOI 10.1002/(SICI)1097-4547(19971215)50:6<937::AID-JNR4>3.0.CO;2-E; Mazan-Mamczarz K, 2008, ONCOGENE, V27, P6151, DOI 10.1038/onc.2008.215; Moore MJ, 2002, CELL, V108, P431, DOI 10.1016/S0092-8674(02)00645-1; Mukherjee D, 2002, EMBO J, V21, P165, DOI 10.1093/emboj/21.1.165; Neugebauer KM, 2002, J CELL SCI, V115, P3865, DOI 10.1242/jcs.00073; Nowak DG, 2008, J CELL SCI, V121, P3487, DOI 10.1242/jcs.016410; Okamoto M, 2002, BBA-GENE STRUCT EXPR, V1574, P24, DOI 10.1016/S0167-4781(01)00345-1; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; Phelan MW, 1998, J LAB CLIN MED, V132, P519, DOI 10.1016/S0022-2143(98)90131-7; Qiu Y, 2009, BIOCHEM SOC T, V37, P1207, DOI 10.1042/BST0371207; Quesada AR, 2007, BIOESSAYS, V29, P1159, DOI 10.1002/bies.20655; RASTINEJAD F, 1989, CELL, V56, P345, DOI 10.1016/0092-8674(89)90238-9; Ren B, 2006, BBA-REV CANCER, V1765, P178, DOI 10.1016/j.bbcan.2005.11.002; Rennel ES, 2008, BRIT J CANCER, V98, P1250, DOI 10.1038/sj.bjc.6604309; Richard P, 2009, GENE DEV, V23, P1247, DOI 10.1101/gad.1792809; Robinson CJ, 2001, J CELL SCI, V114, P853; Sengupta S, 2003, J BIOL CHEM, V278, P25227, DOI 10.1074/jbc.M301813200; Sheflin LG, 2004, BIOCHEM BIOPH RES CO, V322, P644, DOI 10.1016/j.bbrc.2004.07.173; Streit M, 1999, AM J PATHOL, V155, P441, DOI 10.1016/S0002-9440(10)65140-1; Teixeira A, 2004, NATURE, V432, P526, DOI 10.1038/nature03032; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Touriol C, 2000, J BIOL CHEM, V275, P19361, DOI 10.1074/jbc.M908431199; Vasudevan S, 2003, CURR OPIN CELL BIOL, V15, P332, DOI 10.1016/S0955-0674(03)00051-6; VOLPERT OV, 1995, BREAST CANCER RES TR, V36, P119, DOI 10.1007/BF00666034; Volpert OV, 2000, CANCER METAST REV, V19, P87, DOI 10.1023/A:1026560618302; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; WEINSTATSASLOW DL, 1994, CANCER RES, V54, P6504; West S, 2004, NATURE, V432, P522, DOI 10.1038/nature03035; Yamazaki Y, 2006, MOL DIVERS, V10, P515, DOI 10.1007/s11030-006-9027-3; Zhou GL, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-74; Zorio DAR, 2004, EXP CELL RES, V296, P91, DOI 10.1016/j.yexcr.2004.03.019	79	7	7	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2013	32	37					4377	4386		10.1038/onc.2012.464	http://dx.doi.org/10.1038/onc.2012.464			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218AF	23085760	Green Accepted			2022-12-28	WOS:000324404200006
J	Drosten, M; Lechuga, CG; Barbacid, M				Drosten, M.; Lechuga, C. G.; Barbacid, M.			Ras signaling is essential for skin development	ONCOGENE			English	Article						Ras signaling; keratinocytes; senescence; epidermis; hair follicles	HAIR FOLLICLE DEVELOPMENT; K-RAS; EGF RECEPTOR; CELL-CYCLE; EPIDERMAL HOMEOSTASIS; TYROSINE KINASE; STEM-CELLS; ADULT MICE; H-RAS; N-RAS	Proliferation in the epidermis is a tightly controlled process. During skin development, epidermis formation and hair follicle morphogenesis crucially depend on the regulated balance between proliferation and differentiation. Here we deleted all three Ras loci (H-Ras, N-Ras and K-Ras) from keratinocytes in vitro as well as specifically from the epidermis in mice using a K5Cre strain. Upon Ras elimination, keratinocytes ceased proliferation and entered into senescence without any signs of apoptosis induction. Constitutive activation of the mitogen-activated protein kinase pathway was able to partially rescue the proliferative defects. In mice, Ras signaling was essential for proper development of the epidermis and hair follicles. Deletion of the three Ras loci during epidermis formation in mouse embryos caused a dramatic decrease in proliferation, resulting in a substantially thinner epidermis and delayed appearance of differentiation markers. We could not detect apoptotic or senescent cells in these embryos suggesting that loss of Ras protein expression only leads to severe hypoproliferation. These observations provide genetic evidence for an essential role of Ras proteins in the control of keratinocyte and epidermal proliferation.	[Drosten, M.; Lechuga, C. G.; Barbacid, M.] Spanish Natl Canc Res Ctr, CNIO, Mol Oncol Programme, Madrid 28029, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO)	Drosten, M (corresponding author), Spanish Natl Canc Res Ctr, Mol Oncol Programme, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	mdrosten@cnio.es; mbarbacid@cnio.es		Drosten, Matthias/0000-0002-3205-456X	European Research Council [ERC-AG/250297-RAS AHEAD]; Spanish Ministry of Economy and Competitiveness [SAF2011-30173]; Autonomous Community of Madrid [S2011/BDM-2470/ONCOCYCLE]; EU-Framework Programme [LSHG-CT-2007-037665/CHEMORES, HEALTH-F2-2010-259770/LUNGTARGET, HEALTH-2010-260791/EUROCANPLATFORM]	European Research Council(European Research Council (ERC)European Commission); Spanish Ministry of Economy and Competitiveness(Spanish Government); Autonomous Community of Madrid; EU-Framework Programme	We thank the Histopatholoy and Confocal Microscopy Units at the CNIO for their help. This work was supported by grants from the European Research Council (ERC-AG/250297-RAS AHEAD), EU-Framework Programme (LSHG-CT-2007-037665/CHEMORES, HEALTH-F2-2010-259770/LUNGTARGET and HEALTH-2010-260791/EUROCANPLATFORM), Spanish Ministry of Economy and Competitiveness (SAF2011-30173) and Autonomous Community of Madrid (S2011/BDM-2470/ONCOCYCLE) to MB.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Blanpain C, 2009, NAT REV MOL CELL BIO, V10, P207, DOI 10.1038/nrm2636; Buse P, 1999, J BIOL CHEM, V274, P7253, DOI 10.1074/jbc.274.11.7253; BYRNE C, 1994, DEVELOPMENT, V120, P2369; Candi E, 2008, CELL MOL LIFE SCI, V65, P3126, DOI 10.1007/s00018-008-8119-x; Candi E, 2005, NAT REV MOL CELL BIO, V6, P328, DOI 10.1038/nrm1619; Dajee M, 2002, ONCOGENE, V21, P1527, DOI 10.1038/sj.onc.1205287; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; Drosten M, 2010, EMBO J, V29, P1091, DOI 10.1038/emboj.2010.7; Dumesic PA, 2009, J CELL BIOL, V185, P409, DOI 10.1083/jcb.200804038; Esteban LM, 2001, MOL CELL BIOL, V21, P1444, DOI 10.1128/MCB.21.5.1444-1452.2001; FUCHS E, 1990, J CELL BIOL, V111, P2807, DOI 10.1083/jcb.111.6.2807; Fuchs E, 2008, GENE DEV, V22, P976, DOI 10.1101/gad.1645908; Fuchs E, 2007, NATURE, V445, P834, DOI 10.1038/nature05659; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Guerra C, 2011, CANCER CELL, V19, P728, DOI 10.1016/j.ccr.2011.05.011; He J, 2008, NAT STRUCT MOL BIOL, V15, P1169, DOI 10.1038/nsmb.1499; Itahana Koji, 2007, Methods Mol Biol, V371, P21; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Kern F, 2011, BRIT J CANCER, V104, P229, DOI 10.1038/sj.bjc.6606009; Keyes WM, 2005, GENE DEV, V19, P1986, DOI 10.1101/gad.342305; Khavari TA, 2007, CELL CYCLE, V6, P2928, DOI 10.4161/cc.6.23.4998; Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003; Kolch W, 2010, NAT REV CANCER, V10, P618, DOI 10.1038/nrc2900; Koster MI, 2007, ANNU REV CELL DEV BI, V23, P93, DOI 10.1146/annurev.cellbio.23.090506.123357; Koster MI, 2009, ANN NY ACAD SCI, V1170, P7, DOI 10.1111/j.1749-6632.2009.04363.x; Lechler T, 2005, NATURE, V437, P275, DOI 10.1038/nature03922; Lee J, 2012, SEMIN CELL DEV BIOL, V23, P906, DOI 10.1016/j.semcdb.2012.08.003; Lichti U, 2008, NAT PROTOC, V3, P799, DOI 10.1038/nprot.2008.50; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Rojas AM, 2012, J CELL BIOL, V196, P189, DOI 10.1083/jcb.201103008; Millar SE, 2002, J INVEST DERMATOL, V118, P216, DOI 10.1046/j.0022-202x.2001.01670.x; Navas C, 2012, CANCER CELL, V22, P318, DOI 10.1016/j.ccr.2012.08.001; Paus R, 1999, J INVEST DERMATOL, V113, P523, DOI 10.1046/j.1523-1747.1999.00740.x; Petiot A, 2003, DEVELOPMENT, V130, P5493, DOI 10.1242/dev.00788; Potenza N, 2005, EMBO REP, V6, P432, DOI 10.1038/sj.embor.7400397; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Ramirez A, 2004, GENESIS, V39, P52, DOI 10.1002/gene.20025; Scholl FA, 2004, CANCER RES, V64, P6035, DOI 10.1158/0008-5472.CAN-04-0017; Scholl FA, 2007, DEV CELL, V12, P615, DOI 10.1016/j.devcel.2007.03.009; SIBILIA M, 1995, SCIENCE, V269, P234, DOI 10.1126/science.7618085; Simpson CL, 2011, NAT REV MOL CELL BIO, V12, P565, DOI 10.1038/nrm3175; Oskarsson T, 2006, GENE DEV, V20, P2024, DOI 10.1101/gad.381206; Stewart S, 2000, J BIOL CHEM, V275, P8854, DOI 10.1074/jbc.275.12.8854; Tarutani M, 2003, CANCER RES, V63, P319; THREADGILL DW, 1995, SCIENCE, V269, P230, DOI 10.1126/science.7618084; TRIGG MJ, 1972, J ZOOL, V68, P165, DOI 10.1111/j.1469-7998.1972.tb01346.x; Truong AB, 2006, GENE DEV, V20, p[63, 8723]; Vitale-Cross L, 2004, CANCER RES, V64, P8804, DOI 10.1158/0008-5472.CAN-04-2623; Weinberg WC, 2002, CRIT REV ORAL BIOL M, V13, P453, DOI 10.1177/154411130201300603; Yuan JS, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-85	52	26	28	2	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2014	33	22					2857	2865		10.1038/onc.2013.254	http://dx.doi.org/10.1038/onc.2013.254			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EI	23831572				2022-12-28	WOS:000337231800005
J	Chen, YH; Gutmann, DH				Chen, Y-H; Gutmann, D. H.			The molecular and cell biology of pediatric low-grade gliomas	ONCOGENE			English	Review						genetically-engineered mice; brain tumor; glioma; pilocytic astrocytoma; astrocyte; neural stem cell	TYPE-1 GENE-PRODUCT; NEURAL STEM-CELLS; MAPK PATHWAY ACTIVATION; OPTIC-NERVE GLIOMA; RADIAL GLIA CELLS; GROWTH-FACTOR; PILOCYTIC ASTROCYTOMAS; PROGENITOR PROLIFERATION; TUMOR PREDISPOSITION; MALIGNANT GLIOMAS	Pilocytic astrocytoma (PA) is the most common glial cell tumor arising in children. Sporadic cases are associated with KIAA1549:BRAF fusion rearrangements, while 15-20% of children develop PA in the context of the neurofibromatosis 1 (NF1) inherited tumor predisposition syndrome. The unique predilection of these tumors to form within the optic pathway and brainstem (NF1-PA) and cerebellum (sporadic PA) raises the possibility that gliomagenesis requires more than biallelic inactivation of the NF1 tumor suppressor gene or expression of the KIAA1549:BRAF transcript. Several etiologic explanations include differential susceptibilities of preneoplastic neuroglial cell types in different brain regions to these glioma-causing genetic changes, contributions from nonneoplastic cells and signals in the tumor microenvironment, and genomic modifiers that confer glioma risk. As clinically-faithful rodent models of sporadic PA are currently under development, Nf1 genetically-engineered mouse (GEM) models have served as tractable systems to study the role of the cell of origin, deregulated intracellular signaling, non-neoplastic cells in the tumor microenvironment and genomic modifiers in gliomagenesis. In this report, we highlight advances in Nf1-GEM modeling and review new experimental evidence that supports the emerging concept that Nf1- and KIAA1549:BRAF-induced gliomas arise from specific cell types in particular brain locations.	[Chen, Y-H; Gutmann, D. H.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Washington University (WUSTL)	Gutmann, DH (corresponding author), Washington Univ, Sch Med, Dept Neurol, Box 8111,660 South Euclid Ave, St Louis, MO 63110 USA.	gutmannd@neuro.wustl.edu		Gutmann, David/0000-0002-3127-5045	National Institutes of Health [NS065527]; National Brain Tumor Society	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Brain Tumor Society	This work was supported in part by grants from the National Institutes of Health (NS065527) and National Brain Tumor Society (to DHG). Y-HC is a fellow of the American Brain Tumor Association.	Amankulor NM, 2009, J NEUROSCI, V29, P10299, DOI 10.1523/JNEUROSCI.2500-09.2009; Amlin-Van Schaick J, 2012, MAMM GENOME, V23, P277, DOI 10.1007/s00335-011-9380-0; Amlin-Van Schaick JC, 2012, NEURO-ONCOLOGY, V14, P160, DOI 10.1093/neuonc/nor206; ANDERSEN LB, 1993, MOL CELL BIOL, V13, P487, DOI 10.1128/MCB.13.1.487; Armstrong GT, 2011, NEURO-ONCOLOGY, V13, P223, DOI 10.1093/neuonc/noq178; Assanah M, 2006, J NEUROSCI, V26, P6781, DOI 10.1523/JNEUROSCI.0514-06.2006; Bachoo RM, 2002, CANCER CELL, V1, P269, DOI 10.1016/S1535-6108(02)00046-6; Bajenaru ML, 2002, MOL CELL BIOL, V22, P5100, DOI 10.1128/MCB.22.14.5100-5113.2002; Bajenaru ML, 2005, ANN NEUROL, V57, P119, DOI 10.1002/ana.20337; Bajenaru ML, 2003, CANCER RES, V63, P8573; Banerjee S, 2011, P NATL ACAD SCI USA, V108, P15996, DOI 10.1073/pnas.1019012108; Bar EE, 2008, J NEUROPATH EXP NEUR, V67, P878, DOI 10.1097/NEN.0b013e3181845622; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; Binning MJ, 2008, CANCER RES, V68, P7838, DOI 10.1158/0008-5472.CAN-08-1899; Bollag G, 1996, NAT GENET, V12, P144, DOI 10.1038/ng0296-144; BRANNAN CI, 1994, GENE DEV, V8, P1019, DOI 10.1101/gad.8.9.1019; Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020; Calatozzolo C, 2011, CANCER BIOL THER, V11, P242, DOI 10.4161/cbt.11.2.13951; Cin H, 2011, ACTA NEUROPATHOL, V121, P763, DOI 10.1007/s00401-011-0817-z; Costa RM, 2001, NAT GENET, V27, P399, DOI 10.1038/86898; Coull JAM, 2005, NATURE, V438, P1017, DOI 10.1038/nature04223; Daginakatte GC, 2007, HUM MOL GENET, V16, P1098, DOI 10.1093/hmg/ddm059; Daginakatte GC, 2008, CANCER RES, V68, P10358, DOI 10.1158/0008-5472.CAN-08-2506; Dasgupta B, 2005, CANCER RES, V65, P2755, DOI 10.1158/0008-5472.CAN-04-4058; Dasgupta B, 2003, J NEUROSCI, V23, P8949; Dolecek TA, 2012, NEURO-ONCOLOGY, V14, pv1, DOI 10.1093/neuonc/nos218; Eisenhardt AE, 2011, INT J CANCER, V129, P2297, DOI 10.1002/ijc.25893; Elkabes S, 1996, J NEUROSCI, V16, P2508; Fanelli M, 2008, ONCOGENE, V27, P358, DOI 10.1038/sj.onc.1210642; Fisher MJ, 2012, NEURO-ONCOLOGY, V14, P790, DOI 10.1093/neuonc/nos076; Friedmann-Morvinski D, 2012, SCIENCE, V338, P1080, DOI 10.1126/science.1226929; Gibson P, 2010, NATURE, V468, P1095, DOI 10.1038/nature09587; Gronych J, 2011, J CLIN INVEST, V121, P1344, DOI 10.1172/JCI44656; Guillamo JS, 2003, BRAIN, V126, P152, DOI 10.1093/brain/awg016; GUTMANN DH, 1995, CELL GROWTH DIFFER, V6, P315; Gutmann DH, 1999, ANN NEUROL, V46, P777, DOI 10.1002/1531-8249(199911)46:5<777::AID-ANA15>3.0.CO;2-H; GUTMANN DH, 1995, DEV DYNAM, V202, P302, DOI 10.1002/aja.1002020309; Gutmann DH, 2000, NEUROPATH APPL NEURO, V26, P361, DOI 10.1046/j.1365-2990.2000.00258.x; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Hasselblatt M, 2011, NEUROPATH APPL NEURO, V37, P803, DOI 10.1111/j.1365-2990.2011.01193.x; Hawkins C, 2011, CLIN CANCER RES, V17, P4790, DOI 10.1158/1078-0432.CCR-11-0034; Hegedus B, 2008, CANCER RES, V68, P1520, DOI 10.1158/0008-5472.CAN-07-5916; Hoshiko M, 2012, J NEUROSCI, V32, P15106, DOI 10.1523/JNEUROSCI.1167-12.2012; JACKS T, 1994, NAT GENET, V7, P353, DOI 10.1038/ng0794-353; Jacob K, 2009, BRIT J CANCER, V101, P722, DOI 10.1038/sj.bjc.6605179; Jacob K, 2011, CLIN CANCER RES, V17, P4650, DOI 10.1158/1078-0432.CCR-11-0127; Janzarik WG, 2007, NEUROPEDIATRICS, V38, P61, DOI 10.1055/s-2007-984451; Johnson RA, 2010, NATURE, V466, P632, DOI 10.1038/nature09173; Jones DTW, 2009, ONCOGENE, V28, P2119, DOI 10.1038/onc.2009.73; Jones DTW, 2008, CANCER RES, V68, P8673, DOI 10.1158/0008-5472.CAN-08-2097; Jung S, 2000, MOL CELL BIOL, V20, P4106, DOI 10.1128/MCB.20.11.4106-4114.2000; Kalamarides M, 2011, ONCOGENE, V30, P2333, DOI 10.1038/onc.2010.609; Kaul A, 2012, GENE DEV, V26, P2561, DOI 10.1101/gad.200907.112; Kluwe L, 2001, J NEUROPATH EXP NEUR, V60, P917, DOI 10.1093/jnen/60.9.917; Kostianovsky AM, 2008, J IMMUNOL, V181, P5425, DOI 10.4049/jimmunol.181.8.5425; Lau N, 2000, J NEUROPATH EXP NEUR, V59, P759, DOI 10.1093/jnen/59.9.759; Lee DY, 2012, CANCER CELL, V22, P131, DOI 10.1016/j.ccr.2012.05.036; Lee DY, 2010, GENE DEV, V24, P2317, DOI 10.1101/gad.1957110; Lin EY, 2007, CANCER RES, V67, P5064, DOI 10.1158/0008-5472.CAN-07-0912; Lindberg N, 2009, ONCOGENE, V28, P2266, DOI 10.1038/onc.2009.76; Listernick R, 2007, ANN NEUROL, V61, P189, DOI 10.1002/ana.21107; Liu C, 2011, CELL, V146, P209, DOI 10.1016/j.cell.2011.06.014; Llaguno SA, 2009, CANCER CELL, V15, P45, DOI 10.1016/j.ccr.2008.12.006; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Lyustikman Y, 2008, NEOPLASIA, V10, P501, DOI 10.1593/neo.08206; Marin-Teva JL, 2004, NEURON, V41, P535, DOI 10.1016/S0896-6273(04)00069-8; Markovic DS, 2009, P NATL ACAD SCI USA, V106, P12530, DOI 10.1073/pnas.0804273106; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; Masui K, 2010, GLIA, V58, P1050, DOI 10.1002/glia.20986; Merkle FT, 2004, P NATL ACAD SCI USA, V101, P17528, DOI 10.1073/pnas.0407893101; Pfister S, 2008, J CLIN INVEST, V118, P1739, DOI 10.1172/JCI33656; Pfister Stefan, 2009, Recent Results Cancer Res, V171, P67, DOI 10.1007/978-3-540-31206-2_4; Platten M, 2003, ANN NEUROL, V54, P388, DOI 10.1002/ana.10679; Pong WW, 2013, ANN NEUROL, V73, P303, DOI 10.1002/ana.23813; Raabe EH, 2011, CLIN CANCER RES, V17, P3590, DOI 10.1158/1078-0432.CCR-10-3349; Reilly KM, 2000, NAT GENET, V26, P109, DOI 10.1038/79075; Reilly KM, 2004, P NATL ACAD SCI USA, V101, P13008, DOI 10.1073/pnas.0401236101; Robinson JP, 2010, ONCOGENE, V29, P335, DOI 10.1038/onc.2009.333; Roumier A, 2004, J NEUROSCI, V24, P11421, DOI 10.1523/JNEUROSCI.2251-04.2004; Schindler G, 2011, ACTA NEUROPATHOL, V121, P397, DOI 10.1007/s00401-011-0802-6; Schuller U, 2008, CANCER CELL, V14, P123, DOI 10.1016/j.ccr.2008.07.005; Shalitin S, 2011, HORM RES PAEDIAT, V76, P113, DOI 10.1159/000327584; Sharif S, 2006, J CLIN ONCOL, V24, P2570, DOI 10.1200/JCO.2005.03.8349; Sharma MK, 2005, NEUROLOGY, V65, P1335, DOI 10.1212/01.wnl.0000180409.78098.d7; Sharma MK, 2007, CANCER RES, V67, P890, DOI 10.1158/0008-5472.CAN-06-0973; Sievert AJ, 2009, BRAIN PATHOL, V19, P449, DOI 10.1111/j.1750-3639.2008.00225.x; Simmons GW, 2011, J NEUROPATH EXP NEUR, V70, P51, DOI 10.1097/NEN.0b013e3182032d37; Solga AC, 2014, ONCOGENE, V33, P289, DOI 10.1038/onc.2012.580; Sugiarto S, 2011, CANCER CELL, V20, P328, DOI 10.1016/j.ccr.2011.08.011; Taylor MD, 2005, CANCER CELL, V8, P323, DOI 10.1016/j.ccr.2005.09.001; Taylor MD, 2012, ACTA NEUROPATHOL, V123, P465, DOI 10.1007/s00401-011-0922-z; Tchoghandjian A, 2009, BRAIN, V132, P1523, DOI 10.1093/brain/awp048; Tong JY, 2002, NAT NEUROSCI, V5, P95, DOI 10.1038/nn792; WALLACE MR, 1990, SCIENCE, V249, P181, DOI 10.1126/science.2134734; Wang Y, 2009, CANCER CELL, V15, P514, DOI 10.1016/j.ccr.2009.04.001; Warrington NM, 2007, CANCER RES, V67, P8588, DOI 10.1158/0008-5472.CAN-06-2220; Warrington NM, 2010, CANCER RES, V70, P5717, DOI 10.1158/0008-5472.CAN-09-3769; Watters JJ, 2005, J NEUROSCI RES, V81, P447, DOI 10.1002/jnr.20485; Wesolowska A, 2008, ONCOGENE, V27, P918, DOI 10.1038/sj.onc.1210683; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941; Wimmer K, 2002, J NEUROPATH EXP NEUR, V61, P896, DOI 10.1093/jnen/61.10.896; Wisoff JH, 2011, NEUROSURGERY, V68, P1548, DOI 10.1227/NEU.0b013e318214a66e; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; Yeh TH, 2009, GLIA, V57, P1239, DOI 10.1002/glia.20845; Zhu Y, 2005, DEVELOPMENT, V132, P5577, DOI 10.1242/dev.02162	105	47	47	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2014	33	16					2019	2026		10.1038/onc.2013.148	http://dx.doi.org/10.1038/onc.2013.148			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF3GH	23624918	Bronze			2022-12-28	WOS:000334599100002
J	Liao, Q; Zeng, Z; Guo, X; Li, X; Wei, F; Zhang, W; Li, X; Chen, P; Liang, F; Xiang, B; Ma, J; Wu, M; Tang, H; Deng, M; Zeng, X; Tang, K; Xiong, W; Li, G				Liao, Q.; Zeng, Z.; Guo, X.; Li, X.; Wei, F.; Zhang, W.; Li, X.; Chen, P.; Liang, F.; Xiang, B.; Ma, J.; Wu, M.; Tang, H.; Deng, M.; Zeng, X.; Tang, K.; Xiong, W.; Li, G.			LPLUNC1 suppresses IL-6-induced nasopharyngeal carcinoma cell proliferation via inhibiting the Stat3 activation	ONCOGENE			English	Article						nasopharyngeal carcinoma; tumor-associated macrophages; interleukin-6; LPLUNC1; signal transducer and activator of transcription 3	TUMOR-ASSOCIATED MACROPHAGES; CANCER-RELATED INFLAMMATION; UPPER AIRWAYS; INTERLEUKIN-6; EXPRESSION; MICROENVIRONMENT; PLUNC; GENE; PROGRESSION; INITIATION	Tumor-associated macrophage (TAM)-related chronic inflammation and interleukin-6 (IL-6) contribute to the progression of nasopharyngeal carcinoma (NPC). In this study, we characterized TAMs and IL-6 expression in 212 biopsied NPC and 119 non-tumor nasopharyngeal epithelium (NPE) tissues by tissue array. In comparison with that in the NPE tissues, more TAM infiltrates and a higher density of IL-6 expression were detected in NPC tissues, which were associated with the poor survival of NPC patients. In contrast, little or no LPLUNC1, a regulator of inflammation, expression was detected in NPC tissues, and the levels of LPLUNC1 expression in the NPC were associated negatively with the numbers of TAMs and the levels of IL-6 expression, but positively with the survival of NPC patients. Induction of LPLUNC1 overexpression in NPC cells mitigated lipopolysaccharide (LPS)-induced IL-6, IL-8, tumor necrosis factor-alpha and IL-1 beta expression or treatment of THP-1 macrophages with LPLUNC1 inhibited spontaneous and LPS-induced IL-6 expression in vitro. IL-6-promoted NPC cell proliferation in a dose- and time-dependent manner, accompanied by increasing cyclin D1 and Bcl-2 expression and the Stat3 activation, but inhibiting Bax and p21 expression. Induction of LPLUNC1 overexpression inhibited NPC cell proliferation, induced NPC cell arrest, promoted NPC cell apoptosis even after IL-6 stimulation and inhibited the growth of implanted NPC tumors in vivo, which were associated with decreasing cyclin D1 and Bcl-2 expression and the Janus kinase 2 (JAK2)/Stat3 activation, but enhancing Bax and p21 expression. These results suggest that LPLUNC1 can inhibit inflammation and NPC growth by downregulating the Stat3 pathway.	[Liao, Q.; Zeng, Z.; Li, X.; Ma, J.; Wu, M.; Xiong, W.; Li, G.] Cent S Univ, Xiangya Sch Med, Hunan Prov Tumor Hosp, Changsha 410013, Hunan, Peoples R China; [Liao, Q.; Zeng, Z.; Li, X.; Ma, J.; Wu, M.; Xiong, W.; Li, G.] Cent S Univ, Xiangya Sch Med, Affiliated Tumor Hosp, Changsha 410013, Hunan, Peoples R China; [Liao, Q.; Zeng, Z.; Li, X.; Li, X.; Ma, J.; Wu, M.; Xiong, W.; Li, G.] Cent S Univ, Xiangya Hosp 3, Dis Genome Res Ctr, Hunan Key Lab Nonresolving Inflammat & Canc, Changsha 410013, Hunan, Peoples R China; [Liao, Q.; Zeng, Z.; Guo, X.; Li, X.; Wei, F.; Zhang, W.; Chen, P.; Liang, F.; Xiang, B.; Ma, J.; Wu, M.; Tang, H.; Deng, M.; Zeng, X.; Tang, K.; Xiong, W.; Li, G.] Cent S Univ, Canc Res Inst, Minist Hlth, Key Lab Carcinogenesis, Changsha 410013, Hunan, Peoples R China; [Liao, Q.; Zeng, Z.; Guo, X.; Li, X.; Wei, F.; Zhang, W.; Chen, P.; Liang, F.; Xiang, B.; Ma, J.; Wu, M.; Tang, H.; Deng, M.; Zeng, X.; Tang, K.; Xiong, W.; Li, G.] Cent S Univ, Canc Res Inst, Minist Educ, Key Lab Carcinogenesis & Canc Invas, Changsha 410013, Hunan, Peoples R China	Central South University; Central South University; Central South University; Central South University; Central South University	Xiong, W (corresponding author), Cent S Univ, Xiangya Sch Med, Hunan Prov Tumor Hosp, 283 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China.	xiongwei@xysm.net; ligy@xysm.net		Zeng, Xi/0000-0001-6835-9691	National High Technology Research and Development Program of China [2012AA02A206]; National Natural Science Foundation of China [91229122, 81071644, 81172189, 81101509, 81171930, 81272254, 81272298]; 111 project [111-2-12]; Program for New Century Excellent Talents in University [NCET-11-0520]; Hunan Province Natural Sciences Foundation of China [10JJ7003]	National High Technology Research and Development Program of China(National High Technology Research and Development Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); 111 project(Ministry of Education, China - 111 Project); Program for New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET)); Hunan Province Natural Sciences Foundation of China(Natural Science Foundation of Hunan Province)	This study was supported by grants from the National High Technology Research and Development Program of China (2012AA02A206), the National Natural Science Foundation of China (91229122, 81071644, 81172189, 81101509, 81171930, 81272254 and 81272298), the 111 project (111-2-12), the Program for New Century Excellent Talents in University (NCET-11-0520) and the Hunan Province Natural Sciences Foundation of China (10JJ7003).	Allavena P, 2008, CRIT REV ONCOL HEMAT, V66, P1, DOI 10.1016/j.critrevonc.2007.07.004; Ataie-Kachoie P, 2013, CYTOKINE GROWTH F R, V24, P163, DOI 10.1016/j.cytogfr.2012.09.001; Baay M, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/565187; Balkwill F, 2005, CANCER CELL, V7, P211, DOI 10.1016/j.ccr.2005.02.013; Balkwill FR, 2012, SEMIN CANCER BIOL, V22, P33, DOI 10.1016/j.semcancer.2011.12.005; Becker C, 2005, CELL CYCLE, V4, P217; Bingle CD, 2000, BBA-GENE STRUCT EXPR, V1493, P363, DOI 10.1016/S0167-4781(00)00196-2; Bingle CD, 2002, HUM MOL GENET, V11, P937, DOI 10.1093/hmg/11.8.937; Bingle CD, 2010, HISTOCHEM CELL BIOL, V133, P505, DOI 10.1007/s00418-010-0683-0; Bingle L, 2011, BIOCHEM SOC T, V39, P1023, DOI 10.1042/BST0391023; Candido J, 2013, J CLIN IMMUNOL, V33, pS79, DOI 10.1007/s10875-012-9847-0; Canny G, 2008, TRENDS IMMUNOL, V29, P541, DOI 10.1016/j.it.2008.07.012; Chen HL, 2001, J VIROL, V75, P2929, DOI 10.1128/JVI.75.6.2929-2937.2001; Chow KC, 2003, ONCOL REP, V10, P813; Cocco C, 2012, IMMUNOTHERAPY-UK, V4, P667, DOI 10.2217/imt.12.56; de Visser KE, 2006, CONTRIB MICROBIOL, V13, P118, DOI 10.1159/000092969; Di YP, 2003, J BIOL CHEM, V278, P1165, DOI 10.1074/jbc.M210523200; Fan SQ, 2006, HUM PATHOL, V37, P593, DOI 10.1016/j.humpath.2006.01.010; Fukuda Koji, 2012, Front Biosci (Schol Ed), V4, P787; Hao NB, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/948098; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hong DS, 2007, CANCER-AM CANCER SOC, V110, P1911, DOI 10.1002/cncr.22999; Hsiao JR, 2003, BRIT J CANCER, V89, P344, DOI 10.1038/sj.bjc.6601003; Hsu HS, 2012, LUNG CANCER, V75, P167, DOI 10.1016/j.lungcan.2011.07.001; Hussain SP, 2007, INT J CANCER, V121, P2373, DOI 10.1002/ijc.23173; Ishihara K, 2002, CYTOKINE GROWTH F R, V13, P357, DOI 10.1016/S1359-6101(02)00027-8; Kim SR, 2009, BIOCHEM BIOPH RES CO, V387, P342, DOI 10.1016/j.bbrc.2009.07.022; Kishimoto T, 2005, ANNU REV IMMUNOL, V23, P1, DOI 10.1146/annurev.immunol.23.021704.115806; Liao Q, 2011, J CANCER RES CLIN, V138, P57; Lin CM, 2010, J AGR FOOD CHEM, V58, P7082, DOI 10.1021/jf100421w; Lu HT, 2006, MOL CANCER RES, V4, P221, DOI 10.1158/1541-7786.MCR-05-0261; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Mantovani A, 2006, CANCER METAST REV, V25, P315, DOI 10.1007/s10555-006-9001-7; Mantovani A, 2009, NATURE, V457, P36, DOI 10.1038/457036b; Motilva V, 2012, CURR PHARM DESIGN, V18, P3829, DOI 10.2174/138161212802083671; Musa M, 2012, CELL TISSUE RES, V350, P455, DOI 10.1007/s00441-012-1490-9; Park EK, 2007, INFLAMM RES, V56, P45, DOI 10.1007/s00011-007-6115-5; Rodriguez-Vita J, 2010, CYTOKINE GROWTH F R, V21, P61, DOI 10.1016/j.cytogfr.2009.11.006; Sgambato A, 2010, EUR REV MED PHARMACO, V14, P263; Shih J, 2006, J CANC MOL, V2, P6; Shin OS, 2011, J INFECT DIS, V204, P1349, DOI 10.1093/infdis/jir544; Sica A, 2008, CANCER LETT, V267, P204, DOI 10.1016/j.canlet.2008.03.028; Solinas G, 2009, J LEUKOCYTE BIOL, V86, P1065, DOI 10.1189/jlb.0609385; Steidl C, 2010, NEW ENGL J MED, V362, P875, DOI 10.1056/NEJMoa0905680; STRASSMANN G, 1992, J CLIN INVEST, V89, P1681, DOI 10.1172/JCI115767; Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180; Takayama H, 2009, J UROLOGY, V181, P1894, DOI 10.1016/j.juro.2008.11.090; Tan EL, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-227; Vargas PA, 2008, ORAL DIS, V14, P613, DOI 10.1111/j.1601-0825.2007.01429.x; Wang R, 2011, LUNG CANCER, V74, P188, DOI 10.1016/j.lungcan.2011.04.009; Yang YX, 2007, MOL IMMUNOL, V44, P984, DOI 10.1016/j.molimm.2006.03.013; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zhang BC, 2003, GENE CHROMOSOME CANC, V38, P80, DOI 10.1002/gcc.10247; Zhang BC, 2011, MED ONCOL, V28, P1447, DOI 10.1007/s12032-010-9638-5; Zhang XL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020965	55	98	104	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2014	33	16					2098	2109		10.1038/onc.2013.161	http://dx.doi.org/10.1038/onc.2013.161			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF3GH	23708661				2022-12-28	WOS:000334599100009
J	Sokolowski, E; Turina, CB; Kikuchi, K; Langenau, DM; Keller, C				Sokolowski, E.; Turina, C. B.; Kikuchi, K.; Langenau, D. M.; Keller, C.			Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma	ONCOGENE			English	Review						rhabdomyosarcoma; biomarker; proof-of-concept disease; kinase; rare cancers; drug development	TESTING STAGE 1; FACTOR-I RECEPTOR; SMALL-MOLECULE INHIBITOR; ENDOTHELIAL GROWTH-FACTOR; PEDIATRIC SOLID TUMORS; SOFT-TISSUE SARCOMAS; EMBRYONAL RHABDOMYOSARCOMA; GENE-EXPRESSION; MYOGENIC DIFFERENTIATION; CELL-LINES	Rare diseases typically affect fewer than 200 000 patients annually, yet because thousands of rare diseases exist, the cumulative impact is millions of patients worldwide. Every form of childhood cancer qualifies as a rare disease-including the childhood muscle cancer, rhabdomyosarcoma (RMS). The next few years promise to be an exceptionally good era of opportunity for public-private collaboration for rare and childhood cancers. Not only do certain governmental regulation advantages exist, but these advantages are being made permanent with special incentives for pediatric orphan drug-product development. Coupled with a growing understanding of sarcoma tumor biology, synergy with pharmaceutical muscle disease drug-development programs, and emerging publically available preclinical and clinical tools, the outlook for academic-community-industry partnerships in RMS drug development looks promising.	[Sokolowski, E.; Turina, C. B.] Oregon State Univ, Dept Student Affairs, Corvallis, OR 97331 USA; [Turina, C. B.; Kikuchi, K.; Keller, C.] Oregon Hlth & Sci Univ, Pape Family Pediat Res Inst, Dept Pediat, Pediat Canc Biol Program, Portland, OR 97239 USA; [Langenau, D. M.] Massachusetts Gen Hosp, Div Mol Pathol, Boston, MA 02114 USA; [Langenau, D. M.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA; [Langenau, D. M.] Harvard Univ, Sch Med, Boston, MA USA; [Langenau, D. M.] Harvard Stem Cell Inst, Boston, MA USA	Oregon State University; Oregon Health & Science University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University	Keller, C (corresponding author), Oregon Hlth & Sci Univ, Pape Family Pediat Res Inst, Dept Pediat, Pediat Canc Biol Program, 3181 SW Sam Jackson Pk Rd,MC L321, Portland, OR 97239 USA.	keller@ohsu.edu	Kikuchi, Ken/ABG-8290-2020; Langenau, David/GXI-0197-2022	Kikuchi, Ken/0000-0003-3097-7480; Langenau, David/0000-0001-6664-8318; Keller, Charles/0000-0003-2505-7487	Harvard Stem Cell Institute; Ethan Jostad Foundation for Childhood Cancer;  [R01CA133229];  [R01CA15923];  [R21CA156056]; NATIONAL CANCER INSTITUTE [R21CA156056, R01CA133229] Funding Source: NIH RePORTER	Harvard Stem Cell Institute; Ethan Jostad Foundation for Childhood Cancer; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was funded by R01CA133229 (CK), R01CA15923 (DML), R21CA156056 (DML), the Harvard Stem Cell Institute and a gift from the Ethan Jostad Foundation for Childhood Cancer. We thank M Imran Aslam, Lara Davis, Ailin Jiang, Leanna Mah, Marissa Peterson, Victoria Reinke, Teagen Settlemeyer, Suman Malempati and R Lor Randall for their contributions to and discussions regarding this topic. Important input on cell lines was made by Karoly Szuhai, Beat Schafer, Frederic Barr, Javed Khan, Corinne Linardic and Peter Houghton. We are grateful for the critical comments of Douglas Hawkins, Malcolm Smith, Idriss Bennani-Baiti, M Simone Nsouli, Parkash Gill, Kathryn Gould, Sandra Smith, Steven Townson, Max Wallace, John Mackintosh, Tommy Pham, Jay Scott, Nadim Nsouli, Christopher Winter and Owen Lockerbie.	Abraham J, 2012, BIOCHEM BIOPH RES CO, V426, P363, DOI 10.1016/j.bbrc.2012.08.092; Abraham J, 2011, MOL CANCER THER, V10, P697, DOI 10.1158/1535-7163.MCT-10-0695; Adamson PC, 2013, PEDIATR BLOOD CANCER, V60, P955, DOI 10.1002/pbc.24399; Agarwal A, 2011, 53 ASH ANN M EXP AM; Alabran JL, 2013, PEDIATR BLOOD CANCER, V60, P204, DOI 10.1002/pbc.24320; Andrade Cléverton Roberto de, 2010, Braz. Dent. J., V21, P68, DOI 10.1590/S0103-64402010000100011; [Anonymous], 2012, PROOF OF CONC REC PR; Armistead PM, 2007, CANCER, V110, P2293, DOI 10.1002/cncr.23038; Arndt CAS, 2006, J PEDIAT HEMATOL ONC, V28, P563, DOI 10.1097/01.mph.0000212978.21372.97; Arndt CAS, 1999, NEW ENGL J MED, V341, P342, DOI 10.1056/NEJM199907293410507; Barber TD, 2002, GENOMICS, V79, P278, DOI 10.1006/geno.2002.6703; Barber-Rotenberg JS, 2012, ONCOTARGET, V3, P172; Belyea BC, 2011, CLIN CANCER RES, V17, P7324, DOI 10.1158/1078-0432.CCR-11-1004; Bennani-Baiti IM, 2011, EPIGENOMICS-UK, V3, P715, DOI [10.2217/EPI.11.93, 10.2217/epi.11.93]; Bennani-Baiti IM, 2010, CLIN CANCER RES, V16, P3769, DOI 10.1158/1078-0432.CCR-10-0558; Berardi AC, 2008, ANTICANCER RES, V28, P763; Blandford MC, 2006, PEDIATR BLOOD CANCER, V46, P329, DOI 10.1002/pbc.20466; Bouron-Dal Soglio D, 2009, PEDIATR DEVEL PATHOL, V12, P371, DOI 10.2350/08-11-0553.1; Braun MM, 2010, NAT REV DRUG DISCOV, V9, P519, DOI 10.1038/nrd3160; Breneman JC, 2003, J CLIN ONCOL, V21, P78, DOI 10.1200/JCO.2003.06.129; Cam H, 2006, CANCER CELL, V10, P281, DOI 10.1016/j.ccr.2006.08.024; Camboni M, 2012, J PATHOL, V226, P40, DOI 10.1002/path.2996; Canner JA, 2009, BRIT J CANCER, V101, P774, DOI 10.1038/sj.bjc.6605199; Cao L, 2008, CANCER RES, V68, P8039, DOI 10.1158/0008-5472.CAN-08-1712; Cao LA, 2010, CANCER RES, V70, P6497, DOI 10.1158/0008-5472.CAN-10-0582; Carboni JM, 2009, MOL CANCER THER, V8, P3341, DOI 10.1158/1535-7163.MCT-09-0499; Carol H, 2013, PEDIATR BLOOD CANCER, V60, P633, DOI 10.1002/pbc.24235; Carol H, 2011, CANCER CHEMOTH PHARM, V68, P1291, DOI 10.1007/s00280-011-1618-8; Carol H, 2010, PEDIATR BLOOD CANCER, V55, P1329, DOI 10.1002/pbc.22710; Cen L, 2007, BRIT J CANCER, V97, P785, DOI 10.1038/sj.bjc.6603952; Cen L, 2007, MODERN PATHOL, V20, P936, DOI 10.1038/modpathol.3800834; Chadalapaka G, 2013, INT J CANCER, V132, P795, DOI 10.1002/ijc.27730; Chamberlain JS, 2007, FASEB J, V21, P2195, DOI 10.1096/fj.06-7353com; Charytonowicz E, 2012, CLIN TRANSL ONCOL, V14, P197, DOI 10.1007/s12094-012-0784-4; Chen CL, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-111; Chen L, 2013, MANAGE COMMUN Q, V27, P3, DOI 10.1177/0893318913475485; Chen YY, 2007, GENE CHROMOSOME CANC, V46, P348, DOI 10.1002/gcc.20416; Cheney MD, 2008, CANCER BIOL THER, V7, P38, DOI 10.4161/cbt.7.1.5125; Chisholm J., 2012, COMMUNICATIONS; Conboy MJ, 2010, METHODS MOL BIOL, V621, P165, DOI 10.1007/978-1-60761-063-2_11; Corao DA, 2009, PEDIATR DEVEL PATHOL, V12, P275, DOI 10.2350/08-03-0434.1; Davicioni E, 2009, AM J PATHOL, V174, P550, DOI 10.2353/ajpath.2009.080631; Davis L, 2012, AACR ED BOOK, P205; DeFrancesco L, 2011, NAT BIOTECHNOL, V29, P850, DOI 10.1038/nbt1011-851; DeGiovanni C, 1996, CANCER RES, V56, P3898; DEGIOVANNI C, 1995, BRIT J CANCER, V72, P1224, DOI 10.1038/bjc.1995.490; Dhimolea E, 2010, MABS-AUSTIN, V2, P3, DOI 10.4161/mabs.2.1.10328; DIAS P, 1990, INT J CANCER, V45, P593, DOI 10.1002/ijc.2910450403; Diomedi-Camassei F, 2008, CLIN CANCER RES, V14, P4119, DOI 10.1158/1078-0432.CCR-07-4446; Druker BJ, 2004, CELL CYCLE, V3, P833; Dupont, 2012, TEST METH US ONCOMOU; Durbin AD, 2009, J CLIN INVEST, V119, P1558, DOI 10.1172/JCI37958; Eichenmuller M, 2010, BRIT J CANCER, V103, P43, DOI 10.1038/sj.bjc.6605715; ELBADRY OM, 1990, CELL GROWTH DIFFER, V1, P325; Fernandez K, 2010, AM J PATHOL, V176, P416, DOI 10.2353/ajpath.2010.090405; Fiddler TA, 1996, MOL CELL BIOL, V16, P5048; Fine SW, 2005, APPL IMMUNOHISTO M M, V13, P231, DOI 10.1097/00129039-200509000-00003; Fleischmann A, 2003, CANCER CELL, V4, P477, DOI 10.1016/S1535-6108(03)00280-0; Food and Drug Administration US, 2012, FREQ ASK QUEST PAT E; Frascella E, 2000, CANCER GENET CYTOGEN, V121, P139, DOI 10.1016/S0165-4608(00)00258-2; Gaddipati H, 2012, CLIN CANCER RES, V18, P5172, DOI 10.1158/1078-0432.CCR-12-1135; Ganti R, 2006, MODERN PATHOL, V19, P1213, DOI 10.1038/modpathol.3800636; Gee MFW, 2005, ONCOGENE, V24, P8025, DOI 10.1038/sj.onc.1208939; Ghule P, 2006, MED SCI MONITOR, V12, pBR385; Goldstein M, 2007, GENE CHROMOSOME CANC, V46, P1028, DOI 10.1002/gcc.20489; Goldstein M, 2006, NEOPLASIA, V8, P332, DOI 10.1593/neo.05829; Goozner M, 2012, J NATL CANCER I, V104, P84, DOI 10.1093/jnci/djr552; Gore L, 2013, LANCET ONCOL, V14, pE70, DOI 10.1016/S1470-2045(12)70530-2; Gorlick R, 2012, PEDIATR BLOOD CANCER, V59, P1266, DOI 10.1002/pbc.24073; Gorlick R, 2009, PEDIATR BLOOD CANCER, V53, P594, DOI 10.1002/pbc.21989; Grass B, 2009, HISTOPATHOLOGY, V54, P873, DOI 10.1111/j.1365-2559.2009.03303.x; Grymula K, 2010, INT J CANCER, V127, P2554, DOI 10.1002/ijc.25245; Gurney JG, 1999, SOFT TISSUE SARCOMAS; Hahn H, 1998, NAT MED, V4, P619, DOI 10.1038/nm0598-619; HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225; HARVEY M, 1993, FASEB J, V7, P938, DOI 10.1096/fasebj.7.10.8344491; Hawkins DS, 2013, PEDIATR BLOOD CANCER, V60, P1001, DOI 10.1002/pbc.24435; HAYASHI Y, 1990, INT J CANCER, V45, P705, DOI 10.1002/ijc.2910450423; Herper Matthew, 2012, FORBES MAGAZINE; Hettmer S, 2011, P NATL ACAD SCI USA, V108, P20002, DOI 10.1073/pnas.1111733108; Hilari JM, 2009, ANN SURG ONCOL, V16, P177, DOI 10.1245/s10434-008-0183-9; Hirotsu M, 2009, BRIT J CANCER, V101, P2030, DOI 10.1038/sj.bjc.6605407; Horton TM, 2011, EUR J PEDIATR, V170, P555, DOI 10.1007/s00431-010-1374-5; Hoshida Y, 2009, CANCER RES, V69, P7385, DOI 10.1158/0008-5472.CAN-09-1089; Hosoi H, 1999, CANCER RES, V59, P886; Hosoyama T, 2011, CLIN CANCER RES, V17, P2757, DOI 10.1158/1078-0432.CCR-10-3445; Hosur V, 2012, CANCER GENET-NY, V205, P232, DOI 10.1016/j.cancergen.2012.03.005; Hou JX, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-64; Houghton PJ, 2008, PEDIATR BLOOD CANCER, V50, P799, DOI 10.1002/pbc.21296; Houghton PJ, 2007, PEDIATR BLOOD CANCER, V49, P928, DOI 10.1002/pbc.21078; Houghton PJ, 2012, PEDIATR BLOOD CANCER, V58, P636, DOI 10.1002/pbc.23167; Houghton PJ, 2012, PEDIATR BLOOD CANCER, V58, P191, DOI 10.1002/pbc.22935; Houghton PJ, 2010, PEDIATR BLOOD CANCER, V54, P921, DOI 10.1002/pbc.22367; Houghton PJ, 2011, AACR NCI EORTC INT C; Huang E, 2011, PEDIATR BLOOD CANCER, V57, P899, DOI 10.1002/pbc.23136; Huang F, 2009, CANCER RES, V69, P161, DOI 10.1158/0008-5472.CAN-08-0835; Ignatius MS, 2012, CANCER CELL, V21, P680, DOI 10.1016/j.ccr.2012.03.043; Institute of Medicine CoARDRaOPD, RAR DIS ORPH PROD AC; Iolascon A, 1996, GENE CHROMOSOME CANC, V15, P217, DOI 10.1002/(SICI)1098-2264(199604)15:4<217::AID-GCC3>3.3.CO;2-X; Jankowski K, 2003, CANCER RES, V63, P7926; Jenkins C, 2012, ANEMIA, V2012, DOI 10.1155/2012/481583; KALEBIC T, 1994, CANCER RES, V54, P5531; Kantarjian HM, 2007, LEUKEMIA LYMPHOMA, V48, P1922, DOI 10.1080/10428190701545644; Keleti J, 1996, AM J PATHOL, V149, P143; Keller C, 2004, GENE DEV, V18, P2614, DOI 10.1101/gad.1244004; Kesselheim AS, 2011, JAMA-J AM MED ASSOC, V305, P2320, DOI 10.1001/jama.2011.769; KHATIB ZA, 1993, CANCER RES, V53, P5535; Kids-v-Cancer, 2012, KIDS V CANC PROGR PR; Kikuchi K, 2013, ONCOGENE, V32, P286, DOI 10.1038/onc.2012.46; Kikuchi K, 2011, CURR TOP DEV BIOL, V96, P33, DOI 10.1016/B978-0-12-385940-2.00002-4; Kolb EA, 2008, PEDIATR BLOOD CANCER, V50, P1190, DOI 10.1002/pbc.21450; Kolb EA, 2010, PEDIATR BLOOD CANCER, V55, P668, DOI 10.1002/pbc.22576; Kramer DB, 2012, NEW ENGL J MED, V367, P1277, DOI 10.1056/NEJMp1207800; Kusafuka T, 1997, J PEDIATR SURG, V32, P1175, DOI 10.1016/S0022-3468(97)90677-1; Lae M, 2007, J PATHOL, V212, P143, DOI 10.1002/path.2170; Landuzzi L, 1998, INT J CANCER, V78, P441, DOI 10.1002/(SICI)1097-0215(19981109)78:4<441::AID-IJC9>3.3.CO;2-H; Langenau DM, 2008, ONCOGENE, V27, P4242, DOI 10.1038/onc.2008.56; Langenau DM, 2007, GENE DEV, V21, P1382, DOI 10.1101/gad.1545007; Lee MH, 2011, CANCER RES, V71, P3921, DOI 10.1158/0008-5472.CAN-10-3358; Lee Y, 2007, ONCOGENE, V26, P6442, DOI 10.1038/sj.onc.1210467; Lee Y, 2006, CANCER RES, V66, P6964, DOI 10.1158/0008-5472.CAN-06-0505; LI FP, 1969, J NATL CANCER I, V43, P1365; Li HG, 2007, CANCER LETT, V253, P215, DOI 10.1016/j.canlet.2007.01.020; Libura J, 2002, BLOOD, V100, P2597, DOI 10.1182/blood-2002-01-0031; Liu AG, 2011, CANCER SCI, V102, P1381, DOI 10.1111/j.1349-7006.2011.01932.x; Liu L, 2008, ONCOGENE, V27, P4998, DOI 10.1038/onc.2008.137; Lock RB, 2012, PEDIATR BLOOD CANCER, V58, P916, DOI 10.1002/pbc.23176; Loh ML, 2013, BLOOD, V121, P485, DOI 10.1182/blood-2012-04-422691; Lukasiewicz E, 2009, FOLIA HISTOCHEM CYTO, V47, P485, DOI 10.2478/v10042-009-0108-x; Ma HW, 2003, MOL CANCER RES, V1, P739; Malempati S, 2012, PEDIATR BLOOD CANCER, V59, P5, DOI 10.1002/pbc.24118; Malik SM, 2010, CLIN CANCER RES, V16, P4921, DOI 10.1158/1078-0432.CCR-10-1214; Mann BS, 2007, ONCOLOGIST, V12, P1247, DOI 10.1634/theoncologist.12-10-1247; Mao J, 2006, CANCER RES, V66, P10171, DOI 10.1158/0008-5472.CAN-06-0657; Marampon F, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-31; Marampon F, 2009, MOL CANCER THER, V8, P543, DOI 10.1158/1535-7163.MCT-08-0570; Maris JM, 2010, PEDIATR BLOOD CANCER, V55, P26, DOI 10.1002/pbc.22430; Marshall AD, 2012, MOL CARCINOGEN, V51, P807, DOI 10.1002/mc.20848; Martinelli S, 2009, GENE CHROMOSOME CANC, V48, P975, DOI 10.1002/gcc.20702; Mascarenhas L, 2010, J CLIN ONCOL, V28, P4658, DOI 10.1200/JCO.2010.29.7390; Mayeenuddin LH, 2010, ONCOGENE, V29, P6367, DOI 10.1038/onc.2010.364; McDermott U, 2009, CANCER RES, V69, P3937, DOI 10.1158/0008-5472.CAN-08-4327; McKenzie PP, 2002, MOL CANCER THER, V1, P1097; Medic S, 2011, BIOCHEM BIOPH RES CO, V411, P832, DOI 10.1016/j.bbrc.2011.07.053; Michaelis M, 2009, CANCER RES, V69, P416, DOI 10.1158/0008-5472.CAN-08-1856; Miekus K, 2010, FOLIA HISTOCHEM CYTO, V48, P104, DOI 10.2478/v10042-008-0091-7; MINNITI CP, 1992, CANCER RES, V52, P1830; Missiaglia E, 2012, J CLIN ONCOL, V30, P1670, DOI 10.1200/JCO.2011.38.5591; Missiaglia E, 2009, GENE CHROMOSOME CANC, V48, P455, DOI 10.1002/gcc.20655; Miyachi M, 2009, CLIN CANCER RES, V15, P4077, DOI 10.1158/1078-0432.CCR-08-2955; Moreau P, 2012, BLOOD, V120, P947, DOI 10.1182/blood-2012-04-403733; Nanni P, 2003, CANCER RES, V63, P2728; Nanni P, 2009, MOL CANCER THER, V8, P754, DOI 10.1158/1535-7163.MCT-08-0678; Nationwide Children's Hospital Biopathology Center, 2012, TISS MICROARRAYS; Neale G, 2008, CLIN CANCER RES, V14, P4572, DOI 10.1158/1078-0432.CCR-07-5090; Nishijo K, 2009, CANCER RES, V69, P2902, DOI 10.1158/0008-5472.CAN-08-3723; Nitzki F, 2011, ONCOGENE, V30, P4428, DOI 10.1038/onc.2011.157; Nordberg J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050819; Norris RE, 2012, NAT REV CANCER, V12, P776, DOI 10.1038/nrc3370; Northwest Sarcoma Foundation, 2012, LEAV LEG PROGR; Ognjanovic Simona, 2012, Sarcoma, V2012, P492086, DOI 10.1155/2012/492086; Ognjanovic S, 2009, CANCER-AM CANCER SOC, V115, P4218, DOI 10.1002/cncr.24465; Ohali A, 2008, GENE CHROMOSOME CANC, V47, P965, DOI 10.1002/gcc.20600; Onisto M, 2005, INT J ONCOL, V27, P791; Paulson V, 2011, GENE CHROMOSOME CANC, V50, P397, DOI 10.1002/gcc.20864; Perez EA, 2011, J SURG RES, V170, pE243, DOI 10.1016/j.jss.2011.03.001; Phillips DC, 2007, CELL DEATH DIFFER, V14, P1780, DOI 10.1038/sj.cdd.4402198; Pillay K, 2002, HISTOPATHOLOGY, V41, P461, DOI 10.1046/j.1365-2559.2002.01534.x; Pressey JG, 2011, PEDIATR BLOOD CANCER, V57, P930, DOI 10.1002/pbc.23174; Raimondi L, 2012, CELL DEATH DIFFER, V19, P871, DOI 10.1038/cdd.2011.171; Reynolds CP, 2013, PEDIATR BLOOD CANCER, V60, P791, DOI 10.1002/pbc.24301; Ricci C, 2000, INT J CANCER, V87, P29, DOI 10.1002/1097-0215(20000701)87:1<29::AID-IJC5>3.3.CO;2-A; Riuzzi F, 2007, AM J PATHOL, V171, P947, DOI 10.2353/ajpath.2007.070049; Robert NJ, 2011, J CLIN ONCOL, V29, P1252, DOI 10.1200/JCO.2010.28.0982; Rodriguez-Perales S, 2004, CANCER GENET CYTOGEN, V148, P35, DOI 10.1016/S0165-4608(03)00216-4; Roma J, 2011, CLIN CANCER RES, V17, P505, DOI 10.1158/1078-0432.CCR-10-0166; Romualdi C, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-287; Rossi S, 2011, J CELL MOL MED, V15, P2553, DOI 10.1111/j.1582-4934.2011.01364.x; Rossi S, 2011, EUR J CANCER, V47, P761, DOI 10.1016/j.ejca.2010.10.018; Rubin BP, 2011, CANCER CELL, V19, P177, DOI 10.1016/j.ccr.2010.12.023; Santoriello C, 2009, DIS MODEL MECH, V2, P56, DOI 10.1242/dmm.001016; Sarcoma Foundation of America, 2012, PAT REG PROGR; Sartori F, 2006, CANCER, V106, P1766, DOI 10.1002/cncr.21772; Sarver AL, 2010, CANCER RES, V70, P9570, DOI 10.1158/0008-5472.CAN-10-2074; Sateren WB, 2002, J CLIN ONCOL, V20, P2109, DOI 10.1200/JCO.2002.08.056; Schaaf G, 2010, CANCER RES, V70, P762, DOI 10.1158/0008-5472.CAN-09-2532; Schaffer BS, 2010, MOL CANCER THER, V9, P2354, DOI 10.1158/1535-7163.MCT-10-0207; Scotlandi K, 2005, CANCER RES, V65, P3868, DOI 10.1158/0008-5472.CAN-04-3192; Shalaby T, 2010, MOL CANCER THER, V9, P167, DOI 10.1158/1535-7163.MCT-09-0586; SHAPIRO DN, 1990, CANCER RES, V50, P6002; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; Sharp R, 2002, NAT MED, V8, P1276, DOI 10.1038/nm787; Sharpless NE, 2001, MOL CELL, V8, P1187, DOI 10.1016/S1097-2765(01)00425-7; Shor AC, 2007, CANCER RES, V67, P2800, DOI 10.1158/0008-5472.CAN-06-3469; Shukla N, 2012, CLIN CANCER RES, V18, P748, DOI 10.1158/1078-0432.CCR-11-2056; Simon-Keller K, 2013, EXPERT OPIN THER TAR, V17, P127, DOI 10.1517/14728222.2013.734500; Smith MA, 2012, AACR ANN M AM ASS CA; Smith MA, 2012, 54 ASH ANN M EXP AM; Smith MA, 2008, PEDIATR BLOOD CANCER, V51, P34, DOI 10.1002/pbc.21508; Smithey BE, 2002, AM J SURG PATHOL, V26, P486, DOI 10.1097/00000478-200204000-00011; Soundararajan A, 2012, PEDIATR BLOOD CANCER, V59, P485, DOI 10.1002/pbc.24075; Spunt SL, 2012, CANCER-AM CANCER SOC, V118, P3002, DOI 10.1002/cncr.26620; Steinbrook R, 2012, JAMA-J AM MED ASSOC, V308, P1437, DOI 10.1001/jama.2012.12829; Stephens PJ, 2011, CELL, V144, P27, DOI 10.1016/j.cell.2010.11.055; Takahashi Y, 2004, MODERN PATHOL, V17, P660, DOI 10.1038/modpathol.3800101; Takaoka E, 2012, AM J CANCER RES, V2, P141; Taniguchi E, 2008, ONCOGENE, V27, P6550, DOI 10.1038/onc.2008.255; Taylor AC, 2000, MED PEDIATR ONCOL, V35, P96, DOI 10.1002/1096-911X(200008)35:2<96::AID-MPO2>3.0.CO;2-Z; Taylor JG, 2009, J CLIN INVEST, V119, P3395, DOI 10.1172/JCI39703; Thompson CA, 2009, AM J HEALTH-SYST PH, V66, P1890, DOI 10.2146/news090080; Tostar U, 2006, J PATHOL, V208, P17, DOI 10.1002/path.1882; Tostar U, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037761; Tostar Ulrica, 2010, Genes Cancer, V1, P941, DOI 10.1177/1947601910385449; VERNETDERGARABEDIAN B, 1994, J CLIN INVEST, V94, P555, DOI 10.1172/JCI117369; Wachtel M, 2006, J CLIN ONCOL, V24, P816, DOI 10.1200/JCO.2005.03.4934; Wachtel M, 2004, CANCER RES, V64, P5539, DOI 10.1158/0008-5472.CAN-04-0844; Wan XL, 2012, CANCER RES, V72, P5889, DOI 10.1158/0008-5472.CAN-12-1991; Wang H, 2003, INT J EXP PATHOL, V84, P153, DOI 10.1046/j.1365-2613.2003.00347.x; Wang SL, 2010, CANCER SCI, V101, P1108, DOI 10.1111/j.1349-7006.2010.01512.x; Wei CC, 2011, INT J ONCOL, V38, P279, DOI 10.3892/ijo_00000848; Weigel B, 2010, J CLIN ONCOL, V28; Weihkopf T, 2008, EUR J CANCER, V44, P432, DOI 10.1016/j.ejca.2007.11.013; Whiteford CC, 2007, CANCER RES, V67, P32, DOI 10.1158/0008-5472.CAN-06-0610; Williams BA, 2004, J PEDIAT HEMATOL ONC, V26, P243, DOI 10.1097/00043426-200404000-00006; Wysoczynski M, 2007, CANCER RES, V67, P2131, DOI 10.1158/0008-5472.CAN-06-1021; Xu JM, 2010, CANCER RES, V70, P6566, DOI 10.1158/0008-5472.CAN-10-0942; Yamanaka H, 2010, MOL MED REP, V3, P133, DOI 10.3892/mmr_00000230; Yan D, 2009, J BIOL CHEM, V284, P29596, DOI 10.1074/jbc.M109.020511; Yang XHR, 2009, NAT GENET, V41, P1176, DOI 10.1038/ng.454; Ye L, 2005, CHINESE MED J-PEKING, V118, P678; Ye L, 2006, INT J ONCOL, V29, P1149; Yoo JY, 1997, ARCH PATHOL LAB MED, V121, P395; Yoon JW, 2002, J BIOL CHEM, V277, P5548, DOI 10.1074/jbc.M105708200; Yoshida A, 2013, MODERN PATHOL, V26, P772, DOI 10.1038/modpathol.2012.222; Yu SJ, 2004, CLIN CANCER RES, V10, P6750, DOI 10.1158/1078-0432.CCR-04-0223; Zhang JS, 2004, CANCER RES, V64, P6026, DOI 10.1158/0008-5472.CAN-03-2594; Zhang L, 2003, J BIOL CHEM, V278, P27, DOI 10.1074/jbc.M205424200	237	25	25	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2014	33	15					1877	1889		10.1038/onc.2013.129	http://dx.doi.org/10.1038/onc.2013.129			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RK	23665679				2022-12-28	WOS:000334346300001
J	Zhu, X; Guo, Y; Yao, S; Yan, Q; Xue, M; Hao, T; Zhou, F; Zhu, J; Qin, D; Lu, C				Zhu, X.; Guo, Y.; Yao, S.; Yan, Q.; Xue, M.; Hao, T.; Zhou, F.; Zhu, J.; Qin, D.; Lu, C.			Synergy between Kaposi's sarcoma-associated herpesvirus (KSHV) vIL-6 and HIV-1 Nef protein in promotion of angiogenesis and oncogenesis: role of the AKT signaling pathway	ONCOGENE			English	Article						KSHV vIL-6; angiogenesis; tumorigenesis; signal pathway	LYTIC CYCLE REPLICATION; IMMUNODEFICIENCY-VIRUS REPLICATION; IN-VITRO; T-CELLS; TYPE-1; ACTIVATION; AIDS; INFECTION; GP130; INDUCTION	Kaposi's sarcoma-associated herpesvirus (KSHV) is the cause of Kaposi's sarcoma (KS), which is the most common AIDS-associated malignancy. KS is characterized by neovascularization and spindle cell proliferation. The interaction between HIV-1 and KSHV has a central role in promoting the aggressive manifestations of KS in AIDS patients; however, the pathogenesis underlying AIDS-related KS (AIDS-KS) remains unknown. Herein, we examined the potential of HIV-1 negative factor (Nef) to impact KSHV viral interleukin-6 (vIL-6)-induced angiogenesis and tumorigenesis. In vitro experiments showed that exogenous Nef penetrated vIL-6-expressing endothelial cells. Both internalized and ectopic expression of Nef in endothelial cells and fibroblasts synergized with vIL-6 to promote vascular tube formation and cell proliferation. Using a chicken chorioallantoic membrane (CAM) model, we demonstrated that Nef synergistically promotes vIL-6-induced angiogenesis and tumorigenesis. Animal experiments further showed that Nef facilitates vIL-6-induced angiogenesis and tumor formation in athymic nu/nu mice. Mechanistic studies indicated that Nef synergizes with vIL-6 to enhance angiogenesis and tumorigenesis by activating the AKT pathway in the CAM model, as well as nude mice. LY294002, a specific inhibitor of phosphatidylinositol-3-kinase (PI3K), significantly impaired the ability of Nef to promote vIL-6-induced tumorigenesis in an allograft model of nude mice. Our data provide first-line evidence that Nef may contribute to the pathogenesis underlying AIDS-KS in synergy with vIL-6. These novel findings also suggest that targeting the PI3K/AKT signal may be a potentially effective therapeutic approach in AIDS-KS patients.	[Zhu, X.; Lu, C.] Nanjing Med Univ, State Key Lab Reprod Med, Nanjing 210029, Jiangsu, Peoples R China; [Zhu, X.; Lu, C.] Nanjing Med Univ, Key Lab Pathogen Biol Jiangsu Prov, Nanjing 210029, Jiangsu, Peoples R China; [Zhu, X.; Guo, Y.; Yan, Q.; Xue, M.; Hao, T.; Zhou, F.; Qin, D.; Lu, C.] Nanjing Med Univ, Dept Microbiol & Immunol, Nanjing 210029, Jiangsu, Peoples R China; [Zhu, X.] Jiangsu Prov Hosp Tradit Chinese Med, Dept Lab Med, Nanjing, Jiangsu, Peoples R China; [Yao, S.] Quzhou Coll Technol, Sch Med, Quzhou, Peoples R China; [Zhu, J.] Univ Pittsburgh, Inst Canc, Canc Virol Program, Pittsburgh, PA USA	Nanjing Medical University; Nanjing Medical University; Nanjing Medical University; Nanjing University of Chinese Medicine; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Lu, C (corresponding author), Nanjing Med Univ, Dept Microbiol & Immunol, Nanjing 210029, Jiangsu, Peoples R China.	diqin@njmu.edu.cn; clu@njmu.edu.cn		yuanyuan, guo/0000-0002-5122-8545	National Basic Research Program of China (973 Program) [2011CB504803]; National Natural Science Foundation of China [81171552, 30972619, 30900064, 31270199]; Ph.D Programs Foundation of Ministry of Education of China [20123234110006]; Natural Science Foundation of Ministry of Education of Jiangsu Province [10KJA310032, 09KJB310007]; Research Fund for the Doctoral Program of Higher Education of China (New Teacher Fund) [20093234120004]; China Postdoctoral Science Foundation [2012M511304]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ph.D Programs Foundation of Ministry of Education of China(Ministry of Education, China); Natural Science Foundation of Ministry of Education of Jiangsu Province; Research Fund for the Doctoral Program of Higher Education of China (New Teacher Fund); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation)	This work was supported by grants from the National Basic Research Program of China (973 Program) (2011CB504803), National Natural Science Foundation of China (81171552, 30972619, 30900064, 31270199), the Ph.D Programs Foundation of Ministry of Education of China (20123234110006), Natural Science Foundation of Ministry of Education of Jiangsu Province (great project 10KJA310032 and grant 09KJB310007), Research Fund for the Doctoral Program of Higher Education of China (New Teacher Fund, grant 20093234120004) and China Postdoctoral Science Foundation (2012M511304).	AIKEN C, 1994, CELL, V76, P853, DOI 10.1016/0092-8674(94)90360-3; Akula SM, 2003, J VIROL, V77, P7978, DOI 10.1128/JVI.77.14.7978-7990.2003; Aoki Y, 1999, BLOOD, V93, P4034, DOI 10.1182/blood.V93.12.4034.412k38_4034_4043; Aoki Y, 2000, J HEMATOTH STEM CELL, V9, P137, DOI 10.1089/152581600319351; BERAL V, 1990, LANCET, V335, P123, DOI 10.1016/0140-6736(90)90001-L; Blagoveshchenskaya AD, 2002, CELL, V111, P853, DOI 10.1016/S0092-8674(02)01162-5; Blum L, 1997, AIDS, V11, P1653; Boshoff C, 2001, PHILOS T R SOC B, V356, P517, DOI 10.1098/rstb.2000.0778; BOVI PD, 1986, CANCER RES, V46, P6333; Caby MP, 2005, INT IMMUNOL, V17, P879, DOI 10.1093/intimm/dxh267; Cerimele F, 2001, J VIROL, V75, P2435, DOI 10.1128/JVI.75.5.2435-2443.2001; CESARMAN E, 1995, NEW ENGL J MED, V332, P1186, DOI 10.1056/NEJM199505043321802; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Chen XY, 2009, NEOPLASIA, V11, P1272, DOI 10.1593/neo.09494; Choi J, 2005, J VIROL, V79, P11194, DOI 10.1128/JVI.79.17.11194-11204.2005; Choi J, 2005, J VIROL, V79, P264, DOI 10.1128/JVI.79.1.264-276.2005; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; Ensoli B, 1996, EUR J CANCER PREV, V5, P410; ENSOLI B, 1993, J VIROL, V67, P277, DOI 10.1128/JVI.67.1.277-287.1993; Fujii Y, 1996, FEBS LETT, V393, P93, DOI 10.1016/0014-5793(96)00859-9; Ganem D, 2006, ANNU REV PATHOL-MECH, V1, P273, DOI 10.1146/annurev.pathol.1.110304.100133; Greenway AL, 2003, J BIOSCIENCES, V28, P323, DOI 10.1007/BF02970151; Guo HG, 2004, J VIROL, V78, P9336, DOI 10.1128/JVI.78.17.9336-9342.2004; GUY B, 1990, VIROLOGY, V176, P413, DOI 10.1016/0042-6822(90)90011-F; GUY B, 1987, NATURE, V330, P266, DOI 10.1038/330266a0; Hanna Z, 1998, CELL, V95, P163, DOI 10.1016/S0092-8674(00)81748-1; Harrington W, 1997, LANCET, V349, P774; He JCJ, 2004, J CLIN INVEST, V114, P643, DOI 10.1172/JCI200421004; Husain M, 2005, AIDS, V19, P1975, DOI 10.1097/01.aids.0000191918.42110.27; Junkin M, 2011, BIOMATERIALS, V32, P1848, DOI 10.1016/j.biomaterials.2010.11.009; KAAYA EE, 1995, J ACQ IMMUN DEF SYND, V10, P295; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; Leonard JA, 2011, J VIROL, V85, P6867, DOI 10.1128/JVI.00229-11; Linnemann T, 2002, VIROLOGY, V294, P246, DOI 10.1006/viro.2002.1365; Macreadie IG, 1998, J BIOMED SCI, V5, P203, DOI 10.1007/BF02253470; Marecki JC, 2006, AM J RESP CRIT CARE, V174, P437, DOI 10.1164/rccm.200601-005OC; Meads MB, 2004, J BIOL CHEM, V279, P51793, DOI 10.1074/jbc.M407382200; Merat R, 2002, INT J CANCER, V97, P791, DOI 10.1002/ijc.10086; Mercader M, 2000, AM J PATHOL, V156, P1961, DOI 10.1016/S0002-9440(10)65069-9; Mocroft A, 1998, ARCH INTERN MED, V158, P491, DOI 10.1001/archinte.158.5.491; Molden J, 1997, J BIOL CHEM, V272, P19625, DOI 10.1074/jbc.272.31.19625; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; Morris VA, 2008, J VIROL, V82, P8771, DOI 10.1128/JVI.00766-08; Morris VA, 2012, VIROLOGY, V428, P112, DOI 10.1016/j.virol.2012.03.013; Mullberg J, 2000, J IMMUNOL, V164, P4672, DOI 10.4049/jimmunol.164.9.4672; Peter F, 1998, IMMUNITY, V9, P433, DOI 10.1016/S1074-7613(00)80626-3; Qiao XG, 2006, NAT IMMUNOL, V7, P302, DOI 10.1038/ni1302; Qin D, 2008, CELL MICROBIOL, V10, P713, DOI 10.1111/j.1462-5822.2007.01079.x; Qin D, 2011, BMC MICROBIOL, V11, DOI 10.1186/1471-2180-11-240; Raymond AD, 2011, AIDS RES HUM RETROV, V27, P167, DOI 10.1089/aid.2009.0170; Strathdee S A, 1996, AIDS, V10 Suppl A, pS51, DOI 10.1097/00002030-199601001-00008; Suthaus J, 2011, EUR J CELL BIOL, V90, P495, DOI 10.1016/j.ejcb.2010.10.016; Tang Q, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031652; Varthakavi V, 1999, J VIROL, V73, P10329, DOI 10.1128/JVI.73.12.10329-10338.1999; Voelkel NF, 2008, AIDS, V22, pS49, DOI 10.1097/01.aids.0000327516.55041.01; Wan XY, 1999, J VIROL, V73, P8268, DOI 10.1128/JVI.73.10.8268-8278.1999; Wolf D, 2001, NAT MED, V7, P1217, DOI 10.1038/nm1101-1217; Xu WF, 2009, NAT IMMUNOL, V10, P1008, DOI 10.1038/ni.1753; Zeng Y, 2007, J VIROL, V81, P2401, DOI 10.1128/JVI.02024-06; Zhou F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053145; Zhu TS, 2011, CANCER RES, V71, P6061, DOI 10.1158/0008-5472.CAN-10-4269; Zhu XL, 2011, J MOL BIOL, V410, P1035, DOI 10.1016/j.jmb.2011.03.055	62	51	53	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2014	33	15					1986	1996		10.1038/onc.2013.136	http://dx.doi.org/10.1038/onc.2013.136			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RK	23604117				2022-12-28	WOS:000334346300011
J	Zucchini, C; Manara, MC; Pinca, RS; De Sanctis, P; Guerzoni, C; Sciandra, M; Lollini, PL; Cenacchi, G; Picci, P; Valvassori, L; Scotlandi, K				Zucchini, C.; Manara, M. C.; Pinca, R. S.; De Sanctis, P.; Guerzoni, C.; Sciandra, M.; Lollini, P-L; Cenacchi, G.; Picci, P.; Valvassori, L.; Scotlandi, K.			CD99 suppresses osteosarcoma cell migration through inhibition of ROCK2 activity	ONCOGENE			English	Article						CD99; osteosarcoma; cadherins; ezrin; ROCK2; ARP2/3	EWINGS-SARCOMA CELLS; RHO-KINASE-II; MOLECULAR-MECHANISMS; CANCER INVASION; ARP2/3 COMPLEX; IN-VIVO; C-SRC; EXPRESSION; ADHESION; EZRIN	CD99, a transmembrane protein encoded by MIC2 gene is involved in multiple cellular events including cell adhesion and migration, apoptosis, cell differentiation and regulation of protein trafficking either in physiological or pathological conditions. In osteosarcoma, CD99 is expressed at low levels and functions as a tumour suppressor. The full-length protein (CD99wt) and the short-form harbouring a deletion in the intracytoplasmic domain (CD99sh) have been associated with distinct functional outcomes with respect to tumour malignancy. In this study, we especially evaluated modulation of cell-cell contacts, reorganisation of the actin cytoskeleton and modulation of signalling pathways by comparing osteosarcoma cells characterised by different metastasis capabilities and CD99 expression, to identify molecular mechanisms responsible for metastasis. Our data indicate that forced expression of CD99wt induces recruitment of N-cadherin and beta-catenin to adherens junctions. In addition, transfection of CD99wt inhibits the expression of several molecules crucial to the remodelling of the actin cytoskeleton, such as ACTR2, ARPC1A, Rho-associated, coiled-coil containing protein kinase 2 (ROCK2) as well as ezrin, an ezrin/radixin/moesin family member that has been clearly associated with tumour progression and metastatic spread in osteosarcoma. Functional studies point to ROCK2 as a crucial intracellular mediator regulating osteosarcoma migration. By maintaining c-Src in an inactive conformation, CD99wt inhibits ROCK2 signalling and this leads to ezrin decrease at cell membrane while N-cadherin and b-catenin translocate to the plasma membrane and function as main molecular bridges for actin cytoskeleton. Taken together, we propose that the re-expression of CD99wt, which is generally present in osteoblasts but lost in osteosarcoma, through inhibition of c-Src and ROCK2 activity, manages to increase contact strength and reactivate stop-migration signals that counteract the otherwise dominant promigratory action of ezrin in osteosarcoma cells.	[Zucchini, C.; De Sanctis, P.; Lollini, P-L; Valvassori, L.] Univ Bologna, Dept Expt Diagnost & Specialty Med, Bologna, Italy; [Manara, M. C.; Pinca, R. S.; Sciandra, M.; Scotlandi, K.] CRS Dev Biomol Therapies, Bologna, Italy; [Manara, M. C.; Pinca, R. S.; Guerzoni, C.; Picci, P.; Scotlandi, K.] Ist Ortoped Rizzoli, Expt Oncol Lab, I-40136 Bologna, Italy; [Guerzoni, C.; Scotlandi, K.] Ist Ortoped Rizzoli, RIT Dept, STB, PROMETEO Lab, I-40136 Bologna, Italy; [Cenacchi, G.] Univ Bologna, Dept Biomed & Neuromotor Sci, Bologna, Italy	University of Bologna; IRCCS Istituto Ortopedico Rizzoli; IRCCS Istituto Ortopedico Rizzoli; University of Bologna	Scotlandi, K (corresponding author), Ist Ortoped Rizzoli, CRS Dev Biomol Therapies, Via Barbiano 1-10, I-40136 Bologna, Italy.	katia.scotlandi@ior.it	Scotlandi, Katia/J-9009-2016; Manara, Maria Cristina/K-3366-2018; Sciandra, Marika/C-8724-2018; De Sanctis, Paola/HCI-1421-2022; Lollini, Pier Luigi/A-7644-2008; Picci, Piero/J-5979-2016	Scotlandi, Katia/0000-0001-6114-9499; Manara, Maria Cristina/0000-0001-5686-720X; Sciandra, Marika/0000-0001-7147-6960; Lollini, Pier Luigi/0000-0003-1702-4108; Picci, Piero/0000-0002-8519-4101; CENACCHI, GIOVANNA/0000-0001-5824-3118	Italian Association for Cancer Research (AIRC) [IG10452]; Liddy Shriver Sarcoma Initiative; Ricerca Fondamentale Orientata (RFO)	Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); Liddy Shriver Sarcoma Initiative; Ricerca Fondamentale Orientata (RFO)	We are in debt to Cristina Ghinelli for editing the manuscript and to Anming Meng, Department of Biological Sciences and Biotechnology, Tsinghua University, Beijing 100084, China, for kindly providing the plasmid pCMV5-HA3-ROCK2. This work was supported by the Italian Association for Cancer Research (AIRC; IG10452 to K Scotlandi), the Liddy Shriver Sarcoma Initiative (international grant to K Scotlandi) and Ricerca Fondamentale Orientata (RFO 2010 to C Zucchini). Rosa Simona Pinca is a recipient of a fellowship from the Associazione Onlus 'il Pensatore: Matteo Amitrano' and 'Liberi di Vivere Luca Righi.'	Alberti I, 2002, FASEB J, V16, P1946, DOI 10.1096/fj.02-0049fje; Bacci G, 2006, CANCER-AM CANCER SOC, V106, P1154, DOI 10.1002/cncr.21724; Bernard G, 2000, EUR J IMMUNOL, V30, P3061, DOI 10.1002/1521-4141(200010)30:10<3061::AID-IMMU3061>3.0.CO;2-M; Bernard G, 1997, J IMMUNOL, V158, P2543; BERNARD G, 1995, J IMMUNOL, V154, P26; Borensztajn K, 2010, THROMB RES, V125, pE323, DOI 10.1016/j.thromres.2010.02.018; Bruce B, 2007, CLIN EXP METASTAS, V24, P69, DOI 10.1007/s10585-006-9050-x; Bulut G, 2012, ONCOGENE, V31, P269, DOI 10.1038/onc.2011.245; Byun HJ, 2006, J BIOL CHEM, V281, P34833, DOI 10.1074/jbc.M605483200; Cai YP, 2010, J PATHOL, V220, P24, DOI 10.1002/path.2628; Cerisano V, 2004, ONCOGENE, V23, P5664, DOI 10.1038/sj.onc.1207741; Croft DR, 2004, CANCER RES, V64, P8994, DOI 10.1158/0008-5472.CAN-04-2052; D'Souza-Schorey C, 2005, TRENDS CELL BIOL, V15, P19, DOI 10.1016/j.tcb.2004.11.002; Derycke LDM, 2004, INT J DEV BIOL, V48, P463, DOI 10.1387/ijdb.041793ld; Dworzak MN, 1999, BRIT J HAEMATOL, V105, P690, DOI 10.1046/j.1365-2141.1999.01426.x; Dworzak MN, 2004, LEUKEMIA, V18, P703, DOI 10.1038/sj.leu.2403303; Fievet BT, 2004, J CELL BIOL, V164, P653, DOI 10.1083/jcb.200307032; Hahn JH, 1997, J IMMUNOL, V159, P2250; Hall A, 2000, PHILOS T R SOC B, V355, P965, DOI 10.1098/rstb.2000.0632; Hamada K, 2000, EMBO J, V19, P4449, DOI 10.1093/emboj/19.17.4449; Husak Z, 2010, J LEUKOCYTE BIOL, V88, P405, DOI 10.1189/jlb.0210097; Imbert AM, 2006, BLOOD, V108, P2578, DOI 10.1182/blood-2005-12-010827; Jaganathan BG, 2007, STEM CELLS, V25, P1966, DOI 10.1634/stemcells.2007-0167; Jiao XM, 2008, MOL BIOL CELL, V19, P1378, DOI 10.1091/mbc.E07-08-0753; Jung KC, 2003, FEBS LETT, V554, P478, DOI 10.1016/S0014-5793(03)01224-9; Kamai T, 2003, CLIN CANCER RES, V9, P2632; Kamai T, 2004, CLIN CANCER RES, V10, P4799, DOI 10.1158/1078-0432.CCR-0436-03; Kashima T, 2003, INT J CANCER, V104, P147, DOI 10.1002/ijc.10931; Kashima T, 1999, AM J PATHOL, V155, P1549, DOI 10.1016/S0002-9440(10)65471-5; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Kim C, 2009, CANCER RES TREAT, V41, P138, DOI 10.4143/crt.2009.41.3.138; Kim SH, 2000, BLOOD, V95, P294; Laurila E, 2009, GENE CHROMOSOME CANC, V48, P330, DOI 10.1002/gcc.20643; Lee EJ, 2003, EXP MOL MED, V35, P438, DOI 10.1038/emm.2003.57; Lee HH, 2010, J CELL SCI, V123, P3368, DOI 10.1242/jcs.071555; LEVY R, 1979, P NATL ACAD SCI USA, V76, P6552, DOI 10.1073/pnas.76.12.6552; Lock FE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031423; Longhi A, 2006, CANCER TREAT REV, V32, P423, DOI 10.1016/j.ctrv.2006.05.005; Louvet-Vallee S, 2000, BIOL CELL, V92, P305, DOI 10.1016/S0248-4900(00)01078-9; Manara MC, 2006, MOL BIOL CELL, V17, P1910, DOI 10.1091/mbc.E05-10-0971; Nakamura H, 1996, J BONE MINER RES, V11, P1715; Nurnberg A, 2011, NAT REV CANCER, V11, P177, DOI 10.1038/nrc3003; Otsubo T, 2004, MODERN PATHOL, V17, P461, DOI 10.1038/modpathol.3800062; Pankova K, 2010, CELL MOL LIFE SCI, V67, P63, DOI 10.1007/s00018-009-0132-1; Park HR, 2006, PATHOL RES PRACT, V202, P509, DOI 10.1016/j.prp.2006.01.015; Pettersen RD, 2001, J IMMUNOL, V166, P4931, DOI 10.4049/jimmunol.166.8.4931; Ridley AJ, 2003, SCIENCE, V302, P1704, DOI 10.1126/science.1092053; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; Rivat C, 2004, ONCOGENE, V23, P3317, DOI 10.1038/sj.onc.1207437; Salhia B, 2005, CANCER RES, V65, P8792, DOI 10.1158/0008-5472.CAN-05-0160; Schenkel AR, 2007, CELL COMMUN ADHES, V14, P227, DOI 10.1080/15419060701755966; Schenkel AR, 2002, NAT IMMUNOL, V3, P143, DOI 10.1038/ni749; Scotlandi K, 2007, ONCOGENE, V26, P6604, DOI 10.1038/sj.onc.1210481; Sohn HW, 1998, AM J PATHOL, V153, P1937, DOI 10.1016/S0002-9440(10)65707-0; Vishnubhotla R, 2007, LAB INVEST, V87, P1149, DOI 10.1038/labinvest.3700674; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Wong CCL, 2009, HEPATOLOGY, V49, P1583, DOI 10.1002/hep.22836; Yoneda A, 2005, J CELL BIOL, V170, P443, DOI 10.1083/jcb.200412043; Yoneda A, 2007, MOL BIOL CELL, V18, P66, DOI 10.1091/mbc.E06-08-0684; Yu HF, 2011, FRONT BIOSCI-LANDMRK, V16, P1536, DOI 10.2741/3803; Zhang XJ, 2011, CELL MOL BIOL LETT, V16, P279, DOI 10.2478/s11658-011-0006-z; Zhang Y, 2009, J CELL SCI, V122, P2197, DOI 10.1242/jcs.040659; Zheng SH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022439	63	34	34	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2014	33	15					1912	1921		10.1038/onc.2013.152	http://dx.doi.org/10.1038/onc.2013.152			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RK	23644663				2022-12-28	WOS:000334346300004
J	Reyes, D; Ballare, C; Castellano, G; Soronellas, D; Bago, JR; Blanco, J; Beato, M				Reyes, D.; Ballare, C.; Castellano, G.; Soronellas, D.; Bago, J. R.; Blanco, J.; Beato, M.			Activation of mitogen- and stress-activated kinase 1 is required for proliferation of breast cancer cells in response to estrogens or progestins	ONCOGENE			English	Article						breast cancer; xenografts; estrogen receptor; progesterone receptor; T47D; hormone signaling	NF-KAPPA-B; PROGESTERONE-RECEPTOR; HISTONE H3; GENE-REGULATION; PHOSPHORYLATION; PROTEIN; PATHWAY; MSK1; INDUCTION; ESTRADIOL	Growth of breast cancers is often dependent on ovarian steroid hormones making the tumors responsive to antagonists of hormone receptors. However, eventually the tumors become hormone independent, raising the need to identify downstream targets for the inhibition of tumor growth. One possibility is to focus on the signaling mechanisms used by ovarian steroid hormones to induce breast cancer cell proliferation. Here we report that the mitogen- and stress-activated kinase 1 (MSK1) could be a potential druggable target. Using the breast cancer cell line T47D, we show that estrogens (E2) and progestins activate MSK1, which forms a complex with the corresponding hormone receptor. Inhibition of MSK1 activity with H89 or its depletion by MSK1 short hairpin RNAs (shRNAs) specifically abrogates cell proliferation in response to E2 or progestins without affecting serum-induced cell proliferation. MSK1 activity is required for the transition from the G1- to the S-phase of the cell cycle and inhibition of MSK1 compromises both estradiol- and progestin-dependent induction of cell cycle genes. ChIP-seq experiments identified binding of MSK1 to progesterone receptor-binding sites associated with hormone-responsive genes. MSK1 recruitment to epigenetically defined enhancer regions supports the need of MSK1 as a chromatin remodeler in hormone-dependent regulation of gene transcription. In agreement with this interpretation, expression of a histone H3 mutated at S10 eliminates the hormonal effect on cell proliferation and on induction of relevant target genes. Finally, we show that E2- or progestin-dependent growth of T47D cells xenografted in immunodefficient mice is inhibited by depletion of MSK1, indicating that our findings are not restricted to cultured cells, and that MSK1 plays an important role for hormone-dependent breast cancer growth in a more physiological context.	[Reyes, D.; Ballare, C.; Castellano, G.; Soronellas, D.; Beato, M.] CRG, Barcelona 08003, Spain; [Reyes, D.; Ballare, C.; Castellano, G.; Soronellas, D.; Beato, M.] UPF, Barcelona, Spain; [Bago, J. R.; Blanco, J.] CIBER BBN, CSIC ICCC, Cardiovasc Res Ctr, Barcelona, Spain	Barcelona Institute of Science & Technology; Pompeu Fabra University; Centre de Regulacio Genomica (CRG); Pompeu Fabra University; CIBER - Centro de Investigacion Biomedica en Red; CIBERBBN; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Institut Catala de Ciencies Cardiovasculars (ICCC)	Beato, M (corresponding author), CRG, Doctor Aiguader 88, Barcelona 08003, Spain.	miguel.beato@crg.eu	BAGO, JULI R/M-3526-2018; Beato, Miguel/B-5564-2015; Reyes, Diana/GSI-6210-2022; Reyes Garau, Diana/ABF-9958-2021; Reyes, Diana/A-9441-2017; Blanco, Jeronimo/H-2764-2015; Ballare, Cecilia/F-2593-2016	BAGO, JULI R/0000-0002-2862-4048; Beato, Miguel/0000-0002-2878-2222; Reyes Garau, Diana/0000-0002-9746-6485; Blanco, Jeronimo/0000-0003-3765-0640; Ballare, Cecilia/0000-0002-9442-807X; Castellano, Giancarlo/0000-0002-5715-7733	Spanish government [BMC 2003-02902, 2010-15313, CSD2006-00049]; European Union (IP HEROIC); Catalan government (AGAUR); fellowship from the Spanish Ministry of Science	Spanish government(Spanish GovernmentEuropean Commission); European Union (IP HEROIC); Catalan government (AGAUR)(Agencia de Gestio D'Ajuts Universitaris de Recerca Agaur (AGAUR)); fellowship from the Spanish Ministry of Science	We thank Luciano Di Croce, CRG, for providing the expression vector for histone H3, the CRG ultrasequencing facility and Dr Juan Valcarcel for help with the manuscript. The experimental work has been supported by grants from the Spanish government (BMC 2003-02902 and 2010-15313; CSD2006-00049), the European Union (IP HEROIC) and the Catalan government (AGAUR). DR was the recipient of a fellowship from the Spanish Ministry of Science.	Allred DC, 2001, ENDOCR-RELAT CANCER, V8, P47, DOI 10.1677/erc.0.0080047; Arthur JSC, 2004, J NEUROSCI, V24, P4324, DOI 10.1523/JNEUROSCI.5227-03.2004; Ballare C, 2003, MOL CELL BIOL, V23, P1994, DOI 10.1128/MCB.23.6.1994-2008.2003; Ballare C, 2013, MOL CELL, V49, P67, DOI 10.1016/j.molcel.2012.10.019; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; BLOBEL GA, 1995, MOL CELL BIOL, V15, P3147; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; Cerillo G, 1998, J STEROID BIOCHEM, V67, P79, DOI 10.1016/S0960-0760(98)00078-8; Chang S, CANC INVEST, V29, P240; CLARKE CL, 1990, J BIOL CHEM, V265, P12694; Clarke R, 2003, ONCOGENE, V22, P7316, DOI 10.1038/sj.onc.1206937; Cui KR, 2009, CELL STEM CELL, V4, P80, DOI 10.1016/j.stem.2008.11.011; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Drobic B, NUCL ACIDS RES, V38, P3196; Drobic B, 2010, NUCLEIC ACIDS RES, V38, P3196, DOI 10.1093/nar/gkq030; Foidart JM, 1998, FERTIL STERIL, V69, P963, DOI 10.1016/S0015-0282(98)00042-9; Harrell JC, 2007, CANCER RES, V67, P10582, DOI 10.1158/0008-5472.CAN-07-1655; Hewitt SC, 2005, ANNU REV PHYSIOL, V67, P285, DOI 10.1146/annurev.physiol.67.040403.115914; Hirota T, 2005, NATURE, V438, P1176, DOI 10.1038/nature04254; Khan SA, 1998, J NATL CANCER I, V90, P37, DOI 10.1093/jnci/90.1.37; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Kuukasjarvi T, 1996, J CLIN ONCOL, V14, P2584, DOI 10.1200/JCO.1996.14.9.2584; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lauper N, 1998, ONCOGENE, V17, P2637, DOI 10.1038/sj.onc.1202477; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lochner A, 2006, CARDIOVASC DRUG REV, V24, P261, DOI 10.1111/j.1527-3466.2006.00261.x; LYDON JP, 1995, GENE DEV, V9, P2266, DOI 10.1101/gad.9.18.2266; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Migliaccio A, 1998, EMBO J, V17, P2008, DOI 10.1093/emboj/17.7.2008; NANDI S, 1958, J NATL CANCER I, V21, P1039; Vicent GP, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000567; Prigent C, 2003, J CELL SCI, V116, P3677, DOI 10.1242/jcs.00735; Ritchie ME, 2007, BIOINFORMATICS, V23, P2700, DOI 10.1093/bioinformatics/btm412; Sancho M, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000227; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Strutt H, 1999, METH MOL B, V119, P455; Subtil-Rodriguez A, 2008, MOL CELL BIOL, V28, P3830, DOI 10.1128/MCB.01217-07; Thomson S, 1999, SEMIN CELL DEV BIOL, V10, P205, DOI 10.1006/scdb.1999.0302; Vermeulen L, 2003, EMBO J, V22, P1313, DOI 10.1093/emboj/cdg139; Vicent GP, GENES DEV, V25, P845; Vicent GP, 2006, MOL CELL, V24, P367, DOI 10.1016/j.molcel.2006.10.011; Vicent Guillermo P, 2009, Nucl Recept Signal, V7, pe008, DOI 10.1621/nrs.07008; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Weinstein-Oppenheimer CR, 2002, CANCER BIOL THER, V1, P256, DOI 10.4161/cbt.77; Wiggin GR, 2002, MOL CELL BIOL, V22, P2871, DOI 10.1128/MCB.22.8.2871-2881.2002; WILSON JE, 1972, BIOCHIM BIOPHYS ACTA, V276, P568, DOI 10.1016/0005-2744(72)91022-4; Wright RHG, 2012, GENE DEV, V26, P1972, DOI 10.1101/gad.193193.112	50	25	25	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2014	33	12					1570	1580		10.1038/onc.2013.95	http://dx.doi.org/10.1038/onc.2013.95			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD4TS	23604116				2022-12-28	WOS:000333244200010
J	Su, H; Xu, T; Ganapathy, S; Shadfan, M; Long, M; Huang, THM; Thompson, I; Yuan, ZM				Su, H.; Xu, T.; Ganapathy, S.; Shadfan, M.; Long, M.; Huang, T. H-M; Thompson, I.; Yuan, Z-M			Elevated snoRNA biogenesis is essential in breast cancer	ONCOGENE			English	Article						breast cancer; fibrillarin; nucleolar stress; p53; snoRNA	RIBOSOMAL-PROTEIN L23; RNA-POLYMERASE-I; P53 ISOFORMS; TRANSLATION; GENES; INHIBITION; EXPRESSION; NUCLEOLUS; INDUCTION; APOPTOSIS	Hyperactive ribosomal biogenesis is widely observed in cancer, which has been partly attributed to the increased rDNA transcription by Pol I in cancer. However, whether small nucleolar RNAs (snoRNAs), a class of non-coding RNAs crucial in ribosomal RNA (rRNA) maturation and functionality, are involved in cancer remains elusive. We report that snoRNAs and fibrillarin (FBL, an enzymatic small nucleolar ribonucleoprotein, snoRNP) are frequently overexpressed in both murine and human breast cancer as well as in prostate cancers, and significantly, that this overexpression is essential for tumorigenicity in vitro and in vivo. We demonstrate that when the elevated snoRNA pathway is suppressed, the tumor suppressor p53 can act as a sentinel of snoRNP perturbation, the activation of which mediates the growth inhibitory effect. On the other hand, high level of FBL interferes with the activation of p53 by stress. We further show that p53 activation by FBL knockdown is not only regulated by the ribosomal protein-MDM2-mediated protein stabilization pathway, but also by enhanced PTB-dependent, cap-independent translation. Together, our data uncover an essential role of deregulated snoRNA biogenesis in tumors and a new mechanism of nucleolar modulation of p53.	[Su, H.; Xu, T.; Ganapathy, S.; Shadfan, M.; Long, M.; Yuan, Z-M] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiat Oncol, San Antonio, TX 78229 USA; [Ganapathy, S.; Long, M.; Yuan, Z-M] Harvard Univ, Dept Genet & Complex Dis, Boston, MA 02115 USA; [Huang, T. H-M] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78229 USA; [Thompson, I.] Univ Texas Hlth Sci Ctr San Antonio, Dept Urol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio; Harvard University; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio	Yuan, ZM (corresponding author), Harvard Univ, Dept Genet & Complex Dis, Boston, MA 02115 USA.	zyuan@hsph.harvard.edu			 [NIH/NCI. 2 R01 CA85679-10];  [R01 CA125144]; NATIONAL CANCER INSTITUTE [R01CA125144, R01CA085679] Funding Source: NIH RePORTER	; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work is supported by NIH/NCI. 2 R01 CA85679-10; R01 CA125144 for Zhi-Min Yuan.	Barna M, 2008, NATURE, V456, P971, DOI 10.1038/nature07449; Boon K, 2001, EMBO J, V20, P1383, DOI 10.1093/emboj/20.6.1383; CAVANAUGH AH, 1995, NATURE, V374, P177, DOI 10.1038/374177a0; Coller HA, 2000, P NATL ACAD SCI USA, V97, P3260, DOI 10.1073/pnas.97.7.3260; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; DERENZINI M, 1991, INT REV EXP PATHOL, V32, P149; Derenzini M, 2009, HISTOPATHOLOGY, V54, P753, DOI 10.1111/j.1365-2559.2008.03168.x; Gasco M, 2002, BREAST CANCER RES, V4, P70, DOI 10.1186/bcr426; Grover R, 2008, CELL CYCLE, V7, P2189, DOI 10.4161/cc.7.14.6271; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; Kondrashov AV, 2005, J MOL BIOL, V353, P88, DOI 10.1016/j.jmb.2005.07.049; Krastev DB, 2011, NAT CELL BIOL, V13, P809, DOI 10.1038/ncb2264; Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X; Macias E, 2010, CANCER CELL, V18, P231, DOI 10.1016/j.ccr.2010.08.007; Mahata B, 2012, ONCOGENE, V31, P3060, DOI 10.1038/onc.2011.482; Mei YP, 2012, ONCOGENE, V31, P2794, DOI 10.1038/onc.2011.449; Montanaro L, 2008, AM J PATHOL, V173, P301, DOI 10.2353/ajpath.2008.070752; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Ray PS, 2006, EMBO REP, V7, P404, DOI 10.1038/sj.embor.7400623; Ruggero D, 2003, NAT REV CANCER, V3, P179, DOI 10.1038/nrc1015; Su H, 2009, CANCER RES, V69, P1135, DOI 10.1158/0008-5472.CAN-08-2886; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Vogt PK, 2001, TRENDS MOL MED, V7, P482, DOI 10.1016/S1471-4914(01)02161-X; Wang WZ, 2008, FEBS LETT, V582, P2689, DOI 10.1016/j.febslet.2008.06.048; Watkins NJ, 2004, MOL CELL, V16, P789, DOI 10.1016/j.molcel.2004.11.012; White RJ, 2005, NAT REV MOL CELL BIO, V6, P69, DOI 10.1038/nrm1551; Williams GT, 2012, NAT REV CANCER, V12, P84, DOI 10.1038/nrc3195; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003	32	118	125	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2014	33	11					1348	1358		10.1038/onc.2013.89	http://dx.doi.org/10.1038/onc.2013.89			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD0SD	23542174				2022-12-28	WOS:000332943500002
J	Finger, EC; Cheng, CF; Williams, TR; Rankin, EB; Bedogni, B; Tachiki, L; Spong, S; Giaccia, AJ; Powell, MB				Finger, E. C.; Cheng, C-F; Williams, T. R.; Rankin, E. B.; Bedogni, B.; Tachiki, L.; Spong, S.; Giaccia, A. J.; Powell, M. B.			CTGF is a therapeutic target for metastatic melanoma	ONCOGENE			English	Article						connective tissue growth factor (CTGF); melanoma; invasion; metastasis; therapeutic target; hypoxia	TISSUE GROWTH-FACTOR; PANCREATIC TUMOR-GROWTH; GENE-EXPRESSION; MALIGNANT-MELANOMA; HYPOXIC INDUCTION; CANCER; PROGRESSION; PROTEINS; ANGIOGENESIS; MECHANISMS	Metastatic melanoma remains a devastating disease with a 5-year survival rate of less than five percent. Despite recent advances in targeted therapies for melanoma, only a small percentage of melanoma patients experience durable remissions. Therefore, it is critical to identify new therapies for the treatment of advanced melanoma. Here, we define connective tissue growth factor (CTGF) as a therapeutic target for metastatic melanoma. Clinically, CTGF expression correlates with tumor progression and is strongly induced by hypoxia through HIF-1 and HIF-2-dependent mechanisms. Genetic inhibition of CTGF in human melanoma cells is sufficient to significantly reduce orthotopic tumor growth, as well as metastatic tumor growth in the lung of severe combined immunodeficient (SCID) mice. Mechanistically, inhibition of CTGF decreased invasion and migration associated with reduced matrix metalloproteinase-9 expression. Most importantly, the anti-CTGF antibody, FG-3019, had a profound inhibitory effect on the progression of established metastatic melanoma. These results offer the first preclinical validation of anti-CTGF therapy for the treatment of advanced melanoma and underscore the importance of tumor hypoxia in melanoma progression.	[Finger, E. C.; Cheng, C-F; Williams, T. R.; Rankin, E. B.; Tachiki, L.; Giaccia, A. J.; Powell, M. B.] Stanford Univ, Div Radiat & Canc Biol, Dept Radiat Oncol, Stanford, CA 94305 USA; [Bedogni, B.] Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; [Spong, S.] FibroGen Inc, San Francisco, CA USA	Stanford University; Case Western Reserve University; FibroGen	Powell, MB (corresponding author), Stanford Univ, Div Radiat & Canc Biol, Dept Radiat Oncol, 269 Campus Dr,CCSR-S-1250, Stanford, CA 94305 USA.	mbp@stanford.edu		Rankin, Erinn/0000-0002-2045-2296	NIH [CA67166, CA116685, CA120526, T32 CA121940, T32 CA09302]; NATIONAL CANCER INSTITUTE [R01CA120526, R01CA116685, T32CA121940, T32CA009302, P01CA067166] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of the Giaccia Laboratory for their insightful discussions. We kindly thank Dr Boris C Bastian for discussions and review of our tissue array analysis methodology and Dr Adam J Krieg for his insights on the microarray analysis. We appreciate Kathy Brown's guiding hand with the low passage melanoma cell lines. This investigation was supported by NIH grants CA67166 and CA116685 (AJG), CA120526 (MBP), T32 CA121940 (ECF) and T32 CA09302 (TRW).	Aguissa-Toure AH, 2012, CELL MOL LIFE SCI, V69, P1475, DOI 10.1007/s00018-011-0878-0; Bedogni B, 2008, J CLIN INVEST, V118, P3660, DOI 10.1172/JCI36157; Bedogni B, 2009, PIGM CELL MELANOMA R, V22, P166, DOI 10.1111/j.1755-148X.2009.00553.x; Bennewith KL, 2009, CANCER RES, V69, P775, DOI 10.1158/0008-5472.CAN-08-0987; Bindra RS, 2005, ANN NY ACAD SCI, V1059, P184, DOI 10.1196/annals.1339.049; BORK P, 1993, FEBS LETT, V327, P125, DOI 10.1016/0014-5793(93)80155-N; Braig S, 2011, BRIT J CANCER, V105, P231, DOI 10.1038/bjc.2011.226; Chan DA, 2007, CANCER METAST REV, V26, P333, DOI 10.1007/s10555-007-9063-1; Chan DA, 2009, CANCER CELL, V15, P527, DOI 10.1016/j.ccr.2009.04.010; Chen PP, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000534; Chu CY, 2008, J BIOMED SCI, V15, P675, DOI 10.1007/s11373-008-9264-9; Chujo S, 2009, J CELL PHYSIOL, V220, P189, DOI 10.1002/jcp.21750; Cicha I, 2009, BIOFACTORS, V35, P200, DOI 10.1002/biof.30; Dahl C, 2007, APMIS, V115, P1161, DOI 10.1111/j.1600-0463.2007.apm_855.xml.x; Dhar A., 2010, Experimental Oncology, V32, P2; Dornhofer N, 2006, CANCER RES, V66, P5816, DOI 10.1158/0008-5472.CAN-06-0081; Finger EC, 2010, CANCER METAST REV, V29, P285, DOI 10.1007/s10555-010-9224-5; Flaherty KT, 2012, NEW ENGL J MED, V367, P1694, DOI 10.1056/NEJMoa1210093; Hall-Glenn F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030562; Haluska FG, 2006, CLIN CANCER RES, V12, p2301S, DOI 10.1158/1078-0432.CCR-05-2518; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Higgins DF, 2004, AM J PHYSIOL-RENAL, V287, pF1223, DOI 10.1152/ajprenal.00245.2004; Hubble J, 2009, NUCLEIC ACIDS RES, V37, pD898, DOI 10.1093/nar/gkn786; Koliopanos A, 2002, WORLD J SURG, V26, P420, DOI 10.1007/s00268-001-0242-x; Kondo S, 2002, CARCINOGENESIS, V23, P769, DOI 10.1093/carcin/23.5.769; Lartigau E, 1997, MELANOMA RES, V7, P400, DOI 10.1097/00008390-199710000-00006; Liu LY, 2008, WORLD J GASTROENTERO, V14, P2110, DOI 10.3748/wjg.14.2110; Mole DR, 2009, J BIOL CHEM, V284, P16767, DOI 10.1074/jbc.M901790200; Norman JT, 2000, KIDNEY INT, V58, P2351, DOI 10.1046/j.1523-1755.2000.00419.x; PATEL B, 1994, BIOCHEM MOL BIOL INT, V34, P639; Payne SL, 2007, J CELL BIOCHEM, V101, P1338, DOI 10.1002/jcb.21371; Perbal B, 2004, LANCET, V363, P62, DOI 10.1016/S0140-6736(03)15172-0; Rankin EB, 2008, CELL DEATH DIFFER, V15, P678, DOI 10.1038/cdd.2008.21; Riker AI, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-13; Sala-Torra O, 2007, BLOOD, V109, P3080, DOI 10.1182/blood-2006-06-031096; Samarin J, 2010, J BIOL CHEM, V285, P4328, DOI 10.1074/jbc.M109.049650; Shakunaga T, 2000, CANCER, V89, P1466, DOI 10.1002/1097-0142(20001001)89:7<1466::AID-CNCR8>3.0.CO;2-G; SHWEIKI D, 1992, NATURE, V359, P843, DOI 10.1038/359843a0; Turcotte S, 2008, CANCER CELL, V14, P90, DOI 10.1016/j.ccr.2008.06.004; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Xie D, 2004, CLIN CANCER RES, V10, P2072, DOI 10.1158/1078-0432.CCR-0659-03; Zhang B, 2010, DIABETES, V59, P1809, DOI 10.2337/db09-1056; Zhang H, 2003, BLOOD, V101, P2253, DOI 10.1182/blood-2002-02-0629	43	52	58	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2014	33	9					1093	1100		10.1038/onc.2013.47	http://dx.doi.org/10.1038/onc.2013.47			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XT	23435419	Green Accepted			2022-12-28	WOS:000331933800003
J	Walters, ZS; Villarejo-Balcells, B; Olmos, D; Buist, TWS; Missiaglia, E; Allen, R; Al-Lazikani, B; Garrett, MD; Blagg, J; Shipley, J				Walters, Z. S.; Villarejo-Balcells, B.; Olmos, D.; Buist, T. W. S.; Missiaglia, E.; Allen, R.; Al-Lazikani, B.; Garrett, M. D.; Blagg, J.; Shipley, J.			JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells	ONCOGENE			English	Article						rhabdomyosarcoma; PAX3-FOXO1; histone methylation; polycomb repressive complex 2; JARID2; myogenic differentiation	CHILDRENS ONCOLOGY GROUP; HIGH-RISK NEUROBLASTOMA; REPRESSIVE COMPLEX 2; MUSCLE STEM-CELLS; ALVEOLAR RHABDOMYOSARCOMA; GENE-EXPRESSION; HISTONE DEMETHYLASES; 13-CIS-RETINOIC ACID; TRANSCRIPTION FACTOR; CARDIAC DEVELOPMENT	Rhabdomyosarcomas (RMS) are the most frequent soft-tissue sarcoma in children and characteristically show features of developing skeletal muscle. The alveolar subtype is frequently associated with a PAX3-FOXO1 fusion protein that is known to contribute to the undifferentiated myogenic phenotype of RMS cells. Histone methylation of lysine residues controls developmental processes in both normal and malignant cell contexts. Here we show that JARID2, which encodes a protein known to recruit various complexes with histone-methylating activity to their target genes, is significantly overexpressed in RMS with PAX3-FOXO1 compared with the fusion gene-negative RMS (t-test; P<0.0001). Multivariate analyses showed that higher JARID2 levels are also associated with metastases at diagnosis, independent of fusion gene status and RMS subtype (n = 120; P = 0.039). JARID2 levels were altered by silencing or overexpressing PAX3-FOXO1 in RMS cell lines with and without the fusion gene, respectively. Consistent with this, we demonstrated that JARID2 is a direct transcriptional target of the PAX3-FOXO1 fusion protein. Silencing JARID2 resulted in reduced cell proliferation coupled with myogenic differentiation, including increased expression of Myogenin (MYOG) and Myosin Light Chain (MYL1) in RMS cell lines representative of both the alveolar and embryonal subtypes. Induced myogenic differentiation was associated with a decrease in JARID2 levels and this phenotype could be rescued by overexpressing JARID2. Furthermore, we that showed JARID2 binds to and alters the methylation status of histone H3 lysine 27 in the promoter regions of MYOG and MYL1 and that the interaction of JARID2 at these promoters is dependent on EED, a core component of the polycomb repressive complex 2 (PRC2). Therefore, JARID2 is a downstream effector of PAX3-FOXO1 that maintains an undifferentiated myogenic phenotype that is characteristic of RMS. JARID2 and other components of PRC2 may represent novel therapeutic targets for treating RMS patients.	[Walters, Z. S.; Villarejo-Balcells, B.; Olmos, D.; Buist, T. W. S.; Missiaglia, E.; Allen, R.; Shipley, J.] Inst Canc Res, Div Mol Pathol, Sarcoma Mol Pathol Team, London SM2 5NG, England; [Walters, Z. S.; Villarejo-Balcells, B.; Olmos, D.; Buist, T. W. S.; Missiaglia, E.; Allen, R.; Shipley, J.] Inst Canc Res, Div Canc Therapeut, Sarcoma Mol Pathol Team, London SM2 5NG, England; [Olmos, D.] Royal Marsden Hosp NHS Trust, Sarcoma Unit, London, England; [Buist, T. W. S.; Al-Lazikani, B.; Blagg, J.] Inst Canc Res, Div Canc Therapeut, Canc Res UK Canc Therapeut Unit, London SM2 5NG, England; [Missiaglia, E.] Univ Lausanne, Swiss Inst Bioinformat, Bioinformat Core Facil, Lausanne, Switzerland; [Garrett, M. D.] Inst Canc Res, Div Canc Therapeut, Canc Res UK Canc Therapeut Unit, Cell Cycle Control Team, London SM2 5NG, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Swiss Institute of Bioinformatics; University of Lausanne; Cancer Research UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Shipley, J (corresponding author), Inst Canc Res, Div Mol Pathol, Sarcoma Mol Pathol Team, London SM2 5NG, England.	janet.shipley@icr.ac.uk	Al-Lazikani, Bissan/AFK-6457-2022; Al-Lazikani, Bissan/AAG-4723-2022; Olmos, David/L-5664-2015	Al-Lazikani, Bissan/0000-0003-3367-2519; missiaglia, edoardo/0000-0001-9221-0117; Shipley, Janet/0000-0001-6748-8678; Olmos Hidalgo, David/0000-0002-7003-4826; Walters, Zoe/0000-0002-1835-5868	Cancer Research UK [C5066/A10399]; Sarcoma UK; Chris Lucas Trust; Rob's ARTTT Charity; Medical Research Council; Spanish Society of Medical Oncology (SEOM) Translational Research Fellowship; NHS; Cancer Research UK [11566] Funding Source: researchfish; Sarcoma UK [SUK01.2009] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Sarcoma UK; Chris Lucas Trust; Rob's ARTTT Charity; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Spanish Society of Medical Oncology (SEOM) Translational Research Fellowship; NHS; Cancer Research UK(Cancer Research UK); Sarcoma UK	We are very grateful for help and support with tumor collection and annotation from the Children's Cancer and Leukemia Group. We also thank David Landeira for help with the JARID2 antibody. This work was supported by grants from Cancer Research UK (C5066/A10399); Sarcoma UK; the Chris Lucas Trust; Rob's ARTTT Charity; the Medical Research Council for a studentship (TWSB); the Spanish Society of Medical Oncology (SEOM) Translational Research Fellowship (DO). We acknowledge NHS funding to the NIHR Biomedical Research Center.	AGUANNO S, 1990, CANCER RES, V50, P3377; Asp P, 2011, P NATL ACAD SCI USA, V108, pE149, DOI 10.1073/pnas.1102223108; Barlow JW, 2006, PEDIATR BLOOD CANCER, V47, P773, DOI 10.1002/pbc.20650; Bennicelli JL, 1996, P NATL ACAD SCI USA, V93, P5455, DOI 10.1073/pnas.93.11.5455; Calhabeu F, 2013, ONCOGENE, V32, P651, DOI 10.1038/onc.2012.73; Cao LA, 2010, CANCER RES, V70, P6497, DOI 10.1158/0008-5472.CAN-10-0582; Chang CJ, 2012, BRIT J CANCER, V106, P243, DOI 10.1038/bjc.2011.551; Charytonowicz E, 2009, CANCER LETT, V279, P126, DOI 10.1016/j.canlet.2008.09.039; Ciarapica R, 2009, CELL CYCLE, V8, P172, DOI 10.4161/cc.8.1.7292; Cloos PAC, 2008, GENE DEV, V22, P1115, DOI 10.1101/gad.1652908; Davicioni E, 2006, CANCER RES, V66, P6936, DOI 10.1158/0008-5472.CAN-05-4578; Davicioni E, 2009, AM J PATHOL, V174, P550, DOI 10.2353/ajpath.2009.080631; Epstein JA, 1998, MOL CELL BIOL, V18, P4118, DOI 10.1128/MCB.18.7.4118; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; Grimwade D, 2010, CANCER TREAT RES, V145, P219, DOI 10.1007/978-0-387-69259-3_13; Juan AH, 2011, GENE DEV, V25, P789, DOI 10.1101/gad.2027911; Jung J, 2005, J BIOL CHEM, V280, P30916, DOI 10.1074/jbc.M414482200; Kikuchi K, 2008, BIOCHEM BIOPH RES CO, V365, P568, DOI 10.1016/j.bbrc.2007.11.017; Kim T, 2004, MOL CELL BIOL, V24, P10151, DOI 10.1128/MCB.24.23.10151-10160.2004; Kim TG, 2003, J BIOL CHEM, V278, P42247, DOI 10.1074/jbc.M307386200; Klose RJ, 2006, NAT REV GENET, V7, P715, DOI 10.1038/nrg1945; Landeira D, 2010, NAT CELL BIOL, V12, P618, DOI 10.1038/ncb2065; Lee MH, 2011, CANCER RES, V71, P3921, DOI 10.1158/0008-5472.CAN-10-3358; Li G, 2010, GENE DEV, V24, P368, DOI 10.1101/gad.1886410; Linardic CM, 2008, CANCER LETT, V270, P10, DOI 10.1016/j.canlet.2008.03.035; LOLLINI PL, 1991, INVAS METAST, V11, P116; Lu PJ, 1999, J BIOL CHEM, V274, P15633, DOI 10.1074/jbc.274.22.15633; Luo XL, 2011, J AM CHEM SOC, V133, P9451, DOI 10.1021/ja201597b; Matthay KK, 2009, J CLIN ONCOL, V27, P1007, DOI 10.1200/JCO.2007.13.8925; Merlino G, 1999, ONCOGENE, V18, P5340, DOI 10.1038/sj.onc.1203038; Missiaglia E, 2012, J CLIN ONCOL, V30, P1670, DOI 10.1200/JCO.2011.38.5591; Palacios D, 2010, MOL CELL BIOL, V30, P3805, DOI 10.1128/MCB.00050-10; Pasini D, 2010, NATURE, V464, P306, DOI 10.1038/nature08788; Peng JC, 2009, CELL, V139, P1290, DOI 10.1016/j.cell.2009.12.002; Richter GHS, 2009, P NATL ACAD SCI USA, V106, P5324, DOI 10.1073/pnas.0810759106; Schildhaus HU, 2011, HUM PATHOL, V42, P1667, DOI 10.1016/j.humpath.2010.12.025; Schulte JH, 2009, CANCER RES, V69, P2065, DOI 10.1158/0008-5472.CAN-08-1735; Shen XH, 2009, CELL, V139, P1303, DOI 10.1016/j.cell.2009.12.003; Shen XH, 2008, MOL CELL, V32, P491, DOI 10.1016/j.molcel.2008.10.016; Sorensen PHB, 2002, J CLIN ONCOL, V20, P2672, DOI 10.1200/JCO.2002.03.137; Stojic L, 2011, EPIGENET CHROMATIN, V4, DOI 10.1186/1756-8935-4-16; Takeuchi T, 1999, MECH DEVELOP, V86, P29, DOI 10.1016/S0925-4773(99)00100-8; Tonelli R, 2012, CLIN CANCER RES, V18, P796, DOI 10.1158/1078-0432.CCR-11-1981; Upadhyay AK, 2012, J MOL BIOL, V416, P319, DOI 10.1016/j.jmb.2011.12.036; Veal GJ, 2007, BRIT J CANCER, V96, P424, DOI 10.1038/sj.bjc.6603554; Verrier L, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001390; Williamson D, 2010, J CLIN ONCOL, V28, P2151, DOI 10.1200/JCO.2009.26.3814; Xia SJ, 2009, AM J PATHOL, V175, P2600, DOI 10.2353/ajpath.2009.090192; Xiang Y, 2007, P NATL ACAD SCI USA, V104, P19226, DOI 10.1073/pnas.0700735104; Zhang L, 2007, ONCOGENE, V26, P1595, DOI 10.1038/sj.onc.1209958	50	62	65	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2014	33	9					1148	1157		10.1038/onc.2013.46	http://dx.doi.org/10.1038/onc.2013.46			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XT	23435416	Green Accepted, Green Submitted			2022-12-28	WOS:000331933800008
J	Mora-Blanco, EL; Mishina, Y; Tillman, EJ; Cho, YJ; Thom, CS; Pomeroy, SL; Shao, W; Roberts, CWM				Mora-Blanco, E. L.; Mishina, Y.; Tillman, E. J.; Cho, Y-J; Thom, C. S.; Pomeroy, S. L.; Shao, W.; Roberts, C. W. M.			Activation of beta-catenin/TCF targets following loss of the tumor suppressor SNF5	ONCOGENE			English	Article						chromatin remodeling; tumor suppressor; Swi/Snf; beta-catenin; epigenetics	CHROMATIN REMODELING COMPLEXES; GENOMIC INSTABILITY; BINDING REGIONS; RHABDOID TUMORS; MULTIPLE ROLES; CANCER; DIFFERENTIATION; TUMORIGENESIS; MUTATIONS; CELLS	The SWI/SNF chromatin remodeling complex is a master regulator of developmental cell-fate decisions, although the key target pathways are poorly characterized. Here, we interrogated the contribution of the SWI/SNF subunit and tumor suppressor SNF5 to the regulation of developmental pathways using conditional mouse and cell culture models. We find that loss of SNF5 phenocopies beta-catenin hyperactivation and that SNF5 is essential for regulating Wnt/beta-catenin pathway target expression. These data provide insight into chromatin-based mechanisms that underlie developmental regulation and elucidate the emerging theme that mutation of this tumor suppressor complex can activate developmental pathways by uncoupling them from upstream control.	[Mora-Blanco, E. L.; Tillman, E. J.; Thom, C. S.; Roberts, C. W. M.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; [Mora-Blanco, E. L.; Tillman, E. J.; Thom, C. S.; Roberts, C. W. M.] Harvard Univ, Sch Med, Dept Pediat, Div Hematol Oncol,Childrens Hosp Boston, Boston, MA 02115 USA; [Mishina, Y.; Shao, W.] Novartis Inst Biomed Res, Cambridge, MA USA; [Cho, Y-J; Pomeroy, S. L.] Childrens Hosp Boston, Dept Neurol, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Harvard Medical School; Novartis; Harvard University; Boston Children's Hospital	Roberts, CWM (corresponding author), Dana Farber Canc Inst, Dept Pediat Oncol, 450 Brookline Ave, Boston, MA 02115 USA.	Charles_Roberts@dfci.harvard.edu	Roberts, Charles/N-2541-2018	Roberts, Charles/0000-0003-1135-1896; Tillman, Erik/0000-0003-3599-0297	National Cancer Institute, National Institutes of Health [1F31CA130553, R01CA113794, U01-1156106]; Stand Up 2 Cancer Innovative Research Grant; The Garrett B Smith Foundation; Cure AT/RT; Miles for Mary; NATIONAL CANCER INSTITUTE [R01CA113794, F31CA130553, R01CA109467] Funding Source: NIH RePORTER	National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Stand Up 2 Cancer Innovative Research Grant; The Garrett B Smith Foundation; Cure AT/RT; Miles for Mary; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank ES McKenna for critical reading of the manuscript and A Lassar for helpful discussions. The in situ probe constructs were generously provided by C Tabin (Harvard Medical School). This work was supported in part by National Cancer Institute, National Institutes of Health Pre-Doctoral NRSA award 1F31CA130553 (ELMB), R01CA113794 (CWMR) and U01-1156106 (Stuart H Orkin). CWM R is a recipient of a Stand Up 2 Cancer Innovative Research Grant. Miles for Mary, The Garrett B Smith Foundation and Cure AT/RT Now provided additional support.	Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Biegel JA, 1999, CANCER RES, V59, P74; Bottomly D, 2010, NUCLEIC ACIDS RES, V38, P5735, DOI 10.1093/nar/gkq363; Chi TH, 2003, IMMUNITY, V19, P169, DOI 10.1016/S1074-7613(03)00199-7; Chien AJ, 2009, J INVEST DERMATOL, V129, P1614, DOI 10.1038/jid.2008.445; Cho YJ, 2011, J CLIN ONCOL, V29, P1424, DOI 10.1200/JCO.2010.28.5148; Collins RT, 2000, GENE DEV, V14, P3140, DOI 10.1101/gad.854300; Curtis CD, 2012, MOL CELL BIOL, V32, P1312, DOI 10.1128/MCB.06222-11; DasGupta R, 1999, DEVELOPMENT, V126, P4557; de la Serna IL, 2006, NAT REV GENET, V7, P461, DOI 10.1038/nrg1882; Ettenberg SA, 2010, P NATL ACAD SCI USA, V107, P15473, DOI 10.1073/pnas.1007428107; Gresh L, 2005, EMBO J, V24, P3313, DOI 10.1038/sj.emboj.7600802; Griffin CT, 2011, P NATL ACAD SCI USA, V108, P2282, DOI 10.1073/pnas.1013751108; Guidi CJ, 2001, MOL CELL BIOL, V21, P3598, DOI 10.1128/MCB.21.10.3598-3603.2001; Hill TP, 2006, DEVELOPMENT, V133, P1219, DOI 10.1242/dev.02298; Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013; Ho L, 2010, NATURE, V463, P474, DOI 10.1038/nature08911; Hu MC, 2005, DEVELOPMENT, V132, P215, DOI 10.1242/dev.01573; Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356; Jagani Z, 2010, NAT MED, V16, P1429, DOI 10.1038/nm.2251; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Lee RS, 2012, J CLIN INVEST, V122, P2983, DOI 10.1172/JCI64400; Logan M, 2002, GENESIS, V33, P77, DOI 10.1002/gene.10092; Mahmoudi T, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000539; McKenna ES, 2008, MOL CELL BIOL, V28, P6223, DOI 10.1128/MCB.00658-08; McKenna ES, 2009, CELL CYCLE, V8, P23, DOI 10.4161/cc.8.1.7290; Miller KA, 2007, DEV BIOL, V311, P665, DOI 10.1016/j.ydbio.2007.07.022; Ngo-Muller V, 2000, DEV BIOL, V219, P224, DOI 10.1006/dbio.2000.9612; Oruetxebarria I, 2004, J BIOL CHEM, V279, P3807, DOI 10.1074/jbc.M309333200; Park JI, 2009, NATURE, V460, P66, DOI 10.1038/nature08137; Roberts CWM, 2000, P NATL ACAD SCI USA, V97, P13796, DOI 10.1073/pnas.250492697; Roberts CWM, 2002, CANCER CELL, V2, P415, DOI 10.1016/S1535-6108(02)00185-X; Robinson G, 2012, NATURE, V488, P43, DOI 10.1038/nature11213; Schaefer CF, 2009, NUCLEIC ACIDS RES, V37, pD674, DOI 10.1093/nar/gkn653; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Willert Jennifer, 2002, BMC Dev Biol, V2, P8, DOI 10.1186/1471-213X-2-8; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Wilson BG, 2010, CANCER CELL, V18, P316, DOI 10.1016/j.ccr.2010.09.006	38	54	55	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2014	33	7					933	938		10.1038/onc.2013.37	http://dx.doi.org/10.1038/onc.2013.37			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB2MN	23435428	Green Accepted			2022-12-28	WOS:000331626900015
J	Bohringer, M; Obermeier, K; Griner, N; Waldraff, D; Dickinson, E; Eirich, K; Schindler, D; Hagen, M; Jerry, DJ; Wiesmuller, L				Boehringer, M.; Obermeier, K.; Griner, N.; Waldraff, D.; Dickinson, E.; Eirich, K.; Schindler, D.; Hagen, M.; Jerry, D. J.; Wiesmueller, L.			siRNA screening identifies differences in the Fanconi anemia pathway in BALB/c-Trp53+/ - with susceptibility versus C57BL/6-Trp53+/- mice with resistance to mammary tumors	ONCOGENE			English	Article						crosslink repair; Fanconi anemia; modifier of breast cancer susceptibility; Li-Fraumeni mouse model; p53	STRAND BREAK-REPAIR; HOMOLOGOUS RECOMBINATION; CANCER-RISK; DNA-DAMAGE; GENOMIC INSTABILITY; GERMLINE MUTATIONS; P53; BRCA2; GENE; CELLS	BALB/c mice heterozygous for Trp53 develop a high proportion of spontaneous mammary tumors, a phenotype distinct from other mouse strains. BALB/c-Trp53 + /- female mice, thus, resemble the hereditary Li-Fraumeni syndrome (LFS) characterized by earlyonset of breast cancer, even though LFS involves TP53 mutations, which may involve not only loss-but also gain-of-function. Previous analysis of tumors in BALB/c-Trp53 + /- females showed frequent loss of heterozygosity involving the wild-type allele of Trp53 and displayed characteristics indicative of mitotic recombination. Critical involvement of DNA double-strand break (DSB) repair dysfunction, particularly of homologous recombination (HR), was also noticed in the etiology of human breast cancer. To better define functional alterations in BALB/c-Trp53+ /- mice, we applied a fluorescence-based DSB repair assay on mouse embryonic fibroblasts (MEFs) from BALB/c-Trp53 + /- versus C57BL/6J-Trp53 + / - mice. This approach revealed deregulation of HR but not non-homologous end-joining (NHEJ) in BALB/c-Trp53 + /- which was further confirmed for mammary epithelial cells. Screening of a small interfering RNA-library targeting DSB repair, recombination, replication and signaling genes, identified 25 genes causing differences between homologous DSB repair in the two strains upon silencing. Interactome analysis of the hits revealed clustering of replication-related and fanconi anemia (FA)/breast cancer susceptibility (BRCA) genes. Further dissection of the functional change in BALB/c-Trp53_/ +- by immunofluorescence microscopy of nuclear 53BP1, Replication protein A (RPA) and Rad51 foci uncovered differences in crosslink and replication-associated repair. Chromosome breakage, G2 arrest and biochemical analyses indicated a FA pathway defect downstream of FancD2 associated with reduced levels of BRCA2. Consistent with polygenic models for BRCA, mammary carcinogenesis in BALB/c-Trp53+ /- mice may, therefore, be promoted by a BRCA modifier allele in the FA pathway in the context of partial p53 loss-of-function.	[Boehringer, M.; Obermeier, K.; Waldraff, D.; Wiesmueller, L.] Univ Ulm, Dept Obstet & Gynecol, D-89075 Ulm, Germany; [Griner, N.; Dickinson, E.; Hagen, M.; Jerry, D. J.] Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA; [Eirich, K.; Schindler, D.] Univ Wurzburg, Dept Human Genet, Wurzburg, Germany	Ulm University; University of Massachusetts System; University of Massachusetts Amherst; University of Wurzburg	Wiesmuller, L (corresponding author), Univ Ulm, Dept Obstet & Gynecol, Prittwitzstr 43, D-89075 Ulm, Germany.	lisa.wiesmueller@uni-ulm.de		Bohringer, Michael/0000-0001-9150-122X	Foundation of the State Baden-Wurttemberg Germany [10-1907Wi 2]; Ministry for Education and Research, Germany (BMBF) [012P0505]; German Research Foundation (DFG) [WI 3099/7-1, WI 3099/7-2]; National Cancer Institute [R01CA105452]; NATIONAL CANCER INSTITUTE [R01CA105452] Funding Source: NIH RePORTER	Foundation of the State Baden-Wurttemberg Germany; Ministry for Education and Research, Germany (BMBF)(Federal Ministry of Education & Research (BMBF)); German Research Foundation (DFG)(German Research Foundation (DFG)); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are indebted to Bing Xia, The Cancer Institute of New Jersey UMDNJ Robert Wood Johnson Medical School, New Brunswick, NJ, USA, for the generous gift of EUFA1341 cells and expression plasmid for human PALB2, POZ-PALB2. Jeffrey Kane, Amherst, provided assistance with the cloning of mouse Palb2. We cordially thank Marlen Keimling, Ulm, for experimental help during the initial phase of the project and Richard Friedl, Wurzburg, for expert flow cytometry. The drugs KU-55933 and NU7441 were kindly provided by KuDOS Pharmaceuticals Ltd. This work was supported by grants to LW by the Foundation of the State Baden-Wurttemberg Germany (10-1907Wi 2), the Ministry for Education and Research, Germany (BMBF, 012P0505), and the German Research Foundation (DFG, WI 3099/7-1 and -2), as well as to DJJ by the National Cancer Institute (R01CA105452).	Akyuz N, 2002, MOL CELL BIOL, V22, P6306, DOI 10.1128/MCB.22.17.6306-6317.2002; Asaad NA, 2000, ONCOGENE, V19, P5788, DOI 10.1038/sj.onc.1203953; AUERBACH AD, 1989, BLOOD, V73, P391; Bahassi EM, 2008, ONCOGENE, V27, P3977, DOI 10.1038/onc.2008.17; Bertrand P, 2004, TRENDS GENET, V20, P235, DOI 10.1016/j.tig.2004.04.003; Blackburn AC, 2004, CANCER RES, V64, P5140, DOI 10.1158/0008-5472.CAN-03-3435; Blackburn AC, 2003, CANCER RES, V63, P2364; Blackburn AC, 2007, AM J PATHOL, V170, P2030, DOI 10.2353/ajpath.2007.060512; Chompret A, 2000, BRIT J CANCER, V82, P1932; Cordelli E, 2004, MUTAT RES-FUND MOL M, V550, P133, DOI 10.1016/j.mrfmmm.2004.02.012; Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929; Francis R, 2007, GENE DEV, V21, P1064, DOI 10.1101/gad.1522807; Gagou ME, 2010, MOL BIOL CELL, V21, P739, DOI 10.1091/mbc.E09-07-0618; Gatz SA, 2006, CELL DEATH DIFFER, V13, P1003, DOI 10.1038/sj.cdd.4401903; Gohler T, 2008, DNA REPAIR, V7, P775, DOI 10.1016/j.dnarep.2008.02.001; Gutekunst M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019198; Hamimes S, 2005, J BIOL CHEM, V280, P9225, DOI 10.1074/jbc.M412874200; Hayakawa T, 2010, J CELL SCI, V123, P1124, DOI 10.1242/jcs.060178; He XF, 2012, MOL BIOL REP, V39, P5125, DOI 10.1007/s11033-011-1308-y; Heacock ML, 2010, DNA REPAIR, V9, P929, DOI 10.1016/j.dnarep.2010.05.007; Ho V, 2010, ENVIRON MOL MUTAGEN, V51, P552, DOI 10.1002/em.20573; Huertas P, 2010, NAT STRUCT MOL BIOL, V17, P11, DOI 10.1038/nsmb.1710; Jerry DJ, 1998, ONCOGENE, V17, P2305, DOI 10.1038/sj.onc.1202157; Kavitha CV, 2010, BIOCHEM BIOPH RES CO, V399, P575, DOI 10.1016/j.bbrc.2010.07.117; Keimling M, 2012, FASEB J, V26, P2094, DOI 10.1096/fj.11-200790; Keimling M, 2011, FASEB J, V25, P3849, DOI 10.1096/fj.11-185546; Koch JG, 2007, MAMM GENOME, V18, P300, DOI 10.1007/s00335-007-9028-2; Kuperwasser C, 2000, AM J PATHOL, V157, P2151, DOI 10.1016/S0002-9440(10)64853-5; Lin WY, 2011, J MED GENET, V48, P477, DOI 10.1136/jmedgenet-2011-100018; Lu XB, 2003, MUTAT RES-FUND MOL M, V522, P69, DOI 10.1016/S0027-5107(02)00261-0; Ludwig T, 1997, GENE DEV, V11, P1226, DOI 10.1101/gad.11.10.1226; Maloisel L, 2008, MOL CELL BIOL, V28, P1373, DOI 10.1128/MCB.01651-07; Marmorstein LY, 2001, CELL, V104, P247, DOI 10.1016/S0092-8674(01)00209-4; Meindl A, 2010, NAT GENET, V42, P410, DOI 10.1038/ng.569; Mitchell J, 2009, INT J RADIAT ONCOL, V75, P1520, DOI 10.1016/j.ijrobp.2009.07.1722; Okayasu R, 2000, CANCER RES, V60, P4342; Ralhan R, 2007, CANCER LETT, V248, P1, DOI 10.1016/j.canlet.2006.06.004; Schild D, 2010, NUCLEIC ACIDS RES, V38, P1061, DOI 10.1093/nar/gkp1063; Schlacher K, 2011, CELL, V145, P529, DOI 10.1016/j.cell.2011.03.041; Shamseldin HE, 2012, J MED GENET, V49, P184, DOI 10.1136/jmedgenet-2011-100585; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Shao CS, 2000, P NATL ACAD SCI USA, V97, P7405, DOI 10.1073/pnas.97.13.7405; Shevelev Igor V., 2002, TheScientificWorldJOURNAL, V2, P275; Shlien A, 2008, P NATL ACAD SCI USA, V105, P11264, DOI 10.1073/pnas.0802970105; Sy SMH, 2009, J BIOL CHEM, V284, P21127, DOI 10.1074/jbc.C109.023937; Szpirer C, 2007, MAMM GENOME, V18, P817, DOI 10.1007/s00335-007-9073-x; TAINSKY MA, 1995, CANCER METAST REV, V14, P43, DOI 10.1007/BF00690210; Tchatchou S, 2010, HUM MUTAT, V31, P60, DOI 10.1002/humu.21134; Thompson LH, 2009, MUTAT RES-FUND MOL M, V668, P54, DOI 10.1016/j.mrfmmm.2009.02.003; Toyota M, 2010, ADV GENET, V70, P309, DOI [10.1016/B978-0-12-380866-0.60011-3, 10.1016/S0065-2660(10)70011-0]; Varadi V, 2011, BREAST CANCER RES TR, V129, P235, DOI 10.1007/s10549-011-1460-z; Vaz F, 2010, NAT GENET, V42, P406, DOI 10.1038/ng.570; Villani G, 2011, J BIOL CHEM, V286, P32094, DOI 10.1074/jbc.M111.246611; Walsh T, 2007, CANCER CELL, V11, P103, DOI 10.1016/j.ccr.2007.01.010; Xia B, 2007, NAT GENET, V39, P159, DOI 10.1038/ng1942; Zhao XJ, 2005, CANCER RES, V65, P5561, DOI 10.1158/0008-5472.CAN-04-4603	56	6	6	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2013	32	48					5458	5470		10.1038/onc.2013.38	http://dx.doi.org/10.1038/onc.2013.38			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263BE	23435420	hybrid, Green Published			2022-12-28	WOS:000327780800003
J	Rufini, A; Tucci, P; Celardo, I; Melino, G				Rufini, A.; Tucci, P.; Celardo, I.; Melino, G.			Senescence and aging: the critical roles of p53	ONCOGENE			English	Review						senescence; aging; p53; mTOR; mitochondria; ROS	DNA-DAMAGE RESPONSE; CELL-CYCLE ARREST; EXTENDS LIFE-SPAN; E2F FAMILY-MEMBER; KINASE C-ABL; TUMOR-SUPPRESSOR; OXIDATIVE STRESS; MITOCHONDRIAL-FUNCTION; TELOMERE LENGTH; TYROSINE KINASE	p53 functions as a transcription factor involved in cell-cycle control, DNA repair, apoptosis and cellular stress responses. However, besides inducing cell growth arrest and apoptosis, p53 activation also modulates cellular senescence and organismal aging. Senescence is an irreversible cell-cycle arrest that has a crucial role both in aging and as a robust physiological antitumor response, which counteracts oncogenic insults. Therefore, via the regulation of senescence, p53 contributes to tumor growth suppression, in a manner strictly dependent by its expression and cellular context. In this review, we focus on the recent advances on the contribution of p53 to cellular senescence and its implication for cancer therapy, and we will discuss p53's impact on animal lifespan. Moreover, we describe p53-mediated regulation of several physiological pathways that could mediate its role in both senescence and aging.	[Rufini, A.; Tucci, P.; Celardo, I.; Melino, G.] Univ Leicester, Toxicol Unit, Med Res Council, Lancaster LE1 9HN, England; [Tucci, P.] Univ Calabria, Dept Pharmacobiol, I-87036 Arcavacata Di Rende, CS, Italy; [Melino, G.] Univ Roma Tor Vergata, Ist Dermopat Immacolata, Dept Expt Med & Biochem Sci, Rome, Italy; [Melino, G.] Ist Dermopat Immacolata, Biochem Lab, Rome, Italy	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Leicester; University of Calabria; IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Rome Tor Vergata; IRCCS Istituto Dermopatico dell'Immacolata (IDI)	Melino, G (corresponding author), Univ Leicester, Toxicol Unit, Med Res Council, Lancaster LE1 9HN, England.	melino@uniroma2.it		TUCCI, PAOLA/0000-0002-9349-5203	MRC [MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_U132670600] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Afanasyeva EA, 2011, CELL DEATH DIFFER, V18, P974, DOI 10.1038/cdd.2010.164; Agami R, 1999, NATURE, V399, P809; Agarwal B, 2011, ANN NY ACAD SCI, V1215, P138, DOI 10.1111/j.1749-6632.2010.05850.x; Agostini M, 2011, P NATL ACAD SCI USA, V108, P21093, DOI 10.1073/pnas.1112061109; Agostini M, 2011, P NATL ACAD SCI USA, V108, P21099, DOI 10.1073/pnas.1112063108; Ahmed A, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.42; Ajabnoor GMA, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.139; Aksoy O, 2012, GENE DEV, V26, P1546, DOI 10.1101/gad.196238.112; Alessio N, 2010, ONCOGENE, V29, P5452, DOI 10.1038/onc.2010.285; Alimonti A, 2010, J CLIN INVEST, V120, P681, DOI 10.1172/JCI40535; Armata HL, 2007, CANCER RES, V67, P11696, DOI 10.1158/0008-5472.CAN-07-1610; Ashrafi G, 2013, CELL DEATH DIFFER, V20, P31, DOI 10.1038/cdd.2012.81; Assmus B, 2003, CIRC RES, V92, P1049, DOI 10.1161/01.RES.0000070067.64040.7C; Astle MV, 2012, ONCOGENE, V31, P1949, DOI 10.1038/onc.2011.394; Atzmon G, 2010, P NATL ACAD SCI USA, V107, P1710, DOI 10.1073/pnas.0906191106; Baker DJ, 2011, NATURE, V479, P232, DOI 10.1038/nature10600; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Banks AS, 2008, CELL METAB, V8, P333, DOI 10.1016/j.cmet.2008.08.014; Bano D, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.112; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Bellodi C, 2006, CELL CYCLE, V5, P2688, DOI 10.4161/cc.5.22.3504; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Brooks CL, 2009, NAT REV CANCER, V9, P123, DOI 10.1038/nrc2562; Brooks CL, 2004, CELL CYCLE, V3, P895; Brown CJ, 2009, NAT REV CANCER, V9, P862, DOI 10.1038/nrc2763; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Budanov AV, 2008, CELL, V134, P451, DOI 10.1016/j.cell.2008.06.028; Budanov AV, 2004, SCIENCE, V304, P596, DOI 10.1126/science.1095569; Burnett C, 2011, NATURE, V477, P482, DOI 10.1038/nature10296; Caldwell ME, 2012, ONCOGENE, V31, P1599, DOI 10.1038/onc.2011.350; Campagna M, 2011, CELL DEATH DIFFER, V18, P72, DOI 10.1038/cdd.2010.77; Campisi J, 2005, CELL, V120, P513, DOI 10.1016/j.cell.2005.02.003; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Candi E, 2008, CELL MOL LIFE SCI, V65, P3126, DOI 10.1007/s00018-008-8119-x; Candi E, 2006, CELL DEATH DIFFER, V13, P1037, DOI 10.1038/sj.cdd.4401926; Candi E, 2007, CELL CYCLE, V6, P274, DOI 10.4161/cc.6.3.3797; Carvajal LA, 2012, GENE DEV, V26, P1533, DOI 10.1101/gad.184911.111; Cervo PRD, 2012, P NATL ACAD SCI USA, V109, P1133, DOI 10.1073/pnas.1112257109; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Chen YF, 2009, GENE DEV, V23, P1183, DOI 10.1101/gad.1779509; Chin L, 1999, CELL, V97, P527, DOI 10.1016/S0092-8674(00)80762-X; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Collavin L, 2010, CELL DEATH DIFFER, V17, P901, DOI 10.1038/cdd.2010.35; Colombi M, 2011, ONCOGENE, V30, P1551, DOI 10.1038/onc.2010.539; Conforti F, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.27; Cook CC, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.141; Cosme-Blanco W, 2007, EMBO REP, V8, P497, DOI 10.1038/sj.embor.7400937; Cunningham JT, 2007, NATURE, V450, P736, DOI 10.1038/nature06322; de Lange J, 2012, CELL DEATH DIFFER, V19, P980, DOI 10.1038/cdd.2011.182; de Lange J, 2012, ONCOGENE, V31, P1105, DOI 10.1038/onc.2011.309; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Demaria M, 2012, CELL DEATH DIFFER, V19, P1390, DOI 10.1038/cdd.2012.20; Demidenko ZN, 2008, CELL CYCLE, V7, P3355, DOI 10.4161/cc.7.21.6919; Demidenko ZN, 2010, P NATL ACAD SCI USA, V107, P9660, DOI 10.1073/pnas.1002298107; Demidenko ZN, 2009, CELL CYCLE, V8, P1888, DOI 10.4161/cc.8.12.8606; Deng CX, 2009, INT J BIOL SCI, V5, P147, DOI 10.7150/ijbs.5.147; di Fagagna FD, 2008, NAT REV CANCER, V8, P512, DOI 10.1038/nrc2440; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Di Stefano L, 2003, EMBO J, V22, P6289, DOI 10.1093/emboj/cdg613; Dixit D, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.10; Dotsch V, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a004887; Donadelli M, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.36; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; Drullion C, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.111; DULIC V, 1993, P NATL ACAD SCI USA, V90, P11034, DOI 10.1073/pnas.90.23.11034; Durinck S, 2011, CANCER DISCOV, V1, P137, DOI 10.1158/2159-8290.CD-11-0028; Eisenberg T, 2009, NAT CELL BIOL, V11, P1305, DOI 10.1038/ncb1975; Eng CH, 2011, ONCOGENE, V30, P4687, DOI 10.1038/onc.2011.220; Fabrizio P, 2001, SCIENCE, V292, P288, DOI 10.1126/science.1059497; Faraonio R, 2012, CELL DEATH DIFFER, V19, P713, DOI 10.1038/cdd.2011.143; Feldman JL, 2012, J BIOL CHEM, V287, P42419, DOI 10.1074/jbc.R112.378877; Feldser DM, 2007, CANCER CELL, V11, P461, DOI 10.1016/j.ccr.2007.02.026; Feldser DM, 2010, NATURE, V468, P572, DOI 10.1038/nature09535; Feng ZH, 2007, CANCER RES, V67, P3043, DOI 10.1158/0008-5472.CAN-06-4149; Flores ER, 2011, CELL DEATH DIFFER, V18, P381, DOI 10.1038/cdd.2010.178; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Flores I, 2005, SCIENCE, V309, P1253, DOI 10.1126/science.1115025; Francis SP, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.76; Fujitani M, 2010, CURR BIOL, V20, P2058, DOI 10.1016/j.cub.2010.10.029; Galavotti S, 2013, ONCOGENE, V32, P699, DOI 10.1038/onc.2012.111; Gamble LD, 2012, ONCOGENE, V31, P752, DOI 10.1038/onc.2011.270; Gao W, 2011, CELL DEATH DIFFER, V18, P1598, DOI 10.1038/cdd.2011.33; Gatta R, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.45; Gogna R, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.15; Gonfloni S, 2009, NAT MED, V15, P1179, DOI 10.1038/nm.2033; Gong C, 2012, ONCOGENE, DOI [10.1038/onc.2012.252, DOI 10.1038/0NC.2012.252)]; Gong JG, 1999, NATURE, V399, P806; Gottlieb E, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001040; Gough DR, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.96; Grandison RC, 2009, NATURE, V462, P1061, DOI 10.1038/nature08619; Green DR, 2011, SCIENCE, V333, P1109, DOI 10.1126/science.1201940; Gressner O, 2005, EMBO J, V24, P2458, DOI 10.1038/sj.emboj.7600708; Guo XC, 2009, NAT CELL BIOL, V11, P1451, DOI 10.1038/ncb1988; Ha L, 2007, P NATL ACAD SCI USA, V104, P10968, DOI 10.1073/pnas.0611638104; Halliwell B, 2009, FREE RADICAL BIO MED, V46, P531, DOI 10.1016/j.freeradbiomed.2008.11.008; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hande MP, 1999, J CELL BIOL, V144, P589, DOI 10.1083/jcb.144.4.589; HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221; Hars ES, 2007, AUTOPHAGY, V3, P93, DOI 10.4161/auto.3636; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Heiss EH, 2007, J BIOL CHEM, V282, P26759, DOI 10.1074/jbc.M703229200; Herbig U, 2003, AGING CELL, V2, P295, DOI 10.1046/j.1474-9728.2003.00067.x; Herranz D, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1001; Hofius D, 2011, CELL DEATH DIFFER, V18, P1257, DOI 10.1038/cdd.2011.43; Houtkooper RH, 2012, NAT REV MOL CELL BIO, V13, P225, DOI 10.1038/nrm3293; Hussain SP, 2004, CANCER RES, V64, P2350, DOI 10.1158/0008-5472.CAN-2287-2; Iaccarino I, 2011, CELL DEATH DIFFER, V18, P565, DOI 10.1038/cdd.2010.174; Jenkins NC, 2011, ONCOGENE, V30, P265, DOI 10.1038/onc.2010.419; Jia K, 2004, DEVELOPMENT, V131, P3897, DOI 10.1242/dev.01255; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Jung JH, 2011, CELL DEATH DIFFER, V18, P1865, DOI 10.1038/cdd.2011.57; Junttila MR, 2010, NATURE, V468, P567, DOI 10.1038/nature09526; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kaeberlein M, 2005, SCIENCE, V310, P1193, DOI 10.1126/science.1115535; Kang MY, 2013, CELL DEATH DIFFER, V20, P117, DOI 10.1038/cdd.2012.102; Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191; Kang S, CELL DEATH DIFFER, DOI [10.1038/cdd.2012.117, DOI 10.1038/CDD.2012.117)]; Kapahi P, 2004, CURR BIOL, V14, P885, DOI 10.1016/j.cub.2004.03.059; Kapahi P, 2010, CELL METAB, V11, P453, DOI 10.1016/j.cmet.2010.05.001; Karna P, 2010, J BIOL CHEM, V285, P18737, DOI 10.1074/jbc.M109.091694; Kenyon CJ, 2010, NATURE, V464, P504, DOI 10.1038/nature08980; Keyes WM, 2011, CELL STEM CELL, V8, P164, DOI 10.1016/j.stem.2010.12.009; Keyes WM, 2005, GENE DEV, V19, P1986, DOI 10.1101/gad.342305; Killick R, 2011, MOL NEUROBIOL, V43, P139, DOI 10.1007/s12035-011-8172-6; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kimmelman AC, 2011, GENE DEV, V25, P1999, DOI 10.1101/gad.17558811; Klionsky DJ, 2007, NAT REV MOL CELL BIO, V8, P931, DOI 10.1038/nrm2245; Kon N, 2011, CELL DEATH DIFFER, V18, P1366, DOI 10.1038/cdd.2011.12; Koster R, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.33; Krishnamurthty J, 2004, J CLIN INVEST, V114, P1299, DOI 10.1172/JCI200422475; Krummel KA, 2005, P NATL ACAD SCI USA, V102, P10188, DOI 10.1073/pnas.0503068102; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Kumar M, 2011, ONCOGENE, V30, P843, DOI 10.1038/onc.2010.457; Kuwahara Y, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.56; Lambert AJ, 2007, AGING CELL, V6, P607, DOI 10.1111/j.1474-9726.2007.00312.x; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Lanigan F, 2011, ONCOGENE, V30, P2901, DOI 10.1038/onc.2011.34; Laplante M, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011593; Lee HY, 2010, CELL METAB, V12, P668, DOI 10.1016/j.cmet.2010.11.004; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Lee JJ, 2011, CELL DEATH DIFFER, V18, P666, DOI 10.1038/cdd.2010.139; Lee JH, 2010, SCIENCE, V327, P1223, DOI 10.1126/science.1182228; Lemarie A, 2011, CELL DEATH DIFFER, V18, P338, DOI 10.1038/cdd.2010.93; Lena AM, 2008, CELL DEATH DIFFER, V15, P1187, DOI 10.1038/cdd.2008.69; Leonard MK, 2011, CELL DEATH DIFFER, V18, P1924, DOI 10.1038/cdd.2011.73; Leontieva OV, 2010, CELL CYCLE, V9, P4323, DOI 10.4161/cc.9.21.13584; Lepine S, 2011, CELL DEATH DIFFER, V18, P350, DOI 10.1038/cdd.2010.104; Levine AJ, 2011, NAT REV MOL CELL BIO, V12, P259, DOI 10.1038/nrm3086; Levine B, 2009, CELL DEATH DIFFER, V16, P1, DOI 10.1038/cdd.2008.139; Li D, 2011, CELL DEATH DIFFER, V18, P1904, DOI 10.1038/cdd.2011.71; Li L, 2012, CANCER CELL, V21, P266, DOI 10.1016/j.ccr.2011.12.020; Li TY, 2012, CELL, V149, P1269, DOI 10.1016/j.cell.2012.04.026; Liang C, 2010, CELL DEATH DIFFER, V17, P1807, DOI 10.1038/cdd.2010.115; Ling LU, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.12; LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4; Liu DP, 2010, NAT CELL BIOL, V12, P993, DOI 10.1038/ncb2100; Liu J, 2009, NATURE, V459, P387, DOI 10.1038/nature08040; Liu Y, 2009, AGING CELL, V8, P439, DOI 10.1111/j.1474-9726.2009.00489.x; Logan N, 2004, ONCOGENE, V23, P5138, DOI 10.1038/sj.onc.1207649; Lossaint G, 2011, ONCOGENE, V30, P4261, DOI 10.1038/onc.2011.135; Lu T, 2008, EXP CELL RES, V314, P1918, DOI 10.1016/j.yexcr.2008.01.011; Lu WJ, 2011, CELL DEATH DIFFER, V18, P1046, DOI 10.1038/cdd.2010.177; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Macip S, 2003, MOL CELL BIOL, V23, P8576, DOI 10.1128/MCB.23.23.8576-8585.2003; Magenta A, 2011, CELL DEATH DIFFER, V18, P1628, DOI 10.1038/cdd.2011.42; Maier B, 2004, GENE DEV, V18, P306, DOI 10.1101/gad.1162404; Maiuri MC, 2010, CURR OPIN CELL BIOL, V22, P181, DOI 10.1016/j.ceb.2009.12.001; Majumder PK, 2008, CANCER CELL, V14, P146, DOI 10.1016/j.ccr.2008.06.002; Marcel V, 2011, CELL DEATH DIFFER, V18, P1815, DOI 10.1038/cdd.2011.120; Marino G, 2007, J BIOL CHEM, V282, P18573, DOI 10.1074/jbc.M701194200; Marino ML, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.67; Markert EK, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.140; Martin-Montalvo A, 2011, ONCOGENE, V30, P505, DOI 10.1038/onc.2010.492; Matecic M, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000921; Matheu A, 2007, NATURE, V448, P375, DOI 10.1038/nature05949; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; Medema RH, 2012, ONCOGENE, V31, P2601, DOI 10.1038/onc.2011.451; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2011, CELL DEATH DIFFER, V18, P1487, DOI 10.1038/cdd.2011.81; Meltser V, 2011, CELL DEATH DIFFER, V18, P2, DOI 10.1038/cdd.2010.132; Michaelis M, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.35; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Minois N, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.139; Moiseeva O, 2009, MOL CELL BIOL, V29, P4495, DOI 10.1128/MCB.01868-08; Morton JP, 2010, P NATL ACAD SCI USA, V107, P246, DOI 10.1073/pnas.0908428107; Nakamura T, 2011, CELL DEATH DIFFER, V18, P1478, DOI 10.1038/cdd.2011.65; Nardella C, 2008, GENE DEV, V22, P2172, DOI 10.1101/gad.1699608; Nguyen D, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.117; Nogueira L, 2011, ONCOGENE, V30, P3537, DOI 10.1038/onc.2011.74; Oberdoerffer P, 2008, CELL, V135, P907, DOI 10.1016/j.cell.2008.10.025; Olovnikov IA, 2009, SEMIN CANCER BIOL, V19, P32, DOI 10.1016/j.semcancer.2008.11.005; Osawa T, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.70; Ota H, 2007, J MOL CELL CARDIOL, V43, P571, DOI 10.1016/j.yjmcc.2007.08.008; Paris M, 2012, CELL DEATH DIFFER, V19, P186, DOI 10.1038/cdd.2011.181; Parrinello S, 2003, NAT CELL BIOL, V5, P741, DOI 10.1038/ncb1024; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Peche LY, 2012, CELL DEATH DIFFER, V19, P926, DOI 10.1038/cdd.2011.173; Pellegrini L, 2012, CELL DEATH DIFFER, V19, P1815, DOI 10.1038/cdd.2012.62; Pollina EA, 2011, ONCOGENE, V30, P3105, DOI 10.1038/onc.2011.45; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Pospelova TV, 2009, CELL CYCLE, V8, P4112, DOI 10.4161/cc.8.24.10215; Powers RW, 2006, GENE DEV, V20, P174, DOI 10.1101/gad.1381406; Qu XP, 2003, J CLIN INVEST, V112, P1809, DOI 10.1172/JCI200320039; Rai P, 2011, ONCOGENE, V30, P1489, DOI 10.1038/onc.2010.520; Ramadan S, 2005, BIOCHEM BIOPH RES CO, V331, P713, DOI 10.1016/j.bbrc.2005.03.156; Reilly SM, 2010, CELL METAB, V12, P643, DOI 10.1016/j.cmet.2010.11.007; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Romagosa C, 2011, ONCOGENE, V30, P2087, DOI 10.1038/onc.2010.614; Romeo Y, 2012, ONCOGENE, DOI [10.1038/onc.2012.312, DOI 10.1038/0NC.2012.312)]; Rubinsztein DC, 2011, CELL, V146, P682, DOI 10.1016/j.cell.2011.07.030; Rudolph KL, 1999, CELL, V96, P701, DOI 10.1016/S0092-8674(00)80580-2; Rufini A, 2012, GENE DEV, V26, P2009, DOI 10.1101/gad.197640.112; Rufini Alessandro, 2011, Genes Cancer, V2, P491, DOI 10.1177/1947601911408890; Ruggero D, 2004, NAT MED, V10, P484, DOI 10.1038/nm1042; Sage J, 2003, NATURE, V424, P223, DOI 10.1038/nature01764; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; Sahin E, 2012, NAT REV MOL CELL BIO, V13, P397, DOI 10.1038/nrm3352; Sahin E, 2011, NATURE, V470, P359, DOI 10.1038/nature09787; Salomoni P, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2011.122; Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653; Senoo M, 2007, CELL, V129, P523, DOI 10.1016/j.cell.2007.02.045; Sermeus A, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.48; Shalini S, 2012, CELL DEATH DIFFER, V19, P1370, DOI 10.1038/cdd.2012.13; Shalom-Feuerstein R, 2011, CELL DEATH DIFFER, V18, P887, DOI 10.1038/cdd.2010.159; Sharp ZD, 2005, J GERONTOL A-BIOL, V60, P293, DOI 10.1093/gerona/60.3.293; Sharpless NE, 2004, EXP GERONTOL, V39, P1751, DOI 10.1016/j.exger.2004.06.025; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SHERWOOD SW, 1988, P NATL ACAD SCI USA, V85, P9086, DOI 10.1073/pnas.85.23.9086; Shi WY, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.13; Spinnler C, 2011, CELL DEATH DIFFER, V18, P1736, DOI 10.1038/cdd.2011.45; Su XH, 2012, CELL METAB, V16, P511, DOI 10.1016/j.cmet.2012.09.006; Su XH, 2009, CELL STEM CELL, V5, P64, DOI 10.1016/j.stem.2009.04.003; Suh EK, 2006, NATURE, V444, P624, DOI 10.1038/nature05337; Sully K, 2012, ONCOGENE, DOI [10.1038/onc.2012.338, DOI 10.1038/0NC.2012.338)]; Sun PQ, 2007, CELL, V128, P295, DOI 10.1016/j.cell.2006.11.050; Takahashi Y, 2007, NAT CELL BIOL, V9, P1142, DOI 10.1038/ncb1634; Talos F, 2010, CELL DEATH DIFFER, V17, P1816, DOI 10.1038/cdd.2010.131; Talos F, 2007, MOL CELL, V27, P647, DOI 10.1016/j.molcel.2007.06.036; Tan MJ, 1999, J BIOL CHEM, V274, P12061, DOI 10.1074/jbc.274.17.12061; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Tavernarakis N, 2008, AUTOPHAGY, V4, P870, DOI 10.4161/auto.6730; Thomas E, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.69; Tiede LM, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.128; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Tomasini R, 2012, CELL DEATH DIFFER, DOI DOI 10.1038/CDD.2012.123); Tomasini R, 2008, GENE DEV, V22, P2677, DOI 10.1101/gad.1695308; Tomasini R, 2009, P NATL ACAD SCI USA, V106, P797, DOI 10.1073/pnas.0812096106; Tomic T, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.86; Trifunovic A, 2008, J INTERN MED, V263, P167, DOI 10.1111/j.1365-2796.2007.01905.x; Tucci P, 2012, P NATL ACAD SCI USA, V109, P15312, DOI 10.1073/pnas.1110977109; Tucci P, 2012, AGING-US, V4, P525, DOI 10.18632/aging.100481; van Veelen W, 2011, ONCOGENE, V30, P2289, DOI 10.1038/onc.2010.630; Vaseva AV, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.39; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Verhaegen M, 2012, ONCOGENE, V31, P828, DOI 10.1038/onc.2011.277; Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Wang X, 2011, CELL DEATH DIFFER, V18, P5, DOI 10.1038/cdd.2010.106; Wang XD, 2011, CELL DEATH DIFFER, V18, P304, DOI 10.1038/cdd.2010.101; Wen ZH, 2013, ONCOGENE, V32, P160, DOI 10.1038/onc.2012.47; Wetzel MK, 2008, NEURON, V59, P708, DOI 10.1016/j.neuron.2008.07.021; Weyemi U, 2012, ONCOGENE, V31, P1117, DOI 10.1038/onc.2011.327; Wilhelm MT, 2010, GENE DEV, V24, P549, DOI 10.1101/gad.1873910; Wiman KG, 2006, CELL DEATH DIFFER, V13, P921, DOI 10.1038/sj.cdd.4401921; Wiman KG, 2010, ONCOGENE, V29, P4245, DOI 10.1038/onc.2010.188; Wu WKK, 2012, ONCOGENE, V31, P939, DOI 10.1038/onc.2011.295; Xiang T, 2011, ONCOGENE, V30, P2443, DOI 10.1038/onc.2010.603; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang D, 2012, CELL DEATH DIFFER, DOI [10.1038/cdd.2012.113, DOI 10.1038/CDD.2012.113)]; Yasaei H, 2013, ONCOGENE, V32, P171, DOI 10.1038/onc.2012.45; Yi R, 2008, NATURE, V452, P225, DOI 10.1038/nature06642; Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika A, 2001, J BIOL CHEM, V276, P11310, DOI 10.1074/jbc.M005737200; Zid BM, 2009, CELL, V139, P149, DOI 10.1016/j.cell.2009.07.034; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	286	473	494	14	168	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2013	32	43					5129	5143		10.1038/onc.2012.640	http://dx.doi.org/10.1038/onc.2012.640			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240JY	23416979				2022-12-28	WOS:000326093200001
J	Shamanna, RA; Hoque, M; Pe'ery, T; Mathews, MB				Shamanna, R. A.; Hoque, M.; Pe'ery, T.; Mathews, M. B.			Induction of p53, p21 and apoptosis by silencing the NF90/NF45 complex in human papilloma virus-transformed cervical carcinoma cells	ONCOGENE			English	Article						Apoptosis; human papilloma virus; transcription; p53; p21; NF90/NF45	DOUBLE-STRANDED-RNA; TUMOR-SUPPRESSOR P53; IL-2 MESSENGER-RNA; BINDING-PROTEIN; GENE-EXPRESSION; NUCLEAR EXPORT; TRANSLATIONAL CONTROL; NEGATIVE REGULATOR; E6 ONCOPROTEIN; CYCLE ARREST	The heterodimeric nuclear factor (NF) 90/NF45 complex (NF90/NF45) binds nucleic acids and is a multifunctional regulator of gene expression. Here we report that depletion of NF90/NF45 restores the expression of the p53 and p21 proteins in cervical carcinoma cells infected with high-risk human papillomaviruses (HPVs). Knockdown of either NF90 or NF45 by RNA interference led to greatly elevated levels of p53 and p21 proteins in HPV-derived HeLa and SiHa cells but not in other cancerous or normal cell lines. In HeLa cells, p21 messenger-RNA (mRNA) increased concomitantly but the level of p53 mRNA was unaffected. RNA interference directed against p53 prevented the induction of both proteins. These results indicated that the upregulation of p21 is due to p53-dependent transcription, whereas p53 is regulated post-transcriptionally. Proteasome-mediated turnover of p53 is accelerated by the HPV E6 and cellular E6AP proteins. We therefore examined the hypothesis that this pathway is regulated by NF90/NF45. Indeed, depletion of NF90 attenuated the expression of E6 RNA and inhibited transcription from the HPV early promoter, revealing a new role for NF90/NF45 in HPV gene expression. The transcription inhibition was largely independent of the reduction of P-TEFb (positive transcription elongation factor b) levels caused by NF90 depletion. Consistent with p53 derepression, NF90/NF45-depleted HeLa cells displayed elevated poly ADP-ribose polymerase (PARP) cleavage and susceptibility to camptothecin-induced apoptosis. We conclude that high-risk strains of HPV utilize the cellular NF90/NF45 complex for viral E6 expression in infected cervical carcinoma cell lines. Interference with NF90/NF45 function could assist in controlling cervical carcinoma.	[Shamanna, R. A.; Hoque, M.; Mathews, M. B.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, Newark, NJ 07101 USA; [Shamanna, R. A.; Pe'ery, T.; Mathews, M. B.] Univ Med & Dent New Jersey, Grad Sch Biomed Sci, Newark, NJ 07103 USA; [Pe'ery, T.] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center	Mathews, MB (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Biochem & Mol Biol, POB 1709, Newark, NJ 07101 USA.	mathews@umdnj.edu			NIH [R01 AI034552]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034552] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We thank Dr Edward Goodwin for pGL3-HPV18URR-Firefly luciferase plasmid and Dr Betsy Barnes for HCT 116 cell lines. We are indebted to Dr Raymond Birge and Dr Edouard Azzam for discussions and helpful suggestions. The early stages of this work were supported by NIH Grant R01 AI034552 to MBM.	Agbottah ET, 2007, RETROVIROLOGY, V4, DOI 10.1186/1742-4690-4-41; Austin D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036327; Barber GN, 2009, RNA BIOL, V6, P35, DOI 10.4161/rna.6.1.7565; BAUKNECHT T, 1995, J VIROL, V69, P1; Bednarek PH, 1998, J VIROL, V72, P708, DOI 10.1128/JVI.72.1.708-716.1998; Bose SK, 2006, BIOCHEM J, V396, P99, DOI 10.1042/BJ20051548; Brantley-Finley C, 2003, BIOCHEM PHARMACOL, V66, P459, DOI 10.1016/S0006-2952(03)00255-7; Cazanove O, 2008, BIOCHEMISTRY-US, V47, P8350, DOI 10.1021/bi7008486; Chang JTC, 2010, CANCER GENE THER, V17, P827, DOI 10.1038/cgt.2010.38; Chen T, 2004, MOL CELL BIOL, V24, P6608, DOI 10.1128/mcb.24.15.6608-6619.2004; Chesnokov IN, 2003, P NATL ACAD SCI USA, V100, P9150, DOI 10.1073/pnas.1633580100; Chow LT, 2010, APMIS, V118, P422, DOI 10.1111/j.1600-0463.2010.02625.x; Collavin L, 2010, CELL DEATH DIFFER, V17, P901, DOI 10.1038/cdd.2010.35; Corso C, 2011, NUCLEIC ACIDS RES, V39, P7263, DOI 10.1093/nar/gkr278; CORTHESY B, 1994, J BIOL CHEM, V269, P20682; Dey A, 2008, BRIT J CANCER, V98, P4, DOI 10.1038/sj.bjc.6604098; Eldridge AG, 2006, CELL, V124, P367, DOI 10.1016/j.cell.2005.10.038; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gartel AL, 2009, BIOFACTORS, V35, P161, DOI 10.1002/biof.26; Gomila RC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016687; Goodwin EC, 1998, J VIROL, V72, P3925, DOI 10.1128/JVI.72.5.3925-3934.1998; Graber TE, 2010, CELL DEATH DIFFER, V17, P719, DOI 10.1038/cdd.2009.164; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Guan DY, 2008, MOL CELL BIOL, V28, P4629, DOI 10.1128/MCB.00120-08; Gwizdek C, 2004, J BIOL CHEM, V279, P884, DOI 10.1074/jbc.M306808200; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Harashima A, 2010, GENE DEV, V24, P2640, DOI 10.1101/gad.1965010; Hoque M, 2011, J MOL BIOL, V410, P917, DOI 10.1016/j.jmb.2011.03.060; Howie HL, 2009, VIROLOGY, V384, P324, DOI 10.1016/j.virol.2008.11.017; HUIBREGTSE JM, 1991, EMBO J, V10, P4129, DOI 10.1002/j.1460-2075.1991.tb04990.x; Isken O, 2004, RNA, V10, P1637, DOI 10.1261/rna.7290904; Isken O, 2003, EMBO J, V22, P5655, DOI 10.1093/emboj/cdg562; Isken O, 2007, RNA, V13, P1675, DOI 10.1261/rna.594207; Karmakar S, 2010, EMBO J, V29, P3260, DOI 10.1038/emboj.2010.204; Kiesler P, 2010, J BIOL CHEM, V285, P8256, DOI 10.1074/jbc.M109.041004; Krasnoselskaya-Riz I, 2002, AIDS RES HUM RETROV, V18, P591, DOI 10.1089/088922202753747941; Kreis NN, 2010, ONCOGENE, V29, P5591, DOI 10.1038/onc.2010.290; Kuwano Y, 2008, MOL CELL BIOL, V28, P4562, DOI 10.1128/MCB.00165-08; Kuwano Y, 2010, NUCLEIC ACIDS RES, V38, P225, DOI 10.1093/nar/gkp861; Lace MJ, 2009, J VIROL, V83, P7457, DOI 10.1128/JVI.00285-09; Lan KH, 2002, ONCOGENE, V21, P4801, DOI 10.1038/sj.onc.1205589; Lane D, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000893; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; Lee CH, 2007, CANCER SCI, V98, P795, DOI 10.1111/j.1349-7006.2007.00473.x; Li FZ, 1999, NAT CELL BIOL, V1, P461, DOI 10.1038/70242; Liao HJ, 1998, P NATL ACAD SCI USA, V95, P8514, DOI 10.1073/pnas.95.15.8514; Lopez-Saavedra A, 2009, ARCH VIROL, V154, P747, DOI 10.1007/s00705-009-0362-4; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LOWE SW, 1994, SCIENCE, V266, P807, DOI 10.1126/science.7973635; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Manfredi JJ, 2010, GENE DEV, V24, P1580, DOI 10.1101/gad.1941710; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; McCurrach ME, 1997, P NATL ACAD SCI USA, V94, P2345, DOI 10.1073/pnas.94.6.2345; Merrill MK, 2006, J VIROL, V80, P6936, DOI 10.1128/JVI.00243-06; Merrill MK, 2006, J VIROL, V80, P3147, DOI 10.1128/JVI.80.7.3147-3156.2006; Molchadsky A, 2010, CARCINOGENESIS, V31, P1501, DOI 10.1093/carcin/bgq101; Munoz-Fontela C, 2011, J IMMUNOL, V187, P6428, DOI 10.4049/jimmunol.1101459; Nair JS, 2009, MOL BIOL CELL, V20, P2218, DOI 10.1091/mbc.E08-08-0885; Narisawa-Saito M, 2007, CANCER SCI, V98, P1505, DOI 10.1111/j.1349-7006.2007.00546.x; Nie YZ, 2005, MOL CELL BIOL, V25, P6956, DOI 10.1128/MCB.25.16.6956-6963.2005; Pajunk HS, 1997, J GEN VIROL, V78, P3287, DOI 10.1099/0022-1317-78-12-3287; Parker LM, 2001, J BIOL CHEM, V276, P32522, DOI 10.1074/jbc.M104408200; Parrott AM, 2005, J MOL BIOL, V348, P281, DOI 10.1016/j.jmb.2005.02.047; Patel RC, 1999, J BIOL CHEM, V274, P20432, DOI 10.1074/jbc.274.29.20432; Pei Y, 2008, J IMMUNOL, V180, P222, DOI 10.4049/jimmunol.180.1.222; Pfeifer I, 2008, P NATL ACAD SCI USA, V105, P4173, DOI 10.1073/pnas.0711222105; Ranpura SA, 2008, J ANDROL, V29, P186, DOI 10.2164/jandrol.107.003756; Reichman TW, 2002, MOL CELL BIOL, V22, P343, DOI 10.1128/MCB.22.1.343-356.2002; Reichman TW, 2003, CELL SIGNALING HDB, V3, P335; Rezai-Zadeh N, 2003, GENE DEV, V17, P1019, DOI 10.1101/gad.1068003; Saha B, 2012, ONCOGENE, V31, P173, DOI 10.1038/onc.2011.234; Sakamoto S, 1999, BIOCHEMISTRY-US, V38, P3355, DOI 10.1021/bi982099g; Sakamoto S, 2009, MOL CELL BIOL, V29, P3754, DOI 10.1128/MCB.01836-08; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1991, P NATL ACAD SCI USA, V88, P5523, DOI 10.1073/pnas.88.13.5523; Shabman RS, 2011, J INFECT DIS, V204, pS911, DOI 10.1093/infdis/jir343; Shamanna RA, 2011, MOL CELL BIOL, V31, P4832, DOI 10.1128/MCB.05849-11; Shi LF, 2005, J BIOL CHEM, V280, P18981, DOI 10.1074/jbc.M411034200; Shi LF, 2007, J EXP MED, V204, P971, DOI 10.1084/jem.20052078; Shi LF, 2007, NUCLEIC ACIDS RES, V35, P2302, DOI 10.1093/nar/gkm117; Shim J, 2002, MOL CELL, V10, P1331, DOI 10.1016/S1097-2765(02)00730-X; Shin HJ, 2002, ARCH VIROL, V147, P471, DOI 10.1007/s007050200001; Shiohama A, 2007, EXP CELL RES, V313, P4196, DOI 10.1016/j.yexcr.2007.07.020; Smith NL, 2011, CELL PROLIFERAT, V44, P147, DOI 10.1111/j.1365-2184.2011.00742.x; Stricker RLO, 2010, J VIROL, V84, P10592, DOI 10.1128/JVI.02506-09; Suzuki K, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/978312; Tan S, 2012, MOL PHARMACOL, V81, P701, DOI 10.1124/mol.111.076539; Tang J, 2000, J BIOL CHEM, V275, P19866, DOI 10.1074/jbc.M000023200; Thomas M, 2008, ONCOGENE, V27, P7018, DOI 10.1038/onc.2008.351; Tommasino M, 2003, HUM MUTAT, V21, P307, DOI 10.1002/humu.10178; Tran H, 2004, MOL CELL, V13, P101, DOI 10.1016/S1097-2765(03)00481-7; Ulke-Lemee A, 2007, BBA-PROTEINS PROTEOM, V1774, P1339, DOI 10.1016/j.bbapap.2007.07.015; Urcuqui-Inchima S, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-83; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vumbaca F, 2008, MOL CELL BIOL, V28, P772, DOI 10.1128/MCB.02078-06; Wang P, 2009, J VIROL, V83, P7850, DOI 10.1128/JVI.00735-09; Wang XH, 2011, J VIROL, V85, P8080, DOI 10.1128/JVI.00670-11; WANG XW, 1995, CANCER RES, V55, P6012; Yan JP, 2010, J VIROL, V84, P76, DOI 10.1128/JVI.01647-09; Zheltukhin AO, 2010, BIOCHEMISTRY-MOSCOW+, V75, P1692, DOI 10.1134/S0006297910130110; Zhu P, 2010, J IMMUNOL, V185, P5140, DOI 10.4049/jimmunol.1000849; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622; Zilfou JT, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001883	105	53	55	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2013	32	43					5176	5185		10.1038/onc.2012.533	http://dx.doi.org/10.1038/onc.2012.533			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240JY	23208500	Green Accepted			2022-12-28	WOS:000326093200005
J	Higgs, MR; Lerat, H; Pawlotsky, JM				Higgs, M. R.; Lerat, H.; Pawlotsky, J-M			Hepatitis C virus-induced activation of beta-catenin promotes c-Myc expression and a cascade of pro-carcinogenetic events	ONCOGENE			English	Article						hepatitis C virus; hepatocellular carcinoma; c-Myc; oxidative stress; DNA damage; NS5A protein	HEPATOCELLULAR-CARCINOMA; DNA-DAMAGE; MITOCHONDRIAL BIOGENESIS; ROS PRODUCTION; TARGET GENES; PROTEIN; MICE; IDENTIFICATION; NS5A; P53	Chronic infection by hepatitis C virus (HCV) is a major risk factor for the onset and development of hepatocellular carcinoma (HCC), although the underlying mechanisms are unclear. The c-Myc oncogene contributes to the genesis of many types of cancers, including HCC, partly via the induction of genetic damage and the inhibition of the cellular response to genotoxic stress. Here, we show a previously undiscovered mechanistic link between HCV infection and enhanced c-Myc expression. c-Myc expression was augmented in non-tumoral liver tissues from HCV-infected individuals with or without HCC and in hepatocyte cell lines harboring an HCV replicon and the infectious HCV strain JFH1. Increased c-Myc expression was confirmed in vivo in a transgenic murine model expressing the entire HCV open reading frame, demonstrating a direct role for HCV protein expression in c-Myc induction. Mechanistically, activation of Akt by the HCV non-structural protein NS5A, and the subsequent stabilization of the transcription factor beta-catenin, was demonstrated to be responsible for activation of the c-Myc promoter, and for increased c-Myc transcription. beta-Catenin-dependent c-Myc expression in this context led to increased production of reactive oxygen species, mitochondrial perturbation, enhanced DNA damage and aberrant cell-cycle arrest. Together, these data provide a novel insight into the mechanisms involved in HCV-associated HCCs, strongly suggesting that c-Myc has a crucial contributory role in this process.	[Higgs, M. R.; Lerat, H.; Pawlotsky, J-M] Inst Mondor Rech Biomed, INSERM, U955, Creteil, France; [Pawlotsky, J-M] Univ Paris Est, Hop Henri Mondor, Dept Virol, Natl Reference Ctr Viral Hepatitis B C & Delta, Creteil, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	Pawlotsky, JM (corresponding author), Hop Henri Mondor, Dept Virol, 51 Ave Marechal de Lattre de Tassigny, F-94010 Creteil, France.	jean-michel.pawlotsky@hmn.aphp.fr	Pawlotsky, Jean-Michel/R-8159-2018; Higgs, Martin/AAK-2108-2021; LERAT, Hervé/D-4331-2019	Higgs, Martin/0000-0002-8218-0089; LERAT, Hervé/0000-0002-8505-378X; Pawlotsky, Jean-Michel/0000-0003-0745-7559	Agence Nationale de Recherche sur le SIDA et les Hepatites Virales (ANRS); ANRS	Agence Nationale de Recherche sur le SIDA et les Hepatites Virales (ANRS)(ANRSFrench National Research Agency (ANR)); ANRS(ANRSFrench National Research Agency (ANR))	This work was supported by a research grant from the Agence Nationale de Recherche sur le SIDA et les Hepatites Virales (ANRS). MH was supported by a postdoctoral fellowship from the ANRS. We thank Aurore Gaudin and Olivier Gouin for technical assistance; Christine Perret and Thomas Decaens for manuscript comments; Czeslaw Wychowski, Bert Vogelstein and Xi He for JFH-1-infected cultures, pDEL1 and DKK1, respectively; Mark Harris for the NS5A antibody; Paulette Bioulac-Sage for patient biopsies; and Ralf Bartenschlager for the HCV genotype 1b subgenomic replicon, established in our laboratory by Abdelhakim Ahmed-Belkacem.	AbouElella A, 1996, MODERN PATHOL, V9, P95; Boyault S, 2007, HEPATOLOGY, V45, P42, DOI 10.1002/hep.21467; Cadoret A, 2001, CANCER RES, V61, P3245; Dang CV, 2005, CELL CYCLE, V4, P1465, DOI 10.4161/cc.4.11.2121; Disson O, 2004, GASTROENTEROLOGY, V126, P859, DOI 10.1053/j.gastro.2003.12.005; El-Serag HB, 2002, HEPATOLOGY, V36, pS74, DOI 10.1053/jhep.2002.36807; Farinati F, 2007, J VIRAL HEPATITIS, V14, P821, DOI 10.1111/1365-2893.2007.00878.x; GAN FY, 1993, J HISTOCHEM CYTOCHEM, V41, P1185, DOI 10.1177/41.8.7687263; Garcia-Mediavilla MV, 2005, J HEPATOL, V43, P606, DOI 10.1016/j.jhep.2005.04.019; Graves JA, 2009, J BIOL CHEM, V284, P6520, DOI 10.1074/jbc.M807564200; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; He YP, 2002, J VIROL, V76, P9207, DOI 10.1128/JVI.76.18.9207-9217.2002; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; Higgs MR, 2010, CANCER RES, V70, P4901, DOI 10.1158/0008-5472.CAN-09-4554; Hsieh A, 2011, CANCER LETT, V300, P162, DOI 10.1016/j.canlet.2010.09.018; Karlsson A, 2003, P NATL ACAD SCI USA, V100, P9974, DOI 10.1073/pnas.1732638100; Kato J, 2001, CANCER RES, V61, P8697; Kawate S, 1999, ONCOLOGY-BASEL, V57, P157, DOI 10.1159/000012024; Keasler VV, 2006, VIROLOGY, V347, P466, DOI 10.1016/j.virol.2005.11.050; Kim J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001798; Korenaga M, 2005, J BIOL CHEM, V280, P37481, DOI 10.1074/jbc.M506412200; Laurent-Puig P, 2001, GASTROENTEROLOGY, V120, P1763, DOI 10.1053/gast.2001.24798; Legoix P, 1999, ONCOGENE, V18, P4044, DOI 10.1038/sj.onc.1202800; Lerat H, 2002, GASTROENTEROLOGY, V122, P352, DOI 10.1053/gast.2002.31001; Lerat H, 2011, EXPERT REV GASTROENT, V5, P341, DOI [10.1586/egh.11.14, 10.1586/EGH.11.14]; Li F, 2005, MOL CELL BIOL, V25, P6225, DOI 10.1128/MCB.25.14.6225-6234.2005; Li YC, 2007, FASEB J, V21, P2474, DOI 10.1096/fj.06-7345com; Machida K, 2006, J VIROL, V80, P7199, DOI 10.1128/JVI.00321-06; McGivern DR, 2011, ONCOGENE, V30, P1969, DOI 10.1038/onc.2010.594; McGivern DR, 2009, ANNU REV PATHOL-MECH, V4, P399, DOI 10.1146/annurev.pathol.4.110807.092202; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Menssen A, 2007, CELL CYCLE, V6, P339, DOI 10.4161/cc.6.3.3808; Meuleman P, 2008, ANTIVIR RES, V80, P231, DOI 10.1016/j.antiviral.2008.07.006; Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231; Milward A, 2010, J GEN VIROL, V91, P373, DOI 10.1099/vir.0.015305-0; Mitchell C, 2009, AM J PATHOL, V175, P1929, DOI 10.2353/ajpath.2009.090332; Neiman PE, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000132; Nishina S, 2008, GASTROENTEROLOGY, V134, P226, DOI 10.1053/j.gastro.2007.10.011; Nordenstedt H, 2010, DIGEST LIVER DIS, V42, pS206, DOI 10.1016/S1590-8658(10)60507-5; Park CY, 2009, J HEPATOL, V51, P853, DOI 10.1016/j.jhep.2009.06.026; Prochownik EV, 2007, CELL CYCLE, V6, P1024, DOI 10.4161/cc.6.9.4161; RAY RB, 1995, VIRUS RES, V37, P209, DOI 10.1016/0168-1702(95)00034-N; Ray S, 2006, CANCER RES, V66, P6598, DOI 10.1158/0008-5472.CAN-05-3115; Rebouissou S, 2008, J HEPATOL, V48, P163, DOI [10.1016/j.jhep.2007.10.003, 10.1016/j.jhep.2008.02.001]; SAEGUSA M, 1993, J CANCER RES CLIN, V119, P737, DOI 10.1007/BF01195346; Sagun KC, 2006, MUTAT RES-FUND MOL M, V593, P64, DOI 10.1016/j.mrfmmm.2005.06.015; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Semenov MV, 2001, CURR BIOL, V11, P951, DOI 10.1016/S0960-9822(01)00290-1; Si YH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019967; SIMONETTI RG, 1992, ANN INTERN MED, V116, P97, DOI 10.7326/0003-4819-116-2-97; Simonin Y, 2009, HEPATOLOGY, V50, P1370, DOI 10.1002/hep.23169; Stewart B.W., 2003, WORLD CANC REPORT; Street A, 2005, J VIROL, V79, P5006, DOI 10.1128/JVI.79.8.5006-5016.2005; Street A, 2004, J BIOL CHEM, V279, P12232, DOI 10.1074/jbc.M312245200; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Wierstra I, 2008, ADV CANCER RES, V99, P113, DOI 10.1016/S0065-230X(07)99004-1; Yochum GS, 2007, P NATL ACAD SCI USA, V104, P3324, DOI 10.1073/pnas.0611576104; Yu L, 2009, J ONCOL, V2009, DOI 10.1155/2009/780874; Zhang Y, 2012, HEPATOLOGY IN PRESS	61	60	62	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2013	32	39					4683	4693		10.1038/onc.2012.484	http://dx.doi.org/10.1038/onc.2012.484			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226YD	23108410				2022-12-28	WOS:000325072200010
J	Quan, H; Zhou, F; Nie, D; Chen, Q; Cai, X; Shan, X; Zhou, Z; Chen, K; Huang, A; Li, S; Tang, N				Quan, H.; Zhou, F.; Nie, D.; Chen, Q.; Cai, X.; Shan, X.; Zhou, Z.; Chen, K.; Huang, A.; Li, S.; Tang, N.			Hepatitis C virus core protein epigenetically silences SFRP1 and enhances HCC aggressiveness by inducing epithelial-mesenchymal transition	ONCOGENE			English	Article						hepatitis C virus; epigenetic silencing; SFRP1; Wnt/beta-catenin signaling pathway; methylation	BETA-CATENIN; DNA METHYLATION; EXPRESSION; CANCER; TUMOR; DIFFERENTIATION; TARGET; GENES; CELLS; DNMT1	Hepatocellular carcinoma (HCC) is one of the most deadly cancers. Aberrant oncogenic activation of the Wnt/beta-catenin signaling pathway contributes to hepatocellular carcinogenesis. Various epigenetic modifications of the Wnt antagonist secreted frizzledrelated protein (SFRP) family have been implicated in regulating Wnt signaling. Here, we report that Hepatitis C virus (HCV) core protein downregulates SFRP1 expression when it is expressed in Huh7 and HepG2 cells. SFRP1 expression can be effectively restored by using either a DNA methylation inhibitor alone or in combination with a histone deacetylase inhibitor. DNA methylation analysis of the SFRP1 promoter revealed that cytosine-phosphate-guanine (CpG) islands close to the transcriptional start site (TSS) in the SFRP1 promoter were hypermethylated in core-expressing Huh7 cells, suggesting that HCV core protein may downregulate SFRP1 expression by inducing hypermethylation of the SFRP1 promoter. Chromatin immunoprecipitation revealed that HCV core protein markedly increased the expression level and binding of DNA methyltransferase-1 (Dnmt1) and histone deacetylase-1 (HDAC1) to the TSS of the SFRP1 promoter region, resulting in repression of acetyl-histone H3-binding capacity to SFRP1 promoter and the eventual epigenetic silencing of SFRP1 expression. Furthermore, the core protein-promoted cell proliferation, migration and invasiveness were effectively abrogated either by Dnmt1 knockdown or restoration of SFRP1 expression in hepatoma cells. Dnmt1 knockdown or SFRP1 overexpression also inhibited HCV core-induced epithelial-mesenchymal transition (EMT) and significantly decreased the expression levels of activated b-catenin and Wnt/b-catenin target genes, c-Myc and cyclin D1. We further showed that knockdown of Dnmt1 and restoration of SFRP1 inhibited core-induced in vivo tumor growth and aggressiveness in a xenograft HCC model. Taken together, our results strongly suggest that the HCV core-induced epigenetic silencing of SFRP1 may lead to the activation of the Wnt signaling pathway and thus contribute to HCC aggressiveness through induction of EMT.	[Quan, H.; Zhou, F.; Nie, D.; Chen, Q.; Cai, X.; Shan, X.; Zhou, Z.; Chen, K.; Huang, A.; Li, S.; Tang, N.] Chongqing Med Univ, Affiliated Hosp 2, Chongqing 400010, Peoples R China; [Quan, H.; Zhou, F.; Nie, D.; Chen, Q.; Cai, X.; Shan, X.; Zhou, Z.; Chen, K.; Huang, A.; Li, S.; Tang, N.] Chongqing Med Univ, Key Lab Mol Biol Infect Dis, Chinese Minist Educ, Chongqing 400010, Peoples R China	Chongqing Medical University; Chongqing Medical University	Li, S (corresponding author), Chongqing Med Univ, Affiliated Hosp 2, Lin Jiang Rd, Chongqing 400010, Peoples R China.	cqlsw@yahoo.com.cn; nitang809@hotmail.com	Tang, Ni/Z-5133-2019	Tang, Ni/0000-0001-5830-8786	Major National S T program [2013ZX10002002, 2012ZX10002005-003-002]; China National Natural Science Foundation [30972586, 31171307, 81171563]; Natural Science Foundation Project of CQMU	Major National S T program; China National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); Natural Science Foundation Project of CQMU	This study was supported by research grants from Major National S&T program (2013ZX10002002, AH; 2012ZX10002005-003-002, NT), China National Natural Science Foundation (# 30972586, # 31171307, NT; # 81171563, ZZ) and Natural Science Foundation Project of CQMU (NT). We thank Dr T-C He of University of Chicago, USA, for kind provision of adenoviruses AdGFP, AdsiDnmt1 and AdSFRP1. We are also grateful for Dr Takaji Wakita (National Institute of Infectious Diseases, Tokyo) for providing the HCV JFH-1 cDNA clone.	Akkari L, 2012, J HEPATOL, V57, P1021, DOI 10.1016/j.jhep.2012.06.027; Arora P, 2008, CANCER LETT, V261, P244, DOI 10.1016/j.canlet.2007.11.033; Austinat M, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-21; Battaglia S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004355; Benegiamo G, 2012, DIGEST DIS SCI, V57, P1598, DOI 10.1007/s10620-012-2160-1; Bi Y, 2009, J CELL BIOCHEM, V108, P295, DOI 10.1002/jcb.22254; Bose SK, 2012, J VIROL, V86, P13621, DOI 10.1128/JVI.02016-12; Campbell PM, 2003, CARCINOGENESIS, V24, P17, DOI 10.1093/carcin/24.1.17; Cervoni N, 2001, J BIOL CHEM, V276, P40778, DOI 10.1074/jbc.M103921200; Chan EF, 1999, NAT GENET, V21, P410, DOI 10.1038/7747; Chiam K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025634; Clement S, 2010, J HEPATOL, V52, P635, DOI 10.1016/j.jhep.2009.10.035; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; Danam RP, 2005, MOL CANCER THER, V4, P61; Easwaran V, 2003, CANCER RES, V63, P3145; Fang S, 2013, CLIN EXP MED, V13, P127, DOI 10.1007/s10238-012-0182-9; Fuks F, 2000, NAT GENET, V24, P88, DOI 10.1038/71750; Gauger KJ, 2012, BMC DEV BIOL, V12, DOI 10.1186/1471-213X-12-25; Gavert N, 2011, MOL CANCER RES, V9, P14, DOI 10.1158/1541-7786.MCR-10-0406; Gong CM, 2012, TOXICOL LETT, V209, P264, DOI 10.1016/j.toxlet.2012.01.007; Gros C, 2012, BIOCHIMIE, V94, P2280, DOI 10.1016/j.biochi.2012.07.025; Guo N, 2012, J CELL BIOCHEM, V113, P3419, DOI 10.1002/jcb.24218; Huang JY, 2009, LIVER INT, V29, P1569, DOI 10.1111/j.1478-3231.2009.02111.x; Jiang X, 2008, CANCER CELL, V13, P529, DOI 10.1016/j.ccr.2008.04.019; Kaneda A, 2012, CANCER RES, V72, P3445, DOI 10.1158/0008-5472.CAN-11-3919; Kato N, 2000, HEPATOLOGY, V32, P405, DOI 10.1053/jhep.2000.9198; Kaur P, 2012, TUMOR BIOL, V33, P325, DOI 10.1007/s13277-012-0331-5; Lee JY, 2012, J AM CHEM SOC, V134, P173, DOI 10.1021/ja210273w; Li KQK, 2013, ANTI-CANCER AGENT ME, V13, P242; Li VSW, 2012, CELL, V149, P1245, DOI 10.1016/j.cell.2012.05.002; Liu JX, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023098; Mao W, 2011, INVEST OPHTH VIS SCI, V53, P7043; Milavetz B, 2012, EPIGENETICS-US, V7, P528, DOI 10.4161/epi.20057; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Shih YL, 2007, INT J CANCER, V121, P1028, DOI 10.1002/ijc.22750; Sturgeon SR, 2012, EPIGENETICS-US, V7, P1258, DOI 10.4161/epi.22220; Su HY, 2010, INT J CANCER, V127, P555, DOI 10.1002/ijc.25083; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Tang N, 2009, J CELL MOL MED, V13, P2448, DOI 10.1111/j.1582-4934.2008.00569.x; Vaid M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023000; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; Wang XB, 2012, ONCOL LETT, V4, P334, DOI 10.3892/ol.2012.713; Wu DW, 2012, AM J PATHOL, V181, P1796, DOI 10.1016/j.ajpath.2012.07.032	44	72	76	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2014	33	22					2826	2835		10.1038/onc.2013.225	http://dx.doi.org/10.1038/onc.2013.225			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EI	23770846				2022-12-28	WOS:000337231800002
J	Liu, L; Xu, HX; Wang, WQ; Wu, CT; Chen, T; Qin, Y; Liu, C; Xu, J; Long, J; Zhang, B; Xu, YF; Ni, QX; Li, M; Yu, XJ				Liu, L.; Xu, H-X; Wang, W-Q; Wu, C-T; Chen, T.; Qin, Y.; Liu, C.; Xu, J.; Long, J.; Zhang, B.; Xu, Y-F; Ni, Q-X; Li, M.; Yu, X-J			Cavin-1 is essential for the tumor-promoting effect of caveolin-1 and enhances its prognostic potency in pancreatic cancer	ONCOGENE			English	Article						cavin-1; caveolin-1; pancreatic cancer; metastatic potential; prognostic potency	TRANSCRIPT-RELEASE FACTOR; I OVEREXPRESSION; CELL-MIGRATION; POOR-PROGNOSIS; POLYMERASE-I; EXPRESSION; CARCINOMA; GENE; PROGRESSION; INVASION	Caveolin-1 exhibits a stage-dependent, functional fluctuation during pancreatic cancer development, but the underlying mechanisms remain unclear. Here, we report that cavin-1, a structural protein of caveolae, modulates the oncogenic function of caveolin-1 and cooperates with caveolin-1 to enhance pancreatic cancer aggressiveness. Cavin-1 expression is associated with caveolin-1 in pancreatic cancer tissue samples and cell lines, and predicts the metastatic potential of pancreatic cancer. Interactome analyses further revealed the physical interaction of cavin-1 and caveolin-1 and their colocalization in pancreatic cancer cells. Cavin-1 stabilizes caveolin-1 expression or activity by inhibiting its internalization and subsequent lysosomal degradation. More in-depth functional experiments showed that caveolin-1-enhanced aggressiveness of pancreatic cancer cells is dependent on the presence of cavin-1. In contrast, cavin-1 depletion inhibited the invasion and metastasis of pancreatic cancer cells, which could not be restored by caveolin-1-rescue construct. Tissue microarray analyses in two independent clinic cohorts also supported the augment of cavin-1 on the prognostic potency of caveolin-1, and showed that combination of cavin-1 with caveolin-1 predicted worse survival in pancreatic cancer patients. Of note, the phenotypes because of cavin-1 could not be achieved by other cavins such as cavin-2, and the tumor-promoting role of cavin-1 in pancreatic cancer was found to be largely dependent on caveolin-1 expression, which highlights the critical role of cavin-1/caveoin-1 in pancreatic cancer progression, and suggests that the interruption of cavin-1/caveolin-1 interaction is a promising therapeutic strategy for pancreatic cancer.	[Liu, L.; Xu, H-X; Wang, W-Q; Wu, C-T; Chen, T.; Qin, Y.; Liu, C.; Xu, J.; Long, J.; Zhang, B.; Xu, Y-F; Ni, Q-X; Li, M.; Yu, X-J] Fudan Univ, Pancreat Canc Inst, Shanghai 200032, Peoples R China; [Liu, L.; Xu, H-X; Wang, W-Q; Wu, C-T; Chen, T.; Qin, Y.; Liu, C.; Xu, J.; Long, J.; Zhang, B.; Xu, Y-F; Ni, Q-X; Li, M.; Yu, X-J] Fudan Univ, Dept Pancreat & Hepatobiliary Surg, Shanghai Canc Ctr, Shanghai 200032, Peoples R China; [Liu, L.; Xu, H-X; Wang, W-Q; Wu, C-T; Chen, T.; Qin, Y.; Liu, C.; Xu, J.; Long, J.; Zhang, B.; Xu, Y-F; Ni, Q-X; Li, M.; Yu, X-J] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China; [Li, M.] Univ Texas Houston, Sch Med, Vivian L Smith Dept Neurosurg, Houston, TX USA	Fudan University; Fudan University; Fudan University; University of Texas System; University of Texas Health Science Center Houston	Yu, XJ (corresponding author), Fudan Univ, Pancreat Canc Inst, 270 DongAn Rd, Shanghai 200032, Peoples R China.	Min.Li@uth.tmc.edu; yuxianjun88@hotmail.com		yu, xianjun/0000-0002-6697-7143	National Natural Science Foundation of China [81172005, 81172276]; National Natural Science Foundation of Shanghai [11ZR1407000]; PhD Programs Foundation of Ministry of Education of China [20110071120096]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); National Natural Science Foundation of Shanghai; PhD Programs Foundation of Ministry of Education of China(Ministry of Education, China)	We thank Zhi-Qiang Meng for providing the pancreatic cancer cells SW1990HM and Huan-Yu Xia for assistance in collecting the patient data. This research project was supported by grants from the National Natural Science Foundation of China (81172005 and 81172276), the National Natural Science Foundation of Shanghai (11ZR1407000) and PhD Programs Foundation of Ministry of Education of China (20110071120096).	Aung CS, 2011, EUR J CELL BIOL, V90, P136, DOI 10.1016/j.ejcb.2010.06.004; Bastiani M, 2009, J CELL BIOL, V185, P1259, DOI 10.1083/jcb.200903053; Bender FC, 2000, CANCER RES, V60, P5870; Bruns Christiane J., 1999, Neoplasia (New York), V1, P50, DOI 10.1038/sj.neo.7900005; Burgermeister E, 2007, CANCER RES, V67, P8519, DOI 10.1158/0008-5472.CAN-07-1125; Chen ST, 2004, INT J MOL MED, V14, P577; Chiu WT, 2011, CANCER RES, V71, P4932, DOI 10.1158/0008-5472.CAN-10-4249; Fong A, 2003, AM J CLIN PATHOL, V120, P93, DOI 10.1309/292NHAYNWAVREJ37; Gamez-Pozo A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033752; Goetz JG, 2008, CANCER METAST REV, V27, P715, DOI 10.1007/s10555-008-9160-9; Hansen CG, 2010, TRENDS CELL BIOL, V20, P177, DOI 10.1016/j.tcb.2010.01.005; Hansen CG, 2009, NAT CELL BIOL, V11, P807, DOI 10.1038/ncb1887; Harris J, 2002, IMMUNOLOGY, V105, P190, DOI 10.1046/j.1365-2567.2002.01362.x; Hasegawa T, 2000, BIOCHEM J, V347, P55, DOI 10.1042/0264-6021:3470055; Hill MM, 2008, CELL, V132, P113, DOI 10.1016/j.cell.2007.11.042; Ho CC, 2008, LUNG CANCER, V59, P105, DOI 10.1016/j.lungcan.2007.07.024; Huang C, 2012, CANCER RES, V72, P655, DOI 10.1158/0008-5472.CAN-11-3102; Ito Y, 2002, BRIT J CANCER, V86, P912, DOI 10.1038/sj.bjc.6600172; Jansa P, 1998, EMBO J, V17, P2855, DOI 10.1093/emboj/17.10.2855; Joshi B, 2008, CANCER RES, V68, P8210, DOI 10.1158/0008-5472.CAN-08-0343; Kai WC, 2001, AM J PATHOL, V159, P1635, DOI 10.1016/S0002-9440(10)63010-6; Karam JA, 2007, PROSTATE, V67, P614, DOI 10.1002/pros.20557; Kato K, 2002, CANCER, V94, P929, DOI 10.1002/cncr.10329.abs; Li LK, 2001, CANCER RES, V61, P4386; Lin M, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-21; Liu LA, 2010, CLIN CANCER RES, V16, P2740, DOI 10.1158/1078-0432.CCR-09-2610; Liu L, 2010, CANCER SCI, V101, P120, DOI 10.1111/j.1349-7006.2009.01363.x; Liu LB, 2008, J BIOL CHEM, V283, P4314, DOI 10.1074/jbc.M707890200; McMahon KA, 2009, EMBO J, V28, P1001, DOI 10.1038/emboj.2009.46; Murakami S, 2003, BRIT J CANCER, V88, P1234, DOI 10.1038/sj.bjc.6600878; Nabi IR, 2009, NAT CELL BIOL, V11, P789, DOI 10.1038/ncb0709-789; Quest AFG, 2008, J CELL MOL MED, V12, P1130, DOI 10.1111/j.1582-4934.2008.00331.x; Rao X, 2013, ONCOGENE, V32, P4519, DOI 10.1038/onc.2012.474; Shi WD, 2009, CANCER LETT, V283, P84, DOI 10.1016/j.canlet.2009.03.030; Terris B, 2002, AM J PATHOL, V160, P1745, DOI 10.1016/S0002-9440(10)61121-2; Thomas S, 2004, MOL IMMUNOL, V41, P399, DOI 10.1016/j.molimm.2004.03.022; Wiechen K, 2001, AM J PATHOL, V158, P833, DOI 10.1016/S0002-9440(10)64031-X	37	45	46	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2014	33	21					2728	2736		10.1038/onc.2013.223	http://dx.doi.org/10.1038/onc.2013.223			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EH	23770857				2022-12-28	WOS:000337231700006
J	Zhang, H; Yu, C; Dai, J; Keller, JM; Hua, A; Sottnik, JL; Shelley, G; Hall, CL; Park, SI; Yao, Z; Zhang, J; McCauley, LK; Keller, ET				Zhang, H.; Yu, C.; Dai, J.; Keller, J. M.; Hua, A.; Sottnik, J. L.; Shelley, G.; Hall, C. L.; Park, S. I.; Yao, Z.; Zhang, J.; McCauley, L. K.; Keller, E. T.			Parathyroid hormone-related protein inhibits DKK1 expression through c-Jun-mediated inhibition of beta-catenin activation of the DKK1 promoter in prostate cancer	ONCOGENE			English	Article						prostate cancer; DKK1; PTHrP; Wnt/beta-catenin signaling; skeletal metastasis	WNT ANTAGONIST DICKKOPF-1; BONE METASTASES; RECEPTOR; GROWTH; CELLS; PTHRP; TUMOR; GENE; TRANSCRIPTION; TARGET	Prostate cancer (PCa) bone metastases are unique in that majority of them induce excessive mineralized bone matrix, through undefined mechanisms, as opposed to most other cancers that induce bone resorption. Parathyroid hormone-related protein (PTHrP) is produced by PCa cells and intermittent PTHrP exposure has bone anabolic effects, suggesting that PTHrP could contribute to the excess bone mineralization. Wnts are bone-productive factors produced by PCa cells, and the Wnt inhibitor Dickkopfs-1 (DKK1) has been shown to promote PCa progression. These findings, in conjunction with the observation that PTHrP expression increases and DKK1 expression decreases as PCa progresses, led to the hypothesis that PTHrP could be a negative regulator of DKK1 expression in PCa cells and, hence, allow the osteoblastic activity of Wnts to be realized. To test this, we first demonstrated that PTHrP downregulated DKK1 mRNA and protein expression. We then found through multiple mutated DKK1 promoter assays that PTHrP, through c-Jun activation, downregulated the DKK1 promoter through a transcription factor (TCF) response element site. Furthermore, chromatin immunoprecipitation (ChIP) and re-ChIP assays revealed that PTHrP mediated this effect through inducing c-Jun to bind to a transcriptional activator complex consisting of beta-catenin, which binds the most proximal DKK1 promoter, the TCF response element. Together, these results demonstrate a novel signaling linkage between PTHrP and Wnt signaling pathways that results in downregulation of a Wnt inhibitor allowing for Wnt activity that could contribute the osteoblastic nature of PCa.	[Zhang, H.; Yu, C.; Dai, J.; Keller, J. M.; Hua, A.; Sottnik, J. L.; Shelley, G.; Hall, C. L.; Keller, E. T.] Univ Michigan, Sch Med, Dept Urol, Ann Arbor, MI 48109 USA; [Yu, C.; Yao, Z.] Tianjin Med Univ, Dept Immunol, Tianjin Key Lab Cellular & Mol Immunol, Key Lab Educ Minist, Tianjin, Peoples R China; [Park, S. I.; McCauley, L. K.] Univ Michigan, Sch Dent, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA; [Zhang, J.] Guangxi Med Univ, Ctr Translat Med Res, Guangxi, Peoples R China; [McCauley, L. K.; Keller, E. T.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; Tianjin Medical University; University of Michigan System; University of Michigan; Guangxi Medical University; University of Michigan System; University of Michigan	Keller, ET (corresponding author), Univ Michigan, Sch Med, Dept Urol, 5308 CC,1500 East Med Ctr Dr, Ann Arbor, MI 48109 USA.	etkeller@umich.edu	Keller, Evan T/M-1446-2016; ZHANG, JIAN/Q-6334-2018; Dai, Jin/GVT-2414-2022; Park, Serk In/D-2840-2011	Keller, Evan T/0000-0002-7592-7535; Dai, Jin/0000-0003-3063-746X; Park, Serk In/0000-0001-8643-5096; Hall, Christopher/0000-0003-1421-1733	NIH [PO1-CA939000]; US Department of Defense [W81XWH-10-1-0546]; NATIONAL CANCER INSTITUTE [P01CA093900] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000114] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by the NIH PO1-CA939000 (ETK and LKM), and the US Department of Defense W81XWH-10-1-0546 (SIP).	Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439; Akiyama H, 2004, GENE DEV, V18, P1072, DOI 10.1101/gad.1171104; Asadi F, 1996, HUM PATHOL, V27, P1319, DOI 10.1016/S0046-8177(96)90344-5; Azarani A, 1996, J BIOL CHEM, V271, P14931, DOI 10.1074/jbc.271.25.14931; Azari S, 2007, BIOLOGICALS, V35, P195, DOI 10.1016/j.biologicals.2006.10.001; BROWN PH, 1994, ONCOGENE, V9, P791; Chirgwin J. M., 2004, Journal of Musculoskeletal & Neuronal Interactions, V4, P308; Clines GA, 2007, MOL ENDOCRINOL, V21, P486, DOI 10.1210/me.2006-0346; Cowling VH, 2007, MOL CELL BIOL, V27, P5135, DOI 10.1128/MCB.02282-06; Dai JL, 2005, CANCER RES, V65, P8274, DOI 10.1158/0008-5472.CAN-05-1891; Deftos LJ, 2005, BIOCHEM BIOPH RES CO, V327, P468, DOI 10.1016/j.bbrc.2004.11.162; Dennler S, 2000, J BIOL CHEM, V275, P28858, DOI 10.1074/jbc.M910358199; Dougherty KM, 1999, CANCER RES, V59, P6015; Grotewold L, 2002, EMBO J, V21, P966, DOI 10.1093/emboj/21.5.966; GUISE TA, 1993, J CLIN ENDOCR METAB, V77, P40, DOI 10.1210/jc.77.1.40; Hall CL, 2008, PROSTATE, V68, P1396, DOI 10.1002/pros.20805; Hall CL, 2006, CANCER METAST REV, V25, P551, DOI 10.1007/s10555-006-9022-2; Hall CL, 2005, CANCER RES, V65, P7554, DOI 10.1158/0008-5472.CAN-05-1317; HENDERSON E, 1994, MOL CELL BIOL, V14, P655, DOI 10.1128/MCB.14.1.655; IWAMURA M, 1993, CANCER RES, V53, P1724; Kane N, 2008, MOL ENDOCRINOL, V22, P716, DOI 10.1210/me.2007-0316; Keller ET, 2004, J CELL BIOCHEM, V91, P718, DOI 10.1002/jcb.10662; Kitagawa Y, 2005, CANCER RES, V65, P10921, DOI 10.1158/0008-5472.CAN-05-1809; Koh AJ, 1999, ENDOCRINOLOGY, V140, P3154, DOI 10.1210/en.140.7.3154; Koppen A, 2007, CANCER LETT, V256, P218, DOI 10.1016/j.canlet.2007.06.011; Kremer R, 2012, ADV EXP MED BIOL, V720, P145, DOI 10.1007/978-1-4614-0254-1_12; Lee J, 2008, GYNECOL ONCOL, V109, P270, DOI 10.1016/j.ygyno.2008.01.034; Lee YC, 2011, CANCER RES, V71, P5194, DOI 10.1158/0008-5472.CAN-10-4374; Li J, 2008, NAT CELL BIOL, V10, P160, DOI 10.1038/ncb1684; Li ZG, 2008, J CLIN INVEST, V118, P2697, DOI 10.1172/JCI33093; Liao JH, 2008, INT J CANCER, V123, P2267, DOI 10.1002/ijc.23602; Lu Y, 2007, CANCER RES, V67, P3646, DOI 10.1158/0008-5472.CAN-06-1210; Lupp A, 2010, EUR J ENDOCRINOL, V162, P979, DOI 10.1530/EJE-09-0821; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Maehata T, 2008, WORLD J GASTROENTERO, V14, P2702, DOI 10.3748/wjg.14.2702; McCauley LK, 2012, J BONE MINER RES, V27, P1231, DOI 10.1002/jbmr.1617; Muller M, 2009, INT J MOL MED, V24, P373, DOI 10.3892/ijmm_00000242; Muncan V, 2006, MOL CELL BIOL, V26, P8418, DOI 10.1128/MCB.00821-06; Navarro D, 2010, CARCINOGENESIS, V31, P394, DOI 10.1093/carcin/bgp317; Nelson JB, 2003, J UROLOGY, V169, P1143, DOI 10.1097/01.ju.0000042162.08938.27; Perez-Martinez FC, 2007, J CLIN PATHOL, V60, P290, DOI 10.1136/jcp.2006.037853; Pettaway CA, 1996, CLIN CANCER RES, V2, P1627; Qin L, 2003, J BIOL CHEM, V278, P19723, DOI 10.1074/jbc.M212226200; Rabbani SA, 1999, INT J CANCER, V80, P257, DOI 10.1002/(SICI)1097-0215(19990118)80:2<257::AID-IJC15>3.0.CO;2-3; Robinson DR, 2008, CURR DRUG TARGETS, V9, P571; Sepulveda VAT, 2002, REGUL PEPTIDES, V105, P109, DOI 10.1016/S0167-0115(02)00007-1; Thompson EJ, 2002, MOL CARCINOGEN, V35, P157, DOI 10.1002/mc.10090; UY HL, 1995, ENDOCRINOLOGY, V136, P3207, DOI 10.1210/en.136.8.3207; van Bokhoven A, 2003, PROSTATE, V57, P205, DOI 10.1002/pros.10290; Weilbaecher KN, 2011, NAT REV CANCER, V11, P411, DOI 10.1038/nrc3055; Zhang J, 2011, J BONE MINER RES, V26, P1953, DOI 10.1002/jbmr.377; Zhong Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022129	52	16	21	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2014	33	19					2464	2477		10.1038/onc.2013.203	http://dx.doi.org/10.1038/onc.2013.203			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH3OK	23752183	Green Accepted			2022-12-28	WOS:000336033600006
J	Cappello, P; Blaser, H; Gorrini, C; Lin, DCC; Elia, AJ; Wakeham, A; Haider, S; Boutros, PC; Mason, JM; Miller, NA; Youngson, B; Done, SJ; Mak, TW				Cappello, P.; Blaser, H.; Gorrini, C.; Lin, D. C. C.; Elia, A. J.; Wakeham, A.; Haider, S.; Boutros, P. C.; Mason, J. M.; Miller, N. A.; Youngson, B.; Done, S. J.; Mak, T. W.			Role of Nek2 on centrosome duplication and aneuploidy in breast cancer cells	ONCOGENE			English	Article						kinase; aneuploidy; cell cycle; breast cancer; cell death; metastasis	POTENTIAL THERAPEUTIC TARGET; HISTONE H3 PHOSPHORYLATION; PROTEIN-KINASE; SPINDLE CHECKPOINT; TUMORIGENIC GROWTH; CYCLE REGULATION; EXPRESSION; NIMA; REGULATOR; SURVIVAL	Breast cancer is the most common solid tumor and the second most common cause of death in women. Despite a large body of literature and progress in breast cancer research, many molecular aspects of this complex disease are still poorly understood, hindering the design of specific and effective therapeutic strategies. To identify the molecules important in breast cancer progression and metastasis, we tested the in vivo effects of inhibiting the functions of various kinases and genes involved in the regulation/modulation of the cytoskeleton by downregulating them in mouse PyMT mammary tumor cells and human breast cancer cell lines. These kinases and cytoskeletal regulators were selected based on their prognostic values for breast cancer patient survival. PyMT tumor cells, in which a selected gene was stably knocked down were injected into the tail veins of mice, and the formation of tumors in the lungs was monitored. One of the several genes found to be important for tumor growth in the lungs was NIMA-related kinases 2 (Nek2), a cell cycle-related protein kinase. Furthermore, Nek2 was also important for tumor growth in the mammary fat pad. In various human breast cancer cell lines, Nek2 knockdown induced aneuploidy and cell cycle arrest that led to cell death. Significantly, the breast cancer cell line most sensitive to Nek2 depletion was of the triple negative breast cancer subtype. Our data indicate that Nek2 has a pivotal role in breast cancer growth at primary and secondary sites, and thus may be an attractive and novel therapeutic target for this disease	[Cappello, P.; Blaser, H.; Gorrini, C.; Elia, A. J.; Wakeham, A.; Done, S. J.; Mak, T. W.] Univ Hlth Network, Campbell Family Inst Breast Canc Res, Toronto, ON M5G 2M9, Canada; [Cappello, P.] Univ Turin, Dept Mol Biotechnol & Hlth Sci, Turin, Italy; [Lin, D. C. C.; Mason, J. M.] Univ Hlth Network, Campbell Family Inst Breast Canc Res, MaRS Ctr, Toronto, ON M5G 2M9, Canada; [Haider, S.; Boutros, P. C.] Ontario Inst Canc Res, Informat & Biocomp Platform, Toronto, ON, Canada; [Miller, N. A.; Youngson, B.; Done, S. J.] Univ Hlth Network, Lab Med Program, Toronto, ON M5G 2M9, Canada; [Miller, N. A.; Youngson, B.; Done, S. J.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Turin; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Ontario Institute for Cancer Research; University of Toronto; University Toronto Affiliates; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Mak, TW (corresponding author), Univ Hlth Network, Campbell Family Inst Breast Canc Res, 620 Univ Ave,Suite 706, Toronto, ON M5G 2M9, Canada.	tmak@uhnresearch.ca	Cappello, Paola/J-3127-2018	Cappello, Paola/0000-0002-5321-7794; Done, Susan/0000-0002-1770-988X; Gorrini, Chiara/0000-0002-5239-6671; Boutros, Paul/0000-0003-0553-7520; Youngson, Bruce/0000-0001-6526-8081	Canadian Institutes of Health Research [179815]; Ontario Institute for Cancer Research through Government of Ontario	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Ontario Institute for Cancer Research through Government of Ontario	We thank Dr Mary Saunders for the insightful scientific editing. This work was supported by grant no. 179815 from the Canadian Institutes of Health Research to TWM. This work was also performed with the support of the Ontario Institute for Cancer Research to PCB through funding provided by the Government of Ontario.	Arpaia E, 2012, ONCOGENE, V31, P884, DOI 10.1038/onc.2011.288; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Chen YM, 2002, J BIOL CHEM, V277, P49408, DOI 10.1074/jbc.M207069200; Chia SK, 2007, CANCER, V110, P973, DOI 10.1002/cncr.22867; De Souza CPC, 2000, CELL, V102, P293, DOI 10.1016/S0092-8674(00)00035-0; Dey N, 2012, CURR DRUG TARGETS, V13, P1510, DOI 10.2174/138945012803530116; Di Agostino S, 2002, DEVELOPMENT, V129, P1715; Du J, 2008, ONCOGENE, V27, P4107, DOI 10.1038/onc.2008.34; Ferretti C, 2010, CELL CYCLE, V9, P4174, DOI 10.4161/cc.9.20.13457; Fiskus W, 2012, BREAST CANCER RES TR, V135, P433, DOI 10.1007/s10549-012-2171-9; Fry AM, 2002, ONCOGENE, V21, P6184, DOI 10.1038/sj.onc.1205711; FRY AM, 1995, J BIOL CHEM, V270, P12899, DOI 10.1074/jbc.270.21.12899; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; Fry AM, 2012, J CELL SCI, V125, P4423, DOI 10.1242/jcs.111195; Gennari A, 2005, CANCER, V104, P1742, DOI 10.1002/cncr.21359; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Hans F, 2001, ONCOGENE, V20, P3021, DOI 10.1038/sj.onc.1204326; Hayward DG, 2006, CANCER LETT, V237, P155, DOI 10.1016/j.canlet.2005.06.017; Hayward DG, 2010, J BIOMOL SCREEN, V15, P918, DOI 10.1177/1087057110376537; Hayward DG, 2004, CANCER RES, V64, P7370, DOI 10.1158/0008-5472.CAN-04-0960; Hu KJ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3107; Ikui AE, 2005, CELL CYCLE, V4, P1385, DOI 10.4161/cc.4.10.2061; Innocenti P, 2012, J MED CHEM, V55, P3228, DOI 10.1021/jm201683b; Kim YH, 2002, BIOCHEM BIOPH RES CO, V290, P730, DOI 10.1006/bbrc.2001.6212; Kokuryo T, 2007, CANCER RES, V67, P9637, DOI 10.1158/0008-5472.CAN-07-1489; Kolodner RD, 2011, SCIENCE, V333, P942, DOI 10.1126/science.1211154; Komatsu M, 2013, INT J ONCOL, V42, P478, DOI 10.3892/ijo.2012.1744; Lee J, 2013, INT J ONCOL, V42, P839, DOI 10.3892/ijo.2013.1788; Liu QD, 2010, EXP MOL PATHOL, V88, P225, DOI 10.1016/j.yexmp.2009.12.004; Loddo M, 2009, BRIT J CANCER, V100, P959, DOI 10.1038/sj.bjc.6604924; Lou Y, 2004, J BIOL CHEM, V279, P20049, DOI 10.1074/jbc.M314205200; Mardin BR, 2012, J CELL BIOL, V197, P11, DOI 10.1083/jcb.201108006; Mittnacht S, 1998, CURR OPIN GENET DEV, V8, P21, DOI 10.1016/S0959-437X(98)80057-9; O'Regan L, 2007, CELL DIV, V2, DOI 10.1186/1747-1028-2-25; Reddy KB, 2011, CURR ONCOL, V18, pE173; Richardson AL, 2006, CANCER CELL, V9, P121, DOI 10.1016/j.ccr.2006.01.013; Romanelli A, 2012, MOL CANCER THER, V11, P2693, DOI 10.1158/1535-7163.MCT-12-0441-T; Shaukat Z, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047447; Shibata H, 2011, CANCER SCI, V102, P1882, DOI 10.1111/j.1349-7006.2011.02016.x; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Tryfonopoulos D, 2011, ANN ONCOL, V22, P2234, DOI 10.1093/annonc/mdq757; Tsunoda N, 2009, CANCER SCI, V100, P111, DOI 10.1111/j.1349-7006.2008.01007.x; Wang SL, 2012, J CELL BIOCHEM, V113, P1904, DOI 10.1002/jcb.24059; Yunokawa M, 2012, CANCER SCI, V103, P1665, DOI 10.1111/j.1349-7006.2012.02359.x; Zhou W, 2013, CANCER CELL, V23, P48, DOI 10.1016/j.ccr.2012.12.001	45	76	79	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2014	33	18					2375	2384		10.1038/onc.2013.183	http://dx.doi.org/10.1038/onc.2013.183			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AG5ID	23708664	Green Submitted			2022-12-28	WOS:000335451800010
J	Ieguchi, K; Tomita, T; Omori, T; Komatsu, A; Deguchi, A; Masuda, J; Duffy, SL; Coulthard, MG; Boyd, A; Maru, Y				Ieguchi, K.; Tomita, T.; Omori, T.; Komatsu, A.; Deguchi, A.; Masuda, J.; Duffy, S. L.; Coulthard, M. G.; Boyd, A.; Maru, Y.			ADAM12-cleaved ephrin-A1 contributes to lung metastasis	ONCOGENE			English	Article						Eph; tyrosine kinase; cell adhesion; permeability	EPH RECEPTORS; TYROSINE KINASE; CELL-PROLIFERATION; TUMOR-CELLS; ADAM12; CANCER; EXPRESSION; LIGAND; MIGRATION; BINDING	Eph receptor tyrosine kinases and their ephrin ligands have been implicated in neuronal development and neovascularization. Overexpression of ephrin-A1 has been implicated in tumor progression and poor prognosis. However, the mechanisms are not clear. Here, we report a role of the Eph/ephrin system in a cell adhesion mechanism. Clustered erythropoietin-producing hepatocellular receptor A1 ( EphA1)/ephrin-A1 complexes on the plasma membrane did not undergo endocytosis, and the cell remained adherent to one another. The cell-cell contacts were maintained in an Eph tyrosine kinase activity-independent manner even in the absence of E-cadherin. EphA1 and ephrin-A1 co-localized in pulmonary endothelial cells, and regulated vascular permeability and metastasis in the lungs. We identified ADAM12 ( A disintegrin and metalloproteinase 12) as an EphA1-binding partner by yeast two-hybrid screening and found that ADAM12 enhanced ephrin-A1 cleavage in response to transforming growth factor-b1 in primary tumors. Released soluble ephrin-A1 in the serum deteriorated the EphA1/ephrin-A1-mediated cell adhesion in the lungs in an endocrine manner, causing lung hyperpermeability that facilitated tumor cell entry into the lungs. Depletion of soluble ephrin-A1 by its neutralizing antibody significantly inhibited lung metastasis.	[Ieguchi, K.; Tomita, T.; Omori, T.; Komatsu, A.; Deguchi, A.; Masuda, J.; Maru, Y.] Tokyo Womens Med Univ, Dept Pharmacol, Tokyo 1828666, Japan; [Duffy, S. L.] Inst Curie, CNRS, UMR 144, Lab Morphogenese & Signalisat Cellulaires, F-75231 Paris, France; [Coulthard, M. G.; Boyd, A.] Queensland Inst Med Res, Leukemia Fdn Res Lab, Brisbane, Qld 4006, Australia	Tokyo Women's Medical University; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Maru, Y (corresponding author), Tokyo Womens Med Univ, Dept Pharmacol, 8-1 Kawadacho, Tokyo 1828666, Japan.	ymaru@research.twmu.ac.jp	Coulthard, Mark Graeme/E-9444-2010; Coulthard, Mark G/AAT-7735-2021	Coulthard, Mark Graeme/0000-0001-7400-5582; Coulthard, Mark G/0000-0001-7400-5582; Tomita, Takeshi/0000-0001-6815-2244	Ministry of Education, Culture, Sports, Science and Technology of Japan [21117008, 23590347, 25122716, 25870760]; Global COE program, Multidisciplinary Education and Research Center for Regenerative Medicine from Japan	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Global COE program, Multidisciplinary Education and Research Center for Regenerative Medicine from Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	We thank Dr Yoichiro Iwakura at the University of Tokyo for providing EphA2-KO mice, Dr Ulla Wewer at the University of Copenhagen for providing human ADAM12 cDNA clones and Ms. Helen Jeays at the Queensland Institute of Medical Research for proofreading. This work was supported by grant-in-aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan, grant nos. 21117008 (to YM), 23590347 (to TT), 25122716 and 25870760 (to KI), and the Global COE program, Multidisciplinary Education and Research Center for Regenerative Medicine from Japan.	Aasheim HC, 2005, BLOOD, V105, P2869, DOI 10.1182/blood-2004-08-2981; Alford S, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-41; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Atfi A, 2007, J CELL BIOL, V178, P201, DOI 10.1083/jcb.200612046; BARTLEY TD, 1994, NATURE, V368, P558, DOI 10.1038/368558a0; Beauchamp A, 2012, MOL CELL BIOL, V32, P3253, DOI 10.1128/MCB.06791-11; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Blobel CP, 2005, NAT REV MOL CELL BIO, V6, P32, DOI 10.1038/nrm1548; Brantley-Sieders DM, 2006, CANCER RES, V66, P10315, DOI 10.1158/0008-5472.CAN-06-1560; Brantley-Sieders DM, 2005, FASEB J, V19, P1884, DOI 10.1096/fj.05-4038fje; Brantley-Sieders DM, 2004, J CELL SCI, V117, P2037, DOI 10.1242/jcs.01061; Carpenter TC, 2012, AM J RESP CELL MOL, V46, P40, DOI 10.1165/rcmb.2011-0044OC; Davy A, 2000, EMBO J, V19, P5396, DOI 10.1093/emboj/19.20.5396; Davy A, 1999, GENE DEV, V13, P3125, DOI 10.1101/gad.13.23.3125; Dodelet VC, 2000, ONCOGENE, V19, P5614, DOI 10.1038/sj.onc.1203856; Duffy SL, 2008, GENESIS, V46, P553, DOI 10.1002/dvg.20434; Egea J, 2007, TRENDS CELL BIOL, V17, P230, DOI 10.1016/j.tcb.2007.03.004; Frohlich C, 2011, MOL CANCER RES, V9, P1449, DOI 10.1158/1541-7786.MCR-11-0100; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Gilpin BJ, 1998, J BIOL CHEM, V273, P157, DOI 10.1074/jbc.273.1.157; Hafner C, 2004, CLIN CHEM, V50, P490, DOI 10.1373/clinchem.2003.026849; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; Hiratsuka S, 2008, NAT CELL BIOL, V10, P1349, DOI 10.1038/ncb1794; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Hiratsuka S, 2011, P NATL ACAD SCI USA, V108, P3725, DOI 10.1073/pnas.1100446108; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; Ieguchi K, 2007, J BIOL CHEM, V282, P23296, DOI 10.1074/jbc.M700950200; Ieguchi K, 2010, J BIOL CHEM, V285, P31388, DOI 10.1074/jbc.M110.113878; Janes PW, 2005, CELL, V123, P291, DOI 10.1016/j.cell.2005.08.014; Kodama T, 2004, AM J PATHOL, V165, P1743, DOI 10.1016/S0002-9440(10)63429-3; Larson J, 2008, AM J PHYSIOL-LUNG C, V295, pL431, DOI 10.1152/ajplung.90256.2008; Le Pabic H, 2003, HEPATOLOGY, V37, P1056, DOI 10.1053/jhep.2003.50205; Lu X, 2011, CANCER CELL, V20, P701, DOI 10.1016/j.ccr.2011.11.002; Masuda J, 2008, J BIOL CHEM, V283, P13148, DOI 10.1074/jbc.M702164200; Miao H, 2009, CANCER CELL, V16, P9, DOI 10.1016/j.ccr.2009.04.009; Mochizuki S, 2007, CANCER SCI, V98, P621, DOI 10.1111/j.1349-7006.2007.00434.x; Naruse-Nakajima C, 2001, MECH DEVELOP, V102, P95, DOI 10.1016/S0925-4773(01)00290-8; O'Leary DDM, 1999, CURR OPIN NEUROBIOL, V9, P65, DOI 10.1016/S0959-4388(99)80008-7; Okazaki T, 2009, AM J PATHOL, V174, P2388, DOI 10.2353/ajpath.2009.080949; Orsulic S, 2000, J CELL SCI, V113, P1793; Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806; Roy R, 2004, J BIOL CHEM, V279, P51323, DOI 10.1074/jbc.M409565200; Shiomi T, 2003, CANCER METAST REV, V22, P145, DOI 10.1023/A:1023039230052; Sundberg C, 2004, J BIOL CHEM, V279, P51601, DOI 10.1074/jbc.M403753200; Tanaka M, 2005, J BIOL CHEM, V280, P42375, DOI 10.1074/jbc.M503786200; Vihanto MM, 2005, FASEB J, V19, P1689, DOI 10.1096/fj.04-3647fje; Wykosky J, 2008, ONCOGENE, V27, P7260, DOI 10.1038/onc.2008.328; Wykosky J, 2008, MOL CANCER RES, V6, P1795, DOI 10.1158/1541-7786.MCR-08-0244; Yamazaki T, 2009, J CELL SCI, V122, P243, DOI 10.1242/jcs.036467; Yoon S, 2012, ONCOGENE, V31, P3467, DOI 10.1038/onc.2011.517	50	43	44	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2014	33	17					2179	2190		10.1038/onc.2013.180	http://dx.doi.org/10.1038/onc.2013.180			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF8WJ	23686306				2022-12-28	WOS:000334996000004
J	Hill, KS; Erdogan, E; Khoor, A; Walsh, MP; Leitges, M; Murray, NR; Fields, AP				Hill, K. S.; Erdogan, E.; Khoor, A.; Walsh, M. P.; Leitges, M.; Murray, N. R.; Fields, A. P.			Protein kinase C alpha suppresses Kras-mediated lung tumor formation through activation of a p38 MAPK-TGF beta signaling axis	ONCOGENE			English	Article						tumor suppressor; lung adenocarcinoma; bronchio-alveolar stem cells; p38 MAPK; Wilm's Tumor 1 gene; inhibitors of DNA Binding (Id)	ANTISENSE OLIGONUCLEOTIDE INHIBITOR; SMOOTH-MUSCLE-CELLS; TRANSFORMED GROWTH; K-RAS; MOUSE MODELS; PKC-IOTA; CANCER; SENESCENCE; MICE; EXPRESSION	Protein kinase C alpha (PKC alpha) can activate both pro- and anti-tumorigenic signaling depending upon cellular context. Here, we investigated the role of PKC alpha in lung tumorigenesis in vivo. Gene expression data sets revealed that primary human non-small lung cancers (NSCLC) express significantly decreased PKC alpha levels, indicating that loss of PKC alpha expression is a recurrent event in NSCLC. We evaluated the functional relevance of PKC alpha loss during lung tumorigenesis in three murine lung adenocarcinoma models (LSL-Kras, LA2-Kras and urethane exposure). Genetic deletion of PKC alpha resulted in a significant increase in lung tumor number, size, burden and grade, bypass of oncogene-induced senescence, progression from adenoma to carcinoma and a significant decrease in survival in vivo. The tumor promoting effect of PKC alpha loss was reflected in enhanced Kras-mediated expansion of bronchio-alveolar stem cells (BASCs), putative tumor-initiating cells, both in vitro and in vivo. LSL-Kras/Prkca(-/-) mice exhibited a decrease in phospho-p38 MAPK in BASCs in vitro and in tumors in vivo, and treatment of LSL-Kras BASCs with a p38 inhibitor resulted in increased colony size indistinguishable from that observed in LSL-Kras/Prkca(-/-) BASCs. In addition, LSL-Kras/Prkca(-/-) BASCs exhibited a modest but reproducible increase in TGF beta 1 mRNA, and addition of exogenous TGF beta 1 to LSL-Kras BASCs results in enhanced growth similar to untreated BASCs from LSL-Kras/Prkca(-/-) mice. Conversely, a TGF beta R1 inhibitor reversed the effects of PKC alpha loss in LSL-Kras/Prkca(-/-) BASCs. Finally, we identified the inhibitors of DNA binding (Id) Id1-3 and the Wilm's Tumor 1 as potential downstream targets of PKC alpha-dependent tumor suppressor activity in vitro and in vivo. We conclude that PKC alpha suppresses tumor initiation and progression, at least in part, through a PKC alpha-p38MAPK-TGF beta signaling axis that regulates tumor cell proliferation and Kras-induced senescence. Our results provide the first direct evidence that PKC alpha exhibits tumor suppressor activity in the lung in vivo.	[Hill, K. S.; Erdogan, E.; Walsh, M. P.; Murray, N. R.; Fields, A. P.] Mayo Clin, Dept Canc Biol, Jacksonville, FL 32224 USA; [Khoor, A.] Mayo Clin, Dept Pathol, Jacksonville, FL 32224 USA; [Leitges, M.] Oslo Biotechnol Ctr, Oslo, Norway	Mayo Clinic; Mayo Clinic	Fields, AP (corresponding author), Mayo Clin, Dept Canc Biol, Griffin Canc Res Bldg,Rm 212,4500 San Pablo Rd, Jacksonville, FL 32224 USA.	fields.alan@mayo.edu	Leitges, Michael/AAN-1953-2021	Leitges, Michael/0000-0003-4203-6995; Hill, Kristen/0000-0003-3757-2822	National Cancer Institute [R01 CA081436-16, R01 CA140290-03]; NATIONAL CANCER INSTITUTE [R01CA081436, R01CA140290, P30CA015083] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors thank Brandy Edenfield for immunohistochemical staining procedures, Capella Weems for technical assistance, Justin Weems and Dr Lee Jamieson for animal husbandry and members of the Fields laboratory for support, encouragement and critical review of the manuscript. This work was supported in part by grants from the National Cancer Institute (R01 CA081436-16 to APF and R01 CA140290-03 to NRM). APF is the Monica Flynn Jacoby Endowed Professor of Cancer Research.	Advani R, 2004, CANCER-AM CANCER SOC, V100, P321, DOI 10.1002/cncr.11909; Bivona TG, 2006, MOL CELL, V21, P481, DOI 10.1016/j.molcel.2006.01.012; Cacace AM, 1996, ONCOGENE, V13, P2517; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; Collado M, 2010, NAT REV CANCER, V10, P51, DOI 10.1038/nrc2772; Dalgaard P, 2008, STAT COMPUT SER, P1, DOI 10.1007/978-0-387-79054-1_1; Dean N, 1996, CANCER RES, V56, P3499; Dehan E, 2007, LUNG CANCER, V56, P175, DOI 10.1016/j.lungcan.2006.12.010; Eder AM, 2005, P NATL ACAD SCI USA, V102, P12519, DOI 10.1073/pnas.0505641102; Erdogan E, 2006, J BIOL CHEM, V281, P28450, DOI 10.1074/jbc.M606054200; Fasbender A, 1998, J CLIN INVEST, V102, P184, DOI 10.1172/JCI2732; Fields AP, 2007, BIOCHEM SOC T, V35, P996, DOI 10.1042/BST0350996; Fields Alan P, 2003, Methods Mol Biol, V233, P519; Fields AP, 2008, ADV ENZYME REGUL, V48, P166, DOI 10.1016/j.advenzreg.2007.11.014; Galvez AS, 2009, MOL CELL BIOL, V29, P104, DOI 10.1128/MCB.01294-08; Geiger T, 1998, ANTI-CANCER DRUG DES, V13, P35; Grossman SA, 2005, NEURO-ONCOLOGY, V7, P32, DOI 10.1215/S1152851703000353; Grunert S, 2003, NAT REV MOL CELL BIO, V4, P657, DOI 10.1038/nrm1175; Hao F, 2011, J BIOL CHEM, V286, P18104, DOI 10.1074/jbc.M110.208488; Hou J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010312; Hsieh YH, 2007, CANCER RES, V67, P4320, DOI 10.1158/0008-5472.CAN-06-2486; Iwasa H, 2003, GENES CELLS, V8, P131, DOI 10.1046/j.1365-2443.2003.00620.x; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jamieson L, 1999, J BIOL CHEM, V274, P3927, DOI 10.1074/jbc.274.7.3927; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Justilien V, 2010, PROTEIN KINASE C IN CANCER SIGNALING AND THERAPY, P455, DOI 10.1007/978-1-60761-543-9_23; KIKKAWA U, 1983, J BIOL CHEM, V258, P1442; Kikuchi K, 2013, ONCOGENE, V32, P286, DOI 10.1038/onc.2012.46; Kim CFB, 2005, CELL, V121, P823, DOI 10.1016/j.cell.2005.03.032; Leitges M, 2002, MOL ENDOCRINOL, V16, P1203; Lindschau C, 2003, HYPERTENSION, V42, P335, DOI 10.1161/01.HYP.0000087839.72582.DD; Luo XP, 2005, ENDOCRINOLOGY, V146, P1097, DOI 10.1210/en.2004-1377; MALKINSON AM, 1985, J NATL CANCER I, V75, P971, DOI 10.1093/jnci/75.5.971; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; Murray NR, 2004, J CELL BIOL, V164, P797, DOI 10.1083/jcb.200311011; Nakagawa M, 2005, J BIOL CHEM, V280, P33926, DOI 10.1074/jbc.M505748200; Nazarenko I, 2010, MOL CANCER RES, V8, P919, DOI 10.1158/1541-7786.MCR-09-0358; Nikitin AY, 2004, CANCER RES, V64, P2307, DOI 10.1158/0008-5472.CAN-03-3376; Oliva JL, 2008, J BIOL CHEM, V283, P5466, DOI 10.1074/jbc.M707576200; Oster H, 2006, CANCER RES, V66, P6955, DOI 10.1158/0008-5472.CAN-06-0268; Paz-Ares L, 2006, J CLIN ONCOL, V24, P1428, DOI 10.1200/JCO.2005.04.3299; Pysz MA, 2009, EXP CELL RES, V315, P1415, DOI 10.1016/j.yexcr.2009.02.002; Reddig PJ, 1999, CANCER RES, V59, P5710; Reddig PJ, 2000, CANCER RES, V60, P595; Regala RP, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026439; Regala RP, 2009, CANCER RES, V69, P7603, DOI 10.1158/0008-5472.CAN-09-2066; Regala RP, 2005, CANCER RES, V65, P8905, DOI 10.1158/0008-5472.CAN-05-2372; Regala RP, 2005, J BIOL CHEM, V280, P31109, DOI 10.1074/jbc.M505402200; Sanchez-Palencia A, 2011, INT J CANCER, V129, P355, DOI 10.1002/ijc.25704; Scotti ML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030509; Scotti ML, 2010, CANCER RES, V70, P2064, DOI 10.1158/0008-5472.CAN-09-2684; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Stallings-Mann M, 2006, CANCER RES, V66, P1767, DOI 10.1158/0008-5472.CAN-05-3405; Tanaka Y, 2003, J BIOL CHEM, V278, P33753, DOI 10.1074/jbc.M303313200; Tossidou I, 2009, CELL PHYSIOL BIOCHEM, V24, P627, DOI 10.1159/000257518; Tuveson DA, 2004, CANCER CELL, V5, P375, DOI 10.1016/S1535-6108(04)00085-6; Ventura JJ, 2007, NAT GENET, V39, P750, DOI 10.1038/ng2037; Vicent S, 2010, J CLIN INVEST, V120, P3940, DOI 10.1172/JCI44165; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Yang Y, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002220; Zhang L, 2006, CANCER RES, V66, P4627, DOI 10.1158/0008-5472.CAN-05-4527	64	33	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2014	33	16					2134	2144		10.1038/onc.2013.147	http://dx.doi.org/10.1038/onc.2013.147			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF3GH	23604119	Green Accepted			2022-12-28	WOS:000334599100012
J	Asuthkar, S; Velpula, KK; Nalla, AK; Gogineni, VR; Gondi, CS; Rao, JS				Asuthkar, S.; Velpula, K. K.; Nalla, A. K.; Gogineni, V. R.; Gondi, C. S.; Rao, J. S.			Irradiation-induced angiogenesis is associated with an MMP-9-miR-494-syndecan-1 regulatory loop in medulloblastoma cells	ONCOGENE			English	Article						matrix metalloproteinase-9 (MMP-9); syndecan-1 (SDC1); microRNA-494 (miR-494); ionizing radiation (IR); 3 '-untranslated region (3 '-UTR); CpG methylation	PLASMINOGEN-ACTIVATOR RECEPTOR; HISTONE ACETYLTRANSFERASE; TUMOR-GROWTH; SOLUBLE SYNDECAN-1; DNA METHYLATION; DOWN-REGULATION; CANCER; EXPRESSION; INVASION; GENE	Matrix metalloproteinase-9 (MMP-9) represents one of the most prominent proteins associated with tumorigenesis and is a modulator of the tumor microenvironment during angiogenesis. Recently, syndecan-1 (SDC1), a transmembrane heparan sulfatebearing proteoglycan, was also speculated to have a critical role in contributing to angiogenesis when associated with MMP-9. However, the mechanism behind their synergistic regulation is not fully understood. In the current study, we report for the first time that ionizing radiation (IR)-induced MMP-9 enhances SDC1 shedding, corroborating to tube-inducing ability of medulloblastoma (MB) cells. Furthermore, we observed that the tumor angiogenesis is associated with higher MMP-9-SDC1 interactions on both the cell surface and extracellular medium. Our results also revealed the existence of a novel regulatory mechanism where MMP-9 drives the suppression of miR-494, resulting in enhanced SDC1 shedding and angiogenesis. From the in situ hybridization analysis, we found that MMP-9-specific shRNA (shMMP-9) treatment of mouse intracranial tumors resulted in elevated expression of miR-494. This negative correlation between MMP-9 and miR-494 levels was observed to be dependent on the methylation status of a miR-494 promoter-associated CpG island region (- 186 to - 20), which was confirmed by bisulfite-sequencing and methylation-specific PCR (MSP) analysis. Further, validation of MMP-9 and SDC1 3 '-untranslated region (3 '-UTR) targets with luciferase reporter assay provided a more favorable result for miR-494-mediated regulation of SDC1 but not of MMP-9, suggesting that the 3 '-UTR of SDC1 mRNA is a direct target of miR-494. Overall, our results indicate that angiogenesis induced by radiotherapy is associated with an MMP-9-miR-494-SDC1 regulatory loop and that MMP-9-SDC1 activity creates a negative feedback loop by regulating the expression of miR-494.	[Asuthkar, S.; Velpula, K. K.; Nalla, A. K.; Gogineni, V. R.; Gondi, C. S.; Rao, J. S.] Univ Illinois, Coll Med, Dept Canc Biol & Pharmacol, Peoria, IL 61605 USA; [Rao, J. S.] Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Asuthkar, S (corresponding author), Univ Illinois, Coll Med, Dept Canc Biol & Pharmacol, One Illini Dr, Peoria, IL 61605 USA.	asuthkar@uic.edu		Gondi, Christopher/0000-0002-3036-9920	National Cancer Institute Grant [CA138409]; NATIONAL CANCER INSTITUTE [R01CA138409] Funding Source: NIH RePORTER	National Cancer Institute Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Peggy Mankin and Noorjehan Ali for their technical assistance, Susan Renner and Debbie McCollum for manuscript preparation, and Diana Meister and Sushma Jasti for manuscript review. This research was supported by National Cancer Institute Grant CA138409 (to JSR).	ALIOSMAN F, 1990, CANCER RES, V50, P6976; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Artacho-Cordon F, 2012, SURG ONCOL, V21, pE143, DOI 10.1016/j.suronc.2012.06.001; Asuthkar S, 2012, J BIOL CHEM, V287, P20576, DOI 10.1074/jbc.M112.348888; Asuthkar S, 2011, NEURO-ONCOLOGY, V13, P1059, DOI 10.1093/neuonc/nor109; Balasubramanyam K, 2003, J BIOL CHEM, V278, P19134, DOI 10.1074/jbc.M301580200; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799; Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bhoopathi P, 2011, CANCER RES, V71, P4908, DOI 10.1158/0008-5472.CAN-10-3395; BIGNER SH, 1990, CANCER RES, V50, P2347; Brieger J, 2004, ANN NY ACAD SCI, V1030, P37, DOI 10.1196/annals.1329.005; Brule S, 2006, GLYCOBIOLOGY, V16, P488, DOI 10.1093/glycob/cwj098; Das PM, 2004, J CLIN ONCOL, V22, P4632, DOI 10.1200/JCO.2004.07.151; De Marzo AM, 1999, AM J PATHOL, V155, P1985, DOI 10.1016/S0002-9440(10)65517-4; Endo K, 2003, J BIOL CHEM, V278, P40764, DOI 10.1074/jbc.M306736200; Enright AJ, 2004, GENOME BIOL, V5; Ezhilarasan R, 2009, INT J CANCER, V124, P306, DOI 10.1002/ijc.23951; Fandy TE, 2010, EPIGENOMICS-UK, V2, P221, DOI 10.2217/EPI.10.1; Fang JY, 2002, WORLD J GASTROENTERO, V8, P400, DOI 10.3748/wjg.v8.i3.400; Floer M, 2010, AM J PATHOL, V176, P146, DOI 10.2353/ajpath.2010.080639; Gondi CS, 2004, ONCOGENE, V23, P8486, DOI 10.1038/sj.onc.1207879; Han L, 2007, CANCER BIOL THER, V6, P1284; Huang YC, 2011, TOXICOL LETT, V201, P62, DOI 10.1016/j.toxlet.2010.12.006; Ibrahim SA, 2012, INT J CANCER, V131, pE884, DOI 10.1002/ijc.27629; JALKANEN M, 1987, J CELL BIOL, V105, P3087, DOI 10.1083/jcb.105.6.3087; Kertesz M, 2007, NAT GENET, V39, P1278, DOI 10.1038/ng2135; Khotskaya YB, 2009, J BIOL CHEM, V284, P26085, DOI 10.1074/jbc.M109.018473; Kim WK, 2011, CLIN CANCER RES, V17, P7584, DOI 10.1158/1078-0432.CCR-11-0166; Kishikawa Shotaro, 2002, Nucleic Acids Res Suppl, P209; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Kunigal S, 2007, INT J CANCER, V121, P2307, DOI 10.1002/ijc.22962; LEVASSEUR JE, 1975, STROKE, V6, P308, DOI 10.1161/01.STR.6.3.308; Li LC, 2002, BIOINFORMATICS, V18, P1427, DOI 10.1093/bioinformatics/18.11.1427; Li QL, 2002, CELL, V111, P635, DOI 10.1016/S0092-8674(02)01079-6; Li XH, 2011, ONCOL REP, V26, P1431, DOI 10.3892/or.2011.1437; Lindsey JC, 2007, BRIT J CANCER, V97, P267, DOI 10.1038/sj.bjc.6603852; Lindsey JC, 2004, CARCINOGENESIS, V25, P661, DOI 10.1093/carcin/bgh055; Liu SJ, 2008, BLOOD, V111, P2364, DOI 10.1182/blood-2007-08-110171; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Massimino M, 2012, J NEURO-ONCOL, V108, P163, DOI 10.1007/s11060-012-0822-7; Moeller BJ, 2004, CANCER CELL, V5, P429, DOI 10.1016/S1535-6108(04)00115-1; Nikolova V, 2009, CARCINOGENESIS, V30, P397, DOI 10.1093/carcin/bgp001; Oh JH, 2010, INT J GYNECOL CANCER, V20, P751, DOI 10.1111/IGC.0b013e3181e02faa; Oh JH, 2009, GYNECOL ONCOL, V114, P509, DOI 10.1016/j.ygyno.2009.05.027; Olaru AV, 2011, HEPATOLOGY, V54, P2089, DOI 10.1002/hep.24591; Purushothaman A, 2008, J BIOL CHEM, V283, P32628, DOI 10.1074/jbc.M806266200; Purushothaman A, 2011, J BIOL CHEM, V286, P30377, DOI 10.1074/jbc.M111.254789; Purushothaman A, 2010, BLOOD, V115, P2449, DOI 10.1182/blood-2009-07-234757; Seidel C, 2000, BLOOD, V96, P3139, DOI 10.1182/blood.V96.9.3139.h8003139_3139_3146; Semenza GL, 2002, TRENDS MOL MED, V8, pS62, DOI 10.1016/S1471-4914(02)02317-1; Shan SQ, 2001, CLIN CANCER RES, V7, P2590; Sung B, 2008, BLOOD, V111, P4880, DOI 10.1182/blood-2007-10-117994; Taillandier L, 2011, REV NEUROL-FRANCE, V167, P431, DOI 10.1016/j.neurol.2011.01.014; Yang Y, 2007, J BIOL CHEM, V282, P13326, DOI 10.1074/jbc.M611259200; Yu Q, 2000, GENE DEV, V14, P163; Zhang Zhiqian, 2011, Genes Cancer, V2, P782, DOI 10.1177/1947601911429743; Zhao CH, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-224	59	52	54	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2014	33	15					1922	1933		10.1038/onc.2013.151	http://dx.doi.org/10.1038/onc.2013.151			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RK	23728345				2022-12-28	WOS:000334346300005
J	Yu, Y; Zhang, D; Huang, H; Li, J; Zhang, M; Wan, Y; Gao, J; Huang, C				Yu, Y.; Zhang, D.; Huang, H.; Li, J.; Zhang, M.; Wan, Y.; Gao, J.; Huang, C.			NF-kappa B1 p50 promotes p53 protein translation through miR-190 downregulation of PHLPP1	ONCOGENE			English	Article						p50; p53 translation; miR-190; PHLPP1; Akt/S6 ribosomal protein	NF-KAPPA-B; TUMOR-SUPPRESSOR; CANCER CELLS; INDUCED APOPTOSIS; ARSENIC TRIOXIDE; AKT ACTIVATION; DNA-DAMAGE; GROWTH; DEGRADATION; INDUCTION	The biological function of NF-kappa B1 (p50) in the regulation of protein expression is far from well understood owing to the lack of a transcriptional domain. Here, we report a novel function of p50 in its regulation of p53 protein translation under stress conditions. We found that the deletion of p50 (p50-/-) impaired arsenite-induced p53 protein expression, which could be restored after reconstitutive expression of HA-p50 in p50-/- cells, p50-/- (Ad-HA-p50). Further studies indicated that the amounts of p53 mRNA, p53 promoter-driven transcription activity and p53 protein degradation were comparable between wild-type and p50-/- cells. Moreover, we found that p50 was crucial for Akt/S6 ribosomal protein activation via inhibition of the translation of the PH domain and leucine-rich repeat protein phosphatases 1 (PHLPP1), a phosphatase of Akt. Further studies showed that p50-mediated upregulation of miR-190 was responsible for the inhibition of PHLPP1 translation by targeting the 30-untranslated region of its mRNA. Collectively, we have identified a novel function of p50 in modulating p53 protein translation via regulation of the miR-190/PHLPP1/Akt-S6 ribosomal protein pathway.	[Yu, Y.; Zhang, D.; Huang, H.; Li, J.; Zhang, M.; Huang, C.] NYU, Sch Med, Nelson Inst Environm Med, Tuxedo Pk, NY 10987 USA; [Yu, Y.; Wan, Y.] Wuhan Univ, Med Res Ctr, Oversea Lab, Wuhan 430072, Hubei, Peoples R China; [Huang, H.; Zhang, M.; Gao, J.; Huang, C.] Wenzhou Med Coll, Sch Life Sci, Zhejiang Prov Key Lab Technol & Applicat Model Or, Wenzhou, Zhejiang, Peoples R China	New York University; Wuhan University; Wenzhou Medical University	Huang, C (corresponding author), NYU, Sch Med, Nelson Inst Environm Med, 57 Old Forge Rd, Tuxedo Pk, NY 10987 USA.	chuanshu.huang@nyumc.org	Yu, Yonghui/AAZ-3746-2021; Yu, Yonghui/AAZ-4093-2021	Huang, Chuanshu/0000-0003-4133-5096	NIH/NCI [CA112557, NBRPC2012CB525004]; NIH/NIEHS [ES000260];  [NSFC81229002]; NATIONAL CANCER INSTITUTE [R01CA112557, P30CA016087, R01CA177665] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000260] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH/NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Ms Nedda Tichi and Mr Andy Hu for their critical reading of this manuscript. We thank Dr Ping-Yee Law (Department of Pharmacology, University of Minnesota) for providing us with constructs of miR-190 and its control. We also thank Dr Fei Chen (Department of Pharmaceutical Sciences, Wayne State University) for providing us with the PHLPP1 3'-UTR luciferase reporter. This work was partially supported by grants from NSFC81229002, NIH/NCI CA112557, NBRPC2012CB525004 and NIH/NIEHS ES000260.	Beezhold K, 2011, TOXICOL SCI, V123, P411, DOI 10.1093/toxsci/kfr188; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Bellodi C, 2010, EMBO J, V29, P1865, DOI 10.1038/emboj.2010.83; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; BOSARI S, 1995, AM J PATHOL, V147, P790; Chen A, 2002, EUR J PHARMACOL, V448, P11, DOI 10.1016/S0014-2999(02)01901-5; Chen K, 2007, NAT REV GENET, V8, P93, DOI 10.1038/nrg1990; Choudhuri T, 2002, FEBS LETT, V512, P334, DOI 10.1016/S0014-5793(02)02292-5; El-Deiry WS, 2003, ONCOGENE, V22, P7486, DOI 10.1038/sj.onc.1206949; Fiaschi Tania, 2012, Int J Cell Biol, V2012, P762825, DOI 10.1155/2012/762825; Fridman JS, 2003, ONCOGENE, V22, P9030, DOI 10.1038/sj.onc.1207116; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Gebel TW, 1999, SCIENCE, V283, P1458; Guo W, 2011, CELL MOL LIFE SCI, V68, P475, DOI 10.1007/s00018-010-0459-7; Heinrichs S, 2003, ONCOGENE, V22, P555, DOI 10.1038/sj.onc.1206138; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Hinata N, 2003, UROL RES, V31, P387, DOI 10.1007/s00240-003-0355-9; Hutchinson JA, 2011, J BIOL CHEM, V286, P8688, DOI 10.1074/jbc.M110.141754; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Karawajew L, 2005, BLOOD, V105, P4767, DOI 10.1182/blood-2004-09-3428; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; Li JL, 2004, HYBRIDOMA HYBRIDOM, V23, P1, DOI 10.1089/153685904322771962; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Liu J, 2009, ONCOGENE, V28, P994, DOI 10.1038/onc.2008.450; Ljungman M, 2000, NEOPLASIA, V2, P208, DOI 10.1038/sj.neo.7900073; Maillet A, 2012, ANTIOXID REDOX SIGN, V16, P1285, DOI 10.1089/ars.2011.4434; Muller PAJ, 2011, J CELL BIOL, V192, P209, DOI 10.1083/jcb.201009059; Ogawara Y, 2002, J BIOL CHEM, V277, P21843, DOI 10.1074/jbc.M109745200; Peterson RT, 1998, CURR BIOL, V8, pR248, DOI 10.1016/S0960-9822(98)70152-6; Quinn JE, 2003, CANCER RES, V63, P6221; Rossman TG, 2011, METALLOMICS, V3, P1135, DOI 10.1039/c1mt00074h; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Schuler M, 2003, CELL DEATH DIFFER, V10, P451, DOI 10.1038/sj.cdd.4401180; Soignet SL, 1998, NEW ENGL J MED, V339, P1341, DOI 10.1056/NEJM199811053391901; Song L, 2006, J CELL BIOL, V175, P607, DOI 10.1083/jcb.200602149; Stahnke K, 2001, BLOOD, V98, P3066, DOI 10.1182/blood.V98.10.3066; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Teodoro JG, 2006, SCIENCE, V313, P968, DOI 10.1126/science.1126391; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Wang HT, 2007, MOL CELL BIOL, V27, P4374, DOI 10.1128/MCB.02020-06; Wang YJ, 2007, CELL RES, V17, P933, DOI 10.1038/cr.2007.89; Xu DK, 2002, EMBO J, V21, P4081, DOI 10.1093/emboj/cdf413; Yan WS, 2011, J BIOL CHEM, V286, P17478, DOI 10.1074/jbc.M111.231639; Yang DQ, 2006, ONCOGENE, V25, P4613, DOI 10.1038/sj.onc.1209483; Yang X, 2003, CELL DEATH DIFFER, V10, P400, DOI 10.1038/cj.cdd.4401182; Yih LH, 2000, CANCER RES, V60, P6346; YIN YX, 1992, CELL, V70, P937, DOI 10.1016/0092-8674(92)90244-7; Ying SY, 2004, GENE, V342, P25, DOI 10.1016/j.gene.2004.07.025; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Yu YH, 2009, CURR CANCER DRUG TAR, V9, P566, DOI 10.2174/156800909788486759; Zhang XW, 2010, SCIENCE, V328, P240, DOI 10.1126/science.1183424; Zheng H, 2010, J BIOL CHEM, V285, P21994, DOI 10.1074/jbc.M110.112607	53	36	37	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2014	33	8					996	1005		10.1038/onc.2013.8	http://dx.doi.org/10.1038/onc.2013.8			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XO	23396362	Green Accepted			2022-12-28	WOS:000331933200007
J	Kai, K; Iwamoto, T; Kobayashi, T; Arima, Y; Takamoto, Y; Ohnishi, N; Bartholomeusz, C; Horii, R; Akiyama, F; Hortobagyi, GN; Pusztai, L; Saya, H; Ueno, NT				Kai, K.; Iwamoto, T.; Kobayashi, T.; Arima, Y.; Takamoto, Y.; Ohnishi, N.; Bartholomeusz, C.; Horii, R.; Akiyama, F.; Hortobagyi, G. N.; Pusztai, L.; Saya, H.; Ueno, N. T.			Ink4a/Arf(-/-) and HRAS(G12V) transform mouse mammary cells into triple-negative breast cancer containing tumorigenic CD49f(-) quiescent cells	ONCOGENE			English	Article						Ink4a/Arf; HRAS(G12V); Triple-negative breast cancer; Intratumoral heterogeneity; Tumor-initiating cell	TUMOR-INITIATING CELLS; HEPATIC STELLATE CELLS; GENE-EXPRESSION; STEM-CELLS; MOLECULAR CHARACTERIZATION; MESENCHYMAL TRANSITION; RAS ACTIVATION; CLAUDIN-LOW; IDENTIFICATION; MODEL	Intratumoral heterogeneity within individual breast tumors is a well-known phenomenon that may contribute to drug resistance. This heterogeneity is dependent on several factors, such as types of oncogenic drivers and tumor precursor cells. The purpose of our study was to engineer a mouse mammary tumor model with intratumoral heterogeneity by using defined genetic perturbations. To achieve this, we used mice with knockout (-/-) of Ink4a/Arf, a tumor suppressor locus; these mice are known to be susceptible to non-mammary tumors such as fibrosarcoma. To induce mammary tumors, we retrovirally introduced an oncogene, HRAS(G12V), into Ink4a/Arf(-/-) mammary cells in vitro, and those cells were inoculated into syngeneic mice mammary fat pads. We observed 100% tumorigenesis. The tumors formed were negative for estrogen receptor, progesterone receptor and HER2. Further, they had pathological features similar to those of human triple-negative breast cancer (TNBC) (for example, pushing borders, central necrosis). The tumors were found to be heterogeneous and included two subpopulations: CD49f(-) quiescent cells and CD49f(-) cells. Contrary to our expectation, CD49f(-) quiescent cells had high tumor-initiating potential and CD49f(-) cells had relatively low tumor-initiating potential. Gene expression analysis revealed that CD49f(-) quiescent cells overexpressed epithelial-to-mesenchymal transition-driving genes, reminiscent of tumor-initiating cells and claudin-low breast cancer. Our animal model with intratumoral heterogeneity, derived from defined genetic perturbations, allows us to test novel molecular targeted drugs in a setting that mimics the intratumoral heterogeneity of human TNBC.	[Kai, K.; Bartholomeusz, C.; Pusztai, L.; Ueno, N. T.] Univ Texas MD Anderson Canc Ctr, Breast Canc Translat Res Lab, Houston, TX 77030 USA; [Kai, K.; Iwamoto, T.; Bartholomeusz, C.; Hortobagyi, G. N.; Pusztai, L.; Ueno, N. T.] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA; [Kai, K.; Kobayashi, T.; Arima, Y.; Takamoto, Y.; Ohnishi, N.; Saya, H.] Keio Univ, Sch Med, Inst Adv Med Res, Div Gene Regulat, Tokyo, Japan; [Horii, R.; Akiyama, F.] Japanese Fdn Canc Res, Inst Canc, Div Pathol, Tokyo 170, Japan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Keio University; Japanese Foundation for Cancer Research	Saya, H (corresponding author), Keio Univ, Sch Med, Inst Adv Med Res, Div Gene Regulat, Tokyo, Japan.	hsaya@a5.keio.jp; nueno@mdanderson.org	Saya, Hideyuki/J-4325-2013; Pusztai, Lajos/AAB-2901-2019	Arima, Yoshimi/0000-0002-2384-1406; Saya, Hideyuki/0000-0001-6610-1902	Japan Society for the Promotion of Science, Japan; Ministry of Education, Culture, Sports, Science and Technology, Japan; US National Institutes of Health through MD Anderson's Cancer Center Support Grant [5 P30 CA016672-36, R01 CA123318-01A1]; Nellie B Connally Breast Cancer Research Fund; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA123318] Funding Source: NIH RePORTER	Japan Society for the Promotion of Science, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); US National Institutes of Health through MD Anderson's Cancer Center Support Grant; Nellie B Connally Breast Cancer Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank N Suzuki, Y Ito and S Hayashi for excellent animal husbandry, I Ishimatsu for expert assistance with histology and K Hashimoto for expert help in the flow cytometry lab. We thank T Suda and MC Hung for invaluable discussions. Thanks are also owed to M Fujiwara for expert help with microarray analysis, T Ishimoto for technical help with confocal microscopy and SC Patterson for editorial assistance. This work was supported by grants from the Japan Society for the Promotion of Science, Japan (to KK and HS). KK was supported by the program 'Strategic Young Researcher Overseas Visits Program for Accelerating Brain Circulation' by the Ministry of Education, Culture, Sports, Science and Technology, Japan. This research was also supported in part by the US National Institutes of Health through MD Anderson's Cancer Center Support Grant (5 P30 CA016672-36), grant R01 CA123318-01A1 (to NTU) and by the Nellie B Connally Breast Cancer Research Fund and a donation from Mr and Mrs Sidney J Jansma, Jr.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bartholomeusz C, 2012, MOL CANCER THER, V11, P360, DOI 10.1158/1535-7163.MCT-11-0400; Buyse M, 2006, JNCI-J NATL CANCER I, V98, P1183, DOI 10.1093/jnci/djj329; Cardiff RD, 2010, J MAMMARY GLAND BIOL, V15, P225, DOI 10.1007/s10911-010-9184-y; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Cho JJ, 2000, GASTROENTEROLOGY, V118, P1169, DOI 10.1016/S0016-5085(00)70370-2; Cho RW, 2008, STEM CELLS, V26, P364, DOI 10.1634/stemcells.2007-0440; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Cui XS, 2000, ONCOGENE, V19, P5988, DOI 10.1038/sj.onc.1203993; Debies MT, 2008, J CLIN INVEST, V118, P51, DOI 10.1172/JCI33320; Dooley S, 2000, HEPATOLOGY, V31, P1094, DOI 10.1053/he.2000.6126; Eckert LB, 2004, CANCER RES, V64, P4585, DOI 10.1158/0008-5472.CAN-04-0396; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Herschkowitz JI, 2012, P NATL ACAD SCI USA, V109, P2778, DOI 10.1073/pnas.1018862108; Ito K, 2008, NATURE, V453, P1072, DOI 10.1038/nature07016; Iwamoto T, 2011, J NATL CANCER I, V103, P264, DOI 10.1093/jnci/djq524; Joo KM, 2008, LAB INVEST, V88, P808, DOI 10.1038/labinvest.2008.57; Kai K, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-262; Kai K, 2009, CANCER SCI, V100, P2275, DOI 10.1111/j.1349-7006.2009.01318.x; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Liao MJ, 2007, CANCER RES, V67, P8131, DOI 10.1158/0008-5472.CAN-06-4493; Lim E, 2009, NAT MED, V15, P907, DOI 10.1038/nm.2000; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Rakha EA, 2009, PATHOLOGY, V41, P40, DOI 10.1080/00313020802563510; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Schmidt M, 2008, CANCER RES, V68, P5405, DOI 10.1158/0008-5472.CAN-07-5206; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Sherr CJ, 2001, NAT REV MOL CELL BIO, V2, P731, DOI 10.1038/35096061; Shimizu T, 2010, ONCOGENE, V29, P5687, DOI 10.1038/onc.2010.312; Shipitsin M, 2007, CANCER CELL, V11, P259, DOI 10.1016/j.ccr.2007.01.013; Singh SK, 2003, CANCER RES, V63, P5821; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Sugihara E, 2012, ONCOGENE, V31, P2849, DOI 10.1038/onc.2011.462; Svegliati-Baroni G, 1999, HEPATOLOGY, V29, P1743, DOI 10.1002/hep.510290632; Taube JH, 2010, P NATL ACAD SCI USA, V107, P15449, DOI 10.1073/pnas.1004900107; Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008-5472.CAN-08-1949; von Lintig FC, 2000, BREAST CANCER RES TR, V62, P51, DOI 10.1023/A:1006491619920; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Welm BE, 2002, DEV BIOL, V245, P42, DOI 10.1006/dbio.2002.0625; Zhang DW, 2009, CLIN CANCER RES, V15, P6639, DOI 10.1158/1078-0432.CCR-09-0951; Zhang M, 2008, CANCER RES, V68, P4674, DOI 10.1158/0008-5472.CAN-07-6353	47	6	6	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2014	33	4					440	448		10.1038/onc.2012.609	http://dx.doi.org/10.1038/onc.2012.609			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VX	23376849	Green Accepted			2022-12-28	WOS:000330214600005
J	Kwong, LN; Davies, MA				Kwong, L. N.; Davies, M. A.			Targeted therapy for melanoma: rational combinatorial approaches	ONCOGENE			English	Review						melanoma; targeted therapy; BRAF; NRAS	DOSE-ESCALATION; MEK INHIBITION; PHASE-I; METASTATIC MELANOMA; ACQUIRED-RESISTANCE; IMPROVED SURVIVAL; KINASE INHIBITOR; RAF INHIBITORS; MUTANT BRAF; CELL-DEATH	The treatment of melanoma, the most aggressive form of skin cancer, is being revolutionized by the development of personalized targeted therapy approaches. Mutant-selective BRAF inhibitors and MEK inhibitors have demonstrated impressive clinical results in molecularly selected patients. However, emerging understanding of the molecular heterogeneity of this disease and the identification of multiple mechanisms of resistance to targeted therapies strongly support the rationale for combinatorial approaches. In this review, we will discuss the preclinical and clinical studies that are testing leading hypotheses and emerging combinatorial strategies for the future.	[Kwong, L. N.] Univ Texas MD Anderson Canc Ctr, Dept Genom Med, Houston, TX 77054 USA; [Davies, M. A.] Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, Houston, TX 77054 USA; [Davies, M. A.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77054 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Davies, MA (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Melanoma Med Oncol, 7455 Fannin,Unit 0904, Houston, TX 77054 USA.	mdavies@mdanderson.org	Davies, Michael/GWV-2527-2022		NIH/NCI [1R01CA154710-01]; Cancer Prevention Research Institute of Texas; American Society of Clinical Oncology; MD Anderson SPORE in Melanoma [CA093459-06]; Melanoma Research Alliance; American Cancer Society [117842-PF-09-261-TBG]; NATIONAL CANCER INSTITUTE [P50CA093459, R01CA154710] Funding Source: NIH RePORTER	NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Prevention Research Institute of Texas; American Society of Clinical Oncology; MD Anderson SPORE in Melanoma; Melanoma Research Alliance; American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	MAD is supported by funding from the NIH/NCI (1R01CA154710-01), the Cancer Prevention Research Institute of Texas, the American Society of Clinical Oncology, The MD Anderson SPORE in Melanoma (P50 CA093459-06) and the Melanoma Research Alliance. LK is supported by a Postdoctoral Fellowship from the American Cancer Society (117842-PF-09-261-TBG).	Aguissa-Toure AH, 2012, CELL MOL LIFE SCI, V69, P1475, DOI 10.1007/s00018-011-0878-0; Algazi AP, 2012, BRIT J CANCER, V106, P85, DOI 10.1038/bjc.2011.514; Atkins MB, 1999, J CLIN ONCOL, V17, P2105, DOI 10.1200/JCO.1999.17.7.2105; Bedogni B, 2006, MOL CANCER THER, V5, P3071, DOI 10.1158/1535-7163.MCT-06-0269; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Boni A, 2010, CANCER RES, V70, P5213, DOI 10.1158/0008-5472.CAN-10-0118; BOS JL, 1989, CANCER RES, V49, P4682; Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chattopadhyay C, 2012, INT J CANCER, V131, pE56, DOI 10.1002/ijc.26487; Chiarion-Sileni V, 2013, J CLIN ONCOL, V31; Colomba A, 2011, BLOOD CANCER J, V1, DOI 10.1038/bcj.2011.19; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; De Luca A, 2012, EXPERT OPIN THER TAR, V16, pS17, DOI 10.1517/14728222.2011.639361; Deng W, 2012, PIGM CELL MELANOMA R, V25, DOI 10.1111/j.1755-148X.2011.00950.x; Devitt B, 2011, PIGM CELL MELANOMA R, V24, P666, DOI 10.1111/j.1755-148X.2011.00873.x; Dumaz N, 2006, CANCER RES, V66, P9483, DOI 10.1158/0008-5472.CAN-05-4227; Eustace AJ, 2008, J TRANSL MED, V6, DOI 10.1186/1479-5876-6-53; Falchook GS, 2012, LANCET ONCOL, V13, P782, DOI 10.1016/S1470-2045(12)70269-3; Fecher LA, 2008, CURR OPIN ONCOL, V20, P183, DOI 10.1097/CCO.0b013e3282f5271c; Ferguson J, 2013, ONCOGENE, V32, P86, DOI 10.1038/onc.2012.25; Flaherty K, 2011, PIGM CELL MELANOMA R, V24, P1022; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Flaherty KT, 2012, CLIN CANCER RES, V18, P568, DOI 10.1158/1078-0432.CCR-11-0509; Goel VK, 2006, J INVEST DERMATOL, V126, P154, DOI 10.1038/sj.jid.5700026; Gopal YNV, 2010, CANCER RES, V70, P8736, DOI 10.1158/0008-5472.CAN-10-0902; Halaban R, 2010, PIGM CELL MELANOMA R, V23, P190, DOI 10.1111/j.1755-148X.2010.00685.x; Harbour JW, 2010, SCIENCE, V330, P1410, DOI 10.1126/science.1194472; Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Hocker T, 2007, HUM MUTAT, V28, P578, DOI 10.1002/humu.20481; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Homsi J, 2009, MELANOMA RES, V19, P167, DOI 10.1097/CMR.0b013e328304974c; Hong DS, 2012, CLIN CANCER RES, V18, P2326, DOI 10.1158/1078-0432.CCR-11-2515; Ihle NT, 2012, JNCI-J NATL CANCER I, V104, P228, DOI 10.1093/jnci/djr523; Jaiswal BS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005717; Jakob JA, 2012, CANCER-AM CANCER SOC, V118, P4014, DOI 10.1002/cncr.26724; Kim KB, 2011, PIGM CELL MELANOMA R, V24, P1021; Kirkwood JM, 2012, CLIN CANCER RES, V18, P555, DOI 10.1158/1078-0432.CCR-11-1491; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Kwong LN, 2012, NAT MED, V18, P1503, DOI 10.1038/nm.2941; Lai F, 2012, ADV PHARMACOL, V65, P27, DOI 10.1016/B978-0-12-397927-8.00002-6; Lasithiotakis KG, 2008, J INVEST DERMATOL, V128, P2013, DOI 10.1038/jid.2008.44; Long GV, 2011, J CLIN ONCOL, V29, P1239, DOI 10.1200/JCO.2010.32.4327; Martinez-Garcia M, 2012, CLIN CANCER RES, V18, P4806, DOI 10.1158/1078-0432.CCR-12-0742; McArthur GA, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.8502; Means-Powell JA, 2012, J CLIN ONCOL S, V30, P8519; Mishra PJ, 2010, ONCOGENE, V29, P2449, DOI 10.1038/onc.2009.521; Montagut C, 2008, CANCER RES, V68, P4853, DOI 10.1158/0008-5472.CAN-07-6787; Nathanson KL, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.8501; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Onken MD, 2008, INVEST OPHTH VIS SCI, V49, P5230, DOI 10.1167/iovs.08-2145; Paraiso KHT, 2012, CLIN CANCER RES, V18, P2502, DOI 10.1158/1078-0432.CCR-11-2612; Paraiso KHT, 2011, CANCER RES, V71, P2750, DOI 10.1158/0008-5472.CAN-10-2954; Phan GQ, 2001, J CLIN ONCOL, V19, P3477, DOI 10.1200/JCO.2001.19.15.3477; Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662; Poulikakos PI, 2011, CANCER CELL, V19, P11, DOI 10.1016/j.ccr.2011.01.008; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621; Roberts PJ, 2012, CLIN CANCER RES, V18, P5290, DOI 10.1158/1078-0432.CCR-12-0563; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Rodrik-Outmezguine VS, 2011, CANCER DISCOV, V1, P248, DOI 10.1158/2159-8290.CD-11-0085; Sharfman WH, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.8508; Shi HB, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1727; Shi HB, 2011, CANCER RES, V71, P5067, DOI 10.1158/0008-5472.CAN-11-0140; Sosman JA, 2012, J CLIN ONCOL, V30; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Su F, 2012, NEW ENGL J MED, V366, P207, DOI 10.1056/NEJMoa1105358; Tsao H, 2004, NEW ENGL J MED, V351, P998, DOI 10.1056/NEJMra041245; Tsao H, 2004, J INVEST DERMATOL, V122, P337, DOI 10.1046/j.0022-202X.2004.22243.x; Van Raamsdonk CD, 2010, NEW ENGL J MED, V363, P2191, DOI 10.1056/NEJMoa1000584; Vaughn DJ, 2009, NEW ENGL J MED, V360, P423, DOI 10.1056/NEJMc0808558; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Weber JS, 2012, J CLIN ONCOL, V30; Whittaker S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000758; Wilmott JS, 2012, MOL CANCER THER, V11, P2704, DOI 10.1158/1535-7163.MCT-12-0530; Wilmott JS, 2012, CLIN CANCER RES, V18, P1386, DOI 10.1158/1078-0432.CCR-11-2479; Wilson MA, 2012, AACR ANN M, P5557; Woodman SE, 2010, BIOCHEM PHARMACOL, V80, P568, DOI 10.1016/j.bcp.2010.04.032; Xing F, 2012, ONCOGENE, V31, P446, DOI 10.1038/onc.2011.250; Zipfel PA, 2010, ONCOGENE, V29, P4859, DOI 10.1038/onc.2010.224	84	66	78	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2014	33	1					1	9		10.1038/onc.2013.34	http://dx.doi.org/10.1038/onc.2013.34			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	282YU	23416974				2022-12-28	WOS:000329212000001
J	Kitamoto, S; Yokoyama, S; Higashi, M; Yamada, N; Takao, S; Yonezawa, S				Kitamoto, S.; Yokoyama, S.; Higashi, M.; Yamada, N.; Takao, S.; Yonezawa, S.			MUC1 enhances hypoxia-driven angiogenesis through the regulation of multiple proangiogenic factors	ONCOGENE			English	Article						MUC1; hypoxia; pancreatic cancer; angiogenesis; mucin	TISSUE GROWTH-FACTOR; ANTIGEN-EXPRESSION; TUMOR HYPOXIA; CANCER; MUCINS; GENE; OVEREXPRESSION; ACTIVATION; CELLS; CTGF	Pancreatic cancer is one of the most lethal malignancies due to its aggressive growth and rapid development of distant metastases. In this context, mucin 1 (MUC1) overexpression and hypoxia are frequently observed events. However, their functional relationship remains largely unknown. This study provides evidence that MUC1 is overexpressed by hypoxia and contributes to hypoxia-driven angiogenesis. Using the conditioned medium obtained from hypoxia-stressed AsPC1 cells treated with MUC1 siRNAs, we demonstrated that MUC1 enhanced the endothelial tube formation, proliferation and migration ability, which induced by hypoxia-conditioned medium (HCM). In addition, MUC1 was significantly induced by hypoxia, especially in the pancreatic cancer cells derived from metastatic tumors (AsPC1, HPAF2 or Capan1), and MUC1-cytoplasmic tail (MUC1-CT) accumulated in the nucleus under hypoxia. As noted in a previous report, MUC1-CT was recruited to genomic regions upstream of the connective tissue growth factor (CTGF) accompanied with beta-catenin and p53, resulting in the hypoxic induction of CTGF. Moreover, hypoxia-induced MUC1 partially regulated two other hypoxia-inducible proangiogenic factors including vascular endothelial growth factor-A and platelet-derived growth factor-B. The neutralization assay revealed that endothelial tube formation induced by HCM was clearly suppressed by antibodies against these three factors, suggesting the importance of these factors in hypoxia-driven angiogenesis. In summary, this is the first report demonstrating a pivotal role of MUC1 in controlling the hypoxia-driven angiogenesis through the regulation of multiple proangiogenic factors in pancreatic cancer. Our findings provide the novel insights into the understanding of complex interactions between pancreatic cancer cells and tumor microenvironments.	[Kitamoto, S.; Yokoyama, S.; Higashi, M.; Yamada, N.; Yonezawa, S.] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Human Pathol, Field Oncol, Kagoshima 8908544, Japan; [Takao, S.] Kagoshima Univ, Frontier Sci Res Ctr, Kagoshima 8908544, Japan	Kagoshima University; Kagoshima University	Kitamoto, S (corresponding author), Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Human Pathol, Field Oncol, 8-35-1 Sakuragaoka, Kagoshima 8908544, Japan.	s-kita@m3.kufm.kagoshima-u.ac.jp	Kitamoto, Sho/AAE-4549-2021	Kitamoto, Sho/0000-0003-3597-6647	Princess Takamastu Cancer Research Fund [11-24319]; Ministry of Education, Science, Sports, Culture and Technology, Japan [20014022, 23390085, 20590399]; International Educational Research Support Project for Islands, Environment and Medicine; JSPS [239349]; Pancreas Reserch Foundation of Japan; Kodama Memorial Foundation, Japan; Grants-in-Aid for Scientific Research [24701008] Funding Source: KAKEN	Princess Takamastu Cancer Research Fund; Ministry of Education, Science, Sports, Culture and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); International Educational Research Support Project for Islands, Environment and Medicine; JSPS(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science); Pancreas Reserch Foundation of Japan; Kodama Memorial Foundation, Japan; Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by the Princess Takamastu Cancer Research Fund (11-24319; S Yonezawa); by the Scientific Research on Priority Areas 20014022 and Scientific Research (B) 23390085 (S Yonezawa) and Scientific Research (C) 20590399 (M Higashi) grants from the Ministry of Education, Science, Sports, Culture and Technology, Japan; by an International Educational Research Support Project for Islands, Environment and Medicine (S Yokoyama); by a JSPS Fellowship Grant-in-Aid (no. 239349; S Kitamoto); by a Pancreas Reserch Foundation of Japan (S Yokoyama) and Kodama Memorial Foundation, Japan (S Kitamoto, S Yokoyama and M Higashi). We would like to express our gratitude to Dr Ming-Sound Tsao for providing us with the immortalized human pancreatic duct epithelial cells. We also thank Mses Izumi Houjou and Yukari Nishimura for their excellent technical assistance.	Aubert S, 2009, CANCER RES, V69, P5707, DOI 10.1158/0008-5472.CAN-08-4905; Behrens ME, 2010, ONCOGENE, V29, P5667, DOI 10.1038/onc.2010.327; Bennewith KL, 2009, CANCER RES, V69, P775, DOI 10.1158/0008-5472.CAN-08-0987; BHASKAR KR, 1992, NATURE, V360, P458, DOI 10.1038/360458a0; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Carson DD, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.127pe35; Chang Q, 2011, CANCER RES, V71, P3110, DOI 10.1158/0008-5472.CAN-10-4049; Chu CY, 2008, J BIOMED SCI, V15, P675, DOI 10.1007/s11373-008-9264-9; Dewhirst MW, 2008, NAT REV CANCER, V8, P425, DOI 10.1038/nrc2397; Dornhofer N, 2006, CANCER RES, V66, P5816, DOI 10.1158/0008-5472.CAN-06-0081; Furukawa T, 1996, AM J PATHOL, V148, P1763; Giatromanolaki A, 2000, CLIN CANCER RES, V6, P1917; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Higgins DF, 2004, AM J PHYSIOL-RENAL, V287, pF1223, DOI 10.1152/ajprenal.00245.2004; Hollingsworth MA, 2004, NAT REV CANCER, V4, P45, DOI 10.1038/nrc1251; Hong OY, 2000, AM J PATHOL, V157, P1623, DOI 10.1016/S0002-9440(10)64800-6; Kaira K, 2012, INT J SURG PATHOL, V20, P223, DOI 10.1177/1066896911429296; Kaira K, 2012, PATHOL ONCOL RES, V18, P439, DOI 10.1007/s12253-011-9465-9; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Kitamoto S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044108; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Levitin F, 2005, J BIOL CHEM, V280, P33374, DOI 10.1074/jbc.M506047200; Linden SK, 2008, MUCOSAL IMMUNOL, V1, P183, DOI 10.1038/mi.2008.5; Lu X, 2010, CLIN CANCER RES, V16, P5928, DOI 10.1158/1078-0432.CCR-10-1360; Macao B, 2006, NAT STRUCT MOL BIOL, V13, P71, DOI 10.1038/nsmb1035; Mikami Y, 2009, BIOCHEM BIOPH RES CO, V379, P1060, DOI 10.1016/j.bbrc.2009.01.002; Papadopoulos I, 2001, CLIN CANCER RES, V7, P1533; Roy LD, 2011, ONCOGENE, V30, P1449, DOI 10.1038/onc.2010.526; Sahraei M, 2012, ONCOGENE, V31, P4935, DOI 10.1038/onc.2011.651; Sakamoto H, 1997, HUM PATHOL, V28, P1056, DOI 10.1016/S0046-8177(97)90059-9; Semenza GL, 2003, ANNU REV MED, V54, P17, DOI 10.1146/annurev.med.54.101601.152418; Shimo T, 2001, CANCER LETT, V174, P57, DOI 10.1016/S0304-3835(01)00683-8; Vaupel P, 2007, CANCER METAST REV, V26, P225, DOI 10.1007/s10555-007-9055-1; Woo JK, 2012, ONCOGENE, V31, P2187, DOI 10.1038/onc.2011.410; Yao MY, 2011, LUNG, V189, P453, DOI 10.1007/s00408-011-9327-y; Yin L, 2007, J BIOL CHEM, V282, P257, DOI 10.1074/jbc.M610156200; Yonezawa S, 2012, GASTRIC CANCER, DOI [10.1007/S10120-011-0125-2, DOI 10.1007/S10120-011-0125-2)]; Yonezawa S, 2011, PATHOL INT, V61, P697, DOI 10.1111/j.1440-1827.2011.02734.x; Zanetti JS, 2011, VIRCHOWS ARCH, V459, P367, DOI 10.1007/s00428-011-1142-6	40	46	49	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2013	32	39					4614	4621		10.1038/onc.2012.478	http://dx.doi.org/10.1038/onc.2012.478			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226YD	23108411				2022-12-28	WOS:000325072200003
J	Thompson-Wicking, K; Francis, RW; Stirnweiss, A; Ferrari, E; Welch, MD; Baker, E; Murch, AR; Gout, AM; Carter, KW; Charles, AK; Phillips, MB; Kees, UR; Beesley, AH				Thompson-Wicking, K.; Francis, R. W.; Stirnweiss, A.; Ferrari, E.; Welch, M. D.; Baker, E.; Murch, A. R.; Gout, A. M.; Carter, K. W.; Charles, A. K.; Phillips, M. B.; Kees, U. R.; Beesley, A. H.			Novel BRD4-NUT fusion isoforms increase the pathogenic complexity in NUT midline carcinoma	ONCOGENE			English	Article						BRD4; NUT; carcinoma; NMC; RNA-Seq; transcriptome	T(15-19)(Q15-P13) CHROMOSOME ABNORMALITY; BET BROMODOMAIN INHIBITION; THYMIC CARCINOMA; AGGRESSIVE CARCINOMA; YOUNG-PATIENTS; C-MYC; DIFFERENTIATION; REARRANGEMENT; LEUKEMIA; CHROMATIN	Nuclear protein in testis (NUT)-midline carcinoma (NMC) is a rare, aggressive disease typically presenting with a single t(15; 19) translocation that results in the generation of a bromodomain-containing protein 4 (BRD4)-NUT fusion. PER-624 is a cell line generated from an NMC patient with an unusually complex karyotype that gave no initial indication of the involvement of the NUT locus. Analysis of PER-624 next-generation transcriptome sequencing (RNA-Seq) using the algorithm FusionFinder identified a novel transcript in which Exon 15 of BRD4 was fused to Exon 2 of NUT, therefore differing from all published NMC fusion transcripts. The three additional exons contained in the PER-624 fusion encode a series of polyproline repeats, with one predicted to form a helix. In the NMC cell line PER-403, we identified the 'standard' NMC fusion and two novel isoforms. Knockdown by small interfering RNA in either cell line resulted in decreased proliferation, increased cell size and expression of cytokeratins consistent with epithelial differentiation. These data demonstrate that the novel BRD4-NUT fusion in PER-624 encodes a functional protein that is central to the oncogenic mechanism in these cells. Genomic PCR indicated that in both PER-624 and PER-403, the translocation fuses an intron of BRD4 to a region upstream of the NUT coding sequence. Thus, the generation of BRD4-NUT fusion transcripts through post-translocation RNA-splicing appears to be a common feature of these carcinomas that has not previously been appreciated, with the mechanism facilitating the expression of alternative isoforms of the fusion. Finally, ectopic expression of wild-type NUT, a protein normally restricted to the testis, could be demonstrated in PER-403, indicating additional pathways for aberrant cell signaling in NMC. This study contributes to our understanding of the genetic diversity of NMC, an important step towards finding therapeutic targets for a disease that is refractory to current treatments.	[Thompson-Wicking, K.; Stirnweiss, A.; Ferrari, E.; Welch, M. D.; Gout, A. M.; Kees, U. R.; Beesley, A. H.] Univ Western Australia, Div Childrens Leukaemia & Canc Res, Telethon Inst Child Hlth Res, Ctr Child Hlth Res, Perth, WA 6009, Australia; [Francis, R. W.; Carter, K. W.] Univ Western Australia, Div Bioinformat, Telethon Inst Child Hlth Res, Ctr Child Hlth Res, Perth, WA 6009, Australia; [Baker, E.; Murch, A. R.] King Edward Mem Hosp Women, PathWest Lab Med, Dept Cytogenet, Perth, WA, Australia; [Murch, A. R.; Charles, A. K.] Univ Western Australia, Sch Pathol & Lab Med, Perth, WA 6009, Australia; [Charles, A. K.] PathWest Lab Med, Dept Pathol, Perth, WA, Australia; [Phillips, M. B.] Princess Margaret Hosp Children, Dept Haematol & Oncol, Perth, WA, Australia	Telethon Kids Institute; University of Western Australia; Telethon Kids Institute; University of Western Australia; King Edward Memorial Hospital; University of Western Australia; University of Western Australia	Kees, UR (corresponding author), Telethon Inst Child Hlth Res, Div Childrens Leukaemia & Canc Res, POB 855, Subiaco, WA 6872, Australia.	ursula@ichr.uwa.edu.au	Phillips, Marianne/AAA-4971-2021; Francis, Richard/K-2812-2019; Beesley, Alex H/K-5805-2013	Phillips, Marianne/0000-0002-1963-4543; Francis, Richard/0000-0003-1580-7934; Beesley, Alex H/0000-0002-5742-7270; Charles, Adrian/0000-0002-3193-1065	Children's Leukemia and Cancer Research Foundation (CLCRF, Perth, Western Australia, Australia); Apache Energy Limited; Cancer Council of Western Australia; University of Western Australia; WA State Government Centers of Excellence Program	Children's Leukemia and Cancer Research Foundation (CLCRF, Perth, Western Australia, Australia); Apache Energy Limited; Cancer Council of Western Australia(Cancer Council Western Australia); University of Western Australia; WA State Government Centers of Excellence Program	This work was supported by grants from the Children's Leukemia and Cancer Research Foundation (CLCRF, Perth, Western Australia, Australia), Apache Energy Limited, the Cancer Council of Western Australia, the University of Western Australia and the WA State Government Centers of Excellence Program. We would like to thank Maxine Crook, Senior Medical Scientist, PathWest Laboratory Medicine, Perth, for performing the IHC used in this study.	Bauer DE, 2012, CLIN CANCER RES, V18, P5773, DOI 10.1158/1078-0432.CCR-12-1153; Belkina AC, 2012, NAT REV CANCER, V12, P465, DOI 10.1038/nrc3256; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Engleson J, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-69; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Francis RW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039987; French CA, 2008, ONCOGENE, V27, P2237, DOI 10.1038/sj.onc.1210852; French CA, 2004, J CLIN ONCOL, V22, P4135, DOI 10.1200/JCO.2004.02.107; French CA, 2003, CANCER RES, V63, P304; French CA, 2001, AM J PATHOL, V159, P1987, DOI 10.1016/S0002-9440(10)63049-0; French CA, 2012, ANNU REV PATHOL-MECH, V7, P247, DOI 10.1146/annurev-pathol-011811-132438; French CA, 2010, J CLIN PATHOL, V63, P492, DOI 10.1136/jcp.2007.052902; Haack H, 2009, AM J SURG PATHOL, V33, P984, DOI 10.1097/PAS.0b013e318198d666; Haruki N, 2005, J MED GENET, V42, P558, DOI 10.1136/jmg.2004.029686; KEES UR, 1991, AM J PEDIAT HEMATOL, V13, P459; KUBONISHI I, 1991, CANCER RES, V51, P3327; KUZUME T, 1992, INT J CANCER, V50, P259, DOI 10.1002/ijc.2910500216; Mertens F, 2007, PEDIATR BLOOD CANCER, V49, P1015, DOI 10.1002/pbc.20755; Ott CJ, 2012, BLOOD, V120, P2843, DOI 10.1182/blood-2012-02-413021; Prinjha RK, 2012, TRENDS PHARMACOL SCI, V33, P146, DOI 10.1016/j.tips.2011.12.002; Reynoird N, 2010, EMBO J, V29, P2943, DOI 10.1038/emboj.2010.176; Schwartz BE, 2011, CANCER RES, V71, P2686, DOI 10.1158/0008-5472.CAN-10-3513; Shehata BM, 2010, PEDIATR DEVEL PATHOL, V13, P481, DOI 10.2350/09-10-0727-CR.1; Tanaka M, 2012, AM J SURG PATHOL, V36, P381, DOI 10.1097/PAS.0b013e31824230a8; Toretsky JA, 2003, AM J CLIN ONCOL-CANC, V26, P300, DOI 10.1097/00000421-200306000-00019; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Vargas SO, 2001, CANCER, V92, P1195, DOI 10.1002/1097-0142(20010901)92:5<1195::AID-CNCR1438>3.0.CO;2-3; Yan JP, 2011, J BIOL CHEM, V286, P27663, DOI 10.1074/jbc.M111.246975; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	30	27	27	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2013	32	39					4664	4674		10.1038/onc.2012.487	http://dx.doi.org/10.1038/onc.2012.487			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226YD	23128391				2022-12-28	WOS:000325072200008
J	Rodriguez-Paredes, M; de Paz, AM; Simo-Riudalbas, L; Sayols, S; Moutinho, C; Moran, S; Villanueva, A; Vazquez-Cedeira, M; Lazo, PA; Carneiro, F; Moura, CS; Vieira, J; Teixeira, MR; Esteller, M				Rodriguez-Paredes, M.; Martinez de Paz, A.; Simo-Riudalbas, L.; Sayols, S.; Moutinho, C.; Moran, S.; Villanueva, A.; Vazquez-Cedeira, M.; Lazo, P. A.; Carneiro, F.; Moura, C. S.; Vieira, J.; Teixeira, M. R.; Esteller, M.			Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis	ONCOGENE			English	Article						SETDB1; gene amplification; overexpression; lung cancer; histone methyltransferase; chemotherapy	COMPARATIVE GENOMIC HYBRIDIZATION; GROUP PROTEIN EZH2; PROSTATE-CANCER; LYSINE METHYLTRANSFERASES; BREAST-CANCER; C-MYC; LEUKEMIA; CELLS; EXPRESSION; POLYCOMB	Disruption of the histone modification patterns is one of the most common features of human tumors. However, few genetic alterations in the histone modifier genes have been described in tumorigenesis. Herein we show that the histone methyltransferase SETDB1 undergoes gene amplification in non-small and small lung cancer cell lines and primary tumors. The existence of additional copies of the SETDB1 gene in these transformed cells is associated with higher levels of the corresponding mRNA and protein. From a functional standpoint, the depletion of SETDB1 expression in amplified cells reduces cancer growth in cell culture and nude mice models, whereas its overexpression increases the tumor invasiveness. The increased gene dosage of SETDB1 is also associated with enhanced sensitivity to the growth inhibitory effect mediated by the SETDB1-interfering drug mithramycin. Overall, the findings identify SETDB1 as a bona fide oncogene undergoing gene amplification-associated activation in lung cancer and suggest its potential for new therapeutic strategies.	[Rodriguez-Paredes, M.; Martinez de Paz, A.; Simo-Riudalbas, L.; Sayols, S.; Moutinho, C.; Moran, S.; Esteller, M.] Bellvitge Biomed Res Inst IDIBELL, Canc Epigenet & Biol Progrm PEBC, Barcelona, Spain; [Villanueva, A.] Inst Catala Oncol, IDIBELL, Translat Res Lab, Barcelona, Spain; [Vazquez-Cedeira, M.; Lazo, P. A.] Univ Salamanca, CSIC, Inst Biol Mol & Celular Canc, Expt Therapeut & Translat Oncol Program, E-37008 Salamanca, Spain; [Vazquez-Cedeira, M.; Lazo, P. A.] Inst Invest Biomed Salamanca IBSAL, Salamanca, Spain; [Carneiro, F.; Moura, C. S.] Univ Porto IPATIMPU, Ctr Hosp Sao Joao, Fac Med, Dept Pathol, P-4100 Oporto, Portugal; [Carneiro, F.; Moura, C. S.] Univ Porto IPATIMUP, Inst Mol Pathol & Immunol, Oporto, Portugal; [Vieira, J.; Teixeira, M. R.] Univ Porto, Portuguese Oncol Inst, Dept Genet, P-4100 Oporto, Portugal; [Vieira, J.; Teixeira, M. R.] Univ Porto, Biomed Sci Inst ICBAS, P-4100 Oporto, Portugal; [Esteller, M.] Univ Barcelona, Sch Med, Dept Physiol Sci 2, Barcelona, Spain; [Esteller, M.] ICREA, Barcelona, Spain	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Catalan Institute of Oncology; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); University of Barcelona; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); Sao Joao Hospital; Universidade do Porto; Universidade do Porto; Portuguese Institute of Oncology; Universidade do Porto; Universidade do Porto; University of Barcelona; ICREA	Esteller, M (corresponding author), Hosp Duran & Reynals, Canc Epigenet & Biol Program PEBC, 3rd Floor,Ave Gran Via 199-203, Barcelona 08907, Spain.	mesteller@idibell.cat	Rodríguez, Manuel/N-2708-2019; Esteller, Manel/L-5956-2014; Lazo, Pedro A./M-6435-2014; Teixeira, Manuel António Rodrigues/E-4885-2011; Carneiro, Fatima/J-6432-2013; Moran, Sebastian/G-5293-2013; Carneiro, Fatima/AAV-8677-2021; Rodríguez Paredes, Manuel/B-1480-2019; Teixeira, Manuel AC/AAZ-7251-2020	Esteller, Manel/0000-0003-4490-6093; Lazo, Pedro A./0000-0001-8997-3025; Teixeira, Manuel António Rodrigues/0000-0002-4896-5982; Carneiro, Fatima/0000-0002-1964-1006; Moran, Sebastian/0000-0003-4192-8983; Carneiro, Fatima/0000-0002-1964-1006; Rodríguez Paredes, Manuel/0000-0001-5471-4277; Teixeira, Manuel AC/0000-0002-1959-0624; Vieira, Joana/0000-0002-0608-2137; Sayols, Sergi/0000-0002-3877-4170	European Community - CURELUNG project [HEALTH-F2-2010-258677]; Institute of Health Carlos III [(ISCIII)-PI10/02992]; Ministerio de Educacion, Ciencia e Innovacion [SAF2010-14935]; Kutxa-Fundacion INBIOMED; Health and Science Departments of the Catalan Government (Generalitat de Catalunya); ICREA Funding Source: Custom	European Community - CURELUNG project; Institute of Health Carlos III(Instituto de Salud Carlos III); Ministerio de Educacion, Ciencia e Innovacion; Kutxa-Fundacion INBIOMED; Health and Science Departments of the Catalan Government (Generalitat de Catalunya); ICREA(ICREA)	This work was supported by the European Community's Seventh Framework Programme (FP7/2007-2013) under Grant agreement number HEALTH-F2-2010-258677-CURELUNG project, the Institute of Health Carlos III (ISCIII)-PI10/02992, Ministerio de Educacion, Ciencia e Innovacion Grant SAF2010-14935, Kutxa-Fundacion INBIOMED and the Health and Science Departments of the Catalan Government (Generalitat de Catalunya). ME is an ICREA Research Professor.	Albertson DG, 2006, TRENDS GENET, V22, P447, DOI 10.1016/j.tig.2006.06.007; Arteaga CL, 2012, NAT REV CLIN ONCOL, V9, P16, DOI 10.1038/nrclinonc.2011.177; Balsara BR, 1997, CANCER RES, V57, P2116; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Beke L, 2007, ONCOGENE, V26, P4590, DOI 10.1038/sj.onc.1210248; Berdasco M, 2010, DEV CELL, V19, P698, DOI 10.1016/j.devcel.2010.10.005; Berdasco M, 2009, P NATL ACAD SCI USA, V106, P21830, DOI 10.1073/pnas.0906831106; Bilodeau S, 2009, GENE DEV, V23, P2484, DOI 10.1101/gad.1837309; Bracken AP, 2003, EMBO J, V22, P5323, DOI 10.1093/emboj/cdg542; Canaani E, 2004, BRIT J CANCER, V90, P756, DOI 10.1038/sj.bjc.6601639; Ceol CJ, 2011, NATURE, V471, P513, DOI 10.1038/nature09806; Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200; Cho S, 2011, J BIOL CHEM, V286, P41115, DOI 10.1074/jbc.M111.248534; Daigle SR, 2011, CANCER CELL, V20, P53, DOI 10.1016/j.ccr.2011.06.009; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Esteller M, 2006, BRIT J CANCER, V94, P179, DOI 10.1038/sj.bjc.6602918; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Fullgrabe J, 2011, ONCOGENE, V30, P3391, DOI 10.1038/onc.2011.121; Goeze A, 2002, J PATHOL, V196, P8, DOI 10.1002/path.1009; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hayashi M, 2005, ONCOL REP, V14, P1429; JONES DE, 1995, ONCOGENE, V10, P2323; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Karimi MM, 2011, CELL STEM CELL, V8, P676, DOI 10.1016/j.stem.2011.04.004; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Li HW, 2006, J BIOL CHEM, V281, P19489, DOI 10.1074/jbc.M513249200; Luk C, 2001, CANCER GENET CYTOGEN, V125, P87, DOI 10.1016/S0165-4608(00)00363-0; MacGregor S, 2011, NAT GENET, V43, P1114, DOI 10.1038/ng.958; Matsui T, 2010, NATURE, V464, P927, DOI 10.1038/nature08858; Okada Y, 2005, CELL, V121, P167, DOI 10.1016/j.cell.2005.02.020; Rodriguez-Paredes M, 2011, NAT MED, V17, P330, DOI 10.1038/nm.2305; Ryu H, 2006, P NATL ACAD SCI USA, V103, P19176, DOI 10.1073/pnas.0606373103; Schneider R, 2002, TRENDS BIOCHEM SCI, V27, P396, DOI 10.1016/S0968-0004(02)02141-2; Schultz DC, 2002, GENE DEV, V16, P919, DOI 10.1101/gad.973302; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; Sun P, 2009, STEM CELLS, V27, P1473, DOI 10.1002/stem.89; Sy SMH, 2004, EUR J CANCER, V40, P1082, DOI 10.1016/j.ejca.2004.01.012; Taniguchi H, 2012, ONCOGENE, V31, P1988, DOI 10.1038/onc.2011.387; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Watanabe H, 2008, CANCER CELL INT, V8, DOI 10.1186/1475-2867-8-15; Wilkerson MD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036530; Yakut T, 2006, LUNG CANCER, V54, P293, DOI 10.1016/j.lungcan.2006.08.011; Yang L, 2002, ONCOGENE, V21, P148, DOI 10.1038/sj.onc.1204998; Yap DB, 2011, BLOOD, V117, P2451, DOI 10.1182/blood-2010-11-321208; Yoshimi A, 2011, J CELL BIOCHEM, V112, P415, DOI 10.1002/jcb.22972; Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	49	96	100	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2014	33	21					2807	2813		10.1038/onc.2013.239	http://dx.doi.org/10.1038/onc.2013.239			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EH	23770855	Green Published, hybrid			2022-12-28	WOS:000337231700014
J	de Graauw, M; Cao, L; Winkel, L; van Miltenburg, MHAM; le Devedec, SE; Klop, M; Yan, K; Pont, C; Rogkoti, VM; Tijsma, A; Chaudhuri, A; Lalai, R; Price, L; Verbeek, F; van de Water, B				de Graauw, M.; Cao, L.; Winkel, L.; van Miltenburg, M. H. A. M.; le Devedec, S. E.; Klop, M.; Yan, K.; Pont, C.; Rogkoti, V-M; Tijsma, A.; Chaudhuri, A.; Lalai, R.; Price, L.; Verbeek, F.; van de Water, B.			Annexin A2 depletion delays EGFR endocytic trafficking via cofilin activation and enhances EGFR signaling and metastasis formation	ONCOGENE			English	Article						AnxA2; breast cancer; EGFR; endocytosis; metastasis	GROWTH-FACTOR RECEPTOR; BREAST-CANCER CELLS; EARLY ENDOSOMES; PHOSPHORYLATION; INVASION; PATHWAY; ADHESION; RECRUITMENT; EXPRESSION; CARCINOMA	Enhanced epidermal growth factor receptor (EGFR) activity has been strongly linked to breast cancer progression and mediators of EGFR endocytosis may well be involved. We developed a semi-automated high-content fluorescence microscopy-based EGFR endocytosis screen to identify proteins that mediate EGFR endocytosis in human HBL100 breast cancer cells. Knockdown of 172 individual endocytosis and actin-regulatory genes with small interfering RNAs led to the identification of 14 genes of which the contribution to EGFR endocytosis in breast cancer is until now poorly defined, including DNAJC6, GDI2, FGD6, HAX1, NECAP2 and AnxA2. We show that depletion of the actin and endocytosis regulatory protein annexin A2 (AnxA2) in a panel of four triple negative breast cancer (TNBC) cell lines affected EGFR endocytosis. Depletion of AnxA2 in the aggressive and highly metastatic MDA-MB-231 TNBC cell line resulted in the inhibition of EGFR transport beyond the early endosomes. This inhibition coincided with enhanced epidermal growth factor (EGF)-induced cell migration and downstream signaling via c-Jun N-terminal kinase (JNK) and Akt. Moreover, AnxA2 knockdown increased lung metastasis formation in mice. The effect of AnxA2 knockdown on EGFR endocytosis in MDA-MB-231 was related to dephosphorylation/activation of the actin-severing protein cofilin, as re-expression of an inactive S3E-cofilin mutant, but not an active S3A-cofilin mutant, re-established EGFR endocytosis to control levels. Together, our data provide evidence for AnxA2 as a mediator of EGFR endocytosis and signaling in breast cancer via regulation of cofilin activation.	[de Graauw, M.; le Devedec, S. E.; Klop, M.; Pont, C.; Rogkoti, V-M; Tijsma, A.; Chaudhuri, A.; Lalai, R.; Price, L.; van de Water, B.] Leiden Univ, LACDR, Div Toxicol, NL-2300 RA Leiden, Netherlands; [Cao, L.; Yan, K.; Verbeek, F.] Leiden Univ, LIACS, Imaging & Bioinformat Grp, NL-2300 RA Leiden, Netherlands; [Winkel, L.] Erasmus MC, Biomech Lab, Rotterdam, Netherlands; [van Miltenburg, M. H. A. M.] Netherland Canc Inst, Dept Mol Pathol, Amsterdam, Netherlands	Leiden University; Leiden University - Excl LUMC; Leiden University; Leiden University - Excl LUMC; Erasmus University Rotterdam; Erasmus MC; Netherlands Cancer Institute	van de Water, B (corresponding author), Leiden Univ, LACDR, Div Toxicol, Einsteinweg 55,POB 9502, NL-2300 RA Leiden, Netherlands.	m.de.graauw@lacdr.leidenuniv.nl; b.water@lacdr.leidenuniv.nl		Le Devedec, Sylvia/0000-0002-0615-9616; Yan, Kuan/0000-0003-4143-3569	Dutch Cancer Society (KWF) [UL 2006-3538, UL 2007-3860]; EU [201862]; EUFP7 Systems Microscopy NoE [258068]; TI Pharma project [T3-107]; Dutch Organization for Scientific Research [NWO 911-02-022]; Horizon Breakthrough [NWO 93518003]; Centre for Biomedical Genetics	Dutch Cancer Society (KWF)(KWF Kankerbestrijding); EU(European Commission); EUFP7 Systems Microscopy NoE; TI Pharma project; Dutch Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Horizon Breakthrough; Centre for Biomedical Genetics	We thank Dr Erik Danen and Dr Leo Price for critically reading the manuscript. This work was supported by grants from the Dutch Cancer Society (KWF; grant UL 2006-3538 and UL 2007-3860), EU FP7-Metafight (grant no 201862), EUFP7 Systems Microscopy NoE (258068), TI Pharma project T3-107, the Dutch Organization for Scientific Research (NWO 911-02-022), Horizon Breakthrough (NWO 93518003) and Centre for Biomedical Genetics.	Babbin BA, 2007, AM J PATHOL, V170, P951, DOI 10.2353/ajpath.2007.060647; Badovinac-Crnjevic T, 2011, MED ONCOL, V28, pS121, DOI 10.1007/s12032-010-9738-2; Cao L, 2012, P 6 IAPR INT C PATT, P330; Croxtall JD, 2000, BRIT J PHARMACOL, V130, P289, DOI 10.1038/sj.bjp.0703272; de Graauw M, 2005, J BIOL CHEM, V280, P29885, DOI 10.1074/jbc.M412708200; de Graauw M, 2008, MOL CELL BIOL, V28, P1029, DOI 10.1128/MCB.01247-07; de Graauw M, 2010, P NATL ACAD SCI USA, V107, P6340, DOI 10.1073/pnas.0913360107; Eccles SA, 2011, INT J DEV BIOL, V55, P685, DOI 10.1387/ijdb.113396se; Emoto K, 2001, CANCER, V92, P1419, DOI 10.1002/1097-0142(20010915)92:6<1419::AID-CNCR1465>3.0.CO;2-J; Geldner N, 2006, CURR OPIN PLANT BIOL, V9, P589, DOI 10.1016/j.pbi.2006.09.011; Goswami S, 2005, CANCER RES, V65, P5278, DOI 10.1158/0008-5472.CAN-04-1853; Grandal MV, 2008, J CELL MOL MED, V12, P1527, DOI 10.1111/j.1582-4934.2008.00298.x; Grewal T, 2010, INT J BIOCHEM CELL B, V42, P580, DOI 10.1016/j.biocel.2009.12.020; Grieve Adam G, 2012, Int J Cell Biol, V2012, P852430, DOI 10.1155/2012/852430; HARDER T, 1993, J CELL BIOL, V123, P1119, DOI 10.1083/jcb.123.5.1119; Huigsloot M, 2002, J BIOL CHEM, V277, P35869, DOI 10.1074/jbc.M200378200; Jiang XJ, 2003, MOL BIOL CELL, V14, P858, DOI 10.1091/mbc.E02-08-0532; Jost M, 1997, J CELL SCI, V110, P221; Le Devedec SE, 2009, CLIN EXP METASTAS, V26, P673, DOI 10.1007/s10585-009-9267-6; Llado A, 2008, MOL BIOL CELL, V19, P17, DOI 10.1091/mbc.E07-05-0411; Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996; Marcoux N, 2005, CELL SIGNAL, V17, P1449, DOI 10.1016/j.cellsig.2005.03.001; Mayran N, 2003, EMBO J, V22, P3242, DOI 10.1093/emboj/cdg321; Minn AJ, 2007, P NATL ACAD SCI USA, V104, P6740, DOI 10.1073/pnas.0701138104; Miyamoto Y, 2003, J BIOL CHEM, V278, P29890, DOI 10.1074/jbc.M301559200; Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521; Murphy JE, 2009, P NATL ACAD SCI USA, V106, P17615, DOI 10.1073/pnas.0906541106; Nishimura Y, 2006, HISTOCHEM CELL BIOL, V126, P627, DOI 10.1007/s00418-006-0198-x; Okreglak V, 2007, J CELL BIOL, V178, P1251, DOI 10.1083/jcb.200703092; PEPINSKY RB, 1986, NATURE, V321, P81, DOI 10.1038/321081a0; Rescher U, 2008, J CELL SCI, V121, P2177, DOI 10.1242/jcs.028415; Richnau N, 2001, J BIOL CHEM, V276, P35060, DOI 10.1074/jbc.M103540200; Sharma MR, 2006, EXP MOL PATHOL, V81, P146, DOI 10.1016/j.yexmp.2006.03.003; Shetty PK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044299; Sidani M, 2007, J CELL BIOL, V179, P777, DOI 10.1083/jcb.200707009; van Roosmalen W, 2011, METHODS MOL BIOL, V769, P435, DOI 10.1007/978-1-61779-207-6_29; Vila de MS, 2009, ONCOGENE, V28, P363; Wang WG, 2007, NAT REV CANCER, V7, P429, DOI 10.1038/nrc2148; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; White IJ, 2006, EMBO J, V25, P1, DOI 10.1038/sj.emboj.7600759; Wu B, 2012, CELL PROLIFERAT, V45, P189, DOI 10.1111/j.1365-2184.2012.00820.x; Zheng L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019390	42	41	41	1	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2014	33	20					2610	2619		10.1038/onc.2013.219	http://dx.doi.org/10.1038/onc.2013.219			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH9YT	23792445				2022-12-28	WOS:000336502700007
J	Jiang, CC; Croft, A; Tseng, HY; Guo, ST; Jin, L; Hersey, P; Zhang, XD				Jiang, C. C.; Croft, A.; Tseng, H-Y; Guo, S. T.; Jin, L.; Hersey, P.; Zhang, X. D.			Repression of microRNA-768-3p by MEK/ERK signalling contributes to enhanced mRNA translation in human melanoma	ONCOGENE			English	Article						miR-768-3p; eIF4E; mRNA translation; melanoma; RAF/MEK/ERK	CAP-BINDING PROTEIN; INCREASED EXPRESSION; CYCLIN D1; INITIATION; EIF4E; EIF-4E; CELLS; TRANSFORMATION; INHIBITION; DEREGULATION	Increased global protein synthesis and selective translation of mRNAs encoding proteins contributing to malignancy is common in cancer cells. This is often associated with elevated expression of eukaryotic translation initiation factor 4 (eIF4E), the rate-limiting factor of cap-dependent translation initiation. We report here that in human melanoma downregulation of miR-768-3p as a result of activation of the mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway has an important role in the upregulation of eIF4E and enhancement in protein synthesis. Melanoma cells displayed increased nascent protein production and elevated eIF4E expression, which was associated with the downregulation of miR-768-3p that was predicted to target the 30-untranslated region of the eIF4E mRNA. Overexpression of miR-768-3p led to the downregulation of the endogenous eIF4E protein, reduction in nascent protein synthesis and inhibition of cell survival and proliferation. These effects were efficiently reversed when eIF4E was co-overexpressed in melanoma cells. On the other hand, introduction of anti-miR-768-3p into melanocytes upregulated endogenous eIF4E protein expression and increased global protein synthesis. Downregulation of miR-768-3p appeared to be mediated by activation of the MEK/ERK pathway, in that treatment of BRAFV600E melanoma cells with the mutant BRAF inhibitor PLX4720 or exposure of either BRAFV600E or wild-type BRAF melanoma cells to the MEK inhibitor U0126 resulted in the upregulation of miR-768-3p and inhibition of nascent protein synthesis. This inhibition was partially blocked in cells cointroduced with anti-miR-768-3p. Significantly, miR-768-3p was similarly downregulated, which was inversely associated with the expression levels of eIF4E in fresh melanoma isolates. Taken together, these results identify downregulation of miR-768-3p and subsequent upregulation of eIF4E as an important mechanism in addition to phosphorylation of eIF4E responsible for MEK/ERK-mediated enhancement of protein synthesis in melanoma.	[Jiang, C. C.; Croft, A.; Tseng, H-Y; Zhang, X. D.] Univ Newcastle, Prior Res Ctr Canc Res, Callaghan, NSW 2308, Australia; [Jiang, C. C.; Tseng, H-Y; Zhang, X. D.] Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW 2308, Australia; [Croft, A.] Calvary Mater Newcastle Hosp, Oncol & Immunol Unit, Waratah, NSW, Australia; [Guo, S. T.; Zhang, X. D.] Shanxi Canc Hosp & Inst, Dept Mol Biol, Taiyuan, Shanxi, Peoples R China; [Jin, L.; Hersey, P.] Univ Sydney, Kolling Inst Med Res, St Leonards, NSW, Australia	University of Newcastle; University of Newcastle; Calvary Mater Newcastle Hospital; University of Sydney; Kolling Institute of Medical Research	Zhang, XD (corresponding author), Univ Newcastle, Sch Med & Publ Hlth, Prior Res Ctr Canc Res, LS3-49,Life Sci Bldg, Callaghan, NSW 2308, Australia.	Xu.Zhang@newcastle.edu.au	Tseng, Cindy Hsin-Yi/AAB-8958-2022; Jin, Lei/K-2315-2019; zhang, xu/GYE-3558-2022; zhang, xian/GYA-0290-2022; Zhang, xiaoyu/GXA-3206-2022; zhang, xu/GRX-9733-2022; Jin, Lei/J-1896-2019	Tseng, Cindy Hsin-Yi/0000-0002-7499-7515; Jin, Lei/0000-0001-7187-9671; Zhang, Xu Dong/0000-0001-9457-8003	NSW State Cancer Council, Cancer Institute NSW; National Health and Medical Research Council (NHMRC), Australia; NHMRC	NSW State Cancer Council, Cancer Institute NSW(Cancer Council New South Wales); National Health and Medical Research Council (NHMRC), Australia(National Health and Medical Research Council (NHMRC) of Australia); NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	This work was supported by the NSW State Cancer Council, Cancer Institute NSW, and National Health and Medical Research Council (NHMRC), Australia. CCJ is a recipient of postdoctoral training Fellowship of NHMRC. XDZ is supported by a senior research fellowship of NHMRC.	Arroyo JD, 2011, P NATL ACAD SCI USA, V108, P5003, DOI 10.1073/pnas.1019055108; Bemis LT, 2008, CANCER RES, V68, P1362, DOI 10.1158/0008-5472.CAN-07-2912; Bilanges B, 2007, ONCOGENE, V26, P5973, DOI 10.1038/sj.onc.1210431; Bitterman PB, 2012, CELL CYCLE, V11, P1097, DOI 10.4161/cc.11.6.19610; Blais JD, 2004, MOL CELL BIOL, V24, P7469, DOI 10.1128/MCB.24.17.7469-7482.2004; Bonazzi VF, 2012, MELANOMA RES, V22, P101, DOI 10.1097/CMR.0b013e32834f6fbb; Caramuta S, 2010, J INVEST DERMATOL, V130, P2062, DOI 10.1038/jid.2010.63; Coleman LJ, 2009, BRIT J CANCER, V100, P1393, DOI 10.1038/sj.bjc.6605044; Couts KL, 2013, ONCOGENE, V32, P1959, DOI 10.1038/onc.2012.209; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; De Benedetti A, 2004, ONCOGENE, V23, P3189, DOI 10.1038/sj.onc.1207545; Dong L, 2011, ONCOGENE, V30, P3716, DOI 10.1038/onc.2011.87; Felicetti F, 2008, CANCER RES, V68, P2745, DOI 10.1158/0008-5472.CAN-07-2538; Graff JR, 2008, CANCER RES, V68, P631, DOI 10.1158/0008-5472.CAN-07-5635; Grzmil M, 2012, CANCER RES, V72, P3891, DOI 10.1158/0008-5472.CAN-12-0026; Guo ST, 2013, ONCOGENE, V32, P1910, DOI 10.1038/onc.2012.214; Haflidadottir BS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011574; HE L, 2004, NAT REV GENET, V5, P522; Hong DS, 2011, CLIN CANCER RES, V17, P6582, DOI 10.1158/1078-0432.CCR-11-0430; Hou JQ, 2012, ONCOTARGET, V3, P118; Humphreys DT, 2005, P NATL ACAD SCI USA, V102, P16961, DOI 10.1073/pnas.0506482102; Ibrahim AF, 2011, CANCER RES, V71, P5214, DOI 10.1158/0008-5472.CAN-10-4645; Iorio MV, 2009, J CLIN ONCOL, V27, P5848, DOI 10.1200/JCO.2009.24.0317; Jackson RJ, 2010, NAT REV MOL CELL BIO, V11, P113, DOI 10.1038/nrm2838; Jiang CC, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.48; Jin L, 2011, P NATL ACAD SCI USA, V108, P15840, DOI 10.1073/pnas.1019312108; Kiss T, 2004, J CELL SCI, V117, P5949, DOI 10.1242/jcs.01487; KOROMILAS AE, 1992, EMBO J, V11, P4153, DOI 10.1002/j.1460-2075.1992.tb05508.x; Larsson O, 2007, CANCER RES, V67, P6814, DOI 10.1158/0008-5472.CAN-07-0752; LAZARISKARATZAS A, 1992, MOL CELL BIOL, V12, P1234, DOI 10.1128/MCB.12.3.1234; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; Li SC, 2007, DNA CELL BIOL, V26, P195, DOI 10.1089/dna.2006.0558; Lujambio A, 2012, NATURE, V482, P347, DOI 10.1038/nature10888; Mamane Y, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000242; Mathonnet G, 2007, SCIENCE, V317, P1764, DOI 10.1126/science.1146067; Miyoshi K, 2010, MOL GENET GENOMICS, V284, P95, DOI 10.1007/s00438-010-0556-1; Moerke NJ, 2007, CELL, V128, P257, DOI 10.1016/j.cell.2006.11.046; Mueller DW, 2010, PIGM CELL MELANOMA R, V23, P620, DOI 10.1111/j.1755-148X.2010.00734.x; Phillips A, 2008, ONCOGENE, V27, P1645, DOI 10.1038/sj.onc.1210785; Platz A, 2008, MOL ONCOL, V1, P395, DOI 10.1016/j.molonc.2007.12.003; ROSENWALD IB, 1993, MOL CELL BIOL, V13, P7358, DOI 10.1128/MCB.13.12.7358; Rosenwald IB, 2004, ONCOGENE, V23, P3230, DOI 10.1038/sj.onc.1207552; ROSENWALD IB, 1993, P NATL ACAD SCI USA, V90, P6175, DOI 10.1073/pnas.90.13.6175; Silvera D, 2010, NAT REV CANCER, V10, P254, DOI 10.1038/nrc2824; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Stumpf CR, 2011, CURR OPIN GENET DEV, V21, P474, DOI 10.1016/j.gde.2011.03.007; Takatsu H, 1998, J BIOL CHEM, V273, P24693, DOI 10.1074/jbc.273.38.24693; Valleron W, 2012, BLOOD, V120, P3997, DOI 10.1182/blood-2012-06-438135; Wendel HG, 2007, GENE DEV, V21, P3232, DOI 10.1101/gad.1604407; Wilmott JS, 2011, PATHOLOGY, V43, P657, DOI 10.1097/PAT.0b013e32834a7358; Wulfken LM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025787; Yanagiya A, 2012, MOL CELL, V46, P847, DOI 10.1016/j.molcel.2012.04.004; Yang SX, 2007, ONCOL REP, V17, P281	54	23	24	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2014	33	20					2577	2588		10.1038/onc.2013.237	http://dx.doi.org/10.1038/onc.2013.237			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH9YT	23770856	Green Submitted			2022-12-28	WOS:000336502700004
J	Harte, MT; Gorski, JJ; Savage, KI; Purcell, JW; Barros, EW; Burn, PM; McFarlane, C; Mullan, PB; Kennedy, RD; Perkins, ND; Harkin, DP				Harte, M. T.; Gorski, J. J.; Savage, K. I.; Purcell, J. W.; Barros, E. W.; Burn, P. M.; McFarlane, C.; Mullan, P. B.; Kennedy, R. D.; Perkins, N. D.; Harkin, D. P.			NF-kappa B is a critical mediator of BRCA1-induced chemoresistance	ONCOGENE			English	Article						BRCA1; NF-kappa B; DNA damage; apoptosis	DOUBLE-STRAND BREAKS; DNA-REPAIR; BRCA1; CANCER; ACTIVATION; EXPRESSION; SUBUNIT; CHEMOTHERAPY; APOPTOSIS; COMPLEX	BRCA1 mediates resistance to apoptosis in response to DNA-damaging agents, causing BRCA1 wild-type tumours to be significantly more resistant to DNA damage than their mutant counterparts. In this study, we demonstrate that following treatment with the DNA-damaging agents, etoposide or camptothecin, BRCA1 is required for the activation of nuclear factor-kappa B (NF-kappa B), and that BRCA1 and NF-kappa B cooperate to regulate the expression of the NF-kappa B antiapoptotic targets BCL2 and XIAP. We show that BRCA1 and the NF-kappa B subunit p65/RelA associate constitutively, whereas the p50 NF-kappa B subunit associates with BRCA1 only upon DNA damage treatment. Consistent with this BRCA1 and p65 are present constitutively on the promoters of BCL2 and XIAP, whereas p50 is recruited to these promoters only in damage treated cells. Importantly, we demonstrate that the recruitment of p50 onto the promoters of BCL2 and XIAP is dependent upon BRCA1, but independent of its NF-kappa B partner subunit p65. The functional relevance of NF-kappa B activation by BRCA1 in response to etoposide and camptothecin is demonstrated by the significantly reduced survival of BRCA1 wild-type cells upon NF-kappa B inhibition. This study identifies a novel BRCA1-p50 complex, and demonstrates for the first time that NF-kappa B is required for BRCA1-mediated resistance to DNA damage. It reveals a functional interdependence between BRCA1 and NF-kappa B, further elucidating the role played by NF-kappa B in mediating cellular resistance of BRCA1 wild-type tumours to DNA-damaging agents.	[Harte, M. T.; Gorski, J. J.; Savage, K. I.; Barros, E. W.; Burn, P. M.; McFarlane, C.; Mullan, P. B.; Kennedy, R. D.; Harkin, D. P.] Queens Univ Belfast, Ctr Canc Res & Cell Biol, Belfast BT9 7BL, Antrim, North Ireland; [Purcell, J. W.] Abbott Biotherapeut, Global Pharmaceut Res & Dev, Biol Technol, Redwood City, CA USA; [Perkins, N. D.] Newcastle Univ, Sch Med, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England	Queens University Belfast; Newcastle University - UK	Harte, MT (corresponding author), Queens Univ Belfast, Ctr Canc Res & Cell Biol, Lisburn Rd, Belfast BT9 7BL, Antrim, North Ireland.	m.harte@qub.ac.uk; d.harkin@qub.ac.uk	Kennedy, Richard/J-3489-2012	Kennedy, Richard/0000-0003-4737-6163; Savage, Kienan/0000-0002-4898-899X	Medical Research Council; Cancer Research UK; Cancer Focus Northern Ireland; Action Cancer; Medical Research Council [G0600267] Funding Source: researchfish; MRC [G0600267] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Cancer Research UK(Cancer Research UK); Cancer Focus Northern Ireland; Action Cancer; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank Dr Stephen McMahon for help with statistical analysis of survival curves. This study was supported by Medical Research Council (M. T Harte and D. P Harkin); Cancer Research UK (KI Savage, JJ Gorski, P Burn, E Barros and DP Harkin); Cancer Focus Northern Ireland (KI Savage); Action Cancer (J.P Purcell).	Barre B, 2007, EMBO J, V26, P4841, DOI 10.1038/sj.emboj.7601899; Benezra M, 2003, J BIOL CHEM, V278, P26333, DOI 10.1074/jbc.M303076200; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Chapppuis PO, 2002, J MED GENET, V39, P608, DOI 10.1136/jmg.39.8.608; DiDonato JA, 2012, IMMUNOL REV, V246, P379, DOI 10.1111/j.1600-065X.2012.01099.x; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Franken NAP, 2006, NAT PROTOC, V1, P2315, DOI 10.1038/nprot.2006.339; Freneaux P, 2000, BRIT J CANCER, V83, P1318, DOI 10.1054/bjoc.2000.1438; Gorski JJ, 2011, NUCLEIC ACIDS RES, V39, P9536, DOI 10.1093/nar/gkr679; Gorski JJ, 2010, BREAST CANCER RES TR, V122, P721, DOI 10.1007/s10549-009-0565-0; Habraken Y, 2003, ONCOGENE, V22, P6090, DOI 10.1038/sj.onc.1206893; Habraken Y, 2006, BIOCHEM PHARMACOL, V72, P1132, DOI 10.1016/j.bcp.2006.07.015; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; Harte MT, 2010, CANCER RES, V70, P2538, DOI 10.1158/0008-5472.CAN-09-2089; Hartman AR, 2002, NAT GENET, V32, P180, DOI 10.1038/ng953; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; Hosey AM, 2007, J NATL CANCER I, V99, P1683, DOI 10.1093/jnci/djm207; Huen MSY, 2010, NAT REV MOL CELL BIO, V11, P138, DOI 10.1038/nrm2831; Kennedy RD, 2005, CANCER RES, V65, P10265, DOI 10.1158/0008-5472.CAN-05-1841; Kirova YM, 2005, EUR J CANCER, V41, P2304, DOI 10.1016/j.ejca.2005.02.037; McCool KW, 2012, IMMUNOL REV, V246, P311, DOI 10.1111/j.1600-065X.2012.01101.x; McEachern KA, 2003, J CELL BIOCHEM, V89, P120, DOI 10.1002/jcb.10487; Mullan PB, 2006, ONCOGENE, V25, P5854, DOI 10.1038/sj.onc.1209872; Mullan PB, 2006, BBA-REV CANCER, V1766, P205, DOI 10.1016/j.bbcan.2006.07.001; Mullan PB, 2005, ONCOGENE, V24, P5492, DOI 10.1038/sj.onc.1208698; Nakanishi C, 2005, NAT REV CANCER, V5, P297, DOI 10.1038/nrc1588; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Perkins ND, 2012, NAT REV CANCER, V12, P121, DOI 10.1038/nrc3204; Quinn JE, 2003, CANCER RES, V63, P6221; Quinn JE, 2007, CLIN CANCER RES, V13, P7413, DOI 10.1158/1078-0432.CCR-07-1083; Roy R, 2012, NAT REV CANCER, V12, P68, DOI 10.1038/nrc3181; Sabatel H, 2011, BIOCHEM PHARMACOL, V82, P1371, DOI 10.1016/j.bcp.2011.07.105; Schumm K, 2006, EMBO J, V25, P4820, DOI 10.1038/sj.emboj.7601343; Stilmann M, 2009, MOL CELL, V36, P365, DOI 10.1016/j.molcel.2009.09.032; Treszezamsky AD, 2007, CANCER RES, V67, P7078, DOI 10.1158/0008-5472.CAN-07-0601; Volcic M, 2012, NUCLEIC ACIDS RES, V40, P181, DOI 10.1093/nar/gkr687; Wang JX, 2009, EMBO REP, V10, P1272, DOI 10.1038/embor.2009.197	37	31	34	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2014	33	6					713	723		10.1038/onc.2013.10	http://dx.doi.org/10.1038/onc.2013.10			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5IL	23435429	Green Accepted			2022-12-28	WOS:000331129200006
J	Teng, Y; Mei, Y; Hawthorn, L; Cowell, JK				Teng, Y.; Mei, Y.; Hawthorn, L.; Cowell, J. K.			WASF3 regulates miR-200 inactivation by ZEB1 through suppression of KISS1 leading to increased invasiveness in breast cancer cells	ONCOGENE			English	Article						breast cancer; metastasis; invasion; KISS1; WASF3; ZEB1	EPITHELIAL-MESENCHYMAL TRANSITION; WAVE FAMILY PROTEINS; E-CADHERIN; LAMELLIPODIA FORMATION; FEEDBACK LOOP; METASTASIS; EXPRESSION; INVASION; GENE; MIGRATION	The WASF3 gene promotes invasion and metastasis in breast cancer cells, which have undergone epithelial-to-mesenchyme transition (EMT). Overexpression of WASF3 in cells that do not show EMT increases their invasion potential as a result of increased ZEB1/2 levels, which specifically suppress the anti-invasion chromosome 1 miR-200a/200b/429 cluster. ZEB1/2 upregulation by WASF3 results from downregulation of KISS1, leading to the release of inhibition of nuclear factor (NF) kB by IkBa. We further show that ZEB1 expression is regulated by the NFkB transcription factor. Knockdown of WASF3 in breast cancer cells leads to reduced ZEB1 levels and increased miR-200 and E-cadherin levels, resulting in loss of invasion potential. The central regulation of this interactive pathway by WASF3 accounts for the increased invasion associated with increased WASF3 expression seen in aggressive breast cancer cells. WASF3, therefore, is a potential target to suppress invasion and metastasis in breast cancer cells.	[Teng, Y.; Mei, Y.; Hawthorn, L.; Cowell, J. K.] Georgia Hlth Sci Univ, Ctr Canc, Augusta, GA 30912 USA	University System of Georgia; Augusta University	Teng, Y (corresponding author), Georgia Hlth Sci Univ, Ctr Canc, CN 2133,1120 15th St, Augusta, GA 30912 USA.	yteng@georgiahealth.edu; jcowell@georgiahealth.edu	Teng, Yong/AAK-4160-2020	Teng, Yong/0000-0002-1856-7289; Hawthorn, Lesleyann/0000-0001-8179-0937	Georgia Cancer Coalition; NIH; National Institutes of Health [CA120510]; NATIONAL CANCER INSTITUTE [R01CA120510] Funding Source: NIH RePORTER	Georgia Cancer Coalition; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Dr Leslie Ann Lesoon for the technical assistance and helpful comments during the writing of this manuscript. We also thank the staff of Cancer Center Shared Resources at GHSU for assistance during microarray data collection. Dr Cowell is supported by the Georgia Cancer Coalition as a distinguished cancer scholar and funded by the NIH. This study was supported, in part, by the National Institutes of Health Grant CA120510.	Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Ahmad A, 2011, CANCER RES, V71, P3400, DOI 10.1158/0008-5472.CAN-10-0965; Almeida MI, 2010, CELL RES, V20, P603, DOI 10.1038/cr.2010.70; Arumugam T, 2009, CANCER RES, V69, P5820, DOI 10.1158/0008-5472.CAN-08-2819; Brabletz S, 2011, EMBO J, V30, P770, DOI 10.1038/emboj.2010.349; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Cabanillas AM, 1996, DNA CELL BIOL, V15, P643, DOI 10.1089/dna.1996.15.643; Chua HL, 2007, ONCOGENE, V26, P711, DOI 10.1038/sj.onc.1209808; Chuang TC, 2011, CANCER LETT, V311, P11, DOI 10.1016/j.canlet.2011.06.007; Edwards LA, 2011, JNCI-J NATL CANCER I, V103, P1162, DOI 10.1093/jnci/djr224; Elmen J, 2008, NATURE, V452, P896, DOI 10.1038/nature06783; Ghoshal P, 2012, INT J CANCER, V131, pE905, DOI 10.1002/ijc.27631; Gibbons DL, 2009, GENE DEV, V23, P2140, DOI 10.1101/gad.1820209; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Hurst DR, 2009, CANCER RES, V69, P7495, DOI 10.1158/0008-5472.CAN-09-2111; Hurteau GJ, 2007, CANCER RES, V67, P7972, DOI 10.1158/0008-5472.CAN-07-1058; Jechlinger M, 2006, J CLIN INVEST, V116, P1561, DOI 10.1172/JCI24652; Johnson E, 2010, J BIOL CHEM, V285, P29491, DOI 10.1074/jbc.M110.136770; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Kurisu S, 2010, CANCER SCI, V101, P2093, DOI 10.1111/j.1349-7006.2010.01654.x; Levy C, 2010, MOL CELL, V40, P841, DOI 10.1016/j.molcel.2010.11.020; Ma L, 2008, CELL CYCLE, V7, P570, DOI 10.4161/cc.7.5.5547; Mazda M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028688; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Png KJ, 2012, NATURE, V481, P190, DOI 10.1038/nature10661; Pollock CB, 2005, CANCER RES, V65, P1244, DOI 10.1158/0008-5472.CAN-04-1911; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Schliekelman MJ, 2011, CANCER RES, V71, P7670, DOI 10.1158/0008-5472.CAN-11-0964; Sossey-Alaoui K, 2005, EXP CELL RES, V308, P135, DOI 10.1016/j.yexcr.2005.04.011; Sossey-Alaoui K, 2005, J BIOL CHEM, V280, P21748, DOI 10.1074/jbc.M500503200; Sossey-Alaoui K, 2002, ONCOGENE, V21, P5967, DOI 10.1038/sj.onc.1205734; Sossey-Alaoui K, 2007, J BIOL CHEM, V282, P26257, DOI 10.1074/jbc.M701484200; Sossey-Alaoui K, 2007, AM J PATHOL, V170, P2112, DOI 10.2353/ajpath.2007.060975; Spaderna S, 2008, CANCER RES, V68, P537, DOI 10.1158/0008-5472.CAN-07-5682; Steeg Patricia S, 2003, Clin Breast Cancer, V4, P51, DOI 10.3816/CBC.2003.n.012; Takenawa T, 2001, J CELL SCI, V114, P1801; Takenawa T, 2007, NAT REV MOL CELL BIO, V8, P37, DOI 10.1038/nrm2069; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Teng Y, 2010, BRIT J CANCER, V103, P1066, DOI 10.1038/sj.bjc.6605850; Teng Y, 2012, J BIOL CHEM, V287, P10051, DOI 10.1074/jbc.M111.335000; Teng Y, 2011, INT J CANCER, V129, P2825, DOI 10.1002/ijc.25964; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007	45	63	64	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2014	33	2					203	211		10.1038/onc.2012.565	http://dx.doi.org/10.1038/onc.2012.565			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286BY	23318438	Green Accepted			2022-12-28	WOS:000329440700008
J	Lee, JM; Kim, B; Lee, SB; Jeong, Y; Oh, YM; Song, YJ; Jung, S; Choi, J; Lee, S; Cheong, KH; Kim, DU; Park, HW; Han, YK; Kim, GW; Choi, H; Song, PH; Kim, KA				Lee, J. M.; Kim, B.; Lee, S. B.; Jeong, Y.; Oh, Y. M.; Song, Y-J; Jung, S.; Choi, J.; Lee, S.; Cheong, K. H.; Kim, D. U.; Park, H. W.; Han, Y. K.; Kim, G. W.; Choi, H.; Song, P. H.; Kim, K. A.			Cbl-independent degradation of Met: ways to avoid agonism of bivalent Met-targeting antibody	ONCOGENE			English	Article						Met; Cbl; LRIG1; SAIT301; agonism	RECEPTOR TYROSINE KINASE; HEPATOCYTE GROWTH-FACTOR; C-MET; JUXTAMEMBRANE DOMAIN; DOWN-REGULATION; MUTATIONS; LRIG1; AMPLIFICATION; INHIBITORS; CANCER	The Met receptor tyrosine kinase, found to be constitutively activated in many tumors, has become a leading target for cancer therapy. Disruptions in Met downregulation have been associated with aggressive tumor progression with several therapeutic strategies addressing this aspect of Met biology. Castias B-lineage lymphoma (Cbl) E3 ligase-mediated degradation, which attenuates Met signaling via ligand-dependent Met internalization, is a major negative regulator of Met expression. It is believed that one of the mechanisms by which the therapeutic anti-Met antibodies induce cancer cell death in Met overexpressing tumors is via internalization and subsequent degradation of Met from the cell surface. However, a previously reported Met-targeting antibody demonstrated intrinsic agonistic activity while being capable of inducing Cbl-mediated degradation of Met, suggesting that Cbl-mediated degradation requires receptor activation and impedes therapeutic application. We have developed a potent and selective bivalent Met-targeting antibody (SAIT301) that invokes Met degradation using an alternative regulator LRIG1. In this report, we demonstrate that LRIG1 mediates degradation of Met by SAIT301 and this degradation does not require Met activation. Furthermore, SAIT301 was able to downregulate Met and dramatically inhibit growth of tumors with low or no Cbl expression, as well as tumors with Met exon 14 deletion that prevents Met binding to Cbl. In summary, we demonstrate the enhanced therapeutic potential of a novel tumor-inhibiting anti-Met antibody, SAIT301, which utilizes a Cbl-independent, LRIG1-mediated Met degradation pathway and thereby avoids the agonism that limits the effectiveness of previously reported anti-Met antibodies.	[Lee, J. M.; Kim, B.; Lee, S. B.; Jeong, Y.; Oh, Y. M.; Song, Y-J; Jung, S.; Choi, J.; Lee, S.; Cheong, K. H.; Kim, D. U.; Park, H. W.; Han, Y. K.; Kim, G. W.; Choi, H.; Song, P. H.; Kim, K. A.] Samsung Elect Co Ltd, Samsung Adv Inst Technol, BioTherapeut Lab, Yongin 446712, Gyeonggi Do, South Korea	Samsung	Kim, KA (corresponding author), Samsung Elect Co Ltd, Samsung Adv Inst Technol, BioTherapeut Lab, 95 Samsung2 Ro, Yongin 446712, Gyeonggi Do, South Korea.	ka10.kim@samsung.com	Jeong, Yunju/GRS-0008-2022; Lee, Ji Min/ABE-7494-2021	Lee, Ji Min/0000-0003-2978-2440	Korea Healthcare technology R&D project, Ministry for Health & Welfare Affairs, Republic of Korea [A092255]	Korea Healthcare technology R&D project, Ministry for Health & Welfare Affairs, Republic of Korea	This study was supported by a grant of the Korea Healthcare technology R&D project, Ministry for Health & Welfare Affairs, Republic of Korea (A092255). We thank Dr Sangyeul Han for critical discussion and Dr Ogan Gurel for discussion and editing the manuscript. pcDNA-LRIG1 expression plasmid was kindly provided by Dr Hakan Hedman.	Ancot F, 2012, TRAFFIC, V13, P1261, DOI 10.1111/j.1600-0854.2012.01384.x; Asaoka Y, 2010, BIOCHEM BIOPH RES CO, V394, P1042, DOI 10.1016/j.bbrc.2010.03.120; Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104; Benvenuti S, 2007, J CELL PHYSIOL, V213, P316, DOI 10.1002/jcp.21183; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; Comoglio PM, 2001, SEMIN CANCER BIOL, V11, P153, DOI 10.1006/scbi.2000.0366; CREPALDI T, 1994, J CELL BIOL, V125, P313, DOI 10.1083/jcb.125.2.313; Eder JP, 2009, CLIN CANCER RES, V15, P2207, DOI 10.1158/1078-0432.CCR-08-1306; Foveau B, 2009, MOL BIOL CELL, V20, P2495, DOI 10.1091/mbc.E08-09-0969; Greenall SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034658; Guo A, 2008, P NATL ACAD SCI USA, V105, P692, DOI 10.1073/pnas.0707270105; HAMBURGER AW, 1977, SCIENCE, V197, P461, DOI 10.1126/science.560061; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hedman H, 2007, EUR J CANCER, V43, P676, DOI 10.1016/j.ejca.2006.10.021; Jin HK, 2008, CANCER RES, V68, P4360, DOI 10.1158/0008-5472.CAN-07-5960; Kong-Beltran M, 2006, CANCER RES, V66, P283, DOI 10.1158/0008-5472.CAN-05-2749; Krumbach R, 2011, EUR J CANCER, V47, P1231, DOI 10.1016/j.ejca.2010.12.019; Lai AZ, 2012, J BIOL CHEM, V287, P8048, DOI 10.1074/jbc.M112.339820; Lefebvre J, 2012, FASEB J, V26, P1387, DOI 10.1096/fj.11-197723; Liu XD, 2010, TRENDS MOL MED, V16, P37, DOI 10.1016/j.molmed.2009.11.005; Ma PC, 2003, CANCER RES, V63, P6272; Nakagawa T, 2010, CANCER SCI, V101, P210, DOI 10.1111/j.1349-7006.2009.01343.x; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; Oh YM, MOL CELLS IN PRESS; Onozato R, 2009, J THORAC ONCOL, V4, P5, DOI 10.1097/JTO.0b013e3181913e0e; Ordonez-Moran P, 2012, EMBO J, V31, P2064, DOI 10.1038/emboj.2012.73; Pacchiana G, 2010, J BIOL CHEM, V285, P36149, DOI 10.1074/jbc.M110.134031; Petrelli A, 2006, P NATL ACAD SCI USA, V103, P5090, DOI 10.1073/pnas.0508156103; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Qin SA, 2010, J CLIN INVEST, V120, P3617, DOI 10.1172/JCI41531; Sanada M, 2009, NATURE, V460, P904, DOI 10.1038/nature08240; Schelter F, 2010, J BIOL CHEM, V285, P26335, DOI 10.1074/jbc.M110.106435; Sennino B, 2012, CANCER DISCOV, V2, P270, DOI 10.1158/2159-8290.CD-11-0240; Shattuck DL, 2007, MOL CELL BIOL, V27, P1934, DOI 10.1128/MCB.00757-06; Smolen GA, 2006, P NATL ACAD SCI USA, V103, P2316, DOI 10.1073/pnas.0508776103; Stellrecht CM, 2009, CANCER LETT, V280, P1, DOI 10.1016/j.canlet.2008.10.045; Stutz MA, 2008, ONCOGENE, V27, P5741, DOI 10.1038/onc.2008.185; Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012; Vigna E, 2008, CANCER RES, V68, P9176, DOI 10.1158/0008-5472.CAN-08-1688; Wong VWY, 2012, NAT CELL BIOL, V14, P401, DOI 10.1038/ncb2464; Zang ZJ, 2011, CANCER RES, V71, P29, DOI 10.1158/0008-5472.CAN-10-1749	42	57	59	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2014	33	1					34	43		10.1038/onc.2012.551	http://dx.doi.org/10.1038/onc.2012.551			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	282YU	23208509				2022-12-28	WOS:000329212000005
J	Turner-Ivey, B; Manevich, Y; Schulte, J; Kistner-Griffin, E; Jezierska-Drutel, A; Liu, Y; Neumann, CA				Turner-Ivey, B.; Manevich, Y.; Schulte, J.; Kistner-Griffin, E.; Jezierska-Drutel, A.; Liu, Y.; Neumann, C. A.			Role for Prdx1 as a specific sensor in redox-regulated senescence in breast cancer	ONCOGENE			English	Article						redox signaling; peroxiredoxin; senescence; oxidative stress; protein tyrosine phosphatases; p38MAPK	ACTIVATED PROTEIN-KINASE; N-TERMINAL KINASE; MAP KINASE; CATALYTIC ACTIVATION; PREMATURE SENESCENCE; P38; CELLS; PHOSPHATASE-1; PEROXIREDOXIN; STRESS	Recent studies suggest that Peroxiredoxin 1 (Prdx1), in addition to its known H2O2-scavenging function, mediates cell signaling through redox-specific protein-protein interactions. Our data illustrate how Prdx1 specifically coordinates p38MAPK-induced signaling through regulating p38MAPK alpha phosphatases in an H2O2 dose-dependent manner. MAPK phosphatases (MKP-1 and/or MKP-5), which are known to dephosphorylate and deactivate the senescence-inducing MAPK p38 alpha, belong to a group of redox-sensitive phosphatases (protein tyrosine phosphatases) characterized by a low pKa cysteine in their active sites. We found that Prdx1 bound to both MKP-1 and MKP-5, but dissociated from MKP-1 when the Prdx1 peroxidatic cysteine Cys52 was over-oxidized to sulfonic acid, which in turn resulted in MKP-1 oxidation-induced oligomerization and inactivity toward p38MAPK alpha. Conversely, over-oxidation of Prdx1-Cys52 was enhancing in the Prdx1:MKP-5 complex with increasing amounts of H2O2 concentrations and correlated with a protection from oxidation-induced oligomerization and inactivation of MKP-5 so that activation toward p38MAPK was maintained. Further examination of this Prdx1-specific mechanism in a model of reactive oxygen species-induced senescence of human breast epithelial cells revealed the specific activation of MKP-5, resulting in decreased p38MAPK alpha activity. Taken together, our data suggest that Prdx1 orchestrates redox signaling in an H2O2 dose-dependent manner through the oxidation status of its peroxidatic cysteine Cys52.	[Turner-Ivey, B.] Med Univ S Carolina, Dept Pathol, Charleston, SC 29425 USA; [Manevich, Y.; Schulte, J.; Jezierska-Drutel, A.; Neumann, C. A.] Med Univ S Carolina, Dept Cell & Mol Pharmacol & Expt Therapeut Med, Charleston, SC 29425 USA; [Kistner-Griffin, E.] Med Univ S Carolina, Dept Biostat & Epidemiol, Charleston, SC 29425 USA; [Liu, Y.] Nationwide Childrens Hosp, Res Inst, Dept Pediat, Columbus, OH USA; [Neumann, C. A.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15261 USA; [Neumann, C. A.] UPCI, Magee Womens Res Inst, Pittsburgh, PA 15213 USA	Medical University of South Carolina; Medical University of South Carolina; Medical University of South Carolina; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute	Neumann, CA (corresponding author), Univ Pittsburgh, Dept Pharmacol & Chem Biol, E1340 Thomas E Starzl Biomed Sci Tower 200 Lothro, Pittsburgh, PA 15261 USA.	neumannc@upmc.edu	Liu, Yusen/E-3527-2011	Neumann, Carola/0000-0003-2801-9531	 [K22 ES012985-01];  [W81XWH-07-1-0691];  [R01 CA131350];  [CCSG P30 CA138313];  [5T32CA119945-05]; NATIONAL CANCER INSTITUTE [P30CA138313, T32CA119945, R01CA131350] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K22ES012985] Funding Source: NIH RePORTER	; ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We would like to thank Dr Eisuke Nishida for providing the MKP-5 cDNA; Dr Yusen Liu for providing MKP-1 WT and MKP-1 C258S cDNA; and Dr Steve Rosenzweig and Dr Scott Eblen for fruitful discussions. This work has been funded by K22 ES012985-01 (CAN), W81XWH-07-1-0691 (CAN), R01 CA131350, CCSG P30 CA138313 (HCC) and 5T32CA119945-05 (BT).	Bar-Shira A, 2002, ONCOGENE, V21, P849, DOI 10.1038/sj.onc.1205127; Bowers RR, 2012, BIOCHEMISTRY-US, V51, P7740, DOI 10.1021/bi301006w; Cao JX, 2009, EMBO J, V28, P1505, DOI 10.1038/emboj.2009.101; Claiborne A, 1999, BIOCHEMISTRY-US, V38, P15407, DOI 10.1021/bi992025k; Coppe JP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009188; Coulthard LR, 2009, TRENDS MOL MED, V15, P369, DOI 10.1016/j.molmed.2009.06.005; Cross JV, 2006, ANTIOXID REDOX SIGN, V8, P1819, DOI 10.1089/ars.2006.8.1819; Dasari A, 2006, CANCER RES, V66, P10805, DOI 10.1158/0008-5472.CAN-06-1236; Dasgupta J, 2010, J CELL PHYSIOL, V225, P52, DOI 10.1002/jcp.22193; Day AM, 2012, MOL CELL, V45, P398, DOI 10.1016/j.molcel.2011.11.027; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013; Han JH, 2007, TRENDS BIOCHEM SCI, V32, P364, DOI 10.1016/j.tibs.2007.06.007; Han YH, 2005, FEBS LETT, V579, P4897, DOI 10.1016/j.febslet.2005.07.049; Hou N, 2008, ENDOCRINOLOGY, V149, P1654, DOI 10.1210/en.2007-0988; Hutter D, 2000, BIOCHEM J, V352, P155, DOI 10.1042/0264-6021:3520155; Iwasa H, 2003, GENES CELLS, V8, P131, DOI 10.1046/j.1365-2443.2003.00620.x; Jeong DG, 2006, J MOL BIOL, V360, P946, DOI 10.1016/j.jmb.2006.05.059; Kamata H, 2005, CELL, V120, P649, DOI 10.1016/j.cell.2004.12.041; Kim YJ, 2006, CANCER RES, V66, P7136, DOI 10.1158/0008-5472.CAN-05-4446; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Lee JJ, 2010, ONCOGENE, V29, P561, DOI 10.1038/onc.2009.355; LIU YS, 1995, J BIOL CHEM, V270, P8377, DOI 10.1074/jbc.270.15.8377; Neumann CA, 2003, NATURE, V424, P561, DOI 10.1038/nature01819; Neumann CA, 1998, BLOOD, V92, p215A; Neumann CA, 2009, CELL CYCLE, V8, P4072, DOI 10.4161/cc.8.24.10242; Neumann CA, 2007, CURR OPIN PHARMACOL, V7, P375, DOI 10.1016/j.coph.2007.04.007; Nonn L, 2006, CANCER RES, V66, P4516, DOI 10.1158/0008-5472.CAN-05-3796; Nonn L, 2007, CARCINOGENESIS, V28, P1188, DOI 10.1093/carcin/bgl241; Parra E, 2010, ONCOL REP, V24, P1339, DOI 10.3892/or_00000991; Peters GH, 1998, BIOCHEMISTRY-US, V37, P5383, DOI 10.1021/bi971187i; Rhee SG, 2006, SCIENCE, V312, P1882, DOI 10.1126/science.1130481; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Schilder YDC, 2009, FREE RADICAL BIO MED, V46, P1598, DOI 10.1016/j.freeradbiomed.2009.03.013; Schindler EM, 2009, CANCER RES, V69, P4648, DOI 10.1158/0008-5472.CAN-08-4455; Slack DN, 2001, J BIOL CHEM, V276, P16491, DOI 10.1074/jbc.M010966200; Staples CJ, 2010, J BIOL CHEM, V285, P25928, DOI 10.1074/jbc.M110.117911; Tanoue T, 2001, J BIOL CHEM, V276, P26629, DOI 10.1074/jbc.M101981200; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tephly LA, 2007, AM J RESP CELL MOL, V37, P366, DOI 10.1165/rcmb.2006-0268OC; Theodosiou A, 1999, ONCOGENE, V18, P6981, DOI 10.1038/sj.onc.1203185; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Tonks NK, 2006, NAT REV MOL CELL BIO, V7, P833, DOI 10.1038/nrm2039; Tonks NK, 2005, CELL, V121, P667, DOI 10.1016/j.cell.2005.05.016; Trost TM, 2005, CANCER RES, V65, P840; Wang WP, 2002, MOL CELL BIOL, V22, P3389, DOI 10.1128/MCB.22.10.3389-3403.2002; Wang ZQ, 2008, J BIOL CHEM, V283, P21011, DOI 10.1074/jbc.M802229200; Weyemi U, 2012, ONCOGENE, V31, P1117, DOI 10.1038/onc.2011.327; Zhou JY, 2006, CANCER RES, V66, P4888, DOI 10.1158/0008-5472.CAN-05-4229	50	59	64	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2013	32	45					5302	5314		10.1038/onc.2012.624	http://dx.doi.org/10.1038/onc.2012.624			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251IS	23334324	hybrid, Green Accepted			2022-12-28	WOS:000326922100006
J	Tsai, HY; Yang, YF; Wu, AT; Yang, CJ; Liu, YP; Jan, YH; Lee, CH; Hsiao, YW; Yeh, CT; Shen, CN; Lu, PJ; Huang, MS; Hsiao, M				Tsai, H-Y; Yang, Y-F; Wu, A. T.; Yang, C-J; Liu, Y-P; Jan, Y-H; Lee, C-H; Hsiao, Y-W; Yeh, C-T; Shen, C-N; Lu, P-J; Huang, M-S; Hsiao, M.			Endoplasmic reticulum ribosome-binding protein 1 (RRBP1) overexpression is frequently found in lung cancer patients and alleviates intracellular stress-induced apoptosis through the enhancement of GRP78	ONCOGENE			English	Article						RRBP1; GRP78; UPR; apoptosis; lung cancer	GLUCOSE-REGULATED PROTEINS; CHAPERONE GRP78/BIP; DRUG-RESISTANCE; ER; INDUCTION; RECEPTOR; IDENTIFICATION; PROLIFERATION; EXPRESSION; CHEMOTHERAPY	Lung cancer is the leading cause of cancer deaths and is the most occurring malignancy worldwide. Unraveling the molecular mechanisms involved in lung tumorigenesis will greatly improve therapy. During early tumorigenesis, rapid proliferating tumor cells require increased activity of endoplasmic reticulum (ER) for protein synthesis, folding and secretion, thereby are subjected to ER stress. Ribosome-binding protein 1 (RRBP1) was originally identified as a ribosome-binding protein located on the rough ER and associated with unfolding protein response (UPR). In this report, we investigated the role of RRBP1 in lung cancer. RRBP1 was highly expressed in lung cancer tissue, as compared with adjacent normal tissues as assessed by immunohistochemistry (IHC) using lung cancer tissue array (n=87). Knockdown of RRBP1 by short-hairpin RNAs caused ER stress and significantly reduced cell viability and tumorigenicity. This effect was associated with a significant reduction in the expression of glucose-regulated protein 78 (GRP78). UPR regulator GRP78, an anti-apoptotic protein that is widely upregulated in cancer, has a critical role in chemotherapy resistance in some cancers. According to our results, cells with a higher level of RRBP1 were more resistant to ER stress. Ectopic expression of RRBP1 alleviated apoptosis that was induced by the ER-stress agent tunicamycin, 2-deoxy-D-glucose (2DG) or doxorubicin via enhancing GRP78 protein expression. A strong correlation was observed between the expression of RRBP1 and GRP78 in tumor biopsies using the database GSE10072. Our results also indicated that RRBP1 may involve in the regulation of mRNA stability of UPR components including ATF6 and GRP78. Taken together, RRBP1 could alleviate ER stress and help cancer cell survive. RRBP1 is critical for tumor cell survival, which may make it a useful target in lung cancer treatment and a candidate for the development of new targeted therapeutics.	[Tsai, H-Y; Yang, Y-F] Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan; [Tsai, H-Y; Yang, Y-F; Jan, Y-H; Hsiao, Y-W; Shen, C-N; Hsiao, M.] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan; [Wu, A. T.] Taipei Med Univ, Coll Sci & Technol, PhD Program Translat Med, Taipei, Taiwan; [Yang, C-J; Huang, M-S] Kaohsiung Med Univ, Sch Med, Kaohsiung Med Univ Hosp, Dept Internal Med, Kaohsiung, Taiwan; [Liu, Y-P; Lu, P-J] Natl Cheng Kung Univ, Inst Clin Med, Tainan 70101, Taiwan; [Wu, A. T.] Taipei Med Univ Hosp, Ctr Canc, Translat Res Lab, Taipei, Taiwan; [Lee, C-H] Taipei Tzu Chi Gen Hosp, Dept Pharm, Taipei, Taiwan; [Yeh, C-T; Shen, C-N] Taipei Med Univ, Grad Inst Clin Med, Taipei, Taiwan; [Yeh, C-T] Taipei Med Univ, Shuang Ho Hosp, Ctr Canc, Taipei, Taiwan	National Yang Ming Chiao Tung University; Academia Sinica - Taiwan; Taipei Medical University; Kaohsiung Medical University; Kaohsiung Medical University Hospital; National Cheng Kung University; Taipei Medical University; Taipei Medical University Hospital; Buddhist Tzu Chi General Hospital; Taipei Medical University; Taipei Medical University; Shuang Ho Hospital	Hsiao, M (corresponding author), Acad Sinica, Genom Res Ctr, 128 Acad Rd,Sect 2, Taipei 115, Taiwan.	mhsiao@gate.sinica.edu.tw	Hsiao, Michael/U-6238-2019; SHEN, CHIA-NING/C-6878-2011	Hsiao, Michael/0000-0001-8529-9213; SHEN, CHIA-NING/0000-0002-0747-217X; Jan, Yi-Hua/0000-0001-7344-7602	National Science Council; Academia Sinica	National Science Council(Ministry of Science and Technology, Taiwan); Academia Sinica(Academia Sinica - Taiwan)	We thank Miss Tracy Tsai for assisting in the pathological staining analysis. RRBP1 plasmids were kindly provided by Dr Kiyoko, Japan Institute of Leather Research. The study was supported by grants from the National Science Council and Academia Sinica.	Arcamone F, 1997, PHARMACOL THERAPEUT, V76, P117, DOI 10.1016/S0163-7258(97)00096-X; Bai JZ, 2008, CELL BIOL INT, V32, P473, DOI 10.1016/j.cellbi.2007.10.002; Becker F, 1999, J CELL BIOL, V146, P273, DOI 10.1083/jcb.146.2.273; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bi MX, 2005, EMBO J, V24, P3470, DOI 10.1038/sj.emboj.7600777; Chang J, 2008, J PROTEOMICS, V71, P530, DOI 10.1016/j.jprot.2008.08.003; Cox JS, 1997, MOL BIOL CELL, V8, P1805, DOI 10.1091/mbc.8.9.1805; Cui XA, 2012, PLOS BIOL, V10, P1; Dong DZ, 2008, CANCER RES, V68, P498, DOI 10.1158/0008-5472.CAN-07-2950; FIDLER IJ, 1990, CANCER RES, V50, P6130; Fu Y, 2006, CANCER BIOL THER, V5, P741, DOI 10.4161/cbt.5.7.2970; Fulda S, 2006, ONCOGENE, V25, P4798, DOI 10.1038/sj.onc.1209608; Greenlee RT, 2001, CA-CANCER J CLIN, V51, P15, DOI 10.3322/canjclin.51.1.15; Hoffman RM, 1999, INVEST NEW DRUG, V17, P343, DOI 10.1023/A:1006326203858; Hoffman RM, 2005, NAT REV CANCER, V5, P796, DOI 10.1038/nrc1717; Hoffman RM, 2006, NAT PROTOC, V1, P928, DOI 10.1038/nprot.2006.119; Hyde M, 2002, J CELL BIOL, V156, P993, DOI 10.1083/jcb.200112008; Jamora C, 1996, P NATL ACAD SCI USA, V93, P7690, DOI 10.1073/pnas.93.15.7690; Kim YJ, 2000, GENE, V261, P337, DOI 10.1016/S0378-1119(00)00496-0; Kong Q, 1998, MED HYPOTHESES, V51, P405, DOI 10.1016/S0306-9877(98)90036-6; Krasnov GS, 2009, MOL BIOL+, V43, P321, DOI 10.1134/S0026893309020149; Kurtoglu M, 2007, MOL CANCER THER, V6, P3049, DOI 10.1158/1535-7163.MCT-07-0310; Langley R, 1998, DNA CELL BIOL, V17, P449, DOI 10.1089/dna.1998.17.449; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Li JZ, 2006, CURR MOL MED, V6, P45, DOI 10.2174/156652406775574523; Maschek G, 2004, CANCER RES, V64, P31, DOI 10.1158/0008-5472.CAN-03-3294; MUNRO S, 1986, CELL, V46, P291, DOI 10.1016/0092-8674(86)90746-4; Ogawa-Goto K, 2002, J VIROL, V76, P2350, DOI 10.1128/JVI.76.5.2350-2362.2002; Onn A, 2003, CLIN CANCER RES, V9, P5532; Pyrko P, 2007, CANCER RES, V67, P9809, DOI 10.1158/0008-5472.CAN-07-0625; Ranganathan AC, 2006, CANCER RES, V66, P1702, DOI 10.1158/0008-5472.CAN-05-3092; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; Sasaya H, 2008, J BIOCHEM, V144, P251, DOI 10.1093/jb/mvn063; SAVITZ AJ, 1990, NATURE, V346, P540, DOI 10.1038/346540a0; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Shepherd FA, 2000, J CLIN ONCOL, V18, p35S; Sobin LH, 1997, CANCER, V80, P1803, DOI 10.1002/(SICI)1097-0142(19971101)80:9<1803::AID-CNCR16>3.0.CO;2-9; Spear E, 2001, TRAFFIC, V2, P515, DOI 10.1034/j.1600-0854.2001.20801.x; Strauss GM, 2005, HEMATOL ONCOL CLIN N, V19, P263, DOI 10.1016/j.hoc.2005.02.008; Travis WD, 2002, CLIN CHEST MED, V23, P65, DOI 10.1016/S0272-5231(03)00061-3; Uramoto H, 2005, LUNG CANCER, V49, P55, DOI 10.1016/j.lungcan.2004.12.011; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Virrey JJ, 2008, MOL CANCER RES, V6, P1268, DOI 10.1158/1541-7786.MCR-08-0060; Wang Q, 2005, CANCER DETECT PREV, V29, P544, DOI 10.1016/j.cdp.2005.09.010; WANKER EE, 1995, J CELL BIOL, V130, P29, DOI 10.1083/jcb.130.1.29; Yang M, 1998, CANCER RES, V58, P4217; Yeung BHY, 2008, ONCOGENE, V27, P6782, DOI 10.1038/onc.2008.290	50	62	62	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2013	32	41					4921	4931		10.1038/onc.2012.514	http://dx.doi.org/10.1038/onc.2012.514			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235KQ	23318453				2022-12-28	WOS:000325717800008
J	Malatesta, M; Peschiaroli, A; Memmi, EM; Zhang, J; Antonov, A; Green, DR; Barlev, NA; Garabadgiu, AV; Zhou, P; Melino, G; Bernassola, F				Malatesta, M.; Peschiaroli, A.; Memmi, E. M.; Zhang, J.; Antonov, A.; Green, D. R.; Barlev, N. A.; Garabadgiu, A. V.; Zhou, P.; Melino, G.; Bernassola, F.			The Cul4A-DDB1 E3 ubiquitin ligase complex represses p73 transcriptional activity	ONCOGENE			English	Article						apoptosis; p73; protein ubiquitylation	TUMOR-SUPPRESSOR FUNCTIONS; DNA-DAMAGE; PROTEIN; CELLS; DDB1; STABILITY; MDM2; P53; DEGRADATION; INSTABILITY	The Cullin4A (cul4A)-dependent ligase (CDL4A) E3 has been implicated in a variety of biological processes, including cell cycle progression and DNA damage response. Remarkably, CDL4A exerts its function through both proteolytic and non-proteolytic events. Here, we show that the p53 family member p73 is able to interact with the CDL4A complex through its direct binding to the receptor subunit DNA-binding protein 1 (DDB1). As a result, the CDL4A complex is able to monoubiquitylate p73. Modification of p73 by CDL4A-mediated ubiquitylation does not affect p73 protein stability, but negatively regulates p73-dependent transcriptional activity. Indeed, genetic or RNA interference-mediated depletion of DDB1 induces the expression of several p73 target genes in a p53-independent manner. In addition, by exploiting a bioinformatic approach, we found that elevated expression of Cul4A in human breast carcinomas is associated with repression of p73 target genes. In conclusion, our findings add a novel insight into the regulation of p73 by the CDL4A complex, through the inhibition of its transcriptional function.	[Malatesta, M.; Memmi, E. M.; Melino, G.; Bernassola, F.] Univ Roma Tor Vergata, Dept Expt Med & Surg, I-00133 Rome, Italy; [Peschiaroli, A.; Melino, G.] Univ Roma Tor Vergata, IDI IRCCS, Biochem Lab, Dept Expt Med & Surg, I-00133 Rome, Italy; [Peschiaroli, A.] CNR, Inst Cellular Biol & Neurobiol, Dept Biomed, Rome, Italy; [Zhang, J.; Zhou, P.] Weill Cornell Med Coll, Dept Pathol & Lab Med, New York, NY USA; [Zhang, J.; Zhou, P.] Weill Cornell Grad Sch Med Sci, New York, NY USA; [Antonov, A.; Melino, G.] Univ Leicester, MRC, Toxicol Unit, Leicester, Leics, England; [Green, D. R.] St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA; [Barlev, N. A.; Garabadgiu, A. V.; Melino, G.] St Petersburg State Inst Technol, St Petersburg, Russia; [Barlev, N. A.] Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England; [Bernassola, F.] European Inst Oncol, Dept Expt Oncol, Milan, Italy	University of Rome Tor Vergata; IRCCS Istituto Dermopatico dell'Immacolata (IDI); University of Rome Tor Vergata; Consiglio Nazionale delle Ricerche (CNR); Cornell University; Cornell University; Qatar Foundation (QF); Weill Cornell Medical College Qatar; University of Leicester; St Jude Children's Research Hospital; Saint Petersburg State Institute of Technology; University of Leicester; IRCCS European Institute of Oncology (IEO)	Melino, G (corresponding author), Univ Roma Tor Vergata, IDI IRCCS, Biochem Lab, Dept Expt Med & Surg, Via Montpellier 1, I-00133 Rome, Italy.	gerry.melino@uniroma2.it; bernasso@uniroma2.it	Green, Douglas R/N-8083-2018; Barlev, Nikolai A/K-5268-2017	Green, Douglas R/0000-0002-7332-1417; Barlev, Nikolai A/0000-0001-7111-2446; PESCHIAROLI, ANGELO/0000-0001-6311-2382; Garabadjiu, Alexander/0000-0001-9972-8517	MIUR/PRIN [20078P7T3K_001, (20078P7T3K_001)/FIRB, RBIP06LCA9_0023, RBIP06LCA9_0C, 2008MRLSNZ_004]; AIRC [9202, 2008-2010_33-08, 5471]; Medical Research Council, UK; Odysseus, Belgium; VIB, Belgium; Alleanza contro il Cancro [ACC12]; AIRC 5xmille [9979]; Ric Finalizzata [08-GIOV_RIC]; NIH [2R01CA098210, 5R01CA 118085]; RFBS [10-04-01234]; MCB RAS; Russian Federal grants [16.740.11.036, 11.G34.31.0069]; US NIH; Medical Research Council [MC_U132670600] Funding Source: researchfish; MRC [MC_U132670600] Funding Source: UKRI; NATIONAL CANCER INSTITUTE [R01CA118085, R01CA098210] Funding Source: NIH RePORTER	MIUR/PRIN(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); AIRC(Fondazione AIRC per la ricerca sul cancro); Medical Research Council, UK(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Odysseus, Belgium; VIB, Belgium; Alleanza contro il Cancro; AIRC 5xmille(Fondazione AIRC per la ricerca sul cancro); Ric Finalizzata; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); RFBS; MCB RAS; Russian Federal grants; US NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Michele Pagano for fruitful discussions on the topics covered in this article, and to Emre Sayan for providing the His-p73 alpha recombinant protein. This work has been supported by the MIUR/PRIN grant 20078P7T3K_001 and AIRC grant 9202 awarded to FB, the Medical Research Council, UK; Odysseus and VIB, Belgium; grants from 'Alleanza contro il Cancro' (ACC12), MIUR/PRIN (20078P7T3K_001)/FIRB (RBIP06LCA9_0023, RBIP06LCA9_0C), AIRC (2008-2010_33-08) (grant number 5471), AIRC 5xmille (grant number 9979), MIUR/PRIN 2008MRLSNZ_004 to GM, the Ric Finalizzata 08-GIOV_RIC awarded to AP, the NIH grants 2R01CA098210, 5R01CA 118085 and Irma T Hirschl Career Scientist Award to PZ. This work was supported by funding from RFBS (10-04-01234), MCB RAS, Russian Federal grants 16.740.11.036 (to NB) and 11.G34.31.0069 (to GM). DRG was supported by grants from the US NIH.	Angers S, 2006, NATURE, V443, P590, DOI 10.1038/nature05175; Banks D, 2006, CELL CYCLE, V5, P1719, DOI 10.4161/cc.5.15.3150; Busuttil V, 2010, P NATL ACAD SCI USA, V107, P18061, DOI 10.1073/pnas.1006163107; Cang Y, 2007, P NATL ACAD SCI USA, V104, P2733, DOI 10.1073/pnas.0611311104; Cang Y, 2006, CELL, V127, P929, DOI 10.1016/j.cell.2006.09.045; Chen LC, 1998, CANCER RES, V58, P3677; Chen XA, 2001, J BIOL CHEM, V276, P48175, DOI 10.1074/jbc.M106808200; Choi SH, 2010, GENE DEV, V24, P1236, DOI 10.1101/gad.1920310; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Greer SF, 2003, NAT IMMUNOL, V4, P1074, DOI 10.1038/ni985; Groisman R, 2003, CELL, V113, P357, DOI 10.1016/S0092-8674(03)00316-7; Hannah J, 2009, DNA REPAIR, V8, P536, DOI 10.1016/j.dnarep.2009.01.011; HERSHKOVITZROKA.O, 2010, PLOS ONE, V5; Higa LA, 2006, NAT CELL BIOL, V8, P1277, DOI 10.1038/ncb1490; Hu J, 2004, NAT CELL BIOL, V6, P1003, DOI 10.1038/ncb1172; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kopanja D, 2009, ONCOGENE, V28, P2456, DOI 10.1038/onc.2009.86; Lee J, 2007, MOL CELL, V26, P775, DOI 10.1016/j.molcel.2007.06.001; Leung-Pineda V, 2009, CANCER RES, V69, P2630, DOI 10.1158/0008-5472.CAN-08-3382; Li T, 2006, CELL, V124, P105, DOI 10.1016/j.cell.2005.10.033; Liu LR, 2009, MOL CELL, V34, P451, DOI 10.1016/j.molcel.2009.04.020; Melino G, 2004, J BIOL CHEM, V279, P8076, DOI 10.1074/jbc.M307469200; Nag A, 2004, CANCER RES, V64, P8152, DOI 10.1158/0008-5472.CAN-04-2598; Nishitani H, 2008, J BIOL CHEM, V283, P29045, DOI 10.1074/jbc.M806045200; Peschiaroli A, 2009, ONCOGENE, V28, P3157, DOI 10.1038/onc.2009.177; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Sayan AE, 2005, BIOCHEM BIOPH RES CO, V330, P186, DOI 10.1016/j.bbrc.2005.02.145; Tomasini R, 2008, GENE DEV, V22, P2677, DOI 10.1101/gad.1695308; van der Horst A, 2006, NAT CELL BIOL, V8, P1064, DOI 10.1038/ncb1469	30	21	21	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2013	32	39					4721	4726		10.1038/onc.2012.463	http://dx.doi.org/10.1038/onc.2012.463			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226YD	23085759				2022-12-28	WOS:000325072200014
J	Rohwer, N; Zasada, C; Kempa, S; Cramer, T				Rohwer, N.; Zasada, C.; Kempa, S.; Cramer, T.			The growing complexity of HIF-1 alpha's role in tumorigenesis: DNA repair and beyond	ONCOGENE			English	Review						HIF-alpha; cancer; hypoxia; metabolism; DNA-damage response; tumour heterogeneity	HYPOXIA-INDUCIBLE FACTOR-1; ENDOTHELIAL GROWTH-FACTOR; CANCER-CELLS; TRANSCRIPTIONAL ACTIVITY; GASTRIC CARCINOGENESIS; INDUCED ACCUMULATION; GLUCOSE-METABOLISM; VEGF EXPRESSION; GENE-EXPRESSION; DAMAGE RESPONSE	Lack of oxygen (hypoxia) is a central hallmark of cancer and a pivotal driving force of malignant progression. Transcriptional activators of the hypoxia-inducible factor a (HIF alpha) family represent the principal molecular mediators of hypoxia under both physiological and pathophysiological conditions. While HIF-2 alpha is expressed in a tissue-and cell-type-restricted manner, stabilization of HIF-1 alpha was reported in tumours of widely different origin, and functional analyses led to the perception of HIF-1 alpha as an oncoprotein. In this review, we aim to acknowledge HIF alpha's growing complexity by outlining its functional relevance for genomic integrity and tumour heterogeneity, two features of paramount importance for basic and clinical oncology. Pharmaceutical companies around the globe are ambitiously hunting for HIF-1 alpha-inhibiting compounds, some of which are currently being evaluated in phase 1 trials. To avoid the rather disappointing clinical efficacy emblematic of most targeted therapeutics, potential resistance mechanisms of, as well as potential combination partners for, HIF-1 alpha-inhibiting drugs should be evaluated. In this regard, the interrelation of HIF-1 alpha with genomic integrity and tumour heterogeneity offers ample possibilities, potentially resulting in more efficient clinical translation of HIF-1 alpha's pathobiology.	[Rohwer, N.; Cramer, T.] Charite, Med Klin Schwerpunkt Hepatol & Gastroenterol, D-13353 Berlin, Germany; [Zasada, C.; Kempa, S.] Max Delbruck Ctr Mol Med, Berlin Inst Med Syst Biol, Berlin, Germany; [Cramer, T.] Charite, Mol Krebsforsch Zentrum, D-13353 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Cramer, T (corresponding author), Charite, Med Klin Schwerpunkt Hepatol & Gastroenterol, Campus Virchow Klinikum,Augustenburger Pl 1, D-13353 Berlin, Germany.	thorsten.cramer@charite.de	kempa, stefan/C-5213-2008; Cramer, Thorsten/S-2479-2016	kempa, stefan/0000-0002-0696-9299; Cramer, Thorsten/0000-0002-6462-239X; Zasada, Christin/0000-0003-1547-8317; Rohwer, Nadine/0000-0001-6170-1327	Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe; Bundesministerium fur Bildung und Forschung; Cancer Research United Kingdom; Senate of Berlin	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Deutsche Krebshilfe(Deutsche Krebshilfe); Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF)); Cancer Research United Kingdom(Cancer Research UK); Senate of Berlin	Research in the Cramer laboratory is supported by grants from the Deutsche Forschungsgemeinschaft, the Deutsche Krebshilfe, the Bundesministerium fur Bildung und Forschung and (in collaboration) Cancer Research United Kingdom. Stefan Kempa received funding by the Bundesministerium fur Bildung und Forschung and the Senate of Berlin. We thank the members of our laboratories and our collaborators for helpful discussions.	Agani FH, 2000, J BIOL CHEM, V275, P35863, DOI 10.1074/jbc.M005643200; Anderson CJ, 2006, ONCOGENE, V25, P61, DOI 10.1038/sj.onc.1209011; Artandi SE, 2010, CARCINOGENESIS, V31, P9, DOI 10.1093/carcin/bgp268; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Bertheau P, 1998, J CLIN PATHOL, V51, P370, DOI 10.1136/jcp.51.5.370; Bertout JA, 2009, P NATL ACAD SCI USA, V106, P14391, DOI 10.1073/pnas.0907357106; Biswas S, 2010, J ONCOL, V2010, DOI 10.1155/2010/757908; Blouw B, 2003, CANCER CELL, V4, P133, DOI 10.1016/S1535-6108(03)00194-6; Bolderson E, 2009, CLIN CANCER RES, V15, P6314, DOI 10.1158/1078-0432.CCR-09-0096; Brahimi-Horn MC, 2011, CURR OPIN GENET DEV, V21, P67, DOI 10.1016/j.gde.2010.10.006; Bristow RG, 2008, NAT REV CANCER, V8, P180, DOI 10.1038/nrc2344; BROWN JM, 1979, BRIT J RADIOL, V52, P650, DOI 10.1259/0007-1285-52-620-650; Calviello G, 2004, CARCINOGENESIS, V25, P2303, DOI 10.1093/carcin/bgh265; Cam H, 2010, MOL CELL, V40, P509, DOI 10.1016/j.molcel.2010.10.030; Carling D, 2004, TRENDS BIOCHEM SCI, V29, P18, DOI 10.1016/j.tibs.2003.11.005; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; CHAPLIN DJ, 1987, CANCER RES, V47, P597; Ciccia A, 2010, MOL CELL, V40, P179, DOI 10.1016/j.molcel.2010.09.019; Coussens M, 2010, P NATL ACAD SCI USA, V107, P13842, DOI 10.1073/pnas.0913834107; Dang CV, 2010, CANCER RES, V70, P859, DOI 10.1158/0008-5472.CAN-09-3556; Daskalow K, 2010, J MOL MED, V88, P817, DOI 10.1007/s00109-010-0623-4; De Bels D, 2011, NEW ENGL J MED, V365, P1845, DOI 10.1056/NEJMc1110602; DeBerardinis RJ, 2008, CELL METAB, V7, P11, DOI 10.1016/j.cmet.2007.10.002; Denekamp J, 1999, ACTA ONCOL, V38, P903, DOI 10.1080/028418699432590; Dewhirst MW, 2008, NAT REV CANCER, V8, P425, DOI 10.1038/nrc2397; Elser M, 2008, MOL CANCER RES, V6, P282, DOI 10.1158/1541-7786.MCR-07-0377; Evans SM, 2001, AM J CLIN ONCOL-CANC, V24, P467, DOI 10.1097/00000421-200110000-00011; Fan TWM, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-41; Fojo T, 2010, CLIN CANCER RES, V16, P5972, DOI 10.1158/1078-0432.CCR-10-1277; Frede S, 2007, METHOD ENZYMOL, V435, P405, DOI 10.1016/S0076-6879(07)35021-0; Frezza C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024411; Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205; Gordan JD, 2008, CANCER CELL, V14, P435, DOI 10.1016/j.ccr.2008.10.016; Graeber TG, 1996, NATURE, V379, P88, DOI 10.1038/379088a0; Griffiths EA, 2008, BRIT J CANCER, V98, P965, DOI 10.1038/sj.bjc.6604210; Griffiths EA, 2007, BRIT J CANCER, V96, P95, DOI 10.1038/sj.bjc.6603524; Guo SH, 2009, J NEUROCHEM, V108, P1309, DOI 10.1111/j.1471-4159.2009.05877.x; Haase VH, 2009, KIDNEY INT, V76, P492, DOI 10.1038/ki.2009.222; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Holmquist-Mengelbier L, 2006, CANCER CELL, V10, P413, DOI 10.1016/j.ccr.2006.08.026; Hu CJ, 2007, MOL BIOL CELL, V18, P4528, DOI 10.1091/mbc.E06-05-0419; Huang LE, 2007, J MOL MED, V85, P139, DOI 10.1007/s00109-006-0133-6; Huen MSY, 2010, NAT REV MOL CELL BIO, V11, P138, DOI 10.1038/nrm2831; Jacobs T, 1996, LAB INVEST, V74, P88; KALLINOWSKI F, 1987, J CANCER RES CLIN, V113, P209, DOI 10.1007/BF00396375; Kang HJ, 2006, J BIOL CHEM, V281, P13047, DOI 10.1074/jbc.M513033200; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Kasper LH, 2005, EMBO J, V24, P3846, DOI 10.1038/sj.emboj.7600846; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Lau KW, 2007, BRIT J CANCER, V96, P1284, DOI 10.1038/sj.bjc.6603675; Li Z, 2009, CANCER CELL, V15, P501, DOI 10.1016/j.ccr.2009.03.018; Liao D, 2007, CANCER RES, V67, P563, DOI 10.1158/0008-5472.CAN-06-2701; Lienard BM, 2008, CHEM COMMUN, P6393, DOI 10.1039/b814440k; Liu LD, 2012, NATURE, V483, P608, DOI 10.1038/nature10927; Loenarz C, 2011, TRENDS BIOCHEM SCI, V36, P7, DOI 10.1016/j.tibs.2010.07.002; Lord CJ, 2008, CURR OPIN PHARMACOL, V8, P363, DOI 10.1016/j.coph.2008.06.016; Lord CJ, 2012, NATURE, V481, P287, DOI 10.1038/nature10760; Losso JN, 2005, J AGR FOOD CHEM, V53, P3751, DOI 10.1021/jf0479719; Lukas J, 2011, NAT CELL BIOL, V13, P1161, DOI 10.1038/ncb2344; Makino Y, 2001, NATURE, V414, P550, DOI 10.1038/35107085; Martin-Oliva D, 2006, CANCER RES, V66, P5744, DOI 10.1158/0008-5472.CAN-05-3050; Martinez-Romero R, 2008, J CELL BIOCHEM, V104, P2248, DOI 10.1002/jcb.21781; Maynard MA, 2003, J BIOL CHEM, V278, P11032, DOI 10.1074/jbc.M208681200; Medema RH, 2012, ONCOGENE, V31, P2601, DOI 10.1038/onc.2011.451; Melvin A, 2012, CELL SIGNAL, V24, P35, DOI 10.1016/j.cellsig.2011.08.019; Merighi S, 2007, MOL PHARMACOL, V72, P395, DOI 10.1124/mol.106.032920; Nanduri J, 2009, P NATL ACAD SCI USA, V106, P1199, DOI 10.1073/pnas.0811018106; Nilsson H, 2005, EXP CELL RES, V303, P447, DOI 10.1016/j.yexcr.2004.10.003; Nishi H, 2004, MOL CELL BIOL, V24, P6076, DOI 10.1128/MCB.24.13.6076-6083.2004; Palayoor ST, 2003, CLIN CANCER RES, V9, P3150; Peng YJ, 2006, J PHYSIOL-LONDON, V577, P705, DOI 10.1113/jphysiol.2006.114033; Rajendran JG, 2004, CLIN CANCER RES, V10, P2245, DOI 10.1158/1078-0432.CCR-0688-3; Raza A, 2010, AM J HEMATOL, V85, P593, DOI 10.1002/ajh.21745; Reinhold H S, 1977, Bibl Anat, P270; Roberts AM, 2009, CANCER RES, V69, P9056, DOI 10.1158/0008-5472.CAN-09-1770; Rohwer N, 2009, BRIT J CANCER, V100, P772, DOI 10.1038/sj.bjc.6604919; Rohwer N, 2011, DRUG RESIST UPDATE, V14, P191, DOI 10.1016/j.drup.2011.03.001; Rohwer N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012038; Rundqvist H, 2010, CURR TOP MICROBIOL, V345, P121, DOI 10.1007/82_2010_77; Schmitt CA, 2007, BBA-REV CANCER, V1775, P5, DOI 10.1016/j.bbcan.2006.08.005; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2000, BIOCHEM PHARMACOL, V59, P47, DOI 10.1016/S0006-2952(99)00292-0; Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009; Sendoel A, 2010, NATURE, V465, P577, DOI 10.1038/nature09141; Sermeus A, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.48; Shall S, 2000, MUTAT RES-DNA REPAIR, V460, P1, DOI 10.1016/S0921-8777(00)00016-1; Soucek T, 2003, NEURON, V39, P43, DOI 10.1016/S0896-6273(03)00367-2; Sullivan R, 2009, MOL CANCER THER, V8, P1702, DOI 10.1158/1535-7163.MCT-08-1090; Takiyama Y, 2011, DIABETES, V60, P981, DOI 10.2337/db10-0655; Thomas R, 2005, BIOCHEM BIOPH RES CO, V334, P543, DOI 10.1016/j.bbrc.2005.06.114; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; van der Groep P, 2008, BREAST CANCER RES TR, V111, P475, DOI 10.1007/s10549-007-9817-z; Vander Heiden MG, 2011, NAT REV DRUG DISCOV, V10, P671, DOI 10.1038/nrd3504; Vaupel P, 2004, METHOD ENZYMOL, V381, P335; Wamelink M, 2008, J INHERIT METAB DIS, V31, P703, DOI 10.1007/s10545-008-1015-6; Wang F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010002; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Warburg O, 1927, J GEN PHYSIOL, V8, P519, DOI 10.1085/jgp.8.6.519; Weidemann A, 2008, CELL DEATH DIFFER, V15, P621, DOI 10.1038/cdd.2008.12; Wiesener MS, 2002, FASEB J, V16, P271, DOI 10.1096/fj.02-0445fje; Wirthner R, 2008, CARCINOGENESIS, V29, P2306, DOI 10.1093/carcin/bgn231; Xenaki G, 2008, ONCOGENE, V27, P5785, DOI 10.1038/onc.2008.192; YAMAURA H, 1979, INT J RADIAT BIOL, V35, P201, DOI 10.1080/09553007914550241; Yap TA, 2011, CA-CANCER J CLIN, V61, P31, DOI 10.3322/caac.20095; Yatabe N, 2004, ONCOGENE, V23, P3708, DOI 10.1038/sj.onc.1207460; Yoo YG, 2006, EMBO J, V25, P1231, DOI 10.1038/sj.emboj.7601025; Yuan GX, 2005, J BIOL CHEM, V280, P4321, DOI 10.1074/jbc.M407706200; Zhang QZ, 2005, MOL CANCER THER, V4, P1465, DOI 10.1158/1535-7163.MCT-05-0198; Zhu XY, 2008, LIFE SCI, V83, P801, DOI 10.1016/j.lfs.2008.09.029	112	56	62	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 1	2013	32	31					3569	3576		10.1038/onc.2012.510	http://dx.doi.org/10.1038/onc.2012.510			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	194MW	23160373				2022-12-28	WOS:000322638400001
J	Puebla-Osorio, N; Kim, J; Ojeda, S; Zhang, H; Tavana, O; Li, S; Wang, Y; Ma, Q; Schluns, KS; Zhu, C				Puebla-Osorio, N.; Kim, J.; Ojeda, S.; Zhang, H.; Tavana, O.; Li, S.; Wang, Y.; Ma, Q.; Schluns, K. S.; Zhu, C.			A novel Ku70 function in colorectal homeostasis separate from nonhomologous end joining	ONCOGENE			English	Article						nonhomologous end joining; Ku70; colorectal cancer; senescence; beta-catenin; Wnt signaling	DEPENDENT PROTEIN-KINASE; DOUBLE-STRAND BREAKS; DNA-DAMAGE; STEM-CELLS; CYCLIN D1; REPAIR; GENE; TUMORIGENESIS; BINDING; CANCER	Ku70, a known nonhomologous end-joining (NHEJ) factor, also functions in tumor suppression, although this molecular mechanism remains uncharacterized. Previously, we showed that mice deficient for DNA ligase IV (Lig4), another key NHEJ factor, succumbed to aggressive lymphoma in the absence of tumor suppressor p53. However, the tumor phenotype is abrogated by the introduction of a hypomorphic mutant p53(R172P), which impaired p53-mediated apoptosis but not cell-cycle arrest. However, Lig4(-/-)p53(R172P) mice succumbed to severe diabetes. To further elucidate the role of NHEJ and p53-mediated apoptosis in vivo, we bred Ku70(-/-) p53(R172P) mice. Unexpectedly, these mice were free of diabetes, although 80% of the mutant mice had abnormally enlarged colons with pronounced inflammation. Remarkably, most of these mutant mice progressed to dysplasia, adenoma and adenocarcinoma; this is in contrast to the Lig4(-/-) p53(R172P) phenotype, strongly suggesting an NHEJ-independent function of Ku70. Significantly, our analyses of Ku70(-/-) p53(R172P) colonic epithelial cells show nuclear stabilization of beta-catenin accompanied by higher expression of cyclin D1 and c-Myc in affected colon sections than in control samples. This is not due to the p53 mutation, as Ku70(-/-) mice share this phenotype. Our results not only unravel a novel function of Ku70 essential for colon homeostasis, but also establish an excellent in vivo model in which to study how chronic inflammation and abnormal cellular proliferation underlie tumorigenesis and tumor progression in the colon.	[Puebla-Osorio, N.; Kim, J.; Ojeda, S.; Zhang, H.; Tavana, O.; Li, S.; Wang, Y.; Schluns, K. S.; Zhu, C.] Univ Texas MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA; [Tavana, O.; Ma, Q.; Schluns, K. S.; Zhu, C.] Univ Texas Houston, Grad Sch Biomed Sci, Houston, TX USA; [Ma, Q.] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; University of Texas System; UTMD Anderson Cancer Center	Zhu, C (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Immunol, Unit 902,1515 Holcombe Blvd, Houston, TX 77030 USA.	czhu@mdanderson.org	Zhang, Huiyuan/J-2784-2016; Schluns, Kimberly/R-5635-2019	Zhang, Huiyuan/0000-0002-1532-2462; Tavana, Omid/0000-0001-8401-4546; Puebla, Nahum/0000-0001-6498-5230	Institutional Research Grant; sister Institution Fund from The University of Texas MD Anderson Cancer Center; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	Institutional Research Grant; sister Institution Fund from The University of Texas MD Anderson Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the histology core facility from the Department of Immunology at The University of Texas MD Anderson Cancer Center. We thank Dr James You for the help with pathology and Mei Sang for her technical assistance. This study was partially supported by an Institutional Research Grant (CZ) and a sister Institution Fund from The University of Texas MD Anderson Cancer Center (CZ).	Bassing CH, 2004, DNA REPAIR, V3, P781, DOI 10.1016/j.dnarep.2004.06.001; Becker C, 2005, CELL CYCLE, V4, P217; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; Crosnier C, 2006, NAT REV GENET, V7, P349, DOI 10.1038/nrg1840; Difilippantonio MJ, 2002, J EXP MED, V196, P469, DOI 10.1084/jem.20020851; Erdman SE, 2010, TOXICOL PATHOL, V38, P76, DOI 10.1177/0192623309354110; Fearnhead NS, 2002, BRIT MED BULL, V64, P27, DOI 10.1093/bmb/64.1.27; Fell VL, 2012, MOL CELL BIOL, V32, P76, DOI 10.1128/MCB.05661-11; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Frank KM, 1998, NATURE, V396, P173, DOI 10.1038/24172; Gao YJ, 2000, NATURE, V404, P897, DOI 10.1038/35009138; Gao YJ, 1998, CELL, V95, P891, DOI 10.1016/S0092-8674(00)81714-6; Gersemann M, 2009, DIFFERENTIATION, V77, P84, DOI 10.1016/j.diff.2008.09.008; Goldstein NS, 2006, AM J CLIN PATHOL, V125, P146, DOI 10.1309/87BD0C6UCGUG126J; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Gu YS, 1997, P NATL ACAD SCI USA, V94, P8076, DOI 10.1073/pnas.94.15.8076; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hoverter NP, 2012, MOL CELL BIOL, V32, P3648, DOI 10.1128/MCB.06769-11; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Kavela S, 2013, CANCER RES, V73, P205, DOI 10.1158/0008-5472.CAN-12-1394; Lao VV, 2011, NAT REV GASTRO HEPAT, V8, P686, DOI 10.1038/nrgastro.2011.173; Lefrancois L, 2001, CURR PROTOC IMMUNOL, V3; Li GC, 1998, MOL CELL, V2, P1, DOI 10.1016/S1097-2765(00)80108-2; Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537; Liu G, 2004, NAT GENET, V36, P63, DOI 10.1038/ng1282; Ma YM, 2002, CELL, V108, P781, DOI 10.1016/S0092-8674(02)00671-2; Mahaney BL, 2009, BIOCHEM J, V417, P639, DOI 10.1042/BJ20080413; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Novac O, 2001, MOL BIOL CELL, V12, P3386, DOI 10.1091/mbc.12.11.3386; Pfingsten JS, 2012, CELL, V148, P922, DOI 10.1016/j.cell.2012.01.033; Puebla-Osorio N, 2008, IMMUNOL RES, V41, P103, DOI 10.1007/s12026-008-8015-3; Rowan S, 1996, EMBO J, V15, P827, DOI 10.1002/j.1460-2075.1996.tb00418.x; Saif MW, 2010, CANCER J, V16, P196, DOI 10.1097/PPO.0b013e3181e076af; Sekiguchi JM, 2006, CELL, V124, P260, DOI 10.1016/j.cell.2006.01.010; Shirazi T, 2000, POSTGRAD MED J, V76, P473, DOI 10.1136/pmj.76.898.473; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Sipos F, 2012, WORLD J GASTROENTERO, V18, P295, DOI 10.3748/wjg.v18.i4.295; Subramanian C, 2005, P NATL ACAD SCI USA, V102, P4842, DOI 10.1073/pnas.0408351102; Tavana O, DIABETES; Tavana O, 2010, DIABETES, V59, P135, DOI 10.2337/db09-0792; Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Van Nguyen T, 2007, J EXP MED, V204, P1453, DOI 10.1084/jem.20062453; Walker JR, 2001, NATURE, V412, P607, DOI 10.1038/35088000; Westbrook AM, 2010, MUTAT RES-REV MUTAT, V705, P40, DOI 10.1016/j.mrrev.2010.03.001; Weterings E, 2008, CELL RES, V18, P114, DOI 10.1038/cr.2008.3; Zaanan A, 2011, CELL ONCOL, V34, P155, DOI 10.1007/s13402-011-0024-x; Zhu CM, 2002, CELL, V109, P811, DOI 10.1016/S0092-8674(02)00770-5	50	12	12	0	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2014	33	21					2748	2757		10.1038/onc.2013.234	http://dx.doi.org/10.1038/onc.2013.234			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EH	23752193	Green Accepted			2022-12-28	WOS:000337231700008
J	Chandrakesan, P; Roy, B; Jakkula, LUMR; Ahmed, I; Ramamoorthy, P; Tawfik, O; Papineni, R; Houchen, C; Anant, S; Umar, S				Chandrakesan, P.; Roy, B.; Jakkula, L. U. M. R.; Ahmed, I.; Ramamoorthy, P.; Tawfik, O.; Papineni, R.; Houchen, C.; Anant, S.; Umar, S.			Utility of a bacterial infection model to study epithelial-mesenchymal transition, mesenchymal-epithelial transition or tumorigenesis	ONCOGENE			English	Article						bacterial infection; Wnt; Notch; EMT; MET; hyperplasia; inflammation; colon cancer	NF-KAPPA-B; HYPERPLASIA AND/OR COLITIS; TRANSCRIPTION FACTOR SNAIL; BETA-CATENIN EXPRESSION; FUNCTIONAL CROSS-TALK; E-CADHERIN; CITROBACTER-RODENTIUM; STEM-CELLS; TRANSEPITHELIAL MIGRATION; TUMOR PROGRESSION	DCLK1 and Lgr5 have recently been identified as markers of quiescent and cycling stem cells in the small intestinal crypts, respectively. Epithelial-mesenchymal transition (EMT) is a key development program that is often activated during cancer invasion and metastasis, and also imparts a self-renewal capability to disseminating cancer cells. Utilizing the Citrobacter rodentium (CR)-induced transmissible murine colonic hyperplasia (TMCH) model, we observed a relative decrease in DCLK1 expression in the colonic crypts, with significant shift towards stromal staining at peak (12 days post infection) hyperplasia, whereas staining for Lgr5 and Msi-1 increased several fold. When hyperplasia was regressing (days 20-34), an expansion of DCLK1 + ve cells in the CR-infected crypts compared with that seen in uninfected control was recorded. Purified colonic crypt cells exhibiting epigenetic modulation of the transforming growth factor-beta (TGF beta), Wnt and Notch pathways on 12 or 34 days post infection formed monolayers in vitro, and underwent trans-differentiation into fibroblast-like cells that stained positive for vimentin, fibronectin and DCLK1. These cells when trypsinized and regrown in soft agar, formed colonospheres/organoids that developed into crypt-like structures (colonoids) in Matrigel and stained positive for DCLK1. Mice exhibiting 12 or 34 days of TMCH were given azoxymethane once for 8 h (Gp1) or weekly for 3 weeks (Gp2), and subjected to crypt isolation. Crypt cells from Gp1 animals formed monolayers as well as colonospheres in soft agar and nodules/tumors in nude mice. Crypt cells isolated from Gp2 animals failed to form the monolayers, but developed into colonospheres in soft agar and nodules/tumors in nude mice. Thus, both hyperplasia and increased presence of DCLK1 + ve cells promote cellular transformation in response to a second hit. The TMCH model, therefore, provides an excellent template to study how alterations in intestinal stem cells promote trans-differentiation, crypt regeneration or colon carcinogenesis following bacterial infection.	[Chandrakesan, P.; Houchen, C.] Dept Internal Med, Div Gastroenterol, Oklahoma City, OK USA; [Roy, B.; Jakkula, L. U. M. R.; Ahmed, I.; Ramamoorthy, P.; Anant, S.; Umar, S.] Univ Kansas, Med Ctr, Dept Mol & Integrat Physiol, Kansas City, KS 66160 USA; [Tawfik, O.] Univ Kansas, Med Ctr, Dept Anat & Surg Pathol, Kansas City, KS 66160 USA; [Papineni, R.] Carestream Mol Imaging, Woodbridge, CT USA; [Anant, S.; Umar, S.] Univ Kansas, Med Ctr, Ctr Canc, Kansas City, KS 66160 USA	University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center	Umar, S (corresponding author), Univ Kansas, Med Ctr, Ctr Canc, 3901 Rainbow Blvd,4028 Wahl Hall East, Kansas City, KS 66160 USA.	sumar@kumc.edu	Anant, Shrikant/AAF-8020-2020; Chandrakesan, Parthasarathy/AAB-9136-2020	Chandrakesan, Parthasarathy/0000-0002-7587-9553	National Institutes of Health [R01 CA131413]; NIDDK's [U01DK085508-04S1]; University of Kansas Medical Center, Kansas City, KS, USA; NATIONAL CANCER INSTITUTE [R01CA131413] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [U01DK085508] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIDDK's; University of Kansas Medical Center, Kansas City, KS, USA; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This work was supported by the National Institutes of Health Grant R01 CA131413 (to SU), NIDDK's U01DK085508-04S1 (to CWH) and start-up funds from the University of Kansas Medical Center, Kansas City, KS, USA.	Ahmed I, 2013, AM J PHYSIOL-GASTR L, V304, pG356, DOI 10.1152/ajpgi.00372.2012; Ahmed I, 2012, INFECT IMMUN, V80, P3107, DOI 10.1128/IAI.00236-12; Ali N, 2011, J VIROL, V85, P12292, DOI 10.1128/JVI.05920-11; BARTHOLD SW, 1978, VET PATHOL, V15, P223, DOI 10.1177/030098587801500209; BARTHOLD SW, 1977, CANCER RES, V37, P4352; Bataille F, 2008, INFLAMM BOWEL DIS, V14, P1514, DOI 10.1002/ibd.20590; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Betis F, 2003, INFECT IMMUN, V71, P1774, DOI 10.1128/IAI.71.4.1774-1783.2003; Betis F, 2003, INFECT IMMUN, V71, P1068, DOI 10.1128/IAI.71.3.1068-1074.2003; Bierne H, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a010272; Borenshtein D, 2008, CURR OPIN GASTROEN, V24, P32, DOI 10.1097/MOG.0b013e3282f2b0fb; Brabletz S, 2011, EMBO J, V30, P770, DOI 10.1038/emboj.2010.349; Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498; Brabletz T, 2012, NAT REV CANCER, V12, P425, DOI 10.1038/nrc3265; Brown JB, 2011, INFECT IMMUN, V79, P1863, DOI 10.1128/IAI.01025-10; Cane G, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001359; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Chandrakesan P, 2012, INFECT IMMUN, V80, P753, DOI 10.1128/IAI.06101-11; Chandrakesan P, 2010, J BIOL CHEM, V285, P33485, DOI 10.1074/jbc.M110.129353; Colgan SP, 2010, NAT REV GASTRO HEPAT, V7, P281, DOI 10.1038/nrgastro.2010.39; Cun DM, 2011, EUR J PHARM BIOPHARM, V77, P26, DOI 10.1016/j.ejpb.2010.11.008; Deng WY, 2005, INFECT IMMUN, V73, P2135, DOI 10.1128/IAI.73.4.2135-2146.2005; Eltzschig HK, 2011, NEW ENGL J MED, V364, P656, DOI 10.1056/NEJMra0910283; Flier SN, 2010, J BIOL CHEM, V285, P20202, DOI 10.1074/jbc.M110.102012; Fodde R, 2007, CURR OPIN CELL BIOL, V19, P150, DOI 10.1016/j.ceb.2007.02.007; Franci C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005595; Gilles C, 2003, CANCER RES, V63, P2658; Hamon MA, 2008, CELL HOST MICROBE, V4, P100, DOI 10.1016/j.chom.2008.07.009; Hofman P, 2012, GUT MICROBES, V3, P1; Hollier BG, 2009, J MAMMARY GLAND BIOL, V14, P29, DOI 10.1007/s10911-009-9110-3; Hongpaisan J, 2000, CELL BIOL INT, V24, P1, DOI 10.1006/cbir.1999.0448; Humphries A, 2008, NAT REV CANCER, V8, P415, DOI 10.1038/nrc2392; Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343; Julien S, 2007, ONCOGENE, V26, P7445, DOI 10.1038/sj.onc.1210546; Kwatra D, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/702869; Liu XW, 2012, HEPATOL RES, V42, P1024, DOI 10.1111/j.1872-034X.2012.01011.x; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; May R, 2009, STEM CELLS, V27, P2571, DOI 10.1002/stem.193; Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x; Mukherjee T, 2011, SCIENCE, V332, P1210, DOI 10.1126/science.1199643; Mundy R, 2005, CELL MICROBIOL, V7, P1697, DOI 10.1111/j.1462-5822.2005.00625.x; Newman JV, 2001, J INFECT DIS, V184, P227, DOI 10.1086/321998; Niessen K, 2008, J CELL BIOL, V182, P315, DOI 10.1083/jcb.200710067; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pilpilidis I, 2011, J SURG RES, V166, P255, DOI 10.1016/j.jss.2010.02.012; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Ponnurangam S, 2012, MOL CANCER THER, V11, P963, DOI 10.1158/1535-7163.MCT-11-0999; Radisky DC, 2008, CELL STEM CELL, V2, P511, DOI 10.1016/j.stem.2008.05.007; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rubio D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001398; Saito Y, 2010, J EXP MED, V207, P2157, DOI 10.1084/jem.20100602; Sanchez-Tillo E, 2010, ONCOGENE, V29, P3490, DOI 10.1038/onc.2010.102; Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y; Sellin JH, 2001, CANCER RES, V61, P2899; Sellin JH, 2009, EXP CELL RES, V315, P97, DOI 10.1016/j.yexcr.2008.10.019; Sipos F, 2011, WORLD J GASTROENTERO, V17, P2981, DOI 10.3748/wjg.v17.i25.2981; Subramaniam D, 2011, MOL CANCER THER, V10, P2146, DOI 10.1158/1535-7163.MCT-11-0399; SUN NC, 1979, P NATL ACAD SCI USA, V76, P1819, DOI 10.1073/pnas.76.4.1819; Sureban SM, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-40; Sureban SM, 2009, GASTROENTEROLOGY, V137, P649, DOI 10.1053/j.gastro.2009.05.004; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Umar S, 2008, ONCOGENE, V27, P5599, DOI 10.1038/onc.2008.169; Umar S, 2005, ONCOGENE, V24, P6709, DOI 10.1038/sj.onc.1208820; Umar S, 2003, CELL PROLIFERAT, V36, P361, DOI 10.1046/j.1365-2184.2003.00291.x; Umar S, 2007, AM J PHYSIOL-GASTR L, V292, pG599, DOI 10.1152/ajpgi.00343.2006; Umar S, 2009, J BIOL CHEM, V284, P22274, DOI 10.1074/jbc.M109.020941; van der Flier LG, 2009, ANNU REV PHYSIOL, V71, P241, DOI 10.1146/annurev.physiol.010908.163145; Wang Y, 2006, BRIT J PHARMACOL, V148, P814, DOI 10.1038/sj.bjp.0706784; Whitehead RH, 1999, GASTROENTEROLOGY, V117, P858, DOI 10.1016/S0016-5085(99)70344-6; Wu MZ, 2011, MOL CELL, V43, P811, DOI 10.1016/j.molcel.2011.07.012; Xi Y, 2013, ONCOGENE, V32, P5048, DOI 10.1038/onc.2012.530; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yin YF, 2010, GUT, V59, P1037, DOI 10.1136/gut.2009.199794; Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069; Zhang Q, 2013, CARCINOGENESIS, V34, P962, DOI 10.1093/carcin/bgt027; Zhao LJ, 2011, J SURG RES, V171, P819, DOI 10.1016/j.jss.2010.04.059	77	45	46	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2014	33	20					2639	2654		10.1038/onc.2013.210	http://dx.doi.org/10.1038/onc.2013.210			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH9YT	23752178	Green Accepted			2022-12-28	WOS:000336502700010
J	Shin, S; Wolgamott, L; Tcherkezian, J; Vallabhapurapu, S; Yu, Y; Roux, PP; Yoon, SO				Shin, S.; Wolgamott, L.; Tcherkezian, J.; Vallabhapurapu, S.; Yu, Y.; Roux, P. P.; Yoon, S-O			Glycogen synthase kinase-3 beta positively regulates protein synthesis and cell proliferation through the regulation of translation initiation factor 4E-binding protein 1	ONCOGENE			English	Article						GSK-3; translation; 4E-BP1	NEGATIVE BREAST-CANCER; S6 KINASE; HIERARCHICAL PHOSPHORYLATION; 4E-BP1 PHOSPHORYLATION; DIABETES-MELLITUS; RAPAMYCIN; INHIBITION; SURVIVAL; GSK3-BETA; PATHWAY	Protein synthesis has a key role in the control of cell proliferation, and its deregulation is associated with pathological conditions, notably cancer. Rapamycin, an inhibitor of mammalian target of rapamycin complex 1 (mTORC1), was known to inhibit protein synthesis. However, it does not substantially inhibit protein synthesis and cell proliferation in many cancer types. We were interested in finding a novel target in rapamycin-resistant cancer. The rate-limiting factor for translation is eukaryotic translation initiation factor 4E (eIF4E), which is negatively regulated by eIF4E-binding protein 1 (4E-BP1). Here, we provide evidence that glycogen synthase kinase (GSK)-3 beta promotes cell proliferation through positive regulation of protein synthesis. We found that GSK-3 beta phosphorylates and inactivates 4E-BP1, thereby increasing eIF4E-dependent protein synthesis. Considering the clinical relevance of pathways regulating protein synthesis, our study provides a promising new strategy and target for cancer therapy.	[Shin, S.; Wolgamott, L.; Vallabhapurapu, S.; Yoon, S-O] Univ Cincinnati, Coll Med, Dept Canc & Cell Biol, Cincinnati, OH 45267 USA; [Tcherkezian, J.; Roux, P. P.] Univ Montreal, Inst Res Immunol & Canc, Dept Pathol & Cell Biol, Montreal, PQ, Canada; [Yu, Y.] Univ Texas SW Med Ctr Dallas, Dept Biochem, Dallas, TX 75390 USA	University System of Ohio; University of Cincinnati; Universite de Montreal; University of Texas System; University of Texas Southwestern Medical Center Dallas	Yoon, SO (corresponding author), Univ Cincinnati, Coll Med, Dept Canc & Cell Biol, 3125 Eden Ave, Cincinnati, OH 45267 USA.	yoonsh@ucmail.uc.edu	Roux, Philippe P./J-3996-2012	Roux, Philippe P./0000-0002-5962-0250	University of Cincinnati College of Medicine; Marlene Harris-Ride Cincinnati Breast Cancer Pilot Grant Program; Canadian Cancer Society Research Institute; Cancer Research Society; Cancer Prevention and Research Institute of Texas [R1103]; Welch Foundation [I-1800]; University of Texas Southwestern Medical Center	University of Cincinnati College of Medicine; Marlene Harris-Ride Cincinnati Breast Cancer Pilot Grant Program; Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Cancer Research Society; Cancer Prevention and Research Institute of Texas; Welch Foundation(The Welch Foundation); University of Texas Southwestern Medical Center	We thank Drs John Blenis, Do-Hyung Kim, Andrew L Kung, David Baltimore and Anne E Willis for generously providing reagents. We also thank Dr Belinda Peace for editing this manuscript and Teng Teng for polysome analysis. This work was supported by a start-up fund from the University of Cincinnati College of Medicine and the Marlene Harris-Ride Cincinnati Breast Cancer Pilot Grant Program (S-OY), by the Canadian Cancer Society Research Institute and the Cancer Research Society (PPR), and by the Cancer Prevention and Research Institute of Texas (R1103), the Welch Foundation (I-1800), and a start-up fund from the University of Texas Southwestern Medical Center (YY). PP Roux holds a Canada Research Chair in Signal Transduction and Proteomics and Y Yu is a CPRIT scholar in Cancer Research and a Virginia Murchison Linthicum Scholar in Medical Research.	Alessi DR, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.267pe27; Ayuso MI, 2010, J BIOL CHEM, V285, P34355, DOI 10.1074/jbc.M110.135103; Barone BB, 2008, JAMA-J AM MED ASSOC, V300, P2754, DOI 10.1001/jama.2008.824; Birch NW, 2010, CANCER CELL, V17, P529, DOI 10.1016/j.ccr.2010.05.017; Blagden SP, 2011, NAT REV CLIN ONCOL, V8, P280, DOI 10.1038/nrclinonc.2011.16; Chen YQ, 2010, CAN J PHYSIOL PHARM, V88, P285, DOI 10.1139/Y10-010; Choo AY, 2008, P NATL ACAD SCI USA, V105, P17414, DOI 10.1073/pnas.0809136105; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Efeyan A, 2010, CURR OPIN CELL BIOL, V22, P169, DOI 10.1016/j.ceb.2009.10.007; Eldar-Finkelman H, 2002, TRENDS MOL MED, V8, P126, DOI 10.1016/S1471-4914(01)02266-3; Foltz DR, 2002, CURR BIOL, V12, P1006, DOI 10.1016/S0960-9822(02)00888-6; Gingras AC, 2001, GENE DEV, V15, P2852; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Hardt SE, 2002, CIRC RES, V90, P1055, DOI 10.1161/01.RES.0000018952.70505.F1; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Horton LE, 2002, ONCOGENE, V21, P5325, DOI 10.1038/sj.onc.1205662; Hsieh AC, 2010, CANCER CELL, V17, P249, DOI 10.1016/j.ccr.2010.01.021; Hur EM, 2010, NAT REV NEUROSCI, V11, P539, DOI 10.1038/nrn2870; Ikenoue T, 2009, METHOD ENZYMOL, V452, P165, DOI 10.1016/S0076-6879(08)03611-2; Jiang YP, 2001, J BIOL CHEM, V276, P10943, DOI 10.1074/jbc.M007758200; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Keshwani MM, 2011, J BIOL CHEM, V286, P23552, DOI 10.1074/jbc.M111.258004; Kim George R., 2008, P635, DOI 10.1007/978-0-387-69252-4_37; Kulikov R, 2005, MOL CELL BIOL, V25, P7170, DOI 10.1128/MCB.25.16.7170-7180.2005; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Lee JS, 2007, DIABETES RES CLIN PR, V77, pS49, DOI 10.1016/j.diabres.2007.01.033; Liu TR, 2011, MOL CANCER THER, V10, P1460, DOI 10.1158/1535-7163.MCT-10-0925; Lobry C, 2011, J EXP MED, V208, P1931, DOI 10.1084/jem.20111855; Lu Y, 2011, ONCOGENE, V30, P4567, DOI 10.1038/onc.2011.164; Luo J, 2009, CANCER LETT, V273, P194, DOI 10.1016/j.canlet.2008.05.045; Mai W, 2009, CLIN CANCER RES, V15, P6810, DOI 10.1158/1078-0432.CCR-09-0973; Manoukian AS, 2002, ADV CANCER RES, V84, P203, DOI 10.1016/S0065-230X(02)84007-6; Mir MA, 2008, EMBO J, V27, P3129, DOI 10.1038/emboj.2008.228; Mishra R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-144; Miyashita K, 2009, ANTI-CANCER AGENT ME, V9, P1114, DOI 10.2174/187152009789734982; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Oh WJ, 2010, EMBO J, V29, P3939, DOI 10.1038/emboj.2010.271; Ougolkov AV, 2007, BLOOD, V110, P735, DOI 10.1182/blood-2006-12-060947; Ougolkov Andrei V, 2006, Future Oncol, V2, P91, DOI 10.2217/14796694.2.1.91; Ougolkov AV, 2005, CANCER RES, V65, P2076, DOI 10.1158/0008-5472.CAN-04-3642; Patel S, 2008, CANCER CELL, V14, P351, DOI 10.1016/j.ccr.2008.10.013; Qu LK, 2004, GENE DEV, V18, P261, DOI 10.1101/gad.1165804; Rocques N, 2007, MOL CELL, V28, P584, DOI 10.1016/j.molcel.2007.11.009; Roux PP, 2007, J BIOL CHEM, V282, P14056, DOI 10.1074/jbc.M700906200; Shakoori A, 2005, BIOCHEM BIOPH RES CO, V334, P1365, DOI 10.1016/j.bbrc.2005.07.041; Shakoori A, 2007, CANCER SCI, V98, P1388, DOI 10.1111/j.1349-7006.2007.00545.x; Shin S, 2011, P NATL ACAD SCI USA, V108, pE1204, DOI 10.1073/pnas.1110195108; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Tabares-Seisdedos R, 2011, LANCET ONCOL, V12, P604, DOI 10.1016/S1470-2045(11)70041-9; Tullai JW, 2011, CELL CYCLE, V10, DOI 10.4161/cc.10.18.17321; Um SH, 2004, NATURE, V431, P200, DOI 10.1038/nature02866; Vinayagam A, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001699; Wang XM, 2003, MOL CELL BIOL, V23, P1546, DOI 10.1128/MCB.23.5.1546-1557.2003; Wang XM, 2007, METHOD ENZYMOL, V431, P113, DOI 10.1016/S0076-6879(07)31007-0; Wang Z, 2008, NATURE, V455, P1205, DOI 10.1038/nature07284; Wang Z, 2010, CANCER CELL, V17, P597, DOI 10.1016/j.ccr.2010.04.024; Wolf I, 2005, LANCET ONCOL, V6, P103, DOI 10.1016/S1470-2045(05)01736-5; Yu YH, 2011, SCIENCE, V332, P1322, DOI 10.1126/science.1199484; Zeng Q, 2010, EUR J CANCER, V46, P1132, DOI 10.1016/j.ejca.2010.01.014; Zhang YJ, 2012, CELL CYCLE, V11, P594, DOI 10.4161/cc.11.3.19096	60	78	81	0	14	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2014	33	13					1690	1699		10.1038/onc.2013.113	http://dx.doi.org/10.1038/onc.2013.113			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9QY	23584478				2022-12-28	WOS:000334344700009
J	Han, H; Bourboulia, D; Jensen-Taubman, S; Isaac, B; Wei, B; Stetler-Stevenson, WG				Han, H.; Bourboulia, D.; Jensen-Taubman, S.; Isaac, B.; Wei, B.; Stetler-Stevenson, W. G.			An endogenous inhibitor of angiogenesis inversely correlates with side population phenotype and function in human lung cancer cells	ONCOGENE			English	Article						side population; lung cancer; TIMP-2; ABCG2; chemosensitivity; cell migration	STEM-LIKE CELLS; TISSUE INHIBITOR; ABC TRANSPORTERS; TUMOR; RESISTANCE; OVARIAN; TIMP-2; LINES; GROWTH	The side population (SP) in human lung cancer cell lines and tumors is enriched with cancer stem cells. An endogenous inhibitor of angiogenesis known as tissue inhibitor of matrix metalloproteinase-2 (TIMP-2), characterized for its ability to inhibit matrix metalloproteinases (MMPs), has been shown by several laboratories to impede tumor progression through MMP-dependent or -independent mechanisms. We recently reported that forced expression of TIMP-2, as well as the modified form Ala+TIMP-2 (that lacks MMP inhibitory activity) significantly blocks growth of A549 human lung cancer cells in vivo. However, the mechanisms underlying TIMP-2 antitumor effects are not fully characterized. Here, we examine the hypothesis that the TIMP-2 antitumor activity may involve regulation of the SP in human lung cancer cells. Indeed, using Hoechst dye efflux assay and flow cytometry, as well as quantitative reverse transcriptase-PCR analysis, we found that endogenous TIMP-2 mRNA levels showed a significant inverse correlation with SP fraction size in six non-small cell lung cancer cell lines. In A549 cells expressing increased levels of TIMP-2, a significant decrease in SP was observed, and this decrease was associated with lowered gene expression of ABCG2, ABCB1 and AKR1C1. Functional analysis of A549 cells showed that TIMP-2 overexpression increased chemosensitivity to cytotoxic drugs. The SP isolated from TIMP-2-overexpressing A549 cells also demonstrated impaired migratory capacity compared with the SP from empty vector control. More importantly, our data provide strong evidence that these TIMP-2 functions occur independent of MMP inhibition, as A549 cells overexpressing Ala+TIMP-2 exhibited identical behavior to those overexpressing TIMP-2 alone. Our findings provide the first indication that TIMP-2 modulates SP phenotype and function, and suggests that TIMP-2 may act as an endogenous suppressor of the SP in human lung cancer cells.	[Han, H.; Bourboulia, D.; Jensen-Taubman, S.; Isaac, B.; Wei, B.; Stetler-Stevenson, W. G.] NCI, Radiat Oncol Branch, Ctr Canc Res, NIH,Adv Technol Ctr, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Bourboulia, D (corresponding author), NCI, Extracellular Matrix Pathol Sect, Radiat Oncol Branch,Adv Technol Ctr, Ctr Canc Res,NIH, 8717 Grovemont Circle, Bethesda, MD 20892 USA.	bourmpouliad@mail.nih.gov	Stetler-Stevenson, William/AAE-3501-2020; Stetler-Stevenson, William G/H-6956-2012	Stetler-Stevenson, William/0000-0002-5500-5808; Stetler-Stevenson, William G/0000-0002-5500-5808; Issac, Biju/0000-0002-7311-678X	NCI Center for Cancer Research Intramural Research Grant [ZIA SC009179-22]; NATIONAL CANCER INSTITUTE [ZIABC011204, ZIASC009179] Funding Source: NIH RePORTER	NCI Center for Cancer Research Intramural Research Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the Laboratory of Molecular Technology, NCI Frederick for the microarray experiment. We also thank the members of the Extracellular Matrix Pathology Section, Radiation Oncology Branch, NCI for critical discussions. This work was supported by the NCI Center for Cancer Research Intramural Research Grant # ZIA SC009179-22.	Akunuru S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016951; An Y, 2009, EXPERT OPIN DRUG MET, V5, P1529, DOI 10.1517/17425250903228834; Bourboulia D, 2011, AM J PATHOL, V179, P2589, DOI 10.1016/j.ajpath.2011.07.035; Dean M, 2009, J MAMMARY GLAND BIOL, V14, P3, DOI 10.1007/s10911-009-9109-9; Deng HB, 2004, CANCER CHEMOTH PHARM, V54, P301, DOI 10.1007/s00280-004-0815-0; Ding XW, 2010, LIFE SCI, V86, P631, DOI 10.1016/j.lfs.2010.02.012; Fernandez CA, 2003, J BIOL CHEM, V278, P40989, DOI 10.1074/jbc.M306176200; Fernandez CA, 2010, J BIOL CHEM, V285, P41886, DOI 10.1074/jbc.M110.166439; Fletcher JI, 2010, NAT REV CANCER, V10, P147, DOI 10.1038/nrc2789; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Halon A, 2012, J HISTOCHEM CYTOCHEM, V60, P491, DOI 10.1369/0022155412446978; HEPPNER GH, 1983, CANCER METAST REV, V2, P5, DOI 10.1007/BF00046903; Ho MM, 2007, CANCER RES, V67, P4827, DOI 10.1158/0008-5472.CAN-06-3557; Kondo T, 2004, P NATL ACAD SCI USA, V101, P781, DOI 10.1073/pnas.0307618100; Lopez J, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-48; Mitsutake N, 2007, ENDOCRINOLOGY, V148, P1797, DOI 10.1210/en.2006-1553; Salcido CD, 2010, BRIT J CANCER, V102, P1636, DOI 10.1038/sj.bjc.6605668; Seo DC, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-75; Seo DW, 2003, CELL, V114, P171, DOI 10.1016/S0092-8674(03)00551-8; Shimano K, 2003, AM J PATHOL, V163, P3, DOI 10.1016/S0002-9440(10)63624-3; Stetler-Stevenson WG, 2008, CANCER METAST REV, V27, P57, DOI 10.1007/s10555-007-9105-8; Sung JM, 2008, BIOCHEM BIOPH RES CO, V371, P163, DOI 10.1016/j.bbrc.2008.04.038; Szakacs G, 2006, NAT REV DRUG DISCOV, V5, P219, DOI 10.1038/nrd1984; Szotek PP, 2006, P NATL ACAD SCI USA, V103, P11154, DOI 10.1073/pnas.0603672103; Vermeulen L, 2008, CELL DEATH DIFFER, V15, P947, DOI 10.1038/cdd.2008.20; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wanichwatanadecha P, 2012, J GEN VIROL, V93, P1081, DOI 10.1099/vir.0.038265-0; Wu C, 2008, CANCER LETT, V268, P1, DOI 10.1016/j.canlet.2008.03.048; Yoh K, 2004, CLIN CANCER RES, V10, P1691, DOI 10.1158/1078-0432.CCR-0937-3; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	30	10	11	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2014	33	9					1198	1206		10.1038/onc.2013.61	http://dx.doi.org/10.1038/onc.2013.61			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XT	23474755	Green Accepted			2022-12-28	WOS:000331933800013
J	Burks, J; Reed, RE; Desai, SD				Burks, J.; Reed, R. E.; Desai, S. D.			ISGylation governs the oncogenic function of Ki-Ras in breast cancer	ONCOGENE			English	Article						ISG15; Ki-Ras; UbcH8; ISGylation; breast cancer; oncogenic transformation	UBIQUITIN-LIKE PROTEIN; ISG15 MODIFICATION; DOWN-REGULATION; TUMOR-CELLS; GENE; EXPRESSION; PATHWAY; SYSTEM; ENDOCYTOSIS; TRANSITION	Aberrant expression of the oncogenic Kirsten-Ras (Ki-Ras) and interferon-stimulated gene 15 (ISG15) pathways is common in breast and other cancers. However, whether these dysregulated pathways cooperate to promote malignancy is not known. This study links Ki-Ras and ISG15 in a previously unidentified regulatory loop that may underlie malignant transformation of mammary cells. We show that oncogenic Ki-Ras regulates the expression of the ISG15 pathway (free ISG15 and ISG15 conjugates), and ISG15, in turn, stabilizes Ki-Ras protein by inhibiting its targeted degradation via lysosomes in breast cancer cells. Disruption of this loop by silencing either Ki-Ras or the ISG15 pathway restored the disrupted cellular architecture, a hallmark feature of most cancer cells. We also demonstrate that ISG15 and UbcH8 (ISG15-specific conjugating enzyme) shRNAs reversed Ki-Ras mutation-associated phenotypes of cancer cells, such as increased cell proliferation, colony formation, anchorage-independent growth in soft agar, cell migration, and epithelial-mesenchymal transition. As UbcH8-silenced breast cancer cells are devoid of ISG15 conjugates but have free ISG15, our results using UbcH8-silenced cells suggest that ISG15 conjugates, and not free ISG15, contributes to oncogenic Ki-Ras transformation. We have thus identified the conjugated form of ISG15 as a critical downstream mediator of oncogenic Ki-Ras, providing a potential mechanistic link between ISG15 and Ki-Ras-mediated breast tumorigenesis. Our findings, which show that inhibition of the ISGylation reverses the malignant phenotypes of breast cancer cells expressing oncogenic Ki-Ras, support the development of ISG15 conjugation inhibitors for treating breast and also other cancers expressing oncogenic Ki-Ras.	[Burks, J.; Reed, R. E.; Desai, S. D.] LSU Hlth Sci Center, Sch Med, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA		Desai, SD (corresponding author), LSU Hlth Sci Center, Sch Med, Dept Biochem & Mol Biol, 1901 Perdido St, New Orleans, LA 70112 USA.	sdesai@lsuhsc.edu			LSU-Health Science Center School of Medicine	LSU-Health Science Center School of Medicine	This work was supported by start-up funds from the LSU-Health Science Center School of Medicine to SD.	Andersen JB, 2006, BRIT J CANCER, V94, P1465, DOI 10.1038/sj.bjc.6603099; Andersen JB, 2006, CYTOKINE GROWTH F R, V17, P411, DOI 10.1016/j.cytogfr.2006.10.001; Begum R, 2004, EXP MOL MED, V36, P358, DOI 10.1038/emm.2004.47; Bektas N, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2117; BUESORAMOS CE, 1993, BLOOD, V82, P2617; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Ciechanover A, 2005, CELL DEATH DIFFER, V12, P1167, DOI 10.1038/sj.cdd.4401691; Desai SD, 2006, CANCER RES, V66, P921, DOI 10.1158/0008-5472.CAN-05-1123; Desai SD, 2012, EXP BIOL MED, V237, P38, DOI 10.1258/ebm.2011.011236; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Eckert LB, 2004, CANCER RES, V64, P4585, DOI 10.1158/0008-5472.CAN-04-0396; Farassati F, 2008, AM J PATHOL, V173, P1861, DOI 10.2353/ajpath.2008.080376; FRIEDMAN E, 1984, CANCER RES, V44, P3040; Giehl K, 2005, BIOL CHEM, V386, P193, DOI 10.1515/BC.2005.025; Guo YL, 2012, MOL CANCER THER, V11, P1968, DOI 10.1158/1535-7163.MCT-12-0248; HAAS AL, 1987, J BIOL CHEM, V262, P11315; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Handschuh G, 1999, ONCOGENE, V18, P4301, DOI 10.1038/sj.onc.1202790; Harty RN, 2009, J INNATE IMMUN, V1, P397, DOI 10.1159/000226245; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; Hollestelle A, 2007, MOL CANCER RES, V5, P195, DOI 10.1158/1541-7786.MCR-06-0263; Hummer BT, 2001, J VIROL, V75, P7774, DOI 10.1128/JVI.75.16.7774-7777.2001; Jacobsen K, 2002, ONCOGENE, V21, P3058, DOI 10.1038/sj.onc.1205423; Kiessling A, 2009, ONCOGENE, V28, P2606, DOI 10.1038/onc.2009.115; Kim SE, 2009, J CELL SCI, V122, P842, DOI 10.1242/jcs.040493; Konishi H, 2007, CANCER RES, V67, P8460, DOI 10.1158/0008-5472.CAN-07-0108; Kuang ZZ, 2011, J VIROL, V85, P7153, DOI 10.1128/JVI.02610-10; Lauwers E, 2009, J CELL BIOL, V185, P493, DOI 10.1083/jcb.200810114; Lu A, 2009, J CELL BIOL, V184, P863, DOI 10.1083/jcb.200807186; McLaughlin PMJ, 2000, INT J CANCER, V85, P871, DOI 10.1002/(SICI)1097-0215(20000315)85:6<871::AID-IJC22>3.0.CO;2-O; Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521; Mukhopadhyay D, 2007, SCIENCE, V315, P201, DOI 10.1126/science.1127085; Myung J, 2001, MED RES REV, V21, P245, DOI 10.1002/med.1009.abs; NIELSCH U, 1992, J VIROL, V66, P1884, DOI 10.1128/JVI.66.4.1884-1890.1992; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Pickart CM, 1997, FASEB J, V11, P1055, DOI 10.1096/fasebj.11.13.9367341; Pincetic A, 2010, J VIROL, V84, P4725, DOI 10.1128/JVI.02478-09; Pitha-Rowe I, 2004, CANCER RES, V64, P8109, DOI 10.1158/0008-5472.CAN-03-3938; Schneider Gunter, 2003, Mol Cancer, V2, P15, DOI 10.1186/1476-4598-2-15; SCOTT N, 1993, GUT, V34, P621, DOI 10.1136/gut.34.5.621; Shim JH, 2006, J CELL BIOL, V172, P1045, DOI 10.1083/jcb.200509041; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Takeuchi T, 2005, J BIOCHEM, V138, P711, DOI 10.1093/jb/mvi172; Takeuchi T, 2005, BIOCHEM BIOPH RES CO, V336, P9, DOI 10.1016/j.bbrc.2005.08.034; Tripathi MK, 2005, BIOCHEM BIOPH RES CO, V328, P43, DOI 10.1016/j.bbrc.2004.12.142; Tsai YC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024291; Ward DMV, 2005, J BIOL CHEM, V280, P10548, DOI 10.1074/jbc.M413734200; Wood LM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016422; Yamamoto A, 1998, CELL STRUCT FUNCT, V23, P33, DOI 10.1247/csf.23.33; Yin XY, 2009, LUNG CANCER, V63, P194, DOI 10.1016/j.lungcan.2008.05.009; Zou WG, 2007, BIOCHEM BIOPH RES CO, V354, P321, DOI 10.1016/j.bbrc.2006.12.210; Zou WG, 2005, BIOCHEM BIOPH RES CO, V336, P61, DOI 10.1016/j.bbrc.2005.08.038	53	58	58	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2014	33	6					794	803		10.1038/onc.2012.633	http://dx.doi.org/10.1038/onc.2012.633			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5IL	23318454				2022-12-28	WOS:000331129200013
J	Du, Y; Shen, J; Hsu, JL; Han, Z; Hsu, MC; Yang, CC; Kuo, HP; Wang, YN; Yamaguchi, H; Miller, SA; Hung, MC				Du, Y.; Shen, J.; Hsu, J. L.; Han, Z.; Hsu, M-C; Yang, C-C; Kuo, H-P; Wang, Y-N; Yamaguchi, H.; Miller, S. A.; Hung, M-C			Syntaxin 6-mediated Golgi translocation plays an important role in nuclear functions of EGFR through microtubule-dependent trafficking	ONCOGENE			English	Article						EGF receptor; Golgi and nuclear translocation; microtubules; syntaxin 6	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE; MEMBRANE; LOCALIZATION; PROTEIN; PHOSPHORYLATION; EXPRESSION; TRANSPORT; ENDOCYTOSIS; MECHANISM	Receptor tyrosine kinases (RTKs) are cell surface receptors that initiate signal cascades in response to ligand stimulation. Abnormal expression and dysregulated intracellular trafficking of RTKs have been shown to be involved in tumorigenesis. Recent evidence shows that these cell surface receptors translocate from cell surface to different cellular compartments, including the Golgi, mitochondria, endoplasmic reticulum (ER) and the nucleus, to regulate physiological and pathological functions. Although some trafficking mechanisms have been resolved, the mechanism of intracellular trafficking from cell surface to the Golgi is not yet completely understood. Here we report a mechanism of Golgi translocation of epidermal growth factor receptor (EGFR) in which EGF-induced EGFR travels to the Golgi via microtubule-dependent movement by interacting with dynein and fuses with the Golgi through syntaxin 6-mediated membrane fusion. We also demonstrate that the microtubule-and syntaxin 6-mediated Golgi translocation of EGFR is necessary for its consequent nuclear translocation and nuclear functions. Thus, together with previous studies, the microtubule-and syntaxin 6-mediated trafficking pathway from cell surface to the Golgi, ER and the nucleus defines a comprehensive trafficking route for EGFR to travel from cell surface to the Golgi and the nucleus.	[Du, Y.; Shen, J.; Hsu, J. L.; Han, Z.; Hsu, M-C; Yang, C-C; Kuo, H-P; Wang, Y-N; Yamaguchi, H.; Miller, S. A.; Hung, M-C] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Du, Y.; Shen, J.; Yang, C-C; Kuo, H-P; Hung, M-C] Univ Texas Houston, Grad Sch Biomed Sci Houston, Houston, TX USA; [Hsu, J. L.; Wang, Y-N; Hung, M-C] China Med Univ, Grad Inst Canc Biol, Taichung, Taiwan; [Hsu, J. L.; Wang, Y-N; Hung, M-C] China Med Univ, Ctr Mol Med, Taichung, Taiwan; [Hsu, J. L.; Wang, Y-N; Hung, M-C] Asia Univ, Dept Biotechnol, Taichung, Taiwan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; China Medical University Taiwan; China Medical University Taiwan; Asia University Taiwan	Hung, MC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	mhung@mdanderson.org	Hsu, MC/AAE-5310-2020; Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740; Du, Yi/0000-0002-3969-2652; Wang, Ying-Nai/0000-0002-5275-6729	National Institutes of Health [CA109311, CA099031]; Cancer Research Center of Excellence, Taiwan [D0H101-TD-C-111-005]; Private University Grant, Taiwan [NSC99-2632-B-039-001-MY3]; Program for Stem Cell and Regenerative Medicine Frontier Research, Taiwan [NSC100-2321-B-039-002]; International Research-Intensive Centers of Excellence in Taiwan, Taiwan [NSC101-2911-I-002-303]; University of Texas MD Anderson-China Medical University and Hospital Sister Institution Fund; National Institutes of Health through MD Anderson's Cancer Center Support Grant; Center for Biological Pathways [CA016672]; Patel Memorial Breast Cancer Research Fund; NATIONAL CANCER INSTITUTE [P30CA016672, R01CA109311, P01CA099031] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Cancer Research Center of Excellence, Taiwan; Private University Grant, Taiwan; Program for Stem Cell and Regenerative Medicine Frontier Research, Taiwan; International Research-Intensive Centers of Excellence in Taiwan, Taiwan; University of Texas MD Anderson-China Medical University and Hospital Sister Institution Fund; National Institutes of Health through MD Anderson's Cancer Center Support Grant(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Center for Biological Pathways; Patel Memorial Breast Cancer Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr B Storrie (University of Arkansas for Medical Sciences) for providing the GalNac T2-GFP plasmid. This study was partially supported by the following grants: National Institutes of Health Grants CA109311 and CA099031 (to MC Hung); Cancer Research Center of Excellence (D0H101-TD-C-111-005, Taiwan); Private University Grant (NSC99-2632-B-039-001-MY3, Taiwan); Program for Stem Cell and Regenerative Medicine Frontier Research (NSC100-2321-B-039-002, Taiwan); International Research-Intensive Centers of Excellence in Taiwan (NSC101-2911-I-002-303, Taiwan); The University of Texas MD Anderson-China Medical University and Hospital Sister Institution Fund; National Institutes of Health through MD Anderson's Cancer Center Support Grant and the Center for Biological Pathways (CA016672); Patel Memorial Breast Cancer Research Fund.	Akgoz M, 2004, J BIOL CHEM, V279, P51541, DOI 10.1074/jbc.M410639200; Allan VJ, 1999, CURR OPIN CELL BIOL, V11, P476, DOI 10.1016/S0955-0674(99)80068-4; Boerner JL, 2004, MOL CELL BIOL, V24, P7059, DOI 10.1128/MCB.24.16.7059-7071.2004; Bryant DM, 2005, MOL BIOL CELL, V16, P14, DOI 10.1091/mbc.E04-09-0845; Cao XY, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-26; Carpenter G, 2009, EXP CELL RES, V315, P1556, DOI 10.1016/j.yexcr.2008.09.027; Caviston JP, 2006, TRENDS CELL BIOL, V16, P530, DOI 10.1016/j.tcb.2006.08.002; Chen DJ, 2007, CLIN CANCER RES, V13, P6555, DOI 10.1158/1078-0432.CCR-07-1610; Chen YT, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0017876, 10.1371/journal.pone.0021428, 10.1371/journal.pone.0017844, 10.1371/journal.pone.0024144, 10.1371/journal.pone.0027163, 10.1371/journal.pone.0027333]; COLE NB, 1995, CURR OPIN CELL BIOL, V7, P55, DOI 10.1016/0955-0674(95)80045-X; Das AK, 2007, CANCER RES, V67, P5267, DOI 10.1158/0008-5472.CAN-07-0242; Demory ML, 2009, J BIOL CHEM, V284, P36592, DOI 10.1074/jbc.M109.000760; Deribe YL, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000576; Dittmann K, 2010, STRAHLENTHER ONKOL, V186, P1, DOI 10.1007/s00066-009-2026-4; Klaus HD, 2008, INT J RADIAT ONCOL, V70, P203, DOI 10.1016/j.ijrobp.2007.08.065; Feng YY, 1999, BIOCHEM BIOPH RES CO, V256, P192, DOI 10.1006/bbrc.1998.9790; Fourest-Lieuvin A, 2006, MOL BIOL CELL, V17, P1041, DOI 10.1091/mbc.E05-07-0621; Gao YS, 2010, J BIOL CHEM, V285, P11219, DOI 10.1074/jbc.M109.042754; Giri DK, 2005, MOL CELL BIOL, V25, P11005, DOI 10.1128/MCB.25.24.11005-11018.2005; Gschwind A, 2004, NAT REV CANCER, V4, P361, DOI 10.1038/nrc1360; Hanada N, 2006, MOL CARCINOGEN, V45, P10, DOI 10.1002/mc.20147; Heisler FF, 2011, NEURON, V70, P66, DOI 10.1016/j.neuron.2011.03.008; Hsu SC, 2007, J BIOL CHEM, V282, P10432, DOI 10.1074/jbc.M610014200; Hsu SC, 2009, AM J TRANSL RES, V1, P249; Huang WC, 2011, J BIOL CHEM, V286, P20558, DOI 10.1074/jbc.M111.240796; Jahn R, 2006, NAT REV MOL CELL BIO, V7, P631, DOI 10.1038/nrm2002; Johannes L, 2008, CELL, V135, P1175, DOI 10.1016/j.cell.2008.12.009; Kabayama H, 2008, NEUROSCI LETT, V436, P340, DOI 10.1016/j.neulet.2008.03.061; KAMIO T, 1990, HUM PATHOL, V21, P277, DOI 10.1016/0046-8177(90)90227-V; Kermorgant S, 2008, J CELL BIOL, V182, P855, DOI 10.1083/jcb.200806076; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Li C, 2009, ONCOGENE, V28, P3801, DOI 10.1038/onc.2009.234; Li LY, 2011, CANCER RES, V71, P4269, DOI 10.1158/0008-5472.CAN-10-3504; Liao HJ, 2007, MOL BIOL CELL, V18, P1064, DOI 10.1091/mbc.E06-09-0802; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Lo HW, 2006, J CELL BIOCHEM, V98, P1570, DOI 10.1002/jcb.20876; Lo HW, 2006, BRIT J CANCER, V94, P184, DOI 10.1038/sj.bjc.6602941; Lo HW, 2005, CANCER CELL, V7, P575, DOI 10.1016/j.ccr.2005.05.007; Martens S, 2008, NAT REV MOL CELL BIO, V9, P543, DOI 10.1038/nrm2417; MARTI U, 1991, HEPATOLOGY, V13, P15, DOI 10.1016/0270-9139(91)90210-M; Mittar S, 2009, EXP CELL RES, V315, P877, DOI 10.1016/j.yexcr.2008.12.020; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Offterdinger M, 2002, J CELL BIOL, V157, P929, DOI 10.1083/jcb.200109033; Ookata K, 1997, BIOCHEMISTRY-US, V36, P15873, DOI 10.1021/bi971251w; Reilly JF, 2001, J CELL BIOL, V152, P1307, DOI 10.1083/jcb.152.6.1307; ROBERTSON BJ, 1992, ARCH BIOCHEM BIOPHYS, V292, P190, DOI 10.1016/0003-9861(92)90067-7; Sadowski L, 2009, EXP CELL RES, V315, P1601, DOI 10.1016/j.yexcr.2008.09.021; Sehat B, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000628; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Sorkin A, 2009, EXP CELL RES, V315, P683, DOI [10.1016/j.yexcr.2008.07.029, 10.1016/j.yexcr.2008.08.013]; Srinivasan R, 2000, CANCER RES, V60, P1483; Stachowiak MK, 1996, MOL BRAIN RES, V38, P161, DOI 10.1016/0169-328X(96)00010-1; Wang SC, 2004, CANCER CELL, V6, P251, DOI 10.1016/j.ccr.2004.07.012; Wang SC, 2006, NAT CELL BIOL, V8, P1359, DOI 10.1038/ncb1501; Wang SC, 2009, CLIN CANCER RES, V15, P6484, DOI 10.1158/1078-0432.CCR-08-2813; Wang YN, 2010, ONCOGENE, V29, P3997, DOI 10.1038/onc.2010.157; Wang YN, 2010, J BIOL CHEM, V285, P38720, DOI 10.1074/jbc.M110.158659; Wang YN, 2010, BIOCHEM BIOPH RES CO, V399, P498, DOI 10.1016/j.bbrc.2010.07.096; XIE YM, 1994, BIOCHEM BIOPH RES CO, V203, P1589, DOI 10.1006/bbrc.1994.2368; Yarden Y, 2007, CELL, V131, DOI 10.1016/j.cell.2007.11.013	60	36	38	0	6	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2014	33	6					756	770		10.1038/onc.2013.1	http://dx.doi.org/10.1038/onc.2013.1			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5IL	23376851	Green Accepted			2022-12-28	WOS:000331129200010
J	Huang, H; Daniluk, J; Liu, Y; Chu, J; Li, Z; Ji, B; Logsdon, CD				Huang, H.; Daniluk, J.; Liu, Y.; Chu, J.; Li, Z.; Ji, B.; Logsdon, C. D.			Oncogenic K-Ras requires activation for enhanced activity	ONCOGENE			English	Article						cancer; Ras-GTP	PANCREATIC-CANCER; GENE MUTATION; MICE; PROGRESSION; EXPRESSION; INDUCTION; KRAS	Oncogenic Ras mutations are widely considered to be locked in a permanent 'On' state and 'constitutively active'. Yet, many healthy people have cells possessing mutant Ras without apparent harm, and in animal models mutant Ras causes transformation only after upregulation of Ras activity. Here, we demonstrate that oncogenic K-Ras is not constitutively active but can be readily activated by upstream stimulants to lead to prolonged strong Ras activity. These data indicate that in addition to targeting K-Ras downstream effectors, interventions to reduce K-Ras activation may have important cancer-preventive value, especially in patients with oncogenic Ras mutations. As other small G proteins are regulated in a similar manner, this concept is likely to apply broadly to the entire Ras family of molecules.	[Huang, H.; Daniluk, J.; Liu, Y.; Chu, J.; Logsdon, C. D.] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA; [Huang, H.; Li, Z.] Second Mil Med Univ, Changhai Hosp, Dept Gastroenterol, Shanghai, Peoples R China; [Daniluk, J.] Med Univ Bialystok, Dept Gastroenterol & Internal Med, Bialystok, Poland; [Ji, B.] Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; [Logsdon, C. D.] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; Naval Medical University; Medical University of Bialystok; Mayo Clinic; University of Texas System; UTMD Anderson Cancer Center	Ji, B (corresponding author), Mayo Clin, Dept Biochem & Mol Biol, 200 First St SW, Rochester, MN 55905 USA.	ji.baoan@mayo.edu; clogsdon@mdanderson.org	Daniluk, Jaroslaw/T-3437-2018	Daniluk, Jaroslaw/0000-0002-0787-1461	NIH [DK052067, CA016672, P20 CA101936, CA155165, P50 CA102701]; Lockton Endowment; National Natural Science Foundation of China [30910103911]; NATIONAL CANCER INSTITUTE [P20CA101936, K12CA090628, P50CA102701, R21CA155165, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052067] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Lockton Endowment; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr David Tuveson (UK Cambridge Research Institute) for providing the mouse pancreatic cancer cell line K8484. This work was supported by NIH DK052067, CA016672, P20 CA101936, CA155165, P50 CA102701 and the Lockton Endowment. The work was supported in part by grant 30910103911 (to Z Li) from the National Natural Science Foundation of China.	Ardito CM, 2012, CANCER CELL, V22, P304, DOI 10.1016/j.ccr.2012.07.024; Carriere C, 2009, BIOCHEM BIOPH RES CO, V382, P561, DOI 10.1016/j.bbrc.2009.03.068; Daniluk J, 2012, J CLIN INVEST, V122, P1519, DOI 10.1172/JCI59743; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Guerra C, 2007, CANCER CELL, V11, P291, DOI 10.1016/j.ccr.2007.01.012; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Ji BA, 2008, GENESIS, V46, P390, DOI 10.1002/dvg.20411; Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438; KOEFFLER HP, 1991, WESTERN J MED, V155, P505; Lu XH, 2002, CHINESE MED J-PEKING, V115, P1632; Parsons BL, 2009, BIOMARK MED, V3, P757, DOI 10.2217/BMM.09.95; Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106; Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333; Siveke JT, 2007, CANCER CELL, V12, P266, DOI 10.1016/j.ccr.2007.08.002; SPAARGAREN M, 1995, GENE EXPRESSION, V4, P345; Tada M, 1996, GASTROENTEROLOGY, V110, P227, DOI 10.1053/gast.1996.v110.pm8536861; WILLIAMS JA, 1978, AM J PHYSIOL, V235, pE517, DOI 10.1152/ajpendo.1978.235.5.E517; Yakubovskaya MS, 1995, INT J CANCER, V63, P810, DOI 10.1002/ijc.2910630611; Yan L, 2005, GASTROENTEROLOGY, V128, P2124, DOI 10.1053/j.gastro.2005.03.006	21	94	96	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2014	33	4					532	535		10.1038/onc.2012.619	http://dx.doi.org/10.1038/onc.2012.619			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VX	23334325	Green Accepted			2022-12-28	WOS:000330214600014
J	Zhang, H; Pu, J; Qi, T; Qi, M; Yang, C; Li, S; Huang, K; Zheng, L; Tong, Q				Zhang, H.; Pu, J.; Qi, T.; Qi, M.; Yang, C.; Li, S.; Huang, K.; Zheng, L.; Tong, Q.			MicroRNA-145 inhibits the growth, invasion, metastasis and angiogenesis of neuroblastoma cells through targeting hypoxia-inducible factor 2 alpha	ONCOGENE			English	Article						neuroblastoma; microRNA-145; hypoxia-inducible factor 2 alpha	TUMOR-SUPPRESSOR MIR-145; CANCER-CELLS; EXPRESSION; HIF-2-ALPHA; CARCINOMA; FACTOR-1-ALPHA; INVASIVENESS; HIF-1-ALPHA; HEPARANASE; ABOLISHES	Recent evidence shows that hypoxia-inducible factor 2 alpha (HIF-2 alpha) may have critical roles in the growth and progression of neuroblastoma (NB) under non-hypoxic conditions. However, the underlying mechanisms and clinical potentials of normoxic HIF-2 alpha expression in NB still remain largely unknown. In this study, HIF-2 alpha immunostaining was identified in 26/42 NB tissues, which was correlated with clinicopathological features. In subtotal 20 NB cases, microRNA-145 (miR-145) was downregulated and inversely correlated with HIF-2 alpha expression. Bioinformatics analysis revealed a putative miR-145 binding site in the 3'-untranslated region (3'-UTR) of HIF-2 alpha messenger RNA (mRNA). Overexpression or knockdown of miR-145 responsively altered both the mRNA and protein levels of HIF-2 alpha and its downstream genes, cyclin D1, matrix metalloproteinase 14 and vascular endothelial growth factor, in normoxically cultured NB cell lines SH-SY5Y and SK-N-SH. In a luciferase reporter system, miR-145 downregulated the luciferase activity of HIF-2 alpha 3'-UTR, and these effects were abolished by a mutation in the putative miR-145-binding site. Overexpression of miR-145 suppressed the growth, invasion, metastasis and angiogenesis of SH-SY5Y and SK-N-SH cells in vitro and in vivo, while restoration of HIF-2 alpha expression rescued the tumor cells from miR-145-mediated defects in these biological features. Furthermore, anti-miR-145 inhibitor rescued the HIF-2 alpha knockdown-mediated repression on the growth, migration, invasion and angiogenesis of NB cells. These data indicate that miR-145 suppresses HIF-2 alpha expression via the binding site in the 3'-UTR under normoxic conditions, thus inhibiting the aggressiveness and angiogenesis of NB.	[Zhang, H.; Pu, J.; Qi, T.; Qi, M.; Yang, C.; Li, S.; Tong, Q.] Huazhong Univ Sci & Technol, Dept Pediat Surg, Union Hosp, Tongji Med Coll, Wuhan 430022, Hubei Province, Peoples R China; [Huang, K.; Zheng, L.; Tong, Q.] Huazhong Univ Sci & Technol, Clin Ctr Human Genom Res, Union Hosp, Tongji Med Coll, Wuhan 430022, Hubei Province, Peoples R China; [Huang, K.] Huazhong Univ Sci & Technol, Dept Cardiol, Union Hosp, Tongji Med Coll, Wuhan 430022, Hubei Province, Peoples R China; [Zheng, L.] Huazhong Univ Sci & Technol, Dept Pathol, Union Hosp, Tongji Med Coll, Wuhan 430022, Hubei Province, Peoples R China	Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology; Huazhong University of Science & Technology	Zheng, L (corresponding author), Huazhong Univ Sci & Technol, Dept Pathol, Union Hosp, Tongji Med Coll, Wuhan 430022, Hubei Province, Peoples R China.	ld_zheng@hotmail.com; qs_tong@hotmail.com	Tong, Qiangsong/B-4500-2014	Tong, Qiangsong/0000-0002-2615-6404	National Natural Science Foundation of China [30600278, 30772359, 81071997, 81072073, 81272779]; Program for New Century Excellent Talents in University [NCET-06-0641]; Scientific Research Foundation for the Returned Overseas Chinese Scholars [2008-889]; Fundamental Research Funds for the Central Universities [2012QN224]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for New Century Excellent Talents in University(Program for New Century Excellent Talents in University (NCET)); Scientific Research Foundation for the Returned Overseas Chinese Scholars(Scientific Research Foundation for the Returned Overseas Chinese Scholars); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities)	This work was supported by the National Natural Science Foundation of China (Nos. 30600278, 30772359, 81071997, 81072073, 81272779), Program for New Century Excellent Talents in University (NCET-06-0641), Scientific Research Foundation for the Returned Overseas Chinese Scholars (2008-889) and Fundamental Research Funds for the Central Universities (2012QN224).	Acker T, 2005, CANCER CELL, V8, P131, DOI 10.1016/j.ccr.2005.07.003; Aplin AC, 2009, AM J PHYSIOL-CELL PH, V297, pC471, DOI 10.1152/ajpcell.00019.2009; Ara T, 2006, CANCER METAST REV, V25, P645, DOI 10.1007/s10555-006-9028-9; Arndt GM, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-374; Baba M, 2003, ONCOGENE, V22, P2728, DOI 10.1038/sj.onc.1206373; Borel C, 2008, MAMM GENOME, V19, P503, DOI 10.1007/s00335-008-9137-6; Cha ST, 2010, CANCER RES, V70, P2675, DOI 10.1158/0008-5472.CAN-09-2448; Chae KS, 2011, ONCOGENE, V30, P1213, DOI 10.1038/onc.2010.498; Chiyomaru T, 2011, PROSTATE, DOI [10.1002/pros.21372, DOI 10.1002/PR0S.21372)]; Covello KL, 2005, CANCER RES, V65, P2277, DOI 10.1158/0008-5472.CAN-04-3246; Dweep H, 2011, J BIOMED INFORM, V44, P839, DOI 10.1016/j.jbi.2011.05.002; Fischer L, 2011, NEURO-ONCOLOGY, V13, P1090, DOI 10.1093/neuonc/nor107; Foley NH, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-83; Fontana L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002236; Gao P, 2013, ONCOGENE, V32, P491, DOI 10.1038/onc.2012.61; Gotte M, 2010, ONCOGENE, V29, P6569, DOI 10.1038/onc.2010.386; Holmquist-Mengelbier L, 2006, CANCER CELL, V10, P413, DOI 10.1016/j.ccr.2006.08.026; Kano M, 2010, INT J CANCER, V127, P2804, DOI 10.1002/ijc.25284; Koo S, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-143; Landgraf P, 2007, CELL, V129, P1401, DOI 10.1016/j.cell.2007.04.040; Lei Z, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007629; Liu HY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005436; Ma L, 2010, NAT CELL BIOL, V12, P247, DOI 10.1038/ncb2024; Michael MZ, 2003, MOL CANCER RES, V1, P882; Nicoloso MS, 2010, CANCER RES, V70, P2789, DOI 10.1158/0008-5472.CAN-09-3541; Petrella BL, 2005, ONCOGENE, V24, P1043, DOI 10.1038/sj.onc.1208305; Pietras A, 2009, P NATL ACAD SCI USA, V106, P16805, DOI 10.1073/pnas.0904606106; Poincloux R, 2009, J CELL SCI, V122, P3015, DOI 10.1242/jcs.034561; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Shi B, 2007, J BIOL CHEM, V282, P32582, DOI 10.1074/jbc.M702806200; Speranza MC, 2012, ONCOTARGET, V3, P724; Stallings RL, 2009, CURR PHARM DESIGN, V15, P456, DOI 10.2174/138161209787315837; Wang SH, 2009, INT J ONCOL, V34, P1461, DOI 10.3892/ijo_00000275; Wei JS, 2008, ONCOGENE, V27, P5204, DOI 10.1038/onc.2008.154; Xu Q, 2012, NUCLEIC ACIDS RES, V40, P761, DOI 10.1093/nar/gkr730; Zhang JJ, 2011, CANCER-AM CANCER SOC, V117, P86, DOI 10.1002/cncr.25522; Zheng LD, 2009, WORLD J PEDIATR, V5, P206, DOI 10.1007/s12519-009-0039-9; Zheng LD, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-33; Zou C, 2012, CELL CYCLE, V11, P2137, DOI 10.4161/cc.20598	40	111	115	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2014	33	3					387	397		10.1038/onc.2012.574	http://dx.doi.org/10.1038/onc.2012.574			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VR	23222716				2022-12-28	WOS:000330214000013
J	Sarkar, S; Brautigan, DL; Parsons, SJ; Larner, JM				Sarkar, S.; Brautigan, D. L.; Parsons, S. J.; Larner, J. M.			Androgen receptor degradation by the E3 ligase CHIP modulates mitotic arrest in prostate cancer cells	ONCOGENE			English	Article						prostate cancer; androgen receptor; 2-methoxyestradiol; CHIP; mitotic arrest	ENDOGENOUS MAMMALIAN METABOLITE; ACTIVATED PROTEIN-KINASE; INHIBITS ANGIOGENESIS; ESTROGEN METABOLITE; CDC6 TRANSCRIPTION; ENDOTHELIAL-CELLS; CYCLE PROGRESSION; 2-METHOXYESTRADIOL; EXPRESSION; APOPTOSIS	The androgen receptor (AR) has a vital role in the onset and progression of prostate cancer by promoting G1-S progression, possibly by functioning as a licensing factor for DNA replication. We here report that low dose 2-methoxyestradiol (2-ME), an endogenous estrogen metabolite, induces mitotic arrest in prostate cancer cells involving activation of the E3 ligase CHIP (C-terminus of Hsp70-interacting protein) and degradation of the AR. Depletion of the AR by small interfering RNA (siRNA) eliminates 2-ME-induced arrest and introducing AR into PC3-M cells confers 2-ME-induced mitotic arrest. Knockdown of CHIP or MDM2 (mouse homolog of double minute 2 protein) individually or in combination reduced AR degradation and abrogated M phase arrest induced by 2-ME. Our data link AR degradation via ubiquitination to mitotic arrest. Targeting the AR by activating E3 ligases such as CHIP represents a novel strategy for the treatment of prostate cancer.	[Sarkar, S.; Larner, J. M.] Univ Virginia, Sch Med, Hlth Sci Ctr, Dept Radiat Oncol, Charlottesville, VA 22908 USA; [Brautigan, D. L.] Univ Virginia, Ctr Cell Signaling, Charlottesville, VA 22908 USA; [Brautigan, D. L.; Parsons, S. J.] Univ Virginia, Sch Med, Dept Microbiol Immunol & Canc Biol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia; University of Virginia	Larner, JM (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Radiat Oncol, 1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	jml2p@virginia.edu			National Institutes of Health [5R01CA142823-02]; Charles R. Burnett Jr and W. Griffin Burnett Fund; NATIONAL CANCER INSTITUTE [R01CA142823, R01CA120413] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Charles R. Burnett Jr and W. Griffin Burnett Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported, in whole or in part, by the National Institutes of Health grant 5R01CA142823-02 (to J. M. L.) as well as the Charles R. Burnett Jr and W. Griffin Burnett Fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; Cardozo CP, 2003, ARCH BIOCHEM BIOPHYS, V410, P134, DOI 10.1016/S0003-9861(02)00680-X; Casarez EV, 2007, CANCER RES, V67, P8316, DOI 10.1158/0008-5472.CAN-07-1755; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chymkowitch P, 2011, EMBO J, V30, P468, DOI 10.1038/emboj.2010.337; CUSHMAN M, 1995, J MED CHEM, V38, P2041, DOI 10.1021/jm00012a003; D'Antonio JM, 2009, ENDOCR-RELAT CANCER, V16, P325, DOI 10.1677/ERC-08-0205; Day JM, 2003, J STEROID BIOCHEM, V84, P317, DOI 10.1016/S0960-0760(03)00045-1; FOTSIS T, 1994, NATURE, V368, P237, DOI 10.1038/368237a0; Gao XH, 2005, ENDOCRINOLOGY, V146, P1707, DOI 10.1210/en.2004-1198; Gaughan L, 2005, NUCLEIC ACIDS RES, V33, P13, DOI 10.1093/nar/gki141; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Hamel E, 1996, BIOCHEMISTRY-US, V35, P1304, DOI 10.1021/bi951559s; He B, 2004, J BIOL CHEM, V279, P30643, DOI 10.1074/jbc.M403117200; Huang CY, 2005, MOL ENDOCRINOL, V19, P2915, DOI 10.1210/me.2005-0097; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Jin F, 2009, NUCLEIC ACIDS RES, V37, P4826, DOI 10.1093/nar/gkp510; Kumar AP, 2001, MOL CARCINOGEN, V31, P111, DOI 10.1002/mc.1046; Lara PN, 1999, CANCER INVEST, V17, P137; Lee DK, 2003, J CLIN ENDOCR METAB, V88, P4043, DOI 10.1210/jc.2003-030261; Lee HJ, 2003, CELL MOL LIFE SCI, V60, P1613, DOI 10.1007/s00018-003-2309-3; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Litvinov IV, 2006, P NATL ACAD SCI USA, V103, P15085, DOI 10.1073/pnas.0603057103; Mallik I, 2008, BBA-MOL CELL RES, V1783, P1737, DOI 10.1016/j.bbamcr.2008.05.006; Morishima Y, 2008, HUM MOL GENET, V17, P3942, DOI 10.1093/hmg/ddn296; PERTSCHUK LP, 1994, ANN SURG ONCOL, V1, P495, DOI 10.1007/BF02303615; Prins GS, 1998, J UROLOGY, V159, P641, DOI 10.1016/S0022-5347(01)63692-9; Qadan LR, 2001, BIOCHEM BIOPH RES CO, V285, P1259, DOI 10.1006/bbrc.2001.5320; Schiewer MJ, 2012, MOL CELL ENDOCRINOL, V352, P34, DOI 10.1016/j.mce.2011.06.033; Sharifi Nima, 2006, Am J Ther, V13, P166, DOI 10.1097/00045391-200603000-00013; Sharma MJ, 2003, EMBO J, V22, P6101, DOI 10.1093/emboj/cdg585; Szostak MJ, 2000, ONCOL REP, V7, P699; Tsukamoto A, 1998, BIOCHEM BIOPH RES CO, V248, P9, DOI 10.1006/bbrc.1998.8902; Wang AM, 2010, J BIOL CHEM, V285, P15714, DOI 10.1074/jbc.M109.098806; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Yue TL, 1997, MOL PHARMACOL, V51, P951, DOI 10.1124/mol.51.6.951	36	70	72	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2014	33	1					26	33		10.1038/onc.2012.561	http://dx.doi.org/10.1038/onc.2012.561			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	282YU	23246967	Green Accepted			2022-12-28	WOS:000329212000004
J	Xu, C; Fu, H; Gao, L; Wang, L; Wang, W; Li, J; Li, Y; Dou, L; Gao, X; Luo, X; Jing, Y; Chim, CS; Zheng, X; Yu, L				Xu, C.; Fu, H.; Gao, L.; Wang, L.; Wang, W.; Li, J.; Li, Y.; Dou, L.; Gao, X.; Luo, X.; Jing, Y.; Chim, C-S; Zheng, X.; Yu, L.			BCR-ABL/GATA1/miR-138 mini circuitry contributes to the leukemogenesis of chronic myeloid leukemia	ONCOGENE			English	Article						microRNA; imatinib; chronic myeloid leukemia; BCR-ABL	SQUAMOUS-CELL CARCINOMA; CYCLE ARREST; BCR-ABL; MICRORNA; EXPRESSION; DIFFERENTIATION; ONCOGENE; MIR-138; TRANSCRIPTION; GATA-1	Abnormal expression of microRNAs (miRNAs) has been implicated in carcinogenesis. Here we report a novel BCR (breakpoint cluster region)-ABL (c-abl oncogene 1, non-receptor tyrosine kinase)/GATA1/microRNA-138 (miR-138) circuitry in chronic myeloid leukemia (CML). miR-138 expression is downregulated in K562 cells and primary CML samples, which is restored after imatinib treatment. The tumor suppressor activity of miR-138 is demonstrated by the induction of cell cycle arrest at G0/G1, inhibition of cell proliferation and colony forming unit granulocyte-macrophage colony formation and enhanced imatinib-induced apoptosis in K562 and Ku812 cells overexpressing miR-138. Moreover, overexpression of miR-138 led to the downregulation of BCR-ABL. Based on luciferase assay, ABL and BCR-ABL are shown to be the target genes regulated by miR-138. Furthermore, miR-138 binding to ABL was shown to localize to the coding region instead of 30-untranslated regions (30-UTR) of ABL mRNA. In addition, CCND3 is another target of miR-138, which represses CCND3 expression by binding to its 30-UTR. Finally, upregulation of miR-138 upon imatinib treatment is associated with the enhancement of GATA1 activity, which binds to the miR-138 promoter. In conclusion, miR-138 is a tumor suppressor miRNA underexpressed in CML. miR-138 represses expression of both BCR-ABL and CCND3 via binding to the coding region and 30-UTR, respectively. miR-138 expression is activated by GATA1, which in turn is repressed by BCR-ABL. Therefore, miR-138, by virtue of a BCR-ABL/GATA1/miR-138 circuitry, is a tumor suppressor miRNA implicated in the pathogenesis of CML and its clinical response to imatinib.	[Xu, C.; Gao, L.; Wang, L.; Wang, W.; Li, J.; Li, Y.; Dou, L.; Gao, X.; Luo, X.; Jing, Y.; Yu, L.] Chinese Peoples Liberat Army Gen Hosp, Dept Hematol, Beijing 100853, Peoples R China; [Fu, H.; Zheng, X.] Beijing Inst Radiat Med, Dept Biochem & Mol Biol, Beijing, Peoples R China; [Chim, C-S] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China	Chinese People's Liberation Army General Hospital; Academy of Military Medical Sciences - China; University of Hong Kong	Yu, L (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Dept Hematol, 28 Fuxing Rd, Beijing 100853, Peoples R China.	xfzheng100@126.com; chunhuiliyu@yahoo.com		Fu, Hanjiang/0000-0002-4352-1178; Yu, Li/0000-0001-6872-2665; Chim, CS/0000-0003-2427-915X	Chinese State Key Projects for Basic Research [2005CB522408, 2010CB912801]; Chinese National Natural Science Foundation [90919044, 81072021, 30971297, 81170518]; High and New Technology Program of PLA [2010gxjs091]; Capital Medical Development Scientific Research Fund [2007-2040]	Chinese State Key Projects for Basic Research; Chinese National Natural Science Foundation(National Natural Science Foundation of China (NSFC)); High and New Technology Program of PLA; Capital Medical Development Scientific Research Fund	We thank C Li (Beijing Institute of Radiation Medicine, Beijing, China) for kindly providing the GATA1 expression vector. This work was supported partially by Chinese State Key Projects for Basic Research (2005CB522408 and 2010CB912801), Chinese National Natural Science Foundation Projects (90919044, 81072021, 30971297, and 81170518), High and New Technology Program of PLA (2010gxjs091) and Capital Medical Development Scientific Research Fund (no. 2007-2040).	Bandres E, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-29; Bueno MJ, 2008, CANCER CELL, V13, P496, DOI 10.1016/j.ccr.2008.04.018; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Corcoran DL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005279; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; Druker BJ, 2000, J CLIN INVEST, V105, P3, DOI 10.1172/JCI9083; Enright Anton J, 2003, Genome Biol, V5, pR1, DOI 10.1186/gb-2003-5-1-r1; Garzon R, 2007, ONCOGENE, V26, P4148, DOI 10.1038/sj.onc.1210186; Heckman KL, 2007, NAT PROTOC, V2, P924, DOI 10.1038/nprot.2007.132; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Huang DY, 2005, NUCLEIC ACIDS RES, V33, P5331, DOI 10.1093/nar/gki838; Jacquel A, 2003, FASEB J, V17, P2160, DOI 10.1096/fj.03-0322fje; Jiang L, 2011, HUM GENET, V129, P189, DOI 10.1007/s00439-010-0915-3; Kisliouk T, 2011, EUR J NEUROSCI, V33, P224, DOI 10.1111/j.1460-9568.2010.07493.x; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Kruger J, 2006, NUCLEIC ACIDS RES, V34, pW451, DOI 10.1093/nar/gkl243; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li S, 2009, HEPATOLOGY, V49, P1194, DOI 10.1002/hep.22757; Liu Q, 2008, NUCLEIC ACIDS RES, V36, P5391, DOI 10.1093/nar/gkn522; Liu XQ, 2011, BIOCHEM J, V440, P23, DOI 10.1042/BJ20111006; Mitomo S, 2008, CANCER SCI, V99, P280, DOI 10.1111/j.1349-7006.2007.00666.x; Morceau F, 2008, BIOFACTORS, V34, P313, DOI [10.1002/biof.5520340407, 10.3233/BIO-2009-1085]; Morton SU, 2008, P NATL ACAD SCI USA, V105, P17830, DOI 10.1073/pnas.0804673105; Nana-Sinkam SP, 2006, J THORAC ONCOL, V1, P929, DOI 10.1097/01243894-200611000-00002; O'Day E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2484; Obernosterer G, 2006, RNA, V12, P1161, DOI 10.1261/rna.2322506; Pope NJ, 2010, NUCLEIC ACIDS RES, V38, P2190, DOI 10.1093/nar/gkp1159; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Spizzo R, 2009, CELL, V137, P586, DOI 10.1016/j.cell.2009.04.040; Suresh S, 2011, J CELL COMMUN SIGNAL, V5, P183, DOI 10.1007/s12079-011-0139-x; Tay Y, 2008, NATURE, V455, P1124, DOI 10.1038/nature07299; Wang W, 2012, CARCINOGENESIS, V33, P1113, DOI 10.1093/carcin/bgs113; Wong TS, 2008, CLIN CANCER RES, V14, P2588, DOI 10.1158/1078-0432.CCR-07-0666; Xu CW, 2010, EUR J CANCER, V46, P2828, DOI 10.1016/j.ejca.2010.06.127; Yu M, 2009, MOL CELL, V36, P682, DOI 10.1016/j.molcel.2009.11.002; Zanette DL, 2007, BRAZ J MED BIOL RES, V40, P1435, DOI 10.1590/S0100-879X2007001100003	38	52	55	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2014	33	1					44	54		10.1038/onc.2012.557	http://dx.doi.org/10.1038/onc.2012.557			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	282YU	23208504				2022-12-28	WOS:000329212000006
J	Lobo, VJSA; Doni, M; Verrecchia, A; Sanulli, S; Faga, G; Piontini, A; Bianchi, M; Conacci-Sorrell, M; Mazzarol, G; Peg, V; Losa, JH; Ronchi, P; Ponzoni, M; Eisenman, RN; Doglioni, C; Amati, B				Lobo, V. J. Sanchez-Arevalo; Doni, M.; Verrecchia, A.; Sanulli, S.; Faga, G.; Piontini, A.; Bianchi, M.; Conacci-Sorrell, M.; Mazzarol, G.; Peg, V.; Losa, J. H.; Ronchi, P.; Ponzoni, M.; Eisenman, R. N.; Doglioni, C.; Amati, B.			Dual regulation of Myc by Abl	ONCOGENE			English	Article						c-Myc; c-Abl; Pin1; CML; Breast Cancer	KINASE C-ABL; TRANSCRIPTIONAL ACTIVITY; TYROSINE KINASE; BREAST-CANCER; APOPTOTIC RESPONSE; ONCOGENE PRODUCT; PHOSPHORYLATION; ACETYLATION; PIN1; ACTIVATION	The tyrosine kinase c-Abl (or Abl) and the prolyl-isomerase Pin1 cooperatively activate the transcription factor p73 by enhancing recruitment of the acetyltransferase p300. As the transcription factor c-Myc (or Myc) is a known target of Pin1 and p300, we hypothesized that it might be regulated in a similar manner. Consistent with this hypothesis, overexpression of Pin1 augmented the interaction of Myc with p300 and transcriptional activity. The action of Abl, however, was more complex than predicted. On one hand, Abl indirectly enhanced phosphorylation of Myc on Ser 62 and Thr 58, its association with Pin1 and p300 and its acetylation by p300. These effects of Abl were exerted through phosphorylation of substrate(s) other than Myc itself. On the other hand, Abl interacted with the C-terminal domain of Myc and phosphorylated up to five tyrosine residues in its N-terminus, the principal of which was Y74. Indirect immunofluorescence or immunohistochemical staining suggested that the Y74-phosphorylated form of Myc (Myc-pY74) localized to the cytoplasm and coexisted either with active Abl in a subset of mammary carcinomas or with Bcr-Abl in chronic myeloid leukemia. In all instances, Myc-pY74 constituted a minor fraction of the cellular Myc protein. Thus, our data unravel two potential effects of Abl on Myc: first, Abl signaling can indirectly augment acetylation of Myc by p300, and most likely also its transcriptional activity in the nucleus; second, Abl can directly phosphorylate Myc on tyrosine: the resulting form of Myc appears to be cytoplasmic, and its presence correlates with Abl activation in cancer.	[Lobo, V. J. Sanchez-Arevalo; Doni, M.; Verrecchia, A.; Sanulli, S.; Faga, G.; Piontini, A.; Mazzarol, G.; Amati, B.] European Inst Oncol IEO, Dept Expt Oncol, Milan, Italy; [Bianchi, M.] FIRC Inst Mol Oncol IFOM, Milan, Italy; [Conacci-Sorrell, M.; Eisenman, R. N.] Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98104 USA; [Peg, V.; Losa, J. H.] Hospital Vall de Hebron, Barcelona, Spain; [Ronchi, P.] Ist Sci San Raffaele, Immunohematol & Transfus Med Serv, I-20132 Milan, Italy; [Ronchi, P.; Ponzoni, M.] Ist Sci San Raffaele, Leukemia Unit, I-20132 Milan, Italy; [Ponzoni, M.; Doglioni, C.] Ist Sci San Raffaele, Pathol Unit, I-20132 Milan, Italy; [Amati, B.] Fdn Ist Italiano Tecnol IIT, Ctr Genom Sci IIT SEMM, Milan, Italy	IRCCS European Institute of Oncology (IEO); IFOM - FIRC Institute of Molecular Oncology; Fred Hutchinson Cancer Center; Hospital Universitari Vall d'Hebron; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Istituto Italiano di Tecnologia - IIT	Amati, B (corresponding author), IIT, Via Adamello 16, I-20139 Milan, Italy.	bruno.amati@iit.it	Faga, Giovanni/AAB-5540-2021; Doni, Mirko/ABA-9174-2021; Peg., Vicente/AAC-9447-2020; Amati, Bruno/AAM-3418-2020; Peg, Vicente/E-9160-2018; Lobo, Victor Javier vjsal Sanchez-Arevalo/H-1069-2011; Doni, Mirko/AAN-6027-2020; Verrecchia, Alessandro/AAQ-6454-2020; Sorrell, Maralice/ABD-6764-2021; Lobo, Victor Javier Sanchez-Arevalo/N-8641-2019	Doni, Mirko/0000-0001-7099-2701; Peg., Vicente/0000-0002-5203-6166; Peg, Vicente/0000-0002-5203-6166; Lobo, Victor Javier vjsal Sanchez-Arevalo/0000-0002-4561-1505; Verrecchia, Alessandro/0000-0002-8596-6650; Lobo, Victor Javier Sanchez-Arevalo/0000-0002-4561-1505; Amati, Bruno/0000-0002-2958-1799; DOGLIONI, Claudio/0000-0002-4969-5216	Ministerio de Ciencia e Inovacion; European Commission FP7 Program (EuroSyStem); European Commission FP7 Program (MODHEP); European Research Council; Association for International Cancer Research (AICR); Cariplo Foundation; Italian Health Ministry; Italian Association for Cancer Research (AIRC); NATIONAL CANCER INSTITUTE [R01CA020525] Funding Source: NIH RePORTER	Ministerio de Ciencia e Inovacion(Spanish Government); European Commission FP7 Program (EuroSyStem); European Commission FP7 Program (MODHEP); European Research Council(European Research Council (ERC)European Commission); Association for International Cancer Research (AICR); Cariplo Foundation(Fondazione Cariplo); Italian Health Ministry(Ministry of Health, Italy); Italian Association for Cancer Research (AIRC)(Fondazione AIRC per la ricerca sul cancro); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Theresia Kress, Stefano Campaner and Giorgio Scita for critical reading of the manuscript, Gianni Del Sal for scientific discussion and reagents, Warren Pear, Ricardo Sanchez-Prieto, Silvio Gutkind, Michael Cole and Pier-Giuseppe Pelicci for reagents, Celine Ngouenet, Arianna Vino, Lorenzo Spagnuolo and Teresa Moline for technical assistance, and the Antibody facility at the IFOM-IEO Campus. STI571 was supplied by Novartis. VJSAL was supported by a post-doctoral fellowship from the Ministerio de Ciencia e Inovacion. Work in the Amati lab was supported by grants from the European Commission FP7 Program (EuroSyStem and MODHEP), the European Research Council, the Association for International Cancer Research (AICR), the Cariplo Foundation, the Italian Health Ministry and the Italian Association for Cancer Research (AIRC).	Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Adhikary S, 2005, CELL, V123, P409, DOI 10.1016/j.cell.2005.08.016; Agami R, 1999, NATURE, V399, P809; Barila D, 2000, EMBO J, V19, P273, DOI 10.1093/emboj/19.2.273; Bitomsky N, 2004, ONCOGENE, V23, P7484, DOI 10.1038/sj.onc.1208064; BLACKWOOD EM, 1994, MOL BIOL CELL, V5, P597, DOI 10.1091/mbc.5.5.597; Conacci-Sorrell M, 2010, CELL, V142, P480, DOI 10.1016/j.cell.2010.06.037; CRAIG RW, 1993, CELL GROWTH DIFFER, V4, P349; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Faiola F, 2005, MOL CELL BIOL, V25, P10220, DOI 10.1128/MCB.25.23.10220-10234.2005; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Ganguly SS, 2012, ONCOGENE, V31, P1804, DOI 10.1038/onc.2011.361; Gomez-Casares MT, 2013, ONCOGENE, V32, P2239, DOI 10.1038/onc.2012.246; Gong JG, 1999, NATURE, V399, P806; Greasley PJ, 2000, NUCLEIC ACIDS RES, V28, P446, DOI 10.1093/nar/28.2.446; Gregory MA, 2003, J BIOL CHEM, V278, P51606, DOI 10.1074/jbc.M310722200; Haupt Y, 1996, EMBO J, V15, P1596, DOI 10.1002/j.1460-2075.1996.tb00504.x; Huang CC, 2008, INT J BIOCHEM CELL B, V40, P423, DOI 10.1016/j.biocel.2007.08.002; Kharbanda S, 2000, MOL CELL BIOL, V20, P4979, DOI 10.1128/MCB.20.14.4979-4989.2000; Levy D, 2008, MOL CELL, V29, P350, DOI 10.1016/j.molcel.2007.12.022; Lu KP, 2007, NAT CHEM BIOL, V3, P619, DOI 10.1038/nchembio.2007.35; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Lufei C, 2007, ONCOGENE, V26, P7656, DOI 10.1038/sj.onc.1210567; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; Mantovani F, 2004, MOL CELL, V14, P625, DOI 10.1016/j.molcel.2004.05.007; Mantovani F, 2007, NAT STRUCT MOL BIOL, V14, P912, DOI 10.1038/nsmb1306; Monje P, 2005, J BIOL CHEM, V280, P35081, DOI 10.1074/jbc.C500353200; Oh AS, 2008, MOL CELL BIOL, V28, P6580, DOI 10.1128/MCB.00118-08; Pandey P, 1996, J BIOL CHEM, V271, P23775, DOI 10.1074/jbc.271.39.23775; Patel JH, 2004, MOL CELL BIOL, V24, P10826, DOI 10.1128/MCB.24.24.10826-10834.2004; Sanchez-Prieto R, 2002, ONCOGENE, V21, P974, DOI 10.1038/sj.onc.1205134; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Srinivasan D, 2008, ONCOGENE, V27, P1095, DOI 10.1038/sj.onc.1210714; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; SUNDARESAN V, 1987, J CLIN PATHOL, V40, P1274, DOI 10.1136/jcp.40.11.1274; Vervoorts J, 2003, EMBO REP, V4, P484, DOI 10.1038/sj.embor.embor821; WILLIAMS ARW, 1990, J PATHOL, V160, P287, DOI 10.1002/path.1711600404; Wulf GM, 2001, EMBO J, V20, P3459, DOI 10.1093/emboj/20.13.3459; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110; Yi P, 2005, MOL CELL BIOL, V25, P9687, DOI 10.1128/MCB.25.21.9687-9699.2005; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zacchi P, 2002, NATURE, V419, P853, DOI 10.1038/nature01120; Zhang KL, 2005, BIOCHEM BIOPH RES CO, V336, P274, DOI 10.1016/j.bbrc.2005.08.075	44	17	17	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2013	32	45					5261	5271		10.1038/onc.2012.621	http://dx.doi.org/10.1038/onc.2012.621			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251IS	23318434	Green Accepted, hybrid			2022-12-28	WOS:000326922100002
J	Avivar-Valderas, A; Bobrovnikova-Marjon, E; Diehl, JA; Bardeesy, N; Debnath, J; Aguirre-Ghiso, JA				Avivar-Valderas, A.; Bobrovnikova-Marjon, E.; Diehl, J. Alan; Bardeesy, N.; Debnath, J.; Aguirre-Ghiso, J. A.			Regulation of autophagy during ECM detachment is linked to a selective inhibition of mTORC1 by PERK	ONCOGENE			English	Article						anoikis; breast cancer; unfolded protein response	ACTIVATED PROTEIN-KINASE; EXTRACELLULAR-MATRIX DETACHMENT; ENDOPLASMIC-RETICULUM KINASE; ANOIKIS RESISTANCE; UPSTREAM KINASE; CELL-GROWTH; STRESS; PHOSPHORYLATION; SUPPRESSION; SURVIVAL	Adhesion to the extracellular matrix (ECM) is critical for epithelial tissue homeostasis and function. ECM detachment induces metabolic stress and programmed cell death via anoikis. ECM-detached mammary epithelial cells are able to rapidly activate autophagy allowing for survival and an opportunity for re-attachment. However, the mechanisms controlling detachment-induced autophagy remain unclear. Here we uncover that the kinase PERK rapidly promotes autophagy in ECM-detached cells by activating AMP-activated protein kinase (AMPK), resulting in downstream inhibition of mTORC1-p70(S6K) signaling. LKB1 and TSC2, but not TSC1, are required for PERK-mediated inhibition of mammalian target of rapamycinin MCF10A cells and mouse embryo fibroblast cells. Importantly, this pathway shows fast kinetics, is transcription-independent and is exclusively activated during ECM detachment, but not by canonical endoplasmic reticulum stressors. Moreover, enforced PERK or AMPK activation upregulates autophagy and causes luminal filling during acinar morphogenesis by perpetuating a population of surviving autophagic luminal cells that resist anoikis. Hence, we identify a novel pathway in which suspension-activated PERK promotes the activation of LKB1, AMPK and TSC2, leading to the rapid induction of detachment-induced autophagy. We propose that increased autophagy, secondary to persistent PERK and LKB1-AMPK signaling, can robustly protect cells from anoikis and promote luminal filling during early carcinoma progression.	[Avivar-Valderas, A.; Aguirre-Ghiso, J. A.] Mt Sinai Sch Med, Tisch Canc Inst, Black Family Stem Cell Inst, Dept Med, New York, NY 10029 USA; [Avivar-Valderas, A.; Aguirre-Ghiso, J. A.] Mt Sinai Sch Med, Tisch Canc Inst, Black Family Stem Cell Inst, Dept Otolaryngol, New York, NY 10029 USA; [Bobrovnikova-Marjon, E.; Diehl, J. Alan] Univ Penn, Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA; [Bobrovnikova-Marjon, E.; Diehl, J. Alan] Univ Penn, Sch Med, Abramson Canc Res Inst, Philadelphia, PA 19104 USA; [Bardeesy, N.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA; [Debnath, J.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA; [Debnath, J.] Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Harvard University; Harvard Medical School; Massachusetts General Hospital; University of California System; University of California San Francisco; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Aguirre-Ghiso, JA (corresponding author), Mt Sinai Sch Med, Tisch Canc Inst, Black Family Stem Cell Inst, Dept Med, 1 Gustave L Levy Pl, New York, NY 10029 USA.	julio.aguirre-ghiso@mssm.edu		Debnath, Jayanta/0000-0002-8745-4069; Aguirre-Ghiso, Julio/0000-0002-6694-6507	NIH-NCI shared resources [5R24CA095823-04]; NSF Major Research Instrumentation grant [DBI-9724504]; NIH [1 S10RR0 9145-01, RO1 CA126792, CA126792-S1, P01 CA104838]; Samuel Waxman Cancer Research Foundation Tumor Dormancy Program; NIH/National Cancer Institute [CA109182, CA163131]; NIEHS [ES017146]; NYSTEM; Leukemia and Lymphoma Scholar; NATIONAL CANCER INSTITUTE [U54CA163131, R01CA126792, P01CA104838, R24CA095823, R01CA109182] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR009145] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R21ES017146] Funding Source: NIH RePORTER	NIH-NCI shared resources(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NSF Major Research Instrumentation grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Samuel Waxman Cancer Research Foundation Tumor Dormancy Program; NIH/National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NYSTEM; Leukemia and Lymphoma Scholar; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	Confocal laser scanning microscopy was performed at the MSSM-Microscopy Shared Resources Facility, supported with funding from NIH-NCI shared resources grant (5R24CA095823-04), NSF Major Research Instrumentation grant (DBI-9724504) and NIH shared instrumentation grant (1 S10RR0 9145-01). This work is supported by grants from the Samuel Waxman Cancer Research Foundation Tumor Dormancy Program, NIH/National Cancer Institute (CA109182, CA163131), NIEHS (ES017146) and NYSTEM to J. A. A-G, NIH RO1 CA126792, CA126792-S1 (ARRA) to JD, and P01 CA104838 and a Leukemia and Lymphoma Scholar award to JAD.	Alessi DR, 2006, ANNU REV BIOCHEM, V75, P137, DOI 10.1146/annurev.biochem.75.103004.142702; Avivar-Valderas A, 2011, MOL CELL BIOL, V31, P3616, DOI 10.1128/MCB.05164-11; Bobrovnikova-Marjon E, 2008, P NATL ACAD SCI USA, V105, P16314, DOI 10.1073/pnas.0808517105; Chen CH, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001731; Collins NL, 2005, MOL CELL BIOL, V25, P5282, DOI 10.1128/MCB.25.12.5282-5291.2005; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; Espina V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010240; Fuertes G, 2003, BIOCHEM J, V375, P75, DOI 10.1042/BJ20030282; Fung C, 2008, MOL BIOL CELL, V19, P797, DOI 10.1091/mbc.E07-10-1092; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Inoki K, 2003, GENE DEV, V17, P1829, DOI 10.1101/gad.1110003; Kerlikowske K, 2010, JNCI-J NATL CANCER I, V102, P627, DOI 10.1093/jnci/djq101; Kim J, NAT CELL BIOL, V13, P132; Klionsky DJ, 2004, NATURE, V431, P31, DOI 10.1038/431031a; Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011; Leung CT, 2012, NATURE, V482, P410, DOI 10.1038/nature10826; Liu LP, 2006, MOL CELL, V21, P521, DOI 10.1016/j.molcel.2006.01.010; Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500; Lu PD, 2004, EMBO J, V23, P169, DOI 10.1038/sj.emboj.7600030; Nelson CM, 2006, ANNU REV CELL DEV BI, V22, P287, DOI 10.1146/annurev.cellbio.22.010305.104315; Ng TL, 2012, CELL DEATH DIFFER, V19, P501, DOI 10.1038/cdd.2011.119; Ozean U, 2008, MOL CELL, V29, P541, DOI [10.1016/j.moicel.2007.12.023, 10.1016/j.molcel.2007.12.023]; Partanen JI, 2007, P NATL ACAD SCI USA, V104, P14694, DOI 10.1073/pnas.0704677104; Partanen JI, 2012, P NATL ACAD SCI USA, V109, pE388, DOI 10.1073/pnas.1120421109; Peyton KJ, 2012, J PHARMACOL EXP THER, V342, P827, DOI 10.1124/jpet.112.194712; Qin L, 2010, AUTOPHAGY, V6, P239, DOI 10.4161/auto.6.2.11062; Ranganathan AC, 2006, CANCER RES, V66, P1702, DOI 10.1158/0008-5472.CAN-05-3092; Ranganathan AC, 2008, CANCER RES, V68, P3260, DOI 10.1158/0008-5472.CAN-07-6215; Raven JF, 2008, CELL CYCLE, V7, P1146, DOI 10.4161/cc.7.9.5811; Rutkowski DT, 2004, TRENDS CELL BIOL, V14, P20, DOI 10.1016/j.tcb.2003.11.001; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Scott RC, 2004, DEV CELL, V7, P167, DOI 10.1016/j.devcel.2004.07.009; Sequeira SJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000615; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505	39	104	106	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2013	32	41					4932	4940		10.1038/onc.2012.512	http://dx.doi.org/10.1038/onc.2012.512			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235KQ	23160380	Green Accepted			2022-12-28	WOS:000325717800009
J	Jin, S; Mutvei, AP; Chivukula, IV; Andersson, ER; Ramskold, D; Sandberg, R; Lee, KL; Kronqvist, P; Mamaeva, V; Ostling, P; Mpindi, JP; Kallioniemi, O; Screpanti, I; Poellinger, L; Sahlgren, C; Lendahl, U				Jin, S.; Mutvei, A. P.; Chivukula, I. V.; Andersson, E. R.; Ramskold, D.; Sandberg, R.; Lee, K. L.; Kronqvist, P.; Mamaeva, V.; Ostling, P.; Mpindi, J-P; Kallioniemi, O.; Screpanti, I.; Poellinger, L.; Sahlgren, C.; Lendahl, U.			Non-canonical Notch signaling activates IL-6/JAK/STAT signaling in breast tumor cells and is controlled by p53 and IKK alpha/IKKb	ONCOGENE			English	Article						cytokine; inflammation; tumor stroma; estrogen receptor; breast cancer; BCL	ESTROGEN-RECEPTOR; CROSS-TALK; CANCER; EXPRESSION; PATHWAY; BINDING; KINASE; REPRESSION; SUPPRESSOR; INHIBITOR	Notch signaling is frequently hyperactivated in breast cancer, but how the enhanced signaling contributes to the tumor process is less well understood. In this report, we identify the proinflammatory cytokine interleukin-6 (IL-6) as a novel Notch target in breast tumor cells. Enhanced Notch signaling upregulated IL-6 expression, leading to activation of autocrine and paracrine Janus kinase/signal transducers and activators of transcription signaling. IL-6 upregulation was mediated by non-canonical Notch signaling, as it could be effectuated by a cytoplasmically localized Notch intracellular domain and was independent of the DNA-binding protein CSL. Instead, Notch-mediated IL-6 upregulation was controlled by two proteins in the nuclear factor (NF)-kappa B signaling cascade, IK kappa alpha and IKKb (inhibitor of nuclear factor kappa-B kinase subunit alpha and beta, respectively), as well as by p53. Activation of IL-6 by Notch required IKKa/IKKb function, but interestingly, did not engage canonical NF-kB signaling, in contrast to IL-6 activation by inflammatory agents such as lipopolysaccharide. With regard to p53 status, IL-6 expression was upregulated by Notch when p53 was mutated or lost, and restoring wild-type p53 into p53-mutated or -deficient cells abrogated the IL-6 upregulation. Furthermore, Notch-induced transcriptomes from p53 wild-type and -mutated breast tumor cell lines differed extensively, and for a subset of genes upregulated by Notch in a p53-mutant cell line, this upregulation was reduced by wild-type p53. In conclusion, we identify IL-6 as a novel non-canonical Notch target gene, and reveal roles for p53 and IKKa/IKKb in noncanonical Notch signaling in breast cancer and in the generation of cell context-dependent diversity in the Notch signaling output.	[Jin, S.; Mutvei, A. P.; Chivukula, I. V.; Andersson, E. R.; Ramskold, D.; Sandberg, R.; Poellinger, L.; Lendahl, U.] Karolinska Inst, Dept Cell & Mol Biol, SE-17177 Stockholm, Sweden; [Ramskold, D.; Sandberg, R.] Ludwig Inst Canc Res, S-10401 Stockholm, Sweden; [Lee, K. L.; Poellinger, L.] Natl Univ Singapore, Singapore 117548, Singapore; [Kronqvist, P.] Univ Turku, Dept Pathol, Turku, Finland; [Mamaeva, V.; Sahlgren, C.] Univ Turku, Turku Ctr Biotechnol, Turku, Finland; [Mamaeva, V.; Sahlgren, C.] Abo Akad Univ, Turku, Finland; [Ostling, P.; Mpindi, J-P; Kallioniemi, O.] Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki, Finland; [Screpanti, I.] Univ Roma La Sapienza, Dept Mol Med, Rome, Italy	Karolinska Institutet; Ludwig Institute for Cancer Research; National University of Singapore; University of Turku; University of Turku; Abo Akademi University; University of Helsinki; Sapienza University Rome	Lendahl, U (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, Box 285,Eulers Vag 3, SE-17177 Stockholm, Sweden.	Urban.Lendahl@ki.se	Andersson, Emma R/J-4236-2012; Kallioniemi, Olli P/H-5111-2011; LEE, Kian Leong/E-3584-2013; Andersson, Emma/AAB-8532-2019	Andersson, Emma R/0000-0002-8608-625X; Kallioniemi, Olli P/0000-0002-3231-0332; LEE, Kian Leong/0000-0002-0443-2746; Andersson, Emma/0000-0002-8608-625X; Ramskold, Daniel/0000-0003-2892-673X; Ostling, Paivi/0000-0001-5501-466X; Sandberg, Rickard/0000-0001-6473-1740; Lendahl, Urban/0000-0001-9543-8141; Chivukula, Indira/0000-0003-4416-3808; MUTVEI, ANDERS/0000-0002-2498-5225	Swedish Cancer Society; Swedish Research Council; EC; EuroSyStem and NotchIT; Karolinska Institutet (BRECT, Theme Center in Regenerative Medicine and a Distinguished Professor Award)	Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); EC(European CommissionEuropean Commission Joint Research Centre); EuroSyStem and NotchIT; Karolinska Institutet (BRECT, Theme Center in Regenerative Medicine and a Distinguished Professor Award)	This work was financially supported by the Swedish Cancer Society, the Swedish Research Council (DBRM and Project Grant), the EC projects EuroSyStem and NotchIT, Karolinska Institutet (BRECT, Theme Center in Regenerative Medicine and a Distinguished Professor Award). We are grateful to Susanne Bergstedt, Rasmus Niemi and Sinikka Kollanus for technical assistance.	Ak P, 2010, FASEB J, V24, P3643, DOI 10.1096/fj.10-160549; Andersson ER, 2011, DEVELOPMENT, V138, P3593, DOI 10.1242/dev.063610; Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937; Botcheva K, 2011, CELL CYCLE, V10, P4237, DOI 10.4161/cc.10.24.18383; Chapman G, 2006, J CELL BIOL, V175, P535, DOI 10.1083/jcb.200602009; Chua SW, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl024; CHUNG CN, 1994, NUCLEIC ACIDS RES, V22, P2938, DOI 10.1093/nar/22.15.2938; Enerly E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016915; Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heitzler P, 2010, CURR TOP DEV BIOL, V92, P457, DOI 10.1016/S0070-2153(10)92014-0; Johnston DA, 2009, GENE, V435, P36, DOI 10.1016/j.gene.2009.01.003; Kilpinen S, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r139; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Kovall RA, 2010, CURR TOP DEV BIOL, V92, P31, DOI 10.1016/S0070-2153(10)92002-4; Landor SKJ, 2011, P NATL ACAD SCI USA, V108, P18814, DOI 10.1073/pnas.1104943108; Main H, 2010, EXP CELL RES, V316, P1610, DOI 10.1016/j.yexcr.2009.12.012; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Meier-Stiegen F, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011481; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Muggerud AA, 2009, BMC MED GENOMICS, V2, DOI 10.1186/1755-8794-2-26; Murphy SH, 2011, P NATL ACAD SCI USA, V108, P17117, DOI 10.1073/pnas.1114420108; Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065; Osipo C, 2008, LAB INVEST, V88, P11, DOI 10.1038/labinvest.3700700; Pawitan Y, 2005, BREAST CANCER RES, V7, pR953, DOI 10.1186/bcr1325; Pece S, 2004, J CELL BIOL, V167, P215, DOI 10.1083/jcb.200406140; Perumalsamy LR, 2009, CELL DEATH DIFFER, V16, P879, DOI 10.1038/cdd.2009.20; Perumalsamy LR, 2010, P NATL ACAD SCI USA, V107, P6882, DOI 10.1073/pnas.0910060107; Podolin PL, 2005, J PHARMACOL EXP THER, V312, P373, DOI 10.1124/jpet.104.074484; Raafat A, 2009, ONCOGENE, V28, P219, DOI 10.1038/onc.2008.379; Reedijk M, 2005, CANCER RES, V65, P8530, DOI 10.1158/0008-5472.CAN-05-1069; Rizzo P, 2008, CANCER RES, V68, P5226, DOI 10.1158/0008-5472.CAN-07-5744; Robinson DR, 2011, NAT MED, V17, P1646, DOI 10.1038/nm.2580; Sahlgren C, 2008, P NATL ACAD SCI USA, V105, P6392, DOI 10.1073/pnas.0802047105; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Schneider G, 2011, BBA-REV CANCER, V1815, P90, DOI 10.1016/j.bbcan.2010.10.003; Schroeder T, 2000, EMBO J, V19, P2558, DOI 10.1093/emboj/19.11.2558; Selivanova G, 1999, MOL CELL BIOL, V19, P3395; Sethi N, 2011, CANCER CELL, V19, P192, DOI 10.1016/j.ccr.2010.12.022; Song LL, 2008, ONCOGENE, V27, P5833, DOI 10.1038/onc.2008.190; Speiser J, 2012, INT J SURG PATHOL, V20, P139, DOI 10.1177/1066896911427035; Stylianou S, 2006, CANCER RES, V66, P1517, DOI 10.1158/0008-5472.CAN-05-3054; Sun Y, 2011, J CELL SCI, V124, P1067, DOI 10.1242/jcs.068965; Tao LW, 2011, STEM CELLS, V29, P119, DOI 10.1002/stem.552; Turkson J, 2004, EXPERT OPIN THER TAR, V8, P409, DOI 10.1517/14728222.8.5.409; Vanden Berghe W, 1998, J BIOL CHEM, V273, P3285, DOI 10.1074/jbc.273.6.3285; Vilimas T, 2007, NAT MED, V13, P70, DOI 10.1038/nm1524; Vousden KH, 2007, NAT REV MOL CELL BIO, V8, P275, DOI 10.1038/nrm2147; Wang YA, 2008, INT J CANCER, V123, P1536, DOI 10.1002/ijc.23671; Wang YX, 2005, LANCET, V365, P671, DOI 10.1016/S0140-6736(05)17947-1; Wongchana W, 2012, CELL MOL IMMUNOL, V9, P155, DOI 10.1038/cmi.2011.36; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zeng B, 2008, CANCER RES, V68, P5397, DOI 10.1158/0008-5472.CAN-07-6792	53	96	99	1	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2013	32	41					4892	4902		10.1038/onc.2012.517	http://dx.doi.org/10.1038/onc.2012.517			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235KQ	23178494	Green Published, hybrid			2022-12-28	WOS:000325717800005
J	Suh, Y; Yoon, CH; Kim, RK; Lim, EJ; Oh, YS; Hwang, SG; An, S; Yoon, G; Gye, MC; Yi, JM; Kim, MJ; Lee, SJ				Suh, Y.; Yoon, C-H; Kim, R-K; Lim, E-J; Oh, Y. S.; Hwang, S-G; An, S.; Yoon, G.; Gye, M. C.; Yi, J-M; Kim, M-J; Lee, S-J			Claudin-1 induces epithelial-mesenchymal transition through activation of the c-Abl-ERK signaling pathway in human liver cells	ONCOGENE			English	Article						Claudin-1; epithelial-mesenchymal transition; ERK signaling	HUMAN HEPATOCELLULAR-CARCINOMA; TYROSINE KINASE; BREAST-CANCER; TIGHT JUNCTIONS; REDUCED EXPRESSION; METASTASIS; INVASION; GROWTH; GENE; FAMILY	Claudins (CLDNs) are a family of integral membrane proteins central to the formation of tight junctions, structures that are involved in paracellular transport and cellular growth and differentiation, and are critical for the maintenance of cellular polarity. Recent studies have provided evidence that CLDNs are aberrantly expressed in diverse types of human cancers, including hepatocellular carcinomas (HCCs). However, little is known about how CLDN expression is involved in cancer progression. In this study, we show that CLDN1 has a causal role in the epithelial-mesenchymal transition (EMT) in human liver cells, and that the c-Abl-Ras-Raf-1-ERK1/ 2 signaling axis is critical for the induction of malignant progression by CLDN1. Overexpression of CLDN1 induced expression of the EMT-regulating transcription factors Slug and Zeb1, and thereby led to repression of E-cadherin, b-catenin expression, enhanced expression of N-cadherin and Vimentin, a loss of cell adhesion, and increased cell motility in normal liver cells and HCC cells. In line with these findings, inhibition of either c-Abl or ERK clearly attenuated CLDN1-induced EMT, as evidenced by a reversal of N-cadherin and E-cadherin expression patterns, and restored normal motility. Collectively, these results indicate that CLDN1 is necessary for the induction of EMT in human liver cells, and that activation of the c-Abl-Ras-Raf-1-ERK1/ 2 signaling pathway is required for CLDN1-induced acquisition of the malignant phenotype. The present observations suggest that CLDN1 could be exploited as a biomarker for liver cancer metastasis and might provide a pivotal point for therapeutic intervention in HCC.	[Suh, Y.; Yoon, C-H; Kim, R-K; Lim, E-J; Lee, S-J] Hanyang Univ, Res Inst Nat Sci, Dept Chem, Seoul 133791, South Korea; [Oh, Y. S.; Gye, M. C.] Hanyang Univ, Coll Nat Sci, Dept Life Sci, Seoul 133791, South Korea; [Hwang, S-G; Kim, M-J] Korea Inst Radiol & Med Sci, Div Radiat Canc Biol, Seoul, South Korea; [An, S.] Konkuk Univ, Funct Genoproteome Res Ctr, Seoul, South Korea; [Yoon, G.] Ajou Univ, Sch Med, Dept Biochem & Mol Biol, Suwon 441749, South Korea; [Yi, J-M] Dongnam Inst Radiol & Med Sci, Res Ctr, Pusan, South Korea	Hanyang University; Hanyang University; Korea Institute of Radiological & Medical Sciences; Konkuk University; Ajou University; Korea Institute of Radiological & Medical Sciences	Lee, SJ (corresponding author), Hanyang Univ, Res Inst Nat Sci, Dept Chem, Lab Mol Biochem, 17 Haengdang Dong, Seoul 133791, South Korea.	sj0420@hanyang.ac.kr	Yoon, Changhwan/AAK-7842-2021	Yoon, Changhwan/0000-0002-8420-9818; Gye, Myung Chan/0000-0001-5682-3709	National Research Foundation (NRF); Ministry of Education, Science and Technology (MEST); Korean government, through its National Nuclear Technology Program [2012M2A2A7035878]; Converging Research Center Program [2011K000877]; Ministry of Education, Science and Technology	National Research Foundation (NRF); Ministry of Education, Science and Technology (MEST)(Ministry of Education, Science & Technology (MEST), Republic of Korea); Korean government, through its National Nuclear Technology Program(Korean Government); Converging Research Center Program; Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This work was supported by the National Research Foundation (NRF) and Ministry of Education, Science and Technology (MEST), Korean government, through its National Nuclear Technology Program (2012M2A2A7035878) and Converging Research Center Program Grant (2011K000877) funded by the Ministry of Education, Science and Technology.	Agarwal R, 2005, CANCER RES, V65, P7378, DOI 10.1158/0008-5472.CAN-05-1036; Balda MS, 2008, J CELL SCI, V121, P3677, DOI 10.1242/jcs.023887; Balda MS, 2000, EMBO J, V19, P2024, DOI 10.1093/emboj/19.9.2024; Berx G, 2001, BREAST CANCER RES, V3, P289, DOI 10.1186/bcr309; Brennan K, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/460607; Cheung ST, 2005, CLIN CANCER RES, V11, P551; Escudero-Esparza A, 2011, FRONT BIOSCI-LANDMRK, V16, P1069, DOI 10.2741/3736; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Hartsock A, 2008, BBA-BIOMEMBRANES, V1778, P660, DOI 10.1016/j.bbamem.2007.07.012; Huang YY, 1997, ONCOGENE, V15, P1947, DOI 10.1038/sj.onc.1201376; Jallal H, 2007, CANCER RES, V67, P1580, DOI 10.1158/0008-5472.CAN-06-2027; Kang YB, 2004, CELL, V118, P277, DOI 10.1016/j.cell.2004.07.011; Kominsky SL, 2003, ONCOGENE, V22, P2021, DOI 10.1038/sj.onc.1206199; Kramer F, 2000, HUM GENET, V107, P249, DOI 10.1007/s004390000375; Ku Ja-Lok, 2005, Cancer Res Treat, V37, P1, DOI 10.4143/crt.2005.37.1.1; Kummar S, 2003, CLIN ONCOL-UK, V15, P288, DOI 10.1016/S0936-6555(03)00067-0; Maeda M, 2005, J CELL SCI, V118, P873, DOI 10.1242/jcs.01634; Martin TA, 2009, BBA-BIOMEMBRANES, V1788, P872, DOI 10.1016/j.bbamem.2008.11.005; Michl P, 2003, CANCER RES, V63, P6265; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Moffat J, 2006, CELL, V124, P1283, DOI 10.1016/j.cell.2006.01.040; Morin PJ, 2005, CANCER RES, V65, P9603, DOI 10.1158/0008-5472.CAN-05-2782; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; Mullin JM, 1997, J EXP ZOOL, V279, P484, DOI 10.1002/(SICI)1097-010X(19971201)279:5<484::AID-JEZ11>3.0.CO;2-8; Myal Y, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/956897; Noren NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438; Oshima T, 2008, ONCOL REP, V19, P953; Palacios J, 2003, MODERN PATHOL, V16, P674, DOI 10.1097/01.MP.0000073974.42583.F7; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Podtcheko A, 2003, J CLIN ENDOCR METAB, V88, P1889, DOI 10.1210/jc.2002-021230; Poon RTP, 2000, ANN SURG, V232, P10, DOI 10.1097/00000658-200007000-00003; REN J, 1990, CANCER RES, V50, P358; Roberts LR, 2008, NEW ENGL J MED, V359, P420, DOI 10.1056/NEJMe0802241; Sakaguchi T, 2008, J SURG RES, V147, P123, DOI 10.1016/j.jss.2007.07.013; Si SH, 2004, WORLD J GASTROENTERO, V10, P2019, DOI 10.3748/wjg.v10.i14.2019; Silberman I, 2008, CELL CYCLE, V7, P3847, DOI 10.4161/cc.7.24.7267; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Singh A, 2009, CANCER CELL, V15, P489, DOI 10.1016/j.ccr.2009.03.022; Suzuki J, 2007, J BIOCHEM, V141, P453, DOI 10.1093/jb/mvm059; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Tokes AM, 2005, BREAST CANCER RES, V7, pR296, DOI 10.1186/bcr983; Usami Y, 2006, HUM PATHOL, V37, P569, DOI 10.1016/j.humpath.2005.12.018; Wels C, 2011, J INVEST DERMATOL, V131, P1877, DOI 10.1038/jid.2011.142; Woodring PJ, 2003, J CELL SCI, V116, P2613, DOI 10.1242/jcs.00622; Yoon CH, 2012, J BIOL CHEM, V287, P19516, DOI 10.1074/jbc.M111.337428; Yoon CH, 2010, J BIOL CHEM, V285, P226, DOI 10.1074/jbc.M109.054189; Yuan ZM, 1996, NATURE, V382, P272, DOI 10.1038/382272a0	47	132	138	2	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2013	32	41					4873	4882		10.1038/onc.2012.505	http://dx.doi.org/10.1038/onc.2012.505			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235KQ	23160379	Bronze			2022-12-28	WOS:000325717800003
J	Sedgwick, GG; Townsend, K; Martin, A; Shimwell, NJ; Grand, RJA; Stewart, GS; Nilsson, J; Turnell, AS				Sedgwick, G. G.; Townsend, K.; Martin, A.; Shimwell, N. J.; Grand, R. J. A.; Stewart, G. S.; Nilsson, J.; Turnell, A. S.			Transcriptional intermediary factor 1 gamma binds to the anaphase-promoting complex/cyclosome and promotes mitosis	ONCOGENE			English	Article						TIF1 gamma; APC/C; mitosis, spindle assembly checkpoint	SPINDLE-ASSEMBLY CHECKPOINT; CYCLIN-A; SIGNALING PATHWAY; UBIQUITIN LIGASE; APC/C; DEGRADATION; CDC20; DESTRUCTION; COMPLEX; KINASE	The anaphase-promoting complex/cyclosome (APC/C) is an ubiquitin ligase that functions during mitosis. Here we identify the transcriptional regulator, transcriptional intermediary factor 1 gamma, TIF1 gamma, as an APC/C-interacting protein that regulates APC/C function. TIF1 gamma is not a substrate for APC/C-dependent ubiquitylation but instead, associates specifically with the APC/C holoenzyme and Cdc20 to affect APC/C activity and progression through mitosis. RNA interference studies indicate that TIF1 gamma knockdown results in a specific reduction in APC/C ubiquitin ligase activity, the stabilization of APC/C substrates, and an increase in the time taken for cells to progress through mitosis from nuclear envelope breakdown to anaphase. TIF1 gamma knockdown cells are also characterized by the inappropriate presence of cyclin A at metaphase, and an increase in the number of cells that fail to undergo metaphase-to-anaphase transition. Expression of a small interfering RNA-resistant TIF1 gamma species relieves the mitotic phenotype imposed by TIF1 gamma knockdown and allows for mitotic progression. Binding studies indicate that TIF1 gamma is also a component of the APC/C-mitotic checkpoint complex (MCC), but is not required for MCC dissociation from the APC/C once the spindle assembly checkpoint (SAC) is satisfied. TIF1 gamma inactivation also results in chromosome misalignment at metaphase and SAC activation; inactivation of the SAC relieves the mitotic block imposed by TIF1 gamma knockdown. Together these data define novel functions for TIF1 gamma during mitosis and suggest that a reduction in APC/C ubiquitin ligase activity promotes SAC activation.	[Sedgwick, G. G.; Townsend, K.; Martin, A.; Shimwell, N. J.; Grand, R. J. A.; Stewart, G. S.; Turnell, A. S.] Univ Birmingham, Sch Canc Sci, Coll Med & Dent Sci, Birmingham B15 2TT, W Midlands, England; [Sedgwick, G. G.; Nilsson, J.] Univ Copenhagen, NNF Ctr Prot Res, Copenhagen N, Denmark	University of Birmingham; University of Copenhagen	Turnell, AS (corresponding author), Univ Birmingham, Sch Canc Sci, Coll Med & Dent Sci, Birmingham B15 2TT, W Midlands, England.	a.s.turnell@bham.ac.uk		Nilsson, Jakob/0000-0003-4100-1125; Stewart, Grant/0000-0002-0960-3241	CR-UK [C10000/A7542]; University of Birmingham, College of Medical and Dental Sciences Research Development Fund; Danish Cancer Society; Lundbeck Foundation; Cancer Research UK [13030] Funding Source: researchfish	CR-UK(Cancer Research UK); University of Birmingham, College of Medical and Dental Sciences Research Development Fund; Danish Cancer Society(Danish Cancer Society); Lundbeck Foundation(Lundbeckfonden); Cancer Research UK(Cancer Research UK)	We thank Francis Barr, Andrew Fry, Stefano Piccolo, Frank Rauscher III, Hughes de The and Hiroyuki Yamano for reagents. This work was funded by CR-UK (C10000/A7542) and The University of Birmingham, College of Medical and Dental Sciences Research Development Fund. JN is supported by The Danish Cancer Society and the Lundbeck Foundation.	Blackford AN, 2010, P NATL ACAD SCI USA, V107, P12251, DOI 10.1073/pnas.0914605107; Chaudhry MA, 2002, ONCOGENE, V21, P1934, DOI 10.1038/sj.onc.1205264; Choi E, 2009, EMBO J, V28, P2077, DOI 10.1038/emboj.2009.123; Chung EN, 2003, NAT CELL BIOL, V5, P748, DOI 10.1038/ncb1022; D'Angiolella V, 2003, GENE DEV, V17, P2520, DOI 10.1101/gad.267603; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; Di Fiore B, 2010, J CELL BIOL, V190, P501, DOI 10.1083/jcb.201001083; Dupont S, 2005, CELL, V121, P87, DOI 10.1016/j.cell.2005.01.033; Dupont S, 2009, CELL, V136, P123, DOI 10.1016/j.cell.2008.10.051; Ge S, 2009, CELL CYCLE, V8, P167, DOI 10.4161/cc.8.1.7606; Hayes MJ, 2006, NAT CELL BIOL, V8, P607, DOI 10.1038/ncb1410; He W, 2006, CELL, V125, P929, DOI 10.1016/j.cell.2006.03.045; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; Izawa D, 2011, NAT CELL BIOL, V13, P223, DOI 10.1038/ncb2165; Klugbauer S, 1999, ONCOGENE, V18, P4388, DOI 10.1038/sj.onc.1202824; Mansfeld J, 2011, NAT CELL BIOL, V13, P1234, DOI 10.1038/ncb2347; Massague J, 2006, FEBS LETT, V580, P2811, DOI 10.1016/j.febslet.2006.04.033; Matyskiela ME, 2009, MOL CELL, V34, P68, DOI 10.1016/j.molcel.2009.02.027; Miller JJ, 2006, GENE DEV, V20, P2410, DOI 10.1101/gad.1454006; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Nilsson J, 2008, NAT CELL BIOL, V10, P1411, DOI 10.1038/ncb1799; Peng HZ, 2002, J MOL BIOL, V320, P629, DOI 10.1016/S0022-2836(02)00477-1; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Qi W, 2007, J BIOL CHEM, V282, P3672, DOI 10.1074/jbc.M609376200; Ransom DG, 2004, PLOS BIOL, V2, P1188, DOI 10.1371/journal.pbio.0020237; Rasti M, 2006, EMBO J, V25, P2710, DOI 10.1038/sj.emboj.7601169; Reddy SK, 2007, NATURE, V446, P921, DOI 10.1038/nature05734; Reimann JDR, 2001, CELL, V105, P645, DOI 10.1016/S0092-8674(01)00361-0; Ricke RM, 2011, J CELL BIOL, V193, P1049, DOI 10.1083/jcb.201012035; Shimwell NJ, 2009, ONCOGENE, V28, P686, DOI 10.1038/onc.2008.417; Stegmeier F, 2007, NATURE, V446, P876, DOI 10.1038/nature05694; Townsend K, 2009, J BIOL CHEM, V284, P33939, DOI 10.1074/jbc.M109.009191; Turnell AS, 2006, BRIT J CANCER, V95, P555, DOI 10.1038/sj.bjc.6603304; Turnell AS, 2005, NATURE, V438, P690, DOI 10.1038/nature04151; Venturini L, 1999, ONCOGENE, V18, P1209, DOI 10.1038/sj.onc.1202655; Wan Y, 2001, MOL CELL, V8, P1027, DOI 10.1016/S1097-2765(01)00382-3; Wolthuis R, 2008, MOL CELL, V30, P290, DOI 10.1016/j.molcel.2008.02.027; Xu YX, 2007, CELL CYCLE, V6, P2896, DOI 10.4161/cc.6.23.4977; Yang Y, 2009, SCIENCE, V326, P575, DOI 10.1126/science.1177087; Yu H, 2007, MOL CELL, V27, P3, DOI 10.1016/j.molcel.2007.06.009; Zeng X, 2010, CANCER CELL, V18, P382, DOI 10.1016/j.ccr.2010.08.010; Zhang LY, 2011, J BIOL CHEM, V286, P10041, DOI 10.1074/jbc.M110.205518	42	21	22	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2013	32	39					4622	4633		10.1038/onc.2012.501	http://dx.doi.org/10.1038/onc.2012.501			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226YD	23160376	Green Accepted			2022-12-28	WOS:000325072200004
J	Guo, Y; Chirieac, LR; Bueno, R; Pass, H; Wu, W; Malinowska, IA; Kwiatkowski, DJ				Guo, Y.; Chirieac, L. R.; Bueno, R.; Pass, H.; Wu, W.; Malinowska, I. A.; Kwiatkowski, D. J.			Tsc1-Tp53 loss induces mesothelioma in mice, and evidence for this mechanism in human mesothelioma	ONCOGENE			English	Article						TSC1; TSC2; mesothelioma; rapamycin; mTOR	MALIGNANT PLEURAL MESOTHELIOMA; TUBEROUS SCLEROSIS; GENE NF2; CELLS; SURVIVAL; PATHWAY; MTORC1; ACTIVATION; GROWTH; MODEL	Mesothelioma is diagnosed in similar to 2500 patients in the United States every year, most often arising in the pleural space, but also occurring as primary peritoneal mesothelioma. The vast majority of patients with mesothelioma die of their disease within 3 years. We developed a new mouse model of mesothelioma by bladder or intraperitoneal injection of adenovirus Cre into mice with conditional alleles of each of Tp53 and Tsc1. Such mice began to develop malignant ascites about 6 months after injection, which was due to peritoneal mesothelioma, on the basis of tumor morphology and immunohistochemical staining. Mesothelioma cell lines were established, which showed loss of both Tsc1 and Tp53, with mammalian target of rapamycin complex (mTORC)1 activation. Treatment of mice with malignant ascites due to mesothelioma with rapamycin led to a marked reduction in ascites, extended survival and a 95-99% reduction in the mesothelioma tumor volume, in comparison with vehicle-treated mice. To see whether TSC1/TSC2 loss was a common genetic event in human mesothelioma, we examined nine human mesothelioma cell lines, and found that four of nine showed persistent activation of mTORC1, although none had loss of TSC1 or TSC2. A tissue microarray analysis of 198 human mesothelioma specimens showed that 33% of cases had reduced TSC2 expression and 60% showed activation of mTOR, indicating that mTOR activation is common in human mesothelioma, suggesting that it is a potential therapeutic target.	[Guo, Y.; Wu, W.; Malinowska, I. A.; Kwiatkowski, D. J.] Brigham & Womens Hosp, Dept Med, Div Translat Med, Boston, MA 02115 USA; [Guo, Y.; Wu, W.; Malinowska, I. A.; Kwiatkowski, D. J.] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Chirieac, L. R.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Bueno, R.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Thorac Surg, Boston, MA 02115 USA; [Pass, H.] NYU, Dept Cardiothorac Surg, Langone Med Ctr, New York, NY USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; New York University; NYU Langone Medical Center	Kwiatkowski, DJ (corresponding author), Brigham & Womens Hosp, Dept Med, Div Translat Med, Boston, MA 02115 USA.	dk@rics.bwh.harvard.edu	Chirieac, Lucian R./AAD-2030-2019; Malinowska, Izabela/A-4816-2013	Pass, Harvey/0000-0003-3222-3471	National Institutes of Health [1P01CA120964, 2P50CA090578]; Chip Thayer Fund; NATIONAL CANCER INSTITUTE [P50CA090578, P01CA120964] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Chip Thayer Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Nathanael Gray (Dana Farber Cancer Institute, Boston, MA, USA) for kindly providing mTOR inhibitor Torin1 used in this study. This work was supported by Grants 1P01CA120964 and 2P50CA090578 from the National Institutes of Health, and the Chip Thayer Fund.	Altomare DA, 2005, ONCOGENE, V24, P6080, DOI 10.1038/sj.onc.1208744; Auricchio N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031900; BIANCHI AB, 1995, P NATL ACAD SCI USA, V92, P10854, DOI 10.1073/pnas.92.24.10854; Brevet M, 2011, J THORAC ONCOL, V6, P864, DOI 10.1097/JTO.0b013e318215a07d; Burt BM, 2011, CANCER-AM CANCER SOC, V117, P5234, DOI 10.1002/cncr.26143; Dickson MA, 2013, INT J CANCER, V132, P1711, DOI 10.1002/ijc.27800; Ettinger DS, 2012, J NATL COMPR CANC NE, V10, P26, DOI 10.6004/jnccn.2012.0006; Goto J, 2011, P NATL ACAD SCI USA, V108, pE1070, DOI 10.1073/pnas.1106454108; Hammerman PS, 2012, NATURE, V489, P519, DOI 10.1038/nature11404; Hoda MA, 2011, J THORAC ONCOL, V6, P852, DOI 10.1097/JTO.0b013e31820e1a25; Iyer G, 2012, SCIENCE, V338, P221, DOI 10.1126/science.1226344; Jagadeeswaran R, 2006, CANCER RES, V66, P352, DOI 10.1158/0008-5472.CAN-04-4567; James MF, 2009, MOL CELL BIOL, V29, P4250, DOI 10.1128/MCB.01581-08; Jiao YC, 2011, SCIENCE, V331, P1199, DOI 10.1126/science.1200609; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Liang MC, 2010, ONCOGENE, V29, P1588, DOI 10.1038/onc.2009.452; Lopez-Lago MA, 2009, MOL CELL BIOL, V29, P4235, DOI 10.1128/MCB.01578-08; Marino S, 2000, GENE DEV, V14, P994; Meikle L, 2008, J NEUROSCI, V28, P5422, DOI 10.1523/JNEUROSCI.0955-08.2008; Menges CW, 2012, MOL CANCER RES, V10, P1178, DOI 10.1158/1541-7786.MCR-12-0082; Menon S, 2008, Oncogene, V27 Suppl 2, pS43, DOI 10.1038/onc.2009.352; Opitz I, 2008, EUR J CARDIO-THORAC, V33, P501, DOI 10.1016/j.ejcts.2007.09.045; Penno M B, 1995, Cancer J Sci Am, V1, P196; Platt FM, 2009, CLIN CANCER RES, V15, P6008, DOI 10.1158/1078-0432.CCR-09-0898; Qin W, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024919; REDDEL RR, 1989, J NATL CANCER I, V81, P945, DOI 10.1093/jnci/81.12.945; Seager C., 2010, CURR PROTOC PHARM; SEKIDO Y, 1995, CANCER RES, V55, P1227; Suzuki Y, 2009, MOL MED REP, V2, P181, DOI 10.3892/mmr_00000081; Thiele E, 2010, TUBEROUS SCLEROSIS C, P3; Thoreen CC, 2009, J BIOL CHEM, V284, P8023, DOI 10.1074/jbc.M900301200; Tsao AS, 2009, J CLIN ONCOL, V27, P2081, DOI 10.1200/JCO.2008.19.8523; Vogelzang NJ, 2003, J CLIN ONCOL, V21, P2636, DOI 10.1200/JCO.2003.11.136; Wagner AJ, 2010, J CLIN ONCOL, V28, P835, DOI 10.1200/JCO.2009.25.2981; Wilson SM, 2008, AM J RESP CELL MOL, V39, P576, DOI 10.1165/rcmb.2007-0460OC	35	18	18	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2014	33	24					3151	3160		10.1038/onc.2013.280	http://dx.doi.org/10.1038/onc.2013.280			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK4QU	23851502	Green Submitted, Green Accepted			2022-12-28	WOS:000338410000008
J	Li, D; Beisswenger, C; Herr, C; Schmid, RM; Gallo, RL; Han, G; Zakharkina, T; Bals, R				Li, D.; Beisswenger, C.; Herr, C.; Schmid, R. M.; Gallo, R. L.; Han, G.; Zakharkina, T.; Bals, R.			Expression of the antimicrobial peptide cathelicidin in myeloid cells is required for lung tumor growth	ONCOGENE			English	Article						lung cancer; cathelicidin; antimicrobial peptide; inflammation; macrophage	HOST-DEFENSE; PROTEIN HCAP18/LL-37; HUMAN KERATINOCYTES; LL-37; CANCER; GENE; RECEPTOR; MURINE; SKIN; PROLIFERATION	Antimicrobial peptides, such as the cathelicidin LL-37/hCAP-18 and its mouse homolog cathelicidin-related antimicrobial peptide ( CRAMP), are important effectors of the innate immune system with direct anti-bacterial activity. Cathelicidin is possibly involved in the regulation of tumor cell growth. The aim of this study was to characterize the role of cathelicidin expressed in non-tumorous cells in a preclinical mouse model of tumor growth. Wild-type and CRAMP-deficient animals were exposed to cigarette smoke ( CS) and Lewis lung carcinoma cells were injected to initiate the growth of tumors in the lung. CS exposure significantly increased the proliferation of lung tumors in wild-type mice, but not in CRAMP-deficient mice. CS exposure induced the recruitment of myeloid cell into tumor tissue in a CRAMP-dependent manner. Mice lacking RelA/p65 specifically in myeloid cells showed impaired recruitment of CRAMP-positive cells into the lung. In vitro studies with human cells showed that LL-37/hCAP-18 in macrophages is induced by soluble factors derived from cancer cells. Taken together, these data indicate that cathelicidin expressed from myeloid cells promotes CS-induced lung tumor growth by further recruitment of inflammatory cells. The regulation of cathelicidin expression involves myeloid p65/RelA and soluble factor from tumor cells.	[Li, D.; Beisswenger, C.; Herr, C.; Han, G.; Zakharkina, T.; Bals, R.] Saarland Univ Hosp, Dept Internal Med 5, D-66421 Homburg, Germany; [Schmid, R. M.] Tech Univ Munich, Dept Internal Med 2, D-80290 Munich, Germany; [Gallo, R. L.] Univ Calif San Diego, Div Dermatol, San Diego, CA 92103 USA	Universitatsklinikum des Saarlandes; Technical University of Munich; University of California System; University of California San Diego	Bals, R (corresponding author), Saarland Univ Hosp, Dept Internal Med 5, D-66421 Homburg, Germany.	robert.bals@uks.eu	Herr, Christian/AAH-5291-2021; Beisswenger, Christoph/GRO-6580-2022; Gallo, Richard L/A-8931-2009	Gallo, Richard L/0000-0002-1401-7861; Herr, Christian/0000-0001-9422-6569	Deutsche Forschungsgemeinschaft (DFG) [1641/12]; Federal Ministry of Education and Research (FKZ ) [01GI0881-0888]; LOEWE-Schwerpunkt 'Tumor and Inflammation' of the state of Hesse	Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Federal Ministry of Education and Research (FKZ )(Federal Ministry of Education & Research (BMBF)); LOEWE-Schwerpunkt 'Tumor and Inflammation' of the state of Hesse	This work was supported by grants of the Deutsche Forschungsgemeinschaft (DFG Ba 1641/12), the Federal Ministry of Education and Research (FKZ 01GI0881-0888) and the LOEWE-Schwerpunkt 'Tumor and Inflammation' of the state of Hesse (to RB). We thank Thomas Damm, Andreas Kamyschnikow and Anja Honecker for excellent technical support.	Bals R, 2003, CELL MOL LIFE SCI, V60, P711, DOI 10.1007/s00018-003-2186-9; Bals R, 1998, P NATL ACAD SCI USA, V95, P9541, DOI 10.1073/pnas.95.16.9541; Barnes PJ, 2000, NEW ENGL J MED, V343, P269, DOI 10.1056/NEJM200007273430407; Beisswenger C, 2004, RESPIRATION, V71, P402, DOI 10.1159/000079647; Beisswenger C, 2006, J IMMUNOL, V177, P1833, DOI 10.4049/jimmunol.177.3.1833; Bowdish DME, 2005, ANTIMICROB AGENTS CH, V49, P1727, DOI 10.1128/AAC.49.5.1727-1732.2005; Bowdish DME, 2005, CURR PROTEIN PEPT SC, V6, P35, DOI 10.2174/1389203053027494; Buchau AS, 2010, J IMMUNOL, V184, P369, DOI 10.4049/jimmunol.0902110; Buettner M, 2005, J IMMUNOL, V174, P4203, DOI 10.4049/jimmunol.174.7.4203; Chromek M, 2006, NAT MED, V12, P636, DOI 10.1038/nm1407; Coffelt SB, 2008, INT J CANCER, V122, P1030, DOI 10.1002/ijc.23186; Coffelt SB, 2009, P NATL ACAD SCI USA, V106, P3806, DOI 10.1073/pnas.0900244106; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Erdag G, 2002, ANN SURG, V235, P113, DOI 10.1097/00000658-200201000-00015; Frohm M, 1997, J BIOL CHEM, V272, P15258, DOI 10.1074/jbc.272.24.15258; Gallo RL, 1997, J BIOL CHEM, V272, P13088, DOI 10.1074/jbc.272.20.13088; Goldstraw P, 2011, LANCET, V378, P1727, DOI 10.1016/S0140-6736(10)62101-0; Golec M, 2009, ANN AGR ENV MED, V16, P289; Gombart AF, 2005, FASEB J, V19, P1067, DOI 10.1096/fj.04-3284com; Grivennikov SI, 2010, CURR OPIN GENET DEV, V20, P65, DOI 10.1016/j.gde.2009.11.004; Gudmundsson GH, 1996, EUR J BIOCHEM, V238, P325, DOI 10.1111/j.1432-1033.1996.0325z.x; Hase K, 2002, INFECT IMMUN, V70, P953, DOI 10.1128/IAI.70.2.953-963.2002; Heilborn JD, 2005, INT J CANCER, V114, P713, DOI 10.1002/ijc.20795; Heilborn JD, 2003, J INVEST DERMATOL, V120, P379, DOI 10.1046/j.1523-1747.2003.12069.x; Heilborn JD, 2010, EXP DERMATOL, V19, P332, DOI 10.1111/j.1600-0625.2009.00997.x; Hensel JA, 2011, PROSTATE, V71, P659, DOI 10.1002/pros.21282; Hess C, 2010, EUR RESPIR J, V35, P343, DOI 10.1183/09031936.00196408; Koczulla R, 2003, J CLIN INVEST, V111, P1665, DOI 10.1172/JCI200317545; Kovach MA, 2012, J IMMUNOL, V189, P304, DOI 10.4049/jimmunol.1103196; Kurosaka K, 2005, J IMMUNOL, V174, P6257, DOI 10.4049/jimmunol.174.10.6257; Li D, 2014, ONCOGENE, V33, P1239, DOI 10.1038/onc.2013.75; Li GM, 2009, INT ARCH ALLERGY IMM, V150, P122, DOI 10.1159/000218115; Liu PT, 2008, CURR OPIN IMMUNOL, V20, P371, DOI 10.1016/j.coi.2008.05.014; Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933; Mookherjee N, 2006, J IMMUNOL, V176, P2455, DOI 10.4049/jimmunol.176.4.2455; Muehleisen B, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003759; Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444; Niyonsaba Francois, 2003, Current Drug Targets - Inflammation and Allergy, V2, P224, DOI 10.2174/1568010033484115; Nizet V, 2001, NATURE, V414, P454, DOI 10.1038/35106587; Okumura K, 2004, CANCER LETT, V212, P185, DOI 10.1016/j.canlet.2004.04.006; Papi A, 2004, THORAX, V59, P679, DOI 10.1136/thx.2003.018291; Pestonjamasp VK, 2001, PEPTIDES, V22, P1643, DOI 10.1016/S0196-9781(01)00499-5; Scott MG, 2002, J IMMUNOL, V169, P3883, DOI 10.4049/jimmunol.169.7.3883; Shaykhiev R, 2005, AM J PHYSIOL-LUNG C, V289, pL842, DOI 10.1152/ajplung.00286.2004; Sorensen OE, 2003, J IMMUNOL, V170, P5583, DOI 10.4049/jimmunol.170.11.5583; Steinstraesser L, 2006, ANN PLAS SURG, V56, P93, DOI 10.1097/01.sap.0000190883.30005.91; Takahashi H, 2010, CANCER CELL, V17, P89, DOI 10.1016/j.ccr.2009.12.008; Tecle T, 2010, INNATE IMMUN-LONDON, V16, P151, DOI 10.1177/1753425910365734; Tjabringa GS, 2003, J IMMUNOL, V171, P6690, DOI 10.4049/jimmunol.171.12.6690; von Haussen J, 2008, LUNG CANCER, V59, P12, DOI 10.1016/j.lungcan.2007.07.014; Wang TT, 2004, J IMMUNOL, V173, P2909, DOI 10.4049/jimmunol.173.5.2909; Weber G, 2005, J INVEST DERMATOL, V124, P1080, DOI 10.1111/j.0022-202X.2005.23687.x; Yang D, 2000, J EXP MED, V192, P1069, DOI 10.1084/jem.192.7.1069; Young RP, 2009, EUR RESPIR J, V34, P380, DOI 10.1183/09031936.00144208	54	35	43	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2014	33	21					2709	2716		10.1038/onc.2013.248	http://dx.doi.org/10.1038/onc.2013.248			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EH	23812430				2022-12-28	WOS:000337231700004
J	Li, Q; Yao, Y; Eades, G; Liu, Z; Zhang, Y; Zhou, Q				Li, Q.; Yao, Y.; Eades, G.; Liu, Z.; Zhang, Y.; Zhou, Q.			Downregulation of miR-140 promotes cancer stem cell formation in basal-like early stage breast cancer	ONCOGENE			English	Article						microRNAs; ductal carcinoma in situ; cancer stem cells; basal-like breast cancer	CARCINOMA IN-SITU; SURGICAL ADJUVANT BREAST; MESENCHYMAL TRANSITION; MARKERS CD44; EXPRESSION; WOMEN; ALDH1; SOX9; IDENTIFICATION; SULFORAPHANE	The major goal of breast cancer prevention is to reduce the incidence of ductal carcinoma in situ (DCIS), an early stage of breast cancer. However, the biology behind DCIS formation is not well understood. It is suspected that cancer stem cells (CSCs) are already programmed in pre-malignant DCIS lesions and that these tumor-initiating cells may determine the phenotype of DCIS. MicroRNA (miRNA) profiling of paired DCIS tumors revealed that loss of miR-140 is a hallmark of DCIS lesions. Previously, we have found that miR-140 regulates CSCs in luminal subtype invasive ductal carcinoma. Here, we find that miR-140 has a critical role in regulating stem cell signaling in normal breast epithelium and in DCIS. miRNA profiling of normal mammary stem cells and cancer stem-like cells from DCIS tumors revealed that miR-140 is significantly downregulated in cancer stem-like cells compared with normal stem cells, linking miR-140 and dysregulated stem cell circuitry. Furthermore, we found that SOX9 and ALDH1, the most significantly activated stem-cell factors in DCIS stem-like cells, are direct targets of miR-140. Currently, targeted therapies (tamoxifen) are only able to reduce DCIS risk in patients with estrogen receptor alpha (ER alpha)-positive disease. We examined a model of ER alpha-negative/basal-like DCIS and found that restoration of miR-140 via a genetic approach or with the dietary compound sulforaphane decreased SOX9 and ALDH1, and reduced tumor growth in vivo. These results support that a miR-140/ALDH1/SOX9 axis is critical to basal CSC self-renewal and tumor formation in vivo, suggesting that the miR-140 pathway may be a promising target for preventative strategies in patients with basal-like DCIS.	[Li, Q.; Yao, Y.; Eades, G.; Liu, Z.; Zhang, Y.; Zhou, Q.] Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Greenebaum Canc Ctr, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Zhou, Q (corresponding author), Univ Maryland, Sch Med, Dept Biochem & Mol Biol, Greenebaum Canc Ctr, 108 North Greene St,RM 337, Baltimore, MD 21201 USA.	qzhou@som.umaryland.edu	Li, Qinglin/K-2570-2015	Li, Qinglin/0000-0002-4125-1944	Maryland Stem Cell Fund; FAMRI; ACS; NCI; NATIONAL CANCER INSTITUTE [R01CA157779, T32CA154274, R01CA163820, P30CA134274] Funding Source: NIH RePORTER	Maryland Stem Cell Fund; FAMRI; ACS(American Cancer Society); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from Maryland Stem Cell Fund, FAMRI, ACS and NCI R01 (QZ), and NCI T32 training (GE).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; de Beca FF, 2013, J CLIN PATHOL, V66, P187, DOI 10.1136/jclinpath-2012-201169; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Eades G, 2011, J BIOL CHEM, V286, P25992, DOI 10.1074/jbc.M111.229401; Ernster VL, 2002, J NATL CANCER I, V94, P1546; Espina V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010240; Farazi TA, 2011, CANCER RES, V71, P4443, DOI 10.1158/0008-5472.CAN-11-0608; Farnie G, 2007, STEM CELL REV, V3, P169, DOI 10.1007/s12015-007-0023-5; Fisher B, 2001, SEMIN ONCOL, V28, P400, DOI 10.1053/sonc.2001.26151; Fisher B, 1998, J CLIN ONCOL, V16, P2672, DOI 10.1200/JCO.1998.16.8.2672; Fowble B, 1997, INT J RADIAT ONCOL, V38, P949, DOI 10.1016/S0360-3016(97)00153-3; George WD, 2003, LANCET, V362, P95, DOI 10.1016/S0140-6736(03)13859-7; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Hsu A, 2011, CLIN EPIGENETICS, V3, DOI 10.1186/1868-7083-3-3; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146; Kong DJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033729; Kumarswamy R, 2012, INT J CANCER, V130, P2044, DOI 10.1002/ijc.26218; Lehmann U, 2008, J PATHOL, V214, P17, DOI 10.1002/path.2251; LENNINGTON WJ, 1994, CANCER, V73, P118, DOI 10.1002/1097-0142(19940101)73:1<118::AID-CNCR2820730121>3.0.CO;2-R; Leonard GD, 2004, JNCI-J NATL CANCER I, V96, P906, DOI 10.1093/jnci/djh164; Li CI, 2005, CANCER EPIDEM BIOMAR, V14, P1008, DOI 10.1158/1055-9965.EPI-04-0849; Liu SL, 2012, J MAMMARY GLAND BIOL, V17, P15, DOI 10.1007/s10911-012-9242-8; Livasy CA, 2007, HUM PATHOL, V38, P197, DOI 10.1016/j.humpath.2006.08.017; Miller FR, 2000, J NATL CANCER I, V92, P1185, DOI 10.1093/jnci/92.14.1185A; Myzak MC, 2006, CARCINOGENESIS, V27, P811, DOI 10.1093/carcin/bgi265; Ricardo S, 2011, J CLIN PATHOL, V64, P937, DOI 10.1136/jcp.2011.090456; Ruan K, 2009, CANCER LETT, V285, P116, DOI 10.1016/j.canlet.2009.04.031; Scribner KC, 2013, ONCOGENE, V32, P2631, DOI 10.1038/onc.2012.286; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; SILVERSTEIN MJ, 1995, LANCET, V345, P1154; Simonini PDR, 2010, CANCER RES, V70, P9175, DOI 10.1158/0008-5472.CAN-10-1318; SOLIN LJ, 1993, CANCER-AM CANCER SOC, V71, P2532, DOI 10.1002/1097-0142(19930415)71:8<2532::AID-CNCR2820710817>3.0.CO;2-0; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Tait LR, 2007, INT J CANCER, V120, P2127, DOI 10.1002/ijc.22572; Takai Daiya, 2003, In Silico Biology, V3, P235; Takebe N, 2010, CLIN CANCER RES, V16, P3106, DOI 10.1158/1078-0432.CCR-09-2934; Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Volinia S, 2012, P NATL ACAD SCI USA, V109, P3024, DOI 10.1073/pnas.1200010109; Vrba L, 2011, GENOME RES, V21, P2026, DOI 10.1101/gr.123935.111; Yamashita S, 2012, J BIOL CHEM, V287, P22206, DOI 10.1074/jbc.M112.343194; Yang J, 2011, FEBS LETT, V585, P2992, DOI 10.1016/j.febslet.2011.08.013; Zhou WJ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-653	48	126	133	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2014	33	20					2589	2600		10.1038/onc.2013.226	http://dx.doi.org/10.1038/onc.2013.226			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH9YT	23752191	Green Accepted			2022-12-28	WOS:000336502700005
J	Lu, X; Mazur, SJ; Lin, T; Appella, E; Xu, Y				Lu, X.; Mazur, S. J.; Lin, T.; Appella, E.; Xu, Y.			The pluripotency factor nanog promotes breast cancer tumorigenesis and metastasis	ONCOGENE			English	Article						nanog; breast cancer; tumorigenesis; metastasis	GENE-EXPRESSION; STEM-CELLS; SIGNALING PATHWAYS; OCT4; MIGRATION; INVASION; NETWORK; MICE	Nanog is a transcription factor required for maintaining the pluripotency of embryonic stem cells, and is not expressed in most normal adult tissues. However, recent studies have indicated that Nanog is overexpressed in many types of human cancers, including breast cancer. To elucidate the physiological roles of Nanog in tumorigenesis, we developed an inducible Nanog transgenic mouse model, in which the expression of Nanog in adult tissues can be induced via LoxP/Cre-mediated deletion. Our findings indicate that overexpression of Nanog in the mammary gland is not sufficient to induce mammary tumor. However, when coexpressed with Wnt-1 in the mouse mammary gland, it promotes mammary tumorigenesis and metastasis. In this context, Nanog promotes the migration and invasion of breast cancer cells. Microarray analysis has shown that the ectopic expression of Nanog deregulates the expression of numerous genes associated with tumorigenesis and metastasis, such as the PDGFR alpha gene. Our findings demonstrate the involvement of Nanog in breast cancer metastasis, and provide the basis for the reported correlation between Nanog expression and poor prognosis of human breast cancer patients. As Nanog is not expressed in most adult tissues, these findings identify Nanog as a potential therapeutic target in the treatment of Nanog-expressing metastatic breast cancer.	[Lu, X.; Xu, Y.] Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA; [Mazur, S. J.; Appella, E.] NCI, Lab Cell Biol, NIH, Bethesda, MD 20892 USA; [Lin, T.] Guangdong Prov Acad Chinese Med Sci, Ctr Regenerat Med & Translat Med, Guangzhou, Guangdong, Peoples R China	University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Guangzhou University of Chinese Medicine	Xu, Y (corresponding author), Univ Calif San Diego, Div Biol Sci, 9500 Gilman Dr, La Jolla, CA 92093 USA.	yangxu@ucsd.edu	Lin, Tongxiang/I-4695-2013	Lin, Tongxiang/0000-0001-7033-6982; Xu, Yang/0000-0001-5574-921X	NIH [CA94254, CA124834]; Intramural Research Program of the National Cancer Institute, National Institutes of Health; NATIONAL CANCER INSTITUTE [R01CA094254, R01CA124834, ZIABC005599] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Intramural Research Program of the National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Y Li for providing the Wnt-1 transgenic mice. This work was supported by NIH grants (CA94254 and CA124834) to YX and by the Intramural Research Program of the National Cancer Institute, National Institutes of Health.	Almstrup K, 2004, CANCER RES, V64, P4736, DOI 10.1158/0008-5472.CAN-04-0679; Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708; Barbosa-Morais NL, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkp942; Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020; Campeau E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006529; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chen X, 2008, CELL, V133, P1106, DOI 10.1016/j.cell.2008.04.043; Chiou SH, 2010, CANCER RES, V70, P10433, DOI 10.1158/0008-5472.CAN-10-2638; Cho RW, 2008, STEM CELLS, V26, P364, DOI 10.1634/stemcells.2007-0440; Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224; Eckert MA, 2011, CANCER CELL, V19, P372, DOI 10.1016/j.ccr.2011.01.036; Esselens C, 2010, J BIOL CHEM, V285, P2463, DOI 10.1074/jbc.M109.055129; Ezeh UI, 2005, CANCER-AM CANCER SOC, V104, P2255, DOI 10.1002/cncr.21432; Fields S, 2007, SCIENCE, V316, P1441, DOI 10.1126/science.1144479; Gibbs CP, 2005, NEOPLASIA, V7, P967, DOI 10.1593/neo.05394; Guo WJ, 2012, CELL, V148, P1015, DOI 10.1016/j.cell.2012.02.008; Hart AH, 2005, CANCER, V104, P2092, DOI 10.1002/cncr.21435; Hatano S, 2005, MECH DEVELOP, V122, P67, DOI 10.1016/j.mod.2004.08.008; Herman JG, 2007, INT J ONCOL, V30, P1231; Ibrahim EE, 2012, STEM CELLS, V30, P2076, DOI 10.1002/stem.1182; Ishiguro T, 2012, BIOCHEM BIOPH RES CO, V418, P199, DOI 10.1016/j.bbrc.2011.10.123; Jechlinger M, 2006, J CLIN INVEST, V116, P1561, DOI 10.1172/JCI24652; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jeter CR, 2011, ONCOGENE, V30, P3833, DOI 10.1038/onc.2011.114; Jeter CR, 2009, STEM CELLS, V27, P993, DOI 10.1002/stem.29; Johnson DS, 2007, SCIENCE, V316, P1497, DOI 10.1126/science.1141319; Kelleher FC, 2006, ACTA ONCOL, V45, P375, DOI 10.1080/02841860600602946; Kohler EE, 2011, BLOOD, V117, P1761, DOI 10.1182/blood-2010-07-295261; Lee EK, 2010, J PROTEOME RES, V9, P5108, DOI 10.1021/pr100378z; Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338; Liu DP, 2010, ONCOGENE, V29, P949, DOI 10.1038/onc.2009.376; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Nagata T, 2014, BREAST CANCER-TOKYO, V21, P96, DOI 10.1007/s12282-012-0357-y; Nichols J, 1998, CELL, V95, P379, DOI 10.1016/S0092-8674(00)81769-9; Ouyang ZQ, 2009, P NATL ACAD SCI USA, V106, P21521, DOI 10.1073/pnas.0904863106; Park SJ, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-S1-S50; Pesce M, 1998, BIOESSAYS, V20, P722, DOI 10.1002/(SICI)1521-1878(199809)20:9&lt;722::AID-BIES5&gt;3.0.CO;2-I; Polakis P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008052; Sharov AA, 2006, DNA RES, V13, P123, DOI 10.1093/dnares/dsl005; Siu MKY, 2013, ONCOGENE, V32, P3500, DOI 10.1038/onc.2012.363; Sonoshita M, 2011, CANCER CELL, V19, P125, DOI 10.1016/j.ccr.2010.11.008; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Xiao CC, 2008, NAT IMMUNOL, V9, P405, DOI 10.1038/ni1575; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yeom YI, 1996, DEVELOPMENT, V122, P881; Zhang JY, 2010, ONCOL LETT, V1, P457, DOI 10.3892/ol_00000081	52	100	106	2	29	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2014	33	20					2655	2664		10.1038/onc.2013.209	http://dx.doi.org/10.1038/onc.2013.209			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH9YT	23770853	Green Accepted			2022-12-28	WOS:000336502700011
J	Kennedy, CL; Najdovska, M; Tye, H; McLeod, L; Yu, L; Jarnicki, A; Bhathal, PS; Putoczki, T; Ernst, M; Jenkins, BJ				Kennedy, C. L.; Najdovska, M.; Tye, H.; McLeod, L.; Yu, L.; Jarnicki, A.; Bhathal, P. S.; Putoczki, T.; Ernst, M.; Jenkins, B. J.			Differential role of MyD88 and Mal/TIRAP in TLR2-mediated gastric tumourigenesis	ONCOGENE			English	Article						gastric cancer; TLR2; MyD88; Mal/TIRAP	INNATE IMMUNITY; HELICOBACTER-PYLORI; MUTANT MICE; INFLAMMATION; CANCER; STAT3; TLR2; ACTIVATION; SUSCEPTIBILITY; POLYMORPHISM	Signalling by the toll-like receptor (TLR) family of pathogen recognition receptors has emerged as a key molecular component in the pathogenesis of an increasing number of inflammatory-related cancers, among which gastric cancer rates as the second most lethal cancer world-wide. The myeloid differentiation factor 88 (MyD88) adapter molecule has a critical role in mediating innate immune signalling by members of the TLR and interleukin (IL)-1 families, and has been associated with either pro-or antitumourigenic responses in various cancer models. However, little is known about the in vivo role of MyD88 adapter-like (Mal)/TIR-domain containing adapter protein (TIRAP), which is restricted to facilitating TLR4 and TLR2 signalling. To interrogate the role of these innate immune signalling components in gastric tumourigenesis, here we have employed the spontaneous gastric cancer gp130(F/F) mouse model, in which TLR2 promotes the growth of gastric tumours. Genetic ablation of Myd88 in gp130(F/F) mice suppressed tumourigenesis and was associated with increased apoptosis and reduced proliferation in the gastric tumour epithelium, comparable to that observed previously upon deletion of Tlr2 in gp130(F/F) mice. By contrast, the tumour burden in gp130(F/F):Mal(-/-) mice was equivalent to their gp130F/F littermates. At the molecular level, suppressed tumourigenesis in gp130(F/F):Myd88(-/-) mice correlated with reduced expression and activation of TLR2-regulated protumourigenic genes and signalling pathways, respectively. Consistent with the previously defined non-essential role for TLR2 in gastric tumour inflammation, the extent of inflammatory cell infiltrates in gastric tumours from gp130(F/F):Mal(-/-) and gp130(F/F):Myd88(-/-) mice remained unaltered compared with gp130(F/F) mice. Collectively, our data reveal a differential, but inflammation-independent, requirement for Mal and MyD88 during TLR2-promoted gastric tumourigenesis.	[Kennedy, C. L.; Najdovska, M.; Tye, H.; McLeod, L.; Yu, L.; Jenkins, B. J.] Monash Univ, Monash Inst Med Res, Ctr Innate Immun & Infect Dis, Clayton, Vic 3168, Australia; [Jarnicki, A.; Putoczki, T.; Ernst, M.] Royal Melbourne Hosp, Ludwig Inst Canc Res, Parkville, Vic 3050, Australia; [Bhathal, P. S.] Univ Melbourne, Dept Pathol, Melbourne, Vic, Australia	Monash University; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; University of Melbourne	Jenkins, BJ (corresponding author), Monash Univ, Monash Inst Med Res, Ctr Innate Immun & Infect Dis, 27-31 Wright St, Clayton, Vic 3168, Australia.	Brendan.Jenkins@monash.edu	Ernst, Matthias/D-5111-2012	Ernst, Matthias/0000-0002-6399-1177; Kennedy, Catherine/0000-0001-6359-6161; Jenkins, Brendan/0000-0002-7552-4656	Association for International Cancer Research (UK); Cancer Council of Victoria (Australia); National Health and Medical Research Council (Australia); Victorian Government of Australia; Sylvia and Charles Viertel Foundation	Association for International Cancer Research (UK); Cancer Council of Victoria (Australia)(Canadian Institutes of Health Research (CIHR)Cancer Council Victoria); National Health and Medical Research Council (Australia)(National Health and Medical Research Council (NHMRC) of Australia); Victorian Government of Australia; Sylvia and Charles Viertel Foundation	This study was supported by research grants from the Association for International Cancer Research (UK), the Cancer Council of Victoria (Australia) and the National Health and Medical Research Council (Australia), as well as the Operational Infrastructure Support Program by the Victorian Government of Australia. BJ Jenkins is supported by a Senior Medical Research Fellowship awarded by the Sylvia and Charles Viertel Foundation.	Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; Bollrath J, 2009, CANCER CELL, V15, P91, DOI 10.1016/j.ccr.2009.01.002; Cole LE, 2010, J LEUKOCYTE BIOL, V87, P275, DOI 10.1189/jlb.0909619; Coste I, 2010, J CLIN INVEST, V120, P3663, DOI 10.1172/JCI42771; Ernst M, 2008, J CLIN INVEST, V118, P1727, DOI 10.1172/JCI34944; Greenhill CJ, 2011, J IMMUNOL, V186, P1199, DOI 10.4049/jimmunol.1002971; Grivennikov SI, 2012, NATURE, V491, P254, DOI 10.1038/nature11465; Hoebe K, 2006, ADV IMMUNOL, V91, P175, DOI 10.1016/S0065-2776(06)91005-0; Hold GL, 2007, GASTROENTEROLOGY, V132, P905, DOI 10.1053/j.gastro.2006.12.026; Hutchinson E, 2012, NAT REV IMMUNOL, V12, P681, DOI 10.1038/nri3304; Jenkins BJ, 2005, NAT MED, V11, P845, DOI 10.1038/nm1282; Kawai T, 2010, NAT IMMUNOL, V11, P373, DOI 10.1038/ni.1863; Kennedy CL, 2011, J PATHOL, V225, P255, DOI 10.1002/path.2933; Kenny EF, 2009, J IMMUNOL, V183, P3642, DOI 10.4049/jimmunol.0901140; Mandell L, 2004, INFECT IMMUN, V72, P6446, DOI 10.1128/IAI.72.11.6446-6454.2004; Milne AN, 2009, HUM GENET, V126, P615, DOI 10.1007/s00439-009-0722-x; Naugler WE, 2007, SCIENCE, V317, P121, DOI 10.1126/science.1140485; Rakoff-Nahoum S, 2007, SCIENCE, V317, P124, DOI 10.1126/science.1140488; Salcedo R, 2010, J EXP MED, V207, P1625, DOI 10.1084/jem.20100199; Schiechl G, 2011, J CLIN INVEST, V121, P1692, DOI 10.1172/JCI42540; Shen YN, 2010, INFECT IMMUN, V78, P2857, DOI 10.1128/IAI.01138-09; Sierra SS, 2009, EMBO J, V28, P2018, DOI 10.1038/emboj.2009.158; Swann JB, 2008, P NATL ACAD SCI USA, V105, P652, DOI 10.1073/pnas.0708594105; Tahara T, 2007, CANCER SCI, V98, P1790, DOI 10.1111/j.1349-7006.2007.00590.x; Tye H, 2012, CANCER CELL, V22, P466, DOI 10.1016/j.ccr.2012.08.010; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Uno K, 2007, AM J PHYSIOL-GASTR L, V293, pG1004, DOI 10.1152/ajpgi.00096.2007; Uronis JM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006026; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182	29	31	34	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2014	33	19					2540	2546		10.1038/onc.2013.205	http://dx.doi.org/10.1038/onc.2013.205			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH3OK	23728346				2022-12-28	WOS:000336033600014
J	Manning, AL; Benes, C; Dyson, NJ				Manning, A. L.; Benes, C.; Dyson, N. J.			Whole chromosome instability resulting from the synergistic effects of pRB and p53 inactivation	ONCOGENE			English	Article						heterogeneity; aneuploidy; CIN; retinoblastoma; RB1	GENOMIC INSTABILITY; CLONAL EVOLUTION; GENE-EXPRESSION; HUMAN-CELLS; ANEUPLOIDY; TUMOR; RB; PATHWAY; RETINOBLASTOMA; CANCER	Whole chromosome instability (CIN) is a common feature of cancer cells and has been linked to increased tumor evolution and metastasis. Several studies have shown that the loss of the pRB tumor suppressor causes mitotic defects and chromosome missegregation. pRB is inactivated in many types of cancer and this raises the possibility that the loss of pRB may be a general cause of CIN in tumors. Paradoxically, retinoblastoma tumor cells have a relatively stable karyotype and currently the circumstances in which pRB inactivation causes CIN in human cancers are unclear. Here we utilize a fluorescence in situ hybridization-based approach to score numerical heterogeneity in chromosome copy number as a readout of CIN. Using this technique, we show that high levels of CIN correlate with the combined inactivation of pRB and p53 and that this association is evident in two independent panels of cancer cell lines. Retinoblastoma cell lines characteristically retain a wild-type TP53 gene, providing an opportunity to test the relevance of this functional relationship. We show that retinoblastoma cell lines display mitotic defects similar to those seen when pRB is depleted from non-transformed cells, but that the presence of wild-type p53 suppresses the accumulation of aneuploid cells. A similar synergy between pRB and p53 inactivation was observed in HCT116 cells. These results suggest that the loss of pRB promotes segregation errors, whereas loss of p53 allows tolerance and continued proliferation of the resulting, genomically unstable cancer cells. Hence, it is the cooperative effect of inactivation of both pRB and p53 tumor suppressor pathways that promotes CIN.	[Manning, A. L.; Benes, C.; Dyson, N. J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc Res,Canc Ctr, Charlestown, MA 02129 USA	Harvard University; Massachusetts General Hospital	Dyson, NJ (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc Res,Canc Ctr, 149 13th St,MB 7330, Charlestown, MA 02129 USA.	dyson@helix.mgh.harvard.edu	Manning, Amity/AAC-8205-2019	Manning, Amity/0000-0003-1332-9086	American Cancer Society Fellowship; NIH [R01 CA155202]; NATIONAL CANCER INSTITUTE [R01CA155202] Funding Source: NIH RePORTER	American Cancer Society Fellowship(American Cancer Society); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the Lees, Dyer and Pellman labs for sharing cell lines, and Neil Ganem for critical reading of the manuscript. This work was supported by a American Cancer Society Fellowship (A.L.M.) and funding from NIH grant R01 CA155202 (to N.J.D). N.J.D. is the James and Shirley Curvey MGH Research Scholar.	Albertson DG, 2003, NAT GENET, V34, P369, DOI 10.1038/ng1215; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Bunz F, 2002, CANCER RES, V62, P1129; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Cahill DP, 1999, GENOMICS, V58, P181, DOI 10.1006/geno.1999.5831; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Chin K, 2004, NAT GENET, V36, P984, DOI 10.1038/ng1409; Choi CM, 2009, LUNG CANCER, V64, P66, DOI 10.1016/j.lungcan.2008.07.016; Chung NG, 2012, LEUKEMIA LYMPHOMA, V53, P1234, DOI 10.3109/10428194.2011.645819; Cimini D, 2001, J CELL BIOL, V153, P517, DOI 10.1083/jcb.153.3.517; Conklin JF, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2254; Conkrite K, 2012, J CLIN INVEST, V122, P1726, DOI 10.1172/JCI61403; Corson TW, 2007, GENE CHROMOSOME CANC, V46, P617, DOI 10.1002/gcc.20457; Coschi CH, 2012, CELL MOL LIFE SCI, V69, P2009, DOI 10.1007/s00018-011-0910-4; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; Di Leonardo A, 1997, CANCER RES, V57, P1013; Dimaras H, 2008, HUM MOL GENET, V17, P1363, DOI 10.1093/hmg/ddn024; Ertel A, 2010, CELL CYCLE, V9, P4153, DOI 10.4161/cc.9.20.13454; Fuster JJ, 2007, TRENDS MOL MED, V13, P192, DOI 10.1016/j.molmed.2007.03.002; Gao CF, 2007, P NATL ACAD SCI USA, V104, P8995, DOI 10.1073/pnas.0700631104; Gordon GM, 2011, PROTEIN CELL, V2, P864, DOI 10.1007/s13238-011-1117-z; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heilig CE, 2010, J CELL MOL MED, V14, P895, DOI 10.1111/j.1582-4934.2009.00905.x; Herrera RE, 1996, MOL CELL BIOL, V16, P2402; Holland AJ, 2012, EMBO REP, V13, P501, DOI 10.1038/embor.2012.55; Holland EC, 1998, GENE DEV, V12, P3644, DOI 10.1101/gad.12.23.3644; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Janssen A, 2011, SCIENCE, V333, P1895, DOI 10.1126/science.1210214; Kang H, 2004, MOL CELL BIOL, V24, P1188, DOI 10.1128/MCB.24.3.1188-1199.2004; Khan SH, 1998, CANCER RES, V58, P396; Kim MS, 2012, NEOPLASMA, V59, P524, DOI 10.4149/neo_2012_067; Knowlton AL, 2006, CURR BIOL, V16, P1705, DOI 10.1016/j.cub.2006.07.057; KNUDSON AG, 1984, CANCER DETECT PREV, V7, P1; Kuukasjarvi T, 1997, CANCER RES, V57, P1597; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Li M, 2010, P NATL ACAD SCI USA, V107, P14188, DOI 10.1073/pnas.1005960107; Manning AL, 2012, NAT REV CANCER, V12, P220, DOI 10.1038/nrc3216; Manning AL, 2011, TRENDS CELL BIOL, V21, P433, DOI 10.1016/j.tcb.2011.05.003; Manning AL, 2010, EMBO J, V29, P3531, DOI 10.1038/emboj.2010.230; Manning AL, 2010, GENE DEV, V24, P1364, DOI 10.1101/gad.1917310; McClelland SE, 2009, CELL CYCLE, V8, P3262, DOI 10.4161/cc.8.20.9690; Negrini S, 2010, NAT REV MOL CELL BIO, V11, P220, DOI 10.1038/nrm2858; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; Pfau SJ, 2012, EMBO REP, V13, P515, DOI 10.1038/embor.2012.65; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Randle DH, 2001, P NATL ACAD SCI USA, V98, P9654, DOI 10.1073/pnas.171217498; Roschke AV, 2003, CANCER RES, V63, P8634; Roylance R, 2011, CANCER EPIDEM BIOMAR, V20, P2183, DOI 10.1158/1055-9965.EPI-11-0343; Schvartzman JM, 2011, CANCER CELL, V19, P701, DOI 10.1016/j.ccr.2011.04.017; Swanton C, 2009, P NATL ACAD SCI USA, V106, P8671, DOI 10.1073/pnas.0811835106; Thompson SL, 2008, J CELL BIOL, V180, P665, DOI 10.1083/jcb.200712029; Thompson SL, 2010, J CELL BIOL, V188, P369, DOI 10.1083/jcb.200905057; van den Heuvel S, 2008, NAT REV MOL CELL BIO, V9, P713, DOI 10.1038/nrm2469; Wang ZH, 2004, CANCER RES, V64, P2998, DOI 10.1158/0008-5472.CAN-04-0587; Weglarz L, 2006, ACTA BIOCHIM POL, V53, P349; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Xu XLL, 2009, CELL, V137, P1018, DOI 10.1016/j.cell.2009.03.051; Zhang JH, 2012, NATURE, V481, P329, DOI 10.1038/nature10733	62	27	29	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2014	33	19					2487	2494		10.1038/onc.2013.201	http://dx.doi.org/10.1038/onc.2013.201			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH3OK	23792446	Green Accepted			2022-12-28	WOS:000336033600008
J	Hou, Y; Zhang, Z; Xu, Q; Wang, H; Xu, Y; Chen, K				Hou, Y.; Zhang, Z.; Xu, Q.; Wang, H.; Xu, Y.; Chen, K.			Inhibitor of growth 4 induces NF kappa B/p65 ubiquitin-dependent degradation	ONCOGENE			English	Article						ING4; NF kappa B/p65; ubiquitination; degradation	NF-KAPPA-B; TUMOR-SUPPRESSOR GENE; CELL-GROWTH; DOWN-REGULATION; ING4; ACTIVATION; APOPTOSIS; PROTEINS; BINDING; LIGASES	As a tumor suppressor protein, the inhibitor of growth 4 (ING4) has an important role in many cellular processes including cell cycle progression, proliferation, apoptosis, DNA damage response, tumor angiogenesis and contact inhibition. Here, we report that ING4 functions as an E3 ubiquitin ligase to induce nuclear factor-kappa B (NF kappa B)/p65 degradation. The plant homeodomain finger of ING4 interacted with p65 to undergo robust ubiquitination and degradation. ING4 bound to p65 and delivered the Lys-48-linked polyubiquitin to Lys-62 residue of p65, leading to ubiquitination of p65 and degradation. Lys-62 residue of p65 was required for ING4-mediated ubiquitination of p65 and degradation. Further analysis shows that C239 of ING4 was critical for ING4-induced p65 degradation. These findings demonstrate that ING4 acts as an E3 ubiquitin ligase to induce ubiquitination of p65 and degradation, which is critical to terminate NFkB activation.	[Hou, Y.; Zhang, Z.; Xu, Q.; Xu, Y.; Chen, K.] Jiangsu Univ, Inst Life Sci, Zhenjiang 2121300, Jiangsu, Peoples R China; [Wang, H.] Tianjin Univ Tradit Chinese Med, Tianjin, Peoples R China	Jiangsu University; Tianjin University of Traditional Chinese Medicine	Hou, Y (corresponding author), Jiangsu Univ, Inst Life Sci, Zhenjiang 2121300, Jiangsu, Peoples R China.	houyz@ujs.edu.cn	hou, YONGZHONG/K-7771-2013	Hou, Yongzhong/0000-0003-2019-8686; xu, qinggang/0000-0002-8659-7041	Start Fund of Jiangsu University [12JDG071]; National Natural Science Foundation of China [81173592]; Tianjin Applied Basic Research and Frontier Technological Program [11JCZDJC21100]	Start Fund of Jiangsu University; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Tianjin Applied Basic Research and Frontier Technological Program	This work was supported by Start Fund of Jiangsu University (12JDG071). National Natural Science Foundation of China (81173592), Tianjin Applied Basic Research and Frontier Technological Program (11JCZDJC21100).	Baldwin AS, 2001, J CLIN INVEST, V107, P3, DOI 10.1172/JCI11891; Byron SA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046823; Cai LM, 2009, MELANOMA RES, V19, P1, DOI 10.1097/CMR.0b013e32831bc42f; Coles AH, 2010, P NATL ACAD SCI USA, V107, P11423, DOI 10.1073/pnas.0912116107; Coles AH, 2009, J CELL PHYSIOL, V218, P45, DOI 10.1002/jcp.21583; Coscoy L, 2003, TRENDS CELL BIOL, V13, P7, DOI 10.1016/S0962-8924(02)00005-3; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; Garkavtsev I, 2004, NATURE, V428, P328, DOI 10.1038/nature02329; Gunduz M, 2005, GENE, V356, P109, DOI 10.1016/j.gene.2005.02.014; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Hou YZ, 2007, J BIOL CHEM, V282, P9279, DOI 10.1074/jbc.M608523200; Hou YZ, 2010, J BIOL CHEM, V285, P35497, DOI 10.1074/jbc.M109.066035; Hung T, 2009, MOL CELL, V33, P248, DOI 10.1016/j.molcel.2008.12.016; Ivanov AV, 2007, MOL CELL, V28, P823, DOI 10.1016/j.molcel.2007.11.012; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kim S, 2004, P NATL ACAD SCI USA, V101, P16251, DOI 10.1073/pnas.0407158101; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Li XM, 2009, J CANCER RES CLIN, V135, P829, DOI 10.1007/s00432-008-0519-7; Natoli G, 2008, SCI SIGNAL, V1, DOI 10.1126/stke.11pe1; Nozell S, 2008, MOL CELL BIOL, V28, P6632, DOI 10.1128/MCB.00697-08; Ozer A, 2005, P NATL ACAD SCI USA, V102, P7481, DOI 10.1073/pnas.0502716102; Pickart CM, 2004, CURR OPIN CHEM BIOL, V8, P610, DOI 10.1016/j.cbpa.2004.09.009; Russell M, 2006, EXP CELL RES, V312, P951, DOI 10.1016/j.yexcr.2006.01.020; Saccani S, 2004, J EXP MED, V200, P107, DOI 10.1084/jem.20040196; Shen JC, 2007, CANCER RES, V67, P2552, DOI 10.1158/0008-5472.CAN-06-3870; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Tanaka T, 2007, NAT IMMUNOL, V8, P584, DOI 10.1038/ni1464; Uchida D, 2004, J EXP MED, V199, P167, DOI 10.1084/jem.20031291; Unoki M, 2006, J BIOL CHEM, V281, P34677, DOI 10.1074/jbc.M606296200; Wang QS, 2010, HISTOPATHOLOGY, V57, P271, DOI 10.1111/j.1365-2559.2010.03623.x; Xie YF, 2008, CANCER LETT, V271, P105, DOI 10.1016/j.canlet.2008.05.050; Xu P, 2009, CELL, V137, P133, DOI 10.1016/j.cell.2009.01.041; Zhang X, 2005, BIOCHEM BIOPH RES CO, V331, P1032, DOI 10.1016/j.bbrc.2005.04.023; Zhang X, 2004, FEBS LETT, V570, P7, DOI 10.1016/j.febslet.2004.06.010	35	44	45	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2014	33	15					1997	2003		10.1038/onc.2013.135	http://dx.doi.org/10.1038/onc.2013.135			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RK	23624912				2022-12-28	WOS:000334346300012
J	Roth, M; Chen, WY				Roth, M.; Chen, W. Y.			Sorting out functions of sirtuins in cancer	ONCOGENE			English	Review						acquired resistance; cancer; genetic instability; longevity; sirtuin; SIRT1	ACETYLATION-DEPENDENT REGULATION; STRESS-RESPONSIVE DEACETYLASE; RETRACTED ARTICLE. SEE; FINGER ENCODING GENE; FATTY-ACID OXIDATION; BINDING PROTEIN HUR; HISTONE DEACETYLASE; TUMOR-SUPPRESSOR; REGULATES SIRT1; CELL-SURVIVAL	The sirtuins (SIRT 1-7) comprise a family of NAD(+)-dependent protein-modifying enzymes with activities in lysine deacetylation, adenosinediphospho(ADP)-ribosylation, and/or deacylation. These enzymes are involved in the cell's stress response systems and in regulating gene expression, DNA damage repair, metabolism and survival. Sirtuins have complex roles in both promoting and/or suppressing tumorigenesis. This review presents recent research progress concerning sirtuins and cancer. On one hand, functional loss of sirtuin genes, particularly SIRT1, involved in maintaining genome integrity and DNA repair will promote tumorigenesis because of genomic instability upon their loss. On the other hand, cancer cells tend to require sirtuins for these same processes to allow them to survive, proliferate, repair the otherwise catastrophic genomic events and evolve. The bifurcated roles of SIRT1, and perhaps several other sirtuins, in cancer may be in part a result of the nature of the genes that are involved in the cell's genome maintenance systems. The in-depth understanding of sirtuin functions may have significant implication in designing precise modulation of selective sirtuin members to aid cancer prevention or treatment under defined conditions.	[Roth, M.; Chen, W. Y.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Canc Biol, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Chen, WY (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, City Hope, Dept Canc Biol, 1500 E Duarte Rd, Duarte, CA 91010 USA.	wechen@coh.org	Chen, WenYong/D-6748-2012	Chen, WenYong/0000-0001-6913-5729	National Cancer Institute of the National Institutes of Health [R01 CA143421]; State of California Tobacco Related Disease Research Program (TRDRP) [20XT-0121]; NATIONAL CANCER INSTITUTE [R01CA143421] Funding Source: NIH RePORTER	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); State of California Tobacco Related Disease Research Program (TRDRP)(University of California System); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the research support from the National Cancer Institute of the National Institutes of Health under award number R01 CA143421, and the State of California Tobacco Related Disease Research Program (TRDRP) award 20XT-0121 to WYC. The contents are solely the responsibility of the authors and do not represent the official views of the National Institutes of Health.	Abdelmohsen K, 2007, MOL CELL, V25, P543, DOI 10.1016/j.molcel.2007.01.011; Ahn BH, 2008, P NATL ACAD SCI USA, V105, P14447, DOI 10.1073/pnas.0803790105; Alhazzazi TY, 2011, CANCER-AM CANCER SOC, V117, P1670, DOI 10.1002/cncr.25676; Ashraf N, 2006, BRIT J CANCER, V95, P1056, DOI 10.1038/sj.bjc.6603384; Barber MF, 2012, NATURE, V487, P114, DOI 10.1038/nature11043; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bell EL, 2011, ONCOGENE, V30, P2986, DOI 10.1038/onc.2011.37; Bereshchenko OR, 2002, NAT GENET, V32, P606, DOI 10.1038/ng1018; Bradbury C, 2005, LEUKEMIA, V19, P1751, DOI 10.1038/sj.leu.2403910; Brunelle JK, 2009, J CELL SCI, V122, P437, DOI 10.1242/jcs.031682; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Burnett C, 2011, NATURE, V477, P482, DOI 10.1038/nature10296; Byles V, 2012, ONCOGENE, V31, P4619, DOI 10.1038/onc.2011.612; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Cha EJ, 2009, CLIN CANCER RES, V15, P4453, DOI 10.1158/1078-0432.CCR-08-3329; Chang TC, 2007, MOL CELL, V26, P745, DOI 10.1016/j.molcel.2007.05.010; Chase A, 2011, CLIN CANCER RES, V17, P2613, DOI 10.1158/1078-0432.CCR-10-2156; Chen RZ, 1998, NATURE, V395, P89, DOI 10.1038/25779; Chen WY, 2012, ONCOTARGET, V3, P363; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077; Chen WY, 2004, CANCER CELL, V6, P387, DOI 10.1016/j.ccr.2004.08.030; Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100; Chu F, 2005, CANCER RES, V65, P10183, DOI 10.1158/0008-5472.CAN-05-2002; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Cooper HM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004986; Dai JM, 2007, J CELL PHYSIOL, V210, P161, DOI 10.1002/jcp.20831; Daitoku H, 2004, P NATL ACAD SCI USA, V101, P10042, DOI 10.1073/pnas.0400593101; Dan L, 2012, HAEMATOL-HEMATOL J, V97, P551, DOI 10.3324/haematol.2011.055236; Danilin S, 2010, CARCINOGENESIS, V31, P1018, DOI 10.1093/carcin/bgq052; Dansen TB, 2008, TRENDS CELL BIOL, V18, P421, DOI 10.1016/j.tcb.2008.07.004; Das C, 2009, NATURE, V459, P113, DOI 10.1038/nature07861; de Nigris F, 2002, BRIT J CANCER, V86, P917, DOI 10.1038/sj.bjc.6600156; Dioum EM, 2009, SCIENCE, V324, P1289, DOI 10.1126/science.1169956; Du JT, 2011, SCIENCE, V334, P806, DOI 10.1126/science.1207861; Eades G, 2011, J BIOL CHEM, V286, P25992, DOI 10.1074/jbc.M111.229401; Eden A, 2003, SCIENCE, V300, P455, DOI 10.1126/science.1083557; Ferrari R, 2008, SCIENCE, V321, P1086, DOI 10.1126/science.1155546; Figueroa ME, 2010, CANCER CELL, V18, P553, DOI 10.1016/j.ccr.2010.11.015; Finley LWS, 2011, CANCER CELL, V19, P416, DOI 10.1016/j.ccr.2011.02.014; Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020; Ford E, 2006, GENE DEV, V20, P1075, DOI 10.1101/gad.1399706; Ford J, 2008, CELL CYCLE, V7, P3091, DOI 10.4161/cc.7.19.6799; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Frescas D, 2008, NAT REV CANCER, V8, P438, DOI 10.1038/nrc2396; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Furuyama T, 2004, CURR BIOL, V14, P1812, DOI 10.1016/j.cub.2004.09.060; Gao ZG, 2011, J BIOL CHEM, V286, P22227, DOI 10.1074/jbc.M111.228874; Guarani V, 2011, NATURE, V473, P234, DOI 10.1038/nature09917; Guarente L, 2000, GENE DEV, V14, P1021; Guo XM, 2010, J BIOL CHEM, V285, P13223, DOI 10.1074/jbc.M110.102574; Haigis MC, 2006, CELL, V126, P941, DOI 10.1016/j.cell.2006.06.057; Haigis MC, 2010, CANCER RES, V72, P2468; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heinonen M, 2011, J PATHOL, V224, P529, DOI 10.1002/path.2889; Heltweg B, 2006, CANCER RES, V66, P4368, DOI 10.1158/0008-5472.CAN-05-3617; Hennighausen L, 2008, GENE DEV, V22, P711, DOI 10.1101/gad.1643908; Herranz D, 2013, ONCOGENE, V32, P4052, DOI 10.1038/onc.2012.407; Herranz D, 2010, NAT REV CANCER, V10, P819, DOI 10.1038/nrc2962; Herranz D, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1001; Herrero-Yraola A, 2001, EMBO J, V20, P2404, DOI 10.1093/emboj/20.10.2404; Hiratsuka M, 2003, BIOCHEM BIOPH RES CO, V309, P558, DOI 10.1016/j.bbrc.2003.08.029; Hirschey MD, 2010, NATURE, V464, P121, DOI 10.1038/nature08778; Ho KK, 2008, ONCOGENE, V27, P2300, DOI 10.1038/onc.2008.23; Holloway KR, 2010, P NATL ACAD SCI USA, V107, P9216, DOI 10.1073/pnas.0911325107; Horwitz GA, 2008, SCIENCE, V321, P1084, DOI 10.1126/science.1155544; Hou HL, 2012, J CLIN PATHOL, V65, P1088, DOI 10.1136/jclinpath-2012-200940; Houtkooper RH, 2012, NAT REV MOL CELL BIO, V13, P225, DOI 10.1038/nrm3293; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Huang JY, 2010, BBA-PROTEINS PROTEOM, V1804, P1645, DOI 10.1016/j.bbapap.2009.12.021; Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Inoue T, 2007, ONCOGENE, V26, P945, DOI 10.1038/sj.onc.1209857; Inoue T, 2007, CELL CYCLE, V6, P1011, DOI 10.4161/cc.6.9.4219; Inuzuka H, 2012, CELL, V150, P179, DOI 10.1016/j.cell.2012.05.038; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jang KY, 2008, AM J SURG PATHOL, V32, P1523, DOI 10.1097/PAS.0b013e31816b6478; Jang KY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045119; Jin YH, 2008, BIOCHEM BIOPH RES CO, V368, P690, DOI 10.1016/j.bbrc.2008.01.114; Jing EX, 2007, CELL METAB, V6, P105, DOI 10.1016/j.cmet.2007.07.003; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Jung-Hynes B, 2009, J BIOL CHEM, V284, P3823, DOI 10.1074/jbc.M807869200; Kabra N, 2009, J BIOL CHEM, V284, P18210, DOI 10.1074/jbc.M109.000034; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kaidi A, 2010, SCIENCE, V329, P1348, DOI 10.1126/science.1192049; Kanfi Y, 2012, NATURE, V483, P218, DOI 10.1038/nature10815; Kawahara TLA, 2009, CELL, V136, P62, DOI 10.1016/j.cell.2008.10.052; KERCKAERT JP, 1993, NAT GENET, V5, P66, DOI 10.1038/ng0993-66; Kim EJ, 2007, MOL CELL, V28, P277, DOI 10.1016/j.molcel.2007.08.030; Kim HS, 2011, CANCER CELL, V20, P487, DOI 10.1016/j.ccr.2011.09.004; Kim HS, 2010, CANCER CELL, V17, P41, DOI 10.1016/j.ccr.2009.11.023; Kim JE, 2008, NATURE, V451, P583, DOI 10.1038/nature06500; Kim JK, 2013, HEPATOLOGY, V57, P1055, DOI 10.1002/hep.26101; Koptyra M, 2006, BLOOD, V108, P319, DOI 10.1182/blood-2005-07-2815; Kozako T, 2012, INT J CANCER, V131, P2044, DOI 10.1002/ijc.27481; Kriegl L, 2012, ONCOTARGET, V3, P1182; Krishnan J, 2012, GENE DEV, V26, P259, DOI 10.1101/gad.180406.111; Kuzmichev A, 2005, P NATL ACAD SCI USA, V102, P1859, DOI 10.1073/pnas.0409875102; Laemmle A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033433; Lages E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020600; Lain S, 2008, CANCER CELL, V13, P454, DOI 10.1016/j.ccr.2008.03.004; Lavu S, 2008, NAT REV DRUG DISCOV, V7, P841, DOI 10.1038/nrd2665; Lennerz V, 2005, P NATL ACAD SCI USA, V102, P16013, DOI 10.1073/pnas.0500090102; Li L, 2012, CANCER CELL, V21, P266, DOI 10.1016/j.ccr.2011.12.020; Li SD, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010486; Li YZ, 2011, GENES CELLS, V16, P34, DOI 10.1111/j.1365-2443.2010.01460.x; Lim JH, 2010, MOL CELL, V38, P864, DOI 10.1016/j.molcel.2010.05.023; Liszt G, 2005, J BIOL CHEM, V280, P21313, DOI 10.1074/jbc.M413296200; Liu PY, 2013, CELL DEATH DIFFER, V20, P503, DOI 10.1038/cdd.2012.147; Lombard DB, 2007, MOL CELL BIOL, V27, P8807, DOI 10.1128/MCB.01636-07; Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860; Lu LY, 2008, J BIOL CHEM, V283, P31785, DOI 10.1074/jbc.M805880200; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Mao BB, 2011, INT J BIOCHEM CELL B, V43, P1573, DOI 10.1016/j.biocel.2011.07.006; Mao ZY, 2012, P NATL ACAD SCI USA, V109, P11800, DOI 10.1073/pnas.1200583109; Mao ZY, 2011, SCIENCE, V332, P1443, DOI 10.1126/science.1202723; Marshall GM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002135; Mattagajasingh I, 2007, P NATL ACAD SCI USA, V104, P14855, DOI 10.1073/pnas.0704329104; McBurney MW, 2003, MOL CELL BIOL, V23, P38, DOI 10.1128/MCB.23.1.38-54.2003; McCord RA, 2009, AGING-US, V1, P109, DOI 10.18632/aging.100011; Menssen A, 2012, P NATL ACAD SCI USA, V109, pE187, DOI 10.1073/pnas.1105304109; Michan S, 2007, BIOCHEM J, V404, P1, DOI 10.1042/BJ20070140; Michishita E, 2008, NATURE, V452, P492, DOI 10.1038/nature06736; Michishita E, 2009, CELL CYCLE, V8, P2664, DOI 10.4161/cc.8.16.9367; Monti Elena, 2011, Curr Mol Pharmacol, V4, P62; Morris BJ, 2013, FREE RADICAL BIO MED, V56, P133, DOI 10.1016/j.freeradbiomed.2012.10.525; Mostoslavsky R, 2006, CELL, V124, P315, DOI 10.1016/J.CEL.2005.11.044; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Murayama A, 2008, CELL, V133, P627, DOI 10.1016/j.cell.2008.03.030; Nahhas F, 2007, MOL CELL BIOCHEM, V303, P221, DOI 10.1007/s11010-007-9478-6; Nakagawa T, 2009, CELL, V137, P560, DOI 10.1016/j.cell.2009.02.026; Narayan N, 2012, NATURE, V492, P199, DOI 10.1038/nature11700; Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731; Newman JC, 2012, J BIOL CHEM, V287, P42436, DOI 10.1074/jbc.R112.404863; North BJ, 2003, MOL CELL, V11, P437, DOI 10.1016/S1097-2765(03)00038-8; North BJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000784; North BJ, 2007, J BIOL CHEM, V282, P19546, DOI 10.1074/jbc.M702990200; Nosho K, 2009, MODERN PATHOL, V22, P922, DOI 10.1038/modpathol.2009.49; Nowicki MO, 2004, BLOOD, V104, P3746, DOI 10.1182/blood-2004-05-1941; Nowotarski SL, 2010, J BIOL CHEM, V285, P31885, DOI 10.1074/jbc.M110.148767; O'Hagan HM, 2011, CANCER CELL, V20, P606, DOI 10.1016/j.ccr.2011.09.012; O'Hagan HM, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000155; Oberdoerffer P, 2008, CELL, V135, P907, DOI 10.1016/j.cell.2008.10.025; Ogura M, 2010, BIOCHEM BIOPH RES CO, V393, P73, DOI 10.1016/j.bbrc.2010.01.081; Oh WK, 2010, MOL PHARMACOL, V78, P855, DOI 10.1124/mol.110.065961; Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972; Peck B, 2010, MOL CANCER THER, V9, P844, DOI 10.1158/1535-7163.MCT-09-0971; Peng LR, 2011, MOL CELL BIOL, V31, P4720, DOI 10.1128/MCB.06147-11; Peters CJ, 2010, GASTROENTEROLOGY, V139, P1995, DOI 10.1053/j.gastro.2010.05.080; Potente M, 2007, GENE DEV, V21, P2644, DOI 10.1101/gad.435107; Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040; Qiu XL, 2010, CELL METAB, V12, P662, DOI 10.1016/j.cmet.2010.11.015; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Sasaki T, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0004020; Saunders LR, 2007, ONCOGENE, V26, P5489, DOI 10.1038/sj.onc.1210616; Sawada M, 2003, NAT CELL BIOL, V5, P320, DOI 10.1038/ncb950; Scher MB, 2007, GENE DEV, V21, P920, DOI 10.1101/gad.1527307; Schwer B, 2002, J CELL BIOL, V158, P647, DOI 10.1083/jcb.200205057; Sebastian C, 2012, CELL, V151, P1185, DOI 10.1016/j.cell.2012.10.047; Seligson DB, 2009, AM J PATHOL, V174, P1619, DOI 10.2353/ajpath.2009.080874; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Shuai K, 1996, ONCOGENE, V13, P247; Slupianek A, 2006, DNA REPAIR, V5, P243, DOI 10.1016/j.dnarep.2005.10.005; Someya S, 2010, CELL, V143, P802, DOI 10.1016/j.cell.2010.10.002; Sundaresan NR, 2008, MOL CELL BIOL, V28, P6384, DOI 10.1128/MCB.00426-08; Sundaresan NR, 2009, J CLIN INVEST, V119, P2758, DOI 10.1172/JCI39162; Tao RD, 2010, MOL CELL, V40, P893, DOI 10.1016/j.molcel.2010.12.013; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Tiwari N, 2012, SEMIN CANCER BIOL, V22, P194, DOI 10.1016/j.semcancer.2012.02.013; Tudek B, 2010, AM J TRANSL RES, V2, P254; Vakhrusheva O, 2008, CIRC RES, V102, P703, DOI 10.1161/CIRCRESAHA.107.164558; van der Horst A, 2004, J BIOL CHEM, V279, P28873, DOI 10.1074/jbc.M401138200; Van Meter M, 2011, CELL CYCLE, V10, P3153, DOI 10.4161/cc.10.18.17435; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; Vaquero A, 2007, NATURE, V450, P440, DOI 10.1038/nature06268; Vaquero A, 2006, GENE DEV, V20, P1256, DOI 10.1101/gad.1412706; Vaquero A, 2009, INT J DEV BIOL, V53, P303, DOI 10.1387/ijdb.082675av; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Verdin E, 2010, TRENDS BIOCHEM SCI, V35, P669, DOI 10.1016/j.tibs.2010.07.003; Wang B, 2011, ONCOGENE, V30, P907, DOI 10.1038/onc.2010.468; Wang CG, 2006, NAT CELL BIOL, V8, P1025, DOI 10.1038/ncb1468; Wang F, 2012, ONCOGENE, V31, P1546, DOI 10.1038/onc.2011.347; Wang F, 2007, AGING CELL, V6, P505, DOI 10.1111/j.1474-9726.2007.00304.x; Wang JC, 2011, ONCOLOGY-BASEL, V81, P325, DOI 10.1159/000334577; Wang RH, 2008, MOL CELL, V32, P11, DOI 10.1016/j.molcel.2008.09.011; Wang RH, 2008, CANCER CELL, V14, P312, DOI 10.1016/j.ccr.2008.09.001; Wang SL, 2009, CELL MOL IMMUNOL, V6, P327, DOI 10.1038/cmi.2009.43; Wang X, 2006, ONCOGENE, V25, P7148, DOI 10.1038/sj.onc.1209707; Wang Z, 2013, ONCOGENE, V32, P589, DOI 10.1038/onc.2012.83; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Weinberg F, 2010, P NATL ACAD SCI USA, V107, P8788, DOI 10.1073/pnas.1003428107; Weinberg RA, 2007, BIOL CANC, P725; Welch C, 2007, ONCOGENE, V26, P5017, DOI 10.1038/sj.onc.1210293; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789; Xiao MT, 2012, GENE DEV, V26, P1326, DOI 10.1101/gad.191056.112; Xie M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045331; Xu W, 2011, CANCER CELL, V19, P17, DOI 10.1016/j.ccr.2010.12.014; Yamakuchi M, 2008, P NATL ACAD SCI USA, V105, P13421, DOI 10.1073/pnas.0801613105; Yang HY, 2007, CELL, V130, P1095, DOI 10.1016/j.cell.2007.07.035; Yang YH, 2007, NAT CELL BIOL, V9, P1253, DOI 10.1038/ncb1645; YE BH, 1993, SCIENCE, V262, P747, DOI 10.1126/science.8235596; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Yuan HF, 2012, BLOOD, V119, P1904, DOI 10.1182/blood-2011-06-361691; Yuan J, 2009, J CELL BIOL, V185, P203, DOI 10.1083/jcb.200809167; Zhao WH, 2008, NATURE, V451, P587, DOI 10.1038/nature06515; Zhao Y, 2010, NAT CELL BIOL, V12, P665, DOI 10.1038/ncb2069; Zhong L, 2010, CELL, V140, P280, DOI 10.1016/j.cell.2009.12.041	212	175	185	0	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2014	33	13					1609	1620		10.1038/onc.2013.120	http://dx.doi.org/10.1038/onc.2013.120			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9QY	23604120	Green Accepted			2022-12-28	WOS:000334344700001
J	Asiedu, MK; Beauchamp-Perez, FD; Ingle, JN; Behrens, MD; Radisky, DC; Knutson, KL				Asiedu, M. K.; Beauchamp-Perez, F. D.; Ingle, J. N.; Behrens, M. D.; Radisky, D. C.; Knutson, K. L.			AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells	ONCOGENE			English	Article						AXL; EMT; CSCs; BCSCs; tyrosine kinase	TYROSINE KINASE INHIBITOR; TUMOR-GROWTH; THERAPEUTIC TARGET; METASTASIS; EXPRESSION; PROGRESSION; ACTIVATION; INVASION; MP470	Despite significant progress in the treatment of breast cancer, particularly through the use of targeted therapy, relapse and chemoresistance remain a major hindrance to the fight to minimize the burden of the disease. It is becoming increasingly clear that a rare subpopulation of cells known as cancer stern cells (CSC), able to be generated through epithelial-to-mesenchymal transition (EMT) and capable of tumor initiation and self-renewal, contributes to treatment resistance and metastases. This means that a more effective therapy should target both the chemoresistant CSCs and the proliferating epithelial cells that give rise to them to reverse EMT and to attenuate their conversion to CSCs. Here, we demonstrate a novel function of AXL in acting upstream to induce EMT in normal and immortalized human mammary epithelial cells in an apparent positive feedback loop mechanism and regulate breast CSC (BCSC) self-renewal and chemoresistance. Downregulation of AXL using MP470 (Amuvatinib) reversed EMT in mesenchymal normal human mammary epithelial cells and murine BCSCs attenuating self-renewal and restored chemosensitivity of the BCSCs. AXL expression was also found to be associated with the expression of stem cell genes, regulation of metastases genes, increased tumorigenicity and was important for BCSC invasion and migration. Inactivation of AXL also led to the downregulation of nuclear factor-kappa B pathway and reduced tumor formation in vivo. Taken together, our data suggest that targeted therapy against AXL, in combination with systemic therapies, has the potential to improve response to anticancer therapies and to reduce breast cancer recurrence and metastases.	[Asiedu, M. K.; Beauchamp-Perez, F. D.; Behrens, M. D.; Knutson, K. L.] Mayo Clin, Coll Med, Dept Immunol, Rochester, MN 55905 USA; [Ingle, J. N.] Mayo Clin, Coll Med, Dept Oncol, Rochester, MN 55905 USA; [Radisky, D. C.] Mayo Clin, Dept Biochem & Mol Biol, Jacksonville, FL 32224 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Asiedu, MK (corresponding author), Mayo Clin, Coll Med, 228 Med Sci Bldg,200 First St SW, Rochester, MN 55905 USA.	asiedu.michael@mayo.edu; knutson.keith@mayo.edu	Radisky, Derek/B-6569-2018	Radisky, Derek/0000-0002-1962-8784	Martha; Bruce Atwater; Howard Temin Award [K01-CA100764, R01-CA122086]; Mayo Clinic Breast Cancer Specialized Program of Research Excellence Award [P50-CA116201]; NIH/NCRR CTSA [UL1 RR024150]; NATIONAL CANCER INSTITUTE [P30CA015083, R01CA122086, P50CA116201, K01CA100764] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024150] Funding Source: NIH RePORTER	Martha; Bruce Atwater; Howard Temin Award; Mayo Clinic Breast Cancer Specialized Program of Research Excellence Award; NIH/NCRR CTSA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)NIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))	This work was supported by a generous gift from Martha and Bruce Atwater (KLK); Howard Temin Award, K01-CA100764 (KLK); R01-CA122086 (DCR); and the Mayo Clinic Breast Cancer Specialized Program of Research Excellence Award, P50-CA116201 (JNI). This publication was also supported by NIH/NCRR CTSA Grant Number UL1 RR024150. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH. We acknowledge the strong support of the Mayo Clinic Comprehensive Cancer Center for providing access to core facilities.	Asiedu MK, 2011, CANCER RES, V71, P4707, DOI 10.1158/0008-5472.CAN-10-4554; Blick T, 2010, J MAMMARY GLAND BIOL, V15, P235, DOI 10.1007/s10911-010-9175-z; Bose R, 2006, P NATL ACAD SCI USA, V103, P9773, DOI 10.1073/pnas.0603948103; Chen WS, 2011, FRONT BIOSCI-LANDMRK, V16, P1172, DOI 10.2741/3782; Chung BI, 2003, DNA CELL BIOL, V22, P533, DOI 10.1089/10445490360708946; Cowin P, 2007, J MAMMARY GLAND BIOL, V12, P99, DOI 10.1007/s10911-007-9041-9; CRAVEN RJ, 1995, INT J CANCER, V60, P791, DOI 10.1002/ijc.2910600611; Gangemi R, 2009, CURR MED CHEM, V16, P1688, DOI 10.2174/092986709788186147; Gjerdrum C, 2010, P NATL ACAD SCI USA, V107, P1124, DOI 10.1073/pnas.0909333107; Grimshaw MJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2106; Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Hafizi S, 2006, FEBS J, V273, P5231, DOI 10.1111/j.1742-4658.2006.05529.x; Han JS, 2009, INT J ONCOL, V34, P1449, DOI 10.3892/ijo_00000273; Holland SJ, 2010, CANCER RES, V70, P1544, DOI 10.1158/0008-5472.CAN-09-2997; Hutterer M, 2008, CLIN CANCER RES, V14, P130, DOI 10.1158/1078-0432.CCR-07-0862; Keating AK, 2010, MOL CANCER THER, V9, P1298, DOI 10.1158/1535-7163.MCT-09-0707; Koorstra JBM, 2009, CANCER BIOL THER, V8, P618, DOI 10.4161/cbt.8.7.7923; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Lee WP, 1999, MOL CELL BIOL, V19, P8075; Li Y, 2009, ONCOGENE, V28, P3442, DOI 10.1038/onc.2009.212; Liu L, 2009, CANCER RES, V69, P6871, DOI 10.1158/0008-5472.CAN-08-4490; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Meng FY, 2002, J BIOL CHEM, V277, P29674, DOI 10.1074/jbc.M112464200; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Nakano T, 2003, CLIN EXP METASTAS, V20, P665, DOI 10.1023/A:1027355610603; OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016; Qi WQ, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-142; Radisky DC, 2005, J CELL SCI, V118, P4325, DOI 10.1242/jcs.02552; Rankin EB, 2010, CANCER RES, V70, P7570, DOI 10.1158/0008-5472.CAN-10-1267; Santisteban M, 2009, CANCER RES, V69, P2887, DOI 10.1158/0008-5472.CAN-08-3343; Shieh YS, 2005, NEOPLASIA, V7, P1058, DOI 10.1593/neo.05640; Shipitsin M, 2008, LAB INVEST, V88, P459, DOI 10.1038/labinvest.2008.14; Song X, CANCER, V117, P734; Tai KY, 2008, ONCOGENE, V27, P4044, DOI 10.1038/onc.2008.57; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835; Vajkoczy P, 2006, P NATL ACAD SCI USA, V103, P5799, DOI 10.1073/pnas.0510923103; van Ginkel PR, 2004, CANCER RES, V64, P128, DOI 10.1158/0008-5472.CAN-03-0245; Vermeulen L, 2008, CELL DEATH DIFFER, V15, P947, DOI 10.1038/cdd.2008.20; Vicente-Duenas C, 2010, DIS MODEL MECH, V3, P149, DOI 10.1242/dmm.002774; Vuoriluoto K, 2011, ONCOGENE, V30, P1436, DOI 10.1038/onc.2010.509; Welsh JW, 2009, RADIAT ONCOL, V4, DOI 10.1186/1748-717X-4-69; Wicha MS, 2006, CLIN CANCER RES, V12, P5606, DOI 10.1158/1078-0432.CCR-06-1537; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Zhang YX, 2008, CANCER RES, V68, P1905, DOI 10.1158/0008-5472.CAN-07-2661	47	189	193	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2014	33	10					1316	1324		10.1038/onc.2013.57	http://dx.doi.org/10.1038/onc.2013.57			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AC6KI	23474758	Green Accepted			2022-12-28	WOS:000332631100012
J	Fang, M; Simeonova, I; Bardot, B; Lejour, V; Jaber, S; Bouarich-Bourimi, R; Morin, A; Toledo, F				Fang, M.; Simeonova, I.; Bardot, B.; Lejour, V.; Jaber, S.; Bouarich-Bourimi, R.; Morin, A.; Toledo, F.			Mdm4 loss in mice expressing a p53 hypomorph alters tumor spectrum without improving survival	ONCOGENE			English	Article						p53; Mdm4; p21; Plk1; Rb	PROLINE-RICH DOMAIN; THERAPEUTIC TARGET; PATHWAY; REPRESSION; MUTATION; LACKING; RB	The p53 pathway is inactivated in most human cancers, and its reactivation in tumors appears as a promising therapeutic strategy. Overexpression of Mdm4, a p53 negative regulator, occurs in a significant fraction of human cancers. Mouse models were used to evaluate the therapeutic potential of strategies against Mdm4, and encouraging results were obtained for tumor cells in which Mdm4 overexpression prevents wild-type p53 to exert its tumor suppressive functions. However, missense mutations in the p53 gene occur in about half of human cancers, and 15% of such mutations lead to the expression of a mutant protein that retains partial activity. In this report, we used mouse models to address the therapeutic potential of strategies against Mdm4 in tumors expressing an hypomorphic p53 mutant. We found that, in an Rb+/- background promoting pituitary and thyroid tumors, decreased Mdm4 levels improved the survival of mice expressing wild-type p53, but not that of mice expressing p53(Delta P), a p53 hypomorph lacking the proline-rich domain. Importantly, however, most Rb+/- p53(Delta P/Delta P) mice developped pituitary adenomas, but these tumors were rare in Rb+/- p53(Delta P/Delta P) mdm4(-/-) animals, because Mdm4 loss led to increased p21 levels, a suppressor of pituitary tumor growth. On the contrary, Rb+/- p53(Delta P/Delta P) and Rb+/- p53(Delta P/Delta P) Mdm4(-/-) mice developped anaplastic thyroid carcinomas at equal frequencies. Importantly, wild-type p53 represses the Plk1 gene, which encodes a promising therapeutic target in anaplastic thyroid carcinomas, and this repression is improved when Mdm4 levels are decreased. On the opposite, p53(Delta P) is a mediocre transcriptional repressor that is not improved by Mdm4 loss. In sum, depending on the tumor type, strategies against Mdm4 that work in cells expressing wild-type p53 may not work in cells expressing an hypomorphic p53. Furthermore, p53-mediated transcriptional repression should be considered when evaluating strategies to reactivate p53 in tumors.	[Fang, M.; Simeonova, I.; Bardot, B.; Lejour, V.; Jaber, S.; Bouarich-Bourimi, R.; Morin, A.; Toledo, F.] Inst Curie, Ctr Rech, F-75248 Paris 05, France; [Fang, M.; Simeonova, I.; Bardot, B.; Lejour, V.; Jaber, S.; Bouarich-Bourimi, R.; Morin, A.; Toledo, F.] Univ Paris 06, Paris, France; [Fang, M.; Simeonova, I.; Bardot, B.; Lejour, V.; Jaber, S.; Bouarich-Bourimi, R.; Morin, A.; Toledo, F.] CNRS, UMR 3244, Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; Sorbonne Universite; UNICANCER; Institut Curie	Toledo, F (corresponding author), Inst Curie, UMR 3244, Ctr Rech, 26 Rue Ulm, F-75248 Paris 05, France.	franck.toledo@curie.fr	Simeonova, Iva/Y-9412-2019	Jaber, Sara/0000-0002-3796-102X; Toledo, Franck/0000-0003-3798-4106; Bardot, Boris/0000-0003-4976-9593	Fondation de France; Association pour la Recherche sur le Cancer; Ligue Nationale contre le Cancer; Institut National du Cancer; Canceropole Ile de France; Ministere de l'Enseignement Superieur et de la Recherche	Fondation de France(Fondation de France); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Ligue Nationale contre le Cancer(Ligue nationale contre le cancer); Institut National du Cancer(Institut National du Cancer (INCA) France); Canceropole Ile de France(Region Ile-de-France); Ministere de l'Enseignement Superieur et de la Recherche(Estonian Research CouncilEuropean Commission)	We thank members of the Curie technological platforms for their contribution to this study: I Grandjean, C Daviaud and M Garcia from the Animal facility and M Richardson, M Huerre and A Nicolas from the Pathology service. We also thank L Plancke and L Charbonnier for their help with mouse dissections, and GM Wahl and M Debatisse for their support. Funding was provided from the Fondation de France (Comite Tumeurs), the Association pour la Recherche sur le Cancer, the Ligue Nationale contre le Cancer (Comite Ile de France) and the Institut National du Cancer. MF and IS received predoctoral fellowships from the Canceropole Ile de France, the Ministere de l'Enseignement Superieur et de la Recherche and the Ligue Nationale Contre le Cancer.	Bernal F, 2010, CANCER CELL, V18, P411, DOI 10.1016/j.ccr.2010.10.024; Chesnokova V, 2008, P NATL ACAD SCI USA, V105, P17498, DOI 10.1073/pnas.0804810105; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Garcia D, 2011, GENE DEV, V25, P1746, DOI 10.1101/gad.16722111; Gembarska A, 2012, NAT MED, V18, P1239, DOI 10.1038/nm.2863; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Laurie NA, 2006, NATURE, V444, P61, DOI 10.1038/nature05194; Leroy B, 2013, NUCLEIC ACIDS RES, V41, pD962, DOI 10.1093/nar/gks1033; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Marine JC, 2011, CURR TOP DEV BIOL, V94, P45, DOI 10.1016/B978-0-12-380916-2.00003-6; McKenzie L, 2010, CELL CYCLE, V9, P4200, DOI 10.4161/cc.9.20.13532; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Nappi TC, 2009, CANCER RES, V69, P1916, DOI 10.1158/0008-5472.CAN-08-1693; Petitjean A, 2007, HUM MUTAT, V28, P622, DOI 10.1002/humu.20495; Prophet E, 1992, AFIP LAB METHODS HIS; Salvatore G, 2007, CANCER RES, V67, P10158; Simeonova I, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002731; Toledo F, 2006, CANCER CELL, V9, P273, DOI 10.1016/j.ccr.2006.03.014; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Vaseva AV, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.39; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; WILLIAMS BO, 1994, NAT GENET, V7, P480, DOI 10.1038/ng0894-480; Zilfou JT, 2001, MOL CELL BIOL, V21, P3974, DOI 10.1128/MCB.21.12.3974-3985.2001	25	9	9	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2014	33	10					1336	1339		10.1038/onc.2013.62	http://dx.doi.org/10.1038/onc.2013.62			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AC6KI	23474762				2022-12-28	WOS:000332631100014
J	Vereide, DT; Seto, E; Chiu, YF; Hayes, M; Tagawa, T; Grundhoff, A; Hammerschmidt, W; Sugden, B				Vereide, D. T.; Seto, E.; Chiu, Y-F; Hayes, M.; Tagawa, T.; Grundhoff, A.; Hammerschmidt, W.; Sugden, B.			Epstein-Barr virus maintains lymphomas via its miRNAs	ONCOGENE			English	Article						EBV; BART miRNAs; apoptosis; RISC-IP; Burkitt's lymphoma	HUMAN GAMMA-HERPESVIRUSES; MICRORNA TARGETS; DOWN-REGULATION; LMP1 ONCOGENE; PROTEIN; EBV; EXPRESSION; APOPTOSIS; CELLS; BIM	Epstein-Barr virus (EBV) has evolved exquisite controls over its host cells, human B lymphocytes, not only directing these cells during latency to proliferate and thereby expand the pool of infected cells, but also to survive and thereby persist for the lifetime of the infected individual. Although these activities ensure the virus is successful, they also make the virus oncogenic, particularly when infected people are immunosuppressed. Here we show, strikingly, that one set of EBVs microRNAs (miRNAs) both sustain Burkitt's lymphoma (BL) cells in the absence of other viral oncogenes and promote the transformation of primary B lymphocytes. BL cells were engineered to lose EBV and found to die by apoptosis and could be rescued by constitutively expressing viral miRNAs in them. Two of these EBV miRNAs were found to target caspase 3 to inhibit apoptosis at physiological concentrations.	[Vereide, D. T.; Chiu, Y-F; Hayes, M.; Sugden, B.] Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA; [Seto, E.; Tagawa, T.; Hammerschmidt, W.] DZIF German Ctr Infect Res, Res Unit Gene Vectors, Munich, Germany; [Seto, E.; Tagawa, T.; Hammerschmidt, W.] German Res Ctr Environm Hlth, Helmholtz Zentrum Munchen, Munich, Germany; [Grundhoff, A.] Leibniz Inst Expt Virol, Heinrich Pette Inst, Hamburg, Germany	University of Wisconsin System; University of Wisconsin Madison; German Center for Infection Research; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Heinrich Pette Institute	Sugden, B (corresponding author), Univ Wisconsin, McArdle Lab Canc Res, Room 814,1400 Univ Ave, Madison, WI 53706 USA.	sugden@oncology.wisc.edu	Hammerschmidt, Wolfgang/ABG-3921-2021; Tagawa, Takanobu/AAZ-2351-2021; Chiu, Ya-Fang/AAS-7536-2020	Hammerschmidt, Wolfgang/0000-0002-4659-0427; Tagawa, Takanobu/0000-0001-8637-2996; Chiu, Ya-Fang/0000-0002-7506-9032; Grundhoff, Adam/0000-0003-0940-7045	National Cancer Institute, National Institutes of Health [P01 CA022443, R01 CA133027, R01 CA070723]; Deutsche Forschungsgemeinschaft [SFB455, SEBTR5]; National Cancer Center; DAAD, German Academic Exchange Service; NATIONAL CANCER INSTITUTE [P01CA022443, R01CA133027, P30CA014520, T32CA009135, R01CA070723] Funding Source: NIH RePORTER	National Cancer Institute, National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); National Cancer Center; DAAD, German Academic Exchange Service(Deutscher Akademischer Austausch Dienst (DAAD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Alan Rickinson for kindly providing the early passage BL cell lines and Dagmar Pich for her invaluable support This work was funded by grants from the National Cancer Institute, National Institutes of Health (grant P01 CA022443, grants R01 CA133027 and R01 CA070723) and Deutsche Forschungsgemeinschaft (grants SFB455 and SEBTR5). David Vereide was supported by a predoctoral fellowship from the National Cancer Center. Takanobu Tagawa is supported by a predoctoral grant of DAAD, German Academic Exchange Service, Bill Sugden is an American Cancer Society Research Professor,	Altmann M, 2005, PLOS BIOL, V3, P2148, DOI 10.1371/journal.pbio.0030404; Anderton E, 2008, ONCOGENE, V27, P421, DOI 10.1038/sj.onc.1210668; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; BIRKENBACH M, 1993, J VIROL, V67, P2209, DOI 10.1128/JVI.67.4.2209-2220.1993; Choy EYW, 2008, J EXP MED, V205, P2551, DOI 10.1084/jem.20072581; Clybouw C, 2005, J IMMUNOL, V175, P2968, DOI 10.4049/jimmunol.175.5.2968; Dolken L, 2010, CELL HOST MICROBE, V7, P324, DOI 10.1016/j.chom.2010.03.008; GAILLARD C, 1990, NUCLEIC ACIDS RES, V18, P378, DOI 10.1093/nar/18.2.378; Grundhoff A, 2006, RNA, V12, P733, DOI 10.1261/rna.2326106; Kelly G, 2002, NAT MED, V8, P1098, DOI 10.1038/nm758; Kirchmaier AL, 1997, J VIROL, V71, P1766, DOI 10.1128/JVI.71.3.1766-1775.1997; Kuzembayeva M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047409; Lee DY, 2008, BLOOD, V111, P2280, DOI 10.1182/blood-2007-07-100032; Nanbo A, 2007, EMBO J, V26, P4252, DOI 10.1038/sj.emboj.7601853; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Oliver PM, 2006, J EXP MED, V203, P731, DOI 10.1084/jem.20051407; Paschos K, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000492; Pratt ZL, 2012, J VIROL, V86, P4380, DOI 10.1128/JVI.06966-11; Pratt ZL, 2009, VIROLOGY, V386, P387, DOI 10.1016/j.virol.2009.01.006; Pruitt KD, 2009, NUCLEIC ACIDS RES, V37, pD32, DOI 10.1093/nar/gkn721; Rajewsky N, 2006, NAT GENET, V38, pS8, DOI 10.1038/ng1798; Riley KJ, 2012, EMBO J, V31, P2207, DOI 10.1038/emboj.2012.63; Schafer A, 2007, VIROLOGY, V364, P21, DOI 10.1016/j.virol.2007.03.029; Seto E, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1001063; Skalsky RL, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002484; Suffert G, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002405; Ventura A, 2008, CELL, V132, P875, DOI 10.1016/j.cell.2008.02.019; Vereide D, 2010, ADV CANCER RES, V108, P1, DOI 10.1016/S0065.230X(10)08004.8; Vereide DT, 2011, BLOOD, V117, P1977, DOI 10.1182/blood-2010-05-285791; Walz N, 2010, J VIROL, V84, P716, DOI 10.1128/JVI.01302-09	30	110	119	1	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2014	33	10					1258	1264		10.1038/onc.2013.71	http://dx.doi.org/10.1038/onc.2013.71			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AC6KI	23503461	Green Accepted			2022-12-28	WOS:000332631100006
J	Braeutigam, C; Rago, L; Rolke, A; Waldmeier, L; Christofori, G; Winter, J				Braeutigam, C.; Rago, L.; Rolke, A.; Waldmeier, L.; Christofori, G.; Winter, J.			The RNA-binding protein Rbfox2: an essential regulator of EMT-driven alternative splicing and a mediator of cellular invasion	ONCOGENE			English	Article						Rbfox2; epithelial-mesenchymal transition; EMT; alternative splicing	EPITHELIAL-MESENCHYMAL TRANSITION; BREAST-CANCER; IN-VIVO; CARCINOMA; MIGRATION; FOX-1; METASTASIS; EXPRESSION; DYNAMIN; CELLS	The epithelial-mesenchymal transition (EMT), a prerequisite for cancer progression and metastasis formation, is regulated not only at the transcriptional but also at the post-transcriptional level, including at the level of alternative pre-mRNA splicing. Several recent studies have highlighted the involvement of splicing factors, including epithelial splicing regulatory proteins (Esrps) and RNA-binding Fox protein 2 (Rbfox2), in this process. Esrps regulate epithelial-specific splicing, and their expression is downregulated during EMT. By contrast, the role of Rbfox2 is controversial because Rbfox2 regulates epithelial as well as mesenchymal splicing events. Here, we have used several established cell culture models to investigate the functions of Rbfox2 during EMT. We demonstrate that induction of an EMT upregulates the expression of Rbfox2, which correlates with an increase in Rbfox2-regulated splicing events in the cortactin (Cttn), Pard3 and dynamin 2 (Dnm2) transcripts. At the same time, however, the epithelial-specific ability to splice the Enah, Slk and Tsc2 transcripts is either reduced or lost completely by Rbfox2, which might be due, in part, to downregulation of the expression of the Esrps cooperative factors. Depletion of Rbfox2 during EMT did not prevent the activation of transforming growth factor-beta signaling, the upregulation of mesenchymal markers or changes in cell morphology toward a mesenchymal phenotype. In addition, this depletion did not influence cell migration. However, depletion of Rbfox2 in cells that have completed an EMT significantly reduced their invasive potential. Taken together, our results suggest that during an EMT, Rbfox2-regulated splicing shifts from epithelial-to mesenchymal-specific events, leading to a higher degree of tissue invasiveness.	[Braeutigam, C.; Rago, L.; Rolke, A.; Winter, J.] Max Planck Inst Immunobiol & Epigenet, Dept Mol Embryol, D-79108 Freiburg, Germany; [Waldmeier, L.; Christofori, G.] Univ Basel, Dept Biomed, Basel, Switzerland; [Winter, J.] Johannes Gutenberg Univ Mainz, Univ Med Ctr Johannes Gutenberg, Inst Human Genet, D-55122 Mainz, Germany	Max Planck Society; University of Basel; Johannes Gutenberg University of Mainz	Winter, J (corresponding author), Max Planck Inst Immunobiol & Epigenet, Dept Mol Embryol, Stuebeweg 51, D-79108 Freiburg, Germany.	winter@immunbio.mpg.de			Max-Planck Society	Max-Planck Society(Max Planck Society)	This work was supported by the Max-Planck Society. We are grateful to Rolf Kemler for helpful discussions.	Baraniak AP, 2006, MOL CELL BIOL, V26, P1209, DOI 10.1128/MCB.26.4.1209-1222.2006; Barnes EA, 2010, AM J RESP CELL MOL, V43, P617, DOI 10.1165/rcmb.2008-0335OC; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Biamonti G, 2012, CELL MOL LIFE SCI, V69, P2515, DOI 10.1007/s00018-012-0931-7; Brown RL, 2011, J CLIN INVEST, V121, P1064, DOI 10.1172/JCI44540; Cheng CH, 2006, MOL CELL BIOL, V26, P362, DOI 10.1128/MCB.26.1.362-370.2006; Damianov A, 2010, RNA, V16, P405, DOI 10.1261/rna.1838210; Di Marcotullio L, 2011, ONCOGENE, V30, P65, DOI 10.1038/onc.2010.394; Dikshit B, 2013, ONCOGENE, V32, P3798, DOI 10.1038/onc.2012.393; Dow LE, 2008, ONCOGENE, V27, P5988, DOI 10.1038/onc.2008.219; Eppinga RD, 2012, ONCOGENE, V31, P1228, DOI 10.1038/onc.2011.329; Feng H, 2012, ONCOGENE, V31, P2691, DOI 10.1038/onc.2011.436; Ge XJ, 2005, GENOMICS, V86, P127, DOI 10.1016/j.ygeno.2005.04.008; Ghigna C, 2005, MOL CELL, V20, P881, DOI 10.1016/j.molcel.2005.10.026; Goswami S, 2009, CLIN EXP METASTAS, V26, P153, DOI 10.1007/s10585-008-9225-8; Guo M, 2012, CANCER RES, V72, P2017, DOI 10.1158/0008-5472.CAN-11-3985; Hidalgo-Carcedo C, 2011, NAT CELL BIOL, V13, P49, DOI 10.1038/ncb2133; Hirata E, 2012, J CELL SCI, V125, P858, DOI 10.1242/jcs.089995; Horiguchi K, 2012, ONCOGENE, V31, P3190, DOI 10.1038/onc.2011.493; HUH GS, 1994, GENE DEV, V8, P1561, DOI 10.1101/gad.8.13.1561; Jia YL, 2011, HEPATOLOGY, V54, P1808, DOI 10.1002/hep.24562; Jin Y, 2003, EMBO J, V22, P905, DOI 10.1093/emboj/cdg089; Kirkbride KC, 2011, CELL ADHES MIGR, V5, P187, DOI 10.4161/cam.5.2.14773; Kruchten AE, 2006, J CELL SCI, V119, P1683, DOI 10.1242/jcs.02963; Kuroyanagi H, 2009, CELL MOL LIFE SCI, V66, P3895, DOI 10.1007/s00018-009-0120-5; Lapuk A, 2010, MOL CANCER RES, V8, P961, DOI 10.1158/1541-7786.MCR-09-0528; Lehembre F, 2008, EMBO J, V27, P2603, DOI 10.1038/emboj.2008.178; LeMasters KE, 2012, BMC DEV BIOL, V12, DOI 10.1186/1471-213X-12-22; Liu H, 2006, P NATL ACAD SCI USA, V103, P4134, DOI 10.1073/pnas.0511342103; Massimi P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040279; Matsuda Yoko, 2012, Patholog Res Int, V2012, P574768, DOI 10.1155/2012/574768; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Modafferi EF, 1997, MOL CELL BIOL, V17, P6537, DOI 10.1128/MCB.17.11.6537; Moran-Jones K, 2009, CANCER RES, V69, P9219, DOI 10.1158/0008-5472.CAN-09-1852; Nakahata S, 2005, NUCLEIC ACIDS RES, V33, P2078, DOI 10.1093/nar/gki338; Nishikawa Y, 2011, ONCOL REP, V26, P587, DOI 10.3892/or.2011.1324; Oh S, 2012, BBA-REV CANCER, V1826, P1, DOI 10.1016/j.bbcan.2012.02.002; Philippar U, 2008, DEV CELL, V15, P813, DOI 10.1016/j.devcel.2008.09.003; Reed JR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045877; Roovers K, 2009, ONCOGENE, V28, P2839, DOI 10.1038/onc.2009.146; Shapiro IM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002218; Underwood JG, 2005, MOL CELL BIOL, V25, P10005, DOI 10.1128/MCB.25.22.10005-10016.2005; Valacca C, 2010, J CELL BIOL, V191, P87, DOI 10.1083/jcb.201001073; Venables JP, 2006, BIOESSAYS, V28, P378, DOI 10.1002/bies.20390; Venables JP, 2009, NAT STRUCT MOL BIOL, V16, P670, DOI 10.1038/nsmb.1608; Waldmeier L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048651; Warzecha CC, 2010, EMBO J, V29, P3286, DOI 10.1038/emboj.2010.195; Warzecha CC, 2009, MOL CELL, V33, P591, DOI 10.1016/j.molcel.2009.01.025; Wesche J, 2011, BIOCHEM J, V437, P199, DOI 10.1042/BJ20101603; Winter J, 2004, HUM GENET, V114, P541, DOI 10.1007/s00439-004-1114-x; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yeo GW, 2009, NAT STRUCT MOL BIOL, V16, P130, DOI 10.1038/nsmb.1545; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Zhang CL, 2008, GENE DEV, V22, P2550, DOI 10.1101/gad.1703108	54	97	100	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2014	33	9					1082	1092		10.1038/onc.2013.50	http://dx.doi.org/10.1038/onc.2013.50			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XT	23435423				2022-12-28	WOS:000331933800002
J	Li, W; Anderson, RA				Li, W.; Anderson, R. A.			Star-PAP controls HPV E6 regulation of p53 and sensitizes cells to VP-16	ONCOGENE			English	Article						p53; HPV E6; VP-16; Star-PAP; polyadenylation; cell growth and proliferation	CERVICAL-CANCER CELLS; MESSENGER-RNA; E7 ONCOPROTEIN; E6-MEDIATED DEGRADATION; EXPRESSION; RESTORATION; APOPTOSIS; ALPHA; TRANSCRIPTS; COMBINATION	Cervical cancer is the most common genital malignancy and the high-risk human papillomaviruses (HPV type 16, 18 and 31, and so on) are major agents for its cause. A key switch for the onset of cervical cancers by HPVs is the cellular degradation of the tumor-suppressor p53 that is mediated by the HPV-generated E6 protein. E6 forms a complex with the E3 ubiquitin-ligase E6-associated protein (E6AP) leading to p53 degradation. The components that control E6 expression and the mechanisms for regulation of the expression in host cells remain undefined. Here we show that the nuclear noncanonical poly(A) polymerase (PAP) speckle targeted PIPKI alpha regulated PAP (Star-PAP) controls E6 mRNA polyadenylation and expression and modulates wild-type p53 levels as well as cell cycle profile in high-risk HPV-positive cells. In the absence of Star-PAP, treatment of cells with the chemotherapeutic drug VP-16 dramatically reduced E6 and increased p53 levels. This diminished both cell proliferation and anchorage-independent growth required for cancer progression, indicating a synergism between VP-16 treatment and the loss of Star-PAP. This identifies Star-PAP as a potential drug target for the treatment of HPV-positive cancer cells. These data provide a mechanistic basis for increasing the sensitivity and efficiency of chemotherapy in the treatment of cancers that have low levels of wild-type p53.	[Li, W.; Anderson, R. A.] Univ Wisconsin Madison, Mol & Cellular Pharmacol Program, Sch Med & Publ Hlth, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Anderson, RA (corresponding author), Univ Wisconsin Madison, Mol & Cellular Pharmacol Program, 1300 Univ Ave,3750 Med Sci Ctr, Madison, WI 53706 USA.	raanders@wisc.edu		Li, Weimin/0000-0002-2170-7094; Anderson, Richard/0000-0001-6265-8359	US National Institutes of Health [GM051968]; American Heart Association [12SDG12100035]; NATIONAL CANCER INSTITUTE [R01CA104708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM114386, R01GM051968] Funding Source: NIH RePORTER	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Heart Association(American Heart Association); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank members of the Anderson laboratory for discussion and comments, and thank Dr Paul F Lambert's laboratory at UW-Madison for SiHa and CaSki cell lines. This work was supported by a grant (GM051968) from the US National Institutes of Health and a Scientist Development Grant (12SDG12100035) from the American Heart Association.	Clifford B, 2003, CANCER RES, V63, P4074; Fiedler M, 2004, FASEB J, V18, P1120, DOI 10.1096/fj.03-1332fje; Gonzales ML, 2008, J BIOL CHEM, V283, P12665, DOI 10.1074/jbc.M800656200; Hengstermann A, 2001, P NATL ACAD SCI USA, V98, P1218, DOI 10.1073/pnas.031470698; Kanduc D, 2002, J VIROL, V76, P7040, DOI 10.1128/JVI.76.14.7040-7048.2002; KESSIS TD, 1993, P NATL ACAD SCI USA, V90, P3988, DOI 10.1073/pnas.90.9.3988; Koivusalo R, 2005, MOL PHARMACOL, V68, P372, DOI 10.1124/mol.105.011189; Laishram RS, 2011, NUCLEIC ACIDS RES, V39, P7961, DOI 10.1093/nar/gkr549; Laishram RS, 2010, EMBO J, V29, P4132, DOI 10.1038/emboj.2010.287; Lappalainen K, 1996, ANTICANCER RES, V16, P2485; Li WM, 2007, CIRC RES, V100, P79, DOI 10.1161/01.RES.0000253094.03023.3f; Li W, 2012, MOL CELL, V45, P25, DOI 10.1016/j.molcel.2011.11.017; Li W, 2009, P NATL ACAD SCI USA, V106, P486, DOI 10.1073/pnas.0804177106; Liu YM, 2000, J CELL BIOCHEM, V78, P334, DOI 10.1002/(SICI)1097-4644(20000801)78:2<334::AID-JCB15>3.3.CO;2-6; Martins CP, 2006, CELL, V127, P1323, DOI 10.1016/j.cell.2006.12.007; Mellman DL, 2008, NATURE, V451, P1013, DOI 10.1038/nature06666; Munger K, 2002, VIRUS RES, V89, P213, DOI 10.1016/S0168-1702(02)00190-9; Murray EL, 2008, METHOD ENZYMOL, V448, P483, DOI 10.1016/S0076-6879(08)02624-4; Oh KJ, 2006, J VIROL, V80, P7079, DOI 10.1128/JVI.02380-05; Reinstein E, 2000, ONCOGENE, V19, P5944, DOI 10.1038/sj.onc.1203989; SALLES FJ, 1995, PCR METH APPL, V4, P317; Sauter ER, 2002, CANCER GENE THER, V9, P807, DOI 10.1038/sj.cgt.7700492; SCHNEIDERGADICKE A, 1986, EMBO J, V5, P2285, DOI 10.1002/j.1460-2075.1986.tb04496.x; Sigal A, 2000, CANCER RES, V60, P6788; Skladanowski A, 1997, CANCER RES, V57, P818; Sotlar K, 2004, J MED VIROL, V74, P107, DOI 10.1002/jmv.20153; Tang S, 2006, J VIROL, V80, P4249, DOI 10.1128/JVI.80.9.4249-4263.2006; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Vinther J, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-83; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang YX, 2011, J CLIN INVEST, V121, P893, DOI 10.1172/JCI44504; Wesierska-Gadek J, 2002, INT J CANCER, V101, P128, DOI 10.1002/ijc.10580; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Zheng ZM, 2006, FRONT BIOSCI-LANDMRK, V11, P2286, DOI 10.2741/1971	34	10	12	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2014	33	7					928	932		10.1038/onc.2013.14	http://dx.doi.org/10.1038/onc.2013.14			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB2MN	23416977	Green Accepted			2022-12-28	WOS:000331626900014
J	You, X; Liu, F; Zhang, T; Lv, N; Liu, Q; Shan, C; Du, Y; Kong, G; Wang, T; Ye, L; Zhang, X				You, X.; Liu, F.; Zhang, T.; Lv, N.; Liu, Q.; Shan, C.; Du, Y.; Kong, G.; Wang, T.; Ye, L.; Zhang, X.			Hepatitis B virus X protein upregulates Lin28A/Lin28B through Sp-1/c-Myc to enhance the proliferation of hepatoma cells	ONCOGENE			English	Article						hepatitis B virus X protein; Lin28A; Lin28B; proliferation; hepatocellular carcinoma	C-MYC; PROMOTES TRANSFORMATION; LET-7 MICRORNA; MESSENGER-RNA; EXPRESSION; LIN28; BINDING; GROWTH; IDENTIFICATION; ACTIVATION	Hepatitis B virus X protein (HBx) plays critical roles in the pathogenesis of hepatocellular carcinoma (HCC). Here, we were interested in knowing whether the oncogene Lin28A and its homolog Lin28B are involved in the hepatocarcinogenesis mediated by HBx. We showed that the expression levels of Lin28A and Lin28B were increased in clinical HCC tissues, HepG2.2.15 cell line and liver tissues of p21-HBx transgenic mice. Interestingly, the expression levels of HBx were positively associated with those of Lin28A/Lin28B in clinical HCC tissues. Moreover, the overexpression of HBx resulted in the upregulation of Lin28A/Lin28B in hepatoma HepG2/H7402 cell lines by transient transfection, suggesting that HBx was able to upregulate Lin28A and Lin28B. Then, we examined the mechanism by which HBx upregulated Lin28A and Lin28B. We identified that the promoter region of Lin28A regulated by HBx was located at nt -235/-66 that contained Sp-1 binding element. Co-immunoprecipitation showed that HBx was able to interact with Sp-1 in HepG2-X cells. Moreover, chromatin immunoprecipitation (ChIP) demonstrated that HBx could bind to the promoter of Lin28A, which failed to work when Sp-1 was silenced. Electrophoretic mobility shift assay (EMSA) further identified that HBx was able to interact with Sp-1 element in Lin28A promoter via transcription factor Sp-1. In addition, we found that c-Myc was involved in the activation of Lin28B mediated by HBx. In function, Lin28A/Lin28B played important roles in HBx-enhanced proliferation of hepatoma cells in vitro and in vivo. In conclusion, HBx activates Lin28A/Lin28B through Sp-1/c-Myc in hepatoma cells. Lin28A/Lin28B serves as key driver genes in HBx-induced hepatocarcinogenesis.	[You, X.; Zhang, T.; Lv, N.; Shan, C.; Du, Y.; Kong, G.; Wang, T.; Zhang, X.] Nankai Univ, Coll Life Sci, Key Lab Mol Microbiol & Technol, Minist Educ,Dept Canc Res, Tianjin 300071, Peoples R China; [Liu, F.; Liu, Q.; Ye, L.] Nankai Univ, Coll Life Sci, Dept Biochem, Tianjin 300071, Peoples R China	Nankai University; Nankai University	Zhang, X (corresponding author), Nankai Univ, Coll Life Sci, Key Lab Mol Microbiol & Technol, Inst Mol Biol,Minist Educ,Dept Canc Res, 94 Weijin Rd, Tianjin 300071, Peoples R China.	yelihong@nankai.edu.cn; zhangxd@nankai.edu.cn	Zhang, Tao/F-4366-2018; Shan, changliang/L-9029-2016	Zhang, Tao/0000-0002-4749-6774; You, Xiaona/0000-0001-9996-1466	National Basic Research Program of China (973 Program) [2009CB521702]; National Natural Science Foundation of China [81071624, 81272218]	National Basic Research Program of China (973 Program)(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Dr Xiao Yang (from the Genetic Laboratory of Development and Diseases, Institute of Biotechnology, Beijing, People's Republic of China) for kindly providing the HBx transgenic mice. This work was supported in part by National Basic Research Program of China (973 Program, No. 2009CB521702) and National Natural Science Foundation of China (No. 81071624, 81272218).	Abdelrahim M, 2004, CANCER RES, V64, P6740, DOI 10.1158/0008-5472.CAN-04-0713; Ali N, 2011, J VIROL, V85, P12292, DOI 10.1128/JVI.05920-11; Arbuthnot P, 2001, INT J EXP PATHOL, V82, P77, DOI 10.1111/j.1365-2613.2001.iep178.x; Arzumanyan A, 2011, CANCER RES, V71, P3701, DOI 10.1158/0008-5472.CAN-10-3951; Cao DF, 2011, HUM PATHOL, V42, P710, DOI 10.1016/j.humpath.2010.09.007; Carmona S, 2006, MOL THER, V13, P411, DOI 10.1016/j.ymthe.2005.10.013; Chang TC, 2009, P NATL ACAD SCI USA, V106, P3384, DOI 10.1073/pnas.0808300106; Du YM, 2012, J BIOL CHEM, V287, P26302, DOI 10.1074/jbc.M112.342113; Fang H, 2005, MOL BRAIN RES, V136, P1, DOI 10.1016/j.molbrainres.2004.12.024; Guo YQ, 2006, GENE, V384, P51, DOI 10.1016/j.gene.2006.07.011; Hamano R, 2012, BRIT J CANCER, V106, P1415, DOI 10.1038/bjc.2012.90; Helland A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018064; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Kim HH, 2009, GENE DEV, V23, P1743, DOI 10.1101/gad.1812509; King CE, 2011, ONCOGENE, V30, P4185, DOI 10.1038/onc.2011.131; King CE, 2011, CANCER RES, V71, P4260, DOI 10.1158/0008-5472.CAN-10-4637; Kong GY, 2011, ACTA PHARMACOL SIN, V32, P1173, DOI 10.1038/aps.2011.52; Kong GY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019518; Li L, 2012, HEPATOLOGY, V56, P1380, DOI 10.1002/hep.25891; Li WH, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-45; Liang LH, 2010, HEPATOLOGY, V52, P1731, DOI 10.1002/hep.23904; Liu QY, 2011, J BIOL CHEM, V286, P17168, DOI 10.1074/jbc.M110.167783; Michielsen P, 2011, ACTA GASTRO-ENT BELG, V74, P4; Newman MA, 2008, RNA, V14, P1539, DOI 10.1261/rna.1155108; Ng SA, 2011, J GASTROENTEROL, V46, P974, DOI 10.1007/s00535-011-0415-9; Pan L, 2011, MOL CELL BIOCHEM, V355, P257, DOI 10.1007/s11010-011-0862-x; Peng S, 2010, ONCOGENE, V29, P2153, DOI 10.1038/onc.2009.500; Piskounova E, 2008, J BIOL CHEM, V283, P21310, DOI 10.1074/jbc.C800108200; Piskounova E, 2011, CELL, V147, P1066, DOI 10.1016/j.cell.2011.10.039; Polesskaya A, 2007, GENE DEV, V21, P1125, DOI 10.1101/gad.415007; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; Qiu CH, 2010, NUCLEIC ACIDS RES, V38, P1240, DOI 10.1093/nar/gkp1071; Safe S, 2005, EUR J CANCER, V41, P2438, DOI 10.1016/j.ejca.2005.08.006; Sakurai M, 2012, J STEROID BIOCHEM, V131, P101, DOI 10.1016/j.jsbmb.2011.10.007; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Shan CL, 2011, CARCINOGENESIS, V32, P1190, DOI 10.1093/carcin/bgr106; Shan CL, 2010, CELL RES, V20, P563, DOI 10.1038/cr.2010.49; Shona JK, 2009, VIRUS RES, V139, P14, DOI 10.1016/j.virusres.2008.09.006; Sze KMF, 2011, HEPATOLOGY, V53, P1558, DOI 10.1002/hep.24232; Tang H, 2006, CANCER SCI, V97, P977, DOI 10.1111/j.1349-7006.2006.00299.x; Tang H, 2009, HEPATOLOGY, V49, P60, DOI 10.1002/hep.22581; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Wang Q, 2010, NEOPLASIA, V12, P103, DOI 10.1593/neo.91298; Wang YL, 2004, HEPATOLOGY, V39, P318, DOI 10.1002/hep.20076; Wang YC, 2010, CARCINOGENESIS, V31, P1516, DOI 10.1093/carcin/bgq107; Wu HY, 2011, J AGR FOOD CHEM, V59, P1713, DOI 10.1021/jf1045624; Xu BS, 2009, NUCLEIC ACIDS RES, V37, P4256, DOI 10.1093/nar/gkp372; Xu BS, 2009, RNA, V15, P357, DOI 10.1261/rna.1368009; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zhang T, 2012, HEPATOLOGY, V56, P2051, DOI 10.1002/hep.25899; Zhang XD, 2005, J MED VIROL, V77, P374, DOI 10.1002/jmv.20466; Zhang XD, 2005, J LAB CLIN MED, V145, P98, DOI 10.1016/j.lab.2004.11.018	52	48	50	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2014	33	4					449	460		10.1038/onc.2012.618	http://dx.doi.org/10.1038/onc.2012.618			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VX	23318446				2022-12-28	WOS:000330214600006
J	Ammoun, S; Provenzano, L; Zhou, L; Barczyk, M; Evans, K; Hilton, DA; Hafizi, S; Hanemann, CO				Ammoun, S.; Provenzano, L.; Zhou, L.; Barczyk, M.; Evans, K.; Hilton, D. A.; Hafizi, S.; Hanemann, C. O.			Axl/Gas6/NF kappa B signalling in schwannoma pathological proliferation, adhesion and survival	ONCOGENE			English	Article						Gas6/Axl; NF kappa B; merlin; proliferation/adhesion/survival; schwannoma	RECEPTOR TYROSINE KINASE; NF-KAPPA-B; UBIQUITIN LIGASE CRL4(DCAF1); GROWTH-FACTOR; UP-REGULATION; SOLUBLE FORM; ACTIVATION; EXPRESSION; CELLS; MERLIN	TAM family receptor tyrosine kinases comprising Tyro3 (Sky), Axl, and Mer are overexpressed in some cancers, correlate with multidrug resistance and contribute to tumourigenesis by regulating invasion, angiogenesis, cell survival and tumour growth. Mutations in the gene coding for a tumour suppressor merlin cause development of multiple tumours of the nervous system such as schwannomas, meningiomas and ependymomas occurring spontaneously or as part of a hereditary disease neurofibromatosis type 2. The benign character of merlin-deficient tumours makes them less responsive to chemotherapy. We previously showed that, amongst other growth factor receptors, TAM family receptors (Tyro3, Axl and Mer) are significantly overexpressed in schwannoma tissues. As Axl is negatively regulated by merlin and positively regulated by E3 ubiquitin ligase CRL4DCAF1, previously shown to be a key regulator in schwannoma growth we hypothesized that Axl is a good target to study in merlin-deficient tumours. Moreover, Axl positively regulates the oncogene Yes-associated protein, which is known to be under merlin regulation in schwannoma and is involved in increased proliferation of merlin-deficient meningioma and mesothelioma. Here, we demonstrated strong overexpression and activation of Axl receptor as well as its ligand Gas6 in human schwannoma primary cells compared to normal Schwann cells. We show that Gas6 is mitogenic and increases schwannoma cell-matrix adhesion and survival acting via Axl in schwannoma cells. Stimulation of the Gas6/Axl signalling pathway recruits Src, focal adhesion kinase (FAK) and NFkB. We showed that NFkB mediates Gas6/Axl-mediated overexpression of survivin, cyclin D1 and FAK, leading to enhanced survival, cell-matrix adhesion and proliferation of schwannoma. We conclude that Axl/FAK/Src/NF kappa B pathway is relevant in merlin-deficient tumours and is a potential therapeutic target for schwannoma and other merlin-deficient tumours.	[Ammoun, S.; Provenzano, L.; Zhou, L.; Barczyk, M.; Evans, K.; Hanemann, C. O.] Univ Plymouth, Inst Translat & Stratified Med, Peninsula Sch Med, Plymouth PL68BU, Devon, England; [Ammoun, S.; Provenzano, L.; Zhou, L.; Barczyk, M.; Evans, K.; Hanemann, C. O.] Univ Plymouth, Inst Translat & Stratified Med, Peninsula Sch Dent, Plymouth PL68BU, Devon, England; [Hilton, D. A.] Derriford Hosp, Dept Histopathol, Plymouth PL6 8DH, Devon, England; [Hafizi, S.] Univ Portsmouth, IBBS, Div Pharmacol, Portsmouth, Hants, England	University of Plymouth; University of Plymouth; Derriford Hospital; University of Portsmouth	Ammoun, S (corresponding author), Univ Plymouth, Inst Translat & Stratified Med, Peninsula Sch Med, John Bull Bldg,Tamar Sci Pk,Res Way, Plymouth PL68BU, Devon, England.	sylwia.ammoun@pms.ac.uk	Hafizi, Sassan/W-4424-2019; Hanemann, C Oliver/AAV-6257-2020	Hafizi, Sassan/0000-0002-4539-0888; Hanemann, C Oliver/0000-0002-1951-1025	Children tumour foundation	Children tumour foundation	Work was supported by the Children tumour foundation and Dr Hadwen Trust support. We thank Dr Federiko Roncoroli for providing human tissues and Leanne Turner for technical assistance.	Ammoun S, 2012, ONCOGENE, V31, P1710, DOI 10.1038/onc.2011.357; Ammoun S, 2008, CANCER RES, V68, P5236, DOI 10.1158/0008-5472.CAN-07-5849; Ammoun S, 2012, GLIA, V60, P1721, DOI 10.1002/glia.22391; Ammoun S, 2011, NAT REV NEUROL, V7, P392, DOI 10.1038/nrneurol.2011.82; Ammoun S, 2011, NEURO-ONCOLOGY, V13, P759, DOI 10.1093/neuonc/nor056; Ammoun S, 2010, NEURO-ONCOLOGY, V12, P834, DOI 10.1093/neuonc/noq012; Ammoun S, 2010, NEUROBIOL DIS, V37, P141, DOI 10.1016/j.nbd.2009.09.017; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Boyle K, 2005, NEUROBIOL DIS, V20, P412, DOI 10.1016/j.nbd.2005.03.022; Burchert A, 1998, ONCOGENE, V16, P3177, DOI 10.1038/sj.onc.1201865; Cooper J, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002314; Costa M, 1996, J CELL PHYSIOL, V168, P737, DOI 10.1002/(SICI)1097-4652(199609)168:3<737::AID-JCP27>3.0.CO;2-U; Demarchi F, 2001, J BIOL CHEM, V276, P31738, DOI 10.1074/jbc.M104457200; Du J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015940; Flaiz C, 2009, EXP NEUROL, V218, P137, DOI 10.1016/j.expneurol.2009.04.019; Georgakis GV, 2006, EXP HEMATOL, V34, P1670, DOI 10.1016/j.exphem.2006.07.002; Hafizi S, 2006, CYTOKINE GROWTH F R, V17, P295, DOI 10.1016/j.cytogfr.2006.04.004; Hanemann CO, 2006, NEUROPATH APPL NEURO, V32, P605, DOI 10.1111/j.1365-2990.2006.00769.x; Hanemann CO, 1997, ACTA NEUROPATHOL, V94, P310, DOI 10.1007/s004010050712; Hilton DA, 2009, HISTOPATHOLOGY, V55, P744, DOI 10.1111/j.1365-2559.2009.03440.x; Kaempchen K, 2003, HUM MOL GENET, V12, P1211, DOI 10.1093/hmg/ddg146; Kim H, 2002, MOL CELLS, V14, P108; Kim JY, 2002, BIOCHEM BIOPH RES CO, V296, P1295, DOI 10.1016/S0006-291X(02)02077-6; Kim RJ, 2010, CANCER LETT, V287, P172, DOI 10.1016/j.canlet.2009.06.010; Klein EA, 2007, CELL CYCLE, V6, P1115, DOI 10.4161/cc.6.9.4147; Lee H, 2007, MOL CELL BIOL, V27, P2103, DOI 10.1128/MCB.00572-06; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; Li RH, 1996, J NEUROSCI, V16, P2012; Li W, 2010, CELL, V140, P477, DOI 10.1016/j.cell.2010.01.029; Linger RMA, 2008, ADV CANCER RES, V100, P35, DOI 10.1016/S0065-230X(08)00002-X; Liu WG, 2008, CARCINOGENESIS, V29, P1096, DOI 10.1093/carcin/bgn026; Lu Q, 1999, J CELL BIOL, V144, P519, DOI 10.1083/jcb.144.3.519; Mahadevan D, 2007, ONCOGENE, V26, P3909, DOI 10.1038/sj.onc.1210173; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Ou WB, 2011, ONCOGENE, V30, P1643, DOI 10.1038/onc.2010.555; Rexhepaj R, 2010, CELL PHYSIOL BIOCHEM, V25, P715, DOI 10.1159/000315091; Rosenbaum C, 1998, NEUROBIOL DIS, V5, P55, DOI 10.1006/nbdi.1998.0179; Rosenbaum C, 2000, NEUROBIOL DIS, V7, P483, DOI 10.1006/nbdi.2000.0307; Sakai H, 2010, PEPTIDES, V31, P2216, DOI 10.1016/j.peptides.2010.09.012; Sather S, 2007, BLOOD, V109, P1026, DOI 10.1182/blood-2006-05-021634; Sayan AE, 2012, ONCOGENE, V31, P1493, DOI 10.1038/onc.2011.336; Shiozawa Y, 2010, NEOPLASIA, V12, P116, DOI 10.1593/neo.91384; Stenhoff J, 2004, BIOCHEM BIOPH RES CO, V319, P871, DOI 10.1016/j.bbrc.2004.05.070; Taylor ICA, 1995, ONCOGENE, V11, P2619; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Utermark T, 2005, BRAIN PATHOL, V15, P17; Utermark T, 2003, BRAIN PATHOL, V13, P352; Valverde P, 2005, BIOCHEM BIOPH RES CO, V333, P180, DOI 10.1016/j.bbrc.2005.05.086; Wickremesekera A, 2007, J CLIN NEUROSCI, V14, P1199, DOI 10.1016/j.jocn.2007.05.009; Wu CW, 2002, ANTICANCER RES, V22, P1071; Xiao GH, 2005, MOL CELL BIOL, V25, P2384, DOI 10.1128/MCB.25.6.2384-2394.2005; Yi CL, 2010, GENE DEV, V24, P1673, DOI 10.1101/gad.1964810; Zhao YF, 2012, CANCER INVEST, V30, P287, DOI 10.3109/07357907.2012.657816; Zhou L, 2011, NEOPLASIA, V13, P1101, DOI 10.1593/neo.111060	54	63	65	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2014	33	3					336	346		10.1038/onc.2012.587	http://dx.doi.org/10.1038/onc.2012.587			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VR	23318455	Green Published			2022-12-28	WOS:000330214000008
J	Yan, L; Singh, LS; Zhang, L; Xu, Y				Yan, L.; Singh, L. S.; Zhang, L.; Xu, Y.			Role of OGR1 in myeloid-derived cells in prostate cancer	ONCOGENE			English	Article						adoptive transfer; MDSC; macrophages; OGR1; ovarian cancer G protein coupled receptor-1	PROTEIN-COUPLED RECEPTOR; CD8(+) T-CELLS; SUPPRESSOR-CELLS; TUMOR; MOUSE; MACROPHAGES; EXPRESSION; GROWTH; MODEL; DIFFERENTIATION	Ovarian cancer G-protein-coupled-receptor-1 (OGR1) is a tumor metastasis suppressor in prostate cancer (PCa). OGR1 knockout mice (ogr1(-/-)) are grossly normal under physiological conditions, however, reduced melanoma tumorigenesis has been observed, with the mechanisms of this reduction completely unknown. In this work, we demonstrated that OGR1 deficiency in host cells significantly reduced tumorigenesis of PCa in mice. Adoptive transfer of WT CD11b(+) Gr1(+) double positive (DP) cells, but not T cells, was sufficient to allow tumor development in ogr1(-/-) mice. The expression of an M1 macrophage marker, inducible nitric oxide synthase (iNOS) was higher and expression of an M2 macrophage marker, arginase-1 (Arg 1) was lower in tumors from ogr1(-/-) mice compared with WT mice. Furthermore, coinjection of transgenic adenocarcinoma mouse prostate (TRAMP)-C2 cells with WT, but not ogr1(-/-) macrophages, increased tumor incidence in ogr1(-/-) mice. T-cell depletion experiments suggested that T cells were required for tumor rejection in ogr1(-/-) mice, although OGR1 expression in T cells may not be necessary. In summary, the expression of OGR1 in myeloid-derived cells, especially in DP cells, was required for PCa tumor cell-induced immunosuppression.	[Yan, L.; Singh, L. S.; Xu, Y.] Indiana Univ Sch Med, Dept Obstet & Gynecol, Indianapolis, IN 46234 USA; [Singh, L. S.] Manipur Univ, Dept Biotechnol, Imphal, Manipur, India; [Zhang, L.] Univ Toronto, Univ Hlth Net Work, Toronto Gen Res Inst, Dept Lab Med, Toronto, ON, Canada; [Zhang, L.] Univ Toronto, Univ Hlth Net Work, Toronto Gen Res Inst, Dept Pathobiol, Toronto, ON, Canada	Indiana University System; Indiana University Bloomington; Manipur University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Xu, Y (corresponding author), Indiana Univ Sch Med, Dept Obstet & Gynecol, 975 W Walnut St,IB 355A, Indianapolis, IN 46234 USA.	lzhang@uhnresearch.ca; xu2@iupui.edu			National Institutes of Health [RO1 155145]; Mary Fendrich-Hulman Charitable Trust Fund; NATIONAL CANCER INSTITUTE [R01CA155145] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mary Fendrich-Hulman Charitable Trust Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Mrs Helen Jan Chin-Sinex from Dr Marc S. Mendonca's lab at Indiana University School of Medicine for technical assistance in the preparation of irradiated TRAMP-C2 tumor cells. We thank Mrs Huiying Gu from Dr Yansheng Du's lab for technical assistance in the preparation of tumor frozen sections. We also thank Dr Caryl Antalis and Dr Cheryl Dsouza for critical reading and editing of the manuscript. This work was supported in part by the National Institutes of Health (RO1 155145 to YX and LZ); and the Mary Fendrich-Hulman Charitable Trust Fund to YX.	Babiarova K, 2012, J IMMUNOTHER, V35, P478, DOI 10.1097/CJI.0b013e3182618381; BALEY PA, 1995, J STEROID BIOCHEM, V52, P403, DOI 10.1016/0960-0760(95)00001-G; Biswas SK, 2008, J IMMUNOL, V180, P2011, DOI 10.4049/jimmunol.180.4.2011; Corzo CA, 2010, J EXP MED, V207, P2439, DOI 10.1084/jem.20100587; Elkabets M, 2010, EUR J IMMUNOL, V40, P3347, DOI 10.1002/eji.201041037; Eruslanov E, 2010, J LEUKOCYTE BIOL, V88, P839, DOI 10.1189/jlb.1209821; Fasso M, 2008, P NATL ACAD SCI USA, V105, P3509, DOI 10.1073/pnas.0712269105; Foster BA, 1997, CANCER RES, V57, P3325; Fricke I, 2007, CLIN CANCER RES, V13, P4840, DOI 10.1158/1078-0432.CCR-07-0409; Gingrich JR, 1996, CANCER RES, V56, P4096; Grossmann ME, 2001, WORLD J UROL, V19, P365, DOI 10.1007/PL00007104; Hasita H, 2010, CANCER SCI, V101, P1913, DOI 10.1111/j.1349-7006.2010.01614.x; Hong DS, 2007, CANCER-AM CANCER SOC, V110, P1911, DOI 10.1002/cncr.22999; Im DS, 2005, ACTA PHARMACOL SIN, V26, P1435, DOI 10.1111/j.1745-7254.2005.00237.x; Koide N, 2004, AM J GASTROENTEROL, V99, P1667, DOI 10.1111/j.1572-0241.2004.30733.x; LaTulippe E, 2002, CANCER RES, V62, P4499; Li H, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005705; Luczynski W, 2008, POSTEP HIG MED DOSW, V62, P18; Ludwig MG, 2003, NATURE, V425, P93, DOI 10.1038/nature01905; Nagaraj S, 2010, CLIN CANCER RES, V16, P1812, DOI 10.1158/1078-0432.CCR-09-3272; Nagaraj S, 2010, J IMMUNOL, V184, P3106, DOI 10.4049/jimmunol.0902661; Nefedova Y, 2007, CANCER RES, V67, P11021, DOI 10.1158/0008-5472.CAN-07-2593; Ostrand-Rosenberg S, 2012, SEMIN CANCER BIOL, V22, P275, DOI 10.1016/j.semcancer.2012.01.011; Ostrand-Rosenberg S, 2010, CANCER IMMUNOL IMMUN, V59, P1593, DOI 10.1007/s00262-010-0855-8; PEARSON TC, 1993, TRANSPLANTATION, V55, P361, DOI 10.1097/00007890-199302000-00025; Rauhala HE, 2008, INT J CANCER, V123, P1601, DOI 10.1002/ijc.23658; Silliman CC, 1996, TRANSFUSION, V36, P133, DOI 10.1046/j.1537-2995.1996.36296181925.x; Singh LS, 2007, JNCI-J NATL CANCER I, V99, P1313, DOI 10.1093/jnci/djm107; Talmadge JE, 2007, CLIN CANCER RES, V13, P5243, DOI 10.1158/1078-0432.CCR-07-0182; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; Umemura N, 2008, J LEUKOCYTE BIOL, V83, P1136, DOI 10.1189/jlb.0907611; Xu Y, 1996, GENOMICS, V35, P397, DOI 10.1006/geno.1996.0377; Yin DP, 2002, TRANSPLANTATION, V74, P1236, DOI 10.1097/00007890-200211150-00007; Zhang Q, 2005, CANCER RES, V65, P1761, DOI 10.1158/0008-5472.CAN-04-3169	34	45	46	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2014	33	2					157	164		10.1038/onc.2012.566	http://dx.doi.org/10.1038/onc.2012.566			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286BY	23222714				2022-12-28	WOS:000329440700003
J	Savary, K; Caglayan, D; Caja, L; Tzavlaki, K; Bin Nayeem, S; Bergstrom, T; Jiang, Y; Uhrbom, L; Forsberg-Nilsson, K; Westermark, B; Heldin, CH; Ferletta, M; Moustakas, A				Savary, K.; Caglayan, D.; Caja, L.; Tzavlaki, K.; Bin Nayeem, S.; Bergstrom, T.; Jiang, Y.; Uhrbom, L.; Forsberg-Nilsson, K.; Westermark, B.; Heldin, C-H; Ferletta, M.; Moustakas, A.			Snail depletes the tumorigenic potential of glioblastoma	ONCOGENE			English	Article						BMP; glioblastoma multiforme; glioma-initiating cells; invasiveness; snail	GROWTH-FACTOR-BETA; NEURAL STEM-CELLS; HIGH-GRADE GLIOMA; INITIATING CELLS; MESENCHYMAL TRANSITION; RECEPTOR; BRAIN; DIFFERENTIATION; PROGRESSION; SUPPRESSES	Glioblastoma multiforme (GBM) is an aggressive brain malignancy characterized by high heterogeneity and invasiveness. It is increasingly accepted that the refractory feature of GBM to current therapies stems from the existence of few tumorigenic cells that sustain tumor growth and spreading, the so-called glioma-initiating cells (GICs). Previous studies showed that cytokines of the bone morphogenetic protein (BMP) family induce differentiation of the GICs, and thus act as tumor suppressors. Molecular pathways that explain this behavior of BMP cytokines remain largely elusive. Here, we show that BMP signaling induces Smad-dependent expression of the transcriptional regulator Snail in a rapid and sustained manner. Consistent with its already established promigratory function in other cell types, we report that Snail silencing decreases GBM cell migration. Consequently, overexpression of Snail increases GBM invasiveness in a mouse xenograft model. Surprisingly, we found that Snail depletes the GBM capacity to form gliomaspheres in vitro and to grow tumors in vivo, both of which are important features shared by GICs. Thus Snail, acting downstream of BMP signaling, dissociates the invasive capacity of GBM cells from their tumorigenic potential.	[Savary, K.; Caja, L.; Bin Nayeem, S.; Heldin, C-H; Moustakas, A.] Uppsala Univ, Biomed Ctr, Sci Life Lab, Ludwig Inst Canc Res, SE-75124 Uppsala, Sweden; [Caglayan, D.; Bergstrom, T.; Jiang, Y.; Uhrbom, L.; Forsberg-Nilsson, K.; Westermark, B.; Ferletta, M.] Uppsala Univ, Rudbeck Lab, Sci Life Lab, Dept Immunol Genet & Pathol, SE-75185 Uppsala, Sweden; [Tzavlaki, K.; Moustakas, A.] Uppsala Univ, Dept Med Biochem & Microbiol, Sci Life Lab, Biomed Ctr, Uppsala, Sweden	Ludwig Institute for Cancer Research; Uppsala University; Uppsala University; Uppsala University	Ferletta, M (corresponding author), Uppsala Univ, Rudbeck Lab, Sci Life Lab, Dept Immunol Genet & Pathol, SE-75185 Uppsala, Sweden.	Maria.Ferletta@igp.uu.se; Aris.Moustakas@LICR.uu.se	Forsberg-Nilsson, Karin/D-9604-2019; Caja, Laia/J-4618-2019	Forsberg-Nilsson, Karin/0000-0003-0692-6245; Caja, Laia/0000-0002-8786-8763; Westermark, Bengt/0000-0001-7153-5545	Atlantic Philanthropies/Ludwig Institute for Cancer Research Clinical Discovery Program; Goran Gustafsson Foundation; Swedish Cancer Society	Atlantic Philanthropies/Ludwig Institute for Cancer Research Clinical Discovery Program; Goran Gustafsson Foundation; Swedish Cancer Society(Swedish Cancer Society)	We thank: J Grawe, Uppsala University FACS facility; M Kastemar for tumor sampling; I Alafuzoff for tumor pathology; A Ahgren, M Vanlandewijck for tumor immunohistochemistry; H Goransson-Kultima, A Andersson, Uppsala University Microarray facility; A Ostman (Karolinska Institute) for encouragement; M Brenner, A Cano for reagents; K Sampath (Curis, Inc,) for BMP7; T Gahman and A Shiau (Ludwig Institute for Cancer Research, San Diego, USA) for GW6604 and DMH1 inhibitor synthesis; S Thuault, E-J Tan, K Kahata and other group members for discussion. Funding of the authors' work was provided by the Atlantic Philanthropies/Ludwig Institute for Cancer Research Clinical Discovery Program, the Goran Gustafsson Foundation and the Swedish Cancer Society.	Anido J, 2010, CANCER CELL, V18, P655, DOI 10.1016/j.ccr.2010.10.023; Barbera MJ, 2004, ONCOGENE, V23, P7345, DOI 10.1038/sj.onc.1207990; Bogdahn U, 2011, NEURO-ONCOLOGY, V13, P132, DOI 10.1093/neuonc/noq142; Bonavia R, 2011, CANCER RES, V71, P4055, DOI 10.1158/0008-5472.CAN-11-0153; Bruna A, 2007, CANCER CELL, V11, P147, DOI 10.1016/j.ccr.2006.11.023; Chirasani SR, 2010, BRAIN, V133, P1961, DOI 10.1093/brain/awq128; de Gouville AC, 2005, BRIT J PHARMACOL, V145, P166, DOI 10.1038/sj.bjp.0706172; Ferletta M, 2011, INT J CANCER, V129, P45, DOI 10.1002/ijc.25647; Franco DL, 2010, J CELL SCI, V123, P3467, DOI 10.1242/jcs.068692; Fukuda S, 2007, MOL CELL BIOL, V27, P4931, DOI 10.1128/MCB.02435-06; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Gilbertson RJ, 2007, NAT REV CANCER, V7, P733, DOI 10.1038/nrc2246; Hjelmeland MD, 2004, MOL CANCER THER, V3, P737; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Ikushima H, 2009, CELL STEM CELL, V5, P504, DOI 10.1016/j.stem.2009.08.018; Kim MY, 2010, NEUROSCIENCE, V170, P8, DOI 10.1016/j.neuroscience.2010.07.020; Kowanetz M, 2008, J CELL BIOL, V182, P655, DOI 10.1083/jcb.200804107; Kurisaki K, 2003, MOL CELL BIOL, V23, P4494, DOI 10.1128/MCB.23.13.4494-4510.2003; LaBonne C, 2000, DEV BIOL, V221, P195, DOI 10.1006/dbio.2000.9609; Lee J, 2008, CANCER CELL, V13, P69, DOI 10.1016/j.ccr.2007.12.005; Lee Y, 2008, GLIA, V56, P481, DOI 10.1002/glia.20622; Lottaz C, 2010, CANCER RES, V70, P2030, DOI 10.1158/0008-5472.CAN-09-1707; Maire CL, 2010, STEM CELLS, V28, P1611, DOI 10.1002/stem.480; McLendon RE, 2011, J ONCOL, V2011; Ming GL, 2011, NEURON, V70, P687, DOI 10.1016/j.neuron.2011.05.001; Moustakas A, 2009, DEVELOPMENT, V136, P3699, DOI 10.1242/dev.030338; Myung J, 2010, NEUROPATHOLOGY, V30, P224, DOI 10.1111/j.1440-1789.2009.01072.x; Nagane Motoo, 1997, Current Opinion in Oncology, V9, P215, DOI 10.1097/00001622-199709030-00001; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; Olmeda D, 2007, ONCOGENE, V26, P1862, DOI 10.1038/sj.onc.1209997; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Penuelas S, 2009, CANCER CELL, V15, P315, DOI 10.1016/j.ccr.2009.02.011; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Piccirillo SGM, 2006, NATURE, V444, P761, DOI 10.1038/nature05349; Pollard SM, 2009, CELL STEM CELL, V4, P568, DOI 10.1016/j.stem.2009.03.014; Rich JN, 2003, FRONT BIOSCI-LANDMRK, V8, pE245, DOI 10.2741/992; Samanta J, 2004, DEVELOPMENT, V131, P4131, DOI 10.1242/dev.01273; Sun MN, 2011, BBA-MOL CELL RES, V1813, P438, DOI 10.1016/j.bbamcr.2011.01.003; Tate CM, 2012, CELL DEATH DIFFER, V19, P1644, DOI 10.1038/cdd.2012.44; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thuault S, 2008, J BIOL CHEM, V283, P33437, DOI 10.1074/jbc.M802016200; Vega S, 2004, GENE DEV, V18, P1131, DOI 10.1101/gad.294104; Westermark Bengt, 1995, Current Opinion in Oncology, V7, P220, DOI 10.1097/00001622-199505000-00005; Yamada N, 1996, BRIT J CANCER, V73, P624, DOI 10.1038/bjc.1996.108; Yang HW, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-301	45	50	50	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2013	32	47					5409	5420		10.1038/onc.2013.67	http://dx.doi.org/10.1038/onc.2013.67			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	254PM	23524585	hybrid, Green Published			2022-12-28	WOS:000327177600004
J	Zhao, P; Damerow, MS; Stern, P; Liu, AH; Sweet-Cordero, A; Siziopikou, K; Neilson, JR; Sharp, PA; Cheng, C				Zhao, P.; Damerow, M. S.; Stern, P.; Liu, A. H.; Sweet-Cordero, A.; Siziopikou, K.; Neilson, J. R.; Sharp, P. A.; Cheng, C.			CD44 promotes Kras-dependent lung adenocarcinoma	ONCOGENE			English	Article						CD44; Kras; lung adenocarcinoma	BREAST-CANCER CELLS; STEM-CELLS; K-RAS; TUMOR; ACTIVATION; EXPRESSION; IDENTIFICATION; MICE; CARCINOMA	Kras-induced non-small-cell lung adenocarcinoma is the major subtype of lung cancers and is associated with poor prognosis. Using a lung cancer mouse model that expresses a cre-mediated Kras(G12D) mutant, we identified a critical role for the cell surface molecule CD44 in mediating cell proliferation downstream of oncogenic Kras signaling. The deletion of CD44 attenuates lung adenocarcinoma formation and prolongs the survival of these mice. Mechanistically, CD44 is required for the activation of Kras-mediated signaling through the mitogen-activated protein kinase (MAPK) pathway and thus promotes tumor cell proliferation. Together, these results reveal an unrecognized role for CD44 in oncogenic Kras-induced lung adenocarcinoma and suggest that targeting CD44 could be an effective strategy for halting Kras-dependent carcinomas.	[Zhao, P.; Damerow, M. S.; Liu, A. H.; Cheng, C.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Dept Med,Div Hematol Oncol, Chicago, IL 60611 USA; [Stern, P.] Sextant Therapeut Inc, Cambridge, MA USA; [Sweet-Cordero, A.] Stanford Univ, Dept Pediat, Sch Med, Canc Biol Program, Stanford, CA 94305 USA; [Siziopikou, K.] Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60611 USA; [Neilson, J. R.] Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; [Sharp, P. A.] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center; Stanford University; Northwestern University; Feinberg School of Medicine; Baylor College of Medicine; Massachusetts Institute of Technology (MIT)	Cheng, C (corresponding author), Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Dept Med, 303 E Super St, Chicago, IL 60611 USA.	chengc@northwestern.edu		Neilson, Joel R./0000-0002-3408-608X; Liu, Angela/0000-0002-2567-0671	NCI NIH HHS [K99 CA131474, R00 CA131474, P01 CA042063, P30 CA014051] Funding Source: Medline; NIGMS NIH HHS [R01 GM034277] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042063, P30CA014051, R00CA131474, K99CA131474] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034277] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Bourguignon LYW, 1997, J BIOL CHEM, V272, P27913, DOI 10.1074/jbc.272.44.27913; Brown RL, 2011, J CLIN INVEST, V121, P1064, DOI 10.1172/JCI44540; Cheng CH, 2006, MOL CELL BIOL, V26, P362, DOI 10.1128/MCB.26.1.362-370.2006; Cheng CH, 2006, GENE DEV, V20, P1715, DOI 10.1101/gad.1430906; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Davie SA, 2007, TRANSGENIC RES, V16, P193, DOI 10.1007/s11248-006-9056-9; Fillmore C, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1673; Girard L, 2000, CANCER RES, V60, P4894; Godar S, 2008, CELL, V134, P62, DOI 10.1016/j.cell.2008.06.006; Hirata T, 1998, CANCER RES, V58, P1108; Jackson EL, 2001, GENE DEV, V15, P3243, DOI 10.1101/gad.943001; Jin LQ, 2006, NAT MED, V12, P1167, DOI 10.1038/nm1483; Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Liu R, 2007, NEW ENGL J MED, V356, P217, DOI 10.1056/NEJMoa063994; PENNO MB, 1994, CANCER RES, V54, P1381; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Sherman LS, 2000, J CELL BIOL, V150, P1071, DOI 10.1083/jcb.150.5.1071; SLEBOS RJC, 1990, NEW ENGL J MED, V323, P561, DOI 10.1056/NEJM199008303230902; Weg-Remers S, 2001, EMBO J, V20, P4194, DOI 10.1093/emboj/20.15.4194; Yu WH, 2002, GENE DEV, V16, P307, DOI 10.1101/gad.925702	24	32	34	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2013	32	43					5186	5190		10.1038/onc.2012.542	http://dx.doi.org/10.1038/onc.2012.542			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240JY	23208496	Green Accepted			2022-12-28	WOS:000326093200006
J	Choi, HJ; Kim, J; Do, KH; Park, SH; Moon, Y				Choi, H. J.; Kim, J.; Do, K. H.; Park, S-H; Moon, Y.			Enteropathogenic Escherichia coli-induced macrophage inhibitory cytokine 1 mediates cancer cell survival: an in vitro implication of infection-linked tumor dissemination	ONCOGENE			English	Article						epithelial tumor cell survival; enteropathogenic Escherichia coli; macrophage inhibitory cytokine 1	INFLAMMATORY-BOWEL-DISEASE; ACTIN PEDESTAL FORMATION; GENE-EXPRESSION; PROGNOSTIC-SIGNIFICANCE; RHO-GTPASES; MIC-1; APOPTOSIS; INVASION; PROSTATE; RISK	Mucosally adherent Escherichia coli is frequently observed in intestinal surface of patients with colorectal cancer, but rarely in healthy control. Particularly, enteropathogenic Escherichia coli (EPEC) is known to be closely associated with colorectal carcinogenesis in human. In this study, one consequence of EPEC infection in human intestinal cancer cells was induction of macrophage inhibitory cytokine 1 (MIC-1), which is a multifunctional cytokine with biological activities involved in cancer cell growth, differentiation and migration. The present investigation assessed the involvement of MIC-1 protein in EPEC infectionmediated cancer cell survival. The challenge with EPEC induced cancer cell detachment via cytoskeleton rearrangement, which was positively associated with induced MIC-1 expression. Moreover, MIC-1 also mediated RhoA GTPase-linked survival of the detached cancer cells. Blocking of MIC-1 or RhoA activity increased cellular apoptosis of the detached cancer cells. In terms of signaling pathway, MIC-1 triggered transforming growth factorb-activated kinase 1 (TAK1), which enhanced expression of RhoA GTPase. We conclude that EPEC enhances MIC-1 gene expression in the human intestinal cancer cells, which can be associated with enhanced tumor cell resistance to anchorage-dependent tumor cell death via enhanced TAK1 and RhoA GTPase.	[Choi, H. J.; Kim, J.; Do, K. H.; Park, S-H; Moon, Y.] Pusan Natl Univ, Sch Med, Dept Microbiol & Immunol, Lab Mucosal Exposome & Biomodulat, Yangsan 626870, Kyungnam, South Korea; [Choi, H. J.; Kim, J.; Do, K. H.; Park, S-H; Moon, Y.] Pusan Natl Univ, Sch Med, Med Res Inst, Yangsan 626870, Kyungnam, South Korea; [Moon, Y.] Pusan Natl Univ, Res Inst Basic Sci, Pusan, South Korea; [Moon, Y.] Pusan Natl Univ, Med Res Inst, Pusan, South Korea	Pusan National University; Pusan National University Hospital; Pusan National University; Pusan National University Hospital; Pusan National University; Pusan National University	Moon, Y (corresponding author), Pusan Natl Univ, Sch Med, Dept Microbiol & Immunol, Lab Mucosal Exposome & Biomodulat, Room 704, Yangsan 626870, Kyungnam, South Korea.	moon@pnu.edu	Yuseok Moon, ATS/AAE-4364-2020	MOON, YUSEOK/0000-0001-8686-8166	Basic Science Research Program through the National Research Foundation of Korea; Ministry of Education, Science and Technology [2012R1A1A2005837]	Basic Science Research Program through the National Research Foundation of Korea(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This work was supported by the Basic Science Research Program through the National Research Foundation of Korea, funded by Ministry of Education, Science and Technology Grant 2012R1A1A2005837.	Aepfelbacher M, 2005, CURR TOP MICROBIOL, V291, P167; Agarwal MK, 2006, P NATL ACAD SCI USA, V103, P16278, DOI 10.1073/pnas.0607210103; BARTHOLD SW, 1977, CANCER RES, V37, P4352; Batchelor M, 2004, EMBO REP, V5, P104, DOI 10.1038/sj.embor.7400038; Bellizzi A, 2008, INT J MOL MED, V22, P25; Bootcov MR, 1997, P NATL ACAD SCI USA, V94, P11514, DOI 10.1073/pnas.94.21.11514; Borthakur A, 2006, AM J PHYSIOL-GASTR L, V290, pG30, DOI 10.1152/ajpgi.00302.2005; Braga V, 2000, EXP CELL RES, V261, P83, DOI 10.1006/excr.2000.5050; Brown DA, 2003, CLIN CANCER RES, V9, P2642; Brown DA, 2002, LANCET, V359, P2159, DOI 10.1016/S0140-6736(02)09093-1; Campellone KG, 2003, CURR OPIN MICROBIOL, V6, P82, DOI 10.1016/S1369-5274(03)00005-5; Chan CH, 2010, NAT CELL BIOL, V12, P457, DOI 10.1038/ncb2047; Crane JK, 1999, INFECT IMMUN, V67, P2575, DOI 10.1128/IAI.67.5.2575-2584.1999; Dean P, 2006, P NATL ACAD SCI USA, V103, P1876, DOI 10.1073/pnas.0509451103; Detrich R E, 1976, J Maine Med Assoc, V67, P52; Dittert DD, 2008, HUM PATHOL, V39, P1002, DOI 10.1016/j.humpath.2007.11.016; Fairlie WD, 1999, J LEUKOCYTE BIOL, V65, P2, DOI 10.1002/jlb.65.1.2; Faried A, 2007, ANN SURG ONCOL, V14, P3593, DOI 10.1245/s10434-007-9562-x; Gotoh T, 2002, J BIOL CHEM, V277, P12343, DOI 10.1074/jbc.M107988200; Gradel KO, 2009, GASTROENTEROLOGY, V137, P495, DOI 10.1053/j.gastro.2009.04.001; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hecht G, 2001, AM J PHYSIOL-GASTR L, V281, pG1, DOI 10.1152/ajpgi.2001.281.1.G1; Iczkowski KA, 2003, INT J SURG PATHOL, V11, P159, DOI 10.1177/106689690301100302; Kim KS, 2002, GASTROENTEROLOGY, V122, P1388, DOI 10.1053/gast.2002.32972; Lee DH, 2003, CANCER RES, V63, P4648; Lieberman D, 2009, CURR OPIN GASTROEN, V25, P422, DOI 10.1097/MOG.0b013e32832d1e2a; Lim DY, 2009, AM J PHYSIOL-GASTR L, V296, pG1060, DOI 10.1152/ajpgi.90490.2008; Liu T, 2003, CANCER RES, V63, P5034; Lu PD, 2004, EMBO J, V23, P169, DOI 10.1038/sj.emboj.7600030; Maddocks ODK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005517; Mager DL, 2006, J TRANSL MED, V4, DOI 10.1186/1479-5876-4-14; Mahida YR, 2004, CLIN SCI, V107, P331, DOI 10.1042/CS20040136; Martin HM, 2004, GASTROENTEROLOGY, V127, P80, DOI 10.1053/j.gastro.2004.03.054; Matsuzawa T, 2004, EMBO J, V23, P3570, DOI 10.1038/sj.emboj.7600359; MOSCOW JA, 1994, ONCOGENE, V9, P189; Mylonaki M, 2005, INFLAMM BOWEL DIS, V11, P481, DOI 10.1097/01.MIB.0000159663.62651.4f; Nagai T, 2005, J BIOL CHEM, V280, P2998, DOI 10.1074/jbc.M411550200; Newman JV, 2001, J INFECT DIS, V184, P227, DOI 10.1086/321998; Nougayrede JP, 2007, CELL MICROBIOL, V9, P680, DOI 10.1111/j.1462-5822.2006.00820.x; Oliva C A, 1997, Rev Assoc Med Bras (1992), V43, P283; POTTER JD, 1993, EPIDEMIOL REV, V15, P499, DOI 10.1093/oxfordjournals.epirev.a036132; Rathinam R, 2011, FRONT BIOSCI-LANDMRK, V16, P2561, DOI 10.2741/3872; Rihet S, 2001, J CANCER RES CLIN, V127, P733; Rogers AB, 2004, AM J PHYSIOL-GASTR L, V286, pG361, DOI 10.1152/ajpgi.00499.2003; Rogers Arlin B., 2009, V511, P267, DOI 10.1007/978-1-59745-447-6_11; ROTHBAUM R, 1982, GASTROENTEROLOGY, V83, P441; Struckhoff AP, 2011, FRONT BIOSCI-LANDMRK, V16, P1915, DOI 10.2741/3830; Stypulkowska-Misiurewicz H, 1984, Przegl Epidemiol, V38, P19; Swidsinski A, 1998, GASTROENTEROLOGY, V115, P281, DOI 10.1016/S0016-5085(98)70194-5; Thomas R, 2001, INT J CANCER, V93, P47, DOI 10.1002/ijc.1291; Thompson Patricia A, 2009, Expert Rev Gastroenterol Hepatol, V3, P369, DOI 10.1586/egh.09.28; Tomson FL, 2005, MOL MICROBIOL, V56, P447, DOI 10.1111/j.1365-2958.2005.04571.x; Tong S, 2004, LANCET, V363, P129, DOI 10.1016/S0140-6736(03)15265-8; Triantafillidis JK, 2009, ANTICANCER RES, V29, P2727; ULSHEN MH, 1980, NEW ENGL J MED, V302, P99, DOI 10.1056/NEJM198001103020207; Vermeulen SJ, 1999, CLIN EXP METASTAS, V17, P663, DOI 10.1023/A:1006724300022; Vermeulen SJ, 1997, ANN NY ACAD SCI, V833, P186, DOI 10.1111/j.1749-6632.1997.tb48607.x; Viswanathan VK, 2004, CELL MICROBIOL, V6, P987, DOI 10.1111/j.1462-5822.2004.00416.x; Welsh JB, 2003, P NATL ACAD SCI USA, V100, P3410, DOI 10.1073/pnas.0530278100; Wollmann W, 2005, CARCINOGENESIS, V26, P900, DOI 10.1093/carcin/bgi031; Yang H, 2009, BIOCHEM PHARMACOL, V78, P1205, DOI 10.1016/j.bcp.2009.06.012	61	23	24	1	7	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2013	32	41					4960	4969		10.1038/onc.2012.508	http://dx.doi.org/10.1038/onc.2012.508			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235KQ	23503457				2022-12-28	WOS:000325717800012
J	Stebbing, J; Filipovic, A; Giamas, G				Stebbing, J.; Filipovic, A.; Giamas, G.			Claudin-1 as a promoter of EMT in hepatocellular carcinoma	ONCOGENE			English	Editorial Material						Claudin-1; hepatocellular cancer; invasion; Ras; ERK; c-Abl	CANCER; PROTEINS; THERAPY	Claudins are integral structural and functional components of apical cell adhesions (tight junctions). Loss of such adhesions has been associated with malignant transformation, a process most often accompanied by a concomitant loss of claudin expression. A growing body of evidence reveals the highly contextual upregulation of claudin expression in certain cancer types, and moreover their relevance in promoting cancer cell invasion and metastatic progression. In this issue of Oncogene, Suh et al. reported on claudin-1 expression in hepatocellular carcinoma (HCC), including its role as a promoter of the epithelial - to - mesenchymal transition via the c-Abl/Raf/Ras/ERK signaling pathway. Considering the limited therapeutic options in HCC, evaluation of its role as a target merits further investigation.	[Stebbing, J.; Filipovic, A.; Giamas, G.] Univ London Imperial Coll Sci Technol & Med, Div Surg & Canc, London W12 ONN, England	Imperial College London	Giamas, G (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Surg & Canc, Du Cane Rd,ICTEM Bldg, London W12 ONN, England.	g.giamas@imperial.ac.uk	Giamas, Georgios/AAP-3487-2021	Stebbing, Justin/0000-0002-1117-6947; Giamas, Georgios/0000-0002-4417-2707	Cancer Research UK Funding Source: Medline; Department of Health [NIHR-RP-011-053] Funding Source: Medline; Cancer Research UK [14549] Funding Source: researchfish; National Institute for Health Research [NIHR-RP-011-053] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Department of Health; Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR))		Cervello M, 2012, ONCOTARGET, V3, P236, DOI 10.18632/oncotarget.466; Dhawan P, 2005, J CLIN INVEST, V115, P1765, DOI 10.1172/JCI24543; Morin PJ, 2005, CANCER RES, V65, P9603, DOI 10.1158/0008-5472.CAN-05-2782; Myal Y, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/956897; Roxburgh P, 2008, ADV THER, V25, P1089, DOI 10.1007/s12325-008-0113-z; Singh AB, 2010, J ONCOL, V2010, DOI 10.1155/2010/541957; Suh Y, 2013, ONCOGENE, V32, P4873, DOI 10.1038/onc.2012.505; Suzuki H, 2012, ANN NY ACAD SCI, V1258, P65, DOI 10.1111/j.1749-6632.2012.06503.x; Tabaries S, 2012, MOL CELL BIOL, V32, P2979, DOI 10.1128/MCB.00299-12; Turksen K, 2011, BBA-REV CANCER, V1816, P73, DOI 10.1016/j.bbcan.2011.04.001; Yoon CH, 2010, J BIOL CHEM, V285, P226, DOI 10.1074/jbc.M109.054189	11	31	32	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2013	32	41					4871	4872		10.1038/onc.2012.591	http://dx.doi.org/10.1038/onc.2012.591			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235KQ	23318416				2022-12-28	WOS:000325717800002
J	Wen, J; Cerosaletti, K; Schultz, KJ; Wright, JA; Concannon, P				Wen, J.; Cerosaletti, K.; Schultz, K. J.; Wright, J. A.; Concannon, P.			NBN Phosphorylation regulates the accumulation of MRN and ATM at sites of DNA double-strand breaks	ONCOGENE			English	Article						MRN; ATM; nibrin (NBN); I-PpoI and DNA double-strand breaks	DISTINCT FUNCTIONAL DOMAINS; CELL-PENETRATING PEPTIDES; S-PHASE CHECKPOINT; ATAXIA-TELANGIECTASIA; IONIZING-RADIATION; DEPENDENT PHOSPHORYLATION; CHROMOSOMAL INSTABILITY; SYNDROME PROTEIN; DAMAGE RESPONSE; REPAIR	In response to ionizing radiation, the MRE11/RAD50/NBN complex re-distributes to the sites of DNA double-strand breaks (DSBs) where each of its individual components is phosphorylated by the serine-threonine kinase, ATM. ATM phosphorylation of NBN is required for the activation of the S-phase checkpoint, but the mechanism whereby these phosphorylation events signal the checkpoint machinery remains unexplained. Here, we describe the use of direct protein transduction of the homing endonuclease, I-PpoI, into human cells to generate site-specific DSBs. Direct transduction of I-PpoI protein results in rapid accumulation and turnover of the endonuclease in live cells, facilitating comparisons across multiple cell lines. We demonstrate the utility of this system by introducing I-PpoI into isogenic cell lines carrying mutations at the ATM phosphorylation sites in NBN and assaying the effects of these mutations on the spatial distribution and temporal accumulation of NBN and ATM at DSBs by chromatin immunoprecipitation, as well as timing and extent of DSB repair. Although the spatial distribution of NBN and ATM recruited to the sites of DSBs was comparable between control cells and those expressing phosphorylation mutants of NBN, the timing of accumulation of NBN and ATM was altered. Serine-to-alanine mutations that blocked phosphorylation resulted in delayed recruitment of both NBN and ATM to DSBs. Serine-to-glutamic acid substitutions that mimicked the phosphorylation event resulted in both increased and prolonged accumulation of both NBN and ATM at DSBs. The repair of DSBs in cells lacking full-length NBN was significantly delayed compared with control cells, whereas blocking phosphorylation of NBN resulted in a more modest delay in repair. These data indicate that following the induction of DSBs, phosphorylation of NBN regulates its accumulation, and that of ATM, at sites of DNA DSB as well as the timing of the repair of these sites.	[Wen, J.; Wright, J. A.; Concannon, P.] Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; [Cerosaletti, K.] Benaroya Res Inst, Translat Res Program, Seattle, WA USA; [Schultz, K. J.] Univ New Mexico, Sch Med, Albuquerque, NM 87131 USA; [Concannon, P.] Univ Virginia, Ctr Publ Hlth Genom, Charlottesville, VA 22908 USA	University of Virginia; Benaroya Research Institute; University of New Mexico; University of Virginia	Concannon, P (corresponding author), Univ Virginia, Ctr Publ Hlth Genom, Dept Biochem & Mol Genet, POB 800717, Charlottesville, VA 22908 USA.	pjc6n@virginia.edu		Concannon, Patrick/0000-0002-5801-1859	NCI [CA57569]; NATIONAL CANCER INSTITUTE [R01CA057569] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a grant from the NCI (CA57569).	Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bekker-Jensen S, 2006, J CELL BIOL, V173, P195, DOI 10.1083/jcb.200510130; Berkovich E, 2007, NAT CELL BIOL, V9, P683, DOI 10.1038/ncb1599; Carney JP, 1998, CELL, V93, P477, DOI 10.1016/S0092-8674(00)81175-7; Carson CT, 2003, EMBO J, V22, P6610, DOI 10.1093/emboj/cdg630; Cerosaletti K, 2004, J BIOL CHEM, V279, P38813, DOI 10.1074/jbc.M404294200; Cerosaletti K, 2006, MOL CELL BIOL, V26, P1691, DOI 10.1128/MCB.26.5.1691-1699.2006; de Jager M, 2001, MOL CELL, V8, P1129, DOI 10.1016/S1097-2765(01)00381-1; DERZWET MK, 1999, MUTAT RES, V434, P17; Desai-Mehta A, 2001, MOL CELL BIOL, V21, P2184, DOI 10.1128/MCB.21.6.2184-2191.2001; Di VM, 2009, DNA REPAIR, V8, P1311; Difilippantonio S, 2005, NAT CELL BIOL, V7, P675, DOI 10.1038/ncb1270; Dong ZW, 1999, J BIOL CHEM, V274, P19513, DOI 10.1074/jbc.274.28.19513; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2005, NATURE, V434, P605, DOI 10.1038/nature03442; Gatei M, 2000, NAT GENET, V25, P115, DOI 10.1038/75508; Gatei M, 2011, J BIOL CHEM, V286, P31542, DOI 10.1074/jbc.M111.258152; Horejsi Z, 2004, ONCOGENE, V23, P3122, DOI 10.1038/sj.onc.1207447; JASPERS NGJ, 1988, AM J HUM GENET, V42, P66; Kitagawa R, 2004, GENE DEV, V18, P1423, DOI 10.1101/gad.1200304; Lee JH, 2003, J BIOL CHEM, V278, P45171, DOI 10.1074/jbc.M308705200; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lindgren M, 2011, METHODS MOL BIOL, V683, P3, DOI 10.1007/978-1-60761-919-2_1; Lins S, 2009, GENE, V447, P12, DOI 10.1016/j.gene.2009.07.013; Lukas C, 2003, NAT CELL BIOL, V5, P255, DOI 10.1038/ncb945; Lukas C, 2004, EMBO J, V23, P2674, DOI 10.1038/sj.emboj.7600269; Luo GB, 1999, P NATL ACAD SCI USA, V96, P7376, DOI 10.1073/pnas.96.13.7376; Maser RS, 2001, NAT GENET, V27, P417, DOI 10.1038/86920; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Matsuura S, 1998, NAT GENET, V19, P179, DOI 10.1038/549; Milletti F, 2012, DRUG DISCOV TODAY, V17, P850, DOI 10.1016/j.drudis.2012.03.002; Nelms BE, 1998, SCIENCE, V280, P590, DOI 10.1126/science.280.5363.590; O'Driscoll M, 2001, MOL CELL, V8, P1175, DOI 10.1016/S1097-2765(01)00408-7; Paull TT, 1999, GENE DEV, V13, P1276, DOI 10.1101/gad.13.10.1276; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Paull TT, 1998, MOL CELL, V1, P969, DOI 10.1016/S1097-2765(00)80097-0; ROUET P, 1994, MOL CELL BIOL, V14, P8096, DOI 10.1128/MCB.14.12.8096; ROUET P, 1994, P NATL ACAD SCI USA, V91, P6064, DOI 10.1073/pnas.91.13.6064; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; TAALMAN RDFM, 1983, MUTAT RES, V112, P23, DOI 10.1016/0167-8817(83)90021-4; TAALMAN RDFM, 1989, AM J MED GENET, V32, P425, DOI 10.1002/ajmg.1320320332; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Varon R, 1998, CELL, V93, P467, DOI 10.1016/S0092-8674(00)81174-5; Vissinga CS, 2009, MOL CELL BIOL, V29, P1000, DOI 10.1128/MCB.01131-08; WEEMAES CMR, 1981, ACTA PAEDIATR SCAND, V70, P557, DOI 10.1111/j.1651-2227.1981.tb05740.x; Wu XH, 2000, NATURE, V405, P477, DOI 10.1038/35013089; Xiao YH, 1997, NUCLEIC ACIDS RES, V25, P2985, DOI 10.1093/nar/25.15.2985; Zhao S, 2000, NATURE, V405, P473, DOI 10.1038/35013083; Zhu J, 2001, CURR BIOL, V11, P105, DOI 10.1016/S0960-9822(01)00019-7	50	16	17	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2013	32	37					4448	4456		10.1038/onc.2012.443	http://dx.doi.org/10.1038/onc.2012.443			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218AF	23146902	Green Accepted			2022-12-28	WOS:000324404200013
J	Fedorenko, IV; Gibney, GT; Smalley, KSM				Fedorenko, I. V.; Gibney, G. T.; Smalley, K. S. M.			NRAS mutant melanoma: biological behavior and future strategies for therapeutic management	ONCOGENE			English	Review						melanoma; Ras; targeted therapy	INHIBITOR AZD6244 ARRY-142886; BRAF MUTATIONS; ACQUIRED-RESISTANCE; RAS MUTATIONS; MEDIATES RESISTANCE; SIGNALING PATHWAYS; CLINICAL-RESPONSE; IMPROVED SURVIVAL; KINASE INHIBITOR; TYROSINE KINASE	The recent years have seen a significant shift in the expectations for the therapeutic management of disseminated melanoma. The clinical success of BRAF targeted therapy suggests that long-term disease control may one day be a reality for genetically defined subgroups of melanoma patients. Despite this progress, few advances have been made in developing targeted therapeutic strategies for the 50% of patients whose melanomas are BRAF wild-type. The most well-characterized subgroup of BRAF wild-type tumors is the 15-20% of all melanomas that harbor activating NRAS (Neuroblastoma Rat Sarcoma Virus) mutations. Emerging preclinical and clinical evidence suggests that NRAS mutant melanomas have patterns of signal transduction and biological behavior that is distinct from BRAF mutant melanomas. This overview will discuss the unique clinical and prognostic behavior of NRAS mutant melanoma and will summarize the emerging data on how NRAS-driven signaling networks can be translated into novel therapeutic strategies.	[Fedorenko, I. V.; Smalley, K. S. M.] Dept Mol Oncol, Tampa, FL USA; [Fedorenko, I. V.; Gibney, G. T.; Smalley, K. S. M.] Univ S Florida, H Lee Moffitt Canc Ctr, Comprehens Melanoma Res Ctr, Tampa, FL 33612 USA; [Gibney, G. T.; Smalley, K. S. M.] Dept Cutaneous Oncol, Tampa, FL USA	H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Smalley, KSM (corresponding author), Univ S Florida, H Lee Moffitt Canc Ctr, Comprehens Melanoma Res Ctr, Dept Mol Oncol,SRB, 12902 Magnolia Dr, Tampa, FL 33612 USA.	keiran.smalley@moffitt.org	Smalley, Inna/AAR-8638-2021; Smalley, Inna/G-9016-2015	Smalley, Inna/0000-0002-6796-9145; Smalley, Inna/0000-0002-6796-9145; Smalley, Keiran/0000-0003-1089-9307	National Institutes of Health, The Harry Lloyd Trust [U54 CA143970-01, R01 CA161107-01]; State of Florida [09BN-14]; NATIONAL CANCER INSTITUTE [R01CA161107, U54CA143970] Funding Source: NIH RePORTER	National Institutes of Health, The Harry Lloyd Trust(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); State of Florida; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Work in the Smalley lab is supported by Grants U54 CA143970-01 and R01 CA161107-01 from the National Institutes of Health, The Harry Lloyd Trust and the State of Florida (09BN-14).	Adjei AA, 2008, J CLIN ONCOL, V26, P2139, DOI 10.1200/JCO.2007.14.4956; ALBINO AP, 1984, NATURE, V308, P69, DOI 10.1038/308069a0; Ascierto PA, 2012, J CLIN ONCOL, V30; Atefi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028973; Atkins MB, 1997, ROLE CYTOTOXIC CHEMO, P219; Bardeesy N, 2001, MOL CELL BIOL, V21, P2144, DOI 10.1128/MCB.21.6.2144-2153.2001; Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003; Bastian BC, 2000, AM J PATHOL, V157, P967, DOI 10.1016/S0002-9440(10)64609-3; Bauer J, 2007, J INVEST DERMATOL, V127, P179, DOI 10.1038/sj.jid.5700490; Bedard P, 2012, J CLIN ONCOL, V30; Bhatt KV, 2005, ONCOGENE, V24, P3459, DOI 10.1038/sj.onc.1208544; Boisvert-Adamo K, 2008, ONCOGENE, V27, P3301, DOI 10.1038/sj.onc.1211003; BOS JL, 1989, CANCER RES, V49, P4682; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; Chandarlapaty S, 2012, CANCER DISCOV, V2, P311, DOI 10.1158/2159-8290.CD-12-0018; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Cheung M, 2008, CANCER RES, V68, P3429, DOI 10.1158/0008-5472.CAN-07-5867; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; Cho KJ, 2012, CURR BIOL, V22, P945, DOI 10.1016/j.cub.2012.03.067; Colicelli John, 2004, Sci STKE, V2004, pRE13, DOI 10.1126/stke.2502004re13; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Davies MA, 2008, BRIT J CANCER, V99, P1265, DOI 10.1038/sj.bjc.6604637; Davies MA, 2009, CLIN CANCER RES, V15, P7538, DOI 10.1158/1078-0432.CCR-09-1985; Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956; De Ruiter ND, 2001, MOL CELL BIOL, V21, P8225, DOI 10.1128/MCB.21.23.8225-8235.2001; Devitt B, 2011, PIGM CELL MELANOMA R, V24, P666, DOI 10.1111/j.1755-148X.2011.00873.x; Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Duensing S, 2010, BIOCHEM PHARMACOL, V80, P575, DOI 10.1016/j.bcp.2010.04.006; Dumaz N, 2002, MOL CELL BIOL, V22, P3717, DOI 10.1128/MCB.22.11.3717-3728.2002; Dumaz N, 2006, CANCER RES, V66, P9483, DOI 10.1158/0008-5472.CAN-05-4227; Dumaz Nicolas, 2011, Small GTPases, V2, P289; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; Ebi H, 2011, J CLIN INVEST, V121, P4311, DOI 10.1172/JCI57909; Ellerhorst JA, 2011, CLIN CANCER RES, V17, P229, DOI 10.1158/1078-0432.CCR-10-2276; Engelman JA, 2008, NAT MED, V14, P1351, DOI 10.1038/nm.1890; Eskandarpour M, 2009, INT J CANCER, V124, P16, DOI 10.1002/ijc.23876; Fedorenko IV, 2011, BIOCHEM PHARMACOL, V82, P201, DOI 10.1016/j.bcp.2011.05.015; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Frame S, 2001, BIOCHEM J, V359, P1, DOI 10.1042/0264-6021:3590001; Gilmartin AG, 2011, CLIN CANCER RES, V17, P989, DOI 10.1158/1078-0432.CCR-10-2200; Gopal YNV, 2010, CANCER RES, V70, P8736, DOI 10.1158/0008-5472.CAN-10-0902; Gowrishankar K, 2012, J INVEST DERMATOL, V132, P1850, DOI 10.1038/jid.2012.63; Greger JG, 2012, MOL CANCER THER, V11, P909, DOI 10.1158/1535-7163.MCT-11-0989; Haass NK, 2008, CLIN CANCER RES, V14, P230, DOI 10.1158/1078-0432.CCR-07-1440; Halaban R, 2010, PIGM CELL MELANOMA R, V23, P190, DOI 10.1111/j.1755-148X.2010.00685.x; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Jaiswal BS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005717; Jakob JA, 2012, CANCER-AM CANCER SOC, V118, P4014, DOI 10.1002/cncr.26724; Jonsson A, 2010, J INVEST DERMATOL, V130, P2809, DOI 10.1038/jid.2010.216; Joseph RW, 2012, J IMMUNOTHER, V35, P66, DOI 10.1097/CJI.0b013e3182372636; Jovanovic B, 2010, J INVEST DERMATOL, V130, P618, DOI 10.1038/jid.2009.287; Kaplan FM, 2011, ONCOGENE, V30, P366, DOI 10.1038/onc.2010.408; Kissil JL, 2007, CANCER RES, V67, P8089, DOI 10.1158/0008-5472.CAN-07-2300; Konstantinopoulos PA, 2007, NAT REV DRUG DISCOV, V6, P540, DOI 10.1038/nrd2221; Li A, 2012, J INVEST DERMATOL, V132, P2610, DOI 10.1038/jid.2012.186; Lin WM, 2008, CANCER RES, V68, P664, DOI 10.1158/0008-5472.CAN-07-2615; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; Madhunapantula SV, 2009, PIGM CELL MELANOMA R, V22, P400, DOI 10.1111/j.1755-148X.2009.00585.x; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Marquette A, 2011, NAT STRUCT MOL BIOL, V18, P584, DOI 10.1038/nsmb.2022; MCCORMICK F, 1995, MOL REPROD DEV, V42, P500, DOI 10.1002/mrd.1080420419; Means-Powell JA, 2012, J CLIN ONCOL, V30; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Milagre C, 2010, CANCER RES, V70, P5549, DOI 10.1158/0008-5472.CAN-09-4254; Mishra PJ, 2010, ONCOGENE, V29, P2449, DOI 10.1038/onc.2009.521; Molhoek KR, 2011, MELANOMA RES, V21, P274, DOI 10.1097/CMR.0b013e328343a1d6; Mooi WJ, 2006, NEW ENGL J MED, V355, P1037, DOI 10.1056/NEJMra062285; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Niessner H, 2011, J INVEST DERMATOL, V131, P468, DOI 10.1038/jid.2010.297; Oberholzer PA, 2012, J CLIN ONCOL, V30, P316, DOI 10.1200/JCO.2011.36.7680; Omholt K, 2007, MELANOMA RES, V17, P410, DOI 10.1097/CMR.0b013e3282ef4178; Paraiso KHT, 2012, CLIN CANCER RES, V18, P2502, DOI 10.1158/1078-0432.CCR-11-2612; Paraiso KHT, 2011, CANCER RES, V71, P2750, DOI 10.1158/0008-5472.CAN-10-2954; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Ritt DA, 2010, MOL CELL BIOL, V30, P806, DOI 10.1128/MCB.00569-09; Robert C, 2012, J CLIN ONCOL, V30, DOI 10.1200/jco.2012.30.18_suppl.lba8509; Sensi M, 2006, ONCOGENE, V25, P3357, DOI 10.1038/sj.onc.1209379; Sensi M, 2011, J INVEST DERMATOL, V131, P2448, DOI 10.1038/jid.2011.218; Shahabi V, 2012, CANCER IMMUNOL IMMUN, V61, P733, DOI 10.1007/s00262-012-1227-3; Shakhova O, 2012, NAT CELL BIOL, V14, P882, DOI 10.1038/ncb2535; Shao YP, 2010, CANCER RES, V70, P6670, DOI 10.1158/0008-5472.CAN-09-4471; She QB, 2005, CANCER CELL, V8, P287, DOI 10.1016/j.ccr.2005.09.006; She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023; Smalley KSM, 2009, ONCOGENE, V28, P85, DOI 10.1038/onc.2008.362; Smalley Keiran S M, 2012, Pigment Cell Melanoma Res, V25, pE1, DOI 10.1111/j.1755-148X.2011.00943.x; Smalley KSM, 2003, INT J CANCER, V104, P527, DOI 10.1002/ijc.10978; Smalley KSM, 2003, INT J CANCER, V105, P165, DOI 10.1002/ijc.11064; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Su F, 2012, CANCER RES, V72, P969, DOI 10.1158/0008-5472.CAN-11-1875; Su F, 2012, NEW ENGL J MED, V366, P207, DOI 10.1056/NEJMoa1105358; Su YJ, 2012, CLIN CANCER RES, V18, P2184, DOI 10.1158/1078-0432.CCR-11-1122; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Tsao H, 2004, J INVEST DERMATOL, V122, P337, DOI 10.1046/j.0022-202X.2004.22243.x; Tworkoski K, 2011, MOL CANCER RES, V9, P801, DOI 10.1158/1541-7786.MCR-10-0512; Viros A, 2008, PLOS MED, V5, P941, DOI 10.1371/journal.pmed.0050120; Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6; Whitwam T, 2007, ONCOGENE, V26, P4563, DOI 10.1038/sj.onc.1210239; Wu M, 2000, GENE DEV, V14, P301; Zimmer L, 2012, J CLIN ONCOL, V30, P2375, DOI 10.1200/JCO.2011.41.1660; Zipfel PA, 2010, ONCOGENE, V29, P4859, DOI 10.1038/onc.2010.224	111	97	106	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 20	2013	32	25					3009	3018		10.1038/onc.2012.453	http://dx.doi.org/10.1038/onc.2012.453			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	168KX	23069660	Green Accepted			2022-12-28	WOS:000320705700001
J	Pawlus, MR; Wang, L; Hu, CJ				Pawlus, M. R.; Wang, L.; Hu, C-J			STAT3 and HIF1 alpha cooperatively activate HIF1 target genes in MDA-MB-231 and RCC4 cells	ONCOGENE			English	Article						cotranscriptional activation; HIF; hypoxia; STAT3; transcription	HYPOXIA-INDUCIBLE FACTOR-1; ENDOTHELIAL GROWTH-FACTOR; BREAST-CANCER CELLS; REGULATES VEGF EXPRESSION; SMOOTH-MUSCLE-CELLS; SIGNAL TRANSDUCER; TRANSCRIPTION FACTOR; METABOLIC SWITCH; SRC KINASE; KAPPA-B	Solid tumors often exhibit simultaneously inflammatory and hypoxic microenvironments. The 'signal transducer and activator of transcription-3' (STAT3)-mediated inflammatory response and the hypoxia-inducible factor (HIF)-mediated hypoxia response have been independently shown to promote tumorigenesis through the activation of HIF or STAT3 target genes and to be indicative of a poor prognosis in a variety of tumors. We report here for the first time that STAT3 is involved in the HIF1, but not HIF2-mediated hypoxic transcriptional response. We show that inhibiting STAT3 activity in MDA-MB-231 and RCC4 cells by a STAT3 inhibitor or STAT3 small interfering RNA significantly reduces the levels of HIF1, but not HIF2 target genes in spite of normal levels of hypoxia-inducible transcription factor 1 alpha (HIF1 alpha) and HIF2 alpha protein. Mechanistically, STAT3 activates HIF1 target genes by binding to HIF1 target gene promoters, interacting with HIF1a protein and recruiting coactivators CREB binding protein (CBP) and p300, and RNA polymerase II (Pol II) to form enhanceosome complexes that contain HIF1 alpha, STAT3, CBP, p300 and RNA Pol II on HIF1 target gene promoters. Functionally, the effect of STAT3 knockdown on proliferation, motility and clonogenic survival of tumor cells in vitro is phenocopied by HIF1 alpha knockdown in hypoxic cells, whereas STAT3 knockdown in normoxic cells also reduces cell proliferation, motility and clonogenic survival. This indicates that STAT3 works with HIF1 to activate HIF1 target genes and to drive HIF1-depedent tumorigenesis under hypoxic conditions, but also has HIF-independent activity in normoxic and hypoxic cells. Identifying the role of STAT3 in the hypoxia response provides further data supporting the effectiveness of STAT3 inhibitors in solid tumor treatment owing to their usefulness in inhibiting both the STAT3 and HIF1 pro-tumorigenic signaling pathways in some cancer types.	[Pawlus, M. R.; Hu, C-J] Univ Colorado, Grad Sch, Mol Biol Grad Program, Aurora, CO 80045 USA; [Wang, L.; Hu, C-J] Univ Colorado, Sch Dent Med, Dept Craniofacial Biol, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Hu, CJ (corresponding author), Univ Colorado, Sch Dent Med, Dept Craniofacial Biol, Anschutz Med Campus, Aurora, CO 80045 USA.	Cheng-jun.hu@ucdenver.edu		Pawlus, Matthew/0000-0001-6007-7198; Hu, Cheng-Jun/0000-0003-0985-1285	National Cancer Institute [RO1CA134687]; Cancer Leagues of Colorado; NATIONAL CANCER INSTITUTE [P30CA046934, R01CA134687] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008730] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Cancer Leagues of Colorado; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by grants from the National Cancer Institute (RO1CA134687, Hu) and Cancer Leagues of Colorado (Hu).	Adachi M, 2012, ORAL ONCOL, V48, P1220, DOI 10.1016/j.oraloncology.2012.06.006; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bai LF, 2012, INT J CANCER, V130, P2693, DOI 10.1002/ijc.26303; Bando H, 2003, BIOMED PHARMACOTHER, V57, P333, DOI 10.1016/S0753-3322(03)00098-2; Bartoli M, 2003, FASEB J, V17, P1562, DOI 10.1096/fj.02-1084fje; BelAiba RS, 2007, MOL BIOL CELL, V18, P4691, DOI 10.1091/mbc.E07-04-0391; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Carraro F, 2007, J CELL PHYSIOL, V211, P439, DOI 10.1002/jcp.20951; Demaria M, 2010, AGING-US, V2, P823, DOI 10.18632/aging.100232; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; Finger EC, 2010, CANCER METAST REV, V29, P285, DOI 10.1007/s10555-010-9224-5; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Gao XL, 2012, MOL CELL, V45, P598, DOI 10.1016/j.molcel.2012.01.001; Gleadle JM, 1997, BLOOD, V89, P503, DOI 10.1182/blood.V89.2.503; Gomes NP, 2006, GENE DEV, V20, P601, DOI 10.1101/gad.1398206; Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006; Grad JM, 2000, CURR OPIN ONCOL, V12, P543, DOI 10.1097/00001622-200011000-00006; Gray MJ, 2005, ONCOGENE, V24, P3110, DOI 10.1038/sj.onc.1208513; Horiguchi A, 2002, J UROLOGY, V168, P762, DOI 10.1016/S0022-5347(05)64741-6; Horiguchi A, 2010, BRIT J CANCER, V102, P1592, DOI 10.1038/sj.bjc.6605691; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; Hu CJ, 2007, MOL BIOL CELL, V18, P4528, DOI 10.1091/mbc.E06-05-0419; Hu CJ, 2003, MOL CELL BIOL, V23, P9361, DOI 10.1128/MCB.23.24.9361-9374.2003; Hu CJ, 2006, MOL CELL BIOL, V26, P3514, DOI 10.1128/MCB.26.9.3514-3526.2006; Indelicato M, 2010, J CELL PHYSIOL, V223, P359, DOI 10.1002/jcp.22041; Jung JE, 2005, FASEB J, V19, P1296, DOI 10.1096/fj.04-3099fje; Jung JE, 2008, EXP MOL MED, V40, P479, DOI 10.3858/emm.2008.40.5.479; Kaelin WG, 2011, COLD SH Q B, V76, P335, DOI 10.1101/sqb.2011.76.010975; Kang SH, 2010, NEUROSURGERY, V67, P1386, DOI 10.1227/NEU.0b013e3181f1c0cd; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Kim HK, 1997, J BIOL CHEM, V272, P14571, DOI 10.1074/jbc.272.23.14571; Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002; Lee MY, 2006, BREAST, V15, P187, DOI 10.1016/j.breast.2005.05.005; Liu T, 2012, INT J BIOCHEM CELL B, V44, P1337, DOI 10.1016/j.biocel.2012.04.017; Lum JJ, 2007, GENE DEV, V21, P1037, DOI 10.1101/gad.1529107; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Niu GL, 2008, MOL CANCER RES, V6, P1099, DOI 10.1158/1541-7786.MCR-07-2177; Noman MZ, 2009, J IMMUNOL, V182, P3510, DOI 10.4049/jimmunol.0800854; Oh MK, 2011, J BIOL CHEM, V286, P8857, DOI 10.1074/jbc.M110.150557; Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Pawlus MR, 2012, MOL CELL BIOL, V32, P4595, DOI 10.1128/MCB.00724-12; Pham NA, 2009, INT J CANCER, V124, P280, DOI 10.1002/ijc.23912; Piperi C, 2011, CYTOKINE, V55, P387, DOI 10.1016/j.cyto.2011.05.012; Rathinavelu A, 2012, J CELL MOL MED, V16, P1750, DOI 10.1111/j.1582-4934.2011.01472.x; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Ruas JL, 2010, J BIOL CHEM, V285, P2601, DOI 10.1074/jbc.M109.021824; Santra M, 2008, J NEUROCHEM, V105, P324, DOI 10.1111/j.1471-4159.2007.05134.x; Schuringa JJ, 2001, FEBS LETT, V495, P71, DOI 10.1016/S0014-5793(01)02354-7; Selvendiran K, 2009, INT J CANCER, V125, P2198, DOI 10.1002/ijc.24601; Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021; Squarize CH, 2006, NEOPLASIA, V8, P733, DOI 10.1593/neo.06274; Wang HB, 2012, AM J PATHOL, V180, P1243, DOI 10.1016/j.ajpath.2011.11.031; Warnecke C, 2004, FASEB J, V18, P1462, DOI 10.1096/fj.04-1640fje; Wei DY, 2003, ONCOGENE, V22, P319, DOI 10.1038/sj.onc.1206122; WENGER RH, 1995, J BIOL CHEM, V270, P27865, DOI 10.1074/jbc.270.46.27865; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Yuan ZL, 2005, SCIENCE, V307, P269, DOI 10.1126/science.1105166; Zia MK, 2007, INT J MOL MED, V20, P605	62	141	145	2	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2014	33	13					1670	1679		10.1038/onc.2013.115	http://dx.doi.org/10.1038/onc.2013.115			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9QY	23604114	Green Accepted			2022-12-28	WOS:000334344700007
J	Lee, JY; Park, MK; Park, JH; Lee, HJ; Shin, DH; Kang, Y; Lee, CH; Kong, G				Lee, J-Y; Park, M. K.; Park, J-H; Lee, H. J.; Shin, D. H.; Kang, Y.; Lee, C. H.; Kong, G.			Loss of the polycomb protein Mel-18 enhances the epithelial-mesenchymal transition by ZEB1 and ZEB2 expression through the downregulation of miR-205 in breast cancer	ONCOGENE			English	Article						Mel-18; miR-205; ZEB1; ZEB2; epithelial-mesenchymal transition; polycomb	GROWTH-FACTOR-BETA; TUMOR INVASION; MICRORNAS; BMI-1; CELLS; OVEREXPRESSION; REPRESSION; FAMILY	The epithelial-mesenchymal transition (EMT) is the pivotal mechanism underlying the initiation of cancer invasion and metastasis. Although Mel-18 has been implicated in several biological processes in cancer, its function in the EMT of human cancers has not yet been studied. Here, we demonstrate that Mel-18 negatively regulates the EMT by epigenetically modulating miR-205. We identified miR-205 as a novel target of Mel-18 using a microRNA microarray analysis and found that Mel-18 increased miR-205 transcription by the inhibition of DNA methyltransferase-mediated DNA methylation of the miR-205 promoter, thereby downregulating its target genes, ZEB1 and ZEB2. Furthermore, the loss of Mel-18 promoted ZEB1- and ZEB2-mediated downregulation of E-cadherin transcription and also enhanced the expression of mesenchymal markers, leading to increased migration and invasion in MCF-7 cells. In MDA-MB-231 cells, Mel-18 overexpression restored E-cadherin expression, resulting in reduced migration and invasion. These effects were reversed by miR-205 overexpression or inhibition. A tumor xenograft with Mel-18 knockdown MCF-7 cells consistently showed increased ZEB1 and ZEB2 expression and decreased E-cadherin expression. Taken together, these results suggest that Mel-18 functions as a tumor suppressor by its novel negative control of the EMT, achieved through regulating the expression of miR-205 and its target genes, ZEB1 and ZEB2.	[Lee, J-Y; Kong, G.] Hanyang Univ, IBBR, Seoul 133791, South Korea; [Park, M. K.; Lee, H. J.; Lee, C. H.] Dongguk Univ Seoul, Coll Pharm, Seoul 410820, South Korea; [Park, J-H; Shin, D. H.; Kong, G.] Hanyang Univ, Coll Med, Dept Pathol, Seoul 133791, South Korea; [Kang, Y.] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Hanyang University; Dongguk University; Hanyang University; Princeton University	Lee, CH (corresponding author), Dongguk Univ Seoul, Coll Pharm, Seoul 410820, South Korea.	uatheone@gmail.com; gkong@hanyang.ac.kr		Kang, Yibin/0000-0002-1626-6730	Korea Healthcare Technology RD Project [A101836]; Ministry of Health Welfare and Family Affairs; Research Program for New Drug Target Discovery [2011-0030173]	Korea Healthcare Technology RD Project; Ministry of Health Welfare and Family Affairs(Ministry of Health & Welfare (MOHW), Republic of Korea); Research Program for New Drug Target Discovery(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This study was supported by grants from the Korea Healthcare Technology R&D Project (A101836), the Ministry of Health Welfare and Family Affairs and the Research Program for New Drug Target Discovery (2011-0030173).	Alkema MJ, 1997, GENE DEV, V11, P226, DOI 10.1101/gad.11.2.226; AuS Leung-Kuen, 2012, HEPATOLOGY, V56, P622; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Blumenberg M, 2007, CELLS TISSUES ORGANS, V185, P162, DOI 10.1159/000101317; Cao Q, 2011, CANCER CELL, V20, P187, DOI 10.1016/j.ccr.2011.06.016; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Guo WJ, 2007, CANCER RES, V67, P5083, DOI 10.1158/0008-5472.CAN-06-4368; Guo WJ, 2007, MOL BIOL CELL, V18, P536, DOI 10.1091/mbc.E06-05-0447; Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Iorio MV, 2010, BBA-GENE REGUL MECH, V1799, P694, DOI 10.1016/j.bbagrm.2010.05.005; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kashyap V, 2009, STEM CELLS DEV, V18, P1093, DOI 10.1089/scd.2009.0113; Ke XS, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-669; Kim JH, 2004, BREAST, V13, P383, DOI 10.1016/j.breast.2004.02.010; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Lee JY, 2008, CANCER RES, V68, P4201, DOI 10.1158/0008-5472.CAN-07-2570; Liu YN, 2012, MOL CELL BIOL, V32, P941, DOI 10.1128/MCB.06306-11; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Mak P, 2010, CANCER CELL, V17, P319, DOI 10.1016/j.ccr.2010.02.030; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; McDonald OG, 2011, NAT STRUCT MOL BIOL, V18, P867, DOI 10.1038/nsmb.2084; Mohammad HP, 2009, CANCER RES, V69, P6322, DOI 10.1158/0008-5472.CAN-09-0065; Negishi M, 2007, BIOCHEM BIOPH RES CO, V353, P992, DOI 10.1016/j.bbrc.2006.12.166; Park JH, 2011, ONCOGENE, V30, P4578, DOI 10.1038/onc.2011.174; Qian T, 2010, ONCOGENE, V29, P5818, DOI 10.1038/onc.2010.317; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Rush Margaret, 2009, Epigenetics, V4, P404; Sato F, 2011, FEBS J, V278, P1598, DOI 10.1111/j.1742-4658.2011.08089.x; Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001; Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029; Sempere LF, 2007, CANCER RES, V67, P11612, DOI 10.1158/0008-5472.CAN-07-5019; Shin DH, 2011, J CELL PHYSIOL, V226, P1340, DOI 10.1002/jcp.22462; Song LB, 2009, J CLIN INVEST, V119, P3626, DOI 10.1172/JCI39374; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Tellez CS, 2011, CANCER RES, V71, P3087, DOI 10.1158/0008-5472.CAN-10-3035; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Wanami LS, 2008, EXP CELL RES, V314, P2448, DOI 10.1016/j.yexcr.2008.05.004; Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461; Yamagishi M, 2012, CANCER CELL, V21, P121, DOI 10.1016/j.ccr.2011.12.015; Yang AD, 2006, CANCER RES, V66, P46, DOI 10.1158/0008-5472.CAN-05-3086; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099	44	92	94	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2014	33	10					1325	1335		10.1038/onc.2013.53	http://dx.doi.org/10.1038/onc.2013.53			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AC6KI	23474752				2022-12-28	WOS:000332631100013
J	Binsky-Ehrenreich, I; Marom, A; Sobotta, MC; Shvidel, L; Berrebi, A; Hazan-Halevy, I; Kay, S; Aloshin, A; Sagi, I; Goldenberg, DM; Leng, L; Bucala, R; Herishanu, Y; Haran, M; Shachar, I				Binsky-Ehrenreich, I.; Marom, A.; Sobotta, M. C.; Shvidel, L.; Berrebi, A.; Hazan-Halevy, I.; Kay, S.; Aloshin, A.; Sagi, I.; Goldenberg, D. M.; Leng, L.; Bucala, R.; Herishanu, Y.; Haran, M.; Shachar, I.			CD84 is a survival receptor for CLL cells	ONCOGENE			English	Article						CD84; CD74; MIF; survival; apoptosis	CHRONIC LYMPHOCYTIC-LEUKEMIA; MIGRATION-INHIBITORY FACTOR; INVARIANT CHAIN; SLAM FAMILY; FACTOR MIF; TUMOR-GROWTH; B-CELLS; EXPRESSION; CANCER; SAP	Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of CD5+ B lymphocytes in peripheral blood, lymphoid organs and bone marrow. The main feature of the disease is accumulation of the malignant cells due to decreased apoptosis. CD84 belongs to the signaling lymphocyte activating molecule family of immunoreceptors, and has an unknown function in CLL cells. Here, we show that the expression of CD84 is significantly elevated from the early stages of the disease, and is regulated by macrophage migration inhibitory factor and its receptor, CD74. Activation of cell surface CD84 initiates a signaling cascade that enhances CLL cell survival. Both downmodulation of CD84 expression and its immune-mediated blockade induce cell death in vitro and in vivo. In addition, analysis of samples derived from an on-going clinical trial, in which human subjects were treated with humanized anti-CD74 (milatuzumab), shows a decrease in CD84 messenger RNA and protein levels in milatuzumab-treated cells. This downregulation was correlated with reduction of Bcl-2 and Mcl-1 expression. Thus, our data show that overexpression of CD84 in CLL is an important survival mechanism that appears to be an early event in the pathogenesis of the disease. These findings suggest novel therapeutic strategies based on the blockade of this CD84-dependent survival pathway.	[Binsky-Ehrenreich, I.; Marom, A.; Sobotta, M. C.; Shachar, I.] Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel; [Shvidel, L.; Berrebi, A.; Haran, M.] Kaplan Med Ctr, Hematol Inst, Rehovot, Israel; [Hazan-Halevy, I.; Kay, S.; Herishanu, Y.] Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, Dept Hematol, IL-69978 Tel Aviv, Israel; [Aloshin, A.; Sagi, I.] Weizmann Inst Sci, IL-76100 Rehovot, Israel; [Goldenberg, D. M.] Ctr Mol Med & Immunol, Garden State Canc Ctr, Morris Plains, NJ USA; [Leng, L.; Bucala, R.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA	Weizmann Institute of Science; Hebrew University of Jerusalem; Kaplan Medical Center; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center; Weizmann Institute of Science; Yale University	Shachar, I (corresponding author), Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel.	idit.shachar@weizmann.ac.il		Leng, Lin/0000-0002-0605-358X	Israel Science Foundation; Israel Cancer Association; Gurwin Foundation; Israel Cancer Research Foundation (ICRF); NIH; Alliance for Lupus Research; USPHS from the National Cancer Institute, NIH [PO1-CA103985]; United Israel Appeal of Canada; NATIONAL CANCER INSTITUTE [P01CA103985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR050498] Funding Source: NIH RePORTER	Israel Science Foundation(Israel Science Foundation); Israel Cancer Association; Gurwin Foundation; Israel Cancer Research Foundation (ICRF); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Alliance for Lupus Research; USPHS from the National Cancer Institute, NIH; United Israel Appeal of Canada; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	The authors gratefully acknowledge members of the Shachar laboratory team for helpful discussions. This research was supported by the Israel Science Foundation, the Israel Cancer Association, The Gurwin Foundation, Israel Cancer Research Foundation (ICRF), the NIH and the Alliance for Lupus Research (RB, LL), and in part by USPHS grant PO1-CA103985 from the National Cancer Institute, NIH (DMG), and by the United Israel Appeal of Canada. I Shachar is the incumbent of the Dr Morton and Ann Kleiman Professorial Chair.	Bando H, 2002, JPN J CANCER RES, V93, P389, DOI 10.1111/j.1349-7006.2002.tb01269.x; BERNHAGEN J, 1994, BIOCHEMISTRY-US, V33, P14144, DOI 10.1021/bi00251a025; Bifulco C, 2008, CURR PHARM DESIGN, V14, P3790, DOI 10.2174/138161208786898608; Binsky I, 2007, P NATL ACAD SCI USA, V104, P13408, DOI 10.1073/pnas.0701553104; Binsky I, 2010, J IMMUNOL, V184, P4761, DOI 10.4049/jimmunol.0904149; Caligaris-Cappio F, 1999, J CLIN ONCOL, V17, P399, DOI 10.1200/JCO.1999.17.1.399; Calpe S, 2006, IMMUNOGENETICS, V58, P15, DOI 10.1007/s00251-005-0056-3; Cannons JL, 2010, IMMUNITY, V32, P253, DOI 10.1016/j.immuni.2010.01.010; Chesney J, 1999, MOL MED, V5, P181, DOI 10.1007/BF03402061; Cheson BD, 1996, BLOOD, V87, P4990, DOI 10.1182/blood.V87.12.4990.bloodjournal87124990; COCKS BG, 1995, NATURE, V376, P260, DOI 10.1038/376260a0; Cohen S, 2012, J IMMUNOL, V188, P259, DOI 10.4049/jimmunol.1101468; Datta MW, 2000, APPL IMMUNOHISTO M M, V8, P210, DOI 10.1097/00022744-200009000-00007; delaFuente MA, 1997, BLOOD, V90, P2398; Dios A, 2002, J MED CHEM, V45, P2410, DOI 10.1021/jm010534q; Durig J, 2007, CANCER RES, V67, P8653, DOI 10.1158/0008-5472.CAN-07-1198; Engel P, 2003, NAT REV IMMUNOL, V3, P813, DOI 10.1038/nri1202; Flaishon L, 2004, BLOOD, V104, P933, DOI 10.1182/blood-2003-11-4013; Goldman JP, 1998, BRIT J HAEMATOL, V103, P335, DOI 10.1046/j.1365-2141.1998.00980.x; Gordin M, 2010, J IMMUNOL, V185, P2020, DOI 10.4049/jimmunol.0902566; Gore Y, 2008, J BIOL CHEM, V283, P2784, DOI 10.1074/jbc.M703265200; Hallek M, 2008, BLOOD, V111, P5446, DOI 10.1182/blood-2007-06-093906; Haran M, 2004, LEUKEMIA, V18, P1948, DOI 10.1038/sj.leu.2403512; Hartmann TN, 2009, CANCER RES, V69, P3121, DOI 10.1158/0008-5472.CAN-08-4136; HO MK, 1984, METHOD ENZYMOL, V108, P313; Howie D, 2002, BLOOD, V99, P957, DOI 10.1182/blood.V99.3.957; Inabe K, 2002, BLOOD, V99, P584, DOI 10.1182/blood.V99.2.584; Ioachim HL, 1996, AM J SURG PATHOL, V20, P64, DOI 10.1097/00000478-199601000-00007; Ishigami S, 2001, CANCER LETT, V168, P87, DOI 10.1016/S0304-3835(01)00503-1; Kay S, 2006, CYTOM PART B-CLIN CY, V70B, P218, DOI 10.1002/cyto.b.20078; Latour S, 2004, SEMIN IMMUNOL, V16, P409, DOI 10.1016/j.smim.2004.08.020; Lazova R, 1997, CANCER-AM CANCER SOC, V79, P2115, DOI 10.1002/(SICI)1097-0142(19970601)79:11<2115::AID-CNCR8>3.0.CO;2-N; Leng L, 2003, J EXP MED, V197, P1467, DOI 10.1084/jem.20030286; Luger D, 2004, J CLIN IMMUNOL, V24, P579, DOI 10.1007/s10875-004-6245-2; Martin M, 2001, J IMMUNOL, V167, P3668, DOI 10.4049/jimmunol.167.7.3668; Matza D, 2003, TRENDS IMMUNOL, V24, P264, DOI 10.1016/S1471-4906(03)00073-5; Matza D, 2002, IMMUNITY, V17, P549, DOI 10.1016/S1074-7613(02)00455-7; Matza D, 2002, P NATL ACAD SCI USA, V99, P3018, DOI 10.1073/pnas.052703299; Matza D, 2001, J BIOL CHEM, V276, P27203, DOI 10.1074/jbc.M104684200; Meyer-Siegler KL, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-34; MeyerSiegler K, 1996, UROLOGY, V48, P448, DOI 10.1016/S0090-4295(96)00207-5; Mizue Y, 2000, INT J MOL MED, V5, P397; Morra M, 2001, EMBO J, V20, P5840, DOI 10.1093/emboj/20.21.5840; Nagy N, 2000, INT J CANCER, V88, P439, DOI 10.1002/1097-0215(20001101)88:3<439::AID-IJC17>3.0.CO;2-#; Nanda N, 2005, BLOOD, V106, P3028, DOI 10.1182/blood-2005-01-0333; NARNI F, 1986, BLOOD, V68, P372; Nichols KE, 2005, IMMUNOL REV, V203, P180, DOI 10.1111/j.0105-2896.2005.00230.x; Nishihira J, 2003, ANN NY ACAD SCI, V995, P171, DOI 10.1111/j.1749-6632.2003.tb03220.x; Oliver-Vila I, 2008, MOL IMMUNOL, V45, P2138, DOI 10.1016/j.molimm.2007.12.006; Palou E, 2000, TISSUE ANTIGENS, V55, P118, DOI 10.1034/j.1399-0039.2000.550203.x; Romero X, 2005, J IMMUNOL, V174, P7033, DOI 10.4049/jimmunol.174.11.7033; Shachar I, 1996, SCIENCE, V274, P106, DOI 10.1126/science.274.5284.106; Starlets D, 2006, BLOOD, V107, P4807, DOI 10.1182/blood-2005-11-4334; Stein R, 2004, BLOOD, V104, P3705, DOI 10.1182/blood-2004-03-0890; Stein R, 2007, CLIN CANCER RES, V13, p5556S, DOI 10.1158/1078-0432.CCR-07-1167; Stumptner-Cuvelette P, 2002, BBA-MOL CELL RES, V1542, P1, DOI 10.1016/S0167-4889(01)00166-5; Tangye SG, 2002, EUR J IMMUNOL, V32, P1640, DOI 10.1002/1521-4141(200206)32:6<1640::AID-IMMU1640>3.0.CO;2-S; Veenstra H, 1996, CELL IMMUNOL, V171, P68, DOI 10.1006/cimm.1996.0174; Veillette A, 2006, NAT REV IMMUNOL, V6, P56, DOI 10.1038/nri1761; Veillette A, 2003, CURR OPIN IMMUNOL, V15, P277, DOI 10.1016/S0952-7915(03)00041-4; Yan QR, 2007, P NATL ACAD SCI USA, V104, P10583, DOI 10.1073/pnas.0703893104; Young AN, 2001, AM J PATHOL, V158, P1639, DOI 10.1016/S0002-9440(10)64120-X	62	25	26	2	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2014	33	8					1006	1016		10.1038/onc.2013.31	http://dx.doi.org/10.1038/onc.2013.31			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XO	23435417	Green Accepted			2022-12-28	WOS:000331933200008
J	Stebbing, J; Lit, LC; Zhang, H; Darrington, RS; Melaiu, O; Rudraraju, B; Giamas, G				Stebbing, J.; Lit, L. C.; Zhang, H.; Darrington, R. S.; Melaiu, O.; Rudraraju, B.; Giamas, G.			The regulatory roles of phosphatases in cancer	ONCOGENE			English	Review						cancer; phosphatases; solid tumours	PROTEIN-TYROSINE-PHOSPHATASE; TUMOR-SUPPRESSOR GENE; RENAL-CELL CARCINOMA; HUMAN BREAST-CANCER; NF-KAPPA-B; DOXORUBICIN-INDUCED APOPTOSIS; ADENOVIRUS-MEDIATED TRANSFER; FAS-ASSOCIATED PHOSPHATASE-1; HUMAN PROSTATE-CANCER; OVARIAN-CANCER	The relevance of potentially reversible post-translational modifications required for controlling cellular processes in cancer is one of the most thriving arenas of cellular and molecular biology. Any alteration in the balanced equilibrium between kinases and phosphatases may result in development and progression of various diseases, including different types of cancer, though phosphatases are relatively under-studied. Loss of phosphatases such as PTEN (phosphatase and tensin homologue deleted on chromosome 10), a known tumour suppressor, across tumour types lends credence to the development of phosphatidylinositol 3-kinase inhibitors alongside the use of phosphatase expression as a biomarker, though phase 3 trial data are lacking. In this review, we give an updated report on phosphatase dysregulation linked to organ-specific malignancies.	[Stebbing, J.; Lit, L. C.; Zhang, H.; Darrington, R. S.; Melaiu, O.; Rudraraju, B.; Giamas, G.] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Div Canc, London W12 0NN, England	Imperial College London	Giamas, G (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Div Canc, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.	g.giamas@imperial.ac.uk	Zhang, Hua/AAV-2344-2020; Melaiu, Ombretta/Z-3461-2019; Giamas, Georgios/AAP-3487-2021; LIT, LEI CHENG/B-8875-2010; Lit, Lei Cheng/AAS-9778-2021	Zhang, Hua/0000-0001-7704-4712; Melaiu, Ombretta/0000-0001-7118-5186; LIT, LEI CHENG/0000-0002-3210-4491; Lit, Lei Cheng/0000-0002-3210-4491; Giamas, Georgios/0000-0002-4417-2707; Stebbing, Justin/0000-0002-1117-6947	National Institutes of Health Research; Imperial Biomedical Research Centre; Experimental Cancer Medicine Centre; Breast Cancer Campaign; Cancer Research UK; Action Against Cancer; Cancer Research UK [14549] Funding Source: researchfish; National Institute for Health Research [NIHR-RP-011-053] Funding Source: researchfish	National Institutes of Health Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Imperial Biomedical Research Centre; Experimental Cancer Medicine Centre; Breast Cancer Campaign; Cancer Research UK(Cancer Research UK); Action Against Cancer; Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR))	We thank Aleksandra Filipovic for helping in editing the manuscript. JS and GG are supported by grants from the National Institutes of Health Research, Imperial Biomedical Research Centre and Experimental Cancer Medicine Centre, Breast Cancer Campaign, Cancer Research UK and Action Against Cancer.	Abaan OD, 2005, ONCOGENE, V24, P2715, DOI 10.1038/sj.onc.1208247; Albert H, 2012, MOL ONCOL, V6, P542, DOI 10.1016/j.molonc.2012.06.003; Albert H, 2011, CLIN CHEM LAB MED, V49, P1707, DOI 10.1515/CCLM.2011.635; Ali AY, 2012, ONCOGENE, V31, P2175, DOI 10.1038/onc.2011.399; Allard JE, 2012, FRONT ONCOL, V2, P1, DOI 10.3389/fonc.2012.00065; Amant F, 2002, GYNECOL ONCOL, V85, P165, DOI 10.1006/gyno.2002.6601; Anbalagan M, 2012, BREAST CANCER RES TR, V132, P391, DOI 10.1007/s10549-011-1513-3; Antonello D, 2002, CANCER LETT, V183, P179, DOI 10.1016/S0304-3835(01)00802-3; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bakken T, 2010, VIROLOGY, V397, P379, DOI 10.1016/j.virol.2009.11.030; Balavenkatraman KK, 2006, ONCOGENE, V25, P6319, DOI 10.1038/sj.onc.1209647; Balavenkatraman KK, 2011, MOL CANCER RES, V9, P1377, DOI 10.1158/1541-7786.MCR-11-0198; Balko JM, 2012, NAT MED, V18, P1052, DOI 10.1038/nm.2795; Bang YJ, 1998, BIOCHEM BIOPH RES CO, V250, P43, DOI 10.1006/bbrc.1998.9256; Bansal N, 2012, J GYNECOL ONCOL, V23, P35, DOI 10.3802/jgo.2012.23.1.35; Bayascas JR, 2005, CURR BIOL, V15, P1839, DOI 10.1016/j.cub.2005.08.066; Bell HS, 2008, CANCER RES, V68, P4959, DOI 10.1158/0008-5472.CAN-08-0182; Bentires-Alj M, 2007, CANCER RES, V67, P2420, DOI 10.1158/0008-5472.CAN-06-4610; Bhardwaj A, 2011, MOL CANCER THER, V10, P720, DOI 10.1158/1535-7163.MCT-10-1096; Bockelman C, 2011, BRIT J CANCER, V105, P989, DOI 10.1038/bjc.2011.346; Boldrini L, 2007, HUM PATHOL, V38, P1563, DOI 10.1016/j.humpath.2007.03.006; Bompard G, 2002, J BIOL CHEM, V277, P47861, DOI 10.1074/jbc.M208950200; Bonin S, 2006, VIRCHOWS ARCH, V448, P539, DOI 10.1007/s00428-005-0146-5; Boutros R, 2007, NAT REV CANCER, V7, P495, DOI 10.1038/nrc2169; Boyault S, 2012, BREAST CANCER RES TR, V132, P29, DOI 10.1007/s10549-011-1518-y; Brems-Eskildsen AS, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-646; Broggini M, 2000, ANTICANCER RES, V20, P4835; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Cairns P, 1997, CANCER RES, V57, P4997; Cangi MG, 2000, J CLIN INVEST, V106, P753, DOI 10.1172/JCI9174; Cao X, 2012, ANN THORAC SURG, V93, P1674, DOI 10.1016/j.athoracsur.2011.12.056; Carlucci A, 2010, J BIOL CHEM, V285, P39260, DOI 10.1074/jbc.M110.174706; Castro ME, 2008, CARCINOGENESIS, V29, P491, DOI 10.1093/carcin/bgm246; Cejudo-Marin R, 2012, J MOL BIOL, V420, P128, DOI 10.1016/j.jmb.2012.04.004; Chan G, 2008, CANCER METAST REV, V27, P179, DOI 10.1007/s10555-008-9126-y; Chen SY, 2009, J BIOL CHEM, V284, P25576, DOI 10.1074/jbc.M109.043133; Chen Y, 2011, BREAST CANCER RES TR, V128, P69, DOI 10.1007/s10549-010-1024-7; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Cheng Y, 2011, CANCER GENET-NY, V204, P375, DOI 10.1016/j.cancergen.2011.05.002; Chiappinelli KB, 2010, GYNECOL ONCOL, V119, P146, DOI 10.1016/j.ygyno.2010.06.015; Chiarugi P, 2004, ONCOGENE, V23, P3905, DOI 10.1038/sj.onc.1207508; Chitale D, 2009, ONCOGENE, V28, P2773, DOI 10.1038/onc.2009.135; Chiu YT, 2009, J MOL BIOL, V385, P446, DOI 10.1016/j.jmb.2008.10.070; Chow JYC, 2008, AM J PHYSIOL-GASTR L, V294, pG899, DOI 10.1152/ajpgi.00411.2007; Chow JYC, 2010, AM J PHYSIOL-GASTR L, V298, pG275, DOI 10.1152/ajpgi.00344.2009; Chow LML, 2006, CANCER LETT, V241, P184, DOI 10.1016/j.canlet.2005.11.042; Chuang YC, 1997, J UROLOGY, V158, P1684, DOI 10.1016/S0022-5347(01)64095-3; Cohen PTW, 2002, J CELL SCI, V115, P241; Corcoran NM, 2010, BRIT J CANCER, V103, P462, DOI 10.1038/sj.bjc.6605798; Corcoran NM, 2004, J UROLOGY, V171, P907, DOI 10.1097/01.ju.0000092859.16817.8e; Corvinus FM, 2005, NEOPLASIA, V7, P545, DOI 10.1593/neo.04571; Da N, 2009, WORLD J GASTROENTERO, V15, P1499, DOI 10.3748/wjg.15.1499; Dellinger TH, 2009, EXPERT REV ANTICANC, V9, P905, DOI [10.1586/era.09.54, 10.1586/ERA.09.54]; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dong J, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-81; Dromard M, 2007, CANCER RES, V67, P6806, DOI 10.1158/0008-5472.CAN-07-0513; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Cariaga-Martinez AE, 2009, ADV UROL, V2009, DOI 10.1155/2009/723831; Farabaugh SM, 2012, ONCOGENE, V31, P552, DOI 10.1038/onc.2011.259; Farrow B, 2003, BIOCHEM BIOPH RES CO, V301, P50, DOI 10.1016/S0006-291X(02)02983-2; Feng XH, 2005, ANNU REV CELL DEV BI, V21, P659, DOI 10.1146/annurev.cellbio.21.022404.142018; Feng XL, 2011, MOL CELL BIOL, V31, P3457, DOI 10.1128/MCB.05523-11; Fernandez-Marcos PJ, 2009, P NATL ACAD SCI USA, V106, P12962, DOI 10.1073/pnas.0813055106; Fujimoto T, 2009, GYNECOL ONCOL, V112, P342, DOI 10.1016/j.ygyno.2008.10.019; Funato K, 2011, EXP THER MED, V2, P457, DOI 10.3892/etm.2011.231; Furukawa T, 2005, MODERN PATHOL, V18, P1034, DOI 10.1038/modpathol.3800383; Furukawa T, 1998, CYTOGENET CELL GENET, V82, P156, DOI 10.1159/000015091; Furukawa T, 2003, AM J PATHOL, V162, P1807, DOI 10.1016/S0002-9440(10)64315-5; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Glondu-Lassis M, 2010, CANCER RES, V70, P5116, DOI 10.1158/0008-5472.CAN-09-4368; Gloria-Bottini F, 2012, AM J MED SCI, V344, P32, DOI 10.1097/MAJ.0b013e31823e5cfa; Gonzalez-Angulo AM, 2011, MOL CANCER THER, V10, P1093, DOI 10.1158/1535-7163.MCT-10-1089; Goswami A, 2005, MOL CELL, V20, P33, DOI 10.1016/j.molcel.2005.08.016; Grossmann Allie H., 2012, Sarcoma, V2012, P380896, DOI 10.1155/2012/380896; GU MX, 1991, P NATL ACAD SCI USA, V88, P5867, DOI 10.1073/pnas.88.13.5867; Gu MX, 1996, P NATL ACAD SCI USA, V93, P12980, DOI 10.1073/pnas.93.23.12980; Guo K, 2008, CANCER BIOL THER, V7, P750, DOI 10.4161/cbt.7.5.5764; Hager M, 2007, PATHOLOGY, V39, P482, DOI 10.1080/00313020701570012; Hager M, 2011, CANCER INVEST, V29, P427, DOI 10.3109/07357907.2011.584782; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Harima Y, 2009, INT J RADIAT ONCOL, V75, P1232, DOI 10.1016/j.ijrobp.2009.07.002; Hatakeyama M, 2009, J GASTROENTEROL, V44, P239, DOI 10.1007/s00535-009-0014-1; He KX, 2010, J GENET GENOMICS, V37, P249, DOI 10.1016/S1673-8527(09)60043-6; Henkens R, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-147; Hou GQ, 2011, DIGEST DIS SCI, V56, P1315, DOI 10.1007/s10620-010-1474-0; Hou SW, 2010, CANCER RES, V70, P2901, DOI 10.1158/0008-5472.CAN-09-3229; Hsieh SM, 2007, ADV EXP MED BIOL, V599, P31; Huang CC, 2008, ONCOGENE, V27, P2422, DOI 10.1038/sj.onc.1210888; Imai A, 2006, J Obstet Gynaecol, V26, P37; Ito Yasuhiro, 2004, Breast Cancer, V11, P295, DOI 10.1007/BF02984552; Janssens V, 2005, CURR OPIN GENET DEV, V15, P34, DOI 10.1016/j.gde.2004.12.004; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Jiang YJ, 2011, CANCER RES, V71, P234, DOI 10.1158/0008-5472.CAN-10-1487; Julien SG, 2007, NAT GENET, V39, P338, DOI 10.1038/ng1963; Karagoz ID, 2010, TUMOR BIOL, V31, P597, DOI 10.1007/s13277-010-0075-z; Kawaguchi K, 2005, HUM PATHOL, V36, P357, DOI 10.1016/j.humpath.2005.01.017; Kim JS, 2010, DIGEST DIS SCI, V55, P1565, DOI 10.1007/s10620-009-0924-z; Kobayashi I, 2012, LIFE SCI, V90, P212, DOI 10.1016/j.lfs.2011.11.006; Kong WH, 2009, CANCER BIOL THER, V8, P555, DOI 10.4161/cbt.8.6.7742; Korff S, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-329; Kray AE, 2005, J BIOL CHEM, V280, P35974, DOI 10.1074/jbc.M506093200; Krndija D, 2010, ONCOGENE, V29, P2724, DOI 10.1038/onc.2010.25; Krueger AB, 2013, J BIOMOL SCREEN, V18, P85, DOI 10.1177/1087057112453936; Ksiaa F, 2009, CLIN CHIM ACTA, V404, P128, DOI 10.1016/j.cca.2009.03.044; Kuroda N, 1998, VIRCHOWS ARCH, V433, P331, DOI 10.1007/s004280050257; Kurose K, 2001, AM J PATHOL, V158, P2097, DOI 10.1016/S0002-9440(10)64681-0; Kurose K, 2000, GENE CHROMOSOME CANC, V29, P166, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1025>3.3.CO;2-D; Kwon HY, 2008, ARCH PHARM RES, V31, P171, DOI 10.1007/s12272-001-1137-y; Lai MW, 2012, UROL ONCOL-SEMIN ORI, V30, P871, DOI 10.1016/j.urolonc.2010.09.010; Lassmann S, 2007, J MOL MED-JMM, V85, P289, DOI 10.1007/s00109-006-0126-5; Lavecchia A, 2010, EXPERT OPIN THER PAT, V20, P405, DOI 10.1517/13543771003623232; Lax SF, 1998, HUM PATHOL, V29, P924, DOI 10.1016/S0046-8177(98)90197-6; Lee JW, 2007, APMIS, V115, P47, DOI 10.1111/j.1600-0463.2007.apm_554.x; Lee JS, 2003, J SURG ONCOL, V84, P166, DOI 10.1002/jso.10302; Lee S, 2005, GYNECOL ONCOL, V97, P26, DOI 10.1016/j.ygyno.2004.11.051; Lessard L, 2010, BBA-PROTEINS PROTEOM, V1804, P613, DOI 10.1016/j.bbapap.2009.09.018; Li CK, 2008, LINEAR MULTILINEAR A, V56, P1, DOI 10.1080/03081080701538074; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003; Li PF, 2001, J BIOL CHEM, V276, P20444, DOI 10.1074/jbc.M010226200; Li W, 2011, EUR J CANCER, V47, P2654, DOI 10.1016/j.ejca.2011.08.014; Li W, 2011, CANCER LETT, V304, P117, DOI 10.1016/j.canlet.2011.02.009; Li XP, 2011, CANCER-AM CANCER SOC, V117, P4201, DOI 10.1002/cncr.26028; Li ZR, 2007, SURG TODAY, V37, P646, DOI 10.1007/s00595-006-3437-9; Lin HK, 2004, MOL ENDOCRINOL, V18, P2409, DOI 10.1210/me.2004-0117; Lin MS, 2011, ONCOL LETT, V2, P1219, DOI 10.3892/ol.2011.414; Lin Pei-Yin, 2007, Mol Cancer, V6, P16, DOI 10.1186/1476-4598-6-16; Lin Q, 2005, AM J PATHOL, V167, P969, DOI 10.1016/S0002-9440(10)61187-X; Lin X, 2006, CELL, V125, P915, DOI 10.1016/j.cell.2006.03.044; Liu JH, 2000, MOL CARCINOGEN, V29, P143, DOI 10.1002/1098-2744(200011)29:3<143::AID-MC3>3.0.CO;2-A; Liu J, 2011, GYNECOL ONCOL, V122, P430, DOI 10.1016/j.ygyno.2011.04.031; Liu T, 2010, ONCOL RES, V19, P125, DOI 10.3727/096504011X12935427587768; Loda M, 1996, AM J PATHOL, V149, P1553; Ma J, 2012, J HUM GENET, V57, P261, DOI 10.1038/jhg.2012.15; Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052; Malentacchi F, 2005, BIOCHEM BIOPH RES CO, V334, P875, DOI 10.1016/j.bbrc.2005.06.176; Manzano RG, 2002, ONCOGENE, V21, P4435, DOI 10.1038/sj.onc.1205542; Marsit CJ, 2005, HUM PATHOL, V36, P768, DOI 10.1016/j.humpath.2005.05.006; Martin-Granados C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040769; MATOZAKI T, 1994, J BIOL CHEM, V269, P2075; Matozaki T, 2009, CANCER SCI, V100, P1786, DOI 10.1111/j.1349-7006.2009.01257.x; Maurice D, 2001, J BIOL CHEM, V276, P43175, DOI 10.1074/jbc.M105895200; McConechy MK, 2011, J PATHOL, V223, P567, DOI 10.1002/path.2848; Mehdipour P, 2009, CELL BIOL INT, V33, P1050, DOI 10.1016/j.cellbi.2009.06.016; Meinhold-Heerlein I, 2001, AM J PATHOL, V158, P1335, DOI 10.1016/S0002-9440(10)64084-9; Meng F, 2013, J OBSTET GYNAECOL RE, V39, P272, DOI 10.1111/j.1447-0756.2012.01952.x; Miller TW, 2009, CANCER RES, V69, P4192, DOI 10.1158/0008-5472.CAN-09-0042; Minaguchi T, 1999, CANCER RES, V59, P6063; Miskad UA, 2007, VIRCHOWS ARCH, V450, P303, DOI 10.1007/s00428-006-0361-8; Miskad UA, 2004, PATHOBIOLOGY, V71, P176, DOI 10.1159/000078671; Miyazaki T, 2006, J GASTROEN HEPATOL, V21, P84, DOI 10.1111/j.1440-1746.2005.04155.x; Mizuno R, 2005, ONCOL REP, V14, P639; Mizuno R, 2004, J UROLOGY, V172, P723, DOI 10.1097/01.ju.0000124990.37563.00; MOK SC, 1995, GYNECOL ONCOL, V57, P299, DOI 10.1006/gyno.1995.1146; Mollevi DG, 2008, BRIT J CANCER, V99, P1718, DOI 10.1038/sj.bjc.6604747; Moncho-Amor V, 2011, ONCOGENE, V30, P668, DOI 10.1038/onc.2010.449; Montagut C, 2010, BRIT J CANCER, V102, P1137, DOI 10.1038/sj.bjc.6605612; Mori Y, 2004, CANCER RES, V64, P2434, DOI 10.1158/0008-5472.CAN-03-3508; Motiwala T, 2007, CLIN CANCER RES, V13, P3174, DOI 10.1158/1078-0432.CCR-06-1720; Mulholland DJ, 2006, ONCOGENE, V25, P329, DOI 10.1038/sj.onc.1209020; Muller P, 1999, CLIN CANCER RES, V5, P3569; Mundhenk J, 2011, ONCOL LETT, V2, P1089, DOI 10.3892/ol.2011.374; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; Ngan ESW, 2003, ONCOGENE, V22, P734, DOI 10.1038/sj.onc.1206121; Nishioka K, 2001, BRIT J CANCER, V85, P412, DOI 10.1054/bjoc.2001.1934; Nitsche C, 2012, GASTROENTEROLOGY, V142, P377, DOI 10.1053/j.gastro.2011.10.026; Nunes-Xavier CE, 2010, J BIOL CHEM, V285, P26417, DOI 10.1074/jbc.M110.121830; Okami K, 1998, CANCER RES, V58, P509; Olivero M, 2006, MOL CANCER THER, V5, P1126, DOI 10.1158/1535-7163.MCT-06-0013; Omerovic J, 2010, BIOCHEM J, V426, P65, DOI 10.1042/BJ20091413; Ooki A, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-122; Ozen M, 2005, CLIN CANCER RES, V11, P4701, DOI 10.1158/1078-0432.CCR-04-2551; Padma S, 2005, CANCER CELL INT, V5, DOI 10.1186/1475-2867-5-7; Pallen CJ, 2003, CURR TOP MED CHEM, V3, P821, DOI 10.2174/1568026033452320; Pandey RN, 2010, ONCOGENE, V29, P3715, DOI 10.1038/onc.2010.122; Peng LR, 2006, BIOCHEM BIOPH RES CO, V342, P179, DOI 10.1016/j.bbrc.2006.01.102; Pham NA, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-43; Philpott N, 2011, J VIROL, V85, P1140, DOI 10.1128/JVI.01362-10; Planas-Silva MD, 2006, BIOCHEM BIOPH RES CO, V341, P73, DOI 10.1016/j.bbrc.2005.12.164; Polato F, 2005, CLIN CANCER RES, V11, P6835, DOI 10.1158/1078-0432.CCR-04-2357; Prasad S, 2007, LIFE SCI, V81, P1323, DOI 10.1016/j.lfs.2007.07.033; Puzio-Kuter AM, 2009, GENE DEV, V23, P675, DOI 10.1101/gad.1772909; Rahmouni S, 2006, NAT CELL BIOL, V8, P524, DOI 10.1038/ncb1398; Rajarubendra N, 2010, UROLOGY, V76, P782, DOI 10.1016/j.urology.2009.12.050; Ren TT, 2009, PATHOL ONCOL RES, V15, P555, DOI 10.1007/s12253-009-9153-1; Revillion F, 2009, INT J CANCER, V124, P638, DOI 10.1002/ijc.23989; Rodriguez-Ubreva FJ, 2010, ONCOGENE, V29, P345, DOI 10.1038/onc.2009.329; Roy D, 2011, AM J PATHOL, V179, P2108, DOI 10.1016/j.ajpath.2011.06.017; Ruivenkamp C, 2003, ONCOGENE, V22, P3472, DOI 10.1038/sj.onc.1206246; Ruivenkamp CAL, 2002, NAT GENET, V31, P295, DOI 10.1038/ng903; Sadakata H, 2009, GENES CELLS, V14, P295, DOI 10.1111/j.1365-2443.2008.01270.x; Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817; Sangai T, 2012, CLIN CANCER RES, V18, P5816, DOI 10.1158/1078-0432.CCR-12-1141; Sansal I, 2004, J CLIN ONCOL, V22, P2954, DOI 10.1200/jco.2004.02.141; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Schild C, 2009, MOL CARCINOGEN, V48, P1149, DOI 10.1002/mc.20569; Schneider E, 2011, INT J ONCOL, V38, P823, DOI 10.3892/ijo.2010.893; Scrima M, 2012, AM J PATHOL, V180, P1202, DOI 10.1016/j.ajpath.2011.11.038; Seo Y, 1997, BIOCHEM BIOPH RES CO, V231, P705, DOI 10.1006/bbrc.1997.6139; Shamay M, 2012, J VIROL, V86, P5179, DOI 10.1128/JVI.00169-12; Shin CM, 2012, J PATHOL, V226, P654, DOI 10.1002/path.2990; Shor Audrey C, 2008, Cancer Control, V15, P47; Shorning BY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016209; Siligan C, 2005, ONCOGENE, V24, P2512, DOI 10.1038/sj.onc.1208455; Singh AP, 2008, CANCER LETT, V259, P28, DOI 10.1016/j.canlet.2007.09.018; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Small GW, 2007, CANCER RES, V67, P4459, DOI 10.1158/0008-5472.CAN-06-2644; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Su FQ, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3134; Su WP, 2007, BIOCHEM BIOPH RES CO, V356, P181, DOI 10.1016/j.bbrc.2007.02.099; Sugiyama M, 2005, ONCOL REP, V13, P813; Sun TT, 2011, CELL, V144, P703, DOI 10.1016/j.cell.2011.02.003; TABITI K, 1995, CANCER LETT, V93, P239, DOI 10.1016/0304-3835(95)03816-F; Takei Y, 2008, MOL CANCER THER, V7, P704, DOI 10.1158/1535-7163.MCT-06-0724; Tan DSP, 2009, CLIN CANCER RES, V15, P2269, DOI 10.1158/1078-0432.CCR-08-2403; Tang JP, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-128; Tanyi JL, 2003, CLIN CANCER RES, V9, P3534; Tascilar M, 2001, CLIN CANCER RES, V7, P4115; Tassidis H, 2012, TUMOR BIOL; Tassidis H, 2010, INT J CANCER, V126, P2296, DOI 10.1002/ijc.24917; Teng DHF, 1997, CANCER RES, V57, P5221; Trotman LC, 2003, PLOS BIOL, V1, P385, DOI 10.1371/journal.pbio.0000059; Valencia AM, 1997, FEBS LETT, V406, P42, DOI 10.1016/S0014-5793(97)00235-4; Veeriah S, 2009, P NATL ACAD SCI USA, V106, P9435, DOI 10.1073/pnas.0900571106; Vlietstra RJ, 1998, CANCER RES, V58, P2720; Wang Bin, 2004, Ai Zheng, V23, P885; Wang HH, 2007, CANCER RES, V67, P2922, DOI 10.1158/0008-5472.CAN-06-3598; Wang HY, 2003, CANCER LETT, V191, P229, DOI 10.1016/S0304-3835(02)00612-2; Wang JG, 2010, MAGNETIC FRINGE FIELDS AND INTERFERENCE IN HIGH INTENSITY ACCELERATORS, P1; Wang JG, 2012, MED ONCOL, V29, P948, DOI 10.1007/s12032-011-9911-2; Wang LF, 2007, WORLD J GASTROENTERO, V13, P5692, DOI 10.3748/wjg.v13.i43.5692; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wang WX, 1999, CLIN CANCER RES, V5, P119; Wang Y, 2012, ONCOGENE, V31, P2512, DOI 10.1038/onc.2011.435; Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096; Wang Z, 2009, ANN SURG ONCOL, V16, P208, DOI 10.1245/s10434-008-0214-6; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; WIENER JR, 1994, J NATL CANCER I, V86, P372, DOI 10.1093/jnci/86.5.372; Wong LL, 2010, EXP CELL RES, V316, P3387, DOI 10.1016/j.yexcr.2010.06.007; Wong LL, 2009, INT J ONCOL, V34, P1291, DOI 10.3892/ijo_00000256; Wu CW, 2006, CANCER LETT, V242, P95, DOI 10.1016/j.canlet.2005.10.046; Wu CW, 2006, ANTICANCER RES, V26, P1643; Wu Hui-juan, 2011, Zhonghua Zhong Liu Za Zhi, V33, P165; Wu HJ, 2008, CANCER LETT, V271, P205, DOI 10.1016/j.canlet.2008.06.018; Wu SD, 2009, J MED CHEM, V52, P6716, DOI 10.1021/jm901016k; Wu S, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-413; Xu YH, 2006, CELL, V127, P1239, DOI 10.1016/j.cell.2006.11.033; Yamazaki S, 2003, J INFECT DIS, V187, P334, DOI 10.1086/367807; Yang SH, 2005, CLIN CANCER RES, V11, P612; Yao H, 2004, BRIT J CANCER, V91, P1718, DOI 10.1038/sj.bjc.6602136; Yeh LS, 2007, INT J GYNECOL CANCER, V17, P868, DOI 10.1111/j.1525-1438.2007.00880.x; You YJ, 2012, CANCER LETT, V315, P138, DOI 10.1016/j.canlet.2011.08.032; Yu NW, 2010, UROLOGY, V76, DOI 10.1016/j.urology.2010.03.061; Yu XY, 2012, ASIAN PAC J CANCER P, V13, P931, DOI 10.7314/APJCP.2012.13.3.931; Yuan TC, 2010, J BIOL CHEM, V285, P14861, DOI 10.1074/jbc.M109.099879; Zapata PD, 2002, J CLIN ENDOCR METAB, V87, P915, DOI 10.1210/jc.87.2.915; Zeng L, 2003, J CELL BIOL, V160, P137, DOI 10.1083/jcb.200206049; Zeng QY, 2012, CANCER GENET-NY, V205, P442, DOI 10.1016/j.cancergen.2012.06.002; ZHAI YF, 1993, CANCER RES, V53, P2272; Zhang Qingxiu, 2012, Enzyme Res, V2012, P659649, DOI 10.1155/2012/659649; Zhang XD, 2007, P NATL ACAD SCI USA, V104, P4060, DOI 10.1073/pnas.0611665104; Zhao YQ, 2010, P NATL ACAD SCI USA, V107, P2592, DOI 10.1073/pnas.0914884107; Zheng X, 2008, INT J CANCER, V122, P1999, DOI 10.1002/ijc.23321; Zheng YH, 2011, MOL CELL BIOL, V31, P4258, DOI 10.1128/MCB.05547-11; Zhong H, 2000, CANCER RES, V60, P1541; Zhou YA, 2010, BIOSCI BIOTECH BIOCH, V74, P736, DOI 10.1271/bbb.90787; Zhu S, 2007, CANCER RES, V67, P10129, DOI 10.1158/0008-5472.CAN-06-4338	271	71	71	2	42	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2014	33	8					939	953		10.1038/onc.2013.80	http://dx.doi.org/10.1038/onc.2013.80			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XO	23503460	Green Submitted, Bronze			2022-12-28	WOS:000331933200001
J	Kambach, DM; Sodi, VL; Lelkes, PI; Azizkhan-Clifford, J; Reginato, MJ				Kambach, D. M.; Sodi, V. L.; Lelkes, P. I.; Azizkhan-Clifford, J.; Reginato, M. J.			ErbB2, FoxM1 and 14-3-3 zeta prime breast cancer cells for invasion in response to ionizing radiation	ONCOGENE			English	Article						ErbB2; FoxM1; 14-3-3 zeta; invasion; reactive oxygen species	MAMMARY EPITHELIAL-CELLS; GROWTH-FACTOR RECEPTOR; CARCINOMA IN-SITU; SIGNALING NETWORK; OXIDATIVE STRESS; FREE-RADICALS; PROGRESSION; SRC; TRANSCRIPTION; RESISTANCE	ErbB2 is frequently highly expressed in premalignant breast cancers, including ductal carcinoma in situ (DCIS); however, little is known about the signals or pathways it contributes to progression into the invasive/malignant state. Radiotherapy is often used to treat early premalignant lesions regardless of ErbB2 status. Here, we show that clinically relevant doses of ionizing radiation (IR)-induce cellular invasion of ErbB2-expressing breast cancer cells, as well as MCF10A cells overexpressing ErbB2. ErbB2-negative breast cancer cells, such as MCF7 and T47D, do not invade following treatment with IR nor do MCF10A cells overexpressing epidermal growth factor receptor. ErbB2 becomes phosphorylated at tyrosine 877 in a dose- and time- dependent manner following exposure to X-rays, and activates downstream signaling cascades including PI3K/Akt. Inhibition of these pathways, as well as inhibition of reactive oxygen species (ROS) with antioxidants, prevents IR-induced invasion. Activation of ErbB2-dependent signaling results in upregulation of the forkhead family transcription factor, FoxM1, and its transcriptional targets, including matrix metalloproteinase 2 (MMP2). Inhibition of FoxM1 by RNA interference prevented induction of invasion by IR, and overexpression of FoxM1 in MCF10A cells was sufficient to promote IR-induced invasion. Moreover, we found that 14-3-3 zeta is also upregulated by IR in cancer cells in a ROS-dependent manner, is required for IR-induced invasion in ErbB2-positive breast cancer cells and together with FoxM1 is sufficient for invasion in ErbB2-negative breast cancer cells. Thus, our data show that IR-mediated activation of ErbB2 and induction of 14-3-3 zeta collaborate to regulate FoxM1 and promote invasion of breast cancer cells and furthermore, may serve as therapeutic targets to enhance radiosensitivity of breast cancers.	[Kambach, D. M.; Sodi, V. L.; Azizkhan-Clifford, J.; Reginato, M. J.] Drexel Univ, Coll Med, Dept Biochem & Mol Biol, Philadelphia, PA 19102 USA; [Lelkes, P. I.] Drexel Univ, Sch Biomed Engn, Philadelphia, PA 19102 USA	Drexel University; Drexel University	Azizkhan-Clifford, J (corresponding author), Drexel Univ, Coll Med, Dept Biochem & Mol Biol, 245 N 15th St,NCB Rm 11117, Philadelphia, PA 19102 USA.	jane.clifford@drexelmed.edu; Mauricio.Reginato@drexelmed.edu	Lelkes, Peter I/S-1751-2019; Lelkes, Peter/HGA-2907-2022		Drexel University College of Medicine CURE grants; NATIONAL CANCER INSTITUTE [P30CA056036, R01CA155413] Funding Source: NIH RePORTER	Drexel University College of Medicine CURE grants; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Gieira Jones and Prachi Thanawala for technical support and Dr Gianluca Gallo for the PI3K activating peptide. We would also like to thank Drs Jay Reiff and Jacqueline Emrich and the Radiation Oncology Department at Hahnemann University Hospital for their assistance. This work was supported by Drexel University College of Medicine CURE grants (to MJR).	Ahmad A, 2010, BREAST CANCER RES TR, V122, P337, DOI 10.1007/s10549-009-0572-1; Andarawewa KL, 2007, CANCER RES, V67, P8662, DOI 10.1158/0008-5472.CAN-07-1294; Badache A, 2006, J MAMMARY GLAND BIOL, V11, P13, DOI 10.1007/s10911-006-9009-1; Bektas N, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-42; Bergamaschi A, 2012, ONCOGENE, V31, P39, DOI 10.1038/onc.2011.223; Bergamaschi A, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2913; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; Bowers G, 2001, ONCOGENE, V20, P1388, DOI 10.1038/sj.onc.1204255; Caldwell SA, 2010, ONCOGENE, V29, P2831, DOI 10.1038/onc.2010.41; Carr JR, 2010, CANCER RES, V70, P5054, DOI 10.1158/0008-5472.CAN-10-0545; Chabottaux V, 2007, CLIN EXP METASTAS, V24, P647, DOI 10.1007/s10585-007-9113-7; Contessa JN, 2006, BREAST CANCER RES TR, V95, P17, DOI 10.1007/s10549-005-9023-9; Dai B, 2007, ONCOGENE, V26, P6212, DOI 10.1038/sj.onc.1210443; Danes CG, 2008, CANCER RES, V68, P1760, DOI 10.1158/0008-5472.CAN-07-3177; DiGiovanna MP, 2002, CANCER RES, V62, P6667; Feinendegen LE, 2002, HUM EXP TOXICOL, V21, P85, DOI 10.1191/0960327102ht216oa; Francis RE, 2009, INT J ONCOL, V35, P57, DOI 10.3892/ijo_00000313; Garrett TPJ, 2003, MOL CELL, V11, P495, DOI 10.1016/S1097-2765(03)00048-0; Gemenetzidis E, 2010, CANCER RES, V70, P9515, DOI 10.1158/0008-5472.CAN-10-2173; Giannoni E, 2010, FREE RADICAL BIO MED, V49, P516, DOI 10.1016/j.freeradbiomed.2010.04.025; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Haenssen KK, 2010, J CELL SCI, V123, P1373, DOI 10.1242/jcs.050906; Hebner C, 2008, ANNU REV PATHOL-MECH, V3, P313, DOI 10.1146/annurev.pathmechdis.3.121806.151526; Ishizawar RC, 2007, ONCOGENE, V26, P3503, DOI 10.1038/sj.onc.1210138; Kalin TV, 2006, CANCER RES, V66, P1712, DOI 10.1158/0008-5472.CAN-05-3138; Koo CY, 2012, BBA-GENE REGUL MECH, V1819, P28, DOI 10.1016/j.bbagrm.2011.09.004; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Lagadec C, 2012, STEM CELLS, V30, P833, DOI 10.1002/stem.1058; LAWRENCE TS, 2008, CANC PRINCIPLES PRAC, P307; Leach JK, 2001, CANCER RES, V61, P3894; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Littler DR, 2010, NUCLEIC ACIDS RES, V38, P4527, DOI 10.1093/nar/gkq194; Lu J, 2009, CANCER CELL, V16, P195, DOI 10.1016/j.ccr.2009.08.010; Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024; Marcotte R, 2009, MOL CELL BIOL, V29, P5858, DOI 10.1128/MCB.01731-08; McGovern UB, 2009, MOL CANCER THER, V8, P582, DOI 10.1158/1535-7163.MCT-08-0805; Mendes O, 2007, CLIN EXP METASTAS, V24, P341, DOI 10.1007/s10585-007-9071-0; Millour J, 2010, ONCOGENE, V29, P2983, DOI 10.1038/onc.2010.47; Mori K, 2004, CANCER RES, V64, P7464, DOI 10.1158/0008-5472.CAN-04-1725; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Neal CL, 2010, EXPERT OPIN THER TAR, V14, P1343, DOI 10.1517/14728222.2010.531011; Neal CL, 2009, CANCER RES, V69, P3425, DOI 10.1158/0008-5472.CAN-08-2765; O'Toole TE, 2011, J CELL PHYSIOL, V226, P2965, DOI 10.1002/jcp.22644; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Park HJ, 2009, EMBO J, V28, P2908, DOI 10.1038/emboj.2009.239; Raychaudhuri P, 2011, CANCER RES, V71, P4329, DOI 10.1158/0008-5472.CAN-11-0640; SATO K, 1994, BIOCHEM BIOPH RES CO, V205, P1716, DOI 10.1006/bbrc.1994.2866; SchmidtUllrich RK, 1996, RADIAT RES, V145, P81, DOI 10.2307/3579199; Tan M, 2005, CANCER RES, V65, P1858, DOI 10.1158/0008-5472.CAN-04-2353; Tofilon PJ, 2009, CHEM REV, V109, P2974, DOI 10.1021/cr800504x; Tzivion G, 2006, SEMIN CANCER BIOL, V16, P203, DOI 10.1016/j.semcancer.2006.03.004; Vera-Ramirez L, 2011, CRIT REV ONCOL HEMAT, V80, P347, DOI 10.1016/j.critrevonc.2011.01.004; Xiang B, 2006, METHOD ENZYMOL, V406, P692, DOI 10.1016/S0076-6879(06)06054-X; Yang X, 2012, CANCER GENE THER, V19, P153, DOI 10.1038/cgt.2011.85; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhang SY, 2011, NAT MED, V17, P461, DOI 10.1038/nm.2309	56	30	30	2	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2014	33	5					589	598		10.1038/onc.2012.629	http://dx.doi.org/10.1038/onc.2012.629			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5GW	23318431	Green Accepted			2022-12-28	WOS:000331125100007
J	Cante-Barrett, K; Pieters, R; Meijerink, JPP				Cante-Barrett, K.; Pieters, R.; Meijerink, J. P. P.			Myocyte enhancer factor 2C in hematopoiesis and leukemia	ONCOGENE			English	Review						MEF2C; hematopoiesis; leukemia	TRANSCRIPTION FACTOR MEF2C; ACUTE LYMPHOBLASTIC-LEUKEMIA; HELIX-LOOP-HELIX; MADS-BOX; CELL PROLIFERATION; MENTAL-RETARDATION; MUSCLE DEVELOPMENT; GENE-EXPRESSION; DNA-BINDING; T-CELLS	MEF2C is a selectively expressed transcription factor involved in different transcriptional complexes. Originally identified as an essential regulator of muscle development, ectopic expression of MEF2C as a result of chromosomal rearrangements is now linked to leukemia. Specifically, high MEF2C expression has been linked to mixed lineage leukemia-rearranged acute myeloid leukemia as well as to the immature subgroup of T-cell acute lymphoblastic leukemia. This review focuses on the role of MEF2C in the hematopoietic system and on aberrant MEF2C expression in human leukemia.	[Cante-Barrett, K.; Pieters, R.; Meijerink, J. P. P.] ErasmusMC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, NL-3000 CB Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC	Meijerink, JPP (corresponding author), ErasmusMC Sophia Childrens Hosp, Dept Pediat Oncol Hematol, POB 2060, NL-3000 CB Rotterdam, Netherlands.	j.meijerink@erasmusmc.nl	Meijerink, Jules P/D-4393-2017	Meijerink, Jules P/0000-0002-6860-798X; Cante-Barrett, Kirsten/0000-0003-0418-8445	Children Cancer Free Foundation (Stichting Kinderen Kankervrij (KIKA) [2008-029]	Children Cancer Free Foundation (Stichting Kinderen Kankervrij (KIKA)	This work is supported by the Children Cancer Free Foundation (Stichting Kinderen Kankervrij (KIKA), 2008-029 (KCB)).	Ab Hakim NH, 2010, GENES CELLS, V15, P255, DOI 10.1111/j.1365-2443.2009.01378.x; Agarwal P, 2011, DEVELOPMENT, V138, P2555, DOI 10.1242/dev.056804; Agatheeswaran S, 2013, LEUKEMIA, V27, P1578, DOI 10.1038/leu.2012.339; Akhtar MW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034863; Allman D, 2003, NAT IMMUNOL, V4, P168, DOI 10.1038/ni878; Andrews SF, 2012, EUR J IMMUNOL, V42, P1327, DOI 10.1002/eji.201142226; Arnold MA, 2007, DEV CELL, V12, P377, DOI 10.1016/j.devcel.2007.02.004; Barbosa AC, 2008, P NATL ACAD SCI USA, V105, P9391, DOI 10.1073/pnas.0802679105; Bienvenu T, 2013, NEUROGENETICS, V14, P71, DOI 10.1007/s10048-012-0344-7; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Chen SL, 2000, GENE DEV, V14, P1209; Cho EG, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024027; Coustan-Smith E, 2009, LANCET ONCOL, V10, P147, DOI 10.1016/S1470-2045(08)70314-0; Dahl R, 2003, NAT IMMUNOL, V4, P1029, DOI 10.1038/ni973; Dakic A, 2005, J EXP MED, V201, P1487, DOI 10.1084/jem.20050075; Debnath I, 2013, INT IMMUNOL, V25, P99, DOI 10.1093/intimm/dxs088; Dressel U, 2001, J BIOL CHEM, V276, P17007, DOI 10.1074/jbc.M101508200; Du Y, 2005, BLOOD, V106, P2498, DOI 10.1182/blood-2004-12-4840; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; Faber J, 2009, BLOOD, V113, P2375, DOI 10.1182/blood-2007-09-113597; Fazi F, 2005, CELL, V123, P819, DOI 10.1016/j.cell.2005.09.023; Fazi F, 2007, CANCER CELL, V12, P457, DOI 10.1016/j.ccr.2007.09.020; Gagan J, 2012, J BIOL CHEM, V287, P40360, DOI 10.1074/jbc.M112.378414; Gekas C, 2009, BLOOD, V113, P3461, DOI 10.1182/blood-2008-07-167577; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; Gregoire S, 2007, MOL CELL BIOL, V27, P1280, DOI 10.1128/MCB.00882-06; Homminga I, 2011, CANCER CELL, V19, P484, DOI 10.1016/j.ccr.2011.02.008; Ji ZX, 2009, MOL GENET GENOMICS, V281, P1, DOI 10.1007/s00438-008-0393-7; Johnnidis JB, 2008, NATURE, V451, P1125, DOI 10.1038/nature06607; Kang Jungseog, 2006, BMC Biochemistry, V7, DOI 10.1186/1471-2091-7-5; Khiem D, 2008, P NATL ACAD SCI USA, V105, P17067, DOI 10.1073/pnas.0804868105; Kong YF, 1997, MOL CELL BIOL, V17, P4750, DOI 10.1128/MCB.17.8.4750; KOPAN R, 1994, DEVELOPMENT, V120, P2385; Kramer I, 2012, J BONE MINER RES, V27, P360, DOI 10.1002/jbmr.1492; Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980; Le Meur N, 2010, J MED GENET, V47, P22, DOI 10.1136/jmg.2009.069732; Li H, 2008, P NATL ACAD SCI USA, V105, P9397, DOI 10.1073/pnas.0802876105; Li Z, 2008, J NEUROSCI, V28, P6557, DOI 10.1523/JNEUROSCI.0134-08.2008; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Lu JR, 2000, P NATL ACAD SCI USA, V97, P4070, DOI 10.1073/pnas.080064097; Ma KW, 2005, MOL CELL BIOL, V25, P3575, DOI 10.1128/MCB.25.9.3575-3582.2005; McElhinny AS, 2008, ONCOGENE, V27, P5138, DOI 10.1038/onc.2008.228; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; Meijerink JPP, 2010, BEST PRACT RES CL HA, V23, P307, DOI 10.1016/j.beha.2010.08.002; Micheli L, 2005, MOL CELL BIOL, V25, P2242, DOI 10.1128/MCB.25.6.2242-2259.2005; Micheli L, 2011, J BIOL CHEM, V286, P5691, DOI 10.1074/jbc.M110.162842; Mikhail FM, 2011, AM J MED GENET A, V155A, P2386, DOI 10.1002/ajmg.a.34177; Molkentin JD, 1996, MOL CELL BIOL, V16, P2627; Molkentin JD, 1996, P NATL ACAD SCI USA, V93, P9366, DOI 10.1073/pnas.93.18.9366; Morin RD, 2011, NATURE, V476, P298, DOI 10.1038/nature10351; Nagel S, 2008, LEUKEMIA, V22, P600, DOI 10.1038/sj.leu.2405067; Nagel S, 2003, CANCER RES, V63, P5329; Nebbioso A, 2020, EMBO REP, V21, DOI [10.1038/embor.2009.88, 10.15252/embr.202051028]; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; Pallavi SK, 2012, EMBO J, V31, P2895, DOI 10.1038/emboj.2012.129; Prima V, 2007, LEUKEMIA, V21, P2470, DOI 10.1038/sj.leu.2404962; Prima V, 2005, LEUKEMIA, V19, P806, DOI 10.1038/sj.leu.2403684; Przybylski GK, 2006, HAEMATOLOGICA, V91, P317; Ptasinska A, 2012, LEUKEMIA, V26, P1829, DOI 10.1038/leu.2012.49; Ribeiro MSJ, 2009, CURR PROTEIN PEPT SC, V10, P570; Rosenbauer F, 2004, NAT GENET, V36, P624, DOI 10.1038/ng1361; Rothenberg EV, 2008, SEMIN IMMUNOL, V20, P236, DOI 10.1016/j.smim.2008.07.006; Sartorelli V, 1997, MOL CELL BIOL, V17, P1010, DOI 10.1128/MCB.17.2.1010; Schuler A, 2008, BLOOD, V111, P4532, DOI 10.1182/blood-2007-10-116343; Schwieger M, 2009, BLOOD, V114, P2476, DOI 10.1182/blood-2008-05-158196; Sekiyama Y, 2012, CELL MOL NEUROBIOL, V32, P129, DOI 10.1007/s10571-011-9743-9; Shen HX, 2006, GENE DEV, V20, P675, DOI 10.1101/gad.1383706; Stehling-Sun S, 2009, NAT IMMUNOL, V10, P289, DOI 10.1038/ni.1694; Swanson BJ, 1998, MOL IMMUNOL, V35, P445, DOI 10.1016/S0161-5890(98)00058-3; Van Vlierberghe P, 2008, BLOOD, V111, P4668, DOI 10.1182/blood-2007-09-111872; Van Vlierberghe P, 2011, J EXP MED, V208, P2571, DOI 10.1084/jem.20112239; Vangala RK, 2003, BLOOD, V101, P270, DOI 10.1182/blood-2002-04-1288; Verzi MP, 2007, DEV CELL, V12, P645, DOI 10.1016/j.devcel.2007.03.007; Vincentz JW, 2008, DEV DYNAM, V237, P3809, DOI 10.1002/dvdy.21803; Vong LH, 2005, GENESIS, V43, P43, DOI 10.1002/gene.20152; Wang DZ, 2001, DEVELOPMENT, V128, P4623; Wilker PR, 2008, NAT IMMUNOL, V9, P603, DOI 10.1038/ni.1609; Wilson-Rawls J, 1999, MOL CELL BIOL, V19, P2853; Winslow MM, 2006, IMMUNITY, V24, P141, DOI 10.1016/j.immuni.2005.12.013; Youn HD, 1999, SCIENCE, V286, P790, DOI 10.1126/science.286.5440.790; Youn HD, 2000, IMMUNITY, V13, P85, DOI 10.1016/S1074-7613(00)00010-8; Yuki Y, 2004, CANCER SCI, V95, P503, DOI 10.1111/j.1349-7006.2004.tb03240.x; Zhang JH, 2012, NATURE, V481, P157, DOI 10.1038/nature10725; Zhu BM, 2005, J BIOL CHEM, V280, P28749, DOI 10.1074/jbc.M502491200; Zhu BM, 2004, MOL CELL BIOL, V24, P8264, DOI 10.1128/MCB.24.18.8264-8275.2004; Zweier M, 2011, MOL SYNDROMOL, V2, P164, DOI 10.1159/000337496	86	61	63	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2014	33	4					403	410		10.1038/onc.2013.56	http://dx.doi.org/10.1038/onc.2013.56			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VX	23435431				2022-12-28	WOS:000330214600001
J	Liu, Y; Raheja, R; Yeh, N; Ciznadija, D; Pedraza, AM; Ozawa, T; Hukkelhoven, E; Erdjument-Bromage, H; Tempst, P; Gauthier, NP; Brennan, C; Holland, EC; Koff, A				Liu, Y.; Raheja, R.; Yeh, N.; Ciznadija, D.; Pedraza, A. M.; Ozawa, T.; Hukkelhoven, E.; Erdjument-Bromage, H.; Tempst, P.; Gauthier, N. P.; Brennan, C.; Holland, E. C.; Koff, A.			TRIM3, a tumor suppressor linked to regulation of p21(Waf1/Cip1)	ONCOGENE			English	Article						glioma; p21; PDGF; stem/progenitor; TRIM3	NEURAL STEM-CELLS; INTEGRATED GENOMIC ANALYSIS; SELF-RENEWAL; CYCLIN D1; ABERRANT EXPRESSION; MALIGNANT GLIOMA; MOUSE MODELS; IN-VIVO; CANCER; DROSOPHILA	The TRIM family of genes is largely studied because of their roles in development, differentiation and host cell antiviral defenses; however, roles in cancer biology are emerging. Loss of heterozygosity of the TRIM3 locus in similar to 20% of human glioblastomas raised the possibility that this NHL-domain containing member of the TRIM gene family might be a mammalian tumor suppressor. Consistent with this, reducing TRIM3 expression increased the incidence of and accelerated the development of platelet-derived growth factor -induced glioma in mice. Furthermore, TRIM3 can bind to the cdk inhibitor p21(WAF1/CIP1). Thus, we conclude that TRIM3 is a tumor suppressor mapping to chromosome 11p15.5 and that it might block tumor growth by sequestering p21 and preventing it from facilitating the accumulation of cyclin D1-cdk4.	[Liu, Y.; Raheja, R.; Yeh, N.; Ciznadija, D.; Hukkelhoven, E.; Erdjument-Bromage, H.; Tempst, P.; Koff, A.] Mem Sloan Kettering Canc Ctr, Programs Mol Biol, New York, NY 10021 USA; [Gauthier, N. P.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Koff, A (corresponding author), Mem Sloan Kettering Canc Ctr, Programs Mol Biol, 1275 York Ave, New York, NY 10021 USA.	a-koff@ski.mskcc.org	Brennan, Cameron/R-7082-2019	Brennan, Cameron/0000-0003-4064-8891; Koff, Andrew/0000-0003-3271-3067; Erdjument-Bromage, Hediye/0000-0003-0224-3594; Tempst, Paul/0000-0002-6680-3987	Memorial Sloan-Kettering Cancer Center Core Grant [P30CA08748]; Brain Tumor Center; Golfers Against Cancer Foundation;  [CA89563]; NATIONAL CANCER INSTITUTE [P30CA008748, R01CA089563] Funding Source: NIH RePORTER	Memorial Sloan-Kettering Cancer Center Core Grant; Brain Tumor Center; Golfers Against Cancer Foundation; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Marta Kovatcheva and other members of the Koff lab, Pengbo Zhou (Cornell University Medical School), John Petrini (MSKCC) and Hakim Djaballah (MSKCC) for comments on this manuscript, and Max Chan Liu (The Browning School) for his assistance with Id1 staining and image acquisition. This work was supported by the Memorial Sloan-Kettering Cancer Center Core Grant (P30CA08748) and grants to Andrew Koff (CA89563). Funding was also provided by the Brain Tumor Center (YL, DC) and the Golfers Against Cancer Foundation (AK).	Aaltomaa S, 1999, PROSTATE, V39, P8; Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; Arama E, 2000, ONCOGENE, V19, P3706, DOI 10.1038/sj.onc.1203706; Bae DS, 2001, GYNECOL ONCOL, V81, P341, DOI 10.1006/gyno.2001.6196; Baretton GB, 1999, BRIT J CANCER, V80, P546, DOI 10.1038/sj.bjc.6690390; Barrett LE, 2012, CANCER CELL, V21, P11, DOI 10.1016/j.ccr.2011.11.025; Bello B, 2006, DEVELOPMENT, V133, P2639, DOI 10.1242/dev.02429; Betschinger J, 2006, CELL, V124, P1241, DOI 10.1016/j.cell.2006.01.038; Bleau AM, 2009, CELL STEM CELL, V4, P226, DOI 10.1016/j.stem.2009.01.007; Boulay JL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-71; Bowman SK, 2008, DEV CELL, V14, P535, DOI 10.1016/j.devcel.2008.03.004; Brennan C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007752; Broxmeyer HE, 2012, ANN NY ACAD SCI, V1266, P151, DOI 10.1111/j.1749-6632.2012.06509.x; Ceccarelli C, 2001, INT J CANCER, V95, P128; Cerami E, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008918; Charles N, 2010, CELL STEM CELL, V6, P141, DOI 10.1016/j.stem.2010.01.001; Charles NA, 2010, CELL STEM CELL, V6, P6, DOI 10.1016/j.stem.2009.12.005; Chen J, 2012, CELL, V149, P36, DOI 10.1016/j.cell.2012.03.009; Cheung CC, 2010, P NATL ACAD SCI USA, V107, P11883, DOI 10.1073/pnas.1006529107; Cheung TH, 2001, CANCER LETT, V172, P93, DOI 10.1016/S0304-3835(01)00624-3; Choksi SP, 2006, DEV CELL, V11, P775, DOI 10.1016/j.devcel.2006.09.015; Ciznadija D, 2011, CANCER RES, V71, P6174, DOI 10.1158/0008-5472.CAN-11-1031; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; Ferrandina G, 2000, INT J ONCOL, V17, P1231; Gao H, 2004, P NATL ACAD SCI USA, V101, P17204, DOI 10.1073/pnas.0407693101; Hatakeyama S, 2011, NAT REV CANCER, V11, P792, DOI 10.1038/nrc3139; Herranz H, 2010, EMBO J, V29, P1688, DOI 10.1038/emboj.2010.69; Hukkelhoven E, 2012, J BIOL CHEM, V287, P38523, DOI 10.1074/jbc.M112.366542; Huse JT, 2010, NAT REV CANCER, V10, P319, DOI 10.1038/nrc2818; James MK, 2008, MOL CELL BIOL, V28, P498, DOI 10.1128/MCB.02171-06; Januschke J, 2008, ONCOGENE, V27, P6994, DOI 10.1038/onc.2008.349; Katz AM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032453; Lee CY, 2006, DEV CELL, V10, P441, DOI 10.1016/j.devcel.2006.01.017; Lee J, 2009, EXP MOL MED, V41, P765, DOI 10.3858/emm.2009.41.11.102; Liu Y, 2007, EMBO J, V26, P4683, DOI 10.1038/sj.emboj.7601886; Muraoka RS, 2002, MOL CELL BIOL, V22, P2204, DOI 10.1128/MCB.22.7.2204-2219.2002; Nisole S, 2005, NAT REV MICROBIOL, V3, P799, DOI 10.1038/nrmicro1248; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Reichert H, 2011, RESULTS PROBL CELL D, V53, P529, DOI 10.1007/978-3-642-19065-0_21; Reymond A, 2001, EMBO J, V20, P2140, DOI 10.1093/emboj/20.9.2140; Sarbia M, 2000, Recent Results Cancer Res, V155, P15; Schwamborn JC, 2009, CELL, V136, P913, DOI 10.1016/j.cell.2008.12.024; See WL, 2010, ONCOGENE, V29, P1720, DOI 10.1038/onc.2009.465; See WL, 2010, CELL CYCLE, V9, P1562, DOI 10.4161/cc.9.8.11259; Shih AH, 2004, CANCER RES, V64, P4783, DOI 10.1158/0008-5472.CAN-03-3831; Taylor BS, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003179; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Viglietto G, 2002, CELL CYCLE, V1, P394, DOI 10.4161/cc.1.6.263; Vitucci M, 2011, BRIT J CANCER, V104, P545, DOI 10.1038/sj.bjc.6606031; Winters ZE, 2003, BREAST CANCER RES, V5, pR242, DOI 10.1186/bcr654; Wulczyn FG, 2010, ADV EXP MED BIOL, V700, P85, DOI 10.1007/978-1-4419-7823-3_9; Xu XLL, 2009, CELL, V137, P1018, DOI 10.1016/j.cell.2009.03.051; Yan Q, 2005, MOL BIOL CELL, V16, P2470, DOI 10.1091/mbc.e04-11-1014; Yeh N, 2007, MOL CELL BIOL, V27, P5161, DOI 10.1128/MCB.02431-06	55	39	42	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2014	33	3					308	315		10.1038/onc.2012.596	http://dx.doi.org/10.1038/onc.2012.596			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VR	23318451	Green Accepted			2022-12-28	WOS:000330214000005
J	Bergholz, J; Zhang, Y; Wu, J; Meng, L; Walsh, EM; Rai, A; Sherman, MY; Xiao, ZXJ				Bergholz, J.; Zhang, Y.; Wu, J.; Meng, L.; Walsh, E. M.; Rai, A.; Sherman, M. Y.; Xiao, Z-X Jim			Delta Np63 alpha regulates Erk signaling via MKP3 to inhibit cancer metastasis	ONCOGENE			English	Article						p63; MKP3; Erk; metastasis; cancer	SQUAMOUS-CELL CARCINOMA; GENE-EXPRESSION; LUNG-CANCER; BREAST-CANCER; UP-REGULATION; P53 HOMOLOG; EPITHELIAL DEVELOPMENT; PANCREATIC-CANCER; DOWN-REGULATION; GROWTH-FACTOR	Reduced expression of the p53 family member p63 has been suggested to play a causative role in cancer metastasis. Here, we show that Delta Np63 alpha, the predominant p63 isoform, plays a major role in regulation of cell migration, invasion and cancer metastasis. We identified mitogen-activated protein (MAP) kinase phosphatase 3 (MKP3) as a downstream target of Delta Np63 alpha that is required for mediating these effects. We show that Delta Np63 alpha regulates extracellular signal-regulated protein kinases 1 and 2 (Erk1/2) activity via MKP3 in both cancer and non-transformed cells. We further show that exogenous Delta Np63 alpha inhibits cell invasion and is dependent on MKP3 upregulation for repression. Conversely, endogenous pan-p63 ablation results in increased cell migration and invasion, which can be reverted by reintroducing the Delta Np63 alpha isoform alone, but not by other isoforms. Interestingly, these effects require Erk2, but not Erk1 expression, and can be rescued by enforced MKP3 expression. Moreover, MKP3 expression is reduced in invasive cancers, and reduced p63 expression increases metastatic frequency in vivo. Taken together, these results suggest an important role for Delta Np63 alpha in preventing cancer metastasis by inhibition of Erk2 signaling via MKP3.	[Bergholz, J.; Wu, J.; Meng, L.; Walsh, E. M.; Rai, A.; Sherman, M. Y.; Xiao, Z-X Jim] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; [Bergholz, J.; Zhang, Y.; Xiao, Z-X Jim] Sichuan Univ, Ctr Growth Metab & Aging, Coll Life Sci, Chengdu 610014, Sichuan, Peoples R China; [Bergholz, J.; Zhang, Y.; Xiao, Z-X Jim] Sichuan Univ, State Key Lab Biotherapy, Chengdu 610014, Sichuan, Peoples R China	Boston University; Sichuan University; Sichuan University	Xiao, ZXJ (corresponding author), Sichuan Univ, Ctr Growth Metab & Aging, Coll Life Sci, 29 Wangjiang Rd, Chengdu 610014, Sichuan, Peoples R China.	jimzx@scu.edu.cn			NIH [CA79804, GM70017]; National Key Basic Research Program (973 Program) of China [2012CB910700]; United States Department of Defense [W81XWH-10-1-0161]; NATIONAL CANCER INSTITUTE [R01CA079804] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR010888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070017] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Key Basic Research Program (973 Program) of China(National Basic Research Program of China); United States Department of Defense(United States Department of Defense); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Dr Frank McKeon (Harvard Medical School, Boston, MA, USA) for providing the myc-tagged murine pcDNA3-Delta Np63 alpha, pcDNA3-Delta Np63 gamma, pcDNA3-TAp63 alpha and pcDNA3-TAp63 gamma expression plasmids, and Dr Tyler Jacks (Massachusetts Institute of Technology, Cambridge, MA, USA) for providing a plasmid encoding shRNA against human MKP3. We also thank Dr Xixi Cao (Baylor College of Medicine) for help with Oncomine bioinformatics analysis. This work was supported by NIH grants (CA79804 and GM70017) and by the National Key Basic Research Program (973 Program) of China (2012CB910700) to Z-XJX, and United States Department of Defense Congressionally Directed Medical Research Programs grant (W81XWH-10-1-0161) to JB.	Adeyinka A, 2002, CLIN CANCER RES, V8, P1747; Adorno M, 2009, CELL, V137, P87, DOI 10.1016/j.cell.2009.01.039; Barbieri CE, 2006, CANCER RES, V66, P7589, DOI 10.1158/0008-5472.CAN-06-2020; Candi E, 2008, CELL MOL LIFE SCI, V65, P3126, DOI 10.1007/s00018-008-8119-x; Candi E, 2006, CELL DEATH DIFFER, V13, P1037, DOI 10.1038/sj.cdd.4401926; Carroll DK, 2006, NAT CELL BIOL, V8, P551, DOI 10.1038/ncb1420; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; DeYoung MP, 2006, CANCER RES, V66, P9362, DOI 10.1158/0008-5472.CAN-06-1619; Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969; Dumesic PA, 2009, J CELL BIOL, V185, P409, DOI 10.1083/jcb.200804038; Eicheler W, 2002, J HISTOCHEM CYTOCHEM, V50, P197, DOI 10.1177/002215540205000207; Ekerot M, 2008, BIOCHEM J, V412, P287, DOI 10.1042/BJ20071512; Flores ER, 2005, CANCER CELL, V7, P363, DOI 10.1016/j.ccr.2005.02.019; Fu SW, 2003, BREAST CANCER RES, V5, pR82, DOI 10.1186/bcr602; Fukushima H, 2009, CANCER RES, V69, P9263, DOI 10.1158/0008-5472.CAN-09-1188; Furukawa T, 2003, AM J PATHOL, V162, P1807, DOI 10.1016/S0002-9440(10)64315-5; Ginos MA, 2004, CANCER RES, V64, P55, DOI 10.1158/0008-5472.CAN-03-2144; Gonfloni S, 2009, NAT MED, V15, P1179, DOI 10.1038/nm.2033; Haqq C, 2005, P NATL ACAD SCI USA, V102, P6092, DOI 10.1073/pnas.0501564102; Hibi K, 2000, P NATL ACAD SCI USA, V97, P5462, DOI 10.1073/pnas.97.10.5462; Higashikawa K, 2007, CANCER RES, V67, P9207, DOI 10.1158/0008-5472.CAN-07-0932; Higashikawa K, 2009, INT J CANCER, V124, P2837, DOI 10.1002/ijc.24280; Hollestelle A, 2007, MOL CANCER RES, V5, P195, DOI 10.1158/1541-7786.MCR-06-0263; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; Ihrie RA, 2005, CELL, V120, P843, DOI 10.1016/j.cell.2005.01.008; Jinnin M, 2005, NUCLEIC ACIDS RES, V33, P3540, DOI 10.1093/nar/gki648; Karlsson M, 2004, J BIOL CHEM, V279, P41882, DOI 10.1074/jbc.M406720200; Keyes WM, 2011, CELL STEM CELL, V8, P164, DOI 10.1016/j.stem.2010.12.009; Keyes WM, 2005, GENE DEV, V19, P1986, DOI 10.1101/gad.342305; Kommagani R, 2009, J CELL SCI, V122, P2828, DOI 10.1242/jcs.049619; Krueger JS, 2001, ONCOGENE, V20, P4209, DOI 10.1038/sj.onc.1204541; Kuo LY, 2006, J CELL PHYSIOL, V207, P729, DOI 10.1002/jcp.20616; Li CY, 2007, DEVELOPMENT, V134, P167, DOI 10.1242/dev.02701; Lindsay J, 2011, J BIOL CHEM, V286, P3915, DOI 10.1074/jbc.M110.162511; Liu J, 2006, MOL CANCER RES, V4, P803, DOI 10.1158/1541-7786.MCR-06-0201; Liu SY, 2005, CELL PHYSIOL BIOCHEM, V16, P207, DOI 10.1159/000089846; Maillet M, 2008, J BIOL CHEM, V283, P31246, DOI 10.1074/jbc.M806085200; Massion PP, 2003, CANCER RES, V63, P7113; McCawley LJ, 1999, J BIOL CHEM, V274, P4347, DOI 10.1074/jbc.274.7.4347; McGrath JA, 2001, HUM MOL GENET, V10, P221, DOI 10.1093/hmg/10.3.221; Melino G, 2011, CELL DEATH DIFFER, V18, P1487, DOI 10.1038/cdd.2011.81; Meng L, 2010, ONCOGENE, V29, P5204, DOI 10.1038/onc.2010.277; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026; Okudela K, 2009, AM J PATHOL, V175, P867, DOI 10.2353/ajpath.2009.080489; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Senoo M, 2007, CELL, V129, P523, DOI 10.1016/j.cell.2007.02.045; Serber Z, 2002, MOL CELL BIOL, V22, P8601, DOI 10.1128/MCB.22.24.8601-8611.2002; Shalom-Feuerstein R, 2011, CELL DEATH DIFFER, V18, P887, DOI 10.1038/cdd.2010.159; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Su H, 2003, CANCER RES, V63, P3872; Su XH, 2010, NATURE, V467, P986, DOI 10.1038/nature09459; Suh EK, 2006, NATURE, V444, P624, DOI 10.1038/nature05337; Sun YB, 1999, J BIOL CHEM, V274, P11535, DOI 10.1074/jbc.274.17.11535; Talbot SG, 2005, CANCER RES, V65, P3063, DOI 10.1158/0008-5472.CAN-04-1985; Thanos CD, 1999, PROTEIN SCI, V8, P1708, DOI 10.1110/ps.8.8.1708; Vanaja DK, 2003, CANCER RES, V63, P3877; Vicent S, 2004, BRIT J CANCER, V90, P1047, DOI 10.1038/sj.bjc.6601644; Webb CP, 1998, P NATL ACAD SCI USA, V95, P8773, DOI 10.1073/pnas.95.15.8773; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Weber A, 2002, INT J CANCER, V99, P22, DOI 10.1002/ijc.10296; Xu SH, 2005, J HUM GENET, V50, P159, DOI 10.1007/s10038-005-0235-y; Yamamoto T, 2006, CURR BIOL, V16, P1171, DOI 10.1016/j.cub.2006.04.044; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yang SY, 2009, CANCER CELL, V15, P124, DOI 10.1016/j.ccr.2008.12.019; Ying HQ, 2005, MOL CELL BIOL, V25, P6154, DOI 10.1128/MCB.25.14.6154-6164.2005; Zhang ZF, 2010, CARCINOGENESIS, V31, P577, DOI 10.1093/carcin/bgq020; Zhao HJ, 2004, MOL BIOL CELL, V15, P2523, DOI 10.1091/mbc.E03-11-0786	69	35	36	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2014	33	2					212	224		10.1038/onc.2012.564	http://dx.doi.org/10.1038/onc.2012.564			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286BY	23246965	Green Accepted			2022-12-28	WOS:000329440700009
J	Todd, JR; Scurr, LL; Becker, TM; Kefford, RF; Rizos, H				Todd, J. R.; Scurr, L. L.; Becker, T. M.; Kefford, R. F.; Rizos, H.			The MAPK pathway functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma	ONCOGENE			English	Article						c-Kit; stem cell factor; melanoma; melanocytes; MAPK; PI3K	GASTROINTESTINAL STROMAL TUMORS; TYROSINE KINASE; METASTATIC MELANOMA; PROTEIN EXPRESSION; IMATINIB MESYLATE; HUMAN MELANOCYTES; MUCOSAL MELANOMA; MAJOR RESPONSE; RESISTANCE; MUTATIONS	Stimulation of the c-Kit receptor tyrosine kinase has a critical role in the development and migration of melanocytes, and oncogenic c-Kit mutants contribute to the progression of some melanomas. c-Kit signalling activates the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kinase (PI3K) pathways and their relative contribution to the activities of oncogenic and ligand-dependent c-Kit remains uncertain. We show that PI3K is a major regulator of MAPK activation in response to c-Kit activity and the dominant effector of c-Kit-driven melanocyte proliferation and melanoma survival. Nevertheless, inhibition of the PI3K pathway in c-Kit mutant melanoma cells did not replicate the apoptotic efficacy of the c-Kit inhibitor, imatinib mesylate. Instead, the simultaneous suppression of the PI3K and MAPK pathways promoted a strong synergistic apoptotic effect. These data indicate that MAPK functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma. Thus, the concurrent inhibition of PI3K and MAPK signalling is required to suppress oncogenic c-Kit activity and may provide an effective therapeutic strategy in c-Kit mutant melanomas.	[Todd, J. R.; Scurr, L. L.; Becker, T. M.; Kefford, R. F.; Rizos, H.] Univ Sydney, Westmead Inst Canc Res, Westmead Millennium Inst, Westmead Hosp, Westmead, NSW 2145, Australia; [Kefford, R. F.] Melanoma Inst Australia, Sydney, NSW, Australia	University of Sydney; Westmead Institute for Medical Research; Melanoma Institute Australia	Rizos, H (corresponding author), Univ Sydney, Westmead Inst Canc Res, Westmead Millennium Inst, Westmead Hosp, Darcy Rd, Westmead, NSW 2145, Australia.	helen.rizos@sydney.edu.au		Becker, Therese/0000-0002-5636-9902; Kefford, Richard/0000-0001-9251-9229; Rizos, Helen/0000-0002-2094-9198	National Health and Medical Research Council of Australia (NHMRC) [633004]; Health Department of NSW through Sydney West Area Health Service; Australian Cancer Research Foundation; Cancer Institute New South Wales; NHMRC; Australian Postgraduate Award; Westmead Medical Research Foundation; Melanoma Foundation of the University of Sydney	National Health and Medical Research Council of Australia (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Health Department of NSW through Sydney West Area Health Service; Australian Cancer Research Foundation; Cancer Institute New South Wales; NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Australian Postgraduate Award(Australian Government); Westmead Medical Research Foundation; Melanoma Foundation of the University of Sydney(University of Sydney)	We are grateful to Antoni Ribas, Peter Hersey and Meenhard Herlyn for providing c-Kit mutant melanoma cells lines. This work is supported by Programme Grant 633004 and project grants of the National Health and Medical Research Council of Australia (NHMRC) and an infrastructure grant to Westmead Millennium Institute by the Health Department of NSW through Sydney West Area Health Service. Westmead Institute for Cancer Research is the recipient of capital grant funding from the Australian Cancer Research Foundation. HR is a recipient of a Cancer Institute New South Wales, Research Fellowship and a NHMRC Senior Research Fellowship. JT is supported by an Australian Postgraduate Award and a Westmead Medical Research Foundation Top-up Award. The support of the Melanoma Foundation of the University of Sydney and colleagues from Melanoma Institute Australia and the Department of Anatomical Pathology at the Royal Prince Alfred Hospital are also gratefully acknowledged.	Aksamitiene E, 2012, BIOCHEM SOC T, V40, P139, DOI 10.1042/BST20110609; Alexeev V, 2006, J INVEST DERMATOL, V126, P1102, DOI 10.1038/sj.jid.5700125; Antonescu CR, 2007, INT J CANCER, V121, P257, DOI 10.1002/ijc.22681; Atefi M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028973; Bauer S, 2007, ONCOGENE, V26, P7560, DOI 10.1038/sj.onc.1210558; Beadling C, 2008, CLIN CANCER RES, V14, P6821, DOI 10.1158/1078-0432.CCR-08-0575; Carvajal RD, 2011, JAMA-J AM MED ASSOC, V305, P2327, DOI 10.1001/jama.2011.746; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Curtin JA, 2006, J CLIN ONCOL, V24, P4340, DOI 10.1200/JCO.2006.06.2984; Garrido MC, 2010, J INVEST DERMATOL, V130, P20, DOI 10.1038/jid.2009.334; Gopal YNV, 2010, CANCER RES, V70, P8736, DOI 10.1158/0008-5472.CAN-10-0902; Gounder MM, 2011, CANCER CHEMOTH PHARM, V67, P25, DOI 10.1007/s00280-010-1526-3; Guo J, 2011, J CLIN ONCOL, V29, P2904, DOI 10.1200/JCO.2010.33.9275; HALABAN R, 1986, J INVEST DERMATOL, V87, P95, DOI 10.1111/1523-1747.ep12523594; Handolias D, 2010, PIGM CELL MELANOMA R, V23, P210, DOI 10.1111/j.1755-148X.2010.00671.x; Heinrich MC, 2002, J CLIN ONCOL, V20, P1692, DOI 10.1200/JCO.2002.20.6.1692; Hodi FS, 2008, J CLIN ONCOL, V26, P2046, DOI 10.1200/JCO.2007.14.0707; Jeon S, 2009, PIGM CELL MELANOMA R, V22, P77, DOI 10.1111/j.1755-148X.2008.00519.x; Jiang XF, 2008, CLIN CANCER RES, V14, P7726, DOI 10.1158/1078-0432.CCR-08-1144; Kim Kwang Young, 2011, Algae, V26, P1, DOI 10.4490/algae.2011.26.1.001; Kontogianni-Katsarou K, 2008, WORLD J GASTROENTERO, V14, P1891, DOI 10.3748/wjg.14.1891; Larribere L, 2005, GENE DEV, V19, P1980, DOI 10.1101/gad.335905; Larribere L, 2004, CELL DEATH DIFFER, V11, P1084, DOI 10.1038/sj.cdd.4401475; Lefevre G, 2004, J BIOL CHEM, V279, P31769, DOI 10.1074/jbc.M403907200; Liang RX, 2011, PIGM CELL MELANOMA R, V24, P714, DOI 10.1111/j.1755-148X.2011.00870.x; Lutzky J, 2008, PIGM CELL MELANOMA R, V21, P492, DOI 10.1111/j.1755-148X.2008.00475.x; Martin J, 2005, J CLIN ONCOL, V23, P6190, DOI 10.1200/JCO.2005.19.554; Monsel G, 2010, ONCOGENE, V29, P227, DOI 10.1038/onc.2009.320; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Omholt K, 2011, CLIN CANCER RES, V17, P3933, DOI 10.1158/1078-0432.CCR-10-2917; Rivera RS, 2008, VIRCHOWS ARCH, V452, P27, DOI 10.1007/s00428-007-0524-2; Roskoski R, 2005, BIOCHEM BIOPH RES CO, V337, P1, DOI 10.1016/j.bbrc.2005.08.055; Shi HB, 2011, CANCER RES, V71, P5067, DOI 10.1158/0008-5472.CAN-11-0140; Shimizu T, 2012, CLIN CANCER RES, V18, P2316, DOI 10.1158/1078-0432.CCR-11-2381; Si L, 2012, J CLIN ONCOL, V30, pE37, DOI 10.1200/JCO.2011.37.9644; Smalley KSM, 2008, CANCER RES, V68, P5743, DOI 10.1158/0008-5472.CAN-08-0235; Takayama Y, 2008, CANCER LETT, V264, P241, DOI 10.1016/j.canlet.2008.01.035; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Wardelmann E, 2002, MODERN PATHOL, V15, P125, DOI 10.1038/modpathol.3880504; Woodman SE, 2009, MOL CANCER THER, V8, P2079, DOI 10.1158/1535-7163.MCT-09-0459; Yoshida H, 2001, J INVEST DERM SYMP P, V6, P1, DOI 10.1046/j.0022-202x.2001.00006.x	41	40	41	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2014	33	2					236	245		10.1038/onc.2012.562	http://dx.doi.org/10.1038/onc.2012.562			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286BY	23246970	Bronze			2022-12-28	WOS:000329440700011
J	Bojovic, B; Ho, HY; Wu, J; Crowe, DL				Bojovic, B.; Ho, H-Y; Wu, J.; Crowe, D. L.			Stem cell expansion during carcinogenesis in stem cell-depleted conditional telomeric repeat factor 2 null mutant mice	ONCOGENE			English	Article						telomere; DNA damage; apoptosis; genomic instability	HAIR FOLLICLE BULGE; TRF2; CANCER; SKIN; EXPRESSION; PROTEIN; ATM; DEGRADATION; MAINTENANCE; EPIDERMIS	To examine the role of telomeric repeat-binding factor 2 (TRF2) in epithelial tumorigenesis, we characterized conditional loss of TRF2 expression in the basal layer of mouse epidermis. These mice exhibit some characteristics of dyskeratosis congenita, a human stem cell depletion syndrome caused by telomere dysfunction. The epidermis in conditional TRF2 null mice exhibited DNA damage response and apoptosis, which correlated with stem cell depletion. The stem cell population in conditional TRF2 null epidermis exhibited shorter telomeres than those in control mice. Squamous cell carcinomas induced in conditional TRF2 null mice developed with increased latency and slower growth due to reduced numbers of proliferating cells as the result of increased apoptosis. TRF2 null epidermal stem cells were found in both primary and metastatic tumors. Despite the low-grade phenotype of the conditional TRF2 null primary tumors, the number of metastatic lesions was similar to control cancers. Basal cells from TRF2 null tumors demonstrated extreme telomere shortening and dramatically increased numbers of telomeric signals by fluorescence in situ hybridization due to increased genomic instability and aneuploidy in these cancers. DNA damage response signals were detected at telomeres in TRF2 null tumor cells from these mice. The increased genomic instability in these tumors correlated with eightfold expansion of the transformed stem cell population compared with that in control cancers. We concluded that genomic instability resulting from loss of TRF2 expression provides biological advantages to the cancer stem cell population.	[Bojovic, B.; Ho, H-Y; Wu, J.; Crowe, D. L.] Univ Illinois, Ctr Canc, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Crowe, DL (corresponding author), Univ Illinois, Ctr Canc, 801S Paulina St,Room 530C, Chicago, IL 60612 USA.	dlcrowe@uic.edu	Wu, Jianchun/AAX-3533-2020	Wu, Jianchun/0000-0002-8473-9368	National Institutes of Health [DE14283]; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R03DE014283] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This research was supported by National Institutes of Health Grant No. DE14283.	Ancelin K, 2002, MOL CELL BIOL, V22, P3474, DOI 10.1128/MCB.22.10.3474-3487.2002; Artandi SE, 2000, NATURE, V406, P641, DOI 10.1038/35020592; Attwooll CL, 2009, MOL CELL BIOL, V29, P5540, DOI 10.1128/MCB.00479-09; Bailey SM, 2001, SCIENCE, V293, P2462, DOI 10.1126/science.1062560; Blanco R, 2007, GENE DEV, V21, P206, DOI 10.1101/gad.406207; Blanpain C, 2004, CELL, V118, P635, DOI 10.1016/j.cell.2004.08.012; Callicott RJ, 2006, COMPARATIVE MED, V56, P17; Capper R, 2007, GENE DEV, V21, P2495, DOI 10.1101/gad.439107; Celli GB, 2005, NAT CELL BIOL, V7, P712, DOI 10.1038/ncb1275; Clayton E, 2007, NATURE, V446, P185, DOI 10.1038/nature05574; Cotsarelis G, 2006, J INVEST DERMATOL, V126, P1459, DOI 10.1038/sj.jid.5700376; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; Denchi EL, 2007, NATURE, V448, P1068, DOI 10.1038/nature06065; Denchi EL, 2006, GENE DEV, V20, P2648, DOI 10.1101/gad.1453606; Deng YB, 2009, NATURE, V460, P914, DOI 10.1038/nature08196; Dimitrova N, 2008, NATURE, V456, P524, DOI 10.1038/nature07433; Dimitrova N, 2009, MOL CELL BIOL, V29, P5552, DOI 10.1128/MCB.00476-09; Flores I, 2005, SCIENCE, V309, P1253, DOI 10.1126/science.1115025; Flores I, 2008, GENE DEV, V22, P654, DOI 10.1101/gad.451008; Fuchs E, 2008, J CELL BIOL, V180, P273, DOI 10.1083/jcb.200708185; Fuchs E, 2007, NATURE, V445, P834, DOI 10.1038/nature05659; Fuchs E, 2009, CELL, V137, P811, DOI 10.1016/j.cell.2009.05.002; He H, 2009, MOL CELL BIOL, V29, P229, DOI 10.1128/MCB.01400-08; Heath J, 2009, J INVEST DERMATOL, V129, P2358, DOI 10.1038/jid.2009.102; Hockemeyer D, 2008, GENE DEV, V22, P1773, DOI 10.1101/gad.1679208; Ito M, 2005, NAT MED, V11, P1351, DOI 10.1038/nm1328; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Ku TKS, 2007, MOL CANCER RES, V5, P351, DOI 10.1158/1541-7786.MCR-06-0238; Kusumbe AP, 2009, CANCER RES, V69, P9245, DOI 10.1158/0008-5472.CAN-09-2802; Lantuejoul S, 2010, CLIN CANCER RES, V16, P2979, DOI 10.1158/1078-0432.CCR-10-0142; Liang Y, 2010, J BIOL CHEM, V285, P4931, DOI 10.1074/jbc.M109.048397; Liu YP, 2003, J INVEST DERMATOL, V121, P963, DOI 10.1046/j.1523-1747.2003.12600.x; Malanchi I, 2008, NATURE, V452, P650, DOI 10.1038/nature06835; Martinez P, 2009, GENE DEV, V23, P2060, DOI 10.1101/gad.543509; Matsutani N, 2001, INT J ONCOL, V19, P507; Morris RJ, 2004, NAT BIOTECHNOL, V22, P411, DOI 10.1038/nbt950; Munoz P, 2006, CELL CYCLE, V5, P718, DOI 10.4161/cc.5.7.2636; Oh BK, 2005, AM J PATHOL, V166, P73, DOI 10.1016/S0002-9440(10)62233-X; Rossi DJ, 2008, CELL, V132, P681, DOI 10.1016/j.cell.2008.01.036; Sarin KY, 2005, NATURE, V436, P1048, DOI 10.1038/nature03836; Savage SA, 2009, HEMATOL ONCOL CLIN N, V23, P215, DOI 10.1016/j.hoc.2009.01.003; Siegl-Cachedenier I, 2007, J CELL BIOL, V179, P277, DOI 10.1083/jcb.200704141; Smogorzewska A, 2002, EMBO J, V21, P4338, DOI 10.1093/emboj/cdf433; Snippert HJ, 2010, SCIENCE, V327, P1385, DOI 10.1126/science.1184733; Stout GJ, 2009, DIS MODEL MECH, V2, P139, DOI 10.1242/dmm.002121; Trempus CS, 2007, CANCER RES, V67, P4173, DOI 10.1158/0008-5472.CAN-06-3128; Tumbar T, 2004, SCIENCE, V303, P359, DOI 10.1126/science.1092436; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Wang RC, 2004, CELL, V119, P355, DOI 10.1016/j.cell.2004.10.011	50	9	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2013	32	43					5156	5166		10.1038/onc.2012.555	http://dx.doi.org/10.1038/onc.2012.555			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240JY	23178498	Green Accepted			2022-12-28	WOS:000326093200003
J	Yang, WC; Shih, HM				Yang, W-C; Shih, H-M			The deubiquitinating enzyme USP37 regulates the oncogenic fusion protein PLZF/RARA stability	ONCOGENE			English	Article						acute promyelocytic leukemia; deubiquitinating enzyme; USP37; PLZF; RARA	ACUTE PROMYELOCYTIC LEUKEMIA; SMALL-MOLECULE INHIBITOR; PML-RAR-ALPHA; CELLS; PLZF; PATHWAY; CYCLIN; DIFFERENTIATION; PATHOGENESIS; APOPTOSIS	Acute promyelocytic leukemia (APL) is predominantly characterized by chromosomal translocations between the retinoic acid receptor, alpha (RARA) gene and the promyelocytic leukemia (PML) or promyelocytic leukemia zinc finger (PLZF) gene. In APL cells with PML/RARA fusions, arsenic trioxide and all-trans retinoic acid treatments specifically target the fusion protein for proteasome-dependent degradation, thereby promoting cellular differentiation and clinical remission of disease. In contrast, APL cells expressing PLZF/RARA fusion proteins are largely resistant to similar treatments and prognosis for patients with this translocation is poor. Understanding the molecular mechanisms regulating PLZF/RARA protein stability would provide novel therapeutic targets for PLZF/RARA-associated APL. Toward this end, we have performed an RNAi-based screen to identify factors affecting PLZF/RARA stability. Among the factors identified was the ubiquitin-specific peptidase 37 (USP37). We showed that USP37 interacted with PLZF/RARA through the PLZF moiety and sustained PLZF/RARA steady state levels. Domain mapping study revealed that N-terminal domain of USP37 is required for the PLZF/RARA interaction and protein regulation. Furthermore, overexpression or depletion of USP37 caused an increase or decrease of PLZF/RARA protein half-life, correlating with down-or upregulation of PLZF/RARA poly-ubiquitination, respectively. By PLZF/RARA-transduced primary mouse hematopoietic progenitor cells, we demonstrated that Usp37 knockdown alleviated PLZF/RARA-mediated target gene suppression and cell transformation potential. Altogether, our findings of USP37-modulating PLZF/RARA stability and cell transformation suggest that USP37 is a potential therapeutic target for PLZF/RARA-associated APL.	[Yang, W-C; Shih, H-M] Acad Sinica, Taiwan Int Grad Program TIGP, Mol Med Program, Taipei 115, Taiwan; [Yang, W-C; Shih, H-M] Natl Yang Ming Univ, Sch Life Sci, Inst Biochem & Mol Biol, Taipei 112, Taiwan; [Yang, W-C; Shih, H-M] Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University; Academia Sinica - Taiwan	Shih, HM (corresponding author), Acad Sinica, Inst Biomed Sci, 128 Sec 2,Acad Rd, Taipei 115, Taiwan.	hmshih@ibms.sinica.edu.tw	Shih, Hsiu-Ming/S-7023-2018		NSC [NSC100-2321-B-001-004, NSC100-3112-B-001-004]; Academia Sinica Investigator Award	NSC(Ministry of Science and Technology, Taiwan); Academia Sinica Investigator Award(Academia Sinica - Taiwan)	We thank Dr. J Wade Harper for USP37, OTUD6B and USP2 cDNA constructs, Dr Sheng-Chung Lee for anti-ubiquitin antibody, and Dr Yen-Sung Huang for mouse preparation. We also thank for the NRPGM Core RNAi by providing lentiviral constructs for TetOn system and shRNAs of DUBs. We are grateful to Dr Michael J Matunis for comments on the paper. The work was supported by NSC Grants (NSC100-2321-B-001-004; NSC100-3112-B-001-004) and an Academia Sinica Investigator Award to H-M Shih.	Buaas FW, 2004, NAT GENET, V36, P647, DOI 10.1038/ng1366; Chang CC, 2011, MOL CELL, V42, P62, DOI 10.1016/j.molcel.2011.02.022; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; Colland F, 2009, MOL CANCER THER, V8, P2286, DOI 10.1158/1535-7163.MCT-09-0097; Costoya JA, 2004, NAT GENET, V36, P653, DOI 10.1038/ng1367; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; Doulatov S, 2009, GENE DEV, V23, P2076, DOI 10.1101/gad.1788109; Duprez E, 2003, EMBO J, V22, P5806, DOI 10.1093/emboj/cdg556; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Guibal FC, 2009, BLOOD, V114, P5415, DOI 10.1182/blood-2008-10-182071; Huang XD, 2011, MOL CELL, V42, P511, DOI 10.1016/j.molcel.2011.03.027; Ji P, 2005, ONCOGENE, V24, P2739, DOI 10.1038/sj.onc.1208356; Lallemand-Breitenbach V, 2008, NAT CELL BIOL, V10, P547, DOI 10.1038/ncb1717; Lavau C, 1997, EMBO J, V16, P4226, DOI 10.1093/emboj/16.14.4226; Lee BH, 2010, NATURE, V467, P179, DOI 10.1038/nature09299; Li MY, 2004, MOL CELL, V13, P879, DOI 10.1016/S1097-2765(04)00157-1; Lin DY, 2006, MOL CELL, V24, P341, DOI 10.1016/j.molcel.2006.10.019; Lin RJ, 2001, ONCOGENE, V20, P7204, DOI 10.1038/sj.onc.1204853; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; Mistry AR, 2003, BLOOD REV, V17, P71, DOI 10.1016/S0268-960X(02)00075-9; Muller C, 2000, BLOOD, V96, P3894, DOI 10.1182/blood.V96.12.3894.h8003894_3894_3899; Nasr R, 2009, CLIN CANCER RES, V15, P6321, DOI 10.1158/1078-0432.CCR-09-0209; Nasr R, 2008, NAT MED, V14, P1333, DOI 10.1038/nm.1891; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Popov N, 2007, NAT CELL BIOL, V9, P765, DOI 10.1038/ncb1601; Schwickart M, 2010, NATURE, V463, P103, DOI 10.1038/nature08646; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Sowa ME, 2009, CELL, V138, P389, DOI 10.1016/j.cell.2009.04.042; Ventii KH, 2008, BIOCHEM J, V414, P161, DOI 10.1042/BJ20080798; Wang ZY, 2008, BLOOD, V111, P2505, DOI 10.1182/blood-2007-07-102798; Yang R, 1999, BLOOD, V93, P2067; Zhang XW, 2010, SCIENCE, V328, P240, DOI 10.1126/science.1183424	32	23	24	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2013	32	43					5167	5175		10.1038/onc.2012.537	http://dx.doi.org/10.1038/onc.2012.537			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240JY	23208507				2022-12-28	WOS:000326093200004
J	Fritz, V; Benfodda, Z; Henriquet, C; Hure, S; Cristol, JP; Michel, F; Carbonneau, MA; Casas, F; Fajas, L				Fritz, V.; Benfodda, Z.; Henriquet, C.; Hure, S.; Cristol, J-P; Michel, F.; Carbonneau, M-A; Casas, F.; Fajas, L.			Metabolic intervention on lipid synthesis converging pathways abrogates prostate cancer growth	ONCOGENE			English	Article						lipids; cancer; FAS; metabolism; prostate	FATTY-ACID SYNTHASE; PROTEIN-KINASE; MALIC ENZYME; CELLS; INHIBITION; TISSUES; TARGET; AMPK; CYTOTOXICITY; LIPOGENESIS	One of the most conserved features of all cancers is a profound reprogramming of cellular metabolism, favoring biosynthetic processes and limiting catalytic processes. With the acquired knowledge of some of these important changes, we have designed a combination therapy in order to force cancer cells to use a particular metabolic pathway that ultimately results in the accumulation of toxic products. This innovative approach consists of blocking lipid synthesis, at the same time that we force the cell, through the inhibition of AMP-activated kinase, to accumulate toxic intermediates, such as malonyl-coenzyme A (malonyl-CoA) or nicotinamide adenine dinucleotide phosphate. This results in excess of oxidative stress and cancer cell death. Our new therapeutic strategy, based on the manipulation of metabolic pathways, will certainly set up the basis for new upcoming studies defining a new paradigm of cancer treatment.	[Fritz, V.; Hure, S.; Fajas, L.] CNRS, IGMM, Inst Genet Mol Montpellier, F-34293 Montpellier, France; [Fritz, V.; Hure, S.; Fajas, L.] CNRS, UMR5535, F-34293 Montpellier, France; [Fritz, V.; Hure, S.; Fajas, L.] Univ Montpellier 2, Montpellier, France; [Benfodda, Z.] Univ Montpellier 2, IBMM, Inst Biomol Max Mousseron, Lab Acides Amines Peptides & Prot,CNRS UMR5247 CC, Montpellier, France; [Benfodda, Z.] Univ Nimes, Chim Bioorgan Lab, Nimes, France; [Henriquet, C.] Inst Rech Cancerol Montpellier, IRCM, Montpellier, France; [Cristol, J-P; Michel, F.] Ctr Hosp Univ Lapeyronie, Biochim Lab, Montpellier, France; [Cristol, J-P; Michel, F.] Inst Univ Rech Clin, UMR Prevent Malnutr & Pathol Associees 204, Montpellier, France; [Carbonneau, M-A] Inst Univ Rech Clin, UMR NUTRIPASS 204, Montpellier, France; [Casas, F.] INRA, UMR 0866, F-34060 Montpellier, France; [Fajas, L.] Ctr Hosp Reg Univ Montpellier, Montpellier, France; [Fajas, L.] Univ Lausanne, Dept Physiol, Lausanne, Switzerland	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Universite de Montpellier; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); Ecole nationale superieure de chimie de Montpellier; Universite de Montpellier; Universite de Nimes; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; UNICANCER; Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); Universite de Montpellier; CHU de Montpellier; Institut de Recherche pour le Developpement (IRD); Universite de Montpellier; Institut de Recherche pour le Developpement (IRD); Universite de Montpellier; INRAE; Universite de Montpellier; CHU de Montpellier; University of Lausanne	Fajas, L (corresponding author), CNRS, IGMM, Inst Genet Mol Montpellier, 1919 Route Mende, F-34293 Montpellier, France.	lluis.fajas@unil.ch	Coll, Lluis Fajas/C-8567-2014; BENFODDA, Zohra/P-4355-2017	BENFODDA, Zohra/0000-0001-7574-4977; Fajas, Lluis/0000-0002-1283-9503; Francois, Casas/0000-0002-5535-8195	Ligue Contre le Cancer; Agence Nationale de la Recherche (ANR); Institut National du Cancer (INCA)	Ligue Contre le Cancer(Ligue nationale contre le cancer); Agence Nationale de la Recherche (ANR)(French National Research Agency (ANR)); Institut National du Cancer (INCA)(Institut National du Cancer (INCA) France)	Members of Fajas' lab are acknowledged for support and discussions. This work was supported by grants from Ligue Contre le Cancer, Agence Nationale de la Recherche (ANR) and Institut National du Cancer (INCA).	Brusselmans K, 2005, CANCER RES, V65, P6719, DOI 10.1158/0008-5472.CAN-05-0571; Brusselmans K, 2005, J BIOL CHEM, V280, P5636, DOI 10.1074/jbc.M408177200; Eid AA, 2010, J BIOL CHEM, V285, P37503, DOI 10.1074/jbc.M110.136796; Fogarty S, 2010, BBA-PROTEINS PROTEOM, V1804, P581, DOI 10.1016/j.bbapap.2009.09.012; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fritz V, 2010, ONCOGENE, V29, P4369, DOI 10.1038/onc.2010.182; Fritz V, 2010, MOL CANCER THER, V9, P1740, DOI 10.1158/1535-7163.MCT-09-1064; GEER BW, 1979, BIOCHEM GENET, V17, P867, DOI 10.1007/BF00504309; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Kato K, 2002, ONCOGENE, V21, P6082, DOI 10.1038/sj.onc.1205737; Korczynska J, 2004, METABOLISM, V53, P1060, DOI 10.1016/j.metabol.2004.02.015; KUHAJDA FP, 1994, P NATL ACAD SCI USA, V91, P6379, DOI 10.1073/pnas.91.14.6379; Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X; Menendez JA, 2004, INT J ONCOL, V24, P1369; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Pizer ES, 2000, CANCER RES, V60, P213; Sarruf DA, 2005, MOL CELL BIOL, V25, P9985, DOI 10.1128/MCB.25.22.9985-9995.2005; Stelmanska E, 2004, ACTA BIOCHIM POL, V51, P805; Swinnen JV, 2006, CURR OPIN CLIN NUTR, V9, P358, DOI 10.1097/01.mco.0000232894.28674.30; Thupari JN, 2001, BIOCHEM BIOPH RES CO, V285, P217, DOI 10.1006/bbrc.2001.5146; Viollet B, 2010, CRIT REV BIOCHEM MOL, V45, P276, DOI 10.3109/10409238.2010.488215; Zhang J, 2008, MOL CARCINOGEN, V47, P974, DOI 10.1002/mc.20450	22	32	32	2	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2013	32	42					5101	5110		10.1038/onc.2012.523	http://dx.doi.org/10.1038/onc.2012.523			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238IB	23208508	Green Published, hybrid			2022-12-28	WOS:000325937900011
J	Russo, N; Wang, X; Liu, M; Banerjee, R; Goto, M; Scanlon, C; Metwally, T; Inglehart, RC; Tsodikov, A; Duffy, S; Van Tubergen, E; Bradford, C; Carey, T; Wolf, G; Chinnaiyan, AM; D'Silva, NJ				Russo, N.; Wang, X.; Liu, M.; Banerjee, R.; Goto, M.; Scanlon, C.; Metwally, T.; Inglehart, R. C.; Tsodikov, A.; Duffy, S.; Van Tubergen, E.; Bradford, C.; Carey, T.; Wolf, G.; Chinnaiyan, A. M.; D'Silva, N. J.			A novel approach to biomarker discovery in head and neck cancer using an autoantibody signature	ONCOGENE			English	Article						L23; proliferation; tumor antigen	HUMORAL IMMUNE-RESPONSE; SQUAMOUS-CELL CARCINOMA; MOLECULAR-BIOLOGY; P53; IDENTIFICATION; PROTEINS; ANTIGENS; GENES; UBIQUITINATION; IMMUNOTHERAPY	Despite the dismal prognosis for patients with squamous cell carcinoma of the head and neck (SCCHN), there have been no novel treatments in over 40 years. Identification of novel tumor antigens in SCCHN will facilitate the identification of potential novel treatment targets. Tumor antigens are proteins selectively expressed by tumor cells and recognized by the host immune system. Phage-displayed tumor antigens were enriched by biopanning with normal and then SCCHN-specific serum. Ninety-six phage clones were sequenced for identification, and 21 clones were validated using Luminex. One of these proteins, L23, a novel tumor antigen in SCCHN, was validated as an oncogene. L23 is upregulated in SCCHN compared with normal keratinocytes. Knockdown of L23 inhibited proliferation, invasion and cell survival. Overexpression of L23 had the reverse effect. Overexpression of L23 in non malignant cells led to transformation. Injection of SCCHN cells with knockdown of L23 in mice, induced tumors that were significantly smaller than control tumors. In conclusion, the immunomic screen yielded a panel of antigens specific to SCCHN; one of these proteins, L23, is a novel oncogene in SCCHN.	[Russo, N.; Liu, M.; Banerjee, R.; Goto, M.; Scanlon, C.; Metwally, T.; Inglehart, R. C.; Van Tubergen, E.; D'Silva, N. J.] Univ Michigan, Sch Dent, Dept Periodont & Oral Med, Ann Arbor, MI 48109 USA; [Wang, X.; Chinnaiyan, A. M.; D'Silva, N. J.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Wang, X.; Chinnaiyan, A. M.; D'Silva, N. J.] Univ Michigan, Michigan Ctr Translat Pathol, Ann Arbor, MI 48109 USA; [Tsodikov, A.] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA; [Duffy, S.] Univ Michigan, Sch Nursing, Sch Med, Ann Arbor, MI 48109 USA; [Bradford, C.; Carey, T.; Wolf, G.] Univ Michigan, Dept Otolaryngol, Ann Arbor, MI 48109 USA; [Chinnaiyan, A. M.] Univ Michigan, Dept Urol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	D'Silva, NJ (corresponding author), Univ Michigan, Sch Dent, Dept Periodont & Oral Med, 1011N Univ Ave,Room 5217, Ann Arbor, MI 48109 USA.	njdsilva@umich.edu	D'Silva, Nisha J/B-4734-2013	Carey, Thomas/0000-0002-5202-7518; D'Silva, Nisha/0000-0001-7030-3187	NIDCR [DE017977, DE019513]; MICHR CTSA [UL1RR024986]; NCI SPORE [P50 CA97248]; National Institutes of Health through the University of Michigan's Cancer Center Support Grant [5 P30 CA46592]; NATIONAL CANCER INSTITUTE [P50CA097248, P30CA046592] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024986] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [K02DE019513] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE018512, R21DE017977] Funding Source: NIH RePORTER	NIDCR(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); MICHR CTSA; NCI SPORE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institutes of Health through the University of Michigan's Cancer Center Support Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	The authors would like to thank Kenneth Rieger for his artistic assistance with illustrations. This work was supported by NIDCR DE017977, DE019513, MICHR CTSA UL1RR024986, Research Development award from NCI SPORE grant P50 CA97248 (NJD). This research was made possible, in part, by the use of the Cancer Center Flow Cytometry Core which was supported (in part) by the National Institutes of Health through the University of Michigan's Cancer Center Support Grant (5 P30 CA46592).	Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923; Banerjee R, 2011, ONCOGENE, V30, P4339, DOI 10.1038/onc.2011.141; Beck-Engeser GB, 2001, J EXP MED, V194, P285, DOI 10.1084/jem.194.3.285; Bigler LR, 2002, J ORAL PATHOL MED, V31, P421, DOI 10.1034/j.1600-0714.2002.00123.x; Bonnycastle LLC, 1996, J MOL BIOL, V258, P747, DOI 10.1006/jmbi.1996.0284; Brakenhoff RH, 2011, SCIENCE, V333, P1102, DOI 10.1126/science.1210986; Bsoul SA, 2005, J CONT DENT PRACT, V6, P1, DOI DOI 10.5005/JCDP-6-4-1; Chen GA, 2007, CANCER RES, V67, P3461, DOI 10.1158/0008-5472.CAN-06-4475; Chen YT, 1998, P NATL ACAD SCI USA, V95, P6919, DOI 10.1073/pnas.95.12.6919; Chen YT, 1997, P NATL ACAD SCI USA, V94, P1914, DOI 10.1073/pnas.94.5.1914; Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200; Dai MS, 2004, MOL CELL BIOL, V24, P7654, DOI 10.1128/MCB.24.17.7654-7668.2004; Dai MS, 2006, J BIOL CHEM, V281, P24304, DOI 10.1074/jbc.M602596200; DYBWAD A, 1993, EUR J IMMUNOL, V23, P3189, DOI 10.1002/eji.1830231222; Ferris RL, 2010, J CLIN ONCOL, V28, P4390, DOI 10.1200/JCO.2009.27.6360; Goto M, 2010, CLIN CANCER RES, V16, P65, DOI 10.1158/1078-0432.CCR-09-1122; GRIFFITHS AD, 1993, EMBO J, V12, P725, DOI 10.1002/j.1460-2075.1993.tb05706.x; Jemal A, 2011, CA-CANCER J CLIN, V61, P133, DOI [10.3322/caac.20105, 10.3322/caac.20073]; Jin A, 2004, MOL CELL BIOL, V24, P7669, DOI 10.1128/MCB.24.17.7669-7680.2004; Koga M, 2003, TISSUE ANTIGENS, V61, P136, DOI 10.1046/j.0001-2815.2002.00009.x; Laheru DA, 2005, MOL CANCER THER, V4, P1645, DOI 10.1158/1535-7163.MCT-05-0151; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Leethanakul C, 2000, ORAL ONCOL, V36, P474, DOI 10.1016/S1368-8375(00)00039-7; Li G, 2005, CURR PHARM DESIGN, V11, P3501, DOI 10.2174/138161205774414583; Liu Fangli, 2007, Journal of Genetics and Genomics, V34, P189, DOI 10.1016/S1673-8527(07)60020-4; Matsutake T, 2001, P NATL ACAD SCI USA, V98, P3992, DOI 10.1073/pnas.071523398; Mitra RS, 2008, CANCER RES, V68, P3959, DOI 10.1158/0008-5472.CAN-07-2755; Mitra RS, 2003, ONCOGENE, V22, P6243, DOI 10.1038/sj.onc.1206534; MONACH PA, 1995, IMMUNITY, V2, P45, DOI 10.1016/1074-7613(95)90078-0; Nemeth Z, 2005, NEOPLASMA, V52, P95; Neville B. W., 2002, ORAL MAXILLOFACIAL P, P337; Patel V, 2008, CLIN CANCER RES, V14, P1002, DOI 10.1158/1078-0432.CCR-07-1497; Philip M, 2010, IMMUNOLOGY, V130, P494, DOI 10.1111/j.1365-2567.2010.03258.x; SAHIN U, 1995, P NATL ACAD SCI USA, V92, P11810, DOI 10.1073/pnas.92.25.11810; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; Shi YQ, 2004, EXP CELL RES, V296, P337, DOI 10.1016/j.yexcr.2004.02.009; Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121; Stockert E, 1998, J EXP MED, V187, P1349, DOI 10.1084/jem.187.8.1349; Stransky N, 2011, SCIENCE, V333, P1157, DOI 10.1126/science.1208130; Wang XJ, 2005, NEW ENGL J MED, V353, P1224, DOI 10.1056/NEJMoa051931; Wanzel M, 2008, NAT CELL BIOL, V10, P1051, DOI 10.1038/ncb1764; Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024; Zhang ZC, 2006, AM J PATHOL, V168, P585, DOI 10.2353/ajpath.2006.050132	43	12	12	0	13	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2013	32	42					5026	5037		10.1038/onc.2012.532	http://dx.doi.org/10.1038/onc.2012.532			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238IB	23160375	Green Accepted			2022-12-28	WOS:000325937900004
J	Shabbeer, S; Omer, D; Berneman, D; Weitzman, O; Alpaugh, A; Pietraszkiewicz, A; Metsuyanim, S; Shainskaya, A; Papa, MZ; Yarden, RI				Shabbeer, S.; Omer, D.; Berneman, D.; Weitzman, O.; Alpaugh, A.; Pietraszkiewicz, A.; Metsuyanim, S.; Shainskaya, A.; Papa, M. Z.; Yarden, R. I.			BRCA1 targets G2/M cell cycle proteins for ubiquitination and proteasomal degradation	ONCOGENE			English	Article						BRCA1; cyclin B; Cdc25; ubiquitination; proteasome; G2/M cell cycle checkpoint	E3 LIGASE ACTIVITY; KEN-BOX; BINDING; PHOSPHORYLATION; CHECKPOINT; RING; COMPLEX; DOMAIN; CHK1; B1	The BRCA1 tumor suppressor protein heterodimerizes with its partner protein, BARD1, via the RING domain present in both proteins. The heterodimer contains an E3 ubiquitin ligase activity and participates in multiple cellular functions such as cell cycle control, DNA repair and regulation of gene transcription, collectively aimed at maintaining genomic stability and tumor suppression. Yet, the precise role of BRCA1 E3 ligase in these cellular functions is poorly understood. We present data showing that BRCA1 ubiquitinates G2/M cell cycle proteins, cyclin B and Cdc25C, leading to their accelerated degradation via a mechanism that is independent of APC/C. BRCA1-dependent degradation of cyclin B and Cdc25C is reversed by proteasome inhibitors and is enhanced following DNA damage, which may represent a possible mechanism to prevent cyclin B and Cdc25C accumulation, a requirement for mitotic entry. Our data provide mechanistic insight into how BRCA1 E3 ligase activity regulates the G2/M cell cycle checkpoint and, thus, contributes to maintenance of genomic stability.	[Shabbeer, S.; Alpaugh, A.; Pietraszkiewicz, A.; Yarden, R. I.] Georgetown Univ, Med Ctr, Dept Human Sci, SNHS, Washington, DC 20057 USA; [Shabbeer, S.; Yarden, R. I.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20057 USA; [Omer, D.; Berneman, D.; Weitzman, O.; Metsuyanim, S.; Papa, M. Z.; Yarden, R. I.] Chaim Sheba Med Ctr, Dept Surg Oncol, Lab Genom Applicat, IL-52621 Tel Hashomer, Israel; [Shainskaya, A.] Weizmann Inst Sci, Laraine & Alan A Fischer Lab Biol Mass Spectromet, IL-76100 Rehovot, Israel	Georgetown University; Georgetown University; Chaim Sheba Medical Center; Weizmann Institute of Science	Yarden, RI (corresponding author), Georgetown Univ, Med Ctr, Dept Human Sci, SNHS, St Marys Hall Rm 260,3700 Reservoir Rd NW, Washington, DC 20057 USA.	riy2@georgetown.edu		Pietraszkiewicz, Alexandra/0000-0002-9982-6261	Israel Cancer Research Fund; Health Ministry; Israeli Cancer Association; Georgetown University, SNHS; NATIONAL CANCER INSTITUTE [P30CA051008] Funding Source: NIH RePORTER	Israel Cancer Research Fund; Health Ministry; Israeli Cancer Association; Georgetown University, SNHS; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs B Henderson, J Pines, R Agami, E Rosen and M Brandeis for providing plasmids and Dr L Brody for reagents. We thank the microscopy unit in Bar-Ilan University for assistance with immunofluorescence studies and Dr I Goldstein and the flow cytometry unit at the Sheba medical center for assistance with fluorescence-activated cell sorting analysis. We thank Allison Hall for technical assistance. We thank Drs Eliot Rosen, Claire Pollack, Michael Brandeis and Gad Lavie for stimulating discussions and critical reading of the manuscript. This study was supported by a Research Career Development Award from the Israel Cancer Research Fund (to RIY) and by the funding from the Health Ministry (to RIY and MZP), the Israeli Cancer Association (RIY) and funds from Georgetown University, SNHS to RIY.	Acquaviva C, 2006, J CELL SCI, V119, P2401, DOI 10.1242/jcs.02937; Aprelikova O, 2001, J BIOL CHEM, V276, P25647, DOI 10.1074/jbc.C100265200; Au WWY, 2005, J BIOL CHEM, V280, P6993, DOI 10.1074/jbc.M408879200; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; Brodie S G, 2001, Trends Genet, V17, pS18, DOI 10.1016/S0168-9525(01)02451-9; Calvo V, 2011, CANCER RES, V71, P3422, DOI 10.1158/0008-5472.CAN-10-3670; Chen F, 2002, P NATL ACAD SCI USA, V99, P1990, DOI 10.1073/pnas.032428899; Christensen DE, 2007, NAT STRUCT MOL BIOL, V14, P941, DOI 10.1038/nsmb1295; Eakin CM, 2007, P NATL ACAD SCI USA, V104, P5794, DOI 10.1073/pnas.0610887104; Hershko A, 1999, PHILOS T R SOC B, V354, P1571, DOI 10.1098/rstb.1999.0500; Homer HA, 2005, REPRODUCTION, V130, P829, DOI 10.1530/rep.1.00856; Horwitz AA, 2007, P NATL ACAD SCI USA, V104, P6614, DOI 10.1073/pnas.0610481104; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Jin P, 1998, J CELL BIOL, V141, P875, DOI 10.1083/jcb.141.4.875; Kim H, 2007, NAT STRUCT MOL BIOL, V14, P710, DOI 10.1038/nsmb1277; Kirkpatrick DS, 2006, NAT CELL BIOL, V8, P700, DOI 10.1038/ncb1436; Lim KL, 2005, J NEUROSCI, V25, P2002, DOI 10.1523/JNEUROSCI.4474-04.2005; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Ma YX, 2010, MOL ENDOCRINOL, V24, P76, DOI 10.1210/me.2009-0218; Mallery DL, 2002, EMBO J, V21, P6755, DOI 10.1093/emboj/cdf691; Morris JR, 2009, NATURE, V462, P886, DOI 10.1038/nature08593; Ohta T, 2011, FEBS LETT, V585, P2836, DOI 10.1016/j.febslet.2011.05.005; Palacios J, 2005, BREAST CANCER RES TR, V90, P5, DOI 10.1007/s10549-004-1536-0; Pfleger CM, 2000, GENE DEV, V14, P655; Poole AJ, 2006, SCIENCE, V314, P1467, DOI 10.1126/science.1130471; Reid LJ, 2008, P NATL ACAD SCI USA, V105, P20876, DOI 10.1073/pnas.0811203106; Ruffner H, 2001, P NATL ACAD SCI USA, V98, P5134, DOI 10.1073/pnas.081068398; Sato K, 2004, J BIOL CHEM, V279, P30919, DOI 10.1074/jbc.C400169200; Sato K, 2012, CURR BIOL, V22, P1659, DOI 10.1016/j.cub.2012.07.034; Shakya R, 2011, SCIENCE, V334, P525, DOI 10.1126/science.1209909; Sobhian B, 2007, SCIENCE, V316, P1198, DOI 10.1126/science.1139516; Starita LM, 2004, MOL CELL BIOL, V24, P8457, DOI 10.1128/MCB.24.19.8457-8466.2004; Starita LM, 2005, J BIOL CHEM, V280, P24498, DOI 10.1074/jbc.M414020200; Stegmeier F, 2007, NATURE, V446, P876, DOI 10.1038/nature05694; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Wang B, 2007, SCIENCE, V316, P1194, DOI 10.1126/science.1139476; Wang RH, 2004, P NATL ACAD SCI USA, V101, P17108, DOI 10.1073/pnas.0407585101; Wu WW, 2008, CELL DIV, V3, DOI 10.1186/1747-1028-3-1; Wu WW, 2007, CANCER RES, V67, P951, DOI 10.1158/0008-5472.CAN-06-3187; Wu-Baer F, 2003, J BIOL CHEM, V278, P34743, DOI 10.1074/jbc.C300249200; Wu-Baer F, 2010, MOL CELL BIOL, V30, P2787, DOI 10.1128/MCB.01056-09; Xia Y, 2003, J BIOL CHEM, V278, P5255, DOI 10.1074/jbc.M204591200; Xu B, 2002, CANCER RES, V62, P4588; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Yan Y, 2005, ONCOGENE, V24, P3285, DOI 10.1038/sj.onc.1208492; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yarden RI, 2002, NAT GENET, V30, P285, DOI 10.1038/ng837; Yarden RI, 2006, MOL CANCER THER, V5, P1396, DOI 10.1158/1535-7163.MCT-05-0471; Yarden RI, 2012, INT J BIOCHEM CELL B, V44, P1761, DOI 10.1016/j.biocel.2012.06.026; Yu XC, 2003, SCIENCE, V302, P639, DOI 10.1126/science.1088753; Yu XC, 2004, MOL CELL BIOL, V24, P9478, DOI 10.1128/MCB.24.21.9478-9486.2004; Yu XC, 2006, GENE DEV, V20, P1721, DOI 10.1101/gad.1431006; Zhu Q, 2011, NATURE, V477, P179, DOI 10.1038/nature10371	53	43	44	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2013	32	42					5005	5016		10.1038/onc.2012.522	http://dx.doi.org/10.1038/onc.2012.522			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238IB	23246971	Green Accepted			2022-12-28	WOS:000325937900002
J	Arlt, A; Sebens, S; Krebs, S; Geismann, C; Grossmann, M; Kruse, ML; Schreiber, S; Schafer, H				Arlt, A.; Sebens, S.; Krebs, S.; Geismann, C.; Grossmann, M.; Kruse, M-L; Schreiber, S.; Schaefer, H.			Inhibition of the Nrf2 transcription factor by the alkaloid trigonelline renders pancreatic cancer cells more susceptible to apoptosis through decreased proteasomal gene expression and proteasome activity	ONCOGENE			English	Article						chemoresistance; oxidative stress; tumorigenesis; pancreas	COMPONENTS CHLOROGENIC ACID; SIGNALING PATHWAY; OXIDATIVE STRESS; DECAFFEINATED COFFEE; ADAPTIVE RESPONSE; CARCINOMA CELLS; KEAP1 MUTATIONS; ACTIVATION; SUBUNIT; CHEMORESISTANCE	Evidence accumulates that the transcription factor nuclear factor E2-related factor 2 (Nrf2) has an essential role in cancer development and chemoresistance, thus pointing to its potential as an anticancer target and undermining its suitability in chemoprevention. Through the induction of cytoprotective and proteasomal genes, Nrf2 confers apoptosis protection in tumor cells, and inhibiting Nrf2 would therefore be an efficient strategy in anticancer therapy. In the present study, pancreatic carcinoma cell lines (Panc1, Colo357 and MiaPaca2) and H6c7 pancreatic duct cells were analyzed for the Nrf2-inhibitory effect of the coffee alkaloid trigonelline (trig), as well as for its impact on Nrf2-dependent proteasome activity and resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and anticancer drug-induced apoptosis. Chemoresistant Panc1 and Colo357 cells exhibit high constitutive Nrf2 activity, whereas chemosensitive MiaPaca2 and H6c7 cells display little basal but strong tert-butylhydroquinone (tBHQ)-inducible Nrf2 activity and drug resistance. Trig efficiently decreased basal and tBHQ-induced Nrf2 activity in all cell lines, an effect relying on a reduced nuclear accumulation of the Nrf2 protein. Along with Nrf2 inhibition, trig blocked the Nrf2-dependent expression of proteasomal genes (for example, s5a/psmd4 and alpha 5/psma5) and reduced proteasome activity in all cell lines tested. These blocking effects were absent after treatment with Nrf2 siRNA, a condition in which proteasomal gene expression and proteasome activity were already decreased, whereas siRNA against the related transcription factor Nrf1 did not affect proteasome activity and the inhibitory effect of trig. Depending on both Nrf2 and proteasomal gene expression, the sensitivity of all cell lines to anticancer drugs and TRAIL-induced apoptosis was enhanced by trig. Moreover, greater antitumor responses toward anticancer drug treatment were observed in tumor-bearing mice when receiving trig. In conclusion, representing an efficient Nrf2 inhibitor capable of blocking Nrf2-dependent proteasome activity and thereby apoptosis protection in pancreatic cancer cells, trig might be beneficial in improving anticancer therapy.	[Arlt, A.; Krebs, S.; Geismann, C.; Grossmann, M.; Kruse, M-L; Schreiber, S.; Schaefer, H.] UKSH, Lab Mol Gastroenterol & Hepatol, Dept Internal Med 1, Kiel, Germany; [Sebens, S.] Inst Expt Med, Inflammatory Carcinogenesis Res Grp, Kiel, Germany; [Schreiber, S.] UKSH, Inst Clin Mol Biol, Kiel, Germany	University of Kiel; Schleswig Holstein University Hospital; University of Kiel; Schleswig Holstein University Hospital	Schafer, H (corresponding author), Dept Internal Med I, Lab Mol Gastroenterol & Hepatol, Bldg 6,UKSH Campus Kiel,Schittenhelmstr 12, D-24105 Kiel, Germany.	hschaef@1med.uni-kiel.de	Schäfer, Heiner/C-1055-2011; Geismann, Claudia/AAX-8158-2021; Sebens, Susanne/C-1222-2010; Arlt, Alexander/G-7308-2019	Geismann, Claudia/0000-0003-0640-9256; Arlt, Alexander/0000-0002-6160-1059; Schafer, Heiner/0000-0001-6936-9090	German Research Society DFG [SCHA 677/9-1]; Sander Foundation [2010.076.1]; German Cluster of Excellence 'Inflammation-at-Interfaces'	German Research Society DFG(German Research Foundation (DFG)); Sander Foundation; German Cluster of Excellence 'Inflammation-at-Interfaces'	Technical assistance by Frauke Grohmann, Dagmar Leisner and Iris Bauer is acknowledged. The project was funded by the German Research Society DFG (SCHA 677/9-1), the Sander Foundation (2010.076.1) and the German Cluster of Excellence 'Inflammation-at-Interfaces'.	Adam J, 2011, CANCER CELL, V20, P524, DOI 10.1016/j.ccr.2011.09.006; Akhdar H, 2009, EUR J CANCER, V45, P2219, DOI 10.1016/j.ejca.2009.05.017; Arlt A, 2009, ONCOGENE, V28, P3983, DOI 10.1038/onc.2009.264; Arlt A, 2001, ONCOGENE, V20, P859, DOI 10.1038/sj.onc.1204168; Boettler U, 2011, J NUTR BIOCHEM, V22, P426, DOI 10.1016/j.jnutbio.2010.03.011; Chen L, 2005, CANCER RES, V65, P5599, DOI 10.1158/0008-5472.CAN-05-0201; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; Du ZX, 2011, J CLIN ENDOCR METAB, V96, pE763, DOI 10.1210/jc.2010-2642; Eades G, 2011, J BIOL CHEM, V286, P40725, DOI 10.1074/jbc.M111.275495; Elangovan M, 2010, BIOCHEM BIOPH RES CO, V396, P425, DOI 10.1016/j.bbrc.2010.04.108; Fritsche P, 2009, GUT, V58, P1399, DOI 10.1136/gut.2009.180711; Geismann C, 2011, INT J ONCOL, V38, P257, DOI 10.3892/ijo_00000846; Hayes JD, 2009, TRENDS BIOCHEM SCI, V34, P176, DOI 10.1016/j.tibs.2008.12.008; Hong YB, 2010, PANCREAS, V39, P463, DOI 10.1097/MPA.0b013e3181c31314; Hu XT, 2009, ONCOL REP, V22, P1247, DOI 10.3892/or_00000561; Hu Y, 2012, MOL BIOL REP, V39, P4743, DOI 10.1007/s11033-011-1266-4; Jiang T, 2010, CANCER RES, V70, P5486, DOI 10.1158/0008-5472.CAN-10-0713; Kannan S, 2006, CANCER RES, V66, P8421, DOI 10.1158/0008-5472.CAN-06-1181; Kapeta S, 2010, J BIOL CHEM, V285, P8171, DOI 10.1074/jbc.M109.031575; Kim J, 2010, MUTAT RES-FUND MOL M, V690, P12, DOI 10.1016/j.mrfmmm.2009.09.007; Kim SK, 2008, FREE RADICAL BIO MED, V45, P537, DOI 10.1016/j.freeradbiomed.2008.05.011; Kim TH, 2011, CANCER RES, V71, P2260, DOI 10.1158/0008-5472.CAN-10-3007; Kim YR, 2010, J PATHOL, V220, P446, DOI 10.1002/path.2653; Kinch L, 2011, CANCER CELL, V20, P418, DOI 10.1016/j.ccr.2011.10.005; Konstantinopoulos PA, 2011, CANCER RES, V71, P5081, DOI 10.1158/0008-5472.CAN-10-4668; Kwak MK, 2006, BIOCHEM BIOPH RES CO, V345, P1350, DOI 10.1016/j.bbrc.2006.05.043; Kwak MK, 2003, MOL CELL BIOL, V23, P8786, DOI 10.1128/MCB.23.23.8786-8794.2003; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; Kwak MK, 2002, MOL CELL BIOL, V22, P2883, DOI 10.1128/MCB.22.9.2883-2892.2002; Lau A, 2008, PHARMACOL RES, V58, P262, DOI 10.1016/j.phrs.2008.09.003; Lister A, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-37; Muerkoster S, 2005, CANCER RES, V65, P1316, DOI 10.1158/0008-5472.CAN-04-1626; Nguyen T, 2005, J BIOL CHEM, V280, P32485, DOI 10.1074/jbc.M503074200; Nguyen T, 2009, J BIOL CHEM, V284, P13291, DOI 10.1074/jbc.R900010200; Nioi P, 2007, BIOCHEM BIOPH RES CO, V362, P816, DOI 10.1016/j.bbrc.2007.08.051; Niture SK, 2009, J BIOL CHEM, V284, P13856, DOI 10.1074/jbc.M808084200; Olthof MR, 2011, NUTR METAB, V8, DOI 10.1186/1743-7075-8-10; Osburn WO, 2008, MUTAT RES-REV MUTAT, V659, P31, DOI 10.1016/j.mrrev.2007.11.006; Radhakrishnan SK, 2010, MOL CELL, V38, P17, DOI 10.1016/j.molcel.2010.02.029; Ren SR, 2000, ONCOGENE, V19, P1419, DOI 10.1038/sj.onc.1203462; Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006; Rho JH, 2008, J PROTEOME RES, V7, P2959, DOI 10.1021/pr8000892; Schaedler S, 2010, J BIOL CHEM, V285, P41074, DOI 10.1074/jbc.M110.145862; Sebens S, 2011, J BIOL CHEM, V286, P40911, DOI 10.1074/jbc.M111.274902; Shim GS, 2009, FREE RADICAL BIO MED, V47, P1619, DOI 10.1016/j.freeradbiomed.2009.09.006; Singh A, 2006, PLOS MED, V3, P1865, DOI 10.1371/journal.pmed.0030420; Singh A, 2010, ANTIOXID REDOX SIGN, V13, P1627, DOI 10.1089/ars.2010.3219; Singh S, 2010, FREE RADICAL RES, V44, P1267, DOI 10.3109/10715762.2010.507670; Solis LM, 2010, CLIN CANCER RES, V16, P3743, DOI 10.1158/1078-0432.CCR-09-3352; Stathis A, 2010, NAT REV CLIN ONCOL, V7, P163, DOI 10.1038/nrclinonc.2009.236; Steffen J, 2010, MOL CELL, V40, P147, DOI 10.1016/j.molcel.2010.09.012; Taguchi A, 2011, CANCER CELL, V20, P289, DOI 10.1016/j.ccr.2011.08.007; van Dijk AE, 2009, DIABETES CARE, V32, P1023, DOI 10.2337/dc09-0207; Wang R, 2008, BIOCHEM BIOPH RES CO, V373, P151, DOI 10.1016/j.bbrc.2008.06.004; Wang XJ, 2008, CARCINOGENESIS, V29, P1235, DOI 10.1093/carcin/bgn095; Wang XJ, 2007, P NATL ACAD SCI USA, V104, P19589, DOI 10.1073/pnas.0709483104; Xie YM, 2010, CANCER METAST REV, V29, P687, DOI 10.1007/s10555-010-9255-y; Zhang DD, 2010, ANTIOXID REDOX SIGN, V13, P1623, DOI 10.1089/ars.2010.3301; Zhou W, 2007, MOL CELL ENDOCRINOL, V278, P52, DOI 10.1016/j.mce.2007.08.011	59	207	212	5	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	2013	32	40					4825	4835		10.1038/onc.2012.493	http://dx.doi.org/10.1038/onc.2012.493			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229NW	23108405				2022-12-28	WOS:000325274700011
J	Porsch, H; Bernert, B; Mehic, M; Theocharis, AD; Heldin, CH; Heldin, P				Porsch, H.; Bernert, B.; Mehic, M.; Theocharis, A. D.; Heldin, C-H; Heldin, P.			Efficient TGF beta-induced epithelial-mesenchymal transition depends on hyaluronan synthase HAS2	ONCOGENE			English	Article						EMT; growth factors; TGF beta; hyaluronan synthase 2; migration	GROWTH-FACTOR-BETA; INTRACELLULAR HYALURONAN; CELL-PROLIFERATION; EXPRESSION; RECEPTOR; CLONING; TRAF6; FIBROBLASTS; SUPPRESSES; ACTIVATION	Epithelial-mesenchymal transition (EMT) is a developmental program, which can be adopted by cancer cells to increase their migration and ability to form metastases. Transforming growth factor beta (TGF beta) is a well-studied inducer of EMT. We demonstrate that TGF beta potently stimulates hyaluronan synthesis via upregulation of hyaluronan synthase 2 (HAS2) in NMuMG mammary epithelial cells. This stimulatory effect requires the kinase active type I TGF beta receptor and is dependent on Smad signaling and activation of the p38 mitogen-activated protein kinase. Knockdown of HAS2 inhibited the TGF beta-induced EMT by about 50%, as determined by the phase contrast microscopy and immunostaining using the EMT marker ZO-1. Furthermore, real-time PCR analysis of the EMT markers fibronectin, Snail1 and Zeb1 revealed decreased expressions upon HAS2 suppression, using specific small interfering RNA (siRNA) for HAS2. Removal of the extracellular hyaluronan by Streptomyces hyaluronidase or inhibiting the binding to its cell surface receptor CD44 by blocking antibodies, did not inhibit TGF beta-induced EMT. Interestingly, HAS2 suppression completely abolished the TGF beta-induced cell migration, whereas CD44 knockdown did not. These observations suggest that TGF beta-dependent HAS2 expression, but not extracellular hyaluronan, has an important regulatory role in TGF beta-induced EMT.	[Porsch, H.; Bernert, B.; Mehic, M.; Theocharis, A. D.; Heldin, C-H; Heldin, P.] Uppsala Univ, Biomed Ctr, Sci life Lab, Ludwig Inst Canc Res, SE-75124 Uppsala, Sweden	Ludwig Institute for Cancer Research; Uppsala University	Heldin, P (corresponding author), Uppsala Univ, Biomed Ctr, Sci life Lab, Ludwig Inst Canc Res, Box 595, SE-75124 Uppsala, Sweden.	Evi.Heldin@LICR.uu.se	theocharis, achilleas/F-6903-2010	Theocharis, Achilleas/0000-0001-8611-2297; Mehic, Merima/0000-0001-8249-5526	Swedish Cancer Society; Agnes and Mac Rudberg Foundation; Gurli and Edward Brunnberg Foundation; Mizutani Foundation for Glycoscience	Swedish Cancer Society(Swedish Cancer Society); Agnes and Mac Rudberg Foundation; Gurli and Edward Brunnberg Foundation; Mizutani Foundation for Glycoscience	This work was supported in part by grants from the Swedish Cancer Society, Agnes and Mac Rudberg Foundation, Gurli and Edward Brunnberg Foundation and Mizutani Foundation for Glycoscience. We thank Drs A Moustakas and L van der Heide (Ludwig Institute for Cancer Research, Uppsala, Sweden) for advice.	Anttila MA, 2000, CANCER RES, V60, P150; Auvinen P, 2000, AM J PATHOL, V156, P529, DOI 10.1016/S0002-9440(10)64757-8; Bakkers J, 2004, DEVELOPMENT, V131, P525, DOI 10.1242/dev.00954; Bernert B, 2011, J BIOL CHEM, V286, P42349, DOI 10.1074/jbc.M111.278598; Bhowmick NA, 2001, MOL BIOL CELL, V12, P27, DOI 10.1091/mbc.12.1.27; Boregowda Rajeev K, 2006, J Carcinog, V5, P2, DOI 10.1186/1477-3163-5-2; Brinck J, 1999, EXP CELL RES, V252, P342, DOI 10.1006/excr.1999.4645; Camenisch TD, 2000, J CLIN INVEST, V106, P349, DOI 10.1172/JCI10272; Camenisch TD, 2002, NAT MED, V8, P850, DOI 10.1038/nm742; Evanko SP, 2004, J HISTOCHEM CYTOCHEM, V52, P1525, DOI 10.1369/jhc.4A6356.2004; Evanko SP, 2001, INTRACELLULAR HYALUR; Gal A, 2008, ONCOGENE, V27, P1218, DOI 10.1038/sj.onc.1210741; Hascall VC, 2004, BBA-GEN SUBJECTS, V1673, P3, DOI 10.1016/j.bbagen.2004.02.013; HELDIN P, 1989, BIOCHEM J, V258, P919, DOI 10.1042/bj2580919; Heldin P, 1996, ONCOL REP, V3, P1011; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Itano N, 1996, J BIOL CHEM, V271, P9875, DOI 10.1074/jbc.271.17.9875; Jacobson A, 2000, BIOCHEM J, V348, P29, DOI 10.1042/0264-6021:3480029; Karousou E, 2010, J BIOL CHEM, V285, P23647, DOI 10.1074/jbc.M110.127050; Kowanetz M, 2004, MOL CELL BIOL, V24, P4241, DOI 10.1128/MCB.24.10.4241-4254.2004; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Li LL, 2007, BIOCHEM J, V404, P327, DOI 10.1042/BJ20061757; Li Y, 2001, BRIT J CANCER, V85, P600, DOI 10.1054/bjoc.2001.1922; Li YJ, 2000, AM J RESP CELL MOL, V23, P411, DOI 10.1165/ajrcmb.23.3.4102; Li YJ, 2007, INT J CANCER, V120, P2557, DOI 10.1002/ijc.22550; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Meran S, 2007, J BIOL CHEM, V282, P25687, DOI 10.1074/jbc.M700773200; Moustakas A, 2007, CANCER SCI, V98, P1512, DOI 10.1111/j.1349-7006.2007.00550.x; Moustakas A, 2009, DEVELOPMENT, V136, P3699, DOI 10.1242/dev.030338; Mu YB, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1332; Okuda H, 2012, CANCER RES, V72, P537, DOI 10.1158/0008-5472.CAN-11-1678; Olsson M, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001332; Sato N, 2004, CANCER RES, V64, P6950, DOI 10.1158/0008-5472.CAN-04-0677; Schiller M, 2010, J BIOL CHEM, V285, P409, DOI 10.1074/jbc.M109.038620; Shyjan AM, 1996, J BIOL CHEM, V271, P23395, DOI 10.1074/jbc.271.38.23395; Simpson RML, 2010, AM J PATHOL, V176, P1215, DOI 10.2353/ajpath.2010.090802; Sorrentino A, 2008, NAT CELL BIOL, V10, P1199, DOI 10.1038/ncb1780; Spicer AP, 1998, J BIOL CHEM, V273, P1923, DOI 10.1074/jbc.273.4.1923; Spicer AP, 1997, J BIOL CHEM, V272, P8957; Stuhlmeier KM, 2004, J BIOL CHEM, V279, P8753, DOI 10.1074/jbc.M303945200; Takahashi E, 2010, J BIOL CHEM, V285, P4060, DOI 10.1074/jbc.M109.056523; Takebe N, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2876; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tool BP, 2001, SEMIN CELL DEV BIOL, V12, P79, DOI 10.1006/scdb.2000.0244; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Toole BP, 2008, SEMIN CANCER BIOL, V18, P244, DOI 10.1016/j.semcancer.2008.03.009; Unger K, 2010, ENDOCR-RELAT CANCER, V17, P87, DOI 10.1677/ERC-09-0065; Usui T, 2000, INVEST OPHTH VIS SCI, V41, P3261; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wang AM, 2011, FEBS J, V278, P1412, DOI 10.1111/j.1742-4658.2011.08069.x; Watanabe K, 1996, J BIOL CHEM, V271, P22945, DOI 10.1074/jbc.271.38.22945; Williams CM, 2008, CANCER RES, V68, P3185, DOI 10.1158/0008-5472.CAN-07-2673; Yamashita M, 2008, MOL CELL, V31, P918, DOI 10.1016/j.molcel.2008.09.002; Zoltan-Jones A, 2003, J BIOL CHEM, V278, P45801, DOI 10.1074/jbc.M308168200	55	98	102	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2013	32	37					4355	4365		10.1038/onc.2012.475	http://dx.doi.org/10.1038/onc.2012.475			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218AF	23108409	Green Published, hybrid			2022-12-28	WOS:000324404200004
J	Wiseman, DH; Greystoke, BF; Somervaille, TCP				Wiseman, D. H.; Greystoke, B. F.; Somervaille, T. C. P.			The variety of leukemic stem cells in myeloid malignancy	ONCOGENE			English	Review						AML; LSC; myeloid; leukemia; stem cell	ACUTE MYELOGENOUS LEUKEMIA; HEMATOPOIETIC STEM; CLONOGENIC CELLS; INITIATING CELLS; PROGENITOR CELLS; IN-VITRO; XENOTRANSPLANTATION MODEL; CLONAL REMISSIONS; SELF-RENEWAL; BCR-ABL	Human acute myeloid leukemias (AMLs) are sustained by leukemic stem cells (LSCs) that generate through aberrant differentiation the blast cells that make up the bulk of the malignant clone. LSCs were first identified as rare cells with an immunophenotype shared with normal hematopoietic stem cells (HSCs). However, refinements of xenotransplantation assays, alternative methods of quantitation and syngeneic murine models have all led to an appreciation that LSCs display marked variability in frequency, immunophenotype and differentiation potential, both between and even within leukemias. Insights from next-generation sequencing efforts have dramatically extended understanding of the mutational landscape and clonal organization of AML and have added an additional layer of complexity to the biology of LSCs: a requirement to consider the effect of the various recurrently occurring genetic lesions in AML on the initiation and maintenance of leukemic subclones. Despite these advances, cure rates in AML remain substantially unchanged in recent years. A renewed focus on the biological properties of chemotherapy-resistant LSCs, a cellular entity of prime clinical importance, will be required to develop additional therapeutic strategies to enhance patient outcomes.	[Wiseman, D. H.; Greystoke, B. F.; Somervaille, T. C. P.] Univ Manchester, Paterson Inst Canc Res, Canc Res UK Leukaemia Biol Lab, Manchester, Lancs, England	Paterson Institute for Cancer Research; University of Manchester	Somervaille, TCP (corresponding author), Paterson Inst Canc Res, Canc Res UK Leukaemia Biol Lab, Wilmslow Rd, Manchester M20 4BX, Lancs, England.	tsomervaille@picr.man.ac.uk	Wiseman, Daniel/AAG-9914-2020	Wiseman, Daniel/0000-0003-0715-1402; Somervaille, Tim/0000-0002-9188-4379	Leukaemia and Lymphoma Research Clinical Training Fellowships; Cancer Research UK [C5759/A12328]; Cancer Research UK [19280] Funding Source: researchfish	Leukaemia and Lymphoma Research Clinical Training Fellowships; Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK)	We apologize to the many clinicians and scientists who have contributed to this field whose work we were unable to cite because of space constraints. DW and BG are recipients of Leukaemia and Lymphoma Research Clinical Training Fellowships. TS is supported by Cancer Research UK grant number C5759/A12328.	Ailles LE, 1999, BLOOD, V94, P1761, DOI 10.1182/blood.V94.5.1761.417k23_1761_1772; Anderson K, 2011, NATURE, V469, P356, DOI 10.1038/nature09650; Beekman R, 2012, BLOOD, V119, P5071, DOI 10.1182/blood-2012-01-406116; Bereshchenko O, 2009, CANCER CELL, V16, P390, DOI 10.1016/j.ccr.2009.09.036; BLACKSTOCK AM, 1974, LANCET, V2, P1178; Blair A, 1997, BLOOD, V89, P3104, DOI 10.1182/blood.V89.9.3104; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; BUICK RN, 1979, BLOOD, V54, P95; Burnett A, 2011, J CLIN ONCOL, V29, P487, DOI 10.1200/JCO.2010.30.1820; Burnett AK, 2011, J CLIN ONCOL, V29, P369, DOI 10.1200/JCO.2010.31.4310; Busque L, 2012, NAT GENET, V44, P1179, DOI 10.1038/ng.2413; Castaigne S, 2012, LANCET, V379, P1508, DOI 10.1016/S0140-6736(12)60485-1; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; CROWTHER D, 1970, BMJ-BRIT MED J, V4, P513, DOI 10.1136/bmj.4.5734.513; Delhommeau F, 2009, NEW ENGL J MED, V360, P2289, DOI 10.1056/NEJMoa0810069; DICKE KA, 1976, NATURE, V259, P129, DOI 10.1038/259129a0; Ding L, 2012, NATURE, V481, P506, DOI 10.1038/nature10738; Eppert K, 2011, NAT MED, V17, P1086, DOI 10.1038/nm.2415; FEARON ER, 1986, NEW ENGL J MED, V315, P15, DOI 10.1056/NEJM198607033150103; FIALKOW PJ, 1991, BLOOD, V77, P1415; FIALKOW PJ, 1977, AM J MED, V63, P125, DOI 10.1016/0002-9343(77)90124-3; GALE RE, 1993, LANCET, V341, P138, DOI 10.1016/0140-6736(93)90004-Z; Gibbs KD, 2012, CELL STEM CELL, V10, P210, DOI 10.1016/j.stem.2012.01.004; Gilliland DG, 2002, BLOOD, V100, P1532, DOI 10.1182/blood-2002-02-0492; Goardon N, 2011, CANCER CELL, V19, P138, DOI 10.1016/j.ccr.2010.12.012; GRIFFIN JD, 1986, BLOOD, V68, P1185; Guan YH, 2003, BLOOD, V101, P3142, DOI 10.1182/blood-2002-10-3062; Guzman ML, 2001, BLOOD, V98, P2301, DOI 10.1182/blood.V98.8.2301; Harris WJ, 2012, CANCER CELL, V21, P473, DOI 10.1016/j.ccr.2012.03.014; Hosen N, 2007, P NATL ACAD SCI USA, V104, P11008, DOI 10.1073/pnas.0704271104; Huntly BJP, 2004, CANCER CELL, V6, P587, DOI 10.1016/j.ccr.2004.10.015; Ishikawa F, 2007, NAT BIOTECHNOL, V25, P1315, DOI 10.1038/nbt1350; Jamieson CHM, 2004, NEW ENGL J MED, V351, P657, DOI 10.1056/NEJMoa040258; JAN M, 2012, SCI TRANSL MED, V4; JANSSEN JWG, 1989, BLOOD, V73, P248; JINNAI I, 1995, LEUKEMIA, V9, P1756; JONAS D, 1992, BLOOD, V79, P1017; JOWITT SN, 1993, BRIT J HAEMATOL, V85, P698, DOI 10.1111/j.1365-2141.1993.tb03211.x; KEINANEN M, 1988, NEW ENGL J MED, V318, P1153, DOI 10.1056/NEJM198805053181803; Kelly PN, 2007, SCIENCE, V317, P337, DOI 10.1126/science.1142596; Kiel MJ, 2005, CELL, V121, P1109, DOI 10.1016/j.cell.2005.05.026; Kikushige Y, 2010, CELL STEM CELL, V7, P708, DOI 10.1016/j.stem.2010.11.014; Kottaridis PD, 2002, BLOOD, V100, P2393, DOI 10.1182/blood-2002-02-0420; Krivtsov AV, 2006, NATURE, V442, P818, DOI 10.1038/nature04980; LANGE B, 1984, BLOOD, V64, P693; Ley TJ, 2008, NATURE, V456, P66, DOI 10.1038/nature07485; Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689; Ley TJ, 2010, NEW ENGL J MED, V363, P2424, DOI 10.1056/NEJMoa1005143; LOCOCO F, 1993, BLOOD, V82, P606; Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407; Majeti R, 2009, CELL, V138, P286, DOI 10.1016/j.cell.2009.05.045; Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840; Martelli MP, 2010, BLOOD, V116, P3907, DOI 10.1182/blood-2009-08-238899; MARTIN PJ, 1980, NATURE, V287, P49, DOI 10.1038/287049a0; Meyer JA, 2013, NAT GENET, V45, P290, DOI 10.1038/ng.2558; MINDEN MD, 1978, BLOOD, V52, P592; Miyamoto T, 2000, P NATL ACAD SCI USA, V97, P7521, DOI 10.1073/pnas.97.13.7521; Mullighan CG, 2008, SCIENCE, V322, P1377, DOI 10.1126/science.1164266; Nakano Y, 1999, BRIT J HAEMATOL, V104, P659, DOI 10.1046/j.1365-2141.1999.01256.x; Notta F, 2011, SCIENCE, V333, P218, DOI 10.1126/science.1201219; Notta F, 2011, NATURE, V469, P362, DOI 10.1038/nature09733; ORLIC D, 1994, BLOOD, V84, P3991, DOI 10.1182/blood.V84.12.3991.bloodjournal84123991; Osawa M, 1996, SCIENCE, V273, P242, DOI 10.1126/science.273.5272.242; Passegue E, 2003, P NATL ACAD SCI USA, V100, P11842, DOI 10.1073/pnas.2034201100; Patel S, 2012, LEUKEMIA, V26, P2432, DOI 10.1038/leu.2012.154; Pearce DJ, 2006, BLOOD, V107, P1166, DOI 10.1182/blood-2005-06-2325; SABBATH KD, 1985, J CLIN INVEST, V75, P746, DOI 10.1172/JCI111756; Saito Y, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000349; Sanchez PV, 2009, LEUKEMIA, V23, P2109, DOI 10.1038/leu.2009.143; Sarry JE, 2011, J CLIN INVEST, V121, P384, DOI 10.1172/JCI41495; Shih AH, 2012, NAT REV CANCER, V12, P599, DOI 10.1038/nrc3343; Shultz LD, 2005, J IMMUNOL, V174, P6477, DOI 10.4049/jimmunol.174.10.6477; Somervaille TCP, 2006, CANCER CELL, V10, P257, DOI 10.1016/j.ccr.2006.08.020; Somervaille TCP, 2009, CELL STEM CELL, V4, P129, DOI 10.1016/j.stem.2008.11.015; SPANGRUDE GJ, 1991, BLOOD, V78, P1395; SPITZER G, 1976, BLOOD, V48, P795; SWART K, 1982, BLOOD, V59, P816; Taussig DC, 2008, BLOOD, V112, P568, DOI 10.1182/blood-2007-10-118331; Taussig DC, 2010, BLOOD, V115, P1976, DOI 10.1182/blood-2009-02-206565; Taussig DC, 2005, BLOOD, V106, P4086, DOI 10.1182/blood-2005-03-1072; Terpstra W, 1996, BLOOD, V88, P1944, DOI 10.1182/blood.V88.6.1944.bloodjournal8861944; Terpstra W, 1996, BLOOD, V87, P2187, DOI 10.1182/blood.V87.6.2187.bloodjournal8762187; Tzoneva G, 2013, NAT MED, V19, P368, DOI 10.1038/nm.3078; Vago L, 2009, NEW ENGL J MED, V361, P478, DOI 10.1056/NEJMoa0811036; van Rhenen A, 2007, BLOOD, V110, P2659, DOI 10.1182/blood-2007-03-083048; Vargaftig J, 2012, LEUKEMIA, V26, P858, DOI 10.1038/leu.2011.250; Walter MJ, 2012, NEW ENGL J MED, V366, P1090, DOI 10.1056/NEJMoa1106968; WEIDEN PL, 1981, NEW ENGL J MED, V304, P1529, DOI 10.1056/NEJM198106183042507; Welch JS, 2012, CELL, V150, P264, DOI 10.1016/j.cell.2012.06.023; Wilhelm BT, 2011, BLOOD, V117, pE27, DOI 10.1182/blood-2010-07-293332; World Health Organization, 2008, CLASS TUM HAEM LYMPH; Wunderlich M, 2010, LEUKEMIA, V24, P1785, DOI 10.1038/leu.2010.158; Yan XJ, 2011, NAT GENET, V43, P309, DOI 10.1038/ng.788; Yilmaz OH, 2006, NATURE, V441, P475, DOI 10.1038/nature04703; Zuber J, 2009, GENE DEV, V23, P877, DOI 10.1101/gad.1771409	95	42	45	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2014	33	24					3091	3098		10.1038/onc.2013.269	http://dx.doi.org/10.1038/onc.2013.269			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK4QU	23831573				2022-12-28	WOS:000338410000002
J	Hu, C; Liu, D; Zhang, Y; Lou, G; Huang, G; Chen, B; Shen, X; Gao, M; Gong, W; Zhou, P; Dai, S; Zeng, Y; He, F				Hu, C.; Liu, D.; Zhang, Y.; Lou, G.; Huang, G.; Chen, B.; Shen, X.; Gao, M.; Gong, W.; Zhou, P.; Dai, S.; Zeng, Y.; He, F.			LXR alpha-mediated downregulation of FOXM1 suppresses the proliferation of hepatocellular carcinoma cells	ONCOGENE			English	Article						LXRs; FOXM1; cell proliferation; cell cycle; HCC	LIVER-X-RECEPTOR; FORKHEAD BOX M1B; PROSTATE-CANCER CELLS; TRANSCRIPTION FACTOR; BREAST-CANCER; NUCLEAR RECEPTORS; GENE-EXPRESSION; POOR-PROGNOSIS; TUMOR-GROWTH; TARGET GENE	Liver X receptors (LXRs), including LXR alpha and LXR beta isoforms, have important roles in the metabolic regulation of glucose, cholesterol and lipid. Moreover, activation of LXRs also represses the expression of cyclin D1 and cyclin B1, and thus suppresses the proliferation of multiple cancer cells, but the relevant mechanism is not well known. Forkhead box M1 ( FOXM1) is a proliferationspecific member of forkhead box family, which is highly expressed in proliferating normal cells and numerous cancer cells. FOXM1 directly activates transcription of cyclin D1 and cyclin B1, resulting in the enhancement of cell cycle progression and cell proliferation. However, it is unclear whether LXRs are involved in the regulation of FOXM1. In this study, we demonstrated that specific LXRs agonists downregulated expression of FOXM1, cyclin D1 and cyclin B1 in hepatocellular carcinoma ( HCC) cells, which led to cell cycle and cell proliferation arrest. Knockdown of FOXM1 significantly alleviated LXRs activation-mediated cell cycle arrest and cell growth suppression. Reporter assays showed that the activation of LXRs significantly reduced the transcriptional activity of FOXM1 promoter. Electrophoretic mobility shift assay and chromatin immunoprecipitation assays demonstrated that LXRa but not LXRb could bind to an inverted repeat IR2(-52CCGTCAcgTGACCT- 39) in the promoter region of FOXM1 gene. Moreover, the xenograft tumor growth and the corresponding FOXM1 expression in nude mice were dramatically repressed by LXRs agonists. Taken together, we conclude that LXRa but not LXRb functions as a transcriptional repressor for FOXM1 expression. The pathway ` LXRa- FOXM1- cyclin D1/ cyclin B1' is a novel mechanism by which LXRs suppress the proliferation of HCC cells, suggesting that the pathway may be a novel target for HCC treatment.	[Hu, C.; Liu, D.; Zhang, Y.; Lou, G.; Huang, G.; Chen, B.; Shen, X.; Gao, M.; Gong, W.; Zhou, P.; Dai, S.; Zeng, Y.; He, F.] Third Mil Med Univ, Coll Basic Med Sci, Dept Biochem & Mol Biol, Chongqing 400038, Peoples R China; [Liu, D.] Daping Hosp, Depeartment State Key Lab Trauma Burns & Combined, Chongqing, Peoples R China; [Liu, D.] Inst Surg Res, Chongqing, Peoples R China	Army Medical University; Army Medical University	He, F (corresponding author), Third Mil Med Univ, Coll Basic Med Sci, Dept Biochem & Mol Biol, 30 Gaotanyan, Chongqing 400038, Peoples R China.	hefengtian06@aliyun.com	HUANG, GANG/AAO-5503-2020; He, Feng/HHS-6457-2022	He, Feng/0000-0002-1996-0744	National Natural Science Foundation of China [81273226, 81102276]; Key Project of the Natural Science Foundation of Chongqing [cstc2013jjB10015]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Key Project of the Natural Science Foundation of Chongqing	This work was supported by the National Natural Science Foundation of China (nos. 81273226 and 81102276) and the Key Project of the Natural Science Foundation of Chongqing (no. cstc2013jjB10015).	Annicotte JS, 2004, ANAT REC PART A, V277A, P312, DOI 10.1002/ar.a.20015; Beaudet MJ, 2005, BIOCHEM J, V388, P407, DOI 10.1042/BJ20041556; Bensinger SJ, 2008, CELL, V134, P97, DOI 10.1016/j.cell.2008.04.052; Bhat UG, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006593; Blaschke F, 2004, CIRC RES, V95, pE110, DOI 10.1161/01.RES.0000150368.56660.4f; Calvisi DF, 2009, GUT, V58, P679, DOI 10.1136/gut.2008.152652; Cha JY, 2007, J BIOL CHEM, V282, P743, DOI 10.1074/jbc.M605023200; Chen H, 2012, J GENE MED, V14, P231, DOI 10.1002/jgm.2614; Chen WD, 2010, HEPATOLOGY, V51, P953, DOI 10.1002/hep.23390; Chuu CP, 2007, J BIOMED SCI, V14, P543, DOI 10.1007/s11373-007-9160-8; Chuu CP, 2006, CANCER RES, V66, P6482, DOI 10.1158/0008-5472.CAN-06-0632; Chuu CP, 2010, ANTICANCER RES, V30, P3643; Gusarova GA, 2007, J CLIN INVEST, V117, P99, DOI 10.1172/JCI27527; He FT, 2006, CIRC RES, V98, P192, DOI 10.1161/01.RES.0000200400.55539.85; Higuchi N, 2008, HEPATOL RES, V38, P1122, DOI 10.1111/j.1872-034X.2008.00382.x; Jakobsson T, 2012, TRENDS PHARMACOL SCI, V33, P394, DOI 10.1016/j.tips.2012.03.013; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Kalin TV, 2011, CELL CYCLE, V10, P396, DOI 10.4161/cc.10.3.14709; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; Kennedy MA, 2001, J BIOL CHEM, V276, P39438, DOI 10.1074/jbc.M105863200; Kim KH, 2010, J LIPID RES, V51, P3425, DOI 10.1194/jlr.M007989; Koo CY, 2012, BBA-GENE REGUL MECH, V1819, P28, DOI 10.1016/j.bbagrm.2011.09.004; Korver W, 1997, IMMUNOBIOLOGY, V198, P157, DOI 10.1016/S0171-2985(97)80036-8; Laffitte BA, 2001, P NATL ACAD SCI USA, V98, P507, DOI 10.1073/pnas.021488798; Li YW, 2005, MOL CANCER THER, V4, P389; Littler DR, 2010, NUCLEIC ACIDS RES, V38, P4527, DOI 10.1093/nar/gkq194; Mak PA, 2002, J LIPID RES, V43, P2037, DOI 10.1194/jlr.C200014-JLR200; McGovern UB, 2009, MOL CANCER THER, V8, P582, DOI 10.1158/1535-7163.MCT-08-0805; Millour J, 2010, ONCOGENE, V29, P2983, DOI 10.1038/onc.2010.47; Pascual-Garcia M, 2011, J IMMUNOL, V186, P4656, DOI 10.4049/jimmunol.1000585; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Pommier AJC, 2010, ONCOGENE, V29, P2712, DOI 10.1038/onc.2010.30; Ratni H, 2010, CURR OPIN DRUG DISC, V13, P403; Repa JJ, 2000, ANNU REV CELL DEV BI, V16, P459, DOI 10.1146/annurev.cellbio.16.1.459; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Scoles DR, 2010, GYNECOL ONCOL, V116, P109, DOI 10.1016/j.ygyno.2009.09.034; Sun HC, 2011, ONCOL REP, V25, P1533, DOI 10.3892/or.2011.1230; Sun HC, 2011, CANCER LETT, V306, P214, DOI 10.1016/j.canlet.2011.03.009; Uddin S, 2011, AM J PATHOL, V178, P537, DOI 10.1016/j.ajpath.2010.10.020; Uno S, 2009, BIOCHEM PHARMACOL, V77, P186, DOI 10.1016/j.bcp.2008.10.007; Vedin LL, 2009, CARCINOGENESIS, V30, P575, DOI 10.1093/carcin/bgp029; Wang XH, 2002, J BIOL CHEM, V277, P44310, DOI 10.1074/jbc.M207510200; Wang XH, 2001, P NATL ACAD SCI USA, V98, P11468, DOI 10.1073/pnas.201360898; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Wu QF, 2010, ACTA PHARMACOL SIN, V31, P361, DOI 10.1038/aps.2010.4; Xia JT, 2012, PANCREAS, V41, P629, DOI 10.1097/MPA.0b013e31823bcef2; Ye HG, 1999, MOL CELL BIOL, V19, P8570; Zhao CY, 2010, J ENDOCRINOL, V204, P233, DOI 10.1677/JOE-09-0271	50	44	51	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2014	33	22					2888	2897		10.1038/onc.2013.250	http://dx.doi.org/10.1038/onc.2013.250			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EI	23812424				2022-12-28	WOS:000337231800008
J	Damiano, L; Stewart, KM; Cohet, N; Mouw, JK; Lakins, JN; Debnath, J; Reisman, D; Nickerson, JA; Imbalzano, AN; Weaver, VM				Damiano, L.; Stewart, K. M.; Cohet, N.; Mouw, J. K.; Lakins, J. N.; Debnath, J.; Reisman, D.; Nickerson, J. A.; Imbalzano, A. N.; Weaver, V. M.			Oncogenic targeting of BRM drives malignancy through C/EBP beta-dependent induction of alpha 5 integrin	ONCOGENE			English	Article						alpha 5 integrin; Brahma; breast cancer; C/EBP beta; ECM-cell interactions; c-Myc	EPITHELIAL-SPECIFIC DISRUPTION; TRANSGENIC MOUSE MODEL; CELL-PROLIFERATION; SWI/SNF COMPLEX; 3-DIMENSIONAL CULTURE; TRANSCRIPTION FACTOR; MAMMARY-GLAND; CANCER; EXPRESSION; BRG1	Integrin expression and activity are altered in tumors, and aberrant integrin signaling promotes malignancy. However, how integrins become altered in tumors remains poorly understood. We discovered that oncogenic activation of MEK signaling induces cell growth and survival, and promotes the malignant phenotype of mammary epithelial cells (MECs) by increasing alpha 5 integrin expression. We determined that MEK activates c-Myc to reduce the transcription of the SWI/SNF chromatin remodeling enzyme Brahma (BRM). Our studies revealed that reduced BRM expression and/or activity drives the malignant behavior of MECs by epigenetically promoting C/EBP beta expression to directly induce alpha 5 integrin transcription. Consistently, we could show that restoring BRM levels normalized the malignant behavior of transformed MECs in culture and in vivo by preventing C/EBP beta-dependent alpha 5 integrin transcription. Our findings identify a novel mechanism whereby oncogenic signaling promotes malignant transformation by regulating transcription of a key chromatin remodeling molecule that regulates integrin-dependent stromal-epithelial interactions.	[Damiano, L.; Stewart, K. M.; Mouw, J. K.; Lakins, J. N.; Weaver, V. M.] Univ Calif San Francisco, Dept Surg, Ctr Bioengn & Tissue Regenerat, San Francisco, CA 94143 USA; [Cohet, N.; Nickerson, J. A.; Imbalzano, A. N.] Univ Massachusetts, Sch Med, Dept Cell & Dev Biol, Worcester, MA USA; [Debnath, J.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA; [Reisman, D.] Univ Florida, Dept Med, Div Hematol Oncol, Gainesville, FL USA; [Weaver, V. M.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, Dept Anat Bioengn & Therapeut Sci, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of Massachusetts System; University of Massachusetts Worcester; University of California System; University of California San Francisco; State University System of Florida; University of Florida; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center	Weaver, VM (corresponding author), Univ Calif San Francisco, Dept Surg, Ctr Bioengn & Tissue Regenerat, 513 Parnassus Ave,HSE 565,Box 0465, San Francisco, CA 94143 USA.	Valerie.Weaver@ucsfmedctr.org		Weaver, Valerie marie/0000-0003-4786-6752; Mouw, Janna K/0000-0002-9846-8466; Debnath, Jayanta/0000-0002-8745-4069	DOD [BC044791, W81XWH-05-1-0330, BC062562]; NIH/NCI [R01 CA138818, R01 CA085492]; NIEHS [U01ES019458]; NATIONAL CANCER INSTITUTE [R01CA085492, P01CA082834, U54CA163155, R01CA138818, U54CA143836] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [U01ES019458] Funding Source: NIH RePORTER	DOD(United States Department of Defense); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank R Bainer for analyzing the BRM promoter, MP Marinkovich for the BM165 antibody and C Damsky for the AIIB2 antibody. This work was supported by DOD BC044791 (W81XWH-05-1-0330), and NIH/NCI R01 CA138818 (to VMW), NIH/NCI R01 CA085492 (to HLM and VMW), DOD BC062562 (to JKM), and NIEHS U01ES019458 (to ZW).	Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Adeyinka A, 2002, CLIN CANCER RES, V8, P1747; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Bock VL, 2011, BRIT J DERMATOL, V164, P1221, DOI 10.1111/j.1365-2133.2011.10267.x; Cabodi S, 2006, CANCER RES, V66, P4672, DOI 10.1158/0008-5472.CAN-05-2909; Cohet N, 2010, J CELL PHYSIOL, V223, P667, DOI 10.1002/jcp.22072; Corbi AL, 2000, FEBS LETT, V474, P201, DOI 10.1016/S0014-5793(00)01591-X; Dawson PJ, 1996, AM J PATHOL, V148, P313; Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748; Dingemans AMC, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-152; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Gilbert PM, 2010, J CLIN INVEST, V120, P1535, DOI 10.1172/JCI39534; Glaros S, 2007, ONCOGENE, V26, P7058, DOI 10.1038/sj.onc.1210514; Gramling S, 2011, ONCOGENE, V30, P3289, DOI 10.1038/onc.2011.80; Grimm SL, 2003, J MAMMARY GLAND BIOL, V8, P191, DOI 10.1023/A:1025900908026; Guo WJ, 2006, CELL, V126, P489, DOI 10.1016/j.cell.2006.05.047; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Haenssen KK, 2010, J CELL SCI, V123, P1373, DOI 10.1242/jcs.050906; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Herkert Barbara, 2010, Genes Cancer, V1, P580, DOI 10.1177/1947601910379012; Hill DA, 2004, J CELL SCI, V117, P5847, DOI 10.1242/jcs.01502; Huck L, 2010, P NATL ACAD SCI USA, V107, P15559, DOI 10.1073/pnas.1003034107; Kahali B, 2014, ONCOGENE, V33, P653, DOI 10.1038/onc.2012.613; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; KWON H, 1994, NATURE, V370, P477, DOI 10.1038/370477a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Lahlou H, 2007, P NATL ACAD SCI USA, V104, P20302, DOI 10.1073/pnas.0710091104; Lee D, 2002, J BIOL CHEM, V277, P22330, DOI 10.1074/jbc.M111987200; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Liu G, 2011, ONCOGENE, V30, P3295, DOI 10.1038/onc.2011.81; Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Maschler S, 2005, ONCOGENE, V24, P2032, DOI 10.1038/sj.onc.1208423; Muchardt C, 1998, EMBO J, V17, P223, DOI 10.1093/emboj/17.1.223; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Nam JM, 2010, CANCER RES, V70, P5238, DOI 10.1158/0008-5472.CAN-09-2319; Park J, 2004, ONCOGENE, V23, P3474, DOI 10.1038/sj.onc.1207470; Paszek MJ, 2005, CANCER CELL, V8, P241, DOI 10.1016/j.ccr.2005.08.010; Provenzano PP, 2008, AM J PATHOL, V173, P1551, DOI 10.2353/ajpath.2008.080308; Pylayeva Y, 2009, J CLIN INVEST, V119, P252, DOI 10.1172/JCI37160; Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4; Reisman DN, 2003, CANCER RES, V63, P560; Reisman DN, 2002, ONCOGENE, V21, P1196, DOI 10.1038/sj.onc.1205188; Shen H, 2008, CANCER RES, V68, P10154, DOI 10.1158/0008-5472.CAN-08-1794; Sun A, 2007, PROSTATE, V67, P203, DOI 10.1002/pros.20521; Tabaries S, 2011, ONCOGENE, V30, P1318, DOI 10.1038/onc.2010.518; Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; White DE, 2004, CANCER CELL, V6, P159, DOI 10.1016/j.ccr.2004.06.025; Williams CM, 2008, CANCER RES, V68, P3185, DOI 10.1158/0008-5472.CAN-07-2673; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Yang XF, 2009, J CELL SCI, V122, P2473, DOI 10.1242/jcs.049148; Yao ES, 2007, CANCER RES, V67, P659, DOI 10.1158/0008-5472.CAN-06-2768; Yarnamichi N, 2007, CANCER RES, V67, P10727, DOI 10.1158/0008-5472.CAN-07-2601; Yu M, 2012, NATURE, V487, P510, DOI 10.1038/nature11217; Zahnow CA, 1997, J NATL CANCER I, V89, P1887, DOI 10.1093/jnci/89.24.1887	58	12	12	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2014	33	19					2441	2453		10.1038/onc.2013.220	http://dx.doi.org/10.1038/onc.2013.220			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH3OK	23770848	Green Accepted, Green Published			2022-12-28	WOS:000336033600004
J	Bartolome, RA; Barderas, R; Torres, S; Fernandez-Acenero, MJ; Mendes, M; Garcia-Foncillas, J; Lopez-Lucendo, M; Casal, JI				Bartolome, R. A.; Barderas, R.; Torres, S.; Fernandez-Acenero, M. J.; Mendes, M.; Garcia-Foncillas, J.; Lopez-Lucendo, M.; Casal, J. I.			Cadherin-17 interacts with alpha 2 beta 1 integrin to regulate cell proliferation and adhesion in colorectal cancer cells causing liver metastasis	ONCOGENE			English	Article						Cadherin-17; alpha 2 beta 1 integrin; adhesion; proliferation; liver metastasis; colorectal cancer	INTESTINE-CADHERIN; LI-CADHERIN; MATRIX-METALLOPROTEINASE; HEPATOCELLULAR-CARCINOMA; DIAGNOSTIC MARKER; LYMPH-NODE; EXPRESSION; COMPLEX; INVASION; DISEASE	Liver metastasis is the major cause of death associated to colorectal cancer. Cadherin-17 (CDH17) is a non-classical, seven domain, cadherin lacking the conserved cytoplasmic domain of classical cadherins. CDH17 was overexpressed in highly metastatic human KM12SM and present in many other colorectal cancer cells. Using tissue microarrays, we observed a significant association between high expression of CDH17 with liver metastasis and poor survival of the patients. On the basis of these findings, we decided to study cellular functions and signaling mechanisms mediated by CDH17 in cancer cells. In this report, loss-of-function experiments demonstrated that CDH17 caused a significant increase in KM12SM cell adhesion and proliferation. Coimmunoprecipitation experiments demonstrated an interaction between CDH17 and alpha 2 beta 1 integrin with a direct effect on beta 1 integrin activation and talin recruitment. The formation of this complex, together with other proteins, was confirmed by mass spectrometry analysis. CDH17 modulated integrin activation and signaling to induce specific focal adhesion kinase and Ras activation, which led to the activation of extracellular signal-regulated kinase and Jun N-terminal kinase and the increase in cyclin D1 and proliferation. In vivo experiments showed that CDH17 silencing in KM12 cells suppressed tumor growth and liver metastasis after subcutaneous or intrasplenic inoculation in nude mice. Collectively, our data reveal a new function for CDH17, which is to regulate alpha 2 beta 1 integrin signaling in cell adhesion and proliferation in colon cancer cells for liver metastasis.	[Bartolome, R. A.; Barderas, R.; Torres, S.; Mendes, M.; Casal, J. I.] CSIC, CIB, Dept Cellular & Mol Med, Madrid 28040, Spain; [Fernandez-Acenero, M. J.] Fdn Jimenez Diaz, Dept Pathol, Madrid, Spain; [Garcia-Foncillas, J.] Fdn Jimenez Diaz, Dept Oncol, Madrid, Spain; [Lopez-Lucendo, M.] CSIC, CIB, Prote Core Facil, Madrid 28040, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB)	Casal, JI (corresponding author), CSIC, CIB, Dept Cellular & Mol Med, Ramiro De Maeztu 9, Madrid 28040, Spain.	icasal@cib.csic.es	Barderas, Rodrigo/K-3560-2014; Mendes, Marta L/P-4062-2018; Mendes, Marta/AAM-9766-2021; Aceñero, M Jesús Fernández/ABC-5904-2020; Casal, Ignacio/M-2312-2014; Bartolome, Ruben A/M-1873-2014	Barderas, Rodrigo/0000-0003-3539-7469; Mendes, Marta L/0000-0002-3528-7123; Mendes, Marta/0000-0002-3528-7123; Aceñero, M Jesús Fernández/0000-0002-2439-3553; Casal, Ignacio/0000-0003-1085-2840; Bartolome, Ruben A/0000-0002-3292-1491; J, Garcia-Foncillas/0000-0002-7591-8006	Asociacion Espanola Contra el Cancer (AECC); JAE-DOC/FSE Contract (CSIC); Ramon y Cajal program; ProteoRed; Juan de la Cierva program; Spanish Ministry of Science and Innovation [BIO2009-08818]; Comunidad de Madrid [S2010/BMD-2344/ Colomics2]	Asociacion Espanola Contra el Cancer (AECC); JAE-DOC/FSE Contract (CSIC); Ramon y Cajal program(Spanish Government); ProteoRed; Juan de la Cierva program; Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Comunidad de Madrid(Comunidad de Madrid)	We thank Prof John M Luk (Hong Kong University) by the kind supply of CDH17 antibody. RA Bartolome was supported by a grant to established research groups of the Asociacion Espanola Contra el Cancer (AECC). R Barderas was a recipient of a JAE-DOC/FSE Contract (CSIC) and is currently a fellow of the Ramon y Cajal program. S Torres was a recipient of a ProteoRed contract and Juan de la Cierva program. This research was supported by grant BIO2009-08818 from the Spanish Ministry of Science and Innovation, grant to established research groups (AECC) and grant S2010/BMD-2344/ Colomics2 from Comunidad de Madrid.	Barderas R, 2012, CANCER RES, V72, P2780, DOI 10.1158/0008-5472.CAN-11-4090; Bartolome RA, 2006, CANCER RES, V66, P248, DOI 10.1158/0008-5472.CAN-05-2489; Bartolome RA, 2004, CANCER RES, V64, P2534, DOI 10.1158/0008-5472.CAN-03-3398; BERNDORFF D, 1994, J CELL BIOL, V125, P1353, DOI 10.1083/jcb.125.6.1353; Berx G, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a003129; CABANAS C, 1993, P NATL ACAD SCI USA, V90, P5838, DOI 10.1073/pnas.90.12.5838; Canonici A, 2008, INT J CANCER, V122, P572, DOI 10.1002/ijc.23164; Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276; Elzagheid A, 2006, WORLD J GASTROENTERO, V12, P4304, DOI 10.3748/wjg.v12.i27.4304; Gessner R, 2000, ANN NY ACAD SCI, V915, P136; Grotzinger C, 2001, GUT, V49, P73, DOI 10.1136/gut.49.1.73; HERMISTON ML, 1995, SCIENCE, V270, P1203, DOI 10.1126/science.270.5239.1203; Higgins JMG, 1998, J CELL BIOL, V140, P197, DOI 10.1083/jcb.140.1.197; Hinoi T, 2002, GASTROENTEROLOGY, V123, P1565, DOI 10.1053/gast.2002.36598; Hintermann E, 2005, J BIOL CHEM, V280, P8004, DOI 10.1074/jbc.M406301200; Kreft B, 1997, J CELL BIOL, V136, P1109, DOI 10.1083/jcb.136.5.1109; Kwak JM, 2007, DIS COLON RECTUM, V50, P1873, DOI 10.1007/s10350-007-9034-1; Lawson C, 2012, J CELL BIOL, V196, P223, DOI 10.1083/jcb.201108078; Lee NP, 2010, BBA-REV CANCER, V1806, P138, DOI 10.1016/j.bbcan.2010.05.002; Liu LX, 2009, HEPATOLOGY, V50, P1453, DOI 10.1002/hep.23143; Luque-Garcia JL, 2010, PROTEOMICS, V10, P940, DOI 10.1002/pmic.200900441; Marchio S, 2012, EMBO MOL MED, V4, P1156, DOI 10.1002/emmm.201101164; MORIKAWA K, 1988, CANCER RES, V48, P1943; Nguyen DX, 2007, NAT REV GENET, V8, P341, DOI 10.1038/nrg2101; Park JH, 2011, HISTOPATHOLOGY, V58, P316, DOI 10.1111/j.1365-2559.2011.03746.x; Paschos KA, 2009, CELL SIGNAL, V21, P665, DOI 10.1016/j.cellsig.2009.01.006; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sleeman JP, 2000, RECENT RESULTS CANC, V157, P55; Stewart SA, 2003, RNA, V9, P493, DOI 10.1261/rna.2192803; Streuli CH, 2009, J CELL SCI, V122, P171, DOI 10.1242/jcs.018945; Su MC, 2008, MODERN PATHOL, V21, P1379, DOI 10.1038/modpathol.2008.107; Takamura M, 2004, CANCER LETT, V212, P253, DOI 10.1016/j.canlet.2004.03.016; Takamura M, 2003, CANCER SCI, V94, P425, DOI 10.1111/j.1349-7006.2003.tb01459.x; Weinberg RA, 2007, BIOL CANC; Wells A, 2008, CLIN EXP METASTAS, V25, P621, DOI 10.1007/s10585-008-9167-1; Wendeler MW, 2006, CELL MOL LIFE SCI, V63, P1564, DOI 10.1007/s00018-006-6014-x; Wendeler MW, 2007, J MOL BIOL, V370, P220, DOI 10.1016/j.jmb.2007.04.062; Wendeler MW, 2004, EXP CELL RES, V294, P345, DOI 10.1016/j.yexcr.2003.11.022; Wong BW, 2003, BIOCHEM BIOPH RES CO, V311, P618, DOI 10.1016/j.bbrc.2003.10.032; Yoshimura K, 2009, CANCER RES, V69, P7320, DOI 10.1158/0008-5472.CAN-09-0315; Yu QF, 2010, J CANCER RES CLIN, V136, P1641, DOI 10.1007/s00432-010-0822-y	41	75	79	3	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2014	33	13					1658	1669		10.1038/onc.2013.117	http://dx.doi.org/10.1038/onc.2013.117			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9QY	23604127				2022-12-28	WOS:000334344700006
J	West, NR; Murray, JI; Watson, PH				West, N. R.; Murray, J. I.; Watson, P. H.			Oncostatin-M promotes phenotypic changes associated with mesenchymal and stem cell-like differentiation in breast cancer	ONCOGENE			English	Article						oncostatin-M; breast cancer; cancer stem cell; cytokine; epithelial-to-mesenchymal transition; inflammation	PATHOLOGICAL COMPLETE RESPONSE; STEROID-HORMONE RECEPTORS; IN-VITRO PROPAGATION; SIGNAL TRANSDUCER; TRANSITION; EXPRESSION; CARCINOMA; PATHWAY; ALPHA; CHEMOTHERAPY	Cancer stem cell (CSC) biology and the epithelial-to-mesenchymal transition (EMT) are thought to be mechanistically linked and may be key components of cancer development and progression. However, stimuli that induce EMT and CSC-like features ('stemness') are poorly defined. We and others have shown that the inflammatory cytokine oncostatin-M (OSM) mediates phenotypic changes in breast cancer that are consistent with EMT and dedifferentiation, including enhanced migration and loss of hormone receptors. In this study, we have expanded on these prior observations to determine whether OSM is a cell-extrinsic driver of EMT and/or stemness. OSM stimulation of the luminal breast cancer cell lines MCF7 and T47D induced EMT features including loss of membranous E-cadherin and induction of snail and slug expression. OSM treatment markedly enhanced the formation of mammospheres (up to 20-fold, P < 0.001), which displayed high expression of the pluripotency factor SOX2. The proportion of cells with a CD44(high)CD24(-/low) phenotype was similarly increased by OSM (P < 0.001). OSM-induced mammosphere formation and CD44(high)CD24(-/low) induction was dependent on PI3K signalling. In silico analysis of human breast tumours (from a publicly available data set, n = 322) confirmed that co-expression of a PI3K transcriptional signature, but not MAPK or STAT3 signatures, was necessary to detect an association between OSMR and poor prognosis. Assessment of a second in silico data set (n = 241 breast tumours) confirmed a significant relationship between OSMR, markers of EMT and CSCs, and chemotherapy resistance. Direct analysis of mRNA expression by RT-PCR in a third cohort (n = 72 breast tumours) demonstrated that high expression of OSM is associated positively with indicators of EMT (SNAI1, P < 0.001) and stemness (SOX2, P < 0.05). Our data suggest for the first time that OSM may promote a clinically relevant EMT/CSC-like phenotype in human breast cancer via a PI3K-dependent mechanism.	[West, N. R.; Murray, J. I.; Watson, P. H.] British Columbia Canc Agcy, Deeley Res Ctr, Victoria, BC, Canada; [West, N. R.; Watson, P. H.] Univ Victoria, Dept Biochem & Microbiol, Victoria, BC, Canada; [Watson, P. H.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada	British Columbia Cancer Agency; University of Victoria; University of British Columbia	Watson, PH (corresponding author), Deeley Res Ctr, 2410 Lee Ave,3rd Floor Res, Victoria, BC V8R 6V5, Canada.	pwatson@bccancer.bc.ca		West, Nathaniel/0000-0001-9991-0503; Watson, Peter/0000-0002-1642-0638	Canadian Breast Cancer Foundation (CBCF); BC/Yukon chapter; US DOD Breast Cancer Research Program Predoctoral award [W81XWH-08-1-0781]; CBCF BC/Yukon Region postdoctoral fellowship; BC Cancer Foundation	Canadian Breast Cancer Foundation (CBCF); BC/Yukon chapter; US DOD Breast Cancer Research Program Predoctoral award; CBCF BC/Yukon Region postdoctoral fellowship; BC Cancer Foundation	We are grateful to members of the Deeley Research Centre for helpful discussion. We thank the Manitoba Breast Tumour Bank (a member of the Canadian Tumour Repository Network) for providing breast cancer tissue specimens and the authors of the UNC and MAQC cohorts for making their data freely available. Financial support was from the Canadian Breast Cancer Foundation (CBCF), BC/Yukon chapter and the BC Cancer Foundation. NRW was supported by a US DOD Breast Cancer Research Program Predoctoral award (W81XWH-08-1-0781). JIM is supported by a CBCF BC/Yukon Region postdoctoral fellowship.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Alvarez JV, 2005, CANCER RES, V65, P5054, DOI 10.1158/0008-5472.CAN-04-4281; Asiedu MK, 2011, CANCER RES, V71, P4707, DOI 10.1158/0008-5472.CAN-10-4554; Balic M, 2006, CLIN CANCER RES, V12, P5615, DOI 10.1158/1078-0432.CCR-06-0169; Bhat-Nakshatri P, 2004, BRIT J CANCER, V90, P853, DOI 10.1038/sj.bjc.6601541; Blanchard F, 2001, J BIOL CHEM, V276, P47038, DOI 10.1074/jbc.M107971200; Chavey C, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1648; Christiansen JJ, 2006, CANCER RES, V66, P8319, DOI 10.1158/0008-5472.CAN-06-0410; Clarkson RWE, 2006, MOL ENDOCRINOL, V20, P675, DOI 10.1210/me.2005-0392; Colleoni M, 2004, CLIN CANCER RES, V10, P6622, DOI 10.1158/1078-0432.CCR-04-0380; Colleoni M, 2009, BREAST CANCER RES TR, V116, P359, DOI 10.1007/s10549-008-0223-y; Creighton CJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2594; Dangi-Garimella S, 2009, EMBO J, V28, P347, DOI 10.1038/emboj.2008.294; Dhasarathy A, 2007, MOL ENDOCRINOL, V21, P2907, DOI 10.1210/me.2007-0293; Dontu G, 2003, GENE DEV, V17, P1253, DOI 10.1101/gad.1061803; Douglas AM, 1997, ONCOGENE, V14, P661, DOI 10.1038/sj.onc.1200882; Dubois-Marshall S, 2011, CLIN EXP METASTAS, V28, P811, DOI 10.1007/s10585-011-9412-x; Emberley ED, 2005, CANCER RES, V65, P5696, DOI 10.1158/0008-5472.CAN-04-3927; Emberley ED, 2004, BREAST CANCER RES, V6, P153, DOI 10.1186/bcr816; Fulford LG, 2006, HISTOPATHOLOGY, V49, P22, DOI 10.1111/j.1365-2559.2006.02453.x; de Herreros AG, 2010, J MAMMARY GLAND BIOL, V15, P135, DOI 10.1007/s10911-010-9179-8; Ginestier C, 2010, J CLIN INVEST, V120, P485, DOI 10.1172/JCI39397; Grant SL, 2002, ONCOGENE, V21, P460, DOI 10.1038/sj.onc.1205100; Guarneri V, 2006, J CLIN ONCOL, V24, P1037, DOI 10.1200/JCO.2005.02.6914; Guo L, 2013, ONCOGENE, V32, P5272, DOI 10.1038/onc.2012.573; Hardt O, 2012, CANCER LETT, V325, P165, DOI 10.1016/j.canlet.2012.06.010; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Holzer RG, 2004, CLIN EXP METASTAS, V21, P167, DOI 10.1023/B:CLIN.0000024760.02667.db; Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108; Jorcyk CL, 2006, CYTOKINE, V33, P323, DOI 10.1016/j.cyto.2006.03.004; Klymkowsky MW, 2009, AM J PATHOL, V174, P1588, DOI 10.2353/ajpath.2009.080545; Korkaya H, 2011, J CLIN INVEST, V121, P3804, DOI 10.1172/JCI57099; Korkaya H, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000121; Lawson JC, 2009, BREAST CANCER RES TR, V118, P241, DOI 10.1007/s10549-009-0524-9; Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338; Liu JW, 1997, CELL GROWTH DIFFER, V8, P667; Loboda A, 2010, BMC MED GENOMICS, V3, DOI 10.1186/1755-8794-3-26; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; May CD, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2789; Mego M, 2010, NAT REV CLIN ONCOL, V7, P693, DOI 10.1038/nrclinonc.2010.171; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Plath K, 2011, NAT REV GENET, V12, P253, DOI 10.1038/nrg2955; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Popovici V, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2468; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Rakha EA, 2008, HISTOPATHOLOGY, V52, P67, DOI 10.1111/j.1365-2559.2007.02894.x; Ring AE, 2004, BRIT J CANCER, V91, P2012, DOI 10.1038/sj.bjc.6602235; Rodriguez-Pinilla SM, 2007, MODERN PATHOL, V20, P474, DOI 10.1038/modpathol.3800760; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tanaka M, 2004, REV PHYSIOL BIOCH P, V149, P39, DOI 10.1007/s10254-003-0013-1; Teschendorff AE, 2007, PLOS COMPUT BIOL, V3, P1539, DOI 10.1371/journal.pcbi.0030161; West NR, 2010, ONCOGENE, V29, P2083, DOI 10.1038/onc.2009.488; West NR, 2012, ENDOCR-RELAT CANCER, V19, P181, DOI 10.1530/ERC-11-0326; Ye Y, 2010, ONCOGENE, V29, P1451, DOI 10.1038/onc.2009.433; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183; Zhang F, 2003, ONCOGENE, V22, P894, DOI 10.1038/sj.onc.1206158; Zhou JB, 2007, P NATL ACAD SCI USA, V104, P16158, DOI 10.1073/pnas.0702596104	61	69	70	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2014	33	12					1485	1494		10.1038/onc.2013.105	http://dx.doi.org/10.1038/onc.2013.105			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD4TS	23584474				2022-12-28	WOS:000333244200002
J	Liu, Z; Li, T; Reinhold, MI; Naski, MC				Liu, Z.; Li, T.; Reinhold, M. I.; Naski, M. C.			MEK1-RSK2 contributes to hedgehog signaling by stabilizing GLI2 transcription factor and inhibiting ubiquitination	ONCOGENE			English	Article						Hedgehog; GLI2; MEK1; RSK2; ubiquitination; multiple myeloma	CARCINOMA-CELLS; DOWN-REGULATION; CANCER; DEGRADATION; ACTIVATION; PROLIFERATION; METASTASIS; MECHANISMS; EXPRESSION; PROTEINS	The transcription factor GLI2 has an important role in the transduction of Hedgehog signaling and thereby regulates tumorigenesis in a wide variety of human tumors. However, the mechanisms controlling GLI2 protein expression and stabilization are incompletely understood. In this study, we show that the mitogen-activated protein kinase MEK1 modulates GLI2 both at the mRNA and protein level. Constitutively activated MEK1 prolonged the half-life of GLI2 and increased its nuclear translocation, accompanied by attenuated ubiquitination of GLI2 protein. RSK2, a protein kinase lying downstream of MEK-ERK cascade, mimicked the effect of MEK on GLI2 stabilization. MEK1 and RSK2 failed to augment the half-life of GLI2 lacking GSK-3 beta phosphorylation sites, indicating that MEK-RSK stabilizes GLI2 by controlling targeting GSK-3 beta-mediated phosphorylation and ubiquitination of GLI2. The significance of MEK-RSK stabilization was demonstrated in experiments showing that activation of MEK-RSK paralleled higher protein level of GLI2 in several multiple myelomas (MM) cells relative to normal B cells. Moreover, combined treatment with RSK and GLI inhibitors led to an enhanced apoptosis of MM cells. Thus, our results indicate that MEK-RSK cascade positively regulates GLI2 stabilization and represses its degradation via inhibiting GSK-3 beta-dependent phosphorylation and ubiquitination of GLI2.	[Liu, Z.; Reinhold, M. I.; Naski, M. C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA; [Liu, Z.] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA; [Li, T.] Zhejiang Normal Univ, Coll Chem & Life Sci, Dept Biol, Jinhua, Peoples R China; [Reinhold, M. I.] Grand Valley State Univ, Dept Phys Assistant Studies, Grand Rapids, MI USA; [Naski, M. C.] St Marys Hlth Care, Dept Pathol, Grand Rapids, MI USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; UTMD Anderson Cancer Center; Zhejiang Normal University; Grand Valley State University	Liu, Z (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX 77030 USA.	zliu2@mdanderson.org; mikenaski@yahoo.com	Liu, Zhiqiang/E-6950-2014	Liu, Zhiqiang/0000-0002-0677-8097	National Institutes of Health [R01 (AR053100)]; National Natural Sciences Foundation of China [31101057]; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR053100] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Sciences Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))	This work was supported by National Institutes of Health R01 (AR053100) (M C Naski), the National Natural Sciences Foundation of China (31101057), and the Sciences Foundation of Zhejiang Normal University (ZC304009172). We thank Dr Natalia Riobo from Thomas Jefferson University; Dr John Blenis from Department of Cell Biology of Harvard Medical School; Dr Richard L Huganir from the Department of Neuroscience of Howard Hughes Medical Institute; Dr Fritz Aberger, University of Salzburg; and Dr Baolin Wang, Associate Professor of Cell and Developmental Biology Weill Cornell Medical College, for their generous contributions of the plasmids used in this study.	Alexaki VI, 2010, JNCI-J NATL CANCER I, V102, P1148, DOI 10.1093/jnci/djq257; Aza-Blanc P, 2000, DEVELOPMENT, V127, P4293; Bhatia N, 2006, J BIOL CHEM, V281, P19320, DOI 10.1074/jbc.M513203200; Cai Jiaqin, 2010, Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi, V24, P993; Dai P, 1999, J BIOL CHEM, V274, P8143, DOI 10.1074/jbc.274.12.8143; Duman-Scheel M, 2002, NATURE, V417, P299, DOI 10.1038/417299a; Fujii Katsunori, 2009, No To Hattatsu, V41, P247; Grachtchouk M, 2000, NAT GENET, V24, P216, DOI 10.1038/73417; Javelaud D, 2011, CANCER RES, V71, P5606, DOI 10.1158/0008-5472.CAN-11-1194; Jiang J, 2008, DEV CELL, V15, P801, DOI 10.1016/j.devcel.2008.11.010; Jiao X, 2012, GENE CHROMOSOME CANC, V51, P480, DOI 10.1002/gcc.21935; Kim J, 2009, P NATL ACAD SCI USA, V106, P21666, DOI 10.1073/pnas.0912180106; Kim Y, 2007, CANCER RES, V67, P3583, DOI 10.1158/0008-5472.CAN-06-3040; Kump E, 2008, ONCOGENE, V27, P3856, DOI 10.1038/onc.2008.5; Lauth M, 2007, CELL CYCLE, V6, P2458, DOI 10.4161/cc.6.20.4808; Lewis M T, 2006, Ernst Schering Found Symp Proc, P181; Liu ZQ, 2009, BBA-MOL CELL RES, V1793, P300, DOI 10.1016/j.bbamcr.2008.08.013; Marini KD, 2011, GROWTH FACTORS, V29, P221, DOI 10.3109/08977194.2011.610756; Onishi H, 2011, CANCER SCI, V102, P1756, DOI 10.1111/j.1349-7006.2011.02010.x; Pan Y, 2006, MOL CELL BIOL, V26, P3365, DOI 10.1128/MCB.26.9.3365-3377.2006; Pan Y, 2009, DEV BIOL, V326, P177, DOI 10.1016/j.ydbio.2008.11.009; Reinhold MI, 2006, J BIOL CHEM, V281, P1381, DOI 10.1074/jbc.M504875200; Tam Michael, 2010, J Assoc Genet Technol, V36, P111; Teichert AE, 2011, J INVEST DERMATOL, V131, P2289, DOI 10.1038/jid.2011.196; Thiyagarajan S, 2007, CANCER RES, V67, P10642, DOI 10.1158/0008-5472.CAN-07-2015; Thomas GM, 2005, P NATL ACAD SCI USA, V102, P15006, DOI 10.1073/pnas.0507476102; Varjosalo M, 2008, GENE DEV, V22, P2454, DOI 10.1101/gad.1693608	28	23	24	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2014	33	1					65	73		10.1038/onc.2012.544	http://dx.doi.org/10.1038/onc.2012.544			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	282YU	23208494				2022-12-28	WOS:000329212000008
J	van de Kooij, B; Rooswinkel, RW; Kok, F; Herrebout, M; de Vries, E; Paauwe, M; Janssen, GMC; van Veelen, PA; Borst, J				van de Kooij, B.; Rooswinkel, R. W.; Kok, F.; Herrebout, M.; de Vries, E.; Paauwe, M.; Janssen, G. M. C.; van Veelen, P. A.; Borst, J.			Polyubiquitination and proteasomal turnover controls the anti-apoptotic activity of Bcl-B	ONCOGENE			English	Article						apoptosis; Bcl-2 family; Bcl-B; ubiquitination	E3 UBIQUITIN LIGASE; MASS-SPECTROMETRY; LEUKEMIC-CELLS; PROTEIN; FAMILY; MCL-1; DEATH; ABT-737; RESISTANCE; EXPRESSION	Anti-apoptotic Bcl-2 family members can contribute to tumorigenesis and may convey resistance to anti-cancer regimens. Therefore, they are important targets for novel therapeutics, particularly Bcl-2 homology (BH) 3 mimetics. Bcl-B (BCL-2-like protein-10) is a relatively understudied member of the Bcl-2 protein family. Its physiological function is unknown, but it has been proven to have an anti-apoptotic activity and to act as a tumor promoter in mice. In human, high Bcl-B protein expression levels correlate with poor prognosis in various carcinomas and predict treatment resistance in acute myeloid leukemia. We here report that protein expression level and anti-apoptotic activity of Bcl-B are dictated by its ubiquitination. We demonstrate that Bcl-B is polyubiquitinated at steady state, in a unique loop between the BH1 and BH2 domains. Mutagenesis identified lysine (K) 128 as an acceptor site for polyubiquitin chains, and K119 and K120, but not K181, as potential ubiquitination sites. Mass spectrometry confirmed K128 as a ubiquitination site and defined the polyubiquitin chains as K48-linked, which was confirmed by linkage-specific antibodies. Accordingly, Bcl-B proved to be an instable protein that is subject to ubiquitin-dependent proteasomal degradation at steady state. At equal mRNA expression, protein expression of a lysineless, nonubiquitinated Bcl-B mutant was fivefold higher than that of wild-type Bcl-B, demonstrating that ubiquitination is a key determinant for Bcl-B protein expression levels. Ubiquitination controlled the anti-apoptotic capacity of Bcl-B, in response to a variety of conventional and novel anti-cancer drugs. Certain anti-cancer drugs, known to reduce Mcl-1 protein levels, likewise downregulated Bcl-B. Together, these data demonstrate that polyubiquitination and proteasomal turnover dictate the expression level and anti-apoptotic capacity of Bcl-B.	[van de Kooij, B.; Rooswinkel, R. W.; Kok, F.; Herrebout, M.; de Vries, E.; Paauwe, M.; Borst, J.] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Div Immunol, NL-1066 CX Amsterdam, Netherlands; [Janssen, G. M. C.; van Veelen, P. A.] Leiden Univ, Med Ctr, Dept Immunohematol, Leiden, Netherlands; [Janssen, G. M. C.; van Veelen, P. A.] Leiden Univ, Med Ctr, Blood Bank, Leiden, Netherlands	Netherlands Cancer Institute; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Borst, J (corresponding author), Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Div Immunol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.	j.borst@nki.nl	Paauwe, Madelon/C-8244-2018	Borst, Jannie/0000-0002-8043-5009; van Veelen, Peter/0000-0002-7898-9408	Netherlands Organization for Scientific Research [ECHO 700.57.008]; Dutch Cancer Society [NKI 2008-4110]; Netherlands Proteomics Center	Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); Dutch Cancer Society(KWF Kankerbestrijding); Netherlands Proteomics Center	We thank Lennert Janssen, Drs Ricky Johnstone, Henning Walczak and Huib Ovaa for kindly providing reagents, and Drs Abdel Aouacheria and Mark Hinds for advise on the Bcl-B protein structure. This work was supported by grant ECHO 700.57.008 from the Netherlands Organization for Scientific Research and grant NKI 2008-4110 from the Dutch Cancer Society, awarded to JB, and GMCJ was supported by the Netherlands Proteomics Center.	Aichberger KJ, 2005, BLOOD, V105, P3303, DOI 10.1182/blood-2004-02-0749; Aouacheria A, 2001, ONCOGENE, V20, P5846, DOI 10.1038/sj.onc.1204740; Beverly LJ, 2009, ONCOGENE, V28, P1274, DOI 10.1038/onc.2008.466; Beverly LJ, 2012, P NATL ACAD SCI USA, V109, P119, DOI 10.1073/pnas.1119167109; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chipuk JE, 2010, MOL CELL, V37, P299, DOI 10.1016/j.molcel.2010.01.025; Cluzeau T, 2012, ONCOTARGET, V3, P490; El Oualid F, 2010, ANGEW CHEM INT EDIT, V49, P10149, DOI 10.1002/anie.201005995; Fan GF, 2010, BLOOD, V115, P3559, DOI 10.1182/blood-2009-08-236760; Fernandez-Fuentes N, 2007, NUCLEIC ACIDS RES, V35, pW363, DOI 10.1093/nar/gkm341; Gandhi L, 2011, J CLIN ONCOL, V29, P909, DOI 10.1200/JCO.2010.31.6208; Goetze S, 2009, PLOS BIOL, V7, DOI 10.1371/journal.pbio.1000236; Guillemin Y, 2011, MOL BIOL EVOL, V28, P3271, DOI 10.1093/molbev/msr152; Hao ZY, 2012, J EXP MED, V209, P173, DOI 10.1084/jem.20111363; Inuzuka H, 2011, NATURE, V471, P104, DOI 10.1038/nature09732; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Ke N, 2001, J BIOL CHEM, V276, P12481, DOI 10.1074/jbc.C000871200; Kirkpatrick DS, 2005, NAT CELL BIOL, V7, P750, DOI 10.1038/ncb0805-750; Knoops L, 2007, BLOOD, V110, P1116, DOI 10.1182/blood-2007-01-067579; Krajewska M, 2008, CLIN CANCER RES, V14, P3011, DOI 10.1158/1078-0432.CCR-07-1955; Lee RM, 2001, BBA-GENE STRUCT EXPR, V1520, P187, DOI 10.1016/S0167-4781(01)00268-8; MacCallum DE, 2005, CANCER RES, V65, P5399, DOI 10.1158/0008-5472.CAN-05-0233; Meiring HD, 2002, J SEP SCI, V25, P557, DOI 10.1002/1615-9314(20020601)25:9<557::AID-JSSC557>3.0.CO;2-F; Merino D, 2012, BLOOD, V119, P5807, DOI 10.1182/blood-2011-12-400929; Nemunaitis J, 2013, CANCER CHEMOTH PHARM, V71, P35, DOI 10.1007/s00280-012-1963-2; Newton K, 2008, CELL, V134, P668, DOI 10.1016/j.cell.2008.07.039; Nielsen ML, 2008, NAT METHODS, V5, P459, DOI 10.1038/nmeth0608-459; O'Neil J, 2007, J EXP MED, V204, P1813, DOI 10.1084/jem.20070876; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Pepper C, 2008, BLOOD, V112, P3807, DOI 10.1182/blood-2008-05-157131; Rautureau GJP, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.178; Riedl J, 2008, NAT METHODS, V5, P605, DOI 10.1038/nmeth.1220; Rocha N, 2009, J CELL BIOL, V185, P1209, DOI 10.1083/jcb.200811005; Rooswinkel RW, CELL DEATH DIS, V3, pe366; Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542; Schwickart M, 2010, NATURE, V463, P103, DOI 10.1038/nature08646; Stewart DP, 2010, MOL CELL BIOL, V30, P3099, DOI 10.1128/MCB.01266-09; Sutherland BW, 2008, J MASS SPECTROM, V43, P699, DOI 10.1002/jms.1415; Tait SWG, 2007, J CELL BIOL, V179, P1453, DOI 10.1083/jcb.200707063; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Tothova E, 2002, NEOPLASMA, V49, P141; van Delft MF, 2006, CANCER CELL, V10, P389, DOI 10.1016/j.ccr.2006.08.027; van Lummel M, 2012, J BIOL CHEM, V287, P9514, DOI 10.1074/jbc.M111.313940; Verbrugge I, 2008, ONCOGENE, V27, P574, DOI 10.1038/sj.onc.1210696; Wertz IE, 2011, NATURE, V471, P110, DOI 10.1038/nature09779; Whitecross KF, 2009, BLOOD, V113, P1982, DOI 10.1182/blood-2008-05-156851; Wiggins CM, 2011, J CELL SCI, V124, P969, DOI 10.1242/jcs.058438; Yecies D, 2010, BLOOD, V115, P3304, DOI 10.1182/blood-2009-07-233304; Zhai DY, 2008, J BIOL CHEM, V283, P9580, DOI 10.1074/jbc.M708426200; Zhai DY, 2003, BIOCHEM J, V376, P229, DOI 10.1042/BJ20030374; Zhang H, 2001, HUM MOL GENET, V10, P2329, DOI 10.1093/hmg/10.21.2329; Zhong Q, 2005, CELL, V121, P1085, DOI 10.1016/j.cell.2005.06.009	52	11	11	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2013	32	48					5439	5448		10.1038/onc.2013.99	http://dx.doi.org/10.1038/onc.2013.99			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263BE	23563182	Green Published			2022-12-28	WOS:000327780800001
J	Miura, K; Wakayama, Y; Tanino, M; Orba, Y; Sawa, H; Hatakeyama, M; Tanaka, S; Sabe, H; Mochizuki, N				Miura, K.; Wakayama, Y.; Tanino, M.; Orba, Y.; Sawa, H.; Hatakeyama, M.; Tanaka, S.; Sabe, H.; Mochizuki, N.			Involvement of EphA2-mediated tyrosine phosphorylation of Shp2 in Shp2-regulated activation of extracellular signal-regulated kinase	ONCOGENE			English	Article						Shp2; EphA2; Erk; cancer; LEOPARD syndrome	EPIDERMAL-GROWTH-FACTOR; PHOSPHATASE SHP2; LEOPARD-SYNDROME; EPHA2 RECEPTOR; PATHWAY; CANCER; PROTEIN; TARGET; MECHANISM; CELLS	Shp2 is a positive regulator for Erk activation downstream of receptor tyrosine kinases for growth factors. It has been controversial how Shp2 induces Erk activation. We here demonstrate that EphA2 is responsible for Shp2-mediated Erk activation by phosphorylating Tyr542 and Tyr580 of Shp2 in the cells stimulated with growth factors. In NMuMG mammary epithelial cells stimulated with hepatocyte growth factor (HGF), HGF-dependent Erk phosphorylation was prolonged only in the presence of EphA2. This Erk activation paralleled the phosphorylation of Tyr542/580 of Shp2 and the association of Grb2 with Shp2, suggesting the positive signal involving Grb2 signal to activate Ras-Erk pathway. Immunohistochemical studies of mammary cancer specimens revealed that the cancer progression was associated with both Tyr580 phosphorylation of Shp2 and increased expression of EphA2, which were also correlated with increased Erk phosphorylation. Overexpression of either Shp2Thr468Met (a phosphatase-defective mutant found in Lentigines, Electrocardiographic abnormalities, Ocular hypertelorism, Pulmonary stenosis, Abnormal genitalia, Retardation of growth and sensorineural Deafness (LEOPARD) syndrome) or Shp2Asn308Asp (a phosphatase-active mutant found in Noonan syndrome) with EphA2 exhibited comparable activation of Erk and stronger activation than wild-type Shp2, suggesting the phosphatase-independent Erk activation. Expression of Shp2Thr468Met with Tyr542/580Phe mutations resulted in the suppression of Erk activation. Phosphatase-active and -inactive, and wild-type Shp2s bound equally to Grb2, suggesting that phosphorylation of Tyr542/580 of Shp2 was essential but not sufficient for Shp2-mediated Erk activation. We found that Gab1 (Grb2-associated binder 1) was involved in the mutant Shp2-mediated Erk activation. Zebrafish injected with Shp2Thr468Met mRNA showed cardiac edema, whereas those depleted of EphA2b showed less phenotype, suggesting that EphA2 might partly account for the phenotype of LEOPARD syndrome. Collectively, tyrosine phosphorylation of Shp2 by EphA2 contributes to the phosphatase-independent Shp2-mediated activation of Erk and might be involved in Shp2-associated diseases.	[Miura, K.; Wakayama, Y.; Mochizuki, N.] Natl Cerebral & Cardiovasc Ctr, Dept Cell Biol, Res Inst, Suita, Osaka 5658565, Japan; [Tanino, M.; Tanaka, S.] Hokkaido Univ, Grad Sch Med, Lab Canc Res, Dept Pathol,Kita Ku, Sapporo, Hokkaido, Japan; [Orba, Y.; Sawa, H.] Hokkaido Univ, Dept Mol Pathobiol, Res Ctr Zoonosis Control, Sapporo, Hokkaido, Japan; [Hatakeyama, M.] Univ Tokyo, Grad Sch Med, Div Microbiol, Bunkyo Ku, Tokyo, Japan; [Sabe, H.] Hokkaido Univ, Grad Sch Med, Dept Mol Biol, Kita Ku, Sapporo, Hokkaido, Japan	National Cerebral & Cardiovascular Center - Japan; Hokkaido University; Hokkaido University; University of Tokyo; Hokkaido University	Miura, K (corresponding author), Natl Cerebral & Cardiovasc Ctr, Dept Cell Biol, Res Inst, 5-7-1 Fujishirodai, Suita, Osaka 5658565, Japan.	miurako@ri.ncvc.go.jp; nmochizu@ri.ncvc.go.jp	Sawa, Hirofumi/AAW-8816-2021; Sabe, Hisataka/GPF-4385-2022; Sawa, Hirofumi/F-6954-2012; Tanaka, Shinya/D-3586-2011	Sawa, Hirofumi/0000-0003-2569-2755; 	Ministry of Education, Science, Sports and Culture of Japan; Ministry of Health, Labor and Welfare of Japan; Takeda Science Foundation; AstraZeneca; Grants-in-Aid for Scientific Research [22240085, 22114002, 22114001, 24590406] Funding Source: KAKEN	Ministry of Education, Science, Sports and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry of Health, Labor and Welfare of Japan(Ministry of Health, Labour and Welfare, Japan); Takeda Science Foundation(Takeda Science Foundation (TSF)); AstraZeneca(AstraZeneca); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank M Matsuda (Kyoto University), T Akagi (KAN Research Institute), T Hirano (Osaka University) and S Kunimoto (Nippon University) for reagents; M Masuda, S Fukuhara and H Fukui for valuable advice; and M Sone, K Hiratomi, M Minamimoto, H Yonekawa, W Koeda and Y Matsuura for technical assistance. This work was supported, in part, by grants from the Ministry of Education, Science, Sports and Culture of Japan; the Ministry of Health, Labor and Welfare of Japan; Takeda Science Foundation; and AstraZeneca Research Grant.	Agazie YM, 2003, MOL CELL BIOL, V23, P7875, DOI 10.1128/MCB.23.21.7875-7886.2003; Araki T, 2003, J BIOL CHEM, V278, P41677, DOI 10.1074/jbc.M306461200; Araujo J, 2010, CANCER TREAT REV, V36, P492, DOI 10.1016/j.ctrv.2010.02.015; Bin Fang W, 2008, J BIOL CHEM, V283, P16017, DOI 10.1074/jbc.M709934200; Brantley-Sieders DM, 2008, J CLIN INVEST, V118, P64, DOI 10.1172/JCI33154; Cai T, 2002, J CELL BIOL, V159, P103, DOI 10.1083/jcb.200205017; Carvajal-Vergara X, 2010, NATURE, V465, P808, DOI 10.1038/nature09005; Cha Y, 2010, FEBS LETT, V584, P4241, DOI 10.1016/j.febslet.2010.09.016; Chan G, 2008, CANCER METAST REV, V27, P179, DOI 10.1007/s10555-008-9126-y; Cleghon V, 1998, MOL CELL, V2, P719, DOI 10.1016/S1097-2765(00)80287-7; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; Dance M, 2008, CELL SIGNAL, V20, P453, DOI 10.1016/j.cellsig.2007.10.002; Edouard T, 2007, CELL MOL LIFE SCI, V64, P1585, DOI 10.1007/s00018-007-6509-0; Grossmann KS, 2010, ADV CANCER RES, V106, P53, DOI 10.1016/S0065-230X(10)06002-1; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Higashi H, 2002, SCIENCE, V295, P683, DOI 10.1126/science.1067147; Ireton RC, 2005, CURR CANCER DRUG TAR, V5, P149, DOI 10.2174/1568009053765780; Jopling C, 2007, PLOS GENET, V3, P2468, DOI 10.1371/journal.pgen.0030225; Lemeer S, 2007, MOL CELL PROTEOMICS, V6, P2088, DOI 10.1074/mcp.M600482-MCP200; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Lu W, 2001, MOL CELL, V8, P759, DOI 10.1016/S1097-2765(01)00369-0; Macrae M, 2005, CANCER CELL, V8, P111, DOI 10.1016/j.ccr.2005.07.005; Miao H, 2009, CANCER CELL, V16, P9, DOI 10.1016/j.ccr.2009.04.009; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Pasquale EB, 2008, CELL, V133, P38, DOI 10.1016/j.cell.2008.03.011; Pasquale EB, 2010, NAT REV CANCER, V10, P165, DOI 10.1038/nrc2806; Stewart RA, 2010, DEV CELL, V18, P750, DOI [10.1016/j.devcel.2010.03.009, 10.1016/j.devce1.2010.03.009]; Tartaglia M, 2010, ANN NY ACAD SCI, V1214, P99, DOI 10.1111/j.1749-6632.2010.05790.x; Tidyman WE, 2009, CURR OPIN GENET DEV, V19, P230, DOI 10.1016/j.gde.2009.04.001; Wang YJ, 2002, BIOCHEM BIOPH RES CO, V296, P214, DOI 10.1016/S0006-291X(02)00806-9	30	33	39	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 7	2013	32	45					5292	5301		10.1038/onc.2012.571	http://dx.doi.org/10.1038/onc.2012.571			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251IS	23318428	hybrid			2022-12-28	WOS:000326922100005
J	Hagenbuchner, J; Kuznetsov, AV; Obexer, P; Ausserlechner, MJ				Hagenbuchner, J.; Kuznetsov, A. V.; Obexer, P.; Ausserlechner, M. J.			BIRC5/Survivin enhances aerobic glycolysis and drug resistance by altered regulation of the mitochondrial fusion/fission machinery	ONCOGENE			English	Article						chemotherapy; FOXO3; mitochondrial respiration; reactive oxygen species; Warburg effect	OXIDATIVE STRESS; HUMAN NEUROBLASTOMA; CELL-PROLIFERATION; CYTOCHROME-C; EXPRESSION; APOPTOSIS; SURVIVIN; PROTEIN; CANCER; FISSION	Gain of chromosome 17q correlates with high-stage disease, an adverse clinical outcome and leads to the overexpression of the antiapoptotic protein BIRC5/Survivin in neuroblastoma (NB). We have shown before that Survivin defines a threshold for the sensitivity of NB cells to DNA-damaging chemotherapeutic agents that require FOXO3 activation for apoptosis induction. To investigate the molecular basis of apoptosis inhibition we analyzed the function of Survivin at mitochondria and uncovered that Survivin induces mitochondrial fragmentation, reduces mitochondrial respiration and represses BCL2L11/Bim. Mitochondrial fission depends on Survivin-induced recruitment of the fission regulator DNM1L/Drp1 to mitochondria. In parallel, Survivin expression inhibits the respiratory complex-I, thereby preventing reactive oxygen species accumulation and, as a consequence, FOXO3-induced apoptosis. The loss of energy production via oxidative phosphorylation is compensated by increased glycolysis in Survivin-overexpressing NB tumor cells. Glycolysis inhibitors neutralize the antiapoptotic effect of Survivin and sensitize high-stage NB to DNA-damaging drugs. This suggests that glycolysis inhibitors target an 'archilles heel' of Survivin-overexpressing NB and may be highly useful as chemosensitizers in the treatment of high-stage NB.	[Hagenbuchner, J.; Obexer, P.] Med Univ Innsbruck, Dept Pediat 2, A-6020 Innsbruck, Austria; [Hagenbuchner, J.; Obexer, P.; Ausserlechner, M. J.] Tyrolean Canc Res Inst, Innsbruck, Austria; [Kuznetsov, A. V.] Med Univ Innsbruck, Dept Cardiac Surg, Cardiac Surg Res Lab, A-6020 Innsbruck, Austria; [Ausserlechner, M. J.] Med Univ Innsbruck, Dept Pediat 1, A-6020 Innsbruck, Austria	Medical University of Innsbruck; Medical University of Innsbruck; Medical University of Innsbruck	Obexer, P (corresponding author), Med Univ Innsbruck, Dept Pediat 2, Innrain 66, A-6020 Innsbruck, Austria.	Petra.Obexer@i-med.ac.at; Michael.J.Ausserlechner@i-med.ac.at		Ausserlechner, Michael/0000-0002-1015-2302; Hagenbuchner, Judith/0000-0003-1396-3407	COMET Center ONCOTYROL; Austrian Federal Ministries BMVIT/BMWFJ (via FFG); Tiroler Zukunftsstiftung/Standortagentur Tirol (SAT); 'Kinderkrebshilfe Tirol und Vorarlberg'; 'Krebshilfe Sudtirol'; 'SVP-Frauen-Initiative'; 'Kinderkrebshilfe Sudtirol-Regenbogen'; Austrian Science Fund [P22080-B20]; Medical University Innsbruck for young scientists MUI-START [P2012032014]; OeNB Anniversary Fund [P12582]; 'Tiroler Landeskrankenanstalten Ges.m.b.H. (TILAK)'; 'Tyrolean Cancer Society'; Austrian Science Fund (FWF) [P 22080] Funding Source: researchfish	COMET Center ONCOTYROL; Austrian Federal Ministries BMVIT/BMWFJ (via FFG); Tiroler Zukunftsstiftung/Standortagentur Tirol (SAT); 'Kinderkrebshilfe Tirol und Vorarlberg'; 'Krebshilfe Sudtirol'; 'SVP-Frauen-Initiative'; 'Kinderkrebshilfe Sudtirol-Regenbogen'; Austrian Science Fund(Austrian Science Fund (FWF)); Medical University Innsbruck for young scientists MUI-START; OeNB Anniversary Fund; 'Tiroler Landeskrankenanstalten Ges.m.b.H. (TILAK)'; 'Tyrolean Cancer Society'; Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	We thank Dr Martin Hermann und Dr Albert Amberger (Medical University Innsbruck) for valuable discussion. This work was supported by the COMET Center ONCOTYROL, which is funded by the Austrian Federal Ministries BMVIT/BMWFJ (via FFG) and the Tiroler Zukunftsstiftung/Standortagentur Tirol (SAT) and by grants from 'Kinderkrebshilfe Tirol und Vorarlberg', the 'Krebshilfe Sudtirol', the 'SVP-Frauen-Initiative', the 'Kinderkrebshilfe Sudtirol-Regenbogen', the Austrian Science Fund (P22080-B20), by the intramural funding program of the Medical University Innsbruck for young scientists MUI-START (P2012032014) and by the OeNB Anniversary Fund (P12582). The Tyrolean Cancer Research Institute and this study are supported by the 'Tiroler Landeskrankenanstalten Ges.m.b.H. (TILAK)' and the 'Tyrolean Cancer Society'.	Almeida A, 2010, P NATL ACAD SCI USA, V107, P738, DOI 10.1073/pnas.0913668107; Ausserlechner MJ, 2006, MOL CANCER THER, V5, P1927, DOI 10.1158/1535-7163.MCT-05-0500; Benard G, 2007, J CELL SCI, V120, P838, DOI 10.1242/jcs.03381; BRODEUR GM, 1984, SCIENCE, V224, P1121, DOI 10.1126/science.6719137; Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200; Chen K, 2003, J BIOL CHEM, V278, P39527, DOI 10.1074/jbc.M304423200; Chen QR, 2010, J PROTEOME RES, V9, P373, DOI 10.1021/pr900701v; Connell CM, 2008, J BIOL CHEM, V283, P3289, DOI 10.1074/jbc.M704461200; Connor KM, 2005, J BIOL CHEM, V280, P16916, DOI 10.1074/jbc.M410690200; De Lena M, 2001, EUR J CANCER, V37, P364, DOI 10.1016/S0959-8049(00)00400-7; Di Cosimo S, 2003, DRUGS TODAY, V39, P157, DOI 10.1358/dot.2003.39.3.799451; Dohi T, 2004, J BIOL CHEM, V279, P34087, DOI 10.1074/jbc.C400236200; Dohi T, 2007, MOL CELL, V27, P17, DOI 10.1016/j.molcel.2007.06.004; Fischer K, 2007, BLOOD, V109, P3812, DOI 10.1182/blood-2006-07-035972; Frank S, 2001, DEV CELL, V1, P515, DOI 10.1016/S1534-5807(01)00055-7; Geiger K, 2012, MOL BIOL CELL, V23, P2226, DOI 10.1091/mbc.E11-06-0535; Giorgio M, 2005, CELL, V122, P221, DOI 10.1016/j.cell.2005.05.011; Grignani F, 1998, CANCER RES, V58, P14; Guha M, 2009, CANCER RES, V69, P4954, DOI 10.1158/0008-5472.CAN-09-0584; Hagenbuchner J, 2012, J CELL SCI, V125, P1191, DOI 10.1242/jcs.092098; Hagenbuchner J, 2010, J BIOL CHEM, V285, P6904, DOI 10.1074/jbc.M109.038331; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Herrero-Mendez A, 2009, NAT CELL BIOL, V11, P747, DOI 10.1038/ncb1881; Islam A, 2000, ONCOGENE, V19, P617, DOI 10.1038/sj.onc.1203358; Kang BH, 2011, J BIOL CHEM, V286, P16758, DOI 10.1074/jbc.M110.210120; Karbowski M, 2006, NATURE, V443, P658, DOI 10.1038/nature05111; Kudin AP, 2004, J BIOL CHEM, V279, P4127, DOI 10.1074/jbc.M310341200; Kuznetsov AV, 2008, NAT PROTOC, V3, P965, DOI 10.1038/nprot.2008.61; Obexer P, 2007, CELL DEATH DIFFER, V14, P534, DOI 10.1038/sj.cdd.4402017; Obexer P, 2009, MOL BIOL CELL, V20, P2041, DOI 10.1091/mbc.E08-07-0699; Opel D, 2007, CANCER RES, V67, P735, DOI 10.1158/0008-5472.CAN-06-2201; Rossignol R, 2004, CANCER RES, V64, P985, DOI 10.1158/0008-5472.CAN-03-1101; Sheridan C, 2008, MOL CELL, V31, P570, DOI 10.1016/j.molcel.2008.08.002; Simonnet H, 2002, CARCINOGENESIS, V23, P759, DOI 10.1093/carcin/23.5.759; Singh DH, 2005, STRAHLENTHER ONKOL, V181, P507, DOI 10.1007/s00066-005-1320-z; Smith DJ, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-259; Stern R, 2002, EXP CELL RES, V276, P24, DOI 10.1006/excr.2002.5508; Valko M, 2006, CHEM-BIOL INTERACT, V160, P1, DOI 10.1016/j.cbi.2005.12.009; Vazquez A, 2010, BMC SYST BIOL, V4, DOI 10.1186/1752-0509-4-58; Wu SN, 2011, FEBS J, V278, P941, DOI 10.1111/j.1742-4658.2011.08010.x	40	99	103	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	2013	32	40					4748	4757		10.1038/onc.2012.500	http://dx.doi.org/10.1038/onc.2012.500			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229NW	23146905				2022-12-28	WOS:000325274700003
J	Ballarino, M; Jobert, L; Dembele, D; de la Grange, P; Auboeuf, D; Tora, L				Ballarino, M.; Jobert, L.; Dembele, D.; de la Grange, P.; Auboeuf, D.; Tora, L.			TAF15 is important for cellular proliferation and regulates the expression of a subset of cell cycle genes through miRNAs	ONCOGENE			English	Article						FUS/EWS/TAF15 (FET) proteins; miRNAs; transcription; proliferation; neuronal differentiation; neuroblastoma	BINDING PROTEIN; EWS; MICRORNAS; NEUROBLASTOMA; RESOURCE; TARGETS; GROWTH; FUS	TAF15 (formerly TAFII68) is a member of the FET (FUS, EWS, TAF15) family of RNA-and DNA-binding proteins whose genes are frequently translocated in sarcomas. By performing global gene expression profiling, we found that TAF15 knockdown affects the expression of a large subset of genes, of which a significant percentage is involved in cell cycle and cell death. In agreement, TAF15 depletion had a growth-inhibitory effect and resulted in increased apoptosis. Among the TAF15-regulated genes, targets of microRNAs (miRNAs) generated from the onco-miR-17 locus were overrepresented, with CDKN1A/p21 being the top miRNAs-targeted gene. Interestingly, the levels of onco-miR-17 locus coded miRNAs (miR-17-5p and miR-20a) were decreased upon TAF15 depletion and shown to affect the post-transcriptional regulation of TAF15-dependent genes, such as CDKN1A/p21. Thus, our results demonstrate that TAF15 is required to regulate gene expression of cell cycle regulatory genes post-transcriptionally through a pathway involving miRNAs. The findings that high TAF15 levels are needed for rapid cellular proliferation and that endogenous TAF15 levels decrease during differentiation strongly suggest that TAF15 is a key regulator of maintaining a highly proliferative rate of cellular homeostasis.	[Ballarino, M.; Jobert, L.; Dembele, D.; Tora, L.] Univ Strasbourg, Dept Funct Genom & Canc, Inst Genet & Biol Mol & Cellulaire, INSERM,U964,CNRS,UMR 7104, F-67404 Illkirch Graffenstaden, Cu De Strasbour, France; [de la Grange, P.] Hop St Louis, GenoSplice Technol, Paris, France; [Auboeuf, D.] Ctr Leon Berard, INSERM, U1052, Canc Res Ctr Lyon, F-69373 Lyon, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Louis - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard	Tora, L (corresponding author), Univ Strasbourg, Dept Funct Genom & Canc, Inst Genet & Biol Mol & Cellulaire, INSERM,U964,CNRS,UMR 7104, BP 10142, F-67404 Illkirch Graffenstaden, Cu De Strasbour, France.	laszlo@igbmc.fr	Tora, Laszlo/E-9999-2018; Dembélé, Doulaye/O-6513-2017; Auboeuf, Didier/M-4610-2014; ballarino, monica/AAA-5065-2020	Tora, Laszlo/0000-0001-7398-2250; Dembélé, Doulaye/0000-0003-3879-6940; Ballarino, Monica/0000-0002-8595-7105; Auboeuf, Didier/0000-0002-3757-0002	CNRS; INSERM; AICR [09-0258]; Fondation Recherche Medicale; MRET; Association pour la Recherche sur le Cancer	CNRS(Centre National de la Recherche Scientifique (CNRS)); INSERM(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); AICR; Fondation Recherche Medicale; MRET; Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council)	We are very grateful to JF Caceres, VN Kim and ME Fiori for providing the Pri-17-92, Flag-DGCR8 and pGL3-p21-30UTR plasmids, respectively. We also thank N Charlet Berguerand and M Morlando for the advice in miRNA processing assay, D Devys, M Fournier, A Helmrich, P Bheda and P Laneve for critically reading the manuscript, R Contzler for the XCELLigence analysis and the IGBMC cell culture facility. This work was supported by funds from CNRS, INSERM and AICR (09-0258) grants. MB was supported by the Fondation Recherche Medicale and LJ by MRET and Association pour la Recherche sur le Cancer.	Andersson MK, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-37; Bertolotti A, 1996, EMBO J, V15, P5022, DOI 10.1002/j.1460-2075.1996.tb00882.x; Bertolotti A, 1999, ONCOGENE, V18, P8000, DOI 10.1038/sj.onc.1203207; Beveridge NJ, 2009, CELL SIGNAL, V21, P1837, DOI 10.1016/j.cellsig.2009.07.019; Blechingberg J, 2012, GENE, V493, P27, DOI 10.1016/j.gene.2011.11.038; Butler JEF, 2002, GENE DEV, V16, P2583, DOI 10.1101/gad.1026202; Chaulk SG, 2011, RNA BIOL, V8, P1105, DOI 10.4161/rna.8.6.17410; de la Grange P, 2005, NUCLEIC ACIDS RES, V33, P4276, DOI 10.1093/nar/gki738; De Vito C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023592; Fontana L, 2007, NAT CELL BIOL, V9, P775, DOI 10.1038/ncb1613; Fontana L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002236; Greaves MF, 2003, NAT REV CANCER, V3, P639, DOI 10.1038/nrc1164; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Guil S, 2007, NAT STRUCT MOL BIOL, V14, P591, DOI 10.1038/nsmb1250; Hoell JI, 2011, NAT STRUCT MOL BIOL, V18, P1428, DOI 10.1038/nsmb.2163; Hsu SD, 2011, NUCLEIC ACIDS RES, V39, pD163, DOI 10.1093/nar/gkq1107; Ivanovska I, 2008, MOL CELL BIOL, V28, P2167, DOI 10.1128/MCB.01977-07; Jobert L, 2009, EMBO REP, V10, P494, DOI 10.1038/embor.2009.24; Jobert L, 2009, EXP CELL RES, V315, P1273, DOI 10.1016/j.yexcr.2008.12.008; Law Warren J., 2006, Briefings in Functional Genomics & Proteomics, V5, P8, DOI 10.1093/bfgp/ell015; Le Brigand K, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl485; Lee Y, 2007, METHOD ENZYMOL, V427, P89, DOI 10.1016/S0076-6879(07)27005-3; McKinsey EL, 2011, ONCOGENE, V30, P4910, DOI 10.1038/onc.2011.197; Mendell JT, 2008, CELL, V133, P217, DOI 10.1016/j.cell.2008.04.001; Pall GS, 2008, NAT PROTOC, V3, P1077, DOI 10.1038/nprot.2008.67; Pasquinelli AE, 2012, NAT REV GENET, V13, P271, DOI 10.1038/nrg3162; Petrocca F, 2008, CANCER RES, V68, P8191, DOI 10.1158/0008-5472.CAN-08-1768; ROSSI A, 1992, INT J DEV NEUROSCI, V10, P527, DOI 10.1016/0736-5748(92)90053-3; Sankar S, 2011, CANCER GENET-NY, V204, P351, DOI 10.1016/j.cancergen.2011.07.008; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Spitzer JI, 2011, GENE CHROMOSOME CANC, V50, P338, DOI 10.1002/gcc.20858; THIELE CJ, 1985, NATURE, V313, P404, DOI 10.1038/313404a0; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402	33	30	30	2	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2013	32	39					4646	4655		10.1038/onc.2012.490	http://dx.doi.org/10.1038/onc.2012.490			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226YD	23128393				2022-12-28	WOS:000325072200006
J	Tolani, B; Gopalakrishnan, R; Punj, V; Matta, H; Chaudhary, PM				Tolani, B.; Gopalakrishnan, R.; Punj, V.; Matta, H.; Chaudhary, P. M.			Targeting Myc in KSHV-associated primary effusion lymphoma with BET bromodomain inhibitors	ONCOGENE			English	Article						Myc; PEL; BET; bromodomain; KSHV	SARCOMA-ASSOCIATED HERPESVIRUS; C-MYC; NUCLEAR ANTIGEN; SELECTIVE-INHIBITION; RNA INTERFERENCE; TERMINAL REPEAT; LATENCY; EXPRESSION; CANCER; BRD4	Primary effusion lymphoma (PEL) is an aggressive form of non-Hodgkin's B-cell lymphoma associated with infection by Kaposi's sarcoma-associated herpes virus (KSHV). (+)-JQ1 and I-BET151 are two recently described novel small-molecule inhibitors of BET bromodomain chromatin-associated proteins that have shown impressive preclinical activity in cancers in which MYC is overexpressed at the transcriptional level due to chromosomal translocations that bring the MYC gene under the control of a super-enhancer. PEL cells, in contrast, lack structural alterations in the MYC gene, but have deregulated Myc protein due to the activity of KSHV-encoded latent proteins. We report that PEL cell lines are highly sensitive to bromodomain and extra-terminal (BET) bromodomain inhibitors-induced growth inhibition and undergo G(0)/G(1) cell-cycle arrest, apoptosis and cellular senescence, but without the induction of lytic reactivation, upon treatment with these drugs. Treatment of PEL cell lines with BET inhibitors suppressed the expression of MYC and resulted in a genome-wide perturbation of MYC-dependent genes. Silencing of BRD4 and MYC expression blocked cell proliferation and cell-cycle progression, while ectopic expression of MYC from a retroviral promoter rescued cells from (+)-JQ1-induced growth arrest. In a xenograft model of PEL, (+)-JQ1 significantly reduced tumor growth and improved survival. Taken collectively, our results demonstrate that the utility of BET inhibitors may not be limited to cancers in which genomic alterations result in extremely high expression of MYC and they may have equal or perhaps greater activity against cancers in which the MYC genomic locus is structurally intact and c-Myc protein is deregulated at the post-translational level and is only modestly overexpressed.	[Chaudhary, P. M.] Univ So Calif, Keck Sch Med, Jane Anne Nohl Div Hematol, Los Angeles, CA 90033 USA; [Chaudhary, P. M.] Univ So Calif, Keck Sch Med, Ctr Study Blood Dis, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Chaudhary, PM (corresponding author), Univ So Calif, Keck Sch Med, Jane Anne Nohl Div Hematol, Los Angeles, CA 90033 USA.	preet.chaudhary@med.usc.edu	Gopalakrishnan, Ramakrishnan/N-3454-2015; Chaudhary, Preet/E-1970-2018	Gopalakrishnan, Ramakrishnan/0000-0002-5068-6886; Tolani, Bhairavi/0000-0001-9076-866X	National Institutes of Health [CA139119, DE019811, P30CA014089]; STOP Cancer Foundations; National Cancer Institute Cancer Center Shared Grant [P30CA014089]; USC Provost Office Dean's Development Funds; NATIONAL CANCER INSTITUTE [R01CA139119, P30CA014089] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE019811] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); STOP Cancer Foundations; National Cancer Institute Cancer Center Shared Grant; USC Provost Office Dean's Development Funds; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	The authors thank Dr James Bradner (Dana-Farber Cancer Institute, Boston, MA, USA) for his generous contribution of (+)-JQ1 and (-)-JQ1, Dr Peter Howley (Harvard University) for BRD4 antibody, Gary Hayward (Johns Hopkins University) for RTA antibody, and Drs Lossos and Ramos from the University of Miami for UM-PEL-1 and UM-PEL-3 cells, respectively. This work was supported by grants from the National Institutes of Health (CA139119, DE019811 and P30CA014089) and STOP Cancer Foundations. Flow cytometry was performed in the USC Flow Cytometry Core Facility that is supported in part by the National Cancer Institute Cancer Center Shared Grant award P30CA014089 and the USC Provost Office Dean's Development Funds.	Ballestas ME, 2001, J VIROL, V75, P3250, DOI 10.1128/JVI.75.7.3250-3258.2001; Bartholomeeusen K, 2012, J BIOL CHEM, V287, P36609, DOI 10.1074/jbc.M112.410746; Bhatt S, 2011, 53 ASH ANN M EXP; Boulanger E, 2004, AM J HEMATOL, V76, P88, DOI 10.1002/ajh.20048; Boulanger E, 2003, AM J HEMATOL, V73, P143, DOI 10.1002/ajh.10341; Bubman D, 2007, ONCOGENE, V26, P4979, DOI 10.1038/sj.onc.1210299; Chung CW, 2011, J BIOMOL SCREEN, V16, P1170, DOI 10.1177/1087057111421372; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; Dawson MA, 2011, NATURE, V478, P529, DOI 10.1038/nature10509; Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504; Garber AC, 2002, J BIOL CHEM, V277, P27401, DOI 10.1074/jbc.M203489200; Li XD, 2010, J VIROL, V84, P8945, DOI 10.1128/JVI.00244-10; Li ZR, 2003, P NATL ACAD SCI USA, V100, P8164, DOI 10.1073/pnas.1332764100; Liu JY, 2007, J VIROL, V81, P10451, DOI 10.1128/JVI.00804-07; Loven J, 2013, CELL, V153, P320, DOI 10.1016/j.cell.2013.03.036; Lubyova B, 2007, J BIOL CHEM, V282, P31944, DOI 10.1074/jbc.M706430200; Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108; Morris K, 2003, LANCET ONCOL, V4, P5, DOI 10.1016/S1470-2045(03)00969-0; Nador RG, 1996, BLOOD, V88, P645, DOI 10.1182/blood.V88.2.645.bloodjournal882645; Nakamura H, 2003, J VIROL, V77, P4205, DOI 10.1128/JVI.77.7.4205-4220.2003; Nicholas J, 2007, FRONT BIOSCI-LANDMRK, V12, P265, DOI 10.2741/2063; Nicodeme E, 2010, NATURE, V468, P1119, DOI 10.1038/nature09589; Ott CJ, 2012, BLOOD, V120, P2843, DOI 10.1182/blood-2012-02-413021; Ottinger M, 2006, J VIROL, V80, P10772, DOI 10.1128/JVI.00804-06; Pelengaris S, 2002, NAT REV CANCER, V2, P764, DOI 10.1038/nrc904; Sarosiek KA, 2010, P NATL ACAD SCI USA, V107, P13069, DOI 10.1073/pnas.1002985107; Shin KJ, 2006, P NATL ACAD SCI USA, V103, P13759, DOI 10.1073/pnas.0606179103; Shou YP, 2000, P NATL ACAD SCI USA, V97, P228, DOI 10.1073/pnas.97.1.228; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; WABINGA HR, 1993, INT J CANCER, V54, P26, DOI 10.1002/ijc.2910540106; Wu SY, 2007, J BIOL CHEM, V282, P13141, DOI 10.1074/jbc.R700001200; You JX, 2006, J VIROL, V80, P8909, DOI 10.1128/JVI.00502-06; Zhao Hong, 2013, Methods Mol Biol, V965, P83, DOI 10.1007/978-1-62703-239-1_5; Zhao JS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001067; Zhu XC, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-98; Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334	38	73	77	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2014	33	22					2928	2937		10.1038/onc.2013.242	http://dx.doi.org/10.1038/onc.2013.242			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EI	23792448	Green Accepted			2022-12-28	WOS:000337231800012
J	Bonito, NA; Drechsler, J; Stoecker, S; Carmo, CR; Seckl, MJ; Hermanns, HM; Costa-Pereira, AP				Bonito, N. A.; Drechsler, J.; Stoecker, S.; Carmo, C. R.; Seckl, M. J.; Hermanns, H. M.; Costa-Pereira, A. P.			Control of gp130 expression by the mitogen-activated protein kinase ERK2	ONCOGENE			English	Article						ERK; gp130; IL-6-type cytokines; JAK/STAT signalling; receptor expression	LEUKEMIA INHIBITORY FACTOR; CYTOKINE RECEPTOR GP130; INFLAMMATORY CYTOKINES; SIGNAL-TRANSDUCTION; CELL-PROLIFERATION; STAT3 ACTIVATION; CANCER; GROWTH; IL-6; TRANSFORMATION	Interleukin (IL)-6-type cytokines such as IL-6, oncostatin M (OSM) and leukaemia inhibitory factor (LIF) signal through receptor complexes that are critically dependent on gp130. The latter is the common signal-transducing molecule that couples these cytokines to their downstream effectors, Janus kinases (JAKs) and signal transducers and activators of transcription (STATs). IL-6-type cytokine signalling additionally involves the recruitment and activation of extracellular signal-regulated kinase (ERK) 1 and ERK2. Both STATs and ERKs regulate responses mediated by members of the IL-6 family. Here, we show that ERK2, but not ERK1, also controls the expression and function of gp130 per se, as silencing ERK2 in human osteosarcoma U2OS cells inhibits the expression of gp130. This does not simply reflect quantitative differences between ERK1 and ERK2, and the effects are not restricted to osteosarcoma cells, as they can be extended to several other cancer cell types analysed to date (such as breast, prostate, lung and cervical cancer cells). Importantly, ERK2 binds to the GP130 promoter, where it perhaps interacts with the transcriptional machinery. Indeed, its role in the transcriptional regulation of the GP130 gene was corroborated using luciferase reporter assays and messenger RNA stability experiments. Considering the pivotal role that gp130 has in cancer and inflammation these data thus identify novel non-overlapping functions for ERK1 and ERK2 that are biologically relevant.	[Bonito, N. A.; Stoecker, S.; Carmo, C. R.; Seckl, M. J.; Costa-Pereira, A. P.] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Fac Med, London W12 0NN, England; [Drechsler, J.; Hermanns, H. M.] Rudolf Virchow Ctr, DFG Res Ctr Expt Biomed, Wurzburg, Germany; [Carmo, C. R.] Inst Gulbenkian Ciencias, Oeiras, Portugal	Imperial College London; German Research Foundation (DFG); University of Wurzburg; Instituto Gulbenkian de Ciencia	Costa-Pereira, AP (corresponding author), Univ London Imperial Coll Sci Technol & Med, ICTEM, Dept Surg & Canc, Fac Med, Hammersmith Hosp Campus,Du Cane Rd, London W12 0NN, England.	a.costa-pereira@imperial.ac.uk	Costa-Pereira, Ana/AAE-8192-2020	Ramos do Carmo, Catarina/0000-0001-9717-6667; Costa-Pereira, Ana/0000-0001-8265-8065	Foundation for Science and Technology (FCT) ( Lisbon, Portugal), [SFRH/BD/61857/2009]; Cancer Treatment and Research Trust (CTRT); Cancer Research UK; Deutsche Forschungsgemeinschaft (DFG) [FZ82]; Elsie Widdowson Fellowship	Foundation for Science and Technology (FCT) ( Lisbon, Portugal),(Portuguese Foundation for Science and Technology); Cancer Treatment and Research Trust (CTRT); Cancer Research UK(Cancer Research UK); Deutsche Forschungsgemeinschaft (DFG)(German Research Foundation (DFG)); Elsie Widdowson Fellowship	We are grateful to Dr Charles A O'Brien (University of Arkansas for Medical Sciences, Little Rock, USA) for control and full-length gp130 (p2433) luciferase constructs. Within Imperial College London, the authors are indebted to Dr Charlotte Bevan and her research team, Dr Rajat Roy, Mr Richard Schlegel and Dr Olivier Pardo for many helpful discussions, and Dr Anna Maria Tommasi for technical help. NB is funded by a PhD studentship (SFRH/BD/61857/2009) from the Foundation for Science and Technology (FCT) ( Lisbon, Portugal), and CRC is funded by Cancer Treatment and Research Trust (CTRT). APC-P and MJS are funded by Cancer Research UK and CTRT. JD and HMH are funded by the Deutsche Forschungsgemeinschaft (DFG, FZ82). APC-P is also the recipient of an Elsie Widdowson Fellowship.	Bourcier C, 2006, CANCER RES, V66, P2700, DOI 10.1158/0008-5472.CAN-05-3129; Bromberg J, 2009, CANCER CELL, V15, P79, DOI 10.1016/j.ccr.2009.01.009; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Chen Z, 2001, CHEM REV, V101, P2449, DOI 10.1021/cr000241p; Cohen-Armon M, 2007, MOL CELL, V25, P297, DOI 10.1016/j.molcel.2006.12.012; Costa-Pereira AP, 2011, AM J CANCER RES, V1, P806; Ernst M, 2004, TRENDS GENET, V20, P23, DOI 10.1016/j.tig.2003.11.003; Fasnacht N, 2008, SEMIN CELL DEV BIOL, V19, P379, DOI 10.1016/j.semcdb.2008.07.001; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Gough DJ, 2009, SCIENCE, V324, P1713, DOI 10.1126/science.1171721; Grivennikov SI, 2011, ANN RHEUM DIS, V70, pI104, DOI 10.1136/ard.2010.140145; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; Hermanns HM, 2000, J BIOL CHEM, V275, P40742, DOI 10.1074/jbc.M005408200; Hirai H, 2011, BIOCHEM J, V438, P11, DOI 10.1042/BJ20102152; Hu SH, 2009, CELL, V139, P610, DOI 10.1016/j.cell.2009.08.037; Inda MD, 2010, GENE DEV, V24, P1731, DOI 10.1101/gad.1890510; Inghirami G, 2005, CELL CYCLE, V4, P1131, DOI 10.4161/cc.4.9.1985; Jain N, 1998, ONCOGENE, V17, P3157, DOI 10.1038/sj.onc.1202238; Kamimura D, 2004, REV PHYSIOL BIOCH P, V149, P1, DOI 10.1007/s10254-003-0012-2; Koskela HLM, 2012, NEW ENGL J MED, V366, P1905, DOI 10.1056/NEJMoa1114885; Krens SFG, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-196; Lavagni P, 2009, J MOL NEUROSCI, V37, P212, DOI 10.1007/s12031-008-9118-y; Lefloch R, 2008, MOL CELL BIOL, V28, P511, DOI 10.1128/MCB.00800-07; Marchetti A, 2004, CELL DEATH DIFFER, V11, P596, DOI 10.1038/sj.cdd.4401368; Marchi M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003873; Mebratu Y, 2009, CELL CYCLE, V8, P1168, DOI 10.4161/cc.8.8.8147; Neurath MF, 2011, CYTOKINE GROWTH F R, V22, P83, DOI 10.1016/j.cytogfr.2011.02.003; OBrien CA, 1997, J BIOL CHEM, V272, P15003, DOI 10.1074/jbc.272.23.15003; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; Park EJ, 2010, CELL, V140, P197, DOI 10.1016/j.cell.2009.12.052; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pokholok DK, 2006, SCIENCE, V313, P533, DOI 10.1126/science.1127677; Pouyssegur J, 2003, EUR J BIOCHEM, V270, P3291, DOI 10.1046/j.1432-1033.2003.03707.x; Radtke S, 2010, J CELL SCI, V123, P947, DOI 10.1242/jcs.065326; Rebouissou S, 2009, NATURE, V457, P200, DOI 10.1038/nature07475; Rodriguez J, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002324; Roux PP, 2004, MICROBIOL MOL BIOL R, V68, P320, DOI 10.1128/MMBR.68.2.320-344.2004; Roy SK, 2002, P NATL ACAD SCI USA, V99, P7945, DOI 10.1073/pnas.122075799; Saba-El-Leil MK, 2003, EMBO REP, V4, P964, DOI 10.1038/sj.embor.embor939; Santos CI, 2011, BBA-REV CANCER, V1816, P38, DOI 10.1016/j.bbcan.2011.03.003; Schiemann WP, 1997, J BIOL CHEM, V272, P16631, DOI 10.1074/jbc.272.26.16631; Schlessinger K, 2005, CANCER RES, V65, P5828, DOI 10.1158/0008-5472.CAN-05-0317; Shapiro PS, 1999, MOL CELL BIOL, V19, P3551; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Song LX, 2003, ONCOGENE, V22, P4150, DOI 10.1038/sj.onc.1206479; Stuhlmann-Laeisz C, 2006, MOL BIOL CELL, V17, P2986, DOI 10.1091/mbc.E05-12-1129; Vantaggiato Chiara, 2006, J Biol, V5, P14, DOI 10.1186/jbiol38; Voisin L, 2010, MOL CELL BIOL, V30, P2918, DOI 10.1128/MCB.00131-10; Watling D, 2008, P NATL ACAD SCI USA, V105, P6051, DOI 10.1073/pnas.0710814105; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; Yoshimura A, 2006, CANCER SCI, V97, P439, DOI 10.1111/j.1349-7006.2006.00197.x; Yu H, 2004, NAT REV CANCER, V4, P97, DOI 10.1038/nrc1275; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734	53	15	15	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2014	33	17					2255	2263		10.1038/onc.2013.159	http://dx.doi.org/10.1038/onc.2013.159			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF8WJ	23686311				2022-12-28	WOS:000334996000011
J	Wang, H; Han, M; Whetsell, W; Wang, J; Rich, J; Hallahan, D; Han, Z				Wang, H.; Han, M.; Whetsell, W., Jr.; Wang, J.; Rich, J.; Hallahan, D.; Han, Z.			Tax-interacting protein 1 coordinates the spatiotemporal activation of Rho GTPases and regulates the infiltrative growth of human glioblastoma	ONCOGENE			English	Article						ARHGEF7; cell migration; glioblastoma; rhotekin; tax-interacting protein-1; Rho GTPases	CELL POLARIZATION; BETA-CATENIN; ASTROCYTE MIGRATION; EXCHANGE FACTOR; ALPHA-CATENIN; CANCER CELLS; PDZ-DOMAINS; C-TERMINUS; TIP-1; EXPRESSION	PDZ domains represent one group of the major structural units that mediate protein interactions in intercellular contact, signal transduction and assembly of biological machineries. Tax-interacting protein (TIP)-1 protein is composed of a single PDZ domain that distinguishes TIP-1 from other PDZ domain proteins that more often contain multiple protein domains and function as scaffolds for protein complex assembly. However, the biological functions of TIP-1, especially in cell transformation and tumor progression, are still controversial as observed in a variety of cell types. In this study, we have identified ARHGEF7, a guanine nucleotide exchange factor for Rho GTPases, as one novel TIP-1-interacting protein in human glioblastoma cells. We found that the presence of TIP-1 protein is essential to the intracellular redistribution of ARHGEF7 and rhotekin, one Rho effector and the spatiotemporally coordinated activation of Rho GTPases (RhoA, Cdc42 and Rac1) in migrating glioblastoma cells. TIP-1 knockdown resulted in both aberrant localization of ARHGEF7 and rhotekin, as well as abnormal activation of Rho GTPases that was accompanied with impaired motility of glioblastoma cells. Furthermore, TIP-1 knockdown suppressed tumor cell dispersal in orthotopic glioblastoma murine models. We also observed high levels of TIP-1 expression in human glioblastoma specimens, and the elevated TIP-1 levels are associated with advanced staging and poor prognosis in glioma patients. Although more studies are needed to further dissect the mechanism(s) by which TIP-1 modulates the intracellular redistribution and activation of Rho GTPases, this study suggests that TIP-1 holds potential as both a prognostic biomarker and a therapeutic target of malignant gliomas.	[Wang, H.; Han, M.; Han, Z.] Vanderbilt Univ, Sch Med, Dept Radiat Oncol, Nashville, TN 37232 USA; [Wang, H.; Han, Z.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; [Han, M.] Chinese Acad Sci, Key Lab Anim Models & Human Dis Mech, Kunming Inst Zool, Kunming, Peoples R China; [Han, M.] Chinese Acad Sci, Grad Sch, Beijing, Peoples R China; [Whetsell, W., Jr.] Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA; [Wang, J.] Vanderbilt Univ, Sch Med, Dept Neurol Surg, Nashville, TN 37232 USA; [Wang, J.; Han, Z.] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; [Rich, J.] Cleveland Clin, Lerner Res Inst, Dept Stem Cell Biol & Regenerat Med, Cleveland, OH 44106 USA; [Hallahan, D.] Washington Univ, Sch Med, Dept Radiat Oncol, St Louis, MO USA	Vanderbilt University; Vanderbilt University; Chinese Academy of Sciences; Kunming Institute of Zoology; Chinese Academy of Sciences; University of Chinese Academy of Sciences, CAS; Vanderbilt University; Vanderbilt University; Vanderbilt University; Cleveland Clinic Foundation; Washington University (WUSTL)	Han, Z (corresponding author), Vanderbilt Univ, Sch Med, Dept Radiat Oncol, 1301 Med Ctr Dr,B902 TVC, Nashville, TN 37232 USA.	zhaozhong.han@vanderbilt.edu	Wang, Hailun/T-5696-2019; Rich, Jeremy/AAM-1445-2021	Wang, Hailun/0000-0001-8651-2856	NIH [R01CA127482, P50 CA128323, R01CA112385]; NATIONAL CANCER INSTITUTE [R01CA125757, R01CA127482, P50CA128323, R01CA112385] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000448] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS))	We thank Drs Barbara Fingleton, Steven K Hanks and Mike Freeman (Vanderbilt) for critical reading and discussions of this manuscript. We are grateful to Dr Paul A Welling at University of Maryland for the kind gift of TIP-1-expressing constructs. We appreciate the technical assistance and advices from Dr Ling Geng (Pathology, Vanderbilt University) in the animal studies, Dr Heping Yan (Washington University at St Louis) in the antibody development, Dr Bret Mobley (Pathology, Vanderbilt University) in the microscopic examination of tissue blocks and the technical staffs at the Cell Imaging, Histology and Genomics Cores of the Vanderbilt-Ingram Cancer Center. This study was supported in part by NIH Grants R01CA127482 (Z Han), P50 CA128323 (Gore) and R01CA112385 (DE Hallahan).	Akella NS, 2006, J NEUROSCI METH, V153, P183, DOI 10.1016/j.jneumeth.2005.10.026; Alewine C, 2006, MOL BIOL CELL, V17, P4200, DOI 10.1091/mbc.E06-02-0129; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Audebert S, 2004, CURR BIOL, V14, P987, DOI 10.1016/j.cub.2004.05.051; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Besser J, 2007, DEV GROWTH DIFFER, V49, P205, DOI 10.1111/j.1440-169x.2007.00921.x; Beuming T, 2005, BIOINFORMATICS, V21, P827, DOI 10.1093/bioinformatics/bti098; BURGER PC, 1983, J NEUROSURG, V58, P159, DOI 10.3171/jns.1983.58.2.0159; CAVENEE WK, 2000, PATHOLOGY GENETICS T, P10; Dickinson DJ, 2011, SCIENCE, V331, P1336, DOI 10.1126/science.1199633; Durney MA, 2009, J BIOMOL NMR, V45, P329, DOI 10.1007/s10858-009-9361-8; Etienne-Manneville S, 2006, METHOD ENZYMOL, V406, P565, DOI 10.1016/S0076-6879(06)06044-7; Freije WA, 2004, CANCER RES, V64, P6503, DOI 10.1158/0008-5472.CAN-04-0452; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Garcia-Mata R, 2007, TRENDS CELL BIOL, V17, P36, DOI 10.1016/j.tcb.2006.11.004; Geng L, 2006, INT J RADIAT ONCOL, V64, P263, DOI 10.1016/j.ijrobp.2005.08.025; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hampson L, 2004, INT J ONCOL, V25, P1249; Hampson L, 2009, BRIT J CANCER, V101, P829, DOI 10.1038/sj.bjc.6605208; Han MJ, 2013, CANCER LETT, V328, P55, DOI 10.1016/j.canlet.2012.09.011; Han MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045402; Han MJ, 2012, BIOCHEM BIOPH RES CO, V422, P139, DOI 10.1016/j.bbrc.2012.04.123; Hwang SL, 2004, EJSO-EUR J SURG ONC, V30, P68, DOI 10.1016/j.ejso.2003.10.018; Iden S, 2008, NAT REV MOL CELL BIO, V9, P846, DOI 10.1038/nrm2521; Jaffe AB, 2005, ANNU REV CELL DEV BI, V21, P247, DOI 10.1146/annurev.cellbio.21.020604.150721; Ji HT, 2009, MOL CELL, V36, P547, DOI 10.1016/j.molcel.2009.09.034; Kanamori M, 2003, J BIOL CHEM, V278, P38758, DOI 10.1074/jbc.M306324200; Machacek M, 2009, NATURE, V461, P99, DOI 10.1038/nature08242; Mayhew MW, 2006, J PROTEOME RES, V5, P2417, DOI 10.1021/pr060140t; Molina JR, 2012, ONCOGENE, V31, P1264, DOI 10.1038/onc.2011.324; Olalla L, 2001, FEBS LETT, V488, P116, DOI 10.1016/S0014-5793(00)02373-5; Olalla L, 2008, J NEUROSCI RES, V86, P281, DOI 10.1002/jnr.21505; Oliver AW, 2011, BRIT J CANCER, V104, P324, DOI 10.1038/sj.bjc.6606026; Osmani N, 2006, CURR BIOL, V16, P2395, DOI 10.1016/j.cub.2006.10.026; Pertz O, 2006, NATURE, V440, P1069, DOI 10.1038/nature04665; Phillips HS, 2006, CANCER CELL, V9, P157, DOI 10.1016/j.ccr.2006.02.019; Reynaud C, 2000, J BIOL CHEM, V275, P33962, DOI 10.1074/jbc.M000465200; Rincon E, 2011, J CELL SCI, V124, P776, DOI 10.1242/jcs.072447; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; Salhia B, 2008, AM J PATHOL, V173, P1828, DOI 10.2353/ajpath.2008.080043; Stupp R, 2009, LANCET ONCOL, V10, P459, DOI 10.1016/S1470-2045(09)70025-7; Subbaiah VK, 2011, BIOCHEM J, V439, P195, DOI 10.1042/BJ20110903; ten Klooster JP, 2006, J CELL BIOL, V172, P759, DOI 10.1083/jcb.200509096; Wang HL, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012051; Zencir S, 2011, BIOCHEM BIOPH RES CO, V411, P792, DOI 10.1016/j.bbrc.2011.07.029; Zhang JX, 2008, J MOL BIOL, V384, P255, DOI 10.1016/j.jmb.2008.09.034	46	18	19	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2014	33	12					1558	1569		10.1038/onc.2013.97	http://dx.doi.org/10.1038/onc.2013.97			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD4TS	23563176	Green Accepted			2022-12-28	WOS:000333244200009
J	Sung, M; Giannakakou, P				Sung, M.; Giannakakou, P.			BRCA1 regulates microtubule dynamics and taxane-induced apoptotic cell signaling	ONCOGENE			English	Article						BRCA1; microtubule; dynamics; taxane; drug resistance	MESSENGER-RNA EXPRESSION; POSITIVE BREAST-CANCER; GAMMA-TUBULIN-BINDING; ADJUVANT CHEMOTHERAPY; NUCLEAR ACCUMULATION; TUMOR-SUPPRESSOR; SUPPORTIVE CARE; DOCETAXEL PLUS; PROTEIN; PACLITAXEL	The taxanes are effective microtubule-stabilizing chemotherapy drugs used in the treatment of various solid tumors. However, the emergence of drug resistance hampers their clinical efficacy. The molecular basis of clinical taxane resistance remains poorly understood. Breast cancer 1, early onset gene, BRCA1, is a tumor-suppressor gene, whose expression has been correlated with taxane sensitivity in many solid tumors including non-small cell lung cancer. However, the molecular mechanism underlying the relationship between BRCA1 (B1) expression and taxane activity remains unclear. To this end, we created a stable B1 knockdown A549 cell line (B1-KD) to investigate B1's role in microtubule biology and response to taxane treatment. We show that B1-KD rendered A549 cells resistant to paclitaxel (PTX), phenocopying clinical studies showing that low B1 expression correlated with taxane resistance. As previously reported, we show that loss of B1 enhanced centrosomal g-tubulin localization and microtubule nucleation. Interestingly, we found that the B1-KD cells exhibited increased microtubule dynamics as compared with parental A549 cells, as assessed by live-cell confocal microscopy using enhanced green fluorescent protein-tagged a-tubulin or EB1 protein. In addition, we showed that loss of B1 impairs the ability of PTX to induce microtubule polymerization using immunofluorescence microscopy and a cell-based tubulin polymerization assay. Furthermore, B1-KD cells exhibited significantly lower intracellular binding of a fluorescently labeled PTX to microtubules. Recent studies have shown that PTX-stabilized microtubules serves as a scaffold for pro-caspase-8 binding and induction of apoptosis downstream of induced-proximity activation of caspase-8. Here we show that loss of B1 reduces the association of pro-caspase-8 with microtubules and subsequently leads to impaired PTX-induced activation of apoptosis. Taken together, our data show that B1 regulates indirectly endogenous microtubule dynamics and stability while its loss leads to microtubules that are more dynamic and less susceptible to PTX-induced stabilization conferring taxane resistance.	[Sung, M.; Giannakakou, P.] Cornell Univ, Weill Med Coll, Dept Med, Div Hematol & Med Oncol, New York, NY 10065 USA	Cornell University	Giannakakou, P (corresponding author), Cornell Univ, Weill Med Coll, Dept Med, Div Hematol & Med Oncol, 1300 York Ave,C610C, New York, NY 10065 USA.	pag2015@med.cornell.edu			National Institutes of Health [T32 CA062948, RO1 CA137020, NCI U54 CA143876]; NATIONAL CANCER INSTITUTE [R01CA137020, U54CA143876, T32CA062948] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We would like to thank Dr Geri Kreitzer (Weill Cornell Medical College), Dr Mary Ann Jordan (University of California, Santa Barbara) and Dr Richard Baer (Columbia University) for their kind gifts. We would also like to thank Dr Siddhartha Sen for help with the flow cytometry experiments. Work by Matthew Sung was supported by the National Institutes of Health (T32 CA062948, RO1 CA137020, NCI U54 CA143876).	Bieling P, 2007, NATURE, V450, P1100, DOI 10.1038/nature06386; Bouissou A, 2009, J CELL BIOL, V187, P327, DOI 10.1083/jcb.200905060; Buzdar AU, 2002, CLIN CANCER RES, V8, P1073; Byrski T, 2008, BREAST CANCER RES TR, V108, P289, DOI 10.1007/s10549-007-9600-1; Carbonaro M, 2012, J BIOL CHEM, V287, P11859, DOI 10.1074/jbc.M112.345587; Carbonaro M, 2011, J CELL BIOL, V192, P83, DOI 10.1083/jcb.201004145; Chen L, 2012, P NATL ACAD SCI USA, V109, P11842, DOI 10.1073/pnas.1121180109; Choy H, 1999, ONCOLOGY-NY, V13, P23; Coene ED, 2011, J CELL BIOL, V192, P497, DOI 10.1083/jcb.201004136; Darshan MS, 2011, CANCER RES, V71, P6019, DOI 10.1158/0008-5472.CAN-11-1417; de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140-6736(10)61389-X; Etienne-Manneville S, 2010, CURR OPIN CELL BIOL, V22, P104, DOI 10.1016/j.ceb.2009.11.008; Font A, 2011, ANN ONCOL, V22, P139, DOI 10.1093/annonc/mdq333; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Giannakakou P, 2000, NAT CELL BIOL, V2, P709, DOI 10.1038/35036335; Giannakakou P, 2002, P NATL ACAD SCI USA, V99, P10855, DOI 10.1073/pnas.132275599; Goncalves A, 2001, P NATL ACAD SCI USA, V98, P11737, DOI 10.1073/pnas.191388598; Henderson IC, 2003, J CLIN ONCOL, V21, P976, DOI 10.1200/JCO.2003.02.063; Hennessy BTJ, 2010, J CLIN ONCOL, V28, P3570, DOI 10.1200/JCO.2009.27.2997; Hergovich A, 2003, NAT CELL BIOL, V5, P64, DOI 10.1038/ncb899; Hsu LC, 2001, CANCER RES, V61, P7713; Jin SQ, 2009, J BIOL CHEM, V284, P22970, DOI 10.1074/jbc.M109.009134; Jordan MA, 2004, NAT REV CANCER, V4, P253, DOI 10.1038/nrc1317; Joukov V, 2006, CELL, V127, P539, DOI 10.1016/j.cell.2006.08.053; Jourdain L, 1997, BIOCHEMISTRY-US, V36, P10817, DOI 10.1021/bi971491b; Kauh J, 2011, CANCER-AM CANCER SOC, V117, P4049, DOI 10.1002/cncr.26004; Komlodi-Pasztor E, 2011, NAT REV CLIN ONCOL, V8, DOI 10.1038/nrclinonc.2010.228-c2; Lynch HT, 2008, BREAST J, V14, P3, DOI 10.1111/j.1524-4741.2007.00515.x; Mamounas EP, 2005, J CLIN ONCOL, V23, P3686, DOI 10.1200/JCO.2005.10.517; Marcus AI, 2006, CANCER RES, V66, P8838, DOI 10.1158/0008-5472.CAN-06-0699; Marcus AI, 2005, CANCER RES, V65, P3883, DOI 10.1158/0008-5472.CAN-04-3757; Martin M, 2005, NEW ENGL J MED, V352, P2302, DOI 10.1056/NEJMoa043681; Martin M, 2010, NEW ENGL J MED, V363, P2200, DOI 10.1056/NEJMoa0910320; McAlpine JN, 2012, MODERN PATHOL, V25, P740, DOI 10.1038/modpathol.2011.211; Mielgo A, 2009, ONCOGENE, V28, P3551, DOI 10.1038/onc.2009.210; MINOTTI AM, 1991, J BIOL CHEM, V266, P3987; Narod SA, 2004, NAT REV CANCER, V4, P665, DOI 10.1038/nrc1431; Parvin JD, 2009, ENVIRON MOL MUTAGEN, V50, P649, DOI 10.1002/em.20475; PARYSEK LM, 1984, J CELL BIOL, V99, P1309, DOI 10.1083/jcb.99.4.1309; Petrylak DP, 2004, NEW ENGL J MED, V351, P1513, DOI 10.1056/NEJMoa041318; Quinn JE, 2007, CLIN CANCER RES, V13, P7413, DOI 10.1158/1078-0432.CCR-07-1083; Ranson M, 2000, JNCI-J NATL CANCER I, V92, P1074, DOI 10.1093/jnci/92.13.1074; Reguart N, 2008, CLIN LUNG CANCER, V9, P331, DOI 10.3816/CLC.2008.n.048; Rhiem K, 2010, ANTICANCER RES, V30, P3445; Roche H, 2006, J CLIN ONCOL, V24, P5664, DOI 10.1200/JCO.2006.07.3916; Rosell R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005133; Roszkowski K, 2000, LUNG CANCER-J IASLC, V27, P145, DOI 10.1016/S0169-5002(00)00094-5; Russell PA, 2000, INT J CANCER, V87, P317, DOI 10.1002/1097-0215(20000801)87:3<317::AID-IJC2>3.0.CO;2-B; Saiki Y, 2011, INT J OTOLARYNGOL, V2011; Sankaran S, 2005, MOL CELL BIOL, V25, P8656, DOI 10.1128/MCB.25.19.8656-8668.2005; Sankaran S, 2007, CANCER BIOL THER, V6, P1853, DOI 10.4161/cbt.6.12.5164; Schoffski P, 2011, EUR J CANCER, V47, P1006, DOI 10.1016/j.ejca.2011.01.016; Tannock IF, 2004, NEW ENGL J MED, V351, P1502, DOI 10.1056/NEJMoa040720; Tassone P, 2003, BRIT J CANCER, V88, P1285, DOI 10.1038/sj.bjc.6600859; Thoma CR, 2010, J CELL BIOL, V190, P991, DOI 10.1083/jcb.201006059; Vaughan KT, 2005, J CELL BIOL, V171, P197, DOI 10.1083/jcb.200509150; Wei J, 2011, J NATL CANCER I, V103, P1552, DOI 10.1093/jnci/djr326; Wen YD, 2004, KENYON REV, V26, P1; WILSON L, 1995, CHEM BIOL, V2, P569, DOI 10.1016/1074-5521(95)90119-1; Xu GQ, 2010, NAT BIOTECHNOL, V28, P868, DOI 10.1038/nbt.1654; Zhang JR, 2005, MOL CANCER RES, V3, P531, DOI 10.1158/1541-7786.MCR-05-0192; Zhou J, 2009, J BIOL CHEM, V284, P9648, DOI 10.1074/jbc.M808708200; Zumbrunn J, 2001, CURR BIOL, V11, P44, DOI 10.1016/S0960-9822(01)00002-1	63	40	40	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2014	33	11					1418	1428		10.1038/onc.2013.85	http://dx.doi.org/10.1038/onc.2013.85			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD0SD	23524581	Green Accepted			2022-12-28	WOS:000332943500009
J	Wong, CH; Wu, Z; Yu, Q				Wong, C. H.; Wu, Z.; Yu, Q.			CTSL2 is a pro-apoptotic target of E2F1 and a modulator of histone deacetylase inhibitor and DNA damage-induced apoptosis	ONCOGENE			English	Article						E2F1; apoptosis; CTSL2	CELL-DEATH; CANCER; INDUCTION; P53; EXPRESSION; LYSOSOMES; PATHWAYS; THERAPY; GENES; LIFE	Aberrant regulation of the pRB/E2F1 pathway has been invariably linked to inappropriate proliferation and/apoptosis in human cancers. Therefore, understanding the intricacies of the signaling pathway and identification of novel E2F1 targets involved in apoptosis could pave way for new therapeutic manipulation. Here, we identified CTSL2 (cathepsin L2/cathepsin V) as a novel E2F1 target that participates in E2F1-dependent apoptosis. We showed that E2F1 directly binds to CTSL2 promoter and that CTSL2 is regulated by both exogenous and endogenous E2F1. RNAi-mediated depletion of CTSL2 effectively abrogated ectopic E2F1-induced apoptosis, coupled with reduced lysosomal membrane permeabilization (LMP) and mitochondrial membrane depolarization. CTSL2 knockdown also inhibited apoptosis mediated by the endogenous E2F1 activated by DNA damage. Furthermore, we showed that CTSL2 depletion in cancer cells resulted in inhibition of histone deacetylase inhibitor (HDACi)-induced apoptosis, and conversely ectopic overexpression of CTSL2-sensitized cancer cells to HDACi. This study uncovered a novel E2F1 target implicated in LMP and apoptosis activation, as well as in the modulation of HDACi and chemotherapeutic drugs response.	[Wong, C. H.; Yu, Q.] Agcy Sci Technol & Res, Genome Inst Singapore, Canc Biol & Pharmacol, Singapore 138672, Singapore; [Wu, Z.] China Agr Univ, Coll Anim Sci & Technol, State Key Lab Anim Nutr, Beijing 100094, Peoples R China; [Yu, Q.] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore 117595, Singapore; [Yu, Q.] DUKE NUS Grad Med Sch Singapore, Singapore, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); China Agricultural University; National University of Singapore; National University of Singapore	Yu, Q (corresponding author), Agcy Sci Technol & Res, Genome Inst Singapore, Canc Biol & Pharmacol, 60 Biopolis St,02-01, Singapore 138672, Singapore.	yuq@gis.a-star.edu.sg		Yu, Qiang/0000-0003-2132-8278	Agency for Science, Technology and Research for Singapore	Agency for Science, Technology and Research for Singapore	We thank Dr Kristian Helin for the ER-E2F1 plasmids, Dr Joseph Nevins for the adenoviral E2F1, Dr Andrew Turnell for adenoviral E1A and Dr Claudio Brancolini for IMR90-E1A cells. We are grateful to Li Juntao for providing assistance in data analysis. This work was supported by the Agency for Science, Technology and Research for Singapore.	Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Blomgran R, 2007, J LEUKOCYTE BIOL, V81, P1213, DOI 10.1189/jlb.0506359; Bolden JE, 2006, NAT REV DRUG DISCOV, V5, P769, DOI 10.1038/nrd2133; Droga-Mazovec G, 2008, J BIOL CHEM, V283, P19140, DOI 10.1074/jbc.M802513200; Dyniacht BD, 2008, CANCER CELL, V13, P1, DOI 10.1016/j.ccr.2007.12.017; Ginsberg D, 2002, FEBS LETT, V529, P122, DOI 10.1016/S0014-5793(02)03270-2; Hallstrom TC, 2008, CANCER CELL, V13, P11, DOI 10.1016/j.ccr.2007.11.031; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Iaquinta PJ, 2007, CURR OPIN CELL BIOL, V19, P649, DOI 10.1016/j.ceb.2007.10.006; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ivanova S, 2008, METHOD ENZYMOL, V442, P183, DOI 10.1016/S0076-6879(08)01409-2; Jaattela M, 2004, CELL DEATH DIFFER, V11, P135, DOI 10.1038/sj.cdd.4401333; Jiang X, 2008, CANCER CELL, V13, P529, DOI 10.1016/j.ccr.2008.04.019; Johnstone RW, 2002, NAT REV DRUG DISCOV, V1, P287, DOI 10.1038/nrd772; Kreuzaler PA, 2011, NAT CELL BIOL, V13, P303, DOI 10.1038/ncb2171; Lin WC, 2001, GENE DEV, V15, P1833; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Nahle Z, 2002, NAT CELL BIOL, V4, P859, DOI 10.1038/ncb868; Pediconi N, 2003, NAT CELL BIOL, V5, P552, DOI 10.1038/ncb998; Polager S, 2008, TRENDS CELL BIOL, V18, P528, DOI 10.1016/j.tcb.2008.08.003; Putzer BM, 2007, J CELL MOL MED, V11, P239, DOI 10.1111/j.1582-4934.2007.00030.x; Putzer BM, 2000, GENE THER, V7, P1317, DOI 10.1038/sj.gt.3301235; Santamaria I, 1998, CANCER RES, V58, P1624; Sevenich L, 2010, BIOCHIMIE, V92, P1674, DOI 10.1016/j.biochi.2010.03.014; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Tan J, 2006, J BIOL CHEM, V281, P10508, DOI 10.1074/jbc.M512719200; Tan J, 2007, GENE DEV, V21, P1050, DOI 10.1101/gad.1524107; Wu ZL, 2010, CELL DEATH DIFFER, V17, P801, DOI 10.1038/cdd.2009.162; Wu ZL, 2009, INT J BIOCHEM CELL B, V41, P2389, DOI 10.1016/j.biocel.2009.06.004; Zhang Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046749; Zhao Y, 2005, P NATL ACAD SCI USA, V102, P16090, DOI 10.1073/pnas.0505585102	32	7	7	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2014	33	10					1249	1257		10.1038/onc.2013.72	http://dx.doi.org/10.1038/onc.2013.72			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AC6KI	23542171				2022-12-28	WOS:000332631100005
J	Harris, IS; Blaser, H; Moreno, J; Treloar, AE; Gorrini, C; Sasaki, M; Mason, JM; Knobbe, CB; Rufini, A; Halle, M; Elia, AJ; Wakeham, A; Tremblay, ML; Melino, G; Done, S; Mak, TW				Harris, I. S.; Blaser, H.; Moreno, J.; Treloar, A. E.; Gorrini, C.; Sasaki, M.; Mason, J. M.; Knobbe, C. B.; Rufini, A.; Halle, M.; Elia, A. J.; Wakeham, A.; Tremblay, M. L.; Melino, G.; Done, S.; Mak, T. W.			PTPN12 promotes resistance to oxidative stress and supports tumorigenesis by regulating FOXO signaling	ONCOGENE			English	Article						oxidative stress; reactive oxygen species; antioxidant; protein tyrosine phosphatase; breast cancer	3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1; BREAST-CANCER; TRANSCRIPTION FACTORS; REDOX REGULATION; APOPTOSIS; CELLS; PHOSPHORYLATION; METABOLISM; PEST; SGK	It is well known that protein tyrosine phosphatases (PTPs) that become oxidized due to exposure to reactive oxygen species (ROS) undergo a conformational change and are inactivated. However, whether PTPs can actively regulate ROS levels in order to prevent PTP inhibition has yet to be investigated. Here, we demonstrate that PTP non-receptor type 12 (PTPN12) protects cells against aberrant ROS accumulation and death induced by oxidative stress. Murine embryonic fibroblasts (MEFs) deficient in PTPN12 underwent increased ROS-induced apoptosis under conditions of antioxidant depletion. Cells lacking PTPN12 also showed defective activation of FOXO1/3a, transcription factors required for the upregulation of several antioxidant genes. PTPN12-mediated regulation of ROS appeared to be mediated by phosphoinositide-dependent kinase-1 (PDK1), which was hyperstimulated in the absence of PTPN12. As tight regulation of ROS to sustain survival is a key feature of cancer cells, we examined PTPN12 levels in tumors from a cohort of breast cancer patients. Patients whose tumors showed high levels of PTPN12 transcripts had a significantly poorer prognosis. Analysis of tissues from patients with various breast cancer subtypes revealed that more triple-negative breast cancers, the most aggressive breast cancer subtype, showed high PTPN12 expression than any other subtype. Furthermore, both human breast cancer cells and mouse mammary epithelial tumor cells engineered to lack PTPN12 exhibited reduced tumorigenic and metastatic potential in vivo that correlated with their elevated ROS levels. The involvement of PTPN12 in the antioxidant response of breast cancer cells suggests that PTPN12 may represent a novel therapeutic target for this disease.	[Harris, I. S.; Blaser, H.; Moreno, J.; Treloar, A. E.; Gorrini, C.; Sasaki, M.; Mason, J. M.; Knobbe, C. B.; Elia, A. J.; Wakeham, A.; Done, S.; Mak, T. W.] Univ Hlth Network, Princess Margaret Hosp, Campbell Family Inst Breast Canc Res, Toronto, ON M5G 2C1, Canada; [Harris, I. S.; Done, S.; Mak, T. W.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Moreno, J.; Done, S.] Univ Hlth Network, Lab Med Program, Toronto, ON M5G 2C1, Canada; [Moreno, J.; Done, S.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Knobbe, C. B.] Univ Dusseldorf, Dept Neuropathol, Dusseldorf, Germany; [Rufini, A.; Melino, G.] Univ Leicester, MRC Toxicol Unit, Lab Apoptosis Canc, Leicester, Leics, England; [Halle, M.; Tremblay, M. L.] McGill Univ, Rosalind & Morris Goodman Canc Ctr, Dept Biochem, Montreal, PQ, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Heinrich Heine University Dusseldorf; University of Leicester; McGill University	Mak, TW (corresponding author), Univ Hlth Network, Princess Margaret Hosp, Campbell Family Inst Breast Canc Res, 620 Univ Ave,Suite 706, Toronto, ON M5G 2C1, Canada.	tmak@uhnres.utoronto.ca	Knobbe-Thomsen, Christiane/J-4963-2014; Knobbe-Thomsen, Christiane B/D-3116-2019	Knobbe-Thomsen, Christiane/0000-0003-1231-0076; Gorrini, Chiara/0000-0002-5239-6671; Done, Susan/0000-0002-1770-988X; Harris, Isaac/0000-0002-6855-2763	Natural Sciences and Engineering Council of Canada; Canadian Institutes of Health Research [179815]; Medical Research Council [MC_U132670600] Funding Source: researchfish; MRC [MC_U132670600] Funding Source: UKRI	Natural Sciences and Engineering Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	We thank Dr Anne Brustle and Dr Dirk Brenner for helpful discussions, Dr Han You and Dr Walbert Bakker for reagents and Dr Mary Saunders for insightful scientific editing. This work was supported by a PGS-D grant from the Natural Sciences and Engineering Council of Canada (ISH) and grant no. 179815 from the Canadian Institutes of Health Research (TWM).	Allred DC, 1998, MODERN PATHOL, V11, P155; Arpaia E, 2012, ONCOGENE, V31, P884, DOI 10.1038/onc.2011.288; Bailey HH, 1997, J NATL CANCER I, V89, P1789, DOI 10.1093/jnci/89.23.1789; Bakker WJ, 2007, MOL CELL, V28, P941, DOI 10.1016/j.molcel.2007.10.035; Barr AJ, 2009, CELL, V136, P352, DOI 10.1016/j.cell.2008.11.038; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Cairns RA, 2011, NAT REV CANCER, V11, P85, DOI 10.1038/nrc2981; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Cheang MCU, 2008, CLIN CANCER RES, V14, P1368, DOI 10.1158/1078-0432.CCR-07-1658; Cheng ZY, 2009, NAT MED, V15, P1307, DOI 10.1038/nm.2049; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Cote JF, 1998, BIOCHEMISTRY-US, V37, P13128, DOI 10.1021/bi981259l; DeBerardinis RJ, 2010, ONCOGENE, V29, P313, DOI 10.1038/onc.2009.358; Essafi A, 2005, ONCOGENE, V24, P2317, DOI 10.1038/sj.onc.1208421; FORTELEONI G, 1988, TUMORI, V74, P665, DOI 10.1177/030089168807400608; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Hoadley KA, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-258; Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038; Karisch R, 2011, CELL, V146, P826, DOI 10.1016/j.cell.2011.07.020; MEISTER A, 1983, SCIENCE, V220, P472, DOI 10.1126/science.6836290; Myatt SS, 2011, ANTIOXID REDOX SIGN, V14, P675, DOI 10.1089/ars.2010.3383; Nemoto S, 2002, SCIENCE, V295, P2450, DOI 10.1126/science.1069004; Nogueira V, 2008, CANCER CELL, V14, P458, DOI 10.1016/j.ccr.2008.11.003; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Rogoff D, 2010, REDOX REP, V15, P64, DOI 10.1179/174329210X12650506623249; Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268; Storz P, 2011, ANTIOXID REDOX SIGN, V14, P593, DOI 10.1089/ars.2010.3405; Streit S, 2006, CANCER GENET CYTOGEN, V170, P48, DOI 10.1016/j.cancergencyto.2006.05.013; Sun TT, 2011, CELL, V144, P703, DOI 10.1016/j.cell.2011.02.003; Vaughn AE, 2008, NAT CELL BIOL, V10, P1477, DOI 10.1038/ncb1807; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017; Xu D, 2002, DEV CELL, V2, P251, DOI 10.1016/S1534-5807(02)00132-6; Yang KJ, 2008, J BIOL CHEM, V283, P1480, DOI 10.1074/jbc.M706361200; Yerushalmi R, 2012, BREAST CANCER RES TR, V132, P131, DOI 10.1007/s10549-011-1529-8	34	28	29	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2014	33	8					1047	1054		10.1038/onc.2013.24	http://dx.doi.org/10.1038/onc.2013.24			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XO	23435421				2022-12-28	WOS:000331933200012
J	Walczynski, J; Lyons, S; Jones, N; Breitwieser, W				Walczynski, J.; Lyons, S.; Jones, N.; Breitwieser, W.			Sensitisation of c-MYC-induced B-lymphoma cells to apoptosis by ATF2	ONCOGENE			English	Article						ATF2; ATF7; JNK; c-MYC; B lymphoma; apoptosis	ACTIVATING TRANSCRIPTION FACTOR-2; JUN NH2-TERMINAL KINASE; JNK; SUPPRESSOR; INDUCTION; SURVIVAL; PROLIFERATION; PATHWAY; TARGET; ROLES	Transcription factors ATF2 (activating transcription factor 2) and ATF7 (activating transcription factor 7) are highly homologous members of the activator protein 1 (AP-1) family. Their activities are growth factor and stress stimulated and they strictly require phosphorylation by mitogen-activated protein (MAP) kinases for their transcriptional functions. In samples of human B-cell lymphomas as well as E mu-Myc-driven mouse B-cell lymphomas, we find that ATF2 as well as MAP kinase c-Jun N-terminal kinase (JNK) are significantly up-regulated compared with normal human B-cell lines and mouse B cells, respectively. The B cell-specific deletion of ATF2 and ATF7 in mice results in significantly accelerated onset of E mu-Myc-induced lymphoma. In addition, loss of ATF2/7 desensitises E mu-Myc lymphoma cells to spontaneous as well as stress-induced apoptosis. Our results therefore suggest that c-MYC induces stress-mediated activation of ATF2 and ATF7 and that these transcription factors regulate apoptosis in response to oncogenic transformation of B cells.	[Walczynski, J.; Lyons, S.; Jones, N.; Breitwieser, W.] Univ Manchester, Paterson Inst Canc Res, Dept Cell Regulat, Manchester, Lancs, England	Paterson Institute for Cancer Research; University of Manchester	Breitwieser, W (corresponding author), Paterson Inst Canc Res, Cell Regulat Lab, Wilmslow Rd, Manchester M20 4BX, Lancs, England.	WBreitwieser@PICR.man.ac.uk			Cancer Research UK	Cancer Research UK(Cancer Research UK)	We thank Professor Tim Illidge and members of the Targeted Therapy Group for useful discussions and suggestions, and Debby Burt for cell lines. We are grateful to the members of the Paterson Institute Biological Resource Unit, the Histology Department, the Molecular Biology Core Facility and the Flow Cytometry Department for their services and support. We also thank the members of the Cell Regulation Department for their discussions, encouragement and support. The project was entirely funded by a core grant provided by Cancer Research UK.	ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ASKEW DS, 1991, ONCOGENE, V6, P1915; Breitwieser W, 2007, GENE DEV, V21, P2069, DOI 10.1101/gad.430207; Das M, 2011, GENE DEV, V25, P634, DOI 10.1101/gad.1989311; Dhanasekaran DN, 2008, ONCOGENE, V27, P6245, DOI 10.1038/onc.2008.301; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, ONCOGENE, V20, P6983, DOI 10.1038/sj.onc.1204892; El Btaouri H, 2011, BBA-MOL CELL RES, V1813, P695, DOI 10.1016/j.bbamcr.2011.02.004; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Felsher DW, 1999, P NATL ACAD SCI USA, V96, P3940, DOI 10.1073/pnas.96.7.3940; Fuchs SY, 1997, J BIOL CHEM, V272, P32163, DOI 10.1074/jbc.272.51.32163; Gozdecka M, 2012, BIOCHEM SOC T, V40, P230, DOI 10.1042/BST20110630; Grassilli E, 2004, J BIOL CHEM, V279, P21318, DOI 10.1074/jbc.M313532200; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Gururajan M, 2005, BLOOD, V106, P1382, DOI 10.1182/blood-2004-10-3819; Hayakawa J, 2004, MOL CELL, V16, P521, DOI 10.1016/j.molcel.2004.10.024; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; Hess P, 2002, NAT GENET, V32, P201, DOI 10.1038/ng946; Hui LJ, 2008, J CLIN INVEST, V118, P3943, DOI 10.1172/JCI37156; Juin P, 2002, MOL CELL BIOL, V22, P6158, DOI 10.1128/MCB.22.17.6158-6169.2002; Klapproth K, 2010, BRIT J HAEMATOL, V149, P484, DOI 10.1111/j.1365-2141.2010.08159.x; Kool J, 2003, ONCOGENE, V22, P4235, DOI 10.1038/sj.onc.1206611; Kuppers R, 2001, ONCOGENE, V20, P5580, DOI 10.1038/sj.onc.1204640; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Maekawa T, 2007, MOL CELL BIOL, V27, P1730, DOI 10.1128/MCB.01579-06; Pusapati RV, 2006, P NATL ACAD SCI USA, V103, P1446, DOI 10.1073/pnas.0507367103; Rickert RC, 1997, NUCLEIC ACIDS RES, V25, P1317, DOI 10.1093/nar/25.6.1317; Sargent LM, 1996, CANCER RES, V56, P2137; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Ventura JJ, 2003, MOL CELL BIOL, V23, P2871, DOI 10.1128/MCB.23.8.2871-2882.2003; Vinson C, 2002, MOL CELL BIOL, V22, P6321, DOI 10.1128/MCB.22.18.6321-6335.2002; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wang M, 2009, J PATHOL, V218, P95, DOI 10.1002/path.2521; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	40	9	11	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2014	33	8					1027	1036		10.1038/onc.2013.28	http://dx.doi.org/10.1038/onc.2013.28			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XO	23416976				2022-12-28	WOS:000331933200010
J	Wetterskog, D; Shiu, KK; Chong, I; Meijer, T; Mackay, A; Lambros, M; Cunningham, D; Reis-Filho, JS; Lord, CJ; Ashworth, A				Wetterskog, D.; Shiu, K-K; Chong, I.; Meijer, T.; Mackay, A.; Lambros, M.; Cunningham, D.; Reis-Filho, J. S.; Lord, C. J.; Ashworth, A.			Identification of novel determinants of resistance to lapatinib in ERBB2-amplified cancers	ONCOGENE			English	Article						HER2; ERBB2-positive breast cancer; lapatinib resistance; RNAi screen; NIBP; TRAPPC9	GROWTH-FACTOR RECEPTOR; NF-KAPPA-B; NEU DIFFERENTIATION FACTOR; IN-SITU HYBRIDIZATION; HUMAN-BREAST-CANCER; TRASTUZUMAB RESISTANCE; GENE-EXPRESSION; ACTIVATION; INHIBITOR; ANTIBODY	The gene encoding the receptor tyrosine kinase ERBB2, also known as HER2, is amplified and/or overexpressed in up to 15% of breast cancers. These tumours are characterised by an aggressive phenotype and poor clinical outcome. Although therapies targeted at ERBB2 have proven effective, many patients fail to respond to treatment or become resistant and the reasons for this are still largely unknown. Using a high-throughput functional screen we assessed whether genes found to be recurrently amplified and overexpressed in ERBB2+ve breast cancers mediate resistance to the ERBB2-targeted agent lapatinib. Lapatinib-resistant ERBB2-amplified breast cancer cell lines were screened, in the presence or absence of lapatinib, with an RNA interference library targeting 369 genes recurrently amplified and overexpressed in both ERBB2-amplified breast cancer tumours and cell lines. Small interfering RNAs targeting a number of genes caused sensitivity to lapatinib in this context. The mechanisms of resistance conferred by the identified genes were further investigated and in the case of NIBP (TRAPPC9), lapatinib resistance was found to be mediated through NF-kappa B signalling. Our results indicate that specific amplified and/or overexpressed genes found in ERBB2-amplified breast cancer may mediate response to ERBB2-targeting agents.	[Wetterskog, D.; Shiu, K-K; Chong, I.; Meijer, T.; Mackay, A.; Lambros, M.; Reis-Filho, J. S.; Lord, C. J.; Ashworth, A.] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; [Chong, I.; Cunningham, D.] Royal Marsden Hosp, GI Unit, Sutton, Surrey, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust	Reis-Filho, JS (corresponding author), Inst Canc Res, Breakthrough Breast Canc Res Ctr, ICR, 237 Fulham Rd, London SW3 6JB, England.	reisfilj@mskcc.org; Chris.Lord@icr.ac.uk; Alan.Ashworth@icr.ac.uk	Lord, Christopher J/B-3295-2012; Lord, Christopher/AAX-7130-2021	Lord, Christopher J/0000-0002-3226-0515; Cunningham, David/0000-0001-5158-1069; Chong, Irene Y/0000-0003-1692-4411	Breakthrough Breast Cancer; AACR SU2C; NHS	Breakthrough Breast Cancer; AACR SU2C; NHS	We thank Breakthrough Breast Cancer and AACR SU2C for funding this work. We acknowledge NHS funding to the NIHR RMH Biomedical research Centre. We thank Dr David Watkins from the Royal Marsden hospital for the kind donation of the CR-OE33 cell line.	Alvarez RH, 2010, J CLIN ONCOL, V28, P3366, DOI 10.1200/JCO.2009.25.4011; Baehner FL, 2010, J CLIN ONCOL, V28, P4300, DOI 10.1200/JCO.2009.24.8211; Bang YJ, 2010, LANCET, V376, P1302; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Brough R, 2011, CANCER DISCOV, V1, P260, DOI 10.1158/2159-8290.CD-11-0107; Campbell KJ, 2004, CELL CYCLE, V3, P869; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Christianson TA, 1998, CANCER RES, V58, P5123; Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704; Codony-Servat J, 1999, CANCER RES, V59, P1196; Curtis C, 2012, NATURE, V486, P346, DOI 10.1038/nature10983; Dave B, 2011, J CLIN ONCOL, V29, P166, DOI 10.1200/JCO.2009.27.7814; Dokmanovic M, 2009, MOL CANCER THER, V8, P1557, DOI 10.1158/1535-7163.MCT-09-0140; Eichhorn PJA, 2008, CANCER RES, V68, P9221, DOI 10.1158/0008-5472.CAN-08-1740; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; Geyer CE, 2006, NEW ENGL J MED, V355, P2733, DOI 10.1056/NEJMoa064320; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; Harris LN, 2007, CLIN CANCER RES, V13, P1198, DOI 10.1158/1078-0432.CCR-06-1304; Hu WH, 2005, J BIOL CHEM, V280, P29233, DOI 10.1074/jbc.M501670200; Junttila TT, 2009, CANCER CELL, V15, P429, DOI 10.1016/j.ccr.2009.03.020; Konecny GE, 2006, CANCER RES, V66, P1630, DOI 10.1158/0008-5472.CAN-05-1182; Lal P, 2004, AM J CLIN PATHOL, V121, P631, DOI 10.1309/VE7862V2646BR6EX; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Marchio C, 2008, J PATHOL, V216, P399, DOI 10.1002/path.2423; Merkhofer EC, 2010, ONCOGENE, V29, P1238, DOI 10.1038/onc.2009.410; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Owens Marilyn A, 2004, Clin Breast Cancer, V5, P63, DOI 10.3816/CBC.2004.n.011; Park S, 2010, CANCER CELL, V18, P160, DOI 10.1016/j.ccr.2010.06.014; Reis JS, 2011, LANCET, V378, P1812, DOI 10.1016/S0140-6736(11)61539-0; Ritter CA, 2007, CLIN CANCER RES, V13, P4909, DOI 10.1158/1078-0432.CCR-07-0701; Saal LH, 2005, CANCER RES, V65, P2554, DOI 10.1158/0008-5472-CAN-04-3913; Sacher M, 2001, MOL CELL, V7, P433, DOI 10.1016/S1097-2765(01)00190-3; Saini KS, 2011, BREAST, V20, pS20, DOI 10.1016/S0960-9776(11)70289-2; Santarius T, 2010, NAT REV CANCER, V10, P59, DOI 10.1038/nrc2771; Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134; Scaltriti M, 2011, P NATL ACAD SCI USA, V108, P3761, DOI 10.1073/pnas.1014835108; Scaltriti M, 2010, CLIN CANCER RES, V16, P2688, DOI 10.1158/1078-0432.CCR-09-3407; Shiu KK, 2014, ONCOGENE, V33, P619, DOI 10.1038/onc.2012.625; Shiu KK, 2010, FUTURE ONCOL, V6, P967, DOI [10.2217/fon.10.56, 10.2217/FON.10.56]; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Spector NL, 2009, J CLIN ONCOL, V27, P5838, DOI 10.1200/JCO.2009.22.1507; Spencer KSR, 2000, J CELL BIOL, V148, P385, DOI 10.1083/jcb.148.2.385; Sperinde J, 2010, CLIN CANCER RES, V16, P4226, DOI 10.1158/1078-0432.CCR-10-0410; Staaf J, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2568; Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854; Tanner M, 2005, ANN ONCOL, V16, P273, DOI 10.1093/annonc/mdi064; Tse CH, 2011, J CLIN ONCOL, V29, P4168, DOI 10.1200/JCO.2011.36.0107; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; Xia WL, 2010, MOL CANCER THER, V9, P292, DOI 10.1158/1535-7163.MCT-09-1041; Xia WL, 2002, ONCOGENE, V21, P6255, DOI 10.1038/sj.onc.1205794; Yakes FM, 2002, CANCER RES, V62, P4132	55	40	42	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2014	33	8					966	976		10.1038/onc.2013.41	http://dx.doi.org/10.1038/onc.2013.41			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XO	23474757				2022-12-28	WOS:000331933200004
J	Penicud, K; Behrens, A				Penicud, K.; Behrens, A.			DMAP1 is an essential regulator of ATM activity and function	ONCOGENE			English	Article						DMAP1; ATM; TIP60; double-strand break	HISTONE ACETYLTRANSFERASE COMPLEX; DOUBLE-STRAND BREAKS; DNA-DAMAGE RESPONSE; ATAXIA-TELANGIECTASIA; KINASE-ACTIVITY; ACTIVATES ATM; SANT DOMAIN; ACETYLATION; REPAIR; TIP60	The hereditary autosomal recessive disease ataxia telangiectasia (A-T) is caused by mutation in the DNA damage kinase ATM. ATM's main function is to orchestrate DNA repair, thereby maintaining genomic stability. ATM activity is increased in response to several stimuli, including ionising radiation (IR) and hypotonic stress. DNMT1-associated protein 1 (DMAP1) is a member of the TIP60-p400 histone acetyl transferase (HAT) complex, which acetylates histone H4 at lysine 16 (H4K16) to affect chromatin relaxation and modulate ATM activation. Here we demonstrate that DMAP1 is required for both modes of ATM activation. Knockdown of DMAP1 impaired IR-induced ATM activation and consequently resulted in radiosensitivity and impaired the G2/M checkpoint. Moreover, DMAP1 was also required for efficient ATM signalling in response to hypotonic stress. Overexpression of DMAP1 increased IR-induced ATM substrate phosphorylation, suggesting that DMAP1 function is rate limiting for ATM signalling. DMAP1 associated with TIP60-dependent HAT activity, and depletion of DMAP1 reduced H4K16 acetylation in response to DNA damage. Treatment with histone deacetylase inhibitors rescued IR-induced ATM signalling in Dmap1-depleted cells. These results suggest that DMAP1 is a critical regulator of ATM activity and function.	[Penicud, K.; Behrens, A.] Canc Res UK London Res Inst, Mammalian Genet Lab, London WC2A 3LY, England	Cancer Research UK	Behrens, A (corresponding author), Canc Res UK London Res Inst, Mammalian Genet Lab, 44 Lincolns Inn Fields, London WC2A 3LY, England.	axel.behrens@cancer.org.uk		Behrens, Axel/0000-0002-1557-1143	Experimental HistoPathology Unit, Bioinformatics and Biostatistics; Equipment Park, Biological Resources; FACS Lab in the London Research Institute (CR-UK); ERC [281661 ATMINDDR]; Cancer Research UK; Cancer Research UK [15679] Funding Source: researchfish	Experimental HistoPathology Unit, Bioinformatics and Biostatistics; Equipment Park, Biological Resources(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); FACS Lab in the London Research Institute (CR-UK); ERC(European Research Council (ERC)European Commission); Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK)	Support was given from the Experimental HistoPathology Unit, Bioinformatics and Biostatistics, the Equipment Park, Biological Resources and the FACS Lab in the London Research Institute (CR-UK). We thank Dr Cremona and Dr Kanu for critical reading of the manuscript and the Mammalian Genetics Lab for input and discussions. This work was supported by an ERC grant (281661 ATMINDDR) to AB. The London Research Institute is funded by Cancer Research UK.	Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bakkenist CJ, 2004, CELL, V118, P9, DOI 10.1016/j.cell.2004.06.023; Boyer LA, 2004, NAT REV MOL CELL BIO, V5, P158, DOI 10.1038/nrm1314; Boyer LA, 2002, MOL CELL, V10, P935, DOI 10.1016/S1097-2765(02)00634-2; Cai Y, 2003, J BIOL CHEM, V278, P42733, DOI 10.1074/jbc.C300389200; Chun HH, 2004, DNA REPAIR, V3, P1187, DOI 10.1016/j.dnarep.2004.04.010; Doyon Y, 2004, MOL CELL BIOL, V24, P1884, DOI 10.1128/MCB.24.5.1884-1896.2004; Durocher D, 2001, CURR OPIN CELL BIOL, V13, P225, DOI 10.1016/S0955-0674(00)00201-5; Fraga MF, 2005, NAT GENET, V37, P391, DOI 10.1038/ng1531; Frappart PO, 2006, NEUROMOL MED, V8, P495, DOI 10.1385/NMM:8:4:495; Gorrini C, 2007, NATURE, V448, P1063, DOI 10.1038/nature06055; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kim YC, 2009, NAT CELL BIOL, V11, P92, DOI 10.1038/ncb1817; Kuhne M, 2004, CANCER RES, V64, P500, DOI 10.1158/0008-5472.CAN-03-2384; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; Lavin MF, 2008, NAT REV MOL CELL BIO, V9, P759, DOI 10.1038/nrm2514; Lee JH, 2007, ONCOGENE, V26, P7741, DOI 10.1038/sj.onc.1210872; Lukas J, 2004, DNA REPAIR, V3, P997, DOI 10.1016/j.dnarep.2004.03.006; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; Negishi M, 2009, GENES CELLS, V14, P1347, DOI 10.1111/j.1365-2443.2009.01352.x; Rountree MR, 2000, NAT GENET, V25, P269, DOI 10.1038/77023; Sharma GG, 2010, MOL CELL BIOL, V30, P3582, DOI 10.1128/MCB.01476-09; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; SHILOH Y, 1982, EXP CELL RES, V140, P191, DOI 10.1016/0014-4827(82)90169-0; Sun YL, 2007, MOL CELL BIOL, V27, P8502, DOI 10.1128/MCB.01382-07; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Wu JX, 2011, NAT STRUCT MOL BIOL, V18, P761, DOI 10.1038/nsmb.2078	29	18	19	2	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2014	33	4					525	531		10.1038/onc.2012.597	http://dx.doi.org/10.1038/onc.2012.597			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VX	23318425	Green Accepted			2022-12-28	WOS:000330214600013
J	Comstock, CES; Augello, MA; Goodwin, JF; de Leeuw, R; Schiewer, MJ; Ostrander, WF; Burkhart, RA; McClendon, AK; McCue, PA; Trabulsi, EJ; Lallas, CD; Gomella, LG; Centenera, MM; Brody, JR; Butler, LM; Tilley, WD; Knudsen, KE				Comstock, C. E. S.; Augello, M. A.; Goodwin, J. F.; de Leeuw, R.; Schiewer, M. J.; Ostrander, W. F., Jr.; Burkhart, R. A.; McClendon, A. K.; McCue, P. A.; Trabulsi, E. J.; Lallas, C. D.; Gomella, L. G.; Centenera, M. M.; Brody, J. R.; Butler, L. M.; Tilley, W. D.; Knudsen, K. E.			Targeting cell cycle and hormone receptor pathways in cancer	ONCOGENE			English	Article						PD-0332991; cyclin-dependent kinase; retinoblastoma protein; prostate cancer; tumor explants	DEPENDENT KINASE INHIBITOR; ANDROGEN RECEPTOR; CRYSTAL-STRUCTURE; PHASE-I; CDK4/6 INHIBITION; PD 0332991; PHARMACOLOGICAL INHIBITION; ANTITUMOR-ACTIVITY; DNA-REPAIR; FLAVOPIRIDOL	The cyclin/cyclin-dependent kinase (CDK)/retinoblastoma (RB)-axis is a critical modulator of cell cycle entry and is aberrant in many human cancers. New nodes of therapeutic intervention are needed that can delay or combat the onset of malignancies. The antitumor properties and mechanistic functions of PD-0332991 (PD; a potent and selective CDK4/6 inhibitor) were investigated using human prostate cancer (PCa) models and primary tumors. PD significantly impaired the capacity of PCa cells to proliferate by promoting a robust G(1)-arrest. Accordingly, key regulators of the G(1)-S cell cycle transition were modulated including G1 cyclins D, E and A. Subsequent investigation demonstrated the ability of PD to function in the presence of existing hormone-based regimens and to cooperate with ionizing radiation to further suppress cellular growth. Importantly, it was determined that PD is a critical mediator of PD action. The anti-proliferative impact of CDK4/6 inhibition was revealed through reduced proliferation and delayed growth using PCa cell xenografts. Finally, first-in-field effects of PD on proliferation were observed in primary human prostatectomy tumor tissue explants. This study shows that selective CDK4/6 inhibition, using PD either as a single-agent or in combination, hinders key proliferative pathways necessary for disease progression and that RB status is a critical prognostic determinant for therapeutic efficacy. Combined, these pre-clinical findings identify selective targeting of CDK4/6 as a bona fide therapeutic target in both early stage and advanced PCa and underscore the benefit of personalized medicine to enhance treatment response.	[Comstock, C. E. S.; Augello, M. A.; Goodwin, J. F.; de Leeuw, R.; Schiewer, M. J.; Ostrander, W. F., Jr.; McClendon, A. K.; McCue, P. A.; Gomella, L. G.; Knudsen, K. E.] Thomas Jefferson Univ, Dept Canc Biol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Burkhart, R. A.; Brody, J. R.] Thomas Jefferson Univ, Dept Surg, Philadelphia, PA 19107 USA; [McCue, P. A.] Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19107 USA; [Trabulsi, E. J.; Lallas, C. D.; Gomella, L. G.; Knudsen, K. E.] Thomas Jefferson Univ, Dept Urol, Philadelphia, PA 19107 USA; [Centenera, M. M.; Butler, L. M.] Univ Adelaide, Dame Roma Mitchell Canc Res Lab, Sch Med, Hanson Inst, Adelaide, SA, Australia; [Tilley, W. D.; Knudsen, K. E.] Thomas Jefferson Univ, Dept Radiat Oncol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University; Jefferson University; Jefferson University; Hanson Institute; University of Adelaide; Jefferson University	Knudsen, KE (corresponding author), Thomas Jefferson Univ, Dept Canc Biol, Kimmel Canc Ctr, 233 South 10th St,BLSB 1008A, Philadelphia, PA 19107 USA.	karen.knudsen@jefferson.edu	Butler, Lisa M/C-9843-2010; Butler, Lisa/AAP-9088-2020; Comstock, Clay/B-6122-2008	Butler, Lisa/0000-0003-2698-3220; Schiewer, Matthew/0000-0002-2325-4228; centenera, margaret/0000-0002-2206-0632; Knudsen, Karen/0000-0002-1301-890X; de Leeuw, Renee/0000-0002-5550-7613; Comstock, Clay/0000-0001-5867-1489; Tilley, Wayne/0000-0003-1893-2626	National Institutes of Health [CA099996, CA159945]; Department of Defense New Investigator Award [PC094507]; Department of Defense Predoctoral Fellowships [PC094596, PC094195]; National Health and Medical Research Council (NHMRC) of Australia [627185]; Cancer Council of South Australia Senior research Fellowship; Prostate Cancer Foundation of Australia; Enabling Grant from the NHMRC; NATIONAL CANCER INSTITUTE [R01CA159945, R01CA099996] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense New Investigator Award(United States Department of Defense); Department of Defense Predoctoral Fellowships(United States Department of Defense); National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council of South Australia Senior research Fellowship(Cancer Council South Australia); Prostate Cancer Foundation of Australia; Enabling Grant from the NHMRC; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank members of the KEK laboratory for ongoing scientific discussions and Dr Tanmayi Mankame for critical reading of the manuscript. We thank Dr Wen-Shuz Yeow (currently at TheGreenCell; Washington, DC) for assistance with the growth and maintenance of the CRPC cell lines. We especially thank Magdalena Potoczek for assistance regarding RB staining. This work was supported, in whole or in part, by: National Institutes of Health Grants: CA099996 and CA159945 (to KEK); Department of Defense New Investigator Award PC094507 (to CESC); and Department of Defense Predoctoral Fellowships: PC094596 (to MAA) and PC094195 (to MJS); National Health and Medical Research Council (NHMRC) of Australia (627185; to WDT and LMB), a Cancer Council of South Australia Senior research Fellowship (to LMB), and an infrastructure grant from the Prostate Cancer Foundation of Australia and an Enabling Grant from the NHMRC (to WDT).	Anders L, 2011, CANCER CELL, V20, P620, DOI 10.1016/j.ccr.2011.10.001; Aparicio A, 2011, NAT REV UROL, V8, P562, DOI 10.1038/nrurol.2011.107; Baughn LB, 2006, CANCER RES, V66, P7661, DOI 10.1158/0008-5472.CAN-06-1098; Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; Burkhart DL, 2008, NAT REV CANCER, V8, P671, DOI 10.1038/nrc2399; Centenera MM, 2012, CLIN CANCER RES, V18, P3562, DOI 10.1158/1078-0432.CCR-12-0782; Cole AM, 2010, CANCER RES, V70, P8149, DOI 10.1158/0008-5472.CAN-10-0315; Collins I, 2005, CURR OPIN PHARMACOL, V5, P366, DOI 10.1016/j.coph.2005.04.009; Comstock CES, 2011, J BIOL CHEM, V286, P8117, DOI 10.1074/jbc.M110.170720; Day PJ, 2009, P NATL ACAD SCI USA, V106, P4166, DOI 10.1073/pnas.0809645106; Dean JL, 2010, ONCOGENE, V29, P4018, DOI 10.1038/onc.2010.154; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Diaz-Padilla I, 2009, INVEST NEW DRUG, V27, P586, DOI 10.1007/s10637-009-9236-6; Dickson MA, 2009, CURR ONCOL, V16, P120; Drees M, 1997, CLIN CANCER RES, V3, P273; Finn RS, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2419; Flaherty KT, 2012, CLIN CANCER RES, V18, P568, DOI 10.1158/1078-0432.CCR-11-0509; Freemantle SJ, 2007, J CELL BIOCHEM, V102, P869, DOI 10.1002/jcb.21519; Fry DW, 2004, MOL CANCER THER, V3, P1427; Halvorsen OJ, 2000, CANCER, V88, P416, DOI 10.1002/(SICI)1097-0142(20000115)88:2<416::AID-CNCR24>3.3.CO;2-R; Heijink DM, 2011, ONCOGENE, V30, P2026, DOI 10.1038/onc.2010.578; Ismail A, 2011, CLIN CANCER RES, V17, P4513, DOI 10.1158/1078-0432.CCR-11-0244; Jirawatnotai S, 2011, NATURE, V474, P230, DOI 10.1038/nature10155; Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401; Knudsen KE, 2011, EXPERT REV ENDOCRINO, V6, P483, DOI 10.1586/EEM.11.33; Knudsen KE, 1998, J BIOL CHEM, V273, P20213, DOI 10.1074/jbc.273.32.20213; Konecny GE, 2011, CLIN CANCER RES, V17, P1591, DOI 10.1158/1078-0432.CCR-10-2307; Korzynska A, 2008, BIOCYBERN BIOMED ENG, V28, P75; Leonard JP, 2012, BLOOD, V119, P4597, DOI 10.1182/blood-2011-10-388298; Lim JTE, 2005, P NATL ACAD SCI USA, V102, P5156, DOI 10.1073/pnas.0501203102; Liu G, 2004, CLIN CANCER RES, V10, P924, DOI 10.1158/1078-0432.CCR-03-0050; Lolli G, 2004, STRUCTURE, V12, P2067, DOI 10.1016/j.str.2004.08.013; Lu H, 2006, J MED CHEM, V49, P3826, DOI 10.1021/jm0600388; Martin JM, 2011, DRUGS, V71, P1019, DOI 10.2165/11591500-000000000-00000; Marzec M, 2006, BLOOD, V108, P1744, DOI 10.1182/blood-2006-04-016634; Menu E, 2008, CANCER RES, V68, P5519, DOI 10.1158/0008-5472.CAN-07-6404; Michaud K, 2010, CANCER RES, V70, P3228, DOI 10.1158/0008-5472.CAN-09-4559; Miller TW, 2011, CANCER DISCOV, V1, P338, DOI 10.1158/2159-8290.CD-11-0101; Mostaghel EA, 2011, ENDOCRIN METAB CLIN, V40, P625, DOI 10.1016/j.ecl.2011.05.013; Puyol M, 2010, CANCER CELL, V18, P63, DOI 10.1016/j.ccr.2010.05.025; Rivadeneira DB, 2010, GASTROENTEROLOGY, V138, P1920, DOI 10.1053/j.gastro.2010.01.007; Roberts PJ, 2012, JNCI-J NATL CANCER I, V104, P476, DOI 10.1093/jnci/djs002; Rodriguez-Otero P, 2011, BRIT J HAEMATOL, V155, P73, DOI 10.1111/j.1365-2141.2011.08812.x; Rubin MA, 2011, J CLIN ONCOL, V29, P3659, DOI 10.1200/JCO.2011.35.1916; Schiewer MJ, 2012, MOL CELL ENDOCRINOL, V352, P34, DOI 10.1016/j.mce.2011.06.033; Schiewer MJ, 2012, ENDOCR-RELAT CANCER, V19, P1, DOI 10.1530/ERC-11-0072; Schwartz GK, 2011, BRIT J CANCER, V104, P1862, DOI 10.1038/bjc.2011.177; Sedlacek HH, 1996, INT J ONCOL, V9, P1143, DOI 10.3892/ijo.9.6.1143; Senderowicz AM, 1998, J CLIN ONCOL, V16, P2986, DOI 10.1200/JCO.1998.16.9.2986; Sharma A, 2010, J CLIN INVEST, V120, P4478, DOI 10.1172/JCI44239; Sutherland JJ, 2011, MOL CANCER THER, V10, P242, DOI 10.1158/1535-7163.MCT-10-0720; Thangavel C, 2011, ENDOCR-RELAT CANCER, V18, P333, DOI 10.1530/ERC-10-0262; Thomas JP, 2002, CANCER CHEMOTH PHARM, V50, P465, DOI 10.1007/s00280-002-0527-2; Toogood PL, 2005, J MED CHEM, V48, P2388, DOI 10.1021/jm049354h; Tzelepi V, 2012, CLIN CANCER RES, V18, P666, DOI 10.1158/1078-0432.CCR-11-1867; Udayakumar T, 2010, SEMIN RADIAT ONCOL, V20, P258, DOI 10.1016/j.semradonc.2010.05.007; Vaughn DJ, 2009, NEW ENGL J MED, V360, P423, DOI 10.1056/NEJMc0808558; Wang L, 2007, BLOOD, V110, P2075, DOI 10.1182/blood-2007-02-071266; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Wesierska-Gadek J, 2011, J CELL PHYSIOL, V226, P341, DOI 10.1002/jcp.22426; Wetherill YB, 2006, MOL CANCER THER, V5, P3181, DOI 10.1158/1535-7163.MCT-06-0272; Wiedemeyer WR, 2010, P NATL ACAD SCI USA, V107, P11501, DOI 10.1073/pnas.1001613107; Zhang C, 2009, CLIN CANCER RES, V15, P238, DOI 10.1158/1078-0432.CCR-08-0897; Zhang CC, 2012, CLIN CANCER RES, V18, P1303, DOI 10.1158/1078-0432.CCR-11-1433	65	78	79	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2013	32	48					5481	5491		10.1038/onc.2013.83	http://dx.doi.org/10.1038/onc.2013.83			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263BE	23708653	hybrid, Green Published			2022-12-28	WOS:000327780800005
J	Shaw, JA; Graham, TA; Stebbing, J				Shaw, J. A.; Graham, T. A.; Stebbing, J.			Genomic instability in pre-neoplastic colonic lesions	ONCOGENE			English	Editorial Material							NONPOLYPOSIS COLORECTAL-CANCER; GENETIC INSTABILITY; HMLH1 PROMOTER; HYPERMETHYLATION; PROGRESSION; HISTORY	Genomic instability is a characteristic of most cancers and it is argued that genomic instability is a driving force for tumorigenesis. Data herein demonstrate that genomic instability, as evidenced by microsatellite instability (MSI) and promoter methylation of DNA mismatch repair genes, is common in individual glands of pre-malignant colorectal lesions and raises interesting questions about the role of MSI in the development of colorectal carcinoma.	[Shaw, J. A.] Leicester Royal Infirm, Dept Canc Studies & Mol Med, Leicester, Leics, England; [Graham, T. A.] Univ Calif San Francisco, Dept Surg, Helen Diller Family Comprehens Canc Ctr, Ctr Evolut & Canc, San Francisco, CA USA; [Stebbing, J.] Imperial Coll Sch Med, Div Canc, London W12 0NN, England	University of Leicester; University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; Imperial College London	Stebbing, J (corresponding author), Imperial Coll Sch Med, Div Canc, Hammersmith Hosp Campus, London W12 0NN, England.	j.stebbing@imperial.ac.uk		Stebbing, Justin/0000-0002-1117-6947; Shaw, Jacqui/0000-0003-4227-503X	Cancer Research UK [14549] Funding Source: researchfish; National Institute for Health Research [NIHR-RP-011-053] Funding Source: researchfish; Cancer Research UK [13462] Funding Source: Medline; Department of Health [NIHR-RP-011-053] Funding Source: Medline	Cancer Research UK(Cancer Research UK); National Institute for Health Research(National Institute for Health Research (NIHR)); Cancer Research UK(Cancer Research UK); Department of Health		Beggs AD, 2013, ONCOGENE, V32, P5333, DOI 10.1038/onc.2012.584; Bodmer W, 2008, CANCER RES, V68, P3558, DOI 10.1158/0008-5472.CAN-07-6544; Cunningham JM, 1998, CANCER RES, V58, P3455; Datta RS, 2013, EVOL APPL, V6, P20, DOI 10.1111/eva.12024; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Kane MF, 1997, CANCER RES, V57, P808; KIM HG, 1994, AM J PATHOL, V145, P148; Kuismanen SA, 1999, P NATL ACAD SCI USA, V96, P12661, DOI 10.1073/pnas.96.22.12661; LOTHE RA, 1993, CANCER RES, V53, P5849; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; Lynch HT, 1999, J MED GENET, V36, P801; Maley CC, 2004, CANCER RES, V64, P7629, DOI 10.1158/0008-5472.CAN-04-1738; Nakagawa H, 2001, CANCER RES, V61, P6991; Salovaara R, 2000, J CLIN ONCOL, V18, P2193, DOI 10.1200/JCO.2000.18.11.2193	14	0	0	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2013	32	46					5331	5332		10.1038/onc.2013.21	http://dx.doi.org/10.1038/onc.2013.21			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251IU	23396367	Green Published			2022-12-28	WOS:000326922400002
J	Wang, J; Gildea, JJ; Yue, W				Wang, J.; Gildea, J. J.; Yue, W.			Aromatase overexpression induces malignant changes in estrogen receptor a negative MCF-10A cells	ONCOGENE			English	Article						aromatase; MCF-10A; estrogen; breast cancer; stem cell	BREAST-CANCER CELLS; MOLECULAR ETIOLOGY; ADIPOSE-TISSUE; BRCA1; RISK; BIOMARKERS; TUMOR; EXPRESSION; LINK; 17-BETA-ESTRADIOL	Estrogen is a risk factor of breast cancer. Elevated expression of aromatase (estrogen synthase) in breast tissues increases local estradiol concentrations and is associated with breast cancer development, but the causal relationship between aromatase and breast cancer has not been identified. Accumulating data suggest that both estrogen receptor (ER)-dependent and -independent effects are involved in estrogen carcinogenesis. We established a model by expressing aromatase in ER alpha - MCF-10A human breast epithelial cells to investigate ER alpha-independent effects of estrogen in the process of malignant transformation. Overexpression of aromatase significantly increased anchorage-independent growth. Parental- or vector-expressing MCF-10A cells did not form colonies under the same conditions. The anchorage-independent growth of MCF-10A(arom) cells can be completely abolished by pretreatment with the aromatase inhibitor, letrozole. Neither MCF-10A(arom) nor MCF-10A(vector) cells grown in monolayer were affected by short-term exposure to estradiol. Enhanced motility is another characteristic of cellular transformation. Motility of MCF-10A(arom) cells was increased, which could be inhibited by letrozole. Increases in stem cell population in breast cancer tissues are associated with tumor recurrence and metastasis. CD44(high)/CD24(low) is a stem cell marker. We found that CD24 mRNA levels were reduced in MCF-10A(arom) cells compared with those in parental- and vector-transfected cells. By examining individual clones of MCF-10A(arom) with various aromatase activities, we found that the CD24 mRNA levels were inversely correlated with aromatase activity. The ability of MCF-10A(arom) cells to form mammospheres in the absence of serum was increased. Our results suggest that overexpression of aromatase in MCF-10A cells causes malignant transformation. Estrogen metabolite-mediated genotoxicity and induction of a stem cell/progenitor cell population are possible mechanisms. These studies provide additional evidence for ER alpha-independent mechanism(s) in estrogen carcinogenesis and implicate superiority of aromatase inhibitors to antiestrogens for breast cancer prevention.	[Wang, J.; Yue, W.] Univ Virginia Hlth Syst, Dept Med, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Dept Pathol, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Yue, W (corresponding author), Univ Virginia Hlth Syst, Dept Med, Fountaine Res Pk,POB 801416, Charlottesville, VA 22908 USA.	wy9c@virginia.edu			DOD [DOD DAMD17-01-1-0444, DAMD17-01-1-0445]	DOD(United States Department of Defense)	This study is supported by DOD Grants: DOD DAMD17-01-1-0444 and DAMD17-01-1-0445. Human aromatase cDNA plasmid was kindly provided by Dr Shiuan Chen (Beckman Institute at City of Hope, Duarte, CA, USA). Measurement of estrogen metabolites was performed by Dr Cavalieri at the Laboratory of Eppley Institute for Research in Cancer and Allied Diseases (University of Nebraska Medical Center Omaha, NE, USA).	Agarwal VR, 1996, J CLIN ENDOCR METAB, V81, P3843, DOI 10.1210/jc.81.11.3843; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Asselin-Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027; BERKOVITZ GD, 1985, J CLIN INVEST, V75, P1763, DOI 10.1172/JCI111888; BULARD J, 1987, J CLIN ENDOCR METAB, V64, P618, DOI 10.1210/jcem-64-3-618; BULUN SE, 1993, J CLIN ENDOCR METAB, V77, P1622, DOI 10.1210/jc.77.6.1622; Cavalieri E, 2006, BBA-REV CANCER, V1766, P63, DOI 10.1016/j.bbcan.2006.03.001; Chand AL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-148; Chen WY, 2006, ARCH INTERN MED, V166, P1027, DOI 10.1001/archinte.166.9.1027; DEOME KB, 1959, CANCER RES, V19, P515; Diaz-Cruz ES, 2011, CANCER RES, V71, P5477, DOI 10.1158/0008-5472.CAN-10-4652; Dorgan JF, 2002, JNCI-J NATL CANCER I, V94, P606; Fan P, 2007, CANCER RES, V67, P1352, DOI 10.1158/0008-5472.CAN-06-1020; FEINLEIB M, 1968, JNCI-J NATL CANCER I, V41, P315; Fillmore CM, 2010, P NATL ACAD SCI USA, V107, P21737, DOI 10.1073/pnas.1007863107; Foulkes WD, 2004, CLIN CANCER RES, V10, P2029, DOI 10.1158/1078-0432.CCR-03-1061; Gaikwad NW, 2008, INT J CANCER, V122, P1949, DOI 10.1002/ijc.23329; Gaikwad NW, 2009, BREAST CANCER-BASIC, V3, P1; Goss PE, 2011, NEW ENGL J MED, V364, P2381, DOI 10.1056/NEJMoa1103507; Howell A, 2005, LANCET, V365, P60, DOI 10.1016/s0140-6736(04)17666-6; Hu YF, 2005, ONCOGENE, V24, P8343, DOI 10.1038/sj.onc.1208985; Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091; Kaaks R, 2005, ENDOCR-RELAT CANCER, V12, P1071, DOI 10.1677/erc.1.01038; Kotsopoulos J, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2790; Lakhani SR, 2002, J CLIN ONCOL, V20, P2310, DOI 10.1200/JCO.2002.09.023; Lu F, 2007, J STEROID BIOCHEM, V105, P150, DOI 10.1016/j.jsbmb.2006.12.102; Lu ML, 2006, J CLIN ENDOCR METAB, V91, P4514, DOI 10.1210/jc.2006-1364; Maurice KT, 2005, CAN VET J, V46, P644; ONEILL JS, 1988, BRIT MED J, V296, P741, DOI 10.1136/bmj.296.6624.741; Rebbeck TR, 2009, JNCI-J NATL CANCER I, V101, P80, DOI 10.1093/jnci/djn442; Rogan EG, 2003, CARCINOGENESIS, V24, P697, DOI 10.1093/carcin/bgg004; Russo J, 2002, J STEROID BIOCHEM, V80, P149, DOI 10.1016/S0960-0760(01)00183-2; Russo J, 2000, J Natl Cancer Inst Monogr, P17; Russo J, 2006, FASEB J, V20, P1622, DOI 10.1096/fj.05-5399com; Shen YM, 2006, CHEM RES TOXICOL, V19, P1441, DOI 10.1021/tx0601206; Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610; Tekmal RR, 1996, CANCER RES, V56, P3180; Thurlimann B, 2005, NEW ENGL J MED, V353, P2747; TRICHOPOULOS D, 1972, JNCI-J NATL CANCER I, V48, P605; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776; Yager JD, 2012, TRANSL ENDOCRINOL ME, V3, P1; Yue W, 2003, J STEROID BIOCHEM, V86, P265, DOI 10.1016/S0960-0760(03)00366-2; Yue W, 2002, ENDOCRINOLOGY, V143, P3221, DOI 10.1210/en.2002-220186; Yue W, 1998, CANCER RES, V58, P927; Yue W, 2010, INT J CANCER, V127, P1748, DOI 10.1002/ijc.25207; ZHOU D, 1990, CANCER RES, V50, P6949	46	12	15	1	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2013	32	44					5233	5240		10.1038/onc.2012.558	http://dx.doi.org/10.1038/onc.2012.558			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245XH	23178495				2022-12-28	WOS:000326497100006
J	Gupta, A; Jha, S; Engel, DA; Ornelles, DA; Dutta, A				Gupta, A.; Jha, S.; Engel, D. A.; Ornelles, D. A.; Dutta, A.			Tip60 degradation by adenovirus relieves transcriptional repression of viral transcriptional activator EIA	ONCOGENE			English	Article						HAT; Tip60; EIA; adenovirus	DNA-DAMAGE RESPONSE; CELL-CYCLE ARREST; HISTONE ACETYLTRANSFERASE; PROTEIN-VII; ACETYLATION; COMPLEX; E1A; CHROMATIN; P53; TRANSFORMATION	Adenoviruses are linear double-stranded DNA viruses that infect human and rodent cell lines, occasionally transform them and cause tumors in animal models. The host cell challenges the virus in multifaceted ways to restrain viral gene expression and DNA replication, and sometimes even eliminates the infected cells by programmed cell death. To combat these challenges, adenoviruses abrogate the cellular DNA damage response pathway. Tip60 is a lysine acetyltransferase that acetylates histones and other proteins to regulate gene expression, DNA damage response, apoptosis and cell cycle regulation. Tip60 is a bona fide tumor suppressor as mice that are haploid for Tip60 are predisposed to tumors. We have discovered that Tip60 is degraded by adenovirus oncoproteins EIB55K and E4orf6 by a proteasome-mediated pathway. Tip60 binds to the immediate early adenovirus promoter and suppresses adenovirus EIA gene expression, which is a master regulator of adenovirus transcription, at least partly through retention of the virally encoded repressor pVII on this promoter. Thus, degradation of Tip60 by the adenoviral early proteins is important for efficient viral early gene transcription and for changes in expression of cellular genes.	[Gupta, A.; Jha, S.; Dutta, A.] Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA; [Engel, D. A.] Univ Virginia, Sch Med, Dept Microbiol, Charlottesville, VA 22908 USA; [Ornelles, D. A.] Wake Forest Sch Med, Dept Microbiol & Immunol, Winston Salem, NC USA	University of Virginia; University of Virginia; Wake Forest University	Dutta, A (corresponding author), Univ Virginia, Sch Med, Dept Biochem & Mol Genet, 1300 Jefferson Pk Ave,Box 800733, Charlottesville, VA 22908 USA.	ad8q@virginia.edu	Jha, Sudhakar/B-2308-2009; Dutta, Anindya/P-3203-2016; Jha, Sudhakar/S-3550-2019	Jha, Sudhakar/0000-0002-5093-4843; Dutta, Anindya/0000-0002-4319-0073	US army Postdoctoral fellowship for breast cancer research [DOD-W81XWH1110687];  [RO1 GM084465]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM084465] Funding Source: NIH RePORTER	US army Postdoctoral fellowship for breast cancer research; ; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the members of Dutta laboratory for lively discussions and helpful comments. This work was supported by RO1 GM084465 to AD. AG was supported by US army Postdoctoral fellowship for breast cancer research DOD-W81XWH1110687.	Baker A, 2007, J VIROL, V81, P7034, DOI 10.1128/JVI.00029-07; BARKER DD, 1987, VIROLOGY, V156, P107, DOI 10.1016/0042-6822(87)90441-7; Bhoumik A, 2008, J BIOL CHEM, V283, P17605, DOI 10.1074/jbc.M802030200; Blackford AN, 2010, P NATL ACAD SCI USA, V107, P12251, DOI 10.1073/pnas.0914605107; Chen JN, 2007, VIROLOGY, V369, P411, DOI 10.1016/j.virol.2007.08.012; Col E, 2005, EMBO J, V24, P2634, DOI 10.1038/sj.emboj.7600734; Dallaire F, 2009, J VIROL, V83, P5329, DOI 10.1128/JVI.00089-09; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Doyon Y, 2004, CURR OPIN GENET DEV, V14, P147, DOI 10.1016/j.gde.2004.02.009; Ferrari R, 2008, SCIENCE, V321, P1086, DOI 10.1126/science.1155546; Ferrari R, 2009, NAT REV GENET, V10, P290, DOI 10.1038/nrg2539; Ghosh MK, 2003, MOL CELL, V12, P255, DOI 10.1016/S1097-2765(03)00225-9; Gorrini C, 2007, NATURE, V448, P1063, DOI 10.1038/nature06055; Horwitz GA, 2008, SCIENCE, V321, P1084, DOI 10.1126/science.1155544; Hu YF, 2009, DEV DYNAM, V238, P2912, DOI 10.1002/dvdy.22110; Ikura T, 2007, MOL CELL BIOL, V27, P7028, DOI 10.1128/MCB.00579-07; Jha S, 2008, MOL CELL BIOL, V28, P2690, DOI 10.1128/MCB.01983-07; Jha S, 2010, MOL CELL, V38, P700, DOI 10.1016/j.molcel.2010.05.020; Johnson JS, 2004, J VIROL, V78, P6459, DOI 10.1128/JVI.78.12.6459-6468.2004; Karen KA, 2011, J VIROL, V85, P4135, DOI 10.1128/JVI.02540-10; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; Li RF, 2011, CELL HOST MICROBE, V10, P390, DOI 10.1016/j.chom.2011.08.013; MARTON MJ, 1990, J VIROL, V64, P2345, DOI 10.1128/JVI.64.5.2345-2359.1990; MORAN E, 1993, FASEB J, V7, P880, DOI 10.1096/fasebj.7.10.8344487; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; Nevels M, 2001, J VIROL, V75, P3089, DOI 10.1128/JVI.75.7.3089-3094.2001; Niller HH, 2011, CANCER LETT, V305, P200, DOI 10.1016/j.canlet.2010.08.007; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; Reitsma JM, 2011, CELL HOST MICROBE, V9, P103, DOI 10.1016/j.chom.2011.01.006; Ruthenburg AJ, 2007, NAT REV MOL CELL BIO, V8, P983, DOI 10.1038/nrm2298; Sancar A, 2004, ANNU REV BIOCHEM, V73, P39, DOI 10.1146/annurev.biochem.73.011303.073723; Sapountzi V, 2006, INT J BIOCHEM CELL B, V38, P1496, DOI 10.1016/j.biocel.2006.03.003; Seligson DB, 2009, AM J PATHOL, V174, P1619, DOI 10.2353/ajpath.2009.080874; Sha JF, 2010, J VIROL, V84, P4050, DOI 10.1128/JVI.02131-09; Shamay M, 2012, J VIROL, V86, P5179, DOI 10.1128/JVI.00169-12; Squatrito M, 2006, TRENDS CELL BIOL, V16, P433, DOI 10.1016/j.tcb.2006.07.007; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Stracker TH, 2002, NATURE, V418, P348, DOI 10.1038/nature00863; Sun YL, 2007, MOL CELL BIOL, V27, P8502, DOI 10.1128/MCB.01382-07; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Sykes SM, 2006, MOL CELL, V24, P841, DOI 10.1016/j.molcel.2006.11.026; Tang Y, 2006, MOL CELL, V24, P827, DOI 10.1016/j.molcel.2006.11.021; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; ZANTEMA A, 1985, VIROLOGY, V142, P44, DOI 10.1016/0042-6822(85)90421-0	44	47	49	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2013	32	42					5017	5025		10.1038/onc.2012.534	http://dx.doi.org/10.1038/onc.2012.534			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238IB	23178490	Green Accepted, Green Submitted			2022-12-28	WOS:000325937900003
J	Hagemann, N; Ackermann, N; Christmann, J; Brier, S; Yu, F; Erdmann, KS				Hagemann, N.; Ackermann, N.; Christmann, J.; Brier, S.; Yu, F.; Erdmann, K. S.			The serologically defined colon cancer antigen-3 interacts with the protein tyrosine phosphatase PTPN13 and is involved in the regulation of cytokinesis	ONCOGENE			English	Article						endosome; cytokinesis; Arf6; colon; vesicular trafficking; protein tyrosine phosphatase	FAS-MEDIATED APOPTOSIS; FERM DOMAIN; CELL-SURFACE; KINASE; FAP-1; TUMORIGENESIS; BL; AGGRESSIVENESS; TRAFFICKING; ANEUPLOIDY	Cytokinesis is the final step of cell division. Increasing evidence suggests failure of cytokinesis might contribute to the development of cancer. Here, we demonstrate that the serologically defined colon cancer antigen-3 (SDCCAG3) forms a complex with PTPN13, a protein tyrosine phosphatase known to be involved in the regulation of cytokinesis, carcinogenesis and tumor aggressiveness. We show that SDCCAG3 is a novel endosomal protein, primarily localized at the early/recycling endosomal compartment. SDCCAG3 undergoes dynamic localization during cell division with strong accumulation at the midbody during cytokinesis. Overexpression as well as downregulation correlates with the generation of multinucleate cells. Furthermore, we show interaction of SDCCAG3 with the Arf GTPase activating protein GIT1 (G protein-coupled receptor kinase interactor-1). Overexpression of an ArfGAP-negative version of GIT1 also results in an increased number of multinucleate cells suggesting regulation of Arf-mediated vesicular trafficking or signaling via SDCCAG3. Finally, we demonstrate that SDCCAG3 expression levels are elevated in colon cancers. In summary, we have established SDCCAG3 as a novel endosomal protein, which is involved in the regulation of cytokinesis.	[Hagemann, N.; Ackermann, N.; Christmann, J.; Brier, S.; Yu, F.; Erdmann, K. S.] Ruhr Univ Bochum, Dept Biochem 2, D-44780 Bochum, Germany	Ruhr University Bochum	Erdmann, KS (corresponding author), Univ Sheffield, Dept Biomed Sci, Ctr Membrane Interact & Dynam, Sheffield S10 2TN, S Yorkshire, England.	k.erdmann@sheffield.ac.uk	Brier, Sebastien/L-7787-2019	Brier, Sebastien/0000-0003-1758-8237; Christmann, Jens/0000-0002-8625-2991	German research foundation [SFB642]	German research foundation(German Research Foundation (DFG))	We would like to thank Rolf Heumann for longstanding support. This work was supported by a grant from the German research foundation (SFB642) to KSE.	Abaan OD, 2005, ONCOGENE, V24, P2715, DOI 10.1038/sj.onc.1208247; Ai Erkang, 2009, Communicative & Integrative Biology, V2, P444; Bompard G, 2003, J CELL SCI, V116, P2519, DOI 10.1242/jcs.00448; Chesneau L, 2012, CURR BIOL, V22, P147, DOI 10.1016/j.cub.2011.11.058; Claing A, 2000, P NATL ACAD SCI USA, V97, P1119, DOI 10.1073/pnas.97.3.1119; Cuppen E, 1999, J CELL SCI, V112, P3299; Di Paolo G, 2002, NATURE, V420, P85, DOI 10.1038/nature01147; Echard A, 2008, BIOCHEM SOC T, V36, P395, DOI 10.1042/BST0360395; Erdmann KS, 2003, EUR J BIOCHEM, V270, P4789, DOI 10.1046/j.1432-1033.2003.03895.x; Freiss G, 2011, ANTI-CANCER AGENT ME, V11, P78, DOI 10.2174/187152011794941262; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011; Glondu-Lassis M, 2010, CANCER RES, V70, P5116, DOI 10.1158/0008-5472.CAN-09-4368; Gross C, 2001, FEBS LETT, V496, P101, DOI 10.1016/S0014-5793(01)02401-2; Hamada K, 2000, EMBO J, V19, P4449, DOI 10.1093/emboj/19.17.4449; Hendriks W, 1995, J CELL BIOCHEM, V59, P418, DOI 10.1002/jcb.240590403; Herrmann L, 2003, MOL BIOL CELL, V14, P230, DOI 10.1091/mbc.E02-04-0191; Hoover AC, 2009, ONCOGENE, V28, P3960, DOI 10.1038/onc.2009.251; Ivanov VN, 2003, MOL CELL BIOL, V23, P3623, DOI 10.1128/MCB.23.10.3623-3635.2003; Kouranti I, 2006, CURR BIOL, V16, P1719, DOI 10.1016/j.cub.2006.07.020; Lahuna O, 2005, EMBO J, V24, P1364, DOI 10.1038/sj.emboj.7600616; Li Y, 2000, INT J CANCER, V87, P473, DOI 10.1002/1097-0215(20000815)87:4<473::AID-IJC3>3.0.CO;2-1; Montagnac G, 2008, CURR OPIN CELL BIOL, V20, P454, DOI 10.1016/j.ceb.2008.03.011; Montagnac G, 2009, CURR BIOL, V19, P184, DOI 10.1016/j.cub.2008.12.043; Neto H, 2011, BIOCHEM J, V437, P13, DOI 10.1042/BJ20110153; Neznanov N, 2005, DNA CELL BIOL, V24, P777, DOI 10.1089/dna.2005.24.777; Prekeris R, 2008, J CELL SCI, V121, P1569, DOI 10.1242/jcs.018770; Premont RT, 2000, J BIOL CHEM, V275, P22373, DOI 10.1074/jbc.275.29.22373; Premont RT, 1998, P NATL ACAD SCI USA, V95, P14082, DOI 10.1073/pnas.95.24.14082; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Scanlan MJ, 1998, INT J CANCER, V76, P652, DOI 10.1002/(SICI)1097-0215(19980529)76:5<652::AID-IJC7>3.3.CO;2-9; Schickel R, 2010, MOL CELL, V38, P908, DOI 10.1016/j.molcel.2010.05.018; Schmidt A, 2007, EMBO J, V26, P1624, DOI 10.1038/sj.emboj.7601637; Schweitzer JK, 2005, EXP CELL RES, V311, P74, DOI 10.1016/j.yexcr.2005.07.033; Scrima M, 2012, AM J PATHOL, V180, P1202, DOI 10.1016/j.ajpath.2011.11.038; Steigemann P, 2009, CELL, V136, P473, DOI 10.1016/j.cell.2008.12.020; Stelzl U, 2005, CELL, V122, P957, DOI 10.1016/j.cell.2005.08.029; Ungefroren H, 2001, J CELL SCI, V114, P2735; Ungefroren H, 1998, CANCER RES, V58, P1741; Wang ZH, 2004, SCIENCE, V304, P1164, DOI 10.1126/science.1096096; Weaver BAA, 2007, CANCER RES, V67, P10103, DOI 10.1158/0008-5472.CAN-07-2266; Zhao ZS, 2005, MOL CELL, V20, P237, DOI 10.1016/j.molcel.2005.08.035; Zhu JH, 2008, ONCOGENE, V27, P2525, DOI 10.1038/sj.onc.1210922	43	23	28	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2013	32	39					4602	4613		10.1038/onc.2012.485	http://dx.doi.org/10.1038/onc.2012.485			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226YD	23108400				2022-12-28	WOS:000325072200002
J	Rao, X; Evans, J; Chae, H; Pilrose, J; Kim, S; Yan, P; Huang, RL; Lai, HC; Lin, H; Liu, Y; Miller, D; Rhee, JK; Huang, YW; Gu, F; Gray, JW; Huang, THM; Nephew, KP				Rao, X.; Evans, J.; Chae, H.; Pilrose, J.; Kim, S.; Yan, P.; Huang, R-L; Lai, H-C; Lin, H.; Liu, Y.; Miller, D.; Rhee, J-K; Huang, Y-W; Gu, F.; Gray, J. W.; Huang, T. H-M; Nephew, K. P.			CpG island shore methylation regulates caveolin-1 expression in breast cancer	ONCOGENE			English	Article						Cav1; CpG island shore; DNA methylation; breast cancer	ANCHORAGE-INDEPENDENT GROWTH; ESTROGEN-RECEPTOR-ALPHA; DNA METHYLATION; CELL-LINES; GENE-EXPRESSION; BASAL-LIKE; UP-REGULATION; EGF-R; PROMOTER; PROTEIN	Caveolin-1 (Cav1) is an integral membrane, scaffolding protein found in plasma membrane invaginations (caveolae). Cav1 regulates multiple cancer-associated processes. In breast cancer, a tumor suppressive role for Cav1 has been suggested; however, Cav1 is frequently overexpressed in aggressive breast cancer subtypes, suggesting an oncogenic function in advanced-stage disease. To further delineate Cav1 function in breast cancer progression, we evaluated its expression levels among a panel of cell lines representing a spectrum of breast cancer phenotypes. In basal-like (the most aggressive BC subtype) breast cancer cells, Cav1 was consistently upregulated, and positively correlated with increased cell proliferation, anchorage-independent growth, and migration and invasion. To identify mechanisms of Cav1 gene regulation, we compared DNA methylation levels within promoter 'CpG islands' (CGIs) with 'CGI shores', recently described regions that flank CGIs with less CG-density. Integration of genome-wide DNA methylation profiles ('methylomes') with Cav1 expression in 30 breast cancer cell lines showed that differential methylation of CGI shores, but not CGIs, significantly regulated Cav1 expression. In breast cancer cell lines having low Cav1 expression (despite promoter CGI hypomethylation), we found that treatment with a DNA methyltransferase inhibitor induced Cav1 expression via CGI shore demethylation. In addition, further methylome assessments revealed that breast cancer aggressiveness associated with Cav1 CGI shore methylation levels, with shore hypermethylation in minimally aggressive, luminal breast cancer cells and shore hypomethylation in highly aggressive, basal-like cells. Cav1 CGI shore methylation was also observed in human breast tumors, and overall survival rates of breast cancer patients lacking estrogen receptor a (ER alpha) negatively correlated with Cav1 expression. Based on this first study of Cav1 (a potential oncogene) CGI shore methylation, we suggest this phenomenon may represent a new prognostic marker for ER alpha-negative, basal-like breast cancer.	[Rao, X.; Nephew, K. P.] Indiana Univ, Dept Mol & Cellular Biochem, Interdisciplinary Biochem Grad Program, Bloomington, IN USA; [Rao, X.; Pilrose, J.; Miller, D.; Nephew, K. P.] Indiana Univ, Sch Med, Med Sci Program, Bloomington, IN 47405 USA; [Evans, J.; Chae, H.; Kim, S.] Indiana Univ, Sch Informat & Comp, Bioinformat Program, Bloomington, IN USA; [Yan, P.] Ohio State Univ, Ctr Comprehens Canc, NASRIllumina Sequencing Core, Columbus, OH 43210 USA; [Huang, R-L; Lai, H-C] Natl Yang Ming Univ, Inst Biomed Informat, Dept Obstet & Gynecol, Taipei 112, Taiwan; [Lin, H.; Liu, Y.] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; [Rhee, J-K] Seoul Natl Univ, Interdisciplinary Program Bioinformat, Seoul, South Korea; [Huang, Y-W] Med Coll Wisconsin, Dept Obstet & Gynecol, Milwaukee, WI 53226 USA; [Gu, F.; Huang, T. H-M] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, Dept Mol Med, San Antonio, TX 78229 USA; [Gray, J. W.] Oregon Hlth & Sci Univ, Dept Biomed Engn, Portland, OR 97201 USA; [Nephew, K. P.] Indiana Univ Sch Med, IU Simon Canc Ctr, Indianapolis, IN 46202 USA; [Nephew, K. P.] Indiana Univ Sch Med, Dept Cellular Physiol, Indianapolis, IN 46202 USA; [Nephew, K. P.] Indiana Univ Sch Med, Dept Integrat Physiol, Indianapolis, IN 47405 USA	Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; National Yang Ming Chiao Tung University; Indiana University System; Indiana University Bloomington; Seoul National University (SNU); Medical College of Wisconsin; Cancer Therapy & Research Center; University of Texas System; University of Texas Health San Antonio; Oregon Health & Science University; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington; Indiana University System; Indiana University Bloomington	Nephew, KP (corresponding author), Indiana Univ Sch Med, 302 Jordan Hall,1001 East 3rd St, Bloomington, IN 47405 USA.	knephew@indiana.edu	Lin, Hai/N-3860-2016; Yan, Pearlly S/E-4339-2011	Lin, Hai/0000-0002-2094-758X; Yan, Pearlly S/0000-0003-1965-4920; Huang, Rui Lan/0000-0001-6458-4672	NIH [CA085289, CA113001]; Integrated Cancer Biology Program; Walther Cancer Foundation (Indianapolis, IN, USA); NATIONAL CANCER INSTITUTE [R01CA085289] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Integrated Cancer Biology Program; Walther Cancer Foundation (Indianapolis, IN, USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors wish to thank Dr F Fang for pyrosequencing analysis, Dr C Balch for manuscript preparation, and the IUB light Microscopy Imaging Center for microscopy resources. This work was supported by NIH grants CA085289 and CA113001, pilot project funding from the Integrated Cancer Biology Program and the Walther Cancer Foundation (Indianapolis, IN, USA). We acknowledge the use of the ICBP45 Kit in this study.	[Anonymous], 2013, ONCOGENE, P4519; Arpaia E, 2012, ONCOGENE, V31, P884, DOI 10.1038/onc.2011.288; Bachmann N, 2008, CANCER GENET CYTOGEN, V182, P103, DOI 10.1016/j.cancergencyto.2008.01.006; Belanger MM, 2003, ANTI-CANCER DRUG, V14, P281, DOI 10.1097/00001813-200304000-00005; Chan TF, 2003, INT J ONCOL, V23, P599; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Deaton AM, 2011, GENE DEV, V25, P1010, DOI 10.1101/gad.2037511; Doi A, 2009, NAT GENET, V41, P1350, DOI 10.1038/ng.471; Elsheikh SE, 2008, BRIT J CANCER, V99, P327, DOI 10.1038/sj.bjc.6604463; Engelman JA, 1999, FEBS LETT, V448, P221, DOI 10.1016/S0014-5793(99)00365-8; Engelman JA, 1998, FEBS LETT, V429, P330, DOI 10.1016/S0014-5793(98)00619-X; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; Fackler MJ, 2011, CANCER RES, V71, P6195, DOI 10.1158/0008-5472.CAN-11-1630; Fan MY, 2006, CANCER RES, V66, P11954, DOI 10.1158/0008-5472.CAN-06-1666; Fang F, 2010, CANCER-AM CANCER SOC, V116, P4043, DOI 10.1002/cncr.25204; Fiucci G, 2002, ONCOGENE, V21, P2365, DOI 10.1038/sj.onc.1205300; Glait C, 2006, EXP CELL RES, V312, P3899, DOI 10.1016/j.yexcr.2006.08.016; Goetz JG, 2008, CANCER METAST REV, V27, P715, DOI 10.1007/s10555-008-9160-9; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; Han H, 2011, HUM MOL GENET, V20, P4299, DOI 10.1093/hmg/ddr356; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Hurlstone AFL, 1999, ONCOGENE, V18, P1881, DOI 10.1038/sj.onc.1202491; Irizarry RA, 2009, NAT GENET, V41, P178, DOI 10.1038/ng.298; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Jones PA, 2009, NAT REV GENET, V10, P805, DOI 10.1038/nrg2651; Joshi B, 2008, CANCER RES, V68, P8210, DOI 10.1158/0008-5472.CAN-08-0343; Kai WC, 2001, AM J PATHOL, V159, P1635, DOI 10.1016/S0002-9440(10)63010-6; Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146; Lan X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022226; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; Lin SY, 2004, ANTICANCER RES, V24, P1645; Liu PS, 2002, J BIOL CHEM, V277, P41295, DOI 10.1074/jbc.R200020200; Nestl A, 2001, CANCER RES, V61, P1569; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Ooi SKT, 2007, NATURE, V448, P714, DOI 10.1038/nature05987; Ostrom RS, 2004, BRIT J PHARMACOL, V143, P235, DOI 10.1038/sj.bjp.0705930; Park SS, 2005, HISTOPATHOLOGY, V47, P625, DOI 10.1111/j.1365-2559.2005.02303.x; Patani N, 2012, BREAST CANCER RES TR, V131, P307, DOI 10.1007/s10549-011-1761-2; Patani N, 2012, BREAST CANCER RES TR, V131, P1, DOI 10.1007/s10549-011-1751-4; Patel HH, 2008, ANNU REV PHARMACOL, V48, P359, DOI 10.1146/annurev.pharmtox.48.121506.124841; PINK JJ, 1995, CANCER RES, V55, P2583; Ravid D, 2005, ONCOGENE, V24, P1338, DOI 10.1038/sj.onc.1208337; Razandi M, 2002, MOL ENDOCRINOL, V16, P100, DOI 10.1210/me.16.1.100; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Pinilla SMR, 2006, BREAST CANCER RES TR, V99, P85, DOI 10.1007/s10549-006-9184-1; Rollins RA, 2006, GENOME RES, V16, P157, DOI 10.1101/gr.4262006; Rosman DS, 2008, CANCER RES, V68, P1319, DOI 10.1158/0008-5472.CAN-07-5424; Sagara Y, 2004, BRIT J CANCER, V91, P959, DOI 10.1038/sj.bjc.6602029; Savage K, 2007, CLIN CANCER RES, V13, P90, DOI 10.1158/1078-0432.CCR-06-1371; Serre D, 2010, NUCLEIC ACIDS RES, V38, P391, DOI 10.1093/nar/gkp992; Shatz M, 2008, INT J RADIAT BIOL, V84, P177, DOI 10.1080/09553000701745293; Sunaga N, 2004, CANCER RES, V64, P4277, DOI 10.1158/0008-5472.CAN-03-3941; Thomas NBP, 2010, BREAST CANCER RES TR, V119, P575, DOI 10.1007/s10549-009-0355-8; Tost J, 2007, NAT PROTOC, V2, P2265, DOI 10.1038/nprot.2007.314; Tse EYT, 2012, J PATHOL, V226, P645, DOI 10.1002/path.3957; Van den Eynden GG, 2006, BREAST CANCER RES TR, V95, P219, DOI 10.1007/s10549-005-9002-1; Wijayaratne AL, 2001, J BIOL CHEM, V276, P35684, DOI 10.1074/jbc.M101097200; Williams TM, 2005, AM J PHYSIOL-CELL PH, V288, pC494, DOI 10.1152/ajpcell.00458.2004; Zhang Y, 2008, GENOME BIOL, V9, DOI 10.1186/gb-2008-9-9-r137; Zschocke J, 2002, J BIOL CHEM, V277, P38772, DOI 10.1074/jbc.M205664200; Zuo T, 2011, CANCER RES, V71, P1752, DOI 10.1158/0008-5472.CAN-10-3573	61	88	92	2	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2013	32	38					4519	4528		10.1038/onc.2012.474	http://dx.doi.org/10.1038/onc.2012.474			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223SW	23128390	Green Published, hybrid			2022-12-28	WOS:000324831300007
J	Velghe, AI; Van Cauwenberghe, S; Polyansky, AA; Chand, D; Montano-Almendras, CP; Charni, S; Hallberg, B; Essaghir, A; Demoulin, JB				Velghe, A. I.; Van Cauwenberghe, S.; Polyansky, A. A.; Chand, D.; Montano-Almendras, C. P.; Charni, S.; Hallberg, B.; Essaghir, A.; Demoulin, J-B			PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations	ONCOGENE			English	Article						PDGF receptor; tyrosine kinase inhibitors; glioblastoma; leukemia; GIST	RECEPTOR TYROSINE KINASE; HYPEREOSINOPHILIC SYNDROME; CELL PROLIFERATION; EGF RECEPTOR; IMATINIB; ACTIVATION; MEMBRANE; DOMAIN; BETA; GENE	Activating mutations in the platelet-derived growth factor (PDGF) receptor alpha (PDGFRA) have been described in patients with gastrointestinal stromal tumors or myeloid malignancies associated with hypereosinophilia. These patients respond well to imatinib mesylate, raising the question as to whether patients with a PDGF receptor mutation in other tumor types should receive a tyrosine kinase inhibitor treatment. We characterized 10 novel somatic point mutations in PDGFRA that have been reported in isolated cases of glioblastoma, melanoma, acute myeloid leukemia, peripheral nerve sheath tumors and neuroendocrine carcinoma. The PDGFRA transmembrane domain mutation V536E stimulated Ba/F3 cell growth and signaling via ERK and STAT5 in the absence of ligand. This mutant, identified in glioblastoma, was strongly inhibited by imatinib. Modeling suggested that the mutation modulates the packing of the transmembrane domain helices in the receptor dimer. By contrast, two mutations in highly conserved residues affected the receptor traffic to the cell surface or kinase activity, thereby preventing the response to PDGF. The other mutations had no significant impact on the receptor activity. This functional analysis matched the predictions of SIFT and PolyPhen for only five mutations and these algorithms do not discriminate gain from loss of function. Finally, an E996K variant that had been identified in a melanoma cell line was not expressed in these cells. Altogether, several newly identified PDGFRA mutations do not activate the receptor and may therefore represent passenger mutations. Our results also underline the importance of characterizing novel kinase alterations in cancer patients.	[Velghe, A. I.; Van Cauwenberghe, S.; Montano-Almendras, C. P.; Charni, S.; Essaghir, A.; Demoulin, J-B] Catholic Univ Louvain, de Duve Inst, BE-1200 Brussels, Belgium; [Polyansky, A. A.] Univ Vienna, Max F Perutz Labs, Dept Struct & Computat Biol, Vienna, Austria; [Polyansky, A. A.] Russian Acad Sci, MM Shemyakin & Yu A Ovchinnikov Inst Bioorgan Che, Moscow, Russia; [Chand, D.; Hallberg, B.] Umea Univ, Dept Mol Biol, Umea, Sweden	Universite Catholique Louvain; Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Umea University	Demoulin, JB (corresponding author), Catholic Univ Louvain, de Duve Inst, MEXP B1-74-05,Ave Hippocrate 75, BE-1200 Brussels, Belgium.	jb.demoulin@uclouvain.be	Polyansky, Anton A/J-2145-2018	Polyansky, Anton A/0000-0002-1011-2706; Demoulin, Jean-Baptiste/0000-0002-8016-6689	Salus Sanguinis Foundation; 'Action de Recherches Concertees' (Communaute Francaise de Belgique, Belgium)	Salus Sanguinis Foundation; 'Action de Recherches Concertees' (Communaute Francaise de Belgique, Belgium)	We thank Francis Brasseur (Ludwig Institute for Cancer Research, Brussels, Belgium) for the LB373-MEL cell line and Stefan Constantinescu (de Duve Institute) for advices. This work was supported by the Salus Sanguinis Foundation and a grant from 'Action de Recherches Concertees' (Communaute Francaise de Belgique, Belgium).	Alentorn A, 2012, NEURO-ONCOLOGY, V14, P1393, DOI 10.1093/neuonc/nos217; Andrae J, 2008, GENE DEV, V22, P1276, DOI 10.1101/gad.1653708; Arkhipov A, 2013, CELL, V152, P557, DOI 10.1016/j.cell.2012.12.030; Bell CA, 2000, MOL BIOL CELL, V11, P3589, DOI 10.1091/mbc.11.10.3589; Burke CL, 1997, ONCOGENE, V14, P687, DOI 10.1038/sj.onc.1200873; Chiara F, 2004, J BIOL CHEM, V279, P19732, DOI 10.1074/jbc.M314070200; Clarke ID, 2003, ONCOGENE, V22, P722, DOI 10.1038/sj.onc.1206160; Cools J, 2003, NEW ENGL J MED, V348, P1201, DOI 10.1056/NEJMoa025217; Corless CL, 2005, J CLIN ONCOL, V23, P5357, DOI 10.1200/JCO.2005.14.068; David M, 2007, BLOOD, V109, P61, DOI 10.1182/blood-2006-05-024828; Demoulin JB, 2004, J BIOL CHEM, V279, P35392, DOI 10.1074/jbc.M405924200; Demoulin JB, 2003, BIOCHEM J, V376, P505, DOI 10.1042/BJ20030385; Demoulin JB, 1996, MOL CELL BIOL, V16, P4710; Demoulin JB, 2012, AM J BLOOD RES, V2, P44; Dresemann G, 2010, J NEURO-ONCOL, V96, P393, DOI 10.1007/s11060-009-9976-3; Elling C, 2011, BLOOD, V117, P2935, DOI 10.1182/blood-2010-05-286757; Endres NF, 2013, CELL, V152, P543, DOI 10.1016/j.cell.2012.12.032; Frohling S, 2007, CANCER CELL, V12, P501, DOI 10.1016/j.ccr.2007.11.005; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Hiwatari M, 2005, LEUKEMIA, V19, P476, DOI 10.1038/sj.leu.2403638; Holtkamp N, 2006, CARCINOGENESIS, V27, P664, DOI 10.1093/carcin/bgi273; Huss S, 2012, HISTOPATHOLOGY, V61, P59, DOI 10.1111/j.1365-2559.2012.04203.x; KEATING MT, 1989, J BIOL CHEM, V264, P9129; Medves S, 2012, J CELL MOL MED, V16, P237, DOI 10.1111/j.1582-4934.2011.01415.x; Medves S, 2011, HAEMATOL-HEMATOL J, V96, P1406, DOI 10.3324/haematol.2011.040147; Metzgeroth G, 2008, BRIT J HAEMATOL, V143, P707, DOI 10.1111/j.1365-2141.2008.07294.x; Montano-Almendras CR, 2012, HAEMATOL-HEMATOL J, V97, P1064, DOI 10.3324/haematol.2011.047530; Muhle-Goll C, 2012, J BIOL CHEM, V287, P26178, DOI 10.1074/jbc.M111.325555; Omura T, 1997, J BIOL CHEM, V272, P12676, DOI 10.1074/jbc.272.19.12676; Ozawa T, 2010, GENE DEV, V24, P2205, DOI 10.1101/gad.1972310; Paulsson J, 2011, INT J CANCER, V128, P1981, DOI 10.1002/ijc.25528; Polyansky AA, 2012, J AM CHEM SOC, V134, P14390, DOI 10.1021/ja303483k; Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493; Rand V, 2005, P NATL ACAD SCI USA, V102, P14344, DOI 10.1073/pnas.0507200102; Schonerr C, 2012, ONCOGENE, V31, P5193, DOI 10.1038/onc.2012.12; Schonherr C, 2011, TRANSL ONCOL, V4, P248, DOI 10.1593/tlo.11139; Takahashi Y, 2006, EMBO J, V25, P910, DOI 10.1038/sj.emboj.7600979; Toffalini F, 2010, BLOOD, V116, P2429, DOI 10.1182/blood-2010-04-279752; Toffalini F, 2010, J BIOL CHEM, V285, P12268, DOI 10.1074/jbc.M109.076638; Toffalini F, 2009, HAEMATOL-HEMATOL J, V94, P1085, DOI 10.3324/haematol.2008.001149; Verhaak RGW, 2010, CANCER CELL, V17, P98, DOI 10.1016/j.ccr.2009.12.020; Yang Y, 2008, P NATL ACAD SCI USA, V105, P7681, DOI 10.1073/pnas.0802896105; Yuzawa S, 2007, CELL, V130, P323, DOI 10.1016/j.cell.2007.05.055; Zhang J, 2013, P NATL ACAD SCI USA, V110, P1398, DOI 10.1073/pnas.1205299110	44	41	43	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2014	33	20					2568	2576		10.1038/onc.2013.218	http://dx.doi.org/10.1038/onc.2013.218			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH9YT	23752188				2022-12-28	WOS:000336502700003
J	Marino-Enriiquez, A; Ou, WB; Cowley, G; Luo, B; Jonker, AH; Mayeda, M; Okamoto, M; Eilers, G; Czaplinski, JT; Sicinska, E; Wang, Y; Taguchi, T; Demetri, GD; Root, DE; Fletcher, JA				Marino-Enriquez, A.; Ou, W-B; Cowley, G.; Luo, B.; Jonker, A. H.; Mayeda, M.; Okamoto, M.; Eilers, G.; Czaplinski, J. T.; Sicinska, E.; Wang, Y.; Taguchi, T.; Demetri, G. D.; Root, D. E.; Fletcher, J. A.			Genome-wide functional screening identifies CDC37 as a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal tumors	ONCOGENE			English	Article						CDC37; HSP90; GIST; targeted therapy; functional genomics; shRNA library	IMATINIB MESYLATE; RESISTANCE; INHIBITOR; MUTATIONS; ACTIVATION; CANCER; TRIAL	Most gastrointestinal stromal tumors (GISTs) contain KIT or PDGFRA kinase gain-of-function mutations, and therefore respond clinically to imatinib and other tyrosine kinase inhibitor (TKI) therapies. However, clinical progression subsequently results from selection of TKI-resistant clones, typically containing secondary mutations in the KIT kinase domain, which can be heterogeneous between and within GIST metastases in a given patient. TKI-resistant KIT oncoproteins require HSP90 chaperoning and are potently inactivated by HSP90 inhibitors, but clinical applications in GIST patients are constrained by the toxicity resulting from concomitant inactivation of various other HSP90 client proteins, beyond KIT and PDGFRA. To identify novel targets responsible for KIT oncoprotein function, we performed parallel genome-scale short hairpin RNA (shRNA)-mediated gene knockdowns in KIT-mutant GIST-T1 and GIST882. GIST cells were infected with a lentiviral shRNA pooled library targeting 11 194 human genes, and allowed to proliferate for 5-7 weeks, at which point assessment of relative hairpin abundance identified the HSP90 cofactor, CDC37, as one of the top six GIST-specific essential genes. Validations in treatment-naive (GIST-T1, GIST882) vs imatinib-resistant GISTs (GIST48, GIST430) demonstrated that: (1) CDC37 interacts with oncogenic KIT; (2) CDC37 regulates expression and activation of KIT and downstream signaling intermediates in GIST; and (3) unlike direct HSP90 inhibition, CDC37 knockdown accomplishes prolonged KIT inhibition (420 days) in GIST. These studies highlight CDC37 as a key biologic vulnerability in both imatinib-sensitive and imatinib-resistant GIST. CDC37 targeting is expected to be selective for KIT/PDGFRA and a subset of other HSP90 clients, and thereby represents a promising strategy for inactivating the myriad KIT/PDGFRA oncoproteins in TKI-resistant GIST patients.	[Marino-Enriquez, A.; Ou, W-B; Jonker, A. H.; Mayeda, M.; Eilers, G.; Wang, Y.; Fletcher, J. A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA; [Marino-Enriquez, A.] Univ Autonoma Madrid, Hosp Univ La Paz, Fdn Invest Biomed FIBHULP, IdiPAZ,Dept Anat Patol, Madrid, Spain; [Ou, W-B] Tsinghua Univ, Yangtze Delta Reg Inst, Zhejiang Prov Key Lab Appl Enzymol, Jiaxing, Zhejiang, Peoples R China; [Cowley, G.; Luo, B.; Okamoto, M.; Root, D. E.] Harvard & MIT, Broad Inst, RNAi Platform, Cambridge, MA USA; [Czaplinski, J. T.; Sicinska, E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Mol Oncol Pathol Med Oncol, Boston, MA 02115 USA; [Taguchi, T.] Kochi Univ, Grad Sch Kuroshio Sci, Dept Human Hlth & Med Sci, Nankoku, Kochi, Japan; [Demetri, G. D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Sarcoma & Bone Oncol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Autonomous University of Madrid; Hospital Universitario La Paz; Tsinghua University; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Kochi University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Marino-Enriiquez, A (corresponding author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.	admarino@partners.org; jfletcher@partners.org	Jonker, Anneliene/AAW-4326-2020; Ou, Wen-Bin/J-1142-2019	, Wenbin/0000-0002-6311-9442; Marino-Enriquez, Adrian/0000-0002-7680-9901	GI SPORE [1P50CA12703-05]; Virginia and Daniel K Ludwig Trust for Cancer Research; Paul's Posse and Team Cesarini of the Pan Mass Challenge; LifeRaft Group; GIST Cancer Research Fund; Sarcoma Alliance for Research Through Collaboration (SARC) Career Development Award; Qianjiang Talents Project of Zhejiang [2012R10079]; Science and Technology Bureau of Jiaxing, Zhejiang [2012AY1039]; Major Science and Technology Special Project of Zhejiang Province [2012C03007-4]; RNAI Consortium (TRC); NATIONAL CANCER INSTITUTE [P50CA127003] Funding Source: NIH RePORTER	GI SPORE; Virginia and Daniel K Ludwig Trust for Cancer Research; Paul's Posse and Team Cesarini of the Pan Mass Challenge; LifeRaft Group; GIST Cancer Research Fund; Sarcoma Alliance for Research Through Collaboration (SARC) Career Development Award; Qianjiang Talents Project of Zhejiang; Science and Technology Bureau of Jiaxing, Zhejiang; Major Science and Technology Special Project of Zhejiang Province; RNAI Consortium (TRC); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Adrian Marino-Enriquez, Wen-Bin Ou, Yuexiang Wang, Jonathan A Fletcher and George D Demetri, are supported by the GI SPORE 1P50CA12703-05, Virginia and Daniel K Ludwig Trust for Cancer Research, Paul's Posse and Team Cesarini of the Pan Mass Challenge, LifeRaft Group and the GIST Cancer Research Fund. Adrian Marino-Enriquez is also supported by a Sarcoma Alliance for Research Through Collaboration (SARC) Career Development Award. Wen-Bin Ou is also supported by Qianjiang Talents Project of Zhejiang (2012R10079), a grant from the Science and Technology Bureau of Jiaxing, Zhejiang (2012AY1039) and the Major Science and Technology Special Project of Zhejiang Province (2012C03007-4). The RNAI Consortium (TRC) supported the development of pooled screening methods used for these screens.	Agaram NP, 2008, GENE CHROMOSOME CANC, V47, P853, DOI 10.1002/gcc.20589; Antonescu CR, 2005, CLIN CANCER RES, V11, P4182, DOI 10.1158/1078-0432.CCR-04-2245; Antonescu CR, 2011, J PATHOL, V223, P251, DOI 10.1002/path.2798; Bauer S, 2006, CANCER RES, V66, P9153, DOI 10.1158/0008-5472.CAN-06-0165; Chandarlapaty S, 2008, CLIN CANCER RES, V14, P240, DOI 10.1158/1078-0432.CCR-07-1667; Cheung HW, 2011, P NATL ACAD SCI USA, V108, P12372, DOI 10.1073/pnas.1109363108; DeMatteo RP, 2009, LANCET, V373, P1097, DOI 10.1016/S0140-6736(09)60500-6; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Demetri GD, 2010, P GASTR CANC S; Heinrich MC, 2003, SCIENCE, V299, P708, DOI 10.1126/science.1079666; Heinrich MC, 2006, J CLIN ONCOL, V24, P4764, DOI 10.1200/JCO.2006.06.2265; Heinrich MC, 2008, J CLIN ONCOL, V26, P5352, DOI 10.1200/JCO.2007.15.7461; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Lee CH, 2012, P NATL ACAD SCI USA, V109, P929, DOI 10.1073/pnas.1115528109; Liegl B, 2008, J PATHOL, V216, P64, DOI 10.1002/path.2382; Luo B, 2008, P NATL ACAD SCI USA, V105, P20380, DOI 10.1073/pnas.0810485105; Rubin BP, 2001, CANCER RES, V61, P8118; Smith JR, 2009, CELL CYCLE, V8, P362, DOI 10.4161/cc.8.3.7531; Smyth T, 2012, MOL CANCER THER, V11, P1799, DOI 10.1158/1535-7163.MCT-11-1046; Vaughan CK, 2008, MOL CELL, V31, P886, DOI 10.1016/j.molcel.2008.07.021; Verweij J, 2004, LANCET, V364, P1127, DOI 10.1016/S0140-6736(04)17098-0; Xu WP, 2012, MOL CELL, V47, P434, DOI 10.1016/j.molcel.2012.05.015; Zhang T, 2009, J BIOL CHEM, V284, P35381, DOI 10.1074/jbc.M109.051532	23	21	22	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2014	33	14					1872	1876		10.1038/onc.2013.127	http://dx.doi.org/10.1038/onc.2013.127			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RE	23584476	Green Accepted			2022-12-28	WOS:000334345500013
J	Ganapathy, S; Xiao, S; Seo, SJ; Lall, R; Yang, M; Xu, T; Su, H; Shadfan, M; Ha, CS; Yuan, ZM				Ganapathy, S.; Xiao, S.; Seo, S-J; Lall, R.; Yang, M.; Xu, T.; Su, H.; Shadfan, M.; Ha, C. S.; Yuan, Z-M			Low-dose arsenic induces chemotherapy protection via p53/NF-kappa B-mediated metabolic regulation	ONCOGENE			English	Article						chemoprotection; p53; NF-kappa B; metabolism; colon cancer	NF-KAPPA-B; SIGNALING PATHWAYS; DRINKING-WATER; P53; CANCER; CROSSTALK; CELLS	Most chemotherapeutical drugs kill cancer cells chiefly by inducing DNA damage, which unfortunately also causes undesirable injuries to normal tissues, mainly due to p53 activation. We report a novel strategy of normal tissue protection that involves p53/NF-kappa B coordinated metabolic regulation. Pretreatment of untransformed cells with low doses of arsenic induced concerted p53 suppression and NF-kappa B activation, which elicited a marked induction of glycolysis. Significantly, this metabolic shift provided cells effective protection against cytotoxic chemotherapy, coupling the metabolic pathway to cellular resistance. Using both in vitro and in vivo models, we demonstrated an absolute requirement of functional p53 in arsenic-mediated protection. Consistently, a brief arsenic pretreatment selectively protected only normal tissues, but not tumors, from toxicity of chemotherapy. An indispensable role of glycolysis in protecting normal tissues was demonstrated by using an inhibitor of glycolysis, 2-deoxyglucose, which almost totally abolished low-dose arsenic-mediated protection. Together, our work demonstrates that low-dose arsenic renders normal cells and tissues resistant to chemotherapy-induced toxicity by inducting glycolysis.	[Ganapathy, S.; Xiao, S.; Seo, S-J; Lall, R.; Yang, M.; Xu, T.; Su, H.; Shadfan, M.; Ha, C. S.; Yuan, Z-M] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, Dept Radiat Oncol, San Antonio, TX 78229 USA; [Ganapathy, S.; Yang, M.; Yuan, Z-M] Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, Boston, MA 02115 USA	Cancer Therapy & Research Center; University of Texas System; University of Texas Health San Antonio; Harvard University; Harvard T.H. Chan School of Public Health	Yuan, ZM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 655 Huntington Ave,SPH Bldg 1, Boston, MA 02115 USA.	zyuan@hsph.harvard.edu	Ha, C/GZL-9046-2022	yang, mei/0000-0001-9574-2282	NCI/NIH [2 R01 CA085679, R01 CA125144]; NATIONAL CANCER INSTITUTE [R01CA125144, R01CA085679, R01CA167814] Funding Source: NIH RePORTER	NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by NCI/NIH grants 2 R01 CA085679 and R01 CA125144 (to ZMY). We are grateful to Dr Gigi Lozano (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) for the p53-mutant mice. Mouse imaging was performed by Suresh Prajapati, gratefully acknowledged.	Ak P, 2010, FASEB J, V24, P3643, DOI 10.1096/fj.10-160549; Andrew AS, 2003, ENVIRON HEALTH PERSP, V111, P825, DOI 10.1289/ehp.111-1241504; Ben-Neriah Y, 2011, NAT IMMUNOL, V12, P715, DOI 10.1038/ni.2060; Christophorou MA, 2006, NATURE, V443, P214, DOI 10.1038/nature05077; Gudkov AV, 2003, NAT REV CANCER, V3, P117, DOI 10.1038/nrc992; Hinkal G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006654; Huang YL, 2008, CANCER RES, V68, P9131, DOI 10.1158/0008-5472.CAN-08-3025; KAPLAN HS, 1952, J NATL CANCER I, V13, P185; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Lamm SH, 2004, J OCCUP ENVIRON MED, V46, P298, DOI 10.1097/01.jom.0000116801.67556.8f; Mahata J, 2004, MUTAGENESIS, V19, P223, DOI 10.1093/mutage/geh022; Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Tergaonkar V, 2007, MOL CELL, V26, P158, DOI 10.1016/j.molcel.2007.04.006; Vousden KH, 2009, NAT REV CANCER, V9, P691, DOI 10.1038/nrc2715; WANG T, 1976, NATURE, V261, P702, DOI 10.1038/261702a0	16	19	20	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2014	33	11					1359	1366		10.1038/onc.2013.81	http://dx.doi.org/10.1038/onc.2013.81			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD0SD	23524579	Green Accepted, Green Submitted			2022-12-28	WOS:000332943500003
J	Mao, B; Hu, F; Cheng, J; Wang, P; Xu, M; Yuan, F; Meng, S; Wang, Y; Yuan, Z; Bi, W				Mao, B.; Hu, F.; Cheng, J.; Wang, P.; Xu, M.; Yuan, F.; Meng, S.; Wang, Y.; Yuan, Z.; Bi, W.			SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma	ONCOGENE			English	Article						SIRT1; YAP; acetylation; transcription; hepatocellular carcinoma	TRANSCRIPTION FACTORS; GROWTH-CONTROL; DNA-DAMAGE; ACETYLATION; DEACETYLASE; ACTIVATION; YAP; PATHWAY; INACTIVATION; MODULATION	The MST/YAP (mammalian Ste20-like kinase/Yes-associated protein 2) pathway plays an important role in hepatocellular carcinoma (HCC). Although post-translational modification-especially MST/Lats (large tumor suppressor)-mediated phosphorylation and PP1 (protein phosphatase-1)-mediated dephosphorylation-has been found to regulate the activity of YAP2, very little is known about its acetylation. In our experiments, we observed that the expression of SIRT1 is significantly upregulated in the tumor samples of the hepatocarcinoma patients, and SIRT1 mRNA level positively correlates with connective tissue growth factor (CTGF) mRNA level. We then found that SIRT1 deacetylates YAP2 protein in HCC cells and SIRT1-mediated deacetylation increases the YAP2/TEAD4 association, leading to YAP2/TEAD4 transcriptional activation and upregulated cell growth in HCC cells. Moreover, knockdown of SIRT1 blocks the cisplatin (CDDP)-induced nuclear translocation of YAP2 and enhances the chemosensitivity of HCC cells to CDDP treatment. Together, our findings reveal a new regulatory mechanism of YAP2 by the SIRT1-mediated deacetylation that may be involved in HCC tumorigenesis and drug resistance.	[Mao, B.; Cheng, J.; Wang, P.; Yuan, Z.] Chinese Acad Sci, Inst Biophys, Beijing 100101, Peoples R China; [Hu, F.] Tianjin Hosp, Dept Orthoped, Tianjin, Peoples R China; [Xu, M.; Yuan, F.; Wang, Y.; Bi, W.] Chinese Peoples Liberat Army Gen Hosp, Clin Div Surg, Dept Orthoped, Beijing 100853, Peoples R China; [Meng, S.] Dalian Med Univ, Ctr Canc, Inst Canc Stem Cell, Dalian, Peoples R China; [Meng, S.; Yuan, Z.] Chinese Hippo Consortium, Beijing, Peoples R China	Chinese Academy of Sciences; Institute of Biophysics, CAS; Chinese People's Liberation Army General Hospital; Dalian Medical University	Yuan, Z (corresponding author), Chinese Acad Sci, Inst Biophys, Beijing 100101, Peoples R China.	zqyuan@ibp.ac.cn; biwenzhi@sina.com	Yuan, Zengqiang/G-5245-2017		National Science Foundation of China [81172553, 81201564, 81125010, 81030025]; Ministry of Science and Technology of China [973-2009CB918704, 973-2012CB910701]	National Science Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Science and Technology of China(Ministry of Science and Technology, China)	We thank Dr Depei Liu for the gift of all the SIRT1 plasmids; Dr Lei Zhang for the 3*SD binding site artificial-luciferase reporter plasmid; Dr Zhixiong Xiao for the p73 antibody; Ursula Adams for manuscript editing; and Xudong Zhao and Su Liu of IBP core facility center for technical support. This work was supported by the National Science Foundation of China (81172553, 81201564, 81125010 and 81030025), and the Ministry of Science and Technology of China (973-2009CB918704 and 973-2012CB910701).	Brooks CL, 2011, PROTEIN CELL, V2, P456, DOI 10.1007/s13238-011-1063-9; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Camargo FD, 2007, CURR BIOL, V17, P2054, DOI 10.1016/j.cub.2007.10.039; Chan SW, 2009, J BIOL CHEM, V284, P14347, DOI 10.1074/jbc.M901568200; Cohen HY, 2004, MOL CELL, V13, P627, DOI 10.1016/S1097-2765(04)00094-2; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; Dai JM, 2007, J CELL PHYSIOL, V210, P161, DOI 10.1002/jcp.20831; Dong JX, 2007, CELL, V130, P1120, DOI 10.1016/j.cell.2007.07.019; Du ZW, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001462; El-Serag HB, 2007, GASTROENTEROLOGY, V132, P2557, DOI 10.1053/j.gastro.2007.04.061; Firestein R, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002020; Hao YW, 2008, J BIOL CHEM, V283, P5496, DOI 10.1074/jbc.M709037200; Hata S, J BIOL CHEM, V287, P22089; Huang JB, 2005, CELL, V122, P421, DOI 10.1016/j.cell.2005.06.007; Kemper JK, 2009, CELL METAB, V10, P392, DOI 10.1016/j.cmet.2009.09.009; Lan F, 2008, J BIOL CHEM, V283, P27628, DOI 10.1074/jbc.M805711200; Mao BB, 2011, INT J BIOCHEM CELL B, V43, P1573, DOI 10.1016/j.biocel.2011.07.006; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Matsuzaki H, 2005, P NATL ACAD SCI USA, V102, P11278, DOI 10.1073/pnas.0502738102; Molloy D, 2006, VIROLOGY, V355, P115, DOI 10.1016/j.virol.2006.05.004; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Parkin DM, 2001, INT J CANCER, V94, P153, DOI 10.1002/ijc.1440; Urtasun R, 2011, HEPATOLOGY, V54, P2149, DOI 10.1002/hep.24587; Vassilev A, 2001, GENE DEV, V15, P1229, DOI 10.1101/gad.888601; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wang CG, 2006, NAT CELL BIOL, V8, P1025, DOI 10.1038/ncb1468; Wang P, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024288; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244; Zhang H, 2009, J BIOL CHEM, V284, P13355, DOI 10.1074/jbc.M900843200; Zhao B, 2008, GENE DEV, V22, P1962, DOI 10.1101/gad.1664408; Zhao B, 2007, GENE DEV, V21, P2747, DOI 10.1101/gad.1602907; Zhou DW, 2009, CANCER CELL, V16, P425, DOI 10.1016/j.ccr.2009.09.026	32	112	121	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2014	33	11					1468	1474		10.1038/onc.2013.88	http://dx.doi.org/10.1038/onc.2013.88			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD0SD	23542177				2022-12-28	WOS:000332943500014
J	Gonzalez-Flores, A; Aguilar-Quesada, R; Siles, E; Pozo, S; Rodriguez-Lara, MI; Lopez-Jimenez, L; Lopez-Rodriguez, M; Peralta-Leal, A; Villar, D; Martin-Oliva, D; del Peso, L; Berra, E; Oliver, FJ				Gonzalez-Flores, A.; Aguilar-Quesada, R.; Siles, E.; Pozo, S.; Rodriguez-Lara, M. I.; Lopez-Jimenez, L.; Lopez-Rodriguez, M.; Peralta-Leal, A.; Villar, D.; Martin-Oliva, D.; del Peso, L.; Berra, E.; Oliver, F. J.			Interaction between PARP-1 and HIF-2 alpha in the hypoxic response	ONCOGENE			English	Article						hypoxia; PARP-1; HIF-2	RENAL-CELL CARCINOMA; INDUCIBLE FACTOR-I; TRANSCRIPTIONAL ACTIVITY; EMBRYONIC-DEVELOPMENT; PROLYL HYDROXYLATION; HIF-ALPHA; HIF-1-ALPHA; PROMOTES; GENE; POLY(ADP-RIBOSE)	Hypoxia-inducible factors (HIFs) mediate the transcriptional adaptation of hypoxic cells. The extensive transcriptional programm regulated by HIFs involves the induction of genes controlling angiogenesis, cellular metabolism, cell growth, metastasis, apoptosis, extracellular matrix remodeling and others. HIF is a heterodimer of HIF-alpha and HIF-beta subunits. In addition to HIF-1 alpha, HIF-2 alpha has evolved as an isoform that contributes differently to the hypoxic adaptation by performing non-redundant functions. Poly (ADPribose) polymerase-1 (PARP-1) is a nuclear protein involved in the control of DNA repair and gene transcription by modulating chromatin structure and acting as part of gene-specific enhancer/promoter-binding complexes. Previous results have shown that PARP-1 regulates HIF-1 activity. In this study, we focused on the cross-talk between HIF-2 alpha and PARP-1. By using different approaches to suppress PARP-1, we show that HIF-2 alpha mRNA expression, protein levels and HIF-2-dependent gene expression, such as ANGPTL4 and erythropoietin (EPO), are regulated by PARP-1. This regulation occurs at both the transcriptional and post-trancriptional level. We also show a complex formation between HIF-2 alpha with PARP-1. This complex is sensitive to PARP inhibition and seems to protect against the von Hippel-Lindau-dependent HIF-2 alpha degradation. Finally, we show that parp-1(-/-) mice display a significant reduction in the circulating hypoxia-induced EPO levels, number of red cells and hemoglobin concentration. Altogether, these results reveal a complex functional interaction between PARP-1 and the HIF system and suggest that PARP-1 is involved in the fine tuning of the HIF-mediated hypoxic response in vivo.	[Gonzalez-Flores, A.; Aguilar-Quesada, R.; Rodriguez-Lara, M. I.; Lopez-Jimenez, L.; Lopez-Rodriguez, M.; Peralta-Leal, A.; Oliver, F. J.] CSIC, Inst Parasitol & Biomed Lopez Neyra, Granada 18100, Spain; [Siles, E.] Univ Jaen, Dept Expt Biol, Jaen, Spain; [Pozo, S.; Berra, E.] CIC bioGUNE, Derio 48160, Spain; [Villar, D.; del Peso, L.] Autonomous Univ Madrid, Fac Med, CSIC, Inst Biomed Res Alberto Sols, E-28049 Madrid, Spain; [Martin-Oliva, D.] Univ Granada, Fac Sci, Dept Cellular Biol, Granada, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Parasitologia y Biomedicina Lopez-Neyra (IPBLN); Universidad de Jaen; CIC bioGUNE; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); University of Granada	Berra, E (corresponding author), CIC bioGUNE, Parque Tecnol Bizkaia Ed 801A, Derio 48160, Spain.	eberra@cicbiogune.es; joliver@ipb.csic.es	Lara, María Isabel Rodríguez/A-1961-2017; Oliver, Javier/S-1725-2018; Peralta Leal, Andreína Cecilia/AAE-8342-2022; Martín-Oliva, David/L-8472-2014; cancer, biogune/H-7276-2012; Villar, Diego/K-8595-2017; Berra, Edurne/F-9692-2011; del Peso, Luis/K-9391-2014	Lara, María Isabel Rodríguez/0000-0002-2270-0070; Oliver, Javier/0000-0001-8468-1998; Peralta Leal, Andreína Cecilia/0000-0001-7120-9870; Martín-Oliva, David/0000-0002-8095-5442; Villar, Diego/0000-0002-8614-6232; Berra, Edurne/0000-0002-3820-5744; del Peso, Luis/0000-0003-4014-5688; Siles Rivas, Eva/0000-0003-4192-7008; Aguilar-Quesada, Rocio/0000-0003-3125-6634	Ministerio de Ciencia e Innovacion [SAF2006-01094, SAF2009-13281-C02-01]; Fundacion La Caixa [BM06-219-0]; Junta de Andalucia [P07-CTS-0239]; Ministerio de Educacion y Ciencia [SAF2007-64597, SAF-2010-20067]; BIZKAIA XEDE Program from the Bizkaia County	Ministerio de Ciencia e Innovacion(Ministry of Science and Innovation, Spain (MICINN)Instituto de Salud Carlos IIISpanish Government); Fundacion La Caixa(La Caixa Foundation); Junta de Andalucia(Junta de Andalucia); Ministerio de Educacion y Ciencia(Spanish Government); BIZKAIA XEDE Program from the Bizkaia County	We thank Dr Francoise Dantzer, CNRS, Strasbourg (France), for providing the pEGFP-PARP-1 construct. This work was supported by Ministerio de Ciencia e Innovacion (SAF2006-01094 and SAF2009-13281-C02-01), Fundacion La Caixa (BM06-219-0) and Junta de Andalucia (P07-CTS-0239) to FJO; Ministerio de Educacion y Ciencia (SAF2007-64597 and SAF-2010-20067) and the BIZKAIA XEDE Program from the Bizkaia County to EB.	Aguilar-Quesada R, 2007, CURR MED CHEM, V14, P1179, DOI 10.2174/092986707780597998; Aprelikova O, 2006, CANCER RES, V66, P5641, DOI 10.1158/0008-5472.CAN-05-3345; Benizri E, 2008, CELL MOL LIFE SCI, V65, P1133, DOI 10.1007/s00018-008-7472-0; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Covello KL, 2006, GENE DEV, V20, P557, DOI 10.1101/gad.1399906; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Elser M, 2008, MOL CANCER RES, V6, P282, DOI 10.1158/1541-7786.MCR-07-0377; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Flamme I, 1998, AM J PATHOL, V153, P25, DOI 10.1016/S0002-9440(10)65541-1; Gordan JD, 2007, CANCER CELL, V11, P335, DOI 10.1016/j.ccr.2007.02.006; Hochachka PW, 1996, P NATL ACAD SCI USA, V93, P9493, DOI 10.1073/pnas.93.18.9493; Holmquist-Mengelbier L, 2006, CANCER CELL, V10, P413, DOI 10.1016/j.ccr.2006.08.026; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kondo K, 2003, PLOS BIOL, V1, P439, DOI 10.1371/journal.pbio.0000083; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Koshiji M, 2004, EMBO J, V23, P1949, DOI 10.1038/sj.emboj.7600196; Kraus WL, 2003, CELL, V113, P677, DOI 10.1016/S0092-8674(03)00433-1; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Loboda A, 2012, VASC PHARMACOL, V56, P245, DOI 10.1016/j.vph.2012.02.006; Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2; Martinez-Romero R, 2012, J APPL PHYSIOL, V112, P816, DOI 10.1152/japplphysiol.00898.2011; Mastrogiannaki M, 2009, J CLIN INVEST, V119, P1159, DOI 10.1172/JCI38499; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Peng J, 2000, P NATL ACAD SCI USA, V97, P8386, DOI 10.1073/pnas.140087397; Pescador N, 2005, BIOCHEM J, V390, P189, DOI 10.1042/BJ20042121; PUGH CW, 1991, P NATL ACAD SCI USA, V88, P10553, DOI 10.1073/pnas.88.23.10553; Rankin EB, 2007, J CLIN INVEST, V117, P1068, DOI 10.1172/JCI30117; Raval RR, 2005, MOL CELL BIOL, V25, P5675, DOI 10.1128/MCB.25.13.5675-5686.2005; Rosenberger C, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000017223.49823.2A; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Schodel J, 2011, BLOOD, V117, pE207, DOI 10.1182/blood-2010-10-314427; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Tian H, 1998, GENE DEV, V12, P3320, DOI 10.1101/gad.12.21.3320; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Yoon D, 2011, AM J PHYSIOL-CELL PH, V300, pC1215, DOI 10.1152/ajpcell.00044.2011	41	38	39	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2014	33	7					891	898		10.1038/onc.2013.9	http://dx.doi.org/10.1038/onc.2013.9			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB2MN	23455322				2022-12-28	WOS:000331626900010
J	Kang, R; Tang, D; Schapiro, NE; Loux, T; Livesey, KM; Billiar, TR; Wang, H; Van Houten, B; Lotze, MT; Zeh, HJ				Kang, R.; Tang, D.; Schapiro, N. E.; Loux, T.; Livesey, K. M.; Billiar, T. R.; Wang, H.; Van Houten, B.; Lotze, M. T.; Zeh, H. J.			The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics	ONCOGENE			English	Article						HMGB1; RAGE; pancreatic cancer; inflammation; mitochondria; ATP	ADVANCED GLYCATION ENDPRODUCTS; GROUP BOX-1 PROTEIN; RAGE; RECEPTOR; CANCER; AUTOPHAGY; MIGRATION; RELEASE; IMMUNE; SIGNAL	Tumor cells require increased adenosine triphosphate (ATP) to support anabolism and proliferation. The precise mechanisms regulating this process in tumor cells are unknown. Here, we show that the receptor for advanced glycation endproducts (RAGE) and one of its primary ligands, high-mobility group box 1 (HMGB1), are required for optimal mitochondrial function within tumors. We found that RAGE is present in the mitochondria of cultured tumor cells as well as primary tumors. RAGE and HMGB1 coordinately enhanced tumor cell mitochondrial complex I activity, ATP production, tumor cell proliferation and migration. Lack of RAGE or inhibition of HMGB1 release diminished ATP production and slowed tumor growth in vitro and in vivo. These findings link, for the first time, the HMGB1-RAGE pathway with changes in bioenergetics. Moreover, our observations provide a novel mechanism within the tumor microenvironment by which necrosis and inflammation promote tumor progression.	[Kang, R.; Tang, D.; Schapiro, N. E.; Loux, T.; Livesey, K. M.; Billiar, T. R.; Lotze, M. T.; Zeh, H. J.] Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Dept Surg, Pittsburgh, PA 15219 USA; [Wang, H.] NYU, Sch Med, North Shore Univ Hosp, Manhasset, NY USA; [Van Houten, B.] Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Lab Mol & Cell Biol Program, Pittsburgh, PA 15219 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; New York University; Northwell Health; North Shore University Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Tang, D (corresponding author), Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Dept Surg, 5117 Ctr Ave, Pittsburgh, PA 15219 USA.	tangd2@upmc.edu; lotzemt@upcm.edu; zehh@upmc.edu	Van Houten, Bennett/K-2284-2019; Tang, Daolin/B-2905-2010; Wang, Haichao/K-6310-2012; Kang, Rui/ABD-5291-2021; Wang, Haichao/AAU-2237-2021; Tang, Daolin/ABD-5062-2021	Wang, Haichao/0000-0002-0211-9000; Kang, Rui/0000-0003-2725-1574; Wang, Haichao/0000-0002-0211-9000; Tang, Daolin/0000-0002-1903-6180; Loux, Tara/0000-0002-7531-6363	National Institutes of Health [P01 CA 101944, R01CA160417]; University of Pittsburgh;  [P30CA047904]; NATIONAL CANCER INSTITUTE [R01CA160417, P30CA047904, P01CA101944] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Pittsburgh(University of Pittsburgh); ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We dedicate this manuscript to the memory of Angelika Bierhaus, PhD, our friend and benefactor. She was a pioneering RAGE biologist, generous and kind in her dealings with colleagues, who provided us the mice with which we completed this work, and who sadly passed away on 15 April 2012 after a long and courageous battle with cancer. Angelika had a great love of life and she was generous, kind and warm hearted. She was always full of plans for scientific endeavors, even when her disease began to take its toll. She steadfastly denied that she would be defeated, recently celebrating her 50th birthday; however, she was aware that her remaining time was short. She dedicated herself to research, but despite her incredible strength, she was not able to overcome the disease, which tragically took her life. We thank Christine Heiner (University of Pittsburgh. Department of Surgery) for her critical reading of the manuscript. This project was supported by grants from the National Institutes of Health (P01 CA 101944 to MTL, R01CA160417 to DT) and the University of Pittsburgh (DT and HJZ). This project used University of Pittsburgh Cancer Institute shared resources that are supported in part by award P30CA047904. We also thank Dr Donna Stolz and Simon Watkins for providing the confocal microscopy facilities at the Center for Biologic Imaging at University of Pittsburgh School of Medicine.	Alonso M, 2004, J NEUROCHEM, V89, P248, DOI 10.1111/j.1471-4159.2004.02323.x; Andersson U, 2011, ANNU REV IMMUNOL, V29, P139, DOI 10.1146/annurev-immunol-030409-101323; Arciuch VGA, 2009, ADV DRUG DELIVER REV, V61, P1234, DOI 10.1016/j.addr.2009.04.025; Bianchi ME, 2009, J LEUKOCYTE BIOL, V86, P573, DOI 10.1189/jlb.1008585; Calogero S, 1999, NAT GENET, V22, P276, DOI 10.1038/10338; DiNorcia J, 2012, J GASTROINTEST SURG, V16, P104, DOI 10.1007/s11605-011-1754-9; Galli S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007541; Gebhardt C, 2008, J EXP MED, V205, P275, DOI 10.1084/jem.20070679; Gefter JV, 2009, CELL TISSUE RES, V337, P79, DOI 10.1007/s00441-009-0791-0; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021; Huang J, 2012, CANCER RES, V72, P230, DOI 10.1158/0008-5472.CAN-11-2001; Hudson BI, 2008, J BIOL CHEM, V283, P34457, DOI 10.1074/jbc.M801465200; Kang R, 2010, CELL DEATH DIFFER, V17, P666, DOI 10.1038/cdd.2009.149; Kang R., 2012, P NATL ACAD SCI US; Kang R, 2012, P NATL ACAD SCI USA, V109, P7031, DOI 10.1073/pnas.1113865109; Kang R, 2011, ANTIOXID REDOX SIGN, V15, P2175, DOI 10.1089/ars.2010.3378; Liliensiek B, 2004, J CLIN INVEST, V113, P1641, DOI 10.1172/JCI200418704; Livesey KM, 2012, CANCER RES, V72, P1996, DOI 10.1158/0008-5472.CAN-11-2291; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Mantovani A, 2009, NATURE, V457, P36, DOI 10.1038/457036b; Mitola S, 2006, J IMMUNOL, V176, P12, DOI 10.4049/jimmunol.176.1.12; Orlova VV, 2007, EMBO J, V26, P1129, DOI 10.1038/sj.emboj.7601552; Pagliarini DJ, 2006, TRENDS BIOCHEM SCI, V31, P26, DOI 10.1016/j.tibs.2005.11.005; Palumbo R, 2004, J CELL BIOL, V164, P441, DOI 10.1083/jcb.200304135; Poderoso C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001443; Praus M, 1999, GENE THER, V6, P227, DOI 10.1038/sj.gt.3300802; Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497; Rai V, 2012, J BIOL CHEM, V287, P5133, DOI 10.1074/jbc.M111.277731; Scaffidi P, 2002, NATURE, V418, P191, DOI 10.1038/nature00858; Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI200114002; Sparvero LJ, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-17; Stumbo AC, 2008, CELL BIOL INT, V32, P235, DOI 10.1016/j.cellbi.2007.08.031; Tang D, 2010, ONCOGENE, V29, P5299, DOI 10.1038/onc.2010.261; Tang DL, 2007, J IMMUNOL, V179, P1236, DOI 10.4049/jimmunol.179.2.1236; Tang DL, 2011, CELL METAB, V13, P701, DOI 10.1016/j.cmet.2011.04.008; Tang DL, 2010, J CELL BIOL, V190, P881, DOI 10.1083/jcb.200911078; Tang DL, 2010, BBA-GENE REGUL MECH, V1799, P131, DOI 10.1016/j.bbagrm.2009.11.014; Ulloa L, 2002, P NATL ACAD SCI USA, V99, P12351, DOI 10.1073/pnas.192222999; Vakkila J, 2004, NAT REV IMMUNOL, V4, P641, DOI 10.1038/nri1415; Wang SW, 2002, BIOCHEM J, V367, P729, DOI 10.1042/BJ20020752; Wegrzyn J, 2009, SCIENCE, V323, P793, DOI 10.1126/science.1164551; Zhang YS, 2012, BIOCHEM PHARMACOL, V84, P1492, DOI 10.1016/j.bcp.2012.09.015	44	159	168	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2014	33	5					567	577		10.1038/onc.2012.631	http://dx.doi.org/10.1038/onc.2012.631			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5GW	23318458	Green Accepted			2022-12-28	WOS:000331125100005
J	Little, JL; Serzhanova, V; Izumchenko, E; Egleston, BL; Parise, E; Klein-Szanto, AJ; Loudon, G; Shubina, M; Seo, S; Kurokawa, M; Ochs, MF; Golemis, EA				Little, J. L.; Serzhanova, V.; Izumchenko, E.; Egleston, B. L.; Parise, E.; Klein-Szanto, A. J.; Loudon, G.; Shubina, M.; Seo, S.; Kurokawa, M.; Ochs, M. F.; Golemis, E. A.			A requirement for Nedd9 in luminal progenitor cells prior to mammary tumorigenesis in MMTV-HER2/ErbB2 mice	ONCOGENE			English	Article						breast cancer; HER2; mammary precursor cells; drug resistance	FOCAL ADHESION KINASE; EPITHELIAL-SPECIFIC DISRUPTION; SUBSTRATE LYMPHOCYTE TYPE; DOCKING PROTEIN HEF1; HUMAN-BREAST; TRANSCRIPTOME ANALYSES; ANTIGEN RECEPTOR; CANCER; MOUSE; INTEGRIN	Overexpression of the NEDD9/HEF1/Cas-L scaffolding protein is frequent, and drives invasion and metastasis in breast, head and neck, colorectal, melanoma, lung and other types of cancer. We have examined the consequences of genetic ablation of Nedd9 in the MMTV-HER2/ERBB2/neu mouse mammary tumor model. Unexpectedly, we found that only a limited effect on metastasis in MMTV-neu;Nedd9(-/-) mice compared with MMTV-neu;Nedd9(-/-) mice, but instead a dramatic reduction in tumor incidence (18 versus 80%), and a significantly increased latency until tumor appearance. Orthotopic reinjection and tail-vein injection of cells arising from tumors, coupled with in vivo analysis, indicated tumors arising in MMTV-neu;Nedd9(-/-) mice had undergone mutational selection that overcame the initial requirement for Nedd9. To better understand the defects in early tumor growth, we compared mammary progenitor cell pools from MMTV-neu;Nedd9(-/-) versus MMTV-neu;Nedd9(-/-) mice. The MMTV-neu;Nedd9(-/-) genotype selectively reduced both the number and colony-forming potential of mammary luminal epithelial progenitor cells, while not affecting basal epithelial progenitors. MMTV-neu;Nedd9(-/-) mammospheres had striking defects in morphology and cell polarity. All of these defects were seen predominantly in the context of the HER2/neu oncogene, and were not associated with randomization of the plane of mitotic division, but rather with depressed expression the cell attachment protein FAK, accompanied by increased sensitivity to small molecule inhibitors of FAK and SRC. Surprisingly, in spite of these significant differences, only minimal changes were observed in the gene expression profile of Nedd9(-/-) mice, indicating critical Nedd9-dependent differences in cell growth properties were mediated via post-transcriptional regulation of cell signaling. Coupled with emerging data indicating a role for NEDD9 in progenitor cell populations during the morphogenesis of other tissues, these results indicate a functional requirement for NEDD9 in the growth of mammary cancer progenitor cells.	[Little, J. L.; Serzhanova, V.; Izumchenko, E.; Egleston, B. L.; Klein-Szanto, A. J.; Shubina, M.; Golemis, E. A.] Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA; [Parise, E.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA USA; [Little, J. L.; Loudon, G.] Bryn Mawr Coll, Dept Biol, Bryn Mawr, PA 19010 USA; [Seo, S.; Kurokawa, M.] Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Tokyo, Japan; [Ochs, M. F.] Johns Hopkins Univ, Dept Oncol Informat, Baltimore, MD USA; [Ochs, M. F.] Johns Hopkins Univ, Dept Hlth Sci Informat, Baltimore, MD USA	Fox Chase Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Bryn Mawr College; University of Tokyo; Johns Hopkins University; Johns Hopkins University	Golemis, EA (corresponding author), Fox Chase Canc Ctr, Inst Canc Res, 7701 Burholme Ave, Philadelphia, PA 19111 USA.	EA_Golemis@fccc.edu	Little, Joy/K-1463-2015; Little, Joy/AAY-4795-2021; Egleston, Brian L./P-1000-2019	Egleston, Brian L./0000-0002-1633-799X; Golemis, Erica/0000-0003-3618-3673	Pennsylvania Tobacco Settlement funding; NIH [CA06927, T32 CA009035, F32 CA150553]; Pew Charitable Fund; American Associates, Ben-Gurion University of the Negev; Fox Chase Cancer Center Undergraduate Student Summer Fellowship Program;  [R01s CA63366];  [CA113342];  [U54 CA149147];  [R21 LM009382]; NATIONAL CANCER INSTITUTE [P30CA006927, R01CA063366, U54CA149147, T32CA009035, R01CA113342, R29CA063366, F32CA150553] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [R21LM009382] Funding Source: NIH RePORTER	Pennsylvania Tobacco Settlement funding; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Pew Charitable Fund; American Associates, Ben-Gurion University of the Negev; Fox Chase Cancer Center Undergraduate Student Summer Fellowship Program; ; ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))	We are grateful to Emmanuelle Nicolas (Genotyping and Real-Time-PCR Facility of FCCC), Jianming Pei (Cytogenetics and Chromosome Microarray Analysis Facility of FCCC) and Yue-Sheng Liu (Expression Microarray Facility of FCCC), Anthony Lerro and Jackie Valvardi (Laboratory Animal Facility of FCCC), James Oesterling (Cell Sorting Facility of FCCC), Jin Fang (Cell Culture Facility of FCCC), Catherine Renner (Histopathology Facility), Marina Boushra (from Cornell University), Christiaan Honig (from Germantown Academy) and Nicolas G Day (from St John's College) for technical help. We particularly acknowledge Edna Cukierman for expert advice with analysis of microscopic images. R01s CA63366 and CA113342, a U54 CA149147 subcontract, and Pennsylvania Tobacco Settlement funding (to EAG); and NIH core Grant CA06927 and the Pew Charitable Fund (to Fox Chase Cancer Center) supported this work. JLL was supported by NIH T32 CA009035 and F32 CA150553; EI by the American Associates, Ben-Gurion University of the Negev; EP by the Fox Chase Cancer Center Undergraduate Student Summer Fellowship Program. MFO was supported by R21 LM009382.	Aquino JB, 2009, NEUROSCIENCE, V162, P1106, DOI 10.1016/j.neuroscience.2009.05.035; Astier A, 1997, LEUKEMIA LYMPHOMA, V28, P65, DOI 10.3109/10428199709058332; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; Astsaturov I, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001083; Baselga J, 2010, ANN ONCOL, V21, P36, DOI 10.1093/annonc/mdq421; Castello-Cros R, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-94; Dadke D, 2006, MOL BIOL CELL, V17, P1204, DOI 10.1091/mbc.E05-03-0237; Dankort DL, 2000, ONCOGENE, V19, P1038, DOI 10.1038/sj.onc.1203272; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dilworth SM, 2002, NAT REV CANCER, V2, P951, DOI 10.1038/nrc946; Fashena SJ, 2002, J CELL SCI, V115, P99; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hao Y, 2010, CURR BIOL, V20, P1809, DOI 10.1016/j.cub.2010.09.032; Izumchenko E, 2009, CANCER RES, V69, P7198, DOI 10.1158/0008-5472.CAN-09-0795; Keller PJ, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2755; Kong CF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022666; Lahlou H, 2007, P NATL ACAD SCI USA, V104, P20302, DOI 10.1073/pnas.0710091104; Law SF, 1996, MOL CELL BIOL, V16, P3327; Law SF, 2000, MOL CELL BIOL, V20, P5184, DOI 10.1128/MCB.20.14.5184-5195.2000; Li BL, 1997, MOL CELL BIOL, V17, P3155, DOI 10.1128/MCB.17.6.3155; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Lifsted T, 1998, INT J CANCER, V77, P640, DOI 10.1002/(SICI)1097-0215(19980812)77:4<640::AID-IJC26>3.0.CO;2-8; Lim E, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2560; Lo PK, 2012, ONCOGENE, V31, P2614, DOI [10.1038/onc.2011.439, 10.1038/onc.2012.147]; Luo M, 2009, CANCER RES, V69, P466, DOI 10.1158/0008-5472.CAN-08-3078; Manie SN, 1997, J BIOL CHEM, V272, P4230, DOI 10.1074/jbc.272.7.4230; Minegishi M, 1996, J EXP MED, V184, P1365, DOI 10.1084/jem.184.4.1365; Moasser MM, 2007, ONCOGENE, V26, P6469, DOI 10.1038/sj.onc.1210477; Nagashima Takeshi, 2008, Cancer Genomics & Proteomics, V5, P161; O'Neill GM, 2007, CANCER RES, V67, P8975, DOI 10.1158/0008-5472.CAN-07-1328; O'Neill GM, 2001, MOL CELL BIOL, V21, P5094, DOI 10.1128/MCB.21.15.5094-5108.2001; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; Pontier SM, 2009, J CELL SCI, V122, P207, DOI 10.1242/jcs.040394; Provenzano PP, 2008, AM J PATHOL, V173, P1551, DOI 10.2353/ajpath.2008.080308; Pugacheva EN, 2005, NAT CELL BIOL, V7, P937, DOI 10.1038/ncb1309; Pylayeva Y, 2009, J CLIN INVEST, V119, P252, DOI 10.1172/JCI37160; Sanz-Moreno V, 2008, CELL, V135, P510, DOI 10.1016/j.cell.2008.09.043; Seo S, 2005, J IMMUNOL, V175, P3492, DOI 10.4049/jimmunol.175.6.3492; Seo S, 2011, CANCER SCI, V102, P2109, DOI 10.1111/j.1349-7006.2011.02066.x; Shults J, 2007, STATA J, V7, P147, DOI 10.1177/1536867X0700700201; Singh MK, 2010, CANCER RES, V70, P8907, DOI 10.1158/0008-5472.CAN-10-0353; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098; Stingl J, 2006, NATURE, V439, P993, DOI 10.1038/nature04496; Stingl John, 2005, Methods Mol Biol, V290, P249; Tikhmyanova N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022102; Tikhmyanova N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012369; Tikhmyanova N, 2010, CELL MOL LIFE SCI, V67, P1025, DOI 10.1007/s00018-009-0213-1; Tondeur S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008990; Vaillant F, 2007, STEM CELL REV, V3, P114, DOI 10.1007/s12015-007-0018-2; van Miltenburg MHAM, 2009, FASEB J, V23, P3482, DOI 10.1096/fj.08-123398; van Seventer GA, 2001, EUR J IMMUNOL, V31, P1417, DOI 10.1002/1521-4141(200105)31:5<1417::AID-IMMU1417>3.0.CO;2-C; Vogel T, 2010, CEREB CORTEX, V20, P661, DOI 10.1093/cercor/bhp134; Worthington J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-490	56	18	18	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2014	33	4					411	420		10.1038/onc.2012.607	http://dx.doi.org/10.1038/onc.2012.607			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VX	23318423	Green Accepted			2022-12-28	WOS:000330214600002
J	Teoh-Fitzgerald, ML; Fitzgerald, MP; Zhong, W; Askeland, RW; Domann, FE				Teoh-Fitzgerald, M. L.; Fitzgerald, M. P.; Zhong, W.; Askeland, R. W.; Domann, F. E.			Epigenetic reprogramming governs EcSOD expression during human mammary epithelial cell differentiation, tumorigenesis and metastasis	ONCOGENE			English	Article						three-dimensional culture; DNA methylation; experimental lung metastasis; spontaneous metastasis; acinar morphogenesis; laminin-enriched extracellular matrix	EXTRACELLULAR-SUPEROXIDE-DISMUTASE; GENE-EXPRESSION; MATRIX COMPONENTS; DNA METHYLATION; BINDING-SITE; CANCER; GROWTH; INACTIVATION; OVEREXPRESSION; IDENTIFICATION	Expression of the antioxidant enzyme EcSOD in normal human mammary epithelial cells was not recognized until recently. Although expression of EcSOD was not detectable in non-malignant human mammary epithelial cells (HMEC) cultured in conventional two-dimensional (2D) culture conditions, EcSOD protein expression was observed in normal human breast tissues, suggesting that the 2D-cultured condition induces a repressive status of EcSOD gene expression in HMEC. With the use of laminin-enriched extracellular matrix (IrECM), we were able to detect expression of EcSOD when HMEC formed polarized acinar structures in a 3D-culture condition. Repression of the EcSOD-gene expression was again seen when the HMEC acini were sub-cultured as a monolayer, implying that IrECM-induced acinar morphogenesis is essential in EcSOD-gene activation. We have further shown the involvement of DNA methylation in regulating EcSOD expression in HMEC under these cell culture conditions. EcSOD mRNA expression was strongly induced in the 2D-cultured HMEC after treatment with a DNA methyltransferase inhibitor. In addition, epigenetic analyses showed a decrease in the degree of CpG methylation in the EcSOD promoter in the 3D versus 2D-cultured HMEC. More importantly, > 80% of clinical mammary adenocarcinoma samples showed significantly decreased EcSOD mRNA and protein expression levels compared with normal mammary tissues and there is an inverse correlation between the expression levels of EcSOD and the clinical stages of breast cancer. Combined bisulfite restriction analysis analysis of some of the tumors also revealed an association of DNA methylation with the loss of EcSOD expression in vivo. Furthermore, overexpression of EcSOD inhibited breast cancer metastasis in both the experimental lung metastasis model and the syngeneic mouse model. This study suggests that epigenetic silencing of EcSOD may contribute to mammary tumorigenesis and that restoring the extracellular superoxide scavenging activity could be an effective strategy for breast cancer treatment.	[Teoh-Fitzgerald, M. L.; Fitzgerald, M. P.; Domann, F. E.] Univ Iowa, Dept Radiat Oncol, Free Rad & Radiat Biol Program, Iowa City, IA USA; [Zhong, W.] Univ Wisconsin, Dept Pathol & Lab Med, Madison, WI USA; [Askeland, R. W.] Univ Iowa, Dept Pathol, Iowa City, IA 52242 USA	University of Iowa; University of Wisconsin System; University of Wisconsin Madison; University of Iowa	Teoh-Fitzgerald, ML (corresponding author), Univ Nebraska Med Ctr, Dept Biochem & Mol Biol, Omaha, NE 68198 USA.	m.teohfitzgerald@unmc.edu; frederick-domann@uiowa.edu		Domann, Frederick/0000-0002-0489-2179	NIH [R01 CA073612, R01 CA115438]; Susan G Komen for the Cure [KG080437]; SFRBM Research Mini-Fellowship; Oberley Seed Grant; Carver Research Program of Excellence in Redox Biology and Medicine; Holden Comprehensive Cancer Center Breast Cancer Research Fund; NATIONAL CANCER INSTITUTE [P30CA086862, R01CA115438, R01CA073612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES005605] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Susan G Komen for the Cure(Susan G. Komen Breast Cancer Foundation); SFRBM Research Mini-Fellowship; Oberley Seed Grant; Carver Research Program of Excellence in Redox Biology and Medicine; Holden Comprehensive Cancer Center Breast Cancer Research Fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	The authors thank Dr James Crapo (National Jewish Medical and Research Center, Denver, CO, USA) for providing antibodies to EcSOD and Dr Michael Henry (Department of Molecular Physiology and Biophysics, University of Iowa, IA, USA) for providing the 4T1 luc cells. We also thank Justin Fishbaugh from the Flow Cytometry Core Facility for assisting with the DCFH assays as well as the Central Microscopy Research Facility. This study was supported by NIH grant R01 CA073612 and R01 CA115438 (FE Domann), Susan G Komen for the Cure grant KG080437 (M Teoh-Fitzgerald), SFRBM Research Mini-Fellowship (M Teoh-Fitzgerald), Oberley Seed Grant (M Teoh-Fitzgerald), and Carver Research Program of Excellence in Redox Biology and Medicine, and by the Holden Comprehensive Cancer Center Breast Cancer Research Fund.	ADACHI T, 1992, ARCH BIOCHEM BIOPHYS, V297, P155, DOI 10.1016/0003-9861(92)90654-F; Behrend L, 2003, BIOCHEM SOC T, V31, P1441; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BLASCHKE RJ, 1994, METHOD ENZYMOL, V245, P535; Case AJ, 2011, FREE RADICAL BIO MED, V50, P448, DOI 10.1016/j.freeradbiomed.2010.11.025; CHEN LH, 1989, CELL REGUL, V1, P45, DOI 10.1091/mbc.1.1.45; Drake JM, 2005, CLIN EXP METASTAS, V22, P674, DOI 10.1007/s10585-006-9011-4; Edovitsky E, 2004, JNCI-J NATL CANCER I, V96, P1219, DOI 10.1093/jnci/djh230; Garbe JC, 2007, CELL CYCLE, V6, P1927, DOI 10.4161/cc.6.15.4519; Gius D, 2006, ANTIOXID REDOX SIGN, V8, P1249, DOI 10.1089/ars.2006.8.1249; Henrotin Y, 2009, ADV CLIN CHEM, V49, P31, DOI 10.1016/S0065-2423(09)49002-4; Hewetson A, 2002, MOL ENDOCRINOL, V16, P2101, DOI 10.1210/me.2002-0064; HICKS CL, 1979, J DAIRY SCI, V62, P529, DOI 10.3168/jds.S0022-0302(79)83285-3; HICKS CL, 1980, J DAIRY SCI, V63, P1199, DOI 10.3168/jds.S0022-0302(80)83065-7; Jolivet G, 2005, J CELL BIOCHEM, V95, P313, DOI 10.1002/jcb.20397; Jones PA, 2002, ONCOGENE, V21, P5358, DOI 10.1038/sj.onc.1205597; Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004; Laukkanen MO, 1999, ARTERIOSCL THROM VAS, V19, P2171, DOI 10.1161/01.ATV.19.9.2171; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Li YZ, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-7; MARKLUND SL, 1984, J CLIN INVEST, V74, P1398, DOI 10.1172/JCI111550; Novak P, 2009, CANCER RES, V69, P5251, DOI 10.1158/0008-5472.CAN-08-4977; Oberley LW, 2005, BIOMED PHARMACOTHER, V59, P143, DOI 10.1016/j.biopha.2005.03.006; OBERLEY LW, 1979, CANCER RES, V39, P1141; OBERLEY LW, 1981, MED HYPOTHESES, V7, P21, DOI 10.1016/0306-9877(81)90018-9; PETERSEN OW, 1992, P NATL ACAD SCI USA, V89, P9064, DOI 10.1073/pnas.89.19.9064; Raats CJI, 1997, J BIOL CHEM, V272, P26734, DOI 10.1074/jbc.272.42.26734; Rose SL, 2006, GYNECOL ONCOL, V102, P319, DOI 10.1016/j.ygyno.2005.12.025; Shan WH, 2010, FREE RADICAL BIO MED, V49, P2078, DOI 10.1016/j.freeradbiomed.2010.10.691; Svensson RU, 2007, CANCER RES, V67, P10445, DOI 10.1158/0008-5472.CAN-07-1955; Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116; Tang XY, 2011, J BIOL CHEM, V286, P13244, DOI 10.1074/jbc.M110.206615; Teodoridis JM, 2004, DRUG RESIST UPDATE, V7, P267, DOI 10.1016/j.drup.2004.06.005; Teoh ML, 2007, CLIN CANCER RES, V13, P7441, DOI 10.1158/1078-0432.CCR-07-0851; Teoh MLT, 2009, CANCER RES, V69, P6355, DOI 10.1158/0008-5472.CAN-09-1195; Teoh-Fitzgerald MLT, 2012, MOL CANCER RES, V10, P40, DOI 10.1158/1541-7786.MCR-11-0501; Valinluck V, 2007, CANCER RES, V67, P946, DOI 10.1158/0008-5472.CAN-06-3123; VUKICEVIC S, 1992, EXP CELL RES, V202, P1, DOI 10.1016/0014-4827(92)90397-Q; Weaver VM, 2002, CANCER CELL, V2, P205, DOI 10.1016/S1535-6108(02)00125-3; Wu H, 2011, NATURE, V473, P389, DOI 10.1038/nature09934; Xu R, 2007, J BIOL CHEM, V282, P14992, DOI 10.1074/jbc.M610316200	41	58	62	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2014	33	3					358	368		10.1038/onc.2012.582	http://dx.doi.org/10.1038/onc.2012.582			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VR	23318435	Green Accepted			2022-12-28	WOS:000330214000010
J	Wu, J; Patmore, DM; Jousma, E; Eaves, DW; Breving, K; Patel, AV; Schwartz, EB; Fuchs, JR; Cripe, TP; Stemmer-Rachamimov, AO; Ratner, N				Wu, J.; Patmore, D. M.; Jousma, E.; Eaves, D. W.; Breving, K.; Patel, A. V.; Schwartz, E. B.; Fuchs, J. R.; Cripe, T. P.; Stemmer-Rachamimov, A. O.; Ratner, N.			EGFR-STAT3 signaling promotes formation of malignant peripheral nerve sheath tumors	ONCOGENE			English	Article						EGFR; STAT3; sarcoma; MPNST; NF1	GROWTH-FACTOR RECEPTOR; NEUROFIBROMATOSIS TYPE-1; SELF-RENEWAL; MOUSE MODELS; CANCER-CELLS; NF1; TRANSCRIPTION-3; TRANSDUCER; ACTIVATOR; PATHWAY	Malignant peripheral nerve sheath tumors (MPNSTs) develop sporadically or in the context of neurofibromatosis type 1. Epidermal growth factor receptor (EGFR) overexpression has been implicated in MPNST formation, but its precise role and relevant signaling pathways remain unknown. We found that EGFR overexpression promotes mouse neurofibroma transformation to aggressive MPNST (GEM-PNST). Immunohistochemistry demonstrated phosphorylated STAT3 (Tyr705) in both human MPNST and mouse GEM-PNST. A specific JAK2/STAT3 inhibitor FLLL32 delayed MPNST formation in an MPNST xenograft nude mouse model. STAT3 knockdown by shRNA prevented MPNST formation in vivo. Finally, reducing EGFR activity strongly reduced pSTAT3 in vivo. Thus, an EGFR-STAT3 pathway is necessary for MPNST transformation and establishment of MPNST xenografts growth but not for tumor maintenance. Efficacy of the FLLL32 pharmacological inhibitor in delaying MPNST growth suggests that combination therapies targeting JAK/STAT3 might be useful therapeutics.	[Wu, J.; Patmore, D. M.; Jousma, E.; Eaves, D. W.; Breving, K.; Patel, A. V.; Cripe, T. P.; Ratner, N.] Cincinnati Childrens Hosp Med Ctr, Cincinnati Childrens Hosp Res Fdn, Canc & Blood Dis Inst, Cincinnati, OH 45229 USA; [Schwartz, E. B.; Fuchs, J. R.] Ohio State Univ, Coll Pharm, Columbus, OH 43210 USA; [Stemmer-Rachamimov, A. O.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; [Stemmer-Rachamimov, A. O.] Harvard Univ, Sch Med, Boston, MA USA	Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; Ohio State University; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Ratner, N (corresponding author), Cincinnati Childrens Hosp, Dept Pediat, Div Exp Hematol & Canc Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	nancy.ratner@cchmc.org		Fuchs, James/0000-0002-8743-6389; RATNER, NANCY/0000-0001-5030-9354	National Institutes of Health [R01 NS28840, P50 NS057531]; Department of Defense New Investigator Award [NF100053]; Ohio State University Comprehensive Cancer Center Pelotonia Idea Grant; American Cancer Society [IRG-67-003-44]; NATIONAL CANCER INSTITUTE [P30CA016058] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS057531, R01NS028840] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Defense New Investigator Award(United States Department of Defense); Ohio State University Comprehensive Cancer Center Pelotonia Idea Grant; American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Dr Andre Bernards (Massachusetts General Hospital) and Drs Jiayuh Lin, Pui-Kai Li and Gregory B Lesinski (Ohio State University) for helpful discussions. This work was supported by the National Institutes of Health (R01 NS28840 and P50 NS057531 to NR), and Department of Defense New Investigator Award (NF100053) and an Ohio State University Comprehensive Cancer Center Pelotonia Idea Grant (to JW). The American Cancer Society (IRG-67-003-44) supported JRF.	Banerjee S, 2010, CANCER RES, V70, P1356, DOI 10.1158/0008-5472.CAN-09-2178; Battle T. E., 2002, Current Molecular Medicine (Hilversum), V2, P381, DOI 10.2174/1566524023362456; Beert E, 2011, GENE CHROMOSOME CANC, V50, P1021, DOI 10.1002/gcc.20921; Carroll SL, 2008, GLIA, V56, P1590, DOI 10.1002/glia.20776; Cichowski K, 1999, SCIENCE, V286, P2172, DOI 10.1126/science.286.5447.2172; DeClue JE, 2000, J CLIN INVEST, V105, P1233, DOI 10.1172/JCI7610; Evans DGR, 2002, J MED GENET, V39, P311, DOI 10.1136/jmg.39.5.311; Ferner RE, 2002, CANCER RES, V62, P1573; Ferner RE, 2007, EUR J HUM GENET, V15, P131, DOI 10.1038/sj.ejhg.5201676; Frahm S, 2004, NEUROBIOL DIS, V16, P85, DOI 10.1016/j.nbd.2004.01.006; Frohnert PW, 2003, GLIA, V43, P104, DOI 10.1002/glia.10232; Fukuda A, 2011, CANCER CELL, V19, P441, DOI 10.1016/j.ccr.2011.03.002; Guryanova OA, 2011, CANCER CELL, V19, P498, DOI 10.1016/j.ccr.2011.03.004; Joseph NM, 2008, CANCER CELL, V13, P129, DOI 10.1016/j.ccr.2008.01.003; Katz D, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001227; Keizman D, 2009, J NEURO-ONCOL, V94, P383, DOI 10.1007/s11060-009-9862-z; Lesina M, 2011, CANCER CELL, V19, P456, DOI 10.1016/j.ccr.2011.03.009; Li HZ, 2002, CANCER RES, V62, P4507; Lin L, 2010, CANCER RES, V70, P2445, DOI 10.1158/0008-5472.CAN-09-2468; Ling BC, 2005, CANCER CELL, V7, P65, DOI 10.1016/j.ccr.2004.10.016; Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575; LUETTEKE NC, 1994, GENE DEV, V8, P399, DOI 10.1101/gad.8.4.399; Marotta LLC, 2011, J CLIN INVEST, V121, P2723, DOI 10.1172/JCI44745; Miller SJ, 2009, EMBO MOL MED, V1, P236, DOI 10.1002/emmm.200900027; Miller SJ, 2006, CANCER RES, V66, P2584, DOI 10.1158/0008-5472.CAN-05-3330; Perry A, 2002, J NEUROPATH EXP NEUR, V61, P702, DOI 10.1093/jnen/61.8.702; Reilly KM, 2006, CANCER RES, V66, P62, DOI 10.1158/0008-5472.CAN-05-1480; Reilly KM, 2004, P NATL ACAD SCI USA, V101, P13008, DOI 10.1073/pnas.0401236101; Rosenbaum T, 2000, J NEUROSCI RES, V61, P524, DOI 10.1002/1097-4547(20000901)61:5<524::AID-JNR7>3.3.CO;2-Q; Shao H, 2003, CANCER RES, V63, P3923; Sherry MM, 2009, STEM CELLS, V27, P2383, DOI 10.1002/stem.185; Stemmer-Rachamimov AO, 2004, CANCER RES, V64, P3718, DOI 10.1158/0008-5472.CAN-03-4079; Sun Daochun, 2012, Transl Oncogenomics, V5, P1, DOI 10.4137/TOG.S8830; Torres KE, 2011, CLIN CANCER RES, V17, P3943, DOI 10.1158/1078-0432.CCR-11-0193; Tucker T, 2005, NEUROLOGY, V65, P205, DOI 10.1212/01.wnl.0000168830.79997.13; Vigneron A, 2008, CANCER RES, V68, P815, DOI 10.1158/0008-5472.CAN-07-5115; Vogel KS, 1999, SCIENCE, V286, P2176, DOI 10.1126/science.286.5447.2176; Walrath JC, 2009, MAMM GENOME, V20, P214, DOI 10.1007/s00335-009-9179-4; Widemann BC, 2009, CURR ONCOL REP, V11, P322, DOI 10.1007/s11912-009-0045-z; Wu JQ, 2008, CANCER CELL, V13, P105, DOI 10.1016/j.ccr.2007.12.027; Yarden Y, 2001, EUR J CANCER, V37, pS3; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734	42	63	68	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2014	33	2					173	180		10.1038/onc.2012.579	http://dx.doi.org/10.1038/onc.2012.579			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286BY	23318430	Green Accepted			2022-12-28	WOS:000329440700005
J	Hayes, KE; Walk, EL; Ammer, AG; Kelley, LC; Martin, KH; Weed, SA				Hayes, K. E.; Walk, E. L.; Ammer, A. G.; Kelley, L. C.; Martin, K. H.; Weed, S. A.			Ableson kinases negatively regulate invadopodia function and invasion in head and neck squamous cell carcinoma by inhibiting an HB-EGF autocrine loop	ONCOGENE			English	Article						abl; imatinib mesylate; invadopodia; invasion; head and neck cancer; cortactin	SRC FAMILY KINASES; PHASE-II TRIAL; GROWTH-FACTOR; C-ABL; BREAST-CANCER; TYROSINE PHOSPHORYLATION; LUNG-CANCER; MATRIX-METALLOPROTEINASE; SARACATINIB AZD0530; IMATINIB MESYLATE	Head and neck squamous cell carcinoma (HNSCC) has a proclivity for locoregional invasion. HNSCC mediates invasion in part through invadopodia-based proteolysis of the extracellular matrix (ECM). Activation of Src, Erk1/2, Abl and Arg downstream of epidermal growth factor receptor (EGFR) modulates invadopodia activity through phosphorylation of the actin regulatory protein cortactin. In MDA-MB-231 breast cancer cells, Abl and Arg function downstream of Src to phosphorylate cortactin, promoting invadopodia ECM degradation activity and thus assigning a pro-invasive role for Ableson kinases. We report that Abl kinases have an opposite, negative regulatory role in HNSCC where they suppress invadopodia and tumor invasion. Impairment of Abl expression or Abl kinase activity with imatinib mesylate enhanced HNSCC matrix degradation and 3D collagen invasion, functions that were impaired in MDA-MB-231. HNSCC lines with elevated EGFR and Src activation did not contain increased Abl or Arg kinase activity, suggesting that Src could bypass Abl/Arg to phosphorylate cortactin and promote invadopodia ECM degradation. Src-transformed Abl(-/-)/Arg(-/-) fibroblasts produced ECM degrading invadopodia containing pY421 cortactin, indicating that Abl/Arg are dispensable for invadopodia function in this system. Imatinib-treated HNSCC cells had increased EGFR, Erk1/2 and Src activation, enhancing cortactin pY421 and pS405/418 required for invadopodia function. Imatinib stimulated shedding of the EGFR ligand heparin-binding EGF-like growth factor (HB-EGF) from HNSCC cells, where soluble HB-EGF enhanced invadopodia ECM degradation in HNSCC but not in MDA-MB-231. HNSCC cells treated with inhibitors of the EGFR-invadopodia pathway indicated that EGFR and Src are required for invadopodia function. Collectively, our results indicate that Abl kinases negatively regulate HNSCC invasive processes through suppression of an HB-EGF autocrine loop responsible for activating a EGFR-Src-cortactin cascade, in contrast to the invasion promoting functions of Abl kinases in breast and other cancer types. Our results provide mechanistic support for recent failed HNSCC clinical trials utilizing imatinib.	[Hayes, K. E.; Walk, E. L.; Ammer, A. G.; Kelley, L. C.; Martin, K. H.; Weed, S. A.] W Virginia Univ, Mary Babb Randolph Canc Ctr, Program Canc Cell Biol, Dept Neurobiol & Anat, Morgantown, WV 26506 USA	West Virginia University	Weed, SA (corresponding author), W Virginia Univ, Mary Babb Randolph Canc Ctr Morgantown, Morgantown, WV 26506 USA.	scweed@hsc.wvu.edu		Martin, Karen/0000-0001-8916-4092; Weed, Scott/0000-0001-7033-9999	NIH [R01 DE014578, P20 RR16440]; West Virginia University Mary Babb Randolph Cancer Center; Mary Babb Randolph Cancer, NIH [P20 RR16440, P30 RR032138/GM103488]; NATIONAL CENTER FOR RESEARCH RESOURCES [P30RR032138, P20RR016440] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE014578] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM103488] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); West Virginia University Mary Babb Randolph Cancer Center; Mary Babb Randolph Cancer, NIH; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Bruce Mayer (University of Connecticut) for Abl constructs, Anthony Koleske (Yale University) for Abl<SUP>-/-</SUP>/Arg<SUP>-/-</SUP> fibroblasts, Silja Wessler (Paul-Ehrlich Institute) for the Abl shRNA construct, Elena Pugacheva (West Virginia University) for MDA-MB-231LN cells, Jim Bear (University of North Carolina) for pLL5.0 and advice on spheroid assay development. We thank Mark Auble and Barbara Frederick for technical assistance. Saracatinib and gefitinib were provided by AstraZeneca. This study was supported by NIH Grants R01 DE014578, P20 RR16440 (to SAW) and the West Virginia University Mary Babb Randolph Cancer Center. The West Virginia University Microscopy Imaging Facility (supported by the Mary Babb Randolph Cancer, NIH Grants P20 RR16440 and P30 RR032138/GM103488) is gratefully acknowledged.	Allington TM, 2009, FASEB J, V23, P4231, DOI 10.1096/fj.09-138412; Ammer AG, 2008, CELL MOTIL CYTOSKEL, V65, P687, DOI 10.1002/cm.20296; Ammer Amanda Gatesman, 2009, J Cancer Sci Ther, V1, P52; Antoku S, 2008, J CELL SCI, V121, P3071, DOI 10.1242/jcs.031575; Araujo JC, 2012, CANCER-AM CANCER SOC, V118, P63, DOI 10.1002/cncr.26204; Artym VV, 2006, CANCER RES, V66, P3034, DOI 10.1158/0008-5472.CAN-05-2177; Ayala I, 2008, J CELL SCI, V121, P369, DOI 10.1242/jcs.008037; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Boyle SN, 2007, CURR BIOL, V17, P445, DOI 10.1016/j.cub.2007.01.057; Bradley WD, 2009, J CELL SCI, V122, P3441, DOI 10.1242/jcs.039859; Brooks HD, 2011, CANCER-AM CANCER SOC, V117, P2112, DOI 10.1002/cncr.25769; Buccione R, 2009, CANCER METAST REV, V28, P137, DOI 10.1007/s10555-008-9176-1; Cai L, 2008, CELL, V134, P828, DOI 10.1016/j.cell.2008.06.054; Montero JC, 2011, CLIN CANCER RES, V17, P5546, DOI 10.1158/1078-0432.CCR-10-2616; Chen YT, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0017876, 10.1371/journal.pone.0021428, 10.1371/journal.pone.0017844, 10.1371/journal.pone.0024144, 10.1371/journal.pone.0027163, 10.1371/journal.pone.0027333]; Clark ES, 2007, CANCER RES, V67, P4227, DOI 10.1158/0008-5472.CAN-06-3928; Colicelli J, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3139re6; Destaing O, 2011, CURR OPIN CELL BIOL, V23, P597, DOI 10.1016/j.ceb.2011.04.002; Ernst T, 2012, SEMIN ONCOL, V39, P58, DOI 10.1053/j.seminoncol.2011.11.002; Frasca F, 2001, ONCOGENE, V20, P3845, DOI 10.1038/sj.onc.1204531; Fung C, 2010, EXPERT OPIN EMERG DR, V15, P355, DOI 10.1517/14728214.2010.497754; Furlan A, 2011, CELL DEATH DIFFER, V18, P1608, DOI 10.1038/cdd.2011.23; Fury MG, 2011, ANTICANCER RES, V31, P249; Ganguly SS, 2011, ONCOGENE, P5; Guarino M, 2010, J CELL PHYSIOL, V223, P14, DOI 10.1002/jcp.22011; Gucalp A, 2011, CLIN BREAST CANCER, V11, P306, DOI 10.1016/j.clbc.2011.03.021; Hama T, 2012, CLIN EXP METASTAS, V29, P19, DOI 10.1007/s10585-011-9425-5; Hama T, 2009, ONCOLOGIST, V14, P900, DOI 10.1634/theoncologist.2009-0058; Hatakeyama H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012702; Haura EB, 2010, J CLIN ONCOL, V28, P1387, DOI 10.1200/JCO.2009.25.4029; Head JA, 2003, MOL BIOL CELL, V14, P3216, DOI 10.1091/mbc.e02-11-0753; Hennequin LF, 2006, J MED CHEM, V49, P6465, DOI 10.1021/jm060434q; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huang YT, 2002, INT J CANCER, V99, P505, DOI 10.1002/ijc.10373; Johnson FM, 2005, J CELL PHYSIOL, V205, P218, DOI 10.1002/jcp.20383; Johnson FM, 2005, CLIN CANCER RES, V11, P6924, DOI 10.1158/1078-0432.CCR-05-0757; Kalyankrishna S, 2006, J CLIN ONCOL, V24, P2666, DOI 10.1200/JCO.2005.04.8306; Kelley LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013847; Kelley LC, 2010, J CELL SCI, V123, P3923, DOI 10.1242/jcs.075200; Kim LC, 2009, NAT REV CLIN ONCOL, V6, P587, DOI 10.1038/nrclinonc.2009.129; Kirkbride KC, 2011, CELL ADHES MIGR, V5, P187, DOI 10.4161/cam.5.2.14773; Koppikar P, 2008, CLIN CANCER RES, V14, P4284, DOI 10.1158/1078-0432.CCR-07-5226; Lapetina S, 2009, J CELL BIOL, V185, P503, DOI 10.1083/jcb.200809085; Lara PN, 2009, ANTI-CANCER DRUG, V20, P179, DOI 10.1097/CAD.0b013e328325a867; Leemans CR, 2011, NAT REV CANCER, V11, P9, DOI 10.1038/nrc2982; Liberatore RA, 2009, P NATL ACAD SCI USA, V106, P17823, DOI 10.1073/pnas.0905935106; Lin J, 2007, ONCOGENE, V26, P6989, DOI 10.1038/sj.onc.1210500; Linder S, 2011, ANNU REV CELL DEV BI, V27, P185, DOI 10.1146/annurev-cellbio-092910-154216; Mader CC, 2011, CANCER RES, V71, P1730, DOI 10.1158/0008-5472.CAN-10-1432; Martin KH, 2012, JOVE-J VIS EXP, DOI 10.3791/4119; Martinez-Quiles N, 2004, MOL CELL BIOL, V24, P5269, DOI 10.1128/MCB.24.12.5269-5280.2004; Mayer EL, 2010, CLIN CANCER RES, V16, P3526, DOI 10.1158/1078-0432.CCR-09-1834; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; Neiva KG, 2009, NEOPLASIA, V11, P583, DOI 10.1593/neo.09266; Noren NK, 2006, NAT CELL BIOL, V8, P815, DOI 10.1038/ncb1438; O-charoenrat P, 2000, CANCER RES, V60, P1121; Ohnishi Y, 2012, ONCOL REP, V27, P954, DOI 10.3892/or.2011.1616; Oser M, 2010, J CELL SCI, V123, P3662, DOI 10.1242/jcs.068163; Oser M, 2009, J CELL BIOL, V186, P571, DOI 10.1083/jcb.200812176; Plattner R, 2004, MOL CELL BIOL, V24, P2573, DOI 10.1128/mcb.24.6.2573-2583.2004; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Plattner R, 2003, CELL CYCLE, V2, P273, DOI 10.4161/cc.2.4.409; Poincloux R, 2009, J CELL SCI, V122, P3015, DOI 10.1242/jcs.034561; Poppe M, 2007, ONCOGENE, V26, P3462, DOI 10.1038/sj.onc.1210139; Pryor DI, 2011, ASIA-PAC J CLIN ONCO, V7, P236, DOI 10.1111/j.1743-7563.2011.01420.x; Ren G, 2009, CELL MOTIL CYTOSKEL, V66, P865, DOI 10.1002/cm.20380; Rothsschild BL, 2006, CANCER RES, V66, P8017, DOI 10.1158/0008-5472.CAN-05-4490; Sen B, 2009, CANCER RES, V69, P1958, DOI 10.1158/0008-5472.CAN-08-2944; Shor AC, 2007, CANCER RES, V67, P2800, DOI 10.1158/0008-5472.CAN-06-3469; Sibony-Benyamini H, 2012, EUR J CELL BIOL, V91, P896, DOI 10.1016/j.ejcb.2012.04.001; Smith-Pearson PS, 2010, J BIOL CHEM, V285, P40201, DOI 10.1074/jbc.M110.147330; Srinivasan D, 2008, ONCOGENE, V27, P1095, DOI 10.1038/sj.onc.1210714; Srinivasan D, 2006, CANCER RES, V66, P5648, DOI 10.1158/0008-5472.CAN-06-0734; Summy JM, 2006, CLIN CANCER RES, V12, P1398, DOI 10.1158/1078-0432.CCR-05-2692; Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750; Tehrani S, 2007, P NATL ACAD SCI USA, V104, P11933, DOI 10.1073/pnas.0701077104; Tsao AS, 2011, J THORAC ONCOL, V6, P2104, DOI 10.1097/JTO.0b013e31822e7256; Uribe P, 2011, PATHOL RES PRACT, V207, P337, DOI 10.1016/j.prp.2011.03.002; Wang F, 2007, ONCOGENE, V26, P2006, DOI 10.1038/sj.onc.1209999; Wang Y, 2011, INT J HEMATOL, V94, P552, DOI 10.1007/s12185-011-0953-1; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Webb BA, 2007, EUR J CELL BIOL, V86, P189, DOI 10.1016/j.ejcb.2007.01.003; Wheeler DL, 2009, CANCER BIOL THER, V8, P696, DOI 10.4161/cbt.8.8.7903; Yamaguchi H, 2005, J CELL BIOL, V168, P441, DOI 10.1083/jcb.200407076; Yanagawa T, 2000, ORAL ONCOL, V36, P89, DOI 10.1016/S1368-8375(99)00067-6; Yang JL, 2005, CANCER LETT, V225, P61, DOI 10.1016/j.canlet.2004.11.041; Zhang SY, 2012, TRENDS PHARMACOL SCI, V33, P122, DOI 10.1016/j.tips.2011.11.002	87	35	35	1	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2013	32	40					4766	4777		10.1038/onc.2012.513	http://dx.doi.org/10.1038/onc.2012.513			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229NW	23146907	Green Accepted			2022-12-28	WOS:000325274700005
J	Lin, S; Tian, L; Shen, H; Gu, Y; Li, JL; Chen, Z; Sun, X; You, MJ; Wu, L				Lin, S.; Tian, L.; Shen, H.; Gu, Y.; Li, J-L; Chen, Z.; Sun, X.; You, M. James; Wu, L.			DDX5 is a positive regulator of oncogenic NOTCH1 signaling in T cell acute lymphoblastic leukemia	ONCOGENE			English	Article						NOTCH; MAML1; DDX5; T-ALL; leukemia	RNA HELICASES P68; TRANSCRIPTIONAL COACTIVATOR; SOLID TUMORS; MASTERMIND; PROTEINS; CANCER; IDENTIFICATION; ACTIVATION; DIFFERENTIATION; COREGULATORS	Notch signaling is a highly conserved cell-cell communication pathway regulating normal development and tissue homeostasis. Aberrant Notch signaling represents an important oncogenic mechanism for T cell acute lymphoblastic leukemia (T-ALL), an aggressive subset of the most common malignant childhood cancer ALL. Therefore, understanding the molecular regulation of Notch signaling is critical to identify new approaches to block aberrant Notch oncogenic activity. The family of three MAML transcriptional coactivators is crucial for Notch signaling activation. The prototypic member MAML1 is the major coactivator that regulates Notch oncogenic activities in leukemic cells. However, the molecular basis underlying MAML1 coactivator function that contributes to Notch signaling remains unclear. In this study, we performed proteomic studies and identified DDX5, an ATP-dependent DEAD-box RNA helicase, as a component of the MAML1 protein complex. DDX5 interacts with MAML1 in vitro and in vivo, and is associated with the endogenous NOTCH1 transcription activation complex in human T-ALL leukemic cells. Lentivirus-mediated short-hairpin RNA knock-down of DDX5 resulted in decreased expression of Notch target genes, reduced cell proliferation and increased apoptosis in cultured human leukemic cells with constitutive activation of Notch signaling. Also, DDX5 depletion inhibited the growth of human leukemia xenograft in nude mice. Moreover, DDX5 is highly expressed in primary human T-ALL leukemic cells based on the analyses of Oncomine and GEO databases, and Immunohistochemical staining. Our overall findings revealed a critical role of DDX5 in promoting efficient Notch-mediated transcription in leukemic cells, suggesting that DDX5 might be critical for NOTCH1-mediated T-ALL pathogenesis and thus is a potential new target for modulating the Notch signaling in leukemia.	[Lin, S.; Tian, L.; Shen, H.; Gu, Y.; Chen, Z.; Wu, L.] Univ Florida, Dept Mol Genet & Microbiol, Shands Canc Ctr, Gainesville, FL 32610 USA; [Tian, L.; Shen, H.] Sun Yat Sen Univ, Zhongshan Ophthalm Ctr, State Key Lab Ophthalmol, Guangzhou 510275, Guangdong, Peoples R China; [Li, J-L] Sanford Burnham Med Res Inst Lake Nona, Orlando, FL USA; [Sun, X.; You, M. James] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA	State University System of Florida; University of Florida; Sun Yat Sen University; Sanford Burnham Prebys Medical Discovery Institute; University of Texas System; UTMD Anderson Cancer Center	Wu, L (corresponding author), Univ Florida, Dept Mol Genet & Microbiol, Shands Canc Ctr, 2033 Mowry Rd, Gainesville, FL 32610 USA.	lzwu@ufl.edu	Li, J L/E-6100-2018; chen, zirong/S-4042-2016; Li, Jian-Liang/AAE-9315-2019	Li, J L/0000-0002-6487-081X; chen, zirong/0000-0002-0589-4619; Li, Jian-Liang/0000-0002-6487-081X	University of Florida Shands Cancer Center Startup fund; STOP! Children's Cancer, Inc.; Florida Bankhead Coley Cancer Research Program [2BB11, 1BF04]; National Natural Science Foundation of China [81170891]; NIH/NCI [RO1 CA164346]; Developmental Research Awards in Leukemia SPORE [CA100632]; UT MDACC Physician Scientist Award; American Cancer Society IRG; UT MDACC IRG; Ladies Leukemia League; NATIONAL CANCER INSTITUTE [R01CA164346, P30CA016672, P50CA100632] Funding Source: NIH RePORTER	University of Florida Shands Cancer Center Startup fund; STOP! Children's Cancer, Inc.; Florida Bankhead Coley Cancer Research Program; National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Developmental Research Awards in Leukemia SPORE; UT MDACC Physician Scientist Award; American Cancer Society IRG(American Cancer Society); UT MDACC IRG; Ladies Leukemia League; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Vittorio Sartorelli for kindly providing us with DDX5 expression constructs, Marda Jorgensen for helping with immunohistochemical staining and Jameson Kuang for careful reading of the manuscript. This work was supported by the University of Florida Shands Cancer Center Startup fund, STOP! Children's Cancer, Inc., and Florida Bankhead Coley Cancer Research Program (2BB11 and 1BF04 to LW). HS was supported by the National Natural Science Foundation of China (81170891). MJY was supported by NIH/NCI RO1 CA164346, Developmental Research Awards in Leukemia SPORE CA100632, UT MDACC Physician Scientist Award, American Cancer Society IRG, UT MDACC IRG and Ladies Leukemia League.	Artayanis-Tsakonas S, 2010, CURR TOP DEV BIOL, V92, P1, DOI 10.1016/S0070-2153(10)92001-2; Aster JC, 2011, J PATHOL, V223, P262, DOI 10.1002/path.2789; Caretti G, 2007, CELL CYCLE, V6, P1172, DOI 10.4161/cc.6.10.4228; Caretti G, 2006, DEV CELL, V11, P547, DOI 10.1016/j.devcel.2006.08.003; Chiang MY, 2008, J CLIN INVEST, V118, P3181, DOI 10.1172/JCI35090; Clark EL, 2008, CANCER RES, V68, P7938, DOI 10.1158/0008-5472.CAN-08-0932; Cohen AA, 2008, SCIENCE, V322, P1511, DOI 10.1126/science.1160165; Endoh H, 1999, MOL CELL BIOL, V19, P5363; FORD MJ, 1988, NATURE, V332, P736, DOI 10.1038/332736a0; Fryer CJ, 2004, MOL CELL, V16, P509, DOI 10.1016/j.molcel.2004.10.014; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; Fuller-Pace FV, 2008, BIOCHEM SOC T, V36, P609, DOI 10.1042/BST0360609; Fuller-Pace FV, 2011, FUTURE ONCOL, V7, P239, DOI 10.2217/FON.11.1; Germann S, 2012, ONCOGENE, V31, P4536, DOI 10.1038/onc.2011.618; Gu Y, 2012, ONCOGENE, V31, P469, DOI 10.1038/onc.2011.247; Guo DM, 2009, LEUKEMIA RES, V33, P678, DOI 10.1016/j.leukres.2008.10.026; Haferlach T, 2010, J CLIN ONCOL, V28, P2529, DOI 10.1200/JCO.2009.23.4732; Hansson ML, 2009, NUCLEIC ACIDS RES, V37, P2996, DOI 10.1093/nar/gkp163; HIRLING H, 1989, NATURE, V339, P562, DOI 10.1038/339562a0; Homminga I, 2011, CANCER CELL, V19, P484, DOI 10.1016/j.ccr.2011.02.008; Janknecht R, 2010, AM J TRANSL RES, V2, P223; Jensen ED, 2008, J CELL BIOCHEM, V103, P1438, DOI 10.1002/jcb.21526; Koch U, 2010, CURR TOP DEV BIOL, V92, P411, DOI 10.1016/S0070-2153(10)92013-9; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Lin SE, 2002, J BIOL CHEM, V277, P50612, DOI 10.1074/jbc.M209529200; McElhinny AS, 2008, ONCOGENE, V27, P5138, DOI 10.1038/onc.2008.228; Moellering RE, 2009, NATURE, V462, P182, DOI 10.1038/nature08543; Nicol SM, 2010, METHODS MOL BIOL, V587, P265, DOI 10.1007/978-1-60327-355-8_19; Paganin M, 2011, BLOOD REV, V25, P83, DOI 10.1016/j.blre.2010.09.004; Ranganathan P, 2011, NAT REV CANCER, V11, P338, DOI 10.1038/nrc3035; Ribeiro MSJ, 2009, NUCLEIC ACIDS RES, V37, P6691, DOI 10.1093/nar/gkp724; Van Vlierberghe P, 2011, J EXP MED, V208, P2571, DOI 10.1084/jem.20112239; Weng AP, 2003, MOL CELL BIOL, V23, P655, DOI 10.1128/MCB.23.2.655-664.2003; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Wu L, 2002, MOL CELL BIOL, V22, P7688, DOI 10.1128/MCB.22.21.7688-7700.2002; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Yang L, 2007, ONCOGENE, V26, P6082, DOI 10.1038/sj.onc.1210427	37	64	71	1	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2013	32	40					4845	4853		10.1038/onc.2012.482	http://dx.doi.org/10.1038/onc.2012.482			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229NW	23108395	Green Accepted			2022-12-28	WOS:000325274700013
J	Can, G; Akpinar, B; Baran, Y; Zhivotovsky, B; Olsson, M				Can, G.; Akpinar, B.; Baran, Y.; Zhivotovsky, B.; Olsson, M.			5-Fluorouracil signaling through a calcium-calmodulin-dependent pathway is required for p53 activation and apoptosis in colon carcinoma cells	ONCOGENE			English	Article						apoptosis; 5-fluorouracil; calcium; calmodulin; p53; DR5	DNA-DAMAGE; CANCER-CELLS; RIBOSOME BIOGENESIS; C-FLIP; CHECKPOINT; PROTEIN; AGENTS; DEATH; PHOSPHORYLATION; CHEMOTHERAPY	5-Fluorouracil (5-FU) is an anti-metabolite that is in clinical use for treatment of several cancers. In cells, it is converted into three distinct fluoro-based nucleotide analogs, which interfere with DNA synthesis and repair, leading to genome impairment and, eventually, apoptotic cell death. Current knowledge states that in certain cell types, 5-FU-induced stress is signaling through a p53-dependent induction of tumor necrosis factor-receptor oligomerization required for death-inducing signaling complex formation and caspase-8 activation. Here we establish a role of calcium (Ca2+) as a messenger for p53 activation in response to 5-FU. Using a combination of pharmacological and genetic approaches, we show that treatment of colon carcinoma cells stimulates entry of extracellular Ca2+ through long lasting-type plasma membrane channels, which further directs posttranslational phosphorylation of at least three p53 serine residues (S15, S33 and S37) by means of calmodulin (CaM) activity. Obstructing this pathway by the Ca2+-chelator BAPTA (1,2-bis(o-aminophenoxy) ethane-N, N, N', N'-tetraacetic acid) or by inhibitors of CaM efficiently reduces 5-FU-induced caspase activities and subsequent cell death. Moreover, ectopic expression of p53 S15A in HCT116 p53(-/-) cells confirmed the importance of a Ca2+-CaM-p53 axis in 5-FU-induced extrinsic apoptosis. The fact that a widely used therapeutic drug, such as 5-FU, is operating via this pathway could provide new therapeutic intervention points, or specify new combinatorial treatment regimes.	[Can, G.; Akpinar, B.; Zhivotovsky, B.; Olsson, M.] Karolinska Inst, Inst Environm Med, Div Toxicol, SE-17177 Stockholm, Sweden; [Baran, Y.] Izmir Inst Technol, Dept Mol Biol & Genet, Canc Genet & Mol Hematol Lab, Izmir, Turkey	Karolinska Institutet; Izmir Institute of Technology	Zhivotovsky, B (corresponding author), Karolinska Inst, Inst Environm Med, Div Toxicol, SE-17177 Stockholm, Sweden.	Boris.Zhivotovsky@ki.se	Zhivotovsky, Boris/A-4346-2014; Can, Geylani/B-6667-2012; Can, Geylani/M-5538-2019; Olsson, Magnus/E-3140-2012	Zhivotovsky, Boris/0000-0002-2238-3482; Can, Geylani/0000-0002-1716-7830; Can, Geylani/0000-0002-1716-7830; Olsson, Magnus/0000-0002-6370-8423	Swedish Science Foundation; Swedish and Stockholm Cancer Societies; Swedish Childhood Cancer Foundation; EC-FP-6 (Chemores); EC-FP-7 (APO-SYS)	Swedish Science Foundation; Swedish and Stockholm Cancer Societies; Swedish Childhood Cancer Foundation(European Commission); EC-FP-6 (Chemores); EC-FP-7 (APO-SYS)(European CommissionEuropean Commission Joint Research Centre)	We thank Professors Bert Vogelstein, Peter H Krammer, Ladislav Andera, Moshe Oren and Dr Inna Lavrik for their contribution of cells, antibodies and vectors. This study was supported by grants from the Swedish Science Foundation, the Swedish and Stockholm Cancer Societies, the Swedish Childhood Cancer Foundation and the EC-FP-6 (Chemores) and EC-FP-7 (APO-SYS). MO is a fellow of the Swedish Society of Medical Research.	Abdulghani J, 2010, EXPERT OPIN THER TAR, V14, P1091, DOI 10.1517/14728222.2010.519701; Bagnoli M, 2010, INT J BIOCHEM CELL B, V42, P210, DOI 10.1016/j.biocel.2009.11.015; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Berridge MJ, 2002, CELL CALCIUM, V32, P235, DOI 10.1016/S0143416002001823; Borralho PM, 2007, BBA-MOL BASIS DIS, V1772, P40, DOI 10.1016/j.bbadis.2006.09.005; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Burger K, 2010, J BIOL CHEM, V285, P12416, DOI 10.1074/jbc.M109.074211; Coutinho I, 2009, FEBS LETT, V583, P3582, DOI 10.1016/j.febslet.2009.10.030; Craig AL, 2007, MOL CELL BIOL, V27, P3542, DOI 10.1128/MCB.01595-06; de la Cruz-Morcillo MA, 2012, ONCOGENE, V31, P1073, DOI 10.1038/onc.2011.321; Derheimer FA, 2007, P NATL ACAD SCI USA, V104, P12778, DOI 10.1073/pnas.0705317104; Galligan L, 2005, MOL CANCER THER, V4, P2026, DOI 10.1158/1535-7163.MCT-05-0262; GLAZER RI, 1982, MOL PHARMACOL, V21, P468; Harr MW, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a005579; Henry RE, 2012, EMBO J, V31, P1266, DOI 10.1038/emboj.2011.498; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kaeser MD, 2004, J BIOL CHEM, V279, P7598, DOI 10.1074/jbc.M311732200; Kim HD, 2011, ONCOGENE, V30, P3317, DOI 10.1038/onc.2011.47; KUFE DW, 1981, J BIOL CHEM, V256, P9802; Kumar S K, 2001, Curr Oncol Rep, V3, P94, DOI 10.1007/s11912-001-0007-6; Lamprecht SA, 2003, NAT REV CANCER, V3, P601, DOI 10.1038/nrc1144; Lavin MF, 2006, CELL DEATH DIFFER, V13, P941, DOI 10.1038/sj.cdd.4401925; Li Y, 2010, MOL CANCER THER, V9, P113, DOI 10.1158/1535-7163.MCT-08-1189; Longley DB, 2006, ONCOGENE, V25, P838, DOI 10.1038/sj.onc.1209122; Longley DB, 2004, CLIN CANCER RES, V10, P3562, DOI 10.1158/1078-0432.CCR-03-0532; Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074; MacLaine NJ, 2011, CELL CYCLE, V10, P916, DOI 10.4161/cc.10.6.15076; Matuo R, 2009, J APPL TOXICOL, V29, P308, DOI 10.1002/jat.1411; Naka T, 2002, CANCER RES, V62, P5800; Oberle C, 2010, CELL DEATH DIFFER, V17, P1167, DOI 10.1038/cdd.2009.214; OConnor PM, 1997, CANCER RES, V57, P4285; Olsson M, 2011, CELL DEATH DIFFER, V18, P1441, DOI 10.1038/cdd.2011.30; Olsson M, 2009, ONCOGENE, V28, P1949, DOI 10.1038/onc.2009.36; Orrenius S, 2003, NAT REV MOL CELL BIO, V4, P552, DOI 10.1038/nrm1150; Perraud A, 2011, ONCOL REP, V26, P1091, DOI 10.3892/or.2011.1404; Pinton P, 2008, ONCOGENE, V27, P6407, DOI 10.1038/onc.2008.308; Pospisilova S, 2004, BIOCHEM J, V378, P939, DOI 10.1042/BJ20030662; Raveh T, 2001, NAT CELL BIOL, V3, P1, DOI 10.1038/35050500; Seiple L, 2006, NUCLEIC ACIDS RES, V34, P140, DOI 10.1093/nar/gkj430; Stagni V, 2010, CARCINOGENESIS, V31, P1956, DOI 10.1093/carcin/bgq193; Takeda K, 2004, EMBO REP, V5, P161, DOI 10.1038/sj.embor.7400072; Wang SL, 2004, CANCER RES, V64, P6666, DOI 10.1158/0008-5472.CAN-04-1734	43	37	39	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 19	2013	32	38					4529	4538		10.1038/onc.2012.467	http://dx.doi.org/10.1038/onc.2012.467			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223SW	23108402	Green Published			2022-12-28	WOS:000324831300008
J	Hemler, ME; Hoff, J; Li, Q; Yang, XH				Hemler, M. E.; Hoff, J.; Li, Q.; Yang, X. H.			Renal disease appears not to affect carcinogenesis in CD151-null mice	ONCOGENE			English	Letter							TETRASPANIN CD151; DELETION		[Hemler, M. E.; Li, Q.] Dana Farber Canc Inst, Boston, MA 02115 USA; [Hoff, J.; Yang, X. H.] Univ Kentucky, Albert B Chandler Med Ctr, Lexington, KY 40536 USA	Harvard University; Dana-Farber Cancer Institute; University of Kentucky	Hemler, ME (corresponding author), Dana Farber Canc Inst, Boston, MA 02115 USA.	Martin_Hemler@dfci.harvard.edu; xiuwei-yang@uky.edu	Li, Qinglin/K-2570-2015	Li, Qinglin/0000-0002-4125-1944				Baleato RM, 2008, AM J PATHOL, V173, P927, DOI 10.2353/ajpath.2008.071149; Deng XY, 2012, NEOPLASIA, V14, P678, DOI 10.1593/neo.12922; HENNINGS H, 1993, CARCINOGENESIS, V14, P2353, DOI 10.1093/carcin/14.11.2353; Li Q, 2013, ONCOGENE, V32, P1772, DOI 10.1038/onc.2012.205; Sachs N, 2006, J CELL BIOL, V175, P33, DOI 10.1083/jcb.200603073; Takeda Y, 2007, BLOOD, V109, P1524, DOI 10.1182/blood-2006-08-041970	6	5	5	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2013	32	37					4458	4458		10.1038/onc.2013.79	http://dx.doi.org/10.1038/onc.2013.79			1	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218AF	23503459				2022-12-28	WOS:000324404200015
J	Lainey, E; Wolfromm, A; Marie, N; Enot, D; Scoazec, M; Bouteloup, C; Leroy, C; Micol, JB; De Botton, S; Galluzzi, L; Fenaux, P; Kroemer, G				Lainey, E.; Wolfromm, A.; Marie, N.; Enot, D.; Scoazec, M.; Bouteloup, C.; Leroy, C.; Micol, J-B; De Botton, S.; Galluzzi, L.; Fenaux, P.; Kroemer, G.			Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia	ONCOGENE			English	Article						ATPase-binding cassette (ABC) transporters; ABT-263; MG-132; MOLM-13; obatoclax; SKM1	ACUTE MYELOGENOUS LEUKEMIA; CELL LUNG-CANCER; MITOCHONDRIAL-MEMBRANE PERMEABILIZATION; KINASE INHIBITOR; DOWN-REGULATION; MYELODYSPLASTIC SYNDROMES; APOPTOSIS RESISTANCE; SIGNALING PATHWAYS; DRUG-RESISTANCE; MCL-1	The term myelodysplastic syndrome (MDS) identifies a heterogeneous group of clonal disorders originating from bone marrow stem cells that often progress to acute myeloid leukemia (AML). The reference treatments for MDS include the DNA methyltransferase inhibitors azacytidine and decitabine. Recently, the epidermal growth factor receptor (EGFR) inhibitor erlotinib has been shown to exert antileukemic activity in vitro and in vivo, independent of the EGFR. Thanks to this feature, erlotinib is currently being tested as an antileukemic drug in clinical trials. Here, we report that azacytidine and erlotinib mediate synergistic antineoplastic effects in several primary or secondary (post-MDS) AML cell lines. The combination of azacytidine and erlotinib blocked cell-cycle progression and induced caspase-dependent apoptosis more consistently than either of the two agents alone. These effects were not a consequence of cellular differentiation and could be discriminated from each other, as the former depended on caspases whereas the latter did not. The synergy between azacitidine and erlotinib, which involved the proteasomal degradation of the anti-apoptotic Bcl-2 family members MCL-1 and BCL2L10 and the upregulation of their pro-apoptotic counterpart PUMA, was abolished when azacytidine was replaced by decitabine but persisted when erlotinib was substituted with gefitinib, another EGFR inhibitor. Of note, the intracellular accumulation of azacytidine was exacerbated by both erlotinib and gefitinib, pointing to a pharmacokinetic mechanism of synergy. In approximately half of the cases studied, marrow and circulating blasts from MDS and AML patients, respectively, exhibited hyperadditive cytotoxic responses to the combination of azacytidine and erlotinib. These results strongly suggest that the combination of azacytidine and erlotinib may exert clinically relevant antileukemic effects.	[Lainey, E.; Wolfromm, A.; Enot, D.; Scoazec, M.; Bouteloup, C.; Leroy, C.; Fenaux, P.; Kroemer, G.] INSERM, U848, Villejuif, France; [Lainey, E.; Wolfromm, A.; Enot, D.; Scoazec, M.; Bouteloup, C.; Leroy, C.; Galluzzi, L.; Kroemer, G.] Inst Gustave Roussy, F-94805 Villejuif, France; [Lainey, E.] Hop Robert Debre, AP HP, F-75019 Paris, France; [Wolfromm, A.] Univ Paris 07, Paris, France; [Marie, N.] CNRS, UMR8206, Paris, France; [Marie, N.] INSERM, U705, Paris, France; [Marie, N.] Inst Medicament Toxicol Chim Environm, Lab Neuropsychopharmacol Addict, Paris, France; [Micol, J-B; De Botton, S.] Inst Gustave Roussy, Serv Hematol Clin, F-94805 Villejuif, France; [Galluzzi, L.; Kroemer, G.] Univ Paris 05, Sorbonne Paris Cite, Paris, France; [Fenaux, P.] Hop Avicenne, AP HP, Serv Hematol Clin, F-93009 Bobigny, France; [Kroemer, G.] Ctr Rech Cordeliers, Paris, France; [Kroemer, G.] Hop Europeen Georges Pompidou, AP HP, Pole Biol, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite	Kroemer, G (corresponding author), Inst Gustave Roussy, INSERM, U848, PR1, 39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@orange.fr	Kroemer, Guido/AAY-9859-2020; Marie, Nicolas/I-9129-2014; Galluzzi, Lorenzo/AAG-6432-2019; Galluzzi, Lorenzo/AAG-6294-2019; KROEMER, Guido/B-4263-2013; Galluzzi, Lorenzo/AAH-3286-2021	Marie, Nicolas/0000-0002-6491-9898; KROEMER, Guido/0000-0002-9334-4405; 	Ligue Nationale contre le Cancer (Equipe labellisee); Agence Nationale pour la Recherche (ANR AUTOPH, ANR Emergence); European Commission (ChemoRes, ArtForce); Fondation de France; Institut National du Cancer (INCa); Canceropole Ile-de-France; Fondation Bettencourt-Schueller; LabEx Immuno-Oncology; Institut National de la Sante et de la recherche Medicale; Association de recherche sur le cancer (ARC); Fondation de la Recherche Medicale (FRM)	Ligue Nationale contre le Cancer (Equipe labellisee)(Ligue nationale contre le cancer); Agence Nationale pour la Recherche (ANR AUTOPH, ANR Emergence)(French National Research Agency (ANR)); European Commission (ChemoRes, ArtForce); Fondation de France(Fondation de France); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Canceropole Ile-de-France(Region Ile-de-France); Fondation Bettencourt-Schueller; LabEx Immuno-Oncology; Institut National de la Sante et de la recherche Medicale(Institut National de la Sante et de la Recherche Medicale (Inserm)); Association de recherche sur le cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer); Fondation de la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale)	GK is supported by the Ligue Nationale contre le Cancer (Equipe labellisee), Agence Nationale pour la Recherche (ANR AUTOPH, ANR Emergence), European Commission (ChemoRes, ArtForce), Fondation de France, Institut National du Cancer (INCa), Canceropole Ile-de-France, Fondation Bettencourt-Schueller and the LabEx Immuno-Oncology. EL receives a PhD fellowship from Institut National de la Sante et de la recherche Medicale, AW is supported by a fellowship from Association de recherche sur le cancer (ARC) and MS by Fondation de la Recherche Medicale (FRM).	Aimiuwu J, 2012, BLOOD, V119, P5229, DOI 10.1182/blood-2011-11-382226; Boehrer S, 2008, BLOOD, V111, P2170, DOI 10.1182/blood-2007-07-100362; Boehrer S, 2011, CELL CYCLE, V10, P3168, DOI 10.4161/cc.10.18.16599; Boehrer S, 2008, BIOCHEM PHARMACOL, V76, P1417, DOI 10.1016/j.bcp.2008.05.024; Chan G, 2007, BLOOD, V110, P1079, DOI 10.1182/blood-2007-01-069856; Chapuis N, 2010, CLIN CANCER RES, V16, P5424, DOI 10.1158/1078-0432.CCR-10-1102; Chen LS, 2011, BLOOD, V118, P693, DOI 10.1182/blood-2010-12-323022; Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947; Cluzeau T, 2012, ONCOTARGET, V3, P490; Criollo A, 2007, APOPTOSIS, V12, P3, DOI 10.1007/s10495-006-0328-x; Eghtedar A, 2012, BLOOD, V119, P4614, DOI 10.1182/blood-2011-12-400051; Fabiani E, 2010, LEUKEMIA LYMPHOMA, V51, P2275, DOI 10.3109/10428194.2010.528093; Fabre C, 2008, CELL CYCLE, V7, P2139, DOI 10.4161/cc.7.14.6268; Fenaux P, 2009, LANCET ONCOL, V10, P223, DOI 10.1016/S1470-2045(09)70003-8; Galluzzi L, 2012, CELL DEATH DIFFER, V19, P107, DOI 10.1038/cdd.2011.96; Galluzzi L, 2007, APOPTOSIS, V12, P803, DOI 10.1007/s10495-007-0720-1; Galluzzi L, 2012, NAT REV DRUG DISCOV, V11, P215, DOI 10.1038/nrd3626; Galluzzi L, 2010, CANCER RES, V70, P1793, DOI 10.1158/0008-5472.CAN-09-3112; Glaser SP, 2012, GENE DEV, V26, P120, DOI 10.1101/gad.182980.111; Hoffmann J, 2008, CANCER RES, V68, P5301, DOI 10.1158/0008-5472.CAN-08-0237; Huber S, 2011, LEUKEMIA, V25, P838, DOI 10.1038/leu.2011.2; Jemaa M, 2012, EMBO MOL MED, V4, P500, DOI 10.1002/emmm.201200228; Kepp O, 2011, NAT REV DRUG DISCOV, V10, P221, DOI 10.1038/nrd3373; Kimura S, 2012, ANTICANCER RES, V32, P795; Klimek VM, 2012, LEUKEMIA RES, V36, P1093, DOI 10.1016/j.leukres.2012.04.025; Komrokji RS, 2010, BLOOD, V116; Kornblau SM, 2006, BLOOD, V108, P2358, DOI 10.1182/blood-2006-02-003475; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Lainey E, 2011, BIOCHEM PHARMACOL, V82, P1457, DOI 10.1016/j.bcp.2011.05.011; Lee JJ, 2009, STAT BIOPHARM RES, V1, P4, DOI 10.1198/sbr.2009.0001; Meng XW, 2007, J BIOL CHEM, V282, P29831, DOI 10.1074/jbc.M706110200; Noguchi K, 2009, CANCER SCI, V100, P1701, DOI 10.1111/j.1349-7006.2009.01213.x; Pitini V, 2008, J CLIN ONCOL, V26, P3645, DOI 10.1200/JCO.2008.17.0357; Rahmani M, 2005, J BIOL CHEM, V280, P35217, DOI 10.1074/jbc.M506551200; Rahmani M, 2012, BLOOD, V119, P6089, DOI 10.1182/blood-2011-09-378141; Rosen DB, 2012, LEUKEMIA RES, V36, P900, DOI 10.1016/j.leukres.2012.02.022; Rouge TD, 2007, CANCER RES, V67, P6253, DOI 10.1158/0008-5472.CAN-07-0538; Sansonetti A, 2012, LEUKEMIA RES, V36, P358, DOI 10.1016/j.leukres.2011.09.022; Scholl C, 2008, SEMIN ONCOL, V35, P336, DOI 10.1053/j.seminoncol.2008.04.004; Shi Z, 2007, CANCER RES, V67, P11012, DOI 10.1158/0008-5472.CAN-07-2686; Stegmaier K, 2005, BLOOD, V106, P2841, DOI 10.1182/blood-2005-02-0488; Tefferi A, 2009, NAT REV CLIN ONCOL, V6, P627, DOI 10.1038/nrclinonc.2009.149; van Stijn A, 2003, HAEMATOLOGICA, V88, P497; Weber C, 2012, J PROTEOMICS, V75, P1343, DOI 10.1016/j.jprot.2011.11.004; Weisberg E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025351; Youle RJ, 2008, NAT REV MOL CELL BIO, V9, P47, DOI 10.1038/nrm2308; Yu CR, 2005, ONCOGENE, V24, P6861, DOI 10.1038/sj.onc.1208841; Zantl N, 2007, ONCOGENE, V26, P7038, DOI 10.1038/sj.onc.1210510	48	33	35	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2013	32	37					4331	4342		10.1038/onc.2012.469	http://dx.doi.org/10.1038/onc.2012.469			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218AF	23085751				2022-12-28	WOS:000324404200002
J	Vervoort, SJ; van Boxtel, R; Coffer, PJ				Vervoort, S. J.; van Boxtel, R.; Coffer, P. J.			The role of SRY-related HMG box transcription factor 4 (SOX4) in tumorigenesis and metastasis: friend or foe?	ONCOGENE			English	Review						SOX4; cancer; metastasis	GENE-EXPRESSION PATTERNS; GLIOMA-INITIATING CELLS; DIFFERENTIAL EXPRESSION; PROGNOSTIC-SIGNIFICANCE; POSITIVE REGULATOR; BLADDER-CARCINOMA; MINOR-GROOVE; TGF-BETA; IDENTIFICATION; PROTEIN	Development and progression of cancer are mediated by alterations in transcriptional networks, resulting in a disturbed balance between the activity of oncogenes and tumor suppressor genes. Transcription factors have the capacity to regulate global transcriptional profiles, and are consequently often found to be deregulated in their expression and function during tumorigenesis. Sex-determining region Y-related high-mobility-group box transcription factor 4 (SOX4) is a member of the group C subfamily of the SOX transcription factors and has a critical role during embryogenesis, where its expression is widespread and controls the development of numerous tissues. SOX4 expression is elevated in a wide variety of tumors, including leukemia, colorectal cancer, lung cancer and breast cancer, suggesting a fundamental role in the development of these malignancies. In many cancers, deregulated expression of this developmental factor has been correlated with increased cancer cell proliferation, cell survival, inhibition of apoptosis and tumor progression through the induction of an epithelial-to-mesenchymal transition and metastasis. However, in a limited subset of tumors, SOX4 has also been reported to act as a tumor suppressor. These opposing roles suggest that the outcome of SOX4 activation depends on the cellular context and the tumor origin. Indeed, SOX4 expression, transcriptional activity and target gene specificity can be controlled by signaling pathways, including the transforming growth factor-beta and the WNT pathway, as well as at the post-translational level through regulation of protein stability and interaction with specific cofactors, such as TCF, syntenin-1 and p53. Here, we provide an overview of our current knowledge concerning the role of SOX4 in tumor development and progression.	[Vervoort, S. J.; van Boxtel, R.; Coffer, P. J.] Univ Med Ctr Utrecht, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; [Vervoort, S. J.; Coffer, P. J.] Wilhelmina Childrens Hosp, Div Pediat, Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center; Wilhelmina Kinderziekenhuis	Vervoort, SJ (corresponding author), Univ Med Ctr Utrecht, Dept Cell Biol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.	P.J.Coffer@umcutrecht.nl	Coffer, Paul/AAF-7970-2020; Vervoort, Stephin/AAP-7854-2020	Vervoort, Stephin/0000-0001-7459-126X; van Boxtel, Ruben/0000-0003-1285-2836	'Center for Translational Molecular Medicine' (CTMM) grant	'Center for Translational Molecular Medicine' (CTMM) grant	Ruben van Boxtel is supported by a 'Center for Translational Molecular Medicine' (CTMM) grant.	Aaboe M, 2006, CANCER RES, V66, P3434, DOI 10.1158/0008-5472.CAN-05-3456; Ahn SG, 1999, BIOCHEM BIOPH RES CO, V260, P216, DOI 10.1006/bbrc.1999.0856; Ahn SG, 2002, EXP MOL MED, V34, P243, DOI 10.1038/emm.2002.34; Andersen CL, 2009, BRIT J CANCER, V100, P511, DOI 10.1038/sj.bjc.6604884; Aue G, 2011, BLOOD, V118, P4674, DOI 10.1182/blood-2011-04-351528; Bangur CS, 2002, ONCOGENE, V21, P3814, DOI 10.1038/sj.onc.1205480; Beekman JM, 2008, J CELL SCI, V121, P1349, DOI 10.1242/jcs.026401; Beekman JM, 2009, BLOOD, V114, P3917, DOI 10.1182/blood-2009-03-208850; Beekman JM, 2011, ONCOGENE; Bergsland M, 2006, GENE DEV, V20, P3475, DOI 10.1101/gad.403406; Bernard P, 2010, INT J BIOCHEM CELL B, V42, P400, DOI 10.1016/j.biocel.2009.10.017; Bhattaram P, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1008; Bielenberg DR, 2006, EXP CELL RES, V312, P584, DOI 10.1016/j.yexcr.2005.11.024; Bies J, 2010, BLOOD, V116, P979, DOI 10.1182/blood-2009-08-238360; Blick T, 2010, J MAMMARY GLAND BIOL, V15, P235, DOI 10.1007/s10911-010-9175-z; Bowles J, 2000, DEV BIOL, V227, P239, DOI 10.1006/dbio.2000.9883; Boyd KE, 2006, BLOOD, V107, P733, DOI 10.1182/blood-2003-05-1626; Boyer J, 2006, CANCER RES, V66, P2765, DOI 10.1158/0008-5472.CAN-05-2693; Bruch J, 2000, CANCER RES, V60, P4526; Cao DF, 2004, CANCER BIOL THER, V3, P1081, DOI 10.4161/cbt.3.11.1175; Castillo SD, 2012, CANCER RES, V72, P176, DOI 10.1158/0008-5472.CAN-11-3506; Chedotal A, 2005, CELL DEATH DIFFER, V12, P1044, DOI 10.1038/sj.cdd.4401707; Chetty C, 2012, CANCER LETT, V323, P188, DOI 10.1016/j.canlet.2012.04.014; Clemons M, 2001, NEW ENGL J MED, V344, P276, DOI 10.1056/NEJM200101253440407; de Bont JM, 2008, NEURO-ONCOLOGY, V10, P648, DOI 10.1215/15228517-2008-032; Deneault E, 2009, CELL, V137, P369, DOI 10.1016/j.cell.2009.03.026; Dong C, 2004, CYTOGENET GENOME RES, V105, P442, DOI 10.1159/000078217; Du Y, 2005, BLOOD, V106, P2498, DOI 10.1182/blood-2004-12-4840; Duncan EL, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001372; Dy P, 2008, NUCLEIC ACIDS RES, V36, P3101, DOI 10.1093/nar/gkn162; Dyrskjot L, 2009, CANCER RES, V69, P4851, DOI 10.1158/0008-5472.CAN-08-4043; Fevr T, 2007, MOL CELL BIOL, V27, P7551, DOI 10.1128/MCB.01034-07; Fevre-Montange M, 2006, J NEUROPATH EXP NEUR, V65, P675, DOI 10.1097/01.jnen.0000225907.90052.e3; Fortier JM, 2010, LEUKEMIA, V24, P950, DOI 10.1038/leu.2010.61; Friedman RS, 2004, J IMMUNOL, V172, P3319, DOI 10.4049/jimmunol.172.5.3319; Frierson HF, 2002, AM J PATHOL, V161, P1315, DOI 10.1016/S0002-9440(10)64408-2; Geijsen N, 2001, SCIENCE, V293, P1136, DOI 10.1126/science.1059157; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Goldsworthy M, 2008, DIABETES, V57, P2234, DOI 10.2337/db07-0337; Graham JD, 1999, J MOL ENDOCRINOL, V22, P295, DOI 10.1677/jme.0.0220295; Gunes S, 2011, PATHOL RES PRACT, V207, P423, DOI 10.1016/j.prp.2011.05.005; Haram KM, 2008, PROSTATE, V68, P1517, DOI 10.1002/pros.20803; Harley V, 2010, INT J BIOCHEM CELL B, V42, P376, DOI 10.1016/j.biocel.2009.12.004; Heidenblad M, 2008, BMC MED GENOMICS, V1, DOI 10.1186/1755-8794-1-3; Herbst Roy S, 2004, J Natl Compr Canc Netw, V2 Suppl 2, pS41; Herman JG, 2007, INT J ONCOL, V30, P1231; Hershko DD, 2008, CANCER-AM CANCER SOC, V112, P1415, DOI 10.1002/cncr.23317; Hornbeck PV, 2012, NUCLEIC ACIDS RES, V40, pD261, DOI 10.1093/nar/gkr1122; Hoser M, 2008, MOL CELL BIOL, V28, P4675, DOI 10.1128/MCB.00338-08; Hua F, 2011, J CELL SCI, V124, P3235, DOI 10.1242/jcs.082875; Huang YW, 2009, CANCER RES, V69, P9038, DOI 10.1158/0008-5472.CAN-09-1499; Hunt SMN, 1999, BIOL REPROD, V61, P476, DOI 10.1095/biolreprod61.2.476; Hur EH, 2004, BIOCHEM BIOPH RES CO, V325, P59, DOI 10.1016/j.bbrc.2004.09.215; Hur W, 2010, CARCINOGENESIS, V31, P1298, DOI 10.1093/carcin/bgq072; Ikushima H, 2011, J BIOL CHEM, V286, P41434, DOI 10.1074/jbc.M111.300863; Ikushima H, 2009, CELL STEM CELL, V5, P504, DOI 10.1016/j.stem.2009.08.018; Iqbal MS, 2010, INT J HEMATOL, V91, P267, DOI 10.1007/s12185-009-0474-3; Jafarnejad SM, 2010, AM J PATHOL, V177, P2741, DOI 10.2353/ajpath.2010.100377; Jafarnejad SM, 2012, ONCOGENE; Jauch R, 2012, BIOCHEM J, V443, P39, DOI 10.1042/BJ20111768; Jemtland R, 2011, J BONE MINER RES, V26, P1793, DOI 10.1002/jbmr.396; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kim BE, 2004, EXP MOL MED, V36, P444, DOI 10.1038/emm.2004.56; Kim HD, 2011, MOL ENDOCRINOL, V25, P1184, DOI 10.1210/me.2010-0332; Kindla J, 2011, DRUG METAB DISPOS, V39, P1047, DOI 10.1124/dmd.110.037622; Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389; Kuwahara M, 2012, NAT IMMUNOL, V13, P778, DOI 10.1038/ni.2362; Kvinlaug BT, 2011, CANCER RES, V71, P4117, DOI 10.1158/0008-5472.CAN-11-0176; Lai YH, 2011, BMC CELL BIOL, V12, DOI 10.1186/1471-2121-12-50; Lee AK, 2011, ONCOL REP, V25, P559, DOI 10.3892/or.2010.1091; Lee CJ, 2002, J NEURO-ONCOL, V57, P201, DOI 10.1023/A:1015773818302; Li ZX, 2007, ANN NY ACAD SCI, V1106, P95, DOI 10.1196/annals.1392.003; Liao YL, 2008, ONCOGENE, V27, P5578, DOI 10.1038/onc.2008.168; Liber D, 2010, CELL STEM CELL, V7, P114, DOI 10.1016/j.stem.2010.05.020; Lin BY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010210; Lin L, 2011, DEV DYNAM, V240, P52, DOI 10.1002/dvdy.22489; Lioubinski O, 2003, DEV DYNAM, V227, P402, DOI 10.1002/dvdy.10311; Litovkin K. V., 2008, Experimental Oncology, V30, P106; Liu PB, 2006, CANCER RES, V66, P4011, DOI 10.1158/0008-5472.CAN-05-3055; Liu SL, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002751; Locklin RM, 2001, J BONE MINER RES, V16, P2192, DOI 10.1359/jbmr.2001.16.12.2192; Lund PK, 2009, SCAND J CLIN LAB INV, V69, P251, DOI 10.1080/00365510802499399; MARSHALL JC, 1986, NEW ENGL J MED, V315, P1459; Maschhoff KL, 2003, GENE, V320, P23, DOI 10.1016/j.gene.2003.07.002; Mavropoulos A, 2005, DEV BIOL, V285, P211, DOI 10.1016/j.ydbio.2005.06.024; McCracken S, 1997, ONCOGENE, V15, P2929, DOI 10.1038/sj.onc.1201474; Medina PP, 2009, HUM MOL GENET, V18, P1343, DOI 10.1093/hmg/ddp034; Molatore S, 2010, P NATL ACAD SCI USA, V107, P18493, DOI 10.1073/pnas.1003956107; Moreno CS, 2010, AM J PATHOL, V176, P518, DOI 10.2353/ajpath.2010.090657; Neben K, 2004, CANCER RES, V64, P3103, DOI 10.1158/0008-5472.CAN-03-3968; Nissen-Meyer LSH, 2007, J CELL SCI, V120, P2785, DOI 10.1242/jcs.003855; Novershtern N, 2011, CELL, V144, P296, DOI 10.1016/j.cell.2011.01.004; Nowling TK, 2000, J BIOL CHEM, V275, P3810, DOI 10.1074/jbc.275.6.3810; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Pan X, 2006, BIOCHEM BIOPH RES CO, V344, P727, DOI 10.1016/j.bbrc.2006.03.194; Pan X, 2009, P NATL ACAD SCI USA, V106, P3788, DOI 10.1073/pnas.0810147106; Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007; Polakis P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008052; PONTIGGIA A, 1994, EMBO J, V13, P6115, DOI 10.1002/j.1460-2075.1994.tb06958.x; Potthoff MJ, 2007, DEVELOPMENT, V134, P4131, DOI 10.1242/dev.008367; Pramoonjago P, 2006, ONCOGENE, V25, P5626, DOI 10.1038/sj.onc.1209566; Ragvin A, 2010, P NATL ACAD SCI USA, V107, P775, DOI 10.1073/pnas.0911591107; Reichling T, 2005, CANCER RES, V65, P166; Reppe S, 2000, J BONE MINER RES, V15, P2402, DOI 10.1359/jbmr.2000.15.12.2402; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; Ritter AR, 2010, DEV DYNAM, V239, P2685, DOI 10.1002/dvdy.22407; Ruebel KH, 2008, ENDOCRINE, V33, P62, DOI 10.1007/s12020-008-9060-3; Saegusa M, 2012, LAB INVEST, V92, P511, DOI 10.1038/labinvest.2011.196; Sandoval S, 2012, BLOOD, V120, P155, DOI 10.1182/blood-2011-05-357418; Sarkar D, 2008, CANCER RES, V68, P3087, DOI 10.1158/0008-5472.CAN-07-6210; Scharer CD, 2009, CANCER RES, V69, P709, DOI 10.1158/0008-5472.CAN-08-3415; Schilham MW, 1996, NATURE, V380, P711, DOI 10.1038/380711a0; Schilham MW, 1997, EUR J IMMUNOL, V27, P1292, DOI 10.1002/eji.1830270534; Serrero G, 2003, BIOCHEM BIOPH RES CO, V308, P409, DOI 10.1016/S0006-291X(03)01452-9; Shen RZ, 2010, BIOCHEM BIOPH RES CO, V394, P1047, DOI 10.1016/j.bbrc.2010.03.121; Shin MS, 2004, CANCER RES, V64, P4419, DOI 10.1158/0008-5472.CAN-03-3885; Sinner D, 2007, MOL CELL BIOL, V27, P7802, DOI 10.1128/MCB.02179-06; Sitohy B, 2012, CANCER RES, V72, P1909, DOI 10.1158/0008-5472.CAN-11-3406; Sock E, 2004, MOL CELL BIOL, V24, P6635, DOI 10.1128/mcb.24.15.6635-6644.2004; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; Suzuki T, 2002, NAT GENET, V32, P166, DOI 10.1038/ng949; Tanaka S, 2004, MOL CELL BIOL, V24, P8834, DOI 10.1128/MCB.24.20.8834-8846.2004; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Testa U, 2011, ANN HEMATOL, V90, P245, DOI 10.1007/s00277-010-1118-7; Thein DC, 2010, J NEUROCHEM, V115, P131, DOI 10.1111/j.1471-4159.2010.06910.x; Tian CX, 2011, DEVELOPMENT, V138, P1033, DOI 10.1242/dev.062240; Tonks A, 2007, LEUKEMIA, V21, P2495, DOI 10.1038/sj.leu.2404961; TRAVIS A, 1991, GENE DEV, V5, P880, DOI 10.1101/gad.5.5.880; Turner DP, 2007, J CELL BIOCHEM, V102, P549, DOI 10.1002/jcb.21494; van Beest M, 2000, J BIOL CHEM, V275, P27266; Van Der Flier LG, 2007, GASTROENTEROLOGY, V132, P628, DOI 10.1053/j.gastro.2006.08.039; Vanaja DK, 2006, CLIN CANCER RES, V12, P1128, DOI 10.1158/1078-0432.CCR-05-2072; VANDEWETERING M, 1993, EMBO J, V12, P3847, DOI 10.1002/j.1460-2075.1993.tb06063.x; VANDEWETERING M, 1992, EMBO J, V11, P3039, DOI 10.1002/j.1460-2075.1992.tb05374.x; vanHoute LPA, 1995, J BIOL CHEM, V270, P30516, DOI 10.1074/jbc.270.51.30516; Wang CG, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-41; Watanabe T, 2010, EUR J CANCER, V46, P2119, DOI 10.1016/j.ejca.2010.04.019; Weiss MA, 2001, MOL ENDOCRINOL, V15, P353, DOI 10.1210/me.15.3.353; Wilson M, 2002, CURR OPIN GENET DEV, V12, P441, DOI 10.1016/S0959-437X(02)00323-4; Wilson ME, 2005, DIABETES, V54, P3402, DOI 10.2337/diabetes.54.12.3402; WOTTON D, 1995, J BIOL CHEM, V270, P7515, DOI 10.1074/jbc.270.13.7515; Wu QO, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-16; Yager JD, 2006, NEW ENGL J MED, V354, P270, DOI 10.1056/NEJMra050776; Yang LQ, 2012, FUTURE ONCOL, V8, P431, DOI [10.2217/FON.12.27, 10.2217/fon.12.27]; Yokota N, 2004, ONCOGENE, V23, P3444, DOI 10.1038/sj.onc.1207475; Zhang JC, 2012, CANCER RES, V72, P4597, DOI 10.1158/0008-5472.CAN-12-1045	147	153	156	1	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 18	2013	32	29					3397	3409		10.1038/onc.2012.506	http://dx.doi.org/10.1038/onc.2012.506			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	186AZ	23246969				2022-12-28	WOS:000322014900001
J	Panupinthu, N; Yu, S; Zhang, D; Zhang, F; Gagea, M; Lu, Y; Grandis, JR; Dunn, SE; Lee, HY; Mills, GB				Panupinthu, N.; Yu, S.; Zhang, D.; Zhang, F.; Gagea, M.; Lu, Y.; Grandis, J. R.; Dunn, S. E.; Lee, H. Y.; Mills, G. B.			Self-reinforcing loop of amphiregulin and Y-box binding protein-1 contributes to poor outcomes in ovarian cancer	ONCOGENE			English	Article						autoregulation; crosstalk; feedback; G-protein-coupled receptor; receptor tyrosine kinase	GROWTH-FACTOR RECEPTOR; RIBOSOMAL S6 KINASE; LYSOPHOSPHATIDIC ACID PRODUCTION; ALLOSTERIC AKT INHIBITOR; BREAST-CANCER; NUCLEAR-LOCALIZATION; TUMOR-GROWTH; IN-VITRO; CELLS; YB-1	The Y-box binding protein-1 (YB-1) transcription factor is associated with unfavorable clinical outcomes. However, the mechanisms underlying this association remain to be fully elucidated. We demonstrate that YB-1 phosphorylation, indicative of YB-1 activation, is a powerful marker of outcomes for ovarian cancer patients. In ovarian cancer, YB-1 phosphorylation is induced by activation of the lysophosphatidic acid (LPA) receptor (LPAR) via SRC-dependent transactivation of the epidermal growth factor receptor (EGFR) that is coupled to MAPK/p90 ribosomal S6 kinase (p90RSK), but not phosphatidylinositol 3-kinase (PI3K)/AKT signaling. Activation of the LPAR/SRC/EGFR/MAPK/p90RSK/YB-1 axis leads to production of the EGFR ligand amphiregulin (AREG). AREG induces ongoing YB-1 phosphorylation as well as YB-1-dependent AREG expression, thus constituting an AREG/YB-1 self-reinforcing loop. Disruption of transactivation of the EGFR and the downstream self-reinforcing loop decreases invasiveness of ovarian cancer cells in vitro and limits ovarian cancer growth in xenograft models. These findings established the regulation and significance of YB-1 phosphorylation, therefore further exploration of this signaling axis as a therapeutic avenue in ovarian cancer is warranted.	[Panupinthu, N.; Yu, S.; Zhang, D.; Zhang, F.; Lu, Y.; Mills, G. B.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [Panupinthu, N.] Mahidol Univ, Fac Sci, Dept Physiol, Bangkok 10400, Thailand; [Gagea, M.] Univ Texas MD Anderson Canc Ctr, Dept Vet Med & Surg, Houston, TX 77030 USA; [Grandis, J. R.] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA; [Grandis, J. R.] Univ Pittsburgh, Dept Pharmacol & Chem Biol, Pittsburgh, PA USA; [Dunn, S. E.] Univ British Columbia, Child & Family Res Inst, Dept Pediat, Vancouver, BC V5Z 1M9, Canada; [Dunn, S. E.] Univ British Columbia, Child & Family Res Inst, Dept Expt Med, Vancouver, BC V5Z 1M9, Canada; [Lee, H. Y.] Konyang Univ, Coll Med, Dept Pharmacol, Taejon, South Korea	University of Texas System; UTMD Anderson Cancer Center; Mahidol University; University of Texas System; UTMD Anderson Cancer Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Child & Family Research Institute; University of British Columbia; Child & Family Research Institute; University of British Columbia; Konyang University; Konyang University Hospital	Panupinthu, N (corresponding author), Mahidol Univ, Fac Sci, Dept Physiol, 272 Rama VI Rd, Bangkok 10400, Thailand.	nattapon.pan@mahidol.ac.th			NIH [R01CA92160, P01CA099031, R01CA098372]; Breast Cancer Research Foundation; National Research Foundation of Korea [2011-0015761]; Canadian Institutes of Health Research; SPORE in head-and-neck cancer [P50CA197190]; American Cancer Society; CCSG [CA16672]; NATIONAL CANCER INSTITUTE [R01CA092160, P50CA083639, P50CA098258, P01CA099031, R01CA098372, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE023685] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Breast Cancer Research Foundation; National Research Foundation of Korea(National Research Foundation of Korea); Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); SPORE in head-and-neck cancer; American Cancer Society(American Cancer Society); CCSG; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank Drs Meng Gao and Zhiyong Ding at MD Anderson Cancer Center for authenticating the AKT1/AKT2 knockout cell lines.This work was supported by NIH grants R01CA92160 and P01CA099031 (to G.B.M.), and R01CA098372 (to J.R.G.), the Breast Cancer Research Foundation (to G.B.M.), the National Research Foundation of Korea 2011-0015761 (to H.Y.L.), Canadian Institutes of Health Research (to S.E.D.), the SPORE in head-and-neck cancer P50CA197190 (to J.R.G.), the American Cancer Society (to J.R.G.) and CCSG core grant CA16672 (to MD Anderson Cancer Center).	Amit I, 2007, NAT GENET, V39, P503, DOI 10.1038/ng1987; Andreev J, 2001, J BIOL CHEM, V276, P20130, DOI 10.1074/jbc.M102307200; Basaki Y, 2007, ONCOGENE, V26, P2736, DOI 10.1038/sj.onc.1210084; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Bergmann S, 2005, CANCER RES, V65, P4078, DOI 10.1158/0008-5472.CAN-04-4056; Berquin IM, 2005, ONCOGENE, V24, P3177, DOI 10.1038/sj.onc.1208504; Berquin IM, 2001, ONCOGENE, V20, P4019, DOI 10.1038/sj.onc.1204537; Boerner JL, 2005, MOL CARCINOGEN, V44, P262, DOI 10.1002/mc.20138; Busser B, 2010, MOL THER, V18, P528, DOI 10.1038/mt.2009.226; Cherrin C, 2010, CANCER BIOL THER, V9, P493, DOI 10.4161/cbt.9.7.11100; Chetrit A, 2008, J CLIN ONCOL, V26, P20, DOI 10.1200/JCO.2007.11.6905; Clarke-Pearson DL, 2009, NEW ENGL J MED, V361, P170, DOI 10.1056/NEJMcp0901926; Cook SJ, 1996, BIOCHEM J, V320, P237, DOI 10.1042/bj3200237; Eder AM, 2000, CLIN CANCER RES, V6, P2482; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Ericson K, 2010, P NATL ACAD SCI USA, V107, P2598, DOI 10.1073/pnas.0914018107; Evdokimova V, 2009, CANCER CELL, V15, P402, DOI 10.1016/j.ccr.2009.03.017; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Fang XJ, 2004, J BIOL CHEM, V279, P9653, DOI 10.1074/jbc.M306662200; Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012; Jeong KJ, 2013, MOL ONCOL, V7, P121, DOI 10.1016/j.molonc.2012.10.001; Jing JP, 2012, MOL CANCER THER, V11, P720, DOI 10.1158/1535-7163.MCT-11-0505; Jones S, 2012, J PATHOL, V226, P413, DOI 10.1002/path.3967; Jurchott K, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001231; Kamura T, 1999, CANCER, V85, P2450, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2450::AID-CNCR21>3.0.CO;2-U; Lasham A, 2012, JNCI-J NATL CANCER I, V104, P133, DOI 10.1093/jnci/djr512; Law JH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012661; Li C, 2009, ONCOGENE, V28, P3801, DOI 10.1038/onc.2009.234; Lombardo LJ, 2004, J MED CHEM, V47, P6658, DOI 10.1021/jm049486a; Lu Y, 2011, ONCOGENE, V30, P4567, DOI 10.1038/onc.2011.164; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; NORMANNO N, 1994, P NATL ACAD SCI USA, V91, P2790, DOI 10.1073/pnas.91.7.2790; Ohta H, 2003, MOL PHARMACOL, V64, P994, DOI 10.1124/mol.64.4.994; Okita M, 1997, INT J CANCER, V71, P31, DOI 10.1002/(SICI)1097-0215(19970328)71:1<31::AID-IJC7>3.0.CO;2-4; Panupinthu N, 2010, BRIT J CANCER, V102, P941, DOI 10.1038/sj.bjc.6605588; Rhodes N, 2008, CANCER RES, V68, P2366, DOI 10.1158/0008-5472.CAN-07-5783; Rodland KD, 2008, J BIOL CHEM, V283, P31477, DOI 10.1074/jbc.M800456200; Rusnak DW, 2001, MOL CANCER THER, V1, P85; Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166; Siwak DR, 2010, J ONCOL, V2010, DOI 10.1155/2010/568938; Smith JA, 2005, CANCER RES, V65, P1027; Snider AJ, 2010, AM J PHYSIOL-CELL PH, V298, pC163, DOI 10.1152/ajpcell.00001.2009; Stratford AL, 2012, STEM CELLS, V30, P1338, DOI 10.1002/stem.1128; Stratford AL, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2202; Sutherland BW, 2005, ONCOGENE, V24, P4281, DOI 10.1038/sj.onc.1208590; Tabchy A, 2011, NAT STRUCT MOL BIOL, V18, P117, DOI 10.1038/nsmb0211-117; Talavera A, 2009, CANCER RES, V69, P5851, DOI 10.1158/0008-5472.CAN-08-4518; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; Wakeling AE, 2002, CANCER RES, V62, P5749; Wu J, 2006, CANCER RES, V66, P4872, DOI 10.1158/0008-5472.CAN-05-3561; Xu Y, 1995, CLIN CANCER RES, V1, P1223; Yahata H, 2002, J CANCER RES CLIN, V128, P621, DOI 10.1007/s00432-002-0386-6; Yu SX, 2008, JNCI-J NATL CANCER I, V100, P1630, DOI 10.1093/jnci/djn378; Zhang L, 2009, BIOINFORMATICS, V25, P650, DOI 10.1093/bioinformatics/btn663; Zhang Q, 2006, P NATL ACAD SCI USA, V103, P6901, DOI 10.1073/pnas.0509719103; Zhang Q, 2007, MOL CANCER THER, V6, P1414, DOI 10.1158/1535-7163.MCT-06-0678	58	34	37	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2014	33	22					2846	2856		10.1038/onc.2013.259	http://dx.doi.org/10.1038/onc.2013.259			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EI	23851501	Green Accepted			2022-12-28	WOS:000337231800004
J	Davis, FM; Azimi, I; Faville, RA; Peters, AA; Jalink, K; Putney, JW; Goodhill, GJ; Thompson, EW; Roberts-Thomson, SJ; Monteith, GR				Davis, F. M.; Azimi, I.; Faville, R. A.; Peters, A. A.; Jalink, K.; Putney, J. W., Jr.; Goodhill, G. J.; Thompson, E. W.; Roberts-Thomson, S. J.; Monteith, G. R.			Induction of epithelial-mesenchymal transition (EMT) in breast cancer cells is calcium signal dependent	ONCOGENE			English	Article						epithelial-mesenchymal transition; calcium; vimentin; STAT3; signal transduction; breast cancer	UP-REGULATION; MIGRATION; ACTIVATION; CHANNELS; TRPM7; CONTRIBUTES; PROGRESSION; METASTASIS; EXPRESSION; ROLES	Signals from the tumor microenvironment trigger cancer cells to adopt an invasive phenotype through epithelial-mesenchymal transition (EMT). Relatively little is known regarding key signal transduction pathways that serve as cytosolic bridges between cell surface receptors and nuclear transcription factors to induce EMT. A better understanding of these early EMT events may identify potential targets for the control of metastasis. One rapid intracellular signaling pathway that has not yet been explored during EMT induction is calcium. Here we show that stimuli used to induce EMT produce a transient increase in cytosolic calcium levels in human breast cancer cells. Attenuation of the calcium signal by intracellular calcium chelation significantly reduced epidermal growth factor (EGF)-and hypoxia-induced EMT. Intracellular calcium chelation also inhibited EGF-induced activation of signal transducer and activator of transcription 3 (STAT3), while preserving other signal transduction pathways such as Akt and extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation. To identify calcium-permeable channels that may regulate EMT induction in breast cancer cells, we performed a targeted siRNA-based screen. We found that transient receptor potential-melastatin- like 7 (TRPM7) channel expression regulated EGF-induced STAT3 phosphorylation and expression of the EMT marker vimentin. Although intracellular calcium chelation almost completely blocked the induction of many EMT markers, including vimentin, Twist and N-cadherin, the effect of TRPM7 silencing was specific for vimentin protein expression and STAT3 phosphorylation. These results indicate that TRPM7 is a partial regulator of EMT in breast cancer cells, and that other calcium-permeable ion channels are also involved in calcium-dependent EMT induction. In summary, this work establishes an important role for the intracellular calcium signal in the induction of EMT in human breast cancer cells. Manipulation of calcium-signaling pathways controlling EMT induction in cancer cells may therefore be an important therapeutic strategy for preventing metastases.	[Davis, F. M.; Azimi, I.; Peters, A. A.; Roberts-Thomson, S. J.; Monteith, G. R.] Univ Queensland, Sch Pharm, Brisbane, Qld 4072, Australia; [Faville, R. A.; Goodhill, G. J.] Univ Queensland, Queensland Brain Inst, Brisbane, Qld 4072, Australia; [Jalink, K.] Netherlands Canc Inst, Div Cell Biol, Amsterdam, Netherlands; [Putney, J. W., Jr.] NIEHS, Lab Signal Transduct, Res Triangle Pk, NC 27709 USA; [Goodhill, G. J.] Univ Queensland, Sch Math & Phys, Brisbane, Qld 4072, Australia; [Thompson, E. W.] St Vincents Inst, Fitzroy, Vic, Australia; [Thompson, E. W.] Univ Melbourne, St Vincents Hosp, Dept Surg, Fitzroy, Vic 3065, Australia	University of Queensland; University of Queensland; Netherlands Cancer Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); University of Queensland; St. Vincent's Institute of Medical Research; St Vincent's Hospital Melbourne; University of Melbourne	Monteith, GR (corresponding author), Univ Queensland, Sch Pharm, Brisbane, Qld 4072, Australia.	gregm@uq.edu.au	Thompson, Erik/GPK-2067-2022; Azimi, Iman/E-2043-2011; Putney, James W/F-7247-2019; Roberts-Thomson, Sarah/W-5676-2019; Peters, Amelia/AAP-3886-2021; Peters, Amelia A/E-4254-2010; Roberts-Thomson, Sarah J/B-4282-2011; Monteith, Gregory/B-1626-2008; Thompson, Erik W/A-1425-2009; Davis, Felicity M/P-1387-2016	Thompson, Erik/0000-0002-9723-4924; Azimi, Iman/0000-0001-9477-9999; Putney, James W/0000-0002-3379-4789; Roberts-Thomson, Sarah/0000-0001-8202-5786; Peters, Amelia/0000-0002-0700-7817; Roberts-Thomson, Sarah J/0000-0001-8202-5786; Monteith, Gregory/0000-0002-4345-530X; Thompson, Erik W/0000-0002-9723-4924; Davis, Felicity M/0000-0001-9112-118X; Jalink, Kees/0000-0001-7019-3440; Goodhill, Geoffrey/0000-0001-9789-9355	National Health and Medical Research Council (NHMRC) [569645, 1022263]; Intramural Research Program of the US National Institutes of Health, National Institute of Environmental Health Sciences (NIEHS); NHMRC Biomedical Postgraduate Scholarship [511262]; UQ Postdoctoral Fellowship; National Breast Cancer Foundation; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090087] Funding Source: NIH RePORTER; National Breast Cancer Foundation [CG-10-04] Funding Source: researchfish	National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Intramural Research Program of the US National Institutes of Health, National Institute of Environmental Health Sciences (NIEHS); NHMRC Biomedical Postgraduate Scholarship(National Health and Medical Research Council (NHMRC) of Australia); UQ Postdoctoral Fellowship; National Breast Cancer Foundation; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Breast Cancer Foundation	The research was partially supported by the National Health and Medical Research Council (NHMRC; project grants 569645 and 1022263) and the Intramural Research Program of the US National Institutes of Health, National Institute of Environmental Health Sciences (NIEHS). FD was funded by an NHMRC Biomedical Postgraduate Scholarship (511262), RF was funded by a UQ Postdoctoral Fellowship and EWT was funded in part by the National Breast Cancer Foundation.	Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036; Berg T, 2008, CURR OPIN CHEM BIOL, V12, P464, DOI 10.1016/j.cbpa.2008.07.023; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Bonnomet A, 2012, ONCOGENE, V31, P3741, DOI 10.1038/onc.2011.540; Chang HY, 2005, P NATL ACAD SCI USA, V102, P3738, DOI 10.1073/pnas.0409462102; Cheng XP, 2010, CELL, V141, P331, DOI 10.1016/j.cell.2010.03.013; Chubanov V, 2012, BRIT J PHARMACOL, V166, P1357, DOI 10.1111/j.1476-5381.2012.01855.x; Clark K, 2006, EMBO J, V25, P290, DOI 10.1038/sj.emboj.7600931; Colomiere M, 2009, BRIT J CANCER, V100, P134, DOI 10.1038/sj.bjc.6604794; Cook SJ, 1997, J BIOL CHEM, V272, P13309, DOI 10.1074/jbc.272.20.13309; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Davis FM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036923; Davis FM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023464; Dimeo TA, 2009, CANCER RES, V69, P5364, DOI 10.1158/0008-5472.CAN-08-4135; Elgoyhen AB, 2001, P NATL ACAD SCI USA, V98, P3501, DOI 10.1073/pnas.051622798; Gao HX, 2011, CELL CALCIUM, V50, P559, DOI 10.1016/j.ceca.2011.09.003; Gilles C, 1999, J CELL SCI, V112, P4615; Grande M, 2002, J CELL SCI, V115, P4227, DOI 10.1242/jcs.00091; Grice DM, 2010, J BIOL CHEM, V285, P37458, DOI 10.1074/jbc.M110.163329; Hu JJ, 2011, BIOCHEM BIOPH RES CO, V411, P786, DOI 10.1016/j.bbrc.2011.07.025; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Ji QS, 2000, ONCOGENE, V19, P1853, DOI 10.1038/sj.onc.1203517; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Langeslag M, 2007, J BIOL CHEM, V282, P232, DOI 10.1074/jbc.M605300200; Lester RD, 2007, J CELL BIOL, V178, P425, DOI 10.1083/jcb.200701092; Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30; Lo HW, 2007, CANCER RES, V67, P9066, DOI 10.1158/0008-5472.CAN-07-0575; Lundgren K, 2009, BRIT J CANCER, V101, P1769, DOI 10.1038/sj.bjc.6605369; Mancini M, 2009, NAT REV CANCER, V9, P810, DOI 10.1038/nrc2735; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mellstrom B, 2008, PHYSIOL REV, V88, P421, DOI 10.1152/physrev.00041.2005; Middelbeek J, 2012, CANCER RES, V72, P4250, DOI 10.1158/0008-5472.CAN-11-3863; Monet M, 2010, CANCER RES, V70, P1225, DOI 10.1158/0008-5472.CAN-09-2205; Monteith GR, 2012, J BIOL CHEM, V287, P31666, DOI 10.1074/jbc.R112.343061; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Prevarskaya N, 2011, NAT REV CANCER, V11, P609, DOI 10.1038/nrc3105; Proia TA, 2011, CELL STEM CELL, V8, P149, DOI 10.1016/j.stem.2010.12.007; Ramsey IS, 2006, ANNU REV PHYSIOL, V68, P619, DOI 10.1146/annurev.physiol.68.040204.100431; Ronnov-Jessen L, 2009, TRENDS MOL MED, V15, P5, DOI 10.1016/j.molmed.2008.11.001; Sarrio D, 2008, CANCER RES, V68, P989, DOI 10.1158/0008-5472.CAN-07-2017; Shabir S, 2008, CELL CALCIUM, V44, P453, DOI 10.1016/j.ceca.2008.02.008; Su LT, 2011, BIOCHEM J, V434, P513, DOI 10.1042/BJ20101678; Suchanek KM, 2002, MOL CARCINOGEN, V34, P165, DOI 10.1002/mc.10061; Takahashi T, 1999, CIRC RES, V85, P884; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Vultur A, 2004, ONCOGENE, V23, P2600, DOI 10.1038/sj.onc.1207378; Wei CL, 2009, NATURE, V457, P901, DOI 10.1038/nature07577; Wyckoff J, 2004, CANCER RES, V64, P7022, DOI 10.1158/0008-5472.CAN-04-1449; Yang SL, 2009, ONCOGENE, V28, P1320, DOI 10.1038/onc.2008.475; Yang SY, 2009, CANCER CELL, V15, P124, DOI 10.1016/j.ccr.2008.12.019; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183	53	230	238	3	68	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2014	33	18					2307	2316		10.1038/onc.2013.187	http://dx.doi.org/10.1038/onc.2013.187			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AG5ID	23686305	Green Accepted, Green Submitted			2022-12-28	WOS:000335451800004
J	Tian, TV; Tomavo, N; Huot, L; Flourens, A; Bonnelye, E; Flajollet, S; Hot, D; Leroy, X; de Launoit, Y; Duterque-Coquillaud, M				Tian, T. V.; Tomavo, N.; Huot, L.; Flourens, A.; Bonnelye, E.; Flajollet, S.; Hot, D.; Leroy, X.; de Launoit, Y.; Duterque-Coquillaud, M.			Identification of novel TMPRSS2: ERG mechanisms in prostate cancer metastasis: involvement of MMP9 and PLXNA2	ONCOGENE			English	Article						prostate cancer; TMPRSS2: ERG fusion; migration; invasion; MMP9; PLXNA2	GENE FUSION; MATRIX METALLOPROTEINASES; MESENCHYMAL TRANSITION; CELL INVASION; TUMOR-CELLS; EXPRESSION; RESISTANT; FAMILY; MATRIX-METALLOPROTEINASE-9; HETEROGENEITY	Prostate cancer (PCa) is one of the major public health problems in Western countries. Recently, the TMPRSS2: ERG gene fusion, which results in the aberrant expression of the transcription factor ERG, has been shown to be the most common gene rearrangement in PCa. Previous studies have determined the contributions of this fusion in PCa disease initiation and/or progression in vitro and in vivo. In this study on TMPRSS2: ERG regulation in PCa, we used an androgen receptor and TMPRSS2: ERG fusion double-negative PCa cell model: PC3c. In three cell clones with different TMPRSS2: ERG expression levels, ectopic expression of the fusion resulted in significant induction of cell migration and invasion in a dose-dependent manner. In agreement with this phenotype, high-throughput microarray analysis revealed that a set of genes, functionally associated with cell motility and invasiveness, were deregulated in a dose-dependent manner in TMPRSS2: ERG-expressing cells. Importantly, we identified increased MMP9 (Metalloproteinase 9) and PLXNA2 (Plexin A2) expression in TMPRSS2: ERG-positive PCa samples, and their expression levels were significantly correlated with ERG expression in a PCa cohort. In line with these findings, there was evidence that TMPRSS2: ERG directly and positively regulates MMP9 and PLXNA2 expression in PC3c cells. Moreover, PLXNA2 upregulation contributed to TMPRSS2: ERG-mediated enhancements of PC3c cell migration and invasion. Furthermore, and importantly, PLXNA2 expression was upregulated in metastatic PCa tumors compared with localized primary PCa tumors. This study provides novel insights into the role of the TMPRSS2: ERG fusion in PCa metastasis.	[Tian, T. V.; Tomavo, N.; Flourens, A.; Flajollet, S.; de Launoit, Y.; Duterque-Coquillaud, M.] CNRS, UMR8161, Inst Biol Lille, F-59021 Lille, France; [Tian, T. V.; Tomavo, N.; Huot, L.; Flourens, A.; Flajollet, S.; Hot, D.; de Launoit, Y.; Duterque-Coquillaud, M.] Inst Pasteur, IFR142, F-59019 Lille, France; [Tian, T. V.; Tomavo, N.; Huot, L.; Flourens, A.; Flajollet, S.; Hot, D.; Leroy, X.; de Launoit, Y.; Duterque-Coquillaud, M.] Univ Lille Nord France, Lille, France; [Tian, T. V.; Leroy, X.] Univ Droit & Sante Lille II, Fac Med Henri Warembourg, Lille, France; [Huot, L.; Hot, D.] CNRS, UMR8204, INSERM U1019, Ctr Infect & Immunite Lille, Lille, France; [Bonnelye, E.] INSERM, U1033, F-69008 Lyon, France; [Leroy, X.] CHRU Lille, Inst Pathol, F-59037 Lille, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; Universite de Lille; Universite de Lille - ISITE; Universite de Lille; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; Universite de Lille; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Lille - ISITE; CHU Lille	Duterque-Coquillaud, M (corresponding author), CNRS, UMR8161, Inst Biol Lille, 1 Rue Prof Calmette,BP447, F-59021 Lille, France.	martine.duterque@ibl.fr	Bonnelye, Edith/AAT-9134-2021; Hot, David/M-6775-2016; TIAN, TIAN/O-1726-2015	Duterque-Coquillaud, Martine/0000-0003-3943-5629; Hot, David/0000-0002-2361-0616; de Launoit, Yvan/0000-0003-1837-9808; TIAN, TIAN/0000-0002-9906-0980	Centre national de la recherche scientifique (CNRS); La Ligue contre le Cancer (Comite ' du Pas-de- Calais); Institut national du cancer [INCa_4419]; Institut Pasteur of Lille/ Nord-Pas-de-Calais Regional Council (Region Nord- Pas-de-Calais); Association pour la recherche sur le cancer (ARC)	Centre national de la recherche scientifique (CNRS)(Centre National de la Recherche Scientifique (CNRS)); La Ligue contre le Cancer (Comite ' du Pas-de- Calais); Institut national du cancer(Institut National du Cancer (INCA) France); Institut Pasteur of Lille/ Nord-Pas-de-Calais Regional Council (Region Nord- Pas-de-Calais)(Region Hauts-de-France); Association pour la recherche sur le cancer (ARC)(Fondation ARC pour la Recherche sur le Cancer)	We would like to thank A Fradet, M Le Jeune, M Holder, C Delliaux, G Boulay, M Dubuissez, I Loison, Z Kherrouche and N Malaquin for their excellent technical advices; D Lacorre and E Werkmeister from the BioImaging Center Lille Nord de France for their technical assistance; E Lelievre and D Leprince for their stimulating discussions; and C Engel- Gautier for her critical reading of the manuscript. We also like to thank the local Tumor Tissue Bank (Tumorothe` que), Regional Reference Oncology Center (CRRC) ( Head, Pr. MC Copin) in Lille, France. This work was supported by grants from the Centre national de la recherche scientifique (CNRS), La Ligue contre le Cancer (Comite ' du Pas-de- Calais) and the Institut national du cancer (INCa_4419). TV Tian is a recipient of PhD fellowships from the Institut Pasteur of Lille/ Nord-Pas-de-Calais Regional Council (Region Nord- Pas-de-Calais) and the Association pour la recherche sur le cancer (ARC).	Andreoiu M, 2010, HUM PATHOL, V41, P781, DOI 10.1016/j.humpath.2010.02.011; Attard G, 2008, ONCOGENE, V27, P253, DOI 10.1038/sj.onc.1210640; Attard G, 2009, CANCER RES, V69, P2912, DOI 10.1158/0008-5472.CAN-08-3667; Barry M, 2007, UROLOGY, V70, P630, DOI 10.1016/j.urology.2007.08.032; Becker-Santos DD, 2012, CARCINOGENESIS, V33, P2558, DOI 10.1093/carcin/bgs285; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Blanc V, 2011, PROSTATE, V71, P649, DOI 10.1002/pros.21281; Brown CB, 2001, DEVELOPMENT, V128, P3071; Capparuccia L, 2009, J CELL SCI, V122, P1723, DOI 10.1242/jcs.030197; Carver BS, 2009, NAT GENET, V41, P619, DOI 10.1038/ng.370; Castellano G, 2008, CLIN CANCER RES, V14, P7470, DOI 10.1158/1078-0432.CCR-08-0870; Cheng L, 1998, J NATL CANCER I, V90, P233, DOI 10.1093/jnci/90.3.233; Chinnaiyan AM, 2008, NEOPLASIA, V10, P177, DOI 10.1593/neo.07822; Chng KR, 2012, EMBO J, V31, P2810, DOI 10.1038/emboj.2012.112; Clark J, 2007, ONCOGENE, V26, P2667, DOI 10.1038/sj.onc.1210070; Demichelis F, 2007, ONCOGENE, V26, P4596, DOI 10.1038/sj.onc.1210237; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; DHORDAIN P, 1995, MECH DEVELOP, V50, P17, DOI 10.1016/0925-4773(94)00322-E; dos Reis ST, 2009, J UROLOGY, V181, P2320, DOI 10.1016/j.juro.2009.01.012; FitzGerald LM, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-230; Flajollet S, 2009, J IMMUNOL, V183, P6948, DOI 10.4049/jimmunol.0902053; Fradet A, 2010, BONE, V47, pS289, DOI 10.1016/j.bone.2010.01.224; Franco M, 2008, EMBO REP, V9, P865, DOI 10.1038/embor.2008.139; Furusato B, 2010, PROSTATE CANCER P D, V13, P228, DOI 10.1038/pcan.2010.23; Gopalan A, 2009, CANCER RES, V69, P1400, DOI 10.1158/0008-5472.CAN-08-2467; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Guo CC, 2012, HUM PATHOL, V43, P644, DOI 10.1016/j.humpath.2011.06.018; Gupta S, 2010, CANCER RES, V70, P6735, DOI 10.1158/0008-5472.CAN-10-0244; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hance MW, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.389015; Hanzawa M, 2000, CARCINOGENESIS, V21, P1079, DOI 10.1093/carcin/21.6.1079; Hermans KG, 2009, CLIN CANCER RES, V15, P6398, DOI 10.1158/1078-0432.CCR-09-1176; Himelstein BP, 1997, ONCOGENE, V14, P1995, DOI 10.1038/sj.onc.1201012; Hiratsuka S, 2002, CANCER CELL, V2, P289, DOI 10.1016/S1535-6108(02)00153-8; Hoogland AM, 2012, MODERN PATHOL, V25, P471, DOI 10.1038/modpathol.2011.176; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Kato T, 2012, BIOCHEM BIOPH RES CO, V417, P966, DOI 10.1016/j.bbrc.2011.12.047; Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015; King JC, 2009, NAT GENET, V41, P524, DOI 10.1038/ng.371; Klezovitch O, 2008, P NATL ACAD SCI USA, V105, P2105, DOI 10.1073/pnas.0711711105; Kodo K, 2009, P NATL ACAD SCI USA, V106, P13933, DOI 10.1073/pnas.0904744106; KOLODKIN AL, 1993, CELL, V75, P1389, DOI 10.1016/0092-8674(93)90625-Z; Kunderfranco P, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010547; Le Jeune M, 2010, EXP CELL RES, V316, P203, DOI 10.1016/j.yexcr.2009.10.002; Leshem O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021650; Macintosh CA, 1998, CANCER RES, V58, P23; Mehra R, 2008, CANCER RES, V68, P3584, DOI 10.1158/0008-5472.CAN-07-6154; Mehra R, 2007, CANCER RES, V67, P7991, DOI 10.1158/0008-5472.CAN-07-2043; Minner S, 2013, MODERN PATHOL, V26, P106, DOI 10.1038/modpathol.2012.130; Mitelman F, 2007, NAT REV CANCER, V7, P233, DOI 10.1038/nrc2091; Nakamura Y, 2004, J IMMUNOL, V172, P1945, DOI 10.4049/jimmunol.172.3.1945; Nam RK, 2007, BRIT J CANCER, V97, P1690, DOI 10.1038/sj.bjc.6604054; Nam RK, 2007, CANCER BIOL THER, V6, P40, DOI 10.4161/cbt.6.1.3489; Nese N, 2010, ANAL QUANT CYTOL, V32, P90; Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327; Perner S, 2006, CANCER RES, V66, P8337, DOI 10.1158/0008-5472.CAN-06-1482; Perner S, 2010, UROLOGY, V75, P762, DOI 10.1016/j.urology.2009.10.010; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Rubin MA, 2011, J CLIN ONCOL, V29, P3659, DOI 10.1200/JCO.2011.35.1916; Sakurai-Yageta M, 2008, J CELL BIOL, V181, P985, DOI 10.1083/jcb.200709076; Saramaki OR, 2008, CLIN CANCER RES, V14, P3395, DOI 10.1158/1078-0432.CCR-07-2051; Scher HI, 2011, J CLIN ONCOL, V29, P3695, DOI 10.1200/JCO.2011.35.8648; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Squire JA, 2011, ADV CANCER RES, V112, P183, DOI 10.1016/B978-0-12-387688-1.00007-7; Steffan JJ, 2012, J BIOL CHEM, V287, P29968, DOI 10.1074/jbc.M112.379396; Stott SL, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000403; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Toyofuku T, 2008, DEV BIOL, V321, P251, DOI 10.1016/j.ydbio.2008.06.028; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Vlaeminck-Guillem V, 2000, MECH DEVELOP, V91, P331, DOI 10.1016/S0925-4773(99)00272-5; Wang JH, 2008, CANCER RES, V68, P8516, DOI 10.1158/0008-5472.CAN-08-1147; Wang JH, 2006, CANCER RES, V66, P8347, DOI 10.1158/0008-5472.CAN-06-1966; Wei GH, 2010, EMBO J, V29, P2147, DOI 10.1038/emboj.2010.106; Wong OGW, 2007, P NATL ACAD SCI USA, V104, P19040, DOI 10.1073/pnas.0702544104; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Zhou C, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-11; Zong Y, 2009, P NATL ACAD SCI USA, V106, P12465, DOI 10.1073/pnas.0905931106	80	48	51	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2014	33	17					2204	2214		10.1038/onc.2013.176	http://dx.doi.org/10.1038/onc.2013.176			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF8WJ	23708657	Green Submitted, Green Published			2022-12-28	WOS:000334996000006
J	Wu, DW; Lee, MC; Wang, J; Chen, CY; Cheng, YW; Lee, H				Wu, D-W; Lee, M-C; Wang, J.; Chen, C-Y; Cheng, Y-W; Lee, H.			DDX3 loss by p53 inactivation promotes tumor malignancy via the MDM2/Slug/E-cadherin pathway and poor patient outcome in non-small-cell lung cancer	ONCOGENE			English	Article						DDX3; p53 inactivation; survival; relapse; lung cancer	BOX RNA HELICASE; E-CADHERIN EXPRESSION; REPRESSES E-CADHERIN; 16/18 E6 ONCOPROTEIN; HUMAN-PAPILLOMAVIRUS; BETA-CATENIN; HEPATOCELLULAR-CARCINOMA; MESENCHYMAL TRANSITIONS; GENE-EXPRESSION; DOWN-REGULATION	P53 inactivation by p53 mutation and E6 oncoprotein has a crucial role in human carcinogenesis. DDX3 has been shown to be a target of p53. In this study, we hypothesized that DDX3 loss by p53 inactivation may promote tumor malignancy and poor patients' outcome. Mechanically, DDX3 loss by p53 knockdown and E6 overexpression was observed in A549 lung cancer cells. Conversely, DDX3 expression was markedly elevated by wild-type (WT) p53 ectopic expression in p53-null H1299 cells, E6-knockdown TL-1 lung cancer and SiHa cervical cancer cells. Interestingly, DDX3 loss promotes soft-agar growth and invasive capability; however, both capabilities were suppressed by DDX3 overexpression. We next expected that DDX3 loss might result in Slug-suppressed E-cadherin expression via decreased MDM2-mediated Slug degradation. As expected, MDM2 transcription is suppressed by DDX3 loss via decreased SP1 binding activity to the MDM2 promoter. Consequently, Slug expression was elevated by the reduction of MDM2 because of DDX3 loss, and E-cadherin expression was suppressed by Slug. Consistent observations in the correlation of DDX3 loss with MDM2, Slug and E-cadherin were seen in lung tumors from lung cancer patients. In addition, patients with low-DDX3 tumors had poorer survival and relapse than patients with high-DDX3 tumors. In conclusion, we suggest that DDX3 loss by p53 inactivation via MDM2/Slug/E-cadherin pathway promotes tumor malignancy and poor patient outcome.	[Wu, D-W; Cheng, Y-W; Lee, H.] Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Taipei 115, Taiwan; [Lee, M-C] Taichung Vet Gen Hosp, Dept Surg, Div Thorac Surg, Taichung, Taiwan; [Wang, J.] Taichung Vet Gen Hosp, Dept Pathol, Taichung, Taiwan; [Chen, C-Y] China Med Univ Hosp, Dept Surg, Taichung, Taiwan	Taipei Medical University; Taichung Veterans General Hospital; Taichung Veterans General Hospital; China Medical University Taiwan; China Medical University Hospital - Taiwan	Lee, H (corresponding author), Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Room 5,12F,3 Yuancyu St, Taipei 115, Taiwan.	hl@tmu.edu.tw			National Health Research Institute [NHRI96-TD-G-111-006, NHRI97-TD-G-111-006]; National Science Council of Taiwan, ROC [NSC-96-2628-B-040-002-MY3, DOH100-TD-C-111-005]	National Health Research Institute(National Health Research Institutes - Taiwan); National Science Council of Taiwan, ROC(Ministry of Science and Technology, Taiwan)	This work was jointly supported by grants from the National Health Research Institute (NHRI96-TD-G-111-006; NHRI97-TD-G-111-006) and the National Science Council (NSC-96-2628-B-040-002-MY3; DOH100-TD-C-111-005) of Taiwan, ROC.	Al Moustafa AE, 2008, CURR PHARM DESIGN, V14, P2159, DOI 10.2174/138161208785740216; [Anonymous], 2014, ONCOGENE, P1515; BARAK Y, 1994, COLD SPRING HARB SYM, V59, P225, DOI 10.1101/SQB.1994.059.01.027; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Botlagunta M, 2008, ONCOGENE, V27, P3912, DOI 10.1038/onc.2008.33; Boulenouar S, 2010, CARCINOGENESIS, V31, P473, DOI 10.1093/carcin/bgp281; Bremnes RM, 2002, LUNG CANCER, V36, P115, DOI 10.1016/S0169-5002(01)00471-8; Chang PC, 2006, ONCOGENE, V25, P1991, DOI 10.1038/sj.onc.1209239; Chao CH, 2006, CANCER RES, V66, P6579, DOI 10.1158/0008-5472.CAN-05-2415; Cheng YW, 2008, CLIN CANCER RES, V14, P7173, DOI 10.1158/1078-0432.CCR-08-0850; Cheng YW, 2008, CLIN CANCER RES, V14, P4705, DOI 10.1158/1078-0432.CCR-07-4675; Cheng YW, 2007, CANCER RES, V67, P10686, DOI 10.1158/0008-5472.CAN-07-1461; Cheng YW, 2001, ENVIRON MOL MUTAGEN, V37, P304, DOI 10.1002/em.1037; Chien WP, 2010, ANN SURG ONCOL, V17, P1194, DOI 10.1245/s10434-009-0853-2; Coissard CJ, 2005, MODERN PATHOL, V18, P1606, DOI 10.1038/modpathol.3800472; Drane P, 2001, ONCOGENE, V20, P430, DOI 10.1038/sj.onc.1204101; Feldser DM, 2010, NATURE, V468, P572, DOI 10.1038/nature09535; Flatt PM, 2000, CANCER LETT, V156, P63, DOI 10.1016/S0304-3835(00)00441-9; Freedman DA, 1998, MOL CELL BIOL, V18, P7288, DOI 10.1128/MCB.18.12.7288; Hajra KM, 2002, CANCER RES, V62, P1613; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Hsu NY, 2009, ONCOL REP, V21, P81, DOI 10.3892/or_00000192; Jiang M, 2002, ONCOGENE, V21, P6041, DOI 10.1038/sj.onc.1205878; Junttila MR, 2010, NATURE, V468, P567, DOI 10.1038/nature09526; Klein F, 2009, LUNG CANCER, V65, P13, DOI 10.1016/j.lungcan.2008.10.003; Knappskog S, 2011, CANCER CELL, V19, P273, DOI 10.1016/j.ccr.2010.12.019; Koshiol J, 2011, JNCI-J NATL CANCER I, V103, P501, DOI 10.1093/jnci/djr003; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Laurson J, 2010, CARCINOGENESIS, V31, P918, DOI 10.1093/carcin/bgq027; Lim SO, 2011, BMC BIOL, V9, DOI 10.1186/1741-7007-9-83; Lim SO, 2010, FEBS LETT, V584, P2231, DOI 10.1016/j.febslet.2010.04.006; Matthews K, 2003, J VIROL, V77, P8378, DOI 10.1128/JVI.77.15.8378-8385.2003; Muller PAJ, 2011, J CELL BIOL, V192, P209, DOI 10.1083/jcb.201009059; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Ramasami S, 2000, J PATHOL, V192, P427; Retera JMAM, 1998, J CLIN PATHOL, V51, P891, DOI 10.1136/jcp.51.12.891; Sekiguchi T, 2007, BIOCHEM BIOPH RES CO, V356, P668, DOI 10.1016/j.bbrc.2007.03.038; Shih JY, 2011, CARCINOGENESIS, V32, P1299, DOI 10.1093/carcin/bgr110; Shiota M, 2008, ONCOGENE, V27, P5543, DOI 10.1038/onc.2008.176; Simen-Kapeu A, 2010, CANCER EPIDEM BIOMAR, V19, P1879, DOI 10.1158/1055-9965.EPI-10-0356; Soussi T, 2001, NAT REV CANCER, V1, P233, DOI 10.1038/35106009; Sulzer MA, 1998, AM J RESP CRIT CARE, V157, P1319, DOI 10.1164/ajrccm.157.4.9703099; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; Uchikado Y, 2005, CLIN CANCER RES, V11, P1174; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Wu DW, 2011, CLIN CANCER RES, V17, P1895, DOI 10.1158/1078-0432.CCR-10-2316; Wu DW, 2010, CANCER RES, V70, P10392, DOI 10.1158/0008-5472.CAN-10-2341; Wu YH, 2010, CANCER RES, V70, P10422, DOI 10.1158/0008-5472.CAN-10-2615; Yang JY, 2006, MOL CELL BIOL, V26, P7269, DOI 10.1128/MCB.00172-06; Yoshino I, 2002, ANN THORAC SURG, V73, P933, DOI 10.1016/S0003-4975(01)03434-8; Yoshinouchi M, 2003, MOL THER, V8, P762, DOI 10.1016/j.ymthe.2003.08.004; Yuan A, 2002, J CLIN ONCOL, V20, P900, DOI 10.1200/JCO.20.4.900; Zhang KJ, 2011, LAB INVEST, V91, P426, DOI 10.1038/labinvest.2010.201; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	57	72	78	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2014	33	12					1515	1526		10.1038/onc.2013.107	http://dx.doi.org/10.1038/onc.2013.107			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD4TS	23584477				2022-12-28	WOS:000333244200005
J	Kendellen, MF; Bradford, JW; Lawrence, CL; Clark, KS; Baldwin, AS				Kendellen, M. F.; Bradford, J. W.; Lawrence, C. L.; Clark, K. S.; Baldwin, A. S.			Canonical and non-canonical NF-kappa B signaling promotes breast cancer tumor-initiating cells	ONCOGENE			English	Article						NF-kappa B; basal-like breast cancer; tumor-initiating cells; EMT; IL-6; IL-1 beta	EPITHELIAL-MESENCHYMAL TRANSITION; STEM-LIKE CELLS; KINASE-BETA; PROGRESSION; METASTASIS; ACTIVATION; CHEMOTHERAPY; RESISTANCE; INHIBITOR; RADIATION	Tumor-initiating cells (TICs) are a sub-population of cells that exhibit a robust ability to self-renew and contribute to the formation of primary tumors, the relapse of previously treated tumors and the development of metastases. TICs have been identified in various tumors including those of the breast, and are particularly enriched in the basal-like and claudin-low subtypes of breast cancer. The signaling pathways that contribute to the function and maintenance of TlCs are under intense study. We explored the potential involvement of the nuclear factor-kappa B (NF-kappa B) family of transcription factors in TICs in cell lines that are representative of basal-like and claudin-low breast cancer. NF-kappa B was found to be activated in breast cancer cells that form tumorspheres efficiently. Moreover, both canonical and non-canonical NF-kappa B signaling is required for these cells to self-renew in vitro and to form xenograft tumors efficiently in vivo using limiting dilutions of cells. Consistent with this fact, canonical and non-canonical NF-kappa B signaling is activated in TICs isolated from breast cancer cell lines. Experimental results indicate that NF-kappa B promotes the function of TICs by stimulating epithelial-to-mesenchymal transition and by upregulating the expression of the inflammatory cytokines interleukin-1 beta and interleukin-6. The results suggest the use of NE-a inhibitors for clinical therapy of certain breast cancers.	[Kendellen, M. F.; Bradford, J. W.; Lawrence, C. L.; Clark, K. S.; Baldwin, A. S.] Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Baldwin, AS (corresponding author), Univ N Carolina, Sch Med, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	abaldwin@med.unc.edu			T32 National Research Service Award [5-T32-CA009156-37]; F32 National Research Service Award from the National Institutes of Health [1F32CA153439-01, 1F32CA162628-01]; American Cancer Society [120296-PF-11-093-01-DDC]; National Cancer Institute [CA138937, CA73756]; Department of Defense [BC073048]; Samuel Waxman Cancer Research Foundation; NATIONAL CANCER INSTITUTE [R01CA075080, F32CA162628, T32CA009156, R01CA138937, R01CA073756, F32CA153439] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035098] Funding Source: NIH RePORTER	T32 National Research Service Award; F32 National Research Service Award from the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); American Cancer Society(American Cancer Society); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Defense(United States Department of Defense); Samuel Waxman Cancer Research Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	We would like to thank members of the Baldwin lab for helpful discussions and comments. MFK and JWB were supported by a T32 National Research Service Award (5-T32-CA009156-37) awarded to the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill. MFK was also supported by an F32 National Research Service Award (1F32CA153439-01) from the National Institutes of Health and a post-doctoral Fellowship from the American Cancer Society (120296-PF-11-093-01-DDC). JWB was also supported by an F32 National Research Service Award (1F32CA162628-01) from the National Institutes of Health. Research support was provided by National Cancer Institute, grants CA138937 and CA73756, and by Department of Defense grant BC073048. Additional research support was provided by the Samuel Waxman Cancer Research Foundation.	Abraham BK, 2005, CLIN CANCER RES, V11, P1154; Aktas B, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2333; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Basseres DS, 2006, ONCOGENE, V25, P6817, DOI 10.1038/sj.onc.1209942; Bhat-Nakshatri P, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-411; Biswas DK, 2004, P NATL ACAD SCI USA, V101, P10137, DOI 10.1073/pnas.0403621101; Cao YX, 2007, P NATL ACAD SCI USA, V104, P15852, DOI 10.1073/pnas.0706728104; Charafe-Jauffret E, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-202; Charafe-Jauffret E, 2009, CANCER RES, V69, P1302, DOI 10.1158/0008-5472.CAN-08-2741; Cogswell PC, 2000, ONCOGENE, V19, P1123, DOI 10.1038/sj.onc.1203412; Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106; Croker AK, 2008, J CELL MOL MED, V12, P374, DOI 10.1111/j.1582-4934.2007.00211.x; Fillmore C, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1673; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Ginestier C, 2010, J CLIN INVEST, V120, P485, DOI 10.1172/JCI39397; Hambardzumyan D, 2006, CANCER CELL, V10, P454, DOI 10.1016/j.ccr.2006.11.008; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Honeth G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2108; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Iliopoulos D, 2009, CELL, V139, P693, DOI 10.1016/j.cell.2009.10.014; Johnstone PAS, 2002, CURR PROB CANCER, V26, P282, DOI 10.1067/mcn.2002.129997; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Kuperwasser C, 2004, P NATL ACAD SCI USA, V101, P4966, DOI 10.1073/pnas.0401064101; Lawson JC, 2009, BREAST CANCER RES TR, V118, P241, DOI 10.1007/s10549-009-0524-9; Lee HE, 2011, BRIT J CANCER, V104, P1730, DOI 10.1038/bjc.2011.159; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Liu M, 2010, CANCER RES, V70, P10464, DOI 10.1158/0008-5472.CAN-10-0732; Liu SL, 2011, CANCER RES, V71, P614, DOI 10.1158/0008-5472.CAN-10-0538; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mattioli I, 2004, J IMMUNOL, V172, P6336, DOI 10.4049/jimmunol.172.10.6336; Merkhofer EC, 2010, ONCOGENE, V29, P1238, DOI 10.1038/onc.2009.410; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Nakshatri H, 1997, MOL CELL BIOL, V17, P3629, DOI 10.1128/MCB.17.7.3629; Nakshatri H, 2009, CURR STEM CELL RES T, V4, P50, DOI 10.2174/157488809787169110; Pastrana E, 2011, CELL STEM CELL, V8, P486, DOI 10.1016/j.stem.2011.04.007; Phillips TM, 2006, JNCI-J NATL CANCER I, V98, P1777, DOI 10.1093/jnci/djj495; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003; Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635; Rajasekhar VK, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1159; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Sheridan C, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1610; Sovak MA, 1997, J CLIN INVEST, V100, P2952, DOI 10.1172/JCI119848; Steinbrecher KA, 2005, MOL CELL BIOL, V25, P8444, DOI 10.1128/MCB.25.19.8444-8455.2005; Storci G, 2010, J CELL PHYSIOL, V225, P682, DOI 10.1002/jcp.22264; Sullivan NJ, 2009, ONCOGENE, V28, P2940, DOI 10.1038/onc.2009.180; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wilson W, 2008, CANCER RES, V68, P8156, DOI 10.1158/0008-5472.CAN-08-1061; Yamaguchi N, 2009, CANCER SCI, V100, P1668, DOI 10.1111/j.1349-7006.2009.01228.x; Yu Y, 2008, J BIOL CHEM, V283, P24497, DOI 10.1074/jbc.M802825200; Zhou JB, 2008, BREAST CANCER RES TR, V111, P419, DOI 10.1007/s10549-007-9798-y; Ziegelbauer K, 2005, BRIT J PHARMACOL, V145, P178, DOI 10.1038/sj.bjp.0706176	56	83	83	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2014	33	10					1297	1305		10.1038/onc.2013.64	http://dx.doi.org/10.1038/onc.2013.64			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AC6KI	23474754	Green Submitted, Green Accepted			2022-12-28	WOS:000332631100010
J	Chaix, A; Arcangeli, ML; Lopez, S; Voisset, E; Yang, Y; Vita, M; Letard, S; Audebert, S; Finetti, P; Birnbaum, D; Bertucci, F; Aurrand-Lions, M; Dubreuil, P; De Sepulveda, P				Chaix, A.; Arcangeli, M-L; Lopez, S.; Voisset, E.; Yang, Y.; Vita, M.; Letard, S.; Audebert, S.; Finetti, P.; Birnbaum, D.; Bertucci, F.; Aurrand-Lions, M.; Dubreuil, P.; De Sepulveda, P.			KIT-D816V oncogenic activity is controlled by the juxtamembrane docking site Y568-Y570	ONCOGENE			English	Article						receptor; tyrosine kinase; mastocytosis; oncogene; leukemia; mast cell	STEM-CELL FACTOR; RECEPTOR TYROSINE KINASE; C-KIT MUTATIONS; GASTROINTESTINAL STROMAL TUMORS; ACUTE MYELOID-LEUKEMIA; SRC FAMILY KINASES; DOMAIN MUTATIONS; PEDIATRIC MASTOCYTOSIS; ACTIVATING MUTATIONS; SIGNALING PATHWAYS	Mutation of KIT receptor tyrosine kinase at residue D816 results in ligand-independent constitutive kinase activity. This mutation occurs in most patients with mastocytosis, a myeloproliferative neoplasm, and is detected at lower frequencies in acute myeloid leukemia and in germ cell tumors. Other KIT mutations occur in gastrointestinal stromal tumors (GIST) and mucosal melanoma. KIT is considered as a bona fide therapeutic target as c-kit mutations are driving oncogenes in these pathologies. However, several evidences suggest that KIT-D816V mutant is not as aggressive as other KIT mutants. Here, we show that an intracellular docking site in the juxtamembrane region of KIT maintains a negative regulation on KIT-D816V transforming potential. Sixteen signaling proteins were shown to interact with this motif. We further demonstrate that mutation of this site results in signaling modifications, altered gene expression profile and increased transforming activity of KIT-D816V mutant. This result was unexpected as mutations of the homologous sites on wild-type (WT) KIT, or on the related oncogenic FLT3-ITD receptor, impair their function. Our results support the hypothesis that, KIT-D816V mutation is a mild oncogenic event that is sufficient to confer partial transforming properties, but requires additional mutations to acquire its full transforming potential.	[Chaix, A.; Arcangeli, M-L; Lopez, S.; Voisset, E.; Yang, Y.; Vita, M.; Letard, S.; Audebert, S.; Finetti, P.; Birnbaum, D.; Bertucci, F.; Aurrand-Lions, M.; Dubreuil, P.; De Sepulveda, P.] Ctr Rech Cancerol Marseille, INSERM, U1068, F-13009 Marseille, France; [Chaix, A.; Arcangeli, M-L; Lopez, S.; Voisset, E.; Yang, Y.; Vita, M.; Letard, S.; Audebert, S.; Finetti, P.; Birnbaum, D.; Bertucci, F.; Aurrand-Lions, M.; Dubreuil, P.; De Sepulveda, P.] Inst J Paoli I Calmettes, F-13009 Marseille, France; [Chaix, A.; Arcangeli, M-L; Lopez, S.; Voisset, E.; Yang, Y.; Vita, M.; Letard, S.; Audebert, S.; Finetti, P.; Birnbaum, D.; Bertucci, F.; Aurrand-Lions, M.; Dubreuil, P.; De Sepulveda, P.] Aix Marseille Univ, Marseille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite	De Sepulveda, P (corresponding author), Ctr Rech Cancerol Marseille, INSERM, U1068, 27 Blvd Lei Roure, F-13009 Marseille, France.	paulo.de-sepulveda@inserm.fr	Arcangeli, Marie-Laure/L-5991-2017; dubreuil, patrice/F-5346-2011; Voisset, Edwige/AAM-3503-2021; Voisset, Edwige/GSE-5113-2022; Aurrand-Lions, Michel/O-9953-2016; LOPEZ, SOPHIE/R-1917-2016; Dubreuil, Patrice/V-4816-2019; De sepulveda, paulo/K-6043-2015; Finetti, Pascal/O-8669-2017	Arcangeli, Marie-Laure/0000-0002-1726-1472; dubreuil, patrice/0000-0003-1155-1150; Voisset, Edwige/0000-0002-0943-4847; Voisset, Edwige/0000-0002-0943-4847; Aurrand-Lions, Michel/0000-0002-8361-3034; LOPEZ, SOPHIE/0000-0002-5009-5533; Dubreuil, Patrice/0000-0003-1155-1150; De sepulveda, paulo/0000-0001-8295-5414; Finetti, Pascal/0000-0002-2674-3123; Audebert, Stephane/0000-0002-9409-2588; LETARD, Sebastien/0000-0002-6508-7376	Ministere de la Recherche-ENS; ARC; French Society of Hematology; FRM; Institut Lilly; INCa; OSEO; la Ligue Contre le Cancer	Ministere de la Recherche-ENS; ARC(Australian Research Council); French Society of Hematology; FRM(Fondation pour la Recherche Medicale); Institut Lilly; INCa(Institut National du Cancer (INCA) France); OSEO; la Ligue Contre le Cancer(Ligue nationale contre le cancer)	We thank Cyndie Mosca, F Bardin and K Hanssens for technical assistance. AC is a recipient of PhD fellowships from Ministere de la Recherche-ENS, ARC and a financial support from the French Society of Hematology. We acknowledge postdoctoral fellowships from FRM and Institut Lilly to MLA, from INCa and OSEO to SL and from FRM to MV. This project was supported by grants from la Ligue Contre le Cancer and INCa.	Agosti V, 2004, J EXP MED, V199, P867, DOI 10.1084/jem.20031983; Agosti V, 2009, EXP HEMATOL, V37, P159, DOI 10.1016/j.exphem.2008.10.009; Bayle J, 2004, J BIOL CHEM, V279, P12249, DOI 10.1074/jbc.M313381200; Beghini A, 2004, HAEMATOLOGICA, V89, P920; Bodemer C, 2010, J INVEST DERMATOL, V130, P804, DOI 10.1038/jid.2009.281; Bougherara H, 2009, MOL CANCER RES, V7, P1525, DOI 10.1158/1541-7786.MCR-09-0138; Buettner R, 2008, MOL CANCER RES, V6, P1766, DOI 10.1158/1541-7786.MCR-08-0169; Cairoli R, 2006, BLOOD, V107, P3463, DOI 10.1182/blood-2005-09-3640; Casteran N, 2003, ONCOGENE, V22, P4710, DOI 10.1038/sj.onc.1206587; Chaix A, 2011, J BIOL CHEM, V286, P5956, DOI 10.1074/jbc.M110.182642; Chang PM, 2003, MOL CELL BIOL, V23, P3067, DOI 10.1128/MCB.23.9.3067-3078.2003; Curtin JA, 2006, J CLIN ONCOL, V24, P4340, DOI 10.1200/JCO.2006.06.2984; DeBerry C, 1997, BIOCHEM J, V327, P73, DOI 10.1042/bj3270073; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GLOVER HR, 1995, ONCOGENE, V11, P1347; Goemans BF, 2005, LEUKEMIA, V19, P1536, DOI 10.1038/sj.leu.2403870; Hirota S, 1998, SCIENCE, V279, P577, DOI 10.1126/science.279.5350.577; Hong L, 2004, MOL CELL BIOL, V24, P1401, DOI 10.1128/MCB.24.3.1401-1410.2004; Hongyo T, 2000, CANCER RES, V60, P2345; Kemmer K, 2004, AM J PATHOL, V164, P305, DOI 10.1016/S0002-9440(10)63120-3; Kimura Y, 2004, P NATL ACAD SCI USA, V101, P6015, DOI 10.1073/pnas.0305363101; Kozlowski M, 1998, MOL CELL BIOL, V18, P2089, DOI 10.1128/MCB.18.4.2089; Lennartsson J, 1999, ONCOGENE, V18, P5546, DOI 10.1038/sj.onc.1202929; Lievens PMJ, 2004, J BIOL CHEM, V279, P43254, DOI 10.1074/jbc.M405247200; Lim KH, 2009, BLOOD, V113, P5727, DOI 10.1182/blood-2009-02-205237; Longley BJ, 1999, P NATL ACAD SCI USA, V96, P1609, DOI 10.1073/pnas.96.4.1609; Looijenga LHJ, 2003, CANCER RES, V63, P7674; Masson K, 2009, CELL SIGNAL, V21, P1717, DOI 10.1016/j.cellsig.2009.06.002; Mayerhofer M, 2008, J IMMUNOL, V180, P5466, DOI 10.4049/jimmunol.180.8.5466; Price DJ, 1997, J BIOL CHEM, V272, P5915, DOI 10.1074/jbc.272.9.5915; Rocnik JL, 2006, BLOOD, V108, P1339, DOI 10.1182/blood-2005-11-011429; Rubin BP, 2005, CANCER RES, V65, P6631, DOI 10.1158/0008-5472.CAN-05-0891; Sattler M, 1997, J BIOL CHEM, V272, P10248; Schmidt-Arras DE, 2005, MOL CELL BIOL, V25, P3690, DOI 10.1128/MCB.25.9.3690-3703.2005; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Simon C, 2008, BLOOD, V112, P1039, DOI 10.1182/blood-2008-05-154849; Sommer G, 2003, P NATL ACAD SCI USA, V100, P6706, DOI 10.1073/pnas.1037763100; Sun JM, 2009, J BIOL CHEM, V284, P11039, DOI 10.1074/jbc.M808058200; Tan BL, 2003, J BIOL CHEM, V278, P11686, DOI 10.1074/jbc.M207068200; Tian QS, 1999, AM J PATHOL, V154, P1643, DOI 10.1016/S0002-9440(10)65419-3; Timokhina I, 1998, EMBO J, V17, P6250, DOI 10.1093/emboj/17.21.6250; Ueda S, 2002, BLOOD, V99, P3342, DOI 10.1182/blood.V99.9.3342; Valent P, 2005, LEUKEMIA LYMPHOMA, V46, P35, DOI 10.1080/10428190400010775; Vempati S, 2008, CLIN CANCER RES, V14, P4437, DOI 10.1158/1078-0432.CCR-07-1873; Voisset E, 2007, BLOOD, V110, P2593, DOI 10.1182/blood-2007-02-076471; Voisset E, 2010, BIOCHEM BIOPH RES CO, V393, P174, DOI 10.1016/j.bbrc.2010.01.116; Xiang ZF, 2007, MOL CELL BIOL, V27, P267, DOI 10.1128/MCB.01153-06; Yang Y, 2010, BLOOD, V116, P1114, DOI 10.1182/blood-2009-06-226027; Yuzawa S, 2007, CELL, V130, P323, DOI 10.1016/j.cell.2007.05.055; Zappulla JP, 2005, J EXP MED, V202, P1635, DOI 10.1084/jem.20050807	50	17	17	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2014	33	7					872	881		10.1038/onc.2013.12	http://dx.doi.org/10.1038/onc.2013.12			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB2MN	23416972				2022-12-28	WOS:000331626900008
J	Ray, KC; Moss, ME; Franklin, JL; Weaver, CJ; Higginbotham, J; Song, Y; Revetta, FL; Blaine, SA; Bridges, LR; Guess, KE; Coffey, RJ; Crawford, HC; Washington, MK; Means, AL				Ray, K. C.; Moss, M. E.; Franklin, J. L.; Weaver, C. J.; Higginbotham, J.; Song, Y.; Revetta, F. L.; Blaine, S. A.; Bridges, L. R.; Guess, K. E.; Coffey, R. J.; Crawford, H. C.; Washington, M. K.; Means, A. L.			Heparin-binding epidermal growth factor-like growth factor eliminates constraints on activated Kras to promote rapid onset of pancreatic neoplasia	ONCOGENE			English	Article						pancreatic ductal adenocarcinoma; inflammation; transdifferentiation; EGFR	DUCTAL ADENOCARCINOMA; FACTOR RECEPTOR; K-RAS; EPITHELIAL-CELLS; ACINAR-CELLS; EGF RECEPTOR; CANCER; MICE; EXPRESSION; CARCINOMA	Pancreatic cancer remains as one of the most deadly cancers with few treatment options at late stages and little information about how it develops through earlier stages. Activating mutation of the Kras gene has been implicated in, but is not sufficient for, tumorigenesis. In mouse models of pancreatic cancer, loss of tumor suppressor genes in conjunction with Kras mutation leads to gradual stochastic acquisition of neoplastic precursors and carcinomas, whereas many cells remain phenotypically unaltered in younger mice. Here, we demonstrate that two oncogenic events, mutation of Kras and production of the growth factor heparin-binding epidermal growth factor-like growth factor (HB-EGF), are sufficient for rapid and complete neoplastic transformation of the exocrine pancreas. We found that macrophages are the major source of HB-EGF production in pancreatic cancer tissue samples, and that macrophages are present in high density and in close association with human pancreatic cancer lesions. In a mouse model, high macrophage density was observed at the earliest stages of neoplastic transformation. The consequence of elevated HB-EGF signaling was investigated without the confounding effects of other macrophage-produced factors via transgenic overexpression of the active form of HB-EGF. In this model, HB-EGF was sufficient to promote Kras-initiated tumorigenesis, inducing rapid and complete neoplastic transformation of the entire exocrine pancreas shortly after birth. HB-EGF overexpression and Kras(G12D) together, but neither alone, increased proliferation with increased cyclinD1 and decreased Cdkn2a/2d (p16/p19(Ink4A/Arf)). These findings establish the importance of oncogenic synergy in cancer initiation and promotion, and establish a molecular link between inflammation and the earliest stages of tumor induction.	[Ray, K. C.; Moss, M. E.; Weaver, C. J.; Blaine, S. A.; Bridges, L. R.; Guess, K. E.; Means, A. L.] Vanderbilt Univ, Med Ctr, Div Surg Oncol, Nashville, TN 37232 USA; [Franklin, J. L.; Higginbotham, J.; Coffey, R. J.] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37232 USA; [Franklin, J. L.; Coffey, R. J.; Means, A. L.] Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN 37232 USA; [Song, Y.; Crawford, H. C.] SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; [Revetta, F. L.; Washington, M. K.] Vanderbilt Univ, Med Ctr, Dept Pathol, Nashville, TN 37232 USA; [Crawford, H. C.] Vet Affairs Med Ctr, Dept Res, Northport, NY USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Means, AL (corresponding author), Vanderbilt Univ, Med Ctr, Div Surg Oncol, D2300 Med Ctr North,1161 21st Ave S, Nashville, TN 37232 USA.	anna.means@vanderbilt.edu		Moss, M Elizabeth/0000-0002-9761-7263	NIH [CA123061, P30DK058404, P50CA095103, CA136754]; VA Merit; Knapp Chair in Pancreatic Cancer Research; NATIONAL CANCER INSTITUTE [R01CA136754, P50CA095103, R01CA159222, R21CA123061, R01CA046413] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK058404] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); VA Merit(US Department of Veterans Affairs); Knapp Chair in Pancreatic Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank R Daniel Beauchamp for support and helpful discussions, Steven D Leach, Barbara Fingleton and Harold L Moses for critically reading the manuscript, and Heidi Moreno and Christian Kis for technical assistance. This work was supported by NIH grants CA123061 (ALM), P30DK058404 and P50CA095103 (MKW), CA136754, VA Merit, and the Knapp Chair in Pancreatic Cancer Research (HCC).	Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703; ALMOGUERA C, 1988, CELL, V53, P549, DOI 10.1016/0092-8674(88)90571-5; Ardito CM, 2012, CANCER CELL, V22, P304, DOI 10.1016/j.ccr.2012.07.024; Beatty GL, 2011, SCIENCE, V331, P1612, DOI 10.1126/science.1198443; Blaine SA, 2010, DEVELOPMENT, V137, P2289, DOI 10.1242/dev.048421; Blaine SA, 2009, AM J PHYSIOL-GASTR L, V297, pG434, DOI 10.1152/ajpgi.00152.2009; Brand RE, 2007, GUT, V56, P1460, DOI 10.1136/gut.2006.108456; Carriere C, 2009, BIOCHEM BIOPH RES CO, V382, P561, DOI 10.1016/j.bbrc.2009.03.068; Clark CE, 2007, CANCER RES, V67, P9518, DOI 10.1158/0008-5472.CAN-07-0175; DOYLE CM, 1978, DEV BIOL, V65, P11, DOI 10.1016/0012-1606(78)90175-6; Edwards JP, 2006, J LEUKOCYTE BIOL, V80, P1298, DOI 10.1189/jlb.0406249; Elenius K, 1997, EMBO J, V16, P1268, DOI 10.1093/emboj/16.6.1268; FRYKBERG L, 1983, CELL, V32, P227, DOI 10.1016/0092-8674(83)90513-5; Gangarosa LM, 1997, J BIOL CHEM, V272, P18926, DOI 10.1074/jbc.272.30.18926; Goswami S, 2005, CANCER RES, V65, P5278, DOI 10.1158/0008-5472.CAN-04-1853; Hanlon L, 2010, CANCER RES, V70, P4280, DOI 10.1158/0008-5472.CAN-09-4645; Hansel DE, 2003, ANNU REV GENOM HUM G, V4, P237, DOI 10.1146/annurev.genom.4.070802.110341; HIGASHIYAMA S, 1991, SCIENCE, V251, P936, DOI 10.1126/science.1840698; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; Hingorani SR, 2005, CANCER CELL, V7, P469, DOI 10.1016/j.ccr.2005.04.023; Holbro T, 2004, ANNU REV PHARMACOL, V44, P195, DOI 10.1146/annurev.pharmtox.44.101802.121440; Hruban RH, 2001, AM J SURG PATHOL, V25, P579, DOI 10.1097/00000478-200105000-00003; Ijichi H, 2006, GENE DEV, V20, P3147, DOI 10.1101/gad.1475506; Ito Y, 2001, INT J PANCREATOL, V29, P47, DOI 10.1385/IJGC:29:1:47; Ji BA, 2009, GASTROENTEROLOGY, V137, P1072, DOI 10.1053/j.gastro.2009.05.052; Kawaguchi Y, 2002, NAT GENET, V32, P128, DOI 10.1038/ng959; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KOBRIN MS, 1994, BIOCHEM BIOPH RES CO, V202, P1705, DOI 10.1006/bbrc.1994.2131; Kojima K, 2007, CANCER RES, V67, P8121, DOI 10.1158/0008-5472.CAN-06-4167; KORC M, 1992, J CLIN INVEST, V90, P1352, DOI 10.1172/JCI116001; Luttges J, 1999, VIRCHOWS ARCH, V435, P461, DOI 10.1007/s004280050428; Means AL, 2005, DEVELOPMENT, V132, P3767, DOI 10.1242/dev.01925; Mohammed A, 2010, CANCER PREV RES, V3, P1417, DOI 10.1158/1940-6207.CAPR-10-0038; Morris JP, 2010, J CLIN INVEST, V120, P508, DOI 10.1172/JCI40045; Navas C, 2012, CANCER CELL, V22, P318, DOI 10.1016/j.ccr.2012.08.001; Odegaard JI, 2011, ANNU REV PATHOL-MECH, V6, P275, DOI 10.1146/annurev-pathol-011110-130138; Oldham SM, 1998, ONCOGENE, V16, P2565, DOI 10.1038/sj.onc.1201784; Ray KC, 2009, GASTROENTEROLOGY, V137, P1785, DOI 10.1053/j.gastro.2009.07.067; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; Siveke JT, 2007, CANCER CELL, V12, P266, DOI 10.1016/j.ccr.2007.08.002; SMIT VTHBM, 1988, NUCLEIC ACIDS RES, V16, P7773, DOI 10.1093/nar/16.16.7773; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; Vitale-Cross L, 2004, CANCER RES, V64, P8804, DOI 10.1158/0008-5472.CAN-04-2623; Wang XM, 2011, J MOL CELL BIOL, V3, P206, DOI 10.1093/jmcb/mjq038; WARSHAW AL, 1992, NEW ENGL J MED, V326, P455, DOI 10.1056/NEJM199202133260706; Zhu ZW, 2000, BIOCHEM BIOPH RES CO, V273, P1019, DOI 10.1006/bbrc.2000.3033	46	29	29	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2014	33	7					823	831		10.1038/onc.2013.3	http://dx.doi.org/10.1038/onc.2013.3			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB2MN	23376846	Green Accepted			2022-12-28	WOS:000331626900003
J	Watanabe, K; Fallahi, M; Dai, X				Watanabe, K.; Fallahi, M.; Dai, X.			Chromatin effector Pygo2 regulates mammary tumor initiation and heterogeneity in MMTV-Wnt1 mice	ONCOGENE			English	Article						MMTV-Wnt1; pygopus 2; Pygo2; mammary gland; tumor heterogeneity; cancer stem cells	CANCER STEM-CELLS; GENE-EXPRESSION; GLAND HYPERPLASIA; MYELOID-LEUKEMIA; BINDING-PROTEIN; TRANSGENIC MICE; BREAST-CANCER; INDUCE; POPULATIONS; CONTRIBUTE	Little is known about chromatin mechanisms that regulate tumor-initiating cells that are proposed to be responsible for tumor recurrence and relapse. We have previously shown that Pygopus 2 (Pygo2), a chromatin effector and context-dependent Wnt signaling coactivator, regulates mammary gland development by expanding epithelial stem/progenitor cells. However, the role of Pygo2 in mammary tumorigenesis in vivo remains to be addressed. In this study, we show that epithelia-specific ablation of Pygo2 in MMTV-Wnt1 transgenic mice results in delayed mammary ductal elongation, but the hyperbranching phenotype, aberrant accumulation of stem/progenitor-like cells, and canonical Wnt signaling output are largely unaffected. Chronic loss of Pygo2 significantly delays mammary tumor onset in MMTV-Wnt1 females, whereas acute deletion of Pygo2 in MMTV-Wnt1 tumor cells leads to a significant decrease in their tumor-initiating capability upon transplantation. Finally, we provide evidence supporting a role for Pygo2 in modulating the lineage potential of MMTV-Wnt1 tumor initiating cells. Collectively, our results suggest that Pygo2 acts at a step downstream of mammary stem cell accumulation to facilitate transformation, and that it regulates the tumor initiating capacity and lineage preference of the already transformed mammary cells, in MMTV-Wnt1 mice. These findings offer valuable insights into our understanding of the molecular basis of heterogeneity within breast tumors.	[Watanabe, K.; Fallahi, M.; Dai, X.] Univ Calif Irvine, Sch Med, Dept Biol Chem, Irvine, CA 92697 USA	University of California System; University of California Irvine	Dai, X (corresponding author), Univ Calif Irvine, Sch Med, Dept Biol Chem, D250 Med Sci 1, Irvine, CA 92697 USA.	xdai@uci.edu	Watanabe, Kazuhide/C-9667-2017	Watanabe, Kazuhide/0000-0002-5331-0593; Dai, Xing/0000-0001-8134-1365	Susan G Komen grant [KG110897]; NIH [R01-GM083089]; U.S. Department of Defense Breast Cancer Research Program; (DOD BCRP) Postdoctoral Fellowship [W81XWH-10-1-0383]; NATIONAL CANCER INSTITUTE [P30CA062203] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM083089] Funding Source: NIH RePORTER	Susan G Komen grant(Susan G. Komen Breast Cancer Foundation); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); U.S. Department of Defense Breast Cancer Research Program(United States Department of Defense); (DOD BCRP) Postdoctoral Fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank the UCI Genomics High Throughput Facility and Sue and Bill Gross Stem Cell Research Center Core Facility (Vanessa Scarfone) for expert service, Yi Li and Julie Serge for the generous gifts of MMTV-Wnt1 mice and keratin antibodies, respectively, and Eva Lee for discussions. This work was supported by Susan G Komen grant KG110897 and NIH Grant R01-GM083089 (to XD). KW was supported by a U.S. Department of Defense Breast Cancer Research Program. (DOD BCRP) Postdoctoral Fellowship (W81XWH-10-1-0383).	Andrews PGP, 2007, INT J ONCOL, V30, P357; Andrews PGP, 2009, BIOCHEM J, V422, P493, DOI 10.1042/BJ20090134; Asselin-Labat ML, 2007, NAT CELL BIOL, V9, P201, DOI 10.1038/ncb1530; Baker R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008854; Belenkaya TY, 2002, DEVELOPMENT, V129, P4089; Bocchinfuso WP, 1999, CANCER RES, V59, P1869; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Chen JK, 2010, MOL CELL BIOL, V30, P5621, DOI 10.1128/MCB.00465-10; Cicalese A, 2009, CELL, V138, P1083, DOI 10.1016/j.cell.2009.06.048; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Derksen PWB, 2006, CANCER CELL, V10, P437, DOI 10.1016/j.ccr.2006.09.013; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; Fiedler M, 2008, MOL CELL, V30, P507, DOI 10.1016/j.molcel.2008.03.011; Gjorevski N, 2011, NAT REV MOL CELL BIO, V12, P581, DOI 10.1038/nrm3168; Gu BN, 2012, CELL CYCLE, V11, P79, DOI 10.4161/cc.11.1.18402; Gu BN, 2010, J CELL BIOCHEM, V110, P1279, DOI 10.1002/jcb.22650; Gu BN, 2009, J CELL BIOL, V185, P811, DOI 10.1083/jcb.200810133; Guo W, 2008, NATURE, V453, P529, DOI 10.1038/nature06933; Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026; Herschkowitz JI, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r76; Hu YF, 2009, J IMMUNOL METHODS, V347, P70, DOI 10.1016/j.jim.2009.06.008; Jagani Z, 2010, CELL CYCLE, V9, P3449, DOI 10.4161/cc.9.17.12945; Karantza-Wadsworth V, 2008, METHOD ENZYMOL, V446, P61, DOI 10.1016/S0076-6879(08)01604-2; Khalil S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033421; Kim S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019310; Kramps T, 2002, CELL, V109, P47, DOI 10.1016/S0092-8674(02)00679-7; LaMarca HL, 2010, STEM CELLS, V28, P535, DOI 10.1002/stem.297; Li B, 2007, GENESIS, V45, P318, DOI 10.1002/dvg.20299; Li Y, 2000, ONCOGENE, V19, P1002, DOI 10.1038/sj.onc.1203273; Li Y, 2003, P NATL ACAD SCI USA, V100, P15853, DOI 10.1073/pnas.2136825100; Lindeman GJ, 2010, ASIA-PAC J CLIN ONCO, V6, P89, DOI 10.1111/j.1743-7563.2010.01279.x; Liu BY, 2004, P NATL ACAD SCI USA, V101, P4158, DOI 10.1073/pnas.0400699101; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; MUNN RJ, 1995, SEMIN CANCER BIOL, V6, P153, DOI 10.1006/scbi.1995.0020; Parker DS, 2002, DEVELOPMENT, V129, P2565; Raaphorst FM, 2003, TRENDS IMMUNOL, V24, P522, DOI 10.1016/S1471-4906(03)00241-2; Schwab KR, 2007, BMC BIOL, V5, DOI 10.1186/1741-7007-5-15; Shackleton M, 2006, NATURE, V439, P84, DOI 10.1038/nature04372; SMITH GH, 1990, CELL GROWTH DIFFER, V1, P161; Song N, 2007, DEVELOPMENT, V134, P1873, DOI 10.1242/dev.001495; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sun P, 2010, HISTOCHEM CELL BIOL, V133, P213, DOI 10.1007/s00418-009-0662-5; Teissedre B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004537; Tepera SB, 2003, J CELL SCI, V116, P1137, DOI 10.1242/jcs.00334; Thompson B, 2002, NAT CELL BIOL, V4, P367, DOI 10.1038/ncb786; Thorne CA, 2010, NAT CHEM BIOL, V6, P829, DOI 10.1038/NCHEMBIO.453; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Vaillant F, 2008, CANCER RES, V68, P7711, DOI 10.1158/0008-5472.CAN-08-1949; Van Keymeulen A, 2011, NATURE, V479, P189, DOI 10.1038/nature10573; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Visvader JE, 2011, NATURE, V469, P314, DOI 10.1038/nature09781; Visvader JE, 2009, GENE DEV, V23, P2563, DOI 10.1101/gad.1849509; Zhao HJ, 2004, MOL BIOL CELL, V15, P2523, DOI 10.1091/mbc.E03-11-0786	54	20	21	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2014	33	5					632	642		10.1038/onc.2012.620	http://dx.doi.org/10.1038/onc.2012.620			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5GW	23334328	Green Accepted, Green Submitted			2022-12-28	WOS:000331125100011
J	Munugalavadla, V; Mariathasan, S; Slaga, D; Du, C; Berry, L; Del Rosario, G; Yan, Y; Boe, M; Sun, L; Friedman, LS; Chesi, M; Bergsagel, PL; Ebens, A				Munugalavadla, V.; Mariathasan, S.; Slaga, D.; Du, C.; Berry, L.; Del Rosario, G.; Yan, Y.; Boe, M.; Sun, L.; Friedman, L. S.; Chesi, M.; Bergsagel, P. Leif; Ebens, A.			The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma	ONCOGENE			English	Article						GDC-0941; PI3K; multiple myeloma; FoxO3A	ORALLY BIOAVAILABLE INHIBITOR; TARGET; IDENTIFICATION; RAPAMYCIN; PATHWAY; GROWTH; POTENT; KINASE	The phosphatidylinositol 3'-kinase (PI3K) pathway is dysregulated in multiple myeloma (MM); we therefore tested a highly selective class I PI3K inhibitor, GDC-0941, for anti-myeloma activity. Functional and mechanistic studies were first performed in MM cell lines, then extended to primary MM patient samples cultured in vitro. GDC-0941 was then assessed as a single agent and in various combinations in myeloma tumor xenograft models. We show p110 alpha and beta are the predominant PI3K catalytic subunits in MM and that a highly selective class I PI3K inhibitor, GDC-0941, has robust activity as a single agent to induce cell cycle arrest and apoptosis of both MM cell lines and patient myeloma cells. Mechanistic studies revealed an induction of cell cycle arrest at G(0)/G(1), with decreased phospho-FoxO1/3a levels, decreased cyclin D1 and c-myc expression, and an increase in the cell cycle inhibitor, p27kip. Induction of apoptosis correlated with increased expression of the pro-apoptotic BH3-only protein BIM, cleaved caspase 3 and cleaved poly (ADP-ribose) polymerase (PARP). In vitro, GDC-0941 synergized with dexamethasone (Dex) and lenalidomide (combination index values of 0.3-0.4 and 0.4-0.8, respectively); in vivo GDC-0941 has anti-myeloma activity and significantly increases the activity of the standard of care agents in several murine xenograft tumor models (additional tumor growth inhibition of 37-53% (Dex) and 22-72% (lenalidomide)). These data provide a clear therapeutic hypothesis for the inhibition of PI3K and provide a rationale for clinical development of GDC-0941 in myeloma.	[Munugalavadla, V.; Mariathasan, S.; Slaga, D.; Du, C.; Berry, L.; Del Rosario, G.; Sun, L.; Friedman, L. S.; Ebens, A.] Genentech Inc, Dept Canc Immunotherapy & Hematol, San Francisco, CA 94080 USA; [Yan, Y.; Boe, M.] Genentech Inc, Dept Oncol Biomarker Dev, San Francisco, CA 94080 USA; [Chesi, M.; Bergsagel, P. Leif] Mayo Clin, Dept Med, Ctr Comprehens Canc, Scottsdale, AZ USA	Roche Holding; Genentech; Roche Holding; Genentech; Mayo Clinic; Mayo Clinic Phoenix	Munugalavadla, V (corresponding author), Genentech Inc, Dept Canc Immunotherapy & Hematol, 1 DNA Way,MS 231C,Room 14-3166, San Francisco, CA 94080 USA.	veerendm@gene.com	Bergsagel, Peter Leif/A-7842-2011; Du, Changchun/AAW-6540-2020	Bergsagel, Peter Leif/0000-0003-1523-7388; 				Anderson KC, 2011, ANNU REV PATHOL-MECH, V6, P249, DOI 10.1146/annurev-pathol-011110-130249; Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Baumann P, 2009, EXP CELL RES, V315, P485, DOI 10.1016/j.yexcr.2008.11.007; Chanan-Khan AA, BR J HAEMATOL, V151, P3; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Dib Amel, 2008, J Natl Cancer Inst Monogr, P25, DOI 10.1093/jncimonographs/lgn011; Drexler HG, 2000, LEUKEMIA RES, V24, P681, DOI 10.1016/S0145-2126(99)00195-2; Ebens A, 2010, ASH ANN M, V116, P3001; Feldman ME, CURR TOP MICROBIOL I, V347, P241; Folkes AJ, 2008, J MED CHEM, V51, P5522, DOI 10.1021/jm800295d; Gera J, 2011, LEUKEMIA LYMPHOMA, V52, P1857, DOI 10.3109/10428194.2011.580478; Harvey R Donald, 2007, Future Oncol, V3, P639, DOI 10.2217/14796694.3.6.639; Hoang B, 2010, BLOOD, V116, P4560, DOI 10.1182/blood-2010-05-285726; Ikeda H, 2010, BLOOD, V116, P1460, DOI 10.1182/blood-2009-06-222943; Ismail SI, 2010, LEUKEMIA RES, V34, P824, DOI 10.1016/j.leukres.2009.11.018; Jou ST, 2002, MOL CELL BIOL, V22, P8580, DOI 10.1128/MCB.22.24.8580-8591.2002; Kawauchi K, 2009, ANTI-CANCER AGENT ME, V9, P1024, DOI 10.2174/187152009789377772; Kawauchi K, 2009, ANTI-CANCER AGENT ME, V9, P550, DOI 10.2174/187152009788451851; Khwaja A, CURR TOP MICROBIOL I, V347, P169; Kyle RA, 2004, NEW ENGL J MED, V351, P1860, DOI 10.1056/NEJMra041875; Kyle RA, 2009, CLIN LYMPHOMA MYELOM, V9, P278, DOI 10.3816/CLM.2009.n.056; Lee T, 2008, PLOS COMPUT BIOL, V4, DOI 10.1371/journal.pcbi.1000013; McMillin DW, 2009, CANCER RES, V69, P5835, DOI 10.1158/0008-5472.CAN-08-4285; Munugalavadla V, 2010, ASH ANN M, V116, P4084; Munugalavadla V, 2008, MOL CELL BIOL, V28, P7182, DOI 10.1128/MCB.00920-08; O'Brien C, CLIN CANC RES, V16, P3670; Peterson TR, 2009, CELL, V137, P873, DOI 10.1016/j.cell.2009.03.046; Podar K, 2009, LEUKEMIA, V23, P10, DOI 10.1038/leu.2008.259; Rahmani M, 2009, BLOOD, V114, P4507, DOI 10.1182/blood-2008-09-177881; Rajkurnar SV, 2007, BEST PRACT RES CL HA, V20, P665, DOI 10.1016/j.beha.2007.10.002; Raynaud FI, 2009, MOL CANCER THER, V8, P1725, DOI 10.1158/1535-7163.MCT-08-1200; Yasui H, 2006, BRIT J HAEMATOL, V132, P385, DOI 10.1111/j.1365-2141.2005.05860.x; Zhang J, 2003, ONCOGENE, V22, P6289, DOI 10.1038/sj.onc.1206718; Zhao L, 2004, CLIN CANCER RES, V10, P7994, DOI 10.1158/1078-0432.CCR-04-1087; Zollinger A, 2008, BLOOD, V112, P3403, DOI 10.1182/blood-2007-11-119362	35	31	34	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2014	33	3					316	325		10.1038/onc.2012.594	http://dx.doi.org/10.1038/onc.2012.594			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VR	23318440				2022-12-28	WOS:000330214000006
J	Ichim, G; Mola, M; Finkbeiner, MG; Cros, MP; Herceg, Z; Hernandez-Vargas, H				Ichim, G.; Mola, M.; Finkbeiner, M. G.; Cros, M-P; Herceg, Z.; Hernandez-Vargas, H.			The histone acetyltransferase component TRRAP is targeted for destruction during the cell cycle	ONCOGENE			English	Article						APC; Cdc20; Cdh1; TRRAP; mitosis; cell cycle	ANAPHASE-PROMOTING COMPLEX/CYCLOSOME; EARLY MITOTIC DEGRADATION; HAT COFACTOR TRRAP; CHROMATIN; MITOSIS; PROGRESSION; COMPLEX; ACETYLATION; TRANSCRIPTION; CHECKPOINT	Chromosomes are dynamic structures that must be reversibly condensed and unfolded to accommodate mitotic division and chromosome segregation. Histone modifications are involved in the striking chromatin reconfiguration taking place during mitosis. However, the mechanisms that regulate activity and function of histone-modifying factors as cells enter and exit mitosis are poorly understood. Here, we show that the anaphase-promoting complex or cyclosome (APC/C) is involved in the mitotic turnover of TRRAP (TRansformation/tRanscription domain-Associated Protein), a common component of histone acetyltransferase (HAT) complexes, and that the pre-mitotic degradation of TRRAP is mediated by the APC/C ubiquitin ligase activators Cdc20 and Cdh1. Ectopic expression of both Cdh1 and Cdc20 reduced the levels of coexpressed TRRAP protein and induced its ubiquitination. TRRAP overexpression or stabilization induces multiple mitotic defects, including lagging chromosomes, chromosome bridges and multipolar spindles. In addition, lack of sister chromatid cohesion and impaired chromosome condensation were found after TRRAP overexpression or stabilization. By using a truncated form of TRRAP, we show that mitotic delay is associated with a global histone H4 hyperacetylation induced by TRRAP overexpression. These results demonstrate that the chromatin modifier TRRAP is targeted for destruction in a cell cycle-dependent fashion. They also suggest that degradation of TRRAP by the APC/C is necessary for a proper condensation of chromatin and proper chromosome segregation. Chromatin compaction mediated by histone modifiers may represent a fundamental arm for APC/C orchestration of the mitotic machinery.	[Ichim, G.; Mola, M.; Finkbeiner, M. G.; Cros, M-P; Herceg, Z.; Hernandez-Vargas, H.] Int Agcy Res Canc IARC, Epigenet Grp, F-69008 Lyon, Rhone Alpes, France	World Health Organization; International Agency for Research on Cancer (IARC)	Herceg, Z (corresponding author), Int Agcy Res Canc IARC, Epigenet Grp, 150 Rue Albert Thomas, F-69008 Lyon, Rhone Alpes, France.	herceg@iarc.fr; vargash@iarc.fr	Ichim, Gabriel/AAJ-5822-2021	Hernandez-Vargas, Hector/0000-0001-6045-2103; Ichim, Gabriel/0000-0002-8386-7405	Association pour la Recherche sur le Cancer (ARC), France; la Ligue Nationale (Francaise) Contre le Cancer (France); Institut National du Cancer (INCA, France); Association for International Cancer Research (AICR), UK	Association pour la Recherche sur le Cancer (ARC), France(Fondation ARC pour la Recherche sur le Cancer); la Ligue Nationale (Francaise) Contre le Cancer (France)(Ligue nationale contre le cancer); Institut National du Cancer (INCA, France)(Institut National du Cancer (INCA) France); Association for International Cancer Research (AICR), UK	We thank Michael Cole for generous gift of the TRRAP expression vector. This work was supported by the Association pour la Recherche sur le Cancer (ARC), France, la Ligue Nationale (Francaise) Contre le Cancer (France), the Institut National du Cancer (INCA, France) and the Association for International Cancer Research (AICR), UK.	Amador V, 2007, MOL CELL, V27, P462, DOI 10.1016/j.molcel.2007.06.013; Cheung P, 2000, CELL, V103, P263, DOI 10.1016/S0092-8674(00)00118-5; Cummings WJ, 2007, PLOS BIOL, V5, P2145, DOI 10.1371/journal.pbio.0050246; Deran M, 2008, MOL CELL BIOL, V28, P435, DOI 10.1128/MCB.00607-07; Eot-Houllier G, 2008, GENE DEV, V22, P2639, DOI 10.1101/gad.484108; Fu GS, 2007, CELL RES, V17, P608, DOI 10.1038/cr.2007.55; Gabellini D, 2003, EMBO J, V22, P3715, DOI 10.1093/emboj/cdg340; Geley S, 2001, J CELL BIOL, V153, P137, DOI 10.1083/jcb.153.1.137; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hayes MJ, 2006, NAT CELL BIOL, V8, P607, DOI 10.1038/ncb1410; Herceg Z, 2001, NAT GENET, V29, P206, DOI 10.1038/ng725; Herceg Z, 2005, CELL CYCLE, V4, P383, DOI 10.4161/cc.4.3.1546; Herceg Z, 2003, NUCLEIC ACIDS RES, V31, P7011, DOI 10.1093/nar/gkg902; Hernandez-Vargas H, 2007, ONCOGENE, V26, P2902, DOI 10.1038/sj.onc.1210102; Kruhlak MJ, 2001, J BIOL CHEM, V276, P38307; Li H, 2004, EMBO J, V23, P4824, DOI 10.1038/sj.emboj.7600479; Murr R, 2007, ONCOGENE, V26, P5358, DOI 10.1038/sj.onc.1210605; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; Ono T, 2004, MOL BIOL CELL, V15, P3296, DOI 10.1091/mbc.E04-03-0242; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Pfleger CM, 2001, GENE DEV, V15, P2396, DOI 10.1101/gad.918201; Ramaswamy V, 2003, MOL CELL BIOL, V23, P9136, DOI 10.1128/MCB.23.24.9136-9149.2003; Robert F, 2006, MOL CELL BIOL, V26, P402, DOI 10.1128/MCB.26.2.402-412.2006; Sapountzi V, 2006, INT J BIOCHEM CELL B, V38, P1496, DOI 10.1016/j.biocel.2006.03.003; Schueler MG, 2006, ANNU REV GENOM HUM G, V7, P301, DOI 10.1146/annurev.genom.7.080505.115613; Song L, 2011, CELL CYCLE, V10, P52, DOI 10.4161/cc.10.1.14387; Turnell AS, 2005, NATURE, V438, P690, DOI 10.1038/nature04151; Valls E, 2005, J BIOL CHEM, V280, P42592, DOI 10.1074/jbc.M507407200; Vernarecci S, 2008, MOL CELL BIOL, V28, P988, DOI 10.1128/MCB.01366-07; Wu SM, 2010, GENE DEV, V24, P2531, DOI 10.1101/gad.1984210	30	17	19	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2014	33	2					181	192		10.1038/onc.2012.570	http://dx.doi.org/10.1038/onc.2012.570			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286BY	23318449				2022-12-28	WOS:000329440700006
J	Ogami, K; Hosoda, N; Funakoshi, Y; Hoshino, S				Ogami, K.; Hosoda, N.; Funakoshi, Y.; Hoshino, S.			Antiproliferative protein Tob directly regulates c-myc proto-oncogene expression through cytoplasmic polyadenylation element-binding protein CPEB	ONCOGENE			English	Article						Tob; Caf1; CPEB; mRNA decay; deadenylation	MESSENGER-RNA TRANSLATION; CELL-CYCLE PROGRESSION; POLY(A)-BINDING PROTEIN; GROWTH-FACTORS; DEADENYLASE; IDENTIFICATION; COMPLEX; CAF1; PROLIFERATION; HIPPOCAMPUS	The regulation of mRNA deadenylation constitutes a pivotal mechanism of the post-transcriptional control of gene expression. Here we show that the antiproliferative protein Tob, a component of the Caf1-Ccr4 deadenylase complex, is involved in regulating the expression of the proto-oncogene c-myc. The c-myc mRNA contains cis elements (CPEs) in its 3'-untranslated region (3'-UTR), which are recognized by the cytoplasmic polyadenylation element-binding protein (CPEB). CPEB recruits Caf1 deadenylase through interaction with Tob to form a ternary complex, CPEB-Tob-Caf1, and negatively regulates the expression of c-myc by accelerating the deadenylation and decay of its mRNA. In quiescent cells, c-myc mRNA is destabilized by the trans-acting complex (CPEB-Tob-Caf1), while in cells stimulated by the serum, both Tob and Caf1 are released from CPEB, and c-Myc expression is induced early after stimulation by the stabilization of its mRNA as an 'immediate-early gene'. Collectively, these results indicate that Tob is a key factor in the regulation of c-myc gene expression, which is essential for cell growth. Thus, Tob appears to function in the control of cell growth at least, in part, by regulating the expression of c-myc.	[Ogami, K.; Hosoda, N.; Funakoshi, Y.; Hoshino, S.] Nagoya City Univ, Grad Sch Pharmaceut Sci, Dept Biol Chem, Nagoya, Aichi 4678603, Japan	Nagoya City University	Hoshino, S (corresponding author), Nagoya City Univ, Grad Sch Pharmaceut Sci, Dept Biol Chem, Mizuho Ku, 3-1 Tanabe Dori, Nagoya, Aichi 4678603, Japan.	hoshino@phar.nagoya-cu.ac.jp	Ogami, Koichi/K-1160-2019	Ogami, Koichi/0000-0001-9380-9666; Hoshino, Shinichi/0000-0001-6135-7896	Ministry of Education, Culture, Sports, Science and Technology of Japan [20112006]; Grants-in-Aid for Scientific Research [24770116] Funding Source: KAKEN	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank A-B Shyu for anti-Caf1 antibody. This work was supported by a Grant-in-Aid for Scientific Research on Innovative Areas 'RNA regulation' (No. 20112006) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Arumugam K, 2010, EMBO J, V29, P387, DOI 10.1038/emboj.2009.337; Aslam A, 2009, MOL BIOL CELL, V20, P3840, DOI 10.1091/mbc.E09-02-0146; Barnard DC, 2004, CELL, V119, P641, DOI 10.1016/j.cell.2004.10.029; Belloc E, 2008, NATURE, V452, P1017, DOI 10.1038/nature06809; Bianchin C, 2005, RNA, V11, P487, DOI 10.1261/rna.7135305; BLANCHARD JM, 1985, NATURE, V317, P443, DOI 10.1038/317443a0; Burns DM, 2008, GENE DEV, V22, P3449, DOI 10.1101/gad.1697808; DEAN M, 1986, J BIOL CHEM, V261, P9161; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; Eckmann CR, 2011, WIRES RNA, V2, P348, DOI 10.1002/wrna.56; ELLIS RE, 1995, GENETICS, V139, P561; Funakoshi Y, 2007, GENE DEV, V21, P3135, DOI 10.1101/gad.1597707; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; Groisman I, 2002, CELL, V109, P473, DOI 10.1016/S0092-8674(02)00733-X; Groisman I, 2006, GENE DEV, V20, P2701, DOI 10.1101/gad.1438906; Horiuchi M, 2009, J BIOL CHEM, V284, P13244, DOI 10.1074/jbc.M809250200; Hosoda N, 2011, EMBO J, V30, P1311, DOI 10.1038/emboj.2011.37; IIZUKA N, 1994, MOL CELL BIOL, V14, P7322, DOI 10.1128/MCB.14.11.7322; Ikematsu N, 1999, ONCOGENE, V18, P7432, DOI 10.1038/sj.onc.1203193; Jin M, 2005, NEUROSCIENCE, V131, P647, DOI 10.1016/j.neuroscience.2004.10.044; Kerkhoff E, 1998, ONCOGENE, V16, P211, DOI 10.1038/sj.onc.1201520; Kim JH, 2006, MOL CELL, V24, P173, DOI 10.1016/j.molcel.2006.08.016; Kim KC, 2011, J NEUROSCI, V31, P12118, DOI 10.1523/JNEUROSCI.1621-11.2011; KINDY MS, 1986, J BIOL CHEM, V261, P2865; Korner CG, 1998, EMBO J, V17, P5427, DOI 10.1093/emboj/17.18.5427; Macnicol MC, 2010, MOL REPROD DEV, V77, P662, DOI 10.1002/mrd.21191; Maekawa M, 2002, J BIOL CHEM, V277, P37783, DOI 10.1074/jbc.M204506200; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Novoa I, 2010, NAT CELL BIOL, V12, P447, DOI 10.1038/ncb2046; Okochi K, 2005, GENES CELLS, V10, P151, DOI 10.1111/j.1365-2443.2005.00826.x; Pique M, 2008, CELL, V132, P434, DOI 10.1016/j.cell.2007.12.038; Ren YG, 2002, J BIOL CHEM, V277, P5982, DOI 10.1074/jbc.M111515200; Ruan L, 2010, J BIOL CHEM, V285, P27624, DOI 10.1074/jbc.M110.138867; Suzuki T, 2002, GENE DEV, V16, P1356, DOI 10.1101/gad.962802; Tzachanis D, 2001, NAT IMMUNOL, V2, P1174, DOI 10.1038/ni730; Uchida N, 2004, J BIOL CHEM, V279, P1383, DOI 10.1074/jbc.M309125200; Viswanathan P, 2004, J BIOL CHEM, V279, P23988, DOI 10.1074/jbc.M402803200; Wang XM, 2006, BIOCHEM BIOPH RES CO, V340, P1023, DOI 10.1016/j.bbrc.2005.12.125; Wang YY, 2008, DEV BIOL, V317, P454, DOI 10.1016/j.ydbio.2008.02.033; Wu L, 1998, NEURON, V21, P1129, DOI 10.1016/S0896-6273(00)80630-3; Wu XY, 2012, GENE, V500, P10, DOI 10.1016/j.gene.2012.03.021; Xiong B, 2006, DEV CELL, V11, P225, DOI 10.1016/j.devcel.2006.06.012; Yamashita A, 2005, NAT STRUCT MOL BIOL, V12, P1054, DOI 10.1038/nsmb1016; Yoshida Y, 2000, CELL, V103, P1085, DOI 10.1016/S0092-8674(00)00211-7; Zearfoss NR, 2008, J NEUROSCI, V28, P8502, DOI 10.1523/JNEUROSCI.1756-08.2008	45	32	35	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2014	33	1					55	64		10.1038/onc.2012.548	http://dx.doi.org/10.1038/onc.2012.548			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	282YU	23178487				2022-12-28	WOS:000329212000007
J	Kamranvar, SA; Chen, X; Masucci, MG				Kamranvar, S. A.; Chen, X.; Masucci, M. G.			Telomere dysfunction and activation of alternative lengthening of telomeres in B-lymphocytes infected by Epstein-Barr virus	ONCOGENE			English	Article						EBV; telomere; telomerase; ALT; shelterin; TRF2	LYMPHOBLASTOID CELL-LINES; PROMOTES GENOMIC INSTABILITY; HOMOLOGOUS RECOMBINATION; CHROMOSOME ENDS; MAMMALIAN TELOMERES; PROTECTS TELOMERES; PML BODY; MAINTENANCE; TRF2; DAMAGE	Malignant cells achieve replicative immortality by two alternative mechanisms, a common one dependent on de novo synthesis of telomeric DNA by telomerase, and a rare one based on telomere recombination known as alternative lengthening of telomeres (ALT). Epstein-Barr virus (EBV) transforms human B-lymphocytes into lymphoblastoid cell lines with unlimited growth potential in vitro and in vivo. Here we show that newly EBV-infected cells exhibit multiple signs of telomere dysfunction, including the occurrence of extra-chromosomal telomeres, telomere fusion and telomere length heterogeneity, and undergo progressive increase in telomere length without a parallel increase in telomerase activity. This phenotype is accompanied by the accumulation of telomere-associated promyelocytic leukemia nuclear bodies and telomeric-sister chromatid exchange, suggesting that EBV infection promotes the activation of ALT. Newly infected cells also display a significant reduction of telomere-associated TRF2 and express low levels of TRF1, TRF2, POT1 and ATRX, pointing to telomere de-protection as an important correlate of ALT activation. Collectively, these findings highlight the involvement of recombination-dependent mechanisms for maintenance of telomere homeostasis in EBV-induced B-cell immortalization.	[Kamranvar, S. A.; Chen, X.; Masucci, M. G.] Karolinska Inst, Dept Cell & Mol Biol, S-17177 Stockholm, Sweden	Karolinska Institutet	Masucci, MG (corresponding author), Karolinska Inst, Dept Cell & Mol Biol, Box 285, S-17177 Stockholm, Sweden.	maria.masucci@ki.se	Masucci, Maria/AAC-6666-2019	Masucci, Maria/0000-0002-5541-2809; Chen, Xinsong/0000-0002-3214-9075	Swedish Cancer Society; Swedish Medical Research Council; Karolinska Institutet, Stockholm, Sweden; China Scholarship Council	Swedish Cancer Society(Swedish Cancer Society); Swedish Medical Research Council(Swedish Medical Research Council (SMRC)); Karolinska Institutet, Stockholm, Sweden; China Scholarship Council(China Scholarship Council)	This study was supported by grants awarded by the Swedish Cancer Society, the Swedish Medical Research Council and the Karolinska Institutet, Stockholm, Sweden. XC was supported by a fellowship awarded by the China Scholarship Council.	Azzalin CM, 2007, SCIENCE, V318, P798, DOI 10.1126/science.1147182; Bechter OE, 2003, EMBO REP, V4, P1138, DOI 10.1038/sj.embor.7400027; Bellon M, 2008, JNCI-J NATL CANCER I, V100, P98, DOI 10.1093/jnci/djm269; BIRD AG, 1981, NATURE, V289, P300, DOI 10.1038/289300a0; BLACKBURN EH, 1991, NATURE, V350, P569, DOI 10.1038/350569a0; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Bryan TM, 1997, NAT MED, V3, P1271, DOI 10.1038/nm1197-1271; Celli GB, 2006, NAT CELL BIOL, V8, P885, DOI 10.1038/ncb1444; Cerone MA, 2001, HUM MOL GENET, V10, P1945, DOI 10.1093/hmg/10.18.1945; Cesare AJ, 2010, NAT REV GENET, V11, P319, DOI 10.1038/nrg2763; Chen F, 2005, INT J CANCER, V113, P284, DOI 10.1002/ijc.20594; Chung I, 2012, NUCLEUS-PHILA, V3, P263, DOI 10.4161/nucl.20326; De La Fuente R, 2011, REPRODUCTION, V142, P221, DOI 10.1530/REP-10-0380; de Lange T, 2005, GENE DEV, V19, P2100, DOI 10.1101/gad.1346005; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; Denchi EL, 2007, NATURE, V448, P1068, DOI 10.1038/nature06065; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Ford LP, 2001, J BIOL CHEM, V276, P32198, DOI 10.1074/jbc.M104469200; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Gruhne B, 2009, P NATL ACAD SCI USA, V106, P2313, DOI 10.1073/pnas.0810619106; He H, 2006, EMBO J, V25, P5180, DOI 10.1038/sj.emboj.7601294; Henson JD, 2010, FEBS LETT, V584, P3800, DOI 10.1016/j.febslet.2010.06.009; Henson JD, 2009, NAT BIOTECHNOL, V27, P1181, DOI 10.1038/nbt.1587; Hockemeyer D, 2005, EMBO J, V24, P2667, DOI 10.1038/sj.emboj.7600733; Hu J, 2012, CELL, V148, P651, DOI 10.1016/j.cell.2011.12.028; Kamranvar SA, 2007, ONCOGENE, V26, P5115, DOI 10.1038/sj.onc.1210324; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Karlseder J, 2002, SCIENCE, V295, P2446, DOI 10.1126/science.1069523; Kataoka H, 1997, DIFFERENTIATION, V62, P203; Kim S, 2004, J BIOL CHEM, V279, P43799, DOI 10.1074/jbc.M408650200; Lacoste S, 2010, ONCOGENE, V29, P503, DOI 10.1038/onc.2009.359; Lenoir GM, 1985, IARC SCI PUBL, V60, P308; Lovejoy CA, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002772; Makarov VL, 1997, CELL, V88, P657, DOI 10.1016/S0092-8674(00)81908-X; Martinez P, 2011, NAT REV CANCER, V11, P161, DOI 10.1038/nrc3025; Mei YP, 2006, CANCER LETT, V232, P189, DOI 10.1016/j.canlet.2005.02.010; MILLER G, 1972, P NATL ACAD SCI USA, V69, P383, DOI 10.1073/pnas.69.2.383; Nikitin PA, 2010, CELL HOST MICROBE, V8, P510, DOI 10.1016/j.chom.2010.11.004; O'Connor MS, 2006, P NATL ACAD SCI USA, V103, P11874, DOI 10.1073/pnas.0605303103; Opresko PL, 2005, NUCLEIC ACIDS RES, V33, P1230, DOI 10.1093/nar/gki273; Palm W, 2008, ANNU REV GENET, V42, P301, DOI 10.1146/annurev.genet.41.110306.130350; Parish CR, 2009, CURRENT PROT IMMUNOL, V84; PURTILO DT, 1992, LAB INVEST, V67, P5; Ritchie K, 2008, J CELL BIOL, V180, P315, DOI 10.1083/jcb.200706083; Royle NJ, 2008, CYTOGENET GENOME RES, V122, P281, DOI 10.1159/000167814; Sfeir A, 2010, SCIENCE, V327, P1657, DOI 10.1126/science.1185100; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Sugimoto M, 1999, MECH AGEING DEV, V107, P51, DOI 10.1016/S0047-6374(98)00131-6; Sugimoto M, 2004, CANCER RES, V64, P3361, DOI 10.1158/0008-5472.CAN-04-0079; Takai H, 2003, CURR BIOL, V13, P1549, DOI 10.1016/S0960-9822(03)00542-6; Terrin L, 2008, J VIROL, V82, P10175, DOI 10.1128/JVI.00321-08; TORSTEINSDOTTIR S, 1991, CELL IMMUNOL, V137, P501, DOI 10.1016/0008-8749(91)90097-U; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; vanSteensel B, 1997, NATURE, V385, P740, DOI 10.1038/385740a0; Von Zglinicki T, 2000, ANN NY ACAD SCI, V908, P99, DOI 10.1111/j.1749-6632.2000.tb06639.x; Walker JR, 2012, MECH AGEING DEV, V133, P421, DOI 10.1016/j.mad.2012.05.002; Wang RC, 2004, CELL, V119, P355, DOI 10.1016/j.cell.2004.10.011; Xia T, 2008, CANCER RES, V68, P1436, DOI 10.1158/0008-5472.CAN-07-5126; Yang J, 2004, J EXP CLIN CANC RES, V23, P495; Yeager TR, 1999, CANCER RES, V59, P4175; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452; Young LS, 2003, ONCOGENE, V22, P5108, DOI 10.1038/sj.onc.1206556	63	36	38	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2013	32	49					5522	5530		10.1038/onc.2013.189	http://dx.doi.org/10.1038/onc.2013.189			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	269XF	23708666	hybrid, Green Published			2022-12-28	WOS:000328276400003
J	Karantanos, T; Corn, PG; Thompson, TC				Karantanos, T.; Corn, P. G.; Thompson, T. C.			Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches	ONCOGENE			English	Review						castrate-resistant prostate cancer; ADT; alternative pathways	EPITHELIAL-MESENCHYMAL TRANSITION; RECEPTOR TRANSCRIPTIONAL ACTIVITY; SUPPRESSES TUMOR-GROWTH; BETA-CATENIN; IN-VIVO; GENE-EXPRESSION; SIGNALING AXIS; BREAST-CANCER; UP-REGULATION; SIPULEUCEL-T	Prostate cancer is the second-leading cause of cancer-related mortality in men in Western societies. Androgen receptor (AR) signaling is a critical survival pathway for prostate cancer cells, and androgen-deprivation therapy (ADT) remains the principal treatment for patients with locally advanced and metastatic disease. Although a majority of patients initially respond to ADT, most will eventually develop castrate resistance, defined as disease progression despite serum testosterone levels of <20 ng/dl. The recent discovery that AR signaling persists during systemic castration via intratumoral production of androgens led to the development of novel anti-androgen therapies including abiraterone acetate and enzalutamide. Although these agents effectively palliate symptoms and prolong life, metastatic castration-resistant prostate cancer remains incurable. An increased understanding of the mechanisms that underlie the pathogenesis of castrate resistance is therefore needed to develop novel therapeutic approaches for this disease. The aim of this review is to summarize the current literature on the biology and treatment of castrate-resistant prostate cancer.	[Karantanos, T.; Corn, P. G.; Thompson, T. C.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol Res, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Thompson, TC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol Res, Unit 18 3,1515 Holcombe Blvd, Houston, TX 77030 USA.	timthomp@mdanderson.org	KARANTANOS, THEODOROS/ABH-7600-2020	KARANTANOS, THEODOROS/0000-0002-6792-8298	National Institutes of Health [5 P30 CA016672]; NATIONAL CANCER INSTITUTE [P50CA140388, P30CA016672] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research is supported in part by the National Institutes of Health through MD Anderson's Cancer Center Support Grant, 5 P30 CA016672. We thank Karen F Phillips, ELS, for her expert editorial assistance.	Acevedo VD, 2007, CANCER CELL, V12, P559, DOI 10.1016/j.ccr.2007.11.004; Agoulnik IU, 2006, CANCER RES, V66, P10594, DOI 10.1158/0008-5472.CAN-06-1023; Aitchison AA, 2008, PROSTATE, V68, P661, DOI 10.1002/pros.20730; Attard G, 2009, CANCER CELL, V16, P458, DOI 10.1016/j.ccr.2009.11.006; Bakin RE, 2003, CANCER RES, V63, P1975; Baserga R, 2003, INT J CANCER, V107, P873, DOI 10.1002/ijc.11487; Bernard D, 2003, J CLIN INVEST, V112, P1724; Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261; Brognard J, 2007, MOL CELL, V25, P917, DOI 10.1016/j.molcel.2007.02.017; Bubendorf L, 1999, CANCER RES, V59, P803; Burfeind P, 1996, P NATL ACAD SCI USA, V93, P7263, DOI 10.1073/pnas.93.14.7263; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Chang KH, 2011, P NATL ACAD SCI USA, V108, P13728, DOI 10.1073/pnas.1107898108; Chee KG, 2007, CLIN GENITOURIN CANC, V5, P433, DOI 10.3816/CGC.2007.n.031; Chen CD, 2004, NAT MED, V10, P33, DOI 10.1038/nm972; Chesire DR, 2002, ONCOGENE, V21, P8453, DOI 10.1038/sj.onc.1206049; Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641; CULIG Z, 1993, MOL ENDOCRINOL, V7, P1541, DOI 10.1210/me.7.12.1541; Dai BJ, 2010, CANCER RES, V70, P5587, DOI 10.1158/0008-5472.CAN-09-4610; Dayyani F, 2011, JNCI-J NATL CANCER I, V103, P1665, DOI 10.1093/jnci/djr362; De Bono JS, 2011, NEW ENGL J MED, V364, P1995, DOI 10.1056/NEJMoa1014618; de la Taille A, 2003, CLIN CANCER RES, V9, P1801; Dehm SM, 2007, CANCER RES, V67, P10067, DOI 10.1158/0008-5472.CAN-07-1267; Dehm SM, 2011, ENDOCR-RELAT CANCER, V18, pR183, DOI 10.1530/ERC-11-0141; Ding ZH, 2011, NATURE, V470, P269, DOI 10.1038/nature09677; Edwards J, 2003, BRIT J CANCER, V89, P552, DOI 10.1038/sj.bjc.6601127; Efstathiou E, 2012, J CLIN ONCOL, V30, P637, DOI 10.1200/JCO.2010.33.7675; EGAWA S, 1992, MOL CARCINOGEN, V5, P52, DOI 10.1002/mc.2940050110; Ellwood-Yen K, 2003, CANCER CELL, V4, P223, DOI 10.1016/S1535-6108(03)00197-1; Faubert B, 2013, CELL METAB, V17, P113, DOI 10.1016/j.cmet.2012.12.001; Fizazi K, 2012, LANCET ONCOL, V13, P983, DOI 10.1016/S1470-2045(12)70379-0; Gao H, 2006, CANCER RES, V66, P7929, DOI 10.1158/0008-5472.CAN-06-1637; Gregory CW, 2001, CANCER RES, V61, P4315; Guo ZY, 2006, CANCER CELL, V10, P309, DOI 10.1016/j.ccr.2006.08.021; Gurel B, 2008, MODERN PATHOL, V21, P1156, DOI 10.1038/modpathol.2008.111; Ha S, 2011, ENDOCR-RELAT CANCER, V18, P245, DOI 10.1530/ERC-10-0204; Haapala K, 2001, LAB INVEST, V81, P1647, DOI 10.1038/labinvest.3780378; Harris WP, 2009, NAT CLIN PRACT UROL, V6, P76, DOI 10.1038/ncpuro1296; Heidegger I, 2012, ENDOCRINOLOGY, V153, P4633, DOI 10.1210/en.2012-1348; Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809; Heuberger J, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a002915; Higano CS, 2009, CANCER-AM CANCER SOC, V115, P3670, DOI 10.1002/cncr.24429; Holzbeierlein J, 2004, AM J PATHOL, V164, P217, DOI 10.1016/S0002-9440(10)63112-4; Hu R, 2012, CANCER RES, V72, P3457, DOI 10.1158/0008-5472.CAN-11-3892; Hu R, 2011, PROSTATE, V71, P1656, DOI 10.1002/pros.21382; HUGGINS C, 1946, JAMA-J AM MED ASSOC, V131, P576, DOI 10.1001/jama.1946.02870240008003; Iwata T, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009427; Jeter CR, 2011, ONCOGENE, V30, P3833, DOI 10.1038/onc.2011.114; Jiao J, 2007, CANCER RES, V67, P6083, DOI 10.1158/0008-5472.CAN-06-4202; Jones E, 2009, EXPERT OPIN THER TAR, V13, P227, DOI [10.1517/14728220802705696, 10.1517/14728220802705696 ]; Kantoff PW, 2010, NEW ENGL J MED, V363, P411, DOI 10.1056/NEJMoa1001294; Karan D, 2002, CARCINOGENESIS, V23, P967, DOI 10.1093/carcin/23.6.967; Kinkade CW, 2008, J CLIN INVEST, V118, P3051, DOI 10.1172/JCI34764; Knudsen BS, 2002, UROLOGY, V60, P1113, DOI 10.1016/S0090-4295(02)01954-4; Kypta RM, 2012, NAT REV UROL, V9, P418, DOI 10.1038/nrurol.2012.116; Lai SL, 2009, CELL RES, V19, P532, DOI 10.1038/cr.2009.41; LeRoith D, 2003, CANCER LETT, V195, P127, DOI 10.1016/S0304-3835(03)00159-9; Li LK, 2009, MOL CANCER RES, V7, P1781, DOI 10.1158/1541-7786.MCR-09-0255; Li LK, 2003, MOL CELL BIOL, V23, P9389, DOI 10.1128/MCB.23.24.9389-9404.2003; Li LK, 2001, CANCER RES, V61, P4386; Li Y, 2012, ONCOGENE, V31, P4759, DOI 10.1038/onc.2011.637; Li Y., 2012, CANCER RES, V73, P483; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lin YS, 2010, BIOSCIENCE REP, V30, P285, DOI 10.1042/BSR20100020; Locke JA, 2008, CANCER RES, V68, P6407, DOI 10.1158/0008-5472.CAN-07-5997; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Mahajan K, 2010, PROSTATE, V70, P1274, DOI 10.1002/pros.21163; Mao XY, 2010, CANCER RES, V70, P5207, DOI 10.1158/0008-5472.CAN-09-4074; Marques RB, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013500; Massie CE, 2011, EMBO J, V30, P2719, DOI 10.1038/emboj.2011.158; Mellinghoff IK, 2004, CANCER CELL, V6, P517, DOI 10.1016/j.ccr.2004.09.031; Memarzadeh S, 2007, CANCER CELL, V12, P572, DOI 10.1016/j.ccr.2007.11.002; Mitsiades N, 2012, CANCER RES, V72, P6142, DOI 10.1158/0008-5472.CAN-12-1335; Mohler JL, 2004, CLIN CANCER RES, V10, P440, DOI 10.1158/1078-0432.CCR-1146-03; Montgomery RB, 2008, CANCER RES, V68, P4447, DOI 10.1158/0008-5472.CAN-08-0249; Moon JS, 2011, BIOCHEM J, V433, P225, DOI 10.1042/BJ20101104; Mouraviev V, 2002, J UROLOGY, V168, P1589, DOI 10.1016/S0022-5347(05)64526-0; Mulholland DJ, 2012, CANCER RES, V72, P1878, DOI 10.1158/0008-5472.CAN-11-3132; Mulholland DJ, 2011, CANCER CELL, V19, P792, DOI 10.1016/j.ccr.2011.05.006; Mulholland DJ, 2005, ENDOCR REV, V26, P898, DOI 10.1210/er.2003-0034; Mulholland DJ, 2003, ONCOGENE, V22, P5602, DOI 10.1038/sj.onc.1206802; Mulholland DJ, 2002, J BIOL CHEM, V277, P17933, DOI 10.1074/jbc.M200135200; Muranen T, 2012, CANCER CELL, V21, P227, DOI 10.1016/j.ccr.2011.12.024; Nakabayashi M, 2012, BJU INT, V110, P1729, DOI 10.1111/j.1464-410X.2012.11456.x; Nakano A, 2012, J BIOENERG BIOMEMBR, V44, P31, DOI 10.1007/s10863-012-9412-9; Nasu Y, 1998, NAT MED, V4, P1062, DOI 10.1038/2048; Nickerson T, 2001, CANCER RES, V61, P6276; Nupponen NN, 1998, AM J PATHOL, V153, P141, DOI 10.1016/S0002-9440(10)65554-X; Ozen M, 2001, J NATL CANCER I, V93, P1783, DOI 10.1093/jnci/93.23.1783; Padua D, 2009, CELL RES, V19, P89, DOI 10.1038/cr.2008.316; Pandini G, 2005, CANCER RES, V65, P1849, DOI 10.1158/0008-5472.CAN-04-1837; Qi W, 2011, J ANDROL, V33, P27, DOI 10.2164/jandrol.110.011999; Qi W, 2008, BIOCHEM J, V416, P453, DOI 10.1042/BJ20080651; Ros S, 2012, CANCER DISCOV, V2, P328, DOI 10.1158/2159-8290.CD-11-0234; Ruiz C, 2011, P NATL ACAD SCI USA, V108, P12054, DOI 10.1073/pnas.1104009108; Ryan CJ, 2013, NEW ENGL J MED, V368, P138, DOI 10.1056/NEJMoa1209096; Sadar MD, 2011, CANCER RES, V71, P1208, DOI 10.1158/0008-5472.CAN_10-3398; Saloniemi T, 2012, J ENDOCRINOL, V212, P27, DOI 10.1530/JOE-11-0315; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Scher HI, 2012, NEW ENGL J MED, V367, P1187, DOI 10.1056/NEJMoa1207506; Scher HI, 2010, LANCET, V375, P1437, DOI 10.1016/S0140-6736(10)60172-9; Sharma A, 2010, J CLIN INVEST, V120, P4478, DOI 10.1172/JCI44239; Shatz M, 2008, INT J RADIAT BIOL, V84, P177, DOI 10.1080/09553000701745293; Sirotnak FM, 2004, MOL CARCINOGEN, V41, P150, DOI 10.1002/mc.20051; Small EJ, 2006, J CLIN ONCOL, V24, P3089, DOI 10.1200/JCO.2005.04.5252; Smith DC, 2013, J CLIN ONCOL, V31, P412, DOI 10.1200/JCO.2012.45.0494; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; STEINER MS, 1994, ENDOCRINOLOGY, V135, P2240, DOI 10.1210/en.135.5.2240; Steinkamp MP, 2009, CANCER RES, V69, P4434, DOI 10.1158/0008-5472.CAN-08-3605; Sternberg PW, 1999, NAT CELL BIOL, V1, pE35, DOI 10.1038/10028; Stiles B, 2004, DEV BIOL, V273, P175, DOI 10.1016/j.ydbio.2004.06.008; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; Sun YT, 2012, CANCER RES, V72, P527, DOI 10.1158/0008-5472.CAN-11-3004; Suzuki A, 2008, CANCER SCI, V99, P209, DOI 10.1111/j.1349-7006.2007.00670.x; Tahir SA, 2003, CLIN CANCER RES, V9, P3653; Tahir SA, 2008, CANCER RES, V68, P731, DOI 10.1158/0008-5472.CAN-07-2668; Tahir SA, 2006, CLIN CANCER RES, V12, P4872, DOI 10.1158/1078-0432.CCR-06-0417; Tahir SA, 2013, CANCER RES, V73, P1900, DOI 10.1158/0008-5472.CAN-12-3040; Tahir SA, 2013, CANCER BIOL THER, V14, P117, DOI 10.4161/cbt.22633; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Taplin ME, 1999, CANCER RES, V59, P2511; TAPLIN ME, 1995, NEW ENGL J MED, V332, P1393, DOI 10.1056/NEJM199505253322101; Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026; Thompson J, 2003, LAB INVEST, V83, P1709, DOI 10.1097/01.LAB.0000107262.40402.44; Thompson TC, 2010, PROSTATE CANCER P D, V13, P6, DOI 10.1038/pcan.2009.29; THOMPSON TC, 1989, CELL, V56, P917, DOI 10.1016/0092-8674(89)90625-9; TILLEY WD, 1990, CANCER RES, V50, P5382; Tran C, 2009, SCIENCE, V324, P787, DOI 10.1126/science.1168175; Truica CI, 2000, CANCER RES, V60, P4709; Ueda T, 2002, J BIOL CHEM, V277, P38087, DOI 10.1074/jbc.M203313200; Van Themsche C, 2007, J BIOL CHEM, V282, P4794, DOI 10.1074/jbc.M608497200; Varkaris A, 2011, EXPERT OPIN INV DRUG, V20, P1677, DOI 10.1517/13543784.2011.631523; Vaz CV, 2012, INT J BIOCHEM CELL B, V44, P2077, DOI 10.1016/j.biocel.2012.08.013; Verras M, 2007, CANCER RES, V67, P967, DOI 10.1158/0008-5472.CAN-06-3552; Vinals F, 2001, MOL CELL BIOL, V21, P7218, DOI 10.1128/MCB.21.21.7218-7230.2001; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; VISAKORPI T, 1995, CANCER RES, V55, P342; Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3; Wan XH, 2012, CLIN CANCER RES, V18, P726, DOI 10.1158/1078-0432.CCR-11-2521; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Wang SY, 2003, CANCER CELL, V4, P209, DOI 10.1016/S1535-6108(03)00215-0; Wang Y, 2008, ONCOGENE, V27, P7106, DOI 10.1038/onc.2008.318; Wikstrom P, 1998, PROSTATE, V37, P19, DOI 10.1002/(SICI)1097-0045(19980915)37:1<19::AID-PROS4>3.0.CO;2-3; Wilkes MC, 2005, CANCER RES, V65, P10431, DOI 10.1158/0008-5472.CAN-05-1522; Williams TM, 2005, AM J PHYSIOL-CELL PH, V288, pC494, DOI 10.1152/ajpcell.00458.2004; Xu JM, 2009, NAT REV CANCER, V9, P615, DOI 10.1038/nrc2695; Yang G, 1998, CLIN CANCER RES, V4, P1873; Yang G, 2012, MOL CANCER RES, V10, P218, DOI 10.1158/1541-7786.MCR-11-0451; Yee D, 2002, SEMIN ONCOL, V29, P86, DOI 10.1053/sonc.2002.34060; Yuan X, 2009, UROL ONCOL-SEMIN ORI, V27, P36, DOI 10.1016/j.urolonc.2008.03.021; Zhang WS, 2009, CANCER RES, V69, P7466, DOI 10.1158/0008-5472.CAN-08-4385; Zhang XJ, 2000, PROSTATE, V43, P278; Zhao XY, 2000, NAT MED, V6, P703, DOI 10.1038/76287; Zhao YH, 2011, CANCER RES, V71, P4585, DOI 10.1158/0008-5472.CAN-11-0127; Zhu ML, 2010, FASEB J, V24, P769, DOI 10.1096/fj.09-136994	155	486	493	6	101	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2013	32	49					5501	5511		10.1038/onc.2013.206	http://dx.doi.org/10.1038/onc.2013.206			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	269XF	23752182	Green Accepted, hybrid			2022-12-28	WOS:000328276400001
J	Wu, Q; Wang, H; Zhao, X; Shi, Y; Jin, M; Wan, B; Xu, H; Cheng, Y; Ge, H; Zhang, Y				Wu, Q.; Wang, H.; Zhao, X.; Shi, Y.; Jin, M.; Wan, B.; Xu, H.; Cheng, Y.; Ge, H.; Zhang, Y.			Identification of G-protein-coupled receptor 120 as a tumor-promoting receptor that induces angiogenesis and migration in human colorectal carcinoma	ONCOGENE			English	Article						GPR120; colorectal carcinoma; angiogenesis; migration	FREE FATTY-ACIDS; EPITHELIAL-MESENCHYMAL TRANSITION; NF-KAPPA-B; INSULIN-SECRETION; BREAST-CANCER; GPR120; CELLS; INFLAMMATION; BEVACIZUMAB; EXPRESSION	G-protein-coupled receptor 120 (GPR120) functions as a receptor for unsaturated long-chain free fatty acids and has an important role in regulating lipid and glucose metabolism. However, a role for GPR120 in the development of tumors has not yet been clarified. Here, we show that GPR120 signaling promotes angiogenic switching and motility of human colorectal carcinoma (CRC) cells. We show that the expression of GPR120 is significantly induced in CRC tissues and cell lines, which is associated with tumor progression. Activation of GPR120 signaling in human CRC promotes angiogenesis in vitro and in vivo, largely by inducing the expression and secretion of proangiogenic mediators such as vascular endothelial growth factor (VEGF), interleukin-8 and cyclooxygenase-2-derived prostaglandin E-2. The PI3K/Akt-NF-kappa B pathway is activated by GPR120 signaling and is required for GPR120 signaling-induced angiogenic switching in CRC cells. And, GPR120 activation enhances the motility of CRC cells and induces epithelial-mesenchymal transition. Furthermore, in vivo study shows that activation of GPR120 promotes angiogenesis and tumor growth. Finally, we find that GPR120 expression is positively correlated with VEGF expression and inversely correlated with the epithelial marker E-cadherin in CRC tissues. Collectively, our results demonstrate that GPR120 functions as a tumor-promoting receptor in CRC and, therefore, shows promise as a new potential target for cancer therapeutics.	[Wu, Q.; Wang, H.; Zhao, X.; Shi, Y.; Jin, M.; Wan, B.; Xu, H.; Cheng, Y.; Ge, H.; Zhang, Y.] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Key Lab Stem Cell Biol, Shanghai 200025, Peoples R China; [Wu, Q.; Wang, H.; Zhao, X.; Shi, Y.; Jin, M.; Wan, B.; Xu, H.; Cheng, Y.; Ge, H.; Zhang, Y.] Shanghai Jiao Tong Univ, Sch Med SJTUSM, Shanghai 200030, Peoples R China; [Wu, Q.; Wang, H.; Zhao, X.; Shi, Y.; Jin, M.; Wan, B.; Xu, H.; Cheng, Y.; Ge, H.; Zhang, Y.] SJTUSM, Shanghai Inst Immunol, Inst Med Sci, Shanghai, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Chinese Academy of Sciences; Shanghai Jiao Tong University	Zhang, Y (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Key Lab Stem Cell Biol, Shanghai 200025, Peoples R China.	gehl@shsmu.edu.cn; yyzhang@sibs.ac.cn	Shi, Yufang/AAE-4431-2020	Shi, Yufang/0000-0001-8964-319X	Ministry of Science and Technology of China [2011CB966200, 2010CB945600]; Strategic Priority Research Program of the Chinese Academy of Sciences [XDA01040000]; Program of Chinese Academy of Sciences [KSCX1-YW-22]; National Natural Science Foundation of China [81071748, 30873045, 81130057]; China Postdoctoral Science Foundation [2012M510906]; Leading Academic Discipline Project of Shanghai Municipal Education Commission [J50207]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); Strategic Priority Research Program of the Chinese Academy of Sciences(Chinese Academy of Sciences); Program of Chinese Academy of Sciences(Chinese Academy of Sciences); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); China Postdoctoral Science Foundation(China Postdoctoral Science Foundation); Leading Academic Discipline Project of Shanghai Municipal Education Commission(Shanghai Leading Academic Discipline Project)	We thank Dr G Brewer (University of Medicine and Dentistry of New Jersey) for his critical review of the manuscript. This work was supported by the Ministry of Science and Technology of China (2011CB966200, 2010CB945600), the Strategic Priority Research Program of the Chinese Academy of Sciences (XDA01040000), the Program of Chinese Academy of Sciences (KSCX1-YW-22), the National Natural Science Foundation of China (81071748, 30873045, 81130057), the China Postdoctoral Science Foundation (2012M510906) and the Leading Academic Discipline Project of Shanghai Municipal Education Commission (J50207).	Briscoe CP, 2006, BRIT J PHARMACOL, V148, P619, DOI 10.1038/sj.bjp.0706770; Briscoe CP, 2003, J BIOL CHEM, V278, P11303, DOI 10.1074/jbc.M211495200; Cheng JCH, 2006, ONCOGENE, V25, P7009, DOI 10.1038/sj.onc.1209706; Fukata M, 2007, GASTROENTEROLOGY, V133, P1869, DOI 10.1053/j.gastro.2007.09.008; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Habbel P, 2009, WORLD J GASTROENTERO, V15, P1079, DOI 10.3748/wjg.15.1079; Hara T, 2011, J PHARM SCI-US, V100, P3594, DOI 10.1002/jps.22639; Hatanaka H, 2010, CANCER SCI, V101, P54, DOI 10.1111/j.1349-7006.2009.01348.x; Hirasawa A, 2005, NAT MED, V11, P90, DOI 10.1038/nm1168; Hossain Z, 2009, NUTR CANCER, V61, P123, DOI 10.1080/01635580802395725; Ichimura A, 2012, NATURE, V483, P350, DOI 10.1038/nature10798; Im DS, 2012, PROG LIPID RES, V51, P232, DOI 10.1016/j.plipres.2012.02.003; Itoh Y, 2003, NATURE, V422, P173, DOI 10.1038/nature01478; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kotarsky K, 2003, BIOCHEM BIOPH RES CO, V301, P406, DOI 10.1016/S0006-291X(02)03064-4; Koukourakis GV, 2011, CLIN TRANSL ONCOL, V13, P710, DOI 10.1007/s12094-011-0720-z; Oh DY, 2012, CELL METAB, V15, P564, DOI 10.1016/j.cmet.2012.04.009; Oh DY, 2011, CURR OPIN CLIN NUTR, V14, P322, DOI 10.1097/MCO.0b013e3283479230; Oh DY, 2010, CELL, V142, P687, DOI 10.1016/j.cell.2010.07.041; Polozova A, 2007, J MOL NEUROSCI, V33, P56, DOI 10.1007/s12031-007-0039-y; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Roodhart JML, 2011, CANCER CELL, V20, P370, DOI 10.1016/j.ccr.2011.08.010; Sakurai T, 2011, ONCOLOGY-BASEL, V81, P24, DOI 10.1159/000333256; Song LB, 2011, CLIN CANCER RES, V17, P1839, DOI 10.1158/1078-0432.CCR-10-0720; Strickler JH, 2012, ONCOLOGIST, V17, P513, DOI 10.1634/theoncologist.2012-0003; Strieter RM, 2005, NAT MED, V11, P925, DOI 10.1038/nm0905-925; Taborga M, 2007, MINI-REV MED CHEM, V7, P245, DOI 10.2174/138955707780059826; Tanaka T, 2008, N-S ARCH PHARMACOL, V377, P523, DOI 10.1007/s00210-007-0200-8; Turk HF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039682; Wang DZ, 2005, GASTROENTEROLOGY, V128, P1445, DOI 10.1053/j.gastro.2004.09.080; Wang SL, 2009, CELL MOL IMMUNOL, V6, P327, DOI 10.1038/cmi.2009.43; Wang YG, 2012, CANCER RES, V72, P5396, DOI 10.1158/0008-5472.CAN-12-0474; Wendt MK, 2013, ONCOGENE, V32, P2005, DOI 10.1038/onc.2012.230; Williams K, 2012, CANCER RES, V72, P5407, DOI 10.1158/0008-5472.CAN-12-1158; Wu YY, 2011, ONCOGENE, V30, P3682, DOI 10.1038/onc.2011.85; Xu HB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027399; Yeung Y, 2012, EXPERT REV ANTICANC, V12, P1263, DOI [10.1586/era.12.104, 10.1586/ERA.12.104]; Zhao F, 2011, BLOOD, V117, P1723, DOI 10.1182/blood-2010-04-281659; Zheng HX, 2013, ONCOGENE, V32, P1183, DOI 10.1038/onc.2012.126	41	102	105	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2013	32	49					5541	5550		10.1038/onc.2013.264	http://dx.doi.org/10.1038/onc.2013.264			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	269XF	23851494				2022-12-28	WOS:000328276400005
J	Lock, FE; McDonald, PC; Lou, Y; Serrano, I; Chafe, SC; Ostlund, C; Aparicio, S; Winum, JY; Supuran, CT; Dedhar, S				Lock, F. E.; McDonald, P. C.; Lou, Y.; Serrano, I.; Chafe, S. C.; Ostlund, C.; Aparicio, S.; Winum, J-Y; Supuran, C. T.; Dedhar, S.			Targeting carbonic anhydrase IX depletes breast cancer stem cells within the hypoxic niche	ONCOGENE			English	Article						CAIX; cancer stem cell; breast cancer; hypoxia; EMT; mTOR	EPITHELIAL-MESENCHYMAL-TRANSITION; TUMOR-INITIATING CELLS; MAMMALIAN TARGET; METASTASIS; EXPRESSION; IDENTIFICATION; PROLIFERATION; INHIBITORS; RAPAMYCIN; OXYGEN	The sub-population of tumor cells termed 'cancer stem cells' (CSCs) possess the capability to generate tumors, undergo epithelial-mesenchymal transition (EMT) and are implicated in metastasis, making treatments to specifically target CSCs an attractive therapeutic strategy. Tumor hypoxia plays a key role in regulating EMT and cancer stem cell function. Carbonic anhydrase IX (CAIX) is a hypoxia-inducible protein that regulates cellular pH to promote cancer cell survival and invasion in hypoxic microenvironments and is a biomarker of poor prognosis for breast cancer metastasis and survival. Here, we demonstrate that inhibition of CAIX expression or activity with novel small-molecule inhibitors in breast cancer cell lines, or in primary metastatic breast cancer cells, results in the inhibition of breast CSC expansion in hypoxia. We identify the mTORC1 axis as a critical pathway downstream of CAIX in the regulation of cancer stem cell function. CAIX is also required for expression of EMT markers and regulators, as well as drivers of 'stemness', such as Notch1 and Jagged1 in isolated CSCs. In addition, treatment of mice bearing orthotopic breast tumors with CAIX-specific small-molecule inhibitors results in significant depletion of CSCs within these tumors. Furthermore, combination treatment with paclitaxel results in enhanced tumor growth delay and eradication of lung metastases. These data demonstrate that CAIX is a critical mediator of the expansion of breast CSCs in hypoxic niches by sustaining the mesenchymal and 'stemness' phenotypes of these cells, making CAIX an important therapeutic target for selectively depleting breast CSCs.	[Lock, F. E.; McDonald, P. C.; Lou, Y.; Serrano, I.; Chafe, S. C.; Ostlund, C.; Dedhar, S.] BC Canc Res Ctr, Dept Integrat Oncol, Vancouver, BC V5Z 1L3, Canada; [Aparicio, S.] BC Canc Res Ctr, Dept Mol Oncol, Vancouver, BC V5Z 1L3, Canada; [Winum, J-Y] Univ Montpellier 1 & 2, Ecole Natl Super Chim Montpellier, Inst Biomol Max Mousseron, UMR CNRS 5247, Montpellier, France; [Supuran, C. T.] Univ Florence, Dept Lab Chim Bioinorgan, Florence, Italy; [Dedhar, S.] Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V5Z 1M9, Canada	British Columbia Cancer Agency; British Columbia Cancer Agency; Centre National de la Recherche Scientifique (CNRS); Ecole nationale superieure de chimie de Montpellier; Universite de Montpellier; University of Florence; University of British Columbia	Dedhar, S (corresponding author), BC Canc Res Ctr, Dept Integrat Oncol, 675 West 10th Ave, Vancouver, BC V5Z 1L3, Canada.	sdedhar@bccrc.ca	WINUM, Jean-Yves/AAC-9578-2019; WINUM, Jean-Yves/P-3387-2016	WINUM, Jean-Yves/0000-0003-3197-3414; WINUM, Jean-Yves/0000-0003-3197-3414; Dedhar, Shoukat/0000-0003-4355-1657; Aparicio, Samuel/0000-0002-0487-9599; Supuran, Claudiu/0000-0003-4262-0323	Canadian Institutes of Health Research (CIHR)	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	This work was supported by a grant from the Canadian Institutes of Health Research (CIHR) to SD.	Abraham BK, 2005, CLIN CANCER RES, V11, P1154; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Balgi AD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021549; Barnes EA, 2010, AM J PATHOL, V177, P1765, DOI 10.2353/ajpath.2010.090233; Bhat-Nakshatri P, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-411; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Calcagno AM, 2010, JNCI-J NATL CANCER I, V102, P1637, DOI 10.1093/jnci/djq361; Charafe-Jauffret E, 2010, CLIN CANCER RES, V16, P45, DOI 10.1158/1078-0432.CCR-09-1630; Chaudary N, 2007, CLIN CANCER RES, V13, P1947, DOI 10.1158/1078-0432.CCR-06-2971; Creighton CJ, 2010, J MAMMARY GLAND BIOL, V15, P253, DOI 10.1007/s10911-010-9173-1; Croker AK, 2012, BREAST CANCER RES TR, V133, P75, DOI 10.1007/s10549-011-1692-y; Das B, 2008, STEM CELLS, V26, P1818, DOI 10.1634/stemcells.2007-0724; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Grimshaw MJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2106; Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Haase VH, 2009, KIDNEY INT, V76, P492, DOI 10.1038/ki.2009.222; Harma V, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010431; Hartwell KA, 2006, P NATL ACAD SCI USA, V103, P18969, DOI 10.1073/pnas.0608636103; Horree N, 2007, HUM PATHOL, V38, P1232, DOI 10.1016/j.humpath.2007.01.008; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Hwang-Verslues WW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008377; Joo KM, 2012, CANCER RES, V72, P3828, DOI 10.1158/0008-5472.CAN-11-3760; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Knaup KX, 2009, MOL CANCER RES, V7, P88, DOI 10.1158/1541-7786.MCR-08-0288; Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015; Lefkovits I, 1999, LIMITING DILUTION AN, pxvi; Liao ND, 2011, CANCER CYTOPATHOL, V119, P346, DOI 10.1002/cncy.20153; Liu JC, 2007, CANCER RES, V67, P8671, DOI 10.1158/0008-5472.CAN-07-1486; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lou YM, 2011, CANCER RES, V71, P3364, DOI 10.1158/0008-5472.CAN-10-4261; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Marcato P, 2011, STEM CELLS, V29, P32, DOI 10.1002/stem.563; Martinez-Moragon E, 1998, RESPIRATION, V65, P108, DOI 10.1159/000029240; Mohyeldin A, 2010, CELL STEM CELL, V7, P150, DOI 10.1016/j.stem.2010.07.007; O'Brien CA, 2009, SEMIN RADIAT ONCOL, V19, P71, DOI 10.1016/j.semradonc.2008.11.001; Oloumi A, 2000, CANCER RES, V60, P5747; Pacchiano F, 2011, J MED CHEM, V54, P1896, DOI 10.1021/jm101541x; Pannuti A, 2010, CLIN CANCER RES, V16, P3141, DOI 10.1158/1078-0432.CCR-09-2823; Ponti D, 2005, CANCER RES, V65, P5506, DOI 10.1158/0008-5472.CAN-05-0626; Reuben JM, 2011, EUR J CANCER, V47, P1527, DOI 10.1016/j.ejca.2011.01.011; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rota LM, 2012, J MAMMARY GLAND BIOL, V17, P119, DOI 10.1007/s10911-012-9258-0; Russell RC, 2011, DEVELOPMENT, V138, P3343, DOI 10.1242/dev.058230; Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533; Shorning BY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016209; Singh SK, 2003, CANCER RES, V63, P5821; Smith KM, 2010, EMBO MOL MED, V2, P371, DOI 10.1002/emmm.201000093; Supuran CT, 2008, NAT REV DRUG DISCOV, V7, P168, DOI 10.1038/nrd2467; Svastova E, 2003, EXP CELL RES, V290, P332, DOI 10.1016/S0014-4827(03)00351-3; Swietach P, 2010, ONCOGENE, V29, P6509, DOI 10.1038/onc.2010.455; Touisni N, 2011, J MED CHEM, V54, P8271, DOI 10.1021/jm200983e; Trimboli AJ, 2008, CANCER RES, V68, P937, DOI 10.1158/0008-5472.CAN-07-2148; Turner FE, 2006, J BIOL CHEM, V281, P21321, DOI 10.1074/jbc.M509731200; Vignot S, 2005, ANN ONCOL, V16, P525, DOI 10.1093/annonc/mdi113; Wang XY, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-221; Wright MH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1855; Xing F, 2011, ONCOGENE, V30, P4075, DOI 10.1038/onc.2011.122	60	242	247	4	41	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2013	32	44					5210	5219		10.1038/onc.2012.550	http://dx.doi.org/10.1038/onc.2012.550			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245XH	23208505				2022-12-28	WOS:000326497100004
J	Rosano, L; Cianfrocca, R; Tocci, P; Spinella, F; Di Castro, V; Spadaro, F; Salvati, E; Biroccio, AM; Natali, PG; Bagnato, A				Rosano, L.; Cianfrocca, R.; Tocci, P.; Spinella, F.; Di Castro, V.; Spadaro, F.; Salvati, E.; Biroccio, A. M.; Natali, P. G.; Bagnato, A.			beta-arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced beta-catenin signaling	ONCOGENE			English	Article						beta-arrestin; beta-catenin; endothelin A receptor; ovarian carcinoma; chromatin remodeling	EXPORT SIGNAL; ARRESTIN; ACTIVATION; RECEPTOR; GROWTH; AXIS; PROLIFERATION; LOCALIZATION; TRANSITIONS; EXPRESSION	Despite the fundamental pathophysiological importance of beta-catenin in tumor progression, the mechanism underlying its final transcriptional output has been partially elucidated. Here, we report that beta-arrestin-1 (beta-arr1) is an epigenetic regulator of endothelin (ET)-1-induced beta-catenin signaling in epithelial ovarian cancer (EOC). In response to ET A receptor (ETAR) activation by ET-1, beta-arr1 increases its nuclear translocation and direct binding to beta-catenin. This in turn enhanced beta-catenin nuclear accumulation and transcriptional activity, which was prevented by expressing a mutant beta-arr1 incapable of nuclear distribution. beta-arr1-beta-catenin interaction controls beta-catenin target gene expressions, such as ET-1, Axin 2, Matrix metalloproteinase 2, and Cyclin D1, by promoting histone deacetylase 1 (HDAC1) dissociation and the recruitment of p300 acetyltransferase on these promoter genes, resulting in enhanced H3 and H4 histone acetylation, and gene transcription, required for cell migration, invasion and epithelial-to-mesenchymal transition. These effects are abrogated by beta-arr1 silencing or by mutant beta-arr1, as well as by beta-catenin or p300 silencing, confirming that nuclear beta-arr1 forms a functional complex capable of regulating epigenetic changes in beta-catenin-driven invasive behavior. In a murine orthotopic model of metastatic human EOC, silencing of beta-arr1 or mutant beta-arr1 expression, as well as ETAR blockade, inhibits metastasis. In human EOC tissues, beta-arr1-beta-catenin nuclear complexes are selectively enriched at beta-catenin target gene promoters, correlating with tumor grade, confirming a direct in vivo beta-arr1-beta-catenin association at specific set of genes involved in EOC progression. Collectively, our study provides insights into how a beta-arr1-mediated epigenetic mechanism controls beta-catenin activity, unraveling new components required for its nuclear function in promoting metastasis.	[Rosano, L.; Cianfrocca, R.; Tocci, P.; Spinella, F.; Di Castro, V.; Natali, P. G.; Bagnato, A.] Regina Elena Inst Canc Res, Lab Mol Pathol, I-00158 Rome, Italy; [Spadaro, F.] Ist Super Sanita, Dept Haematol Oncol & Mol Med, Sect Expt Immunotherapy, I-00161 Rome, Italy; [Salvati, E.; Biroccio, A. M.] Regina Elena Inst Canc Res, Lab Expt Chemotherapy, I-00158 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Istituto Superiore di Sanita (ISS); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Rosano, L (corresponding author), Regina Elena Inst Canc Res, Lab Mol Pathol, Via Messi DOro 156, I-00158 Rome, Italy.	rosano@ifo.it; bagnato@ifo.it	ROSANO', Laura/AAK-1424-2020; spinella, francesca/AAZ-8982-2020; Biroccio, Annamaria/B-2861-2018; Tocci, Piera/AAX-9815-2021; Di Castro, Valeriana/H-8873-2017; Spadaro, Francesca/M-7512-2017; Rosanò, Laura/AAB-7821-2019; Rosanò, Laura/B-2863-2018; Tocci, Piera/ABH-7630-2020; Bagnato, Anna/G-9747-2016	ROSANO', Laura/0000-0002-9962-6411; Biroccio, Annamaria/0000-0003-3198-3532; Tocci, Piera/0000-0003-3771-013X; Di Castro, Valeriana/0000-0002-1899-3683; Spadaro, Francesca/0000-0002-6610-350X; Rosanò, Laura/0000-0002-3981-8593; Rosanò, Laura/0000-0002-9962-6411; Bagnato, Anna/0000-0002-7269-9522; Salvati, Erica/0000-0002-3373-7442	Associazione Italiana Ricerca sul Cancro	Associazione Italiana Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)	We gratefully acknowledge Valentina Caprara and Aldo Lupo for excellent technical assistance, Maria Vincenza Sarcone for secretarial assistance, Dr Maurizio Fanciulli for valuable comments, Dr Robert Lefkowitz (Howard Hughes Medical Institute, Duke University) for his insightful comments and for kindly providing beta-arr1 expression vector; Dr Zhuohua Zhang (University of California San Diego School of Medicine, La Jolla, CA, USA) for ET-1 promoter reporter and its mutant control, and Dr Tania Merlino for the formal revision of the manuscript. This work was supported by the grant funded by the Associazione Italiana Ricerca sul Cancro.	Ahn S, 2009, J BIOL CHEM, V284, P8846, DOI 10.1074/jbc.M808463200; Bagnato A, 2011, BRIT J PHARMACOL, V163, P220, DOI 10.1111/j.1476-5381.2011.01217.x; Bagnato A, 2008, INT J BIOCHEM CELL B, V40, P1443, DOI 10.1016/j.biocel.2008.01.022; Billin AN, 2000, MOL CELL BIOL, V20, P6882, DOI 10.1128/MCB.20.18.6882-6890.2000; Bonnans C, 2012, P NATL ACAD SCI USA, V109, P3047, DOI 10.1073/pnas.1109457109; Bryja V, 2007, P NATL ACAD SCI USA, V104, P6690, DOI 10.1073/pnas.0611356104; Buchanan FG, 2006, P NATL ACAD SCI USA, V103, P1492, DOI 10.1073/pnas.0510562103; Chen W, 2001, P NATL ACAD SCI USA, V98, P14889, DOI 10.1073/pnas.211572798; Chen W, 2003, SCIENCE, V301, P1391, DOI 10.1126/science.1082808; Chun KS, 2009, CARCINOGENESIS, V30, P1620, DOI 10.1093/carcin/bgp168; Cianfrocca R, 2010, CAN J PHYSIOL PHARM, V88, P796, DOI 10.1139/Y10-052; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Dasgupta P, 2006, J CLIN INVEST, V116, P3083, DOI 10.1172/JCI28164C1; Dasgupta P, 2011, JNCI-J NATL CANCER I, V103, P317, DOI 10.1093/jnci/djq541; Hoeppner CZ, 2012, J BIOL CHEM, V287, P8932, DOI 10.1074/jbc.M111.294058; Jin QH, 2011, EMBO J, V30, P249, DOI 10.1038/emboj.2010.318; Kang JH, 2005, CELL, V123, P833, DOI 10.1016/j.cell.2005.09.011; Kim TH, 2005, ONCOGENE, V24, P597, DOI 10.1038/sj.onc.1208237; Kovacs JJ, 2009, DEV CELL, V17, P443, DOI 10.1016/j.devcel.2009.09.011; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; Li TT, 2009, MOL CANCER RES, V7, P1064, DOI 10.1158/1541-7786.MCR-08-0578; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Ma L, 2007, J CELL SCI, V120, P213, DOI 10.1242/jcs.03338; Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990; Parathath SR, 2010, CELL CYCLE, V9, P4013, DOI 10.4161/cc.9.19.13325; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Rosano L, 2006, MOL CANCER THER, V5, P833, DOI 10.1158/1535-7163.MCT-05-0523; Rosano L, 2005, CANCER RES, V65, P11649, DOI 10.1158/0008-5472.CAN-05-2123; Rosano L, 2001, CANCER RES, V61, P8340; Rosano L, 2011, CLIN CANCER RES, V17, P2350, DOI 10.1158/1078-0432.CCR-10-2325; Rosano L, 2009, CELL CYCLE, V8, P1462; Rosano L, 2009, P NATL ACAD SCI USA, V106, P2806, DOI 10.1073/pnas.0807158106; Scott MGH, 2002, J BIOL CHEM, V277, P37693, DOI 10.1074/jbc.M207552200; Shenoy SK, 2012, ONCOGENE, V31, P282, DOI 10.1038/onc.2011.238; Shenoy Sudha K, 2005, Sci STKE, V2005, pcm10, DOI 10.1126/stke.2005/308/cm10; Shi YF, 2007, NAT IMMUNOL, V8, P817, DOI 10.1038/ni1489; Sun P, 2006, MOL PHARMACOL, V69, P520, DOI 10.1124/mol.105.019620; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Tilley DG, 2009, J BIOL CHEM, V284, P20375, DOI 10.1074/jbc.M109.005793; Wang P, 2003, J BIOL CHEM, V278, P11648, DOI 10.1074/jbc.M208109200; Wu BB, 2007, IMMUNITY, V26, P227, DOI 10.1016/j.immuni.2006.12.007; Xiao K, 2007, P NATL ACAD SCI USA, V104, P12011, DOI 10.1073/pnas.0704849104; Yang M, 2009, BIOCHEM J, V417, P287, DOI 10.1042/BJ20081561; Yue R, 2009, CELL, V139, P535, DOI 10.1016/j.cell.2009.08.038	45	68	68	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2013	32	42					5066	5077		10.1038/onc.2012.527	http://dx.doi.org/10.1038/onc.2012.527			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238IB	23208497				2022-12-28	WOS:000325937900008
J	Zhao, J; Zhang, J; Yu, M; Xie, Y; Huang, Y; Wolff, DW; Abel, PW; Tu, Y				Zhao, J.; Zhang, J.; Yu, M.; Xie, Y.; Huang, Y.; Wolff, D. W.; Abel, P. W.; Tu, Y.			Mitochondrial dynamics regulates migration and invasion of breast cancer cells	ONCOGENE			English	Article						breast cancer; metastasis; lamellipodia; Drp1; mitochondrial dynamics; fission and fusion	ENDOPLASMIC-RETICULUM; FUSION; INHIBITION; ACTIN; PHOSPHORYLATION; CYTOSKELETON; CHEMOTAXIS; FISSION; ROLES	Mitochondria are highly dynamic and undergo constant fusion and fission that are essential for maintaining physiological functions of cells. Although dysfunction of mitochondria has been implicated in tumorigenesis, little is known about the roles of mitochondrial dynamics in metastasis, the major cause of cancer death. In the present study, we found a marked upregulation of mitochondrial fission protein dynamin-related protein 1 (Drp1) expression in human invasive breast carcinoma and metastases to lymph nodes. Compared with non-metastatic breast cancer cells, mitochondria also were more fragmented in metastatic breast cancer cells that express higher levels of total and active Drp1 and less mitochondrial fusion protein 1 (Mfn1). Silencing Drp1 or overexpression of Mfn1 resulted in mitochondria elongation or clusters, respectively, and significantly suppressed metastatic abilities of breast cancer cells. In contrast, silencing Mfn proteins led to mitochondrial fragmentation and enhanced metastatic abilities of breast cancer cells. Interestingly, these manipulations of mitochondrial dynamics altered the subcellular distribution of mitochondria in breast cancer cells. For example, silencing Drp1 or overexpression of Mfn1 inhibited lamellipodia formation, a key step for cancer metastasis, and suppressed chemoattractant-induced recruitment of mitochondria to lamellipodial regions. Conversely, silencing Mfn proteins resulted in more cell spreading and lamellipodia formation, causing accumulation of more mitochondria in lamellipodia regions. More importantly, treatment with a mitochondrial uncoupling agent or adenosine triphosphate synthesis inhibitor reduced lamellipodia formation and decreased breast cancer cell migration and invasion, suggesting a functional importance of mitochondria in breast cancer metastasis. Together, our findings show a new role and mechanism for regulation of cancer cell migration and invasion by mitochondrial dynamics. Thus targeting dysregulated Drp1-dependent mitochondrial fission may provide a novel strategy for suppressing breast cancer metastasis.	[Zhao, J.; Zhang, J.; Yu, M.; Huang, Y.] Chinese Acad Sci, Inst Biophys, Natl Lab Biomacromol, Beijing 100080, Peoples R China; [Zhao, J.; Xie, Y.; Wolff, D. W.; Abel, P. W.; Tu, Y.] Creighton Univ, Sch Med, Dept Pharmacol, Omaha, NE 68178 USA	Chinese Academy of Sciences; Institute of Biophysics, CAS; Creighton University	Tu, Y (corresponding author), Creighton Univ, Sch Med, Dept Pharmacol, 2500 Calif Plaza,551 Criss III, Omaha, NE 68178 USA.	yapingtu@creighton.edu	Yu, Meifang/O-3728-2017; Wolff, Dennis W/E-3013-2015; Yu, Meifang/N-6026-2017	Yu, Meifang/0000-0002-1878-307X; Abel, Peter/0000-0002-6588-1676	National Institutes of Health [CA125661]; Nebraska LB595 program; National Basic Research Program of China [2010CB833701, 2012CB934003]; National Natural Science Foundation of China [31100973]; NATIONAL CANCER INSTITUTE [R01CA125661] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Nebraska LB595 program; National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Professors Fuyu Yang and Quan Chen for their valuable suggestions. This work was supported by the National Institutes of Health (CA125661), Nebraska LB595 program and the National Basic Research Program of China (2010CB833701, 2012CB934003). Dr Juan Zhang is a grant recipient of the National Natural Science Foundation of China (31100973).	Albini A, 2007, NAT PROTOC, V2, P504, DOI 10.1038/nprot.2006.466; BERTINA RM, 1974, BIOCHIM BIOPHYS ACTA, V368, P279, DOI 10.1016/0005-2728(74)90175-3; Biswas S, 1998, FEBS LETT, V425, P411, DOI 10.1016/S0014-5793(98)00273-7; Brand MD, 2011, BIOCHEM J, V435, P297, DOI 10.1042/BJ20110162; Campello S, 2006, J EXP MED, V203, P2879, DOI 10.1084/jem.20061877; Cassidy-Stone A, 2008, DEV CELL, V14, P193, DOI 10.1016/j.devcel.2007.11.019; Chan DC, 2006, DEV CELL, V11, P592, DOI 10.1016/j.devcel.2006.10.009; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Chen HC, 2010, CELL, V141, P280, DOI 10.1016/j.cell.2010.02.026; Condeelis J, 2005, ANNU REV CELL DEV BI, V21, P695, DOI 10.1146/annurev.cellbio.21.122303.120306; Condeelis JS, 2001, SEMIN CANCER BIOL, V11, P119, DOI 10.1006/scbi.2000.0363; Conklin MW, 2005, DEV BIOL, V287, P201, DOI 10.1016/j.ydbio.2005.09.006; COUCHMAN JR, 1982, EUR J CELL BIOL, V27, P47; de Brito OM, 2008, NATURE, V456, P605, DOI 10.1038/nature07534; Detmer SA, 2007, NAT REV MOL CELL BIO, V8, P870, DOI 10.1038/nrm2275; Friedman JR, 2011, SCIENCE, V334, P358, DOI 10.1126/science.1207385; Gogvadze V, 2008, TRENDS CELL BIOL, V18, P165, DOI 10.1016/j.tcb.2008.01.006; Grandemange S, 2009, SEMIN CANCER BIOL, V19, P50, DOI 10.1016/j.semcancer.2008.12.001; Guppy M, 2002, BIOCHEM J, V364, P309, DOI 10.1042/bj3640309; Hollenbeck PJ, 2005, J CELL SCI, V118, P5411, DOI 10.1242/jcs.053850; Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Ishihara N, 2004, J CELL SCI, V117, P6535, DOI 10.1242/jcs.01565; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jose C, 2011, BBA-BIOENERGETICS, V1807, P552, DOI 10.1016/j.bbabio.2010.10.012; Kirui JK, 2010, J PHARMACOL EXP THER, V333, P393, DOI 10.1124/jpet.109.164814; Liesa M, 2009, PHYSIOL REV, V89, P799, DOI 10.1152/physrev.00030.2008; Liu CY, 2004, ANN NY ACAD SCI, V1011, P133, DOI 10.1196/annals.1293.014; Machesky LM, 1997, J CELL BIOL, V138, P913, DOI 10.1083/jcb.138.4.913; Nicholls DG, 2000, PHYSIOL REV, V80, P315, DOI 10.1152/physrev.2000.80.1.315; Platet N, 1998, INT J CANCER, V75, P750, DOI 10.1002/(SICI)1097-0215(19980302)75:5<750::AID-IJC14>3.0.CO;2-A; Pollard TD, 2009, SCIENCE, V326, P1208, DOI 10.1126/science.1175862; Rehman J, 2012, FASEB J, V26, P2175, DOI 10.1096/fj.11-196543; Sanchez-Madrid F, 2009, NAT REV MOL CELL BIO, V10, P353, DOI 10.1038/nrm2680; Suen DF, 2008, GENE DEV, V22, P1577, DOI 10.1101/gad.1658508; Szabadkai G, 2008, PHYSIOLOGY, V23, P84, DOI 10.1152/physiol.00046.2007; Taguchi N, 2007, J BIOL CHEM, V282, P11521, DOI 10.1074/jbc.M607279200; Verburg J, 2008, J NEUROSCI, V28, P8306, DOI 10.1523/JNEUROSCI.2614-08.2008; VONJAGOW G, 1980, ANGEW CHEM INT EDIT, V19, P659, DOI 10.1002/anie.198006593; WERTH JL, 1994, J NEUROSCI, V14, P348; Westermann B, 2010, NAT REV MOL CELL BIO, V11, P872, DOI 10.1038/nrm3013; Xie Y, 2009, CANCER RES, V69, P5743, DOI 10.1158/0008-5472.CAN-08-3564; Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001; Zhang JA, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1099	44	447	462	1	64	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2013	32	40					4814	4824		10.1038/onc.2012.494	http://dx.doi.org/10.1038/onc.2012.494			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229NW	23128392	Green Accepted			2022-12-28	WOS:000325274700010
J	Jackson, JG; Lozano, G				Jackson, J. G.; Lozano, G.			The mutant p53 mouse as a pre-clinical model	ONCOGENE			English	Review						p53; mouse models; treatment response	ADVANCED BREAST-CANCER; LI-FRAUMENI-SYNDROME; IN-VIVO; CELL-CYCLE; TUMOR SUPPRESSION; LUNG-CANCER; GASTROINTESTINAL-SYNDROME; INDUCED APOPTOSIS; TRANSGENIC MICE; CHEMOTHERAPY	The p53 tumor-suppressor pathway is dismantled in the development of most cancers. Mice with various p53 mutant alleles either singly or in combination with other genetic alterations are predisposed to tumor development. Here, we review studies utilizing p53 mutant mice that have recapitulated and informed clinical observations. These studies have demonstrated the p53 contribution, sometimes beneficial and sometimes detrimental, to treatment response in lymphomas, and lung and breast cancers. Further, we examine how p53 mutant mouse models have been used to test the efficacy of p53 reactivation as a therapeutic strategy.	[Jackson, J. G.; Lozano, G.] Univ Texas MD Anderson Canc Ctr, Dept Genet, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Lozano, G (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Genet, 1515 Holcombe Blvd,Unit 1010, Houston, TX 77030 USA.	gglozano@mdanderson.org		Jackson, James Griffith/0000-0002-2640-6442	NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Abbas HA, 2011, CELL CYCLE, V10, P3257, DOI 10.4161/cc.10.19.17721; Abbas HA, 2010, CELL STEM CELL, V7, P606, DOI 10.1016/j.stem.2010.09.013; Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042; Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833; Barrington RE, 1998, MOL CELL BIOL, V18, P85, DOI 10.1128/MCB.18.1.85; Bearss DJ, 2000, ONCOGENE, V19, P1114, DOI 10.1038/sj.onc.1203275; Berns EMJJ, 2000, CANCER RES, V60, P2155; Bertheau P, 2002, LANCET, V360, P852, DOI 10.1016/S0140-6736(02)09969-5; Bertheau P, 2008, PATHOBIOLOGY, V75, P132, DOI 10.1159/000123851; Bonetti A, 1998, CLIN CANCER RES, V4, P2331; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Carey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078-0432.CCR-06-1109; Chabner BA, 2005, NAT REV CANCER, V5, P65, DOI 10.1038/nrc1529; Chen Z, 2012, NATURE, V483, P613, DOI 10.1038/nature10937; Christophorou MA, 2005, NAT GENET, V37, P718, DOI 10.1038/ng1572; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Daniels M, 2012, J THORAC DIS, V4, P155, DOI 10.3978/j.issn.2072-1439.2012.02.01; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; Feldser DM, 2010, NATURE, V468, P572, DOI 10.1038/nature09535; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hurley LH, 2002, NAT REV CANCER, V2, P188, DOI 10.1038/nrc749; Jackson JG, 2012, CANCER CELL, V21, P793, DOI 10.1016/j.ccr.2012.04.027; Junttila MR, 2010, NATURE, V468, P567, DOI 10.1038/nature09526; Karnoub Antoine E, 2006, Breast Dis, V26, P75; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KASTAN MB, 1991, CANCER RES, V51, P6304; Kirsch DG, 2010, SCIENCE, V327, P593, DOI 10.1126/science.1166202; Komarova EA, 2004, ONCOGENE, V23, P3265, DOI 10.1038/sj.onc.1207494; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; Lowe SW, 2004, NATURE, V432, P307, DOI 10.1038/nature03098; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; LUNA RMD, 1995, NATURE, V378, P203; MacCallum DE, 1996, ONCOGENE, V13, P2575; Martins CP, 2006, CELL, V127, P1323, DOI 10.1016/j.cell.2006.12.007; Meylan E, 2009, NATURE, V462, P104, DOI 10.1038/nature08462; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Riley T, 2008, NAT REV MOL CELL BIO, V9, P402, DOI 10.1038/nrm2395; Ringshausen I, 2006, CANCER CELL, V10, P501, DOI 10.1016/j.ccr.2006.10.010; Rottenberg S, 2007, P NATL ACAD SCI USA, V104, P12117, DOI 10.1073/pnas.0702955104; Rouzier R, 2005, CLIN CANCER RES, V11, P5678, DOI 10.1158/1078-0432.CCR-04-2421; Schmitt CA, 1999, GENE DEV, V13, P2670, DOI 10.1101/gad.13.20.2670; Schmitt CA, 2000, NAT MED, V6, P1029, DOI 10.1038/79542; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Soussi T, 2005, BIOCHEM BIOPH RES CO, V331, P834, DOI 10.1016/j.bbrc.2005.03.190; Soussi T, 2011, ADV CANCER RES, V110, P107, DOI 10.1016/B978-0-12-386469-7.00005-0; Suh YA, 2011, CANCER RES, V71, P7168, DOI 10.1158/0008-5472.CAN-11-0459; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Terzian T, 2008, GENE DEV, V22, P1337, DOI 10.1101/gad.1662908; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; Vaahtomeri K, 2011, FEBS LETT, V585, P944, DOI 10.1016/j.febslet.2010.12.034; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Waldman T, 1997, NAT MED, V3, P1034, DOI 10.1038/nm0997-1034; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang YX, 2011, J CLIN INVEST, V121, P893, DOI 10.1172/JCI44504; Weller M, 1998, CELL TISSUE RES, V292, P435, DOI 10.1007/s004410051072; Xu XL, 2001, NAT GENET, V28, P266, DOI 10.1038/90108; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Xue W, 2011, CANCER DISCOV, V1, P236, DOI 10.1158/2159-8290.CD-11-0073; Zenz T, 2008, CELL CYCLE, V7, P3810, DOI 10.4161/cc.7.24.7245	69	46	47	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2013	32	37					4325	4330		10.1038/onc.2012.610	http://dx.doi.org/10.1038/onc.2012.610			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218AF	23318424				2022-12-28	WOS:000324404200001
J	Shortt, J; Hsu, AK; Johnstone, RW				Shortt, J.; Hsu, A. K.; Johnstone, R. W.			Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy	ONCOGENE			English	Review						immune modulation; therapeutics; hematological malignancies	MULTIPLE-MYELOMA CELLS; NATURAL-KILLER-CELL; NF-KAPPA-B; LENALIDOMIDE-INDUCED IMMUNOMODULATION; HUMAN-IMMUNODEFICIENCY-VIRUS; DIAMOND-BLACKFAN ANEMIA; COMMONLY DELETED REGION; NECROSIS-FACTOR-ALPHA; T REGULATORY CELLS; IN-VITRO	Thalidomide and its analogues (lenalidomide and pomalidomide) are small molecule glutamic acid derivatives of the immunomodulatory drug (IMiD) class. In addition to the immuno-adjuvant and anti-inflammatory properties that define an IMiD, the thalidomide analogues demonstrate an overlapping and diverse range of biological activities, including anti-angiogenic, teratogenic and epigenetic effects. Importantly, the IMiDs possess anti-cancer activity with selectivity for molecularly defined subgroups of hematological malignancies, specifically mature B-cell neoplasms and myelodysplasia with deletion of chromosome 5q. Emerging insight into the pathophysiological drivers of these IMiD-responsive disease states can now be synthesized using previously disclosed IMiD activities and recently discovered thalidomide targets to build unifying models of IMiD mechanism of action. Attention to mechanisms of IMiD-induced clinical toxicities, in particular the recently identified association of lenalidomide with second primary malignancies, provides an additional tool for determination of drug mechanism. This review seeks to define the molecular IMiD targets and biological outputs that underpin their anti-neoplastic activity. It is anticipated that elucidation of important IMiD targets will allow the rational development of new-generation therapeutics with the potential to separate thalidomide-analogue efficacy from clinical toxicity.	[Shortt, J.; Johnstone, R. W.] Peter MacCallum Canc Ctr, Canc Therapeut Program, Gene Regulat Lab, Melbourne, Vic, Australia; [Shortt, J.] Monash Med Ctr, Dept Clin Haematol, Clayton, Vic 3168, Australia; [Shortt, J.] Monash Univ, Southern Clin Sch, Dept Med, Clayton, Vic, Australia; [Hsu, A. K.] Peter MacCallum Canc Ctr, Canc Immunol Program, Haematol Immunol Translat Res Lab, Melbourne, Vic, Australia; [Johnstone, R. W.] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic 3052, Australia	Peter Maccallum Cancer Center; Monash University; Monash University; Peter Maccallum Cancer Center; Peter Maccallum Cancer Center; University of Melbourne	Johnstone, RW (corresponding author), Peter MacCallum Canc Inst, Canc Therapeut Program, St Andrews Pl, Melbourne, Vic 3002, Australia.	ricky.johnstone@petermac.org	Johnstone, Ricky w/H-3748-2014	Johnstone, Ricky w/0000-0001-7053-9237; Shortt, Jake/0000-0003-3185-6488				Arastu-Kapur S, 2011, CLIN CANCER RES, V17, P2734, DOI 10.1158/1078-0432.CCR-10-1950; Ashby J, 1997, MUTAT RES-FUND MOL M, V396, P45, DOI 10.1016/S0027-5107(97)00174-7; Attal M, 2012, NEW ENGL J MED, V366, P1782, DOI 10.1056/NEJMoa1114138; Barlow JL, 2010, NAT MED, V16, P59, DOI 10.1038/nm.2063; BARNES PF, 1992, INFECT IMMUN, V60, P1441, DOI 10.1128/IAI.60.4.1441-1446.1992; Bartlett JB, 2004, NAT REV CANCER, V4, P314, DOI 10.1038/nrc1323; Bauer KS, 1998, BIOCHEM PHARMACOL, V55, P1827, DOI 10.1016/S0006-2952(98)00046-X; Benson DM, 2011, BLOOD, V118, P6387, DOI 10.1182/blood-2011-06-360255; Benson DM, 2010, BLOOD, V116, P2286, DOI 10.1182/blood-2010-02-271874; Bernal M, 2009, HUM IMMUNOL, V70, P854, DOI 10.1016/j.humimm.2009.07.004; Boultwood J, 2002, BLOOD, V99, P4638, DOI 10.1182/blood.V99.12.4638; Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837; Chaudhry V, 2008, J PERIPHER NERV SYST, V13, P275, DOI 10.1111/j.1529-8027.2008.00193.x; Cheng JP, 2011, INT J NANOMED, V6, P2007, DOI 10.2147/IJN.S20145; Cheung WC, 2001, LEUKEMIA, V15, P264, DOI 10.1038/sj.leu.2402022; Cook G, 1999, J LEUKOCYTE BIOL, V66, P981, DOI 10.1002/jlb.66.6.981; Corral LG, 1999, J IMMUNOL, V163, P380; Cortes-Hernandez J, 2012, BRIT J DERMATOL, V166, P616, DOI 10.1111/j.1365-2133.2011.10693.x; Croker BA, 2008, SEMIN CELL DEV BIOL, V19, P414, DOI 10.1016/j.semcdb.2008.07.010; DAMATO RJ, 1994, P NATL ACAD SCI USA, V91, P4082, DOI 10.1073/pnas.91.9.4082; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Dauguet N, 2010, CELL IMMUNOL, V264, P163, DOI 10.1016/j.cellimm.2010.06.003; Davies FE, 2001, BLOOD, V98, P210, DOI 10.1182/blood.V98.1.210; Depil S, 2003, LEUKEMIA, V17, P1678, DOI 10.1038/sj.leu.2403012; Draptchinskaia N, 1999, NAT GENET, V21, P169, DOI 10.1038/5951; Dredge K, 2005, MICROVASC RES, V69, P56, DOI 10.1016/j.mvr.2005.01.002; Dredge K, 2002, BRIT J CANCER, V87, P1166, DOI 10.1038/sj.bjc.6600607; Dredge K, 2002, J IMMUNOL, V168, P4914, DOI 10.4049/jimmunol.168.10.4914; Dutt S, 2011, BLOOD, V117, P2567, DOI 10.1182/blood-2010-07-295238; Ebert BL, 2008, NATURE, V451, P335, DOI 10.1038/nature06494; Ehrenpreis ED, 1999, GASTROENTEROLOGY, V117, P1271, DOI 10.1016/S0016-5085(99)70276-3; El-Sherbiny YM, 2007, CANCER RES, V67, P8444, DOI 10.1158/0008-5472.CAN-06-4230; ERIKSSON T, 1995, CHIRALITY, V7, P44, DOI 10.1002/chir.530070109; Escoubet-Lozach L, 2009, CANCER RES, V69, P7347, DOI 10.1158/0008-5472.CAN-08-4898; Ferguson GD, 2007, J CLIN IMMUNOL, V27, P210, DOI 10.1007/s10875-007-9070-6; Figg WD, 1999, J PHARM SCI, V88, P121, DOI 10.1021/js980172i; Frassanito MA, 2001, CLIN EXP IMMUNOL, V125, P190, DOI 10.1046/j.1365-2249.2001.01582.x; Galustian C, 2009, CANCER IMMUNOL IMMUN, V58, P1033, DOI 10.1007/s00262-008-0620-4; Gandhi AK, 2010, CURR CANCER DRUG TAR, V10, P155; Gandhi AK, 2006, LEUKEMIA RES, V30, P849, DOI 10.1016/j.leukres.2006.01.010; Gazda HT, 2006, AM J HUM GENET, V79, P1110, DOI 10.1086/510020; Giamarellos-Bourboulis EJ, 2003, ANTIMICROB AGENTS CH, V47, P2445, DOI 10.1128/AAC.47.8.2445-2449.2003; Giannopoulos K, 2012, BRIT J CANCER, V106, P546, DOI 10.1038/bjc.2011.575; Gorgun G, 2010, BLOOD, V116, P3227, DOI 10.1182/blood-2010-04-279893; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Groen HJM, 2011, J CLIN ONCOL, V29, P4320, DOI 10.1200/JCO.2011.35.5214; Gupta D, 2001, LEUKEMIA, V15, P1950, DOI 10.1038/sj.leu.2402295; Hamuryudan V, 1998, ANN INTERN MED, V128, P443, DOI 10.7326/0003-4819-128-6-199803150-00004; Hansen JM, 2002, DEV DYNAM, V225, P186, DOI 10.1002/dvdy.10150; Haslett PAJ, 2003, J INFECT DIS, V187, P946, DOI 10.1086/368126; Haslett PAJ, 1998, J EXP MED, V187, P1885, DOI 10.1084/jem.187.11.1885; Hayashi T, 2005, BRIT J HAEMATOL, V128, P192, DOI 10.1111/j.1365-2141.2004.05286.x; Hernandez-Ilizaliturri FJ, 2005, CLIN CANCER RES, V11, P5984, DOI 10.1158/1078-0432.CCR-05-0577; Hideshima T, 2000, BLOOD, V96, P2943, DOI 10.1182/blood.V96.9.2943; Higgins JJ, 2004, NEUROLOGY, V63, P1927, DOI 10.1212/01.WNL.0000146196.01316.A2; HIRATA RK, 1993, HEMATOL PATHOL, V7, P225; Hoang B, 2006, BLOOD, V107, P4484, DOI 10.1182/blood-2005-09-3926; Hohberger B, 2009, FEBS LETT, V583, P633, DOI 10.1016/j.febslet.2009.01.018; Hsu AK, 2011, BLOOD, V117, P1605, DOI 10.1182/blood-2010-04-278432; Huang PHT, 1997, TERATOGEN CARCIN MUT, V17, P1, DOI 10.1002/(SICI)1520-6866(1997)17:1<1::AID-TCM2>3.0.CO;2-L; Ito T, 2011, CELL MOL LIFE SCI, V68, P1569, DOI 10.1007/s00018-010-0619-9; Ito T, 2010, SCIENCE, V327, P1345, DOI 10.1126/science.1177319; IYER CGS, 1971, B WORLD HEALTH ORGAN, V45, P719; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Jacobson JM, 1997, NEW ENGL J MED, V336, P1487, DOI 10.1056/NEJM199705223362103; Jadersten M, 2009, HAEMATOL-HEMATOL J, V94, P1762, DOI 10.3324/haematol.2009.011528; Jakubikova J, 2011, BLOOD, V117, P4409, DOI 10.1182/blood-2010-02-267344; Jinushi M, 2008, P NATL ACAD SCI USA, V105, P1285, DOI 10.1073/pnas.0711293105; Jo S, 2005, J NEUROCHEM, V94, P1212, DOI 10.1111/j.1471-4159.2005.03344.x; Johnson DC, 2008, BLOOD, V112, P4924, DOI 10.1182/blood-2008-02-140434; JONSSON NA, 1972, ACTA PHARM SUEC, V9, P543; Kenyon BM, 1997, EXP EYE RES, V64, P971, DOI 10.1006/exer.1997.0292; Knobloch J, 2008, MOL CELL BIOL, V28, P529, DOI 10.1128/MCB.00533-07; Knobloch J, 2007, FASEB J, V21, P1410, DOI 10.1096/fj.06-7603com; Kumar MS, 2011, BLOOD, V118, P4666, DOI 10.1182/blood-2010-12-324715; Kumar S, 2007, LEUKEMIA, V21, P2035, DOI 10.1038/sj.leu.2404801; Kyle RA, 2008, BLOOD, V111, P2962, DOI 10.1182/blood-2007-10-078022; Lacy MQ, 2009, J CLIN ONCOL, V27, P5008, DOI 10.1200/JCO.2009.23.6802; Landowski TH, 2005, CANCER RES, V65, P3828, DOI 10.1158/0008-5472.CAN-04-3684; Lanier LL, 2008, NAT IMMUNOL, V9, P495, DOI 10.1038/ni1581; LeBlanc R, 2004, BLOOD, V103, P1787, DOI 10.1182/blood-2003-02-0361; Lee KM, 2011, BBA-MOL CELL RES, V1813, P448, DOI 10.1016/j.bbamcr.2011.01.005; LENZ W, 1962, LANCET, V1, P45; Leppert ER, 2006, CURR DRUG METAB, V7, P677, DOI 10.2174/138920006778017777; Li SR, 2011, BLOOD, V117, P5157, DOI 10.1182/blood-2010-10-314278; List A, 2006, NEW ENGL J MED, V355, P1456, DOI 10.1056/NEJMoa061292; Lopez-Girona A, 2012, LEUKEMIA, V26, P2326, DOI 10.1038/leu.2012.119; Lu L, 2009, MICROVASC RES, V77, P78, DOI 10.1016/j.mvr.2008.08.003; Luptakova K, CANC IMMUNOL IMMUNOT; Madan S, 2011, BLOOD, V118, P1763, DOI 10.1182/blood-2011-04-350009; Masferrer JL, 2000, CANCER RES, V60, P1306; Matsui W, 2008, CANCER RES, V68, P190, DOI 10.1158/0008-5472.CAN-07-3096; MCBRIDE WG, 1961, LANCET, V2, P1358; McCarthy PL, 2012, NEW ENGL J MED, V366, P1770, DOI 10.1056/NEJMoa1114083; McMillin DW, 2010, NAT MED, V16, P483, DOI 10.1038/nm.2112; MELLIN G W, 1962, N Engl J Med, V267, P1184, DOI 10.1056/NEJM196212062672305; Mileshkin L, 2006, J CLIN ONCOL, V24, P4507, DOI 10.1200/JCO.2006.05.6689; Mitsiades CS, 2007, J CELL BIOCHEM, V101, P950, DOI 10.1002/jcb.21213; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Mitsiades N, 2002, BLOOD, V99, P4525, DOI 10.1182/blood.V99.12.4525; MOREIRA AL, 1993, J EXP MED, V177, P1675, DOI 10.1084/jem.177.6.1675; Muller GW, 1999, BIOORG MED CHEM LETT, V9, P1625, DOI 10.1016/S0960-894X(99)00250-4; Muller GW, 1996, J MED CHEM, V39, P3238, DOI 10.1021/jm9603328; Narayan VA, 1997, J BIOL CHEM, V272, P7801, DOI 10.1074/jbc.272.12.7801; Nefedova Y, 2003, LEUKEMIA, V17, P1175, DOI 10.1038/sj.leu.2402924; Ngo VN, 2011, NATURE, V470, P115, DOI 10.1038/nature09671; Noonan K, 2012, CLIN CANCER RES, V18, P1426, DOI 10.1158/1078-0432.CCR-11-1221; Noonan K, 2010, BLOOD, V116, P3554, DOI 10.1182/blood-2010-05-283895; Pal R, 2010, BLOOD, V115, P605, DOI 10.1182/blood-2009-05-221077; Palumbo A, 2012, NEW ENGL J MED, V366, P1759, DOI 10.1056/NEJMoa1112704; Palumbo A, 2012, EXPERT OPIN DRUG SAF, V11, P107, DOI 10.1517/14740338.2011.619975; Parman T, 1999, NAT MED, V5, P582, DOI 10.1038/8466; Payvandi F, 2005, J INTERF CYTOK RES, V25, P604, DOI 10.1089/jir.2005.25.604; Peacock CD, 2007, P NATL ACAD SCI USA, V104, P4048, DOI 10.1073/pnas.0611682104; Pellagatti A, 2007, P NATL ACAD SCI USA, V104, P11406, DOI 10.1073/pnas.0610477104; Pilarski LM, 2002, CLIN CANCER RES, V8, P3198; Prince HM, 2005, CLIN CANCER RES, V11, P5504, DOI 10.1158/1078-0432.CCR-05-0213; Racanelli V, 2010, BLOOD, V115, P1185, DOI 10.1182/blood-2009-06-228676; Raitakari M, 2000, BRIT J HAEMATOL, V110, P203, DOI 10.1046/j.1365-2141.2000.02131.x; SAMPAIO EP, 1991, J EXP MED, V173, P699, DOI 10.1084/jem.173.3.699; Schafer PH, 2003, J PHARMACOL EXP THER, V305, P1222, DOI 10.1124/jpet.102.048496; Shaffer AL, 2008, NATURE, V454, P226, DOI 10.1038/nature07064; SHESKIN J, 1965, CLIN PHARMACOL THER, V6, P303; Shi YJ, 2011, J BIOL CHEM, V286, P67, DOI 10.1074/jbc.M110.153221; Solomon DH, 2004, CIRCULATION, V109, P2068, DOI 10.1161/01.CIR.0000127578.21885.3E; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Stephens TD, 2000, BIOCHEM PHARMACOL, V59, P1489, DOI 10.1016/S0006-2952(99)00388-3; Sze DMY, 2001, BLOOD, V98, P2817, DOI 10.1182/blood.V98.9.2817; Tai YT, 2005, CANCER RES, V65, P11712, DOI 10.1158/0008-5472.CAN-05-1657; Tai YT, 2012, BLOOD, V119, P2074, DOI 10.1182/blood-2011-06-364521; Cibeira MT, 2011, LEUKEMIA RES, V35, P1178, DOI 10.1016/j.leukres.2011.02.009; Therapontos C, 2009, P NATL ACAD SCI USA, V106, P8573, DOI 10.1073/pnas.0901505106; Tsenova L, 2002, ANTIMICROB AGENTS CH, V46, P1887, DOI 10.1128/AAC.46.6.1887-1895.2002; Tsimberidou AM, 2003, LEUKEMIA RES, V27, P375, DOI 10.1016/S0145-2126(02)00082-6; VANDENBERGHE H, 1974, NATURE, V251, P437, DOI 10.1038/251437a0; Verhelle D, 2007, CANCER RES, V67, P746, DOI 10.1158/0008-5472.CAN-06-2317; Wei S, 2013, ONCOGENE, V32, P1110, DOI 10.1038/onc.2012.139; Wei S, 2009, P NATL ACAD SCI USA, V106, P12974, DOI 10.1073/pnas.0811267106; Welm AL, 2000, J BIOL CHEM, V275, P27406; Wittschieben BO, 2005, J BIOL CHEM, V280, P39982, DOI 10.1074/jbc.M507854200; Wohl DA, 2002, J INFECT DIS, V185, P1359, DOI 10.1086/340133; Xin W, 2008, MOL BIOL REP, V35, P251, DOI 10.1007/s11033-007-9077-3; Yabu T, 2005, BLOOD, V106, P125, DOI 10.1182/blood-2004-09-3679; Yaccoby S, 2002, BLOOD, V100, P4162, DOI 10.1182/blood-2002-03-0939; Yang YB, 2012, CANCER CELL, V21, P723, DOI 10.1016/j.ccr.2012.05.024; Zhu YX, 2011, BLOOD, V118, P4771, DOI 10.1182/blood-2011-05-356063	146	62	62	1	53	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 5	2013	32	36					4191	4202		10.1038/onc.2012.599	http://dx.doi.org/10.1038/onc.2012.599			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214WL	23318436				2022-12-28	WOS:000324168000001
J	Copeland, RA; Moyer, MP; Richon, VM				Copeland, R. A.; Moyer, M. P.; Richon, V. M.			Targeting genetic alterations in protein methyltransferases for personalized cancer therapeutics	ONCOGENE			English	Review						epigenetics; protein methyltransferases; personalized therapeutics; drug discovery; enzyme inhibitors	HISTONE METHYLTRANSFERASE; SOMATIC MUTATIONS; MULTIPLE-MYELOMA; CONFORMATIONAL ADAPTATION; ELONGATION COMPLEX; H3K79 METHYLATION; LYSINE 27; EZH2; LEUKEMIA; INHIBITORS	The human protein methyltransferases (PMTs) constitute a large enzyme class composed of two families, the protein lysine methyltransferases (PKMTs) and the protein arginine methyltransferases (PRMTs). Examples have been reported of both PKMTs and PRMTs that are genetically altered in specific human cancers, and in several cases these alterations have been demonstrated to confer a unique dependence of the cancer cells on PMT enzymatic activity for the tumorigenic phenotype. Examples of such driver alterations in PMTs will be presented together with a review of current efforts towards the discovery and development of small-molecule inhibitors of these enzymes as personalized cancer therapeutics. Oncogene (2013) 32, 939-946; doi:10.1038/onc.2012.552; published online 19 November 2012	[Copeland, R. A.; Moyer, M. P.; Richon, V. M.] R&D Epizyme Inc, Cambridge, MA 02139 USA		Copeland, RA (corresponding author), R&D Epizyme Inc, 325 Vassar St, Cambridge, MA 02139 USA.	RCopeland@Epizyme.com						Allan M, 2009, BIOORG MED CHEM LETT, V19, P1218, DOI 10.1016/j.bmcl.2008.12.075; Allis CD, 2007, CELL, V131, P633, DOI 10.1016/j.cell.2007.10.039; Arrowsmith CH, 2012, NAT REV DRUG DISCOV, V11, P384, DOI 10.1038/nrd3674; Ayton PM, 2004, MOL CELL BIOL, V24, P10470, DOI 10.1128/MCB.24.23.10470-10478.2004; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Basavapathruni A, 2012, CHEM BIOL DRUG DES, V80, P971, DOI 10.1111/cbdd.12050; Benedikt A, 2011, LEUKEMIA, V25, P135, DOI 10.1038/leu.2010.249; Bernt KM, 2011, CANCER CELL, V20, P66, DOI 10.1016/j.ccr.2011.06.010; Burgess J. L., 2012, Patent No. [WO2012005805, 2012005805]; Cao R, 2004, CURR OPIN GENET DEV, V14, P155, DOI 10.1016/j.gde.2004.02.001; Cheng XD, 2005, ANNU REV BIOPH BIOM, V34, P267, DOI 10.1146/annurev.biophys.34.040204.144452; Chesi M, 1998, BLOOD, V92, P3025, DOI 10.1182/blood.V92.9.3025.421k53_3025_3034; Chiang PK, 1998, PHARMACOL THERAPEUT, V77, P115, DOI 10.1016/S0163-7258(97)00089-2; Copeland R. A., 2004, ENZYMES PRACTICAL IN; Copeland R. A., 2012, PCT Int. Appl. Pat., Patent No. [WO 2012034132, 2012034132]; Copeland RA, 2012, DRUG DISCOV TODAY TH, V9, pe83, DOI DOI 10.1016/J.DDSTR.2011.08.001; Copeland RA, 2006, NAT REV DRUG DISCOV, V5, P730, DOI 10.1038/nrd2082; Copeland RA, 2011, FUTURE MED CHEM, V3, P1491, DOI [10.4155/fmc.11.112, 10.4155/FMC.11.112]; Copeland RA, 2010, CURR OPIN CHEM BIOL, V14, P505, DOI 10.1016/j.cbpa.2010.06.174; Copeland RA, 2009, NAT REV DRUG DISCOV, V8, P724, DOI 10.1038/nrd2974; Daigle SR, 2011, CANCER CELL, V20, P53, DOI 10.1016/j.ccr.2011.06.009; Duquenne C., 2011, Indazoles, Patent No. 2011140325; Ernst T, 2010, NAT GENET, V42, P722, DOI 10.1038/ng.621; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; Ferguson A. D., 2011, STRUCTURE; Harris WJ, 2012, CANCER CELL, V21, P473, DOI 10.1016/j.ccr.2012.03.014; He NH, 2011, P NATL ACAD SCI USA, V108, pE636, DOI 10.1073/pnas.1107107108; Hess JL, 2004, P NATL ACAD SCI USA, V101, P16985, DOI 10.1073/pnas.0407898101; Huynh T, 2009, BIOORG MED CHEM LETT, V19, P2924, DOI 10.1016/j.bmcl.2009.04.075; Jo SY, 2011, BLOOD, V117, P4759, DOI 10.1182/blood-2010-12-327668; Keats JJ, 2005, BLOOD, V105, P4060, DOI 10.1182/blood-2004-09-3704; Keats JJ, 2003, BLOOD, V101, P1520, DOI 10.1182/blood-2002-06-1675; Kelly TK, 2010, NAT BIOTECHNOL, V28, P1069, DOI 10.1038/nbt.1678; Knight S. D., 2012, PCT Int. Appl. Pat., Patent No. [WO 2012075080, 2012075080]; Knutson SK, 2012, NAT CHEM BIOL, V8, P890, DOI [10.1038/NCHEMBIO.1084, 10.1038/nchembio.1084]; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Krivtsov AV, 2008, CANCER CELL, V14, P355, DOI 10.1016/j.ccr.2008.10.001; Krivtsov AV, 2007, NAT REV CANCER, V7, P823, DOI 10.1038/nrc2253; Kubicek S, 2007, MOL CELL, V25, P473, DOI 10.1016/j.molcel.2007.01.017; LaFrance L, 2011, Patent No. [WO2011140324, 2011140324]; Lee YH, 2009, MOL ENDOCRINOL, V23, P425, DOI 10.1210/me.2008-0380; Li B, 2009, J BIOL CHEM, V284, P7970, DOI 10.1074/jbc.M808220200; Lin CQ, 2010, MOL CELL, V37, P429, DOI 10.1016/j.molcel.2010.01.026; Liu F, 2009, J MED CHEM, V52, P7950, DOI 10.1021/jm901543m; Luo MK, 2012, ACS CHEM BIOL, V7, P443, DOI 10.1021/cb200519y; Mahmoudi T, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000539; Marango J, 2008, BLOOD, V111, P3145, DOI 10.1182/blood-2007-06-092122; Martinez-Garcia E, 2011, BLOOD, V117, P211, DOI 10.1182/blood-2010-07-298349; McCabe MT, 2012, P NATL ACAD SCI USA, V109, P2989, DOI 10.1073/pnas.1116418109; Mochizuki-Kashio M, 2011, BLOOD, V118, P6553, DOI 10.1182/blood-2011-03-340554; Mori S, 2010, BIOORGAN MED CHEM, V18, P8158, DOI 10.1016/j.bmc.2010.10.022; Morin RD, 2010, NAT GENET, V42, P181, DOI 10.1038/ng.518; Muntean AG, 2010, CANCER CELL, V17, P609, DOI 10.1016/j.ccr.2010.04.012; Nikoloski G, 2010, NAT GENET, V42, P665, DOI 10.1038/ng.620; Ntziachristos P, 2012, NAT MED, V18, P298, DOI 10.1038/nm.2651; Okada Y, 2005, CELL, V121, P167, DOI 10.1016/j.cell.2005.02.020; Onder TT, 2012, NATURE, V483, P598, DOI 10.1038/nature10953; Parsons DW, 2011, SCIENCE, V331, P435, DOI 10.1126/science.1198056; Purandare AV, 2008, BIOORG MED CHEM LETT, V18, P4438, DOI 10.1016/j.bmcl.2008.06.026; Richon VM, 2011, CHEM BIOL DRUG DES, V78, P199, DOI 10.1111/j.1747-0285.2011.01135.x; Robinson G, 2012, NATURE, V488, P43, DOI 10.1038/nature11213; Simon JA, 2008, MUTAT RES-FUND MOL M, V647, P21, DOI 10.1016/j.mrfmmm.2008.07.010; Slany RK, 1998, MOL CELL BIOL, V18, P122, DOI 10.1128/MCB.18.1.122; Slany RK, 2009, HAEMATOL-HEMATOL J, V94, P984, DOI 10.3324/haematol.2008.002436; Sneeringer CJ, 2010, P NATL ACAD SCI USA, V107, P20980, DOI 10.1073/pnas.1012525107; Spannhoff A, 2007, BIOORG MED CHEM LETT, V17, P4150, DOI 10.1016/j.bmcl.2007.05.088; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Thiel AT, 2010, CANCER CELL, V17, P148, DOI 10.1016/j.ccr.2009.12.034; van Haaften G, 2009, NAT GENET, V41, P521, DOI 10.1038/ng.349; Vedadi M, 2011, NAT CHEM BIOL, V7, P566, DOI [10.1038/NCHEMBIO.599, 10.1038/nchembio.599]; Webb KJ, 2010, BIOCHEMISTRY-US, V49, P5225, DOI 10.1021/bi100428x; Yao Y, 2011, J AM CHEM SOC, V133, P16746, DOI 10.1021/ja206312b; ZELEZNIKLE NJ, 1994, P NATL ACAD SCI USA, V91, P10610, DOI 10.1073/pnas.91.22.10610	73	59	59	0	28	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 21	2013	32	8					939	946		10.1038/onc.2012.552	http://dx.doi.org/10.1038/onc.2012.552			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	111LQ	23160372	Green Published, hybrid			2022-12-28	WOS:000316523200001
J	Cremona, CA; Behrens, A				Cremona, C. A.; Behrens, A.			ATM signalling and cancer	ONCOGENE			English	Review						ATM; signalling; cancer	DNA-DAMAGE RESPONSE; NF-KAPPA-B; DOUBLE-STRAND BREAKS; INHIBITS HOMOLOGOUS RECOMBINATION; ONCOGENE-INDUCED SENESCENCE; ATAXIA-TELANGIECTASIA; OXIDATIVE STRESS; KINASE-ACTIVITY; ACTIVATES ATM; DEPENDENT PHOSPHORYLATION	ATM, the protein kinase mutated in the rare human disease ataxia telangiectasia (A-T), has been the focus of intense scrutiny over the past two decades. Initially this was because of the unusual radiosensitive phenotype of cells from A-T patients, and latterly because investigating ATM signalling has yielded valuable insights into the DNA damage response, redox signalling and cancer. With the recent explosion in genomic data, ATM alterations have been revealed both in the germline as a predisposing factor for cancer and as somatic changes in tumours themselves. Here we review these findings, as well as advances in the understanding of ATM signalling mechanisms in cancer and ATM inhibition as a strategy for cancer treatment.	[Cremona, C. A.; Behrens, A.] Canc Res UK London Res Inst, Mammalian Genet Lab, London WC2A 3LY, England	Cancer Research UK	Behrens, A (corresponding author), Canc Res UK London Res Inst, Mammalian Genet Lab, 44 Lincolns Inn Fields, London WC2A 3LY, England.	axel.behrens@cancer.org.uk		Behrens, Axel/0000-0002-1557-1143; Cremona, Catherine/0000-0002-5962-7399	ERC [281661]; Cancer Research UK; Cancer Research UK [15679] Funding Source: researchfish	ERC(European Research Council (ERC)European Commission); Cancer Research UK(Cancer Research UK); Cancer Research UK(Cancer Research UK)	We thank N. Kanu for comments on the manuscript. We apologise to colleagues whose work was not cited due to space considerations. This work was supported by an ERC Grant (281661 ATMINDDR) to AB. The London Research Institute is supported by Cancer Research UK.	Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Ai LB, 2012, J BIOL CHEM, V287, P18330, DOI 10.1074/jbc.M112.339317; Alexander A, 2010, P NATL ACAD SCI USA, V107, P4153, DOI 10.1073/pnas.0913860107; Ammazzalorso F, 2010, EMBO J, V29, P3156, DOI 10.1038/emboj.2010.205; Ando K, 2012, MOL CELL, V47, P681, DOI 10.1016/j.molcel.2012.06.024; Armata HL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024813; Armata HL, 2010, MOL CELL BIOL, V30, P5787, DOI 10.1128/MCB.00347-10; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894; Barlow C, 1996, CELL, V86, P159, DOI 10.1016/S0092-8674(00)80086-0; Bartkova J, 2006, NATURE, V444, P633, DOI 10.1038/nature05268; Batchelor E, 2008, MOL CELL, V30, P277, DOI 10.1016/j.molcel.2008.03.016; Batey MA, 2013, MOL CANCER THER, V12, P959, DOI 10.1158/1535-7163.MCT-12-0707; Beggs AD, 2013, J PATHOL, V229, P697, DOI 10.1002/path.4132; Bencokova Z, 2009, MOL CELL BIOL, V29, P526, DOI 10.1128/MCB.01301-08; Berkovich E, 2007, NAT CELL BIOL, V9, P683, DOI 10.1038/ncb1599; Bhatia N, 2013, J INVEST DERMATOL, V133, P759, DOI 10.1038/jid.2012.355; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Bolderson E, 2004, HUM MOL GENET, V13, P2937, DOI 10.1093/hmg/ddh316; Bonanni B, 2012, J CLIN ONCOL, V30, P2593, DOI 10.1200/JCO.2011.39.3769; Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Bouwman P, 2012, NAT REV CANCER, V12, P587, DOI 10.1038/nrc3342; Brunton H, 2011, MOL CELL BIOL, V31, P4022, DOI 10.1128/MCB.05289-11; Bryant HE, 2006, NUCLEIC ACIDS RES, V34, P1685, DOI 10.1093/nar/gkl108; Bunting SF, 2010, CELL, V141, P243, DOI 10.1016/j.cell.2010.03.012; Burdak-Rothkamm S, 2008, CANCER RES, V68, P7059, DOI 10.1158/0008-5472.CAN-08-0545; Cam H, 2010, MOL CELL, V40, P509, DOI 10.1016/j.molcel.2010.10.030; Chen SJ, 2003, ONCOGENE, V22, P6332, DOI 10.1038/sj.onc.1206760; Cheng WH, 2008, MOL BIOL CELL, V19, P3923, DOI 10.1091/mbc.E07-07-0698; Chiba N, 2012, P NATL ACAD SCI USA, V109, P2760, DOI 10.1073/pnas.1018867108; Cosentino C, 2011, EMBO J, V30, P546, DOI 10.1038/emboj.2010.330; Daniel JA, 2012, J CELL BIOL, V198, P295, DOI 10.1083/jcb.201204035; Daniel JA, 2008, J CELL BIOL, V183, P777, DOI 10.1083/jcb.200805154; Darlington Y, 2012, ONCOGENE, V31, P1155, DOI 10.1038/onc.2011.303; Derheimer FA, 2010, FEBS LETT, V584, P3675, DOI 10.1016/j.febslet.2010.05.031; Di Micco R, 2006, NATURE, V444, P638, DOI 10.1038/nature05327; Di Micco R, 2011, NAT CELL BIOL, V13, P292, DOI 10.1038/ncb2170; Difilippantonio S, 2005, NAT CELL BIOL, V7, P675, DOI 10.1038/ncb1270; Digweed M, 2004, DNA REPAIR, V3, P1207, DOI 10.1016/j.dnarep.2004.03.004; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Dodson GE, 2006, J BIOL CHEM, V281, P1692, DOI 10.1074/jbc.M509577200; Doil C, 2009, CELL, V136, P435, DOI 10.1016/j.cell.2008.12.041; Duan X, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019532; Dupre A, 2006, NAT STRUCT MOL BIOL, V13, P451, DOI 10.1038/nsmb1090; Elson A, 1996, P NATL ACAD SCI USA, V93, P13084, DOI 10.1073/pnas.93.23.13084; Evans JMM, 2005, BMJ-BRIT MED J, V330, P1304, DOI 10.1136/bmj.38415.708634.F7; Fernandes N, 2005, J BIOL CHEM, V280, P15158, DOI 10.1074/jbc.M412065200; Gamper AM, 2012, J BIOL CHEM, V287, P12445, DOI 10.1074/jbc.M112.352310; Ginjala V, 2011, MOL CELL BIOL, V31, P1972, DOI 10.1128/MCB.00981-10; Giovannucci E, 2010, DIABETES CARE, V33, P1674, DOI 10.2337/dc10-0666; Goldgar DE, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2919; Golding SE, 2012, CELL CYCLE, V11, P1167, DOI 10.4161/cc.11.6.19576; Golding SE, 2009, MOL CANCER THER, V8, P2894, DOI 10.1158/1535-7163.MCT-09-0519; Goodarzi AA, 2008, MOL CELL, V31, P167, DOI 10.1016/j.molcel.2008.05.017; Goodarzi AA, 2009, BIOCHEM SOC T, V37, P569, DOI 10.1042/BST0370569; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Guarini A, 2012, HAEMATOL-HEMATOL J, V97, P47, DOI 10.3324/haematol.2011.049270; Gudjonsson T, 2012, CELL, V150, P697, DOI 10.1016/j.cell.2012.06.039; Guo Z, 2010, SCIENCE, V330, P517, DOI 10.1126/science.1192912; Halaby MJ, 2008, CELL SIGNAL, V20, P1555, DOI 10.1016/j.cellsig.2008.04.011; Halazonetis TD, 2008, SCIENCE, V319, P1352, DOI 10.1126/science.1140735; Hayashida T, 2010, P NATL ACAD SCI USA, V107, P1100, DOI 10.1073/pnas.0912710107; He L, 2011, BIOCHEM BIOPH RES CO, V409, P489, DOI 10.1016/j.bbrc.2011.05.032; Helleday T, 2008, NAT REV CANCER, V8, P193, DOI 10.1038/nrc2342; Hickson I, 2004, CANCER RES, V64, P9152, DOI 10.1158/0008-5472.CAN-04-2727; Hollestelle A, 2010, CURR OPIN GENET DEV, V20, P268, DOI 10.1016/j.gde.2010.02.009; Hong YS, 2012, INT J ONCOL, V41, P76, DOI 10.3892/ijo.2012.1448; Huang J, 2011, CANCER RES, V71, P6310, DOI 10.1158/0008-5472.CAN-10-3397; Ichijima Y, 2011, GENE DEV, V25, P959, DOI 10.1101/gad.2030811; Ichijima Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008821; Ismail IH, 2010, J CELL BIOL, V191, P45, DOI 10.1083/jcb.201003034; Ito K, 2004, NATURE, V431, P997, DOI 10.1038/nature02989; Ito K, 2007, J IMMUNOL, V178, P103, DOI 10.4049/jimmunol.178.1.103; Jazayeri A, 2008, EMBO J, V27, P1953, DOI 10.1038/emboj.2008.128; Jiang H, 2009, GENE DEV, V23, P1895, DOI 10.1101/gad.1815309; Jinushi M, 2012, CANCER RES, V72, P56, DOI 10.1158/0008-5472.CAN-11-2028; Jurado S, 2012, J EXP MED, V209, P1629, DOI 10.1084/jem.20120785; Jurado S, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001170; Kalev P, 2012, CANCER RES, V72, P6414, DOI 10.1158/0008-5472.CAN-12-1667; Kanu N, 2007, EMBO J, V26, P2933, DOI 10.1038/sj.emboj.7601733; Kanu N, 2010, J BIOL CHEM, V285, P38534, DOI 10.1074/jbc.M110.145896; Karlseder J, 2004, PLOS BIOL, V2, P1150, DOI 10.1371/journal.pbio.0020240; Keimling M, 2011, FASEB J, V25, P3849, DOI 10.1096/fj.11-185546; Kennedy RD, 2007, J CLIN INVEST, V117, P1440, DOI 10.1172/JCI31245; Kim YC, 2009, NAT CELL BIOL, V11, P92, DOI 10.1038/ncb1817; Kolas NK, 2007, SCIENCE, V318, P1637, DOI 10.1126/science.1150034; Kozlov SV, 2011, J BIOL CHEM, V286, P9107, DOI 10.1074/jbc.M110.204065; Kruger A, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001959; Kruhlak M, 2007, NATURE, V447, P730, DOI 10.1038/nature05842; Kruhlak MJ, 2006, J CELL BIOL, V172, P823, DOI 10.1083/jcb.200510015; Kwong LN, 2008, ONCOGENE, V27, P1013, DOI 10.1038/sj.onc.1210708; Le Guezennec X, 2010, TRENDS BIOCHEM SCI, V35, P109, DOI 10.1016/j.tibs.2009.09.005; Lee JH, 2007, ONCOGENE, V26, P7741, DOI 10.1038/sj.onc.1210872; Lee J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034456; Lee JH, 2005, SCIENCE, V308, P551, DOI 10.1126/science.1108297; Lee MH, 2011, MOL CELL, V43, P180, DOI 10.1016/j.molcel.2011.06.017; Li M, 2010, P NATL ACAD SCI USA, V107, P14188, DOI 10.1073/pnas.1005960107; Li Y, 2010, MOL CANCER THER, V9, P113, DOI 10.1158/1535-7163.MCT-08-1189; Liao MJ, 1999, GENE DEV, V13, P1246, DOI 10.1101/gad.13.10.1246; Llorca O, 2003, ONCOGENE, V22, P3867, DOI 10.1038/sj.onc.1206649; Loizou JI, 2011, CANCER CELL, V19, P587, DOI 10.1016/j.ccr.2011.03.022; Lukas C, 2011, NAT CELL BIOL, V13, P243, DOI 10.1038/ncb2201; Mahajan K, 2012, J BIOL CHEM, V287, P22112, DOI 10.1074/jbc.M112.357384; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Mattiroli F, 2012, CELL, V150, P1182, DOI 10.1016/j.cell.2012.08.005; McNees CJ, 2005, EMBO J, V24, P2447, DOI 10.1038/sj.emboj.7600704; Menissier-de Murcia J, 2001, MOL CELL BIOL, V21, P1828; Miles PD, 2007, AM J PHYSIOL-ENDOC M, V293, pE70, DOI 10.1152/ajpendo.00259.2006; Moyal L, 2011, MOL CELL, V41, P529, DOI 10.1016/j.molcel.2011.02.015; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; Noon AT, 2010, NAT CELL BIOL, V12, P177, DOI 10.1038/ncb2017; O'Sullivan RJ, 2010, NAT REV MOL CELL BIO, V11, P171, DOI 10.1038/nrm2848; Okamoto K, 2013, NATURE, V494, P502, DOI 10.1038/nature11873; Olcina M, 2010, CLIN CANCER RES, V16, P5624, DOI 10.1158/1078-0432.CCR-10-0286; Palmieri D, 2011, ONCOGENE, V30, P3024, DOI 10.1038/onc.2011.21; Pazolli E, 2012, CANCER RES, V72, P2251, DOI 10.1158/0008-5472.CAN-11-3386; Pellegrini M, 2006, NATURE, V443, P222, DOI 10.1038/nature05112; Penicud K, 2014, ONCOGENE, V33, P525, DOI 10.1038/onc.2012.597; Perry J, 2003, CELL, V112, P151, DOI 10.1016/S0092-8674(03)00033-3; Pietzner J, 2013, HUM MOL GENET, V22, P493, DOI 10.1093/hmg/dds448; Pospelova TV, 2009, CELL CYCLE, V8, P4112, DOI 10.4161/cc.8.24.10215; Prise KM, 2009, NAT REV CANCER, V9, P351, DOI 10.1038/nrc2603; Rainey MD, 2008, CANCER RES, V68, P7466, DOI 10.1158/0008-5472.CAN-08-0763; Rashi-Elkeles S, 2011, MOL ONCOL, V5, P336, DOI 10.1016/j.molonc.2011.06.004; Ray A, 2009, MOL CELL BIOL, V29, P6206, DOI 10.1128/MCB.00503-09; Reaper PM, 2011, NAT CHEM BIOL, V7, P428, DOI [10.1038/NCHEMBIO.573, 10.1038/nchembio.573]; Reiman A, 2011, BRIT J CANCER, V105, P586, DOI 10.1038/bjc.2011.266; Reina-San-Martin B, 2004, J EXP MED, V200, P1103, DOI 10.1084/jem.20041162; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Reliene R, 2006, DNA REPAIR, V5, P852, DOI 10.1016/j.dnarep.2006.05.003; Ren J, 2009, CELL RES, V19, P271, DOI 10.1038/cr.2009.6; Renwick A, 2006, NAT GENET, V38, P873, DOI 10.1038/ng1837; Ripka S, 2010, GUT, V59, P1101, DOI 10.1136/gut.2009.189720; Roberts NJ, 2012, CANCER DISCOV, V2, P41, DOI 10.1158/2159-8290.CD-11-0194; Rodier F, 2009, NAT CELL BIOL, V11, P973, DOI 10.1038/ncb1909; Roossink F, 2012, INT J CANCER, V131, P2056, DOI 10.1002/ijc.27488; Sahu RP, 2009, BRIT J CANCER, V100, P1425, DOI 10.1038/sj.bjc.6605039; Salimi M, 2012, MED ONCOL, V29, P1502, DOI 10.1007/s12032-011-0043-5; Savic V, 2009, MOL CELL, V34, P298, DOI 10.1016/j.molcel.2009.04.012; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHALCH DS, 1970, NEW ENGL J MED, V282, P1396, DOI 10.1056/NEJM197006182822503; Schneider JG, 2006, CELL METAB, V4, P377, DOI 10.1016/j.cmet.2006.10.002; Semlitsch M, 2011, DNA REPAIR, V10, P848, DOI 10.1016/j.dnarep.2011.05.004; Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282; Shanbhag NM, 2010, CELL, V141, P970, DOI 10.1016/j.cell.2010.04.038; Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Shiloh Y, 2013, NAT REV MOL CELL BIO, V14, P197, DOI 10.1038/nrm3546; Shiotani B, 2009, MOL CELL, V33, P547, DOI 10.1016/j.molcel.2009.01.024; Sirbu BM, 2011, GENE DEV, V25, P1320, DOI 10.1101/gad.2053211; Skowronska A, 2012, J CLIN ONCOL, V30, P4524, DOI 10.1200/JCO.2011.41.0852; Smith GCM, 1999, MOL CELL BIOL, V19, P6076; So SR, 2009, J CELL BIOL, V187, P977, DOI 10.1083/jcb.200906064; Song H, 2007, NAT CELL BIOL, V9, P573, DOI 10.1038/ncb1571; Song LB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025454; Spring K, 2002, NAT GENET, V32, P185, DOI 10.1038/ng958; Squatrito M, 2010, CANCER CELL, V18, P619, DOI 10.1016/j.ccr.2010.10.034; Stewart GS, 2009, CELL, V136, P420, DOI 10.1016/j.cell.2008.12.042; Stiff T, 2006, EMBO J, V25, P5775, DOI 10.1038/sj.emboj.7601446; Stracker TH, 2011, NAT REV MOL CELL BIO, V12, P90, DOI 10.1038/nrm3047; Sullivan KD, 2012, NAT CHEM BIOL, V8, P646, DOI [10.1038/nchembio.965, 10.1038/NCHEMBIO.965]; SWIFT M, 1987, NEW ENGL J MED, V316, P1289, DOI 10.1056/NEJM198705213162101; Taubes G, 2012, SCIENCE, V335, P286, DOI [10.1126/science.335.6064.29, 10.1126/science.335.6064.28]; Thompson D, 2005, JNCI-J NATL CANCER I, V97, P813, DOI 10.1093/jnci/dji141; Tian B, 2009, NAT CELL BIOL, V11, P211, DOI 10.1038/ncb1829; Umesako S, 2005, BREAST CANCER RES, V7, pR164, DOI 10.1186/bcr968; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; Vadnais C, 2012, NUCLEIC ACIDS RES, V40, P4483, DOI 10.1093/nar/gks041; Valentin-Vega YA, 2012, BLOOD, V119, P1490, DOI 10.1182/blood-2011-08-373639; Vazquez-Martin A, 2011, CELL CYCLE, V10, P1499, DOI 10.4161/cc.10.9.15423; Wang L, 2012, MOL CANCER THER, V11, P2401, DOI 10.1158/1535-7163.MCT-12-0448; Wang N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039446; Wang YA, 1997, P NATL ACAD SCI USA, V94, P14590, DOI 10.1073/pnas.94.26.14590; Westphal CH, 1997, NAT GENET, V16, P397, DOI 10.1038/ng0897-397; White JS, 2008, CELL CYCLE, V7, P1277, DOI 10.4161/cc.7.9.5961; White JS, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000758; Williams BR, 2002, CURR BIOL, V12, P648, DOI 10.1016/S0960-9822(02)00763-7; Williamson CT, 2010, MOL CANCER THER, V9, P347, DOI 10.1158/1535-7163.MCT-09-0872; Wu JX, 2011, NAT STRUCT MOL BIOL, V18, P761, DOI 10.1038/nsmb.2078; Wu J, 2012, MOL CELL, V46, P351, DOI 10.1016/j.molcel.2012.02.018; Wu ZH, 2006, SCIENCE, V311, P1141, DOI 10.1126/science.1121513; Wu ZH, 2008, EMBO J, V27, P1963, DOI 10.1038/emboj.2008.127; Wu ZH, 2010, MOL CELL, V40, P75, DOI 10.1016/j.molcel.2010.09.010; Wuerzberger-Davis SM, 2007, ONCOGENE, V26, P641, DOI 10.1038/sj.onc.1209815; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Yajima H, 2009, J MOL BIOL, V385, P800, DOI 10.1016/j.jmb.2008.11.036; Yamamoto K, 2012, J CELL BIOL, V198, P305, DOI 10.1083/jcb.201204098; Yang CY, 2011, MOL CELL, V44, P597, DOI 10.1016/j.molcel.2011.09.016; Yang YB, 2011, MOL CELL BIOL, V31, P2774, DOI 10.1128/MCB.01139-10; Yin H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024080; Young DB, 2005, J BIOL CHEM, V280, P27587, DOI 10.1074/jbc.M411689200; Zannini L, 2012, J MOL CELL BIOL, V4, P294, DOI 10.1093/jmcb/mjs035; Zenz T, 2010, NAT REV CANCER, V10, P37, DOI 10.1038/nrc2764; Zha S, 2008, P NATL ACAD SCI USA, V105, P9302, DOI 10.1073/pnas.0803520105; Zha S, 2011, NATURE, V469, P250, DOI 10.1038/nature09604; Zhang TY, 2012, CELL REP, V2, P1498, DOI 10.1016/j.celrep.2012.11.002; Zhou KX, 2011, NAT GENET, V43, P117, DOI 10.1038/ng.735; Ziv Y, 2006, NAT CELL BIOL, V8, P870, DOI 10.1038/ncb1446	199	132	135	1	45	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 26	2014	33	26					3351	3360		10.1038/onc.2013.275	http://dx.doi.org/10.1038/onc.2013.275			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK9WM	23851492				2022-12-28	WOS:000338779300001
J	Lin, A; Yao, J; Zhuang, L; Wang, D; Han, J; Lam, EWF; Gan, B				Lin, A.; Yao, J.; Zhuang, L.; Wang, D.; Han, J.; Lam, E. W-F; Gan, B.		TCGA Res Network	The FoxO-BNIP3 axis exerts a unique regulation of mTORC1 and cell survival under energy stress	ONCOGENE			English	Article						FoxO; mTORC1; energy stress; BNIP3	TSC1-TSC2 COMPLEX; TUMOR SUPPRESSORS; MAMMALIAN TARGET; GROWTH-CONTROL; AMPK; LKB1; AUTOPHAGY; KINASE; FOXOS; PHOSPHORYLATION	Normal cells possess adaptive mechanisms to couple energy availability with cell growth (cell size increase) and survival, and imbalances are associated with major diseases such as cancer. Inactivation of critical regulators involved in energy stress response, including adenosine monophosphate-activated protein kinase (AMPK), liver kinase B1 (LKB1), tuberous sclerosis complex 1 (TSC1) and tuberous sclerosis complex 2 (TSC2), leads to uncontrolled cell growth yet increased apoptosis under energy stress. These energy stress regulators are also important in tumor suppression and metabolism. Here, we show that forkhead box O (FoxO) transcription factor, a central regulator of tumor suppression and metabolism, plays a unique role in energy stress response. Fox Os inhibit the mammalian target of rapamycin complex 1 (mTORC1), a key regulator of cell growth, under energy stress, and inactivation of Fox Os alleviates energy stress-mediated mTORC1 repression. Surprisingly, unlike AMPK-, Lkb1- or Tsc1/2-deficient cells, FoxO-deficient cells exhibit decreased apoptosis under energy stress. FoxOs operate to inhibit mTORC1 signaling and cell survival independent of AMPK and TSC. Integrated transcriptomic and functional analyses identified BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3)-a negative regulator of both Rheb and Bcl2 prosurvival family members-as a key downstream target of FoxOs to inhibit mTORC1 function and promote apoptosis in response to energy stress. We show that p38 beta, but not AMPK, is likely to function upstream of FoxO-BNIP3 to mediate energy stress response. Finally, we reveal that low expression of FoxO or BNIP3 correlates with poor clinical outcomes in renal cancer patients. Together, our study uncovers a novel signaling circuit functioning to mediate cellular energy responses to control cell growth and survival. These findings also have important implications to human cancers.	[Lin, A.; Zhuang, L.; Wang, D.; Gan, B.] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA; [Yao, J.] Univ Texas MD Anderson Canc Ctr, Dept Neurooncol, Houston, TX 77030 USA; [Han, J.] Xiamen Univ, Key Lab, Minist Educ Cell Biol & Tumor Cell Engn, Sch Life Sci, Xiamen, Peoples R China; [Lam, E. W-F] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, London, England; [TCGA Res Network] Univ Texas Hlth Sci Ctr Houston, Univ Texas MD Anderson Canc Ctr, TCGA Genome Data Anal Ctr, Houston, TX 77030 USA; [Gan, B.] Univ Texas Houston, Grad Sch Biomed Sci, Program Canc Biol, Houston, TX USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; Xiamen University; Imperial College London; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston	Gan, B (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	bgan@mdanderson.org	Lam, Eric W-F/AAW-8566-2020; Gan, Boyi/HDM-4206-2022; Han, J/G-4671-2010	Lam, Eric W-F/0000-0003-1274-3576; 	MD Anderson Cancer Center, US Department of Defense [TS093049, PC100356]; LAM Foundation [LAM092P01-12]; Concern Foundation; Sidney Kimmel Foundation; TCGA grant from NCI/NIH [U24CA143883]; Cancer Research UK [12011] Funding Source: researchfish; NATIONAL CANCER INSTITUTE [U24CA143883, R01CA181196, P30CA016672] Funding Source: NIH RePORTER	MD Anderson Cancer Center, US Department of Defense(United States Department of Defense); LAM Foundation; Concern Foundation; Sidney Kimmel Foundation; TCGA grant from NCI/NIH; Cancer Research UK(Cancer Research UK); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Junjie Chen and Hui-Kuan Lin for critical reading of the paper. We also thank Dr Benoit Viollet for providing AMPK WT and KO MEFs and Dr Hsiao-Sheng Liu for providing BNIP3 expression plasmid. BG would also like to thank Ron DePinho for his encouragement and suggestions on this study. This study has been supported by grants from MD Anderson Cancer Center, US Department of Defense (TS093049 and PC100356), LAM Foundation (LAM092P01-12), Concern Foundation and Sidney Kimmel Foundation (to BG) and the TCGA grant U24CA143883 from NCI/NIH (to JY). BG is a Kimmel Scholar and a member of the MD Anderson Cancer Center (CA016672).	Accili D, 2004, CELL, V117, P421, DOI 10.1016/S0092-8674(04)00452-0; Bardeesy N, 2002, NATURE, V419, P162, DOI 10.1038/nature01045; Burton TR, 2009, CELL DEATH DIFFER, V16, P515, DOI 10.1038/cdd.2008.185; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Chen CC, 2010, DEV CELL, V18, P592, DOI 10.1016/j.devcel.2010.03.008; Chinnadurai G, 2008, ONCOGENE, V27, pS114, DOI 10.1038/onc.2009.49; Choo AY, 2010, MOL CELL, V38, P487, DOI 10.1016/j.molcel.2010.05.007; Corradetti MN, 2004, GENE DEV, V18, P1533, DOI 10.1101/gad.1199104; Dann SG, 2007, TRENDS MOL MED, V13, P252, DOI 10.1016/j.molmed.2007.04.002; Davila D, 2012, CELL DEATH DIFFER, V19, P1677, DOI 10.1038/cdd.2012.49; Efeyan A, 2013, NATURE, V493, P679, DOI 10.1038/nature11745; Gan BY, 2010, NATURE, V468, P701, DOI 10.1038/nature09595; Gan BY, 2010, CANCER CELL, V18, P472, DOI 10.1016/j.ccr.2010.10.019; Gan B, 2008, P NATL ACAD SCI USA, V105, P19384, DOI 10.1073/pnas.0810584105; Gan BY, 2005, J CELL BIOL, V170, P379, DOI 10.1083/jcb.200411106; Greer EL, 2007, J BIOL CHEM, V282, P30107, DOI 10.1074/jbc.M705325200; Gwinn DM, 2008, MOL CELL, V30, P214, DOI 10.1016/j.molcel.2008.03.003; Hahn-Windgassen A, 2005, J BIOL CHEM, V280, P32081, DOI 10.1074/jbc.M502876200; Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311; Ho KK, 2012, J BIOL CHEM, V287, P1545, DOI 10.1074/jbc.M111.284224; Huang J, 2008, BIOCHEM J, V412, P179, DOI 10.1042/BJ20080281; Inoki K, 2003, CELL, V115, P577, DOI 10.1016/S0092-8674(03)00929-2; Jones RG, 2009, GENE DEV, V23, P537, DOI 10.1101/gad.1756509; Khatri S, 2010, J BIOL CHEM, V285, P15960, DOI 10.1074/jbc.M110.121871; Kim SG, 2013, MOL CELL, V49, P172, DOI 10.1016/j.molcel.2012.10.003; Kobayashi T, 2001, P NATL ACAD SCI USA, V98, P8762, DOI 10.1073/pnas.151033798; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Laderoute KR, 2006, MOL CELL BIOL, V26, P5336, DOI 10.1128/MCB.00166-06; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Li Y, 2004, TRENDS BIOCHEM SCI, V29, P32, DOI 10.1016/j.tibs.2003.11.007; Li Y, 2007, J BIOL CHEM, V282, P35803, DOI 10.1074/jbc.M705231200; Linehan WM, 2004, CANCER CELL, V6, P223, DOI 10.1016/j.ccr.2004.09.006; Ma XJM, 2009, NAT REV MOL CELL BIO, V10, P307, DOI 10.1038/nrm2672; Mammucari C, 2007, CELL METAB, V6, P458, DOI 10.1016/j.cmet.2007.11.001; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Rini BI, 2009, LANCET, V373, P1119, DOI 10.1016/S0140-6736(09)60229-4; Shackelford DB, 2009, NAT REV CANCER, V9, P563, DOI 10.1038/nrc2676; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Shaw RJ, 2004, CANCER CELL, V6, P91, DOI 10.1016/j.ccr.2004.06.007; van der Horst A, 2007, NAT REV MOL CELL BIO, V8, P440, DOI 10.1038/nrm2190; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Zhang J, 2009, CELL DEATH DIFFER, V16, P939, DOI 10.1038/cdd.2009.16; Zheng M, 2011, NAT CELL BIOL, V13, P263, DOI 10.1038/ncb2168	46	59	61	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2014	33	24					3183	3194		10.1038/onc.2013.273	http://dx.doi.org/10.1038/onc.2013.273			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK4QU	23851496	Green Accepted			2022-12-28	WOS:000338410000011
J	Huang, L; Kuwahara, I; Matsumoto, K				Huang, L.; Kuwahara, I.; Matsumoto, K.			EWS represses cofilin 1 expression by inducing nuclear retention of cofilin 1 mRNA	ONCOGENE			English	Article						EWS; CFL1; RNA-binding protein	ACTIN-DEPOLYMERIZING FACTOR; CELL-CYCLE; PROTEIN; CANCER; BINDING; SARCOMA; PHOSPHORYLATION; IDENTIFICATION; INVOLVEMENT; ADF/COFILIN	In Ewing's sarcoma family tumors (ESFTs), the proto-oncogene EWS that encodes an RNA-binding protein is fused by chromosomal translocation to the gene encoding one of the E-twenty six (ETS) family of transcription factors, most commonly friend leukemia virus integration 1 (FLI-1). Although EWS/FLI-1 chimeric proteins are necessary for carcinogenesis, additional events seem to be required for transformation to occur. We have previously reported that a protein product of an EWS mRNA target, whose expression is negatively regulated by EWS but not by EWS/FLI-1, contributes to ESFT development. However, the mechanism by which EWS represses protein expression remains to be elucidated. Here, we report that overexpression of full-length EWS repressed protein expression and induced nuclear retention of reporter mRNAs in a tethering assay. In contrast, when a mutant lacking the EWS C-terminal nuclear localization signal (classified as a PY-NLS) was expressed, reporter protein expression was upregulated, and the number of cells exporting reporter mRNA to the cytoplasm increased. EWS binds to the 3'-untranslated region in another mRNA target, cofilin 1 (CFL1), and negatively regulates the expression of CFL1. Overexpression of EWS induced nuclear retention of CFL1 mRNA. Furthermore, ESFT cell proliferation and metastatic potential were suppressed by small interfering RNA-mediated CFL1 knockdown. Together, our findings suggest that EWS induces nuclear retention of CFL1 mRNA, thereby suppressing expression of CFL1, and that CFL1 promotes development of ESFT. Targeting CFL1 might therefore provide another novel approach for treatment of this aggressive disease.	[Huang, L.; Kuwahara, I.; Matsumoto, K.] RIKEN, Mol Entomol Lab, Wako, Saitama 3510198, Japan; [Huang, L.] Dalian Med Univ, Dept Pathophysiol, Dalian, Peoples R China; [Matsumoto, K.] Japan Sci & Technol Agcy, PRESTO, Kawaguchi, Saitama, Japan	RIKEN; Dalian Medical University; Japan Science & Technology Agency (JST)	Matsumoto, K (corresponding author), RIKEN, Chem Genet Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	matsumok@riken.jp	Huang, Lin/AAI-5740-2020; Matsumoto, Ken/F-9083-2013	Matsumoto, Ken/0000-0002-7864-3394	Ministry of Education, Culture, Sports, Science and Technology of Japan; PRESTO program from Japan Science and Technology Agency; RIKEN Foreign Postdoctoral Researchers Program	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); PRESTO program from Japan Science and Technology Agency; RIKEN Foreign Postdoctoral Researchers Program	We thank Dr Yasufumi Minami for providing plasmids and Dr Shinichi Nakagawa for kindly teaching us the detailed methods for in situ hybridization. This study was supported, in part, by a grant-in-aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan; PRESTO program from Japan Science and Technology Agency; and RIKEN Foreign Postdoctoral Researchers Program. L Huang was a foreign postdoctoral researcher of RIKEN.	Abe H, 1996, J CELL BIOL, V132, P871, DOI 10.1083/jcb.132.5.871; Castro MAA, 2010, CANCER-AM CANCER SOC, V116, P3645, DOI 10.1002/cncr.25125; Amano T, 2002, J BIOL CHEM, V277, P22093, DOI 10.1074/jbc.M201444200; Andersson MK, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-37; Andrianantoandro E, 2006, MOL CELL, V24, P13, DOI 10.1016/j.molcel.2006.08.006; Araya N, 2003, J BIOL CHEM, V278, P5427, DOI 10.1074/jbc.M210234200; Bernstein BW, 2010, TRENDS CELL BIOL, V20, P187, DOI 10.1016/j.tcb.2010.01.001; Chua BT, 2003, NAT CELL BIOL, V5, P1083, DOI 10.1038/ncb1070; Colombrita C, 2012, J BIOL CHEM, V287, P15635, DOI 10.1074/jbc.M111.333450; Davila M, 2003, J BIOL CHEM, V278, P36868, DOI 10.1074/jbc.M306196200; Deneen B, 2001, ONCOGENE, V20, P6731, DOI 10.1038/sj.onc.1204875; Dormann D, 2012, EMBO J, V31, P4258, DOI 10.1038/emboj.2012.261; Dutertre M, 2010, NAT STRUCT MOL BIOL, V17, P1358, DOI 10.1038/nsmb.1912; Estornes Y, 2007, INT J CANCER, V121, P2162, DOI 10.1002/ijc.22911; Felsch JS, 1999, CURR BIOL, V9, P485, DOI 10.1016/S0960-9822(99)80214-0; GUNSALUS KC, 1995, J CELL BIOL, V131, P1243, DOI 10.1083/jcb.131.5.1243; Hoell JI, 2011, NAT STRUCT MOL BIOL, V18, P1428, DOI 10.1038/nsmb.2163; Hotulainen P, 2005, MOL BIOL CELL, V16, P649, DOI 10.1091/mbc.E04-07-0555; Hsu FF, 2010, ONCOGENE, V29, P2864, DOI 10.1038/onc.2010.40; Huang L, 2012, CANCER RES, V72, P1260, DOI 10.1158/0008-5472.CAN-11-2254; Kovar H, 2001, CANCER RES, V61, P5992; Kovar Heinrich, 2011, Sarcoma, V2011, P1, DOI 10.1155/2011/837474; Lee YJ, 2005, MOL BIOTECHNOL, V31, P1, DOI 10.1385/MB:31:1:001; Leemann-Zakaryan Ruzanna P., 2011, Sarcoma, V2011, P218483, DOI 10.1155/2011/218483; Martoglio AM, 2000, MOL MED, V6, P750, DOI 10.1007/BF03402191; Naganuma T, 2012, EMBO J, V31, P4020, DOI 10.1038/emboj.2012.251; Neilsen Paul M., 2011, Sarcoma, V2011, P746939, DOI 10.1155/2011/746939; Nowak D, 2010, EUR J HISTOCHEM, V54, P59, DOI 10.4081/ejh.2010.e14; Paronetto MP, 2011, MOL CELL, V43, P353, DOI 10.1016/j.molcel.2011.05.035; Prasanth KV, 2005, CELL, V123, P249, DOI 10.1016/j.cell.2005.08.033; Rehklau K, 2012, CELL DEATH DIFFER, V19, P958, DOI 10.1038/cdd.2011.180; Solimini NL, 2012, SCIENCE, V337, P104, DOI 10.1126/science.1219580; Sone M, 2007, J CELL SCI, V120, P2498, DOI 10.1242/jcs.009357; Staege MS, 2004, CANCER RES, V64, P8213, DOI 10.1158/0008-5472.CAN-03-4059; Subbiah Vivek, 2011, Sarcoma, V2011, P686985, DOI 10.1155/2011/686985; Tanaka KJ, 2006, J BIOL CHEM, V281, P40096, DOI 10.1074/jbc.M609059200; Terasawa K, 2006, MOL CELL BIOL, V26, P3378, DOI 10.1128/MCB.26.9.3378-3389.2006; Terrier P, 1996, SEMIN DIAGN PATHOL, V13, P250; Toretsky JA, 2010, LANCET ONCOL, V11, P105, DOI 10.1016/S1470-2045(09)70391-2; Turhani D, 2006, ELECTROPHORESIS, V27, P1417, DOI 10.1002/elps.200500510; Tutucci E, 2011, NAT REV MOL CELL BIO, V12, P376, DOI 10.1038/nrm3119; Unwin RD, 2003, PROTEOMICS, V3, P1620, DOI 10.1002/pmic.200300464; Wang WG, 2007, NAT REV CANCER, V7, P429, DOI 10.1038/nrc2148; Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001; Yap CT, 2005, CELL MOTIL CYTOSKEL, V60, P153, DOI 10.1002/cm.20053; Zakaryan RP, 2006, J MOL BIOL, V363, P27, DOI 10.1016/j.jmb.2006.08.018	46	12	12	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2014	33	23					2995	3003		10.1038/onc.2013.255	http://dx.doi.org/10.1038/onc.2013.255			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EL	23831569				2022-12-28	WOS:000337232200006
J	Devine, DJ; Rostas, JW; Metge, BJ; Das, S; Mulekar, MS; Tucker, JA; Grizzle, WE; Buchsbaum, DJ; Shevde, LA; Samant, RS				Devine, D. J.; Rostas, J. W.; Metge, B. J.; Das, S.; Mulekar, M. S.; Tucker, J. A.; Grizzle, W. E.; Buchsbaum, D. J.; Shevde, L. A.; Samant, R. S.			Loss of N-Myc interactor promotes epithelial-mesenchymal transition by activation of TGF-beta/SMAD signaling	ONCOGENE			English	Article						N-Myc interactor; epithelial-mesenchymal transition; SMAD; breast cancer	GROWTH-FACTOR-BETA; CANCER STEM-CELLS; INTERFERON-GAMMA; BREAST; EMT; NMI; METASTASIS; SMAD7; TRANSCRIPTION; PROGRESSION	Epithelial-mesenchymal transition is one of the critical cellular programs that facilitate the progression of breast cancer to an invasive disease. We have observed that the expression of N-myc interactor (NMI) decreases significantly during progression of breast cancer, specifically in invasive and metastatic stages. Recapitulation of this loss in breast cell lines with epithelial morphology (MCF10A (non-tumorigenic) and T47D (tumorigenic)) by silencing NMI expression causes mesenchymal-like morphological changes in 3D growth, accompanied by upregulation of SLUG and ZEB2 and increased invasive properties. Conversely, we found that restoring NMI expression attenuated the mesenchymal attributes of metastatic breast cancer cells, accompanied by distinctly circumscribed 3D growth with basement membrane deposition and decreased invasion. Further investigations into the downstream signaling modulated by NMI revealed that NMI expression negatively regulates SMAD signaling, which is a key regulator of cellular plasticity. We demonstrate that NMI blocks TGF-beta/SMAD signaling via upregulation of SMAD7, a negative feedback regulator of the pathway. We also provide evidence that NMI activates STAT signaling, which negatively modulates TGF-beta/SMAD signaling. Taken together, our findings suggest that loss of NMI during breast cancer progression could be one of the driving factors that enhance the invasive ability of breast cancer by aberrant activation of TGF-beta/SMAD signaling.	[Devine, D. J.; Rostas, J. W.] Univ S Alabama, Mitchell Canc Inst, Mobile, AL 35294 USA; [Rostas, J. W.] Univ S Alabama, Dept Surg, Mobile, AL 35294 USA; [Metge, B. J.; Das, S.; Grizzle, W. E.; Shevde, L. A.; Samant, R. S.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; [Metge, B. J.; Das, S.; Shevde, L. A.; Samant, R. S.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA; [Mulekar, M. S.] Univ S Alabama, Dept Math & Stat, Mobile, AL 35294 USA; [Tucker, J. A.] Univ S Alabama, Dept Pathol, Mobile, AL 35294 USA; [Buchsbaum, D. J.] Univ Alabama Birmingham, Dept Radiat Oncol, Birmingham, AL USA	University of South Alabama; University of South Alabama; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of South Alabama; University of South Alabama; University of Alabama System; University of Alabama Birmingham	Samant, RS (corresponding author), Univ S Alabama, Dept Pathol, WTI 320E,1720,Second Ave S, Mobile, AL 35294 USA.	rsamant@uab.edu		Samant, Rajeev/0000-0001-5681-4976; Buchsbaum, Donald/0000-0003-2797-5847	USPHS [CA140472, CA138850]; American Medical Association Seed Grant; NATIONAL CANCER INSTITUTE [R01CA140472, R01CA138850] Funding Source: NIH RePORTER	USPHS(United States Department of Health & Human ServicesUnited States Public Health Service); American Medical Association Seed Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Grant support: USPHS grants CA140472 and Mayer Mitchell Award (RSS) and CA138850 (LAS). J. Rostas is a recipient of the American Medical Association Seed Grant 2011. We thank Dr Charles V. Clevenger (Northwestern University, Chicago, IL) for the gift of the beta-casein and lactogenic hormone response element reporters and Dr Robert Weinberg (Whitehead Institute, MA) for the gift of HME and HMEC cell lines.	Nieto MA, 2011, ANNU REV CELL DEV BI, V27, P347, DOI 10.1146/annurev-cellbio-092910-154036; Bao JX, 1996, ONCOGENE, V12, P2171; Baxley SE, 2010, CURR DRUG TARGETS, V11, P1089; Blick T, 2008, CLIN EXP METASTAS, V25, P629, DOI 10.1007/s10585-008-9170-6; Cano C, 2010, THESCIENTIFICWORLDJO, V10, P1947, DOI 10.1100/tsw.2010.183; Cocolakis E, 2008, J BIOL CHEM, V283, P1293, DOI 10.1074/jbc.M707492200; Creighton CJ, 2010, J MAMMARY GLAND BIOL, V15, P253, DOI 10.1007/s10911-010-9173-1; De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447; De Wever O, 2008, HISTOCHEM CELL BIOL, V130, P481, DOI 10.1007/s00418-008-0464-1; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Drasin DJ, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3037; Fillmore RA, 2009, INT J CANCER, V125, P556, DOI 10.1002/ijc.24276; Fuxe J, 2010, CELL CYCLE, V9, P2363, DOI 10.4161/cc.9.12.12050; GREENBURG G, 1982, J CELL BIOL, V95, P333, DOI 10.1083/jcb.95.1.333; Gunasinghe NPAD, 2012, CANCER METAST REV, V31, P469, DOI 10.1007/s10555-012-9377-5; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Iwamoto T, 2002, HISTOL HISTOPATHOL, V17, P887, DOI 10.14670/HH-17.887; Joseph MJ, 2009, J CELL BIOCHEM, V108, P726, DOI 10.1002/jcb.22309; Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675; Kang YB, 2006, J CELL BIOCHEM, V98, P1380, DOI 10.1002/jcb.20928; Krantz SB, 2012, J SURG RES, V173, P105, DOI 10.1016/j.jss.2011.09.020; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; Li HC, 2002, J BIOL CHEM, V277, P20965, DOI 10.1074/jbc.M112231200; Micalizzi DS, 2010, J MAMMARY GLAND BIOL, V15, P117, DOI 10.1007/s10911-010-9178-9; Miyazono K, 2009, P JPN ACAD B-PHYS, V85, P314, DOI 10.2183/pjab.85.314; Nawshad A, 2005, CELLS TISSUES ORGANS, V179, P11, DOI 10.1159/000084505; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Papageorgis P, CANC RES, V70, P968; Piek E, 1999, J CELL SCI, V112, P4557; Postigo AA, 2003, EMBO J, V22, P2443, DOI 10.1093/emboj/cdg225; PRICE JE, 1990, CANCER-AM CANCER SOC, V66, P1313, DOI 10.1002/1097-0142(19900915)66:14+<1313::AID-CNCR2820661403>3.0.CO;2-4; Saika S, 2004, LAB INVEST, V84, P1259, DOI 10.1038/labinvest.3700151; SCHMITT E, 1994, EUR J IMMUNOL, V24, P793, DOI 10.1002/eji.1830240403; Smith AL, 2012, ONCOGENE, V31, P5162, DOI 10.1038/onc.2012.11; Takebe N, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2876; Taylor MA, 2010, J MAMMARY GLAND BIOL, V15, P169, DOI 10.1007/s10911-010-9181-1; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Tian F, 2004, CANCER RES, V64, P4523, DOI 10.1158/0008-5472.CAN-04-0030; Tian YC, 2003, AM J PHYSIOL-RENAL, V285, pF130, DOI 10.1152/ajprenal.00408.2002; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Ulloa L, 1999, NATURE, V397, P710, DOI 10.1038/17826; Valcourt U, 2005, MOL BIOL CELL, V16, P1987, DOI 10.1091/mbc.e04-08-0658; Vincent-Salomon A, 2003, BREAST CANCER RES, V5, P101, DOI 10.1186/bcr578; Wakefield LM, 2001, J MAMMARY GLAND BIOL, V6, P67, DOI 10.1023/A:1009568532177; Wang ZW, 2011, NAT REV GASTRO HEPAT, V8, P27, DOI 10.1038/nrgastro.2010.188; Weng HL, 2007, J HEPATOL, V46, P295, DOI 10.1016/j.jhep.2006.09.014; Xiao BG, 1996, CLIN EXP IMMUNOL, V103, P475; Xu J, 2009, CELL RES, V19, P156, DOI 10.1038/cr.2009.5; Yan XH, 2011, BIOCHEM J, V434, P1, DOI 10.1042/BJ20101827; Yan XH, 2009, ACTA BIOCH BIOPH SIN, V41, P263, DOI 10.1093/abbs/gmp018; Yao DB, 2011, MOL CANCER RES, V9, P1608, DOI 10.1158/1541-7786.MCR-10-0568; Yates C, 2012, ADV EXP MED BIOL, V720, P81, DOI 10.1007/978-1-4614-0254-1_7; Yilmaz M, 2009, CANCER METAST REV, V28, P15, DOI 10.1007/s10555-008-9169-0; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4	57	22	23	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2014	33	20					2620	2628		10.1038/onc.2013.215	http://dx.doi.org/10.1038/onc.2013.215			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH9YT	23770854	Green Accepted			2022-12-28	WOS:000336502700008
J	Teshima, K; Nara, M; Watanabe, A; Ito, M; Ikeda, S; Hatano, Y; Oshima, K; Seto, M; Sawada, K; Tagawa, H				Teshima, K.; Nara, M.; Watanabe, A.; Ito, M.; Ikeda, S.; Hatano, Y.; Oshima, K.; Seto, M.; Sawada, K.; Tagawa, H.			Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma	ONCOGENE			English	Article						BMI1; miR-16; Noxa; apoptosis; side population; mantle cell lymphoma	CANCER STEM-CELLS; HOMOZYGOUS DELETIONS; SELF-RENEWAL; MESENCHYMAL TRANSITION; DOWN-REGULATION; MOUSE MODEL; PHASE-II; GENE; PROLIFERATION; MIR-16	The proto-oncogene BMI1 and its product, Bmi1, is overexpressed in various types of tumors, particularly in aggressive tumors and tumors resistant to conventional chemotherapy. BMI1/Bmi1 is also crucially involved in cancer-initiating cell maintenance, and is recurrently upregulated in mantle cell lymphoma (MCL), especially aggressive variants. Recently, side population (SP) cells were shown to exhibit tumor-initiating characteristics in various types of tumors. In this study, we show that recurrent MCL cases significantly exhibit upregulation of BMI1/Bmi1. We further demonstrate that clonogenic MCL SP shows such tumor-initiating characteristics as high tumorigenicity and self-renewal capability, and that BMI1 was upregulated in the SP from recurrent MCL cases and MCL cell lines. On screening for upstream regulators of BMI1, we found that expression of microRNA-16 (miR-16) was downregulated in MCL SP cells by regulating Bmi1 in the SPs, leading to reductions in tumor size following lymphoma xenografts. Moreover, to investigate downstream targets of BMI1 in MCL, we performed cross-linking/chromatin immunoprecipitation assay against MCL cell lines and demonstrated that Bmi1 directly regulated pro-apoptotic genes such as BCL2L11/Bim and PMAIP1/Noxa, leading to enhance anti-apoptotic potential of MCL. Finally, we found that a proteasome inhibitor bortezomib, which has been recently used for relapsed MCL, effectively induced apoptosis among MCL cells while reducing expression of Bmi1 and increasing miR-16 in MCL SP. These results suggest that upregulation of BMI1 and downregulation of miR-16 in MCL SP has a key role in the disease's progression by reducing MCL cell apoptosis. Our results provide important new insight into the pathogenesis of MCL and strongly suggest that targeting BMI1/Bmi1 might be an effective approach to treating MCL, particularly refractory and recurrent cases.	[Teshima, K.; Nara, M.; Watanabe, A.; Ito, M.; Ikeda, S.; Sawada, K.; Tagawa, H.] Akita Univ, Grad Sch Med, Dept Hematol Nephrol & Rheumatol, Hondo, Akita 0108543, Japan; [Hatano, Y.] Yamamoto Kumiai Gen Hosp, Dept Internal Med, Noshiro, Akita, Japan; [Oshima, K.] Kurume Univ, Sch Med, Dept Pathol, Kurume, Fukuoka 830, Japan; [Seto, M.] Aichi Canc Ctr, Res Inst, Dept Mol Med, Nagoya, Aichi 464, Japan	Kurume University; Aichi Cancer Center	Tagawa, H (corresponding author), Akita Univ, Grad Sch Med, Dept Hematol Nephrol & Rheumatol, Hondo, Akita 0108543, Japan.	htagawa0279jp@yahoo.co.jp			Japan Society for the Promotion of Science	Japan Society for the Promotion of Science(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science)	This work is supported by a Grant-in-Aid from the Japan Society for the Promotion of Science (HT). We wish to express our appreciation to Ms E Kobayashi, Y Abc, K Iwamoto, H Kataho and Mr J Yamashita for their outstanding technical assistance, Drs T Nanjo (Akita University, Akita, Japan), S Nakamura (Nagoya University, Nagoya, Japan) and R Ichinohasama (Tohoku University, Sendai, Japan) for their histological and/or clinical diagnosis of MCL. Drs N Takahashi (Akita University), N Takahashi (Akita University), Y Michishita (Akita University), K Honda (Akita University), M Kume (Hiraka General Hospital), H Oyagi (Hiraka General Hospital), M Katayama (Aichi Cancer Center) and F Arakawa (Kurume University) for collection of primary lymphoma samples and constructive discussion.	Bea S, 2001, CANCER RES, V61, P2409; Bea S, 2009, BLOOD, V113, P3059, DOI 10.1182/blood-2008-07-170183; Bhattacharya R, 2009, CANCER RES, V69, P9090, DOI 10.1158/0008-5472.CAN-09-2552; Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507; Bruggeman SWM, 2007, CANCER CELL, V12, P328, DOI 10.1016/j.ccr.2007.08.032; Chen RW, 2008, BLOOD, V112, P822, DOI 10.1182/blood-2008-03-142182; Chiba T, 2008, CANCER RES, V68, P7742, DOI 10.1158/0008-5472.CAN-07-5882; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Dong PX, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-99; Douglas D, 2008, CANCER RES, V68, P6507, DOI 10.1158/0008-5472.CAN-07-6152; Dovey JS, 2008, P NATL ACAD SCI USA, V105, P11857, DOI 10.1073/pnas.0803574105; Feuring-Buske M, 2001, BLOOD, V97, P3882, DOI 10.1182/blood.V97.12.3882; Fisher RI, 2006, J CLIN ONCOL, V24, P4867, DOI 10.1200/JCO.2006.07.9665; Godlewski J, 2008, CANCER RES, V68, P9125, DOI 10.1158/0008-5472.CAN-08-2629; Goodell Margaret A, 2005, Methods Mol Biol, V290, P343; Haraguchi N, 2006, STEM CELLS, V24, P506, DOI 10.1634/stemcells.2005-0282; Ho MM, 2007, CANCER RES, V67, P4827, DOI 10.1158/0008-5472.CAN-06-3557; Hoenerhoff MJ, 2009, ONCOGENE, V28, P3022, DOI 10.1038/onc.2009.165; Inomata M, 2009, BLOOD, V113, P396, DOI 10.1182/blood-2008-07-163907; Ito M, 2002, BLOOD, V100, P3175, DOI 10.1182/blood-2001-12-0207; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Jagani Z, 2010, CANCER RES, V70, P5528, DOI 10.1158/0008-5472.CAN-09-4229; Jares P, 2008, BRIT J HAEMATOL, V142, P149, DOI 10.1111/j.1365-2141.2008.07124.x; Jordan CT, 2006, NEW ENGL J MED, V355, P1253, DOI 10.1056/NEJMra061808; Kim KW, 2012, ENVIRON GEOCHEM HLTH, V34, P1, DOI 10.1007/s10653-011-9402-6; Kimura M, 2011, CANCER SCI, V102, P983, DOI 10.1111/j.1349-7006.2011.01891.x; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Leung C, 2004, NATURE, V428, P337, DOI 10.1038/nature02385; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; Mestre-Escorihuela C, 2007, BLOOD, V109, P271, DOI 10.1182/blood-2006-06-026500; Mitsutake N, 2007, ENDOCRINOLOGY, V148, P1797, DOI 10.1210/en.2006-1553; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; O'Connor OA, 2005, J CLIN ONCOL, V23, P676, DOI 10.1200/JCO.2005.02.050; Ofir M, 2011, MOL CANCER RES, V9, P440, DOI 10.1158/1541-7786.MCR-10-0344; Patrawala L, 2005, CANCER RES, V65, P6207, DOI 10.1158/0008-5472.CAN-05-0592; Pothof J, 2009, EMBO J, V28, P2090, DOI 10.1038/emboj.2009.156; Pouliot LM, 2012, CANCER RES, V72, P5945, DOI 10.1158/0008-5472.CAN-12-1400; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rivas MA, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3187; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Song LB, 2009, J CLIN INVEST, V119, P3626, DOI 10.1172/JCI39374; Sun L, 2012, ONCOGENE, V31, P432, DOI 10.1038/onc.2011.263; Swerdlow SH, 2008, WHO CLASSIFICATION T, P158; Szotek PP, 2006, P NATL ACAD SCI USA, V103, P11154, DOI 10.1073/pnas.0603672103; Tagawa H, 2005, LEUKEMIA, V19, P2013, DOI 10.1038/sj.leu.2403942; Tagawa H, 2005, ONCOGENE, V24, P1348, DOI 10.1038/sj.onc.1208300; VANLOHUIZEN M, 1991, NATURE, V353, P353, DOI 10.1038/353353a0; Wang J, 2007, CANCER RES, V67, P3716, DOI 10.1158/0008-5472.CAN-06-4343; Wu CL, 2007, CANCER RES, V67, P8216, DOI 10.1158/0008-5472.CAN-07-0999; Wu ZH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014648; Yamashita M, 2008, J EXP MED, V205, P1109, DOI 10.1084/jem.20072000; Young LE, 2012, MOL CANCER RES, V10, P167, DOI 10.1158/1541-7786.MCR-11-0337; Zhang XN, 2010, CANCER RES, V70, P7176, DOI 10.1158/0008-5472.CAN-10-0697; Zhao JJ, 2010, BLOOD, V115, P2630, DOI 10.1182/blood-2009-09-243147; Zhou R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030772; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028; Zhu YH, 2011, CLIN CANCER RES, V17, P7105, DOI 10.1158/1078-0432.CCR-11-0071	58	41	44	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2014	33	17					2191	2203		10.1038/onc.2013.177	http://dx.doi.org/10.1038/onc.2013.177			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF8WJ	23686310				2022-12-28	WOS:000334996000005
J	Ito, K; Maruyama, Z; Sakai, A; Izumi, S; Moriishi, T; Yoshida, CA; Miyazaki, T; Komori, H; Takada, K; Kawaguchi, H; Komori, T				Ito, K.; Maruyama, Z.; Sakai, A.; Izumi, S.; Moriishi, T.; Yoshida, C. A.; Miyazaki, T.; Komori, H.; Takada, K.; Kawaguchi, H.; Komori, T.			Overexpression of Cdk6 and Ccnd1 in chondrocytes inhibited chondrocyte maturation and caused p53-dependent apoptosis without enhancing proliferation	ONCOGENE			English	Article						Cdk6; cyclin D1; chondrocyte; apoptosis; p53; Rb	INTEGRIN-LINKED KINASE; CYCLIN D1; CELL-CYCLE; MICE LACKING; P53 LOSS; EXPRESSION; DIFFERENTIATION; OSTEOSARCOMA; P57(KIP2); PROTEIN	Cell proliferation and differentiation are closely coupled. However, we previously showed that overexpression of cyclin-dependent kinase (Cdk6) blocks chondrocyte differentiation without affecting cell-cycle progression in vitro. To investigate whether Cdk6 inhibits chondrocyte differentiation in vivo, we generated chondrocyte-specific Cdk6 transgenic mice using Col2a1 promoter. Unexpectedly, differentiation and cell-cycle progression of chondrocytes in the Cdk6 transgenic mice were similar to those in wildtype mice. Then, we generated chondrocyte-specific Ccnd1 transgenic mice and Cdk6/Ccnd1 double transgenic mice to investigate the possibility that Cdk6 inhibits chondrocyte differentiation through E2f activation. Bromodeoxyuridine (BrdU)-positive chondrocytes and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive chondrocytes were increased in number, and chondrocyte maturation was inhibited only in Cdk6/Ccnd1 transgenic mice (K6H/D1H mice), which showed dwarfism. Retinoblastoma protein (pRb) was highly phosphorylated but p107 was upregulated, and the expression of E2f target genes was dysregulated as shown by upregulation of Cdc6 but downregulation of cyclin E, dihydrofolate reductase (dhfr), Cdc25a and B-Myb in chondrocytes of K6H/D1H mice. Similarly, overexpression of Cdk6/Ccnd1 in a chondrogenic cell line ATDC5 highly phosphorylated pRb, upregulated p107, induced apoptosis, upregulated Cdc6 and downregulated cyclin E, dhfr and B-Myb and p107 small interfering RNA reversed the expression of downregulated genes. Further, introduction of kinase-negative Cdk6 and cyclin D1 abolished all effects by Cdk6/cyclin D1 in ATDC5 cells, indicating the requirement of the kinase activity on these effects. p53 deletion partially restored the size of the skeleton and almost completely rescued chondrocyte apoptosis, but failed to enhance chondrocyte proliferation in K6(H)/D1(H) mice. These findings indicated that Cdk6/Ccnd1 overexpression inhibited chondrocyte maturation and enhanced G1/S cell-cycle transition by phosphorylating pRb, but the chondrocytes failed to accomplish the cell cycle, and underwent p53-dependent apoptosis probably due to the dysregulation of E2f target genes. Our findings also indicated that p53 deletion in addition to the inactivation of Rb was not sufficient to accelerate chondrocyte proliferation, suggesting the resistance of chondrocytes to sarcomagenesis.	[Ito, K.; Maruyama, Z.; Sakai, A.; Izumi, S.; Moriishi, T.; Yoshida, C. A.; Miyazaki, T.; Komori, H.; Komori, T.] Nagasaki Univ, Grad Sch Biomed Sci, Dept Cell Biol, Nagasaki 8528588, Japan; [Ito, K.] Nagasaki Univ, Grad Sch Biomed Sci, Dept Mol Bone Biol, Nagasaki 8528588, Japan; [Ito, K.] Nagasaki Univ, NRGIC, Ctr Genom Instabil & Carcinogenesis, Nagasaki 8528588, Japan; [Maruyama, Z.; Kawaguchi, H.] Univ Tokyo, Fac Med, Dept Orthopaed Surg, Tokyo 113, Japan; [Sakai, A.; Takada, K.] Osaka Univ, Grad Sch Dent, Dept Orthodont & Dentofacial Orthoped, Suita, Osaka, Japan	Nagasaki University; Nagasaki University; Nagasaki University; University of Tokyo; Osaka University	Komori, T (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Dept Cell Biol, 1-7-1 Sakamoto, Nagasaki 8528588, Japan.	komorit@nagasaki-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology, Japan; President's Discretionary Fund of Nagasaki University	Ministry of Education, Culture, Sports, Science and Technology, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); President's Discretionary Fund of Nagasaki University	We thank H Okayama and T Ogasawara for providing DNA plasmids for gene expression, M Hirakawa, M Mori and Y Matsuo for technical assistance, and C Fukuda for secretarial assistance. This work was supported by a grant from the Ministry of Education, Culture, Sports, Science and Technology, Japan, and the President's Discretionary Fund of Nagasaki University.	Beier F, 2001, MOL BIOL CELL, V12, P3852, DOI 10.1091/mbc.12.12.3852; Berman SD, 2008, P NATL ACAD SCI USA, V105, P11851, DOI 10.1073/pnas.0805462105; Burkhart DL, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001003; Chen QH, 2003, ONCOGENE, V22, P992, DOI 10.1038/sj.onc.1206193; Clark JCM, 2008, J CANCER RES CLIN, V134, P281, DOI 10.1007/s00432-007-0330-x; Cobrinik D, 1996, GENE DEV, V10, P1633, DOI 10.1101/gad.10.13.1633; Cocker JH, 1996, NATURE, V379, P180, DOI 10.1038/379180a0; Erhardt JA, 1998, J BIOL CHEM, V273, P23517, DOI 10.1074/jbc.273.36.23517; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fiaschi-Taesch NM, 2010, DIABETES, V59, P1926, DOI 10.2337/db09-1776; Garcia-Espana A, 2005, CANCER RES, V65, P1150, DOI 10.1158/0008-5472.CAN-04-2074; Grashoff C, 2003, EMBO REP, V4, P432, DOI 10.1038/sj.embor.embor801; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; Hurford RK, 1997, GENE DEV, V11, P1447, DOI 10.1101/gad.11.11.1447; Inada M, 1999, DEV DYNAM, V214, P279, DOI 10.1002/(SICI)1097-0177(199904)214:4<279::AID-AJA1>3.0.CO;2-W; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; JIANG W, 1993, ONCOGENE, V8, P3447; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Kronenberg HM, 2003, NATURE, V423, P332, DOI 10.1038/nature01657; Li MT, 1997, J VIROL, V71, P1984, DOI 10.1128/JVI.71.3.1984-1991.1997; Liu M, 1996, GENE DEV, V10, P142, DOI 10.1101/gad.10.2.142; Long FX, 2001, DEVELOPMENT, V128, P5099; LOVEC H, 1994, EMBO J, V13, P3487, DOI 10.1002/j.1460-2075.1994.tb06655.x; Lowe SW, 2003, CURR OPIN GENET DEV, V13, P77, DOI 10.1016/S0959-437X(02)00013-8; Matsumura I, 1997, MOL CELL BIOL, V17, P2933, DOI 10.1128/MCB.17.5.2933; Moro T, 2005, J CELL PHYSIOL, V204, P927, DOI 10.1002/jcp.20350; Mueller A, 1997, CANCER RES, V57, P5542; Musgrove EA, 2011, NAT REV CANCER, V11, P558, DOI 10.1038/nrc3090; Ohnuma S, 1999, CELL, V99, P499, DOI 10.1016/S0092-8674(00)81538-X; Ojala PM, 2000, NAT CELL BIOL, V2, P819, DOI 10.1038/35041064; Ojala PM, 1999, CANCER RES, V59, P4984; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Rossi F, 2002, DEV BIOL, V247, P271, DOI 10.1006/dbio.2002.0691; Schnell JR, 2004, ANNU REV BIOPH BIOM, V33, P119, DOI 10.1146/annurev.biophys.33.110502.133613; SHIMOMURA Y, 1975, CALC TISS RES, V19, P179, DOI 10.1007/BF02564002; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sunters A, 1998, DEV GENET, V22, P386, DOI 10.1002/(SICI)1520-6408(1998)22:4<386::AID-DVG8>3.0.CO;2-2; Takahashi K, 2000, J BIOCHEM-TOKYO, V127, P73, DOI 10.1093/oxfordjournals.jbchem.a022586; Tanaka TU, 1997, CELL, V90, P649, DOI 10.1016/S0092-8674(00)80526-7; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Terpstra L, 2003, J CELL BIOL, V162, P139, DOI 10.1083/jcb.200302066; Ueta C, 2001, J CELL BIOL, V153, P87, DOI 10.1083/jcb.153.1.87; Verschuren EW, 2004, CANCER RES, V64, P581, DOI 10.1158/0008-5472.CAN-03-1863; Verschuren EW, 2002, CANCER CELL, V2, P229, DOI 10.1016/S1535-6108(02)00123-X; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808; Wang GY, 2004, J BIOL CHEM, V279, P13205, DOI 10.1074/jbc.M311427200; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Whelan J, 2012, INT J CANCER, V131, pE508, DOI 10.1002/ijc.26426; Yan Y, 1997, GENE DEV, V11, P973, DOI 10.1101/gad.11.8.973; Yang YZ, 2003, DEVELOPMENT, V130, P1003, DOI 10.1242/dev.00324; Zhang PM, 1997, NATURE, V387, P151, DOI 10.1038/387151a0	55	20	21	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2014	33	14					1862	1871		10.1038/onc.2013.130	http://dx.doi.org/10.1038/onc.2013.130			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RE	23624920				2022-12-28	WOS:000334345500012
J	Lee, M; Dworkin, AM; Gildea, D; Trivedi, NS; Moorhead, GB; Crawford, NPS				Lee, M.; Dworkin, A. M.; Gildea, D.; Trivedi, N. S.; Moorhead, G. B.; Crawford, N. P. S.		NISC Comparative Sequencing Progra	RRP1B is a metastasis modifier that regulates the expression of alternative mRNA isoforms through interactions with SRSF1	ONCOGENE			English	Article						Metastasis; RRP1B; germline modifiers; RNA-seq; alternative splicing; breast cancer	SPLICE-SITE SELECTION; CANCER; PROTEINS; IDENTIFICATION; PATTERNS; SEQUENCE	RRP1B (ribosomal RNA processing 1 homolog B) was first identified as a metastasis susceptibility gene in breast cancer through its ability to modulate gene expression in a manner that can be used to accurately predict prognosis in breast cancer. However, the mechanism(s) by which RRP1B modulates gene expression is currently unclear. Many RRP1B binding candidates are involved in alternative splicing, a mechanism of gene expression regulation that is increasingly recognized to be involved in cancer progression and metastasis. One such target is SRSF1 (serine/arginine-rich splicing factor 1) (SF2/ASF, splicing factor 2/alternative splicing factor), an essential splicing regulator that also functions as an oncoprotein. Earlier studies demonstrated that splicing and transcription occur concurrently and are coupled processes. Given that RRP1B regulates transcriptional activity, we hypothesized that RRP1B also regulates the expression of alternative mRNA isoforms through its interaction with SRSF1. Interaction between RRP1B and SRSF1 was verified by coimmunoprecipitation and coimmunofluorescence. Treatment of cells with transcriptional inhibitors significantly increased this interaction, demonstrating that the association of these two proteins is transcriptionally regulated. To assess the role of RRP1B in the regulation of alternative isoform expression, RNA-sequencing data were generated from control and Rrp1b-knockdown cells. Knockdown of Rrp1b induced a significant change in isoform expression in over 600 genes compared with control cell lines. This was verified by quantitative reverse-transcription PCR using isoform-specific primers. Pathway enrichment analyses identified cell cycle and checkpoint regulation to be those most affected by Rrp1b knockdown. These data suggest that RRP1B suppresses metastatic progression by altering the transcriptome through its interaction with splicing regulators such as SRSF1.	[Lee, M.; Dworkin, A. M.; Crawford, N. P. S.] NHGRI, Canc Genet Branch, NIH, Bethesda, MD 20892 USA; [Gildea, D.; Trivedi, N. S.; NISC Comparative Sequencing Progra] NHGRI, Genome Technol Branch, NIH, Bethesda, MD 20892 USA; [Moorhead, G. B.] Univ Calgary, Dept Biol Sci, Calgary, AB, Canada	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); University of Calgary	Crawford, NPS (corresponding author), NHGRI, Canc Genet Branch, NIH, MSC 8000,50 South Dr,Bldg 50,Room 5154, Bethesda, MD 20892 USA.	crawforn@mail.nih.gov			Intramural Research Program of the National Human Genome Research Institute; National Institutes of Health, USA; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [ZIBHG000196, ZIAHG200380] Funding Source: NIH RePORTER	Intramural Research Program of the National Human Genome Research Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); National Institutes of Health, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	This work was supported by the Intramural Research Program of the National Human Genome Research Institute, National Institutes of Health, USA. We thank Stephen Wincovitch and Sujata Bupp for technical assistance, and Drs Kent Hunter, Tom Misteli and Larry Brody for critical review of the manuscript.	Albulescu LO, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002530; Alexander RD, 2010, MOL CELL, V40, P582, DOI 10.1016/j.molcel.2010.11.005; Arhin GK, 2002, NUCLEIC ACIDS RES, V30, P1842, DOI 10.1093/nar/30.8.1842; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; BAGGA PS, 1995, NUCLEIC ACIDS RES, V23, P1625, DOI 10.1093/nar/23.9.1625; Baumli S, 2010, CHEM BIOL, V17, P931, DOI 10.1016/j.chembiol.2010.07.012; Bensaude O, 2011, TRANSCR-AUSTIN, V2, P103, DOI 10.4161/trns.2.3.16172; Chamousset D, 2010, MOL BIOL CELL, V21, P4212, DOI 10.1091/mbc.E10-04-0287; Crawford NPS, 2007, PLOS GENET, V3, P2296, DOI 10.1371/journal.pgen.0030214; Crawford NPS, 2009, J BIOL CHEM, V284, P28660, DOI 10.1074/jbc.M109.023457; Du KY, 1998, J BIOL CHEM, V273, P35208, DOI 10.1074/jbc.273.52.35208; Grosso AR, 2008, EMBO REP, V9, P1087, DOI 10.1038/embor.2008.189; Hsieh SM, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2412; Hui LJ, 2004, ONCOGENE, V23, P3013, DOI 10.1038/sj.onc.1207362; Ip JY, 2011, GENOME RES, V21, P390, DOI 10.1101/gr.111070.110; Karni R, 2007, NAT STRUCT MOL BIOL, V14, P185, DOI 10.1038/nsmb1209; Kim E, 2008, TRENDS GENET, V24, P7, DOI 10.1016/j.tig.2007.10.001; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; Lee JH, 2008, CANCER RES, V68, P639, DOI 10.1158/0008-5472.CAN-07-2632; Lemischka IR, 2006, CELL CYCLE, V5, P347, DOI 10.4161/cc.5.4.2424; Luco RF, 2010, SCIENCE, V327, P996, DOI 10.1126/science.1184208; Nurtdinov RN, 2003, HUM MOL GENET, V12, P1313, DOI 10.1093/hmg/ddg137; Oesterreich FC, 2010, MOL CELL, V40, P571, DOI 10.1016/j.molcel.2010.11.004; Pei XF, 2004, IN VITRO CELL DEV-AN, V40, P14; Piva F, 2009, BIOINFORMATICS, V25, P1211, DOI 10.1093/bioinformatics/btp124; Puig O, 2007, NUCLEIC ACIDS RES, V35, P5874, DOI 10.1093/nar/gkm505; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Roberts A, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-3-r22; Thorsen K, 2008, MOL CELL PROTEOMICS, V7, P1214, DOI 10.1074/mcp.M700590-MCP200; Trapnell C, 2010, NAT BIOTECHNOL, V28, P511, DOI 10.1038/nbt.1621; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; TRASK DK, 1988, P NATL ACAD SCI USA, V85, P1417, DOI 10.1073/pnas.85.5.1417; Umehara H, 2003, BIOCHEM BIOPH RES CO, V301, P324, DOI 10.1016/S0006-291X(02)03017-6; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Vargas DY, 2011, CELL, V147, P1054, DOI 10.1016/j.cell.2011.10.024; Venables JP, 2004, CANCER RES, V64, P7647, DOI 10.1158/0008-5472.CAN-04-1910; Venables JP, 2006, BIOESSAYS, V28, P378, DOI 10.1002/bies.20390; Venables JP, 2009, NAT STRUCT MOL BIOL, V16, P670, DOI 10.1038/nsmb.1608; Wang ET, 2008, NATURE, V456, P470, DOI 10.1038/nature07509; Wang GS, 2007, NAT REV GENET, V8, P749, DOI 10.1038/nrg2164; Wang ZN, 2003, CANCER RES, V63, P655; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Xu Q, 2003, NUCLEIC ACIDS RES, V31, P5635, DOI 10.1093/nar/gkg786; Yeo G, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r74; Yeo GW, 2005, P NATL ACAD SCI USA, V102, P2850, DOI 10.1073/pnas.0409742102; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZUO P, 1993, EMBO J, V12, P4727, DOI 10.1002/j.1460-2075.1993.tb06161.x	47	16	18	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2014	33	14					1818	1827		10.1038/onc.2013.133	http://dx.doi.org/10.1038/onc.2013.133			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RE	23604122	Green Accepted			2022-12-28	WOS:000334345500008
J	Yamaguchi, H; Chang, SS; Hsu, JL; Hung, MC				Yamaguchi, H.; Chang, S-S; Hsu, J. L.; Hung, M-C			Signaling cross-talk in the resistance to HER family receptor targeted therapy	ONCOGENE			English	Review						signaling cross-talk; EGFR; HER2; drug resistance	GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; NF-KAPPA-B; TYROSINE KINASE INHIBITORS; ACQUIRED-RESISTANCE; BETA-CATENIN; TRASTUZUMAB RESISTANCE; PROMOTES TUMORIGENESIS; CONFERS RESISTANCE; TUBEROUS SCLEROSIS	Epidermal growth factor receptor (EGFR) and human EGFR 2 (HER2) have an important role in the initiation and progression of various types of cancer. Inhibitors targeting these receptor tyrosine kinases are some of the most successful targeted anticancer drugs widely used for cancer treatment; however, cancer cells have mechanisms of intrinsic and acquired drug resistance that pose as major obstacles in drug efficacy. Extensive studies from both clinical and laboratory research have identified several molecular mechanisms underlying resistance. Among them is the role of signaling cross-talk between the EGFR/HER2 and other signaling pathways. In this review, we focus particularly on this signaling cross-talk at the receptor, mediator and effector levels, and further discuss alternative approaches to overcome resistance. In addition to well-recognized signaling cross-talk involved in the resistance, we also introduce the cross-talk between EGFR/HER2-mediated pathways and pathways triggered by other types of receptors, including those of the Notch, Wnt and TNFR/IKK/NF-kappa B pathways, and discuss the potential role of targeting this cross-talk to sensitize cells to EGFR/HER2 inhibitors.	[Yamaguchi, H.; Chang, S-S; Hsu, J. L.; Hung, M-C] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Chang, S-S; Hung, M-C] Univ Texas Hlth Sci Ctr Houston, Grad Sch Biomed Sci, Houston, TX 77030 USA; [Hsu, J. L.; Hung, M-C] China Med Univ, Ctr Mol Med, Taichung, Taiwan; [Hsu, J. L.; Hung, M-C] China Med Univ, Grad Inst Canc Biol, Taichung, Taiwan; [Hsu, J. L.; Hung, M-C] Asia Univ, Dept Biotechnol, Taichung, Taiwan	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; China Medical University Taiwan; China Medical University Taiwan; Asia University Taiwan	Hung, MC (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Unit 108, 1515 Holcombe Blvd, Houston, TX 77030 USA.	mhung@mdanderson.org	Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	National Breast Cancer Foundation; Sister Institution Fund of China Medical University Hospital; MD Anderson Cancer Center; Patel Memorial Breast Cancer Research Fund; Center for Biological Pathways; CCSG [CA16672]; NATIONAL CANCER INSTITUTE [R01CA109311, P30CA016672] Funding Source: NIH RePORTER	National Breast Cancer Foundation; Sister Institution Fund of China Medical University Hospital; MD Anderson Cancer Center; Patel Memorial Breast Cancer Research Fund; Center for Biological Pathways; CCSG; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by the National Breast Cancer Foundation, Sister Institution Fund of China Medical University Hospital and MD Anderson Cancer Center, Patel Memorial Breast Cancer Research Fund, Center for Biological Pathways, and CCSG (CA16672).	Abramson V, 2011, CLIN CANCER RES, V17, P952, DOI 10.1158/1078-0432.CCR-09-1947; Al-Hussaini H, 2011, MOL CANCER THER, V10, P9, DOI 10.1158/1535-7163.MCT-10-0677; Arkenau HT, 2011, BRIT J CANCER, V104, P392, DOI 10.1038/sj.bjc.6606030; Arteaga CL, 2012, NAT REV CLIN ONCOL, V9, P16, DOI 10.1038/nrclinonc.2011.177; Balint E, 2001, BRIT J CANCER, V85, P1813, DOI 10.1054/bjoc.2001.2128; Baselga J, 2005, J CLIN ONCOL, V23, P2445, DOI 10.1200/JCO.2005.11.890; Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104; Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030; Bertotti A, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000643; Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109; Biechele TL, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002274; Bivona TG, 2011, NATURE, V471, P523, DOI 10.1038/nature09870; Booy EP, 2011, ONCOGENE, V30, P2367, DOI 10.1038/onc.2010.616; Bronte Giuseppe, 2011, Front Biosci (Elite Ed), V3, P879; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burgess AW, 2008, GROWTH FACTORS, V26, P263, DOI 10.1080/08977190802312844; Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cappuzzo F, 2008, BRIT J CANCER, V99, P83, DOI 10.1038/sj.bjc.6604439; Carayol N, 2006, CELL SIGNAL, V18, P1941, DOI 10.1016/j.cellsig.2006.02.014; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Catz SD, 2001, ONCOGENE, V20, P7342, DOI 10.1038/sj.onc.1204926; Certo M, 2006, CANCER CELL, V9, P351, DOI 10.1016/j.ccr.2006.03.027; Chan CH, 2012, CELL, V149, P1098, DOI 10.1016/j.cell.2012.02.065; Chan KS, 2004, CANCER RES, V64, P2382, DOI 10.1158/0008-5472.CAN-03-3197; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chen YJ, 2007, J BIOL CHEM, V282, P27215, DOI 10.1074/jbc.M700264200; Chiu HC, 2011, BIOCHEM PHARMACOL, V81, P1263, DOI 10.1016/j.bcp.2011.03.003; Cipriano R, 2012, J CLIN INVEST, V122, P3197, DOI 10.1172/JCI60517; Costa DB, 2007, PLOS MED, V4, P1669, DOI 10.1371/journal.pmed.0040315; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092; Dhomen Nathalie S., 2012, Critical Reviews in Oncogenesis, V17, P31; Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786; Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423; Ding QQ, 2008, CANCER RES, V68, P6109, DOI 10.1158/0008-5472.CAN-08-0579; Ding QQ, 2007, MOL CELL BIOL, V27, P4006, DOI 10.1128/MCB.00620-06; Ding QQ, 2005, MOL CELL, V19, P159, DOI 10.1016/j.molcel.2005.06.009; Dong YY, 2010, CANCER RES, V70, P5465, DOI 10.1158/0008-5472.CAN-10-0173; Eichhorn PJA, 2008, CANCER RES, V68, P9221, DOI 10.1158/0008-5472.CAN-08-1740; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Ercan D, 2012, CANCER DISCOV, V2, P934, DOI 10.1158/2159-8290.CD-12-0103; Esteva FJ, 2010, AM J PATHOL, V177, P1647, DOI 10.2353/ajpath.2010.090885; Faber AC, 2011, CANCER DISCOV, V1, P352, DOI 10.1158/2159-8290.CD-11-0106; Faber AC, 2009, P NATL ACAD SCI USA, V106, P19503, DOI 10.1073/pnas.0905056106; Fan WW, 2011, CANCER RES, V71, P4494, DOI 10.1158/0008-5472.CAN-10-2668; Gan HK, 2009, J CLIN NEUROSCI, V16, P748, DOI 10.1016/j.jocn.2008.12.005; Garofalo M, 2012, NAT MED, V18, P74, DOI 10.1038/nm.2577; Harada D, 2012, CANCER SCI, V103, P1795, DOI 10.1111/j.1349-7006.2012.02363.x; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huang WC, 2005, MOL CELL BIOL, V25, P6592, DOI 10.1128/MCB.25.15.6592-6602.2005; Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Jeong WJ, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002242; Ji HT, 2009, MOL CELL, V36, P547, DOI 10.1016/j.molcel.2009.09.034; Kanarek N, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000166; Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385; Kim SM, 2012, MOL CANCER THER, V11, P2254, DOI 10.1158/1535-7163.MCT-12-0311; Kolev V, 2008, NAT CELL BIOL, V10, DOI 10.1038/ncb1750; Kono SA, 2009, DRUG RESIST UPDATE, V12, P95, DOI 10.1016/j.drup.2009.05.001; Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045; Korkaya H, 2012, MOL CELL, V47, P570, DOI 10.1016/j.molcel.2012.06.014; Lang JY, 2011, CANCER CELL, V20, P341, DOI 10.1016/j.ccr.2011.07.017; Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011; Lee DF, 2008, CLIN CANCER RES, V14, P5656, DOI 10.1158/1078-0432.CCR-08-0123; Lee DF, 2007, CELL, V130, P440, DOI 10.1016/j.cell.2007.05.058; Lee H, 2009, CANCER CELL, V15, P283, DOI 10.1016/j.ccr.2009.02.015; Lee SY, 2012, J CLIN INVEST, V122, P3211, DOI 10.1172/JCI60498; Ley R, 2003, J BIOL CHEM, V278, P18811, DOI 10.1074/jbc.M301010200; Li LY, 2011, ONCOGENE, V30, P1773, DOI 10.1038/onc.2010.558; Liang K, 2010, CANCER CELL, V18, P423, DOI 10.1016/j.ccr.2010.10.025; Liska D, 2011, CLIN CANCER RES, V17, P472, DOI 10.1158/1078-0432.CCR-10-0568; Liu M, 2012, MOL CELL, V45, P171, DOI 10.1016/j.molcel.2011.11.018; Liu ZJ, 2006, CANCER RES, V66, P4182, DOI 10.1158/0008-5472.CAN-05-3589; Lo HW, 2008, CLIN CANCER RES, V14, P6042, DOI 10.1158/1078-0432.CCR-07-4923; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Lu CH, 2007, CLIN CANCER RES, V13, P5883, DOI 10.1158/1078-0432.CCR-06-2837; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Ma L, 2005, CELL, V121, P179, DOI 10.1016/j.cell.2005.02.031; Malmlof M, 2007, J BIOL CHEM, V282, P2288, DOI 10.1074/jbc.M604953200; Maniati E, 2011, J CLIN INVEST, V121, P4685, DOI 10.1172/JCI45797; Maraver A, 2012, CANCER CELL, V22, P222, DOI 10.1016/j.ccr.2012.06.014; Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156; Morgillo F, 2007, CLIN CANCER RES, V13, P2795, DOI 10.1158/1078-0432.CCR-06-2077; Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022; Narayan M, 2009, CANCER RES, V69, P2191, DOI 10.1158/0008-5472.CAN-08-1056; Nickoloff BJ, 2003, ONCOGENE, V22, P6598, DOI 10.1038/sj.onc.1206758; Ohashi K, 2012, P NATL ACAD SCI USA, V109, pE2127, DOI 10.1073/pnas.1203530109; Osipo C, 2008, ONCOGENE, V27, P5019, DOI 10.1038/onc.2008.149; Oxnard GR, 2011, CLIN CANCER RES, V17, P5530, DOI 10.1158/1078-0432.CCR-10-2571; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Palomero T, 2007, NAT MED, V13, P1203, DOI 10.1038/nm1636; Perkins ND, 2007, NAT REV MOL CELL BIO, V8, P49, DOI 10.1038/nrm2083; Perkins ND, 2012, NAT REV CANCER, V12, P121, DOI 10.1038/nrc3204; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Qi XJ, 2006, J BIOL CHEM, V281, P813, DOI 10.1074/jbc.M505546200; Rasola A, 2007, ONCOGENE, V26, P1078, DOI 10.1038/sj.onc.1209859; Regales L, 2009, J CLIN INVEST, V119, P3000, DOI 10.1172/JCI38746; Ren ZY, 2002, J BIOL CHEM, V277, P38486, DOI 10.1074/jbc.M112438200; Rimawi MF, 2010, CANCER-AM CANCER SOC, V116, P1234, DOI 10.1002/cncr.24816; Rouge TD, 2007, CANCER RES, V67, P6253, DOI 10.1158/0008-5472.CAN-07-0538; Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974; Sasaki T, 2010, CANCER RES, V70, P10038, DOI 10.1158/0008-5472.CAN-10-2956; Sen M, 2012, CLIN CANCER RES, V18, P4986, DOI 10.1158/1078-0432.CCR-12-0792; Sequist LV, 2008, ANNU REV MED, V59, P429, DOI 10.1146/annurev.med.59.090506.202405; Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003; Seshacharyulu P, 2012, EXPERT OPIN THER TAR, V16, P15, DOI 10.1517/14728222.2011.648617; Shah NP, 2003, ONCOGENE, V22, P7389, DOI 10.1038/sj.onc.1206942; Sharma MR, 2011, NAT REV CLIN ONCOL, V8, P70, DOI 10.1038/nrclinonc.2010.219; Sharma SV, 2006, CLIN CANCER RES, V12, p4392S, DOI 10.1158/1078-0432.CCR-06-0096; She QB, 2010, CANCER CELL, V18, P39, DOI 10.1016/j.ccr.2010.05.023; Sher YP, 2009, ONCOGENE, V28, P3286, DOI 10.1038/onc.2009.187; Shigematsu H, 2006, INT J CANCER, V118, P257, DOI 10.1002/ijc.21496; Stemke-Hale K, 2008, CANCER RES, V68, P6084, DOI 10.1158/0008-5472.CAN-07-6854; Su JL, 2011, CANCER RES, V71, P6878, DOI 10.1158/0008-5472.CAN-11-0295; Suda K, 2009, J THORAC ONCOL, V4, P1, DOI 10.1097/JTO.0b013e3181913c9f; Takezawa K, 2012, CANCER DISCOV, V2, P922, DOI 10.1158/2159-8290.CD-12-0108; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Wang Y, 2012, CANCER CELL, V21, P374, DOI 10.1016/j.ccr.2011.12.028; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Wong KK, 2010, CURR OPIN GENET DEV, V20, P87, DOI 10.1016/j.gde.2009.11.002; Xie M, 2012, J CELL BIOCHEM, V113, P1501, DOI 10.1002/jcb.24019; Xie XM, 2007, CANCER CELL, V12, P52, DOI 10.1016/j.ccr.2007.05.009; Yamaguchi H, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00015; Yang JY, 2008, NAT CELL BIOL, V10, P138, DOI 10.1038/ncb1676; Yang JY, 2010, CANCER RES, V70, P4709, DOI 10.1158/0008-5472.CAN-09-4524; Yang JY, 2009, CLIN CANCER RES, V15, P752, DOI 10.1158/1078-0432.CCR-08-0124; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Yao Z, 2010, P NATL ACAD SCI USA, V107, P15535, DOI 10.1073/pnas.1009472107; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yen CJ, 2008, CANCER RES, V68, P2632, DOI 10.1158/0008-5472.CAN-07-5460; Yun CH, 2008, P NATL ACAD SCI USA, V105, P2070, DOI 10.1073/pnas.0709662105; Zhang SY, 2011, NAT MED, V17, P461, DOI 10.1038/nm.2309; Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330; Zhou BHP, 2001, NAT CELL BIOL, V3, P973, DOI 10.1038/ncb1101-973; Zhuang GL, 2010, CANCER RES, V70, P299, DOI 10.1158/0008-5472.CAN-09-1845	143	83	85	1	36	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2014	33	9					1073	1081		10.1038/onc.2013.74	http://dx.doi.org/10.1038/onc.2013.74			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XT	23542173	Green Accepted			2022-12-28	WOS:000331933800001
J	Lu, X; Boora, U; Seabra, L; Rabai, EM; Fenton, J; Reiman, A; Nagy, Z; Maher, ER				Lu, X.; Boora, U.; Seabra, L.; Rabai, E. M.; Fenton, J.; Reiman, A.; Nagy, Z.; Maher, E. R.			Knockdown of Slingshot 2 (SSH2) serine phosphatase induces Caspase3 activation in human carcinoma cell lines with the loss of the Birt-Hogg-Dube tumour suppressor gene (FLCN)	ONCOGENE			English	Article						Birt-Hogg-Dube; folicullin; Slingshot phosphatases; synthetic lethality; caspase; therapeutic target	POLYCYSTIC KIDNEYS; RENAL-CARCINOMA; CANCER-THERAPY; MUTATIONS; PATHWAY; INHIBITION; FAMILIES; PROTEIN; MODEL	Birt-Hogg-Dube (BHD) syndrome, is a dominantly inherited familial cancer syndrome associated with susceptibility to renal cell carcinoma (RCC) caused by inactivating mutations in the folliculin (FLCN) gene. The precise functions of the FLCN gene product are still under investigation but RCC from BHD patients show loss of the wild-type allele consistent with a tumor suppressor gene function. In a search for potential synthetic-lethal targets for FLCN using a phosphatase siRNA library screening approach, we found that knockdown of SSH2 serine phosphatase (one of the three members of Slingshot family and previously implicated in actin reorganization) specifically induced Caspase3/7 activity in a dose-dependent manner (up to six-fold increase, 10 nM, 72 h) in two human FLCN-deficient cell lines (BHD-origin renal cell carcinoma UOK257 and thyroid carcinoma FTC133) but not in their folliculin expressing isogenic cell lines. SSH2 siRNA-induced knockdown was accompanied by increased expression of SSH1 and SSH3 (suggesting a compensatory regulatory mechanism among members of SSH family). FLCN-null cells exhibited evidence of dysregulated cofilin de/phosphorylation pathways. Knockdown of SSH2 in FLCN-null cells was associated with an alteration in cell cycle kinetics (20% increase in G1, 30% and 40% decrease in S and G2M, respectively). Combination treatment of multiple SSH family (SSH2 plus SSH1 and/or SSH3) siRNAs potentiated induction of Caspase3/7 activity and changes in the cell cycle kinetics. These data indicate that: (a) apoptotic cell death in FLCN-null cells can be triggered by SSH2 knockdown through cell cycle arrest; (b) SSH2 represents a potential therapeutic target for the development of agents for the treatment of BHD syndrome and, possibly, related tumors.	[Lu, X.; Boora, U.; Seabra, L.; Fenton, J.; Reiman, A.; Maher, E. R.] Univ Birmingham, Coll Med & Dent Sci, Sch Clin & Expt Med, Ctr Rare Dis & Personalised Med, Birmingham B15 2TT, W Midlands, England; [Rabai, E. M.; Nagy, Z.] Univ Birmingham, Coll Med & Dent Sci, Sch Clin & Expt Med, Birmingham B15 2TT, W Midlands, England	University of Birmingham; University of Birmingham	Maher, ER (corresponding author), Univ Birmingham, Coll Med & Dent Sci, Sch Clin & Expt Med, Ctr Rare Dis & Personalised Med, Birmingham B15 2TT, W Midlands, England.	E.R.MAHER@bham.ac.uk	MAHER, EAMONN R/A-9507-2008; Nagy, Zsuzsanna/L-8446-2013	MAHER, EAMONN R/0000-0002-6226-6918; Nagy, Zsuzsanna/0000-0002-6700-4829	Myrovlytis Trust	Myrovlytis Trust	We thank the Myrovlytis Trust for financial support.	Baba M, 2008, JNCI-J NATL CANCER I, V100, P140, DOI 10.1093/jnci/djm288; Banks RE, 2006, CANCER RES, V66, P2000, DOI 10.1158/0008-5472.CAN-05-3074; Bernstein BW, 2010, TRENDS CELL BIOL, V20, P187, DOI 10.1016/j.tcb.2010.01.001; Chen JD, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003581; da Silva NF, 2003, J MED GENET, V40, P820; Dedes KJ, 2011, CELL CYCLE, V10, P1192, DOI 10.4161/cc.10.8.15273; Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212; FOSTER K, 1994, HUM MOL GENET, V3, P2169, DOI 10.1093/hmg/3.12.2169; GNARRA JR, 1994, NAT GENET, V7, P85, DOI 10.1038/ng0594-85; Huang TY, 2006, CURR OPIN CELL BIOL, V18, P26, DOI 10.1016/j.ceb.2005.11.005; Kaelin WG, 2005, COLD SH Q B, V70, P159, DOI 10.1101/sqb.2005.70.001; Kaelin WG, 2009, CANCER-AM CANCER SOC, V115, P2262, DOI 10.1002/cncr.24232; LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574; Lim DHK, 2010, HUM MUTAT, V31, pE1043, DOI 10.1002/humu.21130; Lu XH, 2001, CLIN CANCER RES, V7, P2114; Lu XH, 2011, MOL CANCER THER, V10, P80, DOI 10.1158/1535-7163.MCT-10-0628; Menko FH, 2009, LANCET ONCOL, V10, P1199, DOI 10.1016/S1470-2045(09)70188-3; Mizuno K, 2013, CELL SIGNAL, V25, P457, DOI 10.1016/j.cellsig.2012.11.001; Motzer RJ, 2009, CLIN GENITOURIN CANC, V7, P28, DOI 10.3816/CGC.2009.n.005; Nickerson ML, 2002, CANCER CELL, V2, P157, DOI 10.1016/S1535-6108(02)00104-6; Patel PH, 2006, CLIN CANCER RES, V12, P7215, DOI 10.1158/1078-0432.CCR-06-2254; Plastino J, 2005, CURR OPIN CELL BIOL, V17, P62, DOI 10.1016/j.ceb.2004.12.001; Posadas I, 2012, J NEUROCHEM, V120, P515, DOI 10.1111/j.1471-4159.2011.07599.x; Rehman FL, 2010, NAT REV CLIN ONCOL, V7, P718, DOI 10.1038/nrclinonc.2010.172; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Reinhardt HC, 2009, CELL CYCLE, V8, P3112, DOI 10.4161/cc.8.19.9626; Schmidt LS, 2005, AM J HUM GENET, V76, P1023, DOI 10.1086/430842; Toro JR, 2008, J MED GENET, V45, P321, DOI 10.1136/jmg.2007.054304; Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6; Yang Y, 2008, CANCER GENET CYTOGEN, V180, P100, DOI 10.1016/j.cancergencyto.2007.10.010	30	8	9	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2014	33	8					956	965		10.1038/onc.2013.27	http://dx.doi.org/10.1038/onc.2013.27			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XO	23416984				2022-12-28	WOS:000331933200003
J	Nakanishi, H; Taccioli, C; Palatini, J; Fernandez-Cymering, C; Cui, R; Kim, T; Volinia, S; Croce, CM				Nakanishi, H.; Taccioli, C.; Palatini, J.; Fernandez-Cymering, C.; Cui, R.; Kim, T.; Volinia, S.; Croce, C. M.			Loss of miR-125b-1 contributes to head and neck cancer development by dysregulating TACSTD2 and MAPK pathway	ONCOGENE			English	Article						miRNA; MAPK; TACSTD2; HNSCC; miR-125b	SQUAMOUS-CELL CARCINOMA; TUMOR-SUPPRESSOR; MICRORNA SIGNATURES; ORAL-CANCER; EXPRESSION; IDENTIFICATION; TROP2; HETEROZYGOSITY; PROLIFERATION; DEREGULATION	MicroRNAs (miRNAs) have important roles in the initiation and progression of human cancer, but their role in head and neck cancer development and progression is not well defined. We aimed to determine whether specific miRNAs and their target mRNAs contribute to head and neck cancer pathogenesis and progression. To identify miRNAs associated with head and neck squamous cell carcinomas (HNSCCs), we analyzed HNSCC cell lines, normal head and neck tissues and normal keratinocytes by miRNA profiling; a group of differentially expressed miRNAs was identified, which includes miR-125b. Decreased expression of miR-125b is known to occur in epithelial cancers and many target mRNAs for this miR have been reported. We found decreased expression of miR-125b-1 and hypermethylation of its promoter in HNSCC compared with its non-malignant counterpart. The TACSTD2 (also known as TROP2) gene was identified and validated as a direct target of miR-125b-1. Abnormal expression of TACSTD2 cell-surface glycoprotein has been reported in most epithelial tumors, and the overexpressions of this mRNA and protein product has been considered a useful tumor marker. We report that miR-125b-1 causes mitogen-activated protein kinase pathway dysfunction through regulation of TACSTD2 expression. Thus, loss of miR-125b-1 may have a key role in the pathogenesis and progression of squamous cell carcinomas of head and neck and possibly of other tumors.	[Nakanishi, H.; Taccioli, C.; Palatini, J.; Fernandez-Cymering, C.; Cui, R.; Kim, T.; Volinia, S.; Croce, C. M.] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; [Nakanishi, H.; Taccioli, C.; Palatini, J.; Fernandez-Cymering, C.; Cui, R.; Kim, T.; Volinia, S.; Croce, C. M.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Croce, CM (corresponding author), Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA.	Carlo.Croce@osumc.edu	Taccioli, Cristian/F-8801-2010; Volinia, Stefano/A-3029-2010; Cui, Ri/P-8507-2014; Volinia, Stefano/AAA-9264-2019; Taccioli, Cristian/ABC-3379-2020; Young, Richard A/F-6495-2012; Kim, Taewan/M-5867-2013	Taccioli, Cristian/0000-0003-2995-5612; Volinia, Stefano/0000-0003-0910-3893; Cui, Ri/0000-0001-6202-8779; Volinia, Stefano/0000-0003-0910-3893; Taccioli, Cristian/0000-0003-2995-5612; Young, Richard A/0000-0001-8855-8647; Kim, Taewan/0000-0002-7202-009X; Palatini, Jeffrey/0000-0001-9280-4417	NCI NIH HHS [U01 CA166905, P01 CA129242, P30 CA016058] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA166905, P30CA016058, P01CA129242] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avissar M, 2009, CLIN CANCER RES, V15, P2850, DOI 10.1158/1078-0432.CCR-08-3131; Bueno MJ, 2008, CANCER CELL, V13, P496, DOI 10.1016/j.ccr.2008.04.018; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634; Cubas R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-253; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Fong D, 2008, BRIT J CANCER, V99, P1290, DOI 10.1038/sj.bjc.6604677; Fong D, 2008, MODERN PATHOL, V21, P186, DOI 10.1038/modpathol.3801001; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; GUPTA S, 1994, FEBS LETT, V353, P281, DOI 10.1016/0014-5793(94)01052-8; Hebert C, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-5; Henson BJ, 2009, GENE CHROMOSOME CANC, V48, P569, DOI 10.1002/gcc.20666; Huang L, 2011, INT J CANCER, V128, P1758, DOI 10.1002/ijc.25509; Hui ABY, 2010, CLIN CANCER RES, V16, P1129, DOI 10.1158/1078-0432.CCR-09-2166; Ichimi T, 2009, INT J CANCER, V125, P345, DOI 10.1002/ijc.24390; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Kikkawa N, 2010, BRIT J CANCER, V103, P877, DOI 10.1038/sj.bjc.6605811; Kimura S, 2010, ONCOL REP, V23, P1625, DOI 10.3892/or_00000804; Kozaki KI, 2008, CANCER RES, V68, P2094, DOI 10.1158/0008-5472.CAN-07-5194; Le MTN, 2009, GENE DEV, V23, P862, DOI 10.1101/gad.1767609; Lee Y, 2010, PLOS COMPUT BIOL, V6, DOI 10.1371/journal.pcbi.1000730; Liang LH, 2010, HEPATOLOGY, V52, P1731, DOI 10.1002/hep.23904; Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101; Liu CJ, 2010, CANCER RES, V70, P1635, DOI 10.1158/0008-5472.CAN-09-2291; Mao L, 2004, CANCER CELL, V5, P311, DOI 10.1016/S1535-6108(04)00090-X; Muhlmann G, 2009, J CLIN PATHOL, V62, P152, DOI 10.1136/jcp.2008.060590; Nakanishi H, 2007, P NATL ACAD SCI USA, V104, P14442, DOI 10.1073/pnas.0703211104; Nakashima K, 2004, INT J CANCER, V112, P1029, DOI 10.1002/ijc.20517; NEGRINI M, 1995, CANCER RES, V55, P3003; Ohmachi T, 2006, CLIN CANCER RES, V12, P3057, DOI 10.1158/1078-0432.CCR-05-1961; RASIO D, 1995, CANCER RES, V55, P3988; Scott GK, 2007, J BIOL CHEM, V282, P1479, DOI 10.1074/jbc.M609383200; Shi XB, 2007, P NATL ACAD SCI USA, V104, P19983, DOI 10.1073/pnas.0706641104; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Visone R, 2007, ONCOGENE, V26, P7590, DOI 10.1038/sj.onc.1210564; Xia HF, 2009, CELL PHYSIOL BIOCHEM, V23, P347, DOI 10.1159/000218181; Yamada H, 2008, GENE CHROMOSOME CANC, V47, P810, DOI 10.1002/gcc.20582; Yamamoto N, 1999, ONCOL REP, V6, P1223; Zhang Y, 2011, CANCER RES, V71, P3552, DOI 10.1158/0008-5472.CAN-10-2435	40	57	59	5	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2014	33	6					702	712		10.1038/onc.2013.13	http://dx.doi.org/10.1038/onc.2013.13			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5IL	23416980	Green Accepted, Green Published			2022-12-28	WOS:000331129200005
J	Cao, Y; Marks, JW; Liu, Z; Cheung, LH; Hittelman, WN; Rosenblum, MG				Cao, Y.; Marks, J. W.; Liu, Z.; Cheung, L. H.; Hittelman, W. N.; Rosenblum, M. G.			Design optimization and characterization of Her2/neu-targeted immunotoxins: comparative in vitro and in vivo efficacy studies	ONCOGENE			English	Article						immunotoxin; Her2/neu; gelonin; valency; design optimization	DISULFIDE-STABILIZED FV; SINGLE-CHAIN FV; HER2-POSITIVE BREAST-CANCER; IMPROVED ANTIGEN-BINDING; RECOMBINANT IMMUNOTOXINS; MONOCLONAL-ANTIBODY; ANTITUMOR-ACTIVITY; ONCOGENE PRODUCT; ERBB-2 RECEPTOR; CARCINOMA-CELLS	Targeted therapeutics are potential therapeutic agents because of their selectivity and efficacy against tumors resistant to conventional therapy. The goal of this study was to determine the comparative activity of monovalent, engineered anti-Her2/neu immunotoxins fused to recombinant gelonin (rGel) to the activity of bivalent IgG-containing immunoconjugates. Utilizing Herceptin and its derived humanized single-chain antibody (single-chain fragment variable, designated 4D5), we generated bivalent chemical Herceptin/rGel conjugate, and the corresponding monovalent recombinant immunotoxins in two orientations, 4D5/rGel and rGel/4D5. All the constructs showed similar affinity to Her2/neu-overexpressing cancer cells, but significantly different antitumor activities. The rGel/4D5 orientation construct and Herceptin/rGel conjugate were superior to 4D5/rGel construct in in vitro and in vivo efficacy. The enhanced activity was attributed to improved intracellular toxin uptake into target cells and efficient downregulation of Her2/neu-related signaling pathways. The Her2/neu-targeted immunotoxins effectively targeted cells with Her2/neu expression level > 1.5 x 10(5) sites per cell. Cells resistant to Herceptin or chemotherapeutic agents were not cross-resistant to rGel-based immunotoxins. Against SK-OV-3 tumor xenografts, the rGel/4D5 construct with excellent tumor penetration showed impressive tumor inhibition. Although Herceptin/rGel conjugate demonstrated comparatively longer serum half-life, the in vivo efficacy of the conjugate was similar to the rGel/4D5 fusion. These comparative studies demonstrate that the monovalent, engineered rGel/4D5 construct displayed comparable in vitro and in vivo antitumor efficacy as bivalent Herceptin/rGel conjugate. Immunotoxin orientation can significantly impact the overall functionality and performance of these agents. The recombinant rGel/4D5 construct with excellent tumor penetration and rapid blood clearance may reduce the unwanted toxicity when administrating to patients, and warrants consideration for further clinical evaluation.	[Cao, Y.; Marks, J. W.; Liu, Z.; Cheung, L. H.; Hittelman, W. N.; Rosenblum, M. G.] Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Immunopharmacol & Targeted Therapy Lab, Houston, TX 77054 USA	University of Texas System; UTMD Anderson Cancer Center	Rosenblum, MG (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77054 USA.	mrosenbl@mdanderson.org	Liu, Zhiming/GXG-6785-2022; Cao, Yu/L-6743-2014		NCI NIH HHS [P30 CA016672] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams GP, 2006, CLIN CANCER RES, V12, P1599, DOI 10.1158/1078-0432.CCR-05-2217; Adams GP, 1998, BRIT J CANCER, V77, P1405, DOI 10.1038/bjc.1998.233; Azemar M, 2003, BREAST CANCER RES TR, V82, P155, DOI 10.1023/B:BREA.0000004371.48757.19; Beckman RA, 2007, CANCER-AM CANCER SOC, V109, P170, DOI 10.1002/cncr.22402; Benhar I, 1995, CLIN CANCER RES, V1, P1023; Bera TK, 1999, CANCER RES, V59, P4018; Bera TK, 1998, J MOL BIOL, V281, P475, DOI 10.1006/jmbi.1998.1948; Brand FX, 2006, ANTICANCER RES, V26, P715; Brinkmann U, 2000, IN VIVO, V14, P21; Cao Y, 2012, MOL CANCER THER, V11, P143, DOI 10.1158/1535-7163.MCT-11-0519; Cao Y, 2009, CANCER RES, V69, P8987, DOI 10.1158/0008-5472.CAN-09-2693; Cardinale D, 2010, J CLIN ONCOL, V28, P3910, DOI 10.1200/JCO.2009.27.3615; CARTER P, 1992, P NATL ACAD SCI USA, V89, P4285, DOI 10.1073/pnas.89.10.4285; Daniele L, 2009, RECENT PAT ANTI-CANC, V4, P9, DOI 10.2174/157489209787002489; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Hermanto U, 2001, ONCOGENE, V20, P7551, DOI 10.1038/sj.onc.1204964; Hossann M, 2006, PROTEIN EXPRES PURIF, V46, P73, DOI 10.1016/j.pep.2005.08.029; Jain KK, 2001, EXPERT OPIN BIOL TH, V1, P291, DOI 10.1517/14712598.1.2.291; Jain M, 2007, CLIN CANCER RES, V13, P1374, DOI 10.1158/1078-0432.CCR-06-2436; JAIN RK, 1988, CANCER RES, V48, P7022; Knuefermann C, 2003, ONCOGENE, V22, P3205, DOI 10.1038/sj.onc.1206394; Krauss W C, 2000, Breast Dis, V11, P113; Kreitman RJ, 2003, CURR OPIN MOL THER, V5, P44; MAIER LA, 1991, CANCER RES, V51, P5361; Maurer-Gebhard M, 1998, CANCER RES, V58, P2661; Mazor Y, 2007, CANCER LETT, V257, P124, DOI 10.1016/j.canlet.2007.07.009; McLarty K, 2009, EUR J NUCL MED MOL I, V36, P81, DOI 10.1007/s00259-008-0923-x; Murphy CG, 2010, ONCOLOGY-NY, V24, P410; Nordstrom JL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr3069; Pai-Scherf LH, 1999, CLIN CANCER RES, V5, P2311; Pennell CA, 2002, IMMUNOL RES, V25, P177, DOI 10.1385/IR:25:2:177; Phillips GDL, 2008, CANCER RES, V68, P9280, DOI 10.1158/0008-5472.CAN-08-1776; Pohlmann PR, 2009, CLIN CANCER RES, V15, P7479, DOI 10.1158/1078-0432.CCR-09-0636; Reiter Y, 2001, ADV CANCER RES, V81, P93, DOI 10.1016/S0065-230X(01)81003-4; RODRIGUEZ GC, 1993, AM J OBSTET GYNECOL, V168, P228, DOI 10.1016/S0002-9378(12)90918-7; Rosenblum MG, 1999, CLIN CANCER RES, V5, P865; Rosenblum MG, 2003, CANCER RES, V63, P3995; Scholl S, 2001, ANN ONCOL, V12, P81, DOI 10.1023/A:1011192622688; WELS W, 1992, CANCER RES, V52, P6310; Yee S, 1997, MICROBIOL IMMUNOL, V41, P563, DOI 10.1111/j.1348-0421.1997.tb01892.x; YOKOTA T, 1992, CANCER RES, V52, P3402	41	35	38	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2014	33	4					429	439		10.1038/onc.2012.612	http://dx.doi.org/10.1038/onc.2012.612			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VX	23376850	Green Accepted, Bronze			2022-12-28	WOS:000330214600004
J	Lee-Sherick, AB; Eisenman, KM; Sather, S; McGranahan, A; Armistead, PM; McGary, CS; Hunsucker, SA; Schlegel, J; Martinson, H; Cannon, C; Keating, AK; Earp, HS; Liang, X; DeRyckere, D; Graham, DK				Lee-Sherick, A. B.; Eisenman, K. M.; Sather, S.; McGranahan, A.; Armistead, P. M.; McGary, C. S.; Hunsucker, S. A.; Schlegel, J.; Martinson, H.; Cannon, C.; Keating, A. K.; Earp, H. S.; Liang, X.; DeRyckere, D.; Graham, D. K.			Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia	ONCOGENE			English	Article						tyrosine kinase; targeted therapy; acute leukemia; pediatric	ACUTE LYMPHOBLASTIC-LEUKEMIA; PEDIATRIC AML; FLT3 MUTATIONS; SURVIVAL; CELLS; AXL; PROTOONCOGENE; APOPTOSIS; CREB; OVEREXPRESSION	Acute myeloid leukemia (AML) continues to be extremely difficult to treat successfully, and the unacceptably low overall survival rates mandate that we assess new potential therapies to ameliorate poor clinical response to conventional therapy. Abnormal tyrosine kinase activation in AML has been associated with poor prognosis and provides strategic targets for novel therapy development. We found that Mer receptor tyrosine kinase was over-expressed in a majority of pediatric (29/36, 80%) and adult (10/10, 100%) primary AML patient blasts at the time of diagnosis, and 100% of patient samples at the time of relapse. Mer was also found to be expressed in 12 of 14 AML cell lines (86%). In contrast, normal bone marrow myeloid precursors expressed little to no Mer. Following AML cell line stimulation with Gas6, a Mer ligand, we observed activation of prosurvival and proliferative signaling pathways, including phosphorylation of ERK1/2, p38, MSK1, CREB, ATF1, AKT and STAT6. To assess the phenotypic role of Mer in AML, two independent short-hairpin RNA (shRNA) constructs were used to decrease Mer expression in the AML cell lines Nomo-1 and Kasumi-1. Reduction of Mer protein levels significantly increased rates of myeloblast apoptosis two to threefold in response to serum starvation. Furthermore, myeloblasts with knocked-down Mer demonstrated decreased colony formation by 67-87%, relative to control cell lines (P<0.01). NOD-SCID-gamma mice transplanted with Nomo-1 myeloblasts with reduced levels of Mer had a significant prolongation in survival compared with mice transplanted with the parental or control cell lines (median survival 17 days in parental and control cell lines, versus 32-36 days in Mer knockdown cell lines, P<0.0001). These data suggest a role for Mer in acute myeloid leukemogenesis and indicate that targeted inhibition of Mer may be an effective therapeutic strategy in pediatric and adult AML.	[Lee-Sherick, A. B.; Eisenman, K. M.; Sather, S.; Schlegel, J.; Cannon, C.; Keating, A. K.; DeRyckere, D.; Graham, D. K.] Dept Pediat, Div Hematol Oncol & Bone Marrow Transplantat, Aurora, CO USA; [McGranahan, A.; Liang, X.] Univ Colorado, Dept Pathol, Aurora, CO 80045 USA; [Armistead, P. M.; McGary, C. S.; Hunsucker, S. A.; Earp, H. S.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Sch Med, Chapel Hill, NC 27599 USA; [Martinson, H.] Univ Colorado, Dept Med Oncol, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Colorado System; University of Colorado Anschutz Medical Campus	Graham, DK (corresponding author), Univ Colorado, Dept Pediat, Anschutz Med Campus,12800 E 19th Ave,P18-4408,MS, Aurora, CO 80045 USA.	doug.graham@ucdenver.edu		Lee Sherick, Alisa/0000-0002-1177-7208; Hunsucker, Sally/0000-0002-7034-7355; Armistead, Paul/0000-0003-3983-5534; Martinson, Holly/0000-0003-2745-2755	American Academy of Pediatrics; American Pediatric Society; Eunice Kennedy Shriver National Institute of Child Health and Human Development [K12-HD000850]; National Institutes of Health [R01CA137078]; For Julie Foundation; Damon Runyon Cancer Research Foundation [CI-39-07]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [K12HD000850] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA082086, P30CA046934, R01CA137078] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL113594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK057516] Funding Source: NIH RePORTER	American Academy of Pediatrics; American Pediatric Society; Eunice Kennedy Shriver National Institute of Child Health and Human Development(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); For Julie Foundation; Damon Runyon Cancer Research Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We would like to thank the Children's Oncology Group, AML Biology Reference Laboratory for providing us with the frozen pediatric patient samples, and for the help of Christine Childs and Karen Helm of the University of Colorado Cancer Center Flow Cytometry Shared Resource, and the DERC Molecular Biology Core (NIH P30-DK57516) for expert technical assistance. ABLS is a Fellow of the Pediatric Scientist Development Program, supported by grants from the American Academy of Pediatrics, the American Pediatric Society, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (K12-HD000850). This research was also supported by grants from the National Institutes of Health (R01CA137078, DKG), and the For Julie Foundation (KE). DKG is a Damon Runyon-Novartis Clinical Investigator supported (in part) by the Damon Runyon Cancer Research Foundation (CI-39-07).	Advani AS, 2008, LEUKEMIA RES, V32, P913, DOI 10.1016/j.leukres.2007.08.019; Advani AS, 2010, LEUKEMIA RES, V34, P1622, DOI 10.1016/j.leukres.2010.03.021; Avanzi GC, 1997, EXP HEMATOL, V25, P1219; Brown P, 2004, BLOOD, V104, P1841, DOI 10.1182/blood-2004-03-1034; Bunting KD, 2004, J LEUKOCYTE BIOL, V76, P484, DOI 10.1189/jlb.0903440; Caberoy NB, 2012, J CELL PHYSIOL, V227, P401, DOI 10.1002/jcp.22955; Caberoy NB, 2010, EMBO J, V29, P3898, DOI 10.1038/emboj.2010.265; Graham DK, 2006, CLIN CANCER RES, V12, P2662, DOI 10.1158/1078-0432.CCR-05-2208; Guttridge KL, 2002, J BIOL CHEM, V277, P24057, DOI 10.1074/jbc.M112086200; Hafizi S, 2006, CYTOKINE GROWTH F R, V17, P295, DOI 10.1016/j.cytogfr.2006.04.004; Hong CC, 2008, CANCER LETT, V268, P314, DOI 10.1016/j.canlet.2008.04.017; Keating AK, 2006, ONCOGENE, V25, P6092, DOI 10.1038/sj.onc.1209633; Keating AK, 2010, MOL CANCER THER, V9, P1298, DOI 10.1158/1535-7163.MCT-09-0707; Kinjo K, 2005, CELL CYCLE, V4, P1134, DOI 10.4161/cc.4.9.1991; LING L, 1995, MOL CELL BIOL, V15, P6582; Linger RMA, 2008, ADV CANCER RES, V100, P35, DOI 10.1016/S0065-230X(08)00002-X; Liu J, 2012, ACS MED CHEM LETT, V3, P129, DOI 10.1021/ml200239k; Lunghi P, 2003, LEUKEMIA, V17, P1783, DOI 10.1038/sj.leu.2403032; Meshinchi S, 2006, BLOOD, V108, P3654, DOI 10.1182/blood-2006-03-009233; Migdall-Wilson J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031635; Muller-Tidow C, 2010, BLOOD, V116, P3564, DOI 10.1182/blood-2009-09-240978; Odgerel T, 2010, LEUKEMIA, V24, P1087, DOI 10.1038/leu.2010.48; Pfirrmann M, 2012, LANCET ONCOL, V13, P207, DOI 10.1016/S1470-2045(11)70326-6; Pigazzi M, 2007, HAEMATOLOGICA, V92, P1435, DOI 10.3324/haematol.11122; Png KJ, 2012, NATURE, V481, P190, DOI 10.1038/nature10661; Pui CH, 2011, J CLIN ONCOL, V29, P551, DOI 10.1200/JCO.2010.30.7405; Pulte D, 2010, ANN ONCOL, V21, P335, DOI 10.1093/annonc/mdp309; Rogers AEJ, 2012, ONCOGENE, V31, P4171, DOI 10.1038/onc.2011.588; Sander A, 2010, LEUKEMIA, V24, P1422, DOI 10.1038/leu.2010.127; Sather S, 2007, BLOOD, V109, P1026, DOI 10.1182/blood-2006-05-021634; Shankar DB, 2005, CANCER CELL, V7, P351, DOI 10.1016/j.ccr.2005.02.018; STITT TN, 1995, CELL, V80, P661, DOI 10.1016/0092-8674(95)90520-0; Trifilio SM, 2012, LEUKEMIA RES, V36, P394, DOI 10.1016/j.leukres.2011.10.027; Wang HK, 2007, HAEMATOL-HEMATOL J, V92, P643, DOI 10.3324/haematol.10939; Xu Q, 2003, BLOOD, V102, P972, DOI 10.1182/blood-2002-11-3429	35	62	73	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2013	32	46					5359	5368		10.1038/onc.2013.40	http://dx.doi.org/10.1038/onc.2013.40			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251IU	23474756	Green Published, hybrid			2022-12-28	WOS:000326922400006
J	Kesanakurti, D; Chetty, C; Maddirela, DR; Gujrati, M; Rao, JS				Kesanakurti, D.; Chetty, C.; Maddirela, D. Rajasekhar; Gujrati, M.; Rao, J. S.			Essential role of cooperative NF-kappa B and Stat3 recruitment to ICAM-1 intronic consensus elements in the regulation of radiation-induced invasion and migration in glioma	ONCOGENE			English	Article						chromatin immunoprecipitation (ChIP); glioma; GST pull-down; NF-kappa B; stat3; transactivation domain (TAD)	INTERCELLULAR-ADHESION MOLECULE-1; GENE-EXPRESSION; SIGNALING PATHWAYS; ENDOTHELIAL-CELLS; MALIGNANT GLIOMAS; MYELOID-LEUKEMIA; P65/RELA SUBUNIT; TUMOR PROMOTION; TRANSCRIPTION; INFLAMMATION	Although radiotherapy improves survival in patients, glioblastoma multiformes (GBMs) tend to relapse with augmented tumor migration and invasion even after ionizing radiation (IR). Aberrant nuclear factor-kappa B (NF-kappa B) and signal transducer and activator of transcription factor 3 (Stat3) activation and interaction have been suggested in several human tumors. However, possible NF-kappa B/Stat3 interaction and the role of Stat3 in maintenance of NF-kappa B nuclear retention in GBM still remain unknown. Stat3 and NF-kappa B (p65) physically interact with one another in the nucleus in glioma tumors. Most importantly, glutathione S-transferase pull-down assays identified that Stat3 binds to the p65 transactivation domain and is present in the NF-kappa B DNA-binding complex. Irradiation significantly elevated nuclear phospho-p65/phospho-Stat3 interaction in correlation with increased intercellular adhesion molecule-1 (ICAM-1) and soluble-ICAM-1 levels, migration and invasion in human glioma xenograft cell lines 4910 and 5310. Chromatin immunopreicipitation and promoter luciferase activity assays confirmed the critical role of adjacent NF-kappa B (+399) and Stat3 (+479) binding motifs in the proximal intron-1 in elevating IR-induced ICAM-1 expression. Specific inhibition of Stat3 or NF-kappa B with Stat3. siRNA or JSH-23 severely inhibited IR-induced p65 recruitment onto ICAM-1 intron-1 and suppressed migratory properties in both the cell lines. On the other hand, Stat3C- or IR-induced Stat3 promoter recruitment was significantly decreased in p65-knockdown cells, thereby suggesting the reciprocal regulation between p65 and Stat3. We also observed a significant increase in NF-kappa B enrichment on ICAM-1 intron-1 and ICAM-1 transactivation in Stat3C overexpressing cells. In in vivo orthotopic experiments, suppression of tumor growth in Stat3.si + IR-treated mice was associated with the inhibition of IR-induced p-p65/p-Stat3 nuclear colocalization and ICAM-1 levels. To our knowledge, this is the first study showing the crucial role of NF-kappa B/Stat3 nuclear association in IR-induced ICAM-1 regulation and implies that targeting NF-kappa B/Stat3 interaction may have future therapeutic significance in glioma treatment.	[Kesanakurti, D.; Chetty, C.; Maddirela, D. Rajasekhar; Rao, J. S.] Univ Illinois, Coll Med, Dept Canc Biol & Pharmacol, Peoria, IL 61605 USA; [Gujrati, M.] Univ Illinois, Coll Med, Dept Pathol, Peoria, IL 61656 USA; [Rao, J. S.] Univ Illinois, Coll Med, Dept Neurosurg, Peoria, IL 61656 USA	University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria; University of Illinois System; University of Illinois Peoria	Rao, JS (corresponding author), Univ Illinois, Coll Med, Dept Canc Biol & Pharmacol, Peoria, IL 61605 USA.	jsrao@uic.edu			National Institute of Neurological Disorders and Stroke [NS64535-01A2]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS064535] Funding Source: NIH RePORTER	National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Noorjehan Ali for technical assistance, Shelle Abraham for manuscript preparation, Diana Meister and Sushma Jasti for manuscript review. This research was supported by award NS64535-01A2 (to JSR) from the National Institute of Neurological Disorders and Stroke. Contents are solely the responsibility of the authors and do not necessarily represent the official views of NIH.	Anwar KN, 2004, J IMMUNOL, V173, P6965, DOI 10.4049/jimmunol.173.11.6965; Atkinson GP, 2010, EXPERT REV NEUROTHER, V10, P575, DOI [10.1586/ern.10.21, 10.1586/ERN.10.21]; Badiga AV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020614; Benezra M, 2003, J BIOL CHEM, V278, P26333, DOI 10.1074/jbc.M303076200; Berens Michael E., 1999, Neoplasia (New York), V1, P208, DOI 10.1038/sj.neo.7900034; Bollrath J, 2009, EMBO REP, V10, P1314, DOI 10.1038/embor.2009.243; Brantley EC, 2008, MOL CANCER RES, V6, P675, DOI 10.1158/1541-7786.MCR-07-2180; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Burim RV, 2009, CLIN EXP MED, V9, P157, DOI 10.1007/s10238-009-0040-6; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Dutta J, 2008, J VIROL, V82, P10792, DOI 10.1128/JVI.00903-08; FINE HA, 1993, CANCER, V71, P2585, DOI 10.1002/1097-0142(19930415)71:8<2585::AID-CNCR2820710825>3.0.CO;2-S; Ghizzoni M, 2011, DRUG DISCOV TODAY, V16, P504, DOI 10.1016/j.drudis.2011.03.009; Giannini C, 2005, NEURO-ONCOLOGY, V7, P164, DOI 10.1215/S1152851704000821; Grivennikov SI, 2010, CYTOKINE GROWTH F R, V21, P11, DOI 10.1016/j.cytogfr.2009.11.005; Han SS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-97; Hayden MS, 2008, CELL, V132, P344, DOI 10.1016/j.cell.2008.01.020; He GB, 2011, CELL RES, V21, P159, DOI 10.1038/cr.2010.183; He GB, 2010, CANCER CELL, V17, P286, DOI 10.1016/j.ccr.2009.12.048; Jang HD, 2004, J BIOL CHEM, V279, P24873, DOI 10.1074/jbc.M313018200; Kargiotis O, 2010, J NEURO-ONCOL, V100, P323, DOI 10.1007/s11060-010-0199-4; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kesanakurti D, 2012, ONCOGENE, DOI [10.1038/onc.2012.52, DOI 10.1038/0NC.2012.52)]; Kesanakurti D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019341; Kesanakurti D, 2009, BIOCHEM BIOPH RES CO, V390, P427, DOI 10.1016/j.bbrc.2009.09.046; Lam LT, 2008, BLOOD, V111, P3701, DOI 10.1182/blood-2007-09-111948; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Lee H, 2011, CANCER RES, V71, P3772, DOI 10.1158/0008-5472.CAN-10-3304; Lee H, 2009, CANCER CELL, V15, P283, DOI 10.1016/j.ccr.2009.02.015; Li T, 2011, CANCER GENE THER, V18, P617, DOI 10.1038/cgt.2011.29; Liu SJ, 2008, BLOOD, V111, P2364, DOI 10.1182/blood-2007-08-110171; Liu SJ, 2010, CANCER CELL, V17, P333, DOI 10.1016/j.ccr.2010.03.008; Louis DN, 2006, ANNU REV PATHOL-MECH, V1, P97, DOI 10.1146/annurev.pathol.1.110304.100043; Lowe JM, 2010, J BIOL CHEM, V285, P5249, DOI 10.1074/jbc.M109.034579; Maenpaa A, 1997, ACTA NEUROPATHOL, V94, P216, DOI 10.1007/s004010050696; Magne N, 2006, CANCER LETT, V231, P158, DOI 10.1016/j.canlet.2005.01.022; McDonald MW, 2011, INT J RADIAT ONCOL, V79, P130, DOI 10.1016/j.ijrobp.2009.10.048; Naugler WE, 2008, CURR OPIN GENET DEV, V18, P19, DOI 10.1016/j.gde.2008.01.020; Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065; Rahman A, 2002, CIRC RES, V91, P398, DOI 10.1161/01.RES.0000033520.95242.A2; Rao JS, 2003, NAT REV CANCER, V3, P489, DOI 10.1038/nrc1121; Roebuck KA, 1999, INT J MOL MED, V4, P223; Roland CL, 2007, SURGERY, V141, P705, DOI 10.1016/j.surg.2007.01.016; Roy J, 2001, J BIOL CHEM, V276, P14553, DOI 10.1074/jbc.M005067200; Squarize CH, 2006, NEOPLASIA, V8, P733, DOI 10.1593/neo.06274; Strebovsky J, 2011, FASEB J, V25, P863, DOI 10.1096/fj.10-170597; Surh YJ, 2010, CANCER PREV RES, V3, P1379, DOI 10.1158/1940-6207.CAPR-10-0251; VORABERGER G, 1991, J IMMUNOL, V147, P2777; Wild-Bode C, 2001, CANCER RES, V61, P2744; Xue JP, 2009, PHYSIOL GENOMICS, V38, P42, DOI 10.1152/physiolgenomics.00012.2009	51	97	104	0	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 24	2013	32	43					5144	5155		10.1038/onc.2012.546	http://dx.doi.org/10.1038/onc.2012.546			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	240JY	23178493	Green Accepted			2022-12-28	WOS:000326093200002
J	Semenza, GL				Semenza, G. L.			Cancer-stromal cell interactions mediated by hypoxia-inducible factors promote angiogenesis, lymphangiogenesis, and metastasis	ONCOGENE			English	Review						breast cancer; extravasation; intravasation; lung metastasis; lymph node; lymphatic metastasis; metastatic niche formation	ENDOTHELIAL-GROWTH-FACTOR; ANGIOPOIETIN-LIKE 4; BREAST-CANCER; FACTOR-I; LYMPHATIC METASTASIS; TUMOR HYPOXIA; FACTOR EXPRESSION; MALIGNANT PROGRESSION; HIF-1-ALPHA SYNTHESIS; BONE METASTASES	Interactions between cancer cells and stromal cells, including blood vessel endothelial cells (BECs), lymphatic vessel endothelial cells (LECs), bone marrow-derived angiogenic cells (BMDACs) and other bone marrow-derived cells (BMDCs) play important roles in cancer progression. Intratumoral hypoxia, which affects both cancer and stromal cells, is associated with a significantly increased risk of metastasis and mortality in many human cancers. Recent studies have begun to delineate the molecular mechanisms underlying the effect of intratumoral hypoxia on cancer progression. Reduced O-2 availability induces the activity of hypoxia-inducible factors (HIFs), which activate the transcription of target genes encoding proteins that play important roles in many critical aspects of cancer biology. Included among these are secreted factors, including angiopoietin 2, angiopoietin-like 4, placental growth factor, platelet-derived growth factor B, stem cell factor (kit ligand), stromal-derived factor 1, and vascular endothelial growth factor. These factors are produced by hypoxic cancer cells and directly mediate functional interactions with BECs, LECs, BMDACs and other BMDCs that promote angiogenesis, lymphangiogenesis, and metastasis. In addition, lysyl oxidase (LOX) and LOX-like proteins, which are secreted by hypoxic breast cancer cells, remodel extracellular matrix in the lungs, which leads to BMDC recruitment and metastatic niche formation.	[Semenza, G. L.] Johns Hopkins Univ, Sch Med, Vasc Program, Inst Cell Engn, Baltimore, MD 21205 USA; [Semenza, G. L.] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA; [Semenza, G. L.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; [Semenza, G. L.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA; [Semenza, G. L.] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol, Baltimore, MD 21205 USA; [Semenza, G. L.] Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; [Semenza, G. L.] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Semenza, GL (corresponding author), Johns Hopkins Univ, Sch Med, Vasc Program, Inst Cell Engn, 733 N Broadway,Suite 671, Baltimore, MD 21205 USA.	gsemenza@jhmi.edu			American Cancer Society; National Cancer Institute [U54-CA143868]; Susan G. Komen Breast Cancer Foundation; Johns Hopkins Institute for Cell Engineering; NATIONAL CANCER INSTITUTE [U54CA143868] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Susan G. Komen Breast Cancer Foundation(Susan G. Komen Breast Cancer Foundation); Johns Hopkins Institute for Cell Engineering; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Cancer research in the author's laboratory is supported by grants from the American Cancer Society, National Cancer Institute (U54-CA143868; Johns Hopkins Physical Sciences-Oncology Center), Susan G. Komen Breast Cancer Foundation, and the Johns Hopkins Institute for Cell Engineering. G. L. S. is the C. Michael Armstrong Professor at the Johns Hopkins University School of Medicine and an American Cancer Society Research Professor.	Bissell MJ, 2011, NAT MED, V17, P320, DOI 10.1038/nm.2328; Bos R, 2003, CANCER, V97, P1573, DOI 10.1002/cncr.11246; Bos R, 2005, HISTOPATHOLOGY, V46, P31, DOI 10.1111/j.1365-2559.2005.02045.x; Bosch-Marce M, 2007, CIRC RES, V101, P1310, DOI 10.1161/CIRCRESAHA.107.153346; Branco-Price C, 2012, CANCER CELL, V21, P52, DOI 10.1016/j.ccr.2011.11.017; Brizel DM, 1996, CANCER RES, V56, P941; Cao RH, 2004, CANCER CELL, V6, P333, DOI 10.1016/j.ccr.2004.08.034; Cao YH, 2005, NAT REV CANCER, V5, P735, DOI 10.1038/nrc1693; Ceradini DJ, 2004, NAT MED, V10, P858, DOI 10.1038/nm1075; Chintala S, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-293; Conley SJ, 2012, P NATL ACAD SCI USA, V109, P2784, DOI 10.1073/pnas.1018866109; Dales JP, 2005, INT J CANCER, V116, P734, DOI 10.1002/ijc.20984; Du R, 2008, CANCER CELL, V13, P206, DOI 10.1016/j.ccr.2008.01.034; Dunn LK, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006896; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; Ebos JML, 2011, NAT REV CLIN ONCOL, V8, P210, DOI 10.1038/nrclinonc.2011.21; Erler JT, 2009, CANCER CELL, V15, P35, DOI 10.1016/j.ccr.2008.11.012; Erler JT, 2006, NATURE, V440, P1222, DOI 10.1038/nature04695; Falcon BL, 2009, AM J PATHOL, V175, P2159, DOI 10.2353/ajpath.2009.090391; Ferrara N, 2010, CYTOKINE GROWTH F R, V21, P21, DOI 10.1016/j.cytogfr.2009.11.003; Fidler IJ, 1999, CANCER CHEMOTH PHARM, V43, pS3, DOI 10.1007/s002800051091; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; Hiraga T, 2007, CANCER RES, V67, P4157, DOI 10.1158/0008-5472.CAN-06-2355; Hiratsuka S, 2008, NAT CELL BIOL, V10, P1349, DOI 10.1038/ncb1794; Hiratsuka S, 2006, NAT CELL BIOL, V8, P1369, DOI 10.1038/ncb1507; Hockel M, 1996, CANCER RES, V56, P4509; Imamura T, 2009, INT J CANCER, V124, P763, DOI 10.1002/ijc.24032; Isaacs JS, 2002, J BIOL CHEM, V277, P29936, DOI 10.1074/jbc.M204733200; Kallergi G, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2452; Kaplan RN, 2005, NATURE, V438, P820, DOI 10.1038/nature04186; Keith B, 2012, NAT REV CANCER, V12, P9, DOI 10.1038/nrc3183; Kelly BD, 2003, CIRC RES, V93, P1074, DOI 10.1161/01.RES.0000102937.50486.1B; Kim YN, 2012, INT J CELL BIOL, V2012, DOI DOI 10.1155/2012/306879; Kodama M, 2010, CANCER SCI, V101, P1984, DOI 10.1111/j.1349-7006.2010.01639.x; Koyama Yu, 2003, Clin Breast Cancer, V4, P354, DOI 10.3816/CBC.2003.n.041; Krishnamachary B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044078; Kummar S, 2011, CLIN CANCER RES, V17, P5123, DOI 10.1158/1078-0432.CCR-11-0682; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Lee K, 2009, P NATL ACAD SCI USA, V106, P17910, DOI 10.1073/pnas.0909353106; Lee K, 2009, P NATL ACAD SCI USA, V106, P2353, DOI 10.1073/pnas.0812801106; Levental KR, 2009, CELL, V139, P891, DOI 10.1016/j.cell.2009.10.027; Li H, 2011, HEPATOLOGY, V54, P910, DOI 10.1002/hep.24479; Liu M, 2005, CANCER RES, V65, P5325, DOI 10.1158/0008-5472.CAN-04-4589; Liu YV, 2007, MOL CELL, V25, P207, DOI 10.1016/j.molcel.2007.01.001; Lofstedt T, 2007, CELL CYCLE, V6, P919, DOI 10.4161/cc.6.8.4133; Luwor RB, 2005, ONCOGENE, V24, P4433, DOI 10.1038/sj.onc.1208625; Manalo DJ, 2005, BLOOD, V105, P659, DOI 10.1182/blood-2004-07-2958; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Mole DR, 2009, J BIOL CHEM, V284, P16767, DOI 10.1074/jbc.M901790200; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; Pal SK, 2011, BREAST CANCER RES TR, V125, P627, DOI 10.1007/s10549-010-1293-1; Polyak K, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003244; Potente M, 2011, CELL, V146, P873, DOI 10.1016/j.cell.2011.08.039; Qian DZ, 2006, CANCER RES, V66, P8814, DOI 10.1158/0008-5472.CAN-05-4598; Ran S, 2010, PATHOPHYSIOLOGY, V17, P229, DOI DOI 10.1016/J.PATH0PHYS.2009.11.003; Rapisarda A, 2002, CANCER RES, V62, P4316; Schito L, 2012, P NATL ACAD SCI USA, V109, pE2707, DOI 10.1073/pnas.1214019109; Schoppmann SF, 2006, BREAST CANCER RES TR, V99, P135, DOI 10.1007/s10549-006-9190-3; Schwartz GF, 2012, CANCER-AM CANCER SOC, V118, P2031, DOI 10.1002/cncr.27431; Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441; Semenza GL, 2012, TRENDS PHARMACOL SCI, V33, P207, DOI 10.1016/j.tips.2012.01.005; Simon MP, 2008, J CELL PHYSIOL, V217, P809, DOI 10.1002/jcp.21558; Takano S, 2010, J NEURO-ONCOL, V99, P177, DOI 10.1007/s11060-010-0118-8; Takeda N, 2010, GENE DEV, V24, P491, DOI 10.1101/gad.1881410; Tammela T, 2010, CELL, V140, P460, DOI 10.1016/j.cell.2010.01.045; Tan MJ, 2012, MOL CANCER RES, V10, P677, DOI 10.1158/1541-7786.MCR-11-0519; Thomas GV, 2006, NAT MED, V12, P122, DOI 10.1038/nm1337; Thomas S, 2012, CANCER RES, V72, P5600, DOI 10.1158/0008-5472.CAN-11-3666; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Vaupel P, 2004, METHOD ENZYMOL, V381, P335; Vergis R, 2008, LANCET ONCOL, V9, P342, DOI 10.1016/S1470-2045(08)70076-7; WANG GL, 1993, J BIOL CHEM, V268, P21513; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Wong CCL, 2012, J MOL MED, V90, P803, DOI 10.1007/s00109-011-0855-y; Wong CCL, 2011, P NATL ACAD SCI USA, V108, P16369, DOI 10.1073/pnas.1113483108; Wyckoff JB, 2007, CANCER RES, V67, P2649, DOI 10.1158/0008-5472.CAN-06-1823; Yu Q, 1997, J EXP MED, V186, P1985, DOI 10.1084/jem.186.12.1985; Zhang H, 2012, ONCOGENE, V31, P1757, DOI 10.1038/onc.2011.365; Zhang HF, 2008, P NATL ACAD SCI USA, V105, P19579, DOI 10.1073/pnas.0809763105; Zhu PC, 2011, CANCER CELL, V19, P401, DOI 10.1016/j.ccr.2011.01.018	83	160	168	0	67	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 29	2013	32	35					4057	4063		10.1038/onc.2012.578	http://dx.doi.org/10.1038/onc.2012.578			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	209IG	23222717	Green Accepted, Bronze			2022-12-28	WOS:000323748500001
J	Vascotto, C; Lirussi, L; Poletto, M; Tiribelli, M; Damiani, D; Fabbro, D; Damante, G; Demple, B; Colombo, E; Tell, G				Vascotto, C.; Lirussi, L.; Poletto, M.; Tiribelli, M.; Damiani, D.; Fabbro, D.; Damante, G.; Demple, B.; Colombo, E.; Tell, G.			Functional regulation of the apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor biology	ONCOGENE			English	Article						APE1/Ref-1; NPM1; acute myeloid leukemia; base excision repair	REDOX FACTOR-I; ACUTE MYELOID-LEUKEMIA; BASE EXCISION-REPAIR; N-TERMINAL DOMAIN; OXIDATIVE STRESS; DNA-DAMAGE; TRANSCRIPTIONAL ACTIVITY; LYSINE RESIDUES; NPM1 MUTATIONS; GENE MUTATION	Nucleophosmin 1 (NPM1) is a nucleolar protein involved in ribosome biogenesis, stress responses and maintaining genome stability. One-third of acute myeloid leukemias (AMLs) are associated with aberrant localization of NPM1 to the cytoplasm (NPM1c +). This mutation is critical during leukemogenesis and constitutes a good prognostic factor for chemotherapy. At present, there is no clear molecular basis for the role of NPM1 in DNA repair and the tumorigenic process. We found that the nuclear apurinic/apyrimidinic endonuclease 1 (APE1), a core enzyme in base excision DNA repair (BER) of DNA lesions, specifically interacts with NPM1 within nucleoli and the nucleoplasm. Cytoplasmic accumulation of APE1 is associated with cancers including, as we show, NPM1c + AML. Here we show that NPM1 stimulates APE1 BER activity in cells. We provide evidence that expression of the NPM1c + variant causes cytoplasmic accumulation of APE1 in: (i) a heterologous cell system (HeLa cells); (ii) the myeloid cell line OCI/AML3 stably expressing NPM1c + ; and (iii) primary lymphoblasts of NPM1c + AML patients. Consistent with impaired APE1 localization, OCI/AML3 cells and blasts of AML patients have impaired BER activity. Cytoplasmic APE1 in NPM1c + myeloid cells is truncated due to proteolysis. Thus, the good prognostic response of NPM1c + AML to chemotherapy may result from the cytoplasmic relocalization of APE1 and the consequent BER deficiency. NPM1 thus has an indirect but significant role in BER in vivo that may also be important for NPM1c + tumorigenesis.	[Vascotto, C.; Lirussi, L.; Poletto, M.; Fabbro, D.; Damante, G.; Tell, G.] Univ Udine, Dept Med & Biol Sci, I-33100 Udine, Italy; [Tiribelli, M.; Damiani, D.] Univ Udine, Dept Expt & Clin Med Sci, I-33100 Udine, Italy; [Demple, B.] SUNY Stony Brook, Sch Med, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; [Colombo, E.] Univ Milan, Dept Med Surg & Dent, Milan, Italy	University of Udine; University of Udine; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of Milan	Tell, G (corresponding author), Univ Udine, Dept Med & Biol Sci, Piazzale Kolbe 4, I-33100 Udine, Italy.	gianluca.tell@uniud.it	Tiribelli, Mario/G-7989-2018; Colombo, Emanuela/AAO-7810-2020; Damante, Giuseppe/AAC-5200-2022; Colombo, Emanuela/AAO-8113-2020; damiani, daniela/AAD-4629-2022	Tiribelli, Mario/0000-0001-9449-2621; Colombo, Emanuela/0000-0003-2079-7398; damiani, daniela/0000-0002-1663-4468; Damante, Giuseppe/0000-0003-2312-4009; Tell, Gianluca/0000-0001-8845-6448; vascotto, carlo/0000-0003-4431-029X	AIRC [IG10269]; MIUR [FIRB_RBRN07BMCT, PRIN2008_CCPKRP_003]; UICC Yamagiwa-Yoshida Memorial International Cancer Study Grant	AIRC(Fondazione AIRC per la ricerca sul cancro); MIUR(Ministry of Education, Universities and Research (MIUR)); UICC Yamagiwa-Yoshida Memorial International Cancer Study Grant	We greatly thank the National Center for Advancing Translational Sciences (NCATS) and Dr David M Wilson III for providing the APE1 specific inhibitor (compound 3). We also thank Dr Malgorzata M Kamocka from the Indiana University School of Medicine, Department of Medicine, Division of Nephrology, Indiana Center for Biological Microscopy, Indianapolis, IN, USA. for her helpful suggestions during IF analyses, Dr Laura Cesaratto for cell-viability assays and Sofia Tell for kind support. This work was supported by grants from: AIRC (IG10269) and MIUR (FIRB_RBRN07BMCT and PRIN2008_CCPKRP_003) to GT. This work has been also supported by a UICC Yamagiwa-Yoshida Memorial International Cancer Study Grant to GT.	Angkeow P, 2002, CELL DEATH DIFFER, V9, P717, DOI 10.1038/sj.cdd.4401025; Ballmaier D, 2006, TOXICOLOGY, V221, P166, DOI 10.1016/j.tox.2006.01.009; Barnes T, 2009, NUCLEIC ACIDS RES, V37, P3946, DOI 10.1093/nar/gkp275; Bhakat KK, 2003, EMBO J, V22, P6299, DOI 10.1093/emboj/cdg595; Bonetti P, 2008, J CELL BIOL, V182, P19, DOI 10.1083/jcb.200711040; Chen JY, 2005, NAT REV CANCER, V5, P102, DOI 10.1038/nrc1547; Cilloni D, 2008, LEUKEMIA, V22, P1234, DOI 10.1038/leu.2008.68; Colombo E, 2006, CANCER RES, V66, P3044, DOI 10.1158/0008-5472.CAN-05-2378; Colombo E, 2005, MOL CELL BIOL, V25, P8874, DOI 10.1128/MCB.25.20.8874-8886.2005; Colombo E, 2011, ONCOGENE, V30, P2595, DOI 10.1038/onc.2010.646; Colombo E, 2002, NAT CELL BIOL, V4, P529, DOI 10.1038/ncb814; den Besten W, 2005, CELL CYCLE, V4, P1593; Falini B, 2005, NEW ENGL J MED, V352, P254, DOI 10.1056/NEJMoa041974; Falini B, 2005, NEW ENGL J MED, V352, P740; Falini B, 2007, BLOOD, V109, P874, DOI 10.1182/blood-2006-07-012252; Falini B, 2006, BLOOD, V107, P4514, DOI 10.1182/blood-2005-11-4745; Falini B, 2011, BLOOD, V117, P1109, DOI 10.1182/blood-2010-08-299990; Fan ZS, 2003, NAT IMMUNOL, V4, P145, DOI 10.1038/ni885; Fantini D, 2010, NUCLEIC ACIDS RES, V38, P8239, DOI 10.1093/nar/gkq691; Fung H, 2005, MOL CELL, V17, P463, DOI 10.1016/j.molcel.2004.12.029; Fung H, 2011, J BIOL CHEM, V286, P4968, DOI 10.1074/jbc.M110.146498; Gray MJ, 2005, ONCOGENE, V24, P3110, DOI 10.1038/sj.onc.1208513; Guo YM, 2008, MOL IMMUNOL, V45, P2225, DOI 10.1016/j.molimm.2007.11.020; Gurumurthy M, 2008, J MOL BIOL, V378, P302, DOI 10.1016/j.jmb.2008.02.055; He TR, 2003, AM J PHYSIOL-HEART C, V285, pH804, DOI 10.1152/ajpheart.01080.2002; Hirota K, 1997, P NATL ACAD SCI USA, V94, P3633, DOI 10.1073/pnas.94.8.3633; Izumi T, 2005, P NATL ACAD SCI USA, V102, P5739, DOI 10.1073/pnas.0500986102; Jiang YL, 2009, DNA REPAIR, V8, P1273, DOI 10.1016/j.dnarep.2009.08.003; Kaina B, 2001, PROG NUCLEIC ACID RE, V68, P41; Kelley MR, 2011, ANTIOXID REDOX SIGN, V14, P1387, DOI 10.1089/ars.2010.3410; Lee C, 2005, CANCER RES, V65, P9834, DOI 10.1158/0008-5472.CAN-05-1759; Lirussi L, 2012, MOL BIOL CELL, V23, P4079, DOI 10.1091/mbc.E12-04-0299; Londero AP, EXPRESSION PRO UNPUB; Masuda Y, 1998, J BIOL CHEM, V273, P30352, DOI 10.1074/jbc.273.46.30352; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; Mrozek K, 2007, BLOOD, V109, P431, DOI 10.1182/blood-2006-06-001149; Ozaki M, 2002, FASEB J, V16, P889, DOI 10.1096/fj.01-0664fje; Pianta A, 2010, HEMATOL ONCOL, V28, P151, DOI 10.1002/hon.906; Pitiot AS, 2007, LEUKEMIA, V21, P1564, DOI 10.1038/sj.leu.2404679; Poletto M, 2013, BIOCHEM J, V452, P545, DOI 10.1042/BJ20121277; Quentmeier H, 2005, LEUKEMIA, V19, P1760, DOI 10.1038/sj.leu.2403899; Rai G, 2012, J MED CHEM, V55, P3101, DOI 10.1021/jm201537d; Seemann S, 2005, ONCOGENE, V24, P3853, DOI 10.1038/sj.onc.1208549; Svilar D, 2011, ANTIOXID REDOX SIGN, V14, P2491, DOI 10.1089/ars.2010.3466; Szczesny B, 2008, J BIOL CHEM, V283, P26349, DOI 10.1074/jbc.M803491200; Szczesny B, 2010, MECH AGEING DEV, V131, P330, DOI 10.1016/j.mad.2010.03.009; Tell G, 2005, ANTIOXID REDOX SIGN, V7, P367, DOI 10.1089/ars.2005.7.367; Tell G, 2001, MUTAT RES-DNA REPAIR, V485, P143, DOI 10.1016/S0921-8777(00)00068-9; Tell G, 2010, CELL MOL LIFE SCI, V67, P3589, DOI 10.1007/s00018-010-0486-4; Tell G, 2010, MOL CELL BIOL, V30, P366, DOI 10.1128/MCB.01174-09; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; Vascotto C, 2011, MOL BIOL CELL, V22, P3887, DOI 10.1091/mbc.E11-05-0391; Vascotto C, 2009, MOL CELL BIOL, V29, P1834, DOI 10.1128/MCB.01337-08; Vassiliou GS, 2011, NAT GENET, V43, P470, DOI 10.1038/ng.796; Wang HF, 2011, CANCER RES, V71, P68, DOI 10.1158/0008-5472.CAN-10-0030; Wanzel M, 2008, NAT CELL BIOL, V10, P1051, DOI 10.1038/ncb1764; Wei SJ, 2000, CANCER RES, V60, P6688; Weibrecht I, 2010, EXPERT REV PROTEOMIC, V7, P401, DOI 10.1586/EPR.10.10; Wilson DM, 2010, CELL MOL LIFE SCI, V67, P3621, DOI 10.1007/s00018-010-0488-2; XANTHOUDAKIS S, 1994, P NATL ACAD SCI USA, V91, P23, DOI 10.1073/pnas.91.1.23; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; Yoshida A, 2003, J BIOL CHEM, V278, P37768, DOI 10.1074/jbc.M304914200; Yu ET, 2011, MUTAT RES-GEN TOX EN, V722, P140, DOI 10.1016/j.mrgentox.2010.06.015; Ziel KA, 2004, FASEB J, V18, P986, DOI 10.1096/fj.03-1160fje	64	44	44	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2014	33	22					2876	2887		10.1038/onc.2013.251	http://dx.doi.org/10.1038/onc.2013.251			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EI	23831574				2022-12-28	WOS:000337231800007
J	Sun, T; Wang, X; He, HH; Sweeney, CJ; Liu, SX; Brown, M; Balk, S; Lee, GSM; Kantoff, PW				Sun, T.; Wang, X.; He, H. H.; Sweeney, C. J.; Liu, S. X.; Brown, M.; Balk, S.; Lee, G-S M.; Kantoff, P. W.			MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A	ONCOGENE			English	Article						microRNA; miR-221; castration resistant prostate cancer; androgen receptor signaling	BREAST-CANCER; MESENCHYMAL TRANSITION; TAMOXIFEN RESISTANCE; RECEPTOR; EXPRESSION; GENES; PROGRESSION; CASTRATION; MICRORNAS; PROTEINS	Hormone-sensitive prostate cancer typically progresses to castration resistant prostate cancer (CRPC) after the androgen deprivation therapy. We investigated the impact of microRNAs (miRs) in the transition of prostate cancer to CRPC. MiR-221/-222 was highly expressed in bone metastatic CRPC tumor specimens. We previously demonstrated that transient overexpression of miR-221/-222 in LNCaP promoted the development of the CRPC phenotype. In current study, we show that stably overexpressing miR-221 confers androgen independent (AI) cell growth in LNCaP by rescuing LNCaP cells from growth arrest at G1 phase due to the lack of androgen. Overexpressing of miR-221 in LNCaP reduced the transcription of a subgroup of androgen-responsive genes without affecting the androgen receptor (AR) or AR-androgen integrity. By performing systematic biochemical and bioinformatical analyses, we identified two miR-221 targets, HECTD2 and RAB1A, which could mediate the development of CRPC phenotype in multiple prostate cancer cell lines. Downregulation of HECTD2 significantly affected the androgen-induced and AR-mediated transcription, and downregulation of HECTD2 or RAB1A enhances AI cell growth. As a result of the elevated expression of miR-221, expression of many cell cycle genes was altered and pathways promoting epithelial to mesenchymal transition/tumor metastasis were activated. We hypothesize that a major biological consequence of upregulation of miR-221 is reprogramming of AR signaling, which in turn may mediate the transition to the CRPC phenotype.	[Sun, T.; Wang, X.; He, H. H.; Sweeney, C. J.; Brown, M.; Lee, G-S M.; Kantoff, P. W.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [He, H. H.; Liu, S. X.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA; [Balk, S.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Canc Biol Program,Dept Med, Boston, MA 02215 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Lee, GSM (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.	Gwo-shu_lee@dfci.harvard.edu; philip_kantoff@dfci.harvard.edu	He, Hansen/ABD-8439-2020; Brown, Myles/AAX-5332-2021; Brown, Myles/B-6906-2008	He, Hansen/0000-0003-2898-3363; Brown, Myles/0000-0002-8213-1658; Kantoff, Philip/0000-0001-7275-0597	SPORE in Prostate Cancer [2 P50 CA090381-06]; Department of Defense (DoD) Prostate Cancer Training [W81XWH-09-1-0372]; NATIONAL CANCER INSTITUTE [P01CA163227, P50CA090381] Funding Source: NIH RePORTER	SPORE in Prostate Cancer; Department of Defense (DoD) Prostate Cancer Training; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by a SPORE in Prostate Cancer 2 P50 CA090381-06 and TS was supported by a Department of Defense (DoD) Prostate Cancer Training Award W81XWH-09-1-0372. We thank Dr Peter T Nelson at University of Kentucky and Dr Zissimos Mourelatos at University of Pennsylvania for kindly providing us the anti-AGO antibody. We also thank Dr Wang-xia Wang for technical suggestions on AGO-RIP-Chip experiments.	American Cancer Society, 2012, CANC FACTS FIGS 2012; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Bernassola F, 2008, CANCER CELL, V14, P10, DOI 10.1016/j.ccr.2008.06.001; Bohrer LR, 2010, ENDOCRINOLOGY, V151, P5136, DOI 10.1210/en.2010-0436; Chen Z, 2011, EMBO J, V30, P2405, DOI 10.1038/emboj.2011.154; Coppola V, 2010, ENDOCR-RELAT CANCER, V17, pF1, DOI 10.1677/ERC-09-0172; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Fornari F, 2008, ONCOGENE, V27, P5651, DOI 10.1038/onc.2008.178; Garofalo M, 2009, CANCER CELL, V16, P498, DOI 10.1016/j.ccr.2009.10.014; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Haas AK, 2007, J CELL SCI, V120, P2997, DOI 10.1242/jcs.014225; He HL, 2005, P NATL ACAD SCI USA, V102, P19075, DOI 10.1073/pnas.0509603102; HE L, 2004, NAT REV GENET, V5, P522; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Jia L, 2003, MOL CANCER RES, V1, P385; Jiang F, 2004, PROSTATE, V59, P426, DOI 10.1002/pros.20000; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Klein KA, 1997, NAT MED, V3, P402, DOI 10.1038/nm0497-402; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Love HD, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008384; Miller TE, 2008, J BIOL CHEM, V283, P29897, DOI 10.1074/jbc.M804612200; Mizuno H, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-137; Nelson PT, 2007, RNA, V13, P1787, DOI 10.1261/rna.646007; Nelson PS, 2002, P NATL ACAD SCI USA, V99, P11890, DOI 10.1073/pnas.182376299; Pfeil K, 2004, PROSTATE, V58, P259, DOI 10.1002/pros.10332; Rao X, 2011, ONCOGENE, V30, P1082, DOI 10.1038/onc.2010.487; Rini Brian I, 2002, Curr Treat Options Oncol, V3, P437, DOI 10.1007/s11864-002-0008-1; Saeed AI, 2006, METHOD ENZYMOL, V411, P134, DOI 10.1016/S0076-6879(06)11009-5; Santagata S, 2004, CANCER RES, V64, P6854, DOI 10.1158/0008-5472.CAN-04-2500; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; Stinson S, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001538; Sun T, 2012, PROSTATE, V72, P1093, DOI 10.1002/pros.22456; Sun T, 2009, CANCER RES, V69, P3356, DOI 10.1158/0008-5472.CAN-08-4112; Taneja SS, 2002, J CELL BIOCHEM, V84, P188, DOI 10.1002/jcb.1278; Terasawa K, 2009, FEBS J, V276, P3269, DOI 10.1111/j.1742-4658.2009.07041.x; Vitelli F, 1999, GENOMICS, V55, P335, DOI 10.1006/geno.1998.5666; Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Wang WX, 2010, RNA, V16, P394, DOI 10.1261/rna.1905910; Wang ZW, 2009, CANCER RES, V69, P2400, DOI 10.1158/0008-5472.CAN-08-4312; Watahiki A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024950; Weide T, 2003, BIOCHEM BIOPH RES CO, V306, P79, DOI 10.1016/S0006-291X(03)00918-5; Whitfield ML, 2006, NAT REV CANCER, V6, P99, DOI 10.1038/nrc1802; Winter J, 2009, NAT CELL BIOL, V11, P228, DOI 10.1038/ncb0309-228; Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016; Yuan X, 2009, UROL ONCOL-SEMIN ORI, V27, P36, DOI 10.1016/j.urolonc.2008.03.021; Zhang CZ, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-229; Zhao JJ, 2008, J BIOL CHEM, V283, P31079, DOI 10.1074/jbc.M806041200	50	107	111	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2014	33	21					2790	2800		10.1038/onc.2013.230	http://dx.doi.org/10.1038/onc.2013.230			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EH	23770851	Green Accepted			2022-12-28	WOS:000337231700012
J	Harrison, W; Cochrane, B; Neill, G; Philpott, M				Harrison, W.; Cochrane, B.; Neill, G.; Philpott, M.			The oncogenic GLI transcription factors facilitate keratinocyte survival and transformation upon exposure to genotoxic agents	ONCOGENE			English	Article						Hedgehog; GLI; Genotoxic; Transformation; Keratinocyte	BASAL-CELL CARCINOMAS; EPITHELIAL-MESENCHYMAL TRANSITIONS; GENE-EXPRESSION; HUMAN HOMOLOG; E-CADHERIN; FACTOR SNAIL; DNA-DAMAGE; STEM-CELLS; ACTIVATION; APOPTOSIS	Ultraviolet B (UVB) light is the principal aetiological factor associated with non-melanoma skin cancer, the most prevalent group of malignancies in the Caucasian population. Exposure to environmental chemicals has also been shown to promote skin carcinogenesis and, as for UVB, this is associated with the acquisition of genomic DNA damage. Cells respond to DNA damage by inducing cell cycle arrest to facilitate DNA repair, although apoptosis will occur if the damage is excessive. Oncogenes may drive carcinogenesis by disrupting the balanced control of cell cycle progression, DNA repair and apoptosis, allowing for the propagation of cells with damaged DNA. The transcription factors GLI1 and GLI2 have been implicated in both the initiation and progression of several cancers, including basal cell carcinoma. Here we show that GLI1 and an active mutant of GLI2 (Delta NGLI2) promote apoptotic resistance in N/TERT human keratinocytes upon exposure to UVB and the DNA-alkylating chemicals such as methyl methanesulphonate (MMS) and N-ethyl-N-nitrosurea. Compared with control and untreated N/TERT-GLI1 and -GLI2 cells, those that survived genotoxic insult formed significantly more colonies in soft agar and were significantly more invasive when grown in three-dimensional organotypic collagen gel cultures. Indeed, surviving N/TERT-GLI1 and -GLI2 cells expressed higher levels of the epithelial-to-mesenchymal transition markers Snail and vimentin, and a subpopulation of MMS-treated cells displayed an elongated fibroblast-like morphology with decreased levels of E-cadherin. Finally, whereas Bcl2 was strongly increased in N/TERT-GLI2 cells, the level of induction was weak in N/TERT-GLI1 cells, indicating that GLI1 may activate anti-apoptotic mechanisms(s) independently of Bcl2. In summary, our results show that GLI1 and GLI2 facilitate the propagation of cells with damaged DNA, and thus their expression may be naturally higher in cells that form the earliest precursor tumour lesions.	[Harrison, W.; Neill, G.; Philpott, M.] Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, Ctr Cutaneous Res, London E1 2AT, England; [Cochrane, B.] Unilever, Safety & Environm Assurance Ctr, Bedford, England	University of London; Queen Mary University London; Unilever	Philpott, M (corresponding author), Queen Mary Univ London, Blizard Inst, Barts & London Sch Med & Dent, Ctr Cutaneous Res, 4 Newark St, London E1 2AT, England.	m.p.philpott@qmul.ac.uk		Philpott, Michael/0000-0002-1255-4612	Dr Hadwen Trust for Humane Research and Unilever Research	Dr Hadwen Trust for Humane Research and Unilever Research(Unilever)	This work was funded by a basic science grants from the Dr Hadwen Trust for Humane Research and Unilever Research to Professor Mike Philpott and Dr Graham Neill.	Ahmadian A, 1998, ONCOGENE, V17, P1837, DOI 10.1038/sj.onc.1202080; Alexaki VI, 2010, JNCI-J NATL CANCER I, V102, P1148, DOI 10.1093/jnci/djq257; Almahroos Mona, 2004, Skinmed, V3, P132; Armstrong BK, 2001, J PHOTOCH PHOTOBIO B, V63, P8, DOI 10.1016/S1011-1344(01)00198-1; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Biddle A, 2011, CANCER RES, V71, P5317, DOI 10.1158/0008-5472.CAN-11-1059; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chen XL, 2010, ARCH MED RES, V41, P315, DOI 10.1016/j.arcmed.2010.06.003; Dahmane N, 1997, NATURE, V389, P876, DOI 10.1038/39918; Dickson MA, 2000, MOL CELL BIOL, V20, P1436, DOI 10.1128/MCB.20.4.1436-1447.2000; Fan L, 2004, ENDOCRINOLOGY, V145, P3961, DOI 10.1210/en.2004-0079; Gailani MR, 1996, NAT GENET, V14, P78, DOI 10.1038/ng0996-78; Grachtchouk M, 2011, J CLIN INVEST, V121, P1768, DOI 10.1172/JCI46307; Han G, 2005, J CLIN INVEST, V115, P1714, DOI 10.1172/JCI24399; Hoot KE, 2008, J CLIN INVEST, V118, P2722, DOI 10.1172/JCI33713; Hudson LG, 2009, J DERMATOL SCI, V56, P19, DOI 10.1016/j.jdermsci.2009.06.009; Ikram MS, 2004, J INVEST DERMATOL, V122, P1503, DOI 10.1111/j.0022-202X.2004.22612.x; Javelaud D, 2011, CANCER RES, V71, P5606, DOI 10.1158/0008-5472.CAN-11-1194; Johnson RL, 1996, SCIENCE, V272, P1668, DOI 10.1126/science.272.5268.1668; Kaina B, 1998, MUTAT RES-FUND MOL M, V404, P119, DOI 10.1016/S0027-5107(98)00103-1; Kandala PK, 2012, J BIOL CHEM, V287, P28745, DOI 10.1074/jbc.M112.351379; Kump E, 2008, ONCOGENE, V27, P3856, DOI 10.1038/onc.2008.5; Lear W, 2007, J CUTAN MED SURG, V11, P19, DOI 10.2310/7750.2007.00011; Leonard JM, 2008, J CELL BIOL, V183, P385, DOI 10.1083/jcb.200804042; Li X, 2007, ONCOGENE, V26, P4489, DOI 10.1038/sj.onc.1210241; Li X, 2006, ONCOGENE, V25, P609, DOI 10.1038/sj.onc.1209077; Louro ID, 2002, CANCER RES, V62, P5867; Mah LJ, 2010, LEUKEMIA, V24, P679, DOI 10.1038/leu.2010.6; Mazumdar T, 2011, CANCER RES, V71, P5904, DOI 10.1158/0008-5472.CAN-10-4173; McCalla-Martin AC, 2010, TRANSGENIC RES, V19, P869, DOI 10.1007/s11248-010-9362-0; Nakamura M, 2011, J DERMATOL SCI, V61, P7, DOI 10.1016/j.jdermsci.2010.11.015; Neill GW, 2008, CARCINOGENESIS, V29, P738, DOI 10.1093/carcin/bgn037; Newkirk KM, 2007, AM J PATHOL, V171, P1629, DOI 10.2353/ajpath.2007.070221; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Nystrom ML, 2005, J PATHOL, V205, P468, DOI 10.1002/path.1716; Papanikolaou S, 2010, HISTOPATHOLOGY, V56, P799, DOI 10.1111/j.1365-2559.2010.03556.x; Patil MA, 2006, CANCER BIOL THER, V5, P111, DOI 10.4161/cbt.5.1.2379; Perrot CY, 2013, PHARMACOL THERAPEUT, V137, P183, DOI 10.1016/j.pharmthera.2012.10.002; Ping XL, 2001, J INVEST DERMATOL, V116, P614, DOI 10.1046/j.1523-1747.2001.01301.x; Raj D, 2006, J INVEST DERMATOL, V126, P243, DOI 10.1038/sj.jid.5700008; Regl G, 2004, CANCER RES, V64, P7724, DOI 10.1158/0008-5472.CAN-04-1085; Regl G, 2002, ONCOGENE, V21, P5529, DOI 10.1038/sj.onc.1205748; Reichrath J, 2006, MED INTELL UNIT, P10, DOI 10.1007/0-387-35098-5_2; Rittie L, 2009, AGING CELL, V8, P738, DOI 10.1111/j.1474-9726.2009.00526.x; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sarasin A, 1999, MUTAT RES-FUND MOL M, V428, P5, DOI 10.1016/S1383-5742(99)00025-3; Savagner P, 2005, J CELL PHYSIOL, V202, P858, DOI 10.1002/jcp.20188; Schnidar H, 2009, CANCER RES, V69, P1284, DOI 10.1158/0008-5472.CAN-08-2331; Sheng H, 2002, CANCER RES, V62, P5308; Teh MT, 2002, CANCER RES, V62, P4773; Teh MT, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-45; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thomas ZI, 2011, BRIT J CANCER, V104, P1575, DOI 10.1038/bjc.2011.133; Varnat F, 2009, EMBO MOL MED, V1, P338, DOI 10.1002/emmm.200900039; Vorechovsky I, 1997, ONCOGENE, V15, P361, DOI 10.1038/sj.onc.1201340; Wong CSM, 2003, BMJ-BRIT MED J, V327, P794, DOI 10.1136/bmj.327.7418.794; Yoon JW, 2002, J BIOL CHEM, V277, P5548, DOI 10.1074/jbc.M105708200; Yu M, 2008, J INVEST DERMATOL, V128, P1797, DOI 10.1038/sj.jid.5701243; Yuan JS, 2010, FEBS LETT, V584, P3717, DOI 10.1016/j.febslet.2010.05.021; Zheng X, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049581	60	16	16	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2014	33	19					2432	2440		10.1038/onc.2013.199	http://dx.doi.org/10.1038/onc.2013.199			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH3OK	23792444				2022-12-28	WOS:000336033600003
J	Palla, AR; Piazzolla, D; Abad, M; Li, H; Dominguez, O; Schonthaler, HB; Wagner, EF; Serrano, M				Palla, A. R.; Piazzolla, D.; Abad, M.; Li, H.; Dominguez, O.; Schonthaler, H. B.; Wagner, E. F.; Serrano, M.			Reprogramming activity of NANOGP8, a NANOG family member widely expressed in cancer	ONCOGENE			English	Article						NANOG; NANOGP8; cancer; reprogramming; pluripotency	PLURIPOTENT STEM-CELLS; DIFFERENTIATION; GENE; PROMOTES; ES	NANOG is a key transcription factor for pluripotency in embryonic stem cells. The analysis of NANOG in human cells is confounded by the presence of multiple and highly similar paralogs. In particular, there are three paralogs encoding full-length proteins, namely, NANOG1, NANOG2 and NANOGP8, and at least eight additional paralogs that do not encode full-length NANOG proteins. Here, we have examined NANOG family expression in human embryonic stem cells (hESCs) and in human cancer cell lines using a multi-NANOG PCR that amplifies the three functional paralogs and most of the non-functional ones. As anticipated, we found that hESCs express large amounts of NANOG1 and, interestingly, they also express NANOG2. In contrast, most human cancer cells tested express NANOGP8 and the non-coding paralogs NANOGP4 and NANOGP5. Notably, in some cancer cell lines, the NANOG protein levels produced by NANOGP8 are comparable to those produced by NANOG1 in pluripotent cells. Finally, we show that NANOGP8 is as active as NANOG1 in the reprogramming of human and murine fibroblasts into induced pluripotent stem cells. These results show that cancer-associated NANOGP8 can contribute to promote de-differentiation and/or cellular plasticity.	[Palla, A. R.; Piazzolla, D.; Abad, M.; Li, H.; Serrano, M.] Spanish Natl Canc Res Ctr CNIO, Tumour Suppress Grp, Mol Oncol Programme, E-28029 Madrid, Spain; [Dominguez, O.] Spanish Natl Canc Res Ctr CNIO, Genom Core Unit, Biotechnol Programme, E-28029 Madrid, Spain; [Schonthaler, H. B.; Wagner, E. F.] Spanish Natl Canc Res Ctr CNIO, F BBVA CNIO Canc Cell Biol Programme, Genes Dev & Dis Grp, Madrid, Spain	Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO); Centro Nacional de Investigaciones Oncologicas (CNIO)	Serrano, M (corresponding author), Spanish Natl Canc Res Ctr CNIO, 3 Melchor Fernandez Almagro St, E-28029 Madrid, Spain.	mserrano@cnio.es	Schönthaler, Helia/AAG-4767-2021; Abad, Maria/I-3911-2015; Serrano, Manuel/H-2634-2015; Abad, Maria/AAI-2366-2019; Dominguez, Orlando/M-7515-2018; Vivancos, Ana/AAG-8331-2019	Abad, Maria/0000-0002-1462-2498; Serrano, Manuel/0000-0001-7177-9312; Abad, Maria/0000-0002-1462-2498; Wagner, Erwin F/0000-0001-7872-0196; Vivancos, Ana/0000-0003-2888-6512; Palla, Adelaida/0000-0003-2695-9335	FPI Program of the Spanish Department of Science (MINECO); EMBO Long-Term Fellowship; 'Ramon y Cajal' Program (MINECO); CNIO; MINECO (SAF); European Union (ERC); Regional Government of Madrid; Botin Foundation; Ramon Areces Foundation; AXA Foundation; F-BBVA	FPI Program of the Spanish Department of Science (MINECO); EMBO Long-Term Fellowship(European Molecular Biology Organization (EMBO)); 'Ramon y Cajal' Program (MINECO); CNIO; MINECO (SAF); European Union (ERC)(European Research Council (ERC)European Commission); Regional Government of Madrid; Botin Foundation; Ramon Areces Foundation; AXA Foundation; F-BBVA(BBVA Foundation)	We are grateful to Dr Maria S Soengas (CNIO) for providing us with human primary fibroblasts and to Dr Miguel A Piris (CNIO) for providing us with all the human cancer cell lines. ARP is supported by the FPI Program of the Spanish Department of Science (MINECO). DP was funded by an EMBO Long-Term Fellowship. HL is supported by the 'Ramon y Cajal' Program (MINECO). Work in the laboratory of MS is funded by the CNIO and by grants from the MINECO (SAF), the European Union (ERC Advanced Grant), the Regional Government of Madrid, the Botin Foundation, the Ramon Areces Foundation and the AXA Foundation. Work in the laboratory of EFW is supported by grants from F-BBVA and the European Union (ERC Advanced Grant).	Ambady S, 2010, INT J DEV BIOL, V54, P1743, DOI 10.1387/ijdb.103192sa; Booth HAF, 2004, GENOMICS, V84, P229, DOI 10.1016/j.ygeno.2004.02.014; Carey BW, 2009, P NATL ACAD SCI USA, V106, P157, DOI 10.1073/pnas.0811426106; Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1; Chambers I, 2009, DEVELOPMENT, V136, P2311, DOI 10.1242/dev.024398; Chang DF, 2009, STEM CELLS, V27, P812, DOI 10.1634/stemcells.2008-0657; Do HJ, 2009, J CELL BIOCHEM, V106, P1079, DOI 10.1002/jcb.22089; Eberle I, 2010, NUCLEIC ACIDS RES, V38, P5384, DOI 10.1093/nar/gkq307; Fujita J, 2008, CELL STEM CELL, V2, P595, DOI 10.1016/j.stem.2008.04.001; Grigoriadis AE, 2010, BLOOD, V115, P2769, DOI 10.1182/blood-2009-07-234690; Hanna J, 2009, NATURE, V462, P595, DOI 10.1038/nature08592; Hochedlinger K, 2005, CELL, V121, P465, DOI 10.1016/j.cell.2005.02.018; Ishiguro T, 2012, BIOCHEM BIOPH RES CO, V418, P199, DOI 10.1016/j.bbrc.2011.10.123; Jeter CR, 2011, ONCOGENE, V30, P3833, DOI 10.1038/onc.2011.114; Jeter CR, 2009, STEM CELLS, V27, P993, DOI 10.1002/stem.29; Kim JS, 2005, EXP MOL MED, V37, P601, DOI 10.1038/emm.2005.73; Lowry WE, 2008, P NATL ACAD SCI USA, V105, P2883, DOI 10.1073/pnas.0711983105; Mitsui K, 2003, CELL, V113, P631, DOI 10.1016/S0092-8674(03)00393-3; Moretto-Zita M, 2010, P NATL ACAD SCI USA, V107, P13312, DOI 10.1073/pnas.1005847107; Pan GJ, 2005, J BIOL CHEM, V280, P1401, DOI 10.1074/jbc.M407847200; Ramakrishna S, 2011, STEM CELLS DEV, V20, P1512, DOI 10.1089/scd.2010.0410; Silva J, 2009, CELL, V138, P722, DOI 10.1016/j.cell.2009.07.039; Silva J, 2008, PLOS BIOL, V6, P2237, DOI 10.1371/journal.pbio.0060253; Suva ML, 2013, SCIENCE, V339, P1567, DOI 10.1126/science.1230184; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Theunissen TW, 2011, DEVELOPMENT, V138, P4853, DOI 10.1242/dev.068775; Uchino K, 2012, EXP CELL RES, V318, P1799, DOI 10.1016/j.yexcr.2012.04.011; Wang SH, 2003, GENE EXPR PATTERNS, V3, P99, DOI 10.1016/S1567-133X(03)00005-X; Ying QL, 2008, NATURE, V453, P519, DOI 10.1038/nature06968; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526; Zbinden M, 2010, EMBO J, V29, P2659, DOI 10.1038/emboj.2010.137; Zhang J, 2013, ONCOGENE, V32, P4397, DOI 10.1038/onc.2012.461; Zhang JY, 2010, ONCOL LETT, V1, P457, DOI 10.3892/ol_00000081; Zhang JY, 2006, FEBS J, V273, P1723, DOI 10.1111/j.1742-4658.2006.05186.x	35	31	34	0	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2014	33	19					2513	2519		10.1038/onc.2013.196	http://dx.doi.org/10.1038/onc.2013.196			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH3OK	23752184				2022-12-28	WOS:000336033600011
J	Lu, R; Pal, J; Buon, L; Nanjappa, P; Shi, J; Fulciniti, M; Tai, YT; Guo, L; Yu, M; Gryaznov, S; Munshi, NC; Shammas, MA				Lu, R.; Pal, J.; Buon, L.; Nanjappa, P.; Shi, J.; Fulciniti, M.; Tai, Y-T; Guo, L.; Yu, M.; Gryaznov, S.; Munshi, N. C.; Shammas, M. A.			Targeting homologous recombination and telomerase in Barrett's adenocarcinoma: impact on telomere maintenance, genomic instability and tumor growth	ONCOGENE			English	Article						homologous recombination; telomerase; telomeres; Barrett's adenocarcinoma	LASER CAPTURE MICRODISSECTION; QUADRUPLEX-INTERACTIVE AGENT; MULTIPLE-MYELOMA CELLS; DNA-DAMAGE RESPONSE; TO-END FUSIONS; LEUKEMIA-CELLS; IMMORTAL CELLS; IN-VIVO; TELOMESTATIN SOT-095; MAMMALIAN TELOMERES	Homologous recombination (HR), a mechanism to accurately repair DNA in normal cells, is deregulated in cancer. Elevated/deregulated HR is implicated in genomic instability and telomere maintenance, which are critical lifelines of cancer cells. We have previously shown that HR activity is elevated and significantly contributes to genomic instability in Barrett's esophageal adenocarcinoma (BAC). The purpose of this study was to evaluate therapeutic potential of HR inhibition, alone and in combination with telomerase inhibition, in BAC. We demonstrate that telomerase inhibition in BAC cells increases HR activity, RAD51 expression, and association of RAD51 to telomeres. Suppression of HR leads to shorter telomeres as well as markedly reduced genomic instability in BAC cells over time. Combination of HR suppression (whether transgenic or chemical) with telomerase inhibition, causes a significant increase in telomere attrition and apoptotic death in all BAC cell lines tested, relative to either treatment alone. A subset of treated cells also stain positive for beta-galactosidase, indicating senescence. The combined treatment is also associated with decline in S-phase and a strong G2/M arrest, indicating massive telomere attrition. In a subcutaneous tumor model, the combined treatment resulted in the smallest tumors, which were even smaller (P - 0.001) than those that resulted from either treatment alone. Even the tumors removed from these mice had significantly reduced telomeres and evidence of apoptosis. We therefore conclude that although telomeres are elongated by telomerase, elevated RAD51/HR assist in their maintenance/ stabilization in BAC cells. Telomerase inhibitor prevents telomere elongation but induces RAD51/HR, which contributes to telomere maintenance/ stabilization and prevention of apoptosis, reducing the efficacy of treatment. Combining HR inhibition with telomerase renders telomeres more vulnerable to degradation and significantly increases/ expedites their attrition, leading to apoptosis. We therefore demonstrate that a therapy targeting HR and telomerase has the potential to prevent both tumor growth and genomic evolution in BAC.	[Lu, R.; Pal, J.; Buon, L.; Nanjappa, P.; Shi, J.; Fulciniti, M.; Tai, Y-T; Munshi, N. C.; Shammas, M. A.] Harvard Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA USA; [Lu, R.; Pal, J.; Buon, L.; Nanjappa, P.; Shi, J.; Fulciniti, M.; Tai, Y-T; Munshi, N. C.; Shammas, M. A.] VA Hlth Care Syst, Boston, MA USA; [Lu, R.; Guo, L.; Yu, M.] Fudan Univ, Dept Clin Lab, Shanghai Canc Ctr, Shanghai 200433, Peoples R China; [Lu, R.; Guo, L.; Yu, M.] Shanghai Med Sch, Shanghai, Peoples R China; [Shi, J.; Fulciniti, M.; Tai, Y-T; Munshi, N. C.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA; [Gryaznov, S.] Geron Corp, Dept Nucle Acid Chem, Menlo Pk, CA USA	Fudan University; Harvard University; Harvard Medical School; Geron Corporation	Shammas, MA (corresponding author), Harvard Dana Farber Canc Inst, Dept Adult Oncol, 1400 VFW Pkwy,Bldg 3,Room 2A111, West Roxbury, MA 02132 USA.	Masood_Shammas@DFCI.Harvard.Edu	Munshi, Nikhil/ABE-2338-2021	Shi, Jialan/0000-0001-5642-5436	National Cancer Institute [R01CA125711]; Department of Veterans Affairs Merit Review Awards; National Institutes of Health [RO1-1375555, P50-100007, PO1-78378]; NATIONAL CANCER INSTITUTE [P01CA155258, R01CA125711] Funding Source: NIH RePORTER	National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Department of Veterans Affairs Merit Review Awards(US Department of Veterans Affairs); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Dr David G Beer, Department of Surgery, University of Michigan, Ann Arbor, MI, USA, for providing FLO-1 cells. This work was supported in part by grants from National Cancer Institute R01CA125711 to MAS, from the Department of Veterans Affairs Merit Review Awards (to NCM) and from the National Institutes of Health Grants RO1-1375555, P50-100007 and PO1-78378 to NCM.	Abdallah P, 2009, NAT CELL BIOL, V11, P988, DOI 10.1038/ncb1911; Aggarwal S, 2000, NEOPLASIA, V2, P346, DOI 10.1038/sj.neo.7900097; Akiyama M, 2003, CANCER RES, V63, P6187; ALLSHIRE RC, 1988, NATURE, V332, P656, DOI 10.1038/332656a0; Badie S, 2010, NAT STRUCT MOL BIOL, V17, P1461, DOI 10.1038/nsmb.1943; Bechter OE, 1998, CANCER RES, V58, P4918; BLACKBURN EH, 1989, GENOME, V31, P553, DOI 10.1139/g89-104; Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Cawthon RM, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e47; Cerone MA, 2001, HUM MOL GENET, V10, P1945, DOI 10.1093/hmg/10.18.1945; Collins K, 2000, CURR OPIN CELL BIOL, V12, P378, DOI 10.1016/S0955-0674(00)00103-4; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; DAY JP, 1993, ENVIRON MOL MUTAGEN, V22, P245, DOI 10.1002/em.2850220411; DELANGE T, 1990, MOL CELL BIOL, V10, P518, DOI 10.1128/MCB.10.2.518; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Ducray C, 1999, ONCOGENE, V18, P4211, DOI 10.1038/sj.onc.1202797; Dunham MA, 2000, NAT GENET, V26, P447, DOI 10.1038/82586; Engelhardt M, 1998, ONCOL REP, V5, P1043; Fu WM, 1999, J BIOL CHEM, V274, P7264, DOI 10.1074/jbc.274.11.7264; Ganapathipillai SS, 2008, CANCER RES, V68, P5769, DOI 10.1158/0008-5472.CAN-08-1269; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; Henson JD, 2002, ONCOGENE, V21, P598, DOI 10.1038/sj.onc.1205058; Ijpma AS, 2003, MOL BIOL CELL, V14, P987, DOI 10.1091/mbc.02-04-0057; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lord RVN, 2000, J GASTROINTEST SURG, V4, P135, DOI 10.1016/S1091-255X(00)80049-9; McEachern MJ, 2000, ANNU REV GENET, V34, P331, DOI 10.1146/annurev.genet.34.1.331; Morrish TA, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000357; MOYZIS RK, 1988, P NATL ACAD SCI USA, V85, P6622, DOI 10.1073/pnas.85.18.6622; Munshi NC, 2004, BLOOD, V103, P1799, DOI 10.1182/blood-2003-02-0402; Nakajima A, 2003, LEUKEMIA, V17, P560, DOI 10.1038/sj.leu.2402825; Ogunwobi OO, 2008, AM J GASTROENTEROL, V103, P825, DOI 10.1111/j.1572-0241.2007.01773.x; Opitz OG, 2001, J CLIN INVEST, V108, P725, DOI 10.1172/JCI11909; Pal J, 2011, ONCOGENE, V30, P3585, DOI 10.1038/onc.2011.83; Pal J, 2012, CANCER GENOM PROTEOM, V9, P55; Pierce AJ, 1999, GENE DEV, V13, P2633, DOI 10.1101/gad.13.20.2633; Seimiya H, 2002, MOL CANCER THER, V1, P657; Shammas MA, 2008, LEUKEMIA, V22, P1410, DOI 10.1038/leu.2008.81; Shammas MA, 1999, ONCOGENE, V18, P6191, DOI 10.1038/sj.onc.1203069; Shammas MA, 2004, GASTROENTEROLOGY, V126, P1337, DOI 10.1053/j.gastro.2004.01.026; Shammas MA, 2004, EXP CELL RES, V295, P204, DOI 10.1016/j.yexcr.2004.01.003; Shammas MA, 2004, CLIN CANCER RES, V10, P770, DOI 10.1158/1078-0432.CCR-0793-03; Shammas MA, 2003, MOL CANCER THER, V2, P825; Shammas MA, 2008, CLIN CANCER RES, V14, P4971, DOI 10.1158/1078-0432.CCR-08-0473; Shammas MA, 2006, BLOOD, V108, P2804, DOI 10.1182/blood-2006-05-022814; Shammas MA, 2005, MOL CANCER, V4, DOI 10.1186/1476-4598-4-24; Shammas MA, 2011, METHODS MOL BIOL, V755, P181, DOI 10.1007/978-1-61779-163-5_14; Shammas MA, 2009, BLOOD, V113, P2290, DOI 10.1182/blood-2007-05-089193; Shay JW, 1996, TRENDS GENET, V12, P129, DOI 10.1016/0168-9525(96)30018-8; Shay JW, 1997, J CELL PHYSIOL, V173, P266, DOI 10.1002/(SICI)1097-4652(199711)173:2<266::AID-JCP33>3.0.CO;2-B; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Shi J, 2006, CYTOM PART A, V69A, P1193, DOI 10.1002/cyto.a.20345; Sumi M, 2004, INT J ONCOL, V24, P1481; Tauchi T, 2003, ONCOGENE, V22, P5338, DOI 10.1038/sj.onc.1206833; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; Wai Lin Kah, 2004, MedGenMed, V6, P19; Wallweber G, 2003, BIOCHEMISTRY-US, V42, P589, DOI 10.1021/bi026914a	59	30	31	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2014	33	12					1495	1505		10.1038/onc.2013.103	http://dx.doi.org/10.1038/onc.2013.103			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD4TS	23604115	Green Accepted, Green Submitted			2022-12-28	WOS:000333244200003
J	Lee, SH; Bae, SC; Kim, KW; Lee, YM				Lee, S. H.; Bae, S. C.; Kim, K. W.; Lee, Y. M.			RUNX3 inhibits hypoxia-inducible factor-1 alpha protein stability by interacting with prolyl hydroxylases in gastric cancer cells	ONCOGENE			English	Article						RUNX3; hypoxia; HIF-1 alpha; prolyl hydroxylase; angiogenesis	HIPPEL-LINDAU PROTEIN; TUMOR-SUPPRESSOR; FACTOR 1-ALPHA; KINASE PHOSPHORYLATES; GENE-EXPRESSION; GROWTH-FACTOR; ANGIOGENESIS; OXYGEN; METASTASIS; PATHWAY	RUNX3 is silenced by histone modification and hypoxia-inducible factor (HIF)-1 alpha is stabilized under hypoxia, but little is known of cross-talk between RUNX3 and HIF-1 alpha under hypoxia. In the present study, the authors investigated the effect of RUNX3 on HIF-1 alpha stability in gastric cancer cells. RUNX3 overexpression was found to downregulate HIF-1 alpha stability under normoxic and hypoxic conditions. Furthermore, the activity of a luciferase reporter containing five copies of vascular endothelial growth factor (VEGF) promoter hypoxia-responsive element (5 x HRE) and the amount of secreted VEGF, were diminished in RUNX3-expressing but increased in RUNX3-knockdown cells. When expression of RUNX3 was recovered using epigenetic reagents the expressions of HIF-1 alpha and VEGF were clearly suppressed under hypoxic conditions. RUNX3 also significantly attenuated the half-life of HIF-1 alpha protein, and induced the cytosolic localization and ubiquitination of HIF-1 alpha. In addition, RUNX3 directly interacted with the C-terminal activation domain of HIF-1 alpha and prolyl hydroxylase (PHD) 2 and enhanced the interaction between HIF-1 alpha and PHD2, which potentiated proline hydroxylation and promoted the degradation of HIF-1 alpha. Furthermore, RUNX3 overexpression significantly inhibited hypoxia-induced angiogenesis in vitro and in vivo. Taken together, these results suggest that RUNX3 destabilizes HIF-1 alpha protein by promoting the proline hydroxylation of HIF-1 alpha through binding to HIF-1 alpha/PHD2. RUNX3 appears to be a novel suppressor of HIF-1 alpha and of hypoxia-mediated angiogenesis in gastric cancer cells.	[Lee, S. H.] Kyungpook Natl Univ, Coll Nat Sci, Sch Life Sci & Biotechnol, Taegu 702701, South Korea; [Bae, S. C.] Chungbook Natl Univ, Sch Med, Chongju, South Korea; [Kim, K. W.] Seoul Natl Univ, Coll Pharm, Seoul, South Korea; [Lee, S. H.; Lee, Y. M.] Kyungpook Natl Univ, Coll Pharm, Taegu 702701, South Korea; [Lee, S. H.; Lee, Y. M.] Kyungpook Natl Univ, Res Inst Pharmaceut Sci, Taegu 702701, South Korea	Kyungpook National University; Seoul National University (SNU); Kyungpook National University; Kyungpook National University	Lee, YM (corresponding author), Kyungpook Natl Univ, Coll Pharm, Taegu 702701, South Korea.	lym@knu.ac.kr	Kim, Kyu Won/AAJ-7213-2020		National Research Foundation grant from the Basic Research Lab program [2012-028835]; National Research Foundation grant from Mid-career Researcher Program [2010-0026741]; Korean Ministry of Education, Science Technology (MEST)	National Research Foundation grant from the Basic Research Lab program; National Research Foundation grant from Mid-career Researcher Program; Korean Ministry of Education, Science Technology (MEST)(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This work was supported by a National Research Foundation grant from the Basic Research Lab program (2012-028835) and from Mid-career Researcher Program (2010-0026741) funded by the Korean Ministry of Education, Science Technology (MEST).	An WG, 1998, NATURE, V392, P405, DOI 10.1038/32925; Bae MK, 2005, CANCER RES, V65, P2520, DOI 10.1158/0008-5472.CAN-03-2735; Cao YH, 2007, ADV CANCER RES, V97, P203, DOI 10.1016/S0065-230X(06)97009-2; Chan DA, 2005, MOL CELL BIOL, V25, P6415, DOI 10.1128/MCB.25.15.6415-6426.2005; Chang CC, 2011, J ORAL PATHOL MED, V40, P567, DOI 10.1111/j.1600-0714.2011.01009.x; Chuang LSH, 2010, ONCOGENE, V29, P2605, DOI 10.1038/onc.2010.88; Corish P, 1999, PROTEIN ENG, V12, P1035, DOI 10.1093/protein/12.12.1035; Coulon C, 2010, ARTERIOSCL THROM VAS, V30, P2331, DOI 10.1161/ATVBAHA.110.214106; Ellis L, 2009, CANCER LETT, V280, P145, DOI 10.1016/j.canlet.2008.11.012; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Fujita N, 2012, J BIOL CHEM, V287, P16975, DOI 10.1074/jbc.M111.334466; Goh YM, 2010, J BIOL CHEM, V285, P10122, DOI 10.1074/jbc.M109.071381; Guo WH, 2002, ONCOGENE, V21, P8351, DOI 10.1038/sj.onc.1206037; Hagen T, 2003, SCIENCE, V302, P1975, DOI 10.1126/science.1088805; Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704; Isobe T, 2012, INT J CLIN ONCOL; Ito K, 2005, CANCER RES, V65, P7743, DOI 10.1158/0008-5472.CAN-05-0743; Ito Y, 2008, ADV CANCER RES, V99, P33, DOI 10.1016/S0065-230X(07)99002-8; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jeong CH, 2005, INT J ONCOL, V26, P211; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Kim HR, 2008, J CELL BIOCHEM, V105, P1048, DOI 10.1002/jcb.21906; Kim JH, 2009, J CELL BIOCHEM, V107, P557, DOI 10.1002/jcb.22157; Kim MS, 2001, NAT MED, V7, P437, DOI 10.1038/86507; Lau QC, 2006, CANCER RES, V66, P6512, DOI 10.1158/0008-5472.CAN-06-0369; Lee MN, 2010, J NATL CANCER I, V102, P426, DOI 10.1093/jnci/djq026; Lee SH, 2009, ONCOGENE, V28, P184, DOI 10.1038/onc.2008.377; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lund AH, 2002, CANCER CELL, V1, P213, DOI 10.1016/S1535-6108(02)00049-1; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Nakase Y, 2005, BRIT J CANCER, V92, P562, DOI 10.1038/sj.bjc.6602372; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Peng ZH, 2006, CLIN CANCER RES, V12, P6386, DOI 10.1158/1078-0432.CCR-05-2359; Poon E, 2009, EXPERT REV MOL MED, V11, DOI 10.1017/S1462399409001173; Pore N, 2006, MOL CANCER RES, V4, P471, DOI 10.1158/1541-7786.MCR-05-0234; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Semenza GL, 2003, ANNU REV MED, V54, P17, DOI 10.1146/annurev.med.54.101601.152418; Semenza GL, 2000, CANCER METAST REV, V19, P59, DOI 10.1023/A:1026544214667; Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187; Stiehl DP, 2006, J BIOL CHEM, V281, P23482, DOI 10.1074/jbc.M601719200; Takeda K, 2009, ARTERIOSCL THROM VAS, V29, P2132, DOI 10.1161/ATVBAHA.109.196071; Wei DY, 2005, CANCER RES, V65, P4809, DOI 10.1158/0008-5472.CAN-04-3741; Yano T, 2006, MOL CELL BIOL, V26, P4474, DOI 10.1128/MCB.01926-05; Zhang YQ, 2007, MED SCI MONITOR, V13, pRA175; Zhong H, 2000, CANCER RES, V60, P1541	46	31	33	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 13	2014	33	11					1458	1467		10.1038/onc.2013.76	http://dx.doi.org/10.1038/onc.2013.76			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD0SD	23542169				2022-12-28	WOS:000332943500013
J	Allen-Petersen, BL; Carter, CJ; Ohm, AM; Reyland, ME				Allen-Petersen, B. L.; Carter, C. J.; Ohm, A. M.; Reyland, M. E.			Protein kinase C delta is required for ErbB2-driven mammary gland tumorigenesis and negatively correlates with prognosis in human breast cancer	ONCOGENE			English	Article						PKC delta; breast cancer; ErbB2; Src	GROWTH-FACTOR RECEPTOR; SRC FAMILY KINASES; ERBB RECEPTORS; PKC-DELTA; PANCREATIC-CANCER; NEU PROTOONCOGENE; EPITHELIAL ACINI; CELL-MIGRATION; NUCLEAR IMPORT; ACTIVATION	Protein kinase C delta (PKC delta) regulates apoptosis in the mammary gland, however, the functional contribution of PKC delta to the development or progression of breast cancer has yet to be determined. Meta-analysis of ErbB2-positive breast cancers shows increased PKC delta expression, and a negative correlation between PKC delta expression and prognosis. Here, we present in-vivo evidence that PKC delta is essential for the development of mammary gland tumors in a ErbB2-overexpressing transgenic mouse model, and in-vitro evidence that PKC delta is required for proliferative signaling downstream of the ErbB2 receptor. Mouse mammary tumor virus (MMTV)-ErbB2 mice lacking PKC delta (delta KO) have increased tumor latency compared with MMTV-ErbB2 wild-type (delta WT) mice, and the tumors show a dramatic decrease in Ki-67 staining. To explore the relationship between PKC delta and ErbB2-driven proliferation more directly, we used MCF-10A cells engineered to express a synthetic ligand-inducible form of the ErbB2 receptor. Depletion of PKC delta with short hairpin RNA inhibited ligand-induced growth in both two-dimensional (2D) (plastic) and three-dimensional (3D) (Matrigel) culture, and correlated with decreased phosphorylation of the ErbB2 receptor and reduced activation of Src and MAPK/ERK pathways. Similarly, in human breast cancer cell lines in which ErbB2 is overexpressed, depletion of PKC delta suppresses proliferation, Src and ERK activation. PKC delta appears to drive proliferation through the formation of an active ErbB2/PKC delta/Src signaling complex, as depletion of PKC delta disrupts association of Src with the ErbB2 receptor. Taken together, our studies present the first evidence that PKC delta is a critical regulator of ErbB2-mediated tumorigenesis, and suggest further investigation of PKC delta as a target in ErbB2-positive breast cancer.	[Allen-Petersen, B. L.] Univ Colorado, Sch Med, Program Cell Biol Stem Cells & Dev, Aurora, CO 80045 USA; [Carter, C. J.; Ohm, A. M.; Reyland, M. E.] Univ Colorado, Sch Dent Med, Dept Craniofacial Biol, Aurora, CO 80045 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Reyland, ME (corresponding author), Univ Colorado, Sch Dent Med, Dept Craniofacial Biol, Anschutz Med Campus,Mail Stop 8120,POB 6511, Aurora, CO 80045 USA.	Mary.Reyland@UCDenver.edu	Allen-Petersen, Brittany/AAC-8504-2020	Allen-Petersen, Brittany/0000-0002-7436-9412	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD038129] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA046934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE015648] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA046934] Funding Source: Medline; NICHD NIH HHS [P01 HD038129] Funding Source: Medline; NIDCR NIH HHS [R01 DE015648] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adwan TS, 2011, J BIOL CHEM, V286, P35716, DOI 10.1074/jbc.M111.255950; Allen-Petersen BL, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2009.20; BOUCHARD L, 1989, CELL, V57, P931, DOI 10.1016/0092-8674(89)90331-0; Cheng J, 2007, ENDOCRINOLOGY, V148, P2066, DOI 10.1210/en.2006-1465; D'Costa AM, 2006, ONCOGENE, V25, P378, DOI 10.1038/sj.onc.1209065; Dankort D, 2001, J BIOL CHEM, V276, P38921, DOI 10.1074/jbc.M106239200; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; DeVries TA, 2002, EMBO J, V21, P6050, DOI 10.1093/emboj/cdf606; DeVries-Seimon TA, 2007, J BIOL CHEM, V282, P22307, DOI 10.1074/jbc.M703661200; Evans JD, 2003, AM J CLIN PATHOL, V119, P392, DOI 10.1309/BKPC9DX98R781B87; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Grossoni VC, 2007, MOL CARCINOGEN, V46, P381, DOI 10.1002/mc.20287; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Humphries MJ, 2006, J BIOL CHEM, V281, P9728, DOI 10.1074/jbc.M507851200; Iwabu A, 2004, J BIOL CHEM, V279, P14551, DOI 10.1074/jbc.M311981200; Jackson D, 2005, ONCOGENE, V24, P3067, DOI 10.1038/sj.onc.1208465; Jones JT, 1999, FEBS LETT, V447, P227, DOI 10.1016/S0014-5793(99)00283-5; Keshamouni VG, 2002, J BIOL CHEM, V277, P22558, DOI 10.1074/jbc.M202351200; Kiley SC, 1999, ONCOGENE, V18, P6748, DOI 10.1038/sj.onc.1203101; Kiley SC, 1999, CANCER RES, V59, P3230; Kraus S, 2003, J BIOL CHEM, V278, P32618, DOI 10.1074/jbc.M303886200; Kruger JS, 2003, MOL CANCER RES, V1, P801; Kwon YK, 1997, J NEUROSCI, V17, P8293; Liu Dong, 2000, Shengli Xuebao, V52, P483; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; Marcotte R, 2009, MOL CELL BIOL, V29, P5858, DOI 10.1128/MCB.01731-08; Marmor MD, 2004, INT J RADIAT ONCOL, V58, P903, DOI 10.1016/j.ijrobp.2003.06.002; Matassa AA, 2001, J BIOL CHEM, V276, P29719, DOI 10.1074/jbc.M100273200; Mauro LV, 2010, PANCREAS, V39, pE31, DOI 10.1097/MPA.0b013e3181bce796; McKiernan E, 2008, BRIT J CANCER, V99, P1644, DOI 10.1038/sj.bjc.6604728; Menard S, 2000, J CELL PHYSIOL, V182, P150, DOI 10.1002/(SICI)1097-4652(200002)182:2<150::AID-JCP3>3.0.CO;2-E; Miyamoto A, 2002, NATURE, V416, P865, DOI 10.1038/416865a; Muthuswamy SK, 1999, MOL CELL BIOL, V19, P6845; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; Parker JS, 2009, J CLIN ONCOL, V27, P1160, DOI 10.1200/JCO.2008.18.1370; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093; PONGRACZ J, 1995, INT J CANCER, V61, P35, DOI 10.1002/ijc.2910610107; Rexer BN, 2011, ONCOGENE, V30, P4163, DOI 10.1038/onc.2011.130; Reyland ME, 2009, FRONT BIOSCI-LANDMRK, V14, P2386, DOI 10.2741/3385; Reyland ME, 1999, J BIOL CHEM, V274, P19115, DOI 10.1074/jbc.274.27.19115; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Ringner M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017911; Schade B, 2007, CANCER RES, V67, P7579, DOI 10.1158/0008-5472.CAN-06-4724; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; Symonds JM, 2011, CANCER RES, V71, P2087, DOI 10.1158/0008-5472.CAN-10-1511; Tan M, 2005, CANCER RES, V65, P1858, DOI 10.1158/0008-5472.CAN-04-2353; Tolwinski NS, 1999, J BIOL CHEM, V274, P6168, DOI 10.1074/jbc.274.10.6168; Varga A, 2004, EUR UROL, V46, P462, DOI 10.1016/j.eururo.2004.04.014; Xu WP, 2007, MOL CELL BIOL, V27, P220, DOI 10.1128/MCB.00899-06; Zhang HT, 1998, ONCOGENE, V16, P2835, DOI 10.1038/sj.onc.1201820; Zhang SY, 2011, NAT MED, V17, P461, DOI 10.1038/nm.2309; Zhou XD, 2009, J BIOL CHEM, V284, P12226, DOI 10.1074/jbc.M900020200	61	38	39	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2014	33	10					1306	1315		10.1038/onc.2013.59	http://dx.doi.org/10.1038/onc.2013.59			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AC6KI	23474764	Green Accepted			2022-12-28	WOS:000332631100011
J	Wardwell-Ozgo, J; Dogruluk, T; Gifford, A; Zhang, Y; Heffernan, TP; van Doorn, R; Creighton, CJ; Chin, L; Scott, KL				Wardwell-Ozgo, J.; Dogruluk, T.; Gifford, A.; Zhang, Y.; Heffernan, T. P.; van Doorn, R.; Creighton, C. J.; Chin, L.; Scott, K. L.			HOXA1 drives melanoma tumor growth and metastasis and elicits an invasion gene expression signature that prognosticates clinical outcome	ONCOGENE			English	Article						HOXA1; melanoma; metastasis; MITF; TGF beta	BETA; MITF; THICKNESS; SURVIVAL; ROLES; CELLS	Melanoma is a highly lethal malignancy notorious for its aggressive clinical course and eventual resistance to existing therapies. Currently, we possess a limited understanding of the genetic events driving melanoma progression, and much effort is focused on identifying pro-metastatic aberrations or perturbed signaling networks that constitute new therapeutic targets. In this study, we validate and assess the mechanism by which homeobox transcription factor A1 (HOXA1), a pro-invasion oncogene previously identified in a metastasis screen by our group, contributes to melanoma progression. Transcriptome and pathway profiling analyses of cells expressing HOXA1 reveals upregulation of factors involved in diverse cytokine pathways that include the transforming growth factor beta (TGF beta) signaling axis, which we further demonstrate to be required for HOXA1-mediated cell invasion in melanoma cells. Transcriptome profiling also shows HOXA1's ability to potently downregulate expression of microphthalmia-associated transcription factor (MITF) and other genes required for melanocyte differentiation, suggesting a mechanism by which HOXA1 expression de-differentiates cells into a pro-invasive cell state concomitant with TGF beta activation. Our analysis of publicly available data sets indicate that the HOXA1-induced gene signature successfully categorizes melanoma specimens based on their metastatic potential and, importantly, is capable of stratifying melanoma patient risk for metastasis based on expression in primary tumors. Together, these validation data and mechanistic insights suggest that patients whose primary tumors express HOXA1 are among a high-risk metastasis subgroup that should be considered for anti-TGF beta therapy in adjuvant settings. Moreover, further analysis of HOXA1 target genes in melanoma may reveal new pathways or targets amenable to therapeutic intervention.	[Wardwell-Ozgo, J.; Dogruluk, T.; Gifford, A.; Scott, K. L.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA; [Zhang, Y.; Creighton, C. J.; Scott, K. L.] Baylor Coll Med, Dan L Duncan Canc Ctr, Houston, TX 77030 USA; [Heffernan, T. P.; Chin, L.] Univ Texas MD Anderson Canc Ctr, Inst Appl Canc Sci, Houston, TX 77030 USA; [van Doorn, R.] Leiden Univ, Med Ctr, Dept Dermatol, Leiden, Netherlands; [Chin, L.] Dept Genom Med, Houston, TX USA	Baylor College of Medicine; Baylor College of Medicine; University of Texas System; UTMD Anderson Cancer Center; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Scott, KL (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, One Baylor Plaza,BCM225, Houston, TX 77030 USA.	kls1@bcm.edu		van Doorn, Remco/0000-0002-7019-6673; Dogruluk, Turgut/0000-0002-9212-9471; Wardwell-Ozgo, Joanna/0000-0002-5295-1604	American Cancer Society; Baylor College of Medicine; NIH [RO1 CA93947, U01 CA84313]; NATIONAL CANCER INSTITUTE [R01CA093947, U01CA084313] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008307, T32GM008231] Funding Source: NIH RePORTER	American Cancer Society(American Cancer Society); Baylor College of Medicine; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	KLS was supported by the American Cancer Society, and this work was supported by departmental seed funds to KLS from Baylor College of Medicine. This work was also supported by grants from the NIH (RO1 CA93947, U01 CA84313) to LC.	Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; BRESLOW A, 1970, ANN SURG, V172, P902, DOI 10.1097/00000658-197011000-00017; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; Creighton CJ, 2008, J CLIN ONCOL, V26, P4078, DOI 10.1200/JCO.2007.13.4429; Criscione VD, 2010, J INVEST DERMATOL, V130, P793, DOI 10.1038/jid.2009.328; Ding L, 2010, NATURE, V464, P999, DOI 10.1038/nature08989; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Gavalas A, 2001, DEVELOPMENT, V128, P3017; Gimotty PA, 2007, J CLIN ONCOL, V25, P1129, DOI 10.1200/JCO.2006.08.1463; He W, 2006, CELL, V125, P929, DOI 10.1016/j.cell.2006.03.045; Hoek KS, 2006, PIGM CELL RES, V19, P290, DOI 10.1111/j.1600-0749.2006.00322.x; Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491; Hoek KS, 2010, PIGM CELL MELANOMA R, V23, P746, DOI 10.1111/j.1755-148X.2010.00757.x; Jeffs AR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008461; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Kaminska B, 2005, ACTA BIOCHIM POL, V52, P329; Kim M, 2006, CELL, V125, P1269, DOI 10.1016/j.cell.2006.06.008; Lekmine F, 2007, BIOCHEM BIOPH RES CO, V354, P830, DOI 10.1016/j.bbrc.2007.01.075; Maeda K, 2005, INT J CANCER, V114, P436, DOI 10.1002/ijc.20706; Meerbrey KL, 2011, P NATL ACAD SCI USA, V108, P3665, DOI 10.1073/pnas.1019736108; Mohammad KS, 2011, CANCER RES, V71, P175, DOI 10.1158/0008-5472.CAN-10-2651; Nishimura EK, 2010, CELL STEM CELL, V6, P130, DOI 10.1016/j.stem.2009.12.010; Pinner S, 2009, CANCER RES, V69, P7969, DOI 10.1158/0008-5472.CAN-09-0781; Remacle S, 2002, NUCLEIC ACIDS RES, V30, P2663, DOI 10.1093/nar/gkf372; Scott KL, 2011, CANCER CELL, V20, P92, DOI 10.1016/j.ccr.2011.05.025; Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Svingen T, 2006, HEREDITY, V97, P88, DOI 10.1038/sj.hdy.6800847; Timar J, 2010, CLIN EXP METASTAS, V27, P371, DOI 10.1007/s10585-010-9307-2; Tuong W, 2012, DERMATOL CLIN, V30, P113, DOI 10.1016/j.det.2011.08.006; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; van de Vijver MJ, 2002, NEW ENGL J MED, V347, P1999, DOI 10.1056/NEJMoa021967; Winnepenninckx VR, 2006, JNCI-J NATL CANCER I, V98, P472, DOI 10.1093/jnci/djj103; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	35	48	48	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2014	33	8					1017	1026		10.1038/onc.2013.30	http://dx.doi.org/10.1038/onc.2013.30			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XO	23435427	Green Accepted			2022-12-28	WOS:000331933200009
J	Montero, JC; Esparis-Ogando, A; Re-Louhau, MF; Seoane, S; Abad, M; Calero, R; Ocana, A; Pandiella, A				Montero, J. C.; Esparis-Ogando, A.; Re-Louhau, M. F.; Seoane, S.; Abad, M.; Calero, R.; Ocana, A.; Pandiella, A.			Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer	ONCOGENE			English	Article						mTOR; PI3K; triple-negative breast cancer	PHOSPHATIDYLINOSITOL 3-KINASE/MAMMALIAN TARGET; RAPAMYCIN INHIBITOR; ANTITUMOR-ACTIVITY; NVP-BEZ235; GROWTH; CELLS; PHOSPHORYLATION; ACTIVATION; POTENT; PROLIFERATION	Triple-negative breast cancer (TNBC) is an aggressive form of breast cancer. Despite response to chemotherapy, relapses are frequent and resistance to available treatments is often seen in the metastatic setting. Therefore, identification of new therapeutic targets is required. With this aim, we have profiled the activation status of 44 receptor tyrosine kinases (RTKs) and their major signaling pathways in patient-derived TNBC tumors. Frequent co-activation of several RTKs as well as the extracellular signal-regulated protein kinases 1 and 2 (Erk1/2) and mammalian target of rapamycin (mTOR) routes was found. Pharmacologic targeting of the activated kinases indicated that agents that attack the mTOR route are more potent and efficient antitumoral treatments than agents targeting RTKs. mTOR signals through two multiprotein complexes, mTORC1 and mTORC2. We used a genetic approach to explore the contribution of each of the two mTOR branches to the regulation of cell number of TNBC cells. RNA interference experiments indicated that mTORC1 predominated over mTORC2 in the control of TNBC cell proliferation. Moreover, RNA interference of mTOR had a superior antiproliferative action than separately acting on mTORC1 or mTORC2. To analyze the relevance of mTOR targeting in vivo, we used mice with TNBC. Treatment of these mice with BEZ235, a drug that targets mTOR, slowed tumor growth. Mechanistically, BEZ235 delayed cell cycle progression without affecting cell viability. Our results show that TNBCs are particularly sensitive to inhibition of the mTOR pathway, and indicate that mTOR targeting may be a more efficient anti-TNBC therapy than exclusively acting on the mTORC1 branch of the pathway. This is relevant as most mTOR inhibitors used in the clinic act on mTORC1. Collectively with the fact that BEZ235 synergized with drugs commonly used in the treatment of TNBC, our data support the clinical development of agents that act on mTOR as a therapy for this disease.	[Montero, J. C.; Esparis-Ogando, A.; Re-Louhau, M. F.; Seoane, S.; Pandiella, A.] Univ Salamanca, Inst Biol Mol & Celular Canc, CSIC, E-37008 Salamanca, Spain; [Abad, M.] Hosp Clin Univ Salamanca, Pathol Dept, Salamanca, Spain; [Calero, R.; Ocana, A.] Complejo Hosp Univ Albacete, Serv Oncol Med, Albacete, Spain; [Calero, R.; Ocana, A.] AECC Unit, Albacete, Spain; [Ocana, A.] Univ Toronto, Princess Margaret Hosp, Div Med Oncol & Hematol, Toronto, ON, Canada	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-USAL - Instituto de Biologia Molecular y Celular del Cancer de Salamanca (IBMCC); University of Salamanca; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre	Pandiella, A (corresponding author), Inst Biol Mol & Celular Canc CIC, Campus Miguel Unamuno,Ave Univ Coimbra, Salamanca 37007, Spain.	atanasio@usal.es	Calero, Raul/F-7867-2016; Seoane, Samuel/H-6299-2015; Seoane, Samuel/L-1309-2014; Esparís-Ogando, Aucena/O-5326-2017; Pandiella, Atanasio/O-5180-2014; Montero, Juan Carlos/AAO-1780-2020	Calero, Raul/0000-0003-1525-1921; Seoane, Samuel/0000-0002-9178-0887; Esparís-Ogando, Aucena/0000-0003-4550-4192; Pandiella, Atanasio/0000-0002-4704-8971; Montero, Juan Carlos/0000-0003-4773-053X; Ocana, Alberto/0000-0002-1067-9630	Ministry of Science and Innovation of Spain [BFU2009-07728/BMC, PS09/00868]; Cancer Center Network Program from the ISCIII [RD06/0020/0041]; European Community through the regional development funding program (FEDER); Fundacion Ramon Areces; FISCAM [PI2010/017]; ISCIII [PS09/02144]	Ministry of Science and Innovation of Spain(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Cancer Center Network Program from the ISCIII; European Community through the regional development funding program (FEDER); Fundacion Ramon Areces; FISCAM; ISCIII(Instituto de Salud Carlos III)	This work was supported by grants from the Ministry of Science and Innovation of Spain (BFU2009-07728/BMC to AP, and PS09/00868 to AE-O). JCM and SS were supported by the Cancer Center Network Program from the ISCIII (RD06/0020/0041). The Cancer Research Institute, and the work carried out at AP and AE-O laboratories, receive support from the European Community through the regional development funding program (FEDER), and from the Fundacion Ramon Areces. AO receives research support from the FISCAM (Grant PI2010/017) and from the ISCIII (Grant PS09/02144). We thank Dr J Jonkers (Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands) for the generous gift of the Brca1/p53 conditional mouse model.	Allred DC, 1998, MODERN PATHOL, V11, P155; Barrios CH, 2010, BREAST CANCER RES TR, V121, P121, DOI 10.1007/s10549-010-0788-0; Baselga J, SAN ANT BREAST CANC; Baumann P, 2009, EXP CELL RES, V315, P485, DOI 10.1016/j.yexcr.2008.11.007; Carey L, 2010, NAT REV CLIN ONCOL, V7, P683, DOI 10.1038/nrclinonc.2010.154; Montero JC, 2012, MOL CANCER THER, V11, P1342, DOI 10.1158/1535-7163.MCT-11-0723; Chen ZM, 2006, MOL PHARMACOL, V69, P1527, DOI 10.1124/mol.105.020172; Chiarini F, 2010, CANCER RES, V70, P8097, DOI 10.1158/0008-5472.CAN-10-1814; CHOU TC, 1994, JNCI-J NATL CANCER I, V86, P1517, DOI 10.1093/jnci/86.20.1517; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Cleator S, 2007, LANCET ONCOL, V8, P235, DOI 10.1016/S1470-2045(07)70074-8; Cristofanilli M, 2008, ANN ONCOL, V19, P1713, DOI 10.1093/annonc/mdn352; de Alava E, 2007, J CLIN ONCOL, V25, P2656, DOI 10.1200/JCO.2006.08.6850; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; Diaz-Rodriguez E, 1999, EUR J NEUROSCI, V11, P1421, DOI 10.1046/j.1460-9568.1999.00552.x; Diaz-Rodriguez E, 2010, J CELL SCI, V123, P3146, DOI 10.1242/jcs.070516; Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053; Eichhorn PJA, 2008, CANCER RES, V68, P9221, DOI 10.1158/0008-5472.CAN-08-1740; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Higgins MJ, 2011, J CLIN INVEST, V121, P3797, DOI 10.1172/JCI57152; Hilger R A, 2002, Int J Clin Pharmacol Ther, V40, P567; Hochgrafe F, 2010, CANCER RES, V70, P9391, DOI 10.1158/0008-5472.CAN-10-0911; Hoeflich KP, 2009, CLIN CANCER RES, V15, P4649, DOI 10.1158/1078-0432.CCR-09-0317; Hudis CA, 2011, ONCOLOGIST, V16, P1, DOI 10.1634/theoncologist.2011-S1-01; Hunter T, 2009, CURR OPIN CELL BIOL, V21, P140, DOI 10.1016/j.ceb.2009.01.028; Janes MR, 2010, NAT MED, V16, P205, DOI 10.1038/nm.2091; Laplante M, 2009, J CELL SCI, V122, P3589, DOI 10.1242/jcs.051011; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Liu X, 2007, P NATL ACAD SCI USA, V104, P12111, DOI 10.1073/pnas.0702969104; Maira SM, 2008, MOL CANCER THER, V7, P1851, DOI 10.1158/1535-7163.MCT-08-0017; McMillin DW, 2009, CANCER RES, V69, P5835, DOI 10.1158/0008-5472.CAN-08-4285; Metzger O, 2012, J CLIN ONCOL, V30, P1879, DOI 10.1200/JCO.2011.38.2010; Miller TW, 2010, J CLIN INVEST, V120, P2406, DOI 10.1172/JCI41680; Montero JC, 2011, ONCOGENE, V30, P1059, DOI 10.1038/onc.2010.489; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220; Ocana A, 2011, NAT REV CLIN ONCOL, V8, P200, DOI 10.1038/nrclinonc.2010.194; Rodrik-Outmezguine VS, 2011, CANCER DISCOV, V1, P248, DOI 10.1158/2159-8290.CD-11-0085; Sarbassov DD, 2006, MOL CELL, V22, P159, DOI 10.1016/j.molcel.2006.03.029; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Seoane S, 2010, JNCI-J NATL CANCER I, V102, P1432, DOI 10.1093/jnci/djq315; Serra V, 2011, ONCOGENE, V30, P2547, DOI 10.1038/onc.2010.626; Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008-5472.CAN-08-1385; Shah SP, 2012, NATURE, V486, P395, DOI 10.1038/nature10933; Sun TT, 2011, CELL, V144, P703, DOI 10.1016/j.cell.2011.02.003; Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775; Xia WL, 2002, ONCOGENE, V21, P6255, DOI 10.1038/sj.onc.1205794; Yeh TC, 2007, CLIN CANCER RES, V13, P1576, DOI 10.1158/1078-0432.CCR-06-1150; Yuste L, 2005, CANCER RES, V65, P6801, DOI 10.1158/0008-5472.CAN-04-4023	49	67	71	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2014	33	2					148	156		10.1038/onc.2012.572	http://dx.doi.org/10.1038/onc.2012.572			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286BY	23246963				2022-12-28	WOS:000329440700002
J	Dalvai, M; Mondesert, O; Bugler, B; Manenti, S; Ducommun, B; Dozier, C				Dalvai, M.; Mondesert, O.; Bugler, B.; Manenti, S.; Ducommun, B.; Dozier, C.			Doxorubicin promotes transcriptional upregulation of Cdc25B in cancer cells by releasing Sp1 from the promoter	ONCOGENE			English	Article						Cdc25B; doxorubicin; p53; Sp1	DNA-DAMAGING AGENTS; DOWN-REGULATION; P53; PHOSPHORYLATION; EXPRESSION; PHOSPHATASES; CHECKPOINT; IDENTIFICATION; DEGRADATION; INDUCTION	Cdc25B phosphatases have a key role in G2/M cell-cycle progression by activating the CDK1-cyclinB1 complexes and functioning as important targets of checkpoints. Overexpression of Cdc25B results in a bypass of the G2/M checkpoint and illegitimate entry into mitosis. It can also cause replicative stress, which leads to genomic instability. Thus, fine-tuning of the Cdc25B expression level is critical for correct cell-cycle arrest in response to DNA damage. In response to genotoxic stress, Cdc25B is mainly regulated by post-transcriptional mechanisms affecting either Cdc25B protein stability or translation. Here, we show that upon DNA damage Cdc25B can be regulated at the transcriptional level. Although ionizing radiation downregulates Cdc25B in a p53-dependent pathway, doxorubicin transcriptionally upregulates Cdc25B in p53-proficient cancer cells. We show that in the presence of wild-type p53, doxorubicin activates the Cdc25B promoter by preventing the binding of Sp1 and increasing the binding of NF-Y on the Cdc25B promoter, thus preventing p53 from downregulating this promoter. Our results highlight the mechanistically distinct regulation of the three Cdc25 phosphatases by checkpoint signalling following doxorubicin treatment.	[Dalvai, M.] CNRS, LBME UMR5099, F-31059 Toulouse, France; [Dalvai, M.; Mondesert, O.; Bugler, B.; Manenti, S.; Ducommun, B.; Dozier, C.] Univ Toulouse, Toulouse, France; [Mondesert, O.; Ducommun, B.] CNRS, ITAV UMS 3039, F-31059 Toulouse, France; [Bugler, B.] CNRS, LBCMCP UMR5088, F-31059 Toulouse, France; [Manenti, S.; Dozier, C.] CNRS, Canc Res Ctr Toulouse, Dept Hematol & Immunol, INSERM UMR1037,ERL 5294, F-31059 Toulouse, France; [Manenti, S.; Dozier, C.] CNRS, ERL 5294, F-31059 Toulouse, France; [Ducommun, B.] CHU Toulouse, Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite de Toulouse; Universite Federale Toulouse Midi-Pyrenees (ComUE); Universite Toulouse III - Paul Sabatier; Institut National des Sciences Appliquees de Toulouse; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); CHU de Toulouse	Dozier, C (corresponding author), CNRS, Canc Res Ctr Toulouse, Dept Hematol & Immunol, INSERM UMR1037,ERL 5294, F-31059 Toulouse, France.	christine.dozier@inserm.fr	manenti, stephane/P-1518-2014; DOZIER, Christine/P-1539-2014	manenti, stephane/0000-0002-4793-3196; DUCOMMUN, Bernard/0000-0002-7126-8368	Fondation de la Recherche Medicale; C.N.R.S; Universite Paul Sabatier; la region Midi-Pyrenees; l'Institut National du Cancer [PL2008]; Canceropole Grand Sud-Ouest, le conseil de radioprotection d'EDF et la Ligue Nationale Contre le Cancer (Equipe labellisee)	Fondation de la Recherche Medicale(Fondation pour la Recherche Medicale); C.N.R.S(Centre National de la Recherche Scientifique (CNRS)); Universite Paul Sabatier; la region Midi-Pyrenees(Region Occitanie); l'Institut National du Cancer(Institut National du Cancer (INCA) France); Canceropole Grand Sud-Ouest, le conseil de radioprotection d'EDF et la Ligue Nationale Contre le Cancer (Equipe labellisee)	The authors thank Dr Bert Vogelstein (Howard Hughes Medical Institute, Baltimore USA) for providing the WT and p53 -/- HCT116 cells. MD was a recipient of a post-doctoral fellowship from Fondation de la Recherche Medicale. This work was supported by C.N.R.S, Universite Paul Sabatier, la region Midi-Pyrenees, l'Institut National du Cancer (PL2008), the Canceropole Grand Sud-Ouest, le conseil de radioprotection d'EDF et la Ligue Nationale Contre le Cancer (Equipe labellisee 2008).	Aressy B, 2008, CELL CYCLE, V7, P2234, DOI 10.4161/cc.7.14.6305; Baldin V, 1997, J BIOL CHEM, V272, P32731, DOI 10.1074/jbc.272.52.32731; Bansal P, 2007, CANCER RES, V67, P3356, DOI 10.1158/0008-5472.CAN-06-3685; Beishline K, 2012, MOL CELL BIOL, V32, P3790, DOI 10.1128/MCB.00049-12; Bocangel D, 2009, ANTICANCER RES, V29, P3741; Boutros R, 2006, CURR OPIN CELL BIOL, V18, P185, DOI 10.1016/j.ceb.2006.02.003; Boutros R, 2007, NAT REV CANCER, V7, P495, DOI 10.1038/nrc2169; Bu YQ, 2008, GENES CELLS, V13, P53, DOI 10.1111/j.1365-2443.2007.01144.x; Bugler B, 2006, MOL CANCER THER, V5, P1446, DOI 10.1158/1535-7163.MCT-06-0099; Chu S., GENE, V508, P1; Cuesta A, 2009, BIOCHEM J, V418, P643, DOI 10.1042/BJ20081793; Dalvai M, 2011, ONCOGENE, V30, P2282, DOI 10.1038/onc.2010.588; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Iwahori S, 2008, CELL SIGNAL, V20, P1795, DOI 10.1016/j.cellsig.2008.06.007; Jullien D, 2011, CANCER RES, V71, P1968, DOI 10.1158/0008-5472.CAN-10-2453; Kang CM, 2004, CARCINOGENESIS, V25, P123, DOI 10.1093/carcin/bgg187; Karisson-Rosenthal C, 2006, TRENDS CELL BIOL, V16, P285, DOI 10.1016/j.tcb.2006.04.002; Korner K, 2001, J BIOL CHEM, V276, P9662, DOI 10.1074/jbc.M008696200; Lemaire M, 2006, CELL CYCLE, V5, P1649, DOI 10.4161/cc.5.15.3006; Lindqvist A, 2005, J CELL BIOL, V171, P35, DOI 10.1083/jcb.200503066; Miyata H, 2001, CANCER RES, V61, P3188; Olofsson BA, 2007, MOL CANCER RES, V5, P1319, DOI 10.1158/1541-7786.MCR-07-0374; Rashi-Elkeles S, 2011, MOL ONCOL, V5, P336, DOI 10.1016/j.molonc.2011.06.004; Scian MJ, 2008, ONCOGENE, V27, P2583, DOI 10.1038/sj.onc.1210898; St Clair S, 2004, MOL CELL, V16, P725; Szulawska A, 2005, BIOCHEM PHARMACOL, V69, P7, DOI 10.1016/j.bcp.2004.09.002; Thompson T, 2004, J BIOL CHEM, V279, P53015, DOI 10.1074/jbc.M410233200; Uchida Y, 2004, CANCER RES, V64, P6271, DOI 10.1158/0008-5472.CAN-03-1476; Wang B, 2010, CELL CYCLE, V9, P870, DOI 10.4161/cc.9.5.10825; Xiao Z, 2003, J BIOL CHEM, V278, P21767, DOI 10.1074/jbc.M300229200; Xu J, 2008, CANCER RES, V68, P6718, DOI 10.1158/0008-5472.CAN-08-0657; Yao Y, 1999, ONCOGENE, V18, P5159, DOI 10.1038/sj.onc.1202908; Zhao H, 2002, P NATL ACAD SCI USA, V99, P14795, DOI 10.1073/pnas.182557299	33	12	13	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2013	32	42					5123	5128		10.1038/onc.2012.524	http://dx.doi.org/10.1038/onc.2012.524			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238IB	23160377				2022-12-28	WOS:000325937900013
J	Quizi, JL; Baron, K; Al-Zahrani, KN; O'Reilly, P; Sriram, RK; Conway, J; Laurin, AA; Sabourin, LA				Quizi, J. L.; Baron, K.; Al-Zahrani, K. N.; O'Reilly, P.; Sriram, R. K.; Conway, J.; Laurin, A-A; Sabourin, L. A.			SLK-mediated phosphorylation of paxillin is required for focal adhesion turnover and cell migration	ONCOGENE			English	Article						Ste20; kinase; paxillin; phosphorylation; migration	STE20-LIKE KINASE SLK; EARLY MOLECULAR EVENTS; MICROTUBULE CATASTROPHES; REGULATES ADHESION; ASSOCIATION; ACTIVATION; COMPLEX	Focal adhesion turnover is a complex process required for cell migration. We have previously shown that the Ste20-like kinase (SLK) is required for cell migration and efficient focal adhesion (FA) turnover in a FA kinase (FAK)-dependent manner. However, the role of SLK in this process remains unclear. Using a candidate substrate approach, we show that SLK phosphorylates the adhesion adapter protein paxillin on serine 250. Serine 250 phosphorylation is required for paxillin redistribution and cell motility. Mutation of paxillin serine 250 prevents its phosphorylation by SLK in vitro and results in impaired migration in vivo as evidenced by an accumulation of phospho-FAK-Tyr397 and altered FA turnover rates. Together, our data suggest that SLK phosphorylation of paxillin on serine 250 is required for FAK-dependent FA dynamics.	[Quizi, J. L.; Baron, K.; Al-Zahrani, K. N.; O'Reilly, P.; Sriram, R. K.; Sabourin, L. A.] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada; [Quizi, J. L.; Baron, K.; Al-Zahrani, K. N.; Sriram, R. K.; Conway, J.; Laurin, A-A; Sabourin, L. A.] Ottawa Hosp Res Inst, Canc Therapeut Program, Ottawa, ON K1H 8L6, Canada	University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute	Sabourin, LA (corresponding author), Ottawa Hosp Res Inst, Canc Therapeut Program, 501 Smyth Rd,Box 926, Ottawa, ON K1H 8L6, Canada.	lsabourin@ohri.ca		, Jillian/0000-0003-4354-0026; Baron, Kyla/0000-0002-8859-9251	Canadian Institute for Health Research; Canadian Breast Cancer Foundation; OGSST	Canadian Institute for Health Research(Canadian Institutes of Health Research (CIHR)); Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); OGSST	This work was supported by the Canadian Institute for Health Research and the Canadian Breast Cancer Foundation. JLQ, KB and KNA-Z are the recipient of a Canadian Breast Cancer Foundation scholar award. LAS is the recipient of a CIHR scholar award. PO is the recipient of an OGSST studentship.	Abou Zeid Nancy, 2006, Cell Commun Signal, V4, P8, DOI 10.1186/1478-811X-4-8; Bellis SL, 1997, BIOCHEM J, V325, P375, DOI 10.1042/bj3250375; Broussard JA, 2008, CURR OPIN CELL BIOL, V20, P85, DOI 10.1016/j.ceb.2007.10.009; Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; Brown MC, 2002, INT J BIOCHEM CELL B, V34, P855, DOI 10.1016/S1357-2725(01)00154-6; Canas Benito, 2006, Briefings in Functional Genomics & Proteomics, V4, P295, DOI 10.1093/bfgp/eli002; Delom F, 2006, PROTEOME SCI, V4, DOI 10.1186/1477-5956-4-15; Deramaudt TB, 2011, MOL BIOL CELL, V22, P964, DOI 10.1091/mbc.E10-08-0725; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; Efimov A, 2009, CELL ADHES MIGR, V3, P285, DOI 10.4161/cam.3.3.8858; Efimov A, 2008, J CELL SCI, V121, P196, DOI 10.1242/jcs.012666; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Ezratty EJ, 2005, NAT CELL BIOL, V7, P581, DOI 10.1038/ncb1262; Gilcrease MZ, 2007, CANCER LETT, V247, P1, DOI 10.1016/j.canlet.2006.03.031; Hagel M, 2002, MOL CELL BIOL, V22, P901, DOI 10.1128/MCB.22.3.901-915.2002; Hoellerer MK, 2003, STRUCTURE, V11, P1207, DOI 10.1016/j.str.2003.08.010; Horwitz AR, 1999, SCIENCE, V286, P1102, DOI 10.1126/science.286.5442.1102; Huang C, 2003, NATURE, V424, P219, DOI 10.1038/nature01745; Kaverina I, 1999, J CELL BIOL, V146, P1033, DOI 10.1083/jcb.146.5.1033; Loyet KM, 2005, MOL CELL PROTEOMICS, V4, P235, DOI 10.1074/mcp.R400011-MCP200; Manes S, 2000, IUBMB LIFE, V49, P89; Nayal A, 2006, J CELL BIOL, V173, P587, DOI 10.1083/jcb.200509075; O'Reilly PG, 2005, J BIOL CHEM, V280, P42383, DOI 10.1074/jbc.M510763200; Petit V, 2000, J CELL BIOL, V148, P957, DOI 10.1083/jcb.148.5.957; Romer LH, 2006, CIRC RES, V98, P606, DOI 10.1161/01.RES.0000207408.31270.db; Roovers K, 2009, ONCOGENE, V28, P2839, DOI 10.1038/onc.2009.146; Scheswohl Danielle M, 2008, J Mol Signal, V3, P1, DOI 10.1186/1750-2187-3-1; Storbeck CJ, 2009, MOL BIOL CELL, V20, P4174, DOI 10.1091/mbc.E08-07-0707; Wagner S, 2002, J BIOL CHEM, V277, P37685, DOI 10.1074/jbc.M205899200; Wagner S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001868; Webb DJ, 2003, CURR OPIN CELL BIOL, V15, P614, DOI 10.1016/S0955-0674(03)00105-4; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Webb DJ, 2005, J CELL SCI, V118, P4925, DOI 10.1242/jcs.02563; Wu Hsin-Yi, 2008, Chang Gung Med J, V31, P217; Zaidel-Bar R, 2003, J CELL SCI, V116, P4605, DOI 10.1242/jcs.00792; Zimerman B, 2004, CELL MOTIL CYTOSKEL, V58, P143, DOI 10.1002/cm.20005	36	28	29	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2013	32	39					4656	4663		10.1038/onc.2012.488	http://dx.doi.org/10.1038/onc.2012.488			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	226YD	23128389	Green Submitted			2022-12-28	WOS:000325072200007
J	Deng, M; Zhang, W; Tang, H; Ye, Q; Liao, Q; Zhou, Y; Wu, M; Xiong, W; Zheng, Y; Guo, X; Qin, Z; He, W; Zhou, M; Xiang, J; Li, X; Ma, J; Li, G				Deng, M.; Zhang, W.; Tang, H.; Ye, Q.; Liao, Q.; Zhou, Y.; Wu, M.; Xiong, W.; Zheng, Y.; Guo, X.; Qin, Z.; He, W.; Zhou, M.; Xiang, J.; Li, X.; Ma, J.; Li, G.			Lactotransferrin acts as a tumor suppressor in nasopharyngeal carcinoma by repressing AKT through multiple mechanisms	ONCOGENE			English	Article						nasopharyngeal carcinoma; LTF; AKT; PDK1; keratin 18; 14-3-3	LACTOFERRIN INHIBITS GROWTH; SIMPLE EPITHELIAL KERATINS; CYCLIN-DEPENDENT KINASES; INITIATED COLON-TUMOR; 14-3-3 PROTEINS; BOVINE LACTOFERRIN; DOWN-REGULATION; EXPRESSION; CANCER; PHOSPHORYLATION	LTF (lactotransferrin, also known as lactoferrin) is a key component of innate immune defense. It has recently been found to have anti-tumor and anti-metastatic activity in different cancers. We previously reported LTF to be the most significantly downregulated gene in nasopharyngeal carcinoma (NPC) specimens relative to normal nasopharyngeal epithelial tissues, and it was also negatively associated with the progression and metastasis of NPC. However, the mechanism underlying this remains unclear. In the current study, we revealed that LTF can suppress 3-phosphoinositide-dependent protein kinase 1 expression via the mitogen-activated protein kinase/c-Jun pathway and thus repress AKT signaling. We also showed that LTF interacts with keratin 18 (K18) and so blocks the formation of the K18-14-3-3 complex, leading to downregulation of K18-mediated AKT activation. Thus, LTF suppresses AKT signaling by two separate mechanisms, leading to inhibition of NPC tumorigenesis. This is the first report on the tumor suppressive effects of LTF through repression of AKT signaling in NPC. It suggests that both LTF and AKT signaling merit further study in the field of NPC research.	[Deng, M.; Zhang, W.; Tang, H.; Ye, Q.; Liao, Q.; Zhou, Y.; Wu, M.; Xiong, W.; Zheng, Y.; Guo, X.; Qin, Z.; He, W.; Zhou, M.; Xiang, J.; Li, X.; Ma, J.; Li, G.] Cent S Univ, Key Lab Carcinogenesis & Canc Invas, Hunan Key Lab Nonresolving Inflammat & Canc, Key Lab Carcinogenesis,Minist Hlth,Minist Educ,Ca, Changsha 410078, Hunan, Peoples R China; [Deng, M.; Tang, H.; Liao, Q.] Univ South China, Canc Res Inst, Hengyang, Peoples R China; [Deng, M.] Guangzhou Med Univ, Canc Res Inst, Guangzhou, Guangdong, Peoples R China; [Deng, M.] Guangzhou Med Univ, Canc Hosp, Guangzhou, Guangdong, Peoples R China	Central South University; University of South China; Guangzhou Medical University; Guangzhou Medical University	Ma, J (corresponding author), Cent S Univ, Canc Res Inst, 110 Xiangya Rd, Changsha 410078, Hunan, Peoples R China.	majian@csu.edu.cn; ligy@xysm.net			China 111 Project [111-2-12]; Nature Scientific Foundation of China [30871282, 81071756, 81171988, 91229122]; Ministry of Education [NCET-11-0520]; Hunan Province Natural Sciences Foundation of China [10JJ7003]	China 111 Project; Nature Scientific Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Education; Hunan Province Natural Sciences Foundation of China(Natural Science Foundation of Hunan Province)	This work was supported by the China 111 Project (No. 111-2-12), Nature Scientific Foundation of China (30871282, 81071756, 81171988, 91229122). Ministry of Education (NCET-11-0520, SRF for ROCS). Hunan Province Natural Sciences Foundation of China (10JJ7003).	Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Altomare DA, 2005, ONCOGENE, V24, P7455, DOI 10.1038/sj.onc.1209085; Bayascas JR, 2008, CELL CYCLE, V7, P2978, DOI 10.4161/cc.7.19.6810; BEZAULT J, 1994, CANCER RES, V54, P2310; CAMPBELL T, 1992, BRIT J CANCER, V65, P19, DOI 10.1038/bjc.1992.4; Damiens E, 1999, J CELL BIOCHEM, V74, P486, DOI 10.1002/(SICI)1097-4644(19990901)74:3<486::AID-JCB16>3.3.CO;2-Y; Darling DL, 2005, CURR TOP DEV BIOL, V68, P281, DOI 10.1016/S0070-2153(05)68010-6; Deng M, 2011, J CELL SCI, V124, P2997, DOI 10.1242/jcs.085050; Eriksson JE, 2009, J CLIN INVEST, V119, P1763, DOI 10.1172/JCI38339; Fan SQ, 2006, HUM PATHOL, V37, P593, DOI 10.1016/j.humpath.2006.01.010; Gonzalez-Chavez SA, 2009, INT J ANTIMICROB AG, V33, DOI 10.1016/j.ijantimicag.2008.07.020; Kholodnyuk ID, 2006, INT J CANCER, V119, P99, DOI 10.1002/ijc.21794; Kikani CK, 2005, J CELL BIOCHEM, V96, P1157, DOI 10.1002/jcb.20651; Kim S, 2006, NATURE, V441, P362, DOI 10.1038/nature04659; Kippenberger S, 2010, BBA-MOL CELL RES, V1803, P940, DOI 10.1016/j.bbamcr.2010.03.009; Ku NO, 1998, EMBO J, V17, P1892, DOI 10.1093/emboj/17.7.1892; Ku NO, 2002, P NATL ACAD SCI USA, V99, P4373, DOI 10.1073/pnas.072624299; Li WY, 2011, CANCER BIOTHER RADIO, V26, P477, DOI 10.1089/cbr.2010.0937; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; Lopez-Bergami P, 2010, J BIOL CHEM, V285, P903, DOI 10.1074/jbc.M109.075630; Mariller C, 2007, FEBS J, V274, P2038, DOI 10.1111/j.1742-4658.2007.05747.x; Matsuda Y, 2007, CANCER LETT, V246, P41, DOI 10.1016/j.canlet.2006.01.034; MONTREUIL J, 1960, BIOCHIM BIOPHYS ACTA, V45, P413, DOI 10.1016/0006-3002(60)91478-5; Morrison DK, 2009, TRENDS CELL BIOL, V19, P16, DOI 10.1016/j.tcb.2008.10.003; Obsilova V, 2008, PHYSIOL RES, V57, pS11, DOI 10.33549/physiolres.931598; Omary MB, 2009, J CLIN INVEST, V119, P1794, DOI 10.1172/JCI37762; Rodrigues L, 2009, CRIT REV FOOD SCI, V49, P203, DOI 10.1080/10408390701856157; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sekine K, 1997, JPN J CANCER RES, V88, P523, DOI 10.1111/j.1349-7006.1997.tb00413.x; Shaheduzzaman S, 2007, CANCER BIOL THER, V6, P1088, DOI 10.4161/cbt.6.7.4327; Son HJ, 2006, BIOCHEM CELL BIOL, V84, P345, DOI 10.1139/O06-048; Testa JR, 2005, ONCOGENE, V24, P7391, DOI 10.1038/sj.onc.1209100; TRASK DK, 1990, P NATL ACAD SCI USA, V87, P2319, DOI 10.1073/pnas.87.6.2319; Tsuda H, 1998, ADV EXP MED BIOL, V443, P273; Uenishi T, 2003, CANCER SCI, V94, P851, DOI 10.1111/j.1349-7006.2003.tb01366.x; Varadhachary A, 2004, INT J CANCER, V111, P398, DOI 10.1002/ijc.20271; Ward PP, 2005, CELL MOL LIFE SCI, V62, P2540, DOI 10.1007/s00018-005-5369-8; Wick MJ, 2000, J BIOL CHEM, V275, P40400, DOI 10.1074/jbc.M003937200; Wu MH, 2009, CURR GENOMICS, V10, P216, DOI 10.2174/138920209788488481; Xiao Y, 2004, CLIN CANCER RES, V10, P8683, DOI 10.1158/1078-0432.CCR-04-0988; Yang Y, 2003, CANCER LETT, V191, P155, DOI 10.1016/S0304-3835(02)00677-8; Yi HM, 2006, ONCOL RES, V16, P261, DOI 10.3727/000000006783981008; Zhang DH, 2005, PROTEOMICS, V5, P1797, DOI 10.1002/pmic.200401069; Zhou YH, 2008, INT J CANCER, V123, P2065, DOI 10.1002/ijc.23727	44	57	58	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2013	32	36					4273	4283		10.1038/onc.2012.434	http://dx.doi.org/10.1038/onc.2012.434			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214WL	23069661				2022-12-28	WOS:000324168000009
J	Kao, CJ; Martiniez, A; Shi, XB; Yang, J; Evans, CP; Dobi, A; White, RWD; Kung, HJ				Kao, C-J; Martiniez, A.; Shi, X-B; Yang, J.; Evans, C. P.; Dobi, A.; White, R. W. deVere; Kung, H-J			miR-30 as a tumor suppressor connects EGF/Src signal to ERG and EMT	ONCOGENE			English	Article						prostate cancer; EGF; Src; miRNA; ERG and EMT	PROSTATE-CANCER CELLS; TO-MESENCHYMAL TRANSITION; FAMILY KINASE INHIBITOR; FOCAL ADHESION KINASE; ANDROGEN RECEPTOR; TYROSINE PHOSPHORYLATION; GENE FUSIONS; SRC; EXPRESSION; PATHWAY	Src tyrosine kinase (Src) is implicated in the development of bone metastasis and castration resistance of prostate cancer. Src inhibitors are currently being tested in clinical trials for such diseases. Understanding the molecular and cellular actions of Src inhibitors holds the key to future improvement of this line of therapy. Here we describe the microRNA expression profiles modulated by two Src inhibitors and demonstrate that the miR-30 family members are the most prominently induced species. Consistent with its tumor suppressor role, miR-30 is downmodulated by oncogenic signals such as epidermal growth factor (EGF) and hepatocyte growth factor, and is generally underexpressed in prostate cancer specimens. A number of epithelial-to-mesenchymal transition (EMT)-associated genes are predicted targets of miR-30. Among these genes the Ets-related gene (ERG) is the most frequently overexpressed oncogene in prostate cancer activated by genomic fusion events between promoter upstream sequences of the TMPRSS2 and coding sequences of ERG. We showed by ERG 3' untranslated region reporter and mutagenesis assays that ERG is a direct target of miR-30. Overexpression of miR-30 in prostate cancer cells suppresses EMT phenotypes and inhibits cell migration and invasion. It also inhibits the in vitro and in vivo growth of VCaP cells, which depends on TMPRSS2-ERG for proliferation. TMPRSS2-ERG is generally regulated by androgen at the transcriptional level. Our finding reveals a new post-transcriptional mechanism of TMPRSS2-ERG regulation by Src and growth signals via miR-30 providing a rationale for targeting ERG-positive castration-resistant tumors with Src inhibitors.	[Kao, C-J; Martiniez, A.; Kung, H-J] Univ Calif Davis, Dept Biochem & Mol Med, Sacramento, CA 95817 USA; [Shi, X-B; Yang, J.; Evans, C. P.; White, R. W. deVere] Univ Calif Davis, Dept Urol, Sacramento, CA 95817 USA; [Dobi, A.] Uniformed Serv Univ Hlth Sci, Ctr Prostate Dis Res, Dept Surg, Rockville, MD USA; [Kung, H-J] Natl Hlth Res Inst, Inst Mol & Genom Med, Maioli, Taiwan; [Kung, H-J] Taipei Med Univ, Translat Med & Integrated Lab, Taipei, Taiwan	University of California System; University of California Davis; University of California System; University of California Davis; Uniformed Services University of the Health Sciences - USA; National Health Research Institutes - Taiwan; Taipei Medical University	Kung, HJ (corresponding author), Univ Calif Davis, Dept Biochem & Mol Med, UCDMC Res 3,Room 2400,4645 2nd Ave, Sacramento, CA 95817 USA.	hkung@ucdavis.edu	Kung, Hsing-Jien/C-7651-2013		NIH [CA150197, CA165263]; DOD [PC093350]; DOD postdoctoral fellowship [PC110744]; NATIONAL CANCER INSTITUTE [P30CA093373, R01CA165263, R01CA150197] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); DOD(United States Department of Defense); DOD postdoctoral fellowship; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by NIH grants (CA150197 and CA165263) and DOD grant (PC093350) to HJK. CJK acknowledges the support of DOD postdoctoral fellowship (PC110744). We are grateful to M Bradnam for excellent editorial assistance of this manuscript.	Araujo J, 2009, INT J CANCER, V124, P1, DOI 10.1002/ijc.23998; Bello D, 1997, CARCINOGENESIS, V18, P1215, DOI 10.1093/carcin/18.6.1215; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Braun J, 2010, ONCOGENE, V29, P4237, DOI 10.1038/onc.2010.169; Brunton VG, 2008, CURR OPIN PHARMACOL, V8, P427, DOI 10.1016/j.coph.2008.06.012; Cai CM, 2009, CANCER RES, V69, P6027, DOI 10.1158/0008-5472.CAN-09-0395; Cai HJ, 2011, CANCER RES, V71, P862, DOI 10.1158/0008-5472.CAN-10-1605; Chang YM, 2008, ONCOGENE, V27, P6365, DOI 10.1038/onc.2008.250; Chinnaiyan AM, 2008, NEOPLASIA, V10, P177, DOI 10.1593/neo.07822; Desai SJ, 2006, CANCER RES, V66, P10449, DOI 10.1158/0008-5472.CAN-06-2582; Garofalo M, 2012, NAT MED, V18, P74, DOI 10.1038/nm.2577; Guo ZY, 2006, CANCER CELL, V10, P309, DOI 10.1016/j.ccr.2006.08.021; Gupta S, 2010, CANCER RES, V70, P6735, DOI 10.1158/0008-5472.CAN-10-0244; Hebbard L, 2011, ONCOGENE, V30, P301, DOI 10.1038/onc.2010.412; Hollenhorst Peter C, 2011, Genes Cancer, V1, P1044; Joglekar MV, 2009, ISLETS, V1, P137, DOI 10.4161/isl.1.2.9578; Karni R, 2005, MOL CELL BIOL, V25, P5031, DOI 10.1128/MCB.25.12.5031-5039.2005; King JC, 2009, NAT GENET, V41, P524, DOI 10.1038/ng.371; Klezovitch O, 2008, P NATL ACAD SCI USA, V105, P2105, DOI 10.1073/pnas.0711711105; Kraus S, 2006, CANCER RES, V66, P11047, DOI 10.1158/0008-5472.CAN-06-0596; Kung Hsing-Jien, 2011, Hormones & Cancer, V2, P38, DOI 10.1007/s12672-010-0053-3; Lee LF, 2004, ONCOGENE, V23, P2197, DOI 10.1038/sj.onc.1207344; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; Leshem O, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021650; Li X, 2009, ONCOGENE, V28, P4272, DOI 10.1038/onc.2009.278; Lin CR, 2009, CELL, V139, P1069, DOI 10.1016/j.cell.2009.11.030; Liu C, 2012, CANCER RES, V72, P3393, DOI 10.1158/0008-5472.CAN-11-3864; Mani RS, 2009, SCIENCE, V326, P1230, DOI 10.1126/science.1178124; Martineza I, 2011, P NATL ACAD SCI USA, V108, P522, DOI 10.1073/pnas.1017346108; Nam S, 2005, CANCER RES, V65, P9185, DOI 10.1158/0008-5472.CAN-05-1731; Petrovics G, 2005, ONCOGENE, V24, P3847, DOI 10.1038/sj.onc.1208518; Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533; Quintavalle C, 2013, ONCOGENE, V32, P4001, DOI 10.1038/onc.2012.410; Rothschild SI, 2012, ONCOGENE, V31, P4221, DOI 10.1038/onc.2011.578; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Summy JM, 2006, CLIN CANCER RES, V12, P1398, DOI 10.1158/1078-0432.CCR-05-2692; Sun C, 2008, ONCOGENE, V27, P5348, DOI 10.1038/onc.2008.183; Tatarov O, 2009, CLIN CANCER RES, V15, P3540, DOI 10.1158/1078-0432.CCR-08-1857; Tomlins SA, 2005, SCIENCE, V310, P644, DOI 10.1126/science.1117679; Van der Auwera I, 2010, BRIT J CANCER, V103, P532, DOI 10.1038/sj.bjc.6605787; Volinia S, 2010, GENOME RES, V20, P589, DOI 10.1101/gr.098046.109; Wang JH, 2008, CANCER RES, V68, P8516, DOI 10.1158/0008-5472.CAN-08-1147; Wang JH, 2006, CANCER RES, V66, P8347, DOI 10.1158/0008-5472.CAN-06-1966; Wu Zhaoju, 2010, Genes Cancer, V1, P40, DOI 10.1177/1947601909358324; Yang JC, 2010, MOL CANCER THER, V9, P1629, DOI 10.1158/1535-7163.MCT-09-1058; Yu EY, 2009, CLIN CANCER RES, V15, P7421, DOI 10.1158/1078-0432.CCR-09-1691; Yu F, 2010, ONCOGENE, V29, P4194, DOI 10.1038/onc.2010.167; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Zhang JC, 2012, BIOCHEM BIOPH RES CO, V417, P1100, DOI 10.1016/j.bbrc.2011.12.121; Zhong XM, 2010, J BIOL CHEM, V285, P41961, DOI 10.1074/jbc.M110.169607; Zhou J, 2005, CANCER RES, V65, P9906, DOI 10.1158/0008-5472.CAN-05-1481; Zong Y, 2009, P NATL ACAD SCI USA, V106, P12465, DOI 10.1073/pnas.0905931106	52	119	127	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2014	33	19					2495	2503		10.1038/onc.2013.200	http://dx.doi.org/10.1038/onc.2013.200			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH3OK	23728339	Green Accepted			2022-12-28	WOS:000336033600009
J	Loreni, F; Mancino, M; Biffo, S				Loreni, F.; Mancino, M.; Biffo, S.			Translation factors and ribosomal proteins control tumor onset and progression: how?	ONCOGENE			English	Review						eIF6; ribosome; translation; PKC; ribosomal proteins; ribosomopathy; cancer	DIAMOND-BLACKFAN ANEMIA; IRES-MEDIATED TRANSLATION; MESSENGER-RNA TRANSLATION; BREAST-CANCER CELLS; INITIATION-FACTOR; MULTIPLE-MYELOMA; DYSKERATOSIS-CONGENITA; GENE-EXPRESSION; AMINO-ACIDS; DNA-DAMAGE	Gene expression is shaped by translational control. The modalities and the extent by which translation factors modify gene expression have revealed therapeutic scenarios. For instance, eukaryotic initiation factor ( eIF) 4E activity is controlled by the signaling cascade of growth factors, and drives tumorigenesis by favoring the translation of specific mRNAs. Highly specific drugs target the activity of eIF4E. Indeed, the antitumor action of mTOR complex 1 ( mTORc1) blockers like rapamycin relies on their capability to inhibit eIF4E assembly into functional eIF4F complexes. eIF4E biology, from its inception to recent pharmacological targeting, is proof-of-principle that translational control is druggable. The case for eIF4E is not isolated. The translational machinery is involved in the biology of cancer through many other mechanisms. First, untranslated sequences on mRNAs as well as noncoding RNAs regulate the translational efficiency of mRNAs that are central for tumor progression. Second, other initiation factors like eIF6 show a tumorigenic potential by acting downstream of oncogenic pathways. Third, genetic alterations in components of the translational apparatus underlie an entire class of inherited syndromes known as ` ribosomopathies' that are associated with increased cancer risk. Taken together, data suggest that in spite of their evolutionary conservation and ubiquitous nature, variations in the activity and levels of ribosomal proteins and translation factors generate highly specific effects. Beside, as the structures and biochemical activities of several noncoding RNAs and initiation factors are known, these factors may be amenable to rational pharmacological targeting. The future is to design highly specific drugs targeting the translational apparatus.	[Loreni, F.] Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; [Mancino, M.; Biffo, S.] Osped San Raffaele, San Raffaele Sci Inst, I-20132 Milan, Italy; [Mancino, M.; Biffo, S.] DISIT, Alessandria, Italy	University of Rome Tor Vergata	Loreni, F (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via Ric Sci, I-00133 Rome, Italy.	loreni@uniroma2.it; biffo.stefano@hsr.it	Mancino, Marilena/AAA-5481-2019	Mancino, Marilena/0000-0002-3461-0427; biffo, stefano/0000-0002-3780-1050	Fondazione Buzzi [AIRC IG 10653, PRIN 20104AE23N];  [5 x mille];  [13-0045];  [10653];  [20104AE23N]; Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom; Worldwide Cancer Research [13-0045, 09-0061] Funding Source: researchfish	Fondazione Buzzi; ; ; ; ; Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); Worldwide Cancer Research	We apologize to those whose work we were unable to cite. This work is supported by grants AIRC IG 2011, AIRC 5 x mille, AICR 13-0045 and Fondazione Buzzi to SB, AIRC IG 10653 to FL, PRIN 20104AE23N to SB and FL.	Alain T, 2012, CANCER RES, V72, P6468, DOI 10.1158/0008-5472.CAN-12-2395; Alter BP, 2009, BLOOD, V113, P6549, DOI 10.1182/blood-2008-12-192880; Amsterdam A, 2004, PLOS BIOL, V2, P690, DOI 10.1371/journal.pbio.0020139; Anderson SJ, 2007, IMMUNITY, V26, P759, DOI 10.1016/j.immuni.2007.04.012; Angelini M, 2007, HUM MOL GENET, V16, P1720, DOI 10.1093/hmg/ddm120; Badura M, 2012, P NATL ACAD SCI USA, V109, P18767, DOI 10.1073/pnas.1203853109; Baird TD, 2012, ADV NUTR, V3, P307, DOI 10.3945/an.112.002113; Balvay L, 2009, BBA-GENE REGUL MECH, V1789, P542, DOI 10.1016/j.bbagrm.2009.07.005; Barlow JL, 2010, NAT MED, V16, P59, DOI 10.1038/nm.2063; Barna M, 2008, NATURE, V456, P971, DOI 10.1038/nature07449; Basu A, 2011, MOL CELL BIOL, V31, P4482, DOI 10.1128/MCB.05804-11; Belin S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007147; Bellodi C, 2010, CANCER RES, V70, P6026, DOI 10.1158/0008-5472.CAN-09-4730; Bellodi C, 2010, EMBO J, V29, P1865, DOI 10.1038/emboj.2010.83; Ben-Shem A, 2011, SCIENCE, V334, P1524, DOI 10.1126/science.1212642; Blagden SP, 2011, NAT REV CLIN ONCOL, V8, P280, DOI 10.1038/nrclinonc.2011.16; Blau L, 2012, P NATL ACAD SCI USA, V109, pE2875, DOI 10.1073/pnas.1203659109; Boocock GRB, 2003, NAT GENET, V33, P97, DOI 10.1038/ng1062; Boria I, 2008, HUM MUTAT, V29, pE263, DOI 10.1002/humu.20864; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Brina D, 2011, CELL CYCLE, V10, P3441, DOI 10.4161/cc.10.20.17796; Browne GJ, 2004, MOL CELL BIOL, V24, P2986, DOI 10.1128/MCB.24.7.2986-2997.2004; Burroughs L, 2009, HEMATOL ONCOL CLIN N, V23, P233, DOI 10.1016/j.hoc.2009.01.007; Carrieri C, 2012, NATURE, V491, P454, DOI 10.1038/nature11508; Ceci M, 2003, NATURE, V426, P579, DOI 10.1038/nature02160; Ceci M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035034; Chapman MA, 2011, NATURE, V471, P467, DOI 10.1038/nature09837; Choesmel V, 2007, BLOOD, V109, P1275, DOI 10.1182/blood-2006-07-038372; Cobbold LC, 2010, ONCOGENE, V29, P2884, DOI 10.1038/onc.2010.31; Coldwell MJ, 2000, ONCOGENE, V19, P899, DOI 10.1038/sj.onc.1203407; CROCKER J, 1987, J CLIN PATHOL, V40, P885, DOI 10.1136/jcp.40.8.885; Da Costa L, 2010, TRANSFUS CLIN BIOL, V17, P112, DOI 10.1016/j.tracli.2010.06.001; Dabo S, 2012, VIRUSES-BASEL, V4, P2598, DOI 10.3390/v4112598; Dalton LE, 2012, PROG MOL BIOL TRANSL, V106, P189, DOI 10.1016/B978-0-12-396456-4.00003-1; Danilova N, 2008, BLOOD, V112, P5228, DOI 10.1182/blood-2008-01-132290; Daxinger L, 2012, G3-GENES GENOM GENET, V2, P1393, DOI 10.1534/g3.112.004036; De Keersmaecker K, 2013, NAT GENET, V45, P186, DOI 10.1038/ng.2508; Dephoure N, 2008, P NATL ACAD SCI USA, V105, P10762, DOI 10.1073/pnas.0805139105; Devlin JR, 2013, FEBS J, V280, P5307, DOI 10.1111/febs.12135; Di Nicolantonio F, 2010, J CLIN INVEST, V120, P2858, DOI 10.1172/JCI37539; Diggle TA, 1996, BIOCHEM J, V316, P447, DOI 10.1042/bj3160447; Dobrikov M, 2011, MOL CELL BIOL, V31, P2947, DOI 10.1128/MCB.05589-11; Doerfel LK, 2013, SCIENCE, V339, P85, DOI 10.1126/science.1229017; Donati G, 2012, CANCER RES, V72, P1602, DOI 10.1158/0008-5472.CAN-11-3992; Dong HJ, 2009, LEUKEMIA LYMPHOMA, V50, P974, DOI 10.1080/10428190902895780; Dowling RJ, 2012, SCIENCE, V328, P1172; Drexler HCA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004161; Dumstorf CA, 2010, MOL CANCER THER, V9, P3158, DOI 10.1158/1535-7163.MCT-10-0413; Ebert BL, 2008, NATURE, V451, P335, DOI 10.1038/nature06494; Ellis SR, 2008, CURR TOP DEV BIOL, V82, P217, DOI 10.1016/S0070-2153(07)00008-7; Fabian MR, 2012, NAT STRUCT MOL BIOL, V19, P586, DOI 10.1038/nsmb.2296; Fabian MR, 2010, ANNU REV BIOCHEM, V79, P351, DOI 10.1146/annurev-biochem-060308-103103; Fasolo A, 2012, CURR PHARM DESIGN, V18, P2766, DOI 10.2174/138161212800626210; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; Flygare J, 2007, BLOOD, V109, P980, DOI 10.1182/blood-2006-07-038232; Fumagalli S, 2012, GENE DEV, V26, P1028, DOI 10.1101/gad.189951.112; Fumagalli S, 2009, NAT CELL BIOL, V11, P501, DOI 10.1038/ncb1858; Furic L, 2010, P NATL ACAD SCI USA, V107, P14134, DOI 10.1073/pnas.1005320107; Gallagher JW, 2008, CANCER RES, V68, P8752, DOI 10.1158/0008-5472.CAN-08-1042; Gallinetti J, 2013, BIOCHEM J, V449, P1, DOI 10.1042/BJ20121098; Ganapathi KA, 2008, BRIT J HAEMATOL, V141, P376, DOI 10.1111/j.1365-2141.2008.07095.x; Gandin V, 2008, NATURE, V455, P684, DOI 10.1038/nature07267; Gazda HT, 2008, AM J HUM GENET, V83, P769, DOI 10.1016/j.ajhg.2008.11.004; Gibson TJ, 2012, FEBS LETT, V586, P2787, DOI 10.1016/j.febslet.2012.04.048; Gorrini C, 2005, P NATL ACAD SCI USA, V102, P9200, DOI 10.1073/pnas.0409513102; Graber TE, 2007, MOL BIOSYST, V3, P825, DOI 10.1039/b708867a; Grosso S, 2008, BIOCHEM J, V415, P77, DOI 10.1042/BJ20080463; Grosso S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029136; Gutschner T, 2012, RNA BIOL, V9, P703, DOI 10.4161/rna.20481; Heiss NS, 1998, NAT GENET, V19, P32, DOI 10.1038/ng0598-32; Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270; Holcik M, 2000, ONCOGENE, V19, P4174, DOI 10.1038/sj.onc.1203765; Horos R, 2012, BLOOD, V119, P262, DOI 10.1182/blood-2011-06-358200; Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912; Hsieh AC, 2010, CANCER CELL, V17, P249, DOI 10.1016/j.ccr.2010.01.021; Huntzinger E, 2011, NAT REV GENET, V12, P99, DOI 10.1038/nrg2936; Iadevaia V, 2010, ONCOGENE, V29, P5490, DOI 10.1038/onc.2010.279; Iborra FJ, 2001, SCIENCE, V293, P1139, DOI 10.1126/science.1061216; Idol RA, 2007, BLOOD CELL MOL DIS, V39, P35, DOI 10.1016/j.bcmd.2007.02.001; Ingolia NT, 2011, CELL, V147, P789, DOI 10.1016/j.cell.2011.10.002; Ingolia NT, 2009, SCIENCE, V324, P218, DOI 10.1126/science.1168978; Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209; Jackson RJ, 2010, NAT REV MOL CELL BIO, V11, P113, DOI 10.1038/nrm2838; Jadersten M, 2011, J CLIN ONCOL, V29, P1971, DOI 10.1200/JCO.2010.31.8576; Jannot G, 2011, EMBO REP, V12, P581, DOI 10.1038/embor.2011.66; Jopling CL, 2004, RNA, V10, P287, DOI 10.1261/rna.5138804; Kervestin S, 2012, NAT REV MOL CELL BIO, V13, P700, DOI 10.1038/nrm3454; Kirn-Safran CB, 2007, DEV DYNAM, V236, P447, DOI 10.1002/dvdy.21046; Komar AA, 2012, GENE, V502, P75, DOI 10.1016/j.gene.2012.04.039; Komar AA, 2011, CELL CYCLE, V10, P229, DOI 10.4161/cc.10.2.14472; Kondrashov N, 2011, CELL, V145, P383, DOI 10.1016/j.cell.2011.03.028; Kressler D, 2010, BBA-MOL CELL RES, V1803, P673, DOI 10.1016/j.bbamcr.2009.10.009; Lafontaine DLJ, 1998, GENE DEV, V12, P527, DOI 10.1101/gad.12.4.527; Lam YW, 2007, CURR BIOL, V17, P749, DOI 10.1016/j.cub.2007.03.064; Landry DM, 2009, GENE DEV, V23, P2753, DOI 10.1101/gad.1832209; Lewis SM, 2005, CELL DEATH DIFFER, V12, P547, DOI 10.1038/sj.cdd.4401602; Lindstrom MS, 2010, PLOS ONE, V5, pA116, DOI 10.1371/journal.pone.0009578; Liu JM, 2011, ANN NY ACAD SCI, V1242, P26, DOI 10.1111/j.1749-6632.2011.06348.x; LODISH HF, 1971, J BIOL CHEM, V246, P7131; Luft F, 2010, J MOL MED-JMM, V88, P1, DOI 10.1007/s00109-009-0570-0; MacInnes AW, 2008, P NATL ACAD SCI USA, V105, P10408, DOI 10.1073/pnas.0805036105; Magnuson B, 2012, BIOCHEM J, V441, P1, DOI 10.1042/BJ20110892; Mayer C, 2006, ONCOGENE, V25, P6384, DOI 10.1038/sj.onc.1209883; McGowan KA, 2008, NAT GENET, V40, P963, DOI 10.1038/ng.188; Miluzio A, 2011, CANCER CELL, V19, P765, DOI 10.1016/j.ccr.2011.04.018; Montanaro L, 2008, AM J PATHOL, V173, P301, DOI 10.2353/ajpath.2008.070752; Montanaro L, 2012, BBA-REV CANCER, V1825, P101, DOI 10.1016/j.bbcan.2011.10.006; Montanaro L, 2010, CANCER RES, V70, P4767, DOI 10.1158/0008-5472.CAN-09-4024; Mujtaba T, 2011, DISCOV MED, V12, P471; Nana-Sinkam SP, 2013, CLIN PHARMACOL THER, V93, P98, DOI 10.1038/clpt.2012.192; Narla A, 2010, BLOOD, V115, P3196, DOI 10.1182/blood-2009-10-178129; Obeng EA, 2006, BLOOD, V107, P4907, DOI 10.1182/blood-2005-08-3531; Oh WJ, 2010, EMBO J, V29, P3939, DOI 10.1038/emboj.2010.271; Otsuka M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024359; Panic L, 2007, CELL CYCLE, V6, P20, DOI 10.4161/cc.6.1.3666; Parsyan A, 2011, NAT REV MOL CELL BIO, V12, P235, DOI 10.1038/nrm3083; Payne EM, 2012, BLOOD, V120, P2214, DOI 10.1182/blood-2011-10-382986; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; Pestov DG, 2001, MOL CELL BIOL, V21, P4246, DOI 10.1128/MCB.21.13.4246-4255.2001; Petroulakis E, 2006, BRIT J CANCER, V94, P195, DOI 10.1038/sj.bjc.6602902; Petrov A, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011551; Pichon X, 2012, CURR PROTEIN PEPT SC, V13, P294, DOI 10.2174/138920312801619475; Podar K, 2011, CURR CANCER DRUG TAR, V11, P1005, DOI 10.2174/156800911798073113; Pradet-Balade B, 2001, TRENDS BIOCHEM SCI, V26, P225, DOI 10.1016/S0968-0004(00)01776-X; Proud CG, 2005, SEMIN CELL DEV BIOL, V16, P3, DOI 10.1016/j.semcdb.2004.11.004; Proud CG, 2006, BIOCHEM SOC T, V34, P213, DOI 10.1042/BST0340213; Proud CG, 2007, BIOCHEM J, V403, P217, DOI 10.1042/BJ20070024; Ramirez-Fort MK, 2014, AM J CLIN ONCOL-CANC, V37, P266, DOI 10.1097/COC.0b013e318277d62f; Raught B, 2004, EMBO J, V23, P1761, DOI 10.1038/sj.emboj.7600193; Ridanpaa M, 2001, CELL, V104, P195, DOI 10.1016/S0092-8674(01)00205-7; Robledo S, 2008, RNA, V14, P1918, DOI 10.1261/rna.1132008; RON D, 1995, J BIOL CHEM, V270, P24180, DOI 10.1074/jbc.270.41.24180; Ruan YY, 2012, J CLIN INVEST, V122, P2554, DOI 10.1172/JCI58488; Rubbi CP, 2003, EMBO J, V22, P6068, DOI 10.1093/emboj/cdg579; Ruggero D, 2003, SCIENCE, V299, P259, DOI 10.1126/science.1079447; Ruggero D., 2012, COLD SPRING HARB PER, V5; Ruggero D, 2009, CANCER RES, V69, P8839, DOI 10.1158/0008-5472.CAN-09-1970; Saini P, 2009, NATURE, V459, P118, DOI 10.1038/nature08034; Sanvito F, 1999, J CELL BIOL, V144, P823, DOI 10.1083/jcb.144.5.823; Sanvito F, 2000, CANCER RES, V60, P510; Schewe DM, 2009, CANCER RES, V69, P1545, DOI 10.1158/0008-5472.CAN-08-3858; Schoenberg DR, 2012, NAT REV GENET, V13, P246, DOI 10.1038/nrg3160; Schwanhausser B, 2011, NATURE, V473, P337, DOI 10.1038/nature10098; Scuoppo C, 2012, NATURE, V487, P244, DOI 10.1038/nature11126; Sharma G, 2013, J STRUCT BIOL, V181, P190, DOI 10.1016/j.jsb.2012.11.006; Shaw RJ, 2006, NATURE, V441, P424, DOI 10.1038/nature04869; Si K, 1999, MOL CELL BIOL, V19, P1416; Silvera D, 2010, NAT REV CANCER, V10, P254, DOI 10.1038/nrc2824; Silvera D, 2009, CELL CYCLE, V8, P3091, DOI 10.4161/cc.8.19.9637; Silvera D, 2009, NAT CELL BIOL, V11, P903, DOI 10.1038/ncb1900; Sonenberg N, 2009, CELL, V136, P731, DOI 10.1016/j.cell.2009.01.042; Spizzo R, 2012, ONCOGENE, V31, P4577, DOI 10.1038/onc.2011.621; Spriggs KA, 2008, BIOL CELL, V100, P27, DOI 10.1042/BC20070098; Stumpf CR, 2011, CURR OPIN GENET DEV, V21, P474, DOI 10.1016/j.gde.2011.03.007; Suh DH, 2012, ANN NY ACAD SCI, V1271, P20, DOI 10.1111/j.1749-6632.2012.06739.x; Tabas I, 2011, NAT CELL BIOL, V13, P184, DOI 10.1038/ncb0311-184; Taskinen M, 2008, AM J MED GENET A, V146A, P2370, DOI 10.1002/ajmg.a.32478; Torihara H, 2011, BRIT J HAEMATOL, V152, P648, DOI 10.1111/j.1365-2141.2010.08535.x; Ueda T, 2004, MOL CELL BIOL, V24, P6539, DOI 10.1128/MCB.24.15.6539-6549.2004; Valdez BC, 2004, P NATL ACAD SCI USA, V101, P10709, DOI 10.1073/pnas.0402492101; van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819; Vlachos A, 2012, BLOOD, V119, P3815, DOI 10.1182/blood-2011-08-375972; Volta V, 2013, CELL MOL LIFE SCI, V70, P1439, DOI 10.1007/s00018-012-1215-y; WALDEN WE, 1986, BIOCHEMISTRY-US, V25, P2033, DOI 10.1021/bi00356a030; WALDEN WE, 1981, J BIOL CHEM, V256, P1739; Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038; Wang D, 2011, MOL CELL BIOL, V31, P3670, DOI 10.1128/MCB.05704-11; Wang XM, 2005, MOL CELL BIOL, V25, P2558, DOI 10.1128/MCB.25.7.2558-2572.2005; Wang XM, 2008, MOL CELL BIOL, V28, P1429, DOI 10.1128/MCB.01512-07; Wen F, 2011, PLOS ONE, V7; Wendel HG, 2007, GENE DEV, V21, P3232, DOI 10.1101/gad.1604407; Willimott S, 2010, BIOCHEM SOC T, V38, P1571, DOI 10.1042/BST0381571; Wong CC, 2011, BLOOD, V118, P4305, DOI 10.1182/blood-2011-06-353938; Wu XY, 2013, NUCLEIC ACIDS RES, V41, P2644, DOI 10.1093/nar/gks1453; Xu M, 2012, CELL MOL LIFE SCI, V69, P3601, DOI 10.1007/s00018-012-1129-8; Yoon A, 2006, SCIENCE, V312, P902, DOI 10.1126/science.1123835; Zhang LL, 2008, J BIOL CHEM, V283, P24047, DOI 10.1074/jbc.M800956200; Zinzalla V, 2011, CELL, V144, P757, DOI 10.1016/j.cell.2011.02.014; Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025	179	62	63	0	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2014	33	17					2145	2156		10.1038/onc.2013.153	http://dx.doi.org/10.1038/onc.2013.153			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF8WJ	23644661	Green Published			2022-12-28	WOS:000334996000001
J	Sato, T; Tran, TH; Peck, AR; Girondo, MA; Liu, C; Goodman, CR; Neilson, LM; Freydin, B; Chervoneva, I; Hyslop, T; Kovatich, AJ; Hooke, JA; Shriver, CD; Fuchs, SY; Rui, H				Sato, T.; Tran, T. H.; Peck, A. R.; Girondo, M. A.; Liu, C.; Goodman, C. R.; Neilson, L. M.; Freydin, B.; Chervoneva, I.; Hyslop, T.; Kovatich, A. J.; Hooke, J. A.; Shriver, C. D.; Fuchs, S. Y.; Rui, H.			Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression	ONCOGENE			English	Article						breast cancer; CK5; BCL6; prolactin; progesterone; Stat5	SIGNAL TRANSDUCER; STEM-CELLS; TRANSCRIPTION FACTOR; GENE-REGULATION; IN-VITRO; STAT5; ACTIVATOR; HORMONE; RECEPTORS; PHOSPHORYLATION	Prolactin controls the development and function of milk-producing breast epithelia but also supports growth and differentiation of breast cancer, especially luminal subtypes. A principal signaling mediator of prolactin, Stat5, promotes cellular differentiation of breast cancer cells in vitro, and loss of active Stat5 in tumors is associated with antiestrogen therapy failure in patients. In luminal breast cancer, progesterone induces a cytokeratin-5 (CK5)-positive basal cell-like population. This population possesses characteristics of tumor stem cells including quiescence, therapy resistance and tumor-initiating capacity. Here we report that prolactin counteracts induction of the CK5-positive population by the synthetic progestin (Pg) R5020 in luminal breast cancer cells both in vitro and in vivo. CK5-positive cells were chemoresistant as determined by fourfold reduced rate of apoptosis following docetaxel exposure. Pg-induction of CK5 was preceded by marked upregulation of BCL6, an oncogene and transcriptional repressor critical for the maintenance of leukemia-initiating cells. Knockdown of BCL6 prevented induction of CK5-positive cell population by Pg. Prolactin suppressed Pg-induced BCL6 through Jak2-Stat5 but not Erk-or Akt-dependent pathways. In premenopausal but not postmenopausal patients with hormone receptor-positive breast cancer, tumor protein levels of CK5 correlated positively with BCL6, and high BCL6 or CK5-protein levels were associated with unfavorable clinical outcome. Suppression of Pg-induction of CK5positive cells represents a novel prodifferentiation effect of prolactin in breast cancer. The present progress may have direct implications for breast cancer progression and therapy as loss of prolactin receptor-Stat5 signaling occurs frequently and BCL6 inhibitors currently being evaluated for lymphomas may have value for breast cancer.	[Sato, T.; Tran, T. H.; Peck, A. R.; Girondo, M. A.; Liu, C.; Goodman, C. R.; Neilson, L. M.; Rui, H.] Thomas Jefferson Univ, Dept Canc Biol, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; [Freydin, B.; Chervoneva, I.; Hyslop, T.] Thomas Jefferson Univ, Div Biostat, Philadelphia, PA 19107 USA; [Kovatich, A. J.] MDR Global Syst LLC, Windber, PA USA; [Hooke, J. A.; Shriver, C. D.] Walter Reed Natl Mil Med Ctr, Bethesda, MD USA; [Fuchs, S. Y.] Univ Penn, Sch Vet Med, Dept Anim Biol, Philadelphia, PA 19104 USA; [Fuchs, S. Y.] Univ Penn, Sch Vet Med, Mari Lowe Ctr Comparat Oncol, Philadelphia, PA 19104 USA	Jefferson University; Jefferson University; Walter Reed National Military Medical Center; University of Pennsylvania; University of Pennsylvania	Rui, H (corresponding author), Thomas Jefferson Univ, Dept Canc Biol, 233S 10th St,BLSB 330, Philadelphia, PA 19107 USA.	hallgeir.rui@jefferson.edu		Goodman, Chelain/0000-0001-9083-3652; Kovatich, Albert/0000-0002-5169-4087	Komen for the Cure Promise Grant [KG091116]; NIH [CA101841, CA118740, CA092900]; NCI [1P30CA56036]; Commonwealth University Research Enhancement Program; Pennsylvania Department of Health; NATIONAL CANCER INSTITUTE [R01CA101841, R01CA092900, R01CA142425, P30CA056036, R01CA118740] Funding Source: NIH RePORTER	Komen for the Cure Promise Grant; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Commonwealth University Research Enhancement Program; Pennsylvania Department of Health; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by Komen for the Cure Promise Grant KG091116 (HR, TH, JAH, AJK, CDS, TS, ARP, MAG, CL, BF, and IC), NIH grants CA101841 (HR), CA118740 (HR), CA092900 (SYF) and NCI Support Grant 1P30CA56036 to the Kimmel Cancer Center. The Project is funded, in part, under a Commonwealth University Research Enhancement Program grant with the Pennsylvania Department of Health (HR). The Department specifically disclaims responsibility for any analyses, interpretations or conclusions. The views expressed in this article are those of the authors and do not reflect the official policy of the Department of the Army, Department of Defense or US Government.	Aldaz CM, 1996, CARCINOGENESIS, V17, P2069, DOI 10.1093/carcin/17.9.2069; Asselin-Labat ML, 2010, NATURE, V465, P798, DOI 10.1038/nature09027; Banks E, 2003, LANCET, V362, P419, DOI 10.1016/S0140-6736(03)14065-2; Cattoretti G, 2005, CANCER CELL, V7, P445, DOI 10.1016/j.ccr.2005.03.037; Cerchietti LC, 2010, CANCER CELL, V17, P400, DOI 10.1016/j.ccr.2009.12.050; Cerchietti LC, 2009, BLOOD, V113, P3397, DOI 10.1182/blood-2008-07-168773; Cotarla I, 2004, INT J CANCER, V108, P665, DOI 10.1002/ijc.11619; Dagvadorj A, 2008, CLIN CANCER RES, V14, P1317, DOI 10.1158/1078-0432.CCR-07-2024; Daniel AR, 2009, P NATL ACAD SCI USA, V106, P14287, DOI 10.1073/pnas.0905118106; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Duy C, 2011, NATURE, V473, P384, DOI 10.1038/nature09883; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Haughian JM, 2012, P NATL ACAD SCI USA, V109, P2742, DOI 10.1073/pnas.1106509108; Horwitz KB, 2008, J CLIN ENDOCR METAB, V93, P3295, DOI 10.1210/jc.2008-0938; Horwitzt KB, 2008, P NATL ACAD SCI USA, V105, P5774, DOI 10.1073/pnas.0706216105; Hurtz C, 2011, J EXP MED, V208, P2163, DOI 10.1084/jem.20110304; Jacobsen BM, 2005, MOL ENDOCRINOL, V19, P574, DOI 10.1210/me.2004-0287; Johnson KJ, 2010, AM J PATHOL, V177, P2971, DOI 10.2353/ajpath.2010.090399; Joshi PA, 2010, NATURE, V465, P803, DOI 10.1038/nature09091; Kabos P, 2011, BREAST CANCER RES TR, V128, P45, DOI 10.1007/s10549-010-1078-6; Keen JC, 2003, CANCER-AM CANCER SOC, V97, P825, DOI 10.1002/cncr.11126; Knutson TP, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3211; Lee HJ, 2012, MOL CELL ENDOCRINOL, V357, P101, DOI 10.1016/j.mce.2011.09.020; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Lim E, 2012, ONCOLOGY-NY, V26, P688; Liu R, 2011, MOL ENDOCRINOL, V25, P1137, DOI 10.1210/me.2010-0497; LIU XW, 1995, P NATL ACAD SCI USA, V92, P8831, DOI 10.1073/pnas.92.19.8831; Logarajah S, 2003, ONCOGENE, V22, P5572, DOI 10.1038/sj.onc.1206689; Neilson LM, 2007, MOL ENDOCRINOL, V21, P2218, DOI 10.1210/me.2007-0173; Nevalainen MT, 2004, J CLIN ONCOL, V22, P2053, DOI 10.1200/JCO.2004.11.046; Nouhi Z, 2006, CANCER RES, V66, P1824, DOI 10.1158/0008-5472.CAN-05-2292; Peck AR, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3328; Peck AR, 2011, J CLIN ONCOL, V29, P2448, DOI 10.1200/JCO.2010.30.3552; Pierson-Mullany LK, 2004, MOL CELL BIOL, V24, P10542, DOI 10.1128/MCB.24.24.10542-10557.2004; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Richer JK, 2002, J BIOL CHEM, V277, P5209, DOI 10.1074/jbc.M110090200; Rossouw JE, 2002, JAMA-J AM MED ASSOC, V288, P321, DOI 10.1001/jama.288.3.321; Sartorius CA, 2005, CANCER RES, V65, P9779, DOI 10.1158/0008-5472.CAN-05-0505; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Sultan AS, 2008, CANCER SCI, V99, P272, DOI 10.1111/j.1349-7006.2007.00685.x; Sultan AS, 2005, ONCOGENE, V24, P746, DOI 10.1038/sj.onc.1208203; Tran TH, 2010, CANCER RES, V70, P1711, DOI 10.1158/0008-5472.CAN-09-2314; Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029; Tunyaplin C, 2004, J IMMUNOL, V173, P1158, DOI 10.4049/jimmunol.173.2.1158; Walker SR, 2009, MOL CANCER RES, V7, P966, DOI 10.1158/1541-7786.MCR-08-0238; Yamashita H, 2006, ENDOCR-RELAT CANCER, V13, P885, DOI 10.1677/erc.1.01095	47	34	36	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2014	33	17					2215	2224		10.1038/onc.2013.172	http://dx.doi.org/10.1038/onc.2013.172			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF8WJ	23708665	Green Accepted			2022-12-28	WOS:000334996000007
J	Vanoirbeek, E; Eelen, G; Verlinden, L; Carmeliet, G; Mathieu, C; Bouillon, R; O'Connor, R; Xiao, G; Verstuyf, A				Vanoirbeek, E.; Eelen, G.; Verlinden, L.; Carmeliet, G.; Mathieu, C.; Bouillon, R.; O'Connor, R.; Xiao, G.; Verstuyf, A.			PDLIM2 expression is driven by vitamin D and is involved in the pro-adhesion, and anti-migration and -invasion activity of vitamin D	ONCOGENE			English	Article						PDLIM2; breast cancer; vitamin D; metastasis; DNA methylation	DOMAIN-CONTAINING PROTEIN-2; CANCER; CELLS; GENES; DNA; 1-ALPHA,25-DIHYDROXYVITAMIN-D-3; IDENTIFICATION; INHIBITION; REPRESSION; MECHANISM	1Alpha, 25-dihydroxyvitamin D-3[1,25(OH)(2)D-3], the biologically active form of vitamin D-3, is a pleiotropic hormone that exerts its effects on a wide range of tissues, resulting in different biological responses such as anticancer activity. It is the ligand of the vitamin D receptor (VDR), a nuclear receptor with transactivating capacity. We demonstrated in this study that 1,25(OH)(2)D-3 induces PDZ-LIM domain-containing protein 2 (PDLIM2) expression. PDLIM2 is an adaptor molecule that links different components of the cytoskeleton, and was recently shown to be repressed in human breast cancer cells by hypermethylation of regulatory promoter regions, leading to enhanced tumorigenicity. We demonstrated that PDLIM2 was a direct target gene of 1,25(OH)(2)D-3; its upregulation was VDR-dependent and a functional VDRE in the promoter was identified. Moreover, 1,25(OH)(2)D-3 induced demethylation of the PDLIM2 promoter, leading to enhanced transcription. Finally, PDLIM2 was found to be crucial for 1,25(OH)(2)D-3-induced cell adhesion and for mediating the ability of 1,25(OH)(2)D-3 to suppress cancer cell migration and invasion. This study provides mechanistic insights into the anticancer activities of 1,25(OH)(2)D-3 in human breast cancer cells.	[Vanoirbeek, E.; Eelen, G.; Verlinden, L.; Carmeliet, G.; Mathieu, C.; Bouillon, R.; Verstuyf, A.] Katholieke Univ Leuven, Lab Clin & Expt Endocrinol, Leuven, Belgium; [Eelen, G.] Katholieke Univ Leuven, VIB, Vesalius Res Ctr, Lab Angiogenesis & Neurovasc Link, Leuven, Belgium; [O'Connor, R.] Univ Coll, Dept Biochem, Cork, Ireland; [Xiao, G.] Univ Pittsburgh, Hillman Canc Ctr Res Pavil, Pittsburgh, PA USA	KU Leuven; Flanders Institute for Biotechnology (VIB); KU Leuven; University College Cork; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Verstuyf, A (corresponding author), Afdeling Expt Geneeskunde Endocrinol, UZ Herestr 49,Bus 902,O&NI, B-3000 Louvain, Belgium.	mieke.verstuyf@med.kuleuven.be	O'Connor, Rosemary/B-7902-2014; mathieu, chantal/ABD-5505-2021	O'Connor, Rosemary/0000-0002-0687-3422; mathieu, chantal/0000-0002-4055-5233; Verlinden, Lieve/0000-0002-9621-3662; Verstuyf, Annemieke/0000-0003-3193-2698	University of Leuven [GOA/04/10]; Flanders Research Foundation (FWO) [G.0587.09, G.0859.11]; Stichting tegen Kanker [212-2008]	University of Leuven(KU Leuven); Flanders Research Foundation (FWO)(FWO); Stichting tegen Kanker	We thank Ine Beullens, Mark Van Camp, Suzanne Marcelis and Biauw Keng Tan for excellent technical assistance. This work was supported by grants from the University of Leuven (GOA/04/10), Flanders Research Foundation (FWO G.0587.09 and G.0859.11) and Stichting tegen Kanker (212-2008).	Buss F, 2002, TRAFFIC, V3, P851, DOI 10.1034/j.1600-0854.2002.31201.x; CHEN KS, 1995, BBA-GENE STRUCT EXPR, V1263, P1, DOI 10.1016/0167-4781(95)00060-T; Cheng XD, 2010, BIOCHEMISTRY-US, V49, P2999, DOI 10.1021/bi100213t; Dalmay T, 2006, ONCOGENE, V25, P6170, DOI 10.1038/sj.onc.1209911; Deeb KK, 2007, NAT REV CANCER, V7, P684, DOI 10.1038/nrc2196; Doig CL, 2013, CARCINOGENESIS, V34, P248, DOI 10.1093/carcin/bgs331; Dusso AS, 2005, AM J PHYSIOL-RENAL, V289, pF8, DOI 10.1152/ajprenal.00336.2004; Eelen G, 2007, CURR MED CHEM, V14, P1893; Eelen G, 2004, J BONE MINER RES, V19, P133, DOI 10.1359/JBMR.0301204; Estecio MRH, 2011, FEBS LETT, V585, P2078, DOI 10.1016/j.febslet.2010.12.001; Healy NC, 2009, J LEUKOCYTE BIOL, V85, P481, DOI 10.1189/jlb.0408238; Hsu JW, 2011, AM J PATHOL, V178, P872, DOI 10.1016/j.ajpath.2010.10.036; Ishteiwy RA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052106; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Liu W, 2011, LAB INVEST, V91, P147, DOI 10.1038/labinvest.2010.144; Lopes N, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-483; Lopez-Serra L, 2006, CANCER RES, V66, P8342, DOI 10.1158/0008-5472.CAN-06-1932; Loughran G, 2005, MOL BIOL CELL, V16, P1811, DOI 10.1091/mbc.E04-12-1052; Luo W, 2010, CANCER RES, V70, P5953, DOI 10.1158/0008-5472.CAN-10-0617; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Pereira F, 2012, CELL CYCLE, V11, P1081, DOI 10.4161/cc.11.6.19508; Qu ZX, 2010, CANCER RES, V70, P1766, DOI 10.1158/0008-5472.CAN-09-3263; Qu ZX, 2010, J BIOL CHEM, V285, P11786, DOI 10.1074/jbc.M109.086561; Raemaekers T, 2003, J CELL BIOL, V162, P1017, DOI 10.1083/jcb.200302129; Shah AK, 1999, BIOL CELL, V91, P131, DOI 10.1016/S0248-4900(99)80037-9; Torrado M, 2004, INVEST OPHTH VIS SCI, V45, P3955, DOI 10.1167/iovs.04-0721; Vanoirbeek E, 2009, ANTICANCER RES, V29, P3585; Verlinden L, 2005, J BIOL CHEM, V280, P37319, DOI 10.1074/jbc.M503587200; Verlinden L, 1998, MOL CELL ENDOCRINOL, V142, P57, DOI 10.1016/S0303-7207(98)00117-8; Verlinden L, 2007, CANCER RES, V67, P6574, DOI 10.1158/0008-5472.CAN-06-3545; Verstuyf A, 1998, J BONE MINER RES, V13, P549, DOI 10.1359/jbmr.1998.13.4.549; Wang TT, 2005, MOL ENDOCRINOL, V19, P2685, DOI 10.1210/me.2005-0106; Wang WD, 2011, J INEQUAL APPL, DOI 10.1186/1029-242X-2011-6; Wang XN, 2009, CELL CYCLE, V8, P736, DOI 10.4161/cc.8.5.7870; Wei QZ, 2000, MOL BIOL CELL, V11, P3617, DOI 10.1091/mbc.11.10.3617; Zijlstra A, 2008, CANCER CELL, V13, P221, DOI 10.1016/j.ccr.2008.01.031	36	36	37	0	8	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2014	33	15					1904	1911		10.1038/onc.2013.123	http://dx.doi.org/10.1038/onc.2013.123			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RK	23584482				2022-12-28	WOS:000334346300003
J	Tripathi, P; Wang, Y; Coussens, M; Manda, KR; Casey, AM; Lin, C; Poyo, E; Pfeifer, JD; Basappa, N; Bates, CM; Ma, L; Zhang, H; Pan, M; Ding, L; Chen, F				Tripathi, P.; Wang, Y.; Coussens, M.; Manda, K. R.; Casey, A. M.; Lin, C.; Poyo, E.; Pfeifer, J. D.; Basappa, N.; Bates, C. M.; Ma, L.; Zhang, H.; Pan, M.; Ding, L.; Chen, F.			Activation of NFAT signaling establishes a tumorigenic microenvironment through cell autonomous and non-cell autonomous mechanisms	ONCOGENE			English	Article						NFAT; tumorigenesis; tumor; microenvironment	TRANSCRIPTION FACTOR; CALCINEURIN; EXPRESSION; CANCER; MICE; CA2+/CALCINEURIN; PROLIFERATION; CALCIUM; GENE	NFAT (the nuclear factor of activated T cells) upregulation has been linked to cellular transformation intrinsically, but it is unclear whether and how tissue cells with NFAT activation change the local environment for tumor initiation and progression. Direct evidence showing NFAT activation initiates primary tumor formation in vivo is also lacking. Using inducible transgenic mouse systems, we show that tumors form in a subset of, but not all, tissues with NFATc1 activation, indicating that NFAT oncogenic effects depend on cell types and tissue contexts. In NFATc1-induced skin and ovarian tumors, both cells with NFATc1 activation and neighboring cells without NFATc1 activation have significant upregulation of c-Myc and activation of Stat3. Besides known and suspected NFATc1 targets, such as Spp1 and Osm, we have revealed the early upregulation of a number of cytokines and cytokine receptors, as key molecular components of an inflammatory microenvironment that promotes both NFATc1(+) and NFATc1(-) cells to participate in tumor formation. Cultured cells derived from NFATc1-induced tumors were able to establish a tumorigenic microenvironment, similar to that of the primary tumors, in an NFATc1-dependent manner in nude mice with T-cell deficiency, revealing an addiction of these tumors to NFATc1 activation and downplaying a role for T cells in the NFATc1-induced tumorigenic microenvironment. These findings collectively suggest that beyond the cell autonomous effects on the upregulation of oncogenic proteins, NFATc1 activation has non-cell autonomous effects through the establishment of a promitogenic microenvironment for tumor growth. This study provides direct evidence for the ability of NFATc1 in inducing primary tumor formation in vivo and supports targeting NFAT signaling in anti-tumor therapy.	[Tripathi, P.; Wang, Y.; Coussens, M.; Manda, K. R.; Casey, A. M.; Lin, C.; Ma, L.; Chen, F.] Washington Univ, Sch Med, Dept Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; [Poyo, E.] Washington Univ, Sch Med, Dept Engn, St Louis, MO 63110 USA; [Pfeifer, J. D.] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; [Basappa, N.] Univ Maryland, Dept Biol, Baltimore, MD 21201 USA; [Bates, C. M.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA; [Zhang, H.] Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; [Pan, M.] Kaiser Permanente Med Ctr, Div Oncol, Santa Clara, CA USA; [Ding, L.] Washington Univ, Sch Med, Genome Inst, Dept Med, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University System of Maryland; University of Maryland Baltimore; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Massachusetts System; University of Massachusetts Worcester; Kaiser Permanente; Washington University (WUSTL)	Chen, F (corresponding author), Washington Univ, Sch Med, Dept Cell Biol & Physiol, Campus Box 8126, St Louis, MO 63110 USA.	fchen@dom.wustl.edu	Pan, Minggui/AAB-7371-2020		Department of Medicine at Washington University School of Medicine; NIH [DK81592, DK67386]; George M. O'Brien Center for Kidney Disease Research at Washington University [George M. O'Brien Center for Kidney Disease Research at Washington University (P30DK079333]; Genome Technology Access Center [P30 CA91842, UL1RR024992]; NATIONAL CANCER INSTITUTE [P30CA091842] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [UL1RR024992] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK081592, P30DK079333, R01DK067386, R01DK087960] Funding Source: NIH RePORTER	Department of Medicine at Washington University School of Medicine; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); George M. O'Brien Center for Kidney Disease Research at Washington University; Genome Technology Access Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr Crabtree for providing the TetO-NFATc1<SUP>Nuc</SUP> mice and Dr Yuan Zhu for helpful discussion of the study. FC is supported in part by institutional funds from the Department of Medicine at Washington University School of Medicine and NIH grants (DK81592 and DK67386). We also thank the George M. O'Brien Center for Kidney Disease Research at Washington University (P30DK079333) for core services. We thank Michael Heinz from the Genome Technology Access Center (P30 CA91842, UL1RR024992) in the Department of Genetics at Washington University School of Medicine for help with gene expression analysis.	ANDERSON B, 1987, GYNECOL ONCOL, V26, P183, DOI 10.1016/0090-8258(87)90272-1; Barriere C, 2007, MOL ONCOL, V1, P72, DOI 10.1016/j.molonc.2007.03.001; Belteki G, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni051; Buchholz M, 2006, EMBO J, V25, P3714, DOI 10.1038/sj.emboj.7601246; Chang CP, 2004, J CLIN INVEST, V113, P1051, DOI 10.1172/JCI200420049; Graef IA, 2001, CURR OPIN GENET DEV, V11, P505, DOI 10.1016/S0959-437X(00)00225-2; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; Guo QS, 2011, J UROLOGY, V185, P2320, DOI 10.1016/j.juro.2011.02.044; Horsley V, 2008, CELL, V132, P299, DOI 10.1016/j.cell.2007.11.047; JANIK P, 1975, CANCER RES, V35, P3698; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Lesina M, 2011, CANCER CELL, V19, P456, DOI 10.1016/j.ccr.2011.03.009; Li SZ, 2007, AM J PHYSIOL-CELL PH, V292, pC1606, DOI 10.1152/ajpcell.00588.2005; Li W, 2009, P NATL ACAD SCI USA, V106, P486, DOI 10.1073/pnas.0804177106; Lin CX, 2009, GENESIS, V47, P352, DOI 10.1002/dvg.20506; Marafiot T, 2005, BRIT J HAEMATOL, V128, P333, DOI 10.1111/j.1365-2141.2004.05313.x; McCormick F, 2011, J SURG ONCOL, V103, P464, DOI 10.1002/jso.21749; McDill BW, 2006, P NATL ACAD SCI USA, V103, P6952, DOI 10.1073/pnas.0602087103; Medyouf H, 2007, NAT MED, V13, P736, DOI 10.1038/nm1588; Muller MR, 2010, NAT REV IMMUNOL, V10, P645, DOI 10.1038/nri2818; Neal JW, 2003, J BIOL CHEM, V278, P17246, DOI 10.1074/jbc.M300528200; Pan MG, CURR MOL ME IN PRESS; Pan MG, 2007, J IMMUNOL, V178, P4315, DOI 10.4049/jimmunol.178.7.4315; Pham LV, 2005, BLOOD, V106, P3940, DOI 10.1182/blood-2005-03-1167; Rao A, 2009, NAT IMMUNOL, V10, P3, DOI 10.1038/ni0109-3; Sansone P, 2011, CURR OPIN GENET DEV, V21, P80, DOI 10.1016/j.gde.2010.11.001; Torti D, 2011, EMBO MOL MED, V3, P623, DOI 10.1002/emmm.201100176; Wang YQ, 2010, J AM SOC NEPHROL, V21, P1657, DOI 10.1681/ASN.2009121253; Wong SY, 2011, P NATL ACAD SCI USA, V108, P4093, DOI 10.1073/pnas.1013098108; Wu H, 2007, TRENDS CELL BIOL, V17, P251, DOI 10.1016/j.tcb.2007.04.006; Yasaka Nami, 1995, Journal of Dermatology (Tokyo), V22, P88; Zhao HT, 2004, DEV BIOL, V276, P403, DOI 10.1016/j.ydbio.2004.09.002	32	24	24	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2014	33	14					1840	1849		10.1038/onc.2013.132	http://dx.doi.org/10.1038/onc.2013.132			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RE	23624921	Green Accepted			2022-12-28	WOS:000334345500010
J	Park, J; Schwarzbauer, JE				Park, J.; Schwarzbauer, J. E.			Mammary epithelial cell interactions with fibronectin stimulate epithelial-mesenchymal transition	ONCOGENE			English	Article						fibronectin; EMT; MCF-10A cells; breast cancer; TGF beta	HUMAN BREAST-CANCER; EXTRACELLULAR-MATRIX COMPONENTS; FOCAL ADHESION KINASE; TGF-BETA; BASEMENT-MEMBRANE; GLAND DEVELOPMENT; UP-REGULATION; E-CADHERIN; EXPRESSION; BINDING	In the mammary gland, the stromal extracellular matrix (ECM) undergoes dramatic changes during development and in tumorigenesis. For example, normal adult breast tissue is largely devoid of the ECM protein fibronectin (FN) whereas high FN levels have been detected in the stroma of breast tumors. FN is an established marker for epithelial-mesenchymal transition (EMT), which occurs during development and has been linked to cancer. During EMT, epithelial cell adhesion switches from cell-cell contacts to mainly cell-ECM interactions, raising the possibility that FN may have a role in promoting this transition. Using MCF-10A mammary epithelial cells, we show that exposure to exogenous FN induces an EMT response including upregulation of the EMT markers FN, Snail, N-cadherin, vimentin, the matrix metalloprotease MMP2, alpha-smooth muscle actin and phospho-Smad2, as well as acquisition of cell migratory behavior. FN-induced EMT depends on Src kinase and extracellular signal-regulated kinase/mitogen-activated protein (ERK/MAP) kinase signaling but not on the immediate early gene EGR-1. FN initiates EMT under serum-free conditions; this response is partially reversed by a transforming growth factor (TGF)beta-neutralizing antibody, suggesting that FN enhances the effect of endogenous TGF beta. EMT marker expression is upregulated in cells on a fragment of FN containing the integrin-binding domain but not other domains. Differences in gene expression between FN and Matrigel are maintained with addition of a subthreshold level of TGF beta 1. Together, these results show that cells interacting with FN are primed to respond to TGF beta. The ability of FN to induce EMT shows an active role for the stromal ECM in this process and supports the notion that the increased levels of FN observed in breast tumors facilitate tumorigenesis.	[Park, J.; Schwarzbauer, J. E.] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Schwarzbauer, JE (corresponding author), Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA.	jschwarz@princeton.edu		Schwarzbauer, Jean/0000-0003-1012-7593	NIH [R01 GM059383, R01 CA160611]; Ruth L Kirschstein National Research Service Award [T32 CA 009528]; NATIONAL CANCER INSTITUTE [R01CA160611, T32CA009528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007388, R01GM059383] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Ruth L Kirschstein National Research Service Award(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank Jina Hong for assistance with some experiments. We thank Dr Keith Johnson (University of Nebraska Medical Center) for generously providing N-cadherin antibody. This work was supported by grants from the NIH (R01 GM059383 and R01 CA160611 to JES). JP received support from a Ruth L Kirschstein National Research Service Award (T32 CA 009528).	BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; CHRISTENSEN L, 1992, APMIS, V100, P1; Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Duband JL, 2009, DEV GROWTH DIFFER, V51, P25, DOI 10.1111/j.1440-169X.2009.01076.x; ENGVALL E, 1977, INT J CANCER, V20, P1, DOI 10.1002/ijc.2910200102; Neira RE, 2012, INT J BIOCHEM CELL B, V44, P2194, DOI 10.1016/j.biocel.2012.08.018; Gaggioli C, 2005, ONCOGENE, V24, P1423, DOI 10.1038/sj.onc.1208318; Geiger B, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a005033; Ghajar CM, 2008, HISTOCHEM CELL BIOL, V130, P1105, DOI 10.1007/s00418-008-0537-1; Giancotti FG, 2003, ANNU REV CELL DEV BI, V19, P173, DOI 10.1146/annurev.cellbio.19.031103.133334; Goyal A, 2008, WORLD J SURG ONCOL, V6, DOI 10.1186/1477-7819-6-56; Grotegut S, 2006, EMBO J, V25, P3534, DOI 10.1038/sj.emboj.7601213; Helleman J, 2008, CLIN CANCER RES, V14, P5555, DOI 10.1158/1078-0432.CCR-08-0555; Ioachim E, 2002, EUR J CANCER, V38, P2362, DOI 10.1016/S0959-8049(02)00210-1; Kadar A, 2002, SEMIN CANCER BIOL, V12, P243, DOI 10.1016/S1044-579X(02)00027-5; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kalluri R, 2009, J CLIN INVEST, V119, P1417, DOI 10.1172/JCI39675; Kasai H, 2005, RESP RES, V6, DOI 10.1186/1465-9921-6-56; Kaufmann K, 2001, BIOL CHEM, V382, P1077, DOI 10.1515/BC.2001.135; Kim ES, 2004, INT J ONCOL, V25, P1375; Klinowska TCM, 1999, DEV BIOL, V215, P13, DOI 10.1006/dbio.1999.9435; Komiya E, 2012, CANCER SCI, V103, P691, DOI 10.1111/j.1349-7006.2012.02203.x; KOUKOULIS GK, 1993, J SUBMICR CYTOL PATH, V25, P285; Lee JM, 2006, J CELL BIOL, V172, P973, DOI 10.1083/jcb.200601018; LI ML, 1987, P NATL ACAD SCI USA, V84, P136, DOI 10.1073/pnas.84.1.136; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Mao Y, 2005, J CELL SCI, V118, P4427, DOI 10.1242/jcs.02566; Martinez-Orozco R, 2010, EUR J CELL BIOL, V89, P476, DOI 10.1016/j.ejcb.2009.12.005; Martino MM, 2010, FASEB J, V24, P4711, DOI 10.1096/fj.09-151282; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; Nelson CM, 2006, ANNU REV CELL DEV BI, V22, P287, DOI 10.1146/annurev.cellbio.22.010305.104315; Nieman MT, 1999, J CELL BIOL, V147, P631, DOI 10.1083/jcb.147.3.631; RUELLAND A, 1988, CLIN CHIM ACTA, V178, P283, DOI 10.1016/0009-8981(88)90236-7; Sandal T, 2007, AM J PATHOL, V170, P1739, DOI 10.2353/ajpath.2007.060922; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Sechler JL, 2001, J CELL BIOL, V154, P1081, DOI 10.1083/jcb.200102034; Shekhar MPV, 2003, BREAST CANCER RES, V5, P130, DOI 10.1186/bcr580; Shin S, 2010, MOL CELL, V38, P114, DOI 10.1016/j.molcel.2010.02.020; Slade MJ, 1999, EXP CELL RES, V247, P267, DOI 10.1006/excr.1998.4340; Smith AP, 2009, ONCOGENE, V28, P422, DOI 10.1038/onc.2008.395; Williams CM, 2008, CANCER RES, V68, P3185, DOI 10.1158/0008-5472.CAN-07-2673; Willis BC, 2007, AM J PHYSIOL-LUNG C, V293, pL525, DOI 10.1152/ajplung.00163.2007; Wiseman BS, 2002, SCIENCE, V296, P1046, DOI 10.1126/science.1067431; Xu QS, 2012, J BIOL CHEM, V287, P16563, DOI 10.1074/jbc.M111.262154; Yao ES, 2007, CANCER RES, V67, P659, DOI 10.1158/0008-5472.CAN-06-2768; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927	48	151	156	1	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2014	33	13					1649	1657		10.1038/onc.2013.118	http://dx.doi.org/10.1038/onc.2013.118			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9QY	23624917	Green Accepted			2022-12-28	WOS:000334344700005
J	Santini, S; Stagni, V; Giambruno, R; Fianco, G; Di Benedetto, A; Mottolese, M; Pellegrini, M; Barila, D				Santini, S.; Stagni, V.; Giambruno, R.; Fianco, G.; Di Benedetto, A.; Mottolese, M.; Pellegrini, M.; Barila, D.			ATM kinase activity modulates ITCH E3-ubiquitin ligase activity	ONCOGENE			English	Article						Ataxia Telangiectasia; ATM kinase; ITCH E3-ubiquitin ligase; c-FLIP-L; c-Jun; protein ubiquitination and degradation	E3 UBIQUITIN LIGASES; INDUCED CELL-DEATH; C-FLIPL; ACTIVATION; PROTEIN; DEGRADATION; APOPTOSIS; CASPASE-8; PHOSPHORYLATION; PROLIFERATION	Ataxia Telangiectasia Mutated (ATM) kinase, a central regulator of the DNA damage response, regulates the activity of several E3-ubiquitin ligases, and the ubiquitination-proteasome system is a consistent target of ATM. ITCH is an E3-ubiquitin ligase that modulates the ubiquitination of several targets, therefore participating to the regulation of several cellular responses, such as the DNA damage response, tumor necrosis factor alpha (TNF alpha), Notch and Hedgehog signaling, and the differentiation of 'naive' lymphocytes into T helper type 2 cells. Here we uncover ATM as a novel positive modulator of ITCH E3-ubiquitin ligase activity. A single residue on ITCH protein, S161, which is part of an ATM SQ consensus motif, is required for ATM-dependent activation of ITCH. ATM activity enhances ITCH enzymatic activity, which in turn drives the ubiquitination and degradation of c-FLIP-L and c-Jun, previously identified as ITCH substrates. Importantly, ATM-deficient mice show resistance to hepatocyte cell death, similarly to Itch-deficient animals, providing in vivo genetic evidence for this circuit. Our data identify ITCH as a novel component of the ATM-dependent signaling pathway and suggest that the impairment of the correct functionality of ITCH caused by Atm deficiency may contribute to the complex clinical features linked to Ataxia Telangiectasia.	[Santini, S.; Stagni, V.; Fianco, G.; Barila, D.] Univ Roma Tor Vergata, Dept Biol, I-00143 Rome, Italy; [Santini, S.; Stagni, V.; Fianco, G.; Barila, D.] Ist Ricovero Cura Carattere, Lab Cell Signaling, Rome, Italy; [Giambruno, R.] Austrian Acad Sci, CeMM Res Ctr Mol Med, A-1010 Vienna, Austria; [Di Benedetto, A.; Mottolese, M.] Regina Elena Inst Canc Res, Dept Pathol, Rome, Italy; [Pellegrini, M.] Univ Roma La Sapienza, Dept Expt Med, I-00185 Rome, Italy	University of Rome Tor Vergata; Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Sapienza University Rome	Barila, D (corresponding author), Univ Roma Tor Vergata, Dept Biol, Fdn Santa Lucia Via Fosso Fiorano 64, I-00143 Rome, Italy.	daniela.barila@uniroma2.it	Pellegrini, manuela/AAC-1423-2022; Barilà, Daniela/K-8506-2016; Giambruno, Roberto/W-4868-2017; Giambruno, Roberto/AAI-6717-2021	Barilà, Daniela/0000-0002-6192-1562; Giambruno, Roberto/0000-0002-4566-261X; Giambruno, Roberto/0000-0002-4566-261X; Di Benedetto, Anna/0000-0002-9853-8671; stagni, venturina/0000-0002-3971-0398; pellegrini, manuela/0000-0001-6387-5187	Italian Telethon Foundation 'Comitato Telethon Fondazione Onlus' [GGP07252]; AIRC [IG10590, MFAG8904, IG8706]; Fondazione Santa Lucia	Italian Telethon Foundation 'Comitato Telethon Fondazione Onlus'(Fondazione Telethon); AIRC(Fondazione AIRC per la ricerca sul cancro); Fondazione Santa Lucia	We acknowledge Y Shiloh, Y Lerenthal, M Kastan, J Melino, M Rossi, S Polo, D Bohmann and J Tschopp for kindly providing reagents; G Cesareni for critical reading of the manuscript; A Totaro for technical support for point mutagenesis; and D Giaccari for helping with the in vivo experiments performed in compliance with the 'Tor Vergata' University Institutional Animal Care. This work has been supported by research grants from Italian Telethon Foundation 'Comitato Telethon Fondazione Onlus' (GGP07252) and by AIRC (IG10590) to DB, AIRC (MFAG8904) to MP and AIRC (IG8706) to MM. SS has been supported by Fondazione Santa Lucia.	Altaba AR, 2002, NAT REV CANCER, V2, P361, DOI 10.1038/nrc796; Bar-Shira A, 2002, ONCOGENE, V21, P849, DOI 10.1038/sj.onc.1205127; Barila D, 2003, MOL CELL BIOL, V23, P2790, DOI 10.1128/MCB.23.8.2790-2799.2003; Bernassola F, 2008, CANCER CELL, V14, P10, DOI 10.1016/j.ccr.2008.06.001; Bhatti S, 2011, CELL MOL LIFE SCI, V68, P2977, DOI 10.1007/s00018-011-0683-9; Biton S, 2006, J BIOL CHEM, V281, P17482, DOI 10.1074/jbc.M601895200; Chang LF, 2006, CELL, V124, P601, DOI 10.1016/j.cell.2006.01.021; Cheng Q, 2010, CELL CYCLE, V9, P472, DOI 10.4161/cc.9.3.10556; Daugherity EK, 2012, CELL CYCLE, V11, P1918, DOI 10.4161/cc.20259; Di Marcotullio L, 2011, ONCOGENE, V30, P65, DOI 10.1038/onc.2010.394; Di Marcotullio L, 2006, NAT CELL BIOL, V8, P1415, DOI 10.1038/ncb1510; Gallagher E, 2006, P NATL ACAD SCI USA, V103, P1717, DOI 10.1073/pnas.0510664103; Ganten TM, 2004, CELL DEATH DIFFER, V11, pS86, DOI 10.1038/sj.cdd.4401437; Gao BX, 2006, J BIOL CHEM, V281, P29711, DOI 10.1074/jbc.M604596200; Gao M, 2004, SCIENCE, V306, P271, DOI 10.1126/science.1099414; Gilot D, 2005, CARCINOGENESIS, V26, P2086, DOI 10.1093/carcin/bgi187; Hansen TM, 2007, BIOCHEM BIOPH RES CO, V361, P33, DOI 10.1016/j.bbrc.2007.06.104; Kee Y, 2007, BIOCHEM BIOPH RES CO, V354, P329, DOI 10.1016/j.bbrc.2007.01.025; Lens SMA, 2002, MOL CELL BIOL, V22, P5419, DOI 10.1128/MCB.22.15.5419-5433.2002; Liu YC, 2007, SEMIN IMMUNOL, V19, P197, DOI 10.1016/j.smim.2007.02.003; Matei IR, 2006, IMMUNOL REV, V209, P142, DOI 10.1111/j.0105-2896.2006.00361.x; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Melino G, 2008, CELL DEATH DIFFER, V15, P1103, DOI 10.1038/cdd.2008.60; Mongiardi MP, 2011, CELL CYCLE, V10, P4311, DOI 10.4161/cc.10.24.18663; Mouchantaf R, 2006, J BIOL CHEM, V281, P38738, DOI 10.1074/jbc.M605959200; Moyal L, 2011, MOL CELL, V41, P529, DOI 10.1016/j.molcel.2011.02.015; Mu JJ, 2007, J BIOL CHEM, V282, P17330, DOI 10.1074/jbc.C700079200; Mund T, 2009, EMBO REP, V10, P501, DOI 10.1038/embor.2009.30; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Schattenberg JM, 2011, J HEPATOL, V55, P1272, DOI 10.1016/j.jhep.2011.03.008; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Stagni V, 2008, BLOOD, V111, P829, DOI 10.1182/blood-2007-04-085399; Stagni V, 2010, CARCINOGENESIS, V31, P1956, DOI 10.1093/carcin/bgq193; Stokes MP, 2007, P NATL ACAD SCI USA, V104, P19855, DOI 10.1073/pnas.0707579104; Weizman N, 2003, J BIOL CHEM, V278, P6741, DOI 10.1074/jbc.M211168200; Winter M, 2008, NAT CELL BIOL, V10, P812, DOI 10.1038/ncb1743; Yang C, 2006, MOL CELL, V21, P135, DOI 10.1016/j.molcel.2005.11.014; Yu JW, 2008, ONCOGENE, V27, P6216, DOI 10.1038/onc.2008.299	38	28	29	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2014	33	9					1113	1123		10.1038/onc.2013.52	http://dx.doi.org/10.1038/onc.2013.52			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XT	23435430	Green Accepted			2022-12-28	WOS:000331933800005
J	Byrne, FL; Yang, L; Phillips, PA; Hansford, LM; Fletcher, JI; Ormandy, CJ; McCarroll, JA; Kavallaris, M				Byrne, F. L.; Yang, L.; Phillips, P. A.; Hansford, L. M.; Fletcher, J. I.; Ormandy, C. J.; McCarroll, J. A.; Kavallaris, M.			RNAi-mediated stathmin suppression reduces lung metastasis in an orthotopic neuroblastoma mouse model	ONCOGENE			English	Article						orthotopic xenograft; cytoskeleton; cofilin; tubulin	CELL-MIGRATION; POOR-PROGNOSIS; EARLY RECURRENCE; ACTIN DYNAMICS; CANCER CELLS; LIM KINASES; RHO-KINASE; TUMOR; INVASION; MOTILITY	Metastatic neuroblastoma is an aggressive childhood cancer of neural crest origin. Stathmin, a microtubule destabilizing protein, is highly expressed in neuroblastoma although its functional role in this malignancy has not been addressed. Herein, we investigate stathmin's contribution to neuroblastoma tumor growth and metastasis. Small interfering RNA (siRNA)-mediated stathmin suppression in two independent neuroblastoma cell lines, BE(2)-C and SH-SY5Y, did not markedly influence cell proliferation, viability or anchorage-independent growth. In contrast, stathmin suppression significantly reduced cell migration and invasion in both the neuroblastoma cell lines. Stathmin suppression altered neuroblastoma cell morphology and this was associated with changes in the cytoskeleton, including increased tubulin polymer levels. Stathmin suppression also modulated phosphorylation of the actin-regulatory proteins, cofilin and myosin light chain (MLC). Treatment of stathmin-suppressed neuroblastoma cells with the ROCKI and ROCKII inhibitor, Y-27632, ablated MLC phosphorylation and returned the level of cofilin phosphorylation and cell invasion back to that of untreated control cells. ROCKII inhibition (H-1152) and siRNA suppression also reduced cofilin phosphorylation in stathmin-suppressed cells, indicating that ROCKII mediates stathmin's regulation of cofilin phosphorylation. This data demonstrates a link between stathmin and the regulation of cofilin and MLC phosphorylation via ROCK. To examine stathmin's role in neuroblastoma metastasis, stathmin short hairpin RNA (shRNA)\luciferase-expressing neuroblastoma cells were injected orthotopically into severe combined immunodeficiency-Beige mice, and tumor growth monitored by bioluminescent imaging. Stathmin suppression did not influence neuroblastoma cell engraftment or tumor growth. In contrast, stathmin suppression significantly reduced neuroblastoma lung metastases by 71% (P<0.008) compared with control. This is the first study to confirm a role for stathmin in hematogenous spread using a clinically relevant orthotopic cancer model, and has identified stathmin as an important contributor of cell invasion and metastasis in neuroblastoma.	[Byrne, F. L.; Yang, L.; McCarroll, J. A.; Kavallaris, M.] Univ New S Wales, Lowy Canc Res Ctr, Childrens Canc Inst Australia, Tumour Biol & Targeting Program, Randwick, NSW 2031, Australia; [Phillips, P. A.] Univ New S Wales, Sch Med Sci, Pancreat Canc Translat Res Grp, Randwick, NSW 2031, Australia; [Hansford, L. M.] Univ Toronto, Hosp Sick Children, Cell Biol Program, Toronto, ON M5G 1X8, Canada; [Fletcher, J. I.] Univ New S Wales, Lowy Canc Res Ctr, Childrens Canc Inst Australia, Expt Therapeut Program, Randwick, NSW 2031, Australia; [Ormandy, C. J.] St Vincents Hosp, Garvan Inst Med Res, Canc Res Program, Darlinghurst, NSW 2010, Australia; [McCarroll, J. A.; Kavallaris, M.] Univ New S Wales, Australian Ctr Nanomed, Randwick, NSW 2031, Australia	Children's Cancer Institute; University of New South Wales Sydney; University of New South Wales Sydney; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); Children's Cancer Institute; University of New South Wales Sydney; Garvan Institute of Medical Research; St Vincents Hospital Sydney; University of New South Wales Sydney	Kavallaris, M (corresponding author), Univ New S Wales, Lowy Canc Res Ctr, Childrens Canc Inst Australia, Tumour Biol & Targeting Program, POB 81, Randwick, NSW 2031, Australia.	jmccarroll@ccia.unsw.edu.au; mkavallaris@ccia.unsw.edu.au	Kavallaris, Maria/J-5240-2014; Phillips, Phoebe A/E-6006-2010; McCarroll, Joshua/E-8481-2010; Ormandy, Chris/G-4165-2014; Fletcher, Jamie/V-4667-2019; Byrne, Frances/AAW-7748-2020	Phillips, Phoebe A/0000-0002-4481-8782; McCarroll, Joshua/0000-0001-8807-3623; Byrne, Frances/0000-0002-8897-8438; Ormandy, Christopher/0000-0002-2504-7919; Fletcher, Jamie/0000-0003-2949-9469	Children's Cancer Institute Australia for Medical Research; Anthony Rothe Memorial Trust; National Health and Medical Research Council (NHMRC); Cancer Council New South Wales Program Grant; Cure Cancer Australia Foundation Grant; Cancer Institute New South Wales Early Career Development Fellowship; NHMRC	Children's Cancer Institute Australia for Medical Research; Anthony Rothe Memorial Trust; National Health and Medical Research Council (NHMRC)(National Health and Medical Research Council (NHMRC) of Australia); Cancer Council New South Wales Program Grant(Cancer Council New South Wales); Cure Cancer Australia Foundation Grant; Cancer Institute New South Wales Early Career Development Fellowship; NHMRC(National Health and Medical Research Council (NHMRC) of Australia)	We thank Dr Vladimir Ponomarev (Memorial Sloan Kettering Cancer Center) for kindly providing the TGL reporter vector, Dr Michael Shum and Dr Toby Trahair for helpful discussions and Zillan Neiron for technical assistance. Biological Resources Imaging Laboratory and the Biomedical Imaging Facility, Mark Wainwright Analytical Center, University of New South Wales. This study was financially supported by: Children's Cancer Institute Australia for Medical Research, which is affiliated with the University of New South Wales and the Sydney Children's Hospital. Funding from the Anthony Rothe Memorial Trust (F Byrne, The Anthony Rothe Scholarship) and grants from the National Health and Medical Research Council (NHMRC) (M Kavallaris and J McCarroll), Cancer Council New South Wales Program Grant (M Kavallaris), Cure Cancer Australia Foundation Grant (J McCarroll), Cancer Institute New South Wales Early Career Development Fellowship (J McCarroll, J Fletcher), NHMRC Career Development Fellowship (P Phillips) and an NHMRC Senior Research Fellowship (M Kavallaris).	Ara T, 2006, CANCER METAST REV, V25, P645, DOI 10.1007/s10555-006-9028-9; Balasubramani M, 2011, MUTAT RES-GEN TOX EN, V722, P154, DOI 10.1016/j.mrgentox.2010.08.019; Baldassarre G, 2005, CANCER CELL, V7, P51, DOI 10.1016/j.ccr.2004.11.025; Belletti B, 2008, MOL BIOL CELL, V19, P2003, DOI 10.1091/mbc.E07-09-0894; Belletti B, 2010, MOL CELL BIOL, V30, P2229, DOI 10.1128/MCB.00723-09; Bernard O, 2007, INT J BIOCHEM CELL B, V39, P1071, DOI 10.1016/j.biocel.2006.11.011; Campostrini N, 2004, J CHROMATOGR B, V808, P279, DOI 10.1016/j.jchromb.2004.05.013; Curmi PA, 1999, CELL STRUCT FUNCT, V24, P345; Don S, 2004, MOL CANCER THER, V3, P1137; DuBois SG, 1999, J PEDIAT HEMATOL ONC, V21, P181, DOI 10.1097/00043426-199905000-00005; DuBois SG, 2008, PEDIATR BLOOD CANCER, V51, P589, DOI 10.1002/pbc.21684; Gutierrez JC, 2007, PEDIATR SURG INT, V23, P637, DOI 10.1007/s00383-007-1933-7; Gutjahr MC, 2005, EXP CELL RES, V308, P422, DOI 10.1016/j.yexcr.2005.05.001; HAILAT N, 1990, ONCOGENE, V5, P1615; Henriksson KC, 2004, CLIN EXP METASTAS, V21, P563, DOI 10.1007/s10585-004-4091-5; Hsieh SY, 2010, MOL CARCINOGEN, V49, P476, DOI 10.1002/mc.20627; Insall RH, 2009, DEV CELL, V17, P310, DOI 10.1016/j.devcel.2009.08.012; Jeon TY, 2010, BRIT J CANCER, V102, P710, DOI 10.1038/sj.bjc.6605537; Kadir S, 2011, J CELL SCI, V124, P2642, DOI 10.1242/jcs.087965; Khanna C, 2002, IN VIVO, V16, P77; McCarroll JA, 2010, CANCER RES, V70, P4995, DOI 10.1158/0008-5472.CAN-09-4487; Narumiya S, 2000, METHOD ENZYMOL, V325, P273; Nevo I, 2008, NEOPLASIA, V10, P817, DOI 10.1593/neo.08402; Phillips PA, 2003, GUT, V52, P677, DOI 10.1136/gut.52.5.677; Ponomarev V, 2004, EUR J NUCL MED MOL I, V31, P740, DOI 10.1007/s00259-003-1441-5; Saal LH, 2007, P NATL ACAD SCI USA, V104, P7564, DOI 10.1073/pnas.0702507104; Sadow PM, 2008, ENDOCR PATHOL, V19, P97, DOI 10.1007/s12022-008-9028-0; Salvesen HB, 2009, P NATL ACAD SCI USA, V106, P4834, DOI 10.1073/pnas.0806514106; Scott RW, 2010, J CELL BIOL, V191, P169, DOI 10.1083/jcb.201002041; Singer S, 2009, CANCER RES, V69, P2234, DOI 10.1158/0008-5472.CAN-08-3338; Takahashi K, 2010, CELL SIGNAL, V22, P510, DOI 10.1016/j.cellsig.2009.11.005; Takahashi K, 2009, CELL SIGNAL, V21, P695, DOI 10.1016/j.cellsig.2009.01.007; Takesono A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008774; Tamura M, 2005, BBA-PROTEINS PROTEOM, V1754, P245, DOI 10.1016/j.bbapap.2005.06.015; Torka R, 2006, EXP CELL RES, V312, P3857, DOI 10.1016/j.yexcr.2006.08.025; Trovik J, 2011, CLIN CANCER RES, V17, P3368, DOI 10.1158/1078-0432.CCR-10-2412; Wittmann T, 2001, J CELL SCI, V114, P3795; Yamaguchi H, 2007, BBA-MOL CELL RES, V1773, P642, DOI 10.1016/j.bbamcr.2006.07.001; Yilmaz M, 2010, MOL CANCER RES, V8, P629, DOI 10.1158/1541-7786.MCR-10-0139; Yuan RH, 2006, J PATHOL, V209, P549, DOI 10.1002/path.2011	40	52	53	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2014	33	7					882	890		10.1038/onc.2013.11	http://dx.doi.org/10.1038/onc.2013.11			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB2MN	23396365				2022-12-28	WOS:000331626900009
J	Fulda, S				Fulda, S.			Regulation of cell migration, invasion and metastasis by IAP proteins and their antagonists	ONCOGENE			English	Review						IAP proteins; Smac; migration; invasion	NF-KAPPA-B; X-LINKED INHIBITOR; ALPHA-DEPENDENT APOPTOSIS; C-RAF KINASE; TNF-ALPHA; CASPASE INHIBITION; MULTIPLE-MYELOMA; STRUCTURAL BASIS; INNATE IMMUNITY; THERAPEUTIC INTERVENTION	Inhibitor of apoptosis (IAP) proteins are a family comprised of a total of eight mammalian members that were initially described to act as endogenous inhibitors of caspases. In addition, extensive evidence has been accumulated over the last years showing that IAP proteins can regulate various signal transduction pathways, thereby exerting non-apoptotic functions beyond the inhibition of apoptosis. For example, IAP proteins have been implied in the control of cell motility, migration, invasion and metastasis. However, currently the question is controversially discussed whether or not they positively or negatively control these processes. As small-molecule inhibitors of IAP proteins have entered the stage of clinical evaluation as experimental cancer therapeutics, a better understanding of their various cellular effects will be critical for their rational use in the treatment of human diseases.	Goethe Univ Frankfurt, Inst Expt Canc Res, D-60528 Frankfurt, Hesse, Germany	Goethe University Frankfurt	Fulda, S (corresponding author), Goethe Univ Frankfurt, Inst Expt Canc Res, Komturstr 3a, D-60528 Frankfurt, Hesse, Germany.	simone.fulda@kgu.de		Fulda, Simone/0000-0002-0459-6417	Deutsche Forschungsgemeinschaft; Ministerium fur Bildung und Forschung [01GM0871, 01GM1104C]; European Community; Jose Carreras Stiftung	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Ministerium fur Bildung und Forschung; European Community(European Commission); Jose Carreras Stiftung	The expert secretarial assistance of C Hugenberg is greatly appreciated. This work has been partially supported by grants from the Deutsche Forschungsgemeinschaft, the Ministerium fur Bildung und Forschung (01GM0871, 01GM1104C), European Community and Jose Carreras Stiftung.	Ahn S, 2012, BIOCHEM BIOPH RES CO, V419, P419, DOI 10.1016/j.bbrc.2012.02.037; Ahn S, 2010, BIOCHEM BIOPH RES CO, V399, P256, DOI 10.1016/j.bbrc.2010.07.064; Annunziata CM, 2007, CANCER CELL, V12, P115, DOI 10.1016/j.ccr.2007.07.004; Asselin E, 2001, CANCER RES, V61, P1862; Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014; Bertrand MJM, 2009, IMMUNITY, V30, P789, DOI 10.1016/j.immuni.2009.04.011; Beug ST, 2012, TRENDS IMMUNOL, V33, P535, DOI 10.1016/j.it.2012.06.004; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; Blankenship JW, 2009, BIOCHEM J, V417, P149, DOI 10.1042/BJ20081885; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Chen ZH, 1999, BIOCHEM BIOPH RES CO, V264, P847, DOI 10.1006/bbrc.1999.1585; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Csomos RA, 2009, BIOCHEM J, V420, P83, DOI 10.1042/BJ20082140; Damgaard RB, 2012, MOL CELL, V46, P746, DOI 10.1016/j.molcel.2012.04.014; Dejardin E, 2006, BIOCHEM PHARMACOL, V72, P1161, DOI 10.1016/j.bcp.2006.08.007; Demchenko YN, 2010, BLOOD, V115, P3541, DOI 10.1182/blood-2009-09-243535; Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421; Dogan T, 2008, NAT CELL BIOL, V10, P1447, DOI 10.1038/ncb1804; Dueber EC, 2011, SCIENCE, V334, P376, DOI 10.1126/science.1207862; Dynek JN, 2010, EMBO J, V29, P4198, DOI 10.1038/emboj.2010.300; Eckelman BP, 2006, EMBO REP, V7, P988, DOI 10.1038/sj.embor.7400795; Fingas CD, 2010, HEPATOLOGY, V52, P550, DOI 10.1002/hep.23729; Fulda S, 2012, NAT REV DRUG DISCOV, V11, P109, DOI 10.1038/nrd3627; Garcia-Fernandez M, 2010, GENE DEV, V24, P2282, DOI 10.1101/gad.1970110; Geisbrecht ER, 2004, CELL, V118, P111, DOI 10.1016/j.cell.2004.06.020; Glinsky GV, 2006, CELL CYCLE, V5, P1208, DOI 10.4161/cc.5.11.2796; Grech AP, 2004, IMMUNITY, V21, P629, DOI 10.1016/j.immuni.2004.09.011; Gyrd-Hansen M, 2008, NAT CELL BIOL, V10, P1309, DOI 10.1038/ncb1789; Haas TL, 2009, MOL CELL, V36, P831, DOI 10.1016/j.molcel.2009.10.013; Hauser HP, 1998, J CELL BIOL, V141, P1415, DOI 10.1083/jcb.141.6.1415; He JQ, 2006, J EXP MED, V203, P2413, DOI 10.1084/jem.20061166; Heasman SJ, 2008, NAT REV MOL CELL BIO, V9, P690, DOI 10.1038/nrm2476; Hofer-Warbinek R, 2000, J BIOL CHEM, V275, P22064, DOI 10.1074/jbc.M910346199; Huang YH, 2001, CELL, V104, P781, DOI 10.1016/S0092-8674(01)00273-2; Jeyaprakash AA, 2007, CELL, V131, P271, DOI 10.1016/j.cell.2007.07.045; Keats JJ, 2007, CANCER CELL, V12, P131, DOI 10.1016/j.ccr.2007.07.003; Kim J, 2010, AM J PHYSIOL-HEART C, V299, pH300, DOI 10.1152/ajpheart.00180.2010; Krieg A, 2009, P NATL ACAD SCI USA, V106, P14524, DOI 10.1073/pnas.0907131106; Labbe K, 2011, IMMUNITY, V35, P897, DOI 10.1016/j.immuni.2011.10.016; Launay S, 2005, ONCOGENE, V24, P5137, DOI 10.1038/sj.onc.1208524; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Liu JY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035682; Liu JY, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.176982; Lopez J, 2011, MOL CELL, V42, P569, DOI 10.1016/j.molcel.2011.04.008; Lopez J, 2010, CURR OPIN CELL BIOL, V22, P872, DOI 10.1016/j.ceb.2010.08.025; Lu M, 2007, MOL CELL, V26, P689, DOI 10.1016/j.molcel.2007.05.006; Mahoney DJ, 2008, P NATL ACAD SCI USA, V105, P11778, DOI 10.1073/pnas.0711122105; Mao AP, 2010, J BIOL CHEM, V285, P9470, DOI 10.1074/jbc.M109.071043; Mehrotra S, 2010, CANCER CELL, V17, P53, DOI 10.1016/j.ccr.2009.11.021; Min CY, 2008, J CELL BIOCHEM, V104, P733, DOI 10.1002/jcb.21695; Mollereau B, 2013, CELL DEATH DIFFER, V20, P181, DOI 10.1038/cdd.2012.82; Ndubaku C, 2009, FUTURE MED CHEM, V1, P1509, DOI 10.4155/FMC.09.116; Oberoi TK, 2012, EMBO J, V31, P14, DOI 10.1038/emboj.2011.423; Oberoi-Khanuja TK, 2012, J BIOL CHEM, V287, P28445, DOI 10.1074/jbc.M112.341297; Reffey SB, 2001, J BIOL CHEM, V276, P26542, DOI 10.1074/jbc.M100331200; Riedl SJ, 2001, CELL, V104, P791, DOI 10.1016/S0092-8674(02)02036-6; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Sanna MG, 2002, MOL CELL BIOL, V22, P1754, DOI 10.1128/MCB.22.6.1754-1766.2002; Scheidereit C, 2006, ONCOGENE, V25, P6685, DOI 10.1038/sj.onc.1209934; Schile AJ, 2008, GENE DEV, V22, P2256, DOI 10.1101/gad.1663108; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shiozaki EN, 2003, MOL CELL, V11, P519, DOI 10.1016/S1097-2765(03)00054-6; Silke J, 2001, EMBO J, V20, P3114, DOI 10.1093/emboj/20.12.3114; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Tian S, 2006, INT J ONCOL, V29, P861; Tseng PH, 2010, NAT IMMUNOL, V11, P70, DOI 10.1038/ni.1819; Varfolomeev E, 2008, J BIOL CHEM, V283, P24295, DOI 10.1074/jbc.C800128200; Varfolomeev E, 2008, CELL CYCLE, V7, P1511, DOI 10.4161/cc.7.11.5959; Varfolomeev E, 2007, CELL, V131, P669, DOI 10.1016/j.cell.2007.10.030; Varfolomeev E, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2001878; Vaux DL, 2005, NAT REV MOL CELL BIO, V6, P287, DOI 10.1038/nrm1621; Vince JE, 2008, J CELL BIOL, V182, P171, DOI 10.1083/jcb.200801010; Vince JE, 2007, CELL, V131, P682, DOI 10.1016/j.cell.2007.10.037; Vince JE, 2012, IMMUNITY, V36, P215, DOI 10.1016/j.immuni.2012.01.012; Vucic D, 2005, BIOCHEM J, V385, P11, DOI 10.1042/BJ20041108; Vucic D, 2011, 13 INT TNF C AW JAP; Vucic D, 2011, NAT REV MOL CELL BIO, V12, P439, DOI 10.1038/nrm3143; Wilmanski JM, 2008, J LEUKOCYTE BIOL, V83, P13, DOI 10.1189/jlb.0607402; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Yu JX, 2012, J BIOL CHEM, V287, P13752, DOI 10.1074/jbc.M111.337469	80	26	27	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2014	33	6					671	676		10.1038/onc.2013.63	http://dx.doi.org/10.1038/onc.2013.63			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5IL	23474760				2022-12-28	WOS:000331129200001
J	Zheng, H; Chen, L; Pledger, WJ; Fang, J; Chen, J				Zheng, H.; Chen, L.; Pledger, W. J.; Fang, J.; Chen, J.			p53 promotes repair of heterochromatin DNA by regulating JMJD2b and SUV39H1 expression	ONCOGENE			English	Article						p53; JMJD2b; SUV39H1; heterochromatin; DNA damage; repair	DOUBLE-STRAND BREAKS; TELOMERIC REPEAT-LENGTH; RADIATION SENSITIVITY; H2AX PHOSPHORYLATION; MAMMALIAN-CELLS; ATM-DEFICIENT; CANCER; DAMAGE; P53-DEFICIENT; SENESCENCE	Constitutive heterochromatin (HC) is important for maintaining chromosome stability, but also delays the repair of DNA double-strand breaks (DSBs). DSB repair in complex mammalian genomes involves a fast phase (2-6 h) in which most of the breaks are rapidly repaired, and a slow phase (up to 24 h) in which the remaining damages in HC are repaired. We found that p53 deficiency delays the slow-phase DNA repair after ionizing irradiation. p53 deficiency prevents downregulation of histone H3K9 trimethylation at the pericentric HC after DNA damage. Moreover, p53 directly induces expression of the H3K9 demethylase Jumonji domain 2 family demethylase (JMJD2b) through promoter binding. The p53 activation also indirectly downregulates expression of the H3K9 methyltransferase SUV39H1. Depletion of JMJD2b or sustained expression of SUV39H1 delays the repair of HC DNA and reduces clonogenic survival after ionizing irradiation. The results suggest that by regulating JMJD2b and SUV39H1 expression, p53 not only controls transcription but also promotes HC relaxation to accelerate a rate-limiting step in the repair of complex genomes.	[Zheng, H.; Chen, L.; Pledger, W. J.; Fang, J.; Chen, J.] H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute	Chen, J (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Mol Oncol, MRC3057A,12902 Magnolia Dr, Tampa, FL 33612 USA.	Jiandong.chen@moffitt.org		Fang, Jia/0000-0001-8583-1652	Florida Department of Health James and Esther King Biomedical Research Program; National Institutes of Health [CA141244, CA109636]; NATIONAL CANCER INSTITUTE [R01CA109636, R01CA141244, P30CA076292] Funding Source: NIH RePORTER	Florida Department of Health James and Esther King Biomedical Research Program; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank the Moffitt Molecular Genomics Core for DNA sequence analyses, and Analytic Microscopy Core for image quantification. We also want to thank Dr. Savitha Sharma for providing the inducible p27 cell line. H Zheng is supported by a postdoctoral fellowship from the Florida Department of Health James and Esther King Biomedical Research Program. This work is supported by grants from the National Institutes of Health to J Chen (CA141244, CA109636).	Ayoub N, 2008, NATURE, V453, P682, DOI 10.1038/nature06875; Ayoub N, 2009, CELL CYCLE, V8, P2945; Banath JP, 2004, CANCER RES, V64, P7144, DOI 10.1158/0008-5472.CAN-04-1433; BATZER MA, 1994, GENET ANAL-BIOMOL E, V11, P34, DOI 10.1016/1050-3862(94)90058-2; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; Bertheau P, 2002, LANCET, V360, P852, DOI 10.1016/S0140-6736(02)09969-5; Bertheau P, 2007, PLOS MED, V4, P585, DOI 10.1371/journal.pmed.0040090; BISCHOFF FZ, 1990, CANCER RES, V50, P7979; Bishop AJR, 2003, CANCER RES, V63, P5335; Bonner WM, 2008, NAT REV CANCER, V8, P957, DOI 10.1038/nrc2523; Bosch-Presegue L, 2011, MOL CELL, V42, P210, DOI 10.1016/j.molcel.2011.02.034; BOUFFLER SD, 1995, CANCER RES, V55, P3883; Boyd KE, 1998, P NATL ACAD SCI USA, V95, P13887, DOI 10.1073/pnas.95.23.13887; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Carrier F, 1999, MOL CELL BIOL, V19, P1673; Chen LH, 2010, EMBO J, V29, P2538, DOI 10.1038/emboj.2010.140; Cheng Q, 2009, EMBO J, V28, P3857, DOI 10.1038/emboj.2009.294; Chiolo I, 2011, CELL, V144, P732, DOI 10.1016/j.cell.2011.02.012; Cowell IG, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001057; Cuddihy AR, 2004, CANCER METAST REV, V23, P237, DOI 10.1023/B:CANC.0000031764.81141.e4; Dikomey E, 1998, INT J RADIAT BIOL, V73, P269, DOI 10.1080/095530098142365; DONEHOWER LA, 1995, GENE DEV, V9, P882, DOI 10.1101/gad.9.7.882; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Finelli P, 1996, GENOMICS, V38, P325, DOI 10.1006/geno.1996.0635; Fodor BD, 2006, GENE DEV, V20, P1557, DOI 10.1101/gad.388206; Garcia-Cao M, 2004, NAT GENET, V36, P94, DOI 10.1038/ng1278; Goodarzi AA, 2008, MOL CELL, V31, P167, DOI 10.1016/j.molcel.2008.05.017; Goodarzi AA, 2010, DNA REPAIR, V9, P1273, DOI 10.1016/j.dnarep.2010.09.013; Goodier JL, 2008, CELL, V135, P23, DOI 10.1016/j.cell.2008.09.022; Gudkov AV, 2003, NAT REV CANCER, V3, P117, DOI 10.1038/nrc992; HARVEY M, 1993, ONCOGENE, V8, P2457; Helton ES, 2007, J CELL BIOCHEM, V100, P883, DOI 10.1002/jcb.21091; HIYAMA K, 1995, ONCOGENE, V10, P937; Huang BY, 2009, MOL CANCER RES, V7, P1497, DOI 10.1158/1541-7786.MCR-09-0144; Jackson JG, 2012, CANCER CELL, V21, P793, DOI 10.1016/j.ccr.2012.04.027; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; KEMP CJ, 1994, NAT GENET, V8, P66, DOI 10.1038/ng0994-66; Kondo Y, 2003, J BIOL CHEM, V278, P27658, DOI 10.1074/jbc.M304072200; Kroger N, 2006, CLIN CANCER RES, V12, P159, DOI 10.1158/1078-0432.CCR-05-1340; Kuhne M, 2004, CANCER RES, V64, P500, DOI 10.1158/0008-5472.CAN-03-2384; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lohr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200; Luijsterburg MS, 2009, J CELL BIOL, V185, P577, DOI 10.1083/jcb.200810035; Martens JHA, 2005, EMBO J, V24, P800, DOI 10.1038/sj.emboj.7600545; Mekeel KL, 1997, ONCOGENE, V14, P1847, DOI 10.1038/sj.onc.1201143; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Mungamuri SK, 2012, NAT STRUCT MOL BIOL, V19, P478, DOI 10.1038/nsmb.2271; Murga M, 2007, J CELL BIOL, V178, P1101, DOI 10.1083/jcb.200704140; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Ohki S, 2003, INT J MOL MED, V11, P485; Palomera-Sanchez Z, 2010, J BIOL CHEM, V285, P31370, DOI 10.1074/jbc.M110.128462; Peng JC, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000435; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Puerto S, 2001, MUTAGENESIS, V16, P291, DOI 10.1093/mutage/16.4.291; Rubbi CP, 2003, EMBO J, V22, P975, DOI 10.1093/emboj/cdg082; Scott SL, 2003, CANCER RES, V63, P7190; Sengupta S, 2005, NAT REV MOL CELL BIO, V6, P44, DOI 10.1038/nrm1546; Sharma SS, 2012, ONCOGENE, V31, P3989, DOI 10.1038/onc.2011.550; Slee RB, 2012, ONCOGENE, V31, P3244, DOI 10.1038/onc.2011.502; TAKAHASHI K, 1985, INT J RADIAT BIOL, V48, P389, DOI 10.1080/09553008514551391; Taneja N, 2004, J BIOL CHEM, V279, P2273, DOI 10.1074/jbc.M310030200; Tjeertes JV, 2009, EMBO J, V28, P1878, DOI 10.1038/emboj.2009.119; Yan WS, 2010, J BIOL CHEM, V285, P14229, DOI 10.1074/jbc.M109.097253; Ziv Y, 2006, NAT CELL BIOL, V8, P870, DOI 10.1038/ncb1446	65	45	45	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2014	33	6					734	744		10.1038/onc.2013.6	http://dx.doi.org/10.1038/onc.2013.6			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5IL	23376847	Green Accepted			2022-12-28	WOS:000331129200008
J	Reynolds, MR; Lane, AN; Robertson, B; Kemp, S; Liu, Y; Hill, BG; Dean, DC; Clem, BF				Reynolds, M. R.; Lane, A. N.; Robertson, B.; Kemp, S.; Liu, Y.; Hill, B. G.; Dean, D. C.; Clem, B. F.			Control of glutamine metabolism by the tumor suppressor Rb	ONCOGENE			English	Article						retinoblastoma protein; metabolism; glutamine; cancer; tumor suppressor	ENERGY-METABOLISM; CELL-PROLIFERATION; GROWTH-FACTOR; G(1) CONTROL; FACTOR-I; INHIBITION; PROTEIN; CANCER; GLYCOLYSIS; APOPTOSIS	Retinoblastoma (Rb) protein is a tumor suppressor that is dysregulated in a majority of human cancers. Rb functions to inhibit cell cycle progression in part by directly disabling the E2F family of cell cycle-promoting transcription factors. Because the de novo synthesis of multiple glutamine-derived anabolic precursors is required for cell cycle progression, we hypothesized that Rb also may directly regulate proteins involved in glutamine metabolism. We examined glutamine metabolism in mouse embryonic fibroblasts (MEFs) isolated from mice that have triple knock-outs (TKO) of all three Rb family members (Rb-1, Rbl1 and Rbl2) and found that loss of global Rb function caused a marked increase in C-13-glutamine uptake and incorporation into glutamate and tricarboxylic acid cycle (TCA) intermediates in part via upregulated expression of the glutamine transporter ASCT2 and the activity of glutaminase 1 (GLS1). The Rb-controlled transcription factor E2F-3 altered glutamine uptake by direct regulation of ASCT2 mRNA and protein expression, and E2F-3 was observed to associate with the ASCT2 promoter. We next examined the functional consequences of the observed increase in glutamine uptake and utilization and found that glutamine exposure potently increased oxygen consumption, whereas glutamine deprivation selectively decreased ATP concentration in the Rb TKO MEFs but not the wildtype (WT) MEFs. In addition, TKO MEFs exhibited elevated production of glutathione from exogenous glutamine and had increased expression of gamma-glutamylcysteine ligase relative to WT MEFs. Importantly, this metabolic shift towards glutamine utilization was required for the proliferation of Rb TKO MEFs but not for the proliferation of the WT MEFs. Last, addition of the TCA cycle intermediate alpha-ketoglutarate to the Rb TKO MEFs reversed the inhibitory effects of glutamine deprivation on ATP, GSH levels and viability. Taken together, these studies demonstrate that the Rb/E2F cascade directly regulates a major energetic and anabolic pathway that is required for neoplastic growth.	[Reynolds, M. R.; Lane, A. N.; Robertson, B.; Kemp, S.; Hill, B. G.; Clem, B. F.] Univ Louisville, Dept Med, Louisville, KY 40202 USA; [Reynolds, M. R.; Hill, B. G.; Dean, D. C.; Clem, B. F.] Univ Louisville, Dept Biochem & Mol Biol, Louisville, KY 40202 USA; [Reynolds, M. R.; Robertson, B.; Kemp, S.; Liu, Y.; Dean, D. C.; Clem, B. F.] Univ Louisville, Mol Targets Grp, Louisville, KY 40202 USA; [Lane, A. N.] Univ Louisville, James Graham Brown Canc Ctr, Struct Biol Program, Louisville, KY 40202 USA; [Liu, Y.; Dean, D. C.] Univ Louisville, Dept Ophthalmol & Visual Sci, Louisville, KY 40202 USA; [Hill, B. G.] Univ Louisville, Inst Mol Cardiol, Diabetes & Obes Ctr, Louisville, KY 40202 USA	University of Louisville; University of Louisville; University of Louisville; University of Louisville; University of Louisville; University of Louisville	Clem, BF (corresponding author), Univ Louisville, Dept Med, 505 S Hancock St,CTRB,Rm 422, Louisville, KY 40202 USA.	bfclem01@louisville.edu	Hill, Bradford/I-4154-2013	Hill, Bradford/0000-0001-5332-8286	Brown Foundation; NCCRR [1P20 RR18733]; Center of Biomedical Research Excellence in Molecular Targets grant from the National Center for Research Resources [3P20RR018733-09-BFC];  [RR024489]; NATIONAL CANCER INSTITUTE [R01CA166327] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR024489, P20RR018733] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P30GM106396] Funding Source: NIH RePORTER	Brown Foundation; NCCRR; Center of Biomedical Research Excellence in Molecular Targets grant from the National Center for Research Resources; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	The authors gratefully acknowledge Jason Chesney, Sucheta Telang and John Eaton for their insightful discussions, and thank Tyler Jacks for the kind gift of the TKO MEFs. NMR experiments were carried out at the James Graham Brown Cancer Center NMR facility, supported in part by the Brown Foundation and NCCRR grant 1P20 RR18733. This work was supported by a Center of Biomedical Research Excellence in Molecular Targets (3P20RR018733-09-BFC) grant from the National Center for Research Resources and by RR024489 (BGH).	Bensaad K, 2006, CELL, V126, P107, DOI 10.1016/j.cell.2006.05.036; Blanchet E, 2011, NAT CELL BIOL, V13, P1146, DOI 10.1038/ncb2309; Ciavarra G, 2010, J CELL BIOL, V191, P291, DOI 10.1083/jcb.201005067; Classon M, 2002, NAT REV CANCER, V2, P910, DOI 10.1038/nrc950; Clem BF, 2011, ONCOGENE, V30, P3370, DOI 10.1038/onc.2011.51; Clem B, 2008, MOL CANCER THER, V7, P110, DOI 10.1158/1535-7163.MCT-07-0482; Dali-Youcef N, 2007, P NATL ACAD SCI USA, V104, P10703, DOI 10.1073/pnas.0611568104; Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014; Dang CV, 2009, CLIN CANCER RES, V15, P6479, DOI 10.1158/1078-0432.CCR-09-0889; Dang CV, 1997, J BIOENERG BIOMEMBR, V29, P345, DOI 10.1023/A:1022446730452; Dannenberg JH, 2000, GENE DEV, V14, P3051, DOI 10.1101/gad.847700; Dannenberg JH, 2004, GENE DEV, V18, P2952, DOI 10.1101/gad.322004; DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104; Dranka BP, 2011, FREE RADICAL BIO MED, V51, P1621, DOI 10.1016/j.freeradbiomed.2011.08.005; Fan TWM, 2011, METABOLOMICS, V7, P257, DOI 10.1007/s11306-010-0249-0; Fuchs BC, 2005, SEMIN CANCER BIOL, V15, P254, DOI 10.1016/j.semcancer.2005.04.005; Gaglio D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004715; Gao P, 2009, NATURE, V458, P762, DOI 10.1038/nature07823; Gillies RJ, 2008, J NUCL MED, V49, p24S, DOI 10.2967/jnumed.107.047258; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hill BG, 2009, BIOCHEM J, V424, P99, DOI 10.1042/BJ20090934; Hsieh MCF, 2008, J BIOL CHEM, V283, P27410, DOI 10.1074/jbc.M802418200; Hu WW, 2010, P NATL ACAD SCI USA, V107, P7455, DOI 10.1073/pnas.1001006107; Kim JW, 2007, MOL CELL BIOL, V27, P7381, DOI 10.1128/MCB.00440-07; Knudsen ES, 2008, NAT REV CANCER, V8, P714, DOI 10.1038/nrc2401; Le A, 2012, CELL METAB, V15, P110, DOI 10.1016/j.cmet.2011.12.009; Liu M, 2010, CIRC RES, V107, P967, DOI 10.1161/CIRCRESAHA.110.220673; Liu Y, 2007, BIOCHEM J, V408, P79, DOI 10.1042/BJ20070344; Lora J, 2004, EUR J BIOCHEM, V271, P4298, DOI 10.1111/j.1432-1033.2004.04370.x; Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863; McClellan KA, 2009, MOL CELL BIOL, V29, P4701, DOI 10.1128/MCB.01767-08; Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602; Moreno-Sanchez R, 2007, FEBS J, V274, P1393, DOI 10.1111/j.1742-4658.2007.05686.x; Mullen AR, 2012, NATURE, V481, P385, DOI 10.1038/nature10642; Perez J, 2010, BIOCHEM J, V428, P255, DOI 10.1042/BJ20100090; Sage J, 2000, GENE DEV, V14, P3037, DOI 10.1101/gad.843200; Seltzer MJ, 2010, CANCER RES, V70, P8981, DOI 10.1158/0008-5472.CAN-10-1666; Takahashi C, 2012, CANCER SCI, V103, P1182, DOI 10.1111/j.1349-7006.2012.02284.x; Wang JB, 2010, CANCER CELL, V18, P207, DOI 10.1016/j.ccr.2010.08.009; Warburg O, 1924, BIOCHEM Z, V152, P319; Wells J, 2000, MOL CELL BIOL, V20, P5797, DOI 10.1128/MCB.20.16.5797-5807.2000; Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105; Yuneva M, 2007, J CELL BIOL, V178, P93, DOI 10.1083/jcb.200703099	43	134	138	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2014	33	5					556	566		10.1038/onc.2012.635	http://dx.doi.org/10.1038/onc.2012.635			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5GW	23353822	Green Accepted			2022-12-28	WOS:000331125100004
J	Ceppi, P; Peter, ME				Ceppi, P.; Peter, M. E.			MicroRNAs regulate both epithelial-to-mesenchymal transition and cancer stem cells	ONCOGENE			English	Review						miRNAs; epithelial-to-mesenchymal transition; cancer stem cells	E-CADHERIN EXPRESSION; HUMAN OVARIAN-CANCER; DRUG-RESISTANCE; MIR-200 FAMILY; ALDEHYDE DEHYDROGENASE; PROSTATE-CANCER; DOWN-REGULATION; STEM/PROGENITOR CELLS; UNFAVORABLE PROGNOSIS; DYNAMIC EQUILIBRIUM	Concepts and experimental models derived from basic research have been successfully applied to the field of molecular oncology, tremendously increasing our knowledge of the nature and the progression of tumors. The process of epithelial-to-mesenchymal transition, the cancer stem cell hypothesis, and their functional association and interdependence represent some of the most significant examples. The molecular determinants underlying the plasticity of cancers are currently the object of extensive research efforts, and a substantial body of evidence suggests that these models can be connected by the regulatory role of microRNAs, small noncoding RNA molecules with a fundamental role in many cellular functions. This review will highlight and discuss this link and its possible implications for the fight against cancer.	[Ceppi, P.; Peter, M. E.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Peter, ME (corresponding author), Northwestern Univ, Div Hematol Oncol, Feinberg Sch Med, 303 East Super St,Lurie 6-123, Chicago, IL 60611 USA.	m-peter@northwestern.edu	Ceppi, Paolo/GPS-8668-2022	Peter, Marcus Ernst/0000-0003-3216-036X; Ceppi, Paolo/0000-0002-3632-8476				Abbott AL, 2005, DEV CELL, V9, P403, DOI 10.1016/j.devcel.2005.07.009; Achuthan S, 2011, J BIOL CHEM, V286, P37813, DOI 10.1074/jbc.M110.200675; Adam L, 2009, CLIN CANCER RES, V15, P5060, DOI 10.1158/1078-0432.CCR-08-2245; Adhikari AS, 2010, CANCER RES, V70, P4602, DOI 10.1158/0008-5472.CAN-09-3463; Aghdassi A, 2012, GUT, V61, P439, DOI 10.1136/gutjnl-2011-300060; Ahn YH, 2012, J CLIN INVEST, V122, P3170, DOI 10.1172/JCI63608; Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Akunuru S, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.93; Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; Bao B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043726; Bao B, 2011, J CELL BIOCHEM, V112, P2296, DOI 10.1002/jcb.23150; Barroso-delJesus A, 2008, MOL CELL BIOL, V28, P6609, DOI 10.1128/MCB.00398-08; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Beillard E, 2012, RNA, V18, P1091, DOI 10.1261/rna.031831.111; Bindels S, 2006, ONCOGENE, V25, P4975, DOI 10.1038/sj.onc.1209511; Bitarte N, 2011, STEM CELLS, V29, P1661, DOI 10.1002/stem.741; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Bourguignon LYW, 2012, ONCOGENE, V31, P149, DOI 10.1038/onc.2011.222; Boyer B, 2000, BIOCHEM PHARMACOL, V60, P1091, DOI 10.1016/S0006-2952(00)00427-5; Boyerinas B, 2008, CANCER RES, V68, P2587, DOI 10.1158/0008-5472.CAN-08-0264; Boyerinas B, 2012, INT J CANCER, V130, P1787, DOI 10.1002/ijc.26190; Boyerinas B, 2010, ENDOCR-RELAT CANCER, V17, pF19, DOI 10.1677/ERC-09-0184; Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694; Brown BD, 2007, NAT BIOTECHNOL, V25, P1457, DOI 10.1038/nbt1372; Burgos-Ojeda D, 2012, CANCER LETT, V322, P1, DOI 10.1016/j.canlet.2012.02.002; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Calcagno AM, 2010, JNCI-J NATL CANCER I, V102, P1637, DOI 10.1093/jnci/djq361; Campbell LL, 2007, CELL CYCLE, V6, P2332, DOI 10.4161/cc.6.19.4914; Cao Q, 2008, ONCOGENE, V27, P7274, DOI 10.1038/onc.2008.333; Celia-Terrassa T, 2012, J CLIN INVEST, V122, P1849, DOI 10.1172/JCI59218; Ceppi P, 2010, MOL CANCER RES, V8, P1207, DOI 10.1158/1541-7786.MCR-10-0052; Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108; Chang CJ, 2011, ONCOL REP, V26, P1003, DOI 10.3892/or.2011.1360; Chang CJ, 2011, NAT CELL BIOL, V13, P317, DOI 10.1038/ncb2173; Charafe-Jauffret E, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-202; Chearwae W, 2008, BRIT J CANCER, V99, P2044, DOI 10.1038/sj.bjc.6604786; Chen YT, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0017876, 10.1371/journal.pone.0021428, 10.1371/journal.pone.0017844, 10.1371/journal.pone.0024144, 10.1371/journal.pone.0027163, 10.1371/journal.pone.0027333]; Chiou GY, 2012, J CONTROL RELEASE, V159, P240, DOI 10.1016/j.jconrel.2012.01.014; Choi YJ, 2011, NAT CELL BIOL, V13, P1353, DOI 10.1038/ncb2366; Chow EKH, 2012, HEPATOLOGY, V56, P1331, DOI 10.1002/hep.25776; Concepcion CP, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002797; Connelly CM, 2012, J BIOMOL SCREEN, V17, P822, DOI 10.1177/1087057112439606; Cullen BR, 2004, MOL CELL, V16, P861, DOI 10.1016/j.molcel.2004.12.002; Dahiya N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002436; Davalos V, 2012, ONCOGENE, V31, P2062, DOI 10.1038/onc.2011.383; Davies JA, 1996, ACTA ANAT, V156, P187; Di Fiore R, 2009, J CELL PHYSIOL, V219, P301, DOI 10.1002/jcp.21667; Di Stefano B, 2011, STEM CELLS, V29, P1684, DOI 10.1002/stem.726; Dong PX, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-99; Du ZY, 2011, DIGEST DIS SCI, V56, P741, DOI 10.1007/s10620-010-1340-0; Duong HQ, 2012, INT J ONCOL, V41, P855, DOI 10.3892/ijo.2012.1516; Dykxhoorn DM, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007181; Dylla SJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002428; Eramo A, 2008, CELL DEATH DIFFER, V15, P504, DOI 10.1038/sj.cdd.4402283; Falso MJS, 2012, ANTICANCER RES, V32, P733; Fan XL, 2011, INT J COLORECTAL DIS, V26, P1279, DOI 10.1007/s00384-011-1248-y; Fillmore CM, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr1982; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Fujii H, 2009, INT J ONCOL, V34, P1381, DOI 10.3892/ijo_00000265; Garibaldi F, 2012, CELL DEATH DIFFER, V19, P937, DOI 10.1038/cdd.2011.175; Gentner B, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001522; Ghosh G, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-95; Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722; Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026; Gupta PB, 2009, NAT MED, V15, P1010, DOI 10.1038/nm0909-1010; Guttilla IK, 2012, BREAST CANCER RES TR, V132, P75, DOI 10.1007/s10549-011-1534-y; Han M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032383; Han ML, 2012, CANCER SCI, V103, P1058, DOI 10.1111/j.1349-7006.2012.02281.x; Hirschmann-Jax C, 2004, P NATL ACAD SCI USA, V101, P14228, DOI 10.1073/pnas.0400067101; Hong SP, 2009, INT J CANCER, V125, P2323, DOI 10.1002/ijc.24573; Hurt EM, 2008, BRIT J CANCER, V98, P756, DOI 10.1038/sj.bjc.6604242; Ibarra I, 2007, GENE DEV, V21, P3238, DOI 10.1101/gad.1616307; Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108; Iliopoulos D, 2010, MOL CELL, V39, P761, DOI 10.1016/j.molcel.2010.08.013; Iliopoulos D, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000356; Inada S, 1999, SURG TODAY, V29, P493, DOI 10.1007/BF02482343; Iorio MV, 2007, CANCER RES, V67, P8699, DOI 10.1158/0008-5472.CAN-07-1936; Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209; Jaggupilli A, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/708036; Jesus ABD, 2009, CELL CYCLE, V8, P394; Ji Q, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006816; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Jung DE, 2011, PANCREAS, V40, P1180, DOI 10.1097/MPA.0b013e318221b33e; Kamata M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011834; Kanellopoulou C, 2005, GENE DEV, V19, P489, DOI 10.1101/gad.1248505; Kim HH, 2009, GENE DEV, V23, P1743, DOI 10.1101/gad.1812509; Kim NH, 2011, J CELL BIOL, V195, P417, DOI 10.1083/jcb.201103097; Kim T, 2011, J EXP MED, V208, P875, DOI 10.1084/jem.20110235; Klonisch T, 2008, TRENDS MOL MED, V14, P450, DOI 10.1016/j.molmed.2008.08.003; Kobayashi Y, 2011, GYNECOL ONCOL, V121, P390, DOI 10.1016/j.ygyno.2010.12.366; Kong DJ, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012445; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200; Korpal M, 2011, NAT MED, V17, P1101, DOI 10.1038/nm.2401; Kota J, 2009, CELL, V137, P1005, DOI 10.1016/j.cell.2009.04.021; Kumarswamy R, 2012, INT J CANCER, V130, P2044, DOI 10.1002/ijc.26218; Kwon O, 2010, CARCINOGENESIS, V31, P1194, DOI 10.1093/carcin/bgq071; Lang MF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036248; Latifi A, 2011, J CELL BIOCHEM, V112, P2850, DOI 10.1002/jcb.23199; Leskela S, 2011, ENDOCR-RELAT CANCER, V18, P85, DOI 10.1677/ERC-10-0148; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li MA, 2012, BIOESSAYS, V34, P670, DOI 10.1002/bies.201200019; Lien HC, 2007, ONCOGENE, V26, P7859, DOI 10.1038/sj.onc.1210593; Lin SL, 2008, RNA, V14, P2115, DOI 10.1261/rna.1162708; Ling ZQ, 2011, INT J MOL MED, V27, P625, DOI 10.3892/ijmm.2011.640; Liu C, 2012, CANCER RES, V72, P3393, DOI 10.1158/0008-5472.CAN-11-3864; Liu XQ, 2011, BIOCHEM J, V440, P23, DOI 10.1042/BJ20111006; Lombaerts M, 2006, BRIT J CANCER, V94, P661, DOI 10.1038/sj.bjc.6602996; Ma L, 2010, ACTA BIOCH BIOPH SIN, V42, P593, DOI 10.1093/abbs/gmq067; Ma S, 2008, MOL CANCER RES, V6, P1146, DOI 10.1158/1541-7786.MCR-08-0035; Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Mansfield JH, 2004, NAT GENET, V36, P1079, DOI 10.1038/ng1421; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013; Mikhail S, 2011, INT J HEPATOL, V2011, DOI 10.4061/2011/486954; Miyoshi N, 2011, CELL STEM CELL, V8, P633, DOI 10.1016/j.stem.2011.05.001; Nalls D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024099; Nam EJ, 2008, CLIN CANCER RES, V14, P2690, DOI 10.1158/1078-0432.CCR-07-1731; Nam EJ, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-18; Park SM, 2008, GENE DEV, V22, P894, DOI 10.1101/gad.1640608; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Pestereva E, 2012, BRIT J CANCER, V106, P1702, DOI 10.1038/bjc.2012.161; Peter ME, 2009, CELL CYCLE, V8, P843, DOI 10.4161/cc.8.6.7907; Phuc PV, 2011, ONCOTARGETS THER, V4, P71, DOI 10.2147/OTT.S21431; Puhr M, 2012, AM J PATHOL, V181, P2188, DOI 10.1016/j.ajpath.2012.08.011; Qian PX, 2012, CANCER RES, V72, P6036, DOI 10.1158/0008-5472.CAN-12-1507; Richards M, 2004, STEM CELLS, V22, P51, DOI 10.1634/stemcells.22-1-51; Rosivatz E, 2002, AM J PATHOL, V161, P1881, DOI 10.1016/S0002-9440(10)64464-1; Sabisz M, 2009, CELL CYCLE, V8, P3208, DOI 10.4161/cc.8.19.9758; Saigusa S, 2009, ANN SURG ONCOL, V16, P3488, DOI 10.1245/s10434-009-0617-z; Salahshor S, 2001, BREAST CANCER RES, V3, P199, DOI 10.1186/bcr295; Samavarchi-Tehrani P, 2010, CELL STEM CELL, V7, P64, DOI 10.1016/j.stem.2010.04.015; Sampson VB, 2007, CANCER RES, V67, P9762, DOI 10.1158/0008-5472.CAN-07-2462; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029; Semb H, 1998, AM J HUM GENET, V63, P1588, DOI 10.1086/302173; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Shmelkov SV, 2008, J CLIN INVEST, V118, P2111, DOI 10.1172/JCI34401; Siitonen SM, 1996, AM J CLIN PATHOL, V105, P394; Silva IA, 2011, CANCER RES, V71, P3991, DOI 10.1158/0008-5472.CAN-10-3175; Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215; Singh SK, 2004, ONCOGENE, V23, P7267, DOI 10.1038/sj.onc.1207946; Smith AL, 2012, ONCOGENE, V31, P5162, DOI 10.1038/onc.2012.11; Steg AD, 2012, CLIN CANCER RES, V18, P869, DOI 10.1158/1078-0432.CCR-11-2188; Stuelten CH, 2010, STEM CELLS, V28, P649, DOI 10.1002/stem.324; Subramanyam D, 2011, NAT BIOTECHNOL, V29, P443, DOI 10.1038/nbt.1862; Sugimura K, 2012, CLIN CANCER RES, V18, P5144, DOI 10.1158/1078-0432.CCR-12-0701; Sulzer MA, 1998, AM J RESP CRIT CARE, V157, P1319, DOI 10.1164/ajrccm.157.4.9703099; Sun L, 2012, ONCOGENE, V31, P432, DOI 10.1038/onc.2011.263; Tamada M, 2012, CANCER RES, V72, P1438, DOI 10.1158/0008-5472.CAN-11-3024; Tanei T, 2009, CLIN CANCER RES, V15, P4234, DOI 10.1158/1078-0432.CCR-08-1479; Tang Qing-Lian, 2011, Chin J Cancer, V30, P426; Tellez CS, 2011, CANCER RES, V71, P3087, DOI 10.1158/0008-5472.CAN-10-3035; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Tiwari N, 2012, SEMIN CANCER BIOL, V22, P194, DOI 10.1016/j.semcancer.2012.02.013; Tonelli DDP, 2006, BIOTECHNIQUES, V41, P727, DOI 10.2144/000112296; Trang P, 2010, ONCOGENE, V29, P1580, DOI 10.1038/onc.2009.445; Trang P, 2011, MOL THER, V19, P1116, DOI 10.1038/mt.2011.48; Uchida Y, 2010, ONCOL REP, V24, P1147, DOI 10.3892/or_00000966; UMBAS R, 1994, CANCER RES, V54, P3929; Vira D, 2012, CANCER METAST REV, V31, P733, DOI 10.1007/s10555-012-9382-8; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007; Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392; Vlashi E, 2009, JNCI-J NATL CANCER I, V101, P350, DOI 10.1093/jnci/djn509; Vrba L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008697; Wang CX, 2012, ONCOL REP, V28, P1301, DOI 10.3892/or.2012.1951; Wang LJ, 2012, MOL CELL BIOCHEM, V363, P257, DOI 10.1007/s11010-011-1178-6; Wang LX, 2012, ONCOL LETT, V3, P119, DOI 10.3892/ol.2011.431; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998; Wiklund ED, 2011, INT J CANCER, V128, P1327, DOI 10.1002/ijc.25461; Wu C, 2008, CANCER LETT, V268, P1, DOI 10.1016/j.canlet.2008.03.048; Wu N, 2012, FEBS LETT, V586, P3831, DOI 10.1016/j.febslet.2012.08.023; Wu YJ, 2009, STEM CELLS DEV, V18, P1127, DOI 10.1089/scd.2008.0338; Xia HP, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044206; Xia HP, 2010, J BIOL CHEM, V285, P36995, DOI 10.1074/jbc.M110.133744; Xu CX, 2012, J BIOL CHEM, V287, P34970, DOI 10.1074/jbc.M112.374611; Xu XT, 2012, BRIT J CANCER, V106, P1320, DOI 10.1038/bjc.2012.88; Xue ZF, 2012, J CELL BIOCHEM, V113, P302, DOI 10.1002/jcb.23356; Yang G, 2012, BRIT J CANCER, V106, P1512, DOI 10.1038/bjc.2012.126; Yang H, 2008, CANCER RES, V68, P425, DOI 10.1158/0008-5472.CAN-07-2488; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009; Yang MH, 2010, NAT CELL BIOL, V12, P982, DOI 10.1038/ncb2099; Yang YN, 2011, J CLIN INVEST, V121, P1373, DOI 10.1172/JCI42579; Yang YP, 2012, BIOMATERIALS, V33, P1462, DOI 10.1016/j.biomaterials.2011.10.071; Yi H, 2012, KOREAN J PHYSIOL PHA, V16, P11, DOI 10.4196/kjpp.2012.16.1.11; Yu F, 2007, CELL, V131, P1109, DOI 10.1016/j.cell.2007.10.054; Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927; Zhang L, 2008, P NATL ACAD SCI USA, V105, P7004, DOI 10.1073/pnas.0801615105; Zhang L, 2006, P NATL ACAD SCI USA, V103, P9136, DOI 10.1073/pnas.0508889103; Zhang LL, 2012, J CANCER RES CLIN, V138, P675, DOI 10.1007/s00432-011-1146-2	193	91	97	2	36	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2014	33	3					269	278		10.1038/onc.2013.55	http://dx.doi.org/10.1038/onc.2013.55			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VR	23455327				2022-12-28	WOS:000330214000001
J	Inagaki-Ohara, K; Mayuzumi, H; Kato, S; Minokoshi, Y; Otsubo, T; Kawamura, YI; Dohi, T; Matsuzaki, G; Yoshimura, A				Inagaki-Ohara, K.; Mayuzumi, H.; Kato, S.; Minokoshi, Y.; Otsubo, T.; Kawamura, Y. I.; Dohi, T.; Matsuzaki, G.; Yoshimura, A.			Enhancement of leptin receptor signaling by SOCS3 deficiency induces development of gastric tumors in mice	ONCOGENE			English	Article						leptin; SOCS3; gastric tumor	MOUSE OBESE GENE; HUMAN STOMACH; OB-R; INTESTINAL INFLAMMATION; GASTROINTESTINAL-TRACT; COLORECTAL-CANCER; BINDING PROTEIN; PROTECTIVE ROLE; STEM-CELLS; EXPRESSION	Leptin acts on its receptor (ObR) in the hypothalamus to inhibit food intake and energy expenditure. Leptin and ObR are also expressed in the gastrointestinal tract; however, the physiological significance of leptin signaling in the gut remains uncertain. Suppressor of cytokine signaling 3 (SOCS3) is a key negative feedback regulator of ObR-mediated signaling in the hypothalamus. We now show that gastrointestinal epithelial cell-specific SOCS3 conditional knockout (T3b-SOCS3 cKO) mice developed gastric tumors by enhancing leptin production and the ObRb/signal transducer and activator of transcription 3 (STAT3) signaling pathway. All T3b-SOCS3 cKO mice developed tumors in the stomach but not in the bowels by 2 months of age, even though the SOCS3 deletion occurred in both the epithelium of stomach and bowels. The tumors developed in the absence of the inflammatory response and all cKO mice died within 6 months. These tumors displayed pathology and molecular alterations, such as an increase in MUC2 (Mucin 2, oligomeric mucus/gel-forming) and TFF3 (trefoil factor 3), resembling human intestinal-type gastric tumors. Administration of antileptin antibody to T3b-SOCS3 cKO mice reduced hyperplasia of gastric mucosa, which is the step of the initiation of gastric tumor. These data suggest that SOCS3 is an antigastric tumor gene that suppresses leptin overexpression and ObRb/STAT3 hyperactivation, supporting the hypothesis that the leptin/ObRb/STAT3 axis accelerates tumorigenesis and that it may represent a new therapeutic target for the treatment of gastric cancer.	[Inagaki-Ohara, K.; Mayuzumi, H.; Matsuzaki, G.] Univ Ryukyus, Trop Biosphere Res Ctr, Ctr Mol Biosci COMB, Mol Microbiol Grp, Nishihara, Okinawa 90301, Japan; [Inagaki-Ohara, K.; Minokoshi, Y.] Natl Inst Physiol Sci, Dept Dev Physiol, Div Endocrinol & Metab, Okazaki, Aichi 444, Japan; [Inagaki-Ohara, K.; Otsubo, T.; Kawamura, Y. I.; Dohi, T.] Natl Ctr Global Hlth & Med NCGM, Res Inst, Res Ctr Hepatitis & Immunol, Dept Gastroenterol, Ichikawa, Chiba 2728516, Japan; [Kato, S.] Univ Ryukyus, Grad Sch, Dept Pathol & Cell Biol, Nishihara, Okinawa 90301, Japan; [Kato, S.] Univ Ryukyus, Fac Med, Nishihara, Okinawa 90301, Japan; [Yoshimura, A.] Keio Univ, Sch Med, Dept Microbiol & Immunol, Shinjyuku Ku, Tokyo, Japan	University of the Ryukyus; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); University of the Ryukyus; University of the Ryukyus; Keio University	Inagaki-Ohara, K (corresponding author), Natl Ctr Global Hlth & Med NCGM, Res Inst, Res Ctr Hepatitis & Immunol, Dept Gastroenterol, Konodai 1-7-1, Ichikawa, Chiba 2728516, Japan.	kyoinagaki@ri.ncgm.go.jp	Otsubo, Takeshi/G-6123-2014; Yoshimura, Akihiko/K-5515-2013; Matsuzaki, Goro/AAX-3110-2020	Minokoshi, Yasuhiko/0000-0002-7119-4805	Ministry of Education, Culture, Sports, Science and Technology of Japan [17590373, 19590432, 20599015, 23590272]; Takeda Science Foundation; Public Trust Haraguchi Memorial Cancer Research Fund; Ministry of Education, Science, Technology, Sports, and Culture of Japan	Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Takeda Science Foundation(Takeda Science Foundation (TSF)); Public Trust Haraguchi Memorial Cancer Research Fund; Ministry of Education, Science, Technology, Sports, and Culture of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by grants from Grants-in-Aid for Scientific Research (C) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (17590373, 19590432, 20599015 and 23590272), the Takeda Science Foundation and the Public Trust Haraguchi Memorial Cancer Research Fund (to KI-O) and Grants-in-aid for Scientific Research (S) from the Ministry of Education, Science, Technology, Sports, and Culture of Japan (to AY). We greatly thank Dr Jun-ichi Miyazaki (Osaka University) for the gift of the T3b-IL-12 vector, Ms Kozue Takahashi and Mr Takashi Kanna (University of the Ryukyus) for animal care, Dr Atsuo T Sasaki (Harvard University) for help in creating the T3b-cre construction, Dr Richard Blumberg (Harvard Medical School) and Dr Mayu Inaba (University of Michigan) for their constructive discussion and Dr Adrian L Smith (Oxford University) for reading carefully. We also thank Dr Takeshi Arakawa (University of the Ryukyus), Dr Shiki Okamoto, Ms Kumiko Saito (NIPS), Dr Miwa Tamura-Nakano and Dr Takeshi Nitta (NCGM) for steadfast supporting and encouraging us.	Aihara T, 1999, FEBS LETT, V463, P185, DOI 10.1016/S0014-5793(99)01608-7; Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; Bado A, 1998, NATURE, V394, P790, DOI 10.1038/29547; Banks AS, 2000, J BIOL CHEM, V275, P14563, DOI 10.1074/jbc.275.19.14563; Bennett BD, 1996, CURR BIOL, V6, P1170, DOI 10.1016/S0960-9822(02)70684-2; Bjorbaek C, 1999, J BIOL CHEM, V274, P30059, DOI 10.1074/jbc.274.42.30059; Bjorbaek C, 1997, J BIOL CHEM, V272, P32686, DOI 10.1074/jbc.272.51.32686; Bjorbaek C, 2000, J BIOL CHEM, V275, P40649, DOI 10.1074/jbc.M007577200; Bjorbaek C, 1998, MOL CELL, V1, P619, DOI 10.1016/S1097-2765(00)80062-3; Buyse M, 2001, J CLIN INVEST, V108, P1483, DOI 10.1172/JCI13219; Cascio S, 2009, J CELL PHYSIOL, V221, P189, DOI 10.1002/jcp.21843; Cinti S, 2000, INT J OBESITY, V24, P789, DOI 10.1038/sj.ijo.0801228; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Du R, 2008, CANCER CELL, V13, P206, DOI 10.1016/j.ccr.2008.01.034; Ernst M, 2008, J CLIN INVEST, V118, P1727, DOI 10.1172/JCI34944; Eyckerman S, 2000, FEBS LETT, V486, P33, DOI 10.1016/S0014-5793(00)02205-5; Feldman DE, 2012, P NATL ACAD SCI USA, V109, P829, DOI 10.1073/pnas.1114438109; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Guilmeau S, 2004, CURR OPIN PHARMACOL, V4, P561, DOI 10.1016/j.coph.2004.06.008; HE YF, 1995, J BIOL CHEM, V270, P28887, DOI 10.1074/jbc.270.48.28887; Howard JM, 2010, OBES REV, V11, P863, DOI 10.1111/j.1467-789X.2010.00718.x; Inagaki-Ohara K, 2006, GUT, V55, P212, DOI 10.1136/gut.2004.062653; Inagaki-Ohara K, 2004, J IMMUNOL, V173, P1390, DOI 10.4049/jimmunol.173.2.1390; Inagaki-Ohara K, 2011, IMMUNOLOGY, V134, P448, DOI 10.1111/j.1365-2567.2011.03503.x; Ishikawa M, 2006, WORLD J GASTROENTERO, V12, P5517, DOI 10.3748/wjg.v12.i34.5517; Judd LM, 2006, GASTROENTEROLOGY, V131, P1073, DOI 10.1053/j.gastro.2006.07.018; Kidder BL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003932; Kim BM, 2005, DEV CELL, V8, P611, DOI 10.1016/j.devcel.2005.01.015; Koda M, 2007, J CLIN PATHOL, V60, P902, DOI 10.1136/jcp.2006.041004; La Cava A, 2004, NAT REV IMMUNOL, V4, P371, DOI 10.1038/nri1350; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Li Y, 2010, GUT, V59, P227, DOI 10.1136/gut.2009.184176; Mix H, 2000, GUT, V47, P481, DOI 10.1136/gut.47.4.481; MONTERO C, 1980, HISTOPATHOLOGY, V4, P281, DOI 10.1111/j.1365-2559.1980.tb02922.x; Moody SE, 2005, CANCER CELL, V8, P197, DOI 10.1016/j.ccr.2005.07.009; Mori H, 2004, NAT MED, V10, P739, DOI 10.1038/nm1071; Morton NM, 1998, J BIOL CHEM, V273, P26194, DOI 10.1074/jbc.273.40.26194; Nduati V, 2007, J BIOL CHEM, V282, P1359, DOI 10.1074/jbc.M604267200; Park HY, 2001, EXP MOL MED, V33, P95, DOI 10.1038/emm.2001.17; Rigby RJ, 2007, ONCOGENE, V26, P4833, DOI 10.1038/sj.onc.1210286; Rosivatz E, 2006, VIRCHOWS ARCH, V448, P277, DOI 10.1007/s00428-005-0118-9; Sitaraman S, 2004, FASEB J, V18, P696, DOI 10.1096/fj.03-0422fje; Sobhani I, 2000, GUT, V47, P178, DOI 10.1136/gut.47.2.178; Stringer EJ, 2008, FEBS LETT, V582, P2555, DOI 10.1016/j.febslet.2008.06.024; Suh E, 1996, MOL CELL BIOL, V16, P619; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Wu LY, 2011, AM J PATHOL, V179, P2131, DOI 10.1016/j.ajpath.2011.06.028; Yasukawa H, 2003, NAT IMMUNOL, V4, P551, DOI 10.1038/ni938; Zhang YJ, 2007, J CELL BIOCHEM, V102, P1256, DOI 10.1002/jcb.21356; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhao L, 2005, WORLD J GASTROENTERO, V11, P7666, DOI 10.3748/wjg.v11.i48.7666; Zhao XL, 2007, J GASTROEN HEPATOL, V22, P1317, DOI 10.1111/j.1440-1746.2007.04941.x	53	46	47	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2014	33	1					74	84		10.1038/onc.2012.540	http://dx.doi.org/10.1038/onc.2012.540			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	282YU	23178499				2022-12-28	WOS:000329212000009
J	Huang, WH; Chang, MC; Tsai, KS; Hung, MC; Chen, HL; Hung, SC				Huang, W-H; Chang, M-C; Tsai, K-S; Hung, M-C; Chen, H-L; Hung, S-C			Mesenchymal stem cells promote growth and angiogenesis of tumors in mice	ONCOGENE			English	Article						mesenchymal stem cells; cancer cells; endothelial cells; IL-6; endothelian-1; angiogenesis	STROMAL FIBROBLASTS; EXPANSION; RELEASE; PATHWAY	Though the early integration of mesenchymal stem cells (MSCs) into tumor-associated stroma of cancer has been demonstrated, the functional contributions and underlying mechanisms of these cells to tumor growth and angiogenesis remain to be clarified. Using a xenograft model, human colorectal cancer cells, MSCs, and their cell mixture were introduced to a subcutaneous site of immunodeficient mice. The tumor growth rate and angiogenesis of each transplantation was then compared. We demonstrate that a variety of colorectal cancer cells, when mixed with otherwise non-tumorigenic MSCs, increase the tumor growth rate and angiogenesis more than that when mixed with carcinoma-associated fibroblasts or normal colonic fibroblasts. The secretion of interleukin-6 (IL-6) from MSCs increases the secretion of endothelin-1 (ET-1) in cancer cells, which induces the activation of Akt and ERK in endothelial cells, thereby enhancing their capacities for recruitment and angiogenesis to tumor. The IL-6/ET-1/Akt or ERK pathway of tumor-stroma interaction can be targeted by an antibody against IL-6 or Lentiviral-mediated RNAi against IL-6 in MSCs, by inhibition or knockdown of ET-1 in cancer cells, or by inhibition of ERK and Akt in host endothelial cells. These demonstrate that attempts to interrupt the interaction of MSCs and cancer cells help to abrogate angiogenesis and inhibit tumor growth in tumors formed by cancer cells admixed with MSCs. These data demonstrate that the tumor microenvironment, namely, MSCs-secreted IL-6, may enrich the proangiognic factors secreted by cancer cells to increase angiogenesis and tumor growth and that targeting this interaction may lead to novel therapeutic and preventive strategies.	[Huang, W-H; Chen, H-L] Natl Yang Ming Univ, Inst Oral Biol, Dept Dent, Taipei 112, Taiwan; [Chang, M-C; Tsai, K-S] Natl Yang Ming Univ, Inst Anat & Cell Biol, Dept Dent, Taipei 112, Taiwan; [Chang, M-C; Hung, S-C] Taipei Vet Gen Hosp, Dept Orthopaed & Traumatol, Taipei, Taiwan; [Tsai, K-S; Hung, S-C] Taipei Vet Gen Hosp, Dept Med Res & Educ, Stem Cell Lab, Taipei, Taiwan; [Hung, M-C] Univ Texas MD Anderson Canc Ctr, Dept Mol & Cellular Biol, Houston, TX 77030 USA; [Hung, M-C] China Med Univ & Hosp, Coll Med, Grad Inst Canc Biol, Taichung, Taiwan; [Hung, M-C] China Med Univ & Hosp, Ctr Mol Med, Taichung, Taiwan; [Hung, S-C] Natl Yang Ming Univ, Inst Clin Med, Dept Dent, Taipei 112, Taiwan; [Hung, S-C] Natl Yang Ming Univ, Inst Pharmacol, Dept Dent, Taipei 112, Taiwan	National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital; Taipei Veterans General Hospital; University of Texas System; UTMD Anderson Cancer Center; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung University	Chen, HL (corresponding author), Natl Yang Ming Univ, Inst Oral Biol, Dept Dent, 155,Sect 2,Li Ron St, Taipei 112, Taiwan.	hlchen2@ym.edu.tw; hungsc@vghtpe.gov.tw	Hung, Mien-Chie/ABD-5911-2021	Hung, Mien-Chie/0000-0003-4317-4740	National Science Council [99-3111-B-010-005-, 100-2321-B-010-022-]; Taipei Veterans General Hospital [V99E1-011]; National Yang-Ming University, Ministry of Education	National Science Council(Ministry of Science and Technology, Taiwan); Taipei Veterans General Hospital(Taipei Veterans General Hospital); National Yang-Ming University, Ministry of Education	National Science Council (99-3111-B-010-005-; 100-2321-B-010-022-), Taipei Veterans General Hospital (V99E1-011) and National Yang-Ming University, Ministry of Education. The study sponsors do not have a role in the study design, collection, analysis and interpretation of date.	Basile JR, 2007, J BIOL CHEM, V282, P6899, DOI 10.1074/jbc.M609570200; Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478; Coffelt SB, 2009, P NATL ACAD SCI USA, V106, P3806, DOI 10.1073/pnas.0900244106; Dwyer RM, 2007, CLIN CANCER RES, V13, P5020, DOI 10.1158/1078-0432.CCR-07-0731; Eldesoky A, 2011, SAUDI J GASTROENTERO, V17, P170, DOI 10.4103/1319-3767.80378; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; FOLKMAN J, 1973, J EXP MED, V138, P745, DOI 10.1084/jem.138.4.745; Hung SC, 2005, CLIN CANCER RES, V11, P7749, DOI 10.1158/1078-0432.CCR-05-0876; Hung SC, 2007, STEM CELLS, V25, P2363, DOI 10.1634/stemcells.2006-0686; Joyce JA, 2005, CANCER CELL, V7, P513, DOI 10.1016/j.ccr.2005.05.024; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; Lis R, 2011, INT J CANCER, V128, P715, DOI 10.1002/ijc.25619; Liu Y, 2011, J BIOL CHEM, V286, P25007, DOI 10.1074/jbc.M110.213108; Mishra PJ, 2008, CANCER RES, V68, P4331, DOI 10.1158/0008-5472.CAN-08-0943; Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444; Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Patel SA, 2010, J IMMUNOL, V184, P5885, DOI 10.4049/jimmunol.0903143; Piperi C, 2011, CYTOKINE, V55, P387, DOI 10.1016/j.cyto.2011.05.012; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Quante M, 2011, CANCER CELL, V19, P257, DOI 10.1016/j.ccr.2011.01.020; Roodhart JML, 2011, CANCER CELL, V20, P370, DOI 10.1016/j.ccr.2011.08.010; Sekiya I, 2002, STEM CELLS, V20, P530, DOI 10.1634/stemcells.20-6-530; Shinagawa K, 2010, INT J CANCER, V127, P2323, DOI 10.1002/ijc.25440; Shojaei F, 2008, CANCER RES, V68, P5501, DOI 10.1158/0008-5472.CAN-08-0925; Spaeth EL, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004992; Stagg J, 2008, STEM CELL REV, V4, P119, DOI 10.1007/s12015-008-9030-4; Tsai KS, 2011, GASTROENTEROLOGY, V141, P1046, DOI 10.1053/j.gastro.2011.05.045; Yamanashi T, 2009, ONCOLOGY-BASEL, V77, P53, DOI 10.1159/000226112	29	146	151	3	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 12	2013	32	37					4343	4354		10.1038/onc.2012.458	http://dx.doi.org/10.1038/onc.2012.458			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218AF	23085755				2022-12-28	WOS:000324404200003
J	Dalvai, M; Bellucci, L; Fleury, L; Lavigne, AC; Moutahir, F; Bystricky, K				Dalvai, M.; Bellucci, L.; Fleury, L.; Lavigne, A-C; Moutahir, F.; Bystricky, K.			H2A.Z-dependent crosstalk between enhancer and promoter regulates Cyclin D1 expression	ONCOGENE			English	Article						H2A.Z; chromatin; acetylation; enhancer; intragenic loop; cyclin D1	BREAST-CANCER CELLS; ESTROGEN-RECEPTOR-ALPHA; RNA-POLYMERASE-II; BETA-GLOBIN LOCUS; GENE-EXPRESSION; HISTONE H2A.Z; TRANSCRIPTIONAL ACTIVATION; CHROMOSOME CONFORMATION; CHROMATIN DYNAMICS; IN-VIVO	H2A.Z association with specific genomic loci is thought to contribute to a chromatin structure that promotes transcription activation. Acetylation of H2A.Z at promoters of oncogenes has been linked to tumorigenesis. The mechanism is unknown. Here, we show that in triple negative breast cancer cells, H2A.Z bound to the promoter of the constitutively, weakly expressed cyclin D1 oncogene (CCND1), a key regulator of cellular proliferation. Depleting the pool of H2A.Z stimulated transcription of CCND1 in the absence of its cognate transcription factor, the estrogen receptor (ER). During activation of CCND1, H2A.Z was released from the transcription start site (TSS) and downstream enhancer (enh2) sequences. Concurrently, acetylation of H2A.Z, H3 and H4 at the TSS was increased but only H2A.Z was acetylated at enh2. Acetylation of H2A.Z required the Tip60 acetyltransferase to be associated with the activated CCND1 on both TSS and enh2 sites. Depletion of Tip60 prevented CCND1 activation. Chromosome conformation capture experiments (3C) revealed specific contacts between the TSS and enh2 chromatin regions. These results suggest that release of a histone H2A.Z-mediated repression loop activates CCND1 for transcription. Our findings open new avenues for controlling and understanding aberrant gene expression associated with tumorigenesis.	[Dalvai, M.; Bellucci, L.; Fleury, L.; Lavigne, A-C; Moutahir, F.; Bystricky, K.] Univ Toulouse, LBME, F-31062 Toulouse, France; [Dalvai, M.; Bellucci, L.; Fleury, L.; Lavigne, A-C; Moutahir, F.; Bystricky, K.] CNRS, LBME, UMR 5099, Toulouse, France	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier	Bystricky, K (corresponding author), Univ Toulouse, LBME, 118 Route Narbonne, F-31062 Toulouse, France.	kerstin@biotoul.fr	Lavigne, Anne-Claire/O-8805-2015; Bystricky, Kerstin/AAA-3003-2020; BYSTRICKY, Kerstin/B-8670-2009	Bystricky, Kerstin/0000-0001-6717-3721; BYSTRICKY, Kerstin/0000-0001-6717-3721	Ligue Nationale Contre le Cancer; Institut National du Cancer (INCa) [34696]; Fondation pour la Recherche Medicale (FRM)	Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer); Institut National du Cancer (INCa)(Institut National du Cancer (INCA) France); Fondation pour la Recherche Medicale (FRM)(Fondation pour la Recherche Medicale)	We would like to thank Dr Didier Trouche for the Tip60 expressing vector and insightful discussions, J Eeckhoute, Lille for sharing unpublished work, and David Laperriere, IRIC, Montreal, for expert advice on genome database use. This work was supported by the Ligue Nationale Contre le Cancer (fellowship to LB), the Institut National du Cancer (INCa grant no. 34696) and the Fondation pour la Recherche Medicale (FRM, fellowship to MD).	Adam M, 2001, MOL CELL BIOL, V21, P6270, DOI 10.1128/MCB.21.18.6270-6279.2001; Altaf M, 2009, BIOCHEM CELL BIOL, V87, P35, DOI 10.1139/O08-140; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; BARTKOVA J, 1994, J PATHOL, V172, P237, DOI 10.1002/path.1711720303; Barzily-Rokni M, 2011, NUCLEIC ACIDS RES, V39, P1326, DOI 10.1093/nar/gkq994; Bhaumik SR, 2007, NAT STRUCT MOL BIOL, V14, P1008, DOI 10.1038/nsmb1337; Boulon S, 2002, MOL CELL BIOL, V22, P7769, DOI 10.1128/MCB.22.22.7769-7779.2002; Bray F, 2002, EUR J CANCER, V38, P99, DOI 10.1016/S0959-8049(01)00350-1; Brookes E, 2009, EMBO REP, V10, P1213, DOI 10.1038/embor.2009.221; Bruzzese F, 2011, J CELL PHYSIOL, V226, P2378, DOI 10.1002/jcp.22574; Carroll JS, 2006, NAT GENET, V38, P1289, DOI 10.1038/ng1901; Chambeyron S, 2004, CURR OPIN CELL BIOL, V16, P256, DOI 10.1016/j.ceb.2004.03.004; Chu S, 1997, MOL CELL ENDOCRINOL, V132, P195, DOI 10.1016/S0303-7207(97)00133-0; Dalvai M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011011; Dalvai M, 2010, J MAMMARY GLAND BIOL, V15, P19, DOI 10.1007/s10911-010-9167-z; Dekker J, 2002, SCIENCE, V295, P1306, DOI 10.1126/science.1067799; Deschenes J, 2007, J BIOL CHEM, V282, P17335, DOI 10.1074/jbc.C700030200; Eeckhoute J, 2006, GENE DEV, V20, P2513, DOI 10.1101/gad.1446006; Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI 10.1056/NEJMra072067; Farris SD, 2005, J BIOL CHEM, V280, P25298, DOI 10.1074/jbc.M501784200; Fleury L, 2008, ONCOGENE, V27, P4075, DOI 10.1038/onc.2008.41; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Fu MF, 2004, ENDOCRINOLOGY, V145, P5439, DOI 10.1210/en.2004-0959; Fullwood MJ, 2009, NATURE, V462, P58, DOI 10.1038/nature08497; Gamble MJ, 2010, GENE DEV, V24, P21, DOI 10.1101/gad.1876110; Gevry N, 2009, GENE DEV, V23, P1522, DOI 10.1101/gad.1787109; Giamarchi C, 1999, ONCOGENE, V18, P533, DOI 10.1038/sj.onc.1202317; Guillemette B, 2005, PLOS BIOL, V3, P2100, DOI 10.1371/journal.pbio.0030384; Hajkova P, 2008, NATURE, V452, P877, DOI 10.1038/nature06714; Henikoff S, 2005, ANNU REV CELL DEV BI, V21, P133, DOI 10.1146/annurev.cellbio.21.012704.133518; Hua SJ, 2009, CELL, V137, P1259, DOI 10.1016/j.cell.2009.04.043; Iacovoni JS, 2010, EMBO J, V29, P1446, DOI 10.1038/emboj.2010.38; Ikura T, 2007, MOL CELL BIOL, V27, P7028, DOI 10.1128/MCB.00579-07; JENSEN EV, 1967, ARCH ANAT MICROSC MO, V56, P547; Jeong KW, 2011, NAT STRUCT MOL BIOL, V18, P1358, DOI 10.1038/nsmb.2153; Jin CY, 2009, NAT GENET, V41, P941, DOI 10.1038/ng.409; Jin FL, 2011, P NATL ACAD SCI USA, V108, P5290, DOI 10.1073/pnas.1017214108; Keogh MC, 2006, GENE DEV, V20, P660, DOI 10.1101/gad.1388106; Kimura A, 1998, GENES CELLS, V3, P789, DOI 10.1046/j.1365-2443.1998.00229.x; Kocanova S, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000922; Lee S, 2010, J BIOL CHEM, V285, P21399, DOI 10.1074/jbc.M110.128413; Legube G, 2004, J BIOL CHEM, V279, P44825, DOI 10.1074/jbc.M407478200; Lehn S, 2010, AM J PATHOL, V177, P2886, DOI 10.2353/ajpath.2010.100303; Lupien M, 2008, CELL, V132, P958, DOI 10.1016/j.cell.2008.01.018; Ma XJ, 2009, DRUGS, V69, P1911, DOI 10.2165/11315680-000000000-00000; March-Diaz R, 2008, PLANT J, V53, P475, DOI 10.1111/j.1365-313X.2007.03361.x; Mattera L, 2009, ONCOGENE, V28, P1506, DOI 10.1038/onc.2008.499; Mattera L, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000983; Metivier R, 2003, CELL, V115, P751, DOI 10.1016/S0092-8674(03)00934-6; Metivier R, 2002, MOL CELL, V10, P1019, DOI 10.1016/S1097-2765(02)00746-3; Millar CB, 2006, GENE DEV, V20, P711, DOI 10.1101/gad.1395506; Noordermeer D, 2011, NAT CELL BIOL, V13, P944, DOI 10.1038/ncb2278; Ogawa S, 1998, NUCLEIC ACIDS RES, V26, P3505, DOI 10.1093/nar/26.15.3505; Ong CT, 2011, NAT REV GENET, V12, P283, DOI 10.1038/nrg2957; OTTAVIANO YL, 1994, CANCER RES, V54, P2552; Planas-Silva MD, 1999, CANCER RES, V59, P4788; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; Serandour AA, 2011, GENOME RES, V21, P555, DOI 10.1101/gr.111534.110; Shia WJ, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-5-217; Simonis M, 2006, NAT GENET, V38, P1348, DOI 10.1038/ng1896; Soulez M, 2001, J MOL ENDOCRINOL, V27, P259, DOI 10.1677/jme.0.0270259; Splinter E, 2004, METHOD ENZYMOL, V375, P493; Stadhouders R, 2012, EMBO J, V31, P986, DOI 10.1038/emboj.2011.450; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Suganuma T, 2008, CELL, V135, P604, DOI 10.1016/j.cell.2008.10.036; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; THOMPSON EW, 1992, J CELL PHYSIOL, V150, P534, DOI 10.1002/jcp.1041500314; Tobin NP, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-417; Tolhuis B, 2002, MOL CELL, V10, P1453, DOI 10.1016/S1097-2765(02)00781-5; TOUITOU I, 1991, J STEROID BIOCHEM, V40, P231, DOI 10.1016/0960-0760(91)90187-A; Updike DL, 2006, PLOS GENET, V2, P1500, DOI 10.1371/journal.pgen.0020161; Vakoc CR, 2005, MOL CELL, V17, P453, DOI 10.1016/j.molcel.2004.12.028; Valdes-Mora F, 2012, GENOME RES, V22, P307, DOI 10.1101/gr.118919.110; Vigushin DM, 2001, CLIN CANCER RES, V7, P971; Vogelmann J, 2011, NUCLEUS-PHILA, V2, P358, DOI 10.4161/nucl.2.5.17860; Voss TC, 2011, CELL, V146, P544, DOI 10.1016/j.cell.2011.07.006; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Yang XW, 2001, CANCER RES, V61, P7025; Yun MY, 2011, CELL RES, V21, P564, DOI 10.1038/cr.2011.42	79	28	28	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 5	2013	32	36					4243	4251		10.1038/onc.2012.442	http://dx.doi.org/10.1038/onc.2012.442			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	214WL	23108396				2022-12-28	WOS:000324168000006
J	Lin, YH; Huang, YH; Wu, MH; Wu, SM; Chi, HC; Liao, CJ; Chen, CY; Tseng, YH; Tsai, CY; Tsai, MM; Lin, KH				Lin, Y-H; Huang, Y-H; Wu, M-H; Wu, S-M; Chi, H-C; Liao, C-J; Chen, C-Y; Tseng, Y-H; Tsai, C-Y; Tsai, M-M; Lin, K-H			Thyroid hormone suppresses cell proliferation through endoglin-mediated promotion of p21 stability	ONCOGENE			English	Article						thyroid hormome; endoglin; hepatocellular carcinoma; cell proliferation	HEPATOCELLULAR-CARCINOMA; PITUITARY-TUMOR; CANCER-CELLS; CYCLE ARREST; EXPRESSION; RECEPTOR; INVASION; GENE; MIGRATION; BINDING	Hypothyroidism has been associated with significantly elevated risk for hepatocellular carcinoma (HCC), although the precise underlying mechanisms remain unknown at present. Thyroid hormone (T-3) and its receptor (TR) are involved in metabolism and growth. Endoglin is a T-3/TR candidate target gene identified from our previous studies. Here, we demonstrated that T-3 positively regulates endoglin mRNA and protein levels, both in vitro and in vivo. The thyroid hormone response elements of endoglin were identified at positions -2114/-2004 and -2032/-1973 of the promoter region using the electrophoretic mobility shift assay and chromatin immunoprecipitation assay. Endoglin was downregulated in the subgroups of HCC patients and significantly associated with histology grade (negative association, P = 0.001), and this expression level was significantly associated with TR alpha 1 in these HCC patients. Our results clearly indicate that p21 is involved in T-3-mediated suppression of cell proliferation. Knock down of endoglin expression in HCC cells facilitated p21 polyubiquitination and promoted cell proliferation in the presence of T-3. The data collectively suggest that T-3/TR signaling suppresses cell proliferation by upregulating endoglin, in turn, affecting p21 stability. The results indicate that endoglin has a suppressor role to inhibit cell proliferation in HCC cell lines.	[Lin, Y-H; Wu, M-H; Wu, S-M; Chi, H-C; Liao, C-J; Chen, C-Y; Tseng, Y-H; Tsai, C-Y; Lin, K-H] Chang Gung Univ, Dept Biochem, Coll Med, Tao Yuan, Taiwan; [Huang, Y-H] Chang Gung Mem Hosp, Liver Res Ctr, Linkou, Taiwan; [Tsai, M-M] Chang Gung Univ Sci & Technol, Dept Nursing, Tao Yuan, Taiwan	Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University of Science & Technology	Lin, KH (corresponding author), Chang Gung Univ, Dept Biochem, 259 Wen Hwa 1 Rd, Tao Yuan, Taiwan.	khlin@mail.cgu.edu.tw			Chang-Gung University, Taoyuan, Taiwan [CMRPD 34013, NMRP 140511]; National Science Council of the Republic of China [NSC 94-2320-B-182-052]	Chang-Gung University, Taoyuan, Taiwan; National Science Council of the Republic of China(Ministry of Science and Technology, Taiwan)	This work was supported by Grants from Chang-Gung University, Taoyuan, Taiwan (CMRPD 34013, NMRP 140511) and from the National Science Council of the Republic of China (NSC 94-2320-B-182-052).	Aliouat-Denis CM, 2005, MOL CANCER RES, V3, P627, DOI 10.1158/1541-7786.MCR-05-0121; Ando S, 2001, MOL ENDOCRINOL, V15, P1529, DOI 10.1210/me.15.9.1529; Barbara NP, 1999, J BIOL CHEM, V274, P584, DOI 10.1074/jbc.274.2.584; BELLON T, 1993, EUR J IMMUNOL, V23, P2340, DOI 10.1002/eji.1830230943; Benetti A, 2008, CANCER RES, V68, P8626, DOI 10.1158/0008-5472.CAN-08-1218; Bloom J, 2003, CELL, V115, P71, DOI 10.1016/S0092-8674(03)00755-4; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; Cayrol C, 1998, ONCOGENE, V16, P311, DOI 10.1038/sj.onc.1201543; Chamba A, 1996, J CLIN ENDOCR METAB, V81, P360, DOI 10.1210/jc.81.1.360; Chen RN, 2008, ENDOCRINOLOGY, V149, P3817, DOI 10.1210/en.2007-0989; Chen RN, 2008, CANCER RES, V68, P1697, DOI 10.1158/0008-5472.CAN-07-5492; Cheng S Y, 2000, Rev Endocr Metab Disord, V1, P9, DOI 10.1023/A:1010052101214; Craft CS, 2007, ONCOGENE, V26, P7240, DOI 10.1038/sj.onc.1210533; Fonsatti E, 2003, ONCOGENE, V22, P6557, DOI 10.1038/sj.onc.1206813; GOUGOS A, 1988, J IMMUNOL, V141, P1934; GOUGOS A, 1990, J BIOL CHEM, V265, P8361; Harvey CB, 2002, THYROID, V12, P441, DOI 10.1089/105072502760143791; Hassan MM, 2009, HEPATOLOGY, V49, P1563, DOI 10.1002/hep.22793; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Henry LA, 2011, ONCOGENE, V30, P1046, DOI 10.1038/onc.2010.488; Huang Ya-Hui, 2008, Chang Gung Med J, V31, P325; Kagawa S, 1999, CELL DEATH DIFFER, V6, P765, DOI 10.1038/sj.cdd.4400549; Kress E, 2010, GASTROENTEROLOGY, V138, P1863, DOI 10.1053/j.gastro.2010.01.041; Laptenko O, 2011, P NATL ACAD SCI USA, V108, P10385, DOI 10.1073/pnas.1105680108; Lastres P, 1996, J CELL BIOL, V133, P1109, DOI 10.1083/jcb.133.5.1109; Lee H, 2006, J BIOL CHEM, V281, P26876, DOI 10.1074/jbc.M605366200; Lee JY, 2007, MOL CELL BIOL, V27, P3187, DOI 10.1128/MCB.01461-06; Li Y, 2002, J BIOL CHEM; Liao CH, 2012, HEPATOLOGY, V55, P910, DOI 10.1002/hep.24740; Liao CH, 2010, ENDOCR-RELAT CANCER, V17, P99, DOI 10.1677/ERC-09-0050; Liao CJ, 2011, CANCER SCI, V102, P2255, DOI 10.1111/j.1349-7006.2011.02102.x; Lin KH, 2000, ENDOCRINOLOGY, V141, P2540, DOI 10.1210/en.141.7.2540; Lin KH, 2001, ENDOCRINOLOGY, V142, P653, DOI 10.1210/en.142.2.653; Liu YQ, 2002, ONCOGENE, V21, P8272, DOI 10.1038/sj.onc.1206117; Martinez-Iglesias O, 2009, CANCER RES, V69, P501, DOI 10.1158/0008-5472.CAN-08-2198; Oxmann D, 2008, ONCOGENE, V27, P3567, DOI 10.1038/sj.onc.1211025; Perez-Gomez E, 2007, CANCER RES, V67, P10268, DOI 10.1158/0008-5472.CAN-07-1348; Puzianowska-Kuznicka M, 2002, J CLIN ENDOCR METAB, V87, P1120, DOI 10.1210/jc.87.3.1120; Suzuki H, 2002, THYROID, V12, P963, DOI 10.1089/105072502320908295; Wu SM, 2011, ONCOGENE, V30, P2057, DOI 10.1038/onc.2010.585; Yen CC, 2006, J MOL ENDOCRINOL, V36, P9, DOI 10.1677/jme.1.01911; Yen PM, 2001, PHYSIOL REV, V81, P1097, DOI 10.1152/physrev.2001.81.3.1097; Yoo YD, 1999, INT J CANCER, V83, P512, DOI 10.1002/(SICI)1097-0215(19991112)83:4<512::AID-IJC13>3.0.CO;2-Z; Yu DC, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-122	44	24	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2013	32	33					3904	3914		10.1038/onc.2013.5	http://dx.doi.org/10.1038/onc.2013.5			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202JH	23376845				2022-12-28	WOS:000323210200013
J	Surova, O; Zhivotovsky, B				Surova, O.; Zhivotovsky, B.			Various modes of cell death induced by DNA damage	ONCOGENE			English	Review						DNA damage; cell death; p53; senescence; response	REPLICATIVE SENESCENCE; P53; AUTOPHAGY; APOPTOSIS; CANCER; POLY(ADP-RIBOSE); CHECKPOINT; PATHWAYS; CONTRIBUTES; ACTIVATION	The consequences of DNA damage depend on the cell type and the severity of the damage. Mild DNA damage can be repaired with or without cell-cycle arrest. More severe and irreparable DNA injury leads to the appearance of cells that carry mutations or causes a shift towards induction of the senescence or cell death programs. Although for many years it was argued that DNA damage kills cells via apoptosis or necrosis, technical and methodological progress during the last few years has helped to reveal that this injury might also activate death by autophagy or mitotic catastrophe, which may then be followed by apoptosis or necrosis. The molecular basis underlying the decision-making process is currently the subject of intense investigation. Here, we review current knowledge about the response to DNA damage and subsequent signaling, with particular attention to cell death induction and the molecular switches between different cell death modalities following damage.	[Surova, O.; Zhivotovsky, B.] Karolinska Inst, Div Toxicol, Inst Environm Med, SE-17177 Stockholm, Sweden	Karolinska Institutet	Zhivotovsky, B (corresponding author), Karolinska Inst, Div Toxicol, Inst Environm Med, Nobels Vag 13,Box 210, SE-17177 Stockholm, Sweden.	Boris.Zhivotovsky@ki.se	Zhivotovsky, Boris/A-4346-2014	Zhivotovsky, Boris/0000-0002-2238-3482	Swedish Research Council; Swedish Cancer Society; Stockholm Cancer Society; Swedish Childhood Cancer Foundation; FP7 (Apo-Sys) program; Swedish Institute; Karolinska Institutet	Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Cancer Society(Swedish Cancer Society); Stockholm Cancer Society; Swedish Childhood Cancer Foundation(European Commission); FP7 (Apo-Sys) program; Swedish Institute; Karolinska Institutet(Karolinska Institutet)	The work in the author's laboratory was supported by grants from the Swedish Research Council, the Swedish and the Stockholm Cancer Societies, the Swedish Childhood Cancer Foundation, and the FP7 (Apo-Sys) program. OS was supported by a fellowship from the Swedish Institute and Karolinska Institutet. We apologize to those authors whose primary references could not be cited due to space limitations.	Abedin MJ, 2007, CELL DEATH DIFFER, V14, P500, DOI 10.1038/sj.cdd.4402039; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Alexander A, 2010, AUTOPHAGY, V6, P672, DOI 10.4161/auto.6.5.12509; Artus C, 2010, EMBO J, V29, P1585, DOI 10.1038/emboj.2010.43; Bai SC, 2004, MOL CANCER THER, V3, P613; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Beausejour CM, 2003, EMBO J, V22, P4212, DOI 10.1093/emboj/cdg417; BERGER NA, 1985, RADIAT RES, V101, P4, DOI 10.2307/3576299; Borges HL, 2008, CELL RES, V18, P17, DOI 10.1038/cr.2007.110; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Castedo M, 2004, ONCOGENE, V23, P2825, DOI 10.1038/sj.onc.1207528; Castedo M, 2004, ONCOGENE, V23, P4353, DOI 10.1038/sj.onc.1207573; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; de Leseleuc L, 2006, CELL DEATH DIFFER, V13, P293, DOI 10.1038/sj.cdd.4401737; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; deMurcia JM, 1997, P NATL ACAD SCI USA, V94, P7303, DOI 10.1073/pnas.94.14.7303; Dorstyn L, 2012, CELL DEATH DIFFER, V19, P1288, DOI 10.1038/cdd.2012.36; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Flores ER, 2002, NATURE, V416, P560, DOI 10.1038/416560a; Freeman AK, 2010, CELL COMMUN SIGNAL, V8, DOI 10.1186/1478-811X-8-27; Gresko E, 2006, EMBO J, V25, P1883, DOI 10.1038/sj.emboj.7601077; He L, 2007, NATURE, V447, P1130, DOI 10.1038/nature05939; Hock AK, 2012, CELL, V149, P1183, DOI 10.1016/j.cell.2012.05.024; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Jin ZY, 2005, CANCER BIOL THER, V4, P139, DOI 10.4161/cbt.4.2.1508; Kaminskyy VO, 2012, AUTOPHAGY, V8, P1032, DOI 10.4161/auto.20123; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kim H, 2011, MOL CELL, V44, P797, DOI 10.1016/j.molcel.2011.09.023; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Levine B, 2008, NAT CELL BIOL, V10, P637, DOI 10.1038/ncb0608-637; Li H, 2000, SCIENCE, V289, P1159, DOI 10.1126/science.289.5482.1159; Liaudet L, 2000, P NATL ACAD SCI USA, V97, P10203, DOI 10.1073/pnas.170226797; Lorin S, 2010, AUTOPHAGY, V6, P153, DOI 10.4161/auto.6.1.10537; Morandell S, 2012, PROG MOL BIOL TRANSL, V110, P289, DOI 10.1016/B978-0-12-387665-2.00011-0; Moubarak RS, 2007, MOL CELL BIOL, V27, P4844, DOI 10.1128/MCB.02141-06; Munoz-Gomez JA, 2009, AUTOPHAGY, V5, P61, DOI 10.4161/auto.5.1.7272; Nelyudova A, 2007, CELL CYCLE, V6, P2171, DOI 10.4161/cc.6.17.4610; Norberg E, 2010, EMBO J, V29, P3869, DOI 10.1038/emboj.2010.253; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Oral O, 2012, APOPTOSIS, V17, P810, DOI 10.1007/s10495-012-0735-0; Otera H, 2005, EMBO J, V24, P1375, DOI 10.1038/sj.emboj.7600614; Pallis AG, 2010, CANCER METAST REV, V29, P677, DOI 10.1007/s10555-010-9258-8; Paull TT, 2005, CELL CYCLE, V4, P737, DOI 10.4161/cc.4.6.1715; Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; Rebbaa A, 2003, ONCOGENE, V22, P2805, DOI 10.1038/sj.onc.1206366; Reinhardt HC, 2007, CANCER CELL, V11, P175, DOI 10.1016/j.ccr.2006.11.024; Rinaldo C, 2007, MOL CELL, V25, P739, DOI 10.1016/j.molcel.2007.02.008; Robert T, 2011, NATURE, V471, P74, DOI 10.1038/nature09803; Ruscetti T, 1998, J BIOL CHEM, V273, P14461, DOI 10.1074/jbc.273.23.14461; Samara C, 2008, CELL DEATH DIFFER, V15, P105, DOI 10.1038/sj.cdd.4402231; Saretzki G, 2010, CURR PHARM DESIGN, V16, P79, DOI 10.2174/138161210789941874; Sasaki M, 2010, LAB INVEST, V90, P835, DOI 10.1038/labinvest.2010.56; Sayan AE, 2008, ONCOGENE, V27, P4363, DOI 10.1038/onc.2008.64; Schmitt CA, 2002, CELL, V109, P335, DOI 10.1016/S0092-8674(02)00734-1; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Stuck M, 2004, DNA REPAIR, V3, P953, DOI 10.1016/j.dnarep.2004.03.007; Tasdemir E, 2008, NAT CELL BIOL, V10, P676, DOI 10.1038/ncb1730; Tinel A, 2004, SCIENCE, V304, P843, DOI 10.1126/science.1095432; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P555, DOI 10.1038/sj.cdd.4402286; Vakifahmetoglu H, 2008, CELL DEATH DIFFER, V15, P1153, DOI 10.1038/cdd.2008.47; Virag L, 1998, IMMUNOLOGY, V94, P345, DOI 10.1046/j.1365-2567.1998.00534.x; Vitale I, 2011, NAT REV MOL CELL BIO, V12, P384, DOI 10.1038/nrm3115; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang B, 2002, SCIENCE, V298, P1435, DOI 10.1126/science.1076182; Wang JYJ, 2004, ADV PROTEIN CHEM, V69, P101; Ward I, 2004, CURR TOP DEV BIOL, V63, P1, DOI 10.1016/S0070-2153(04)63001-8; Webley K, 2000, MOL CELL BIOL, V20, P2803, DOI 10.1128/MCB.20.8.2803-2808.2000; Yee KS, 2009, CELL DEATH DIFFER, V16, P1135, DOI 10.1038/cdd.2009.28; Young ARJ, 2009, GENE DEV, V23, P798, DOI 10.1101/gad.519709; Zeng XH, 2010, CELL RES, V20, P665, DOI 10.1038/cr.2010.40	72	190	194	1	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 15	2013	32	33					3789	3797		10.1038/onc.2012.556	http://dx.doi.org/10.1038/onc.2012.556			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	202JH	23208502				2022-12-28	WOS:000323210200001
J	Wormann, SM; Diakopoulos, KN; Lesina, M; Algul, H				Woermann, S. M.; Diakopoulos, K. N.; Lesina, M.; Alguel, H.			The immune network in pancreatic cancer development and progression	ONCOGENE			English	Review						pancreatic ductal adenocarcinoma; tumor microenvironment; immune system; cytokines; pattern recognition receptors; immune cells	REGULATORY T-CELLS; TUMOR-INFILTRATING LYMPHOCYTES; CIRCULATING DENDRITIC CELLS; KAPPA-B ACTIVATION; GROWTH-FACTOR-BETA; SUPPRESSOR-CELLS; MAST-CELLS; INFLAMMATORY CELLS; CARCINOMA-CELLS; MURINE MODEL	The presence of stromal desmoplasia is a hallmark of spontaneous pancreatic ductal adenocarcinoma, forming a unique microenvironment that comprises many cell types. Only recently, the immune system has entered the pathophysiology of pancreatic ductal adenocarcinoma development. Tumor cells in the pancreas seem to dysbalance the immune system, thus facilitating spontaneous cancer development. This review will try to assemble all relevant data to demonstrate the implications of the immune network on spontaneous cancer development.	[Woermann, S. M.; Diakopoulos, K. N.; Lesina, M.; Alguel, H.] Tech Univ Munich, Klinikum Rechts Isar, Med Klin, D-81675 Munich, Germany	Technical University of Munich	Algul, H (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Med Klin 2, D-81675 Munich, Germany.	hana.alguel@lrz.tum.de	Lesina, Marina/AAV-3845-2020	Algul, Hana/0000-0002-5067-7031; Diakopoulos, Kalliope/0000-0002-9236-0489				Ademmer K, 1998, CLIN EXP IMMUNOL, V112, P21; Algful H, 2007, NAT CLIN PRACT GASTR, V4, P454, DOI 10.1038/ncpgasthep0881; Allen SJ, 2007, ANNU REV IMMUNOL, V25, P787, DOI 10.1146/annurev.immunol.24.021605.090529; Andrianifahanana M, 2006, AM J GASTROENTEROL, V101, P2319, DOI 10.1111/j.1572-0241.2006.00871.x; Angst E, 2008, SURGERY, V144, P57, DOI 10.1016/j.surg.2008.03.024; Arlt A, 2002, CANCER RES, V62, P910; Ashida A, 2006, INT J ONCOL, V28, P1345; Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0; Balkwill FR, 2012, J PATHOL, V226, P148, DOI 10.1002/path.3029; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Bang S, 2006, PANCREAS, V32, P29, DOI 10.1097/01.mpa.0000191651.32420.41; Barber MD, 1999, CLIN SCI, V96, P83, DOI 10.1042/CS19980185; Bayne LJ, 2012, CANCER CELL, V21, P822, DOI 10.1016/j.ccr.2012.04.025; Beatty GL, 2011, SCIENCE, V331, P1612, DOI 10.1126/science.1198443; Bellone G, 1999, AM J PATHOL, V155, P537, DOI 10.1016/S0002-9440(10)65149-8; Bellone G, 2006, CANCER IMMUNOL IMMUN, V55, P684, DOI 10.1007/s00262-005-0047-0; Bellone G, 2006, J IMMUNOL, V177, P3448, DOI 10.4049/jimmunol.177.5.3448; Ben-Baruch A, 2006, SEMIN CANCER BIOL, V16, P38, DOI 10.1016/j.semcancer.2005.07.006; Benson DD, 2012, AM J PHYSIOL-REG I, V302, pR1067, DOI 10.1152/ajpregu.00320.2011; Berkovic MC, 2012, DNA CELL BIOL, V31, P531, DOI 10.1089/dna.2011.1317; Bharadwaj U, 2007, CANCER RES, V67, P5479, DOI 10.1158/0008-5472.CAN-06-3963; Borish Larry C., 2003, Journal of Allergy and Clinical Immunology, V111, pS460; Cai SW, 2011, SURGERY, V149, P576, DOI 10.1016/j.surg.2010.10.009; Chang DZ, 2011, CLIN CANCER RES, V17, P7015, DOI 10.1158/1078-0432.CCR-11-0607; Chen JG, 2011, INT J BIOL SCI, V7, P53, DOI 10.7150/ijbs.7.53; Chen LL, 2010, J IMMUNOL, V184, P2602, DOI 10.4049/jimmunol.0901593; Chen X, 2010, LUNG CANCER, V69, P348, DOI 10.1016/j.lungcan.2009.11.013; Chen Y, 2012, WORLD J GASTROENTERO, V18, P1123, DOI 10.3748/wjg.v18.i10.1123; Clark CE, 2007, CANCER RES, V67, P9518, DOI 10.1158/0008-5472.CAN-07-0175; Clark E J, 2007, HPB (Oxford), V9, P456, DOI 10.1080/13651820701774891; Cui K, 2011, J SURG RES, V171, P143, DOI 10.1016/j.jss.2010.03.001; Curiel TJ, 2004, NAT MED, V10, P942, DOI 10.1038/nm1093; Dallal RM, 2002, SURGERY, V131, P135, DOI 10.1067/msy.2002.119937; De Monte L, 2011, J EXP MED, V208, P469, DOI 10.1084/jem.20101876; Du J, 2012, MED ONCOL, V29, P2814, DOI 10.1007/s12032-012-0175-2; Dunn GP, 2004, ANNU REV IMMUNOL, V22, P329, DOI 10.1146/annurev.immunol.22.012703.104803; Ebrahimi B, 2004, CANCER-AM CANCER SOC, V101, P2727, DOI 10.1002/cncr.20672; Elia AR, 2008, J LEUKOCYTE BIOL, V84, P1472, DOI 10.1189/jlb.0208082; Ellermeier J, 2013, CANCER RES, V73, P1709, DOI 10.1158/0008-5472.CAN-11-3850; Esposito I, 2004, J CLIN PATHOL, V57, P630, DOI 10.1136/jcp.2003.014498; Esposito I, 2002, LAB INVEST, V82, P1481, DOI 10.1097/01.LAB.0000036875.21209.F9; Evans A, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00270; Feurino LW, 2006, CANCER INVEST, V24, P696, DOI 10.1080/07357900600981398; Formentini A, 2009, INT J COLORECTAL DIS, V24, P57, DOI 10.1007/s00384-008-0550-9; Fortis C, 1996, CANCER LETT, V104, P1, DOI 10.1016/0304-3835(96)04213-9; Fridlender ZG, 2009, CANCER CELL, V16, P183, DOI 10.1016/j.ccr.2009.06.017; Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245; FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U; Fukuda A, 2011, CANCER CELL, V19, P441, DOI 10.1016/j.ccr.2011.03.002; Fukunaga A, 2004, PANCREAS, V28, pE26, DOI 10.1097/00006676-200401000-00023; Gabitass RF, 2011, CANCER IMMUNOL IMMUN, V60, P1419, DOI 10.1007/s00262-011-1028-0; Gabrilovich D, 2004, NAT REV IMMUNOL, V4, P941, DOI 10.1038/nri1498; Gabrilovich DI, 2012, NAT REV IMMUNOL, V12, P253, DOI 10.1038/nri3175; Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139; Garbe AI, 2006, CANCER RES, V66, P508, DOI 10.1158/0008-5472.CAN-05-2383; Geng L, 2008, J CANCER RES CLIN, V134, P1021, DOI 10.1007/s00432-008-0364-8; Ghiringhelli F, 2005, J EXP MED, V202, P919, DOI 10.1084/jem.20050463; Gnerlich JL, 2010, J IMMUNOL, V185, P4063, DOI 10.4049/jimmunol.0902609; Goedegebuure P, 2011, CURR CANCER DRUG TAR, V11, P734, DOI 10.2174/156800911796191024; Greten TF, 2011, INT IMMUNOPHARMACOL, V11, P802, DOI 10.1016/j.intimp.2011.01.003; Hamacher R, 2009, CYTOKINE, V46, P182, DOI 10.1016/j.cyto.2009.01.005; Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022; He DG, 2010, J IMMUNOL, V184, P2281, DOI 10.4049/jimmunol.0902574; He SB, 2011, INT J MOL SCI, V12, P7424, DOI 10.3390/ijms12117424; Herber DL, 2010, NAT MED, V16, P880, DOI 10.1038/nm.2172; Hidalgo M, 2010, NEW ENGL J MED, V362, P1605, DOI 10.1056/NEJMra0901557; Hill KS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040420; Hiraoka N, 2006, CLIN CANCER RES, V12, P5423, DOI 10.1158/1078-0432.CCR-06-0369; Hirooka S, 2011, ANTICANCER RES, V31, P3827; Hodges Kyle, 2012, Transl Gastrointest Cancer, V1, P138; Huang B, 2008, ONCOGENE, V27, P218, DOI 10.1038/sj.onc.1210904; Ijichi H, 2011, J CLIN INVEST, V121, P4106, DOI 10.1172/JCI42754; Ino Y, 2013, BRIT J CANCER, V108, P914, DOI 10.1038/bjc.2013.32; Kaisho T, 2002, INT IMMUNOL, V14, P695, DOI 10.1093/intimm/dxf039; Kang R, 2012, P NATL ACAD SCI USA, V109, P7031, DOI 10.1073/pnas.1113865109; Kapsenberg ML, 2003, NAT REV IMMUNOL, V3, P984, DOI 10.1038/nri1246; Kawai O, 2008, CANCER-AM CANCER SOC, V113, P1387, DOI 10.1002/cncr.23712; Kiefel H, 2010, ONCOGENE, V29, P4766, DOI 10.1038/onc.2010.230; Kim Ji Sung, 2012, Immune Netw, V12, P247, DOI 10.4110/in.2012.12.6.247; Kimsey TF, 2004, CANCER J, V10, P374, DOI 10.1097/00130404-200411000-00007; Kornmann M, 1999, ANTICANCER RES, V19, P125; Kulhankova K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043609; Kurahara H, 2011, J SURG RES, V167, pE211, DOI 10.1016/j.jss.2009.05.026; Kusuda T, 2005, ONCOL REP, V13, P1153; Lawrence T, 2011, NAT REV IMMUNOL, V11, P750, DOI 10.1038/nri3088; Lee BN, 2006, CANCER-AM CANCER SOC, V107, P999, DOI 10.1002/cncr.22092; Leffers N, 2009, CANCER IMMUNOL IMMUN, V58, P449, DOI 10.1007/s00262-008-0583-5; Lesina M, 2011, CANCER CELL, V19, P456, DOI 10.1016/j.ccr.2011.03.009; Li AH, 2011, AM J PATHOL, V178, P1340, DOI 10.1016/j.ajpath.2010.11.058; Ling JH, 2012, CANCER CELL, V21, P105, DOI 10.1016/j.ccr.2011.12.006; Liu YJ, 2007, ANNU REV IMMUNOL, V25, P193, DOI 10.1146/annurev.immunol.25.022106.141718; Lu TY, 2011, J CLIN INVEST, V121, P4015, DOI 10.1172/JCI45862; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Mahmoud SMA, 2011, J CLIN ONCOL, V29, P1949, DOI 10.1200/JCO.2010.30.5037; Maker AV, 2011, CLIN CANCER RES, V17, P1502, DOI 10.1158/1078-0432.CCR-10-1561; Makinoshima H, 2009, FEBS LETT, V583, P3697, DOI 10.1016/j.febslet.2009.10.061; Mancino A, 2008, BLOOD, V112, P3723, DOI 10.1182/blood-2008-02-142091; Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205; Marchesi F, 2008, CANCER RES, V68, P9060, DOI 10.1158/0008-5472.CAN-08-1810; Matsuo Y, 2009, J SURG RES, V153, P274, DOI 10.1016/j.jss.2008.04.040; Melisi D, 2009, MOL CANCER RES, V7, P624, DOI 10.1158/1541-7786.MCR-08-0201; Monti P, 2004, VIRCHOWS ARCH, V445, P236, DOI 10.1007/s00428-004-1053-x; Monti P, 2003, CANCER RES, V63, P7451; Moo-Young TA, 2009, J IMMUNOTHER, V32, P12, DOI 10.1097/CJI.0b013e318189f13c; Moses AGW, 2009, ONCOL REP, V21, P1091, DOI 10.3892/or_00000328; Mroczko B, 2010, J CLIN LAB ANAL, V24, P256, DOI 10.1002/jcla.20395; Muerkoster S, 2004, MED KLIN, V99, P185, DOI 10.1007/s00063-004-1027-4; Muerkoster S, 2004, CANCER RES, V64, P1331, DOI 10.1158/0008-5472.CAN-03-1860; Nakano O, 2001, CANCER RES, V61, P5132; NATHAN CF, 1983, J EXP MED, V158, P670, DOI 10.1084/jem.158.3.670; Nevala WK, 2009, CLIN CANCER RES, V15, P1931, DOI 10.1158/1078-0432.CCR-08-1980; Niu JG, 2004, J BIOL CHEM, V279, P16452, DOI 10.1074/jbc.M309789200; Norian LA, 2009, CANCER RES, V69, P3086, DOI 10.1158/0008-5472.CAN-08-2826; Ochi A, 2012, J CLIN INVEST, V122, P4118, DOI 10.1172/JCI63606; Ochi A, 2012, J EXP MED, V209, P1671, DOI 10.1084/jem.20111706; Okada S, 1998, JPN J CLIN ONCOL, V28, P12, DOI 10.1093/jjco/28.1.12; Okudaira K, 2007, MICROCIRCULATION, V14, P241, DOI 10.1080/10739680601139393; Ormandy LA, 2006, WORLD J GASTROENTERO, V12, P3275, DOI 10.3748/wjg.v12.i20.3275; Osawa E, 2006, INT J CANCER, V118, P2232, DOI 10.1002/ijc.21639; Pages F, 2009, J CLIN ONCOL, V27, P5944, DOI 10.1200/JCO.2008.19.6147; Perrot I, 2007, J IMMUNOL, V178, P2763, DOI 10.4049/jimmunol.178.5.2763; PIGNATELLI M, 1994, J PATHOL, V174, P243, DOI 10.1002/path.1711740403; Pilon-Thomas S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027729; Pinzon-Charry A, 2007, BRIT J CANCER, V97, P1251, DOI 10.1038/sj.bjc.6604018; Pinzon-Charry A, 2005, IMMUNOL CELL BIOL, V83, P451, DOI 10.1111/j.1440-1711.2005.01371.x; Poch B, 2007, LANGENBECK ARCH SURG, V392, P353, DOI 10.1007/s00423-006-0140-7; Porembka MR, 2012, CANCER IMMUNOL IMMUN, V61, P1373, DOI 10.1007/s00262-011-1178-0; Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024; Rakoff-Nahoum S, 2009, NAT REV CANCER, V9, P57, DOI 10.1038/nrc2541; Reid MD, 2011, MODERN PATHOL, V24, P1612, DOI 10.1038/modpathol.2011.113; Ruffell B, 2012, TRENDS IMMUNOL, V33, P119, DOI 10.1016/j.it.2011.12.001; Sakamoto H, 2012, JPN J CLIN ONCOL, V42, P105, DOI 10.1093/jjco/hyr178; Sato E, 2005, P NATL ACAD SCI USA, V102, P18538, DOI 10.1073/pnas.0509182102; Sawai H, 2006, BMC CELL BIOL, V7, DOI 10.1186/1471-2121-7-8; Sawai H, 2005, MED SCI MONITOR, V11, pBR343; Sawai H, 2003, ONCOLOGY-BASEL, V65, P167, DOI 10.1159/000072343; Sawai H, 2001, PANCREAS, V23, P399, DOI 10.1097/00006676-200111000-00011; Schmid MC, 2011, CANCER RES, V71, P6965, DOI 10.1158/0008-5472.CAN-11-0588; SCHREIBER RD, 1983, J IMMUNOL, V131, P826; Scola L, 2009, ANN NY ACAD SCI, V1155, P284, DOI 10.1111/j.1749-6632.2008.03686.x; Sgouroudis E, 2011, AUTOIMMUNITY, V44, P406, DOI 10.3109/08916934.2010.536795; Skinnider BF, 2001, BLOOD, V97, P250, DOI 10.1182/blood.V97.1.250; Smirne C, 1999, Minerva Gastroenterol Dietol, V45, P21; Smyth MJ, 2006, ADV IMMUNOL, V90, P1, DOI 10.1016/S0065-2776(06)90001-7; Soucek L, 2007, NAT MED, V13, P1211, DOI 10.1038/nm1649; Sperveslage J, 2012, INT J CANCER, V131, pE371, DOI 10.1002/ijc.26502; Steinman RM, 2003, PATHOL BIOL, V51, P59, DOI 10.1016/S0369-8114(03)00096-8; Strouch MJ, 2010, CLIN CANCER RES, V16, P2257, DOI 10.1158/1078-0432.CCR-09-1230; Talar-Wojnarowska R, 2009, NEOPLASMA, V56, P56, DOI 10.4149/neo_2009_01_56; Talar-Wojnarowska R, 2009, DIGEST DIS SCI, V54, P683, DOI 10.1007/s10620-008-0390-z; Tan MCB, 2009, J IMMUNOL, V182, P1746, DOI 10.4049/jimmunol.182.3.1746; Tang Rui-Fang, 2005, Hepatobiliary Pancreat Dis Int, V4, P460; Tassi E, 2008, J IMMUNOL, V181, P6595, DOI 10.4049/jimmunol.181.9.6595; Tassi E, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007234; Tatsumi T, 2002, J EXP MED, V196, P619, DOI 10.1084/jem.20012142; Tjomsland V, 2011, CLIN DEV IMMUNOL, DOI 10.1155/2011/212810; Tjomsland V, 2011, NEOPLASIA, V13, P664, DOI 10.1593/neo.11332; Tosolini M, 2011, CANCER RES, V71, P1263, DOI 10.1158/0008-5472.CAN-10-2907; Ubukata H, 2010, J SURG ONCOL, V102, P742, DOI 10.1002/jso.21725; Verma G, 2012, CANCER LETT, V320, P86, DOI 10.1016/j.canlet.2012.01.036; Vizio B, 2012, EXP THER MED, V4, P70, DOI 10.3892/etm.2012.553; von Bernstorff W, 2001, CLIN CANCER RES, V7, p925S; Wigmore SJ, 2002, INT J ONCOL, V21, P881; Wynn TA, 2004, NAT REV IMMUNOL, V4, P583, DOI 10.1038/nri1412; Xiao MJ, 2009, CANCER RES, V69, P2010, DOI 10.1158/0008-5472.CAN-08-3479; Xu DH, 2010, J SURG ONCOL, V102, P469, DOI 10.1002/jso.21530; Yamasaki A, 2010, CANCER IMMUNOL IMMUN, V59, P675, DOI 10.1007/s00262-009-0783-7; Yanagimoto H, 2005, CLIN IMMUNOL, V114, P52, DOI 10.1016/j.clim.2004.09.007; Yang MX, 2010, IMMUNOL CELL BIOL, V88, P165, DOI 10.1038/icb.2009.77; Yu X., 2012, TRANSL MED, V2, P105, DOI DOI 10.4172/2161-1025.1000105; Zhang B, 2008, BIOCHEM BIOPH RES CO, V374, P533, DOI 10.1016/j.bbrc.2008.07.060; Zhang DL, 2008, ANN CLIN LAB SCI, V38, P113; Zhang JP, 2009, J HEPATOL, V50, P980, DOI 10.1016/j.jhep.2008.12.033; Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177; Zhang QY, 2012, CANCER RES, V72, P2589, DOI 10.1158/0008-5472.CAN-11-3795; Zhang YL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-4; Zischek C, 2009, ANN SURG, V250, P747, DOI 10.1097/SLA.0b013e3181bd62d0; Zoglmeier C, 2011, CLIN CANCER RES, V17, P1765, DOI 10.1158/1078-0432.CCR-10-2672; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3	179	135	139	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2014	33	23					2956	2967		10.1038/onc.2013.257	http://dx.doi.org/10.1038/onc.2013.257			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EL	23851493				2022-12-28	WOS:000337232200002
J	Kale, S; Raja, R; Thorat, D; Soundararajan, G; Patil, TV; Kundu, GC				Kale, S.; Raja, R.; Thorat, D.; Soundararajan, G.; Patil, T. V.; Kundu, G. C.			Osteopontin signaling upregulates cyclooxygenase-2 expression in tumor-associated macrophages leading to enhanced angiogenesis and melanoma growth via alpha 9 beta 1 integrin	ONCOGENE			English	Article						osteopontin; tumor-associated macrophages; COX-2 and melanoma growth	BREAST-CANCER; ALPHA(V)BETA(3) INTEGRIN; CRUCIAL ROLE; INFILTRATION; METASTASIS; KINASE; PROGRESSION; INHIBITION; PROTEIN; M2	Tumor-associated macrophages (TAMs) have multifaceted roles in tumor development, particularly linked with tumor angiogenesis and invasion, but the molecular mechanism underlying this association remains unclear. In this study, we report that lack of osteopontin (OPN) suppresses melanoma growth in opn -/- mice and macrophages are the crucial component responsible for OPN-regulated melanoma growth. In tumor microenvironment, OPN activates macrophages and influences angiogenesis by enhancing cyclooxygenase-2 (COX-2)-dependent prostaglandin E-2 (PGE(2)) production in an autocrine manner. Furthermore, we identify alpha 9b1 integrin as a functional receptor for OPN that mediates its effect and activates ERK and p38 signaling, which ultimately leads to COX-2 expression in macrophages. The major role played by OPN and PGE(2) in angiogenesis are further amplified by upregulation of MMP-9. OPN-activated macrophages promote the migration of endothelial and cancer cells via PGE(2). These findings provide evidence that TAMs serve as source of key components such as OPN and COX-2-derived PGE(2) and MMP-9 in melanoma microenvironment. Clinical specimens analyses revealed that increased infiltration of OPN-positive TAMs correlate with melanoma growth and angiogenesis. These data provide compelling evidence that OPN and COX-2 expressing macrophages are obligatory factors in melanoma growth. We conclude that OPN signaling is involved in macrophage recruitment into tumor, and our results emphasize the potential role of macrophage in modulation of tumor microenvironment via secretion of OPN, PGE(2) and MMP-9, which trigger angiogenesis and melanoma growth. Thus, blockade of OPN and its regulated signaling network provides unique strategy to eradicate melanoma by manipulating TAMs.	[Kale, S.; Raja, R.; Thorat, D.; Soundararajan, G.; Kundu, G. C.] Natl Ctr Cell Sci, Lab Tumor Biol Angiogenesis & Nanomed Res, Pune 411007, Maharashtra, India; [Patil, T. V.] YCM Hosp, Dept Pathol, Pune, Maharashtra, India	Department of Biotechnology (DBT) India; National Centre for Cell Science, Pune (NCCS)	Kundu, GC (corresponding author), Natl Ctr Cell Sci, Lab Tumor Biol Angiogenesis & Nanomed Res, NCCS Complex, Pune 411007, Maharashtra, India.	kundu@nccs.res.in	Kundu, Gopal C./ABA-9897-2020; Raja, Remya/GXM-8598-2022	Raja, Remya/0000-0002-7576-6778	Department of Biotechnology (DBT), Government of India; Council of Scientific and Industrial Research (CSIR), Government of India; Indian Council of Medical Research (ICMR), Government of India; Department of Science and Technology (DST), Government of India	Department of Biotechnology (DBT), Government of India(Department of Biotechnology (DBT) India); Council of Scientific and Industrial Research (CSIR), Government of India(Council of Scientific & Industrial Research (CSIR) - India); Indian Council of Medical Research (ICMR), Government of India(Indian Council of Medical Research (ICMR)); Department of Science and Technology (DST), Government of India(Department of Science & Technology (India))	We thank Dr B Ramanamurthy, In-charge, Experimental Animal Facility, National Center for Cell Science, Pune, India for breeding and maintaining the Opn<SUP>-/-</SUP> mice. We also thank Dr S Ghaskabdi and Dr K Pai, Department of Zoology, University of Pune, India for providing the facility for CAM assay. Skillful assistance was provided by Dr S Vishwakarma, Department of Pathology, YCM Hospital, Pune, India for preparation of Cryosections. The project was supported by Department of Biotechnology (DBT) (GCK), Council of Scientific and Industrial Research (CSIR) (SK and GS), Indian Council of Medical Research (ICMR) (RR) and Department of Science and Technology (DST) (DT), Government of India.	Ahmed M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-101; Bachmann IM, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-362; BAXEVANIS CN, 1993, CANCER-AM CANCER SOC, V72, P491, DOI 10.1002/1097-0142(19930715)72:2<491::AID-CNCR2820720227>3.0.CO;2-1; Behera R, 2010, CARCINOGENESIS, V31, P192, DOI 10.1093/carcin/bgp289; Bhowmick NA, 2005, CURR OPIN GENET DEV, V15, P97, DOI 10.1016/j.gde.2004.12.003; Bianchini F, 2007, PROSTAG OTH LIPID M, V83, P320, DOI 10.1016/j.prostaglandins.2007.03.003; BROWN LF, 1994, AM J PATHOL, V145, P610; Chakraborty G, 2008, MOL MED REP, V1, P641, DOI 10.3892/mmr_00000005; Chakraborty G, 2008, CANCER RES, V68, P152, DOI 10.1158/0008-5472.CAN-07-2126; Cheng JS, 2007, CANCER RES, V67, P5141, DOI 10.1158/0008-5472.CAN-06-4763; Crawford HC, 1998, CANCER RES, V58, P5206; DENHARDT DT, 1993, FASEB J, V7, P1475, DOI 10.1096/fasebj.7.15.8262332; FENG B, 1995, CLIN EXP METASTAS, V13, P453, DOI 10.1007/BF00118184; Finetti F, 2009, CIRC RES, V105, P657, DOI 10.1161/CIRCRESAHA.109.203760; Fujimoto J, 2000, CANCER RES, V60, P2632; Gazzaniga S, 2007, J INVEST DERMATOL, V127, P2031, DOI 10.1038/sj.jid.5700827; Giraudo E, 2004, J CLIN INVEST, V114, P623, DOI 10.1172/JCI200422087; GORELIK E, 1982, INT J CANCER, V29, P575, DOI 10.1002/ijc.2910290514; Green CE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006713; Heusinkveld M, 2011, J IMMUNOL, V187, P1157, DOI 10.4049/jimmunol.1100889; Hsu HP, 2010, CANCER BIOL THER, V10, P144, DOI 10.4161/cbt.10.2.12160; Jain S, 2008, CANCER RES, V68, P7750, DOI 10.1158/0008-5472.CAN-07-6689; Jain S, 2006, CANCER RES, V66, P6638, DOI 10.1158/0008-5472.CAN-06-0661; Kumar V, 2010, CANCER RES, V70, P10381, DOI 10.1158/0008-5472.CAN-10-1470; Lazar-Molnar E, 2000, CYTOKINE, V12, P547, DOI 10.1006/cyto.1999.0614; Leek RD, 1996, CANCER RES, V56, P4625; LEWIS CE, 1995, J LEUKOCYTE BIOL, V57, P747, DOI 10.1002/jlb.57.5.747; Liguori Manuela, 2011, Cancers (Basel), V3, P3740, DOI 10.3390/cancers3043740; Lin EY, 2006, CANCER RES, V66, P11238, DOI 10.1158/0008-5472.CAN-06-1278; Lissbrant IF, 2000, INT J ONCOL, V17, P445; Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5; Mueller MM, 2004, NAT REV CANCER, V4, P839, DOI 10.1038/nrc1477; Nakanishi Y, 2011, CARCINOGENESIS, V32, P1333, DOI 10.1093/carcin/bgr128; Nakao S, 2005, J CLIN INVEST, V115, P2979, DOI 10.1172/JCI23298; NAYLOR MS, 1994, INT J CANCER, V58, P50, DOI 10.1002/ijc.2910580110; Nemoto H, 2001, J BONE MINER RES, V16, P652, DOI 10.1359/jbmr.2001.16.4.652; Nesbit M, 2001, J IMMUNOL, V166, P6483, DOI 10.4049/jimmunol.166.11.6483; Nikkola J, 2005, CLIN CANCER RES, V11, P5158, DOI 10.1158/1078-0432.CCR-04-2478; Nishie A, 1999, CLIN CANCER RES, V5, P1107; Ojalvo LS, 2009, AM J PATHOL, V174, P1048, DOI 10.2353/ajpath.2009.080676; Panda D, 1997, P NATL ACAD SCI USA, V94, P9308, DOI 10.1073/pnas.94.17.9308; Rangaswami H, 2006, TRENDS CELL BIOL, V16, P79, DOI 10.1016/j.tcb.2005.12.005; Rangaswami H, 2004, J BIOL CHEM, V279, P38921, DOI 10.1074/jbc.M404674200; Rhodes DR, 2007, NEOPLASIA, V9, P166, DOI 10.1593/neo.07112; Salvesen HB, 1999, INT J CANCER, V84, P539; Sharma P, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-178; Shin Hun Sub, 2004, Korean Journal of Internal Medicine, V19, P48; Solinas G, 2010, J IMMUNOL, V185, P642, DOI 10.4049/jimmunol.1000413; Torisu H, 2000, INT J CANCER, V85, P182, DOI 10.1002/(SICI)1097-0215(20000115)85:2<182::AID-IJC6>3.3.CO;2-D; Vosseler S, 2005, CANCER RES, V65, P1294, DOI 10.1158/0008-5472.CAN-03-3986; Wang S, 2006, J BIOL CHEM, V281, P9439, DOI 10.1074/jbc.M504977200; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509	52	79	81	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2014	33	18					2295	2306		10.1038/onc.2013.184	http://dx.doi.org/10.1038/onc.2013.184			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AG5ID	23728342				2022-12-28	WOS:000335451800003
J	Bossuyt, W; Chen, CL; Chen, Q; Sudol, M; McNeill, H; Pan, D; Kopp, A; Halder, G				Bossuyt, W.; Chen, C-L; Chen, Q.; Sudol, M.; McNeill, H.; Pan, D.; Kopp, A.; Halder, G.			An evolutionary shift in the regulation of the Hippo pathway between mice and flies	ONCOGENE			English	Article						Hippo signaling; evolution; Fat; Dachs; Angiomotin; Yap	PLANAR CELL POLARITY; ORGAN SIZE CONTROL; TUMOR-SUPPRESSOR PATHWAY; NUCLEAR-LOCALIZATION; PROTOCADHERINS FAT; SIGNALING-PATHWAY; CRUMBS COMPLEX; YAP PATHWAY; WW DOMAIN; DROSOPHILA	The Hippo pathway plays a key role in controlling organ growth in many animal species and its deregulation is associated with different types of cancer. Understanding the regulation of the Hippo pathway and discovering upstream regulators is thus a major quest. Interestingly, while the core of the Hippo pathway contains a highly conserved kinase cascade, different components have been identified as upstream regulators in Drosophila and vertebrates. However, whether the regulation of the Hippo pathway is indeed different between Drosophila and vertebrates or whether these differences are due to our limited analysis of these components in different organisms is not known. Here we show that the mouse Fat4 cadherin, the ortholog of the Hippo pathway regulator Fat in Drosophila, does not apparently regulate the Hippo pathway in the murine liver. In fact, we uncovered an evolutionary shift in many of the known upstream regulators at the base of the arthropod lineage. In this evolutionary transition, Fat and the adaptor protein Expanded gained novel domains that connected them to the Hippo pathway, whereas the cell-adhesion receptor Echinoid evolved as a new protein. Subsequently, the junctional adaptor protein Angiomotin (Amot) was lost and the downstream effector Yap lost its PDZ-binding motif that interacts with cell junction proteins. We conclude that fundamental differences exist in the upstream regulatory mechanisms of Hippo signaling between Drosophila and vertebrates.	[Bossuyt, W.; Halder, G.] VIB, Ctr Biol Dis, Louvain, Belgium; [Bossuyt, W.; Halder, G.] Kuleuven, Ctr Human Genet, Louvain, Belgium; [Bossuyt, W.; Chen, C-L; Halder, G.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA; [Chen, Q.; Pan, D.] Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biol & Genet, Baltimore, MD 21205 USA; [Sudol, M.] Weis Ctr Res, Geisinger Clin, Lab Signal Transduct, Weis Ctr Res, Danville, PA 17822 USA; [McNeill, H.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; [Kopp, A.] Univ Calif Davis, Dept Ecol & Evolut, Davis, CA 95616 USA	Flanders Institute for Biotechnology (VIB); KU Leuven; University of Texas System; UTMD Anderson Cancer Center; Howard Hughes Medical Institute; Johns Hopkins University; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of California System; University of California Davis	Halder, G (corresponding author), Katholieke Univ Leuven VIB, Ctr Human Genet, Herestr 49,Box 602, B-3000 Louvain, Belgium.	georg.halder@vib.be	McNeill, Helen/E-4579-2013; Halder, Georg/F-2966-2015	McNeill, Helen/0000-0003-1126-5154; Halder, Georg/0000-0001-7580-3236	Department of Defense [NF093145, BC093902]; National Institute of Health [GM067997]; NATIONAL CANCER INSTITUTE [P30CA006973] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067997] Funding Source: NIH RePORTER	Department of Defense(United States Department of Defense); National Institute of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We are grateful to Drs Alfred Handler, Giuliano Gasperi and Stephen Richards of the Medfly Whole Genome Sequencing Consortium for providing the draft genome sequence of Ceratitis capitata. We thank Lisa McCord for assistance with graphical representation, and also Dr Ryan Udan, Dr Maria Willecke and Chunyao Tao for help in performing the screen, experimental input and valuable discussions. This study was supported in part by grants from Department of Defense (NF093145 to DP) and from the National Institute of Health (GM067997 to GH). QC is a recipient of a Breast Cancer Research Postdoctoral Fellowship from the Department of Defense (BC093902). DP is an investigator of the Howard Hughes Medical Institute.	Ambegaonkar AA, 2012, CURR BIOL, V22, P1302, DOI 10.1016/j.cub.2012.05.049; Angus L, 2012, ONCOGENE, V31, P238, DOI 10.1038/onc.2011.224; Avruch J, 2011, BRIT J CANCER, V104, P24, DOI 10.1038/sj.bjc.6606011; Badouel C, 2009, DEV CELL, V16, P411, DOI 10.1016/j.devcel.2009.01.010; Baumgartner R, 2010, DEV CELL, V18, P309, DOI 10.1016/j.devcel.2009.12.013; Benhamouche S, 2010, GENE DEV, V24, P1718, DOI 10.1101/gad.1938710; Bennett FC, 2006, CURR BIOL, V16, P2101, DOI 10.1016/j.cub.2006.09.045; Bischof J, 2007, P NATL ACAD SCI USA, V104, P3312, DOI 10.1073/pnas.0611511104; BOEDIGHEIMER M, 1993, DEVELOPMENT, V118, P1291; Boedigheimer MJ, 1997, DEV GENET, V20, P103, DOI 10.1002/(SICI)1520-6408(1997)20:2<103::AID-DVG3>3.0.CO;2-B; Boggiano JC, 2012, DEV CELL, V22, P695, DOI 10.1016/j.devcel.2012.03.013; Bosveld F, 2012, SCIENCE, V336, P724, DOI 10.1126/science.1221071; Brittle A, 2012, CURR BIOL, V22, P907, DOI 10.1016/j.cub.2012.03.053; Bu X, 2005, ONCOGENE, V24, P2398, DOI 10.1038/sj.onc.1208466; Bulgakova NA, 2009, J CELL SCI, V122, P2587, DOI 10.1242/jcs.023648; BURGLIN TR, 1991, CELL, V66, P11, DOI 10.1016/0092-8674(91)90132-I; Castillejo-Lopez C, 2004, J BIOL CHEM, V279, P24034, DOI 10.1074/jbc.M313878200; Chan SW, 2011, J BIOL CHEM, V286, P7018, DOI 10.1074/jbc.C110.212621; Chen CL, 2010, P NATL ACAD SCI USA, V107, P15810, DOI 10.1073/pnas.1004060107; Chen HI, 1997, J BIOL CHEM, V272, P17070, DOI 10.1074/jbc.272.27.17070; Cho E, 2004, DEVELOPMENT, V131, P4489, DOI 10.1242/dev.01315; Cho E, 2006, NAT GENET, V38, P1142, DOI 10.1038/ng1887; Enomoto M, 2013, EMBO REP, V14, P65, DOI 10.1038/embor.2012.185; Ernkvist M, 2006, FEBS J, V273, P2000, DOI 10.1111/j.1742-4658.2006.05216.x; Gaffney CJ, 2012, GENE, V509, P215, DOI 10.1016/j.gene.2012.08.025; Genevet A, 2011, BIOCHEM J, V436, P213, DOI 10.1042/BJ20110217; Genevet A, 2010, DEV CELL, V18, P300, DOI 10.1016/j.devcel.2009.12.011; Grzeschik NA, 2010, CELL CYCLE, V9, P3202, DOI 10.4161/cc.9.16.12633; Grzeschik NA, 2010, CURR BIOL, V20, P573, DOI 10.1016/j.cub.2010.01.055; Halder G, 2011, DEVELOPMENT, V138, P9, DOI 10.1242/dev.045500; Hamaratoglu F, 2006, NAT CELL BIOL, V8, P27, DOI 10.1038/ncb1339; Heallen T, 2011, SCIENCE, V332, P458, DOI 10.1126/science.1199010; Hilman D, 2011, MOL BIOL EVOL, V28, P2403, DOI 10.1093/molbev/msr065; Humbert PO, 2008, ONCOGENE, V27, P6888, DOI 10.1038/onc.2008.341; Ishiuchi T, 2009, J CELL BIOL, V185, P959, DOI 10.1083/jcb.200811030; Jaramillo BE, 2004, EXP CELL RES, V297, P247, DOI 10.1016/j.yexcr.2004.03.021; Kango-Singh M, 2002, DEVELOPMENT, V129, P5719, DOI 10.1242/dev.00168; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kim NG, 2011, P NATL ACAD SCI USA, V108, P11930, DOI 10.1073/pnas.1103345108; Langer EM, 2008, DEV CELL, V14, P424, DOI 10.1016/j.devcel.2008.01.005; Lawrence PA, 2008, NAT CELL BIOL, V10, P1379, DOI 10.1038/ncb1208-1379; Lee KP, 2010, P NATL ACAD SCI USA, V107, P8248, DOI 10.1073/pnas.0912203107; Leys SP, 2012, J EXP ZOOL PART B, V318B, P438, DOI 10.1002/jez.b.21442; Ling C, 2010, P NATL ACAD SCI USA, V107, P10532, DOI 10.1073/pnas.1004279107; Liu CY, 2010, J BIOL CHEM, V285, P37159, DOI 10.1074/jbc.M110.152942; Liu KC, 2012, MOL BIOL CELL, V23, P1675, DOI 10.1091/mbc.E11-04-0358; Liu-Chittenden Y, 2012, GENE DEV, V26, P1300, DOI 10.1101/gad.192856.112; Lu L, 2010, P NATL ACAD SCI USA, V107, P1437, DOI 10.1073/pnas.0911427107; MacDougall N, 2001, DEVELOPMENT, V128, P665; Mao YL, 2011, GENE DEV, V25, P131, DOI 10.1101/gad.610511; Mao YP, 2006, DEVELOPMENT, V133, P2539, DOI 10.1242/dev.02427; Mao YP, 2011, DEVELOPMENT, V138, P947, DOI 10.1242/dev.057166; Marie H, 2003, J BIOL CHEM, V278, P1220, DOI 10.1074/jbc.M205391200; Matakatsu H, 2008, CURR BIOL, V18, P1390, DOI 10.1016/j.cub.2008.07.067; Matakatsu H, 2006, DEVELOPMENT, V133, P2315, DOI 10.1242/dev.02401; Matakatsu H, 2012, DEVELOPMENT, V139, P1498, DOI 10.1242/dev.070367; Mauviel A, 2012, ONCOGENE, V31, P1743, DOI 10.1038/onc.2011.363; McCartney BM, 2000, DEVELOPMENT, V127, P1315; Menendez J, 2010, P NATL ACAD SCI USA, V107, P14651, DOI 10.1073/pnas.1009376107; Milton CC, 2010, DEVELOPMENT, V137, P735, DOI 10.1242/dev.042309; Muller HAJ, 2003, MECH DEVELOP, V120, P1231, DOI 10.1016/j.mod.2003.06.001; Muramatsu T, 2011, CARCINOGENESIS, V32, P389, DOI 10.1093/carcin/bgq254; Oh H, 2009, DEV BIOL, V335, P188, DOI 10.1016/j.ydbio.2009.08.026; Oh S, 2009, MOL CELL BIOL, V29, P6309, DOI 10.1128/MCB.00551-09; Oka T, 2012, ONCOGENE, V31, P128, DOI 10.1038/onc.2011.216; Oka T, 2010, BIOCHEM J, V432, P461, DOI 10.1042/BJ20100870; Oka T, 2009, GENES CELLS, V14, P607, DOI 10.1111/j.1365-2443.2009.01292.x; Pan DJ, 2010, DEV CELL, V19, P491, DOI 10.1016/j.devcel.2010.09.011; Parsons LM, 2010, FLY, V4, P288, DOI 10.4161/fly.4.4.13116; Pellock BJ, 2007, DEV BIOL, V304, P102, DOI 10.1016/j.ydbio.2006.12.021; Polesello C, 2007, CURR BIOL, V17, P1864, DOI 10.1016/j.cub.2007.09.049; Reddy BVVG, 2008, DEVELOPMENT, V135, P2827, DOI 10.1242/dev.020974; Remue E, 2010, FEBS LETT, V584, P4175, DOI 10.1016/j.febslet.2010.09.020; Robinson BS, 2010, CURR BIOL, V20, P582, DOI 10.1016/j.cub.2010.03.019; Rogulja D, 2008, DEV CELL, V15, P309, DOI 10.1016/j.devcel.2008.06.003; Saburi S, 2008, NAT GENET, V40, P1010, DOI 10.1038/ng.179; Schlegelmilch K, 2011, CELL, V144, P782, DOI 10.1016/j.cell.2011.02.031; Sebe-Pedros A, 2012, CELL REP, V1, P13, DOI 10.1016/j.celrep.2011.11.004; Silva E, 2006, CURR BIOL, V16, P2081, DOI 10.1016/j.cub.2006.09.004; Silvis MR, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001823; Song H, 2010, P NATL ACAD SCI USA, V107, P1431, DOI 10.1073/pnas.0911409107; Sopko R, 2009, CURR OPIN CELL BIOL, V21, P717, DOI 10.1016/j.ceb.2009.07.001; Sudol M, 2010, TRENDS BIOCHEM SCI, V35, P627, DOI 10.1016/j.tibs.2010.05.010; Toyoshima F, 2007, EMBO J, V26, P1487, DOI 10.1038/sj.emboj.7601599; Tyler DM, 2007, DEV BIOL, V305, P187, DOI 10.1016/j.ydbio.2007.02.004; Van Hateren NJ, 2011, DEVELOPMENT, V138, P1893, DOI 10.1242/dev.064204; Varelas X, 2010, DEV CELL, V19, P831, DOI 10.1016/j.devcel.2010.11.012; Viktorinova I, 2009, DEVELOPMENT, V136, P4123, DOI 10.1242/dev.039099; Visser-Grieve S, 2012, ONCOGENE, V31, P1189, DOI 10.1038/onc.2011.318; Wang WQ, 2011, J BIOL CHEM, V286, P4364, DOI 10.1074/jbc.C110.205401; Webb C, 2011, BIOCHEMISTRY-US, V50, P3300, DOI 10.1021/bi2001888; Weber KL, 2004, NATURE, V431, P325, DOI 10.1038/nature02834; Willecke M, 2006, CURR BIOL, V16, P2090, DOI 10.1016/j.cub.2006.09.005; Yu FX, 2012, CELL, V150, P780, DOI 10.1016/j.cell.2012.06.037; Yu JZ, 2010, DEV CELL, V18, P288, DOI 10.1016/j.devcel.2009.12.012; Yue T, 2012, DEV CELL, V22, P255, DOI 10.1016/j.devcel.2011.12.011; Zhang HQ, 2004, NAT CELL BIOL, V6, P523, DOI 10.1038/ncb1136; Zhang NL, 2010, DEV CELL, V19, P27, DOI 10.1016/j.devcel.2010.06.015; Zhao B, 2011, GENE DEV, V25, P51, DOI 10.1101/gad.2000111; Zhao B, 2010, GENE DEV, V24, P862, DOI 10.1101/gad.1909210; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zhou DW, 2009, CANCER CELL, V16, P425, DOI 10.1016/j.ccr.2009.09.026; Ziosi M, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001140	103	78	79	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2014	33	10					1218	1228		10.1038/onc.2013.82	http://dx.doi.org/10.1038/onc.2013.82			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AC6KI	23563179	Green Accepted			2022-12-28	WOS:000332631100002
J	Oh, ET; Park, MT; Song, MJ; Lee, H; Cho, YU; Kim, SJ; Chu, YC; Choi, EK; Park, HJ				Oh, E-T; Park, M-T; Song, M-J; Lee, H.; Cho, Y. U.; Kim, S. J.; Chu, Y-C; Choi, E. K.; Park, H. J.			Radiation-induced angiogenic signaling pathway in endothelial cells obtained from normal and cancer tissue of human breast	ONCOGENE			English	Article						angiogenesis; cancer endothelial cells; ionizing radiation	MATRIX METALLOPROTEINASE-2 EXPRESSION; IONIZING-RADIATION; TUMOR-GROWTH; IN-VITRO; INTERLEUKIN-6 EXPRESSION; GENE-EXPRESSION; C-JUN; ANGIOSTATIN; RADIOSENSITIVITY; INHIBITOR	Despite strong possibility that endothelial cells (ECs) of tumors and normal tissues may differ in various aspects, most previous studies on ECs have used normal cells. Here, we purified ECs from tumorous and normal human breast tissues, and studied the effect of radiation on angiogenesis and relevant molecular mechanisms in these cells. We found that in normal tissue-derived ECs (NECs), 4 Gy irradiation increased tube formation, matrix metalloproteinase 2 (MMP-2) expression and extracellular signal-regulated kinase (ERK) pathway activation. In cancer-derived ECs (CECs), however, 4Gy irradiation significantly reduced tube formation, increased the production of angiostatin and interleukin-6 (IL-6), and upregulated AKT and c-Jun N-terminal kinase (JNK) pathway activation. Knockdown experiments showed that siMMP-2 efficiently inhibited tube formation by irradiated NECs, whereas siPlasminogen effectively attenuated the radiation-induced suppression of tube formation and the upregulation of angiostatin in CECs. Moreover, silL-6 clearly inhibited the radiation-induced generation of angiostatin in CECs. Inhibition of ERK with a pharmacological inhibitor or small interfering RNAs (siRNAs) markedly suppressed the radiation-induced tube formation and MMP-2 upregulation in NECs, whereas the inhibition of either AKT or JNK with pharmacological inhibitor or siRNA treatment of CECs markedly attenuated the inhibition of tube formation and the upregulation of angiostatin and IL-6 caused by 4 Gy irradiation. These observations collectively demonstrate that there are distinct differences in the radiation responses of NECs and CECs, and might provide important clues for improving the efficacy of radiation therapy.	[Oh, E-T; Park, M-T; Song, M-J; Lee, H.; Park, H. J.] Inha Univ, Coll Med, Dept Microbiol, Ctr Adv Med Educ,Project BK21, Inchon 400712, South Korea; [Cho, Y. U.; Kim, S. J.] Inha Univ, Coll Med, Dept Surg, Inchon 400712, South Korea; [Chu, Y-C] Inha Univ, Coll Med, Dept Pathol, Inchon 400712, South Korea; [Choi, E. K.] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiat Oncol, Seoul, South Korea	Inha University; Inha University; Inha University; University of Ulsan; Asan Medical Center	Park, HJ (corresponding author), Inha Univ, Coll Med, Dept Microbiol, Jungsuck B-D B Dong 3F,7-241,3rd St, Inchon 400712, South Korea.	park001@inha.ac.kr			National Nuclear R&D Program through the National Research Foundation of Korea (NRF); Ministry of Education, Science and Technology [2011-0015230, 2009-0093747]; Korean Health Technology R&D Project, Ministry of Health and Welfare [A062254]	National Nuclear R&D Program through the National Research Foundation of Korea (NRF)(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea); Korean Health Technology R&D Project, Ministry of Health and Welfare	This research was supported by the National Nuclear R&D Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2011-0015230 and 2009-0093747), and by a grant of the Korean Health Technology R&D Project, Ministry of Health and Welfare (A062254).	Adya R, 2008, CARDIOVASC RES, V78, P356, DOI 10.1093/cvr/cvm111; Ahmad M, 2007, MICROVASC RES, V73, P14, DOI 10.1016/j.mvr.2006.08.005; Badiga AV, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020614; Bannach FG, 2004, J THROMB HAEMOST, V2, P2205, DOI 10.1111/j.1538-7836.2004.01022.x; Barcellos-Hoff MH, 2005, NAT REV CANCER, V5, P867, DOI 10.1038/nrc1735; Brown M, 2003, SCIENCE, V302; Burwick NR, 2005, J BIOL CHEM, V280, P1740, DOI 10.1074/jbc.M405947200; Bussink J, 2008, LANCET ONCOL, V9, P288, DOI 10.1016/S1470-2045(08)70073-1; Chan DA, 2007, CANCER METAST REV, V26, P333, DOI 10.1007/s10555-007-9063-1; Chen FH, 2011, INT J RADIAT ONCOL, V80, P1512, DOI 10.1016/j.ijrobp.2011.02.055; Chou CH, 2009, INT J RADIAT ONCOL, V75, P1553, DOI 10.1016/j.ijrobp.2009.08.034; Creemers EEJM, 2001, CIRC RES, V89, P201, DOI 10.1161/hh1501.094396; Djonov V, 2002, INT J ONCOL, V21, P25; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Fee D, 2000, CYTOKINE, V12, P655, DOI 10.1006/cyto.1999.0599; Fokas E, 2012, CANCER METAST REV, V31, P823, DOI 10.1007/s10555-012-9394-4; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Garcia-Barros M, 2003, SCIENCE, V300, P1155, DOI 10.1126/science.1082504; Gerweck LE, 2006, CANCER RES, V66, P8352, DOI 10.1158/0008-5472.CAN-06-0533; Gorski DH, 1998, CANCER RES, V58, P5686; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Haimovitz-Fredman A., 1995, RADIAT ONCOL INVEST, V3, P1; Hatzi E, 2002, ONCOGENE, V21, P3552, DOI 10.1038/sj.onc.1205440; Hida K, 2004, CANCER RES, V64, P8249, DOI 10.1158/0008-5472.CAN-04-1567; Hida K, 2008, CANCER SCI, V99, P459, DOI 10.1111/j.1349-7006.2007.00704.x; Ji WDR, 1998, FASEB J, V12, P1731, DOI 10.1096/fasebj.12.15.1731; Karar J, 2009, CANCER BIOL THER, V8, P1994, DOI 10.4161/cbt.8.21.9988; Kim KH, 2011, IMMUNE NETW, V11, P123, DOI DOI 10.4110/IN.2011.11.2.123; Konerding MA, 2001, BRIT J CANCER, V84, P1354, DOI 10.1054/bjoc.2001.1809; Lin HY, 2011, J CELL PHYSIOL, V226, P1573, DOI 10.1002/jcp.22489; Lunt SJ, 2009, CLIN EXP METASTAS, V26, P19, DOI 10.1007/s10585-008-9182-2; Milliat F, 2006, AM J PATHOL, V169, P1484, DOI 10.2353/ajpath.2006.060116; Moeller BJ, 2004, CANCER CELL, V5, P429, DOI 10.1016/S1535-6108(04)00115-1; Nguyen V, 2000, RADIAT RES, V154, P531, DOI 10.1667/0033-7587(2000)154[0531:LEOIRO]2.0.CO;2; Nilsson MB, 2005, CANCER RES, V65, P10794, DOI 10.1158/0008-5472.CAN-05-0623; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Pang XF, 2009, CANCER RES, V69, P5893, DOI 10.1158/0008-5472.CAN-09-0755; Park HJ, 2012, RADIAT RES, V177, P311, DOI 10.1667/RR2773.1; Park HJ, 2003, RADIAT RES, V159, P86, DOI 10.1667/0033-7587(2003)159[0086:IOEPOG]2.0.CO;2; Park MT, 2012, J RADIAT RES, V53, P570, DOI 10.1093/jrr/rrs011; Park MT, 2012, MICROVASC RES, V84, P140, DOI 10.1016/j.mvr.2012.06.002; Ribatti D, 2009, LEUKEMIA RES, V33, P638, DOI 10.1016/j.leukres.2008.11.019; Shao ZL, 2006, CIRC RES, V98, P111, DOI 10.1161/01.RES.0000197781.20524.b9; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; Skuli N, 2009, CANCER RES, V69, P3308, DOI 10.1158/0008-5472.CAN-08-2158; Soff GA, 2000, CANCER METAST REV, V19, P97, DOI 10.1023/A:1026525121027; Song CW, 1971, CANCER RES, V4, P31; St Croix B, 2000, SCIENCE, V289, P1197; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Sweeney NV, 2004, CARDIOVASC RES, V63, P625, DOI 10.1016/j.cardiores.2004.05.008; Truman JP, 2010, PLOS ONE, V5, DOI [10.1371/annotation/6e222ad5-b175-4a00-9d04-4d120568a897, 10.1371/journal.pone.0012310]; Vala IS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011222; VanderMeeren A, 1997, MEDIAT INFLAMM, V6, P185, DOI 10.1080/09629359791677; Verhoeff JJC, 2009, EUR J CANCER, V45, P3074, DOI 10.1016/j.ejca.2009.08.004; Vincenti S, 2007, MICROVASC RES, V73, P14; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Vorotnikova E, 2004, RADIAT RES, V161, P174, DOI 10.1667/RR3107; Wei JW, 2007, ANTICANCER RES, V27, P1415; Wu WT, 2005, ENDOCRINOLOGY, V146, P3387, DOI 10.1210/en.2004-1654; Zhao WL, 2004, RADIAT RES, V161, P418, DOI 10.1667/3155	61	25	26	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2014	33	10					1229	1238		10.1038/onc.2013.70	http://dx.doi.org/10.1038/onc.2013.70			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AC6KI	23503466				2022-12-28	WOS:000332631100003
J	Lu, D; Han, C; Wu, T				Lu, D.; Han, C.; Wu, T.			15-PGDH inhibits hepatocellular carcinoma growth through 15-keto-PGE(2)/PPAR gamma-mediated activation of p21(WAF1/Cip1)	ONCOGENE			English	Article						hepatocellular carcinoma (HCC); 15-hydroxyprostaglandin dehydrogenase (15-PGDH); 15-keto-PGE(2); p21; PPAR gamma; liver	15-HYDROXYPROSTAGLANDIN DEHYDROGENASE EXPRESSION; PCNA BINDING DOMAINS; COLORECTAL-CANCER; TUMOR-SUPPRESSOR; LUNG-CANCER; GASTRIC-CANCER; RENAL-FUNCTION; BETA-CATENIN; FATTY-ACIDS; PPAR-GAMMA	15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is a key enzyme in prostaglandin (PG) metabolism. This study provides important evidence for inhibition of hepatocellular carcinoma (HCC) growth by 15-PGDH through the 15-keto-prostaglandin E-2 (15-keto-PGE(2))/peroxisome proliferator-activated receptor-gamma (PPAR gamma)/p21(WAF1/Cip1) signaling pathway. Forced overexpression of 15-PGDH inhibited HCC cell growth in vitro, whereas knockdown of 15-PGDH enhanced tumor growth parameters. In a tumor xenograft model in severe combined immunodeficiency mice, inoculation of human HCC cells (Huh7) with overexpression of 15-PGDH led to significant inhibition of tumor growth, whereas knockdown of 15-PGDH enhanced tumor growth. In a separate tumor xenograft model in which mouse HCC cells (Hepa1-6) were inoculated into syngeneic C57BL/6 mice, intratumoral injection of adenovirus vector expressing 15-PGDH (pAd-15-PGDH) significantly inhibited xenograft tumor growth. The antitumor effect of 15-PGDH is mediated through its enzymatic product, 15-keto-PGE(2), which serves as an endogenous PPAR gamma ligand. Activation of PPAR gamma by 15-PGDH-derived 15-keto-PGE(2) enhanced the association of PPAR gamma with the p21(WAF1/Cip1) promoter and increased p21 expression and association with cyclin-dependent kinase 2 (CDK2), CDK4 and proliferating cell nuclear antigen. Depletion of p21 by short hairpin RNA reversed 15-PGDH-induced inhibition of HCC cell growth; overexpression of p21 prevented 15-PGDH knockdown-induced tumor cell growth. These results show a key 15-PGDH/15-keto-PGE(2)-mediated activation of PPAR gamma and p21WAF1/Cip1 signaling cascade that regulates hepatocarcinogenesis and tumor progression.	[Lu, D.; Han, C.; Wu, T.] Tulane Univ, Sch Med, Dept Pathol, New Orleans, LA 70112 USA; [Lu, D.; Han, C.; Wu, T.] Tulane Univ, Sch Med, Lab Med, New Orleans, LA 70112 USA; [Lu, D.] Tongji Univ, Sch Life Sci & Technol, Shanghai 200092, Peoples R China	Tulane University; Tulane University; Tongji University	Wu, T (corresponding author), Tulane Univ, Sch Med, Dept Pathol, 1430 Tulane Ave,SL-79, New Orleans, LA 70112 USA.	twu@tulane.edu			National Institutes of Health [CA102325, CA106280, CA134568, DK077776]; NATIONAL CANCER INSTITUTE [R01CA134568, R01CA102325, R01CA106280] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK077776, R01DK077776] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	We thank Dr Hsin-Hsiung Tai at the University of Kentucky for providing the 15-PGDH-adenoviral vector. This work was supported by National Institutes of Health grants CA102325, CA106280, CA134568 and DK077776.	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Backlund MG, 2005, J BIOL CHEM, V280, P3217, DOI 10.1074/jbc.M411221200; Backlund MG, 2008, CANCER RES, V68, P9331, DOI 10.1158/0008-5472.CAN-08-2893; Baron JA, 2006, GASTROENTEROLOGY, V131, P1674, DOI 10.1053/j.gastro.2006.08.079; Bosch-Marce M, 1999, GASTROENTEROLOGY, V116, P1167, DOI 10.1016/S0016-5085(99)70020-X; Breinig M, 2007, CURR PHARM DESIGN, V13, P3305, DOI 10.2174/138161207782360627; Cervello M, 2006, WORLD J GASTROENTERO, V12, P5113; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Chou WL, 2007, J BIOL CHEM, V282, P18162, DOI 10.1074/jbc.M702289200; Claria J, 2005, HEPATOLOGY, V41, P579, DOI 10.1002/hep.20595; Couzin J, 2004, SCIENCE, V306, P1673, DOI 10.1126/science.306.5702.1673; Ding YF, 2005, CARCINOGENESIS, V26, P65, DOI 10.1093/carcin/bgh277; Dotto GP, 2000, BBA-REV CANCER, V1471, pM43, DOI 10.1016/S0304-419X(00)00019-6; El-Serag HB, 2012, GASTROENTEROLOGY, V142, P1264, DOI 10.1053/j.gastro.2011.12.061; El-Serag HB, 2011, NEW ENGL J MED, V365, P1118, DOI 10.1056/NEJMra1001683; Eruslanov E, 2009, J IMMUNOL, V182, P7548, DOI 10.4049/jimmunol.0802358; Farazi PA, 2006, NAT REV CANCER, V6, P674, DOI 10.1038/nrc1934; Frank B, 2011, CARCINOGENESIS, V32, P190, DOI 10.1093/carcin/bgq231; Grosser T, 2006, J CLIN INVEST, V116, P4, DOI 10.1172/JCI27291; Huang GS, 2008, CANCER RES, V68, P5040, DOI 10.1158/0008-5472.CAN-07-6575; Jung YS, 2010, CELL SIGNAL, V22, P1003, DOI 10.1016/j.cellsig.2010.01.013; Kaliberova LN, 2009, MOL CANCER THER, V8, P3130, DOI 10.1158/1535-7163.MCT-09-0270; Kawai M, 2010, NAT REV ENDOCRINOL, V6, P629, DOI 10.1038/nrendo.2010.155; Lim K, 2008, CANCER RES, V68, P553, DOI 10.1158/0008-5472.CAN-07-2295; Lim K, 2009, MOL CANCER THER, V8, P3046, DOI 10.1158/1535-7163.MCT-09-0551; Liu ZX, 2008, CARCINOGENESIS, V29, P1219, DOI 10.1093/carcin/bgm297; Llovet JM, 2008, HEPATOLOGY, V48, P1312, DOI 10.1002/hep.22506; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; Moore AE, 2009, CARCINOGENESIS, P30; Myung SJ, 2006, P NATL ACAD SCI USA, V103, P12098, DOI 10.1073/pnas.0603235103; Rousseau D, 1999, ONCOGENE, V18, P4313, DOI 10.1038/sj.onc.1202686; Starostina NG, 2012, TRENDS CELL BIOL, V22, P33, DOI 10.1016/j.tcb.2011.10.004; Tai HH, 2011, CANCER METAST REV, V30, P409, DOI 10.1007/s10555-011-9314-z; Tatsuwaki H, 2010, CANCER SCI, V101, P550, DOI 10.1111/j.1349-7006.2009.01390.x; Thiel A, 2009, CLIN CANCER RES, V15, P4572, DOI 10.1158/1078-0432.CCR-08-2518; Tong M, 2006, CARCINOGENESIS, V27, P2170, DOI 10.1093/carcin/bgl053; Tontonoz P, 2008, ANNU REV BIOCHEM, V77, P289, DOI 10.1146/annurev.biochem.77.061307.091829; Tseng-Rogenski S, 2010, AM J PATHOL, V176, P1462, DOI 10.2353/ajpath.2010.090875; Vanchieri C, 2004, J NATL CANCER I, V96, P1734, DOI 10.1093/jnci/96.23.1734; Wakimoto N, 2008, CANCER RES, V68, P6978, DOI 10.1158/0008-5472.CAN-07-5675; Wolf I, 2006, CANCER RES, V66, P7818, DOI 10.1158/0008-5472.CAN-05-4368; Wu T, 2006, CANCER TREAT REV, V32, P28, DOI 10.1016/j.ctrv.2005.10.004; Yan M, 2009, P NATL ACAD SCI USA, V106, P9409, DOI 10.1073/pnas.0902367106; Yang L, 2007, CANCER RES, V67, P5587, DOI 10.1158/0008-5472.CAN-06-2287	44	32	33	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 27	2014	33	9					1101	1112		10.1038/onc.2013.69	http://dx.doi.org/10.1038/onc.2013.69			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XT	23542179	Green Accepted			2022-12-28	WOS:000331933800004
J	DeWitt, J; Ochoa, V; Urschitz, J; Elston, M; Moisyadi, S; Nishi, R				DeWitt, J.; Ochoa, V.; Urschitz, J.; Elston, M.; Moisyadi, S.; Nishi, R.			Constitutively active TrkB confers an aggressive transformed phenotype to a neural crest-derived cell line	ONCOGENE			English	Article						neuroblastoma; neural crest; transformation; TrkB; MYCN	NEUROTROPHIC FACTOR ACTIVATION; PROTECTS NEUROBLASTOMA-CELLS; C-MET; UP-REGULATION; EXPRESSION; RECEPTOR; MYC; BDNF; OVEREXPRESSION; PROTOONCOGENE	Neuroblastoma arises from sympathoadrenal progenitors of the neural crest and expression of the neurotrophin receptor TrkB and its ligand, brain-derived neurotrophic factor (BDNF), is correlated with poor prognosis. Although activated TrkB signaling promotes a more aggressive phenotype in established neuroblastoma cell lines, whether TrkB signaling is sufficient to transform neural crest-derived cells has not been investigated. To address the role of TrkB signaling in malignant transformation, we removed two immunoglobulin-like domains from the extracellular domain of the full-length rat TrkB receptor to create a Delta IgTrkB that is constitutively active. In the pheochromocytoma-derived cell line PC12, Delta IgTrkB promotes differentiation by stimulating process outgrowth; however, in the rat neural crest-derived cell line NCM-1, Delta IgTrkB signaling produces a markedly transformed phenotype characterized by increased proliferation, anchorage-independent cell growth, anoikis resistance and matrix invasion. Furthermore, expression of Delta IgTrkB leads to the upregulation of many transcripts encoding cancer-associated genes including cyclind1, twist1 and hgf, as well as downregulation of tumor suppressors such as pten and rb1. In addition, Delta IgTrkB NCM-1 cells show a 21-fold increase in mRNA for MYCN, the most common genetic marker for a poor prognosis in neuroblastoma. When injected into NOD SCID mice, control GFP NCM-1 cells fail to grow whereas Delta IgTrkB NCM-1 cells form rapidly growing and invasive tumors necessitating euthanasia of all mice by 15 days post injection. In summary, these results indicate that activated TrkB signaling is sufficient to promote the formation of a highly malignant phenotype in neural crest-derived cells.	[DeWitt, J.; Ochoa, V.; Nishi, R.] Univ Vermont, Dept Anat & Neurobiol, Burlington, VT 05405 USA; [DeWitt, J.; Ochoa, V.; Nishi, R.] Univ Vermont, Neurosci Grad Program, Burlington, VT 05405 USA; [Urschitz, J.; Elston, M.; Moisyadi, S.] Univ Hawaii, John A Burns Sch Med, Depat Anat Biochem & Physiol, Honolulu, HI USA; [Moisyadi, S.] Manoa BioSci, Honolulu, HI USA	University of Vermont; University of Vermont; University of Hawaii System; University of Hawaii System; University of Hawaii Manoa	Nishi, R (corresponding author), Univ Vermont, Dept Anat & Neurobiol, HSRF 406,149 Beaumont Ave, Burlington, VT 05405 USA.	Rae.Nishi@med.uvm.edu			Alex's Lemonade Foundation [R21NS25788, P30RR032135, P30GM103498, 5P20RR024206, R01GM083158-01A1]; NATIONAL CENTER FOR RESEARCH RESOURCES [P30RR032135, P20RR024206] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P20GM103457, R01GM083158, P30GM103498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R21NS076969] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [U54MD007584] Funding Source: NIH RePORTER	Alex's Lemonade Foundation; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))	We would like to thank Felix Eckenstein, Andy McKenzie and Nourine Ahmed for technical assistance. We also thank Alan Howe for helpful comments on our manuscript and for assistance with the 'donut' assay. Portions of this work were performed in the DNA Analysis Facility at the Vermont Cancer Center and the Neuroscience COBRE Molecular Cellular Core at the University of Vermont. This work was funded by Alex's Lemonade Foundation (RN); R21NS25788 (RN); P30RR032135 (COBRE); P30GM103498 (COBRE); 5P20RR024206 (SM); and R01GM083158-01A1 (SM).	Arevalo JC, 2000, MOL CELL BIOL, V20, P5908, DOI 10.1128/MCB.20.16.5908-5916.2000; Brodeur GM, 2009, CLIN CANCER RES, V15, P3244, DOI 10.1158/1078-0432.CCR-08-1815; Brodeur GM, 1997, J NEURO-ONCOL, V31, P49, DOI 10.1023/A:1005729329526; Brodeur GM, 2003, NAT REV CANCER, V3, P203, DOI 10.1038/nrc1014; Chiarugi P, 2008, BIOCHEM PHARMACOL, V76, P1352, DOI 10.1016/j.bcp.2008.07.023; Cimmino F, 2009, ONCOGENE, V28, P2015, DOI 10.1038/onc.2009.70; De Bernardi B, 2005, CANCER LETT, V228, P283, DOI 10.1016/j.canlet.2005.01.053; De Bernardi B, 2001, J CLIN ONCOL, V19, P183, DOI 10.1200/JCO.2001.19.1.183; Douma S, 2004, NATURE, V430, P1034, DOI 10.1038/nature02765; Eggert A, 2002, CANCER RES, V62, P1802; Feldman JP, 2009, J APPL QUANT METHODS, V4, P455, DOI DOI 10.1111/J.2042-3306.2010.TB05629.X; FURUKAWA T, 1995, AM J PATHOL, V147, P889; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hecht M, 2005, CARCINOGENESIS, V26, P2105, DOI 10.1093/carcin/bgi192; Ho R, 2002, CANCER RES, V62, P6462; Huang YT, 2010, INT J ONCOL, V36, P1469, DOI 10.3892/ijo_00000633; Jaboin J, 2002, CANCER RES, V62, P6756; Jian Z, 1996, CELL SIGNAL, V8, P365, DOI 10.1016/0898-6568(96)00069-1; KAPLAN DR, 1991, NATURE, V350, P158, DOI 10.1038/350158a0; Kim CJ, 1999, AM J PATHOL, V155, P1661, DOI 10.1016/S0002-9440(10)65481-8; KLEIN R, 1991, CELL, V66, P395, DOI 10.1016/0092-8674(91)90628-C; Kupferman ME, 2010, ONCOGENE, V29, P2047, DOI 10.1038/onc.2009.486; Lengyel E, 2005, INT J CANCER, V113, P678, DOI 10.1002/ijc.20598; Li CW, 2012, CANCER RES, V72, P1290, DOI 10.1158/0008-5472.CAN-11-3123; LIU C, 1992, ONCOGENE, V7, P181; LO LC, 1991, DEV BIOL, V145, P139, DOI 10.1016/0012-1606(91)90220-W; LUGO TG, 1989, MOL CELL BIOL, V9, P1263, DOI 10.1128/MCB.9.3.1263; Maris JM, 2007, LANCET, V369, P2106, DOI 10.1016/S0140-6736(07)60983-0; MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0; MATSUMOTO K, 1995, CANCER RES, V55, P1798; McKenzie AJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026552; Miller FD, 2001, CELL MOL LIFE SCI, V58, P1045, DOI 10.1007/PL00000919; Minturn JE, 2011, CANCER CHEMOTH PHARM, V68, P1057, DOI 10.1007/s00280-011-1581-4; Molenaar JJ, 2012, GENE CHROMOSOME CANC, V51, P10, DOI 10.1002/gcc.20926; NAKAGAWARA A, 1994, MOL CELL BIOL, V14, P759, DOI 10.1128/MCB.14.1.759; Nakagawara A, 1998, Hum Cell, V11, P115; Nakamura K, 2006, CANCER RES, V66, P4249, DOI 10.1158/0008-5472.CAN-05-2789; Plantaz D, 1996, CANCER, V78, P311, DOI 10.1002/(SICI)1097-0142(19960715)78:2<311::AID-CNCR19>3.3.CO;2-O; Ramirez R, 2000, CLIN ENDOCRINOL, V53, P635, DOI 10.1046/j.1365-2265.2000.01124.x; RAMSAY GM, 1990, P NATL ACAD SCI USA, V87, P2102, DOI 10.1073/pnas.87.6.2102; Reichardt LF, 2006, PHILOS T R SOC B, V361, P1545, DOI 10.1098/rstb.2006.1894; Reiff T, 2010, J NEUROSCI, V30, P905, DOI 10.1523/JNEUROSCI.5368-09.2010; Scala S, 1996, CANCER RES, V56, P3737; Schramm A, 2005, CANCER LETT, V228, P143, DOI 10.1016/j.canlet.2005.02.051; Schulte JH, 2013, ONCOGENE, V32, P1059, DOI 10.1038/onc.2012.106; SCHWAB M, 1984, P NATL ACAD SCI-BIOL, V81, P4940, DOI 10.1073/pnas.81.15.4940; Screaton RA, 1997, J CELL BIOL, V137, P939, DOI 10.1083/jcb.137.4.939; SEEGER RC, 1985, NEW ENGL J MED, V313, P1111, DOI 10.1056/NEJM198510313131802; Singh RK, 2007, BIOORG MED CHEM LETT, V17, P5846, DOI 10.1016/j.bmcl.2007.08.032; Straub JA, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-10; Tacconelli A, 2004, CANCER CELL, V6, P347, DOI 10.1016/j.ccr.2004.09.011; Thullberg M, 2008, CELL CYCLE, V7, P984, DOI 10.4161/cc.7.8.5674; Tokunou M, 2001, AM J PATHOL, V158, P1451, DOI 10.1016/S0002-9440(10)64096-5; Urschitz J, 2010, P NATL ACAD SCI USA, V107, P8117, DOI 10.1073/pnas.1003674107; Valsesia-Wittmann S, 2004, CANCER CELL, V6, P625, DOI 10.1016/j.ccr.2004.09.033; Weiss WA, 1997, EMBO J, V16, P2985, DOI 10.1093/emboj/16.11.2985; Yu YJ, 2010, APMIS, V118, P188, DOI 10.1111/j.1600-0463.2009.02577.x; Zhang SY, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-43	59	12	12	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2014	33	8					977	985		10.1038/onc.2013.39	http://dx.doi.org/10.1038/onc.2013.39			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XO	23455321	Green Accepted			2022-12-28	WOS:000331933200005
J	Li, T; Lu, YY; Zhao, XD; Guo, HQ; Liu, CH; Li, H; Zhou, L; Han, YN; Wu, KC; Nie, YZ; Shi, YQ; Fan, DM				Li, T.; Lu, Y. Y.; Zhao, X. D.; Guo, H. Q.; Liu, C. H.; Li, H.; Zhou, L.; Han, Y. N.; Wu, K. C.; Nie, Y. Z.; Shi, Y. Q.; Fan, D. M.			MicroRNA-296-5p increases proliferation in gastric cancer through repression of Caudal-related homeobox 1	ONCOGENE			English	Article						CDX1; miR-296-5p; gastric cancer; proliferation; apoptosis	MESSENGER-RNA EXPRESSION; HELICOBACTER-PYLORI; EPITHELIAL-CELLS; GENE-EXPRESSION; DOWN-REGULATION; KINASE PATHWAY; CDX1; CARCINOMA; MIR-296; TARGET	Caudal-related homeobox 1 (CDX1), an intestinal-specific transcription factor, has been reported to have vital roles in gastric intestinal metaplasia (IM). Although IM is a high-risk factor for gastric cancer (GC), the specific role of CDX1 in GC is largely unknown. In this study, we investigated the expression of CDX1 and its functional roles in GC, and its upstream regulatory mechanisms at the microRNA (miRNA) level were further explored. We found that CDX1 is lost in GC when compared with adjacent IM tissues. Gain-of-function studies showed that CDX1 significantly inhibited GC cell growth by inducing cell cycle arrest and apoptosis. Interestingly, we identified and verified an onco-mir, miR-296-5p, as a direct upstream regulator of CDX1. miR-296-5p overexpression significantly promoted GC cell growth and attenuated the CDX1-induced anti-growth effects by recurring cell cycle distribution and apoptotic status, whereas knockdown of miR-296-5p decreased GC cell growth. Furthermore, we found that the extracellular signal-regulated kinases 1 and 2 (ERK1/2) activation and the subsequent downstream changes in protein levels related to cell cycle and apoptosis partly account for the miR-296-5p-CDX1-induced GC growth promotion. In addition, the detection of miR-296-5p and expression of CDX1 in primary GC tissues and adjacent IM tissues revealed that miR-296-5p is inversely correlated with CDX1, further supporting our in vitro results. Our results showed an anti-growth effect of CDX1 and identified its miRNA regulatory mechanism in GC. The identification of this novel miR-296-5p-CDX1-ERK1/2 axis sheds new light on the understanding of the process from IM to GC and may provide therapeutic targets for the treatment of GC.	Fourth Mil Med Univ, Xijing Hosp, State Key Lab Canc Biol, Xian 710032, Peoples R China; Fourth Mil Med Univ, Xijing Hosp, Dept Gastroenterol, Xian 710032, Peoples R China	Air Force Military Medical University; Air Force Military Medical University	Shi, YQ (corresponding author), Xijing Hosp Digest Dis, State Key Lab Canc Biol, West Changle Rd, Xian 710032, Shaan Xi, Peoples R China.	shiyquan@fmmu.edu.cn; daimingfan@fmmu.edu.cn	Shi, Yongquan/AAE-3954-2020		National 973 Project of China [2010CB732405, 2010CB529300, 2010CB529302, 2010CB529305, 2010CB529306]; National Natural Science Foundation of China [81030044, 81270445, 81172062]	National 973 Project of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We acknowledge Z CHEN, GB TANG, JH DOU and G REN from the State Key Laboratory of Cancer Biology for the assistance in tissue sample collection. This work was supported by the National 973 Project of China (no. 2010CB732405, 05; 2010CB529300, 02, 05, 06) and the National Natural Science Foundation of China (no. 81030044, 81270445, 81172062).	ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Boussioutas A, 2003, CANCER RES, V63, P2569; Camilo V, 2012, CARCINOGENESIS, V33, P1985, DOI 10.1093/carcin/bgs233; Chan CWM, 2009, P NATL ACAD SCI USA, V106, P1936, DOI 10.1073/pnas.0812904106; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chaudhuri K, 2007, DNA CELL BIOL, V26, P321, DOI 10.1089/dna.2006.0549; Darido C, 2011, CANCER CELL, V20, P635, DOI 10.1016/j.ccr.2011.10.014; Domon-Dell C, 2003, ONCOGENE, V22, P7913, DOI 10.1038/sj.onc.1206756; Fornari F, 2010, CANCER RES, V70, P5184, DOI 10.1158/0008-5472.CAN-10-0145; Guo RJ, 2004, J BIOL CHEM, V279, P36865, DOI 10.1074/jbc.M405213200; Hong L, 2010, ANN SURG, V251, P1056, DOI 10.1097/SLA.0b013e3181dd4ea9; Hou J, 2011, CANCER CELL, V19, P232, DOI 10.1016/j.ccr.2011.01.001; Ito K, 2011, GASTROENTEROLOGY, V140, P1536, DOI 10.1053/j.gastro.2011.01.043; Jeon SH, 2007, J BIOL CHEM, V282, P14482, DOI 10.1074/jbc.M611129200; Johnstone CN, 2002, J BIOL CHEM, V277, P34531, DOI 10.1074/jbc.M204865200; Kan T, 2009, GASTROENTEROLOGY, V136, P1689, DOI 10.1053/j.gastro.2009.02.002; Kazumori H, 2009, GUT, V58, P620, DOI 10.1136/gut.2008.152975; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lynch J, 2003, ONCOGENE, V22, P6395, DOI 10.1038/sj.onc.1206770; Lynch J, 2000, J BIOL CHEM, V275, P4499, DOI 10.1074/jbc.275.6.4499; Lynch JP, 2008, NEOPLASIA, V10, P8, DOI 10.1593/neo.07703; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; Meloche S, 2007, ONCOGENE, V26, P3227, DOI 10.1038/sj.onc.1210414; Mutoh H, 2004, GUT, V53, P1416, DOI 10.1136/gut.2003.032482; Papagiannakopoulos T, 2008, CANCER RES, V68, P8164, DOI 10.1158/0008-5472.CAN-08-1305; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Petrocca F, 2008, CANCER CELL, V13, P272, DOI 10.1016/j.ccr.2008.02.013; Pucci B, 2009, J CELL BIOCHEM, V108, P1166, DOI 10.1002/jcb.22345; Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; Silberg DG, 1997, GASTROENTEROLOGY, V113, P478, DOI 10.1053/gast.1997.v113.pm9247467; Soubeyran P, 1999, GASTROENTEROLOGY, V117, P1326, DOI 10.1016/S0016-5085(99)70283-0; Soubeyran P, 2001, ONCOGENE, V20, P4180, DOI 10.1038/sj.onc.1204551; Suh ER, 2002, J BIOL CHEM, V277, P35795, DOI 10.1074/jbc.M205567200; Uemura N, 2001, NEW ENGL J MED, V345, P784, DOI 10.1056/NEJMoa001999; Vaira V, 2012, ONCOGENE, V31, P27, DOI 10.1038/onc.2011.209; Wong NACS, 2005, P NATL ACAD SCI USA, V102, P7565, DOI 10.1073/pnas.0502031102; Wong NACS, 2004, P NATL ACAD SCI USA, V101, P574, DOI 10.1073/pnas.0307190101; Wurdinger T, 2008, CANCER CELL, V14, P382, DOI 10.1016/j.ccr.2008.10.005; Xia L, 2008, INT J CANCER, V123, P372, DOI 10.1002/ijc.23501; Xu N, 2009, CELL, V137, P647, DOI 10.1016/j.cell.2009.02.038; Xu Y, 2012, ONCOGENE, V31, P1398, DOI 10.1038/onc.2011.340; Xu Y, 2012, J ENG FIBER FABR, V7, P7; Yoon A, 2011, NUCLEIC ACIDS RES, V39, P8078, DOI 10.1093/nar/gkr492; You WC, 1999, INT J CANCER, V83, P615, DOI 10.1002/(SICI)1097-0215(19991126)83:5&lt;615::AID-IJC8&gt;3.0.CO;2-L; Zhao X, 2013, ONCOGENE, V32, P1363, DOI 10.1038/onc.2012.156	48	82	86	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2014	33	6					783	793		10.1038/onc.2012.637	http://dx.doi.org/10.1038/onc.2012.637			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5IL	23353818				2022-12-28	WOS:000331129200012
J	Yang, Q; Jie, Z; Ye, S; Li, Z; Han, Z; Wu, J; Yang, C; Jiang, Y				Yang, Q.; Jie, Z.; Ye, S.; Li, Z.; Han, Z.; Wu, J.; Yang, C.; Jiang, Y.			Genetic variations in miR-27a gene decrease mature miR-27a level and reduce gastric cancer susceptibility	ONCOGENE			English	Article						gastric tumorigenesis; microRNA; miR-27a; single-nucleotide polymorphisms	HOX GENES; DROSHA-DGCR8 COMPLEX; MICRORNA NETWORKS; EXPRESSION; RISK; TARGET; CELLS; MIRNA; TRANSFORMATION; TUMORIGENESIS	MicroRNAs (miRNAs) are noncoding RNAs that function as post-transcriptional regulators of tumor oncogenes and suppressors. Single-nucleotide polymorphisms (SNPs) in miRNA genes are a novel class of genetic variations in the human genome that are currently being identified and investigated in human cancers. In this study, we aimed to investigate whether SNPs in the miR-27a gene affect miR-27a expression and alter susceptibility to gastric cancer. Therefore, we conducted a case-control population study and the allele and genotype frequencies for polymorphism rs11671784 in miR-27a gene were examined in the study population. As a result, we found that the G/A polymorphism in the miR-27a gene exhibited a significant effect on gastric cancer risk. Compared with GG homozygotes, subjects who were GA heterozygotes or AA homozygotes exhibited a decreased risk of gastric cancer. The G/A polymorphism impaired the processing of pre-miR-27a to mature miR-27a, resulting in significantly reduced expression of mature miR-27a and an increased level of its target HOXA10. Furthermore, we confirmed these findings in in vitro studies by overexpressing pre-miR-27a carrying G or A allele. It provided further evidence demonstrating that allelic difference of rs11671784 is linked to gastric tumorigenesis. In summary, our results indicate that the G/A polymorphism in miR-27a gene (rs11671784) decreases miR-27a expression, reduces gastric cancer risk and plays a role in gastric tumorigenesis. This is the first study to address the role and function of miR-27a polymorphism rs11671784 in gastric cancer. These results could be useful to assess individual susceptibility of gastric cancer and will improve our understanding of the potential contribution of miRNA SNPs to cancer pathogenesis.	[Yang, Q.; Han, Z.; Wu, J.; Jiang, Y.] Guangzhou Med Univ, Inst Chem Carcinogenesis, State Key Lab Resp Dis, Guangzhou 510182, Guangdong, Peoples R China; [Jie, Z.; Li, Z.] Nanchang Univ, Dept Gen Surg, Affiliated Hosp 1, Nanchang, Peoples R China; [Ye, S.] Sun Yat Sen Univ, Dept Med Oncol, Affiliated Hosp 1, Guangzhou 510275, Guangdong, Peoples R China; [Yang, C.] Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; [Yang, C.] Michigan State Univ, Ctr Integrat Toxicol, E Lansing, MI 48824 USA	Guangzhou Medical University; State Key Laboratory of Respiratory Disease; Nanchang University; Sun Yat Sen University; Michigan State University; Michigan State University	Jiang, Y (corresponding author), Guangzhou Med Univ, Inst Chem Carcinogenesis, 195 Dongfeng Rd West, Guangzhou 510182, Guangdong, Peoples R China.	jiangyiguo@yahoo.com		Jiang, Yiguo/0000-0002-9499-2594	National Natural Science Foundation of China [30771780, 30972443, 81102099]; Natural Science Foundation of Guangdong Province [9251018201000004]; University Talent Program of Guangdong [2010-79]; University Talent Program of Guangzhou [10A003D]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Natural Science Foundation of Guangdong Province(National Natural Science Foundation of Guangdong Province); University Talent Program of Guangdong; University Talent Program of Guangzhou	We thank Xin Zhou and Wei Li (Department of General Surgery, First Affiliated Hospital of Nanchang University) for collecting the clinicopathologic information utilized in this study. We thank Chengjie Liang (Laboratory Animal Center, Guangzhou Medical University) for assistance with the nude mice assays. This work was supported by the National Natural Science Foundation of China (30771780, 30972443 to YJ and 81102099 to QY), the Natural Science Foundation of Guangdong Province (9251018201000004 to YJ), the University Talent Program of Guangdong (2010-79 to YJ) and the University Talent Program of Guangzhou (10A003D to YJ).	Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Bandres E, 2009, CLIN CANCER RES, V15, P2281, DOI 10.1158/1078-0432.CCR-08-1818; Bornschein J, 2011, HELICOBACTER, V16, P45, DOI 10.1111/j.1523-5378.2011.00880.x; Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997; Calin GA, 2006, CANCER RES, V66, P7390, DOI 10.1158/0008-5472.CAN-06-0800; Cantile M, 2011, CURR MED CHEM, V18, P4872, DOI 10.2174/092986711797535182; Carthew RW, 2009, CELL, V136, P642, DOI 10.1016/j.cell.2009.01.035; Catucci I, 2012, BREAST CANCER RES TR, V133, P805, DOI 10.1007/s10549-012-2011-y; Chintharlapalli S, 2009, INT J CANCER, V125, P1965, DOI 10.1002/ijc.24530; Cillo C, 2011, INT J CANCER, V129, P2577, DOI 10.1002/ijc.25941; Duan RH, 2007, HUM MOL GENET, V16, P1124, DOI 10.1093/hmg/ddm062; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; Gonzalez CA, 2012, INT J CANCER, V130, P745, DOI 10.1002/ijc.26430; Han JJ, 2006, CELL, V125, P887, DOI 10.1016/j.cell.2006.03.043; Han JJ, 2004, GENE DEV, V18, P3016, DOI 10.1101/gad.1262504; Hu Y, 2011, RNA BIOL, V8, P861, DOI 10.4161/rna.8.5.16034; Iorio MV, 2009, J CLIN ONCOL, V27, P5848, DOI 10.1200/JCO.2009.24.0317; Jazdzewski K, 2008, P NATL ACAD SCI USA, V105, P7269, DOI 10.1073/pnas.0802682105; Jazdzewski K, 2009, P NATL ACAD SCI USA, V106, P1502, DOI 10.1073/pnas.0812591106; Katada T, 2009, INT J ONCOL, V34, P537, DOI 10.3892/ijo_00000179; Kelley JR, 2003, J CLIN EPIDEMIOL, V56, P1, DOI 10.1016/S0895-4356(02)00534-6; Kogo R, 2011, CLIN CANCER RES, V17, P4277, DOI 10.1158/1078-0432.CCR-10-2866; Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003; Labbaye C, 2008, NAT CELL BIOL, V10, P788, DOI 10.1038/ncb1741; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lerner M, 2011, CELL CYCLE, V10, P2172, DOI 10.4161/cc.10.13.16248; Leung WK, 2008, LANCET ONCOL, V9, P279, DOI 10.1016/S1470-2045(08)70072-X; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Liu T, 2009, CANCER LETT, V273, P233, DOI 10.1016/j.canlet.2008.08.003; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Nunes Fabio Daumas, 2003, Pesqui Odontol Bras, V17, P94; Plowright L, 2009, BRIT J CANCER, V100, P470, DOI 10.1038/sj.bjc.6604857; Ryan BM, 2010, NAT REV CANCER, V10, P389, DOI 10.1038/nrc2867; Saunders MA, 2007, P NATL ACAD SCI USA, V104, P3300, DOI 10.1073/pnas.0611347104; Shah N, 2010, NAT REV CANCER, V10, P361, DOI 10.1038/nrc2826; Sun GH, 2009, RNA, V15, P1640, DOI 10.1261/rna.1560209; Sun QM, 2010, CANCER SCI, V101, P2241, DOI 10.1111/j.1349-7006.2010.01667.x; Wang Q, 2011, ONCOGENE, V30, P3875, DOI 10.1038/onc.2011.103; Yang L, 2005, CANCER EPIDEM BIOMAR, V14, P243; Yang QY, 2011, CARCINOGENESIS, V32, P713, DOI 10.1093/carcin/bgr035; Zhang M, 2012, EUR J CANCER CARE, V21, P274, DOI 10.1111/j.1365-2354.2011.01308.x; Zhou Y, 2012, J CANCER RES CLIN, V138, P939, DOI 10.1007/s00432-012-1164-8	44	61	63	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 9	2014	33	2					193	202		10.1038/onc.2012.569	http://dx.doi.org/10.1038/onc.2012.569			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	286BY	23246964				2022-12-28	WOS:000329440700007
J	Wang, X; Sun, Y; Wong, J; Conklin, DS				Wang, X.; Sun, Y.; Wong, J.; Conklin, D. S.			PPAR gamma maintains ERBB2-positive breast cancer stem cells	ONCOGENE			English	Article						PPAR gamma; HER2/neu positive; stem cells	ACTIVATED-RECEPTOR-GAMMA; FATTY-ACID SYNTHASE; INHIBIT GROWTH; EXPRESSION; RESISTANCE; ERBB2; HER2; CARCINOMA; SURVIVAL; LIGAND	Overexpression of the adverse prognostic marker ERBB2 occurs in 30% of breast cancers and is associated with aggressive disease and poor outcomes. Our recent findings have shown that NR1D1 and the peroxisome proliferator-activated receptor-gamma (PPAR gamma)-binding protein (PBP) act through a common pathway in upregulating several genes in the de novo fatty acid synthesis network, which is highly active in ERBB2-positive breast cancer cells. NR1D1 and PBP are functionally related to PPARg, a well-established positive regulator of adipogenesis and lipid storage. Here, we report that inhibition of the PPARg pathway reduces the aldehyde dehydrogenase (ALDH)-positive population in ERBB2-positive breast cancer cells. Results from in vitro tumorsphere formation assays demonstrate that the PPARg antagonists GW9662 and T0070907 decrease tumorsphere formation in ERBB2-positive cells, but not other breast cells. We show that the mechanism by which GW9662 treatment causes a reduction in ALDH-positive population cells is partially due to ROS, as it can be rescued by treatment with N-acetyl-cysteine. Furthermore, global gene expression analyses show that GW9662 treatment suppresses the expression of several lipogenic genes, including ACLY, MIG12, FASN and NR1D1, and the stem-cell related genes KLF4 and ALDH in BT474 cells. Antagonist treatment also decreases the level of acetylation in histone 3 and histone 4 in BT474 cells, compared with MCF7 cells. In vivo, GW9662 pre-treatment inhibits the tumor-seeding ability of BT474 cells. Together, these results show that the PPARg pathway is critical for the cancer stem cell properties of ERBB2-positive breast cancer cells.	[Wang, X.; Sun, Y.; Wong, J.; Conklin, D. S.] SUNY Albany, Canc Res Ctr, Dept Biomed Sci, Rensselaer, NY 12144 USA	State University of New York (SUNY) System; State University of New York (SUNY) Albany	Conklin, DS (corresponding author), SUNY Albany, Canc Res Ctr, Dept Biomed Sci, CRC 305,1 Discovery Dr, Rensselaer, NY 12144 USA.	dconklin@albany.edu		Conklin, Douglas/0000-0003-4922-4307	NCI [1R01CA136658]; NATIONAL CANCER INSTITUTE [R01CA136658] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Jan Baumann and other members of the UAlbany CRC for helpful suggestions. This work was supported by NCI 1R01CA136658 to DSC.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; [Anonymous], 2011, PHARMACOGENOMICS, V12, P12; Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236; Baumann J., 2012, BREAST CANC RECENT A, P17; Bedard PL, 2009, J MAMMARY GLAND BIOL, V14, P55, DOI 10.1007/s10911-009-9116-x; Bertucci F, 2004, ONCOGENE, V23, P2564, DOI 10.1038/sj.onc.1207361; Burton JD, 2008, PPAR RES, V2008, DOI 10.1155/2008/494161; Chearwae W, 2008, BRIT J CANCER, V99, P2044, DOI 10.1038/sj.bjc.6604786; Chin K, 2006, CANCER CELL, V10, P529, DOI 10.1016/j.ccr.2006.10.009; Christgen Matthias, 2012, Methods Mol Biol, V878, P201, DOI 10.1007/978-1-61779-854-2_13; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Diehn M, 2006, J NATL CANCER I, V98, P1755, DOI 10.1093/jnci/djj505; Dressman MA, 2003, CANCER RES, V63, P2194; Elstner E, 2002, BREAST CANCER RES TR, V74, P155, DOI 10.1023/A:1016114026769; Evans RM, 2004, NAT MED, V10, P355, DOI 10.1038/nm1025; Eyler CE, 2008, J CLIN ONCOL, V26, P2839, DOI 10.1200/JCO.2007.15.1829; Ferguson EM, 2006, MOL REPROD DEV, V73, P1195, DOI 10.1002/mrd.20494; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Glazer RI, 2008, PPAR RES, V2008, DOI 10.1155/2008/247379; Hauser S, 2000, J BIOL CHEM, V275, P18527, DOI 10.1074/jbc.M001297200; He X, 2012, ANN ONCOL, V23, P1771, DOI 10.1093/annonc/mdr534; Kauraniemi P, 2006, ENDOCR-RELAT CANCER, V13, P39, DOI 10.1677/erc.1.01147; Kim KY, 2006, BIOCHEM PHARMACOL, V72, P530, DOI 10.1016/j.bcp.2006.05.009; Korkaya H, 2008, ONCOGENE, V27, P6120, DOI 10.1038/onc.2008.207; Kourtidis A, 2010, CANCER RES, V70, P1783, DOI 10.1158/0008-5472.CAN-09-1550; Kourtidis A, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2240; Kumar-Sinha C, 2003, CANCER RES, V63, P132; Kuniyasu H, 2008, PPAR RES, V2008, DOI 10.1155/2008/529720; LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0; Lee JJ, 2012, ONCOGENE, V31, P3818, DOI 10.1038/onc.2011.543; Lehrke M, 2005, CELL, V123, P993, DOI 10.1016/j.cell.2005.11.026; Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123; Liu H, 2003, BREAST CANCER RES TR, V79, P63, DOI 10.1023/A:1023366117157; Mehta RG, 2000, J NATL CANCER I, V92, P418, DOI 10.1093/jnci/92.5.418; Menard S, 2001, ONCOLOGY-BASEL, V61, P67, DOI 10.1159/000055404; Menendez JA, 2004, P NATL ACAD SCI USA, V101, P10715, DOI 10.1073/pnas.0403390101; Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Oliveras-Ferraros C, 2010, BIOCHEM BIOPH RES CO, V397, P27, DOI 10.1016/j.bbrc.2010.05.041; Patrawala L, 2005, CANCER RES, V65, P6207, DOI 10.1158/0008-5472.CAN-05-0592; Pignatelli M, 2001, J CELL SCI, V114, P4117; Rageul J, 2009, INT J CANCER, V125, P2802, DOI 10.1002/ijc.24683; Reka AK, 2010, MOL CANCER THER, V9, P3221, DOI 10.1158/1535-7163.MCT-10-0570; Robbins GT, 2012, FRONT BIOSCI-LANDMRK, V17, P1816, DOI 10.2741/4021; Sebastiani V, 2006, ANTICANCER RES, V26, P2983; Silva SD, 2004, ORAL ONCOL, V40, P688, DOI 10.1016/j.oraloncology.2004.01.004; Smalley M, 2003, NAT REV CANCER, V3, P832, DOI 10.1038/nrc1212; Sutton-McDowall ML, 2012, THERIOGENOLOGY, V77, P1632, DOI 10.1016/j.theriogenology.2011.12.008; Swinnen JV, 2006, CURR OPIN CLIN NUTR, V9, P358, DOI 10.1097/01.mco.0000232894.28674.30; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Tian LF, 2009, CANCER RES, V69, P9236, DOI 10.1158/0008-5472.CAN-09-2067; Tsao T, 2010, CANCER RES, V70, P4949, DOI 10.1158/0008-5472.CAN-09-1962; Vogel CL, 2002, J CLIN ONCOL, V20, P719, DOI 10.1200/JCO.20.3.719; Wang X, 2011, ONCOGENE, V30, P1901, DOI 10.1038/onc.2010.563; Wellen KE, 2009, SCIENCE, V324, P1076, DOI 10.1126/science.1164097; Wu L, 2012, BLOOD, V119, P115, DOI 10.1182/blood-2011-06-363093; Yang ZB, 2003, CLIN CANCER RES, V9, P3198; Yin F, 2001, BIOCHEM BIOPH RES CO, V286, P916, DOI 10.1006/bbrc.2001.5491; Yuan HY, 2012, ONCOTARGET, V3, P345; Zhu YJ, 1999, P NATL ACAD SCI USA, V96, P10848, DOI 10.1073/pnas.96.19.10848; Zu XY, 2012, RECENT PAT ANTI-CANC, V7, P154, DOI 10.2174/157489212799972954	61	51	55	2	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	DEC 5	2013	32	49					5512	5521		10.1038/onc.2013.217	http://dx.doi.org/10.1038/onc.2013.217			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	269XF	23770845	Green Published			2022-12-28	WOS:000328276400002
J	Beggs, AD; Domingo, E; Abulafi, M; Hodgson, SV; Tomlinson, IPM				Beggs, A. D.; Domingo, E.; Abulafi, M.; Hodgson, S. V.; Tomlinson, I. P. M.			A study of genomic instability in early preneoplastic colonic lesions	ONCOGENE			English	Article						colorectal cancer; gland; heterogeneity; methylation; microsatellite instability	MICROSATELLITE INSTABILITY; COLORECTAL ADENOMAS; NORMAL MUCOSA; CANCER; METHYLATION; HYPERMETHYLATION; PROMOTER; POLYPS; MUTATIONS; TUMORS	It is difficult to explain the differential rates of progression of premalignant colonic lesions and differences in behaviour of morphologically similar lesions. Heterogeneity for microsatellite instability (MSI) and promoter methylation in driving these phenomena forward may explain this; however, no previous analysis has examined this in detail at the gland level, the smallest unit of colorectal premalignant lesions. We aimed to carry out an analysis of gland level genomic instability for MSI and promoter methylation. MSI occurred significantly more frequently (20%) in colonic glands than has previously been observed in whole colorectal polyps. Significant promoter methylation was seen in MLH1, PMS2, MLH3 and MSH3 as well as significant heterogeneity for both MSI and promoter methylation. Methylation and MSI may have a significant role in driving forward colorectal carcinogenesis, although in the case of MSI, this association is less clear as it occurs significantly more frequently than previously thought, and may simply be a passenger in the adenoma-carcinoma sequence. Promoter methylation in MLH1, MLH3, MSH3 and PMS2 was also found to be significantly associated with MSI and should be investigated further. A total of 273 colorectal glands (126 hyperplastic, 147 adenomatous) were isolated via laser capture microdissection (targeted at regions of MLH1 loss) from 93 colonic polyps and tested for MSI, and promoter methylation of the DNA mismatch repair genes MLH1, MSH2, MLH3, MSH6, PMS2, MGMT and MLH3 via methylation specific multiplex ligation-dependent probe amplification. Logistic regression modelling was then used to identify significant associations between promoter methylation and gland histological type and MSI status.	[Beggs, A. D.; Domingo, E.; Tomlinson, I. P. M.] Univ Oxford, Mol & Populat Genet Lab, Oxford OX3 7BN, England; [Beggs, A. D.; Domingo, E.; Tomlinson, I. P. M.] Univ Oxford, NIHR Comprehens Biomed Res Ctr, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; [Beggs, A. D.; Abulafi, M.] Croydon Univ Hosp, Dept Surg, Croydon, England; [Hodgson, S. V.] St Georges Univ London, Dept Med Genet, London, England	University of Oxford; University of Oxford; Wellcome Centre for Human Genetics; Croydon University Hospital; St Georges University London	Beggs, AD (corresponding author), Univ Oxford, Mol & Populat Genet Lab, Roosevelt Dr, Oxford OX3 7BN, England.	a.beggs@bham.ac.uk	Beggs, Andrew D/A-6912-2013; Domingo, Enric/A-9099-2018	Beggs, Andrew D/0000-0003-0784-2967; Domingo, Enric/0000-0003-4390-8767	Mason Medical Foundation; Peel Medical Research Trust; St George's Hospital Charity; Cancer Research UK; Wellcome Trust [090532/Z/09/Z]; Cancer Research UK [16459] Funding Source: researchfish	Mason Medical Foundation; Peel Medical Research Trust; St George's Hospital Charity; Cancer Research UK(Cancer Research UK); Wellcome Trust(Wellcome TrustEuropean Commission); Cancer Research UK(Cancer Research UK)	ADB was funded by a Mason Medical Foundation Research Fellowship and grants from the Peel Medical Research Trust and St George's Hospital Charity; IPMT acknowledges funding from Cancer Research UK and the Wellcome Trust 090532/Z/09/Z.	AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; Ahlquist T, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-94; Belshaw NJ, 2010, CARCINOGENESIS, V31, P1158, DOI 10.1093/carcin/bgq077; Brueckl WM, 2000, INT J COLORECTAL DIS, V15, P189, DOI 10.1007/s003840000241; Cunningham JM, 1998, CANCER RES, V58, P3455; FEARON ER, 1987, SCIENCE, V238, P193, DOI 10.1126/science.2889267; Guerrette S, 1998, MOL CELL BIOL, V18, P6616, DOI 10.1128/MCB.18.11.6616; Jeuken JW, 2007, LAB INVEST, V87, P1055, DOI 10.1038/labinvest.3700664; Kloor M, 2012, LANCET ONCOL, V13, P598, DOI 10.1016/S1470-2045(12)70109-2; Koh DC, 2007, COLORECTAL DIS, V9, P521, DOI 10.1111/j.1463-1318.2007.01175.x; Lanza G, 2002, MODERN PATHOL, V15, P741, DOI 10.1097/01.MP.0000018979.68686.B2; Lipkin SM, 2000, NAT GENET, V24, P27, DOI 10.1038/71643; LOTHE RA, 1995, GENE CHROMOSOME CANC, V14, P182, DOI 10.1002/gcc.2870140305; Park CK, 2011, NEURO-ONCOLOGY, V13, P195, DOI 10.1093/neuonc/noq162; Poynter JN, 2008, CANCER EPIDEM BIOMAR, V17, P3208, DOI 10.1158/1055-9965.EPI-08-0512; Rashid A, 1999, GUT, V44, P826, DOI 10.1136/gut.44.6.826; Samowitz WS, 1997, AM J PATHOL, V151, P33; Samowitz WS, 1997, GASTROENTEROLOGY, V112, P1515, DOI 10.1016/S0016-5085(97)70032-5; Sieber OM, 2003, NAT REV CANCER, V3, P701, DOI 10.1038/nrc1170; Umetani N, 2006, MOL CANCER RES, V4, P303, DOI 10.1158/1541-7786.MCR-05-0199; Yurgelun MB, 2012, CANCER PREV RES, V5, P574, DOI 10.1158/1940-6207.CAPR-11-0519	21	20	21	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2013	32	46					5333	5337		10.1038/onc.2012.584	http://dx.doi.org/10.1038/onc.2012.584			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251IU	23246972	hybrid, Green Published			2022-12-28	WOS:000326922400003
J	Sankar, S; Bell, R; Stephens, B; Zhuo, R; Sharma, S; Bearss, DJ; Lessnick, SL				Sankar, S.; Bell, R.; Stephens, B.; Zhuo, R.; Sharma, S.; Bearss, D. J.; Lessnick, S. L.			Mechanism and relevance of EWS/FLI-mediated transcriptional repression in Ewing sarcoma	ONCOGENE			English	Article						Ewing sarcoma; EWS/FLI; NuRD; transcription; repression	PEDIATRIC SOLID TUMORS; DNA-BINDING; RESPONSE ELEMENTS; PROTEIN-PROTEIN; FUSION GENE; EXPRESSION; REVEALS; TARGET; CELLS; TRANSFORMATION	Ewing sarcoma provides an important model for transcription-factor-mediated oncogenic transformation because of its reliance on the ETS-type fusion oncoprotein EWS/FLI. EWS/FLI functions as a transcriptional activator and transcriptional activation is required for its oncogenic activity. Here, we demonstrate that a previously less-well characterized transcriptional repressive function of the EWS/FLI fusion is also required for the transformed phenotype of Ewing sarcoma. Through comparison of EWS/FLI transcriptional profiling and genome-wide localization data, we define the complement of EWS/FLI direct downregulated target genes. We demonstrate that LOX is a previously undescribed EWS/FLI-repressed target that inhibits the transformed phenotype of Ewing sarcoma cells. Mechanistic studies demonstrate that the NuRD co-repressor complex interacts with EWS/FLI, and that its associated histone deacetylase and LSD1 activities contribute to the repressive function. Taken together, these data reveal a previously unknown molecular function for EWS/FLI, demonstrate a more highly coordinated oncogenic transcriptional hierarchy mediated by EWS/FLI than previously suspected, and implicate a new paradigm for therapeutic intervention aimed at controlling NuRD activity in Ewing sarcoma tumors.	[Sankar, S.; Stephens, B.; Sharma, S.; Bearss, D. J.; Lessnick, S. L.] Huntsman Canc Inst, Sch Med, Dept Oncol Sci, Salt Lake City, UT 84112 USA; [Bell, R.; Zhuo, R.; Lessnick, S. L.] Huntsman Canc Inst, Ctr Childrens Canc Res, Salt Lake City, UT 84112 USA; [Stephens, B.; Bearss, D. J.] Huntsman Canc Inst, Ctr Invest Therapeut, Salt Lake City, UT 84112 USA; [Sharma, S.] Univ Utah, Sch Med, Div Med Oncol, Salt Lake City, UT USA; [Lessnick, S. L.] Univ Utah, Sch Med, Div Pediat Hematol Oncol, Salt Lake City, UT USA	Huntsman Cancer Institute; Huntsman Cancer Institute; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Lessnick, SL (corresponding author), Huntsman Canc Inst, Ctr Childrens Canc Res, 2000 Circle Hope,Room 4242, Salt Lake City, UT 84112 USA.	stephen.lessnick@hci.utah.edu	Bearss, David/Q-9141-2019; SANKAR, SAVITA/R-6821-2017	Bearss, David/0000-0002-4280-5670; Bearss, David/0000-0002-4458-826X	HHMI Med into Grad program at the University of Utah (U2M2G); NIH/NCI [R01 CA140394, P30 CA042014]; Huntsman Cancer Institute; NATIONAL CANCER INSTITUTE [P30CA042014, R01CA140394] Funding Source: NIH RePORTER	HHMI Med into Grad program at the University of Utah (U2M2G); NIH/NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Huntsman Cancer Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Drs Cairns, Engel and Bhaskara for discussions and critical reading of this manuscript and members of the Lessnick laboratory, and Drs Denny and Ayer, for discussions and reagents. SS acknowledges support from the HHMI Med into Grad program at the University of Utah (U2M2G). This work was supported by NIH/NCI Grants R01 CA140394 (to SLL) and P30 CA042014 (to Huntsman Cancer Institute) and funding from Imaging Diagnostics and Therapeutics Program at Huntsman Cancer Institute (to Sunil Sharma).	Arvand A, 2001, CANCER RES, V61, P5311; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; Barker HE, 2012, NAT REV CANCER, V12, P540, DOI 10.1038/nrc3319; Bennani-Baiti IM, 2012, HUM PATHOL, V43, P1300, DOI 10.1016/j.humpath.2011.10.010; Braunreiter CL, 2006, CELL CYCLE, V5, P2753, DOI 10.4161/cc.5.23.3505; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Gangwal K, 2008, CELL CYCLE, V7, P3127, DOI 10.4161/cc.7.20.6892; Gangwal K, 2008, P NATL ACAD SCI USA, V105, P10149, DOI 10.1073/pnas.0801073105; Hahm KB, 1999, NAT GENET, V23, P222, DOI 10.1038/13854; Hancock JD, 2008, CELL CYCLE, V7, P250, DOI 10.4161/cc.7.2.5229; Hollenhorst PC, 2007, GENE DEV, V21, P1882, DOI 10.1101/gad.1561707; Hollenhorst PC, 2011, GENE DEV, V25, P2147, DOI 10.1101/gad.17546311; Jaboin J, 2002, CANCER RES, V62, P6108; Kauer M, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005415; Keshelava N, 2009, PEDIATR BLOOD CANCER, V53, P505, DOI 10.1002/pbc.21988; Kim J, 2009, NAT PROTOC, V4, P506, DOI 10.1038/nprot.2009.23; Kinsey M, 2006, MOL CANCER RES, V4, P851, DOI 10.1158/1541-7786.MCR-06-0090; Kinsey M, 2009, CANCER RES, V69, P9047, DOI 10.1158/0008-5472.CAN-09-1540; Lessnick SL, 2002, CANCER CELL, V1, P393, DOI 10.1016/S1535-6108(02)00056-9; LESSNICK SL, 1995, ONCOGENE, V10, P423; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; Owen LA, 2006, CELL CYCLE, V5, P2049, DOI 10.4161/cc.5.18.3213; Owen LA, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001965; Perissi V, 2010, NAT REV GENET, V11, P109, DOI 10.1038/nrg2736; Petermann R, 1998, ONCOGENE, V17, P603, DOI 10.1038/sj.onc.1201964; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; Ramakrishnan R, 2004, ONCOGENE, V23, P7087, DOI 10.1038/sj.onc.1207927; Schaefer KL, 2008, EUR J CANCER, V44, P699, DOI 10.1016/j.ejca.2008.01.020; Seth A, 2005, EUR J CANCER, V41, P2462, DOI 10.1016/j.ejca.2005.08.013; Shukla N, 2012, CLIN CANCER RES, V18, P748, DOI 10.1158/1078-0432.CCR-11-2056; Smith R, 2006, CANCER CELL, V9, P405, DOI 10.1016/j.ccr.2006.04.004; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Wang Y, 2009, CELL, V138, P660, DOI 10.1016/j.cell.2009.05.050	34	94	96	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2013	32	42					5089	5100		10.1038/onc.2012.525	http://dx.doi.org/10.1038/onc.2012.525			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238IB	23178492	Green Accepted			2022-12-28	WOS:000325937900010
J	Janssen, A; Medema, RH				Janssen, A.; Medema, R. H.			Genetic instability: tipping the balance	ONCOGENE			English	Review						chromosome instability; cancer; mitosis; DNA damage; translocations; aneuploidy	SPINDLE-ASSEMBLY CHECKPOINT; MEROTELIC KINETOCHORE ORIENTATION; TUMOR-SUPPRESSOR GENE; CANCER CELL-LINES; COMPARATIVE GENOMIC HYBRIDIZATION; PREMATURE CHROMATID SEPARATION; MOSAIC VARIEGATED ANEUPLOIDY; WHOLE CHROMOSOME INSTABILITY; AGING-ASSOCIATED PHENOTYPES; MAMMALIAN TISSUE-CELLS	Tumor cells typically contain a genome that is highly divergent from the genome of normal, non-transformed cells. This genetic divergence is caused by a number of distinct changes that the tumor cell acquires during its transformation from a normal cell into a tumorigenic counterpart. Changes to the genome include mutations, deletions, insertions, and also gross chromosomal aberrations, such as chromosome translocations and whole chromosome gains or losses. This genetic disorder of the tumor cell has complicated the identification of crucial driver mutations that cause cancer. Moreover, the large genetic divergence between different tumors causes them to behave very differently, and makes it difficult to predict response to therapy. In addition, tumor cells are genetically unstable and frequently acquire new mutations and/or gross chromosomal aberrations as they divide. This is beneficial for the overall capacity of a tumor to adapt to changes in its environment, but newly acquired genetic alterations can also compromise the genetic dominance of the tumor cell and thus affect tumor cell viability. Here, we review the mechanisms that can cause gross chromosomal aberrations, and discuss how these affect tumor cell viability.	[Janssen, A.; Medema, R. H.] Netherlands Canc Inst, Div Cell Biol, NL-1066 CX Amsterdam, Holland, Netherlands; [Janssen, A.] Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands; [Janssen, A.] Univ Med Ctr Utrecht, Canc Genom Ctr, Utrecht, Netherlands	Netherlands Cancer Institute; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	Medema, RH (corresponding author), Netherlands Canc Inst, Div Cell Biol, Plesmanlaan 121, NL-1066 CX Amsterdam, Holland, Netherlands.	r.medema@nki.nl	Medema, Rene H/E-2981-2013	Medema, Rene/0000-0002-6754-0381; Janssen, Aniek/0000-0001-6731-6657				Abdel-Rahman WM, 2001, P NATL ACAD SCI USA, V98, P2538, DOI 10.1073/pnas.041603298; Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Allshire RC, 2008, NAT REV GENET, V9, P923, DOI 10.1038/nrg2466; Guerrero AA, 2010, P NATL ACAD SCI USA, V107, P4159, DOI 10.1073/pnas.0912143106; Aoki K, 2007, ONCOGENE, V26, P3511, DOI 10.1038/sj.onc.1210141; Aoki K, 2007, J CELL SCI, V120, P3327, DOI 10.1242/jcs.03485; Babu JR, 2003, J CELL BIOL, V160, P341, DOI 10.1083/jcb.200211048; Baker DJ, 2008, NAT CELL BIOL, V10, P825, DOI 10.1038/ncb1744; Baker DJ, 2009, CANCER CELL, V16, P475, DOI 10.1016/j.ccr.2009.10.023; Baker DJ, 2004, NAT GENET, V36, P744, DOI 10.1038/ng1382; Baker DJ, 2006, J CELL BIOL, V172, P529, DOI 10.1083/jcb.200507081; Bakhoum SF, 2011, CLIN CANCER RES, V17, P7704, DOI 10.1158/1078-0432.CCR-11-2049; Bakhoum SF, 2009, CURR BIOL, V19, P1937, DOI 10.1016/j.cub.2009.09.055; Bakhoum SF, 2009, NAT CELL BIOL, V11, P27, DOI 10.1038/ncb1809; Barber TD, 2008, P NATL ACAD SCI USA, V105, P3443, DOI 10.1073/pnas.0712384105; Barnhart MC, 2011, J CELL BIOL, V194, P229, DOI 10.1083/jcb.201012017; Bartek J, 2003, CANCER CELL, V3, P421, DOI 10.1016/S1535-6108(03)00110-7; Baudis M, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-226; BENDER MA, 1974, MUTAT RES, V23, P197, DOI 10.1016/0027-5107(74)90140-7; Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822; Bin OY, 2002, CLIN ENDOCRINOL, V56, P341, DOI 10.1046/j.1365-2265.2002.01475.x; Birkbak NJ, 2011, CANCER RES, V71, P3447, DOI 10.1158/0008-5472.CAN-10-3667; Boveri T, 1914, FRAGE ENTSTEHUNG MAL, V1; Burds AA, 2005, P NATL ACAD SCI USA, V102, P11296, DOI 10.1073/pnas.0505053102; Cahill DP, 1999, GENOMICS, V58, P181, DOI 10.1006/geno.1999.5831; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Carter SL, 2006, NAT GENET, V38, P1043, DOI 10.1038/ng1861; Castro MAA, 2006, MUTAT RES-FUND MOL M, V600, P150, DOI 10.1016/j.mrfmmm.2006.04.003; Chan KL, 2009, NAT CELL BIOL, V11, P753, DOI 10.1038/ncb1882; Chan KL, 2007, EMBO J, V26, P3397, DOI 10.1038/sj.emboj.7601777; Chesnokova V, 2005, MOL ENDOCRINOL, V19, P2371, DOI 10.1210/me.2005-0137; Chi YH, 2009, INT J CANCER, V124, P1483, DOI 10.1002/ijc.24094; Choi CM, 2009, LUNG CANCER, V64, P66, DOI 10.1016/j.lungcan.2008.07.016; Cimini D, 2004, CURR BIOL, V14, P2149, DOI 10.1016/j.cub.2004.11.029; Cimini D, 2003, J CELL SCI, V116, P4213, DOI 10.1242/jcs.00716; Cimini D, 2002, J CELL SCI, V115, P507; Cimini D, 2001, J CELL BIOL, V153, P517, DOI 10.1083/jcb.153.3.517; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Crasta K, 2012, NATURE, V482, P53, DOI 10.1038/nature10802; Dai W, 2004, CANCER RES, V64, P440, DOI 10.1158/0008-5472.CAN-03-3119; Daniel J, 2011, P NATL ACAD SCI USA, V108, P5384, DOI 10.1073/pnas.1007645108; Davidson JM, 2000, BRIT J CANCER, V83, P1309, DOI 10.1054/bjoc.2000.1458; Davoli T, 2012, CANCER CELL, V21, P765, DOI 10.1016/j.ccr.2012.03.044; Diaz-Rodriguez E, 2008, P NATL ACAD SCI USA, V105, P16719, DOI 10.1073/pnas.0803504105; Dikovskaya D, 2007, J CELL BIOL, V176, P183, DOI 10.1083/jcb.200610099; Dobles M, 2000, CELL, V101, P635, DOI 10.1016/S0092-8674(00)80875-2; Draviam VM, 2006, EMBO J, V25, P2814, DOI 10.1038/sj.emboj.7601168; Duesberg P, 2004, IUBMB LIFE, V56, P65, DOI 10.1080/15216540410001667902; Duesberg P, 1998, P NATL ACAD SCI USA, V95, P13692, DOI 10.1073/pnas.95.23.13692; Duesberg P, 2000, P NATL ACAD SCI USA, V97, P14295, DOI 10.1073/pnas.97.26.14295; Duesberg P, 2007, DRUG RESIST UPDATE, V10, P51, DOI 10.1016/j.drup.2007.02.003; Duker NJ, 2002, AM J MED GENET, V115, P125, DOI 10.1002/ajmg.10688; Duncan AW, 2010, NATURE, V467, P707, DOI 10.1038/nature09414; Fabarius A, 2003, CANCER GENET CYTOGEN, V143, P59, DOI 10.1016/S0165-4608(03)00003-7; Fodde R, 2001, NAT CELL BIOL, V3, P433, DOI 10.1038/35070129; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Ganem NJ, 2009, NATURE, V460, P278, DOI 10.1038/nature08136; Gao CF, 2007, P NATL ACAD SCI USA, V104, P8995, DOI 10.1073/pnas.0700631104; Garber ME, 2001, P NATL ACAD SCI USA, V98, P13784, DOI 10.1073/pnas.241500798; Garcia-Higuera I, 2008, NAT CELL BIOL, V10, P802, DOI 10.1038/ncb1742; Gascoigne KE, 2008, CANCER CELL, V14, P111, DOI 10.1016/j.ccr.2008.07.002; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; Gisselsson D, 2001, AM J PATHOL, V158, P199, DOI 10.1016/S0002-9440(10)63958-2; Gisselsson D, 2001, P NATL ACAD SCI USA, V98, P12683, DOI 10.1073/pnas.211357798; Gisselsson D, 2000, P NATL ACAD SCI USA, V97, P5357, DOI 10.1073/pnas.090013497; Grabsch H, 2003, J PATHOL, V200, P16, DOI 10.1002/path.1324; Hanks S, 2004, NAT GENET, V36, P1159, DOI 10.1038/ng1449; Hansemann D., 1890, ARCH PATHOL ANAT PH, V119, P299, DOI DOI 10.1007/BF01882039; Harrigan JA, 2011, J CELL BIOL, V193, P97, DOI 10.1083/jcb.201011083; Haruki N, 2001, CANCER LETT, V162, P201, DOI 10.1016/S0304-3835(00)00675-3; HASTIE ND, 1989, TRENDS GENET, V5, P326, DOI 10.1016/0168-9525(89)90137-6; HEIM S, 1986, CANCER GENET CYTOGEN, V22, P99, DOI 10.1016/0165-4608(86)90169-X; Hempen PM, 2003, HUM MUTAT, V21, DOI 10.1002/humu.9120; HENEEN WK, 1975, EXP CELL RES, V91, P57, DOI 10.1016/0014-4827(75)90140-8; Hernando E, 2004, NATURE, V430, P797, DOI 10.1038/nature02820; Heun P, 2006, DEV CELL, V10, P303, DOI 10.1016/j.devcel.2006.01.014; Holland AJ, 2012, EMBO REP, V13, P501, DOI 10.1038/embor.2012.55; Hu Z, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2487; Ichijima Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0008821; Iwaizumi M, 2009, GUT, V58, P249, DOI 10.1136/gut.2008.149468; Iwanaga Y, 2007, CANCER RES, V67, P160, DOI 10.1158/0008-5472.CAN-06-3326; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; Janssen A, 2011, ONCOGENE, V30, P2799, DOI 10.1038/onc.2011.30; Janssen A, 2011, SCIENCE, V333, P1895, DOI 10.1126/science.1210214; Janssen A, 2011, NAT CELL BIOL, V13, P199, DOI 10.1038/ncb0311-199; Janssen A, 2009, P NATL ACAD SCI USA, V106, P19108, DOI 10.1073/pnas.0904343106; Jeganathan K, 2007, J CELL BIOL, V179, P255, DOI 10.1083/jcb.200706015; Kabeche L, 2012, CURR BIOL, V22, P638, DOI 10.1016/j.cub.2012.02.030; Kalitsis P, 2000, GENE DEV, V14, P2277, DOI 10.1101/gad.827500; Kalitsis P, 2005, GENE CHROMOSOME CANC, V44, P29, DOI 10.1002/gcc.20215; Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123; Kasai T, 2002, J BIOL CHEM, V277, P5187, DOI 10.1074/jbc.M110295200; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; Kolodner RD, 2011, SCIENCE, V333, P942, DOI 10.1126/science.1211154; Kops GJPL, 2004, P NATL ACAD SCI USA, V101, P8699, DOI 10.1073/pnas.0401142101; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Kracjovic M, 2010, NATURE CELL BIOL; Kuukasjarvi T, 1997, CANCER RES, V57, P1597; Lee AJX, 2011, CANCER RES, V71, P1858, DOI 10.1158/0008-5472.CAN-10-3604; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Li M, 2010, P NATL ACAD SCI USA, V107, P14188, DOI 10.1073/pnas.1005960107; Li M, 2009, J CELL BIOL, V185, P983, DOI 10.1083/jcb.200904020; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lukas C, 2011, NAT CELL BIOL, V13, P243, DOI 10.1038/ncb2201; LUONGO C, 1994, CANCER RES, V54, P5947; Malureanu L, 2010, J CELL BIOL, V191, P313, DOI 10.1083/jcb.201003090; Manning AL, 2011, TRENDS CELL BIOL, V21, P433, DOI 10.1016/j.tcb.2011.05.003; Manning AL, 2010, GENE DEV, V24, P1364, DOI 10.1101/gad.1917310; Matsuura S, 2000, AM J HUM GENET, V67, P483, DOI 10.1086/303022; Matsuura S, 2006, AM J MED GENET A, V140A, P358, DOI 10.1002/ajmg.a.31069; McClelland SE, 2009, CELL CYCLE, V8, P3262, DOI 10.4161/cc.8.20.9690; McClintock B, 1938, GENETICS, V23, P315; McClintock B, 1941, GENETICS, V26, P234; McGranahan N, 2012, EMBO REP, V13, P528, DOI 10.1038/embor.2012.61; Michel L, 2004, P NATL ACAD SCI USA, V101, P4459, DOI 10.1073/pnas.0306069101; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Minhas KM, 2003, INT J CANCER, V107, P46, DOI 10.1002/ijc.11341; Mitelman F, 1997, CANCER GENET CYTOGEN, V95, P1, DOI 10.1016/S0165-4608(96)00252-X; Mitelman F, 2012, MITELMAN DATABASE CH; Mitelman F, 2007, NAT REV CANCER, V7, P233, DOI 10.1038/nrc2091; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; Myrie KA, 2000, CANCER LETT, V152, P193, DOI 10.1016/S0304-3835(00)00340-2; Nambiar M, 2008, BBA-REV CANCER, V1786, P139, DOI 10.1016/j.bbcan.2008.07.005; Nasmyth K, 2009, ANNU REV GENET, V43, P525, DOI 10.1146/annurev-genet-102108-134233; Natarajan AT, 2008, MUTAT RES-GEN TOX EN, V657, P3, DOI 10.1016/j.mrgentox.2008.08.017; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Nishizaki T, 1997, INT J CANCER, V74, P513, DOI 10.1002/(SICI)1097-0215(19971021)74:5<513::AID-IJC6>3.3.CO;2-X; Nishizaki T, 1997, GENE CHROMOSOME CANC, V19, P267, DOI 10.1002/(SICI)1098-2264(199708)19:4<267::AID-GCC9>3.0.CO;2-V; Nowak MA, 2002, P NATL ACAD SCI USA, V99, P16226, DOI 10.1073/pnas.202617399; NOWELL P C, 1962, Blut, V8, P65; Obe G, 2010, CYTOGENET GENOME RES, V128, P8, DOI 10.1159/000303328; Obe G, 2002, MUTAT RES-FUND MOL M, V504, P17, DOI 10.1016/S0027-5107(02)00076-3; Olszak AM, 2011, NAT CELL BIOL, V13, P799, DOI 10.1038/ncb2272; Overholtzer M, 2008, NAT REV MOL CELL BIO, V9, P796, DOI 10.1038/nrm2504; Overholtzer M, 2007, CELL, V131, P966, DOI 10.1016/j.cell.2007.10.040; Pampalona J, 2010, GENE CHROMOSOME CANC, V49, P368, DOI 10.1002/gcc.20749; Pavelka N, 2010, NATURE, V468, P321, DOI 10.1038/nature09529; Pei L, 1997, MOL ENDOCRINOL, V11, P433, DOI 10.1210/me.11.4.433; Pfau SJ, 2012, EMBO REP, V13, P515, DOI 10.1038/embor.2012.65; Pihan GA, 2001, CANCER RES, V61, P2212; Rajagopalan H, 2004, NATURE, V432, P338, DOI 10.1038/nature03099; Rajagopalan H, 2003, NAT REV CANCER, V3, P695, DOI 10.1038/nrc1165; Rancati G, 2008, CELL, V135, P879, DOI 10.1016/j.cell.2008.09.039; Rao CV, 2005, P NATL ACAD SCI USA, V102, P4365, DOI 10.1073/pnas.0407822102; Rehen SK, 2005, J NEUROSCI, V25, P2176, DOI 10.1523/JNEUROSCI.4560-04.2005; Remeseiro S, 2012, EMBO J, V31, P2076, DOI 10.1038/emboj.2012.11; Ricke RM, 2008, TRENDS GENET, V24, P457, DOI 10.1016/j.tig.2008.07.002; Ricke RM, 2011, J CELL BIOL, V193, P1049, DOI 10.1083/jcb.201012035; Roschke AV, 2003, CANCER RES, V63, P8634; Roylance R, 2011, CANCER EPIDEM BIOMAR, V20, P2183, DOI 10.1158/1055-9965.EPI-11-0343; Rusan NM, 2008, J CELL BIOL, V181, P719, DOI 10.1083/jcb.200802107; Ryan SD, 2012, P NATL ACAD SCI USA, V109, pE2205, DOI 10.1073/pnas.1201911109; Saeki A, 2002, CANCER-AM CANCER SOC, V94, P2047, DOI 10.1002/cncr.10448; Salimian KJ, 2011, CURR BIOL, V21, P1158, DOI 10.1016/j.cub.2011.06.015; Sato N, 2001, CANCER GENET CYTOGEN, V126, P13, DOI 10.1016/S0165-4608(00)00384-8; Schliekelman M, 2009, CANCER RES, V69, P45, DOI 10.1158/0008-5472.CAN-07-6330; Schvartzman JM, 2011, CANCER CELL, V19, P701, DOI 10.1016/j.ccr.2011.04.017; Sheffer M, 2009, P NATL ACAD SCI USA, V106, P7131, DOI 10.1073/pnas.0902232106; Sheltzer JM, 2011, SCIENCE, V333, P1026, DOI 10.1126/science.1206412; Shi QH, 2005, NATURE, V437, P1038, DOI 10.1038/nature03958; Silkworth WT, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006564; Sluder G, 1997, J CELL SCI, V110, P421; Solomon DA, 2011, SCIENCE, V333, P1039, DOI 10.1126/science.1203619; Sotillo R, 2007, CANCER CELL, V11, P9, DOI 10.1016/j.ccr.2006.10.019; Sotillo R, 2010, NATURE, V464, P436, DOI 10.1038/nature08803; Stewenius Y, 2007, CLIN CANCER RES, V13, P6593, DOI 10.1158/1078-0432.CCR-07-1081; Stolz A, 2010, NAT CELL BIOL, V12, P492, DOI 10.1038/ncb2051; Suijkerbuijk SJE, 2010, CANCER RES, V70, P4891, DOI 10.1158/0008-5472.CAN-09-4319; Swanton C, 2009, P NATL ACAD SCI USA, V106, P8671, DOI 10.1073/pnas.0811835106; Sze KMF, 2004, J BIOMED SCI, V11, P920, DOI 10.1159/000081839; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Tanaka K, 2001, JPN J CANCER RES, V92, P952, DOI 10.1111/j.1349-7006.2001.tb01186.x; Thompson SL, 2008, J CELL BIOL, V180, P665, DOI 10.1083/jcb.200712029; Thompson SL, 2011, P NATL ACAD SCI USA, V108, P17974, DOI 10.1073/pnas.1109720108; Thompson SL, 2010, J CELL BIOL, V188, P369, DOI 10.1083/jcb.200905057; Tighe A, 2001, EMBO REP, V2, P609, DOI 10.1093/embo-reports/kve127; Tomonaga T, 2003, CANCER RES, V63, P3511; Torres EM, 2007, SCIENCE, V317, P916, DOI 10.1126/science.1142210; Torres EM, 2010, CELL, V143, P71, DOI 10.1016/j.cell.2010.08.038; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; van der Waal MS, 2012, EXP CELL RES, V318, P1407, DOI 10.1016/j.yexcr.2012.03.015; Van Hooser AA, 2001, J CELL SCI, V114, P3529; van Ree JH, 2010, J CELL BIOL, V188, P83, DOI 10.1083/jcb.200906147; Walther A, 2008, GUT, V57, P941, DOI 10.1136/gut.2007.135004; Wang Q, 2004, BLOOD, V103, P1278, DOI 10.1182/blood-2003-06-2158; Wang XH, 2002, CANCER RES, V62, P1662; Wang XH, 2000, CARCINOGENESIS, V21, P2293, DOI 10.1093/carcin/21.12.2293; Wang ZH, 2004, CANCER RES, V64, P2998, DOI 10.1158/0008-5472.CAN-04-0587; Wang ZY, 2001, MOL ENDOCRINOL, V15, P1870, DOI 10.1210/me.15.11.1870; Weaver BAA, 2003, J CELL BIOL, V162, P551, DOI 10.1083/jcb.200303167; Weaver BAA, 2007, CANCER CELL, V11, P25, DOI 10.1016/j.ccr.2006.12.003; Weaver BAA, 2006, CURR OPIN CELL BIOL, V18, P658, DOI 10.1016/j.ceb.2006.10.002; Weitzel DH, 2000, CELL TISSUE RES, V300, P57, DOI 10.1007/s004410000189; Williams BR, 2008, SCIENCE, V322, P703, DOI 10.1126/science.1160058; Yoon DS, 2002, AM J PATHOL, V161, P391, DOI 10.1016/S0002-9440(10)64194-6; Yuan BB, 2006, CLIN CANCER RES, V12, P405, DOI 10.1158/1078-0432.CCR-05-0903; Zhang DW, 2004, ONCOGENE, V23, P8720, DOI 10.1038/sj.onc.1208153; Zhang JY, 2007, J CELL BIOL, V178, P773, DOI 10.1083/jcb.200702138; Zhang NG, 2008, P NATL ACAD SCI USA, V105, P13033, DOI 10.1073/pnas.0801610105	202	69	72	1	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2013	32	38					4459	4470		10.1038/onc.2012.576	http://dx.doi.org/10.1038/onc.2012.576			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223SW	23246960				2022-12-28	WOS:000324831300001
J	Ray-David, H; Romeo, Y; Lavoie, G; Deleris, P; Tcherkezian, J; Galan, JA; Roux, PP				Ray-David, H.; Romeo, Y.; Lavoie, G.; Deleris, P.; Tcherkezian, J.; Galan, J. A.; Roux, P. P.			RSK promotes G2 DNA damage checkpoint silencing and participates in melanoma chemoresistance	ONCOGENE			English	Article						MAPK; RSK; Chk1; DNA damage; melanoma; chemoresistance	RIBOSOMAL S6 KINASE; SIGNAL-REGULATED KINASE; PROTEIN-KINASE; CHK1; PHOSPHORYLATION; RAS; INHIBITION; RESISTANCE; SURVIVAL; PATHWAY	The incidence of malignant melanoma is growing rapidly worldwide and there is still no effective therapy for metastatic disease. This type of cancer is highly resistant to conventional DNA-damaging chemotherapeutics, and intense research has been dedicated for understanding the molecular pathways underlying chemoresistance. The Ras/mitogen-activated protein kinase (MAPK) signalling pathway is often deregulated in melanoma, which frequently harbours activating mutations in NRAS or BRAF. Herein, we demonstrate that the MAPK-activated protein kinase RSK (p90 ribosomal S6 kinase) contributes to melanoma chemoresistance by altering their response to chemotherapeutic agents. We find that RSK phosphorylates checkpoint kinase 1 (Chk1) at an inhibitory site, Ser280, both in vitro and in vivo. Our results indicate that RSK is the predominant protein kinase operating downstream of mitogens and oncogenes of the Ras/MAPK pathway, and consistent with this, we find that RSK constitutively phosphorylates Chk1 in melanoma. We show that RSK inhibition increases Chk1 activity in response to DNA-damaging agents, suggesting that the Ras/MAPK pathway modulates Chk1 function and the response to DNA damage. Accordingly, we demonstrate that RSK promotes G2 DNA damage checkpoint silencing in a Chk1-dependent manner, and find that RSK inhibitors sensitize melanoma cells to DNA-damaging agents. Together, our results identify a novel link between the Ras/MAPK pathway and the DNA damage response, and suggest that RSK inhibitors may be used to modulate chemosensitivity, which is one of the major obstacles to melanoma treatment.	[Ray-David, H.; Romeo, Y.; Lavoie, G.; Deleris, P.; Tcherkezian, J.; Galan, J. A.; Roux, P. P.] Univ Montreal, Inst Res Immunol & Canc, Montreal, PQ H3C 3J7, Canada; [Roux, P. P.] Univ Montreal, Fac Med, Dept Pathol & Cell Biol, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Universite de Montreal	Roux, PP (corresponding author), Univ Montreal, Inst Res Immunol & Canc, POB 6128,Stn Ctr Ville, Montreal, PQ H3C 3J7, Canada.	philippe.roux@umontreal.ca	Roux, Philippe P./J-3996-2012; Romeo, Yves/AAC-1669-2021	Roux, Philippe P./0000-0002-5962-0250; Galan, Jacob/0000-0003-3304-0474	Canadian Cancer Society Research Institute [700878]; Cancer Research Society [DF121153]; Canadian Institutes of Health Research (CIHR)	Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS)); Cancer Research Society; Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR))	We thank all the members of our laboratory for their insightful discussions and comments on the manuscript and the data. This work was supported by grants from the Canadian Cancer Society Research Institute (700878) and the Cancer Research Society (DF121153) PP Roux holds a Canada Research Chair in Signal Transduction and Proteomics. JA Galan holds a postdoctoral fellowship from the Canadian Institutes of Health Research (CIHR). IRIC core facilities are supported by the FRSQ.	Bain J, 2007, BIOCHEM J, V408, P297, DOI 10.1042/BJ20070797; Cargnello M, 2011, MICROBIOL MOL BIOL R, V75, P50, DOI 10.1128/MMBR.00031-10; Caron E, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.68; Carriere A, 2008, CURR BIOL, V18, P1269, DOI 10.1016/j.cub.2008.07.078; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chen Y, 2008, FRONT BIOSCI-LANDMRK, V13, P5016; Clark DE, 2005, CANCER RES, V65, P3108; Cohen MS, 2005, SCIENCE, V308, P1318, DOI 10.1126/science1108367; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Dhomen N, 2007, CURR OPIN GENET DEV, V17, P31, DOI 10.1016/j.gde.2006.12.005; Eton O, 1998, J CLIN ONCOL, V16, P1103, DOI 10.1200/JCO.1998.16.3.1103; Fecher LA, 2008, CURR OPIN ONCOL, V20, P183, DOI 10.1097/CCO.0b013e3282f5271c; Flaherty KT, 2006, CLIN CANCER RES, V12, p2366S, DOI 10.1158/1078-0432.CCR-05-2505; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Gogas HJ, 2007, CANCER-AM CANCER SOC, V109, P455, DOI 10.1002/cncr.22427; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Joseph EW, 2010, P NATL ACAD SCI USA, V107, P14903, DOI 10.1073/pnas.1008990107; Julien LA, 2010, MOL CELL BIOL, V30, P908, DOI 10.1128/MCB.00601-09; King FW, 2004, CELL CYCLE, V3, P634; Koberle B, 2010, BBA-REV CANCER, V1806, P172, DOI 10.1016/j.bbcan.2010.07.004; Li P, 2012, MOL BIOL CELL, V23, P1582, DOI 10.1091/mbc.E11-10-0883; Liu XS, 2010, PROTEIN CELL, V1, P999, DOI 10.1007/s13238-010-0131-x; Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097; Mamely I, 2006, CURR BIOL, V16, P1950, DOI 10.1016/j.cub.2006.08.026; Markovic SN, 2007, MAYO CLIN PROC, V82, P490, DOI 10.4065/82.4.490; Meloche S, 2007, ONCOGENE, V26, P3227, DOI 10.1038/sj.onc.1210414; Michaloglou C, 2008, ONCOGENE, V27, P877, DOI 10.1038/sj.onc.1210704; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Niida H, 2007, MOL CELL BIOL, V27, P2572, DOI 10.1128/MCB.01611-06; Old WM, 2009, MOL CELL, V34, P115, DOI 10.1016/j.molcel.2009.03.007; Peschiaroli A, 2006, MOL CELL, V23, P319, DOI 10.1016/j.molcel.2006.06.013; Puc J, 2005, CANCER CELL, V7, P193, DOI 10.1016/j.ccr.2005.01.009; Romeo Y, 2012, BIOCHEM J, V441, P553, DOI 10.1042/BJ20110289; Romeo Y, 2011, EXPERT OPIN THER TAR, V15, P5, DOI 10.1517/14728222.2010.531014; Roux PP, 2007, J BIOL CHEM, V282, P14056, DOI 10.1074/jbc.M700906200; Roux PP, 2003, MOL CELL BIOL, V23, P4796, DOI 10.1128/MCB.23.14.4796-4804.2003; Roux PP, 2004, P NATL ACAD SCI USA, V101, P13489, DOI 10.1073/pnas.0405659101; Rubinfeld H, 2005, MOL BIOTECHNOL, V31, P151, DOI 10.1385/MB:31:2:151; Sapkota GP, 2007, BIOCHEM J, V401, P29, DOI 10.1042/BJ20061088; Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109; Shtivelman E, 2002, CURR BIOL, V12, P919, DOI 10.1016/S0960-9822(02)00843-6; Smith JA, 2005, CANCER RES, V65, P1027; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; van de Weerdt BCM, 2006, CELL CYCLE, V5, P853, DOI 10.4161/cc.5.8.2692; Walker M, 2009, ONCOGENE, V28, P2314, DOI 10.1038/onc.2009.102; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218	49	26	29	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2013	32	38					4480	4489		10.1038/onc.2012.472	http://dx.doi.org/10.1038/onc.2012.472			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223SW	23108403				2022-12-28	WOS:000324831300003
J	Eberlein, C; Kendrew, J; McDaid, K; Alfred, A; Kang, JS; Jacobs, VN; Ross, SJ; Rooney, C; Smith, NR; Rinkenberger, J; Cao, A; Churchman, A; Marshall, JF; Weir, HM; Bedian, V; Blakey, DC; Foltz, IN; Barry, ST				Eberlein, C.; Kendrew, J.; McDaid, K.; Alfred, A.; Kang, J. S.; Jacobs, V. N.; Ross, S. J.; Rooney, C.; Smith, N. R.; Rinkenberger, J.; Cao, A.; Churchman, A.; Marshall, J. F.; Weir, H. M.; Bedian, V.; Blakey, D. C.; Foltz, I. N.; Barry, S. T.			A human monoclonal antibody 264RAD targeting alpha v beta 6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo	ONCOGENE			English	Article						integrin; alpha v beta 6; alpha v beta 8; beta-6; beta-8; TGF-beta	SQUAMOUS CARCINOMA-CELLS; EPITHELIAL OVARIAN-CANCER; MOUTH-DISEASE VIRUS; FACTOR-BETA; BREAST-CANCER; UP-REGULATION; ACTIVATION; EXPRESSION; FIBROSIS; INVASION	alpha v beta 6 integrin expression is upregulated on a wide range of epithelial tumours, and is thought to play a role in modulating tumour growth. Here we describe a human therapeutic antibody 264RAD, which binds and inhibits alpha v beta 6 integrin function. 264RAD cross-reacts with human, mouse and cynomolgus monkey alpha v beta 6, and inhibits binding to all ligands including the latency-associated peptide of TGF-beta. Screening across a range of integrins revealed that 264RAD also binds and inhibits the related integrin alpha v beta 8, but not the integrins alpha 5 beta 1, alpha v beta 3, alpha v beta 5 and alpha 4 beta 1. In vitro 264RAD inhibited invasion of VB6 and Detroit 562 cells in a Matrigel invasion assay and alpha v beta 6 mediated production of matrix metalloproteinase-9 in Calu-3 cells. It inhibited TGF-beta-mediated activation of dermal skin fibroblasts by preventing local activation of TGF-beta by NCI-H358 tumour cells in a tumour cell - fibroblast co-culture assay. In vivo 264RAD showed dose-dependent inhibition of Detroit 562 tumour growth, regressing established tumours when dosed at 20 mg/kg once weekly. The reduction in growth associated with 264RAD was related to a dose-dependent inhibition of Ki67 and phospho-ERK and a reduction of alpha v beta 6 expression in the tumour cells, coupled to a reduction in fibronectin and alpha smooth muscle actin expression in stromal fibroblasts. 264RAD also reduced the growth and metastasis of orthotopic 4T1 tumours. At 20 mg/kg growth of both the primary tumour and the number of metastatic deposits in lung were reduced. The data support the conclusion that 264RAD is a potent inhibitor of alpha v beta 6 integrin, with some activity against alpha v beta 8 integrin, that reduces both tumour growth and metastasis.	[Eberlein, C.; Kendrew, J.; McDaid, K.; Jacobs, V. N.; Ross, S. J.; Rooney, C.; Smith, N. R.; Weir, H. M.; Blakey, D. C.; Barry, S. T.] AstraZeneca, Oncol iMED, Macclesfield SK10 4TG, Cheshire, England; [Alfred, A.; Kang, J. S.; Rinkenberger, J.; Foltz, I. N.] Amgen Inc, Burnaby, BC, Canada; [Cao, A.; Bedian, V.] AstraZeneca R&D Boston, Oncol iMED, Waltham, MA USA; [Churchman, A.; Marshall, J. F.] Queen Mary Univ London, Barts Canc Inst, London, England	AstraZeneca; AstraZeneca; University of London; Queen Mary University London	Barry, ST (corresponding author), AstraZeneca, Oncol iMED, Alderley Pk, Macclesfield SK10 4TG, Cheshire, England.	Simon.T.Barry@astrazeneca.com		Marshall, John/0000-0002-0494-2295	MRC; Medical Research Council [G0800825] Funding Source: researchfish; MRC [G0800825] Funding Source: UKRI	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	Adrian Churchman was funded by a MRC Pilot Award.	Ahmed N, 2002, ONCOGENE, V21, P1370, DOI 10.1038/sj.onc.1205286; Ahmed N, 2002, J HISTOCHEM CYTOCHEM, V50, P1371, DOI 10.1177/002215540205001010; Ahmed N, 2002, CARCINOGENESIS, V23, P237, DOI 10.1093/carcin/23.2.237; Al-Hazmi N, 2007, EUR J ORAL SCI, V115, P454, DOI 10.1111/j.1600-0722.2007.00481.x; Aluwihare P, 2009, J CELL SCI, V122, P227, DOI 10.1242/jcs.035246; Annes JP, 2004, J CELL BIOL, V165, P723, DOI 10.1083/jcb.200312172; Arihiro K, 2000, Breast Cancer, V7, P19, DOI 10.1007/BF02967183; Azare J, 2007, MOL CELL BIOL, V27, P4444, DOI 10.1128/MCB.02404-06; Babcook JS, 1996, P NATL ACAD SCI USA, V93, P7843, DOI 10.1073/pnas.93.15.7843; Bates RC, 2005, J CLIN INVEST, V115, P339, DOI 10.1172/JCI200523183; BREUSS JM, 1995, J CELL SCI, V108, P2241; BUSK M, 1992, J BIOL CHEM, V267, P5790; Cambier S, 2005, AM J PATHOL, V166, P1883, DOI 10.1016/S0002-9440(10)62497-2; Cambier S, 2000, CANCER RES, V60, P7084; Culhane AC, 2009, CANCER RES, V69, P7480, DOI 10.1158/0008-5472.CAN-08-3350; DeRose YS, 2011, NAT MED, V17, P1514, DOI 10.1038/nm.2454; DiCara D, 2007, J BIOL CHEM, V282, P9657, DOI 10.1074/jbc.M610461200; Elayadi AN, 2007, CANCER RES, V67, P5889, DOI 10.1158/0008-5472.CAN-07-0245; Fang L, 2011, ONCOGENE, V30, P806, DOI 10.1038/onc.2010.465; Fleming YM, 2009, ONCOGENE, V28, P983, DOI 10.1038/onc.2008.449; Hahm K, 2007, AM J PATHOL, V170, P110, DOI 10.2353/ajpath.2007.060158; Hannigan A, 2010, J CLIN INVEST, V120, P2842, DOI 10.1172/JCI36125; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Horan GS, 2008, AM J RESP CRIT CARE, V177, P56, DOI 10.1164/rccm.200706-805OC; Jenkins RG, 2006, J CLIN INVEST, V116, P1606, DOI 10.1172/JCI27183; Kogelberg H, 2008, J MOL BIOL, V382, P385, DOI 10.1016/j.jmb.2008.07.013; Ludbrook SB, 2003, BIOCHEM J, V369, P311, DOI 10.1042/BJ20020809; Ma LJ, 2003, AM J PATHOL, V163, P1261, DOI 10.1016/S0002-9440(10)63486-4; Marsh D, 2008, CANCER RES, V68, P3295, DOI 10.1158/0008-5472.CAN-08-0174; Mateu MG, 1996, J BIOL CHEM, V271, P12814, DOI 10.1074/jbc.271.22.12814; Morgan MR, 2011, ONCOGENE, V30, P1422, DOI 10.1038/onc.2010.535; Morgan MR, 2004, J BIOL CHEM, V279, P26533, DOI 10.1074/jbc.M401736200; Mu DZ, 2002, J CELL BIOL, V157, P493, DOI 10.1083/jcb.200109100; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Popov Y, 2008, J HEPATOL, V48, P453, DOI 10.1016/j.jhep.2007.11.021; Puthawala K, 2008, AM J RESP CRIT CARE, V177, P82, DOI 10.1164/rccm.200706-806OC; Ramsay AG, 2007, CANCER RES, V67, P5275, DOI 10.1158/0008-5472.CAN-07-0318; Regezi JA, 2002, ORAL ONCOL, V38, P332, DOI 10.1016/S1368-8375(01)00062-8; RONNOVJESSEN L, 1993, LAB INVEST, V68, P696; Ryer EJ, 2006, ARTERIOSCL THROM VAS, V26, P780, DOI 10.1161/01.ATV.0000209517.00220.cd; SHEPPARD D, 1990, J BIOL CHEM, V265, P11502; Sipos B, 2004, HISTOPATHOLOGY, V45, P226, DOI 10.1111/j.1365-2559.2004.01919.x; Su H, 2010, AM J PATHOL, V176, P1018, DOI 10.2353/ajpath.2010.090453; Thomas GJ, 2002, BRIT J CANCER, V87, P859, DOI 10.1038/sj.bjc.6600545; Thomas GJ, 2001, INT J CANCER, V92, P641, DOI 10.1002/1097-0215(20010601)92:5<641::AID-IJC1243>3.0.CO;2-P; Thomas GJ, 2001, J INVEST DERMATOL, V117, P67, DOI 10.1046/j.0022-202x.2001.01379.x; Van Aarsen LAK, 2008, CANCER RES, V68, P561, DOI 10.1158/0008-5472.CAN-07-2307; Yokosaki Y, 1996, J BIOL CHEM, V271, P24144, DOI 10.1074/jbc.271.39.24144; Zhong ZJ, 2010, CLIN CANCER RES, V16, P1191, DOI 10.1158/1078-0432.CCR-09-1634	49	59	64	1	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 12	2013	32	37					4406	4416		10.1038/onc.2012.460	http://dx.doi.org/10.1038/onc.2012.460			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	218AF	23108397				2022-12-28	WOS:000324404200009
J	Cai, Y; Geutjes, EJ; de Lint, K; Roepman, P; Bruurs, L; Yu, LR; Wang, W; van Blijswijk, J; Mohammad, H; de Rink, I; Bernards, R; Baylin, SB				Cai, Y.; Geutjes, E-J; de Lint, K.; Roepman, P.; Bruurs, L.; Yu, L-R; Wang, W.; van Blijswijk, J.; Mohammad, H.; de Rink, I.; Bernards, R.; Baylin, S. B.			The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes	ONCOGENE			English	Article						NuRD; DNMTs; tumor suppressor genes; silencing; colon cancer; WNT signaling	HISTONE DEACETYLASE INHIBITION; CHROMATIN-REMODELING COMPLEX; DNA METHYLATION; FACTOR CHD4; CANCER; METHYLTRANSFERASE; HYPERMETHYLATION; DEMETHYLATION; EXPRESSION; DAMAGE	Many tumor suppressor genes (TSGs) are silenced through synergistic layers of epigenetic regulation including abnormal DNA hypermethylation of promoter CpG islands, repressive chromatin modifications and enhanced nucleosome deposition over transcription start sites. The protein complexes responsible for silencing of many of such TSGs remain to be identified. Our previous work demonstrated that multiple silenced TSGs in colorectal cancer cells can be partially reactivated by DNA demethylation in cells disrupted for the DNA methyltransferases 1 and 3B (DNMT1 and 3B) or by DNMTi inhibitors (DNMTi). Herein, we used proteomic and functional genetic approaches to identify additional proteins that cooperate with DNMTs in silencing these key silenced TSGs in colon cancer cells. We discovered that DNMTs and the core components of the NuRD (Mi-2/nucleosome remodeling and deacetylase) nucleosome remodeling complex, chromo domain helicase DNA-binding protein 4 (CHD4) and histone deacetylase 1 (HDAC1) occupy the promoters of several of these hypermethylated TSGs and physically and functionally interact to maintain their silencing. Consistent with this, we find an inverse relationship between expression of HDAC1 and 2 and these TSGs in a large panel of primary colorectal tumors. We demonstrate that DNMTs and NuRD cooperate to maintain the silencing of several negative regulators of the WNT and other signaling pathways. We find that depletion of CHD4 is synergistic with DNMT inhibition in reducing the viability of colon cancer cells in correlation with reactivation of TSGs, suggesting that their combined inhibition may be beneficial for the treatment of colon cancer. Since CHD4 has ATPase activity, our data identify CHD4 as a potentially novel drug target in cancer.	[Cai, Y.; Wang, W.; Mohammad, H.; Baylin, S. B.] Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21287 USA; [Cai, Y.; Wang, W.; Mohammad, H.; Baylin, S. B.] Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21287 USA; [Geutjes, E-J; de Lint, K.; Bruurs, L.; van Blijswijk, J.; Bernards, R.] Netherlands Canc Inst, Div Mol Carcinogenesis, Ctr Biomed Genet, NL-1066 CX Amsterdam, North Holland, Netherlands; [Geutjes, E-J; de Lint, K.; Bruurs, L.; van Blijswijk, J.; Bernards, R.] Netherlands Canc Inst, Canc Genom Ctr, NL-1066 CX Amsterdam, North Holland, Netherlands; [Roepman, P.] Agendia NV, Dept Res & Dev, Amsterdam, Netherlands; [Yu, L-R] US FDA, Div Syst Biol, Ctr Excellence Prote, Natl Ctr Toxicol Res, Jefferson, AR USA; [de Rink, I.] Netherlands Canc Inst, Cent Microarray & Deep Sequencing Core Facil, NL-1066 CX Amsterdam, North Holland, Netherlands	Johns Hopkins University; Johns Hopkins University; Johns Hopkins Medicine; Netherlands Cancer Institute; Netherlands Cancer Institute; Agendia; US Food & Drug Administration (FDA); Netherlands Cancer Institute	Bernards, R (corresponding author), Netherlands Canc Inst, Div Mol Carcinogenesis, 121 Plesmanlaan, NL-1066 CX Amsterdam, North Holland, Netherlands.	r.bernards@nki.nl; sbaylin@jhmi.edu		Yu, Li-Rong/0000-0001-6084-991X; Wang, Wei/0000-0003-1339-4080; de Lint, Klaas/0000-0001-7134-444X; Bernards, Rene/0000-0001-8677-3423	Netherlands Organization for Scientific Research (NWO); National Institute of Environmental Health Sciences (NIEHS) [ES011858]; National Cancer Institute (NCI) [CA043318]; NATIONAL CANCER INSTITUTE [R01CA043318] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES011858] Funding Source: NIH RePORTER	Netherlands Organization for Scientific Research (NWO)(Netherlands Organization for Scientific Research (NWO)); National Institute of Environmental Health Sciences (NIEHS)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); National Cancer Institute (NCI)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank JH Dannenberg for the gift of Hdac1 plasmids. We thank JH Dannenberg, P Kumar and members of the Bernards, Baylin laboratory for discussions and Kathy Bender and H. Liu for manuscript preparation. This work was supported by a grant from the Netherlands Organization for Scientific Research (NWO) to RB, and by grants ES011858 National Institute of Environmental Health Sciences (NIEHS) CA043318 National Cancer Institute (NCI) to SB. The views presented in this article do not necessarily reflect those of the US Food and Drug Administration.	Aleman A, 2008, BRIT J CANCER, V98, P466, DOI 10.1038/sj.bjc.6604143; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chodavarapu RK, 2010, NATURE, V466, P388, DOI 10.1038/nature09147; Choy JS, 2010, J AM CHEM SOC, V132, P1782, DOI 10.1021/ja910264z; Chuang LSH, 1997, SCIENCE, V277, P1996, DOI 10.1126/science.277.5334.1996; Clements EG, 2012, NUCLEIC ACIDS RES, V40, P4334, DOI 10.1093/nar/gks031; Di Croce L, 2002, SCIENCE, V295, P1079, DOI 10.1126/science.1065173; Esteve PO, 2006, GENE DEV, V20, P3089, DOI 10.1101/gad.1463706; Hashimshony T, 2003, NAT GENET, V34, P187, DOI 10.1038/ng1158; Huang Y, 2009, CLIN CANCER RES, V15, P7217, DOI 10.1158/1078-0432.CCR-09-1293; Huss M, 2009, J EXP BIOL, V212, P341, DOI 10.1242/jeb.024067; Jin QH, 2011, EMBO J, V30, P249, DOI 10.1038/emboj.2010.318; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Jurkin J, 2011, CELL CYCLE, V10, P406, DOI 10.4161/cc.10.3.14712; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691; Kazantsev AG, 2008, NAT REV DRUG DISCOV, V7, P854, DOI 10.1038/nrd2681; Kouzarides T, 2007, CELL, V128, P693, DOI 10.1016/j.cell.2007.02.005; Lai AY, 2011, NAT REV CANCER, V11, P588, DOI 10.1038/nrc3091; Larsen DH, 2010, J CELL BIOL, V190, P731, DOI 10.1083/jcb.200912135; Lin JC, 2007, CANCER CELL, V12, P432, DOI 10.1016/j.ccr.2007.10.014; Lunyak VV, 2002, SCIENCE, V298, P1747, DOI 10.1126/science.1076469; Mohammad HP, 2009, CANCER RES, V69, P6322, DOI 10.1158/0008-5472.CAN-09-0065; Morey L, 2008, MOL CELL BIOL, V28, P5912, DOI 10.1128/MCB.00467-08; Myant K, 2008, MOL CELL BIOL, V28, P215, DOI 10.1128/MCB.01073-07; Nan XS, 1998, NATURE, V393, P386, DOI 10.1038/30764; Park M, 2002, NAT CELL BIOL, V4, P20, DOI 10.1038/ncb716; Phesse TJ, 2008, MOL CELL BIOL, V28, P6094, DOI 10.1128/MCB.00539-08; Piekarz RL, 2009, J CLIN ONCOL, V27, P5410, DOI 10.1200/JCO.2008.21.6150; Polo SE, 2010, EMBO J, V29, P3130, DOI 10.1038/emboj.2010.188; Portela A, 2010, NAT BIOTECHNOL, V28, P1057, DOI 10.1038/nbt.1685; Reale A, 2005, ONCOGENE, V24, P13, DOI 10.1038/sj.onc.1208005; Rhee I, 2002, NATURE, V416, P552, DOI 10.1038/416552a; Salazar R, 2011, J CLIN ONCOL, V29, P17, DOI 10.1200/JCO.2010.30.1077; Sansom OJ, 2003, NAT GENET, V34, P145, DOI 10.1038/ng1155; Schuebel KE, 2007, PLOS GENET, V3, P1709, DOI 10.1371/journal.pgen.0030157; Smeenk G, 2010, J CELL BIOL, V190, P741, DOI 10.1083/jcb.201001048; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Suzuki H, 2002, NAT GENET, V31, P141, DOI 10.1038/ng892; Ting AH, 2006, GENE DEV, V20, P3215, DOI 10.1101/gad.1464906; Trapnell C, 2009, BIOINFORMATICS, V25, P1105, DOI 10.1093/bioinformatics/btp120; Vire E, 2006, NATURE, V439, P871, DOI 10.1038/nature04431; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Weichert W, 2008, CLIN CANCER RES, V14, P1669, DOI 10.1158/1078-0432.CCR-07-0990; Weichert W, 2009, CANCER LETT, V280, P168, DOI 10.1016/j.canlet.2008.10.047; Wilting RH, 2010, EMBO J, V29, P2586, DOI 10.1038/emboj.2010.136; Wozniak RJ, 2007, ONCOGENE, V26, P77, DOI 10.1038/sj.onc.1209763; Ying Y, 2009, EPIGENETICS-US, V4, P307, DOI 10.4161/epi.4.5.9371; Yu LR, 2007, J PROTEOME RES, V6, P4150, DOI 10.1021/pr070152u; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	51	80	82	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2014	33	17					2157	2168		10.1038/onc.2013.178	http://dx.doi.org/10.1038/onc.2013.178			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF8WJ	23708667	Green Accepted			2022-12-28	WOS:000334996000002
J	Lee, EK; Diehl, JA				Lee, E. K.; Diehl, J. A.			SCFs in the new millennium	ONCOGENE			English	Review						Skp1; cullin 1; F-box; ubiquitin	E3 UBIQUITIN LIGASE; PHOSPHORYLATION-DEPENDENT UBIQUITINATION; BOX PROTEIN BETA-TRCP1; ALPHA-B-CRYSTALLIN; BETA-TRCP; TUMOR-SUPPRESSOR; CYCLIN D1; COP9 SIGNALOSOME; MTOR INHIBITOR; C-MYC	Substrate-specific degradation is a key feature of the ubiquitin proteasome system. Substrate specificity is typically directed by the E3 or ubiquitin ligase; such specificity can be conferred either by ligase modification or expression or conversely via modification of substrates that permit their recognition by a specific E3 ligase. The most well-known example of such complexes are the Cullin-RING ligases (CRLs). CRLs are composed of one of seven cullin-family scaffold proteins; the CRL serves as a scaffold that interacts directly with a RING-domain enzyme (Rbx1/2) through an extensive protein-protein interface within the globular C-terminal domain. At the N terminus, the cullin associates with an adaptor protein through cullin-repeat motifs. This adaptor, in turn, facilitates recruitment of a substrate-specifying factor that recruits the target to be ubiquitylated. The prototypical CRL is the cul1-containing complex, commonly referred to as the Skp1-Cul1-Fbox (SCF) ligase. SCF ligases contribute to the timely destruction of numerous substrates thereby ensuring normal cell growth. The importance of SCF function is highlighted by cancer-specific alterations in either the expression or the function of select F-box substrate-specific adaptors that results in neoplastic conversion. Herein, we discuss the current understanding of SCF function and contribution to cell biology.	[Lee, E. K.; Diehl, J. A.] Leonard & Madlyn Abramson Family Canc Res Inst, Philadelphia, PA USA; [Lee, E. K.; Diehl, J. A.] Univ Penn, Perelman Sch Med, Dept Canc Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Pennsylvania Medicine	Diehl, JA (corresponding author), Abramson Family Canc Res Inst, 438 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	adiehl@mail.med.upenn.edu			 [CA133154]; NATIONAL CANCER INSTITUTE [R01CA133154] Funding Source: NIH RePORTER	; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by CA133154.	Akhoondi S, 2007, CANCER RES, V67, P9006, DOI 10.1158/0008-5472.CAN-07-1320; Barbash O, 2011, ONCOGENE, V30, P1995, DOI 10.1038/onc.2010.584; Barbash O, 2008, CANCER CELL, V14, P68, DOI 10.1016/j.ccr.2008.05.017; Bashir T, 2004, NATURE, V428, P190, DOI 10.1038/nature02330; Beier F, 2012, BLOOD, V120, P2990, DOI 10.1182/blood-2012-03-418038; Benzeno S, 2006, ONCOGENE, V25, P6291, DOI 10.1038/sj.onc.1209644; Busino L, 2012, NAT CELL BIOL, V14, P375, DOI 10.1038/ncb2463; Cope GA, 2002, SCIENCE, V298, P608, DOI 10.1126/science.1075901; Davis M, 2002, GENE DEV, V16, P439, DOI 10.1101/gad.218702; den Engelsman J, 2003, J BIOL CHEM, V278, P4699, DOI 10.1074/jbc.M211403200; Deshaies RJ, 2009, ANNU REV BIOCHEM, V78, P399, DOI 10.1146/annurev.biochem.78.101807.093809; Doronkin S, 2003, DEV CELL, V4, P699, DOI 10.1016/S1534-5807(03)00121-7; Duda DM, 2008, CELL, V134, P995, DOI 10.1016/j.cell.2008.07.022; Duda DM, 2012, MOL CELL, V47, P371, DOI 10.1016/j.molcel.2012.05.044; Elcheva I, 2009, MOL CELL, V35, P240, DOI 10.1016/j.molcel.2009.06.007; Emanuele MJ, 2011, CELL, V147, P459, DOI 10.1016/j.cell.2011.09.019; Emberley ED, 2012, J BIOL CHEM, V287, P29679, DOI 10.1074/jbc.M112.352484; Enchev RI, 2012, CELL REPORTS, V2, P616, DOI 10.1016/j.celrep.2012.08.019; Fischer ES, 2011, CELL, V147, P1024, DOI 10.1016/j.cell.2011.10.035; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Gao DM, 2011, MOL CELL, V44, P290, DOI 10.1016/j.molcel.2011.08.030; Gladden AB, 2006, ONCOGENE, V25, P998, DOI 10.1038/sj.onc.1209147; Goldenberg SJ, 2004, CELL, V119, P517, DOI 10.1016/j.cell.2004.10.019; Guardavaccaro D, 2003, DEV CELL, V4, P799, DOI 10.1016/S1534-5807(03)00154-0; Guardavaccaro D, 2008, NATURE, V452, P365, DOI 10.1038/nature06641; Hao B, 2007, MOL CELL, V26, P131, DOI 10.1016/j.molcel.2007.02.022; Hara T, 2001, J BIOL CHEM, V276, P48937, DOI 10.1074/jbc.M107274200; He Q, 2005, GENE DEV, V19, P1518, DOI 10.1101/gad.1322205; Hiramatsu Y, 2006, CANCER RES, V66, P8477, DOI 10.1158/0008-5472.CAN-06-1603; Hu R, 2010, PIGM CELL MELANOMA R, V23, P201, DOI 10.1111/j.1755-148X.2010.00668.x; Huang GC, 2011, J BIOL CHEM, V286, P10297, DOI 10.1074/jbc.M110.203729; Hulit J, 2006, CANCER RES, V66, P8529, DOI 10.1158/0008-5472.CAN-06-0149; Inuzuka H, 2011, NATURE, V471, P104, DOI 10.1038/nature09732; Inuzuka H, 2010, CANCER CELL, V18, P147, DOI 10.1016/j.ccr.2010.06.015; Ji P, 2004, MOL CELL, V16, P47, DOI 10.1016/j.molcel.2004.09.029; Jiang H, 2005, MOL CELL, V18, P699, DOI 10.1016/j.molcel.2005.05.011; Kamura T, 2004, NAT CELL BIOL, V6, P1229, DOI 10.1038/ncb1194; Kanarek N, 2010, GENE DEV, V24, P470, DOI 10.1101/gad.551610; Kim AY, 2008, J BIOL CHEM, V283, P33211, DOI 10.1074/jbc.M804440200; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Kossatz U, 2004, GENE DEV, V18, P2602, DOI 10.1101/gad.321004; Kudo Y, 2004, MOL CELL BIOL, V24, P8184, DOI 10.1128/MCB.24.18.8184-8194.2004; Kurz T, 2005, NATURE, V435, P1257, DOI 10.1038/nature03662; Lee TH, 2006, J BIOL CHEM, V281, P759, DOI 10.1074/jbc.M509855200; Lin DI, 2006, MOL CELL, V24, P355, DOI 10.1016/j.molcel.2006.09.007; Lin HK, 2010, NATURE, V464, P374, DOI 10.1038/nature08815; Lin HK, 2009, NAT CELL BIOL, V11, P420, DOI 10.1038/ncb1849; Liu H, 2007, GENE DEV, V21, P2385, DOI 10.1101/gad.1574507; Liu JD, 2002, MOL CELL, V10, P1511, DOI 10.1016/S1097-2765(02)00783-9; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Malyukova A, 2007, CANCER RES, V67, P5611, DOI 10.1158/0008-5472.CAN-06-4381; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Matsumoto ML, 2010, MOL CELL, V39, P477, DOI 10.1016/j.molcel.2010.07.001; Matsuoka S, 2008, GENE DEV, V22, P986, DOI 10.1101/gad.1621808; Mendez J, 2002, MOL CELL, V9, P481, DOI 10.1016/S1097-2765(02)00467-7; MIKOSHA A S, 1970, Problemy Endokria, V16, P90; Min SH, 2012, MOL CELL, V46, P771, DOI 10.1016/j.molcel.2012.04.012; Minella AC, 2008, GENE DEV, V22, P1677, DOI 10.1101/gad.1650208; Nakamura M, 2002, FEBS LETT, V514, P193, DOI 10.1016/S0014-5793(02)02363-3; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Olson BL, 2008, GENE DEV, V22, P252, DOI 10.1101/gad.1624208; Otto T, 2009, CANCER CELL, V15, P67, DOI 10.1016/j.ccr.2008.12.005; Passmore LA, 2005, MOL CELL, V20, P855, DOI 10.1016/j.molcel.2005.11.003; Petroski MD, 2006, MOL CELL, V24, P523, DOI 10.1016/j.molcel.2006.10.010; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Petroski MD, 2005, CELL, V123, P1107, DOI 10.1016/j.cell.2005.09.033; Petroski MD, 2003, MOL CELL, V11, P1435, DOI 10.1016/S1097-2765(03)00221-1; Pierce NW, 2009, NATURE, V462, P615, DOI 10.1038/nature08595; Popov N, 2007, NAT CELL BIOL, V9, P765, DOI 10.1038/ncb1601; Popov N, 2010, NAT CELL BIOL, V12, P973, DOI 10.1038/ncb2104; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Reed SE, 2004, CANCER RES, V64, P795, DOI 10.1158/0008-5472.CAN-03-3417; Saha A, 2008, MOL CELL, V32, P21, DOI 10.1016/j.molcel.2008.08.021; Schwechheimer C, 2001, SCIENCE, V292, P1379, DOI 10.1126/science.1059776; Shim EH, 2003, CANCER RES, V63, P1583; Spruck CH, 2002, CANCER RES, V62, P4535; Sundqvist A, 2005, CELL METAB, V1, P379, DOI 10.1016/j.cmet.2005.04.010; Tanaka T, 2012, MOL ONCOL, V6, P267, DOI 10.1016/j.molonc.2012.01.003; Tang X, 2007, CELL, V129, P1165, DOI 10.1016/j.cell.2007.04.042; Tedesco D, 2002, GENE DEV, V16, P2946, DOI 10.1101/gad.1011202; Vaites LP, 2011, MOL CELL BIOL, V31, P4513, DOI 10.1128/MCB.05733-11; van Drogen F, 2006, MOL CELL, V23, P37, DOI 10.1016/j.molcel.2006.05.020; Wei W, 2004, NATURE, V428, P194, DOI 10.1038/nature02381; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Wertz IE, 2011, NATURE, V471, P110, DOI 10.1038/nature09779; Westbrook L, 2007, CANCER RES, V67, P11393, DOI 10.1158/0008-5472.CAN-06-4173; Westbrook TF, 2008, NATURE, V452, P370, DOI 10.1038/nature06780; Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720; Wu G, 2003, MOL CELL, V11, P1445, DOI 10.1016/S1097-2765(03)00234-X; Wu K, 2010, MOL CELL, V37, P784, DOI 10.1016/j.molcel.2010.02.025; Xu P, 2009, CELL, V137, P133, DOI 10.1016/j.cell.2009.01.041; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yamoah K, 2008, P NATL ACAD SCI USA, V105, P12230, DOI 10.1073/pnas.0806155105; Yen HCS, 2008, SCIENCE, V322, P923, DOI 10.1126/science.1160462; Yen JL, 2012, MOL CELL, V48, P288, DOI 10.1016/j.molcel.2012.08.015; Yoshida Y, 2002, NATURE, V418, P438, DOI 10.1038/nature00890; Zhang W, 2006, MOL CANCER RES, V4, P935, DOI 10.1158/1541-7786.MCR-06-0253; Zhao B, 2010, GENE DEV, V24, P72, DOI 10.1101/gad.1843810; Zhao D, 2010, CANCER RES, V70, P4728, DOI 10.1158/0008-5472.CAN-10-0040; Zhao YC, 2011, MOL CELL, V44, P304, DOI 10.1016/j.molcel.2011.08.029; Zheng JY, 2002, MOL CELL, V10, P1519, DOI 10.1016/S1097-2765(02)00784-0; Zhou XZ, 2003, J CELL BIOCHEM, V89, P19, DOI 10.1002/jcb.10496	103	49	50	0	19	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2014	33	16					2011	2018		10.1038/onc.2013.144	http://dx.doi.org/10.1038/onc.2013.144			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF3GH	23624913				2022-12-28	WOS:000334599100001
J	Ordonez-Moran, P; Irmisch, A; Barbachano, A; Chicote, I; Tenbaum, S; Landolfi, S; Tabernero, J; Huelsken, J; Munoz, A; Palmer, HG				Ordonez-Moran, P.; Irmisch, A.; Barbachano, A.; Chicote, I.; Tenbaum, S.; Landolfi, S.; Tabernero, J.; Huelsken, J.; Munoz, A.; Palmer, H. G.			SPROUTY2 is a beta-catenin and FOXO3a target gene indicative of poor prognosis in colon cancer	ONCOGENE			English	Article						SPROUTY2; wnt pathway; beta-catenin; FOXO3a; colon cancer	GROWTH-FACTOR RECEPTOR; E-CADHERIN; EXPRESSION; PROTEINS; CELLS; TRANSCRIPTION; INHIBITOR; PHOSPHORYLATION; DIFFERENTIATION; BINDING	SPROUTY2 (SPRY2) is an intracellular regulator of receptor tyrosine kinase signaling involved in cell growth, differentiation and tumorigenesis. Here, we show that SPRY2 is a target gene of the Wnt/beta-catenin pathway that is abnormally activated in more than 90% of colon carcinomas. In human colon cancer cells, SPRY2 expression is induced by beta-catenin in co-operation with the transcription factor FOXO3a instead of lymphoid enhancer factor/T-cell factor proteins. We found binding of beta-catenin to the SPRY2 promoter at FOXO3a response elements. In vivo, cells marked by nuclear beta-catenin and FOXO3a express SPRY2 in proliferative epithelial tissues, such as intestinal mucosa and epidermis. Consistently, inducible beta-catenin deletion in mice reduced Spry2 expression in the small intestine. Moreover, SPRY2 protein expression correlated with nuclear beta-catenin and FOXO3a colocalization in human colon carcinomas. Importantly, the amount of SPRY2 protein correlated with shorter overall survival of colon cancer patients. Our data reveal SPRY2 as a novel Wnt beta-catenin and FOXO3a target gene indicative of poor prognosis in colon cancer.	[Ordonez-Moran, P.; Barbachano, A.; Munoz, A.] Univ Autonoma Madrid, CSIC, Inst Invest Biomed Alberto Sols, Madrid, Spain; [Ordonez-Moran, P.; Irmisch, A.; Huelsken, J.] Ecole Polytech Fed Lausanne, Swiss Inst Expt Canc Res, Lausanne, Switzerland; [Chicote, I.; Tenbaum, S.; Palmer, H. G.] VHIO, Stem Cells & Canc Lab, Translat Res Program, Barcelona 08035, Spain; [Landolfi, S.] Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Dept Pathol, Barcelona, Spain; [Tabernero, J.] Univ Autonoma Barcelona, Vall Hebron Univ Hosp, Dept Med Oncol, Barcelona, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Institute Experimental Cancer Research; Vall d'Hebron Institut d'Oncologia (VHIO); Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron	Palmer, HG (corresponding author), VHIO, Stem Cells & Canc Lab, Translat Res Program, Passeig Vall Hebron 119-129, Barcelona 08035, Spain.	hgpalmer@vhio.net	Barbachano, Antonio/O-7731-2015; Palmer, Héctor G./AAG-8332-2019; Huelsken, Joerg/AAC-9581-2021; Munoz, Alberto/O-6393-2014; Tabernero, Josep/AAG-5026-2019; Ordonez-Moran, Paloma/B-6371-2016	Barbachano, Antonio/0000-0002-1248-5143; Huelsken, Joerg/0000-0003-3105-9606; Munoz, Alberto/0000-0003-3890-4251; Tabernero, Josep/0000-0002-2495-8139; Ordonez-Moran, Paloma/0000-0001-7688-1252; Palmer, Hector/0000-0002-9823-5638; Landolfi, Stefania/0000-0002-1059-635X	Fondo Europeo de Desarrollo Regional-Instituto de Salud Carlos III; Spanish Cooperative Research Network on Cancer (RTICC) [FIS-PI081356, RD12/0036/0001, RD12/0036/0021, RD12/0036/0012]; Plan Nacional de Biomedicina, Ministerio de Economia y Competitividad [SAF-18302]; Comunidad de Madrid [S2010/BMD-2344 Colomics2]; Miguel Servet Program; Instituto de Salud Carlos III (ISCIII); EMBO	Fondo Europeo de Desarrollo Regional-Instituto de Salud Carlos III; Spanish Cooperative Research Network on Cancer (RTICC); Plan Nacional de Biomedicina, Ministerio de Economia y Competitividad; Comunidad de Madrid(Comunidad de Madrid); Miguel Servet Program; Instituto de Salud Carlos III (ISCIII)(Instituto de Salud Carlos IIIEuropean Commission); EMBO(European Molecular Biology Organization (EMBO))	We thank T Martinez for technical assistance and Hans Clevers for providing the LS174T-tetOn-Delta NTCF4 cells. Experiments were supported by grants from Fondo Europeo de Desarrollo Regional-Instituto de Salud Carlos III and Spanish Cooperative Research Network on Cancer (RTICC) (FIS-PI081356, RD12/0036/0001, RD12/0036/0021 and RD12/0036/0012), Plan Nacional de Biomedicina, Ministerio de Economia y Competitividad (SAF-18302) and Comunidad de Madrid (S2010/BMD-2344 Colomics2). HGP was supported by the Miguel Servet Program, Instituto de Salud Carlos III (ISCIII) and PO-M by an EMBO research fellowship.	Barbachano A, 2010, ONCOGENE, V29, P4800, DOI 10.1038/onc.2010.225; Barker N, 2007, GASTROENTEROLOGY, V133, P1755, DOI 10.1053/j.gastro.2007.10.029; Bloethner S, 2005, CARCINOGENESIS, V26, P1224, DOI 10.1093/carcin/bgi066; Cabrita MA, 2008, ANGIOGENESIS, V11, P53, DOI 10.1007/s10456-008-9089-1; Calnan DR, 2008, ONCOGENE, V27, P2276, DOI 10.1038/onc.2008.21; Christofori G, 2003, NAT CELL BIOL, V5, P377, DOI 10.1038/ncb0503-377; Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025; DaSilva J, 2006, MOL CELL BIOL, V26, P1898, DOI 10.1128/MCB.26.5.1898-1907.2006; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Ding W, 2003, GENE, V322, P175, DOI 10.1016/j.gene.2003.09.004; Egan JE, 2002, P NATL ACAD SCI USA, V99, P6041, DOI 10.1073/pnas.052090899; Essers MAG, 2005, SCIENCE, V308, P1181, DOI 10.1126/science.1109083; Fevr T, 2007, MOL CELL BIOL, V27, P7551, DOI 10.1128/MCB.01034-07; Filali M, 2002, J BIOL CHEM, V277, P33398, DOI 10.1074/jbc.M107977200; Fiske WH, 2009, EXP CELL RES, V315, P583, DOI 10.1016/j.yexcr.2008.10.043; Fong CW, 2006, CANCER RES, V66, P2048, DOI 10.1158/0008-5472.CAN-05-1072; Fong CW, 2003, J BIOL CHEM, V278, P33456, DOI 10.1074/jbc.M301317200; Frank MJ, 2009, BLOOD, V113, P2478, DOI 10.1182/blood-2008-05-156943; Guy GR, 2009, J ENDOCRINOL, V203, P191, DOI 10.1677/JOE-09-0110; Haglund K, 2005, EMBO REP, V6, P635, DOI 10.1038/sj.embor.7400453; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Holgren C, 2010, ONCOGENE, V29, P5241, DOI 10.1038/onc.2010.264; Hoogeboom D, 2008, J BIOL CHEM, V283, P9224, DOI 10.1074/jbc.M706638200; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jensen KB, 2009, CELL STEM CELL, V4, P427, DOI 10.1016/j.stem.2009.04.014; Kim HJ, 2007, CURR BIOL, V17, P455, DOI 10.1016/j.cub.2007.01.059; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Lao DH, 2007, J BIOL CHEM, V282, P9117, DOI 10.1074/jbc.M607563200; Lo TL, 2006, CANCER LETT, V242, P141, DOI 10.1016/j.canlet.2005.12.032; Mason JM, 2006, TRENDS CELL BIOL, V16, P45, DOI 10.1016/j.tcb.2005.11.004; Mulholland DJ, 2005, ENDOCR REV, V26, P898, DOI 10.1210/er.2003-0034; Olson LE, 2006, CELL, V125, P593, DOI 10.1016/j.cell.2006.02.046; Oriol A, 2012, PROTOCOL EXCHANGE; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; Palmer HG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001483; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Raghav SK, 2012, METHODS MOL BIOL, V786, P247, DOI 10.1007/978-1-61779-292-2_15; Sanchez A, 2008, ONCOGENE, V27, P4969, DOI 10.1038/onc.2008.129; Schneider MR, 2008, AM J PATHOL, V173, P14, DOI 10.2353/ajpath.2008.070942; Shim K, 2005, DEV CELL, V8, P553, DOI 10.1016/j.devcel.2005.02.009; Silva-Vargas V, 2005, DEV CELL, V9, P121, DOI 10.1016/j.devcel.2005.04.013; Song K, 2012, HEPATOB PANCREAT DIS, V11, P177, DOI 10.1016/S1499-3872(12)60145-3; Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772; Tsavachidou D, 2004, CANCER RES, V64, P5556, DOI 10.1158/0008-5472.CAN-04-1669; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Van Der Flier LG, 2007, GASTROENTEROLOGY, V132, P628, DOI 10.1053/j.gastro.2006.08.039; Watt FM, 2009, EMBO MOL MED, V1, P260, DOI 10.1002/emmm.200900033; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493	51	19	20	1	15	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2014	33	15					1975	1985		10.1038/onc.2013.140	http://dx.doi.org/10.1038/onc.2013.140			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RK	23624922	Green Submitted			2022-12-28	WOS:000334346300010
J	Wu, K; Liu, J; Tseng, SF; Gore, C; Ning, Z; Sharifi, N; Fazli, L; Gleave, M; Kapur, P; Xiao, G; Sun, X; Oz, OK; Min, W; Alexandrakis, G; Yang, CR; Hsieh, CL; Wu, HC; He, D; Xie, D; Hsieh, JT				Wu, K.; Liu, J.; Tseng, S-F; Gore, C.; Ning, Z.; Sharifi, N.; Fazli, L.; Gleave, M.; Kapur, P.; Xiao, G.; Sun, X.; Oz, O. K.; Min, W.; Alexandrakis, G.; Yang, C-R; Hsieh, C-L; Wu, H-C; He, D.; Xie, D.; Hsieh, J-T			The role of DAB2IP in androgen receptor activation during prostate cancer progression	ONCOGENE			English	Article						prostate cancer; DAB2IP; androgen receptor; Src; genomic pathway	ABERRANT PROMOTER METHYLATION; PROTEIN HDAB2IP GENE; SERINE 81 PHOSPHORYLATION; BREAST-CANCER; CELL-GROWTH; SH3 DOMAINS; TRANSCRIPTION; KINASE; TUMOR; LOCALIZATION	Altered androgen-receptor (AR) expression and/ or constitutively active AR are commonly associated with prostate cancer (PCa) progression. Targeting AR remains a focal point for designing new strategy of PCa therapy. Here, we have shown that DAB2IP, a novel tumor suppressor in PCa, can inhibit AR-mediated cell growth and gene activation in PCa cells via distinct mechanisms. DAB2IP inhibits the genomic pathway by preventing AR nuclear translocation or phosphorylation and suppresses the non-genomic pathway via its unique functional domain to inactivate c-Src. Also, DAB2IP is capable of suppressing AR activation in an androgen-independent manner. In addition, DAB2IP can inhibit several AR splice variants showing constitutive activity in PCa cells. In DAB2IP(-/-)mice, the prostate gland exhibits hyperplastic epithelia, in which AR becomes more active. Consistently, DAB2IP expression inversely correlates with AR activation status particularly in recurrent or metastatic PCa patients. Taken together, DAB2IP is a unique intrinsic AR modulator in normal cells, and likely can be further developed into a therapeutic agent for PCa.	[Wu, K.; Gore, C.; Hsieh, J-T] Univ Texas SW Med Ctr Dallas, Dept Urol, Dallas, TX 75390 USA; [Wu, K.; Ning, Z.; He, D.] Xi An Jiao Tong Univ, Affiliated Hosp 1, Sch Med, Dept Urol, Xian, Shaanxi, Peoples R China; [Liu, J.; Sun, X.; Oz, O. K.] Univ Texas SW Med Ctr Dallas, Dept Radiol, Dallas, TX 75390 USA; [Tseng, S-F; Alexandrakis, G.] Univ Texas Arlington, Dept Bioengn, Arlington, TX 76019 USA; [Sharifi, N.] Univ Texas SW Med Ctr Dallas, Dept Internal Med, Div Hematol Oncol, Dallas, TX 75390 USA; [Fazli, L.; Gleave, M.] Univ British Columbia, Vancouver Prostate Ctr, Vancouver, BC, Canada; [Kapur, P.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA; [Xiao, G.] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA; [Min, W.] Yale Univ, Sch Med, Interdept Program Vasc Biol & Transplant, New Haven, CT USA; [Min, W.] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA; [Yang, C-R; Wu, H-C] China Med Univ Hosp, Dept Urol, Taichung, Taiwan; [Hsieh, C-L; Hsieh, J-T] China Med Univ Hosp, Grad Inst Canc Biol, Taichung, Taiwan; [Hsieh, C-L] China Med Univ Hosp, Ctr Mol Med, Taichung, Taiwan; [Hsieh, C-L] Asia Univ, Dept Biotechnol, Taichung, Taiwan; [Wu, H-C] China Med Univ, Sch Med, Taichung, Taiwan; [Xie, D.] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Canc Res Inst, Dept Gen Surg, Wuhan 430074, Hubei, Peoples R China	University of Texas System; University of Texas Southwestern Medical Center Dallas; Xi'an Jiaotong University; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Arlington; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of British Columbia; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Yale University; Yale University; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; China Medical University Taiwan; China Medical University Hospital - Taiwan; Asia University Taiwan; China Medical University Taiwan; Huazhong University of Science & Technology	Hsieh, JT (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Urol, J8-134,5323 Harry Hines Blvd, Dallas, TX 75390 USA.	dxxie@tjh.tjmu.edu.cn; jt.hsieh@utsouthwestern.edu	Oz, Orhan/GVT-7264-2022	Gleave, Martin/0000-0003-4235-0167	United States Army [W81XWH-04-1-0222 (JTH)]; National Natural Science Foundation of China [NSFC 81202014]	United States Army(United States Department of DefenseUnited States Army); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC))	We thank Dr Jiang Min for editorial assistant and Rui Li for technical support. This work is supported in part by United States Army Grant W81XWH-04-1-0222 (JTH) and the National Natural Science Foundation of China (NSFC 81202014 to KW).	Araujo JC, 2012, CANCER-AM CANCER SOC, V118, P63, DOI 10.1002/cncr.26204; Brooke GN, 2009, CURR GENOMICS, V10, P18, DOI 10.2174/138920209787581307; Cai HJ, 2011, CANCER RES, V71, P862, DOI 10.1158/0008-5472.CAN-10-1605; Cao WH, 2000, J BIOL CHEM, V275, P38131, DOI 10.1074/jbc.C000592200; Chen H, 2005, J BIOL CHEM, V280, P22437, DOI 10.1074/jbc.M501379200; Chen H, 2003, J BIOL CHEM, V278, P3121, DOI 10.1074/jbc.M208230200; Chen SY, 2012, J BIOL CHEM, V287, P8571, DOI 10.1074/jbc.M111.325290; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; Debes JD, 2004, NEW ENGL J MED, V351, P1488, DOI 10.1056/NEJMp048178; Dote H, 2004, CLIN CANCER RES, V10, P2082, DOI 10.1158/1078-0432.CCR-03-0236; Dote H, 2005, BRIT J CANCER, V92, P1117, DOI 10.1038/sj.bjc.6602458; Duggan D, 2007, JNCI-J NATL CANCER I, V99, P1836, DOI 10.1093/jnci/djm250; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; Gioeli D, 2006, MOL ENDOCRINOL, V20, P503, DOI 10.1210/me.2005-0351; Gordon V, 2010, MOL ENDOCRINOL, V24, P2267, DOI 10.1210/me.2010-0238; Guo ZY, 2009, CANCER RES, V69, P2305, DOI 10.1158/0008-5472.CAN-08-3795; Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Hu R, 2009, CANCER RES, V69, P16, DOI 10.1158/0008-5472.CAN-08-2764; Huggins C, 1941, CANCER RES, V1, P293; Kesler CT, 2007, MOL ENDOCRINOL, V21, P2071, DOI 10.1210/me.2007-0240; Mayer BJ, 2001, J CELL SCI, V114, P1253; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100; Min W, 2008, CIRC RES, V102, P840, DOI 10.1161/CIRCRESAHA.107.168153; Qiu GH, 2007, J HEPATOL, V46, P655, DOI 10.1016/j.jhep.2006.11.012; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Sun SH, 2010, J CLIN INVEST, V120, P2715, DOI 10.1172/JCI41824; Tatarov O, 2009, CLIN CANCER RES, V15, P3540, DOI 10.1158/1078-0432.CCR-08-1857; Verras M, 2004, CANCER RES, V64, P8860, DOI 10.1158/0008-5472.CAN-04-2370; Vidal M, 2001, CRIT REV ONCOL HEMAT, V40, P175, DOI 10.1016/S1040-8428(01)00142-1; VISAKORPI T, 1995, NAT GENET, V9, P401, DOI 10.1038/ng0495-401; Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Wang Z, 2002, J BIOL CHEM, V277, P12622, DOI 10.1074/jbc.M110568200; Watson PA, 2010, P NATL ACAD SCI USA, V107, P16759, DOI 10.1073/pnas.1012443107; Wen Y, 2000, CANCER RES, V60, P6841; Wright CD, 2008, CIRC RES, V103, P992, DOI 10.1161/CIRCRESAHA.108.176024; Xie DX, 2010, P NATL ACAD SCI USA, V107, P2485, DOI 10.1073/pnas.0908133107; Xie DX, 2009, P NATL ACAD SCI USA, V106, P19878, DOI 10.1073/pnas.0908458106; Yang CS, 2005, MOL CELL BIOL, V25, P1298, DOI 10.1128/MCB.25.4.1298-1308.2005; Yano M, 2005, INT J CANCER, V113, P59, DOI 10.1002/ijc.20531; Yu EY, 2009, CLIN CANCER RES, V15, P7421, DOI 10.1158/1078-0432.CCR-09-1691; Zhou XE, 2010, J BIOL CHEM, V285, P9161, DOI 10.1074/jbc.M109.085779	44	32	36	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2014	33	15					1954	1963		10.1038/onc.2013.143	http://dx.doi.org/10.1038/onc.2013.143			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RK	23604126				2022-12-28	WOS:000334346300008
J	Vultur, A; Villanueva, J; Krepler, C; Rajan, G; Chen, Q; Xiao, M; Li, L; Gimotty, PA; Wilson, M; Hayden, J; Keeney, F; Nathanson, KL; Herlyn, M				Vultur, A.; Villanueva, J.; Krepler, C.; Rajan, G.; Chen, Q.; Xiao, M.; Li, L.; Gimotty, P. A.; Wilson, M.; Hayden, J.; Keeney, F.; Nathanson, K. L.; Herlyn, M.			MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines	ONCOGENE			English	Article						melanoma; MEK; STAT3; targeted therapy; invasion; resistance	RAF INHIBITORS; ACQUIRED-RESISTANCE; KINASE INHIBITOR; AZD6244 ARRY-142886; DRIVEN RESISTANCE; IMPROVED SURVIVAL; POTENT INHIBITOR; BRAF INHIBITION; ACTIVATION; MIGRATION	Elevated activity of the mitogen-activated protein kinase (MAPK) signaling cascade is found in the majority of human melanomas and is known to regulate proliferation, survival and invasion. Current targeted therapies focus on decreasing the activity of this pathway; however, we do not fully understand how these therapies impact tumor biology, especially given that melanoma is a heterogeneous disease. Using a three-dimensional (3D), collagen-embedded spheroid melanoma model, we observed that MEK and BRAF inhibitors can increase the invasive potential of B20% of human melanoma cell lines. The invasive cell lines displayed increased receptor tyrosine kinase (RTK) activity and activation of the Src/FAK/signal transducers and activators of transcription-3 (STAT3) signaling axis, also associated with increased cell-to-cell adhesion and cadherin engagement following MEK inhibition. Targeting various RTKs, Src, FAK and STAT3 with small molecule inhibitors in combination with a MEK inhibitor prevented the invasive phenotype, but only STAT3 inhibition caused cell death in the 3D context. We further show that STAT3 signaling is induced in BRAF-inhibitor-resistant cells. Our findings suggest that MEK and BRAF inhibitors can induce STAT3 signaling, causing potential adverse effects such as increased invasion. We also provide the rationale for the combined targeting of the MAPK pathway along with inhibitors of RTKs, SRC or STAT3 to counteract STAT3-mediated resistance phenotypes.	[Vultur, A.; Villanueva, J.; Krepler, C.; Rajan, G.; Chen, Q.; Xiao, M.; Li, L.; Herlyn, M.] Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, Philadelphia, PA 19104 USA; [Gimotty, P. A.] Univ Penn, Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; [Wilson, M.; Nathanson, K. L.] Univ Penn, Perelman Sch Med, Abramson Canc Ctr, Philadelphia, PA 19104 USA; [Hayden, J.; Keeney, F.; Herlyn, M.] Wistar Inst Anat & Biol, Div Mol & Cellular Biol, Imaging Facil, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; The Wistar Institute	Herlyn, M (corresponding author), Wistar Inst Anat & Biol, Mol & Cellular Oncogenesis Program, 3601 Spruce St, Philadelphia, PA 19104 USA.	herlynm@wistar.org	Gimotty, Phyllis/GWZ-4136-2022	Gimotty, Phyllis/0000-0002-3850-9799; Wilson, Melissa/0000-0002-5391-7838; Nathanson, Katherine/0000-0002-6740-0901; Vultur, Adina/0000-0003-0068-9496	NIH [PO1 CA114046, P01 CA025874, P30 CA010815, R01 CA047159, CA076674]; Dr Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF); NATIONAL CANCER INSTITUTE [R01CA047159, T32CA009615, P30CA016520, K01CA175269, P01CA114046, P01CA025874, P30CA010815] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Dr Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank P Sompalli and F Raman for technical assistance. We thank GlaxoSmithKline for SB590885, and Dr L Raptis (Queen's University, Canada) for CPA-7. We also thank R Delgiacco of the Wistar Histology Facility. AV, JV, KLN and MH are members of the ITMAT-University of Pennsylvania. This work was supported by NIH grants PO1 CA114046, P01 CA025874, P30 CA010815, R01 CA047159 and CA076674, and by the Dr Miriam and Sheldon G. Adelson Medical Research Foundation (AMRF).	Arulanandam R, 2009, MOL CANCER RES, V7, P1310, DOI 10.1158/1541-7786.MCR-08-0469; Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454; Buettner R, 2008, MOL CANCER RES, V6, P1766, DOI 10.1158/1541-7786.MCR-08-0169; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Christofori G, 2003, EMBO J, V22, P2318, DOI 10.1093/emboj/cdg228; Debidda M, 2005, J BIOL CHEM, V280, P17275, DOI 10.1074/jbc.M413187200; Dry JR, 2010, CANCER RES, V70, P2264, DOI 10.1158/0008-5472.CAN-09-1577; Dudka AA, 2010, CANCER RES, V70, P3391, DOI 10.1158/0008-5472.CAN-09-3033; Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021; Fecher LA, 2007, J CLIN ONCOL, V25, P1606, DOI 10.1200/JCO.2006.06.0442; Ferguson J, 2013, ONCOGENE, V32, P86, DOI 10.1038/onc.2012.25; Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Fukunaga-Kalabis M, 2006, J CELL BIOL, V175, P563, DOI 10.1083/jcb.200602132; Gopal YNV, 2010, CANCER RES, V70, P8736, DOI 10.1158/0008-5472.CAN-10-0902; Gowrishankar K, 2012, J INVEST DERMATOL, V132, P1850, DOI 10.1038/jid.2012.63; Greger JG, 2012, MOL CANCER THER, V11, P909, DOI 10.1158/1535-7163.MCT-11-0989; Haass NK, 2008, CLIN CANCER RES, V14, P230, DOI 10.1158/1078-0432.CCR-07-1440; Haass NK, 2004, J MOL HISTOL, V35, P309; Halaban R, 2010, PIGM CELL MELANOMA R, V23, P190, DOI 10.1111/j.1755-148X.2010.00685.x; Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; ILIOPOULOS D, 1989, J NATL CANCER I, V81, P440, DOI 10.1093/jnci/81.6.440; Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627; Lee JT, 2010, PIGM CELL MELANOMA R, V23, P820, DOI 10.1111/j.1755-148X.2010.00763.x; Littlefield SL, 2008, INORG CHEM, V47, P2798, DOI 10.1021/ic702057q; MacConaill LE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007887; Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626; Nissan MH, 2011, CURR ONCOL REP, V13, P479, DOI 10.1007/s11912-011-0198-4; Niu G, 2002, ONCOGENE, V21, P7001, DOI 10.1038/sj.onc.1205859; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902; Ragoussis J, 2006, PLOS GENET, V2, P920, DOI 10.1371/journal.pgen.0020100; Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020; Sakaguchi M, 2012, J INVEST DERMATOL, V132, P1877, DOI 10.1038/jid.2012.45; Satyamoorthy K, 2003, CANCER RES, V63, P756; Senft C, 2011, J NEURO-ONCOL, V101, P393, DOI 10.1007/s11060-010-0273-y; Shi HB, 2011, CANCER RES, V71, P5067, DOI 10.1158/0008-5472.CAN-11-0140; Smalley KSM, 2008, CANCER RES, V68, P5743, DOI 10.1158/0008-5472.CAN-08-0235; Smalley KSM, 2006, MOL CANCER THER, V5, P1136, DOI 10.1158/1535-7163.MCT-06-0084; Smalley KSM, 2005, ANN NY ACAD SCI, V1059, P16, DOI 10.1196/annals.1339.005; Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304; Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302; Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183; Thomas RK, 2007, NAT GENET, V39, P347, DOI 10.1038/ng1975; Vasudevan KM, 2009, CANCER CELL, V16, P21, DOI 10.1016/j.ccr.2009.04.012; Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023; Vultur A, 2004, ONCOGENE, V23, P2600, DOI 10.1038/sj.onc.1207378; Vultur A, 2008, MOL CANCER THER, V7, P1185, DOI 10.1158/1535-7163.MCT-08-0126; Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312; Wang YZ, 2000, ONCOGENE, V19, P2075, DOI 10.1038/sj.onc.1203548; Weng YI, 2008, ALCOHOL, V42, P397, DOI 10.1016/j.alcohol.2008.02.004; Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249; Zipser MC, 2011, PIGM CELL MELANOMA R, V24, P326, DOI 10.1111/j.1755-148X.2010.00823.x; Zong CS, 2000, J BIOL CHEM, V275, P15099, DOI 10.1074/jbc.M000089200	55	66	70	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2014	33	14					1850	1861		10.1038/onc.2013.131	http://dx.doi.org/10.1038/onc.2013.131			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RE	23624919	Green Accepted			2022-12-28	WOS:000334345500011
J	Antonov, AV; Krestyaninova, M; Knight, RA; Rodchenkov, I; Melino, G; Barlev, NA				Antonov, A. V.; Krestyaninova, M.; Knight, R. A.; Rodchenkov, I.; Melino, G.; Barlev, N. A.			PPISURV: a novel bioinformatics tool for uncovering the hidden role of specific genes in cancer survival outcome	ONCOGENE			English	Article						bioinformatics; computational oncology; survival	P73 TRANSCRIPTIONAL ACTIVITY; BREAST-CANCER; PROGNOSTIC MARKER; MICROARRAY DATA; ONLINE TOOL; P53; BIOMARKERS; RESOURCE; DATABASE; THERAPY	Multiple clinical studies have correlated gene expression with survival outcome in cancer on a genome-wide scale. However, in many cases, no obvious correlation between expression of well-known tumour-related genes (that is, p53, p73 and p21) and survival rates of patients has been observed. This can be mainly explained by the complex molecular mechanisms involved in cancer, which mask the clinical relevance of a gene with multiple functions if only gene expression status is considered. As we demonstrate here, in many such cases, the expression of the gene interaction partners (gene 'interactome') correlates significantly with cancer survival and is indicative of the role of that gene in cancer. On the basis of this principle, we have implemented a free online datamining tool (http://www.bioprofiling.de/PPISURV). PPISURV automatically correlates expression of an input gene interactome with survival rates on >40 publicly available clinical expression data sets covering various tumours involving about 8000 patients in total. To derive the query gene interactome, PPISURV employs several public databases including protein-protein interactions, regulatory and signalling pathways and protein post-translational modifications.	[Antonov, A. V.; Knight, R. A.; Melino, G.] Univ Leicester, Med Res Council, Toxicol Unit, Leicester LE1 9HN, Leics, England; [Antonov, A. V.; Melino, G.; Barlev, N. A.] Technol Univ, Mol Pharmacol Lab, St Petersburg, Russia; [Krestyaninova, M.] Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki, Finland; [Rodchenkov, I.] Univ Toronto, Donnelly Ctr Cellular & Biomol Res, Toronto, ON, Canada; [Melino, G.] Univ Roma Tor Vergata, Dept Expt Med & Surg, Rome, Italy; [Barlev, N. A.] Univ Leicester, Dept Biochem, Leicester LE1 9HN, Leics, England; [Barlev, N. A.] Russian Acad Sci, Inst Cytol, Gene Express Programme, St Petersburg 194064, Russia	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); University of Leicester; University of Helsinki; University of Toronto; University of Rome Tor Vergata; University of Leicester; Russian Academy of Sciences; St. Petersburg Scientific Centre of the Russian Academy of Sciences; Institute of Cytology RAS	Antonov, AV (corresponding author), Univ Leicester, Med Res Council, Toxicol Unit, Hodgkin Bldg,POB 138, Leicester LE1 9HN, Leics, England.	aa668@le.ac.uk; nb155@le.ac.uk	Barlev, Nikolai A/K-5268-2017	Barlev, Nikolai A/0000-0001-7111-2446; Krestyaninova, Maria/0000-0002-8705-8111	UK Medical Research Council (MRC); Russian Federal [14.B37.21.1967, 16.740.11.036, 11.G34.31.0069]; Medical Research Council [MC_U132670600] Funding Source: researchfish; MRC [MC_U132670600] Funding Source: UKRI	UK Medical Research Council (MRC)(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Russian Federal; Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	This work was supported by the UK Medical Research Council (MRC) and funding from Russian Federal grants 14.B37.21.1967 (to AA) 16.740.11.036 (to NB) and 11.G34.31.0069 (to GM).	Antonov AV, 2013, CELL DEATH DIFFER, V20, P367, DOI 10.1038/cdd.2012.137; Antonov AV, 2011, NUCLEIC ACIDS RES, V39, pW323, DOI 10.1093/nar/gkr372; Antonov AV, 2010, NUCLEIC ACIDS RES, V38, pW78, DOI 10.1093/nar/gkq482; Barrett T, 2009, NUCLEIC ACIDS RES, V37, pD885, DOI 10.1093/nar/gkn764; Callagy GM, 2006, CLIN CANCER RES, V12, P2468, DOI 10.1158/1078-0432.CCR-05-2719; Castiglione F, 1999, ANTICANCER RES, V19, P4555; Ciardiello F, 2002, ANN ONCOL, V13, P501, DOI 10.1093/annonc/mdf191; Croft D, 2011, NUCLEIC ACIDS RES, V39, pD691, DOI 10.1093/nar/gkq1018; Dawson SJ, 2010, BRIT J CANCER, V103, P668, DOI 10.1038/sj.bjc.6605736; Dietmann S, 2010, NUCLEIC ACIDS RES, V38, pW118, DOI 10.1093/nar/gkq515; Gartel AL, 2005, CANCER RES, V65, P3980, DOI 10.1158/0008-5472.CAN-04-3995; Gyorffy B, 2012, ENDOCR-RELAT CANCER, V19, P197, DOI 10.1530/ERC-11-0329; Gyorffy B, 2010, BREAST CANCER RES TR, V123, P725, DOI 10.1007/s10549-009-0674-9; HARRINGTON DP, 1982, BIOMETRIKA, V69, P553, DOI 10.2307/2335991; Harris MA, 2004, NUCLEIC ACIDS RES, V32, pD258, DOI 10.1093/nar/gkh036; HOCHBERG Y, 1990, STAT MED, V9, P811, DOI 10.1002/sim.4780090710; Hornbeck PV, 2012, NUCLEIC ACIDS RES, V40, pD261, DOI 10.1093/nar/gkr1122; Kerrien S, 2012, NUCLEIC ACIDS RES, V40, pD841, DOI 10.1093/nar/gkr1088; Lee JT, 2010, CELL DEATH DIFFER, V17, P86, DOI 10.1038/cdd.2009.77; Levine AJ, 2011, NAT REV MOL CELL BIO, V12, P259, DOI 10.1038/nrm3086; Malatesta M, 2013, ONCOGENE, V32, P4721, DOI 10.1038/onc.2012.463; Miller LD, 2005, P NATL ACAD SCI USA, V102, P13550, DOI 10.1073/pnas.0506230102; Na II, 2007, J KOREAN MED SCI, V22, P393, DOI 10.3346/jkms.2007.22.3.393; Rufini Alessandro, 2011, Genes Cancer, V2, P491, DOI 10.1177/1947601911408890; Suzuki A, 1998, ONCOGENE, V17, P931, DOI 10.1038/sj.onc.1202021; Tandon S, 2010, CANCER EPIDEM BIOMAR, V19, P574, DOI 10.1158/1055-9965.EPI-09-0981; Tomasini R, 2008, TRENDS CELL BIOL, V18, P244, DOI 10.1016/j.tcb.2008.03.003; Wu H, 2011, MOL CANCER RES, V9, P1780, DOI 10.1158/1541-7786.MCR-11-0157; Xia WY, 2004, CLIN CANCER RES, V10, P3815, DOI 10.1158/1078-0432.CCR-03-0527	29	49	49	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2014	33	13					1621	1628		10.1038/onc.2013.119	http://dx.doi.org/10.1038/onc.2013.119			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9QY	23686313				2022-12-28	WOS:000334344700002
J	Rajabi, H; Alam, M; Takahashi, H; Kharbanda, A; Guha, M; Ahmad, R; Kufe, D				Rajabi, H.; Alam, M.; Takahashi, H.; Kharbanda, A.; Guha, M.; Ahmad, R.; Kufe, D.			MUC1-C oncoprotein activates the ZEB1/miR-200c regulatory loop and epithelial-mesenchymal transition	ONCOGENE			English	Article						MUC1-C; ZEB1; miR-200c; breast cancer; EMT	BREAST-CANCER CELLS; FACTOR-KAPPA-B; TRANSCRIPTION FACTOR; DOWN-REGULATION; FEEDBACK LOOP; STEM-CELLS; E-CADHERIN; ZEB1; METASTASIS; FAMILY	The epithelial-mesenchymal transition (EMT) is activated in cancer cells by ZEB1, a member of the zinc finger/homeodomain family of transcriptional repressors. The mucin 1 (MUC1) heterodimeric protein is aberrantly overexpressed in human carcinoma cells. The present studies in breast cancer cells demonstrate that the oncogenic MUC1-C subunit induces expression of ZEB1 by a NF-kappa B (nuclear factor kappa B) p65-dependent mechanism. MUC1-C occupies the ZEB1 promoter with NF-kappa B p65 and thereby promotes ZEB1 transcription. In turn, ZEB1 associates with MUC1-C and the ZEB1/MUC1-C complex contributes to the transcriptional suppression of miR-200c, an inducer of epithelial differentiation. The co-ordinate upregulation of ZEB1 and suppression of miR-200c has been linked to the induction of EMT. In concert with the effects of MUC1-C on ZEB1 and miR-200c, we show that MUC1-C induces EMT and cellular invasion by a ZEB1-mediated mechanism. These findings indicate that (i) MUC1-C activates ZEB1 and suppresses miR-200c with the induction of EMT and (ii) targeting MUC1-C could be an effective approach for the treatment of breast and possibly other types of cancers that develop EMT properties.	[Rajabi, H.; Alam, M.; Takahashi, H.; Kharbanda, A.; Guha, M.; Ahmad, R.; Kufe, D.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02215 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 450 Brookline Ave,Dana 830, Boston, MA 02215 USA.	donald_kufe@dfci.harvard.edu			National Cancer Institute of the National Institutes of Health [CA97098, CA166480]; NATIONAL CANCER INSTITUTE [R01CA166480, R01CA097098] Funding Source: NIH RePORTER	National Cancer Institute of the National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Research reported in this publication was supported by the National Cancer Institute of the National Institutes of Health under award numbers CA97098 and CA166480.	Ahmad R, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001426; Ahmad R, 2009, CANCER RES, V69, P7013, DOI 10.1158/0008-5472.CAN-09-0523; Aigner K, 2007, ONCOGENE, V26, P6979, DOI 10.1038/sj.onc.1210508; Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117; Bracken CP, 2008, CANCER RES, V68, P7846, DOI 10.1158/0008-5472.CAN-08-1942; Burk U, 2008, EMBO REP, V9, P582, DOI 10.1038/embor.2008.74; Chua HL, 2007, ONCOGENE, V26, P711, DOI 10.1038/sj.onc.1209808; Eger A, 2005, ONCOGENE, V24, P2375, DOI 10.1038/sj.onc.1208429; Horn G, 2009, EXP CELL RES, V315, P1490, DOI 10.1016/j.yexcr.2009.02.011; Hu XT, 2001, CANCER RES, V61, P6290; Huang L, 2005, CANCER RES, V65, P10413, DOI 10.1158/0008-5472.CAN-05-2474; Jin CN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039432; Kufe DW, 2013, ONCOGENE, V32, P1073, DOI 10.1038/onc.2012.158; Kufe DW, 2009, NAT REV CANCER, V9, P874, DOI 10.1038/nrc2761; Leng YM, 2007, J BIOL CHEM, V282, P19321, DOI 10.1074/jbc.M703222200; Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Mehrotra S, 2010, CANCER CELL, V17, P53, DOI 10.1016/j.ccr.2009.11.021; Morel AP, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002888; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Panchamoorthy G, 2011, HYBRIDOMA, V30, P531, DOI 10.1089/hyb.2011.0070; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Raina D, 2012, INT J ONCOL, V40, P1644, DOI 10.3892/ijo.2011.1308; Rajabi H, 2012, PROSTATE, V72, P1659, DOI 10.1002/pros.22519; Rajabi H, 2012, J BIOL CHEM, V287, P10703, DOI 10.1074/jbc.M111.323311; Rajabi Hasan, 2010, Genes Cancer, V1, P62; Ren J, 2004, CANCER CELL, V5, P163, DOI 10.1016/S1535-6108(04)00020-0; Roy LD, 2011, ONCOGENE, V30, P1449, DOI 10.1038/onc.2010.526; Sanchez-Tillo E, 2011, P NATL ACAD SCI USA, V108, P19204, DOI 10.1073/pnas.1108977108; Shimono Y, 2009, CELL, V138, P592, DOI 10.1016/j.cell.2009.07.011; Spaderna S, 2008, CANCER RES, V68, P537, DOI 10.1158/0008-5472.CAN-07-5682; Spaderna S, 2006, GASTROENTEROLOGY, V131, P830, DOI 10.1053/j.gastro.2006.06.016; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Vandewalle C, 2009, CELL MOL LIFE SCI, V66, P773, DOI 10.1007/s00018-008-8465-8; Wang QB, 2005, MOL CELL, V19, P631, DOI 10.1016/j.molcel.2005.07.018; Wang ZW, 2006, CANCER RES, V66, P2778, DOI 10.1158/0008-5472.CAN-05-4281; Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998	37	78	83	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2014	33	13					1680	1689		10.1038/onc.2013.114	http://dx.doi.org/10.1038/onc.2013.114			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9QY	23584475	Green Accepted			2022-12-28	WOS:000334344700008
J	Yu, M; Trobridge, P; Wang, Y; Kanngurn, S; Morris, SM; Knoblaugh, S; Grady, WM				Yu, M.; Trobridge, P.; Wang, Y.; Kanngurn, S.; Morris, S. M.; Knoblaugh, S.; Grady, W. M.			Inactivation of TGF-beta signaling and loss of PTEN cooperate to induce colon cancer in vivo	ONCOGENE			English	Article						colon cancer; transforming growth factor-beta; PTEN; p21(Cip1)	RECEPTOR-TYPE-II; COLORECTAL-CANCER; TUMOR-SUPPRESSOR; MICROSATELLITE INSTABILITY; CELL-PROLIFERATION; APC MUTATION; GROWTH; GENE; EXPRESSION; PATHWAY	The accumulation of genetic and epigenetic alterations mediates colorectal cancer (CRC) formation by deregulating key signaling pathways in cancer cells. In CRC, one of the most commonly inactivated signaling pathways is the transforming growth factor-beta (TGF-beta) signaling pathway, which is often inactivated by mutations of TGF-beta type II receptor (TGFBR2). Another commonly deregulated pathway in CRC is the phosphoinositide-3-kinase (PI3K)-AKT pathway. Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is an important negative regulator of PI3K-AKT signaling and is silenced in similar to B30% of CRC. The combination of TGFBR2 inactivation and loss of PTEN is particularly common in microsatellite-unstable CRCs. Consequently, we determined in vivo if deregulation of these two pathways cooperates to affect CRC formation by analyzing tumors arising in mice that lack Tgfbr2 and/or Pten specifically in the intestinal epithelium. We found that lack of Tgfbr2 (Tgfbr2(IEKO)) alone is not sufficient for intestinal tumor formation and lack of Pten (Pten(IEKO)) alone had a weak effect on intestinal tumor induction. However, the combination of Tgfbr2 inactivation with Pten loss (Pten(IEKO); Tgfbr(2IEKO)) led to malignant tumors in both the small intestine and colon in 86% of the mice and to metastases in 8% of the tumor-bearing mice. Moreover, these tumors arose via a beta-catenin-independent mechanism. Inactivation of TGF-beta signaling and loss of Pten in the tumors led to increased cell proliferation, decreased apoptosis and decreased expression of cyclin-dependent kinase inhibitors. Thus, inactivation of TGF-beta signaling and loss of PTEN cooperate to drive intestinal cancer formation and progression by suppressing cell cycle inhibitors.	[Yu, M.; Trobridge, P.; Kanngurn, S.; Morris, S. M.; Grady, W. M.] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA; [Wang, Y.] Univ Washington, Dept Microbiol, Seattle, WA 98195 USA; [Wang, Y.; Grady, W. M.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA; [Kanngurn, S.] Prince Songkla Univ, Dept Pathol, Hat Yai, Thailand; [Knoblaugh, S.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Prince of Songkla University; Fred Hutchinson Cancer Center	Grady, WM (corresponding author), Fred Hutchinson Canc Res Ctr, Div Clin Res, 1100 Fairview Ave North,Mailstop D4-100, Seattle, WA 98109 USA.	wgrady@fhcrc.org			NIH [RO1CA115513, P30CA15704, UO1CA152756, U54CA143862, P01CA077852]; Burroughs Wellcome Fund Translational Research Award for Clinician Scientist (WMG); Interdisciplinary Training in Cancer Research Grant [T32 CA080416]; NATIONAL CANCER INSTITUTE [P30CA015704, U54CA143862, U01CA152756, T32CA080416, P01CA077852, R01CA115513] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Burroughs Wellcome Fund Translational Research Award for Clinician Scientist (WMG); Interdisciplinary Training in Cancer Research Grant; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Support for these studies was provided by the NIH (RO1CA115513, P30CA15704, UO1CA152756, U54CA143862, and P01CA077852 WMG), a Burroughs Wellcome Fund Translational Research Award for Clinician Scientist (WMG), and an Interdisciplinary Training in Cancer Research Grant (T32 CA080416 SMM).	Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657; Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Alimonti A, 2010, J CLIN INVEST, V120, P681, DOI 10.1172/JCI40535; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bauer J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039381; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Biswas S, 2004, CANCER RES, V64, P4687, DOI 10.1158/0008-5472.CAN-03-3255; Byun DS, 2011, AM J PHYSIOL-GASTR L, V301, pG856, DOI 10.1152/ajpgi.00178.2011; Chen CN, 2005, J CLIN ONCOL, V23, P7286, DOI 10.1200/JCO.2004.00.2253; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Chittenden TW, 2008, GENOMICS, V91, P508, DOI 10.1016/j.ygeno.2008.03.002; Chu IM, 2008, NAT REV CANCER, V8, P253, DOI 10.1038/nrc2347; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; DATTO MB, 1995, J BIOL CHEM, V270, P28623, DOI 10.1074/jbc.270.48.28623; Di Cristofano A, 2000, CELL, V100, P387, DOI 10.1016/S0092-8674(00)80674-1; Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664; Fearon ER., ANN REV PATHOL, V6, P479; Glick AB, 1996, CANCER RES, V56, P3645; Gomes LR, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-26; Grady WM, 2008, GASTROENTEROLOGY, V135, P1079, DOI 10.1053/j.gastro.2008.07.076; Grady William M., 2008, P889; Grady WM, 1998, CANCER RES, V58, P3101; Grady WM, 2006, INT J CANCER, V118, P600, DOI 10.1002/ijc.21399; Grady WM, 1999, CANCER RES, V59, P320; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Ise K, 2000, ONCOGENE, V19, P2951, DOI 10.1038/sj.onc.1203600; Jaiswal BS, 2009, CANCER CELL, V16, P463, DOI 10.1016/j.ccr.2009.10.016; Jass JR, 2007, HISTOPATHOLOGY, V50, P113, DOI 10.1111/j.1365-2559.2006.02549.x; Jung B, 2004, GASTROENTEROLOGY, V126, P654, DOI 10.1053/j.gastro.2004.01.008; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Langlois MJ, 2009, FASEB J, V23, P1835, DOI 10.1096/fj.08-123125; Lee MH, 2001, CELL MOL LIFE SCI, V58, P1907, DOI 10.1007/PL00000826; Lesche R, 2002, GENESIS, V32, P148, DOI 10.1002/gene.10036; LEVY DB, 1994, CANCER RES, V54, P5953; Leystra AA, 2012, CANCER RES, V72, P2931, DOI 10.1158/0008-5472.CAN-11-4097; Liang J, 2002, NAT MED, V8, P1153, DOI 10.1038/nm761; Liu PX, 2009, NAT REV DRUG DISCOV, V8, P627, DOI 10.1038/nrd2926; Liu XQ, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M111.221697; Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Majumder PK, 2008, CANCER CELL, V14, P146, DOI 10.1016/j.ccr.2008.06.002; Marsh V, 2008, NAT GENET, V40, P1436, DOI 10.1038/ng.256; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; MOSES HL, 1990, CELL, V63, P245, DOI 10.1016/0092-8674(90)90155-8; Muncan V, 2006, MOL CELL BIOL, V26, P8418, DOI 10.1128/MCB.00821-06; Munoz NM, 2006, CANCER RES, V66, P9837, DOI 10.1158/0008-5472.CAN-06-0890; Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252; Naguib A, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-123; Panopoulou E, 2005, CANCER RES, V65, P1877, DOI 10.1158/0008-5472.CAN-04-2828; Parsons DW, 2005, NATURE, V436, P792, DOI 10.1038/436792a; Philp AJ, 2001, CANCER RES, V61, P7426; Pritchard CC, 2011, GUT, V60, P116, DOI 10.1136/gut.2009.206250; Roy HK, 2002, CARCINOGENESIS, V23, P201, DOI 10.1093/carcin/23.1.201; Samowitz WS, 1999, CANCER RES, V59, P1442; Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042; Shin I, 2001, MOL BIOL CELL, V12, P3328, DOI 10.1091/mbc.12.11.3328; Shin KH, 2001, CANCER LETT, V174, P189, DOI 10.1016/S0304-3835(01)00691-7; Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138; Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Trobridge P, 2009, GASTROENTEROLOGY, V136, P1680, DOI 10.1053/j.gastro.2009.01.066; VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901; Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2; Yilmaz M, 2010, MOL CANCER RES, V8, P629, DOI 10.1158/1541-7786.MCR-10-0139; Young LC, 2008, BRIT J DERMATOL, V158, P59, DOI 10.1111/j.1365-2133.2007.08249.x; Zhou XP, 2002, AM J PATHOL, V161, P439, DOI 10.1016/S0002-9440(10)64200-9	69	57	58	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2014	33	12					1538	1547		10.1038/onc.2013.102	http://dx.doi.org/10.1038/onc.2013.102			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD4TS	23604118	Green Accepted			2022-12-28	WOS:000333244200007
J	Blanchard, JM				Blanchard, J. M.			To be or not to be a proliferation marker?	ONCOGENE			English	Editorial Material							CYCLIN-A; CANCER; MYC	Whether it is nobler in the mind to suffer the slings and arrows of outrageous proliferation, or to take arms against stroma, and favor metastasis... This pastiche of Hamlet's famous monologue illustrates recent reports on the paradoxical functions of well-established proliferation markers such as c-Myc or cyclin A2 that have revealed their ambiguous roles in the control of proliferation and metastasis. On the one hand, overexpression of c-Myc, while stimulating local proliferation, inhibits invasiveness of cancer cells, whereas on the other, downregulation of cyclin A2 leads to increased motility of transformed cells.	[Blanchard, J. M.] Inst Genet Mol Montpellier, CNRS, F-34293 Montpellier, France; [Blanchard, J. M.] Univ Montpellier 2, Montpellier, France; [Blanchard, J. M.] Univ Montpellier I, Montpellier, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Universite de Montpellier; Universite de Montpellier	Blanchard, JM (corresponding author), Inst Genet Mol Montpellier, CNRS, 1919 Route Mende, F-34293 Montpellier, France.	jean-marie.blanchard@igmm.cnrs.fr						Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Arsic N, 2012, J CELL BIOL, V196, P147, DOI 10.1083/jcb.201102085; Bissell MJ, 2011, NAT MED, V17, P320, DOI 10.1038/nm.2328; Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490; Kalaszczynska I, 2009, CELL, V138, P352, DOI 10.1016/j.cell.2009.04.062; Lindqvist A, 2009, J CELL BIOL, V185, P193, DOI 10.1083/jcb.200812045; Liu H, 2012, NAT CELL BIOL, V14, P567, DOI 10.1038/ncb2491; Lu PF, 2012, J CELL BIOL, V196, P395, DOI 10.1083/jcb.201102147; Murphy M, 1997, NAT GENET, V15, P83, DOI 10.1038/ng0197-83; Ohtoshi A, 2000, BIOCHEM BIOPH RES CO, V267, P947, DOI 10.1006/bbrc.1999.2007; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; Partanen JI, 2007, P NATL ACAD SCI USA, V104, P14694, DOI 10.1073/pnas.0704677104; Sahai E, 2002, NAT CELL BIOL, V4, P408, DOI 10.1038/ncb796	13	2	2	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 20	2014	33	8					954	955		10.1038/onc.2013.19	http://dx.doi.org/10.1038/onc.2013.19			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB6XO	23396366				2022-12-28	WOS:000331933200002
J	Shukla, A; Edwards, R; Yang, Y; Hahn, A; Folkers, K; Ding, J; Padmakumar, VC; Cataisson, C; Suh, KS; Yuspa, SH				Shukla, A.; Edwards, R.; Yang, Y.; Hahn, A.; Folkers, K.; Ding, J.; Padmakumar, V. C.; Cataisson, C.; Suh, K. S.; Yuspa, S. H.			CLIC4 regulates TGF-beta-dependent myofibroblast differentiation to produce a cancer stroma	ONCOGENE			English	Article						CLIC; alpha-SMA; p38; microenvironment; PPM1a	EPITHELIAL-MESENCHYMAL TRANSITION; CHLORIDE CHANNEL PROTEIN; MUSCLE ACTIN EXPRESSION; CONTRACTILE ACTIVITY; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; CELL CARCINOMA; FIBROBLASTS; GROWTH; PHOSPHATASE	Cancer stroma has a profound influence on tumor development and progression. The conversion of fibroblasts to activated myofibroblasts is a hallmark of reactive tumor stroma. Among a number of factors involved in this conversion, transforming growth factor (TGF)-beta has emerged as a major regulator. CLIC4, an integral protein in TGF-beta signaling, is highly upregulated in stroma of multiple human cancers, and overexpression of CLIC4 in stromal cells enhances the growth of cancer xenografts. In this study, we show that conditioned media from tumor cell lines induces expression of both CLIC4 and the myofibroblast marker alpha smooth muscle actin (alpha-SMA) in stromal fibroblasts via TGF-beta signaling. Genetic ablation of CLIC4 in primary fibroblasts prevents or reduces constitutive or TGF-beta-induced expression of alpha-SMA and extracellular matrix components that are markers of myofibroblasts. CLIC4 is required for the activation of p38 map kinase by TGF-beta, a pathway that signals myofibroblast conversion in stromal cells. This requirement involves the interaction of CLIC4 with PPM1a, the selective phosphatase of activated p38. Conditioned media from fibroblasts overexpressing CLIC4 increases tumor cell migration and invasion in a TGF-beta-dependent manner and promotes epithelial to mesenchymal transition indicating that high stromal CLIC4 serves to enhance tumor invasiveness and progression. Thus, CLIC4 is significantly involved in the development of a nurturing tumor microenvironment by enhancing TGF-beta signaling in a positive feedback loop. Targeting CLIC4 in tumor stroma should be considered as a strategy to mitigate some of the tumor enhancing effects of the cancer stroma.	[Shukla, A.; Edwards, R.; Yang, Y.; Hahn, A.; Folkers, K.; Padmakumar, V. C.; Cataisson, C.; Yuspa, S. H.] NCI, Lab Canc Biol & Genet, Ctr Canc Res, Bethesda, MD 20892 USA; [Ding, J.] NIA, Neurogenet Lab, Bethesda, MD 20892 USA; [Suh, K. S.] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Hackensack University Medical Center	Yuspa, SH (corresponding author), NCI, Lab Canc Biol & Genet, Ctr Canc Res, 37 Convent Dr, Bethesda, MD 20892 USA.	yuspas@mail.nih.gov	Shukla, Anjali/G-4046-2014	Edwards Mayhew, Rebecca/0000-0003-3503-9637	Center for Cancer Research, National Cancer Institute; NATIONAL CANCER INSTITUTE [ZIABC005445] Funding Source: NIH RePORTER	Center for Cancer Research, National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Lalage Wakefield, National Cancer Institute, Bethesda for providing Smad3 KO mice and MI, MII, MIII, MIV cell lines, Dr Ed Leof, Department of Biochemistry and Molecular Biology, Mayo Clinic, Minnesota for providing anti-phospho Smad3 antibody and Dr Akira Oshima, National Cancer Institute for help with immunofluorescence. This work was supported by the intramural research program of the Center for Cancer Research, National Cancer Institute.	Adegboyega PA, 2010, HUM PATHOL, V41, P1128, DOI 10.1016/j.humpath.2009.12.014; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Bohman S, 2005, J BIOL CHEM, V280, P42397, DOI 10.1074/jbc.M506724200; Brenmoehl J, 2009, WORLD J GASTROENTERO, V15, P1431, DOI 10.3748/wjg.15.1431; Caraci F, 2008, PHARMACOL RES, V57, P274, DOI 10.1016/j.phrs.2008.02.001; Cheng AY, 2000, J BIOL CHEM, V275, P34744, DOI 10.1074/jbc.M006210200; Connolly EC, 2011, CANCER RES, V71, P2339, DOI 10.1158/0008-5472.CAN-10-2941; Das AK, 1996, EMBO J, V15, P6798, DOI 10.1002/j.1460-2075.1996.tb01071.x; De Wever O, 2003, J PATHOL, V200, P429, DOI 10.1002/path.1398; De Wever O, 2008, INT J CANCER, V123, P2229, DOI 10.1002/ijc.23925; Duncan RR, 1997, J BIOL CHEM, V272, P23880, DOI 10.1074/jbc.272.38.23880; Evans RA, 2003, EXP CELL RES, V282, P90, DOI 10.1016/S0014-4827(02)00015-0; Fernandez-Salas E, 1999, J BIOL CHEM, V274, P36488, DOI 10.1074/jbc.274.51.36488; Hinz B, 2001, MOL BIOL CELL, V12, P2730, DOI 10.1091/mbc.12.9.2730; Hinz B, 2001, AM J PATHOL, V159, P1009, DOI 10.1016/S0002-9440(10)61776-2; Hinz B, 2007, J INVEST DERMATOL, V127, P526, DOI 10.1038/sj.jid.5700613; Hu B, 2003, AM J RESP CELL MOL, V29, P397, DOI 10.1165/rcmb.2003-0063OC; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Lichti U, 2008, NAT PROTOC, V3, P799, DOI 10.1038/nprot.2008.50; Lin X, 2006, CELL, V125, P915, DOI 10.1016/j.cell.2006.03.044; Littler DR, 2010, FEBS LETT, V584, P2093, DOI 10.1016/j.febslet.2010.01.027; Littler DR, 2005, FEBS J, V272, P4996, DOI 10.1111/j.1742-4658.2005.04909.x; Littler DR, 2004, J BIOL CHEM, V279, P9298, DOI 10.1074/jbc.M308444200; Liu M, 2011, INT J CANCER, V129, P1795, DOI 10.1002/ijc.26116; Lu SL, 2006, GENE DEV, V20, P1331, DOI 10.1101/gad.1413306; Meyer-ter-Vehn T, 2006, INVEST OPHTH VIS SCI, V47, P1500, DOI 10.1167/iovs.05-0361; Micke P, 2004, LUNG CANCER, V45, pS163, DOI 10.1016/j.lungcan.2004.07.977; Miyazono K, 2009, P JPN ACAD B-PHYS, V85, P314, DOI 10.2183/pjab.85.314; Olumi AF, 1999, CANCER RES, V59, P5002; Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034; Padmakumar VC, 2012, AM J PATHOL, V181, P74, DOI 10.1016/j.ajpath.2012.03.025; Qian ZJ, 1999, J BIOL CHEM, V274, P1621, DOI 10.1074/jbc.274.3.1621; RHEINWALD JG, 1981, CANCER RES, V41, P1657; Ronnov-Jessen L, 2002, AM J PATHOL, V161, P471, DOI 10.1016/S0002-9440(10)64203-4; RonnovJessen L, 1996, PHYSIOL REV, V76, P69, DOI 10.1152/physrev.1996.76.1.69; RonnovJessen L, 1996, J CELL BIOL, V134, P67, DOI 10.1083/jcb.134.1.67; Santner SJ, 2001, BREAST CANCER RES TR, V65, P101, DOI 10.1023/A:1006461422273; Saunier EF, 2006, CURR CANCER DRUG TAR, V6, P565, DOI 10.2174/156800906778742460; Shorning BY, 2003, DEV GENES EVOL, V213, P514, DOI 10.1007/s00427-003-0356-2; Shukla A, 2010, NUCLEUS-PHILA, V1, P144; Shukla A, 2009, NAT CELL BIOL, V11, P777, DOI 10.1038/ncb1885; Suh KS, 2005, CURR PHARM DESIGN, V11, P2753, DOI 10.2174/1381612054546806; Suh KS, 2007, CLIN CANCER RES, V13, P121, DOI 10.1158/1078-0432.CCR-06-1562; Sun WJ, 2009, CELL SIGNAL, V21, P95, DOI 10.1016/j.cellsig.2008.09.012; Takekawa M, 1998, EMBO J, V17, P4744, DOI 10.1093/emboj/17.16.4744; Tang BW, 2003, J CLIN INVEST, V112, P1116, DOI 10.1172/JCI200318899; Tlsty TD, 2001, SEMIN CANCER BIOL, V11, P97, DOI 10.1006/scbi.2000.0361; Tsujino T, 2007, CLIN CANCER RES, V13, P2082, DOI 10.1158/1078-0432.CCR-06-2191; Tung JJ, 2009, ANGIOGENESIS, V12, P209, DOI 10.1007/s10456-009-9139-3; Tuxhorn JA, 2002, CANCER RES, V62, P3298; Uemura M, 2005, MOL BIOL CELL, V16, P4214, DOI 10.1091/mbc.E05-02-0149; Ulmasov B, 2009, AM J PATHOL, V174, P1084, DOI 10.2353/ajpath.2009.080625; Yao Q, 2009, ONCOL REP, V22, P541, DOI 10.3892/or_00000469; Yingling JM, 2004, NAT REV DRUG DISCOV, V3, P1011, DOI 10.1038/nrd1580	54	47	51	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2014	33	7					842	850		10.1038/onc.2013.18	http://dx.doi.org/10.1038/onc.2013.18			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB2MN	23416981	Green Accepted			2022-12-28	WOS:000331626900005
J	Yu, L; Yuan, X; Wang, D; Barakat, B; Williams, ED; Hannigan, GE				Yu, L.; Yuan, X.; Wang, D.; Barakat, B.; Williams, E. D.; Hannigan, G. E.			Selective regulation of p38 beta protein and signaling by integrin-linked kinase mediates bladder cancer cell migration	ONCOGENE			English	Article						integrin-linked kinase; p38(MAPK) protein kinases; p38 beta isoform; bladder cancer; cell migration; heat shock protein 27	P38-ALPHA MAP KINASE; IN-SITU; PROXIMITY LIGATION; ENDOTHELIAL-CELLS; P38; GROWTH; CARCINOMA; EXPRESSION; ADHESION; ILK	Integrin-linked kinase (ILK) and p38(MAPK) are protein kinases that transduce extracellular signals regulating cell migration and actin cytoskeletal organization. ILK-dependent regulation of p38(MAPK) is critical for mammalian kidney development and in smooth muscle cell migration, however, specific p38 isoforms has not been previously examined in ILK-regulated responses. Signaling by ILK and p38(MAPK) is often dysregulated in bladder cancer, and here we report a strong positive correlation between protein levels of ILK and p38 beta, which is the predominant isoform found in bladder cancer cells, as well as in patient-matched normal bladder and tumor samples. Knockdown by RNA interference of either p38 beta or ILK disrupts serum-induced, Rac1-dependent migration and actin cytoskeletal organization in bladder cancer cells. Surprisingly, ILK knockdown causes the selective reduction in p38 beta cellular protein level, without inhibiting p38 beta messenger RNA (mRNA) expression. The loss of p38 beta protein in ILK-depleted cells is partially rescued by the 26S proteasomal inhibitor MG132. Using co-precipitation and bimolecular fluorescent complementation assays, we find that ILK selectively forms cytoplasmic complexes with p38 beta. In situ proximity ligation assays further demonstrate that serum-stimulated assembly of endogenous ILK-p38 beta complexes is sensitive to QLT-0267, a small molecule ILK kinase inhibitor. Finally, inhibition of ILK reduces the amplitude and period of serum-induced activation of heat shock protein 27 (Hsp27), a target of p38 beta implicated in actin cytoskeletal reorganization. Our work identifies Hsp27 as a novel target of ILK-p38 beta signaling complexes, playing a key role in bladder cancer cell migration.	[Yu, L.; Yuan, X.; Wang, D.; Barakat, B.; Williams, E. D.; Hannigan, G. E.] Monash Univ, Monash Inst Med Res, Ctr Canc Res, Clayton, Vic, Australia; [Yuan, X.] Univ Sch Med, Xinhua Hosp, Dept Clin Lab, Shanghai, Peoples R China	Monash University	Williams, ED (corresponding author), Monash Univ, Monash Inst Med Res, Ctr Canc Res, Clayton, Vic, Australia.	elizabeth.williams@monash.edu; greg.hannigan@monash.edu	Yu, Liang/D-6771-2014; Wang, Die/H-8860-2017; Williams, Elizabeth D/B-1538-2008	Wang, Die/0000-0001-7628-7309; Williams, Elizabeth D/0000-0002-3364-6655	National Health and Medical Research Council of Australia; Victorian Government's Operational Infrastructure Support Program	National Health and Medical Research Council of Australia(National Health and Medical Research Council (NHMRC) of Australia); Victorian Government's Operational Infrastructure Support Program	We thank Drs Aaron Irving, Dakang Xu and Howard Yim (Centre for Cancer Research, MIMR) for consultation and helpful discussions. Dr S Dedhar (University of British Columbia) kindly provided QLT-0267. This work was supported by grants to GH and EDW from the National Health and Medical Research Council of Australia, with additional support through the Victorian Government's Operational Infrastructure Support Program.	Cabodi S, 2010, NAT REV CANCER, V10, P858, DOI 10.1038/nrc2967; Chaffer CL, 2005, CLIN EXP METASTAS, V22, P115, DOI 10.1007/s10585-005-5141-3; Cornford PA, 2000, CANCER RES, V60, P7099; Coso S, 2011, EXP CELL RES, V317, P2397, DOI 10.1016/j.yexcr.2011.07.023; Coulthard LR, 2009, TRENDS MOL MED, V15, P369, DOI 10.1016/j.molmed.2009.06.005; Cuenda A, 2007, BBA-MOL CELL RES, V1773, P1358, DOI 10.1016/j.bbamcr.2007.03.010; Barrantes IDB, 2011, P NATL ACAD SCI USA, V108, P12764, DOI 10.1073/pnas.1015013108; DJAKIEW D, 1993, CANCER RES, V53, P1416; Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013; Esfandiarei Mitra, 2010, BMC Cell Biol, V11, P16, DOI 10.1186/1471-2121-11-16; Estrada Y, 2009, PIGM CELL MELANOMA R, V22, P66, DOI 10.1111/j.1755-148X.2008.00520.x; Filipenko NR, 2005, ONCOGENE, V24, P5837, DOI 10.1038/sj.onc.1208737; Fukuda T, 2003, J BIOL CHEM, V278, P51324, DOI 10.1074/jbc.M309122200; Gao J, 2011, INT J BIOCHEM CELL B, V43, P1294, DOI 10.1016/j.biocel.2011.05.003; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; Hannigan G, 2005, NAT REV CANCER, V5, P51, DOI 10.1038/nrc1524; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; Herbsleb M, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-37; Hui LJ, 2007, NAT GENET, V39, P741, DOI 10.1038/ng2033; Irving AT, 2012, IMMUNITY, V36, P795, DOI 10.1016/j.immuni.2012.02.020; Cerezo-Guisado MI, 2011, CARCINOGENESIS, V32, P1093, DOI 10.1093/carcin/bgr079; Jarvius M, 2007, MOL CELL PROTEOMICS, V6, P1500, DOI 10.1074/mcp.M700166-MCP200; Jones TJ, 2012, J CELL PHYSIOL, V227, P70, DOI 10.1002/jcp.22704; Junttila MR, 2007, ONCOGENE, V26, P5267, DOI 10.1038/sj.onc.1210332; Kumar B, 2010, CANCER RES, V70, P832, DOI 10.1158/0008-5472.CAN-09-2918; Leung-Hagesteijn C, 2005, MOL CELL BIOL, V25, P3648, DOI 10.1128/MCB.25.9.3648-3657.2005; Li QX, 2008, J BIOL CHEM, V283, P11014, DOI 10.1074/jbc.M709682200; Lu HZ, 2006, CIRCULATION, V114, P2271, DOI 10.1161/CIRCULATIONAHA.106.642330; Mackinnon AC, 2002, CURR BIOL, V12, P787, DOI 10.1016/S0960-9822(02)00810-2; Matsui Y, 2012, INT J CANCER, V130, P521, DOI 10.1002/ijc.26008; Maydan M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012356; Mongroo PS, 2004, ONCOGENE, V23, P8959, DOI 10.1038/sj.onc.1208112; Montanez E, 2009, EMBO J, V28, P3132, DOI 10.1038/emboj.2009.295; Nakrieko KA, 2008, MOL BIOL CELL, V19, P1462, DOI 10.1091/mbc.E07-06-0526; New L, 2003, MOL BIOL CELL, V14, P2603, DOI 10.1091/mbc.E02-08-0538; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; Otto KB, 2011, UROL ONCOL, V30, P415; Qian Y, 2005, ONCOGENE, V24, P3154, DOI 10.1038/sj.onc.1208525; Remy G, 2010, CELL SIGNAL, V22, P660, DOI 10.1016/j.cellsig.2009.11.020; Roussos ET, 2011, NAT REV CANCER, V11, P573, DOI 10.1038/nrc3078; Sakai T, 2003, GENE DEV, V17, P926, DOI 10.1101/gad.255603; Schindler EM, 2009, CANCER RES, V69, P4648, DOI 10.1158/0008-5472.CAN-08-4455; Shyu YJ, 2008, NAT PROTOC, V3, P588, DOI 10.1038/nprot.2008.16; Silva G, 2006, J IMMUNOL, V177, P1894, DOI 10.4049/jimmunol.177.3.1894; Smeeton J, 2010, DEVELOPMENT, V137, P3233, DOI 10.1242/dev.052845; Soderberg O, 2006, NAT METHODS, V3, P995, DOI 10.1038/nmeth947; Song HY, 2006, J CANCER RES CLIN, V132, P92, DOI 10.1007/s00432-005-0044-x; Tan C, 2002, J BIOL CHEM, V277, P3109, DOI 10.1074/jbc.M108673200; Ventura JJ, 2007, NAT GENET, V39, P750, DOI 10.1038/ng2037; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wang AX, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-167; Yong HY, 2009, EXPERT OPIN INV DRUG, V18, P1893, DOI 10.1517/13543780903321490; Zervas CG, 2001, J CELL BIOL, V152, P1007, DOI 10.1083/jcb.152.5.1007; Zhu ZK, 2010, MOL PHARMACEUT, V7, P1283, DOI 10.1021/mp100073s	54	25	26	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2014	33	6					690	701		10.1038/onc.2013.20	http://dx.doi.org/10.1038/onc.2013.20			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5IL	23435415				2022-12-28	WOS:000331129200004
J	Hawinkels, LJAC; Paauwe, M; Verspaget, HW; Wiercinska, E; van der Zon, JM; van der Ploeg, K; Koelink, PJ; Lindeman, JHN; Mesker, W; ten Dijke, P; Sier, CFM				Hawinkels, L. J. A. C.; Paauwe, M.; Verspaget, H. W.; Wiercinska, E.; van der Zon, J. M.; van der Ploeg, K.; Koelink, P. J.; Lindeman, J. H. N.; Mesker, W.; ten Dijke, P.; Sier, C. F. M.			Interaction with colon cancer cells hyperactivates TGF-beta signaling in cancer-associated fibroblasts	ONCOGENE			English	Article						CAF; colorectal cancer; MMP; signaling; TGF-beta; tumor microenvironment	GROWTH-FACTOR-BETA; MUSCLE ACTIN EXPRESSION; MYOFIBROBLAST DIFFERENTIATION; CELLULAR-LOCALIZATION; MAMMARY-GLAND; BREAST-CANCER; TUMOR-CELLS; ACTIVATION; TGF-BETA-1; CARCINOMA	The interaction between epithelial cancer cells and cancer-associated fibroblasts (CAFs) has a major role in cancer progression and eventually in metastasis. In colorectal cancer (CRC), CAFs are present in high abundance, but their origin and functional interaction with epithelial tumor cells has not been elucidated. In this study we observed strong activation of the transforming growth factor-beta (TGF-beta)/ Smad signaling pathway in CRC CAFs, accompanied by decreased signaling in epithelial tumor cells. We evaluated the TGF-beta 1 response and the expression of target genes including matrix metalloproteinases (MMPs) and plasminogen activator inhibitor (PAI)-1 of various epithelial CRC cell lines and primary CAFs in vitro. TGF-beta 1 stimulation caused high upregulation of MMPs, PAI-1 and TGF-beta 1 itself. Next we showed that incubation of CAFs with conditioned medium (CM) from epithelial cancer cells led to hyperactivation of the TGF-beta signaling pathway, enhanced expression of target genes like PAI-1, and the expression of alpha-smooth muscle actin (alpha-SMA). We propose that the interaction of tumor cells with resident fibroblasts results in hyperactivated TGF-beta 1 signaling and subsequent transdifferentiation of the fibroblasts into alpha-SMA-positive CAFs. In turn this leads to cumulative production of TGF-beta and proteinases within the tumor microenvironment, creating a cancer-promoting feedback loop.	[Hawinkels, L. J. A. C.; Verspaget, H. W.; van der Zon, J. M.; Koelink, P. J.; Sier, C. F. M.] Leiden Univ, Med Ctr, Dept Gastroenterol Hepatol, NL-2300 RC Leiden, Netherlands; [Hawinkels, L. J. A. C.; Paauwe, M.; Wiercinska, E.; van der Ploeg, K.; ten Dijke, P.] Leiden Univ, Med Ctr, Dept Mol Cell Biol, NL-2300 RC Leiden, Netherlands; [Hawinkels, L. J. A. C.; Paauwe, M.; Wiercinska, E.; van der Ploeg, K.; ten Dijke, P.] Leiden Univ, Med Ctr, Ctr Biomed Genet, NL-2300 RC Leiden, Netherlands; [Lindeman, J. H. N.] Leiden Univ, Med Ctr, Dept Vasc Surg, NL-2300 RC Leiden, Netherlands; [Mesker, W.; Sier, C. F. M.] Leiden Univ, Med Ctr, Dept Surg, NL-2300 RC Leiden, Netherlands; [ten Dijke, P.] Uppsala Univ, Ludwig Inst Canc Res, Uppsala, Sweden	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Ludwig Institute for Cancer Research; Uppsala University	Hawinkels, LJAC (corresponding author), Leiden Univ, Med Ctr, Dept Mol Cell Biol, Bldg 2,S1-P,POB 9600, NL-2300 RC Leiden, Netherlands.	L.J.A.C.Hawinkels@LUMC.nl	Hawinkels, Lukas/Q-5098-2019; Paauwe, Madelon/C-8244-2018; Sier, Cornelis/A-7664-2008; Dijke, Peter ten/AAG-4660-2021	Hawinkels, Lukas/0000-0002-2274-9325; Sier, Cornelis/0000-0002-4337-2758; Dijke, Peter ten/0000-0002-7234-342X; Wiercinska, Eliza/0000-0002-8434-6492	EC [090773]; Bas Mulder Award [UL2011-5051]	EC(European CommissionEuropean Commission Joint Research Centre); Bas Mulder Award	We thank Dr R Hanemaaijer (TNO Quality of Life BioSciences, Leiden, The Netherlands) for helpful suggestions and reagents. Eveline de Jonge-Muller (Department of Gastroenterology-Hepatology, LUMC), Adri Mulder-Stapel (TNO) and Gabi van Pelt (Department Surgery, LUMC) are acknowledged for excellent technical support. This work was supported by the EC Tumor-host genomic project, the Centre for Biomedical Genetics, the Swedish Cancer Fonden 090773 (EW, PtD) and the Bas Mulder Award 2011 (LJACH, MP, UL2011-5051).	Adegboyega PA, 2002, ARCH PATHOL LAB MED, V126, P829; Akhurst RJ, 2001, TRENDS CELL BIOL, V11, pS44, DOI 10.1016/S0962-8924(01)82259-5; Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Barcellos-Hoff MH, 2000, BREAST CANCER RES, V2, P92, DOI 10.1186/bcr40; BARCELLOSHOFF MH, 1994, J CLIN INVEST, V93, P892, DOI 10.1172/JCI117045; Bierie B, 2006, NAT REV CANCER, V6, P506, DOI 10.1038/nrc1926; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Cirri P, 2012, CANCER METAST REV, V31, P195, DOI 10.1007/s10555-011-9340-x; De Wever O, 2003, J PATHOL, V200, P429, DOI 10.1002/path.1398; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; DESMOULIERE A, 1993, J CELL BIOL, V122, P103, DOI 10.1083/jcb.122.1.103; Dooley S, 2003, GASTROENTEROLOGY, V125, P178, DOI 10.1016/S0016-5085(03)00666-8; Elenbaas B, 2001, EXP CELL RES, V264, P169, DOI 10.1006/excr.2000.5133; Ge GX, 2006, J CELL BIOL, V175, P111, DOI 10.1083/jcb.200606058; Hawinkels LJAC, 2007, BRIT J CANCER, V97, P398, DOI 10.1038/sj.bjc.6603877; Hawinkels LJAC, 2008, EUR J CANCER, V44, P1904, DOI 10.1016/j.ejca.2008.06.031; Hawinkels LJAC, 2007, BIOCHEM BIOPH RES CO, V364, P549, DOI 10.1016/j.bbrc.2007.10.032; Hawinkels LJAC, 2011, GROWTH FACTORS, V29, P140, DOI 10.3109/08977194.2011.595411; Hawinkels LJAC, 2010, CANCER RES, V70, P4141, DOI 10.1158/0008-5472.CAN-09-4466; Hawinkels LJAC, 2009, CANCER SCI, V100, P663, DOI 10.1111/j.1349-7006.2009.01100.x; Huet E, 2008, FASEB J, V22, P1144, DOI 10.1096/fj.07-8748com; Jenkins G, 2008, INT J BIOCHEM CELL B, V40, P1068, DOI 10.1016/j.biocel.2007.11.026; Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877; Kankuri E, 2005, CANCER RES, V65, P9914, DOI 10.1158/0008-5472.CAN-05-1559; Kankuri E, 2008, INT J CANCER, V122, P1243, DOI 10.1002/ijc.23179; Kunz-Schughart LA, 2001, EXP CELL RES, V266, P74, DOI 10.1006/excr.2001.5210; Leivonen SK, 2007, INT J CANCER, V121, P2119, DOI 10.1002/ijc.23113; Lewis MP, 2004, BRIT J CANCER, V90, P822, DOI 10.1038/sj.bjc.6601611; Lieubeau B, 1999, INT J CANCER, V81, P629, DOI 10.1002/(SICI)1097-0215(19990517)81:4<629::AID-IJC20>3.3.CO;2-#; Lindeman JHN, 2004, AM J PATHOL, V165, P593, DOI 10.1016/S0002-9440(10)63323-8; LYONS RM, 1990, J CELL BIOL, V110, P1361, DOI 10.1083/jcb.110.4.1361; Mesker WE, 2007, CELL ONCOL, V29, P387; Meulmeester E, 2011, J PATHOL, V223, P205, DOI 10.1002/path.2785; Micke P, 2004, LUNG CANCER, V45, pS163, DOI 10.1016/j.lungcan.2004.07.977; Munoz NM, 2006, CANCER RES, V66, P9837, DOI 10.1158/0008-5472.CAN-06-0890; Nishimura SL, 2009, AM J PATHOL, V175, P1362, DOI 10.2353/ajpath.2009.090393; Pardali E, 2011, ONCOGENE, V30, P334, DOI 10.1038/onc.2010.418; Park CC, 2000, MOL MED TODAY, V6, P324, DOI 10.1016/S1357-4310(00)01756-1; Persson U, 1998, FEBS LETT, V434, P83, DOI 10.1016/S0014-5793(98)00954-5; Pourreyron C, 2003, INT J CANCER, V104, P28, DOI 10.1002/ijc.10898; Powell DW, 2005, AM J PHYSIOL-GASTR L, V289, pG2, DOI 10.1152/ajpgi.00075.2005; RONNOVJESSEN L, 1995, J CLIN INVEST, V95, P859, DOI 10.1172/JCI117736; Ruiter D, 2002, LANCET ONCOL, V3, P35, DOI 10.1016/S1470-2045(01)00620-9; Shephard P, 2004, AM J PATHOL, V164, P2055, DOI 10.1016/S0002-9440(10)63764-9; Sier CFM, 2008, MATRIX BIOL, V27, P267, DOI 10.1016/j.matbio.2007.10.006; Stolle K, 2005, GENE, V351, P119, DOI 10.1016/j.gene.2005.03.012; ten Dijke P, 2007, NAT REV MOL CELL BIO, V8, P857, DOI 10.1038/nrm2262; Wipff PJ, 2008, EUR J CELL BIOL, V87, P601, DOI 10.1016/j.ejcb.2008.01.012; Woodford-Richens KL, 2001, P NATL ACAD SCI USA, V98, P9719, DOI 10.1073/pnas.171321498; Yoshinaga K, 2008, P NATL ACAD SCI USA, V105, P18758, DOI 10.1073/pnas.0805411105	51	154	159	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2014	33	1					97	107		10.1038/onc.2012.536	http://dx.doi.org/10.1038/onc.2012.536			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	282YU	23208491				2022-12-28	WOS:000329212000011
J	Ki, MK; Jeoung, MH; Choi, JR; Rho, SS; Kwon, YG; Shim, H; Chung, J; Hong, HJ; Song, BD; Lee, S				Ki, M. K.; Jeoung, M. H.; Choi, J. R.; Rho, S-S; Kwon, Y-G; Shim, H.; Chung, J.; Hong, H. J.; Song, B. D.; Lee, S.			Human antibodies targeting the C-type lectin-like domain of the tumor endothelial cell marker clec14a regulate angiogenic properties in vitro	ONCOGENE			English	Article						Clec14a; C-type lectin-like domain; antibody; angiogenesis; endothelial cell; regulation	METASTATIC COLORECTAL-CANCER; EPIDERMAL-GROWTH-FACTOR; MONOCLONAL-ANTIBODY; INHIBITS ANGIOGENESIS; BEVACIZUMAB; THERAPY; FLUOROURACIL; LEUCOVORIN; CHEMOKINES; VESSELS	It has been suggested that clec14a may be involved in tumor angiogenesis. However, a molecular mechanism has not been clearly identified. In this study, we show for the first time that C-type lectin-like domain (CTLD) of clec14a may be important for regulating cell migration and filopodia formation. Using phage display technology, recombinant human antibodies specific to the CTLDs of human and mouse clec14a (clec14a-CTLD (immunoglobulin G) IgG) were selected. Functional assays using the antibodies showed that clec14a-CTLD IgGs specifically blocked endothelial cell migration and tube formation without affecting cell viability or activation. Further, clec14a-CTLD IgGs inhibited clec14a-mediated cell-cell contact by blocking interaction between CTLDs. Finally, clec14a cross-linking by the clec14a-CTLD IgGs significantly downregulated clec14a expression on the surface of endothelial cells. These results strongly suggest that the clec14a-CTLD may be a key domain in angiogenesis, and that clec14a-CTLD IgGs specifically inhibit angiogenesis by modulating CTLD-mediated cell interactions and clec14a expression on the surface of endothelial cells.	[Ki, M. K.; Jeoung, M. H.; Choi, J. R.; Song, B. D.; Lee, S.] Scripps Korea Antibody Inst, Lab Mol Canc Therapeut, Chunchon 200701, South Korea; [Rho, S-S; Kwon, Y-G] Yonsei Univ, Dept Biochem, Coll Life Sci & Biotechnol, Seoul 120749, South Korea; [Shim, H.] Ewha Womans Univ, Div Life & Pharmaceut Sci, Seoul, South Korea; [Chung, J.] Seoul Natl Univ, Coll Med, Dept Biochem & Mol Biol, Seoul, South Korea; [Hong, H. J.] Kangwon Natl Univ, Dept Syst Immunol, Coll Biomed Sci, Chunchon, South Korea	Yonsei University; Ewha Womans University; Seoul National University (SNU); Kangwon National University	Lee, S (corresponding author), Scripps Korea Antibody Inst, Lab Mol Canc Therapeut, Hyoja 2 Dong, Chunchon 200701, South Korea.	Lees@skai.or.kr			Scripps Korea Antibody Institute; Basic Science Research Program through the National Research Foundation of Korea; Ministry of Education, Science and Technology [2012R1A2A1A01002916]	Scripps Korea Antibody Institute; Basic Science Research Program through the National Research Foundation of Korea(National Research Foundation of Korea); Ministry of Education, Science and Technology(Ministry of Education, Science & Technology (MEST), Republic of Korea)	This work was supported by grants from Scripps Korea Antibody Institute and partly by Basic Science Research Program through the National Research Foundation of Korea funded by the Ministry of Education, Science and Technology (2012R1A2A1A01002916).	Alon R, 2002, SEMIN IMMUNOL, V14, P93, DOI 10.1006/smim.2001.0346; Barbas C.F., 2001, PHAGE DISPLAY LAB MA; Bergsland E, 2004, ONCOLOGIST, V9, P36, DOI 10.1634/theoncologist.9-suppl_1-36; Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478; Dienstmann R, 2012, CURR CLIN PHARMACOL, V7, P137, DOI 10.2174/157488412800228929; Gordon MS, 2001, J CLIN ONCOL, V19, P843, DOI 10.1200/JCO.2001.19.3.843; Huang SM, 2002, MOL CANCER THER, V1, P507; Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691; Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066; Kim HY, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0024749, 10.1371/journal.pone.0019867]; Koch S, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006502; Kopetz S, 2010, J CLIN ONCOL, V28, P453, DOI 10.1200/JCO.2009.24.8252; Lee SH, 2011, ARCH PHARM RES, V34, P1223, DOI 10.1007/s12272-011-0821-9; Lee S, 2007, INT IMMUNOL, V19, P1349, DOI 10.1093/intimm/dxm104; Leow CC, 2012, INT J ONCOL, V40, P1321, DOI 10.3892/ijo.2012.1366; Lucio-Eterovic AK, 2009, CLIN CANCER RES, V15, P4589, DOI 10.1158/1078-0432.CCR-09-0575; Mura M, 2012, ONCOGENE, V31, P293, DOI 10.1038/onc.2011.233; Perrotte P, 1999, CLIN CANCER RES, V5, P257; Petit AMV, 1997, AM J PATHOL, V151, P1523; Rho SS, 2011, BIOCHEM BIOPH RES CO, V404, P103, DOI 10.1016/j.bbrc.2010.11.075; Sambrook J., 2001, MOL CLONING LAB MANU; Shukla AA, 2007, J CHROMATOGR B, V848, P28, DOI 10.1016/j.jchromb.2006.09.026; Spratlin J, 2011, CURR ONCOL REP, V13, P97, DOI 10.1007/s11912-010-0149-5; Teillaud Jean-Luc, 2012, Methods Mol Biol, V911, P3, DOI 10.1007/978-1-61779-968-6_1; Tortora G, 2004, CURR PHARM DESIGN, V10, P11, DOI 10.2174/1381612043453595; Van Meter KE, 2008, ARCH INSECT BIOCHEM, V69, P107, DOI 10.1002/arch.20271; Vestweber D, 2003, EUR J IMMUNOL, V33, P1361, DOI 10.1002/eji.200324011; Vincenzi B, 2008, CRIT REV ONCOL HEMAT, V68, P93, DOI 10.1016/j.critrevonc.2008.07.006; Zilian Olav, 2012, Hum Vaccin Immunother, V8, P1370, DOI 10.4161/hv.21413	29	27	29	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2013	32	48					5449	5457		10.1038/onc.2013.156	http://dx.doi.org/10.1038/onc.2013.156			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263BE	23644659	Green Published, hybrid			2022-12-28	WOS:000327780800002
J	Ho, L; Ali, SA; Al-Jazrawe, M; Kandel, R; Wunder, JS; Alman, BA				Ho, L.; Ali, S. A.; Al-Jazrawe, M.; Kandel, R.; Wunder, J. S.; Alman, B. A.			Primary cilia attenuate hedgehog signalling in neoplastic chondrocytes	ONCOGENE			English	Article						chondrosarcoma; primary cilia; hedgehog pathway; enchondroma; cartilage	RENAL-CELL CARCINOMA; INTRAFLAGELLAR TRANSPORT; GROWTH-PLATE; CARTILAGE HISTOPATHOLOGY; REPRESSOR FUNCTIONS; EXPRESSION; ACTIVATOR; DEFECTS; PATHWAY; CANCER	Primary cilia can act as either a negative or positive regulator of the hedgehog (Hh) signaling pathway. Many cartilage tumors are characterized by abnormal activation of the Hh pathway. Here, we report that the presence of primary cilia occurs at a low frequency (12.4%) in neoplastic chondrocytes from malignant human chondrosarcomas, compared with chondrocytes from normal articular cartilage (67.7%). To determine the function of primary cilia in cartilaginous neoplasia, we studied benign cartilage tumors that are formed in mice by chondrocyte-specific overexpression of Gli2, a downstream transcriptional activator of the Hh pathway. Col2A1-Gli2 mice were crossed with Ift88+/- mice, which display a partial loss of ciliogenesis. Surprisingly, cartilage tumors developed in Ift88+/- mice that were phenotypically similar to those that arise in Col2A1-Gli2 mice. Further activation of the Hh pathway was observed in Col2A1-Gli2; Ift88+/- mice compared with either Col2A1-Gli2 or Ift88+/- mice, which was associated with an increased incidence of cartilage tumors. Chondrosarcomas were established in explant cultures, and treated with choral hydrate, which disrupts the functional primary cilia. Thus, treatment resulted in hyperactivity of the Hh signaling pathway, as well as cellular changes that could promote tumor growth. Primary cilia functions to inhibit Hh signaling in neoplastic chondrocytes. The activation of Hh signaling is sufficient to induce benign cartilage tumors without another oncogenic initiating event. Moreover, as primary cilia suppress Hh pathway activation in chondrosarcoma, cellular mechanisms inhibiting proper cilia function may be important in maintaining the neoplastic phenotype.	[Ho, L.; Ali, S. A.; Al-Jazrawe, M.; Alman, B. A.] Hosp Sick Children, Program Dev & Stem Cell Biol, Toronto, ON M5G 1X8, Canada; [Ho, L.; Al-Jazrawe, M.; Kandel, R.; Alman, B. A.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Ali, S. A.] Univ Toronto, Inst Med Sci, Toronto, ON, Canada; [Kandel, R.; Wunder, J. S.] Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; [Wunder, J. S.; Alman, B. A.] Univ Toronto, Dept Surg, Div Orthopaed Surg, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto	Alman, BA (corresponding author), Hosp Sick Children, Program Dev & Stem Cell Biol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	benjamin.alman@sickkids.ca	Kandel, Rita/E-2149-2017; Kandel, Rita/AAU-9908-2021	Kandel, Rita/0000-0003-4047-3913; Kandel, Rita/0000-0003-4047-3913; Ali, Shabana/0000-0002-4339-9467	Canadian Institutes of Health Research [MOP- 37913]; University of Toronto Fellowship; Hospital for Sick Children (RESTRACOMP); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK074038] Funding Source: NIH RePORTER	Canadian Institutes of Health Research(Canadian Institutes of Health Research (CIHR)); University of Toronto Fellowship(University of Toronto); Hospital for Sick Children (RESTRACOMP); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Wewould like to acknowledge the Canadian Institutes of Health Research for supporting this research project through operating grant no, MOP- 37913. Funding by the University of Toronto Fellowship and Hospital for Sick Children (RESTRACOMP) is also gratefully acknowledged.	Chang CF, 2012, OSTEOARTHR CARTILAGE, V20, P152, DOI 10.1016/j.joca.2011.11.009; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; de Andrea CE, 2010, LAB INVEST, V90, P1091, DOI 10.1038/labinvest.2010.81; Dormoy V, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-123; Goetz SC, 2010, NAT REV GENET, V11, P331, DOI 10.1038/nrg2774; Hallor KH, 2009, CLIN CANCER RES, V15, P2685, DOI 10.1158/1078-0432.CCR-08-2330; Han YG, 2009, NAT MED, V15, P1062, DOI 10.1038/nm.2020; Haycraft CJ, 2005, PLOS GENET, V1, P480, DOI 10.1371/journal.pgen.0010053; Haycraft CJ, 2007, DEVELOPMENT, V134, P307, DOI 10.1242/dev.02732; Ho L, 2009, CANCER CELL, V16, P126, DOI 10.1016/j.ccr.2009.05.013; Hopyan S, 2002, NAT GENET, V30, P306, DOI 10.1038/ng844; Hsu SHC, 2011, DEVELOPMENT, V138, P3791, DOI 10.1242/dev.069492; Huangfu D, 2005, P NATL ACAD SCI USA, V102, P11325, DOI 10.1073/pnas.0505328102; Kim J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027410; LEE GM, 1987, J CELL SCI, V88, P603; Lin AC, 2009, NAT MED, V15, P1421, DOI 10.1038/nm.2055; Liu AM, 2005, DEVELOPMENT, V132, P3103, DOI 10.1242/dev.01894; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; May SR, 2005, DEV BIOL, V287, P378, DOI 10.1016/j.ydbio.2005.08.050; McGlashan SR, 2008, DEV DYNAM, V237, P2013, DOI 10.1002/dvdy.21501; McGlashan SR, 2007, MATRIX BIOL, V26, P234, DOI 10.1016/j.matbio.2006.12.003; Moser JJ, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-448; Pansuriya TC, 2011, ORPHANET J RARE DIS, V6, DOI 10.1186/1750-1172-6-2; Pauli C, 2012, OSTEOARTHR CARTILAGE, V20, P476, DOI 10.1016/j.joca.2011.12.018; Poon R, 2001, ONCOGENE, V20, P451, DOI 10.1038/sj.onc.1204107; Praetorius HA, 2003, J MEMBRANE BIOL, V191, P69, DOI 10.1007/s00232-002-1042-4; Pritzker KPH, 2006, OSTEOARTHR CARTILAGE, V14, P13, DOI 10.1016/j.joca.2005.07.014; Schraml P, 2009, MODERN PATHOL, V22, P31, DOI 10.1038/modpathol.2008.132; Seeley ES, 2009, CANCER RES, V69, P422, DOI 10.1158/0008-5472.CAN-08-1290; Serra R, 2008, ANAT REC, V291, P1049, DOI 10.1002/ar.20634; Song B, 2007, DEV BIOL, V305, P202, DOI 10.1016/j.ydbio.2007.02.003; Tiet TD, 2006, AM J PATHOL, V168, P321, DOI 10.2353/ajpath.2006.050001; Tobin JL, 2009, GENET MED, V11, P386, DOI 10.1097/GIM.0b013e3181a02882; Wong SY, 2009, NAT MED, V15, P1055, DOI 10.1038/nm.2011; Yan TQ, 2008, CLIN ORTHOP RELAT R, V466, P2184, DOI 10.1007/s11999-008-0332-2; Yuan K, 2010, J HISTOCHEM CYTOCHEM, V58, P857, DOI 10.1369/jhc.2010.955856	36	40	44	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2013	32	47					5388	5396		10.1038/onc.2012.588	http://dx.doi.org/10.1038/onc.2012.588			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	254PM	23246966	Green Published, hybrid			2022-12-28	WOS:000327177600002
J	Pagliuca, A; Valvo, C; Fabrizi, E; di Martino, S; Biffoni, M; Runci, D; Forte, S; De Maria, R; Ricci-Vitiani, L				Pagliuca, A.; Valvo, C.; Fabrizi, E.; di Martino, S.; Biffoni, M.; Runci, D.; Forte, S.; De Maria, R.; Ricci-Vitiani, L.			Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression	ONCOGENE			English	Article						RAS/MAPK; signaling pathway; miRNA; microarray; colorectal cancer	MESSENGER-RNAS; MICRORNA-143; EXPRESSION; TARGETS; SYSTEM; KRAS; CLUSTER; GROWTH	MicroRNAs (miRNAs) from the gene cluster miR-143-145 are diminished in cells of colorectal tumor origin when compared with normal colon epithelia. Until now, no report has addressed the coordinate action of these miRNAs in colorectal cancer (CRC). In this study, we performed a comprehensive molecular and functional analysis of the miRNA cluster regulatory network. First, we evaluated proliferation, migration, anchorage-independent growth and chemoresistance in the colon tumor cell lines after miR-143 and miR-145 restoration. Then, we assessed the contribution of single genes targeted by miR-143 and miR-145 by reinforcing their expression and checking functional recovery. Restoring miR-143 and miR-145 in colon cancer cells decreases proliferation, migration and chemoresistance. We identified cluster of differentiation 44 (CD44), Kruppel-like factor 5 (KLF5), Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) as proteins targeted by miR-143 and miR145. Their re-expression can partially revert a decrease in transformation properties caused by the overexpression of miR-143 and miR145. In addition, we determined a set of mRNAs that are diminished after reinforcing miR-143 and miR-145 expression. The whole transcriptome analysis ascertained that downregulated transcripts are enriched in predicted target genes in a statistically significant manner. A number of additional genes, whose expression decreases as a direct or indirect consequence of miR-143 and miR-145, reveals a complex regulatory network that affects cell signaling pathways involved in transformation. In conclusion, we identified a coordinated program of gene repression by miR-143 and miR-145, in CRC, where either of the two miRNAs share a target transcript, or where the target transcripts share a common signaling pathway. Major mediators of the oncosuppression by miR-143 and miR-145 are genes belonging to the growth factor receptor-mitogen-activated protein kinase network and to the p53 signaling pathway.	[Pagliuca, A.; Fabrizi, E.; di Martino, S.; Biffoni, M.; Runci, D.; Ricci-Vitiani, L.] Ist Super Sanita, Dept Hematol Oncol & Mol Med, I-00161 Rome, Italy; [Valvo, C.; De Maria, R.] Italian Natl Canc Inst Regina Elena, Rome, Italy; [Forte, S.] IOM Ric Srl, Viagrande, CT, Italy	Istituto Superiore di Sanita (ISS); Consiglio Nazionale delle Ricerche (CNR); Istituto Officina dei Materiali (IOM-CNR)	Pagliuca, A (corresponding author), Ist Super Sanita, Dept Hematol Oncol & Mol Med, Viale Regina Elena 299, I-00161 Rome, Italy.	alfredo.pagliuca@iss.it; lriccivitiani@yahoo.it	Ricci Vitiani, Lucia/J-8320-2016; Pagliuca, Alfredo/AAI-3689-2020; Biffoni, Mauro/J-8318-2016; De Maria, Ruggero/S-6385-2019; di Martino, Simona SdM/K-9304-2016; Forte, Stefano/D-3645-2013	Ricci Vitiani, Lucia/0000-0001-7336-5615; Biffoni, Mauro/0000-0002-1304-9060; De Maria, Ruggero/0000-0003-2255-0583; di Martino, Simona SdM/0000-0003-4533-3776; Forte, Stefano/0000-0001-5746-7451; pagliuca, alfredo/0000-0002-8703-2077	Associazione Italiana per la Ricerca sul Cancro, AIRC [6326]	Associazione Italiana per la Ricerca sul Cancro, AIRC(Fondazione AIRC per la ricerca sul cancro)	This work was supported by grant from Associazione Italiana per la Ricerca sul Cancro, AIRC (Start-up 6326 to LR-V and Regional Fellowship to CV). We thank Tania Merlino for contribution in editing the manuscript.	Baek D, 2008, NATURE, V455, P64, DOI 10.1038/nature07242; Baron U, 2000, METHOD ENZYMOL, V327, P401, DOI 10.1016/S0076-6879(00)27292-3; Baron U, 1997, NUCLEIC ACIDS RES, V25, P2723, DOI 10.1093/nar/25.14.2723; Batliner J, 2012, LEUKEMIA RES, V36, P237, DOI 10.1016/j.leukres.2011.10.006; Bockmeyer CL, 2011, BREAST CANCER RES TR, V130, P735, DOI 10.1007/s10549-010-1303-3; Brest P, 2011, NAT GENET, V43, P242, DOI 10.1038/ng.762; Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406; Chen X, 2009, ONCOGENE, V28, P1385, DOI 10.1038/onc.2008.474; Cordes KR, 2009, NATURE, V460, P705, DOI 10.1038/nature08195; Dennis G, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-9-r60; Elcheva I, 2009, MOL CELL, V35, P240, DOI 10.1016/j.molcel.2009.06.007; Esau C, 2004, J BIOL CHEM, V279, P52361, DOI 10.1074/jbc.C400438200; Friedman RC, 2009, GENOME RES, V19, P92, DOI 10.1101/gr.082701.108; Gao W, 2010, BIOMED PHARMACOTHER, V64, P399, DOI 10.1016/j.biopha.2010.01.018; Godar S, 2008, CELL, V134, P62, DOI 10.1016/j.cell.2008.06.006; Guo HL, 2010, NATURE, V466, P835, DOI 10.1038/nature09267; Hsu JBK, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-300; Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211; Kent OA, 2013, ONCOGENE, V32, P2576, DOI 10.1038/onc.2012.266; Kent OA, 2010, GENE DEV, V24, P2754, DOI 10.1101/gad.1950610; Kloosterman WP, 2006, DEV CELL, V11, P441, DOI 10.1016/j.devcel.2006.09.009; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Nandan MO, 2008, GASTROENTEROLOGY, V134, P120, DOI 10.1053/j.gastro.2007.10.023; Ng EKO, 2009, BRIT J CANCER, V101, P699, DOI 10.1038/sj.bjc.6605195; Nonne N, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkp1100; Ricci-Vitiani L, 2004, J EXP MED, V200, P1257, DOI 10.1084/jem.20040921; Ricci-Vitiani L, 2010, FASEB J, V24, P4291, DOI 10.1096/fj.10-159970; Rubinson DA, 2003, NAT GENET, V33, P401, DOI 10.1038/ng1117; Sachdeva M, 2009, P NATL ACAD SCI USA, V106, P3207, DOI 10.1073/pnas.0808042106; Selbach M, 2008, NATURE, V455, P58, DOI 10.1038/nature07228; Shi B, 2007, J BIOL CHEM, V282, P32582, DOI 10.1074/jbc.M702806200; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Takagi T, 2009, ONCOLOGY-BASEL, V77, P12, DOI 10.1159/000218166; Villadsen SB, 2012, BRIT J CANCER, V106, P366, DOI 10.1038/bjc.2011.520; Zhu HY, 2011, MOL CANCER RES, V9, P960, DOI 10.1158/1541-7786.MCR-10-0531	35	151	159	0	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2013	32	40					4806	4813		10.1038/onc.2012.495	http://dx.doi.org/10.1038/onc.2012.495			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229NW	23128394				2022-12-28	WOS:000325274700009
J	Lu, X; An, H; Jin, R; Zou, M; Guo, Y; Su, PF; Liu, D; Shyr, Y; Yarbrough, WG				Lu, X.; An, H.; Jin, R.; Zou, M.; Guo, Y.; Su, P-F; Liu, D.; Shyr, Y.; Yarbrough, W. G.			PPM1A is a RelA phosphatase with tumor suppressor-like activity	ONCOGENE			English	Article						NF-kappa B; PPM1A; phosphatase; prostate cancer; tumor suppressor	NF-KAPPA-B; MONOCYTE CHEMOATTRACTANT PROTEIN-1; THERAPEUTIC TARGET; WIP1 PHOSPHATASE; PROSTATE; PHOSPHORYLATION; GENE; GROWTH; P65; BONE	Nuclear factor-kappa B (NF-kappa B) signaling contributes to human disease processes, notably inflammatory diseases and cancer. NF-kappa B has a role in tumorigenesis and tumor growth, as well as promotion of metastases. Mechanisms responsible for abnormal NF-kappa B activation are not fully elucidated; however, RelA phosphorylation, particularly at serine residues S536 and S276, is critical for RelA function. Kinases that phosphorylate RelA promote oncogenic behaviors, suggesting that phosphatases targeting RelA could have tumor-inhibiting activities; however, few RelA phosphatases have been identified. Here, we identified tumor inhibitory and RelA phosphatase activities of the protein phosphatase 2C (PP2C) phosphatase family member, PPM1A. We show that PPM1A directly dephosphorylated RelA at residues S536 and S276 and selectively inhibited NF-kappa B transcriptional activity, resulting in decreased expression of monocyte chemotactic protein-1/chemokine (C-C motif) ligand 2 and interleukin-6, cytokines implicated in cancer metastasis. PPM1A depletion enhanced NF-kappa B-dependent cell invasion, whereas PPM1A expression inhibited invasion. Analyses of human expression data revealed that metastatic prostate cancer deposits had lower PPM1A expression compared with primary tumors without distant metastases. A hematogenous metastasis mouse model revealed that PPM1A expression inhibited bony metastases of prostate cancer cells after vascular injection. In summary, our findings suggest that PPM1A is a RelA phosphatase that regulates NF-kappa B activity and that PPM1A has tumor suppressor-like activity. Our analyses also suggest that PPM1A inhibits prostate cancer metastases and as neither gene deletions nor inactivating mutations of PPM1A have been described, increasing PPM1A activity in tumors represents a potential therapeutic strategy to inhibit NF-kappa B signaling or bony metastases in human cancer.	[Lu, X.; An, H.; Guo, Y.] Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37235 USA; [An, H.] Vanderbilt Univ, Div Surg Sci, Nashville, TN 37235 USA; [Jin, R.] Vanderbilt Univ, Vanderbilt Prostate Canc Ctr, Nashville, TN 37235 USA; [Jin, R.] Vanderbilt Univ, Dept Urol, Nashville, TN 37235 USA; [Zou, M.; Liu, D.; Yarbrough, W. G.] Yale Univ, Div Otolaryngol, Dept Surg, New Haven, CT 06519 USA; [Su, P-F; Shyr, Y.] Vanderbilt Univ, Dept Biostat, Nashville, TN 37235 USA; [Yarbrough, W. G.] Yale Univ, Dept Pathol, New Haven, CT 06519 USA; [Yarbrough, W. G.] Yale Canc Ctr, New Haven, CT USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Yale University; Vanderbilt University; Yale University; Yale University	Yarbrough, WG (corresponding author), Yale Univ, Sch Med, Dept Surg, Div Otolaryngol, 800 Howard Ave,4th Floor, New Haven, CT 06519 USA.	Wendell.yarbrough@yale.edu			Vanderbilt Ingram Cancer Center; Department of Otolaryngology at Vanderbilt University; Vanderbilt Bill Wilkerson Center;  [NIH R01 DE013173]; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE013173] Funding Source: NIH RePORTER	Vanderbilt Ingram Cancer Center; Department of Otolaryngology at Vanderbilt University; Vanderbilt Bill Wilkerson Center; ; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	We thank W Sun, LA Donehower, N Perkins, Reuven Agami and IM Verma for providing constructs and cell lines. We are extremely grateful to A Richmond, R Matusik, J McLean, A Weaver, D Webb and to Baker Lab members for insightful advice. This work was supported by Grant NIH R01 DE013173 (to WGY) and by funds provided through an endowment from Barry and Amy Baker to the Barry Baker Laboratory for Head & Neck Oncology, from the Vanderbilt Ingram Cancer Center, from the Department of Otolaryngology at Vanderbilt University and from the Vanderbilt Bill Wilkerson Center.	Abdelmohsen K, 2007, MOL CELL, V25, P543, DOI 10.1016/j.molcel.2007.01.011; An HB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016427; Arun P, 2009, CLIN CANCER RES, V15, P5974, DOI 10.1158/1078-0432.CCR-09-1352; Azevedo A, 2011, WORLD J CLIN ONCOL, V2, P384, DOI 10.5306/wjco.v2.i12.384; Browning DD, 1997, J BIOL CHEM, V272, P7995, DOI 10.1074/jbc.272.12.7995; Buss H, 2004, J BIOL CHEM, V279, P49571, DOI 10.1074/jbc.C400442200; Cao YX, 2003, J MAMMARY GLAND BIOL, V8, P215, DOI 10.1023/A:1025905008934; Chandran UR, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-64; Chaturvedi MM, 2011, ONCOGENE, V30, P1615, DOI 10.1038/onc.2010.566; Chen LF, 2004, NAT REV MOL CELL BIO, V5, P392, DOI 10.1038/nrm1368; Chew J, 2009, NAT CELL BIOL, V11, P659, DOI 10.1038/ncb1873; Coward J, 2011, CLIN CANCER RES, V17, P6083, DOI 10.1158/1078-0432.CCR-11-0945; Craig MJ, 2006, CANCER METAST REV, V25, P611, DOI 10.1007/s10555-006-9027-x; Drake JM, 2005, CLIN EXP METASTAS, V22, P674, DOI 10.1007/s10585-006-9011-4; Gardam S, 2011, EXPERT OPIN THER TAR, V15, P207, DOI 10.1517/14728222.2011.548861; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Ghosh S, 2008, NAT REV IMMUNOL, V8, P837, DOI 10.1038/nri2423; Grivennikov SI, 2010, CURR OPIN GENET DEV, V20, P65, DOI 10.1016/j.gde.2009.11.004; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Kim JS, 2006, BIOCHEM BIOPH RES CO, V351, P253, DOI 10.1016/j.bbrc.2006.10.028; Lammers T, 2007, CRIT REV BIOCHEM MOL, V42, P437, DOI 10.1080/10409230701693342; Lammers T, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-65; Lin X, 2006, CELL, V125, P915, DOI 10.1016/j.cell.2006.03.044; Lu XB, 2007, CANCER CELL, V12, P342, DOI 10.1016/j.ccr.2007.08.033; Lu Y, 2006, PROSTATE, V66, P1311, DOI 10.1002/pros.20464; Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100; Mueller L, 2010, BIOCHEM BIOPH RES CO, V397, P586, DOI 10.1016/j.bbrc.2010.05.163; Nelson DE, 2004, SCIENCE, V306, P704, DOI 10.1126/science.1099962; Nelson WG, 2003, NEW ENGL J MED, V349, P366, DOI 10.1056/NEJMra021562; Neumann M, 2007, FASEB J, V21, P2642, DOI 10.1096/fj.06-7615rev; Oeckinghaus A, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a000034; Orlowski RZ, 2002, TRENDS MOL MED, V8, P385, DOI 10.1016/S1471-4914(02)02375-4; Perkins ND, 2006, ONCOGENE, V25, P6717, DOI 10.1038/sj.onc.1209937; Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138; Sakurai H, 2003, J BIOL CHEM, V278, P36916, DOI 10.1074/jbc.M301598200; Schwabe RF, 2005, FASEB J, V19, P1758, DOI 10.1096/fj.05-3736fje; Shohat M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032438; Smale ST, 2011, NAT IMMUNOL, V12, P689, DOI 10.1038/ni.2070; Sosnoski DM, 2012, INT J BREAST CANCER, V2012, DOI 10.1155/2012/160265; Sun WJ, 2009, CELL SIGNAL, V21, P95, DOI 10.1016/j.cellsig.2008.09.012; UEDA A, 1994, J IMMUNOL, V153, P2052; Ueda A, 1997, J BIOL CHEM, V272, P31092, DOI 10.1074/jbc.272.49.31092; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang JL, 2007, CANCER CELL, V12, P239, DOI 10.1016/j.ccr.2007.07.002; Wolf MJ, 2012, CANCER CELL, V22, P91, DOI 10.1016/j.ccr.2012.05.023; Wu JT, 2005, J SURG RES, V123, P158, DOI 10.1016/j.jss.2004.06.006; Wu TT, 1998, INT J CANCER, V77, P887, DOI 10.1002/(SICI)1097-0215(19980911)77:6<887::AID-IJC15>3.0.CO;2-Z; Yamaguchi H, 2005, BIOCHEMISTRY-US, V44, P5285, DOI 10.1021/bi0476634; Yamaguchi H, 2007, BIOCHEMISTRY-US, V46, P12594, DOI 10.1021/bi701096s; Yang JM, 2001, J BIOL CHEM, V276, P47828, DOI 10.1074/jbc.M106103200; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158; Zhang BH, 2009, HISTOCHEM CELL BIOL, V132, P169, DOI 10.1007/s00418-009-0601-5; Zhang J, 2010, PROG MOL BIOL TRANSL, V95, P31, DOI 10.1016/B978-0-12-385071-3.00003-4; Zhang J, 2010, CYTOKINE GROWTH F R, V21, P41, DOI 10.1016/j.cytogfr.2009.11.009; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X; Zollo M, 2012, CLIN EXP METASTAS, V29, P585, DOI 10.1007/s10585-012-9473-5	56	33	38	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2014	33	22					2918	2927		10.1038/onc.2013.246	http://dx.doi.org/10.1038/onc.2013.246			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EI	23812431	Green Accepted			2022-12-28	WOS:000337231800011
J	Huang, J; Xiao, D; Li, G; Ma, J; Chen, P; Yuan, W; Hou, F; Ge, J; Zhong, M; Tang, Y; Xia, X; Chen, Z				Huang, J.; Xiao, D.; Li, G.; Ma, J.; Chen, P.; Yuan, W.; Hou, F.; Ge, J.; Zhong, M.; Tang, Y.; Xia, X.; Chen, Z.			EphA2 promotes epithelial-mesenchymal transition through the Wnt/beta-catenin pathway in gastric cancer cells	ONCOGENE			English	Article						EphA2; gastric cancer; epithelial-mensenchymal transition; Wnt/beta-catenin	DEPENDENT TRANSCRIPTION; COLORECTAL-CANCER; RECEPTOR; ACTIVATION; EXPRESSION	This study aims to investigate the significance of erythropoietin-producing hepatocellular (Eph)A2 expression and the mechanism by which EphA2 is involved in the epithelial-mensenchymal transition (EMT) of gastric cancer cells. EphA2 expression levels were upregulated and positively correlated with metastasis and EMT markers in human gastric cancer specimens. Modulation of EphA2 expression levels had distinct effects on cell proliferation, cell cycle, migration, invasion and morphology in the gastric cancer cell lines SGC7901 and AGS in vitro and in vivo. Overexpression of EphA2 resulted in the upregulation of the EMT molecular markers N-cadherin and Snail, as well as the Wnt/beta-catenin targets TCF4, Cyclin-D1 and c-Myc, while silencing EphA2 using short hairpin RNA had the opposite effect. Furthermore, inhibition of the Wnt/beta-catenin pathway by XAV939 negated the effect of EphA2 overexpression, whereas activation of the Wnt/beta-catenin pathway by LiCl impaired the effect of the EphA2 knockdown on EMT. These observations demonstrate that EphA2 upregulation is a common event in gastric cancer specimens that is closely correlated with cancer metastasis and that EphA2 promotes EMT of gastric cancer cells through activation of Wnt/beta-catenin signaling.	[Huang, J.; Zhong, M.; Tang, Y.] Cent S Univ, Xiangya Hosp, Dept Oncol, Changsha 410008, Hunan, Peoples R China; [Xiao, D.] Cent S Univ, Xiangya Hosp, Dept Pathol, Changsha 410008, Hunan, Peoples R China; [Li, G.; Ma, J.; Chen, P.] Cent S Univ, Hunan Key Lab Nonresolving Inflammat & Canc, Canc Res Inst, Changsha 410008, Hunan, Peoples R China; [Yuan, W.; Hou, F.; Ge, J.; Chen, Z.] Cent S Univ, Xiangya Hosp, Dept Gen Surg, Changsha 410008, Hunan, Peoples R China; [Xia, X.] Weill Cornell Sch Med, Methodist Hosp Res Inst, Ctr Genom Med, Houston, TX USA	Central South University; Central South University; Central South University; Central South University; Cornell University; The Methodist Hospital System; The Methodist Hospital - Houston; The Methodist Hospital Research Institute	Chen, Z (corresponding author), Cent S Univ, Xiangya Hosp, Dept Gen Surg, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China.	zihuachenxy@126.com			Nature Scientific Foundation of China [81172297]; Ministry of Education (SRF for ROCS) [NCET-11-0520]; Hunan Province Natural Sciences Foundation of China [B2010-010]	Nature Scientific Foundation of China(National Natural Science Foundation of China (NSFC)); Ministry of Education (SRF for ROCS)(Scientific Research Foundation for the Returned Overseas Chinese Scholars); Hunan Province Natural Sciences Foundation of China(Natural Science Foundation of Hunan Province)	This work was supported by Nature Scientific Foundation of China (81172297), Ministry of Education (NCET-11-0520, SRF for ROCS) and Hunan Province Natural Sciences Foundation of China (B2010-010). We thank Yangchun Xie and Liyang Zhang for their technical help.	Amit I, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100195; Baeten CIM, 2009, DIS COLON RECTUM, V52, P2028, DOI 10.1007/DCR.0b013e3181beb4ff; Brannan JM, 2009, CLIN CANCER RES, V15, P4423, DOI 10.1158/1078-0432.CCR-09-0473; Cui XD, 2010, INT J CANCER, V126, P940, DOI 10.1002/ijc.24798; Fukuyama R, 2008, ONCOGENE, V27, P6044, DOI 10.1038/onc.2008.204; Howard S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023899; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Huber O, 1996, CURR OPIN CELL BIOL, V8, P685, DOI 10.1016/S0955-0674(96)80110-4; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Li X, 2010, TUMOR BIOL, V31, P477, DOI 10.1007/s13277-010-0060-6; Lovatt M, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012794; Lu C, 2008, CANCER BIOL THER, V7, P1098, DOI 10.4161/cbt.7.7.6168; Macrae M, 2005, CANCER CELL, V8, P111, DOI 10.1016/j.ccr.2005.07.005; Malanchi I, 2008, NATURE, V452, P650, DOI 10.1038/nature06835; Menges CW, 2008, ONCOGENE, V27, P2934, DOI 10.1038/sj.onc.1210957; Merritt WM, 2010, CANCER BIOL THER, V10, P1306, DOI 10.4161/cbt.10.12.13582; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Pratt RL, 2002, ONCOGENE, V21, P7690, DOI 10.1038/sj.onc.1205758; Song SM, 2009, CANCER RES, V69, P1343, DOI 10.1158/0008-5472.CAN-08-4153; Sulman EP, 1997, GENOMICS, V40, P371, DOI 10.1006/geno.1996.4569; Sundaram Meera V, 2006, WormBook, P1; Taddei ML, 2011, MOL CANCER RES, V9, P149, DOI 10.1158/1541-7786.MCR-10-0298; Tandon M, 2011, EXPERT OPIN THER TAR, V15, P31, DOI 10.1517/14728222.2011.538682; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Udayakumar D, 2011, ONCOGENE, V30, P4921, DOI 10.1038/onc.2011.210; Voulgari A, 2009, BBA-REV CANCER, V1796, P75, DOI 10.1016/j.bbcan.2009.03.002; Wang Q, 2010, ONCOGENE, V29, P128, DOI 10.1038/onc.2009.302; Yuan W, 2012, NEOPLASMA, V59, P105, DOI 10.4149/neo_2012_014; Yuan WJ, 2009, DIGEST DIS SCI, V54, P2410, DOI 10.1007/s10620-008-0649-4; Yuan WJ, 2009, PATHOL ONCOL RES, V15, P473, DOI 10.1007/s12253-008-9132-y; Zhang GQ, 2008, CANCER RES, V68, P1691, DOI 10.1158/0008-5472.CAN-07-2372	31	159	180	2	47	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2014	33	21					2737	2747		10.1038/onc.2013.238	http://dx.doi.org/10.1038/onc.2013.238			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EH	23752181				2022-12-28	WOS:000337231700007
J	Li, ZJ; Mack, SC; Mak, TH; Angers, S; Taylor, MD; Hui, CC				Li, Z. J.; Mack, S. C.; Mak, T. H.; Angers, S.; Taylor, M. D.; Hui, C-C			Evasion of p53 and G(2)/M checkpoints are characteristic of Hh-driven basal cell carcinoma	ONCOGENE			English	Article						Sufu; Ptc1; Hedgehog; basal cell carcinoma; cell cycle; p53	CYCLE PROGRESSION; SIGNALING PATHWAY; SMAD PROTEINS; HEDGEHOG; SKIN; MICE; EXPRESSION; TUMORIGENESIS; SUPPRESSOR; PROLIFERATION	Basal cell carcinoma (BCC), the most common type of cancer, is characterized by aberrant Hedgehog (Hh) pathway activity. Mutations in pathway components, such as PATCHED1 (PTCH1), are commonly found in BCC. While the tumor suppressor role of PTCH1 in BCC is well established, how Hh pathway activation disrupts normal skin homeostasis to promote BCC formation remains poorly understood. Like Ptc1, Sufu is a major negative regulator of the Hh pathway. Previously, we showed that inactivation of Sufu in the skin does not result in BCC formation. Why loss of Ptc1, but not Sufu, in the epidermis induces BCC formation is unclear. In this report, we utilized gene expression profiling to identify biological pathways and processes that distinguish Sufu from Ptc1 mutants, and discovered a novel role for Sufu in cell cycle regulation. We demonstrated that the Hh pathway activation in Sufu and Ptc1 mutant skin is associated with abnormal cell cycle entry, ectopic expression of D-type cyclins and increased DNA damage. However, despite the presence of DNA damage, p53 stabilization was impaired in the mutant skin. Alternative mechanism to halt genomic instability is the activation of G2/M cell cycle checkpoint, which can occur independent of p53. We found that while Ptc1 mutant cells continue to cycle, which would favor genomic instability, loss of Sufu results in G2/M cell cycle arrest. This finding may explain why inactivation of Sufu is not sufficient to drive BCC formation. Taken together, these studies revealed a unique role for Sufu in G2/M phase progression, and uncovered the molecular and cellular features associated with Hh-driven BCC.	[Li, Z. J.; Mack, S. C.; Mak, T. H.; Taylor, M. D.; Hui, C-C] Hosp Sick Children, Program Dev & Stem Cell Biol, Toronto, ON M5G 1L7, Canada; [Li, Z. J.; Hui, C-C] Univ Toronto, Dept Mol Genet, Toronto, ON, Canada; [Mack, S. C.; Taylor, M. D.] Hosp Sick Children, Arthur & Sonia Labatt Brain Tumor Res Ctr, Div Neurosurg, Toronto, ON M5G 1X8, Canada; [Mack, S. C.; Taylor, M. D.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada; [Angers, S.] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON, Canada; [Angers, S.] Univ Toronto, Dept Biochem, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto	Hui, CC (corresponding author), Hosp Sick Children, Program Dev & Stem Cell Biol, 101 Coll St,TMDT East Tower,Room 13-314, Toronto, ON M5G 1L7, Canada.	cchui@sickkids.ca	Angers, Stephane/E-1432-2014	Angers, Stephane/0000-0001-7241-9044; Mack, Stephen C./0000-0001-9620-4742; Taylor, Michael/0000-0001-7009-3466	Canadian Cancer Society Research Institute [2011-700774]	Canadian Cancer Society Research Institute(Canadian Cancer Society (CCS))	We thank E Nieuwenhuis and W Nien for initial characterization of the Sufu and Ptc1 mutants, and T Satkunendran for technical help. This research is funded by the Canadian Cancer Society Research Institute (2011-700774) to CCH.	Abe Y, 2008, P NATL ACAD SCI USA, V105, P4838, DOI 10.1073/pnas.0712216105; Adolphe C, 2006, CANCER RES, V66, P2081, DOI 10.1158/0008-5472.CAN-05-2146; Aszterbaum M, 1999, NAT MED, V5, P1285, DOI 10.1038/15242; Barnes EA, 2001, EMBO J, V20, P2214, DOI 10.1093/emboj/20.9.2214; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Cooper AF, 2005, DEVELOPMENT, V132, P4407, DOI 10.1242/dev.02021; Cwinn MA, 2011, J NEUROSCI, V31, P5169, DOI 10.1523/JNEUROSCI.5495-10.2011; Epstein EH, 2008, NAT REV CANCER, V8, P743, DOI 10.1038/nrc2503; Fan HR, 1999, J CELL BIOL, V147, P71, DOI 10.1083/jcb.147.1.71; Gambichler T, 2007, EUR J MED RES, V12, P509; Goodrich LV, 1996, GENE DEV, V10, P301, DOI 10.1101/gad.10.3.301; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Grachtchouk M, 2000, NAT GENET, V24, P216, DOI 10.1038/73417; Grachtchouk V, 2003, EMBO J, V22, P2741, DOI 10.1093/emboj/cdg271; Howell BG, 2005, J DERMATOL SCI, V39, P39, DOI 10.1016/j.jdermsci.2005.02.004; Humke EW, 2010, GENE DEV, V24, P670, DOI 10.1101/gad.1902910; Hutchin ME, 2005, GENE DEV, V19, P214, DOI 10.1101/gad.1258705; Kasper M, 2011, P NATL ACAD SCI USA, V108, P4099, DOI 10.1073/pnas.1014489108; Kenney AM, 2003, DEVELOPMENT, V130, P15, DOI 10.1242/dev.00182; Kenney AM, 2000, MOL CELL BIOL, V20, P9055, DOI 10.1128/MCB.20.23.9055-9067.2000; Lange D, 1999, INT J ONCOL, V14, P1049; Li ZJ, 2012, DEVELOPMENT, V139, P4152, DOI 10.1242/dev.081190; Mancuso M, 2004, CANCER RES, V64, P934, DOI 10.1158/0008-5472.CAN-03-2460; Merico D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013984; Mill P, 2003, GENE DEV, V17, P282, DOI 10.1101/gad.1038103; Mill P, 2005, DEV CELL, V9, P293, DOI 10.1016/j.devcel.2005.05.009; Ng D, 2005, AM J MED GENET A, V134A, P399, DOI 10.1002/ajmg.a.30653; Nieuwenhuis E, 2006, MOL CELL BIOL, V26, P6609, DOI 10.1128/MCB.00295-06; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; O'Driscoll L, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-74; Oro AE, 2003, DEV BIOL, V255, P238, DOI 10.1016/S0012-1606(02)00042-8; Reifenberger J, 2005, BRIT J DERMATOL, V152, P43, DOI 10.1111/J.1365-2133.2005.06353.X; Ribeiro GRH, 2004, J DERMATOL SCI, V36, P79, DOI 10.1016/j.jdermsci.2004.08.003; Sardi I, 2000, ONCOL REP, V7, P1119; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Svard J, 2006, DEV CELL, V10, P187, DOI 10.1016/j.devcel.2005.12.013; Takizawa CG, 2000, CURR OPIN CELL BIOL, V12, P658, DOI 10.1016/S0955-0674(00)00149-6; Tukachinsky H, 2010, J CELL BIOL, V191, P415, DOI 10.1083/jcb.201004108; Van Haren R, 2009, BRIT J DERMATOL, V161, P1278, DOI 10.1111/j.1365-2133.2009.09338.x; Villani RM, 2010, CANCER PREV RES, V3, P1222, DOI 10.1158/1940-6207.CAPR-10-0082; Welss T, 2003, INT J CANCER, V104, P66, DOI 10.1002/ijc.10912	41	16	17	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 15	2014	33	20					2674	2680		10.1038/onc.2013.212	http://dx.doi.org/10.1038/onc.2013.212			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH9YT	23752195				2022-12-28	WOS:000336502700013
J	Borgdorff, V; Rix, U; Winter, GE; Gridling, M; Muller, AC; Breitwieser, FP; Wagner, C; Colinge, J; Bennett, KL; Superti-Furga, G; Wagner, SN				Borgdorff, V.; Rix, U.; Winter, G. E.; Gridling, M.; Mueller, A. C.; Breitwieser, F. P.; Wagner, C.; Colinge, J.; Bennett, K. L.; Superti-Furga, G.; Wagner, S. N.			A chemical biology approach identifies AMPK as a modulator of melanoma oncogene MITF	ONCOGENE			English	Article						MITF; melanoma; AMPK; compound C; midostaurin; sunitinib	ACTIVATED PROTEIN-KINASE; TRANSCRIPTION FACTOR; GLUCOSE DEPRIVATION; SIGNALING PATHWAYS; LINEAGE SURVIVAL; ENERGY SENSOR; CELL-GROWTH; MICROPHTHALMIA; CANCER; PROLIFERATION	The microphthalmia-associated transcription factor (MITF) is indispensable for the viability of melanocytic cells, is an oncogene in melanoma and has a cell type-specific expression pattern. As the modulation of MITF activity by direct chemical targeting remains a challenge, we assessed a panel of drugs for their ability to downregulate MITF expression or activity by targeting its upstream modulators. We found that the multi-kinase inhibitors midostaurin and sunitinib downregulate MITF protein levels. To identify the target molecules shared by both the drugs in melanocytic cells, a chemical proteomic approach was applied and AMP-activated kinase (AMPK) was identified as the relevant target for the observed phenotype. RNA interference and chemical inhibition of AMPK led to a decrease in MITF protein levels. Reduction of MITF protein levels was the result of proteasomal degradation, which was preceded by enhanced phosphorylation of MITF mediated by ERK. As expected, downregulation of MITF protein levels by AMPK inhibition was associated with decreased viability. Together, these results identify AMPK as an important regulator for the maintenance of MITF protein levels in melanocytic cells.	[Borgdorff, V.; Wagner, C.; Wagner, S. N.] Med Univ Vienna, Dept Dermatol, Div Immunol Allergy & Infect Dis, A-1090 Vienna, Austria; [Borgdorff, V.; Rix, U.; Winter, G. E.; Gridling, M.; Mueller, A. C.; Breitwieser, F. P.; Colinge, J.; Bennett, K. L.; Superti-Furga, G.; Wagner, S. N.] Austrian Acad Sci, CeMM Res Ctr Mol Med, A-1010 Vienna, Austria	Medical University of Vienna; Austrian Academy of Sciences; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences	Wagner, SN (corresponding author), Med Univ Vienna, Dept Dermatol, Div Immunol Allergy & Infect Dis, Waehringer Guertel 18-20, A-1090 Vienna, Austria.	vborgdorff@gmail.com; stephan.wagner@meduniwien.ac.at	Superti-Furga, Giulio/F-4755-2015; Superti-Furga, Giulio/AAE-5681-2019; Colinge, Jacques/Z-2613-2019; Colinge, Jacques/D-1578-2017	Superti-Furga, Giulio/0000-0002-0570-1768; Colinge, Jacques/0000-0003-2466-4824; Colinge, Jacques/0000-0003-2466-4824; Winter, Georg/0000-0001-6606-1437; Wagner, Stephan/0000-0003-4941-7029; Mueller, Andre/0000-0002-0608-8176; Bennett, Keiryn L./0000-0001-9356-7708; Breitwieser, Florian P/0000-0001-6192-0853	FWF-Austrian Science Fund [L590-B12]; Austrian Academy of Sciences; GEN-AU initiative of the Austrian Federal Ministry for Science and Research (PLACEBO GZ) [BMWF-70.081/0018-II/1a/2008, APP-III 820965]; Austrian Science Fund (FWF) [P 24321, L 590] Funding Source: researchfish	FWF-Austrian Science Fund(Austrian Science Fund (FWF)); Austrian Academy of Sciences; GEN-AU initiative of the Austrian Federal Ministry for Science and Research (PLACEBO GZ); Austrian Science Fund (FWF)(Austrian Science Fund (FWF))	We thank Hans Widlund (Harvard Skin Disease Research Center, Brigham and Women's Hospital, Boston, MA, USA) for providing us with human immortalised melanocytes with and without ectopic expression of BRAF<SUP>V600E</SUP> and HA-MITF as described in Garraway et al.<SUP>1</SUP> We thank Gaurav Pathria for helpful discussions and critical reading of the manuscript. This study was funded by FWF-Austrian Science Fund (L590-B12) to SNW. The team at CeMM is supported by the Austrian Academy of Sciences, and the GEN-AU initiative of the Austrian Federal Ministry for Science and Research (PLACEBO GZ BMWF-70.081/0018-II/1a/2008 and APP-III 820965).	Bennett KL, 2011, J PROTEOMICS, V74, P151, DOI 10.1016/j.jprot.2010.10.002; Bertolotto C, 2011, NATURE, V480, P94, DOI 10.1038/nature10539; Bodmer M, 2010, DIABETES CARE, V33, P1304, DOI 10.2337/dc09-1791; Breitwieser FP, 2011, J PROTEOME RES, V10, P2758, DOI 10.1021/pr1012784; CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014-5793(87)80292-2; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Cheli Y, 2011, ONCOGENE, V30, P2307, DOI 10.1038/onc.2010.598; Colinge J, 2003, PROTEOMICS, V3, P1454, DOI 10.1002/pmic.200300485; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Du JH, 2008, BIOCHEM BIOPH RES CO, V368, P402, DOI 10.1016/j.bbrc.2008.01.099; Esteve-Puig R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004771; Fay JR, 2009, CANCER PREV RES, V2, P301, DOI 10.1158/1940-6207.CAPR-08-0166; Fernbach NV, 2009, J PROTEOME RES, V8, P4753, DOI 10.1021/pr900455x; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Gilar M, 2005, J SEP SCI, V28, P1694, DOI 10.1002/jssc.200500116; Giuliano S, 2010, CANCER RES, V70, P3813, DOI 10.1158/0008-5472.CAN-09-2913; Goding CR, 2011, ONCOGENE, V30, P2304, DOI 10.1038/onc.2010.641; HA J, 1994, J BIOL CHEM, V269, P22162; Hagelkruys Astrid, 2011, Handb Exp Pharmacol, V206, P13, DOI 10.1007/978-3-642-21631-2_2; Hardie DG, 2011, GENE DEV, V25, P1895, DOI 10.1101/gad.17420111; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hemesath TJ, 1998, NATURE, V391, P298, DOI 10.1038/34681; Hoek KS, 2010, PIGM CELL MELANOMA R, V23, P746, DOI 10.1111/j.1755-148X.2010.00757.x; Horike N, 2010, PIGM CELL MELANOMA R, V23, P809, DOI 10.1111/j.1755-148X.2010.00760.x; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Janjetovic K, 2011, EUR J PHARMACOL, V668, P373, DOI 10.1016/j.ejphar.2011.07.004; Junttila MR, 2008, FASEB J, V22, P954, DOI 10.1096/fj.06-7859rev; Karaman MW, 2008, NAT BIOTECHNOL, V26, P127, DOI 10.1038/nbt1358; Kim KY, 2009, CANCER RES, V69, P4018, DOI 10.1158/0008-5472.CAN-08-2641; Kim MJ, 2010, J BIOL CHEM, V285, P14617, DOI 10.1074/jbc.M109.085456; Laderoute KR, 2006, MOL CELL BIOL, V26, P5336, DOI 10.1128/MCB.00166-06; Laderoute KR, 2010, CANCER BIOL THER, V10, P68, DOI 10.4161/cbt.10.1.12162; Lee KH, 2011, J BIOL CHEM, V286, P39247, DOI 10.1074/jbc.M111.264598; McGill GG, 2002, CELL, V109, P707, DOI 10.1016/S0092-8674(02)00762-6; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; Miller AJ, 2005, J BIOL CHEM, V280, P146, DOI 10.1074/jbc.M411757200; Murakami H, 2005, PIGM CELL RES, V18, P265, DOI 10.1111/j.1600-0749.2005.00234.x; Park HU, 2009, MOL CANCER THER, V8, P733, DOI 10.1158/1535-7163.MCT-08-0631; Rappsilber J, 2003, ANAL CHEM, V75, P663, DOI 10.1021/ac026117i; Rix U, 2007, BLOOD, V110, P4055, DOI 10.1182/blood-2007-07-102061; Ross PL, 2004, MOL CELL PROTEOMICS, V3, P1154, DOI 10.1074/mcp.M400129-MCP200; STEINGRIMSSON E, 1994, NAT GENET, V8, P256, DOI 10.1038/ng1194-256; Strub T, 2011, ONCOGENE, V30, P2319, DOI 10.1038/onc.2010.612; Takeda K, 2000, HUM MOL GENET, V9, P125, DOI 10.1093/hmg/9.1.125; Tomic T, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.86; Vaahtomeri K, 2011, FEBS LETT, V585, P944, DOI 10.1016/j.febslet.2010.12.034; Wellbrock C, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002734; Widlund HR, 2003, ONCOGENE, V22, P3035, DOI 10.1038/sj.onc.1206443; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Wu M, 2000, GENE DEV, V14, P301; Yokoyama S, 2008, PIGM CELL MELANOMA R, V21, P457, DOI 10.1111/j.1755-148X.2008.00480.x; Yokoyama S, 2011, NATURE, V480, P99, DOI 10.1038/nature10630; Zarrinkar PP, 2009, BLOOD, V114, P2984, DOI 10.1182/blood-2009-05-222034; Zheng B, 2009, MOL CELL, V33, P237, DOI 10.1016/j.molcel.2008.12.026; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI13505	55	21	22	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2014	33	19					2531	2539		10.1038/onc.2013.185	http://dx.doi.org/10.1038/onc.2013.185			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH3OK	23728343				2022-12-28	WOS:000336033600013
J	Okochi-Takada, E; Hattori, N; Tsukamoto, T; Miyamoto, K; Ando, T; Ito, S; Yamamura, Y; Wakabayashi, M; Nobeyama, Y; Ushijima, T				Okochi-Takada, E.; Hattori, N.; Tsukamoto, T.; Miyamoto, K.; Ando, T.; Ito, S.; Yamamura, Y.; Wakabayashi, M.; Nobeyama, Y.; Ushijima, T.			ANGPTL4 is a secreted tumor suppressor that inhibits angiogenesis	ONCOGENE			English	Article						epigenetics; angiogenesis; tumor suppressor; gastric cancer; DNA methylation	ANGIOPOIETIN-LIKE 4; ISLAND METHYLATOR PHENOTYPE; VASCULAR-PERMEABILITY; EPIGENETIC FIELD; DNA METHYLATION; FREQUENT LOSS; PROTEINS; CANCER; 19P13.3; GENES	Tumor suppressors with extracellular function are likely to have advantages as targets for cancer therapy, but few are known. Here, we focused on angiopoietin-like 4 (ANGPTL4), which is a secreted glycoprotein involved in lipoprotein metabolism and angiogenesis, is methylation-silenced in human cancers, but has unclear roles in cancer development and progression. We found a deletion mutation in its coiled-coil domain at its N-terminal in human gastric cancers, in addition to hypermethylation of the ANGPTL4 promoter CpG islands. Forced expression of wild-type ANGPTL4, but not ANGPTL4 with the deletion, at physiological levels markedly suppressed in vivo tumorigenicity and tumor angiogenesis, indicating that the latter caused the former. Tumor-derived ANGPTL4 suppressed in vitro vascular tube formation and proliferation of human umbilical vascular endothelial cells, partly due to suppression of ERK signaling. These showed that ANGPTL4 is a genetically and epigenetically inactivated secreted tumor suppressor that inhibits tumor angiogenesis.	[Okochi-Takada, E.; Hattori, N.; Ando, T.; Wakabayashi, M.; Nobeyama, Y.; Ushijima, T.] Natl Canc Ctr, Div Epigen, Tokyo 1040045, Japan; [Tsukamoto, T.] Aichi Canc Ctr, Res Inst, Oncol Pathol Div, Nagoya, Aichi 464, Japan; [Miyamoto, K.] Natl Hosp Org, Kure Med Ctr, Div Mol Oncol, Kureshi, Japan; [Miyamoto, K.] Chugoku Canc Ctr, Kureshi, Japan; [Ando, T.] Toyama Univ, Dept Internal Med 3, Toyama 930, Japan; [Ito, S.; Yamamura, Y.] Aichi Canc Ctr, Cent Hosp, Dept Surg Gastroenterol, Nagoya, Aichi 464, Japan; [Nobeyama, Y.] Jikei Univ, Sch Med, Dept Dermatol, Tokyo, Japan	National Cancer Center - Japan; Aichi Cancer Center; University of Toyama; Aichi Cancer Center; Jikei University	Ushijima, T (corresponding author), Natl Canc Ctr, Div Epigen, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	tushijim@ncc.go.jp	Tsukamoto, Tetsuya/ABD-4397-2020; Ushijima, Toshikazu/AAP-5742-2021	Tsukamoto, Tetsuya/0000-0002-7502-8724; Ushijima, Toshikazu/0000-0003-3405-7817; Hattori, Naoko/0000-0002-0901-4869	Third-term Comprehensive Cancer Control Strategy from the Ministry of Health, Labour and Welfare, Japan; National Cancer Center Research and Development Fund; Research Resident Fellowships from the Foundation for Promotion of Cancer Research	Third-term Comprehensive Cancer Control Strategy from the Ministry of Health, Labour and Welfare, Japan; National Cancer Center Research and Development Fund(National Cancer Center - Japan); Research Resident Fellowships from the Foundation for Promotion of Cancer Research	We are grateful to Dr Masabumi Shibuya, Tokyo Medical and Dental University, for his expert advice. This study was supported by the Third-term Comprehensive Cancer Control Strategy from the Ministry of Health, Labour and Welfare, Japan and by National Cancer Center Research and Development Fund. YN is a recipient of a Research Resident Fellowships from the Foundation for Promotion of Cancer Research.	Ando T, 2009, INT J CANCER, V124, P2367, DOI 10.1002/ijc.24219; Asada K, 2013, ONCOGENE, V32, P2140, DOI 10.1038/onc.2012.228; Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130; Chomel C, 2009, FASEB J, V23, P940, DOI 10.1096/fj.08-115170; Enomoto S, 2007, CANCER SCI, V98, P1853, DOI 10.1111/j.1349-7006.2007.00625.x; Galaup A, 2006, P NATL ACAD SCI USA, V103, P18721, DOI 10.1073/pnas.0609025103; Ge HF, 2004, J BIOL CHEM, V279, P2038, DOI 10.1074/jbc.M307583200; Hato T, 2008, TRENDS CARDIOVAS MED, V18, P6, DOI 10.1016/j.tcm.2007.10.003; Hattori N, 2011, CANCER SCI, V102, P1337, DOI 10.1111/j.1349-7006.2011.01955.x; Hermann LM, 2005, CLIN IMMUNOL, V115, P93, DOI 10.1016/j.clim.2004.12.002; Hoglund M, 1998, GENE CHROMOSOME CANC, V21, P8; Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507; Ito Y, 2003, CANCER RES, V63, P6651; Kaneda A, 2002, CANCER RES, V62, P6645; Kishore R, 2007, J MOL CELL CARDIOL, V42, P461, DOI 10.1016/j.yjmcc.2006.11.012; Knudson AG, 2001, NAT REV CANCER, V1, P157, DOI 10.1038/35101031; Lane DP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001222; Levine AJ, 2009, NAT REV CANCER, V9, P749, DOI 10.1038/nrc2723; Li KQ, 2004, CHINESE MED J-PEKING, V117, P1364; Ma T, 2010, P NATL ACAD SCI USA, V107, P14363, DOI 10.1073/pnas.1001065107; Mei R, 2000, GENOME RES, V10, P1126, DOI 10.1101/gr.10.8.1126; Miida T, 2010, CURR OPIN LIPIDOL, V21, P70, DOI 10.1097/MOL.0b013e328333269e; Nakayama T, 2010, ONCOL REP, V24, P599, DOI 10.3892/or_00000897; Oike Y, 2005, TRENDS MOL MED, V11, P473, DOI 10.1016/j.molmed.2005.08.002; Ota N, 2006, ANTICANCER RES, V26, P3729; Padua D, 2008, CELL, V133, P66, DOI 10.1016/j.cell.2008.01.046; Shi Y, 2007, ACTA PHARMACOL SIN, V28, P1499, DOI 10.1111/j.1745-7254.2007.00692.x; Sobottka SB, 2000, J NEURO-ONCOL, V49, P187, DOI 10.1023/A:1006442024874; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Tanner JE, 2004, MOL CANCER RES, V2, P281; Trojan J, 2000, GUT, V47, P272, DOI 10.1136/gut.47.2.272; Ushijima T, 2007, J BIOCHEM MOL BIOL, V40, P142; Yang YH, 2008, ARTERIOSCL THROM VAS, V28, P835, DOI 10.1161/ATVBAHA.107.157776; Yin W, 2009, J BIOL CHEM, V284, P13213, DOI 10.1074/jbc.M900553200; Zhu HB, 2004, ONCOGENE, V23, P4984, DOI 10.1038/sj.onc.1207645; Zhu PC, 2011, CANCER CELL, V19, P401, DOI 10.1016/j.ccr.2011.01.018	36	43	44	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2014	33	17					2273	2278		10.1038/onc.2013.174	http://dx.doi.org/10.1038/onc.2013.174			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF8WJ	23686315				2022-12-28	WOS:000334996000013
J	Moreno, A; Soleto, I; Garcia-Sanz, P; Moreno-Bueno, G; Palmero, I				Moreno, A.; Soleto, I.; Garcia-Sanz, P.; Moreno-Bueno, G.; Palmero, I.			ING4 regulates a secretory phenotype in primary fibroblasts with dual effects on cell proliferation and tumor growth	ONCOGENE			English	Article						ING4; p53; tumor suppression; secretory phenotype	SUPPRESSOR PROTEIN ING4; SENESCENCE; CANCER; GENES; P53; ACETYLATION; INHIBITOR; STRESS; TUMORIGENESIS; ANGIOGENESIS	ING proteins have an essential role in the control of a variety of cellular functions whose deregulation is associated with tumor formation and dissemination, such as proliferation, apoptosis, senescence or invasion. Accordingly, loss of function of ING proteins is a frequent event in many types of human tumors. In this report, we have studied the function of ING4, a member of the ING family of tumor suppressors, in the context of normal, non-transformed primary fibroblasts. We show that ING4 negatively regulates cell proliferation in this cell type. The antiproliferative action of ING4 requires its ability to recognize chromatin marks, it is p53-dependent at least in part, and it is lost in an ING4 cancer-associated mutant. Gene expression analysis shows that ING4 regulates the expression and release of soluble factors of the chemokine family. The secretory phenotype regulated by ING4 in primary fibroblasts displays a selective paracrine effect on proliferation, fostering the division of tumor cells, while inhibiting division in primary fibroblasts. Consistently, ING4-expressing fibroblasts promoted tumor growth in vivo in co-injection tumorigenesis assays. Collectively, our results show that ING4 not only can regulate the proliferation of primary non-transformed human fibroblasts, but also orchestrates a secretory phenotype in these cells that promotes tumor cell proliferation in vitro and in vivo. These findings support a critical role for ING4 expression in normal cells in the non-cell-autonomous regulation of tumor growth.	[Moreno, A.; Soleto, I.; Garcia-Sanz, P.; Moreno-Bueno, G.; Palmero, I.] CSIC UAM, Inst Invest Biomed Alberto Sols, E-28029 Madrid, Spain; [Garcia-Sanz, P.; Moreno-Bueno, G.] Univ Autonoma Madrid, IdiPAZ Inst Invest Sanitaria La Paz, Dept Bioquim, Madrid, Spain; [Garcia-Sanz, P.; Moreno-Bueno, G.] Fdn MD Anderson Int, Madrid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid; University of Texas System; UTMD Anderson Cancer Center	Palmero, I (corresponding author), CSIC UAM, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, E-28029 Madrid, Spain.	ipalmero@iib.uam.es	Moreno-Bueno, Gema/K-9354-2016; Palmero, Ignacio/B-4346-2013; soleto, irene/AAF-8123-2019	Moreno-Bueno, Gema/0000-0002-5030-6687; soleto, irene/0000-0002-8005-2411	Spanish Ministry of Science and Innovation [SAF2009-09031, SAF2012-32117]; Madrid Regional Government [S2010/BMD-2303];  [SAF2010-20175]	Spanish Ministry of Science and Innovation(Ministry of Science and Innovation, Spain (MICINN)Spanish Government); Madrid Regional Government; 	We thank R Gomis, J Massague, G Peters, D Peeper and A Cano for providing cell lines and reagents, V Miguel for help in some experiments and I Peruzza for technical assistance. This work was supported by grants from the Spanish Ministry of Science and Innovation to IP (SAF2009-09031 and SAF2012-32117) and GM-B (SAF2010-20175), and from the Madrid Regional Government (S2010/BMD-2303) to GM-B.	Abad M, 2011, AGING CELL, V10, P158, DOI 10.1111/j.1474-9726.2010.00651.x; Acosta JC, 2008, CELL CYCLE, V7, P2956, DOI 10.4161/cc.7.19.6780; Acosta JC, 2008, CELL, V133, P1006, DOI 10.1016/j.cell.2008.03.038; Aguissa-Toure AH, 2011, CELL MOL LIFE SCI, V68, P45, DOI 10.1007/s00018-010-0509-1; Campisi J, 2007, NAT REV MOL CELL BIO, V8, P729, DOI 10.1038/nrm2233; Chicas A, 2010, CANCER CELL, V17, P376, DOI 10.1016/j.ccr.2010.01.023; Chien YC, 2011, GENE DEV, V25, P2125, DOI 10.1101/gad.17276711; Coles AH, 2010, P NATL ACAD SCI USA, V107, P11423, DOI 10.1073/pnas.0912116107; Coles AH, 2009, J CELL PHYSIOL, V218, P45, DOI 10.1002/jcp.21583; Colla S, 2007, BLOOD, V110, P4464, DOI 10.1182/blood-2007-02-074617; Collado M, 2007, CELL, V130, P223, DOI 10.1016/j.cell.2007.07.003; Coppe JP, 2010, ANNU REV PATHOL-MECH, V5, P99, DOI 10.1146/annurev-pathol-121808-102144; Coppe JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041; Garkavtsev I, 2004, NATURE, V428, P328, DOI 10.1038/nature02329; Goeman F, 2005, MOL CELL BIOL, V25, P422, DOI 10.1128/MCB.25.1.422-431.2005; Gomez-Cabello D, 2010, CANCER RES, V70, P1866, DOI 10.1158/0008-5472.CAN-09-2088; Hung T, 2009, MOL CELL, V33, P248, DOI 10.1016/j.molcel.2008.12.016; Jafarnejad SM, 2012, CANCER METAST REV, V31, P55, DOI 10.1007/s10555-011-9329-5; Kim S, 2004, P NATL ACAD SCI USA, V101, P16251, DOI 10.1073/pnas.0407158101; Krtolica A, 2001, P NATL ACAD SCI USA, V98, P12072, DOI 10.1073/pnas.211053698; Kuilman T, 2008, CELL, V133, P1019, DOI 10.1016/j.cell.2008.03.039; Kuilman T, 2010, GENE DEV, V24, P2463, DOI 10.1101/gad.1971610; Kuilman T, 2009, NAT REV CANCER, V9, P81, DOI 10.1038/nrc2560; Larrieu D, 2009, EMBO REP, V10, P1168, DOI 10.1038/embor.2009.180; Lazennec G, 2010, TRENDS MOL MED, V16, P133, DOI 10.1016/j.molmed.2010.01.003; Li J, 2008, CARCINOGENESIS, V29, P1373, DOI 10.1093/carcin/bgn086; Liu F, 2011, NAT CELL BIOL, V13, P254, DOI 10.1038/ncb2167; Menendez C, 2009, CURR DRUG TARGETS, V10, P406, DOI 10.2174/138945009788185077; Minn AJ, 2005, NATURE, V436, P518, DOI 10.1038/nature03799; Moreno A, 2010, CARCINOGENESIS, V31, P1932, DOI 10.1093/carcin/bgq171; Nozell S, 2008, MOL CELL BIOL, V28, P6632, DOI 10.1128/MCB.00697-08; Palmero I, 2002, ONCOGENE, V21, P2939, DOI 10.1038/sj/onc/1205371; Pedeux R, 2005, MOL CELL BIOL, V25, P6639, DOI 10.1128/MCB.25.15.6639-6648.2005; Pena PV, 2006, NATURE, V442, P100, DOI 10.1038/nature04814; Perkins ND, 2012, NAT REV CANCER, V12, P121, DOI 10.1038/nrc3204; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Shen JC, 2007, CANCER RES, V67, P2552, DOI 10.1158/0008-5472.CAN-06-3870; Shiseki M, 2003, CANCER RES, V63, P2373; Tapia C, 2011, HUM PATHOL, V42, P983, DOI 10.1016/j.humpath.2010.10.012; Wong RPC, 2011, NUCLEIC ACIDS RES, V39, P3632, DOI 10.1093/nar/gkq1337; Ythier D, 2008, INT J CANCER, V123, P1483, DOI 10.1002/ijc.23790	43	15	15	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2014	33	15					1945	1953		10.1038/onc.2013.145	http://dx.doi.org/10.1038/onc.2013.145			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RK	23604125				2022-12-28	WOS:000334346300007
J	Laser-Azogui, A; Diamant-Levi, T; Israeli, S; Roytman, Y; Tsarfaty, I				Laser-Azogui, A.; Diamant-Levi, T.; Israeli, S.; Roytman, Y.; Tsarfaty, I.			Met-induced membrane blebbing leads to amoeboid cell motility and invasion	ONCOGENE			English	Article						Met; blebbing; amoeboid cell motility; invasion; metastasis	HEPATOCYTE GROWTH-FACTOR; FACTOR INHIBITS ANOIKIS; FC-EPSILON-RI; C-MET; PSEUDOPODIAL PROTRUSION; LUNG-CANCER; RECEPTOR; ACTIVATION; MICRODOMAINS; METASTASIS	Met tyrosine kinase has been implicated in tumorigenesis and metastasis; its overexpression and deregulation is often observed in cancer. Although Met's functions in cell motility has been studied extensively, its involvement in bleb-based, amoeboid motility is yet to be determined. The aim of this work is to study the role of Met in amoeboid cell motility and invasion. We show that aggressive breast cancer cells expressing high levels of endogenous Met, as well as HEK293T cells over expressing fluorescent Met, exhibit constitutive, ligand-independent Met activation, leading to Met-dependent membrane blebbing and amoeboid cell motility; HEK293T cells over expressing fluorescent Met were able to invade in three-dimensional matrix. Hyper-activated Met mutant significantly enhances blebbing and cell motility. Met inhibition by either a Met-specific inhibitor or by exogenous expression of a dominant-negative Met remarkably repressed membrane blebbing and invasion. Inhibition of Rho signaling pathway by a ROCK inhibitor also represses Met-induced blebbing, suggesting that Met regulates the blebbing machinery through Rho-ROCK pathway, which controls the actin-myosin contractile force. Either de-polymerization or hyper-polymerization of the actin cytoskeleton abrogates Met-induced blebbing, signifying that actin polymerization has a role in halting and retracting Met-induced mature blebs. Indeed, when blebs retract, membrane wrinkles containing high levels of Met and actin are generated, indicating localized formation of Met-signaling microdomains. We suggest that this bleb-based activity is induced by amplification of Met signaling in unique membrane domains generated by bleb retraction. Our results indicate that Met-induced blebbing has an important role in cell detachment, amoeboid motility and invasion ability, which are utilized by cancer cells for migration and metastasis.	[Laser-Azogui, A.; Diamant-Levi, T.; Israeli, S.; Roytman, Y.; Tsarfaty, I.] Tel Aviv Univ, Sackler Sch Med, Dept Clin Microbiol & Immunol, IL-69978 Tel Aviv, Israel	Tel Aviv University; Sackler Faculty of Medicine	Tsarfaty, I (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Clin Microbiol & Immunol, IL-69978 Tel Aviv, Israel.	ilants@post.tau.ac.il		Tsarfaty, Ilan/0000-0002-5230-7093	Breast Cancer Research Foundation; United States-Israel Binational Science Foundation; Federico Foundation Grants	Breast Cancer Research Foundation; United States-Israel Binational Science Foundation(US-Israel Binational Science Foundation); Federico Foundation Grants	We thank Professor Iafa Keydar for T47D cells and Dr Joyce Taylor-Papadimitriou for HB2 cells. We also thank Dr Yifat Merbl (Harvard medical school) for her critical review of this manuscript. This work was supported by research grants from the Breast Cancer Research Foundation, the United States-Israel Binational Science Foundation and the Federico Foundation Grants.	Abella JV, 2010, J BIOL CHEM, V285, P24956, DOI 10.1074/jbc.M110.127985; Abella JV, 2010, J CELL SCI, V123, P1306, DOI 10.1242/jcs.062570; Andrews NL, 2008, NAT CELL BIOL, V10, P955, DOI 10.1038/ncb1755; Arni S, 1996, BIOCHEM BIOPH RES CO, V225, P801, DOI 10.1006/bbrc.1996.1254; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Charras GT, 2008, BIOPHYS J, V94, P1836, DOI 10.1529/biophysj.107.113605; Charras GT, 2006, J CELL BIOL, V175, P477, DOI 10.1083/jcb.200602085; Christensen JG, 2005, CANCER LETT, V225, P1, DOI 10.1016/j.canlet.2004.09.044; Corso S, 2008, ONCOGENE, V27, P684, DOI 10.1038/sj.onc.1210697; CUNNINGHAM CC, 1995, J CELL BIOL, V129, P1589, DOI 10.1083/jcb.129.6.1589; Danilkovitch-Miagkova A, 2002, J CLIN INVEST, V109, P863; Douglass AD, 2005, CELL, V121, P937, DOI 10.1016/j.cell.2005.04.009; Firon M, 2000, ONCOGENE, V19, P2386, DOI 10.1038/sj.onc.1203557; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Gadea G, 2007, J CELL BIOL, V178, P23, DOI 10.1083/jcb.200701120; Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205; Holowka D, 2000, J CELL SCI, V113, P1009; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jia ZJ, 2006, BIOL CELL, V98, P337, DOI 10.1042/BC20050088; Jiang WG, 2005, CRIT REV ONCOL HEMAT, V53, P35, DOI 10.1016/j.critrevonc.2004.09.004; Jung KH, 2012, ARCH PHARM RES, V35, P595, DOI 10.1007/s12272-012-0402-6; Keller HU, 1996, CELL MOTIL CYTOSKEL, V33, P241, DOI 10.1002/(SICI)1097-0169(1996)33:4<241::AID-CM1>3.0.CO;2-C; Kitzing TM, 2007, GENE DEV, V21, P1478, DOI 10.1101/gad.424807; Ma PC, 2007, BRIT J CANCER, V97, P368, DOI 10.1038/sj.bjc.6603884; Maulik G, 2002, CLIN CANCER RES, V8, P620; Maxfield FR, 2002, CURR OPIN CELL BIOL, V14, P483, DOI 10.1016/S0955-0674(02)00351-4; Miller M, 2001, PROTEINS, V44, P32, DOI 10.1002/prot.1069; Moffatt OD, 1999, J IMMUNOL, V162, P6800; Moshitch-Moshkovitz S, 2006, NEOPLASIA, V8, P353, DOI 10.1593/neo.05634; Nguyen TN, 2000, EXP CELL RES, V258, P171, DOI 10.1006/excr.2000.4929; Peters S, 2012, NAT REV CLIN ONCOL, V9, P314, DOI 10.1038/nrclinonc.2012.71; Pinner S, 2008, NAT CELL BIOL, V10, P127, DOI 10.1038/ncb1675; RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731; Sahai E, 2003, NAT CELL BIOL, V5, P711, DOI 10.1038/ncb1019; SAMBROOK A, 1989, MOL CLONING LAB MANU; Tournaviti S, 2007, J CELL SCI, V120, P3820, DOI 10.1242/jcs.011130; Vadnais J, 2002, J BIOL CHEM, V277, P48342, DOI 10.1074/jbc.M209481200; Vasiliev JM, 2004, P NATL ACAD SCI USA, V101, P12526, DOI 10.1073/pnas.0404723101; Wolf K, 2003, J CELL BIOL, V160, P267, DOI 10.1083/jcb.200209006; Yoshida K, 2006, J CELL SCI, V119, P3833, DOI 10.1242/jcs.03152; Zeng QH, 2002, J BIOL CHEM, V277, P50137, DOI 10.1074/jbc.M208952200; Zeng QH, 2002, J BIOL CHEM, V277, P25203, DOI 10.1074/jbc.M201598200	43	30	30	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 3	2014	33	14					1788	1798		10.1038/onc.2013.138	http://dx.doi.org/10.1038/onc.2013.138			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RE	23665680				2022-12-28	WOS:000334345500005
J	Kyula, JN; Khan, AA; Mansfield, D; Karapanagiotou, EM; McLaughlin, M; Roulstone, V; Zaidi, S; Pencavel, T; Touchefeu, Y; Seth, R; Chen, NG; Yu, YA; Zhang, Q; Melcher, AA; Vile, RG; Pandha, HS; Ajaz, M; Szalay, AA; Harrington, KJ				Kyula, J. N.; Khan, A. A.; Mansfield, D.; Karapanagiotou, E. M.; McLaughlin, M.; Roulstone, V.; Zaidi, S.; Pencavel, T.; Touchefeu, Y.; Seth, R.; Chen, N. G.; Yu, Y. A.; Zhang, Q.; Melcher, A. A.; Vile, R. G.; Pandha, H. S.; Ajaz, M.; Szalay, A. A.; Harrington, K. J.			Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in (V600D/E)BRAF mutant melanoma depends on JNK and TNF-alpha signaling	ONCOGENE			English	Article						oncolytic vaccinia; GLV-1h68; JNK; TNF-alpha; RT; apoptosis	NECROSIS-FACTOR-ALPHA; PROTEIN-KINASE; CELL LUNG; NUDE-MICE; VIRUS; CANCER; ACTIVATION; THERAPY; BRAF; COMBINATION	Melanoma is an aggressive skin cancer that carries an extremely poor prognosis when local invasion, nodal spread or systemic metastasis has occurred. Recent advances in melanoma biology have revealed that RAS-RAF-MEK-ERK signaling has a pivotal role in governing disease progression and treatment resistance. Proof-of-concept clinical studies have shown that direct BRAF inhibition yields impressive responses in advanced disease but these are short-lived as treatment resistance rapidly emerges. Therefore, there is a pressing need to develop new targeted strategies for BRAF mutant melanoma. As such, oncolytic viruses represent a promising cancer-specific approach with significant activity in melanoma. This study investigated interactions between genetically-modified vaccinia virus (GLV-1h68) and radiotherapy in melanoma cell lines with BRAF mutant, Ras mutant or wild-type genotype. Preclinical studies revealed that GLV-1h68 combined with radiotherapy significantly increased cytotoxicity and apoptosis relative to either single agent in (V600D)BRAF/(V600E)BRAF mutant melanoma in vitro and in vivo. The mechanism of enhanced cytotoxicity with GLV-1h68/radiation (RT) was independent of viral replication and due to attenuation of JNK, p38 and ERK MAPK phosphorylation specifically in BRAF mutant cells. Further studies showed that JNK pathway inhibition sensitized BRAF mutant cells to GLV-1h68-mediated cell death, mimicking the effect of RT. GLV-1h68 infection activated MAPK signaling in (V600D)BRAF/(V600E)BRAF mutant cell lines and this was associated with TNF-alpha secretion which, in turn, provided a prosurvival signal. Combination GLV-1h68/RT (or GLV-1h68/JNK inhibition) caused abrogation of TNF-alpha secretion. These data provide a strong rationale for combining GLV-1h68 with irradiation in (V600D/E)BRAF mutant tumors.	[Kyula, J. N.; Khan, A. A.; Mansfield, D.; Karapanagiotou, E. M.; McLaughlin, M.; Roulstone, V.; Zaidi, S.; Pencavel, T.; Touchefeu, Y.; Seth, R.; Harrington, K. J.] Inst Canc Res, Div Canc Biol, Targeted Therapy Team, London SW3 6JB, England; [Chen, N. G.; Yu, Y. A.; Zhang, Q.; Szalay, A. A.] Genelux Corp, San Diego Sci Ctr, San Diego, CA USA; [Melcher, A. A.; Vile, R. G.] Leeds Inst Mol Med, Leeds, W Yorkshire, England; [Vile, R. G.] Mayo Clin, Mol Med Program, Rochester, MN USA; [Pandha, H. S.; Ajaz, M.] Univ Surrey, Postgrad Med Sch, Guildford GU2 5XH, Surrey, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of Leeds; Mayo Clinic; University of Surrey	Kyula, JN (corresponding author), Inst Canc Res, Div Canc Biol, Targeted Therapy Team, 237 Fulham Rd, London SW3 6JB, England.	Joan.Kyula@icr.ac.uk	Touchefeu, Yann/M-2969-2015; Touchefeu, Yann/AGH-7655-2022; Khan, Aadil/AAB-6853-2021	Touchefeu, Yann/0000-0001-8421-3182; Khan, Aadil/0000-0003-1284-6049; Melcher, Alan/0000-0002-2042-3380; McLaughlin, Martin/0000-0002-9739-7133; Harrington, Kevin/0000-0002-6014-348X	Myfanwy Townsend Melanoma Research Fund; Cotswold Trust; Cancer Research UK [13244] Funding Source: researchfish; Rosetrees Trust [M236-CD1] Funding Source: researchfish	Myfanwy Townsend Melanoma Research Fund; Cotswold Trust; Cancer Research UK(Cancer Research UK); Rosetrees Trust(Rosetrees Trust)	We would like to thank Dr Khin Thway and Dr Michelle Wilkinson for their assistance with data acquisition and analysis. This work was supported in part by research grants from the Myfanwy Townsend Melanoma Research Fund and the Cotswold Trust.	Amaravadi RK, 2009, CLIN CANCER RES, V15, P7711, DOI 10.1158/1078-0432.CCR-09-2074; Andrade AA, 2004, BIOCHEM J, V381, P437, DOI 10.1042/BJ20031375; Ascierto ML, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-451; Beyaert R, 2002, INT REV CYTOL, V214, P225; BLISS CI, 1956, BACTERIOL REV, V20, P243, DOI 10.1128/MMBR.20.4.243-258.1956; Buck E, 2006, MOL CANCER THER, V5, P2676, DOI 10.1158/1535-7163.MCT-06-0166; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Chudnovsky Y, 2005, J CLIN INVEST, V115, P813, DOI 10.1172/JCI200524808; Comins C, 2010, CLIN CANCER RES, V16, P5564, DOI 10.1158/1078-0432.CCR-10-1233; de Magalhaes JC, 2001, J BIOL CHEM, V276, P38353, DOI 10.1074/jbc.M100183200; Dent P, 2003, ONCOGENE, V22, P5885, DOI 10.1038/sj.onc.1206701; Gentschev I, 2009, CANCER GENE THER, V16, P320, DOI 10.1038/cgt.2008.87; Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661; Gray-Schopfer VC, 2007, CANCER RES, V67, P122, DOI 10.1158/0008-5472.CAN-06-1880; GRECO WR, 1995, PHARMACOL REV, V47, P331; Gutermann A, 2006, HUM GENE THER, V17, P1241, DOI 10.1089/hum.2006.17.1241; Harrington KJ, 2010, CLIN CANCER RES, V16, P3067, DOI 10.1158/1078-0432.CCR-10-0054; Hayden MS, 2004, GENE DEV, V18, P2195, DOI 10.1101/gad.1228704; Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040; Heinemann L, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-221; Kelly KJ, 2008, HUM GENE THER, V19, P774, DOI 10.1089/hum.2008.036; Khan N, 2011, INT J RADIAT ONCOL, V80, P645, DOI 10.1016/j.ijrobp.2010.12.071; King AJ, 2006, CANCER RES, V66, P11100, DOI 10.1158/0008-5472.CAN-06-2554; Lin SF, 2008, J CLIN ENDOCR METAB, V93, P4403, DOI 10.1210/jc.2008-0316; Maki RG, 2009, J CLIN ONCOL, V27, P3133, DOI 10.1200/JCO.2008.20.4495; Mansfield D, 2013, ORAL ONCOL, V49, P108, DOI 10.1016/j.oraloncology.2012.07.019; Moore RJ, 1999, NAT MED, V5, P828, DOI 10.1038/10552; Pandha HS, 2009, CLIN CANCER RES, V15, P6158, DOI 10.1158/1078-0432.CCR-09-0796; Pawlik TM, 2002, CANCER-AM CANCER SOC, V95, P1171, DOI 10.1002/cncr.10776; Post DE, 2004, CLIN CANCER RES, V10, P8603, DOI 10.1158/1078-0432.CCR-04-1432; Raki M, 2005, GENE THER, V12, P1198, DOI 10.1038/sj.gt.3302517; Soares JAP, 2009, J VIROL, V83, P6883, DOI 10.1128/JVI.00245-09; Tawbi HA, 2007, SEMIN ONCOL, V34, P532, DOI 10.1053/j.seminoncol.2007.09.008; Toyoizumi T, 1999, HUM GENE THER, V10, P3013, DOI 10.1089/10430349950016410; Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105; Twigger K, 2008, CLIN CANCER RES, V14, P912, DOI 10.1158/1078-0432.CCR-07-1400; Tyminski E, 2005, CANCER RES, V65, P6850, DOI 10.1158/0008-5472.CAN-05-0154; Wang G, 2006, P NATL ACAD SCI USA, V103, P4640, DOI 10.1073/pnas.0509341103; Wullaert A, 2006, BIOCHEM PHARMACOL, V72, P1090, DOI 10.1016/j.bcp.2006.07.003; Yu YA, 2009, MOL CANCER THER, V8, P141, DOI 10.1158/1535-7163.MCT-08-0533; Yu ZJ, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-45; Zhang Q, 2007, CANCER RES, V67, P10038, DOI 10.1158/0008-5472.CAN-07-0146	42	30	31	1	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2014	33	13					1700	1712		10.1038/onc.2013.112	http://dx.doi.org/10.1038/onc.2013.112			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9QY	23624923	Bronze, Green Accepted			2022-12-28	WOS:000334344700010
J	Rapino, F; Jung, M; Fulda, S				Rapino, F.; Jung, M.; Fulda, S.			BAG3 induction is required to mitigate proteotoxicity via selective autophagy following inhibition of constitutive protein degradation pathways	ONCOGENE			English	Article						BAG3; autophagy; proteasome inhibitor; HDAC6; cancer	QUALITY-CONTROL; AGGRESOME FORMATION; CO-CHAPERONES; CANCER CELLS; HEAT-STRESS; APOPTOSIS; MACROAUTOPHAGY; COMPLEX; TARGET; ACTIVATION	Simultaneous inhibition of the two major constitutive protein quality control (PQC) pathways, that is, the ubiquitin-proteasome system (UPS) and the aggresome-autophagy system, has been suggested as a promising strategy to trigger cell death in cancer cells. However, we observed that one third of rhabdomyosarcoma (RMS) cells survives parallel inhibition of the UPS by Bortezomib and the aggresome-autophagy pathway by the cytoplasmic histone deacetylase 6 inhibitor ST80, and is able to regrow upon drug removal, thus pointing to the induction of compensatory pathways. Here, we identify Bcl-2-associated athanogene 3 (BAG3) as a critical mediator of inducible resistance in surviving cells after concomitant blockage of constitutive PQC pathways by mitigating ST80/Bortezomib-triggered proteotoxicity via selective autophagy. ST80/Bortezomib cotreatment upregulates BAG3 mRNA and protein levels in surviving cells in addition to triggering the accumulation of insoluble protein aggregates. Intriguingly, knockdown of BAG3 by RNA interference severely impairs clearance of protein aggregates, significantly increases cell death and reduces long-term survival and clonogenic growth during recovery after ST80/Bortezomib cotreatment. Similarly, inhibition of autophagy by inducible autophagy-related protein 7 knockdown prevents removal of protein aggregates and cell regrowth during recovery after ST80/Bortezomib cotreatment. Also, the inhibition of lysosomal degradation using the V-ATPase pump inhibitor Bafilomycin A1 enhances accumulation of protein aggregates, and completely abolishes regrowth after Bortezomib/ST80-induced proteotoxic stress. By identifying BAG3 as a key mediator of inducible resistance by mitigating proteotoxicity via selective autophagy after inhibition of constitutive PQC systems, our study provides new insights into the regulation of PQC pathways in cancer cells and identifies new targets for therapeutic intervention.	[Rapino, F.; Fulda, S.] Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, D-60528 Frankfurt, Germany; [Jung, M.] Univ Freiburg, Inst Pharmaceut Sci, D-79106 Freiburg, Germany	Goethe University Frankfurt; University of Freiburg	Fulda, S (corresponding author), Goethe Univ Frankfurt, Inst Expt Canc Res Pediat, D-60528 Frankfurt, Germany.	simone.fulda@kgu.de	Jung, Manfred/Q-8029-2016	Jung, Manfred/0000-0002-6361-7716; Fulda, Simone/0000-0002-0459-6417; Rapino, Francesca/0000-0002-4343-3805	Wilhelm-Sander Stiftung; Deutsche Krebshilfe; Bundesministerium fur Bildung und Forschung [01GM1104C]; Deutsche Forschungsgemeinschaft [JU 295/9-1, SPP1463, JU 295/10-2, CRU 201]	Wilhelm-Sander Stiftung; Deutsche Krebshilfe(Deutsche Krebshilfe); Bundesministerium fur Bildung und Forschung(Federal Ministry of Education & Research (BMBF)); Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	We thank C Hugenberg for expert secretarial assistance. This work has been partially supported by grants from the Wilhelm-Sander Stiftung, the Deutsche Krebshilfe and the Bundesministerium fur Bildung und Forschung (01GM1104C) (to S F). Work on HDAC inhibitors in the Jung group is supported by the Deutsche Forschungsgemeinschaft (JU 295/9-1 within SPP1463, JU 295/10-2 within CRU 201).	Ammirante M, 2010, P NATL ACAD SCI USA, V107, P7497, DOI 10.1073/pnas.0907696107; Aveic S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026097; Basit F, 2012, J BIOL CHEM, V287, P38767, DOI 10.1074/jbc.M112.398966; Bazzaro M, 2008, CLIN CANCER RES, V14, P7340, DOI 10.1158/1078-0432.CCR-08-0642; Behl C, 2011, AUTOPHAGY, V7, P795, DOI 10.4161/auto.7.7.15844; Behrends Christian, 2012, Int J Cell Biol, V2012, P673290, DOI 10.1155/2012/673290; Bersani F, 2008, EUR J CANCER, V44, P876, DOI 10.1016/j.ejca.2008.02.022; Carew JS, 2010, J CELL MOL MED, V14, P2448, DOI 10.1111/j.1582-4934.2009.00832.x; Carra S, 2008, J BIOL CHEM, V283, P1437, DOI 10.1074/jbc.M706304200; Chiappetta G, 2007, J CLIN ENDOCR METAB, V92, P1159, DOI 10.1210/jc.2006-1712; Ding WX, 2008, AUTOPHAGY, V4, P141, DOI 10.4161/auto.5190; Du ZX, 2009, J CELL PHYSIOL, V218, P631, DOI 10.1002/jcp.21634; Festa M, 2011, AM J PATHOL, V178, P2504, DOI 10.1016/j.ajpath.2011.02.002; Frankland-Searby S, 2012, BBA-REV CANCER, V1825, P64, DOI 10.1016/j.bbcan.2011.10.003; Fulda S, 1997, CANCER RES, V57, P3823; Gamerdinger M, 2011, J MOL MED, V89, P1175, DOI 10.1007/s00109-011-0795-6; Gamerdinger M, 2011, EMBO REP, V12, P149, DOI 10.1038/embor.2010.203; Gamerdinger M, 2009, EMBO J, V28, P889, DOI 10.1038/emboj.2009.29; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; Gonzalez P, 2012, CELL DEATH DIFFER, V19, P1337, DOI 10.1038/cdd.2012.10; Humphreys RC, 2008, ADV EXP MED BIOL, V615, P127, DOI 10.1007/978-1-4020-6554-5_7; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Kubota H, 2009, J BIOCHEM, V146, P609, DOI 10.1093/jb/mvp139; Lamark Trond, 2012, Int J Cell Biol, V2012, P736905, DOI 10.1155/2012/736905; Lee JY, 2010, EMBO J, V29, P969, DOI 10.1038/emboj.2009.405; Liao Q, 2001, FEBS LETT, V503, P151, DOI 10.1016/S0014-5793(01)02728-4; Milani M, 2009, CANCER RES, V69, P4415, DOI 10.1158/0008-5472.CAN-08-2839; Nakatogawa H, 2009, NAT REV MOL CELL BIO, V10, P458, DOI 10.1038/nrm2708; Nivon M, 2012, J CELL SCI, V125, P1141, DOI 10.1242/jcs.091041; Rodriguez-Gonzalez A, 2008, CANCER RES, V68, P2557, DOI 10.1158/0008-5472.CAN-07-5989; Romano MF, 2003, CANCER BIOL THER, V2, P508, DOI 10.4161/cbt.2.5.524; Scott GK, 2008, MOL CANCER RES, V6, P1250, DOI 10.1158/1541-7786.MCR-07-2110; Seidel K, 2012, NEUROPATH APPL NEURO, V38, P39, DOI 10.1111/j.1365-2990.2011.01198.x; Tsukahara F, 2010, BLOOD, V116, P3582, DOI 10.1182/blood-2009-10-249623; Wang HQ, 2008, BIOCHEM BIOPH RES CO, V365, P381, DOI 10.1016/j.bbrc.2007.11.001; Wanker EE, 1999, METHOD ENZYMOL, V309, P375; Wu WKK, 2010, DRUG RESIST UPDATE, V13, P87, DOI 10.1016/j.drup.2010.04.003; Yao Tso-Pang, 2010, Genes Cancer, V1, P779; Zhang Y, 2012, ONCOL REP, V27, P109, DOI 10.3892/or.2011.1486; Zufferey R, 1997, NAT BIOTECHNOL, V15, P871, DOI 10.1038/nbt0997-871	40	34	34	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2014	33	13					1713	1724		10.1038/onc.2013.110	http://dx.doi.org/10.1038/onc.2013.110			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9QY	23644654	Green Published, Green Submitted			2022-12-28	WOS:000334344700011
J	Czyzyk-Krzeska, MF; Zhang, X				Czyzyk-Krzeska, M. F.; Zhang, X.			MiR-155 at the heart of oncogenic pathways	ONCOGENE			English	Editorial Material							HUMAN BREAST-TUMORS; MOLECULAR PORTRAITS; CANCER CELLS; MICRORNA-155; EXPRESSION; HYPOXIA; GROWTH	MicroRNAs are increasingly being recognized as oncogenes and tumor suppressors in cancer. MicroRNA-155 (miR-155) is an established oncomiR in breast cancer and regulates several pro-oncogenic pathways. In light of this, Chiang's group has discovered a novel pathway regulated by miR-155. MiR-155 directly targets the VHL tumor suppressor and, by doing so, promotes the activity of HIF transcription factors and angiogenesis. This pathway appears to be particularly relevant in triple-negative breast cancer.	[Czyzyk-Krzeska, M. F.; Zhang, X.] Univ Cincinnati, Vontz Ctr Mol Studies, Coll Med, Dept Canc Biol, Cincinnati, OH 45267 USA; [Czyzyk-Krzeska, M. F.] Dept Vet Affairs, VA Res Serv, Cincinnati, OH USA	University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati VA Medical Center	Czyzyk-Krzeska, MF (corresponding author), Univ Cincinnati, Vontz Ctr Mol Studies, Coll Med, Dept Canc Biol, 3125 Eden Ave, Cincinnati, OH 45267 USA.	Maria.Czyzykkrzeska@uc.edu			NCI NIH HHS [NCI CA122346, R01 CA122346] Funding Source: Medline; BLRD VA [I01 BX001110] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA122346] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); BLRD VA; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Babar IA, 2011, CANCER BIOL THER, V12, P908, DOI 10.4161/cbt.12.10.17681; Bruning U, 2011, MOL CELL BIOL, V31, P4087, DOI 10.1128/MCB.01276-10; Chang SH, 2011, NAT MED, V17, P1275, DOI 10.1038/nm.2459; Chen J, 2012, J SURG ONCOL, V106, P260, DOI 10.1002/jso.22153; Gironella M, 2007, P NATL ACAD SCI USA, V104, P16170, DOI 10.1073/pnas.0703942104; Jiang S, 2012, EMBO J, V31, P1985, DOI 10.1038/emboj.2012.45; Jiang SA, 2010, CANCER RES, V70, P3119, DOI 10.1158/0008-5472.CAN-09-4250; Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412; Kong W, 2014, ONCOGENE, V33, P679, DOI 10.1038/onc.2012.636; Kong W, 2008, MOL CELL BIOL, V28, P6773, DOI 10.1128/MCB.00941-08; Kong W, 2010, J BIOL CHEM, V285, P17869, DOI 10.1074/jbc.M110.101055; Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093	12	41	43	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2014	33	6					677	678		10.1038/onc.2013.26	http://dx.doi.org/10.1038/onc.2013.26			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5IL	23416982	Green Accepted			2022-12-28	WOS:000331129200002
J	Kahali, B; Gramling, SJB; Marquez, SB; Thompson, K; Lu, L; Reisman, D				Kahali, B.; Gramling, S. J. B.; Marquez, S. B.; Thompson, K.; Lu, L.; Reisman, D.			Identifying targets for the restoration and reactivation of BRM	ONCOGENE			English	Article						epigenetic; histone transferase; SWI/SNF; histone deacetylase complex; tumor suppressor; brahma	HUMAN LUNG-CANCER; CHROMATIN-REMODELING FACTOR; II HISTONE DEACETYLASES; SWI/SNF COMPLEX; GENE-EXPRESSION; BREAST-CANCER; CELL-LINES; TRANSCRIPTIONAL ACTIVITY; RAS MUTATIONS; DNA-BINDING	Brahma (BRM) is a novel anticancer gene, which is frequently inactivated in a variety of tumor types. Unlike many anticancer genes, BRM is not mutated, but rather epigenetically silenced. In addition, histone deacetylase complex (HDAC) inhibitors are known to reverse BRM silencing, but they also inactivate it via acetylation of its C-terminus. High-throughput screening has uncovered many compounds that are effective at pharmacologically restoring BRM and thereby inhibit cancer cell growth. As we do not know which specific proteins, if any, regulate BRM, we sought to identify the proteins, which underlie the epigenetic suppression of BRM. By selectively knocking down each HDAC, we found that HDAC3 and HDAC9 regulate BRM expression, whereas HDAC2 controls its acetylation. Similarly, we ectopically overexpressed 21 different histone acetyltransferases and found that KAT6A, KAT6B and KAT7 induce BRM expression, whereas KAT2B and KAT8 induce its acetylation. We also investigated the role of two transcription factors (TFs) linked to either BRM (GATA3) or HDAC9 (MEF2D) expression. Knockdown of either GATA3 and/or MEF2D downregulated HDAC9 and induced BRM. As targets for molecular biotherapy are typically uniquely, or simply differentially expressed in cancer cells, we also determined if any of these proteins are dysregulated. However, by sequencing, no mutations were found in any of these BRM-regulating HDACs, HATs or TFs. We selectively knocked down GATA3, MEF2D, HDAC3 and HDAC9, and found that each gene-specific knockdown induced growth inhibition. We observed that both GATA3 and HDAC9 were greatly overexpressed only in BRM-negative cell lines indicating that HDAC9 may be a good target for therapy. We also found that the mitogen-activated protein (MAP) kinase pathway regulates both BRM acetylation and BRM silencing as MAP kinase pathway inhibitors both induced BRM as well as caused BRM deacetylation. Together, these data identify a cadre of key proteins, which underlie the epigenetic regulation of BRM.	[Kahali, B.; Gramling, S. J. B.; Marquez, S. B.; Thompson, K.; Reisman, D.] Univ Florida, Dept Med, Dept Hematol Oncol, Gainesville, FL 32610 USA; [Lu, L.] Univ Florida, Dept Pathol, Gainesville, FL 32611 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Reisman, D (corresponding author), Univ Florida, Dept Med, Dept Hematol Oncol, Gainesville, FL 32610 USA.	dnreisman@ufl.edu	Kahali, Bhaskar/N-6398-2018	Kahali, Bhaskar/0000-0003-4160-7979	 [5R01CA136683-03]; NATIONAL CANCER INSTITUTE [R01CA136683] Funding Source: NIH RePORTER	; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Rachel Dresbeck for her time and effort in editing the manuscript. This research was supported by 5R01CA136683-03 Identifying Agents which Restored BRM expression.	Albergaria A, 2009, BREAST CANCER RES, V11, DOI 10.1186/bcr2327; Avvakumov N, 2007, ONCOGENE, V26, P5395, DOI 10.1038/sj.onc.1210608; Avvakumov Nikita, 2007, Subcell Biochem, V41, P295; Balch C, 2005, FRONT BIOSCI-LANDMRK, V10, P1897, DOI 10.2741/1668; Berger AH, 2011, NATURE, V476, P163, DOI 10.1038/nature10275; Bertos NR, 2001, BIOCHEM CELL BIOL, V79, P243, DOI 10.1139/bcb-79-3-243; Bilanges B, 2007, ONCOGENE, V26, P5973, DOI 10.1038/sj.onc.1210431; Bock VL, 2011, BRIT J DERMATOL, V164, P1221, DOI 10.1111/j.1365-2133.2011.10267.x; Bourachot B, 2003, EMBO J, V22, P6505, DOI 10.1093/emboj/cdg621; Brose MS, 2002, CANCER RES, V62, P6997; Bultman S, 2000, MOL CELL, V6, P1287, DOI 10.1016/S1097-2765(00)00127-1; Bultman SJ, 2008, ONCOGENE, V27, P460, DOI 10.1038/sj.onc.1210664; Califano R, 2012, DRUGS, V72, P28, DOI 10.2165/1163012-S0-000000000-00000; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; de Castro-Carpeno J, 2008, CLIN TRANSL ONCOL, V10, P6, DOI 10.1007/s12094-008-0147-3; DelBove J, 2011, EPIGENETICS-US, V6, P1444, DOI 10.4161/epi.6.12.18492; DUNAIEF JL, 1994, CELL, V79, P119, DOI 10.1016/0092-8674(94)90405-7; Duong V, 2008, MOL CANCER RES, V6, P1908, DOI 10.1158/1541-7786.MCR-08-0299; Dwarakanath BS, 2008, INDIAN J MED RES, V128, P13; Fukuoka J, 2004, CLIN CANCER RES, V10, P4314, DOI 10.1158/1078-0432.CCR-03-0489; Gervais C, 2008, LEUKEMIA, V22, P1567, DOI 10.1038/leu.2008.128; Glaros S, 2007, ONCOGENE, V26, P7058, DOI 10.1038/sj.onc.1210514; Glaros S, 2008, CANCER RES, V68, P3689, DOI 10.1158/0008-5472.CAN-07-6652; Glozak MA, 2007, ONCOGENE, V26, P5420, DOI 10.1038/sj.onc.1210610; Gordon VS, 2010, ONCOL REV, V4, P89, DOI 10.1007/s12156-010-0040-5; Gramling S, 2011, ONCOGENE, V30, P3289, DOI 10.1038/onc.2011.80; Gramling S, 2011, LETT DRUG DES DISCOV, V8, P93, DOI 10.2174/157018011793663840; Gregoire S, 2006, J BIOL CHEM, V281, P4423, DOI 10.1074/jbc.M509471200; Gregoire S, 2007, MOL CELL BIOL, V27, P1280, DOI 10.1128/MCB.00882-06; Haber DA, 2005, COLD SH Q B, V70, P419, DOI 10.1101/sqb.2005.70.043; Haberland M, 2007, MOL CELL BIOL, V27, P518, DOI 10.1128/MCB.01415-06; Hess-Stumpp H, 2005, EUR J CELL BIOL, V84, P109, DOI 10.1016/j.ejcb.2004.12.010; Ho IC, 2007, CELL MOL IMMUNOL, V4, P15; Itoh T, 2008, BIOCHEM BIOPH RES CO, V366, P827, DOI 10.1016/j.bbrc.2007.12.026; KHAVARI PA, 1993, NATURE, V366, P170, DOI 10.1038/366170a0; Konofaos P, 2006, SURG ONCOL, V15, P257, DOI 10.1016/j.suronc.2007.03.004; Lamonica JM, 2006, BLOOD, V108, P3736, DOI 10.1182/blood-2006-07-032847; LAURENT BC, 1993, COLD SPRING HARB SYM, V58, P257, DOI 10.1101/SQB.1993.058.01.030; Lee JH, 2005, MOL CELLS, V19, P289; Liu G, 2011, ONCOGENE, V30, P3295, DOI 10.1038/onc.2011.81; Ma KW, 2005, MOL CELL BIOL, V25, P3575, DOI 10.1128/MCB.25.9.3575-3582.2005; Mai A, 2005, MED RES REV, V25, P261, DOI 10.1002/med.20024; Maneechotesuwan K, 2007, J IMMUNOL, V178, P2491, DOI 10.4049/jimmunol.178.4.2491; Marijon H, 2011, B CANCER, V98, P1011, DOI 10.1684/bdc.2011.1379; Medina PP, 2008, HUM MUTAT, V29, P617, DOI 10.1002/humu.20730; Medina PP, 2004, GENE CHROMOSOME CANC, V41, P170, DOI 10.1002/gcc.20068; Milde T, 2010, CLIN CANCER RES, V16, P3240, DOI 10.1158/1078-0432.CCR-10-0395; Mizutani T, 2002, J BIOL CHEM, V277, P15859, DOI 10.1074/jbc.M112421200; Moore SDP, 2004, CANCER RES, V64, P5570, DOI 10.1158/0008-5472.CAN-04-0050; Moreno DA, 2010, BRIT J HAEMATOL, V150, P665, DOI 10.1111/j.1365-2141.2010.08301.x; Muchardt C, 1999, SEMIN CELL DEV BIOL, V10, P189, DOI 10.1006/scdb.1999.0300; Muchardt C, 1998, EMBO J, V17, P223, DOI 10.1093/emboj/17.1.223; Muchardt C, 1999, J MOL BIOL, V293, P187, DOI 10.1006/jmbi.1999.2999; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; Nakada S, 2001, ANTICANCER RES, V21, P167; Oh J, 2008, J BIOL CHEM, V283, P11924, DOI 10.1074/jbc.M705401200; Ozawa Y, 2001, BLOOD, V98, P2116, DOI 10.1182/blood.V98.7.2116; Petrie K, 2003, J BIOL CHEM, V278, P16059, DOI 10.1074/jbc.M212935200; Potthoff MJ, 2007, DEVELOPMENT, V134, P4131, DOI 10.1242/dev.008367; Reisman D, 2009, ONCOGENE, V28, P1653, DOI 10.1038/onc.2009.4; Reisman DN, 2005, APPL IMMUNOHISTO M M, V13, P66, DOI 10.1097/00129039-200503000-00011; Reisman DN, 2003, CANCER RES, V63, P560; Reisman DN, 2002, ONCOGENE, V21, P1196, DOI 10.1038/sj.onc.1205188; Reyes JC, 1997, J CELL BIOL, V137, P263, DOI 10.1083/jcb.137.2.263; Rodriguez-Nieto S, 2011, HUM MUTAT, V32, pE1999, DOI 10.1002/humu.21415; Sakurai K, 2011, CANCER RES, V71, P1680, DOI 10.1158/0008-5472.CAN-10-2345; Skov V, 2012, LEUKEMIA LYMPHOMA, V53, P123, DOI 10.3109/10428194.2011.597905; Strobeck MW, 2000, P NATL ACAD SCI USA, V97, P7748, DOI 10.1073/pnas.97.14.7748; Strobeck MW, 2002, J BIOL CHEM, V277, P4782, DOI 10.1074/jbc.M109532200; Strobeck MW, 2001, J BIOL CHEM, V276, P9273, DOI 10.1074/jbc.M009747200; Strober BE, 1996, MOL CELL BIOL, V16, P1576; Tagliabue E, 2010, EXPERT OPIN BIOL TH, V10, P711, DOI 10.1517/14712591003689972; Tsou JA, 2002, ONCOGENE, V21, P5450, DOI 10.1038/sj.onc.1205605; Wang WD, 1998, P NATL ACAD SCI USA, V95, P492, DOI 10.1073/pnas.95.2.492; Wang WD, 1996, EMBO J, V15, P5370, DOI 10.1002/j.1460-2075.1996.tb00921.x; Wang WD, 1996, GENE DEV, V10, P2117, DOI 10.1101/gad.10.17.2117; Weichert W, 2009, CANCER LETT, V280, P168, DOI 10.1016/j.canlet.2008.10.047; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Xu Y, 2007, J BIOL CHEM, V282, P37429, DOI 10.1074/jbc.M706039200; Yamamichi N, 2005, ONCOGENE, V24, P5471, DOI 10.1038/sj.onc.1208716; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X; Zhang XH, 2004, MOL CELL BIOL, V24, P5106, DOI 10.1128/MCB.24.12.5106-5118.2004; Zheng Rena, 2010, Genes Cancer, V1, P1178, DOI 10.1177/1947601911404223	85	38	40	1	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2014	33	5					653	664		10.1038/onc.2012.613	http://dx.doi.org/10.1038/onc.2012.613			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5GW	23524580				2022-12-28	WOS:000331125100013
J	Nishi, M; Sakai, Y; Akutsu, H; Nagashima, Y; Quinn, G; Masui, S; Kimura, H; Perrem, K; Umezawa, A; Yamamoto, N; Lee, SW; Ryo, A				Nishi, M.; Sakai, Y.; Akutsu, H.; Nagashima, Y.; Quinn, G.; Masui, S.; Kimura, H.; Perrem, K.; Umezawa, A.; Yamamoto, N.; Lee, S. W.; Ryo, A.			Induction of cells with cancer stem cell properties from nontumorigenic human mammary epithelial cells by defined reprogramming factors	ONCOGENE			English	Article						cancer stem cell; reprogramming factors; oncogenesis; MCF-10A; p16INK4a	EXPRESSION; PHOSPHORYLATION; IMMORTALIZATION; IDENTIFICATION; MARKER; SOX2	Cancer stem cells (CSCs), a small and elusive population of undifferentiated cancer cells within tumors that drive tumor growth and recurrence, are believed to resemble normal stem cells. Although surrogate markers have been identified and compelling CSC theoretical models abound, actual proof for the existence of CSCs can only be had retrospectively. Hence, great store has come to be placed in isolating CSCs from cancers for in-depth analysis. On the other hand, although induced pluripotent stem cells (iPSCs) hold great promise for regenerative medicine, concern exists over the inadvertent co-transplantation of partially or undifferentiated stem cells with tumorigenic capacity. Here we demonstrate that the introduction of defined reprogramming factors (OCT4, SOX2, Klf4 and c-Myc) into MCF-10A nontumorigenic mammary epithelial cells, followed by partial differentiation, transforms the bulk of cells into tumorigenic CD44(+)/CD24(low) cells with CSC properties, termed here as induced CSC-like-10A or iCSCL-10A cells. These reprogrammed cells display a malignant phenotype in culture and form tumors of multiple lineages when injected into immunocompromised mice. Compared with other transformed cell lines, cultured iCSCL-10A cells exhibit increased resistance to the chemotherapeutic compounds, Taxol and Actinomycin D, but higher susceptibility to the CSC-selective agent Salinomycin and the Pin1 inhibitor Juglone. Restored expression of the cyclin-dependent kinase inhibitor p16INK4a abrogated the CSC properties of iCSCL-10A cells, by inducing cellular senescence. This study provides some insight into the potential oncogenicity that may arise via cellular reprogramming, and could represent a valuable in vitro model for studying the phenotypic traits of CSCs per se.	[Nishi, M.; Sakai, Y.; Quinn, G.; Ryo, A.] Yokohama City Univ, Sch Med, Dept Microbiol, Yokohama, Kanagawa 2360004, Japan; [Akutsu, H.; Umezawa, A.] Natl Res Inst Child Hlth & Dev, Dept Reprod Biol, Tokyo, Japan; [Nagashima, Y.] Yokohama City Univ, Sch Med, Dept Mol Pathol, Yokohama, Kanagawa 2360004, Japan; [Masui, S.] Kyoto Univ, Ctr iPS Cell Res & Applicat CiRA, Kyoto, Japan; [Kimura, H.] Natl Inst Infect Dis, Infect Dis Surveillance Ctr, Tokyo, Japan; [Perrem, K.] CSIRO, Dickson, ACT, Australia; [Yamamoto, N.] Natl Univ Singapore, Dept Microbiol, Singapore 117548, Singapore; [Lee, S. W.] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA USA; [Lee, S. W.] Harvard Univ, Sch Med, Charlestown, MA USA	Yokohama City University; National Center for Child Health & Development - Japan; Yokohama City University; Kyoto University; National Institute of Infectious Diseases (NIID); Commonwealth Scientific & Industrial Research Organisation (CSIRO); National University of Singapore; Harvard University; Massachusetts General Hospital; Harvard University	Ryo, A (corresponding author), Yokohama City Univ, Sch Med, Dept Microbiol, Kanazawa Ku, 3-9 Fuku Ura, Yokohama, Kanagawa 2360004, Japan.	aryo@yokohama-cu.ac.jp	Nagashima, Yoji/AAA-2591-2021	Masui, Shinji/0000-0001-7417-0019	Japan Health Sciences Foundation; Uehara Memorial Foundation; Takeda Science Foundation; NATIONAL CANCER INSTITUTE [P01CA080058] Funding Source: NIH RePORTER	Japan Health Sciences Foundation; Uehara Memorial Foundation(Uehara Memorial Foundation); Takeda Science Foundation(Takeda Science Foundation (TSF)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank A Kondo, T Taniguchi, Y Kojima, Y Watanabe, M Tanaka and N Sakurai for technical assistance and discussion. This work was in part supported by Grant-in-Aid for Scientific Research on Innovative Areas and the Japan Health Sciences Foundation, and grants from the Uehara Memorial Foundation and Takeda Science Foundation to AR.	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Banito A, 2009, GENE DEV, V23, P2134, DOI 10.1101/gad.1811609; Bhat-Nakshatri P, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-411; Carette JE, 2010, BLOOD, V115, P4039, DOI 10.1182/blood-2009-07-231845; Chen L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033544; Chen YP, 2008, J BIOL CHEM, V283, P17969, DOI 10.1074/jbc.M802917200; Clark AT, 2007, STEM CELL REV, V3, P49, DOI 10.1007/s12015-007-0002-x; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Cowell JK, 2005, CANCER GENET CYTOGEN, V163, P23, DOI 10.1016/j.cancergencyto.2005.04.019; Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Desbaillets I, 2000, EXP PHYSIOL, V85, P645, DOI 10.1017/S0958067000021047; Dey D, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005329; Dick JE, 2009, NAT BIOTECHNOL, V27, P44, DOI 10.1038/nbt0109-44; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Hochedlinger K, 2005, CELL, V121, P465, DOI 10.1016/j.cell.2005.02.018; Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338; Lengerke C, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-42; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Li H, 2009, NATURE, V460, P1136, DOI 10.1038/nature08290; Liu MR, 2009, P NATL ACAD SCI USA, V106, P19035, DOI 10.1073/pnas.0910009106; Lu PJ, 2002, J BIOL CHEM, V277, P2381, DOI 10.1074/jbc.C100228200; Marion RM, 2009, NATURE, V460, P1149, DOI 10.1038/nature08287; Miyoshi N, 2010, P NATL ACAD SCI USA, V107, P40, DOI 10.1073/pnas.0912407107; Moretto-Zita M, 2010, P NATL ACAD SCI USA, V107, P13312, DOI 10.1073/pnas.1005847107; Nishi M, 2011, J BIOL CHEM, V286, P11593, DOI 10.1074/jbc.M110.187989; Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972; Rosen JM, 2009, SCIENCE, V324, P1670, DOI 10.1126/science.1171837; Ryo A, 2005, CLIN CANCER RES, V11, P7523, DOI 10.1158/1078-0432.CCR-05-0457; Sarig R, 2010, J EXP MED, V207, P2127, DOI 10.1084/jem.20100797; Scaffidi P, 2011, NAT CELL BIOL, V13, P1051, DOI 10.1038/ncb2308; Silva J, 2008, PLOS BIOL, V6, P2237, DOI 10.1371/journal.pbio.0060253; Singh SK, 2003, CANCER RES, V63, P5821; SOULE HD, 1990, CANCER RES, V50, P6075; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Utikal J, 2009, J CELL SCI, V122, P3502, DOI 10.1242/jcs.054783; Utikal J, 2009, NATURE, V460, P1145, DOI 10.1038/nature08285; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wei DY, 2006, CARCINOGENESIS, V27, P23, DOI 10.1093/carcin/bgi243; Werbowetski-Ogilvie TE, 2009, NAT BIOTECHNOL, V27, P91, DOI 10.1038/nbt.1516; Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526	44	79	81	0	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2014	33	5					643	652		10.1038/onc.2012.614	http://dx.doi.org/10.1038/onc.2012.614			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5GW	23318426	Green Accepted			2022-12-28	WOS:000331125100012
J	Wen, W; Peng, C; Kim, MO; Jeong, CH; Zhu, F; Yao, K; Zykova, T; Ma, W; Carper, A; Langfald, A; Bode, AM; Dong, Z				Wen, W.; Peng, C.; Kim, M. O.; Jeong, C. Ho; Zhu, F.; Yao, K.; Zykova, T.; Ma, W.; Carper, A.; Langfald, A.; Bode, A. M.; Dong, Z.			Knockdown of RNF2 induces apoptosis by regulating MDM2 and p53 stability	ONCOGENE			English	Article						RNF2; PcG; p53; MDM2; ubiquitination	DEVELOPMENTAL REGULATORS; POLYCOMB COMPLEXES; CELL-PROLIFERATION; BREAST-CANCER; EZH2; ENHANCER; BMI-1; METHYLATION; PROTEINS; TARGET	RNF2, also known as Ring1B/Ring2, is a component of the polycomb repression complex 1. RNF2 is highly expressed in many tumors, suggesting that it might have an oncogenic function, but the mechanism is unknown. Here, we show that knockdown of RNF2 significantly inhibits both cell proliferation and colony formation in soft agar, and induces apoptosis in cancer cells. Knockdown of RNF2 in HCT116 p53(+/+) cells resulted in significantly more apoptosis than was observed in RNF2 knockdown HCT116 p53(-/-) cells, indicating that RNF2 knockdown-induced apoptosis is partially dependent on p53. Various p53-targeted genes were increased in RNF2 knockdown cells. Further studies revealed that in RNF2 knockdown cells, the p53 protein level was increased, the half-life of p53 was prolonged and p53 ubiquitination was decreased. In contrast, cells overexpressing RNF2 showed a decreased p53 protein level, a shorter p53 half-life and increased p53 ubiquitination. Importantly, we found that RNF2 directly binds with both p53 and MDM2 and promotes MDM2-mediated p53 ubiquitination. RNF2 overexpression could also increase the half-life of MDM2 and inhibit its ubiquitination. The regulation on p53 and MDM2 stability by RNF2 was also observed during the etoposide-induced DNA damage response. These results provide a possible mechanism explaining the oncogenic function of RNF2, and because RNF2 is important for cancer cell survival and proliferation, it might be an ideal target for cancer therapy or prevention.	[Wen, W.; Peng, C.; Kim, M. O.; Jeong, C. Ho; Zhu, F.; Yao, K.; Zykova, T.; Ma, W.; Carper, A.; Langfald, A.; Bode, A. M.; Dong, Z.] Univ Minnesota, Hormel Inst, Austin, MN 55912 USA; [Wen, W.] Fourth Mil Med Univ, Dept Immunol, State Key Lab Canc Biol, Xian 710032, Peoples R China; [Kim, M. O.] Kyungpook Natl Univ, Ctr Lab Anim Resources, Taegu, South Korea	University of Minnesota System; Air Force Military Medical University; Kyungpook National University	Dong, Z (corresponding author), Univ Minnesota, Hormel Inst, 801 16th Ave NE, Austin, MN 55912 USA.	zgdong@hi.umn.edu	温, 家琦/GYV-3177-2022; ZHU, Feng/C-1303-2010	Zhu, Feng/0000-0003-1172-0102	Hormel Foundation; National Institutes of Health [CA077646, CA027502, CA111536, CA120388, R37CA081064, ES017548]; National Natural Sciences Foundation of China [81171924]; NATIONAL CANCER INSTITUTE [R37CA081064, R01CA077646, P01CA027502, R01CA111536, R01CA120388, R01CA111356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES016548] Funding Source: NIH RePORTER	Hormel Foundation; National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Natural Sciences Foundation of China(National Natural Science Foundation of China (NSFC)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))	We thank Dr Bert Vogelstein (Johns Hopkins Oncology Center) for the HCT116 p53<SUP>+/+</SUP>, HCT116 p53<SUP>-/-</SUP> cells, Dr Seongman Kang (Korea University, South Korea) for the pCDNA3-Xpress-RNF2 plasmid. We also thank Dr Yibin Deng at The Hormel Institute for very helpful discussion and advice. We thank Tonya M Poorman for help submitting our manuscript. This work was supported by The Hormel Foundation and National Institutes of Health Grants CA077646, CA027502, CA111536, CA120388, R37CA081064, ES017548 and the National Natural Sciences Foundation of China (No. 81171924).	Alajez NM, 2009, CELL DEATH DIFFER, V16, P1469, DOI 10.1038/cdd.2009.85; Boyer LA, 2006, NATURE, V441, P349, DOI 10.1038/nature04733; Cao R, 2002, SCIENCE, V298, P1039, DOI 10.1126/science.1076997; Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503; Fujii S, 2008, J BIOL CHEM, V283, P17324, DOI 10.1074/jbc.M800224200; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Jagani Z, 2010, CANCER RES, V70, P5528, DOI 10.1158/0008-5472.CAN-09-4229; Kalushkova A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011483; Kirmizis A, 2004, GENE DEV, V18, P1592, DOI 10.1101/gad.1200204; Kleer CG, 2003, P NATL ACAD SCI USA, V100, P11606, DOI 10.1073/pnas.1933744100; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kuzmichev A, 2002, GENE DEV, V16, P2893, DOI 10.1101/gad.1035902; Lee SJ, 2001, FEBS LETT, V503, P61, DOI 10.1016/S0014-5793(01)02689-8; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Levine SS, 2004, TRENDS BIOCHEM SCI, V29, P478, DOI 10.1016/j.tibs.2004.07.007; Liu L, 2006, ONCOGENE, V25, P4370, DOI 10.1038/sj.onc.1209454; Lund AH, 2004, CURR OPIN CELL BIOL, V16, P239, DOI 10.1016/j.ceb.2004.03.010; Ougolkov AV, 2008, CLIN CANCER RES, V14, P6790, DOI 10.1158/1078-0432.CCR-08-1013; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Sanchez-Beato M, 2006, MODERN PATHOL, V19, P684, DOI 10.1038/modpathol.3800577; Sparmann A, 2006, NAT REV CANCER, V6, P846, DOI 10.1038/nrc1991; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Varambally S, 2002, NATURE, V419, P624, DOI 10.1038/nature01075; Voncken JW, 2003, P NATL ACAD SCI USA, V100, P2468, DOI 10.1073/pnas.0434312100; Wang HB, 2004, NATURE, V431, P873, DOI 10.1038/nature02985; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Yang XJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005011	29	43	47	0	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2014	33	4					421	428		10.1038/onc.2012.605	http://dx.doi.org/10.1038/onc.2012.605			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VX	23318437	Green Accepted			2022-12-28	WOS:000330214600003
J	Jin, L; Craven, RJ				Jin, L.; Craven, R. J.			The Rak/Frk tyrosine kinase associates with and internalizes the epidermal growth factor receptor	ONCOGENE			English	Article						signaling; tyrosine kinase; Rak; Frk; EGFR; SH2; SH3	CELL LUNG-CANCER; CLINICAL-RESPONSE; BREAST-CANCER; PROTEIN; EGFR; MUTATIONS; FAMILY; RAK; ENDOCYTOSIS; ACTIVATION	Src is the founding member of a diverse family of intracellular tyrosine kinases, and Src has a key role in promoting cancer growth, in part, through its association with receptor tyrosine kinases. However, some Src-related proteins have widely divergent physiological roles, and these proteins include the Rak/Frk tyrosine kinase (Frk stands for Fyn-related kinase), which inhibits cancer cell growth and suppresses tumorigenesis. Rak/Frk phosphorylates and stabilizes the Pten tumor suppressor, protecting it from degradation, and Rak/Frk associates with the retinoblastoma (Rb) tumor suppressor. However, the role of Rak/Frk in receptor-mediated signaling is largely unknown. Here, we demonstrate that Rak/Frk associates with epidermal growth factor receptor (EGFR), increasing in activity and EGFR binding after EGF stimulation, when it decreases the pool of EGFR present at the plasma membrane. EGFR-Rak binding is direct, requires the SH2 and SH3 domains of Rak/Frk for efficient complex formation and is not dependent on the Grb2 adaptor protein. EGFR mutations are associated with increased EGFR activity and tumorigenicity, and we found that Rak/Frk associates preferentially with an EGFR exon 19 mutant, EGFR Delta 747-749/A750P, compared with wild-type EGFR. Furthermore, Rak/Frk inhibited mutant EGFR phosphorylation at an activating site and dramatically decreased the levels of EGFR Delta 747-749/A750P from the plasma membrane. Taken together, the results suggest that Rak/Frk inhibits EGFR signaling in cancer cells and has elevated activity against EGFR exon 19 mutants.	[Jin, L.; Craven, R. J.] Univ Kentucky, Lucille P Markey Canc Ctr, Dept Mol & Biomed Pharmacol, Lexington, KY 40536 USA	University of Kentucky	Craven, RJ (corresponding author), Univ Kentucky, Med Ctr, Dept Mol & Biomed Pharmacol, Lucille P Markey Canc Ctr, Lexington, KY 40536 USA.	rolf.craven@uky.edu			Kentucky Lung Cancer Research Program, cycle 9	Kentucky Lung Cancer Research Program, cycle 9	This work was supported by the Kentucky Lung Cancer Research Program, cycle 9. We thank Drs Gengxian Shi and Doug Andres for advice and reagents, Mary Gail Engle of the University of Kentucky Imaging Core Facility for expertise in microscopy and Woodrow Friend for reading of the manuscript.	Arteaga CL, 2003, EXP CELL RES, V284, P122, DOI 10.1016/S0014-4827(02)00104-0; Berclaz G, 2000, INT J CANCER, V85, P889; Boggon TJ, 2004, ONCOGENE, V23, P7918, DOI 10.1038/sj.onc.1208081; Brauer PM, 2010, BBA-REV CANCER, V1806, P66, DOI 10.1016/j.bbcan.2010.02.003; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CANCE WG, 1994, CELL GROWTH DIFFER, V5, P1347; CANCE WG, 1993, INT J CANCER, V54, P571, DOI 10.1002/ijc.2910540409; Chandrasekharan S, 2002, MOL CELL BIOL, V22, P5235, DOI 10.1128/MCB.22.14.5235-5247.2002; CRAVEN RJ, 1995, CANCER RES, V55, P3969; Crudden G, 2005, TUMOR BIOL, V26, P142, DOI 10.1159/000086485; Emlet DR, 1997, J BIOL CHEM, V272, P4079, DOI 10.1074/jbc.272.7.4079; Furukawa M, 2007, DNA CELL BIOL, V26, P178, DOI 10.1089/dna.2006.0573; Ganti AK, 2010, CANCER INVEST, V28, P515, DOI 10.3109/07357900903476760; Gazdar AF, 2009, ONCOGENE, V28, pS24, DOI 10.1038/onc.2009.198; Georgescu Maria-Magdalena, 2010, Genes Cancer, V1, P1170, DOI 10.1177/1947601911407325; Giubellino A, 2008, EXPERT OPIN THER TAR, V12, P1021, DOI 10.1517/14728222.12.8.1021 ; Goeze A, 2002, J PATHOL, V196, P8, DOI 10.1002/path.1009; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Haegebarth A, 2006, MOL CELL BIOL, V26, P4949, DOI 10.1128/MCB.01901-05; Hsu JM, 2011, NAT CELL BIOL, V13, P174, DOI 10.1038/ncb2158; Jin GA, 2011, LUNG CANCER, V71, P115, DOI 10.1016/j.lungcan.2010.10.002; Katso RM, 2006, MOL BIOL CELL, V17, P3729, DOI 10.1091/mbc.E05-11-1083; Keilhack H, 1998, J BIOL CHEM, V273, P24839, DOI 10.1074/jbc.273.38.24839; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; LEE J, 1994, GENE, V138, P247, DOI 10.1016/0378-1119(94)90817-6; Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011; Li X, 2012, ONCOGENE, V31, P4372, DOI 10.1038/onc.2011.608; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Meyer T, 2003, INT J CANCER, V104, P139, DOI 10.1002/ijc.10925; Oberg-Welsh C, 1998, GROWTH FACTORS, V16, P111; OKUTANI T, 1994, J BIOL CHEM, V269, P31310; Padron D, 2007, CANCER RES, V67, P7695, DOI 10.1158/0008-5472.CAN-07-0484; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Palka-Hamblin HL, 2010, J CELL SCI, V123, P236, DOI 10.1242/jcs.053264; Rivera F, 2008, ANTI-CANCER DRUG, V19, P99, DOI 10.1097/CAD.0b013e3282f23287; Sequist LV, 2008, ANNU REV MED, V59, P429, DOI 10.1146/annurev.med.59.090506.202405; Serfas MS, 2003, ONCOL RES, V13, P409; SMITHGALL TE, 1995, J PHARMACOL TOX MET, V34, P125, DOI 10.1016/1056-8719(95)00082-7; Sorkin A, 2009, EXP CELL RES, V315, P683, DOI [10.1016/j.yexcr.2008.07.029, 10.1016/j.yexcr.2008.08.013]; Tanos B, 2006, J BIOL CHEM, V281, P32714, DOI 10.1074/jbc.M603126200; THUVESON M, 1995, BIOCHEM BIOPH RES CO, V209, P582, DOI 10.1006/bbrc.1995.1540; Yim EK, 2009, CANCER CELL, V15, P304, DOI 10.1016/j.ccr.2009.02.012; Zheng Y, 2012, J BIOL CHEM, V287, P148, DOI 10.1074/jbc.M111.298117; Zheng Y, 2010, MOL CELL BIOL, V30, P4280, DOI 10.1128/MCB.00024-10	45	8	8	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 16	2014	33	3					326	335		10.1038/onc.2012.589	http://dx.doi.org/10.1038/onc.2012.589			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VR	23318459	Green Submitted			2022-12-28	WOS:000330214000007
J	Calero-Nieto, FJ; Joshi, A; Bonadies, N; Kinston, S; Chan, WI; Gudgin, E; Pridans, C; Landry, JR; Kikuchi, J; Huntly, BJ; Gottgens, B				Calero-Nieto, F. J.; Joshi, A.; Bonadies, N.; Kinston, S.; Chan, W-I; Gudgin, E.; Pridans, C.; Landry, J-R; Kikuchi, J.; Huntly, B. J.; Gottgens, B.			HOX-mediated LMO2 expression in embryonic mesoderm is recapitulated in acute leukaemias	ONCOGENE			English	Article						gene regulation; haematopoiesis; HOX; leukaemia; LMO2	ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; T-CELL LEUKEMIA; TRANSCRIPTION FACTOR; STEM-CELL; ONCOGENIC PATHWAYS; CALM/AF10 FUSION; GENE; CANCER; PROMOTER	The Lim Domain Only 2 (LMO2) leukaemia oncogene encodes an LIM domain transcriptional cofactor required for early haematopoiesis. During embryogenesis, LMO2 is also expressed in developing tail and limb buds, an expression pattern we now show to be recapitulated in transgenic mice by an enhancer in LMO2 intron 4. Limb bud expression depended on a cluster of HOX binding sites, while posterior tail expression required the HOX sites and two E-boxes. Given the importance of both LMO2 and HOX genes in acute leukaemias, we further demonstrated that the regulatory hierarchy of HOX control of LMO2 is activated in leukaemia mouse models as well as in patient samples. Moreover, Lmo2 knock-down impaired the growth of leukaemic cells, and high LMO2 expression at diagnosis correlated with poor survival in cytogenetically normal AML patients. Taken together, these results establish a regulatory hierarchy of HOX control of LMO2 in normal development, which can be resurrected during leukaemia development. Redeployment of embryonic regulatory hierarchies in an aberrant context is likely to be relevant in human pathologies beyond the specific example of ectopic activation of LMO2.	[Calero-Nieto, F. J.; Joshi, A.; Bonadies, N.; Kinston, S.; Chan, W-I; Gudgin, E.; Pridans, C.; Landry, J-R; Huntly, B. J.; Gottgens, B.] Univ Cambridge, Dept Haematol, Wellcome Trust, Cambridge CB2 0XY, England; [Calero-Nieto, F. J.; Joshi, A.; Bonadies, N.; Kinston, S.; Chan, W-I; Gudgin, E.; Pridans, C.; Landry, J-R; Huntly, B. J.; Gottgens, B.] Univ Cambridge, MRC Cambridge Stem Cell Inst, Cambridge Inst Med Res, Cambridge CB2 0XY, England; [Kikuchi, J.] Jichi Med Sch, Div Stem Cell Regulat, Ctr Mol Med, Shimotsuke, Tochigi, Japan	University of Cambridge; Wellcome Trust Sanger Institute; University of Cambridge; Jichi Medical University	Calero-Nieto, FJ (corresponding author), Univ Cambridge, Dept Haematol, Wellcome Trust, Hills Rd, Cambridge CB2 0XY, England.	fjc28@cam.ac.uk; bg200@cam.ac.uk	Bonadies, Nicolas/F-2388-2017; huntly, brian JP/E-6725-2014; Pridans, Clare/AAF-9953-2020	Bonadies, Nicolas/0000-0001-8761-2066; huntly, brian JP/0000-0003-0312-161X; Pridans, Clare/0000-0001-9423-557X; Calero-Nieto, Fernando/0000-0003-3358-8253; Gottgens, Berthold/0000-0001-6302-5705; Joshi, Anagha/0000-0003-1184-3305	Leukaemia and Lymphoma Research; MRC; BBSRC; CRUK; Leukaemia and Lymphoma Society; Swiss National Science Foundation; EMBO long term fellowship; EG holds a Kay Kendall Clinical Research Training Fellowship; Biotechnology and Biological Sciences Research Council [BB/I00050X/1] Funding Source: researchfish; Cancer Research UK [12765] Funding Source: researchfish; Medical Research Council [MC_PC_12009] Funding Source: researchfish; National Centre for the Replacement [G0900729/1] Funding Source: researchfish; BBSRC [BB/I00050X/1] Funding Source: UKRI	Leukaemia and Lymphoma Research; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); CRUK(Cancer Research UK); Leukaemia and Lymphoma Society; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); EMBO long term fellowship(European Molecular Biology Organization (EMBO)); EG holds a Kay Kendall Clinical Research Training Fellowship; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Cancer Research UK(Cancer Research UK); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); National Centre for the Replacement; BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	We are grateful to Terry Rabbitts for providing the Lmo2 LacZ knock-in mice, Dr Shubha Anand for discussion of results and technical help; Ms Frances Stedham for technical support; and Dr Val Wilson for advice on early embryonic expression patterns. Work in the authors' laboratories is supported by grants from Leukaemia and Lymphoma Research, the MRC, BBSRC, CRUK and Leukaemia and Lymphoma Society. NB was supported by the Swiss National Science Foundation, AJ is the recipient of an EMBO long term fellowship and EG holds a Kay Kendall Clinical Research Training Fellowship.	Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Ayton PM, 2003, GENE DEV, V17, P2298, DOI 10.1101/gad.1111603; Berger MF, 2008, CELL, V133, P1266, DOI 10.1016/j.cell.2008.05.024; BOEHM T, 1991, P NATL ACAD SCI USA, V88, P4367, DOI 10.1073/pnas.88.10.4367; Bohlander SK, 2000, LEUKEMIA, V14, P93, DOI 10.1038/sj.leu.2401614; Bonadies N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016330; Cambray N, 2007, DEVELOPMENT, V134, P2829, DOI 10.1242/dev.02877; Carlson KM, 2000, LEUKEMIA, V14, P100, DOI 10.1038/sj.leu.2401629; Coustan-Smith E, 2009, LANCET ONCOL, V10, P147, DOI 10.1016/S1470-2045(08)70314-0; Cozzio A, 2003, GENE DEV, V17, P3029, DOI 10.1101/gad.1143403; Crable SC, 2003, BLOOD, V101, P4757, DOI 10.1182/blood-2002-09-2702; Dash AB, 2002, P NATL ACAD SCI USA, V99, P7622, DOI 10.1073/pnas.102583199; Deshpande AJ, 2006, CANCER CELL, V10, P363, DOI 10.1016/j.ccr.2006.08.023; Dik WA, 2005, LEUKEMIA, V19, P1948, DOI 10.1038/sj.leu.2403891; Ferrando AA, 2002, CANCER CELL, V1, P75, DOI 10.1016/S1535-6108(02)00018-1; FISCH P, 1992, ONCOGENE, V7, P2389; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gottgens B, 1997, ONCOGENE, V15, P2419, DOI 10.1038/sj.onc.1201426; Hammond SM, 2005, LEUKEMIA RES, V29, P89, DOI 10.1016/j.leukres.2004.05.013; Homminga I, 2011, CANCER CELL, V19, P484, DOI 10.1016/j.ccr.2011.02.008; Huang YS, 2012, BLOOD, V119, P388, DOI 10.1182/blood-2011-03-341081; Huntly BJP, 2005, NATURE, V435, P1169, DOI 10.1038/4351169a; Kvinlaug BT, 2011, CANCER RES, V71, P4117, DOI 10.1158/0008-5472.CAN-11-0176; La Celle PT, 2001, J BIOL CHEM, V276, P32844, DOI 10.1074/jbc.M104598200; Landry JR, 2009, BLOOD, V113, P5783, DOI 10.1182/blood-2008-11-187757; Landry JR, 2005, BLOOD, V106, P2680, DOI 10.1182/blood-2004-12-4755; McCormack MP, 2010, SCIENCE, V327, P879, DOI 10.1126/science.1182378; Mead PE, 2001, DEVELOPMENT, V128, P2301; Metzeler KH, 2008, BLOOD, V112, P4193, DOI 10.1182/blood-2008-02-134411; Okada Y, 2006, NAT CELL BIOL, V8, P1017, DOI 10.1038/ncb1464; Oram SH, 2010, ONCOGENE, V29, P5796, DOI 10.1038/onc.2010.320; Raimondi SC, 2007, ATLAS GENET CYTOGENE, V11, P639; ROYERPOKORA B, 1991, ONCOGENE, V6, P1887; Sell S, 2004, CRIT REV ONCOL HEMAT, V51, P1, DOI 10.1016/j.critrevonc.2004.04.007; Soulier J, 2005, BLOOD, V106, P274, DOI 10.1182/blood-2004-10-3900; Tan BT, 2006, LAB INVEST, V86, P1203, DOI 10.1038/labinvest.3700488; Treanor LM, 2011, BLOOD, V118, P24, DOI 10.1182/blood.V118.21.47.47; Tripic T, 2009, BLOOD, V113, P2191, DOI 10.1182/blood-2008-07-169417; Van Vlierberghe P, 2008, BLOOD, V111, P4668, DOI 10.1182/blood-2007-09-111872; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; WARREN AJ, 1994, CELL, V78, P45, DOI 10.1016/0092-8674(94)90571-1; Wei J, 2008, CANCER CELL, V13, P483, DOI 10.1016/j.ccr.2008.04.020; Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160; Yamada Y, 2000, P NATL ACAD SCI USA, V97, P320, DOI 10.1073/pnas.97.1.320; Zeng CY, 1998, P NATL ACAD SCI USA, V95, P10637, DOI 10.1073/pnas.95.18.10637; Zhang JH, 2012, NATURE, V481, P157, DOI 10.1038/nature10725	46	10	11	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 28	2013	32	48					5471	5480		10.1038/onc.2013.175	http://dx.doi.org/10.1038/onc.2013.175			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	263BE	23708655	hybrid, Green Published			2022-12-28	WOS:000327780800004
J	Gordon, LK; Kiyohara, M; Fu, M; Braun, J; Dhawan, P; Chan, A; Goodglick, L; Wadehra, M				Gordon, L. K.; Kiyohara, M.; Fu, M.; Braun, J.; Dhawan, P.; Chan, A.; Goodglick, L.; Wadehra, M.			EMP2 regulates angiogenesis in endometrial cancer cells through induction of VEGF	ONCOGENE			English	Article						EMP2; VEGF; neoangiogenesis	EPITHELIAL MEMBRANE PROTEIN-2; ENDOTHELIAL GROWTH-FACTOR; COLLAGEN GEL CONTRACTION; TUMOR ANGIOGENESIS; SPLICE VARIANTS; EXPRESSION; TARGET; GLIOBLASTOMA; INHIBITION; RECEPTOR	Understanding tumor-induced angiogenesis is a challenging problem with important consequences for the diagnosis and treatment of cancer. In this study, we define a novel function for epithelial membrane protein-2 (EMP2) in the control of angiogenesis. EMP2 functions as an oncogene in endometrial cancer, and its expression has been linked to decreased survival. Using endometrial cancer xenografts, modulation of EMP2 expression resulted in profound changes to the tumor microvasculature. Under hypoxic conditions, upregulation of EMP2 promoted vascular endothelial growth factors (VEGF) expression through a HIF-1 alpha-dependent pathway and resulted in successful capillary-like tube formation. In contrast, reduction of EMP2 correlated with reduced HIF-1 alpha and VEGF expression with the net consequence of poorly vascularized tumors in vivo. We have previously shown that targeting of EMP2 using diabodies in endometrial cancer resulted in a reduction of tumor load, and since then we have constructed a fully human EMP2 IgG1. Treatment of endometrial cancer cells with EMP2-IgG1 reduced tumor load with a significant improvement in survival. These results support the role of EMP2 in the control of the tumor microenvironment and confirm the cytotoxic effects observed by EMP2 treatment in vivo.	[Gordon, L. K.; Chan, A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA; [Kiyohara, M.; Fu, M.; Braun, J.; Chan, A.; Goodglick, L.; Wadehra, M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; [Braun, J.; Goodglick, L.; Wadehra, M.] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; [Dhawan, P.] Harbor UCLA Med Ctr, Dept Surg, Torrance, CA 90509 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Wadehra, M (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA.	mwadehra@mednet.ucla.edu		Braun, Jonathan/0000-0003-1646-2974	Early Detection Research Network NCI [CA-86366]; NIH [CA16042, CA131756, CA163971]; Stein Oppenheimer Award; Richard and Barbara Braun fund; NATIONAL CANCER INSTITUTE [R01CA163971, U24CA086366, R21CA131756, P30CA016042] Funding Source: NIH RePORTER	Early Detection Research Network NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Stein Oppenheimer Award; Richard and Barbara Braun fund; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We are grateful to Dr Heather Christofk and her laboratory for use of the hypoxic chamber, and thankful to Dr Judith Berliner and Dr Sangderk Lee for providing HAEC cells. This work was generously supported by the Early Detection Research Network NCI CA-86366 (LG), NIH grants CA16042 (JB), CA131756 (MW), CA163971 (MW), the Stein Oppenheimer Award (MW) and Richard and Barbara Braun fund.	Aplin AE, 1999, J BIOL CHEM, V274, P31223, DOI 10.1074/jbc.274.44.31223; Arnaoutova I, 2010, NAT PROTOC, V5, P628, DOI 10.1038/nprot.2010.6; Arsham AM, 2002, J BIOL CHEM, V277, P15162, DOI 10.1074/jbc.M111162200; Barnett SF, 2005, BIOCHEM J, V385, P399, DOI 10.1042/BJ20041140; Bates DO, 2006, CLIN SCI, V110, P575, DOI 10.1042/CS20050292; Cebe-Suarez S, 2006, CELL MOL LIFE SCI, V63, P601, DOI 10.1007/s00018-005-5426-3; de Oliveira RL, 2011, MOL ASPECTS MED, V32, P71, DOI 10.1016/j.mam.2011.04.001; Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088; Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909; Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381; Freije WA, 2004, CANCER RES, V64, P6503, DOI 10.1158/0008-5472.CAN-04-0452; Fu MY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019945; Fu MY, 2010, CLIN CANCER RES, V16, P3954, DOI 10.1158/1078-0432.CCR-10-0368; Habeeb O, 2010, CANCER-AM CANCER SOC, V116, P4718, DOI 10.1002/cncr.25259; Inoue M, 2002, CANCER CELL, V1, P193, DOI 10.1016/S1535-6108(02)00031-4; Kadenhe-Chiweshe A, 2008, MOL CANCER RES, V6, P1, DOI 10.1158/1541-7786.MCR-07-0101; Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596; Kilarski WW, 2009, NAT MED, V15, P657, DOI 10.1038/nm.1985; Lu KV, 2009, CANCER RES, V69, P6889, DOI 10.1158/0008-5472.CAN-09-0347; Mahimainathan L, 2005, AM J PHYSIOL-RENAL, V289, pF72, DOI 10.1152/ajprenal.00277.2004; Mancuso MR, 2006, J CLIN INVEST, V116, P2610, DOI 10.1172/JCI24612; Merdzhanova G, 2010, ONCOGENE, V29, P5392, DOI 10.1038/onc.2010.281; Morales SA, 2007, EXP EYE RES, V85, P790, DOI 10.1016/j.exer.2007.08.014; Morales SA, 2009, INVEST OPHTH VIS SCI, V50, P4949, DOI 10.1167/iovs.08-3315; Morales SA, 2009, INVEST OPHTH VIS SCI, V50, P462, DOI 10.1167/iovs.07-1598; Ogawa K, 2000, ONCOGENE, V19, P6043, DOI 10.1038/sj.onc.1204004; Okada F, 1998, P NATL ACAD SCI USA, V95, P3609, DOI 10.1073/pnas.95.7.3609; PARK JE, 1993, MOL BIOL CELL, V4, P1317, DOI 10.1091/mbc.4.12.1317; Robinson CJ, 2001, J CELL SCI, V114, P853; Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021; Seton-Rogers S, 2011, NAT REV CANCER, V11, P391, DOI 10.1038/nrc3074; Shimazaki K, 2008, CLIN CANCER RES, V14, P7367, DOI 10.1158/1078-0432.CCR-08-1016; Tang N, 2004, CANCER CELL, V6, P485, DOI 10.1016/j.ccr.2004.09.026; Travasso RDM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019989; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Wadehra M, 2006, DEV BIOL, V292, P430, DOI 10.1016/j.ydbio.2006.01.015; Wadehra M, 2005, DEV BIOL, V287, P336, DOI 10.1016/j.ydbio.2005.09.003; Wadehra M, 2002, BIOTECHNIQUES, V32, P242, DOI 10.2144/02322bm02; Wadehra M, 2002, J BIOL CHEM, V277, P41094, DOI 10.1074/jbc.M206868200; Wadehra M, 2006, CANCER-AM CANCER SOC, V107, P90, DOI 10.1002/cncr.21957; Wang B, 2003, CANCER CELL, V4, P19, DOI 10.1016/S1535-6108(03)00164-8; Wang MY, 2006, CANCER RES, V66, P7864, DOI 10.1158/0008-5472.CAN-04-4392; Zagzag D, 2006, LAB INVEST, V86, P1221, DOI 10.1038/labinvest.3700482	43	36	42	2	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 14	2013	32	46					5369	5376		10.1038/onc.2012.622	http://dx.doi.org/10.1038/onc.2012.622			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	251IU	23334331	Green Published, hybrid			2022-12-28	WOS:000326922400007
J	Chapman-Rothe, N; Curry, E; Zeller, C; Liber, D; Stronach, E; Gabra, H; Ghaem-Maghami, S; Brown, R				Chapman-Rothe, N.; Curry, E.; Zeller, C.; Liber, D.; Stronach, E.; Gabra, H.; Ghaem-Maghami, S.; Brown, R.			Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells	ONCOGENE			English	Article						bivalent genes; ChIPseq; tumor sustaining cells; chemo-resistant cells; ovarian cancer	EMBRYONIC STEM-CELLS; MANAGEMENT; POLYCOMB; CHIP; IDENTIFICATION; CHEMOTHERAPY; STRATEGIES; PATHWAY; GENOME; MEMORY	In embryonic stem (ES) cells, bivalent chromatin domains containing H3K4me3 and H3K27me3 marks silence developmental genes, while keeping them poised for activation following differentiation. We have identified gene sets associated with H3K27me3 and H3K4me3 marks at transcription start sites in a high-grade ovarian serous tumour and examined their association with epigenetic silencing and malignant progression. This revealed novel silenced bivalent marked genes, not described previously for ES cells, which are significantly enriched for the PI3K (P < 10(-7)) and TGF-beta signalling pathways (P < 10(-5)). We matched histone marked gene sets to gene expression sets of eight normal fallopian tubes and 499 high-grade serous malignant ovarian samples. This revealed a significant decrease in gene expression for the H3K27me3 and bivalent gene sets in malignant tissue. We then correlated H3K27me3 and bivalent gene sets to gene expression data of ovarian tumour 'stem cell-like' sustaining cells versus non-sustaining cells. This showed a significantly lower expression for the H3K27me3 and bivalent gene sets in the tumour-sustaining cells. Similarly, comparison of matched chemo-sensitive and chemo-resistant ovarian cell lines showed a significantly lower expression of H3K27me3/bivalent marked genes in the chemo-resistant compared with the chemo-sensitive cell line. Our analysis supports the hypothesis that bivalent marks are associated with epigenetic silencing in ovarian cancer. However it also suggests that additional tumour specific bivalent marks, to those known in ES cells, are present in tumours and may potentially influence the subsequent development of drug resistance and tumour progression.	[Chapman-Rothe, N.; Zeller, C.; Liber, D.; Ghaem-Maghami, S.; Brown, R.] Univ London Imperial Coll Sci Technol & Med, Dept Surg & Canc, Epigenet Unit, London W12 0NN, England; [Curry, E.; Liber, D.; Stronach, E.; Gabra, H.; Brown, R.] Univ London Imperial Coll Sci Technol & Med, Ovarian Canc Act Res Ctr, London W12 0NN, England	Imperial College London; Imperial College London	Brown, R (corresponding author), Univ London Imperial Coll Sci Technol & Med, IRDB 4th Floor,Hammersmith Hosp Campus,Cane Rd, London W12 0NN, England.	b.brown@imperial.ac.uk		Curry, Edward/0000-0002-5603-6956; Ghaem-Maghami, Sadaf/0000-0002-7369-5080; Gabra, Hani/0000-0002-3322-4399; Brown, Robert/0000-0001-7960-5755	Ovarian Cancer Action; Cancer Research UK; Imperial Experimental Cancer Research and Biomedical Research Centres; Cancer Research UK [13086] Funding Source: researchfish; Ovarian Cancer Action [OCA3] Funding Source: researchfish	Ovarian Cancer Action(Ovarian Cancer Action); Cancer Research UK(Cancer Research UK); Imperial Experimental Cancer Research and Biomedical Research Centres; Cancer Research UK(Cancer Research UK); Ovarian Cancer Action(Ovarian Cancer Action)	This work was supported by funding from Ovarian Cancer Action; and Cancer Research UK; as well as the Imperial Experimental Cancer Research and Biomedical Research Centres. We are grateful for help from the Gynaecological Oncology team at Hammersmith Hospital and members of the Ovarian Cancer Action Research Centre, in particular Elham Shamsaei, Nona Rama, and Kay Dawson from Dept Pathology. We thank Prof Edison T Liu, Genome Institute of Singapore, and the Agency for Science Technology and Research of Singapore for supporting the microarray expression data on the ovarian tumour and benign samples. Gene expression data generated by The Cancer Genome Atlas (TCGA) Pilot Project established by the NCI and NHGRI were used in the study.	Agarwal R, 2003, NAT REV CANCER, V3, P502, DOI 10.1038/nrc1123; Aletti GD, 2007, MAYO CLIN PROC, V82, P751; Bell D, 2011, NATURE, V474, P609, DOI 10.1038/nature10166; Berkenblit A, 2005, J REPROD MED, V50, P426; Bernstein BE, 2006, CELL, V125, P315, DOI 10.1016/j.cell.2006.02.041; Ho JWK, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-134; Hu L, 2010, BRIT J CANCER, V102, P1276, DOI 10.1038/sj.bjc.6605626; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Irizarry RA, 2009, STAT METHODS MED RES, V18, P565, DOI 10.1177/0962280209351908; LANGDON SP, 1988, CANCER RES, V48, P6166; Langmead B, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r25; Lee TI, 2006, CELL, V125, P301, DOI 10.1016/j.cell.2006.02.043; Lu CH, 2010, CANCER CELL, V18, P185, DOI 10.1016/j.ccr.2010.06.016; Matsumura N, 2011, GENOME RES, V21, P74, DOI 10.1101/gr.108803.110; Meng Q, 2006, CELL SIGNAL, V18, P2262, DOI 10.1016/j.cellsig.2006.05.019; Nelson JD, 2006, NAT PROTOC, V1, P179, DOI 10.1038/nprot.2006.27; Ohm JE, 2007, NAT GENET, V39, P237, DOI 10.1038/ng1972; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Rizzo S, 2011, MOL CANCER THER, V10, P325, DOI 10.1158/1535-7163.MCT-10-0788; Schwartz YB, 2007, NAT REV GENET, V8, P9, DOI 10.1038/nrg1981; Smyth G.K., 2004, STAT APPL GENET MOL, V3, P3, DOI [10.2202/1544-6115.1027, DOI 10.2202/1544-6115.1027]; Stronach EA, 2011, CANCER RES, V71, P4412, DOI 10.1158/0008-5472.CAN-10-4111; Szotek PP, 2006, P NATL ACAD SCI USA, V103, P11154, DOI 10.1073/pnas.0603672103; Thomas PD, 2006, NUCLEIC ACIDS RES, V34, pW645, DOI 10.1093/nar/gkl229; Tothill RW, 2008, CLIN CANCER RES, V14, P5198, DOI 10.1158/1078-0432.CCR-08-0196; Widschwendter M, 2007, NAT GENET, V39, P157, DOI 10.1038/ng1941; Wu D, 2010, BIOINFORMATICS, V26, P2176, DOI 10.1093/bioinformatics/btq401; Zang CZ, 2009, BIOINFORMATICS, V25, P1952, DOI 10.1093/bioinformatics/btp340; Zeller C, 2012, ONCOGENE, V31, P4567, DOI 10.1038/onc.2011.611; Zhang HY, 2009, EUR J OBSTET GYN R B, V146, P81, DOI 10.1016/j.ejogrb.2009.04.035; Zhang S, 2008, CANCER RES, V68, P4311, DOI 10.1158/0008-5472.CAN-08-0364; Zhao XD, 2007, CELL STEM CELL, V1, P286, DOI 10.1016/j.stem.2007.08.004	32	55	57	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2013	32	38					4586	4592		10.1038/onc.2012.477	http://dx.doi.org/10.1038/onc.2012.477			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223SW	23128397				2022-12-28	WOS:000324831300015
J	Duran, RV; MacKenzie, ED; Boulahbel, H; Frezza, C; Heiserich, L; Tardito, S; Bussolati, O; Rocha, S; Hall, MN; Gottlieb, E				Duran, R. V.; MacKenzie, E. D.; Boulahbel, H.; Frezza, C.; Heiserich, L.; Tardito, S.; Bussolati, O.; Rocha, S.; Hall, M. N.; Gottlieb, E.			HIF-independent role of prolyl hydroxylases in the cellular response to amino acids	ONCOGENE			English	Article						prolyl hydroxylases; PHD; alpha-ketoglutarate; amino acids; HIF; mTOR	FISSION YEAST; HYPOXIA; GROWTH; MTOR; 4-HYDROXYLASES; DEFICIENCY; EXPRESSION; AUTOPHAGY; PATHWAY; FAMILY	Hypoxia-inducible factor (HIF) prolyl hydroxylases (PHDs) are alpha-ketoglutarate (alpha KG)-dependent dioxygenases that function as cellular oxygen sensors. However, PHD activity also depends on factors other than oxygen, especially aKG, a key metabolic compound closely linked to amino-acid metabolism. We examined the connection between amino-acid availability and PHD activity. We found that amino-acid starvation leads to alpha KG depletion and to PHD inactivation but not to HIF stabilization. Furthermore, pharmacologic or genetic inhibition of PHDs induced autophagy and prevented mammalian target of rapamycin complex 1 (mTORC1) activation by amino acids in a HIF-independent manner. Therefore, PHDs sense not only oxygen but also respond to amino acids, constituting a broad intracellular nutrient-sensing network.	[Duran, R. V.; MacKenzie, E. D.; Boulahbel, H.; Frezza, C.; Heiserich, L.; Tardito, S.; Gottlieb, E.] Beatson Inst Canc Res, Canc Res UK, Apoptosis & Tumour Metab Lab, Glasgow G61 1BD, Lanark, Scotland; [Duran, R. V.; Hall, M. N.] Univ Basel, Biozentrum, Basel, Switzerland; [Tardito, S.; Bussolati, O.] Univ Parma, Dept Expt Med, Unit Gen & Clin Pathol, I-43100 Parma, Italy; [Rocha, S.] Univ Dundee, Coll Life Sci, Wellcome Trust Ctr Gene Regulat & Express, Dundee, Scotland	Beatson Institute; Cancer Research UK; University of Basel; University of Parma; University of Dundee	Gottlieb, E (corresponding author), Beatson Inst Canc Res, Canc Res UK, Apoptosis & Tumour Metab Lab, Switchback Rd, Glasgow G61 1BD, Lanark, Scotland.	e.gottlieb@beatson.gla.ac.uk	Frezza, Christian/G-2174-2010; Tardito, Saverio/AAJ-7727-2020; Bussolati, Ovidio/B-7589-2013; Gottlieb, Eyal/G-6450-2010; Duran, Raul V./E-4764-2011	Frezza, Christian/0000-0002-3293-7397; Tardito, Saverio/0000-0002-5294-8683; Bussolati, Ovidio/0000-0002-4301-2939; Gottlieb, Eyal/0000-0002-9770-0956; Duran, Raul V./0000-0002-2249-9215; Hall, Michael N/0000-0002-2998-0757	Cancer Research UK; Swiss National Science Foundation; Cancer Research UK [12918] Funding Source: researchfish	Cancer Research UK(Cancer Research UK); Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Cancer Research UK(Cancer Research UK)	PHD2 and PHD3 antibodies were provided by Kevin Gatter. We thank David Sabatini and Fuyuhiko Tamanoi for kindly providing Rag and Rheb plasmids. We thank David Kwiatkowski for TSC2<SUP>+/+</SUP> and TSC2<SUP>-/-</SUP> mouse embryonic fibroblasts. This work was supported by the Cancer Research UK and by the Swiss National Science Foundation.	Aragones J, 2008, NAT GENET, V40, P170, DOI 10.1038/ng.2007.62; Avruch J, 2009, AM J PHYSIOL-ENDOC M, V296, pE592, DOI 10.1152/ajpendo.90645.2008; Bentzinger CF, 2008, CELL METAB, V8, P411, DOI 10.1016/j.cmet.2008.10.002; Berra E, 2006, EMBO REP, V7, P41, DOI 10.1038/sj.embor.7400598; Brugarolas J, 2004, GENE DEV, V18, P2893, DOI 10.1101/gad.1256804; Cummins EP, 2006, P NATL ACAD SCI USA, V103, P18154, DOI 10.1073/pnas.0602235103; DalL'Asta V, 1999, AM J PHYSIOL-CELL PH, V276, pC865, DOI 10.1152/ajpcell.1999.276.4.C865; Duran RV, 2012, MOL CELL, V47, P349, DOI 10.1016/j.molcel.2012.05.043; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Frei C, 2004, DEV CELL, V6, P241, DOI 10.1016/S1534-5807(03)00409-X; Hirsila M, 2003, J BIOL CHEM, V278, P30772, DOI 10.1074/jbc.M304982200; Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; Hughes BT, 2008, EMBO J, V27, P1491, DOI 10.1038/emboj.2008.83; Kaelin WG, 2005, ANNU REV BIOCHEM, V74, P115, DOI 10.1146/annurev.biochem.74.082803.133142; Kaelin WG, 2008, MOL CELL, V30, P393, DOI 10.1016/j.molcel.2008.04.009; Keskiaho K, 2007, PLANT CELL, V19, P256, DOI 10.1105/tpc.106.042739; Kim J, 2011, ANNU REV BIOCHEM, V80, P1001, DOI 10.1146/annurev-biochem-062209-094414; MacKenzie ED, 2007, MOL CELL BIOL, V27, P3282, DOI 10.1128/MCB.01927-06; Mihaylova MM, 2011, NAT CELL BIOL, V13, P1016, DOI 10.1038/ncb2329; Nicklin P, 2009, CELL, V136, P521, DOI 10.1016/j.cell.2008.11.044; Pan Y, 2007, MOL CELL BIOL, V27, P912, DOI 10.1128/MCB.01223-06; Rocha S, 2003, MOL CELL BIOL, V23, P4713, DOI 10.1128/MCB.23.13.4713-4727.2003; Sancak Y, 2008, SCIENCE, V320, P1496, DOI 10.1126/science.1157535; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Schofield CJ, 2004, NAT REV MOL CELL BIO, V5, P343, DOI 10.1038/nrm1366; Scott RC, 2004, DEV CELL, V7, P167, DOI 10.1016/j.devcel.2004.07.009; Selak MA, 2005, CANCER CELL, V7, P77, DOI 10.1016/j.ccr.2004.11.022; SENER A, 1980, NATURE, V288, P187, DOI 10.1038/288187a0; Taylor MS, 2001, GENE, V275, P125, DOI 10.1016/S0378-1119(01)00633-3; Tennant DA, 2009, ONCOGENE, V28, P4009, DOI 10.1038/onc.2009.250; Urano J, 2007, P NATL ACAD SCI USA, V104, P3514, DOI 10.1073/pnas.0608510104; West CM, 2007, DEVELOPMENT, V134, P3349, DOI 10.1242/dev.000893; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yuneva M, 2007, J CELL BIOL, V178, P93, DOI 10.1083/jcb.200703099; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000; Zhong H, 2000, CANCER RES, V60, P1541	36	80	84	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2013	32	38					4549	4556		10.1038/onc.2012.465	http://dx.doi.org/10.1038/onc.2012.465			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223SW	23085753	hybrid, Green Published, Green Accepted			2022-12-28	WOS:000324831300010
J	Skeen, VR; Collard, TJ; Southern, SL; Greenhough, A; Hague, A; Townsend, PA; Paraskeva, C; Williams, AC				Skeen, V. R.; Collard, T. J.; Southern, S. L.; Greenhough, A.; Hague, A.; Townsend, P. A.; Paraskeva, C.; Williams, A. C.			BAG-1 suppresses expression of the key regulatory cytokine transforming growth factor beta (TGF-beta 1) in colorectal tumour cells	ONCOGENE			English	Article						BAG-1; TGF-beta 1; colorectal cancer; adenoma; transcriptional repression	HUMAN COLONIC ADENOMA; NF-KAPPA-B; TGF-BETA; GLUCOCORTICOID-RECEPTOR; GENE-EXPRESSION; IN-VIVO; PROGRESSION; INHIBITION; ISOFORMS; BUTYRATE	As colorectal cancer remains the second highest cause of cancer-related deaths in much of the industrialised world, identifying novel strategies to prevent colorectal tumour development remains an important challenge. BAG-1 is a multi-functional protein, the expression of which is up-regulated at relatively early stages in colorectal tumorigenesis. Importantly, BAG-1 is thought to enhance colorectal tumour progression through promoting tumour cell survival. Here, we report for the first time a novel role for BAG-1, establishing it as a suppressor of transforming growth factor beta (TGF-beta 1) expression in colorectal tumour cells. Microarray analysis first highlighted the possibility that BAG-1 may regulate TGF-beta 1 expression, a key cytokine in normal colonic tissue homoeostasis. Q-RT-PCR and ELISA demonstrated TGFB1 mRNA and protein expression to be significantly increased when BAG1 levels were reduced by small interfering RNA; additionally, induction of BAG-1L caused suppression of TGFB1 mRNA in colorectal tumour cells. Using reporter and chromatin immunoprecipitation assays, a direct association of BAG-1 with the TGFB1 gene regulatory region was identified. Immunohistochemistry and Weiser fraction data indicated that the levels of BAG-1 and TGF-beta 1 are inversely correlated in the normal colonic epithelium in vivo, consistent with a role for BAG-1-mediated repression of TGF-beta 1 production. In vitro studies showed that the change in TGF-beta 1 production following manipulation of BAG-1 is functionally relevant; through induction of anchorage-independent growth in TGF-beta 1-dependent normal rat kidney fibroblasts and regulation of SMAD2 phosphorylation in TGF-beta 1-sensitive adenoma cells. Taken together, this study identifies the anti-apoptotic protein BAG-1 as a suppressor of the inhibitory growth factor TGF-beta 1, suggesting that high expression of BAG-1 can impact on a number of the hallmarks of cancer, of potential importance in promoting the early stages of colorectal tumorigenesis. Establishing BAG-1 as a repressor of TGF-beta 1 has important biological implications, and highlights a new role for BAG-1 in colorectal tumorigenesis.	[Skeen, V. R.; Collard, T. J.; Southern, S. L.; Greenhough, A.; Paraskeva, C.; Williams, A. C.] Univ Bristol, Sch Cellular & Mol Med, Bristol BS8 1TD, Avon, England; [Hague, A.] Univ Bristol, Sch Oral & Dent Sci, Bristol BS8 1TD, Avon, England; [Townsend, P. A.] Univ Southampton, Southampton Gen Hosp, Sch Med, Southampton, Hants, England	University of Bristol; University of Bristol; University of Southampton	Williams, AC (corresponding author), Univ Bristol, Sch Cellular & Mol Med, Med Sci Bldg,Univ Walk, Bristol BS8 1TD, Avon, England.	PATownsend@soton.ac.uk; Ann.C.Williams@bristol.ac.uk	Greenhough, Alexander/J-9308-2012; Townsend, Paul/AAF-8234-2020; Greenhough, Alexander/Y-6728-2019	Greenhough, Alexander/0000-0002-8306-811X; Greenhough, Alexander/0000-0002-8306-811X; Townsend, Paul/0000-0001-8956-9508; Williams, Ann/0000-0002-6009-7137	Cancer Research UK programme grant; Citrina Foundation; John James Bristol Foundation; CORE; Cancer Research UK [11975] Funding Source: researchfish	Cancer Research UK programme grant(Cancer Research UK); Citrina Foundation; John James Bristol Foundation; CORE(Luxembourg National Research Fund); Cancer Research UK(Cancer Research UK)	This work was funded by a Cancer Research UK programme grant, the Citrina Foundation, CORE and by the John James Bristol Foundation. We thank members of the CP group for useful discussion.	Arhel NJ, 2003, INT J CANCER, V106, P364, DOI 10.1002/ijc.11257; AVERY A, 1993, BRIT J CANCER, V68, P137, DOI 10.1038/bjc.1993.301; Babyatsky MW, 1996, GASTROENTEROLOGY, V110, P798; BARNARD JA, 1993, GASTROENTEROLOGY, V105, P67, DOI 10.1016/0016-5085(93)90011-Z; BARNARD JA, 1993, CELL GROWTH DIFFER, V4, P495; Barnes JD, 2005, APOPTOSIS, V10, P301, DOI 10.1007/s10495-005-0804-8; Brimmell M, 1999, BRIT J CANCER, V81, P1042, DOI 10.1038/sj.bjc.6690805; Clemo NK, 2008, CARCINOGENESIS, V29, P849, DOI 10.1093/carcin/bgn004; Cutress RI, 2003, ONCOGENE, V22, P4973, DOI 10.1038/sj.onc.1206688; DATTO MB, 1995, P NATL ACAD SCI USA, V92, P5545, DOI 10.1073/pnas.92.12.5545; FRIEDMAN E, 1995, CANCER EPIDEM BIOMAR, V4, P549; Gehring U, 2009, INT J MOL SCI, V10, P906, DOI 10.3390/ijms10030906; Hague A, 1997, GASTROENTEROLOGY, V112, P1036, DOI 10.1053/gast.1997.v112.agast971036; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Heldin CH, 2009, CURR OPIN CELL BIOL, V21, P166, DOI 10.1016/j.ceb.2009.01.021; Hong W, 2008, J MOL BIOL, V384, P22, DOI 10.1016/j.jmb.2008.09.010; Hong W, 2009, FEBS LETT, V583, P2451, DOI 10.1016/j.febslet.2009.07.010; Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853; Kaidi A, 2007, NAT CELL BIOL, V9, P210, DOI 10.1038/ncb1534; Kikuchi R, 2002, BRIT J CANCER, V87, P1136, DOI 10.1038/sj.bjc.6600579; KIM SJ, 1989, J BIOL CHEM, V264, P402; Lampropoulos P, 2012, CANCER LETT, V314, P1, DOI 10.1016/j.canlet.2011.09.041; Lee KY, 2006, J IMMUNOL, V176, P603, DOI 10.4049/jimmunol.176.1.603; MANNING AM, 1991, ONCOGENE, V6, P1471; Mariadason JM, 2005, GASTROENTEROLOGY, V128, P1081, DOI 10.1053/j.gastro.2005.01.054; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Moustakas A, 2009, DEVELOPMENT, V136, P3699, DOI 10.1242/dev.030338; MULDER KM, 1988, BIOCHEM BIOPH RES CO, V150, P711, DOI 10.1016/0006-291X(88)90449-4; Myant K, 2011, EXP CELL RES, V317, P2725, DOI 10.1016/j.yexcr.2011.08.001; Niyaz Y, 2001, J CELL SCI, V114, P1839; Packham G, 1997, BIOCHEM J, V328, P807, DOI 10.1042/bj3280807; PARASKEVA C, 1989, CANCER RES, V49, P1282; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Picon A, 1998, CANCER EPIDEM BIOMAR, V7, P497; POLYAK K, 1994, GENE DEV, V8, P9, DOI 10.1101/gad.8.1.9; Sharp Adam, 2004, Expert Reviews in Molecular Medicine, V6, P1, DOI 10.1017/S1462399404007537; Sharp A, 2009, FEBS LETT, V583, P3405, DOI 10.1016/j.febslet.2009.09.047; Sharp A, 2009, J PHARMACOL EXP THER, V331, P680, DOI 10.1124/jpet.109.153601; Shatkina L, 2003, MOL CELL BIOL, V23, P7189, DOI 10.1128/MCB.23.20.7189-7197.2003; Siegel PM, 2003, NAT REV CANCER, V3, P807, DOI 10.1038/nrc1208; Skeen VR, 2012, CURR PHARM DESIGN, V18, P3874; Smartt HJM, 2012, GUT, V61, P1306, DOI 10.1136/gutjnl-2011-300817; Strathdee CA, 1999, GENE, V229, P21, DOI 10.1016/S0378-1119(99)00045-1; Takayama S, 1998, CANCER RES, V58, P3116; Townsend PA, 2005, INT J BIOCHEM CELL B, V37, P251, DOI 10.1016/j.biocel.2004.03.016; Tsushima H, 1996, GASTROENTEROLOGY, V110, P375, DOI 10.1053/gast.1996.v110.pm8566583; WANG G, 1992, EXP CELL RES, V198, P27, DOI 10.1016/0014-4827(92)90144-W; Wang XH, 2009, BRIT J CANCER, V100, P1347, DOI 10.1038/sj.bjc.6604985; WILLIAMS AC, 1993, ONCOGENE, V8, P3063; Xu WQ, 2007, EXP MOL PATHOL, V82, P284, DOI 10.1016/j.yexmp.2006.10.011; Zeiner M, 1999, P NATL ACAD SCI USA, V96, P10194, DOI 10.1073/pnas.96.18.10194; Zhang XY, 2011, MOL CELL BIOL, V31, P5037, DOI 10.1128/MCB.06297-11; Zhang YE, 2009, CELL RES, V19, P128, DOI 10.1038/cr.2008.328	53	13	15	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 19	2013	32	38					4490	4499		10.1038/onc.2012.480	http://dx.doi.org/10.1038/onc.2012.480			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223SW	23108401	Green Accepted			2022-12-28	WOS:000324831300004
J	Kao, SH; Wang, WL; Chen, CY; Chang, YL; Wu, YY; Wang, YT; Wang, SP; Nesvizhskii, AI; Chen, YJ; Hong, TM; Yang, PC				Kao, S-H; Wang, W-L; Chen, C-Y; Chang, Y-L; Wu, Y-Y; Wang, Y-T; Wang, S-P; Nesvizhskii, A. I.; Chen, Y-J; Hong, T-M; Yang, P-C			GSK3 beta controls epithelial-mesenchymal transition and tumor metastasis by CHIP-mediated degradation of Slug	ONCOGENE			English	Article						GSK3 beta; Slug; CHIP; post-translational modification	UBIQUITIN LIGASE CHIP; GLYCOGEN-SYNTHASE KINASE-3; E-CADHERIN; TRANSCRIPTION FACTORS; CANCER; PROTEIN; PHOSPHORYLATION; CHAPERONE; INHIBITION; EXPRESSION	Glycogen synthase kinase 3 beta (GSK3 beta) is highly inactivated in epithelial cancers and is known to inhibit tumor migration and invasion. The zinc-finger-containing transcriptional repressor, Slug, represses E-cadherin transcription and enhances epithelial mesenchymal transition (EMT). In this study, we find that the GSK3 beta-pSer9 level is associated with the expression of Slug in non-small cell lung cancer. GSK3 beta-mediated phosphorylation of Slug facilitates Slug protein turnover. Proteomic analysis reveals that the carboxyl terminus of Hsc70-interacting protein (CHIP) interacts with wild-type Slug (wtSlug). Knockdown of CHIP stabilizes the wtSlug protein and reduces Slug ubiquitylation and degradation. In contrast, nonphosphorylatable Slug-4SA is not degraded by CHIP. The accumulation of nondegradable Slug may further lead to the repression of E-cadherin expression and promote cancer cell migration, invasion and metastasis. Our findings provide evidence of a de novo GSK3 beta-CHIP-Slug pathway that may be involved in the progression of metastasis in lung cancer.	[Kao, S-H; Yang, P-C] Natl Taiwan Univ, Inst Mol Med, Taipei 100, Taiwan; [Wang, W-L; Chen, C-Y; Wu, Y-Y; Wang, S-P; Yang, P-C] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan; [Chen, C-Y] Chang Gung Univ Sci & Technol, Dept Nutr & Hlth Sci, Taoyuan, Taiwan; [Chang, Y-L] Natl Taiwan Univ, Dept Pathol, Taipei 100, Taiwan; [Chang, Y-L] Natl Taiwan Univ, Grad Inst Pathol, Taipei 100, Taiwan; [Wu, Y-Y; Hong, T-M] Natl Cheng Kung Univ, Grad Inst Clin Med, Taipei, Taiwan; [Wang, Y-T; Chen, Y-J] Acad Sinica, Chem Biol & Mol Biophys Program, Taiwan Int Grad Program, Taipei 115, Taiwan; [Wang, Y-T; Chen, Y-J] Acad Sinica, Inst Chem, Taipei, Taiwan; [Wang, Y-T] Natl Taiwan Univ, Inst Biochem Sci, Coll Life Sci, Taipei 100, Taiwan; [Wang, S-P] Rockefeller Univ, Lab Biochem & Mol Biol, New York, NY 10021 USA; [Nesvizhskii, A. I.] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; [Nesvizhskii, A. I.] Univ Michigan, Dept Computat Med & Bioinformat, Ann Arbor, MI 48109 USA; [Yang, P-C] Natl Taiwan Univ Hosp, Dept Internal Med, Taipei 100, Taiwan; [Yang, P-C] Natl Taiwan Univ, Coll Med, NTU Ctr Genom Med, Taipei 100, Taiwan	National Taiwan University; Academia Sinica - Taiwan; Chang Gung University of Science & Technology; National Taiwan University; National Taiwan University; National Cheng Kung University; Academia Sinica - Taiwan; Academia Sinica - Taiwan; National Taiwan University; Rockefeller University; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; National Taiwan University; National Taiwan University Hospital; National Taiwan University	Hong, TM (corresponding author), Natl Cheng Kung Univ, Coll Med, Inst Clin Med, 138 Sheng Li Rd, Tainan 704, Taiwan.	tmhong@mail.ncku.edu.tw; pcyang@ntu.edu.tw	Wang, Shu-Ping/S-4379-2018; Nesvizhskii, Alexey/A-5410-2012; Chen, Yu-Ju/E-9481-2015	Wang, Shu-Ping/0000-0002-5895-1269; Nesvizhskii, Alexey/0000-0002-2806-7819; Chen, Yu-Ju/0000-0002-3178-6697; CHANG, YIH-LEONG/0000-0001-5309-0554; YANG, PAN-CHYR/0000-0001-6330-6048	National Science Council, Taiwan [NSC99-2628-B-006-031-MY3 NSC101-2325-B-006-018, NSC100-2321-8-002-071, NSC101-2321-B002-068]; National Taiwan University, Taiwan [10R71601-2]; National Institute of Health, USA [R01-GM-094231]; Human Frontier Science Program long-term fellowship; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM094231] Funding Source: NIH RePORTER	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); National Taiwan University, Taiwan(National Taiwan University); National Institute of Health, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Human Frontier Science Program long-term fellowship(Human Frontier Science Program); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	We thank MC Hung (Department of Molecular and Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, USA) for providing the plasmids for GSK3 beta, and Wen-Lung Wang, Yi-Ying Wu, Chi-Yuan Chen for technical assistance. This work was supported by grants from the National Science Council, Taiwan (NSC99-2628-B-006-031-MY3 NSC101-2325-B-006-018, NSC100-2321-8-002-071 and NSC101-2321-B002-068), National Taiwan University, Taiwan (10R71601-2), and National Institute of Health, USA (R01-GM-094231, to AIN). SP Wang is supported by a Human Frontier Science Program long-term fellowship. shRNA constructs were obtained from the National RNAi Core Facility at the Institute of Molecular Biology/Genomic Research Center, Academia Sinica, Taipei, Taiwan.	Ahmed SF, 2012, J BIOL CHEM, V287, P15996, DOI 10.1074/jbc.M111.321083; Al-Mulla F, 2011, CANCER RES, V71, P1334, DOI 10.1158/0008-5472.CAN-10-3102; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Buss H, 2004, J BIOL CHEM, V279, P49571, DOI 10.1074/jbc.C400442200; Byles V, 2012, ONCOGENE, V31, P4619, DOI 10.1038/onc.2011.612; Cheng JC, PLOS ONE, V7; Choi H, 2011, NAT METHODS, V8, P70, DOI 10.1038/NMETH.1541; Ciani L, 2005, NAT REV NEUROSCI, V6, P351, DOI 10.1038/nrn1665; Come C, 2004, J MAMMARY GLAND BIOL, V9, P183, DOI 10.1023/B:JOMG.0000037161.91969.de; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; DEGROOT RP, 1993, ONCOGENE, V8, P841; Dickey CA, 2006, J NEUROSCI, V26, P6985, DOI 10.1523/JNEUROSCI.0746-06.2006; Ding QQ, 2007, MOL CELL BIOL, V27, P4006, DOI 10.1128/MCB.00620-06; Ellerbroek SM, 2001, CANCER RES, V61, P1855; Esser C, 2005, J BIOL CHEM, V280, P27443, DOI 10.1074/jbc.M501574200; Esser C, 2004, BBA-MOL CELL RES, V1695, P171, DOI 10.1016/j.bbamcr.2004.09.020; Farago M, 2005, CANCER RES, V65, P5792, DOI 10.1158/0008-5472.CAN-05-1021; Friedl P, 2011, CELL, V147, P992, DOI 10.1016/j.cell.2011.11.016; G-Amlak M, 2002, BIOCHEM BIOPH RES CO, V297, P760, DOI 10.1016/S0006-291X(02)02278-7; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hajra KM, 2002, CANCER RES, V62, P1613; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714; Inuzuka H, 2011, NATURE, V471, P104, DOI 10.1038/nature09732; John JK, 2012, J INVEST DERMATOL, V132, P2818, DOI 10.1038/jid.2012.237; Kajiro M, 2009, NAT CELL BIOL, V11, P312, DOI 10.1038/ncb1839; Kang T, 2008, CANCER CELL, V13, P36, DOI 10.1016/j.ccr.2007.12.002; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Karrasch T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026340; Katoh Y, 2009, CURR MOL MED, V9, P873, DOI 10.2174/156652409789105570; Kim JY, 2012, FEBS J, V279, P2929, DOI 10.1111/j.1742-4658.2012.08674.x; Lee HY, 2005, CLIN CANCER RES, V11, P6065, DOI 10.1158/1078-0432.CCR-05-0009; Leis H, 2002, MOL CARCINOGEN, V35, P180, DOI 10.1002/mc.10087; Luo J, 2009, CANCER LETT, V273, P194, DOI 10.1016/j.canlet.2008.05.045; Maurer U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009; McDonough H, 2003, CELL STRESS CHAPERON, V8, P303, DOI 10.1379/1466-1268(2003)008<0303:CALBTC>2.0.CO;2; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Mishra R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-144; Onder TT, 2008, CANCER RES, V68, P3645, DOI 10.1158/0008-5472.CAN-07-2938; Patel R, 2013, J CLIN INVEST, V123, P1157, DOI 10.1172/JCI63672; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Rees I, 2006, BBA-PROTEINS PROTEOM, V1764, P1073, DOI 10.1016/j.bbapap.2006.03.013; Schmalhofer O, 2009, CANCER METAST REV, V28, P151, DOI 10.1007/s10555-008-9179-y; Shih JY, 2011, CARCINOGENESIS, V32, P1299, DOI 10.1093/carcin/bgr110; Shih JY, 2005, CLIN CANCER RES, V11, P8070, DOI 10.1158/1078-0432.CCR-05-0687; Shimura H, 2004, J BIOL CHEM, V279, P4869, DOI 10.1074/jbc.M305838200; Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469; Tateishi Y, 2004, EMBO J, V23, P4813, DOI 10.1038/sj.emboj.7600472; Taylor CT, 2000, P NATL ACAD SCI USA, V97, P12091, DOI 10.1073/pnas.220211797; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thornton TM, 2008, SCIENCE, V320, P667, DOI 10.1126/science.1156037; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Wang SY, 2013, GUT, V62, P496, DOI 10.1136/gutjnl-2011-301522; Wang SP, 2009, NAT CELL BIOL, V11, P694, DOI 10.1038/ncb1875; Winter M, 2008, NAT CELL BIOL, V10, P812, DOI 10.1038/ncb1743; Wu ZQ, 2012, P NATL ACAD SCI USA, V109, P16654, DOI 10.1073/pnas.1205822109; Xu C, 2009, CELL CYCLE, V8, P4032, DOI 10.4161/cc.8.24.10111; Xu WP, 2002, P NATL ACAD SCI USA, V99, P12847, DOI 10.1073/pnas.202365899; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yang L, 2007, CANCER RES, V67, P5587, DOI 10.1158/0008-5472.CAN-06-2287; Ye Y, 2010, ONCOGENE, V29, P1451, DOI 10.1038/onc.2009.433; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Zheng HC, 2007, ANTICANCER RES, V27, P3561; Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173	68	92	94	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2014	33	24					3172	3182		10.1038/onc.2013.279	http://dx.doi.org/10.1038/onc.2013.279			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK4QU	23851495	Green Accepted			2022-12-28	WOS:000338410000010
J	Darr, J; Klochendler, A; Isaac, S; Eden, A				Darr, J.; Klochendler, A.; Isaac, S.; Eden, A.			Loss of IGFBP7 expression and persistent AKT activation contribute to SMARCB1/Snf5-mediated tumorigenesis	ONCOGENE			English	Article						SMARCB1/Snf5; Swi/Snf; malignant rhabdoid tumors	TUMOR-SUPPRESSOR GENE; CHROMATIN REMODELING COMPLEX; FACTOR BINDING-PROTEINS; CELL-CYCLE ARREST; GROWTH-FACTOR; SWI/SNF COMPLEX; RHABDOID TUMORS; BREAST-CANCER; INSULIN; APOPTOSIS	SMARCB1 (Snf5/Ini1/Baf47) is a potent tumor suppressor, the loss of which serves as the diagnostic feature in malignant rhabdoid tumors (MRT) and atypical teratoid/rhabdoid tumors (AT/RT), two highly aggressive forms of pediatric neoplasms. SMARCB1 is a core subunit of Swi/Snf chromatin remodeling complexes, and loss of SMARCB1 or other subunits of these complexes has been observed in a variety of tumor types. Here, we restore Smarcb1 expression in cells derived from Smarcb1-deficient tumors, which developed in Smarcb1 heterozygous p53(-/-) mice. We find that while re-introduction of Smarcb1 does not induce growth arrest, it restores sensitivity to programmed cell death and completely abolishes the ability of the tumor cells to grow as xenografts. We describe persistent activation of AKT signaling in Smarcb1-deficient cells, which stems from PI3K (phosphatidylinositol 3'-kinase)-mediated signaling and which contributes to the survival and proliferation of the tumor cells. We further demonstrate that inhibition of AKT is effective in preventing proliferation of Smarcb1-deficient cells in vitro and inhibits the development of xenografted tumors in vivo. Profiling Smarcb1-dependent gene expression, we find genes that require Smarcb1 and Swi/Snf for their expression to be enriched for extracellular matrix and cell adhesion functions. We find that Smarcb1 is required for transcriptional activation of Igfbp7, a member of the insulin-like growth factor-binding proteins family and a tumor suppressor in itself, and show that re-introduction of Igfbp7 alone can hinder tumor development. Our results define a novel mechanism for Smarcb1-mediated tumorigenesis and highlight potential therapeutic targets.	[Darr, J.; Klochendler, A.; Isaac, S.; Eden, A.] Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Cell & Dev Biol, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Eden, A (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Cell & Dev Biol, Edmond J Safra Campus, IL-91904 Jerusalem, Israel.	eden@vms.huji.ac.il		Jonatan, Darr/0000-0002-2992-4448	Israel Cancer Research Fund (ICRF) [2011-3094-PG]; Association for International Cancer Research [AICR 03-109]	Israel Cancer Research Fund (ICRF); Association for International Cancer Research	We thank Dr Ittai Ben-Porath, Professor Eli Keshet and Professor Alex Levitzki for reagents and helpful discussions. This work was funded by the Israel Cancer Research Fund (ICRF, 2011-3094-PG) and by the Association for International Cancer Research (AICR 03-109).	Ae K, 2002, ONCOGENE, V21, P3112, DOI 10.1038/sj.onc.1205414; Aguilar RC, 2005, P NATL ACAD SCI USA, V102, P2679, DOI 10.1073/pnas.0500213102; Ahmed S, 2003, BIOCHEM BIOPH RES CO, V310, P612, DOI 10.1016/j.bbrc.2003.09.058; Arcaro A, 2007, BIOCHEM J, V406, P57, DOI 10.1042/BJ20070309; Barzily-Rokni M, 2011, NUCLEIC ACIDS RES, V39, P1326, DOI 10.1093/nar/gkq994; Beattie J, 2009, BIOCHEM BIOPH RES CO, V381, P572, DOI 10.1016/j.bbrc.2009.02.088; Benatar T, 2012, BREAST CANCER RES TR, V133, P563, DOI 10.1007/s10549-011-1816-4; Betz BL, 2002, ONCOGENE, V21, P5193, DOI 10.1038/sj.onc.1205706; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Burger AM, 2005, EUR J CANCER, V41, P1515, DOI 10.1016/j.ejca.2005.04.023; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Charboneau A, 2006, J CELL PHYSIOL, V209, P422, DOI 10.1002/jcp.20737; Chen D, 2011, CLIN CANCER RES, V17, P6693, DOI 10.1158/1078-0432.CCR-10-2774; Cheng SWG, 1999, NAT GENET, V22, P102, DOI 10.1038/8811; CollettSolberg PF, 1996, ENDOCRIN METAB CLIN, V25, P591, DOI 10.1016/S0889-8529(05)70342-X; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Drobic B, 2010, NUCLEIC ACIDS RES, V38, P3196, DOI 10.1093/nar/gkq030; EUHUS DM, 1986, J SURG ONCOL, V31, P229, DOI 10.1002/jso.2930310402; Evdokimova V, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003184; FIGUEROA JA, 1993, J CELL PHYSIOL, V157, P229, DOI 10.1002/jcp.1041570204; Foster K, 2009, CANCER CHEMOTH PHARM, V63, P783, DOI 10.1007/s00280-008-0796-5; Hendricks KB, 2004, MOL CELL BIOL, V24, P362, DOI 10.1128/MCB.24.1.362-376.2004; Hollmann TJ, 2011, AM J SURG PATHOL, V35, pE47, DOI 10.1097/PAS.0b013e31822b325b; Hooper AT, 2009, CIRC RES, V105, P201, DOI 10.1161/CIRCRESAHA.109.196790; Isakoff MS, 2005, P NATL ACAD SCI USA, V102, P17745, DOI 10.1073/pnas.0509014102; Jagani Z, 2010, NAT MED, V16, P1429, DOI 10.1038/nm.2251; Jozwiak J, 2010, FOLIA NEUROPATHOL, V48, P185; Klochendler-Yeivin A, 2006, MOL CELL BIOL, V26, P2661, DOI 10.1128/MCB.26.7.2661-2674.2006; Klochendler-Yeivin A, 2000, EMBO REP, V1, P500, DOI 10.1093/embo-reports/kvd129; Le Roy C, 2005, NAT REV MOL CELL BIO, V6, P112, DOI 10.1038/nrm1571; Lee RS, 2012, J CLIN INVEST, V122, P2983, DOI 10.1172/JCI64400; Medjkane S, 2004, CANCER RES, V64, P3406, DOI 10.1158/0008-5472.CAN-03-3004; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; MUCHARDT C, 1995, NUCLEIC ACIDS RES, V23, P1127, DOI 10.1093/nar/23.7.1127; Naviaux RK, 1996, J VIROL, V70, P5701, DOI 10.1128/JVI.70.8.5701-5705.1996; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Nocentini S, 2003, CANCER CELL INT, V3, DOI 10.1186/1475-2867-3-11; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; Oruetxebarria I, 2004, J BIOL CHEM, V279, P3807, DOI 10.1074/jbc.M309333200; Pen A, 2011, CANCER BIOL THER, V12, P634, DOI 10.4161/cbt.12.7.17171; Phelan ML, 1999, MOL CELL, V3, P247, DOI 10.1016/S1097-2765(00)80315-9; Reincke BS, 2003, J CELL PHYSIOL, V194, P303, DOI 10.1002/jcp.10201; Reisman DN, 2003, CANCER RES, V63, P560; Roberts CWM, 2002, CANCER CELL, V2, P415, DOI 10.1016/S1535-6108(02)00185-X; Ruvinsky I, 2005, GENE DEV, V19, P2199, DOI 10.1101/gad.351605; Sato Y, 2007, CANCER SCI, V98, P1055, DOI 10.1111/j.1349-7006.2007.00502.x; Smith MJ, 2012, HUM MOL GENET, V21, P5239, DOI 10.1093/hmg/dds370; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tamura K, 2009, EUR J PHARMACOL, V610, P61, DOI 10.1016/j.ejphar.2009.01.045; Tsikitis M, 2005, P NATL ACAD SCI USA, V102, P12129, DOI 10.1073/pnas.0505300102; Varela I, 2011, NATURE, V469, P539, DOI 10.1038/nature09639; Versteege I, 2002, ONCOGENE, V21, P6403, DOI 10.1038/sj.onc.1205841; Versteege I, 1998, NATURE, V394, P203, DOI 10.1038/28212; Vizioli MG, 2010, ONCOGENE, V29, P3835, DOI 10.1038/onc.2010.136; Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032; Wang L, 2005, MOL CELL BIOL, V25, P7953, DOI 10.1128/MCB.25.18.7953-7965.2005; Wang X, 2009, CANCER RES, V69, P8094, DOI 10.1158/0008-5472.CAN-09-0733; Wilson BG, 2011, NAT REV CANCER, V11, P481, DOI 10.1038/nrc3068; Xi QR, 2008, J BIOL CHEM, V283, P1146, DOI 10.1074/jbc.M707479200; Yamanaka Y, 1997, J BIOL CHEM, V272, P30729, DOI 10.1074/jbc.272.49.30729; Zhang M, 2007, J BIOL CHEM, V282, P25708, DOI 10.1074/jbc.M701925200; Zhang ZK, 2002, MOL CELL BIOL, V22, P5975, DOI 10.1128/MCB.22.16.5975-5988.2002	63	24	24	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 5	2014	33	23					3024	3032		10.1038/onc.2013.261	http://dx.doi.org/10.1038/onc.2013.261			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EL	23851500				2022-12-28	WOS:000337232200009
J	Sangar, F; Schreurs, AS; Umana-Diaz, C; Claperon, A; Desbois-Mouthon, C; Calmel, C; Mauger, O; Zaanan, A; Miquel, C; Flejou, JF; Praz, F				Sangar, F.; Schreurs, A-S; Umana-Diaz, C.; Claperon, A.; Desbois-Mouthon, C.; Calmel, C.; Mauger, O.; Zaanan, A.; Miquel, C.; Flejou, J-F; Praz, F.			Involvement of small ArfGAP1 (SMAP1), a novel Arf6-specific GTPase-activating protein, in microsatellite instability oncogenesis	ONCOGENE			English	Article						colorectal cancer; microsatellite instability; small ArfGAP1 (SMAP1); cell invasion; cell cycle; epithelial-to-mesenchymal transition	COLORECTAL CANCERS; MESSENGER-RNA; ARF6; INTERACTS; CLATHRIN; CELLS; REQUIREMENT; ENDOCYTOSIS; MUTATIONS; MIGRATION	Small ArfGAP1 (stromal membrane-associated protein 1, SMAP1), a GTPase-activating protein specific for ADP-ribosylation factor 6 (Arf6), which is a small GTPase acting on membrane trafficking and actin remodeling, is frequently mutated in various tumors displaying microsatellite instability (MSI), notably in MSI colorectal cancers (CRC). Genotyping of 93 MSI CRCs (40 stage II, 32 stage III and 21 stage IV) allowed us to underscore that SMAP1 mutation frequency was inversely correlated with disease stage (P = 0.01). Analysis of 46 cancer cell lines showed that SMAP1 mutations occurred only in MSI tumors, and consisted exclusively in short insertion or deletion in the coding 10-adenine repeat, generating a premature termination codon located downstream the ArfGAP domain. SMAP1 transcript levels were significant decreased (P = 0.006), and truncated SMAP1 protein could not be detected in cells displaying biallelic SMAP1 mutations, owing to its sensitivity to proteasome degradation. To investigate the role of SMAP1 mutations, we used the SMAP1-null HCT116 cell line and we established three isogenic SMAP1-complemented clones. Cell proliferation was first assessed in vivo using subcutaneous xenografts into immunodeficient mice. Tumors developed in all animals regardless of the cell line injected, but tumor volumes were significantly smaller for both SMAP1-complemented clones compared with HCT116 (P < 0.0001, at the time of killing). In vitro, SMAP1 mutations also increased cell clonogenicity (P = 0.02-0.04), cell proliferation (P = 0.008) by shortening the G2/M phase and decreased cell invasiveness (P = 0.03-0.003). In keeping, SMAP1-complemented HCT116 gained several mesenchymal markers (Snail, Slug and vimentin) considered as a hallmark of epithelial-to-mesenchymal transition. These observations are reminiscent of some clinical characteristics of MSI CRCs, notably their larger size and lower rate of metastasis. Our observations suggest that SMAP1 loss-of-function mutations in MSI CRC may contribute to the emerging oncogenic pathway involving abnormal Arf6 regulation.	[Sangar, F.; Schreurs, A-S; Umana-Diaz, C.; Claperon, A.; Desbois-Mouthon, C.; Calmel, C.; Mauger, O.; Zaanan, A.; Flejou, J-F; Praz, F.] INSERM, UMR S 938, St Antoine Res Ctr, Paris, France; [Sangar, F.; Schreurs, A-S; Umana-Diaz, C.; Claperon, A.; Desbois-Mouthon, C.; Calmel, C.; Mauger, O.; Zaanan, A.; Flejou, J-F; Praz, F.] Univ Paris 06, UMR S 938, St Antoine Res Ctr, Paris, France; [Miquel, C.] Univ Paris 05, St Anne Hosp, Dept Pathol, Paris, France; [Flejou, J-F] St Antoine Hosp, AP HP, Dept Pathol, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite; GHU PARIS Psychiatrie Neurosciences; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite	Praz, F (corresponding author), INSERM UPMC UMR S 938, Ctr Rech St Antoine, Batiment Kourilsky,184 Rue Faubourg St Antoine, F-75571 Paris 12, France.	francoise.praz@upmc.fr	Desbois-Mouthon, Christele/M-7076-2017; PRAZ, Françoise/A-7291-2008; PRAZ, Françoise/AAF-7761-2020	Desbois-Mouthon, Christele/0000-0002-0772-1711; PRAZ, Françoise/0000-0002-5353-8889; PRAZ, Françoise/0000-0002-5353-8889	'Ministe re de l'Enseignement Superieur et de la Recherche; 'Fondation ARC pour la Recherche sur le Cancer; Association pour la Recherche sur le Cancer [5091]; Ligue Nationale Contre le Cancer [RS10/75-72, RS11/75-89]	'Ministe re de l'Enseignement Superieur et de la Recherche(Estonian Research CouncilEuropean Commission); 'Fondation ARC pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le Cancer); Association pour la Recherche sur le Cancer(Fondation ARC pour la Recherche sur le CancerAustralian Research Council); Ligue Nationale Contre le Cancer(Ligue nationale contre le cancer)	We thank Drs Mathieu Boissan, Philippe Chavrier, Marie-Lise Lacombe and Guillaume Montagnac for their constant support and helpful discussions, as well as Dr Peggy Cuilliere-Dartigues for sharing some data. We are grateful to Martine Mergey, Anne-Marie Faussat and Philippe Fontanges for their invaluable help in RT-PCRq analyses, cytometry and confocal microscopy, respectively. We further acknowledge the expert technical assistance of Fatiha Merabtene in performing immunohistochemical analyses of mouse and human tumor samples. We are indebted to the members of INSERM UMR_S 903 for sharing the ImageJ plugin. Fatiha Sangar received a 3-year fellowship from 'Ministe re de l'Enseignement Superieur et de la Recherche' followed by a 6-month funding from 'Fondation ARC pour la Recherche sur le Cancer'. This work has been supported by grants from the Association pour la Recherche sur le Cancer (# 5091) and from the Ligue Nationale Contre le Cancer (RS10/75-72 and RS11/75-89).	Claperon A, 2012, ONCOGENE, V31, P1376, DOI 10.1038/onc.2011.334; D'Souza-Schorey C, 2006, NAT REV MOL CELL BIO, V7, P347, DOI 10.1038/nrm1910; Duval A, 2002, CANCER RES, V62, P2447; El-Bchiri J, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002583; Gardner LB, 2010, MOL CANCER RES, V8, P295, DOI 10.1158/1541-7786.MCR-09-0502; Hashimoto S, 2004, P NATL ACAD SCI USA, V101, P6647, DOI 10.1073/pnas.0401753101; Hempen PM, 2003, CANCER RES, V63, P994; Isken O, 2007, GENE DEV, V21, P1833, DOI 10.1101/gad.1566807; Kon S, 2008, EXP CELL RES, V314, P1415, DOI 10.1016/j.yexcr.2007.11.006; Loire E, 2009, MOL BIOL EVOL, V26, P111, DOI 10.1093/molbev/msn230; Marcos I, 2002, GENE, V292, P167, DOI 10.1016/S0378-1119(02)00645-5; Miquel C, 2007, ONCOGENE, V26, P5919, DOI 10.1038/sj.onc.1210419; Montagnac G, 2009, CURR BIOL, V19, P184, DOI 10.1016/j.cub.2008.12.043; Muralidharan-Chari V, 2009, CANCER RES, V69, P2201, DOI 10.1158/0008-5472.CAN-08-1301; Natsume W, 2006, MOL BIOL CELL, V17, P2592, DOI 10.1091/mbc.E05-10-0909; Palacios F, 2001, EMBO J, V20, P4973, DOI 10.1093/emboj/20.17.4973; Peltomaki P, 2005, FAM CANCER, V4, P227, DOI 10.1007/s10689-004-7993-0; Sabe H, 2003, J BIOCHEM, V134, P485, DOI 10.1093/jb/mvg181; Tanabe K, 2005, MOL BIOL CELL, V16, P1617, DOI 10.1091/mbc.E04-08-0683; Tanabe K, 2006, CANCER SCI, V97, P801, DOI 10.1111/j.1349-7006.2006.00251.x; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; Woerner SM, 2010, NUCLEIC ACIDS RES, V38, pD682, DOI 10.1093/nar/gkp839; Zaanan A, 2011, CELL ONCOL, V34, P155, DOI 10.1007/s13402-011-0024-x	23	10	10	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2014	33	21					2758	2767		10.1038/onc.2013.211	http://dx.doi.org/10.1038/onc.2013.211			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EH	23752192				2022-12-28	WOS:000337231700009
J	Rosebeck, S; Rehman, AO; Apel, IJ; Kohrt, D; Appert, A; O'Donnell, MA; Ting, AT; Du, MQ; Baens, M; Lucas, PC; McAllister-Lucas, LM				Rosebeck, S.; Rehman, A. O.; Apel, I. J.; Kohrt, D.; Appert, A.; O'Donnell, M. A.; Ting, A. T.; Du, M-Q; Baens, M.; Lucas, P. C.; McAllister-Lucas, L. M.			The API2-MALT1 fusion exploits TNFR pathway-associated RIP1 ubiquitination to promote oncogenic NF-kappa B signaling	ONCOGENE			English	Article						MALT1; TRAF2; RIP1; lymphoma; ubiquitination	NECROSIS-FACTOR RECEPTOR; MALT LYMPHOMA; CELL LYMPHOMA; DNA-DAMAGE; ACTIVATION; KINASE; APOPTOSIS; BCL10; PROTEIN; POLYUBIQUITINATION	The API2-MALT1 fusion oncoprotein is created by the recurrent t(11;18)(q21;q21) chromosomal translocation in mucosa-associated lymphoid tissue (MALT) lymphoma. We identified receptor interacting protein-1 (RIP1) as a novel API2-MALT1-associated protein, and demonstrate that RIP1 is required for API2-MALT1 to stimulate canonical nuclear factor kappa B (NF-kappa B). API2-MALT1 promotes ubiquitination of RIP1 at lysine (K) 377, which is necessary for full NF-kappa B activation. Furthermore, we found that TNF receptor-associated factor 2 (TRAF2) recruitment is required for API2-MALT1 to induce RIP1 ubiquitination, NF-kappa B activation and cellular transformation. Although both TRAF2 and RIP1 interact with the API2 moiety of API2-MALT1, this moiety alone is insufficient to induce RIP1 ubiquitination or activate NF-kappa B, indicating that API2-MALT1-dependent RIP1 ubiquitination represents a gain of function requiring the concerted actions of both the API2 and MALT1 moieties of the fusion. Intriguingly, constitutive RIP1 ubiquitination was recently demonstrated in several solid tumors, and now our study implicates RIP1 ubiquitination as a critical component of API2-MALT1-dependent lymphomagenesis.	[Rosebeck, S.; Rehman, A. O.; Kohrt, D.; McAllister-Lucas, L. M.] Univ Michigan, Sch Med, Dept Pediat & Communicable Dis, Ann Arbor, MI USA; [Apel, I. J.; Lucas, P. C.] Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI USA; [Du, M-Q] Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Div Mol Histopathol, Cambridge CB2 2QQ, England; [O'Donnell, M. A.; Ting, A. T.] Icahn Sch Med Mt Sinai, Inst Immunol, New York, NY USA; [Baens, M.] Catholic Univ Louvain, Ctr Human Genet, Human Genome Lab, B-3000 Louvain, Belgium; [Baens, M.] VIB, Dept Mol & Dev Genet, Human Genome Lab, Louvain, Belgium	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Icahn School of Medicine at Mount Sinai; Universite Catholique Louvain; Flanders Institute for Biotechnology (VIB)	Lucas, PC (corresponding author), Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Pathol, 5123 Rangos Res Bldg,4401 Penn Ave, Pittsburgh, PA 15224 USA.	lucaspc@upmc.edu; linda.mcallister@chp.edu		Du, Ming-Qing/0000-0002-1017-5045; Lucas, Peter/0000-0003-4880-7172	Shirley K Schlafer Foundation; Elizabeth Caroline Crosby Fund; University of Michigan Comprehensive Cancer Center [G007839]; National Cancer Institute, NIH [R01CA124540]; National Heart, Lung and Blood Institute, NIH [T32-HL007622-21A2]; Nancy Newton Loeb Pediatric Cancer Research Award; AACI Fellowship for Translational Cancer Research; NATIONAL CANCER INSTITUTE [R01CA124540] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082914, T32HL007622] Funding Source: NIH RePORTER	Shirley K Schlafer Foundation; Elizabeth Caroline Crosby Fund; University of Michigan Comprehensive Cancer Center; National Cancer Institute, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Heart, Lung and Blood Institute, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Nancy Newton Loeb Pediatric Cancer Research Award; AACI Fellowship for Translational Cancer Research; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	We thank Gabriel Nunez for contributing plasmids, Shaomeng Wang for providing smac mimetic compounds and Linda Klei for laboratory management. This work was supported by the Shirley K Schlafer Foundation, the Elizabeth Caroline Crosby Fund, and grants from the University of Michigan Comprehensive Cancer Center (G007839) and the National Cancer Institute, NIH (R01CA124540). SR was supported by the National Heart, Lung and Blood Institute, NIH (T32-HL007622-21A2), the Nancy Newton Loeb Pediatric Cancer Research Award and the AACI Fellowship for Translational Cancer Research.	Akagi T, 1999, ONCOGENE, V18, P5785, DOI 10.1038/sj.onc.1203018; Alvarez SE, 2010, NATURE, V465, P1084, DOI 10.1038/nature09128; Baens M, 2006, CANCER RES, V66, P5270, DOI 10.1158/0008-5472.CAN-05-4590; Bellail AC, 2012, CANCER DISCOV, V2, P140, DOI 10.1158/2159-8290.CD-11-0172; Bertrand MJM, 2008, MOL CELL, V30, P689, DOI 10.1016/j.molcel.2008.05.014; Biton S, 2011, CELL, V145, P92, DOI 10.1016/j.cell.2011.02.023; Cardamone MD, 2012, MOL CELL, V46, P91, DOI 10.1016/j.molcel.2012.01.025; Conze DB, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000518; Coornaert B, 2008, NAT IMMUNOL, V9, P263, DOI 10.1038/ni1561; Degterev A, 2008, NAT CHEM BIOL, V4, P313, DOI 10.1038/nchembio.83; Dierlamm J, 1999, BLOOD, V93, P3601, DOI 10.1182/blood.V93.11.3601; Duprez L, 2012, J BIOL CHEM, V287, P14863, DOI 10.1074/jbc.M111.288670; Ea CK, 2006, MOL CELL, V22, P245, DOI 10.1016/j.molcel.2006.03.026; Garrison JB, 2009, ONCOGENE, V28, P1584, DOI 10.1038/onc.2009.17; Gerlach B, 2011, NATURE, V471, P591, DOI 10.1038/nature09816; Hasegawa M, 2008, EMBO J, V27, P373, DOI 10.1038/sj.emboj.7601962; Hoffmann A, 2006, IMMUNOL REV, V210, P171, DOI 10.1111/j.0105-2896.2006.00375.x; Hsu HL, 1996, IMMUNITY, V4, P387, DOI 10.1016/S1074-7613(00)80252-6; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Kanayama A, 2004, MOL CELL, V15, P535, DOI 10.1016/j.molcel.2004.08.008; Lee TH, 2004, J BIOL CHEM, V279, P33185, DOI 10.1074/jbc.M404206200; Li HX, 2006, J BIOL CHEM, V281, P13636, DOI 10.1074/jbc.M600620200; Liu HX, 2001, BLOOD, V98, P1182, DOI 10.1182/blood.V98.4.1182; Liu HX, 2002, GASTROENTEROLOGY, V122, P1286, DOI 10.1053/gast.2002.33047; Lu JF, 2008, CANCER RES, V68, P9384, DOI 10.1158/0008-5472.CAN-08-2655; Lucas PC, 2007, ONCOGENE, V26, P5643, DOI 10.1038/sj.onc.1210342; Lucas PC, 2001, J BIOL CHEM, V276, P19012, DOI 10.1074/jbc.M009984200; Morgan JA, 1999, CANCER RES, V59, P6205; Noels H, 2007, J BIOL CHEM, V282, P10180, DOI 10.1074/jbc.M611038200; O'Donnell MA, 2007, CURR BIOL, V17, P418, DOI 10.1016/j.cub.2007.01.027; Oeckinghaus A, 2007, EMBO J, V26, P4634, DOI 10.1038/sj.emboj.7601897; Peng C, 2012, J BIOL CHEM, V287, P25881, DOI 10.1074/jbc.M112.359521; Rosebeck S, 2011, SCIENCE, V331, P468, DOI 10.1126/science.1198946; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; Shembade N, 2010, SCIENCE, V327, P1135, DOI 10.1126/science.1182364; Staal J, 2011, EMBO J, V30, P1742, DOI 10.1038/emboj.2011.85; Stoffel A, 2004, P NATL ACAD SCI USA, V101, P9079, DOI 10.1073/pnas.0402415101; Streubel B, 2003, BLOOD, V101, P2335, DOI 10.1182/blood-2002-09-2963; Sun LJ, 2004, MOL CELL, V14, P289, DOI 10.1016/S1097-2765(04)00236-9; Takaesu G, 2003, J MOL BIOL, V326, P105, DOI 10.1016/S0022-2836(02)01404-3; Thome M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a003004; Ting AT, 1996, EMBO J, V15, P6189, DOI 10.1002/j.1460-2075.1996.tb01007.x; Uren AG, 2000, MOL CELL, V6, P961, DOI 10.1016/S1097-2765(05)00086-9; Varfolomeev E, 2008, J BIOL CHEM, V283, P24295, DOI 10.1074/jbc.C800128200; Vince JE, 2009, J BIOL CHEM, V284, P35906, DOI 10.1074/jbc.M109.072256; Willis TG, 1999, CELL, V96, P35, DOI 10.1016/S0092-8674(00)80957-5; Wu CJ, 2006, NAT CELL BIOL, V8, P398, DOI 10.1038/ncb1384; Yang YB, 2011, MOL CELL BIOL, V31, P2774, DOI 10.1128/MCB.01139-10; Yin Q, 2009, BIOCHEMISTRY-US, V48, P10558, DOI 10.1021/bi901462e; Zhang QG, 1999, NAT GENET, V22, P63, DOI 10.1038/8767; Zhou HL, 2005, CANCER CELL, V7, P425, DOI 10.1016/j.ccr.2005.04.012; Zhou HL, 2004, NATURE, V427, P167, DOI 10.1038/nature02273	53	20	22	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2014	33	19					2520	2530		10.1038/onc.2013.195	http://dx.doi.org/10.1038/onc.2013.195			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH3OK	23770847	Green Accepted			2022-12-28	WOS:000336033600012
J	Brown, L; Waseem, A; Cruz, IN; Szary, J; Gunic, E; Mannan, T; Unadkat, M; Yang, M; Valderrama, F; O'Toole, EA; Wan, H				Brown, L.; Waseem, A.; Cruz, I. N.; Szary, J.; Gunic, E.; Mannan, T.; Unadkat, M.; Yang, M.; Valderrama, F.; O'Toole, E. A.; Wan, H.			Desmoglein 3 promotes cancer cell migration and invasion by regulating activator protein 1 and protein kinase C-dependent-Ezrin activation	ONCOGENE			English	Article						desmoglein; ERM proteins; AP-1 transcription factor; cell migration and invasion; keratinocytes	PEMPHIGUS-VULGARIS-IGG; EZRIN/RADIXIN/MOESIN ERM PROTEINS; CARCINOMA-CELLS; RHO-KINASE; HEPATOCELLULAR-CARCINOMA; ACTIN REORGANIZATION; UPSTREAM REGULATOR; ENDOTHELIAL-CELLS; INHIBITS INVASION; EPIDERMAL-GROWTH	Desmoglein 3 (Dsg3), the pemphigus vulgaris antigen, has recently been shown to be upregulated in squamous cell carcinoma (SCC) and has been identified as a good tumor-specific marker for clinical staging of cervical sentinel lymph nodes in head and neck SCC. However, little is known about its biological function in cancer. The actin-binding protein Ezrin and the activator protein 1 (AP-1) transcription factor are implicated in cancer progression and metastasis. Here, we report that Dsg3 regulates the activity of c-Jun/AP-1 as well as protein kinase C (PKC)-mediated phosphorylation of Ezrin-Thr567, which contributes to the accelerated motility of cancer cells. Ectopic expression of Dsg3 in cancer cell lines caused enhanced phosphorylation at Ezrin-Thr567 with concomitant augmented membrane protrusions, cell spreading and invasive phenotype. We showed that Dsg3 formed a complex with Ezrin at the plasma membrane that was required for its proper function of interacting with F-actin and CD44 as Dsg3 knockdown impaired these associations. The increased Ezrin phosphorylation in Dsg3-overexpressing cells could be abrogated substantially by various pharmacological inhibitors for Ser/Thr kinases, including PKC and Rho kinase that are known to activate Ezrin. Furthermore, a marked increase in c-Jun S63 phosphorylation, among others, was found in Dsg3-overexpressing cells and the activation of c-Jun/AP-1 was further supported by a luciferase reporter assay. Taken together, our study identifies a novel Dsg3mediated c-Jun/AP-1 regulatory mechanism and PKC-dependent Ezrin phosphorylation that could be responsible for Dsg3-associated cancer metastasis.	[Brown, L.; Waseem, A.; Szary, J.; Gunic, E.; Mannan, T.; Unadkat, M.; Wan, H.] Queen Mary Univ London, Barts & London Sch Med & Dent, Ctr Clin & Diagnost Oral Sci, Inst Dent, London E1 2AT, England; [Cruz, I. N.; Yang, M.] UCL Sch Pharm, Dept Pharmaceut & Biol Chem, London, England; [Valderrama, F.] Univ London, Div Biomed Sci, London, England; [O'Toole, E. A.] Queen Mary Univ London, Barts & London Sch Med & Dent, Ctr Cutaneous Res, Blizard Inst, London E1 2AT, England	University of London; Queen Mary University London; University of London; University College London; University of London; University of London; Queen Mary University London	Wan, H (corresponding author), Queen Mary Univ London, Barts & London Sch Med & Dent, Ctr Clin & Diagnost Oral Sci, Inst Dent, Blizard Bldg, London E1 2AT, England.	h.wan@qmul.ac.uk		O'Toole, Edel/0000-0002-4084-4836	British Skin Foundation; Institute of Dentistry; Facial Surgery Research Foundation-Saving Faces; Engineering and Physical Sciences Research Council [EP/K023071/1] Funding Source: researchfish; EPSRC [EP/K023071/1] Funding Source: UKRI	British Skin Foundation; Institute of Dentistry; Facial Surgery Research Foundation-Saving Faces; Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))	We thank Dr MT Teh, Professor K Parkinson, Dr SM Tsang, Dr MS Ikram and members of CDOS for helpful discussion and technical assistance. This work was supported by a British Skin Foundation-funded studentship awarded to HW and in part by the Institute of Dentistry as well as The Facial Surgery Research Foundation-Saving Faces.	AMAGAI, 1994, J INVEST DERMATOL, V103, P608, DOI 10.1111/1523-1747.ep12397292; AMAGAI M, 1991, CELL, V67, P869, DOI 10.1016/0092-8674(91)90360-B; Aoyama Y, 1999, EUR J IMMUNOL, V29, P2233, DOI 10.1002/(SICI)1521-4141(199907)29:07<2233::AID-IMMU2233>3.0.CO;2-4; Belkina NV, 2009, P NATL ACAD SCI USA, V106, P4707, DOI 10.1073/pnas.0805963106; Berkowitz P, 2005, J BIOL CHEM, V280, P23778, DOI 10.1074/jbc.M501365200; Bogatcheva NV, 2011, AM J RESP CELL MOL, V45, P1185, DOI 10.1165/rcmb.2011-0092OC; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Calkins CC, 2006, J BIOL CHEM, V281, P7623, DOI 10.1074/jbc.M512447200; Chen YJ, 2007, ONCOGENE, V26, P467, DOI 10.1038/sj.onc.1209802; Chen Y, 2011, CANCER RES, V71, P1721, DOI 10.1158/0008-5472.CAN-09-4683; Chidgey M, 2007, BRIT J CANCER, V96, P1783, DOI 10.1038/sj.bjc.6603808; Chuan YC, 2006, J BIOL CHEM, V281, P29938, DOI 10.1074/jbc.M602237200; Crepaldi T, 1997, J CELL BIOL, V138, P423, DOI 10.1083/jcb.138.2.423; Cui YZ, 2010, CANCER INVEST, V28, P242, DOI 10.3109/07357900903124498; Delva E, 2008, J BIOL CHEM, V283, P18303, DOI 10.1074/jbc.M710046200; Elliott BE, 2004, J CELL BIOCHEM, V92, P16, DOI 10.1002/jcb.20033; Elzagheid A, 2008, HUM PATHOL, V39, P1737, DOI 10.1016/j.humpath.2008.04.020; Fan LL, 2011, CANCER BIOL THER, V11, P746, DOI 10.4161/cbt.11.8.14691; Fehon RG, 2010, NAT REV MOL CELL BIO, V11, P276, DOI 10.1038/nrm2866; Ferris RL, 2005, CANCER RES, V65, P2147, DOI 10.1158/0008-5472.CAN-04-3717; Ferris RL, 2011, CLIN CANCER RES, V17, P1858, DOI 10.1158/1078-0432.CCR-10-3110; Fievet BT, 2004, J CELL BIOL, V164, P653, DOI 10.1083/jcb.200307032; Gao Y, 2004, P NATL ACAD SCI USA, V101, P7618, DOI 10.1073/pnas.0307512101; GARY R, 1993, P NATL ACAD SCI USA, V90, P10846, DOI 10.1073/pnas.90.22.10846; Gliem M, 2010, AM J PHYSIOL-CELL PH, V299, pC606, DOI 10.1152/ajpcell.00075.2010; Goley ED, 2006, NAT REV MOL CELL BIO, V7, P713, DOI 10.1038/nrm2026; Hong SH, 2011, VET COMP ONCOL, V9, P207, DOI 10.1111/j.1476-5829.2010.00249.x; Huang CC, 2010, LARYNGOSCOPE, V120, P26, DOI 10.1002/lary.20151; Hunter KW, 2004, TRENDS MOL MED, V10, P201, DOI 10.1016/j.molmed.2004.03.001; Ivanov AI, 2009, BMC CELL BIOL, V10, DOI 10.1186/1471-2121-10-36; Jensen PV, 2004, HISTOCHEM CELL BIOL, V121, P361, DOI 10.1007/s00418-004-0648-2; Jeong HJ, 2011, KOREAN J PHYSIOL PHA, V15, P245, DOI 10.4196/kjpp.2011.15.4.245; Johnston IMP, 2000, ONCOGENE, V19, P5348, DOI 10.1038/sj.onc.1203927; Kanno M, 2008, EXP CELL RES, V314, P1683, DOI 10.1016/j.yexcr.2008.01.031; KARPATI S, 1994, DERMATOLOGY, V189, P24, DOI 10.1159/000246923; Khanna C, 2004, NAT MED, V10, P182, DOI 10.1038/nm982; Kobel M, 2006, INT J GYNECOL PATHOL, V25, P121, DOI 10.1097/01.pgp.0000185410.39050.ac; Koivunen J, 2004, CANCER RES, V64, P5693, DOI 10.1158/0008-5472.CAN-03-3511; Koss M, 2006, J IMMUNOL, V176, P1218, DOI 10.4049/jimmunol.176.2.1218; Legg JW, 2002, NAT CELL BIOL, V4, P399, DOI 10.1038/ncb797; Legg JW, 1998, CURR BIOL, V8, P705, DOI 10.1016/S0960-9822(98)70277-5; Ling ZQ, 2010, CANCER SCI, V101, P624, DOI 10.1111/j.1349-7006.2009.01470.x; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Meng YX, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-61; Morgan MR, 2011, ONCOGENE, V30, P1422, DOI 10.1038/onc.2010.535; Muller EJ, 2008, J INVEST DERMATOL, V128, P501, DOI 10.1038/sj.jid.5701248; Ng T, 2001, EMBO J, V20, P2723, DOI 10.1093/emboj/20.11.2723; Nystrom ML, 2005, J PATHOL, V205, P468, DOI 10.1002/path.1716; Ozanne BW, 2007, ONCOGENE, V26, P1, DOI 10.1038/sj.onc.1209759; Patel V, 2013, ORAL ONCOL, V49, P93, DOI 10.1016/j.oraloncology.2012.08.001; Payne AS, 2004, CURR OPIN CELL BIOL, V16, P536, DOI 10.1016/j.ceb.2004.07.006; Pujuguet P, 2003, MOL BIOL CELL, V14, P2181, DOI 10.1091/mbc.E02-07-0410; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Ren L, 2009, ONCOGENE, V28, P792, DOI 10.1038/onc.2008.437; Sahai E, 2002, NAT CELL BIOL, V4, P408, DOI 10.1038/ncb796; Savci-Heijink CD, 2009, AM J PATHOL, V174, P1629, DOI 10.2353/ajpath.2009.080778; Shinohara M, 1998, J PATHOL, V184, P369, DOI 10.1002/(SICI)1096-9896(199804)184:4<369::AID-PATH1236>3.0.CO;2-L; Solassol J, 2010, BRIT J CANCER, V102, P181, DOI 10.1038/sj.bjc.6605470; Stapleton G, 2002, J CELL SCI, V115, P2713; Tamma G, 2007, AM J PHYSIOL-CELL PH, V292, pC1476, DOI 10.1152/ajpcell.00375.2006; Tang FQ, 2011, J BIOL CHEM, V286, P36956, DOI 10.1074/jbc.M111.259234; Teh MT, 2011, J ORAL PATHOL MED, V40, P67, DOI 10.1111/j.1600-0714.2010.00951.x; Tsang SM, 2012, EXP CELL RES, V318, P2269, DOI 10.1016/j.yexcr.2012.07.002; Tsang SM, 2012, J PATHOL, V227, P81, DOI 10.1002/path.3982; Tsang SM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014211; TSUKITA S, 1994, J CELL BIOL, V126, P391, DOI 10.1083/jcb.126.2.391; van Baal J, 2005, J BIOL CHEM, V280, P9870, DOI 10.1074/jbc.M409301200; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Wald FA, 2008, J CELL SCI, V121, P644, DOI 10.1242/jcs.016246; Wang HJ, 2009, J DIGEST DIS, V10, P258, DOI 10.1111/j.1751-2980.2009.00394.x; Wang Longyun, 2010, Zhong Nan Da Xue Xue Bao Yi Xue Ban, V35, P969, DOI 10.3969/j.issn.1672-7347.2010.09.012; Wang YY, 2011, ORAL SURG ORAL MED O, V112, P96, DOI 10.1016/j.tripleo.2011.02.018; Williamson L, 2006, EMBO J, V25, P3298, DOI 10.1038/sj.emboj.7601224; Xie JJ, 2009, INT J CANCER, V124, P2549, DOI 10.1002/ijc.24216; Yeh CN, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-233; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yonemura S, 2002, J CELL SCI, V115, P2569; Zh LX, 2007, AM J PHYSIOL-CELL PH, V293, pC874, DOI 10.1152/ajpcell.00111.2007; Zhu LX, 2010, AM J PHYSIOL-CELL PH, V299, pC431, DOI 10.1152/ajpcell.00090.2010	80	42	44	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2014	33	18					2363	2374		10.1038/onc.2013.186	http://dx.doi.org/10.1038/onc.2013.186			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AG5ID	23752190				2022-12-28	WOS:000335451800009
J	Martin, D; Nguyen, Q; Molinolo, A; Gutkind, JS				Martin, D.; Nguyen, Q.; Molinolo, A.; Gutkind, J. S.			Accumulation of dephosphorylated 4EBP after mTOR inhibition with rapamycin is sufficient to disrupt paracrine transformation by the KSHV vGPCR oncogene	ONCOGENE			English	Article						Kaposi's sarcoma; mTOR; PI3K; 4EBP; rapamycin; cancer	KAPOSIS-SARCOMA; MAMMALIAN TARGET; PROTEIN; CELL; INFECTION; GROWTH; PATHOGENESIS; EXPRESSION; SIROLIMUS; CYTOKINES	Dysregulation of the PI3K/Akt/mTOR pathway is one of the most frequent events in human cancer. However, the clinical benefits of PI3K/Akt/mTOR inhibitors have not yet achieved their predicted potential in many of the most prevalent human cancers. Of interest, treatment of Kaposi's sarcoma (KS) patients with rapamycin provided the first evidence of the antineoplastic activity of mTOR inhibitors in humans, becoming the standard of care for KS arising in renal transplant patients. Thus, the study of KS may provide a unique opportunity to dissect the contribution of specific mTOR downstream targets to cancer development. The KS associated herpesvirus (KSHV) is the etiological agent for KS, and the KSHV-encoded oncogene viral-G protein-coupled receptor (vGPCR) promotes the potent activation of the PI3K-Akt-mTOR pathway by both direct and paracrine mechanisms. We focused on a direct target of mTOR, EIF4EBP1/2/3 (4EBP), which inhibits the translation of eukaryotic initiation factor 4E (eiF4E)-bound mRNAs. 4EBP phosphorylation by mTOR relieves its inhibitory activity, hence resulting in increased eiF4E-dependent mRNA translation. We developed a paracrine transformation model, recapitulating the cellular composition of KS lesions, in which vGPCR-expressing cells promote the rapid proliferation of endothelial cells, thus expressing KSHV-latent genes by the release of growth factors. Using this model, we show here that the accumulation of dephosphorylated 4EBP in response to rapamycin or by the expression of an mTOR-insensitive mutant of 4EBP1 is sufficient to disrupt the eiF4E function downstream of mTOR to a similar extent than the mTOR catalytic inhibitor Torin2 and to halt KS development. We also provide evidence that eiF4E contributes to paracrine neoplastic, signaling through the release of pro-angiogenic factors that are acting on endothelial cells, expressing KSHV-latent genes. These findings may provide a preclinical platform and the rationale for the development of novel mTOR, inhibiting agents that may selectively disrupt the mTOR-4EBP interaction for the treatment of KS and other tumor lesions, exhibiting hyperactive mTOR pathway function.	[Martin, D.; Nguyen, Q.; Molinolo, A.; Gutkind, J. S.] Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Gutkind, JS (corresponding author), Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bldg 30 Room 320,30 Convent Dr MSC 4340, Bethesda, MD 20892 USA.	sg39v@nih.gov	Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482; Martin Izquierdo, Daniel/0000-0002-8880-9087	National Institutes of Health Intramural AIDS-Targeted Antiviral Program; National Institute of Dental and Craniofacial Research; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER	National Institutes of Health Intramural AIDS-Targeted Antiviral Program; National Institute of Dental and Craniofacial Research(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))	This research was supported by the National Institutes of Health Intramural AIDS-Targeted Antiviral Program and the National Institute of Dental and Craniofacial Research. We apologize to colleagues whose primary research papers may not have been cited due to space constraints.	Alain T, 2012, CANCER RES, V72, P6468, DOI 10.1158/0008-5472.CAN-12-2395; Atkins MB, 2004, J CLIN ONCOL, V22, P909, DOI 10.1200/JCO.2004.08.185; Benjamin D, 2011, NAT REV DRUG DISCOV, V10, P868, DOI 10.1038/nrd3531; Bieleski L, 2001, J VIROL, V75, P1864, DOI 10.1128/JVI.75.4.1864-1869.2001; Cesarman E, 2000, J EXP MED, V191, P417, DOI 10.1084/jem.191.3.417; CHANG Y, 1994, SCIENCE, V266, P1865, DOI 10.1126/science.7997879; Dancey J, 2010, NAT REV CLIN ONCOL, V7, P209, DOI 10.1038/nrclinonc.2010.21; Dann SG, 2007, TRENDS MOL MED, V13, P252, DOI 10.1016/j.molmed.2007.04.002; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Ganem D, 2006, ANNU REV PATHOL-MECH, V1, P273, DOI 10.1146/annurev.pathol.1.110304.100133; Gasperini P, 2009, LEUKEMIA, V23, P1867, DOI 10.1038/leu.2009.117; Gasperini P, 2008, J LEUKOCYTE BIOL, V84, P994, DOI 10.1189/jlb.1107777; Hosseini-Moghaddam SM, 2012, TRANSPL INFECT DIS, V14, P338, DOI 10.1111/j.1399-3062.2011.00714.x; Laplante M, 2012, CELL, V149, P274, DOI 10.1016/j.cell.2012.03.017; Liu QS, 2012, METHODS MOL BIOL, V821, P447, DOI 10.1007/978-1-61779-430-8_29; Martin D, 2008, ONCOGENE, V27, P1844, DOI [10.1038/sj.onc.1210817, 10.1038/onc.2009.351]; Mesri EA, 2010, NAT REV CANCER, V10, P707, DOI 10.1038/nrc2888; Minchinton AI, 2006, NAT REV CANCER, V6, P583, DOI 10.1038/nrc1893; Montaner S, 2003, CANCER CELL, V3, P23, DOI 10.1016/S1535-6108(02)00237-4; Mutlu AD, 2007, CANCER CELL, V11, P245, DOI 10.1016/j.ccr.2007.01.015; Sodhi A, 2004, P NATL ACAD SCI USA, V101, P4821, DOI 10.1073/pnas.0400835101; Sodhi A, 2006, CANCER CELL, V10, P133, DOI 10.1016/j.ccr.2006.05.026; Stallone G, 2005, NEW ENGL J MED, V352, P1317, DOI 10.1056/NEJMoa042831; Stallone G, 2008, TRANSPL INT, V21, P825, DOI 10.1111/j.1432-2277.2008.00697.x; Vilar E, 2011, MOL CANCER THER, V10, P395, DOI 10.1158/1535-7163.MCT-10-0905; Vitale-Cross L, 2012, CANCER PREV RES, V5, P562, DOI 10.1158/1940-6207.CAPR-11-0502; Vuiblet V, 2012, NEPHROL DIAL TRANSPL, V27, P411, DOI 10.1093/ndt/gfr261; Yanagiya A, 2012, MOL CELL, V46, P847, DOI 10.1016/j.molcel.2012.04.004	28	14	15	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 1	2014	33	18					2405	2412		10.1038/onc.2013.193	http://dx.doi.org/10.1038/onc.2013.193			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AG5ID	23708663	Bronze			2022-12-28	WOS:000335451800013
J	Koyama-Nasu, R; Haruta, R; Nasu-Nishimura, Y; Taniue, K; Katou, Y; Shirahige, K; Todo, T; Ino, Y; Mukasa, A; Saito, N; Matsui, M; Takahashi, R; Hoshino-Okubo, A; Sugano, H; Manabe, E; Funato, K; Akiyama, T				Koyama-Nasu, R.; Haruta, R.; Nasu-Nishimura, Y.; Taniue, K.; Katou, Y.; Shirahige, K.; Todo, T.; Ino, Y.; Mukasa, A.; Saito, N.; Matsui, M.; Takahashi, R.; Hoshino-Okubo, A.; Sugano, H.; Manabe, E.; Funato, K.; Akiyama, T.			The pleiotrophin-ALK axis is required for tumorigenicity of glioblastoma stem cells	ONCOGENE			English	Article						ALK; cancer stem cell; glioblastoma; kinase; pleiotrophin; SOX2	ANAPLASTIC LYMPHOMA KINASE; EMBRYONIC STEM; MOUSE MODELS; LUNG-CANCER; HB-GAM; SOX2; EXPRESSION; GENE; IDENTIFICATION; MOLECULE	Increasing evidence suggests that brain tumors arise from the transformation of neural stem/precursor/progenitor cells. Much current research on human brain tumors is focused on the stem-like properties of glioblastoma. Here we show that anaplastic lymphoma kinase (ALK) and its ligand pleiotrophin are required for the self-renewal and tumorigenicity of glioblastoma stem cells (GSCs). Furthermore, we demonstrate that pleiotrophin is transactivated directly by SOX2, a transcription factor essential for the maintenance of both neural stem cells and GSCs. We speculate that the pleiotrophin-ALK axis may be a promising target for the therapy of glioblastoma.	[Koyama-Nasu, R.; Haruta, R.; Nasu-Nishimura, Y.; Taniue, K.; Takahashi, R.; Hoshino-Okubo, A.; Sugano, H.; Manabe, E.; Funato, K.; Akiyama, T.] Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, Tokyo 1130032, Japan; [Katou, Y.; Shirahige, K.] Univ Tokyo, Inst Mol & Cellular Biosci, Ctr Epigenet Dis, Lab Genome Struct & Funct,Bunkyo Ku, Tokyo 1130032, Japan; [Todo, T.; Ino, Y.; Mukasa, A.; Saito, N.] Tokyo Univ Hosp, Dept Neurosurg, Bunkyo Ku, Tokyo 113, Japan	University of Tokyo; University of Tokyo; University of Tokyo	Akiyama, T (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Lab Mol & Genet Informat, Bunkyo Ku, Yayoi 1-1-1, Tokyo 1130032, Japan.	akiyama@iam.u-tokyo.ac.jp	Mukasa, Akitake/H-7615-2019	Mukasa, Akitake/0000-0001-7776-9086; Funato, Kosuke/0000-0003-2437-1116; Todo, Tomoki/0000-0003-0523-8010	Research Program of Innovative Cell Biology by Innovative Technology (Integrated Systems Analysis of Cellular Oncogenic Signaling Networks); Global COE Program (Integrative Life Science Based on the Study of Biosignaling Mechanisms), MEXT, Japan; Grants-in-Aid for Scientific Research [25670138] Funding Source: KAKEN	Research Program of Innovative Cell Biology by Innovative Technology (Integrated Systems Analysis of Cellular Oncogenic Signaling Networks); Global COE Program (Integrative Life Science Based on the Study of Biosignaling Mechanisms), MEXT, Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	This work was supported by the Research Program of Innovative Cell Biology by Innovative Technology (Integrated Systems Analysis of Cellular Oncogenic Signaling Networks), Grants-in-Aid for Scientific Research on Innovative Areas (Integrative Research on Cancer Microenvironment Network), Takeda Science Foundation and, in part, by Global COE Program (Integrative Life Science Based on the Study of Biosignaling Mechanisms), MEXT, Japan.	Amet LEA, 2001, MOL CELL NEUROSCI, V17, P1014, DOI 10.1006/mcne.2001.0998; Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127; Bernhardt M, 2012, BIOTECHNOL J, V7, P810, DOI 10.1002/biot.201100347; Camidge DR, 2012, NAT REV CLIN ONCOL, V9, P268, DOI 10.1038/nrclinonc.2012.43; Carpenter EL, 2012, NAT REV CLIN ONCOL, V9, P391, DOI 10.1038/nrclinonc.2012.72; Cavallaro M, 2008, DEVELOPMENT, V135, P541, DOI 10.1242/dev.010801; Chen J, 2012, CELL, V149, P36, DOI 10.1016/j.cell.2012.03.009; Chen SS, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0050456, 10.1371/journal.pone.0036784, 10.1371/journal.pone.0049275, 10.1371/journal.pone.0045763]; Chew JL, 2005, MOL CELL BIOL, V25, P6031, DOI 10.1128/MCB.25.14.6031-6046.2005; Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385; Dirks WG, 2002, INT J CANCER, V100, P49, DOI 10.1002/ijc.10435; Episkopou V, 2005, TRENDS NEUROSCI, V28, P219, DOI 10.1016/j.tins.2005.03.003; Ferri ALM, 2004, DEVELOPMENT, V131, P3805, DOI 10.1242/dev.01204; Furnari FB, 2007, GENE DEV, V21, P2683, DOI 10.1101/gad.1596707; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Gandhi L, 2012, CLIN CANCER RES, V18, P3737, DOI 10.1158/1078-0432.CCR-11-2393; Gangemi RMR, 2009, STEM CELLS, V27, P40, DOI 10.1634/stemcells.2008-0493; Hienola A, 2004, MOL CELL NEUROSCI, V26, P75, DOI 10.1016/j.mcn.2004.01.018; Kadomatsu KJ, 2004, CANCER LETT, V204, P127, DOI 10.1016/S0304-3835(03)00450-6; Kim J, 2010, CELL, V143, P313, DOI 10.1016/j.cell.2010.09.010; Kondo T, 2004, GENE DEV, V18, P2963, DOI 10.1101/gad.309404; Koyama-Nasu R, 2013, ONCOGENE, V32, P3840, DOI 10.1038/onc.2012.399; Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030; Leis O, 2012, ONCOGENE, V31, P1354, DOI 10.1038/onc.2011.338; Lottaz C, 2010, CANCER RES, V70, P2030, DOI 10.1158/0008-5472.CAN-09-1707; McDermott U, 2008, CANCER RES, V68, P3389, DOI 10.1158/0008-5472.CAN-07-6186; Melosky B, 2012, CURR ONCOL, V19, pS59, DOI 10.3747/co.19.1054; Meng K, 2000, P NATL ACAD SCI USA, V97, P2603, DOI 10.1073/pnas.020487997; Mizrak D, 2008, J PATHOL, V214, P3, DOI 10.1002/path.2283; Palmer RH, 2009, BIOCHEM J, V420, P345, DOI 10.1042/BJ20090387; Parikh JR, 2010, NUCLEIC ACIDS RES, V38, pW109, DOI 10.1093/nar/gkq424; Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382; Perez-Pinera P, 2007, CELL CYCLE, V6, P2877, DOI 10.4161/cc.6.23.5090; Powers C, 2002, J BIOL CHEM, V277, P14153, DOI 10.1074/jbc.M112354200; Raetz EA, 2002, AM J PATHOL, V161, P875, DOI 10.1016/S0002-9440(10)64248-4; RAULO E, 1994, J BIOL CHEM, V269, P12999; Sarkar A, 2013, CELL STEM CELL, V12, P15, DOI 10.1016/j.stem.2012.12.007; Schmitz M, 2007, BRIT J CANCER, V96, P1293, DOI 10.1038/sj.bjc.6603696; Sell S, 2006, TUMOR BIOL, V27, P59, DOI 10.1159/000092323; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Stylianou DC, 2009, ONCOGENE, V28, P3296, DOI 10.1038/onc.2009.184; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tavazoie S, 1999, NAT GENET, V22, P281, DOI 10.1038/10343; Turner SD, 2005, LEUKEMIA, V19, P1128, DOI 10.1038/sj.leu.2403797; Wurdak H, 2010, CELL STEM CELL, V6, P37, DOI 10.1016/j.stem.2009.11.002; Ying M, 2011, ONCOGENE, V30, P3454, DOI 10.1038/onc.2011.58; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635; Zhang JM, 2009, NAT REV CANCER, V9, P28, DOI 10.1038/nrc2559	50	25	26	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 24	2014	33	17					2236	2244		10.1038/onc.2013.168	http://dx.doi.org/10.1038/onc.2013.168			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF8WJ	23686309				2022-12-28	WOS:000334996000009
J	Laval, S; Laklai, H; Fanjul, M; Pucelle, M; Laurell, H; Billon-Gales, A; Le Guellec, S; Delisle, MB; Sonnenberg, A; Susini, C; Pyronnet, S; Bousquet, C				Laval, S.; Laklai, H.; Fanjul, M.; Pucelle, M.; Laurell, H.; Billon-Gales, A.; Le Guellec, S.; Delisle, M-B; Sonnenberg, A.; Susini, C.; Pyronnet, S.; Bousquet, C.			Dual roles of hemidesmosomal proteins in the pancreatic epithelium: the phosphoinositide 3-kinase decides	ONCOGENE			English	Article						pancreatic ductal epithelium; hemidesmosome; phosphoinositide 3-kinase; cell migration and invasion; G protein-coupled somatostatin receptor	SST2 SOMATOSTATIN RECEPTOR; BETA-4 INTEGRIN; CANCER; PHOSPHORYLATION; ALPHA-6-BETA-4; PROGRESSION; EXPRESSION; CELLS; ADENOCARCINOMA; MIGRATION	Given the failure of chemo-and biotherapies to fight advanced pancreatic cancer, one major challenge is to identify critical events that initiate invasion. One priming step in epithelia carcinogenesis is the disruption of epithelial cell anchorage to the basement membrane which can be provided by hemidesmosomes (HDs). However, the existence of HDs in pancreatic ductal epithelium and their role in carcinogenesis remain unexplored. HDs have been explored in normal and cancer pancreatic cells, and patient samples. Unique cancer cell models where HD assembly can be pharmacologically manipulated by somatostatin/sst2 signaling have been then used to investigate the role and molecular mechanisms of dynamic HD during pancreatic carcinogenesis. We surprisingly report the presence of mature type-1 HDs comprising the integrin alpha 6 beta 4 and bullous pemphigoid antigen BP180 in the human pancreatic ductal epithelium. Importantly, HDs are shown to disassemble during pancreatic carcinogenesis. HD breakdown requires phosphoinositide 3-kinase (P13K)-dependent induction of the matrix-metalloprotease MMP-9, which cleaves BP180. Consequently, integrin alpha 6 beta 4 delocalizes to the cell-leading edges where it paradoxically promotes cell migration and invasion through S100A4 activation. As S100A4 in turn stimulates MMP-9 expression, a vicious cycle maintains BP180 cleavage. Inactivation of this P13K-MMP9- S100A4 signaling loop conversely blocks BP180 cleavage, induces HD reassembly and inhibits cell invasion. We conclude that mature type-1 HDs are critical anchoring structures for the pancreatic ductal epithelium whose disruption, upon P13K activation during carcinogenesis, provokes pancreatic cancer cell migration and invasion.	[Laval, S.; Laklai, H.; Fanjul, M.; Pucelle, M.; Laurell, H.; Billon-Gales, A.; Susini, C.; Pyronnet, S.; Bousquet, C.] CRCT, INSERM UMR 1037, Lab Excellence Toulouse Canc Labex TOUCAN, Equipe Labellisee Ligue Natl Contre Canc LNCC, Toulouse, France; [Laval, S.; Laklai, H.; Fanjul, M.; Laurell, H.; Billon-Gales, A.; Susini, C.; Pyronnet, S.; Bousquet, C.] Univ Toulouse 3, F-31062 Toulouse, France; [Le Guellec, S.; Delisle, M-B] Hop Rangueil, Serv Anat & Cytol Pathol, Toulouse, France; [Sonnenberg, A.] Netherlands Canc Inst, Dept Cell Biol, Amsterdam, Netherlands	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; CHU de Toulouse; Netherlands Cancer Institute	Bousquet, C (corresponding author), CRCT, INSERM, UMR 1037, 1 Ave Jean Poulhes,BP84225, F-31432 Toulouse 4, France.	corinne.bousquet@inserm.fr	Fanjul, Marjorie/G-2429-2017; Bousquet, Corinne/P-2917-2014; Pyronnet, Stéphane/P-2419-2014	Bousquet, Corinne/0000-0002-2501-0593; Laurell, Henrik/0000-0001-7328-935X	ARC (Association pour la Recherche Contre le Cancer) [5000]; LNCC (Ligue Nationale Contre le Cancer) [RAB09006BBA]; Laboratoire d'Excellence Toulouse Cancer LABEX TOUCAN; Canceropole Grand Sud-Ouest [RMA04002BPA]; ANR (Agence Nationale pour la Recherche) [R06423BS]; University Paul Sabatier of Toulouse [CR27 A01BQR-2007]; INSERM-Region Midi-Pyrenees	ARC (Association pour la Recherche Contre le Cancer)(Fondation ARC pour la Recherche sur le Cancer); LNCC (Ligue Nationale Contre le Cancer); Laboratoire d'Excellence Toulouse Cancer LABEX TOUCAN; Canceropole Grand Sud-Ouest; ANR (Agence Nationale pour la Recherche)(French National Research Agency (ANR)); University Paul Sabatier of Toulouse; INSERM-Region Midi-Pyrenees(Region Occitanie)	This work was supported by ARC (grant no. 5000, Association pour la Recherche Contre le Cancer), LNCC (Ligue Nationale Contre le Cancer RAB09006BBA), the Laboratoire d'Excellence Toulouse Cancer LABEX TOUCAN, the Canceropole Grand Sud-Ouest (RMA04002BPA), the ANR (Agence Nationale pour la Recherche, project no. R06423BS) and the University Paul Sabatier of Toulouse (CR27 A01BQR-2007). SL was recipient of a fellowship from LNCC. HL was recipient of a fellowship from INSERM-Region Midi-Pyrenees. MP was contracted by the RTRS-RITC (Toulouse). We thank Dr K Owaribe (University of Nagoya, Japan) for providing antibodies to BP180, BP230 and plectin, and Dr Tsao, University of Toronto for providing HPV-16E6E7immortalized HPDE cells.	Bausch D, 2011, CLIN CANCER RES, V17, P302, DOI 10.1158/1078-0432.CCR-10-0999; BERGSTRAESSER LM, 1995, AM J PATHOL, V147, P1823; Bon G, 2009, CANCER RES, V69, P5978, DOI 10.1158/0008-5472.CAN-09-0244; Bousquet C, 2006, EMBO J, V25, P3943, DOI 10.1038/sj.emboj.7601279; Bruns Christiane J., 1999, Neoplasia (New York), V1, P50, DOI 10.1038/sj.neo.7900005; Buscail L, 1996, CANCER RES, V56, P1823; Chen M, 2009, J BIOL CHEM, V284, P1484, DOI 10.1074/jbc.M803997200; Cruz-Monserrate Z, 2007, MODERN PATHOL, V20, P656, DOI 10.1038/modpathol.3800782; de Pereda JM, 2009, EMBO J, V28, P1180, DOI 10.1038/emboj.2009.48; Durlik Marek, 2012, Pol Przegl Chir, V84, P377, DOI 10.2478/v10035-012-0064-6; Dutta U, 2008, CANCER RES, V68, P8779, DOI 10.1158/0008-5472.CAN-08-2125; Fontao L, 1999, EXP CELL RES, V250, P298, DOI 10.1006/excr.1999.4549; Franzke CW, 2009, J BIOL CHEM, V284, P23386, DOI 10.1074/jbc.M109.034090; Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075; Frijns E, 2012, MOL BIOL CELL, V23, P1475, DOI 10.1091/mbc.E11-11-0957; Germain EC, 2009, MOL BIOL CELL, V20, P56, DOI 10.1091/mbc.E08-06-0646; Gleason B, 2005, J HISTOCHEM CYTOCHEM, V53, P799, DOI 10.1369/jhc.4B6522.2005; Hirako Y, 2003, J BIOCHEM, V133, P197, DOI 10.1093/jb/mvg024; Kelly KA, 2008, PLOS MED, V5, P657, DOI 10.1371/journal.pmed.0050085; Laklai H, 2009, P NATL ACAD SCI USA, V106, P17769, DOI 10.1073/pnas.0908674106; Margadant C, 2008, CURR OPIN CELL BIOL, V20, P589, DOI 10.1016/j.ceb.2008.05.001; Pal-Ghosh S, 2011, J CELL SCI, V124, P2666, DOI 10.1242/jcs.085480; Pyronnet S, 2008, MOL CELL ENDOCRINOL, V286, P230, DOI 10.1016/j.mce.2008.02.002; Radutovich N, 2008, METHOD ENZYMOL, V439, P1, DOI 10.1016/S0076-6879(07)00401-6; Shimanovich I, 2004, J PATHOL, V204, P519, DOI 10.1002/path.1674; Stathis A, 2010, NAT REV CLIN ONCOL, V7, P163, DOI 10.1038/nrclinonc.2009.236; Wilhelmsen K, 2006, MOL CELL BIOL, V26, P2877, DOI 10.1128/MCB.26.8.2877-2886.2006; Yu PT, 2012, INT J CANCER, V131, P1744, DOI 10.1002/ijc.27447	28	34	34	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2014	33	15					1934	1944		10.1038/onc.2013.146	http://dx.doi.org/10.1038/onc.2013.146			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RK	23624916				2022-12-28	WOS:000334346300006
J	Lin, H; Lin, Q; Liu, M; Lin, Y; Wang, X; Chen, H; Xia, Z; Lu, B; Ding, F; Wu, Q; Wang, HR				Lin, H.; Lin, Q.; Liu, M.; Lin, Y.; Wang, X.; Chen, H.; Xia, Z.; Lu, B.; Ding, F.; Wu, Q.; Wang, H-R			PKA/Smurf1 signaling-mediated stabilization of Nur77 is required for anticancer drug cisplatin-induced apoptosis	ONCOGENE			English	Article						Smurf1; Nur77; apoptosis; PKA; JNK; cisplatin	UBIQUITIN LIGASE SMURF2; NUCLEAR RECEPTOR NUR77; N-TERMINAL KINASE; PROTEIN-KINASE; CELL APOPTOSIS; CANCER-CELLS; DEGRADATION; PHOSPHORYLATION; MECHANISMS; POLARITY	The orphan nuclear receptor Nur77 regulates diverse cellular activities, including cell proliferation, differentiation and apoptosis. The c-Jun N-terminal kinase (JNK) have a dual role in controlling the function of Nur77. While JNK-mediated phosphorylation of Nur77 positively regulates its translocation to the mitochondria to induce apoptosis, it negatively regulates the stability of Nur77. The underlying mechanism for the dual role of JNK in regulating Nur77, however, is unclear. Here, we report that E3 ubiquitin ligase Smad ubiquitination regulatory factor 1 (Smurf1) prevents Nur77 degradation through mediating its unconventional ubiquitination, thereby mitigating the JNK-mediated downregulating effect, which leads to Nur77 accumulation and subsequent translocation to mitochondria to trigger apoptosis. In this process, protein kinase A (PKA)-mediated phosphorylation of Smurf1 at Thr306 is a prerequisite step. Accordingly, cyclic AMP/PKA signaling switches the fate of Nur77 from degradation to triggering apoptosis in chemotherapy drug cisplatin-treated cells. Hence, our study revealed a novel mechanism, by which PKA/Smurf1 antagonizes the downregulating effect of JNK on Nur77, leading to the accumulation of Nur77 for apoptosis induction triggered by cisplatin.	[Lin, H.; Lin, Q.; Liu, M.; Lin, Y.; Wang, X.; Chen, H.; Ding, F.; Wu, Q.; Wang, H-R] Xiamen Univ, Sch Life Sci, State Key Lab Cellular Stress Biol, Xiamen 361102, Fujian, Peoples R China; [Xia, Z.] Zhejiang Univ, Inst Life Sci, Hangzhou 310003, Zhejiang, Peoples R China; [Xia, Z.] Zhejiang Univ, Coll Med, Hangzhou 310003, Zhejiang, Peoples R China; [Lu, B.] Univ Pittsburgh, Sch Med, Dept Immunol, Pittsburgh, PA USA	Xiamen University; Zhejiang University; Zhejiang University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Wang, HR (corresponding author), Xiamen Univ, Sch Life Sci, State Key Lab Cellular Stress Biol, D301,Huang Chao Yang Bldg, Xiamen 361102, Fujian, Peoples R China.	wanghr@xmu.edu.cn	Ding, Feng/AAH-7335-2019; Lin, Huayue/G-8760-2017	Lin, Huayue/0000-0003-0151-3206; Wang, Hong-Rui/0000-0002-2916-8849	Ministry of Science and Technology of China [2011CB910800]; National Natural Science Foundation of China [31070771, 30970614, 81272248]; Fundamental Research Funds for the Central Universities [2010121087]; Specialized Research Fund for the Doctoral Program of Higher Education of China [20090121120017]; State Bureau of Foreign Experts and Ministry of Education [B12001]	Ministry of Science and Technology of China(Ministry of Science and Technology, China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Fundamental Research Funds for the Central Universities(Fundamental Research Funds for the Central Universities); Specialized Research Fund for the Doctoral Program of Higher Education of China(Specialized Research Fund for the Doctoral Program of Higher Education (SRFDP)); State Bureau of Foreign Experts and Ministry of Education	This work was supported by the Ministry of Science and Technology of China (2011CB910800), the National Natural Science Foundation of China (31070771, 30970614, 81272248), the Fundamental Research Funds for the Central Universities (2010121087), the Specialized Research Fund for the Doctoral Program of Higher Education of China (20090121120017) and Project 111 sponsored by the State Bureau of Foreign Experts and Ministry of Education (B12001). We thank SC Lin for commenting on the manuscript.	Cepeda V, 2007, ANTI-CANCER AGENT ME, V7, P3, DOI 10.2174/187152007779314044; Chen HZ, 2012, GUT, V61, P714, DOI 10.1136/gutjnl-2011-300783; Cheng PL, 2011, NEURON, V69, P231, DOI 10.1016/j.neuron.2010.12.021; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384; Han YH, 2006, ONCOGENE, V25, P2974, DOI 10.1038/sj.onc.1209358; HAZEL TG, 1991, MOL CELL BIOL, V11, P3239, DOI 10.1128/MCB.11.6.3239; HIRATA Y, 1993, J BIOL CHEM, V268, P24808; Hoeller D, 2006, NAT REV CANCER, V6, P776, DOI 10.1038/nrc1994; Holmes WF, 2003, ONCOGENE, V22, P6377, DOI 10.1038/sj.onc.1206694; Hsu SC, 2003, BLOOD, V101, P970, DOI 10.1182/blood-2002-03-0744; Insel PA, 2012, ACTA PHYSIOL, V204, P277, DOI 10.1111/j.1748-1716.2011.02273.x; Izzi L, 2004, ONCOGENE, V23, P2071, DOI 10.1038/sj.onc.1207412; Jacobs CM, 2004, J BIOL CHEM, V279, P50097, DOI 10.1074/jbc.M409145200; Jin YH, 2004, J BIOL CHEM, V279, P29409, DOI 10.1074/jbc.M313120200; Kartalou M, 2001, MUTAT RES-FUND MOL M, V478, P23, DOI 10.1016/S0027-5107(01)00141-5; Kulathu Y, 2012, NAT REV MOL CELL BIO, V13, P508, DOI 10.1038/nrm3394; Lebwohl D, 1998, EUR J CANCER, V34, P1522, DOI 10.1016/S0959-8049(98)00224-X; Lee SO, 2011, EXPERT OPIN THER TAR, V15, P195, DOI 10.1517/14728222.2011.547481; Lin BZ, 2004, CELL, V116, P527, DOI 10.1016/S0092-8674(04)00162-X; Liu B, 2007, ENDOCRINOLOGY, V148, P34, DOI 10.1210/en.2006-0800; Liu JJ, 2010, CANCER RES, V70, P3628, DOI 10.1158/0008-5472.CAN-09-3160; LIU ZG, 1994, NATURE, V367, P281, DOI 10.1038/367281a0; Masuyama N, 2001, J BIOL CHEM, V276, P32799, DOI 10.1074/jbc.M105431200; Moll UM, 2006, ONCOGENE, V25, P4725, DOI 10.1038/sj.onc.1209601; Narimatsu M, 2009, CELL, V137, P295, DOI 10.1016/j.cell.2009.02.025; Nie J, 2010, J BIOL CHEM, V285, P22816, DOI 10.1074/jbc.M110.126920; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Pearen MA, 2010, MOL ENDOCRINOL, V24, P1891, DOI 10.1210/me.2010-0015; Pekarsky Y, 2001, P NATL ACAD SCI USA, V98, P3690, DOI 10.1073/pnas.051003198; Popov N, 2010, NAT CELL BIOL, V12, P973, DOI 10.1038/ncb2104; Sanna MG, 2002, MOL CELL BIOL, V22, P1754, DOI 10.1128/MCB.22.6.1754-1766.2002; Schwamborn JC, 2007, EMBO J, V26, P1410, DOI 10.1038/sj.emboj.7601580; Wang AB, 2009, J IMMUNOL, V183, P3268, DOI 10.4049/jimmunol.0900894; Wang HR, 2006, METHOD ENZYMOL, V406, P437, DOI 10.1016/S0076-6879(06)06032-0; Wang HR, 2003, SCIENCE, V302, P1775, DOI 10.1126/science.1090772; Wiesner S, 2007, CELL, V130, P651, DOI 10.1016/j.cell.2007.06.050; Wingate AD, 2006, BIOCHEM J, V393, P715, DOI 10.1042/BJ20050967; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Yamashita M, 2005, CELL, V121, P101, DOI 10.1016/j.cell.2005.01.035; Yang H, 2011, HEPATOLOGY, V53, P865, DOI 10.1002/hep.24101; Yao LM, 2012, CARCINOGENESIS, V33, P301, DOI 10.1093/carcin/bgr287; Yoon K, 2011, CARCINOGENESIS, V32, P836, DOI 10.1093/carcin/bgr040; Yu H, 2007, CANCER BIOL THER, V6, P405, DOI 10.4161/cbt.6.3.3755; Zambon AC, 2005, P NATL ACAD SCI USA, V102, P8561, DOI 10.1073/pnas.0503363102; Zhang LZ, 2008, J BIOL CHEM, V283, P4304, DOI 10.1074/jbc.M708673200; Zhao M, 2003, J BIOL CHEM, V278, P27939, DOI 10.1074/jbc.M304132200	47	25	29	1	23	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 27	2014	33	13					1629	1639		10.1038/onc.2013.116	http://dx.doi.org/10.1038/onc.2013.116			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9QY	23584473				2022-12-28	WOS:000334344700003
J	Wu, X; Liu, T; Fang, O; Leach, LJ; Hu, X; Luo, Z				Wu, X.; Liu, T.; Fang, O.; Leach, L. J.; Hu, X.; Luo, Z.			miR-194 suppresses metastasis of non-small cell lung cancer through regulating expression of BMP1 and p27(kip1)	ONCOGENE			English	Article						non-small cell lung cancer; metastasis; miR-194; regulatory and signaling pathway; TGF beta; RhoA	TGF-BETA; MICRORNA; ACTIVATION; TARGET; GROWTH; IDENTIFICATION; INVASION; MIR-31; LIVER; RNAS	MicroRNAs (miRNAs) are increasingly implicated in regulating tumor malignance through their capacity to coordinately repress expression of tumor-related genes. Here, we show that overexpression of miR-194 in lung cancer cell lines, results in suppressing metastasis of lung cancer cells, while inhibiting its expression through miRNA sponge promotes the cancer cells to metastasize. miR-194 expression is also found to be in strongly negative association with metastasis in clinical specimens of non-small cell lung cancer. We demonstrate that miR-194 directly targets both BMP1 and p27(kip1). The resulting downregulation of BMP1 leads to suppression of TGF beta activity and, thus, to downregulation of the expression of key oncogenic genes (matrix metalloproteinases MMP2 and MMP9). This leads, in turn, to decreased tumor invasion. In addition, the miRNA-194-induced suppression of p27(kip1) activates the RhoA pathway, producing enhanced development of actin stress fibers and impaired migration of cancer cells. These findings reveal two structurally independent but functionally linked branches of the regulatory and signaling pathway that together provide a bridge between the metastasis-depressing miRNA and the key genes that govern the malignancy of lung cancers.	[Wu, X.; Liu, T.; Fang, O.; Hu, X.; Luo, Z.] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai 200433, Peoples R China; [Leach, L. J.; Luo, Z.] Univ Birmingham, Sch Biosci, Birmingham, W Midlands, England	Fudan University; University of Birmingham	Luo, Z (corresponding author), Fudan Univ, Sch Life Sci, Shanghai 200433, Peoples R China.	xhhu@fudan.edu.cn; z.luo@bham.ac.uk		Compton, Lindsey/0000-0002-8441-2381	National Basic Research Program of China [2012CB316505]; National Natural Science Foundation of China [81172006]; Leverhulme Trust (UK)	National Basic Research Program of China(National Basic Research Program of China); National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Leverhulme Trust (UK)(Leverhulme Trust)	We owe gratefully to two anonymous reviewers whose constructively critical comments have been very helpful to improve the quality and presentation of an earlier version of the paper. We thank the unnamed patients for their consent to allow us to use the lung tissue samples in this research. This work was supported by the National Basic Research Program of China (2012CB316505) and National Natural Science Foundation of China (81172006). ZWL is also supported by the Leverhulme Trust (UK).	Aigner A, 2011, J MOL MED, V89, P445, DOI 10.1007/s00109-010-0716-0; Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002; Besson A, 2004, GENE DEV, V18, P862, DOI 10.1101/gad.1185504; Besson A, 2007, GENE DEV, V21, P1731, DOI 10.1101/gad.1556607; Bommer GT, 2007, CURR BIOL, V17, P1298, DOI 10.1016/j.cub.2007.06.068; Chadrick ED, 2010, J THORAC CARDIOV SUR, V140, P505; D'Amico TA, 2008, ANN THORAC SURG, V85, pS737, DOI 10.1016/j.athoracsur.2007.11.047; Dong PX, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-99; Ebert MS, 2007, NAT METHODS, V4, P721, DOI 10.1038/NMETH1079; Fidler IJ, 2003, NAT REV CANCER, V3, P453, DOI 10.1038/nrc1098; Garzon R, 2008, CURR OPIN HEMATOL, V15, P352, DOI 10.1097/MOH.0b013e328303e15d; Ge GX, 2006, J CELL BIOL, V175, P111, DOI 10.1083/jcb.200606058; Grimson A, 2007, MOL CELL, V27, P91, DOI 10.1016/j.molcel.2007.06.017; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Harpole DH, 2007, THORAC SURG CLIN, V17, P67; Hayashita Y, 2005, CANCER RES, V65, P9628, DOI 10.1158/0008-5472.CAN-05-2352; Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010; Jenkins RH, 2012, BIOCHEM J, V443, P407, DOI 10.1042/BJ20111861; Kawauchi T, 2006, NAT CELL BIOL, V8, P17, DOI 10.1038/ncb1338; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Kruger J, 2006, NUCLEIC ACIDS RES, V34, pW451, DOI 10.1093/nar/gkl243; Krutzfeldt J, 2012, HEPATOLOGY, V55, P98, DOI 10.1002/hep.24658; Kumar MS, 2008, P NATL ACAD SCI USA, V105, P3903, DOI 10.1073/pnas.0712321105; Liu X, 2010, J CLIN INVEST, V120, P1298, DOI 10.1172/JCI39566; Massague J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001; Meng ZP, 2010, HEPATOLOGY, V52, P2148, DOI 10.1002/hep.23915; Pan TL, 2012, J PROTEOMICS, V75, P4676, DOI 10.1016/j.jprot.2012.02.017; Pichiorri F, 2010, CANCER CELL, V18, P367, DOI 10.1016/j.ccr.2010.09.005; Raver-Shapira N, 2007, MOL CELL, V26, P731, DOI 10.1016/j.molcel.2007.05.017; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sehgal I, 1999, MOL BIOL CELL, V10, P407, DOI 10.1091/mbc.10.2.407; Sicinski P, 2007, GENE DEV, V21, P1703, DOI 10.1101/gad.1583207; Song YX, 2012, ANN SURG ONCOL, V19, pS509, DOI 10.1245/s10434-011-1999-2; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Valastyan S, 2011, GENE DEV, V25, P646, DOI 10.1101/gad.2004211; Valastyan S, 2009, CELL, V137, P1032, DOI 10.1016/j.cell.2009.03.047; Ventura A, 2009, CELL, V136, P586, DOI 10.1016/j.cell.2009.02.005; Wang JW, 2009, CANCER LETT, V281, P71, DOI 10.1016/j.canlet.2009.02.020; Wang JC, 2007, GENE CHROMOSOME CANC, V46, P192, DOI 10.1002/gcc.20400; Xiong SD, 2011, INT J BIOL SCI, V7, P805, DOI 10.7150/ijbs.7.805; Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025; 张斯良, 2006, [中华放射肿瘤学杂志, Chinese Journal of Radiation Oncology], V15, P430	42	80	86	0	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 20	2014	33	12					1506	1514		10.1038/onc.2013.108	http://dx.doi.org/10.1038/onc.2013.108			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AD4TS	23584484				2022-12-28	WOS:000333244200004
J	Arensman, MD; Kovochich, AN; Kulikauskas, RM; Lay, AR; Yang, PT; Li, X; Donahue, T; Major, MB; Moon, RT; Chien, AJ; Dawson, DW				Arensman, M. D.; Kovochich, A. N.; Kulikauskas, R. M.; Lay, A. R.; Yang, P-T; Li, X.; Donahue, T.; Major, M. B.; Moon, R. T.; Chien, A. J.; Dawson, D. W.			WNT7B mediates autocrine Wnt/beta-catenin signaling and anchorage-independent growth in pancreatic adenocarcinoma	ONCOGENE			English	Article						pancreatic cancer; WNT7B; Wnt/beta-catenin signaling	BETA-CATENIN; HUMAN-DISEASE; TUMOR-CELLS; E-CADHERIN; CANCER; EXPRESSION; PATHWAY; SURVIVAL; TUMORIGENICITY; STABILIZATION	Developmental and cancer models show Wnt/beta-catenin-dependent signaling mediates diverse phenotypic outcomes in the pancreas that are dictated by context, duration and strength of activation. While generally assumed to be pro-tumorigenic, it is unclear to what extent dysregulation of Wnt/beta-catenin signaling impacts tumor progression in pancreatic adenocarcinoma (PDAC). In the present study, Wnt/beta-catenin activity was characterized across a spectrum of PDAC cell lines and primary tumors. Reporter and gene expression-based assays revealed wide heterogeneity in Wnt/beta-catenin transcriptional activity across PDAC cell lines and patient tumors, as well as variable responsiveness to exogenous Wnt ligand stimulation. An experimentally generated, pancreas-specific gene expression signature of Wnt/beta-catenin transcriptional activation was used to stratify pathway activation across a cohort of resected, early-stage PDAC tumors (N = 41). In this cohort, higher Wnt/beta-catenin activation was found to significantly correlate with lymphvascular invasion and worse disease-specific survival (median survival time 20.3 versus 43.9 months, log-rank P = 0.03). Supporting the importance of Wnt ligand in mediating autocrine Wnt signaling, Wnt/beta-catenin activity was significantly inhibited in PDAC cell lines by WLS gene silencing and the small-molecule inhibitor IWP-2, both of which functionally block Wnt ligand processing and secretion. Transcriptional profiling revealed elevated expression of WNT7B occurred in PDAC cell lines with high levels of cell autonomous Wnt/beta-catenin activity. Gene-knockdown studies in AsPC-1 and HPAF-2 cell lines confirmed WNT7B-mediated cell autonomous Wnt/beta-catenin activation, as well as an anchorage-independent growth phenotype. Our findings indicate WNT7B can serve as a primary determinant of differential Wnt/beta-catenin activation in PDAC. Disrupting the interaction between Wnt ligands and their receptors may be a particularly suitable approach for therapeutic modulation of Wnt/beta-catenin signaling in PDAC and other cancer contexts where Wnt activation is mediated by ligand expression rather than mutations in canonical pathway members.	[Arensman, M. D.; Kovochich, A. N.; Lay, A. R.; Li, X.; Dawson, D. W.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pathol & Lab Med, Los Angeles, CA 90095 USA; [Kulikauskas, R. M.; Yang, P-T; Moon, R. T.; Chien, A. J.] Univ Washington, Sch Med, Dept Pharmacol, Howard Hughes Med Inst, Seattle, WA 98195 USA; [Kulikauskas, R. M.; Yang, P-T; Moon, R. T.; Chien, A. J.] Univ Washington, Sch Med, Inst Stem Cell & Regenerat Med, Seattle, WA 98195 USA; [Li, X.; Donahue, T.; Dawson, D. W.] Univ Calif Los Angeles, David Geffen Sch Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; [Donahue, T.] Univ Calif Los Angeles, David Geffen Sch Med, Inst Mol Med & Mol & Med Pharmacol, Dept Surg,Div Gen Surg, Los Angeles, CA 90095 USA; [Major, M. B.] Univ North Carolina Chapel Hill, Sch Med, Lineberger Comprehens Canc Ctr, Dept Cell Biol & Physiol, Chapel Hill, NC USA; [Chien, A. J.] Univ Washington, Sch Med, Dept Med, Div Dermatol, Seattle, WA 98195 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of Washington; University of Washington Seattle	Chien, AJ (corresponding author), Univ Washington, Sch Med, Dept Pharmacol, Howard Hughes Med Inst, Box 357370, Seattle, WA 98195 USA.	chien@u.washington.edu; ddawson@mednet.ucla.edu	Moon, Randall T/B-1743-2014; Dawson, David/I-5917-2014; Moon, Randall/M-5605-2019	Moon, Randall T/0000-0002-9352-1408; Moon, Randall/0000-0002-9352-1408; Major, Michael/0000-0002-6753-8513	American Cancer Society Research Scholar Grant; American Association for Cancer Research/Pancreatic Cancer Action Network; UCLA Department of Pathology; NCI/NIH [1K08128565]; University of Washington Office of the Provost; UCLA Tumor Biology Program (USHHS Ruth L. Kirschstein Institutional National Research Service Award) [T32 CA009056]; NATIONAL CANCER INSTITUTE [P30CA016042, P01CA163200, K08CA128565, T32CA009056] Funding Source: NIH RePORTER	American Cancer Society Research Scholar Grant(American Cancer Society); American Association for Cancer Research/Pancreatic Cancer Action Network; UCLA Department of Pathology; NCI/NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); University of Washington Office of the Provost; UCLA Tumor Biology Program (USHHS Ruth L. Kirschstein Institutional National Research Service Award); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	DWD was supported by an American Cancer Society Research Scholar Grant, an American Association for Cancer Research/Pancreatic Cancer Action Network Career Development Award in memory of Seena Magowitz and a Research Services Research Fund Grant from the UCLA Department of Pathology. AJC was supported by a Career Development Award (1K08128565) from the NCI/NIH and Bridge Funding from the University of Washington Office of the Provost. MDA was supported by the UCLA Tumor Biology Program (USHHS Ruth L. Kirschstein Institutional National Research Service Award # T32 CA009056).	American Council of the Teaching of Foreign Language, 2012, CLEARVOICETM TECHN F, P1; Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717; Kovochich AN, 2013, CANCER-AM CANCER SOC, V119, P529, DOI 10.1002/cncr.27725; Biankin AV, 2012, NATURE, V491, P399, DOI 10.1038/nature11547; Bilechele Travis L., 2008, V468, P99, DOI 10.1007/978-1-59745-249-6_8; Caca K, 1999, CELL GROWTH DIFFER, V10, P369; Chang JT, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-443; Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137; Chien AJ, 2007, FRONT BIOSCI-LANDMRK, V12, P448, DOI 10.2741/2074; Chien AJ, 2009, J INVEST DERMATOL, V129, P1614, DOI 10.1038/jid.2008.445; Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012; di Magliano MP, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001155; Donahue TR, 2012, CLIN CANCER RES, V18, P1352, DOI 10.1158/1078-0432.CCR-11-1539; Froeling FEM, 2011, GASTROENTEROLOGY, V141, P1486, DOI 10.1053/j.gastro.2011.06.047; Froeling FEM, 2009, AM J PATHOL, V175, P636, DOI 10.2353/ajpath.2009.090131; Gerdes B, 1999, DIGESTION, V60, P544, DOI 10.1159/000007704; Gurney A, 2012, P NATL ACAD SCI USA, V109, P11717, DOI 10.1073/pnas.1120068109; Heiser PW, 2008, GASTROENTEROLOGY, V135, P1288, DOI 10.1053/j.gastro.2008.06.089; Hong SM, 2011, ARCH PATHOL LAB MED, V135, P716, DOI 10.1043/2010-0566-RA.1; Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356; Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002; Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Liu N, 1998, AM J PATHOL, V153, P263, DOI 10.1016/S0002-9440(10)65567-8; Lowe AW, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000323; Lucero OM, 2010, CURR ONCOL REP, V12, P314, DOI 10.1007/s11912-010-0114-3; Maitra A, 2008, ANNU REV PATHOL-MECH, V3, P157, DOI 10.1146/annurev.pathmechdis.3.121806.154305; Morris JP, 2010, NAT REV CANCER, V10, P683, DOI 10.1038/nrc2899; Morris JP, 2010, J CLIN INVEST, V120, P508, DOI 10.1172/JCI40045; Nawroth R, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000392; Port F, 2010, TRAFFIC, V11, P1265, DOI 10.1111/j.1600-0854.2010.01076.x; Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0; Vincent A, 2011, CLIN CANCER RES, V17, P4341, DOI 10.1158/1078-0432.CCR-10-3431; Wang LD, 2009, CANCER CELL, V15, P207, DOI 10.1016/j.ccr.2009.01.018; White BD, 2012, GASTROENTEROLOGY, V142, P219, DOI 10.1053/j.gastro.2011.12.001; Yu M, 2012, NATURE, V487, P510, DOI 10.1038/nature11217; Zeng G, 2006, NEOPLASIA, V8, P279, DOI 10.1593/neo.05607; Zhong Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022129	38	77	81	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2014	33	7					899	908		10.1038/onc.2013.23	http://dx.doi.org/10.1038/onc.2013.23			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB2MN	23416978	Green Submitted, Green Accepted			2022-12-28	WOS:000331626900011
J	Gao, M; Liang, J; Lu, Y; Guo, H; German, P; Bai, S; Jonasch, E; Yang, X; Mills, GB; Ding, Z				Gao, M.; Liang, J.; Lu, Y.; Guo, H.; German, P.; Bai, S.; Jonasch, E.; Yang, X.; Mills, G. B.; Ding, Z.			Site-specific activation of AKT protects cells from death induced by glucose deprivation	ONCOGENE			English	Article						glucose deprivation; site-specific AKT phosphorylation; substrate-specific AKT activation; cell survival	GROWTH-FACTORS; IN-VITRO; KINASE; PATHWAY; PHOSPHORYLATION; INHIBITOR; TARGET; SURVIVAL; IDENTIFICATION; PHOSPHATASE	The serine/threonine kinase AKT is a key mediator of cancer cell survival. We demonstrate that transient glucose deprivation modestly induces AKT phosphorylation at both Thr308 and Ser473. In contrast, prolonged glucose deprivation induces selective AKTThr308 phosphorylation and phosphorylation of a distinct subset of AKT downstream targets leading to cell survival under metabolic stress. Glucose-deprivation-induced AKTThr308 phosphorylation is dependent on PDK1 and PI3K but not EGF receptor or IGF1R. Prolonged glucose deprivation induces the formation of a complex of AKT, PDK1 and the GRP78 chaperone protein, directing phosphorylation of AKTThr308 but not AKTSer473. Our results reveal a novel mechanism of AKT activation under prolonged glucose deprivation that protects cells from metabolic stress. The selective activation of AKTThr308 phosphorylation that occurs during prolonged nutrient deprivation may provide an unexpected opportunity for the development and implementation of drugs targeting cell metabolism and aberrant AKT signaling.	[Gao, M.; Yang, X.] Shandong Univ, Qilu Hosp, Dept Obstet & Gynecol, Jinan 250100, Peoples R China; [Gao, M.; Liang, J.; Lu, Y.; Guo, H.; Mills, G. B.; Ding, Z.] Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, Houston, TX 77030 USA; [German, P.; Bai, S.; Jonasch, E.] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX 77030 USA	Shandong University; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Mills, GB (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Syst Biol, 1515 Holcombe Blvd, Houston, TX 77030 USA.	gmills@mdanderson.org; zding@mdanderson.org			National Institutes of Health (NIH) [5R21CA126700]; University of Texas MD Anderson Cancer Center Kidney Cancer Multidisciplinary Research Program; AstraZeneca; GlaxoSmithKline; NIH [CA016672];  [P01CA099031];  [P50CA083639];  [SU2C-AACR-DT0209]; NATIONAL CANCER INSTITUTE [R21CA126700, P50CA098258, P01CA099031, P50CA083639, P30CA016672] Funding Source: NIH RePORTER	National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Texas MD Anderson Cancer Center Kidney Cancer Multidisciplinary Research Program; AstraZeneca(AstraZeneca); GlaxoSmithKline(GlaxoSmithKline); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; ; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Qinghua Yu and Nancy Shih for technical assistance for RPPA experiments. The work was supported by National Institutes of Health (NIH) grant 5R21CA126700, a grant from The University of Texas MD Anderson Cancer Center Kidney Cancer Multidisciplinary Research Program and research support from AstraZeneca to ZD, and P01CA099031, P50CA083639, SU2C-AACR-DT0209 and research support from AstraZeneca and GlaxoSmithKline to GBM. RPPA was performed at the MD Anderson RPPA Core Facility (supported by NIH grant CA016672).	Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Brazil DP, 2004, TRENDS BIOCHEM SCI, V29, P233, DOI 10.1016/j.tibs.2004.03.006; Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751; Ding ZY, 2006, P NATL ACAD SCI USA, V103, P15014, DOI 10.1073/pnas.0606917103; Ding ZY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009910; Duncia JV, 1998, BIOORG MED CHEM LETT, V8, P2839, DOI 10.1016/S0960-894X(98)00522-8; Ericson K, 2010, P NATL ACAD SCI USA, V107, P2598, DOI 10.1073/pnas.0914018107; Folkes AJ, 2008, J MED CHEM, V51, P5522, DOI 10.1021/jm800295d; Folkman J, 2003, SEMIN CANCER BIOL, V13, P159, DOI 10.1016/S1044-579X(02)00133-5; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fu Y, 2008, P NATL ACAD SCI USA, V105, P19444, DOI 10.1073/pnas.0807691105; Gao TY, 2005, MOL CELL, V18, P13, DOI 10.1016/j.molcel.2005.03.008; Gewinner C, 2009, CANCER CELL, V16, P115, DOI 10.1016/j.ccr.2009.06.006; Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Hennessy BT, 2009, CLIN CANCER RES, V15, P417, DOI 10.1158/1078-0432.CCR-08-2620; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Higuchi M, 2008, NAT CELL BIOL, V10, P1356, DOI 10.1038/ncb1795; Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012; Jacinto E, 2006, CELL, V127, P125, DOI 10.1016/j.cell.2006.08.033; Kim KY, 2009, CANCER RES, V69, P4018, DOI 10.1158/0008-5472.CAN-08-2641; Knight ZA, 2006, CELL, V125, P733, DOI 10.1016/j.cell.2006.03.035; Kuma A, 2004, NATURE, V432, P1032, DOI 10.1038/nature03029; Lu Y, 2011, ONCOGENE, V30, P4567, DOI 10.1038/onc.2011.164; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; MacDonald ML, 2006, NAT CHEM BIOL, V2, P329, DOI 10.1038/nchembio790; Macias AT, 2011, J MED CHEM, V54, P4034, DOI 10.1021/jm101625x; Manning BD, 2005, GENE DEV, V19, P1773, DOI 10.1101/gad.1314605; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; Najafov A, 2011, BIOCHEM J, V433, P357, DOI 10.1042/BJ20101732; Nakamura A, 2008, MOL CELL BIOL, V28, P5996, DOI 10.1128/MCB.00114-08; O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925; Pelicano H, 2006, J CELL BIOL, V175, P913, DOI 10.1083/jcb.200512100; Pfaffenbach KT, 2011, CURR OPIN CELL BIOL, V23, P150, DOI 10.1016/j.ceb.2010.09.007; Roberts HR, 2011, CARCINOGENESIS, V32, P1741, DOI 10.1093/carcin/bgr210; Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148; Sengupta S, 2010, MOL CELL, V40, P310, DOI 10.1016/j.molcel.2010.09.026; Tremblay F, 2007, P NATL ACAD SCI USA, V104, P14056, DOI 10.1073/pnas.0706517104; Vincent EE, 2011, BRIT J CANCER, V104, P1755, DOI 10.1038/bjc.2011.132; von der Crone S, 2000, EUR J CELL BIOL, V79, P943, DOI 10.1078/0171-9335-00118; Wheeler DL, 2010, NAT REV CLIN ONCOL, V7, P493, DOI 10.1038/nrclinonc.2010.97; Worster DT, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2001986; Zhong DS, 2008, MOL CANCER THER, V7, P809, DOI 10.1158/1535-7163.MCT-07-0559; Zhong DS, 2009, J BIOL CHEM, V284, P23225, DOI 10.1074/jbc.M109.005280	48	44	44	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2014	33	6					745	755		10.1038/onc.2013.2	http://dx.doi.org/10.1038/onc.2013.2			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5IL	23396361	Green Accepted			2022-12-28	WOS:000331129200009
J	Tripathi, V; Popescu, NC; Zimonjic, DB				Tripathi, V.; Popescu, N. C.; Zimonjic, D. B.			DLC1 induces expression of E-cadherin in prostate cancer cells through Rho pathway and suppresses invasion	ONCOGENE			English	Article						E-cadherin; DLC1; Rho; invasion; prostate cancer	GTPASE-ACTIVATING PROTEIN; EPITHELIAL TUMOR-CELLS; HEPATOCELLULAR-CARCINOMA; ADHERENS JUNCTIONS; BREAST-CANCER; RHO/ROCK PATHWAY; GENE-EXPRESSION; FAMILY GTPASES; IN-VIVO; ADHESION	E-cadherin is a cell-cell adhesion molecule that acts as a suppressor of cancer cell invasion and its expression is downregulated in many advanced, poorly differentiated, human cancers. In this study, we found that the expression of DLC1 (deleted in liver cancer 1) tumor-suppressor gene in metastatic prostate carcinoma (PCA) cells increased the expression of E-cadherin and resulted in an elevated rate of cell-cell aggregation as measured by aggregation assay. DLC1-mediated increase in E-cadherin expression was not dependent on alpha-catenin, a DLC1-binding protein associated with E-cadherin, and/or cellular density. The increase of E-cadherin expression occurred at mRNA level and relied on DLC1 RhoGAP function, leading to suppression of high level of RhoA-GTP and RhoC-GTP activity in metastatic PCA cells. Application of Rho/ROCK inhibitors produced the same effect as introduction of DLC1. Knocking down of RhoA produced a moderate increase in E-cadherin whereas knocking down of RhoC resulted in a significant increase of E-cadherin. Downregulation of E-cadherin caused by constitutively active RhoA(V14) and RhoC(V14) could not be reversed by expression of DLC1 in DLC1-negative cell line. DLC1-mediated suppression of metastatic PCA cells invasion was comparable with the one associated with ectopic E-cadherin expression, or caused by suppression of Rho pathway either by Rho/ROCK inhibitors, or by shRNA repression. This study demonstrates that DLC1 expression positively regulates E-cadherin and suppresses highly metastatic PCA cell invasion by modulating Rho pathway, which appears as a feasible therapeutic target in cancers with high activity of RhoGTPases.	[Tripathi, V.; Popescu, N. C.; Zimonjic, D. B.] NCI, Expt Carcinogenesis Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Popescu, NC (corresponding author), NCI, Expt Carcinogenesis Lab, NIH, Bldg 37,Room 4128B,37 Convent Dr,MSC 4262, Bethesda, MD 20892 USA.	popescun@mail.nih.gov	Zimonjic, Drazen/AAX-7513-2020		National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA	National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This research was supported by the Intramural Research Program of the National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.	Annicotte JS, 2006, MOL CELL BIOL, V26, P7561, DOI 10.1128/MCB.00605-06; Asnaghi L, 2010, ONCOGENE, V29, P2760, DOI 10.1038/onc.2010.39; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Braga VMM, 2005, CURR OPIN CELL BIOL, V17, P466, DOI 10.1016/j.ceb.2005.08.012; Brouxhon S, 2007, CANCER RES, V67, P7654, DOI 10.1158/0008-5472.CAN-06-4415; Burbelo P, 2004, BREAST CANCER RES TR, V84, P43, DOI 10.1023/B:BREA.0000018422.02237.f9; Chang YWE, 2006, CANCER RES, V66, P11700, DOI 10.1158/0008-5472.CAN-06-1818; Cheng L, 1996, AM J PATHOL, V148, P1375; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Conacci-Sorrell M, 2003, J CELL BIOL, V163, P847, DOI 10.1083/jcb.200308162; Durkin ME, 2007, J CELL MOL MED, V11, P1185, DOI 10.1111/j.1582-4934.2007.00098.x; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; Goodison S, 2005, CANCER RES, V65, P6042, DOI 10.1158/0008-5472.CAN-04-3043; Guan M, 2008, CANCER GENE THER, V15, P371, DOI 10.1038/cgt.2008.13; Guan M, 2006, CLIN CANCER RES, V12, P1412, DOI 10.1158/1078-0432.CCR-05-1906; Hajra KM, 2002, CANCER RES, V62, P1613; Healy KD, 2008, MOL CARCINOGEN, V47, P326, DOI 10.1002/mc.20389; Hodge JC, 2003, CANCER RES, V63, P1359; Jeong KJ, 2012, ONCOGENE, V31, P4279, DOI 10.1038/onc.2011.595; JIANG WG, 1995, CANCER RES, V55, P5043; Kamai T, 2003, CLIN CANCER RES, V9, P2632; Koksal IT, 2002, PATHOLOGY, V34, P233, DOI 10.1080/00313020220131282; Lahoz A, 2008, GENE DEV, V22, P1724, DOI 10.1101/gad.1691408; Li GR, 2011, P NATL ACAD SCI USA, V108, P17129, DOI 10.1073/pnas.1112122108; Li LC, 2001, J UROLOGY, V166, P705, DOI 10.1016/S0022-5347(05)66047-8; Liao YC, 2007, J CELL BIOL, V176, P43, DOI 10.1083/jcb.200608015; Lozano E, 2003, BIOESSAYS, V25, P452, DOI 10.1002/bies.10262; Mege RM, 2006, CURR OPIN CELL BIOL, V18, P541, DOI 10.1016/j.ceb.2006.08.004; Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521; Noe V, 2001, J CELL SCI, V114, P111; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Qian XL, 2007, P NATL ACAD SCI USA, V104, P9012, DOI 10.1073/pnas.0703033104; Rashid MG, 2001, CANCER RES, V61, P489; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; Sahai E, 2002, NAT CELL BIOL, V4, P408, DOI 10.1038/ncb796; Sawada K, 2008, METHOD ENZYMOL, V439, P395, DOI 10.1016/S0076-6879(07)00428-4; Sawada K, 2008, CANCER RES, V68, P2329, DOI 10.1158/0008-5472.CAN-07-5167; Sequeira L, 2008, CLIN EXP METASTAS, V25, P569, DOI 10.1007/s10585-008-9173-3; Suwa H, 1998, BRIT J CANCER, V77, P147, DOI 10.1038/bjc.1998.23; Thiolloy S, 2011, SEMIN CANCER BIOL, V21, P89, DOI 10.1016/j.semcancer.2010.12.008; Tripathi V, 2012, MOL CELL BIOL, V32, P2145, DOI 10.1128/MCB.06580-11; Vega FM, 2008, FEBS LETT, V582, P2093, DOI 10.1016/j.febslet.2008.04.039; Vigil D, 2010, NAT REV CANCER, V10, P842, DOI 10.1038/nrc2960; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Weaver VM, 1997, J CELL BIOL, V137, P231, DOI 10.1083/jcb.137.1.231; Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033; Wong CCL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002779; Wu M, 2010, CANCER-AM CANCER SOC, V116, P2768, DOI 10.1002/cncr.25181; Xue W, 2008, GENE DEV, V22, P1439, DOI 10.1101/gad.1672608; Yam JWP, 2006, CANCER RES, V66, P8367, DOI 10.1158/0008-5472.CAN-05-2850; Zhou Q, 2009, MOL CANCER THER, V8, P1684, DOI 10.1158/1535-7163.MCT-09-0191; Zhou XL, 2004, ONCOGENE, V23, P1308, DOI 10.1038/sj.onc.1207246; Zimonjic DB, 2012, INT J ONCOL, V41, P393, DOI 10.3892/ijo.2012.1474	57	28	30	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 6	2014	33	6					724	733		10.1038/onc.2013.7	http://dx.doi.org/10.1038/onc.2013.7			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5IL	23376848				2022-12-28	WOS:000331129200007
J	Azar, WJ; Zivkovic, S; Werther, GA; Russo, VC				Azar, W. J.; Zivkovic, S.; Werther, G. A.; Russo, V. C.			IGFBP-2 nuclear translocation is mediated by a functional NLS sequence and is essential for its pro-tumorigenic actions in cancer cells	ONCOGENE			English	Article						IGFBP-2; cancer cells; VEGF; angiogenesis and CAM assay; NLS; Importin alpha/beta	GROWTH-FACTOR-BINDING; ACID-LABILE SUBUNIT; LOCALIZATION SIGNAL; BREAST-CANCER; IN-VIVO; IMPORTIN-ALPHA; NUCLEOCYTOPLASMIC TRANSPORT; PROMOTER ACTIVITY; STRUCTURAL BASIS; PROTEIN IMPORT	IGFBP-2 is highly expressed in both the serum and tumor tissues of most cancers, and is considered one of the most significant genes in the signature of major cancers. IGFBP-2 mainly modulates IGF actions in the pericellular space; however, there is considerable evidence to suggest that IGFBP-2 may also act independently of the IGFs. These IGF-independent actions of IGFBP-2 are exerted either via interactions at the cell surface or intracellularly, via interaction with cytoplasmic or nuclear-binding partners. The precise mechanism underlying the intracellular/intranuclear localization of IGFBP-2 remains unclear. In this study, we investigated IGFBP-2 nuclear localization in several common cancer cells with the aim of dissecting the mechanism of its nuclear trafficking. IGFBP-2 is detected in the nuclei of common cancer cells, including breast, prostate and several neuroblastoma cell lines, using cell fractionation and confocal microscopy. Via nuclear import assays, we show that nuclear entry of IGFBP-2 is mediated by the classical nuclear import mechanisms, primarily through importin-alpha, as demonstrated by the use of blocking, competition and co-immunoprecipitation assays. Bioinformatics analysis of the IGFBP-2 protein sequence with PSORT II identified a classical nuclear localization signal (cNLS) sequence at 179PKKLRPP185, within the IGFBP-2 linker domain, mutagenesis of which abolishes IGFBP-2 nuclear import. Accordingly, the NLS(mut)IGFBP-2 fails to activate the VEGF promoter, which would otherwise occur in the presence of wild-type IGFBP-2. As a consequence, no activation of angiogenic processes were observed in NLS(mut)IGFBP-2 expressing SHEP cells when implanted onto our in vivo quail chorio-allantoic membrane model. Taken together, these data show for the first time that IGFBP-2 possesses a functional NLS sequence and that IGFBP-2 actively translocates into the nucleus by a classical nuclear import mechanism, involving formation of IGFBP-2 complexes with importin-alpha. Nuclear IGFBP-2 is required for the activation of VEGF expression and consequent angiogenesis.	[Azar, W. J.; Zivkovic, S.; Werther, G. A.; Russo, V. C.] Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; [Azar, W. J.; Werther, G. A.; Russo, V. C.] Univ Melbourne, Dept Paediat, Parkville, Vic 3052, Australia	Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; University of Melbourne	Russo, VC (corresponding author), Royal Childrens Hosp, Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	vince.russo@mcri.edu.au			National Health and Medical Research Council (NHMRC) of Australia [1008062]; Melbourne University (MRS)	National Health and Medical Research Council (NHMRC) of Australia(National Health and Medical Research Council (NHMRC) of Australia); Melbourne University (MRS)	We wish to thank Professor Dev Mukhopadhyay (Mayo Clinic, Rochester, MN, USA) for kindly supplying the VEGF constructs used in these studies, Dr Mark Denham (Neuroscience, University of Melbourne) for his assistance in developing the GFP-SHEP cells clones, Dr Donald Newgreen (MCRI) for his assistance in developing CAM assays and Dr Sheena Azar for constant assistance during manuscript preparation. This work was supported by the National Health and Medical Research Council (NHMRC) of Australia Project Grants 1008062 (to GAW and VCR). WJA is the recipient of a Melbourne University (MRS) PhD scholarship.	ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; Azar WJ, 2011, ENDOCRINOLOGY, V152, P3332, DOI 10.1210/en.2011-1121; Ben-Shmuel A, 2012, ONCOGENE, V6, P340; Besnard V, 2001, BBA-MOL CELL RES, V1538, P47, DOI 10.1016/S0167-4889(00)00136-1; BOOTH BA, 1995, GROWTH REGULAT, V5, P1; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; Busund LT, 2005, J CLIN PATHOL, V58, P361, DOI 10.1136/jcp.2004.020834; Butt AJ, 2003, J BIOL CHEM, V278, P29676, DOI 10.1074/jbc.M301965200; Catimel B, 2001, J BIOL CHEM, V276, P34189, DOI 10.1074/jbc.M103531200; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; CHI NC, 1995, J CELL BIOL, V130, P265, DOI 10.1083/jcb.130.2.265; CHIDA K, 1992, P NATL ACAD SCI USA, V89, P4290, DOI 10.1073/pnas.89.10.4290; Chook YM, 2001, CURR OPIN STRUC BIOL, V11, P703, DOI 10.1016/S0959-440X(01)00264-0; Cingolani G, 2002, MOL CELL, V10, P1345, DOI 10.1016/S1097-2765(02)00727-X; COHEN P, 1993, J CLIN ENDOCR METAB, V76, P1031, DOI 10.1210/jc.76.4.1031; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; DUBOIS V, 1993, BIOCHEM BIOPH RES CO, V192, P295, DOI 10.1006/bbrc.1993.1413; Elmlinger MW, 2001, ENDOCRINOLOGY, V142, P1652, DOI 10.1210/en.142.4.1652; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Firth SM, 1998, J BIOL CHEM, V273, P2631, DOI 10.1074/jbc.273.5.2631; Firth SM, 2001, ENDOCRINOLOGY, V142, P2147, DOI 10.1210/en.142.5.2147; Flyvbjerg A, 1997, J CLIN ENDOCR METAB, V82, P2308, DOI 10.1210/jc.82.7.2308; Forwood JK, 2001, MOL BIOL CELL, V12, p500A; Forwood JK, 2001, J BIOL CHEM, V276, P46575, DOI 10.1074/jbc.M101668200; Forwood JK, 2001, BIOCHEMISTRY-US, V40, P5208, DOI 10.1021/bi002732+; Fukushima T, 2007, J BIOL CHEM, V282, P18634, DOI 10.1074/jbc.M609567200; Fuller GN, 1999, CANCER RES, V59, P4228; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; GORLICH D, 1994, CELL, V79, P767, DOI 10.1016/0092-8674(94)90067-1; Higgins S, 2009, ENDOCRINOLOGY, V150, P4044, DOI 10.1210/en.2008-1797; Hodel AE, 2006, J BIOL CHEM, V281, P23545, DOI 10.1074/jbc.M601718200; Hodel MR, 2001, J BIOL CHEM, V276, P1317, DOI 10.1074/jbc.M008522200; Hoeflich A, 2004, BIOCHEM BIOPH RES CO, V324, P705, DOI 10.1016/j.bbrc.2004.09.111; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; IMAMURA T, 1992, J BIOL CHEM, V267, P5676; Iosef C, 2008, ENDOCRINOLOGY, V149, P1214, DOI 10.1210/en.2007-0959; Ivanova IA, 2007, CELL CYCLE, V6, P2186, DOI 10.4161/cc.6.17.4650; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; KALDERON D, 1984, CELL, V39, P499, DOI 10.1016/0092-8674(84)90457-4; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; Kehlenbach RH, 1998, J CELL BIOL, V141, P863, DOI 10.1083/jcb.141.4.863; Koike M, 1999, ONCOGENE, V18, P7495, DOI 10.1038/sj.onc.1203247; Lange A, 2007, J BIOL CHEM, V282, P5101, DOI 10.1074/jbc.R600026200; Lee SJ, 2005, NATURE, V435, P693, DOI 10.1038/nature03578; Lufei CC, 2009, FEBS LETT, V583, P271, DOI 10.1016/j.febslet.2008.12.011; Marfori M, 2012, TRAFFIC, V13, P532, DOI 10.1111/j.1600-0854.2012.01329.x; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Miyako K, 2009, MOL ENDOCRINOL, V23, P169, DOI 10.1210/me.2008-0168; Mohan S, 2002, J ENDOCRINOL, V175, P19, DOI 10.1677/joe.0.1750019; Moore MG, 2003, INT J CANCER, V105, P14, DOI 10.1002/ijc.11015; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; Nakai K, 1999, TRENDS BIOCHEM SCI, V24, P34, DOI 10.1016/S0968-0004(98)01336-X; Nam TJ, 1997, ENDOCRINOLOGY, V138, P2972, DOI 10.1210/en.138.7.2972; Oh Y, 1998, INT CONGR SER, V1151, P125; Pereira JJ, 2004, CANCER RES, V64, P977, DOI 10.1158/0008-5472.CAN-03-3056; Perks CM, 1999, J MOL ENDOCRINOL, V22, P141, DOI 10.1677/jme.0.0220141; RICHARDSON WD, 1986, CELL, V44, P77, DOI 10.1016/0092-8674(86)90486-1; Rivera J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006433; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Russo V. C., 1995, Progress in Growth Factor Research, V6, P329, DOI 10.1016/0955-2235(95)00018-6; Russo VC, 2005, ENDOCR REV, V26, P916, DOI 10.1210/er.2004-0024; Russo VC, 1997, ENDOCRINOLOGY, V138, P4858, DOI 10.1210/en.138.11.4858; Russo VC, 2005, ENDOCRINOLOGY, V146, P4445, DOI 10.1210/en.2005-0467; Russo VC, 2004, 12 INT C END MED INT; Schedlich LJ, 2004, BIOCHEM BIOPH RES CO, V314, P83, DOI 10.1016/j.bbrc.2003.12.049; Schedlich LJ, 1998, J BIOL CHEM, V273, P18347, DOI 10.1074/jbc.273.29.18347; Schedlich LJ, 2000, J BIOL CHEM, V275, P23462, DOI 10.1074/jbc.M002208200; Schedlich LJ, 2007, MOL ENDOCRINOL, V21, P2378, DOI 10.1210/me.2006-0558; Schutt BS, 2004, J MOL ENDOCRINOL, V32, P859, DOI 10.1677/jme.0.0320859; Shen XC, 2012, MOL CELL BIOL, V32, P4116, DOI 10.1128/MCB.01011-12; So AI, 2008, CLIN CANCER RES, V14, P6944, DOI 10.1158/1078-0432.CCR-08-0408; Song SW, 2003, P NATL ACAD SCI USA, V100, P13970, DOI 10.1073/pnas.2332186100; TAGAWA T, 1995, J CELL BIOL, V130, P255, DOI 10.1083/jcb.130.2.255; Terrien X, 2005, BIOCHEM J, V392, P457, DOI 10.1042/BJ20050517; Twigg SM, 1998, J BIOL CHEM, V273, P6074, DOI 10.1074/jbc.273.11.6074; Wang H, 2003, CANCER RES, V63, P4315; Weinzimer SA, 2001, J CLIN ENDOCR METAB, V86, P1806, DOI 10.1210/jc.86.4.1806; Zhou GL, 2010, BMC CELL BIOL, V11, DOI 10.1186/1471-2121-11-74	79	57	62	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2014	33	5					578	588		10.1038/onc.2012.630	http://dx.doi.org/10.1038/onc.2012.630			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5GW	23435424				2022-12-28	WOS:000331125100006
J	Guo, W; Frenette, PS				Guo, W.; Frenette, P. S.			Alternative CD44 splicing in intestinal stem cells and tumorigenesis	ONCOGENE			English	Editorial Material							CANCER; IDENTIFICATION	As an important player in stem cells and cancer, CD44 is expressed in multiple isoforms via alternative mRNA splicing. Whether, and if so, how various isoforms play distinct roles in normal stem cells and tumorigenesis remains unclear. In this issue of Oncogene, Zeilstra et al. report studies showing that intestinal stem cells express a specific CD44 variant that promotes intestinal tumorigenesis induced by the activation of Wnt signaling, whereas the more commonly expressed standard CD44 isoform is not expressed by stem cells and does not promote tumor formation. This finding demonstrates an isoform-specific function of CD44 in intestinal stem cells and tumorigenesis.	[Guo, W.; Frenette, P. S.] Albert Einstein Coll Med, Ruth L & David S Gottesman Inst Stem Cell & Regen, Dept Cell Biol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Guo, W (corresponding author), Albert Einstein Coll Med, Ruth L & David S Gottesman Inst Stem Cell & Regen, Dept Cell Biol, 1301 Morris Pk,Room 101B, Bronx, NY 10461 USA.	wenjun.guo@einstein.yu.edu; paul.frenette@einstein.yu.edu	Frenette, Paul S/J-8272-2012	Frenette, Paul S/0000-0003-0862-9922	NHLBI NIH HHS [R01 HL069438] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL069438] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196; Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602; Brown RL, 2011, J CLIN INVEST, V121, P1064, DOI 10.1172/JCI44540; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Godar S, 2008, CELL, V134, P62, DOI 10.1016/j.cell.2008.06.006; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Jin LQ, 2006, NAT MED, V12, P1167, DOI 10.1038/nm1483; Katayama Y, 2005, J EXP MED, V201, P1183, DOI 10.1084/jem.20042014; Krause DS, 2006, NAT MED, V12, P1175, DOI 10.1038/nm1489; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Warzecha CC, 2012, SEMIN CANCER BIOL, V22, P417, DOI 10.1016/j.semcancer.2012.04.003; Zeilstra J, 2008, CANCER RES, V68, P3655, DOI 10.1158/0008-5472.CAN-07-2940; Zoller M, 2011, NAT REV CANCER, V11, P254, DOI 10.1038/nrc3023	15	27	27	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 30	2014	33	5					537	538		10.1038/onc.2013.260	http://dx.doi.org/10.1038/onc.2013.260			2	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AA5GW	23831568				2022-12-28	WOS:000331125100001
J	Wu, L; Runkle, C; Jin, HJ; Yu, J; Li, J; Yang, X; Kuzel, T; Lee, C; Yu, J				Wu, L.; Runkle, C.; Jin, H-J; Yu, J.; Li, J.; Yang, X.; Kuzel, T.; Lee, C.; Yu, J.			CCN3/NOV gene expression in human prostate cancer is directly suppressed by the androgen receptor	ONCOGENE			English	Article						androgen receptor; polycomb EZH2; NOV; CCN3	DIFFERENTIAL EXPRESSION; CCN PROTEINS; NOV; TRANSCRIPTION; MECHANISM; POLYCOMB; GROWTH; INHIBITION; REPRESSION; CASTRATION	Androgen receptor (AR) has essential roles during prostate cancer progression. With genome-wide AR-binding sites mapped to high resolution, studies have recently reported AR as a transcriptional repressor. How AR inhibits gene expression and how this contributes to prostate cancer, however, are incompletely understood. Through meta-analysis of microarray data, here we nominate nephroblastoma overexpressed (NOV) as a top androgen-repressed gene. We show that NOV is directly suppressed by androgen through the AR. AR occupies the NOV enhancer and communicates with the NOV promoter through DNA looping. AR activation recruits the polycomb group protein EZH2, which subsequently catalyzes histone H3 lysine 27 tri-methylation around the NOV promoter, thus leading to repressive chromatin remodeling and epigenetic silencing. Concordantly, AR and EZH2 inhibition synergistically restored NOV expression. NOV is downregulated in human prostate cancer wherein AR and EZH2 are upregulated. Functionally, NOV inhibits prostate cancer cell growth in vitro and in vivo. NOV reconstitution reverses androgen-induced cell growth and NOV knockdown drives androgen-independent cell growth. In addition, NOV expression is restored by hormone-deprivation therapies in mice and prostate cancer patients. Therefore, using NOV as a model gene we gained further understanding of the mechanisms underlying AR-mediated transcriptional repression. Our findings establish a tumor-suppressive role of NOV in prostate cancer and suggest that one important, but previously underestimated, manner by which AR contributes to prostate cancer progression is through inhibition of key tumor-suppressor genes.	[Wu, L.; Runkle, C.; Jin, H-J; Yu, J.; Li, J.; Kuzel, T.; Yu, J.] Northwestern Univ, Feinberg Sch Med, Div Hematol Oncol, Dept Med, Chicago, IL 60611 USA; [Yang, X.; Kuzel, T.; Lee, C.; Yu, J.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Feinberg School of Medicine; Robert H. Lurie Comprehensive Cancer Center	Yu, J (corresponding author), Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol,Dept Med, 303 E Super St Lurie 5-117, Chicago, IL 60611 USA.	jindan-yu@northwestern.edu	WU, Longtao/G-6477-2014	WU, Longtao/0000-0003-3463-4127; Jin, Hongjian/0000-0003-3833-7170	NIH [P50CA090386, U54CA143869, K99/R00CA129565, R01HG005119]; US Department of Defense [W81XWH-09-1-0193]; Research Scholar Award from the American Cancer Society [RSG-12-085-01]; NATIONAL CANCER INSTITUTE [P30CA062203, P50CA090386, U54CA143869, K99CA129565, R01CA172384, R00CA129565] Funding Source: NIH RePORTER; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG005119] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Defense(United States Department of Defense); Research Scholar Award from the American Cancer Society(American Cancer Society); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	We thank Dr Bernard Perbal (University of Paris) for the K19M anti-NOV antibody, Dr Kurt Engeland (Universitatsfrauenklinik Leipzig) for the NOV constructs, Dr Raymond Bergan for the PC-3M cells, and Dr Stephen Plymate for AR overexpression constructs. We are also grateful to Jonathan Zhao and Jung Kim for technical assistance. This work was supported by funding from the NIH P50CA090386 (to CL, JY), U54CA143869 pilot project (to JY), K99/R00CA129565 (to JY), R01HG005119 (to JY), the US Department of Defense W81XWH-09-1-0193 (to JY) and the Research Scholar Award RSG-12-085-01 (to JY) from the American Cancer Society.	Bao BY, 2008, PROSTATE, V68, P839, DOI 10.1002/pros.20749; Benini S, 2005, ONCOGENE, V24, P4349, DOI 10.1038/sj.onc.1208620; Best CJM, 2005, CLIN CANCER RES, V11, P6823, DOI 10.1158/1078-0432.CCR-05-0585; Bohlig L, 2008, CELL CYCLE, V7, P1254, DOI 10.4161/cc.7.9.5812; Cai CM, 2011, CANCER CELL, V20, P457, DOI 10.1016/j.ccr.2011.09.001; Fu CT, 2004, J BIOL CHEM, V279, P36943, DOI 10.1074/jbc.M403952200; Fukunaga-Kalabis M, 2008, ONCOGENE, V27, P2552, DOI 10.1038/sj.onc.1210896; Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125; Jiang WG, 2004, ENDOCR-RELAT CANCER, V11, P781, DOI 10.1677/erc.1.00825; JOLIOT V, 1992, MOL CELL BIOL, V12, P10, DOI 10.1128/MCB.12.1.10; Jun JI, 2011, NAT REV DRUG DISCOV, V10, P945, DOI 10.1038/nrd3599; Kimura A, 2010, J BIOL CHEM, V285, P32704, DOI 10.1074/jbc.M110.141804; Lamont KR, 2011, MOL ENDOCRINOL, V25, P897, DOI 10.1210/me.2010-0469; Lanzino M, 2010, NUCLEIC ACIDS RES, V38, P5351, DOI 10.1093/nar/gkq278; Lin BY, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006589; Liu YN, 2008, MOL CELL BIOL, V28, P7096, DOI 10.1128/MCB.00449-08; Maillard M, 2001, J CLIN PATHOL-MOL PA, V54, P275, DOI 10.1136/mp.54.4.275; MARTINERIE C, 1992, ONCOGENE, V7, P2529; Massie CE, 2011, EMBO J, V30, P2719, DOI 10.1038/emboj.2011.158; McCallum L, 2009, BLOOD REV, V23, P79, DOI 10.1016/j.blre.2008.07.002; McCallum L, 2006, BLOOD, V108, P1716, DOI 10.1182/blood-2006-04-016113; Ohgawara T, 2011, J CELL COMMUN SIGNAL, V5, P291, DOI 10.1007/s12079-011-0133-3; Ouellet V, 2011, AM J PATHOL, V178, P2377, DOI 10.1016/j.ajpath.2011.01.033; Perbal B, 2008, J CELL COMMUN SIGNAL, V2, P3, DOI 10.1007/s12079-008-0028-0; Sin WC, 2009, J BIOL CHEM, V284, P29935, DOI 10.1074/jbc.M109.042630; Vallacchi V, 2008, CANCER RES, V68, P715, DOI 10.1158/0008-5472.CAN-07-2103; Verras M, 2007, CANCER RES, V67, P967, DOI 10.1158/0008-5472.CAN-06-3552; Wang D, 2011, NATURE, V474, P390, DOI 10.1038/nature10006; Wang QB, 2007, MOL CELL, V27, P380, DOI 10.1016/j.molcel.2007.05.041; Wang QB, 2009, CELL, V138, P245, DOI 10.1016/j.cell.2009.04.056; Wang XD, 2007, DIFFERENTIATION, V75, P219, DOI 10.1111/j.1432-0436.2006.00135.x; Welsbie DS, 2009, CANCER RES, V69, P958, DOI 10.1158/0008-5472.CAN-08-2216; Yu J, 2010, ONCOGENE, V29, P5370, DOI 10.1038/onc.2010.269; Yu J, 2007, CANCER CELL, V12, P419, DOI 10.1016/j.ccr.2007.10.016; Yu J, 2007, CANCER RES, V67, P10657, DOI 10.1158/0008-5472.CAN-07-2498; Yu JD, 2010, CANCER CELL, V17, P443, DOI 10.1016/j.ccr.2010.03.018; Zhao JC, 2012, GENOME RES, V22, P322, DOI 10.1101/gr.131508.111; Zuo GW, 2010, HISTOL HISTOPATHOL, V25, P795, DOI 10.14670/HH-25.795	38	36	38	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN 23	2014	33	4					504	513		10.1038/onc.2012.602	http://dx.doi.org/10.1038/onc.2012.602			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	296VX	23318417	Green Accepted			2022-12-28	WOS:000330214600011
J	Vaites, LP; Lian, Z; Lee, EK; Yin, B; DeMicco, A; Bassing, CH; Diehl, JA				Vaites, L. P.; Lian, Z.; Lee, E. K.; Yin, B.; DeMicco, A.; Bassing, C. H.; Diehl, J. A.			ATM deficiency augments constitutively nuclear cyclin D1-driven genomic instability and lymphomagenesis	ONCOGENE			English	Article						cyclin D1T286A; ATM; genomic instability; lymphoma; c-Myc	C-MYC; D1 PHOSPHORYLATION; DNA; REPLICATION; P53; ACTIVATION; EXPRESSION; OVEREXPRESSION; PROTEOLYSIS; DELETION	Cyclin D1 deregulation is implicated in the genesis of multiple human cancers. Importantly, nuclear cyclin D1 retention during S-phase promotes DNA re-replication and subsequent genomic instability, providing a direct correlation between aberrant cyclin D1/CDK4 activity, transcriptional regulation and double strand DNA break (DSB) induction. Together, these molecular events catalyze the genomic instability necessary for neoplastic transformation. Given that replication-associated DNA damage is central to cyclin D1-driven neoplasia, inactivation of critical checkpoint mediators should augment cyclin D1-dependent tumorigenesis in vivo. To interrogate potential synergy between constitutively nuclear cyclin D1 expression and impaired DSB-induced checkpoint integrity, Ataxia Telangiectasia Mutated (ATM)-deficient mice harboring the Em-D1T286A transgene were generated and evaluated for tumor onset. Em-D1T286A/ATM -/- mice exhibit dramatically accelerated incidence of both B-and T-cell lymphomas relative to Em-D1T286A or ATM -/- control cohorts. Lymphomas exhibit clonal chromosomal alterations distinct from ATM -/- mice, which typically acquire translocations involving the Tcra/d locus during V(D)J recombination, and instead harbor alterations at the c-Myc locus. Collectively, these findings reveal an intricate relationship wherein nuclear cyclin D1/CDK4 drives genomic instability in the absence of ATM function and clonal selection of cells harboring alterations within the murine c-Myc locus, ultimately facilitating transformation and tumor formation.	[Vaites, L. P.; Lian, Z.; Lee, E. K.; Diehl, J. A.] Univ Penn, Leonard & Madlyn Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; [Vaites, L. P.; Lian, Z.; Lee, E. K.; Diehl, J. A.] Univ Penn, Dept Canc Biol, Philadelphia, PA 19104 USA; [Yin, B.; DeMicco, A.; Bassing, C. H.] Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Diehl, JA (corresponding author), Univ Penn, Leonard & Madlyn Abramson Family Canc Res Inst, 438 BRB 2 3,421 Curie Blvd, Philadelphia, PA 19104 USA.	adiehl@mail.med.upenn.edu	Lian, Zhaorui/AAW-2379-2020		NIH [CA93237]; NATIONAL CANCER INSTITUTE [R01CA093237] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	The authors wish to thank Margarita Romero for excellent technical assistance and maintenance of the mouse colony, Dr Eric Brown for providing ATM+/- mice for colony generation and insightful comments on the work, the AFCRI histology core for assistance with tissue paraffin embedding and sectioning, and Dr Priya Aggarwal for assistance with flow cytometry and cytogenetic techniques. This work was supported by a grant from the NIH (CA93237) (JAD).	Aggarwal P, 2007, GENE DEV, V21, P2908, DOI 10.1101/gad.1586007; Aggarwal P, 2010, CANCER CELL, V18, P329, DOI 10.1016/j.ccr.2010.08.012; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Ghosh M, 2006, MOL CELL BIOL, V26, P5270, DOI 10.1128/MCB.02137-05; Girard-Reydet C, 2004, GENE, V332, P129, DOI 10.1016/j.gene.2004.02.031; Gladden AB, 2006, ONCOGENE, V25, P998, DOI 10.1038/sj.onc.1209147; Gostissa M, 2009, NATURE, V462, P803, DOI 10.1038/nature08633; Greiner TC, 2006, P NATL ACAD SCI USA, V103, P2352, DOI 10.1073/pnas.0510441103; Hakim O, 2012, NATURE, V484, P69, DOI 10.1038/nature10909; Hemmer S, 2001, AM J PATHOL, V158, P1355, DOI 10.1016/S0002-9440(10)64086-2; Jares P, 2008, BRIT J HAEMATOL, V142, P149, DOI 10.1111/j.1365-2141.2008.07124.x; Jin JP, 2006, MOL CELL, V23, P709, DOI 10.1016/j.molcel.2006.08.010; Lin AW, 1998, GENE DEV, V12, P3008, DOI 10.1101/gad.12.19.3008; Lin DI, 2008, ONCOGENE, V27, P1231, DOI 10.1038/sj.onc.1210738; Liyanage M, 2000, BLOOD, V96, P1940, DOI 10.1182/blood.V96.5.1940.h8001940_1940_1946; Lowndes NF, 2005, CURR BIOL, V15, pR99, DOI 10.1016/j.cub.2005.01.029; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; Monni O, 1999, BRIT J HAEMATOL, V104, P665, DOI 10.1046/j.1365-2141.1999.01257.x; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nagy B, 2003, BRIT J HAEMATOL, V120, P434, DOI 10.1046/j.1365-2141.2003.04121.x; Nishitani H, 2006, EMBO J, V25, P1126, DOI 10.1038/sj.emboj.7601002; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; Norio P, 2005, MOL CELL, V20, P575, DOI 10.1016/j.molcel.2005.10.029; Pontano LL, 2008, MOL CELL BIOL, V28, P7245, DOI 10.1128/MCB.01085-08; QUELLE DE, 1993, GENE DEV, V7, P1559, DOI 10.1101/gad.7.8.1559; Ramiro AR, 2006, NATURE, V440, P105, DOI 10.1038/nature04495; Robbiani DF, 2008, CELL, V135, P1028, DOI 10.1016/j.cell.2008.09.062; SERRANO M, 1995, SCIENCE, V267, P249, DOI 10.1126/science.7809631; Slotta-Huspenina J, 2012, HAEMATOL-HEMATOL J, V97, P1422, DOI 10.3324/haematol.2011.055715; Walker DR, 1999, ONCOGENE, V18, P211, DOI 10.1038/sj.onc.1202298; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; Xu Y, 1996, GENE DEV, V10, P2411, DOI 10.1101/gad.10.19.2411; Zha S, 2010, J EXP MED, V207, P1369, DOI 10.1084/jem.20100285; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; Zhou J, 2002, P NATL ACAD SCI USA, V99, P13693, DOI 10.1073/pnas.212392399	38	14	14	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2014	33	1					129	133		10.1038/onc.2012.577	http://dx.doi.org/10.1038/onc.2012.577			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	282YU	23318439	Green Accepted			2022-12-28	WOS:000329212000014
J	Pandey, PR; Xing, F; Sharma, S; Watabe, M; Pai, SK; Iiizumi-Gairani, M; Fukuda, K; Hirota, S; Mo, YY; Watabe, K				Pandey, P. R.; Xing, F.; Sharma, S.; Watabe, M.; Pai, S. K.; Iiizumi-Gairani, M.; Fukuda, K.; Hirota, S.; Mo, Y-Y; Watabe, K.			Elevated lipogenesis in epithelial stem-like cell confers survival advantage in ductal carcinoma in situ of breast cancer	ONCOGENE			English	Article						lipogenesis; ductal carcinoma in situ; breast cancer; stem-like cells; apoptosis; resveratrol	FATTY-ACID SYNTHASE; ACTIVATION; EXPRESSION; RAS; PROGRESSION; APOPTOSIS; RECEPTOR; PATHWAY; GENE; GROWTH	Upregulation of lipogenesis is a hallmark of cancer and blocking the lipogenic pathway is known to cause tumor cell death by apoptosis. However, the exact role of lipogenesis in tumor initiation is as yet poorly understood. We examined the expression profile of key lipogenic genes in clinical samples of ductal carcinoma in situ (DCIS) of breast cancer and found that these genes were significantly upregulated in DCIS. We also isolated cancer stem-like cells (CSCs) from DCIS.com cell line using cell surface markers (CS24(-)CD44(+)ESA(+)) and found that this cell population has significantly higher tumor-initiating ability to generate DCIS compared with the non-stem-like population. Furthermore, the CSCs showed significantly higher level of expression of all lipogenic genes than the counterpart population from non-tumorigenic breast cancer cell line, MCF10A. Importantly, ectopic expression of SREBP1, the master regulator of lipogenic genes, in MCF10A significantly enhanced lipogenesis in stem-like cells and promoted cell growth as well as mammosphere formation. Moreover, SREBP1 expression significantly increased the ability of cell survival of CSCs from MCF10AT, another cell line that is capable of generating DCIS, in mouse and in cell culture. These results indicate that upregulation of lipogenesis is a pre-requisite for DCIS formation by endowing the ability of cell survival. We have also shown that resveratrol was capable of blocking the lipogenic gene expression in CSCs and significantly suppressed their ability to generate DCIS in animals, which provides us with a strong rationale to use this agent for chemoprevention against DCIS.	[Pandey, P. R.; Xing, F.; Sharma, S.; Watabe, M.; Pai, S. K.; Iiizumi-Gairani, M.; Fukuda, K.; Watabe, K.] So Illinois Univ, Sch Med, Dept Med Microbiol Immunol & Cell Biol, Springfield, IL USA; [Hirota, S.] Iwate Med Univ, Sch Med, Dept Gastroenterol & Hepatol, Morioka, Iwate 020, Japan; [Xing, F.; Mo, Y-Y; Watabe, K.] Univ Mississippi, Med Ctr, Inst Canc, Jackson, MS 39216 USA	Southern Illinois University System; Southern Illinois University; Iwate Medical University; University of Mississippi; University of Mississippi Medical Center	Watabe, K (corresponding author), Univ Mississippi, Med Ctr, Inst Canc, 2500 N State St,Arthur Guyton Res Bldg G654, Jackson, MS 39216 USA.	kwatabe@umc.edu	Xia, Bo/P-9380-2016; Mo, Yin-Yuan/R-8255-2019		National Institutes of Health [R01CA124650, R01CA129000, R01CA124650-04S1]; US Department of Defense [BC096982]; McElroy Foundation; NATIONAL CANCER INSTITUTE [R01CA124650, R01CA129000] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); US Department of Defense(United States Department of Defense); McElroy Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by the National Institutes of Health (Grants R01CA124650, R01CA129000 and R01CA124650-04S1 to KW), the US Department of Defense (BC096982 to KW) and McElroy Foundation (to KW).	Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Alberola-Ila J, 2003, IMMUNOL REV, V191, P79, DOI 10.1034/j.1600-065X.2003.00012.x; Allan Alison L, 2006, Breast Dis, V26, P87; Bandyopadhyay S, 2006, CANCER RES, V66, P5934, DOI 10.1158/0008-5472.CAN-05-3197; Barnes NLP, 2012, BMJ-BRIT MED J, V344, DOI 10.1136/bmj.e797; Baron A, 2004, J CELL BIOCHEM, V91, P47, DOI 10.1002/jcb.10708; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Caron RW, 2005, CELL CYCLE, V4, P456, DOI 10.4161/cc.4.3.1249; Chuthapisith S, 2010, SURG ONCOL, V19, P27, DOI 10.1016/j.suronc.2009.01.004; Dallas NA, 2009, CANCER RES, V69, P1951, DOI 10.1158/0008-5472.CAN-08-2023; Damonte P, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2104; Dawson PJ, 1996, AM J PATHOL, V148, P313; Diehn M, 2006, J NATL CANCER I, V98, P1755, DOI 10.1093/jnci/djj505; Esslimani-Sahla M, 2007, INT J CANCER, V120, P224, DOI 10.1002/ijc.22202; Furuta E, 2008, CANCER RES, V68, P1003, DOI 10.1158/0008-5472.CAN-07-2489; Gu GY, 2007, CANCER RES, V67, P4807, DOI 10.1158/0008-5472.CAN-06-4608; Guillet-Deniau I, 2004, J CELL SCI, V117, P1937, DOI 10.1242/jcs.01069; Heppner Gloria H., 1999, Breast J, V5, P122, DOI 10.1046/j.1524-4741.1999.00136.x; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; Huang WC, 2012, MOL CANCER RES, V10, P133, DOI 10.1158/1541-7786.MCR-11-0206; JANES PW, 1994, ONCOGENE, V9, P3601; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Lee CM, 2005, GYNECOL ONCOL, V99, P415, DOI 10.1016/j.ygyno.2005.05.045; Liu W, 2011, BREAST CANCER RES TR, V128, P57, DOI 10.1007/s10549-010-1076-8; Ma XJ, 2003, P NATL ACAD SCI USA, V100, P5974, DOI 10.1073/pnas.0931261100; McCubrey JA, 2006, ADV ENZYME REGUL, V46, P249, DOI 10.1016/j.advenzreg.2006.01.004; Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222; Menendez JA, 2006, CURR OPIN CLIN NUTR, V9, P346, DOI 10.1097/01.mco.0000232893.21050.15; Migita T, 2009, JNCI-J NATL CANCER I, V101, P519, DOI 10.1093/jnci/djp030; Milgraum LZ, 1997, CLIN CANCER RES, V3, P2115; MILLER FR, 1993, J NATL CANCER I, V85, P1725, DOI 10.1093/jnci/85.21.1725; Okuda H, 2012, CANCER RES, V72, P537, DOI 10.1158/0008-5472.CAN-11-1678; Pandey PR, 2012, RECENT PAT ANTI-CANC, V7, P185; Pandey PR, 2011, BREAST CANCER RES TR, V130, P387, DOI 10.1007/s10549-010-1300-6; Piyathilake CJ, 2000, HUM PATHOL, V31, P1068, DOI 10.1053/hupa.2000.9842; Pizer ES, 1998, CANCER RES, V58, P4611; Porter DA, 2001, CANCER RES, V61, P5697; Ramjaun AR, 2007, CELL CYCLE, V6, P2902, DOI 10.4161/cc.6.23.4996; Rashid A, 1997, AM J PATHOL, V150, P201; Shimano H, 2001, PROG LIPID RES, V40, P439, DOI 10.1016/S0163-7827(01)00010-8; Swinnen JV, 2006, CURR OPIN CLIN NUTR, V9, P358, DOI 10.1097/01.mco.0000232894.28674.30; Uttarwar L, 2012, AM J PHYSIOL-RENAL, V302, pF329, DOI 10.1152/ajprenal.00136.2011; Valverde AM, 1998, EXP CELL RES, V243, P274, DOI 10.1006/excr.1998.4154; Vazquez-Martin A, 2008, CELL PROLIFERAT, V41, P59, DOI 10.1111/j.1365-2184.2007.00498.x; von Lintig FC, 2000, BREAST CANCER RES TR, V62, P51, DOI 10.1023/A:1006491619920; Yamashita T, 2009, J HEPATOL, V50, P100, DOI 10.1016/j.jhep.2008.07.036	46	59	60	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2013	32	42					5111	5122		10.1038/onc.2012.519	http://dx.doi.org/10.1038/onc.2012.519			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238IB	23208501				2022-12-28	WOS:000325937900012
J	Buchwald, M; Pietschmann, K; Brand, P; Gunther, A; Mahajan, NP; Heinzel, T; Kramer, OH				Buchwald, M.; Pietschmann, K.; Brand, P.; Guenther, A.; Mahajan, N. P.; Heinzel, T.; Kraemer, O. H.			SIAH ubiquitin ligases target the nonreceptor tyrosine kinase ACK1 for ubiquitinylation and proteasomal degradation	ONCOGENE			English	Article						ACK1; estrogen; proteasome; SIAH1; SIAH2; TNK2	BREAST-CANCER-CELLS; ANDROGEN RECEPTOR; DOWN-REGULATION; E3 LIGASE; STABILITY; PATHWAY; ACTIVATION; EXPRESSION; PROTEINS; PHOSPHORYLATION	Activated Cdc42-associated kinase 1 (ACK1) is a nonreceptor tyrosine kinase linked to cellular transformation. The aberrant regulation of ACK1 promotes tumor progression and metastasis. Therefore, ACK1 is regarded as a valid target in cancer therapy. Seven in absentia homolog (SIAH) ubiquitin ligases facilitate substrate ubiquitinylation that targets proteins to the proteasomal degradation pathway. Here we report that ACK1 and SIAH1 from Homo sapiens interact in a yeast two-hybrid screen. Protein-protein interaction studies and protein degradation analyses using deletion and point mutants of ACK1 verify that SIAH1 and the related SIAH2 interact with ACK1. The association between SIAHs and ACK1 depends on the integrity of a highly conserved SIAH-binding motif located in the far C-terminus of ACK1. Furthermore, we demonstrate that the interaction of ACK1 with SIAH1 and the induction of proteasomal degradation of ACK1 by SIAH1 are independent of ACK1's kinase activity. Chemical inhibitors blocking proteasomal activity corroborate that SIAH1 and SIAH2 destabilize the ACK1 protein by inducing its proteasomal turnover. This mechanism apparently differs from the lysosomal pathway targeting ACK1 after stimulation with the epidermal growth factor. Our data also show that ACK1, but not ACK1 mutants lacking the SIAH binding motif, has a discernable negative effect on SIAH levels. Additionally, knockdown approaches targeting the SIAH2 mRNA uncover specifically that the induction of SIAH2 expression, by hormonally-induced estrogen receptor (ER) activation, decreases the levels of ACK1 in luminal human breast cancer cells. Collectively, our data provide novel insights into the molecular mechanisms modulating ACK1 and they position SIAH ubiquitin ligases as negative regulators of ACK1 in transformed cells.	[Buchwald, M.; Pietschmann, K.; Brand, P.; Heinzel, T.; Kraemer, O. H.] Univ Jena, Ctr Mol Biomed, Inst Biochem & Biophys, D-07745 Jena, Germany; [Guenther, A.] Univ Giessen, Lung Ctr, Dept Internal Med 2, D-35390 Giessen, Germany; [Mahajan, N. P.] Univ S Florida, H Lee Moffitt Canc Ctr, Drug Discovery Dept, Tampa, FL 33682 USA	Friedrich Schiller University of Jena; Justus Liebig University Giessen; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Kramer, OH (corresponding author), Univ Jena, Ctr Mol Biomed, Inst Biochem & Biophys, Hans Knoll St 2, D-07745 Jena, Germany.	Oliver.Kraemer@uni-jena.de	Heinzel, Thorsten/B-1013-2015; Krämer, Oliver H/L-9266-2015	Krämer, Oliver H/0000-0003-3973-045X	German Cancer Aid [FKZ102362]; Wilhelm-Sander Foundation [2010.078.1]; NATIONAL CANCER INSTITUTE [R01CA135328] Funding Source: NIH RePORTER	German Cancer Aid(Deutsche Krebshilfe); Wilhelm-Sander Foundation; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank C. Kosan, M. Korfei and S. Scheiding for their discussions and their excellent help. We are grateful to M. Kogl, N. Varin-Blank, Z. Ronai, R. Marschalek, H. Bursen, A. Baniahmad, O. Werz and O. Huber for providing material. Grant support: German Cancer Aid (FKZ102362); Wilhelm-Sander Foundation (No. 2010.078.1).	Ahmed AU, 2008, JNCI-J NATL CANCER I, V100, P1606, DOI 10.1093/jnci/djn365; Buchwald M, 2010, LEUKEMIA, V24, P1412, DOI 10.1038/leu.2010.114; Bursen A, 2004, ONCOGENE, V23, P6237, DOI 10.1038/sj.onc.1207837; Calzado MA, 2009, NAT CELL BIOL, V11, P85, DOI 10.1038/ncb1816; Chan W, 2009, J BIOL CHEM, V284, P8185, DOI 10.1074/jbc.M806877200; Chua BT, 2010, MOL ONCOL, V4, P323, DOI 10.1016/j.molonc.2010.03.001; Depaux A, 2006, BIOCHEM BIOPH RES CO, V348, P857, DOI 10.1016/j.bbrc.2006.07.092; Frasor J, 2005, P NATL ACAD SCI USA, V102, P13153, DOI 10.1073/pnas.0502782102; Fukushima T, 2006, IMMUNITY, V24, P29, DOI 10.1016/j.immuni.2005.12.002; Habelhah H, 2002, EMBO J, V21, P5756, DOI 10.1093/emboj/cdf576; Holliday DL, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2889; House CM, 2006, STRUCTURE, V14, P695, DOI 10.1016/j.str.2005.12.013; House CM, 2009, CANCER RES, V69, P8835, DOI 10.1158/0008-5472.CAN-09-1676; Howlin J, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2087; Jansen MPHM, 2009, BREAST CANCER RES TR, V116, P263, DOI 10.1007/s10549-008-0125-z; Khurana A, 2006, J BIOL CHEM, V281, P35316, DOI 10.1074/jbc.M606568200; Korzeniewski N, 2010, MOL BIOL CELL, V21, P3942, DOI 10.1091/mbc.E09-12-1049; Kramer OH, 2008, FASEB J, V22, P1369, DOI 10.1096/fj.06-8050com; Kramer OH, 2003, EMBO J, V22, P3411, DOI 10.1093/emboj/cdg315; Kramer OH, 2012, LEUKEMIA IN PRESS; Li C, 2004, ONCOGENE, V23, P9336, DOI 10.1038/sj.onc.1208114; Lin Qi, 2010, Bulletin of Botanical Research, V30, P4; Liu M, 2012, MOL CELL, V46, P325, DOI 10.1016/j.molcel.2012.03.007; Lu M, 2005, ONCOGENE, V24, P4362, DOI 10.1038/sj.onc.1208661; Mahajan K, 2012, AM J PATHOL, V180, P1386, DOI 10.1016/j.ajpath.2011.12.028; Mahajan K, 2010, PROSTATE, V70, P1274, DOI 10.1002/pros.21163; Mahajan K, 2010, J CELL PHYSIOL, V224, P327, DOI 10.1002/jcp.22162; Mahajan K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009646; Mahajan NP, 2005, CANCER RES, V65, P10514, DOI 10.1158/0008-5472.CAN-05-1127; Mahajan NP, 2007, P NATL ACAD SCI USA, V104, P8438, DOI 10.1073/pnas.0700420104; Metzger MB, 2012, J CELL SCI, V125, P531, DOI 10.1242/jcs.091777; Mogk A, 2007, TRENDS CELL BIOL, V17, P165, DOI 10.1016/j.tcb.2007.02.001; Nadeau RJ, 2007, J CELL BIOCHEM, V100, P151, DOI 10.1002/jcb.21040; Nagano Y, 2011, CELL CYCLE, V10, P2592, DOI 10.4161/cc.10.15.16912; Osborne CK, 2011, CLIN CANCER RES, V17, P1147, DOI 10.1158/1078-0432.CCR-10-1869; Pao-Chun L, 2009, J BIOL CHEM, V284, P34954, DOI 10.1074/jbc.M109.072660; Perissi V, 2008, MOL CELL, V29, P755, DOI 10.1016/j.molcel.2008.01.020; Pietschmann K, 2012, MOL CANC TH IN PRESS; Pietschmann K, 2012, INT J BIOCHEM CELL B, V44, P132, DOI 10.1016/j.biocel.2011.10.008; Prieto-Echagile V., 2011, J SIGNAL TRANSDUCT, V2011; Sarkar TR, 2012, MOL CELL BIOL, V32, P320, DOI 10.1128/MCB.05790-11; Stebbing J, 2012, ONCOGENE IN PRESS; Twomey E, 2010, EXP CELL RES, V316, P68, DOI 10.1016/j.yexcr.2009.09.001; van der Horst EH, 2005, P NATL ACAD SCI USA, V102, P15901, DOI 10.1073/pnas.0508014102; Venables JP, 2004, HUM MOL GENET, V13, P1525, DOI 10.1093/hmg/ddh165; Wen YY, 2010, MOL CARCINOGEN, V49, P440, DOI 10.1002/mc.20615; Wen YY, 2010, CANCER SCI, V101, P73, DOI 10.1111/j.1349-7006.2009.01339.x; Winter M, 2008, NAT CELL BIOL, V10, P812, DOI 10.1038/ncb1743; Wu HL, 2010, BIOCHEM BIOPH RES CO, V397, P391, DOI 10.1016/j.bbrc.2010.05.024; Xu ZH, 2006, J BIOL CHEM, V281, P303, DOI 10.1074/jbc.M509060200; Yokoyama N, 2003, J BIOL CHEM, V278, P47713, DOI 10.1074/jbc.M306716200; Yun S, 2008, J BIOL CHEM, V283, P1034, DOI 10.1074/jbc.M705874200; Zhao HL, 2010, BIOCHEM BIOPH RES CO, V399, P623, DOI 10.1016/j.bbrc.2010.07.127	53	26	29	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2013	32	41					4913	4920		10.1038/onc.2012.515	http://dx.doi.org/10.1038/onc.2012.515			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235KQ	23208506	Green Accepted			2022-12-28	WOS:000325717800007
J	Li, N; Du, ZX; Zong, ZH; Liu, BQ; Li, C; Zhang, Q; Wang, HQ				Li, N.; Du, Z-X; Zong, Z-H; Liu, B-Q; Li, C.; Zhang, Q.; Wang, H-Q			PKC delta-mediated phosphorylation of BAG3 at Ser187 site induces epithelial - mesenchymal transition and enhances invasiveness in thyroid cancer FRO cells	ONCOGENE			English	Article						BAG3; PKC delta; EMT; invasion	PROTEIN-KINASE-C; ACTIVATION MECHANISMS; QUALITY CONTROL; PHORBOL ESTER; BETA-CATENIN; APOPTOSIS; EXPRESSION; MIGRATION; PATHWAY; STRESS	Protein kinase C delta (PKC delta) is a serine (Ser)/threonine kinase, which regulates numerous cellular processes, including proliferation, differentiation, migration and apoptosis. In the current study, Chinese hamster ovary cells were transfected with either a constitutively activated PKCd or a dominant negative PKC delta, phosphoprotein enrichment, two-dimensional difference gel electrophoresis and mass spectrometry was combined to globally identified candidates of PKC delta cascade. We found that Bcl-2 associated athanogene 3 (BAG3) was one of the targets of PKC delta cascade, and BAG3 interacted with PKC delta in vivo. In addition, we clarified that BAG3 was phosphorylate at Ser187 site in a PKC delta-dependent manner in vivo. BAG3 has been implicated in multiple cellular functions, including proliferation, differentiation, apoptosis, migration, invasion, macroautophagy and so on. We generated wild-type (WT)-, Ser187Ala (S187A)- or Ser187Asp (S187D)-BAG3 stably expressing FRO cells, and noticed that phosphorylation state of BAG3 influenced FRO morphology. Finally, for the first time, we showed that BAG3 was implicated in epithelial - mesenchymal transition (EMT) procedure, and phosphorylation state at Ser187 site had a critical role in EMT regulation by BAG3. Collectively, the current study indicates that BAG3 is a novel substrate of PKC delta, and PKC delta-mediated phosphorylation of BAG3 is implicated in EMT and invasiveness of thyroid cancer cells.	[Li, N.; Zong, Z-H; Liu, B-Q; Li, C.; Zhang, Q.; Wang, H-Q] China Med Univ, Dept Biochem & Mol Biol, Shenyang 110001, Liaoning, Peoples R China; [Li, N.; Wang, H-Q] China Med Univ, Minist Publ Hlth, Key Lab Cell Biol, Shenyang 110001, Liaoning, Peoples R China; [Li, N.; Wang, H-Q] China Med Univ, Minist Educ, Key Lab Med Cell Biol, Shenyang 110001, Liaoning, Peoples R China; [Du, Z-X] China Med Univ, Affiliated Hosp 1, Dept Endocrinol & Metab, Shenyang 110001, Liaoning, Peoples R China	China Medical University; China Medical University; China Medical University; China Medical University	Wang, HQ (corresponding author), China Med Univ, Dept Biochem & Mol Biol, 92 Beier, Shenyang 110001, Liaoning, Peoples R China.	wanghq_doctor@hotmail.com			National Natural Science Foundation of China [31070697, 31170727]; Program for LNET [LJQ2011083]; Foundation of Liaoning Educational Committee [L2010561]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Program for LNET; Foundation of Liaoning Educational Committee	This work was supported by National Natural Science Foundation of China (31070697 and 31170727), Program for LNET (LJQ2011083) and Foundation of Liaoning Educational Committee (L2010561) to H- Q Wang.	Arias AM, 2001, CELL, V105, P425, DOI 10.1016/S0092-8674(01)00365-8; Bozdogan O, 2005, TUMORI J, V91, P539, DOI 10.1177/030089160509100615; Brabletz T, 1998, PATHOL RES PRACT, V194, P701, DOI 10.1016/S0344-0338(98)80129-5; Carra S, 2008, J BIOL CHEM, V283, P1437, DOI 10.1074/jbc.M706304200; Carra S, 2009, AUTOPHAGY, V5, P428, DOI 10.4161/auto.5.3.7894; Carra S, 2009, J BIOL CHEM, V284, P5523, DOI 10.1074/jbc.M807440200; Chiappetta G, 2007, J CLIN ENDOCR METAB, V92, P1159, DOI 10.1210/jc.2006-1712; Doong H, 2002, CANCER LETT, V188, P25, DOI 10.1016/S0304-3835(02)00456-1; Doong H, 2000, ONCOGENE, V19, P4385, DOI 10.1038/sj.onc.1203797; Du ZX, 2008, BIOCHEM BIOPH RES CO, V369, P894, DOI 10.1016/j.bbrc.2008.02.112; Du ZX, 2011, J CLIN ENDOCR METAB, V96, pE763, DOI 10.1210/jc.2010-2642; Du ZX, 2009, J CELL PHYSIOL, V218, P631, DOI 10.1002/jcp.21634; Fan JH, 2006, J INVEST DERMATOL, V126, P1233, DOI 10.1038/sj.jid.5700149; Gamerdinger M, 2011, J MOL MED, V89, P1175, DOI 10.1007/s00109-011-0795-6; Gamerdinger M, 2009, EMBO J, V28, P889, DOI 10.1038/emboj.2009.29; Gavert N, 2007, J CELL BIOCHEM, V102, P820, DOI 10.1002/jcb.21505; Haynes J, MOL BIOL CELL, V22, P4750; Huber MA, 2005, CURR OPIN CELL BIOL, V17, P548, DOI 10.1016/j.ceb.2005.08.001; Hugo H, 2007, J CELL PHYSIOL, V213, P374, DOI 10.1002/jcp.21223; Humphries MJ, 2006, J BIOL CHEM, V281, P9728, DOI 10.1074/jbc.M507851200; Iwasaki M, 2007, CANCER RES, V67, P10252, DOI 10.1158/0008-5472.CAN-07-0618; Kassis JN, 2006, EXP CELL RES, V312, P2962, DOI 10.1016/j.yexcr.2006.05.023; Kikkawa U, 2002, J BIOCHEM, V132, P831, DOI 10.1093/oxfordjournals.jbchem.a003294; Lee JH, 1999, ONCOGENE, V18, P6183, DOI 10.1038/sj.onc.1203043; Li CH, 2003, FASEB J, V17, P2106, DOI 10.1096/fj.03-0150fje; Liao Q, 2001, FEBS LETT, V503, P151, DOI 10.1016/S0014-5793(01)02728-4; Liu P, 2009, FEBS LETT, V583, P401, DOI 10.1016/j.febslet.2008.12.032; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; Mitsiades CS, 2006, BLOOD, V107, P1092, DOI 10.1182/blood-2005-03-1158; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Pagliuca MG, 2003, FEBS LETT, V541, P11, DOI 10.1016/S0014-5793(03)00274-6; Romano MF, 2003, CANCER BIOL THER, V2, P508, DOI 10.4161/cbt.2.5.524; Romano MF, 2003, CELL DEATH DIFFER, V10, P383, DOI 10.1038/sj.cdd.4401167; Rosati A, 2007, INT J BIOCHEM CELL B, V39, P1337, DOI 10.1016/j.biocel.2007.03.007; Rosati A, 2007, J CELL PHYSIOL, V210, P676, DOI 10.1002/jcp.20865; Shi J, 2008, BLOOD, V111, P1309, DOI 10.1182/blood-2007-03-078535; Steinberg SF, 2004, BIOCHEM J, V384, P449, DOI 10.1042/BJ20040704; Suzuki M, 2011, CANCER LETT, V303, P65, DOI 10.1016/j.canlet.2011.01.019; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183	43	31	33	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 19	2013	32	38					4539	4548		10.1038/onc.2012.466	http://dx.doi.org/10.1038/onc.2012.466			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	223SW	23108398				2022-12-28	WOS:000324831300009
J	Kalakonda, S; Nallar, SC; Lindner, DJ; Sun, P; Lorenz, RR; Lamarre, E; Reddy, SP; Kalvakolanu, DV				Kalakonda, S.; Nallar, S. C.; Lindner, D. J.; Sun, P.; Lorenz, R. R.; Lamarre, E.; Reddy, S. P.; Kalvakolanu, D. V.			GRIM-19 mutations fail to inhibit v-Src-induced oncogenesis	ONCOGENE			English	Article						tyrosine kinases; tumor suppression; cytoskeleton; metastasis; cytokines	SQUAMOUS-CELL CARCINOMA; REGULATORY GENE-PRODUCT; C-SRC; RETINOIC ACID; BONE METASTASIS; FAMILY KINASES; TUMOR-CELLS; COMPLEX-I; CANCER; CORTACTIN	The non-receptor tyrosine kinase Src is a major player in multiple physiological responses including growth, survival and differentiation. Overexpression and/or oncogenic mutation in the Src gene have been documented in human tumors. The v-Src protein is an oncogenic mutant of Src, which promotes cell survival, migration, invasion and division. GRIM-19 is an antioncogene isolated using a genome-wide knockdown screen. Genes associated with Retinoid-IFN-induced Mortality (GRIM)-19 binds to transcription factor STAT3 and ablates its pro-oncogenic effects while v-Src activates STAT3 to promote its oncogenic effects. However, we found that GRIM-19 inhibits the pro-oncogenic effects of v-Src independently of STAT3. Here, we report the identification of functionally inactivating GRIM-19 mutations in a set of head and neck cancer patients. While wild-type GRIM-19 strongly ablated v-Src-induced cell migration, cytoskeletal remodeling and tumor metastasis, the tumor-derived mutants ((LP)-P-71, (LP)-P-91 and A(95)T) did not. These mutants were also incapable of inhibiting the drug resistance of v-Src-transformed cells. v-Src downregulated the expression of Pag1, a lipid raft-associated inhibitor of Src, which was restored by wild-type GRIM-19. The tumor-derived mutant GRIM-19 proteins failed to upregulate Pag1. These studies show a novel mechanism that deregulates Src activity in cancer cells.	[Kalakonda, S.; Nallar, S. C.; Sun, P.; Kalvakolanu, D. V.] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Program Oncol,Greenebaum Canc Ctr, Baltimore, MD 21201 USA; [Lindner, D. J.] Taussig Canc Ctr, Cleveland, OH USA; [Lorenz, R. R.; Lamarre, E.] Cleveland Clin Fdn, Head & Neck Inst, Cleveland, OH 44195 USA; [Reddy, S. P.] Univ Illinois, Coll Med, Dept Pediat, Chicago, IL USA	University System of Maryland; University of Maryland Baltimore; Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Kalvakolanu, DV (corresponding author), Univ Maryland, Sch Med, Dept Microbiol & Immunol, Program Oncol,Greenebaum Canc Ctr, 660 West Redwood St,Howard Hall Room 324, Baltimore, MD 21201 USA.	dkalvako@umaryland.edu	Lindner, Daniel/ABB-5440-2020		National Institutes of Health [CA105005]; University of Maryland Greenebaum Cancer Center; NATIONAL CANCER INSTITUTE [R01CA105005] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Maryland Greenebaum Cancer Center; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Dr Michael Kahn (University of California at Los Angeles, CA) for lentiviral luciferase (pCCL-c-MNDU3c-Luc) vector. This study is supported by the National Institutes of Health grant CA105005 and an intramural award from the Cigarette restitution funds of the University of Maryland Greenebaum Cancer Center to DVK.	Alchanati I, 2006, ONCOGENE, V25, P7138, DOI 10.1038/sj.onc.1209708; Angell JE, 2000, J BIOL CHEM, V275, P33416, DOI 10.1074/jbc.M003929200; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Buday L, 2007, BBA-REV CANCER, V1775, P263, DOI 10.1016/j.bbcan.2006.12.002; Byers LA, 2009, CLIN CANCER RES, V15, P6852, DOI 10.1158/1078-0432.CCR-09-0767; Chen JYF, 2008, NEOPLASIA, V10, P1393, DOI 10.1593/neo.08854; Fearnley IM, 2001, J BIOL CHEM, V276, P38345, DOI 10.1074/jbc.C100444200; Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111; Giannoni E, 2010, FREE RADICAL BIO MED, V49, P516, DOI 10.1016/j.freeradbiomed.2010.04.025; Gong Long-Bo, 2007, Ai Zheng, V26, P683; Hofman ER, 1998, MOL CELL BIOL, V18, P6493, DOI 10.1128/MCB.18.11.6493; Huang GC, 2004, MOL CELL BIOL, V24, P8447, DOI 10.1128/MCB.24.19.8447-8456.2004; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jiang LQ, 2006, ONCOGENE, V25, P5495, DOI 10.1038/sj.onc.1209554; Kalakonda S, 2007, AM J PATHOL, V171, P1352, DOI 10.2353/ajpath.2007.070241; Koppenol WH, 2011, NAT REV CANCER, V11, P325, DOI 10.1038/nrc3038; Koppikar P, 2008, CLIN CANCER RES, V14, P4284, DOI 10.1158/1078-0432.CCR-07-5226; Li XH, 2008, INT J ONCOL, V33, P69; Li YS, 2001, CANCER RES, V61, P6906; Lindner DJ, 1997, CLIN CANCER RES, V3, P931; Liu Yan-bo, 2011, Zhonghua Nan Ke Xue, V17, P21; Lufei CC, 2003, EMBO J, V22, P1325, DOI 10.1093/emboj/cdg135; MATSOUKA PT, 1989, MOL ENDOCRINOL, V3, P1845, DOI 10.1210/mend-3-11-1845; Mazurek S, 2011, INT J BIOCHEM CELL B, V43, P969, DOI 10.1016/j.biocel.2010.02.005; Murphy DA, 2011, NAT REV MOL CELL BIO, V12, P413, DOI 10.1038/nrm3141; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; Oneyama C, 2008, MOL CELL, V30, P426, DOI 10.1016/j.molcel.2008.03.026; Patel AS, 1998, ONCOGENE, V16, P3227, DOI 10.1038/sj.onc.1201850; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Sena LA, 2012, MOL CELL, V48, P158, DOI 10.1016/j.molcel.2012.09.025; Stark GR, 2012, IMMUNITY, V36, P503, DOI 10.1016/j.immuni.2012.03.013; Sun P, 2009, ONCOGENE, V28, P1339, DOI 10.1038/onc.2008.480; SUPERTIFURGA G, 1993, EMBO J, V12, P2625, DOI 10.1002/j.1460-2075.1993.tb05923.x; Suzuki K, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.195362; Theocharis S, 2012, J CANCER RES CLIN, V138, P1369, DOI 10.1007/s00432-012-1215-1; Valle Casuso JC, 2012, PLOS ONE, V7; van Oijen MGCT, 1998, J ORAL PATHOL MED, V27, P147; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; WHITE MK, 1991, MOL CELL BIOL, V11, P4448, DOI 10.1128/MCB.11.9.4448; Yamada S, 2010, PATHOL ONCOL RES, V16, P523, DOI 10.1007/s12253-009-9245-y; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734; Zhang J, 2003, P NATL ACAD SCI USA, V100, P9342, DOI 10.1073/pnas.1633516100; Zhang XHF, 2009, CANCER CELL, V16, P67, DOI 10.1016/j.ccr.2009.05.017; Zhang YM, 2011, CANCER SCI, V102, P1991, DOI 10.1111/j.1349-7006.2011.02059.x; Zhou Ai-Min, 2009, Ai Zheng, V28, P431; Zhou Y, 2009, J INTERF CYTOK RES, V29, P695, DOI 10.1089/jir.2009.0003	47	5	5	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUN 12	2014	33	24					3195	3204		10.1038/onc.2013.271	http://dx.doi.org/10.1038/onc.2013.271			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AK4QU	23851499	Green Accepted			2022-12-28	WOS:000338410000012
J	Tien, SC; Chang, ZF				Tien, S-C; Chang, Z-F			Oncogenic Shp2 disturbs microtubule regulation to cause HDAC6-dependent ERK hyperactivation	ONCOGENE			English	Article						ERK; HDAC6; microtubule acetylation; Shp2	TYROSINE-PHOSPHATASE SHP-2; SMALL-MOLECULE INHIBITOR; SIGNALING PATHWAY; DEACETYLASE HDAC6; PTPN11 MUTATIONS; NOONAN-SYNDROME; BREAST-CANCER; ACTIVATION; RECEPTOR; KINASE	Deregulation of Shp2, a non-receptor tyrosine phosphatase, causes hyperactivation of extracellular signal-regulated kinase (ERK), leading to growth abnormality. Here, we show that inhibition of RhoA-Dia is sufficient to upregulate ERK activation in epithelial cells. Oncogenic Shp2 expression attenuates RhoA-Dia signaling, by which microtubule (MT) is destabilized with reduced level of acetylation. Either MT stabilization, silencing of histone deacetylase 6 (HDAC6) or enforcing RhoA-Dia signal prevents oncogenic Shp2-induced ERK hyperactivation. We provide evidence that downregulation of RhoA-Dia-EB1 pathway by oncogenic Shp2 leads to HDAC6-mediated reduction in MT acetylation, in turn affecting ERK regulation. In response to serum stimulation, cells expressing wild-type Shp2 display transient ERK activation. In contrast, cells expressing oncogenic Shp2 have prolonged ERK activation. HDAC6 inhibition diminishes sustained activation of ERK and slows down the growth of these cells. Likewise, in human cancer cells, blocking Shp2 increases MT acetylation and decreases ERK phosphorylation, which are reversed by inhibition of Dia. As such, HDAC6 inhibition in these cells also reduces ERK activity. Our findings link MT regulation by HDAC6 to oncogenic Shp2 and ERK regulation, implicating the therapeutic potential of HDAC6 inhibitor in diseases involving Shp2 deregulation.	[Tien, S-C; Chang, Z-F] Natl Taiwan Univ, Inst Biochem & Mol Biol, Coll Med, Taipei 10764, Taiwan; [Chang, Z-F] Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan	National Taiwan University; National Yang Ming Chiao Tung University	Chang, ZF (corresponding author), Natl Yang Ming Univ, Inst Biochem & Mol Biol, 155,Sect 2,Linong St, Taipei 112, Taiwan.	zfchang@ym.edu.tw			National Science Council, Taiwan [NSC98-3112-B-010-021]; UST-UCSD International Center of Excellence in Advanced Bio-Engineering; National Science Council I-RiCE Program, Taiwan [NSC101-2911-I-009-101]; Ministry of Education, Taiwan	National Science Council, Taiwan(Ministry of Science and Technology, Taiwan); UST-UCSD International Center of Excellence in Advanced Bio-Engineering; National Science Council I-RiCE Program, Taiwan; Ministry of Education, Taiwan(Ministry of Education, Taiwan)	We thank TS Jou (Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University) for providing MDCK cells and GP135 antibody, TP Yao (Department of Pharmacology and Cancer Bioloby, Duke University, Durham, North Carolina) for providing pCDNA-HDAC6-Flag and EGFP-tubulin-K40R plasmids and JC Kuo (Institute of Biochemistry and Molecular Biology, National Yang Ming University) for detyrosinated (Glu) tubulin antibody, the technical supports from the second core laboratory, Department of Medical Research, National Taiwan University Hospital and the Instrumentation Resource Center of National Yang-Ming University. This research is supported by grants from National Science Council, Taiwan (NSC98-3112-B-010-021), the UST-UCSD International Center of Excellence in Advanced Bio-Engineering sponsored by National Science Council I-RiCE Program, Taiwan (NSC101-2911-I-009-101), and Aim for Top University Plan in National Yang-Ming University sponsored by the Ministry of Education, Taiwan.	Agazie YM, 2003, MOL CELL BIOL, V23, P7875, DOI 10.1128/MCB.23.21.7875-7886.2003; Bard-Chapeau EA, 2011, CANCER CELL, V19, P629, DOI 10.1016/j.ccr.2011.03.023; Chang YC, 2006, CELL DEATH DIFFER, V13, P2023, DOI 10.1038/sj.cdd.4401901; Cleghon V, 1998, MOL CELL, V2, P719, DOI 10.1016/S1097-2765(00)80287-7; Gao YS, 2010, J BIOL CHEM, V285, P11219, DOI 10.1074/jbc.M109.042754; Gelb BD, 2006, HUM MOL GENET, V15, pR220, DOI 10.1093/hmg/ddl197; Gross I, 2001, J BIOL CHEM, V276, P46460, DOI 10.1074/jbc.M108234200; Haggarty SJ, 2003, P NATL ACAD SCI USA, V100, P4389, DOI 10.1073/pnas.0430973100; Hanafusa H, 2002, NAT CELL BIOL, V4, P850, DOI 10.1038/ncb867; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Hubbert C, 2002, NATURE, V417, P455, DOI 10.1038/417455a; Kawaguchi Y, 2003, CELL, V115, P727, DOI 10.1016/S0092-8674(03)00939-5; Kodama A, 2000, MOL BIOL CELL, V11, P2565, DOI 10.1091/mbc.11.8.2565; Kontaridis MI, 2004, MOL CELL BIOL, V24, P5340, DOI 10.1128/MCB.24.12.5340-5352.2004; Kovacs JJ, 2005, MOL CELL, V18, P601, DOI 10.1016/j.molcel.2005.04.021; Lee HH, 2008, J CELL BIOL, V181, P999, DOI 10.1083/jcb.200710187; Lee HH, 2010, J CELL SCI, V123, P3368, DOI 10.1242/jcs.071555; Lee YS, 2008, CANCER RES, V68, P7561, DOI 10.1158/0008-5472.CAN-08-0188; Loh ML, 2004, BLOOD, V103, P2325, DOI 10.1182/blood-2003-09-3287; Maroun CR, 2000, MOL CELL BIOL, V20, P8513, DOI 10.1128/MCB.20.22.8513-8525.2000; Mohi MG, 2007, CURR OPIN GENET DEV, V17, P23, DOI 10.1016/j.gde.2006.12.011; Mohi MG, 2005, CANCER CELL, V7, P179, DOI 10.1016/j.ccr.2005.01.010; Rizvi SA, 2009, CHEM BIOL, V16, P1158, DOI 10.1016/j.chembiol.2009.10.006; Sahai E, 2002, NAT CELL BIOL, V4, P408, DOI 10.1038/ncb796; Sattler M, 2002, CANCER CELL, V1, P479, DOI 10.1016/S1535-6108(02)00074-0; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Tartaglia M, 2006, AM J HUM GENET, V78, P279, DOI 10.1086/499925; Tartaglia M, 2004, CURR OPIN HEMATOL, V11, P44, DOI 10.1097/00062752-200401000-00007; Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772; Tsutsumi R, 2006, MOL CELL BIOL, V26, P261, DOI 10.1128/MCB.26.1.261-276.2006; Ukropec JA, 2000, J BIOL CHEM, V275, P5983, DOI 10.1074/jbc.275.8.5983; Valenzuela-Fernandez A, 2008, TRENDS CELL BIOL, V18, P291, DOI 10.1016/j.tcb.2008.04.003; Wen Y, 2004, NAT CELL BIOL, V6, P820, DOI 10.1038/ncb1160; Yoshida N, 2004, CANCER SCI, V95, P496, DOI 10.1111/j.1349-7006.2004.tb03239.x; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4; Zhang XH, 2007, MOL CELL, V27, P197, DOI 10.1016/j.molcel.2007.05.033; Zhang Y, 2008, MOL CELL BIOL, V28, P1688, DOI 10.1128/MCB.01154-06; Zhou XD, 2008, CELL DEATH DIFFER, V15, P988, DOI 10.1038/cdd.2008.54	38	17	19	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 29	2014	33	22					2938	2946		10.1038/onc.2013.241	http://dx.doi.org/10.1038/onc.2013.241			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EI	23770849				2022-12-28	WOS:000337231800013
J	Yang, XW; Wang, P; Liu, JQ; Zhang, H; Xi, WD; Jia, XH; Wang, KK				Yang, X-W; Wang, P.; Liu, J-Q; Zhang, H.; Xi, W-D; Jia, X-H; Wang, K-K			Coordinated regulation of the immunoproteasome subunits by PML/RAR alpha and PU.1 in acute promyelocytic leukemia	ONCOGENE			English	Article						immunoproteasome subunits; PML/RAR alpha; PU.1; APL; ATRA	TRANS-RETINOIC ACID; ACUTE MYELOID-LEUKEMIA; I PRESENTATION PATHWAY; LONG-TERM EFFICACY; RAR-ALPHA; GRANULOCYTIC DIFFERENTIATION; CELL-DEVELOPMENT; FUSION PROTEIN; HLA-DR; PML	Recognition and elimination of malignant cells by cytotoxic T lymphocytes depends on antigenic peptides generated by proteasomes. It has been established that impairment of the immunoproteasome subunits, that is, PSMB8, PSMB9 and PSMB10 (PSMBs), is critical for malignant cells to escape immune recognition. We report here the regulatory mechanism of the repression of PU.1-dependent activation of PSMBs by PML/RAR alpha in the pathogenesis of acute promyelocytic leukemia (APL) and the unidentified function of all-trans retinoic acid (ATRA) as an immunomodulator in the treatment of APL. Chromatin immunoprecipitation and luciferase reporter assays showed that PU.1 directly bound to and coordinately transactivated the promoters of PSMBs, indicating that PSMBs were transcriptional targets of PU.1 and PU.1 regulated their basal expression. Analysis of expression profiling data from a large population of acute myeloid leukemia (AML) patients revealed that the expression levels of PSMBs were significantly lower in APL patients than in non-APL AML patients. Further evidence demonstrated that the decrease in their expression was achieved through PML/RAR alpha-mediated repression of both PU.1-dependent transactivation and PU.1 expression. Moreover, ATRA but not arsenic trioxide induced the expression of PSMBs in APL cells, indicating that ATRA treatment might activate the antigen-processing/ presentation machinery. Finally, the above observations were confirmed in primary APL samples. Collectively, our data demonstrate that PML/RARa suppresses PU.1-dependent activation of the immunosubunits, which may facilitate the escape of APL cells from immune surveillance in leukemia development, and ATRA treatment is able to reactivate their expression, which would promote more efficient T-cell-mediated recognition in the treatment.	[Yang, X-W; Wang, P.; Liu, J-Q; Zhang, H.; Xi, W-D; Jia, X-H; Wang, K-K] Shanghai Jiao Tong Univ, Sch Med SJTU SM, Ruijin Hosp, State Key Lab Med Genom,Shanghai Inst Hematol, Shanghai 200025, Peoples R China	Chinese Academy of Sciences; Shanghai Jiao Tong University	Wang, KK (corresponding author), Shanghai Jiao Tong Univ, Sch Med SJTU SM, Ruijin Hosp, State Key Lab Med Genom,Shanghai Inst Hematol, 197 Ruijin Rd 2, Shanghai 200025, Peoples R China.	kankanwang@shsmu.edu.cn	Xi, Wenda/GYR-3972-2022		Ministry of Science and Technology Grants of China [2009CB825607, 2012AA02A211, 2011CB910202]; National Natural Science Foundation Grants of China [31171257, 81270625, 31100942]	Ministry of Science and Technology Grants of China; National Natural Science Foundation Grants of China(National Natural Science Foundation of China (NSFC))	This work was supported, in part, by Ministry of Science and Technology Grants of China (2009CB825607, 2012AA02A211 and 2011CB910202) and National Natural Science Foundation Grants of China (31171257, 81270625 and 31100942).	Aptsiauri N, 2007, INT REV CYTOL, V256, P139, DOI 10.1016/S0074-7696(07)56005-5; Carotta S, 2010, IMMUNOL REV, V238, P63, DOI 10.1111/j.1600-065X.2010.00955.x; Carotta S, 2010, IMMUNITY, V32, P628, DOI 10.1016/j.immuni.2010.05.005; Carroll JS, 2005, CELL, V122, P33, DOI 10.1016/j.cell.2005.05.008; Carter BZ, 2001, BLOOD, V97, P2784, DOI 10.1182/blood.V97.9.2784; Collins SJ, 2008, CURR OPIN HEMATOL, V15, P346, DOI 10.1097/MOH.0b013e3283007edf; DOUCAS V, 1993, P NATL ACAD SCI USA, V90, P9345, DOI 10.1073/pnas.90.20.9345; Goldberg AL, 1995, COLD SPRING HARB SYM, V60, P479, DOI 10.1101/SQB.1995.060.01.052; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; Hallermalm K, 2001, BLOOD, V98, P1108, DOI 10.1182/blood.V98.4.1108; Hoemme C, 2008, BLOOD, V111, P2887, DOI 10.1182/blood-2007-03-079921; Hu J, 2009, P NATL ACAD SCI USA, V106, P3342, DOI 10.1073/pnas.0813280106; Hu ZB, 1998, BLOOD, V92, P1768, DOI 10.1182/blood.V92.5.1768.417k19_1768_1775; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; Idres N, 2001, CANCER RES, V61, P700; JANSEN JH, 1995, P NATL ACAD SCI USA, V92, P7401, DOI 10.1073/pnas.92.16.7401; JINNAI I, 1990, LEUKEMIA RES, V14, P227, DOI 10.1016/0145-2126(90)90130-2; Kanada S, 2011, BLOOD, V117, P2211, DOI 10.1182/blood-2010-06-291898; LARSEN F, 1993, HUM MOL GENET, V2, P1589, DOI 10.1093/hmg/2.10.1589; LECCHI M, 1989, LEUKEMIA RES, V13, P221, DOI 10.1016/0145-2126(89)90015-5; Lin RJ, 2001, ONCOGENE, V20, P7204, DOI 10.1038/sj.onc.1204853; Lloberas J, 1999, IMMUNOL TODAY, V20, P184, DOI 10.1016/S0167-5699(99)01442-5; Lowenberg Bob, 2003, Hematology Am Soc Hematol Educ Program, P82; Maeda Y, 1996, BRIT J HAEMATOL, V93, P973, DOI 10.1046/j.1365-2141.1996.d01-1749.x; Meijerink J, 2001, J MOL DIAGN, V3, P55, DOI 10.1016/S1525-1578(10)60652-6; Nigten J, 2005, LEUKEMIA, V19, P799, DOI 10.1038/sj.leu.2403699; Olive V, 2007, DEVELOPMENT, V134, P3815, DOI 10.1242/dev.003467; Padua RA, 2003, NAT MED, V9, P1413, DOI 10.1038/nm949; Promsuwicha O, 2009, ASIAN PAC J ALLERGY, V27, P209; Robin M, 2006, BLOOD, V108, P1972, DOI 10.1182/blood-2006-03-013177; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; Ross ME, 2004, BLOOD, V104, P3679, DOI 10.1182/blood-2004-03-1154; ROUSSELOT P, 1994, ONCOGENE, V9, P545; Schlenk RF, 2004, LEUKEMIA, V18, P1798, DOI 10.1038/sj.leu.2403528; Seliger B, 2000, IMMUNOL TODAY, V21, P455, DOI 10.1016/S0167-5699(00)01692-3; Shen ZX, 2004, P NATL ACAD SCI USA, V101, P5328, DOI 10.1073/pnas.0400053101; Singh H, 2008, J IMMUNOL, V181, P1595, DOI 10.4049/jimmunol.181.3.1595; Smith-Garvin JE, 2009, ANNU REV IMMUNOL, V27, P591, DOI 10.1146/annurev.immunol.021908.132706; Spain LM, 1999, J IMMUNOL, V163, P2681; Tomasson MH, 2008, BLOOD, V111, P4797, DOI 10.1182/blood-2007-09-113027; Tsuzuki S, 2000, MOL CELL BIOL, V20, P6276, DOI 10.1128/MCB.20.17.6276-6286.2000; Vertuani S, 2003, CANCER RES, V63, P8006; Wang KK, 2010, CANCER CELL, V17, P186, DOI 10.1016/j.ccr.2009.12.045; Wang ZY, 2008, BLOOD, V111, P2505, DOI 10.1182/blood-2007-07-102798; Wouters BJ, 2009, BLOOD, V113, P3088, DOI 10.1182/blood-2008-09-179895; Zhang YM, 2013, CANCER-AM CANCER SOC, V119, P115, DOI 10.1002/cncr.27650; Zheng P, 1998, NATURE, V396, P373, DOI 10.1038/24628; Zheng PZ, 2005, P NATL ACAD SCI USA, V102, P7653, DOI 10.1073/pnas.0502825102; Zheng XM, 2007, HAEMATOLOGICA, V92, P323, DOI 10.3324/haematol.10541; Zhu XH, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-22; Zou DD, 2012, LEUKEMIA RES, V36, P219, DOI 10.1016/j.leukres.2011.09.012	52	18	19	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 22	2014	33	21					2700	2708		10.1038/onc.2013.224	http://dx.doi.org/10.1038/onc.2013.224			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AI9EH	23770850				2022-12-28	WOS:000337231700003
J	Damsky, WE; Theodosakis, N; Bosenberg, M				Damsky, W. E.; Theodosakis, N.; Bosenberg, M.			Melanoma metastasis: new concepts and evolving paradigms	ONCOGENE			English	Review						melanocyte; melanoma; metastasis; BRAF; beta-catenin	EPITHELIAL-MESENCHYMAL TRANSITION; BETA-CATENIN EXPRESSION; SENTINEL LYMPH-NODE; MALIGNANT-MELANOMA; TUMOR PROGRESSION; NEVUS CELLS; SOMATIC MUTATIONS; GROWTH REQUIRES; BREAST-CANCER; MOUSE MODEL	Melanoma progression is typically depicted as a linear and stepwise process in which metastasis occurs relatively late in disease progression. Significant evidence suggests that in a subset of melanomas, progression is much more complex and less linear in nature. Epidemiologic and experimental observations in melanoma metastasis are reviewed here and are incorporated into a comprehensive model for melanoma metastasis, which takes into account the varied natural history of melanoma formation and progression.	[Damsky, W. E.; Theodosakis, N.; Bosenberg, M.] Yale Univ, Sch Med, Dept Dermatol, New Haven, CT 06510 USA; [Damsky, W. E.] Univ Vermont, Coll Med, Dept Pathol, Burlington, VT 05495 USA	Yale University; University of Vermont	Damsky, WE (corresponding author), Univ Vermont, Coll Med, Dept Pathol, Given Box A14,189 Beaumont Ave, Burlington, VT 05495 USA.	william.damsky@gmail.com; marcus.bosenberg@yale.edu						Ackermann J, 2005, CANCER RES, V65, P4005, DOI 10.1158/0008-5472.CAN-04-2970; Algra AM, 2012, LANCET ONCOL, V13, P518, DOI 10.1016/S1470-2045(12)70112-2; Arozarena I, 2011, ONCOGENE, V30, P4531, DOI 10.1038/onc.2011.162; Arozarena I, 2011, CANCER CELL, V19, P45, DOI 10.1016/j.ccr.2010.10.029; Bakalian S, 2008, CLIN CANCER RES, V14, P951, DOI 10.1158/1078-0432.CCR-06-2630; Balch C.M., 2003, CUTANEOUS MELANOMA; Balch CM, 2009, J CLIN ONCOL, V27, P6199, DOI 10.1200/JCO.2009.23.4799; BALCH CM, 1993, ANN SURG, V218, P262, DOI 10.1097/00000658-199309000-00005; BAUTISTA NC, 1994, AM J CLIN PATHOL, V102, P102, DOI 10.1093/ajcp/102.1.102; Bedrosian I, 2000, ANN SURG ONCOL, V7, P262, DOI 10.1007/s10434-000-0262-z; Bernards R, 2002, NATURE, V418, P823, DOI 10.1038/418823a; Bertolotto C, 2011, NATURE, V480, P94, DOI 10.1038/nature10539; Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922; Bissell MJ, 2011, NAT MED, V17, P320, DOI 10.1038/nm.2328; Boni R, 1996, J AM ACAD DERMATOL, V35, P416, DOI 10.1016/S0190-9622(96)90607-6; Borthwick NJ, 2011, J CLIN PATHOL, V64, P666, DOI 10.1136/jcp.2010.087999; Bos PD, 2010, CURR OPIN PHARMACOL, V10, P571, DOI 10.1016/j.coph.2010.06.003; BUTLER TP, 1975, CANCER RES, V35, P512; Calle EE, 2003, NEW ENGL J MED, V348, P1625, DOI 10.1056/NEJMoa021423; Carmi Y, 2011, J IMMUNOL, V186, P3462, DOI 10.4049/jimmunol.1002901; Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406; Carson KF, 1996, AM J SURG PATHOL, V20, P834, DOI 10.1097/00000478-199607000-00006; Chambers AF, 2002, NAT REV CANCER, V2, P563, DOI 10.1038/nrc865; Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782; Cheli Y, 2012, ONCOGENE, V31, P2461, DOI 10.1038/onc.2011.425; Chin L, 1997, GENE DEV, V11, P2822, DOI 10.1101/gad.11.21.2822; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; CLARK WH, 1984, HUM PATHOL, V15, P1147, DOI 10.1016/S0046-8177(84)80310-X; Clawson GA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041052; Coleman RE, 2009, EUR J CANCER, V45, P1909, DOI 10.1016/j.ejca.2009.04.022; Colombino M, 2012, J CLIN ONCOL, V30, P2522, DOI 10.1200/JCO.2011.41.2452; Crawford NPS, 2006, BREAST CANCER RES, V8, DOI 10.1186/bcr1389; CROWLEY NJ, 1990, ANN SURG, V212, P173, DOI 10.1097/00000658-199008000-00010; Damsky WE, 2011, CANCER CELL, V20, P741, DOI 10.1016/j.ccr.2011.10.030; Damsky William E, 2010, Cancers (Basel), V3, P126, DOI 10.3390/cancers3010126; Damsky WE, 2010, PIGM CELL MELANOMA R, V23, P853, DOI 10.1111/j.1755-148X.2010.00777.x; Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356; Das SK, 2012, FRONT BIOSCI-LANDMRK, V17, P1, DOI 10.2741/3911; DASGUPTA T, 1964, CANCER, V17, P1323; De Giorgi V, 2010, ARCH DERMATOL, V146, P1120, DOI 10.1001/archdermatol.2010.264; Demicheli R, 2007, NAT CLIN PRACT ONCOL, V4, P699, DOI 10.1038/ncponc0999; Demunter A, 2002, MODERN PATHOL, V15, P454, DOI 10.1038/modpathol.3880546; Eichhoff OM, 2011, PIGM CELL MELANOMA R, V24, P631, DOI 10.1111/j.1755-148X.2011.00871.x; El-Osta H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025806; Ernfors P, 2010, EXP CELL RES, V316, P1397, DOI 10.1016/j.yexcr.2010.02.042; Eskelin S, 2000, OPHTHALMOLOGY, V107, P1443, DOI 10.1016/S0161-6420(00)00182-2; Eyles J, 2010, J CLIN INVEST, V120, P2030, DOI 10.1172/JCI42002; Faraji F, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002926; Ferguson J, 2013, ONCOGENE, V32, P86, DOI 10.1038/onc.2012.25; FIDLER IJ, 1970, JNCI-J NATL CANCER I, V45, P773; FISHER CJ, 1994, J CLIN PATHOL, V47, P245, DOI 10.1136/jcp.47.3.245; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Forbes SA, 2010, NUCLEIC ACIDS RES, V38, pD652, DOI 10.1093/nar/gkp995; Frahm SO, 2001, HUM PATHOL, V32, P1376, DOI 10.1053/hupa.2001.29658; Gallagher SJ, 2013, ONCOGENE, V32, P2230, DOI 10.1038/onc.2012.229; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Gartner JJ, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-505; GIULIANO AE, 1980, ANN SURG, V191, P98, DOI 10.1097/00000658-198001000-00018; Gnant M, 2009, NEW ENGL J MED, V360, P679, DOI 10.1056/NEJMoa0806285; Gradilone A, 2012, EUR REV MED PHARMACO, V16, P1367; Grossmann AH, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2003398; Haakinson DJ, 2012, ANN SURG ONCOL, V19, P3012, DOI 10.1245/s10434-012-2320-8; Harbour JW, 2010, SCIENCE, V330, P1410, DOI 10.1126/science.1194472; Hari L, 2002, J CELL BIOL, V159, P867, DOI 10.1083/jcb.200209039; Hendrix MJC, 2007, NAT REV CANCER, V7, P246, DOI 10.1038/nrc2108; Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466; Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024; Hoek KS, 2010, PIGM CELL MELANOMA R, V23, P746, DOI 10.1111/j.1755-148X.2010.00757.x; Hood JL, 2011, CANCER RES, V71, P3792, DOI 10.1158/0008-5472.CAN-10-4455; Huang FW, 2013, SCIENCE, V339, P957, DOI 10.1126/science.1229259; Husemann Y, 2008, CANCER CELL, V13, P58, DOI 10.1016/j.ccr.2007.12.003; Ireland A, 2011, CLIN EXP METASTAS, V28, P327, DOI 10.1007/s10585-010-9368-2; Izraely S, 2012, INT J CANCER, V131, P1071, DOI 10.1002/ijc.27324; Jakob JA, 2012, CANCER-AM CANCER SOC, V118, P4014, DOI 10.1002/cncr.26724; Jarrett SG, 2013, CLIN EXP METASTAS, V30, P25, DOI 10.1007/s10585-012-9495-z; Javelaud D, 2011, PIGM CELL MELANOMA R, V24, P932, DOI 10.1111/j.1755-148X.2011.00893.x; Jensen TO, 2009, J CLIN ONCOL, V27, P3330, DOI 10.1200/JCO.2008.19.9919; Journe F, 2011, BRIT J CANCER, V105, P1726, DOI 10.1038/bjc.2011.451; Kabbarah O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010770; Kageshita T, 2001, BRIT J DERMATOL, V145, P210, DOI 10.1046/j.1365-2133.2001.04336.x; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Karnezis T, 2012, CANCER CELL, V21, P181, DOI 10.1016/j.ccr.2011.12.026; Kielhorn E, 2003, INT J CANCER, V103, P652, DOI 10.1002/ijc.10893; Kienast Y, 2010, NAT MED, V16, P116, DOI 10.1038/nm.2072; Kim M, 2006, CELL, V125, P1269, DOI 10.1016/j.cell.2006.06.008; Kingham TP, 2010, ANN SURG ONCOL, V17, P514, DOI 10.1245/s10434-009-0836-3; Klein CA, 2009, NAT REV CANCER, V9, P302, DOI 10.1038/nrc2627; Ko JM, 2010, SEMIN CUTAN MED SURG, V29, P210, DOI 10.1016/j.sder.2010.10.004; Koebel CM, 2007, NATURE, V450, P903, DOI 10.1038/nature06309; Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359; Kumar R, 2004, J INVEST DERMATOL, V122, P342, DOI 10.1046/j.0022-202X.2004.22225.x; Larue L, 2006, FRONT BIOSCI-LANDMRK, V11, P733, DOI 10.2741/1831; LEE YTN, 1980, CA-CANCER J CLIN, V30, P137, DOI 10.3322/canjclin.30.3.137; Lindsay CR, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1560; Little EG, 2012, DERMATOL CLIN, V30, P355, DOI 10.1016/j.det.2012.04.001; Liu WJ, 2012, CANCER CELL, V21, P751, DOI 10.1016/j.ccr.2012.03.048; Lopez-Bergami P, 2011, PIGM CELL MELANOMA R, V24, P902, DOI 10.1111/j.1755-148X.2011.00908.x; Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002-9440(10)65628-3; Madhunapantula SV, 2009, PIGM CELL MELANOMA R, V22, P400, DOI 10.1111/j.1755-148X.2009.00585.x; Makhzami S, 2012, PIGM CELL MELANOMA R, V25, P783, DOI 10.1111/pcmr.12013; McAllister SS, 2008, CELL, V133, P994, DOI 10.1016/j.cell.2008.04.045; MCCARTHY SW, 1974, PATHOLOGY, V6, P351, DOI 10.3109/00313027409077346; McGill GG, 2006, J BIOL CHEM, V281, P10365, DOI 10.1074/jbc.M513094200; Melnikova VO, 2009, PIGM CELL MELANOMA R, V22, P257, DOI 10.1111/j.1755-148X.2009.00570.x; Mervic L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032955; Meyer S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038222; Miller AJ, 2006, NEW ENGL J MED, V355, P51, DOI 10.1056/NEJMra052166; Mitra D, 2009, HEMATOL ONCOL CLIN N, V23, P447, DOI 10.1016/j.hoc.2009.03.003; Nagel G, 2012, BRIT J DERMATOL, V167, P59, DOI 10.1111/j.1365-2133.2012.10974.x; Nazarian RM, 2010, J CUTAN PATHOL, V37, P41, DOI 10.1111/j.1600-0560.2010.01505.x; Njauw CNJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035295; Nogueira C, 2010, ONCOGENE, V29, P6222, DOI 10.1038/onc.2010.349; Ocana OH, 2012, CANCER CELL, V22, P709, DOI 10.1016/j.ccr.2012.10.012; Omholt K, 2001, INT J CANCER, V92, P839, DOI 10.1002/ijc.1270; Orgaz JL, 2013, PIGM CELL MELANOMA R, V26, P39, DOI 10.1111/pcmr.12041; Ossowski L, 2010, PIGM CELL MELANOMA R, V23, P41, DOI 10.1111/j.1755-148X.2009.00647.x; Paget S., 1889, LANCET, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0; Parlakian A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009299; PATEL JK, 1978, AM J SURG, V135, P807, DOI 10.1016/0002-9610(78)90171-X; Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753; Peinado H, 2011, SEMIN CANCER BIOL, V21, P139, DOI 10.1016/j.semcancer.2011.01.002; Pierard GE, 2012, DERMATOL RES PRACT, V2012; Pinner S, 2009, CANCER RES, V69, P7969, DOI 10.1158/0008-5472.CAN-09-0781; Pittet MJ, 2011, CELL, V147, P983, DOI 10.1016/j.cell.2011.11.004; Pleasance ED, 2010, NATURE, V463, P191, DOI 10.1038/nature08658; Podsypanina K, 2008, SCIENCE, V321, P1841, DOI 10.1126/science.1161621; Prickett TD, 2011, NAT GENET, V43, P1119, DOI 10.1038/ng.950; Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014; Rabbani P, 2011, CELL, V145, P941, DOI 10.1016/j.cell.2011.05.004; REINTGEN DS, 1983, SURG GYNECOL OBSTET, V156, P335; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Riker AI, 2012, BMC MED, V10, DOI [10.1186/PREACCEPT-2032291833666638, 10.1186/1741-7015-10-19]; Rimm DL, 1999, AM J PATHOL, V154, P325, DOI 10.1016/S0002-9440(10)65278-9; Ross AL, 2011, ISRN DERMATOL, V2011; Rothberg BEG, 2009, J CLIN ONCOL, V27, P5772, DOI 10.1200/JCO.2009.22.8239; Rothwell PM, 2012, LANCET, V379, P1591, DOI 10.1016/S0140-6736(12)60209-8; Rozenberg GI, 2010, MELANOMA RES, V20, P361, DOI 10.1097/CMR.0b013e328336ee17; Schon CA, 2006, PATHOL RES PRACT, V202, P351, DOI 10.1016/j.prp.2005.12.008; Scott KL, 2011, CANCER CELL, V20, P92, DOI 10.1016/j.ccr.2011.05.025; Seong I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031477; Sharpless NE, 2006, NAT REV DRUG DISCOV, V5, P741, DOI 10.1038/nrd2110; Sinnberg T, 2010, CANCER RES, V70, P6999, DOI 10.1158/0008-5472.CAN-10-0645; SLINGLUFF CL, 1992, CANCER-AM CANCER SOC, V70, P1917, DOI 10.1002/1097-0142(19921001)70:7<1917::AID-CNCR2820700719>3.0.CO;2-5; Stahl JM, 2004, CANCER RES, V64, P7002, DOI 10.1158/0008-5472.CAN-04-1399; Stoecklein NH, 2010, INT J CANCER, V126, P589, DOI 10.1002/ijc.24916; Takahashi Y, 2008, INT J CANCER, V123, P2315, DOI 10.1002/ijc.23812; Tarin D, 2005, CANCER RES, V65, P5996, DOI 10.1158/0008-5472.CAN-05-0699; Taube JM, 2009, AM J SURG PATHOL, V33, P568, DOI 10.1097/PAS.0b013e31818a64fb; Timar J, 2010, CLIN EXP METASTAS, V27, P371, DOI 10.1007/s10585-010-9307-2; Tsai JH, 2012, CANCER CELL, V22, P725, DOI 10.1016/j.ccr.2012.09.022; Tsao HS, 1998, ONCOGENE, V16, P3397, DOI 10.1038/sj.onc.1201881; Tucci MG, 2007, BRIT J DERMATOL, V157, P1212, DOI 10.1111/j.1365-2133.2007.08246.x; Turajlic S, 2012, GENOME RES, V22, P196, DOI 10.1101/gr.125591.111; Ugurel S, 2007, CLIN CANCER RES, V13, P6344, DOI 10.1158/1078-0432.CCR-06-2682; Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024; Valsesia A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018369; van Akkooi ACJ, 2008, ANN SURG, V248, P949, DOI 10.1097/SLA.0b013e31818fefe0; van der Ploeg APT, 2011, J CLIN ONCOL, V29, P2206, DOI 10.1200/JCO.2010.31.6760; van der Ploeg APT, 2010, EUR J CANCER, V46, P2414, DOI 10.1016/j.ejca.2010.06.003; Walker GJ, 2011, PIGM CELL MELANOMA R, V24, P1158, DOI 10.1111/j.1755-148X.2011.00923.x; Webster MR, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004114; Widlund HR, 2002, J CELL BIOL, V158, P1079, DOI 10.1083/jcb.200202049; Wirtz D, 2011, NAT REV CANCER, V11, P512, DOI 10.1038/nrc3080; Wong SL, 2006, ANN SURG ONCOL, V13, P809, DOI 10.1245/ASO.2006.03.058; Wu CW, 2013, BJU INT, V111, pE310, DOI 10.1111/j.1464-410X.2012.11687.x; Yaguchi T, 2012, J IMMUNOL, V189, P2110, DOI 10.4049/jimmunol.1102282; Yajima I, 2011, J SKIN CANCER, V2011, DOI 10.1155/2011/730170; Yang PT, 2012, EMBO MOL MED, V4, P1294, DOI 10.1002/emmm.201201486; Yokoyama S, 2011, NATURE, V480, P99, DOI 10.1038/nature10630; Zhou XP, 2000, AM J PATHOL, V157, P1123, DOI 10.1016/S0002-9440(10)64627-5	170	86	91	2	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2014	33	19					2413	2422		10.1038/onc.2013.194	http://dx.doi.org/10.1038/onc.2013.194			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH3OK	23728340				2022-12-28	WOS:000336033600001
J	Tanaka, M; Suzuki, HI; Shibahara, J; Kunita, A; Isagawa, T; Yoshimi, A; Kurokawa, M; Miyazono, K; Aburatani, H; Ishikawa, S; Fukayama, M				Tanaka, M.; Suzuki, H. I.; Shibahara, J.; Kunita, A.; Isagawa, T.; Yoshimi, A.; Kurokawa, M.; Miyazono, K.; Aburatani, H.; Ishikawa, S.; Fukayama, M.			EVI1 oncogene promotes KRAS pathway through suppression of microRNA-96 in pancreatic carcinogenesis	ONCOGENE			English	Article						pancreatic cancer; PanIN; EVI1; KRAS; microRNA	DUCTAL ADENOCARCINOMA; EXPRESSION PROFILES; DOWN-REGULATION; RAS ACTIVITY; BETA; MODULATION; CLAUDIN-18; MUTATIONS; PROGNOSIS; NEOPLASMS	Despite frequent KRAS mutation, the early molecular mechanisms of pancreatic ductal adenocarcinoma (PDAC) development have not been fully elucidated. By tracking a potential regulator of another feature of PDAC precursors, acquisition of foregut or gastric epithelial gene signature, we herein report that aberrant overexpression of ecotropic viral integration site 1 (EVI1) oncoprotein, which is usually absent in normal pancreatic duct, is a widespread marker across the full spectrum of human PDAC precursors and PDAC. In pancreatic cancer cells, EVI1 depletion caused remarkable inhibition of cell growth and migration, indicating its oncogenic roles. Importantly, we found that EVI1 upregulated KRAS expression through suppression of a potent KRAS suppressor, miR-96, in pancreatic cancer cells. Collectively, the present findings suggest that EVI1 overexpression and KRAS mutation converge on activation of the KRAS pathway in early phases of pancreatic carcinogenesis and propose EVI1 and/or miR-96 as early markers and therapeutic targets in this dismal disease.	[Tanaka, M.; Shibahara, J.; Kunita, A.; Ishikawa, S.; Fukayama, M.] Univ Tokyo, Dept Pathol, Tokyo 1130033, Japan; [Suzuki, H. I.; Miyazono, K.] Univ Tokyo, Dept Mol Pathol, Tokyo 1130033, Japan; [Isagawa, T.] Univ Tokyo, Dept Cardiovasc Med, Tokyo 1130033, Japan; [Yoshimi, A.; Kurokawa, M.] Univ Tokyo, Grad Sch Med, Dept Hematol & Oncol, Tokyo 1130033, Japan; [Aburatani, H.] Univ Tokyo, RCAST, Genome Sci Div, Tokyo 1130033, Japan	University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo; University of Tokyo	Fukayama, M (corresponding author), Univ Tokyo, Grad Sch Med, Dept Pathol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	mfukayama-tky@umin.ac.jp	Yoshimi, Akihide/I-3792-2019	Yoshimi, Akihide/0000-0002-0664-7281; Suzuki, Hiroshi/0000-0003-4682-5086	Industrial Technology Research Grant Program from the New Energy and Industrial Technology Development Organization (NEDO) of Japan; Ministry of Education, Culture, Sports, Science and Technology of Japan; Cell Science Research Foundation; Grants-in-Aid for Scientific Research [26860474] Funding Source: KAKEN	Industrial Technology Research Grant Program from the New Energy and Industrial Technology Development Organization (NEDO) of Japan(New Energy and Industrial Technology Development Organization (NEDO)); Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Cell Science Research Foundation(Cell Science Research Foundation, Japan); Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))	We thank all members of the Department of Pathology, University of Tokyo. This work was supported by the Industrial Technology Research Grant Program (2008) from the New Energy and Industrial Technology Development Organization (NEDO) of Japan (SI), the Grant-in-Aid for Scientific Research on Innovative Areas (SI),<SUP>46</SUP> the Grant-in-Aid for Young Scientists (A),<SUP>46</SUP> the GCOE Program for 'Integrative Life Science Based on the Study of Biosignaling Mechanisms' (HIS, KM), and for 'Chemical Biology of the Diseases' (MF and MK) from the Ministry of Education, Culture, Sports, Science and Technology of Japan and the Cell Science Research Foundation (HIS, KM).	Bosman FT, 2010, WHO CLASSIFICATION T, P279; Cartharius K, 2005, BIOINFORMATICS, V21, P2933, DOI 10.1093/bioinformatics/bti473; Chen X, 2009, ONCOGENE, V28, P1385, DOI 10.1038/onc.2008.474; Collisson EA, 2011, NAT MED, V17, P500, DOI 10.1038/nm.2344; De Weer A, 2011, BRIT J HAEMATOL, V154, P337, DOI 10.1111/j.1365-2141.2011.08737.x; Dickstein J, 2010, P NATL ACAD SCI USA, V107, P9783, DOI 10.1073/pnas.1004297107; Gao JS, 2011, FEBS LETT, V585, P693, DOI 10.1016/j.febslet.2011.01.033; Ge XJ, 2005, GENOMICS, V86, P127, DOI 10.1016/j.ygeno.2005.04.008; Gomez-Benito M, 2010, BRIT J CANCER, V103, P1292, DOI 10.1038/sj.bjc.6605874; Goyama S, 2009, CANCER SCI, V100, P990, DOI 10.1111/j.1349-7006.2009.01152.x; Guerra C, 2003, CANCER CELL, V4, P111, DOI 10.1016/S1535-6108(03)00191-0; Gysin S, 2005, CANCER RES, V65, P4870, DOI 10.1158/0008-5472.CAN-04-2848; Hingorani SR, 2003, CANCER CELL, V4, P437, DOI 10.1016/S1535-6108(03)00309-X; HRUBAN RH, 2007, AFIP ATLAS TUMOR PAT, P51; Izutsu K, 2001, BLOOD, V97, P2815, DOI 10.1182/blood.V97.9.2815; Jean-Paul D, 2008, P NATL ACAD SCI USA, V105, P18907, DOI 10.1073/pnas.0810111105; Ji BA, 2009, GASTROENTEROLOGY, V137, P1072, DOI 10.1053/j.gastro.2009.05.052; Jimenez RE, 1999, ANN SURG, V230, P501, DOI 10.1097/00000658-199910000-00006; Kanda M, 2012, GASTROENTEROLOGY, V142, P730, DOI 10.1053/j.gastro.2011.12.042; Kim GE, 2002, GASTROENTEROLOGY, V123, P1052, DOI 10.1053/gast.2002.36018; Kitago M, 2004, INT J CANCER, V110, P177, DOI 10.1002/ijc.20084; Kurokawa M, 1998, NATURE, V394, P92, DOI 10.1038/27945; Kurokawa M, 2000, EMBO J, V19, P2958, DOI 10.1093/emboj/19.12.2958; Kwei KA, 2008, PLOS GENET, V4, DOI 10.1371/journal.pgen.1000081; Liu Y, 2006, ONCOGENE, V25, P3565, DOI 10.1038/sj.onc.1209403; Logsdon CD, 2009, CLIN GASTROENTEROL H, V7, pS40, DOI 10.1016/j.cgh.2009.07.040; Matsuyama H, 2011, BLOOD, V118, P6881, DOI 10.1182/blood-2011-05-354654; Morris JP, 2010, NAT REV CANCER, V10, P683, DOI 10.1038/nrc2899; Nagaraja AK, 2010, MOL ENDOCRINOL, V24, P447, DOI 10.1210/me.2009-0295; Nanjundan M, 2007, CANCER RES, V67, P3074, DOI 10.1158/0008-5472.CAN-06-2366; Prasad NB, 2005, CANCER RES, V65, P1619, DOI 10.1158/0008-5472.CAN-04-1413; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Sentani K, 2008, AM J SURG PATHOL, V32, P1182, DOI 10.1097/PAS.0b013e318163a8f8; Senyuk V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020793; Shin KH, 2011, BIOCHEM BIOPH RES CO, V404, P896, DOI 10.1016/j.bbrc.2010.12.055; Song Y, 2010, CANCER RES, V70, P2115, DOI 10.1158/0008-5472.CAN-09-2979; Suzuki HI, 2011, J BIOCHEM, V149, P15, DOI 10.1093/jb/mvq113; Suzuki HI, 2010, J MOL MED, V88, P1085, DOI 10.1007/s00109-010-0650-1; Suzuki HI, 2009, NATURE, V460, P529, DOI 10.1038/nature08199; Szafranska AE, 2007, ONCOGENE, V26, P4442, DOI 10.1038/sj.onc.1210228; Tanaka M, 2011, J HISTOCHEM CYTOCHEM, V59, P942, DOI 10.1369/0022155411420569; Vazquez I, 2011, HAEMATOL-HEMATOL J, V96, P1448, DOI 10.3324/haematol.2011.040535; Yonezawa S, 2010, J HEPATO-BIL-PAN SCI, V17, P108, DOI 10.1007/s00534-009-0174-7; Yoshimi A, 2011, ONCOTARGET, V2, P575, DOI 10.18632/oncotarget.304; Yoshimi A, 2011, BLOOD, V117, P3617, DOI 10.1182/blood-2009-12-261602; Yu SN, 2010, CANCER RES, V70, P6015, DOI 10.1158/0008-5472.CAN-09-4531	46	46	46	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAY 8	2014	33	19					2454	2463		10.1038/onc.2013.204	http://dx.doi.org/10.1038/onc.2013.204			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AH3OK	23752186				2022-12-28	WOS:000336033600005
J	Ding, Z; Joy, M; Bhargava, R; Gunsaulus, M; Lakshman, N; Miron-Mendoza, M; Petroll, M; Condeelis, J; Wells, A; Roy, P				Ding, Z.; Joy, M.; Bhargava, R.; Gunsaulus, M.; Lakshman, N.; Miron-Mendoza, M.; Petroll, M.; Condeelis, J.; Wells, A.; Roy, P.			Profilin-1 downregulation has contrasting effects on early vs late steps of breast cancer metastasis	ONCOGENE			English	Article						profilin-1; breast cancer; metastasis	TUMOR-CELLS; CARCINOMA-CELLS; MIGRATION; PROLIFERATION; CYTOKINESIS; MOTILITY; PROTEIN; OVEREXPRESSION; LAMELLIPODIN; INHIBITION	Profilin1 (Pfn1), a ubiquitously expressed actin-binding protein, has an indispensable role in migration and proliferation of normal cells. Seemingly contrary to its essential cellular functions, Pfn1's expression is downregulated in breast cancer, the significance of which is unclear. In this study, expression profiling of Pfn1 in human breast cancer specimens correlates lower Pfn1 expression levels with propensity to metastasize. Xenograft experiments further establish a causal relationship between loss of Pfn1 expression and increased dissemination of breast cancer cells (BCCs) from the primary mammary tumor. BCCs exhibit a hyperinvasive phenotype (marked by matrix metalloproteinase-9 upregulation, faster invasion through collagen matrix) and acquire increased proficiency to transmigrate through endothelial barrier (an obligatory step for vascular dissemination) when Pfn1 expression is suppressed. In Pfn1-deficient cells, hyperinvasiveness involves a phosphatidylinositol 3-kinase-PI(3,4)P-2 signaling axis while augmented transendothelial migration occurs in a vascular endothelial growth factor-dependent manner. Contrasting these dissemination promoting activities, loss of Pfn1, however, dramatically inhibits metastatic outgrowth of disseminated BCCs, suggesting that Pfn1 has a key role in the metastatic colonization process. In summary, this study shows that Pfn1 has a dichotomous role in early vs late steps of breast cancer metastasis.	[Ding, Z.; Joy, M.; Gunsaulus, M.; Wells, A.; Roy, P.] Univ Pittsburgh, Dept Bioengn, Pittsburgh, PA 15219 USA; [Bhargava, R.; Wells, A.; Roy, P.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15219 USA; [Bhargava, R.] Magee Womens Hosp, Pittsburgh, PA USA; [Lakshman, N.; Miron-Mendoza, M.; Petroll, M.] Univ Texas SW Med Ctr Dallas, Dept Ophthalmol, Dallas, TX 75390 USA; [Condeelis, J.] Albert Einstein Coll Med, Dept Cell Biol & Anat, New York, NY USA; [Wells, A.; Roy, P.] Univ Pittsburgh, McGowan Inst Regenerat Med, Pittsburgh, PA 15219 USA; [Roy, P.] Univ Pittsburgh, Magee Womens Res Inst, Pittsburgh, PA 15219 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Texas System; University of Texas Southwestern Medical Center Dallas; Yeshiva University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Magee-Womens Research Institute	Roy, P (corresponding author), Univ Pittsburgh, Dept Bioengn, 306 Ctr Bioengn,300 Technol Dr, Pittsburgh, PA 15219 USA.	par19@pitt.edu		Wells, Alan/0000-0002-1637-8150; Roy, Partha/0000-0002-4946-8531; Petroll, W. Matthew/0000-0003-0795-4539	National Cancer Institute of the National Institute of Health [2R01CA108607-07]; Magee Women's Research Institute; NATIONAL CANCER INSTITUTE [R01CA108607] Funding Source: NIH RePORTER	National Cancer Institute of the National Institute of Health; Magee Women's Research Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported by grants from the National Cancer Institute of the National Institute of Health (2R01CA108607-07) and the Magee Women's Research Institute to PR.	Artym Vira V., 2009, V522, P211, DOI 10.1007/978-1-59745-413-1_15; Bae YH, 2010, P NATL ACAD SCI USA, V107, P21547, DOI 10.1073/pnas.1002309107; Bae YH, 2009, J CELL PHYSIOL, V219, P354, DOI 10.1002/jcp.21677; Barkan D, 2008, CANCER RES, V68, P6241, DOI 10.1158/0008-5472.CAN-07-6849; Bottcher RT, 2009, EMBO J, V28, P1157, DOI 10.1038/emboj.2009.58; Chao Y, 2012, CANCER MICROENVIRON, V5, P19, DOI 10.1007/s12307-011-0085-4; Chao YL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-179; Ding ZJ, 2006, J CELL SCI, V119, P4127, DOI 10.1242/jcs.03178; Ding ZJ, 2009, EXP CELL RES, V315, P2963, DOI 10.1016/j.yexcr.2009.07.004; Fedele CG, 2010, P NATL ACAD SCI USA, V107, P22231, DOI 10.1073/pnas.1015245107; Gau D, 2011, CELL MOL BIOENG, V4, P1, DOI 10.1007/s12195-010-0133-z; Gewinner C, 2009, CANCER CELL, V16, P115, DOI 10.1016/j.ccr.2009.06.006; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; Gorges TM, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-178; Gronborg M, 2006, MOL CELL PROTEOMICS, V5, P157, DOI 10.1074/mcp.M500178-MCP200; HAUGWITZ M, 1994, CELL, V79, P303, DOI 10.1016/0092-8674(94)90199-6; Ho MY, 2012, MOL CANCER RES, V10, P1109, DOI 10.1158/1541-7786.MCR-12-0160; Janke J, 2000, J EXP MED, V191, P1675, DOI 10.1084/jem.191.10.1675; Jockusch BM, 2007, REV PHYSIOL BIOCH P, V159, P131, DOI 10.1007/112_2007_704; Karlsson R, 2007, MOL BIOL INTELL UNIT, P29, DOI 10.1007/978-0-387-46407-7_3; Khadka DK, 2009, DEV BIOL, V332, P396, DOI 10.1016/j.ydbio.2009.06.008; Kim A, 2010, INVEST OPHTH VIS SCI, V51, P864, DOI 10.1167/iovs.09-4200; Krause M, 2004, DEV CELL, V7, P571, DOI 10.1016/j.devcel.2004.07.024; Kullmann JA, 2012, EMBO REP, V13, P75, DOI 10.1038/embor.2011.211; Lederer M, 2005, J CELL SCI, V118, P331, DOI 10.1242/jcs.01618; Poincloux R, 2011, P NATL ACAD SCI USA, V108, P1943, DOI 10.1073/pnas.1010396108; Roy P, 2004, CELL MOTIL CYTOSKEL, V57, P84, DOI 10.1002/cm.10160; Sato A, 2006, DEVELOPMENT, V133, P4219, DOI 10.1242/dev.02590; Severson AF, 2002, CURR BIOL, V12, P2066, DOI 10.1016/S0960-9822(02)01355-6; Shibue T, 2009, P NATL ACAD SCI USA, V106, P10290, DOI 10.1073/pnas.0904227106; Smith K, 2010, CELL HOST MICROBE, V7, P13, DOI 10.1016/j.chom.2009.12.004; VERHEYEN EM, 1994, DEVELOPMENT, V120, P717; Witke W, 2004, TRENDS CELL BIOL, V14, P461, DOI 10.1016/j.tcb.2004.07.003; Wu N, 2006, PROTEOMICS, V6, P6095, DOI 10.1002/pmic.200500321; Zoidakis J, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.009449; Zou L, 2007, BRIT J CANCER, V97, P1361, DOI 10.1038/sj.bjc.6604038; Zou L, 2009, CELL MOTIL CYTOSKEL, V66, P1048, DOI 10.1002/cm.20407	38	41	41	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 17	2014	33	16					2065	2074		10.1038/onc.2013.166	http://dx.doi.org/10.1038/onc.2013.166			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AF3GH	23686314	Green Accepted			2022-12-28	WOS:000334599100006
J	Kim, H; Claps, G; Moller, A; Bowtell, D; Lu, X; Ronai, ZA				Kim, H.; Claps, G.; Moeller, A.; Bowtell, D.; Lu, X.; Ronai, Z. A.			Siah2 regulates tight junction integrity and cell polarity through control of ASPP2 stability	ONCOGENE			English	Article						ASPP2; Siah2; epithelial polarity; tight junction; hypoxia	APOPTOSIS-STIMULATING PROTEIN; UBIQUITIN LIGASE; P53; ASPP2/(53BP2L); TUMORIGENESIS; INHIBITION; HOMOLOG; HYPOXIA; GROWTH; HIF	Changes in cell adhesion and polarity are closely associated with epithelial cell transformation and metastatic capacity. The tumor suppressor protein ASPP (Apoptosis-Stimulating Proteins of p53) 2 has been implicated in control of cell adhesion and polarity through its effect on the PAR complex. Here we demonstrate that under hypoxic conditions, the ubiquitin ligase Siah (seven in absentia homolog) 2 controls ASPP2 availability, with concomitant effect on epithelial cell polarity. LC-MS/MS analysis identified ASPP2 and ASPP1 as Siah2-interacting proteins. Biochemical analysis confirmed this interaction and mapped degron motifs within ASPP2, which are required for Siah2-mediated ubiquitination and proteasomal-dependent degradation. Inhibition of Siah2 expression increases ASPP2 levels and enhances ASPP2-dependent maintenance of tight junction (TJ) integrity, and polarized architecture in three dimensional (3D) organotypic culture. Conversely, increase of Siah2 expression under hypoxia decreases ASPP2 levels and the formation of apical polarity in 3D culture. In all, our studies demonstrate the role of Siah2 in regulation of TJ integrity and cell polarity under hypoxia, through its regulation of ASPP2 stability.	[Kim, H.; Claps, G.; Ronai, Z. A.] Sanford Burnham Med Res Inst, Ctr Canc, Signal Transduct Program, La Jolla, CA 92037 USA; [Moeller, A.; Bowtell, D.] Peter MacCallum Canc Ctr, Div Res, Melbourne, Vic, Australia; [Bowtell, D.] Univ Melbourne, Dept Biochem, Parkville, Vic 3052, Australia; [Lu, X.] Ludwig Inst Canc Res, Nuffield Dept Med, Oxford, England	Sanford Burnham Prebys Medical Discovery Institute; Peter Maccallum Cancer Center; University of Melbourne; Ludwig Institute for Cancer Research; University of Oxford	Ronai, ZA (corresponding author), Sanford Burnham Med Res Inst, Ctr Canc, Signal Transduct Program, La Jolla, CA 92037 USA.	ronai@sbmri.org	Möller, Andreas/O-1063-2015; Bowtell, David/H-1007-2016; Claps, Giuseppina/G-6180-2018	Möller, Andreas/0000-0002-8618-6998; Bowtell, David/0000-0001-9089-7525; Lu, Xin/0000-0002-6587-1152; Kim, Hyungsoo/0000-0002-8189-5939; Claps, Giuseppina/0000-0002-3064-0063; RONAI, ZEEV/0000-0002-3859-0400	NCI [CA111515, CA128814]; NATIONAL CANCER INSTITUTE [P01CA128814, R01CA111515, P30CA030199] Funding Source: NIH RePORTER	NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	We thank Laurence M Brill of the SBMRI Proteomics Facility for mass spectrometric analysis of the Siah2-binding proteins. Support by NCI grants CA111515 and CA128814 (to ZR) is gratefully acknowledged.	Ahmed AU, 2008, JNCI-J NATL CANCER I, V100, P1606, DOI 10.1093/jnci/djn365; Bergamaschi D, 2003, NAT GENET, V33, P162, DOI 10.1038/ng1070; Bryant DM, 2010, NAT CELL BIOL, V12, P1035, DOI 10.1038/ncb2106; Calzado MA, 2009, BIOL CHEM, V390, P1079, DOI 10.1515/BC.2009.112; Chen D, 2005, CELL DEATH DIFFER, V12, P358, DOI 10.1038/sj.cdd.4401536; Chen MF, 2011, P NATL ACAD SCI USA, V108, P9119, DOI 10.1073/pnas.1100028108; Cong WL, 2010, CURR BIOL, V20, P1408, DOI 10.1016/j.cub.2010.06.024; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Feigin ME, 2009, CURR OPIN CELL BIOL, V21, P694, DOI 10.1016/j.ceb.2009.07.003; Fogal V, 2005, CELL DEATH DIFFER, V12, P369, DOI 10.1038/sj.cdd.4401562; Habelhah H, 2004, J BIOL CHEM, V279, P53782, DOI 10.1074/jbc.M410315200; House CM, 2003, P NATL ACAD SCI USA, V100, P3101, DOI 10.1073/pnas.0534783100; House CM, 2009, CANCER RES, V69, P8835, DOI 10.1158/0008-5472.CAN-09-1676; Kampa KM, 2009, P NATL ACAD SCI USA, V106, P4390, DOI 10.1073/pnas.0809080106; Kim H, 2011, MOL CELL, V44, P532, DOI 10.1016/j.molcel.2011.08.045; Langton PF, 2009, CURR BIOL, V19, P1969, DOI 10.1016/j.cub.2009.10.027; Li SH, 1997, CELL, V90, P469, DOI 10.1016/S0092-8674(00)80507-3; Liu ZJ, 2005, FEBS LETT, V579, P1587, DOI 10.1016/j.febslet.2005.01.069; Moller A, 2009, ONCOGENE, V28, P289, DOI 10.1038/onc.2008.382; Nakayama K, 2004, CELL, V117, P941, DOI 10.1016/j.cell.2004.06.001; Ozdamar B, 2005, SCIENCE, V307, P1603, DOI 10.1126/science.1105718; Qi JF, 2008, P NATL ACAD SCI USA, V105, P16713, DOI 10.1073/pnas.0804063105; Qi JF, 2010, CANCER CELL, V18, P23, DOI 10.1016/j.ccr.2010.05.024; Samuels-Lev Y, 2001, MOL CELL, V8, P781, DOI 10.1016/S1097-2765(01)00367-7; Schmidt RL, 2007, CANCER RES, V67, P11798, DOI 10.1158/0008-5472.CAN-06-4471; Sen N, 2008, NAT CELL BIOL, V10, P866, DOI 10.1038/ncb1747; Sottocornola R, 2010, DEV CELL, V19, P126, DOI 10.1016/j.devcel.2010.06.003; Szczepanowski M, 2007, BIOCHEM BIOPH RES CO, V362, P485, DOI 10.1016/j.bbrc.2007.08.042; Viloria-Petit AM, 2009, P NATL ACAD SCI USA, V106, P14028, DOI 10.1073/pnas.0906796106; Vives V, 2006, GENE DEV, V20, P1262, DOI 10.1101/gad.374006; Zhu ZY, 2005, J BIOL CHEM, V280, P34473, DOI 10.1074/jbc.M503736200	31	17	17	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	APR 10	2014	33	15					2004	2010		10.1038/onc.2013.149	http://dx.doi.org/10.1038/onc.2013.149			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AE9RK	23644657	Green Accepted			2022-12-28	WOS:000334346300013
J	Li, D; Beisswenger, C; Herr, C; Hellberg, J; Han, G; Zakharkina, T; Voss, M; Wiewrodt, R; Bohle, RM; Menger, MD; Schmid, RM; Stockel, D; Lenhof, HP; Bals, R				Li, D.; Beisswenger, C.; Herr, C.; Hellberg, J.; Han, G.; Zakharkina, T.; Voss, M.; Wiewrodt, R.; Bohle, R. M.; Menger, M. D.; Schmid, R. M.; Stoeckel, D.; Lenhof, H-P; Bals, R.			Myeloid cell RelA/p65 promotes lung cancer proliferation through Wnt/beta-catenin signaling in murine and human tumor cells	ONCOGENE			English	Article						lung cancer; NF-kappa B; inflammation; chronic obstructive disease; Wnt signaling pathway	NF-KAPPA-B; NECROSIS-FACTOR-ALPHA; IKK-BETA; INFLAMMATION; MACROPHAGES; WNT; TUMORIGENESIS; INHIBITION; PATHWAY; ANGIOGENESIS	Smoking is the most important risk factor for both lung cancer (LC) and chronic obstructive pulmonary disease. The aim of this study was to investigate the role of myeloid cell nuclear factor-kappa B in the regulation of tumor cell growth signaling. We subjected mice lacking myeloid RelA/p65 (rela(Delta-/-)) to a metastatic LC model. Cigarette smoke (CS) exposure significantly increased the proliferation of Lewis lung carcinoma cell tumors in wild-type mice. In CS-exposed rela(Delta-/-) mice, the tumor growth was largely inhibited. Transcriptome and pathway analysis of cancer tissue revealed a fundamental impact of myeloid cells on various growth signaling pathways, including the Wnt/beta-catenin pathway. In conclusion, myeloid RelA/p65 is necessary to link smoke-induced inflammation with LC growth and has a role in the activation of Wnt/beta-catenin signaling in tumor cells.	[Li, D.; Beisswenger, C.; Herr, C.; Hellberg, J.; Han, G.; Zakharkina, T.; Voss, M.; Bals, R.] Saarland Univ Hosp, Dept Internal Med Pulmonol 5, Homburg, Germany; [Wiewrodt, R.] Munster Univ Hosp, Dept Med A, Div Pulm, Munster, Germany; [Bohle, R. M.] Saarland Univ Hosp, Dept Pathol, Homburg, Germany; [Menger, M. D.] Univ Saarland, Inst Clin & Expt Surg, D-66421 Homburg, Saarland, Germany; [Schmid, R. M.] Tech Univ Munich, Dept Internal Med 2, D-80290 Munich, Germany; [Stoeckel, D.; Lenhof, H-P] Univ Saarland, Ctr Bioinformat, D-66123 Saarbrucken, Germany	Universitatsklinikum des Saarlandes; University of Munster; Universitatsklinikum des Saarlandes; Saarland University; Technical University of Munich; Saarland University	Bals, R (corresponding author), Univ Saarland, Dept Internal Med Pulmonol 5, Kirrbergerstr 1, D-66421 Homburg, Saarland, Germany.	robert.bals@uks.eu	Beisswenger, Christoph/GRO-6580-2022; Herr, Christian/AAH-5291-2021	Herr, Christian/0000-0001-9422-6569	Deutsche Forschungsgemeinschaft [DFG Ba 1641/12]; Federal Ministry of Education and Research [FKZ 01G10881-0888]; LOEWE-Schwerpunkt	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Federal Ministry of Education and Research(Federal Ministry of Education & Research (BMBF)); LOEWE-Schwerpunkt	This work was supported by Grants of the Deutsche Forschungsgemeinschaft (DFG Ba 1641/12), the Federal Ministry of Education and Research (FKZ 01G10881-0888), and the LOEWE-Schwerpunkt 'Tumor and Inflammation of the state of Hesse to RB. We thank Thomas Damm, Andreas Kamyschnikow and Anja Honecker for excellent technical support. We thank Professor Ingrid Forster for making the LysMcre animal available for this study.	Alalwani SM, 2010, EUR J IMMUNOL, V40, P1118, DOI 10.1002/eji.200939275; Algul H, 2007, J CLIN INVEST, V117, P1490, DOI 10.1172/JCI29882; Backes C, 2007, NUCLEIC ACIDS RES, V35, pW186, DOI 10.1093/nar/gkm323; Balkwill F, 2002, CYTOKINE GROWTH F R, V13, P135, DOI 10.1016/S1359-6101(01)00020-X; Barnes PJ, 2000, NEW ENGL J MED, V343, P269, DOI 10.1056/NEJM200007273430407; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; Berschneider B, 2011, INT J BIOCHEM CELL B, V43, P306, DOI 10.1016/j.biocel.2010.11.013; Blake JA, 2012, NUCLEIC ACIDS RES, V40, pD559, DOI 10.1093/nar/gkr1028; Chen JJW, 2005, J CLIN ONCOL, V23, P953, DOI 10.1200/JCO.2005.12.172; Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Green CE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006713; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; Grivennikov SI, 2011, ANN RHEUM DIS, V70, pI104, DOI 10.1136/ard.2010.140145; Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025; Hess C, 2010, EUR RESPIR J, V35, P343, DOI 10.1183/09031936.00196408; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Hu Mickey C-T, 2005, Future Oncol, V1, P67, DOI 10.1517/14796694.1.1.67; Hussain SP, 2003, NAT REV CANCER, V3, P276, DOI 10.1038/nrc1046; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Kaler P, 2009, CANCER MICROENVIRON, V2, P69, DOI 10.1007/s12307-009-0030-y; Kanehisa M, 2010, NUCLEIC ACIDS RES, V38, pD355, DOI 10.1093/nar/gkp896; Karin M, 2005, NAT REV IMMUNOL, V5, P749, DOI 10.1038/nri1703; Kim S, 2009, NATURE, V457, P102, DOI 10.1038/nature07623; Koczulla R, 2003, J CLIN INVEST, V111, P1665, DOI 10.1172/JCI200317545; Lemjabbar-Alaoui H, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000093; Li XG, 2008, NAT MED, V14, P863, DOI 10.1038/nm1783; Luo JL, 2004, CANCER CELL, V6, P297, DOI 10.1016/j.ccr.2004.08.012; Moghaddam SJ, 2009, AM J RESP CELL MOL, V40, P443, DOI 10.1165/rcmb.2008-0198OC; Murdoch C, 2008, NAT REV CANCER, V8, P618, DOI 10.1038/nrc2444; Oeckinghaus A, 2011, NAT IMMUNOL, V12, P695, DOI 10.1038/ni.2065; Oguma K, 2008, EMBO J, V27, P1671, DOI 10.1038/emboj.2008.105; Papi A, 2004, THORAX, V59, P679, DOI 10.1136/thx.2003.018291; Perkins ND, 2012, NAT REV CANCER, V12, P121, DOI 10.1038/nrc3204; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Punturieri A, 2009, JNCI-J NATL CANCER I, V101, P554, DOI 10.1093/jnci/djp023; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Sharma M, 2002, J BIOL CHEM, V277, P30935, DOI 10.1074/jbc.M201919200; Stathopoulos GT, 2008, MOL CANCER RES, V6, P364, DOI 10.1158/1541-7786.MCR-07-0309; Takahashi H, 2010, CANCER CELL, V17, P89, DOI 10.1016/j.ccr.2009.12.008; Takanami I, 1999, ONCOLOGY-BASEL, V57, P138, DOI 10.1159/000012021; Tennis M, 2007, J THORAC ONCOL, V2, P889, DOI 10.1097/JTO.0b013e318153fdb1; Walser Tonya, 2008, Proc Am Thorac Soc, V5, P811, DOI 10.1513/pats.200809-100TH; Waterfield MR, 2003, MOL CELL, V11, P685, DOI 10.1016/S1097-2765(03)00070-4; Xu X, 2011, J THORAC ONCOL, V6, P716, DOI 10.1097/JTO.0b013e31820c5189; Yao PL, 2005, AM J RESP CELL MOL, V32, P540, DOI 10.1165/rcmb.2004-0223OC; Young RP, 2009, EUR RESPIR J, V34, P380, DOI 10.1183/09031936.00144208; Zaynagetdinov R, 2011, J IMMUNOL, V187, P5703, DOI 10.4049/jimmunol.1100558; Zhu BQ, 2003, CANCER CELL, V4, P191, DOI 10.1016/S1535-6108(03)00219-8	49	50	61	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	MAR 6	2014	33	10					1239	1248		10.1038/onc.2013.75	http://dx.doi.org/10.1038/onc.2013.75			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AC6KI	23563178				2022-12-28	WOS:000332631100004
J	Liu, L; Dong, Z; Liang, J; Cao, C; Sun, J; Ding, Y; Wu, D				Liu, L.; Dong, Z.; Liang, J.; Cao, C.; Sun, J.; Ding, Y.; Wu, D.			As an independent prognostic factor, FAT10 promotes hepatitis B virus-related hepatocellular carcinoma progression via Akt/GSK3 beta pathway	ONCOGENE			English	Article						FAT10; hepatocellular carcinoma; hepatitis B virus; prognosis; progression; Akt	EPITHELIAL-MESENCHYMAL TRANSITION; CLASS-I REGION; POOR-PROGNOSIS; NASOPHARYNGEAL CARCINOMA; INCREASED EXPRESSION; UBIQUITIN-BINDING; CANCER; LIVER; GENE; PATHOGENESIS	FAT10 is an oncogene that is localized at 6q21.3, a region frequently amplified in hepatocellular carcinoma (HCC). Recently, growing attention has been paid to its effect in the initiation of various cancers. However, there has been little research into the influence of FAT10 on the progression and prognosis of HCC, especially in hepatitis B virus (HBV)-related HCC. Here, we aimed at investigating clincopathological significance of FAT10 in HBV-related HCC and its underlying mechanisms. Based on the analysis of FAT10 expression in a reliable and large number of cases with 5-year follow-up, we showed that FAT10 was significantly increased in 260 samples from HBV-related HCC patients, compared with 30 normal tissue, 50 cirrhosis and matched adjacent nontumor tissues. FAT10 expression is correlated with recurrence and poor prognosis in HBV-related HCC. In addition, ectopic expression of FAT10 enhanced cell proliferation, inhibited apoptosis and induced cell cycle progression, whereas silencing FAT10 expression suppressed cell proliferation and induced apoptosis. FAT10 also induced the epithelial-mesenchymal transition (EMT) and promoted invasion of HCC cells. Furthermore, we found Akt/GSK3 beta pathway contributed to the effects of FAT10 in HCC cells. Blocking the Akt pathway significantly inhibited the actions of FAT10. Taken together, the ubiquitin-like protein FAT10 has a central role in regulating diverse aspects of the pathogenesis of HCC, indicating that it might be a potential therapeutic target.	[Liu, L.; Ding, Y.] Southern Med Univ, Nanfang Hosp, Hepatol Unit, Guangzhou 510515, Guangdong, Peoples R China; [Liu, L.; Ding, Y.] Southern Med Univ, Nanfang Hosp, Dept Infect Dis, Guangzhou 510515, Guangdong, Peoples R China; [Dong, Z.; Liang, J.; Cao, C.; Sun, J.; Ding, Y.; Wu, D.] Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, Guangzhou 510515, Guangdong, Peoples R China	Southern Medical University - China; Southern Medical University - China; Southern Medical University - China	Liu, L (corresponding author), Southern Med Univ, Nanfang Hosp, Hepatol Unit, 1838 Guangzhoudadaobei Rd, Guangzhou 510515, Guangdong, Peoples R China.	liuli.fimmu@gmail.com; wudehua.gd@gmail.com		Liu, Li/0000-0002-5265-4159; Dong, Zhong-Yi/0000-0001-9967-0060; Wu, De-Hua/0000-0003-0560-0016	National Nature Science Foundation of China [81172056, 81172586]	National Nature Science Foundation of China(National Natural Science Foundation of China (NSFC))	This work was supported by the National Nature Science Foundation of China (Grant No. 81172056 and 81172586).	Bardag-Gorce F, 2010, EXP MOL PATHOL, V88, P353, DOI 10.1016/j.yexmp.2010.03.001; Bett JS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030866; Canaan A, 2006, MOL CELL BIOL, V26, P5180, DOI 10.1128/MCB.00966-05; Carnero A, 2010, CURR PHARM DESIGN, V16, P34, DOI 10.2174/138161210789941865; Cheng GZ, 2008, CURR CANCER DRUG TAR, V8, P2; Chung JS, 2012, GASTROENTEROLOGY, V143, P1084, DOI 10.1053/j.gastro.2012.06.038; Cooke VG, 2012, CANCER CELL, V21, P66, DOI 10.1016/j.ccr.2011.11.024; Dikic I, 2009, NAT REV MOL CELL BIO, V10, P659, DOI 10.1038/nrm2767; Fan WF, 1996, IMMUNOGENETICS, V44, P97, DOI 10.1007/s002510050095; French SW, 2010, EXP MOL PATHOL, V88, P219, DOI 10.1016/j.yexmp.2010.01.005; Fu J, 2011, HEPATOLOGY, V53, P181, DOI 10.1002/hep.24015; Gong PF, 2010, J AM SOC NEPHROL, V21, P316, DOI 10.1681/ASN.2009050479; Groettrup M, 2008, TRENDS BIOCHEM SCI, V33, P230, DOI 10.1016/j.tibs.2008.01.005; Gruen JR, 1996, GENOMICS, V36, P70, DOI 10.1006/geno.1996.0427; Hoeller D, 2006, NAT REV CANCER, V6, P776, DOI 10.1038/nrc1994; Kirkin V, 2007, CURR OPIN CELL BIOL, V19, P199, DOI 10.1016/j.ceb.2007.02.002; Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091; Lee CGL, 2003, ONCOGENE, V22, P2592, DOI 10.1038/sj.onc.1206337; Li JC, 2010, GASTROENTEROLOGY, V139, P2146, DOI 10.1053/j.gastro.2010.08.004; Li QQ, 2009, CLIN CANCER RES, V15, P2657, DOI 10.1158/1078-0432.CCR-08-2372; Lim CB, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-20; Liu YC, 1999, P NATL ACAD SCI USA, V96, P4313, DOI 10.1073/pnas.96.8.4313; Lukasiak S, 2008, ONCOGENE, V27, P6068, DOI 10.1038/onc.2008.201; Nejak-Bowen KN, 2011, SEMIN CANCER BIOL, V21, P44, DOI 10.1016/j.semcancer.2010.12.010; Oliva J, 2008, EXP MOL PATHOL, V84, P102, DOI 10.1016/j.yexmp.2007.12.003; Poon RTP, 2011, HEPATOLOGY, V54, P757, DOI 10.1002/hep.24569; Qing X, 2011, EXP MOL PATHOL, V90, P51, DOI 10.1016/j.yexmp.2010.09.005; Raasi S, 2001, J BIOL CHEM, V276, P35334, DOI 10.1074/jbc.M105139200; Rani N, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1752; Ren JW, 2011, J CELL SCI, V124, P3665, DOI 10.1242/jcs.087403; Ren JW, 2006, J BIOL CHEM, V281, P11413, DOI 10.1074/jbc.M507218200; Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025; Sabbah M, 2008, DRUG RESIST UPDATE, V11, P123, DOI 10.1016/j.drup.2008.07.001; Teufel A, 2012, J HEPATOL, V56, P279, DOI 10.1016/j.jhep.2011.05.035; Thorgeirsson SS, 2002, NAT GENET, V31, P339, DOI 10.1038/ng0802-339; Tommasi S, 2007, CURR PHARM DESIGN, V13, P3279, DOI 10.2174/138161207782360663; Wangsa D, 2008, BRIT J CANCER, V99, P1121, DOI 10.1038/sj.bjc.6604633; Watson IR, 2011, CANCER CELL, V19, P168, DOI 10.1016/j.ccr.2011.01.002; Wu D, 2008, J PATHOL, V216, P167, DOI 10.1002/path.2391; Wu D, 2010, ANN ONCOL, V21, P589, DOI 10.1093/annonc/mdp333; Xia LM, 2012, J HEPATOL, V57, P600, DOI 10.1016/j.jhep.2012.04.020; Yuen MF, 2009, J GASTROEN HEPATOL, V24, P346, DOI 10.1111/j.1440-1746.2009.05784.x; Zhang DW, 2006, ONCOGENE, V25, P2318, DOI 10.1038/sj.onc.1209220; Zou JJ, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-97	44	55	63	2	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	FEB 13	2014	33	7					909	920		10.1038/onc.2013.236	http://dx.doi.org/10.1038/onc.2013.236			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	AB2MN	23812429				2022-12-28	WOS:000331626900012
J	Lin, MZ; Marzec, KA; Martin, JL; Baxter, RC				Lin, M. Z.; Marzec, K. A.; Martin, J. L.; Baxter, R. C.			The role of insulin-like growth factor binding protein-3 in the breast cancer cell response to DNA-damaging agents	ONCOGENE			English	Article						EGFR; IGFBP-3; breast cancer; DNA-PK; DNA-damaging therapy	DOUBLE-STRAND BREAK; FACTOR RECEPTOR; NUCLEAR EGFR; RECURRENT GLIOBLASTOMA; TUMOR SUPPRESSION; EPITHELIAL-CELLS; LIPID RAFTS; PHASE-II; EXPRESSION; KINASE	Following exposure to radiation and chemotherapeutic agents, the epidermal growth factor receptor (EGFR) can modulate the repair of DNA double-strand breaks (DSB) by forming protein complexes that include the catalytic subunit of DNA-dependent protein kinase (DNA-PKcs). This is one of the key mechanism by which tumors become resistant to DNA-damaging therapies. Our previous studies have shown that insulin-like growth factor binding protein-3 (IGFBP-3) is a substrate for DNA-PKcs, and can transactivate EGFR. We therefore questioned whether IGFBP-3 might interact with the EGFR - DNA-PK complex that regulates the DNA damage response. The aim of this study was to delineate the role of IGFBP-3 in the response of breast cancer cells to DSB-inducing chemotherapeutic agents. In the estrogen receptor-negative breast cancer cell lines MDA-MB-468 and Hs578T, which express IGFBP-3 highly, nuclear localization of EGFR and IGFBP-3 was enhanced by treatment with cytotoxic drugs etoposide or doxorubicin and reduced by the EGFR kinase inhibitor gefitinib. Enhanced association among IGFBP-3, EGFR and DNA-PKcs, following the exposure to DNA-damaging drugs was supported by both co-immunoprecipitation analysis and direct visualization by proximity ligation assay. The activation of DNA-PKcs at Ser2056, DNA repair as measured by a nonhomologous end-joining assay, and the increase in EGFR and DNA-PKcs interaction induced by DNA-damaging agents, were all decreased by IGFBP-3 silencing, suggesting that IGFBP-3 has an obligatory role in the DNA repair response to DNA-damaging therapy. In conclusion, IGFBP-3 co-translocation to the nucleus of breast cancer cells and its formation of a complex with DNA-PKcs and EGFR in response to DNA damage shows its potential involvement in the regulation of DNA repair. This suggests the possibility of a therapeutic approach for sensitizing breast cancer to chemo-or radiotherapy by targeting the DNA repair function of IGFBP-3.	[Lin, M. Z.; Marzec, K. A.; Martin, J. L.; Baxter, R. C.] Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, Hormones & Canc Div, St Leonards, NSW 2065, Australia	Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research	Baxter, RC (corresponding author), Univ Sydney, Royal N Shore Hosp, Kolling Inst Med Res, Hormones & Canc Div, St Leonards, NSW 2065, Australia.	robert.baxter@sydney.edu.au	Baxter, Robert C/F-3927-2012	Baxter, Robert C/0000-0001-5061-2142; Marzec, Kamila/0000-0002-3051-2205	RCB from the Australian Research Council [DP0984232]	RCB from the Australian Research Council(Australian Research Council)	This work was supported by Grant Number DP0984232 to RCB from the Australian Research Council.	Abulrob A, 2004, ONCOGENE, V23, P6967, DOI 10.1038/sj.onc.1207911; Andrin C, 2004, J BIOL CHEM, V279, P25017, DOI 10.1074/jbc.M401805200; Andrin C, 2012, NUCLEUS-PHILA, V3, P384, DOI 10.4161/nucl.21055; Arnes JB, 2009, J CLIN PATHOL, V62, P139, DOI 10.1136/jcp.2008.056291; BAXTER RC, 1993, TRENDS ENDOCRIN MET, V4, P91, DOI 10.1016/1043-2760(93)90085-S; Butt AJ, 2004, J CLIN ENDOCR METAB, V89, P1950, DOI 10.1210/jc.2003-030914; Butt AJ, 2000, J BIOL CHEM, V275, P39174, DOI 10.1074/jbc.M908888199; Carpenter G, 2009, EXP CELL RES, V315, P1556, DOI 10.1016/j.yexcr.2008.09.027; Chen BPC, 2005, J BIOL CHEM, V280, P14709, DOI 10.1074/jbc.M408827200; Chen S, 2001, J BIOL CHEM, V276, P24323, DOI 10.1074/jbc.M010544200; Chuang ST, 2008, J UROLOGY, V179, P445, DOI 10.1016/j.juro.2007.09.106; Ciardiello F, 2006, BRIT J CANCER, V94, P1604, DOI 10.1038/sj.bjc.6603141; CLEMMONS DR, 1990, ENDOCRINOLOGY, V127, P2679, DOI 10.1210/endo-127-6-2679; Cobb LJ, 2006, CANCER RES, V66, P10878, DOI 10.1158/0008-5472.CAN-06-0585; Coleman MP, 2011, LANCET, V377, P127, DOI 10.1016/S0140-6736(10)62231-3; Dennison GJ, 2008, BREAST CANCER RES, V10, pS21, DOI 10.1186/bcr1924; DeSantis C, 2011, CA-CANCER J CLIN, V61, P409, DOI 10.3322/caac.20134; Dittmann K, 2005, J BIOL CHEM, V280, P31182, DOI 10.1074/jbc.M506591200; Dittmann K, 2010, STRAHLENTHER ONKOL, V186, P1, DOI 10.1007/s00066-009-2026-4; Dittmann K, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-69; Dominguez-Brauer C, 2010, CELL CYCLE, V9, P86, DOI 10.4161/cc.9.1.10350; Feldmann E, 2000, NUCLEIC ACIDS RES, V28, P2585, DOI 10.1093/nar/28.13.2585; Ferguson DO, 2001, ONCOGENE, V20, P5572, DOI 10.1038/sj.onc.1204767; Firth SM, 2002, ENDOCR REV, V23, P824, DOI 10.1210/er.2001-0033; Friedmann BJ, 2006, MOL CANCER THER, V5, P209, DOI 10.1158/1535-7163.MCT-05-0239; GRKOVIC S, 2012, ONCOGENE, DOI DOI 10.1038/0NC.2012.264; Hanzal-Bayer MF, 2007, FEBS LETT, V581, P2098, DOI 10.1016/j.febslet.2007.03.019; Hasty P, 2008, CELL CYCLE, V7, P1139, DOI 10.4161/cc.7.9.5807; Hsu SC, 2009, AM J TRANSL RES, V1, P249; Irwin ME, 2011, J CELL PHYSIOL, V226, P2316, DOI 10.1002/jcp.22570; Jeggo PA, 1998, RADIAT RES, V150, pS80, DOI 10.2307/3579810; Kenworthy AK, 2000, MOL BIOL CELL, V11, P1645, DOI 10.1091/mbc.11.5.1645; Kinzler KW, 1997, NATURE, V386, P763; Lee KW, 2004, J BIOL CHEM, V279, P469, DOI 10.1074/jbc.M307316200; Li ML, 2012, TRENDS BIOCHEM SCI, V37, P418, DOI 10.1016/j.tibs.2012.06.007; Liccardi G, 2011, CANCER RES, V71, P1103, DOI 10.1158/0008-5472.CAN-10-2384; Martin JL, 2007, ENDOCRINOLOGY, V148, P2532, DOI 10.1210/en.2006-1335; Martin JL, 2009, J BIOL CHEM, V284, P25542, DOI 10.1074/jbc.M109.007120; Martin JL, 2003, J BIOL CHEM, V278, P2969, DOI 10.1074/jbc.M210739200; McIntosh J, 2010, J BIOL CHEM, V285, P38788, DOI 10.1074/jbc.M110.177311; McPherson K, 2000, BMJ-BRIT MED J, V321, P624, DOI 10.1136/bmj.321.7261.624; Micutkova L, 2012, INT J CANCER, V130, P1544, DOI 10.1002/ijc.26149; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Muller C, 1998, BLOOD, V92, P2213, DOI 10.1182/blood.V92.7.2213.2213_2213_2219; O'Han MK, 2009, GROWTH FACTORS, V27, P394, DOI 10.3109/08977190903185032; Paharkova-Vatchkova V, 2010, ENDOCR-RELAT CANCER, V17, P293, DOI 10.1677/ERC-09-0106; Probst-Hensch NM, 2010, CLIN CANCER RES, V16, P1025, DOI 10.1158/1078-0432.CCR-09-0957; Putti TC, 2005, MODERN PATHOL, V18, P26, DOI 10.1038/modpathol.3800255; Reardon DA, 2010, J NEURO-ONCOL, V96, P219, DOI 10.1007/s11060-009-9950-0; Renehan AG, 2004, LANCET, V363, P1346, DOI 10.1016/S0140-6736(04)16044-3; Rinaldi S, 2006, ENDOCR-RELAT CANCER, V13, P593, DOI 10.1677/erc.1.01150; Rocha RL, 1996, J NATL CANCER I, V88, P601, DOI 10.1093/jnci/88.9.601; Santer FR, 2006, CANCER RES, V66, P3024, DOI 10.1158/0008-5472.CAN-05-2013; Schedlich LJ, 2003, ENDOCRINOLOGY, V144, P1984, DOI 10.1210/en.2002-220798; Schedlich LJ, 1998, J BIOL CHEM, V273, P18347, DOI 10.1074/jbc.273.29.18347; Schedlich LJ, 2000, J BIOL CHEM, V275, P23462, DOI 10.1074/jbc.M002208200; Singh D, 2002, CANCER CELL, V1, P203, DOI 10.1016/S1535-6108(02)00030-2; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; van den Bent MJ, 2009, J CLIN ONCOL, V27, P1268, DOI 10.1200/JCO.2008.17.5984; van Gent DC, 2001, NAT REV GENET, V2, P196, DOI 10.1038/35056049; Wang XQ, 2006, J INVEST DERMATOL, V126, P951, DOI 10.1038/sj.jid.5700282; Williams AC, 2000, CANCER RES, V60, P22; Xi YG, 2006, MOL CANCER THER, V5, P3078, DOI 10.1158/1535-7163.MCT-06-0424; Xue A, 2008, PANCREAS, V36, P160, DOI 10.1097/MPA.0b013e31815750f0; Yarden RI, 2012, INT J BIOCHEM CELL B, V44, P1761, DOI 10.1016/j.biocel.2012.06.026; Yoon JH, 2012, BIOCHEM PHARMACOL, V83, P747, DOI 10.1016/j.bcp.2011.12.029; Yu H, 1996, BRIT J CANCER, V74, P1242, DOI 10.1038/bjc.1996.523	67	51	53	2	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JAN	2014	33	1					85	96		10.1038/onc.2012.538	http://dx.doi.org/10.1038/onc.2012.538			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	282YU	23178489	Bronze			2022-12-28	WOS:000329212000010
J	Ling, LS; Voskas, D; Woodgett, JR				Ling, L. S.; Voskas, D.; Woodgett, J. R.			Activation of PDK-1 maintains mouse embryonic stem cell self-renewal in a PKB-dependent manner	ONCOGENE			English	Article						PDK-1; GSK-3; embryonic stem cell; pluripotency	PROTEIN-KINASE-B; BETA-CATENIN; PHOSPHATIDYLINOSITOL 3-KINASES; INSULIN; PLURIPOTENCY; PHOSPHORYLATION; INHIBITION; GROWTH; AKT; PROLIFERATION	The phosphatidylinositol 30 kinase (PI3K) pathway is involved in many cellular processes including cell proliferation, survival and glucose transport, and is implicated in various disease states, such as cancer and diabetes. Although there have been numerous studies dissecting the role of PI3K signaling in different cell types and disease models, the mechanism by which PI3K signaling regulates embryonic stem (ES) cell fate remains unclear. It is believed that in addition to proliferation and tumorigenesis, PI3K activity may also be important for ES cell self-renewal. Paling et al. reported that the inhibition of PI3K led to a reduction in the ability of leukemia inhibitory factor to maintain self-renewal, causing cells to differentiate. Studies in our lab have revealed that ES cells completely lacking glycogen synthase kinase-3 (GSK-3) remain undifferentiated compared with wild-type ES cells. GSK-3 is negatively regulated by PI3K, suggesting that PI3K may have a vital role in maintaining pluripotency in ES cells through GSK-3. By using a modified Flp recombinase system, we expressed activated alleles of 3-phosphoinositide-dependent protein kinase-1 and protein kinase B to create stable, isogenic ES cell lines to further study the role of the PI3K signaling pathway in stem cell fate determination. In vitro characterization of the transgenic cell lines revealed a strong tendency toward the maintenance of pluripotency, and this phenotype was found to be independent of canonical Wnt signal transduction. In summary, PI3K signaling is sufficient to maintain the self-renewal and survival of stem cells. As this pathway is frequently mutationally activated in cancers, its effect on suppressing differentiation may contribute to its oncogenicity.	[Ling, L. S.; Woodgett, J. R.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Ling, L. S.; Voskas, D.; Woodgett, J. R.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute	Woodgett, JR (corresponding author), Mt Sinai Hosp, Samuel Lunenfeld Res Inst, 600 Univ Ave,Room 982, Toronto, ON M5G 1X5, Canada.	woodgett@lunenfeld.ca	Woodgett, Jim/F-1087-2010	Woodgett, Jim/0000-0003-3731-5797	NSERC Canada Graduate Scholarship; Heart and Stroke Foundation of Canada Fellowship; CIHR [FRN 12858]	NSERC Canada Graduate Scholarship(Natural Sciences and Engineering Research Council of Canada (NSERC)); Heart and Stroke Foundation of Canada Fellowship(Heart & Stroke Foundation of Canada); CIHR(Canadian Institutes of Health Research (CIHR))	We thank Brad Doble for generously sharing reagents and protocols, Malgosia Kownacka for providing feeder cells, Mike Parsons and Elizabeth Rubie for technical expertise and advice, and Eric Ho and Satish Patel for troubleshooting and helpful discussions. LSL was supported by a NSERC Canada Graduate Scholarship and DV was supported by a Heart and Stroke Foundation of Canada Fellowship. These studies were funded by a CIHR operating grant (FRN 12858).	Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Armstrong L, 2006, HUM MOL GENET, V15, P1894, DOI 10.1093/hmg/ddl112; Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Desbois-Mouthon C, 2001, ONCOGENE, V20, P252, DOI 10.1038/sj.onc.1204064; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Doble BW, 2007, DEV CELL, V12, P957, DOI 10.1016/j.devcel.2007.04.001; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Gu DY, 2007, FEBS LETT, V581, P382, DOI 10.1016/j.febslet.2006.12.043; Hawkins PT, 2006, BIOCHEM SOC T, V34, P647, DOI 10.1042/BST0340647; He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430; Huang H, 2008, CURR OPIN CELL BIOL, V20, P119, DOI 10.1016/j.ceb.2008.01.009; Ishibe S, 2006, MOL CELL BIOL, V26, P9232, DOI 10.1128/MCB.01312-06; Jirmanova L, 2002, ONCOGENE, V21, P5515, DOI 10.1038/sj.onc.1205728; Kingham E, 2009, J CELL SCI, V122, P2311, DOI 10.1242/jcs.046557; Kobielak K, 2007, P NATL ACAD SCI USA, V104, P10063, DOI 10.1073/pnas.0703004104; Lianguzova MS, 2007, CELL BIOL INT, V31, P330, DOI 10.1016/j.cellbi.2007.01.019; Lin YJ, 2012, MOL CELL, V48, P627, DOI 10.1016/j.molcel.2012.08.030; Logie L, 2007, DIABETES, V56, P2218, DOI 10.2337/db07-0343; MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016; Maes C, 2010, EMBO J, V29, P424, DOI 10.1038/emboj.2009.361; Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009; McManus EJ, 2005, EMBO J, V24, P1571, DOI 10.1038/sj.emboj.7600633; Mora A, 2004, SEMIN CELL DEV BIOL, V15, P161, DOI 10.1016/j.semcdb.2003.12.022; Murakami M, 2004, MOL CELL BIOL, V24, P6710, DOI 10.1128/mcb.24.15.6710-6718.2004; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Ng SW, 2009, J BIOL CHEM, V284, P24767, DOI 10.1074/jbc.M109.011692; Niwa H, 2009, NATURE, V460, P118, DOI 10.1038/nature08113; Orlando L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030234; Paling NRD, 2004, J BIOL CHEM, V279, P48063, DOI 10.1074/jbc.M406467200; Sato N, 2004, NAT MED, V10, P55, DOI 10.1038/nm979; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Scheid MP, 2005, MOL CELL BIOL, V25, P2347, DOI 10.1128/MCB.25.6.2347-2363.2005; Storm MP, 2009, STEM CELLS, V27, P764, DOI 10.1002/stem.3; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Takahashi K, 2005, BIOCHEM SOC T, V33, P1522, DOI 10.1042/BST0331522; Watanabe S, 2006, ONCOGENE, V25, P2697, DOI 10.1038/sj.onc.1209307; Wu G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004926; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Zhao JJ, 2005, P NATL ACAD SCI USA, V102, P18443, DOI 10.1073/pnas.0508988102	40	13	13	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	NOV 21	2013	32	47					5397	5408		10.1038/onc.2013.44	http://dx.doi.org/10.1038/onc.2013.44			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	254PM	23455320	Green Published, hybrid			2022-12-28	WOS:000327177600003
J	Nagano, O; Okazaki, S; Saya, H				Nagano, O.; Okazaki, S.; Saya, H.			Redox regulation in stem-like cancer cells by CD44 variant isoforms	ONCOGENE			English	Review						cancer stem cell; CD44; reactive oxygen species; cystine-glutamate transporter	EPITHELIAL-MESENCHYMAL TRANSITION; CYSTINE/GLUTAMATE EXCHANGE TRANSPORTER; BREAST-CANCER; OXIDATIVE STRESS; CARCINOMA-CELLS; INITIATING CELLS; GROWTH-FACTOR; TUMOR-GROWTH; PROSPECTIVE IDENTIFICATION; GLUTATHIONE METABOLISM	Increasing evidence indicates that several types of solid tumor are hierarchically organized and sustained by a distinct population of cancer stem cells (CSCs). CSCs possess enhanced mechanisms of protection from stress induced by reactive oxygen species (ROS) that render them resistant to chemo- and radiotherapy. Expression of CD44, especially variant isoforms (CD44v) of this major CSC marker, contributes to ROS defense through upregulation of the synthesis of reduced glutathione (GSH), the primary intracellular antioxidant. CD44v interacts with and stabilizes xCT, a subunit of the cystine-glutamate transporter xc(-), and thereby promotes cystine uptake for GSH synthesis. Given that cancer cells are often exposed to high levels of ROS during tumor progression, the ability to avoid the consequences of such exposure is required for cancer cell survival and propagation in vivo. CSCs, in which defense against ROS is enhanced by CD44v are thus thought to drive tumor growth, chemoresistance and metastasis. Therapy targeted to the CD44v-xCT system may therefore impair the ROS defense ability of CSCs and thereby sensitize them to currently available treatments.	[Nagano, O.; Okazaki, S.; Saya, H.] Keio Univ, Sch Med, Inst Adv Med Res, Div Gene Regulat,Shinjuku Ku, Tokyo 1608582, Japan; [Saya, H.] Japan Sci & Technol Agcy, CREST, Chiyoda Ku, Tokyo, Japan	Keio University; Japan Science & Technology Agency (JST)	Nagano, O (corresponding author), Keio Univ, Sch Med, Inst Adv Med Res, Div Gene Regulat,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	osmna@sb3.so-net.ne.jp	Saya, Hideyuki/J-4325-2013; Okazaki, Shogo/A-8119-2014	Saya, Hideyuki/0000-0001-6610-1902	Ministry of Education, Culture, Sports, Science, and Technology of Japan; Ministry's Project for Development of Innovative Research on Cancer Therapeutics	Ministry of Education, Culture, Sports, Science, and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Ministry's Project for Development of Innovative Research on Cancer Therapeutics	We thank K Arai for help in preparation of the manuscript. The work in the authors' laboratory was supported by grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan (to HS) as well as by the Ministry's Project for Development of Innovative Research on Cancer Therapeutics (P-Direct, to ON).	Adam-Vizi V, 2006, TRENDS PHARMACOL SCI, V27, P639, DOI 10.1016/j.tips.2006.10.005; Ailles LE, 2007, CURR OPIN BIOTECH, V18, P460, DOI 10.1016/j.copbio.2007.10.007; Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100; Anasagasti MJ, 1998, HEPATOLOGY, V27, P1249, DOI 10.1002/hep.510270510; ARRICK BA, 1984, CANCER RES, V44, P4224; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; Baek S, 2012, CLIN CANCER RES, V18, P5427, DOI 10.1158/1078-0432.CCR-12-0214; Balaban RS, 2005, CELL, V120, P483, DOI 10.1016/j.cell.2005.02.001; Balic M, 2006, CLIN CANCER RES, V12, P5615, DOI 10.1158/1078-0432.CCR-06-0169; BARTOLAZZI A, 1995, J CELL SCI, V108, P1723; Baumann M, 2008, NAT REV CANCER, V8, P545, DOI 10.1038/nrc2419; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; BENNETT KL, 1995, J CELL BIOL, V131, P1623, DOI 10.1083/jcb.131.6.1623; BENNETT KL, 1995, J CELL BIOL, V128, P687, DOI 10.1083/jcb.128.4.687; Boccaccio C, 2006, NAT REV CANCER, V6, P637, DOI 10.1038/nrc1912; Bourguignon LYW, 2012, ONCOGENE, V31, P149, DOI 10.1038/onc.2011.222; Brown RL, 2011, J CLIN INVEST, V121, P1064, DOI 10.1172/JCI44540; Chiang AC, 2008, NEW ENGL J MED, V359, P2814, DOI 10.1056/NEJMra0805239; Clevers H, 2011, NAT MED, V17, P313, DOI 10.1038/nm.2304; Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018; Conklin Kenneth A, 2004, Integr Cancer Ther, V3, P294, DOI 10.1177/1534735404270335; Cooke VG, 2012, CANCER CELL, V21, P66, DOI 10.1016/j.ccr.2011.11.024; Croker AK, 2009, J CELL MOL MED, V13, P2236, DOI 10.1111/j.1582-4934.2008.00455.x; Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104; Dalton TP, 2004, FREE RADICAL BIO MED, V37, P1511, DOI 10.1016/j.freeradbiomed.2004.06.040; De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189; DeGrendele HC, 1997, SCIENCE, V278, P672, DOI 10.1126/science.278.5338.672; Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733; Dieter SM, 2011, CELL STEM CELL, V9, P357, DOI 10.1016/j.stem.2011.08.010; Dolado I, 2007, CANCER CELL, V11, P191, DOI 10.1016/j.ccr.2006.12.013; Du L, 2008, CLIN CANCER RES, V14, P6751, DOI 10.1158/1078-0432.CCR-08-1034; Golden EB, 2012, FRONT ONCOL, V2, P1, DOI [10.3389/fonc.2012.00088, 10.3389/fonc.2012.00153]; Granot Z, 2011, CANCER CELL, V20, P300, DOI 10.1016/j.ccr.2011.08.012; Gregory AD, 2011, CANCER RES, V71, P2411, DOI 10.1158/0008-5472.CAN-10-2583; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hanley WD, 2005, CANCER RES, V65, P5812, DOI 10.1158/0008-5472.CAN-04-4557; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Hendry JH, 1997, INT J RADIAT BIOL, V71, P709, DOI 10.1080/095530097143716; Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002; Hill RP, 2009, SEMIN RADIAT ONCOL, V19, P106, DOI 10.1016/j.semradonc.2008.12.002; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Huang Y, 2005, CANCER RES, V65, P7446, DOI 10.1158/0008-5472.CAN-04-4267; ISHII T, 1987, J CELL PHYSIOL, V133, P330, DOI 10.1002/jcp.1041330217; Ishimoto T, 2011, CANCER CELL, V19, P387, DOI 10.1016/j.ccr.2011.01.038; Ito K, 2006, NAT MED, V12, P446, DOI 10.1038/nm1388; Jin LQ, 2006, NAT MED, V12, P1167, DOI 10.1038/nm1483; Kalluri R, 2003, J CLIN INVEST, V112, P1776, DOI 10.1172/JCI200320530; Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104; Kannagi R, 2010, CANCER SCI, V101, P586, DOI 10.1111/j.1349-7006.2009.01455.x; Keith B, 2007, CELL, V129, P465, DOI 10.1016/j.cell.2007.04.019; Krishnamachary B, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044078; Lapidot T, 2005, BLOOD, V106, P1901, DOI 10.1182/blood-2005-04-1417; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Lewerenz J, 2012, CELL DEATH DIFFER, V19, P847, DOI 10.1038/cdd.2011.165; Lewerenz J, 2009, J BIOL CHEM, V284, P1106, DOI 10.1074/jbc.M807325200; Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030; Li J, 2006, MOL BIOL CELL, V17, P3978, DOI 10.1091/mbc.E05-06-0532; Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284; Liu HP, 2010, P NATL ACAD SCI USA, V107, P18115, DOI 10.1073/pnas.1006732107; Lo M, 2008, J CELL PHYSIOL, V215, P593, DOI 10.1002/jcp.21366; Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154; Lopez JI, 2005, CANCER RES, V65, P6755, DOI 10.1158/0008-5472.CAN-05-0863; Macleod KF, 2008, NAT REV CANCER, V8, P769, DOI 10.1038/nrc2504; MEISTER A, 1988, J BIOL CHEM, V263, P17205; Mielgo A, 2006, CELL DEATH DIFFER, V13, P465, DOI 10.1038/sj.cdd.4401763; Mima K, 2012, CANCER RES, V72, P3414, DOI 10.1158/0008-5472.CAN-12-0299; Nagano O, 2004, CANCER SCI, V95, P930, DOI 10.1111/j.1349-7006.2004.tb03179.x; Naor D, 2008, SEMIN CANCER BIOL, V18, P260, DOI 10.1016/j.semcancer.2008.03.015; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Obrador E, 2002, HEPATOLOGY, V35, P74, DOI 10.1053/jhep.2002.30277; OBrien ML, 1996, EUR J CANCER, V32A, P967, DOI 10.1016/0959-8049(96)00051-2; Ohata H, 2012, CANCER RES, V72, P5101, DOI 10.1158/0008-5472.CAN-11-3812; Orian-Rousseau V, 2002, GENE DEV, V16, P3074, DOI 10.1101/gad.242602; Owusu-Ansah E, 2009, NATURE, V461, P537, DOI 10.1038/nature08313; Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327; Pham PV, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-209; Phillips TM, 2006, JNCI-J NATL CANCER I, V98, P1777, DOI 10.1093/jnci/djj495; Ponta H, 2003, NAT REV MOL CELL BIO, V4, P33, DOI 10.1038/nrm1004; Preston Marnie, 2011, Front Biosci (Schol Ed), V3, P1165; Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104; Qu Y, 2011, J CLIN INVEST, V121, P212, DOI 10.1172/JCI43144; Raj L, 2011, NATURE, V475, P231, DOI 10.1038/nature10167; REBER S, 1990, INT J CANCER, V46, P919, DOI 10.1002/ijc.2910460528; Sackstein R, 2008, NAT MED, V14, P181, DOI 10.1038/nm1703; Sasaki H, 2002, J BIOL CHEM, V277, P44765, DOI 10.1074/jbc.M208704200; Sato H, 2005, J BIOL CHEM, V280, P37423, DOI 10.1074/jbc.M506439200; SEITER S, 1993, J EXP MED, V177, P443, DOI 10.1084/jem.177.2.443; Shapiro IM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002218; Shi XK, 2012, ANTIOXID REDOX SIGN, V16, P1215, DOI 10.1089/ars.2012.4529; Slomiany MG, 2009, CANCER RES, V69, P1293, DOI 10.1158/0008-5472.CAN-08-2491; Spitz DR, 2004, CANCER METAST REV, V23, P311, DOI 10.1023/B:CANC.0000031769.14728.bc; Sun SR, 2009, KIDNEY INT, V75, P1278, DOI 10.1038/ki.2009.62; Takahashi A, 2006, NAT CELL BIOL, V8, P1291, DOI 10.1038/ncb1491; Takahashi E, 2010, J BIOL CHEM, V285, P4060, DOI 10.1074/jbc.M109.056523; TANABE KK, 1993, LANCET, V341, P725, DOI 10.1016/0140-6736(93)90490-8; TEW KD, 1994, CANCER RES, V54, P4313; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Toole BP, 2008, DRUG RESIST UPDATE, V11, P110, DOI 10.1016/j.drup.2008.04.002; Tothova Z, 2007, CELL STEM CELL, V1, P140, DOI 10.1016/j.stem.2007.07.017; Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009; Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803; Verrey F, 2004, PFLUG ARCH EUR J PHY, V447, P532, DOI 10.1007/s00424-003-1086-z; Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499; Wang HY, 2003, BIOCHEM BIOPH RES CO, V305, P611, DOI 10.1016/S0006-291X(03)00808-8; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Warzecha CC, 2010, EMBO J, V29, P3286, DOI 10.1038/emboj.2010.195; Warzecha CC, 2009, MOL CELL, V33, P591, DOI 10.1016/j.molcel.2009.01.025; Weber GF, 2002, CANCER RES, V62, P2281; Yae T, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1892; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691; Yu WH, 2002, GENE DEV, V16, P307, DOI 10.1101/gad.925702; Zeilstra J, 2008, CANCER RES, V68, P3655, DOI 10.1158/0008-5472.CAN-07-2940; Zoller M, 2011, NAT REV CANCER, V11, P254, DOI 10.1038/nrc3023	115	193	197	3	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 31	2013	32	44					5191	5198		10.1038/onc.2012.638	http://dx.doi.org/10.1038/onc.2012.638			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	245XH	23334333				2022-12-28	WOS:000326497100001
J	Xi, Y; Wei, Y; Sennino, B; Ulsamer, A; Kwan, I; Brumwell, AN; Tan, K; Aghi, MK; McDonald, DM; Jablons, DM; Chapman, HA				Xi, Y.; Wei, Y.; Sennino, B.; Ulsamer, A.; Kwan, I.; Brumwell, A. N.; Tan, K.; Aghi, M. K.; McDonald, D. M.; Jablons, D. M.; Chapman, H. A.			Identification of pY654-beta-catenin as a critical co-factor in hypoxia-inducible factor-1 alpha signaling and tumor responses to hypoxia	ONCOGENE			English	Article						hypoxia; signaling; transcription; tumor; epithelial	EPITHELIAL-MESENCHYMAL TRANSITION; BETA-CATENIN; ANTIANGIOGENIC THERAPY; GENE-EXPRESSION; CELL INVASION; C-SRC; ACTIVATION; METASTASIS; MET; MECHANISMS	Hypoxia is linked to epithelial-mesenchymal transition (EMT) and tumor progression in numerous carcinomas. Responses to hypoxia are thought to operate via hypoxia-inducible factors (HIFs), but the importance of co-factors that regulate HIF signaling within tumors is not well understood. Here, we elucidate a signaling pathway that physically and functionally couples tyrosine phosphorylation of beta-catenin to HIF1 alpha signaling and HIF1 alpha-mediated tumor EMT. Primary human lung adenocarcinomas accumulate pY654-beta-catenin and HIF1 alpha. All pY654-beta-catenin, and only the tyrosine phosphorylated form, was found complexed with HIF1 alpha and active Src, both within the human tumors and in lung tumor cell lines exposed to hypoxia. Phosphorylation of Y654, generated by hypoxia mediated, reactive oxygen species (ROS)-dependent Src kinase activation, was required for beta-catenin to interact with HIF1 alpha and Src, to promote HIF1 alpha transcriptional activity, and for hypoxia-induced EMT. Mice bearing hypoxic pancreatic islet adenomas, generated by treatment with anti-vascular endothelial growth factor antibodies, accumulate HIF1 alpha/pY654-beta-catenin complexes and develop an invasive phenotype. Concurrent administration of the ROS inhibitor N-acetylcysteine abrogated beta-catenin/HIF pathway activity and restored adenoma architecture. Collectively, the findings implicate accumulation of pY654-beta-catenin specifically complexed to HIF1 alpha and Src kinase as critically involved in HIF1 alpha signaling and tumor invasion. The findings also suggest that targeting ROS-dependent aspects of the pY654-beta-catenin/HIF1 alpha pathway may attenuate untoward biological effects of anti-angiogenic agents and tumor hypoxia.	[Xi, Y.; Wei, Y.; Ulsamer, A.; Kwan, I.; Brumwell, A. N.; Tan, K.; Chapman, H. A.] Univ Calif San Francisco, Div Pulm & Crit Care, Dept Med, San Francisco, CA 94143 USA; [Sennino, B.; McDonald, D. M.] Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; [Sennino, B.; McDonald, D. M.] Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; [Aghi, M. K.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; [Aghi, M. K.] Univ Calif San Francisco, Brain Tumor Res Ctr, San Francisco, CA 94143 USA; [Jablons, D. M.] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Wei, Y (corresponding author), Univ Calif San Francisco, Div Pulm & Crit Care, 513 Parnassus Ave, San Francisco, CA 94143 USA.	ying.wei@ucsf.edu; hal.chapman@ucsf.edu	Ulsamer, A/H-7994-2014	Ulsamer, A/0000-0001-7808-1005	NIH [HL-44712, CA-125564]; NATIONAL CANCER INSTITUTE [R01CA125564] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059157, P01HL024136, R01HL044712] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS079697, K02NS064167] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	We thank Roshni Ray, Mazen Sidani, Toshina Ishiguro-Oonuma, Casey W Williamson, Thomas Kim, Yonghyun Kim, Yang Gao and Ronald Tsang for technical assistance; and Drs Miguel Ramalho Santos and Martin Brown for generous gifts of reagents. This work was supported by NIH Grants to HL-44712 and CA-125564 (HAC).	Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460; Cannito S, 2008, CARCINOGENESIS, V29, P2267, DOI 10.1093/carcin/bgn216; Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005; De Bock K, 2011, NAT REV CLIN ONCOL, V8, P393, DOI 10.1038/nrclinonc.2011.83; Grepin R, 2010, J ONCOL, V2010, DOI 10.1155/2010/835680; Hung JJ, 2009, THORAX, V64, P1082, DOI 10.1136/thx.2009.115691; Jiang BH, 1997, CANCER RES, V57, P5328; Jones S, 2008, P NATL ACAD SCI USA, V105, P4283, DOI 10.1073/pnas.0712345105; Kaidi A, 2007, NAT CELL BIOL, V9, P210, DOI 10.1038/ncb1534; Kaluz S, 2008, CLIN CHIM ACTA, V395, P6, DOI 10.1016/j.cca.2008.05.002; Karni R, 2002, J BIOL CHEM, V277, P42919, DOI 10.1074/jbc.M206141200; Keunen O, 2011, P NATL ACAD SCI USA, V108, P3749, DOI 10.1073/pnas.1014480108; Kim KK, 2009, J CLIN INVEST, V119, P213, DOI 10.1172/JCI36940; Kim WY, 2009, J CLIN INVEST, V119, P2160, DOI 10.1172/JCI38443; Kim Y, 2009, J CELL BIOL, V184, P309, DOI 10.1083/jcb.200806067; Klimova T, 2008, CELL DEATH DIFFER, V15, P660, DOI 10.1038/sj.cdd.4402307; Krishnamachary B, 2006, CANCER RES, V66, P2725, DOI 10.1158/0008-5472.CAN-05-3719; Lilien J, 2005, CURR OPIN CELL BIOL, V17, P459, DOI 10.1016/j.ceb.2005.08.009; Littlepage LE, 2010, CANCER RES, V70, P2224, DOI 10.1158/0008-5472.CAN-09-3515; Lluis JM, 2007, CANCER RES, V67, P7368, DOI 10.1158/0008-5472.CAN-07-0515; Lou YW, 2008, FEBS J, V275, P69, DOI 10.1111/j.1742-4658.2007.06173.x; Lu KV, 2012, CANCER CELL, V22, P21, DOI 10.1016/j.ccr.2012.05.037; Lu X, 2010, CLIN CANCER RES, V16, P5928, DOI 10.1158/1078-0432.CCR-10-1360; Luo DC, 2011, MOL CANCER RES, V9, P234, DOI 10.1158/1541-7786.MCR-10-0214; Mao WG, 1997, ONCOGENE, V15, P3083, DOI 10.1038/sj.onc.1201496; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Paez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027; Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0; Pham NA, 2009, INT J CANCER, V124, P280, DOI 10.1002/ijc.23912; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polyak K, 2009, NAT REV CANCER, V9, P265, DOI 10.1038/nrc2620; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Ruan K, 2009, J CELL BIOCHEM, V107, P1053, DOI 10.1002/jcb.22214; Sennino B, 2012, CANCER DISCOV, V2, P270, DOI 10.1158/2159-8290.CD-11-0240; Setsukinai K, 2003, J BIOL CHEM, V278, P3170, DOI 10.1074/jbc.M209264200; Stemmer V, 2008, ONCOGENE, V27, P5075, DOI 10.1038/onc.2008.140; Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007; Turley EA, 2008, NAT CLIN PRACT ONCOL, V5, P280, DOI 10.1038/ncponc1089; Ulsamer A, 2012, J BIOL CHEM, V287, P5164, DOI 10.1074/jbc.M111.322123; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yang MH, 2008, NAT CELL BIOL, V10, P295, DOI 10.1038/ncb1691; Yang WW, 2011, NATURE, V480, P118, DOI 10.1038/nature10598; Yook JI, 2006, NAT CELL BIOL, V8, P1398, DOI 10.1038/ncb1508; Zeng G, 2006, EXP CELL RES, V312, P3620, DOI 10.1016/j.yexcr.2006.08.003; Zhou GF, 2009, AM J PHYSIOL-LUNG C, V297, pL1120, DOI 10.1152/ajplung.00007.2009	45	28	28	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2013	32	42					5048	5057		10.1038/onc.2012.530	http://dx.doi.org/10.1038/onc.2012.530			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	238IB	23246962	Green Accepted			2022-12-28	WOS:000325937900006
J	Chen, Y; Soong, J; Mohanty, S; Xu, L; Scott, G				Chen, Y.; Soong, J.; Mohanty, S.; Xu, L.; Scott, G.			The neural guidance receptor Plexin C1 delays melanoma progression	ONCOGENE			English	Article						melanoma; semaphorin; plexin; R-Ras; melanocyte	R-RAS GAP; CELL-MIGRATION; SEMAPHORIN 7A; TUMOR-SUPPRESSOR; DENDRITE FORMATION; AXON GUIDANCE; RHO; ACTIVATION; SIGNALS; ROLES	Plexin C1 is a type I transmembrane receptor with intrinsic R-Ras GTPase activity, which regulates cytoskeletal remodeling and adhesion in normal human melanocytes. Melanocytes are pigment-producing cells of the epidermis, precursors for melanoma, and express high levels of Plexin C1, which is lost in melanoma in vitro and in vivo. To determine if Plexin C1 is a tumor suppressor for melanoma, we introduced Plexin C1 into a primary human melanoma cell line, and phenotypes including migration, apoptosis, proliferation and tumor growth in mice were analyzed. Complimentary studies in which Plexin C1 was silenced in human melanocytes were performed. Plexin C1 significantly inhibited migration and proliferation in melanoma, whereas in melanocytes, loss of Plexin C1 increased migration and proliferation. In mouse xenografts, Plexin C1 delayed tumor growth of melanoma at early time points, but tumors eventually escaped the suppressive effects of Plexin C1, due to Plexin C1-dependent activation of the pro-survival protein Akt. R-Ras activation stimulates melanoma migration. Plexin C1 lowered R-Ras activity in melanoma and melanocytes, consistent with inhibitory effects of Plexin C1 on migration of melanocytes and melanoma. To determine if R-Ras is expressed in melanocytic lesions in vivo, staining of tissue microarrays of nevi and melanoma were performed. R-Ras expression was highly limited in melanocytic lesions, being essentially confined to primary melanoma, and almost completely absent in nevi and metastatic melanoma. These data suggest that loss of Plexin C1 in melanoma may promote early steps in melanoma progression through suppression of migration and proliferation, but pro-survival effects of Plexin C1 ultimately abrogate the tumor suppressive effects of Plexin C1. In primary melanoma, loss of Plexin C1 may function in early steps of melanoma progression by releasing inhibition of R-Ras activation, and stimulating migration.	[Chen, Y.; Soong, J.; Scott, G.] Univ Rochester, Sch Med, Dept Dermatol, Rochester, NY 14618 USA; [Soong, J.; Scott, G.] Univ Rochester, Sch Med, Dept Pathol, Rochester, NY 14618 USA; [Mohanty, S.; Xu, L.] Univ Rochester, Sch Med, Dept Biomed Genet, Rochester, NY 14618 USA	University of Rochester; University of Rochester; University of Rochester	Scott, G (corresponding author), Univ Rochester, Sch Med, Dept Dermatol, Box 697,601 Elmwood Ave, Rochester, NY 14618 USA.	Glynis_Scott@urmc.rochester.edu			NIH [5T32AR007472]; Department of Biogenetics, University of Rochester;  [R01CA136499]; NATIONAL CANCER INSTITUTE [R01CA136499] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Biogenetics, University of Rochester; ; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	This work was supported in part by R01CA136499 (GS), by NIH training Grant 5T32AR007472 (JS), and by the Department of Biogenetics, University of Rochester (LX). We also thank Lori Moll (Oncogene Inc.,) for assistance with subcloning of Plexin C1.	Abi-Habib RJ, 2005, MOL CANCER THER, V4, P1303, DOI 10.1158/1535-7163.MCT-05-0145; Argast GM, 2009, ONCOGENE, V28, P2697, DOI 10.1038/onc.2009.133; Artigiani S, 1999, IUBMB LIFE, V48, P477, DOI 10.1080/713803563; Aurandt J, 2002, P NATL ACAD SCI USA, V99, P12085, DOI 10.1073/pnas.142433199; Balakrishnan A, 2009, HUM MUTAT, V30, P1167, DOI 10.1002/humu.21017; Barberis D, 2005, J CELL SCI, V118, P4689, DOI 10.1242/jcs.02590; Barton WA, 2004, ADV PROTEIN CHEM, V68, P65; Comeau MR, 1998, IMMUNITY, V8, P473, DOI 10.1016/S1074-7613(00)80552-X; Gao L, 2006, CANCER RES, V66, P7880, DOI 10.1158/0008-5472.CAN-06-0254; Gawecka JE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011269; Giger RJ, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001867; HARA M, 1994, J CELL SCI, V107, P2739; Holly SP, 2005, MOL BIOL CELL, V16, P2458, DOI 10.1091/mbc.E03-12-0917; Itahana Koji, 2007, Methods Mol Biol, V371, P21; Iwasawa N, 2012, MOL BIOL CELL, V23, P2793, DOI 10.1091/mbc.E12-02-0103; Iwashita S, 2007, J BIOL CHEM, V282, P3413, DOI 10.1074/jbc.C600293200; Keely PJ, 1999, J CELL BIOL, V145, P1077, DOI 10.1083/jcb.145.5.1077; Lallier TE, 2004, J DENT RES, V83, P677, DOI 10.1177/154405910408300904; Lazova R, 2009, AM J DERMATOPATH, V31, P177, DOI 10.1097/DAD.0b013e318196672d; Liu HL, 2010, CELL, V142, P749, DOI 10.1016/j.cell.2010.07.040; Maddodi N, 2008, PHOTOCHEM PHOTOBIOL, V84, P528, DOI 10.1111/j.1751-1097.2007.00283.x; Messina A, 2011, HUM MOL GENET, V20, P4759, DOI 10.1093/hmg/ddr403; Oinuma I, 2006, J CELL BIOL, V173, P601, DOI 10.1083/jcb.200508204; Pasterkamp RJ, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-98; Pasterkamp RJ, 2003, NATURE, V424, P398, DOI 10.1038/nature01790; Perala N, 2012, DIFFERENTIATION, V83, P77, DOI 10.1016/j.diff.2011.08.001; Puschel AW, 2007, ADV EXP MED BIOL, V600, P12; Scott G, 2002, PIGM CELL RES, V15, P322, DOI 10.1034/j.1600-0749.2002.02056.x; Scott G, 2003, PIGM CELL RES, V16, P139, DOI 10.1034/j.1600-0749.2003.00022.x; Scott GA, 2008, J INVEST DERMATOL, V128, P151, DOI 10.1038/sj.jid.5700974; Scott GA, 2009, J INVEST DERMATOL, V129, P954, DOI 10.1038/jid.2008.329; Stevens L, 2010, J INVEST DERMATOL, V130, P1636, DOI 10.1038/jid.2010.13; Suzuki K, 2007, J SYN ORG CHEM JPN, V65, P1; Uesugi K, 2009, J BIOL CHEM, V284, P6743, DOI 10.1074/jbc.M805213200; Walzer T, 2005, INT IMMUNOL, V17, P943, DOI 10.1093/intimm/dxh274; Wang YX, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002636; Winograd-Katz SE, 2006, ONCOGENE, V25, P7381, DOI 10.1038/sj.onc.1209737; Wozniak MA, 2005, MOL BIOL CELL, V16, P84, DOI 10.1091/mbc.E04-04-0277; Xu C, 2007, MOL ENDOCRINOL, V21, P1234, DOI 10.1210/me.2007-0034; Yang D, 2011, ONCOGENE, V30, P4590, DOI [10.1038/onc.2011.541, 10.1038/onc.2011.166]; Yazdani U, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-3-211; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	42	20	21	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2013	32	41					4941	4949		10.1038/onc.2012.511	http://dx.doi.org/10.1038/onc.2012.511			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235KQ	23160370	Green Accepted			2022-12-28	WOS:000325717800010
J	Sia, D; Tovar, V; Moeini, A; Llovet, JM				Sia, D.; Tovar, V.; Moeini, A.; Llovet, J. M.			Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies	ONCOGENE			English	Review						cholangiocarcinoma; molecular pathogenesis; targeted therapies	GROWTH-FACTOR-RECEPTOR; BILIARY-TRACT CANCER; PRIMARY LIVER CANCERS; GENOME-WIDE ANALYSIS; C VIRUS-INFECTION; PHASE-II; HEPATOCELLULAR-CARCINOMA; GENE-EXPRESSION; UNITED-STATES; BILE-DUCT	Intrahepatic cholangiocarcinoma (ICC) is an aggressive malignancy with very poor prognosis. Genome-wide, high-throughput technologies have made major advances in understanding the molecular basis of this disease, although important mechanisms are still unclear. Recent data have revealed specific genetic mutations (for example, KRAS, IDH1 and IDH2), epigenetic silencing, aberrant signaling pathway activation (for example, interleukin (IL)-6/signal transducer and activator of transcription 3 (STAT3), tyrosine kinase receptor-related pathways) and molecular subclasses with unique alterations (for example, proliferation and inflammation subclasses). In addition, some ICCs share common genomic traits with hepatocellular carcinoma. All this information provides the basis to explore novel targeted therapies. Currently, surgery at early stage is the only effective therapy. At more advanced stages, chemotherapy regimens are emerging (that is, cisplatin plus gemcitabine), along with molecular targeted agents tested in several ongoing clinical trials. Nonetheless, a first-line conclusive treatment remains an unmet need. Similarly, there are no studies assessing tumor response related with genetic alterations. This review explores the recent advancements in the knowledge of the molecular alterations underlying ICC and the future prospects in terms of therapeutic strategies leading towards a more personalized treatment of this neoplasm.	[Sia, D.; Tovar, V.; Moeini, A.; Llovet, J. M.] Hosp Clin Barcelona, Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona Clin Liver Canc Grp, HCC Translat Res Lab,Liver Unit, E-08036 Barcelona, Catalonia, Spain; [Sia, D.] Natl Canc Inst, Gastrointestinal Surg & Liver Transplantat Unit, I-20133 Milan, Italy; [Llovet, J. M.] Mt Sinai Sch Med, Tisch Canc Inst, Dept Med, Div Liver Dis,Mt Sinai Liver Canc Program, New York, NY USA; [Llovet, J. M.] Inst Catalana Recerca & Estudis Avancats, Barcelona, Catalonia, Spain; [Llovet, J. M.] Univ Barcelona, Barcelona, Catalonia, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Fondazione IRCCS Istituto Nazionale Tumori Milan; Icahn School of Medicine at Mount Sinai; ICREA; University of Barcelona	Llovet, JM (corresponding author), Hosp Clin Barcelona, Inst Invest Biomed August Pi I Sunyer IDIBAPS, Barcelona Clin Liver Canc Grp, HCC Translat Res Lab,Liver Unit, Villarroel 170, E-08036 Barcelona, Catalonia, Spain.	jmllovet@clinic.ub.es	Llovet, Josep M/ABB-6264-2021; Llovet, Josep M/D-4340-2014	Llovet, Josep M/0000-0003-0547-2667; Llovet, Josep M/0000-0003-0547-2667; Sia, Daniela/0000-0002-9000-611X	US National Institutes of Diabetes and Digestive and Kidney Diseases [1R01DK076986]; European Commission [259744]; Asociacion Espanola Contra el Cancer; Spanish National Health Institute [SAF-2010-16055]; Samuel Waxman Cancer Research Foundation; ICREA Funding Source: Custom; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK076986] Funding Source: NIH RePORTER	US National Institutes of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); European Commission(European CommissionEuropean Commission Joint Research Centre); Asociacion Espanola Contra el Cancer; Spanish National Health Institute(Spanish Government); Samuel Waxman Cancer Research Foundation; ICREA(ICREA); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Josep M Llovet is supported by grants from the US National Institutes of Diabetes and Digestive and Kidney Diseases (1R01DK076986), the European Commission's Framework Programme 7 (HEPTROMIC; 259744), the Asociacion Espanola Contra el Cancer, the Spanish National Health Institute (SAF-2010-16055) and the Samuel Waxman Cancer Research Foundation.	Aishima S, 2007, AM J SURG PATHOL, V31, P1059, DOI 10.1097/PAS.0b013e31802b34b6; Andersen JB, 2012, GASTROENTEROLOGY, V142, P1021, DOI 10.1053/j.gastro.2011.12.005; Bekaii-Saab T, 2011, J CLIN ONCOL, V29, P2357, DOI 10.1200/JCO.2010.33.9473; Bengala C, 2010, BRIT J CANCER, V102, P68, DOI 10.1038/sj.bjc.6605458; Berthiaume EP, 2004, SEMIN LIVER DIS, V24, P127, DOI 10.1055/s-2004-828890; Blechacz B, 2008, HEPATOLOGY, V48, P308, DOI 10.1002/hep.22310; Borbath C, 6 ILCA ANN C 2012; Borger DR, 2012, ONCOLOGIST, V17, P72, DOI 10.1634/theoncologist.2011-0386; Bragazzi MC., 2012, TRANSL GASTROINTEST, V1, P21, DOI [10.3978/j.issn.2224-4778.2011.11.04, DOI 10.3978/J.ISSN.2224-4778.2011.11.04]; Chen L, 2009, J HEPATOL, V50, P358, DOI 10.1016/j.jhep.2008.09.015; Chen TC, 2012, ANN SURG ONCOL, V19, pS675, DOI [10.1245/s10434-012-2224-7, 10.1245/s10434-012-2451-y]; Chiang DY, 2008, CANCER RES, V68, P6779, DOI 10.1158/0008-5472.CAN-08-0742; Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530; Dachrut S, 2009, ASIAN PAC J CANCER P, V10, P575; de Jong MC, 2011, J CLIN ONCOL, V29, P3140, DOI 10.1200/JCO.2011.35.6519; Deshpande V, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-60; Edge SB., 2010, AJCC CANC STAGING MA; El-Khoueiry AB, 2012, INVEST NEW DRUG, V30, P1646, DOI 10.1007/s10637-011-9719-0; El-Serag HB, 2009, HEPATOLOGY, V49, P116, DOI 10.1002/hep.22606; Endo K, 2002, HEPATOLOGY, V36, P439, DOI 10.1053/jhep.2002.34435; Esteller M, 2007, NAT REV GENET, V8, P286, DOI 10.1038/nrg2005; Farazi PA, 2006, CANCER RES, V66, P6622, DOI 10.1158/0008-5472.CAN-05-4609; Fingas CD, 2011, HEPATOLOGY, V54, P2076, DOI 10.1002/hep.24588; Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011; Furubo S, 1999, HISTOPATHOLOGY, V35, P230; Gruenberger B, 2010, LANCET ONCOL, V11, P1142, DOI 10.1016/S1470-2045(10)70247-3; Guedj N, 2009, J HEPATOL, V51, P93, DOI 10.1016/j.jhep.2009.03.017; Hammill CW, 2008, J AM COLL SURGEONS, V207, P594, DOI 10.1016/j.jamcollsurg.2008.04.031; Han C, 2004, CANCER RES, V64, P1369, DOI 10.1158/0008-5472.CAN-03-1086; Hasita H, 2010, CANCER SCI, V101, P1913, DOI 10.1111/j.1349-7006.2010.01614.x; Hedvat M, 2009, CANCER CELL, V16, P487, DOI 10.1016/j.ccr.2009.10.015; Hezel AF, 2010, J CLIN ONCOL, V28, P3531, DOI 10.1200/JCO.2009.27.4787; Hodge DR, 2001, J BIOL CHEM, V276, P39508, DOI 10.1074/jbc.C100343200; Homayounfar K, 2009, HUM PATHOL, V40, P834, DOI 10.1016/j.humpath.2008.11.005; Hoshida Y, 2009, CANCER RES, V69, P7385, DOI 10.1158/0008-5472.CAN-09-1089; Isa T, 2002, HEPATO-GASTROENTEROL, V49, P604; Isomoto H, 2007, GASTROENTEROLOGY, V132, P384, DOI 10.1053/j.gastro.2006.10.037; Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.20115, 10.3322/caac.20107]; Jensen LH, 2012, ANN ONCOL, V23, P2341, DOI 10.1093/annonc/mds008; Jimeno A, 2005, CANCER RES, V65, P3003, DOI 10.1158/0008-5472.CAN-04-3586; Jinawath N, 2006, HEPATOLOGY, V44, P1025, DOI 10.1002/hep.21330; Karamitopoulou E, 2008, AM J CLIN PATHOL, V130, P780, DOI 10.1309/AJCP35FDCAVANWMM; Khan SA, 2005, LANCET, V366, P1303, DOI 10.1016/S0140-6736(05)67530-7; Kiguchi K, 2001, CANCER RES, V61, P6971; Kipp BR, 2012, HUM PATHOL, V43, P1552, DOI 10.1016/j.humpath.2011.12.007; Kobayashi M, 2000, CANCER, V88, P2471, DOI 10.1002/1097-0142(20000601)88:11<2471::AID-CNCR7>3.0.CO;2-T; Kobayashi S, 2005, GASTROENTEROLOGY, V128, P2054, DOI 10.1053/j.gastro.2005.03.010; Koo SH, 2001, CANCER GENET CYTOGEN, V130, P22, DOI 10.1016/S0165-4608(01)00460-5; Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448; Lee J, 2012, LANCET ONCOL, V13, P181, DOI 10.1016/S1470-2045(11)70301-1; Lee JS, 2006, NAT MED, V12, P410, DOI 10.1038/nm1377; Lee S, 2002, AM J PATHOL, V161, P1015, DOI 10.1016/S0002-9440(10)64262-9; Leelawat K, 2006, J SURG RES, V136, P78, DOI 10.1016/j.jss.2006.05.031; Leelawat K, 2009, BMC GASTROENTEROL, V9, DOI 10.1186/1471-230X-9-30; Leone F, 2006, CLIN CANCER RES, V12, P1680, DOI 10.1158/1078-0432.CCR-05-1692; Li B, 2012, FEBS J, V279, P2393, DOI 10.1111/j.1742-4658.2012.08618.x; Li H, 2012, LIVER INT, V32, P38, DOI 10.1111/j.1478-3231.2011.02646.x; Lubner SJ, 2010, J CLIN ONCOL, V28, P3491, DOI 10.1200/JCO.2010.28.4075; Lujambio A, 2012, NATURE, V482, P347, DOI 10.1038/nature10888; Malhi H, 2006, J HEPATOL, V45, P856, DOI 10.1016/j.jhep.2006.09.001; Meng F, 2008, ONCOGENE, V27, P378, DOI 10.1038/sj.onc.1210648; Meng FY, 2006, GASTROENTEROLOGY, V130, P2113, DOI 10.1053/j.gastro.2006.02.057; Meng F, 2006, J HEPATOL, V44, P1055, DOI 10.1016/j.jhep.2005.10.030; Mesa RA, 2012, NAT REV DRUG DISCOV, V11, P103, DOI 10.1038/nrd3652; Miller G, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-62; Miyamoto M, 2011, BRIT J CANCER, V105, P131, DOI 10.1038/bjc.2011.199; Momoi H, 2001, J HEPATOL, V35, P235, DOI 10.1016/S0168-8278(01)00106-4; Nakazawa K, 2005, J PATHOL, V206, P356, DOI 10.1002/path.1779; Nathan H, 2010, CURR OPIN GASTROEN, V26, P269, DOI 10.1097/MOG.0b013e328337c899; O'Dell MR, 2012, CANCER RES, V72, P1557, DOI 10.1158/0008-5472.CAN-11-3596; Obama K, 2005, HEPATOLOGY, V41, P1339, DOI 10.1002/hep.20718; Oishi N, 2012, HEPATOLOGY, V56, P1792, DOI 10.1002/hep.25890; Okabe H, 2009, ANN SURG ONCOL, V16, P2555, DOI 10.1245/s10434-009-0568-4; Okuda K, 2002, J GASTROEN HEPATOL, V17, P1049, DOI 10.1046/j.1440-1746.2002.02781.x; Ong CK, 2012, NAT GENET, V44, P690, DOI 10.1038/ng.2273; Palmer WC, 2012, J HEPATOL, V57, P69, DOI 10.1016/j.jhep.2012.02.022; Pardanani A, 2011, J CLIN ONCOL, V29, P789, DOI 10.1200/JCO.2010.32.8021; Park BK, 2006, AM J CLIN ONCOL-CANC, V29, P138, DOI 10.1097/01.coc.0000204402.29830.08; Park J, 1999, HEPATOLOGY, V30, P1128, DOI 10.1002/hep.510300522; Parkin DM, 2002, CANC INCIDENCE 5 CON, VVIII; Pascher Andreas, 2003, J Hepatobiliary Pancreat Surg, V10, P282, DOI 10.1007/s00534-002-0731-9; Patel T, 2001, HEPATOLOGY, V33, P1353, DOI 10.1053/jhep.2001.25087; Philip PA, 2006, J CLIN ONCOL, V24, P3069, DOI 10.1200/JCO.2005.05.3579; Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256; Radaeva S, 1999, HEPATOLOGY, V29, P1453, DOI 10.1002/hep.510290524; Ramanathan RK, 2009, CANCER CHEMOTH PHARM, V64, P777, DOI 10.1007/s00280-009-0927-7; Roskams T, 2006, ONCOGENE, V25, P3818, DOI 10.1038/sj.onc.1209558; Sandhu DS, 2008, LIVER INT, V28, P12, DOI 10.1111/j.1478-3231.2007.01624.x; Selaru FM, 2009, HEPATOLOGY, V49, P1595, DOI 10.1002/hep.22838; Sempoux C, 2011, SEMIN LIVER DIS, V31, P49, DOI 10.1055/s-0031-1272839; Settakorn J, 2005, J CLIN PATHOL, V58, P1249, DOI 10.1136/jcp.2005.026575; Shaib Y, 2004, SEMIN LIVER DIS, V24, P115, DOI 10.1055/s-2004-828889; Shaib YH, 2005, GASTROENTEROLOGY, V128, P620, DOI 10.1053/j.gastro.2004.12.048; Shaib YH, 2004, J HEPATOL, V40, P472, DOI 10.1016/j.jhep.2003.11.030; Shibahara H, 2004, HEPATOLOGY, V39, P220, DOI 10.1002/hep.20031; Shin HR, 2010, CANCER SCI, V101, P579, DOI 10.1111/j.1349-7006.2009.01458.x; Sia D, 2013, GASTROENTER IN PRESS; Siddiquee K, 2007, P NATL ACAD SCI USA, V104, P7391, DOI 10.1073/pnas.0609757104; Sirica AE, 2002, SEMIN LIVER DIS, V22, P303, DOI 10.1055/s-2002-34507; Sirica AE, 2008, HEPATOLOGY, V47, P1178, DOI 10.1002/hep.22088; Sirica AE, 2012, NAT REV GASTRO HEPAT, V9, P44, DOI 10.1038/nrgastro.2011.222; Sirica AE, 2011, CURR OPIN GASTROEN, V27, P276, DOI 10.1097/MOG.0b013e32834405c3; Sirica AE, 2009, CLIN GASTROENTEROL H, V7, pS68, DOI 10.1016/j.cgh.2009.08.023; Sirica AE, 2008, WORLD J GASTROENTERO, V14, P7033, DOI 10.3748/wjg.14.7033; Sirica AE, 2008, HEPATOLOGY, V48, P2040, DOI 10.1002/hep.22623; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; Sugimachi K, 2001, MODERN PATHOL, V14, P900, DOI 10.1038/modpathol.3880409; Sugiyama H, 2011, J GASTROENTEROL, V46, P779, DOI 10.1007/s00535-011-0380-3; Tabernero J, 2007, MOL CANCER RES, V5, P203, DOI 10.1158/1541-7786.MCR-06-0404; Tannapfel A, 2000, DIGEST DIS SCI, V45, P317, DOI 10.1023/A:1005412626515; Tannapfel A, 2000, GUT, V47, P721, DOI 10.1136/gut.47.5.721; Tannapfel A, 2003, GUT, V52, P706, DOI 10.1136/gut.52.5.706; Tannapfel A, 2002, J PATHOL, V197, P624, DOI 10.1002/path.1139; Terada T, 1998, HUM PATHOL, V29, P175, DOI 10.1016/S0046-8177(98)90229-5; Tischoff I, 2005, INT J CANCER, V115, P684, DOI 10.1002/ijc.20944; Tokumoto N, 2005, INT J ONCOL, V27, P973; Tsao MS, 2005, NEW ENGL J MED, V353, P133, DOI 10.1056/NEJMoa050736; Uhm KO, 2005, CANCER GENET CYTOGEN, V157, P37, DOI 10.1016/j.cancergencyto.2004.05.007; Valle Juan, 2010, N Engl J Med, V362, P1273, DOI 10.1056/NEJMoa0908721; Verstovsek S, 2010, NEW ENGL J MED, V363, P1117, DOI 10.1056/NEJMoa1002028; Wang P, 2012, CANC RES; Wehbe H, 2006, CANCER RES, V66, P10517, DOI 10.1158/0008-5472.CAN-06-2130; Welzel TM, 2011, HEPATOLOGY, V54, P463, DOI 10.1002/hep.24397; Wong N, 2002, J HEPATOL, V37, P633, DOI 10.1016/S0168-8278(02)00269-6; Woo HG, 2010, CANCER RES, V70, P3034, DOI 10.1158/0008-5472.CAN-09-2823; Wu GS, 2003, WORLD J GASTROENTERO, V9, P1302, DOI 10.3748/wjg.v9.i6.1302; Wu T, 2004, MOL CANCER THER, V3, P299; Xin H, 2011, CANCER RES, V71, P6601, DOI 10.1158/0008-5472.CAN-11-1217; Yamagiwa Y, 2006, LIFE SCI, V78, P2494, DOI 10.1016/j.lfs.2005.10.015; Yamamoto S, 2004, CANCER SCI, V95, P592, DOI 10.1111/j.1349-7006.2004.tb02492.x; Yamashita T, 2009, GASTROENTEROLOGY, V136, P1012, DOI 10.1053/j.gastro.2008.12.004; Yang B, 2005, MODERN PATHOL, V18, P412, DOI 10.1038/modpathol.3800287; Yi JH, 2012, EUR J CANCER, V48, P196, DOI 10.1016/j.ejca.2011.11.017; Yoon JH, 2004, J HEPATOL, V41, P808, DOI 10.1016/j.jhep.2004.07.016; Yoshikawa D, 2008, BRIT J CANCER, V98, P418, DOI 10.1038/sj.bjc.6604129; Yoshikawa D, 2009, BRIT J CANCER, V100, P1257, DOI 10.1038/sj.bjc.6604988; Zhang ZC, 2010, HEPATOLOGY, V52, P975, DOI 10.1002/hep.23773; Zhu AX, 2011, HEPATOLOGY, V53, P695, DOI 10.1002/hep.24145; Zhu AX, 2010, LANCET ONCOL, V11, P48, DOI 10.1016/S1470-2045(09)70333-X	139	162	172	0	28	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2013	32	41					4861	4870		10.1038/onc.2012.617	http://dx.doi.org/10.1038/onc.2012.617			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	235KQ	23318457	Green Accepted			2022-12-28	WOS:000325717800001
J	Saunders, PO; Weiss, J; Welschinger, R; Baraz, R; Bradstock, KF; Bendall, LJ				Saunders, P. O.; Weiss, J.; Welschinger, R.; Baraz, R.; Bradstock, K. F.; Bendall, L. J.			RAD001 (everolimus) induces dose-dependent changes to cell cycle regulation and modifies the cell cycle response to vincristine	ONCOGENE			English	Article						acute lymphoblastic leukemia; RAD001; mTOR inhibitors; chemotherapy; checkpoint regulation; mitosis	ACUTE LYMPHOBLASTIC-LEUKEMIA; DNA-DAMAGE RESPONSE; MAMMALIAN TARGET; MITOTIC CATASTROPHE; AURORA-B; PROGRESSION; INHIBITORS; APOPTOSIS; MTOR; ACTIVATION	More than 50% of adults and similar to 20% of children with pre-B acute lymphoblastic leukemia (ALL) relapse following treatment. Dismal outcomes for patients with relapsed or refractory disease mandate novel approaches to therapy. We have previously shown that the combination of the mTOR inhibitor RAD001 (everolimus) and the chemotherapeutic agent vincristine increases the survival of non-obese diabetic/severe combined immuno-deficient (NOD/SCID) mice bearing human ALL xenografts. We have also shown that 16 mu M RAD001 synergized with agents that cause DNA damage or microtubule disruption in pre-B ALL cells in vitro. Here, we demonstrate that RAD001 has dose-dependent effects on the cell cycle in ALL cells, with 1.5 mu M RAD001 inhibiting pRb, Ki67 and PCNA expression and increasing G(0/1) cell cycle arrest, whereas 16 mu M RAD001 increases pRb, cyclin D1, Ki67 and PCNA, with no evidence of an accumulation of cells in G(0/1). Transition from G(2) into mitosis was promoted by 16 mu M RAD001 with reduced phosphorylation of cdc2 in cells with 4N DNA content. However, 16 mu M RAD001 preferentially induced cell death in cells undergoing mitosis. When combined with vincristine, 16 mu M RAD001 reduced the vincristine-induced accumulation of cells in mitosis, probably as a result of increased death in this population. Although 16 mu M RAD001 weakly activated Chk1 and Chk2, it suppressed strong vincristine-induced activation of these cell cycle checkpoint regulators. We conclude that RAD001 enhances chemosensitivity at least in part through suppression of cell cycle checkpoint regulation in response to vincristine and increased progression from G(2) into mitosis.	[Saunders, P. O.; Weiss, J.; Welschinger, R.; Baraz, R.; Bradstock, K. F.; Bendall, L. J.] Univ Sydney, Westmead Millennium Inst, Westmead Inst Canc Res, Westmead, NSW 2145, Australia	University of Sydney; Westmead Institute for Medical Research	Bendall, LJ (corresponding author), Univ Sydney, Westmead Millennium Inst, Westmead Inst Canc Res, POB 412 Darcy Rd, Westmead, NSW 2145, Australia.	linda_bendall@wmi.usyd.edu.au			University of Sydney; NHMRC CDA2 [511965]; NHMRC [352326]; Leukemia and Lymphoma Society Translational Program [6105-08]	University of Sydney(University of Sydney); NHMRC CDA2(National Health and Medical Research Council (NHMRC) of Australia); NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Leukemia and Lymphoma Society Translational Program(Leukemia and Lymphoma Society)	RAD001 (everolimus) was kindly provided by Novartis. This work was supported by a University of Sydney Postgraduate Award (PS), NHMRC CDA2 No. 511965 (LB) and project grant no. 352326 (RB, JW), and the Leukemia and Lymphoma Society Translational Program grant no. 6105-08 (RW).	Avellino R, 2005, BLOOD, V106, P1400, DOI 10.1182/blood-2005-03-0929; BENDALL LJ, 1993, BLOOD, V82, P3125; Blajeski AL, 2002, J CLIN INVEST, V110, P91, DOI 10.1172/JCI200213275; Bradstock K, 1996, LEUKEMIA, V10, P813; Branzei D, 2010, NAT REV MOL CELL BIO, V11, P208, DOI 10.1038/nrm2852; Castedo M, 2004, ONCOGENE, V23, P4362, DOI 10.1038/sj.onc.1207572; Crazzolara R, 2009, AUTOPHAGY, V5, P727, DOI 10.4161/auto.5.5.8507; Crazzolara R, 2009, BLOOD, V113, P3297, DOI 10.1182/blood-2008-02-137752; Ehrhardt H, 2011, BLOOD, V118, P6123, DOI 10.1182/blood-2010-02-269811; Gao N, 2003, BIOCHEM BIOPH RES CO, V310, P1124, DOI 10.1016/j.bbrc.2003.09.132; Gao N, 2004, AM J PHYSIOL-CELL PH, V287, pC281, DOI 10.1152/ajpcell.00422.2003; Gokbuget N, 2009, SEMIN HEMATOL, V46, P64, DOI 10.1053/j.seminhematol.2008.09.003; Grunwald V, 2002, CANCER RES, V62, P6141; Haritunians T, 2007, LEUKEMIA, V21, P333, DOI 10.1038/sj.leu.2404471; Harper JW, 2007, MOL CELL, V28, P739, DOI 10.1016/j.molcel.2007.11.015; Hawkins DS, 1996, CANCER RES, V56, P892; Ito D, 2010, ADV EXP MED BIOL, V676, P15; Juarez J, 2003, LEUKEMIA, V17, P1294, DOI 10.1038/sj.leu.2402998; Law M, 2006, CANCER RES, V66, P1070, DOI 10.1158/0008-5472.CAN-05-1672; Mabuchi S, 2007, CLIN CANCER RES, V13, P4261, DOI 10.1158/1078-0432.CCR-06-2770; Moricke A, 2010, LEUKEMIA, V24, P265, DOI 10.1038/leu.2009.257; MORICE WG, 1993, J BIOL CHEM, V268, P3734; Nguyen K, 2008, LEUKEMIA, V22, P2142, DOI 10.1038/leu.2008.251; Peng A, 2010, ONCOGENE, V29, P5977, DOI 10.1038/onc.2010.371; Peponi E, 2006, AM J PATHOL, V169, P2171, DOI 10.2353/ajpath.2006.051078; Petersen J, 2007, NAT CELL BIOL, V9, P1263, DOI 10.1038/ncb1646; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Portugal J, 2010, CURR PHARM DESIGN, V16, P69, DOI 10.2174/138161210789941801; Saunders P, 2011, HAEMATOL-HEMATOL J, V96, P69, DOI 10.3324/haematol.2010.026997; Segurado M, 2009, BIOL CELL, V101, P617, DOI 10.1042/BC20090053; Silverman LB, 2010, LEUKEMIA, V24, P320, DOI 10.1038/leu.2009.253; Song JX, 2007, NAT IMMUNOL, V8, P64, DOI 10.1038/ni1413; Su WC, 2009, FEBS LETT, V583, P2793, DOI 10.1016/j.febslet.2009.07.027; Tavernier E, 2007, LEUKEMIA, V21, P1907, DOI 10.1038/sj.leu.2404824; Teachey DT, 2008, BLOOD, V112, P2020, DOI 10.1182/blood-2008-02-137141; Wanner K, 2006, BRIT J HAEMATOL, V134, P475, DOI 10.1111/j.1365-2141.2006.06210.x; Wu MYW, 2007, EMBO J, V26, P371, DOI 10.1038/sj.emboj.7601487; Yang CY, 2011, MOL CELL, V44, P597, DOI 10.1016/j.molcel.2011.09.016	38	18	19	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2013	32	40					4789	4797		10.1038/onc.2012.498	http://dx.doi.org/10.1038/onc.2012.498			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	229NW	23128395				2022-12-28	WOS:000325274700007
